the	O
impact	O
of	O
deployment	B-C2825812
on	O
parental	B-C0030551
,	O
family	B-C0015576
and	O
child	B-C0008059
adjustment	B-C0376209
in	O
military	B-C3850016
families	I-C3850016
since	O
9/11	O
,	O
military	B-C1550414
service	I-C1550414
in	O
the	O
united	B-C0041703
states	I-C0041703
has	O
been	O
characterized	O
by	O
wartime	B-C1254367
deployments	B-C2825812
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-C0038435
for	O
military	B-C3850016
families	I-C3850016
.	O
	
research	B-C0035168
indicates	O
the	O
negative	B-C1513916
impact	I-C1513916
of	O
wartime	O
deployment	B-C2825812
on	O
the	O
well	B-C0018684
being	I-C0018684
of	O
service	B-C1550414
members	B-C0680022
,	O
military	B-C3245458
spouses	B-C0162409
,	O
and	O
children	B-C0008059
.	O
	
yet	O
,	O
few	O
studies	O
have	O
considered	O
how	O
parental	B-C0030551
deployments	B-C2825812
may	O
affect	O
adjustment	B-C0376209
in	O
young	B-C0728836
children	I-C0728836
and	O
their	O
families	B-C3850016
.	O
	
using	O
deployment	B-C2825812
records	O
and	O
parent	O
-	O
reported	O
measures	O
from	O
primary	O
caregiving	O
n	O
=	O
680	O
and	O
military	O
n	O
=	O
310	O
parents	O
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	B-C0034869
on	O
adjustment	O
in	O
military	O
families	O
with	O
children	O
ages	O
0-10	O
years	O
.	O
	
greater	O
deployment	O
exposure	O
was	O
related	O
to	O
impaired	O
family	O
functioning	O
and	O
marital	O
instability	O
.	O
	
parental	O
depressive	O
and	O
posttraumatic	O
stress	O
symptoms	O
were	O
associated	O
with	O
impairments	O
in	O
social	O
emotional	O
adjustment	O
in	O
young	O
children	O
,	O
increased	O
anxiety	O
in	O
early	O
childhood	O
,	O
and	O
adjustment	O
problems	O
in	O
school-age	O
children	O
.	O
	
conversely	O
,	O
parental	O
sensitivity	O
was	O
associated	O
with	O
improved	O
social	O
and	O
emotional	O
outcomes	O
across	O
childhood	O
.	O
	
these	O
findings	O
provide	O
guidance	O
to	O
developing	O
preventive	O
approaches	O
for	O
military	O
families	O
with	O
young	O
children	B-C0008059
beyond	O
neutral	B-C1254372
and	O
forbidden	B-C1254372
links	I-C1254372
morphological	B-C0543482
matches	B-C1708943
and	O
the	O
assembly	B-C0441833
of	O
mutualistic	B-C1254366
hawkmoth	B-C0599456
-	O
plant	B-C0032098
networks	B-C1882071
a	O
major	O
challenge	O
in	O
evolutionary	B-C0013546
ecology	I-C0013546
is	O
to	O
understand	O
how	O
co-evolutionary	B-C1522240
processes	I-C1522240
shape	O
patterns	B-C0449774
of	O
interactions	B-C1704675
between	O
species	B-C1705920
at	O
community	B-C0009462
level	B-C0441889
.	O
	
pollination	B-C1522786
of	O
flowers	B-C0330090
with	O
long	B-C2699452
corolla	I-C2699452
tubes	I-C2699452
by	O
long-tongued	B-C0599456
hawkmoths	I-C0599456
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	B-C0026336
of	O
co-evolution	B-C0015219
.	O
	
recently	O
,	O
optimal	O
foraging	O
models	B-C0026336
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	B-C0439849
between	O
mouthparts'	B-C1444754
length	I-C1444754
and	O
the	O
corolla	B-C2699452
depth	B-C0205125
of	O
the	O
visited	O
flowers	B-C0330090
,	O
thus	O
favouring	O
trait	B-C0599883
convergence	B-C2700387
and	O
specialization	B-C0037776
at	O
community	B-C0009462
level	O
.	O
	
here	O
,	O
we	O
assessed	B-C1516048
whether	O
hawkmoths	B-C0599456
more	O
frequently	O
pollinate	B-C0032098
plants	I-C0032098
with	O
floral	B-C2698828
tube	I-C2698828
lengths	B-C1444754
similar	O
to	O
their	O
proboscis	B-C3463932
lengths	B-C1444754
morphological	B-C0543482
match	B-C1708943
hypothesis	B-C1512571
against	O
abundance	B-C2346714
-based	O
processes	B-C1522240
neutral	B-C1512571
hypothesis	I-C1512571
and	O
ecological	B-C0599883
trait	I-C0599883
mismatches	B-C1881865
constraints	B-C2986806
forbidden	B-C1254372
links	I-C1254372
hypothesis	B-C1512571
,	O
and	O
how	O
these	O
processes	B-C1522240
structure	B-C0678594
hawkmoth	B-C0599456
-	O
plant	B-C0032098
mutualistic	B-C1882071
networks	I-C1882071
from	O
five	O
communities	B-C0009462
in	O
four	O
biogeographical	B-C0017446
regions	I-C0017446
of	O
south	B-C0037713
america	I-C0037713
.	O
	
we	O
found	O
convergence	B-C2700387
in	O
morphological	B-C0543482
traits	B-C0599883
across	O
the	O
five	O
communities	B-C0009462
and	O
that	O
the	O
distribution	B-C1704711
of	O
morphological	B-C0543482
differences	O
between	O
hawkmoths	B-C0599456
and	O
plants	B-C0032098
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	B-C0543482
match	B-C1708943
hypothesis	B-C1512571
in	O
three	O
of	O
the	O
five	O
communities	B-C0009462
.	O
	
in	O
the	O
two	O
remaining	O
communities	B-C0009462
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical	B-C0017446
areas	I-C0017446
,	O
interactions	B-C1704675
are	O
better	O
predicted	O
by	O
the	O
neutral	B-C1512571
hypothesis	I-C1512571
.	O
	
our	O
findings	B-C2607943
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co-evolution	B-C0015219
drives	O
the	O
evolution	B-C0015219
of	O
extremely	O
long	B-C3463932
proboscises	I-C3463932
and	O
flower	B-C0330090
tubes	I-C0330090
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	B-C0543482
traits	B-C0599883
,	O
beyond	O
the	O
forbidden	B-C1254372
links	I-C1254372
hypothesis	B-C1512571
,	O
in	O
structuring	O
interactions	B-C1704675
between	O
mutualistic	B-C0441833
partners	I-C0441833
,	O
revealing	O
that	O
the	O
role	B-C1705810
of	O
niche-based	B-C1522240
processes	I-C1522240
nosocomial	B-C0949083
pneumonia	I-C0949083
caused	O
by	O
methicillin-resistant	B-C1265292
staphylococcus	I-C1265292
aureus	I-C1265292
treated	B-C0332293
with	I-C0332293
linezolid	B-C0663241
or	O
vancomycin	B-C0042313
a	O
secondary	O
economic	B-C0680954
analysis	I-C0680954
of	O
resource	B-C1704738
use	I-C1704738
from	O
a	O
spanish	B-C0037747
perspective	B-C0680951
adopting	O
a	O
unique	O
spanish	B-C0037747
perspective	B-C0680951
,	O
this	O
study	B-C2603343
aims	O
to	O
assess	O
healthcare	B-C1704738
resource	I-C1704738
utilization	I-C1704738
hcru	B-C1704738
and	O
the	O
costs	B-C0085552
of	O
treating	B-C1522326
nosocomial	B-C0949083
pneumonia	I-C0949083
np	B-C0949083
produced	O
by	O
methicillin-resistant	B-C1265292
staphylococcus	I-C1265292
aureus	I-C1265292
mrsa	B-C1265292
in	O
hospitalized	B-C0701159
adults	I-C0701159
using	O
linezolid	B-C0663241
or	O
vancomycin	B-C0042313
.	O
	
an	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal	B-C0035078
failure	I-C0035078
rate	B-C1521828
and	O
related	O
economic	B-C1274040
outcomes	I-C1274040
between	O
study	B-C0681860
groups	I-C0681860
.	O
	
an	O
economic	O
post	B-C1254363
hoc	I-C1254363
evaluation	I-C1254363
of	O
a	O
randomized	B-C2986910
,	O
double-blind	B-C0013072
,	O
multicenter	B-C0282462
phase	I-C0282462
4	I-C0282462
study	I-C0282462
was	O
carried	O
out	O
.	O
	
nosocomial	B-C0949083
pneumonia	I-C0949083
due	O
to	O
mrsa	B-C1265292
in	O
hospitalized	B-C0701159
adults	I-C0701159
.	O
	
the	O
modified	B-C1292734
intent	I-C1292734
to	I-C1292734
treat	I-C1292734
mitt	B-C1292734
population	B-C1257890
comprised	O
224	O
linezolid	B-C0663241
-	O
and	O
224	O
vancomycin	B-C0042313
-	O
treated	B-C0332293
patients	B-C0030705
.	O
	
costs	B-C0085552
and	O
hcru	B-C1704738
were	O
evaluated	O
between	O
patients	B-C0030705
administered	B-C1521801
either	O
linezolid	B-C0663241
or	O
vancomycin	B-C0042313
,	O
and	O
between	O
patients	B-C0030705
who	O
developed	O
renal	B-C0035078
failure	I-C0035078
and	O
those	O
who	O
did	O
not	O
.	O
	
analysis	O
of	O
hcru	B-C1704738
outcomes	B-C1274040
and	O
costs	B-C0085552
.	O
	
total	O
costs	B-C0085552
were	O
similar	O
between	O
the	O
linezolid	B-C0663241
-	O
17	O
and	O
vancomycin	B-C0042313
-	O
treated	B-C0332293
patients	B-C0030705
17	O
p=	O
.	O
	
the	O
renal	B-C0035078
failure	I-C0035078
rate	B-C1521828
was	O
significantly	O
lower	O
in	O
the	O
linezolid	B-C0663241
-	O
treated	B-C0332293
patients	B-C0030705
4%	O
vs	O
.	O
	
15%	O
p<	O
.	O
	
the	O
total	O
costs	B-C0085552
tended	O
to	O
be	O
higher	O
in	O
patients	B-C0030705
who	O
developed	O
renal	B-C0035078
failure	I-C0035078
19	O
vs	O
.	O
	
17	O
p=	O
.	O
	
among	O
the	O
patients	B-C0030705
who	O
developed	O
renal	B-C0035078
failure	I-C0035078
,	O
hcru	B-C1704738
days	B-C0439228
on	O
mechanical	B-C0199470
ventilation	I-C0199470
13.2	O
vs	O
.	O
	
7.6	O
days	B-C0439228
p=	O
icu	B-C1254367
stay	I-C1254367
14.4	O
vs	O
.	O
	
9.9	O
days	B-C0439228
p=	O
hospital	B-C3489408
stay	I-C3489408
19.5	O
vs	O
.	O
	
16.1	O
days	B-C0439228
p=	O
and	O
cost	B-C0085552
17	O
vs	O
.	O
	
20	O
p=	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	B-C0663241
-	O
vs	O
.	O
	
vancomycin	B-C0042313
-	O
treated	B-C0332293
patients	B-C0030705
.	O
	
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	B-C0085552
per	O
patient	B-C0030705
-	O
day	B-C0439228
between	O
cohorts	B-C0599755
after	O
correcting	O
for	O
mortality	B-C0392762
1000	O
vs	O
.	O
	
1	O
p=	O
.	O
	
from	O
a	O
spanish	B-C0037747
perspective	B-C0680951
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	B-C0085552
between	O
the	O
linezolid	B-C0663241
and	O
vancomycin	B-C0042313
pneumonia	B-C0032285
cohorts	B-C0599755
.	O
	
the	O
drug	B-C0085123
cost	I-C0085123
corresponding	O
to	O
linezolid	B-C0663241
was	O
partially	O
offset	B-C1711330
by	O
fewer	O
renal	B-C0035078
failure	I-C0035078
adverse	B-C0877248
events	I-C0877248
.	O
	
herg1	B-C1566128
potassium	B-C0032824
channel	I-C0032824
expression	B-C1171362
in	O
potentially	B-C3245505
malignant	B-C0006826
disorders	I-C0006826
of	O
the	O
oral	B-C0026639
mucosa	I-C0026639
and	O
prognostic	B-C0220901
relevance	B-C2347946
in	O
oral	B-C0585362
squamous	I-C0585362
cell	I-C0585362
carcinoma	I-C0585362
herg1	B-C1566128
potassium	B-C0032824
channel	I-C0032824
plays	O
a	O
critical	B-C1511545
role	B-C1705810
in	O
the	O
cell	B-C0596290
proliferation	I-C0596290
.	O
	
herg1	B-C1566128
protein	I-C1566128
expression	B-C1171362
was	O
analyzed	B-C0936012
by	O
immunohistochemistry	B-C0021044
ihc	B-C0021044
in	O
62	O
patients	B-C0030705
with	O
oral	B-C0023532
leukoplakias	I-C0023532
and	O
100	O
patients	B-C0030705
with	O
oral	B-C0585362
squamous	I-C0585362
cell	I-C0585362
carcinomas	I-C0585362
oscc	B-C0585362
.	O
	
herg1	B-C1416571
mrna	B-C0035696
levels	B-C0441889
were	O
assessed	B-C1516048
by	O
real-time	B-C0599161
reverse	I-C0599161
transcriptase-polymerase	I-C0599161
chain	I-C0599161
reaction	I-C0599161
rt-pcr	B-C0599161
in	O
22	O
patients	B-C0030705
with	O
primary	B-C0205225
head	B-C1168401
and	I-C1168401
neck	I-C1168401
squamous	I-C1168401
cell	I-C1168401
carcinoma	I-C1168401
hnscc	B-C1168401
.	O
	
statistically	B-C0237881
significant	I-C0237881
associations	B-C0439849
were	O
found	O
between	O
herg1	B-C1566128
expression	B-C1171362
and	O
tobacco	B-C0543414
consumption	I-C0543414
,	O
disease	B-C0699749
stage	I-C0699749
,	O
tumor	B-C0027651
differentiation	B-C0007589
,	O
tumor	B-C0521158
recurrence	I-C0521158
,	O
and	O
reduced	B-C0392756
survival	B-C0038952
.	O
	
there	O
was	O
no	B-C1518422
association	B-C0439849
between	O
herg1	B-C1566128
expression	B-C1171362
and	O
the	O
risk	B-C0035647
of	O
progression	B-C0178874
from	O
oral	B-C0023532
leukoplakia	I-C0023532
to	O
oscc	B-C0585362
.	O
	
in	O
addition	O
,	O
a	O
high	B-C0205250
proportion	B-C1709707
of	O
tumors	B-C0027651
80%	O
showed	O
increased	B-C0205217
herg1	B-C1416571
mrna	B-C0035696
levels	B-C0441889
compared	B-C1707455
to	O
normal	B-C0026724
mucosa	I-C0026724
from	O
nononcologic	B-C0030705
patients	I-C0030705
.	O
	
aberrant	B-C0443127
herg1	B-C1566128
expression	B-C1171362
increases	B-C0442805
as	O
oral	O
tumorigenesis	B-C0178874
progresses	I-C0178874
from	O
oral	B-C1400010
hyperplasia	I-C1400010
to	O
oscc	B-C0585362
.	O
	
increased	B-C0205217
herg1	B-C1416571
mrna	B-C0035696
levels	B-C0441889
were	O
also	O
frequently	O
detected	B-C0442726
in	O
oscc	B-C0585362
and	O
other	O
hnscc	B-C1168401
subsites	B-C1710234
.	O
	
herg1	B-C1566128
expression	B-C1171362
emerges	O
as	O
a	O
clinically	B-C0205210
relevant	B-C2347946
feature	B-C2348519
during	O
tumor	B-C0178874
progression	I-C0178874
and	O
a	O
potential	B-C3245505
poor	B-C2700379
prognostic	B-C0220901
biomarker	B-C0005516
for	O
oscc	B-C0585362
.	O
	
nationwide	B-C1254362
reduction	B-C0547047
in	O
the	O
number	O
of	O
corneal	B-C0010042
transplantations	I-C0010042
for	O
keratoconus	B-C0022578
following	O
the	O
implementation	B-C1708476
of	O
cross-linking	B-C4065848
keratoconus	B-C0022578
is	O
characterized	O
by	O
corneal	B-C0155135
ectasia	I-C0155135
and	O
irregular	B-C0152194
astigmatism	I-C0152194
,	O
which	O
can	O
lead	O
to	O
diminished	B-C0042798
vision	I-C0042798
and	O
corneal	B-C0349702
scarring	I-C0349702
.	O
	
approximately	O
10-20%	O
of	O
patients	B-C0030705
with	O
keratoconus	B-C0022578
eventually	O
require	O
a	O
corneal	B-C0010042
transplant	I-C0010042
.	O
	
corneal	B-C4065848
cross-linking	I-C4065848
cxl	B-C4065848
is	O
a	O
relatively	O
new	O
treatment	B-C0087111
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-C0010042
transplantation	I-C0010042
.	O
	
here	O
,	O
we	O
investigated	B-C1292732
whether	O
the	O
introduction	B-C0579004
of	O
cxl	B-C4065848
has	O
reduced	O
the	O
number	O
of	O
corneal	B-C0010042
transplants	I-C0010042
performed	B-C0884358
annually	B-C0332181
.	O
	
data	B-C1511726
regarding	O
the	O
transplantation	B-C0040732
procedures	I-C0040732
performed	B-C0884358
in	O
patients	B-C0030705
under	O
the	O
age	B-C0001779
of	O
50	O
years	B-C0439234
were	O
extracted	O
from	O
the	O
dutch	B-C0034975
national	I-C0034975
organ	I-C0034975
transplant	I-C0034975
registry	I-C0034975
.	O
	
the	O
number	O
of	O
corneal	B-C0010042
transplants	I-C0010042
performed	B-C0884358
prior	O
to	O
i.e	O
.	O
	
in	O
2005	O
through	O
2007	O
and	O
following	O
the	O
introduction	B-C0579004
of	O
cxl	B-C4065848
i.e	O
.	O
	
in	O
2012	O
through	O
2014	O
were	O
compared	B-C1707455
.	O
	
furthermore	O
,	O
a	O
trend	B-C0681702
analysis	I-C0681702
on	O
annual	B-C0332181
keratoplasties	B-C0010042
over	O
time	O
was	O
performed	B-C0884358
.	O
	
approximately	O
25%	O
fewer	O
corneal	B-C0010042
transplants	I-C0010042
were	O
performed	B-C0884358
in	O
the	O
3-	O
year	B-C0439234
period	O
following	O
the	O
introduction	B-C0579004
of	O
cxl	B-C4065848
compared	B-C1707455
to	O
the	O
3-	O
year	B-C0439234
period	O
prior	O
to	O
the	O
introduction	B-C0579004
of	O
cxl	B-C4065848
201	O
versus	O
269	O
transplants	B-C0010042
,	O
respectively	O
p	O
=	O
0.005	O
.	O
	
age	B-C0001779
,	O
gender	B-C0079399
and	O
visual	B-C0042812
acuity	I-C0042812
were	O
similar	O
between	O
the	O
patient	B-C0030705
groups	O
in	O
the	O
two	O
time	B-C1948053
periods	I-C1948053
.	O
	
trend	B-C0681702
analysis	I-C0681702
also	O
demonstrated	O
a	O
significant	O
decrease	B-C0547047
in	O
the	O
amount	O
of	O
corneal	B-C0010042
transplants	I-C0010042
p	O
=	O
0.001	O
.	O
	
significantly	O
fewer	O
corneal	B-C0010042
transplants	I-C0010042
were	O
performed	O
for	O
treating	O
keratoconus	B-C0022578
following	O
the	O
nationwide	B-C1254362
introduction	B-C0579004
of	O
cxl	B-C4065848
.	O
	
this	O
reduction	B-C0547047
suggests	O
that	O
corneal	B-C4065848
cross-linking	I-C4065848
can	O
significantly	O
reduce	B-C0392756
the	O
need	O
for	O
corneal	B-C0010042
transplantation	I-C0010042
.	O
	
basal	B-C0678121
and	O
maximal	B-C0205289
metabolic	B-C0870882
rates	I-C0870882
differ	O
in	O
their	O
response	B-C0871261
to	O
rapid	O
temperature	B-C0450031
change	I-C0450031
among	O
avian	B-C0005595
species	B-C1705920
in	O
birds	B-C0005595
,	O
acclimation	B-C0000934
and	O
acclimatization	B-C0000934
to	O
temperature	B-C0039476
are	O
associated	O
with	O
changes	O
in	O
basal	B-C0678121
bmr	B-C0678121
,	O
summit	B-C0870882
msum	B-C0870882
and	O
maximal	B-C0205289
mmr	B-C0870882
metabolic	B-C0870882
rates	I-C0870882
but	O
little	O
is	O
known	O
about	O
the	O
rate	B-C0870882
at	O
which	O
species	B-C1705920
adjust	O
their	O
phenotype	B-C0031437
to	O
short-term	B-C0443303
temperature	B-C0039476
variations	B-C0205419
.	O
	
our	O
aims	B-C1947946
were	O
1	O
to	O
determine	O
the	O
pattern	B-C0449774
of	O
metabolic	B-C0311400
adjustments	O
following	O
a	O
rapid	O
temperature	B-C0450031
change	I-C0450031
,	O
2	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	B-C0870882
during	O
exposure	B-C0332157
to	I-C0332157
warm	B-C0563030
or	O
cold	B-C0241842
environments	I-C0241842
,	O
and	O
3	O
to	O
determine	O
if	O
bmr	B-C0678121
,	O
msum	B-C0870882
and	O
mmr	B-C0870882
change	O
at	O
comparable	O
rates	B-C0870882
during	O
thermal	B-C0018837
acclimation	B-C0000934
.	O
	
we	O
measured	O
these	O
parameters	O
in	O
white-throated	B-C1093387
sparrows	I-C1093387
zonotrichia	B-C1093387
albicollis	I-C1093387
,	O
black-capped	B-C0326488
chickadees	I-C0326488
poecile	B-C0326488
atricapillus	I-C0326488
,	O
and	O
snow	B-C0326923
buntings	I-C0326923
plectrophenax	B-C0326923
nivalis	I-C0326923
after	O
acclimation	B-C0000934
to	O
10	O
c	O
day	B-C0439228
0	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	B-C0439228
of	O
acclimation	B-C0000934
to	O
either	O
-5	O
or	O
28	O
c	O
.	O
	
birds	B-C0005595
changed	O
their	O
metabolic	B-C0311400
phenotype	B-C0031437
within	O
8	O
days	B-C0439228
with	O
patterns	B-C0449774
differing	O
among	O
species	B-C1705920
.	O
	
sparrows	B-C1093387
expressed	O
the	O
expected	O
metabolic	B-C0311400
increases	B-C0442805
in	O
the	O
cold	B-C0241842
and	O
decreases	O
at	O
thermoneutrality	B-C0680444
while	O
performance	O
in	O
chickadees	B-C0326488
and	O
buntings	B-C0326923
was	O
not	O
influenced	B-C4054723
by	O
temperature	B-C0039476
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	B-C0449774
.	O
	
our	O
results	B-C0683954
suggest	O
that	O
bmr	B-C0678121
varies	O
at	O
comparable	O
rates	B-C0870882
in	O
warm	B-C0563030
and	O
cold	B-C0241842
environments	I-C0241842
but	O
changes	O
faster	O
than	O
msum	B-C0870882
and	O
mmr	B-C0870882
,	O
likely	O
due	O
to	O
limitations	B-C0449295
in	O
the	O
rate	B-C0870882
of	O
change	O
in	O
organ	B-C1450569
size	I-C1450569
and	O
function	B-C0542341
.	O
	
they	O
also	O
suggest	O
that	O
maximal	B-C0205289
metabolic	B-C0311400
capacity	B-C1516240
is	O
lost	B-C0745777
faster	O
in	O
a	O
warm	B-C0563030
environment	I-C0563030
than	O
it	O
is	O
gained	B-C1517378
in	O
a	O
cold	B-C0241842
environment	I-C0241842
.	O
	
with	O
the	O
expected	O
increase	O
in	O
temperature	B-C0039476
stochasticity	B-C0038347
at	O
northern	B-C0017446
latitudes	I-C0017446
,	O
a	O
loss	B-C1517945
of	O
thermogenic	B-C0018837
capacity	B-C1516240
during	O
warm	B-C0563030
winter	B-C0241737
days	B-C0439228
could	O
,	O
therefore	O
,	O
be	O
detrimental	O
if	O
birds	B-C0005595
are	O
slow	O
to	O
readjust	O
their	O
phenotype	B-C0031437
with	O
the	O
return	O
of	O
cold	B-C0241842
days	B-C0439228
.	O
	
a	O
prime	B-C3825344
a	O
day	O
keeps	O
calories	B-C1556156
away	O
the	O
effects	B-C1704420
of	I-C1704420
supraliminal	B-C3825344
priming	I-C3825344
on	O
food	B-C2983605
consumption	I-C2983605
and	O
the	O
moderating	B-C1704326
role	I-C1704326
of	O
gender	B-C0079399
and	O
eating	B-C0451424
restraint	I-C0451424
the	O
link	O
between	O
intentions	B-C0162425
and	O
action	B-C3266814
in	O
weight	B-C0920298
control	I-C0920298
is	O
weaker	O
than	O
previously	O
thought	O
,	O
so	O
recent	O
research	B-C0035168
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-C0920298
control	I-C0920298
that	O
bypass	O
conscious	B-C0234421
intentions	B-C0162425
.	O
	
priming	B-C3825344
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	B-C0038535
cognition	B-C0009240
.	O
	
this	O
paper	O
investigates	O
the	O
effects	B-C1704420
of	I-C1704420
semantic	B-C0871332
priming	I-C0871332
using	O
healthy	B-C3898900
body	B-C0005891
image	I-C0005891
,	O
goal-oriented	B-C0042926
words	I-C0042926
on	O
food	B-C2983605
consumption	I-C2983605
.	O
	
the	O
moderating	B-C1704326
role	I-C1704326
of	O
both	O
restrained	B-C0451424
eating	I-C0451424
and	O
gender	B-C0079399
is	O
investigated	O
.	O
	
161	O
participants	B-C0679646
were	O
involved	O
in	O
an	O
experiment	B-C0681814
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	B-C0876929
priming	B-C3825344
game	B-C0150593
.	O
	
the	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	B-C0439259
consumed	B-C0513065
,	O
examined	O
using	O
a	O
between	O
subjects	O
ancova	B-C0814908
with	O
priming	B-C3825344
,	O
gender	B-C0079399
,	O
restrained	B-C0451424
eating	I-C0451424
index	I-C0451424
,	O
self-reported	B-C2700446
bmi	B-C1305855
,	O
and	O
two	O
interaction	B-C1704675
terms	O
priming	B-C3825344
x	O
gender	B-C0079399
,	O
and	O
priming	B-C3825344
x	O
restrained	B-C0451424
eating	I-C0451424
index	I-C0451424
.	O
	
there	O
was	O
no	O
main	O
effect	B-C1704420
of	I-C1704420
priming	B-C3825344
but	O
there	O
was	O
an	O
interaction	B-C1704675
of	O
priming	B-C3825344
with	O
gender	B-C0079399
.	O
	
females	B-C0086287
consumed	O
significantly	O
fewer	O
kilocalories	B-C0439259
after	O
being	O
exposed	O
to	O
priming	B-C3825344
words	B-C0042926
related	O
to	O
a	O
healthy	B-C3898900
body	B-C0005891
image	I-C0005891
i.e	O
.	O
	
"""slim"""	O
,	O
"""fit"	O
compared	O
to	O
females	B-C0086287
receiving	O
the	O
neutral	O
prime	B-C3825344
,	O
with	O
a	O
medium	O
effect	O
size	O
d	O
=	O
0.58	O
.	O
	
the	O
body	B-C0005891
image	I-C0005891
prime	B-C3825344
did	O
not	O
significantly	O
affect	O
food	B-C0013470
intake	I-C0013470
for	O
males	B-C0086582
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained	B-C0679646
eaters	I-C0679646
.	O
	
this	O
study	O
shows	O
that	O
priming	B-C3825344
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	B-C0086287
to	O
reduce	O
food	B-C0013470
intake	I-C0013470
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	B-C0679646
or	O
unrestrained	B-C0679646
eaters	I-C0679646
.	O
	
future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	B-C3825344
words	B-C0042926
related	O
to	O
a	O
male's	B-C0086582
healthy	B-C3898900
body	B-C0005891
image	I-C0005891
goal	O
i.e	O
.	O
	
"""buff"	O
""""	O
muscles	B-C0026845
""""	O
etc	O
would	O
similarly	O
reduce	O
food	B-C0013470
intake	I-C0013470
for	O
neurotrophins	B-C0027754
and	O
specific	B-C0254837
receptors	I-C0254837
in	O
the	O
oviduct	B-C0029954
tracts	I-C0029954
of	O
japanese	B-C0022345
quail	I-C0022345
coturnix	B-C0022345
coturnix	I-C0022345
japonica	I-C0022345
neurotrophins	B-C0027754
ngf	B-C0027752
,	O
bdnf	B-C0107103
and	O
nt-3	B-C0083735
and	O
their	O
specific	B-C0254837
receptors	I-C0254837
trka	B-C0072482
,	O
trkb	B-C0084873
and	O
trkc	B-C0132300
were	O
studied	B-C2603343
in	O
the	O
oviduct	B-C0029954
of	O
egg	B-C1622979
laying	I-C1622979
quails	B-C0022345
.	O
	
neurotrophins	B-C0027754
nts	B-C0027754
are	O
mainly	O
involved	O
in	O
the	O
development	B-C1527148
and	O
maintenance	B-C0587894
of	O
neuronal	B-C0027882
populations	I-C0027882
in	O
the	O
central	B-C3714787
and	O
peripheral	B-C0206417
nervous	I-C0206417
system	I-C0206417
,	O
but	O
also	O
in	O
reproductive	B-C1261210
system	I-C1261210
.	O
	
in	O
this	O
survey	O
,	O
we	O
first	O
studied	B-C2603343
the	O
morphological	B-C0332437
organization	B-C0029237
of	O
the	O
quail	B-C0022345
oviduct	B-C0029954
,	O
distinguished	O
in	O
infundibulum	B-C0227911
,	O
magnum	B-C0229962
,	O
isthmus	B-C0227909
,	O
uterus	B-C0042149
and	O
vagina	B-C0042232
,	O
and	O
then	O
we	O
analyzed	B-C0936012
the	O
expression	B-C1171362
and	O
localization	B-C0007613
of	O
nts	B-C0027754
and	O
trks	B-C0254837
receptors	I-C0254837
in	O
the	O
whole	O
tracts	B-C0029954
.	O
	
by	O
western	B-C0005863
blotting	I-C0005863
we	O
detected	O
that	O
the	O
investigated	B-C1292732
nts	B-C0027754
and	O
trks	B-C0254837
receptors	I-C0254837
are	O
expressed	B-C1171362
in	O
all	O
oviductal	B-C0029954
tracts	I-C0029954
.	O
	
by	O
immunohistochemistry	B-C0021044
we	O
were	O
able	O
to	O
define	O
the	O
distribution	B-C0872250
of	O
nts	B-C0027754
and	O
trks	B-C0254837
.	O
	
specifically	O
,	O
ngf	B-C0027752
,	O
bdnf	B-C0107103
and	O
nt3	B-C0083735
were	O
localized	O
in	O
lining	B-C1254362
and	O
ductal	B-C1512085
epithelial	I-C1512085
cells	I-C1512085
,	O
and	O
ngf	B-C0027752
was	O
also	O
detected	O
in	O
secretory	B-C1519221
cells	I-C1519221
of	O
tubular	B-C1179446
glands	I-C1179446
and	O
in	O
nervous	B-C0027749
fibers	I-C0027749
of	O
vessel	B-C0507777
wall	I-C0507777
.	O
	
trka	B-C0072482
and	O
trkb	B-C0084873
were	O
present	O
in	O
the	O
lining	B-C1254362
and	O
ductal	B-C1512086
epithelium	I-C1512086
trka	B-C0072482
and	O
trkc	B-C0132300
were	O
present	O
in	O
nervous	B-C0027749
fibers	I-C0027749
of	O
vessel	B-C0507777
wall	I-C0507777
in	O
all	O
oviductal	B-C0029954
tracts	I-C0029954
.	O
	
furthermore	O
,	O
we	O
also	O
observed	O
ngf	B-C0027752
and	O
bdnf	B-C0107103
co-localized	O
with	O
trka	B-C0072482
and	O
trkb	B-C0084873
in	O
cells	B-C0007634
of	O
the	O
lining	B-C1254362
and	O
ductal	B-C1512086
epithelium	I-C1512086
,	O
suggesting	O
an	O
autocrine	B-C3825249
mechanism	I-C3825249
of	O
the	O
influence	O
of	O
liposomal	B-C0023828
formulation	B-C1705957
on	O
the	O
incorporation	B-C0243126
and	O
retention	B-C0333117
of	O
pna	B-C0600500
oligomers	I-C0600500
liposomal	B-C0023828
formulations	B-C1705957
composed	O
of	O
phospholipids	B-C0031676
with	O
different	O
unsaturation	B-C0522535
degrees	I-C0522535
,	O
head	B-C0205245
groups	I-C0205245
and	O
at	O
different	O
cholesterol	B-C0201950
content	I-C0201950
have	I-C0201950
been	I-C0201950
tested	I-C0201950
for	O
the	O
encapsulation	B-C2348438
of	O
peptide	B-C0600500
nucleic	I-C0600500
acid	I-C0600500
pna	I-C0600500
oligomers	I-C0600500
.	O
	
the	O
best	B-C3714444
loading	I-C3714444
capability	I-C3714444
177μg	O
,	O
er	B-C0456603
%=87	O
was	O
obtained	O
for	O
pure	O
liposomes	B-C0023828
of	O
phosphatidylglycerol	B-C0043840
dopg	B-C0043840
with	O
negatively	B-C0003075
charged	I-C0003075
head	B-C0205245
group	I-C0205245
.	O
	
the	O
insertion	B-C0441587
of	O
a	O
10-20%	O
of	O
cholesterol	B-C0008377
in	O
dopg	B-C0043840
based	O
liposomes	B-C0023828
provides	O
a	O
slight	O
decrease	B-C0547047
160μg	O
of	O
the	O
pna	B-C0600500
loading	B-C1708715
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
cholesterol	B-C0008377
addition	B-C1524062
20-30%	O
slows	O
down	O
the	O
pna's	B-C0600500
release	B-C3850077
27%	O
in	O
fetal	B-C3812213
bovine	I-C3812213
serum	I-C3812213
from	O
the	O
liposomal	B-C0023828
formulation	B-C1705957
.	O
	
based	O
on	O
the	O
encapsulation	B-C2348438
and	O
the	O
release	B-C3850077
properties	I-C3850077
,	O
pegylated	B-C0032483
dopg	B-C0043840
liposomes	B-C0023828
with	O
a	O
percentage	O
of	O
cholesterol	B-C0008377
of	O
10-20%	O
are	O
the	O
optimal	B-C0524527
formulation	I-C0524527
for	O
the	O
loading	B-C1708715
of	O
histopathology	B-C0677043
of	O
the	O
filum	B-C0016109
terminale	I-C0016109
in	O
children	B-C0008059
with	O
and	O
without	B-C0332288
tethered	B-C0080218
cord	I-C0080218
syndrome	I-C0080218
with	O
attention	O
to	O
the	O
elastic	B-C0013762
tissue	I-C0013762
within	O
the	O
filum	B-C0016109
to	O
compare	B-C1707455
histologically	B-C0205462
transected	B-C0332847
fila	B-C0016109
from	O
pediatric	B-C1521725
patients	B-C0030705
with	O
tethered	B-C0080218
cord	I-C0080218
syndrome	I-C0080218
tcs	B-C0080218
,	O
with	O
and	O
without	B-C0332288
a	O
low	B-C1548802
conus	B-C0149601
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	B-C0225333
and	O
elastic	B-C0013762
tissue	I-C0013762
.	O
	
thirty	O
fila	B-C0016109
from	O
patients	B-C0030705
with	O
tcs	B-C0080218
,	O
including	O
5	O
where	O
minimal	B-C0547040
cautery	B-C0007471
was	O
used	O
prior	O
to	O
filum	B-C0016109
section	B-C0700320
,	O
were	O
compared	B-C1707455
with	O
fila	B-C0016109
from	O
27	O
pediatric	B-C1521725
cadavers	B-C0006629
without	B-C0332288
tcs	B-C0080218
controls	B-C0009932
.	O
	
sections	B-C1522472
of	O
fila	B-C0016109
were	O
stained	B-C0487602
with	O
h	B-C0523207
,	O
masson	B-C1294297
trichrome	I-C1294297
and	O
verhoeff	B-C1294321
von	I-C1294321
gieson	I-C1294321
elastic	I-C1294321
stains	I-C1294321
,	O
and	O
7	O
with	O
gordon	B-C1293950
and	I-C1293950
sweet's	I-C1293950
reticulin	I-C1293950
stain	I-C1293950
.	O
	
fila	B-C0016109
from	O
controls	B-C0009932
showed	O
loose	B-C0205407
fibrous	B-C1184823
connective	I-C1184823
tissue	I-C1184823
fct	B-C1184823
with	O
thin	B-C0205168
and	O
evenly	B-C1704711
dispersed	I-C1704711
elastic	B-C0230899
fibers	I-C0230899
efs	B-C0230899
.	O
	
reticulin	B-C0035285
fibers	I-C0035285
rfs	B-C0035285
were	O
seen	O
in	O
blood	B-C1180033
vessel	I-C1180033
walls	I-C1180033
and	O
nerve	B-C0027740
twigs	O
.	O
	
fat	B-C0015677
was	O
identified	B-C0205396
microscopically	B-C0205288
in	O
2	O
fila	B-C0016109
.	O
	
all	O
fila	B-C0016109
from	O
patients	B-C0030705
with	O
tcs	B-C0080218
had	O
dense	B-C0225333
fct	I-C0225333
.	O
	
the	O
efs	B-C0230899
were	O
in	O
normal	B-C0205307
numbers	O
in	O
17	O
,	O
and	O
focally	B-C0205234
or	O
diffusely	B-C0332261
decreased	B-C0205216
in	O
13	O
.	O
	
all	O
25	O
patients	B-C0030705
where	O
the	O
fila	B-C0016109
were	O
cauterized	B-C0007471
during	O
resection	B-C0728940
had	O
thick	B-C1280412
and	O
coiled	B-C1880179
efs	B-C0230899
.	O
	
coiling	B-C0444764
was	O
not	O
seen	O
when	O
minimal	B-C0547040
cautery	B-C0007471
was	O
applied	O
.	O
	
rfs	B-C0035285
were	O
seen	O
in	O
blood	B-C1180033
vessel	I-C1180033
walls	I-C1180033
and	O
nerve	O
twigs	O
.	O
	
fat	B-C0015677
was	O
identified	B-C0205396
in	O
19	O
patients	B-C0030705
.	O
	
findings	B-C0243095
were	O
similar	B-C2348205
,	O
whether	O
the	O
conus	B-C0149601
termination	O
was	O
normal	B-C0205307
or	O
low	B-C0441994
.	O
	
the	O
fila	B-C0016109
of	O
all	O
patients	B-C0030705
with	O
tcs	B-C0080218
,	O
whether	O
or	O
not	O
the	O
conus	B-C0149601
was	O
low	B-C0441994
,	O
showed	O
abnormal	B-C0205161
fct	B-C1184823
.	O
	
efs	B-C0230899
were	O
decreased	B-C0205216
in	O
48	O
%	O
of	O
patients	B-C0030705
however	O
,	O
there	O
were	O
thick	B-C1280412
and	O
coiled	B-C1880179
efs	B-C0230899
in	O
all	O
patients	B-C0030705
.	O
	
coiling	B-C0444764
of	O
efs	B-C0230899
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	B-C1704258
in	O
patients	B-C0030705
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	B-C0808233
of	O
cautery	B-C0007471
i.e	O
,	O
artifactual	B-C0085089
/	O
iatrogenic	B-C0439669
coiling	B-C0444764
.	O
	
clinical	B-C2826293
value	I-C2826293
of	O
pathologic	B-C4086729
examination	I-C4086729
of	O
non-neoplastic	B-C0022646
kidney	I-C0022646
in	O
patients	B-C0030705
with	O
upper	B-C1278977
urinary	I-C1278977
tract	I-C1278977
malignancies	B-C4282132
while	O
surgical	B-C0728940
resection	I-C0728940
remains	O
the	O
standard	O
of	O
care	B-C1947933
in	O
the	O
treatment	B-C0087111
of	O
upper	B-C1278977
urinary	I-C1278977
tract	I-C1278977
malignancies	B-C4282132
,	O
nephrectomy	B-C0027695
is	O
a	O
risk	B-C0035648
factor	I-C0035648
for	O
the	O
development	B-C1527148
of	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
ckd	B-C1561643
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
whether	O
histologic	B-C0205462
evaluation	B-C0220825
of	O
non-neoplastic	B-C0022646
kidney	I-C0022646
could	O
enable	O
early	B-C0814435
identification	I-C0814435
of	O
unrecognized	O
kidney	B-C0022658
disease	I-C0022658
and	O
could	O
be	O
of	O
prognostic	B-C0220901
value	O
in	O
predicting	O
postoperative	B-C0032790
renal	B-C0022646
outcomes	B-C0085415
.	O
	
we	O
retrospectively	B-C0035363
analyzed	I-C0035363
51	O
patients	B-C0030705
with	O
upper	B-C1278977
urinary	I-C1278977
tract	I-C1278977
malignancies	B-C4282132
who	O
received	O
uninephrectomy	B-C0027695
or	O
uninephroureterectomy	B-C0027732
.	O
	
a	O
thorough	O
pathologic	B-C1521733
evaluation	B-C0220825
of	O
non-neoplastic	B-C0022646
kidney	I-C0022646
including	O
special	B-C2038188
stains	I-C2038188
,	O
immunofluorescence	B-C0079603
,	O
and	O
electron	B-C0026019
microscopic	I-C0026019
studies	I-C0026019
was	O
performed	O
.	O
	
the	O
degree	B-C0449286
of	O
parenchymal	B-C0933845
changes	B-C0392747
was	O
graded	O
from	O
0	O
to	O
15	O
.	O
	
of	O
51	O
patients	B-C0030705
,	O
only	O
13	O
showed	O
normal	O
kidney	B-C0022646
pathology	B-C0030664
.	O
	
fifteen	O
patients	B-C0030705
showed	O
glomerular	B-C1398788
abnormalities	I-C1398788
,	O
14	O
showed	O
diabetic	B-C0011881
nephropathy	I-C0011881
,	O
and	O
11	O
showed	O
vascular	B-C0005847
nephropathy	B-C0027695
.	O
	
there	O
was	O
one	O
case	O
each	O
of	O
reflux	B-C3495566
nephropathy	I-C3495566
and	O
chronic	B-C0085697
pyelonephritis	I-C0085697
.	O
	
the	O
median	O
histologic	B-C0449820
score	I-C0449820
was	O
5	O
points	O
.	O
	
only	O
25.4	O
of	O
patients	B-C0030705
had	O
3	O
points	O
.	O
	
score	B-C0449820
more	O
than	O
5	O
was	O
observed	O
in	O
47.1	O
of	O
patients	B-C0030705
.	O
	
postoperative	B-C0032790
estimated	B-C3811844
glomerular	I-C3811844
filtration	I-C3811844
rate	I-C3811844
egfr	B-C3811844
at	O
3	O
to	O
36	O
months	B-C0439231
were	O
obtained	O
from	O
90.2	O
of	O
patients	B-C0030705
,	O
and	O
of	O
those	O
,	O
34.8	O
had	O
de	O
novo	O
ckd	B-C1561643
.	O
	
since	O
no	O
one	O
had	O
ckd	B-C1561643
in	O
partial	O
nephrectomized	B-C0030705
patients	I-C0030705
,	O
we	O
determined	O
risk	B-C0035648
factors	I-C0035648
for	O
ckd	B-C1561643
in	O
radical	O
nephrectomized	B-C0030705
patients	I-C0030705
.	O
	
cox	B-C0034980
regression	I-C0034980
analysis	I-C0034980
revealed	O
that	O
postoperative	B-C0032790
aki	B-C2609414
,	O
preoperative	B-C0445204
egfr	B-C3811844
,	O
and	O
histologic	B-C0205462
score	O
of	O
non-neoplastic	B-C0022646
kidney	I-C0022646
were	O
the	O
independent	O
predictors	B-C2698872
for	O
ckd	B-C1561643
.	O
	
we	O
conclude	O
that	O
routine	O
pathologic	B-C1521733
evaluation	B-C0220825
of	O
non-neoplastic	B-C0022646
kidney	I-C0022646
provides	O
valuable	O
diagnostic	B-C0348026
and	O
prognostic	B-C0220901
concordant	O
but	O
varied	O
phenotypes	B-C0031437
among	O
duchenne	B-C0013264
muscular	I-C0013264
dystrophy	I-C0013264
patient	B-C0030705
-specific	O
myoblasts	B-C0596995
derived	O
using	O
a	O
human	B-C0086418
ipsc	B-C2717959
-based	O
model	B-C0684309
duchenne	B-C0013264
muscular	I-C0013264
dystrophy	I-C0013264
dmd	B-C0013264
remains	O
an	O
intractable	O
genetic	B-C0019247
disease	I-C0019247
.	O
	
althogh	O
there	O
are	O
several	O
animal	B-C0012644
models	I-C0012644
of	O
dmd	B-C0013264
,	O
there	O
is	O
no	O
human	B-C0682523
cell	I-C0682523
model	O
that	O
carries	O
patient	B-C0030705
-specific	O
dystrophin	B-C1414083
mutations	B-C0596611
.	O
	
here	O
,	O
we	O
present	O
a	O
human	B-C0086418
dmd	B-C0013264
model	B-C0684309
using	O
human	B-C3658289
induced	I-C3658289
pluripotent	I-C3658289
stem	I-C3658289
cells	I-C3658289
hipscs	B-C3658289
.	O
	
our	O
model	O
reveals	O
concordant	O
disease	B-C0012634
-	O
related	B-C1552599
phenotypes	B-C0031437
with	O
patient	B-C0030705
-	O
dependent	B-C0851827
variation	B-C0205419
,	O
which	O
are	O
partially	O
reversed	O
by	O
genetic	B-C0314603
and	O
pharmacological	B-C0205464
approaches	O
.	O
	
our	O
""""	O
chemical-compound	B-C0220806
"-based"""	O
strategy	B-C0035171
successfully	O
directs	O
hipscs	B-C3658289
into	O
expandable	O
myoblasts	B-C0596995
,	O
which	O
exhibit	O
a	O
myogenic	B-C0040649
transcriptional	I-C0040649
program	B-C3484370
,	O
forming	O
striated	B-C0205364
contractile	B-C1752744
myofibers	B-C3179197
and	O
participating	O
in	O
muscle	B-C1850849
regeneration	I-C1850849
in	B-C1515655
vivo	I-C1515655
.	O
	
dmd	B-C0013264
-	O
hipsc	B-C3658289
-derived	O
myoblasts	B-C0596995
show	O
disease	B-C0012634
-	O
related	B-C1552599
phenotypes	B-C0031437
with	O
patient	B-C0030705
-to-	O
patient	B-C0030705
variability	B-C2827666
,	O
including	O
aberrant	B-C0443127
expression	O
of	O
inflammation	B-C0021368
or	O
immune-response	B-C0086344
genes	I-C0086344
and	O
collagens	B-C0009325
,	O
increased	O
bmp	B-C1155364
/	O
tgfβ	B-C1155363
signaling	I-C1155363
,	O
and	O
reduced	O
fusion	O
competence	O
.	O
	
furthermore	O
,	O
by	O
genetic	B-C0314603
correction	B-C1947976
and	O
pharmacological	B-C0205464
"""dual-"	O
smad	B-C1571580
""""	O
inhibition	B-C1519312
,	O
the	O
dmd	B-C0013264
-	O
hipsc	B-C3658289
-derived	O
myoblasts	B-C0596995
and	O
genetically	B-C0314603
corrected	O
isogenic	B-C2348628
myoblasts	B-C0596995
form	O
"""rescued"""	O
multi	B-C0439064
-	O
nucleated	B-C1979936
myotubes	B-C0242697
.	O
	
in	O
conclusion	O
,	O
our	O
findings	O
demonstrate	O
the	O
feasibility	O
of	O
establishing	O
a	O
human	B-C0086418
""""	O
dmd	B-C0013264
"-in-a-dish"""	O
model	B-C0684309
using	O
hipsc	B-C3658289
-based	O
disease	B-C0684309
modeling	I-C0684309
.	O
	
snai1	B-C4308198
promotes	B-C0033414
the	O
development	B-C1527148
of	O
hcc	B-C2239176
through	O
the	O
enhancement	B-C2349975
of	O
proliferation	B-C1514485
and	O
inhibition	B-C1512772
of	I-C1512772
apoptosis	I-C1512772
snai1	B-C4308198
,	O
a	O
zinc-finger	B-C0040648
transcription	I-C0040648
factor	I-C0040648
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	B-C0205263
of	O
epithelial-mesenchymal	B-C1523298
transition	I-C1523298
emt	B-C1523298
in	O
various	O
cancers	B-C0006826
.	O
	
however	O
,	O
the	O
possible	O
functions	O
of	O
snai1	B-C4308198
in	O
the	O
proliferation	B-C1514485
and	O
apoptosis	B-C0162638
of	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
have	O
not	O
been	O
clearly	O
identified	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
investigated	O
the	O
effects	B-C1280500
and	O
mechanisms	B-C0441712
of	O
snai1	B-C4308198
in	O
the	O
proliferation	B-C1514485
and	O
apoptosis	B-C0162638
of	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
using	O
clinical	B-C0205210
samples	B-C0370003
and	O
cell	B-C0085983
lines	I-C0085983
.	O
	
we	O
found	O
that	O
snai1	B-C4308198
is	O
highly	O
expressed	B-C1171362
in	O
the	O
tissues	B-C0040300
of	O
liver	B-C2239176
cancer	I-C2239176
compared	O
with	O
adjacent	O
nontumor	B-C0040300
tissues	I-C0040300
.	O
	
snai1	B-C4308198
is	O
also	O
highly	O
expressed	B-C1171362
in	O
the	O
hepatoma	B-C2717940
cell	I-C2717940
lines	I-C2717940
hepg2	I-C2717940
,	O
smmc-7721	B-C0085983
,	O
and	O
bel-7402	B-C0085983
compared	O
with	O
the	O
human	B-C0682523
normal	I-C0682523
liver	I-C0682523
cell	I-C0682523
line	I-C0682523
l02	I-C0682523
.	O
	
we	O
also	O
observed	O
that	O
snai1	B-C4308198
expression	B-C1171362
was	O
correlated	O
with	O
distal	B-C4255448
metastasis	I-C4255448
,	O
incomplete	O
tumor	B-C0027671
capsule	I-C0027671
formation	I-C0027671
,	O
and	O
histological	B-C1511938
differentiation	I-C1511938
in	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
hcc	B-C2239176
.	O
	
moreover	O
,	O
we	O
demonstrated	O
that	O
knockdown	B-C2350567
of	O
snai1	B-C1420267
via	O
lentiviral	B-C0079679
vectors	B-C1520007
of	O
rnai	B-C1136031
against	O
snai	B-C4308198
inhibited	O
cell	B-C1514485
proliferation	I-C1514485
by	O
inducing	O
g1	B-C3178834
arrest	I-C3178834
,	O
which	O
was	O
accompanied	O
by	O
the	O
downregulation	B-C0013081
of	O
cyclin	B-C0174680
d1	I-C0174680
but	O
not	O
that	O
of	O
cyclin	B-C0079184
a	I-C0079184
.	O
	
in	O
addition	O
,	O
knockdown	B-C2350567
of	O
snai1	B-C1420267
promoted	B-C0033414
apoptosis	B-C0162638
by	O
decreasing	O
the	O
expression	B-C1171362
of	O
bcl-2	B-C4042483
.	O
	
in	O
conclusion	O
,	O
our	O
findings	O
revealed	O
that	O
snai1	B-C4308198
is	O
involved	O
in	O
the	O
development	B-C1527148
of	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
via	O
regulating	B-C1160191
the	I-C1160191
growth	I-C1160191
and	O
apoptosis	B-C0162638
of	O
tumor	B-C0597032
cells	I-C0597032
.	O
	
quantitative	B-C0034384
assessment	I-C0034384
of	O
fluorescent	B-C0033684
proteins	I-C0033684
the	O
advent	O
of	O
fluorescent	B-C0033684
proteins	I-C0033684
fps	B-C0033684
for	O
genetic	B-C1513384
labeling	I-C1513384
of	O
molecules	B-C0567416
and	O
cells	B-C0007634
has	O
revolutionized	O
fluorescence	B-C0026022
microscopy	I-C0026022
.	O
	
genetic	B-C0178659
manipulations	I-C0178659
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
fps	B-C0033684
spanning	O
blue	B-C1254362
to	I-C1254362
red	I-C1254362
spectral	I-C1254362
regions	I-C1254362
.	O
	
common	O
to	O
autofluorescent	B-C0544711
fps	B-C0033684
is	O
their	O
tight	O
β-barrel	B-C0599216
structure	I-C0599216
,	O
which	O
provides	O
the	O
rigidity	B-C0205556
and	O
chemical	B-C0220806
environment	B-C0014406
needed	O
for	O
effectual	O
fluorescence	B-C0016315
.	O
	
despite	O
the	O
common	O
structure	B-C0026383
,	O
each	O
fp	B-C0033684
has	O
unique	O
properties	B-C0871161
.	O
	
thus	O
,	O
there	O
is	O
no	O
single	O
'best'	O
fp	B-C0033684
for	O
every	O
circumstance	O
,	O
and	O
each	O
fp	B-C0033684
has	O
advantages	O
and	O
disadvantages	O
.	O
	
to	O
guide	O
decisions	O
about	O
which	O
fp	B-C0033684
is	O
right	O
for	O
a	O
given	O
application	O
,	O
we	O
have	O
quantitatively	B-C0392762
characterized	O
the	O
brightness	B-C0678578
,	O
photostability	B-C0243095
,	O
ph	B-C0020283
stability	B-C0205360
and	O
monomeric	B-C0596973
properties	B-C0871161
of	O
more	O
than	O
40	O
fps	B-C0033684
to	O
enable	O
straightforward	B-C1272701
and	O
direct	O
comparison	B-C1707455
between	O
them	O
.	O
	
we	O
focus	O
on	O
popular	O
and/or	O
top-performing	O
fps	B-C0033684
in	O
each	O
spectral	B-C1254362
region	I-C1254362
.	O
	
consumption	B-C1271941
of	I-C1271941
fruits	I-C1271941
and	I-C1271941
vegetables	I-C1271941
associated	B-C0332281
with	I-C0332281
other	O
risk	B-C0086931
behaviors	I-C0086931
among	O
adolescents	B-C0205653
in	O
northeast	B-C0006137
brazil	I-C0006137
to	O
determine	O
the	O
prevalence	B-C0220900
of	O
consumption	B-C1271941
of	I-C1271941
fruits	I-C1271941
and	I-C1271941
vegetables	I-C1271941
and	O
identify	O
the	O
association	B-C0332281
with	I-C0332281
low	B-C0205251
level	B-C0441889
of	O
physical	B-C0026606
activity	I-C0026606
,	O
exposure	B-C0332157
to	I-C0332157
sedentary	B-C3824706
behavior	I-C3824706
,	O
consumption	B-C2983605
of	O
soft	B-C3489624
drinks	I-C3489624
and	O
overweight	B-C0497406
/	O
obesity	B-C0028754
in	O
adolescents	B-C0205653
.	O
	
this	O
is	O
a	O
cross-sectional	B-C0010362
school-based	I-C0010362
study	I-C0010362
with	O
a	O
representative	O
sample	B-C0370003
of	O
3992	O
students	B-C0038492
aged	O
14-19	O
years	B-C1510829
from	O
the	O
state	B-C1301808
of	I-C1301808
sergipe	I-C1301808
,	O
brazil	B-C0006137
.	O
	
the	O
outcome	B-C1274040
was	O
low	B-C0205251
consumption	B-C1271941
of	I-C1271941
fruits	I-C1271941
and	I-C1271941
vegetables	I-C1271941
<5	O
servings/day	B-C0439505
.	O
	
independent	B-C0870693
variables	I-C0870693
were	O
level	B-C0441889
of	O
physical	B-C0026606
activity	I-C0026606
,	O
sedentary	B-C3824706
behavior	I-C3824706
,	O
consumption	B-C2983605
of	O
soft	B-C3489624
drinks	I-C3489624
,	O
and	O
overweight	B-C0497406
/	O
obesity	B-C0028754
.	O
	
global	B-C0034394
student	I-C0034394
health	I-C0034394
survey	I-C0034394
questionnaire	I-C0034394
and	O
body	B-C3698309
mass	I-C3698309
and	O
height	B-C0005890
measurements	B-C0947289
were	O
used	O
,	O
as	O
well	O
as	O
chi-square	B-C0008041
test	I-C0008041
and	O
crude	B-C0206031
and	I-C0206031
adjusted	I-C0206031
binary	I-C0206031
logistic	I-C0206031
regression	I-C0206031
.	O
	
the	O
significance	B-C0814896
level	I-C0814896
adopted	O
was	O
5%	O
.	O
	
the	O
prevalence	B-C0220900
of	O
inadequate	B-C0205412
consumption	B-C1271941
of	I-C1271941
fruits	I-C1271941
and	I-C1271941
vegetables	I-C1271941
was	O
high	B-C0205250
-	O
88.6	O
95%	O
ci	B-C0009667
=87	O
.	O
	
higher	B-C0205250
likelihood	O
of	O
low	B-C0205251
consumption	B-C1271941
of	I-C1271941
fruits	I-C1271941
and	I-C1271941
vegetables	I-C1271941
was	O
verified	O
among	O
boys	B-C0870221
who	O
were	O
exposed	B-C0332157
to	I-C0332157
sedentary	B-C3824706
behavior	I-C3824706
or	B-C0028873
=1	O
95%	O
ci	B-C0009667
=1	O
,	O
who	O
consumed	B-C2983605
soft	B-C3489624
drinks	I-C3489624
or	B-C0028873
=3	O
95%	O
ci	B-C0009667
=2	O
,	O
with	O
insufficiently	B-C0231180
physical	B-C0026606
activity	I-C0026606
or	B-C0028873
=1	O
95%	O
ci	B-C0009667
=1	O
and	O
girls	B-C0870604
who	O
consumed	B-C2983605
soft	B-C3489624
drinks	I-C3489624
or	B-C0028873
=1	O
95%	O
ci	B-C0009667
=1	O
and	O
those	O
with	O
overweight	B-C0497406
/	O
obesity	B-C0028754
or	B-C0028873
=1	O
95%	O
ci	B-C0009667
=1	O
.	O
	
there	O
is	O
a	O
need	O
of	O
public	B-C0034033
policies	I-C0034033
aimed	O
at	O
encouraging	O
the	O
consumption	B-C2983605
of	I-C2983605
healthy	I-C2983605
foods	I-C2983605
among	O
cobalamin	B-C0086024
protection	B-C1545588
against	O
oxidative	B-C0242606
stress	I-C0242606
in	O
the	O
acidophilic	B-C0333931
iron-oxidizing	B-C0004611
bacterium	I-C0004611
leptospirillum	B-C2758310
group	I-C2758310
ii	I-C2758310
cf-1	I-C2758310
members	O
of	O
the	O
genus	O
leptospirillum	B-C0995279
are	O
aerobic	B-C1510824
iron-oxidizing	B-C0004611
bacteria	I-C0004611
belonging	O
to	O
the	O
phylum	B-C0995591
nitrospira	I-C0995591
.	O
	
they	O
are	O
important	O
members	O
of	O
microbial	B-C0599840
communities	B-C1253910
that	O
catalyze	B-C2350294
the	O
biomining	B-C0026175
of	O
sulfidic	B-C0567321
ores	I-C0567321
,	O
thereby	O
solubilizing	O
metal	B-C0022023
ions	I-C0022023
.	O
	
these	O
microorganisms	B-C0445623
live	O
under	O
extremely	O
acidic	O
and	O
metal	B-C0025552
-loaded	O
environments	B-C0014406
and	O
thus	O
must	O
tolerate	O
high	O
concentrations	B-C1446561
of	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
.	O
	
cobalamin	B-C0086024
vitamin	B-C0042845
b12	I-C0042845
is	O
a	O
cobalt	B-C0009148
-containing	O
tetrapyrrole	B-C0076335
cofactor	B-C0178555
involved	O
in	O
intramolecular	B-C0596965
rearrangement	I-C0596965
reactions	I-C0596965
and	O
has	O
recently	O
been	O
suggested	O
to	O
be	O
an	O
intracellular	B-C0178719
antioxidant	B-C0003402
.	O
	
in	O
this	O
work	O
,	O
we	O
investigated	B-C1292732
the	O
effect	B-C1280500
of	O
the	O
exogenous	B-C0205228
addition	O
of	O
cobalamin	B-C0086024
on	O
oxidative	B-C0242606
stress	I-C0242606
parameters	B-C0549193
in	O
leptospirillum	B-C2758310
group	I-C2758310
ii	I-C2758310
strain	I-C2758310
cf-1	I-C2758310
.	O
	
our	O
results	O
revealed	B-C0443289
that	O
the	O
external	B-C0681579
supplementation	I-C0681579
of	O
cobalamin	B-C0086024
reduces	O
the	O
levels	O
of	O
intracellular	B-C0178719
ross	B-C0162772
and	O
the	O
damage	B-C1883709
to	O
biomolecules	B-C0574031
,	O
and	O
also	O
stimulates	B-C1948023
the	O
growth	B-C0018270
and	O
survival	B-C0007620
of	I-C0007620
cells	I-C0007620
exposed	O
to	O
oxidative	B-C0242606
stress	I-C0242606
exerted	O
by	O
ferric	B-C2346593
ion	I-C2346593
,	O
hydrogen	B-C0020281
peroxide	I-C0020281
,	O
chromate	B-C0008543
and	O
diamide	B-C0011953
.	O
	
furthermore	O
,	O
exposure	O
of	O
strain	B-C0995279
cf-1	I-C0995279
to	O
oxidative	B-C0242606
stress	I-C0242606
elicitors	O
resulted	O
in	O
the	O
transcriptional	B-C0162493
activation	I-C0162493
of	O
the	O
cbia	B-C0017337
gene	I-C0017337
encoding	O
cbia	B-C0033684
of	O
the	O
cobalamin	B-C0086024
biosynthetic	B-C1721101
pathway	I-C1721101
.	O
	
altogether	O
,	O
these	O
data	B-C1511726
suggest	O
that	O
cobalamin	B-C0086024
plays	O
an	O
important	O
role	O
in	O
redox	B-C0030012
protection	B-C1545588
of	O
leptospirillum	B-C0995279
strain	I-C0995279
cf-1	I-C0995279
,	O
supporting	O
survival	O
of	O
this	O
microorganism	B-C0445623
under	O
extremely	O
oxidative	B-C0311404
environmental	B-C0348080
conditions	I-C0348080
.	O
	
understanding	O
the	O
mechanisms	B-C0441712
underlying	O
the	O
protective	B-C1545588
effect	B-C1280500
of	O
cobalamin	B-C0086024
against	O
oxidative	B-C0242606
stress	I-C0242606
may	O
help	O
to	O
develop	O
strategies	O
to	O
make	O
biomining	B-C0026175
processes	B-C1522240
more	O
a	O
longitudinal	B-C0023981
study	I-C0023981
assessing	O
childcare	B-C0683807
services'	B-C0557854
adoption	O
of	O
obesity	B-C0028754
prevention	B-C1254363
policies	I-C1254363
and	I-C1254363
practices	I-C1254363
despite	O
ongoing	O
investments	O
to	O
improve	O
the	O
obesogenic	B-C0028754
environments	B-C0014406
of	O
childcare	B-C0683807
settings	O
,	O
little	O
is	O
known	O
regarding	O
how	O
these	O
services	B-C0557854
have	O
changed	O
their	O
physical	B-C0026606
activity	I-C0026606
and	O
nutrition-promoting	B-C1521729
practices	I-C1521729
.	O
	
this	O
study	O
aims	O
to	O
describe	O
changes	O
in	O
the	O
proportion	O
of	O
australian	B-C0238711
childcare	B-C0683807
services	B-C0557854
that	O
have	O
adopted	O
best-practice	B-C1254363
healthy	B-C0452415
eating	I-C0452415
and	O
physical	B-C0026606
activity	I-C0026606
practices	B-C1254363
between	O
2006	O
and	O
2013	O
and	O
to	O
assess	O
whether	O
adoption	O
varied	O
by	O
socio-economic	B-C0086996
status	I-C0086996
and	O
locality	B-C1254362
.	O
	
a	O
randomly	B-C0150105
selected	I-C0150105
sample	I-C0150105
of	O
nominated	O
supervisors	B-C0403172
n	O
=	O
358	O
from	O
childcare	B-C0683807
services	B-C0557854
located	O
in	O
new	B-C0027975
south	I-C0027975
wales	I-C0027975
,	O
australia	B-C0004340
,	O
participated	O
in	O
a	O
telephone	B-C0681820
survey	I-C0681820
in	O
2006	O
,	O
2009	O
,	O
2010	O
and	O
2013	O
.	O
	
supervisors	B-C0403172
reported	O
on	O
their	O
service's	B-C0557854
adoption	O
of	O
six	O
practices	B-C1254363
i	O
having	O
written	O
nutrition	B-C1521729
and	O
physical	B-C0026606
activity	I-C0026606
policies	B-C0242456
ii	O
staff	B-C0851286
trained	O
in	O
physical	B-C0026606
activity	I-C0026606
and	O
nutrition	B-C1521729
in	O
the	O
past	O
year	O
iii	O
scheduled	O
time	B-C0040223
for	O
fundamental	O
movement	B-C0026649
skills	B-C0678856
and	O
iv	O
outdoor	B-C0032214
play	I-C0032214
v	O
weekly	B-C0332174
or	O
less	O
screen	B-C4038978
time	I-C4038978
opportunitie	I-C4038978
s	O
and	O
vi	O
serving	O
only	O
non-sweetened	B-C0005329
beverages	I-C0005329
.	O
	
a	O
significant	O
increase	O
in	O
the	O
prevalence	B-C0220900
of	O
services	B-C0557854
adopting	O
all	O
but	O
one	O
practice	B-C1254363
,	O
between	O
2006	O
and	O
2013	O
was	O
identified	O
.	O
	
ninety	O
one	O
percent	O
of	O
services	B-C0557854
adopted	O
four	O
or	O
more	O
practices	B-C1254363
,	O
a	O
significant	O
increase	O
from	O
38%	O
in	O
2006	O
.	O
	
there	O
were	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
services	B-C0557854
adopting	O
each	O
practice	B-C1254363
by	O
locality	B-C1254362
and	O
socio-economic	B-C0086996
status	I-C0086996
.	O
	
government	B-C0018104
investment	B-C3242637
in	O
obesity	B-C0028754
prevention	B-C1254363
programmes	I-C1254363
can	O
equitably	O
improve	O
childcare	B-C0683807
service's	O
adoption	O
of	O
healthy	B-C0452415
eating	I-C0452415
and	O
physical	B-C0026606
activity	I-C0026606
promoting	O
practices	B-C1254363
on	O
a	O
jurisdiction	B-C0680647
-wide	O
basis	O
.	O
	
the	O
establishment	O
of	O
a	O
routine	O
system	O
to	O
monitor	O
adoption	O
of	O
a	O
broader	O
range	O
of	O
practices	B-C1254363
by	O
childcare	B-C0683807
services	B-C0557854
isolation	B-C0205409
and	O
characterization	B-C1880022
of	O
burkholderia	B-C4130454
sp	I-C4130454
.	O
	
strain	I-C4130454
cca53	I-C4130454
exhibiting	O
ligninolytic	B-C1156998
potential	B-C3245505
microbial	B-C0599840
degradation	B-C0699900
of	O
lignin	B-C0023705
releases	O
fermentable	B-C0242209
sugars	I-C0242209
,	O
effective	B-C1704419
utilization	B-C0457083
of	O
which	O
could	O
support	O
biofuel	B-C2717891
production	B-C0033268
from	O
lignocellulosic	B-C0064974
biomass	B-C0005535
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
a	O
lignin-degrading	B-C1156998
bacterium	B-C0004611
was	O
isolated	B-C0205409
from	O
leaf	B-C0242724
soil	B-C0037592
and	O
identified	O
as	O
burkholderia	B-C1264855
sp	I-C1264855
.	O
	
based	O
on	O
16s	B-C3537372
rrna	I-C3537372
gene	B-C1294197
sequencing	I-C1294197
.	O
	
this	O
strain	B-C0456178
was	O
named	O
cca53	B-C4130454
,	O
and	O
its	O
lignin-degrading	B-C1156998
capability	B-C2698977
was	O
assessed	B-C1516048
by	O
observing	O
its	O
growth	B-C0018270
on	O
medium	B-C0010454
containing	O
alkali	B-C0023705
lignin	I-C0023705
or	O
lignin	B-C0023705
-associated	O
aromatic	B-C0596973
monomers	I-C0596973
as	O
the	O
sole	O
carbon	B-C0007009
source	B-C0449416
.	O
	
alkali	B-C0023705
lignin	I-C0023705
and	O
at	O
least	O
eight	O
lignin	B-C0023705
-associated	O
aromatic	B-C0596973
monomers	I-C0596973
supported	O
growth	B-C0018270
of	O
this	O
strain	B-C0456178
,	O
and	O
the	O
most	O
effective	B-C1704419
utilization	B-C0457083
was	O
observed	O
for	O
p-hydroxybenzene	B-C0596973
monomers	I-C0596973
.	O
	
these	O
findings	B-C0243095
indicate	O
that	O
burkholderia	B-C4130454
sp	I-C4130454
.	O
	
strain	I-C4130454
cca53	I-C4130454
has	O
fragmentary	B-C0441655
activity	I-C0441655
for	O
lignin	B-C1156998
degradation	I-C1156998
.	O
	
diagnostic	B-C0348026
utility	B-C0457083
of	O
additional	O
conventional	B-C0205214
techniques	B-C0430022
after	O
endobronchial	B-C2959489
ultrasonography	I-C2959489
guidance	B-C0150600
during	O
transbronchial	B-C0863477
biopsy	I-C0863477
endobronchial	B-C2959489
ultrasonography	I-C2959489
with	O
a	O
guide	B-C0025080
sheath	I-C0025080
transbronchial	B-C0863477
biopsy	I-C0863477
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
has	O
been	O
used	O
to	O
diagnose	B-C0011900
peripheral	B-C0577916
pulmonary	I-C0577916
lesions	I-C0577916
ppls	B-C0577916
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
evaluated	O
the	O
diagnostic	B-C0348026
utility	B-C0457083
of	O
conventional	B-C0205214
tbb	B-C0863477
after	O
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
.	O
	
a	O
retrospective	B-C0035363
analysis	I-C0035363
of	O
patients	B-C0030705
who	O
underwent	O
conventional	B-C0205214
tbb	B-C0863477
after	O
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
for	O
ppl	B-C0577916
between	O
august	O
1	O
,	O
2012	O
and	O
december	O
31	O
,	O
2014	O
.	O
	
we	O
performed	O
multivariate	B-C0026777
analysis	I-C0026777
to	O
examine	O
the	O
association	B-C0439849
of	O
various	O
clinical	B-C0205210
factors	B-C1521761
,	O
including	O
ebus	B-C2959489
probe	B-C0182400
distance	B-C0012751
and	O
sample	B-C0242618
size	I-C0242618
area	B-C0205146
,	O
with	O
diagnostic	B-C0205556
yield	I-C0205556
.	O
	
of	O
88	O
eligible	O
patients	B-C0030705
,	O
57	O
65%	O
were	O
successfully	O
diagnosed	B-C0011900
by	O
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
.	O
	
in	O
31	O
patients	B-C0030705
not	O
diagnosed	B-C0011900
by	O
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
,	O
15	O
48%	O
were	O
successfully	O
diagnosed	B-C0011900
by	O
additional	O
conventional	B-C0205214
tbb	B-C0863477
.	O
	
ground	B-C3827002
glass	I-C3827002
opacity	I-C3827002
ggo	B-C3827002
was	O
a	O
significant	B-C0750502
factor	B-C1521761
associated	O
with	O
the	O
diagnostic	B-C0205556
yield	I-C0205556
of	O
additional	O
conventional	B-C0205214
tbb	B-C0863477
following	O
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
and	O
receiver	B-C0035787
operator	I-C0035787
curves	I-C0035787
revealed	O
that	O
distance	B-C0012751
between	O
the	O
ppl	B-C0577916
and	O
the	O
ebus	B-C2959489
probe	B-C0182400
of	O
less	O
than	O
2.55	O
mm	O
favored	O
the	O
utility	B-C0457083
of	O
conventional	B-C0205214
tbb	B-C0863477
.	O
	
additional	O
conventional	B-C0205214
tbb	B-C0863477
after	O
ebus	B-C2959489
-	O
gs	B-C0025080
tbb	B-C0863477
could	O
be	O
a	O
useful	O
procedure	B-C0430022
for	O
the	O
diagnosis	B-C0011900
of	O
ground	B-C3827002
glass	I-C3827002
opacity	I-C3827002
ppls	B-C0577916
and	O
in	O
cases	B-C0868928
of	O
a	O
distance	B-C0012751
of	O
less	O
than	O
2.55	O
mm	O
between	O
the	O
ebus	B-C2959489
probe	B-C0182400
and	O
the	O
active	B-C0205177
diffusion	B-C0012222
and	O
microtubule-based	B-C2755890
transport	I-C2755890
oppose	O
myosin	B-C0033684
forces	B-C0441722
to	O
position	B-C0733755
organelles	B-C0029219
in	O
cells	B-C0007634
even	O
distribution	B-C1704711
of	O
peroxisomes	B-C0752063
pos	B-C0752063
and	O
lipid	B-C0230704
droplets	I-C0230704
lds	B-C0230704
is	O
critical	O
to	O
their	O
role	B-C1705810
in	O
lipid	B-C0023779
and	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
homeostasis	B-C0019868
.	O
	
how	O
even	O
distribution	B-C1704711
is	O
achieved	O
remains	O
elusive	O
,	O
but	O
diffusive	B-C0012222
motion	I-C0012222
and	O
directed	O
motility	B-C0007608
may	O
play	O
a	O
role	B-C1705810
.	O
	
here	O
we	O
show	O
that	O
in	O
the	O
fungus	B-C0016832
ustilago	B-C0446013
maydis	I-C0446013
95%	O
of	O
pos	B-C0752063
and	O
lds	B-C0230704
undergo	O
diffusive	B-C0012222
motions	I-C0012222
.	O
	
these	O
movements	B-C0007608
require	O
atp	B-C0001480
and	O
involve	O
bidirectional	B-C1706937
early	O
endosome	B-C0034850
motility	B-C0007608
,	O
indicating	O
that	O
microtubule	B-C0026046
-	O
associated	B-C0332281
membrane	B-C0596901
trafficking	B-C0599896
enhances	B-C2349975
diffusion	B-C0012222
of	O
organelles	B-C0029219
.	O
	
when	O
early	O
endosome	B-C1156042
transport	I-C1156042
is	O
abolished	O
,	O
pos	B-C0752063
and	O
lds	B-C0230704
drift	O
slowly	O
towards	O
the	O
growing	B-C3159038
cell	I-C3159038
end	I-C3159038
.	O
	
this	O
pole-ward	B-C0007613
drift	I-C0007613
is	O
facilitated	O
by	O
anterograde	B-C0598952
delivery	I-C0598952
of	O
secretory	B-C0597427
cargo	I-C0597427
to	O
the	O
cell	B-C1656978
tip	I-C1656978
by	O
myosin-5	B-C0969679
.	O
	
modelling	B-C0870071
reveals	O
that	O
microtubule-based	B-C2755890
directed	I-C2755890
transport	I-C2755890
and	O
active	B-C0205177
diffusion	B-C0012222
support	O
distribution	B-C1704711
,	O
mobility	B-C1516353
and	O
mixing	O
of	O
pos	B-C0752063
.	O
	
in	O
mammalian	B-C0024660
cos-7	B-C1257858
cells	I-C1257858
,	O
microtubules	B-C0026046
and	O
f-actin	B-C1180307
also	O
counteract	O
each	O
other	O
to	O
distribute	B-C1704711
pos	B-C0752063
.	O
	
this	O
highlights	O
the	O
importance	O
of	O
opposing	O
cytoskeletal	B-C0010853
forces	B-C0441722
in	O
organelle	B-C0029219
positioning	B-C0733755
in	O
the	O
role	O
of	O
catheter	B-C0162563
ablation	I-C0162563
in	O
the	O
management	B-C0376636
of	O
atrial	B-C0004238
fibrillation	I-C0004238
atrial	B-C0004238
fibrillation	I-C0004238
is	O
driven	O
by	O
spontaneous	O
electrical	B-C1658783
activation	I-C1658783
emerging	O
from	O
the	O
pulmonary	B-C0034090
veins	I-C0034090
.	O
	
catheter	B-C0162563
ablation	I-C0162563
using	O
either	O
radiofrequency	B-C0850292
or	O
cryothermal	B-C0010412
energy	I-C0010412
electrically	B-C0442828
isolates	B-C0205409
these	O
veins	B-C0034090
from	O
the	O
left	B-C0225860
atrium	I-C0225860
,	O
both	O
reducing	B-C0392756
the	O
burden	B-C2828008
of	O
atrial	B-C0004238
fibrillation	I-C0004238
episodes	B-C1254367
and	O
improving	O
the	O
patient's	B-C0030705
symptoms	B-C1457887
.	O
	
catheter	B-C0162563
ablation	I-C0162563
is	O
superior	O
to	O
antiarryhthmic	B-C0003195
drugs	I-C0003195
when	O
patients	B-C0030705
are	O
carefully	O
selected	O
.	O
	
underlying	O
medical	B-C1715372
problems	I-C1715372
-	O
including	O
obesity	B-C0028754
,	O
hypertension	B-C0020538
and	O
obstructive	B-C0520679
sleep	I-C0520679
apnoea	I-C0520679
-	O
should	O
be	O
optimally	O
treated	B-C1522326
before	O
considering	O
ablation	B-C0547070
.	O
	
although	O
this	O
treatment	B-C0087111
has	O
the	O
potential	B-C3245505
to	O
cure	B-C1880198
patients	B-C0030705
of	O
their	O
symptoms	B-C1457887
,	O
they	O
should	O
be	O
aware	O
of	O
the	O
important	O
associated	O
procedural	B-C0742724
complications	I-C0742724
.	O
	
the	O
chinese	B-C3146288
herbal	I-C3146288
mixture	B-C0439962
tien-hsien	B-C1528399
liquid	I-C1528399
augments	B-C0205217
the	O
anticancer	B-C2986475
immunity	B-C0020964
in	O
tumor	B-C0597032
cell	I-C0597032
-	O
vaccinated	B-C1116171
mice	B-C0025929
background	O
the	O
chinese	B-C3146288
herbal	I-C3146288
mixture	B-C0439962
,	O
tien-hsien	B-C1528399
liquid	I-C1528399
thl	B-C1528399
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	B-C2986475
dietary	B-C0242295
supplement	I-C0242295
for	O
more	O
than	O
20	O
years	B-C0439234
.	O
	
our	O
previous	B-C0205156
studies	B-C2603343
have	O
shown	O
that	O
thl	B-C1528399
can	O
modulate	B-C0443264
immune	B-C0301872
response	I-C0301872
and	O
inhibit	B-C3463820
tumor	B-C0598934
growth	I-C0598934
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
further	O
evaluated	B-C0220825
the	O
effect	B-C1280500
of	O
thl	B-C1528399
on	O
anticancer	B-C2986475
immune	B-C0301872
response	I-C0301872
in	O
mice	B-C0025929
vaccinated	B-C1116171
with	O
γ-ray	B-C0017011
-	O
irradiated	B-C1282930
tumor	B-C0597032
cells	I-C0597032
.	O
	
methods	O
the	O
antitumor	B-C2986475
effect	B-C1280500
of	O
thl	B-C1528399
was	O
determined	B-C0521095
in	O
mice	B-C0025929
vaccinated	B-C1116171
with	O
low-tumorigenic	B-C0085983
ct-26-low	I-C0085983
colon	I-C0085983
cancer	I-C0085983
cells	I-C0085983
or	O
γ-ray-irradiated	B-C2985557
high-tumorigenic	B-C0085983
ct-26-high	I-C0085983
colon	I-C0085983
cancer	I-C0085983
cells	I-C0085983
.	O
	
the	O
number	B-C0237753
of	O
natural	B-C0022688
killer	I-C0022688
nk	I-C0022688
cells	I-C0022688
and	O
t	B-C0039194
lymphocytes	I-C0039194
in	O
the	O
spleen	B-C0037993
was	O
analyzed	B-C0936012
by	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
the	O
tumor	B-C0027651
-	O
killing	B-C0599733
activities	B-C0441655
of	O
nk	B-C0022688
cells	I-C0022688
and	O
cytotoxic	B-C0039195
t	I-C0039195
lymphocytes	I-C0039195
ctls	B-C0039195
were	O
analyzed	B-C0936012
by	O
flow	B-C0016263
cytometry	I-C0016263
using	O
yac-1	B-C0085983
and	O
ct-26-high	B-C0085983
cells	I-C0085983
,	O
respectively	O
,	O
as	O
target	B-C1521840
cells	B-C0007634
.	O
	
the	O
levels	B-C0441889
of	O
ifn-γ	B-C0021745
,	O
il-2	B-C0021756
,	O
and	O
tnf-α	B-C1456820
were	O
determined	B-C0521095
by	I-C0521095
elisa	B-C0014441
.	O
	
results	O
thl	B-C1528399
suppressed	B-C1260953
the	O
growth	B-C0018270
of	O
ct-26-high	B-C0085983
tumor	I-C0085983
in	O
mice	B-C0025929
previously	O
vaccinated	B-C1116171
with	O
low-tumorigenic	B-C0085983
ct-26-low	I-C0085983
cells	I-C0085983
or	O
γ-irradiated	B-C2985557
ct-26-high	B-C0085983
cells	I-C0085983
.	O
	
thl	B-C1528399
increased	B-C0205217
the	O
populations	O
of	O
nk	B-C0022688
cells	I-C0022688
and	O
cd4+	B-C0039215
t	I-C0039215
lymphocytes	I-C0039215
in	O
the	O
spleen	B-C0037993
and	O
enhanced	B-C2349975
the	O
tumor	B-C0027651
-	O
killing	B-C0599733
activities	B-C0441655
of	O
nk	B-C0022688
cells	I-C0022688
and	O
ctl	B-C0039195
in	O
mice	B-C0025929
vaccinated	B-C1116171
with	O
γ-irradiated	B-C2985557
ct-26-high	B-C0085983
cells	I-C0085983
.	O
	
thl	B-C1528399
increased	B-C0205217
the	O
production	B-C0205245
of	O
ifn-γ	B-C0021745
,	O
il-2	B-C0021756
,	O
and	O
tnf-α	B-C1456820
in	O
mice	B-C0025929
vaccinated	B-C1116171
with	O
γ-irradiated	B-C2985557
ct-26-high	B-C0085983
cells	I-C0085983
.	O
	
conclusion	O
thl	B-C1528399
can	O
enhance	B-C2349975
the	O
antitumor	B-C2986475
immune	B-C0301872
responses	I-C0301872
in	O
mice	B-C0025929
vaccinated	B-C1116171
with	O
killed	B-C0205245
tumor	B-C0597032
cells	I-C0597032
.	O
	
these	O
results	B-C1274040
suggest	O
that	O
thl	B-C1528399
may	O
be	O
used	O
as	O
a	O
complementary	B-C1148474
medicine	I-C1148474
for	O
cancer	B-C0006826
patients	B-C0030705
previously	B-C0205156
treated	B-C1522326
with	O
killed	B-C0376659
tumor	I-C0376659
cell	I-C0376659
vaccines	I-C0376659
,	O
radiotherapy	B-C1522449
,	O
or	O
timing	B-C0449243
of	O
false	O
ring	B-C0243056
formation	I-C0243056
in	O
pinus	B-C1028806
halepensis	I-C1028806
and	O
arbutus	B-C1036425
unedo	I-C1036425
in	O
southern	B-C1710133
italy	B-C0022277
outlook	B-C0420834
from	O
an	O
analysis	B-C0936012
of	O
xylogenesis	B-C0243056
and	O
tree-ring	B-C0040811
chronologies	B-C0008717
mediterranean	B-C0282645
tree	B-C0040811
rings	I-C0040811
are	O
characterized	B-C1880022
by	O
intra-annual	B-C0231241
density	I-C0231241
fluctuations	I-C0231241
iadfs	B-C0231241
due	O
to	O
partly	O
climate-driven	B-C0008946
cambial	B-C0243056
activity	I-C0243056
.	O
	
iadfs	B-C0231241
are	O
used	O
as	O
structural	B-C0678594
signals	B-C0010439
to	O
gain	O
information	B-C1533716
on	O
relations	B-C0439849
between	B-C0205103
environmental	B-C0014406
conditions	B-C0348080
and	O
eco-physiological	B-C0243056
processes	B-C1522240
during	B-C0347984
xylogenesis	B-C0243056
,	O
with	O
intra-annual	B-C0332181
resolution	B-C2699488
.	O
	
to	O
reach	O
an	O
unbiased	B-C1711255
synchronization	B-C0439580
of	O
the	O
iadf	B-C0231241
position	B-C0733755
within	O
tree	B-C0040811
rings	B-C0521164
and	O
seasonal	B-C1254367
fluctuations	B-C0231239
in	O
environmental	B-C0014406
conditions	B-C0348080
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
timing	B-C0449243
of	O
cambial	B-C0243056
activity	I-C0243056
and	O
wood	B-C0043217
formation	B-C1522492
,	O
which	O
are	O
species-	B-C0205556
and	O
site-specific	B-C0205556
processes	B-C1522240
.	O
	
we	O
applied	B-C4048755
the	O
microcoring	B-C0449851
technique	I-C0449851
to	O
analyze	B-C0936012
xylogenesis	B-C0243056
in	O
pinus	B-C1028806
halepensis	I-C1028806
and	O
arbutus	B-C1036425
unedo	I-C1036425
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
attempt	B-C1516084
to	O
study	B-C2603343
xylogenesis	B-C0243056
in	O
a	O
hardwood	B-C0043217
species	B-C1705920
forming	O
frequent	B-C0332183
iadfs	B-C0231241
.	O
	
both	O
species	B-C1705920
co-occur	B-C1709305
at	O
a	O
site	B-C0205145
in	O
southern	B-C1710133
italy	B-C0022277
characterized	B-C1880022
by	O
a	O
mediterranean	B-C0282645
climate	B-C0008946
.	O
	
to	O
facilitate	O
tree-ring	B-C2350279
dating	I-C2350279
and	O
identification	B-C0205396
of	O
iadfs	B-C0231241
,	O
we	O
performed	B-C0884358
traditional	B-C0443324
dendroecological	B-C0205556
analysis	B-C0936012
.	O
	
we	O
analyzed	B-C0936012
xylogenesis	B-C0243056
during	B-C0347984
summer	B-C0241301
,	O
which	O
is	O
considered	B-C0750591
a	O
constraint	B-C0443288
for	O
xylogenesis	B-C0243056
and	O
a	O
trigger	O
for	O
iadf	B-C0231241
formation	B-C1522492
.	O
	
we	O
followed	O
the	O
different	B-C1705242
phases	B-C0205390
of	O
cell	B-C0815089
development	I-C0815089
in	O
the	O
current	B-C0521116
wood	B-C0043217
increment	B-C1705117
with	O
the	O
aim	O
of	O
evaluating	O
whether	O
and	O
which	O
type	O
of	O
iadfs	B-C0231241
were	O
formed	B-C0205431
.	O
	
we	O
additionally	O
analyzed	B-C0936012
the	O
same	O
phases	B-C0205390
again	O
in	O
september	B-C3828193
and	O
in	O
winter	B-C0241737
to	O
verify	B-C1711411
the	O
possible	B-C0332149
formation	B-C1522492
of	O
iadfs	B-C0231241
in	O
fall	B-C0238715
and	O
whether	O
cell	B-C3178867
production	B-C0243056
and	O
differentiation	B-C0007589
was	O
completed	B-C0205197
by	O
the	O
end	O
of	O
the	O
calendar	B-C0456586
year	I-C0456586
.	O
	
both	O
species	B-C1705920
formed	B-C0205431
the	O
same	O
type	O
of	O
iadfs	B-C0231241
earlywood	B-C0043217
-like	O
cells	B-C3178867
within	O
latewood	B-C0043217
,	O
due	O
to	O
temporary	B-C0205374
growth	B-C2911660
restoration	B-C0243095
triggered	B-C1444748
by	I-C1444748
rain	B-C0034640
events	B-C0441471
during	B-C0347984
the	O
period	B-C1948053
of	O
summer	B-C0241301
drought	B-C0013140
.	O
	
at	O
the	O
end	O
of	O
the	O
calendar	B-C0456586
year	I-C0456586
,	O
no	O
cells	B-C3178867
in	O
the	O
phases	B-C0205390
of	O
enlargement	B-C0442800
and	O
secondary	B-C1167351
cell	I-C1167351
wall	I-C1167351
deposition	B-C0333562
occurred	B-C1709305
.	O
	
a	B-C1036425
.	O
	
unedo	I-C1036425
was	O
more	O
sensitive	B-C0332324
than	O
p	B-C1028806
.	O
	
halepensis	I-C1028806
because	O
iadf	B-C0231241
s	O
were	O
formed	B-C0205431
earlier	B-C1279919
in	O
the	O
season	B-C0036497
and	O
were	O
more	O
frequent	B-C0332183
in	O
the	O
tree-ring	B-C0040811
series	O
.	O
	
the	O
dendro-anatomical	B-C0205556
approach	O
,	O
combining	O
analysis	B-C0936012
of	O
tree-ring	B-C0040811
series	O
and	O
of	O
xylogenesis	B-C0243056
,	O
helped	O
to	O
detect	B-C0442726
the	O
period	B-C1948053
of	O
iadf	B-C0231241
formation	B-C1522492
in	O
the	O
two	O
species	B-C1705920
.	O
	
results	B-C1274040
are	O
discussed	O
in	O
functional	B-C0205245
terms	B-C1705313
,	O
highlighting	O
the	O
environmental	B-C0014406
conditions	B-C0348080
triggering	B-C1444748
iadfs	B-C0231241
,	O
and	O
also	O
in	O
methodological	B-C0815254
terms	B-C1705313
,	O
evaluating	O
the	O
applicability	B-C4048755
of	O
xylogenesis	B-C0243056
analysis	B-C0936012
in	O
mediterranean	B-C0282645
woods	B-C0043217
,	O
especially	O
when	O
the	O
formation	B-C1522492
of	O
iadfs	B-C0231241
is	O
not	O
uniform	B-C0205375
around	O
the	O
emergence	B-C0205556
of	O
family	B-C0015607
medicine	I-C0015607
in	O
ethiopia	B-C0015024
corrected	O
an	O
international	B-C1512888
collaborative	B-C0282116
education	B-C3161035
model	I-C3161035
family	B-C0015607
medicine	I-C0015607
fm	B-C0015607
is	O
a	O
new	O
specialty	B-C0037778
in	O
ethiopia	B-C0015024
.	O
	
the	O
first	B-C1704221
seven	I-C1704221
family	I-C1704221
physicians	I-C1704221
graduated	B-C0588053
in	O
february	B-C3830166
2016	O
from	O
the	O
inaugural	O
residency	B-C0035182
programme	B-C0010478
at	O
addis	B-C0041740
ababa	I-C0041740
university	I-C0041740
.	O
	
cooperation	B-C0392337
amongst	O
ethiopian	B-C0239304
and	O
expatriate	B-C3842568
decision-makers	B-C0554244
and	O
physicians	B-C0031831
was	O
needed	O
to	O
begin	B-C0439659
the	O
programme	B-C0010478
.	O
	
intentional	B-C1512888
replacement	B-C0559956
of	O
expatriates	B-C3842568
with	O
ethiopian	B-C0239304
family	B-C1704221
physicians	I-C1704221
has	O
begun	B-C0439659
.	O
	
barriers	B-C0205556
include	O
lack	B-C0332268
of	I-C0332268
understanding	B-C0162340
of	O
fm	B-C0015607
and	O
the	O
human	B-C0024752
and	O
financial	B-C0516918
resources	I-C0516918
needed	O
for	O
scaling	B-C0392762
up	I-C0392762
the	O
programme	B-C0010478
.	O
	
regular	B-C0205272
programme	B-C0010478
review	B-C1704362
with	O
resident	B-C1320928
physician	I-C1320928
involvement	B-C0009476
has	O
allowed	O
the	O
fm	B-C0015607
training	B-C0040607
programme	I-C0040607
to	O
adapt	B-C0205556
and	O
fit	B-C2349186
the	O
ethiopian	B-C0239304
context	B-C0449255
.	O
	
further	O
successes	B-C0597535
will	O
result	B-C1274040
from	O
ongoing	O
support	B-C0037438
and	O
advocacy	B-C0150446
from	O
the	O
federal	B-C0013562
ministry	I-C0013562
of	I-C0013562
health	I-C0013562
and	O
other	O
ethiopian	B-C0239304
,	O
african	B-C0027567
,	O
and	O
international	B-C1512888
primary	O
care	O
organisations	I-C0596660
the	O
experience	B-C0596545
of	O
women	B-C0043210
veterans	B-C0042610
coming	O
back	O
from	O
war	B-C0043027
issues	B-C4061796
surrounding	I-C4061796
mental	I-C4061796
health	I-C4061796
are	O
common	O
for	O
women	B-C0043210
veterans	B-C0042610
who	O
have	O
served	O
in	O
iraq	B-C0022066
and	O
afghanistan	B-C0001732
wars	B-C0043027
.	O
	
the	O
goal	O
of	O
this	O
phenomenological	B-C0871071
study	B-C2603343
was	O
to	O
document	B-C1301746
themes	B-C0869035
in	O
the	O
stories	B-C0282574
gathered	O
from	O
eight	O
women	B-C0043210
veterans	B-C0042610
who	O
had	O
come	O
back	O
from	O
war	B-C0043027
.	O
	
themes	B-C0869035
in	O
the	O
stories	B-C0282574
were	O
arriving	O
with	O
mixed	O
sentiments	B-C0683293
evolving	O
to	O
a	O
changed	B-C0392747
view	B-C0242498
of	I-C0242498
self	I-C0242498
permeating	B-C0243095
aggravation	I-C0243095
confounding	B-C2371543
broken	I-C2371543
relationships	I-C2371543
,	O
frequent	B-C2321230
deployments	I-C2321230
,	O
and	O
change	B-C1550416
in	I-C1550416
military	I-C1550416
status	I-C1550416
remembering	B-C0034770
war	B-C0043027
experiences	B-C0596545
and	O
seeking	B-C0243095
opportunity	I-C0243095
for	I-C0243095
what	I-C0243095
is	I-C0243095
possible	I-C0243095
.	O
	
mental	B-C4061796
health	I-C4061796
issues	I-C4061796
can	O
be	O
observed	O
in	O
the	O
themes	B-C0869035
.	O
	
including	O
story	B-C0282574
as	O
part	O
of	O
the	O
mental	B-C0025353
health	I-C0025353
visit	O
with	O
veterans	B-C0042610
may	O
be	O
beneficial	O
to	O
veterans	B-C0042610
as	O
they	O
deal	O
with	O
the	O
transition	B-C2700061
of	I-C2700061
coming	I-C2700061
back	I-C2700061
.	O
	
trajectories	B-C0205134
of	O
health	B-C0018684
and	O
behavioral	B-C0009472
health	I-C0009472
services	I-C0009472
use	B-C0457083
among	O
community	B-C0009462
corrections	B-C1947976
-involved	O
rural	B-C0240919
adults	B-C0001675
this	O
article	O
seeks	O
to	O
establish	O
time-based	O
trajectories	B-C0205134
of	O
health	B-C0018684
and	O
behavioral	B-C0009472
health	I-C0009472
services	I-C0009472
utilization	B-C0457083
for	O
community	B-C0009463
corrections-involved	I-C0009463
cci	B-C0009463
adults	B-C0001675
and	O
to	O
examine	O
demographic	B-C0011292
and	O
clinical	B-C0205210
correlates	O
associated	O
with	O
these	O
trajectories	B-C0205134
.	O
	
to	O
accomplish	O
this	O
aim	O
,	O
the	O
authors	O
applied	O
a	O
latent	B-C0936012
class	I-C0936012
growth	I-C0936012
analysis	I-C0936012
lcga	B-C0936012
to	O
services	B-C0009472
use	O
data	O
from	O
a	O
sample	O
of	O
rural	B-C0240919
cci	B-C0009463
adults	B-C0001675
who	O
reported	O
their	O
medical	B-C0205476
,	O
mental	B-C0025353
health	I-C0025353
,	O
and	O
substance	B-C1705534
use	I-C1705534
treatment	B-C0815187
utilization	I-C0815187
behavior	B-C0004927
every	O
60	O
days	B-C0439228
for	O
1.5	O
years	B-C0439234
.	O
	
lcga	B-C0936012
established	O
1.5	B-C0439234
trajectories	B-C0205134
and	O
demographic	B-C0011292
correlates	O
of	O
health	B-C0018747
services	I-C0018747
among	O
rural	B-C0240919
cci	B-C0009463
adults	B-C0001675
.	O
	
for	O
medical	B-C0199168
services	I-C0199168
,	O
three	O
classes	O
emerged	O
stable-low	O
users	B-C1706077
,	O
13%	O
stable-intermediate	O
users	B-C1706077
,	O
40%	O
and	O
stable-high	O
users	B-C1706077
,	O
47%	O
.	O
	
for	O
mental	B-C0025353
health	I-C0025353
and	O
substance	B-C1705534
use	I-C1705534
services	B-C0009472
,	O
three	O
classes	O
emerged	O
stable-low	O
,	O
69%	O
and	O
61%	O
,	O
respectively	O
low-baseline-increase	O
,	O
10%	O
and	O
12%	O
,	O
respectively	O
high-baseline	O
decline	O
,	O
21%	O
and	O
28%	O
,	O
respectively	O
.	O
	
employment	B-C0014003
,	O
gender	B-C0079399
,	O
medication	B-C0240320
usage	I-C0240320
,	O
and	O
depression	B-C0011570
severity	B-C0439793
predicted	O
membership	B-C0680038
across	O
all	O
services	B-C0009472
.	O
	
results	O
underscore	O
the	O
importance	O
of	O
social	B-C0037444
workers	I-C0037444
and	O
other	O
community	B-C0009472
services	I-C0009472
providers	B-C0018724
aligning	O
health	B-C0018747
services	I-C0018747
access	O
with	O
the	O
needs	O
of	O
the	O
cci	B-C0009463
population	O
,	O
and	O
highlight	O
cci	B-C0009463
adults	B-C0001675
as	O
being	O
at	O
risk	B-C0035647
of	O
underservice	O
in	O
critical	O
prevention	B-C0199176
and	O
intervention	B-C0184661
domains	I-C0184661
.	O
	
data	B-C0150098
set	I-C0150098
of	O
interactomes	B-C0872079
and	O
metabolic	B-C1291081
pathways	I-C1291081
of	O
proteins	B-C0033684
differentially	O
expressed	B-C1171362
in	O
brains	B-C0006104
with	O
alzheimer	B-C0002395
disease	I-C0002395
alzheimer	B-C0002395
disease	I-C0002395
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	B-C0497327
in	O
the	O
elderly	B-C0001792
and	O
its	O
frequency	B-C0439603
is	O
on	O
the	O
rise	O
worldwide	B-C2700280
.	O
	
it	O
is	O
considered	O
the	O
result	O
of	O
complex	B-C0439855
interactions	B-C1704675
between	O
genetic	B-C0814299
and	O
environmental	B-C0686732
factors	I-C0686732
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O
	
therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	B-C0033684
players	I-C0033684
for	O
the	O
understanding	O
of	O
this	O
disease	B-C0002395
.	O
	
in	O
this	O
data	B-C1511726
article	B-C1706852
we	O
determined	O
the	O
protein	B-C1171362
expression	I-C1171362
profiles	O
of	O
whole	O
protein	B-C0033684
extracts	B-C2828366
from	O
cortex	B-C0458324
regions	I-C0458324
of	I-C0458324
brains	I-C0458324
from	O
patients	B-C0030705
with	O
alzheimer	B-C0002395
disease	I-C0002395
in	O
comparison	O
to	O
a	O
normal	B-C0006104
brain	I-C0006104
.	O
	
we	O
identified	B-C0205396
721	O
itraq-labeled	B-C2986808
polypeptides	B-C1305923
with	O
more	O
than	O
95%	O
in	O
confidence	O
.	O
	
we	O
analyzed	B-C0936012
all	O
proteins	B-C0033684
that	O
changed	O
in	O
their	O
expression	B-C3244092
level	I-C3244092
and	O
located	O
them	O
in	O
the	O
kegg	B-C3826812
metabolic	I-C3826812
pathways	I-C3826812
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	B-C1325653
complexes	I-C1325653
of	I-C1325653
the	I-C1325653
electron	I-C1325653
transport	I-C1325653
chain	I-C1325653
and	O
atp	B-C0949692
synthase	I-C0949692
.	O
	
in	O
addition	O
,	O
we	O
analyzed	B-C0936012
the	O
over-	B-C1305923
and	I-C1305923
sub-expressed	I-C1305923
polypeptides	I-C1305923
through	O
ipa	B-C0037585
software	I-C0037585
,	O
specifically	O
core	B-C0037589
i	I-C0037589
and	I-C0037589
biomarkers	I-C0037589
i	I-C0037589
modules	I-C0037589
.	O
	
data	B-C1511726
in	O
this	O
article	B-C1706852
is	O
related	O
to	O
the	O
research	B-C0035168
article	B-C1706852
"""identification"	O
of	O
proteins	B-C0033684
that	O
are	O
differentially	O
expressed	B-C1171362
in	O
brains	B-C0006104
with	O
alzheimer's	B-C0002395
disease	I-C0002395
using	O
itraq	B-C0022885
labeling	I-C0022885
and	O
tandem	B-C0599748
mass	I-C0599748
spectrometry	I-C0599748
emergency	B-C2216322
general	I-C2216322
surgery	I-C2216322
specific	B-C4075886
frailty	I-C4075886
index	I-C4075886
a	O
validation	B-C0681836
study	I-C0681836
assessment	B-C0220825
of	O
operative	B-C0747003
risk	I-C0747003
in	O
geriatric	B-C0870602
patients	I-C0870602
undergoing	O
emergency	B-C2216322
general	I-C2216322
surgery	I-C2216322
egs	B-C2216322
is	O
challenging	O
.	O
	
frailty	B-C0424594
is	O
an	O
established	O
measure	B-C0079809
for	O
risk	B-C0086930
assessment	I-C0086930
in	O
surgical	B-C1706256
cases	I-C1706256
.	O
	
the	O
aim	O
of	O
our	O
study	B-C2603343
was	O
to	O
validate	B-C1519941
a	O
modified	O
15	O
variable	B-C0439828
emergency	B-C4075415
general	I-C4075415
surgery	I-C4075415
specific	I-C4075415
frailty	I-C4075415
index	I-C4075415
egsfi	B-C4075415
.	O
	
we	O
prospectively	O
collected	B-C1516695
geriatric	B-C1704440
age	B-C0522003
>	I-C0522003
65	I-C0522003
emergency	B-C2216322
general	I-C2216322
surgery	I-C2216322
patients	B-C0870602
for	O
1-	O
year	B-C0439234
.	O
	
post-operative	B-C0032787
complications	I-C0032787
were	O
collected	B-C1516695
.	O
	
frailty	B-C4075886
index	I-C4075886
was	O
calculated	B-C1443182
for	O
200	O
patients	B-C0030705
based	O
on	O
their	O
pre-admission	B-C0559269
condition	B-C0348080
using	O
50-	O
variable	B-C0439828
modified	O
rockwood	B-C4075886
frailty	I-C4075886
index	I-C4075886
fi	B-C4075886
.	O
	
egsfi	B-C4075415
was	O
developed	O
based	O
on	O
the	O
regression	B-C0034980
model	I-C0034980
for	O
complications	B-C0032787
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
fi	B-C4075886
.	O
	
roc	B-C0035787
curve	I-C0035787
analysis	I-C0035787
was	O
performed	O
to	O
determine	O
cutoff	B-C1442160
for	O
frail	B-C0871754
status	B-C0449438
.	O
	
we	O
validated	B-C1519941
our	O
results	B-C1274040
using	O
60	O
patients	B-C0030705
for	O
predicting	B-C0681842
complications	B-C0032787
.	O
	
a	O
total	O
of	O
260	O
patients	B-C0030705
200	O
developing	O
,	O
60	O
validation	B-C1519941
were	O
enrolled	B-C1516879
in	O
this	O
study	B-C2603343
.	O
	
mean	B-C0001779
age	I-C0001779
was	O
71	O
11	O
years	B-C0439234
,	O
and	O
33%	O
developed	O
complications	B-C0032787
.	O
	
most	O
common	B-C0205214
complications	B-C0032787
were	O
pneumonia	B-C0032285
12%	O
,	O
uti	B-C0042029
9%	O
,	O
and	O
wound	B-C0043241
infection	I-C0043241
7%	O
.	O
	
univariate	B-C0683962
analysis	I-C0683962
identified	O
15	O
variables	B-C0439828
significantly	O
associated	B-C0332281
with	I-C0332281
complications	B-C0032787
that	O
were	O
used	O
to	O
develop	O
the	O
egsfi	B-C4075415
.	O
	
a	O
cutoff	B-C1442160
frailty	B-C4075885
score	I-C4075885
of	O
0.325	O
was	O
identified	O
using	O
roc	B-C0035787
curve	I-C0035787
analysis	I-C0035787
for	O
frail	B-C0871754
status	B-C0449438
sixty-	O
patients	B-C0030705
frail	B-C0871754
18	O
,	O
non-frail	B-C0871754
42	O
were	O
enrolled	B-C1516879
in	O
the	O
validation	B-C1519941
cohort	B-C0599755
.	O
	
frail	B-C0871754
patients	B-C0030705
were	O
more	O
likely	O
to	O
have	O
post-operative	B-C0032787
complications	I-C0032787
47%	O
vs	O
.	O
	
20%	O
,	O
p	O
<	O
0.001	O
compared	O
to	O
nonfrail	B-C0870602
patients	I-C0870602
.	O
	
frail	B-C0871754
status	B-C0449438
based	O
on	O
egsfi	B-C4075415
was	O
a	O
significant	B-C2698872
predictor	I-C2698872
of	O
post-operative	B-C0032787
complications	I-C0032787
or	B-C0028873
=7	O
,	O
95%	O
ci	B-C0009667
=	O
1.7	O
-	O
19.8	O
p=0	O
.	O
	
age	B-C0001779
was	O
not	O
associated	B-C0332281
with	I-C0332281
postoperative	B-C0032787
complications	I-C0032787
or	B-C0028873
=0	O
,	O
95%	O
ci	B-C0009667
=	O
0.92	O
-1	O
p=0	O
.	O
	
the	O
15-	O
variable	B-C0439828
validated	B-C1519941
egsfi	B-C4075415
is	O
a	O
simple	O
and	O
reliable	O
bedside	B-C4286058
tool	I-C4286058
to	O
determine	O
the	O
frailty	B-C0424594
status	I-C0424594
of	O
patients	B-C0030705
undergoing	O
emergency	B-C2216322
general	I-C2216322
surgery	I-C2216322
.	O
	
frail	B-C0871754
status	B-C0449438
as	O
determined	O
by	O
abstract	O
the	O
egsfi	B-C4075415
is	O
an	O
independent	B-C2698872
predictor	I-C2698872
of	O
post-operative	B-C0032787
complications	I-C0032787
and	O
mortality	B-C0205848
in	O
geriatric	B-C1704440
emergency	B-C2216322
general	I-C2216322
surgery	I-C2216322
patients	B-C0870602
.	O
	
level	O
ii	O
,	O
prognostic	B-C0242481
studies	I-C0242481
-	O
investigating	B-C1292732
the	O
effect	B-C1280500
of	O
a	O
patient	B-C1285579
characteristic	I-C1285579
on	O
the	O
outcome	B-C0679250
of	I-C0679250
disease	I-C0679250
.	O
	
comparative	O
epidemiologic	B-C0014508
characteristics	B-C1521970
of	O
pertussis	B-C0043167
in	O
10	O
central	B-C0454714
and	O
eastern	B-C0015177
european	I-C0015177
countries	I-C0015177
,	O
2000-2013	O
we	O
undertook	O
an	O
epidemiological	B-C0376688
survey	I-C0376688
of	O
the	O
annual	B-C0332181
incidence	B-C0021149
of	O
pertussis	B-C0043167
reported	B-C0700287
from	O
2000	O
to	O
2013	O
in	O
ten	O
central	B-C0454714
and	O
eastern	B-C0015177
european	I-C0015177
countries	I-C0015177
to	O
ascertain	O
whether	O
increased	O
pertussis	B-C0043167
reports	B-C0025102
in	O
some	O
countries	B-C0454664
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	B-C2348519
in	O
each	O
country	B-C0454664
.	O
	
the	O
annual	B-C0332181
incidence	B-C0021149
of	O
pertussis	B-C0043167
in	O
the	O
participating	O
countries	B-C0454664
was	O
obtained	O
from	O
relevant	O
government	B-C2607850
institutions	I-C2607850
and/or	O
national	B-C1708333
surveillance	I-C1708333
systems	I-C1708333
.	O
	
we	O
reviewed	B-C1709940
the	O
changes	B-C0392747
in	O
the	O
pertussis	B-C0043167
incidence	B-C1708485
rates	I-C1708485
in	O
each	O
country	B-C0454664
to	O
explore	O
differences	B-C1705242
and/or	O
similarities	B-C2348205
between	O
countries	B-C0454664
in	O
relation	O
to	O
pertussis	B-C0043167
surveillance	B-C0220920
case	B-C0679227
definitions	I-C0679227
for	O
detection	B-C0442726
and	O
confirmation	B-C0521091
of	O
pertussis	B-C0043167
incidence	B-C0021149
and	O
number	B-C0021149
of	I-C0021149
cases	I-C0021149
of	O
pertussis	B-C0043167
by	O
year	B-C0439234
,	O
overall	O
and	O
by	O
age	B-C0027362
group	I-C0027362
population	B-C1257890
by	O
year	B-C0439234
,	O
overall	O
and	O
by	O
age	B-C0027362
group	I-C0027362
pertussis	B-C0043167
immunization	B-C0020972
schedule	I-C0020972
and	O
coverage	B-C1999244
,	O
and	O
switch	O
from	O
whole-cell	B-C0031237
pertussis	I-C0031237
vaccines	I-C0031237
wp	B-C0031237
to	O
acellular	B-C0982332
pertussis	I-C0982332
vaccines	I-C0982332
ap	B-C0982332
.	O
	
there	O
was	O
heterogeneity	B-C0019409
in	O
the	O
reported	B-C0700287
annual	B-C0332181
incidence	B-C1708485
rates	I-C1708485
and	O
trends	O
observed	O
across	O
countries	B-C0454664
.	O
	
reported	B-C0700287
pertussis	B-C0043167
incidence	B-C1708485
rates	I-C1708485
varied	O
considerably	O
,	O
ranging	O
from	O
0.01	O
to	O
96	O
per	O
100	O
population	B-C1257890
,	O
with	O
the	O
highest	B-C1522410
rates	B-C1521828
generally	O
reported	B-C0700287
in	O
estonia	B-C0014908
and	O
the	O
lowest	B-C1708760
in	O
hungary	B-C0020174
and	O
serbia	B-C0036708
.	O
	
the	O
greatest	O
burden	B-C2828008
appears	O
for	O
the	O
most	O
part	O
in	O
infants	B-C0021270
<1	O
year	B-C0439234
in	O
bulgaria	B-C0006368
,	O
hungary	B-C0020174
,	O
latvia	B-C0023128
,	O
romania	B-C0035826
,	O
and	O
serbia	B-C0036708
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	B-C0454664
where	O
the	O
burden	B-C2828008
may	O
have	O
shifted	O
to	O
older	B-C0008059
children	I-C0008059
,	O
though	O
surveillance	B-C0220920
of	O
adults	B-C0001675
may	O
be	O
inappropriate	O
.	O
	
there	O
was	O
no	O
consistent	O
pattern	O
associated	B-C0332281
with	I-C0332281
the	O
switch	O
from	O
wp	B-C0031237
to	O
ap	B-C0982332
vaccines	I-C0982332
on	O
reported	B-C0700287
pertussis	B-C0043167
incidence	B-C1708485
rates	I-C1708485
.	O
	
the	O
heterogeneity	B-C0019409
in	O
reported	B-C0700287
data	B-C1511726
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	B-C1521761
including	O
surveillance	B-C0220920
system	B-C0449913
characteristics	B-C1521970
or	O
capabilities	B-C2698977
,	O
different	O
case	B-C0679227
definitions	I-C0679227
,	O
type	B-C0332307
of	O
pertussis	B-C0043167
confirmation	B-C0022885
tests	I-C0022885
used	O
,	O
public	B-C0678367
awareness	B-C1328734
of	O
the	O
disease	B-C0043167
,	O
as	O
well	O
as	O
real	O
differences	B-C1705241
in	O
the	O
magnitude	B-C1704240
of	O
the	O
disease	B-C0043167
,	O
or	O
a	O
combination	O
of	O
these	O
factors	B-C1521761
.	O
	
our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	B-C0043167
detection	B-C0442726
and	O
confirmation	B-C0521091
in	O
surveillance	B-C1515095
programs	I-C1515095
across	O
europe	B-C0015176
,	O
complemented	O
with	O
carefully-designed	O
seroprevalence	B-C0600367
studies	I-C0600367
using	O
the	O
same	O
protocols	B-C0442711
and	O
identification	B-C0205396
and	O
characterization	B-C1880022
of	O
dichelobacter	B-C0314932
nodosus	I-C0314932
serogroup	B-C0449555
h	I-C0449555
from	O
ovine	B-C1123019
footrot	B-C0016513
in	O
india	B-C0021201
a	O
total	O
of	O
56	O
foot	B-C0183753
swabs	I-C0183753
were	O
collected	O
from	O
inter	B-C0230506
digital	I-C0230506
spaces	I-C0230506
of	O
sheep	B-C0036945
with	O
footrot	B-C0016513
lesions	B-C0221198
were	O
screened	B-C1710031
for	O
16	O
rrna	B-C0035701
of	O
dichelobacter	B-C0314932
nodosus	I-C0314932
by	O
pcr	B-C0032520
.	O
	
out	O
of	O
the	O
56	O
samples	B-C2347026
,	O
38	O
were	O
found	O
to	O
be	O
positive	B-C1514241
.	O
	
all	O
the	O
positive	B-C1514241
samples	B-C2347026
were	O
subjected	O
to	O
multiplex	B-C3179032
pcr	I-C3179032
targeting	B-C0242613
fima	I-C0242613
gene	I-C0242613
for	O
identification	B-C0205396
of	O
serogroups	B-C0449543
of	O
d	B-C0314932
.	O
	
nodosus	I-C0314932
.	O
	
serogroup	B-C0449555
h	I-C0449555
was	O
found	O
along	O
with	O
serogroup	B-C0456771
b	I-C0456771
in	O
12	O
55.26	O
samples	B-C2347026
and	O
with	O
serogroup	B-C0449543
i	I-C0449543
in	O
8	O
22.2	O
samples	B-C2347026
.	O
	
the	O
serogroup	B-C0449555
h	I-C0449555
was	O
identified	B-C0205396
for	O
the	O
first	O
time	O
from	O
the	O
indian	B-C0454693
subcontinent	I-C0454693
.	O
	
the	O
phylogenetic	B-C1519068
analysis	I-C1519068
of	O
the	O
present	O
sequence	B-C0004793
with	O
the	O
available	O
serogroup	B-C0449555
h	I-C0449555
sequences	B-C0004793
of	O
genbank	B-C0598211
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	B-C0449943
h1	I-C0449943
.	O
	
conservation	B-C0013652
education	I-C0013652
and	O
habitat	B-C0871648
restoration	B-C0205245
for	O
the	O
endangered	B-C2717882
sagalla	B-C2999417
caecilian	I-C2999417
boulengerula	B-C2999417
niedeni	I-C2999417
in	O
sagalla	B-C0022558
hill	I-C0022558
,	O
kenya	B-C0022558
the	O
sagalla	B-C2999417
caecilian	I-C2999417
boulengerula	B-C2999417
niedeni	I-C2999417
is	O
an	O
endangered	B-C2717882
amphibian	B-C0002668
endemic	B-C0681784
to	O
sagalla	B-C0022558
hill	I-C0022558
in	O
the	O
taita	B-C0022558
hills	I-C0022558
.	O
	
this	O
burrowing	B-C0018893
worm	I-C0018893
-like	O
species	B-C1705920
prefers	O
soft	B-C0205358
soil	B-C0037592
with	O
high	B-C0205250
moisture	B-C0868994
and	O
organic	B-C0439861
matter	I-C0439861
.	O
	
the	O
major	B-C0205164
threats	B-C0749385
to	O
the	O
sagalla	B-C2999417
caecilian	I-C2999417
are	O
soil	B-C1254365
erosion	I-C1254365
caused	B-C0678227
by	O
steep	B-C1254362
slopes	I-C1254362
,	O
bare	O
ground	B-C0242744
and	O
water	B-C1254366
siphoning	I-C1254366
/	O
soil	B-C1254366
hardening	I-C1254366
from	O
exotic	B-C0015148
eucalyptus	I-C0015148
trees	I-C0015148
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
get	O
a	O
better	B-C0332272
understanding	B-C0162340
of	O
the	O
local	B-C0205276
people's	B-C0027361
attitude	B-C0004271
towards	O
this	O
species	B-C1705920
and	O
how	O
they	O
can	O
contribute	B-C1880177
to	O
its	O
continued	B-C0549178
conservation	B-C2347858
through	O
restoration	B-C0205245
of	O
its	O
remaining	B-C1527428
habitat	B-C0871648
.	O
	
in	O
this	O
study	B-C2603343
,	O
it	O
was	O
found	B-C0150312
that	O
96%	O
of	O
sagalla	B-C0022558
people	B-C0027361
are	O
aware	B-C0004448
of	O
the	O
species	B-C1705920
,	O
its	O
habits	B-C0018464
and	O
its	O
association	O
with	O
soils	B-C0037592
high	B-C0205250
in	O
organic	B-C0439861
matter	I-C0439861
.	O
	
it	O
was	O
also	O
found	B-C0150312
that	O
96%	O
of	O
sagalla	B-C0022558
people	B-C0027361
use	O
organic	B-C0747055
manure	B-C0024765
from	O
cow	B-C0007452
dung	B-C0015733
in	O
their	O
farms	B-C0557759
.	O
	
habitat	B-C0871648
restoration	B-C0205245
through	O
planting	B-C0441655
of	O
indigenous	B-C0205276
plants	B-C0032098
was	O
found	B-C0150312
to	O
be	O
ongoing	B-C0549178
,	O
especially	B-C0205555
on	O
compounds	B-C1706082
of	O
public	B-C1552744
institutions	I-C1552744
as	O
well	O
as	O
on	O
private	B-C0681784
lands	I-C0681784
.	O
	
although	O
drought	B-C0013140
was	O
found	B-C0150312
to	O
be	O
a	O
challenge	O
for	O
seedlings	B-C0242437
development	B-C1527148
especially	O
on	O
the	O
low	B-C0205251
elevation	B-C0702240
sites	B-C0205145
,	O
destruction	B-C1948029
by	O
livestock	B-C2936506
especially	O
during	B-C0347984
the	O
dry	B-C0205222
season	B-C0036497
is	O
also	O
a	O
major	B-C0205164
threat	B-C0749385
.	O
	
in	O
this	O
study	B-C2603343
,	O
it	O
was	O
recommended	B-C0034866
that	O
any	O
future	B-C0016884
habitat	B-C0871648
restoration	B-C0205245
initiative	B-C0424093
should	O
include	B-C0332257
strong	B-C0442821
chain-link	B-C3273359
fencing	B-C0441655
to	O
protect	O
the	O
seedlings	B-C0242437
from	O
livestock	B-C2936506
activity	B-C0441655
.	O
	
recognizing	O
that	O
the	O
preferred	B-C0558295
habitats	B-C0871648
for	O
the	O
species	B-C1705920
are	O
in	O
the	O
valleys	B-C0563004
,	O
systematic	B-C0220922
planting	B-C0441655
of	O
keystone	B-C0032098
plant	I-C0032098
species	B-C1705920
such	O
as	O
fig	B-C0969754
trees	I-C0969754
ficus	B-C0969754
creates	B-C1706214
the	O
best	O
microhabitats	B-C0871648
.	O
	
these	O
are	O
better	B-C0332272
than	O
general	B-C0205246
woodlots	B-C1254362
of	O
indigenous	B-C0205276
trees	B-C0040811
.	O
	
the	O
clinical	B-C0205210
and	O
economic	B-C0013557
burden	B-C2828008
of	O
significant	B-C0750502
bleeding	B-C0019080
during	B-C0347984
lung	B-C0396565
resection	I-C0396565
surgery	I-C0396565
a	O
retrospective	B-C2985505
matched	I-C2985505
cohort	I-C2985505
analysis	I-C2985505
of	O
real	B-C0205238
-	O
world	B-C2700280
data	B-C1511726
the	O
objective	B-C1571702
of	O
this	O
retrospective	B-C0035363
study	I-C0035363
was	O
to	O
quantify	B-C1709793
the	O
clinical	B-C0205210
and	O
economic	B-C0013557
burden	B-C2828008
of	O
significant	B-C0750502
bleeding	B-C0019080
in	O
lung	B-C0396565
resection	I-C0396565
surgery	I-C0396565
in	O
the	O
us	B-C0041703
.	O
	
this	O
study	B-C2603343
utilized	B-C1524063
2009-2012	O
data	B-C1511726
from	O
the	O
premier	B-C0242356
perspective	I-C0242356
database	I-C0242356
.	O
	
adult	B-C0001675
patients	B-C0030705
with	O
primary	B-C0189497
pulmonary	I-C0189497
lobectomy	I-C0189497
or	O
segmentectomy	B-C0189488
procedures	I-C0189488
were	O
categorized	B-C0871968
by	O
the	O
surgical	B-C0449446
approach	I-C0449446
vats	B-C0752151
vs	O
open	B-C4283938
and	O
primary	B-C0332137
diagnosis	I-C0332137
primary	B-C0920688
or	O
metastatic	B-C0920688
lung	I-C0920688
cancer	I-C0920688
vs	O
non-lung	B-C0430022
cancer	I-C0430022
.	O
	
patients	B-C0030705
requiring	O
3	O
units	B-C0439148
of	O
blood	B-C0456388
products	I-C0456388
with	O
at	B-C1524031
least	I-C1524031
1	O
unit	B-C0439148
of	O
prbcs	B-C2316467
""""	O
significant	B-C0750502
bleeding	B-C0019080
""""	O
cohort	B-C0599755
those	O
requiring	O
<3	O
units	B-C0439148
""""	O
non-significant	B-C1273937
bleeding	B-C0019080
""""	O
cohort	B-C0599755
and	O
those	O
not	O
requiring	O
blood	B-C0456388
products	I-C0456388
""""	O
no	B-C1518422
bleeding	B-C0019080
""""	O
cohort	B-C0599755
.	O
	
a	O
matched	O
cohort	B-C0086027
analysis	I-C0086027
was	O
performed	B-C0884358
between	O
the	O
""""	O
significant	B-C0750502
bleeding	B-C0019080
""""	O
and	O
the	O
""""	O
no	B-C1518422
bleeding	B-C0019080
cohort	B-C0599755
""""	O
using	O
matching	B-C0815175
variables	I-C0815175
hospital	B-C0019994
,	O
lung	B-C0920688
cancer	I-C0920688
diagnosis	I-C0920688
,	O
year	B-C0439234
of	I-C0439234
surgery	I-C0439234
,	O
apr-drg	B-C0457451
severity	I-C0457451
score	I-C0457451
,	O
procedure	B-C0944777
type	I-C0944777
and	O
approach	B-C0449446
,	O
age	B-C0001779
,	O
and	O
gender	B-C0079399
.	O
	
the	O
""""	O
all	B-C0444868
-	O
patient	B-C0030705
""""	O
cohort	B-C0599755
comprised	O
21	O
patients	B-C0030705
213	O
""""	O
significant	B-C0750502
bleeding	B-C0019080
""""	O
2	O
""""	O
non-significant	B-C1273937
bleeding	B-C0019080
""""	O
and	O
18	O
""""	O
no	B-C1518422
bleeding	B-C0019080
""""	O
.	O
	
overall	B-C1561607
incidence	B-C0021149
of	O
significant	B-C0750502
chest	B-C0817096
bleeding	B-C0019080
was	O
0.99	O
.	O
	
patients	B-C0030705
from	O
""""	O
significant	B-C0750502
bleeding	B-C0019080
""""	O
cohort	B-C0599755
and	O
""""	O
non-significant	B-C1273937
bleeding	B-C0019080
""""	O
cohort	B-C0599755
had	O
2.5	O
days	B-C0439228
and	O
2	O
days	B-C0439228
p	O
<	O
0.0001	O
longer	B-C0205166
length	B-C0023303
of	I-C0023303
stay	I-C0023303
in	O
the	O
hospital	B-C0019994
compared	B-C1707455
to	O
those	O
in	O
the	O
""""	O
no	B-C1518422
bleeding	B-C0019080
""""	O
cohort	B-C0599755
,	O
respectively	O
.	O
	
overall	B-C1561607
,	O
hospital	B-C0206174
costs	I-C0206174
for	O
""""	O
significant	B-C0750502
bleeding	B-C0019080
""""	O
cohort	B-C0599755
were	O
higher	B-C0205250
than	O
""""	O
no	B-C1518422
bleeding	B-C0019080
""""	O
cohort	B-C0599755
for	O
those	O
who	O
were	O
covered	B-C0439844
under	O
medicare	B-C0018717
59	O
vs	O
23	O
,	O
were	O
76	O
years	B-C1510829
of	I-C1510829
age	I-C1510829
64	O
vs	O
24	O
,	O
had	O
greater	B-C1704243
severity	B-C0521117
of	I-C0521117
illness	I-C0521117
97	O
vs	O
51	O
and	O
underwent	O
open	O
segmentectomy	B-C2987624
74	O
vs	O
21	O
.	O
	
hospital	B-C0206174
costs	I-C0206174
for	O
""""	O
significant	B-C0750502
bleeding	B-C0019080
""""	O
cohort	B-C0599755
and	O
""""	O
non-significant	B-C1273937
bleeding	B-C0019080
""""	O
were	O
significantly	B-C0750502
higher	B-C0205250
11	O
and	O
5	O
,	O
respectively	O
,	O
p	O
<	O
0.0001	O
than	O
no	B-C1518422
bleeding	B-C0019080
cohort	B-C0599755
.	O
	
although	O
significant	B-C0750502
bleeding	B-C0019080
during	B-C0347984
lung	B-C0396565
resection	I-C0396565
surgery	I-C0396565
is	O
rare	B-C0522498
,	O
patients	B-C0030705
with	O
such	O
complication	B-C0009566
could	O
stay	B-C3489408
longer	B-C0205166
at	O
the	O
hospital	B-C0019994
and	O
cost	B-C0206174
laceration	B-C0043246
of	O
a	O
branch	B-C1253959
of	I-C1253959
the	O
profunda	B-C0226455
femoris	I-C0226455
artery	I-C0226455
caused	B-C0678227
by	O
a	O
spike	B-C0243095
of	O
the	O
displaced	B-C0012727
lesser	B-C0223866
trochanter	I-C0223866
in	O
an	O
inter-trochanteric	B-C0229984
femoral	B-C0015802
fracture	I-C0015802
.	O
	
a	O
case	B-C0007320
report	I-C0007320
injury	B-C3263722
of	O
femoral	B-C1116455
vessels	I-C1116455
is	O
an	O
extremely	B-C0205403
rare	B-C0522498
complication	B-C0009566
in	O
intertrochanteric	B-C0229984
femoral	B-C0015802
fractures	I-C0015802
.	O
	
in	O
most	O
cases	B-C0220856
reported	B-C0700287
,	O
the	O
vascular	B-C1402315
lesion	I-C1402315
involves	B-C1314939
the	O
superficial	B-C0447106
femoral	I-C0447106
artery	I-C0447106
,	O
whereas	O
in	O
very	O
few	O
cases	B-C0220856
does	O
it	O
involve	B-C1314939
the	O
profunda	B-C0226455
femoris	I-C0226455
artery	I-C0226455
.	O
	
we	O
report	B-C0684224
a	O
case	B-C0220856
of	O
acute	B-C0333276
bleeding	I-C0333276
due	O
to	O
laceration	B-C0043246
of	O
a	O
perforating	B-C0549099
branch	B-C1253959
of	I-C1253959
the	O
profunda	B-C0226455
femoris	I-C0226455
artery	I-C0226455
caused	B-C0678227
by	O
a	O
sharp	B-C1444775
fragment	B-C0332255
of	I-C0332255
the	O
displaced	B-C0012727
lesser	B-C0223866
trochanter	I-C0223866
in	O
an	O
intertrochanteric	B-C0229984
femoral	B-C0015802
fracture	I-C0015802
the	O
lesion	B-C0221198
was	O
treated	B-C1522326
by	O
transcatheter	B-C0203006
embolization	I-C0203006
.	O
	
the	O
arterial	B-C0340652
injury	I-C0340652
may	O
be	O
iatrogenic	B-C0439669
,	O
occurring	B-C1709305
during	O
intramedullary	B-C2732619
internal	B-C0016642
fixation	I-C0016642
,	O
or	O
less	O
frequently	B-C0332183
,	O
the	O
injury	B-C3263722
may	O
be	O
due	O
to	O
the	O
fracture	B-C0016658
itself	O
,	O
caused	B-C0678227
by	O
a	O
sharp	B-C1444775
bone	B-C3698366
fragment	I-C3698366
that	O
damages	B-C1883709
the	O
profunda	B-C0226455
femoris	I-C0226455
artery	I-C0226455
or	O
one	O
of	O
its	O
perforating	B-C0549099
branches	B-C1253959
.	O
	
we	O
believe	O
that	O
intertrochanteric	B-C0229984
femoral	B-C0015802
fractures	I-C0015802
with	O
avulsed	B-C0262386
lesser	B-C0223866
trochanter	I-C0223866
are	O
at	B-C1444641
risk	I-C1444641
for	O
femoral	B-C1116455
vessel	I-C1116455
injuries	B-C3263722
caused	B-C0678227
by	O
the	O
displaced	B-C0012727
bone	B-C0262950
spike	B-C0243095
,	O
and	O
we	O
advise	O
meticulous	B-C0205556
clinical	B-C0205210
and	O
laboratory	B-C3165364
monitoring	I-C3165364
pre-	B-C0445204
and	O
post-operatively	B-C0032790
to	O
prevent	B-C0547286
serious	I-C0547286
complications	I-C0547286
.	O
	
direct	O
contact	O
with	O
perivascular	B-C0005847
tumor	B-C0597032
cells	I-C0597032
enhances	O
integrin	B-C1138427
αvβ3	I-C1138427
signaling	B-C1514762
and	O
migration	B-C1622501
of	O
endothelial	B-C0225336
cells	I-C0225336
the	O
secretion	B-C1327616
of	O
soluble	O
pro-angiogenic	B-C0002976
factors	I-C0002976
by	O
tumor	B-C0597032
cells	I-C0597032
and	O
stromal	B-C0162597
cells	I-C0162597
in	O
the	O
perivascular	B-C0005847
niche	O
promotes	O
the	O
aggressive	B-C1519670
angiogenesis	I-C1519670
that	O
is	O
typical	O
of	O
glioblastoma	B-C0017636
gbm	B-C0017636
.	O
	
here	O
,	O
we	O
show	O
that	O
angiogenesis	B-C1519670
also	O
can	O
be	O
promoted	O
by	O
a	O
direct	O
interaction	O
between	O
brain	B-C0006104
tumor	B-C0597032
cells	I-C0597032
,	O
including	O
tumor	B-C0597032
cells	I-C0597032
with	O
cancer	B-C1956422
stem	I-C1956422
-like	O
properties	O
cscs	B-C1956422
,	O
and	O
endothelial	B-C0225336
cells	I-C0225336
ecs	B-C0225336
.	O
	
as	O
shown	O
in	B-C1533691
vitro	I-C1533691
,	O
this	O
direct	O
interaction	O
is	O
mediated	O
by	O
binding	B-C0597358
of	O
integrin	B-C1138427
αvβ3	I-C1138427
expressed	B-C0597360
on	O
ecs	B-C0225336
to	O
the	O
rgd-peptide	B-C0052350
in	O
l1cam	B-C0950625
expressed	B-C1171362
on	O
cscs	B-C1956422
.	O
	
it	O
promotes	O
both	O
ec	B-C0225336
network	B-C0007613
formation	I-C0007613
and	O
enhances	O
directed	O
migration	B-C1622501
toward	O
basic	O
fibroblast	B-C0016026
growth	I-C0016026
factor	I-C0016026
.	O
	
activation	B-C1879547
of	O
αvβ3	B-C1138427
and	O
bone	B-C1384557
marrow	I-C1384557
tyrosine	I-C1384557
kinase	I-C1384557
on	I-C1384557
chromosome	I-C1384557
x	I-C1384557
bmx	B-C1453891
is	O
required	O
for	O
migration	B-C1622501
stimulated	O
by	O
direct	O
binding	B-C0597358
but	O
not	O
for	O
migration	B-C1622501
stimulated	O
by	O
soluble	O
factors	O
.	O
	
rgd-peptide	B-C0052350
treatment	B-C1522326
of	O
mice	B-C0025929
with	O
established	O
intracerebral	B-C0442111
gbm	B-C0017636
xenografts	B-C0522537
significantly	O
reduced	O
the	O
percentage	O
of	O
sox2	B-C0300483
-positive	O
tumor	B-C0597032
cells	I-C0597032
and	O
cscs	B-C1956422
in	O
close	O
proximity	O
to	O
ecs	B-C0225336
,	O
decreased	O
integrin	B-C1138427
αvβ3	I-C1138427
and	O
bmx	B-C1453891
activation	O
and	O
p130cas	B-C1451358
phosphorylation	B-C1158886
in	O
the	O
ecs	B-C0225336
,	O
and	O
reduced	O
the	O
vessel	B-C0005847
surface	B-C0205146
area	I-C0205146
.	O
	
these	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
aspect	O
of	O
the	O
regulation	B-C1327622
of	O
angiogenesis	B-C1519670
in	O
gbm	B-C0017636
that	O
can	O
impact	O
therapeutic	B-C0302350
anti-angiogenic	B-C0596087
the	O
use	O
of	O
ocimum	B-C1483717
americanum	I-C1483717
essential	B-C0028910
oil	I-C0028910
against	O
the	O
pathogens	B-C0450254
aeromonas	B-C0085491
hydrophila	I-C0085491
and	O
gyrodactylus	B-C1211435
sp	I-C1211435
.	O
	
in	O
silver	B-C1939719
catfish	I-C1939719
rhamdia	B-C1194855
quelen	I-C1194855
the	O
bactericidal	B-C1271650
activity	I-C1271650
mic-test	B-C0427978
of	O
ocimum	B-C1483717
americanum	I-C1483717
inflorescences	B-C2697680
essential	B-C0028910
oil	I-C0028910
oaeo	B-C0028910
against	O
aeromonas	B-C0085491
hydrophila	I-C0085491
was	O
determined	O
in	O
this	O
study	O
.	O
	
it	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
oaeo	B-C0028910
and	O
the	O
main	O
compound	B-C0205198
found	O
in	O
the	O
oil	B-C0028908
linalool	B-C0064997
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	B-C0243077
of	O
hemolysis	B-C0019054
caused	O
by	O
aer	B-C0085491
.	O
	
hydrophila	I-C0085491
in	O
fish	B-C1939719
erythrocytes	B-C0014792
.	O
	
an	O
in	B-C0681829
vivo	I-C0681829
experiment	I-C0681829
was	O
conducted	O
to	O
evaluate	O
survival	B-C0038952
of	O
fish	B-C0016163
rhamdia	B-C1194855
quelen	I-C1194855
experimentally	B-C0681814
infected	B-C0439663
with	O
aer	B-C0085491
.	O
	
hydrophila	I-C0085491
and	O
exposed	B-C0332157
to	O
oaeo	B-C0028910
.	O
	
a	O
second	O
experiment	B-C0681814
was	O
conducted	O
to	O
evaluate	O
the	O
in	B-C0681828
vitro	I-C0681828
and	O
in	B-C0681829
vivo	I-C0681829
activity	O
of	O
oaeo	B-C0028910
mix	O
from	O
inflorescences	B-C2697680
and	O
leaves	B-C0242724
against	O
the	O
parasite	B-C1211435
gyrodactylus	I-C1211435
sp	I-C1211435
.	O
	
the	O
oaeo	B-C0028910
showed	O
weak	B-C1762617
in	B-C0681828
vitro	I-C0681828
activity	O
against	O
aer	B-C0085491
.	O
	
hydrophila	I-C0085491
6400	O
μg	O
ml	O
.	O
	
at	O
subinhibitory	O
concentrations	O
oaeo	B-C0028910
100	O
μg	O
ml	O
inhibited	B-C3463820
hemolysis	B-C0019054
90%	O
caused	O
by	O
aer	B-C0085491
.	O
	
hydrophila	I-C0085491
in	O
fish	B-C1939719
erythrocytes	B-C0014792
,	O
however	O
,	O
linalool	B-C0064997
did	O
not	B-C0332197
present	I-C0332197
hemolysis	B-C0019054
inhibition	B-C3463820
activity	I-C3463820
.	O
	
at	O
low	O
concentrations	O
10	O
and	O
20	O
mg	O
l	O
added	O
to	O
the	O
water	B-C0043047
oaeo	B-C0028910
promoted	B-C0033414
survival	B-C0038952
of	O
experimentally	O
infected	B-C0439663
fish	B-C1939719
with	O
aer	B-C0085491
.	O
	
hydrophila	I-C0085491
.	O
	
lastly	O
,	O
oaeo	B-C0028910
-mix	O
50	O
mg	O
l	O
was	O
effective	B-C1704419
against	O
gyrodactylus	B-C1211435
sp	I-C1211435
.	O
	
significantly	B-C4055638
reducing	I-C4055638
60%	O
the	O
number	O
of	O
parasites	B-C0030498
in	O
the	O
fish	B-C1939719
.	O
	
interleukin-1β	B-C0021753
induced	O
stress	B-C1325596
granules	I-C1325596
sequester	B-C0333312
cox-2	B-C0387583
mrna	B-C0035696
and	O
regulates	B-C1327622
its	O
stability	B-C2350440
and	O
translation	B-C0678935
in	O
human	B-C0086418
oa	B-C0029408
chondrocytes	B-C0225369
enhanced	B-C2349975
and	O
immediate	O
expression	B-C0017262
of	O
cyclooxygenase-2	B-C1367485
cox-2	B-C1367485
mrna	B-C0035696
is	O
observed	O
in	O
il-1β	B-C0021753
-	O
stimulated	B-C1292856
oa	B-C0029408
chondrocytes	B-C0225369
but	O
the	O
synthesis	B-C0597295
of	I-C0597295
protein	I-C0597295
found	O
significantly	O
delayed	B-C0205421
.	O
	
here	O
we	O
investigated	O
the	O
role	O
of	O
stress	B-C1325596
granules	I-C1325596
sgs	B-C1325596
,	O
ribonucleoprotein	B-C1167298
complexes	I-C1167298
that	O
regulate	B-C1327622
mrna	B-C0678935
translation	I-C0678935
,	O
in	O
the	O
delayed	B-C0205421
translation	B-C0678935
of	O
cox-2	B-C1367485
mrnas	B-C0035696
in	O
il-1β	B-C0021753
-	O
stimulated	B-C1292856
oa	B-C0029408
chondrocytes	B-C0225369
.	O
	
stimulation	B-C1292856
of	O
human	B-C0086418
chondrocytes	B-C0225369
with	O
il-1β	B-C0021753
activated	O
the	O
stress	B-C0149784
response	I-C0149784
genes	B-C0017337
and	O
the	O
phosphorylation	B-C1158886
of	O
eif2α	B-C0013733
that	O
triggered	B-C1444748
the	O
assembly	B-C2247634
of	I-C2247634
sgs	I-C2247634
.	O
	
using	O
combined	O
immunofluorescence	B-C0079603
staining	I-C0079603
of	O
sgs	B-C1325596
markers	B-C0005516
and	O
cox-2	B-C0387583
protein	I-C0387583
,	O
rna	B-C0035668
fluorescence	B-C0162789
in	I-C0162789
situ	I-C0162789
hybridization	I-C0162789
and	O
rna	B-C0035668
immunoprecipitation	B-C0021069
,	O
the	O
cox-2	B-C1367485
mrnas	B-C0035696
were	O
found	O
sequestered	B-C0333312
in	O
sgs	B-C1325596
in	O
il-1β	B-C0021753
-	O
stimulated	B-C1292856
oa	B-C0029408
chondrocytes	B-C0225369
.	O
	
no	B-C1513916
increase	B-C0442805
in	O
cox-2	B-C0387583
protein	B-C1171362
expression	I-C1171362
was	O
observed	O
during	O
the	O
persistence	B-C0439590
of	O
sgs	B-C1325596
but	O
enhanced	B-C2349975
expression	B-C1171362
of	O
cox-2	B-C0387583
protein	I-C0387583
was	O
noted	O
upon	O
clearance	B-C0449297
of	O
the	O
sgs	B-C1325596
.	O
	
inhibition	B-C3463820
of	O
sgs	B-C1325596
clearance	B-C0449297
blocked	B-C0332206
cox-2	B-C1367485
mrna	B-C0035696
translation	B-C0678935
whereas	O
blocking	B-C0332206
the	O
assembly	B-C2247634
of	I-C2247634
sgs	I-C2247634
by	O
tia-1	B-C1429678
depletion	B-C0333668
resulted	O
in	O
rapid	O
and	O
increased	B-C0205217
production	B-C0005572
of	O
cox-2	B-C0387583
and	O
pge2	B-C0012472
.	O
	
our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	B-C2247634
of	I-C2247634
sgs	I-C2247634
and	O
sequestration	B-C0333312
of	O
cox-2	B-C1367485
mrnas	B-C0035696
in	O
human	B-C0086418
oa	B-C0029408
chondrocytes	B-C0225369
under	O
pathological	B-C0039058
conditions	I-C0039058
.	O
	
post-transcriptional	B-C1514248
regulation	I-C1514248
of	O
cox-2	B-C1367485
mrnas	B-C0678935
translation	I-C0678935
by	O
sgs	B-C1325596
indicates	O
a	O
role	O
in	O
il-1β	B-C0021753
-mediated	O
catabolic	B-C0311402
response	B-C0871261
that	O
could	O
be	O
therapeutically	B-C0087111
targeted	O
in	O
spatio-temporal	B-C1704711
distribution	I-C1704711
of	O
bark	B-C0949119
and	O
ambrosia	B-C0331432
beetles	B-C0009276
in	O
a	O
brazilian	B-C0006137
tropical	B-C0086312
dry	I-C0086312
forest	I-C0086312
bark	B-C0949119
and	O
the	O
ambrosia	B-C0331432
beetles	B-C0009276
dig	O
into	O
host	B-C0868970
plants	I-C0868970
and	O
live	O
most	O
of	O
their	O
lives	O
in	O
concealed	O
tunnels	B-C1116506
.	O
	
we	O
assessed	B-C1516048
beetle	B-C0009276
community	B-C0009462
dynamics	B-C0237587
in	O
tropical	B-C0086312
dry	I-C0086312
forest	I-C0086312
sites	B-C0205145
in	O
early	B-C1279919
,	O
intermediate	B-C1254367
,	O
and	O
late	B-C0205087
successional	B-C1306673
stages	I-C1306673
,	O
evaluating	O
the	O
influence	O
of	O
resource	B-C0035201
availability	B-C0470187
and	O
seasonal	B-C0036496
variations	I-C0036496
in	O
guild	B-C0205556
structure	I-C0205556
.	O
	
we	O
collected	B-C1516695
a	O
total	O
of	O
763	O
beetles	B-C0009276
from	O
23	O
species	B-C1705920
,	O
including	O
14	O
bark	B-C0949119
beetle	B-C0009276
species	B-C1705920
,	O
and	O
9	O
ambrosia	B-C0331432
beetle	B-C0009276
species	B-C1705920
.	O
	
local	B-C0205276
richness	B-C0205556
of	O
bark	B-C0949119
and	O
ambrosia	B-C0331432
beetles	B-C0009276
was	O
estimated	O
at	O
31	O
species	B-C1705920
.	O
	
bark	B-C0949119
and	O
ambrosia	B-C0331432
composition	B-C1254370
was	O
similar	O
over	O
the	O
successional	B-C1306673
stages	I-C1306673
gradient	B-C0812409
,	O
and	O
beta	B-C1880371
diversity	I-C1880371
among	O
sites	B-C0205145
was	O
primarily	O
determined	O
by	O
species	B-C1705920
turnover	O
,	O
mainly	O
in	O
the	O
bark	B-C0949119
beetle	B-C0009276
community	B-C0009462
.	O
	
bark	B-C0949119
beetle	B-C0009276
richness	B-C0205556
and	O
abundance	B-C2346714
were	O
higher	O
at	O
intermediate	B-C1306673
stages	I-C1306673
availability	B-C0470187
of	I-C0470187
wood	B-C0043217
was	O
the	O
main	O
spatial	B-C0441712
mechanism	I-C0441712
.	O
	
climate	B-C0008946
factors	B-C1521761
were	O
effectively	O
non-seasonal	B-C0205556
.	O
	
ambrosia	B-C0331432
beetles	B-C0009276
were	O
not	O
influenced	O
by	O
successional	B-C1306673
stages	I-C1306673
,	O
however	O
the	O
increase	B-C0442805
in	O
wood	B-C0043217
resulted	O
in	O
increased	B-C0205217
abundance	B-C2346714
.	O
	
we	O
found	O
higher	O
richness	B-C0205556
at	O
the	O
end	O
of	O
the	O
dry	B-C0036497
and	O
wet	B-C0036497
seasons	I-C0036497
,	O
and	O
abundance	B-C2346714
increased	B-C0205217
with	O
air	B-C0001861
moisture	B-C0868994
and	O
decreased	O
with	O
higher	O
temperatures	B-C0039476
and	O
greater	O
rainfall	B-C0034640
.	O
	
in	O
summary	O
,	O
bark	B-C0949119
beetle	B-C0009276
species	B-C1705920
accumulation	B-C0205245
was	O
higher	O
at	O
sites	B-C0205145
with	O
better	O
wood	B-C0043217
production	B-C0441655
,	O
while	O
the	O
needs	O
of	O
fungi	B-C0016832
host	B-C0868970
and	O
air	B-C0001861
moisture	B-C0868994
,	O
resulted	O
in	O
a	O
favorable	O
conditions	B-C0348080
for	O
species	B-C1705920
accumulation	B-C0205245
of	O
ambrosia	B-C0331432
.	O
	
the	O
overall	O
biological	B-C0205460
pattern	B-C0205556
among	O
guilds	O
differed	O
from	O
tropical	B-C0086312
rain	I-C0086312
forests	I-C0086312
,	O
showing	O
patterns	O
similar	O
to	O
dry	B-C0086312
forest	I-C0086312
areas	I-C0086312
.	O
	
detection	B-C1511790
and	O
characterization	O
of	O
flat	B-C1510713
aberrant	I-C1510713
crypt	I-C1510713
foci	I-C1510713
flat	I-C1510713
acf	I-C1510713
in	O
the	O
novel	O
a/j	B-C2986594
min/+	I-C2986594
mouse	I-C2986594
flat	B-C1510713
aberrant	I-C1510713
crypt	I-C1510713
foci	I-C1510713
flat	B-C1510713
acf	I-C1510713
and	O
mucin-depleted	B-C3828884
foci	I-C3828884
mdf	B-C3828884
have	O
previously	O
been	O
described	O
as	O
preneoplastic	B-C1514395
colonic	I-C1514395
lesions	I-C1514395
.	O
	
we	O
used	O
the	O
novel	O
a/j	B-C2986594
min/+	I-C2986594
mouse	I-C2986594
model	I-C2986594
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon	B-C0699790
carcinogenesis	I-C0699790
to	O
refine	O
the	O
method	O
of	O
detection	B-C1511790
of	O
flat	B-C1510713
acf	I-C1510713
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	B-C0221198
by	O
histological	B-C0019637
examination	I-C0019637
and	O
comparison	O
with	O
mdf	B-C3828884
.	O
	
colons	B-C0009368
were	O
stained	B-C1319310
with	I-C1319310
methylene	I-C1319310
blue	I-C1319310
mb	B-C0025746
for	O
flat	B-C1510713
acf	I-C1510713
detection	B-C1511790
and	O
restained	B-C0487602
with	O
high-iron	B-C0062712
diamine-alcian	I-C0062712
blue	I-C0062712
hid-ab	B-C0062712
for	O
mdf	B-C3828884
detection	B-C1511790
.	O
	
optimal	O
flat	B-C1510713
acf	I-C1510713
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post-	O
mb	B-C1319310
staining	I-C1319310
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics	O
.	O
	
the	O
fraction	B-C1264633
of	I-C1264633
flat	B-C1510713
acf	I-C1510713
corresponding	O
with	O
mdf	B-C3828884
was	O
93%	O
.	O
	
flat	B-C1510713
acf	I-C1510713
/	O
mdf	B-C3828884
displayed	O
the	O
same	O
picture	O
of	O
severe	B-C0334048
dysplasia	I-C0334048
,	O
lack	B-C0332268
of	I-C0332268
mucus	B-C1513729
and	O
goblet	B-C0014597
cells	I-C0014597
and	O
accumulation	B-C4055506
of	O
cytoplasmic	B-C0521449
β-catenin	B-C0105770
.	O
	
the	O
easily	O
detectable	O
flat	B-C1510713
acf	I-C1510713
are	O
reliable	O
surface	B-C0699040
biomarkers	B-C0005516
of	O
apc	B-C0162832
-driven	O
colon	B-C0699790
carcinogenesis	I-C0699790
.	O
	
transcriptional	B-C0162493
enhancement	I-C0162493
of	O
smn	B-C1420257
levels	B-C0428479
in	O
motoneurons	B-C0026609
is	O
crucial	O
for	O
proper	O
axon	B-C0004461
morphology	B-C0332437
in	O
zebrafish	B-C0043457
an	O
unresolved	O
mystery	O
in	O
the	O
field	O
of	O
spinal	B-C0026847
muscular	I-C0026847
atrophy	I-C0026847
sma	B-C0026847
is	O
why	O
a	O
reduction	O
of	O
the	O
ubiquitously	O
expressed	O
smn	B-C1571507
protein	I-C1571507
causes	O
defects	B-C0241225
mostly	O
in	O
motoneurons	B-C0026609
.	O
	
we	O
addressed	O
the	O
possibility	O
that	O
this	O
restricted	O
vulnerability	O
stems	O
from	O
elevated	O
smn	B-C1171362
expression	I-C1171362
in	O
motoneurons	B-C0026609
.	O
	
to	O
explore	O
this	O
,	O
we	O
established	O
an	O
ex	B-C4305352
vivo	I-C4305352
zebrafish	I-C4305352
culture	I-C4305352
system	I-C4305352
of	O
gfp	O
-	O
marked	O
motoneurons	O
to	O
quantitatively	O
measure	O
smn	O
protein	O
and	O
smn	O
mrna	O
levels	O
as	O
well	O
as	O
promoter	O
activity	O
in	O
motoneurons	O
versus	O
other	O
cell	O
types	O
.	O
	
importantly	O
,	O
we	O
uncovered	O
that	O
smn	O
levels	O
are	O
elevated	O
in	O
motoneurons	O
by	O
means	O
of	O
transcriptional	O
activation	O
.	O
	
in	O
addition	O
,	O
we	O
identified	O
the	O
ets	O
family	O
transcription	O
factor	O
etv5b	O
to	O
be	O
responsible	O
for	O
increased	O
smn	O
transcription	O
in	O
motoneurons	O
.	O
	
moreover	O
,	O
we	O
established	O
that	O
the	O
additional	O
supply	O
of	O
smn	O
protein	O
in	O
motoneurons	O
is	O
necessary	O
for	O
proper	O
axonogenesis	O
in	O
a	O
cell-autonomous	O
manner	O
.	O
	
these	O
findings	O
demonstrate	O
the	O
reliance	O
of	O
motoneurons	O
on	O
more	O
smn	O
,	O
thereby	O
adding	O
a	O
novel	O
piece	O
of	O
evidence	O
for	O
their	O
increased	O
vulnerability	O
under	O
sma	O
conditions	I-C0026847
evaluation	B-C0220825
of	O
response	O
from	O
axitinib	B-C1700874
per	O
response	B-C1709926
evaluation	I-C1709926
criteria	I-C1709926
in	I-C1709926
solid	I-C1709926
tumors	I-C1709926
versus	O
choi	B-C0935549
criteria	I-C0935549
in	O
previously	O
treated	B-C0332154
patients	B-C0030705
with	O
metastatic	B-C0278678
renal	I-C0278678
cell	I-C0278678
carcinoma	I-C0278678
axitinib	B-C1700874
,	O
a	O
selective	O
and	O
potent	O
tyrosine	B-C1268567
kinase	I-C1268567
inhibitor	I-C1268567
of	O
vascular	B-C0148199
endothelial	I-C0148199
growth	I-C0148199
factor	I-C0148199
receptors	I-C0148199
,	O
was	O
available	O
to	O
patients	B-C0030705
from	O
canada	B-C0006823
and	O
australia	B-C0004340
,	O
prior	O
to	O
regulatory	O
approval	B-C2346845
of	O
axitinib	B-C1700874
in	O
these	O
countries	B-C0454664
,	O
for	O
treatment	B-C0087111
of	O
clear-cell	B-C2931852
metastatic	I-C2931852
renal	I-C2931852
cell	I-C2931852
carcinoma	I-C2931852
mrcc	B-C2931852
after	O
failure	O
of	O
one	O
prior	O
systemic	O
regimen	B-C0040808
.	O
	
this	O
single-arm	B-C2826346
,	O
open-label	B-C1709323
study	I-C1709323
of	O
axitinib	B-C1700874
evaluated	O
the	O
efficacy	B-C1707887
,	O
safety	B-C1705187
,	O
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
qol	B-C0034380
in	O
patients	B-C0030705
with	O
mrcc	B-C2931852
whose	O
disease	B-C0012634
progressed	B-C0242656
after	O
one	O
prior	O
systemic	O
first-line	B-C1708063
regimen	I-C1708063
.	O
	
primary	O
objective	O
was	O
objective	O
response	B-C0237629
rate	I-C0237629
evaluated	B-C0220825
per	O
response	B-C1709926
evaluation	I-C1709926
criteria	I-C1709926
in	I-C1709926
solid	I-C1709926
tumors	I-C1709926
recist	B-C1709926
and	O
choi	B-C0935549
criteria	I-C0935549
.	O
	
progression-free	B-C0242792
survival	I-C0242792
,	O
overall	B-C4086681
survival	I-C4086681
,	O
safety	B-C1705187
,	O
and	O
qol	B-C0034380
were	O
secondary	O
end	O
points	O
.	O
	
due	O
to	O
the	O
small	O
study	B-C2603343
size	O
,	O
analyses	O
comprised	O
of	O
descriptive	O
statistics	B-C2717898
.	O
	
fifteen	O
patients	B-C0030705
were	O
recruited	O
,	O
five	O
from	O
canada	B-C0006823
and	O
ten	O
from	O
australia	B-C0004340
,	O
over	O
a	O
limited	O
recruitment	O
period	O
.	O
	
thirteen	O
patients	B-C0030705
received	O
sunitinib	B-C1176020
as	O
prior	O
therapy	B-C0087111
.	O
	
all	O
patients	B-C0030705
had	O
clear-cell	B-C0206681
carcinoma	I-C0206681
,	O
eleven	O
had	O
prior	O
nephrectomy	B-C0027695
.	O
	
liver	B-C0023884
,	O
lung	B-C0024109
,	O
and	O
lymph	B-C0024204
nodes	I-C0024204
were	O
the	O
most	O
frequent	O
sites	O
of	O
metastases	B-C0027627
one	O
patient	B-C0030705
had	O
brain	B-C0220650
metastasis	I-C0220650
.	O
	
median	B-C0876920
time	O
on	O
axitinib	B-C1700874
was	O
118.0	O
days	B-C0439228
range	B-C1514721
3.5	O
days	B-C0439228
estimated	O
survival	B-C0038952
probability	O
at	O
12	O
months	B-C0439231
was	O
57.8	O
.	O
	
two	O
13.3	O
patients	B-C0030705
had	O
objective	O
responses	B-C0871261
per	O
recist	B-C1709926
versus	O
nine	O
60.0	O
per	O
choi	B-C0935549
criteria	I-C0935549
.	O
	
six	O
patients	B-C0030705
had	O
progressive	B-C0242656
disease	B-C0012634
based	O
on	O
recist	B-C1709926
versus	O
three	O
per	O
choi	B-C0935549
criteria	I-C0935549
.	O
	
nine	O
60.0	O
events	O
of	O
progression	B-C0242656
or	O
death	B-C0011065
occurred	O
by	O
the	O
end	O
of	O
study	B-C2603343
,	O
and	O
three	O
patients	B-C0030705
continued	O
to	O
receive	O
the	O
study	B-C2603343
drug	B-C1254351
.	O
	
fatigue	B-C0015672
33%	O
and	O
diarrhea	B-C0011991
20%	O
were	O
the	O
most	O
common	O
grade	O
3	O
all-causality	O
,	O
treatment	B-C0087111
-emergent	O
adverse	B-C0877248
events	I-C0877248
.	O
	
the	O
mean	B-C0444504
change	O
in	O
european	B-C0015176
quality	B-C0034380
of	I-C0034380
life	I-C0034380
-	O
5	O
dimensions	O
score	B-C0449820
from	O
baseline	B-C1442488
to	O
end	O
of	O
treatment	B-C0087111
was	O
-0	O
.	O
	
the	O
small	O
number	O
of	O
patients	B-C0030705
and	O
lack	O
of	O
a	O
comparator	O
arm	O
limit	O
the	O
ability	O
to	O
draw	O
definitive	B-C0443196
conclusions	B-C1707478
however	O
,	O
safety	B-C1705187
and	O
efficacy	B-C1707887
profiles	O
of	O
axitinib	B-C1700874
were	O
consistent	O
with	O
reports	O
from	O
previous	O
studies	B-C2603343
in	O
patients	B-C0030705
with	O
mrcc	B-C2931852
,	O
and	O
patients	B-C0030705
generally	O
maintained	O
qol	B-C0034380
.	O
	
the	O
sizeable	O
difference	O
observed	O
in	O
objective	O
response	B-C0237629
rate	I-C0237629
by	O
recist	B-C1709926
versus	O
choi	B-C0935549
criteria	I-C0935549
merits	O
further	O
biochemical	B-C0205474
characteristics	B-C1521970
of	O
atfar2	B-C4307379
,	O
a	O
fatty	B-C0060094
acid	I-C0060094
reductase	I-C0060094
from	O
arabidopsis	B-C0162740
thaliana	I-C0162740
that	O
reduces	O
fatty	B-C0001374
acyl-coa	I-C0001374
and	O
-	O
acp	B-C0001369
substrates	I-C0001369
into	O
fatty	B-C0015694
alcohols	I-C0015694
fatty	B-C0015694
alcohols	I-C0015694
and	O
derivatives	B-C0243072
are	O
important	B-C3898777
for	O
proper	O
deposition	B-C0333562
of	O
a	O
functional	B-C0205245
pollen	B-C1820005
wall	I-C1820005
.	O
	
mutations	B-C0596611
in	O
specific	O
genes	B-C0017337
encoding	O
fatty	B-C0060094
acid	I-C0060094
reductases	I-C0060094
far	B-C0060094
responsible	O
for	O
fatty	B-C0015694
alcohol	I-C0015694
production	B-C0205245
cause	O
abnormal	B-C0205161
development	B-C1527148
of	O
pollen	B-C0032385
.	O
	
a	O
disrupted	B-C0332454
atfar2	B-C1428496
ms2	I-C1428496
gene	I-C1428496
in	O
arabidopsis	B-C0162740
thaliana	I-C0162740
results	B-C1274040
in	O
pollen	B-C0032385
developing	B-C1527148
an	O
abnormal	B-C0205161
exine	B-C1820006
layer	I-C1820006
and	O
a	O
reduced	B-C0243095
fertility	I-C0243095
phenotype	B-C0031437
.	O
	
atfar2	B-C4307379
has	O
been	O
shown	O
to	O
be	O
targeted	B-C1521840
to	O
chloroplasts	B-C0008266
and	O
in	O
a	O
purified	B-C0348078
form	I-C0348078
to	O
be	O
specific	B-C0205369
for	O
acyl-acp	B-C0001369
substrates	I-C0001369
.	O
	
here	O
,	O
we	O
present	O
data	B-C1511726
on	O
the	O
in	B-C1533691
vitro	I-C1533691
and	O
in	O
planta	B-C0032098
characterizations	B-C1880022
of	O
atfar2	B-C4307379
from	O
a	B-C0162740
.	O
	
thaliana	I-C0162740
and	O
show	O
that	O
this	O
enzyme	B-C0014442
has	O
the	O
ability	O
to	O
use	O
both	O
,	O
c16	B-C0001369
and	O
c16	B-C0030239
,	O
as	O
substrates	B-C0178623
to	O
produce	O
c16	B-C0055152
.	O
	
our	O
results	O
further	O
show	O
that	O
atfar2	B-C4307379
is	O
highly	O
similar	O
in	O
properties	B-C0205556
and	O
substrate	B-C0178623
specificity	B-C0037791
to	O
atfar6	B-C0060094
for	O
which	O
in	B-C1533691
vitro	I-C1533691
data	B-C1511726
has	O
been	O
published	O
,	O
and	O
which	O
is	O
also	O
a	O
chloroplast	B-C0008266
localized	B-C0392752
enzyme	B-C0014442
.	O
	
this	O
suggests	O
that	O
although	O
atfar2	B-C4307379
is	O
the	O
major	O
enzyme	B-C0014442
responsible	O
for	O
exine	B-C1820006
layer	I-C1820006
functionality	B-C0542341
,	O
atfar6	B-C0060094
might	O
provide	O
functional	B-C0205245
redundancy	B-C1313915
to	O
comparing	B-C1707455
time	B-C0040226
perception	I-C0040226
among	O
morphine	B-C0026549
-	O
derived	B-C1441547
drugs	B-C0013227
addicts	B-C0858354
and	O
controls	B-C0009932
the	O
aim	B-C1947946
of	O
the	O
present	O
study	B-C2603343
is	O
to	O
compare	B-C1707455
time	B-C0040226
perception	I-C0040226
among	O
drug	B-C0700285
addicts	I-C0700285
and	O
controls	B-C0009932
.	O
	
30	O
drug	B-C0700285
addicts	I-C0700285
were	O
selected	B-C1707391
,	O
and	O
30	O
non-addict	B-C0237401
individuals	I-C0237401
were	O
selected	B-C1707391
as	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
the	O
two	O
groups	B-C0441833
performed	O
three	O
tests	B-C0392366
of	O
time	B-C0040223
reproduction	B-C0035150
,	O
time	B-C0871937
estimation	I-C0871937
,	O
and	O
time	B-C0040223
discrimination	B-C0012632
.	O
	
there	O
was	O
a	O
significant	B-C0750502
difference	B-C1705242
between	O
the	O
addicts	B-C0858354
group	B-C0441833
and	O
the	O
control	B-C0009932
group	I-C0009932
regarding	O
the	O
error	B-C0743559
of	O
time	B-C0040223
reproduction	B-C0035150
and	O
time	B-C0871937
estimation	I-C0871937
.	O
	
the	O
addict	B-C0858354
group	B-C0441833
in	O
comparison	B-C1707455
to	O
the	O
control	B-C0009932
group	I-C0009932
had	O
a	O
lower	B-C2003888
under-	O
reproduction	B-C0035150
and	O
a	O
higher	B-C0205250
over-	O
reproduction	B-C0035150
error	B-C0743559
,	O
and	O
also	O
a	O
lower	B-C2003888
under-	O
estimation	B-C0680844
and	O
higher	B-C0205250
over-	O
estimation	B-C0680844
error	B-C0743559
.	O
	
however	O
,	O
regarding	O
time	B-C0040223
discrimination	B-C0012632
,	O
no	O
significant	B-C0750502
difference	B-C1705242
was	O
observed	O
between	O
the	O
errors	B-C0743559
committed	O
by	O
both	O
groups	B-C0441833
.	O
	
on	O
the	O
other	O
hand	O
,	O
when	O
showing	O
images	B-C1704922
of	O
drug	B-C0678263
consumption	I-C0678263
tools	B-C0336791
and	O
normal	B-C0205307
images	B-C1704922
with	O
same	O
durations	B-C0449238
,	O
the	O
normal	B-C0205307
group	B-C0441833
believed	O
that	O
the	O
images	B-C1704922
related	O
to	O
drug	B-C0678263
consumption	I-C0678263
tools	B-C0336791
were	O
shown	O
for	O
a	O
shorter	B-C1806781
period	B-C1948053
of	O
time	B-C0040223
.	O
	
time	B-C0040226
perception	I-C0040226
is	O
different	B-C1705242
between	O
morphine	B-C0026549
-	O
derived	B-C1441547
drugs	B-C0013227
addicts	B-C0858354
and	O
co-delivery	B-C1705822
of	O
pemetrexed	B-C0210657
and	O
mir-21	B-C0079925
antisense	I-C0079925
oligonucleotide	I-C0079925
by	O
lipid	B-C0023779
-	O
polymer	B-C0032521
hybrid	B-C1450054
nanoparticles	I-C1450054
and	O
effects	B-C1280500
on	O
glioblastoma	B-C0017636
cells	B-C0007634
combination	B-C0009429
therapy	I-C0009429
using	O
anticancer	B-C0003392
drugs	I-C0003392
and	O
nucleic	B-C0028606
acid	I-C0028606
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug	B-C0242640
resistance	I-C0242640
in	O
cancer	B-C0027651
and	O
to	O
enhance	O
apoptosis	B-C0162638
.	O
	
in	O
this	O
study	B-C2603343
,	O
lipid	B-C0023779
-	O
polymer	B-C0032521
hybrid	B-C1450054
nanoparticles	I-C1450054
lpns	B-C1713964
,	O
which	O
contain	O
both	O
pemetrexed	B-C0210657
and	O
mir-21	B-C0079925
antisense	I-C0079925
oligonucleotide	I-C0079925
anti-mir-21	B-C0079925
,	O
have	O
been	O
developed	O
for	O
treatment	B-C1522326
of	O
glioblastoma	B-C0017636
,	O
the	O
most	O
aggressive	B-C2945759
type	O
of	O
brain	B-C0006118
tumor	I-C0006118
.	O
	
prepared	O
lpns	B-C1713964
have	O
been	O
well	O
characterized	O
by	O
particle	B-C0030608
size	I-C0030608
distribution	B-C1704711
and	O
zeta	B-C0597697
potential	I-C0597697
measurements	B-C0242485
,	O
determination	O
of	O
encapsulation	B-C2348438
efficiency	B-C0013682
,	O
and	O
in	B-C1533691
vitro	I-C1533691
release	B-C0681814
experiments	I-C0681814
.	O
	
morphology	B-C0332437
of	O
lpns	B-C1713964
was	O
determined	O
by	O
transmission	B-C0678118
electron	I-C0678118
microscopy	I-C0678118
.	O
	
lpns	B-C1713964
had	O
a	O
hydrodynamic	B-C2936194
size	B-C0456389
below	O
100	O
nm	O
and	O
exhibited	O
sustained	B-C0391871
release	I-C0391871
of	O
pemetrexed	B-C0210657
up	O
to	O
10	O
h	O
.	O
	
encapsulation	B-C2348438
of	O
pemetrexed	B-C0210657
in	O
lpns	B-C1713964
increased	O
cellular	B-C0007613
uptake	I-C0007613
from	O
6%	O
to	O
78%	O
.	O
	
results	O
of	O
confocal	B-C0242842
microscopy	I-C0242842
analysis	I-C0242842
have	O
shown	O
that	O
co-delivery	B-C1705822
of	O
anti-mir-21	B-C0079925
significantly	O
improved	O
accumulation	B-C4055506
of	O
lpns	B-C1713964
in	O
the	O
nucleus	B-C0007610
of	O
u87mg	B-C0007634
cells	I-C0007634
.	O
	
nevertheless	O
,	O
more	O
effective	O
cytotoxicity	B-C0596402
results	B-C1274040
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	B-C0678563
of	O
anti-mir-21	B-C0079925
,	O
loaded	O
in	O
lpns	B-C1713964
.	O
	
we	O
expect	O
that	O
the	O
effective	O
drug	B-C0085104
delivery	I-C0085104
systems	I-C0085104
can	O
be	O
obtained	O
with	O
higher	O
concentration	B-C0678563
of	O
anti-mir-21	B-C0079925
for	O
the	O
treatment	B-C0087111
of	O
expert	B-C1522486
position	B-C0282574
paper	I-C0282574
on	O
prolonged	B-C0439590
dual	B-C1096021
antiplatelet	I-C1096021
therapy	I-C1096021
in	O
secondary	B-C0679699
prevention	I-C0679699
following	O
myocardial	B-C0027051
infarction	I-C0027051
the	O
protective	B-C1280500
effect	I-C1280500
of	O
dual	B-C1096021
antiplatelet	I-C1096021
therapy	I-C1096021
dapt	B-C1096021
following	O
acute	B-C0948089
coronary	I-C0948089
syndrome	I-C0948089
is	O
undisputed	O
,	O
but	O
its	O
duration	B-C0449238
is	O
subject	O
of	O
debate	B-C0870392
.	O
	
several	O
studies	B-C2603343
show	O
that	O
prolonged	B-C0439590
therapy	B-C0087111
provides	O
a	O
clinical	B-C0205210
benefit	B-C0814225
in	O
patients	B-C0030705
following	O
acute	B-C0948089
coronary	I-C0948089
syndrome	I-C0948089
.	O
	
the	O
aim	O
of	O
this	O
position	B-C0282574
paper	I-C0282574
authored	O
by	O
austrian	B-C0337795
experts	B-C1522486
is	O
to	O
outline	O
the	O
current	B-C0521116
evidence	B-C3887511
and	O
provide	O
an	O
overview	O
of	O
recent	O
studies	B-C2603343
.	O
	
it	O
is	O
also	O
intended	O
to	O
serve	O
as	O
a	O
practical	B-C0681467
guide	I-C0681467
to	O
identify	O
those	O
patients	B-C0030705
who	O
may	O
benefit	B-C0814225
from	O
prolonged	B-C0439590
dapt	B-C1096021
.	O
	
medulloblastoma	B-C0025149
molecular	B-C1704259
pathways	I-C1704259
and	O
histopathological	B-C0243140
classification	B-C0008902
malignant	B-C0153633
brain	I-C0153633
tumors	I-C0153633
are	O
the	O
leading	B-C1522538
cause	B-C0015127
of	O
cancer	B-C0006826
death	B-C1306577
among	O
pediatric	B-C1521725
patients	B-C0030705
,	O
and	O
medulloblastoma	B-C0025149
constitutes	O
20%	O
of	O
them	O
.	O
	
currently	O
,	O
the	O
treatment	B-C0087111
is	O
risk-adapted	O
.	O
	
maximum	O
surgical	B-C0015252
resection	I-C0015252
is	O
recommended	B-C0034866
,	O
always	O
followed	O
by	O
chemotherapy	B-C3665472
and	O
neuroaxis	B-C3714787
radiotherapy	B-C1522449
.	O
	
in	O
spite	O
of	O
the	O
improving	B-C1272745
survival	B-C0038954
rate	I-C0038954
,	O
survivors	B-C0206194
succumb	O
to	O
treatment	B-C0087111
-	O
induced	B-C0205263
side	B-C0879626
effects	I-C0879626
.	O
	
to	O
reduce	B-C0392756
toxic	B-C0600688
effects	I-C0600688
,	O
molecular-targeted	B-C2699893
treatment	I-C2699893
is	O
proposed	O
.	O
	
medulloblastoma	B-C0025149
research	B-C0035168
is	O
very	O
robust	B-C2986815
,	O
and	O
new	O
articles	B-C1706852
on	O
the	O
subject	O
are	O
published	B-C0034037
daily	O
.	O
	
in	O
the	O
current	O
review	B-C0282443
we	O
have	O
tried	O
to	O
bring	O
together	O
molecular	B-C1521991
pathophysiology	B-C0031847
of	O
the	O
neoplasm	B-C0027651
and	O
current	O
pathological	B-C1521733
classification	B-C0008902
,	O
thus	O
making	O
an	O
effort	O
to	O
relate	O
tumor	B-C1519672
biology	I-C1519672
and	O
the	O
histological	B-C1301121
picture	I-C1301121
.	O
	
spatio-temporal	B-C3494293
history	I-C3494293
of	O
hiv-1	B-C3656358
crf35_ad	I-C3656358
in	O
afghanistan	B-C0001732
and	O
iran	B-C0022065
hiv-1	B-C0019704
circulating	I-C0019704
recombinant	I-C0019704
form	I-C0019704
35_ad	I-C0019704
crf35_ad	B-C3656358
has	O
an	O
important	O
position	O
in	O
the	O
epidemiological	B-C0014507
profile	B-C2003903
of	O
afghanistan	B-C0001732
and	O
iran	B-C0022065
.	O
	
despite	O
the	O
presence	O
of	O
this	O
clade	B-C0029235
in	O
afghanistan	B-C0001732
and	O
iran	B-C0022065
for	O
over	O
a	O
decade	O
,	O
our	O
understanding	O
of	O
its	O
origin	O
and	O
dissemination	B-C0332261
patterns	O
is	O
limited	O
.	O
	
in	O
this	O
study	O
,	O
we	O
performed	O
a	O
bayesian	B-C0242196
phylogeographic	I-C0242196
analysis	I-C0242196
to	O
reconstruct	O
the	O
spatio-temporal	B-C0332261
dispersion	I-C0332261
pattern	I-C0332261
of	O
this	O
clade	B-C0029235
using	O
eligible	O
crf35_ad	B-C3656358
gag	B-C0004793
and	I-C0004793
pol	I-C0004793
sequences	I-C0004793
available	O
in	O
the	O
los	B-C3829256
alamos	I-C3829256
hiv	B-C0950132
database	I-C0950132
432	O
sequences	B-C0004793
available	O
from	O
iran	B-C0022065
,	O
16	O
sequences	B-C0004793
available	O
from	O
afghanistan	B-C0001732
,	O
and	O
a	O
single	O
crf35_ad	B-C3656358
-like	O
pol	B-C0004793
sequence	I-C0004793
available	O
from	O
usa	B-C0041703
.	O
	
bayesian	B-C0002045
markov	I-C0002045
chain	I-C0002045
monte	I-C0002045
carlo	I-C0002045
algorithm	I-C0002045
was	O
implemented	O
in	O
beast	B-C0037585
v1.8	I-C0037585
.	O
	
between-country	O
dispersion	O
rates	O
were	O
tested	O
with	O
bayesian	B-C0034980
stochastic	I-C0034980
search	I-C0034980
variable	I-C0034980
selection	I-C0034980
method	I-C0034980
and	O
were	O
considered	O
significant	O
where	O
bayes	B-C1553908
factor	I-C1553908
values	I-C1553908
were	O
greater	O
than	O
three	O
.	O
	
the	O
findings	O
suggested	O
that	O
crf35_ad	B-C3656358
sequences	B-C0004793
were	O
genetically	O
similar	O
to	O
parental	B-C0004793
sequences	I-C0004793
from	O
kenya	B-C0022558
and	O
uganda	B-C0041573
,	O
and	O
to	O
a	O
set	O
of	O
subtype	B-C3656358
a1	I-C3656358
sequences	B-C0004793
available	O
from	O
afghan	B-C0001732
refugees	B-C0034961
living	O
in	O
pakistan	B-C0030211
.	O
	
our	O
results	O
also	O
showed	O
that	O
across	O
all	O
phylogenies	B-C0031797
,	O
afghan	B-C0001732
and	O
iranian	B-C0022065
crf35_ad	B-C3656358
sequences	B-C0004793
formed	O
a	O
monophyletic	B-C1704332
cluster	I-C1704332
posterior	O
clade	O
credibility>	O
0.7	O
.	O
	
the	O
divergence	O
date	O
of	O
this	O
cluster	B-C1704332
was	O
estimated	O
to	O
be	O
between	O
1990	O
and	O
1992	O
.	O
	
within	O
this	O
cluster	B-C1704332
,	O
a	O
bidirectional	B-C1706937
dispersion	B-C0332261
of	O
the	O
virus	B-C0042776
was	O
observed	O
across	O
afghanistan	B-C0001732
and	O
iran	B-C0022065
.	O
	
we	O
could	O
not	O
clearly	O
identify	O
if	O
afghanistan	B-C0001732
or	O
iran	B-C0022065
first	O
established	O
or	O
received	O
this	O
epidemic	B-C0277548
,	O
as	O
the	O
root	O
location	O
of	O
this	O
cluster	B-C1704332
could	O
not	O
be	O
robustly	O
estimated	O
.	O
	
three	O
crf35_ad	B-C3656358
sequences	B-C0004793
from	O
afghan	B-C0001732
refugees	B-C0034961
living	B-C0337646
in	I-C0337646
pakistan	B-C0030211
nested	O
among	O
afghan	B-C0001732
and	O
iranian	B-C0022065
crf35_ad	B-C3656358
branches	O
.	O
	
however	O
,	O
the	O
crf35_ad	B-C3656358
-like	O
sequence	B-C0004793
available	O
from	O
usa	B-C0041703
diverged	O
independently	O
from	O
kenyan	B-C0022558
subtype	B-C3656358
a1	I-C3656358
sequences	B-C0004793
,	O
suggesting	O
it	O
not	O
to	O
be	O
a	O
true	O
crf35_ad	B-C3656358
lineage	O
.	O
	
potential	B-C3245505
factors	B-C1521761
contributing	O
to	O
viral	B-C0042776
exchange	O
between	O
afghanistan	B-C0001732
and	O
iran	B-C0022065
could	O
be	O
injection	O
drug	O
networks	O
and	O
mass	B-C0600210
migration	I-C0600210
of	O
afghan	B-C0001732
refugees	B-C0034961
and	O
labours	B-C0022867
to	O
iran	B-C0022065
,	O
which	O
calls	O
for	O
extensive	B-C0205231
preventive	B-C1456501
the	O
benefits	B-C0814225
of	O
combination	B-C0009429
therapy	I-C0009429
with	O
esomeprazole	B-C0937846
and	O
rebamipide	B-C0069562
in	O
symptom	B-C1457887
improvement	B-C2986411
in	O
reflux	B-C0014869
esophagitis	I-C0014869
an	O
international	B-C1512888
multicenter	B-C1096776
study	I-C1096776
to	O
investigate	B-C1292732
the	O
effects	B-C1280500
of	O
esomeprazole	B-C0937846
and	O
rebamipide	B-C0069562
combination	B-C0009429
therapy	I-C0009429
on	O
symptomatic	B-C1457887
improvement	B-C2986411
in	O
patients	B-C0030705
with	O
reflux	B-C0014869
esophagitis	I-C0014869
.	O
	
a	O
total	O
of	O
501	O
patients	B-C0030705
with	O
reflux	B-C0014869
esophagitis	I-C0014869
were	O
randomized	B-C0206034
into	O
one	O
of	O
the	O
following	O
two	O
treatment	B-C0040808
regimens	I-C0040808
40	O
mg	O
esomeprazole	B-C0937846
plus	O
300	O
mg	O
rebamipide	B-C0069562
daily	B-C0332173
combination	B-C0009429
therapy	I-C0009429
group	B-C0441833
or	O
40	O
mg	O
esomeprazole	B-C0937846
daily	B-C0332173
monotherapy	B-C0087111
group	B-C0441833
.	O
	
we	O
used	O
a	O
symptom	B-C1457887
questionnaire	B-C0034394
that	O
evaluated	B-C1292732
heartburn	B-C0018834
,	O
acid	B-C0849747
regurgitation	I-C0849747
,	O
and	O
four	O
upper	B-C0857493
gastrointestinal	I-C0857493
symptoms	I-C0857493
.	O
	
the	O
primary	O
efficacy	B-C1280519
end	O
point	O
was	O
the	O
mean	O
decrease	B-C0547047
in	O
the	O
total	O
symptom	B-C3476546
score	I-C3476546
.	O
	
the	O
mean	O
decreases	B-C0547047
in	O
the	O
total	O
symptom	B-C3476546
score	I-C3476546
at	O
4	O
weeks	B-C0439230
were	O
estimated	O
to	O
be	O
-18	O
in	O
the	O
combination	B-C0009429
therapy	I-C0009429
group	B-C0441833
and	O
-15	O
in	O
the	O
monotherapy	B-C0087111
group	B-C0441833
p=0	O
.	O
	
changes	O
in	O
reflux	B-C0014869
symptom	B-C1457887
s	O
from	O
baseline	B-C1442488
after	O
4	O
weeks	B-C0439230
of	O
treatment	B-C0087111
were	O
-8	O
in	O
the	O
combination	B-C0009429
therapy	I-C0009429
group	B-C0441833
and	O
-6	O
in	O
the	O
monotherapy	B-C0087111
group	B-C0441833
p=0	O
.	O
	
over	O
a	O
4-	O
week	B-C0439230
treatment	B-C0087111
course	O
,	O
esomeprazole	B-C0937846
and	O
rebamipide	B-C0069562
combination	B-C0009429
therapy	I-C0009429
was	O
more	O
effective	B-C1704419
in	O
decreasing	B-C0442797
the	O
symptoms	B-C1457887
of	O
reflux	B-C0014869
esophagitis	I-C0014869
than	O
esomeprazole	B-C0937846
monotherapy	B-C0087111
.	O
	
integrating	B-C0205195
palliative	B-C0030231
care	I-C0030231
in	O
pediatric	B-C1518931
oncology	I-C1518931
evidence	O
for	O
an	O
evolving	B-C0332253
paradigm	B-C0681797
for	O
comprehensive	B-C0009586
cancer	B-C0920687
care	I-C0920687
the	O
demonstrated	O
benefit	O
of	O
integrating	B-C0205195
palliative	B-C0030231
care	I-C0030231
pc	B-C0030231
into	O
cancer	B-C0920425
treatment	I-C0920425
has	O
triggered	O
an	O
increased	B-C0205217
need	O
for	O
pc	B-C0030231
services	O
.	O
	
the	O
trajectory	O
of	O
integrating	B-C0205195
pc	B-C0030231
in	O
comprehensive	B-C0009586
cancer	B-C1516604
centers	I-C1516604
,	O
particularly	O
pediatric	B-C0020017
centers	I-C0020017
,	O
is	O
unknown	O
.	O
	
we	O
describe	O
our	O
8-	O
year	B-C0439234
experience	O
of	O
initiating	O
and	O
establishing	B-C0443211
pc	B-C0030231
with	O
the	O
quality	B-C0008079
of	I-C0008079
life	I-C0008079
service	I-C0008079
qols	B-C0008079
at	O
st	B-C1519168
.	O
	
jude	I-C1519168
children's	I-C1519168
research	I-C1519168
hospital	I-C1519168
.	O
	
we	O
retrospectively	O
reviewed	O
records	B-C0025102
of	I-C0025102
patients	I-C0025102
seen	O
by	O
the	O
qols	B-C0008079
n=615	O
from	O
march	B-C3829202
2007	O
to	O
december	B-C3830550
2014	O
.	O
	
variables	B-C1705098
analyzed	O
for	O
each	O
year	B-C0439234
,	O
using	O
descriptive	O
statistics	B-C1456551
,	O
included	O
diagnostic	B-C0011928
groups	I-C0011928
,	O
qols	B-C0008079
encounters	B-C1512346
,	O
goals	B-C2930505
of	I-C2930505
care	I-C2930505
,	O
duration	B-C2919551
of	I-C2919551
survival	I-C2919551
,	O
and	O
location	B-C2924451
of	I-C2924451
death	I-C2924451
.	O
	
total	O
qols	B-C0008079
patient	B-C0030705
encounters	B-C1512346
increased	B-C0205217
from	O
58	O
2007	O
to	O
1	O
2014	O
,	O
new	O
consults	B-C0009818
increased	B-C0205217
from	O
17	O
2007	O
to	O
115	O
2014	O
,	O
and	O
mean	O
encounters	B-C1512346
per	O
patient	B-C0030705
increased	B-C0205217
from	O
5.06	O
2007	O
to	O
16.11	O
2014	O
.	O
	
goal	B-C2930505
of	I-C2930505
care	I-C2930505
at	O
initial	B-C2065349
consultation	I-C2065349
shifted	O
from	O
primarily	O
comfort	B-C1331418
to	O
an	O
increasing	B-C0442808
goal	B-C3897861
of	I-C3897861
cure	I-C3897861
.	O
	
the	O
median	O
number	O
of	O
days	O
from	O
initial	B-C2065349
consult	I-C2065349
to	O
death	B-C1306577
increased	B-C0205217
from	O
52	O
days	O
2008	O
to	O
223	O
days	O
2014	O
.	O
	
a	O
trend	O
toward	O
increased	B-C0205217
outpatient	B-C0029921
location	B-C2924451
of	I-C2924451
death	I-C2924451
was	O
noted	O
with	O
42%	O
outpatient	B-C0029921
deaths	B-C1306577
in	O
2007	O
,	O
increasing	B-C0442808
to	O
a	O
majority	B-C0205164
in	O
each	O
subsequent	O
year	B-C0439234
range	O
,	O
51%-74%	O
.	O
	
hospital-wide	B-C1510665
,	O
patients	B-C0030705
receiving	O
pc	B-C0030231
services	O
before	O
death	B-C1306577
increased	B-C0205217
from	O
approximately	B-C0332232
50%	O
to	O
nearly	O
100%	O
.	O
	
since	O
its	O
inception	O
,	O
the	O
qols	B-C0008079
experienced	O
a	O
dramatic	O
increase	B-C0205217
in	O
referrals	B-C0034927
and	O
encounters	B-C1512346
per	O
patient	B-C0030705
,	O
increased	B-C0205217
use	O
by	O
all	O
clinical	B-C1704289
services	I-C1704289
,	O
a	O
trend	O
toward	O
earlier	B-C1279919
consultation	B-C0009818
and	O
longer	B-C0443252
term	I-C0443252
follow-up	B-C1522577
,	O
increasing	B-C0442808
outpatient	B-C0029921
location	B-C2924451
of	I-C2924451
death	I-C2924451
,	O
and	O
near-	O
universal	B-C0175671
pc	B-C0030231
involvement	O
at	O
the	O
end-of-life	B-C0039548
.	O
	
the	O
successful	O
integration	B-C0205195
of	O
pc	B-C0030231
in	O
a	O
comprehensive	B-C0009586
cancer	B-C1516604
center	I-C1516604
,	O
and	O
the	O
resulting	O
potential	O
for	O
improved	O
care	B-C3244104
provision	I-C3244104
over	O
time	B-C0040223
,	O
can	O
serve	O
as	O
a	O
model	B-C3161035
for	O
other	O
programs	B-C0679897
protective	B-C1704420
effects	I-C1704420
of	I-C1704420
dipeptidyl	B-C1827106
peptidase-4	I-C1827106
inhibitors	I-C1827106
on	O
progression	B-C0242656
of	O
diabetic	B-C0011884
retinopathy	I-C0011884
in	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
to	O
investigate	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
dipeptidyl	B-C1827106
peptidase-4	I-C1827106
inhibitors	I-C1827106
dpp4	B-C1827106
on	O
the	O
progression	B-C0242656
of	O
diabetic	B-C0011884
retinopathy	I-C0011884
dr	B-C0011884
in	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
based	O
on	O
the	O
dr	B-C0011884
severity	B-C0392762
scale	I-C0392762
.	O
	
the	O
medical	B-C0025102
records	I-C0025102
of	O
82	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	B-C1514923
reviewed	B-C1709940
.	O
	
fundus	B-C0200189
photographs	I-C0200189
were	O
graded	B-C0441800
using	O
early	B-C3899277
treatment	I-C3899277
diabetic	I-C3899277
retinopathy	I-C3899277
study	I-C3899277
methods	I-C3899277
.	O
	
the	O
associations	B-C0332281
between	O
baseline	B-C1442488
risk	B-C0035648
factors	I-C0035648
and	O
progression	B-C0242656
of	O
dr	B-C0011884
were	O
investigated	B-C1292732
.	O
	
seven	O
of	O
28	O
patients	B-C0030705
treated	B-C1522326
with	O
dpp4	B-C1827106
inhibitors	I-C1827106
and	O
26	O
of	O
54	O
treated	B-C1522326
with	O
other	O
hypoglycemic	B-C0020616
agents	I-C0020616
showed	O
progression	B-C0242656
of	O
retinopathy	B-C0011884
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
early	B-C0392762
treatment	I-C0392762
diabetic	I-C0392762
retinopathy	I-C0392762
study	I-C0392762
scale	I-C0392762
p	O
=	O
0.043	O
.	O
	
only	O
treatment	B-C1522326
with	O
dpp4	B-C1827106
inhibitors	I-C1827106
significantly	O
reduced	B-C0392756
the	O
progression	B-C0242656
of	O
dr	B-C0011884
in	O
patients	B-C0030705
after	O
propensity	B-C2718044
score	I-C2718044
matching	O
p	O
=	O
0.009	O
.	O
	
treatment	B-C1522326
with	O
dpp4	B-C1827106
inhibitors	I-C1827106
was	O
associated	B-C0332281
with	I-C0332281
a	O
lower	B-C2003888
risk	B-C0035647
of	O
dr	B-C0011884
progression	B-C0242656
p	O
=	O
0.011	O
.	O
	
treatment	B-C1522326
with	O
dpp4	B-C1827106
inhibitors	I-C1827106
was	O
the	O
independent	B-C0085862
protective	B-C1521761
factor	I-C1521761
against	O
the	O
progression	B-C0242656
of	O
dr	B-C0011884
,	O
aside	O
from	O
improving	B-C0243095
glycemic	I-C0243095
control	I-C0243095
.	O
	
this	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	B-C0814225
of	O
dpp4	B-C1827106
inhibitors	I-C1827106
in	O
reducing	B-C0392756
dr	B-C0011884
progression	B-C0242656
,	O
and	O
provides	O
encouraging	O
preliminary	B-C0439611
data	B-C1511726
for	O
further	O
evaluation	B-C0220825
of	O
dpp4	B-C1827106
inhibitors	I-C1827106
in	O
the	O
progression	B-C0242656
of	O
dr	B-C0011884
in	O
a	O
randomized	B-C0034656
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C0599724
trial	I-C0599724
.	O
	
production	B-C0033268
of	O
laccase	B-C0064566
by	O
cochliobolus	B-C0009206
sp	I-C0009206
.	O
	
isolated	B-C0205409
from	O
plastic	B-C0032167
dumped	B-C0037592
soils	I-C0037592
and	O
their	O
ability	B-C0085732
to	O
degrade	B-C0678637
low	B-C0032624
molecular	I-C0032624
weight	I-C0032624
pvc	I-C0032624
one	O
of	O
the	O
utmost	O
man-made	B-C2963156
problems	I-C2963156
faced	O
today	O
has	O
been	O
the	O
ever	B-C3887636
-	O
increasing	B-C0442808
plastic	B-C0032167
waste	B-C0043045
filling	B-C1708059
the	O
world	O
.	O
	
it	O
accounts	O
for	O
an	O
estimated	O
20-30%	O
by	O
volume	O
of	O
municipal	B-C1550151
solid	I-C1550151
waste	I-C1550151
in	O
landfill	B-C0563007
sites	I-C0563007
worldwide	O
.	O
	
research	O
on	O
plastic	B-C0032167
biodegradation	B-C0005482
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades	O
.	O
	
several	O
fungi	B-C0016832
have	O
been	O
identified	O
that	O
produce	O
enzymes	B-C0014442
capable	O
of	O
plastic	B-C0032167
degradation	B-C0005482
in	O
various	O
laboratory	B-C2826637
conditions	I-C2826637
.	O
	
this	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	B-C0085732
of	O
fungi	B-C0016832
to	O
degrade	B-C0678637
low	B-C0032624
molecular	I-C0032624
weight	I-C0032624
polyvinyl	I-C0032624
chloride	I-C0032624
pvc	B-C0032624
by	O
the	O
enzyme	B-C0064566
laccase	I-C0064566
.	O
	
we	O
have	O
isolated	B-C0205409
a	O
fungal	B-C0016832
species	B-C1705920
,	O
cochliobolus	B-C0009206
sp	I-C0009206
,	O
from	O
plastic	B-C0032167
dumped	B-C0037592
soils	I-C0037592
and	O
they	O
were	O
cultured	B-C0200954
on	O
czapek	B-C0010454
dox	I-C0010454
agar	I-C0010454
slants	I-C0010454
at	O
30	O
.	O
	
the	O
effectiveness	B-C1280519
of	O
this	O
fungal	B-C0016832
species	B-C1705920
on	O
the	O
degradation	B-C0005482
of	O
commercial	O
low	B-C0032624
molecular	I-C0032624
weight	I-C0032624
polyvinyl	I-C0032624
chloride	I-C0032624
pvc	B-C0032624
was	O
studied	O
under	O
laboratory	B-C2826637
conditions	I-C2826637
.	O
	
significant	O
differences	O
were	O
observed	O
from	O
the	O
ftir	B-C0206055
,	O
gc-ms	B-C0024868
,	O
and	O
sem	B-C0026020
results	O
in	O
between	O
control	B-C1550141
and	O
cochliobolus	B-C0009206
sp	I-C0009206
.	O
	
treated	O
effects	B-C1704420
of	I-C1704420
cerium	B-C0055114
and	O
titanium	B-C0145999
oxide	I-C0145999
nanoparticles	B-C1721060
in	O
soil	B-C0037592
on	O
the	O
nutrient	B-C0678695
composition	B-C0486616
of	O
barley	B-C0331554
hordeum	B-C0331554
vulgare	I-C0331554
l	I-C0331554
kernels	B-C0453143
the	O
implications	B-C0205245
of	O
metal	B-C1721060
nanoparticles	I-C1721060
menps	B-C1721060
are	O
still	O
unknown	B-C0439673
for	O
many	B-C0439064
food	B-C0242775
crops	I-C0242775
.	O
	
the	O
purpose	B-C1285529
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
effects	B-C1704420
of	I-C1704420
cerium	B-C0055114
oxide	I-C0055114
nceo₂	B-C0055114
and	O
titanium	B-C0145999
oxide	I-C0145999
ntio₂	B-C0145999
nanoparticles	B-C1721060
in	O
soil	B-C0037592
at	O
0	O
,	O
500	O
and	O
1000	O
mg	O
on	O
the	O
nutritional	B-C1521739
parameters	I-C1521739
of	O
barley	B-C0331554
hordeum	B-C0331554
vulgare	I-C0331554
l	I-C0331554
kernels	B-C0453143
.	O
	
mineral	B-C0682741
nutrients	I-C0682741
,	O
amylose	B-C0002732
,	O
β-glucans	B-C1134651
,	O
amino	B-C0002520
acid	I-C0002520
and	O
crude	B-C0033684
protein	I-C0033684
cp	B-C0033684
concentrations	B-C1446561
were	I-C1446561
measured	I-C1446561
in	O
kernels	B-C0453143
.	O
	
whole	B-C0444667
flour	B-C0016260
samples	O
were	O
analyzed	O
by	O
icp-aes/ms	B-C2930679
,	O
hplc	B-C0008562
and	O
elemental	B-C1706246
chns	I-C1706246
analyzer	I-C1706246
.	O
	
results	O
showed	O
that	O
ce	B-C0007828
and	O
ti	B-C0040302
accumulation	B-C4055506
under	O
menps	B-C1721060
treatments	B-C1522326
did	O
not	O
differ	O
from	O
the	O
control	B-C1522326
treatment	I-C1522326
.	O
	
however	O
,	O
nceo₂	B-C0055114
and	O
ntio₂	B-C0145999
had	O
an	O
impact	B-C4049986
on	O
composition	B-C0486616
and	O
nutritional	B-C3489446
quality	I-C3489446
of	O
barley	B-C0331554
kernels	B-C0453143
in	O
contrasting	B-C0205556
ways	I-C0205556
.	O
	
both	O
menps	B-C1721060
left	O
β-glucans	B-C1134651
unaffected	B-C2986417
but	O
reduced	O
amylose	B-C0002732
content	O
by	O
approximately	O
21%	O
.	O
	
most	O
amino	B-C0002520
acids	I-C0002520
and	O
cp	B-C0033684
increased	B-C0205217
.	O
	
among	O
amino	B-C0002520
acids	I-C0002520
,	O
lysine	B-C0024337
followed	O
by	O
proline	B-C0033382
saw	O
the	O
largest	B-C0442805
increase	I-C0442805
51%	O
and	O
37%	O
,	O
respectively	O
.	O
	
potassium	B-C0032821
and	O
s	B-C0038774
were	O
both	O
negatively	B-C4049986
impacted	I-C4049986
by	O
menps	B-C1721060
,	O
while	O
b	O
was	O
only	O
affected	B-C0392760
by	O
500	O
mg	O
nceo₂	B-C0055114
kg	O
.	O
	
on	O
the	O
contrary	O
zn	B-C0373748
and	O
mn	B-C0373677
concentrations	I-C0373677
were	O
improved	O
by	O
500	O
mg	O
ntio₂	B-C0145999
kg	O
,	O
and	O
ca	O
by	O
both	O
ntio₂	B-C0145999
treatments	B-C1522326
.	O
	
generally	O
,	O
our	O
findings	O
demonstrated	B-C3687625
that	O
kernels	B-C0453143
are	O
negatively	B-C1513916
affected	I-C1513916
by	O
nceo₂	B-C0055114
while	O
ntio₂	B-C0145999
can	O
potentially	O
have	O
beneficial	B-C0205556
effects	I-C0205556
.	O
	
however	O
,	O
both	O
menps	B-C1721060
have	O
the	O
potential	O
to	O
negatively	B-C4049986
impact	I-C4049986
malt	B-C0024651
and	O
feed	B-C4042899
production	I-C4042899
.	O
	
quantifying	B-C1709793
nonlinear	O
contributions	B-C1880177
to	O
cortical	B-C0853990
responses	I-C0853990
evoked	I-C0853990
by	O
continuous	B-C1293270
wrist	I-C1293270
manipulation	I-C1293270
cortical	B-C0853990
responses	I-C0853990
to	O
continuous	B-C0542478
stimuli	I-C0542478
as	O
recorded	O
using	O
either	O
magneto-	B-C0024489
or	O
electroencephalography	B-C0013819
eeg	B-C0013819
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated	B-C0237630
frequency	I-C0237630
,	O
indicating	O
nonlinear	B-C0004927
behavior	I-C0004927
.	O
	
even	O
though	O
the	O
selection	O
of	O
analysis	B-C0936012
techniques	B-C0449851
depends	O
on	O
the	O
linearity	B-C0205132
of	O
the	O
system	O
under	O
study	O
,	O
the	O
importance	O
of	O
nonlinear	O
contributions	B-C1880177
to	O
cortical	B-C0853990
responses	I-C0853990
has	O
not	O
been	O
formally	O
addressed	O
.	O
	
the	O
goal	B-C0018017
of	I-C0018017
this	I-C0018017
paper	I-C0018017
is	O
to	O
quantify	B-C1709793
the	O
nonlinear	O
contributions	B-C1880177
to	O
the	O
cortical	B-C0853990
response	I-C0853990
obtained	O
from	O
continuous	B-C0549178
sensory	B-C0150763
stimulation	I-C0150763
.	O
	
eeg	B-C0013819
was	O
used	O
to	O
record	O
the	O
cortical	B-C0853990
response	I-C0853990
evoked	I-C0853990
by	O
continuous	B-C0575717
movement	I-C0575717
of	I-C0575717
the	I-C0575717
wrist	I-C0575717
joint	I-C0575717
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic	B-C0336537
manipulator	I-C0336537
.	O
	
multisine	O
stimulus	B-C0234402
signals	I-C0234402
i.e	O
,	O
the	O
sum	O
of	O
several	B-C0443302
sinusoids	B-C0682624
elicit	O
a	O
periodic	B-C0332182
cortical	B-C0853990
response	I-C0853990
and	O
allow	O
to	O
assess	B-C1516048
the	O
nonlinear	O
contributions	B-C1880177
to	O
the	O
response	O
.	O
	
wrist	B-C0454465
dynamics	I-C0454465
relation	O
between	O
joint	B-C0022417
angle	I-C0022417
and	O
torque	B-C0376590
were	O
successfully	O
linearized	B-C0205132
,	O
explaining	O
99%	O
of	O
the	O
response	O
.	O
	
in	O
contrast	O
,	O
the	O
cortical	B-C0853990
response	I-C0853990
revealed	O
a	O
highly	O
nonlinear	O
relation	O
where	O
most	O
power	O
80	O
%	O
occurred	O
at	O
non-stimulated	O
frequencies	O
.	O
	
moreover	O
,	O
only	O
10%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric	B-C0242932
linear	I-C0242932
model	I-C0242932
.	O
	
these	O
results	B-C0683954
indicate	O
that	O
the	O
recorded	O
evoked	B-C0853990
cortical	I-C0853990
responses	I-C0853990
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	B-C0205132
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical	B-C0234402
stimulus	I-C0234402
and	O
cortical	B-C0596450
response	I-C0596450
.	O
	
using	B-C1524063
melanopsin	B-C0670514
to	O
study	B-C2603343
g	B-C1517335
protein	I-C1517335
signaling	I-C1517335
in	O
cortical	B-C0007776
neurons	B-C0027882
our	O
understanding	B-C0162340
of	O
g	B-C0682972
protein-coupled	I-C0682972
receptors	I-C0682972
gpcrs	B-C0682972
in	O
the	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
cns	B-C3714787
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	B-C3273359
allowing	O
for	O
the	O
study	B-C2603343
of	O
their	O
signaling	B-C3537152
with	O
precise	B-C1547902
temporal	I-C1547902
control	B-C2587213
.	O
	
to	O
overcome	B-C2983310
this	O
,	O
we	O
tested	B-C0039593
the	O
utility	O
of	O
the	O
bistable	B-C0205360
mammalian	B-C0024660
opsin	B-C2355587
melanopsin	B-C0670514
to	O
examine	O
g	B-C1517335
protein	I-C1517335
signaling	I-C1517335
in	O
cns	B-C3714787
neurons	B-C0027882
.	O
	
specifically	O
,	O
we	O
used	B-C1524063
biolistic	B-C0376638
gene	B-C0920531
gun	I-C0920531
approaches	O
to	O
transfect	B-C0670514
melanopsin	I-C0670514
into	O
cortical	B-C0007776
pyramidal	B-C0206441
cells	I-C0206441
maintained	B-C1314677
in	O
organotypic	B-C0040284
slice	I-C0040284
culture	I-C0040284
.	O
	
whole	B-C0242624
cell	I-C0242624
recordings	I-C0242624
from	O
transfected	B-C0027882
neurons	I-C0027882
indicated	O
that	O
application	O
of	O
blue	B-C0303896
light	I-C0303896
effectively	B-C1704419
activated	B-C1515877
the	O
transfected	B-C0670514
melanopsin	I-C0670514
to	O
elicit	B-C0449265
the	O
canonical	O
biphasic	B-C0205184
modulation	B-C0678672
of	O
membrane	B-C0596901
excitability	B-C0235169
previously	O
associated	B-C0332281
with	I-C0332281
the	O
activation	B-C1515877
of	O
gpcrs	B-C0682972
coupling	B-C1948027
to	O
gαq-11	B-C1333650
remarkably	O
,	O
full	O
mimicry	O
of	O
exogenous	B-C0205228
agonist	B-C2987634
concentration	B-C1446561
could	O
be	O
obtained	B-C1301820
with	O
pulses	B-C1947910
as	O
short	O
as	O
a	O
few	B-C0205388
milliseconds	B-C0439223
,	O
suggesting	O
that	O
their	O
triggering	B-C1444748
required	O
a	O
single	B-C0205171
melanopsin	B-C0670514
activation-deactivation	B-C1254367
cycle	I-C1254367
.	O
	
the	O
resulting	B-C1274040
temporal	B-C2587213
control	I-C2587213
over	O
melanopsin	B-C0670514
activation	B-C1515877
allowed	O
us	O
to	O
compare	B-C1707455
the	O
activation	B-C1515877
kinetics	B-C0022702
of	O
different	O
components	O
of	O
the	O
electrophysiological	B-C2350527
response	B-C0871261
.	O
	
we	O
also	O
replaced	O
the	O
intracellular	B-C0178719
loops	B-C0445022
of	O
melanopsin	B-C0670514
with	O
those	O
of	O
the	O
5-ht2a	B-C0289174
receptor	I-C0289174
to	O
create	O
a	O
light-activated	B-C1254366
gpcr	B-C0682972
capable	O
of	O
interacting	B-C1704675
with	O
the	O
5-ht2a	B-C0289174
receptor	I-C0289174
interacting	B-C1704675
proteins	B-C0033684
.	O
	
the	O
resulting	B-C1274040
chimera	B-C0162768
expressed	B-C0205245
weak	B-C1762617
activity	B-C0441655
but	O
validated	B-C1519941
the	O
potential	B-C3245505
usefulness	B-C3827682
of	O
melanopsin	B-C0670514
as	O
a	O
tool	B-C3273359
for	O
the	O
study	B-C2603343
of	O
g	B-C1517335
protein	I-C1517335
signaling	I-C1517335
in	O
cns	B-C3714787
neurons	B-C0027882
.	O
	
maternal	B-C0026591
vitamin	B-C0042866
d	I-C0042866
levels	B-C0441889
and	O
the	O
risk	B-C0035647
of	O
perinatal	B-C0455986
death	I-C0455986
to	O
determine	O
the	O
association	B-C0439849
between	O
maternal	B-C0026591
vitamin	B-C0042866
d	I-C0042866
levels	B-C0441889
and	O
perinatal	B-C0455986
death	I-C0455986
.	O
	
a	O
retrospective	B-C1514923
cross-sectional	B-C0010362
study	I-C0010362
of	O
all	O
non-anomalous	O
,	O
singleton	B-C1313913
births	B-C0005615
24	O
weeks	B-C0439230
with	O
perinatal	B-C0455986
death	I-C0455986
compared	O
to	O
a	O
matched	O
control	B-C0009932
group	I-C0009932
.	O
	
only	O
pregnancies	B-C0032961
with	O
a	O
recorded	O
vitamin	B-C0042866
d	I-C0042866
level	B-C0441889
at	O
booking	O
8-19	O
weeks	B-C0439230
gestation	B-C0032961
were	O
included	O
for	O
analysis	B-C0936012
.	O
	
maternal	B-C0026591
vitamin	B-C0042866
d	I-C0042866
levels	B-C0441889
were	O
categorized	O
into	O
normal	B-C0205307
,	O
deficient	B-C0011155
and	O
insufficient	B-C0231180
cohorts	B-C0599755
and	O
variables	B-C0439828
compared	O
between	O
the	O
three	O
groups	B-C0599755
.	O
	
there	O
were	O
31	O
perinatal	B-C0455986
deaths	I-C0455986
which	O
were	O
compared	O
to	O
111	O
controls	B-C0009932
.	O
	
median	O
vitamin	B-C0042866
d	I-C0042866
levels	B-C0441889
were	O
lower	O
in	O
the	O
perinatal	B-C0455986
death	I-C0455986
cohort	B-C0599755
compared	O
to	O
the	O
control	B-C0009932
group	I-C0009932
55	O
nmol/l	O
versus	O
64	O
nmol/l	O
,	O
p	O
=	O
0.43	O
.	O
	
there	O
was	O
no	O
significant	O
increase	O
in	O
deaths	B-C0011065
between	O
the	O
normal	B-C0205307
and	O
deficient	B-C0011155
p	O
=	O
0.33	O
or	O
insufficient	B-C0231180
p	O
=	O
0.09	O
groups	B-C0599755
.	O
	
low	O
maternal	B-C0026591
vitamin	B-C0042866
d	I-C0042866
levels	B-C0441889
at	O
booking	O
were	O
not	O
associated	B-C0332281
with	I-C0332281
an	O
increased	O
risk	B-C0035647
of	O
perinatal	B-C0455986
demise	I-C0455986
.	O
	
effect	B-C1280500
of	O
constitutive	B-C0598496
inactivation	I-C0598496
of	O
the	O
myostatin	B-C1333667
gene	I-C1333667
on	O
the	O
gain	B-C1517378
in	O
muscle	B-C0517349
strength	I-C0517349
during	O
postnatal	B-C0243109
growth	I-C0243109
in	O
two	O
murine	B-C0025929
models	B-C0599779
the	O
effect	B-C1280500
of	O
constitutive	B-C0598496
inactivation	I-C0598496
of	O
the	O
gene	B-C1333667
encoding	I-C1333667
myostatin	I-C1333667
on	O
the	O
gain	B-C1517378
in	O
muscle	B-C0517349
performance	I-C0517349
during	O
postnatal	B-C0243109
growth	I-C0243109
has	O
not	O
been	O
well	O
characterized	O
.	O
	
we	O
analyzed	O
2	O
murine	B-C0025929
myostatin	B-C1333667
knockout	B-C1171353
ko	I-C1171353
models	I-C1171353
,	O
i	O
the	O
lee	B-C0599779
model	I-C0599779
ko	B-C0206745
and	O
ii	O
the	O
grobet	B-C0599779
model	I-C0599779
ko	B-C0206745
,	O
and	O
measured	B-C0444706
the	O
contraction	B-C0026820
of	O
tibialis	B-C0242690
anterior	I-C0242690
muscle	I-C0242690
in	B-C0444498
situ	I-C0444498
.	O
	
absolute	B-C0022205
maximal	I-C0022205
isometric	I-C0022205
force	I-C0022205
was	O
increased	B-C0205217
in	O
6-month-old	O
ko	B-C0206745
and	O
ko	B-C0206745
mice	I-C0206745
,	O
as	O
compared	B-C1707455
to	O
wild-type	B-C0026809
mice	I-C0026809
.	O
	
similarly	O
,	O
absolute	B-C0517349
maximal	I-C0517349
power	I-C0517349
was	O
increased	B-C0205217
in	O
6-month-old	O
ko	B-C0206745
mice	I-C0206745
.	O
	
in	O
contrast	O
,	O
specific	B-C0205369
maximal	B-C0517349
force	I-C0517349
relative	B-C0205345
maximal	B-C0517349
force	I-C0517349
per	O
unit	O
of	O
muscle	B-C0026845
mass	B-C0577559
was	O
decreased	B-C0205216
in	O
all	O
6-month-old	O
male	B-C0086582
and	O
female	B-C0086287
ko	B-C0206745
mice	I-C0206745
,	O
except	B-C0332300
in	O
6-month	B-C0439231
-old	O
female	B-C0086287
ko	B-C0206745
mice	I-C0206745
,	O
whereas	O
specific	B-C0205369
maximal	B-C2371225
power	I-C2371225
was	O
reduced	B-C0392756
only	O
in	O
male	B-C0086582
ko	B-C0206745
mice	I-C0206745
.	O
	
genetic	B-C0598496
inactivation	I-C0598496
of	O
myostatin	B-C1333667
increases	B-C0442805
maximal	B-C0517349
force	I-C0517349
and	O
power	B-C2371225
,	O
but	O
in	O
return	B-C0332156
it	O
reduces	B-C0392756
muscle	B-C0026845
quality	B-C0332306
,	O
particularly	O
in	O
male	B-C0086582
mice	B-C0026809
.	O
	
methylation	B-C0376452
status	B-C0449438
of	O
the	O
promoter	B-C0033413
region	I-C0033413
of	O
the	O
human	B-C0086418
frizzled	B-C1333589
9	I-C1333589
gene	I-C1333589
in	O
acute	B-C0023465
myeloid	I-C0023465
leukemia	I-C0023465
the	O
fzd9	B-C1333589
gene	I-C1333589
is	O
located	O
at	O
chromosome	B-C4267768
7q11.23	I-C4267768
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	B-C0079427
suppressor	I-C0079427
gene	I-C0079427
.	O
	
the	O
present	O
study	B-C2603343
examined	B-C0332128
the	O
involvement	B-C1314939
of	O
fzd9	B-C1333589
promoter	B-C0086860
methylation	B-C0376452
in	O
the	O
downregulation	B-C0013081
of	O
fzd9	B-C1333589
expression	B-C0017262
in	O
leukemia	B-C0023418
cells	B-C0007634
.	O
	
the	O
expression	B-C0017262
of	O
the	O
fzd9	B-C1333589
gene	I-C1333589
was	O
absent	B-C0332197
in	O
various	O
leukemic	B-C0023418
cell	B-C0085983
lines	I-C0085983
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	B-C1522326
with	O
dna	B-C0029224
demethylating	I-C0029224
agent	I-C0029224
5-aza-2'-deoxycytidine	B-C0029224
.	O
	
bisulfite	B-C3831347
sequencing	I-C3831347
analysis	I-C3831347
of	O
the	O
fzd9	B-C1333589
promoter	B-C0033413
region	I-C0033413
showed	O
that	O
it	O
was	O
partially	O
methylated	B-C0376452
in	O
cell	B-C0085983
lines	I-C0085983
in	O
which	O
fzd9	B-C1333589
gene	I-C1333589
was	O
not	O
expressed	B-C0017262
.	O
	
thus	O
,	O
dna	B-C0025723
methylation	I-C0025723
in	O
the	O
promoter	B-C0033413
region	I-C0033413
may	O
lead	O
to	O
inactivation	B-C0544461
of	O
the	O
fzd9	B-C1333589
gene	I-C1333589
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	B-C0332281
with	I-C0332281
leukemia	B-C0023418
,	O
since	O
dna	B-C0012854
was	O
not	O
methylated	B-C0376452
in	O
normal	O
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
.	O
	
methylation	B-C0376452
-specific	O
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
analysis	I-C0032520
revealed	O
that	O
the	O
promoter	B-C0033413
region	I-C0033413
of	O
the	O
fzd9	B-C1333589
gene	I-C1333589
was	O
frequently	B-C0332183
methylated	B-C0376452
in	O
primary	B-C0205225
or	O
relapse	B-C0035020
acute	B-C0023465
myeloid	I-C0023465
leukemia	I-C0023465
52.9	O
excluding	O
acute	B-C0023487
promyelocytic	I-C0023487
leukemia	I-C0023487
however	O
,	O
methylation	B-C0376452
was	O
infrequent	O
in	O
b-cell	B-C0004561
acute	B-C0023449
lymphocytic	I-C0023449
leukemia	I-C0023449
5.6	O
.	O
	
in	O
conclusion	O
,	O
the	O
present	O
study	B-C2603343
indicated	O
that	O
the	O
methylation	B-C0376452
profile	B-C1979963
of	O
the	O
fzd9	B-C1333589
gene	I-C1333589
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor-suppressor	B-C0079427
gene	I-C0079427
in	O
acute	B-C0023465
myeloid	I-C0023465
leukemia	I-C0023465
.	O
	
identification	B-C0205396
of	O
a	O
group	B-C0441833
of	O
xths	B-C1175650
genes	B-C0017337
responding	O
to	O
heavy	B-C0347988
metal	I-C0347988
mercury	B-C0025424
,	O
salinity	B-C0871732
and	I-C0871732
drought	I-C0871732
stresses	I-C0871732
in	O
medicago	B-C0330774
truncatula	I-C0330774
xyloglucan	B-C1175650
endotransglucosylase/hydrolases	I-C1175650
xth	B-C1175650
are	O
one	O
of	O
the	O
key	O
enzymes	B-C0014442
regulating	B-C1327622
cell	B-C1156159
wall	I-C1156159
construction	I-C1156159
,	O
extension	B-C0231448
and	O
metabolism	B-C3826603
.	O
	
in	O
the	O
study	B-C0008972
,	O
44	O
xth	B-C1175650
protein	I-C1175650
genes	B-C0017337
from	O
medicago	B-C0330774
truncatula	I-C0330774
genome	B-C0017428
were	O
identified	O
using	O
bioinformatics	B-C1140694
,	O
microarray	B-C1709016
and	O
rt-pcr	B-C0599161
.	O
	
each	O
xth	B-C1175650
was	O
showed	O
to	O
possess	O
a	O
highly	B-C1514562
conserved	I-C1514562
domain	I-C1514562
d/n	O
,	O
and	O
most	O
of	O
xths	B-C1175650
possess	O
four	O
cys	B-C0010654
in	O
the	O
c	B-C1514562
terminal	I-C1514562
region	I-C1514562
,	O
which	O
suggests	O
the	O
potential	B-C3245505
for	O
generating	O
disulfide	B-C1511997
bonds	I-C1511997
.	O
	
based	O
on	O
the	O
xth	B-C1175650
protein	B-C0002518
sequences	I-C0002518
,	O
these	O
xths	B-C1175650
can	O
be	O
classified	O
into	O
three	O
major	O
families	B-C1335532
and	O
each	O
family	B-C1335532
can	O
be	O
subdivided	O
into	O
more	O
groups	B-C0441833
.	O
	
examination	O
of	O
the	O
genomic	B-C1880951
location	I-C1880951
of	O
xth	B-C0017337
genes	I-C0017337
on	O
m	B-C0330774
.	O
	
truncatula	I-C0330774
chromosomes	B-C0008633
showed	O
that	O
the	O
evolutional	B-C0282688
expansion	I-C0282688
of	O
the	O
genes	B-C0017337
was	O
possibly	O
attributed	O
to	O
localized	B-C0392752
gene	B-C0017261
duplications	I-C0017261
.	O
	
to	O
investigate	O
the	O
possible	O
involvement	B-C1314939
of	O
the	O
xths	B-C1175650
responding	O
to	O
heavy	B-C0347988
metals	I-C0347988
and	O
other	O
abiotic	B-C0871732
stresses	I-C0871732
,	O
the	O
xth	B-C0017337
genes	I-C0017337
were	O
exposed	O
to	O
heavy	B-C0347988
metal	I-C0347988
hg	B-C0025424
or	O
cu	B-C0009968
,	O
salt	B-C0871732
and	I-C0871732
drought	I-C0871732
stresses	I-C0871732
.	O
	
there	O
were	O
28	O
,	O
21	O
and	O
21	O
mtxth	B-C0017337
genes	I-C0017337
found	O
to	O
respond	O
to	O
hgcl2	B-C0025417
,	O
salt	B-C0871732
and	I-C0871732
drought	I-C0871732
stresses	I-C0871732
,	O
respectively	O
,	O
but	O
their	O
expression	B-C0017262
were	O
different	O
under	O
the	O
stresses	B-C0871732
.	O
	
some	O
of	O
the	O
xth	B-C0017337
genes	I-C0017337
were	O
well	O
confirmed	O
by	O
quantitative	B-C0392762
rt-pcr	B-C0599161
qrt-pcr	B-C0599161
.	O
	
we	O
further	O
specified	B-C0205369
expression	B-C0017262
of	O
a	O
xth	B-C0017337
gene	I-C0017337
medtr4g128580	B-C0017337
mtxth3	B-C0017337
under	O
different	O
environmental	B-C0871732
stresses	I-C0871732
,	O
and	O
showed	O
that	O
mtxth3	B-C0017337
was	O
induced	O
by	O
hg	B-C0025424
exposure	B-C0332157
.	O
	
these	O
results	B-C1274040
indicated	O
that	O
a	O
group	B-C0441833
of	O
mtxths	B-C0017337
could	O
be	O
differentially	O
expressed	B-C1171362
under	O
the	O
environmental	B-C0871732
stresses	I-C0871732
.	O
	
vestibular	B-C0042594
disorders	I-C0042594
and	O
nausea	B-C0027497
during	O
head	B-C0751177
and	O
neck	B-C0746787
intensity-modulated	B-C1512814
radiation	I-C1512814
therapy	I-C1512814
we	O
studied	O
whether	O
there	O
is	O
a	O
relationship	B-C0439849
between	O
nausea	B-C0027497
and	O
vestibular	B-C0042594
disorders	I-C0042594
in	O
patients	B-C0030705
treated	B-C0332293
with	I-C0332293
intensity	B-C1512814
modulated	I-C1512814
radiation	I-C1512814
therapy	I-C1512814
imrt	B-C1512814
for	O
head	B-C0751177
and	O
neck	B-C0746787
cancer	I-C0746787
.	O
	
we	O
performed	O
a	O
prospective	B-C0033522
single-centre	I-C0033522
study	I-C0033522
that	O
enrolled	B-C1516879
31	O
patients	B-C0030705
.	O
	
a	O
videonystagmography	B-C0087111
was	O
carried	O
out	O
before	O
and	O
within	O
15	O
days	O
after	O
radiation	B-C1522449
therapy	I-C1522449
for	O
each	O
patient	B-C0030705
.	O
	
nausea	B-C0027497
was	O
assessed	O
at	O
baseline	B-C1442488
,	O
every	O
week	O
,	O
and	O
at	O
the	O
post-radiotherapy	B-C1522449
videonystagmography	B-C0087111
visit	O
.	O
	
twenty-six	O
patients	B-C0030705
had	O
benefited	O
from	O
a	O
complete	O
interpretable	O
videonystagmography	B-C0087111
.	O
	
for	O
14	O
of	O
these	O
patients	B-C0030705
vestibular	B-C0235928
damage	I-C0235928
was	O
diagnosed	B-C0011900
post-radiotherapy	B-C1522449
.	O
	
during	O
irradiation	B-C1282930
,	O
six	O
patients	B-C0030705
felt	O
nauseous	B-C0027497
,	O
but	O
without	O
dizziness	B-C0012833
.	O
	
in	O
univariate	B-C0683962
analysis	I-C0683962
,	O
we	O
found	O
a	O
relationship	B-C0439849
statistically	B-C0237881
significant	I-C0237881
between	O
the	O
average	O
dose	B-C0178602
received	O
by	O
the	O
vestibules	B-C0042606
and	O
vestibular	B-C0042594
disorder	I-C0042594
videonystagmography	B-C0087111
p=0	O
,	O
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
1.08	O
1.025	O
,	O
but	O
there	O
was	O
no	B-C1513916
relationship	B-C0439849
between	O
vestibular	B-C0042594
disorder	I-C0042594
videonystagmography	B-C0087111
and	O
nausea	B-C0027497
p=0	O
.	O
	
irradiation	B-C1282930
of	O
the	O
vestibular	B-C0682674
system	I-C0682674
during	O
imrt	B-C1512814
does	O
not	O
seem	O
to	O
explain	O
the	O
preventing	O
youth	B-C0087178
internalizing	B-C1398215
symptoms	I-C1398215
through	O
the	O
familias	B-C0814781
unidas	I-C0814781
intervention	B-C0683495
examining	O
variation	B-C1705241
in	O
response	B-C0521982
prevention	B-C0679717
programs	I-C0679717
that	O
strengthen	O
parenting	B-C0085092
and	O
family	B-C0680051
functioning	I-C0680051
have	O
been	O
found	O
to	O
reduce	B-C0441610
poor	B-C1398200
behavioral	I-C1398200
outcomes	O
in	O
adolescents	B-C0205653
,	O
including	O
substance	B-C0237123
use	I-C0237123
,	O
hiv	B-C0744979
risk	I-C0744979
,	O
externalizing	O
and	O
internalizing	B-C1398215
problems	I-C1398215
.	O
	
however	O
,	O
there	O
is	O
evidence	O
that	O
not	O
all	O
youth	B-C0087178
benefit	O
similarly	O
from	O
these	O
programs	B-C0679717
.	O
	
familias	B-C0814781
unidas	I-C0814781
is	O
a	O
family-focused	B-C0683495
intervention	I-C0683495
designed	O
to	O
prevent	O
substance	B-C0237123
use	I-C0237123
and	O
sexual	B-C1563228
risk	I-C1563228
among	O
hispanic	B-C0086409
youth	B-C0087178
and	O
has	O
recently	O
demonstrated	O
unanticipated	O
reductions	B-C0441610
in	O
internalizing	B-C1398215
symptoms	I-C1398215
for	O
some	O
youth	B-C0087178
.	O
	
this	O
paper	O
examines	O
variation	O
in	O
intervention	B-C0683495
response	O
for	O
internalizing	B-C1398215
symptoms	I-C1398215
using	O
individual-level	B-C0814855
data	I-C0814855
pooled	O
across	O
four	O
distinct	O
familias	B-C0814781
unidas	I-C0814781
trials	B-C1515364
1	O
266	O
eighth	B-C2135624
grade	I-C2135624
students	B-C0038492
recruited	O
from	O
the	O
general	O
school	B-C0242445
population	I-C0242445
2	O
160	O
ninth	B-C2135625
grade	I-C2135625
students	B-C0038492
from	O
the	O
general	O
school	B-C0242445
population	I-C0242445
3	O
213	O
adolescents	B-C0205653
with	O
conduct	B-C0149654
,	O
aggression	B-C0001807
,	O
and/or	O
attention	B-C3843050
problems	I-C3843050
and	O
4	O
242	O
adolescents	B-C0205653
with	O
a	O
delinquency	B-C0522174
history	O
.	O
	
causal	B-C0814921
inference	I-C0814921
growth	I-C0814921
mixture	I-C0814921
modeling	I-C0814921
suggests	O
a	O
three-	O
class	B-C0008902
model	B-C3161035
.	O
	
the	O
two	O
largest	O
classes	B-C0008902
represent	O
youth	B-C0087178
with	O
low	B-C0205251
60	O
%	O
and	O
medium	B-C0439536
27	O
%	O
internalizing	B-C1398215
symptoms	I-C1398215
at	O
baseline	B-C1442488
,	O
and	O
both	O
intervention	B-C0683495
and	O
control	B-C0009932
participants	B-C0679646
show	O
reductions	B-C0441610
in	O
internalizing	B-C1398215
symptoms	I-C1398215
.	O
	
the	O
third	O
class	B-C0008902
13	O
%	O
represents	O
youth	B-C0087178
with	O
high	B-C0205250
levels	B-C0441889
of	O
baseline	B-C1442488
internalizing	B-C1398215
symptoms	I-C1398215
who	O
remain	O
at	O
steady	B-C0205361
levels	B-C0441889
of	O
internalizing	B-C1398215
symptoms	I-C1398215
when	O
exposed	B-C0332157
to	I-C0332157
the	O
intervention	B-C0683495
,	O
but	O
who	O
experience	O
an	O
increase	O
in	O
symptoms	B-C1398215
under	O
the	O
control	B-C0243148
condition	I-C0243148
.	O
	
female	B-C0086287
gender	I-C0086287
,	O
low	B-C0205251
baseline	B-C1442488
levels	B-C0441889
of	O
parent	B-C0030551
-	O
adolescent	B-C0205653
communication	B-C0009452
,	O
and	O
older	B-C1999167
age	I-C1999167
were	O
associated	O
with	O
membership	O
in	O
the	O
high-risk	B-C0332167
class	B-C0008902
.	O
	
these	O
synthesis	O
analyses	O
involving	O
a	O
large	O
sample	O
of	O
youth	B-C0087178
with	O
varying	O
initial	B-C3166291
risk	I-C3166291
levels	I-C3166291
represent	O
a	O
further	O
step	O
toward	O
strengthening	O
our	O
knowledge	O
of	O
preventive	B-C0683495
intervention	I-C0683495
response	B-C0521982
and	O
improving	O
preventive	B-C0683495
interventions	I-C0683495
.	O
	
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
severity	B-C0439793
and	O
long-term	B-C0443252
readmission	B-C0030700
and	O
mortality	B-C0205848
after	O
cardiac	B-C0018821
surgery	I-C0018821
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
aki	B-C2609414
is	O
a	O
common	O
complication	B-C0009566
after	O
cardiac	B-C0018821
surgery	I-C0018821
.	O
	
while	O
aki	B-C2609414
severity	B-C0439793
is	O
known	O
to	O
be	O
associated	B-C0332281
with	I-C0332281
increased	O
risk	B-C0035647
of	O
short-term	B-C0443303
outcomes	O
,	O
its	O
long-term	B-C0443252
impact	O
is	O
less	O
well	O
understood	O
.	O
	
adult	O
patients	B-C0030705
undergoing	O
isolated	O
coronary	B-C0010055
artery	I-C0010055
bypass	I-C0010055
graft	I-C0010055
surgery	I-C0010055
at	O
eight	O
centers	O
were	O
enrolled	O
into	O
the	O
northern	B-C0034975
new	I-C0034975
england	I-C0034975
biomarker	I-C0034975
registry	I-C0034975
n	O
=	O
1	O
.	O
	
patients	B-C0030705
were	O
excluded	O
if	O
they	O
had	O
renal	B-C0035078
failure	I-C0035078
n	O
=	O
15	O
or	O
died	B-C1306577
during	O
index	B-C0030673
admission	I-C0030673
n	O
=	O
38	O
.	O
	
severity	B-C0439793
of	O
aki	B-C2609414
was	O
defined	O
using	O
the	O
acute	B-C0008902
kidney	I-C0008902
injury	I-C0008902
network	I-C0008902
akin	B-C0008902
.	O
	
we	O
linked	O
our	O
cohort	B-C0009247
to	O
national	B-C0596896
medicare	I-C0596896
and	O
state	B-C0282574
all-payer	I-C0282574
claims	I-C0282574
to	O
ascertain	O
readmissions	B-C0030700
and	O
to	O
the	O
national	B-C3889680
death	I-C3889680
index	I-C3889680
to	O
ascertain	O
survival	B-C0220921
.	O
	
kaplan-meier	B-C1720943
and	O
multivariate	B-C0010235
cox	I-C0010235
proportional	I-C0010235
hazards	I-C0010235
modeling	I-C0010235
was	O
conducted	O
for	O
time	O
to	O
readmission	B-C0030700
and	O
death	B-C1306577
over	O
5	O
years	O
.	O
	
within	O
5	O
years	O
,	O
513	O
patients	B-C0030705
33.8	O
had	O
aki	B-C2609414
with	O
akin	B-C0008902
stage	O
1	O
29.9	O
and	O
stage	O
2	O
to	O
3	O
3.9	O
.	O
	
there	O
were	O
620	O
readmissions	B-C0030700
39.9	O
and	O
370	O
deaths	B-C1306577
23.8	O
.	O
	
after	O
adjustment	O
,	O
stage	O
1	O
aki	B-C2609414
patients	B-C0030705
had	O
a	O
31%	O
increased	O
risk	B-C0035647
of	O
readmission	B-C0030700
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
1.10	O
to	O
1.57	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-C0030705
had	O
a	O
98%	O
increased	O
risk	B-C0035647
95%	O
ci	B-C0009667
1.41	O
to	O
2.78	O
compared	O
with	O
patients	B-C0030705
having	O
no	B-C1513916
aki	B-C2609414
.	O
	
relative	O
to	O
patients	B-C0030705
without	O
aki	B-C2609414
,	O
stage	O
1	O
patients	B-C0030705
had	O
a	O
56%	O
increased	O
risk	B-C0035647
of	O
mortality	B-C0205848
95%	O
ci	B-C0009667
1.14	O
to	O
2.13	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-C0030705
had	O
a	O
3.5	O
times	O
higher	O
risk	B-C0035647
95%	O
ci	B-C0009667
2.16	O
to	O
5.60	O
.	O
	
severity	B-C0439793
of	O
aki	B-C2609414
using	O
the	O
akin	B-C0008902
stage	O
criteria	O
is	O
associated	B-C0332281
with	I-C0332281
a	O
significantly	O
increased	O
risk	B-C0035647
of	O
5-year	O
readmission	B-C0030700
and	O
mortality	B-C0205848
.	O
	
our	O
findings	O
suggest	O
that	O
efforts	O
to	O
reduce	O
aki	B-C2609414
in	O
the	O
perioperative	B-C2712230
period	I-C2712230
may	O
have	O
a	O
significant	O
long-term	B-C0443252
impact	O
on	O
patients	B-C0030705
and	O
payers	O
in	O
reducing	O
mortality	B-C0205848
and	O
health	B-C0030672
care	I-C0030672
utilization	I-C0030672
.	O
	
association	B-C0439849
of	O
abdominal	B-C1563742
fat	I-C1563742
with	O
serum	B-C0229671
amylase	B-C0002712
in	O
an	O
older	B-C0001792
cohort	B-C0599755
the	O
baltimore	B-C0004716
longitudinal	B-C0023981
study	I-C0023981
of	O
aging	B-C0001811
abdominal	B-C1563742
fat	I-C1563742
is	O
a	O
major	O
determinant	B-C1521761
of	O
metabolic	B-C0025517
diseases	I-C0025517
in	O
older	B-C0001792
individuals	B-C0237401
.	O
	
obesity	B-C0028754
and	O
diabetes	B-C0011847
are	O
associated	B-C0332281
with	I-C0332281
low	B-C0205251
serum	B-C0729348
amylase	I-C0729348
sa	I-C0729348
levels	I-C0729348
,	O
but	O
the	O
association	B-C0439849
between	O
sa	B-C0729348
and	O
metabolic	B-C0025517
disease	I-C0025517
is	O
poorly	O
understood	O
.	O
	
we	O
investigated	B-C1292732
the	O
association	B-C0439849
of	O
low	B-C0205251
sa	B-C0729348
with	O
diabetes	B-C0011847
and	O
sex	B-C1522384
-	O
specific	B-C0205369
associations	B-C0439849
of	O
serum	B-C0229671
amylase	B-C0002712
with	O
abdominal	B-C1563742
fat	I-C1563742
in	O
older	B-C0001675
adults	I-C0001675
.	O
	
in	O
community-dwelling	B-C4045975
volunteers	B-C0020155
from	O
the	O
baltimore	B-C0004716
longitudinal	B-C0023981
study	I-C0023981
of	O
aging	B-C0001811
778	O
participants	B-C0679646
,	O
age	B-C0001779
66.8	O
years	B-C0439234
,	O
we	O
assessed	B-C1516048
abdominal	B-C1563742
fat	I-C1563742
by	O
computed	B-C0040405
tomography	I-C0040405
and	O
diabetes	B-C1317301
status	I-C1317301
using	O
the	O
american	B-C1705019
diabetes	I-C1705019
association	I-C1705019
criteria	B-C0243161
.	O
	
linear	B-C0023733
regression	I-C0023733
analyses	I-C0023733
assessed	B-C1516048
the	O
cross-sectional	B-C0439849
associations	I-C0439849
between	O
abdominal	B-C1563742
fat	I-C1563742
and	O
sa	B-C0729348
,	O
and	O
logistic	B-C0206031
regression	I-C0206031
assessed	B-C1516048
the	O
odds	B-C0028873
of	O
diabetes	B-C0011847
,	O
given	O
low	B-C0205251
sa	B-C0729348
.	O
	
in	O
unadjusted	B-C0936012
analyses	I-C0936012
,	O
individuals	B-C0237401
in	O
the	O
lowest	B-C0205251
sa	B-C0729348
quartile	B-C2828255
<48μ/l	O
had	O
1.97	O
greater	O
odds	B-C0028873
of	O
diabetes	B-C0011847
,	O
95%	O
ci	B-C0009667
,	O
1.01	O
than	O
those	O
in	O
the	O
highest	O
quartile	B-C2828255
80μ/l	O
.	O
	
this	O
association	B-C0439849
was	O
no	O
longer	O
significant	B-C0750502
after	O
adjusting	O
for	O
visceral	B-C1563740
adipose	I-C1563740
tissue	I-C1563740
area	I-C1563740
vat	B-C1563740
,	O
dm	O
,	O
abdominal	B-C1563741
subcutaneous	I-C1563741
adipose	I-C1563741
tissue	I-C1563741
sat	B-C1563741
,	O
dm	O
or	O
bmi	B-C1305855
.	O
	
in	O
adjusted	B-C0936012
analyses	I-C0936012
,	O
vat	B-C1563740
and	O
sat	B-C1563741
were	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
sa	B-C0729348
in	O
both	O
sexes	B-C1522384
.	O
	
among	O
women	B-C0043210
,	O
sa	B-C0729348
was	O
more	O
strongly	O
associated	B-C0332281
with	I-C0332281
vat	B-C1563740
than	O
with	O
sat	B-C1563741
or	O
bmi	B-C1305855
vat	B-C1563740
β=-0	O
,	O
p<0	O
,	O
sat	B-C1563741
β=-0	O
,	O
p=0	O
and	O
bmi	B-C1305855
β=-0	O
,	O
p=0	O
.	O
	
the	O
association	B-C0439849
between	O
sa	B-C0002712
and	O
diabetes	B-C0011847
was	O
explained	O
mainly	O
by	O
abdominal	B-C1563740
visceral	I-C1563740
fat	I-C1563740
.	O
	
in	O
women	B-C0043210
,	O
sa	B-C0002712
was	O
more	O
strongly	O
associated	B-C0332281
with	I-C0332281
vat	B-C1563740
than	O
with	O
bmi	B-C1305855
or	O
sat	B-C1563741
.	O
	
these	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	B-C2698671
studies	I-C2698671
on	O
sa's	B-C0002712
role	O
in	O
metabolic	B-C0025517
diseases	I-C0025517
.	O
	
efficacy	B-C1280519
of	O
intravenous	B-C0348016
chlorothiazide	B-C0008273
for	O
refractory	B-C0205269
acute	B-C1609524
decompensated	I-C1609524
heart	I-C1609524
failure	I-C1609524
unresponsive	B-C0205269
to	O
adjunct	B-C1719882
metolazone	B-C0025854
to	O
assess	O
the	O
efficacy	B-C1280519
of	O
intravenous	B-C0348016
chlorothiazide	B-C0008273
in	O
patients	B-C0030705
with	O
acute	B-C1609524
decompensated	I-C1609524
heart	I-C1609524
failure	I-C1609524
adhf	B-C1609524
who	O
were	O
determined	O
to	O
be	O
loop	B-C0354100
diuretic	I-C0354100
resistant	B-C0332325
and	O
refractory	B-C0205269
to	O
metolazone	B-C0025854
.	O
	
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
with	O
patients	B-C0030705
serving	O
as	O
their	O
own	O
controls	B-C0009932
.	O
	
large	B-C0549177
,	O
academic	B-C1510747
,	O
tertiary	B-C0337954
care	I-C0337954
hospital	I-C0337954
.	O
	
forty-five	O
patients	B-C0030705
with	O
adhf	B-C1609524
who	O
had	O
an	O
inadequate	B-C0205412
response	B-C0871261
to	O
high-dose	B-C0444956
loop	B-C0354100
diuretics	I-C0354100
and	O
then	O
received	O
at	O
least	O
one	O
dose	B-C0178602
of	O
oral	B-C0442027
metolazone	B-C0025854
5	O
mg	O
or	O
greater	B-C1704243
metolazone	B-C0025854
index	B-C0178602
dose	I-C0178602
followed	O
by	O
at	O
least	O
one	O
dose	B-C0178602
of	O
intravenous	B-C0348016
chlorothiazide	B-C0008273
500	O
mg	O
chlorothiazide	B-C0008273
index	B-C0178602
dose	I-C0178602
if	O
the	O
response	O
to	O
metolazone	B-C0025854
was	O
considered	O
inadequate	B-C0205412
,	O
according	O
to	O
the	O
institutional	B-C0442711
protocol	I-C0442711
,	O
between	O
february	O
4	O
,	O
2013	O
,	O
and	O
february	O
28	O
,	O
2015	O
,	O
were	O
included	O
.	O
	
if	O
multiple	O
doses	B-C0178602
of	O
metolazone	B-C0025854
were	O
administered	B-C0806914
,	O
the	O
last	O
dose	B-C0178602
given	O
before	O
the	O
chlorothiazide	B-C0008273
index	B-C0178602
dose	I-C0178602
was	O
considered	O
the	O
index	B-C0178602
dose	I-C0178602
the	O
metolazone	B-C0025854
index	B-C0178602
dose	I-C0178602
had	O
to	O
have	O
been	O
administered	B-C0806914
more	O
than	O
2	O
hours	B-C0439227
before	O
the	O
chlorothiazide	B-C0008273
index	B-C0178602
dose	I-C0178602
.	O
	
data	B-C1511726
for	O
a	O
total	O
of	O
90	O
diuretic	B-C0354100
doses	B-C0178602
45	O
metolazone	B-C0025854
,	O
45	O
chlorothiazide	B-C0008273
were	O
included	O
in	O
the	O
analysis	B-C0936012
.	O
	
the	O
median	O
dose	B-C0178602
of	O
loop	B-C0354100
diuretic	I-C0354100
in	O
intravenous	B-C0348016
furosemide	B-C0016860
equivalents	O
given	O
over	O
the	O
24-	O
hour	B-C0439227
period	B-C1948053
before	O
the	O
metolazone	B-C0025854
index	B-C0178602
dose	I-C0178602
was	O
400	O
mg	O
.	O
	
the	O
average	O
length	O
of	O
stay	B-C3489408
was	O
34.7	O
days	B-C0439228
,	O
and	O
in-hospital	B-C0085556
mortality	I-C0085556
was	O
35.6	O
16/45	O
patients	B-C0030705
.	O
	
the	O
primary	O
end	B-C2349179
point	I-C2349179
of	O
a	O
net-negative	B-C0205160
urine	B-C0232856
output	I-C0232856
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	B-C0439227
after	O
the	O
index	B-C0178602
dose	I-C0178602
occurred	O
in	O
42.2	O
19/45	O
patients	B-C0030705
and	O
35.5	O
16/45	O
patients	B-C0030705
for	O
the	O
chlorothiazide	B-C0008273
and	O
metolazone	B-C0025854
doses	B-C0178602
,	O
respectively	O
p=0	O
.	O
	
the	O
median	O
12-	O
hour	B-C0439227
urine	B-C0232856
output	I-C0232856
following	O
administration	B-C0001555
of	O
metolazone	B-C0025854
was	O
810	O
ml	O
interquartile	B-C1711350
range	I-C1711350
iqr	B-C1711350
866	O
ml	O
versus	O
1075	O
ml	O
iqr	B-C1711350
940	O
ml	O
following	O
administration	B-C0001555
of	O
chlorothiazide	B-C0008273
p=0	O
.	O
	
compared	B-C1707455
with	O
metolazone	B-C0025854
,	O
the	O
chlorothiazide	B-C0008273
doses	B-C0178602
did	O
not	O
result	O
in	O
an	O
increase	B-C0442805
in	O
urine	B-C0232856
output	I-C0232856
of	O
at	O
least	O
500	O
ml	O
during	O
the	O
12	O
hours	B-C0439227
following	O
the	O
dose	B-C0178602
relative	O
to	O
the	O
12	O
hours	B-C0439227
before	O
the	O
dose	B-C0178602
31.1	O
vs	O
22.2	O
,	O
p=0	O
.	O
	
no	O
significant	O
difference	O
in	O
achievement	O
of	O
net-negative	B-C0205160
urine	B-C0232856
output	I-C0232856
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	B-C0439227
following	O
the	O
chlorothiazide	B-C0008273
or	O
metolazone	B-C0025854
dose	B-C0178602
was	O
noted	O
42.2	O
for	O
chlorothiazide	B-C0008273
vs	O
35.5	O
for	O
metolazone	B-C0025854
,	O
p=0	O
.	O
	
the	O
addition	O
of	O
intravenous	B-C0348016
chlorothiazide	B-C0008273
did	O
not	O
result	O
in	O
improved	B-C0184511
diuresis	B-C0012797
in	O
patients	B-C0030705
with	O
adhf	B-C1609524
determined	O
to	O
be	O
refractory	B-C0205269
to	O
loop	B-C0354100
diuretic	I-C0354100
s	O
and	O
adjunctive	B-C1719882
oral	B-C0442027
metolazone	B-C0025854
.	O
	
comparisons	B-C1707455
of	O
safety	B-C0036043
and	O
clinical	B-C0205210
outcomes	B-C1274040
between	O
multiple-level	B-C0035139
and	O
single-level	B-C0035139
cervical	I-C0035139
disk	I-C0035139
replacement	I-C0035139
for	O
cervical	B-C1384641
spondylosis	I-C1384641
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0282458
this	O
is	O
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0282458
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	B-C1292732
the	O
efficacy	B-C1280519
and	O
safety	B-C0036043
of	O
multiple-level	B-C0035139
cervical	I-C0035139
disk	I-C0035139
replacement	I-C0035139
cdr	B-C0035139
over	O
single-level	B-C0035139
cdr	I-C0035139
for	O
the	O
treatment	B-C0087111
of	O
cervical	B-C1384641
spondylosis	I-C1384641
.	O
	
some	O
authors	O
advocate	O
for	O
the	O
multiple-level	B-C0035139
cdr	I-C0035139
instead	O
of	O
anterior	B-C0205094
decompression	B-C1829459
and	O
fusion	B-C1293131
in	O
cervical	B-C1384641
multiple-level	I-C1384641
spondylosis	I-C1384641
.	O
	
however	O
,	O
whether	O
the	O
efficacy	B-C1280519
and	O
safety	B-C0036043
of	O
multi-level	B-C0035139
cdr	I-C0035139
are	O
as	O
favorable	O
as	O
that	O
of	O
single-level	B-C0035139
cdr	I-C0035139
remains	O
controversial	O
.	O
	
medline	B-C0025141
,	O
embase	B-C0242356
,	O
and	O
cochrane	B-C0242356
library	I-C0242356
databases	I-C0242356
were	O
searched	O
up	O
to	O
november	O
2015	O
for	O
controlled	B-C0681867
studies	I-C0681867
that	O
compared	B-C1707455
the	O
clinical	B-C0205210
outcomes	B-C1274040
of	O
single-level	B-C0035139
and	O
multiple-level	B-C0035139
cdr	I-C0035139
for	O
the	O
treatment	B-C0087111
of	O
cervical	B-C1384641
spondylosis	I-C1384641
.	O
	
the	O
following	O
outcomes	B-C1274040
were	O
extracted	O
and	O
analyzed	B-C0936012
prevalence	B-C0033105
of	O
heterotopic	B-C0029396
ossification	I-C0029396
and	O
reoperation	B-C0035110
,	O
preoperative	B-C0445204
and	O
postoperative	B-C0032790
neck	B-C2959538
disability	I-C2959538
index	I-C2959538
scores	I-C2959538
,	O
preoperative	B-C0445204
and	O
postoperative	B-C0032790
visual	B-C2960751
analog	I-C2960751
scale	I-C2960751
scores	I-C2960751
,	O
and	O
success	B-C0679864
rate	B-C1521828
using	O
the	O
odom	B-C0008902
grading	I-C0008902
system	I-C0008902
.	O
	
ten	O
studies	B-C2603343
involving	O
1402	O
patients	B-C0030705
were	O
included	O
including	O
3	O
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
,	O
5	O
prospective	B-C0033522
studies	I-C0033522
,	O
and	O
3	O
retrospective	B-C0035363
studies	I-C0035363
.	O
	
no	O
significant	O
differences	O
between	O
single-level	B-C0035139
and	O
multiple-level	B-C0035139
groups	O
were	O
found	O
in	O
terms	O
of	O
the	O
prevalence	B-C0033105
of	O
heterotopic	B-C0029396
ossification	I-C0029396
and	O
reoperation	B-C0035110
rate	B-C1521828
,	O
neck	B-C2959538
disability	I-C2959538
index	I-C2959538
score	I-C2959538
,	O
visual	B-C2960751
analog	I-C2960751
scale	I-C2960751
score	I-C2960751
,	O
and	O
success	B-C0679864
rate	B-C1521828
using	O
the	O
odom	B-C0008902
grading	I-C0008902
system	I-C0008902
.	O
	
on	O
the	O
basis	O
of	O
this	O
meta-analysis	B-C0282458
,	O
clinical	B-C0205210
outcomes	B-C1274040
of	O
multiple-level	B-C0035139
cdr	I-C0035139
are	O
similar	O
to	O
those	O
of	O
single-level	B-C0035139
cdr	I-C0035139
for	O
cervical	B-C1384641
spondylosis	I-C1384641
,	O
which	O
suggests	O
the	O
multiple-level	B-C0035139
cdr	I-C0035139
is	O
as	O
effective	B-C1704419
and	O
safe	B-C0036043
as	O
the	O
single-level	B-C0035139
cdr	I-C0035139
.	O
	
nonetheless	O
,	O
more	O
well-designed	O
studies	B-C2603343
are	O
needed	O
for	O
further	O
evaluation	B-C0220825
of	O
the	O
effects	B-C1704420
of	I-C1704420
intravenous	B-C0348016
and	O
percutaneous	B-C0522523
low	B-C0279027
level	I-C0279027
laser	I-C0279027
therapy	I-C0279027
in	O
the	O
management	B-C0002766
of	O
shoulder	B-C0037004
myofascial	B-C0027073
pain	I-C0027073
syndrome	I-C0027073
myofascial	B-C0027073
pain	I-C0027073
syndrome	I-C0027073
mps	B-C0027073
treatment	B-C0087111
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment	B-C0087111
frame	I-C0087111
.	O
	
therefore	O
research	O
on	O
new	O
,	O
more	O
efficient	B-C0442799
and	O
long	O
lasting	O
effect	O
treatment	B-C0087111
modalities	B-C0695347
is	O
necessary	O
.	O
	
this	O
study	O
looked	O
at	O
the	O
effects	B-C1704420
of	I-C1704420
intravenous	B-C0348016
laser	B-C1955835
therapy	I-C1955835
ivl	B-C1955835
and	O
percutaneous	B-C0522523
low	B-C0279027
level	I-C0279027
laser	I-C0279027
plll	B-C0279027
in	O
the	O
management	B-C0002766
of	O
shoulder	B-C0037004
mps	B-C0027073
.	O
	
in	O
this	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
,	O
30	O
patients	B-C0030705
fulfilling	O
inclusion	B-C1512693
criteria	I-C1512693
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups	O
,	O
control	B-C0009932
,	O
ivl	B-C1257890
and	O
plll	B-C1257890
.	O
	
control	B-C0009932
group	I-C0009932
received	O
12	O
sessions	O
of	O
placebo	B-C1706408
low	B-C0279027
level	I-C0279027
laser	I-C0279027
,	O
ivl	B-C1257890
group	I-C1257890
received	O
12	O
sessions	O
of	O
ivl	B-C1955835
therapy	I-C1955835
,	O
and	O
plll	B-C1257890
group	I-C1257890
received	O
12	O
sessions	O
of	O
plll	B-C0279027
therapy	I-C0279027
.	O
	
all	O
patients	B-C0030705
were	O
trained	O
for	O
better	B-C0332272
body	B-C1262869
posture	I-C1262869
,	O
body	B-C0598002
mechanics	I-C0598002
,	O
gentle	B-C0150347
massage	I-C0150347
of	O
trigger	B-C0458343
points	I-C0458343
,	O
stretching	B-C0600080
exercises	I-C0600080
of	O
affected	B-C0392760
muscle	B-C0026845
trapezius	B-C0224361
,	O
and	O
received	O
10	O
mg	O
of	O
oral	B-C0442027
nortriptyline	B-C0028420
regimen	B-C0040808
every	O
night	O
for	O
3	O
months	O
.	O
	
outcomes	O
included	O
pain	B-C1507013
severity	I-C1507013
,	O
functional	B-C0872173
disability	I-C0872173
,	O
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
patients	B-C0030705
were	O
assessed	O
using	O
numeric	B-C4050142
rating	I-C4050142
scale	I-C4050142
nrs	B-C4050142
,	O
pain	B-C0282574
disability	I-C0282574
index	I-C0282574
pdi	B-C0282574
,	O
and	O
short	B-C0451286
form	I-C0451286
health	I-C0451286
survey	I-C0451286
sf-12	B-C1519135
.	O
	
data	B-C4019276
collected	I-C4019276
were	O
analyzed	B-C0936012
using	O
analysis	B-C0002780
of	I-C0002780
variance	I-C0002780
anova	B-C0002780
,	O
mann-whitney	B-C1708930
and	O
t	B-C0871472
tests	I-C0871472
.	O
	
the	O
mean	O
of	O
pdi	B-C0282574
and	O
maximum	O
pain	B-C1320357
intensity	I-C1320357
during	O
day	O
and	O
night	O
significantly	O
reduced	B-C0392756
in	O
both	O
plll	B-C1257890
and	O
ivl	B-C1257890
groups	I-C1257890
compared	O
to	O
control	B-C0009932
group	I-C0009932
.	O
	
although	O
pain	O
severity	O
and	O
pdi	B-C0282574
reduction	O
was	O
more	O
pronounced	O
in	O
ivl	B-C1257890
group	I-C1257890
compared	O
to	O
plll	B-C1257890
group	I-C1257890
,	O
the	O
differences	O
were	O
not	O
statistically	B-C0237881
significant	I-C0237881
.	O
	
also	O
,	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
statistically	B-C0237881
significantly	I-C0237881
improved	O
in	O
both	O
ivl	B-C1257890
and	O
plll	B-C1257890
groups	I-C1257890
compared	O
to	O
control	B-C0009932
group	I-C0009932
was	O
more	O
,	O
and	O
although	O
higher	O
in	O
ivl	B-C1257890
group	I-C1257890
,	O
the	O
difference	O
was	O
not	O
statistically	B-C0237881
significant	I-C0237881
when	O
compared	O
to	O
plll	B-C1257890
group	I-C1257890
.	O
	
no	B-C1963761
side	I-C1963761
effects	I-C1963761
were	O
observed	O
in	O
the	O
intervention	B-C2986530
groups	I-C2986530
.	O
	
intravenous	B-C0348016
laser	B-C1955835
and	O
plll	B-C0279027
therapy	I-C0279027
had	O
a	O
positive	O
effect	B-C1280500
on	O
pain	B-C1507013
severity	I-C1507013
and	O
pdi	B-C0282574
reduction	O
,	O
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
in	O
this	O
study	O
.	O
	
also	O
no	B-C1963761
adverse	I-C1963761
event	I-C1963761
was	O
recorded	O
.	O
	
thus	O
,	O
intravenous	B-C0348016
lasers	B-C1955835
and	O
plll	B-C0279027
therapy	I-C0279027
seem	O
to	O
be	O
effective	B-C1704419
complementary	O
modalities	B-C0695347
in	O
managing	B-C0002766
patients	B-C0030705
with	O
shoulder	B-C0037004
mps	B-C0027073
.	O
	
structural	B-C0678594
insights	B-C0233820
into	O
5-ht1a	B-C0379900
/	O
d4	B-C0114835
selectivity	B-C1510827
of	O
way-100635	B-C0290799
analogues	B-C0243071
molecular	B-C0600115
modeling	I-C0600115
,	O
synthesis	B-C1883254
,	O
and	O
in	B-C1533691
vitro	I-C1533691
binding	B-C1167622
the	O
resurgence	O
of	O
interest	O
in	O
5-ht1a	B-C0379900
receptors	I-C0379900
as	O
a	O
therapeutic	B-C0302350
target	B-C1521840
requires	O
the	O
existence	O
of	O
highly	O
selective	B-C0205556
5-ht1a	B-C0379900
ligands	B-C0023688
.	O
	
to	O
date	O
,	O
way-100635	B-C0290799
has	O
been	O
the	O
prototypical	B-C0243076
antagonist	I-C0243076
of	O
these	O
receptors	B-C0597357
.	O
	
however	O
,	O
this	O
compound	B-C0205198
also	O
has	O
significant	O
affinity	B-C0683185
for	O
and	O
activity	O
at	O
d4	B-C0114835
dopamine	I-C0114835
receptors	I-C0114835
.	O
	
in	O
this	O
context	O
,	O
this	O
work	O
was	O
aimed	O
at	O
better	O
understanding	O
the	O
5-ht1a	B-C0379900
/	O
d4	B-C0114835
selectivity	B-C1510827
of	O
way-100635	B-C0290799
and	O
analogues	B-C0243071
from	O
a	O
structural	B-C0678594
point	O
of	O
view	O
.	O
	
in	B-C3489666
silico	I-C3489666
investigations	B-C1292732
revealed	O
two	O
key	O
interactions	B-C1704675
for	O
the	O
5-ht1a	B-C0379900
/	O
d4	B-C0114835
selectivity	B-C1510827
of	O
way-100635	B-C0290799
and	O
analogues	B-C0243071
.	O
	
first	O
,	O
a	O
hydrogen	B-C0020276
bond	I-C0020276
only	O
found	O
with	O
the	O
ser	B-C0036720
7.36	I-C0036720
of	O
d4	B-C0114835
receptor	I-C0114835
appeared	O
to	O
be	O
the	O
key	O
for	O
a	O
higher	O
d4	B-C0114835
affinity	B-C0683185
for	O
newly	O
synthesized	B-C1883254
aza	B-C0004471
analogues	B-C0243071
.	O
	
the	O
role	O
of	O
ser	B-C0036720
7.36	I-C0036720
was	O
confirmed	O
as	O
the	O
affinity	B-C0683185
of	O
aza	B-C0004471
analogues	B-C0243071
for	O
the	O
mutant	B-C0596988
d4	B-C0114835
receptor	I-C0114835
s7.36a	I-C0114835
was	O
reduced	O
.	O
	
then	O
,	O
the	O
formation	O
of	O
another	O
hydrogen	B-C0020276
bond	I-C0020276
with	O
the	O
conserved	O
ser	B-C0036720
5.42	I-C0036720
residue	I-C0036720
appeared	O
to	O
be	O
also	O
critical	O
for	O
d4	B-C0114835
binding	B-C1167622
.	O
	
genomic	B-C3854164
analysis	I-C3854164
of	O
nontypeable	B-C0038410
pneumococci	I-C0038410
causing	O
invasive	B-C1320214
pneumococcal	I-C1320214
disease	I-C1320214
in	O
south	B-C0037712
africa	I-C0037712
,	O
2003-2013	O
the	O
capsular	B-C1979807
polysaccharide	I-C1979807
is	O
the	O
principal	O
virulence	B-C1136170
factor	I-C1136170
of	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
and	O
a	O
target	B-C1521840
for	O
current	O
pneumococcal	B-C0358314
vaccines	I-C0358314
.	O
	
however	O
,	O
some	O
pathogenic	B-C3816499
pneumococci	B-C0038410
are	O
serologically	B-C0449943
nontypeable	I-C0449943
nontypeable	B-C0038410
pneumococci	I-C0038410
ntpn	B-C0038410
.	O
	
due	O
to	O
their	O
relative	O
rarity	B-C0522498
,	O
ntpn	B-C0038410
are	O
poorly	O
characterized	B-C1880022
,	O
and	O
,	O
as	O
such	O
,	O
limited	O
data	B-C1511726
exist	O
which	O
describe	O
these	O
organisms	B-C0029235
.	O
	
we	O
aimed	O
to	O
describe	O
disease	B-C0012634
and	O
genotypically	B-C0017431
characterize	B-C1880022
ntpn	B-C0038410
causing	O
invasive	B-C1320214
pneumococcal	I-C1320214
disease	I-C1320214
in	O
south	B-C0037712
africa	I-C0037712
.	O
	
isolates	B-C1764827
were	O
detected	O
through	O
national	O
,	O
laboratory	B-C0022877
-	O
based	B-C1705938
surveillance	B-C0220920
for	O
invasive	B-C1320214
pneumococcal	I-C1320214
disease	I-C1320214
in	O
south	B-C0037712
africa	I-C0037712
and	O
characterized	B-C1880022
by	O
whole	O
genome	B-C3854164
analysis	I-C3854164
.	O
	
we	O
predicted	O
ancestral	B-C0439660
serotypes	B-C0449943
serotypes	B-C0449943
from	O
which	O
ntpn	B-C0038410
may	O
have	O
originated	O
for	O
group	B-C0441833
i	I-C0441833
ntpn	B-C0038410
using	O
multilocus	B-C2936544
sequence	I-C2936544
typing	I-C2936544
and	O
capsular	B-C1254362
region	I-C1254362
sequence	B-C0162801
analyses	I-C0162801
.	O
	
antimicrobial	B-C1456627
resistance	I-C1456627
patterns	B-C0449774
and	O
mutations	B-C0026882
potentially	B-C3245505
causing	O
nontypeability	B-C0449943
were	O
identified	B-C0205396
.	O
	
from	O
2003-2013	O
,	O
39	O
0.1	O
%	O
,	O
39/32	O
ntpn	B-C0038410
were	O
reported	O
.	O
	
twenty-two	B-C4284772
56	O
%	O
had	O
partial	B-C0728938
capsular	B-C0017337
genes	I-C0017337
group	B-C0441833
i	I-C0441833
and	O
17	O
44	O
%	O
had	O
complete	B-C0205197
capsular	B-C0017260
deletion	I-C0017260
of	O
which	O
15	O
had	O
replacement	B-C0559956
by	O
other	O
genes	B-C0017337
group	B-C0441833
ii	I-C0441833
.	O
	
seventy-nine	B-C3828184
percent	B-C0439165
31/39	O
of	O
our	O
ntpn	B-C0038410
isolates	B-C1764827
were	O
derived	O
from	O
encapsulated	B-C0205223
s	B-C0038410
.	O
	
pneumoniae	I-C0038410
.	O
	
ancestral	O
serotypes	B-C0449943
1	O
27	O
%	O
,	O
6/22	O
and	O
8	O
14	O
%	O
,	O
3/22	O
were	O
most	O
prevalent	O
,	O
and	O
59	O
%	O
13/22	O
of	O
ancestral	B-C0439660
serotypes	B-C0449943
were	O
serotypes	B-C0449943
included	O
in	O
the	O
13-valent	B-C3152625
pneumococcal	I-C3152625
conjugate	I-C3152625
vaccine	I-C3152625
.	O
	
we	O
identified	O
a	O
variety	O
of	O
mutations	B-C0026882
within	O
the	O
capsular	B-C1254362
region	I-C1254362
of	O
group	B-C0441833
i	I-C0441833
ntpn	B-C0038410
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	B-C0449943
phenotype	B-C0031437
.	O
	
nonsusceptibility	B-C2827756
to	O
tetracycline	B-C0039644
and	O
erythromycin	B-C0014806
was	O
higher	O
in	O
ntpn	B-C0038410
than	O
encapsulated	B-C0205223
s	B-C0038410
.	O
	
pneumoniae	I-C0038410
.	O
	
ntpn	B-C0038410
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive	B-C1320214
pneumococcal	I-C1320214
disease	I-C1320214
in	O
south	B-C0037712
africa	I-C0037712
pre-hypertension	B-C1696708
,	O
pre-diabetes	B-C0362046
or	O
both	O
which	O
is	O
best	O
at	O
predicting	B-C0681842
cardiovascular	B-C1320716
events	I-C1320716
in	O
the	O
long	B-C0443252
term	I-C0443252
the	O
present	O
study	B-C2603343
aimed	O
to	O
assess	O
the	O
value	O
of	O
pre-diabetes	B-C0362046
and	O
pre-hypertension	B-C1696708
in	O
predicting	B-C0681842
cardiovascular	B-C1320716
events	I-C1320716
.	O
	
a	O
population	B-C0032659
-based	O
,	O
cross-sectional	B-C0010362
survey	I-C0010362
was	O
conducted	O
,	O
representing	O
a	O
large	O
sample	O
of	O
the	O
general	O
iranian	B-C1553355
population	B-C0683971
aged	O
35	O
years	B-C0439234
and	O
older	O
from	O
the	O
isfahan	B-C0017446
province	I-C0017446
and	O
determined	O
using	O
a	O
random	B-C2347298
,	O
multistage	I-C2347298
cluster-sampling	I-C2347298
10-year	O
cohort	B-C0599755
.	O
	
the	O
five	O
end	O
points	O
considered	O
as	O
study	B-C2985619
outcome	I-C2985619
were	O
unstable	B-C0002965
angina	I-C0002965
ua	B-C0002965
,	O
acute	B-C0205178
occurrence	B-C2745955
of	O
myocardial	B-C0027051
infarction	I-C0027051
mi	B-C0027051
,	O
sudden	B-C0085298
cardiac	I-C0085298
death	I-C0085298
scd	B-C0085298
,	O
brain	B-C3844825
stroke	I-C3844825
and	O
cardiovascular	B-C0007222
disease	I-C0007222
cvd	B-C0007222
.	O
	
of	O
the	O
6323	O
subjects	O
scheduled	O
for	O
assessment	B-C0220825
of	O
diabetes	B-C0011849
state	I-C0011849
617	O
were	O
diabetics	B-C0241863
and	O
712	O
were	O
pre-diabetic	B-C0243095
.	O
	
in	O
addition	O
,	O
of	O
these	O
subjects	O
,	O
1754	O
had	O
hypertension	B-C0020538
and	O
2500	O
had	O
pre-hypertension	B-C1696708
.	O
	
analysing	O
only	O
pre-hypertension	B-C1696708
,	O
pre-diabetes	B-C0362046
and	O
its	O
combination	O
and	O
adjusted	O
for	O
gender	B-C0079399
and	O
age	O
variables	O
,	O
pre-hypertension	B-C1696708
and	O
pre-diabetes	B-C0362046
status	O
together	O
,	O
could	O
only	O
effectively	O
predict	O
occurrence	B-C2745955
of	O
mi	B-C0027051
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
1.06	O
,	O
p=0	O
.	O
	
in	O
the	O
same	O
cox	B-C3161035
regression	I-C3161035
models	I-C3161035
,	O
pre-hypertension	B-C1696708
status	O
could	O
predict	O
ua	B-C0002965
and	O
cvd	B-C0007222
occurrence	B-C2745955
hr	B-C2985465
=2	O
,	O
95%	O
ci	B-C0009667
1.68	O
,	O
p<0	O
and	O
hr	B-C2985465
=1	O
,	O
95%	O
ci	B-C0009667
1.23	O
,	O
p=0	O
,	O
respectively	O
.	O
	
however	O
,	O
pre-diabetes	B-C0362046
status	O
could	O
not	O
predict	O
any	O
of	O
these	O
events	O
after	O
adjustment	O
for	O
gender	B-C0079399
and	O
age	B-C0001779
.	O
	
our	O
data	B-C1511726
provide	O
valuable	O
evidence	B-C3887511
of	O
the	O
triggering	O
role	O
of	O
pre-hypertension	B-C1696708
and	O
pre-diabetes	B-C0362046
together	O
,	O
on	O
appearance	B-C0700364
and	O
progression	B-C0242656
of	O
mi	B-C0027051
even	O
in	O
healthy	B-C1708335
individuals	I-C1708335
and	O
the	O
significant	O
predicting	B-C0681842
value	O
of	O
pre-hypertension	B-C1696708
on	O
the	O
occurrence	B-C2745955
of	O
ua	B-C0002965
and	O
cvd	B-C0007222
.	O
	
in	O
this	O
regard	O
,	O
the	O
value	O
of	O
pre-hypertension	B-C1696708
and	O
pre-diabetes	B-C0362046
together	O
,	O
and	O
the	O
pre-hypertension	B-C1696708
state	O
alone	O
,	O
are	O
clearly	O
superior	O
to	O
pre-diabetes	B-C0362046
state	O
alone	O
in	O
predicting	B-C0681842
cardiovascular	B-C1320716
events	I-C1320716
.	O
	
strategies	B-C0683852
for	O
successful	B-C1272703
clinical	B-C0205210
teaching	B-C0220924
this	O
article	B-C1706852
is	O
one	O
in	O
a	O
series	O
on	O
the	O
roles	B-C1705810
of	O
adjunct	B-C0015538
clinical	I-C0015538
faculty	I-C0015538
and	O
preceptors	B-C0221457
,	O
who	O
teach	B-C0039401
nursing	B-C0038496
students	I-C0038496
and	O
new	B-C0205314
graduates	B-C0588053
to	O
apply	B-C4048755
knowledge	B-C0376554
in	O
clinical	B-C3176918
settings	I-C3176918
.	O
	
this	O
article	B-C1706852
describes	O
teaching	B-C0683852
strategies	I-C0683852
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
learning	B-C1510556
environment	I-C1510556
.	O
	
learned	B-C0018897
helplessness	I-C0018897
at	O
fifty	O
insights	B-C0233820
from	O
neuroscience	B-C0027910
learned	B-C0018897
helplessness	I-C0018897
,	O
the	O
failure	B-C0231174
to	O
escape	B-C0870509
shock	B-C0036974
induced	B-C0205263
by	O
uncontrollable	O
aversive	B-C1510994
events	I-C1510994
,	O
was	O
discovered	O
half	O
a	O
century	O
ago	O
.	O
	
seligman	B-C0086418
and	I-C0086418
maier	I-C0086418
1967	O
theorized	B-C0871935
that	O
animals	B-C0003062
learned	B-C0023185
that	O
outcomes	B-C1274040
were	O
independent	B-C0332291
of	I-C0332291
their	O
responses	B-C0871261
-that	O
nothing	O
they	O
did	O
mattered-and	O
that	O
this	O
learning	B-C0023185
undermined	O
trying	O
to	O
escape	B-C0870509
.	O
	
the	O
mechanism	O
of	O
learned	B-C0018897
helplessness	I-C0018897
is	O
now	O
very	O
well-charted	B-C0205460
biologically	I-C0205460
,	O
and	O
the	O
original	O
theory	B-C0871935
got	O
it	O
backward	O
.	O
	
passivity	B-C0679170
in	O
response	B-C0871261
to	O
shock	B-C0036974
is	O
not	O
learned	B-C0023185
.	O
	
it	O
is	O
the	O
default	O
,	O
unlearned	O
response	B-C0871261
to	O
prolonged	B-C0439590
aversive	B-C1510994
events	I-C1510994
and	O
it	O
is	O
mediated	O
by	O
the	O
serotonergic	B-C1148560
activity	I-C1148560
of	O
the	O
dorsal	B-C0175392
raphe	I-C0175392
nucleus	I-C0175392
,	O
which	O
in	O
turn	O
inhibits	B-C3463820
escape	B-C0870509
.	O
	
this	O
passivity	B-C0679170
can	O
be	O
overcome	O
by	O
learning	B-C0023185
control	B-C0243148
,	O
with	O
the	O
activity	O
of	O
the	O
medial	B-C3498368
prefrontal	I-C3498368
cortex	I-C3498368
,	O
which	O
subserves	O
the	O
detection	B-C0442726
of	O
control	B-C0243148
leading	O
to	O
the	O
automatic	B-C0205554
inhibition	B-C3463820
of	O
the	O
dorsal	B-C0175392
raphe	I-C0175392
nucleus	I-C0175392
.	O
	
so	O
animals	B-C0003062
learn	B-C0023185
that	O
they	O
can	O
control	B-C0243148
aversive	B-C1510994
events	I-C1510994
,	O
but	O
the	O
passive	B-C3686820
failure	B-C0231174
to	O
learn	B-C0023185
to	O
escape	B-C0870509
is	O
an	O
unlearned	O
reaction	B-C0443286
to	O
prolonged	B-C0439590
aversive	B-C0870183
stimulation	I-C0870183
.	O
	
in	O
addition	O
,	O
alterations	B-C1515926
of	O
the	O
ventromedial	B-C3850122
prefrontal	I-C3850122
cortex	I-C3850122
-	O
dorsal	B-C0175392
raphe	I-C0175392
pathway	B-C1705987
can	O
come	O
to	O
subserve	O
the	O
expectation	B-C0679138
of	O
control	B-C0243148
.	O
	
we	O
speculate	O
that	O
default	O
passivity	B-C0679170
and	O
the	O
compensating	B-C0205432
detection	B-C0442726
and	O
expectation	B-C0679138
of	O
control	B-C0243148
may	O
have	O
substantial	O
implications	O
for	O
how	O
to	O
treat	B-C1292734
depression	B-C0011570
.	O
	
a	O
peptide	B-C0030956
from	O
human	B-C1999611
β	I-C1999611
thymosin	I-C1999611
as	O
a	O
platform	O
for	O
the	O
development	O
of	O
new	O
anti-biofilm	B-C3548526
agents	O
for	O
staphylococcus	O
spp	O
.	O
	
and	O
pseudomonas	O
aeruginosa	O
conventional	O
antibiotics	O
might	O
fail	O
in	O
the	O
treatment	O
of	O
biofilm	O
-associated	O
infections	O
causing	O
infection	O
recurrence	O
and	O
chronicity	O
.	O
	
the	O
search	O
for	O
antimicrobial	O
peptides	O
has	O
been	O
performed	O
with	O
the	O
aim	O
to	O
discover	O
novel	O
anti-infective	O
agents	O
active	O
on	O
pathogens	O
in	O
both	O
planktonic	O
and	O
biofilm	O
associated	O
forms	O
.	O
	
the	O
fragment	O
9-19	O
of	O
human	O
thymosin	O
β4	O
was	O
studied	O
through	O
1	O
μs	O
md	O
simulation	O
.	O
	
two	O
main	O
conformations	O
of	O
the	O
peptide	O
were	O
detected	O
,	O
both	O
constituted	O
by	O
a	O
central	O
hydrophobic	O
core	O
and	O
by	O
the	O
presence	O
of	O
peripheral	O
charged	O
residues	O
suggesting	O
a	O
possible	O
mechanism	O
of	O
interaction	O
with	O
two	O
models	O
of	O
biological	O
membranes	O
,	O
related	O
to	O
eukaryotic	O
or	O
bacterial	O
membrane	O
respectively	O
.	O
	
in	O
addition	O
,	O
the	O
peptide	O
was	O
chemically	O
synthesized	O
and	O
its	O
antimicrobial	O
activity	O
was	O
tested	O
in	O
vitro	O
against	O
planktonic	O
and	O
biofilm	O
form	O
of	O
a	O
group	O
of	O
reference	O
strains	O
of	O
staphylococcus	O
spp	O
.	O
	
and	O
one	O
p	O
.	O
	
aeruginosa	O
strain	O
.	O
	
the	O
human	O
thymosin	O
β4	O
fragment	O
eiekfdksklk	O
showed	O
antibacterial	O
activity	O
against	O
staphylococcal	O
strains	O
and	O
pseudomonas	O
aeruginosa	O
atcc	O
15442	O
at	O
concentrations	O
from	O
12.5	O
to	O
6.2	O
mg/ml	O
and	O
inhibited	O
biofilm	O
formation	O
at	O
sub-inhibitory	O
concentrations	O
3.1	O
mg/ml	O
.	O
	
the	O
activity	O
of	O
the	O
fragment	O
in	O
inhibiting	O
biofilm	O
formation	O
,	O
could	O
be	O
due	O
to	O
the	O
conformations	O
highlighted	O
by	O
the	O
md	O
simulations	O
,	O
suggesting	O
its	O
interaction	O
with	O
the	O
bacterial	O
membrane	O
.	O
	
human	O
thymosin	O
β4	O
fragment	O
can	O
be	O
considered	O
a	O
promising	O
lead	O
compound	O
to	O
develop	O
novel	O
synthetic	O
or	O
recombinant	O
derivatives	O
with	O
improved	O
pharmaceutical	O
structural	B-C0678594
basis	B-C1527178
for	O
simvastatin	B-C0074554
competitive	B-C0013159
antagonism	I-C0013159
of	O
complement	B-C0079785
receptor	I-C0079785
3	I-C0079785
the	O
complement	B-C0009498
system	I-C0009498
is	O
an	O
important	O
part	O
of	O
the	O
innate	B-C0020969
immune	I-C0020969
response	I-C0020969
to	O
infection	B-C0009450
but	O
may	O
also	O
cause	O
severe	B-C3495031
complications	I-C3495031
during	O
inflammation	B-C0021368
.	O
	
small	B-C1328819
molecule	I-C1328819
antagonists	B-C0243076
to	O
complement	B-C0079785
receptor	I-C0079785
3	I-C0079785
cr3	B-C0079785
have	O
been	O
widely	O
sought	O
,	O
but	O
a	O
structural	B-C0678594
basis	B-C1527178
for	O
their	O
mode	B-C1524059
of	I-C1524059
action	I-C1524059
is	O
not	O
available	O
.	O
	
we	O
report	B-C0684224
here	O
on	O
the	O
structure	B-C0678594
of	O
the	O
human	B-C0086418
cr3	B-C0079785
ligand-binding	B-C0682969
i	I-C0682969
domain	I-C0682969
in	O
complex	B-C1704241
with	O
simvastatin	B-C0074554
.	O
	
simvastatin	B-C0074554
targets	B-C1521840
the	O
metal	B-C0025552
ion-dependent	B-C0205556
adhesion	B-C1254362
site	I-C1254362
of	O
the	O
open	O
,	O
ligand-binding	B-C1517880
conformation	B-C0026377
of	O
the	O
cr3	B-C0079785
i	B-C1514562
domain	I-C1514562
by	O
direct	O
contact	B-C0332158
with	I-C0332158
the	O
chelated	B-C0719248
mg	I-C0719248
ion	I-C0719248
.	O
	
simvastatin	B-C0074554
antagonizes	B-C0243095
i	B-C0682969
domain	I-C0682969
binding	I-C0682969
to	O
the	O
complement	B-C0009498
fragments	I-C0009498
ic3b	B-C0369029
and	O
c3d	B-C0056184
but	O
not	O
to	O
intercellular	B-C0063695
adhesion	I-C0063695
molecule-1	I-C0063695
.	O
	
by	O
virtue	B-C0042764
of	O
the	O
i	B-C1514562
domain's	I-C1514562
wide	O
distribution	B-C0037775
in	O
binding	B-C0031327
kinetics	I-C0031327
to	O
ligands	B-C0023688
,	O
it	O
was	O
possible	B-C0332149
to	O
identify	O
ligand	B-C1517880
binding	I-C1517880
kinetics	B-C0031327
as	O
discriminator	O
for	O
simvastatin	B-C0074554
antagonism	B-C0013159
.	O
	
in	O
static	B-C0441463
cellular	B-C0178539
experiments	B-C0681814
,	O
15-25	O
μm	O
simvastatin	B-C0074554
reduced	B-C0392756
adhesion	B-C3714578
by	O
k562	B-C0600432
cells	I-C0600432
expressing	B-C0597360
recombinant	B-C1514798
cr3	B-C0079785
and	O
by	O
primary	B-C0205225
human	B-C0086418
monocytes	B-C0026473
,	O
with	O
an	O
endogenous	B-C0205227
expression	B-C0597360
of	O
this	O
receptor	B-C0597357
.	O
	
application	B-C0185125
of	O
force	B-C0441722
to	O
adhering	B-C3714578
monocytes	B-C0026473
potentiated	O
the	O
effects	B-C1704420
of	I-C1704420
simvastatin	B-C0074554
where	O
only	O
a	O
50-100	O
nm	O
concentration	B-C1446561
of	O
the	O
drug	B-C1254351
reduced	B-C0392756
the	O
adhesion	B-C3714578
by	O
20-40%	O
compared	B-C1707455
with	O
untreated	B-C0205556
cells	B-C0007634
.	O
	
the	O
ability	B-C0085732
of	O
simvastatin	B-C0074554
to	O
target	B-C1521840
cr3	B-C0079785
in	O
its	O
ligand	B-C1517880
binding	I-C1517880
-	O
activated	B-C1879547
conformation	B-C0026377
is	O
a	O
novel	B-C0205314
mechanism	B-C0678659
to	O
explain	O
the	O
known	O
anti-inflammatory	B-C1515999
effects	I-C1515999
of	O
this	O
compound	B-C1706082
,	O
in	O
particular	O
because	O
this	O
cr3	B-C0079785
conformation	B-C0026377
is	O
found	O
in	O
pro-inflammatory	B-C0205556
environments	B-C0014406
.	O
	
our	O
report	B-C0684224
points	O
to	O
new	O
designs	B-C0013171
of	O
cr3	B-C0079785
antagonists	B-C0243076
and	O
opens	O
new	O
perspectives	O
and	O
identifies	B-C0243095
druggable	B-C0205556
receptors	B-C0597357
from	O
characterization	B-C1880022
of	O
the	O
ligand	B-C1517880
binding	I-C1517880
kinetics	B-C0031327
in	O
the	O
presence	B-C3854307
of	O
common	B-C0205214
laboratory	B-C0022877
parameters	B-C0449381
for	O
differentiating	B-C2945687
between	O
community-acquired	B-C0694549
and	O
healthcare-associated	B-C1443237
pneumonia	I-C1443237
the	O
correct	B-C2349182
diagnosis	B-C0011900
of	O
healthcare-associated	B-C1443237
pneumonia	I-C1443237
hcap	B-C1443237
as	O
opposed	O
to	O
community-acquired	B-C0694549
pneumonia	I-C0694549
is	O
essential	B-C0205224
for	O
the	O
selection	B-C1707391
of	O
a	O
correct	B-C2349182
empirical	B-C1880496
antimicrobial	B-C1136254
approach	O
,	O
reserving	O
the	O
broad-spectrum	B-C2827424
or	O
highly	B-C3245505
potent	I-C3245505
antimicrobial	B-C0087111
therapies	I-C0087111
for	O
resistant	B-C0332325
strains	B-C1518614
most	O
commonly	O
present	O
in	O
hcap	B-C1443237
,	O
whereas	O
treating	B-C1522326
the	O
less	O
resistant	B-C0332325
strains	B-C1518614
,	O
most	O
commonly	O
associated	B-C0332281
with	I-C0332281
community	B-C0009462
and	O
long-term	B-C1708733
care	I-C1708733
facility	I-C1708733
-	O
acquired	B-C3714514
infections	I-C3714514
,	O
with	O
a	O
more	O
targeted	B-C1521840
empirical	B-C0871728
approach	I-C0871728
.	O
	
the	O
standard	B-C0205556
approach	I-C0205556
today	B-C0750526
is	O
to	O
differentiate	B-C2945687
between	O
the	O
two	O
based	O
on	O
the	O
medical	B-C0262926
history	I-C0262926
of	O
the	O
past	B-C1444699
90	O
days	B-C0439228
prior	O
to	O
admission	B-C0184666
.	O
	
measurable	B-C1513040
,	O
quantitative	B-C0392762
assessment	B-C0220825
may	O
be	O
able	O
to	O
assist	B-C1269765
in	O
this	O
decision	B-C0679006
.	O
	
the	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	B-C1513040
method	B-C0025663
of	O
differentiating	B-C2945687
between	O
community-acquired	B-C0694549
and	O
healthcare-associated	B-C1443237
pneumonias	I-C1443237
.	O
	
the	O
records	B-C0034869
of	O
126	O
patients	B-C0030705
admitted	B-C0184666
with	O
a	O
diagnosis	B-C0011900
of	O
pneumonia	B-C0032285
were	O
divided	O
into	O
two	O
groups	B-C0441833
based	O
on	O
the	O
probable	O
cause	B-C0679232
of	I-C0679232
their	I-C0679232
disease	I-C0679232
,	O
in	O
accordance	O
with	O
common	B-C0237607
practice	I-C0237607
.	O
	
the	O
routine	B-C0205547
laboratory	B-C0022885
work	I-C0022885
taken	O
upon	O
admittance	B-C0184666
was	O
analyzed	B-C0936012
using	O
logistical	B-C0206031
regression	I-C0206031
and	O
student's	B-C0871453
t-test	I-C0871453
.	O
	
we	O
have	O
found	O
that	O
the	O
red	B-C0427460
blood	I-C0427460
cell	I-C0427460
distribution	I-C0427460
width	I-C0427460
and	O
the	O
neutrophil	B-C0027950
-to-	O
lymphocyte	O
ratio	O
,	O
both	O
routine	O
parameters	O
obtained	O
in	O
a	O
simple	O
blood	O
count	O
,	O
can	O
each	O
assist	O
in	O
differentiating	O
between	O
community-acquired	O
and	O
healthcare-associated	O
pneumonias	O
.	O
	
we	O
have	O
found	O
two	O
statistically	O
significant	O
parameters	O
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical	O
history	O
,	O
chest	O
radiography	O
and	O
other	O
parameters	O
in	O
forming	O
an	O
immediate	O
clinical	O
impression	O
of	O
a	O
patient	O
presenting	O
with	O
pneumonia	B-C0032285
a	O
quasi-experimental	B-C0681814
study	I-C0681814
of	O
a	O
reminiscence	B-C0150321
program	I-C0150321
focused	O
on	O
autobiographical	B-C0561843
memory	I-C0561843
in	O
institutionalized	O
older	B-C0001792
adults	I-C0001792
with	O
cognitive	B-C0338656
impairment	I-C0338656
working	O
with	O
past	B-C0233793
memories	I-C0233793
through	O
reminiscence	B-C0150321
interventions	I-C0150321
has	O
been	O
practiced	O
for	O
several	B-C2981279
decades	I-C2981279
with	O
successful	O
outcomes	B-C1274040
on	O
mental	B-C0025353
health	I-C0025353
in	O
older	B-C0001792
adults	I-C0001792
.	O
	
few	O
studies	B-C2603343
however	O
have	O
focused	O
on	O
autobiographical	B-C0561843
memory	I-C0561843
recall	B-C0034770
in	O
older	B-C3826770
individuals	I-C3826770
with	O
cognitive	B-C0338656
impairment	I-C0338656
.	O
	
this	O
study	B-C2603343
aims	O
to	O
analyze	O
the	O
impact	O
of	O
an	O
individual	B-C0237401
reminiscence	B-C0150321
program	I-C0150321
in	O
a	O
group	O
of	O
older	B-C3826770
persons	I-C3826770
with	O
cognitive	B-C0234985
decline	I-C0234985
living	O
in	O
nursing	B-C0028688
homes	I-C0028688
on	O
the	O
dimensions	O
of	O
cognition	B-C0009240
,	O
autobiographical	B-C0561843
memory	I-C0561843
,	O
mood	B-C0026516
,	O
behavior	B-C0004927
and	O
anxiety	B-C0003469
.	O
	
a	O
two-group	O
pre-test	B-C0032919
and	I-C0032919
post-test	I-C0032919
design	I-C0032919
with	O
single	B-C0220825
blinded	I-C0220825
assessment	I-C0220825
was	O
conducted	O
.	O
	
forty-one	O
participants	B-C0679646
were	O
randomized	O
to	O
an	O
experimental	B-C1257890
group	I-C1257890
n=20	O
and	O
a	O
control	B-C0009932
group	I-C0009932
n=21	O
.	O
	
the	O
first	O
group	O
attended	O
five	O
weekly	O
individual	B-C0237401
reminiscence	B-C0871247
sessions	B-C1883016
.	O
	
changes	O
in	O
the	O
outcome	B-C0086749
measures	I-C0086749
were	O
examined	B-C0332128
for	O
cognition	B-C0009240
montreal	B-C3496286
cognitive	I-C3496286
assessment	I-C3496286
autobiographical	B-C0392366
memory	I-C0392366
test	I-C0392366
,	O
behavior	B-C0004927
alzheimer	B-C0450989
disease	I-C0450989
assessment	I-C0450989
subscale	I-C0450989
non-cog	I-C0450989
and	O
emotional	B-C0243095
status	I-C0243095
cornell	B-C0679604
scale	I-C0679604
for	I-C0679604
depression	I-C0679604
in	O
dementia	B-C0497327
geriatric	B-C0451184
depression	I-C0451184
scale	I-C0451184
,	O
and	O
geriatric	B-C0282574
anxiety	I-C0282574
inventory	I-C0282574
.	O
	
participants	B-C0679646
attending	O
reminiscence	B-C1883016
sessions	I-C1883016
exhibited	O
better	O
outcomes	B-C1274040
compared	O
to	O
the	O
control	B-C0009932
group	I-C0009932
in	O
cognition	B-C0009240
,	O
anxiety	B-C0003469
and	O
depression	B-C0011570
p<0	O
,	O
and	O
presented	O
a	O
higher	O
number	O
of	O
retrieved	B-C0034770
autobiographical	B-C0441471
events	I-C0441471
,	O
specificity	O
of	O
evoked	O
memories	B-C0025260
and	O
positive	O
valence	O
of	O
events	B-C0441471
p<0	O
,	O
and	O
also	O
presented	O
lower	O
latency	O
time	O
for	O
recalling	B-C0034770
events	B-C0441471
,	O
and	O
lower	O
negative	O
recalled	B-C0034770
events	B-C0441471
p<0	O
.	O
	
this	O
study	O
supports	O
the	O
potential	O
value	O
of	O
reminiscence	B-C0150321
therapy	I-C0150321
in	O
improving	O
the	O
recall	B-C0034770
of	O
autobiographical	B-C0561843
memory	I-C0561843
.	O
	
reminiscence	B-C0150321
therapy	I-C0150321
can	O
be	O
helpful	O
to	O
maintain	O
or	O
improve	O
cognitive	B-C0392335
function	I-C0392335
,	O
decrease	O
anxiety	B-C0003469
and	O
manage	O
depressive	B-C0086132
symptoms	I-C0086132
and	O
altered	B-C0542299
behavior	I-C0542299
,	O
economic	B-C1512163
burden	I-C1512163
of	O
illness	B-C0221423
among	O
patients	B-C0030705
with	O
severe	B-C0581126
asthma	I-C0581126
in	O
a	O
managed	O
care	B-C4034203
setting	I-C4034203
despite	O
intensive	O
pharmacotherapy	B-C0013216
,	O
a	O
considerable	O
number	B-C0237753
of	O
patients	B-C0030705
with	O
severe	B-C0581126
asthma	I-C0581126
have	O
inadequate	B-C0205412
disease	B-C0012634
control	B-C0243148
.	O
	
patients	B-C0030705
with	O
severe	B-C0581126
asthma	I-C0581126
who	O
experience	B-C0596545
exacerbations	B-C0349790
consume	O
significant	O
health	B-C0683535
care	I-C0683535
resources	I-C0683535
.	O
	
to	O
assess	B-C1516048
health	B-C0683535
care	I-C0683535
resource	I-C0683535
utilization	B-C0042153
and	O
associated	O
costs	B-C0085123
among	O
patients	B-C0030705
with	O
persistent	B-C0205322
severe	B-C0581126
asthma	I-C0581126
who	O
experienced	B-C0596545
exacerbations	B-C0349790
compared	O
with	O
patients	B-C0030705
with	O
persistent	B-C0205322
but	O
nonsevere	O
asthma	B-C0004096
.	O
	
this	O
retrospective	B-C1514923
analysis	B-C0936012
of	O
a	O
national	B-C0242356
administrative	I-C0242356
claims	I-C0242356
database	I-C0242356
identified	B-C0205396
patients	B-C0030705
aged	B-C0001779
12	O
years	B-C0439234
who	O
had	O
at	O
least	O
1	O
medical	B-C0586198
claim	I-C0586198
with	O
an	O
asthma	B-C0004096
diagnosis	B-C0011900
in	O
2012	O
and	O
had	O
continuous	O
medical	B-C2136534
and	O
pharmacy	B-C2114292
coverage	I-C2114292
under	O
a	O
commercial	B-C0680536
or	O
medicare	B-C3844556
advantage	I-C3844556
plan	I-C3844556
from	O
january	O
1	O
,	O
2012	O
,	O
to	O
december	O
31	O
,	O
2013	O
.	O
	
patients	B-C0030705
were	O
assigned	B-C1516050
to	O
1	O
of	O
2	O
mutually	O
exclusive	O
cohorts	B-C0599755
-	O
persistent	B-C3266628
asthma	I-C3266628
pa	B-C3266628
or	O
severe	B-C0581126
asthma	I-C0581126
sa	B-C0581126
to	O
an	O
established	O
algorithm	B-C0002045
based	O
on	O
asthma	B-C0004096
-related	O
health	B-C0683535
care	I-C0683535
resource	I-C0683535
use	B-C0457083
and	O
pharmacy	B-C2114292
claims	I-C2114292
for	O
controller	B-C0013227
medication	I-C0013227
.	O
	
sa	B-C0581126
patients	B-C0030705
were	O
required	O
to	O
meet	B-C1550543
pa	B-C3266628
criteria	B-C0243161
and	O
also	O
have	O
evidence	B-C3887511
of	O
2	O
asthma	B-C0349790
exacerbations	I-C0349790
in	O
2012	O
.	O
	
asthma	B-C0004096
-related	O
health	B-C0683535
care	I-C0683535
resource	I-C0683535
utilization	B-C0042153
and	O
costs	B-C0085123
were	O
computed	B-C1880157
from	O
asthma	B-C0004096
medication	B-C2081612
use	B-C0457083
rescue	B-C0039798
and	O
controller	B-C0039798
therapy	I-C0039798
and	O
medical	B-C0586198
claims	I-C0586198
with	O
an	O
asthma	B-C0004096
diagnosis	B-C0011900
in	O
the	O
primary	B-C0444508
position	I-C0444508
in	O
2012	O
and	O
2013	O
.	O
	
adherence	B-C1510802
to	O
controller	B-C0039798
therapy	I-C0039798
was	O
assessed	B-C1516048
over	O
365	O
days	B-C0439228
by	O
using	O
the	O
proportion	B-C1254367
of	I-C1254367
days	I-C1254367
covered	I-C1254367
pdc	B-C1254367
,	O
starting	O
with	O
the	O
first	O
claim	B-C0586198
for	O
controller	B-C0039798
therapy	I-C0039798
in	O
2012	O
.	O
	
differences	B-C1705242
between	O
the	O
pa	B-C3266628
and	O
sa	B-C0581126
cohorts	B-C0599755
were	O
analyzed	B-C0936012
by	O
t-test	B-C0871472
for	O
continuous	B-C0439828
variables	I-C0439828
and	O
chi-square	B-C0008041
test	I-C0008041
for	O
categorical	B-C0439828
variables	I-C0439828
.	O
	
asthma	B-C0004096
-related	O
costs	B-C0085123
in	O
2013	O
were	O
also	O
analyzed	B-C0936012
using	O
a	O
generalized	O
linear	B-C0023732
model	I-C0023732
with	O
a	O
gamma	B-C1708185
distribution	I-C1708185
and	O
log	B-C0026348
link	I-C0026348
,	O
adjusted	B-C0456081
for	O
patient	B-C0030705
demographics	B-C1698647
age	B-C0001779
,	O
gender	B-C0079399
,	O
region	B-C0017446
,	O
and	O
insurance	B-C0680873
type	I-C0680873
and	O
quan-charlson	B-C0449820
comorbidity	I-C0449820
score	I-C0449820
.	O
	
a	O
total	O
of	O
65	O
patients	B-C0030705
were	O
included	O
63	O
97.3	O
pa	B-C3266628
patients	B-C0030705
and	O
1	O
sa	B-C0581126
patients	B-C0030705
2.7	O
.	O
	
compared	B-C1707455
with	O
the	O
pa	B-C3266628
cohort	B-C0599755
,	O
the	O
sa	B-C0581126
cohort	B-C0599755
was	O
older	B-C3826770
mean	B-C0001779
age	I-C0001779
=	O
50.8	O
years	B-C0439234
vs	O
.	O
	
46.5	O
years	B-C0439234
,	O
p	O
<	O
0.001	O
and	O
had	O
higher	O
mean	O
comorbidity	B-C0449820
score	I-C0449820
1.47	O
vs	O
.	O
	
1.31	O
,	O
p<	O
0.001	O
.	O
	
the	O
mean	O
count	O
of	O
all	O
asthma	B-C0004096
medications	B-C2081612
fills	O
was	O
2.2	O
2012	O
and	O
2.1	O
2013	O
higher	O
in	O
the	O
sa	B-C0581126
cohort	B-C0599755
,	O
compared	B-C1707455
with	O
the	O
pa	B-C3266628
cohort	B-C0599755
p<	O
0.001	O
.	O
	
mean	O
pdc	B-C1254367
for	O
all	O
oral	B-C1272919
and	O
inhaled	B-C0004048
controller	B-C0087111
therapy	I-C0087111
was	O
also	O
higher	O
in	O
the	O
sa	B-C0581126
cohort	B-C0599755
compared	B-C1707455
with	O
the	O
pa	B-C3266628
cohort	B-C0599755
0.80	O
vs	O
.	O
	
0.65	O
,	O
p<	O
0.001	O
.	O
	
sa	B-C0581126
patients	B-C0030705
had	O
a	O
significantly	O
greater	B-C1704243
mean	I-C1704243
count	I-C1704243
of	O
asthma	B-C0004096
-related	O
hospitalizations	B-C0019993
,	O
emergency	B-C0586082
room	I-C0586082
visits	I-C0586082
,	O
and	O
ambulatory	B-C4035875
visits	I-C4035875
in	O
2012	O
and	O
2013	O
p<	O
0.001	O
.	O
	
unadjusted	O
mean	O
annual	O
asthma	B-C0004096
-related	O
costs	B-C0010186
in	O
the	O
sa	B-C0581126
versus	O
pa	B-C3266628
cohorts	B-C0599755
were	O
6	O
versus	O
2	O
p	O
<	O
0.001	O
in	O
2012	O
and	O
5	O
versus	O
1	O
p<	O
0.001	O
in	O
2013	O
.	O
	
higher	O
asthma	B-C0004096
-related	O
costs	B-C0010186
were	O
driven	O
by	O
greater	O
mean	O
annual	O
asthma	B-C0004096
medication	B-C2081612
costs	B-C0010186
in	O
2012	O
4	O
vs	O
.	O
	
1	O
,	O
p<	O
0.001	O
and	O
2013	O
4	O
vs	O
.	O
	
1	O
,	O
p<	O
0.001	O
.	O
	
adjusted	B-C0456081
mean	O
annual	O
asthma	B-C0004096
-related	O
costs	B-C0010186
in	O
2013	O
were	O
3	O
greater	O
cost	B-C0392762
ratio	I-C0392762
=2	O
,	O
p<	O
0.001	O
in	O
the	O
sa	B-C0581126
cohort	B-C0599755
,	O
and	O
adjusted	B-C0456081
mean	O
annual	O
asthma	B-C0004096
medication	B-C2081612
costs	B-C0010186
were	O
2	O
higher	O
cost	O
ratio=2	O
,	O
p<	O
0.001	O
in	O
the	O
sa	B-C0581126
cohort	B-C0599755
.	O
	
patients	B-C0030705
with	O
sa	B-C0581126
who	O
experienced	B-C0596545
2	O
or	O
more	O
exacerbations	B-C0349790
had	O
2.1	O
greater	O
use	B-C0457083
of	O
controller	B-C0087111
medications	I-C0087111
across	O
both	O
study	O
years	B-C0439234
and	O
were	O
more	O
adherent	B-C0334154
to	O
controller	B-C0039798
therapy	I-C0039798
than	O
patients	B-C0030705
with	O
pa	B-C3266628
.	O
	
despite	O
more	O
intensive	O
pharmacotherapy	B-C0013216
,	O
sa	B-C0581126
patients	B-C0030705
incurred	O
2.9	O
higher	O
adjusted	B-C0456081
asthma	B-C0004096
-related	O
costs	B-C0010186
and	O
3-fold	O
higher	O
adjusted	B-C0456081
asthma	B-C0004096
medication	B-C2081612
costs	B-C0010186
than	O
pa	B-C3266628
patients	B-C0030705
.	O
	
patients	B-C0030705
with	O
sa	B-C0581126
consistently	B-C0332290
demonstrated	O
a	O
higher	O
rate	O
of	O
health	B-C0086388
care	I-C0086388
utilization	B-C0042153
.	O
	
funding	B-C0243098
for	O
this	O
study	B-C2603343
ho-14-14443	O
was	O
provided	O
by	O
glaxosmithkline	B-C1552903
gsk	B-C1552903
.	O
	
all	O
listed	O
authors	B-C3812881
meet	B-C1550543
the	O
criteria	B-C0243161
for	O
authorship	B-C0004351
set	O
forth	O
by	O
the	O
international	B-C2699414
committee	I-C2699414
for	I-C2699414
medical	I-C2699414
journal	I-C2699414
editors	I-C2699414
.	O
	
albers	B-C0805191
,	O
forshag	B-C0805191
,	O
and	O
yancey	B-C0805191
are	O
employees	B-C0599987
of	O
gsk	B-C1552903
and	O
hold	O
stock	O
in	O
gsk	B-C1552903
.	O
	
dalal	B-C0805191
,	O
nagar	B-C0805191
,	O
and	O
ortega	B-C0805191
were	O
employees	B-C0599987
of	O
gsk	B-C1552903
at	O
the	O
time	B-C0040223
this	O
research	B-C0035168
was	O
conducted	O
.	O
	
chastek	B-C0805191
and	O
korrer	B-C0805191
are	O
employees	B-C0599987
of	O
optum	B-C0596660
,	O
which	O
received	O
consulting	B-C0015751
fees	I-C0015751
from	O
gsk	B-C1552903
for	O
research	B-C0035168
related	O
to	O
this	O
study	B-C2603343
.	O
	
study	B-C0178566
concept	I-C0178566
and	O
design	B-C1707689
were	O
contributed	B-C1880177
by	O
chastek	B-C0805191
,	O
nagar	B-C0805191
,	O
and	O
dalal	B-C0805191
.	O
	
korrer	B-C0805191
took	O
the	O
lead	O
in	O
data	B-C0010995
collection	I-C0010995
,	O
along	O
with	O
chastek	B-C0805191
,	O
and	O
data	B-C0010998
interpretation	I-C0010998
was	O
performed	O
by	O
chastek	B-C0805191
,	O
ortega	B-C0805191
,	O
forshag	B-C0805191
,	O
and	O
dalal	B-C0805191
.	O
	
the	O
manuscript	B-C0600659
was	O
written	O
by	O
chastek	B-C0805191
and	O
dalal	B-C0805191
and	O
revised	B-C3244319
by	O
albers	B-C0805191
and	O
yancy	B-C0805191
,	O
assisted	B-C1269765
by	O
the	O
other	O
differential	B-C1325907
regulation	I-C1325907
of	O
spontaneous	B-C0205359
and	O
evoked	B-C1444748
inhibitory	B-C2255939
synaptic	I-C2255939
transmission	I-C2255939
in	O
somatosensory	B-C0037658
cortex	I-C0037658
by	O
retinoic	B-C0040845
acid	I-C0040845
retinoic	B-C0040845
acid	I-C0040845
ra	B-C0040845
,	O
a	O
developmental	B-C0458003
morphogen	B-C1254351
,	O
has	O
emerged	O
in	O
recent	O
studies	O
as	O
a	O
novel	B-C0205314
synaptic	B-C4236609
signaling	B-C1519315
molecule	I-C1519315
that	O
acts	O
in	O
mature	B-C0205286
hippocampal	B-C0019564
neurons	B-C0027882
to	O
modulate	B-C0678672
excitatory	B-C0234107
and	O
inhibitory	B-C2255939
synaptic	I-C2255939
transmission	I-C2255939
in	O
the	O
context	O
of	O
homeostatic	B-C0019868
synaptic	B-C0027880
plasticity	I-C0027880
.	O
	
however	O
,	O
it	O
is	O
unclear	O
whether	O
ra	B-C0040845
is	O
capable	O
of	O
modulating	B-C0678672
neural	B-C0814033
circuits	I-C0814033
outside	B-C0205101
of	O
the	O
hippocampus	B-C0019564
,	O
and	O
if	O
so	O
,	O
whether	O
the	O
mode	B-C1524059
of	I-C1524059
ra's	I-C1524059
action	I-C1524059
at	O
synapses	B-C0039062
is	O
similar	B-C2348205
to	O
that	O
within	B-C0332285
the	O
hippocampal	B-C0019564
network	O
.	O
	
here	O
we	O
explore	O
for	O
the	O
first	O
time	O
ra	B-C0040845
's	O
synaptic	B-C0027793
function	I-C0027793
outside	B-C0205101
the	O
hippocampus	B-C0019564
and	O
uncover	O
a	O
novel	B-C0205314
function	B-C0542341
of	O
all-trans	B-C0040845
retinoic	I-C0040845
acid	I-C0040845
at	O
inhibitory	B-C1512777
synapses	I-C1512777
.	O
	
acute	B-C0205178
ra	B-C0040845
treatment	B-C1522326
increases	B-C0442805
spontaneous	B-C0205359
inhibitory	B-C2255939
synaptic	I-C2255939
transmission	I-C2255939
in	O
l2/3	B-C0206441
pyramidal	I-C0206441
neurons	I-C0206441
of	O
the	O
somatosensory	B-C0037658
cortex	I-C0037658
,	O
and	O
this	O
effect	B-C1280500
requires	O
expression	B-C0597360
of	O
ra's	B-C0140279
receptor	I-C0140279
rarα	B-C0140279
both	O
pre-	B-C0027793
and	I-C0027793
post-synaptically	I-C0027793
.	O
	
intriguingly	O
,	O
ra	B-C0040845
does	O
not	O
seem	O
to	O
affect	O
evoked	B-C1444748
inhibitory	B-C2255939
transmission	I-C2255939
assayed	O
with	O
either	O
extracellular	B-C0521119
stimulation	O
or	O
direct	O
activation	B-C4233793
of	I-C4233793
action	I-C4233793
potentials	I-C4233793
in	O
presynaptic	B-C0206181
interneurons	B-C0021792
at	O
connected	O
pairs	O
of	O
interneurons	B-C0021792
and	O
pyramidal	B-C0206441
neurons	I-C0206441
.	O
	
taken	O
together	O
,	O
these	O
results	B-C0683954
suggest	O
that	O
ra's	B-C0040845
action	B-C3266814
at	O
synapses	B-C0039062
is	O
not	O
monotonous	O
,	O
but	O
is	O
diverse	B-C1880371
depending	O
on	O
the	O
type	O
of	O
synaptic	B-C0027793
connection	I-C0027793
excitatory	B-C0234107
versus	O
inhibitory	B-C2255939
and	O
circuit	B-C0814033
hippocampal	B-C0019564
versus	O
cortical	B-C0007776
.	O
	
thus	O
,	O
synaptic	B-C4236609
signaling	I-C4236609
of	O
ra	B-C0040845
may	O
mediate	O
multi-faceted	O
regulation	B-C1326639
of	I-C1326639
synaptic	I-C1326639
plasticity	I-C1326639
.	O
	
in	O
addition	O
to	O
its	O
classic	B-C1705810
roles	I-C1705810
in	O
brain	B-C1160340
development	I-C1160340
,	O
retinoic	B-C0040845
acid	I-C0040845
ra	B-C0040845
has	O
recently	O
been	O
shown	O
to	O
regulate	B-C1325907
excitatory	B-C0234107
and	O
inhibitory	B-C2255939
transmission	I-C2255939
in	O
the	O
adult	B-C0001675
brain	B-C0006104
.	O
	
here	O
,	O
the	O
authors	B-C3812881
show	O
that	O
in	O
layer	B-C0934502
2/3	I-C0934502
l2/3	B-C0934502
of	O
the	O
somatosensory	B-C0037658
cortex	I-C0037658
s1	B-C0037658
,	O
acute	B-C0205178
ra	B-C0040845
induces	B-C0205263
increases	B-C0442805
in	O
spontaneous	B-C0205359
but	O
not	O
action-potential	B-C0001272
evoked	B-C1444748
transmission	B-C0027793
,	O
and	O
that	O
this	O
requires	O
retinoic	B-C0140279
acid	I-C0140279
receptor	I-C0140279
rarα	B-C0140279
both	O
in	O
presynaptic	B-C0206181
pv	B-C0030616
-positive	O
interneurons	B-C0021792
and	O
postsynaptic	B-C0682686
pyramidal	B-C0206441
pn	I-C0206441
neurons	I-C0206441
.	O
	
utilization	B-C0013223
pattern	B-C0449774
and	O
drug	B-C0871719
use	I-C0871719
of	O
traditional	B-C0025131
chinese	I-C0025131
medicine	I-C0025131
,	O
western	O
medicine	O
,	O
and	O
integrated	O
chinese-western	O
medicine	O
treatments	O
for	O
allergic	O
rhinitis	O
under	O
the	O
national	O
health	O
insurance	O
program	O
in	O
taiwan	O
patients	O
in	O
taiwan	O
with	O
allergic	O
rhinitis	O
seek	O
not	O
only	O
western	O
medicine	O
treatment	O
but	O
also	O
traditional	O
chinese	B-C0025123
medicine	O
treatment	O
or	O
integrated	O
chinese-western	O
medicine	O
treatment	O
.	O
	
various	O
studies	O
have	O
conducted	O
pairwise	O
comparison	O
on	O
traditional	O
chinese	O
medicine	O
,	O
western	B-C1879848
medicine	O
,	O
and	O
integrated	O
chinese-western	O
medicine	O
treatments	O
.	O
	
however	O
,	O
none	O
conducted	O
simultaneous	O
analysis	O
of	O
the	O
three	O
treatments	O
.	O
	
this	O
study	O
analyzed	O
patients	O
with	O
allergic	O
rhinitis	O
receiving	O
the	O
three	O
treatments	O
to	O
identify	O
differences	O
in	O
demographic	O
characteristic	O
and	O
medical	O
use	O
and	O
thereby	O
to	O
determine	O
drug	O
use	O
patterns	O
of	O
different	O
treatments	O
.	O
	
the	O
national	O
health	O
insurance	O
research	O
database	O
was	O
the	O
data	O
source	O
,	O
and	O
included	O
patients	O
were	O
those	O
diagnosed	O
with	O
allergic	O
rhinitis	O
international	O
classification	O
of	O
diseases	O
,	O
ninth	O
revision	O
,	O
clinical	O
modification	O
codes	O
470-478	O
.	O
	
chi-square	O
test	O
and	O
tukey	O
studentized	O
range	O
honest	O
significant	O
difference	O
test	O
were	O
conducted	O
to	O
investigate	O
the	O
differences	O
among	O
the	O
three	O
treatments	O
.	O
	
visit	O
frequency	O
for	O
allergic	O
rhinitis	O
treatment	O
was	O
higher	O
in	O
female	O
than	O
male	O
patients	O
,	O
regardless	O
of	O
treatment	O
with	O
traditional	O
chinese	O
medicine	I-C1879848
,	O
western	O
medicine	O
,	O
or	O
integrated	O
chinese-western	O
medicine	O
.	O
	
persons	O
aged	O
0-19	O
years	O
ranked	O
the	O
highest	O
in	O
proportion	O
of	O
visits	O
for	O
allergic	O
rhinitis	O
.	O
	
traditional	O
chinese	O
medicine	O
treatment	O
had	O
more	O
medical	O
items	O
per	O
person-time	O
and	O
daily	O
drug	O
cost	O
per	O
person-time	O
and	O
had	O
the	O
lowest	O
total	O
expenditure	O
per	O
person-time	O
.	O
	
in	O
contrast	O
,	O
western	O
medicine	O
had	O
the	O
lowest	O
daily	O
drug	O
cost	O
per	O
person-time	O
and	O
the	O
highest	O
total	O
expenditure	O
per	O
person-time	O
.	O
	
the	O
total	O
expenditure	O
per	O
person-time	O
,	O
daily	O
drug	O
cost	O
per	O
person-time	O
,	O
and	O
medical	O
items	O
per	O
person-time	O
of	O
integrated	O
chinese-western	O
medicine	O
treatment	O
lay	O
between	O
those	O
seen	O
with	O
traditional	O
chinese	O
medicine	O
and	O
western	O
medicine	O
treatments	O
.	O
	
although	O
only	O
6.82	O
%	O
of	O
patients	O
with	O
allergic	O
rhinitis	O
chose	O
integrated	O
chinese-western	O
medicine	O
treatment	O
,	O
the	O
visit	O
frequency	O
per	O
person-year	O
of	O
integrated	O
chinese-western	O
medicine	O
ranked	O
highest	O
.	O
	
in	O
addition	O
,	O
multiple-composition	O
medicines	O
were	O
used	O
more	O
frequently	O
than	O
single-composition	O
medicines	O
,	O
and	O
mar	O
huang	O
ephedra	O
sinica	O
stapf	O
was	O
seldom	O
used	O
to	O
decrease	O
the	O
risk	O
of	O
combining	O
medications	B-C0013227
tlr9	B-C1423633
deficiency	B-C0011155
leads	O
to	O
accelerated	B-C0521110
renal	B-C0022658
disease	I-C0022658
and	O
myeloid	B-C0007634
lineage	I-C0007634
abnormalities	B-C1704258
in	O
pristane	B-C0071986
-induced	O
murine	B-C0026809
lupus	B-C0012634
systemic	B-C0024141
lupus	I-C0024141
erythematosus	I-C0024141
sle	B-C0024141
is	O
a	O
chronic	B-C0205191
,	O
life-threatening	B-C2826244
autoimmune	B-C0004364
disorder	I-C0004364
,	O
leading	O
to	O
multiple	O
organ	B-C0178784
pathologies	B-C0030664
and	O
kidney	B-C0022646
destruction	B-C1948029
.	O
	
analyses	O
of	O
numerous	O
murine	B-C0026809
models	B-C0012644
of	O
spontaneous	O
sle	B-C0024141
have	O
revealed	O
a	O
critical	O
role	O
for	O
endosomal	B-C1820047
tlrs	B-C0670896
in	O
the	O
production	O
of	O
autoantibodies	B-C0004358
and	O
development	O
of	O
other	O
clinical	B-C0205210
disease	B-C0012634
manifestations	B-C0205319
.	O
	
nevertheless	O
,	O
the	O
corresponding	O
tlr9	B-C1423633
-	O
deficient	B-C0011155
autoimmune	B-C0443146
-prone	O
strains	B-C1518614
consistently	O
develop	O
more	O
severe	O
disease	B-C0012634
pathology	B-C0030664
.	O
	
injection	B-C1533685
of	O
balb/c	B-C0025919
mice	I-C0025919
with	O
2	B-C0071986
tmpd	B-C0071986
,	O
commonly	O
known	O
as	O
pristane	B-C0071986
,	O
also	O
results	O
in	O
the	O
development	O
of	O
sle-like	B-C0012634
disease	I-C0012634
.	O
	
we	O
now	O
show	O
that	O
tlr9	B-C1423633
balb/c	B-C0025919
mice	I-C0025919
injected	B-C0021493
i.p	I-C0021493
.	O
	
with	O
tmpd	B-C0071986
develop	O
more	O
severe	O
autoimmunity	B-C0004368
than	O
do	O
their	O
tlr	B-C0670896
-sufficient	O
cohorts	O
.	O
	
early	O
indications	O
include	O
an	O
increased	O
accumulation	B-C4055506
of	O
tlr7	B-C1336639
-	O
expressing	B-C0017262
ly6c	B-C1530208
inflammatory	B-C0333348
monocytes	B-C0026473
at	O
the	O
site	B-C2700396
of	I-C2700396
injection	I-C2700396
,	O
upregulation	B-C0041904
of	O
ifn	B-C0021747
-regulated	O
gene	B-C0017262
expression	I-C0017262
in	O
the	O
peritoneal	B-C1704247
cavity	I-C1704247
,	O
and	O
an	O
increased	O
production	O
of	O
myeloid	B-C0007634
lineage	I-C0007634
precursors	I-C0007634
common	B-C1956319
myeloid	I-C1956319
progenitors	I-C1956319
and	O
granulocyte	B-C0018183
myeloid	B-C0007634
precursors	I-C0007634
in	O
the	O
bone	B-C0005953
marrow	I-C0005953
.	O
	
tmpd	B-C0071986
-	O
injected	B-C1533685
tlr9	B-C1423633
balb/c	B-C0025919
mice	I-C0025919
develop	O
higher	O
autoantibody	B-C0004358
titers	O
against	O
rna	B-C0035668
,	O
neutrophil	B-C0027950
cytoplasmic	B-C0521449
ags	B-C0003320
,	O
and	O
myeloperoxidase	B-C0027021
than	O
do	O
tmpd	B-C0071986
-	O
injected	B-C1533685
wild-type	B-C0025919
balb/c	I-C0025919
mice	I-C0025919
.	O
	
the	O
tmp	B-C0071986
-	O
injected	B-C1533685
tlr9	B-C1423633
mice	B-C0026809
,	O
and	O
not	O
the	O
wild-type	B-C1520150
mice	I-C1520150
,	O
also	O
develop	O
a	O
marked	O
increase	O
in	O
glomerular	B-C0020852
igg	I-C0020852
deposition	B-C0333562
and	O
infiltrating	O
granulocytes	B-C0018183
,	O
much	O
more	O
severe	O
glomerulonephritis	B-C0017658
,	O
and	O
a	O
reduced	B-C0392756
lifespan	B-C0870809
.	O
	
collectively	O
,	O
the	O
data	O
point	O
to	O
a	O
major	O
role	O
for	O
tlr7	B-C1336639
in	O
the	O
response	B-C0871261
to	O
self-antigens	B-C0004359
in	O
this	O
model	B-C0012644
of	O
experimental	O
autoimmunity	B-C0004368
.	O
	
therefore	O
,	O
the	O
balb/c	B-C0025919
pristane	B-C0071986
model	B-C0012644
recapitulates	O
other	O
tlr7	B-C1336639
-driven	O
spontaneous	O
models	B-C0012644
of	O
sle	B-C0024141
and	O
is	O
negatively	B-C0205160
regulated	O
by	O
effect	B-C1280500
of	O
xenotransplantation	B-C0520484
site	B-C0205145
on	O
microrna	B-C1101610
expression	B-C0017262
of	O
human	B-C0086418
colon	B-C0699790
cancer	I-C0699790
stem	B-C0038250
cells	I-C0038250
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
cscs	B-C1956422
have	O
a	O
high	B-C0205250
tumorigenic	B-C0007621
ability	B-C0085732
to	O
form	O
patient-derived	B-C4050317
tumor	I-C4050317
xenografts	I-C4050317
pdxs	B-C4050317
.	O
	
pdxs	B-C4050317
are	O
an	O
attractive	B-C2346874
pre-clinical	B-C1514292
model	I-C1514292
,	O
but	O
gene	B-C0017262
expression	I-C0017262
and	O
biological	B-C0001398
behavior	I-C0001398
of	O
cancer	B-C0334227
cells	I-C0334227
in	O
the	O
tumor	B-C0027651
will	O
change	B-C0392747
during	O
establishment	B-C0443211
and	O
passage	O
of	O
pdxs	B-C4050317
.	O
	
human	B-C0086418
colon	B-C0699790
cancer	I-C0699790
pdx	B-C4050317
was	O
established	B-C0443211
and	O
passaged	B-C1709474
either	O
subcutaneously	B-C0443315
or	O
orthotopically	B-C0574893
into	O
the	O
murine	B-C0025929
intestine	B-C0021853
.	O
	
histology	B-C0019638
and	O
flow	B-C0016263
cytometric	I-C0016263
profile	B-C1979963
of	O
the	O
surgical	B-C0543467
specimen	B-C2347026
and	O
the	O
pdx	B-C4050317
were	O
analyzed	B-C0936012
.	O
	
cscs	B-C1956422
were	O
then	O
isolated	B-C0205409
from	O
the	O
tumors	B-C0027651
and	O
their	O
microrna	B-C1101610
mirna	B-C1101610
expression	B-C0017262
was	O
analyzed	B-C0936012
by	O
semi-quantitative	B-C2733022
polymerase	I-C2733022
chain	I-C2733022
reaction	I-C2733022
.	O
	
the	O
surgical	B-C0543467
specimens	B-C2347026
and	O
pdxs	B-C4050317
were	O
histologically	B-C0019638
similar	B-C2348205
.	O
	
the	O
size	B-C0456389
of	O
csc	B-C1956422
population	B-C1257890
increased	B-C0205217
and	O
expression	B-C0017262
of	O
mirna	B-C1101610
s	O
in	O
cscs	B-C1956422
changed	B-C0392747
in	O
the	O
passaged	B-C1709474
pdxs	B-C4050317
.	O
	
expression	B-C0017262
of	O
oncogenic	B-C0007090
mirnas	B-C1101610
was	O
highly	B-C0205250
up-regulated	B-C0041904
in	O
the	O
cscs	B-C1956422
of	O
the	O
orthotopically	B-C0574893
passaged	B-C1709474
pdxs	B-C4050317
.	O
	
the	O
xenotransplantation	B-C0520484
site	B-C0205145
and	O
the	O
number	B-C0237753
of	O
tumor	B-C0027651
passages	B-C1709474
affect	B-C0001721
the	O
mirna	B-C1101610
expression	B-C0017262
of	O
human	B-C0086418
colon	B-C0009368
cscs	B-C1956422
.	O
	
chemosensitivity	B-C2347610
,	O
cardiovascular	B-C1113685
risk	I-C1113685
,	O
and	O
the	O
ventilatory	B-C1321070
response	I-C1321070
to	O
exercise	B-C0015259
in	O
copd	B-C0024117
copd	B-C0024117
is	O
associated	O
with	O
elevated	B-C3163633
cardiovascular	B-C1113685
risk	I-C1113685
and	O
a	O
potentiated	B-C1704419
ventilatory	B-C1321070
response	I-C1321070
to	O
exercise	B-C0015259
.	O
	
enhanced	O
carotid	B-C0741968
chemoreceptor	B-C0008010
cc	B-C0008010
activity	B-C0234208
/	O
sensitivity	B-C0234208
is	O
present	O
in	O
other	O
clinical	O
conditions	O
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	O
vasoconstrictor	O
outflow	O
,	O
and	O
is	O
predictive	O
of	O
mortality	O
.	O
	
cc	O
activity	O
/	O
sensitivity	B-C0234208
,	O
and	O
the	O
resulting	O
functional	O
significance	O
,	O
has	O
not	O
been	O
well	O
examined	O
in	O
copd	O
.	O
	
we	O
hypothesized	O
that	O
cc	O
activity	O
/	O
sensitivity	O
would	O
be	O
elevated	O
in	O
copd	O
,	O
and	O
related	O
to	O
increased	O
pulse	O
wave	O
velocity	O
a	O
marker	O
of	O
cv	O
risk	O
and	O
the	O
ventilatory	O
response	O
to	O
exercise	O
.	O
	
30	O
copd	O
patients	O
and	O
10	O
healthy	O
age-matched	O
controls	O
were	O
examined	O
.	O
	
participants	O
performed	O
baseline	O
cardiopulmonary	O
exercise	O
and	O
pulmonary	O
function	O
testing	O
.	O
	
cc	O
activity	O
was	O
later	O
evaluated	O
by	O
the	O
drop	O
in	O
ventilation	O
with	O
breathing	O
100%	O
o2	O
,	O
and	O
cc	O
sensitivity	O
was	O
then	O
assessed	O
by	O
the	O
ventilatory	O
response	O
to	O
hypoxia	O
δve/δs	O
po2	O
.	O
	
peripheral	O
arterial	O
stiffness	O
was	O
subsequently	O
evaluated	O
by	O
measurement	O
of	O
pulse	O
wave	O
velocity	O
pwv	O
using	O
applanation	O
tonometry	O
while	O
the	O
subjects	O
were	O
breathing	O
room	O
air	O
,	O
and	O
then	O
following	O
chemoreceptor	O
inhibition	O
by	O
breathing	O
100%	O
o2	O
for	O
2	O
minutes	O
.	O
	
cc	O
activity	O
,	O
cc	O
sensitivity	O
,	O
pwv	O
and	O
the	O
ventilatory	O
response	O
to	O
exercise	O
were	O
all	O
increased	O
in	O
copd	O
relative	O
to	O
controls	O
.	O
	
cc	O
sensitivity	O
was	O
related	O
to	O
pwv	O
however	O
,	O
neither	O
cc	O
activity	O
nor	O
cc	O
sensitivity	O
was	O
related	O
to	O
the	O
ventilatory	O
response	O
to	O
exercise	O
in	O
copd	O
.	O
	
cc	O
inhibition	O
by	O
breathing	O
100%	O
o2	O
normalized	O
pwv	O
in	O
copd	O
,	O
while	O
no	O
effect	O
was	O
observed	O
in	O
controls	O
.	O
	
cc	O
activity	O
and	O
sensitivity	O
are	O
elevated	O
in	O
copd	O
,	O
and	O
appear	O
related	O
to	O
cardiovascular	O
risk	O
however	O
,	O
cc	O
activity	O
/	O
sensitivity	O
does	O
not	O
contribute	O
to	O
the	O
potentiated	O
ventilatory	O
response	O
to	O
exercise	B-C0015259
isolation	B-C0007616
of	I-C0007616
cells	I-C0007616
specialized	B-C1704211
in	O
anticancer	B-C0003392
alkaloid	B-C1158456
metabolism	I-C1158456
by	O
fluorescence-activated	B-C0079366
cell	I-C0079366
sorting	I-C0079366
plant	B-C0032098
specialized	B-C1704211
metabolism	B-C0025519
often	O
presents	O
a	O
complex	B-C0439855
cell	B-C0007634
-	O
specific	B-C0205369
compartmentation	B-C0007583
essential	O
to	O
accomplish	O
the	O
biosynthesis	B-C0005572
of	O
valuable	O
plant	B-C0032098
natural	B-C1566558
products	I-C1566558
.	O
	
hence	O
,	O
the	O
disclosure	O
and	O
potential	O
manipulation	B-C0392747
of	O
such	O
pathways	B-C1705987
may	O
depend	O
on	O
the	O
capacity	O
to	O
isolate	B-C0220862
and	O
characterize	B-C1880022
specific	B-C0205369
cell	B-C0449475
types	I-C0449475
.	O
	
catharanthus	B-C0331124
roseus	I-C0331124
is	O
the	O
source	O
of	O
several	O
medicinal	B-C0013227
terpenoid	B-C1449663
indole	I-C1449663
alkaloids	I-C1449663
,	O
including	O
the	O
low-level	O
anticancer	B-C0003392
vinblastine	B-C0042670
and	O
vincristine	B-C0042679
,	O
for	O
which	O
the	O
late	O
biosynthetic	B-C0005572
steps	I-C0005572
occur	O
in	O
specialized	B-C1704211
mesophyll	B-C2936408
cells	I-C2936408
called	O
idioblasts	B-C3178867
.	O
	
here	O
,	O
the	O
optical	B-C0029144
,	O
fluorescence	B-C0016315
,	O
and	O
alkaloid	B-C0301258
-	O
accumulating	B-C4055506
properties	O
of	O
c	B-C0331124
.	O
	
roseus	I-C0331124
leaf	B-C0242724
idioblasts	B-C3178867
are	O
characterized	B-C1880022
,	O
and	O
a	O
methodology	B-C3266812
for	O
the	O
isolation	B-C0220862
of	O
idioblast	B-C3178867
protoplasts	B-C0033731
by	O
fluorescence-activated	B-C0079366
cell	I-C0079366
sorting	I-C0079366
is	O
established	O
,	O
taking	O
advantage	O
of	O
the	O
distinctive	O
autofluorescence	B-C0544711
of	O
these	O
cells	B-C0007634
.	O
	
this	O
achievement	O
represents	O
a	O
crucial	O
step	O
for	O
the	O
development	O
of	O
differential	O
omic	B-C0035171
strategies	I-C0035171
leading	O
to	O
the	O
identification	B-C0205396
of	O
candidate	B-C0017337
genes	I-C0017337
putatively	O
involved	O
in	O
the	O
biosynthesis	B-C0005572
,	O
pathway	B-C1705987
regulation	B-C1327622
,	O
and	O
transmembrane	B-C1519624
transport	I-C1519624
leading	O
to	O
the	O
anticancer	B-C0243095
alkaloids	B-C0301258
from	O
c	B-C0331124
.	O
	
roseus	I-C0331124
.	O
	
interaction	B-C1704675
of	O
the	O
antimicrobial	B-C4084937
peptides	I-C4084937
rhesus	B-C1450181
θ-defensin	I-C1450181
and	O
porcine	B-C3665571
protegrin-1	B-C0300260
with	O
anionic	B-C0031676
phospholipid	I-C0031676
monolayers	I-C0031676
a	O
combination	O
of	O
langmuir	B-C0282574
isotherm	I-C0282574
,	O
brewster	B-C0026018
angle	I-C0026018
microscopy	I-C0026018
bam	B-C0026018
,	O
and	O
neutron	B-C0242481
reflectivity	I-C0242481
studies	I-C0242481
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	B-C0596899
bacterial	B-C0007603
cell	I-C0007603
membranes	I-C0007603
of	O
the	O
antimicrobial	B-C4084937
peptides	I-C4084937
,	O
rhesus	B-C1450181
θ-defensin	I-C1450181
1	I-C1450181
rtd-1	B-C1450181
,	O
and	O
porcine	B-C3665571
protegrin	B-C0300260
1	I-C0300260
pg-1	B-C0300260
.	O
	
the	O
peptides	B-C0030956
were	O
interacted	B-C1704675
with	O
monolayers	B-C0031676
spread	O
at	O
the	O
air	B-C0001861
-	O
water	B-C0043047
interface	O
and	O
prepared	O
from	O
a	O
3	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	B-C1450468
and	O
phosphatidylglycerol	B-C0031614
used	O
to	O
approximate	B-C0332232
the	O
cell	B-C0007603
membranes	I-C0007603
of	O
gram	B-C0018154
positive	I-C0018154
bacteria	I-C0018154
.	O
	
the	O
langmuir	B-C1561572
film	I-C1561572
balance	O
measurements	B-C0242485
show	O
that	O
both	O
peptides	B-C0030956
perturb	B-C0332453
the	O
lipid	B-C0031676
monolayers	I-C0031676
causing	O
an	O
increase	O
in	O
surface	B-C0004180
pressure	I-C0004180
,	O
and	O
the	O
bam	B-C0026018
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small	B-C1514562
domains	I-C1514562
within	O
the	O
lipid	B-C0596899
films	I-C0596899
,	O
around	O
5	O
μm	O
diameter	O
.	O
	
the	O
overall	O
change	O
in	O
monolayer	B-C0031676
surface	B-C0004180
pressure	I-C0004180
caused	O
by	O
pg-1	B-C0300260
,	O
however	O
,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
rtd-1	B-C1450181
+8	O
mn	O
vs	O
+5	O
mn	O
,	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	B-C1704675
with	O
the	O
monolayer	B-C0031676
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
rtd-1	B-C1450181
.	O
	
the	O
neutron	B-C0026336
reflectivity	I-C0026336
studies	I-C0026336
also	O
show	O
differences	O
for	O
pg-1	B-C0300260
and	O
rtd-1	B-C1450181
,	O
with	O
the	O
model	B-C0596899
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	B-C0002671
pg-1	B-C0300260
becomes	O
fully	O
embedded	B-C1707903
within	O
the	O
lipid	B-C0596899
film	I-C0596899
-causing	O
an	O
extension	O
of	O
the	O
lipid	B-C1254355
acyl	I-C1254355
chains	I-C1254355
but	O
leaving	O
the	O
thickness	B-C1280412
of	O
the	O
lipid	B-C1254355
headgroup	I-C1254355
layer	I-C1254355
unaffected-while	O
rtd-1	B-C1450181
is	O
seen	O
to	O
insert	O
less	O
deeply-causing	O
the	O
same	O
extension	O
of	O
the	O
lipid	B-C1254355
acyl	I-C1254355
chains	I-C1254355
as	O
pg-1	B-C0300260
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	B-C1280412
of	O
the	O
lipid	B-C1254355
headgroup	I-C1254355
layer	I-C1254355
.	O
	
the	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	B-C0030956
on	O
anionic	B-C0031676
lipid	I-C0031676
monolayers	I-C0031676
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic	B-C0009542
activities	I-C0009542
,	O
and	O
their	O
proposed	O
differing	B-C2718044
propensities	I-C2718044
to	O
form	O
transmembrane	B-C1167322
pores	B-C1325742
.	O
	
development	B-C0243107
of	O
chrysin	B-C0055661
loaded	O
poloxamer	B-C0600615
micelles	O
and	O
toxicity	B-C0040539
evaluation	B-C0220825
in	O
fish	B-C0016163
embryos	B-C0013935
poloxamer	B-C0600615
micelles	B-C0025938
promise	O
safety	O
and	O
efficacy	O
for	O
many	O
water	O
insoluble	O
drugs	O
.	O
	
chrysin	O
has	O
been	O
reported	O
to	O
have	O
anticancer	O
,	O
anti-inflammatory	O
,	O
antioxidant	O
,	O
and	O
anti-aromatase	O
activities	O
but	O
its	O
water	O
insoluble	O
properties	O
limit	O
its	O
pharmaceutical	O
application	O
.	O
	
in	O
the	O
present	O
study	O
,	O
chrysin	O
loaded	O
poloxamer	O
micelles	B-C0025938
were	O
developed	O
.	O
	
two	O
types	O
of	O
poloxamers	O
,	O
pluronic	O
f-68	O
and	O
pluronic	O
f-127	O
were	O
compared	O
.	O
	
it	O
was	O
found	O
that	O
chrysin	O
loaded	O
pluronic	O
f-68	O
micelles	O
cs-p68	O
and	O
chrysin	O
loaded	O
pluronic	O
f-127	O
micelles	O
cs-p127	O
obviously	O
increase	O
the	O
aqueous	O
solubility	O
of	O
chrysin	O
.	O
	
the	O
results	O
also	O
indicated	O
that	O
the	O
type	O
of	O
polymer	O
and	O
ratio	O
of	O
drug	O
to	O
polymer	O
affected	O
size	O
and	O
desirable	O
characteristics	O
of	O
the	O
micelles	O
.	O
	
the	O
micelle	O
system	O
of	O
cs-p68	O
and	O
cs-p127	O
formed	O
at	O
drug	O
to	O
polymer	O
ratios	O
of	O
1	O
and	O
1	O
,	O
respectively	O
,	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
monodispersed	O
system	O
with	O
a	O
nanosize-range	O
diameter	O
.	O
	
the	O
in	O
vivo	O
study	O
in	O
zebrafish	O
eggs	O
indicates	O
that	O
the	O
toxicity	O
of	O
cs-p68	O
and	O
cs-p127	O
is	O
a	O
dose	O
response	O
.	O
	
cs-p68	O
and	O
cs-p127	O
at	O
a	O
drug	O
dose	O
of	O
10	O
ng/ml	O
or	O
less	O
is	O
safe	O
for	O
zebrafish	O
embryo	O
growth	O
.	O
	
the	O
results	O
of	O
this	O
study	O
indicate	O
enhanced	O
water	O
solubility	O
of	O
chrysin	O
.	O
	
chrysin	O
loaded	O
poloxamer	O
micelles	O
are	O
promising	O
for	O
further	O
use	O
in	O
in	O
vivo	O
studies	O
in	O
mammalian	O
animals	O
and	O
humans	B-C0086418
adenoviral	B-C0001483
delivery	B-C0011209
of	O
tumor	B-C1456820
necrosis	I-C1456820
factor-α	I-C1456820
and	O
interleukin-2	B-C0021756
enables	O
successful	O
adoptive	B-C0079613
cell	I-C0079613
therapy	I-C0079613
of	O
immunosuppressive	B-C0021081
melanoma	B-C0025202
adoptive	B-C0376517
t-cell	I-C0376517
transfer	I-C0376517
is	O
a	O
promising	O
treatment	B-C0679624
approach	I-C0679624
for	O
metastatic	B-C0027627
cancer	I-C0027627
,	O
but	O
efficacy	B-C1280519
in	O
solid	B-C0280100
tumors	I-C0280100
has	O
only	O
been	O
achieved	O
with	O
toxic	B-C1407029
pre-	O
and	O
postconditioning	O
regimens	O
.	O
	
thus	O
,	O
adoptive	B-C0079613
t-cell	I-C0079613
therapies	I-C0079613
would	O
benefit	B-C0814225
from	O
complementary	O
modalities	B-C0695347
that	O
enable	O
their	O
full	B-C0443225
potential	B-C3245505
without	O
excessive	B-C0442802
toxicity	B-C0040539
.	O
	
we	O
aimed	B-C1947946
to	O
improve	B-C1272745
the	O
efficacy	B-C1280519
and	O
safety	B-C0205556
of	O
adoptive	B-C0376517
t-cell	I-C0376517
transfer	I-C0376517
by	O
using	O
adenoviral	B-C1510800
vectors	I-C1510800
for	O
direct	O
delivery	B-C1705822
of	O
immunomodulatory	B-C1963758
murine	B-C0026809
cytokines	B-C0079189
into	O
b16.ova	B-C0029974
melanoma	B-C0004565
tumors	I-C0004565
with	O
concomitant	O
t-cell	O
receptor	O
transgenic	O
ot-i	O
t-cell	O
transfer	O
.	O
	
armed	O
adenoviruses	O
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	O
when	O
injected	O
into	O
b16.ova	O
tumors	B-C0027651
,	O
suggesting	O
safety	O
of	O
virus-mediated	O
cytokine	O
delivery	O
.	O
	
antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	O
coding	O
for	O
murine	O
interleukin-2	O
mil-2	O
and	O
tumor	O
necrosis	O
factor-α	O
mtnfα	O
when	O
compared	O
with	O
t-cell	O
transfer	O
alone	O
or	O
viruses	O
alone	O
.	O
	
further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mil-2	O
,	O
mtnfα	O
,	O
and	O
ot-i	O
t-cells	O
.	O
	
mechanistic	O
studies	O
suggest	O
that	O
mil-2	O
has	O
an	O
important	O
role	O
in	O
activating	O
t-cells	O
at	O
the	O
tumor	O
,	O
while	O
mtnfα	O
induces	O
chemokine	O
expression	O
.	O
	
furthermore	O
,	O
adenovirus	O
treatments	O
enhanced	O
tumor	O
-	O
infiltration	O
of	O
ot-i	O
t-cells	O
as	O
demonstrated	O
by	O
spect/ct	O
imaging	O
of	O
111	O
cells	O
.	O
	
our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine-coding	O
adenoviruses	O
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	O
t-cell	O
therapies	I-C0079613
the	O
maternal	B-C1858460
legacy	B-C0242538
female	B-C0086287
identity	B-C3826248
predicts	O
offspring	B-C0680063
sex	B-C0036893
ratio	I-C0036893
in	O
the	O
loggerhead	B-C0999068
sea	I-C0999068
turtle	I-C0999068
in	O
organisms	B-C0029235
with	O
temperature-dependent	B-C0039476
sex	B-C1367886
determination	I-C1367886
,	O
the	O
incubation	B-C0014406
environment	I-C0014406
plays	O
a	O
key	O
role	O
in	O
determining	O
offspring	B-C0680063
sex	B-C0036893
ratios	I-C0036893
.	O
	
given	O
that	O
global	B-C2348867
temperatures	B-C0039476
have	O
warmed	B-C0687712
approximately	O
0.6	O
c	O
in	O
the	O
last	O
century	O
,	O
it	O
is	O
necessary	O
to	O
consider	O
how	O
organisms	B-C0029235
will	O
adjust	B-C2364069
to	O
climate	B-C2718051
change	I-C2718051
.	O
	
to	O
better	O
understand	O
the	O
degree	B-C0441889
to	O
which	O
mothers	B-C0026591
influence	B-C4054723
the	O
sex	B-C0036893
ratios	I-C0036893
of	O
their	O
offspring	B-C0680063
,	O
we	O
use	O
24	O
years	B-C0439234
of	O
nesting	B-C1511726
data	I-C1511726
for	O
individual	B-C0237401
female	B-C0086287
loggerhead	B-C0999068
sea	I-C0999068
turtles	I-C0999068
caretta	B-C0999068
caretta	I-C0999068
observed	O
on	O
bald	B-C0022130
head	I-C0022130
island	I-C0022130
,	O
north	B-C0028407
carolina	I-C0028407
.	O
	
we	O
find	O
that	O
maternal	B-C1858460
identity	B-C3826248
is	O
the	O
best	O
predictor	O
of	O
nest	B-C1254362
sex	B-C0036893
ratio	I-C0036893
in	O
univariate	B-C0683962
and	O
multivariate	B-C0242481
predictive	I-C0242481
models	I-C0242481
.	O
	
we	O
find	O
significant	O
variability	B-C2827666
in	O
estimated	O
nest	B-C1254362
sex	B-C0036893
ratios	I-C0036893
among	O
mothers	B-C0026591
,	O
but	O
a	O
high	O
degree	O
of	O
consistency	B-C0332529
within	O
mothers	B-C0026591
,	O
despite	O
substantial	O
spatial	B-C1254362
and	O
temporal	B-C0040223
thermal	B-C2584332
variation	I-C2584332
.	O
	
our	O
results	O
suggest	O
that	O
individual	B-C0237401
differences	O
in	O
nesting	B-C0027776
preferences	I-C0027776
are	O
the	O
main	O
driver	O
behind	O
divergences	B-C0443204
in	O
nest	B-C1254362
sex	B-C0036893
ratios	I-C0036893
.	O
	
as	O
such	O
,	O
a	O
female's	B-C0086287
ability	O
to	O
plastically	O
adjust	O
her	O
nest	B-C1254362
sex	B-C0036893
ratios	I-C0036893
in	O
response	O
to	O
environmental	B-C0014406
conditions	B-C0348080
is	O
constrained	B-C1707494
,	O
potentially	O
limiting	O
how	O
individuals	B-C0237401
behaviorally	O
mitigate	B-C1553901
the	O
effects	O
of	O
environmental	B-C4060636
change	I-C4060636
.	O
	
given	O
that	O
many	O
loggerhead	B-C0999068
populations	B-C1257890
already	O
show	O
female-biased	B-C0242568
offspring	B-C0680063
sex	B-C0036893
ratios	I-C0036893
,	O
understanding	O
maternal	B-C0024919
behavioral	I-C0024919
responses	O
is	O
critical	B-C1511545
for	O
predicting	O
the	O
future	O
of	O
long-lived	O
species	B-C1705920
vulnerable	B-C0231204
to	O
increased	O
rhoa	B-C0643681
activity	B-C1537044
predicts	O
worse	B-C1457868
overall	B-C4086681
survival	I-C4086681
in	O
patients	B-C0030705
undergoing	O
surgical	B-C0015252
resection	I-C0015252
for	O
lauren	B-C3829311
diffuse-type	B-C0279635
gastric	I-C0279635
adenocarcinoma	I-C0279635
several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
rhoa	B-C0812234
mutations	B-C0596611
in	O
the	O
lauren	B-C3829311
diffuse-type	B-C0279635
gastric	I-C0279635
adenocarcinoma	I-C0279635
ga	B-C0278701
but	O
not	O
in	O
intestinal-type	B-C0279633
ga	I-C0279633
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
rhoa	B-C0643681
activity	B-C1537044
is	O
prognostic	B-C1514474
for	O
overall	B-C4086681
survival	I-C4086681
os	B-C4086681
in	O
patients	B-C0030705
with	O
resectable	O
ga	B-C0278701
.	O
	
retrospective	B-C0035363
review	I-C0035363
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
ga	B-C0278701
patients	B-C0030705
who	O
underwent	O
potentially	O
curative	B-C1511562
resection	I-C1511562
between	O
2003	O
and	O
2012	O
at	O
a	O
single	B-C2607850
institution	I-C2607850
.	O
	
tissue	B-C0040300
microarrays	B-C1709016
were	O
constructed	O
from	O
surgical	B-C1254419
specimens	I-C1254419
and	O
analyzed	O
for	O
phosphorylated	B-C1519061
rhoa	B-C0643681
,	O
a	O
marker	B-C0005516
of	O
inactive	O
rhoa	B-C0643681
signaling	B-C2611812
.	O
	
os	B-C4086681
was	O
estimated	O
by	O
the	O
kaplan-meier	B-C2827659
method	I-C2827659
,	O
and	O
multivariate	B-C0026777
analysis	I-C0026777
was	O
performed	O
by	O
cox	B-C0010235
proportional	I-C0010235
hazards	I-C0010235
regression	I-C0010235
modeling	I-C0010235
.	O
	
one	O
hundred	O
thirty-six	O
patients	B-C0030705
with	O
diffuse-type	B-C0279635
ga	I-C0279635
and	O
129	O
patients	B-C0030705
with	O
intestinal-type	B-C0279633
ga	I-C0279633
were	O
examined	O
.	O
	
compared	O
to	O
intestinal-type	B-C0279633
ga	I-C0279633
,	O
diffuse-type	B-C0279635
ga	I-C0279635
tumors	B-C0027651
were	O
significantly	O
associated	B-C0332281
with	I-C0332281
increased	O
tumor	B-C0475440
size	I-C0475440
and	O
advanced	B-C1515169
tumor	I-C1515169
,	O
node	I-C1515169
,	O
metastasis	I-C1515169
tnm	I-C1515169
classification	I-C1515169
system	I-C1515169
stage	I-C1515169
.	O
	
in	O
patients	B-C0030705
with	O
diffuse-type	B-C0279635
ga	I-C0279635
,	O
high	O
rhoa	B-C0643681
activity	B-C1537044
was	O
associated	B-C0332281
with	I-C0332281
significantly	O
worse	B-C1457868
os	B-C4086681
when	O
compared	O
to	O
low	O
rhoa	B-C0643681
activity	B-C1537044
5-year	O
os	B-C4086681
52.5	O
vs	O
.	O
	
81.0	O
%	O
,	O
p	O
=	O
0.017	O
.	O
	
this	O
difference	O
in	O
os	B-C4086681
was	O
not	O
observed	O
in	O
patients	B-C0030705
with	O
intestinal-type	B-C0279633
ga	I-C0279633
5-year	O
os	B-C4086681
83.9	O
vs	O
.	O
	
81.6	O
%	O
,	O
p	O
=	O
0.766	O
.	O
	
on	O
multivariate	B-C0026777
analysis	I-C0026777
of	O
diffuse-type	B-C0279635
ga	I-C0279635
patients	B-C0030705
,	O
high	O
rhoa	B-C0643681
activity	B-C1537044
was	O
an	O
independent	O
negative	O
prognostic	B-C1514474
factor	I-C1514474
for	O
os	B-C4086681
hazard	B-C2985465
ratio	I-C2985465
2.38	O
,	O
95	O
%	O
confidence	B-C0009667
interval	I-C0009667
1.07	O
.	O
	
increased	O
rhoa	B-C0643681
activity	B-C1537044
is	O
predictive	O
of	O
worse	B-C1457868
os	B-C4086681
in	O
patients	B-C0030705
with	O
diffuse-type	B-C0279635
ga	I-C0279635
who	O
undergo	O
potentially	O
curative	B-C1511562
surgical	I-C1511562
resection	I-C1511562
.	O
	
along	O
with	O
findings	O
from	O
genomic	B-C0887950
studies	I-C0887950
,	O
these	O
results	O
suggest	O
rhoa	B-C0643681
may	O
be	O
a	O
novel	O
therapeutic	B-C0087111
target	B-C1521840
in	O
diffuse-type	B-C0279635
ga	I-C0279635
.	O
	
doxifluridine	B-C0048808
-	O
conjugated	B-C0522529
2-5a	B-C0045143
analog	B-C0243071
shows	O
strong	B-C0442821
rnase	B-C0071795
l	I-C0071795
activation	B-C0599177
ability	B-C2698977
and	O
tumor	B-C1519692
suppressive	I-C1519692
effect	B-C1280500
rnase	B-C0071795
l	I-C0071795
is	O
activated	B-C0599177
by	O
2'	B-C0045143
2-5a	B-C0045143
at	O
subnanomolar	B-C0392762
levels	B-C0441889
to	O
cleave	B-C0205242
single-stranded	B-C3272452
rna	I-C3272452
.	O
	
we	O
previously	O
reported	B-C0684224
the	O
hypothesis	B-C1512571
that	O
the	O
introduction	B-C0579004
of	O
an	O
8-methyladenosine	B-C0100309
residue	O
at	O
the	O
2'-	O
terminus	B-C1705315
of	O
the	O
2-5a	B-C0092311
tetramer	I-C0092311
shifts	B-C0333051
the	O
2-5a	B-C0045143
binding	B-C0005456
site	I-C0005456
of	O
rnase	B-C0071795
l	I-C0071795
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
synthesized	B-C1883254
various	O
5'-	O
modified	B-C0392747
2-5a	B-C0045143
analog	B-C0243071
s	O
with	O
8-methyladenosine	B-C0100309
at	O
the	O
2'-	O
terminus	B-C1705315
.	O
	
the	O
doxifluridine	B-C0048808
-	O
conjugated	B-C0522529
8-methyladenosine	B-C0100309
-	O
substituted	B-C1706204
2-5a	B-C0045143
analog	B-C0243071
was	O
significantly	B-C4055637
more	I-C4055637
effective	B-C1704419
as	O
an	O
activator	B-C1879547
of	O
rnase	B-C0071795
l	I-C0071795
than	O
the	O
parent	B-C2699423
5'-	O
monophophorylated	B-C1327237
2-5a	B-C0092311
tetramer	I-C0092311
and	O
showed	O
a	O
tumor	B-C1519692
suppressive	I-C1519692
effect	B-C1280500
against	B-C0521124
human	B-C0086418
cervical	B-C4048328
cancer	I-C4048328
cells	B-C0007634
.	O
	
does	O
video	B-C2363575
laryngoscopy	I-C2363575
offer	O
advantages	B-C0205556
over	O
direct	B-C0392823
laryngoscopy	I-C0392823
during	B-C0347984
cardiopulmonary	B-C0007203
resuscitation	I-C0007203
interruption	B-C1512900
of	O
chest	B-C4032596
compressions	I-C4032596
should	O
be	O
minimized	B-C0392756
because	O
of	O
its	O
negative	B-C0205160
effects	B-C1280500
on	O
survival	B-C0038954
.	O
	
this	O
randomized	B-C0034656
,	O
controlled	B-C2587213
,	O
cross-over	B-C0150097
study	I-C0150097
aimed	B-C1947946
to	O
analyze	B-C0936012
the	O
effectiveness	B-C1280519
of	O
macintosh	B-C1531939
,	O
miller	B-C1532566
,	O
mccoy	B-C0563580
and	O
mcgrath	B-C0180453
laryngoscopes	I-C0180453
during	B-C0347984
with	O
or	O
without	O
chest	B-C4032596
compressions	I-C4032596
in	O
the	O
scope	B-C1710028
of	O
a	O
simulated	O
cardiopulmonary	B-C0007203
resuscitation	I-C0007203
scenario	B-C0683579
.	O
	
the	O
time	B-C0040223
required	B-C1514873
for	O
successful	B-C1272703
tracheal	B-C0021932
intubation	I-C0021932
,	O
number	B-C3163850
of	I-C3163850
attempts	I-C3163850
,	O
dental	B-C1301685
trauma	I-C1301685
severity	B-C0439793
and	O
the	O
need	B-C0027552
for	O
optimization	B-C2698650
manoeuvres	B-C0441655
were	O
recorded	B-C0243095
during	B-C0347984
cardiopulmonary	B-C0007203
resuscitation	I-C0007203
with	O
and	O
without	O
chest	B-C4032596
compressions	I-C4032596
.	O
	
the	O
experience	B-C0596545
with	O
computer	B-C0870328
games	I-C0870328
during	B-C0347984
the	O
last	O
10	O
years	B-C0439234
were	O
asked	O
to	O
the	O
participants	B-C0679646
and	O
recorded	B-C0243095
.	O
	
mccoy	B-C0563580
laryngoscope	I-C0563580
yielded	O
the	O
shortest	B-C0040223
time	I-C0040223
for	O
successful	B-C1272703
tracheal	B-C0021932
intubation	I-C0021932
both	O
in	O
the	O
presence	B-C0150312
of	O
and	O
without	O
chest	B-C4032596
compressions	I-C4032596
.	O
	
during	B-C0347984
the	O
use	B-C0042153
of	O
mccoy	B-C0563580
laryngoscopes	I-C0563580
,	O
fewer	B-C0205388
tracheal	B-C0021932
intubation	I-C0021932
attempts	B-C1516084
,	O
lower	B-C0021149
incidence	I-C0021149
of	O
dental	B-C1301685
trauma	I-C1301685
and	O
lower	B-C2003888
visual	B-C2960751
analogue	I-C2960751
scale	I-C2960751
scores	I-C2960751
on	O
the	O
ease	O
of	O
intubation	B-C0021925
were	O
recorded	B-C0243095
.	O
	
participants	B-C0679646
who	O
are	O
experienced	B-C0596545
computer	B-C0870328
game	I-C0870328
players	B-C1257890
using	O
macintosh	B-C1531939
,	O
mccoy	B-C0563580
and	O
mcgrath	B-C0180453
achieved	B-C0432600
successful	B-C1272703
tracheal	B-C0021932
intubation	I-C0021932
in	O
a	O
significantly	B-C0750502
shorter	B-C0040223
time	I-C0040223
during	B-C0347984
resuscitation	B-C0035273
without	O
chest	B-C4032596
compressions	I-C4032596
.	O
	
dental	B-C1301685
trauma	I-C1301685
incidence	B-C0021149
and	O
number	B-C0237753
of	O
tracheal	B-C0021932
intubation	I-C0021932
attempts	B-C1516084
did	O
not	O
show	O
any	O
significant	B-C0750502
difference	B-C1705242
between	O
the	O
four	B-C0205450
laryngoscopes	B-C0180453
being	O
related	O
to	O
the	O
rate	B-C1521828
of	O
playing	B-C0441655
computer	B-C0870328
games	I-C0870328
.	O
	
mcgrath	B-C2363575
video	I-C2363575
laryngoscopes	I-C2363575
do	O
not	O
appear	O
to	O
have	O
advantages	B-C0205556
over	O
direct	B-C0392823
laryngoscopes	I-C0392823
for	O
securing	O
a	O
smooth	B-C0205556
and	O
successful	B-C1272703
tracheal	B-C0021932
intubation	I-C0021932
during	B-C0347984
rhythmic	B-C4032596
chest	I-C4032596
compressions	I-C4032596
.	O
	
we	O
believe	O
that	O
as	O
mccoy	B-C0563580
laryngoscope	I-C0563580
provided	B-C1999230
tracheal	B-C0021932
intubation	I-C0021932
in	O
a	O
shorter	B-C0040223
time	I-C0040223
and	O
with	O
fewer	B-C0205388
attempts	B-C1516084
,	O
this	O
laryngoscope	B-C0180453
may	O
increase	B-C0442805
the	O
success	B-C1521828
rate	I-C1521828
of	O
the	O
nurse-patient	B-C0870983
communication	I-C0870983
voices	O
from	O
nursing	B-C0038496
students	I-C0038496
effective	B-C0870313
communication	I-C0870313
skills	I-C0870313
have	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
pivotal	B-C1521761
factors	I-C1521761
in	O
building	O
positive	B-C0021797
interpersonal	I-C0021797
relationships	I-C0021797
.	O
	
little	O
is	O
known	O
about	O
nursing	B-C0038496
undergraduates	I-C0038496
'	O
perspectives	B-C0678958
on	O
communicating	B-C0205196
with	O
patients	B-C0030705
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
explore	O
nursing	B-C0038496
students'	I-C0038496
perspectives	B-C0678958
and	O
experiences	B-C0596545
of	O
nurse-patient	B-C0870983
communication	I-C0870983
in	O
their	O
clinical	B-C0205210
placement	B-C1524072
.	O
	
the	O
participants	B-C0679646
included	O
21	O
second-year	B-C0682177
undergraduates	I-C0682177
and	O
21	O
first-year	B-C0682177
master's	I-C0682177
students	I-C0682177
.	O
	
interviews	B-C0021822
were	O
conducted	O
in	O
cantonese	B-C0023008
and	O
then	O
transcribed	O
in	O
chinese	B-C0008120
and	O
translated	O
into	O
english	B-C0376245
.	O
	
a	O
content	B-C0681915
analysis	I-C0681915
approach	B-C0449445
was	O
adopted	O
to	O
analyze	O
the	O
data	B-C1511726
.	O
	
five	O
themes	B-C0869035
emerged	O
from	O
the	O
interview	B-C1511726
data	I-C1511726
.	O
	
'the	O
necessity	O
of	O
nurse-patient	B-C0870983
communication	I-C0870983
'	O
reveals	B-C0443289
why	O
the	O
students	B-C0038492
valued	O
nurse-patient	B-C0870983
communication	I-C0870983
.	O
	
'the	O
conversation	B-C0582166
contents	I-C0582166
'	O
describes	O
the	O
content	B-C0582166
of	I-C0582166
the	I-C0582166
conversations	I-C0582166
that	O
students	B-C0038492
typically	O
had	O
with	O
patients	B-C0030705
.	O
	
the	O
third	O
theme	B-C0869035
is	O
'	O
self-reflection	B-C0243095
on	O
the	O
nurse-patient	B-C0870983
communication	I-C0870983
'	O
.	O
	
the	O
last	O
two	O
themes	B-C0869035
,	O
'the	O
communication	B-C4061885
pattern	I-C4061885
in	I-C4061885
different	I-C4061885
hospital	B-C0019994
settings	I-C0019994
'	O
and	O
'the	O
obstacles	O
impeding	O
nurse-patient	B-C0870983
communication	I-C0870983
'	O
,	O
are	O
about	O
the	O
students'	B-C0038492
communication	B-C0205556
styles	I-C0205556
in	O
different	O
hospitals	B-C0019994
and	O
the	O
barriers	O
they	O
encounter	B-C1947978
.	O
	
to	O
improve	B-C0184511
students'	B-C0038492
communication	B-C0870313
skills	I-C0870313
,	O
educators	B-C0259853
and	O
clinical	B-C0851286
staff	I-C0851286
should	O
listen	O
to	O
students	B-C0038492
,	O
enhance	B-C2349975
students'	B-C0038492
reflective	B-C0678856
skills	I-C0678856
and	O
strengthen	O
their	O
confidence	B-C1704726
.	O
	
through	O
understanding	B-C0162340
students'	B-C0038492
difficulties	B-C0332218
in	O
the	O
nurse-patient	B-C0870983
communication	I-C0870983
experience	B-C0596545
and	O
the	O
skills	B-C0678856
that	O
they	O
lack	O
,	O
educators	B-C0259853
can	O
provide	O
them	O
with	O
helpful	O
recommendations	B-C0034866
to	O
improve	B-C0184511
their	O
communication	B-C0870313
skills	I-C0870313
in	O
clinical	B-C0205897
practice	I-C0205897
.	O
	
the	O
results	O
of	O
this	O
study	B-C2603343
reveal	B-C0443289
that	O
students'	B-C0038492
nurse-patient	B-C0870983
communication	I-C0870983
skills	B-C0870313
need	O
to	O
be	O
early	O
hippocampal	B-C0019564
volume	B-C0243095
loss	I-C0243095
as	O
a	O
marker	B-C0005516
of	O
eventual	O
memory	B-C0233794
deficits	I-C0233794
caused	O
by	O
repeated	B-C0038435
stress	I-C0038435
exposure	B-C0332157
to	I-C0332157
severe	B-C0205082
and	O
prolonged	B-C0439590
stress	B-C0038435
has	O
detrimental	B-C0243095
effects	I-C0243095
on	O
the	O
hippocampus	B-C0019564
.	O
	
however	O
,	O
relatively	B-C0205345
little	B-C0700321
is	O
known	B-C0205309
about	O
the	O
gradual	B-C0439833
changes	B-C0392747
in	O
hippocampal	B-C0019564
structure	I-C0019564
,	O
and	O
its	O
behavioral	B-C0004927
consequences	B-C0686907
,	O
over	O
the	O
course	O
of	O
repeated	B-C0038435
stress	I-C0038435
.	O
	
behavioral	B-C1160858
analyses	I-C1160858
during	O
10	O
days	O
of	O
chronic	B-C1510527
stress	I-C1510527
pointed	O
to	O
a	O
delayed	O
decline	B-C0547047
in	O
spatial	B-C0814087
memory	I-C0814087
,	O
the	O
full	O
impact	B-C4049986
of	O
which	O
is	O
evident	O
only	O
after	O
the	O
end	O
of	O
stress	B-C0038435
.	O
	
in	O
contrast	O
,	O
concurrent	B-C0205420
volumetric	B-C0079809
measurements	I-C0079809
in	O
the	O
same	O
animals	B-C0003062
revealed	O
significant	O
reduction	B-C0392756
in	O
hippocampal	B-C0019564
volumes	B-C0392762
in	O
stressed	B-C0038435
animals	B-C0003062
relative	O
to	O
their	O
unstressed	B-C0231300
counterparts	I-C0231300
,	O
as	O
early	O
as	O
the	O
third	O
day	O
of	O
stress	B-C0038435
.	O
	
notably	O
,	O
animals	B-C0003062
that	O
were	O
behaviorally	B-C0004927
the	O
worst	B-C1522166
affected	B-C1292725
at	O
the	O
end	O
of	O
chronic	B-C1510527
stress	I-C1510527
suffered	B-C0683278
the	O
most	O
pronounced	O
early	B-C0243095
loss	I-C0243095
in	I-C0243095
hippocampal	I-C0243095
volume	I-C0243095
.	O
	
together	O
,	O
these	O
findings	O
support	O
the	O
view	O
that	O
not	O
only	O
is	O
smaller	O
hippocampal	B-C0019564
volume	B-C0392762
linked	O
to	O
stress	B-C0038435
-	O
induced	B-C0205263
memory	B-C0233794
deficits	I-C0233794
,	O
but	O
it	O
may	O
also	O
act	O
as	O
an	O
early	O
risk	B-C0035648
factor	I-C0035648
for	O
the	O
eventual	O
development	O
of	O
cognitive	B-C0338656
impairments	I-C0338656
seen	O
in	O
stress-related	B-C0599909
psychiatric	I-C0599909
disorders	I-C0599909
.	O
	
the	O
association	B-C0439849
between	O
c9orf72	B-C1428691
repeats	B-C0004793
and	O
risk	B-C0035647
of	O
alzheimer's	B-C0002395
disease	I-C0002395
and	O
amyotrophic	B-C0002736
lateral	I-C0002736
sclerosis	I-C0002736
a	O
meta-analysis	B-C0920317
c9orf72	B-C1428691
is	O
the	O
most	O
common	O
genetic	B-C0314603
cause	B-C0015127
of	O
amyotrophic	B-C0002736
lateral	I-C0002736
sclerosis	I-C0002736
als	B-C0002736
and	O
frontotemporal	B-C0338451
dementia	I-C0338451
ftd	B-C0338451
in	O
caucasian	B-C0043157
populations	I-C0043157
.	O
	
however	O
,	O
the	O
relationship	B-C0439849
between	O
c9orf72	B-C1428691
repeats	B-C0004793
and	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
was	O
not	B-C3845108
clear	I-C3845108
.	O
	
additionally	O
,	O
there	O
were	O
few	O
articles	B-C0282420
assessing	B-C1516048
c9orf72	B-C1428691
in	O
other	O
ethnicities	B-C0243103
with	O
als	B-C0002736
.	O
	
in	O
this	O
meta-analysis	B-C0920317
,	O
we	O
aimed	O
to	O
investigate	B-C1292732
the	O
relationship	B-C0439849
between	O
c9orf72	B-C1428691
repeat	B-C1257790
expansions	I-C1257790
30	O
repeats	B-C0004793
and	O
intermediate	B-C0205103
repeat	B-C0004793
copies	I-C0004793
20-29	O
repeats	B-C0004793
and	O
ad	B-C0002395
or	O
als	B-C0002736
.	O
	
the	O
results	B-C1274040
suggested	O
positive	B-C1446409
correlations	B-C1707520
between	O
c9orf72	B-C1428691
repeat	B-C1257790
expansions	I-C1257790
and	O
the	O
risk	B-C0035647
of	O
alzheimer's	B-C0002395
disease	I-C0002395
or	B-C0028873
=	O
6.36	O
,	O
95%	O
ci	B-C0009667
=	O
3.13	O
,	O
and	O
p	B-C1709380
<	O
0.00001	O
,	O
while	O
intermediate	B-C0205103
repeat	B-C0004793
copies	I-C0004793
of	O
c9orf72	B-C1428691
gene	I-C1428691
were	O
not	O
associated	B-C0332281
with	I-C0332281
the	O
risk	B-C0035647
of	O
the	O
disease	B-C0012634
.	O
	
c9orf72	B-C1428691
repeat	B-C1257790
expansions	I-C1257790
were	O
positively	B-C1446409
correlated	B-C1707520
with	O
the	O
risk	B-C0035647
of	O
familial	B-C1862939
and	O
sporadic	B-C1862941
als	I-C1862941
or	B-C0028873
=	O
293.25	O
,	O
95%	O
ci	B-C0009667
=	O
148.17	O
,	O
and	O
p	B-C1709380
<	O
0.00001	O
or	B-C0028873
=	O
35.57	O
,	O
95%	O
ci	B-C0009667
=	O
19.61	O
,	O
and	O
p	B-C1709380
<	O
0.00001	O
.	O
	
there	O
was	O
a	O
positive	B-C1446409
correlation	B-C1707520
between	O
the	O
gene	B-C0042333
variations	I-C0042333
and	O
als	B-C0002736
risk	B-C0035647
among	O
caucasians	B-C0043157
and	O
asians	B-C0078988
or	B-C0028873
=	O
57.56	O
,	O
95%	O
ci	B-C0009667
=	O
36.73	O
,	O
and	O
p	B-C1709380
<	O
0.00001	O
or	B-C0028873
=	O
6.35	O
,	O
95%	O
ci	B-C0009667
=	O
1.39	O
,	O
and	O
p	B-C1709380
demonstration	O
and	O
validation	B-C1519941
of	O
a	O
new	O
pressure	B-C0033095
-based	O
mri	B-C0336660
-safe	O
pain	B-C0162703
tolerance	I-C0162703
device	B-C0025080
one	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	B-C0004927
and	O
emotional	B-C0013987
effects	B-C1280500
of	O
pain	B-C0030193
using	O
functional	B-C0376335
magnetic	I-C0376335
resonance	I-C0376335
imaging	I-C0376335
fmri	B-C0376335
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
mri	B-C0336660
-	O
compatible	B-C1524057
,	O
pressure	B-C0033095
-based	O
algometer	B-C0025080
to	O
elicit	B-C0449265
pain	B-C0030193
.	O
	
the	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
mri	B-C0336660
-safe	O
apparatus	B-C0025080
capable	O
of	O
delivering	O
incremental	B-C1705117
,	O
measurable	B-C1513040
amounts	O
of	O
pressure	B-C0033095
inside	O
a	O
scanning	B-C0183115
bore	I-C0183115
.	O
	
we	O
introduced	O
an	O
mr-safe	O
device	B-C0025080
used	O
to	O
administer	O
pressure	B-C0033095
-based	O
pain	B-C0030193
.	O
	
to	O
test	B-C0022885
against	O
a	O
commercially	O
available	O
,	O
mri	B-C0336660
-	O
incompatible	B-C1524057
algometer	B-C0025080
algomed	B-C0025080
,	O
199	O
participants	O
reported	O
their	O
pain	B-C0162703
tolerance	I-C0162703
for	O
both	O
devices	O
.	O
	
a	O
second	O
experiment	O
tested	B-C0022885
the	O
validity	O
of	O
pressure	B-C0033095
-based	O
pain	B-C0030193
in	O
an	O
mri	B-C0336660
environment	B-C0014406
by	O
comparing	O
brain	B-C0006104
activation	B-C1879547
with	O
established	O
neural	B-C0242406
networks	I-C0242406
for	O
pain	B-C0030193
.	O
	
10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-C0022885
for	O
pain	B-C0030193
tolerance	O
while	O
being	O
scanned	B-C0441633
in	O
a	O
7t	O
mri	B-C0336660
scanner	I-C0336660
.	O
	
results	O
support	O
the	O
validity	B-C0035036
and	I-C0035036
reliability	I-C0035036
of	O
our	O
novel	O
device	B-C0025080
.	O
	
in	O
study	O
1	O
,	O
pain	B-C0162703
tolerance	I-C0162703
with	O
this	O
device	B-C0025080
was	O
strongly	O
correlated	O
with	O
pain	B-C0162703
tolerance	I-C0162703
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	B-C0025080
r=0	O
.	O
	
in	O
study	O
2	O
,	O
this	O
device	B-C0025080
yielded	O
bold	B-C1655730
activation	O
within	O
the	O
insula	B-C0021640
ba	B-C2326439
13	I-C2326439
and	O
anterior	B-C0175190
cingulate	I-C0175190
gyrus	I-C0175190
ba	B-C2334367
24	I-C2334367
as	O
pressure	B-C0033095
increased	B-C0205217
,	O
activation	O
in	O
these	O
areas	O
parametrically	B-C0681933
increased	B-C0205217
.	O
	
these	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	B-C2032530
,	O
electrical	B-C2032523
,	O
or	O
mechanical	B-C0699886
pain	B-C0521491
applications	I-C0521491
.	O
	
behavioral	B-C0004927
and	O
functional	B-C0205245
data	B-C1511726
demonstrate	O
that	O
this	O
new	O
device	B-C0025080
is	O
a	O
valid	O
method	O
of	O
administering	B-C1533734
pressure	B-C0033095
-related	O
pain	B-C0030193
in	O
mri	B-C0336660
environments	B-C0014406
.	O
	
our	O
novel	O
mri	B-C0336660
-safe	O
device	B-C0025080
is	O
a	O
valid	O
instrument	B-C0348000
to	O
measure	B-C0242485
and	O
administer	B-C1621583
pressure	B-C0033095
-based	O
anti-inflammatory	B-C1515999
properties	I-C1515999
of	O
menthol	B-C0025368
and	O
menthone	B-C0065950
in	O
schistosoma	B-C0036330
mansoni	I-C0036330
infection	I-C0036330
schistosomiasis	B-C0036323
is	O
a	O
parasitic	B-C0030499
disease	I-C0030499
caused	O
by	O
several	O
species	B-C1705920
of	O
trematode	B-C3662558
worms	I-C3662558
and	O
it	O
is	O
believed	O
that	O
more	O
than	O
261	O
million	O
people	B-C0027361
are	O
affected	B-C0392760
worldwide	O
.	O
	
new	O
drug	B-C0872152
development	I-C0872152
has	O
become	O
essential	B-C0205224
because	O
there	O
is	O
a	O
risk	O
of	O
the	O
parasite	B-C0030498
becoming	O
resistant	B-C1514892
to	O
praziquantel	B-C0032911
,	O
the	O
only	O
drug	B-C0013227
available	O
for	O
this	O
infection	B-C3714514
.	O
	
this	O
study	B-C2603343
evaluated	B-C0220825
parasitological	B-C0205468
,	O
immunological	B-C0205470
and	O
histological	B-C0205462
parameters	B-C0449381
in	O
mice	B-C0025929
infected	B-C0439663
with	O
schistosoma	B-C0036319
mansoni	I-C0036319
and	O
treated	B-C0332293
with	I-C0332293
an	O
herbal	B-C2240391
commercial	I-C2240391
medicine	I-C2240391
.	O
	
this	O
drug	B-C0013227
consists	O
of	O
menthol	B-C0025368
30-55%	O
and	O
menthone	B-C0065950
14-32%	O
.	O
	
a	O
60	O
day	O
treatment	B-C0040808
regimen	I-C0040808
with	O
the	O
herbal	B-C2240391
medicine	I-C2240391
decreased	B-C0205216
the	O
number	O
of	O
s	B-C0036319
.	O
	
mansoni	I-C0036319
eggs	B-C0686887
in	O
the	O
feces	B-C0015733
,	O
liver	B-C0023884
,	O
and	O
intestine	B-C0021853
and	O
reduced	B-C0392756
the	O
number	O
of	O
hepatic	B-C0745754
granulomas	I-C0745754
.	O
	
we	O
observed	B-C1441672
a	O
reduction	B-C0441610
of	O
84%	O
in	O
blood	B-C0014457
eosinophilia	I-C0014457
and	O
a	O
decrease	B-C0205216
in	O
the	O
il-4	B-C0021758
and	O
il-10	B-C0085295
blood	B-C0005768
levels	I-C0005768
after	O
treatment	B-C0087111
.	O
	
therefore	O
,	O
we	O
propose	O
that	O
schistosomiasis	B-C0036323
treatment	B-C0087111
with	O
this	O
herbal	B-C2240391
medicine	I-C2240391
for	O
60	O
days	O
has	O
an	O
immunomodulatory	B-C0205556
and	O
anti-inflammatory	B-C1515999
action	I-C1515999
in	O
this	O
animal	B-C0599779
model	I-C0599779
for	O
schistosomiasis	B-C0036323
thus	O
contributing	B-C1880177
to	O
the	O
decrease	B-C0205216
in	O
physio	O
pathological	B-C1521733
effects	B-C1280500
caused	O
by	O
s	B-C0036330
.	O
	
mansoni	I-C0036330
infection	I-C0036330
.	O
	
catastrophic	B-C0007397
health	B-C0015318
expenditure	I-C0015318
a	O
comparative	B-C0683941
analysis	I-C0683941
of	O
empty-nest	B-C0870492
and	O
non-empty-nest	B-C1254370
households	B-C0020052
with	O
seniors	B-C0001792
in	O
shandong	B-C0008115
,	O
china	I-C0008115
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
compare	B-C1707455
the	O
catastrophic	B-C0007397
health	B-C0015318
expenditure	I-C0015318
che	B-C0015318
prevalence	B-C0683919
and	O
its	O
determinants	B-C1521761
between	O
empty-nest	B-C0870492
and	O
non-empty-nest	B-C1254370
elderly	B-C0001792
households	B-C0020052
.	O
	
shandong	B-C0008115
province	I-C0008115
of	I-C0008115
china	I-C0008115
.	O
	
a	O
total	B-C0439810
of	O
2761	O
elderly	B-C0001792
households	B-C0020052
are	O
included	B-C0332257
in	O
the	O
analysis	B-C0936012
.	O
	
che	B-C0015318
incidence	B-C0021149
among	O
elderly	B-C0001792
households	B-C0020052
was	O
44.9	O
.	O
	
the	O
che	B-C0015318
incidence	B-C0021149
of	O
empty-nest	B-C0870492
singles	B-C1549113
59.3	O
,	O
p=0	O
,	O
or=3	O
and	O
empty-nest	B-C0870492
couples	B-C0010222
52.9	O
,	O
p=0	O
,	O
or=2	O
are	O
both	O
statistically	B-C0871425
higher	B-C0205250
than	O
that	O
of	O
non-empty-nest	B-C1254370
elderly	B-C0001792
households	B-C0020052
31.4	O
.	O
	
an	O
inverse	B-C1708567
association	I-C1708567
was	O
observed	B-C1441672
between	O
che	B-C0015318
incidence	B-C0021149
and	O
income	B-C0870689
level	I-C0870689
in	O
all	O
elderly	B-C0001792
household	B-C0020052
types	B-C0332307
.	O
	
factors	B-C1521761
including	B-C0332257
1	O
or	O
more	O
household	B-C0020052
elderly	B-C0001792
members	I-C0001792
with	O
non-communicable	B-C0008679
chronic	I-C0008679
diseases	I-C0008679
in	O
the	O
past	O
6	O
months	O
,	O
1	O
or	O
more	O
elderly	B-C0001792
household	B-C0015578
members	I-C0015578
being	O
hospitalised	B-C0701159
in	O
the	O
past	B-C4086728
year	I-C4086728
and	O
lower	B-C2003888
household	B-C0020052
income	B-C0021162
,	O
are	O
significant	B-C0750502
risk	B-C0035648
factors	I-C0035648
for	O
che	B-C0015318
in	O
all	O
3	O
household	B-C0020052
types	B-C0332307
p<0	O
.	O
	
health	B-C0021682
insurance	I-C0021682
status	B-C0449438
was	O
found	O
to	O
be	O
a	O
significant	B-C0750502
determinant	B-C1521761
of	O
che	B-C0015318
among	O
empty-nest	B-C0870492
singles	B-C1549113
and	O
non-empty-nest	B-C1254370
households	B-C0020052
p<0	O
.	O
	
che	B-C0015318
incidence	B-C0021149
among	O
elderly	B-C0001792
households	B-C0020052
is	O
high	B-C0205250
in	O
china	B-C0008115
.	O
	
empty-nest	B-C0870492
households	B-C0020052
are	O
at	O
higher	B-C0205250
risk	B-C0035647
for	O
che	B-C0015318
than	O
non-empty-nest	B-C1254370
households	B-C0020052
.	O
	
based	O
on	O
these	O
findings	B-C0243095
,	O
we	O
suggest	B-C1705535
that	O
special	B-C0205555
insurance	B-C0021682
be	O
developed	O
to	O
broaden	B-C0332464
the	O
coverage	B-C1551362
of	O
health	B-C0018747
services	I-C0018747
and	O
heighten	B-C0442803
the	O
reimbursement	B-C0554896
rate	I-C0554896
for	O
empty-nest	B-C0870492
elderly	B-C0001792
in	O
the	O
existing	O
health	B-C0021682
insurance	I-C0021682
schemes	B-C1519193
.	O
	
financial	B-C2350008
and	O
social	B-C0242457
protection	I-C0242457
interventions	B-C0262765
are	O
also	O
essential	B-C0205224
for	O
identifie	B-C0205396
d	O
at-risk	B-C1444641
subgroups	B-C1515021
among	O
different	O
types	O
of	O
elderly	B-C0001792
households	B-C0020052
.	O
	
role	O
of	O
agonistic	B-C0004358
autoantibodies	I-C0004358
against	O
type-1	B-C0529330
angiotensin	I-C0529330
ii	I-C0529330
receptor	I-C0529330
in	O
the	O
pathogenesis	B-C0699748
of	O
retinopathy	B-C0035309
in	O
preeclampsia	B-C0032914
to	O
investigate	B-C1292732
the	O
mechanism	B-C0441712
underlying	O
at1-aa	B-C0021054
-induced	O
retinopathy	B-C0035309
in	O
severe	O
preeclampsia	B-C0032914
by	O
measuring	O
the	O
positive	B-C1521828
rate	I-C1521828
and	O
titer	B-C0475208
of	O
at1-aa	B-C0021054
in	O
plasma	B-C0032105
from	O
women	B-C0043210
with	O
severe	B-C0341950
preeclampsia	I-C0341950
and	O
normal	O
pregnant	B-C0033011
women	I-C0033011
to	O
see	O
whether	O
at1-aa	B-C0021054
titer	B-C0475208
was	O
correlated	B-C1707520
with	O
the	O
grade	O
of	O
retinopathy	B-C0035309
.	O
	
a	O
preeclampsia	B-C0032914
rat	B-C0034721
model	B-C0887965
was	O
also	O
established	O
by	O
intravenous	B-C0021494
injection	I-C0021494
of	O
at1-aa	B-C0021054
extracted	O
from	O
the	O
plasma	B-C0032105
of	O
patient	B-C0030705
suffering	O
from	O
severe	B-C0341950
preeclampsia	I-C0341950
.	O
	
the	O
results	O
showed	O
that	O
the	O
plasma	B-C0032105
titer	B-C0475208
and	O
positive	B-C1521828
rate	I-C1521828
of	O
at1-aa	B-C0021054
were	O
significantly	O
higher	O
in	O
women	B-C0043210
with	O
severe	B-C0341950
preeclampsia	I-C0341950
than	O
normal	O
pregnant	B-C0033011
women	I-C0033011
.	O
	
the	O
antibody	B-C0003241
titer	B-C0475208
in	O
cases	O
of	O
severe	O
preeclampsia	B-C0032914
was	O
associated	O
with	O
the	O
grade	O
of	O
retinopathy	B-C0035309
,	O
and	O
positively	O
correlated	B-C1707520
with	O
the	O
level	O
of	O
tnf-α	B-C1456820
and	O
vegf	B-C1256770
.	O
	
the	O
animal	B-C0205664
experiment	I-C0205664
results	B-C1274040
showed	O
that	O
the	O
modeled	B-C0034721
rats	I-C0034721
presented	O
symptoms	B-C1457887
very	O
similar	O
to	O
symptoms	B-C1457887
of	O
human	B-C0086418
preeclampsia	B-C0032914
,	O
including	O
retinopathy	B-C0035309
.	O
	
ocular	B-C4071854
fundus	I-C4071854
examination	B-C0582103
showed	O
retinal	B-C0035300
microvascular	I-C0035300
abnormalities	I-C0035300
,	O
hemorrhaging	B-C0019080
and	O
leakage	B-C4281748
in	O
the	O
severe	B-C0341950
preeclampsia	I-C0341950
.	O
	
morphological	B-C1254362
changes	I-C1254362
included	O
edema	B-C0013604
,	O
thickening	B-C0205400
of	O
the	O
inl	B-C1512784
and	O
onl	B-C0507777
,	O
and	O
pigment	B-C0243095
atrophy	I-C0243095
.	O
	
tnf-α	B-C1456820
and	O
vegf	B-C1256770
levels	O
were	O
increased	O
in	O
the	O
vitreous	B-C0229096
humor	I-C0229096
and	O
retina	B-C0035298
of	O
the	O
model	B-C0034721
rats	I-C0034721
.	O
	
our	O
studies	B-C2603343
results	B-C1274040
suggest	O
that	O
abnormal	B-C0017262
expression	I-C0017262
of	O
at1-aa	B-C0021054
could	O
induce	O
damage	B-C1883709
to	O
retinal	B-C0225336
capillary	I-C0225336
endothelial	I-C0225336
cells	I-C0225336
and	O
increase	O
vascular	B-C0162337
permeability	I-C0162337
,	O
resulting	B-C0332294
in	I-C0332294
retinopathy	B-C0035309
.	O
	
characterizing	B-C1880022
sexual	B-C0278092
function	I-C0278092
in	O
patients	B-C0030705
with	O
generalized	B-C0270549
anxiety	I-C0270549
disorder	I-C0270549
a	O
pooled	B-C0242481
analysis	I-C0242481
of	O
three	O
vilazodone	B-C1530072
studies	B-C0002783
vilazodone	B-C1530072
has	O
been	O
shown	O
to	O
reduce	B-C0392756
core	B-C1457887
symptoms	I-C1457887
of	O
generalized	B-C0270549
anxiety	I-C0270549
disorder	I-C0270549
gad	B-C0270549
in	O
three	O
randomized	B-C0206035
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C0599724
trials	I-C0599724
.	O
	
since	O
sexual	B-C0549622
dysfunction	I-C0549622
sd	B-C0549622
is	O
not	O
well	O
characterized	O
in	O
gad	B-C0270549
,	O
a	O
post	B-C0242481
hoc	I-C0242481
analysis	I-C0242481
of	O
these	O
trials	B-C0008976
was	O
conducted	O
to	O
evaluate	B-C0220825
the	O
effects	B-C1704420
of	I-C1704420
vilazodone	B-C1530072
on	O
sexual	B-C0278092
functioning	I-C0278092
in	O
gad	B-C0270549
patients	B-C0030705
.	O
	
data	B-C1511726
were	O
pooled	B-C2349200
from	O
one	O
fixed-dose	B-C0008976
trial	I-C0008976
of	O
vilazodone	B-C1530072
20	O
and	O
40	O
mg/day	B-C0439422
nct01629966	B-C0282574
and	O
two	O
flexible-dose	B-C0242481
studies	I-C0242481
of	O
vilazodone	B-C1530072
20-40	O
mg/day	B-C0439422
nct01766401	B-C0282574
,	O
nct01844115	B-C0282574
in	O
adults	B-C0001675
with	O
gad	B-C0270549
.	O
	
sexual	B-C0278092
functioning	I-C0278092
was	O
assessed	B-C1516048
using	O
the	O
changes	B-C0034394
in	I-C0034394
sexual	I-C0034394
functioning	I-C0034394
questionnaire	I-C0034394
csfq	B-C0034394
.	O
	
outcomes	B-C0086750
included	O
mean	B-C0392762
change	I-C0392762
from	I-C0392762
baseline	I-C0392762
to	I-C0392762
end	I-C0392762
of	I-C0392762
treatment	I-C0392762
eot	B-C0205556
in	O
csfq	B-C2960025
total	I-C2960025
score	I-C2960025
and	O
percentage	B-C0439165
of	O
patients	B-C0030705
shifting	B-C0333051
from	O
sd	B-C0549622
at	O
baseline	B-C1442488
csfq	B-C2960025
total	I-C2960025
score	I-C2960025
47	O
for	O
males	B-C0025266
,	O
41	O
for	O
females	B-C0043210
to	O
normal	B-C4296962
functioning	I-C4296962
at	O
eot	B-C0205556
.	O
	
treatment-emergent	B-C0877248
adverse	I-C0877248
events	I-C0877248
related	O
to	O
sexual	B-C0278092
functioning	I-C0278092
were	O
also	O
analyzed	B-C0936012
.	O
	
a	O
total	B-C0439810
of	O
1	O
patients	B-C0030705
were	O
included	O
in	O
the	O
analyses	B-C0936012
.	O
	
sd	B-C0549622
at	O
baseline	B-C1442488
was	O
more	O
common	O
in	O
females	B-C0043210
placebo	B-C1696465
,	O
46.4	O
vilazodone	B-C1530072
,	O
49%	O
than	O
in	O
males	B-C0025266
placebo	B-C1696465
,	O
35.1	O
vilazodone	B-C1530072
,	O
40.9	O
.	O
	
csfq	B-C2960025
total	I-C2960025
score	I-C2960025
improvement	B-C2986411
was	O
found	O
in	O
both	O
females	B-C0043210
placebo	B-C1696465
,	O
+1	O
vilazodone	B-C1530072
,	O
+1	O
and	O
males	B-C0025266
placebo	B-C1696465
,	O
+2	O
vilazodone	B-C1530072
,	O
+1	O
,	O
with	O
no	B-C3842396
statistically	I-C3842396
significant	I-C3842396
differences	I-C3842396
between	O
treatment	B-C1522326
groups	B-C0441833
.	O
	
the	O
percentage	B-C0439165
of	O
patients	B-C0030705
who	O
shifted	B-C0333051
from	O
sd	B-C0549622
at	O
baseline	B-C1442488
to	O
normal	B-C0205307
sexual	B-C0278092
functioning	I-C0278092
at	O
eot	B-C0205556
was	O
higher	O
in	O
males	B-C0025266
placebo	B-C1696465
,	O
40.6	O
vilazodone	B-C1530072
,	O
35.7	O
than	O
in	O
females	B-C0043210
placebo	B-C1696465
,	O
24.9	O
vilazodone	B-C1530072
,	O
34.9	O
no	B-C3841003
statistical	I-C3841003
testing	I-C3841003
was	O
performed	O
.	O
	
except	O
for	O
erectile	B-C0242350
dysfunction	I-C0242350
and	O
delayed	B-C0234047
ejaculation	I-C0234047
in	O
vilazodone	B-C1530072
-	O
treated	B-C1522326
males	B-C0025266
2.4	O
and	O
2.1	O
,	O
respectively	O
,	O
no	B-C1963761
treatment-emergent	I-C1963761
adverse	I-C1963761
events	I-C1963761
related	O
to	O
sexual	B-C0278092
functioning	I-C0278092
occurred	B-C1709305
in	O
2%	O
of	O
patients	B-C0030705
in	O
either	O
treatment	B-C1522326
group	B-C0441833
.	O
	
approximately	B-C0332232
35%-50%	O
of	O
patients	B-C0030705
in	O
the	O
vilazodone	B-C1530072
gad	B-C0270549
studies	B-C0002783
had	O
sd	B-C0549622
at	O
baseline	B-C1442488
.	O
	
vilazodone	B-C1530072
and	O
placebo	B-C1696465
had	O
similar	O
effects	B-C1280500
on	O
csfq	B-C0034394
outcomes	B-C0086750
in	O
both	O
females	B-C0043210
and	O
males	B-C0025266
,	O
indicating	O
a	O
limited	B-C0439801
adverse	B-C0879626
impact	I-C0879626
on	O
sexual	B-C0278092
functioning	I-C0278092
with	O
biogeochemical	B-C0205474
controls	B-C0243148
of	O
uranium	B-C0041928
bioavailability	B-C0005508
from	O
the	O
dissolved	B-C1948047
phase	I-C1948047
in	O
natural	B-C0205296
freshwaters	B-C0016710
to	O
gain	O
insights	O
into	O
the	O
risks	B-C0035647
associated	B-C0332281
with	I-C0332281
uranium	B-C0041928
u	B-C0041928
mining	B-C0026175
and	O
processing	B-C1709694
,	O
we	O
investigated	B-C1292732
the	O
biogeochemical	B-C0205474
controls	B-C0243148
of	O
u	B-C0041928
bioavailability	B-C0005508
in	O
the	O
model	O
freshwater	B-C0016710
species	B-C1705920
lymnaea	B-C0323913
stagnalis	I-C0323913
gastropoda	B-C0324023
.	O
	
bioavailability	B-C0005508
of	O
dissolved	B-C0041928
u	I-C0041928
was	O
characterized	B-C1880022
in	O
controlled	B-C2587213
laboratory	B-C0022877
experiments	B-C0681814
over	O
a	O
range	O
of	O
water	B-C0043047
hardness	B-C0018599
,	O
ph	B-C0020283
,	O
and	O
in	O
the	O
presence	B-C0150312
of	O
complexing	B-C0023688
ligands	I-C0023688
in	O
the	O
form	O
of	O
dissolved	B-C0567360
natural	I-C0567360
organic	I-C0567360
matter	I-C0567360
dom	B-C0567360
.	O
	
results	B-C0456984
show	O
that	O
dissolved	B-C0041928
u	I-C0041928
is	O
bioavailable	B-C0935763
under	O
all	O
the	O
geochemical	B-C0017448
conditions	I-C0017448
tested	B-C0039593
.	O
	
uranium	B-C0041928
uptake	B-C0243144
rates	B-C1521828
follow	O
first	B-C0878685
order	I-C0878685
kinetics	I-C0878685
over	O
a	O
range	O
encompassing	O
most	O
environmental	B-C0014406
concentrations	B-C1446561
.	O
	
uranium	B-C0041928
uptake	B-C0243144
rates	B-C1521828
in	O
l	B-C0323913
.	O
	
stagnalis	I-C0323913
ultimately	O
demonstrate	O
saturation	B-C0522534
uptake	B-C0243144
kinetics	B-C0022702
when	O
exposure	B-C0332157
concentrations	B-C1446561
exceed	O
100	O
nm	O
,	O
suggesting	B-C1705535
uptake	B-C0243144
via	O
a	O
finite	O
number	O
of	O
carriers	O
or	O
ion	B-C0022009
channels	I-C0022009
.	O
	
the	O
lack	O
of	O
a	O
relationship	O
between	O
u	B-C0041928
uptake	B-C0243144
rate	O
constants	B-C1547014
and	O
ca	B-C0006675
uptake	B-C0243144
rates	B-C1521828
suggest	B-C1705535
that	O
u	B-C0041928
does	O
not	O
exclusively	O
use	O
ca	B-C0006675
membrane	B-C0596902
transporters	I-C0596902
.	O
	
in	O
general	O
,	O
u	B-C0041928
bioavailability	B-C0005508
decreases	B-C0442797
with	O
increasing	B-C0442808
ph	B-C0020283
,	O
increasing	B-C0442808
ca	B-C0006675
and	O
mg	B-C0024467
concentrations	B-C1446561
,	O
and	O
when	O
dom	B-C0567360
is	O
present	B-C0150312
.	O
	
competing	O
ions	B-C0022023
did	O
not	O
affect	O
u	B-C0041928
uptake	B-C0243144
rates	B-C1521828
.	O
	
speciation	B-C0870071
modeling	I-C0870071
that	O
includes	O
formation	B-C1522492
constants	B-C1547014
for	O
u	B-C0041928
ternary	B-C1254350
complexes	I-C1254350
reveals	B-C0443289
that	O
the	O
aqueous	B-C0599956
concentration	B-C1446561
of	O
dicarbonato	B-C0041928
u	I-C0041928
species	B-C1705920
uo2	O
best	O
predicts	O
u	B-C0041928
bioavailability	B-C0005508
to	O
l	B-C0323913
.	O
	
stagnalis	I-C0323913
,	O
challenging	O
the	O
free-ion	B-C0441655
activity	I-C0441655
interleukin-21	B-C0962190
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	B-C0699748
and	O
severity	O
of	O
type	B-C4303164
i	I-C4303164
autoimmune	I-C4303164
hepatitis	I-C4303164
recently	O
,	O
the	O
number	O
of	O
follicular	B-C1571705
helper	B-C0018894
t	I-C0018894
tfh	I-C0018894
cells	I-C0018894
expressing	O
interleukin	B-C0962190
il	I-C0962190
was	O
found	O
to	O
increase	O
in	O
peripheral	B-C0229664
blood	I-C0229664
of	O
human	B-C0086418
and	O
murine	B-C0026809
models	B-C0012644
of	O
autoimmune	B-C0241910
hepatitis	I-C0241910
aih	B-C0241910
.	O
	
il-21	B-C0962190
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type-i	B-C0079189
cytokine	I-C0079189
family	I-C0079189
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	B-C0020962
system	I-C0020962
,	O
including	O
b	B-C1155003
cell	I-C1155003
activation	I-C1155003
,	O
plasma	B-C1817697
cell	I-C1817697
differentiation	I-C1817697
,	O
and	O
immunoglobulin	B-C0003261
production	I-C0003261
.	O
	
we	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	B-C0229671
il-21	B-C0962190
levels	B-C0441889
in	O
patients	B-C0030705
with	O
type	B-C4303164
i	I-C4303164
aih	I-C4303164
with	O
clinical	B-C0205210
and	O
laboratory	B-C0022877
parameters	B-C0549193
and	O
histology	B-C0019638
.	O
	
ninety-two	O
japanese	B-C1556094
patients	B-C0030705
with	O
liver	B-C0023895
disease	I-C0023895
22	O
aih	B-C0241910
,	O
20	O
primary	B-C0008312
biliary	I-C0008312
cholangitis	I-C0008312
,	O
19	O
drug-induced	B-C0860207
liver	I-C0860207
injury	I-C0860207
,	O
8	O
acute	B-C0276609
hepatitis	I-C0276609
b	I-C0276609
,	O
8	O
chronic	B-C0524910
hepatitis	I-C0524910
c	I-C0524910
,	O
10	O
non-alcoholic	B-C3241937
steatohepatitis	I-C3241937
,	O
5	O
viral	B-C0042721
hepatitis	I-C0042721
and	O
10	O
healthy	B-C1708335
volunteers	I-C1708335
were	O
recruited	O
.	O
	
serum	B-C0229671
il-21	B-C0962190
levels	B-C0441889
were	O
detected	O
by	O
enzyme-linked	B-C0014441
immunosorbent	I-C0014441
assay	I-C0014441
.	O
	
real-time	B-C1709846
polymerase	I-C1709846
chain	I-C1709846
reaction	I-C1709846
measured	O
mrna	B-C0035696
levels	B-C0441889
of	O
bcl-6	B-C1332399
,	O
il-21	B-C1416406
,	O
and	O
cxcr5	B-C1332421
tfh-related	B-C0033684
factors	I-C0033684
in	O
peripheral	B-C0205100
mononuclear	B-C0806987
cells	I-C0806987
.	O
	
mean	O
age	O
at	O
diagnosis	B-C0011900
of	O
aih	B-C0241910
was	O
58.6	O
years	O
,	O
male-to-female	B-C0243095
ratio	I-C0243095
was	O
4	O
,	O
18.2	O
%	O
of	O
participants	O
had	O
cirrhosis	B-C0023890
,	O
and	O
22.7	O
%	O
had	O
severe	B-C0205082
disease	B-C0012634
.	O
	
il-21	B-C0962190
levels	B-C0441889
were	O
significantly	O
increased	B-C0205217
in	O
the	O
serum	B-C0229671
of	O
patients	B-C0030705
with	O
aih	B-C0241910
compared	O
to	O
those	O
with	O
other	B-C0156194
liver	I-C0156194
diseases	I-C0156194
and	O
controls	B-C0009932
p	O
<	O
0.0001	O
.	O
	
particularly	O
,	O
serum	B-C0229671
il-21	B-C0962190
levels	B-C0441889
were	O
significantly	O
increased	B-C0205217
in	O
severe	B-C0205082
aih	B-C0241910
cases	O
compared	O
to	O
non-severe	O
cases	O
p	O
<	O
0.05	O
.	O
	
serum	B-C0229671
il-21	B-C0962190
levels	B-C0441889
correlated	O
positively	O
with	O
total	O
serum	B-C0229671
bilirubin	B-C0344395
levels	I-C0344395
r	O
=	O
0.46	O
,	O
p	O
<	O
0.05	O
,	O
grading	B-C1954433
of	I-C1954433
necroinflammatory	I-C1954433
activity	I-C1954433
r	O
=	O
0.68	O
,	O
p	O
<	O
0.005	O
and	O
negatively	O
with	O
serum	B-C0728877
albumin	I-C0728877
levels	I-C0728877
in	O
patients	B-C0030705
with	O
aih	B-C0241910
r	O
=	O
-0	O
,	O
p	O
<	O
0.05	O
.	O
	
in	O
patients	B-C0030705
with	O
biochemical	B-C0205474
remission	B-C0544452
of	O
aih	B-C0241910
,	O
serum	B-C0229671
il-21	B-C0962190
levels	B-C0441889
remained	O
elevated	B-C3163633
and	O
correlated	B-C1707520
positively	B-C1514241
with	O
serum	B-C2732508
igg	I-C2732508
levels	I-C2732508
r	O
=	O
0.84	O
,	O
p	O
<	O
0.01	O
.	O
	
expression	B-C1171362
of	O
tfh-related	B-C0033684
factors	I-C0033684
,	O
such	O
as	O
bcl-6	B-C1448774
and	O
il-21	B-C0962190
,	O
in	O
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
of	O
patients	B-C0030705
with	O
aih	B-C0241910
was	O
significantly	O
higher	B-C0205250
than	O
that	O
in	O
healthy	B-C1708335
volunteers	I-C1708335
.	O
	
il-21	B-C0962190
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-C0699748
and	O
severity	O
of	O
aih	B-C0241910
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
aih	B-C0241910
therapy	B-C0039798
.	O
	
resistance	B-C4281815
exercise	B-C0015259
in	O
pregnancy	B-C0032961
and	O
outcome	B-C0032972
as	O
the	O
health	B-C0086387
benefits	I-C0086387
of	O
exercise	B-C0015259
are	O
increasingly	O
recognized	O
,	O
the	O
traditional	B-C0150600
advice	I-C0150600
to	O
rest	B-C0035253
during	O
pregnancy	B-C0032961
has	O
changed	B-C0392747
toward	O
a	O
more	O
healthy	B-C3898900
and	O
active	B-C0205177
pregnancy	B-C0032961
,	O
therefore	O
different	O
forms	O
of	O
exercise	B-C0015259
have	O
been	O
integrated	O
into	O
the	O
life	B-C0376558
of	O
the	O
pregnant	B-C0033011
woman	I-C0033011
.	O
	
although	O
the	O
benefits	B-C0814225
of	O
using	O
a	O
combination	B-C0205195
of	O
resistance	B-C4281815
and	O
aerobic	B-C0001701
exercises	I-C0001701
are	O
not	O
yet	O
determined	O
,	O
studies	B-C2603343
about	O
resistance	B-C4281815
and	O
strengthen	O
training	B-C0040607
programs	I-C0040607
are	O
few	O
although	O
no	B-C0853204
adverse	I-C0853204
outcomes	B-C0032972
custom	O
ocular	B-C0015417
prosthesis	I-C0015417
in	O
rehabilitation	B-C0034991
of	O
a	O
child	B-C0008059
operated	O
for	O
retinoblastoma	B-C0035335
a	O
maxillofacial	B-C2193570
prosthodontist	I-C2193570
forms	O
an	O
important	B-C3898777
link	O
in	O
the	O
interdisciplinary	O
management	B-C1610129
of	I-C1610129
a	I-C1610129
patient	I-C1610129
with	O
anopthalmosis	B-C0003119
.	O
	
prosthetic	B-C0087111
management	I-C0087111
of	O
an	O
anopthalmic	B-C0003119
defect	I-C0003119
aims	O
to	O
deliver	O
a	O
well-fitting	O
ocular	B-C0015417
prosthesis	I-C0015417
that	O
can	O
mimic	O
the	O
original	O
eye	B-C0015392
as	O
closely	O
as	O
possible	O
,	O
and	O
thus	O
restoring	O
the	O
patient's	B-C0030705
self-confidence	B-C0237529
and	O
thereby	O
rehabilitating	B-C0034992
them	O
in	O
the	O
society	B-C0037455
.	O
	
the	O
fabrication	B-C0087111
of	O
a	O
custom	O
ocular	B-C0015417
prosthesis	I-C0015417
is	O
a	O
demanding	O
art	O
.	O
	
this	O
case	B-C0007320
report	I-C0007320
presents	O
a	O
simplified	O
technique	B-C0449851
for	O
the	O
fabrication	B-C0087111
of	O
a	O
custom	O
ocular	B-C0015417
prosthesis	I-C0015417
for	O
a	O
child	B-C0008059
who	O
had	O
lost	B-C0745777
his	O
eye	B-C0015392
to	O
enucleation	B-C0014392
following	O
retinoblastoma	B-C0035335
.	O
	
early	O
and	O
effective	O
rehabilitation	B-C0034991
of	O
the	O
defect	O
goes	O
a	O
long	O
way	O
in	O
restoring	O
the	O
self-image	B-C2712201
of	O
a	O
child	B-C0008059
pulmonary	B-C0231921
function	I-C0231921
and	O
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
1-	O
year	B-C0439234
follow	B-C1522577
up	I-C1522577
after	O
cardiac	B-C0018821
surgery	I-C0018821
pulmonary	B-C0231921
function	I-C0231921
is	O
severely	B-C0205082
reduced	B-C0392756
in	O
the	O
early	B-C1279919
period	B-C1948053
after	O
cardiac	B-C0018821
surgery	I-C0018821
,	O
and	O
impairments	B-C0684336
have	O
been	O
described	O
up	O
to	O
4-6	O
months	B-C0439231
after	B-C0032790
surgery	I-C0032790
.	O
	
evaluation	B-C0220825
of	O
pulmonary	B-C0231921
function	I-C0231921
in	O
a	O
longer	O
perspective	O
is	O
lacking	B-C0332268
.	O
	
in	O
this	O
prospective	B-C0033522
study	I-C0033522
pulmonary	B-C0231921
function	I-C0231921
and	O
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
were	O
investigated	B-C1292732
1	O
year	B-C0439234
after	O
cardiac	B-C0018821
surgery	I-C0018821
.	O
	
pulmonary	B-C0231921
function	I-C0231921
measurements	B-C0242485
,	O
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
sf-36	B-C1519136
,	O
dyspnoea	B-C0013404
,	O
subjective	B-C0439655
breathing	B-C0035203
and	O
coughing	B-C0010200
ability	B-C0085732
and	O
pain	B-C0030193
were	O
evaluated	B-C0220825
before	B-C0332152
and	O
1	O
year	B-C0439234
after	B-C0032790
surgery	I-C0032790
in	O
150	O
patients	B-C0030705
undergoing	O
coronary	B-C0010055
artery	I-C0010055
bypass	I-C0010055
grafting	I-C0010055
,	O
valve	B-C0543467
surgery	I-C0543467
or	O
combined	O
surgery	B-C0543467
.	O
	
one	O
year	B-C0439234
after	B-C0032790
surgery	I-C0032790
the	O
forced	B-C0231958
vital	I-C0231958
capacity	I-C0231958
and	O
forced	B-C0016529
expiratory	I-C0016529
volume	I-C0016529
in	O
1	O
s	O
were	O
significantly	O
decreased	B-C0205216
by	O
4-5	O
%	O
compared	B-C1707455
to	O
preoperative	B-C0445204
values	B-C1522609
p	O
<	O
0.05	O
.	O
	
saturation	B-C2317096
of	I-C2317096
peripheral	I-C2317096
oxygen	I-C2317096
was	O
unchanged	B-C0442739
1	O
year	B-C0439234
postoperatively	B-C0032790
compared	B-C1707455
to	O
baseline	B-C1442488
.	O
	
a	O
significantly	O
improved	B-C0184511
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
was	O
found	O
1	O
year	B-C0439234
after	B-C0032790
surgery	I-C0032790
,	O
with	O
improvements	B-C2986411
in	O
all	O
eight	O
aspects	B-C1879746
of	O
sf-36	B-C1519136
p	O
<	O
0.001	O
.	O
	
sternotomy	B-C0185792
-related	O
pain	B-C0030193
was	O
low	B-C0205251
1	O
year	B-C0439234
postoperatively	B-C0032790
at	B-C0443144
rest	I-C0443144
median	O
0	O
min-max	O
0-7	O
,	O
while	O
taking	O
a	O
deep	B-C1321587
breath	I-C1321587
0	O
0-4	O
and	O
while	O
coughing	B-C0010200
0	O
0-8	O
.	O
	
a	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	B-C0231921
function	I-C0231921
was	O
associated	B-C0332281
with	I-C0332281
dyspnoea	B-C0013404
limitations	B-C0449295
and	O
impaired	B-C0684336
subjective	B-C0439655
breathing	B-C0035203
and	O
coughing	B-C0010200
ability	B-C0085732
.	O
	
one	O
year	B-C0439234
after	O
cardiac	B-C0018821
surgery	I-C0018821
static	B-C0441463
and	O
dynamic	B-C0729333
lung	B-C0024119
function	I-C0024119
measurements	I-C0024119
were	O
slightly	O
decreased	B-C0205216
,	O
while	O
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
was	O
improved	B-C0184511
in	O
comparison	B-C1707455
to	O
preoperative	B-C0445204
values	B-C1522609
.	O
	
measured	B-C0444706
levels	B-C0441889
of	O
pain	B-C0030193
were	O
low	B-C0205251
and	O
saturation	B-C2317096
of	I-C2317096
peripheral	I-C2317096
oxygen	I-C2317096
was	O
same	B-C0445247
as	O
impact	B-C4049986
of	O
soil	B-C0037592
salinity	B-C0392762
on	O
the	O
structure	B-C0678594
of	O
the	O
bacterial	B-C0004611
endophytic	B-C1265415
community	B-C0009462
identified	B-C0205396
from	O
the	O
roots	B-C0242726
of	O
caliph	B-C0330774
medic	I-C0330774
medicago	B-C0330774
truncatula	I-C0330774
in	O
addition	O
to	O
being	O
a	O
forage	B-C0032098
crop	I-C0032098
,	O
caliph	B-C0330774
medic	I-C0330774
medicago	B-C0330774
truncatula	I-C0330774
is	O
also	O
a	O
model	B-C1514135
legume	I-C1514135
plant	I-C1514135
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	B-C1880022
characterization	I-C1880022
of	O
the	O
interaction	B-C1704675
between	O
rhizobia	B-C0004611
and	O
plants	B-C0032098
.	O
	
however	O
,	O
the	O
endophytic	B-C1956108
microbiome	I-C1956108
in	O
this	O
plant	B-C0032098
is	O
poorly	O
defined	O
.	O
	
endophytic	B-C1265415
bacteria	B-C0004611
play	O
a	O
role	O
in	O
supplying	O
plants	B-C0032098
with	O
the	O
basic	O
requirements	B-C1514873
necessary	O
for	O
growth	B-C0597252
and	O
development	B-C0597252
.	O
	
moreover	O
,	O
these	O
bacteria	B-C0004611
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	B-C0441712
of	O
salinity	B-C1254365
stress	I-C1254365
adaptation	B-C0392673
in	O
plants	B-C0032098
.	O
	
as	O
a	O
prelude	O
to	O
the	O
isolation	B-C0220862
and	O
utilization	B-C0042153
of	O
these	O
bacteria	B-C0004611
in	O
caliph	B-C0330774
medic	I-C0330774
farming	B-C0557759
,	O
41	O
bacterial	B-C0004611
otus	B-C0008902
were	O
identified	B-C0205396
in	O
this	O
project	O
from	O
within	O
the	O
interior	B-C0205102
of	O
the	O
roots	B-C0242726
of	O
this	O
plant	B-C0032098
by	O
pyrosequencing	B-C2732543
of	O
the	O
small	B-C0017337
ribosomal	I-C0017337
subunit	I-C0017337
gene	I-C0017337
16s	B-C0017337
rdna	I-C0017337
using	O
a	O
cultivation-independent	B-C0022885
approach	I-C0022885
.	O
	
in	O
addition	O
,	O
the	O
differential	B-C0443199
abundance	B-C2346714
of	O
these	O
bacteria	B-C0004611
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	B-C0032098
to	O
salinity	B-C1254365
stress	I-C1254365
.	O
	
about	O
29	O
high-quality	B-C0392762
reads	I-C0392762
were	O
obtained	O
from	O
the	O
sequencing	B-C1294197
of	O
six	O
libraries	B-C0017272
prepared	O
from	O
control	B-C0040300
and	O
salinity-treated	B-C0040300
tissues	I-C0040300
.	O
	
statistical	B-C0871424
analysis	I-C0871424
revealed	O
that	O
the	O
abundance	B-C2346714
of	O
70%	O
of	O
the	O
otus	B-C0008902
was	O
significantly	O
p	O
0.05	O
altered	O
in	O
roots	B-C0242726
that	O
were	O
exposed	B-C0332157
to	I-C0332157
salinity	B-C1254365
stress	I-C1254365
.	O
	
sequence	B-C0162801
analysis	I-C0162801
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	B-C0205396
species	B-C1705920
and	O
other	O
,	O
known	O
,	O
growth-promoting	B-C0004611
bacteria	I-C0004611
,	O
marine	B-C0599383
and	O
salt-stressed	B-C0004611
soil-borne	I-C0004611
bacteria	I-C0004611
,	O
and	O
nitrogen-fixing	B-C4277688
bacterial	I-C4277688
isolates	B-C1764827
.	O
	
determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	B-C0004611
l	O
community	B-C0009462
due	O
to	O
salinity	B-C1254365
stress	I-C1254365
in	O
caliph	B-C0330774
medic	I-C0330774
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	B-C0439849
of	O
these	O
endophytes	B-C1265415
,	O
under	O
salt	B-C1254365
stress	I-C1254365
conditions	I-C1254365
,	O
in	O
this	O
model	B-C1514135
plant	I-C1514135
.	O
	
to	O
provide	O
direct	O
evidence	B-C3887511
regarding	O
their	O
growth	B-C0441655
promoting	I-C0441655
activity	I-C0441655
,	O
a	O
group	B-C0441833
of	O
endophytic	B-C1265415
bacteria	B-C0004611
were	O
isolated	B-C0205409
from	O
inside	O
of	O
plant	B-C0242726
roots	I-C0242726
using	O
a	O
cultivation-dependent	B-C0022885
approach	I-C0022885
.	O
	
several	O
of	O
these	O
isolates	B-C1764827
were	O
able	O
to	O
produce	O
acc-deaminase	B-C0044278
,	O
ammonia	B-C0002607
and	O
iaa	B-C0936060
and	O
to	O
solubilize	B-C0205245
zn+2	B-C0043481
and	O
po4-3	B-C1601799
.	O
	
this	O
data	B-C1511726
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	B-C2745955
based	O
on	O
cultivation-independent	B-C0022885
techniques	I-C0022885
of	O
these	O
bacteria	B-C0004611
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	B-C1265415
bacteria	B-C0004611
in	O
caliph	B-C0330774
medic	I-C0330774
when	O
grown	O
under	O
normal	B-C0205307
and	O
saline	B-C0036082
conditions	B-C0348080
.	O
	
eliminating	O
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
in	O
cml	B-C0023473
with	O
combination	O
transcriptional	B-C0040649
therapy	B-C0087111
leukemia	B-C0023418
stem	B-C1956422
cells	I-C1956422
lscs	B-C1956422
are	O
resistant	O
to	O
current	O
therapies	B-C0087111
used	O
to	O
treat	O
chronic	B-C0023473
myeloid	I-C0023473
leukemia	I-C0023473
cml	B-C0023473
.	O
	
abraham	O
et	O
al	O
.	O
	
2016	O
have	O
identified	O
a	O
molecular	B-C1148560
network	I-C1148560
critical	B-C0231242
for	O
cml	B-C0023473
lsc	B-C1956422
survival	B-C0007620
and	O
propose	O
that	O
simultaneously	O
targeting	O
two	O
of	O
their	O
major	O
transcriptional	B-C0040648
regulators	I-C0040648
,	O
p53	B-C0079419
and	O
c-myc	B-C0314684
,	O
may	O
facilitate	O
their	O
crocetin	B-C0056501
improves	B-C0184511
the	O
quality	B-C0332306
of	O
in	B-C1533691
vitro	I-C1533691
-	O
produced	B-C0205245
bovine	B-C3667982
embryos	B-C0013935
implications	O
for	O
blastocyst	B-C1326531
development	I-C1326531
,	O
cryotolerance	B-C1704410
,	O
and	O
apoptosis	B-C0162638
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	B-C0184514
the	O
effect	B-C1280500
of	O
supplementation	B-C0087111
of	O
bovine	B-C3667982
culture	B-C0010454
medium	I-C0010454
with	O
the	O
natural	B-C0003402
antioxidant	I-C0003402
crocetin	B-C0056501
on	O
in	B-C1533691
vitro	I-C1533691
blastocyst	B-C1326531
development	I-C1326531
and	O
quality	B-C0332306
.	O
	
this	O
was	O
evaluated	B-C0220825
as	O
cryotolerance	B-C1704410
,	O
apoptosis	B-C0918012
index	I-C0918012
,	O
and	O
total	B-C0007584
cells	I-C0007584
number	I-C0007584
and	O
allocation	B-C1706778
.	O
	
abattoir	B-C0000715
-derived	O
oocytes	B-C0029045
were	O
matured	B-C0205286
and	O
fertilized	B-C0232904
in	B-C1533691
vitro	I-C1533691
according	O
to	O
standard	B-C1710183
procedure	I-C1710183
.	O
	
twenty	O
hours	B-C0439227
after	O
ivf	B-C0015915
,	O
presumptive	B-C3640893
zygotes	B-C0043544
were	O
cultured	B-C0430400
in	O
synthetic	B-C0029954
oviduct	I-C0029954
fluid	B-C1705217
medium	I-C1705217
,	O
supplemented	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μm	O
crocetin	B-C0056501
experiment	O
1	O
at	O
39	O
c	O
under	O
humidified	B-C0508271
air	I-C0508271
with	O
5%	O
co2	B-C0007012
,	O
7%	O
o2	B-C0030054
,	O
and	O
88%	O
n2	B-C0028158
.	O
	
on	O
day	B-C0439228
7	O
,	O
embryo	B-C0392762
yields	I-C0392762
were	O
assessed	B-C1516048
and	O
the	O
blastocysts	B-C1281743
were	O
vitrified	O
by	O
cryotop	B-C0025663
method	I-C0025663
in	O
16.5	O
ethylene	B-C0015083
glycol	I-C0015083
,	O
16.5	O
dmso	B-C0012403
,	O
and	O
0.5	O
m	O
sucrose	B-C0038636
.	O
	
finally	O
,	O
blastocysts	B-C1281743
produced	O
on	O
day	B-C0439228
8	O
in	O
the	O
absence	B-C0332197
control	B-C0009932
and	O
presence	B-C0150312
of	O
1	O
μm	O
crocetin	B-C0056501
were	O
used	O
for	O
terminal	B-C1515232
deoxynucleotidyl	I-C1515232
transferase-mediated	I-C1515232
dutp	I-C1515232
nick	I-C1515232
end	I-C1515232
labelling	I-C1515232
and	O
differential	B-C0487602
staining	I-C0487602
to	O
evaluate	B-C0220825
,	O
respectively	O
,	O
the	O
apoptotic	B-C1521828
rate	I-C1521828
and	O
the	O
allocation	B-C1706778
of	O
cells	B-C0007634
into	O
inner	B-C1283994
cell	I-C1283994
mass	I-C1283994
icm	B-C1283994
and	O
trophectoderm	B-C0041178
te	B-C0041178
lineages	B-C1881379
experiment	O
2	O
.	O
	
embryo	B-C0013936
development	I-C0013936
was	O
higher	O
in	O
the	O
1	O
μm	O
crocetin	B-C0441833
group	I-C0441833
compared	O
to	O
the	O
control	B-C0009932
,	O
both	O
in	O
terms	O
of	O
total	B-C0439810
embryo	B-C0013935
output	B-C4263297
37.7	O
4.2	O
,	O
52.9	O
6.3	O
,	O
40.9	O
7.6	O
,	O
and	O
42.4	O
8.7	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μm	O
p	O
<	O
0.01	O
and	O
grade	B-C1275673
1	I-C1275673
and	O
2	B-C1275673
blastocysts	B-C1281743
33.6	O
4.9	O
,	O
46.1	O
7.3	O
,	O
37.8	O
7.9	O
,	O
and	O
39.4	O
7.9	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μm	O
p	O
<	O
0.05	O
.	O
	
moreover	O
,	O
the	O
percentage	B-C1549488
of	O
fast-developing	B-C0013936
embryos	I-C0013936
increased	B-C0205217
in	O
1	O
μm	O
crocetin	B-C0441833
group	I-C0441833
compared	O
to	O
the	O
control	B-C0009932
23.4	O
4.7	O
,	O
32.7	O
6.6	O
,	O
27.2	O
6.6	O
,	O
and	O
30.1	O
7.2	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2.5	O
,	O
and	O
5	O
μm	O
p	O
<	O
0.05	O
.	O
	
in	O
addition	O
,	O
the	O
enrichment	B-C3503937
of	I-C3503937
culture	I-C3503937
medium	I-C3503937
with	O
1	O
μm	O
crocetin	B-C0056501
improved	B-C0184511
embryo	B-C0013935
cryotolerance	B-C1704410
compared	O
to	O
the	O
control	B-C0009932
,	O
as	O
indicated	O
by	O
higher	O
hatching	B-C0598016
rates	B-C1521828
recorded	O
after	O
48	O
hours	B-C0439227
postwarming	B-C0010454
culture	I-C0010454
46.5	O
vs	O
.	O
	
60.4	O
p	O
<	O
0.05	O
.	O
	
furthermore	O
,	O
1	O
μm	O
crocetin	B-C0056501
decreased	B-C0205216
both	O
the	O
average	O
number	O
9.9	O
0.4	O
vs	O
.	O
	
7.1	O
0.3	O
and	O
the	O
percentage	B-C1549488
of	O
apoptotic	B-C1516044
cells	B-C0007634
7.1	O
0.4	O
vs	O
.	O
	
4.2	O
0.2	O
in	O
blastocysts	B-C1281743
compared	O
to	O
the	O
control	B-C0009932
p	O
<	O
0.01	O
.	O
	
however	O
,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
icm	B-C1283994
,	O
te	B-C0041178
,	O
and	O
total	B-C0439810
cells	O
between	O
1	O
μm	O
crocetin	O
and	O
control	O
groups	O
.	O
	
in	O
conclusion	O
,	O
the	O
enrichment	O
of	O
bovine	O
culture	O
medium	O
with	O
1	O
μm	O
crocetin	O
increased	O
both	O
blastocyst	O
yield	O
and	O
quality	O
,	O
as	O
indicated	O
by	O
the	O
improved	O
chronology	O
of	O
embryo	O
development	O
,	O
increased	O
resistance	O
to	O
cryopreservation	O
,	O
and	O
reduced	O
incidence	O
of	O
apoptosis	B-C0162638
matrix	B-C0022885
solid-phase	I-C0022885
dispersion	I-C0022885
combined	O
to	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
for	O
the	O
determination	B-C1148554
of	O
paraben	B-C0030398
preservatives	B-C0033086
in	O
mollusks	B-C0026391
a	O
method	B-C0449341
for	I-C0449341
the	I-C0449341
extraction	I-C0449341
and	O
determination	B-C1148554
of	O
seven	O
parabens	B-C0030398
,	O
esters	B-C0014898
of	O
4-hydroxybenzoic	B-C0048323
acid	I-C0048323
,	O
widely	O
used	O
as	O
preservatives	B-C0033086
in	O
personal	B-C4288402
care	I-C4288402
products	I-C4288402
,	O
pharmaceuticals	B-C1254351
,	O
etc	O
,	O
and	O
two	O
chlorinated	B-C0020247
derivatives	I-C0020247
mono-	B-C0066415
and	O
di-chloro	B-C0066415
methyl	I-C0066415
paraben	I-C0066415
from	O
mollusk	B-C0026391
samples	B-C2347026
was	O
developed	O
by	O
combining	O
matrix	B-C0022885
solid-phase	I-C0022885
dispersion	I-C0022885
mspd	B-C0022885
and	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
.	O
	
mspd	B-C2825207
parameters	I-C2825207
,	O
such	O
as	O
solvent	B-C0037638
,	O
solid	B-C1254353
support	I-C1254353
and	O
clean-up	B-C1254353
sorbent	I-C1254353
,	O
were	O
optimized	B-C2698650
.	O
	
besides	O
,	O
since	O
blank	O
problems	O
were	O
observed	O
for	O
some	O
parabens	B-C0030398
,	O
these	O
were	O
investigated	B-C1292732
and	O
blanks	O
were	O
tackled	O
by	O
precleaning	B-C1947930
all	O
sorbents	B-C1254353
prior	O
to	O
use	O
.	O
	
under	O
final	O
conditions	O
,	O
0.5g	O
of	O
freeze-dried	B-C0016698
mollusk	B-C0026391
were	O
dispersed	B-C0332624
with	O
1.2g	O
of	O
silica	B-C0037098
and	O
packed	B-C2828395
into	O
a	O
cartridge	B-C1553461
containing	O
3g	O
of	O
c18	B-C0029224
,	O
as	O
on-line	O
clean-up	B-C1254353
sorbent	I-C1254353
.	O
	
this	O
cartridge	B-C1553461
was	O
eluted	O
with	O
10ml	O
of	O
acetonitrile	B-C0050456
,	O
evaporated	B-C0596539
and	O
reconstituted	B-C0441655
in	O
methanol	B-C0001963
for	O
analysis	B-C0936012
.	O
	
in	O
the	O
validation	B-C1519941
stage	O
,	O
successful	O
linearity	O
r	O
,	O
recoveries	B-C0237820
between	O
71	O
and	O
117%	O
for	O
most	O
analytes	B-C0443354
,	O
precision	B-C1706245
rsd	O
lower	O
than	O
21%	O
and	O
limits	B-C2718050
of	I-C2718050
detection	I-C2718050
and	O
quantification	B-C0392762
lod	B-C2718050
and	O
loq	B-C1519941
,	O
lower	O
than	O
0.4	O
and	O
1.4ngg	O
dry	B-C1439839
weight	I-C1439839
respectively	O
levels	B-C0441889
were	O
achieved	O
.	O
	
finally	O
,	O
the	O
new	O
methodology	B-C0969625
was	O
applied	O
to	O
mussel	B-C0026871
,	O
clam	B-C0008894
and	O
cockle	B-C0453050
samples	B-C2347026
.	O
	
methyl	B-C0066415
paraben	I-C0066415
was	O
above	O
the	O
loq	B-C0392762
in	O
five	O
of	O
the	O
six	O
samples	B-C2347026
not	O
found	O
in	O
one	O
clam	B-C0008894
sample	B-C2347026
at	O
concentrations	B-C1446561
up	O
to	O
7ngg	O
dry	B-C1439839
weight	I-C1439839
.	O
	
ethyl	B-C0059788
paraben	I-C0059788
was	O
found	O
above	O
the	O
loq	B-C0392762
in	O
mussel	B-C0026871
and	O
cockle	B-C0453050
samples	B-C2347026
at	O
a	O
concentration	B-C1446561
level	I-C1446561
around	O
0.3ngg	O
.	O
	
n-propyl	B-C0072238
paraben	I-C0072238
was	O
only	O
above	O
the	O
loq	B-C0392762
in	O
one	O
mussel	B-C0026871
sample	B-C2347026
.	O
	
two-stage	O
reconstructive	B-C0524865
overlapping	B-C0038257
stent	I-C0038257
leo+	B-C0038257
and	O
silk	B-C0025080
for	O
treatment	B-C0087111
of	O
intracranial	B-C0524466
circumferential	B-C0205113
fusiform	B-C0333099
aneurysms	I-C0333099
in	O
the	O
posterior	B-C1254362
circulation	B-C0005775
intracranial	B-C0524466
circumferential	B-C0205113
fusiform	B-C0333099
aneurysms	I-C0333099
of	O
the	O
posterior	B-C1254362
circulation	B-C0005775
involving	O
arterial	B-C0003842
branches	I-C0003842
or	O
perforating	B-C0549099
vessels	B-C0005847
are	O
difficult	O
to	O
treat	O
.	O
	
this	O
article	O
shows	O
an	O
endovascular	O
reconstruction	O
technique	O
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	O
self-expandable	O
stent	O
leo+	O
and	O
flow-diverter	O
device	O
silk	O
at	O
different	O
surgical	O
times	O
.	O
	
two	O
patients	O
with	O
circumferential	O
fusiform	O
aneurysm	O
,	O
one	O
being	O
an	O
aneurysm	O
of	O
the	O
segments	O
p2	O
and	O
p3	O
of	O
the	O
posterior	O
cerebral	O
artery	O
,	O
diagnosed	O
after	O
a	O
headache	O
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	O
aneurysm	O
of	O
the	O
lower	O
basilar	O
artery	O
,	O
diagnosed	O
following	O
ischemia	O
of	O
the	O
brain	O
stem	O
.	O
	
endovascular	O
treatment	O
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	O
reconstruction	O
technique	O
that	O
used	O
at	O
different	O
surgical	O
times	O
overlapping	O
a	O
telescoped	O
self-expandable	O
stent	O
,	O
leo+	O
and	O
a	O
flow-diverter	O
device	O
,	O
silk	O
.	O
	
angiographic	O
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	O
patency	O
,	O
flow	O
maintenance	O
in	O
the	O
arterial	O
branches	O
and	O
perforating	O
vessels	B-C0005847
,	O
and	O
thrombosis	O
of	O
the	O
aneurysm	O
.	O
	
the	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self-expandable	O
stent	O
and	O
flow-diverter	O
device	O
was	O
technically	O
successful	O
in	O
both	O
patients	O
.	O
	
there	O
were	O
no	O
complications	O
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long-term	O
follow-up	O
with	O
full	O
arterial	O
vascular	O
reconstruction	O
,	O
maintenance	O
of	O
cerebral	O
perfusion	O
and	O
complete	O
aneurysm	O
occlusion	O
at	O
the	O
6-	O
and	O
12-	O
month	O
angiographic	O
follow-up	O
.	O
	
there	O
was	O
no	O
aneurysm	O
recanalization	O
nor	O
intra-stent	O
stenosis	O
.	O
	
circumferential	O
fusiform	O
aneurysm	O
of	O
the	O
posterior	O
circulation	O
involving	O
arterial	O
branches	O
or	O
perforating	O
vessels	O
to	O
the	O
brain	O
stem	O
may	O
be	O
treated	O
with	O
this	O
arterial	O
reconstruction	O
technique	O
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self-expandable	O
stent	O
called	O
leo+	O
and	O
the	O
flow-diverter	O
device	O
silk	O
,	O
minimizing	O
the	O
risk	O
of	O
complications	O
and	O
failure	O
of	O
the	O
endovascular	O
technique	O
,	O
with	O
the	O
potential	O
for	O
arterial	O
reconstruction	O
with	O
thrombosis	O
of	O
the	O
aneurysmatic	O
sac	O
,	O
as	O
well	O
as	O
flow	O
maintenance	O
in	O
the	O
eloquent	O
arteries	O
,	O
in	O
this	O
type	O
of	O
cerebral	O
aneurysm	I-C0333099
polysaccharide	B-C0032595
-	O
specific	B-C0205369
memory	B-C0682638
b	I-C0682638
cells	I-C0682638
predict	O
protection	B-C1545588
against	O
experimental	B-C1517586
human	B-C0086418
pneumococcal	B-C0038410
carriage	B-C0853960
we	O
have	O
previously	B-C0205156
demonstrated	O
that	O
experimental	B-C1517586
pneumococcal	B-C0038410
carriage	B-C0853960
enhances	B-C2349975
immunity	B-C0020964
and	O
protects	B-C1545588
healthy	B-C3898900
adults	B-C0001675
against	B-C0521124
carriage	B-C0853960
reacquisition	B-C1706701
after	O
rechallenge	B-C2347900
with	O
a	O
homologous	B-C0301883
strain	B-C1518614
.	O
	
to	O
investigate	O
the	O
role	O
of	O
naturally	B-C0205296
acquired	B-C0439661
pneumococcal	B-C0004627
protein	I-C0004627
and	O
polysaccharide	B-C0032595
ps	B-C0032595
specific	B-C0205369
immunity	B-C0020964
in	O
protection	B-C1545588
against	B-C0521124
carriage	B-C0853960
acquisition	B-C1706701
using	O
a	O
heterologous	B-C3658217
challenge	I-C3658217
model	O
.	O
	
we	O
identified	O
healthy	B-C1708335
volunteers	I-C1708335
that	O
were	O
naturally	B-C0205296
colonized	B-C1947989
with	O
pneumococcus	B-C0038410
and	O
,	O
after	O
clearance	B-C0449297
of	O
their	O
natural	B-C0205296
carriage	B-C0853960
episode	B-C0332189
,	O
challenged	O
them	O
with	O
a	O
heterologous	B-C0301884
6b	B-C1688613
strain	I-C1688613
.	O
	
in	O
another	O
cohort	B-C0599755
of	O
volunteers	B-C1708335
we	O
assessed	O
6bps	B-C0032595
-	O
specific	B-C0205369
,	O
pspa	B-C0071312
-	O
specific	B-C0205369
,	O
and	O
pspc	B-C2000489
-	O
specific	B-C0205369
igg	B-C0020852
and	O
iga	B-C0020835
plasma	B-C0032112
and	O
memory	B-C0682638
b-cell	I-C0682638
populations	I-C0682638
before	B-C0332152
and	O
7	O
,	O
14	O
,	O
and	O
35	O
days	O
after	B-C0687676
experimental	B-C1517586
pneumococcal	B-C0038410
inoculation	B-C2987620
.	O
	
heterologous	B-C3658217
challenge	I-C3658217
with	O
6b	B-C1688613
resulted	O
in	O
50%	O
carriage	B-C0853960
among	O
volunteers	B-C1708335
with	O
previous	B-C0205156
natural	B-C0205296
pneumococcal	B-C0038410
carriage	B-C0853960
.	O
	
protection	B-C1545588
from	O
carriage	B-C0853960
was	O
associated	B-C0332281
with	I-C0332281
a	O
high	B-C0205250
number	O
of	O
circulating	B-C0175630
6bps	B-C0032595
igg	B-C0020852
-	O
secreting	B-C1327616
memory	B-C0682638
b	I-C0682638
cells	I-C0682638
at	O
baseline	B-C1442488
.	O
	
there	O
were	O
no	O
associations	B-C0439849
between	O
protection	B-C1545588
from	O
carriage	B-C0853960
and	O
baseline	B-C1442488
levels	B-C0441889
of	O
6bps	B-C0032595
igg	B-C0020852
in	O
serum	B-C0229671
or	O
nasal	B-C0206289
wash	I-C0206289
,	O
pspa	B-C0071312
-	O
specific	B-C0205369
,	O
or	O
pspc	B-C2000489
-	O
specific	B-C0205369
memory	B-C0682638
b	I-C0682638
cells	I-C0682638
or	O
plasma	B-C0032112
cells	I-C0032112
.	O
	
in	O
volunteers	B-C1708335
who	O
did	O
not	B-C0243095
develop	I-C0243095
carriage	B-C0853960
,	O
the	O
number	O
of	O
circulating	B-C0175630
6bps	B-C0032595
memory	B-C0682638
b	I-C0682638
cells	I-C0682638
decreased	B-C0205216
and	O
the	O
number	O
of	O
6bps	B-C0032595
plasma	B-C0032112
cells	I-C0032112
increased	B-C0205217
postinoculation	B-C0231291
.	O
	
our	O
data	O
indicate	O
that	O
naturally	B-C0205296
acquired	B-C0439661
ps	B-C0032595
-	O
specific	B-C0205369
memory	B-C0682638
b	I-C0682638
cells	I-C0682638
,	O
but	O
not	B-C0243095
levels	I-C0243095
of	O
circulating	B-C0175630
igg	B-C0020852
at	O
time	O
of	O
pneumococcal	B-C0038410
exposure	B-C0332157
,	O
are	O
associated	B-C0332281
with	I-C0332281
protection	B-C1545588
against	B-C0521124
carriage	B-C0853960
acquisition	B-C1706701
.	O
	
hounsfield	B-C1552985
unit	I-C1552985
recovery	B-C0237820
in	O
clinical	B-C0205210
cone	B-C1956110
beam	I-C1956110
ct	I-C1956110
images	B-C1551337
of	O
the	O
thorax	B-C0817096
acquired	O
for	O
image	B-C3179062
guided	I-C3179062
radiation	I-C3179062
therapy	I-C3179062
a	O
comprehensive	B-C1880156
artefact	B-C0085089
correction	B-C1947976
method	B-C0025663
for	O
clinical	B-C0205210
cone	B-C1956110
beam	I-C1956110
ct	I-C1956110
cbct	B-C1956110
images	B-C1551337
acquired	O
for	O
image	B-C3179062
guided	I-C3179062
radiation	I-C3179062
therapy	I-C3179062
igrt	B-C3179062
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O
	
the	O
method	B-C0025663
is	O
demonstrated	O
to	O
reduce	B-C0392756
artefacts	B-C0085089
and	O
recover	B-C0237820
ct	B-C0040405
-like	O
hounsfield	B-C1552985
units	I-C1552985
hu	B-C1552985
in	O
reconstructed	B-C0020912
cbct	B-C1956110
images	B-C1551337
of	O
five	O
lung	B-C0242379
cancer	I-C0242379
patients	B-C0030705
.	O
	
projection	B-C1551337
image	I-C1551337
based	O
artefact	B-C0085089
corrections	B-C1947976
of	O
image	B-C0085089
lag	I-C0085089
,	O
detector	B-C0085089
scatter	I-C0085089
,	O
body	B-C0085089
scatter	I-C0085089
and	O
beam	B-C2828112
hardening	I-C2828112
are	O
described	O
and	O
applied	O
to	O
cbct	B-C1956110
images	B-C1551337
of	O
five	O
lung	B-C0242379
cancer	I-C0242379
patients	B-C0030705
.	O
	
image	B-C0806487
quality	I-C0806487
is	O
evaluated	B-C0220825
through	O
visual	B-C0234621
appearance	B-C0700364
of	O
the	O
reconstructed	B-C0020912
images	B-C1551337
,	O
hu	B-C1552985
-correspondence	O
with	O
the	O
planning	O
ct	B-C0040405
images	B-C1551337
,	O
and	O
total	B-C0449468
volume	I-C0449468
hu	B-C1552985
error	B-C0743559
.	O
	
artefacts	B-C0085089
are	O
reduced	B-C0392756
and	O
ct	B-C0040405
-like	O
hus	B-C1552985
are	O
recovered	B-C0237820
in	O
the	O
artefact	B-C0085089
corrected	B-C0205202
cbct	B-C1956110
images	B-C1551337
.	O
	
visual	B-C3669138
inspection	I-C3669138
confirms	B-C0750484
that	O
artefacts	B-C0085089
are	O
indeed	O
suppressed	B-C1260953
by	O
the	O
proposed	O
method	B-C0025663
,	O
and	O
the	O
hu	B-C1552985
root	B-C2347976
mean	I-C2347976
square	I-C2347976
difference	B-C1705241
between	O
reconstructed	B-C0020912
cbcts	B-C1956110
and	O
the	O
reference	B-C1706462
ct	B-C0040405
images	B-C1551337
are	O
reduced	B-C0392756
by	O
31%	O
when	O
using	O
the	O
artefact	B-C0085089
corrections	B-C1947976
compared	B-C1707455
to	O
the	O
standard	B-C1442989
clinical	B-C0205210
cbct	B-C1956110
reconstruction	B-C0020912
.	O
	
a	O
versatile	O
artefact	B-C0085089
correction	B-C1947976
method	B-C0025663
for	O
clinical	B-C0205210
cbct	B-C1956110
images	B-C1551337
acquired	O
for	O
igrt	B-C3179062
has	O
been	O
developed	O
.	O
	
hu	B-C1552985
values	B-C1522609
are	O
recovered	B-C0237820
in	O
the	O
corrected	B-C0205202
cbct	B-C1956110
images	B-C1551337
.	O
	
the	O
proposed	O
method	B-C0025663
relies	O
on	O
post	B-C0449935
processing	I-C0449935
of	O
clinical	B-C0205210
projection	B-C1551337
images	I-C1551337
,	O
and	O
does	O
not	O
require	O
patient	B-C0030705
specific	B-C0205369
optimisation	B-C2698650
.	O
	
it	O
is	O
thus	O
a	O
powerful	O
tool	B-C0037589
for	O
image	B-C1551337
quality	B-C0332306
improvement	B-C2986411
of	O
large	B-C0549177
numbers	B-C0237753
of	O
cbct	B-C1956110
images	B-C1551337
.	O
	
risk	B-C0035648
factors	I-C0035648
for	O
infection	B-C3714514
after	O
knee	B-C1304878
arthroscopy	I-C1304878
analysis	B-C0936012
of	O
595	O
cases	B-C0868928
from	O
3	O
united	B-C0041703
states	I-C0041703
databases	B-C0242356
to	O
identify	B-C0205396
and	O
quantify	B-C1709793
patient-	B-C0035648
and	O
procedure-related	B-C0035648
risk	I-C0035648
factors	I-C0035648
for	O
post-arthroscopic	B-C1254367
knee	B-C1400580
infections	I-C1400580
using	O
a	O
large	O
dataset	B-C0150098
.	O
	
an	O
administrative	B-C0242356
health	I-C0242356
care	I-C0242356
database	I-C0242356
including	O
8	O
years	B-C0439234
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	B-C0021675
and	O
medicare	B-C0018717
a	O
5%	O
random	B-C0150105
sample	I-C0150105
was	O
queried	O
to	O
identify	O
all	O
knee	B-C1304878
arthroscopies	I-C1304878
performed	B-C0884358
on	O
patients	B-C0030705
aged	B-C0001779
at	O
least	O
15	O
years	B-C0439234
using	O
current	B-C1136322
procedural	I-C1136322
terminology	I-C1136322
cpt	I-C1136322
codes	I-C1136322
.	O
	
each	O
cpt	B-C1136322
code	I-C1136322
was	O
designated	O
as	O
a	O
high-	B-C1292781
or	O
low-complexity	B-C1292781
procedure	I-C1292781
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	B-C0184898
or	O
increased	O
operative	B-C3494201
time	I-C3494201
.	O
	
deep	O
infections	B-C3714514
were	O
identified	O
by	O
a	O
cpt	B-C1136322
code	I-C1136322
for	O
incision	B-C0184898
and	O
drainage	B-C0013103
within	O
90	O
days	B-C0439228
of	O
surgery	B-C0038895
.	O
	
superficial	B-C3714514
infections	I-C3714514
were	O
identified	O
by	O
international	B-C2346503
classification	I-C2346503
of	I-C2346503
diseases	I-C2346503
,	O
ninth	I-C2346503
revision	I-C2346503
infection	I-C2346503
codes	I-C2346503
without	O
any	O
record	B-C0034869
of	O
incision	B-C0184898
and	O
drainage	B-C0013103
.	O
	
patients	B-C0030705
were	O
compared	O
based	O
on	O
age	B-C0001779
,	O
sex	B-C1522384
,	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
,	O
tobacco	B-C0543414
use	I-C0543414
,	O
presence	B-C3854307
of	O
diabetes	B-C0011847
,	O
and	O
charlson	B-C1516737
comorbidity	I-C1516737
index	I-C1516737
.	O
	
a	O
total	O
of	O
526	O
patients	B-C0030705
underwent	O
595	O
arthroscopic	B-C1304878
knee	I-C1304878
procedures	I-C1304878
.	O
	
deep	O
postoperative	B-C0392618
infections	I-C0392618
occurred	O
at	O
a	O
rate	O
of	O
0.22	O
.	O
	
superficial	B-C3714514
infections	I-C3714514
occurred	O
at	O
a	O
rate	O
of	O
0.29	O
.	O
	
tobacco	B-C0543414
use	I-C0543414
and	O
morbid	B-C0028756
obesity	I-C0028756
were	O
the	O
largest	O
risk	B-C0035648
factors	I-C0035648
for	O
deep	B-C3714514
and	O
superficial	B-C3714514
infections	I-C3714514
,	O
respectively	O
p	O
<	O
001	O
relative	B-C0242492
risk	I-C0242492
of	O
1.90	O
and	O
2.19	O
,	O
respectively	O
.	O
	
there	O
were	O
also	O
higher	O
infection	B-C3714514
rates	I-C3714514
among	O
patients	B-C0030705
undergoing	O
relatively	O
high-complexity	B-C1304878
arthroscopies	I-C1304878
,	O
men	B-C0025266
,	O
obese	B-C0028754
patients	B-C0030705
,	O
diabetic	B-C0011847
patients	B-C0030705
,	O
and	O
younger	B-C0332239
patients	B-C0030705
in	O
order	O
of	O
decreasing	O
relative	B-C0242492
risk	I-C0242492
.	O
	
increased	O
charlson	B-C1516737
comorbidity	I-C1516737
index	I-C1516737
was	O
associated	B-C0332281
with	I-C0332281
superficial	B-C3714514
and	O
total	B-C3714514
infections	I-C3714514
p	O
<	O
001	O
.	O
	
post-arthroscopic	B-C1254367
knee	B-C1400580
infections	I-C1400580
were	O
more	O
frequent	O
among	O
morbidly	B-C0028756
obese	I-C0028756
patients	B-C0030705
,	O
tobacco	B-C3853727
users	I-C3853727
,	O
patients	B-C0030705
undergoing	O
relatively	O
complex	B-C1292781
procedures	I-C1292781
,	O
men	B-C0025266
,	O
obese	B-C0030705
patients	I-C0030705
,	O
diabetic	B-C0030705
patients	I-C0030705
,	O
relatively	O
young	B-C0030705
patients	I-C0030705
,	O
and	O
patients	B-C0030705
with	O
increased	O
comorbidity	B-C0009488
burdens	O
in	O
this	O
study	O
population	B-C0032659
.	O
	
this	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative	B-C0920638
counseling	I-C0920638
,	O
aid	B-C0582175
surgeons	I-C0582175
in	O
patient	B-C0242802
selection	I-C0242802
,	O
and	O
facilitate	O
infection	B-C0547605
prevention	I-C0547605
by	O
targeting	O
individuals	B-C0237401
with	O
higher	O
inherent	B-C0035647
risk	I-C0035647
.	O
	
level	O
iv	O
,	O
cross-sectional	B-C0010362
study	I-C0010362
.	O
	
association	B-C0439849
of	O
prenatal	B-C0678804
and	O
early	O
life	O
exposure	B-C0332157
to	I-C0332157
tetrachloroethylene	B-C0039637
pce	B-C0039637
with	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
and	O
other	O
reproductive	B-C1659749
disorders	I-C1659749
in	O
the	O
cape	B-C0017446
cod	I-C0017446
health	B-C0008972
study	I-C0008972
a	O
retrospective	B-C0035363
cohort	I-C0035363
study	I-C0035363
tetrachloroethylene	B-C0039637
pce	B-C0039637
is	O
an	O
organic	B-C0747055
lipophilic	B-C0598631
solvent	B-C0037638
with	O
possible	O
neuroendocrine	B-C0027912
toxicity	B-C0040539
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
the	O
association	B-C0439849
of	O
prenatal	B-C0678804
and	O
early	B-C0599196
childhood	I-C0599196
exposure	B-C0332157
to	I-C0332157
pce	B-C0039637
-	O
contaminated	B-C0205279
drinking	B-C0599638
water	I-C0599638
and	O
development	B-C0243107
of	O
adult-onset	B-C1853562
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
pcos	B-C0032460
,	O
endometriosis	B-C0014175
,	O
difficulty	B-C0013418
conceiving	I-C0013418
and	O
miscarriage	B-C0000786
.	O
	
five-hundred	O
exposed	B-C0332157
and	O
331	O
unexposed	B-C2349018
female	B-C0086287
participants	B-C0679646
born	O
between	O
1969	O
and	O
1983	O
completed	B-C0205197
questionnaires	B-C0034394
on	O
demographic	B-C0011292
and	O
lifestyle	B-C0023676
characteristics	B-C1521970
,	O
and	O
reproductive	B-C1659749
disorders	I-C1659749
.	O
	
residential	B-C0442506
locations	I-C0442506
from	O
the	O
prenatal	B-C0678804
period	B-C1948053
through	O
five	O
years	O
of	O
age	B-C0001779
were	O
used	O
to	O
estimate	B-C0750572
early	O
life	O
pce	B-C0039637
exposure	B-C0332157
with	O
water	B-C0037585
modeling	I-C0037585
software	I-C0037585
.	O
	
for	O
any	O
early	O
life	O
exposure	B-C0332157
to	I-C0332157
pce	B-C0039637
,	O
the	O
adjusted	B-C0242492
risk	I-C0242492
ratio	I-C0242492
for	O
pcos	B-C0032460
was	O
0.9	O
95%	O
ci	B-C0009667
0.5	O
.	O
	
no	O
statistically	B-C0237881
significan	I-C0237881
t	O
associations	B-C0439849
were	O
observed	B-C1441672
for	O
increasing	B-C0442808
levels	B-C0441889
of	O
exposure	B-C0332157
with	O
pcos	B-C0032460
or	O
the	O
other	O
reproductive	B-C1659749
disorders	I-C1659749
.	O
	
no	O
meaningful	O
associations	B-C0439849
were	O
found	B-C0150312
among	O
adult	B-C0001675
women	B-C0043210
with	O
early	O
life	O
exposure	B-C0332157
to	I-C0332157
pce	B-C0039637
-	O
contaminated	B-C0205279
drinking	B-C0599638
water	I-C0599638
and	O
adult-onset	B-C1853562
reproductive	B-C1659749
disorders	I-C1659749
.	O
	
host	B-C0032098
plant	I-C0032098
affects	O
the	O
sexual	B-C0029235
attractiveness	I-C0029235
of	O
the	O
female	B-C0086287
white-spotted	B-C0009276
longicorn	I-C0009276
beetle	I-C0009276
,	O
anoplophora	B-C1229576
malasiaca	I-C1229576
anoplophora	B-C1229576
malasiaca	I-C1229576
coleoptera	B-C0009276
cerambycidae	B-C1005233
is	O
a	O
serious	O
pest	O
that	O
destroys	O
various	O
landscape	B-C0870781
and	O
crop	B-C0242775
trees	B-C0040811
in	O
japan	B-C0022341
.	O
	
we	O
evaluated	O
the	O
precopulatory	B-C0205556
responses	B-C0871261
of	O
three	O
different	O
a	B-C1229576
.	O
	
malasiaca	I-C1229576
populations	B-C1257890
collected	O
from	O
mandarin	B-C0884217
orange	I-C0884217
,	O
willow	B-C0995181
and	O
blueberry	B-C0950036
trees	I-C0950036
.	O
	
most	O
of	O
the	O
males	B-C0086582
accepted	O
mates	O
from	O
within	O
the	O
same	O
host	B-C0032098
plant	I-C0032098
population	B-C1257890
as	O
well	O
as	O
females	B-C0086287
from	O
the	O
willow	B-C0995181
and	O
blueberry	B-C0950036
populations	B-C0032659
.	O
	
however	O
,	O
significant	O
number	O
of	O
males	B-C0086582
from	O
the	O
blueberry	B-C0950036
and	O
willow	B-C0995181
populations	B-C1257890
rejected	O
females	B-C0086287
from	O
the	O
mandarin	B-C0884217
orange	I-C0884217
population	B-C0032659
immediately	O
after	O
touching	O
them	O
with	O
their	O
antennae	B-C2936203
.	O
	
because	O
all	O
three	O
of	O
the	O
female	B-C0086287
populations	B-C1257890
produced	O
contact	O
sex	B-C0036863
pheromones	I-C0036863
on	O
their	O
elytra	B-C0229962
,	O
the	O
females	B-C0086287
of	O
the	O
mandarin	B-C0884217
orange	I-C0884217
population	B-C0032659
were	O
predicted	O
to	O
possess	O
extra	O
chemicals	B-C0220806
that	O
repelled	O
the	O
males	B-C0086582
of	O
the	O
other	O
two	O
populations	B-C0032659
.	O
	
β-elemene	B-C1101268
was	O
identified	O
as	O
a	O
key	O
component	O
that	O
was	O
only	O
found	O
in	O
mandarin	B-C0884217
orange	I-C0884217
-fed	O
females	B-C0086287
and	O
induced	O
a	O
rejection	B-C1548437
response	B-C0871261
in	O
willow	B-C0995181
-fed	O
males	B-C0086582
.	O
	
our	O
results	O
represent	O
the	O
first	O
example	O
of	O
a	O
female	B-C0086287
-acquired	O
repellent	B-C0544309
against	O
conspecific	O
males	B-C0086582
of	O
different	O
host	B-C0032098
plant	I-C0032098
populations	B-C0032659
,	O
indicating	O
that	O
the	O
host	B-C0032098
plant	I-C0032098
greatly	O
affects	O
the	O
female's	B-C0086287
sexual	B-C0029235
attractiveness	I-C0029235
.	O
	
molecular	B-C1521991
detection	B-C1511790
of	O
infection	B-C3714514
homogeneity	B-C1881065
and	O
impact	B-C4049986
of	O
miltefosine	B-C0068006
treatment	B-C1522326
in	O
a	O
syrian	B-C0018561
golden	I-C0018561
hamster	I-C0018561
model	O
of	O
leishmania	B-C0023273
donovani	I-C0023273
and	O
l	B-C0023272
.	O
	
infantum	I-C0023272
visceral	B-C0023290
leishmaniasis	I-C0023290
control	B-C2587213
of	O
visceral	B-C0023290
leishmaniasis	I-C0023290
caused	O
by	O
leishmania	B-C0023272
infantum	I-C0023272
and	O
leishmania	B-C0023273
donovani	I-C0023273
primarily	O
relies	O
on	O
chemotherapy	B-C3665472
using	O
an	O
increasingly	O
compromised	B-C2945640
repertoire	O
of	O
antileishmanial	B-C0304339
compounds	I-C0304339
.	O
	
for	O
evaluation	B-C0220825
of	O
novel	B-C0205314
drugs	B-C1254351
,	O
the	O
syrian	B-C0018561
golden	I-C0018561
hamster	I-C0018561
is	O
considered	O
as	O
a	O
clinically	B-C0205210
relevant	B-C2347946
laboratory	B-C0086272
model	I-C0086272
.	O
	
in	O
this	O
study	B-C2603343
,	O
two	O
molecular	B-C1294355
parasite	I-C1294355
detection	I-C1294355
assays	I-C1294355
were	O
developed	O
targeting	B-C1521840
cathepsin-like	B-C0699919
cysteine	I-C0699919
protease	I-C0699919
b	I-C0699919
cpb	B-C0699919
dna	B-C0012854
and	O
18s	O
rrna	B-C0035701
to	O
achieve	O
absolute	B-C0205344
amastigote	B-C0686878
quantification	B-C1709793
in	O
the	O
major	O
target	B-C1521840
organs	B-C0178784
liver	B-C0023884
and	O
spleen	B-C0037993
.	O
	
both	O
quantitative	B-C1709846
pcr	I-C1709846
qpcr	B-C1709846
techniques	I-C1709846
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	B-C1707520
with	O
the	O
conventional	O
microscopic	B-C0369671
reading	I-C0369671
of	O
giemsa-stained	B-C0523205
tissue	B-C0040300
smears	B-C1272593
.	O
	
using	O
multiple	B-C0439064
single	B-C0205171
tissue	B-C0040300
pieces	I-C0040300
and	O
all	O
three	O
detection	B-C0442726
methods	B-C0025663
,	O
we	O
confirmed	O
homogeneity	B-C1881065
of	O
infection	B-C3714514
in	O
liver	B-C0023884
and	O
spleen	B-C0037993
and	O
the	O
robustness	B-C2986815
of	O
extrapolating	O
whole	B-C0005884
organ	I-C0005884
burdens	I-C0005884
from	O
a	O
small	B-C0700321
single	B-C0205171
tissue	B-C0040300
piece	I-C0040300
.	O
	
comparison	B-C1707455
of	O
pre	B-C3539075
-	O
and	O
post-treatment	B-C2709088
burdens	B-C2828008
in	O
infected	B-C0439663
hamsters	B-C0018561
using	O
the	O
three	O
detection	B-C0442726
methods	B-C0025663
consistently	O
revealed	B-C0443289
a	O
stronger	O
parasite	B-C0030498
reduction	B-C0392756
in	O
the	O
spleen	B-C0037993
compared	B-C1707455
to	O
the	O
liver	B-C0023884
,	O
indicating	O
an	O
organ	B-C0178784
-	O
dependent	B-C0851827
clearance	B-C0449297
efficacy	B-C1280519
for	O
miltefosine	B-C0068006
.	O
	
in	O
conclusion	B-C1707478
,	O
this	O
study	B-C2603343
in	O
the	O
hamster	B-C0018561
demonstrated	O
high	B-C0205250
homogeneity	B-C1881065
of	O
infection	B-C3714514
in	O
liver	B-C0023884
and	O
spleen	B-C0037993
and	O
advocates	O
the	O
use	O
of	O
molecular	B-C1521991
detection	B-C1511790
methods	B-C0025663
for	O
assessment	B-C0220825
of	O
low	B-C0205251
post-treatment	B-C2709088
tissue	B-C0040300
burdens	B-C2828008
.	O
	
approximate	B-C0332232
bayesian	B-C1553908
computation	I-C1553908
for	O
estimating	B-C0750572
number	B-C1446561
concentrations	I-C1446561
of	O
monodisperse	B-C0205556
nanoparticles	B-C1450054
in	O
suspension	B-C1382107
by	O
optical	B-C0026018
microscopy	I-C0026018
we	O
present	B-C0449450
an	O
approximate	B-C0332232
bayesian	B-C1553908
computation	I-C1553908
scheme	B-C1519193
for	O
estimating	B-C0750572
number	B-C1446561
concentrations	I-C1446561
of	O
monodisperse	B-C0205556
diffusing	B-C0012222
nanoparticles	B-C1450054
in	O
suspension	B-C1382107
by	O
optical	B-C0026018
particle	I-C0026018
tracking	I-C0026018
microscopy	I-C0026018
.	O
	
the	O
method	B-C0449851
is	O
based	B-C1705938
on	O
the	O
probability	B-C3826440
distribution	I-C3826440
of	O
the	O
time	B-C0040223
spent	B-C0680968
by	O
a	O
particle	B-C0597177
inside	B-C0205102
a	O
detection	B-C1511790
region	B-C0205147
.	O
	
we	O
validate	O
the	O
method	B-C0449851
on	O
suspensions	B-C1382107
of	O
well-controlled	B-C3853142
reference	B-C1706462
particles	B-C0597177
.	O
	
we	O
illustrate	O
its	O
usefulness	B-C3827682
with	O
an	O
application	B-C4048755
in	O
gene	B-C0017296
therapy	I-C0017296
,	O
applying	B-C4048755
the	O
method	B-C0449851
to	O
estimate	B-C0750572
number	B-C1446561
concentrations	I-C1446561
of	O
plasmid	B-C0032136
dna	B-C0012854
molecules	I-C0012854
and	O
the	O
average	B-C1510992
number	I-C1510992
of	O
dna	B-C0012854
molecules	I-C0012854
complexed	B-C1704241
with	O
liposomal	B-C0023828
drug	B-C0085104
delivery	I-C0085104
particles	B-C0597177
.	O
	
gestational	B-C0017504
age	I-C0017504
specific	O
stillbirth	B-C0595939
risk	B-C0035647
among	O
indigenous	B-C1512704
and	O
non	B-C1518422
-	O
indigenous	B-C1512704
women	B-C0043210
in	O
queensland	B-C0034391
,	O
australia	B-C0004340
a	O
population	B-C1709599
based	I-C1709599
study	I-C1709599
in	O
australia	B-C0004340
,	O
significant	O
disparity	O
persists	O
in	O
stillbirth	B-C0595939
rates	B-C1521828
between	O
aboriginal	B-C0935542
and	O
torres	B-C1257890
strait	I-C1257890
islander	I-C1257890
indigenous	B-C3826690
australian	I-C3826690
and	O
non	B-C1518422
-	O
indigenous	B-C1512704
women	B-C0043210
.	O
	
diabetes	B-C0011847
,	O
hypertension	B-C0020538
,	O
antepartum	B-C0269608
haemorrhage	I-C0269608
and	O
small-for-gestational	B-C0235991
age	I-C0235991
sga	B-C0235991
have	O
been	O
identified	B-C0205396
as	O
important	B-C3898777
contributors	O
to	O
higher	O
rates	B-C1521828
among	O
indigenous	B-C1512704
women	B-C0043210
.	O
	
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
examine	O
gestational	B-C0017504
age	I-C0017504
specific	O
risk	B-C0035647
of	O
stillbirth	B-C0595939
associated	B-C0332281
with	I-C0332281
these	O
conditions	B-C0348080
among	O
indigenous	B-C1512704
and	O
non	B-C1518422
-	O
indigenous	B-C1512704
women	B-C0043210
.	O
	
retrospective	B-C1514923
population-based	B-C1709599
study	I-C1709599
of	O
all	O
singleton	B-C1313913
births	B-C0005608
of	O
at	O
least	O
20	O
weeks	B-C0439230
gestation	B-C0032961
or	O
at	O
least	O
400	O
grams	B-C0439208
birthweight	B-C0005612
in	O
queensland	B-C0034391
between	O
july	B-C3829447
2005	O
and	O
december	B-C3830550
2011	O
using	O
data	B-C1511726
from	O
the	O
queensland	B-C0034391
perinatal	B-C0178795
data	B-C0010995
collection	I-C0010995
,	O
which	O
is	O
a	O
routinely-maintained	B-C0242356
database	I-C0242356
that	O
collects	O
data	B-C1511726
on	O
all	O
births	B-C0005608
in	O
queensland	B-C0034391
.	O
	
multivariate	B-C0206031
logistic	I-C0206031
regression	I-C0206031
was	O
used	O
to	O
calculate	O
adjusted	B-C0028873
odds	I-C0028873
ratios	I-C0028873
aor	B-C0028873
and	O
95	O
%	O
confidence	B-C0009667
intervals	I-C0009667
,	O
adjusting	O
for	O
maternal	B-C1858460
demographic	B-C0011292
and	O
pregnancy	B-C3533185
factors	I-C3533185
.	O
	
of	O
360987	O
births	B-C0005608
analysed	B-C0936012
,	O
20273	O
5.6	O
%	O
were	O
to	O
indigenous	B-C1512704
women	B-C0043210
and	O
340714	O
94.4	O
%	O
were	O
to	O
non	B-C1518422
-	O
indigenous	B-C1512704
women	B-C0043210
.	O
	
stillbirth	B-C0595939
rates	B-C1521828
were	O
7.9	O
95	O
%	O
ci	B-C0009667
6.8	O
and	O
4.1	O
95	O
%	O
ci	B-C0009667
3.9	O
per	O
1000	O
births	B-C0005608
,	O
respectively	O
.	O
	
for	O
both	O
indigenous	B-C1512704
and	O
non	B-C1518422
-	O
indigenous	B-C1512704
women	B-C0043210
across	O
most	O
gestational	B-C0439671
age	B-C0027362
groups	I-C0027362
,	O
antepartum	B-C0269608
haemorrhage	I-C0269608
,	O
sga	B-C0235991
,	O
pre-existing	B-C2114054
diabetes	I-C2114054
and	O
pre-existing	B-C2114056
hypertension	I-C2114056
were	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
risk	B-C0035647
of	O
stillbirth	B-C0595939
.	O
	
there	O
were	O
mixed	O
results	O
for	O
pre-eclampsia	B-C0032914
and	O
eclampsia	B-C0013537
and	O
a	O
consistently	O
raised	O
risk	B-C0035647
of	O
stillbirth	B-C0595939
was	O
not	O
seen	O
for	O
gestational	B-C0085207
diabetes	I-C0085207
.	O
	
this	O
study	B-C2603343
highlights	O
gestational	B-C0017504
age	I-C0017504
specific	O
stillbirth	B-C0595939
risk	B-C0035647
for	O
indigenous	B-C1512704
and	O
non	B-C1518422
-	O
indigenous	B-C1512704
women	B-C0043210
and	O
disparity	O
in	O
risk	B-C0035647
at	O
term	B-C0032961
gestations	I-C0032961
.	O
	
improving	O
access	O
to	O
and	O
utilisation	O
of	O
appropriate	B-C1548787
and	O
responsive	B-C0205342
healthcare	B-C0086388
may	O
help	O
to	O
address	O
disparities	O
in	O
stillbirth	B-C0595939
risk	B-C0035647
for	O
indigenous	B-C1512704
women	B-C0043210
.	O
	
defining	B-C0509805
,	O
describing	B-C0678257
,	O
and	O
categorizing	B-C0871968
public	B-C0699943
health	I-C0699943
infrastructure	I-C0699943
priorities	B-C0439607
for	O
tropical	B-C0337000
cyclone	I-C0337000
,	O
flood	B-C0016248
,	O
storm	B-C1254365
,	O
tornado	B-C0040476
,	O
and	O
tsunami-related	B-C0027485
disasters	I-C0027485
the	O
study	B-C2603343
aim	O
was	O
to	O
undertake	O
a	O
qualitative	O
research	O
literature	B-C0282441
review	I-C0282441
to	O
analyze	O
available	O
databases	B-C0242356
to	O
define	B-C0509805
,	O
describe	B-C0678257
,	O
and	O
categorize	B-C0871968
public	B-C0699943
health	I-C0699943
infrastructure	I-C0699943
phi	B-C0699943
priorities	B-C0439607
for	O
tropical	B-C0337000
cyclone	I-C0337000
,	O
flood	B-C0016248
,	O
storm	B-C1254365
,	O
tornado	B-C0040476
,	O
and	O
tsunami-related	B-C0027485
disasters	I-C0027485
.	O
	
five	O
electronic	O
publication	B-C0993637
databases	I-C0993637
were	O
searched	O
to	O
define	B-C0509805
,	O
describe	B-C0678257
,	O
or	O
categorize	B-C0871968
phi	B-C0699943
and	O
discuss	B-C2584313
tropical	B-C0337000
cyclone	I-C0337000
,	O
flood	B-C0016248
,	O
storm	B-C1254365
,	O
tornado	B-C0040476
,	O
and	O
tsunami-related	B-C0027485
disasters	I-C0027485
and	O
their	O
impact	B-C4049986
on	O
phi	B-C0699943
.	O
	
the	O
data	B-C1511726
were	O
analyzed	O
through	O
aggregation	B-C0332621
of	O
individual	O
articles	B-C1706852
to	O
create	O
an	O
overall	O
data	B-C1511726
description	O
.	O
	
the	O
data	O
were	O
grouped	B-C1522242
into	O
phi	B-C0699943
themes	B-C0869035
,	O
which	O
were	O
then	O
prioritized	B-C0439607
on	O
the	O
basis	O
of	O
degree	O
of	O
interdependency	O
.	O
	
sixty-seven	O
relevant	O
articles	B-C1706852
were	O
identified	O
.	O
	
phi	B-C0699943
was	O
categorized	B-C0871968
into	O
13	O
themes	B-C0869035
with	O
a	O
total	O
of	O
158	O
descriptors	B-C0282354
.	O
	
the	O
highest	O
priority	B-C0439607
phi	B-C0699943
identified	O
was	O
workforce	B-C0024752
.	O
	
this	O
was	O
followed	O
by	O
water	B-C0599638
,	O
sanitation	B-C0036172
,	O
equipment	B-C0014672
,	O
communication	B-C0009452
,	O
physical	B-C0556997
structure	I-C0556997
,	O
power	B-C0032865
,	O
governance	B-C0220842
,	O
prevention	B-C2700409
,	O
supplies	B-C1561604
,	O
service	B-C0557854
,	O
transport	B-C1317949
,	O
and	O
surveillance	B-C0220920
.	O
	
this	O
review	B-C0282443
identified	O
workforce	B-C0024752
as	O
the	O
most	O
important	O
of	O
the	O
13	O
thematic	B-C0869035
areas	I-C0869035
related	O
to	O
phi	B-C0699943
and	O
disasters	B-C0027485
.	O
	
if	O
its	O
functionality	O
fails	O
,	O
workforce	B-C0024752
has	O
the	O
greatest	O
impact	O
on	O
the	O
performance	O
of	O
health	B-C0018747
services	I-C0018747
.	O
	
if	O
addressed	O
post-disaster	B-C1254367
,	O
the	O
remaining	O
forms	O
of	O
phi	B-C0699943
will	O
then	O
be	O
progressively	O
addressed	O
.	O
	
these	O
findings	O
are	O
a	O
step	O
toward	O
providing	O
an	O
evidence	O
base	O
to	O
inform	O
phi	B-C0699943
priorities	B-C0439607
in	O
the	O
disaster	B-C0027485
fragment	B-C1335533
-based	O
discovery	B-C1880355
of	O
5-arylisatin	B-C0022115
-based	O
inhibitors	B-C1513016
of	O
matrix	B-C0172537
metalloproteinases	I-C0172537
2	I-C0172537
and	O
13	B-C0255672
matrix	B-C0623362
metalloproteinases	I-C0623362
mmps	B-C0623362
are	O
well-established	O
targets	O
for	O
several	O
pathologies	B-C0699748
.	O
	
in	O
particular	O
,	O
mmp-2	B-C0172537
and	O
mmp-13	B-C0255672
play	O
a	O
prominent	O
role	O
in	O
cancer	B-C1947901
progression	I-C1947901
.	O
	
in	O
this	O
study	B-C2603343
,	O
a	O
structure-based	B-C1710032
screening	I-C1710032
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	B-C0623362
-oriented	O
fragments	B-C1335533
.	O
	
this	O
computational	B-C0009609
model	I-C0009609
was	O
applied	O
to	O
a	O
representative	O
fragment	B-C1335533
set	B-C1705195
from	O
the	O
publically	O
available	O
edasa	B-C0282574
scientific	I-C0282574
compound	I-C0282574
library	I-C0282574
.	O
	
these	O
fragments	B-C1335533
were	O
prioritized	O
,	O
and	O
the	O
top-ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-C0005507
assay	I-C0005507
to	O
validate	B-C1519941
the	O
model	B-C0009609
.	O
	
two	O
scaffolds	B-C1179132
showed	O
consistent	O
activity	B-C0441655
in	O
the	O
assay	B-C0005507
,	O
and	O
the	O
isatin-based	B-C0022115
compounds	I-C0022115
were	O
the	O
most	O
interesting	O
.	O
	
these	O
latter	O
fragments	B-C1335533
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	B-C1707689
and	O
realization	O
of	O
novel	O
mmp	B-C1513016
inhibitors	I-C1513016
.	O
	
in	O
addition	O
to	O
their	O
micromolar	B-C0441655
activity	I-C0441655
,	O
the	O
chemical	B-C0007987
synthesis	I-C0007987
affords	O
flexible	B-C0443220
and	O
creative	B-C0444454
access	I-C0444454
to	O
their	O
incidence	B-C0021149
of	O
environmental	B-C0686732
and	O
genetic	B-C0814299
factors	I-C0814299
causing	O
congenital	B-C0009691
cataract	I-C0009691
in	O
children	B-C0008059
of	O
lahore	B-C0681784
to	O
check	O
the	O
incidence	B-C0021149
of	O
environmental	B-C0686732
and	O
genetic	B-C0814299
factors	I-C0814299
causing	O
congenital	B-C0009691
cataract	I-C0009691
in	O
infants	B-C0021270
.	O
	
the	O
descriptive	B-C0008972
study	I-C0008972
was	O
conducted	O
at	O
layton	B-C1708333
rahmatullah	I-C1708333
benevolent	I-C1708333
trust	I-C1708333
,	O
lahore	B-C0681784
,	O
pakistan	B-C0030211
,	O
from	O
october	O
2013	O
to	O
april	O
2014	O
,	O
and	O
comprised	O
children	B-C0008059
under	O
15	O
years	B-C1510829
of	O
age	B-C0001779
who	O
had	O
rubella	B-C0748452
syndrome	I-C0748452
,	O
herpes	B-C0019348
simplex	I-C0019348
,	O
birth	B-C2145877
trauma	I-C2145877
,	O
trisomy	B-C3537167
21	I-C3537167
,	O
nance-horan	B-C0796085
syndrome	I-C0796085
or	O
lowe's	B-C0028860
syndrome	I-C0028860
.	O
	
of	O
the	O
38	O
cases	B-C0021149
examined	O
,	O
120	O
patients	B-C0030705
were	O
diagnosed	B-C0011900
with	O
congenital	B-C0009691
cataract	I-C0009691
.	O
	
of	O
them	O
,	O
52	O
aged	B-C0001779
between	O
2	O
and	O
5	O
years	B-C1510829
22	O
<11	O
years	B-C1510829
and	O
10	O
15	O
years	B-C1510829
.	O
	
bilateral	B-C3277059
congenital	I-C3277059
cataract	I-C3277059
was	O
observed	O
in	O
91	O
patients	B-C0030705
and	O
unilateral	B-C3640028
congenital	I-C3640028
cataract	I-C3640028
in	O
29	O
.	O
	
environmental	B-C0686732
factors	I-C0686732
caused	O
72	O
cases	B-C0021149
and	O
genetic	B-C0814299
factors	I-C0814299
caused	O
44	O
.	O
	
congenital	B-C0009691
cataract	I-C0009691
predominated	B-C0332251
in	O
boys	B-C0870221
compared	O
to	O
girls	B-C0870604
.	O
	
early	O
diagnosis	B-C0011900
and	O
adequate	O
therapy	B-C0087111
requires	O
specific	O
technology	B-C0039421
,	O
as	O
well	O
as	O
long-term	B-C0443252
and	O
permanent	B-C0205355
care	B-C1947933
transcriptome	B-C3178810
and	O
metabolome	B-C2350399
analyses	B-C0936012
of	O
glucosinolates	B-C0017767
in	O
two	O
broccoli	B-C0330498
cultivars	I-C0330498
following	O
jasmonate	B-C1176128
treatment	B-C1522326
for	O
the	O
induction	B-C0205263
of	O
glucosinolate	B-C0017767
defense	B-C1880266
to	O
trichoplusia	B-C0998450
ni	I-C0998450
hübner	B-C0805191
lepidopteran	B-C0023338
larvae	B-C0023047
growth	B-C0018270
is	O
influenced	B-C4054723
by	O
host	B-C1167395
plant	B-C0032098
glucosinolate	B-C0017767
gs	B-C0017767
concentrations	B-C1446561
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	B-C4054723
by	O
the	O
phytohormone	B-C0032082
jasmonate	B-C1176128
ja	B-C1176128
.	O
	
in	O
order	O
to	O
elucidate	O
insect	B-C0021585
resistance	B-C4281815
biomarkers	B-C0017393
to	O
lepidopteran	B-C0023338
pests	B-C0869004
,	O
transcriptome	B-C3178810
and	O
metabolome	B-C2350399
analyses	B-C0936012
following	O
ja	B-C1176128
treatments	B-C1522326
were	O
conducted	O
with	O
two	O
broccoli	B-C0330498
cultivars	I-C0330498
,	O
green	B-C0330498
magic	I-C0330498
and	O
vi-158	B-C0330498
,	O
which	O
have	O
differentially	O
induced	B-C0205263
indole	B-C0017767
gss	I-C0017767
,	O
neoglucobrassicin	B-C2975109
and	O
glucobrassicin	B-C0061370
,	O
respectively	O
.	O
	
to	O
test	B-C0039593
these	O
two	O
inducible	B-C0205263
gss	B-C0017767
on	O
growth	B-C0018270
of	O
cabbage	B-C0684063
looper	I-C0684063
trichoplusia	B-C0998450
ni	I-C0998450
,	O
eight	O
neonate	O
cabbage	B-C0023047
looper	I-C0023047
larvae	I-C0023047
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	B-C0032098
per	O
ja	B-C1176128
treatments	B-C1522326
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µm	O
three	O
days	B-C0439228
after	O
treatment	B-C1522326
.	O
	
after	O
five	O
days	B-C0439228
of	O
feeding	B-C2987508
,	O
weight	B-C0043100
of	O
larvae	B-C0023047
and	O
their	O
survival	B-C0038954
rate	I-C0038954
was	O
found	O
to	O
decrease	B-C0547047
with	O
increasing	B-C0442805
ja	B-C1176128
concentrations	B-C1446561
in	O
both	O
broccoli	B-C0330498
cultivars	I-C0330498
.	O
	
ja	B-C1176128
-	O
inducible	B-C0205263
gss	B-C0017767
were	O
measured	B-C0444706
by	O
high	B-C0008562
performance	I-C0008562
liquid	I-C0008562
chromatography	I-C0008562
.	O
	
neoglucobrassicin	B-C2975109
in	O
green	B-C0330498
magic	I-C0330498
and	O
glucobrassicin	B-C0061370
in	O
vi-158	B-C0330498
leaves	B-C0242724
were	O
increased	B-C0205217
in	O
a	O
dose-dependent	B-C1512045
manner	O
.	O
	
one	O
or	O
both	O
of	O
these	O
glucosinolates	B-C0017767
and/or	O
their	O
hydrolysis	B-C0020291
products	B-C1514468
showed	O
significant	O
inverse	B-C0439850
correlations	B-C1707520
with	O
larval	B-C0023047
weight	B-C0043100
and	O
survival	B-C0038952
five	O
days	B-C0439228
after	O
treatment	B-C1522326
while	O
being	O
positively	B-C1446409
correlated	B-C1707520
with	O
the	O
number	O
of	O
days	B-C0439228
to	O
pupation	B-C1326578
.	O
	
this	O
implies	O
that	O
these	O
two	O
ja	B-C1176128
-	O
inducible	B-C0205263
glucosinolates	B-C0017767
can	O
influence	B-C4054723
the	O
growth	B-C0018270
and	O
survival	B-C0038952
of	O
cabbage	B-C0023047
looper	I-C0023047
larvae	I-C0023047
.	O
	
transcriptome	B-C0752248
profiling	I-C0752248
supported	O
the	O
observed	O
changes	B-C0392747
in	O
glucosinolate	B-C0017767
and	O
their	O
hydrolysis	B-C0020291
product	B-C1514468
concentrations	B-C1446561
following	O
ja	B-C1176128
treatments	B-C1522326
.	O
	
several	O
genes	B-C0017337
related	O
to	O
gs	B-C0017767
metabolism	B-C0025519
differentiate	B-C2945687
the	O
two	O
broccoli	B-C0330498
cultivars	I-C0330498
in	O
their	O
pattern	B-C0449774
of	O
transcriptional	B-C0040649
response	B-C0871261
to	O
ja	B-C1176128
treatments	B-C1522326
.	O
	
indicative	O
of	O
the	O
corresponding	O
change	B-C0392747
in	O
indole	B-C0017767
gs	I-C0017767
concentrations	B-C1446561
,	O
transcripts	B-C1519595
of	O
the	O
transcription	B-C0040648
factor	I-C0040648
myb122	B-C0040648
,	O
core	O
structure	O
biosynthesis	B-C0005572
genes	B-C0017337
cyp79b2	B-C0017337
,	O
ugt74b1	B-C0017337
,	O
sur1	B-C1412082
,	O
sot16	B-C0017337
,	O
sot17	B-C0017337
,	O
and	O
sot18	B-C0017337
,	O
an	O
indole	B-C1254350
glucosinolate	I-C1254350
side	O
chain	O
modification	B-C3840684
gene	B-C0017337
igmt1	B-C0017337
,	O
and	O
several	O
glucosinolate	B-C0017767
hydrolysis	B-C0020291
genes	O
tgg1	B-C0017337
,	O
tgg2	B-C0017337
,	O
and	O
esm1	B-C1414460
were	O
significantly	O
increased	B-C0205217
in	O
green	B-C0330498
magic	I-C0330498
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µm	O
while	O
ugt74b1	B-C0017337
and	O
myb122	B-C0017337
were	O
significantly	O
increased	B-C0205217
in	O
vi-158	B-C0330498
.	O
	
therefore	O
,	O
these	O
metabolite	B-C0870883
and	O
transcript	B-C1519595
biomarker	B-C0017393
results	O
indicate	O
that	O
transcriptome	B-C0752248
profiling	I-C0752248
can	O
identify	B-C0205396
genes	B-C0017337
associated	O
with	O
the	O
formation	B-C1522492
of	O
two	O
different	O
indole	B-C0017767
gs	I-C0017767
and	O
their	O
hydrolysis	B-C0020291
products	B-C1514468
.	O
	
therefore	O
,	O
these	O
metabolite	B-C0870883
and	O
transcript	B-C1519595
biomarkers	B-C0017393
could	O
be	O
useful	O
in	O
an	O
effective	B-C1704419
marker	B-C0017393
-	O
assisted	B-C1269765
breeding	B-C0006159
strategy	O
for	O
resistance	B-C4281815
to	O
generalist	O
lepidopteran	B-C0023338
pests	B-C0869004
in	O
broccoli	B-C0330498
and	O
potentially	O
other	O
brassica	B-C0453113
vegetables	I-C0453113
.	O
	
the	O
clinical	B-C1317293
prognosis	I-C1317293
of	O
implants	B-C0021102
that	O
are	O
placed	O
against	O
super-erupted	B-C3839493
opposing	O
dentition	B-C0011443
if	O
teeth	B-C0040426
are	O
missing	B-C0080233
,	O
super-eruption	B-C3839493
of	I-C3839493
teeth	I-C3839493
in	O
the	O
opposing	B-C1254362
arch	I-C1254362
can	O
occur	O
in	O
the	O
area	B-C0205146
and	O
can	O
change	O
the	O
occlusal	B-C0524544
plane	I-C0524544
.	O
	
when	O
missing	B-C0080233
teeth	I-C0080233
are	O
replaced	O
with	O
implants	B-C0021102
,	O
the	O
oral	B-C0260272
surgeon	I-C0260272
must	O
determine	O
whether	O
or	O
not	O
the	O
super-erupted	B-C0040426
teeth	I-C0040426
need	O
to	O
be	O
treated	B-C1522326
in	O
order	O
to	O
normalize	B-C1882115
the	O
occlusal	B-C0524544
plane	I-C0524544
.	O
	
in	O
this	O
study	B-C0008972
,	O
we	O
evaluated	B-C0220825
the	O
clinical	B-C1317293
prognosis	I-C1317293
of	O
dentition	B-C0011443
after	O
implant	B-C0021107
placement	I-C0021107
and	O
prosthetic	B-C0204076
treatment	I-C0204076
were	O
completed	B-C0205197
in	O
an	O
occlusal	B-C0524544
plane	I-C0524544
altered	O
by	O
super-erupted	B-C0040426
teeth	I-C0040426
in	O
the	O
opposing	B-C1254362
arch	I-C1254362
without	O
additional	O
treatment	B-C1522326
of	O
the	O
super-erupted	B-C0040426
teeth	I-C0040426
.	O
	
twenty-two	O
patients	B-C0030705
9	O
males	B-C0086582
,	O
13	O
females	B-C0086287
were	O
treated	B-C1522326
with	O
implants	B-C0021102
and	O
prosthetics	B-C0175649
without	O
addressing	O
the	O
super-erupted	B-C3839493
opposing	O
dentition	B-C0011443
from	O
april	O
2004	O
to	O
august	O
2012	O
at	O
seoul	B-C3850150
national	B-C0019994
university	I-C0019994
bundang	I-C0019994
hospital	I-C0019994
.	O
	
a	O
total	O
of	O
33	O
implants	B-C0021102
were	O
placed	O
.	O
	
values	O
of	O
crestal	B-C0002382
bone	I-C0002382
loss	I-C0002382
,	O
survival	B-C0038954
rates	I-C0038954
,	O
and	O
surgical	B-C0274311
and	O
prosthetic	B-C0274320
complications	I-C0274320
for	O
an	O
average	O
of	O
29.6	O
months	B-C0439231
after	O
prosthetic	B-C0204076
loading	I-C0204076
were	O
recorded	O
.	O
	
in	O
one	O
case	B-C1706256
,	O
the	O
cover	B-C0021102
screw	I-C0021102
was	O
exposed	O
after	O
implant	B-C0543467
surgery	I-C0543467
.	O
	
the	O
mean	O
crestal	B-C0002382
bone	I-C0002382
loss	I-C0002382
was	O
0.09	O
mm	O
.	O
	
of	O
the	O
33	O
implants	B-C0021102
,	O
31	O
survived	B-C3179277
,	O
a	O
survival	B-C0038954
rate	I-C0038954
of	O
93.94	O
.	O
	
a	O
prosthetic	B-C0274320
complication	I-C0274320
occurred	O
in	O
one	O
case	B-C1706256
but	O
functioned	O
well	O
after	O
correction	O
.	O
	
favorable	O
clinical	B-C0456984
results	I-C0456984
from	O
prosthetic	B-C0274320
complications	I-C0274320
,	O
crestal	B-C0002382
bone	I-C0002382
loss	I-C0002382
,	O
and	O
implant	B-C0021102
survival	B-C0038954
rates	I-C0038954
were	O
exhibited	O
in	O
implants	B-C0021102
next	O
to	O
a	O
super-erupted	B-C0040426
opposing	I-C0040426
tooth	I-C0040426
.	O
	
evaluation	B-C0034375
of	O
mathisen's	B-C0449851
technique	I-C0449851
for	O
ureteral	B-C0401287
reimplantation	I-C0401287
in	O
children	B-C0008059
with	O
primary	B-C0205225
vesicoureteral	B-C0042580
reflux	I-C0042580
although	O
cross-trigonal	B-C0401296
ureteral	I-C0401296
reimplantation	I-C0401296
cohen	I-C0401296
is	O
a	O
commonly	O
used	O
technique	B-C0449851
in	O
children	B-C0008059
,	O
it	O
represents	O
a	O
non-physiological	B-C0025361
transfer	I-C0025361
of	O
the	O
ureteral	B-C0447577
orifices	I-C0447577
and	O
may	O
prove	O
challenging	O
with	O
regard	O
to	O
endoscopic	B-C0401343
ureteral	I-C0401343
operations	I-C0401343
in	O
later	B-C0205087
life	B-C0376558
.	O
	
in	O
1964	O
,	O
mathisen	O
described	B-C1552738
an	O
alternative	B-C1523987
method	B-C0449851
of	O
ureteral	B-C0401287
reimplantation	I-C0401287
with	O
lateralization	B-C0542341
of	O
the	O
neohiatus	B-C1254362
,	O
creating	O
an	O
orthotopic	B-C0574893
course	B-C0750729
of	O
the	O
submucosal	B-C0227684
ureter	I-C0227684
.	O
	
we	O
have	O
evaluated	B-C1516048
success	B-C0679864
and	O
complication	B-C2362589
rates	B-C1521828
of	O
both	O
techniques	B-C0449851
that	O
were	O
applied	B-C4048755
sequentially	B-C1519249
at	O
our	O
departments	B-C1704729
.	O
	
forty-eight	O
consecutive	B-C1707491
patients	B-C0030705
83	O
ureters	B-C2348561
,	O
24	O
males	B-C0025266
/24	O
females	B-C0043210
following	O
mathisen	B-C0401287
reimplantation	I-C0401287
were	O
compared	B-C1707455
with	O
53	O
consecutive	B-C1707491
patients	B-C0030705
98	O
ureters	B-C2348561
,	O
30	O
males	B-C0025266
/23	O
females	B-C0043210
following	O
cohen	B-C0401296
reimplantation	I-C0401296
.	O
	
inclusion	B-C1512693
criteria	B-C0243161
were	O
primary	B-C0205225
vesicoureteral	B-C0042580
reflux	I-C0042580
vur	B-C0042580
and	O
no	O
previous	B-C0205156
intervention	B-C0184661
.	O
	
reflux	B-C0042580
grades	B-C1511980
mathisen	O
58	O
ureters	B-C2348561
/69	O
vur	B-C3274338
iii	I-C3274338
cohen	O
66	O
ureters	B-C2348561
/66	O
vur	B-C3274338
iii	I-C3274338
and	O
the	O
occurence	O
of	O
other	O
complicating	B-C1522701
factors	B-C1521761
ureteroceles	B-C0041960
,	O
megaureters	B-C0521620
,	O
posterior	B-C0238506
urethral	I-C0238506
valves	I-C0238506
in	O
both	O
groups	B-C0441833
were	O
comparable	B-C1707455
.	O
	
after	O
cohen's	B-C0401296
reimplantation	I-C0401296
there	O
were	O
no	O
immediate	B-C0205253
complications	B-C0009566
requiring	O
intervention	B-C0184661
during	B-C0347984
follow-up	B-C1522577
mean	B-C0444504
28.2	O
months	B-C0439231
three	O
patients	B-C0030705
5.6	O
suffered	B-C0683278
febrile	B-C3875265
urinary	I-C3875265
tract	I-C3875265
infections	I-C3875265
utis	B-C3875265
,	O
of	O
which	O
one	O
1.8	O
was	O
diagnosed	B-C0011900
with	O
a	O
persisting	B-C0549178
vur	B-C0042580
.	O
	
persistent	B-C0549178
hydronephroses	B-C0020295
ii	O
sfu	B-C0020295
were	O
recorded	O
in	O
six	O
patients	B-C0030705
13.2	O
.	O
	
after	O
reimplantation	B-C0401287
using	O
mathisen's	B-C0449851
technique	I-C0449851
,	O
two	O
patients	B-C0030705
4.1	O
suffered	B-C0683278
significant	B-C0750502
intravesical	B-C1390213
bleeding	I-C1390213
during	O
follow-up	B-C1522577
mean	B-C0444504
23.06	O
months	B-C0439231
four	O
patients	B-C0030705
8.3	O
suffered	B-C0683278
febrile	B-C3875265
utis	I-C3875265
,	O
and	O
seven	O
patients	B-C0030705
14.5	O
were	O
diagnosed	B-C0011900
with	O
persisting	B-C0549178
vur	B-C0042580
after	O
a	O
mean	B-C0444504
follow-up	B-C1522577
of	O
10.8	O
months	B-C0439231
.	O
	
the	O
patients	B-C0030705
with	O
persistent	B-C0549178
vur	B-C0042580
had	O
more	O
commonly	O
high-grade	B-C0205556
iv	O
and	O
v	O
vur	B-C0042580
initially	O
,	O
compared	B-C1707455
to	O
the	O
whole	B-C0441833
group	I-C0441833
.	O
	
two	O
patients	B-C0030705
4.1	O
had	O
persistent	B-C0549178
hydronephroses	B-C0020295
ii	O
sfu	B-C0020295
.	O
	
mathisen's	B-C0449851
technique	I-C0449851
for	O
ureteral	B-C0401287
reimplantation	I-C0401287
yielded	O
a	O
significantly	B-C0750502
p	O
=	O
0.0256	O
patients	B-C0030705
,	O
p	O
=	O
0.006	O
ureterorenal	B-C1519795
units	I-C1519795
lower	B-C0441994
success	B-C0679864
rate	B-C1521828
85.5	O
patients	B-C0030705
,	O
89.2	O
ureterorenal	B-C1519795
units	I-C1519795
in	O
comparison	B-C1707455
with	O
cohen's	B-C0449851
technique	I-C0449851
98.2	O
patients	B-C0030705
,	O
99%	O
ureterorenal	B-C1519795
units	I-C1519795
.	O
	
although	O
there	O
was	O
no	O
intervention	B-C0184661
for	O
obstruction	B-C0028778
,	O
persistent	B-C0549178
hydronephrosis	B-C0020295
was	O
more	O
common	O
in	O
the	O
cohen	B-C0441833
group	I-C0441833
13.2	O
vs	O
.	O
	
4.1	O
,	O
n.s	O
.	O
	
despite	O
the	O
advantages	O
of	O
an	O
orthotopic	B-C0574893
ureteral	B-C0447577
orifice	I-C0447577
close	O
to	O
the	O
bladder	B-C0227716
neck	I-C0227716
,	O
as	O
achieved	O
by	O
mathisen's	B-C0401287
reimplantation	I-C0401287
,	O
cross-trigonal	B-C0401296
ureteral	I-C0401296
reimplantation	I-C0401296
proved	O
more	O
reliable	B-C3858758
for	O
vur	B-C0042580
correction	B-C1947976
.	O
	
as	O
regards	O
optimizing	O
the	O
results	O
,	O
patient	B-C0242802
selection	I-C0242802
for	O
either	O
technique	B-C0449851
could	O
prove	B-C0205224
essential	I-C0205224
.	O
	
nevertheless	O
,	O
as	O
regards	O
the	O
difficulties	B-C0332218
with	O
ectopic	B-C0574895
ureteral	B-C0447577
orifices	I-C0447577
in	O
the	O
cohen	B-C0449851
technique	I-C0449851
in	O
the	O
long-term	B-C0443252
follow-up	B-C1522577
,	O
the	O
concept	B-C0178566
of	O
anatomic	B-C0220784
,	O
orthotopic	B-C0574893
ureteral	B-C0401287
reimplantation	I-C0401287
should	O
be	O
pursued	O
and	O
the	O
technique	B-C0449851
the	O
use	B-C1524063
of	I-C1524063
neonatal	B-C2939425
extracorporeal	B-C0015357
life	I-C0015357
support	I-C0015357
in	O
pediatric	B-C1521725
cardiac	B-C0587446
intensive	I-C0587446
care	I-C0587446
unit	I-C0587446
the	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-C0220825
extracorporeal	B-C0015357
life	I-C0015357
support	I-C0015357
system	I-C0015357
ecls	B-C0015357
employed	O
in	O
neonates	B-C0021289
in	O
pediatric	B-C1521725
cardiac	B-C0587446
intensive	I-C0587446
care	I-C0587446
unit	I-C0587446
.	O
	
twenty-five	O
neonates	B-C0021289
that	O
required	O
ecls	B-C0015357
in	O
between	O
november	O
2010	O
and	O
november	O
2015	O
were	O
evaluated	B-C0220825
.	O
	
the	O
median	B-C0876920
age	B-C0001779
was	O
12	O
days	B-C0439228
range	B-C1514721
3-28	O
days	B-C0439228
and	O
the	O
median	B-C0876920
body	B-C0005910
weight	I-C0005910
was	O
3	O
kg	O
range	B-C1514721
2.5	O
kg	O
.	O
	
venoarterial	B-C0450124
ecls	B-C0015357
was	O
performed	B-C0884358
in	O
all	O
of	O
the	O
cases	O
.	O
	
ascendan	B-C0003956
aorta	I-C0003956
-	O
right	B-C0225844
atrial	I-C0225844
cannulation	B-C0917707
in	O
22	O
patients	B-C0030705
and	O
neck	B-C0027530
cannulation	B-C0917707
in	O
three	O
patients	B-C0030705
were	O
performed	B-C0884358
.	O
	
the	O
reason	O
for	O
ecls	B-C0015357
was	O
e-cpr	B-C0007203
in	O
two	O
patients	B-C0030705
,	O
inability	B-C0243095
to	I-C0243095
wean	I-C0243095
from	O
cardiopulmonary	B-C0007202
bypass	I-C0007202
cpb	B-C0007202
in	O
seven	O
patients	B-C0030705
,	O
respiratory	B-C0035229
insufficiency	I-C0035229
and	O
hypoxia	B-C0242184
in	O
nine	O
patients	B-C0030705
,	O
low	B-C0600177
cardiac	I-C0600177
output	I-C0600177
lcos	B-C0600177
in	O
seven	O
patients	B-C0030705
.	O
	
median	B-C0876920
duration	B-C0449238
of	O
ecls	B-C0015357
was	O
four	O
days	B-C0439228
range	B-C1514721
1-15	O
.	O
	
hemorrhagic	B-C0333275
complications	B-C0009566
developed	O
in	O
15	O
,	O
renal	B-C1408259
complications	I-C1408259
in	O
13	O
,	O
pulmonary	B-C0281169
complications	I-C0281169
in	O
12	O
,	O
infectious	B-C0009450
complications	B-C0009566
in	O
11	O
,	O
neurologic	B-C0235029
complications	I-C0235029
in	O
three	O
and	O
mechanical	B-C0009566
complications	I-C0009566
in	O
two	O
of	O
the	O
patients	B-C0030705
.	O
	
weaning	B-C0043084
was	O
successful	B-C1272703
in	O
15	O
of	O
the	O
patients	B-C0030705
.	O
	
eleven	O
patients	B-C0030705
were	O
successfully	B-C1272703
discharged	B-C0030685
.	O
	
ecls	B-C0015357
is	O
an	O
important	B-C3898777
treatment	B-C0683525
option	I-C0683525
that	O
is	O
performed	B-C0884358
successfully	B-C1272703
in	O
many	O
centers	B-C0475309
around	O
the	O
world	B-C2700280
to	O
maintain	B-C0024501
life	B-C0521300
support	I-C0521300
in	O
patients	B-C0030705
unresponsive	B-C0205269
to	I-C0205269
medical	I-C0205269
treatment	I-C0205269
.	O
	
the	O
utilization	B-C0042153
of	O
this	O
modality	B-C0695347
especially	O
in	O
newborns	B-C0021289
with	O
congenital	B-C0152021
heart	I-C0152021
disease	I-C0152021
medicare	B-C0018717
claims	B-C3242446
indicators	B-C1522602
of	O
healthcare	B-C0086388
utilization	B-C0042153
differences	B-C1705242
after	O
hospitalization	B-C0019993
for	O
ischemic	B-C0948008
stroke	I-C0948008
race	B-C0034510
,	O
gender	B-C0079399
,	O
and	O
caregiving	B-C1947933
effects	B-C1280500
background	B-C1706907
differences	B-C1705242
in	O
healthcare	B-C0086388
utilization	B-C0042153
after	O
stroke	B-C0948008
may	O
partly	O
explain	O
race	B-C0034510
or	O
gender	B-C0079399
differences	B-C1705242
in	O
stroke	B-C0948008
outcomes	O
and	O
identify	O
factors	B-C1521761
that	O
might	O
reduce	B-C0392756
post	B-C0687676
-	O
acute	B-C0751956
stroke	I-C0751956
care	B-C0086600
costs	I-C0086600
.	O
	
aim	O
to	O
examine	O
systematic	B-C0220922
differences	B-C1705242
in	O
medicare	B-C0018717
claims	B-C3242446
for	O
healthcare	B-C0086388
utilization	B-C0042153
after	O
hospitalization	B-C0019993
for	O
ischemic	B-C0948008
stroke	I-C0948008
in	O
a	O
us	B-C0041703
population	B-C1257890
-based	O
sample	B-C0681850
.	O
	
methods	O
claims	B-C3242446
were	O
examined	B-C0332128
over	O
a	O
six-month	B-C0439231
period	B-C1948053
after	O
hospitalization	B-C0019993
for	O
279	O
ischemic	B-C0948008
stroke	I-C0948008
survivors	B-C0206194
65	O
years	B-C0439234
or	O
older	B-C0001792
from	O
the	O
reasons	B-C0392360
for	O
geographic	B-C1171306
and	O
racial	B-C0682075
differences	I-C0682075
in	O
stroke	B-C0948008
regards	B-C0948008
study	O
.	O
	
statistical	B-C0871424
analyses	I-C0871424
examined	B-C0332128
differences	B-C1705242
in	O
post	B-C0687676
-	O
acute	B-C0679878
healthcare	I-C0679878
utilization	B-C0042153
,	O
adjusted	O
for	O
pre	B-C0332152
-	O
stroke	B-C0948008
utilization	B-C0042153
,	O
as	O
a	O
function	B-C0542341
of	O
race	B-C0034510
african-american	B-C0085756
vs	O
.	O
	
white	B-C0007457
,	O
gender	B-C0079399
,	O
age	B-C0001779
,	O
stroke	B-C0681784
belt	I-C0681784
residence	B-C0237096
,	O
income	B-C0021162
,	O
medicaid	B-C3494385
dual-eligibility	I-C3494385
,	O
charlson	B-C3714916
comorbidity	I-C3714916
index	I-C3714916
,	O
and	O
whether	O
the	O
person	B-C0027361
lived	B-C2982691
with	O
an	O
available	B-C0470187
caregiver	B-C0085537
.	O
	
results	O
after	O
adjusting	O
for	O
covariates	O
,	O
women	B-C0043210
were	O
more	O
likely	O
than	O
men	B-C0025266
to	O
receive	B-C1514756
home	B-C3845073
health	I-C3845073
care	I-C3845073
and	O
to	O
use	O
emergency	B-C0374899
department	I-C0374899
services	I-C0374899
during	O
the	O
post	B-C0687676
-	O
acute	B-C0679878
care	I-C0679878
period	B-C1948053
.	O
	
these	O
effects	B-C1280500
were	O
maintained	B-C1314677
even	O
after	O
further	B-C1517331
adjustment	B-C0456081
for	O
acute	B-C0751956
stroke	I-C0751956
severity	B-C0439793
.	O
	
african-americans	B-C0085756
had	O
more	O
home	B-C3845073
health	I-C3845073
care	I-C3845073
visits	B-C1512346
than	O
whites	B-C0007457
among	O
patients	B-C0030705
who	O
received	B-C1709850
some	O
home	B-C3845073
health	I-C3845073
care	I-C3845073
.	O
	
having	O
a	O
co-residing	B-C2982691
caregiver	B-C0085537
was	O
associated	B-C0332281
with	I-C0332281
reduced	B-C0392756
acute	B-C0019993
hospitalization	I-C0019993
length	B-C0023303
of	I-C0023303
stay	I-C0023303
and	O
fewer	O
post	B-C0687676
-	O
acute	B-C0586082
emergency	I-C0586082
department	I-C0586082
and	O
primary	B-C3251682
care	I-C3251682
physician	I-C3251682
visits	I-C3251682
.	O
	
conclusions	O
underutilization	B-C4042758
of	I-C4042758
healthcare	I-C4042758
after	O
stroke	B-C0948008
does	O
not	O
appear	O
to	O
explain	O
poorer	O
long-term	B-C0443252
stroke	B-C0948008
outcomes	O
for	O
women	B-C0043210
and	O
african-americans	B-C0085756
in	O
this	O
epidemiologically	B-C0014508
-derived	O
sample	B-C0681850
.	O
	
caregiver	B-C0085537
availability	B-C0470187
may	O
contribute	B-C1880177
to	O
reduced	B-C0392756
formal	B-C1947933
care	I-C1947933
and	O
cost	B-C0010186
during	O
the	O
post	B-C0687676
-	O
acute	B-C0679878
period	B-C1948053
.	O
	
do	O
dynamic	B-C3161035
global	I-C3161035
vegetation	I-C3161035
models	I-C3161035
capture	O
the	O
seasonality	B-C0683922
of	O
carbon	B-C2936196
fluxes	I-C2936196
in	O
the	O
amazon	B-C0017446
basin	I-C0017446
a	O
data	B-C1511726
-	O
model	B-C3161035
intercomparison	B-C0683958
to	O
predict	O
forest	B-C0086312
response	B-C0871261
to	O
long-term	B-C0443252
climate	B-C2718051
change	I-C2718051
with	O
high	O
confidence	O
requires	O
that	O
dynamic	B-C3161035
global	I-C3161035
vegetation	I-C3161035
models	I-C3161035
dgvms	B-C3161035
be	O
successfully	O
tested	O
against	O
ecosystem	B-C0162358
response	B-C0871261
to	O
short-term	B-C0443303
variations	B-C0036496
in	O
environmental	B-C0014406
drivers	I-C0014406
,	O
including	O
regular	O
seasonal	B-C0683922
patterns	I-C0683922
.	O
	
here	O
,	O
we	O
used	O
an	O
integrated	O
dataset	B-C0150098
from	O
four	O
forests	B-C0086312
in	O
the	O
brasil	B-C0242356
flux	I-C0242356
network	I-C0242356
,	O
spanning	O
a	O
range	O
of	O
dry-season	B-C0036497
intensities	B-C0522510
and	O
lengths	B-C1444754
,	O
to	O
determine	O
how	O
well	O
four	O
state-of-the-art	O
models	B-C3161035
ibis	B-C3161035
,	O
ed2	B-C3161035
,	O
jules	B-C3161035
,	O
and	O
clm3.5	B-C3161035
simulated	O
the	O
seasonality	B-C0683922
of	O
carbon	B-C2936196
exchanges	I-C2936196
in	O
amazonian	B-C0017446
tropical	B-C0086312
forests	I-C0086312
.	O
	
we	O
found	O
that	O
most	O
dgvms	B-C3161035
poorly	O
represented	O
the	O
annual	O
cycle	O
of	O
gross	B-C0033269
primary	I-C0033269
productivity	I-C0033269
gpp	B-C0033269
,	O
of	O
photosynthetic	B-C1516240
capacity	I-C1516240
pc	B-C1516240
,	O
and	O
of	O
other	O
fluxes	B-C2348693
and	O
pools	O
.	O
	
models	B-C3161035
simulated	O
consistent	O
dry-season	B-C0036497
declines	B-C0547047
in	O
gpp	B-C0033269
in	O
the	O
equatorial	B-C0017446
amazon	I-C0017446
manaus	B-C0017446
k34	I-C0017446
,	O
santarem	B-C0017446
k67	I-C0017446
,	O
and	O
caxiuanã	B-C0017446
cax	I-C0017446
a	O
contrast	O
to	O
observed	O
gpp	B-C0033269
increases	O
.	O
	
model	B-C3161035
simulated	O
dry-season	B-C0036497
gpp	B-C0033269
reductions	B-C0392756
were	O
driven	O
by	O
an	O
external	O
environmental	B-C0014406
factor	B-C1521761
,	O
'	O
soil	B-C0038435
water	I-C0038435
stress	I-C0038435
'	O
and	O
consequently	O
by	O
a	O
constant	O
or	O
decreasing	O
photosynthetic	B-C0031764
infrastructure	I-C0031764
pc	B-C1516240
,	O
while	O
observed	O
dry-season	B-C0036497
gpp	B-C0033269
resulted	O
from	O
a	O
combination	O
of	O
internal	O
biological	B-C0205460
leaf	B-C0242724
-flush	O
and	O
abscission	B-C1177284
and	O
increased	O
pc	B-C1516240
and	O
environmental	B-C0014406
incoming	O
radiation	B-C0851346
causes	O
.	O
	
moreover	O
,	O
we	O
found	O
models	B-C3161035
generally	O
overestimated	O
observed	O
seasonal	O
net	B-C0392762
ecosystem	I-C0392762
exchange	I-C0392762
nee	B-C0392762
and	O
respiration	B-C0035203
re	B-C0035203
at	O
equatorial	O
locations	O
.	O
	
in	O
contrast	O
,	O
a	O
southern	B-C0017446
amazon	I-C0017446
forest	B-C0086312
jarú	O
rja	O
exhibited	O
dry-season	B-C0036497
declines	B-C0547047
in	O
gpp	B-C0033269
and	O
re	B-C0035203
consistent	O
with	O
most	O
dgvms	B-C3161035
simulations	B-C0679083
.	O
	
while	O
water	O
limitation	O
was	O
represented	O
in	O
models	B-C3161035
and	O
the	O
primary	O
driver	O
of	O
seasonal	O
photosynthesis	B-C0031764
in	O
southern	B-C0017446
amazonia	I-C0017446
,	O
changes	O
in	O
internal	O
biophysical	B-C1511162
processes	I-C1511162
,	O
light-harvesting	B-C1158303
adaptations	B-C0001398
e.g	O
,	O
variations	O
in	O
leaf	B-C0918012
area	I-C0918012
index	I-C0918012
lai	B-C0918012
and	O
increasing	O
leaf	B-C0242724
-level	O
assimilation	B-C3714634
rate	B-C1521828
related	O
to	O
leaf	B-C0011298
demography	I-C0011298
,	O
and	O
allocation	O
lags	O
between	O
leaf	B-C0242724
and	O
wood	B-C0032098
,	O
dominated	O
equatorial	B-C0017446
amazon	I-C0017446
carbon	B-C2936196
flux	I-C2936196
dynamics	O
and	O
were	O
deficient	O
or	O
absent	O
from	O
current	O
model	B-C3161035
formulations	O
.	O
	
correctly	O
simulating	O
flux	B-C2348693
seasonality	B-C0683922
at	O
tropical	B-C0086312
forests	I-C0086312
requires	O
a	O
greater	O
understanding	O
and	O
the	O
incorporation	O
of	O
internal	O
biophysical	B-C1148560
mechanisms	I-C1148560
in	O
future	O
model	B-C0920595
developments	I-C0920595
.	O
	
blood	B-C0005823
pressure	I-C0005823
and	O
all-cause	B-C0007465
mortality	I-C0007465
by	O
level	B-C0441889
of	O
cognitive	B-C0392335
function	I-C0392335
in	O
the	O
elderly	B-C0001792
results	B-C0683954
from	O
a	O
population-based	B-C1709599
study	I-C1709599
in	O
rural	B-C0018226
greece	I-C0018226
this	O
study	B-C1709599
aimed	B-C1947946
to	O
investigate	B-C1292732
whether	O
the	O
effect	B-C1280500
of	O
blood	B-C0005823
pressure	I-C0005823
bp	B-C0005823
on	O
mortality	B-C1306577
differs	O
by	O
levels	B-C0441889
of	O
cognitive	B-C0392335
function	I-C0392335
.	O
	
the	O
associations	B-C0439849
of	O
brachial	B-C0445456
systolic	B-C0871470
bp	I-C0871470
,	O
diastolic	B-C0428883
bp	I-C0428883
,	O
mean	B-C0428886
arterial	I-C0428886
pressure	I-C0428886
map	B-C0428886
,	O
and	O
pulse	B-C0949236
pressure	I-C0949236
with	O
all-cause	B-C0007465
mortality	I-C0007465
were	O
prospectively	B-C0243095
explored	I-C0243095
follow-up	B-C1522577
7.0	O
years	B-C0439234
in	O
660	O
community-dwelling	B-C4045975
individuals	B-C0237401
60	B-C4062292
years	I-C4062292
using	O
adjusted	B-C0010234
cox	I-C0010234
models	I-C0010234
,	O
stratified	B-C0205363
by	O
cognitive	B-C0338656
impairment	I-C0338656
mini-mental	B-C0451306
state	I-C0451306
examination	I-C0451306
mmse	B-C0451306
<24	O
.	O
	
no	B-C0205556
association	I-C0205556
between	O
brachial	B-C0445456
bp	B-C0005823
variables	B-C0439828
and	O
mortality	B-C1306577
was	O
shown	O
for	O
the	O
total	B-C0439810
sample	B-C0370003
in	O
quartiles	B-C0871424
analysis	I-C0871424
however	O
,	O
map	B-C0428886
in	O
the	O
highest	B-C2828255
quartile	I-C2828255
,	O
compared	B-C1707455
with	O
the	O
second	B-C0205436
,	O
was	O
associated	B-C0332281
with	I-C0332281
mortality	B-C1306577
hazard	B-C2985465
ratio	I-C2985465
,	O
1.85	O
95%	O
confidence	B-C0009667
intervals	I-C0009667
,	O
1.09	O
among	O
cognitively	B-C0338656
impaired	I-C0338656
individuals	B-C0237401
.	O
	
the	O
fractional-polynomials	B-C0242481
approach	I-C0242481
for	O
bp	B-C0005823
confirmed	B-C0750484
this	O
finding	B-C0243095
and	O
further	B-C1517331
showed	O
,	O
solely	B-C0205171
in	O
the	O
mmse	B-C0451306
<24	O
subcohort	B-C0009247
,	O
u-shaped	B-C0040833
trends	I-C0040833
of	O
map	B-C0428886
and	O
systolic	B-C0871470
bp	I-C0871470
,	O
with	O
increased	B-C0205217
mortality	B-C0035647
risk	I-C0035647
in	O
extremely	B-C0205403
low	B-C0205556
or	I-C0205556
high	I-C0205556
values	I-C0205556
no	O
such	O
pattern	B-C0449774
was	O
evident	B-C3887511
for	O
patients	B-C0030705
with	O
mmse	B-C0451306
24	O
.	O
	
elderly	B-C0001792
individuals	B-C0237401
with	O
cognitive	B-C0338656
impairment	I-C0338656
might	O
be	O
more	B-C0205172
susceptible	B-C0231204
to	O
the	O
detrimental	B-C0879626
effects	I-C0879626
of	O
low	B-C0205251
and	O
elevated	B-C3163633
map	B-C0428886
and	O
systolic	B-C0871470
bp	I-C0871470
.	O
	
hypovitaminosis	B-C0042870
d	I-C0042870
and	O
associated	O
cardiometabolic	B-C0035647
risk	I-C0035647
in	O
women	B-C0043210
with	O
pcos	B-C0032460
women	B-C0043210
with	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
pcos	B-C0032460
frequently	O
suffer	O
from	O
metabolic	B-C0746556
disturbances	I-C0746556
like	O
insulin	B-C0021655
resistance	I-C0021655
,	O
hypertension	B-C0020538
and	O
atherogenic	B-C0242339
dyslipidemia	I-C0242339
.	O
	
accumulating	B-C4055506
evidences	O
suggest	O
that	O
vitamin	B-C0042870
d	I-C0042870
deficiency	I-C0042870
is	O
common	O
in	O
pcos	B-C0032460
and	O
may	O
be	O
associated	B-C0332281
with	I-C0332281
metabolic	B-C0025517
and	O
endocrinal	B-C1397856
dysfunctions	I-C1397856
in	O
pcos	B-C0032460
.	O
	
thus	O
women	B-C0043210
with	O
pcos	B-C0032460
may	O
be	O
at	O
elevated	O
risk	B-C0035647
of	O
cardiovascular	B-C0007222
disease	I-C0007222
.	O
	
present	O
study	B-C2603343
aims	O
to	O
evaluate	O
vitamin	B-C0042866
d	I-C0042866
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	B-C0025517
and	O
endocrinal	B-C1397856
dysregulations	I-C1397856
in	O
women	B-C0043210
with	O
pcos	B-C0032460
,	O
which	O
might	O
help	O
in	O
early	B-C0814435
identification	I-C0814435
and	O
prevention	B-C0679698
of	O
future	O
symptomatic	B-C0231220
cardiac	B-C0018799
disease	I-C0018799
.	O
	
a	O
total	O
of	O
44	O
women	B-C0043210
with	O
pcos	B-C0032460
,	O
diagnosed	O
by	O
rotterdam	B-C0679228
criteria	I-C0679228
and	O
45	O
healthy	B-C2986479
control	I-C2986479
without	O
pcos	B-C0032460
,	O
were	O
evaluated	O
for	O
vitamin	B-C0042866
d	I-C0042866
and	O
cardiometabolic	B-C0035648
risk	I-C0035648
factors	I-C0035648
,	O
including	O
fasting	B-C1318375
plasma	I-C1318375
glucose	I-C1318375
,	O
insulin	B-C0021655
resistance	I-C0021655
,	O
dyslipidemia	B-C0242339
,	O
hs-crp	B-C0742906
.	O
	
that	O
apart	O
,	O
several	O
endocrinal	B-C0521425
parameters	B-C0549193
of	O
hyperandrogenism	B-C0206081
were	O
also	O
examined	O
.	O
	
several	O
correlation	B-C0010101
studies	I-C0010101
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
vitamin	B-C0042866
d	I-C0042866
as	O
a	O
cardiometabolic	B-C0035648
risk	I-C0035648
factor	I-C0035648
in	O
pcos	B-C0032460
.	O
	
results	O
were	O
expressed	O
as	O
mean	O
and	O
were	O
statistically	B-C0871424
analysed	I-C0871424
using	O
spss	B-C0037585
software	I-C0037585
version	I-C0037585
16	I-C0037585
,	O
unpaired	B-C1710574
student's	I-C1710574
t-test	I-C1710574
and	O
pearson's	B-C0871052
correlation	I-C0871052
coefficient	I-C0871052
.	O
	
we	O
found	O
lower	O
levels	O
of	O
vitamin	B-C0042866
d	I-C0042866
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
hyperinsulinemia	B-C0020459
,	O
rise	O
in	O
insulin	B-C0021655
resistance	I-C0021655
and	O
marked	O
dyslipidemia	B-C0242339
was	O
observed	O
in	O
the	O
present	O
study	B-C2603343
.	O
	
another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
vitamin	B-C0042866
d	I-C0042866
with	O
insulin	B-C0021641
and	O
homeostatic	B-C3639411
model	I-C3639411
of	I-C3639411
assessment-	I-C3639411
insulin	I-C3639411
resistance	I-C3639411
index	I-C3639411
homa-ir	B-C3639411
.	O
	
hypovitaminosis	B-C0042870
d	I-C0042870
was	O
prevalent	O
in	O
pcos	B-C0032460
.	O
	
this	O
was	O
related	O
to	O
metabolic	B-C0025517
and	O
hormonal	B-C3263685
disorders	I-C3263685
in	O
pcos	B-C0032460
.	O
	
possibly	O
this	O
combined	O
with	O
impaired	B-C1272092
fasting	I-C1272092
glucose	I-C1272092
,	O
ir	B-C0021655
and	O
dyslipidemia	B-C0242339
,	O
could	O
account	O
for	O
cardio	B-C0035647
vascular	I-C0035647
risks	I-C0035647
in	O
pcos	B-C0032460
.	O
	
further	O
prospective	O
observational	B-C3658316
studies	I-C3658316
and	O
randomized	B-C0206035
control	I-C0206035
trials	I-C0206035
are	O
required	O
to	O
explore	O
the	O
above	O
family	B-C0015576
close	B-C1821461
but	O
friends	B-C0079382
closer	B-C1821461
exploring	O
social	B-C0037438
support	I-C0037438
and	O
resilience	B-C0683253
in	O
older	B-C0001792
spousal	B-C0162409
dementia	B-C0497327
carers	B-C1305660
spousal	B-C0162409
dementia	B-C0497327
carers	B-C1305660
have	O
unique	O
support	B-C0037438
needs	B-C0027552
they	O
are	O
likely	O
to	O
disengage	B-C0205556
from	O
their	O
existing	B-C2987476
social	B-C0150775
networks	I-C0150775
as	O
they	O
need	O
to	O
devote	O
more	O
time	B-C0040223
to	O
caring	B-C0150499
as	O
the	O
disease	B-C0242656
progresses	I-C0242656
.	O
	
previously	O
we	O
showed	O
that	O
support	B-C0037438
resources	B-C0035201
can	O
facilitate	O
resilience	B-C0683253
in	O
carers	B-C1305660
,	O
but	O
the	O
relationship	B-C0439849
is	O
complex	B-C0439855
and	O
varies	O
by	O
relationship	B-C2826982
type	I-C2826982
.	O
	
the	O
current	O
paper	O
aims	O
to	O
explore	O
social	B-C0037438
support	I-C0037438
as	O
a	O
key	O
component	O
of	O
resilience	B-C0683253
to	O
identify	O
the	O
availability	B-C0470187
,	O
function	B-C0542341
and	O
perceived	B-C0205245
functional	I-C0205245
aspects	I-C0205245
of	O
support	B-C0037438
provided	O
to	O
older	B-C0001792
spousal	B-C0162409
dementia	B-C0497327
carers	B-C1305660
.	O
	
we	O
conducted	O
23	O
in-depth	B-C0021822
qualitative	I-C0021822
interviews	I-C0021822
with	O
spousal	B-C0162409
carers	B-C1305660
from	O
two	O
carer	B-C1305660
support	B-C0036606
groups	I-C0036606
and	O
a	O
care	O
home	O
in	O
north	B-C0014282
west	I-C0014282
england	I-C0014282
.	O
	
family	B-C0015576
and	O
friends	B-C0079382
served	O
a	O
wide	O
range	O
of	O
functions	B-C0542341
but	O
were	O
equally	O
available	O
to	O
resilient	B-C0679646
and	O
non-resilient	B-C0679646
participants	I-C0679646
.	O
	
family	B-C0150232
support	I-C0150232
was	O
perceived	B-C0030971
as	O
unhelpful	O
if	O
it	O
created	B-C1706214
feelings	B-C1527305
of	O
over-dependence	B-C0205556
.	O
	
participants	B-C0679646
were	O
less	O
likely	O
to	O
resist	B-C1314939
involvement	I-C1314939
of	O
grandchildren	B-C0337548
due	O
to	O
their	O
relatively	O
narrow	B-C0037438
and	I-C0037438
low-level	I-C0037438
support	I-C0037438
functions	I-C0037438
.	O
	
friend	B-C0079382
support	B-C0037438
was	O
perceived	B-C0030971
as	O
most	O
helpful	B-C3898897
when	O
it	O
derived	O
from	O
those	O
in	O
similar	O
circumstances	B-C0851364
.	O
	
neighbours	B-C1553702
played	O
a	O
functionally	O
unique	O
role	O
of	O
crisis	B-C0262762
management	I-C0262762
.	O
	
these	O
perceptions	B-C0030971
may	O
moderate	B-C0205081
the	O
effect	B-C1280500
of	O
support	B-C0037438
on	O
resilience	B-C0683253
.	O
	
family	B-C0150232
and	O
friend	B-C0079382
support	B-C0037438
is	O
not	O
always	O
sufficient	B-C0205410
to	O
facilitate	O
resilience	B-C0683253
.	O
	
support	B-C0037438
functions	I-C0037438
facilitate	O
resilience	B-C0683253
only	O
if	O
they	O
are	O
perceived	B-C0030971
to	O
match	O
need	B-C0027552
.	O
	
implications	B-C0243095
of	O
these	O
findings	B-C2607943
measure	B-C0205787
up	I-C0205787
pressure	I-C0205787
down	I-C0205787
provider	I-C0205787
toolkit	I-C0205787
to	O
improve	B-C2986411
hypertension	B-C0020538
control	B-C1753303
hypertension	B-C0020538
is	O
one	O
of	O
the	O
most	O
important	O
risk	B-C0035648
factors	I-C0035648
for	O
heart	B-C0018799
disease	I-C0018799
,	O
stroke	B-C0038454
,	O
kidney	B-C0035078
failure	I-C0035078
,	O
and	O
diabetes	B-C0342257
complications	I-C0342257
.	O
	
nearly	O
one	O
in	O
three	O
americans	B-C0596070
adults	B-C0001675
has	O
high	B-C0020538
blood	I-C0020538
pressure	I-C0020538
,	O
and	O
the	O
cost	B-C0087112
associated	B-C0332281
with	I-C0332281
treating	B-C0087111
this	O
condition	B-C0020538
is	O
staggering	O
.	O
	
the	O
measure	B-C0205787
up	I-C0205787
pressure	I-C0205787
down	I-C0205787
provider	I-C0205787
toolkit	I-C0205787
to	O
improve	B-C2986411
hypertension	B-C0020538
control	B-C1753303
is	O
a	O
resource	B-C0018741
developed	B-C1527148
by	O
the	O
american	B-C1708333
medical	I-C1708333
group	I-C1708333
foundation	I-C1708333
in	O
partnership	B-C1711206
with	O
the	O
american	B-C1708333
medical	I-C1708333
group	I-C1708333
association	I-C1708333
.	O
	
the	O
goal	B-C0018017
of	O
this	O
toolkit	B-C1301746
is	O
to	O
mobilize	O
health	B-C1709627
care	I-C1709627
practitioners	I-C1709627
to	O
work	B-C0043227
together	B-C1883357
through	O
team	B-C0871489
-based	O
approaches	O
to	O
achieve	O
an	O
80%	O
control	B-C1753303
rate	B-C1521828
of	O
high	B-C0020538
blood	I-C0020538
pressure	I-C0020538
among	O
their	O
patient	B-C0030705
population	I-C0030705
.	O
	
the	O
toolkit	B-C1301746
can	O
be	O
used	O
by	O
health	B-C1136362
educators	I-C1136362
,	O
clinic	B-C0019949
administrators	I-C0019949
,	O
physicians	B-C0031831
,	O
students	B-C0038492
,	O
and	O
other	O
clinic	B-C0851286
staff	I-C0851286
as	O
a	O
step-by-step	O
resource	B-C0018741
for	O
developing	B-C1527148
the	O
infrastructure	B-C1512763
needed	O
to	O
better	O
identify	O
and	O
treat	B-C0087111
individuals	B-C0027361
with	O
high	B-C0020538
blood	I-C0020538
pressure	I-C0020538
or	O
other	O
chronic	B-C0008679
conditions	I-C0008679
.	O
	
potentiation	B-C0279023
of	O
lps	B-C0023810
-	O
induced	B-C0007994
apoptotic	B-C0162638
cell	I-C0162638
death	I-C0162638
in	O
human	B-C2717940
hepatoma	I-C2717940
hepg2	I-C2717940
cells	I-C2717940
by	O
aspirin	B-C0004057
via	O
ros	B-C0162772
and	O
mitochondrial	B-C4021734
dysfunction	I-C4021734
protection	B-C1545588
by	O
n-acetyl	B-C0001047
cysteine	I-C0001047
cytotoxicity	B-C0596402
and	O
inflammation	B-C0021368
-	O
associated	B-C0243082
toxic	B-C1407029
responses	B-C0871261
have	O
been	O
observed	B-C1441672
to	O
be	O
induced	B-C0205263
by	O
bacterial	B-C0521009
lipopolysaccharides	B-C0023810
lps	B-C0023810
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
respectively	O
.	O
	
use	O
of	O
nonsteroidal	B-C0003211
anti-inflammatory	I-C0003211
drugs	I-C0003211
nsaids	B-C0003211
,	O
such	O
as	O
aspirin	B-C0004057
,	O
has	O
been	O
reported	B-C0700287
to	O
be	O
beneficial	O
in	O
inflammation	B-C0021368
-	O
associated	B-C0243083
diseases	I-C0243083
like	O
cancer	B-C0006826
,	O
diabetes	B-C0011847
and	O
cardiovascular	B-C0007222
disorders	I-C0007222
.	O
	
their	O
precise	O
molecular	B-C1521991
mechanisms	B-C0441712
,	O
however	O
,	O
are	O
not	O
clearly	O
understood	O
.	O
	
our	O
previous	O
studies	B-C0008972
on	O
aspirin	B-C0004057
treated	B-C0332293
hepg2	B-C2717940
cells	I-C2717940
strongly	O
suggest	O
cell	B-C1155873
cycle	I-C1155873
arrest	I-C1155873
and	O
induction	B-C0205263
of	O
apoptosis	B-C0162638
associated	B-C0332281
with	I-C0332281
mitochondrial	B-C4021734
dysfunction	I-C4021734
.	O
	
in	O
the	O
present	O
study	B-C0008972
,	O
we	O
have	O
further	O
demonstrated	O
that	O
hepg2	B-C2717940
cells	I-C2717940
treated	B-C0332293
with	I-C0332293
lps	B-C0023810
alone	O
or	O
in	O
combination	B-C0205195
with	O
aspirin	B-C0004057
induces	B-C0205263
subcellular	B-C0729605
toxic	B-C3549372
responses	I-C3549372
which	O
are	O
accompanied	O
by	O
increase	B-C0442805
in	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
production	O
,	O
oxidative	B-C0242606
stress	I-C0242606
,	O
mitochondrial	B-C4021734
respiratory	I-C4021734
dysfunction	I-C4021734
and	O
apoptosis	B-C0162638
.	O
	
the	O
lps	B-C0023810
/	O
aspirin	B-C0004057
induced	B-C0205263
toxicity	B-C0600688
was	O
attenuated	B-C0599946
by	O
pre-treatment	B-C2709094
of	O
cells	B-C0007634
with	O
n-acetyl	B-C0001047
cysteine	I-C0001047
nac	B-C0001047
.	O
	
alterations	O
in	O
oxidative	B-C0242606
stress	I-C0242606
and	O
glutathione	B-C0017817
-	O
dependent	B-C0851827
redox-homeostasis	B-C1156287
were	O
more	O
pronounced	O
in	O
mitochondria	B-C0026237
compared	B-C1707455
to	O
extra	B-C1254362
-	O
mitochondrial	B-C0026237
cellular	B-C1166607
compartments	I-C1166607
.	O
	
pre-treatment	B-C2709094
of	O
hepg2	B-C2717940
cells	I-C2717940
with	O
nac	B-C0001047
exhibited	O
a	O
selective	O
protection	B-C1545588
in	O
redox	B-C1156287
homeostasis	I-C1156287
and	O
mitochondrial	B-C4021734
dysfunction	I-C4021734
.	O
	
our	O
results	B-C0683954
suggest	O
that	O
the	O
altered	B-C0392747
redox	B-C1156287
metabolism	I-C1156287
,	O
oxidative	B-C0242606
stress	I-C0242606
and	O
mitochondrial	B-C0026237
function	B-C0542341
in	O
hepg2	B-C2717940
cells	I-C2717940
play	O
a	O
critical	O
role	O
in	O
lps	B-C0023810
/	O
aspirin	B-C0004057
-	O
induced	B-C0205263
cytotoxicity	B-C0596402
.	O
	
these	O
results	B-C0683954
may	O
help	O
in	O
better	O
understanding	O
the	O
pharmacological	B-C0205464
,	O
toxicological	B-C0205472
and	O
therapeutic	B-C0039798
properties	I-C0039798
of	O
nsaids	B-C0003211
in	O
cancer	B-C0334227
cells	I-C0334227
exposed	B-C0332157
to	O
bacterial	B-C0014264
endotoxins	I-C0014264
.	O
	
placental	B-C0032043
pathologic	B-C0205469
associations	B-C0439849
with	O
morbidly	B-C0405107
adherent	I-C0405107
placenta	I-C0405107
potential	O
insights	O
into	O
pathogenesis	B-C0699748
the	O
pathology	B-C0205469
that	O
underlies	O
morbidly	B-C0405107
adherent	I-C0405107
placenta	I-C0405107
map	B-C0405107
is	O
poorly	O
understood	O
.	O
	
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
placental	B-C0032043
pathology	B-C0205469
,	O
especially	O
implantation	B-C0230992
site	I-C0230992
pathology	B-C0205469
,	O
associated	B-C0332281
with	I-C0332281
map	B-C0405107
.	O
	
this	O
was	O
a	O
single	B-C0205171
institution	B-C2607850
,	O
retrospective	B-C0035363
case-control	I-C0035363
study	I-C0035363
design	O
examining	O
placentas	B-C0032043
of	O
patients	B-C0030705
who	O
delivered	B-C0566687
between	O
january	O
2008	O
and	O
september	O
2013	O
.	O
	
map	B-C0405107
cases	B-C1706256
were	O
defined	O
by	O
the	O
need	O
for	O
clinical	B-C0205210
intervention	B-C1273869
at	O
delivery	B-C0011209
beyond	O
spontaneous	B-C0205359
placental	B-C0404381
delivery	I-C0404381
or	O
simple	O
manual	B-C0391874
extraction	I-C0391874
of	O
the	O
placenta	B-C0032043
.	O
	
controls	B-C0009932
consisted	O
of	O
patients	B-C0030705
with	O
placentas	B-C0032043
sent	O
for	O
examination	B-C0582103
due	O
to	O
a	O
history	B-C0032967
of	O
maternal	B-C0026591
malignancy	B-C0006826
with	O
no	B-C1513916
clinical	B-C0205210
suspicion	B-C0750491
of	O
accreta	B-C0032044
.	O
	
placental	B-C0032043
pathologic	B-C1317598
findings	I-C1317598
of	O
maternal	B-C0012634
vascular	I-C0012634
underperfusion	I-C0012634
mvu	B-C0012634
,	O
acute	B-C0333361
inflammation	I-C0333361
,	O
chronic	B-C0021376
inflammation	I-C0021376
,	O
fetal	B-C0015965
vascular	B-C1096458
obstruction	I-C1096458
and	O
hemorrhage	B-C0019080
were	O
recorded	O
and	O
compared	O
using	O
bivariable	B-C0814907
and	I-C0814907
multivariable	I-C0814907
analyses	I-C0814907
.	O
	
three	O
categories	B-C0683312
of	O
pathologic	B-C0205469
changes	B-C0392747
were	O
seen	O
more	O
commonly	O
in	O
map	B-C0405107
placentas	B-C0032043
n=101	O
than	O
control	B-C0009932
placentas	B-C0032043
n=110	O
chronic	B-C0021376
basal	I-C0021376
inflammation	I-C0021376
,	O
villous	O
changes	B-C0392747
of	O
mvu	B-C0012634
and	O
retromembranous	B-C0019080
and	O
retromembranous	O
/	O
intervillous	B-C0269801
hemorrhage	I-C0269801
.	O
	
in	O
multivariable	B-C0026777
analyses	I-C0026777
adjusted	O
for	O
confounders	B-C0009673
,	O
chronic	B-C1300128
basal	I-C1300128
villitis	I-C1300128
aor	B-C0028873
5.6	O
,	O
1.73	O
,	O
plasma	B-C3899627
cell	I-C3899627
deciduitis	I-C3899627
aor	B-C0028873
2.63	O
,	O
1.08	O
,	O
increased	B-C3898771
syncytial	I-C3898771
knots	I-C3898771
aor	B-C0028873
3.92	O
,	O
1.57	O
,	O
villous	O
agglutination	O
aor	B-C0028873
24.85	O
,	O
2.78	O
,	O
increased	B-C0243095
perivillous	I-C0243095
fibrin	I-C0243095
aor	B-C0028873
5.08	O
,	O
1.49	O
,	O
and	O
the	O
presence	O
of	O
subchorionic	B-C0087086
/	O
intervillous	B-C3898711
thrombi	I-C3898711
aor	B-C0028873
4.01	O
,	O
1.63	O
remained	O
associated	B-C0332281
with	I-C0332281
map	B-C0405107
.	O
	
map	B-C0405107
is	O
highly	O
associated	B-C0332281
with	I-C0332281
evidence	O
of	O
intraparenchymal	B-C0542014
placental	I-C0542014
hemorrhage	I-C0542014
villous	B-C1519984
changes	B-C0392747
of	O
mvu	B-C0012634
,	O
and	O
a	O
lymphoplasmacytic	B-C1334467
infiltrate	I-C1334467
at	O
the	O
implantation	B-C0230992
site	I-C0230992
.	O
	
the	O
contribution	O
of	O
this	O
basal	B-C1333036
chronic	I-C1333036
inflammatory	I-C1333036
infiltrate	I-C1333036
to	O
map	B-C0405107
an	O
ion-gating	O
multinanochannel	O
system	O
based	O
on	O
a	O
copper	B-C0009968
-	O
responsive	B-C0205342
self	B-C0036588
-	O
cleaving	B-C0205242
dnazyme	B-C0540193
we	O
developed	O
an	O
ion-gating	O
nanochannel	O
composite	O
system	O
by	O
immobilizing	B-C0205245
a	O
cu	B-C0009968
-	O
responsive	B-C0205342
self	B-C0036588
-	O
cleaving	B-C0205242
dnazyme	B-C0540193
into	O
pet	B-C0032485
conical	B-C0005479
multinanochannels	I-C0005479
,	O
which	O
could	O
control	B-C2587213
the	O
ion	B-C0162585
transport	I-C0162585
by	O
regulating	B-C1327622
the	O
surface	B-C0205148
charge	B-C1706211
density	B-C0178587
of	O
the	O
high-intensity	B-C4277545
intermittent	I-C4277545
training	I-C4277545
positively	B-C1446409
affects	B-C1280500
aerobic	B-C0001701
and	O
anaerobic	B-C3841233
performance	I-C3841233
in	O
judo	B-C0079650
athletes	B-C0238703
independently	O
of	O
exercise	B-C0015259
mode	I-C0015259
the	O
present	O
study	O
investigated	O
the	O
effects	B-C1280500
of	O
high-intensity	B-C4277545
intermittent	I-C4277545
training	I-C4277545
hiit	B-C4277545
on	O
lower	B-C1268088
-	O
and	O
upper-body	B-C1268087
graded	B-C0015259
exercise	I-C0015259
and	O
high-intensity	B-C4277545
intermittent	I-C4277545
exercise	I-C4277545
hiie	B-C4277545
,	O
four	O
wingate	O
bouts	O
performance	B-C1882330
,	O
and	O
on	O
physiological	B-C0205463
and	O
muscle	B-C0410158
damage	I-C0410158
markers	B-C0243095
responses	I-C0243095
in	O
judo	B-C0079650
athletes	B-C0238703
.	O
	
thirty-five	O
subjects	B-C0080105
were	O
randomly	B-C0034656
allocated	I-C0034656
to	O
a	O
control	B-C0009932
group	I-C0009932
n	O
=	O
8	O
or	O
to	O
one	O
of	O
the	O
following	O
hiit	B-C4277545
groups	B-C0441833
n	O
=	O
9	O
for	O
each	O
and	O
tested	B-C0032919
pre-	I-C0032919
and	I-C0032919
post	I-C0032919
-four	O
weeks	O
2	O
training	O
d	O
1	O
lower-body	B-C1268088
cycle-ergometer	B-C2107077
2	O
upper-body	O
cycle-ergometer	B-C2107077
3	O
uchi-komi	B-C0449851
judo	B-C0449851
technique	I-C0449851
entrance	I-C0449851
.	O
	
all	O
hiit	B-C4277545
were	O
constituted	O
by	O
two	O
blocks	O
of	O
10	O
sets	O
of	O
20	O
s	O
of	O
all	O
out	O
effort	O
interspersed	O
by	O
10	O
s	O
set	O
intervals	O
and	O
5-min	O
between	O
blocks	O
.	O
	
for	O
the	O
upper-body	B-C1268087
group	B-C0441833
there	O
was	O
an	O
increase	B-C0442805
in	O
maximal	B-C2371107
aerobic	I-C2371107
power	I-C2371107
in	O
graded	O
upper-body	B-C1268087
exercise	B-C0429687
test	I-C0429687
12.3	O
.	O
	
the	O
lower-body	B-C1268088
group	B-C0441833
increased	B-C0442805
power	B-C2371107
at	O
onset	B-C3824990
blood	I-C3824990
lactate	I-C3824990
in	O
graded	O
upper-body	B-C1268087
exercise	B-C0429687
test	I-C0429687
22.1	O
.	O
	
the	O
uchi-komi	B-C0441833
group	I-C0441833
increased	B-C0442805
peak	O
power	O
in	O
upper	B-C1268087
-	O
16.7	O
and	O
lower-body	B-C1268088
8.5	O
,	O
while	O
the	O
lower-body	B-C1268088
group	O
increased	B-C0442805
lower-body	B-C1268088
mean	O
power	O
14.2	O
during	O
the	O
hiie	B-C4277545
.	O
	
there	O
was	O
a	O
decrease	B-C0547047
in	O
the	O
delta	B-C3824990
blood	I-C3824990
lactate	I-C3824990
for	O
the	O
uchi-komi	B-C0559197
training	I-C0559197
group	B-C0441833
and	O
in	O
the	O
third	O
and	O
fourth	O
bouts	O
for	O
the	O
upper-body	B-C1268087
training	B-C0220931
group	B-C0441833
.	O
	
training	B-C0220931
induced	O
testosterone-cortisol	B-C4035023
ratio	B-C0456603
increased	B-C0442805
in	O
the	O
lower-body	B-C1268088
hiie	B-C4277545
for	O
the	O
lower-body	B-C1268088
14.9	O
and	O
uchi-komi	B-C0559197
61.4	I-C0559197
training	I-C0559197
groups	B-C0441833
.	O
	
thus	O
,	O
short-duration	B-C0439593
low-volume	O
hiit	B-C4277545
added	O
to	O
regular	B-C0220931
judo	I-C0220931
training	I-C0220931
was	O
able	O
to	O
increase	B-C0442805
upper-body	B-C1268087
aerobic	B-C2371107
power	I-C2371107
,	O
lower	B-C1268088
-	O
and	O
upper-body	B-C1268087
hiie	B-C4277545
performance	B-C1882330
.	O
	
microbiomes	B-C1956108
of	O
muricea	B-C1093383
californica	I-C1093383
and	O
m	B-C1011258
.	O
	
fruticosa	I-C1011258
comparative	B-C0683941
analyses	I-C0683941
of	O
two	O
co-occurring	O
eastern	B-C0030168
pacific	I-C0030168
octocorals	B-C0997913
octocorals	B-C0997913
are	O
sources	O
of	O
novel	O
but	O
understudied	B-C2603343
microbial	B-C0599840
diversity	B-C1880371
.	O
	
conversely	O
,	O
scleractinian	B-C0997908
or	O
reef-building	B-C1956108
coral	I-C1956108
microbiomes	I-C1956108
have	O
been	O
heavily	O
examined	B-C0332128
in	O
light	O
of	O
the	O
threats	B-C0749385
of	O
climate	B-C2718051
change	I-C2718051
.	O
	
muricea	B-C1093383
californica	I-C1093383
and	O
muricea	B-C1011258
fruticosa	I-C1011258
are	O
two	O
co-occurring	B-C1705920
species	I-C1705920
of	O
gorgonian	B-C0997913
octocoral	I-C0997913
abundantly	B-C0150312
found	I-C0150312
in	O
the	O
kelp	B-C0036500
forests	B-C0086312
of	O
southern	B-C0006754
california	I-C0006754
,	O
and	O
thus	O
provide	O
an	O
excellent	B-C1527178
basis	I-C1527178
to	O
determine	O
if	O
octocoral	B-C0997913
microbiomes	B-C1956108
are	O
host	B-C1167395
specific	B-C0205369
.	O
	
using	O
illumina	B-C2348563
miseq	I-C2348563
amplicon	I-C2348563
sequencing	I-C2348563
and	O
replicate	B-C1609629
samples	I-C1609629
,	O
we	O
evaluated	O
the	O
microbiomes	B-C1956108
collected	O
from	O
multiple	B-C0439158
colonies	I-C0439158
of	O
both	O
species	B-C1705920
of	O
muricea	B-C1093383
to	O
measure	B-C0079809
both	O
inter-	B-C1947989
and	O
intra-colony	B-C1947989
microbiome	B-C1956108
variabilities	B-C2827666
.	O
	
in	O
addition	O
,	O
microbiomes	B-C1956108
from	O
overlying	O
sea	B-C0036499
water	I-C0036499
and	O
nearby	O
zoanthids	B-C0684063
another	O
benthic	B-C0021948
invertebrate	I-C0021948
were	O
also	O
included	O
in	O
the	O
analysis	B-C0936012
to	O
evaluate	O
whether	O
bacterial	B-C0682467
taxa	I-C0682467
specifically	O
associate	B-C0332281
with	I-C0332281
octocorals	B-C0997913
.	O
	
this	O
is	O
also	O
the	O
first	B-C0684224
report	I-C0684224
of	O
microbiomes	B-C1956108
from	O
these	O
species	B-C1705920
of	O
muricea	B-C1093383
.	O
	
we	O
show	O
that	O
microbiomes	B-C1956108
isolated	B-C0205409
from	O
each	O
sample	B-C2347029
type	I-C2347029
are	O
distinct	B-C1705242
,	O
and	O
specifically	O
,	O
that	O
octocoral	B-C0997913
species	B-C1705920
type	B-C0332307
had	O
the	O
greatest	O
effect	O
on	O
predicting	B-C0681842
the	O
composition	B-C0486616
of	O
the	O
muricea	B-C1093383
microbiome	B-C1956108
.	O
	
bacterial	B-C0682467
taxa	I-C0682467
contributing	O
to	O
compositional	B-C1705241
differences	I-C1705241
include	O
distinct	B-C1705242
strains	B-C1518614
of	O
mycoplasma	B-C0026934
associated	B-C0332281
with	I-C0332281
either	O
m	B-C1093383
.	O
	
californica	I-C1093383
or	O
m	B-C1011258
.	O
	
fruticosa	I-C1011258
,	O
an	O
abundance	B-C2346714
of	O
spirochaetes	B-C1222582
observed	B-C1441672
on	O
m	B-C1093383
.	O
	
californica	I-C1093383
,	O
and	O
a	O
greater	B-C1704243
diversity	B-C1880371
of	O
γ-proteobacteria	B-C0751988
associated	B-C0332281
with	I-C0332281
m	B-C1011258
.	O
	
fruticosa	I-C1011258
.	O
	
many	O
of	O
the	O
bacterial	B-C0682467
taxa	I-C0682467
contributing	O
to	O
these	O
differences	B-C1705241
are	O
known	O
for	O
their	O
presence	B-C0150312
in	O
photosymbiont-containing	B-C0021948
invertebrate	I-C0021948
microbiomes	B-C1956108
.	O
	
2	B-C0045643
nephropathy	B-C0022658
identified	O
as	O
cause	B-C0015127
of	O
end-stage	B-C0022661
renal	I-C0022661
disease	I-C0022661
after	O
renal	B-C0022671
transplant	I-C0022671
adenine	B-C0001414
phosphoribosyltransferase	I-C0001414
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
of	O
uric	O
acid	O
metabolism	O
that	O
leads	O
to	O
formation	O
and	O
excretion	O
of	O
2	O
into	O
urine	O
.	O
	
the	O
low	O
solubility	O
of	O
2	O
results	O
in	O
precipitation	O
and	O
formation	O
of	O
urinary	O
crystals	O
and	O
renal	O
stones	O
.	O
	
patients	O
with	O
this	O
disorder	O
usually	O
have	O
recurrent	O
nephrolithiasis	O
and	O
can	O
develop	O
nephropathy	O
secondary	O
to	O
crystal	O
precipitation	O
in	O
the	O
renal	O
parenchyma	O
.	O
	
the	O
disease	O
is	O
most	O
often	O
underdiagnosed	O
and	O
can	O
recur	O
in	O
renal	O
transplant	O
,	O
causing	O
graft	O
failure	O
.	O
	
lack	O
of	O
specific	O
clinical	O
manifestations	O
,	O
chemical	O
and	O
radiologic	O
features	O
identical	O
to	O
those	O
shown	O
with	O
uric	O
acid	O
stones	O
,	O
and	O
lack	O
of	O
awareness	O
among	O
clinicians	O
are	O
among	O
the	O
causes	O
for	O
the	O
underdiagnoses	O
of	O
this	O
treatable	O
disease	O
.	O
	
allopurinol	O
,	O
a	O
xanthine	O
dehydrogenase	O
inhibitor	O
,	O
is	O
the	O
mainstay	O
of	O
treatment	O
,	O
supported	O
by	O
high	O
fluid	O
intake	O
and	O
dietary	O
modifications	O
.	O
	
the	O
possibility	O
of	O
adenine	O
phosphoribosyl	O
transferase	O
deficiency	O
should	O
be	O
considered	O
in	O
all	O
cases	O
of	O
urolithiasis	O
in	O
children	O
,	O
patients	O
with	O
recurrent	O
urolithiasis	O
,	O
and	O
patients	O
with	O
urolithiasis	O
associated	O
with	O
renal	O
failure	O
of	O
unknown	O
cause	O
,	O
including	O
patients	O
with	O
end-stage	O
renal	O
disease	O
and	O
renal	O
transplant	O
recipients	O
.	O
	
here	O
,	O
we	O
report	O
a	O
case	O
of	O
a	O
41-year-old	O
female	O
patient	O
who	O
had	O
a	O
late	O
diagnosis	O
of	O
2	O
nephropathy	O
-induced	O
end-stage	O
renal	O
disease	O
,	O
made	O
on	O
the	O
native	O
nephrectomy	O
that	O
accompanied	O
the	O
renal	O
transplant	O
,	O
and	O
who	O
had	O
a	O
timely	O
intervention	O
that	O
prevented	O
recurrence	O
in	O
the	O
graft	B-C1262018
social	B-C1510639
capital	I-C1510639
and	O
healthy	B-C3898900
ageing	B-C0001811
in	O
indonesia	B-C0021247
a	O
large	B-C0549177
international	B-C1512888
literature	B-C0023866
has	O
found	O
a	O
positive	B-C1446409
association	B-C0439849
between	O
social	B-C1510639
capital	I-C1510639
and	O
measures	B-C0079809
of	O
physical	B-C0517226
and	O
mental	B-C0025353
health	I-C0025353
.	O
	
however	O
,	O
there	O
is	O
a	O
paucity	O
of	O
research	B-C0035168
on	O
the	O
links	B-C0439849
between	O
social	B-C1510639
capital	I-C1510639
and	O
healthy	B-C3898900
ageing	B-C0001811
in	O
a	O
developing	B-C0011750
country	I-C0011750
environment	B-C0014406
,	O
where	O
universal	B-C0037435
social	I-C0037435
security	I-C0037435
coverage	I-C0037435
is	O
absent	B-C0332197
and	O
health	B-C0018684
infrastructure	I-C0018684
is	O
poor	B-C0542537
.	O
	
in	O
this	O
paper	O
,	O
we	O
develop	O
and	O
empirically	O
test	B-C0039593
a	O
model	B-C3161035
of	O
the	O
linkages	B-C0332280
between	O
social	B-C1510639
capital	I-C1510639
and	O
the	O
health	B-C1550208
outcomes	I-C1550208
for	O
older	B-C0001792
adults	I-C0001792
in	O
indonesia	B-C0021247
,	O
using	O
data	B-C1511726
from	O
the	O
indonesian	B-C0038951
family	I-C0038951
life	I-C0038951
survey-east	I-C0038951
ifls-east	B-C0038951
,	O
conducted	O
in	O
2012	O
.	O
	
using	O
multivariate	B-C0034980
regression	I-C0034980
analysis	I-C0034980
,	O
we	O
examine	O
whether	O
social	B-C1510639
capital	I-C1510639
plays	O
a	O
role	B-C1705810
in	O
mitigating	B-C0205556
poor	B-C0683321
health	I-C0683321
among	O
older	B-C0001792
individuals	B-C0237401
aged	B-C0001779
50	O
years	B-C0439234
and	O
above	O
in	O
indonesia	B-C0021247
's	O
most	O
vulnerable	B-C1514578
provinces	I-C1514578
.	O
	
we	O
test	B-C0039593
the	O
robustness	B-C2986815
of	O
these	O
social	B-C1510639
capital	I-C1510639
variables	B-C0439828
across	O
different	O
health	B-C0018684
measures	B-C0079809
self-assessed	B-C1516048
health	B-C0018684
,	O
activities	B-C0001288
of	I-C0001288
daily	I-C0001288
living	I-C0001288
adl	B-C0001288
,	O
measures	B-C0079809
of	O
chronic	B-C0008679
illness	I-C0008679
and	O
mental	B-C0025353
health	I-C0025353
measures	B-C0079809
,	O
as	O
well	O
as	O
across	O
different	O
demographic	B-C0011298
groups	B-C0441833
,	O
after	O
controlling	B-C2587213
for	O
an	O
array	B-C1510941
of	O
socio-economic	B-C0086996
,	O
demographic	B-C0011298
and	O
geographic	B-C1517526
characteristics	B-C1521970
.	O
	
our	O
findings	B-C0243095
show	O
that	O
access	B-C0444454
to	O
better	O
social	B-C1510639
capital	I-C1510639
using	O
measures	B-C0079809
of	O
neighbourhood	B-C1553702
trust	B-C0237935
and	O
community	B-C0009476
participation	I-C0009476
is	O
associated	B-C0332281
with	I-C0332281
a	O
higher	B-C0205250
degree	B-C0449286
of	O
physical	B-C0871081
mobility	I-C0871081
,	O
independence	B-C0085862
,	O
and	O
mental	B-C0025353
well-being	I-C0025353
among	O
older	B-C0001792
individuals	B-C0237401
but	O
has	O
no	O
influence	B-C4054723
on	O
chronic	B-C0008679
illnesses	I-C0008679
.	O
	
these	O
results	B-C1274040
are	O
consistent	B-C0332290
when	O
we	O
estimate	B-C0750572
samples	B-C0681850
disaggregated	O
by	O
gender	B-C0079399
,	O
rural	B-C0240919
/	O
urban	B-C2700386
residence	B-C0237096
,	O
and	O
by	O
age	B-C0001779
categories	B-C0683312
.	O
	
from	O
a	O
policy	B-C0242456
perspective	O
these	O
results	B-C1274040
point	O
to	O
the	O
importance	O
of	O
social	B-C1510639
capital	I-C1510639
measures	B-C1879489
in	O
moderating	B-C1881878
the	O
influence	B-C4054723
of	O
poor	B-C0683321
health	I-C0683321
,	O
particularly	O
in	O
the	O
activities	B-C0001288
of	I-C0001288
daily	I-C0001288
living	I-C0001288
.	O
	
modulation	B-C0443264
of	O
interleukins	B-C0021764
in	O
sepsis	B-C0036690
-	O
associated	B-C0332281
clotting	B-C0005779
disorders	I-C0005779
interplay	O
with	O
hemostatic	B-C0005779
derangement	I-C0005779
interleukins	B-C0021764
play	O
a	O
central	B-C0205099
role	B-C1705810
in	O
the	O
immune	B-C0020962
system	I-C0020962
and	O
are	O
involved	B-C1314939
in	O
a	O
variety	O
of	O
immunological	B-C0021053
,	O
inflammatory	B-C1290884
,	O
and	O
infectious	B-C0009450
disease	I-C0009450
states	B-C1442792
including	O
sepsis	B-C0036690
syndrome	I-C0036690
.	O
	
levels	B-C0441889
of	O
interleukins	B-C0021764
may	O
correlate	B-C1707520
with	O
overall	B-C4086681
survival	I-C4086681
and	O
may	O
directly	B-C1947931
or	O
indirectly	B-C0439852
affect	B-C0001721
some	O
of	O
the	O
regulators	B-C0005525
of	O
coagulation	B-C0005778
and	O
fibrinolysis	B-C0016017
,	O
thereby	O
disrupting	O
hemostasis	B-C0019116
and	O
thrombosis	B-C0040053
.	O
	
our	O
hypothesis	B-C1512571
is	O
that	O
in	O
sepsis-associated	B-C0005779
coagulopathies	I-C0005779
sacs	B-C0005779
,	O
interleukins	B-C0021764
may	O
be	O
upregulated	B-C0041904
,	O
leading	O
to	O
hemostatic	B-C0005779
imbalance	I-C0005779
by	O
generating	O
thrombogenic	B-C0574031
mediators	I-C0574031
.	O
	
we	O
profiled	B-C2003903
the	O
levels	B-C0441889
of	O
interleukins	B-C0021764
il-1α	B-C0600251
,	O
il-1β	B-C0021753
,	O
il-2	B-C0021756
,	O
il-4	B-C0021758
,	O
il-6	B-C0021760
,	O
il-8	B-C0079633
,	O
and	O
il-10	B-C0085295
in	B-C0332287
addition	I-C0332287
to	I-C0332287
d-dimer	B-C0060323
dd	B-C0060323
in	O
patients	B-C0030705
with	O
sac	B-C0005779
and	O
in	O
normal	B-C0205307
donors	B-C0005795
.	O
	
we	O
observed	B-C1441672
the	O
highest	B-C1522410
increase	B-C0442805
in	O
interleukins	B-C0021764
il-6	B-C0021760
322-fold	B-C1880833
,	O
il-8	B-C0079633
48-fold	B-C1880833
,	O
il-10	B-C0085295
72-fold	B-C1880833
,	O
and	O
dd	B-C0060323
18-fold	B-C1880833
.	O
	
this	O
suggests	B-C1705535
that	O
interleukins	B-C0021764
such	O
as	O
il-6	B-C0021760
and	O
il-10	B-C0085295
have	O
a	O
close	O
association	B-C0332281
with	I-C0332281
coagulopathy	B-C0005779
and	O
fibrinolytic	B-C0543673
dysregulation	I-C0543673
in	O
sepsis	B-C0036690
and	O
can	O
be	O
considered	B-C0750591
as	O
candidates	B-C0021764
for	O
potential	B-C3245505
therapeutic	B-C0302350
targets	B-C1521840
in	O
thymosin	B-C0076616
β4	I-C0076616
roles	O
in	O
development	B-C1527148
,	O
repair	B-C0043240
,	O
and	O
engineering	B-C0205245
of	O
the	O
cardiovascular	B-C0007226
system	I-C0007226
the	O
burden	O
of	O
cardiovascular	B-C0007222
disease	I-C0007222
is	O
a	O
growing	O
worldwide	O
issue	O
that	O
demands	O
attention	O
.	O
	
while	O
many	O
clinical	B-C0008976
trials	I-C0008976
are	O
ongoing	O
to	O
test	B-C0039593
therapies	B-C0087111
for	O
treating	B-C1522326
the	O
heart	B-C0018787
after	O
myocardial	B-C0027051
infarction	I-C0027051
mi	B-C0027051
and	O
heart	B-C0018801
failure	I-C0018801
,	O
there	O
are	O
few	O
options	O
doctors	B-C0031831
able	O
to	O
currently	O
give	O
patients	B-C0030705
to	O
repair	B-C0189919
the	I-C0189919
heart	I-C0189919
.	O
	
this	O
eventually	O
leads	O
to	O
decreased	O
ventricular	B-C1258017
contractility	I-C1258017
and	O
increased	O
systemic	B-C0442893
disease	I-C0442893
,	O
including	O
vascular	B-C0042373
disorders	I-C0042373
that	O
could	O
result	O
in	O
stroke	B-C0038454
.	O
	
small	O
peptides	B-C0030956
such	O
as	O
thymosin	B-C0076616
β4	I-C0076616
tβ4	B-C0076616
are	O
upregulated	O
in	O
the	O
cardiovascular	B-C3887460
niche	B-C0333343
during	O
fetal	B-C4246208
development	I-C4246208
and	O
after	O
injuries	B-C0018805
such	O
as	O
mi	B-C0027051
,	O
providing	O
increased	O
neovasculogenesis	B-C0027671
and	O
paracrine	B-C0525011
signals	I-C0525011
for	O
endogenous	B-C0205227
stem	O
cell	O
recruitment	O
to	O
aid	O
in	O
wound	O
repair	O
.	O
	
new	O
research	O
is	O
looking	O
into	O
the	O
effects	O
of	O
in	O
vivo	O
administration	O
of	O
tβ4	O
through	O
injections	O
and	O
coatings	O
on	O
implants	O
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
cell	O
differentiation	O
.	O
	
results	O
so	O
far	O
demonstrate	O
tβ4	O
administration	O
leads	O
to	O
robust	O
increases	O
in	O
angiogenesis	O
and	O
wound	O
healing	O
in	O
the	O
heart	O
after	O
mi	O
and	O
the	O
brain	O
after	O
stroke	O
,	O
and	O
can	O
differentiate	O
adult	O
stem	O
cells	O
toward	O
the	O
cardiac	O
lineage	O
for	O
implantation	O
to	O
the	O
heart	O
to	O
increase	O
contractility	O
and	O
survival	O
.	O
	
future	O
work	O
,	O
some	O
of	O
which	O
is	O
currently	O
in	O
clinical	O
trials	O
,	O
will	O
demonstrate	O
the	O
in	O
vivo	O
effect	O
of	O
these	O
therapies	O
on	O
human	O
patients	O
,	O
with	O
the	O
goal	O
of	O
helping	O
the	O
millions	O
of	O
people	O
worldwide	O
affected	O
by	O
cardiovascular	O
disease	I-C0007222
yersinia	B-C1257868
ruckeri	I-C1257868
isolates	B-C3494793
recovered	B-C0521108
from	I-C0521108
diseased	B-C0012634
atlantic	B-C0327949
salmon	I-C0327949
salmo	B-C0327949
salar	I-C0327949
in	O
scotland	B-C0036453
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	B-C0036108
trout	I-C0036108
oncorhynchus	B-C0036108
mykiss	I-C0036108
and	O
represent	B-C1882932
distinct	O
subpopulations	B-C1257890
yersinia	B-C1257868
ruckeri	I-C1257868
is	O
the	O
etiological	B-C1314792
agent	I-C1314792
of	O
enteric	B-C0275759
redmouth	I-C0275759
erm	B-C0275759
disease	B-C0012634
of	O
farmed	O
salmonids	B-C0036129
.	O
	
enteric	B-C0275759
redmouth	I-C0275759
disease	I-C0275759
is	O
traditionally	O
associated	B-C0332281
with	I-C0332281
rainbow	B-C0036108
trout	I-C0036108
oncorhynchus	B-C0036108
mykiss	I-C0036108
,	O
walbaum	B-C0036108
,	O
but	O
its	O
incidence	B-C0021149
in	O
atlantic	B-C0327949
salmon	I-C0327949
salmo	B-C0327949
salar	I-C0327949
is	O
increasing	B-C0442808
.	O
	
yersinia	B-C1257868
ruckeri	I-C1257868
isolates	B-C3494793
recovered	B-C0521108
from	I-C0521108
diseased	B-C0012634
atlantic	B-C0327949
salmon	I-C0327949
have	O
been	O
poorly	B-C1880022
characterized	I-C1880022
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	B-C0439849
of	O
the	O
isolates	B-C3494793
associated	B-C0332281
with	I-C0332281
these	O
two	O
species	B-C1705920
.	O
	
phenotypic	B-C0031437
approaches	O
were	O
used	O
to	O
characterize	O
109	O
y	B-C1257868
.	O
	
ruckeri	I-C1257868
isolates	B-C3494793
recovered	O
over	O
a	O
14-year	O
period	O
from	O
infected	B-C0439663
atlantic	B-C0327949
salmon	I-C0327949
in	O
scotland	B-C0036453
26	O
isolates	B-C3494793
from	O
infected	B-C0439663
rainbow	B-C0036108
trout	I-C0036108
were	O
also	O
characterized	B-C1880022
.	O
	
biotyping	B-C0441707
,	O
serotyping	B-C0036759
,	O
and	O
comparison	B-C1707455
of	O
outer	B-C1167331
membrane	I-C1167331
protein	B-C3463810
profiles	I-C3463810
identified	O
19	O
y	B-C1257868
.	O
	
ruckeri	I-C1257868
clones	B-C1522642
associated	B-C0332281
with	I-C0332281
atlantic	B-C0327949
salmon	I-C0327949
but	O
only	O
five	O
associated	B-C0332281
with	I-C0332281
rainbow	B-C0036108
trout	I-C0036108
none	O
of	O
the	O
atlantic	B-C0327949
salmon	I-C0327949
clones	B-C1522642
occurred	O
in	O
rainbow	B-C0036108
trout	I-C0036108
and	O
vice	O
versa	O
these	O
findings	B-C0243095
suggest	O
that	O
distinct	O
subpopulations	B-C1257890
of	O
y	B-C1257868
.	O
	
ruckeri	I-C1257868
are	O
associated	B-C0332281
with	I-C0332281
each	O
species	B-C1705920
.	O
	
a	O
new	O
o	B-C0449549
serotype	I-C0449549
designated	O
o8	O
was	O
identified	O
in	O
56	B-C0449562
biotype	I-C0449562
1	I-C0449562
atlantic	B-C0327949
salmon	I-C0327949
isolates	B-C3494793
and	O
was	O
the	O
most	O
common	O
serotype	B-C0449943
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	B-C1512456
prevalence	I-C1512456
during	O
the	O
time	O
period	O
sampled	O
.	O
	
rainbow	B-C0036108
trout	I-C0036108
isolates	B-C3494793
were	O
represented	B-C1882932
almost	O
exclusively	O
by	O
the	O
same	O
biotype	B-C0449562
2	I-C0449562
,	O
serotype	B-C0449549
o1	I-C0449549
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
erm	B-C0275759
outbreaks	O
in	O
this	O
species	B-C1705920
within	O
the	O
united	B-C0041700
kingdom	I-C0041700
since	O
the	O
1980s	O
.	O
	
however	O
,	O
the	O
identification	O
of	O
two	O
biotype	B-C0449562
2	I-C0449562
,	O
serotype	B-C0449549
o8	I-C0449549
isolates	B-C3494793
in	O
rainbow	B-C0036108
trout	I-C0036108
suggests	O
that	O
vaccines	B-C0042210
containing	O
serotypes	B-C0449549
o1	I-C0449549
and	I-C0449549
o8	I-C0449549
should	O
be	O
evaluated	O
in	O
both	O
rainbow	B-C0036108
trout	I-C0036108
and	O
atlantic	B-C0327949
salmon	I-C0327949
for	O
application	O
in	O
scotland	B-C0036453
.	O
	
vaccination	B-C0042196
plays	O
an	O
important	O
role	O
in	O
protecting	O
atlantic	B-C0327949
salmon	I-C0327949
against	O
the	O
bacterial	B-C0004611
pathogen	O
yersinia	B-C1257868
ruckeri	I-C1257868
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	B-C0442808
incidence	B-C0021149
of	O
vaccine	B-C0042210
breakdown	O
in	O
salmon	B-C0036110
.	O
	
this	O
is	O
largely	O
because	O
current	O
vaccines	B-C0042210
are	O
aimed	O
at	O
rainbow	B-C0036108
trout	I-C0036108
and	O
are	O
based	O
on	O
serotypes	B-C0449943
specific	O
for	O
this	O
species	B-C1705920
.	O
	
a	O
wider	O
range	O
of	O
serotypes	B-C0449943
is	O
responsible	O
for	O
infection	B-C3714514
in	O
atlantic	B-C0327949
salmon	I-C0327949
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	B-C0327949
and	O
their	O
relationships	B-C0439849
to	O
those	O
recovered	B-C0521108
from	I-C0521108
rainbow	B-C0036108
trout	I-C0036108
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
y	B-C1257868
.	O
	
ruckeri	I-C1257868
isolates	B-C3494793
recovered	B-C0521108
from	I-C0521108
diseased	B-C0012634
atlantic	B-C0327949
salmon	I-C0327949
in	O
scotland	B-C0036453
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	B-C0036108
trout	I-C0036108
furthermore	O
,	O
isolates	B-C3494793
from	O
the	O
two	O
species	B-C1705920
represent	B-C1882932
distinct	O
subpopulations	B-C1257890
.	O
	
in	O
addition	O
,	O
a	O
new	O
o	B-C0449549
serotype	I-C0449549
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	B-C0750502
proportion	B-C1709707
of	O
the	O
disease	B-C0012634
in	O
atlantic	B-C0327949
salmon	I-C0327949
.	O
	
our	O
findings	B-C0243095
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	B-C0597634
of	I-C0597634
improved	I-C0597634
vaccines	I-C0597634
against	O
y	B-C1257868
.	O
	
ruckeri	I-C1257868
.	O
	
cd84	B-C0666283
mediates	O
cll	B-C0023434
-	O
microenvironment	B-C3494179
interactions	B-C0007582
chronic	B-C0023434
lymphocytic	I-C0023434
leukemia	I-C0023434
cll	B-C0023434
is	O
a	O
malignant	B-C0442867
disease	I-C0442867
of	O
small	O
mature	B-C1513026
lymphocytes	I-C1513026
.	O
	
signals	B-C1710082
from	O
the	O
cll	B-C0023434
microenvironment	B-C3494179
promote	B-C0033414
progression	B-C0242656
of	I-C0242656
the	I-C0242656
disease	I-C0242656
and	O
induce	B-C0205263
drug	B-C0013203
resistance	I-C0013203
.	O
	
this	O
phenomenon	B-C1882365
is	O
largely	O
dependent	B-C0851827
on	O
direct	O
contact	O
between	O
the	O
malignant	B-C0079731
b	I-C0079731
cells	I-C0079731
and	O
stromal	B-C1518246
cells	I-C1518246
.	O
	
cd84	B-C0666283
belongs	O
to	O
the	O
signaling	B-C4277631
lymphocyte	I-C4277631
activation	I-C4277631
molecule	I-C4277631
family	I-C4277631
of	O
immunoreceptors	B-C0597357
,	O
which	O
self-associates	B-C1819957
,	O
forming	O
an	O
orthogonal	B-C0596448
homophilic	I-C0596448
dimer	I-C0596448
.	O
	
we	O
therefore	O
hypothesized	O
that	O
cd84	B-C0666283
may	O
bridge	O
between	O
cll	B-C0023434
cells	B-C0007634
and	O
their	O
microenvironment	B-C3494179
,	O
promoting	B-C0033414
cell	B-C0007620
survival	I-C0007620
.	O
	
our	O
in	B-C1533691
vitro	I-C1533691
results	B-C1274040
show	O
that	O
cd84	B-C1171362
expressed	I-C1171362
on	O
cll	B-C0023434
cells	B-C0007634
interact	B-C1704675
with	O
cd84	B-C1171362
expressed	I-C1171362
on	O
cells	B-C0007634
in	O
their	O
microenvironment	B-C3494179
,	O
inducing	B-C0205263
cell	B-C0007620
survival	I-C0007620
in	O
both	O
sides	O
.	O
	
blocking	B-C0332206
cd84	B-C0666283
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
disrupt	B-C0332454
the	O
interaction	B-C1704675
of	O
cll	B-C0023434
cells	B-C0007634
with	O
their	O
microenvironment	B-C3494179
,	O
resulting	B-C0332294
in	I-C0332294
induced	B-C0205263
cell	B-C0007587
death	I-C0007587
.	O
	
thus	O
,	O
our	O
findings	B-C0243095
suggest	O
novel	B-C0205314
therapeutic	B-C0302350
strategies	O
based	O
on	O
the	O
blockade	B-C3540676
of	O
this	O
cd84	B-C0666283
-	O
dependent	B-C0851827
survival	B-C0007620
pathway	B-C1704259
.	O
	
aurantimonas	B-C1207105
endophytica	I-C1207105
sp	I-C1207105
.	O
	
nov	I-C1207105
,	O
a	O
novel	O
endophytic	B-C1265415
bacterium	I-C1265415
isolated	O
from	O
roots	B-C0242726
of	O
anabasis	B-C3012678
elatior	I-C3012678
c	I-C3012678
.	O
	
a	I-C3012678
.	O
	
mey	I-C3012678
schischk	I-C3012678
an	O
orange-coloured	B-C1313858
,	O
aerobic	B-C1510824
,	O
motile	B-C1979933
and	O
short-rods	B-C0004611
bacterial	I-C0004611
strain	I-C0004611
,	O
designated	O
egi	B-C0004611
6500337t	I-C0004611
,	O
was	O
isolated	O
from	O
the	O
surface-sterilized	O
root	B-C0242726
of	O
a	O
halophyte	B-C2350261
anabasis	B-C3012678
elatior	I-C3012678
c	I-C3012678
.	O
	
a	I-C3012678
.	O
	
mey	I-C3012678
schischk	I-C3012678
collected	O
from	O
urumqi	B-C0017446
,	O
xinjiang	B-C0017446
province	I-C0017446
,	O
north-west	B-C0008115
china	I-C0008115
.	O
	
growth	B-C0018270
occurred	O
at	O
5-35	O
c	O
optimum	O
30	O
c	O
,	O
at	O
ph	B-C0020283
6.0	O
optimum	O
ph	B-C0020283
7.0	O
,	O
and	O
in	O
the	O
presence	O
of	O
0-6	O
%	O
nacl	B-C0037494
w/v	O
optimum	O
0-1	O
%	O
.	O
	
phylogenetic	B-C1519069
tree	I-C1519069
based	O
on	O
16s	B-C3537372
rrna	I-C3537372
gene	B-C0162327
sequences	I-C0162327
indicated	O
that	O
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
formed	O
a	O
distinct	O
lineage	O
in	O
the	O
cluster	O
that	O
comprised	O
the	O
genera	B-C1207105
aurantimonas	I-C1207105
and	O
aureimonas	B-C1894985
in	O
the	O
family	B-C1494877
aurantimonadaceae	I-C1494877
.	O
	
the	O
16s	B-C3537372
rrna	I-C3537372
gene	B-C0162327
sequence	I-C0162327
of	O
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
shared	O
the	O
highest	O
similarities	O
to	O
those	O
of	O
aurantimonas	B-C1207106
coralicida	I-C1207106
dsm	I-C1207106
14790t	I-C1207106
97.15	O
%	O
and	O
aurantimonas	B-C2783928
manganoxydans	I-C2783928
dsm	I-C2783928
21871t	I-C2783928
97.15	O
%	O
.	O
	
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
contained	O
q-10	B-C0034435
as	O
the	O
dominant	O
isoprenoid	B-C0034435
quinone	I-C0034435
.	O
	
the	O
major	O
cellular	O
fatty	B-C0015684
acids	I-C0015684
were	O
c18	B-C2599892
7c	I-C2599892
66.4	O
%	O
and	O
c19	B-C0015684
8c	I-C0015684
cyclo	I-C0015684
23.3	O
%	O
.	O
	
the	O
polar	O
lipid	B-C0023779
profile	I-C0023779
of	O
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
contained	O
diphosphatidylglycerol	B-C0023779
,	O
phosphatidylglycerol	B-C0031619
,	O
phosphatidylcholine	B-C1959616
,	O
phosphatidylethanolamine	B-C0031618
as	O
major	O
components	O
,	O
similarly	O
to	O
the	O
members	O
of	O
the	O
genus	B-C1207105
aurantimonas	I-C1207105
.	O
	
the	O
dna	B-C0012854
g+c	B-C1135899
content	I-C1135899
of	O
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
was	O
66.8	O
mol%	O
.	O
	
the	O
dna	B-C0012854
-	O
dna	B-C0012854
relatedness	O
between	O
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
and	O
aurantimonas	B-C1207106
coralicida	I-C1207106
dsm	I-C1207106
14790t	I-C1207106
was	O
24.7	O
2.9	O
%	O
.	O
	
on	O
the	O
basis	O
of	O
the	O
phylogenetic	B-C1519068
analysis	I-C1519068
,	O
chemotaxonomic	B-C1511726
data	I-C1511726
and	O
phenotypic	B-C0031437
characteristics	I-C0031437
,	O
strain	B-C0004611
egi	I-C0004611
6500337t	I-C0004611
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	B-C1207105
aurantimonas	I-C1207105
,	O
for	O
which	O
the	O
name	O
aurantimonas	B-C1207105
endophytica	I-C1207105
sp	I-C1207105
.	O
	
nov	I-C1207105
.	O
	
is	O
proposed	O
.	O
	
the	O
type	O
strain	B-C0004611
is	O
egi	B-C0004611
6500337t	I-C0004611
=	O
kctc	B-C0004611
52296t	I-C0004611
=	O
cpcc	B-C0004611
100904t	I-C0004611
.	O
	
assessment	B-C0220825
and	O
classification	B-C0008902
of	O
protocol	B-C1705236
deviations	I-C1705236
deviations	B-C1705236
from	O
the	O
approved	O
trial	B-C2599718
protocol	I-C2599718
are	O
common	O
during	O
clinical	B-C0008976
trials	I-C0008976
.	O
	
they	O
have	O
been	O
conventionally	O
classified	B-C0008902
as	O
deviations	B-C1705236
or	O
violations	B-C1709750
,	O
depending	O
on	O
their	O
impact	B-C4049986
on	O
the	O
trial	B-C0008976
.	O
	
a	O
new	O
method	O
has	O
been	O
proposed	O
by	O
which	O
deviations	B-C1705236
are	O
classified	B-C0008902
in	O
five	O
grades	B-C0008902
from	I-C0008902
1	I-C0008902
to	I-C0008902
5	I-C0008902
.	O
	
a	O
deviation	B-C1705236
of	O
grade	B-C0687695
1	I-C0687695
has	O
no	B-C1513916
impact	B-C4049986
on	O
the	O
subjects'	B-C2349001
well-being	B-C0424578
or	O
on	O
the	O
quality	B-C0242483
of	I-C0242483
data	I-C0242483
.	O
	
at	O
the	O
maximum	O
,	O
a	O
deviation	B-C1705236
grade	B-C0441804
5	I-C0441804
leads	O
to	O
the	O
death	B-C1306577
of	O
the	O
subject	B-C2349001
.	O
	
this	O
method	O
of	O
classification	B-C0008902
was	O
applied	O
to	O
deviations	B-C1705236
noted	O
in	O
the	O
center	O
over	O
the	O
last	O
3	O
years	O
.	O
	
it	O
was	O
observed	O
that	O
most	O
deviations	B-C1705236
were	O
of	O
grades	B-C0008902
1	I-C0008902
and	I-C0008902
2	I-C0008902
,	O
with	O
fewer	O
falling	O
in	O
grades	B-C0008902
3	I-C0008902
and	I-C0008902
4	I-C0008902
.	O
	
there	O
were	O
no	O
deviations	B-C1705236
that	O
led	O
to	O
the	O
death	B-C3897054
of	I-C3897054
the	I-C3897054
subject	I-C3897054
grade	O
5	O
.	O
	
this	O
method	O
of	O
classification	B-C0008902
would	O
help	O
trial	B-C0008976
managers	B-C0335141
decide	O
on	O
the	O
action	O
to	O
be	O
taken	O
on	O
the	O
occurrence	B-C2745955
of	O
deviations	B-C1705236
,	O
which	O
would	O
be	O
based	O
on	O
their	O
fabrication	B-C1254366
and	O
modelling	B-C0870071
of	O
fractal	B-C0205148
,	O
biomimetic	B-C0205148
,	O
micro	B-C0205148
and	O
nano-topographical	B-C0205148
surfaces	I-C0205148
natural	B-C0205296
surface	B-C0459111
topographies	I-C0459111
are	O
often	O
self-similar	O
with	O
hierarchical	B-C2348519
features	I-C2348519
at	O
the	O
micro	B-C1254372
and	O
nanoscale	B-C1254372
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	B-C1254367
tissue	B-C0596171
engineering	I-C0596171
and	O
biomaterial	B-C0005479
design	B-C1707689
limitations	B-C0449295
.	O
	
specifically	O
,	O
a	O
cell's	B-C3179020
microenvironment	I-C3179020
within	O
the	O
human	B-C0242821
body	I-C0242821
contains	O
highly	O
optimised	O
,	O
fractal	B-C0005898
topographical	I-C0005898
cues	I-C0005898
,	O
which	O
directs	O
precise	O
cell	B-C0007634
behaviour	B-C0004927
.	O
	
however	O
,	O
recreating	B-C0205245
biomimetic	B-C0870781
,	O
fractal	B-C0870781
topographies	I-C0870781
in	B-C1533691
vitro	I-C1533691
is	O
not	O
a	O
trivial	B-C1522240
process	I-C1522240
and	O
a	O
number	O
of	O
fabrication	B-C1254366
methods	I-C1254366
have	O
been	O
proposed	O
but	O
often	O
fail	B-C0231175
to	O
precisely	O
control	B-C0243148
the	O
spatial	B-C1254362
resolution	I-C1254362
of	O
features	B-C2348519
at	O
different	B-C1705242
lengths	B-C1444754
scales	B-C0183110
and	O
hence	O
,	O
to	O
provide	O
true	O
biomimetic	B-C0871161
properties	I-C0871161
.	O
	
here	O
,	O
we	O
propose	O
a	O
method	B-C0025663
of	O
accurately	B-C0443131
reproducing	B-C0205245
the	O
self-similar	O
,	O
micro	B-C0870781
and	O
nanoscale	B-C0870781
topography	I-C0870781
of	O
a	O
human	B-C0086418
biological	B-C0457457
tissue	I-C0457457
into	O
a	O
synthetic	B-C0440257
polymer	I-C0440257
through	O
an	O
innovative	O
fabrication	B-C1254366
process	I-C1254366
.	O
	
the	O
biological	B-C0457457
tissue	I-C0457457
surface	B-C0205148
was	O
characterised	B-C1880022
using	O
atomic	B-C0242849
force	I-C0242849
microscopy	I-C0242849
afm	B-C0242849
to	O
obtain	O
spatial	B-C1254362
data	B-C1511726
in	O
x	O
,	O
y	O
and	O
z	O
,	O
which	O
was	O
converted	O
into	O
a	O
grayscale	B-C2827989
'digital	I-C2827989
photomask'	I-C2827989
.	O
	
as	O
a	O
result	O
of	O
maskless	B-C0599199
grayscale	I-C0599199
optical	I-C0599199
lithography	I-C0599199
followed	O
by	O
modified	B-C1254366
deep	I-C1254366
reactive	I-C1254366
ion	I-C1254366
etching	I-C1254366
and	O
replica	B-C1254366
molding	I-C1254366
,	O
we	O
were	O
able	O
to	O
accurately	B-C0443131
reproduce	O
the	O
fractal	B-C0870781
topography	I-C0870781
of	O
acellular	B-C3494272
dermal	I-C3494272
matrix	I-C3494272
adm	B-C3494272
into	O
polydimethylsiloxane	B-C0137758
pdms	B-C0137758
.	O
	
characterisation	B-C1880022
using	O
afm	B-C0242849
at	O
three	O
different	B-C1705242
length	B-C1444754
scales	B-C0183110
revealed	O
that	O
the	O
nano	B-C0870781
and	O
micro-topographical	B-C0870781
features	B-C2348519
,	O
in	O
addition	O
to	O
the	O
fractal	B-C0439534
dimension	I-C0439534
,	O
of	O
native	B-C0302891
adm	B-C3494272
were	O
reproduced	B-C0205245
in	O
pdms	B-C0137758
.	O
	
in	O
conclusion	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal	B-C0870781
topography	I-C0870781
of	O
biological	B-C0205148
surfaces	I-C0205148
can	O
be	O
mimicked	O
in	O
synthetic	B-C0440251
materials	I-C0440251
using	O
the	O
novel	B-C0205314
fabrication	B-C1254366
process	I-C1254366
outlined	O
,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical	B-C0025080
device	I-C0025080
biocompatibility	B-C0596177
and	O
investigating	B-C1292732
effects	B-C1704420
of	I-C1704420
acidic	B-C0020283
ph	I-C0020283
on	O
proliferation	B-C0596290
,	O
invasion	B-C2699153
and	O
drug	B-C1254351
-	O
induced	B-C0205263
apoptosis	B-C0162638
in	O
lymphoblastic	B-C0023448
leukemia	I-C0023448
some	O
studies	O
have	O
shown	O
that	O
extracellular	B-C0015352
ph	B-C0020283
in	O
tumors	B-C0027651
,	O
which	O
results	O
in	O
tumor	B-C0178874
progression	I-C0178874
,	O
is	O
less	O
than	O
that	O
in	O
normal	B-C0205307
tissues	B-C0040300
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
extracellular	B-C0015352
acidic	B-C0020283
ph	I-C0020283
on	O
proliferation	B-C0596290
,	O
invasion	B-C2699153
,	O
and	O
drug	B-C1254351
-	O
induced	B-C0205263
apoptosis	B-C0162638
in	O
acute	B-C0883208
lymphoblastic	I-C0883208
cells	I-C0883208
.	O
	
the	O
cells	B-C0883208
were	O
cultured	O
in	O
different	B-C1705242
ph	B-C0020283
ph	B-C0020283
6.6	O
and	O
ph	B-C0020283
7.4	O
for	O
12	O
days	B-C0439228
.	O
	
cell	B-C0596290
proliferation	I-C0596290
was	O
assessed	B-C1516048
by	O
mtt	B-C2986858
assay	I-C2986858
and	O
cell	B-C2699153
invasion	I-C2699153
was	O
assayed	O
by	O
invasion	B-C0022885
assay	I-C0022885
and	O
gene	B-C1880945
expression	I-C1880945
analysis	I-C1880945
of	O
mmp-9	B-C0165519
.	O
	
drug	B-C1254351
-	O
induced	B-C0205263
apoptosis	B-C0162638
was	O
evaluated	O
after	O
exposure	B-C0332157
to	I-C0332157
doxorubicin	B-C0013089
for	O
24	O
hours	O
by	O
annexin	B-C0059249
v	I-C0059249
/	O
pi	B-C0033470
staining	B-C0487602
and	O
gene	B-C1880945
expression	I-C1880945
analysis	I-C1880945
of	O
bax	B-C0219474
pro-apoptotic	I-C0219474
protein	I-C0219474
.	O
	
the	O
results	O
indicated	O
the	O
enhanced	O
growth	B-C0007595
and	O
invasion	B-C2699153
of	O
leukemic	B-C0023418
cells	B-C0007634
at	O
ph	B-C0020283
6.6	O
p	O
0.05	O
.	O
	
furthermore	O
,	O
the	O
cells	B-C0007634
at	O
ph	B-C0020283
6.6	O
were	O
resistant	B-C0332325
to	O
apoptosis	B-C0162638
by	O
doxorubicin	B-C0013089
p	O
0.05	O
.	O
	
it	O
can	O
be	O
concluded	O
that	O
acidic	B-C0020283
ph	I-C0020283
increases	B-C0442805
the	O
proliferation	B-C0596290
,	O
invasion	B-C2699153
and	O
reduces	B-C0392756
the	O
drug	B-C1254351
-	O
induced	B-C0205263
apoptosis	B-C0162638
in	O
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
.	O
	
extracellular	B-C0015352
acidity	B-C0020283
can	O
influence	O
the	O
behavior	O
of	O
leukemic	B-C0023418
cells	B-C0007634
and	O
therefore	O
,	O
the	O
manipulation	B-C0205245
of	O
extracellular	B-C0015349
liquid	I-C0015349
can	O
be	O
selected	O
as	O
a	O
therapeutic	B-C0087111
strategy	I-C0087111
for	O
leukemia	B-C0023418
,	O
especially	O
for	O
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
.	O
	
gold	B-C0018026
-	O
nanosponge	B-C0441126
-based	O
multistimuli-responsive	B-C0042444
drug	I-C0042444
vehicles	I-C0042444
for	O
targeted	B-C1521840
chemo-photothermal	B-C0087111
therapy	I-C0087111
gold	B-C0018026
-	O
nanosponge	B-C0441126
-based	O
multistimuli-responsive	B-C0042444
drug	I-C0042444
vehicles	I-C0042444
are	O
constructed	O
for	O
combined	O
chemo-photothermal	B-C0087111
therapy	I-C0087111
with	O
pinpointed	O
drug	B-C1254351
delivery	B-C1705822
and	O
release	B-C0391871
capabilities	O
and	O
minimized	O
nonspecific	B-C0750540
systemic	B-C0205373
spread	B-C0332261
of	O
drugs	B-C0013227
,	O
remarkably	O
enhancing	B-C2349975
the	O
therapeutic	B-C2348767
efficiency	I-C2348767
while	O
minimizing	O
acute	B-C0205178
side	B-C0041755
effects	I-C0041755
.	O
	
hemodynamic	B-C0019010
correlates	O
of	O
transient	B-C0338656
cognitive	I-C0338656
impairment	I-C0338656
after	O
transient	B-C0007787
ischemic	I-C0007787
attack	I-C0007787
and	O
minor	B-C0038454
stroke	I-C0038454
a	O
transcranial	B-C0554756
doppler	I-C0554756
study	I-C0554756
transient	B-C0338656
cognitive	I-C0338656
impairment	I-C0338656
tci	B-C0338656
on	O
the	O
mini	B-C0451306
mental	I-C0451306
state	I-C0451306
evaluation	I-C0451306
score	B-C0449820
is	O
common	O
after	O
transient	B-C0007787
ischemic	I-C0007787
attack	I-C0007787
/	O
minor	B-C0038454
stroke	I-C0038454
and	O
might	O
identify	B-C0205396
patients	B-C0030705
at	O
increased	O
risk	B-C0035647
of	O
dementia	B-C0497327
.	O
	
we	O
aimed	B-C1947946
to	O
replicate	B-C1883725
tci	B-C0338656
using	O
the	O
montreal	B-C3496286
cognitive	I-C3496286
assessment	I-C3496286
moca	B-C3496286
,	O
compare	B-C1707455
it	O
with	O
persistent	B-C1270972
mild	I-C1270972
cognitive	I-C1270972
impairment	I-C1270972
pmci	B-C1270972
,	O
and	O
to	O
determine	O
whether	O
global	B-C2348867
cerebral	B-C0228174
hemodynamic	B-C0019010
changes	B-C0392747
could	O
explain	O
transient	B-C0205374
impairment	B-C0221099
.	O
	
consecutive	O
patients	B-C0030705
with	O
transient	B-C0007787
ischemic	I-C0007787
attack	I-C0007787
/	O
minor	B-C0038454
stroke	I-C0038454
nihss	O
3	O
were	O
assessed	B-C1516048
with	O
the	O
moca	B-C3496286
and	O
transcranial	B-C0206077
doppler	I-C0206077
ultrasound	I-C0206077
acutely	B-C0205178
and	O
at	O
1	O
month	O
.	O
	
we	O
compared	B-C1707455
patients	B-C0030705
with	O
tci	B-C0338656
baseline	B-C1442488
moca	B-C3496286
<	O
26	O
with	O
2	O
points	B-C1552961
increase	B-C0442805
at	O
1	O
month	O
,	O
pmci	B-C1270972
moca	B-C3496286
<	O
26	O
with	O
<	O
2	O
points	B-C1552961
increase	B-C0442805
,	O
and	O
no	B-C4230628
cognitive	I-C4230628
impairment	I-C4230628
nci	B-C4230628
moca	B-C3496286
26	O
.	O
	
of	O
326	O
patients	B-C0030705
,	O
46	O
14.1	O
had	O
pmci	B-C1270972
,	O
98	O
30.1	O
tci	B-C0338656
,	O
and	O
182	O
55.8	O
nci	B-C4230628
.	O
	
at	O
baseline	B-C1442488
,	O
tci	B-C0338656
patients	B-C0030705
had	O
higher	B-C0277884
systolic	I-C0277884
blood	I-C0277884
pressure	I-C0277884
150.95	O
21.52	O
vs	O
144.86	O
22.44	O
mmhg	O
,	O
p	O
=	O
0.02	O
and	O
lower	B-C0205251
cerebral	B-C0005798
blood	I-C0005798
flow	I-C0005798
velocities	I-C0005798
,	O
particularly	O
end-diastolic	B-C0439830
velocity	I-C0439830
30.16	O
9.63	O
vs	O
35.02	O
9.01	O
cm/s	O
,	O
p	O
<	O
0.001	O
and	O
mean	B-C4287833
flow	I-C4287833
velocity	I-C4287833
48.95	O
12.72	O
vs	O
54	O
12.46	O
cm/s	O
,	O
p	O
=	O
0.001	O
than	O
those	O
with	O
nci	B-C4230628
,	O
but	O
similar	O
clinical	B-C0205210
and	O
hemodynamic	B-C0019010
profiles	B-C1979963
to	O
those	O
with	O
pmci	B-C1270972
.	O
	
systolic	B-C0277885
bp	I-C0277885
fell	I-C0277885
between	O
baseline	B-C1442488
and	O
1	O
month	O
mean	B-C0444504
reduction	B-C0441610
=	O
14.01	O
21.26	O
mmhg	O
and	O
end-diastolic	B-C0439830
velocity	I-C0439830
and	O
mean	B-C4287833
flow	I-C4287833
velocity	I-C4287833
increased	B-C0442805
mean	B-C0444504
increase	B-C0442805
=	O
+	O
2.42	O
6.41	O
and	O
1.89	O
8.77	O
cm/s	O
,	O
respectively	O
,	O
but	O
these	O
changes	B-C0392747
did	O
not	B-C3842396
differ	I-C3842396
between	O
patients	B-C0030705
with	O
tci	B-C0338656
,	O
pmci	B-C1270972
,	O
and	O
nci	B-C4230628
.	O
	
tci	B-C0338656
is	O
detectable	B-C3830527
with	O
the	O
moca	B-C3496286
after	O
transient	B-C0007787
ischemic	I-C0007787
attack	I-C0007787
and	O
minor	B-C0038454
stroke	I-C0038454
and	O
has	O
similar	O
clinical	B-C0205210
and	O
hemodynamic	B-C0019010
profile	B-C1979963
to	O
pmci	B-C1270972
.	O
	
however	O
,	O
tci	B-C0338656
does	O
not	B-C0332197
appear	I-C0332197
to	O
be	O
due	O
to	O
exaggerated	B-C0442801
acute	B-C0205178
reversible	B-C0205343
global	B-C2348867
hemodynamic	B-C0019010
changes	B-C0392747
.	O
	
apixaban	B-C1831808
5	O
mg	O
twice	B-C1948050
daily	B-C0332173
and	O
clinical	B-C0205210
outcomes	B-C1274040
in	O
patients	B-C0030705
with	O
atrial	B-C0004238
fibrillation	I-C0004238
and	O
advanced	B-C0205179
age	B-C0001779
,	O
low	B-C0205251
body	B-C0005910
weight	I-C0005910
,	O
or	O
high	B-C0205250
creatinine	B-C0010294
a	O
secondary	B-C0683944
analysis	I-C0683944
of	O
a	O
randomized	B-C0206034
clinical	I-C0206034
trial	I-C0206034
in	O
the	O
apixaban	B-C1831808
for	O
reduction	B-C0392756
of	O
stroke	B-C0038454
and	O
other	O
thromboembolic	B-C0040038
complications	I-C0040038
in	O
atrial	B-C0004238
fibrillation	I-C0004238
aristotle	B-C0008976
trial	B-C0008976
,	O
the	O
standard	O
dose	B-C0178602
of	O
apixaban	B-C1831808
was	O
5	O
mg	O
twice	B-C1948050
daily	B-C0332173
patients	B-C0030705
with	O
at	O
least	O
2	O
dose	B-C0178602
-	O
reduction	B-C0392756
criteria-80	O
years	B-C0439234
or	O
older	O
,	O
weight	B-C0005910
60	O
kg	O
or	O
less	O
,	O
and	O
creatinine	B-C0428279
level	I-C0428279
1.5	O
mg/dl	O
or	O
higher-received	O
a	O
reduced	O
dose	O
of	O
apixaban	O
of	O
2.5	O
mg	O
twice	O
daily	O
.	O
	
little	O
is	O
known	O
about	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
who	O
received	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
.	O
	
to	O
determine	O
the	O
frequency	O
of	O
1	O
dose	O
-	O
reduction	O
criterion	O
and	O
whether	O
the	O
effects	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
on	O
stroke	O
or	O
systemic	O
embolism	O
and	O
bleeding	O
varied	O
among	O
patients	O
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
.	O
	
among	O
18	O
201	O
patients	O
in	O
the	O
aristotle	O
trial	O
,	O
17	O
322	O
were	O
included	O
in	O
this	O
analysis	O
.	O
	
annualized	O
event	O
rates	O
of	O
stroke	O
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	O
and	O
hazard	O
ratios	O
hrs	O
and	O
95%	O
cis	O
were	O
evaluated	O
.	O
	
interactions	O
between	O
the	O
effects	O
of	O
apixaban	O
vs	O
warfarin	O
and	O
the	O
presence	O
of	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
were	O
assessed	O
.	O
	
the	O
first	O
patient	O
was	O
enrolled	O
in	O
the	O
aristotle	O
trial	O
on	O
december	O
19	O
,	O
2006	O
,	O
and	O
follow-up	O
was	O
completed	O
on	O
january	O
30	O
,	O
2011	O
.	O
	
data	O
were	O
analyzed	O
from	O
january	O
2015	O
to	O
may	O
30	O
,	O
2016	O
.	O
	
analysis	O
of	O
major	O
bleeding	O
included	O
events	O
during	O
study	O
drug	O
treatment	O
.	O
	
analysis	O
of	O
stroke	O
or	O
systemic	O
embolism	O
was	O
based	O
on	O
intention	O
to	O
treat	O
.	O
	
of	O
the	O
patients	O
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
assigned	O
to	O
receive	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
or	O
warfarin	O
,	O
3966	O
had	O
1	O
dose	O
-	O
reduction	O
criterion	O
these	O
patients	O
had	O
higher	O
rates	O
of	O
stroke	O
or	O
systemic	O
embolism	O
hr	O
,	O
1.47	O
95%	O
ci	O
,	O
1.20	O
and	O
major	O
bleeding	O
hr	O
,	O
1.89	O
95%	O
ci	O
,	O
1.62	O
compared	O
with	O
those	O
with	O
no	O
dose	O
-	O
reduction	O
criteria	O
n	O
=	O
13	O
356	O
.	O
	
the	O
benefit	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
n	O
=	O
8665	O
compared	O
with	O
warfarin	O
n	O
=	O
8657	O
on	O
stroke	O
or	O
systemic	O
embolism	O
in	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
hr	O
,	O
0.94	O
95%	O
ci	O
,	O
0.66	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
hr	O
,	O
0.77	O
95%	O
ci	O
,	O
0.62	O
were	O
similar	O
p	O
for	O
interaction	O
=	O
36	O
.	O
	
similarly	O
,	O
the	O
benefit	O
of	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
compared	O
with	O
warfarin	O
on	O
major	O
bleeding	O
in	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
hr	O
,	O
0.68	O
95%	O
ci	O
,	O
0.53	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
hr	O
,	O
0.72	O
95%	O
ci	O
,	O
0.60	O
were	O
similar	O
p	O
for	O
interaction	O
=	O
71	O
.	O
	
similar	O
patterns	O
were	O
seen	O
for	O
each	O
dose	O
-	O
reduction	O
criterion	O
and	O
across	O
the	O
spectrum	O
of	O
age	O
,	O
body	O
weight	O
,	O
creatinine	O
level	B-C0441889
,	O
and	O
creatinine	O
clearance	O
.	O
	
patients	O
with	O
atrial	O
fibrillation	O
and	O
isolated	O
advanced	O
age	O
,	O
low	O
body	O
weight	O
,	O
or	O
renal	O
dysfunction	O
have	O
a	O
higher	O
risk	O
of	O
stroke	O
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	O
but	O
show	O
consistent	O
benefits	O
with	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
vs	O
warfarin	O
compared	O
with	O
patients	O
without	O
these	O
characteristics	O
.	O
	
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	O
is	O
safe	O
,	O
efficacious	O
,	O
and	O
appropriate	O
for	O
patients	O
with	O
only	O
1	O
dose	O
-	O
reduction	O
criterion	O
.	O
	
clinicaltrials.gov	O
identifier	O
transition	B-C2700061
from	O
hospital	B-C0019994
to	O
home	B-C0442519
in	O
preterm	B-C4048294
infants	I-C4048294
and	O
their	O
families	B-C0015576
when	O
the	O
day	B-C0439228
of	O
discharge	B-C0030685
from	O
a	O
neonatal	B-C0021709
intensive	I-C0021709
care	I-C0021709
unit	I-C0021709
nicu	B-C0021709
comes	O
for	O
the	O
parents	B-C0030551
of	O
newborn	B-C0021289
infants	I-C0021289
,	O
they	O
are	O
filled	O
with	O
long-awaited	O
joy	B-C0018592
and	O
happiness	B-C0018592
.	O
	
they	O
go	O
home	B-C0442519
feeling	B-C1527305
as	O
parents	B-C0030551
,	O
away	O
from	O
scheduled	B-C0205547
routines	I-C0205547
of	O
the	O
hospital	B-C0019994
,	O
monitor	B-C2091666
alarms	I-C2091666
,	O
clinical	B-C1456356
rounds	I-C1456356
,	O
numerous	B-C0439064
tests	B-C0022885
,	O
and	O
so	O
on	O
.	O
	
what	O
do	O
we	O
know	O
about	O
what	O
happens	B-C1709305
after	O
these	O
little	B-C0030705
patients	I-C0030705
and	O
their	O
families	B-C0015576
leave	B-C1706081
the	O
nicu	B-C0021709
what	O
happens	B-C1709305
from	O
the	O
point	O
of	O
leaving	B-C1706081
the	O
hospital	B-C0019994
until	O
when	O
things	O
get	O
settled	O
and	O
life	B-C0376558
becomes	O
perceived	B-C0030971
as	O
normal	B-C0205307
this	O
article	B-C0282420
presents	O
a	O
short	O
summary	B-C1706244
of	O
research	B-C0035168
conducted	O
with	O
the	O
vulnerable	B-C0949366
population	I-C0949366
of	O
high-risk	B-C0332167
and	O
preterm	B-C4048294
infants	I-C4048294
and	O
their	O
families	B-C0015576
postdischarge	B-C0586003
.	O
	
available	O
evidence	B-C3887511
suggests	O
that	O
transition	B-C2700061
to	O
home	B-C0442519
after	O
hospital	B-C0586003
discharge	I-C0586003
,	O
a	O
phenomenon	B-C1882365
that	O
many	O
families	B-C0015576
experience	B-C0596545
,	O
is	O
challenging	B-C0205556
and	O
requires	O
attention	B-C1283164
from	O
clinicians	B-C0871685
and	O
researchers	B-C0687734
if	O
we	O
are	O
to	O
provide	O
effective	B-C1704419
,	O
efficient	B-C0442799
,	O
and	O
high-quality	B-C0034379
care	I-C0034379
.	O
	
visual	B-C0042825
analytics	I-C0042825
for	O
pattern	B-C1518918
discovery	I-C1518918
in	O
home	B-C0994454
care	I-C0994454
.	O
	
clinical	B-C2347946
relevance	I-C2347946
for	O
quality	B-C2936612
improvement	I-C2936612
visualization	B-C0175631
can	O
reduce	O
the	O
cognitive	B-C0870301
load	I-C0870301
of	I-C0870301
information	I-C0870301
,	O
allowing	O
users	O
to	O
easily	O
interpret	B-C1285553
and	O
assess	B-C0184514
large	I-C0184514
amounts	I-C0184514
of	I-C0184514
data	I-C0184514
.	O
	
the	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home	B-C3878819
health	I-C3878819
data	I-C3878819
using	O
visual	B-C3536884
analysis	I-C3536884
techniques	I-C3536884
to	O
discover	O
clinically	B-C0449440
salient	I-C0449440
associations	B-C0750490
between	O
patient	B-C0815172
characteristics	I-C0815172
with	O
problem-oriented	B-C1550208
health	I-C1550208
outcomes	I-C1550208
of	O
older	B-C1443513
adult	I-C1443513
home	I-C1443513
health	I-C1443513
patients	I-C1443513
during	O
the	O
home	B-C0184605
health	I-C0184605
service	I-C0184605
period	O
.	O
	
knowledge	B-C0376554
,	O
behavior	B-C0004927
and	O
status	B-C0681889
ratings	I-C0681889
at	O
discharge	B-C0030685
as	O
well	O
as	O
change	O
from	O
admission	B-C0030673
to	O
discharge	B-C0030685
that	O
was	O
coded	O
using	O
the	O
omaha	B-C1140113
system	I-C1140113
was	O
collected	O
from	O
a	O
dataset	B-C0150098
on	O
988	O
de-identified	O
patient	B-C2707520
data	I-C2707520
from	O
15	O
home	B-C0019859
health	I-C0019859
agencies	I-C0019859
.	O
	
spss	B-C0037589
visualization	I-C0037589
designer	I-C0037589
v1.0	I-C0037589
was	O
used	O
to	O
visually	B-C0042825
analyze	I-C0042825
patterns	I-C0042825
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat	B-C1609081
maps	I-C1609081
and	O
histograms	B-C2348974
.	O
	
visualizations	B-C0175631
suggesting	O
clinical	B-C2826293
salience	I-C2826293
were	O
tested	B-C0039593
for	O
significance	O
using	O
correlation	B-C0010101
analysis	I-C0010101
.	O
	
the	O
mean	O
age	O
of	O
the	O
patients	B-C0030705
was	O
80	O
years	O
,	O
with	O
the	O
majority	O
female	B-C0086287
66%	O
.	O
	
of	O
the	O
150	O
visualizations	B-C0175631
,	O
69	O
potentially	O
meaningful	B-C1609081
patterns	I-C1609081
were	O
statistically	O
evaluated	O
through	O
bivariate	B-C0681927
associations	I-C0681927
,	O
revealing	O
21	O
significant	O
associations	B-C0750490
.	O
	
further	O
,	O
14	O
associations	B-C0750490
between	O
episode	O
length	O
and	O
charlson	B-C3714916
co-morbidity	I-C3714916
index	I-C3714916
mainly	O
with	O
urinary	B-C1524119
related	O
diagnoses	B-C0338067
and	I-C0338067
problems	I-C0338067
remained	O
significant	O
after	O
adjustment	O
analyses	O
.	O
	
through	O
visual	B-C0042825
analysis	I-C0042825
,	O
the	O
adverse	O
association	B-C0750490
of	O
the	O
longer	O
home	B-C0085554
health	I-C0085554
episode	I-C0085554
length	O
and	O
higher	O
charlson	B-C3714916
co-morbidity	I-C3714916
index	I-C3714916
with	O
behavior	B-C0243095
or	I-C0243095
status	I-C0243095
outcomes	I-C0243095
for	O
patients	B-C0030705
with	O
impaired	B-C0871563
urinary	I-C0871563
function	I-C0871563
was	O
revealed	O
.	O
	
we	O
have	O
demonstrated	O
the	O
use	O
of	O
visual	B-C0042825
analysis	I-C0042825
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high-needs	O
subgroups	B-C1515021
among	O
the	O
older	B-C2361270
home	I-C2361270
health	I-C2361270
patient	I-C2361270
population	I-C2361270
.	O
	
the	O
effective	O
presentation	O
of	O
these	O
data	B-C1609081
patterns	I-C1609081
can	O
allow	O
clinicians	B-C0871685
to	O
identify	O
areas	O
of	O
patient	B-C3858649
improvement	I-C3858649
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home	B-C1553498
health	I-C1553498
interventions	I-C1553498
to	O
improve	O
patient	B-C0030698
outcomes	I-C0030698
.	O
	
transforming	B-C1704256
growth	I-C1704256
factor	I-C1704256
beta	I-C1704256
1	I-C1704256
tgf-β1	B-C1704256
in	O
thyroid	B-C0007115
cancer	I-C0007115
patients	B-C0030705
a	O
view	O
from	O
the	O
peripheral	B-C0229664
blood	I-C0229664
transforming	B-C0040690
growth	I-C0040690
factor	I-C0040690
beta	I-C0040690
tgf-β	B-C0040690
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	B-C0031847
conditions	B-C0348080
,	O
including	O
cancer	B-C0006826
.	O
	
the	O
level	B-C0441889
of	O
tgf-β	B-C0040690
in	O
patients	B-C0030705
with	O
differentiated	B-C1337013
thyroid	I-C1337013
cancer	I-C1337013
dtc	B-C1337013
has	O
not	O
been	O
examined	B-C0332128
so	O
far	O
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
measure	O
tgf-β	B-C0040690
concentration	B-C1446561
in	O
serum	B-C1550100
samples	I-C1550100
and	O
in	O
pha	B-C0031858
-	O
stimulated	B-C0038337
whole	B-C0370231
blood	I-C0370231
culture	B-C0200949
in	B-C1533691
vitro	I-C1533691
and	O
to	O
analyze	B-C0936012
possible	O
associations	O
of	O
tgf-β1	B-C1704256
levels	B-C0441889
with	O
leukocyte	B-C0023516
,	O
lymphocyte	B-C0024264
and	O
platelets	B-C0005821
counts	B-C0007584
,	O
the	O
histological	B-C0205462
type	O
of	O
thyroid	B-C0007115
cancer	I-C0007115
,	O
and	O
stage	B-C0699749
of	I-C0699749
disease	I-C0699749
.	O
	
tgf-β1	B-C1704256
was	O
measured	O
in	O
22	O
dtc	B-C1337013
patients	B-C0030705
and	O
20	O
healthy	B-C3898900
controls	B-C0009932
using	O
the	O
duoset	B-C0812225
elisa	I-C0812225
development	I-C0812225
kit	I-C0812225
for	O
human	B-C0080222
tgf-β1	I-C0080222
.	O
	
the	O
concentration	B-C1446561
of	O
tgf-β1	B-C1704256
in	O
serum	B-C1550100
samples	I-C1550100
from	O
both	O
groups	B-C1257890
correlated	O
positively	O
with	O
the	O
platelet	B-C0005821
counts	B-C0007584
.	O
	
there	O
was	O
no	O
statistically	B-C0237881
significant	I-C0237881
difference	O
in	O
the	O
serum	B-C0683149
concentrations	I-C0683149
of	O
tgf-β1	B-C1704256
between	O
dtc	B-C1337013
patients	B-C0030705
and	O
control	B-C0009932
subjects	I-C0009932
,	O
but	O
pha	B-C0031858
stimulated	B-C0038337
whole	B-C0370231
blood	I-C0370231
cultures	B-C0200949
of	O
dtc	B-C1337013
patients	B-C0030705
produced	O
less	O
tgf-β1	B-C1704256
than	O
those	O
from	O
controls	B-C0009932
.	O
	
additional	O
studies	B-C2603343
are	O
needed	O
to	O
determine	O
the	O
significance	B-C0750502
of	O
these	O
in	B-C1533691
vitro	I-C1533691
findings	B-C0243095
.	O
	
p-glycoprotein	B-C0242643
traffics	B-C0205245
from	O
the	O
nucleus	B-C0007610
to	O
the	O
plasma	B-C0007603
membrane	I-C0007603
in	O
rat	B-C1882598
brain	I-C1882598
endothelium	B-C0014257
during	O
inflammatory	B-C0234251
pain	I-C0234251
p-glycoprotein	B-C0242643
pgp	B-C0242643
,	O
a	O
drug	B-C1254351
efflux	B-C3824504
pump	I-C3824504
in	O
blood-brain	B-C0005854
barrier	I-C0005854
endothelial	B-C0225336
cells	I-C0225336
,	O
is	O
a	O
major	O
clinical	B-C0205210
obstacle	B-C0679881
for	O
effective	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
drug	B-C0087111
delivery	I-C0087111
.	O
	
identifying	B-C1254363
pgp	B-C0242643
regulatory	B-C1514829
pathways	I-C1514829
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
drug	B-C0087111
delivery	I-C0087111
.	O
	
we	O
previously	O
found	O
that	O
pgp	B-C1753353
activity	I-C1753353
increases	B-C0442805
in	O
rat	B-C1882598
brain	I-C1882598
microvessels	B-C2350570
concomitant	B-C0521115
with	O
decreased	B-C0205216
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
drug	B-C0087111
delivery	I-C0087111
in	O
response	O
to	O
acute	B-C0205178
peripheral	B-C0205100
inflammatory	B-C0234251
pain	I-C0234251
.	O
	
in	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
pgp	B-C0242643
traffics	B-C0205245
to	O
the	O
luminal	B-C0524462
plasma	B-C0007603
membrane	I-C0007603
of	O
the	O
microvessel	B-C2350570
endothelial	B-C0225336
cells	I-C0225336
from	O
intracellular	B-C0178719
stores	B-C1698986
during	O
peripheral	B-C0205100
inflammatory	B-C0234251
pain	I-C0234251
.	O
	
using	O
immunofluorescence	B-C0079604
microscopy	I-C0079604
,	O
we	O
detected	B-C0442726
pgp	B-C0242643
in	O
endothelial	B-C0225336
cell	I-C0225336
nuclei	B-C0007610
and	O
in	O
the	O
luminal	B-C0524462
plasma	B-C0007603
membrane	I-C0007603
in	O
control	B-C1511501
animals	I-C1511501
.	O
	
following	O
peripheral	B-C0205100
inflammatory	B-C0234251
pain	I-C0234251
,	O
luminal	B-C0524462
pgp	B-C0242643
staining	B-C0487602
increased	B-C0205217
while	O
staining	B-C0487602
in	O
the	O
nucleus	B-C0007610
decreased	B-C0205216
.	O
	
biochemical	B-C3495389
analysis	I-C3495389
of	O
nuclear	B-C0007610
pgp	B-C0242643
content	B-C0456205
confirmed	O
our	O
visual	B-C0199219
observations	I-C0199219
.	O
	
peripheral	B-C0205100
inflammatory	B-C0234251
pain	I-C0234251
also	O
increased	B-C0205217
endothelial	B-C0225336
cell	I-C0225336
luminal	B-C0524462
staining	B-C0487602
of	O
polymerase	B-C1419128
1	I-C1419128
and	I-C1419128
transcript	I-C1419128
release	I-C1419128
factor	I-C1419128
/	O
cavin1	B-C1419128
and	O
serum	B-C1419916
deprivation	I-C1419916
response	I-C1419916
protein	I-C1419916
/	O
cavin2	B-C1419916
,	O
two	O
caveolar	B-C0033684
scaffold	I-C0033684
proteins	I-C0033684
,	O
without	O
changing	O
caveolin1	B-C0033684
or	O
protein	B-C1418917
kinase	I-C1418917
c	I-C1418917
delta	I-C1418917
binding	I-C1418917
protein	I-C1418917
/	O
cavin3	B-C1418917
location	B-C0450429
.	O
	
our	O
data	B-C1511726
a	O
indicate	O
that	O
pgp	B-C0242643
traffics	B-C0205245
from	O
stores	B-C1698986
in	O
the	O
nucleus	B-C0007610
to	O
the	O
endothelial	B-C0225336
cell	I-C0225336
luminal	B-C0597895
membrane	I-C0597895
in	O
response	O
to	O
peripheral	B-C0205100
inflammatory	B-C0234251
pain	I-C0234251
b	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	B-C0302523
that	O
peripheral	B-C0205100
inflammatory	B-C0234251
pain	I-C0234251
inhibits	B-C3463820
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
drug	B-C1254351
uptake	B-C0243144
and	O
c	O
suggest	O
a	O
novel	B-C0205314
regulatory	B-C0243095
mechanism	I-C0243095
for	O
pgp	B-C1753353
activity	I-C1753353
in	O
rat	B-C1882598
brain	I-C1882598
.	O
	
functional	B-C0205245
impairment	B-C0221099
in	O
children	B-C0008059
with	O
externalizing	B-C0004930
behavior	I-C0004930
disorders	I-C0004930
psychometric	B-C0033920
properties	B-C0871161
of	O
the	O
weiss	B-C0282574
functional	I-C0282574
impairment	I-C0282574
rating	I-C0282574
scale-parent	I-C0282574
report	I-C0282574
in	O
a	O
german	B-C0017480
clinical	B-C0370003
sample	I-C0370003
to	O
examine	O
the	O
psychometric	B-C0033920
properties	B-C0871161
of	O
a	O
german	B-C0017480
adaptation	O
of	O
the	O
weiss	B-C0282574
functional	I-C0282574
impairment	I-C0282574
rating	I-C0282574
scale-parent	I-C0282574
report	I-C0282574
wfirs-p	B-C0282574
in	O
a	O
clinical	B-C0370003
sample	I-C0370003
of	O
children	B-C0008059
4-12	O
years	B-C0439234
with	O
externalizing	B-C0004930
behavior	I-C0004930
disorders	I-C0004930
.	O
	
data	B-C1511726
were	O
collected	B-C1516698
within	O
two	O
clinical	B-C0008976
trials	I-C0008976
n	O
=	O
264	O
.	O
	
factorial	B-C0871742
validity	I-C0871742
,	O
reliability	B-C2347947
,	O
and	O
divergent	B-C0392762
validity	I-C0392762
from	O
symptoms	B-C1457887
of	O
adhd	B-C1263846
and	O
oppositional	B-C0029121
defiant	I-C0029121
disorder	I-C0029121
odd	B-C0029121
were	O
assessed	B-C1516048
.	O
	
confirmatory	B-C0870334
factor	I-C0870334
analyses	I-C0870334
revealed	B-C0443289
that	O
a	O
bifactor	B-C3161035
model	I-C3161035
consistent	B-C0332290
with	I-C0332290
the	O
theoretical	B-C0871935
assumption	I-C0871935
of	O
a	O
general	B-C2827421
construct	I-C2827421
of	O
impairment	B-C0221099
total	O
scale	O
and	O
additional	B-C1524062
specific	B-C1521761
factors	I-C1521761
subscales	O
provided	O
satisfactory	B-C0205410
data	B-C1511726
fit	I-C1511726
.	O
	
model	B-C3161035
-based	O
reliability	B-C2347947
estimates	B-C0750572
showed	O
that	O
both	O
the	O
general	B-C2827421
construct	I-C2827421
and	O
specific	B-C1521761
factors	I-C1521761
accounted	O
for	O
item	O
variance	B-C1711260
.	O
	
internal	O
consistencies	B-C0332529
were	O
>	O
,	O
part-whole	O
corrected	O
item-scale	O
correlations	B-C1707520
mostly	O
>	O
.	O
	
correlations	B-C1707520
between	O
the	O
wfirs-p	B-C0282574
scales	I-C0282574
and	O
adhd	B-C1263846
and	O
odd	B-C0029121
symptoms	B-C1457887
were	O
low	B-C0205251
to	O
moderate	B-C0205081
.	O
	
the	O
results	B-C1274040
support	O
the	O
factorial	B-C0871742
validity	I-C0871742
,	O
reliability	B-C2347947
,	O
and	O
divergent	B-C0392762
validity	I-C0392762
of	O
the	O
what	O
can	O
the	O
canadians	B-C1257890
and	O
americans	B-C0596070
learn	B-C0023185
from	O
each	O
other's	O
health	B-C0018696
care	I-C0018696
systems	I-C0018696
numerous	O
papers	B-C0282420
have	O
been	O
written	O
comparing	B-C1707455
the	O
canadian	B-C1257890
and	O
us	B-C0041703
healthcare	B-C0018696
systems	I-C0018696
,	O
and	O
a	O
number	O
of	O
health	B-C0018735
policy	I-C0018735
experts	B-C0009817
have	O
recommended	B-C0034866
that	O
the	O
americans	B-C0596070
implement	B-C1708476
their	O
single-payer	B-C0282487
system	I-C0282487
to	O
save	O
12-20%	O
of	O
its	O
healthcare	B-C0015318
expenditures	I-C0015318
.	O
	
this	O
paper	B-C0282420
is	O
different	O
in	O
that	O
it	O
assumes	O
that	O
neither	O
country	B-C0454664
will	O
undertake	O
a	O
significant	B-C0750502
philosophic	B-C2986477
or	O
structural	B-C0678594
change	B-C0392747
in	O
their	O
healthcare	B-C0018696
system	I-C0018696
,	O
but	O
there	O
are	O
lessons	O
to	O
be	O
learned	B-C0023185
that	O
are	O
inherent	O
in	O
one	O
that	O
could	O
be	O
a	O
major	O
breakthrough	B-C0444503
for	O
the	O
other	O
.	O
	
following	O
the	O
model	B-C0006823
in	O
canada	B-C0006823
and	O
in	O
western	B-C0043129
europe	I-C0043129
,	O
the	O
usa	B-C0041703
could	O
implement	B-C1708476
universal	B-C0175671
health	B-C0021682
insurance	I-C0021682
so	O
that	O
the	O
32.0	O
million	O
2015	O
americans	B-C0596070
still	O
uninsured	B-C0087134
would	O
have	O
at	O
least	O
minimal	B-C0547040
coverage	B-C1551362
when	O
incurring	O
medical	B-C0015318
expenditures	I-C0015318
.	O
	
also	O
,	O
the	O
usa	B-C0041703
could	O
use	O
smart	B-C1519382
cards	I-C1519382
to	O
evaluate	B-C0013893
eligibility	I-C0013893
and	O
to	O
process	B-C1522240
health	B-C3824919
insurance	I-C3824919
claims	I-C3824919
these	O
changes	O
resulting	B-C0332294
in	I-C0332294
an	O
estimated	B-C0750572
15%	O
reduction	B-C0392756
in	O
us	B-C0041703
health	B-C0015318
expenditures	I-C0015318
without	O
adversely	O
effecting	B-C1280500
access	B-C0018748
or	O
quality	B-C0034379
of	I-C0034379
care	I-C0034379
.	O
	
such	O
a	O
strategy	O
would	O
result	B-C1274040
in	O
the	O
eventual	O
loss	B-C1517945
of	O
2.5	O
million	O
white-collar	B-C0028811
jobs	I-C0028811
at	O
hospitals	B-C0019994
,	O
physician	B-C0031834
offices	I-C0031834
and	O
insurance	B-C1549448
companies	I-C1549448
,	O
a	O
long-term	B-C0443252
economic	B-C0013557
gain	B-C1517378
.	O
	
only	O
a	O
few	O
would	O
agree	O
with	O
the	O
statement	O
that	O
canada	B-C0006823
already	O
functions	B-C0542341
with	O
a	O
multi-payer	B-C2348942
reimbursement	B-C0035002
system	I-C0035002
as	O
evidenced	O
by	O
1	O
a	O
federal	B-C0015737
-	O
provincial	B-C1514578
,	O
tax	B-C0039371
-	O
supported	B-C1521721
plan	B-C0679909
,	O
administered	O
by	O
each	O
of	O
the	O
provinces	B-C1514578
,	O
providing	O
universal	B-C0376640
coverage	I-C0376640
for	O
hospital	B-C0019994
and	O
physician	B-C0587569
services	I-C0587569
and	O
2	O
roughly	O
60%	O
of	O
its	O
residents	B-C2347958
receiving	O
employer-paid	B-C3824871
health	B-C0021682
insurance	I-C0021682
benefits	B-C0814225
,	O
underwritten	O
primarily	O
by	O
investor-owned	O
plans	O
,	O
that	O
are	O
less	O
than	O
effective	B-C1280519
to	O
reimburse	B-C0205432
for	O
pharmaceuticals	B-C0031321
,	O
dental	B-C0011365
and	O
other	O
healthcare	B-C0018747
services	I-C0018747
.	O
	
what	O
could	O
be	O
learned	O
from	O
the	O
usa	B-C0041703
and	O
particularly	O
from	O
western	B-C0043129
european	I-C0043129
countries	I-C0043129
is	O
possibly	O
implementing	B-C1708476
an	O
approach	O
,	O
whereby	O
at	O
least	O
upper-income	B-C0871944
canadians	B-C1257890
could	O
opt	O
out	O
of	O
their	O
federal	B-C0015737
-	O
provincial	B-C1514578
plan	B-C0679909
and	O
purchase	O
private	B-C0679727
insurance	B-C0376629
coverage	I-C0376629
-	O
being	O
eligible	O
for	O
far	O
more	O
comprehensive	O
"""private"""	O
benefits	O
for	O
hospital	B-C0019994
,	O
physician	B-C0587569
,	O
pharmaceutical	B-C0031321
,	O
dental	B-C0011365
and	O
other	O
healthcare	B-C0018747
services	I-C0018747
.	O
	
aside	O
from	O
generating	O
billions	O
of	O
additional	O
needed	O
revenues	B-C0681042
from	O
the	O
private	B-C0033176
sector	I-C0033176
,	O
it	O
could	O
1	O
help	O
eliminate	B-C1883720
long	O
waits	O
for	O
non-emergent	O
physicians'	O
care	O
by	O
appointing	O
newly	O
minted	O
specialists	B-C1611835
to	O
their	O
medical	B-C0025106
staffs	I-C0025106
2	O
offer	O
prompt	B-C0871157
admissions	B-C0184666
for	O
elective	B-C0745036
cases	I-C0745036
to	O
""""	O
private	B-C0033173
""""	O
wings	B-C0019994
of	I-C0019994
hospitals	I-C0019994
3	O
increase	B-C0205217
available	O
funding	B-C0243098
for	O
what	O
is	O
currently	B-C0521116
an	O
undercapitalized	B-C0243095
system	B-C0449913
4	O
enhance	B-C2349975
the	O
system's	O
sluggish	B-C3842079
operations	B-C3241922
and	O
5	O
encourage	O
more	O
competition	B-C0013550
among	O
various	O
providers	O
.	O
	
although	O
such	O
a	O
two-tier	B-C0025663
approach	I-C0025663
,	O
such	O
as	O
available	O
in	O
the	O
usa	B-C0041703
and	O
elsewhere	O
,	O
is	O
politically	O
dead	O
on	O
arrival	O
in	O
canada	B-C0006823
today	O
,	O
private	B-C3845555
insurance	I-C3845555
being	O
already	O
legal	B-C1301860
and	O
commonly	O
available	O
there	O
.	O
	
interestingly	O
,	O
this	O
recommended	B-C0034866
solution	O
is	O
utilized	O
in	O
most	O
western	B-C0043129
european	I-C0043129
countries	I-C0043129
where	O
there	O
is	O
a	O
higher	O
percentagea	B-C0439165
than	O
in	O
canada	B-C0006823
of	O
public	B-C0678367
versus	O
private	O
funding	B-C0243098
of	O
their	O
total	O
health	B-C0015318
expenditures	I-C0015318
.	O
	
because	O
of	O
various	O
vested	O
interests	O
,	O
attempts	B-C1516084
to	O
implement	B-C1708476
any	O
of	O
the	O
aforementioned	O
proposals	O
will	O
undoubtedly	O
result	B-C1274040
in	O
considerable	O
political	B-C0032379
rancor	B-C0542301
.	O
	
there	O
is	O
greater	O
likelihood	O
,	O
however	O
,	O
that	O
the	O
canadians	B-C1257890
because	O
their	O
need	O
to	O
be	O
more	O
effective	B-C1280519
and	O
efficient	B-C0442799
in	O
their	O
delivery	B-C0011211
of	I-C0011211
care	I-C0011211
,	O
and	O
their	O
overall	O
long-term	B-C0443252
fiscal	B-C0681005
outlook	O
will	O
agree	B-C3641827
to	O
the	O
further	O
privatization	B-C0033180
of	O
their	O
healthcare	B-C0018696
system	I-C0018696
before	O
the	O
americans	B-C0596070
will	O
mandate	O
universal	O
access	O
,	O
use	O
the	O
smart	B-C1519382
card	I-C1519382
to	O
process	O
insurance	B-C0680867
eligibility	I-C0680867
and	O
claims	O
or	O
will	O
impose	O
price	O
controls	B-C2587213
on	O
high-tech	O
services	O
and	O
on	O
pharmaceuticals	B-C1254351
.	O
	
optimal	B-C2698651
duration	B-C0449238
of	O
coronary	B-C0396819
ligation	I-C0396819
and	O
reperfusion	B-C0027054
for	O
reperfusion	B-C0035126
injury	I-C0035126
study	B-C2603343
in	O
a	O
rat	B-C0034721
model	B-C0026339
reperfusion	B-C0035126
injury	I-C0035126
ri	B-C0035126
has	O
an	O
important	B-C3898777
impact	B-C4049986
on	O
the	O
clinical	B-C0205210
prognosis	B-C3854082
for	O
patients	B-C0030705
with	O
acute	B-C0746730
myocardial	I-C0746730
injury	I-C0746730
who	O
had	O
their	O
coronary	B-C1522318
blood	B-C0232338
flow	I-C0232338
reestablished	B-C0443211
.	O
	
however	O
,	O
no	O
studies	B-C2603343
to	O
date	O
have	O
investigated	B-C1292732
the	O
timeframe	B-C0332168
of	O
coronary	B-C0151814
occlusion	I-C0151814
and	O
reperfusion	B-C0027054
effects	B-C1280500
on	O
ri	B-C0035126
.	O
	
a	O
total	O
of	O
100	O
rats	B-C0034721
were	O
divided	O
into	O
4	O
groups	B-C0441833
based	O
on	O
the	O
coronary	B-C0396819
ligation	I-C0396819
period	B-C1948053
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
,	O
and	O
each	O
group	B-C0441833
was	O
further	O
divided	O
into	O
5	O
subgroups	B-C0441833
with	O
different	B-C1705242
reperfusion	B-C0027054
periods	B-C1948053
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
.	O
	
r0	O
was	O
the	O
baseline	B-C1442488
of	O
each	O
subgroup	B-C0441833
.	O
	
all	O
animals	B-C0003062
received	O
the	O
same	O
protocols	B-C0542547
for	O
designed	B-C1707689
ligation	B-C0023690
and	O
reperfusion	B-C0027054
periods	B-C1948053
.	O
	
evans	B-C0015205
blue	I-C0015205
and	O
2	B-C0146883
chloride	I-C0146883
were	O
used	O
to	O
distinguish	O
different	B-C1705242
myocardial	B-C0746730
injury	I-C0746730
areas	B-C0205146
area	B-C0205146
at	B-C1444641
risk	I-C1444641
aar	B-C0205146
and	O
myocardial	B-C1442837
necrosis	I-C1442837
.	O
	
the	O
differences	B-C1705242
of	O
the	O
ratios	B-C0456603
of	O
the	O
necrotic	B-C0027540
area	B-C0205146
to	O
aar	B-C0205146
between	O
each	O
subgroup	B-C0441833
and	O
baseline	B-C1442488
were	O
further	O
averaged	B-C1510992
to	O
calculate	B-C1441506
an	O
overall	B-C1561607
value	B-C1522609
of	O
each	O
heart	B-C0018787
.	O
	
the	O
relative	O
ri	B-C0035126
percentages	B-C0439165
showed	O
significant	B-C0750502
differences	B-C1705242
0.8	O
2.3	O
,	O
4.9	O
3.3	O
,	O
10.8	O
3.1	O
,	O
and	O
20.3	O
3.6	O
respectively	O
,	O
p	O
<	O
0.001	O
at	O
different	B-C1705242
time	B-C2348792
points	I-C2348792
of	O
reperfusion	B-C0027054
but	O
not	O
at	O
different	B-C1705242
time	B-C2348792
points	I-C2348792
of	O
ligation	B-C0023690
p	O
=	O
0.593	O
.	O
	
the	O
effects	B-C1280500
of	O
different	B-C1705242
time	B-C0449247
courses	I-C0449247
in	O
ri	B-C0035126
showed	O
that	O
the	O
l120r180	O
group	B-C0441833
43.4	O
2.3	O
had	O
the	O
highest	B-C1522410
ri	B-C0035126
difference	B-C1705242
with	O
the	O
baseline	B-C1442488
group	B-C0441833
.	O
	
maximal	B-C0205289
ri	B-C0035126
occurred	O
at	O
the	O
timeframe	B-C0332168
of	O
l120r180	O
in	O
our	O
animal	B-C0026339
model	I-C0026339
.	O
	
this	O
result	B-C1274040
may	O
be	O
utilized	O
to	O
assess	B-C1516048
the	O
substantial	O
benefits	B-C0814225
of	O
ri	B-C0035124
therapies	I-C0035124
in	O
an	O
experimental	B-C0012644
rat	I-C0012644
model	I-C0012644
derivation	B-C1441547
of	O
a	O
predictive	B-C0681890
score	B-C0449820
for	O
hemorrhagic	B-C0019080
progression	B-C0449258
of	O
cerebral	B-C0750971
contusions	I-C0750971
in	O
moderate	B-C3508473
and	O
severe	B-C3508474
traumatic	I-C3508474
brain	I-C3508474
injury	I-C3508474
after	O
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
tbi	B-C0876926
,	O
hemorrhagic	B-C0019080
progression	B-C0449258
of	O
contusions	B-C0009938
hpcs	B-C0009938
occurs	O
frequently	B-C0332183
.	O
	
however	O
,	O
there	O
is	O
no	O
established	B-C0443211
predictive	B-C0681890
score	B-C0449820
to	O
identify	O
high-risk	B-C0332167
patients	B-C0030705
for	O
hpc	B-C0009938
.	O
	
consecutive	B-C1707491
patients	B-C0030705
who	O
were	O
hospitalized	B-C0701159
2008-2013	O
with	O
non-penetrating	O
moderate	B-C3508473
or	O
severe	B-C3508474
tbi	I-C3508474
were	O
studied	O
.	O
	
the	O
primary	B-C3274433
outcome	I-C3274433
was	O
hpc	B-C0009938
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	B-C0442805
in	O
contusion	B-C0009938
volume	B-C0449468
by	O
30	O
%	O
and	O
an	O
absolute	B-C0205344
increase	B-C0442805
by	O
10	O
ml	O
on	O
serial	B-C0203640
imaging	I-C0203640
.	O
	
logistic	B-C0023965
regression	I-C0023965
models	I-C0023965
were	O
created	B-C1706214
to	O
identify	O
independent	O
risk	B-C0035648
factors	I-C0035648
for	O
hpc	B-C0009938
.	O
	
the	O
hpc	B-C0009938
score	B-C0449820
was	O
then	O
derived	B-C1441547
based	O
on	O
the	O
final	B-C3161035
model	I-C3161035
.	O
	
among	O
a	O
total	O
of	O
286	O
eligible	O
patients	B-C0030705
,	O
61	O
21	O
%	O
patients	B-C0030705
developed	O
hpc	B-C0009938
.	O
	
on	O
univariate	B-C0683962
analyses	I-C0683962
,	O
hpc	B-C0009938
was	O
associated	B-C0332281
with	I-C0332281
older	B-C0001779
age	I-C0001779
,	O
higher	B-C0436789
initial	I-C0436789
blood	I-C0436789
pressure	I-C0436789
,	O
antiplatelet	B-C0085826
medications	I-C0085826
,	O
anticoagulants	B-C0003280
,	O
subarachnoid	B-C0038525
hemorrhage	I-C0038525
sah	B-C0038525
subdural	B-C0018946
hematoma	I-C0018946
sdh	B-C0018946
,	O
skull	B-C0037304
fracture	I-C0037304
,	O
frontal	B-C0016732
contusion	B-C0009938
,	O
larger	B-C0549177
contusion	B-C0009938
volume	B-C0449468
,	O
and	O
shorter	B-C1272706
interval	I-C1272706
from	O
injury	B-C0178314
to	O
initial	B-C0040405
ct	I-C0040405
.	O
	
in	O
the	O
final	B-C3161035
model	I-C3161035
,	O
sah	B-C0038525
or	B-C0028873
6.33	O
,	O
95	O
%	O
ci	B-C0009667
,	O
1.80	O
,	O
sdh	B-C0018946
or	B-C0028873
3.46	O
,	O
95	O
%	O
ci	B-C0009667
,	O
1.39	O
,	O
and	O
skull	B-C0037304
fracture	I-C0037304
or	B-C0028873
2.67	O
,	O
95	O
%	O
ci	B-C0009667
,	O
1.28	O
were	O
associated	B-C0332281
with	I-C0332281
hpc	B-C0009938
.	O
	
based	O
on	O
these	O
factors	B-C1521761
,	O
the	O
hpc	B-C0009938
score	B-C0449820
was	O
derived	B-C1441547
sah	B-C0038525
=	O
2	O
points	O
,	O
sdh	B-C0018946
=	O
1	O
point	O
,	O
and	O
skull	B-C0037304
fracture	I-C0037304
=	O
1	O
point	O
.	O
	
this	O
score	B-C0449820
had	O
an	O
area	O
under	O
the	O
receiver	B-C0035787
operating	I-C0035787
curve	I-C0035787
of	O
0.77	O
.	O
	
patients	B-C0030705
with	O
a	O
score	B-C0449820
of	O
0-2	O
had	O
a	O
4.0	O
%	O
incidence	B-C0021149
of	O
hpc	B-C0009938
,	O
while	O
patients	B-C0030705
with	O
a	O
score	B-C0449820
of	O
3-4	O
had	O
a	O
34.6	O
%	O
incidence	B-C0021149
of	O
hpc	B-C0009938
.	O
	
a	O
simple	O
hpc	B-C0009938
score	B-C0449820
was	O
developed	O
for	O
early	O
risk	B-C0035647
stratification	B-C1514984
of	O
hpc	B-C0009938
in	O
patients	B-C0030705
with	O
moderate	B-C3508473
or	O
severe	B-C3508474
tbi	I-C3508474
.	O
	
expressing	B-C0565975
sexuality	B-C0036915
in	O
nursing	B-C0028688
homes	I-C0028688
.	O
	
the	O
experience	B-C0683573
of	O
older	B-C0043210
women	I-C0043210
a	O
qualitative	B-C0949415
study	I-C0949415
in	O
nursing	B-C0028688
homes	I-C0028688
,	O
a	O
number	O
of	O
barriers	B-C4045969
to	O
the	O
expression	B-C0565975
of	O
sexuality	B-C0036915
exist	B-C2987476
,	O
such	O
as	O
the	O
lack	B-C2712041
of	I-C2712041
privacy	I-C2712041
,	O
certain	O
attitudes	B-C0004271
on	O
behalf	O
of	O
the	O
staff	B-C0028698
and	O
the	O
family	B-C0015576
,	O
the	O
lack	O
of	O
a	O
sexual	B-C0036911
partner	I-C0036911
,	O
and	O
physical	B-C0243095
limitations	I-C0243095
.	O
	
the	O
aim	O
of	O
this	O
study	B-C0949415
was	O
to	O
describe	O
the	O
lived	B-C0683573
experience	I-C0683573
of	O
sexuality	B-C0036915
in	O
elderly	B-C3161473
spanish	I-C3161473
women	I-C3161473
residing	O
in	O
nursing	B-C0028688
homes	I-C0028688
.	O
	
a	O
qualitative	B-C0949415
phenomenological	I-C0949415
approach	I-C0949415
was	O
followed	O
.	O
	
data	B-C1511726
were	O
collected	B-C0010995
over	O
an	O
18-	O
month	B-C0439231
period	I-C0439231
between	O
2013	O
and	O
2015	O
.	O
	
purposeful	O
sampling	B-C0870078
was	O
conducted	O
with	O
spanish	B-C2347958
residents	I-C2347958
in	O
nursing	B-C0028688
homes	I-C0028688
in	O
madrid	B-C0017446
.	O
	
data	B-C1511726
were	O
collected	O
using	O
unstructured	B-C0021822
and	I-C0021822
semi-structured	I-C0021822
interviews	I-C0021822
.	O
	
the	O
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
thematic	B-C0242481
analysis	I-C0242481
.	O
	
twenty	O
female	B-C0086287
residents	B-C2347958
participated	O
.	O
	
three	O
main	O
themes	B-C0869035
emerged	O
from	O
the	O
data	B-C1511726
a	O
expressing	B-C0565975
sexuality	B-C0036915
,	O
b	O
sexuality	B-C0036915
as	O
a	O
duty	B-C0028702
and	O
c	O
respecting	O
vows	B-C1254367
.	O
	
female	B-C0086287
residents	B-C2347958
reported	O
key	O
elements	O
influencing	O
how	O
they	O
manage	B-C0184516
their	O
sexuality	B-C0036915
in	O
nursing	B-C0028688
homes	I-C0028688
.	O
	
these	O
results	O
serve	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
expression	B-C0565975
of	O
sexuality	B-C0036915
in	O
older	B-C0086287
female	I-C0086287
nursing	B-C0028688
home	I-C0028688
residents	B-C2347958
.	O
	
xylan-based	B-C0062221
temperature	B-C0039476
/	O
ph	B-C0020283
sensitive	B-C0332324
hydrogels	B-C0600484
for	O
drug	B-C1707506
controlled	I-C1707506
release	I-C1707506
xylan-based	B-C0062221
temperature	B-C0039476
/	O
ph	B-C0020283
sensitive	B-C0332324
hydrogels	B-C0600484
were	O
prepared	O
by	O
the	O
crosslinking	B-C1880180
copolymerization	I-C1880180
of	O
xylan	B-C0062221
with	O
n-isopropylacrylamide	B-C0083668
nipam	B-C0083668
and	O
acrylic	B-C1321887
acid	I-C1321887
aa	B-C1321887
using	O
n	B-C0067314
mba	B-C0067314
as	O
a	O
cross-linker	B-C0034760
and	O
2	B-C1121773
as	O
a	O
photoinitiator	B-C0029224
via	O
ultraviolet	B-C0041625
irradiation	I-C0041625
.	O
	
the	O
influence	B-C4054723
of	O
the	O
nipam	B-C0083668
,	O
aa	B-C1321887
and	O
mba	B-C0067314
amount	O
on	O
properties	O
of	O
xylan-based	B-C0062221
hydrogels	B-C0600484
was	O
discussed	O
.	O
	
the	O
morphology	B-C0332437
and	O
interactions	B-C1704675
of	O
hydrogels	B-C0600484
were	O
characterized	B-C1880022
by	O
sem	B-C0026020
and	O
ftir	B-C0206055
.	O
	
the	O
lower	B-C0039476
critical	I-C0039476
solution	I-C0039476
temperature	I-C0039476
lcst	B-C0039476
of	O
hydrogels	B-C0600484
was	O
investigated	B-C1292732
by	O
dsc	B-C0006780
.	O
	
the	O
results	B-C0683954
indicated	O
that	O
the	O
lcst	B-C0039476
of	O
hydrogels	B-C0600484
emerged	O
at	O
around	O
34	O
and	O
increased	O
with	O
increasing	O
the	O
aa	B-C1321887
content	O
.	O
	
the	O
drug	B-C0013227
encapsulation	B-C2348438
efficiency	B-C0013682
of	O
as-prepared	O
hydrogels	B-C0600484
reached	O
to	O
97.60	O
and	O
the	O
cumulative	B-C1511559
release	B-C3850077
rate	B-C1521828
of	O
acetylsalicylic	B-C0004057
acid	I-C0004057
was	O
90.12	O
and	O
26.35	O
in	O
the	O
intestinal	B-C0021853
and	O
gastric	B-C2828094
fluid	I-C2828094
,	O
respectively	O
.	O
	
xylan-based	B-C0062221
hydrogels	B-C0600484
were	O
proved	O
to	O
be	O
biocompatible	B-C1524057
with	O
nih3t3	B-C0007600
cell	I-C0007600
by	O
mtt	B-C2986858
assay	I-C2986858
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	B-C0013161
carriers	I-C0013161
for	O
the	O
intestinal	B-C0021853
-	O
targeted	B-C1521840
oral	B-C0001563
drug	I-C0001563
delivery	I-C0001563
.	O
	
isolation	B-C0220862
and	O
prebiotic	B-C2717875
activity	B-C0205177
of	O
water-soluble	B-C0492715
polysaccharides	B-C0032594
fractions	B-C1264633
from	O
the	O
bamboo	B-C4040751
shoots	I-C4040751
phyllostachys	B-C1639319
praecox	I-C1639319
the	O
water-soluble	B-C0492715
polysaccharides	B-C0032594
from	O
bamboo	B-C4040751
shoots	I-C4040751
phyllostachys	B-C1639319
praecox	I-C1639319
wbp	B-C0032594
were	O
isolated	B-C0205409
,	O
and	O
the	O
characterizations	B-C0243175
as	O
well	O
as	O
prebiotic	B-C2717875
activities	B-C0205177
were	O
investigated	B-C1292732
.	O
	
the	O
yield	B-C0392762
of	O
wbp	B-C0032594
was	O
7.58	O
under	O
optimal	O
hot-water	B-C0337023
extraction	B-C0684295
conditions	O
.	O
	
two	O
fractions	B-C1264633
,	O
i.e	O
,	O
wbp-1	B-C0032594
and	O
wbp-2	B-C0032594
with	O
molecular	B-C0026385
weight	I-C0026385
of	O
83.50kda	O
and	O
80.08kda	O
,	O
respectively	O
,	O
were	O
purified	O
by	O
chromatography	B-C0008550
.	O
	
both	O
the	O
polysaccharides	B-C0032594
fractions	B-C1264633
were	O
identified	O
as	O
heteropolysaccharides-protein	B-C1704241
complexes	I-C1704241
composed	O
of	O
15	O
kinds	O
of	O
common	O
amino	B-C0002520
acids	I-C0002520
in	O
protein	B-C0033684
part	O
and	O
rhamnose	B-C0035417
,	O
arabinose	B-C0003682
,	O
xylose	B-C0043375
,	O
mannose	B-C0024742
,	O
glucose	B-C0017725
and	O
galactose	B-C0016945
in	O
different	O
molar	B-C2825550
ratios	I-C2825550
in	O
polysaccharide	B-C0032594
part	O
.	O
	
the	O
existence	O
of	O
α-	B-C0006999
and	O
β-glycosidic	B-C0006999
linkages	I-C0006999
between	O
the	O
sugar	B-C0007004
units	O
was	O
confirmed	O
by	O
ftir	B-C0206055
and	O
nmr	B-C0877853
spectra	I-C0877853
.	O
	
compared	O
with	O
the	O
blank	O
control	O
and	O
the	O
reference	O
of	O
fos	O
,	O
wbp-1	B-C0032594
and	O
wbp-2	B-C0032594
significantly	O
increased	O
the	O
numbers	O
of	O
bifidobacterium	B-C0314972
adolescentis	I-C0314972
and	O
bifidobacterium	B-C0314974
bifidum	I-C0314974
p<0	O
,	O
which	O
contributed	O
to	O
the	O
production	B-C0205245
of	O
organic	B-C0369760
acids	I-C0369760
,	O
suggesting	O
that	O
the	O
polysaccharides	B-C0032594
have	O
potential	B-C3245505
prebiotic	B-C2717875
properties	B-C0871161
.	O
	
evaluation	O
of	O
nutraceutical	B-C0243095
and	O
antinutritional	B-C0243095
properties	I-C0243095
in	O
barnyard	B-C1075468
and	O
finger	B-C0026145
millet	I-C0026145
varieties	B-C1254372
grown	O
in	O
himalayan	B-C0681784
region	I-C0681784
five	O
elite	O
varieties	B-C1254372
of	O
barnyard	B-C1075468
echinochloa	B-C1075468
frumentacea	I-C1075468
and	O
finger	B-C0997163
eleusine	B-C0997163
coracana	I-C0997163
growing	O
at	O
northwestern	B-C0681784
himalaya	I-C0681784
were	O
investigated	B-C1292732
for	O
nutraceutical	B-C0243095
and	O
antinutritional	B-C0243095
properties	I-C0243095
.	O
	
barnyard	B-C0026145
millet	I-C0026145
contained	O
higher	O
amount	B-C1265611
of	O
crude	B-C2348013
fiber	I-C2348013
,	O
total	B-C0012173
dietary	I-C0012173
fiber	I-C0012173
,	O
tryptophan	B-C0041249
content	B-C0456205
,	O
total	B-C0007271
carotenoids	I-C0007271
,	O
α-tocopherol	B-C0969677
compared	O
to	O
the	O
finger	B-C0026145
millet	I-C0026145
whereas	O
the	O
finger	B-C0026145
millet	I-C0026145
contains	O
higher	O
amount	B-C1265611
of	O
methionine	B-C0025646
and	O
ascorbic	B-C0003968
acid	I-C0003968
as	O
compared	O
to	O
the	O
barnyard	B-C0026145
millet	I-C0026145
.	O
	
the	O
secondary	B-C0870883
metabolites	I-C0870883
of	O
biological	B-C3714634
functions	I-C3714634
were	O
analyzed	O
and	O
found	O
that	O
barnyard	B-C0026145
millet	I-C0026145
contained	O
the	O
higher	O
amount	B-C1265611
of	O
polyphenols	B-C0071649
,	O
tannins	B-C0039294
and	O
ortho-dihydroxy	B-C0029224
phenol	I-C0029224
content	B-C0456205
compared	O
to	O
finger	B-C0026145
millet	I-C0026145
.	O
	
among	O
antinutitional	B-C0029224
compounds	I-C0029224
barnyard	B-C0026145
millet	I-C0026145
contained	O
lower	O
phytic	B-C0031855
acid	I-C0031855
content	B-C0456205
compare	O
to	O
finger	B-C0026145
millet	I-C0026145
whereas	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
in	O
trypsin	B-C1148560
inhibition	I-C1148560
activity	I-C1148560
of	O
barnyard	B-C0026145
millet	I-C0026145
and	O
finger	B-C0026145
millet	I-C0026145
varieties	B-C1254372
were	O
found	O
.	O
	
barnyard	B-C0026145
millet	I-C0026145
contained	O
higher	O
acid	B-C0001109
phosphatase	I-C0001109
,	O
α-galactosidase	B-C0016955
and	O
α-amylase	B-C1152556
inhibitor	I-C1152556
activity	I-C1152556
compared	O
to	O
finger	B-C0026145
millet	I-C0026145
.	O
	
finger	B-C0026145
millet	I-C0026145
seeds	I-C0026145
contained	O
about	O
10-13	O
folds	O
higher	O
calcium	B-C0006675
content	B-C0456205
and	O
double	O
amount	B-C1265611
of	O
manganese	B-C0024706
content	B-C0456205
in	O
comparison	O
to	O
barnyard	B-C0026145
millet	I-C0026145
seeds	I-C0026145
.	O
	
present	O
study	O
suggests	O
that	O
barnyard	B-C0026145
millet	I-C0026145
varieties	B-C1254372
studied	O
under	O
present	O
investigation	O
were	O
found	O
nutritionally	O
superior	O
compared	O
to	O
finger	B-C0026145
millet	I-C0026145
varieties	B-C1254372
.	O
	
polymorphisms	B-C0752046
in	O
inflammatory	B-C0333348
mediator	B-C0017337
genes	I-C0017337
and	O
risk	B-C0035647
of	O
preeclampsia	B-C0032914
in	O
taiyuan	B-C0681784
,	O
china	B-C0008115
excessive	B-C0442802
maternal	B-C1858460
inflammatory	B-C1155266
response	I-C1155266
is	O
involved	O
in	O
the	O
pathogenesis	B-C0699748
of	O
preeclampsia	B-C0032914
.	O
	
few	O
epidemiologic	B-C0002783
studies	I-C0002783
have	O
investigated	B-C1292732
the	O
associations	B-C0439849
between	O
genetic	B-C0042333
variations	I-C0042333
in	O
the	O
inflammatory	B-C0333348
mediator	B-C0017337
genes	I-C0017337
and	O
preeclampsia	B-C0032914
risk	B-C0035647
,	O
and	O
these	O
studies	B-C0002783
have	O
reached	O
inconsistent	O
results	O
.	O
	
we	O
examined	O
31	O
single-nucleotide	B-C0752046
polymorphisms	I-C0752046
in	O
il-1a	B-C1708430
,	O
il-1b	B-C1334112
,	O
il-1r1	B-C0391754
,	O
il-2ra	B-C1101536
,	O
il-5ra	B-C1704269
,	O
il-6	B-C1334122
,	O
il-6r	B-C0063717
,	O
tnfsf11	B-C1367028
,	O
tnfrsf11a	B-C1420805
,	O
il-28ra	B-C1425622
,	O
irak4	B-C1334137
,	O
and	O
kit	B-C1416655
genes	I-C1416655
and	O
the	O
risk	B-C0035647
of	O
preeclampsia	B-C0032914
and	O
its	O
clinical	B-C0205210
subtypes	B-C0449560
in	O
a	O
nested	B-C0027775
case-control	I-C0027775
study	I-C0027775
including	O
203	O
preeclampsia	B-C0032914
cases	B-C1706256
and	O
233	O
controls	B-C0009932
.	O
	
we	O
found	O
that	O
il-1r1	B-C0391754
,	O
il-5ra	B-C1704269
,	O
il-6r	B-C0063717
,	O
and	O
tnfsf11	B-C1367028
were	O
associated	B-C0332281
with	I-C0332281
the	O
risk	B-C0035647
of	O
preeclampsia	B-C0032914
.	O
	
although	O
the	O
significant	B-C0750502
associations	B-C0439849
observed	O
for	O
preeclampsia	B-C0032914
overall	B-C1561607
were	O
mainly	O
seen	O
for	O
late-onset	B-C4025592
preeclampsia	B-C0032914
and	O
severe	B-C0205082
preeclampsia	B-C0032914
,	O
il-6r	B-C0063717
rs2229238	B-C0282574
and	O
tnfsf11	B-C1367028
rs9525643	B-C0282574
polymorphisms	B-C0752046
were	O
associated	B-C0332281
with	I-C0332281
the	O
risk	B-C0035647
of	O
early-onset	O
preeclampsia	B-C0032914
.	O
	
tnfsf11	B-C1367028
rs2200287	B-C0282574
and	O
rs2148072	B-C0282574
polymorphisms	B-C0752046
were	O
associated	B-C0332281
with	I-C0332281
risk	B-C0035647
of	O
mild	O
preeclampsia	B-C0032914
.	O
	
our	O
study	B-C2603343
provided	O
the	O
first	O
evidence	B-C3887511
that	O
genetic	B-C0042333
variations	I-C0042333
in	O
inflammatory	B-C0333348
mediator	B-C0017337
genes	I-C0017337
il-1r1	B-C0391754
,	O
il-6r	B-C0063717
,	O
tnfsf11	B-C1367028
,	O
and	O
il-5ra	B-C1704269
were	O
associated	B-C0332281
with	I-C0332281
preeclampsia	B-C0032914
risk	B-C0035647
,	O
and	O
the	O
risk	B-C0035647
varied	O
by	O
preeclampsia	B-C0032914
subtypes	B-C0449560
.	O
	
a	O
closer	O
look	O
at	O
school	B-C0036375
bonding	B-C0237497
among	O
african	B-C0085756
american	I-C0085756
adolescents	B-C0205653
in	O
low-income	B-C0024045
communities	I-C0024045
a	O
latent	B-C0242481
class	I-C0242481
analysis	I-C0242481
positive	B-C1446409
school	B-C0036375
bonding	B-C0237497
is	O
a	O
significant	B-C0750502
precursor	B-C1709634
to	O
students	B-C0038492
'	O
school	B-C0036375
success	B-C0597535
.	O
	
however	O
,	O
african	B-C0085756
american	I-C0085756
youth	B-C0087178
report	O
lower	B-C0205251
school	B-C0036375
success	B-C0597535
compared	O
with	O
their	O
white	B-C1257890
counterparts	I-C1257890
.	O
	
this	O
study	B-C2603343
examined	O
correlates	B-C1707520
of	O
school	B-C0036375
bonding	B-C0237497
among	O
633	O
african	B-C0085756
american	I-C0085756
youth	B-C0087178
who	O
were	O
recruited	B-C2949735
from	O
community	B-C0009462
settings	I-C0009462
in	O
chicago	B-C0008044
.	O
	
major	B-C0205164
findings	B-C0243095
indicated	O
that	O
negative	B-C1513916
peer	I-C1513916
norms	I-C1513916
,	O
exposure	B-C0332157
to	I-C0332157
community	B-C4061413
violence	I-C4061413
,	O
and	O
poor	B-C2700379
mental	B-C0025353
health	I-C0025353
were	O
negatively	B-C0205160
correlated	B-C1707520
with	O
school	B-C0036375
bonding	B-C0237497
,	O
while	O
parental	B-C0814580
monitoring	I-C0814580
,	O
positive	B-C1821524
self-regard	I-C1821524
,	O
and	O
future	B-C0016884
orientation	B-C0029266
were	O
correlated	B-C1707520
with	O
higher	B-C0205250
school	B-C0036375
motivation	B-C0026605
.	O
	
students	B-C0038492
classified	B-C0008902
as	O
having	O
high	B-C0205250
or	O
moderate	B-C0205081
school	B-C0036375
bonding	B-C0237497
were	O
more	O
likely	O
to	O
live	B-C2982691
with	O
both	O
parents	B-C0030551
,	O
experience	B-C0596545
higher	B-C0205250
levels	B-C0441889
of	O
parental	B-C0814580
monitoring	I-C0814580
,	O
and	O
exhibit	B-C1821524
positive	I-C1821524
self-regard	I-C1821524
.	O
	
implications	O
are	O
discussed	O
in	O
view	O
of	O
these	O
depression	B-C0011570
,	O
anxiety	B-C0003469
,	O
stress	B-C0038443
,	O
and	O
their	O
associated	B-C0332281
factors	B-C1521761
among	O
corps	B-C0680022
members	I-C0680022
serving	O
in	O
kebbi	B-C0681784
state	I-C0681784
depression	B-C0011570
,	O
anxiety	B-C0003469
and	O
stress	B-C0038443
,	O
are	O
not	O
only	O
health	B-C1446377
problems	I-C1446377
by	O
themselves	O
,	O
but	O
also	O
associated	B-C0332281
with	I-C0332281
other	O
negative	B-C1513916
health	B-C0018684
consequences	B-C0686907
.	O
	
the	O
national	B-C1561598
youth	I-C1561598
service	I-C1561598
is	O
usually	O
characterized	B-C1880022
by	O
a	O
number	O
of	O
new	O
challenges	O
and	O
experiences	B-C0596545
which	O
may	O
require	O
life	B-C0023676
style	I-C0023676
adjustments	B-C0376209
by	O
the	O
corps	B-C0680022
member	I-C0680022
.	O
	
however	O
,	O
no	O
previous	O
study	O
on	O
psychological	B-C0033898
factors	I-C0033898
has	O
been	O
conducted	O
among	O
corps	B-C0680022
members	I-C0680022
.	O
	
this	O
study	B-C2603343
was	O
conducted	O
to	O
determine	O
the	O
prevalence	B-C0683921
of	O
depression	B-C0011570
,	O
anxiety	B-C0003469
and	O
,	O
stress	B-C0038443
and	O
their	O
associated	B-C0332281
factors	B-C1521761
among	O
corps	B-C0680022
members	I-C0680022
serving	O
in	O
kebbi	B-C0681784
state	I-C0681784
.	O
	
a	O
cross-sectional	B-C0010362
study	I-C0010362
was	O
conducted	O
among	O
264	O
corps	B-C0680022
members	I-C0680022
from	O
four	O
local	B-C0681785
government	I-C0681785
areas	I-C0681785
of	O
the	O
state	B-C1301808
.	O
	
selection	O
of	O
the	O
local	B-C0681785
government	I-C0681785
areas	I-C0681785
and	O
the	O
individual	O
participants	B-C0679646
was	O
by	O
simple	B-C0681878
random	I-C0681878
sampling	I-C0681878
.	O
	
data	B-C1511726
was	O
collected	O
from	O
may	B-C3812381
to	O
june	B-C3829443
2014	O
using	O
a	O
self-administered	B-C0034394
questionnaire	I-C0034394
.	O
	
data	B-C0010992
analysis	I-C0010992
used	O
chi-square	B-C0008041
test	I-C0008041
to	O
identify	O
the	O
relationship	B-C0439849
between	O
categorical	B-C0439828
variables	I-C0439828
and	O
multivariate	B-C0206031
logistic	I-C0206031
regression	I-C0206031
to	O
identify	O
the	O
independent	O
factors	B-C1521761
for	O
depression	B-C0011570
,	O
anxiety	B-C0003469
and	O
stress	B-C0038443
each	O
.	O
	
the	O
response	B-C0237629
rate	I-C0237629
was	O
97%	O
.	O
	
most	O
of	O
the	O
respondents	B-C0282122
were	O
males	B-C0086582
63.6	O
,	O
single	B-C0037179
85.5	O
,	O
and	O
above	O
20	O
years	B-C1510829
of	O
age	B-C0001779
71.6	O
.	O
	
the	O
overall	O
prevalences	B-C0033105
of	O
depression	B-C0011570
,	O
anxiety	B-C0003469
and	O
stress	B-C0038443
among	O
the	O
respondents	B-C0282122
were	O
36.4	O
,	O
54.5	O
and	O
18.2	O
respectively	O
.	O
	
the	O
independent	O
factors	B-C1521761
for	O
depression	B-C0011570
were	O
being	O
from	O
the	O
north	B-C0017446
central	I-C0017446
or	B-C0028873
=	O
5.99	O
95%	O
ci	B-C0009667
2.194	O
or	O
south-south	B-C0017446
and	O
the	O
perception	B-C0030971
of	O
earning	B-C0680989
enough	O
income	B-C0021162
or	B-C0028873
=	O
2.987	O
95%	O
ci	B-C0009667
1.062	O
.	O
	
for	O
anxiety	O
,	O
male	O
gender	O
or	O
=	O
0.411	O
95%	O
ci	B-C0009667
0.169	O
and	O
being	O
from	O
the	O
north	O
central	O
were	O
significant	O
risk	O
factors	O
or	O
=	O
3.731	O
95%	O
ci	O
1.450	O
.	O
	
being	O
above	O
26	O
years	O
of	O
age	O
was	O
an	O
independent	O
risk	O
factor	O
for	O
stress	O
or	O
=	O
0.083	O
95%	O
ci	O
0.018	O
.	O
	
also	O
,	O
those	O
who	O
had	O
ever	O
schooled	O
outside	O
their	O
towns	O
of	O
residence	O
were	O
less	O
likely	O
to	O
be	O
stressed	O
compared	O
to	O
those	O
who	O
had	O
never	O
or	O
=	O
0.30	O
95%	O
ci	O
0.110	O
.	O
	
all	O
other	O
factors	O
did	O
not	O
show	O
any	O
significant	O
association	O
with	O
any	O
of	O
the	O
outcome	O
variables	O
in	O
multivariate	O
analysis	O
.	O
	
in	O
conclusion	O
,	O
the	O
prevalences	O
of	O
depression	O
,	O
anxiety	B-C0003469
and	O
stress	O
are	O
high	O
among	O
corps	O
members	O
serving	O
in	O
kebbi	O
state	O
.	O
	
there	O
is	O
need	O
to	O
expand	O
the	O
scope	O
of	O
this	O
study	O
to	O
a	O
national	O
level	O
so	O
as	O
to	O
get	O
a	O
bigger	O
picture	O
of	O
the	O
problem	B-C0033213
trans-oral	B-C0442366
fine	B-C2236896
needle	I-C2236896
aspiration	I-C2236896
cytology	I-C2236896
in	O
cervical	B-C0223098
c1	I-C0223098
and	I-C0223098
c2	I-C0223098
vertebral	I-C0223098
lesions	B-C0221198
a	O
novel	O
diagnostic	B-C0430022
approach	I-C0430022
fine	B-C2236896
needle	I-C2236896
aspiration	I-C2236896
fna	I-C2236896
cytology	I-C2236896
is	O
a	O
relatively	O
non-invasive	B-C0205303
method	O
for	O
diagnosing	B-C0011900
both	O
superficial	B-C1336528
and	O
deep-seated	B-C0027651
neoplastic	I-C0027651
and	O
non-neoplastic	B-C0221198
lesions	I-C0221198
.	O
	
in	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	B-C0348026
utility	I-C0348026
of	O
trans-oral	B-C0442366
fna	B-C2236896
in	O
cervical	B-C0223098
c1	I-C0223098
and	I-C0223098
c2	I-C0223098
vertebral	I-C0223098
and	O
paravertebral	B-C0446501
lesions	B-C0221198
.	O
	
eighteen	O
fna	B-C2236896
cases	O
of	O
cervical	B-C0223098
vertebral	I-C0223098
and	O
paravertebral	B-C0446501
lesions	B-C0221198
performed	O
by	O
a	O
trans-oral	B-C0442366
route	I-C0442366
without	O
any	O
image-guidance	B-C1254363
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	B-C0010819
department	B-C1704729
at	O
pgimer	B-C0035172
,	O
chandigarh	B-C0681784
and	O
reviewed	O
.	O
	
out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	B-C0011900
was	O
given	O
in	O
15	O
cases	O
83.3	O
.	O
	
the	O
commonest	O
diagnosis	B-C0011900
seen	O
was	O
granulomatous	B-C0553697
inflammation	I-C0553697
consistent	O
with	O
tuberculosis	B-C0041296
33.3	O
.	O
	
trans-oral	B-C0442366
fna	B-C2236896
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	B-C1299353
procedure	I-C1299353
for	O
sampling	O
c1	B-C0223098
and	I-C0223098
c2	I-C0223098
vertebral	I-C0223098
and	O
paravertebral	B-C0446501
lesions	B-C0221198
,	O
which	O
are	O
clinically	B-C0683325
and	O
radiologically	B-C0039431
difficult	O
to	O
approach	O
.	O
	
it	O
helps	O
in	O
the	O
early	B-C0596473
diagnosis	I-C0596473
and	O
management	B-C1610129
of	I-C1610129
these	I-C1610129
patients	I-C1610129
.	O
	
neonatal	B-C0854706
infections	I-C0854706
case	B-C1704788
definition	I-C1704788
and	O
guidelines	B-C0162791
for	O
data	B-C0010995
collection	I-C0010995
,	O
analysis	B-C0936012
,	O
and	O
presentation	B-C0449450
of	O
immunisation	B-C0020971
safety	B-C1511726
data	I-C1511726
maternal	B-C1858460
vaccination	B-C0042196
is	O
an	O
important	O
area	O
of	O
research	B-C0035168
and	O
requires	O
appropriate	O
and	O
internationally	O
comparable	O
definitions	B-C1704788
and	O
safety	B-C2828392
standards	I-C2828392
.	O
	
the	O
gaia	B-C1522486
group	I-C1522486
,	O
part	O
of	O
the	O
brighton	B-C1522486
collaboration	I-C1522486
was	O
created	O
with	O
the	O
mandate	O
of	O
proposing	O
standardised	O
definitions	B-C1704788
applicable	O
to	O
maternal	B-C1858460
vaccine	B-C0042210
research	B-C0035168
.	O
	
this	O
study	B-C2603343
proposes	O
international	O
definitions	B-C1704788
for	O
neonatal	B-C0854706
infections	I-C0854706
.	O
	
the	O
neonatal	B-C0854706
infections	I-C0854706
gaia	B-C1522486
working	B-C1883562
group	I-C1883562
performed	O
a	O
literature	B-C0023866
review	B-C0565989
using	O
medline	B-C0025141
,	O
embase	B-C0242356
and	O
the	O
cochrane	B-C1882071
collaboration	I-C1882071
and	O
collected	O
definitions	B-C1704788
in	O
use	O
in	O
neonatal	B-C1882071
and	O
public	B-C1882071
health	I-C1882071
networks	I-C1882071
.	O
	
the	O
common	O
criteria	B-C0243161
derived	B-C1441547
from	O
the	O
extensive	O
search	O
formed	O
the	O
basis	O
for	O
a	O
consensus	B-C0376298
process	I-C0376298
that	O
resulted	O
in	O
three	O
separate	O
definitions	B-C1704788
for	O
neonatal	B-C0021289
blood	B-C2316160
stream	I-C2316160
infections	I-C2316160
bsi	B-C2316160
,	O
meningitis	B-C0025289
and	O
lower	B-C0149725
respiratory	I-C0149725
tract	I-C0149725
infections	I-C0149725
lrti	B-C0149725
.	O
	
for	O
each	O
definition	B-C1704788
three	O
levels	O
of	O
evidence	O
are	O
proposed	O
to	O
ensure	O
the	O
applicability	O
of	O
the	O
definitions	B-C1704788
to	O
different	O
settings	O
.	O
	
recommendations	O
about	O
data	B-C0010995
collection	I-C0010995
,	O
analysis	B-C0936012
and	O
presentation	B-C0449450
are	O
presented	O
and	O
harmonized	B-C0150103
with	O
the	O
brighton	B-C1522486
collaboration	I-C1522486
and	O
gaia	B-C1522486
format	B-C1301627
and	O
other	O
existing	O
international	B-C2828392
standards	I-C2828392
for	O
study	B-C2603343
reporting	B-C0011000
.	O
	
beneficial	B-C0814225
effects	B-C1280500
of	O
dark	B-C3853217
chocolate	I-C3853217
on	O
exercise	B-C0015259
capacity	B-C1516240
in	O
sedentary	B-C0205254
subjects	B-C2349001
underlying	O
mechanisms	B-C0441712
.	O
	
a	O
double	B-C0013072
blind	I-C0013072
,	O
randomized	B-C0034656
,	O
placebo	B-C1706408
controlled	I-C1706408
trial	B-C0008976
in	O
heart	B-C0018801
failure	I-C0018801
patients	B-C0030705
the	O
consumption	B-C1947907
of	O
-	B-C1881340
-	B-C1881340
cocoa	B-C0009209
can	O
restore	O
skeletal	B-C0242692
muscle	I-C0242692
skm	B-C0242692
mitochondrial	B-C0026237
structure	B-C0678594
and	O
decrease	B-C0547047
biomarkers	B-C0005516
of	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
however	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	B-C1280500
on	O
exercise	B-C0015259
capacity	B-C1516240
and	O
underlying	O
mechanisms	B-C0441712
in	O
normal	B-C0205307
,	O
sedentary	B-C0205254
subjects	B-C2349001
.	O
	
twenty	O
normal	B-C0205307
,	O
sedentary	B-C0205254
subjects	B-C2349001
50	O
years	B-C0001675
old	I-C0001675
were	O
randomized	B-C0034656
to	O
placebo	B-C0032042
or	O
dark	B-C3853217
chocolate	I-C3853217
dc	B-C3853217
groups	B-C0441833
and	O
consumed	B-C2983605
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	B-C0439231
.	O
	
subjects	B-C2349001
underwent	O
before	O
and	O
after	O
treatment	B-C0087111
,	O
bicycle	B-C0857787
ergometry	I-C0857787
to	O
assess	B-C0184514
vo2	B-C0429693
max	I-C0429693
and	O
work	B-C0043227
,	O
skm	B-C2315740
biopsy	I-C2315740
to	O
assess	B-C0184514
changes	O
in	O
mitochondrial	B-C0026237
density	B-C0178587
,	O
function	B-C0542341
and	O
oxidative	B-C0242606
stress	I-C0242606
and	O
blood	B-C0005834
sampling	I-C0005834
to	O
assess	B-C0184514
metabolic	B-C0311400
endpoints	B-C2349179
.	O
	
seventeen	O
subjects	B-C2349001
completed	O
the	O
trial	B-C0008976
.	O
	
in	O
the	O
dc	B-C3853217
group	O
n	O
=	O
9	O
,	O
vo2	B-C0429693
max	I-C0429693
increased	B-C0442805
17%	O
increase	B-C0442805
,	O
p	O
=	O
0.056	O
as	O
well	O
as	O
maximum	O
work	B-C0043227
watts	B-C0439261
achieved	O
p	O
=	O
0.026	O
with	O
no	O
changes	O
with	O
placebo	B-C0032042
n	O
=	O
8	O
.	O
	
the	O
dc	B-C3853217
group	O
evidenced	O
increases	B-C0442805
in	O
hdl	B-C0023821
levels	O
p	O
=	O
0.005	O
and	O
decreased	B-C0205216
triglycerides	B-C0041004
p	O
=	O
0.07	O
.	O
	
with	O
dc	B-C3853217
,	O
skm	B-C0242692
evidenced	O
significant	B-C0750502
increases	B-C0442805
in	O
protein	B-C0033684
levels	O
for	O
lkb1	B-C1431123
,	O
ampk	B-C2350345
and	O
pgc1α	B-C1452082
and	O
in	O
their	O
active	B-C0205177
forms	O
phosphorylated	B-C0031715
ampk	B-C2350345
and	O
lkb1	B-C1431123
as	O
well	O
as	O
in	O
citrate	B-C2258114
synthase	I-C2258114
activity	I-C2258114
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	B-C0026237
density	B-C0178587
.	O
	
with	O
dc	B-C3853217
,	O
significant	B-C0750502
increases	B-C0442805
in	O
skm	B-C0242692
reduced	O
glutathione	B-C0017817
levels	O
and	O
decreases	B-C0547047
in	O
protein	B-C1563721
carbonylation	I-C1563721
were	O
observed	O
.	O
	
improvements	O
in	O
maximum	O
work	B-C0043227
achieved	O
and	O
vo2	B-C0429693
max	I-C0429693
may	O
be	O
due	O
to	O
dc	B-C3853217
activation	B-C1879547
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
skm	B-C0242692
mitochondria	B-C0026237
efficiency	B-C0013682
.	O
	
larger	O
clinical	B-C0008972
studies	I-C0008972
are	O
warranted	O
to	O
confirm	O
these	O
reduction	B-C0392756
in	O
hospital-wide	B-C0019994
clinical	B-C0200344
laboratory	I-C0200344
specimen	I-C0200344
identification	I-C0200344
errors	B-C0743559
following	O
process	B-C0814452
interventions	I-C0814452
a	O
10-	O
year	B-C0439234
retrospective	B-C0035363
observational	I-C0035363
study	I-C0035363
accurate	B-C0443131
patient	B-C1269815
identification	I-C1269815
and	O
specimen	B-C1254363
labeling	I-C1254363
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	B-C1254372
steps	I-C1254372
in	O
the	O
prevention	B-C1706420
of	O
medical	B-C0376531
errors	I-C0376531
,	O
thereby	O
improving	B-C1272745
patient	B-C1113679
safety	I-C1113679
.	O
	
all	O
patient	B-C1292459
specimen	I-C1292459
identification	B-C0205396
errors	B-C0743559
that	O
occurred	B-C1709305
in	O
the	O
outpatient	B-C1547116
department	I-C1547116
opd	B-C1547116
,	O
emergency	B-C0562508
department	I-C0562508
ed	B-C0562508
,	O
and	O
inpatient	B-C1547116
department	I-C1547116
ipd	B-C1547116
of	O
a	O
3	O
bed	B-C0004916
academic	B-C0000872
medical	I-C0000872
center	I-C0000872
in	O
taiwan	B-C0039260
were	O
documented	B-C1301725
and	O
analyzed	B-C1254363
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O
	
to	O
reduce	B-C0392756
such	O
errors	B-C0743559
,	O
the	O
following	O
series	B-C0205549
of	O
strategies	B-C0679716
were	O
implemented	O
a	O
restrictive	B-C0680575
specimen	I-C0680575
acceptance	I-C0680575
policy	I-C0680575
for	O
the	O
ed	B-C0562508
and	O
ipd	B-C1547116
in	O
2006	O
a	O
computer-assisted	B-C2362103
barcode	B-C0004738
positive	B-C0009612
patient	I-C0009612
identification	I-C0009612
system	I-C0009612
for	O
the	O
ed	B-C0562508
and	O
ipd	B-C1547116
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	B-C0205554
sample	B-C1254363
labeling	I-C1254363
combined	B-C0205195
with	O
electronic	B-C3687093
identification	I-C3687093
systems	I-C3687093
introduced	B-C1292748
to	O
the	O
opd	B-C1547116
in	O
2009	O
.	O
	
of	O
the	O
2000345	O
specimens	B-C1550655
collected	B-C1516698
in	O
2005	O
,	O
1023	O
0.0511	O
were	O
identified	B-C0243095
as	O
having	O
patient	B-C1269815
identification	I-C1269815
errors	B-C0743559
,	O
compared	O
with	O
58	O
errors	B-C0743559
0.0015	O
among	O
3761238	O
specimens	B-C1550655
collected	B-C1516698
in	O
2014	O
,	O
after	O
serial	O
interventions	B-C1273869
this	O
represents	O
a	O
97%	O
relative	B-C0205345
reduction	B-C0392756
.	O
	
the	O
total	B-C4288115
number	I-C4288115
rate	B-C1521828
of	O
institutional	B-C1254363
identification	I-C1254363
errors	B-C0743559
contributed	O
from	O
the	O
ed	B-C0562508
,	O
ipd	B-C1547116
,	O
and	O
opd	B-C1547116
over	O
a	O
10-	O
year	B-C0439234
period	B-C1948053
were	O
423	O
0.1058	O
,	O
556	O
0.0587	O
,	O
and	O
44	O
0.0067	O
errors	B-C0743559
before	B-C0332152
the	O
interventions	B-C1273869
,	O
and	O
3	O
0.0007	O
,	O
52	O
0.0045	O
and	O
3	O
0.0001	O
after	B-C0687676
interventions	B-C1273869
,	O
representing	O
relative	B-C0205345
99%	O
,	O
92%	O
and	O
98%	O
reductions	B-C0392756
,	O
respectively	O
.	O
	
accurate	B-C0443131
patient	B-C1269815
identification	I-C1269815
is	O
a	O
challenge	O
of	O
patient	B-C1113679
safety	I-C1113679
in	O
different	O
health	B-C0018684
settings	B-C1318139
.	O
	
the	O
data	B-C4019276
collected	I-C4019276
in	O
our	O
study	B-C2603343
indicate	O
that	O
a	O
restrictive	B-C0680575
specimen	I-C0680575
acceptance	I-C0680575
policy	I-C0680575
,	O
computer-generated	B-C0022885
positive	B-C0009612
identification	I-C0009612
systems	I-C0009612
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	B-C0392756
patient	B-C1269815
identification	I-C1269815
errors	B-C0743559
.	O
	
management	B-C0376636
of	O
skin	B-C0852000
and	I-C0852000
soft-tissue	I-C0852000
infections	I-C0852000
at	O
a	O
community	O
teaching	B-C0020027
hospital	I-C0020027
using	O
a	O
severity-of-illness	B-C0449851
tool	I-C0449851
skin	B-C0852000
and	I-C0852000
soft-tissue	I-C0852000
infections	I-C0852000
sstis	B-C0852000
encompass	O
a	O
diverse	B-C1880371
range	B-C1514721
of	O
infections	B-C3714514
of	O
varying	O
severity	B-C0439793
.	O
	
the	O
clinical	B-C0162791
resource	I-C0162791
efficiency	I-C0162791
support	I-C0162791
team	I-C0162791
crest	I-C0162791
scoring	I-C0162791
system	I-C0162791
stratifies	B-C0008902
patients	B-C0030705
into	O
four	O
classes	B-C0008902
i	O
=	O
least	O
severe	B-C0205082
to	O
iv	O
=	O
most	O
severe	B-C0205082
based	O
on	O
the	O
standardized	B-C2919819
early	I-C2919819
warning	I-C2919819
score	I-C2919819
sews	B-C2919819
.	O
	
the	O
objective	B-C2985627
of	O
this	O
study	B-C2603343
was	O
to	O
apply	O
crest	B-C0162791
to	O
hospitalized	B-C0870668
patients	I-C0870668
with	O
sstis	B-C0852000
in	O
order	O
to	O
quantify	O
disease	B-C0521117
severity	I-C0521117
and	O
evaluate	B-C0220825
appropriateness	O
of	O
antibiotic	B-C0003232
management	O
.	O
	
this	O
was	O
a	O
retrospective	B-C0035363
,	O
hypothesis	B-C1512571
-generating	O
,	O
single-centre	O
evaluation	B-C0220825
of	O
hospitalized	B-C0870668
patients	I-C0870668
with	O
sstis	B-C0852000
admitted	B-C0184666
in	O
2011	O
.	O
	
based	O
on	O
crest	B-C0162791
classification	O
,	O
the	O
empirical	B-C1880496
antimicrobial	B-C1136254
choices	O
were	O
categorized	B-C0871968
as	O
appropriate	O
,	O
over-treatment	B-C4046039
or	O
under-treatment	B-C0087111
.	O
	
a	O
total	O
of	O
369	O
patients	B-C0030705
were	O
screened	O
and	O
200	O
met	O
the	O
inclusion	B-C1512693
criteria	I-C1512693
.	O
	
the	O
majority	O
of	O
patients	B-C0030705
were	O
classified	B-C0008902
as	O
either	O
crest	B-C0162791
class	B-C1550329
i	I-C1550329
n	O
=	O
68	O
or	O
class	B-C1550329
i	I-C1550329
i	O
n	O
=	O
102	O
.	O
	
over-treatment	B-C4046039
was	O
more	O
common	O
in	O
the	O
less	O
severe	B-C0205082
classes	B-C0008902
88%	O
and	O
32%	O
in	O
class	B-C1550329
i	I-C1550329
and	O
class	B-C1550329
ii	I-C1550329
,	O
respectively	O
p	O
<	O
0.05	O
.	O
	
sixty-three	O
percent	B-C0439165
of	O
class	B-C1550329
i	I-C1550329
n	O
=	O
43	O
were	O
over-treated	B-C4046039
due	O
to	O
both	O
the	O
use	O
of	O
intravenous	B-C1522726
antibiotic	B-C0003232
s	O
when	O
oral	B-C0559681
therapy	I-C0559681
was	O
sufficient	O
and	O
use	O
of	O
unnecessarily	O
broad-spectrum	B-C0003232
antibiotics	I-C0003232
.	O
	
in	O
contrast	O
,	O
25%	O
n	O
=	O
26	O
of	O
class	B-C1550329
ii	I-C1550329
were	O
over-treated	B-C4046039
due	O
to	O
use	O
of	O
unnecessarily	O
broad-spectrum	B-C0003232
antibiotics	I-C0003232
.	O
	
overall	O
clinical	B-C3640841
failure	I-C3640841
rates	O
remained	O
low	O
with	O
only	O
1%	O
,	O
4%	O
and	O
17%	O
of	O
patients	B-C0030705
unable	O
to	O
achieve	O
initial	O
response	B-C0521982
in	O
class	B-C1550329
ii	I-C1550329
,	O
class	B-C1550329
iii	I-C1550329
and	O
class	B-C1550329
iv	I-C1550329
.	O
	
retrospective	B-C1514923
application	B-C0185125
of	O
crest	B-C0162791
identified	O
opportunities	O
to	O
improve	O
the	O
management	B-C0376636
of	O
sstis	B-C0852000
.	O
	
crest	B-C0162791
can	O
be	O
of	O
great	O
value	O
in	O
discriminating	O
less-	O
severe	B-C0205082
sstis	B-C0852000
,	O
which	O
can	O
be	O
treated	B-C0087111
on	O
an	O
outpatient	B-C0029921
breakthrough	B-C0444503
viridans	B-C0152965
streptococcal	I-C0152965
bacteremia	I-C0152965
in	O
allogeneic	B-C4255274
hematopoietic	I-C4255274
stem	I-C4255274
cell	I-C4255274
transplant	I-C4255274
recipients	B-C0376387
receiving	B-C1514756
levofloxacin	B-C0282386
prophylaxis	B-C0199176
in	O
a	O
japanese	B-C0022341
hospital	B-C0019994
breakthrough	B-C0444503
viridans	B-C0152965
streptococcal	I-C0152965
bacteremia	I-C0152965
vsb	B-C0152965
in	O
patients	B-C0030705
with	O
hematological	B-C0376545
malignancy	I-C0376545
receiving	B-C1514756
levofloxacin	B-C0282386
prophylaxis	B-C0199176
is	O
a	O
major	B-C0205164
blood	B-C0004610
stream	I-C0004610
infection	I-C0004610
bsi	B-C0004610
occurring	B-C1709305
during	B-C0347984
febrile	B-C0746883
neutropenia	I-C0746883
.	O
	
however	O
,	O
clinical	B-C1516606
data	I-C1516606
focused	B-C1285542
on	O
vsb	B-C0152965
in	O
allogeneic	B-C4255274
hematopoietic	I-C4255274
stem	I-C4255274
cell	I-C4255274
transplant	I-C4255274
allo-hsct	B-C4255274
recipients	B-C0376387
are	O
lacking	B-C0332268
.	O
	
the	O
medical	B-C0025102
records	I-C0025102
of	O
allo-hsct	B-C4255274
recipients	B-C0376387
who	O
received	B-C1514756
oral	B-C1527415
levofloxacin	B-C0282386
prophylaxis	B-C0199176
between	O
january	O
2011	O
and	O
august	O
2013	O
at	O
toranomon	B-C0019994
hospital	I-C0019994
were	O
reviewed	B-C1709940
to	O
evaluate	B-C0220825
breakthrough	B-C0444503
vsb	B-C0152965
.	O
	
stored	O
viridans	B-C1140704
streptococcal	I-C1140704
vgs	B-C1140704
species	B-C1705920
were	O
identified	B-C0205396
by	O
using	B-C1524063
soda	B-C0017337
gene	I-C0017337
sequencing	B-C1294197
,	O
and	O
were	O
assessed	B-C1516048
for	O
drug	B-C1326871
susceptibility	I-C1326871
.	O
	
among	O
the	O
184	O
allo-hsct	B-C4255274
recipients	B-C0376387
on	O
levofloxacin	B-C0282386
prophylaxis	B-C0199176
,	O
28	O
15.2	O
%	O
experienced	O
breakthrough	B-C0444503
vsb	B-C0152965
.	O
	
all	O
of	O
the	O
28	O
recipients	B-C0376387
with	O
vsb	B-C0152965
were	O
treated	B-C1522326
with	O
a	O
cefepime	B-C0055003
-	O
based	B-C1527178
or	O
piperacillin/tazobactam	B-C0250480
-	O
based	B-C1527178
regimen	B-C0040808
.	O
	
the	O
susceptibility	B-C1326871
rates	B-C1521828
of	O
the	O
vgs	B-C1140704
strains	B-C1518614
for	O
levofloxacin	B-C0282386
,	O
cefepime	B-C0055003
,	O
piperacillin/tazobactam	B-C0250480
,	O
meropenem	B-C0066005
,	O
and	O
vancomycin	B-C0042313
were	O
0	O
%	O
,	O
95	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O
.	O
	
both	O
the	O
mic50	B-C0427978
minimum	B-C0427978
inhibitory	I-C0427978
concentration	I-C0427978
and	O
the	O
mic90	B-C0427978
of	O
ceftazidim	B-C0007559
0.5	O
μg/ml	O
and	O
2	O
μg/ml	O
,	O
respectively	O
were	O
higher	B-C0205250
than	O
the	O
mic90	B-C0427978
of	O
all	O
the	O
other	O
anti-pseudomonal	B-C1254351
beta-lactams	I-C1254351
apbls	B-C1254351
.	O
	
only	O
1	O
vgs	B-C1140704
strain	B-C1518614
had	O
a	O
penicillin	B-C0220892
mic	B-C0427978
2	O
μg/ml	O
by	O
the	O
etest	B-C3850116
3.6	O
%	O
.	O
	
there	O
were	O
no	B-C1518422
cases	B-C0868928
with	O
acute	B-C1848829
respiratory	I-C1848829
distress	I-C1848829
syndrome	I-C1848829
ards	B-C1848829
that	O
was	O
associated	B-C0332281
with	I-C0332281
vsb	B-C0152965
,	O
although	O
the	O
rate	B-C1521828
of	O
viridans	B-C0152965
group	I-C0152965
streptococcal	I-C0152965
shock	I-C0152965
syndrome	I-C0152965
was	O
high	B-C0205250
26	O
%	O
.	O
	
the	O
crude	O
30-day	B-C0439228
mortality	B-C0205848
rate	I-C0205848
in	O
the	O
vsb	B-C0152965
group	B-C0681860
10.7	O
%	O
did	O
not	B-C1518422
differ	B-C1705242
significantly	B-C0750502
from	O
that	O
in	O
the	O
bsi	B-C0004610
without	B-C0332288
vsb	B-C0152965
group	B-C0681860
9.3	O
%	O
or	O
non	B-C1518422
-	O
bsi	B-C0004610
group	B-C0681860
7.0	O
%	O
p	O
=	O
0.77	O
.	O
	
also	O
,	O
vsb	B-C0152965
was	O
not	B-C1518422
a	O
risk	B-C0035648
factor	I-C0035648
for	O
all-cause	O
mortality	B-C0205848
up	O
to	O
60	B-C0439228
days	I-C0439228
following	B-C0332282
allo-hsct	B-C4255274
p	O
=	O
0.43	O
.	O
	
apbl	B-C1254351
with	O
increased	B-C0205217
anti-vgs	B-C0243095
activity	I-C0243095
apbl-va	B-C0243095
monotherapy	B-C0087111
would	O
typically	O
be	O
optimal	B-C2698651
for	O
treating	B-C1522326
the	O
vgs	B-C1140704
strains	B-C1518614
in	O
this	O
setting	O
.	O
	
indication	O
of	O
adding	O
an	O
empiric	O
anti-gram-positive	B-C1254351
agent	I-C1254351
to	O
apbl-va	B-C0243095
for	O
treating	B-C1522326
vsb	B-C0152965
should	O
depend	O
on	O
local	B-C0205276
factors	B-C1521761
,	O
such	O
as	O
the	O
susceptibility	B-C1326871
results	B-C1274040
.	O
	
in	O
addition	O
,	O
breakthrough	B-C0444503
vsb	B-C0152965
is	O
probably	O
not	B-C1518422
a	O
major	B-C0205164
cause	B-C0007465
of	I-C0007465
death	I-C0007465
in	O
allo-hsct	B-C4255274
settings	O
,	O
where	O
beta-lactam	B-C0282215
non-susceptible	B-C1140704
vgs	I-C1140704
and	O
the	O
ards	B-C1848829
are	O
the	O
lost	O
art	O
of	O
the	O
splenorrhaphy	B-C1261005
in	O
the	O
case	O
of	O
the	O
hemodynamically	B-C0948268
unstable	I-C0948268
child	B-C0008059
,	O
splenorrhaphy	B-C1261005
is	O
preferred	O
to	O
splenectomy	B-C0037995
to	O
avert	O
postsplenectomy	B-C3854596
sepsis	B-C0243026
.	O
	
however	O
,	O
successful	O
splenorrhaphy	B-C1261005
requires	O
familiarity	B-C0600269
with	O
the	O
procedure	B-C0087111
.	O
	
we	O
sought	O
to	O
determine	O
how	O
many	O
splenectomies	B-C0037995
or	O
splenorrhaphies	B-C1261005
for	O
trauma	B-C3714660
the	O
average	O
pediatric	B-C0586905
surgeon	I-C0586905
can	O
be	O
expected	O
to	O
perform	B-C0884358
during	O
their	O
career	B-C0178534
.	O
	
the	O
pediatric	B-C0242356
health	I-C0242356
information	I-C0242356
system	I-C0242356
phis	I-C0242356
database	I-C0242356
was	O
queried	O
for	O
patients	B-C0030705
18	O
years	B-C0439234
coded	O
with	O
an	O
international	B-C2346503
classification	I-C2346503
of	I-C2346503
diseases	I-C2346503
9th	I-C2346503
edition	I-C2346503
diagnosis	B-C1550350
code	I-C1550350
of	O
a	O
splenic	B-C0160405
injury	I-C0160405
from	O
2004	O
to	O
2013	O
.	O
	
age	B-C0001779
,	O
gender	B-C0079399
,	O
grade	B-C0441800
of	O
splenic	B-C0160405
injury	I-C0160405
,	O
and	O
operations	B-C0543467
performed	B-C0884358
were	O
extracted	B-C1516695
.	O
	
numbers	O
of	O
pediatric	B-C0586905
surgeons	I-C0586905
per	O
hospital	B-C0019994
were	O
obtained	O
.	O
	
9567	O
children	B-C0008059
were	O
identified	B-C0205396
.	O
	
2.1	O
underwent	O
a	O
splenectomy	B-C0037995
and	O
0.8	O
underwent	O
a	O
splenorrhaphy	B-C1261005
.	O
	
the	O
average	O
surgeon	B-C0582175
performed	B-C0884358
0.6	O
sd=0	O
splenectomies	B-C0037995
and	O
0.2	O
sd=0	O
splenorrhaphies	B-C1261005
for	O
trauma	B-C3714660
.	O
	
if	O
these	O
rates	B-C1521828
remain	O
constant	B-C1948059
over	O
time	O
,	O
the	O
average	O
surgeon	B-C0582175
would	O
perform	B-C0884358
1.8	O
sd	O
=1	O
splenectomies	B-C0037995
and	O
0.6	O
sd	O
=1	O
splenorrhaphies	B-C1261005
for	O
trauma	B-C3714660
over	O
a	O
30-	O
year	B-C0439234
surgical	B-C0178534
career	I-C0178534
.	O
	
nonoperative	B-C0161969
management	I-C0161969
is	O
associated	O
with	O
a	O
host	O
of	O
benefits	O
,	O
but	O
has	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
experience	B-C0870520
level	I-C0870520
of	O
the	O
pediatric	B-C0586905
surgeons	I-C0586905
expected	O
to	O
perform	B-C0884358
an	O
emergency	O
splenectomy	B-C0037995
or	O
splenorrhaphy	B-C1261005
vestibular	B-C0042606
-dependent	O
inter-stimulus	B-C0870743
interval	I-C0870743
effects	B-C1280500
on	O
sound	B-C0015215
evoked	I-C0015215
potentials	I-C0015215
of	O
central	B-C0205099
origin	B-C0439659
todd	O
et	O
al	O
.	O
	
2014ab	O
have	O
recently	O
demonstrated	O
the	O
presence	B-C0150312
of	O
vestibular	B-C0042606
-dependent	O
contributions	B-C1880177
to	O
auditory	B-C0015215
evoked	I-C0015215
potentials	I-C0015215
aeps	B-C0015215
when	O
passing	O
through	O
the	O
vestibular	B-C0042606
threshold	B-C0004312
as	O
determined	O
by	O
vestibular	B-C2936453
evoked	I-C2936453
myogenic	I-C2936453
potentials	I-C2936453
vemps	B-C2936453
,	O
including	O
a	O
particular	O
deflection	B-C0012727
labeled	B-C1708632
as	O
an	O
n42/p52	O
prior	B-C0332152
to	O
the	O
long	B-C0205166
-	O
latency	B-C0242465
aeps	B-C0015215
n1	O
and	O
p2	O
.	O
	
in	O
this	O
paper	O
we	O
report	B-C0700287
the	O
results	B-C2825142
of	O
an	O
experiment	B-C0681814
to	O
determine	O
the	O
effect	B-C1704420
of	I-C1704420
inter-stimulus	B-C0870743
interval	I-C0870743
isi	B-C0870743
and	O
regularity	B-C0449581
on	O
potentials	B-C0015214
recorded	O
above	B-C1282910
and	O
below	B-C0542339
vemp	B-C2936453
threshold	B-C0004312
.	O
	
five	O
healthy	B-C3898900
,	O
right-handed	B-C0344333
subjects	B-C2349001
were	O
recruited	O
and	O
evoked	B-C0015214
potentials	I-C0015214
were	O
recorded	O
to	O
binaurally	O
presented	O
sound	B-C0001164
stimulation	I-C0001164
,	O
above	B-C1282910
and	O
below	B-C0542339
vestibular	B-C0042606
threshold	B-C0004312
,	O
at	O
seven	O
stimulus	B-C0234402
rates	B-C1521828
with	O
isis	B-C0870743
of	O
212	O
,	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
and	O
1696	O
ms	O
.	O
	
the	O
inner	O
five	O
intervals	B-C0870743
,	O
i.e	O
.	O
	
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
ms	O
,	O
were	O
presented	B-C0449450
twice	O
in	O
both	O
regular	B-C0205272
and	O
irregular	B-C0205271
conditions	O
.	O
	
anova	B-C0002780
on	O
the	O
global	B-C0392762
field	I-C0392762
power	I-C0392762
gfp	B-C0392762
were	O
conducted	O
for	O
each	O
of	O
four	O
waves	O
,	O
n42	O
,	O
p52	O
,	O
n1	O
and	O
p2	O
with	O
factors	O
of	O
intensity	B-C0237686
,	O
isi	B-C0870743
and	O
regularity	B-C0449581
.	O
	
both	O
n42	O
and	O
p52	O
waves	O
showed	O
significant	B-C0750502
anova	B-C0002780
effects	B-C1704420
of	I-C1704420
intensity	B-C0237686
but	O
no	O
other	O
main	O
effects	B-C1280500
or	O
interactions	B-C1704675
.	O
	
in	O
contrast	O
both	O
n1	O
and	O
p2	O
showed	O
additional	B-C1524062
effects	B-C1704420
of	I-C1704420
isi	B-C0870743
,	O
as	O
well	O
as	O
intensity	B-C0237686
,	O
and	O
evidence	B-C0332120
of	I-C0332120
non	B-C1518422
-	O
linear	B-C0205132
interactions	B-C1704675
between	O
isi	B-C0870743
and	O
intensity	B-C0237686
.	O
	
a	O
source	B-C0936012
analysis	I-C0936012
was	O
carried	O
out	O
consistent	B-C0332290
with	I-C0332290
prior	B-C0332152
work	O
suggesting	O
that	O
when	O
above	B-C1282910
vestibular	B-C0042606
threshold	B-C0004312
,	O
in	B-C0332287
addition	I-C0332287
to	I-C0332287
bilateral	B-C0238767
superior	B-C1282910
temporal	B-C0039485
cortex	I-C0039485
,	O
ocular	B-C0015392
,	O
cerebellar	B-C0007765
and	O
cingulate	B-C0228272
sources	B-C0449416
are	O
recruited	O
.	O
	
further	O
statistical	B-C0871424
analysis	I-C0871424
of	O
the	O
source	B-C0449416
currents	B-C1705970
indicated	O
that	O
the	O
origin	O
of	O
the	O
interactions	B-C1704675
with	O
intensity	B-C0237686
may	O
be	O
the	O
isi	B-C0870743
sensitivity	B-C0036667
of	O
the	O
vestibular	B-C0042606
-dependent	O
sources	B-C0449416
.	O
	
this	O
in	O
turn	O
may	O
reflect	O
a	O
specific	B-C0205369
vestibular	B-C0042606
preference	B-C0558295
for	O
stimulus	B-C0234402
rates	B-C1521828
associated	B-C0332281
with	I-C0332281
locomotion	B-C0023946
,	O
i.e	O
.	O
	
rates	B-C1521828
close	O
to	O
2	O
hz	O
,	O
or	O
isis	B-C0870743
close	O
to	O
500	O
ms	O
,	O
where	O
saccular	B-C0205137
afferents	B-C0205115
show	O
increased	B-C0205217
gain	B-C1517378
and	O
the	O
corresponding	O
reflexes	B-C0034929
are	O
most	O
a	O
systematic	B-C1955832
review	I-C1955832
of	O
the	O
diagnostic	B-C0348026
and	O
prognostic	B-C1514475
value	I-C1514475
of	O
urinary	B-C1524119
protein	B-C0033684
biomarkers	B-C0005516
in	O
urothelial	B-C0751571
bladder	I-C0751571
cancer	I-C0751571
for	O
over	O
80	O
years	O
,	O
cystoscopy	B-C0010702
has	O
remained	O
the	O
gold-standard	B-C0150110
for	O
detecting	B-C0442726
tumours	B-C0027651
of	O
the	O
urinary	B-C0005682
bladder	I-C0005682
.	O
	
since	O
bladder	B-C0005695
tumours	I-C0005695
have	O
a	O
tendency	O
to	O
recur	B-C0034897
and	O
progress	B-C0242656
,	O
many	O
patients	B-C0030705
are	O
subjected	O
to	O
repeated	O
cystoscopies	B-C0010702
during	O
long-term	B-C0443252
surveillance	B-C0733511
,	O
with	O
the	O
procedure	B-C0184661
being	O
both	O
unpleasant	O
for	O
the	O
patient	B-C0030705
and	O
expensive	O
for	O
healthcare	B-C0018724
providers	I-C0018724
.	O
	
the	O
identification	B-C0205396
and	O
validation	B-C1519941
of	O
bladder	B-C0005695
tumour	I-C0005695
specific	O
molecular	B-C0005516
markers	I-C0005516
in	O
urine	B-C0042036
could	O
enable	O
tumour	B-C0027651
detection	B-C0442726
and	O
reduce	O
reliance	B-C0599403
on	O
cystoscopy	B-C0010702
,	O
and	O
numerous	O
classes	O
of	O
biomarkers	B-C0005516
have	O
been	O
studied	O
.	O
	
proteins	B-C0033684
represent	O
the	O
most	O
intensively	O
studied	B-C0681852
class	I-C0681852
of	I-C0681852
biomolecule	I-C0681852
in	O
this	O
setting	O
.	O
	
as	O
an	O
aid	O
to	O
researchers	B-C0035173
searching	O
for	O
better	O
urinary	B-C1524119
biomarkers	B-C0005516
,	O
we	O
report	O
a	O
comprehensive	B-C1955832
systematic	I-C1955832
review	I-C1955832
of	O
the	O
literature	B-C0023866
and	O
a	O
searchable	O
database	B-C0242356
of	O
proteins	B-C0033684
that	O
have	O
been	O
investigated	B-C0220825
to	O
date	O
.	O
	
our	O
objective	O
was	O
to	O
classify	O
these	O
proteins	B-C0033684
as	O
1	O
those	O
with	O
robustly	O
characterised	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
for	O
bladder	B-C0005695
cancer	I-C0005695
detection	B-C0442726
2	O
those	O
that	O
show	O
potential	O
but	O
further	O
investigation	B-C0220825
is	O
required	O
3	O
those	O
unlikely	O
to	O
warrant	O
further	O
investigation	B-C0220825
and	O
4	O
those	O
investigated	B-C0220825
as	O
prognostic	B-C1514475
markers	I-C1514475
.	O
	
this	O
work	O
should	O
help	O
to	O
prioritise	O
certain	O
biomarkers	B-C0005516
for	O
rigorous	B-C0681836
validation	I-C0681836
,	O
whilst	O
preventing	B-C1292733
wasted	O
effort	O
on	O
proteins	B-C0033684
that	O
have	O
shown	O
no	O
association	O
whatsoever	O
with	O
the	O
disease	B-C0012634
,	O
or	O
only	O
modest	O
biomarker	B-C0005516
performance	O
despite	O
large-scale	B-C0814860
efforts	I-C0814860
at	O
well	O
,	O
i	O
wouldn't	O
be	O
any	O
worse	O
off	O
,	O
would	O
i	O
,	O
than	O
i	O
am	O
now	O
a	O
qualitative	B-C0949415
study	I-C0949415
of	O
decision-making	B-C0011109
,	O
hopes	B-C0392347
,	O
and	O
realities	B-C0871222
of	O
adults	B-C0001675
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
undergoing	O
islet	B-C0079646
cell	I-C0079646
transplantation	I-C0079646
for	O
selected	O
individuals	B-C0237401
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
,	O
pancreatic	B-C0079646
islet	I-C0079646
transplantation	I-C0079646
it	B-C0079646
prevents	O
recurrent	O
severe	O
hypoglycemia	B-C0020615
and	O
optimizes	B-C3267174
glycemia	I-C3267174
,	O
although	O
ongoing	O
systemic	B-C0021079
immunosuppression	I-C0021079
is	O
needed	O
.	O
	
our	O
aim	O
was	O
to	O
explore	O
candidates	B-C1257890
and	O
recipients	B-C0376387
'	O
expectations	O
of	O
transplantation	B-C0040732
,	O
their	O
experience	O
of	O
being	O
on	O
the	O
waiting	B-C0586018
list	I-C0586018
,	O
and	O
for	O
recipients	B-C0376387
the	O
procedure	O
and	O
life	O
posttransplant	B-C1254367
.	O
	
cross-sectional	O
qualitative	B-C0205556
research	B-C0035171
design	I-C0035171
using	O
semistructured	O
interviews	B-C0683518
with	O
16	O
adults	B-C0001675
8	O
pretransplant	B-C1254367
,	O
8	O
posttransplant	B-C1254367
from	O
4	O
uk	B-C0041700
centers	B-C0475309
n	O
=	O
13	O
and	O
1	O
canadian	B-C0006823
center	B-C0475309
n	O
=	O
3	O
.	O
	
interviews	B-C0683518
were	O
audio-recorded	B-C2316646
,	O
transcribed	O
,	O
and	O
underwent	O
inductive	B-C0936012
thematic	I-C0936012
analysis	I-C0936012
.	O
	
interviewees	B-C0489844
were	O
aged	O
mean	O
sd	O
52	O
10	O
years	B-C0439234
range	O
,	O
30-64	O
duration	B-C0449238
of	O
diabetes	B-C0011847
,	O
36	O
9	O
years	B-C0439234
range	O
,	O
21-56	O
12	O
75%	O
were	O
women	B-C0043210
.	O
	
narrative	O
accounts	O
centered	O
on	O
expectations	B-C0679138
,	O
hopes	B-C0392347
,	O
and	O
realities	B-C0871222
decision-making	B-C0011109
waiting	O
and	O
uncertainty	O
the	O
procedure	O
,	O
hospital	B-C3489408
stay	I-C3489408
,	O
and	O
follow-up	B-C1522577
.	O
	
expected	O
benefits	O
included	O
fewer	O
severe	O
hypoglycemic	B-C0745153
episodes	I-C0745153
,	O
reduced	B-C0392756
need	O
for	O
insulin	B-C0021641
,	O
preventing	O
onset/progression	O
of	O
complications	B-C0009566
and	O
improved	O
psychological	B-C0424578
well-being	I-C0424578
.	O
	
these	O
were	O
realized	O
for	O
most	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O
	
most	O
interviewees	B-C0489844
described	O
well-informed	O
,	O
shared	O
decision-making	B-C0011109
with	O
clinicians	B-C0871685
and	O
family	B-C0015576
,	O
and	O
managing	O
their	O
expectations	O
.	O
	
although	O
life	O
"""on"	O
the	O
"list"""	O
could	O
be	O
stressful	B-C0231297
,	O
and	O
immunosuppressant	B-C0021081
side	B-C0879626
effects	I-C0879626
were	O
severe	B-C0205082
,	O
interviewees	B-C0489844
reported	O
""""	O
no	B-C1513916
regrets	B-C0080101
""""	O
posttransplant	B-C1254367
,	O
interviewees	B-C0489844
experienced	O
increased	O
confidence	B-C0237529
,	O
through	O
freedom	B-C0243095
from	I-C0243095
hypoglycemia	I-C0243095
and	O
regained	O
glycemic	B-C3267174
control	I-C3267174
,	O
which	O
tempered	O
any	O
disappointment	O
about	O
continued	O
reliance	O
on	O
insulin	B-C0021641
.	O
	
most	O
viewed	O
their	O
transplant	B-C0040732
as	O
a	O
success	O
,	O
though	O
several	O
reflected	O
upon	O
setbacks	O
and	O
hidden	O
hopes	B-C0392347
for	O
becoming	O
""""	O
insulin-free	B-C0243095
""""	O
independently	O
undertaken	O
interviews	B-C0683518
demonstrated	O
realistic	O
and	O
balanced	O
expectations	O
of	O
it	B-C0079646
and	O
indicate	O
how	O
to	O
optimize	O
the	O
process	O
and	O
support	O
for	O
future	O
it	B-C0079646
candidates	B-C1257890
.	O
	
the	O
nanocomposite	B-C0205199
nature	O
of	O
bone	B-C0262950
drives	O
its	O
strength	B-C0237897
and	O
damage	B-C1883709
resistance	B-C4281815
in	O
human	B-C0277764
bone	I-C0277764
,	O
an	O
amorphous	B-C1979848
mineral	B-C0026162
serves	O
as	O
a	O
precursor	B-C1709634
to	O
the	O
formation	B-C1522492
of	O
a	O
highly	O
substituted	O
nanocrystalline	B-C1721058
apatite	B-C0003522
.	O
	
however	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	B-C1979848
mineral	B-C0026162
remains	O
unknown	O
.	O
	
here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-C0678118
electron	I-C0678118
microscopy	I-C0678118
that	O
100-300	O
nm	O
amorphous	B-C1979848
calcium	B-C0006711
phosphate	I-C0006711
regions	B-C0005898
are	O
present	O
in	O
the	O
disordered	B-C1254362
phase	I-C1254362
of	O
trabecular	B-C0222660
bone	I-C0222660
.	O
	
nanomechanical	B-C0681814
experiments	I-C0681814
on	O
cylindrical	B-C0946010
samples	B-C0370003
,	O
with	O
diameters	B-C1301886
between	O
250	O
nm	O
and	O
3	O
nm	O
,	O
of	O
the	O
bone's	B-C0262950
ordered	B-C1254362
and	O
disordered	B-C1254362
phases	I-C1254362
revealed	O
a	O
transition	B-C2700061
from	O
plastic	B-C0678558
deformation	B-C0575133
to	O
brittle	B-C3810845
failure	B-C0016658
and	O
at	O
least	O
a	O
factor-of-2	O
higher	O
strength	B-C0237897
in	O
the	O
smaller	B-C0547044
samples	B-C0370003
.	O
	
we	O
postulate	O
that	O
this	O
transition	B-C2700061
in	O
failure	B-C0231174
mechanism	B-C0441712
is	O
caused	O
by	O
the	O
suppression	B-C1260953
of	O
extrafibrillar	B-C0225328
shearing	B-C0205013
in	O
the	O
smaller	O
samples	B-C0370003
,	O
and	O
that	O
the	O
emergent	O
smaller	B-C0547044
-is-	O
stronger	B-C0442821
size	B-C0814843
effect	I-C0814843
is	O
related	O
to	O
the	O
sample-size	B-C0242618
scaling	B-C1947916
of	O
the	O
distribution	O
of	O
flaws	O
.	O
	
our	O
findings	B-C0243095
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi-scale	B-C0349590
nature	I-C0349590
of	O
bone	B-C0262950
and	O
provide	O
insights	O
into	O
the	O
biomineralization	B-C0006660
process	B-C1522240
.	O
	
assessing	B-C1516048
the	O
physiological	B-C0205463
relevance	B-C2347946
of	O
alternate	O
architectures	B-C0678594
of	O
the	O
p7	B-C0257097
protein	I-C0257097
of	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
in	O
different	O
environments	B-C0014406
the	O
viroporin	B-C3820740
p7	B-C0257097
of	O
the	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
forms	O
multimeric	B-C0022009
channels	I-C0022009
eligible	O
for	O
ion	B-C0162585
transport	I-C0162585
across	O
the	O
endoplasmic	B-C0230770
reticulum	I-C0230770
membrane	I-C0230770
.	O
	
currently	O
the	O
subject	B-C1706203
of	O
many	O
studies	B-C2603343
and	O
discussion	O
,	O
the	O
molecular	B-C0872376
assembly	I-C0872376
of	O
the	O
ion	B-C0022009
channel	I-C0022009
and	O
the	O
structural	B-C0678594
characteristics	B-C1521970
of	O
the	O
p7	B-C0257097
monomer	B-C0596973
are	O
not	O
yet	O
fully	O
understood	O
.	O
	
structural	B-C0678594
investigation	B-C1292732
of	O
p7	B-C0257097
has	O
been	O
carried	O
out	O
only	O
in	O
detergent	B-C0011740
environments	B-C0014406
,	O
making	O
the	O
interpretation	O
of	O
the	O
experimental	O
results	O
somewhat	O
questionable	O
.	O
	
here	O
,	O
we	O
analyze	B-C0936012
by	O
means	O
of	O
molecular	B-C2717775
dynamics	I-C2717775
simulations	I-C2717775
the	O
structure	B-C0678594
of	O
the	O
p7	B-C0257097
monomer	B-C0596973
as	O
a	O
function	O
of	O
its	O
sequence	B-C0002518
,	O
initial	O
conformation	B-C0026377
and	O
environment	B-C0014406
.	O
	
we	O
investigate	O
the	O
conductance	B-C0678840
properties	O
of	O
three	O
models	B-C0026339
of	O
a	O
hexameric	B-C1254350
p7	B-C0257097
ion	B-C0022009
channel	I-C0022009
by	O
examining	O
ion	B-C0162585
translocation	I-C0162585
in	O
a	O
pure	O
lipid	B-C0023768
bilayer	I-C0023768
.	O
	
it	O
is	O
noteworthy	O
that	O
although	O
none	O
of	O
the	O
models	B-C0026339
reflects	O
the	O
experimentally	O
observed	O
trend	O
to	O
conduct	O
preferentially	O
cations	B-C0007447
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
position	B-C1550045
and	O
orientation	B-C1704322
of	O
titratable	O
acidic	B-C1709915
or	I-C1709915
basic	I-C1709915
residues	I-C1709915
playing	O
a	O
crucial	O
role	O
in	O
ion	B-C0022023
selectivity	B-C1707391
and	O
in	O
the	O
overall	O
conductance	B-C0678840
of	O
the	O
channel	B-C0022009
.	O
	
in	O
addition	O
,	O
too	O
compact	O
a	O
packing	B-C1148560
of	O
the	O
monomers	B-C0596973
leads	O
to	O
channel	B-C0022009
collapse	B-C0332521
rather	O
than	O
formation	O
of	O
a	O
reasonable	O
pore	B-C1325742
,	O
amenable	O
to	O
ion	B-C0162585
translocation	I-C0162585
.	O
	
the	O
present	O
findings	O
are	O
envisioned	O
to	O
help	O
assess	O
the	O
physiological	B-C0205463
relevance	B-C2347946
of	O
p7	B-C0257097
ion	B-C0022009
channel	I-C0022009
models	B-C0026339
consisting	O
of	O
multimeric	B-C0678594
structures	I-C0678594
obtained	O
in	O
non-native	O
the	O
genome	B-C0017428
-scale	O
dna-binding	B-C1148673
profile	B-C1979963
of	O
barr	B-C0033684
,	O
a	O
β-alanine	B-C0000392
responsive	B-C0205342
transcription	B-C0040648
factor	I-C0040648
in	O
the	O
archaeon	B-C0003732
sulfolobus	B-C0085459
acidocaldarius	I-C0085459
the	O
leucine-responsive	B-C0125575
regulatory	I-C0125575
protein	I-C0125575
lrp	B-C0125575
family	B-C1335532
is	O
a	O
widespread	O
family	B-C1335532
of	O
regulatory	B-C0040648
transcription	I-C0040648
factors	I-C0040648
in	O
prokaryotes	B-C0686817
.	O
	
barr	B-C0033684
is	O
an	O
lrp	B-C0125575
-like	O
transcription	B-C0040648
factor	I-C0040648
in	O
the	O
model	O
archaeon	B-C0003732
sulfolobus	B-C0085459
acidocaldarius	I-C0085459
that	O
activates	B-C1879547
the	O
expression	B-C0017262
of	O
a	O
β-alanine	B-C0017337
aminotransferase	I-C0017337
gene	I-C0017337
,	O
which	O
is	O
involved	O
in	O
β-alanine	B-C1156738
degradation	I-C1156738
.	O
	
in	O
contrast	O
to	O
classical	O
lrp	B-C0125575
-like	O
transcription	B-C0040648
factors	I-C0040648
,	O
barr	B-C0033684
is	O
not	B-C0237284
responsive	I-C0237284
to	O
any	O
of	O
the	O
α-amino	B-C0311462
acids	I-C0311462
but	O
interacts	O
specifically	O
with	O
β-alanine	B-C0000392
.	O
	
besides	O
the	O
juxtaposed	O
β-alanine	B-C0017337
aminotransferase	I-C0017337
gene	I-C0017337
,	O
other	O
regulatory	O
targets	O
of	O
barr	B-C0033684
have	O
not	O
yet	O
been	O
identified	O
although	O
β-alanine	B-C0000392
is	O
the	O
precursor	B-C0014436
of	O
coenzyme	B-C0009226
a	I-C0009226
and	O
thus	O
an	O
important	O
central	O
metabolite	B-C0870883
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
dna-binding	B-C1148673
characteristics	B-C1521970
of	O
barr	B-C0033684
and	O
of	O
its	O
corresponding	O
regulon	B-C0206522
from	O
a	O
local	B-C0205276
to	O
a	O
genome	B-C0017428
-wide	O
perspective	O
.	O
	
we	O
characterized	O
the	O
genome-wide	B-C2986505
binding	I-C2986505
profile	I-C2986505
of	O
barr	B-C0033684
using	O
chromatin	B-C1328856
immunoprecipation	I-C1328856
combined	O
with	O
high-throughput	B-C2936621
sequencing	I-C2936621
chip-seq	B-C2936621
.	O
	
this	O
revealed	O
21	O
genomic	B-C0017428
binding	B-C1167622
loci	B-C1708726
.	O
	
high-enrichment	O
binding	B-C3158196
regions	I-C3158196
were	O
validated	O
to	O
interact	O
with	O
purified	O
barr	B-C0033684
protein	I-C0033684
in	B-C1533691
vitro	I-C1533691
using	O
electrophoretic	B-C0949632
mobility	I-C0949632
shift	I-C0949632
assays	I-C0949632
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	B-C0009802
semi-palindromic	B-C2350254
binding	B-C1514535
motif	I-C1514535
.	O
	
only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic	B-C0017428
sites	I-C0017428
are	O
located	O
in	O
intergenic	B-C0887859
regions	I-C0887859
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	B-C0086860
,	O
and	O
qrt-pcr	B-C2733022
analysis	I-C2733022
demonstrated	O
that	O
only	O
one	O
additional	O
operon	B-C0029073
is	O
under	O
activation	B-C0599177
of	O
barr	B-C0033684
,	O
namely	O
the	O
glutamine	B-C0029073
synthase	I-C0029073
operon	I-C0029073
.	O
	
the	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
lrp	B-C0125575
-like	O
transcription	B-C0040648
factors	I-C0040648
.	O
	
detailed	O
inspection	O
of	O
the	O
barr	B-C0033684
chip-seq	B-C3463810
profile	I-C3463810
at	O
the	O
β-alanine	B-C0033413
aminotransferase	I-C0033413
promoter	I-C0033413
region	I-C0033413
in	O
combination	B-C0205195
with	O
binding	B-C1514535
motif	I-C1514535
predictions	O
indicate	O
that	O
the	O
operator	B-C0086734
structure	I-C0086734
is	O
more	O
complicated	B-C0231242
than	O
previously	O
anticipated	O
,	O
consisting	O
of	O
multiple	B-C0086734
major	I-C0086734
and	I-C0086734
auxiliary	I-C0086734
operators	I-C0086734
.	O
	
barr	B-C0033684
has	O
a	O
limited	B-C0439801
regulon	B-C0206522
,	O
and	O
includes	O
also	O
glutamine	B-C0017337
synthase	I-C0017337
genes	I-C0017337
besides	O
the	O
previously	O
characterized	O
β-alanine	B-C0017337
aminotransferase	I-C0017337
.	O
	
regulation	B-C1327622
of	O
glutamine	B-C0017801
synthase	I-C0017801
is	O
suggestive	O
of	O
a	O
link	O
between	O
β-alanine	B-C1156837
and	O
α-amino	B-C3547146
acid	I-C3547146
metabolism	I-C3547146
in	O
s	B-C0085459
.	O
	
acidocaldarius	I-C0085459
.	O
	
furthermore	O
,	O
this	O
work	O
reveals	O
that	O
the	O
barr	B-C0033684
regulon	B-C0206522
overlaps	O
with	O
that	O
of	O
other	O
lrp	B-C0125575
-like	O
gh32	B-C0017976
family	I-C0017976
activity	B-C0243102
a	O
topological	B-C0026377
approach	O
through	O
protein	B-C3178902
contact	I-C3178902
networks	I-C3178902
the	O
application	O
of	O
protein	B-C3178902
contact	I-C3178902
networks	I-C3178902
methodology	I-C3178902
allowed	O
to	O
highlight	O
a	O
novel	O
response	O
of	O
border	B-C1254362
region	I-C1254362
between	O
the	O
two	O
domains	B-C0682969
to	I-C0682969
substrate	I-C0682969
binding	I-C0682969
.	O
	
glycoside	B-C0017976
hydrolases	I-C0017976
gh	B-C0017976
are	O
enzymes	B-C0014442
that	O
mainly	O
hydrolyze	B-C0020291
the	O
glycosidic	B-C0813982
bond	I-C0813982
between	O
two	O
carbohydrates	B-C0007004
or	O
a	O
carbohydrate	B-C0007004
and	O
a	O
non-carbohydrate	B-C1254350
moiety	I-C1254350
.	O
	
these	O
enzymes	B-C0014442
are	O
involved	O
in	O
many	O
fundamental	O
and	O
diverse	O
biological	B-C3714634
processes	I-C3714634
in	O
plants	B-C0032098
.	O
	
we	O
have	O
focused	O
on	O
the	O
gh32	B-C0017976
family	I-C0017976
,	O
including	O
enzymes	B-C0014442
very	O
similar	O
in	O
both	O
sequence	B-C0002518
and	O
structure	B-C0596527
,	O
each	O
having	O
however	O
clear	O
specificities	O
of	O
substrate	B-C0178623
preferences	B-C0558295
and	O
kinetic	B-C0220865
properties	I-C0220865
.	O
	
structural	B-C1510464
and	O
topological	B-C0026377
differences	O
among	O
proteins	B-C0033684
of	O
the	O
gh32	B-C0017976
family	I-C0017976
have	O
been	O
here	O
identified	O
by	O
means	O
of	O
an	O
emerging	O
approach	O
protein	B-C3178902
contact	I-C3178902
network	I-C3178902
,	O
pcn	B-C3178902
based	O
on	O
the	O
formalization	O
of	O
3d	B-C0026377
structures	I-C0026377
as	O
contact	B-C3178902
networks	I-C3178902
among	O
amino-acid	B-C0002518
residues	I-C0002518
.	O
	
the	O
pcn	B-C3178902
approach	O
proved	O
successful	O
in	O
both	O
reconstructing	O
the	O
already	O
known	O
functional	B-C0205245
domains	B-C1514562
and	O
in	O
identifying	O
the	O
structural	B-C1510464
counterpart	O
of	O
the	O
properties	O
of	O
gh32	B-C0017976
enzymes	I-C0017976
,	O
which	O
remain	O
uncertain	O
,	O
like	O
their	O
allosteric	B-C0002146
character	O
.	O
	
the	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	O
discovery	O
of	O
the	O
activation	B-C0014429
upon	O
binding	B-C1517880
of	I-C1517880
the	I-C1517880
border	I-C1517880
cleft	I-C1517880
region	I-C1517880
between	O
the	O
two	O
domains	B-C1514562
.	O
	
this	O
reveals	O
the	O
allosteric	B-C0002146
nature	O
of	O
the	O
enzymatic	B-C0243102
activity	I-C0243102
for	O
all	O
the	O
analyzed	O
forms	O
in	O
the	O
gh32	B-C0017976
family	I-C0017976
,	O
a	O
character	O
yet	O
to	O
be	O
highlighted	O
in	O
biochemical	B-C0430027
studies	I-C0430027
.	O
	
furthermore	O
,	O
we	O
have	O
been	O
able	O
to	O
recognize	O
a	O
topological	B-C0026377
signature	I-C0026377
graph	O
energy	O
of	O
the	O
different	O
affinity	B-C1510827
of	O
the	O
enzymes	B-C0017976
towards	O
small	O
and	O
large	O
grasping	B-C0220843
at	O
the	O
moon	B-C0079853
enhancing	B-C2349975
access	B-C0444454
to	O
careers	B-C0178534
in	O
the	O
health	B-C0018722
professions	I-C0018722
a	O
former	B-C0750523
hhs	B-C0041711
secretary	B-C0341647
reflects	B-C0558058
on	O
what's	O
needed	O
to	O
enable	O
more	O
minorities	B-C0026192
to	O
become	O
doctors	B-C0031831
and	O
other	O
health	B-C1704312
professionals	I-C1704312
.	O
	
multivariate	B-C0026777
imaging	B-C0011923
genetics	B-C2827447
study	I-C2827447
of	O
mri	B-C0024485
gray	B-C0018220
matter	I-C0018220
volume	B-C0449468
and	O
snps	B-C0752046
reveals	O
biological	B-C0205460
pathways	B-C1705987
correlated	B-C1707520
with	O
brain	B-C0006104
structural	B-C0678594
differences	B-C1705241
in	O
attention	B-C1263846
deficit	I-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
attention	B-C1263846
deficit	I-C1263846
hyperactivity	I-C1263846
disorder	I-C1263846
adhd	B-C1263846
is	O
a	O
prevalent	B-C0220900
neurodevelopmental	B-C1535926
disorder	I-C1535926
affecting	B-C0392760
children	B-C0008059
,	O
adolescents	B-C0205653
,	O
and	O
adults	B-C0001675
.	O
	
its	O
etiology	B-C1314792
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	B-C1274040
from	O
diverse	B-C1880371
pathophysiologies	B-C0277785
that	O
affect	B-C0392760
the	O
structure	B-C0678594
and	O
function	B-C0542341
of	O
specific	B-C0205369
brain	B-C0682723
circuits	I-C0682723
.	O
	
although	O
one	O
of	O
the	O
best-studied	O
neurobiological	B-C0027765
abnormalities	I-C0027765
in	O
adhd	B-C1263846
is	O
reduced	B-C0392756
fronto-striatal-cerebellar	B-C3850014
gray	I-C3850014
matter	I-C3850014
gm	B-C0018220
volume	B-C0449468
,	O
its	O
specific	O
genetic	B-C0314603
correlates	B-C1707520
are	O
largely	O
unknown	B-C0439673
.	O
	
in	O
this	O
study	B-C2603343
,	O
t1-weighted	B-C2454640
mr	I-C2454640
images	I-C2454640
of	I-C2454640
brain	I-C2454640
structure	I-C2454640
were	O
collected	O
from	O
198	O
adolescents	B-C0205653
63	O
adhd	B-C1263846
-	O
diagnosed	B-C0011900
.	O
	
a	O
multivariate	B-C0026777
parallel	I-C0026777
independent	I-C0026777
component	I-C0026777
analysis	I-C0026777
para-ica	B-C0026777
technique	B-C0449851
-identified	O
imaging	B-C0011923
genetic	B-C0314603
relationships	B-C0439849
between	O
regional	B-C0205147
gm	B-C0018220
volume	B-C0449468
and	O
single	B-C0752046
nucleotide	I-C0752046
polymorphism	I-C0752046
data	B-C1511726
.	O
	
para-ica	B-C0026777
analyses	I-C0026777
extracted	O
14	O
components	O
from	O
genetic	B-C0872179
data	I-C0872179
and	O
9	O
from	O
mr	B-C0024485
data	B-C1511726
.	O
	
an	O
iterative	B-C0681935
cross-validation	I-C0681935
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	B-C0205360
of	O
these	O
ica	B-C0026777
solutions	B-C2699488
.	O
	
a	O
series	O
of	O
partial	B-C0678931
correlation	I-C0678931
analyses	I-C0678931
controlling	B-C2239193
for	O
age	B-C0001779
,	O
sex	B-C1522384
,	O
and	O
ethnicity	B-C0243103
revealed	O
two	O
genotype-phenotype	B-C0678920
component	B-C1705248
pairs	B-C1709450
significantly	O
differed	O
between	O
adhd	B-C1263846
and	O
non-adhd	B-C0243095
groups	B-C0441833
,	O
after	O
a	O
bonferroni	B-C2347434
correction	I-C2347434
for	O
multiple	B-C0439064
comparisons	B-C1707455
.	O
	
the	O
brain	B-C0006104
phenotype	B-C0031437
component	B-C1705248
not	O
only	O
included	O
structures	B-C0678594
frequently	O
found	O
to	O
have	O
abnormally	B-C1299352
low	I-C1299352
volume	B-C0449468
in	O
previous	O
adhd	B-C1263846
studies	B-C2603343
but	O
was	O
also	O
significantly	O
associated	B-C0332281
with	I-C0332281
adhd	B-C1263846
differences	O
in	O
symptom	B-C1319166
severity	I-C1319166
and	O
performance	B-C1882330
on	O
cognitive	B-C0392366
tests	I-C0392366
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	B-C0030705
diagnosed	B-C0011900
with	O
the	O
disorder	B-C0012634
.	O
	
pathway	B-C0868995
analysis	I-C0868995
of	O
the	O
genotype	B-C0017431
component	B-C1705248
identified	O
several	O
different	O
biological	B-C0205460
pathways	B-C1705987
linked	O
to	O
these	O
structural	B-C0678594
abnormalities	B-C1704258
in	O
adhd	B-C1263846
.	O
	
some	O
of	O
these	O
pathways	B-C1705987
implicate	O
well-known	O
dopaminergic	B-C0234101
neurotransmission	I-C0234101
and	O
neurodevelopment	B-C0599855
hypothesized	B-C1512571
to	O
be	O
abnormal	B-C0205161
in	O
adhd	B-C1263846
.	O
	
other	O
more	O
recently	O
implicated	O
pathways	B-C1705987
included	O
glutamatergic	B-C1523698
and	O
gaba-eric	B-C0234105
physiological	I-C0234105
systems	I-C0234105
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
adhd	B-C1263846
,	O
such	O
as	O
sleep	B-C0037317
abnormalities	I-C0037317
.	O
	
clinicopathological	B-C0282421
and	O
immunohistochemical	B-C1441616
characteristics	O
of	O
verruciform	B-C3872816
xanthoma	I-C3872816
of	O
the	O
lower	B-C0227123
gingiva	I-C0227123
a	O
case	B-C0085973
report	I-C0085973
verruciform	B-C3872816
xanthoma	I-C3872816
vx	B-C3872816
is	O
a	O
rare	O
benign	B-C0086692
lesion	I-C0086692
and	O
mainly	O
effects	O
the	O
oral	B-C0026639
mucosa	I-C0026639
.	O
	
this	O
slow-growing	B-C4086857
asymptomatic	B-C0231221
lesion	B-C0086692
typically	O
develops	O
along	O
the	O
gingival	B-C1184544
margin	I-C1184544
of	O
the	O
masticatory	B-C0005654
mucosa	B-C0026724
,	O
followed	O
by	O
the	O
hard	B-C0226901
palate	I-C0226901
,	O
tongue	B-C0040408
,	O
buccal	B-C1578559
mucosa	I-C1578559
,	O
floor	B-C0026638
of	I-C0026638
the	I-C0026638
mouth	I-C0026638
,	O
alveolar	B-C4239924
mucosa	I-C4239924
,	O
soft	B-C0030219
palate	I-C0030219
and	O
junction	B-C0205144
between	O
the	O
hard	B-C0226901
and	O
soft	B-C0030219
palate	I-C0030219
.	O
	
moreover	O
,	O
this	O
lesion	B-C0086692
can	O
also	O
affect	O
the	O
skin	B-C1123023
and	O
genital	B-C0017420
organs	I-C0017420
.	O
	
clinically	B-C0205210
,	O
vx	B-C3872816
generally	O
presents	O
a	O
sessile	B-C1335952
or	O
pedunculated	B-C1335371
appearance	I-C1335371
,	O
forming	O
a	O
papule	B-C0332563
or	O
single	B-C2221189
plaque	I-C2221189
with	O
verrucous	B-C0206706
or	O
papillomatous	B-C0030354
mucosal	B-C0026724
growth	B-C1621966
.	O
	
the	O
colour	B-C0009393
white	B-C0220938
,	O
pink	B-C0332585
,	O
grey	B-C1269776
,	O
or	O
yellow	B-C0221205
depends	O
on	O
the	O
thickness	B-C1280412
of	O
the	O
overlying	O
epidermis	B-C0014520
.	O
	
in	O
fact	O
,	O
the	O
clinical	B-C0205210
findings	B-C0243095
of	O
vx	B-C3872816
are	O
similar	O
to	O
those	O
of	O
verrucous	B-C0206706
carcinoma	I-C0206706
and	O
other	O
benign	B-C0086692
tumours	I-C0086692
,	O
such	O
as	O
squamous	B-C0205874
papilloma	I-C0205874
,	O
verruca	B-C0043037
vulgaris	I-C0043037
and	O
mucosal	B-C0016045
fibroma	I-C0016045
.	O
	
for	O
this	O
reason	O
,	O
clinical	B-C0205210
and	O
histopathological	B-C0243140
examinations	B-C0031809
are	O
essential	O
for	O
accurate	B-C0011906
differential	I-C0011906
diagnosis	I-C0011906
.	O
	
histologically	B-C0205462
,	O
vx	B-C3872816
is	O
characterized	O
by	O
parakeratosis	B-C0030436
,	O
rete	B-C1516920
ridges	I-C1516920
of	O
uniform	O
depth	O
and	O
the	O
accumulation	B-C4055506
of	O
foam	B-C0016390
cells	I-C0016390
,	O
which	O
are	O
also	O
called	O
""""	O
xanthoma	B-C1520164
cells	I-C1520164
""""	O
.	O
	
here	O
,	O
we	O
describe	O
the	O
clinicopathological	B-C0282421
and	O
immunohistochemical	B-C1441616
findings	B-C0243095
of	O
a	O
vx	B-C3872816
located	O
on	O
the	O
lower	B-C0227123
gingiva	I-C0227123
of	O
a	O
64-year-old	O
male	B-C0150904
patient	I-C0150904
.	O
	
microrna	B-C2825314
101b	I-C2825314
is	O
downregulated	B-C0013081
in	O
the	O
prefrontal	B-C0162783
cortex	I-C0162783
of	O
a	O
genetic	B-C0026343
model	I-C0026343
of	O
depression	B-C0011581
and	O
targets	B-C1521840
the	O
glutamate	B-C0061467
transporter	I-C0061467
slc1a1	B-C1529079
eaat3	B-C1529079
in	B-C1533691
vitro	I-C1533691
micrornas	B-C1101610
mirnas	B-C1101610
are	O
small	B-C0700321
regulatory	B-C1704735
molecules	B-C0567416
that	O
cause	O
translational	B-C1519619
repression	I-C1519619
by	O
base	B-C2263416
pairing	I-C2263416
with	I-C2263416
target	I-C2263416
mrnas	I-C2263416
.	O
	
cumulative	B-C1511559
evidence	B-C3887511
suggests	O
that	O
changes	B-C0392747
in	O
mirna	B-C2825314
expression	B-C0017262
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	B-C0031847
and	O
treatment	B-C0087111
of	O
neuropsychiatric	B-C2015799
disorders	I-C2015799
,	O
including	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
mdd	B-C1269683
.	O
	
a	O
mirna	B-C2825314
expression	B-C0017262
assay	B-C0005507
that	O
can	O
simultaneously	B-C0521115
detect	O
423	O
rat	O
mirnas	B-C2825314
mirbase	O
v.17	O
was	O
used	O
to	O
profile	B-C1979963
the	O
prefrontal	B-C0162783
cortex	I-C0162783
pfc	B-C0162783
of	O
a	O
genetic	B-C0026343
rat	I-C0026343
model	I-C0026343
of	O
mdd	B-C1269683
the	O
flinders	B-C0026343
sensitive	I-C0026343
line	I-C0026343
fsl	B-C0026343
and	O
the	O
controls	B-C0009932
,	O
the	O
flinders	B-C0026343
resistant	I-C0026343
line	I-C0026343
frl	B-C0026343
.	O
	
gene	B-C0017262
expression	I-C0017262
data	B-C1511726
from	O
the	O
pfc	B-C0162783
of	O
fsl	B-C0026343
/	O
frl	B-C0026343
animals	B-C0003062
geo	O
accession	O
no	O
.	O
	
gse20388	O
were	O
used	O
to	O
guide	O
mrna	B-C0035696
target	B-C1521840
selection	B-C1707391
.	O
	
luciferase	B-C0005507
reporter	I-C0005507
assays	I-C0005507
were	O
used	O
to	O
verify	B-C1711411
mirna	B-C2825314
targets	B-C1521840
in	B-C1533691
vitro	I-C1533691
.	O
	
we	O
identified	B-C0205396
23	O
mirnas	B-C2825314
that	O
were	O
downregulated	B-C0013081
in	O
the	O
pfc	B-C0162783
of	O
the	O
fsl	B-C0026343
model	I-C0026343
compared	B-C1707455
with	O
controls	B-C0009932
.	O
	
interestingly	O
,	O
one	O
of	O
the	O
identified	B-C0205396
mirnas	B-C2825314
mir-101b	B-C2825314
is	O
highly	O
conserved	B-C2347858
between	O
rat	B-C0086893
and	O
human	B-C0086418
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	B-C0013081
in	O
the	O
pfc	B-C0162783
of	O
depressed	B-C1579931
suicide	B-C0038661
subjects	B-C0681850
.	O
	
using	O
a	O
combination	B-C0205195
of	O
in	B-C3489666
silico	I-C3489666
and	O
in	B-C1533691
vitro	I-C1533691
analyses	B-C0936012
,	O
we	O
found	O
that	O
mir-101b	B-C2825314
targets	B-C1521840
the	O
neuronal	B-C0027882
glutamate	B-C0061467
transporter	I-C0061467
slc1a1	B-C1529079
also	O
known	O
as	O
eaac1	B-C1529079
or	O
eaat3	B-C1529079
.	O
	
accordingly	O
,	O
both	O
mrna	B-C0035696
and	O
protein	B-C0428479
levels	I-C0428479
of	O
slc1a1	B-C1529079
were	O
found	O
to	O
be	O
upregulated	B-C0041904
in	O
the	O
pfc	B-C0162783
of	O
the	O
fsl	B-C0026343
model	I-C0026343
.	O
	
besides	O
providing	O
a	O
list	O
of	O
novel	O
mirnas	B-C2825314
associated	B-C0332281
with	I-C0332281
depression-like	B-C0344315
states	I-C0344315
,	O
this	O
preclinical	B-C1709631
study	I-C1709631
replicated	B-C0205173
the	O
human	B-C0086418
association	B-C0439849
of	O
mir-101	B-C2825314
with	O
depression	B-C0011581
.	O
	
in	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	B-C1521840
of	O
mir-101b	B-C2825314
appears	O
to	O
be	O
a	O
glutamate	B-C0061467
transporter	I-C0061467
,	O
our	O
preclinical	B-C1709630
data	B-C1511726
support	O
the	O
hypothesis	B-C1512571
of	O
a	O
glutamatergic	B-C0242899
dysregulation	B-C0243095
being	O
implicated	O
in	O
the	O
etiology	B-C1314792
of	O
a	O
practical	B-C0181090
guide	I-C0181090
to	O
forensic	B-C1721027
nursing	I-C1721027
incorporating	B-C0332257
forensic	B-C1721027
principles	B-C1882460
into	O
nursing	B-C0028687
practice	I-C0028687
amar	B-C0086418
angela	I-C0086418
f	I-C0086418
and	O
sekula	B-C0086418
l	I-C0086418
kathleen	I-C0086418
a	O
practical	B-C0181090
guide	I-C0181090
to	O
forensic	B-C1721027
nursing	I-C1721027
incorporating	O
forensic	B-C1721027
principles	B-C1882460
into	O
nursing	B-C0028687
practice	I-C0028687
392pp	O
us	O
sigma	O
theta	O
tau	O
international	O
honor	O
society	O
of	O
nursing	O
9781940446349	O
1940446341	O
formula	O
see	O
text	O
george	B-C0086418
bernard	I-C0086418
shaw	I-C0086418
described	O
britons	B-C0337925
and	O
americans	B-C0596070
as	O
'	O
divided	B-C0332849
by	O
a	O
common	B-C0023008
language	I-C0023008
'	O
,	O
and	O
that	O
is	O
made	O
very	O
clear	O
in	O
this	O
fascinating	B-C0034036
publication	I-C0034036
that	O
describes	O
in	O
depth	O
the	O
roles	B-C3890565
and	I-C3890565
responsibilities	I-C3890565
of	O
forensic	B-C0028661
nurses	I-C0028661
in	O
the	O
incidence	B-C0021149
of	O
diabetes	B-C0011849
mellitus	I-C0011849
and	O
obesity	B-C0028754
and	O
the	O
overlap	B-C1948020
of	O
comorbidities	B-C0009488
in	O
hiv+	B-C0019699
hispanics	B-C0086409
initiating	B-C1704686
antiretroviral	B-C1963724
therapy	I-C1963724
cardiovascular	B-C0007222
disease	I-C0007222
cvd	B-C0007222
is	O
a	O
leading	O
health	B-C0018684
threat	B-C0749385
for	O
hiv+	B-C0019699
patients	B-C0030705
on	O
antiretroviral	B-C1963724
therapy	I-C1963724
art	B-C1963724
cardiometabolic	B-C0025517
comorbidities	B-C0009488
are	O
key	O
predictors	B-C0035648
of	I-C0035648
risk	I-C0035648
.	O
	
data	B-C1511726
are	O
limited	O
on	O
incidence	B-C0021149
of	O
metabolic	B-C0311400
comorbidities	B-C0009488
in	O
hiv+	B-C0019699
individuals	B-C0237401
initiating	B-C1704686
art	B-C1963724
in	O
low	B-C0870823
and	O
middle	B-C0870890
income	I-C0870890
countries	B-C0454664
lmics	B-C0454664
,	O
particularly	B-C0205556
for	O
hispanics	B-C0086409
.	O
	
we	O
examined	B-C0332128
incidence	B-C0021149
of	O
diabetes	B-C0011847
and	O
obesity	B-C0028754
in	O
a	O
prospective	B-C0599755
cohort	I-C0599755
of	O
those	O
initiating	B-C1704686
art	B-C1963724
in	O
the	O
dominican	B-C0013014
republic	I-C0013014
.	O
	
participants	B-C0679646
18	O
years	B-C0439234
,	O
initiating	B-C1704686
art	B-C1963724
<90	O
days	B-C0439228
prior	O
to	O
study	B-C2603343
enrollment	B-C1516879
,	O
were	O
examined	B-C0332128
for	O
incidence	B-C0021149
of	O
impaired	B-C1272092
fasting	I-C1272092
glucose	I-C1272092
ifg	B-C1272092
,	O
diabetes	B-C0011849
mellitus	I-C0011849
dm	B-C0011849
,	O
overweight	B-C1561826
,	O
and	I-C1561826
obesity	I-C1561826
.	O
	
fasting	B-C0583513
plasma	I-C0583513
glucose	I-C0583513
fpg	B-C0583513
100-125mg/dl	O
defined	O
ifg	B-C1272092
fpg	B-C0583513
126	O
mg/dl	O
,	O
diagnosis	B-C1704656
per	O
medical	B-C0025102
record	I-C0025102
,	O
or	O
use	O
of	O
hypoglycemic	B-C0020616
medication	I-C0020616
defined	O
dm	B-C0011849
.	O
	
overweight	B-C1561826
and	I-C1561826
obesity	I-C1561826
were	O
bmi	B-C1305855
25-30	O
and	O
30kg/m2	O
,	O
respectively	O
.	O
	
dyslipidemia	B-C0242339
was	O
total	B-C0543421
cholesterol	I-C0543421
240mg/dl	O
or	O
use	B-C1524063
of	I-C1524063
lipid-lowering	B-C0003367
medication	I-C0003367
.	O
	
framingham	B-C3176199
risk	I-C3176199
equation	I-C3176199
was	O
used	B-C1273517
to	O
determine	B-C0521095
ten-year	B-C0439234
cvd	B-C0007222
risk	B-C0086930
at	O
the	O
end	B-C0302523
of	I-C0302523
observation	I-C0302523
.	O
	
of	O
153	O
initiating	B-C1704686
art	B-C1963724
,	O
8	O
6%	O
had	O
dm	B-C0011849
and	O
23	O
16%	O
had	O
ifg	B-C1272092
at	O
baseline	B-C1442488
,	O
6	O
developed	O
dm	B-C0011849
28/1000	O
person	B-C0027361
-	O
years	B-C0439234
follow	B-C1522577
up	I-C1522577
pyfu	B-C1522577
and	O
46	O
developed	O
ifg	B-C1272092
329/1000	O
pyfu	B-C1522577
.	O
	
at	O
baseline	B-C1442488
,	O
24	O
18%	O
were	O
obese	B-C0028754
and	O
36	O
27%	O
were	O
overweight	B-C0497406
,	O
15	O
became	O
obese	B-C0028754
69/1000	O
pyfu	B-C1522577
and	O
22	O
became	O
overweight	B-C0497406
163/1000	O
pyfu	B-C1522577
.	O
	
median	B-C2939193
observation	B-C0700325
periods	B-C1948053
for	O
the	O
diabetes	B-C0011847
and	O
obesity	B-C0028754
analyses	B-C0936012
were	O
23.5	O
months	B-C0439231
and	O
24.3	O
months	B-C0439231
,	O
respectively	O
.	O
	
increased	B-C0205217
cvd	B-C0007222
risk	B-C0086930
10%	O
10-year	B-C4086295
framingham	I-C4086295
risk	I-C4086295
score	I-C4086295
was	O
present	B-C0150312
for	O
13%	O
of	O
the	O
cohort	B-C0599755
79%	O
of	O
the	O
cohort	B-C0599755
had	O
1	O
cardiometabolic	B-C0009488
comorbidity	I-C0009488
,	O
48%	O
had	O
2	O
,	O
and	O
13%	O
had	O
all	O
three	O
.	O
	
in	O
this	O
hispanic	B-C0086409
cohort	B-C0599755
in	O
an	O
lmic	B-C0454664
,	O
incidences	B-C0021149
of	O
ifg	B-C1272092
/	O
dm	B-C0011849
and	O
overweight	B-C0497406
/	O
obesity	B-C0028754
were	O
similar	B-C2348205
to	O
or	O
higher	B-C0205250
than	I-C0205250
that	O
found	B-C0150312
in	O
high	B-C0948433
income	I-C0948433
countries	B-C0454664
,	O
and	O
cardiometabolic	B-C0025517
disorders	I-C0025517
affected	B-C0392760
three-quarters	O
of	O
those	O
initiating	B-C1704686
art	B-C1963724
.	O
	
care	B-C0596657
models	I-C0596657
incorporating	O
cardiovascular	B-C0850624
risk	I-C0850624
reduction	B-C0441610
into	O
hiv	B-C0019693
treatment	B-C0679841
programs	I-C0679841
are	O
needed	B-C0027552
to	O
prevent	B-C1292733
cvd	B-C0007222
-	O
associated	B-C0332281
mortality	B-C0205848
in	O
this	O
vulnerable	B-C0949366
population	I-C0949366
.	O
	
laparoscopic	B-C0031150
approach	I-C0031150
for	O
thermoablation	B-C3854551
microwave	I-C3854551
in	O
the	O
treatment	B-C0087111
of	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
a	O
single	O
center	O
experience	B-C0596545
the	O
surgical	B-C0543467
therapy	I-C0543467
of	O
choice	O
for	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
hcc	B-C2239176
is	O
liver	B-C0023911
transplantation	I-C0023911
lt	B-C0023911
or	O
hepatic	B-C0400440
resection	I-C0400440
,	O
although	O
only	O
a	O
small	B-C0700321
percentage	B-C0439165
of	O
patients	B-C0030705
can	O
undergo	O
these	O
procedures	B-C2700391
.	O
	
microwave	B-C3854551
thermal	I-C3854551
ablation	I-C3854551
mwta	B-C3854551
can	O
be	O
an	O
effective	B-C1280519
alternative	B-C1523987
treatment	B-C0087111
for	O
hcc	B-C2239176
that	O
complicates	B-C0231242
a	O
cirrhotic	B-C0023890
liver	I-C0023890
disease	I-C0023890
,	O
either	O
as	O
a	O
final	B-C3853528
procedure	B-C2700391
or	O
for	O
downstaging	B-C0430022
patients	B-C0030705
on	O
the	O
waiting	O
list	O
for	O
lt	B-C0023911
,	O
or	O
in	O
combination	B-C0205195
with	O
resective	B-C0015252
surgery	B-C0543467
to	O
achieve	O
oncological	B-C0027651
radicality	B-C0439807
.	O
	
the	O
purpose	O
of	O
this	O
retrospective	B-C0035363
study	I-C0035363
was	O
to	O
evaluate	B-C0220825
experience	B-C0596545
with	O
the	O
laparoscopic	B-C0031150
approach	I-C0031150
of	O
mwta	B-C3854551
at	O
our	O
center	O
.	O
	
in	O
a	O
cohort	B-C0599755
of	O
35	O
consecutive	B-C1707491
patients	B-C0030705
undergoing	O
mwta	B-C3854551
with	O
laparoscopic	B-C0031150
approach	I-C0031150
between	O
january	O
,	O
2013	O
and	O
may	O
,	O
2016	O
,	O
we	O
reviewed	O
the	O
demographic	B-C0011289
data	I-C0011289
,	O
the	O
barcelona	B-C3899974
clinic	I-C3899974
liver	I-C3899974
cancer	I-C3899974
stage	I-C3899974
,	O
the	O
severity	B-C0439793
of	O
cirrhotic	B-C0023890
liver	I-C0023890
disease	I-C0023890
,	O
the	O
size	B-C0456389
of	O
the	O
ablated	B-C0547070
lesion	B-C0221198
,	O
the	O
duration	B-C0449238
of	O
the	O
procedure	B-C2700391
,	O
and	O
complications	B-C0231242
occurring	O
within	O
90	O
days	B-C0439228
of	O
surgery	B-C0543467
.	O
	
mwta	B-C3854551
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	B-C0205054
parenchymal	B-C4277702
insertions	B-C0441587
mean	B-C0444504
1.8	O
per	O
patient	B-C0030705
.	O
	
the	O
mean	B-C0444504
duration	B-C0449238
of	O
surgery	B-C0543467
was	O
163	O
18	O
minutes	B-C0439232
.	O
	
there	O
was	O
no	O
blood	B-C3163616
loss	I-C3163616
in	O
any	O
of	O
the	O
procedures	B-C2700391
.	O
	
complete	O
necrosis	B-C0027540
on	O
ct	B-C0040405
scan	I-C0040405
was	O
achieved	O
in	O
26/35	O
patients	B-C0030705
75%	O
.	O
	
the	O
mean	B-C0444504
hospital	B-C3489408
stay	I-C3489408
was	O
4.6	O
range	O
2-7	O
days	B-C0439228
major	O
complications	B-C0231242
were	O
postablation	B-C1292448
syndrome	B-C0039082
in	O
2/35	O
5.7	O
,	O
peritoneal	B-C0003964
fluid	I-C0003964
in	O
4/35	O
11.4	O
,	O
and	O
transient	B-C0205374
jaundice	B-C0022354
in	O
1/35	O
2.8	O
patients	B-C0030705
.	O
	
there	O
was	O
no	B-C0243095
mortality	I-C0243095
.	O
	
laparoscopic	B-C0031150
mwta	B-C3854551
is	O
a	O
safe	O
and	O
effective	B-C1280519
treatment	B-C0087111
for	O
unresectable	B-C1519810
hcc	B-C2239176
and	O
when	O
a	O
percutaneous	B-C0522523
procedure	B-C2700391
structured	B-C0678594
instruction	B-C1442085
with	O
modified	B-C0392747
storybooks	B-C0814818
to	O
teach	B-C0039401
morphosyntax	B-C0023741
and	O
vocabulary	B-C0042926
to	O
preschoolers	B-C0008100
who	O
are	O
deaf	B-C3824904
/	O
hard	B-C0525064
of	I-C0525064
hearing	I-C0525064
children	B-C0008059
who	O
are	O
deaf	B-C3824904
/	O
hard	B-C0525064
of	I-C0525064
hearing	I-C0525064
d	B-C3824904
/	O
hh	B-C0525064
are	O
at	B-C1444641
risk	I-C1444641
for	O
diminished	B-C0205216
morphosyntactical	B-C0023741
and	O
vocabulary	B-C0042926
development	B-C1527148
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	B-C1704420
of	I-C1704420
repeated	B-C0205341
reading	B-C0034754
combined	B-C0205195
with	O
structured	B-C0678594
instruction	B-C1442085
.	O
	
targets	B-C1521840
were	O
a	O
morphosyntactical	B-C0023741
form	I-C0023741
and	O
novel	O
vocabulary	B-C0042926
words	I-C0042926
.	O
	
participants	B-C0679646
were	O
3	O
preschoolers	B-C0008100
who	O
are	O
d	B-C3824904
/	O
hh	B-C0525064
who	O
were	O
receiving	B-C1514756
instruction	B-C1442085
with	O
an	O
oral	B-C0442027
approach	O
.	O
	
data	B-C1511726
from	O
a	O
multiple	B-C0439064
baseline	B-C0282121
design	I-C0282121
indicated	O
that	O
all	O
children	B-C0008059
acquired	B-C1706701
the	O
targeted	B-C1521840
skills	B-C0678856
and	O
demonstrated	O
high	O
levels	O
of	O
generalization	B-C0237635
of	O
these	O
skills	B-C0678856
to	O
untrained	B-C0243095
context	B-C0449255
.	O
	
implications	B-C0205556
for	O
teaching	B-C0039401
young	B-C0332239
children	B-C0008059
who	O
are	O
d	B-C3824904
/	O
hh	B-C0525064
using	B-C1524063
repeated	B-C0205341
storybook	B-C0814818
reading	B-C0034754
application	B-C0185125
of	O
braf	B-C3250916
v600e	I-C3250916
mutation	B-C0026882
-	O
specific	B-C0205369
immunohistochemistry	B-C0021044
in	O
diagnosis	B-C0011900
of	O
gastrointestinal	B-C0238198
stromal	I-C0238198
tumors	I-C0238198
to	O
evaluate	B-C0220825
the	O
utility	O
of	O
braf	B-C3250916
v600e	I-C3250916
allele	B-C0002085
-	O
specific	B-C0205369
antibody	B-C0003241
in	O
the	O
diagnosis	B-C0011900
of	O
gastrointestinal	B-C0238198
stromal	I-C0238198
tumors	I-C0238198
gists	B-C0238198
.	O
	
braf	B-C3250916
v600e	I-C3250916
mutation	B-C0026882
-	O
specific	B-C0205369
immunohistochemistry	B-C0021044
and	O
braf	B-C0812241
sequencing	B-C1561491
were	O
performed	O
in	O
24	O
consecutive	B-C1707491
gists	B-C0238198
,	O
including	O
14	O
cases	B-C0868928
of	O
kit	B-C1511353
or	O
pdgfra	B-C1518782
mutations	I-C1518782
and	O
10	O
cases	B-C0868928
of	O
kit	B-C1416655
/	O
pdgfra	B-C1705319
wild	I-C1705319
gists	B-C0238198
.	O
	
gists	B-C0238198
of	O
11	O
men	B-C0025266
and	O
13	O
women	B-C0043210
with	O
a	O
mean	B-C2347634
age	B-C0001779
54	O
years	O
29-75	O
years	O
were	O
included	O
with	O
tumors	B-C0027651
arising	O
from	O
stomach	B-C0038351
16	O
cases	B-C0868928
,	O
small	B-C0021852
bowel	I-C0021852
7	O
cases	B-C0868928
,	O
and	O
peritoneal	B-C1704247
cavity	I-C1704247
1	O
case	B-C0868928
.	O
	
strong	B-C0442821
and	O
diffuse	B-C0205219
cytoplasmic	B-C0521449
braf	B-C1259929
staining	B-C1704680
was	O
noted	B-C4288581
in	O
4	O
of	O
24	O
cases	B-C0868928
17%	O
,	O
while	O
1	O
of	O
24	O
cases	B-C0868928
4%	O
showed	O
weak	B-C1762617
staining	B-C1704680
,	O
and	O
19	O
of	O
24	O
cases	B-C0868928
79%	O
had	O
no	B-C0332197
staining	B-C1704680
.	O
	
the	O
four	O
cases	B-C0868928
with	O
strong	B-C0442821
braf	B-C1259929
immunostain	B-C0038128
were	O
confirmed	B-C0521093
to	O
have	O
braf	B-C1511021
mutations	I-C1511021
,	O
including	O
3	O
cases	B-C0868928
in	O
the	O
stomach	B-C0038351
and	O
1	O
case	B-C0868928
in	O
the	O
small	B-C0021852
intestine	I-C0021852
.	O
	
all	O
tumors	B-C0027651
showed	O
spindle	B-C0682540
cell	I-C0682540
morphology	B-C0332437
.	O
	
only	O
one	O
case	B-C0868928
had	O
progressive	B-C1335499
disease	I-C1335499
.	O
	
no	B-C0332197
braf	B-C1511021
mutations	I-C1511021
were	O
detected	B-C0442726
in	O
cases	B-C0868928
with	O
weak	B-C1762617
or	O
negative	B-C0205160
braf	B-C1259929
immunostain	B-C0038128
.	O
	
braf	B-C3250916
v600e	I-C3250916
mutation	B-C0026882
-	O
specific	B-C0205369
immunohistochemistry	B-C0021044
is	O
a	O
highly	B-C0439822
sensitive	I-C0439822
and	O
specific	B-C0205369
marker	B-C0005516
for	O
detecting	B-C0442726
braf-mutated	B-C1511021
gists	B-C0238198
.	O
	
efficacy	O
of	O
pegylated	B-C0015133
liposomal	I-C0015133
etoposide	I-C0015133
nanoparticles	I-C0015133
on	O
breast	B-C1512505
cancer	I-C1512505
cell	I-C1512505
lines	I-C1512505
this	O
study	O
aimed	O
to	O
investigate	O
the	O
efficacy	B-C1280519
of	I-C1280519
pegylated	B-C0015133
liposomal	I-C0015133
etoposide	I-C0015133
nanoparticles	I-C0015133
nps	O
against	O
t-47d	B-C3897399
and	O
mcf-7	B-C0596890
breast	I-C0596890
cancer	I-C0596890
cell	I-C0596890
lines	I-C0596890
.	O
	
pegylated	B-C0015133
liposomal	I-C0015133
etoposide	I-C0015133
nps	I-C0015133
were	O
prepared	O
by	O
reverse	B-C0596539
phase	I-C0596539
evaporation	I-C0596539
method	I-C0596539
.	O
	
the	O
size	B-C0456389
,	O
size	B-C0037775
distribution	I-C0037775
,	O
and	O
zeta	B-C0597697
potential	I-C0597697
of	O
the	O
nps	B-C0015133
was	O
measured	O
by	O
a	O
zetasizer	B-C0348000
instrument	I-C0348000
.	O
	
the	O
cytotoxicity	B-C0596402
of	O
nps	B-C0015133
was	O
inspected	O
by	O
methyl	B-C2986858
thiazol	I-C2986858
tetrazolium	I-C2986858
assay	I-C2986858
.	O
	
the	O
release	B-C0360812
pattern	I-C0360812
of	I-C0360812
the	I-C0360812
drug	I-C0360812
from	I-C0360812
the	I-C0360812
vesicles	I-C0360812
was	O
studied	O
by	O
the	O
dialysis	B-C3483167
method	I-C3483167
.	O
	
drug	B-C0678767
loading	I-C0678767
and	O
encapsulation	B-C2348438
efficiency	I-C2348438
ee	B-C2348438
were	O
also	O
measured	O
.	O
	
the	O
mean	B-C0456389
size	I-C0456389
,	O
size	B-C0037775
distribution	I-C0037775
,	O
and	O
zeta	B-C0597697
potential	I-C0597697
of	O
pegylated	B-C0015133
liposomal	I-C0015133
etoposide	I-C0015133
nps	I-C0015133
were	O
491	O
15.5	O
nm	O
,	O
0.504	O
0.14	O
,	O
and	O
-35	O
2.5	O
mv	O
,	O
respectively	O
.	O
	
drug	B-C0678767
loading	I-C0678767
and	O
ee	B-C2348438
were	O
10.3	O
1.6	O
and	O
99.1	O
2.8	O
,	O
respectively	O
.	O
	
the	O
etoposide	B-C1707824
release	I-C1707824
in	I-C1707824
the	I-C1707824
formulation	I-C1707824
was	O
estimated	O
at	O
about	O
3.48	O
after	O
48	O
h	O
.	O
	
the	O
cytotoxicity	B-C0596402
effect	I-C0596402
of	O
etoposide	B-C0015133
nps	I-C0015133
on	O
t-47d	B-C3897399
and	O
mcf-7	B-C0596890
cell	I-C0596890
lines	I-C0596890
of	I-C0596890
breast	I-C0596890
cancer	I-C0596890
showed	O
higher	O
antitumor	B-C2986475
activity	I-C2986475
as	O
compared	O
with	O
those	O
of	O
the	O
free	B-C0678752
drug	I-C0678752
.	O
	
liposome-based	B-C0015133
nps	I-C0015133
may	O
hold	O
great	O
potential	O
as	O
a	O
drug	B-C0085104
delivery	I-C0085104
system	I-C0085104
.	O
	
the	O
bindex	B-C1875843
ultrasound	I-C1875843
device	I-C1875843
reliability	B-C2347947
of	O
cortical	B-C0222652
bone	I-C0222652
thickness	B-C1280412
measures	B-C0079809
and	O
their	O
relationship	B-C0439849
to	O
regional	B-C0205147
bone	B-C0005938
mineral	I-C0005938
density	I-C0005938
the	O
bindex	B-C1875843
quantitative	I-C1875843
ultrasound	I-C1875843
qus	I-C1875843
device	I-C1875843
is	O
currently	O
available	O
and	O
this	O
study	B-C2603343
analyzed	B-C0936012
i	O
its	O
relative	B-C0205345
and	O
absolute	B-C0205344
intra-	B-C2347947
and	I-C2347947
inter-session	I-C2347947
reliability	I-C2347947
and	O
ii	O
the	O
relationship	B-C0439849
between	O
the	O
data	B-C1511726
provided	O
by	O
bindex	B-C1875843
and	O
the	O
bone	B-C0005938
mineral	I-C0005938
density	I-C0005938
bmd	B-C0005938
measured	B-C0444706
by	O
dual-energy	B-C1510486
x-ray	I-C1510486
absorptiometry	I-C1510486
at	O
corresponding	O
skeletal	B-C1282387
sites	I-C1282387
in	O
young	B-C0080105
and	O
healthy	B-C1708335
subjects	I-C1708335
age	B-C0001779
25.0	O
3.6	O
years	B-C1510829
.	O
	
bindex	B-C1875843
calculates	B-C1441506
a	O
density	B-C0005938
index	I-C0005938
on	O
the	O
basis	O
of	O
the	O
thickness	B-C1280412
of	O
cortical	B-C0222652
bone	I-C0222652
measured	B-C0444706
at	O
the	O
distal	B-C0588207
radius	I-C0588207
and	O
the	O
distal	B-C0588200
plus	O
proximal	B-C0588198
tibia	I-C0588198
.	O
	
the	O
data	B-C1511726
show	O
a	O
very	O
good	O
relative	B-C0205345
and	O
absolute	B-C0205344
intra-	B-C2347947
icc	B-C0392762
=	O
0.977	O
,	O
cv	B-C0681921
=	O
1.5	O
and	O
inter-session	B-C2347947
reliability	I-C2347947
icc	B-C0392762
=	O
0.978	O
,	O
cv	B-C0681921
=	O
1.4	O
for	O
the	O
density	B-C0005938
index	I-C0005938
.	O
	
the	O
highest	B-C1522410
positive	B-C1446409
correlations	B-C1707520
were	O
found	O
between	O
cortical	B-C0222652
thickness	B-C1280412
and	O
bmd	B-C0005938
for	O
the	O
distal	B-C0588207
radius	I-C0588207
and	O
distal	B-C0588200
tibia	I-C0588200
r	O
0.71	O
,	O
p	O
<	O
0.001	O
.	O
	
the	O
data	B-C1511726
indicate	O
that	O
the	O
bindex	B-C1875843
parameters	B-C0449381
are	O
repeatable	O
within	O
and	O
between	O
measurement	B-C0242485
sessions	B-C1883017
.	O
	
furthermore	O
,	O
the	O
measurements	B-C0242485
reflect	O
the	O
bmd	B-C0005938
at	O
specific	B-C0205369
skeletal	B-C1282387
sites	I-C1282387
.	O
	
bindex	B-C1875843
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	B-C0242485
of	O
skeletal	B-C2248552
adaptations	I-C2248552
.	O
	
botulinum	B-C0006055
toxin	I-C0006055
use	O
in	O
refractory	B-C0030200
pain	I-C0030200
and	O
other	O
symptoms	B-C1457887
in	O
parkinsonism	B-C0242422
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
and	O
other	O
parkinsonian	B-C0242422
syndromes	I-C0242422
are	O
chronic	B-C0205191
,	O
progressive	B-C0205329
neurodegenerative	B-C0524851
diseases	I-C0524851
.	O
	
with	O
advancing	O
disease	B-C0012634
,	O
both	O
motor	B-C0426980
and	O
non-motor	B-C1457887
symptoms	I-C1457887
represent	O
a	O
considerable	O
burden	B-C2828008
and	O
symptom	B-C1457887
relief	B-C0564405
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
improvement	B-C2986411
become	O
the	O
main	O
goal	B-C0018017
of	O
treatment	B-C0087111
.	O
	
botulinum	B-C0006055
toxins	I-C0006055
btx	B-C0006055
are	O
an	O
effective	B-C1704419
treatment	B-C0087111
modality	B-C0695347
for	O
many	O
neurological	B-C0027765
conditions	I-C0027765
.	O
	
to	O
understand	O
the	O
potential	B-C3245505
usefulness	B-C3827682
of	O
btx	B-C0006055
in	O
this	O
population	B-C1257890
,	O
we	O
performed	B-C0884358
a	O
retrospective	B-C1514923
chart	B-C0541653
review	I-C0541653
of	O
all	O
patients	B-C0030705
with	O
a	O
clinical	B-C0332140
diagnosis	I-C0332140
of	O
idiopathic	B-C0865475
pd	I-C0865475
and	O
atypical	B-C4302185
parkinsonism	I-C4302185
who	O
received	O
treatment	B-C0039798
with	O
btx	B-C1321035
injections	I-C1321035
in	O
our	O
center	B-C1708333
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	B-C1457887
.	O
	
response	B-C0871261
to	O
btx	B-C0006055
was	O
assessed	B-C1516048
using	O
a	O
subjective	B-C3639708
clinical	I-C3639708
global	I-C3639708
impression	I-C3639708
.	O
	
records	B-C0034869
of	O
160	O
patients	B-C0030705
were	O
reviewed	B-C1709940
.	O
	
probable	O
idiopathic	B-C0865475
pd	I-C0865475
was	O
the	O
diagnosis	B-C0011900
in	O
117	O
patients	B-C0030705
73.1	O
.	O
	
the	O
main	O
indication	B-C3146298
for	O
btx	B-C0006055
treatment	B-C0087111
was	O
pain	B-C0030193
50.6	O
of	O
cases	O
.	O
	
other	O
indications	B-C3146298
were	O
the	O
treatment	B-C0087111
of	O
functional	B-C4062321
impairment	I-C4062321
resulting	B-C0678226
from	O
dystonia	B-C0013421
26.25	O
,	O
sialorrhea	B-C0037036
18.75	O
,	O
freezing	B-C0860515
of	I-C0860515
gait	I-C0860515
,	O
and	O
camptocormia	B-C0264162
.	O
	
considering	O
pain	B-C0030193
as	O
indication	B-C3146298
,	O
81%	O
of	O
all	O
patients	B-C0030705
with	O
pd	B-C0030567
reported	B-C0700287
benefits	B-C0814225
after	O
the	O
first	O
btx	B-C1321035
injections	I-C1321035
.	O
	
this	O
benefit	B-C0814225
was	O
maintained	B-C1314677
after	O
the	O
last	B-C1512346
recorded	I-C1512346
visit	I-C1512346
without	O
significant	O
difference	B-C1705242
in	O
outcome	B-C1274040
compared	B-C1707455
with	O
the	O
first	O
injection	B-C0021485
p=0	O
.	O
	
similar	O
results	B-C1274040
were	O
observed	O
in	O
patients	B-C0030705
with	O
atypical	B-C4302185
parkinsonism	I-C4302185
.	O
	
our	O
results	B-C1274040
confirm	O
the	O
safety	O
and	O
efficacy	B-C1280519
of	O
different	B-C1705242
uses	B-C0457083
of	O
btx	B-C0006055
in	O
the	O
symptomatic	B-C0231220
treatment	B-C1522326
of	O
patients	B-C0030705
with	O
parkinsonism	B-C0242422
even	O
in	O
advanced	B-C0205179
stages	B-C1306673
of	O
the	O
disease	B-C0012634
,	O
and	O
suggest	B-C1705535
btx	B-C0006055
treatment	B-C0087111
could	O
have	O
a	O
safe	O
and	O
useful	O
role	B-C1705810
in	O
the	O
treatment	B-C1522326
of	O
pain	B-C0030193
in	O
this	O
chronic	B-C0743284
exposure	I-C0743284
to	I-C0743284
haloperidol	B-C0018546
and	O
olanzapine	B-C0171023
leads	O
to	O
common	O
and	O
divergent	O
shape	B-C1562006
changes	I-C1562006
in	O
the	O
rat	B-C0034693
hippocampus	B-C0019564
in	O
the	O
absence	O
of	O
grey-matter	B-C0018220
volume	B-C0205245
loss	I-C0205245
one	O
of	O
the	O
most	O
consistently	O
reported	O
brain	B-C4021085
abnormalities	I-C4021085
in	O
schizophrenia	B-C0036341
scz	B-C0036341
is	O
decreased	O
volume	B-C1562006
and	I-C1562006
shape	I-C1562006
deformation	I-C1562006
of	O
the	O
hippocampus	B-C0019564
.	O
	
however	O
,	O
the	O
potential	O
contribution	O
of	O
chronic	B-C0040615
antipsychotic	I-C0040615
medication	I-C0040615
exposure	B-C0743284
to	O
these	O
phenomena	O
remains	O
unclear	O
.	O
	
we	O
examined	O
the	O
effect	O
of	O
chronic	B-C0743284
exposure	I-C0743284
8	O
weeks	O
to	O
clinically	O
relevant	B-C0178602
doses	I-C0178602
of	O
either	O
haloperidol	B-C0018546
hal	B-C0018546
or	O
olanzapine	B-C0171023
olz	B-C0171023
on	O
adult	O
rat	B-C0034693
hippocampal	B-C3496509
volume	B-C0243095
and	I-C0243095
shape	I-C0243095
using	O
ex	B-C2348480
vivo	I-C2348480
structural	B-C0024485
mri	I-C0024485
with	O
the	O
brain	B-C0037303
retained	I-C0037303
inside	I-C0037303
the	I-C0037303
cranium	I-C0037303
to	O
prevent	O
distortions	B-C0332482
due	O
to	O
dissection	B-C0012737
,	O
followed	O
by	O
tensor-based	B-C0200760
morphometry	I-C0200760
tbm	B-C0200760
and	O
elastic	B-C0936012
surface-based	I-C0936012
shape	I-C0936012
deformation	I-C0936012
analysis	I-C0936012
.	O
	
the	O
volume	O
of	O
the	O
hippocampus	B-C0019564
was	O
also	O
measured	O
post-mortem	B-C0004398
from	O
brain	B-C0459385
tissue	I-C0459385
sections	O
in	O
each	O
group	O
.	O
	
chronic	B-C0743284
exposure	I-C0743284
to	O
either	O
hal	B-C0018546
or	O
olz	B-C0171023
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	B-C0019564
,	O
even	O
at	O
exploratory	B-C0430009
thresholds	I-C0430009
,	O
which	O
was	O
confirmed	O
post-mortem	B-C0004398
.	O
	
in	O
contrast	O
,	O
shape	B-C0936012
deformation	I-C0936012
analysis	I-C0936012
revealed	O
that	O
chronic	O
hal	B-C0018546
and	O
olz	B-C0171023
exposure	B-C0743284
lead	O
to	O
both	O
common	O
and	O
divergent	B-C1562006
shape	I-C1562006
deformations	I-C1562006
q	O
=	O
0.05	O
,	O
fdr-corrected	O
in	O
the	O
rat	B-C0034693
hippocampus	B-C0019564
.	O
	
in	O
particular	O
,	O
in	O
the	O
dorsal	B-C0019564
hippocampus	I-C0019564
,	O
hal	B-C0018546
exposure	B-C0743284
led	O
to	O
inward	B-C1562006
shape	I-C1562006
deformation	I-C1562006
,	O
whereas	O
olz	B-C0171023
exposure	B-C0743284
led	O
to	O
outward	B-C1562006
shape	I-C1562006
deformation	I-C1562006
.	O
	
interestingly	O
,	O
outward	B-C1562006
shape	I-C1562006
deformations	I-C1562006
that	O
were	O
common	O
to	O
both	O
drugs	B-C0013227
occurred	O
in	O
the	O
ventral	B-C0019564
hippocampus	I-C0019564
.	O
	
these	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	B-C0019564
volume	O
suggesting	O
true	O
shape	B-C1562006
changes	I-C1562006
.	O
	
chronic	B-C0743284
exposure	I-C0743284
to	O
either	O
hal	B-C0018546
or	O
olz	B-C0171023
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	B-C0034693
hippocampal	B-C0175202
shape	I-C0175202
shear	B-C1254365
and	O
extensional	B-C1254365
properties	I-C1254365
of	O
kefiran	B-C0628688
kefiran	B-C0628688
is	O
a	O
neutral	B-C0032594
polysaccharide	I-C0032594
constituted	O
by	O
glucose	B-C0017725
and	O
galactose	B-C0016945
produced	O
by	O
lactobacillus	B-C0317649
kefiranofaciens	I-C0317649
.	O
	
it	O
is	O
included	O
into	O
kefir	B-C4280055
grains	I-C4280055
and	O
has	O
several	O
health	B-C1254365
promoting	I-C1254365
properties	I-C1254365
.	O
	
in	O
the	O
present	O
work	O
,	O
shear	B-C1254365
and	O
extensional	B-C1254365
properties	I-C1254365
of	O
different	B-C1705242
kefiran	B-C0628688
aqueous	B-C0439861
dispersions	I-C0439861
0.5	O
,	O
1	O
and	O
2%	O
wt	O
were	O
assessed	B-C1516048
and	O
compared	B-C1707455
to	O
other	O
neutral	B-C0029224
gums	I-C0029224
commonly	O
used	O
in	O
food	B-C0016452
,	O
cosmetic	B-C0010164
and	O
pharmaceutics	B-C0013185
industries	I-C0013185
methylcellulose	B-C0025729
,	O
locust	B-C3190255
bean	I-C3190255
gum	I-C3190255
and	O
guar	B-C0061996
gum	I-C0061996
.	O
	
kefiran	B-C0628688
showed	O
shear	B-C1254365
flow	I-C1254365
characteristics	I-C1254365
similar	O
to	O
that	O
displayed	O
by	O
other	O
representative	O
neutral	B-C0029224
gums	I-C0029224
,	O
although	O
it	O
always	O
yielded	O
lower	B-C0205251
viscosities	B-C0042784
at	O
a	O
given	O
concentration	B-C0392762
.	O
	
for	O
each	O
gum	B-C0029224
system	B-C0449913
it	O
was	O
possible	O
to	O
find	O
a	O
correlation	B-C1707520
between	O
dynamic	B-C1254365
and	I-C1254365
steady	I-C1254365
shear	I-C1254365
properties	I-C1254365
by	O
a	O
master	B-C0205134
curve	I-C0205134
including	O
both	O
the	O
apparent	B-C0750489
and	O
complex	B-C0439855
viscosities	B-C0042784
.	O
	
when	O
studying	O
extensional	B-C1254365
properties	I-C1254365
of	O
selected	O
gums	B-C0029224
at	O
2%	O
wt	O
.	O
	
by	O
means	O
of	O
a	O
capillary	B-C0699733
break-up	I-C0699733
rheometer	I-C0699733
,	O
kefiran	B-C0628688
solutions	B-C0037633
did	O
not	O
show	O
important	O
extensional	B-C1254365
properties	I-C1254365
,	O
displaying	O
a	O
behaviour	B-C1521970
close	O
the	O
air	B-C0001861
tamponade	B-C0332459
of	O
the	O
heart	B-C0018787
pneumopericardium	B-C0032319
is	O
a	O
rare	B-C0678236
disease	I-C0678236
defined	O
as	O
the	O
presence	B-C0150312
of	O
air	B-C0001861
or	O
gas	B-C0017110
in	O
the	O
pericardial	B-C0031050
sac	I-C0031050
.	O
	
among	O
the	O
etiological	B-C1521761
factors	I-C1521761
,	O
the	O
following	O
stand	O
out	O
chest	B-C0039980
trauma	I-C0039980
,	O
barotrauma	B-C0004760
,	O
air	B-C0001861
-containing	O
fistulas	B-C0016169
between	O
the	O
pericardium	B-C0031050
and	O
the	O
surrounding	B-C1282914
structures	B-C0678594
,	O
secondary	B-C0205245
gas	I-C0205245
production	I-C0205245
by	O
microorganisms	B-C0445623
growing	O
in	O
the	O
pericardial	B-C0031050
sac	I-C0031050
,	O
and	O
iatrogenic	B-C0439669
factors	B-C1521761
.	O
	
until	O
now	O
,	O
spontaneous	B-C0205359
pneumopericardium	B-C0032319
has	O
been	O
considered	B-C0750591
a	O
harmless	B-C0205556
and	O
temporary	B-C0205374
state	B-C1442792
,	O
but	O
a	O
review	B-C0699752
of	I-C0699752
clinical	B-C1706256
cases	I-C1706256
indicates	O
that	O
the	O
presence	B-C0150312
of	O
air	B-C0001861
in	O
the	O
pericardium	B-C0031050
can	O
lead	O
to	O
cardiac	B-C0007177
tamponade	I-C0007177
and	O
life-threatening	B-C2826244
hemodynamic	B-C0019010
disturbances	B-C2699787
.	O
	
we	O
present	B-C0150312
the	O
case	O
of	O
an	O
80-	O
year-old	B-C1510829
patient	B-C0030705
with	O
a	O
chronic	B-C0205191
bronchopericardial	B-C1186133
fistula	B-C0016169
,	O
who	O
suffered	O
from	O
a	O
cardiac	B-C0018790
arrest	I-C0018790
due	O
to	O
air	B-C0001861
tamponade	B-C0332459
of	O
the	O
the	O
complete	B-C0205197
chloroplast	B-C1955992
genome	I-C1955992
sequence	B-C0314659
of	O
the	O
medicinal	B-C0032100
plant	I-C0032100
swertia	B-C1624947
mussotii	I-C1624947
using	O
the	O
pacbio	B-C1609455
rs	I-C1609455
ii	I-C1609455
platform	I-C1609455
swertia	B-C1624947
mussotii	I-C1624947
is	O
an	O
important	O
medicinal	B-C0032100
plant	I-C0032100
that	O
has	O
great	B-C0549177
economic	B-C0392762
and	O
medicinal	B-C1254351
value	I-C1254351
and	O
is	O
found	O
on	O
the	O
qinghai	B-C0681784
tibetan	I-C0681784
plateau	I-C0681784
.	O
	
the	O
complete	B-C0205197
chloroplast	B-C1955992
cp	I-C1955992
genome	I-C1955992
of	O
s	B-C1624947
.	O
	
mussotii	I-C1624947
is	O
153	O
bp	O
in	O
size	B-C3178847
,	O
with	O
a	O
pair	B-C1709450
of	O
inverted	B-C2350250
repeat	I-C2350250
ir	I-C2350250
regions	I-C2350250
of	O
25	O
bp	O
each	O
that	O
separate	B-C0443299
an	O
large	B-C0314659
single-copy	I-C0314659
lsc	I-C0314659
region	I-C0314659
of	O
83	O
bp	O
and	O
an	O
a	O
small	B-C0314659
single-copy	I-C0314659
ssc	I-C0314659
region	I-C0314659
of	O
18	O
bp	O
.	O
	
the	O
s	B-C1624947
.	O
	
mussotii	I-C1624947
cp	B-C1955992
genome	I-C1955992
encodes	B-C2700640
84	O
protein-coding	B-C3839127
genes	I-C3839127
,	O
37	O
transfer	B-C0035711
rna	I-C0035711
trna	B-C0035711
genes	B-C0017337
,	O
and	O
eight	O
ribosomal	B-C0035899
rna	I-C0035899
rrna	I-C0035899
genes	I-C0035899
.	O
	
the	O
identity	O
,	O
number	O
,	O
and	O
gc	B-C1135899
content	I-C1135899
of	O
s	B-C1624947
.	O
	
mussotii	I-C1624947
cp	B-C1955992
genes	I-C1955992
were	O
similar	O
to	O
those	O
in	O
the	O
genomes	B-C0017428
of	O
other	O
gentianales	B-C1080874
species	B-C1705920
.	O
	
via	O
analysis	B-C0936012
of	O
the	O
repeat	B-C0314659
structure	I-C0314659
,	O
11	O
forward	O
repeats	B-C0314659
,	O
eight	O
palindromic	B-C2350254
repeats	I-C2350254
,	O
and	O
one	O
reverse	O
repeat	O
were	O
detected	B-C0442726
in	O
the	O
s	B-C1624947
.	O
	
mussotii	I-C1624947
cp	B-C1955992
genome	I-C1955992
.	O
	
there	O
are	O
45	O
ssrs	B-C1519302
in	O
the	O
s	B-C1624947
.	O
	
mussotii	I-C1624947
cp	B-C1955992
genome	I-C1955992
,	O
the	O
majority	B-C0205164
of	O
which	O
are	O
mononucleotides	B-C0028630
found	O
in	O
all	O
other	O
gentianales	B-C1080874
species	B-C1705920
.	O
	
an	O
entire	B-C0439751
cp	B-C1955992
genome	I-C1955992
comparison	B-C1579762
study	I-C1579762
of	O
s	B-C1624947
.	O
	
mussotii	I-C1624947
and	O
two	O
other	O
species	B-C1705920
in	O
gentianaceae	B-C0950077
was	O
conducted	O
.	O
	
the	O
complete	B-C0205197
cp	B-C1955992
genome	I-C1955992
sequence	B-C0314659
provides	O
intragenic	B-C0017337
information	B-C1533716
for	O
the	O
cp	B-C0008266
genetic	B-C0017387
engineering	I-C0017387
of	O
this	O
medicinal	B-C0032100
plant	I-C0032100
.	O
	
meta-analysis	B-C0920317
of	O
29	O
experiments	B-C0681814
evaluating	B-C1261322
the	O
effects	B-C1704420
of	I-C1704420
rapamycin	B-C0072980
on	O
life	B-C0870809
span	I-C0870809
in	O
the	O
laboratory	B-C0025929
mouse	I-C0025929
rapamycin	B-C0072980
has	O
favorable	O
effects	B-C1280500
on	O
aging	B-C0001811
in	O
mice	B-C0025929
and	O
may	O
eventually	O
be	O
applied	B-C4048755
to	O
encourage	O
""""	O
healthy	B-C3898900
aging	B-C0001811
""""	O
in	O
humans	B-C0086418
.	O
	
this	O
study	B-C2603343
analyzed	B-C0936012
raw	B-C1709843
data	B-C1511726
from	O
29	O
survival	B-C0038953
studies	I-C0038953
of	O
rapamycin	B-C0072980
-	O
and	O
control	B-C1550141
-	O
treated	B-C1522326
mice	B-C0025929
,	O
with	O
the	O
goals	B-C0018017
of	O
estimating	B-C0750572
summary	B-C1706244
statistics	B-C0600673
and	O
identifying	B-C0205396
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
effect	B-C0814843
size	I-C0814843
heterogeneity	B-C0019409
.	O
	
meta-analysis	B-C0920317
demonstrated	B-C0443289
significant	B-C0750502
heterogeneity	B-C0019409
across	O
studies	B-C0947630
,	O
with	O
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
estimates	B-C0750572
ranging	B-C1514721
from	O
0.22	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.06	O
to	O
0.92	O
95%	O
ci	B-C0009667
0.65	O
.	O
	
sex	B-C1522384
was	O
the	O
major	B-C0205164
factor	B-C1521761
accounting	B-C0586014
for	O
effect	B-C0814843
size	I-C0814843
variation	B-C0205419
,	O
and	O
mortality	B-C0205848
was	O
decreased	B-C0205216
more	B-C0205172
in	O
females	B-C0086287
hr	B-C2985465
=	O
0.41	O
95%	O
ci	B-C0009667
0.35	O
as	O
compared	B-C1707455
with	O
males	B-C0086582
hr	B-C2985465
=	O
0.63	O
95%	O
ci	B-C0009667
0.55	O
.	O
	
rapamycin	B-C0072980
effects	B-C1280500
were	O
also	O
genotype	B-C0017431
dependent	B-C1701901
,	O
however	O
,	O
with	O
stronger	B-C0442821
survivorship	B-C0038955
increases	B-C0442805
in	O
hybrid	B-C0020205
mice	B-C0025929
14.4	O
95%	O
ci	B-C0009667
12.5	O
relative	B-C0205345
to	O
pure	B-C0599804
inbred	B-C0025927
strains	I-C0025927
8.8	O
95%	O
ci	B-C0009667
6.2	O
.	O
	
number	B-C0237753
needed	B-C1514873
to	O
treat	B-C1522326
was	O
applied	B-C4048755
as	O
an	O
effect	B-C0814843
size	I-C0814843
metric	B-C0025867
,	O
which	O
consistently	O
identified	B-C0205396
early	O
senescence	B-C0231337
as	O
the	O
age	B-C0001779
of	O
peak	B-C0444505
treatment	B-C0039798
benefit	B-C0814225
.	O
	
these	O
results	B-C1274040
provide	B-C1999230
synthesis	B-C1883254
of	O
existing	B-C2987476
data	B-C1511726
to	O
support	B-C1521721
the	O
potential	O
translation	B-C3494164
of	O
findings	B-C0243095
from	O
mouse	B-C0025929
to	O
primate	B-C0033147
species	I-C0033147
.	O
	
because	O
rapamycin's	B-C0072980
effect	B-C1280500
on	O
survival	B-C0038952
depends	B-C1701901
on	O
sex	B-C1522384
and	O
genotype	B-C0017431
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	B-C1521761
shape	O
treatment	B-C0039798
response	B-C0871261
.	O
	
transfusion	B-C1273858
medicine	I-C1273858
in	O
medical	B-C0013631
education	I-C0013631
an	O
analysis	B-C0936012
of	O
curricular	B-C0681363
grids	I-C0681363
in	O
brazil	B-C0006137
and	O
a	O
review	B-C1552617
of	O
the	O
current	B-C0023866
literature	I-C0023866
blood	B-C0005841
transfusions	I-C0005841
are	O
one	O
of	O
the	O
most	O
performed	O
medical	B-C0199171
procedures	I-C0199171
in	O
the	O
world	B-C2700280
.	O
	
thus	O
,	O
as	O
education	B-C0013621
in	O
transfusion	B-C1273858
medicine	I-C1273858
is	O
vital	B-C0442732
to	O
medical	B-C0496675
care	I-C0496675
,	O
it	O
should	O
aim	O
to	O
promote	B-C0033414
a	O
responsible	O
practice	B-C0033284
with	O
the	O
rational	O
use	O
of	O
blood	B-C0005767
by	O
doctors	B-C0031831
.	O
	
this	O
study	O
aims	O
to	O
investigate	B-C1292732
the	O
situation	O
of	O
the	O
teaching	B-C0039401
of	O
transfusion	B-C1273858
medicine	I-C1273858
in	O
medical	B-C0036378
schools	I-C0036378
in	O
brazil	B-C0006137
.	O
	
the	O
websites	B-C2349146
of	O
the	O
249	O
brazilian	B-C1257890
medical	B-C0036378
schools	I-C0036378
in	O
operation	B-C3241922
in	O
june	O
2015	O
were	O
visited	O
and	O
the	O
curricula	B-C0010478
of	O
the	O
medical	B-C0013652
courses	I-C0013652
were	O
investigated	B-C1292732
in	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
a	O
transfusion	B-C1273858
medicine	I-C1273858
discipline	I-C1273858
.	O
	
when	O
available	O
,	O
the	O
subject	O
grids	O
were	O
analyzed	B-C0936012
to	O
verify	O
whether	O
a	O
description	B-C0678257
of	I-C0678257
content	I-C0678257
regarding	O
transfusion	B-C1273858
medicine	I-C1273858
was	O
given	O
within	O
other	O
disciplines	B-C1518533
.	O
	
of	O
the	O
249	O
medical	B-C0036378
school	I-C0036378
sites	O
visited	O
,	O
information	B-C1533716
on	O
the	O
curriculum	B-C0010478
was	O
obtained	O
from	O
178	O
.	O
	
of	O
the	O
medical	B-C0036378
schools	I-C0036378
that	O
published	B-C0034037
their	O
curriculum	B-C0010478
,	O
132	O
74.1	O
did	O
not	O
have	O
disciplines	B-C1273858
of	I-C1273858
transfusion	I-C1273858
medicine	I-C1273858
or	O
hematology	B-C0018943
and	O
only	O
seven	O
3.9	O
had	O
a	O
discipline	B-C1273858
of	I-C1273858
transfusion	I-C1273858
medicine	I-C1273858
in	O
the	O
curricular	B-C0681363
grid	I-C0681363
.	O
	
education	B-C0013621
on	O
transfusion	B-C1273858
medicine	I-C1273858
is	O
of	O
fundamental	B-C3898777
importance	I-C3898777
for	O
safe	B-C1879316
and	I-C1879316
efficient	I-C1879316
transfusion	I-C1879316
practices	I-C1879316
.	O
	
deficiencies	B-C0011155
in	O
medical	B-C0205476
knowledge	B-C0376554
of	O
this	O
subject	O
have	O
been	O
found	O
worldwide	O
.	O
	
the	O
results	O
of	O
this	O
study	O
indicate	O
a	O
possible	O
deficiency	B-C0011155
in	O
teaching	B-C0039401
the	O
basics	B-C1527178
of	O
this	O
specialty	O
.	O
	
thus	O
,	O
additional	O
prospective	B-C0033522
studies	I-C0033522
to	O
assess	B-C0184514
the	O
knowledge	B-C0376554
and	O
practice	O
of	O
transfusion	B-C1273858
medicine	I-C1273858
in	O
brazilian	B-C1257890
medical	B-C0036378
schools	I-C0036378
are	O
warranted	O
,	O
which	O
could	O
prompt	O
a	O
discussion	O
on	O
the	O
importance	B-C3898777
of	O
offering	O
training	B-C0220931
in	O
transfusion	B-C1273858
medicine	I-C1273858
to	O
medical	B-C0038495
students	I-C0038495
.	O
	
advanced	B-C0205179
interlocking	B-C0025080
systems	I-C0025080
to	O
improve	B-C0184511
heavy	B-C0439539
-	O
load-bearing	B-C1318107
characteristics	B-C1521970
of	O
flexible	B-C0443220
intramedullary	B-C0021885
nailing	I-C0021885
flexible	B-C0443220
intramedullary	B-C0021885
nailing	I-C0021885
fin	B-C0021885
is	O
a	O
minimally	B-C0282624
invasive	I-C0282624
and	O
widespread	B-C0205391
standard	B-C1442989
method	B-C0087111
for	O
osteosynthesis	B-C0016643
of	O
pediatric	B-C1521725
long	B-C0240231
bone	I-C0240231
fractures	I-C0240231
.	O
	
in	O
the	O
case	O
of	O
unstable	B-C0559876
fractures	I-C0559876
of	O
the	O
lower	B-C0023216
extremity	I-C0023216
,	O
interlocking	B-C0025080
systems	I-C0025080
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	B-C0205131
shortening	B-C0441636
and	O
subsequent	B-C0332282
perforation	B-C1881710
of	O
the	O
nail	B-C0441224
at	O
its	O
insertion	B-C0449682
site	I-C0449682
.	O
	
in	O
the	O
present	O
study	B-C0008972
,	O
four	O
different	O
screw	B-C0005975
-fixed	O
interlocking	B-C0025080
systems	I-C0025080
for	O
fins	B-C0021885
hofer	B-C0038932
twinplug	I-C0038932
with	O
two	O
3-mm	O
titanium	B-C0040302
interlocking	B-C0441273
screws	I-C0441273
,	O
hofer	B-C0038932
fixplug	I-C0038932
with	O
3-mm	O
titanium	B-C0040302
interlocking	B-C0441273
screw	I-C0441273
,	O
hofer	B-C0038932
plug	I-C0038932
with	O
3.5	O
titanium	B-C0040302
interlocking	B-C0441273
screw	I-C0441273
,	O
and	O
hofer	B-C0038932
plug	I-C0038932
with	O
3-mm	O
titanium	B-C0040302
interlocking	B-C0441273
screw	I-C0441273
in	O
comparison	B-C1707455
with	O
the	O
commonly	O
used	O
ender	O
stainless	B-C0038126
steel	I-C0038126
nails	B-C0441224
locked	O
with	O
3.5	O
screw	B-C0005975
were	O
experimentally	B-C1292732
investigated	I-C1292732
in	O
cadaveric	B-C0006629
lamb	B-C1123019
tibiae	B-C0588199
,	O
regarding	O
their	O
load	B-C1708715
characteristics	B-C1521970
and	O
failure	B-C0014678
modes	B-C1513371
in	O
the	O
case	O
of	O
heavy	B-C0439539
loading	B-C1708715
.	O
	
the	O
specimens	B-C0370003
were	O
subjected	O
to	O
sequential	B-C1705294
axial	B-C0205131
cyclic	B-C1511572
loading	B-C1708715
of	O
5000	O
cycles	B-C1511572
with	O
stepwise	B-C0442805
increase	I-C0442805
of	O
the	O
load	B-C1708715
amplitude	B-C2346753
until	O
failure	B-C0014678
.	O
	
migration	B-C1881827
of	O
locking	B-C0441273
screws	I-C0441273
and	O
internal	B-C0205102
damage	B-C0010957
of	O
bone	B-C0391978
tissue	I-C0391978
was	O
quantified	O
by	O
micro-computed	B-C0729619
tomography	I-C0729619
ct	I-C0729619
imaging	I-C0729619
.	O
	
ender	B-C0441224
nails	I-C0441224
failed	B-C0231175
on	O
average	B-C1510992
at	O
a	O
peak	B-C0444505
load	B-C1708715
of	O
800	O
n	O
,	O
twinplugs	B-C0038932
at	O
1367	O
n	O
,	O
fixplugs	B-C0038932
at	O
1222	O
n	O
,	O
plugs	B-C0038932
3.5mm	O
at	O
1225	O
n	O
and	O
plugs	B-C0038932
3.0mm	O
at	O
971	O
n	O
.	O
	
twinplugs	B-C0038932
,	O
fixplugs	B-C0038932
,	O
and	O
plugs	B-C0038932
3.5mm	O
failed	B-C0231175
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	B-C1708715
cycles	B-C1511572
,	O
whereas	O
ender	B-C0441224
nails	I-C0441224
and	O
plugs	B-C0038932
3.0mm	O
exhibited	O
abrupt	B-C1276802
failure	B-C0014678
without	O
any	O
prior	B-C0332152
indication	B-C3146298
.	O
	
our	O
results	O
confirm	O
that	O
axial	B-C0205131
stability	B-C0205360
of	O
fin	B-C0021885
can	O
be	O
further	O
improved	B-C0184511
by	O
screw	B-C0005975
-fixed	O
plugs	B-C0038932
by	O
simultaneously	B-C0521115
avoiding	O
shortcomings	O
of	O
an	O
eye-locked	B-C1704459
system	I-C1704459
,	O
which	O
the	O
ender	B-C0441224
nails	I-C0441224
are	O
.	O
	
considering	O
biomechanical	B-C3658372
results	B-C0683954
,	O
plug	B-C0038932
interlocking	B-C0025080
systems	I-C0025080
with	O
3.5	O
screws	B-C0005975
should	O
be	O
favored	O
over	O
conventional	B-C0439858
ender	B-C0441224
nails	I-C0441224
and	O
plugs	B-C0038932
with	O
3-mm	O
surgical	B-C0543467
guidance	B-C1959633
via	O
multiplexed	B-C1537028
molecular	I-C1537028
imaging	I-C1537028
of	O
fresh	O
tissues	B-C0040300
labeled	B-C1522485
with	O
sers	B-C1720804
-coded	O
nanoparticles	B-C1450054
the	O
imaging	B-C0011923
of	O
dysregulated	O
cell-surface	B-C0034800
receptors	I-C0034800
or	O
biomarkers	B-C0005516
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	B-C0150312
of	O
cancer	B-C0006826
with	O
high	O
sensitivity	B-C0332324
and	O
specificity	B-C1511884
.	O
	
however	O
,	O
due	O
to	O
heterogeneities	B-C0019409
in	O
the	O
expression	B-C1171362
of	I-C1171362
protein	I-C1171362
biomarkers	B-C0041366
in	O
tumors	B-C0027651
,	O
molecular	B-C1537028
imaging	I-C1537028
technologies	B-C0752188
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed	B-C1254353
panel	I-C1254353
of	O
cancer	B-C0041366
biomarkers	I-C0041366
.	O
	
recently	O
,	O
surface-enhanced	B-C1720804
raman-scattering	I-C1720804
sers	B-C1720804
nanoparticles	B-C1450054
nps	B-C1450054
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	B-C0332324
and	O
multiplexed	B-C1254353
biomarker	I-C1254353
detection	B-C1511790
.	O
	
in	O
this	O
review	B-C0282443
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	B-C0027651
imaging	B-C0011923
using	O
sers	B-C1720804
-coded	O
nps	B-C1450054
.	O
	
a	O
brief	O
introduction	O
of	O
the	O
structure	B-C0678594
and	O
optical	B-C1254365
properties	I-C1254365
of	O
sers	B-C1720804
nps	B-C1450054
is	O
provided	O
,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-C0011923
issues	O
such	O
as	O
the	O
administration	B-C1621583
of	O
nps	B-C1450054
in	O
tissue	B-C0040300
topical	B-C0332237
versus	O
systemic	B-C0205373
,	O
the	O
optical	B-C0678647
configuration	I-C0678647
and	O
imaging	B-C0011923
approach	O
of	O
raman	B-C1257898
imaging	I-C1257898
systems	I-C1257898
,	O
spectral	B-C1537028
demultiplexing	I-C1537028
methods	I-C1537028
for	O
quantifying	B-C1709793
np	B-C1450054
concentrations	B-C1446561
,	O
and	O
the	O
disambiguation	B-C2346729
of	O
specific	B-C0205369
vs	O
.	O
	
nonspecific	B-C0750540
sources	O
of	O
contrast	O
through	O
ratiometric	B-C0011923
imaging	I-C0011923
of	O
targeted	B-C1521840
and	O
untargeted	B-C1550141
control	B-C1550141
np	B-C1450054
expression	B-C0017262
and	O
methylation	B-C0376452
in	O
posttraumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
and	O
resilience	B-C0683253
evidence	B-C3887511
of	O
a	O
role	B-C1705810
for	O
odorant	B-C0164313
receptors	I-C0164313
post-traumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
is	O
a	O
common	O
and	O
potentially	B-C3245505
disabling	B-C0596452
disorder	I-C0596452
that	O
develops	O
in	O
1/5	O
to	O
1/3	O
of	O
people	B-C0027361
exposed	B-C0332157
to	I-C0332157
severe	B-C0205082
trauma	B-C3714660
.	O
	
twin	B-C1096782
studies	I-C1096782
indicate	O
that	O
genetic	B-C0314603
factors	B-C1521761
account	O
for	O
at	O
least	O
one	O
third	O
of	O
the	O
variance	B-C1711260
in	O
the	O
risk	O
for	O
developing	O
ptsd	B-C0038436
,	O
however	O
,	O
the	O
specific	B-C0205369
role	B-C1705810
for	O
genetic	B-C0314603
factors	B-C1521761
in	O
the	O
pathogenesis	B-C0699748
of	O
ptsd	B-C0038436
is	O
not	O
well	O
understood	O
.	O
	
we	O
studied	O
genome-wide	B-C2350277
gene	B-C0017262
expression	I-C0017262
and	O
dna	B-C0376452
methylation	I-C0376452
profiles	B-C0237801
in	O
12	O
participants	B-C0679646
with	O
ptsd	B-C0038436
and	O
12	O
participants	B-C0679646
who	O
were	O
resilient	B-C0683253
to	O
similar	O
severity	B-C0392364
trauma	B-C3714660
exposure	B-C0332157
.	O
	
close	O
to	O
4000	O
genes	B-C0017337
were	O
differentially	B-C0443199
expressed	B-C0017262
with	O
adjusted	B-C0456081
p<0	O
,	O
fold-change	B-C1880833
>2	O
,	O
with	O
all	O
but	O
3	O
upregulated	B-C0041904
with	O
ptsd	B-C0038436
.	O
	
eight	O
odorant/olfactory	B-C0164313
receptor	I-C0164313
related	O
genes	B-C0017337
were	O
up-regulated	B-C0041904
with	O
ptsd	B-C0038436
as	O
well	O
as	O
genes	B-C0017337
related	O
to	O
immune	B-C1155000
activation	I-C1155000
,	O
the	O
gamma-aminobutyric	B-C0206518
acid	I-C0206518
a	I-C0206518
gabaa	I-C0206518
receptor	I-C0206518
,	O
and	O
vitamin	B-C1157731
d	I-C1157731
synthesis	I-C1157731
.	O
	
no	O
differences	O
with	O
adjusted	B-C0456081
significance	B-C0750502
for	O
dna	B-C0376452
methylation	I-C0376452
were	O
found	O
.	O
	
we	O
conclude	O
that	O
increased	B-C0205217
gene	B-C0017262
expression	I-C0017262
may	O
play	O
an	O
important	B-C3898777
role	B-C1705810
in	O
ptsd	B-C0038436
and	O
this	O
expression	B-C0017262
may	O
not	O
be	O
a	O
consequence	B-C0686907
of	I-C0686907
dna	B-C0376452
methylation	I-C0376452
.	O
	
the	O
role	B-C1705810
of	O
odorant	B-C0164313
receptor	I-C0164313
expression	B-C0597360
warrants	O
independent	B-C0332291
replication	B-C0598312
.	O
	
absorption	B-C0220777
characteristics	I-C0220777
of	O
vertebrate	B-C0042567
non	B-C1518422
-	O
visual	B-C0234621
opsin	B-C0967413
,	O
opn3	I-C0967413
most	O
animals	B-C0003062
possess	B-C3154893
multiple	B-C0439064
opsins	B-C2355587
which	O
sense	B-C0042789
light	B-C0023693
for	O
visual	B-C0234621
and	O
non	B-C1518422
-	O
visual	B-C0042789
functions	I-C0042789
.	O
	
here	O
,	O
we	O
show	O
spectral	B-C1883073
characteristics	B-C1521970
of	O
non	B-C1518422
-	O
visual	B-C0234621
opsins	B-C2355587
,	O
vertebrate	B-C0042567
opn3s	B-C0967413
,	O
which	O
are	O
widely	O
distributed	B-C1704711
among	O
vertebrates	B-C0042567
.	O
	
we	O
successfully	B-C1272703
expressed	B-C1171362
zebrafish	B-C0043457
opn3	B-C2355587
in	O
mammalian	B-C0024660
cultured	B-C0007635
cells	I-C0007635
and	O
measured	B-C0444706
its	O
absorption	B-C0037812
spectrum	I-C0037812
spectroscopically	I-C0037812
.	O
	
when	O
incubated	B-C1439852
with	O
11-cis	B-C0085717
retinal	I-C0085717
,	O
zebrafish	B-C0043457
opn3	B-C2355587
formed	O
a	O
blue-sensitive	B-C0035323
photopigment	I-C0035323
with	O
an	O
absorption	B-C0234682
maximum	B-C0806909
around	O
465	O
nm	O
.	O
	
the	O
opn3	B-C0967413
converts	B-C0439836
to	O
an	O
all-trans	B-C0035331
retinal-bearing	I-C0035331
photoproduct	B-C1550506
with	O
an	O
absorption	B-C0037812
spectrum	I-C0037812
similar	B-C2348205
to	O
the	O
dark	B-C0010985
state	I-C0010985
following	O
brief	B-C1879313
blue-light	B-C0303896
irradiation	B-C1282930
.	O
	
the	O
photoproduct	B-C1550506
experienced	O
a	O
remarkable	O
blue-shift	B-C0449819
,	O
with	O
changes	O
in	B-C1550045
position	I-C1550045
of	O
the	O
isosbestic	B-C0449819
point	I-C0449819
,	O
during	O
further	O
irradiation	B-C1282930
.	O
	
we	O
then	O
used	O
a	O
camp	B-C0001455
-	O
dependent	B-C3244310
luciferase	B-C0024075
reporter	B-C1522485
assay	B-C1510438
to	O
investigate	B-C1292732
light	B-C0023693
-	O
dependent	B-C3244310
camp	B-C0001455
responses	B-C1657589
in	O
cultured	B-C0007635
cells	I-C0007635
expressing	B-C1171362
zebrafish	B-C0043457
,	O
pufferfish	B-C0936076
,	O
anole	B-C0327220
and	O
chicken	B-C0008051
opn3	B-C2355587
.	O
	
the	O
wild	B-C1883559
type	I-C1883559
opsins	B-C2355587
did	O
not	O
produce	O
responses	B-C1657589
,	O
but	O
cells	B-C0007634
expressing	B-C1171362
chimera	B-C0008109
mutants	B-C1564139
wt	B-C0967413
opn3s	I-C0967413
in	O
which	O
the	O
third	B-C0178719
intracellular	I-C0178719
loops	B-C0002518
were	O
replaced	B-C0559956
with	O
the	O
third	B-C0178719
intracellular	I-C0178719
loop	B-C0002518
of	O
a	O
gs-coupled	B-C0289372
jellyfish	B-C0022381
opsin	B-C2355587
displayed	B-C0870432
light	B-C0023693
-	O
dependent	B-C3244310
changes	B-C0443172
in	O
camp	B-C0001455
.	O
	
the	O
results	O
suggest	O
that	O
opn3	B-C0967413
is	O
capable	O
of	O
activating	B-C0599177
g	B-C0086376
protein	I-C0086376
in	O
a	O
light	B-C0023693
-	O
dependent	B-C3244310
manner	O
.	O
	
finally	O
,	O
we	O
used	O
this	O
assay	B-C1510438
to	O
measure	B-C0079809
the	O
relative	B-C0205345
wavelength	B-C0449819
-	O
dependent	B-C3244310
response	B-C0871261
of	O
cells	B-C0007634
expressing	B-C1171362
opn3	B-C0967413
chimeras	B-C0008109
to	O
multiple	B-C0439064
quantally	B-C0034385
-	O
matched	B-C1708943
stimuli	B-C0234402
.	O
	
the	O
inferred	B-C3245504
spectral	B-C0871405
sensitivity	I-C0871405
curve	B-C0205134
of	O
zebrafish	B-C0043457
opn3	B-C2355587
accurately	B-C0443131
matched	B-C1708943
the	O
measured	B-C0444706
absorption	B-C0037812
spectrum	I-C0037812
.	O
	
we	O
were	O
unable	O
to	O
estimate	O
the	O
spectral	B-C0871405
sensitivity	I-C0871405
curve	B-C0205134
of	O
mouse	B-C0026809
or	O
anole	B-C0327220
opn3	B-C2355587
,	O
but	O
,	O
like	O
zebrafish	B-C0043457
opn3	B-C2355587
,	O
the	O
chicken	B-C0008051
and	O
pufferfish	B-C0936076
opn3-jil3	B-C1564139
chimeras	B-C0008109
also	O
formed	O
blue-sensitive	B-C0381986
pigments	I-C0381986
.	O
	
these	O
findings	O
suggest	O
that	O
vertebrate	B-C0042567
opn3s	B-C0967413
may	O
form	O
blue-sensitive	B-C0289372
g	I-C0289372
protein-coupled	I-C0289372
pigments	I-C0289372
.	O
	
further	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
,	O
combining	O
a	O
camp	B-C0001455
-	O
dependent	B-C3244310
luciferase	B-C0024075
reporter	B-C1522485
assay	B-C1510438
with	O
chimeric	B-C0008109
opsins	B-C2355587
possessing	O
the	O
third	B-C0178719
intracellular	I-C0178719
loop	B-C0002518
of	O
jellyfish	B-C0022381
opsin	B-C2355587
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	B-C0750572
absorption	B-C0037812
spectra	I-C0037812
of	O
opsins	B-C2355587
with	O
unknown	O
signaling	B-C2611812
cascades	I-C2611812
or	O
for	O
which	O
absorption	B-C0037812
spectra	I-C0037812
are	O
difficult	B-C0332218
effectiveness	B-C1280519
of	O
offloading	B-C2922211
methods	B-C0087111
in	O
preventing	B-C0679698
primary	B-C0205225
diabetic	B-C1456868
foot	I-C1456868
ulcers	I-C1456868
in	O
adults	B-C0001675
with	O
diabetes	B-C0011847
a	O
systematic	B-C1955832
review	I-C1955832
the	O
incidence	B-C0021149
of	O
foot	B-C0085119
ulceration	I-C0085119
related	O
to	O
diabetes	B-C0011847
is	O
increasing	B-C0442808
.	O
	
many	O
foot	B-C0150240
care	I-C0150240
professionals	B-C0679924
recommend	O
offloading	B-C2922211
measures	O
as	O
part	O
of	O
management	B-C1254363
strategies	I-C1254363
for	O
modulating	O
excess	B-C1979886
pressure	B-C4284008
to	O
prevent	B-C0679698
development	O
of	O
diabetic	B-C1456868
foot	I-C1456868
ulcers	I-C1456868
dfus	B-C1456868
.	O
	
these	O
measures	B-C0079809
may	O
include	O
padding	B-C0455069
,	O
insoles	B-C0493044
/	O
orthotic	B-C0029365
devices	I-C0029365
and	O
footwear	B-C0336894
.	O
	
there	O
is	O
a	O
lack	O
of	O
evidence	B-C3887511
-based	O
guidance	O
on	O
the	O
effectiveness	B-C1280519
of	O
the	O
different	O
offloading	B-C2922211
options	O
for	O
preventing	B-C0679698
primary	B-C0205225
ulceration	B-C0085119
in	O
those	O
with	O
diabetes	B-C0011847
.	O
	
to	O
identify	O
,	O
critically	O
appraise	O
and	O
synthesize	O
the	O
best	O
available	O
evidence	B-C3887511
on	O
methods	B-C0087111
of	O
offloading	B-C2922211
to	O
prevent	B-C0679698
the	O
development	B-C1527148
,	O
and	O
reduce	B-C0392756
the	O
risk	B-C0035647
,	O
of	O
primary	B-C0205225
foot	B-C0085119
ulceration	I-C0085119
in	O
adults	B-C0001675
with	O
diabetes	B-C0011847
the	O
question	B-C0681799
addressed	B-C0376649
by	O
the	O
review	B-C0282443
was	O
what	O
is	O
the	O
effectiveness	B-C1280519
of	O
methods	B-C0087111
of	O
offloading	B-C2922211
in	O
preventing	B-C0679698
primary	B-C0205225
dfus	B-C1456868
in	O
adults	B-C0001675
with	O
diabetes	B-C0011847
adults	B-C0001675
18	O
years	B-C0439234
and	O
older	O
with	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
regardless	O
of	O
age	B-C0001779
,	O
gender	B-C0079399
,	O
ethnicity	B-C0243103
,	O
duration	B-C0449238
or	O
type	B-C0332307
of	O
diabetes	B-C0011847
,	O
with	O
no	O
history	B-C1287400
of	O
dfus	B-C1456868
and	O
in	O
any	O
clinical	B-C3176918
setting	I-C3176918
will	O
be	O
included	O
.	O
	
interventions	B-C0184661
will	O
include	O
all	O
external	O
methods	B-C0087111
of	O
offloading	B-C2922211
.	O
	
all	O
comparators	O
will	O
be	O
considered	O
.	O
	
studies	B-C2603343
that	O
utilize	O
interventions	B-C0184661
not	O
considered	O
usual	B-C3538928
practice	B-C0087111
in	O
the	O
prevention	B-C0679698
of	O
dfus	B-C1456868
will	O
be	O
excluded	B-C1554077
.	O
	
the	O
primary	B-C0205225
outcome	B-C1274040
will	O
be	O
primary	B-C0205225
foot	B-C0085119
ulceration	I-C0085119
.	O
	
the	O
secondary	B-C0205436
outcome	B-C1274040
will	O
be	O
indications	O
of	O
changes	O
in	O
plantar	B-C0230463
pressure	B-C4284008
.	O
	
this	O
review	B-C0282443
will	O
consider	O
all	O
quantitative	B-C0392762
study	B-C0035171
designs	I-C0035171
.	O
	
a	O
three-step	O
strategy	O
for	O
published	O
and	O
unpublished	O
literature	B-C0023866
will	O
be	O
used	O
.	O
	
fourteen	O
databases	B-C0242356
will	O
be	O
searched	O
for	O
studies	B-C2603343
in	O
english	B-C0376245
up	O
to	O
november	O
2013	O
.	O
	
the	O
jbi-mastari	B-C0037589
extraction	I-C0037589
tool	I-C0037589
was	O
used	O
to	O
extract	O
relevant	O
data	B-C1511726
.	O
	
results	B-C1274040
were	O
summarized	B-C1553398
using	O
narrative	B-C0815257
and	O
tables	B-C1706074
.	O
	
three	O
studies	B-C2603343
which	O
examined	O
the	O
effectiveness	B-C1280519
of	O
four	O
different	O
offloading	B-C2922211
interventions	B-C0184661
met	O
the	O
inclusion	B-C1512693
criteria	I-C1512693
.	O
	
there	O
is	O
limited	O
evidence	B-C3887511
that	O
use	O
of	O
a	O
footwear	B-C0336894
system	O
prototype	B-C0036988
shoe	I-C0036988
plus	I-C0036988
polyurethane	I-C0036988
or	O
cork	B-C3873740
insole	I-C3873740
may	O
prevent	B-C0679698
a	O
break	O
in	O
the	O
skin	B-C1123023
use	O
of	O
customized	O
rigid	O
orthotic	B-C0029365
devices	I-C0029365
may	O
contribute	O
to	O
a	O
reduction	B-C0392756
in	O
the	O
grade	B-C0205082
and	O
number	B-C0237753
of	O
calluses	B-C0457978
and	O
a	O
manufactured	O
shoe	B-C0036988
plus	I-C0036988
customized	O
insole	B-C3873740
may	O
reduce	O
plantar	B-C0230463
pressure	B-C4284008
and	O
therefore	O
reduce	O
the	O
potential	O
risk	B-C0035647
of	O
skin	B-C0085119
ulceration	I-C0085119
.	O
	
there	O
is	O
limited	O
and	O
low-quality	O
evidence	B-C3887511
that	O
in	O
a	O
population	B-C1257890
of	O
adults	B-C0001675
with	O
diabetes	B-C0011847
with	O
no	O
history	B-C1287400
of	O
dfu	B-C1456868
,	O
the	O
use	O
of	O
footwear	B-C0336894
with	O
customized	O
or	O
prefabricated	O
orthotic	B-C0029365
devices	I-C0029365
may	O
provide	O
some	O
reduction	O
in	O
plantar	B-C0230463
pressure	B-C4284008
and	O
therefore	O
help	O
to	O
prevent	B-C0679698
a	O
primary	B-C0205225
dfu	B-C1456868
.	O
	
there	O
is	O
a	O
lack	O
of	O
evidence	B-C3887511
on	O
the	O
relative	O
effectiveness	B-C1280519
of	O
different	O
offloading	B-C2922211
punch	B-C0004930
injury	B-C0043251
self-harm	B-C0424366
in	O
young	B-C0087178
people	I-C0087178
punch	B-C0004930
injuries	B-C0043251
are	O
a	O
form	B-C0348078
of	O
self-harm	B-C0424366
characterised	B-C1880022
by	O
the	O
intentional	B-C1283828
act	B-C0441655
of	I-C0441655
striking	I-C0441655
an	O
object	B-C0347997
with	O
a	O
closed	B-C0587267
fist	B-C0336667
.	O
	
we	O
aimed	B-C1947946
to	O
describe	O
the	O
characteristics	B-C1521970
and	O
trends	B-C1521798
in	O
young	B-C0087178
people	I-C0087178
presenting	B-C0449450
with	O
injuries	B-C0043251
sustained	B-C0443318
via	O
the	O
punch	B-C0004930
mechanism	B-C0441712
.	O
	
a	O
comprehensive	B-C1880156
retrospective	B-C0035363
review	I-C0035363
of	O
medical	B-C0025102
records	I-C0025102
was	O
completed	B-C0205197
of	O
all	O
young	B-C0087178
people	I-C0087178
aged	B-C0001779
10-18	O
years	B-C0439234
presenting	B-C0449450
to	O
our	O
central	B-C1708333
london	I-C1708333
emergency	I-C1708333
department	I-C1708333
over	O
a	O
12-month	B-C4082117
period	I-C4082117
.	O
	
a	O
subset	B-C1515021
of	I-C1515021
the	I-C1515021
total	I-C1515021
group	I-C1515021
was	O
identified	B-C0205396
as	O
the	O
punch	B-C0004930
injury	B-C0043251
subgroup	B-C1515021
.	O
	
a	O
total	O
of	O
78	O
punch	B-C0004930
injury	B-C0043251
presentations	B-C0449450
were	O
identified	B-C0205396
.	O
	
in	O
this	O
subgroup	B-C1515021
,	O
the	O
male	B-C0086582
female	B-C0086287
ratio	B-C0456603
is	O
4.57	O
37.18	O
of	O
presentations	B-C0449450
were	O
associated	B-C0332281
with	I-C0332281
a	O
fracture	B-C0016658
n	O
=	O
29	O
and	O
35.90	O
n	O
=	O
28	O
of	O
patients	B-C0030705
re-presented	B-C0449450
following	O
another	O
punch	B-C0004930
injury	B-C0043251
,	O
as	O
a	O
victim	B-C2711168
of	I-C2711168
violence	I-C2711168
,	O
or	O
by	O
other	O
psychiatric	B-C0205487
presentation	B-C0449450
.	O
	
in	O
conclusion	B-C1707478
,	O
a	O
male	B-C0243095
preponderance	I-C0243095
was	O
observed	B-C1441672
,	O
with	O
frequent	B-C0332183
re-presentations	B-C0449450
,	O
often	O
in	O
high-risk	B-C0332167
circumstances	B-C0868928
.	O
	
an	O
opportunity	O
for	O
screening	B-C1710032
,	O
including	O
mental	B-C0025353
health	I-C0025353
,	O
social	B-C0728831
and	O
substance	B-C4061432
misuse	I-C4061432
,	O
was	O
identified	B-C0205396
.	O
	
further	O
research	B-C0035168
is	O
needed	B-C0027552
to	O
enable	O
targeted	B-C1521840
effective	B-C1704419
interventions	B-C1273869
in	O
this	O
delayed	B-C0205421
recognition	B-C1285650
of	O
deterioration	B-C0563273
of	O
patients	B-C0030705
in	O
general	B-C0043030
wards	I-C0043030
is	O
mostly	O
caused	O
by	O
human	B-C0086418
related	O
monitoring	B-C1283169
failures	B-C0231175
a	O
root	B-C3179036
cause	I-C3179036
analysis	I-C3179036
of	O
unplanned	O
icu	B-C0583239
admissions	I-C0583239
an	O
unplanned	O
icu	B-C0583239
admission	I-C0583239
of	O
an	O
inpatient	B-C0021562
is	O
a	O
serious	B-C1519255
adverse	I-C1519255
event	I-C1519255
sae	B-C1519255
.	O
	
so	O
far	O
,	O
no	O
in	O
depth-study	O
has	O
been	O
performed	O
to	O
systematically	O
analyse	O
the	O
root	B-C3179036
causes	I-C3179036
of	O
unplanned	O
icu-admissions	B-C0583239
.	O
	
the	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
healthcare	B-C0018724
worker	I-C0018724
-	O
,	O
organisational	B-C0220885
-	O
,	O
technical	B-C0402239
-	O
disease	B-C0012634
-	O
and	O
patient	B-C0030705
-	O
related	O
causes	O
that	O
contribute	O
to	O
acute	O
unplanned	O
icu	B-C0583239
admissions	I-C0583239
from	O
general	B-C0043030
wards	I-C0043030
using	O
a	O
root-cause	B-C3179036
analysis	I-C3179036
tool	I-C3179036
called	O
prisma-medical	B-C0199168
.	O
	
although	O
a	O
track	B-C0681689
and	I-C0681689
trigger	I-C0681689
system	I-C0681689
mews	I-C0681689
was	O
introduced	O
in	O
our	O
hospital	B-C0019994
a	O
few	O
years	O
ago	O
,	O
it	O
was	O
implemented	O
without	O
a	O
clear	O
protocol	B-C0008971
.	O
	
therefore	O
,	O
the	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
adherence	O
to	O
a	O
track	B-C0681689
and	I-C0681689
trigger	I-C0681689
system	I-C0681689
to	O
identify	O
deterioration	B-C0563273
on	O
general	B-C0043030
hospital	I-C0043030
wards	I-C0043030
in	O
patients	B-C0030705
eventually	O
transferred	O
to	O
the	O
icu	B-C0021708
.	O
	
retrospective	B-C1518527
observational	I-C1518527
study	I-C1518527
in	O
49	O
consecutive	O
adult	O
patients	B-C0030705
acutely	O
admitted	B-C0184666
to	O
the	O
intensive	B-C0021708
care	I-C0021708
unit	I-C0021708
from	O
a	O
general	B-C0204637
nursing	I-C0204637
ward	I-C0204637
.	O
	
1	O
.	O
	
prisma-analysis	B-C0936012
on	O
root	B-C3179036
causes	I-C3179036
of	O
unplanned	O
icu	B-C0583239
admissions	I-C0583239
2	O
.	O
	
assessment	O
of	O
protocol	B-C0008971
adherence	O
to	O
the	O
early	B-C2919393
warning	I-C2919393
score	I-C2919393
system	I-C2919393
.	O
	
out	O
of	O
49	O
cases	O
,	O
156	O
root	B-C3179036
causes	I-C3179036
were	O
identified	O
.	O
	
the	O
most	O
frequent	O
root	B-C3179036
causes	I-C3179036
were	O
healthcare	B-C0018724
worker	I-C0018724
related	O
46%	O
,	O
which	O
were	O
mainly	O
failures	B-C0231175
in	O
monitoring	B-C1283169
the	O
patient	B-C0030705
.	O
	
they	O
were	O
followed	O
by	O
disease	B-C0012634
-related	O
45%	O
,	O
patient	B-C0030705
-related	O
causes	O
7	O
,	O
5%	O
,	O
and	O
organisational	B-C0220885
root	B-C3179036
causes	I-C3179036
3%	O
.	O
	
in	O
only	O
40%	O
of	O
the	O
patients	B-C0030705
vital	B-C0549193
parameters	I-C0549193
were	O
monitored	O
as	O
was	O
instructed	O
by	O
the	O
doctor	B-C0031831
.	O
	
477	O
vital	B-C0549193
parameter	I-C0549193
sets	O
were	O
found	O
in	O
the	O
48	O
hours	O
before	O
icu	B-C0583239
admission	I-C0583239
,	O
in	O
only	O
1%	O
a	O
correct	O
mews	B-C0681689
was	O
explicitly	O
documented	B-C1301725
in	O
the	O
record	O
.	O
	
this	O
in-depth	B-C0936012
analysis	I-C0936012
demonstrates	O
that	O
almost	O
half	O
of	O
the	O
unplanned	O
icu	B-C0583239
admissions	I-C0583239
from	O
the	O
general	B-C0043030
ward	I-C0043030
had	O
healthcare	B-C0018724
worker	I-C0018724
related	O
root	B-C3179036
causes	I-C3179036
,	O
mostly	O
due	O
to	O
monitoring	B-C1283169
failures	B-C0231175
in	O
clinically	B-C0563273
deteriorating	I-C0563273
patients	B-C0030705
.	O
	
in	O
order	O
to	O
reduce	O
unplanned	O
icu	B-C0583239
admissions	I-C0583239
,	O
improving	O
the	O
monitoring	B-C1283169
of	O
patients	B-C0030705
effects	O
of	O
a	O
novel	O
phosphodiesterase	B-C0031638
10a	I-C0031638
inhibitor	I-C0031638
in	O
non-human	B-C0237798
primates	I-C0237798
a	O
therapeutic	B-C0039798
approach	I-C0039798
for	O
schizophrenia	B-C0036341
with	O
improved	O
side	B-C0879626
effect	I-C0879626
profile	I-C0879626
schizophrenia	B-C0036341
symptoms	B-C1457887
are	O
associated	B-C0332281
with	I-C0332281
alterations	B-C0004782
in	I-C0004782
basal	I-C0004782
ganglia-cortical	I-C0004782
networks	I-C0004782
that	O
include	O
the	O
cyclic	B-C0028631
nucleotides	I-C0028631
camp	B-C0001455
/	O
cgmp	B-C0018338
signaling	B-C0037080
pathways	I-C0037080
.	O
	
phosphodiesterase	B-C0031638
10a	I-C0031638
pde10a	I-C0031638
inhibitors	I-C0031638
have	O
been	O
considered	O
as	O
therapeutic	B-C1611640
agents	I-C1611640
for	O
schizophrenia	B-C0036341
because	O
the	O
regulation	B-C2613288
of	I-C2613288
camp	I-C2613288
and	O
cgmp	B-C2612051
in	O
the	O
striatum	B-C0010097
by	O
pde10a	B-C1447737
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	B-C0037080
mechanisms	I-C0037080
of	O
the	O
striatal-cortical	B-C0682726
network	I-C0682726
,	O
and	O
thereby	O
in	O
cognitive	B-C0392335
function	I-C0392335
.	O
	
in	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non-human	B-C0237798
primates	I-C0237798
nhps	B-C0237798
the	O
effects	O
of	O
a	O
novel	O
pde10a	B-C0031638
inhibitor	I-C0031638
frm-6308	B-C0031638
that	O
has	O
demonstrated	O
high	B-C1656349
potency	I-C1656349
and	O
selectivity	O
for	O
human	B-C1447737
recombinant	I-C1447737
pde10a	I-C1447737
in	B-C0681828
vitro	I-C0681828
.	O
	
the	O
behavioral	B-C0243095
effects	I-C0243095
of	O
frm-6308	B-C0031638
in	O
a	O
dose	B-C0178602
range	I-C0178602
were	O
determined	O
in	O
rhesus	B-C0024400
monkeys	I-C0024400
using	O
a	O
standardized	B-C4228195
motor	I-C4228195
disability	I-C4228195
scale	I-C4228195
for	O
primates	B-C0033147
,	O
motor	B-C0556033
tasks	I-C0556033
,	O
and	O
the	O
""""	O
drug	B-C0678802
effects	I-C0678802
on	I-C0678802
the	I-C0678802
nervous	I-C0678802
"system"""	I-C0678802
dens	I-C0678802
scale	I-C0678802
.	O
	
the	O
neuronal	B-C0521390
metabolic	B-C2945675
effects	I-C2945675
of	O
frm-6308	B-C0031638
were	O
determined	O
with	O
18	B-C2315783
pet	I-C2315783
imaging	I-C2315783
.	O
	
results	O
showed	O
that	O
frm-6308	B-C0031638
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	B-C0682711
system	I-C0682711
at	O
s.c	B-C0021499
.	O
	
doses	I-C0021499
up	O
to	O
0.32	O
mg/kg	O
in	O
nhps	B-C0237798
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
fdg	B-C0046056
-	O
suv	B-C2348529
in	O
striatum	B-C0010097
f	O
16.069	O
,	O
p	O
<	O
0.05	O
and	O
cortical	B-C1181303
f	O
15.181	O
,	O
p	O
<	O
0.05	O
regions	O
.	O
	
higher	B-C0444956
doses	I-C0444956
induced	O
sedation	B-C0235195
and	O
occasional	B-C0427086
involuntary	I-C0427086
movements	I-C0427086
with	O
clear	O
development	O
of	O
tolerance	B-C0743284
after	I-C0743284
repeated	I-C0743284
exposures	I-C0743284
.	O
	
these	O
findings	O
suggest	O
that	O
frm-6308	B-C0031638
has	O
the	O
adequate	B-C1320678
pharmacological	I-C1320678
profile	I-C1320678
to	O
advance	O
testing	O
in	O
clinical	B-C0008976
trials	I-C0008976
and	O
demonstrate	O
antipsychotic	B-C3179403
efficacy	I-C3179403
of	O
pde10a	B-C1447737
inhibition	B-C3463820
for	O
the	O
treatment	B-C1522326
of	O
schizophrenia	B-C0036341
patients	B-C0030705
.	O
	
agglomeration	B-C1704332
of	O
luminescent	B-C1450275
porous	B-C1881977
silicon	B-C0037107
nanoparticles	B-C1450054
in	O
colloidal	B-C0009361
solutions	I-C0009361
we	O
have	O
prepared	B-C4082130
colloidal	B-C0009361
solutions	I-C0009361
of	O
clusters	B-C1704332
composed	O
from	O
porous	B-C1881977
silicon	B-C0037107
nanoparticles	B-C1450054
in	O
methanol	B-C0001963
,	O
water	B-C0043047
and	O
phosphate-buffered	B-C0036082
saline	I-C0036082
pbs	B-C0036082
.	O
	
even	O
if	O
the	O
size	B-C0456389
of	O
the	O
nanoclusters	B-C1704332
is	O
between	O
60	O
and	O
500	O
nm	O
,	O
due	O
to	O
their	O
highly	B-C0205250
porous	B-C1881977
"""cauliflower""-like"	B-C0678594
structure	I-C0678594
,	O
the	O
porous	B-C1881977
silicon	B-C0037107
nanoparticles	B-C1450054
are	O
composed	O
of	O
interconnected	B-C0449379
nanocrystals	B-C1721058
having	O
around	O
2.5	O
nm	O
in	O
size	B-C0456389
and	O
showing	O
strong	B-C0442821
visible	B-C0205379
luminescence	B-C1450275
in	O
the	O
orange	B-C1313858
-	O
red	B-C1260956
spectral	B-C2827424
region	B-C0205147
centred	O
at	O
600-700	O
nm	O
.	O
	
hydrophilic	B-C0475370
behaviour	I-C0475370
and	O
good	B-C0205170
solubility	B-C0037628
of	O
the	O
nanoclusters	B-C1704332
in	O
water	B-C0043047
and	O
water	B-C0043047
-	O
based	B-C1705938
solutions	B-C0037633
were	O
obtained	B-C1301820
by	O
adding	O
hydrogen	B-C0020281
peroxide	I-C0020281
into	O
the	O
etching	B-C2350458
solution	B-C0037633
during	O
preparation	B-C1521827
and	O
16	O
min	O
long	O
after-bath	B-C1549544
in	O
hydrogen	B-C0020281
peroxide	I-C0020281
.	O
	
by	O
simple	B-C0205352
filtration	B-C0016107
of	O
the	O
solutions	B-C0037633
with	O
syringe	B-C0180875
filters	I-C0180875
,	O
we	O
have	O
extracted	B-C0849355
smaller	B-C0700321
nanoclusters	B-C1704332
with	O
sizes	B-C0456389
of	O
approx	B-C0332232
.	O
	
60-70	O
nm	O
however	O
,	O
these	O
nanoclusters	B-C1704332
in	O
water	B-C0043047
and	O
pbs	B-C0036082
solution	I-C0036082
ph	B-C1882074
neutral	I-C1882074
are	O
prone	B-C0231204
to	O
agglomeration	B-C1704332
,	O
as	O
was	O
confirmed	B-C0750484
by	O
zeta	B-C0597697
potential	I-C0597697
measurements	B-C0242485
.	O
	
when	O
the	O
samples	B-C0370003
were	O
left	O
at	O
ambient	B-C1879688
conditions	I-C1879688
for	O
several	B-C0443302
weeks	O
,	O
the	O
typical	B-C3538928
nanocluster	B-C1704332
size	B-C0456389
increased	B-C0205217
to	O
approx	B-C0332232
.	O
	
330-400	O
nm	O
and	O
then	O
remained	O
stable	B-C0205360
.	O
	
however	O
,	O
both	O
freshly	B-C0443224
filtered	B-C1704449
and	O
aged	B-C2362314
samples	B-C0370003
with	O
agglomerated	B-C1704332
porous	B-C1881977
silicon	B-C0037107
nanoparticles	B-C1450054
of	O
porous	B-C1881977
silicon	B-C0037107
in	O
water	B-C0043047
and	O
pbs	B-C0036082
solutions	I-C0036082
can	O
be	O
further	O
used	O
for	O
biological	B-C0205460
studies	B-C2603343
or	O
as	O
luminescent	B-C1450275
markers	B-C0005516
in	O
living	B-C0007634
cells	I-C0007634
.	O
	
development	B-C1527148
of	O
a	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
method	B-C0449851
for	O
quantitative	B-C0681919
analysis	I-C0681919
of	O
trace	B-C0442822
d-amino	B-C0002520
acids	I-C0002520
d-amino	B-C0002520
acids	I-C0002520
have	O
recently	B-C0332185
attracted	O
much	O
attention	B-C0004268
in	O
various	O
research	B-C0242481
fields	I-C0242481
including	B-C0332257
medical	B-C0205476
,	O
clinical	B-C0205210
and	O
food	B-C0524863
industry	I-C0524863
due	O
to	O
their	O
important	B-C3898777
biological	B-C3714634
functions	I-C3714634
that	O
differ	O
from	O
l-amino	B-C0002520
acid	I-C0002520
.	O
	
most	O
chiral	B-C3539649
amino	B-C0002520
acid	I-C0002520
separation	B-C1441514
techniques	B-C0449851
require	B-C1514873
complicated	B-C0231242
derivatization	B-C0596319
procedures	B-C0025664
in	O
order	O
to	O
achieve	O
the	O
desirable	B-C0205556
chromatographic	B-C0205556
behavior	O
and	O
detectability	B-C0442726
.	O
	
thus	O
,	O
the	O
aim	B-C1947946
of	O
this	O
research	B-C0035168
is	O
to	O
develop	B-C1527148
a	O
highly	B-C0439822
sensitive	I-C0439822
analytical	B-C0178476
method	I-C0178476
for	O
the	O
enantioseparation	B-C1441514
of	O
chiral	B-C3539649
amino	B-C0002520
acids	I-C0002520
without	O
any	O
derivatization	B-C0596319
process	B-C1522240
using	O
liquid	B-C4049918
chromatography-tandem	I-C4049918
mass	I-C4049918
spectrometry	I-C4049918
lc-ms/ms	B-C4049918
.	O
	
by	O
optimizing	B-C2698650
ms/ms	B-C2123592
parameters	B-C0549193
,	O
we	O
established	B-C0443211
a	O
quantification	B-C1709793
method	B-C0449851
that	O
allowed	O
the	O
simultaneous	B-C0521115
analysis	B-C0936012
of	O
18	O
d-amino	B-C0002520
acids	I-C0002520
with	O
high	B-C2346484
sensitivity	I-C2346484
and	O
reproducibility	B-C1514863
.	O
	
additionally	O
,	O
we	O
applied	B-C4048755
the	O
method	B-C0449851
to	O
food	B-C0444315
sample	I-C0444315
vinegar	B-C0148405
for	O
the	O
validation	B-C1519941
,	O
and	O
successfully	O
quantified	B-C1709793
trace	B-C0442822
levels	I-C0442822
of	O
d-amino	B-C0002520
acids	I-C0002520
in	O
samples	B-C0370003
.	O
	
these	O
results	B-C0456984
demonstrated	O
the	O
applicability	B-C1706839
and	O
feasibility	B-C0205556
of	O
the	O
lc-ms/ms	B-C4049918
method	B-C0449851
as	O
a	O
novel	B-C0205314
,	O
effective	B-C1704419
tool	O
for	O
d-amino	B-C0002520
acid	I-C0002520
measurement	B-C0242485
in	O
various	O
biological	B-C2347026
samples	I-C2347026
.	O
	
the	O
multi-center	B-C0282574
evaluation	I-C0282574
of	I-C0282574
the	I-C0282574
accuracy	I-C0282574
of	I-C0282574
the	I-C0282574
contrast	I-C0282574
medium	I-C0282574
induced	I-C0282574
pd/pa	I-C0282574
ratio	I-C0282574
in	O
predicting	O
ffr	B-C1299469
memento	B-C0282574
-	O
ffr	B-C1299469
study	B-C2603343
adenosine	B-C0001443
administration	B-C1533734
is	O
needed	O
for	O
the	O
achievement	O
of	O
maximal	B-C0205289
hyperaemia	B-C0020452
fractional	B-C1299469
flow	I-C1299469
reserve	I-C1299469
ffr	B-C1299469
assessment	B-C0220825
.	O
	
the	O
objective	O
was	O
to	O
test	O
the	O
accuracy	B-C0443131
of	O
pd	B-C1254360
/	O
pa	B-C0456180
ratio	B-C0456603
registered	O
during	O
submaximal	B-C0205556
hyperaemia	B-C0020452
induced	O
by	O
non-ionic	B-C1875544
contrast	I-C1875544
medium	I-C1875544
contrast	B-C1299469
ffr	I-C1299469
cffr	B-C1299469
in	O
predicting	O
ffr	B-C1299469
and	O
comparing	O
it	O
to	O
the	O
performance	O
of	O
resting	B-C0679218
pd	B-C1254360
/	O
pa	B-C0456180
in	O
a	O
collaborative	B-C0681804
registry	O
of	O
926	O
patients	B-C0030705
enrolled	O
in	O
10	O
hospitals	B-C0019994
from	O
four	B-C0205450
european	B-C0681784
countries	I-C0681784
italy	B-C0022277
,	O
spain	B-C0037747
,	O
france	B-C0016674
and	O
portugal	B-C0032729
.	O
	
resting	B-C0679218
pd	B-C1254360
/	O
pa	B-C0456180
,	O
cffr	B-C1299469
and	O
ffr	B-C1299469
were	O
measured	O
in	O
1	O
coronary	B-C0242231
stenoses	I-C0242231
functionally	B-C0205245
evaluated	O
using	O
commercially	O
available	O
pressure	B-C0025080
wires	I-C0025080
.	O
	
cffr	B-C1299469
was	O
obtained	O
after	O
intracoronary	B-C1554869
injection	I-C1554869
of	O
contrast	B-C0009924
medium	I-C0009924
,	O
while	O
ffr	B-C1299469
was	O
measured	O
after	O
administration	B-C1533734
of	O
adenosine	B-C0001443
.	O
	
resting	B-C0679218
pd	B-C1254360
/	O
pa	B-C0456180
and	O
cffr	B-C1299469
were	O
significantly	O
higher	B-C0205250
than	O
ffr	B-C1299469
0.93	O
vs	O
.	O
	
0.87	O
vs	O
.	O
	
0.84	O
,	O
p<0	O
.	O
	
a	O
strong	O
correlation	B-C1707520
and	O
a	O
close	O
agreement	O
at	O
bland-altman	B-C0282574
analysis	I-C0282574
between	O
cffr	B-C1299469
and	O
ffr	B-C1299469
were	O
observed	O
r=0	O
,	O
p<0	O
and	O
95%	O
ci	B-C0009667
of	O
disagreement	O
from	O
-0	O
to	O
0.11	O
.	O
	
roc	B-C0035787
curve	I-C0035787
analysis	B-C0936012
showed	O
an	O
excellent	O
accuracy	B-C0443131
89%	O
of	O
the	O
cffr	B-C1299469
cut-off	O
of	O
0.85	O
in	O
predicting	O
an	O
ffr	B-C1299469
value	O
0.80	O
auc	O
0.95	O
95%	O
ci	B-C0009667
0.94	O
,	O
significantly	O
better	O
than	O
that	O
observed	O
using	O
resting	B-C0679218
pd	B-C1254360
/	O
pa	B-C0456180
auc	O
0.90	O
,	O
95%	O
ci	B-C0009667
0.88	O
p<0	O
.	O
	
a	O
cffr	B-C1299469
/	O
ffr	B-C1299469
hybrid	B-C0282574
approach	I-C0282574
showed	O
a	O
significantly	O
lower	B-C0205251
number	O
of	O
lesions	B-C0221198
requiring	O
adenosine	B-C0001443
than	O
a	O
resting	B-C0679218
pd	B-C1254360
/	O
pa	B-C0456180
/	O
ffr	B-C1299469
hybrid	B-C0282574
approach	I-C0282574
22%	O
vs	O
.	O
	
44%	O
,	O
p<0	O
.	O
	
cffr	B-C1299469
is	O
accurate	B-C0443131
in	O
predicting	O
the	O
functional	B-C0205245
significance	O
of	O
coronary	B-C0242231
stenosis	I-C0242231
.	O
	
this	O
could	O
allow	O
limiting	O
the	O
use	O
of	O
adenosine	B-C0001443
to	O
obtain	O
ffr	B-C1299469
to	O
a	O
minority	O
of	O
stenoses	B-C1261287
with	O
considerable	O
savings	O
of	O
time	B-C0040223
and	O
transfemoral	B-C0021107
aortic	I-C0021107
valve	I-C0021107
implantation	I-C0021107
with	O
the	O
repositionable	B-C0184252
lotus	I-C0184252
valve	I-C0184252
for	O
treatment	B-C0087111
of	O
patients	B-C0030705
with	O
symptomatic	B-C0231220
severe	B-C0205082
aortic	B-C0003507
stenosis	I-C0003507
results	B-C1274040
from	O
a	O
single-centre	B-C0237607
experience	I-C0237607
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
evaluate	B-C0220825
the	O
procedural	O
and	O
30-	O
day	B-C0439228
results	B-C1274040
for	O
the	O
repositionable	B-C0184252
lotus	I-C0184252
valve	I-C0184252
in	O
patients	B-C0030705
undergoing	O
transfemoral	B-C0021107
aortic	I-C0021107
valve	I-C0021107
implantation	I-C0021107
in	O
a	O
single-centre	B-C0237607
experience	I-C0237607
.	O
	
we	O
prospectively	O
enrolled	O
110	O
patients	B-C0030705
with	O
severe	B-C0205082
symptomatic	B-C0231220
aortic	B-C0003507
stenosis	I-C0003507
nct02162069	B-C3274381
.	O
	
all	O
procedures	B-C2700391
were	O
performed	O
without	O
general	B-C0002915
anaesthesia	I-C0002915
by	O
the	O
transfemoral	B-C0087111
approach	I-C0087111
.	O
	
patients	B-C0030705
were	O
followed	O
for	O
30	O
days	B-C0439228
.	O
	
patients	B-C0030705
received	B-C1514756
the	O
23	O
mm	O
n=20	O
,	O
25	O
mm	O
n=43	O
or	O
27	O
mm	O
n=47	O
lotus	B-C0184252
device	I-C0184252
.	O
	
mean	B-C0392762
oversizing	I-C0392762
in	O
relation	O
to	O
annulus	B-C2262860
or	O
left	B-C4284103
ventricular	I-C4284103
outflow	I-C4284103
tract	I-C4284103
lvot	B-C4284103
did	O
not	O
differ	O
among	O
groups	B-C0441833
.	O
	
there	O
was	O
no	B-C0746917
residual	I-C0746917
moderate	B-C0205081
or	O
severe	B-C0205082
aortic	B-C0003504
regurgitation	I-C0003504
.	O
	
the	O
rate	B-C0392762
of	I-C0392762
mild	I-C0392762
aortic	I-C0392762
regurgitation	I-C0392762
was	O
low	O
at	O
9.1	O
.	O
	
there	O
was	O
no	O
valve	O
embolisation	O
,	O
no	O
need	O
for	O
a	O
second	O
valve	O
and	O
no	O
conversion	O
to	O
surgery	O
.	O
	
the	O
need	O
for	O
a	O
new	O
pacemaker	O
implantation	O
due	O
to	O
complete	O
third	O
degree	O
or	O
type	O
ii	O
mobitz	O
second	O
degree	O
atrioventricular	O
block	O
was	O
24.1	O
,	O
excluding	O
patients	O
with	O
previously	O
implanted	O
devices	O
.	O
	
within	O
30	O
days	O
the	O
rates	O
of	O
all-cause	O
mortalit	O
y	O
and	O
stroke	O
were	O
low	O
.	O
	
in	O
patients	O
with	O
severe	O
aortic	B-C0003504
stenosis	O
,	O
transfemoral	O
tavi	O
with	O
the	O
repositionable	O
lotus	O
valve	O
was	O
associated	O
with	O
a	O
high	O
rate	O
of	O
device	O
success	O
,	O
no	O
moderate	O
or	O
severe	O
residual	O
aortic	O
regurgitation	I-C0003504
,	O
low	O
rates	O
of	O
major	O
vascular	O
complications	O
and	O
mortality	O
within	O
30	O
days	B-C0439228
a	O
comparison	B-C1707455
between	O
measured	B-C0444706
concentration	B-C0457929
of	O
3h	B-C0041119
in	O
kalpakkam	B-C0681784
environment	I-C0681784
with	O
predicted	B-C0026336
atmospheric	I-C0026336
dispersion	I-C0026336
model	I-C0026336
the	O
field	B-C3539073
measurements	B-C0242485
of	O
3h	B-C0041119
in	O
the	O
form	O
of	O
hto	B-C0077315
present	O
in	O
air	B-C0935443
moisture	B-C0868994
carried	O
out	O
around	O
madras	B-C0562516
atomic	I-C0562516
power	I-C0562516
station	I-C0562516
were	O
compared	B-C1707455
with	O
predicted	O
values	O
using	O
atmospheric	B-C0026336
dispersion	I-C0026336
modeling	I-C0026336
.	O
	
air	B-C1546536
3h	I-C1546536
samples	I-C1546536
were	O
collected	B-C1516695
from	O
different	O
sectors	B-C1708237
at	O
the	O
site	B-C0205145
boundary	B-C2828371
of	O
the	O
operating	B-C3241922
reactors	B-C0028591
for	O
the	O
period	B-C1948053
of	O
2	O
y	B-C0439234
and	O
compared	B-C1707455
with	O
gaussian	B-C0026336
plume	I-C0026336
model	I-C0026336
.	O
	
the	O
predictions	B-C0681842
were	O
comparable	O
with	O
the	O
measured	B-C0444706
value	B-C1522609
.	O
	
the	O
slight	B-C2937276
variation	B-C0205419
observed	B-C1441672
between	O
the	O
two	O
methods	B-C0025663
is	O
attributed	O
to	O
the	O
uncertainty	B-C0087130
involved	O
in	O
the	O
measurement	B-C0242485
of	O
air	B-C0001861
3h	B-C0041119
concentration	B-C0457929
and	O
in	O
the	O
measurement	B-C0242485
of	O
site-specific	B-C0449604
meteorological	B-C0025594
parameters	I-C0025594
.	O
	
the	O
radiation	B-C4019308
dose	I-C4019308
imparted	B-C0332289
to	O
members	B-C0678367
of	I-C0678367
public	I-C0678367
due	O
to	O
the	O
levels	B-C0441889
observed	B-C1441672
is	O
well	O
within	O
station	B-C0562516
technical	B-C0439801
specification	I-C0439801
limit	I-C0439801
for	O
the	O
four-component	O
aureocin	B-C1101398
a70	I-C1101398
as	O
a	O
promising	B-C0450442
agent	I-C0450442
for	O
food	B-C0016484
biopreservation	I-C0016484
aureocin	B-C1101398
a70	I-C1101398
is	O
the	O
only	O
four-component	O
bacteriocin	B-C0004641
described	O
to	O
date	O
.	O
	
as	O
it	O
inhibits	B-C2249823
the	I-C2249823
growth	I-C2249823
of	O
a	O
wide	O
range	O
of	O
gram-positive	B-C0018154
bacteria	I-C0018154
,	O
including	O
listeria	B-C0023861
monocytogenes	I-C0023861
strains	B-C1518614
isolated	O
from	O
food	B-C0016452
,	O
its	O
potential	O
for	O
improving	O
food	B-C1456535
safety	I-C1456535
was	O
investigated	O
in	O
this	O
study	O
.	O
	
aureocin	B-C1101398
a70	I-C1101398
10	O
proved	O
to	O
be	O
bactericidal	B-C0004635
,	O
but	O
not	O
extensively	O
lytic	B-C0439680
,	O
against	O
listerial	B-C0023861
strains	B-C1518614
.	O
	
the	O
antibacterial	B-C0441655
activity	I-C0441655
of	O
aureocin	B-C1101398
a70	I-C1101398
16au/ml	O
was	O
then	O
tested	O
in	O
uht-treated	B-C3179136
skimmed	B-C0349375
milk	I-C0349375
inoculated	B-C1439852
with	O
the	O
food	B-C0016452
-associated	O
l	B-C0023861
.	O
	
monocytogenes	I-C0023861
l12	I-C0023861
strain	I-C0023861
4-log	O
cfu/ml	O
during	O
storage	B-C1698986
at	O
4	O
for	O
one	O
week	O
.	O
	
aureocin	B-C1101398
a70	I-C1101398
caused	O
a	O
time-dependent	O
reduction	B-C0301630
in	O
the	O
listerial	B-C0023861
viable	B-C0007584
cell	I-C0007584
counts	I-C0007584
5.51	O
units	O
up	O
to	O
7days	O
of	O
incubation	B-C1439852
.	O
	
aureocin	B-C1101398
a70	I-C1101398
was	O
neither	O
toxic	B-C1407029
to	O
the	O
vero	B-C0042542
and	O
the	O
l-929	B-C0007634
cell	I-C0007634
lines	I-C0007634
nor	O
exhibited	O
a	O
hemolytic	B-C0302110
activity	I-C0302110
against	O
sheep	B-C0036945
red	B-C0014792
blood	I-C0014792
cells	I-C0014792
.	O
	
aureocin	B-C1101398
a70	I-C1101398
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25	O
,	O
16weeks	O
at	O
4	O
and	O
20weeks	O
at	O
-20	O
.	O
	
aureocin	B-C1101398
a70	I-C1101398
exhibited	O
a	O
time-dependent	O
susceptibility	B-C1547045
to	O
simulated	B-C1948023
gastric	B-C0017133
juice	I-C0017133
and	O
bile	B-C0005404
salts	I-C0005404
mimicking	O
gastrointestinal	B-C4061136
conditions	I-C4061136
.	O
	
the	O
entrapment	B-C2825784
of	O
aureocin	B-C1101398
a70	I-C1101398
in	O
an	O
alginate	B-C0102137
/	O
gelatin	B-C1533434
matrix	I-C1533434
revealed	O
that	O
this	O
bacteriocin	B-C0004641
can	O
be	O
released	O
from	O
this	O
matrix	O
.	O
	
moreover	O
,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low-density	B-C0752344
polyethylene	I-C0752344
plastic	I-C0752344
surface	O
suggesting	O
that	O
aureocin	B-C1101398
a70	I-C1101398
may	O
be	O
employed	O
in	O
bioactive	B-C3714412
packaging	B-C2828395
to	O
control	B-C2249823
the	I-C2249823
growth	I-C2249823
of	O
undesirable	O
bacteria	B-C0004611
.	O
	
taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin	B-C1101398
a70	I-C1101398
is	O
a	O
promising	B-C0450442
alternative	I-C0450442
to	O
be	O
used	O
in	O
food	B-C0016484
applications	I-C0016484
.	O
	
folate	B-C0178638
-	O
conjugated	B-C0522529
gene	B-C0017337
-	O
carrying	B-C0872177
microbubbles	B-C1258018
with	O
focused	B-C1517281
ultrasound	I-C1517281
for	O
concurrent	B-C0205420
blood-brain	B-C0005854
barrier	I-C0005854
opening	B-C1254362
and	O
local	B-C0205276
gene	B-C0872177
delivery	I-C0872177
previous	B-C0205156
studies	B-C2603343
have	O
demonstrated	O
that	O
circulating	B-C0175630
dna	B-C0012854
-	O
encapsulated	B-C0205223
microbubbles	B-C1258018
mbs	B-C1258018
combined	B-C0205195
with	O
focused	B-C1517281
ultrasound	I-C1517281
fus	B-C1517281
can	O
be	O
used	B-C1524063
for	O
local	B-C0205276
blood-brain	B-C0005854
barrier	I-C0005854
bbb	B-C0005854
opening	B-C1254362
and	O
gene	B-C0872177
delivery	I-C0872177
.	O
	
however	O
,	O
few	O
studies	B-C2603343
focused	B-C1285542
on	O
how	O
to	O
increase	B-C0442805
the	O
efficiency	B-C0013682
of	O
gene	B-C0872177
delivery	I-C0872177
to	O
brain	B-C0006118
tumors	I-C0006118
after	O
the	O
released	B-C0391871
gene	B-C0017337
penetrating	B-C0205321
the	O
bbb	B-C0005854
.	O
	
here	O
,	O
we	O
proposed	O
the	O
use	B-C1524063
of	I-C1524063
folate	B-C0178638
-	O
conjugated	O
dna	O
-	O
loaded	O
cationic	B-C1258018
mbs	I-C1258018
fcmbs	B-C1258018
.	O
	
when	O
combined	B-C0205195
with	O
fus	B-C1517281
as	O
a	O
trigger	B-C1444748
for	O
bbb	B-C0005854
opening	O
,	O
fcmbs	B-C1258018
were	O
converted	O
into	O
nanometer	B-C0439202
-	O
sized	B-C0456389
vesicles	B-C1622418
that	O
were	O
transported	B-C0005528
to	O
the	O
brain	B-C0006104
parenchyma	B-C0933845
.	O
	
the	O
fcmbs	B-C1258018
can	O
selectively	O
aggregate	B-C0205418
around	O
tumor	B-C0597032
cells	I-C0597032
that	O
overexpressed	B-C1514559
the	O
folate	B-C2955669
receptor	I-C2955669
,	O
thus	O
enhancing	B-C2349975
gene	B-C0872177
delivery	I-C0872177
via	O
folate	B-C2955669
-	O
stimulated	B-C1948023
endocytosis	B-C0014139
.	O
	
our	O
results	B-C1274040
confirmed	B-C0521093
that	O
fcmbs	B-C1258018
can	O
carry	B-C0872177
dna	B-C0012854
on	O
the	O
surface	B-C0205148
of	O
the	O
mb	B-C1258018
shell	B-C1948022
and	O
have	O
good	B-C0205170
targeting	B-C1521840
ability	B-C1516240
on	O
c6	B-C0007634
glioma	I-C0007634
cells	I-C0007634
.	O
	
in	O
addition	O
,	O
the	O
optimized	O
fus	B-C1517281
parameters	B-C0549193
for	O
fcmbs	B-C1258018
-	O
enhanced	B-C2349975
gene	B-C0872177
delivery	I-C0872177
were	O
confirmed	B-C0521093
by	I-C0521093
cell	B-C0007634
experiments	B-C0681814
center	B-C1705502
frequency	I-C1705502
=	O
1	O
mhz	O
acoustic	B-C4284008
pressure	I-C4284008
=	O
700	O
kpa	O
pulse	B-C1947910
repetition	B-C0205341
frequency	B-C1705502
=	O
5	O
hz	O
cycle	B-C1511572
number	B-C0237753
=	O
10000	O
exposure	B-C0332157
time	B-C0040223
=	O
1	O
min	O
fcmbs	B-C1258018
concentration	B-C1446561
=	O
4	O
10	O
mb/ml	O
.	O
	
in	B-C1515655
vivo	I-C1515655
data	B-C1511726
also	O
indicated	B-C1444656
that	O
fcmbs	B-C1258018
show	O
better	B-C0332272
gene	B-C0017337
transfection	B-C0314641
efficiency	B-C0013682
than	O
mbs	B-C1258018
without	B-C0332288
folate	B-C2955669
conjugation	B-C1160466
and	O
the	O
traditional	B-C0443324
approach	B-C0449445
of	O
directly	B-C1947931
injecting	B-C1533685
the	O
gene	B-C0017337
.	O
	
this	O
study	B-C2603343
described	O
our	O
novel	B-C0205314
development	B-C1527148
of	O
multifunctional	B-C0205245
mbs	B-C1258018
for	O
fus	B-C1517281
-	O
triggered	B-C1444748
gene	B-C0872177
delivery	I-C0872177
/	O
modulation	B-C0443264
of	O
il-6	B-C0021760
induced	B-C0205263
rankl	B-C0666364
expression	B-C1171362
in	O
arthritic	B-C0003864
synovium	B-C0039099
by	O
a	O
transcription	B-C2350546
factor	I-C2350546
sox5	I-C2350546
receptor	B-C0666364
activator	I-C0666364
of	I-C0666364
nuclear	I-C0666364
factor	I-C0666364
κb	I-C0666364
ligand	I-C0666364
rankl	B-C0666364
is	O
critically	B-C1511545
involved	O
in	O
bone	B-C0587240
erosion	I-C0587240
of	O
rheumatoid	B-C0003873
arthritis	I-C0003873
ra	B-C0003873
.	O
	
we	O
previously	B-C0205156
reported	O
association	O
between	O
younger	B-C0001779
age	I-C0001779
at	O
onset	O
of	O
ra	B-C0003873
and	O
a	O
rankl	B-C0666364
promoter	O
snp	B-C0752046
that	O
conferred	O
an	O
elevated	B-C3163633
promoter	O
activity	O
via	O
binding	B-C1145667
to	O
a	O
transcription	B-C2350546
factor	I-C2350546
sox5	I-C2350546
.	O
	
here	O
we	O
study	B-C2603343
the	O
regulation	B-C1157519
of	O
sox5	B-C2350546
levels	O
in	O
relation	O
to	O
rankl	B-C0666364
expression	B-C1171362
in	O
ra	B-C0003873
synovial	B-C0039099
fibroblasts	B-C0016030
sf	B-C0016030
and	O
the	O
development	B-C1527148
of	O
bone	B-C0587240
erosion	I-C0587240
in	O
the	O
collagen-induced	B-C0971858
arthritis	I-C0971858
cia	B-C0971858
mouse	B-C0026809
.	O
	
our	O
data	B-C0150098
indicated	B-C1444656
sox5	B-C2350546
levels	O
were	O
higher	O
in	O
synovium	B-C0039099
and	O
synovial	B-C0039097
fluid	I-C0039097
from	O
ra	B-C0003873
compared	B-C1707455
to	O
osteoarthritis	B-C0029408
patients	B-C0030705
.	O
	
pro-inflammatory	B-C0333348
cytokines	B-C0079189
upregulated	B-C0041904
sox5	B-C2350546
and	O
rankl	B-C0666364
expression	B-C1171362
in	O
both	O
primary	O
ra	B-C0003873
sf	B-C0016030
and	O
the	O
rheumatoid	O
synovial	O
fibroblast	B-C0682524
cell	I-C0682524
line	I-C0682524
,	O
mh7a	B-C0007634
.	O
	
overexpression	B-C1514559
of	O
sox5	B-C2350546
resulted	B-C1274040
in	O
significantly	B-C0205217
increased	I-C0205217
rankl	B-C0666364
levels	O
,	O
while	O
knockdown	B-C2350567
of	O
sox5	B-C1420328
resulted	B-C1274040
in	O
diminished	B-C0205216
il-6	B-C0021760
mediated	O
rankl	B-C0666364
upregulation	B-C0041904
in	O
mh7a	B-C0007634
cells	I-C0007634
.	O
	
chromatin	B-C1328856
immunoprecipitation	I-C1328856
chip	B-C1328856
showed	O
approximately	B-C0332232
3-fold	O
enrichment	O
of	O
rankl-specific	B-C0012854
dna	I-C0012854
in	O
anti-sox5	B-C0301871
immunoprecipitate	I-C0301871
in	O
il-6	B-C0021760
treated	B-C1522326
mh7a	B-C0007634
cells	I-C0007634
as	O
compared	B-C1707455
to	O
untreated	B-C0243095
cells	I-C0243095
.	O
	
locally	O
silencing	B-C0598496
sox5	B-C1420328
gene	I-C1420328
significantly	B-C0205216
diminished	I-C0205216
rankl	B-C0666364
positive	B-C1514241
cells	B-C0007634
and	O
bone	B-C0587240
erosion	I-C0587240
in	O
cia	B-C0971858
mice	B-C0026809
.	O
	
these	O
findings	B-C0243095
suggest	B-C1705535
sox5	B-C2350546
is	O
an	O
important	O
regulator	B-C1704735
of	O
il-6	B-C0021760
-	O
induced	B-C0205263
rankl	B-C0666364
expression	B-C1171362
in	O
ra	B-C0003873
sf	B-C0016030
.	O
	
intracameral	B-C1636767
cefuroxime	B-C0007562
in	O
the	O
prevention	B-C0679698
of	O
postoperative	B-C1282227
endophthalmitis	I-C1282227
an	O
experience	B-C0596545
from	O
hong	B-C0019907
kong	I-C0019907
the	O
purpose	O
was	O
to	O
study	B-C2603343
the	O
effect	B-C1280500
of	O
introducing	B-C0579004
intracameral	B-C1636767
cefuroxime	B-C0007562
,	O
which	O
was	O
compounded	B-C0013164
by	O
a	O
hospital	B-C0260123
pharmacy	I-C0260123
,	O
on	O
postoperative	B-C1282227
endophthalmitis	I-C1282227
in	O
a	O
tertiary	B-C0596660
eye	I-C0596660
centre	I-C0596660
in	O
hong	B-C0019907
kong	I-C0019907
.	O
	
all	O
cases	O
that	O
underwent	O
cataract	B-C2939459
surgeries	I-C2939459
over	O
a	O
12-year	O
period	O
january	O
2004	O
to	O
december	O
2015	O
were	O
included	O
.	O
	
the	O
routine	B-C0205547
use	B-C0457083
of	O
intracameral	B-C1636767
cefuroxime	B-C0007562
at	O
the	O
end	O
of	O
cataract	B-C2939459
surgery	I-C2939459
was	O
introduced	O
at	O
our	O
centre	O
after	O
april	O
2010	O
.	O
	
all	O
cefuroxime	B-C0007562
aliquots	B-C1510844
were	O
prepared	O
by	O
the	O
hospital	B-C0260123
pharmacy	I-C0260123
using	O
an	O
aseptic	B-C0232920
compounding	O
technique	O
.	O
	
the	O
rates	O
of	O
postoperative	O
endophthalmitis	O
before	O
april	O
2010	O
group	O
1	O
,	O
no	O
intracameral	O
cefuroxime	O
and	O
after	O
april	O
2010	O
group	O
2	O
,	O
routine	O
use	O
of	O
intracameral	O
cefuroxime	O
were	O
compared	O
.	O
	
a	O
total	O
of	O
30	O
eyes	O
7	O
in	O
group	O
1	O
and	O
23	O
in	O
group	O
2	O
were	O
studied	O
.	O
	
eight	O
cases	O
developed	O
postoperative	O
endophthalmitis	O
1.09	O
in	O
1000	O
0.11	O
%	O
in	O
group	O
1	O
whereas	O
no	O
cases	O
developed	O
endophthalmitis	O
0	O
%	O
in	O
group	O
2	O
.	O
	
the	O
rate	O
of	O
reduction	O
was	O
statistically	O
significant	O
p	O
<	O
0.0001	O
.	O
	
seven	O
out	O
of	O
eight	O
cases	O
of	O
endophthalmitis	O
were	O
confirmed	O
by	O
positive	O
culture	O
.	O
	
organisms	O
identified	O
were	O
group	O
g	O
streptococcus	O
two	O
cases	O
,	O
group	O
b	O
streptococcus	O
,	O
staphylococcus	O
aureus	O
,	O
serratia	O
marcescens	O
,	O
and	O
coagulase-negative	O
staphylococcus	O
two	O
cases	O
.	O
	
antibiotic	O
susceptibility	O
testing	O
results	O
were	O
available	O
in	O
six	O
cases	O
.	O
	
four	O
out	O
of	O
six	O
organisms	O
were	O
susceptible	O
to	O
the	O
penicillin	O
group	O
.	O
	
no	O
adverse	O
events	O
related	O
to	O
the	O
use	O
of	O
intracameral	O
cefuroxime	O
were	O
encountered	O
.	O
	
the	O
use	O
of	O
intracameral	O
cefuroxime	O
could	O
significantly	O
reduce	O
the	O
rate	O
of	O
postoperative	O
endophthalmitis	O
in	O
a	O
tertiary	O
centre	O
in	O
hong	O
kong	O
.	O
	
the	O
use	O
of	O
aseptic	B-C0013164
compounding	I-C0013164
to	O
prepare	O
cefuroxime	O
aliquots	O
by	O
hospital	O
pharmacy	O
appeared	O
to	O
be	O
safe	O
and	O
a	O
standardized	O
approach	O
for	O
the	O
assessment	B-C1261322
and	O
treatment	B-C0087111
of	O
internationally	B-C1512888
adopted	B-C0337541
children	I-C0337541
with	O
a	O
previously	O
repaired	O
anorectal	B-C3495676
malformation	I-C3495676
arm	B-C3495676
a	O
significant	O
number	O
of	O
internationally	B-C1512888
adopted	B-C0337541
children	I-C0337541
have	O
congenital	B-C0000768
birth	I-C0000768
defects	I-C0000768
.	O
	
as	O
a	O
specialist	O
center	O
for	O
colorectal	B-C0555952
diagnoses	B-C0430022
,	O
we	O
evaluate	O
such	O
children	B-C0008059
with	O
an	O
anorectal	B-C3495676
malformation	I-C3495676
arm	B-C3495676
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	B-C0035110
.	O
	
knowledge	B-C0518904
of	O
the	O
common	O
complications	B-C0009566
following	O
arm	B-C3495676
surgery	B-C0543467
has	O
led	O
us	O
to	O
develop	O
treatment	B-C0087111
algorithms	B-C0002045
for	O
patients	B-C0030705
with	O
unknown	O
past	B-C0455458
medical	I-C0455458
and	O
surgical	B-C0744961
history	I-C0744961
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	B-C0425382
population	B-C1257890
.	O
	
the	O
results	O
of	O
investigations	B-C1261322
,	O
indications	B-C3146298
,	O
and	O
rate	B-C1521828
of	O
reoperation	B-C0035110
were	O
assessed	O
for	O
adopted	B-C0337541
children	I-C0337541
with	O
an	O
arm	B-C3495676
evaluated	O
between	O
2014	O
and	O
2016	O
.	O
	
56	O
patients	B-C0030705
28	O
males	B-C0086582
were	O
identified	O
.	O
	
76.8	O
required	O
reoperative	B-C0035110
surgery	I-C0035110
.	O
	
mislocation	O
of	O
the	O
anus	B-C0003461
outside	B-C0205101
the	O
sphincter	B-C1409894
complex	O
was	O
seen	O
in	O
50%	O
of	O
males	B-C0086582
and	O
39.3	O
of	O
females	B-C0086287
.	O
	
anal	B-C0266229
stricture	I-C0266229
,	O
rectal	B-C0034888
prolapse	I-C0034888
,	O
retained	B-C0333118
vaginal	B-C0431649
septum	I-C0431649
,	O
and	O
a	O
strictured	B-C1261287
vaginal	B-C0458952
introitus	I-C0458952
were	O
also	O
common	O
.	O
	
the	O
reoperative	B-C0035110
surgery	I-C0035110
rate	B-C1521828
in	O
the	O
internationally	B-C1512888
adopted	B-C0337541
child	I-C0337541
with	O
an	O
arm	B-C3495676
is	O
high	O
.	O
	
complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	B-C0008059
is	O
required	O
to	O
identify	O
complications	B-C0009566
following	O
initial	O
repair	B-C1705181
.	O
	
development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	B-C0520254
care	I-C0520254
these	O
children	B-C0008059
highly	O
fluorescent	B-C0016315
gold	B-C0018026
nanoclusters	B-C1721060
stabilized	O
by	O
food	B-C0012177
proteins	I-C0012177
from	O
preparation	O
to	O
application	O
in	O
detection	B-C1511790
of	O
food	B-C0016452
contaminants	B-C2827365
and	O
bioactive	B-C3714412
nutrients	I-C3714412
applications	O
of	O
nanotechnology	B-C0872323
in	O
food	B-C0016452
have	O
rapidly	O
increased	O
in	O
the	O
past	O
decades	O
.	O
	
ultra-small	B-C1721060
gold	I-C1721060
nanoclusters	I-C1721060
au	B-C1721060
ncs	I-C1721060
,	O
composed	O
of	O
several	O
to	O
roughly	O
a	O
hundred	O
atoms	O
,	O
represent	O
a	O
kind	O
of	O
novel	O
nanomaterials	B-C1450053
.	O
	
the	O
au	B-C1721060
ncs	I-C1721060
directed	O
by	O
food	B-C0012177
proteins	I-C0012177
have	O
drawn	O
considerable	O
research	O
attention	O
due	O
to	O
their	O
environmentally	B-C2350565
friendly	I-C2350565
preparation	I-C2350565
,	O
strong	O
fluorescence	B-C0016315
,	O
excellent	O
photo-stability	B-C0205556
and	O
favorable	O
biocompatibility	B-C0596177
.	O
	
these	O
interesting	O
protein-au	B-C1721059
hybrids	I-C1721059
have	O
opened	O
up	O
a	O
new	O
area	O
at	O
the	O
nano-bio-food	B-C1708333
interface	I-C1708333
,	O
not	O
only	O
did	O
they	O
provide	O
the	O
missing	O
link	O
between	O
single	B-C0567415
metal	I-C0567415
atoms	I-C0567415
and	O
plasmonic	B-C2603343
metal	B-C1721060
nanoparticles	I-C1721060
,	O
but	O
also	O
developed	O
the	O
hybrid	B-C1881073
system	I-C1881073
between	O
biomacromolecule	B-C1179809
and	O
inorganic	B-C1881215
ions	B-C0022023
.	O
	
in	O
this	O
review	O
,	O
we	O
highlighted	O
the	O
synthesis	B-C1883254
strategies	O
and	O
optical	B-C0871161
properties	I-C0871161
of	O
the	O
au	B-C1721060
ncs	I-C1721060
stabilized	O
by	O
typical	O
food	B-C0012177
proteins	I-C0012177
as	O
well	O
as	O
their	O
applications	O
in	O
detection	B-C1511790
of	O
food	B-C0016452
contaminants	B-C2827365
or	O
bioactive	B-C3714412
nutrients	I-C3714412
.	O
	
in	O
addition	O
,	O
we	O
discussed	O
current	O
challenges	O
and	O
future	O
development	O
in	O
food	B-C0012177
proteins	I-C0012177
directed	O
gold	B-C1721060
nanoclusters	I-C1721060
for	O
size-controlled	O
synthesis	B-C1883254
sub-lethal	B-C3151529
effects	I-C3151529
of	O
dietary	B-C0012155
neonicotinoid	B-C1997222
insecticide	I-C1997222
exposure	B-C0332157
on	O
honey	B-C0323351
bee	I-C0323351
queen	I-C0323351
fecundity	B-C0015895
and	O
colony	B-C1947989
development	B-C0243107
many	O
factors	B-C1521761
can	O
negatively	B-C0205160
affect	O
honey	B-C0323351
bee	I-C0323351
apis	B-C0323351
mellifera	I-C0323351
l	I-C0323351
health	B-C0018684
including	O
the	O
pervasive	B-C0205391
use	O
of	O
systemic	B-C0205373
neonicotinoid	B-C1997222
insecticides	I-C1997222
.	O
	
through	O
direct	O
consumption	B-C1947907
of	O
contaminated	B-C0205279
nectar	B-C2717960
and	O
pollen	B-C0032385
from	O
treated	B-C1522326
plants	B-C0032098
,	O
neonicotinoids	B-C1997222
can	O
affect	O
foraging	B-C2752984
,	O
learning	B-C0023185
,	O
and	O
memory	B-C0025260
in	O
worker	B-C0004923
bees	I-C0004923
.	O
	
less	O
well	O
studied	O
are	O
the	O
potential	O
effects	O
of	O
neonicotinoids	B-C1997222
on	O
queen	B-C0004923
bees	I-C0004923
,	O
which	O
may	O
be	O
exposed	O
indirectly	O
through	O
trophallaxis	B-C0237876
,	O
or	O
food	B-C0016452
-	O
sharing	B-C0237876
.	O
	
to	O
assess	B-C0184514
effects	O
on	O
queen	B-C0004923
productivity	B-C0033269
,	O
small	B-C0700321
colonies	B-C1947989
of	O
different	O
sizes	B-C0456389
1500	O
,	O
3000	O
,	O
and	O
7000	O
bees	B-C0004923
were	O
fed	B-C2987508
imidacloprid	B-C0218499
0	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ppb	O
in	O
syrup	B-C0458173
for	O
three	O
weeks	B-C0439230
.	O
	
we	O
found	O
adverse	B-C0879626
effects	I-C0879626
of	O
imidacloprid	B-C0218499
on	O
queens	B-C0004923
egg-laying	B-C1622979
and	O
locomotor	B-C0023946
activity	I-C0023946
,	O
worker	B-C0004923
bees	I-C0004923
foraging	B-C2752984
and	O
hygienic	B-C0020405
activities	B-C0441655
,	O
and	O
colony	B-C1947989
development	B-C0678723
brood	B-C0004923
production	O
and	O
pollen	B-C0032385
stores	O
in	O
all	O
treated	B-C1522326
colonies	B-C1947989
.	O
	
some	O
effects	O
were	O
less	B-C0547044
evident	O
as	O
colony	B-C1947989
size	B-C0456389
increased	B-C0205217
,	O
suggesting	O
that	O
larger	B-C1704243
colony	B-C1947989
populations	B-C1257890
may	O
act	O
as	O
a	O
buffer	O
to	O
pesticide	B-C2220281
exposure	I-C2220281
.	O
	
this	O
study	B-C2603343
is	O
the	O
first	O
to	O
show	O
adverse	B-C0879626
effects	I-C0879626
of	O
imidacloprid	B-C0218499
on	O
queen	B-C0004923
bee	I-C0004923
fecundity	B-C0015895
and	O
behavior	B-C0004927
and	O
improves	B-C1272747
our	O
understanding	B-C0162340
of	O
how	O
neonicotinoids	B-C1997222
may	O
impair	B-C0221099
short-term	O
colony	B-C1947989
functioning	B-C0205245
.	O
	
these	O
data	B-C1511726
indicate	O
that	O
risk-mitigation	B-C4296788
efforts	I-C4296788
should	O
focus	O
on	O
reducing	B-C0392756
neonicotinoid	B-C1997222
exposure	B-C0332157
in	O
the	O
early	B-C0241232
spring	I-C0241232
when	O
colonies	B-C1947989
are	O
smallest	B-C0700321
and	O
queens	B-C0004923
are	O
most	O
vulnerable	B-C0231204
to	O
therapeutic	B-C0039798
applications	I-C0039798
of	O
crispr	B-C3658200
rna-guided	B-C0082774
genome	B-C4279981
editing	I-C4279981
the	O
rapid	O
development	O
of	O
programmable	B-C0597094
nuclease	I-C0597094
-based	O
genome	B-C4279981
editing	I-C4279981
technologies	B-C0039421
has	O
enabled	O
targeted	B-C1521840
gene	B-C0017337
disruption	B-C0332453
and	O
correction	B-C1720855
both	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
this	O
revolution	O
opens	O
up	O
the	O
possibility	O
of	O
precise	O
genome	B-C4279981
editing	I-C4279981
at	O
target	B-C1521840
genomic	B-C1880951
sites	I-C1880951
to	O
modulate	O
gene	B-C0314627
function	I-C0314627
in	O
animals	B-C0003062
and	O
plants	B-C0032098
.	O
	
among	O
several	O
programmable	B-C0597094
nucleases	I-C0597094
,	O
the	O
type	B-C3658200
ii	I-C3658200
clustered	I-C3658200
regularly	I-C3658200
interspaced	I-C3658200
short	I-C3658200
palindromic	I-C3658200
repeats	I-C3658200
crispr	B-C3658200
crispr-associated	B-C3658355
nuclease	I-C3658355
9	I-C3658355
cas9	I-C3658355
system	I-C3658355
has	O
progressed	O
remarkably	O
in	O
recent	O
years	O
,	O
leading	O
to	O
its	O
widespread	O
use	O
in	O
research	B-C0035168
,	O
medicine	B-C0025118
and	O
biotechnology	B-C0005574
.	O
	
in	O
particular	O
,	O
crispr-cas9	B-C3658355
shows	O
highly	O
efficient	O
gene	B-C4279981
editing	I-C4279981
activity	O
for	O
therapeutic	B-C0039798
purposes	I-C0039798
in	O
systems	O
ranging	O
from	O
patient	B-C0030705
stem	B-C0038250
cells	I-C0038250
to	O
animal	B-C0599779
models	I-C0599779
.	O
	
however	O
,	O
the	O
development	O
of	O
therapeutic	B-C0039798
approaches	I-C0039798
and	O
delivery	B-C0565867
methods	I-C0565867
remains	O
a	O
great	O
challenge	O
for	O
biomedical	B-C1879848
applications	B-C0039798
.	O
	
herein	O
,	O
we	O
review	O
therapeutic	B-C0039798
applications	I-C0039798
that	O
use	O
the	O
crispr-cas9	B-C3658355
system	I-C3658355
design	B-C1707689
and	O
characteristics	B-C1521970
of	O
cytotoxic	B-C1511636
fibroblast	B-C0079349
growth	I-C0079349
factor	I-C0079349
1	I-C0079349
conjugate	B-C1254351
for	O
fibroblast	B-C0060369
growth	I-C0060369
factor	I-C0060369
receptor	I-C0060369
-	O
targeted	B-C3854476
cancer	I-C3854476
therapy	I-C3854476
fibroblast	B-C0060369
growth	I-C0060369
factor	I-C0060369
receptors	I-C0060369
fgfrs	B-C0060369
are	O
attractive	O
candidate	O
cancer	B-C0920425
therapy	I-C0920425
targets	B-C1521840
as	O
they	O
are	O
overexpressed	B-C1514559
in	O
multiple	B-C0439064
types	O
of	O
tumors	B-C0027651
,	O
such	O
as	O
breast	B-C1458155
,	O
prostate	B-C0033578
,	O
bladder	B-C0005695
,	O
and	O
lung	B-C0242379
cancer	I-C0242379
.	O
	
in	O
this	O
study	O
,	O
a	O
natural	B-C1749457
ligand	I-C1749457
of	O
fgfr	B-C0060369
,	O
an	O
engineered	B-C0034861
variant	I-C0034861
of	O
fibroblast	B-C0079349
growth	I-C0079349
factor	I-C0079349
1	I-C0079349
fgf1v	B-C0079349
,	O
was	O
conjugated	B-C0522529
to	O
a	O
potent	B-C0304497
cytotoxic	I-C0304497
drug	I-C0304497
,	O
monomethyl	B-C1565020
auristatin	I-C1565020
e	I-C1565020
mmae	B-C1565020
,	O
and	O
used	O
as	O
a	O
targeting	B-C0599894
agent	I-C0599894
for	O
cancer	B-C0334227
cells	I-C0334227
overexpressing	B-C1514559
fgfrs	B-C0060369
,	O
similar	O
to	O
antibodies	B-C0003241
in	O
antibody-drug	B-C2346828
conjugates	I-C2346828
.	O
	
the	O
fgf1v-valine-citrulline-mmae	B-C1254351
conjugate	I-C1254351
showed	O
a	O
favorable	O
stability	B-C1327386
profile	I-C1327386
,	O
bound	B-C1167622
fgfrs	B-C0060369
on	O
the	O
cell	B-C0699040
surface	I-C0699040
specifically	B-C0205369
,	O
and	O
efficiently	B-C0442799
released	B-C1283071
the	O
drug	B-C1565020
mmae	I-C1565020
upon	O
cleavage	B-C0597304
by	O
the	O
lysosomal	B-C0699919
protease	I-C0699919
cathepsin	I-C0699919
b	I-C0699919
.	O
	
importantly	O
,	O
the	O
conjugate	B-C1254351
showed	O
a	O
prominent	B-C0205402
cytotoxic	B-C0596402
effect	I-C0596402
toward	O
cell	B-C0334227
lines	I-C0334227
expressing	B-C0597360
fgfr	B-C0060369
.	O
	
fgf1v-vcmmae	B-C1254351
was	O
highly	O
cytotoxic	B-C1511636
at	O
concentrations	B-C1446561
even	O
an	O
order	O
of	O
magnitude	O
lower	B-C2003888
than	O
those	O
found	O
for	O
free	O
mmae	B-C1565020
.	O
	
this	O
effect	O
was	O
fgfr	B-C0060369
-specific	O
as	O
cells	B-C0334227
lacking	B-C0332268
fgfr	B-C0060369
did	B-C1513916
not	I-C1513916
show	I-C1513916
any	O
increased	B-C0205217
mortality	B-C0007587
.	O
	
effects	O
of	O
morphology	B-C0332437
and	O
surface	B-C0700307
hydroxyl	I-C0700307
on	O
the	O
toxicity	B-C0600688
of	O
biocl	B-C0053787
in	O
human	B-C0086418
hacat	B-C0022567
cells	I-C0022567
recently	O
,	O
bismuth	B-C0053787
oxychloride	I-C0053787
nanomaterials	B-C1881976
biocls	B-C0053787
are	O
showing	O
great	O
promise	O
in	O
pollutant	B-C0599786
removal	B-C1883720
.	O
	
residues	B-C0599786
from	O
these	O
environmental	B-C3853059
remediations	I-C3853059
are	O
potential	O
hazardous	B-C0018626
materials	I-C0018626
.	O
	
unfortunately	O
,	O
human	B-C0086418
health	B-C0086930
risks	I-C0086930
of	O
biocls	B-C0053787
are	O
still	O
unexplored	O
widely	O
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical	B-C0871161
properties	I-C0871161
on	O
the	O
cytotoxicity	B-C0596402
of	O
biocls	B-C0053787
toward	O
a	O
human	B-C0086418
skin	B-C1123023
derived	O
cell	B-C0007634
line	I-C0007634
hacat	B-C0022567
.	O
	
results	O
showed	O
that	O
morphology	B-C0332437
and	O
surface	B-C0700307
hydroxyl	I-C0700307
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	B-C0600688
of	O
biocls	B-C0053787
.	O
	
microsphere-shaped	B-C0332479
biocl	B-C0053787
caused	O
less	O
toxicity	B-C0600688
than	O
nanosheet-shaped	B-C0332479
biocl	B-C0053787
because	O
of	O
weaker	B-C0007613
particle-membrane	I-C0007613
interactions	I-C0007613
,	O
while	O
the	O
presence	O
of	O
surface	B-C0700307
hydroxyl	I-C0700307
on	O
microsphere-shaped	B-C0332479
biocl	B-C0053787
significantly	O
raised	O
the	O
toxicity	B-C0600688
owing	O
to	O
the	O
increased	O
interaction	B-C0007613
with	O
cell	B-C0007603
membrane	I-C0007603
.	O
	
both	O
microsphere-shaped	B-C0332479
biocl	B-C0053787
with	O
surface	B-C0700307
hydroxyl	I-C0700307
and	O
nanosheet-shaped	B-C0332479
biocl	B-C0053787
caused	O
significant	O
cell	B-C0007603
membrane	I-C0007603
damage	B-C0599732
pi	B-C0033470
uptake	O
and	O
ldh	O
release	O
,	O
however	O
,	O
based	O
on	O
the	O
different	O
mechanism	O
.	O
	
the	O
former	O
may	O
be	O
a	O
predominant	O
"""chemical"""	O
mechanism	O
involved	O
an	O
oxidative	O
stress	O
paradigm	O
,	O
as	O
manifested	O
by	O
elevated	O
ros	O
and	O
depleted	O
gsh	O
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
""""	O
physical	O
""""	O
damage	O
to	O
cell	O
membrane	O
.	O
	
both	O
""""	O
physical	O
""""	O
and	O
"""chemical"""	O
response	O
led	O
to	O
cell	O
death	O
.	O
	
furthermore	O
,	O
a	O
set	O
of	O
experiments	O
including	O
mmp	O
collapse	O
,	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
/	O
necrosis	O
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological	O
aspects	O
of	O
biocls	O
.	O
	
data	O
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational	O
design	O
of	O
biocls	O
for	O
either	O
reducing	O
their	O
unintended	O
consequences	O
or	O
increasing	O
their	O
application	O
potentials	I-C3245505
reduced	B-C0392756
haemodynamic	B-C4042905
coupling	I-C4042905
and	O
exercise	B-C0015259
are	O
associated	B-C0332281
with	I-C0332281
vascular	B-C3178781
stiffening	I-C3178781
in	O
pulmonary	B-C2973725
arterial	I-C2973725
hypertension	I-C2973725
inadequate	B-C0205412
right	B-C0225883
ventricular	I-C0225883
rv	B-C0225883
and	O
pulmonary	B-C0034052
arterial	I-C0034052
pa	B-C0034052
functional	B-C0205245
responses	B-C0205245
to	O
exercise	B-C0015259
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	B-C2973725
arterial	I-C2973725
hypertension	I-C2973725
pah	B-C2973725
.	O
	
this	O
study	B-C2603343
combined	O
invasive	B-C0683468
catheterisation	B-C0007430
with	O
echocardiography	B-C0013516
to	O
assess	B-C1516048
rv	B-C0225883
afterload	O
,	O
rv	B-C0080311
function	I-C0080311
and	O
ventricular	B-C0018827
-	O
vascular	B-C0005847
coupling	B-C1254358
in	O
subjects	B-C0080105
with	O
pah	B-C2973725
.	O
	
twenty-six	O
subjects	B-C0080105
with	O
pah	B-C2973725
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	B-C0225808
heart	I-C0225808
catheterisation	B-C0007430
and	O
doppler	B-C0013520
echocardiography	I-C0013520
at	O
rest	B-C0035253
and	O
during	O
incremental	B-C1705117
exercise	B-C0015259
,	O
and	O
cardiac	B-C0412692
mri	I-C0412692
at	O
rest	B-C0035253
.	O
	
measurements	B-C0242485
at	O
rest	B-C0035253
included	O
basic	O
haemodynamics	B-C0019010
,	O
rv	B-C0080311
function	I-C0080311
and	O
coupling	B-C0013682
efficiency	I-C0013682
η	B-C0013682
.	O
	
measurements	B-C0242485
during	O
incremental	B-C1705117
exercise	B-C0015259
included	O
pulmonary	B-C0456261
vascular	I-C0456261
resistance	I-C0456261
z0	B-C0456261
,	O
characteristic	B-C0007185
impedance	I-C0007185
zc	B-C0007185
,	O
a	O
measure	B-C0242485
of	O
proximal	B-C0205107
pa	B-C0034052
stiffness	B-C0599949
and	O
proximal	B-C0205107
and	O
distal	B-C0205108
pa	O
compliance	O
cpa	O
.	O
	
in	O
patients	B-C0030705
with	O
pah	B-C2973725
,	O
the	O
proximal	B-C0205107
pas	B-C0034052
were	O
significantly	B-C0750502
stiffer	B-C0205400
at	O
maximum	B-C0806909
exercise	B-C0015259
zc	B-C0007185
=2	O
vs	O
1.33	O
wu	O
at	O
rest	B-C0035253
p=0	O
and	O
pa	O
compliance	O
was	O
decreased	B-C0205216
cpa	O
=0	O
vs	O
1.32	O
ml/mm	O
hg/m	O
at	O
rest	B-C0035253
p=0	O
.	O
	
z0	B-C0456261
did	O
not	O
change	O
with	O
exercise	B-C0015259
.	O
	
as	O
a	O
result	O
,	O
the	O
resistance-compliance	B-C0392762
rc	I-C0392762
time	I-C0392762
decreased	B-C0205216
with	O
exercise	B-C0015259
0.67	O
vs	O
1.00	O
s	O
at	O
rest	B-C0035253
p<10	O
.	O
	
when	O
patients	B-C0030705
were	O
grouped	O
according	O
to	O
resting	B-C0035253
coupling	B-C0013682
efficiency	I-C0013682
,	O
those	O
with	O
poorer	O
η	B-C0013682
exhibited	O
stiffer	B-C0205400
proximal	B-C0205107
pas	B-C0034052
at	O
rest	B-C0035253
,	O
a	O
lower	O
maximum	B-C0806909
exercise	B-C0015259
level	B-C0441889
,	O
and	O
more	O
limited	O
cpa	O
reduction	B-C0392756
at	O
maximum	B-C0806909
exercise	B-C0015259
.	O
	
in	O
pah	B-C2973725
,	O
exercise	B-C0015259
causes	O
proximal	B-C0205107
and	O
distal	B-C0205108
pa	B-C0034052
stiffening	B-C0599949
,	O
which	O
combined	O
with	O
preserved	O
z0	B-C0456261
results	O
in	O
decreased	B-C0205216
rc	B-C0392762
time	I-C0392762
with	O
exercise	B-C0015259
.	O
	
stiff	B-C0034052
pas	I-C0034052
at	O
rest	B-C0035253
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	B-C4042905
coupling	I-C4042905
,	O
reflecting	O
reduced	B-C0392756
pulmonary	B-C0459963
vascular	I-C0459963
reserve	O
that	O
contributes	B-C1880177
to	O
limit	O
the	O
maximum	B-C0806909
exercise	B-C0015259
level	B-C0441889
altered	B-C1138565
ph	I-C1138565
gradient	I-C1138565
at	O
the	O
plasma	B-C0007603
membrane	I-C0007603
of	O
osteosarcoma	B-C0029463
cells	B-C0007634
is	O
a	O
key	O
mechanism	B-C0441712
of	O
drug	B-C0013203
resistance	I-C0013203
current	O
therapy	B-C0087111
of	O
osteosarcoma	B-C0029463
os	B-C0029463
,	O
the	O
most	O
common	O
primary	B-C4282132
bone	I-C4282132
malignancy	I-C4282132
,	O
is	O
based	O
on	O
a	O
combination	B-C0920442
of	I-C0920442
surgery	I-C0920442
and	I-C0920442
chemotherapy	I-C0920442
.	O
	
multidrug	B-C0242640
resistance	I-C0242640
mediated	O
by	O
p-glycoprotein	B-C0242643
p-gp	B-C0242643
overexpression	B-C1514559
has	O
been	O
previously	O
associated	O
with	O
treatment	B-C0162643
failure	I-C0162643
and	O
progression	B-C0242656
of	O
os	B-C0029463
,	O
although	O
other	O
mechanisms	B-C0441712
may	O
also	O
play	O
a	O
role	O
.	O
	
we	O
considered	O
the	O
typical	O
acidic	B-C0020283
extracellular	I-C0020283
ph	I-C0020283
phe	B-C0020283
of	O
sarcomas	B-C1261473
,	O
and	O
found	O
that	O
doxorubicin	B-C0013089
dxr	B-C0013089
cytotoxicity	B-C0596402
is	O
reduced	B-C0392756
in	O
p-gp	B-C0376623
negative	O
os	B-C0029463
cells	B-C0007635
cultured	I-C0007635
at	O
phe	B-C0020283
6.5	O
compared	O
to	O
standard	O
7.4	O
.	O
	
short-time	B-C0443303
24-48	O
hours	O
exposure	B-C0332157
to	I-C0332157
low	O
phe	B-C0020283
significantly	B-C1707919
increased	I-C1707919
the	O
number	O
and	O
acidity	B-C0368606
of	O
lysosomes	B-C0024369
,	O
and	O
the	O
combination	B-C0205195
of	O
dxr	B-C0013089
with	O
omeprazole	B-C0028978
,	O
a	O
proton	B-C0358591
pump	I-C0358591
inhibitor	I-C0358591
targeting	O
lysosomal	B-C1156062
acidity	I-C1156062
,	O
significantly	B-C1707919
enhanced	I-C1707919
dxr	B-C0013089
cytotoxicity	B-C0596402
.	O
	
in	O
os	B-C0029463
xenografts	B-C0522537
,	O
the	O
combination	B-C0013218
treatment	I-C0013218
of	O
dxr	B-C0013089
and	O
omeprazole	B-C0028978
significantly	B-C3890174
reduced	I-C3890174
tumor	B-C0475276
volume	I-C0475276
and	O
body	B-C1262477
weight	I-C1262477
loss	I-C1262477
.	O
	
the	O
impaired	B-C0013221
toxicity	I-C0013221
of	O
dxr	B-C0013089
at	O
low	O
phe	B-C0020283
was	O
not	O
associated	O
with	O
increased	B-C0205217
autophagy	B-C0004391
or	O
lysosomal	B-C1156062
acidification	I-C1156062
,	O
but	O
rather	O
,	O
as	O
shown	O
by	O
snarf	B-C0084578
staining	B-C0487602
,	O
with	O
a	O
reversal	B-C0443290
of	O
the	O
ph	B-C1138565
gradient	I-C1138565
at	O
the	O
plasma	B-C0007603
membrane	I-C0007603
δphcm	B-C1138565
,	O
eventually	O
leading	O
to	O
a	O
reduced	B-C0392756
dxr	B-C0013089
intracellular	B-C0178719
accumulation	B-C4055506
.	O
	
finally	O
,	O
the	O
reversal	B-C0443290
of	O
δphcm	B-C1138565
in	O
os	B-C0029463
cells	B-C0007634
promoted	O
resistance	B-C4281815
not	O
only	O
to	O
dxr	B-C0013089
,	O
but	O
also	O
to	O
cisplatin	B-C0008838
and	O
methotrexate	B-C0025677
,	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
vincristine	B-C0042679
.	O
	
altogether	O
,	O
our	O
findings	O
show	O
that	O
,	O
in	O
os	B-C0029463
cells	B-C0007634
,	O
short-term	B-C0443303
acidosis	B-C0001122
induces	O
resistance	B-C4281815
to	O
different	O
chemotherapeutic	B-C0003392
drugs	I-C0003392
by	O
a	O
reversal	B-C0443290
of	O
δphcm	B-C1138565
,	O
suggesting	O
that	O
buffer	B-C0006353
therapies	B-C0087111
or	O
regimens	B-C2945654
including	O
proton	B-C0358591
pump	I-C0358591
inhibitors	I-C0358591
in	O
combination	B-C0205195
to	O
low	O
concentrations	B-C1446561
of	O
conventional	O
anticancer	B-C0003392
agents	I-C0003392
may	O
offer	O
novel	B-C0205314
solutions	O
to	O
overcome	B-C2983310
drug	B-C0013203
resistance	I-C0013203
.	O
	
boston	B-C1261333
keratoprosthesis	I-C1261333
type	I-C1261333
1	I-C1261333
a	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
of	O
fresh	B-C0443224
versus	O
frozen	B-C1548793
corneal	B-C0030705
donor	I-C0030705
carriers	I-C0030705
with	O
long-term	B-C0443252
follow-up	B-C1522577
to	O
compare	B-C1707455
the	O
long-term	B-C0443252
clinical	B-C1274040
outcomes	I-C1274040
of	O
fresh	B-C0443224
versus	O
frozen	B-C1548793
corneal	B-C0030705
graft	I-C0030705
carriers	I-C0030705
for	O
the	O
boston	B-C1261333
keratoprosthesis	I-C1261333
type	I-C1261333
1	I-C1261333
b-kpro	B-C1261333
.	O
	
prospective	O
,	O
single-center	O
,	O
nonblinded	B-C2986424
,	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
all	O
participants	B-C0679646
were	O
followed	O
through	O
the	O
initial	B-C0205265
study	B-C2348563
protocol	I-C2348563
of	O
24	O
months	B-C0439231
and	O
were	O
approached	O
to	O
enter	O
an	O
extension	B-C0231448
phase	B-C0205390
,	O
with	O
continuing	O
follow-up	B-C0589121
visits	I-C0589121
to	O
60	O
months	B-C0439231
.	O
	
all	O
patients	B-C0030705
undergoing	O
b-kpro	B-C0176217
surgery	I-C0176217
between	O
october	O
2008	O
and	O
december	O
2009	O
by	O
a	O
single	O
experienced	B-C0582175
surgeon	I-C0582175
at	O
the	O
centre	O
hospitalier	B-C0020028
de	I-C0020028
l'université	I-C0020028
de	I-C0020028
montréal	I-C0020028
using	O
an	O
allograft	B-C0348047
carrier	I-C0348047
were	O
considered	O
.	O
	
patients	B-C0030705
were	O
excluded	B-C2828389
if	O
they	O
had	O
previously	B-C0205156
undergone	O
b-kpro	B-C1261333
implantation	B-C0021107
.	O
	
participants	B-C0679646
were	O
randomized	B-C3815594
individually	O
to	O
receive	B-C1514756
a	O
b-kpro	B-C1261333
using	O
a	O
frozen	B-C1548793
or	O
a	O
fresh	B-C0443224
corneal	B-C0348047
graft	I-C0348047
carrier	I-C0348047
on	O
the	O
basis	O
of	O
tissue	B-C0040300
availability	B-C0470187
on	O
the	O
day	B-C0439228
of	O
surgery	B-C0543467
,	O
as	O
determined	O
by	O
the	O
local	O
eye	B-C0015394
bank	I-C0015394
.	O
	
the	O
primary	O
outcome	B-C0086749
measure	I-C0086749
was	O
device	B-C0243095
retention	I-C0243095
at	O
24	O
and	O
60	O
months	B-C0439231
.	O
	
secondary	O
outcome	O
measures	O
included	O
surgical	B-C0243095
feasibility	I-C0243095
,	O
visual	B-C0042812
acuity	I-C0042812
va	B-C0042812
,	O
and	O
complications	B-C0009566
.	O
	
thirty-seven	O
eyes	B-C0015392
of	O
37	O
patients	B-C0030705
were	O
enrolled	O
in	O
the	O
initial	B-C0205265
study	B-C2348563
protocol	I-C2348563
,	O
with	O
19	O
eyes	B-C0015392
randomized	B-C0034656
to	O
fresh	B-C0443224
and	O
18	O
to	O
frozen	B-C1548793
carrier	B-C0348047
grafts	I-C0348047
.	O
	
thirty-six	O
eyes	B-C0015392
were	O
followed	O
through	O
to	O
24	O
months	B-C0439231
,	O
with	O
1	O
lost	O
to	O
follow-up	B-C1522577
.	O
	
of	O
these	O
,	O
26	O
were	O
enrolled	O
in	O
the	O
extension	B-C0231448
11	O
eyes	B-C0015392
with	O
a	O
frozen	B-C1548793
and	O
15	O
eyes	B-C0015392
with	O
a	O
fresh	B-C0443224
carrier	B-C0348047
graft	I-C0348047
.	O
	
there	O
were	O
no	B-C3842396
differences	I-C3842396
in	O
the	O
baseline	B-C1442488
characteristics	B-C1521970
of	O
patients	B-C0030705
enrolled	O
in	O
the	O
extension	B-C0231448
phase	B-C0205390
versus	O
those	O
who	O
were	O
not	O
.	O
	
at	O
60	O
months	B-C0439231
,	O
median	O
corrected	O
distance	O
va	B-C0042812
in	O
the	O
fresh	B-C0441833
group	I-C0441833
had	O
improved	B-C0184511
to	O
20/150	O
from	O
a	O
baseline	B-C1442488
of	O
counting	O
fingers	O
,	O
whereas	O
the	O
frozen	B-C0441833
group	I-C0441833
improved	B-C0184511
to	O
20/400	O
from	O
a	O
baseline	B-C1442488
of	O
hand	O
motions	O
.	O
	
device	B-C0243095
retention	I-C0243095
was	O
100%	O
at	O
24	O
months	B-C0439231
and	O
96%	O
at	O
60	O
months	B-C0439231
.	O
	
there	O
were	O
no	O
significant	O
differences	B-C1705242
in	O
the	O
rate	B-C1521828
of	O
complications	B-C0009566
between	O
groups	B-C0441833
.	O
	
fresh	B-C0443224
and	O
frozen	B-C1548793
corneal	B-C0524358
donors	I-C0524358
offer	O
similar	O
clinical	B-C1274040
outcomes	I-C1274040
when	O
used	O
as	O
carriers	B-C0348047
for	O
the	O
b-kpro	B-C1261333
,	O
with	O
no	O
significant	O
differences	B-C1705242
in	O
device	B-C0243095
retention	I-C0243095
,	O
visual	B-C0243095
rehabilitation	I-C0243095
,	O
or	O
rates	B-C1521828
of	O
complications	B-C0009566
at	O
24	O
or	O
60	O
impact	B-C4049986
of	O
an	O
educational	B-C0281163
intervention	I-C0281163
to	O
improve	B-C0184511
antibiotic	B-C0003232
prescribing	B-C2239117
for	O
nurse	B-C0028657
practitioners	I-C0028657
in	O
a	O
pediatric	B-C0008059
urgent	B-C1710587
care	I-C1710587
center	I-C1710587
up	O
to	O
21%	O
of	O
pediatric	B-C1444717
visits	I-C1444717
result	O
in	O
an	O
antibiotic	B-C0003232
prescription	B-C0033080
,	O
and	O
a	O
large	O
portion	O
of	O
these	O
are	O
unnecessary	O
.	O
	
to	O
determine	O
if	O
educational	B-C1276369
sessions	I-C1276369
would	O
reduce	B-C0392756
inappropriate	B-C1548788
antibiotic	B-C0003232
use	B-C0457083
.	O
	
intervention	B-C1096775
study	I-C1096775
evaluating	B-C0220825
antibiotic	B-C0003232
prescribing	B-C2239117
following	O
educational	B-C1276369
sessions	I-C1276369
for	O
urinary	B-C0042029
tract	I-C0042029
infection	I-C0042029
,	O
skin	B-C0037278
and	O
soft	B-C0149778
tissue	I-C0149778
infection	I-C0149778
,	O
pharyngitis	B-C0031350
,	O
upper	B-C0041912
respiratory	I-C0041912
tract	I-C0041912
infection	I-C0041912
,	O
acute	B-C0271429
otitis	I-C0271429
media	I-C0271429
,	O
and	O
acute	B-C0275556
bacterial	I-C0275556
sinusitis	I-C0275556
.	O
	
a	O
total	O
of	O
26	O
out	O
of	O
43	O
60%	O
nurse	B-C0028657
practitioners	I-C0028657
in	O
4	O
urgent	B-C1710587
care	I-C1710587
centers	I-C1710587
were	O
enrolled	B-C1516879
in	O
the	O
study	B-C2603343
.	O
	
the	O
rate	B-C1521828
of	O
inappropriate	B-C1548788
antibiotic	B-C0003232
use	B-C0457083
among	O
all	O
conditions	O
was	O
10%	O
before	O
and	O
8%	O
after	O
the	O
intervention	B-C0184661
p	O
=	O
02	O
.	O
	
a	O
decrease	B-C0547047
in	O
inappropriate	B-C1548788
antibiotic	B-C0003232
prescribing	B-C2239117
was	O
seen	O
after	O
the	O
educational	B-C1276369
session	I-C1276369
p	O
<	O
01	O
.	O
	
the	O
most	O
common	O
reasons	O
for	O
inappropriate	B-C1548788
antibiotic	B-C0003232
prescribing	B-C2239117
were	O
too	O
broad	O
41%	O
,	O
wrong	B-C3845820
dosage	I-C3845820
22%	O
,	O
and	O
not	B-C1444655
indicated	I-C1444655
17%	O
.	O
	
educational	B-C1276369
sessions	I-C1276369
led	O
to	O
improvement	B-C2986411
in	O
overall	O
inappropriate	B-C1548788
antibiotic	B-C0003232
use	B-C0457083
.	O
	
additional	O
stewardship	B-C1554086
interventions	B-C0184661
are	O
needed	O
to	O
further	O
reduce	B-C0392756
unnecessary	O
antibiotic	B-C0003232
use	B-C0457083
.	O
	
zika	B-C0318793
virus	I-C0318793
disrupts	B-C0332454
phospho-tbk1	B-C1449326
localization	B-C1159772
and	O
mitosis	B-C0026255
in	O
human	B-C0086418
neuroepithelial	B-C1518280
stem	B-C0038250
cells	I-C0038250
and	O
radial	B-C3661481
glia	I-C3661481
the	O
mechanisms	B-C0441712
underlying	O
zika	B-C0318793
virus	I-C0318793
zikv	B-C0318793
microcephaly	B-C0025958
and	O
other	O
neurodevelopment	B-C0599855
defects	B-C1457869
remain	O
poorly	B-C0205169
understood	B-C0162340
.	O
	
here	O
,	O
we	O
describe	O
the	O
derivation	B-C1441547
and	O
characterization	B-C1880022
,	O
including	O
single-cell	B-C0162327
rna-seq	I-C0162327
,	O
of	O
neocortical	B-C0175173
and	O
spinal	B-C0037925
cord	I-C0037925
neuroepithelial	B-C1518280
stem	B-C0038250
nes	I-C0038250
cells	I-C0038250
to	O
model	O
early	B-C1279919
human	B-C0086418
neurodevelopment	B-C0599855
and	O
zikv	B-C0318793
-related	O
neuropathogenesis	B-C1518296
.	O
	
by	O
analyzing	O
human	B-C0086418
nes	B-C0038250
cells	I-C0038250
,	O
organotypic	B-C0205556
fetal	B-C0015965
brain	B-C0006104
slices	B-C1519355
,	O
and	O
a	O
zikv	B-C0318793
-	O
infected	B-C0439663
micrencephalic	B-C0025958
brain	B-C0006104
,	O
we	O
show	O
that	O
zikv	B-C0318793
infects	B-C0439663
both	O
neocortical	B-C0175173
and	O
spinal	B-C0037925
nes	B-C0038250
cells	I-C0038250
as	O
well	O
as	O
their	O
fetal	B-C0015965
homolog	O
,	O
radial	B-C3661481
glial	I-C3661481
cells	I-C3661481
rgcs	B-C3661481
,	O
causing	O
disrupted	B-C0332454
mitoses	B-C0026255
,	O
supernumerary	B-C1883702
centrosomes	B-C0242608
,	O
structural	B-C0678594
disorganization	B-C4061689
,	O
and	O
cell	B-C0007587
death	I-C0007587
.	O
	
zikv	B-C0276289
infection	I-C0276289
of	O
nes	B-C0038250
cells	I-C0038250
and	O
rgcs	B-C3661481
causes	O
centrosomal	B-C0242608
depletion	B-C0333668
and	O
mitochondrial	B-C0026237
sequestration	B-C0443301
of	O
phospho-tbk1	B-C1449326
during	O
mitosis	B-C0026255
.	O
	
we	O
also	O
found	O
that	O
nucleoside	B-C1579410
analogs	I-C1579410
inhibit	B-C3463820
zikv	B-C0318793
replication	B-C0042774
in	O
nes	B-C0038250
cells	I-C0038250
,	O
protecting	O
them	O
from	O
zikv	B-C0318793
-	O
induced	B-C0205263
ptbk1	B-C1449326
relocalization	B-C0007613
and	O
cell	B-C0007587
death	I-C0007587
.	O
	
we	O
established	B-C0443211
a	O
model	B-C3161035
system	I-C3161035
of	O
human	B-C0086418
neural	B-C1113654
stem	I-C1113654
cells	I-C1113654
to	O
reveal	O
cellular	B-C0007634
and	O
molecular	B-C1521991
mechanisms	B-C0441712
underlying	O
neurodevelopmental	B-C0599855
defects	B-C1457869
associated	B-C0332281
with	I-C0332281
zikv	B-C0276289
infection	I-C0276289
and	O
its	O
potential	B-C3245505
treatment	B-C0087111
.	O
	
prevalence	B-C0033105
of	O
hpv	B-C0021344
genotypes	B-C0017431
in	O
cervical	B-C0279672
adenocarcinoma	I-C0279672
a	O
study	B-C2603343
in	O
greek	B-C0337806
women	B-C0043210
to	O
study	B-C2603343
the	O
prevalence	B-C0033105
of	O
human	B-C0021344
papillomavirus	I-C0021344
hpv	B-C0021344
genotypes	B-C0017431
among	O
cervical	B-C0279672
adenocarcinomas	I-C0279672
in	O
greek	B-C0337806
women	B-C0043210
.	O
	
the	O
study	B-C0681860
group	I-C0681860
comprised	O
78	O
adenocarcinoma	B-C0001418
cases	B-C1706256
20	O
in	B-C0007099
situ	I-C0007099
and	O
58	O
invasive	B-C1334274
.	O
	
hpv	B-C3872595
dna	I-C3872595
was	O
amplified	B-C0683230
using	O
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
pcr	B-C0032520
and	O
hpv	B-C0021344
genotypes	B-C0017431
were	O
identified	B-C0205396
by	O
reverse	B-C0221902
hybridization	I-C0221902
.	O
	
there	O
was	O
a	O
high	B-C0033105
prevalence	I-C0033105
of	O
hpv	B-C0343641
infection	I-C0343641
both	O
for	O
in	B-C0007099
situ	I-C0007099
95%	O
or	O
invasive	B-C1334274
94.83	I-C1334274
adenocarcinomas	I-C1334274
,	O
comprising	O
also	O
cancers	B-C0006826
of	O
unusual	B-C0332437
morphology	I-C0332437
.	O
	
hpv	B-C0999806
16	I-C0999806
was	O
the	O
commonest	B-C0205214
strain	B-C1518614
n=57	O
,	O
73.08	O
followed	O
by	O
hpv	B-C0999807
18	I-C0999807
n=28	O
,	O
35.90	O
.	O
	
interestingly	O
,	O
13	O
cases	B-C1706256
16.67	O
were	O
also	O
hpv	B-C3641016
52	I-C3641016
positive	I-C3641016
as	O
co-infection	B-C0275524
with	O
hpv	B-C0999806
16	I-C0999806
or	O
18	B-C0999807
.	O
	
all	O
other	O
strains	B-C1518614
with	O
the	O
exception	B-C1705847
of	O
hpv	B-C3641020
66	I-C3641020
were	O
found	O
only	O
as	O
co-infections	B-C0275524
.	O
	
no	O
significant	O
age	B-C0699810
difference	I-C0699810
was	O
noted	O
in	O
terms	O
of	O
any	O
hpv	B-C0021344
strain	B-C1518614
positivity	B-C1446409
.	O
	
hpv	B-C3872595
dna	I-C3872595
was	O
found	O
in	O
the	O
large	B-C0680220
majority	I-C0680220
of	O
cervical	B-C0279672
adenocarcinomas	I-C0279672
.	O
	
as	O
opposed	O
to	O
other	O
studies	B-C0008972
,	O
hpv	B-C3641016
52	I-C3641016
was	O
the	O
third	O
most	O
commonly	B-C0205214
encountered	B-C0422301
strain	B-C1518614
after	O
hpv	B-C0999806
16	I-C0999806
and	O
hpv	B-C0999807
18	I-C0999807
.	O
	
the	O
above	O
findings	O
would	O
probably	O
be	O
of	O
help	B-C1269765
in	O
decision	B-C0011109
making	I-C0011109
concerning	O
vaccination	B-C0042196
policy	B-C0242456
for	O
the	O
prevention	B-C2700409
of	O
hpv	B-C0343641
infection	I-C0343641
in	O
glucose	B-C0596620
metabolism	I-C0596620
-	O
weighted	B-C0011923
imaging	I-C0011923
with	O
chemical	B-C0024485
exchange-sensitive	I-C0024485
mri	I-C0024485
of	O
2-deoxyglucose	B-C4049845
2dg	B-C4049845
in	O
brain	B-C0006104
sensitivity	B-C1511883
and	O
biological	B-C0205460
sources	B-C0449416
recent	B-C2603343
proof-of-principle	I-C2603343
studies	I-C2603343
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	B-C0243144
and	O
metabolism	B-C0025519
of	O
non-labeled	O
2-deoxy-d-glucose	B-C4049845
2dg	B-C4049845
by	O
a	O
chemical	B-C0024485
exchange-sensitive	I-C0024485
spin-lock	I-C0024485
cesl	I-C0024485
mri	I-C0024485
approach	I-C0024485
.	O
	
in	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach	O
,	O
we	O
performed	O
dynamic	B-C0729333
in	B-C1515655
vivo	I-C1515655
cesl	B-C0024485
mri	I-C0024485
on	O
healthy	B-C3898900
rat	B-C0086893
brains	B-C0006104
with	O
an	O
intravenous	B-C0021494
injection	I-C0021494
of	O
2dg	B-C4049845
under	O
various	O
conditions	O
at	O
9.4t	O
.	O
	
for	O
three	O
2dg	B-C4049845
doses	B-C0178602
of	O
0.25	O
,	O
0.5	O
and	O
1g/kg	O
,	O
we	O
found	O
that	O
2dg	B-C4049845
-	O
cesl	B-C0024485
signals	B-C1710082
increased	B-C0205217
linearly	O
with	O
injection	B-C1533685
dose	B-C0178602
at	O
the	O
initial	O
<20min	O
but	O
not	O
the	O
later	O
period	O
>40min	O
suggesting	O
time-dependent	O
differential	O
weightings	O
of	O
2dg	B-C4049845
transport	B-C0005528
and	O
metabolism	B-C0025519
.	O
	
remaining	O
2dg	B-C4049845
-	O
cesl	B-C0024485
studies	O
were	O
performed	O
with	O
0.25g	O
2dg	B-C4049845
.	O
	
since	O
a	O
higher	B-C0205250
isoflurane	B-C0022180
level	B-C0441889
reduces	B-C0392756
glucose	B-C0596620
metabolism	I-C0596620
and	O
increases	B-C0442805
blood	B-C0232338
flow	I-C0232338
,	O
2dg	B-C4049845
-	O
cesl	B-C0024485
was	O
measured	B-C0444706
under	O
0.5	O
,	O
1.5	O
and	O
2.2	O
isoflurane	B-C0022180
.	O
	
the	O
2dg	B-C4049845
-	O
cesl	B-C0024485
signal	B-C1710082
was	O
reduced	B-C0392756
at	O
higher	B-C0205250
isoflurane	B-C0022180
levels	O
correlating	O
well	O
with	O
the	O
2dg	B-C4049845
phosphorylation	B-C0031715
in	O
the	O
intracellular	B-C0682581
space	I-C0682581
.	O
	
to	O
detect	O
regional	B-C0086833
heterogeneities	I-C0086833
of	O
glucose	B-C0596620
metabolism	I-C0596620
,	O
2dg	B-C4049845
-	O
cesl	B-C0024485
with	O
0.33	O
resolution	O
was	O
obtained	O
,	O
which	O
indeed	O
showed	O
a	O
higher	B-C0205250
response	O
in	O
the	O
cortex	B-C0007776
compared	O
to	O
the	O
corpus	B-C0010090
callosum	I-C0010090
.	O
	
lastly	O
,	O
unlike	O
cesl	B-C0024485
mri	I-C0024485
with	O
the	O
injection	B-C1533685
of	O
non-transportable	B-C0024730
mannitol	I-C0024730
,	O
the	O
2dg	B-C4049845
-	O
cesl	B-C0024485
response	O
decreased	B-C0205216
with	O
an	O
increased	B-C0205217
spin-lock	B-C3854080
pulse	I-C3854080
power	I-C3854080
confirming	O
that	O
2dg	B-C4049845
-	O
cesl	B-C0024485
is	O
dominated	O
by	O
chemical	B-C0220806
exchange	B-C4019011
processes	B-C1522240
in	O
the	O
extravascular	B-C1254362
space	I-C1254362
.	O
	
taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
2dg	B-C4049845
-	O
cesl	B-C0024485
mri	I-C0024485
signals	B-C1710082
mainly	O
indicate	O
glucose	B-C0178666
transport	I-C0178666
and	O
metabolism	B-C0596620
and	O
may	O
be	O
a	O
useful	O
biomarker	B-C0005516
for	O
metabolic	B-C0311400
studies	B-C2603343
of	O
normal	B-C0006104
and	O
diseased	B-C0012634
brains	B-C0006104
.	O
	
parental	B-C0030551
perceptions	B-C0030971
of	O
children	B-C0237463
agency	I-C0237463
parental	B-C0814578
warmth	I-C0814578
,	O
school	B-C0700132
achievement	I-C0700132
and	O
adjustment	B-C0376209
the	O
present	O
study	B-C2603343
examined	O
swedish	B-C1710263
mothers'	B-C0026591
and	O
fathers'	B-C0015671
warmth	B-C0814578
towards	O
their	O
children	B-C0008059
in	O
relation	O
to	O
their	O
children	B-C0237463
agency	I-C0237463
.	O
	
it	O
also	O
examined	O
the	O
longitudinal	O
relation	O
between	O
agency	B-C0237463
and	O
children's	B-C0008059
externalizing	O
,	O
internalizing	O
,	O
and	O
school	B-C0700132
achievement	I-C0700132
.	O
	
swedish	B-C1710263
children's	B-C0008059
mothers	B-C0026591
and	O
fathers	B-C0015671
n	O
=	O
103	O
were	O
interviewed	B-C0021822
at	O
three	O
time	B-C1442880
points	I-C1442880
when	O
children	B-C0008059
were	O
8	O
,	O
9	O
,	O
and	O
10	O
years	B-C0439234
old	O
about	O
their	O
warmth	B-C0814578
towards	O
their	O
children	B-C0008059
,	O
children's	B-C0237463
agency	I-C0237463
,	O
and	O
children's	B-C0008059
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
school	B-C0700132
achievement	I-C0700132
.	O
	
parental	B-C0814578
warmth	I-C0814578
at	O
time	B-C0040223
1	O
was	O
significantly	O
correlated	B-C1707520
with	O
child	B-C0237463
agency	I-C0237463
at	O
time	B-C0040223
2	O
,	O
which	O
was	O
significantly	O
correlated	B-C1707520
with	O
child	B-C0008059
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
academic	B-C0700132
achievement	I-C0700132
at	O
time	B-C0040223
3	O
.	O
	
there	O
were	O
no	O
differences	O
between	O
girls	B-C0870604
and	O
boys	B-C0870221
.	O
	
results	O
from	O
this	O
study	B-C2603343
indicate	O
that	O
swedish	B-C1710263
parents'	B-C0814578
warmth	I-C0814578
is	O
directly	O
related	O
to	O
subsequent	O
perceptions	B-C0030971
of	O
children's	B-C0237463
agency	I-C0237463
,	O
which	O
in	O
turn	O
are	O
related	O
to	O
subsequently	O
lower	O
child	B-C0008059
externalizing	O
and	O
internalizing	O
problems	B-C0033213
and	O
higher	O
academic	B-C0700132
achievement	I-C0700132
.	O
	
these	O
findings	B-C0243095
held	O
in	O
the	O
context	O
of	O
a	O
three-	O
year	B-C0439234
longitudinal	B-C0023981
study	I-C0023981
and	O
for	O
both	O
boys	B-C0870221
and	O
girls	B-C0870604
,	O
suggesting	O
the	O
importance	O
of	O
child	B-C0237463
agency	I-C0237463
in	O
the	O
link	O
between	O
parental	B-C0814578
warmth	I-C0814578
and	O
children's	B-C0008059
adjustment	B-C0376209
.	O
	
vasopressin	B-C0042413
regulates	B-C0596286
the	I-C0596286
growth	I-C0596286
of	O
the	O
biliary	B-C3686472
epithelium	I-C3686472
in	O
polycystic	B-C0158683
liver	I-C0158683
disease	I-C0158683
the	O
neurohypophysial	B-C0032017
hormone	I-C0032017
arginine	B-C0003779
vasopressin	I-C0003779
avp	B-C0003779
acts	O
by	O
three	O
distinct	O
receptor	B-C0597357
subtypes	O
v1a	B-C0284725
,	O
v1b	B-C0284726
,	O
and	O
v2	B-C0162829
.	O
	
in	O
the	O
liver	B-C0023884
,	O
avp	B-C0003779
is	O
involved	B-C1314939
in	O
ureogenesis	B-C0597619
,	O
glycogenolysis	B-C0596624
,	O
neoglucogenesis	B-C0598530
and	O
regeneration	B-C0034963
.	O
	
no	O
data	O
exist	O
about	O
the	O
presence	B-C0150312
of	O
avp	B-C0003779
in	O
the	O
biliary	B-C3686472
epithelium	I-C3686472
.	O
	
cholangiocytes	B-C3686472
are	O
the	O
target	B-C0221284
cells	I-C0221284
in	O
a	O
number	O
of	O
animal	B-C0012644
models	I-C0012644
of	O
cholestasis	B-C0008370
,	O
including	O
bile	B-C0005400
duct	I-C0005400
ligation	B-C0023690
bdl	B-C0023690
,	O
and	O
in	O
several	O
human	B-C0086418
pathologies	B-C0030664
,	O
such	O
as	O
polycystic	B-C0158683
liver	I-C0158683
disease	I-C0158683
characterized	B-C1880022
by	O
the	O
presence	B-C0150312
of	O
cysts	B-C0010709
that	O
bud	O
from	O
the	O
biliary	B-C3686472
epithelium	I-C3686472
.	O
	
in	B-C1515655
vivo	I-C1515655
,	O
liver	B-C0023884
fragments	B-C0486805
from	O
normal	O
and	O
bdl	B-C0023690
mice	B-C0025929
and	O
rats	B-C0034721
as	O
well	O
as	O
liver	B-C0586689
samples	I-C0586689
from	O
normal	O
and	O
adpkd	B-C0085413
patients	B-C0030705
were	O
collected	O
to	O
evaluate	O
i	O
intrahepatic	B-C1512948
bile	B-C0005400
duct	I-C0005400
mass	B-C0577559
by	O
immunohistochemistry	B-C0021044
for	O
cytokeratin-19	B-C0010803
and	O
ii	O
expression	B-C0597360
of	O
v1a	B-C0284725
,	O
v1b	B-C0284726
and	O
v2	B-C0162829
by	O
immunohistochemistry	B-C0021044
,	O
immunofluorescence	B-C0079603
and	O
real-time	B-C1709846
pcr	I-C1709846
.	O
	
in	B-C1533691
vitro	I-C1533691
,	O
small	O
and	O
large	O
mouse	B-C0025929
cholangiocytes	B-C3686472
,	O
h69	B-C0007634
non-malignant	B-C1518371
human	B-C0086418
cholangiocytes	B-C3686472
and	O
lcde	B-C0007634
human	B-C0086418
cholangiocytes	B-C3686472
from	O
the	O
cystic	B-C0259770
epithelium	I-C0259770
were	O
stimulated	B-C0038337
with	O
vasopressin	B-C0042413
in	O
the	O
absence/	O
presence	B-C0150312
of	O
avp	B-C1719946
antagonists	I-C1719946
such	O
as	O
opc-31260	B-C0171458
and	O
tolvaptan	B-C1176308
,	O
before	O
assessing	O
cellular	B-C0007595
growth	I-C0007595
by	O
mtt	B-C0201596
assay	I-C0201596
and	O
camp	B-C0001455
levels	O
.	O
	
cholangiocytes	B-C3686472
express	O
v2	B-C0162829
receptor	I-C0162829
that	O
was	O
upregulated	B-C0041904
following	O
bdl	B-C0023690
and	O
in	O
adpkd	B-C0085413
liver	B-C0586689
samples	I-C0586689
.	O
	
administration	B-C1533734
of	O
avp	B-C0003779
increased	B-C0205217
proliferation	B-C0596290
and	O
camp	B-C0001455
levels	O
of	O
small	O
cholangiocytes	B-C3686472
and	O
lcde	B-C0007634
cells	I-C0007634
.	O
	
we	O
found	O
no	B-C1301751
effect	I-C1301751
in	O
the	O
proliferation	B-C0596290
of	O
large	O
mouse	B-C0025929
cholangiocytes	B-C3686472
and	O
h69	B-C0007634
cells	I-C0007634
.	O
	
increases	B-C0442805
were	O
blocked	B-C0332206
by	O
preincubation	B-C1441618
with	O
the	O
avp	B-C1719946
antagonists	I-C1719946
.	O
	
these	O
results	B-C1274040
showed	O
that	O
avp	B-C0003779
and	O
its	O
receptors	B-C0597357
may	O
be	O
important	O
in	O
the	O
modulation	B-C0544633
of	O
the	O
proliferation	B-C0812425
rate	I-C0812425
of	O
the	O
biliary	B-C3686472
epithelium	I-C3686472
.	O
	
central	B-C1720164
corneal	I-C1720164
thickness	I-C1720164
reproducibility	B-C0035149
among	O
ten	O
different	O
instruments	B-C1518597
to	O
assess	B-C0184514
agreement	O
between	O
one	O
ultrasonic	B-C1875843
us	B-C1875843
and	O
nine	O
optical	B-C1518597
instruments	I-C1518597
for	O
the	O
measurement	B-C0242485
of	O
central	B-C1720164
corneal	I-C1720164
thickness	I-C1720164
cct	B-C1720164
,	O
and	O
to	O
evaluate	B-C0220825
intra-	B-C0035149
and	I-C0035149
inter-operator	I-C0035149
reproducibility	I-C0035149
.	O
	
in	O
this	O
observational	O
cross-sectional	B-C0010362
study	I-C0010362
,	O
two	O
masked	O
operators	O
measured	O
cct	B-C1720164
thickness	O
twice	O
in	O
28	O
healthy	B-C3898900
eyes	B-C0015392
.	O
	
we	O
used	O
seven	O
spectral-domain	B-C3876157
optical	I-C3876157
coherence	I-C3876157
tomography	I-C3876157
sd-oct	I-C3876157
devices	I-C3876157
,	O
one	B-C4052697
time-domain	I-C4052697
oct	I-C4052697
,	O
one	O
scheimpflug	B-C0179543
camera	I-C0179543
,	O
and	O
one	O
us-based	B-C1875843
instrument	I-C1875843
.	O
	
inter-	B-C1514863
and	I-C1514863
intra-operator	I-C1514863
reproducibility	I-C1514863
was	O
evaluated	B-C0220825
by	O
intraclass	B-C0010100
correlation	I-C0010100
coefficient	I-C0010100
icc	B-C0010100
,	O
coefficient	B-C0681921
of	I-C0681921
variation	I-C0681921
cv	B-C0681921
,	O
and	O
bland-altman	B-C0870616
test	I-C0870616
analysis	B-C0936012
.	O
	
instrument	B-C0348000
-to-	O
instrument	B-C0348000
reproducibility	B-C0035149
was	O
determined	O
by	O
anova	B-C0002780
for	O
repeated	O
measurements	O
.	O
	
we	O
also	O
tested	B-C0039593
how	O
the	O
devices	B-C0025080
disagreed	O
regarding	O
systemic	B-C0205373
bias	B-C0242568
and	O
random	B-C0439605
error	B-C0743559
using	O
a	O
structural	B-C0681947
equation	I-C0681947
model	I-C0681947
.	O
	
mean	O
cct	B-C1720164
of	O
all	O
instruments	B-C0348000
ranged	O
from	O
536	O
42	O
μm	O
to	O
577	O
40	O
μm	O
.	O
	
an	O
instrument	B-C0348000
-to-	O
instrument	B-C0348000
correlation	B-C1707521
test	I-C1707521
showed	O
high	B-C0205250
values	B-C0042295
among	O
the	O
10	O
investigated	B-C1292732
devices	B-C0025080
correlation	B-C0010100
coefficient	I-C0010100
range	B-C1514721
0.852	O
p	B-C1709380
values	I-C1709380
<0	O
in	O
all	O
cases	O
.	O
	
the	O
highest	O
correlation	O
coefficient	O
values	O
were	O
registered	O
between	O
3d	O
oct-2000	O
topcon-spectral	B-C1518597
oct/slo	I-C1518597
opko	I-C1518597
0.995	O
and	O
cirrus	B-C1518597
hd-oct	I-C1518597
zeiss-rs-3000	I-C1518597
nidek	I-C1518597
0.995	O
,	O
whereas	O
the	O
lowest	O
were	O
seen	O
between	O
ss-1000	B-C1518597
casia	I-C1518597
and	O
spectral	B-C1518597
oct/slo	I-C1518597
opko	I-C1518597
0.852	O
.	O
	
icc	B-C0010100
and	O
cv	B-C0681921
showed	O
excellent	O
inter-	B-C1514863
and	I-C1514863
intra-operator	I-C1514863
reproducibility	I-C1514863
for	O
all	O
optic	B-C0029144
-based	O
devices	B-C0025080
,	O
except	O
for	O
the	O
us	B-C1875843
-based	O
device	B-C0025080
.	O
	
bland-altman	B-C0870616
analysis	B-C0936012
demonstrated	O
low	O
mean	O
biases	B-C0242568
between	O
operators	O
.	O
	
despite	O
highlighting	O
good	O
intra-	B-C1514863
and	I-C1514863
inter-operator	I-C1514863
reproducibility	I-C1514863
,	O
we	O
found	O
that	O
a	O
scale	B-C0349674
bias	B-C0242568
between	O
instruments	B-C0348000
might	O
interfere	B-C0521102
with	I-C0521102
thorough	O
cct	B-C1720164
monitoring	B-C1283169
.	O
	
we	O
suggest	O
that	O
optimal	B-C2698651
monitoring	B-C1283169
is	O
achieved	O
with	O
the	O
same	O
operator	O
and	O
the	O
same	O
predictors	B-C2698872
of	O
neurologic	B-C0006110
and	O
nonneurologic	B-C1306577
death	I-C1306577
in	O
patients	B-C0030705
with	O
brain	B-C0220650
metastasis	I-C0220650
initially	O
treated	B-C1522326
with	O
upfront	B-C0085203
stereotactic	I-C0085203
radiosurgery	I-C0085203
without	O
whole-brain	B-C1520143
radiation	I-C1520143
therapy	I-C1520143
in	O
this	O
study	B-C2603343
we	O
attempted	O
to	O
discern	O
the	O
factors	B-C1521761
predictive	B-C0681890
of	O
neurologic	B-C0006110
death	I-C0006110
in	O
patients	B-C0030705
with	O
brain	B-C0220650
metastasis	I-C0220650
treated	B-C1522326
with	O
upfront	B-C0085203
stereotactic	I-C0085203
radiosurgery	I-C0085203
srs	B-C0085203
without	O
whole	B-C1520143
brain	I-C1520143
radiation	I-C1520143
therapy	I-C1520143
wbrt	B-C1520143
while	O
accounting	O
for	O
the	O
competing	B-C0035647
risk	I-C0035647
of	O
nonneurologic	B-C1306577
death	I-C1306577
.	O
	
we	O
performed	O
a	O
retrospective	B-C1514923
single-institution	B-C2607850
analysis	B-C0936012
of	O
patients	B-C0030705
with	O
brain	B-C0220650
metastasis	I-C0220650
treated	B-C1522326
with	O
upfront	O
srs	B-C0085203
without	O
wbrt	B-C1520143
.	O
	
competing	B-C0814767
risks	I-C0814767
analysis	I-C0814767
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard	B-C2985465
ratios	I-C2985465
hrs	B-C2985465
for	O
neurologic	B-C0006110
and	O
nonneurologic	B-C1306577
death	I-C1306577
for	O
predictor	B-C2698872
variables	O
of	O
interest	O
.	O
	
of	O
738	O
patients	B-C0030705
treated	B-C1522326
with	O
upfront	B-C0085203
srs	I-C0085203
alone	O
,	O
neurologic	B-C0006110
death	I-C0006110
occurred	O
in	O
226	O
30.6	O
,	O
while	O
nonneurologic	B-C1306577
death	I-C1306577
occurred	O
in	O
309	O
41.9	O
.	O
	
multivariate	B-C0026777
competing	I-C0026777
risks	I-C0026777
analysis	I-C0026777
identified	O
an	O
increased	B-C0205217
hazard	B-C2985465
of	O
neurologic	B-C0006110
death	I-C0006110
associated	O
with	O
diagnosis-specific	B-C0282574
graded	I-C0282574
prognostic	I-C0282574
assessment	I-C0282574
ds-gpa	B-C0282574
2	O
p	O
=	O
005	O
,	O
melanoma	B-C0025202
histology	B-C0344441
p	O
=	O
009	O
,	O
and	O
increased	B-C0205217
number	O
of	O
brain	B-C0220650
metastases	I-C0220650
p<	O
,	O
while	O
there	O
was	O
a	O
decreased	B-C0205216
hazard	B-C2985465
associated	O
with	O
higher	O
srs	B-C0085203
dose	B-C0178602
p	O
=	O
004	O
.	O
	
targeted	B-C1254351
agents	I-C1254351
were	O
associated	O
with	O
a	O
decreased	B-C0205216
hr	B-C2985465
of	O
neurologic	B-C0006110
death	I-C0006110
in	O
the	O
first	O
1.5	O
years	B-C0439234
p	O
=	O
04	O
but	O
not	O
afterwards	O
.	O
	
an	O
increased	B-C0205217
hazard	B-C2985465
of	O
nonneurologic	B-C1306577
death	I-C1306577
was	O
seen	O
with	O
increasing	O
age	B-C0001779
p	O
=	O
,	O
nonmelanoma	B-C0344441
histology	I-C0344441
p<	O
,	O
presence	O
of	O
extracranial	B-C0012634
disease	I-C0012634
p<	O
,	O
and	O
progressive	B-C0205329
systemic	B-C0442893
disease	I-C0442893
p	O
=	O
.	O
	
melanoma	B-C0025202
,	O
ds-gpa	B-C0282574
,	O
number	B-C0237753
of	O
brain	B-C0220650
metastases	I-C0220650
,	O
and	O
srs	B-C0085203
dose	B-C0178602
are	O
predictive	B-C0681890
of	O
neurologic	B-C0006110
death	I-C0006110
,	O
while	O
age	B-C0001779
,	O
nonmelanoma	B-C0344441
histology	I-C0344441
,	O
and	O
more	O
advanced	O
systemic	B-C0442893
disease	I-C0442893
are	O
predictive	B-C0681890
of	O
nonneurologic	B-C1306577
death	I-C1306577
.	O
	
targeted	B-C1254351
agents	I-C1254351
appear	O
to	O
delay	B-C0205421
neurologic	B-C0006110
death	I-C0006110
.	O
	
pharmacological	B-C0007992
actions	I-C0007992
of	O
glucagon-like	B-C0061355
peptide-1	I-C0061355
,	O
gastric	B-C0017132
inhibitory	I-C0017132
polypeptide	I-C0017132
,	O
and	O
glucagon	B-C0017687
glucagon	B-C0017687
family	I-C0017687
of	O
peptide	B-C0597192
hormones	I-C0597192
is	O
a	O
group	O
of	O
structurally	O
related	O
brain-gut	B-C0030956
peptides	I-C0030956
that	O
exert	O
their	O
pleiotropic	B-C2936488
actions	I-C2936488
through	O
interactions	B-C0596610
with	O
unique	B-C0008902
members	I-C0008902
of	I-C0008902
class	I-C0008902
b1	I-C0008902
g	B-C0682972
protein-coupled	I-C0682972
receptors	I-C0682972
gpcrs	B-C0682972
.	O
	
they	O
are	O
key	O
regulators	B-C1704735
of	O
hormonal	B-C0458083
homeostasis	B-C0019868
and	O
are	O
important	O
drug	B-C0085104
targets	I-C0085104
for	O
metabolic	B-C0025517
disorders	I-C0025517
such	O
as	O
type-2	B-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
t2dm	B-C0011860
,	O
obesity	B-C0028754
,	O
and	O
dysregulations	B-C0027765
of	I-C0027765
the	I-C0027765
nervous	I-C0027765
systems	I-C0027765
such	O
as	O
migraine	B-C0149931
,	O
anxiety	B-C0003469
,	O
depression	B-C0011570
,	O
neurodegeneration	B-C0027746
,	O
psychiatric	B-C0004936
disorders	I-C0004936
,	O
and	O
cardiovascular	B-C0007222
diseases	I-C0007222
.	O
	
the	O
current	O
review	O
aims	O
to	O
provide	O
a	O
detailed	O
overview	B-C0814812
of	O
the	O
current	O
understanding	O
of	O
the	O
pharmacological	B-C0007992
actions	I-C0007992
and	O
therapeutic	B-C0087111
advances	I-C0087111
of	O
three	O
members	O
within	O
this	O
family	O
including	O
glucagon-like	B-C0061355
peptide-1	I-C0061355
glp-1	B-C0061355
,	O
gastric	B-C0017132
inhibitory	I-C0017132
polypeptide	I-C0017132
gip	B-C0017132
,	O
and	O
endemic	B-C1254362
hydrothermal	B-C3178903
vent	I-C3178903
species	B-C1705920
identified	B-C0205396
in	O
the	O
open	O
ocean	B-C1547972
seed	B-C4042839
bank	I-C4042839
hydrothermal	B-C3178903
vent	I-C3178903
systems	B-C0449913
host	O
microbial	B-C0599840
communities	B-C0009462
among	O
which	O
several	B-C0443302
microorganisms	B-C0445623
have	O
been	O
considered	B-C0750591
endemic	B-C1254362
to	O
this	O
type	O
of	O
habitat	B-C0871648
.	O
	
it	O
is	O
still	O
unclear	B-C3845108
how	O
these	O
organisms	B-C0029235
colonize	B-C4289767
geographically	B-C0017446
distant	B-C0443203
hydrothermal	B-C0205556
environments	B-C0014406
.	O
	
based	O
on	O
16s	B-C3537372
rrna	I-C3537372
gene	B-C0162326
sequences	I-C0162326
,	O
we	O
compare	B-C1707455
the	O
bacterial	B-C0521009
communities	B-C0009462
of	O
sixteen	O
atlantic	B-C0004167
hydrothermal	B-C3178903
vent	I-C3178903
samples	B-C2347026
with	O
our	O
own	O
and	O
publicly	O
available	B-C0470187
global	B-C2348867
open	O
ocean	B-C1547972
samples	B-C0370003
.	O
	
analysing	B-C0936012
sequences	B-C0162326
obtained	B-C1301820
from	O
63	O
million	O
16s	B-C3537372
rrna	I-C3537372
genes	B-C0017337
,	O
the	O
genera	B-C1708235
we	O
could	O
identify	O
in	O
the	O
open	O
ocean	B-C1547972
waters	I-C1547972
contained	B-C0332256
99.9	O
of	O
the	O
vent	B-C0043187
reads	O
.	O
	
this	O
suggests	B-C1705535
that	O
previously	B-C0205156
observed	B-C1441672
vent	B-C0043187
exclusiveness	B-C0243095
is	O
,	O
in	O
most	O
cases	B-C0868928
,	O
probably	B-C0750492
an	O
artefact	B-C0243095
of	O
lower	B-C2003888
sequencing	B-C1294197
depth	B-C0205556
.	O
	
these	O
findings	B-C0243095
are	O
a	O
further	O
step	O
towards	O
elucidating	O
the	O
role	B-C1704326
of	O
the	O
open	O
ocean	B-C1547972
as	O
a	O
seed	B-C4042839
bank	I-C4042839
.	O
	
they	O
can	O
explain	O
the	O
predicament	B-C0243095
of	O
how	O
species	B-C1705920
expected	B-C1517001
to	O
be	O
endemic	B-C1254362
to	O
vent	B-C0043187
systems	B-C0449913
are	O
able	B-C1299581
to	O
colonize	B-C4289767
geographically	B-C0017446
distant	B-C0443203
hydrothermal	B-C0205556
habitats	B-C0871648
and	O
contribute	B-C1880177
to	O
our	O
understanding	B-C0162340
cerebral	B-C0085315
toxoplasmosis	I-C0085315
in	O
patients	B-C0030705
with	O
acquired	B-C0001175
immune	I-C0001175
deficiency	I-C0001175
syndrome	I-C0001175
in	O
the	O
neurological	B-C0562508
emergency	I-C0562508
department	I-C0562508
of	O
a	O
tertiary	B-C0337954
hospital	I-C0337954
cerebral	B-C0085315
toxoplasmosis	I-C0085315
is	O
the	O
most	O
common	O
cause	B-C0015127
of	O
space	B-C1883067
occupying	O
brain	B-C0221505
lesion	I-C0221505
in	O
patients	B-C0030705
with	O
hiv/aids	B-C0497169
in	O
brazil	B-C0006137
.	O
	
in	O
the	O
post-haart	B-C0681698
era	I-C0681698
,	O
it	O
is	O
responsible	O
for	O
high	B-C0205250
rates	B-C1521828
of	O
morbidity	B-C0026538
and	O
mortality	B-C0205848
worldwide	O
.	O
	
this	O
study	B-C2603343
consists	O
of	O
a	O
case	B-C0150093
series	I-C0150093
of	O
56	O
patients	B-C0030705
diagnosed	B-C0011900
with	O
cerebral	B-C0085315
toxoplasmosis	I-C0085315
whose	O
clinical	B-C0205210
features	B-C1521970
,	O
brain	B-C0203860
imaging	I-C0203860
and	O
cerebrospinal	B-C0007806
fluid	I-C0007806
aspects	B-C1879746
were	O
analyzed	B-C0936012
.	O
	
cerebral	B-C0085315
toxoplasmosis	I-C0085315
led	O
to	O
the	O
diagnosis	B-C0011900
of	O
infection	B-C3714514
by	O
the	O
human	B-C0019682
immunodeficiency	I-C0019682
virus	I-C0019682
hiv	B-C0019682
in	O
27	O
48.2	O
of	O
the	O
patients	B-C0030705
,	O
while	O
29	O
51.2	O
others	O
already	O
knew	O
to	O
be	O
hiv	B-C0019699
seropositive	I-C0019699
.	O
	
however	O
,	O
at	O
the	O
time	B-C0040223
of	O
diagnosis	B-C0011900
of	O
cerebral	B-C0085315
toxoplasmosis	I-C0085315
,	O
only	O
9	O
16.6	O
reported	B-C0700287
being	O
under	O
antiretroviral	B-C1963724
therapy	I-C1963724
and	O
5	O
8.9	O
were	O
receiving	B-C1514756
primary	B-C0205225
prophylaxis	B-C0199176
for	O
toxoplasmosis	B-C0085315
.	O
	
headache	B-C0018681
,	O
strength	B-C1457887
deficit	I-C1457887
and	O
fever	B-C0015967
were	O
the	O
most	O
frequent	O
signs	B-C0037088
and	I-C0037088
symptoms	I-C0037088
throughout	O
the	O
study	B-C2603343
.	O
	
fifty-three	O
patients	B-C0030705
showed	O
changes	B-C0392747
consistent	B-C0332290
with	I-C0332290
toxoplasmosis	B-C0085315
in	O
ct	B-C0040405
or	O
mri	B-C0024485
.	O
	
thirty-four	O
60.7	O
csf	B-C1292530
samples	I-C1292530
were	O
positive	B-C1446409
in	O
the	O
indirect	B-C0022885
haemagglutination	I-C0022885
test	I-C0022885
and	O
for	O
the	O
reaction	B-C0443286
of	O
toxoplasma	B-C0370074
gondii	I-C0370074
igg	I-C0370074
elisa	B-C0014441
,	O
while	O
31	O
55.4	O
were	O
positive	B-C1446409
in	O
the	O
direct	B-C0022885
haemagglutination	I-C0022885
test	I-C0022885
.	O
	
fifty	O
89.3	O
patients	B-C0030705
underwent	O
first-line	B-C1708063
treatment	I-C1708063
for	O
toxoplasmosis	B-C0085315
.	O
	
cerebral	B-C0085315
toxoplasmosis	I-C0085315
is	O
still	O
a	O
very	O
relevant	B-C2347946
neurological	B-C0027765
disease	I-C0027765
in	O
individuals	B-C0237401
with	O
aids	B-C0001175
admitted	B-C0184666
to	O
neurology	B-C0027855
emergency	B-C0562508
departments	I-C0562508
.	O
	
early	B-C0596473
diagnosis	I-C0596473
and	O
initiation	B-C1704686
of	O
empiric	B-C0749647
treatment	I-C0749647
and	O
antiretroviral	B-C1963724
therapy	I-C1963724
are	O
important	O
for	O
good	O
maf1	B-C1825934
-mediated	O
regulation	B-C1327622
of	O
yeast	B-C0043393
rna	B-C0035680
polymerase	I-C0035680
iii	I-C0035680
is	O
correlated	B-C1707520
with	O
cca	B-C1158763
addition	I-C1158763
at	I-C1158763
the	I-C1158763
3'	I-C1158763
end	I-C1158763
of	I-C1158763
trna	I-C1158763
precursors	O
in	O
eukaryotic	O
cells	O
trna	B-C0041133
synthesis	O
is	O
negatively	O
regulated	O
by	O
the	O
protein	O
maf1	O
,	O
conserved	O
from	O
yeast	O
to	O
humans	O
.	O
	
maf1	O
from	O
yeast	O
saccharomyces	O
cerevisiae	O
mediates	O
repression	O
of	O
trna	O
transcription	O
when	O
cells	O
are	O
transferred	O
from	O
medium	O
with	O
glucose	O
to	O
medium	O
with	O
glycerol	O
,	O
a	O
non-fermentable	O
carbon	O
source	O
.	O
	
the	O
strain	O
with	O
deleted	O
gene	O
encoding	O
maf1	O
maf1δ	O
is	O
viable	O
but	O
accumulates	O
trna	O
precursors	I-C0041133
.	O
	
in	O
this	O
study	O
trna	O
precursors	O
were	O
analysed	O
by	O
rna-seq	O
and	O
northern	O
hybridization	O
in	O
wild	O
type	O
strain	O
and	O
maf1δ	O
mutant	O
grown	O
in	O
glucose	O
medium	O
or	O
upon	O
shift	O
to	O
repressive	O
conditions	O
.	O
	
a	O
negative	O
effect	O
of	O
maf1δ	O
mutant	O
on	O
the	O
addition	O
of	O
the	O
auxiliary	O
cca	O
nucleotides	O
to	O
the	O
3'	O
end	O
of	O
pre-trnas	O
was	O
observed	O
in	O
cells	O
shifted	O
to	O
unfavourable	O
growth	O
conditions	O
.	O
	
this	O
effect	O
was	O
reduced	O
by	O
overexpression	O
of	O
the	O
yeast	O
cca1	O
gene	O
encoding	O
atp	O
nucleotidyltransferase	O
.	O
	
the	O
cca	O
sequence	O
at	O
the	O
3'	O
end	O
is	O
important	O
for	O
export	O
of	O
trna	O
precursors	O
from	O
the	O
nucleus	O
and	O
essential	O
for	O
trna	O
charging	O
with	O
amino	O
acids	O
.	O
	
data	O
presented	O
here	O
indicate	O
that	O
cca-addition	O
to	O
intron	O
-containing	O
end-processed	O
trna	O
precursors	O
is	O
a	O
limiting	O
step	O
in	O
trna	O
maturation	O
when	O
there	O
is	O
no	O
maf1	O
mediated	O
rna	O
polymerase	O
iii	O
pol	O
iii	O
repression	O
.	O
	
the	O
correlation	O
between	O
cca	O
synthesis	O
and	O
pol	O
iii	O
regulation	O
by	O
maf1	O
could	O
be	O
important	O
in	O
coordination	O
of	O
trna	O
transcription	O
,	O
processing	O
and	O
regulation	O
of	O
translation	I-C1157519
pre-existing	B-C2347662
renal	B-C0022646
lesions	B-C0221198
revealed	O
after	O
renal	B-C0022646
trauma	B-C3714660
,	O
difficulties	O
in	O
diagnosis	B-C1704656
and	O
accountability	B-C0078889
about	O
14	O
cases	B-C1706256
pre-existing	B-C2347662
renal	B-C0022646
lesions	B-C0221198
perl	B-C0221198
may	O
interfere	O
with	O
the	O
patho-physiology	B-C0031847
of	O
trauma	B-C3714660
,	O
alter	O
the	O
radiographic	B-C0457276
imaging	I-C0457276
and	O
influence	B-C4054723
the	O
therapeutic	B-C0087111
approach	O
.	O
	
the	O
aims	B-C1947946
of	O
this	O
study	B-C2603343
were	O
to	O
record	O
the	O
perl	B-C0221198
found	O
incidentally	O
during	O
blunt	B-C1997138
renal	B-C0022646
trauma	B-C3714660
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative	B-C0459914
management	I-C0459914
and	O
to	O
determin	O
the	O
estimated	O
partial	B-C2080701
permanent	I-C2080701
disability	I-C2080701
ppd	B-C2080701
.	O
	
the	O
medical	B-C0025102
records	I-C0025102
of	O
14	O
patients	B-C0030705
with	O
perl	B-C0221198
and	O
blunt	B-C1997138
renal	B-C0022646
trauma	B-C3714660
were	O
reviewed	O
.	O
	
in	O
each	O
patient	B-C0030705
,	O
pre-existing	B-C2347662
renal	B-C0022646
abnormalities	O
,	O
clinical	B-C0205210
symptoms	B-C1457887
,	O
ct	B-C0040405
scan	I-C0040405
study	B-C2603343
findings	B-C0243095
,	O
associated	O
injuries	B-C3263723
,	O
therapeutic	B-C0087111
approach	O
,	O
the	O
accountability	B-C0078889
criteria	O
and	O
the	O
estimated	O
ppd	B-C2080701
were	O
recorded	O
.	O
	
there	O
were	O
11	O
men	B-C0025266
and	O
3	O
women	B-C0043210
with	O
a	O
mean	B-C0444504
age	B-C0001779
of	O
35	O
years	B-C0439234
range	O
19-66	O
years	B-C0439234
.	O
	
renal	B-C0022646
trauma	B-C3714660
was	O
due	O
to	O
a	O
traffic	B-C0000932
accident	I-C0000932
in	O
8	O
patients	B-C0030705
.	O
	
renal	B-C0022646
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	B-C0439793
of	O
the	O
trauma	B-C3714660
minor	O
trauma	B-C3714660
.	O
	
they	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	B-C3714660
to	O
other	O
abdominal	B-C0446633
organs	I-C0446633
four	O
patients	B-C0030705
only	O
.	O
	
urinary	B-C0042018
stones	I-C0042018
were	O
present	O
in	O
5	O
patients	B-C0030705
,	O
pelvi-ureteric	B-C0521619
junction	I-C0521619
obstruction	I-C0521619
in	O
3	O
,	O
horseshoe	B-C0221353
kidny	I-C0221353
in	O
3	O
,	O
ectopic	B-C0238207
kidney	I-C0238207
in	O
2	O
and	O
upper	O
urinary	B-C2007041
tract	I-C2007041
carcinoma	I-C2007041
in	O
one	O
case	O
.	O
	
early	O
nephrectomy	B-C0027695
was	O
required	O
in	O
three	O
cases	B-C1706256
for	O
hemodynamic	B-C0948268
instability	I-C0948268
.	O
	
ureteral	B-C0183518
stenting	I-C0183518
was	O
indicated	O
in	O
3	O
cases	B-C1706256
.	O
	
six	O
patients	B-C0030705
were	O
operated	B-C0543467
later	O
because	O
of	O
their	O
underlying	O
renal	B-C0022646
pathology	B-C0919386
.	O
	
a	O
conservative	B-C0459914
treatment	I-C0459914
was	O
possible	O
only	O
in	O
7	O
of	O
cases	B-C1706256
.	O
	
the	O
ppd	B-C2080701
related	O
to	O
renal	B-C0022646
trauma	B-C3714660
varide	O
from	O
0	O
to	O
13%	O
in	O
all	O
cases	B-C1706256
.	O
	
perl	B-C0221198
may	O
complicate	O
a	O
negligible	O
renal	B-C0022646
trauma	B-C3714660
while	O
in	O
some	O
cases	B-C1706256
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient's	B-C0030705
final	O
outcome	O
.	O
	
the	O
imaging	O
findings	B-C0243095
are	O
crucial	O
but	O
may	O
be	O
confusing	O
.	O
	
the	O
therapeutic	B-C0087111
approach	O
is	O
,	O
to	O
a	O
large	O
extent	O
,	O
dependent	O
on	O
the	O
type	O
of	O
perl	B-C0221198
and	O
the	O
severity	B-C0439793
of	O
damage	B-C1883709
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo-dynamically	B-C0578150
stable	I-C0578150
patient	B-C0030705
.	O
	
accountability	B-C0078889
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
ppd	B-C2080701
depends	O
on	O
the	O
perl	B-C0221198
and	O
the	O
renal	B-C0160420
injuries	I-C0160420
severity	B-C0439793
.	O
	
polymeric	B-C0032521
nanostructure	B-C1450053
compiled	O
with	O
multifunctional	B-C1705248
components	I-C1705248
to	O
exert	O
tumor	B-C0027651
-	O
targeted	B-C0920677
delivery	I-C0920677
of	O
antiangiogenic	B-C3179230
gene	B-C0017337
for	O
tumor	B-C0598934
growth	I-C0598934
suppression	B-C2700409
nucleic	B-C0028606
acid-based	I-C0028606
therapy	B-C0087111
has	O
emerged	O
as	O
a	O
revolutionary	B-C3266812
methodology	I-C3266812
for	O
treatment	B-C1522326
of	O
the	O
diseases	B-C0012634
related	O
to	O
protein	B-C0033684
dysfunction	B-C3887504
however	O
,	O
lack	B-C0332268
of	I-C0332268
systemically	B-C0205373
applicable	B-C1706839
synthetic	B-C0920677
delivery	I-C0920677
systems	I-C0920677
limits	O
its	O
current	O
usage	O
in	O
local	B-C1393254
applications	I-C1393254
,	O
particularly	O
for	O
dna-based	B-C0012854
therapy	B-C0087111
with	O
regard	O
to	O
the	O
poor	B-C0005508
bioavailability	I-C0005508
in	O
the	O
systemic	B-C0678812
administrations	I-C0678812
.	O
	
to	O
overcome	O
this	O
obstacle	O
,	O
we	O
compiled	O
multiple	B-C0439064
chemistry-based	B-C3178923
strategies	I-C3178923
into	O
the	O
manufacture	B-C0870840
of	O
the	O
gene	B-C0920677
delivery	I-C0920677
formulations	I-C0920677
to	O
pursue	O
improved	B-C0184511
tolerability	B-C4053931
of	O
dna	B-C0012854
to	O
the	O
enzymatic	B-C1511131
degradation	B-C0314674
in	O
the	O
biological	B-C0205460
milieu	B-C0014406
and	O
prolonged	B-C1753315
retention	I-C1753315
in	O
the	O
systemic	O
circulation	O
.	O
	
here	O
,	O
we	O
constructed	O
a	O
distinctive	B-C0205556
multilayered	I-C0205556
functional	B-C0205245
architecture	B-C1254362
plasmid	B-C0032136
dna	I-C0032136
pdna	B-C0032136
was	O
electrostatically	B-C2348396
complexed	I-C2348396
with	O
cationic	B-C0007447
poly	B-C0032426
polyplex	B-C0032521
as	O
the	O
interior	B-C0205102
pdna	B-C0032136
reservoir	B-C1254362
,	O
which	O
was	O
further	O
cross-linked	B-C0178576
by	O
redox	B-C0030012
-	O
responsive	B-C0205342
disulfide	B-C0012771
cross-linking	B-C0332220
to	O
minimize	O
the	O
occurrence	B-C2745955
of	O
polyplex	B-C0032521
disassembly	B-C1707798
through	O
exchange	B-C1148560
reaction	I-C1148560
with	O
the	O
biological	B-C0205460
charged	B-C0022023
components	I-C0022023
.	O
	
still	O
,	O
the	O
pdna	B-C0032136
reservoir	B-C1254362
was	O
spatially	O
protected	O
by	O
a	O
sequential	B-C1705294
thermoresponsive	B-C0205245
poly	B-C0071490
palisade	B-C1704513
as	O
the	O
intermediate	B-C1704513
barrier	I-C1704513
and	O
a	O
biocompatible	B-C0005479
hydrophilic	B-C0475370
poly	B-C0032483
glycol	I-C0032483
peg	B-C0032483
shell	B-C1948022
with	O
the	O
aim	O
of	O
preventing	O
the	O
accessibility	B-C0814423
of	O
the	O
biological	B-C0205460
species	B-C1705920
,	O
particularly	O
the	O
nuclease	B-C0597094
degradation	B-C0243125
to	O
the	O
pdna	B-C0032136
payload	O
.	O
	
subsequent	O
investigations	B-C0220825
validated	O
the	O
utilities	O
of	O
these	O
strategies	B-C0679199
in	O
accomplishing	O
prolonged	O
blood	B-C0005767
retention	B-C0268000
.	O
	
in	O
an	O
attempt	O
to	O
apply	O
this	O
method	B-C0025663
for	O
tumor	O
therapy	B-C0087111
,	O
ligand	B-C1685100
cyclic	I-C1685100
arg-gly-asp	I-C1685100
peptide	I-C1685100
was	O
attached	O
at	O
the	O
distal	O
end	O
of	O
peg	B-C0032483
,	O
validating	O
prompted	O
tumor	B-C0027651
-	O
targeted	B-C1521840
delivery	B-C1524066
and	O
gene	B-C0017262
expression	I-C0017262
of	O
the	O
loaded	O
antiangiogenic	B-C3179230
gene	B-C0017337
at	O
the	O
targeted	B-C1521840
tumor	B-C0597032
cells	I-C0597032
and	O
accordingly	O
exerting	B-C0015264
antiangiogenesis	B-C3179230
of	O
the	O
tumors	B-C0027651
for	O
abrogation	B-C2746065
of	O
tumor	B-C0598934
growth	I-C0598934
.	O
	
together	O
with	O
its	O
excellent	O
safe	O
profile	O
,	O
the	O
proposed	O
formulation	O
suggests	O
potential	B-C3245505
utility	O
as	O
a	O
practical	O
gene	B-C0920677
delivery	I-C0920677
system	I-C0920677
for	O
treatment	B-C1522326
of	O
intractable	B-C0205269
diseases	B-C0012634
.	O
	
evaluation	B-C0220825
of	O
the	O
vidas	B-C0005507
anti-hcv	I-C0005507
assay	I-C0005507
for	O
detection	B-C1511790
of	O
hepatitis	B-C4288963
c	I-C4288963
virus	I-C4288963
infection	I-C4288963
anti-hepatitis	B-C0166049
c	I-C0166049
virus	I-C0166049
antibody	I-C0166049
anti-hcv	B-C0166049
assays	B-C0005507
are	O
recommended	O
for	O
screening	B-C1710032
hcv	B-C0220847
-infected	O
persons	O
.	O
	
the	O
vidas	O
anti-hcv	O
assay	O
biomérieux	O
,	O
france	O
,	O
based	O
on	O
the	O
enzyme-linked	O
fluorescence	O
test	O
principle	O
,	O
was	O
recently	O
introduced	O
in	O
korea	O
.	O
	
we	O
evaluated	O
the	O
clinical	O
performance	O
of	O
the	O
vidas	O
assay	O
.	O
	
one	O
hundred	O
hcv-positive	O
and	O
1	O
hcv-negative	O
blood	O
samples	O
confirmed	O
by	O
architect	O
anti-hcv	O
abbott	O
laboratories	O
,	O
usa	O
and	O
cobas	O
taqman	O
hcv	B-C0027361
real-time	O
pcr	O
roche	O
diagnostics	O
,	O
usa	O
or	O
the	O
procleix	O
ultrio	O
plus	O
assay	O
gen-probe	O
incorporated	O
,	O
usa	O
were	O
obtained	O
from	O
the	O
human	O
serum	O
bank	O
hsb	O
and	O
tested	O
by	O
vidas	O
.	O
	
in	O
case	O
of	O
discrepant	O
results	O
,	O
we	O
conducted	O
a	O
recombinant	O
immunoblot	O
assay	O
riba	O
.	O
	
the	O
agreement	O
rates	O
for	O
known	O
hcv-positive	O
and	O
hcv-negative	O
samples	O
between	O
the	O
vidas	O
assay	O
and	O
the	O
hsb	O
testing	O
were	O
100%	O
95%	O
confidence	O
interval	O
ci	O
96.4	O
and	O
99.5	O
95%	O
ci	O
98.8	O
,	O
respectively	O
.	O
	
one	O
of	O
the	O
five	O
discrepant	O
samples	O
was	O
positive	O
for	O
core	O
2+	O
and	O
ns3-2	O
2+	O
reactivity	O
,	O
two	O
samples	O
were	O
negative	O
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
ns4	O
2+	O
reactivity	O
in	O
riba	O
.	O
	
we	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	O
between	O
the	O
titers	O
of	O
vidas	O
and	O
architect	O
assays	O
r=0	O
,	O
p<0	O
.	O
	
the	O
vidas	O
anti-hcv	O
assay	O
,	O
developed	O
on	O
the	O
vidas	O
automated	O
immunoassay	O
platform	O
based	O
on	O
the	O
ready-to-use	O
,	O
single-sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small-to-medium-sized	O
laboratories	O
.	O
	
it	O
showed	O
good	O
agreement	O
with	O
architect	O
anti-hcv	O
and	O
cobas	O
pcr	O
assays	O
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
hcv	O
infection	O
.	O
	
weakly	O
test-positive	O
ambiguous	O
samples	O
require	O
additional	O
testing	O
by	O
another	O
anti-hcv	O
,	O
riba	O
,	O
or	O
hcv	O
rna	O
assay	I-C0005507
reassembly	B-C1254358
of	I-C1254358
excitable	I-C1254358
domains	I-C1254358
after	O
cns	B-C3714787
axon	B-C1621980
regeneration	I-C1621980
action	B-C4236548
potential	I-C4236548
initiation	I-C4236548
and	O
propagation	B-C4236672
in	O
myelinated	B-C0682682
axons	I-C0682682
require	O
ion	B-C1660767
channel	I-C1660767
clustering	I-C1660767
at	O
axon	B-C1179989
initial	I-C1179989
segments	I-C1179989
ais	B-C1179989
and	O
nodes	B-C0034667
of	I-C0034667
ranvier	I-C0034667
.	O
	
disruption	B-C0332453
of	O
these	O
domains	O
after	O
injury	B-C3263723
impairs	B-C1883709
nervous	B-C0027767
system	I-C0027767
function	I-C0027767
.	O
	
traditionally	O
,	O
injured	B-C0332664
cns	B-C3714787
axons	B-C0004461
are	O
considered	O
refractory	B-C0034954
to	O
regeneration	B-C1621980
,	O
but	O
some	O
recent	O
approaches	O
challenge	O
this	O
view	O
by	O
showing	O
robust	B-C2986815
long-distance	B-C0012751
regeneration	B-C1621980
.	O
	
however	O
,	O
whether	O
these	O
approaches	O
allow	O
remyelination	B-C0334220
and	O
promote	O
the	O
reestablishment	B-C1254358
of	O
ais	B-C1179989
and	O
nodes	B-C0034667
of	I-C0034667
ranvier	I-C0034667
is	O
unknown	B-C0439673
.	O
	
using	O
mouse	B-C0025929
optic	B-C0029130
nerve	I-C0029130
crush	B-C0332679
as	O
a	O
model	B-C0012644
for	O
cns	B-C3714787
traumatic	B-C3263723
injury	I-C3263723
,	O
we	O
performed	O
a	O
detailed	O
analysis	B-C0936012
of	O
ais	B-C1179989
and	O
node	B-C0034667
disruption	B-C0332453
after	O
nerve	B-C0161479
crush	I-C0161479
.	O
	
we	O
found	O
significant	O
disruption	B-C0332453
of	O
ais	B-C1179989
and	O
loss	B-C1517945
of	O
nodes	B-C0034667
within	O
days	O
of	O
the	O
crush	B-C0332679
,	O
and	O
complete	O
loss	B-C1517945
of	O
nodes	B-C0034667
1	O
week	O
after	O
injury	B-C3263723
.	O
	
genetic	B-C0017260
deletion	I-C0017260
of	O
the	O
tumor	B-C0694888
suppressor	I-C0694888
phosphatase	I-C0694888
and	I-C0694888
tensin	I-C0694888
homolog	I-C0694888
pten	B-C0694888
in	O
retinal	B-C0035316
ganglion	I-C0035316
cells	I-C0035316
rgcs	B-C0035316
,	O
coupled	O
with	O
stimulation	B-C0007613
of	O
rgcs	B-C0035316
by	O
inflammation	B-C0021368
and	O
camp	B-C0001455
,	O
dramatically	O
enhanced	O
regeneration	B-C1621980
.	O
	
with	O
this	O
treatmen	B-C3161471
t	O
,	O
we	O
found	O
significant	O
reestablishment	B-C1254358
of	O
rgc	B-C0035316
ais	B-C1179989
,	O
remyelination	B-C0334220
,	O
and	O
even	O
reassembly	B-C1254358
of	O
nodes	B-C0034667
in	O
regions	B-C0205107
proximal	I-C0205107
,	O
within	B-C0332285
,	O
and	O
distal	B-C0205108
to	O
the	O
crush	B-C0332679
site	B-C1515974
.	O
	
remyelination	B-C0334220
began	O
near	B-C0459620
the	I-C0459620
retina	I-C0459620
,	O
progressed	B-C1272688
distally	B-C0205108
,	O
and	O
was	O
confirmed	O
by	O
electron	B-C0026019
microscopy	I-C0026019
.	O
	
although	O
axons	B-C0004461
grew	B-C0007595
rapidly	B-C0456962
,	O
remyelination	B-C0334220
and	O
nodal	B-C1660767
ion	I-C1660767
channel	I-C1660767
clustering	I-C1660767
was	O
much	O
slower	B-C0439834
.	O
	
finally	O
,	O
genetic	B-C0017260
deletion	I-C0017260
of	O
ankyring	B-C1384562
from	O
rgcs	B-C0035316
to	O
block	B-C0332206
ais	B-C1179989
reassembly	B-C1254358
did	O
not	O
affect	O
axon	B-C1621980
regeneration	I-C1621980
,	O
indicating	O
that	O
preservation	O
of	O
neuronal	B-C0085304
polarity	I-C0085304
is	O
not	B-C0243095
required	I-C0243095
for	O
axon	B-C1621980
regeneration	I-C1621980
.	O
	
together	O
,	O
our	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerating	B-C1621980
cns	B-C3714787
axons	B-C0004461
can	O
be	O
remyelinated	B-C0334220
and	O
reassemble	B-C1254358
new	O
ais	B-C1179989
and	O
nodes	B-C0034667
of	I-C0034667
ranvier	I-C0034667
.	O
	
we	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerated	B-C1621980
cns	B-C3714787
axons	B-C0004461
have	O
the	O
capacity	B-C1516240
to	O
both	O
remyelinate	B-C0334220
and	O
reassemble	B-C1254358
the	O
axon	B-C1179989
initial	I-C1179989
segments	I-C1179989
and	O
nodes	B-C0034667
of	I-C0034667
ranvier	I-C0034667
necessary	O
for	O
rapid	B-C0456962
and	O
efficient	B-C0442799
action	B-C4236672
potential	I-C4236672
propagation	I-C4236672
.	O
	
clinicopathological	B-C0030667
relevance	O
of	O
kinesin	B-C1610793
family	I-C1610793
member	I-C1610793
18a	I-C1610793
expression	B-C1171362
in	O
invasive	B-C0853879
breast	I-C0853879
cancer	I-C0853879
recently	O
,	O
kinesin	B-C0085139
motor	B-C1720835
proteins	I-C1720835
have	O
been	O
focused	O
on	O
as	O
targets	B-C1521840
for	O
cancer	B-C0920425
therapy	I-C0920425
.	O
	
kinesins	B-C0085139
are	O
microtubule	B-C0026042
-based	O
motor	B-C1720835
proteins	I-C1720835
that	O
mediate	O
diverse	B-C0542341
functions	I-C0542341
within	O
the	O
cell	B-C0007634
,	O
including	O
the	O
transport	B-C0005528
of	O
vesicles	B-C1622418
,	O
organelles	B-C0029219
,	O
chromosomes	B-C0008633
and	O
protein	B-C1180347
complexes	I-C1180347
,	O
as	O
well	O
as	O
the	O
movement	B-C1156033
of	I-C1156033
microtubules	I-C1156033
.	O
	
in	O
the	O
current	O
study	O
,	O
the	O
expression	B-C1171362
of	O
kinesin	B-C1610793
family	I-C1610793
member	I-C1610793
18a	I-C1610793
kif18a	B-C1610793
,	O
a	O
member	B-C0085139
of	I-C0085139
kinesin	I-C0085139
superfamily	I-C0085139
,	O
was	O
investigated	B-C1292732
in	O
breast	B-C0006142
cancer	I-C0006142
using	O
immunohistochemistry	B-C0021044
,	O
and	O
its	O
effect	O
on	O
breast	B-C0006142
cancer	I-C0006142
prognosis	O
was	O
examined	O
.	O
	
kif18a	B-C1610793
expression	B-C3244092
level	I-C3244092
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
lymph	B-C0686619
node	I-C0686619
metastasis	I-C0686619
p=0	O
.	O
	
in	O
patients	B-C0030705
with	O
high	O
levels	O
of	O
kif18a	B-C1610793
expression	B-C1171362
,	O
survival	B-C0038952
was	O
significantly	O
poorer	O
compared	O
to	O
patients	B-C0030705
with	O
low	O
levels	O
of	O
kif18a	B-C1610793
expression	B-C1171362
disease-free	B-C0242793
survival	I-C0242793
,	O
p=0	O
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
revealed	O
that	O
venous	B-C1710625
invasion	I-C1710625
hazard	B-C2985465
ratio	I-C2985465
,	O
9.22	O
95%	O
confidence	B-C0009667
interval	I-C0009667
,	O
3.90	O
p<0	O
and	O
kif18a	B-C1610793
expression	B-C1171362
hazard	B-C2985465
ratio	I-C2985465
,	O
3.20	O
95%	O
confidence	B-C0009667
interval	I-C0009667
,	O
1.34	O
p=0	O
were	O
independent	O
predictive	B-C0683956
factors	I-C0683956
for	O
lymph	B-C0686619
node	I-C0686619
metastasis	I-C0686619
.	O
	
kif18a	B-C1610793
may	O
be	O
a	O
useful	O
predictive	B-C0683956
marker	B-C0005516
for	O
lymph	B-C0686619
node	I-C0686619
metastasis	I-C0686619
in	O
breast	B-C0006142
cancer	I-C0006142
,	O
which	O
could	O
facilitate	O
curative	B-C3846124
adjuvant	I-C3846124
treatment	B-C0087111
.	O
	
the	O
underlying	O
inflammatory	B-C1290886
chronic	I-C1290886
disease	I-C1290886
influences	B-C4054723
infliximab	B-C0666743
pharmacokinetics	B-C0031328
infliximab	B-C0666743
is	O
an	O
anti-tumor	B-C1562242
necrosis	I-C1562242
factor	I-C1562242
monoclonal	B-C0003250
antibody	I-C0003250
approved	O
in	O
chronic	B-C1290886
inflammatory	I-C1290886
diseases	I-C1290886
such	O
as	O
rheumatoid	B-C0003873
arthritis	I-C0003873
ra	B-C0003873
,	O
psoriatic	B-C0003872
arthritis	I-C0003872
psa	B-C0003872
,	O
ankylosing	B-C0038013
spondylitis	I-C0038013
as	B-C0038013
,	O
crohn's	B-C0010346
disease	I-C0010346
cd	B-C0010346
and	O
ulcerative	B-C0009324
colitis	I-C0009324
uc	B-C0009324
.	O
	
infliximab	B-C0666743
pharmacokinetics	B-C0031328
is	O
variable	O
between	O
patients	B-C0030705
,	O
but	O
influence	B-C4054723
of	O
the	O
underlying	B-C0012634
disease	I-C0012634
was	O
never	O
assessed	B-C1516048
.	O
	
this	O
study	O
aimed	O
at	O
assessing	O
this	O
influence	B-C4054723
using	O
a	O
cohort	B-C0599755
of	O
patients	B-C0030695
monitored	I-C0030695
in	O
a	O
single	O
center	O
and	O
with	O
the	O
same	O
assay	B-C1510438
.	O
	
infliximab	B-C0666743
trough	O
concentrations	B-C1446561
were	O
determined	B-C0521095
on	O
samples	B-C0200345
collected	I-C0200345
between	O
weeks	O
0	O
and	O
22	O
after	O
treatment	B-C1522326
initiation	B-C1704686
in	O
218	O
patients	B-C0030705
treated	B-C1522326
for	O
ra	B-C0003873
,	O
psa	B-C0003872
,	O
as	B-C0038013
,	O
cd	B-C0010346
or	O
uc	B-C0009324
.	O
	
infliximab	B-C0666743
pharmacokinetics	B-C0031328
was	O
analyzed	B-C0936012
by	O
a	O
one-compartment	O
population	B-C1257890
model	O
with	O
first-order	O
elimination	B-C2735304
rate	B-C2986811
constant	I-C2986811
.	O
	
in	O
as	B-C0038013
patients	B-C0030705
,	O
volume	B-C0683148
of	I-C0683148
distribution	I-C0683148
v	B-C0683148
and	O
elimination	B-C2735304
clearance	B-C0449297
cl	B-C0449297
were	O
5.4	O
l	O
and	O
0.24	O
l/day	O
,	O
respectively	O
.	O
	
in	O
cd	B-C0010346
and	O
uc	B-C0009324
patients	B-C0030705
,	O
v	O
was	O
49%	O
and	O
52%	O
higher	O
than	O
in	O
as	B-C0038013
,	O
respectively	O
,	O
and	O
cl	B-C0449297
was	O
47%	O
and	O
60%	O
higher	O
than	O
in	O
as	B-C0038013
,	O
respectively	O
.	O
	
in	O
ra	B-C0003873
patients	B-C0030705
,	O
cl	B-C0449297
was	O
49%	O
higher	O
than	O
in	O
as	B-C0038013
patients	B-C0030705
.	O
	
simulations	B-C0679083
showed	O
that	O
without	O
methotrexate	B-C0025677
,	O
a	O
3	O
mg/kg	O
dosing	B-C0178602
regimen	B-C0040808
would	O
lead	O
only	O
16%	O
of	O
ra	B-C0003873
patients	B-C0030705
to	O
reach	O
the	O
target	B-C1521840
concentration	B-C1446561
2.5	O
mg/l	O
at	O
week	O
22	O
,	O
whereas	O
target	B-C1521840
concentrations	B-C1446561
would	O
be	O
reached	O
in	O
approximately	B-C0332232
half	O
of	O
ra	B-C0003873
patients	B-C0030705
cotreated	B-C1522326
with	O
methotrexate	B-C0025677
,	O
as	O
well	O
as	O
half	O
of	O
cd	B-C0010346
3.5	O
mg/l	O
and	O
uc	B-C0009324
3.7	O
mg/l	O
patients	B-C0030705
.	O
	
the	O
suboptimality	O
of	O
approved	O
dosing	B-C0178602
regimens	B-C0040808
supports	O
the	O
development	B-C1527148
of	O
dosing	B-C0178602
optimization	B-C2698650
based	O
on	O
concentration	B-C1446561
measurements	I-C1446561
.	O
	
international	B-C1512888
validation	B-C1519941
of	O
a	O
urinary	B-C1610733
biomarker	B-C0005516
panel	B-C0022885
for	O
identification	O
of	O
active	B-C0205177
lupus	B-C0024143
nephritis	I-C0024143
in	O
children	B-C0008059
conventional	O
markers	B-C0005516
of	O
juvenile-onset	B-C1274834
systemic	I-C1274834
lupus	I-C1274834
erythematosus	I-C1274834
jsle	B-C1274834
disease	B-C4065474
activity	I-C4065474
fail	O
to	O
adequately	O
identify	O
lupus	B-C0024143
nephritis	I-C0024143
ln	B-C0024143
.	O
	
while	O
individual	O
novel	B-C0205314
urine	B-C0042036
biomarkers	B-C0005516
are	O
good	O
at	O
detecting	B-C1511790
ln	B-C0024143
flares	B-C1517205
,	O
biomarker	B-C0005516
panels	B-C0022885
may	O
improve	O
diagnostic	B-C0598285
accuracy	I-C0598285
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
assess	B-C1516048
the	O
performance	O
of	O
a	O
biomarker	B-C0005516
panel	B-C0022885
to	O
identify	O
active	B-C0205177
ln	B-C0024143
in	O
two	O
international	B-C1512888
jsle	B-C1274834
cohorts	B-C0599755
.	O
	
novel	O
urinary	B-C1610733
biomarkers	B-C0005516
,	O
namely	O
vascular	B-C0078056
cell	I-C0078056
adhesion	I-C0078056
molecule-1	I-C0078056
vcam-1	B-C0078056
,	O
monocyte	B-C0128897
chemoattractant	I-C0128897
protein	I-C0128897
1	I-C0128897
mcp-1	B-C0128897
,	O
lipocalin-like	B-C0072296
prostaglandin	I-C0072296
d	I-C0072296
synthase	I-C0072296
lpgds	B-C0072296
,	O
transferrin	B-C0040679
tf	B-C0040679
,	O
ceruloplasmin	B-C0007841
,	O
alpha-1-acid	B-C0029297
glycoprotein	I-C0029297
agp	B-C0029297
and	O
neutrophil	B-C0215955
gelatinase-associated	I-C0215955
lipocalin	I-C0215955
ngal	B-C0215955
,	O
were	O
quantified	B-C0392762
in	O
a	O
cross-sectional	B-C0010362
study	I-C0010362
that	O
included	O
participants	B-C0679646
of	O
the	O
uk	B-C0041700
jsle	B-C1274834
cohort	B-C0009247
study	I-C0009247
cohort	B-C0599755
1	I-C0599755
and	O
validated	O
within	O
the	O
einstein	B-C1708333
lupus	I-C1708333
cohort	B-C0599755
cohort	B-C0599755
2	I-C0599755
.	O
	
binary	B-C1706942
logistic	B-C0206031
regression	I-C0206031
modelling	I-C0206031
and	O
receiver	B-C0034772
operating	I-C0034772
characteristic	I-C0034772
curve	B-C0392762
analysis	I-C0392762
area	B-C0376690
under	I-C0376690
the	I-C0376690
curve	I-C0376690
auc	B-C0376690
were	O
used	O
to	O
identify	O
and	O
assess	B-C1516048
combinations	B-C0205195
of	O
biomarkers	B-C0005516
for	O
diagnostic	B-C0598285
accuracy	I-C0598285
.	O
	
a	O
total	O
of	O
91	O
jsle	B-C1274834
patients	B-C0030705
were	O
recruited	O
across	O
both	O
cohorts	B-C0599755
,	O
of	O
whom	O
31	O
34	O
%	O
had	O
active	B-C0205177
ln	B-C0024143
and	O
60	O
66	O
%	O
had	O
no	O
ln	B-C0024143
.	O
	
urinary	B-C1610733
agp	B-C0029297
,	O
ceruloplasmin	B-C0007841
,	O
vcam-1	B-C0078056
,	O
mcp-1	B-C0128897
and	O
lpgds	B-C0072296
levels	B-C0441889
were	O
significantly	B-C4055637
higher	I-C4055637
in	O
those	O
patients	B-C0030705
with	O
active	B-C0205177
ln	B-C0024143
than	O
in	O
non	B-C1518422
-	O
ln	B-C0024143
patients	B-C0030705
all	O
corrected	O
p	O
values	O
p	O
c	O
<	O
0.05	O
across	O
both	O
cohorts	B-C0599755
.	O
	
urinary	B-C1610733
tf	B-C0040679
also	O
differed	O
between	O
patient	B-C0030705
groups	O
in	O
cohort	B-C0599755
2	I-C0599755
p	O
c	O
=	O
0.001	O
.	O
	
within	O
cohort	B-C0599755
1	I-C0599755
,	O
the	O
optimal	B-C2698651
biomarker	B-C0005516
panel	B-C0022885
included	O
agp	B-C0029297
,	O
ceruloplasmin	B-C0007841
,	O
lpgds	B-C0072296
and	O
tf	B-C0040679
auc	B-C0376690
0.920	O
for	O
active	B-C0205177
ln	B-C0024143
identification	O
.	O
	
these	O
results	O
were	O
validated	O
in	O
cohort	B-C0599755
2	I-C0599755
,	O
with	O
the	O
same	O
markers	B-C0005516
resulting	O
in	O
the	O
optimal	B-C2698651
urine	B-C0042036
biomarker	B-C0005516
panel	B-C0022885
auc	B-C0376690
0.991	O
.	O
	
in	O
two	O
international	B-C1512888
jsle	B-C1274834
cohorts	B-C0599755
,	O
urinary	B-C1610733
agp	B-C0029297
,	O
ceruloplasmin	B-C0007841
,	O
lpgds	B-C0072296
and	O
tf	B-C0040679
demonstrate	O
an	O
'excellent'	O
ability	O
for	O
accurately	O
identifying	O
active	B-C0205177
ln	B-C0024143
in	O
fine	O
structure	O
of	O
interleukin	B-C0666963
18	I-C0666963
il-18	I-C0666963
receptor	I-C0666963
-	O
immunoreactive	B-C0020962
neurons	B-C0027882
in	O
the	O
retrosplenial	B-C4085586
cortex	I-C4085586
and	O
its	O
changes	O
in	O
il18	B-C1334109
knockout	B-C0206745
mice	I-C0206745
interleukin	B-C0383327
18	I-C0383327
il-18	B-C0383327
participates	O
in	O
the	O
inflammatory	B-C0333348
immune	B-C0301872
response	I-C0301872
of	O
lymphocytes	O
.	O
	
delay	O
in	O
learning	O
or	O
memory	O
are	O
common	O
in	O
the	O
il-18	O
knockout	O
mouse	O
.	O
	
many	O
il-18	O
-	O
immunoreactive	O
neurons	O
are	O
found	O
in	O
the	O
retrosplenial	O
cortex	O
rsc	O
and	O
the	O
subiculum	O
.	O
	
these	O
neurons	O
also	O
contain	O
the	O
il-18	O
receptor	O
.	O
	
we	O
determined	O
the	O
location	O
and	O
the	O
ultrastructure	O
of	O
the	O
il-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
rsc	O
and	O
observed	O
changes	O
in	O
the	O
il-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
of	O
the	O
il-18	O
knockout	O
mouse	O
.	O
	
the	O
il-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
were	O
found	O
specifically	O
in	O
layer	O
v	O
of	O
the	O
granular	O
rsc	O
.	O
	
they	O
were	O
medium-sized	O
neurons	O
with	O
a	O
light	O
oval	O
nucleus	O
and	O
had	O
little	O
cytoplasm	O
with	O
many	O
free	O
ribosomes	O
,	O
rough	O
endoplasmic	O
reticulum	O
and	O
many	O
mitochondria	O
,	O
but	O
no	O
nissl	O
bodies	O
.	O
	
the	O
number	O
of	O
axosomatic	O
terminals	O
was	O
about	O
six	O
per	O
section	O
.	O
	
the	O
il-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
were	O
not	O
found	O
in	O
the	O
rsc	O
in	O
the	O
il-18	O
knockout	O
mouse	O
at	O
5	O
or	O
9	O
weeks	O
of	O
age	O
.	O
	
however	O
,	O
many	O
small	O
electron-dense	O
neurons	O
were	O
found	O
in	O
layer	O
v	O
.	O
	
both	O
the	O
nucleus	O
and	O
cytoplasm	O
were	O
electron-dense	O
,	O
but	O
not	O
necrotic	O
.	O
	
the	O
mitochondria	O
and	O
rough	O
endoplasmic	O
reticulum	O
were	O
swollen	O
.	O
	
the	O
il-18	O
receptor	O
-	O
immunoreactive	O
neurons	O
were	O
presumed	O
to	O
be	O
degenerating	O
.	O
	
the	O
degeneration	O
of	O
the	O
il18-receptor	O
-	O
immunoreactive	O
neurons	O
in	O
the	O
rsc	O
may	O
cause	O
the	O
abnormal	O
behaviors	O
of	O
the	O
il-18	O
knockout	O
mice	I-C0206745
exploring	O
the	O
genetic	B-C0314603
variability	B-C2827666
in	O
water	B-C0043047
use	B-C0457083
efficiency	B-C0013682
evaluation	O
of	O
inter	B-C1548610
and	O
intra	B-C0032098
cultivar	I-C0032098
genetic	B-C0042333
diversity	I-C0042333
in	O
grapevines	B-C0330100
genetic	B-C0314603
improvement	B-C2986411
of	O
crop	B-C0242775
water	B-C0043047
use	B-C0457083
efficiency	B-C0013682
wue	B-C0013682
is	O
a	O
general	O
goal	B-C1571704
because	O
the	O
increasing	B-C0442808
water	B-C0043047
scarcity	B-C0231179
and	O
the	O
trend	O
to	O
a	O
more	O
sustainable	B-C0443318
agriculture	B-C0001829
.	O
	
for	O
grapevines	B-C0330100
,	O
this	O
subject	B-C1706203
is	O
relevant	B-C2347946
and	O
need	O
an	O
urgent	O
response	O
because	O
their	O
wide	O
distribution	B-C1704711
in	O
semi-arid	B-C0011673
areas	B-C0205146
.	O
	
new	O
cultivars	B-C0032098
are	O
difficult	B-C0332218
to	O
introduce	B-C1292748
in	O
viticulture	B-C0681558
due	O
to	O
the	O
narrow	O
dependency	O
of	O
consumer	B-C1707496
appreciation	B-C2346843
often	O
linked	O
to	O
a	O
certain	O
particular	O
wine	B-C0043188
taste	B-C1547046
.	O
	
clones	B-C1522642
of	O
reputed	O
cultivars	B-C0032098
would	O
presumably	O
be	O
more	O
accepted	B-C1272684
but	O
little	O
is	O
known	O
on	O
the	O
intra-cultivar	B-C0032098
genetic	B-C0314603
variability	B-C2827666
of	O
the	O
wue	B-C0013682
.	O
	
the	O
present	O
work	O
compares	B-C1707455
,	O
on	O
the	O
basis	O
of	O
two	O
field	B-C0001829
assays	O
,	O
the	O
variability	B-C2827666
of	O
intrinsic	O
water	B-C0043047
use	B-C0457083
efficiency	B-C0013682
wuei	B-C0013682
in	O
a	O
large	O
collection	B-C1516698
of	O
cultivars	B-C0032098
in	O
contrast	B-C1979874
with	O
a	O
collection	B-C1516698
of	O
clones	B-C1522642
of	O
tempranillo	B-C0032098
cultivar	I-C0032098
.	O
	
the	O
results	B-C1274040
show	O
that	O
clonal	B-C1704387
variability	B-C2827666
of	O
wuei	B-C0013682
was	O
around	B-C0750503
80%	O
of	O
the	O
inter-cultivar	B-C0032098
,	O
thus	O
providing	O
a	O
first	O
assessment	B-C1516048
on	O
the	O
opportunity	O
for	O
clonal	B-C1704387
selection	B-C1707391
by	O
wue	B-C0013682
.	O
	
plotting	O
the	O
wuei	B-C0013682
data	B-C1511726
against	O
stem	B-C0242767
water	B-C0043047
potential	B-C3245505
or	O
stomatal	B-C1326524
conductance	I-C1326524
it	O
was	O
possible	B-C0332149
to	O
identify	B-C0205396
cultivars	B-C0032098
and	O
clones	B-C1522642
out	O
of	O
the	O
confidence	B-C0009667
intervals	I-C0009667
of	O
this	O
linear	B-C0023733
regression	I-C0023733
thus	O
with	O
significantly	B-C4055637
higher	I-C4055637
and	O
lower	B-C4055638
wuei	B-C0013682
values	B-C1522609
.	O
	
the	O
present	O
results	B-C1274040
contribute	B-C1880177
to	O
open	O
the	O
expectative	O
for	O
a	O
genetic	B-C0314603
improvement	B-C2986411
of	O
grapevine	B-C0330100
wue	B-C0013682
.	O
	
comparison	O
of	O
methods	O
for	O
isolating	B-C0220862
primary	B-C0205225
hepatocytes	B-C0227525
from	O
mini	B-C0039011
pigs	I-C0039011
successful	O
porcine	B-C0039005
hepatocyte	B-C0227525
isolation	B-C0220862
is	O
crucial	O
for	O
the	O
development	B-C1527148
of	O
bioartificial	B-C0336562
liver	I-C0336562
devices	I-C0336562
and	O
hepatocyte	B-C1998344
transplantation	I-C1998344
.	O
	
serva	B-C0162745
collagenase	I-C0162745
nb	I-C0162745
grades	I-C0162745
are	O
formulated	O
collagenases	B-C0162745
that	O
are	O
suitable	O
for	O
various	O
tissue	B-C0040300
isolation	B-C0220862
applications	O
.	O
	
n-acetylcysteine	B-C0001047
nac	B-C0001047
can	O
improve	O
the	O
viability	B-C0443348
of	O
human	B-C0086418
hepatocytes	B-C0227525
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	B-C1280519
of	O
two	O
collagenases	B-C0162745
and	O
effect	B-C1704420
of	I-C1704420
nac	B-C0001047
on	O
hepatocyte	B-C0227525
isolation	B-C0220862
from	O
porcine	B-C0039005
liver	B-C0736268
tissue	I-C0736268
.	O
	
porcine	B-C0039005
hepatocytes	B-C0227525
were	O
isolated	B-C0220862
using	O
the	O
perfusion	B-C0031001
method	I-C0031001
from	O
bama	O
mini	B-C0039011
pigs	I-C0039011
assigned	O
to	O
the	O
serva	B-C0162745
nb	I-C0162745
4	I-C0162745
group	B-C0441833
n=6	O
,	O
the	O
serva	B-C0162745
nb	I-C0162745
8	I-C0162745
group	B-C0441833
n=6	O
,	O
or	O
the	O
nb	B-C0162745
8	I-C0162745
+	O
nac	B-C0001047
group	B-C0441833
n=6	O
.	O
	
viability	B-C0443348
and	O
yield	O
were	O
defined	O
as	O
fresh	O
hepatocytes	B-C0227525
and	O
their	O
spheroids	B-C1844596
formation	I-C1844596
after	O
24-hour	O
rocker	B-C0430400
culture	I-C0430400
in	O
serum-free	B-C0085414
medium	I-C0085414
.	O
	
metabolic	B-C0025519
function	I-C0025519
was	O
assessed	O
by	O
gene	B-C0017262
expression	I-C0017262
,	O
albumin	B-C0001924
,	O
and	O
urea	B-C0041942
synthesis	B-C0220781
.	O
	
all	O
procedures	O
resulted	O
in	O
successful	O
hepatocyte	B-C0227525
isolation	B-C0220862
.	O
	
cells	B-C0007634
from	O
the	O
nb	B-C0162745
8	I-C0162745
+	O
nac	B-C0001047
group	B-C0441833
had	O
97.8	O
viability	B-C0443348
,	O
which	O
was	O
higher	O
than	O
the	O
nb	B-C0162745
8	I-C0162745
group	B-C0441833
with	O
94.4	O
and	O
the	O
nb	B-C0162745
4	I-C0162745
group	B-C0441833
with	O
94.5	O
p<	O
.	O
	
the	O
final	O
cell	B-C0007634
yield	O
reached	O
11.8	O
cells	B-C0007634
in	O
the	O
nb	B-C0162745
8	I-C0162745
+	O
nac	B-C0001047
group	B-C0441833
,	O
compared	O
to	O
9.5	O
cells	B-C0007634
in	O
the	O
nb	B-C0162745
8	I-C0162745
group	B-C0441833
p<	O
and	O
9.1	O
10	O
cells	B-C0007634
in	O
the	O
nb	B-C0162745
4	I-C0162745
group	B-C0441833
p<	O
.	O
	
the	O
secretion	B-C0036536
of	O
albumin	B-C0001924
was	O
superior	O
in	O
the	O
nb	B-C0162745
8	I-C0162745
+	O
nac	B-C0001047
group	B-C0441833
at	O
a	O
concentration	O
of	O
425.8	O
ng/ml	O
compared	O
to	O
the	O
nb	B-C0162745
8	I-C0162745
group	B-C0441833
339.1	O
ng/ml	O
p	O
<	O
and	O
nb	B-C0162745
4	I-C0162745
group	B-C0441833
293.6	O
ng/ml	O
p	O
<	O
.	O
	
the	O
injury	B-C0178314
of	O
hepatocytes	B-C0227525
also	O
decreased	O
in	O
the	O
nb	B-C0162745
8	I-C0162745
+	O
nac	B-C0001047
group	B-C0441833
p<	O
.	O
	
the	O
data	O
are	O
presented	O
as	O
means	B-C0444504
sd	I-C0444504
.	O
	
formulated	O
collagenase	B-C0162745
serva	I-C0162745
nb	I-C0162745
8	I-C0162745
and	O
nac	B-C0001047
could	O
improve	O
the	O
porcine	B-C0039005
hepatocyte	B-C0227525
isolation	B-C0220862
,	O
resulting	O
in	O
higher	O
yields	O
of	O
viable	B-C1441322
cells	I-C1441322
.	O
	
endothermal	B-C2242647
venous	I-C2242647
ablation	I-C2242647
of	O
the	O
saphenous	B-C0036186
vein	I-C0036186
on	O
patients	B-C0030705
who	O
are	O
on	O
anticoagulation	B-C0003281
therapy	I-C0003281
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
risks	B-C0035647
of	O
bleeding	B-C0019080
,	O
deep	B-C0149871
venous	I-C0149871
thrombosis	I-C0149871
dvt	B-C0149871
,	O
endovenous	B-C0042487
heat	I-C0042487
induced	I-C0042487
thrombosis	I-C0042487
ehit	B-C0042487
and	O
failure	B-C0231174
of	O
ablation	B-C0547070
on	O
patients	B-C0030705
who	O
undergo	O
ablation	B-C0547070
while	O
on	O
oral	B-C0003281
anticoagulation	I-C0003281
.	O
	
we	O
compared	B-C1707455
378	O
3.4	O
out	O
of	O
11252	O
patients	B-C0030705
group	B-C0441835
a	I-C0441835
who	O
had	O
undergone	O
724	O
endovenous	B-C2242647
ablation	I-C2242647
of	O
the	O
saphenous	B-C0036186
veins	I-C0036186
from	O
january	O
1	O
,	O
2011	O
to	O
september	O
30	O
,	O
2014	O
while	O
on	O
oral	B-C0003281
anticoagulation	I-C0003281
to	O
a	O
randomly	O
selected	O
375	O
patients	B-C0030705
group	B-C0441836
b	I-C0441836
who	O
underwent	O
641	O
endovenous	B-C2242647
ablation	I-C2242647
in	O
the	O
same	O
time	B-C1948053
period	I-C1948053
but	O
were	O
not	O
on	O
anticoagulation	B-C0003281
.	O
	
the	O
demographic	B-C0392762
data	I-C0392762
,	O
history	B-C0332119
of	I-C0332119
dvt	B-C0149871
,	O
the	O
clinical	B-C0205210
,	O
etiologic	B-C0205556
,	O
anatomic	B-C0220784
,	O
pathologic	B-C1521733
ceap	B-C0205556
classification	B-C0008902
and	O
the	O
vcss	B-C0392762
venous	B-C0392762
clinical	I-C0392762
severity	I-C0392762
score	I-C0392762
scores	O
were	O
analyzed	O
.	O
	
the	O
indications	B-C3146298
for	O
anticoagulation	B-C0003281
,	O
the	O
anticoagulants	B-C0003280
used	O
were	O
recorded	O
.	O
	
the	O
primary	O
endpoints	O
were	O
bleeding	B-C0019080
,	O
development	O
of	O
dvt	B-C0149871
or	O
ehit	B-C0042487
,	O
and	O
failure	B-C0231174
of	O
ablation	B-C0547070
.	O
	
patients	B-C0030705
in	O
group	B-C0441835
a	I-C0441835
were	O
older	B-C3826770
,	O
had	O
more	O
men	B-C0025266
,	O
more	O
history	O
of	O
dvt	B-C0149871
and	O
pe	B-C0034065
,	O
had	O
higher	O
ceap	B-C0205556
and	O
vcss	B-C0392762
scores	O
compared	O
to	O
group	B-C0441836
b	I-C0441836
.	O
	
the	O
type	O
of	O
anticoagulation	B-C0003281
used	O
was	O
warfarin	B-C0043031
in	O
77.2	O
direct	B-C1254351
oral	I-C1254351
inhibitors	I-C1254351
dois	B-C1254351
in	O
22.8	O
.	O
	
the	O
rate	B-C1521828
of	O
failure	B-C0231174
of	O
ablation	B-C0547070
at	O
3	O
days	B-C0439228
was	O
39	O
5.6	O
for	O
group	B-C0441835
a	I-C0441835
and	O
3	O
0.5	O
for	O
group	B-C0441836
b	I-C0441836
p<0	O
and	O
at	O
one	B-C4082115
month	I-C4082115
it	O
was	O
46	O
10.1	O
vs	O
.	O
	
27	O
6.7	O
p=0	O
.	O
	
the	O
number	O
of	O
ehit	B-C0042487
cases	B-C0868928
in	O
group	B-C0441835
a	I-C0441835
at	O
3	O
days	B-C0439228
was	O
2	O
0.3	O
,	O
compared	O
to	O
6	O
0.9	O
in	O
group	B-C0441836
b	I-C0441836
p=0	O
and	O
at	O
1	B-C4082115
month	I-C4082115
it	O
was	O
0	O
compared	O
to	O
4	O
1.0	O
p=0	O
.	O
	
the	O
dvt	B-C0149871
,	O
svt	B-C0039240
,	O
hematoma	B-C0018944
and	O
wound	B-C0043241
infection	I-C0043241
rates	B-C1521828
were	O
similar	O
in	O
the	O
two	O
groups	B-C0441833
.	O
	
ablation	B-C0547070
of	O
the	O
saphenous	B-C0036186
veins	I-C0036186
in	O
patients	B-C0030705
who	O
are	O
on	O
oral	B-C0003281
anticoagulation	I-C0003281
is	O
safe	O
and	O
does	O
not	O
increase	O
the	O
risk	B-C0035647
of	O
bleeding	B-C0019080
or	O
hematoma	B-C0018944
,	O
but	O
it	O
may	O
slightly	O
lower	O
the	O
incidence	B-C0021149
of	O
ehit	B-C0042487
and	O
increase	O
the	O
incidence	B-C0021149
of	O
failure	B-C0231174
of	O
variation	B-C0242481
analysis	I-C0242481
of	O
prim1	B-C1335259
gene	I-C1335259
in	O
chinese	B-C0152035
patients	B-C0030705
with	O
primary	B-C0085215
ovarian	I-C0085215
insufficiency	I-C0085215
insights	O
into	O
common	O
genetic	B-C0314657
susceptibility	I-C0314657
between	O
primary	B-C0085215
ovarian	I-C0085215
insufficiency	I-C0085215
poi	B-C0085215
and	O
natural	B-C0856856
or	O
early	B-C0025322
menopause	I-C0025322
have	O
delivered	B-C1705822
an	O
innovative	O
way	O
of	O
assessing	O
the	O
genetic	B-C0017399
mechanisms	I-C0017399
involved	O
in	O
poi	B-C0085215
.	O
	
prim1	B-C1335259
plays	O
a	O
crucial	O
role	O
in	O
dna	B-C0598312
replication	I-C0598312
by	O
synthesizing	B-C1883254
rna	B-C0073429
primers	I-C0073429
for	O
okazaki	B-C0069390
fragments	I-C0069390
.	O
	
it	O
is	O
closely	O
associated	B-C0332281
with	I-C0332281
age	B-C0001779
at	O
natural	B-C0856856
menopause	I-C0856856
,	O
early	B-C0025322
menopause	I-C0025322
and	O
poi	B-C0085215
in	O
european	B-C0239307
women	B-C0043210
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
aimed	O
to	O
investigate	B-C1292732
whether	O
mutations	B-C0026882
in	O
prim1	B-C1335259
contribute	O
to	O
poi	B-C0085215
in	O
chinese	B-C0152035
women	B-C0043210
.	O
	
all	O
exons	B-C0015295
and	O
exon-intron	B-C0028606
boundaries	I-C0028606
of	O
prim1	B-C1335259
gene	I-C1335259
were	O
sequenced	B-C1294197
in	O
192	O
han	B-C0814942
chinese	I-C0814942
women	B-C0043210
with	O
non-syndromic	O
poi	B-C0085215
.	O
	
no	O
plausible	O
mutations	B-C0026882
were	O
identified	B-C0205396
.	O
	
the	O
results	O
suggest	O
that	O
the	O
perturbations	B-C0332453
in	O
prim1	B-C1335259
gene	I-C1335259
are	O
not	O
a	O
common	O
explanation	O
for	O
poi	B-C0085215
in	O
chinese	B-C0152035
women	B-C0043210
.	O
	
selection	B-C1707391
of	O
a	O
marker	B-C0017337
gene	I-C0017337
to	O
construct	O
a	O
reference	B-C0023621
library	I-C0023621
for	O
wetland	B-C1721088
plants	B-C0032098
,	O
and	O
the	O
application	O
of	O
metabarcoding	B-C2936547
to	O
analyze	B-C0936012
the	O
diet	B-C0012155
of	O
wintering	B-C0241737
herbivorous	B-C0562691
waterbirds	B-C0005595
food	B-C0016452
availability	B-C0470187
and	O
diet	B-C0012155
selection	B-C1707391
are	O
important	O
factors	B-C1521761
influencing	B-C4054723
the	O
abundance	B-C2346714
and	O
distribution	B-C1704711
of	O
wild	B-C0445392
waterbirds	B-C0005595
.	O
	
in	O
order	O
to	O
better	O
understand	O
changes	B-C0392747
in	O
waterbird	B-C0005595
population	B-C0032659
,	O
it	O
is	O
essential	O
to	O
figure	O
out	O
what	O
they	O
feed	B-C3853577
on	I-C3853577
.	O
	
however	O
,	O
analyzing	B-C0936012
their	O
diet	B-C0012155
could	O
be	O
difficult	B-C0332218
and	O
inefficient	B-C0231185
using	O
traditional	O
methods	B-C0025664
such	O
as	O
microhistologic	B-C0019637
observation	I-C0019637
.	O
	
here	O
,	O
we	O
addressed	O
this	O
gap	O
of	O
knowledge	O
by	O
investigating	O
the	O
diet	B-C0012155
of	O
greater	B-C1015285
white-fronted	I-C1015285
goose	I-C1015285
anser	I-C1015285
albifrons	I-C1015285
and	O
bean	B-C1015285
goose	I-C1015285
anser	I-C1015285
fabalis	I-C1015285
,	O
which	O
are	O
obligate	B-C0562691
herbivores	I-C0562691
wintering	B-C0241737
in	O
china	B-C0008115
,	O
mostly	O
in	O
the	O
middle	B-C0017446
and	O
lower	B-C0017446
yangtze	I-C0017446
river	I-C0017446
floodplain	I-C0017446
.	O
	
first	O
,	O
we	O
selected	B-C1707391
a	O
suitable	B-C3900053
and	O
high-resolution	O
marker	B-C0017337
gene	I-C0017337
for	O
wetland	B-C1721088
plants	B-C0032098
that	O
these	O
geese	B-C0017225
would	O
consume	O
during	O
the	O
wintering	B-C0241737
period	I-C0241737
.	O
	
eight	O
candidate	B-C0017337
genes	I-C0017337
were	O
included	O
rbcl	B-C0017337
,	O
rpoc1	B-C0017337
,	O
rpob	B-C0017337
,	O
matk	B-C1334485
,	O
trnh-psba	B-C2936548
,	O
trnl	B-C1421162
uaa	B-C1956149
,	O
atpf-atph	B-C2936548
,	O
and	O
psbk-psbi	B-C2936548
.	O
	
the	O
selection	B-C1707391
was	O
performed	O
via	O
analysis	B-C0936012
of	O
representative	B-C1882932
sequences	B-C0162326
from	O
ncbi	B-C1705803
and	O
comparison	B-C1707455
of	O
amplification	B-C0017256
efficiency	B-C0013682
and	O
resolution	O
power	O
of	O
plant	B-C0032098
samples	B-C0370003
collected	O
from	O
the	O
wintering	B-C0017446
area	I-C0017446
.	O
	
the	O
trnl	B-C1421162
gene	I-C1421162
was	O
chosen	O
at	O
last	O
with	O
c/h	B-C0206416
primers	I-C0206416
,	O
and	O
a	O
local	B-C0205276
plant	B-C0032098
reference	B-C0023621
library	I-C0023621
was	O
constructed	B-C2827421
with	O
this	O
gene	B-C0017337
.	O
	
then	O
,	O
utilizing	O
dna	B-C2936547
metabarcoding	I-C2936547
,	O
we	O
discovered	B-C1880355
15	O
food	B-C0016452
items	I-C0016452
in	O
total	O
from	O
the	O
feces	B-C0015733
of	O
these	O
birds	B-C0005595
.	O
	
of	O
the	O
15	O
unique	O
dietary	B-C0012155
sequences	B-C0162326
,	O
10	O
could	O
be	O
identified	O
at	O
specie	B-C1705920
level	B-C0441889
.	O
	
as	O
for	O
greater	B-C1015285
white-fronted	I-C1015285
goose	I-C1015285
,	O
73%	O
of	O
sequences	B-C0162326
belonged	O
to	O
poaceae	B-C0018210
spp	I-C0018210
,	O
and	O
26%	O
belonged	O
to	O
carex	B-C1000671
spp	I-C1000671
.	O
	
in	O
contrast	O
,	O
almost	O
all	O
sequences	B-C0162326
of	O
bean	B-C1064115
goose	I-C1064115
belonged	O
to	O
carex	B-C1000671
spp	I-C1000671
.	O
	
99%	O
.	O
	
using	O
the	O
same	O
samples	B-C0370003
,	O
microhistology	B-C0019637
provided	O
consistent	B-C0332290
food	B-C0459115
composition	I-C0459115
with	O
metabarcoding	B-C2936547
results	B-C1274040
for	O
greater	B-C1015285
white-fronted	I-C1015285
goose	I-C1015285
,	O
while	O
13%	O
of	O
poaceae	B-C0018210
was	O
recovered	O
for	O
bean	B-C1064115
goose	I-C1064115
.	O
	
in	O
addition	O
,	O
two	O
other	O
taxa	B-C1515221
were	O
discovered	B-C1880355
only	O
through	O
microhistologic	B-C0019637
analysis	I-C0019637
.	O
	
although	O
most	O
of	O
the	O
identified	O
taxa	B-C1515221
matched	B-C1708943
relatively	O
well	O
between	O
the	O
two	O
methods	B-C0025664
,	O
dna	B-C2936547
metabarcoding	I-C2936547
gave	O
taxonomically	B-C0008903
more	O
detailed	B-C1533716
information	I-C1533716
.	O
	
discrepancies	B-C1290905
were	O
likely	O
due	O
to	O
biased	B-C0242568
pcr	B-C0032520
amplification	B-C0017256
in	O
metabarcoding	B-C2936547
,	O
low	O
discriminating	B-C2987623
power	B-C3854080
of	O
current	O
marker	B-C0017337
genes	I-C0017337
for	O
monocots	B-C0331451
,	O
and	O
biases	B-C0242568
in	O
microhistologic	B-C0019637
analysis	I-C0019637
.	O
	
the	O
diet	B-C0012155
differences	B-C1705242
between	O
two	O
geese	B-C0017225
species	B-C1705920
might	O
indicate	O
deeper	O
ecological	B-C0162358
significance	B-C0750502
beyond	O
the	O
scope	O
of	O
this	O
study	B-C2603343
.	O
	
we	O
concluded	O
that	O
dna	B-C2936547
metabarcoding	I-C2936547
provides	O
new	O
perspectives	B-C0683498
for	O
studies	B-C2603343
of	O
herbivorous	B-C0562691
waterbird	B-C0005595
diets	B-C0012155
and	O
inter-specific	B-C1704675
interactions	I-C1704675
,	O
as	O
well	O
as	O
new	O
possibilities	O
to	O
investigate	B-C1292732
interactions	B-C1704675
between	O
herbivores	B-C0562691
and	O
plants	B-C0032098
.	O
	
in	O
addition	O
,	O
microhistologic	B-C0019637
analysis	I-C0019637
should	O
be	O
used	O
together	O
with	O
metabarcoding	B-C2936547
methods	I-C2936547
to	O
integrate	O
this	O
expressions	B-C1171362
of	O
cd8	B-C0085358
+	O
tils	B-C0079722
,	O
pd-l1	B-C0965245
and	O
foxp3	B-C1504797
+	O
tils	B-C0079722
in	O
stage	B-C0278504
i	I-C0278504
nsclc	I-C0278504
guiding	O
adjuvant	B-C0085533
chemotherapy	I-C0085533
decisions	B-C0679006
currently	O
,	O
adjuvant	B-C0085533
chemotherapy	I-C0085533
is	O
recommended	B-C0034866
for	O
patients	B-C0030705
with	O
high	B-C0332167
risk	I-C0332167
stage	B-C0278504
i	I-C0278504
non-small	I-C0278504
cell	I-C0278504
lung	I-C0278504
cancer	I-C0278504
nsclc	B-C0007131
.	O
	
however	O
,	O
identifying	B-C0205396
high	B-C0332167
risk	I-C0332167
patients	B-C0030705
remains	O
a	O
challenge	O
.	O
	
this	O
study	B-C2603343
aims	B-C1947946
to	O
identify	B-C0205396
the	O
patient	B-C0030705
cohorts	B-C0599755
more	O
likely	O
to	O
benefit	O
from	O
adjuvant	B-C0085533
chemotherapy	I-C0085533
based	O
on	O
the	O
tumor	B-C0027651
micro-immune	B-C0439662
environment	B-C0014406
.	O
	
cd8	B-C0085358
+	O
tils	B-C0079722
significantly	B-C0332281
associated	I-C0332281
with	I-C0332281
disease-free	B-C0242793
survival	I-C0242793
dfs	B-C0242793
and	O
overall	B-C4086681
survial	I-C4086681
os	B-C4086681
p=0	O
0.040	O
.	O
	
patients	B-C0030705
with	O
high	B-C1830377
risk	I-C1830377
factors	I-C1830377
may	O
also	O
predict	O
shorter	O
dfs	B-C0242793
p=0	O
.	O
	
when	O
compared	B-C1707455
together	O
,	O
patients	B-C0030705
with	O
high	B-C0205250
-	O
cd8	B-C0085358
+	O
tils	B-C0079722
showed	O
better	O
dfs	B-C0242793
than	O
patients	B-C0030705
with	O
low	B-C0205251
-	O
cd8	B-C0085358
+	O
tils	B-C0079722
,	O
no	O
matter	O
their	O
risk	B-C1830377
factors	I-C1830377
status	O
.	O
	
there's	O
no	B-C0243095
correlation	I-C0243095
between	O
pd-l1	B-C0965245
expressions	B-C1171362
and	O
survival	B-C0220921
.	O
	
pd-l1	B-C0965245
was	O
highly	B-C0205250
expressed	B-C1171362
in	O
men	B-C0025266
,	O
squamous	B-C1182670
and	O
well	B-C0205615
differentiated	I-C0205615
carcinoma	B-C0278504
.	O
	
in	O
addition	O
,	O
foxp3	B-C1504797
+	O
tils	B-C0079722
alone	O
didn't	O
show	O
any	O
prognostic	O
effects	O
,	O
but	O
low	B-C0205251
-	O
foxp3	B-C1504797
/	O
high	B-C0205250
-	O
cd8	B-C0085358
+	O
tils	B-C0079722
were	O
associated	B-C0332281
with	I-C0332281
prolonged	B-C0439590
dfs	B-C0242793
p=0	O
.	O
	
a	O
total	O
of	O
126	O
patients	B-C0030705
with	O
surgically	B-C1521996
resected	I-C1521996
stage	B-C0278504
i	I-C0278504
nsclc	I-C0278504
were	O
included	B-C0332257
to	O
perform	O
immunohistochemistry	B-C0021044
of	O
cd8	B-C0085358
+	O
tumor	B-C0079722
infiltrating	I-C0079722
lymphocytes	I-C0079722
tils	B-C0079722
,	O
programmed	B-C0965245
death	I-C0965245
ligand-1	I-C0965245
pd-l1	B-C0965245
and	O
forkhead	B-C1504797
box	I-C1504797
p3	I-C1504797
foxp3	B-C1504797
tils	B-C0079722
.	O
	
cd8	B-C0085358
+	O
tils	B-C0079722
are	O
effective	B-C1704419
prognostic	O
predictors	O
.	O
	
patients	B-C0030705
with	O
surgically	B-C1521996
resected	I-C1521996
stage	B-C0278504
i	I-C0278504
nsclc	I-C0278504
showing	O
low	O
cd8	B-C0085358
+	O
tils	B-C0079722
could	O
be	O
considered	O
for	O
adjuvant	B-C0085533
chemotherapy	I-C0085533
,	O
even	O
if	O
they	O
have	O
no	O
high	B-C0332167
risk	I-C0332167
unaffected	O
twins	B-C2609166
discordant	I-C2609166
for	O
affective	B-C0001723
disorders	I-C0001723
show	O
changes	O
in	O
anterior	B-C0226208
callosal	I-C0226208
white	B-C0682708
matter	I-C0682708
microstructure	B-C0678594
the	O
neurobiological	B-C0027817
mechanisms	B-C0441712
mediating	O
an	O
increased	O
risk	B-C0035647
to	O
develop	O
affective	B-C0001723
disorders	I-C0001723
remain	O
poorly	O
understood	O
.	O
	
in	O
a	O
group	B-C0027361
of	I-C0027361
individuals	I-C0027361
with	O
a	O
family	B-C0241889
history	I-C0241889
of	O
major	B-C1269683
depressive	I-C1269683
mdd	B-C1269683
or	O
bipolar	B-C0005586
disorder	I-C0005586
bd	B-C0005586
,	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white	B-C0682708
matter	I-C0682708
fiber	B-C3499212
tracts	I-C3499212
,	O
that	O
is	O
,	O
cingulum	B-C0228272
bundle	I-C0228272
,	O
uncinate	B-C0228271
fasciculus	I-C0228271
,	O
anterior	B-C0152342
limb	I-C0152342
of	I-C0152342
the	I-C0152342
internal	I-C0152342
capsule	I-C0152342
,	O
and	O
corpus	B-C0010090
callosum	I-C0010090
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain	B-C1273723
regions	I-C1273723
implicated	O
in	O
affective	B-C0001723
disorders	I-C0001723
.	O
	
eighty-nine	O
healthy	O
mono	B-C0041432
-	O
or	O
dizygotic	B-C0041429
twins	I-C0041429
with	O
a	O
co-twin	B-C0041427
diagnosed	B-C0011900
with	O
mdd	B-C1269683
or	O
bd	B-C0005586
high-risk	B-C1257890
and	O
57	O
healthy	B-C3898900
twins	B-C0872326
with	O
a	O
co-twin	B-C0041427
with	O
no	B-C0332123
familial	I-C0332123
history	I-C0332123
of	I-C0332123
affective	B-C0001723
disorders	I-C0001723
low-risk	O
were	O
included	O
in	O
a	O
diffusion	B-C1537007
tensor	I-C1537007
imaging	I-C1537007
study	I-C1537007
.	O
	
the	O
high-risk	B-C1257890
group	I-C1257890
showed	O
decreased	O
fractional	B-C2348041
anisotropy	I-C2348041
fa	B-C2348041
,	O
a	O
measure	O
of	O
water	B-C0043047
diffusion	B-C0012222
directionality	B-C1707761
,	O
and	O
increased	O
radial	B-C0442038
diffusivity	B-C3899378
in	O
the	O
anterior	B-C0152325
region	I-C0152325
of	I-C0152325
corpus	I-C0152325
callosum	I-C0152325
compared	O
to	O
the	O
low-risk	B-C1257890
group	I-C1257890
.	O
	
this	O
abnormality	B-C1704258
was	O
not	O
associated	O
with	O
zygosity	B-C1710709
or	O
type	O
of	O
depressive	B-C0011581
disorder	I-C0011581
of	O
co-twin	B-C0041427
.	O
	
the	O
observed	O
decreased	O
anterior	B-C0010090
callosal	I-C0010090
fiber	I-C0010090
fa	B-C2348041
in	O
the	O
high-risk	B-C1257890
group	I-C1257890
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric	B-C0870728
communication	I-C0870728
between	O
left	B-C0228194
and	O
right	B-C0228193
frontal	I-C0228193
regions	I-C0228193
critically	O
involved	O
in	O
mood	B-C2370884
regulation	I-C2370884
.	O
	
reduced	O
anterior	B-C0010090
callosal	I-C0010090
fa	B-C2348041
may	O
act	O
as	O
a	O
vulnerability	B-C0679109
marker	B-C0005516
for	O
affective	B-C0001723
disorders	I-C0001723
in	O
individuals	B-C0237401
at	O
familial	B-C0035647
risk	I-C0035647
.	O
	
a	O
window	O
on	O
the	O
study	B-C0004415
of	I-C0004415
aversive	I-C0004415
instrumental	B-C0009651
learning	I-C0009651
strains	B-C1518614
,	O
performance	B-C1882330
,	O
neuroendocrine	B-C0027912
,	O
and	O
immunologic	B-C0020962
systems	I-C0020962
the	O
avoidance	B-C0870186
response	B-C0871261
is	O
present	O
in	O
pathological	B-C1521733
anxiety	B-C0003467
and	O
interferes	O
with	O
normal	B-C0542341
daily	I-C0542341
functions	I-C0542341
.	O
	
the	O
aim	O
of	O
this	O
article	O
is	O
to	O
shed	O
light	O
on	O
performance	B-C1882330
markers	O
of	O
active	B-C0871637
avoidance	I-C0871637
aa	B-C0871637
using	O
two	O
different	O
rat	B-C1514734
strains	I-C1514734
,	O
sprague-dawley	B-C2699239
sd	B-C2699239
and	O
wistar	B-C2700262
.	O
	
specifically	O
,	O
good	O
and	O
poor	O
performers	B-C1550480
were	O
evaluated	B-C0220825
regarding	O
anxiety	B-C0003467
traits	B-C0599883
exhibited	O
in	O
the	O
elevated	B-C0870866
plus	I-C0870866
maze	I-C0870866
epm	B-C0870866
and	O
corticosterone	B-C0857657
levels	I-C0857657
and	O
motor	B-C0234130
activity	I-C0234130
in	O
the	O
open	B-C0022885
field	I-C0022885
test	I-C0022885
.	O
	
in	O
addition	O
,	O
the	O
plasma	B-C0022885
levels	I-C0022885
of	O
interleukin-6	B-C0021760
il-6	B-C0021760
,	O
interleukin-1beta	B-C0021753
il-1beta	B-C0021753
,	O
nerve	B-C0027753
growth	I-C0027753
factor	I-C0027753
beta	I-C0027753
ngf-beta	B-C0027753
,	O
tumor	B-C0041368
necrosis	I-C0041368
factor-alpha	I-C0041368
tnf-alpha	B-C0041368
and	O
cytokine-induced	B-C0378112
neutrophil	I-C0378112
chemoattractant	I-C0378112
1	I-C0378112
cinc-1	B-C0378112
were	O
compared	O
in	O
the	O
good	O
and	O
poor	O
performers	B-C1550480
to	O
better	O
understand	O
the	O
role	O
of	O
the	O
immunologic	B-C0020962
system	I-C0020962
in	O
aversive	B-C0004415
learning	I-C0004415
.	O
	
behavioral	B-C2986890
criteria	I-C2986890
were	O
employed	O
to	O
identify	O
subpopulations	B-C1257890
of	O
sd	B-C0034715
and	O
wistar	B-C0034716
rats	I-C0034716
based	O
on	O
their	O
behavioral	B-C2986890
scores	I-C2986890
during	O
a	O
two-way	O
aa	B-C0871637
test	B-C0392366
.	O
	
the	O
animals	B-C0003062
were	O
tested	B-C0392366
for	O
anxiety	B-C0003467
-like	O
behavior	B-C0004927
in	O
the	O
epm	B-C0870866
and	O
motor	B-C0234130
activity	I-C0234130
in	O
the	O
open-field	B-C0022885
test	I-C0022885
.	O
	
plasma	B-C0857657
corticosterone	I-C0857657
levels	I-C0857657
were	O
measured	B-C0444706
at	O
the	O
end	O
of	O
the	O
avoidance	B-C0870186
test	B-C0392366
.	O
	
cytokine	B-C2699541
levels	I-C2699541
of	O
il-6	B-C0021760
,	O
il-1beta	B-C0021753
,	O
ngf-beta	B-C0027753
,	O
tnf-alpha	B-C0041368
,	O
and	O
cinc-1	B-C0378112
were	O
measured	B-C0444706
in	O
the	O
plasma	B-C0032105
of	O
the	O
wistar	B-C0034716
rats	I-C0034716
.	O
	
sixty-six	O
percent	O
of	O
the	O
wistar	B-C0034716
rats	I-C0034716
and	O
35%	O
of	O
the	O
sd	B-C0034715
rats	I-C0034715
exhibited	O
a	O
poor	O
performance	B-C1882330
.	O
	
this	O
feature	O
was	O
associated	B-C0332281
with	I-C0332281
a	O
decrease	O
in	O
anxiety	B-C0003467
-like	O
behavior	B-C0004927
in	O
the	O
epm	B-C0870866
.	O
	
the	O
poor	O
and	O
good	O
performers	B-C1550480
exhibited	O
lower	O
levels	B-C0857657
of	I-C0857657
corticosterone	I-C0857657
compared	O
with	O
the	O
control	B-C1511501
animals	I-C1511501
,	O
which	O
suggests	O
that	O
training	O
alters	O
corticosterone	B-C0857657
levels	I-C0857657
,	O
thereby	O
leading	O
to	O
hypocortisolism	B-C0001403
,	O
independent	O
of	O
the	O
performance	B-C1882330
.	O
	
the	O
cinc-1	B-C0378112
levels	B-C0441889
were	O
increased	O
in	O
the	O
poor	O
performers	B-C1550480
,	O
which	O
reinforces	O
the	O
role	O
of	O
immunologic	B-C0020962
system	I-C0020962
activation	B-C1879547
in	O
learning	B-C0851265
deficits	I-C0851265
.	O
	
our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
complex	B-C0439855
interactions	B-C1704675
that	O
underlie	O
neuroimmune	B-C0682644
consequences	B-C0686907
and	O
their	O
implications	O
for	O
costing	B-C0220812
'	O
healthy'	B-C0453857
food	I-C0453857
baskets	I-C0453857
in	O
australia	B-C0004340
-	O
a	O
systematic	B-C1955832
review	I-C1955832
of	O
food	B-C0016452
price	B-C0080045
and	O
affordability	B-C0814630
monitoring	B-C0282574
tools	I-C0282574
,	O
protocols	B-C0442711
and	O
methods	B-C0025663
to	O
undertake	O
a	O
systematic	B-C1955832
review	I-C1955832
to	O
determine	O
similarities	B-C2348205
and	O
differences	B-C1705242
in	O
metrics	B-C0025867
and	O
results	B-C1274040
between	O
recently	B-C0332185
and/or	O
currently	B-C0521116
used	O
tools	B-C0282574
,	O
protocols	B-C0442711
and	O
methods	B-C0025663
for	O
monitoring	B-C1283169
australian	B-C0004340
healthy	B-C0453857
food	I-C0453857
prices	B-C0080045
and	O
affordability	B-C0814630
.	O
	
electronic	B-C0242356
databases	I-C0242356
of	O
peer-reviewed	B-C0023866
literature	I-C0023866
and	O
online	B-C0023866
grey	I-C0023866
literature	I-C0023866
were	O
systematically	B-C0220922
searched	B-C1706202
using	O
the	O
prisma	B-C0242481
approach	O
for	O
articles	B-C1706852
and	O
reports	B-C0684224
relating	O
to	O
healthy	B-C0453857
food	I-C0453857
and	O
diet	B-C0282574
price	I-C0282574
assessment	I-C0282574
tools	I-C0282574
,	O
protocols	B-C0442711
,	O
methods	B-C0025663
and	O
results	B-C1274040
that	O
utilised	O
retail	B-C0080045
pricing	I-C0080045
.	O
	
national	B-C0681784
,	O
state	B-C1301808
,	O
regional	B-C0205147
and	O
local	B-C0017446
areas	I-C0017446
of	O
australia	B-C0004340
from	O
1995	O
to	O
2015	O
.	O
	
assessment	B-C0282574
tools	I-C0282574
,	O
protocols	B-C0442711
and	O
methods	B-C0025663
to	O
measure	B-C0079809
the	O
price	B-C0080045
of	O
'healthy'	B-C0453857
foods	I-C0453857
and	O
diets	B-C0012155
.	O
	
the	O
search	O
identified	B-C0205396
fifty-nine	O
discrete	O
surveys	B-C0038951
of	O
'	O
healthy'	B-C0453857
food	I-C0453857
pricing	B-C0080045
incorporating	O
six	O
major	O
food	B-C0282574
pricing	I-C0282574
tools	I-C0282574
those	O
used	O
in	O
multiple	B-C4266465
areas	I-C4266465
and	O
time	B-C1948053
periods	I-C1948053
and	O
five	O
minor	B-C0205165
food	B-C0282574
pricing	I-C0282574
tools	I-C0282574
those	O
used	O
in	O
a	O
single	B-C0445260
survey	I-C0445260
area	I-C0445260
or	O
time	B-C1948053
period	I-C1948053
.	O
	
analysis	B-C0936012
demonstrated	O
methodological	B-C3266812
differences	B-C1705242
regarding	O
included	B-C0332257
foods	B-C0016452
reference	B-C0020052
households	I-C0020052
use	O
of	O
availability	B-C0470187
and/or	O
quality	B-C3242457
measures	I-C3242457
household	B-C0557163
income	I-C0557163
sources	B-C0449416
store	B-C0680165
sampling	B-C0449370
methods	I-C0449370
data	B-C0010995
collection	I-C0010995
protocols	B-C0442711
analysis	B-C3900047
methods	I-C3900047
and	O
results	B-C1274040
.	O
	
'	O
healthy'	B-C0453857
food	I-C0453857
price	B-C0080045
assessment	B-C1516048
methods	B-C0025663
used	O
in	O
australia	B-C0004340
lack	B-C0332268
comparability	B-C1707455
across	O
all	O
metrics	B-C0025867
and	O
most	O
do	O
not	O
fully	O
align	O
with	O
a	O
'	O
healthy'	B-C0012155
diet	I-C0012155
as	O
recommended	B-C0034866
by	O
the	O
current	O
australian	B-C3658297
dietary	I-C3658297
guidelines	I-C3658297
.	O
	
none	O
have	O
been	O
applied	O
nationally	O
.	O
	
assessment	B-C1516048
of	O
the	O
price	B-C0080045
,	O
price	B-C1549478
differential	I-C1549478
and	O
affordability	B-C0814630
of	O
healthy	B-C0452415
recommended	B-C0034866
and	O
current	B-C0521116
unhealthy	B-C3805118
diets	I-C3805118
would	O
provide	B-C1999230
more	O
robust	B-C2986815
and	O
meaningful	O
data	B-C1511726
to	O
inform	O
health	B-C0681005
and	I-C0681005
fiscal	I-C0681005
policy	I-C0681005
in	O
australia	B-C0004340
.	O
	
the	O
informas	B-C0282574
'	O
optimal	B-C2698651
'	O
approach	O
provides	O
a	O
potential	B-C3245505
framework	O
for	O
development	B-C1527148
of	O
these	O
consecutive	B-C1707491
endovascular	B-C2936204
treatment	I-C2936204
of	O
20	O
ruptured	B-C0443294
very	O
small	B-C0700321
<3	O
mm	O
anterior	B-C0740386
communicating	I-C0740386
artery	I-C0740386
aneurysms	I-C0740386
small	B-C0700321
aneurysms	B-C0740386
located	O
at	O
the	O
anterior	B-C0149562
communicating	I-C0149562
artery	I-C0149562
carry	O
significant	O
procedural	O
challenges	O
due	O
to	O
a	O
complex	O
anatomy	B-C0700276
.	O
	
recent	O
advances	O
in	O
endovascular	B-C2936204
technologies	I-C2936204
have	O
expanded	O
the	O
use	O
of	O
coil	B-C0189713
embolization	I-C0189713
for	O
small	B-C0700321
aneurysm	B-C0740386
treatment	B-C1522326
.	O
	
however	O
,	O
limited	O
reports	O
describe	O
their	O
safety	B-C0036043
and	O
efficacy	B-C1280519
profiles	O
in	O
very	O
small	B-C0700321
anterior	B-C0740386
communicating	I-C0740386
artery	I-C0740386
aneurysms	I-C0740386
.	O
	
we	O
sought	O
to	O
review	O
and	O
report	O
the	O
immediate	O
and	O
long-term	B-C0085415
clinical	I-C0085415
as	O
well	O
as	O
radiographic	B-C0085415
outcomes	I-C0085415
of	O
consecutive	B-C1707491
patients	B-C0030705
with	O
ruptured	B-C0443294
very	O
small	B-C0700321
anterior	B-C0740386
communicating	I-C0740386
artery	I-C0740386
aneurysms	I-C0740386
treated	O
with	O
current	O
endovascular	B-C0189713
coil	I-C0189713
embolization	I-C0189713
techniques	I-C0189713
.	O
	
a	O
prospectively	O
maintained	O
single-institution	O
neuroendovascular	B-C0242356
database	I-C0242356
was	O
accessed	O
to	O
identify	O
consecutive	O
cases	O
of	O
very	O
small	B-C0700321
<3	O
mm	O
ruptured	B-C0443294
anterior	B-C0740386
communicating	I-C0740386
artery	I-C0740386
aneurysms	I-C0740386
treated	O
endovascularly	O
between	O
2006	O
and	O
2013	O
.	O
	
a	O
total	O
of	O
20	O
patients	B-C0030705
with	O
ruptured	B-C0443294
very	O
small	B-C0700321
<3	O
mm	O
anterior	B-C0740386
communicating	I-C0740386
artery	I-C0740386
aneurysms	I-C0740386
were	O
consecutively	B-C1707491
treated	O
with	O
coil	B-C0189713
embolization	I-C0189713
.	O
	
the	O
average	O
maximum	O
diameter	B-C1301886
was	O
2.66	O
0.41	O
mm	O
.	O
	
complete	O
aneurysm	B-C0189724
occlusion	I-C0189724
was	O
achieved	O
for	O
17	O
85%	O
aneurysms	B-C0740386
and	O
near-complete	O
aneurysm	B-C0189724
occlusion	I-C0189724
for	O
3	O
15%	O
aneurysms	B-C0740386
.	O
	
intraoperative	B-C0456904
perforation	B-C0549099
was	O
seen	O
in	O
2	O
10%	O
patients	B-C0030705
without	O
any	O
clinical	B-C1546960
worsening	I-C1546960
or	O
need	O
for	O
an	O
external	B-C0844106
ventricular	I-C0844106
drain	I-C0844106
.	O
	
a	O
thromboembolic	B-C0040038
event	I-C0040038
occurred	O
in	O
1	O
5	O
%	O
patient	B-C0030705
without	O
clinical	B-C1546960
worsening	I-C1546960
or	O
radiologic	B-C0021308
infarct	I-C0021308
.	O
	
median	O
clinical	O
follow-up	B-C1522577
was	O
12	O
14.1	O
months	B-C0439231
and	O
median	O
imaging	O
follow-up	B-C1522577
was	O
12	O
18.4	O
months	B-C0439231
.	O
	
this	O
report	O
describes	O
the	O
largest	O
series	O
of	O
consecutive	B-C1707491
endovascular	B-C2936204
treatments	I-C2936204
of	O
ruptured	B-C0443294
very	O
small	B-C0700321
anterior	B-C0740386
communicating	I-C0740386
artery	I-C0740386
aneurysms	I-C0740386
.	O
	
these	O
findings	O
suggest	O
that	O
coil	B-C0189713
embolization	I-C0189713
of	O
very	O
small	B-C0700321
aneurysms	B-C0740386
in	O
this	O
location	B-C0450429
can	O
be	O
performed	O
with	O
acceptable	O
rates	O
of	O
complications	B-C0009566
and	O
factors	B-C1521761
affecting	B-C0392760
the	O
formation	B-C1522492
of	O
nitrogenous	B-C0012683
disinfection	I-C0012683
by-products	B-C0684298
during	O
chlorination	B-C2728946
of	O
aspartic	B-C0004015
acid	I-C0004015
in	O
drinking	B-C0599638
water	I-C0599638
the	O
formation	B-C1522492
of	O
emerging	O
nitrogenous	B-C0012683
disinfection	I-C0012683
by-products	B-C0684298
n-dbps	B-C0684298
from	O
the	O
chlorination	B-C2728946
of	O
aspartic	B-C0004015
acid	I-C0004015
asp	B-C0004015
was	O
investigated	B-C1292732
.	O
	
the	O
yield	O
of	O
dichloroacetonitrile	B-C0057843
dcan	B-C0057843
was	O
higher	O
than	O
other	O
n-dbps	B-C0684298
,	O
such	O
as	O
dichloroacetamide	B-C0045293
dcacam	B-C0045293
and	O
chloropicrin	B-C0055437
tcnm	B-C0055437
during	O
the	O
chlorination	B-C2728946
of	O
asp	B-C0004015
.	O
	
the	O
formation	B-C1522492
of	O
dcan	B-C0057843
,	O
dcacam	B-C0045293
,	O
and	O
tcnm	B-C0055437
all	O
showed	O
a	O
trend	O
of	O
first	O
increasing	B-C0442808
and	O
then	O
decreasing	B-C0442797
during	O
the	O
chlorination	B-C2728946
of	O
asp	B-C0004015
with	O
increasing	B-C0442808
contact	B-C1254367
time	I-C1254367
.	O
	
the	O
dosage	B-C0178602
of	O
chlorine	B-C0008209
had	O
an	O
impact	O
on	O
the	O
formation	B-C1522492
of	O
dcan	B-C0057843
,	O
dcacam	B-C0045293
,	O
and	O
tcnm	B-C0055437
.	O
	
the	O
highest	O
yields	B-C0392762
of	O
dcan	B-C0057843
and	O
dcacam	B-C0045293
appeared	O
when	O
the	O
cl2	B-C0008209
/	O
asp	B-C0004015
molar	B-C2825550
ratio	I-C2825550
was	O
about	O
20	O
,	O
the	O
yield	B-C0392762
of	O
tcnm	B-C0055437
increased	B-C0205217
with	O
increasing	B-C0442808
the	O
cl2	B-C0008209
/	O
asp	B-C0004015
molar	B-C2825550
ratio	I-C2825550
from	O
5	O
to	O
30	O
and	O
tcnm	B-C0055437
was	O
not	O
produced	O
when	O
the	O
ratio	B-C2825550
was	O
less	O
than	O
5	O
.	O
	
cyanogen	B-C0056659
chloride	I-C0056659
cncl	B-C0056659
was	O
detected	O
when	O
the	O
cl2	B-C0008209
/	O
asp	B-C0004015
molar	B-C2825550
ratio	I-C2825550
was	O
lower	O
than	O
5	O
.	O
	
n-dbps	B-C0684298
formation	B-C1522492
was	O
influenced	O
by	O
ph	B-C0020283
.	O
	
dcan	B-C0057843
formation	B-C1522492
increased	B-C0205217
with	O
increasing	B-C0442808
ph	B-C0020283
from	O
5	O
to	O
6	O
and	O
then	O
decreased	B-C0205216
with	O
increasing	B-C0442808
ph	B-C0020283
from	O
6	O
to	O
9	O
,	O
but	O
dcacam	B-C0045293
and	O
tcnm	B-C0055437
increased	B-C0205217
with	O
increasing	B-C0442808
ph	B-C0020283
from	O
5	O
to	O
8	O
and	O
then	O
decreased	B-C0205216
.	O
	
higher	O
temperatures	B-C0039476
reduced	B-C0392756
the	O
formation	B-C1522492
of	O
dcan	B-C0057843
and	O
dcacam	B-C0045293
,	O
but	O
increased	B-C0205217
tcnm	B-C0055437
formation	B-C1522492
.	O
	
dcan	B-C0057843
and	O
dcacam	B-C0045293
formation	B-C1522492
decreased	B-C0205216
,	O
and	O
relatively	O
stable	B-C0205360
tcnm	B-C0055437
formation	B-C1522492
increased	B-C0205217
,	O
with	O
increasing	B-C0442808
free	O
chlorine	B-C0008209
contact	B-C1254367
time	I-C1254367
during	O
chloramination	B-C1254366
.	O
	
n-nitrosodimethylamine	B-C0012431
ndma	B-C0012431
was	O
produced	O
during	O
chloramination	B-C1254366
of	O
asp	B-C0004015
and	O
increased	B-C0205217
with	O
prolonged	B-C0439590
chloramination	B-C1254366
contact	B-C1254367
time	I-C1254367
.	O
	
the	O
presence	O
of	O
bromide	B-C3848571
ions	I-C3848571
enhanced	B-C2349975
the	O
yields	B-C0392762
of	O
haloacetonitriles	B-C0001004
and	O
shifted	O
n-dbps	B-C0684298
to	O
more	O
brominated	B-C0029224
species	I-C0029224
.	O
	
midodrine	B-C0026078
and	O
tolvaptan	B-C1176308
in	O
patients	B-C0030705
with	O
cirrhosis	B-C0023890
and	O
refractory	B-C3532188
or	O
recurrent	B-C0741243
ascites	I-C0741243
a	O
randomised	B-C0034656
pilot	B-C0031928
study	I-C0031928
splanchnic	B-C1372887
arterial	I-C1372887
vasodilatation	I-C1372887
and	O
subsequent	O
sodium	B-C0020488
and	O
water	B-C0542203
retention	I-C0542203
play	O
an	O
important	O
role	O
in	O
cirrhotic	B-C0401037
ascites	I-C0401037
.	O
	
midodrine	B-C0026078
and	O
tolvaptan	B-C1176308
have	O
been	O
used	O
separately	O
in	O
these	O
patients	B-C0030705
.	O
	
however	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
use	O
of	O
combination	B-C0013218
of	O
midodrine	B-C0026078
and	O
tolvaptan	B-C1176308
in	O
the	O
control	O
of	O
ascites	B-C0401037
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-C0220825
the	O
safety	B-C0036043
and	O
efficacy	B-C1280519
of	O
midodrine	B-C0026078
,	O
tolvaptan	B-C1176308
and	O
their	O
combination	B-C0013218
in	O
control	O
of	O
refractory	B-C3532188
or	O
recurrent	B-C0741243
ascites	I-C0741243
in	O
cirrhotics	B-C0023890
.	O
	
fifty	O
cirrhotic	B-C0439686
patients	B-C0030705
with	O
refractory	B-C3532188
or	O
recurrent	B-C0741243
ascites	I-C0741243
were	O
randomised	B-C0034656
to	O
receive	O
midodrine	B-C0026078
n=13	O
,	O
tolvaptan	B-C1176308
n=12	O
or	O
both	O
n=13	O
plus	O
standard	O
medical	B-C0418981
therapy	I-C0418981
smt	B-C0418981
or	O
smt	B-C0418981
alone	O
n=12	O
.	O
	
a	O
significant	B-C1287298
increase	I-C1287298
in	I-C1287298
urinary	I-C1287298
volume	I-C1287298
and	O
urinary	B-C3671887
sodium	I-C3671887
at	O
1	O
and	O
3	O
months	B-C0439231
p<	O
was	O
observed	O
in	O
all	O
groups	B-C1257890
except	O
smt	B-C0418981
.	O
	
there	O
was	O
no	O
worsening	B-C0332271
of	O
renal	B-C0232805
or	O
hepatic	B-C0232741
function	I-C0232741
in	O
any	O
group	B-C1257890
.	O
	
there	O
was	O
deterioration	B-C0868945
of	O
model	B-C3826979
for	I-C3826979
end-stage	I-C3826979
liver	I-C3826979
disease	I-C3826979
meld	B-C3826979
in	O
smt	O
.	O
	
midodrine	B-C0026078
as	O
well	O
as	O
combination	B-C0013218
of	O
midodrine	B-C0026078
and	O
tolvaptan	B-C1176308
but	O
not	O
tolvaptan	B-C1176308
alone	O
was	O
superior	O
to	O
smt	B-C0418981
in	O
control	O
of	O
ascites	B-C0401037
at	O
3	O
months	B-C0439231
p<	O
.	O
	
the	O
combination	B-C0013218
therapy	I-C0013218
was	O
also	O
superior	O
to	O
midodrine	B-C0026078
in	O
the	O
control	O
of	O
ascites	B-C0401037
at	O
1	O
month	B-C0439231
.	O
	
the	O
morbidity	B-C0026538
and	O
mortality	B-C0205848
were	O
similar	O
in	O
all	O
the	O
groups	B-C1257890
except	O
smt	B-C0418981
.	O
	
the	O
results	O
of	O
this	O
pilot	B-C0031928
study	I-C0031928
suggest	O
that	O
midodrine	B-C0026078
and	O
combination	B-C0013218
with	O
tolvaptan	B-C1176308
better	O
controls	O
ascites	B-C0401037
without	O
any	O
renal	B-C1565489
or	O
hepatic	B-C0086565
dysfunction	I-C0086565
.	O
	
the	O
combination	B-C0013218
therapy	I-C0013218
rapidly	O
controls	O
ascites	B-C0401037
as	O
compared	O
to	O
midodrine	B-C0026078
or	O
tolvaptan	B-C1176308
acute	B-C0149512
complicated	I-C0149512
sinusitis	I-C0149512
ten	O
years	B-C0439234
experience	B-C0596545
from	O
the	O
university	B-C0020028
hospital	I-C0020028
of	O
the	O
west	B-C0043122
indies	I-C0043122
complicated	B-C0149512
sinusitis	I-C0149512
is	O
rare	B-C0678236
.	O
	
it	O
might	O
not	O
be	O
identified	O
early	O
and	O
might	O
expose	O
the	O
patient	B-C0030705
to	O
an	O
unfavourable	B-C1274040
outcome	I-C1274040
.	O
	
there	O
is	O
a	O
paucity	O
of	O
data	B-C1511726
regarding	O
this	O
condition	B-C0012634
in	O
the	O
caribbean	B-C0043122
.	O
	
this	O
study	B-C2603343
was	O
undertaken	O
to	O
describe	O
the	O
clinical	B-C0683325
characteristics	I-C0683325
and	O
treatment	B-C0085415
outcomes	I-C0085415
of	O
patients	B-C0030705
admitted	B-C0184666
with	O
this	O
condition	B-C0012634
.	O
	
a	O
retrospective	B-C1514923
chart	B-C0553620
review	I-C0553620
was	O
performed	O
on	O
patients	B-C0030705
admitted	B-C0184666
to	O
the	O
university	B-C0020028
hospital	I-C0020028
of	I-C0020028
the	I-C0020028
west	I-C0020028
indies	I-C0020028
uhwi	B-C0020028
with	O
complicated	B-C0149512
sinusitis	I-C0149512
between	O
1999	O
to	O
2011	O
.	O
	
the	O
data	B-C1511726
was	O
analysed	B-C0936012
using	O
spss	B-C0600673
statistics	I-C0600673
22	I-C0600673
software	I-C0600673
.	O
	
there	O
were	O
30	O
patients	B-C0030705
23	O
males	B-C0086582
and	O
7	O
females	B-C0086287
.	O
	
the	O
mean	B-C0444504
sd	B-C0871420
age	B-C0001779
was	O
19	O
13.96	O
years	B-C1510829
.	O
	
twenty-two	O
had	O
orbital	B-C0029180
complications	B-C0009566
,	O
two	O
had	O
intracranial	B-C0524466
complications	B-C0009566
and	O
one	O
had	O
both	O
.	O
	
the	O
most	O
common	B-C0205214
organisms	B-C0029235
isolated	B-C0205409
were	O
streptococcus	B-C0038402
and	O
the	O
most	O
common	B-C0205214
sensitivity	B-C0237865
was	O
to	O
amoxicillin	B-C0002645
and	O
clavulinic	B-C0055860
acid	I-C0055860
.	O
	
sixteen	O
patients	B-C0030705
who	O
had	O
an	O
external	B-C0205101
surgical	B-C0449446
approach	I-C0449446
had	O
a	O
mean	B-C0444504
sd	B-C0871420
hospital	B-C3489408
stay	I-C3489408
of	O
8.8	O
3.71	O
days	B-C0439228
compared	O
to	O
three	O
patients	B-C0030705
who	O
had	O
a	O
purely	O
endoscopic	B-C0442418
approach	I-C0442418
who	O
had	O
a	O
mean	B-C0444504
sd	B-C0871420
hospital	B-C3489408
stay	I-C3489408
of	O
7.67	O
0.577	O
days	B-C0439228
.	O
	
there	O
was	O
no	B-C0205160
statistical	B-C1705241
difference	I-C1705241
in	O
mean	B-C0444504
hospital	B-C3489408
stay	I-C3489408
between	O
these	O
two	O
groups	B-C0441833
95%	O
ci	O
p	O
=	O
0.609	O
.	O
	
the	O
mean	B-C0444504
duration	B-C0449238
of	O
hospital	B-C3489408
stay	I-C3489408
for	O
those	O
treated	B-C0237726
medically	I-C0237726
was	O
six	O
days	B-C0439228
versus	O
ten	O
days	B-C0439228
for	O
the	O
surgical	B-C0449446
group	B-C0441833
.	O
	
the	O
mean	B-C0444504
difference	B-C1705241
was	O
three	O
days	B-C0439228
95%	O
ci	O
,	O
0.193	O
p	O
=	O
0.039	O
.	O
	
acute	B-C0149512
complicated	I-C0149512
sinusitis	I-C0149512
is	O
seen	O
more	O
commonly	B-C0205214
in	O
adolescent	B-C0001589
males	I-C0001589
.	O
	
the	O
most	O
common	B-C0205214
complication	B-C0009566
was	O
orbital	B-C0029180
.	O
	
surgical	B-C0543467
treatment	I-C0543467
is	O
indicated	O
for	O
those	O
patients	B-C0030705
who	O
fail	B-C0231175
medical	B-C0205476
management	B-C1273870
and	O
should	O
consist	O
of	O
an	O
endoscopic	B-C0442418
approach	I-C0442418
comparative	O
proteomic	B-C0022885
analysis	I-C0022885
reveals	O
alterations	B-C1515926
in	O
development	B-C0597252
and	O
photosynthesis	B-C0031764
-related	O
proteins	B-C0033684
in	O
diploid	B-C0012568
and	O
triploid	B-C3536727
rice	B-C1140671
polyploidy	B-C0032578
has	O
pivotal	O
influences	B-C4054723
on	O
rice	B-C1140671
oryza	B-C1140671
sativa	I-C1140671
l	I-C1140671
morphology	B-C0332437
and	O
physiology	B-C0031843
,	O
and	O
is	O
very	O
important	O
for	O
understanding	O
rice	B-C1140671
domestication	B-C0175819
and	O
improving	O
agricultural	B-C0599883
traits	I-C0599883
.	O
	
diploid	B-C0012568
dp	B-C0012568
and	O
triploid	B-C3536727
tp	B-C3536727
rice	B-C1140671
shows	O
differences	B-C1705242
in	O
morphological	B-C0332437
parameters	B-C0449381
,	O
such	O
as	O
plant	B-C0032098
height	B-C0489786
,	O
leaf	B-C0242724
length	B-C1444754
,	O
leaf	B-C0242724
width	B-C0487742
and	O
the	O
physiological	B-C0205463
index	B-C0918012
of	O
chlorophyll	B-C0008260
content	B-C0456205
.	O
	
however	O
,	O
the	O
underlying	O
mechanisms	B-C0441712
determining	O
these	O
morphological	B-C0332437
differences	B-C1705242
are	O
remain	O
to	O
be	O
defined	O
.	O
	
to	O
better	O
understand	O
the	O
proteomic	B-C0033684
changes	B-C0392747
between	O
dp	B-C0012568
and	O
tp	B-C3536727
,	O
tandem	B-C2123592
mass	I-C2123592
tags	I-C2123592
tmt	I-C2123592
mass	I-C2123592
spectrometry	I-C2123592
ms	I-C2123592
/	O
ms	B-C0037813
was	O
used	O
to	O
detect	O
the	O
significant	O
changes	B-C0392747
to	O
protein	B-C1171362
expression	I-C1171362
between	O
dp	B-C0012568
and	O
tp	B-C3536727
.	O
	
results	O
indicated	O
that	O
both	O
photosynthesis	B-C0031764
and	O
metabolic	B-C1291081
pathways	I-C1291081
were	O
highly	O
significantly	O
associated	B-C0332281
with	I-C0332281
proteomic	B-C1514563
alteration	I-C1514563
between	O
dp	B-C0012568
and	O
tp	B-C3536727
based	O
on	O
biological	B-C3714634
process	I-C3714634
and	O
pathway	B-C0022885
enrichment	I-C0022885
analysis	I-C0022885
,	O
and	O
13	O
higher	O
abundance	B-C2346714
chloroplast	B-C3178938
proteins	I-C3178938
involving	O
in	O
these	O
two	O
pathways	B-C1704259
were	O
identified	B-C0205396
in	O
tp	B-C3536727
.	O
	
quantitative	B-C3179034
real-time	I-C3179034
pcr	I-C3179034
analysis	I-C3179034
demonstrated	O
that	O
5	O
of	O
the	O
13	O
chloroplast	B-C3178938
proteins	I-C3178938
atpf	B-C0033684
,	O
psaa	B-C0033684
,	O
psab	B-C0084235
,	O
psbb	B-C0033684
and	O
rbl	B-C0033684
in	O
tp	B-C3536727
were	O
higher	O
abundance	B-C2346714
compared	O
with	O
those	O
in	O
dp	B-C0012568
.	O
	
this	O
study	B-C2603343
integrates	O
morphology	B-C0332437
,	O
physiology	B-C0031843
and	O
proteomic	B-C1327760
profiling	I-C1327760
alteration	B-C1515926
of	O
dp	B-C0012568
and	O
tp	B-C3536727
to	O
address	O
their	O
underlying	O
different	O
molecular	B-C3537153
mechanisms	I-C3537153
.	O
	
our	O
finding	O
revealed	O
that	O
atpf	B-C0033684
,	O
psaa	B-C0033684
,	O
psab	B-C0084235
,	O
psbb	B-C0033684
and	O
rbl	B-C0033684
can	O
induce	O
considerable	O
expression	B-C1171362
changes	B-C0392747
in	O
tp	B-C3536727
and	O
may	O
affect	O
the	O
development	B-C0597252
and	O
growth	B-C0597252
of	O
rice	B-C1140671
through	O
photosynthesis	B-C0031764
and	O
metabolic	B-C1291081
pathways	I-C1291081
.	O
	
correlation	B-C1707520
of	O
cardiopulmonary	B-C2959886
exercise	I-C2959886
testing	I-C2959886
parameters	B-C0549193
with	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
in	O
stable	B-C0677946
copd	B-C0024117
patients	B-C0030705
the	O
precise	O
head	O
to	O
head	O
relationships	B-C0439849
between	O
cardio-pulmonary	B-C2959886
exercise	I-C2959886
testing	I-C2959886
cpet	B-C2959886
parameters	B-C0549193
and	O
patients	B-C0030705
'	O
daily	B-C0436354
symptoms	I-C0436354
/	O
activities	B-C0871707
and	O
the	O
disease	B-C0012634
social	B-C0162468
/	O
emotional	B-C1514593
impact	I-C1514593
are	O
less	O
well	O
defined	O
.	O
	
in	O
this	O
study	O
,	O
the	O
correlation	B-C1707520
of	O
copd	B-C0024117
daily	B-C0436354
symptoms	I-C0436354
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
assessed	O
by	O
st	B-C0451500
.	O
	
george's	I-C0451500
respiratory	I-C0451500
questionnaire	I-C0451500
sgrq	B-C0451500
and	O
copd	B-C0024117
severity	B-C4053940
index	I-C4053940
bode-index	B-C4053940
with	O
cpet	B-C2959886
parameters	B-C0549193
were	O
investigated	O
.	O
	
symptom	B-C1457887
-limited	O
cpet	B-C2959886
was	O
performed	O
in	O
37	O
consecutive	B-C1707491
copd	B-C0024117
gold	B-C0699749
i-iii	I-C0699749
subjects	O
during	O
non-	O
exacerbation	B-C0740304
phase	B-C0205390
.	O
	
the	O
sgrq	B-C0451500
was	O
also	O
completed	O
by	O
each	O
patient	B-C0030705
.	O
	
sgrq-score	B-C3472502
correlated	B-C1707520
negatively	B-C0205160
with	O
fev1	B-C0849974
r=-0	O
,	O
p<0	O
,	O
predicted	B-C0681842
maximal	B-C0744679
work-rate	I-C0744679
%wr-max	B-C0744679
r=-0	O
,	O
p<0	O
,	O
v'o2	B-C0429627
/	O
wr	B-C0018810
r=-0	O
,	O
p<0	O
and	O
breathing	B-C0392762
reserve	I-C0392762
r=-0	O
,	O
p<0	O
.	O
	
however	O
it	O
did	B-C0243095
not	I-C0243095
correlate	I-C0243095
with	O
peak-v'o2	B-C0429693
%	O
predicted	O
r=-0	O
,	O
p=0	O
.	O
	
in	O
20	O
54.1	O
subjects	O
in	O
which	O
leg	B-C2036296
fatigue	I-C2036296
was	I-C2036296
the	I-C2036296
main	I-C2036296
cause	I-C2036296
for	I-C2036296
stopping	I-C2036296
the	I-C2036296
test	I-C2036296
,	O
peak-v'o2	B-C0429693
,	O
%wr-max	B-C0744679
,	O
hr-reserve	B-C0392762
and	O
breathing	B-C0392762
reserve	I-C0392762
were	O
higher	O
p=0	O
,	O
<0	O
,	O
0.04	O
and	O
<0	O
respectively	O
than	O
the	O
others	O
.	O
	
there	O
was	O
also	O
a	O
significant	B-C0237881
correlation	B-C1707520
between	O
bode-index	B-C4053940
and	O
vo2	B-C0429627
/	O
wr	B-C0018810
r=-0	O
,	O
p<0	O
and	O
breathing-reserve	B-C0392762
r=-0	O
,	O
p=0	O
.	O
	
the	O
observed	O
relationships	B-C0439849
between	O
cpet	B-C2959886
parameter	B-C0549193
and	O
daily	B-C0332173
subjective	B-C2936631
complaints	I-C2936631
in	O
copd	B-C0024117
were	O
not	O
strong	O
.	O
	
those	O
who	O
discontinued	O
the	O
cpet	B-C2959886
because	B-C2036296
of	I-C2036296
leg	I-C2036296
fatigue	I-C2036296
were	O
in	O
the	O
earlier	B-C2363430
stages	I-C2363430
of	O
copd	B-C0024117
.	O
	
significant	O
negative	B-C0205160
correlation	B-C1707520
between	O
vo2	B-C0429627
/	O
wr	B-C0018810
and	O
bode-index	B-C4053940
suggests	O
that	O
along	O
with	O
copd	B-C0024117
progression	B-C0242656
,	O
regardless	O
of	O
negative	B-C3699386
past	I-C3699386
history	I-C3699386
,	O
other	O
comorbidities	B-C0009488
such	O
as	O
cardiac	B-C0262402
/	O
musculoskeletal	B-C0026859
problems	I-C0026859
intrapartum	B-C0456337
cervical	B-C0007851
laceration	I-C0007851
and	O
subsequent	O
pregnancy	B-C0032972
outcomes	I-C0032972
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
describe	O
pregnancy	B-C0032972
outcomes	I-C0032972
,	O
including	O
cervical	B-C1401059
insufficiency	I-C1401059
and	O
preterm	B-C0151526
birth	I-C0151526
,	O
in	O
the	O
subsequent	O
pregnancy	B-C0032961
following	B-C0332282
an	O
intrapartum	B-C0456337
cervical	B-C0007851
laceration	I-C0007851
.	O
	
retrospective	O
cohort	B-C0599755
of	O
women	B-C0043210
with	O
their	O
first	O
two	O
consecutive	B-C1707491
singleton	B-C0341899
pregnancies	I-C0341899
carried	O
to	O
20	O
weeks	B-C0439230
'	O
gestation	B-C0032961
within	O
a	O
tertiary	B-C0018696
health	I-C0018696
care	I-C0018696
system	I-C0018696
from	O
2002	O
to	O
2012	O
.	O
	
cervical	B-C0007851
laceration	I-C0007851
cases	B-C1706256
were	O
identified	B-C0205396
by	O
icd9	B-C1550213
codes	I-C1550213
and	O
included	B-C0332257
if	O
suture	B-C0087111
repair	I-C0087111
was	O
required	B-C1514873
.	O
	
in	O
this	O
study	B-C2603343
,	O
55	O
women	B-C0043210
were	O
confirmed	B-C0750484
to	O
have	O
a	O
cervical	B-C0007851
laceration	I-C0007851
in	O
the	O
first	O
delivery	B-C0005615
43	O
lacerations	B-C0043246
after	O
vaginal	B-C1541822
delivery	I-C1541822
vd	B-C1541822
and	O
12	O
after	O
cesarean	B-C0007876
delivery	I-C0007876
cd	B-C0007876
.	O
	
the	O
median	B-C0876920
gestational	B-C0017504
age	I-C0017504
of	O
the	O
first	O
delivery	B-C0005615
was	O
40	O
weeks	B-C0439230
and	O
the	O
median	B-C0876920
birth	B-C0005612
weight	I-C0005612
3	O
g	O
these	O
did	O
not	O
differ	B-C1705242
between	O
vd	B-C1541822
and	O
cd	B-C0007876
.	O
	
in	O
the	O
second	O
pregnancy	B-C0032961
,	O
2	O
of	O
55	O
women	B-C0043210
4.6	O
had	O
a	O
prophylactic	B-C0445202
cerclage	B-C0195681
placed	O
1	O
carried	B-C0206243
to	O
term	B-C0233324
and	O
the	O
other	O
delivered	B-C0151526
at	O
35	O
weeks	B-C0439230
.	O
	
in	O
total	B-C0439810
,	O
four	O
women	B-C0043210
9.3	O
delivered	B-C0151526
the	O
second	O
pregnancy	B-C0032961
<	O
37	O
weeks	B-C0439230
three	O
had	O
a	O
prior	B-C0332152
term	B-C0233324
vd	B-C1541822
and	O
one	O
had	O
a	O
prior	B-C0332152
34	O
weeks	B-C0439230
vd	B-C1541822
.	O
	
there	O
was	O
only	O
one	O
case	B-C1706256
of	O
recurrent	B-C2945760
cervical	B-C0007851
laceration	I-C0007851
,	O
occurring	B-C1709305
in	O
the	O
setting	B-C0868928
of	O
vaginal	B-C1541822
deliveries	I-C1541822
.	O
	
obstetric	B-C0205484
cervical	B-C0007851
lacerations	I-C0007851
are	O
uncommon	B-C0522498
.	O
	
complications	B-C0009566
in	O
the	O
following	B-C0332282
pregnancy	B-C0032961
were	O
low	B-C0205251
,	O
despite	O
lack	B-C0332268
of	O
additional	O
prophylactic	B-C0445202
cerclage	B-C0195681
a	O
wnt	B-C1520113
pathway	I-C1520113
activator	B-C3659232
induces	B-C1326205
apoptosis	I-C1326205
and	O
cell	B-C0007587
death	I-C0007587
in	O
mouse	B-C1521831
monocytic	I-C1521831
leukemia	I-C1521831
cells	B-C0007634
a	O
wnt	B-C3659232
agonist	I-C3659232
,	O
2-amino-4-	B-C3659232
pyrimidine	I-C3659232
,	O
is	O
a	O
cell-permeable	B-C0007605
pyrimidine	B-C3659232
compound	I-C3659232
that	O
has	O
been	O
shown	O
to	O
mimic	O
the	O
effect	O
of	O
wnt	B-C0753137
.	O
	
in	O
this	O
study	O
,	O
leukemic	B-C1517806
mouse	I-C1517806
cell	I-C1517806
lines	I-C1517806
,	O
raw	B-C4042840
264.7	I-C4042840
and	O
j774.1	B-C1517806
,	O
were	O
incubated	O
with	O
the	O
wnt	B-C3659232
agonist	I-C3659232
.	O
	
the	O
wnt	B-C3659232
agonist	I-C3659232
showed	O
cell	B-C0007587
death	I-C0007587
in	O
the	O
concentration	O
of	O
1-10	O
μm	O
.	O
	
the	O
wnt	B-C3659232
agonist	I-C3659232
did	O
not	O
show	O
inhibition	B-C3463820
of	O
gsk-3β	B-C0244988
activity	B-C0243102
but	O
induced	B-C0205263
β-catenin	B-C1511110
accumulation	I-C1511110
in	O
the	O
nucleus	B-C0007610
.	O
	
the	O
wnt	B-C3659232
agonist	I-C3659232
showed	O
caspase-independent	B-C3820502
cell	I-C3820502
death	I-C3820502
,	O
but	O
no	O
further	O
involvement	O
in	O
cell	B-C2610698
death	I-C2610698
er	I-C2610698
stress	I-C2610698
signaling	I-C2610698
.	O
	
here	O
we	O
discuss	O
the	O
possible	O
mechanism	O
of	O
wnt	B-C3659232
agonist	I-C3659232
-	O
induced	B-C1326205
apoptotic	I-C1326205
cell	I-C1326205
death	I-C1326205
in	O
raw	B-C4042840
264.7	I-C4042840
cells	I-C4042840
.	O
	
extracorporeal	B-C0015357
membrane	I-C0015357
oxygenation	I-C0015357
outcomes	B-C1274040
in	O
children	B-C0008059
with	O
hemophagocytic	B-C0024291
lymphohistiocytosis	I-C0024291
pediatric	B-C1521725
patients	B-C0030705
with	O
hemophagocytic	B-C0024291
lymphohistiocytosis	I-C0024291
hlh	B-C0024291
may	O
develop	O
refractory	B-C0205269
respiratory	B-C1145670
or	O
cardiac	B-C0018801
failure	I-C0018801
that	O
warrants	O
consideration	B-C0518609
for	O
extracorporeal	B-C0015357
membrane	I-C0015357
oxygenation	I-C0015357
ecmo	B-C0015357
support	B-C0183683
.	O
	
the	O
purposes	B-C1285529
of	O
this	O
study	B-C0008972
were	O
to	O
describe	O
the	O
use	B-C0457083
and	O
outcomes	B-C0085415
of	O
ecmo	B-C0015357
in	O
pediatric	B-C1521725
hlh	B-C0024291
patients	B-C0030705
,	O
to	O
identify	B-C0205396
risk	B-C0035648
factors	I-C0035648
for	O
hospital	B-C0085556
mortality	I-C0085556
and	O
to	O
compare	B-C1707455
their	O
ecmo	B-C0015357
use	B-C0457083
and	O
outcomes	B-C0085415
to	O
the	O
ecmo	B-C0015357
population	B-C1257890
as	O
a	O
whole	O
.	O
	
pediatric	B-C1521725
patients	B-C0030705
18	O
years	B-C1510829
with	O
a	O
diagnosis	B-C0011900
of	O
hlh	B-C0024291
in	O
the	O
extracorporeal	B-C3161508
life	I-C3161508
support	I-C3161508
organization	I-C3161508
elso	B-C3161508
registry	B-C0034975
were	O
included	B-C0332257
.	O
	
between	O
1983	O
and	O
2014	O
,	O
data	B-C1511726
for	O
30	O
children	B-C0008059
with	O
hlh	B-C0024291
were	O
available	O
in	O
the	O
elso	B-C3161508
registry	B-C0034975
and	O
all	O
were	O
included	B-C0332257
in	O
this	O
study	B-C0008972
.	O
	
all	O
cases	B-C1706256
occurred	B-C1709305
in	O
the	O
last	B-C0205156
decade	B-C2981279
.	O
	
of	O
the	O
30	O
hlh	B-C0024291
patients	B-C0030705
,	O
24	O
80%	O
had	O
a	O
respiratory	B-C1145670
indication	B-C3146298
for	O
ecmo	B-C0015357
and	O
six	O
20%	O
had	O
a	O
cardiac	B-C0018801
indication	B-C3146298
of	O
which	O
4	O
were	O
e	B-C0442087
-	O
cpr	B-C0007203
and	O
2	O
cardiac	B-C0018801
failure	I-C0018801
.	O
	
of	O
the	O
24	O
respiratory	B-C1145670
ecmo	B-C0015357
patients	B-C0030705
,	O
63%	O
were	O
placed	O
on	O
va	B-C3863606
ecmo	I-C3863606
.	O
	
compared	B-C1707455
with	O
all	O
pediatric	B-C1521725
patients	B-C0030705
in	O
the	O
elso	B-C3161508
registry	B-C0034975
during	O
the	O
study	B-C0489652
period	I-C0489652
n=17	O
,	O
hlh	B-C0024291
patients	B-C0030705
had	O
worse	O
hospital	B-C0220921
survival	I-C0220921
non-hlh	O
59%	O
vs	O
hlh	B-C0024291
30%	O
,	O
p	B-C1709380
=0	O
.	O
	
in	O
pediatric	B-C1521725
hlh	B-C0024291
patients	B-C0030705
,	O
no	O
pre-	O
ecmo	B-C0015357
risk	B-C0035648
factors	I-C0035648
for	O
mortality	B-C0178686
were	O
identified	B-C0205396
.	O
	
the	O
development	B-C1527148
of	O
a	O
hemorrhagic	B-C0333275
complication	B-C0009566
on	O
ecmo	B-C0015357
was	O
associated	B-C0332281
with	I-C0332281
decreased	B-C0547047
mortality	B-C0178686
p	B-C1709380
=0	O
.	O
	
comparing	B-C1707455
hlh	B-C0024291
patients	B-C0030705
with	O
respiratory	B-C1145670
failure	I-C1145670
to	O
patients	B-C0030705
with	O
other	O
immune	B-C4284394
compromised	I-C4284394
conditions	I-C4284394
,	O
the	O
overall	O
survival	B-C0038954
rate	I-C0038954
is	O
similar	O
hlh	B-C0024291
38%	O
vs	O
.	O
	
non-hlh	O
immune	B-C4284394
compromised	I-C4284394
31%	O
,	O
p	B-C1709380
=0	O
.	O
	
hlh	B-C0024291
is	O
an	O
uncommon	B-C0522498
indication	B-C3146298
for	O
ecmo	B-C0015357
and	O
these	O
patients	B-C0030705
have	O
increased	B-C0205217
mortality	B-C0178686
compared	B-C1707455
to	O
the	O
overall	O
pediatric	B-C1521725
ecmo	B-C0015357
population	B-C1257890
.	O
	
these	O
data	B-C1511726
should	O
be	O
factored	O
into	O
decision-making	B-C0011109
when	O
considering	O
ecmo	B-C0015357
for	O
pediatric	B-C1521725
hlh	B-C0024291
patients	B-C0030705
.	O
	
gut	B-C2985398
microbiome	I-C2985398
alterations	B-C1515926
in	O
patients	B-C0030705
with	O
stage	B-C0205585
4	I-C0205585
hepatitis	B-C0019196
c	I-C0019196
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
hcv	B-C0220847
causes	O
debilitating	O
liver	B-C0023895
diseases	I-C0023895
,	O
which	O
may	O
progress	O
to	O
cirrhosis	B-C0023890
and	O
cancer	B-C0006826
,	O
and	O
claims	O
500	O
annual	O
lives	O
worldwide	B-C0043236
.	O
	
while	O
hcv	B-C0220847
epidemiology	B-C0002783
,	O
pathophysiology	B-C0277785
,	O
and	O
therapy	B-C0039798
are	O
being	O
deeply	O
studied	O
,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal	B-C0596935
interactions	I-C0596935
between	O
hcv	B-C4288963
infection	I-C4288963
,	O
hcv	B-C0220847
-induced	O
chronic	B-C0341439
liver	I-C0341439
diseases	I-C0341439
,	O
and	O
the	O
human	B-C0086418
gut	B-C2985398
microbiome	I-C2985398
.	O
	
as	O
egypt	B-C0013715
has	O
the	O
world's	B-C2700280
highest	B-C1512456
prevalence	I-C1512456
of	O
hcv	B-C4288963
infections	I-C4288963
,	O
we	O
launched	O
this	O
study	B-C2603343
to	O
monitor	O
differences	O
in	O
the	O
gut	B-C2985398
microbial	I-C2985398
community	I-C2985398
composition	B-C0486616
of	O
egyptian	B-C0337801
hcv	B-C0220847
patients	B-C0030705
that	O
may	O
affect	O
,	O
or	O
result	O
from	O
,	O
the	O
patients	B-C0030705
'	O
liver	B-C0023884
state	B-C1442792
.	O
	
to	O
this	O
end	O
,	O
we	O
analyzed	O
stool	B-C1550661
samples	I-C1550661
from	O
six	O
stage	B-C0205585
4	I-C0205585
-	O
hcv	B-C0220847
patients	B-C0030705
and	O
eight	O
healthy	B-C1708335
individuals	I-C1708335
by	O
high-throughput	B-C0872186
16s	B-C1294197
rrna	I-C1294197
gene	I-C1294197
sequencing	I-C1294197
using	O
illumina	B-C0348000
miseq	I-C0348000
.	O
	
overall	O
,	O
the	O
alpha-diversity	B-C0282469
of	O
the	O
healthy	B-C1708335
persons'	I-C1708335
gut	B-C2985398
microbiomes	I-C2985398
was	O
higher	B-C0205250
than	O
those	O
of	O
the	O
hcv	B-C0220847
patients	B-C0030705
.	O
	
whereas	O
members	O
of	O
phylum	B-C0995456
bacteroidetes	I-C0995456
were	O
more	O
abundant	O
in	O
hcv	B-C0220847
patients	B-C0030705
,	O
healthy	B-C1708335
individuals	I-C1708335
had	O
higher	B-C0205250
abundance	B-C2346714
of	O
firmicutes	B-C1254144
,	O
proteobacteria	B-C0751985
,	O
and	O
actinobacteria	B-C0600148
.	O
	
genus	B-C1708235
-level	O
analysis	B-C0936012
showed	O
differential	O
abundance	B-C2346714
of	O
prevotella	B-C0242946
and	O
faecalibacterium	B-C1229075
higher	B-C0205250
in	O
hcv	B-C0220847
patients	B-C0030705
vs	O
.	O
	
ruminococcus	B-C0318074
and	O
clostridium	B-C0009054
healthy	B-C0441833
group	I-C0441833
,	O
indicating	O
that	O
the	O
higher	B-C0205250
abundance	B-C2346714
of	O
bacteroidetes	B-C0995456
in	O
hcv	B-C0220847
patients	B-C0030705
is	O
most	O
likely	O
due	O
to	O
prevotella	B-C0242946
overabundance	B-C2346714
.	O
	
the	O
probiotic	B-C0525033
genus	I-C0525033
,	O
bifidobacterium	B-C0005380
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	B-C2985398
of	O
healthy	B-C1708335
individuals	I-C1708335
.	O
	
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	B-C2603343
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	B-C1709533
and	O
genera	B-C1708235
differentiating	O
stage	B-C0205585
4	I-C0205585
-	O
hcv	B-C0220847
patients	B-C0030705
from	O
healthy	B-C1708335
individuals	I-C1708335
and	O
suggests	O
possible	O
microbiome	B-C1956108
remodeling	O
in	O
chronic	B-C0524910
hepatitis	I-C0524910
c	I-C0524910
,	O
possibly	O
shaped	O
by	O
bacterial	B-C0282583
translocation	I-C0282583
as	O
well	O
as	O
the	O
liver's	B-C0023884
impaired	B-C0231410
role	I-C0231410
in	O
digestion	B-C0012238
and	O
protein	B-C0597295
synthesis	I-C0597295
.	O
	
future	O
studies	O
will	O
investigate	O
the	O
microbiome	B-C1956108
composition	B-C0486616
and	O
functional	O
capabilities	B-C2698977
in	O
more	O
patients	B-C0030705
while	O
tracing	O
some	O
potential	O
biomarker	B-C0005516
taxa	O
e.g	O
,	O
prevotella	B-C0242946
,	O
faecalibacterium	B-C1229075
vs	O
.	O
	
peptide	B-C0030956
-mediated	O
interference	B-C0042730
of	O
pb2	B-C0753209
-	O
eif4g1	B-C1505487
interaction	B-C0872079
inhibits	B-C3463820
influenza	B-C0029347
a	I-C0029347
viruses	I-C0029347
'	O
replication	B-C0042774
in	B-C0681828
vitro	I-C0681828
and	O
in	B-C0681829
vivo	I-C0681829
influenza	B-C0029341
viruses	I-C0029341
are	O
obligate	B-C0562628
parasites	I-C0562628
that	O
hijack	B-C1154502
the	I-C1154502
host	I-C1154502
cellular	I-C1154502
system	I-C1154502
.	O
	
previous	O
results	O
have	O
shown	O
that	O
the	O
influenza	B-C1611366
virus	I-C1611366
pb2	I-C1611366
subunit	O
confers	O
a	O
dependence	O
of	O
host	B-C1505487
eukaryotic	I-C1505487
translation	I-C1505487
initiation	I-C1505487
factor	I-C1505487
4-γ	I-C1505487
1	I-C1505487
eif4g1	B-C1505487
for	O
viral	B-C1154505
mrna	I-C1154505
translation	I-C1154505
.	O
	
here	O
,	O
we	O
demonstrated	O
that	O
peptide	B-C0030956
-mediated	O
interference	B-C0042730
of	O
the	O
pb2	B-C0753209
-	O
eif4g1	B-C1505487
interaction	B-C0872079
inhibited	B-C3463820
virus	B-C0042774
replication	I-C0042774
in	B-C0681828
vitro	I-C0681828
and	O
in	B-C0681829
vivo	I-C0681829
.	O
	
remarkably	O
,	O
intranasal	B-C0001560
administration	I-C0001560
of	O
the	O
peptide	B-C0030956
provided	O
100%	O
protection	B-C1545588
against	O
lethal	B-C3151529
challenges	B-C0805586
of	O
influenza	B-C0029347
a	I-C0029347
viruses	I-C0029347
in	O
balb/c	B-C0025919
mice	I-C0025919
,	O
including	O
h1n1	B-C1615607
,	O
h5n1	B-C1613950
,	O
and	O
h7n9	B-C3658219
influenza	I-C3658219
virus	I-C3658219
subtypes	I-C3658219
.	O
	
mapping	B-C0949728
of	O
the	O
pb2	B-C0753209
protein	I-C0753209
indicated	O
that	O
the	O
eif4g1	B-C1505487
binding	B-C0005456
sites	I-C0005456
resided	O
within	O
the	O
pb2	B-C0753209
cap	I-C0753209
-	O
binding	B-C1149343
domain	I-C1149343
.	O
	
virtual	B-C3494274
docking	I-C3494274
analysis	I-C3494274
suggested	O
that	O
the	O
inhibitory	B-C3463820
peptide	B-C0030956
associated	B-C0332281
with	I-C0332281
the	O
conserved	O
amino	B-C0002520
acid	I-C0002520
residues	I-C0002520
that	O
were	O
essential	O
to	O
pb2	B-C0753209
cap-binding	B-C0201711
activity	I-C0201711
.	O
	
overall	O
,	O
our	O
results	O
identified	O
the	O
pb2	B-C0753209
-	O
eif4g1	B-C1505487
interactive	B-C0005456
site	I-C0005456
as	O
a	O
druggable	B-C1254351
target	O
for	O
influenza	B-C0021400
therapeutics	B-C0087111
.	O
	
drg1	B-C1414151
is	O
a	O
potential	O
oncogene	B-C0029016
in	O
lung	B-C0152013
adenocarcinoma	I-C0152013
and	O
promotes	B-C0033414
tumor	B-C0178874
progression	I-C0178874
via	O
spindle	B-C3156402
checkpoint	I-C3156402
signaling	I-C3156402
regulation	B-C1327622
developmentally	O
regulated	O
gtp	B-C1430718
binding	I-C1430718
protein	I-C1430718
1	I-C1430718
drg1	B-C0905573
,	O
a	O
member	O
of	O
the	O
drg	B-C1335532
family	I-C1335532
,	O
plays	O
important	O
roles	O
in	O
regulating	B-C0596286
cell	I-C0596286
growth	I-C0596286
.	O
	
however	O
,	O
the	O
molecular	B-C1853126
basis	I-C1853126
of	O
drg1	B-C0905573
in	O
cell	B-C1156235
proliferation	I-C1156235
regulation	I-C1156235
and	O
the	O
relationship	O
between	O
drg1	B-C0905573
and	O
tumor	B-C0178874
progression	I-C0178874
remain	O
poorly	O
understood	O
.	O
	
here	O
,	O
we	O
demonstrate	O
that	O
drg1	B-C0905573
is	O
elevated	O
in	O
lung	B-C0152013
adenocarcinomas	I-C0152013
while	O
weakly	O
expressed	B-C1171362
in	O
adjacent	O
lung	B-C0024109
tissues	B-C0040300
.	O
	
drg1	B-C1414151
knockdown	B-C2350567
causes	O
growth	B-C2244509
inhibition	I-C2244509
of	O
tumor	B-C0597032
cells	I-C0597032
by	O
significantly	O
increasing	O
the	O
proportion	O
of	O
cells	B-C0007634
in	O
m	B-C0007591
phase	I-C0007591
.	O
	
overexpression	B-C1171362
of	O
drg1	B-C0905573
leads	O
to	O
chromosome	B-C0008633
missegregation	B-C0314627
which	O
is	O
an	O
important	O
index	O
for	O
tumorigenesis	B-C0007621
.	O
	
interestingly	O
,	O
ectopic	B-C1512167
of	O
drg1	B-C1414151
reduces	O
taxol	B-C0678133
induced	B-C0205263
apoptosis	B-C0162638
of	O
lung	B-C0152013
adenocarcinoma	I-C0152013
cells	B-C0007634
.	O
	
mechanistic	B-C0598002
analyses	B-C0936012
confirm	O
that	O
drg1	B-C0905573
localizes	B-C0392752
at	O
mitotic	B-C0026258
spindles	I-C0026258
in	O
dividing	B-C0230517
cells	I-C0230517
and	O
binds	B-C1167622
to	O
spindle	B-C3156402
checkpoint	I-C3156402
signaling	I-C3156402
proteins	B-C1335962
in	B-C1515655
vivo	I-C1515655
.	O
	
these	O
studies	B-C2603343
highlight	O
the	O
expanding	O
role	O
of	O
drg1	B-C1414151
in	O
tumorigenesis	B-C0007621
and	O
reveal	O
a	O
mechanism	B-C0441712
of	O
drg1	B-C1414151
in	O
taxol	B-C0678133
gelsolin	B-C0061187
in	O
onychophora	B-C1001576
and	O
tardigrada	B-C1010027
with	O
notes	O
on	O
its	O
variability	B-C2827666
in	O
the	O
ecdysozoa	B-C3578917
rearrangements	B-C0596965
of	O
the	O
filamentous	B-C1180307
actin	I-C1180307
network	I-C1180307
involve	O
a	O
broad	O
range	B-C1514721
of	O
actin	B-C0001239
binding	I-C0001239
proteins	I-C0001239
.	O
	
among	O
these	O
,	O
the	O
gelsolin	B-C0061187
proteins	I-C0061187
sever	O
actin	B-C0025979
filaments	I-C0025979
,	O
cap	O
their	O
fast	B-C4086299
growing	I-C4086299
end	O
and	O
nucleate	B-C1155976
actin	B-C2610250
assembly	I-C2610250
in	O
a	O
calcium	B-C0006675
-	O
dependent	B-C0851827
manner	O
.	O
	
here	O
,	O
we	O
focus	O
on	O
the	O
gelsolin	B-C0061187
of	O
the	O
onychophoran	B-C1001576
peripatoides	B-C1083155
novaezealandiae	I-C1083155
and	O
the	O
eutardigrade	B-C1010027
hypsibius	B-C1465325
dujardini	I-C1465325
.	O
	
from	O
the	O
cdna	B-C0006556
of	O
p	B-C1083155
.	O
	
novaezealandiae	I-C1083155
we	O
obtained	B-C1301820
the	O
complete	O
coding	B-C0079941
sequence	I-C0079941
with	O
an	O
open	B-C0079941
reading	I-C0079941
frame	I-C0079941
of	O
2178	O
bp	B-C0600436
.	O
	
it	O
encodes	B-C2700640
a	O
protein	B-C0033684
of	O
726	O
amino	B-C0002520
acids	I-C0002520
with	O
a	O
calculated	B-C1441506
molecular	B-C3152252
mass	I-C3152252
of	O
82	O
and	O
a	O
pi	O
of	O
5.57	O
.	O
	
this	O
sequence	B-C0002518
is	O
comprised	B-C2700400
of	O
six	O
segments	B-C0441635
s1-s6	O
.	O
	
however	O
,	O
analysis	B-C0936012
of	O
data	B-C1511726
from	O
tardibase	B-C0242356
reveals	B-C0443289
that	O
the	O
gelsolin	B-C0061187
of	O
the	O
eutardigrade	B-C1010027
hypsibius	B-C1465325
dujardini	I-C1465325
has	O
only	O
three	O
segments	B-C0441635
s1-s3	O
.	O
	
the	O
coding	B-C0079941
sequence	I-C0079941
consist	O
of	O
1119	O
bp	B-C0600436
for	O
373	O
amino	B-C0002520
acids	I-C0002520
with	O
a	O
calculated	B-C1441506
molecular	B-C3152252
mass	I-C3152252
of	O
42	O
and	O
a	O
pi	O
of	O
6.17	O
.	O
	
the	O
peripatoides	B-C1014425
and	O
hypsibius	B-C1481832
gelsolin	B-C0061187
revealed	B-C0443289
both	O
conserved	B-C0009802
binding	B-C1956035
motifs	I-C1956035
for	O
g-actin	B-C0016890
,	O
f-actin	B-C1180307
and	O
phosphatidylinositol	B-C0070798
4	I-C0070798
pip2	B-C0070798
,	O
along	O
with	O
a	O
full	O
set	O
of	O
type-1	B-C0005456
and	O
type-2	B-C0005456
ca	B-C0596235
-	O
binding	B-C0005456
sites	I-C0005456
which	O
could	O
result	B-C1274040
in	O
the	O
binding	B-C1167622
of	O
eight	O
and	O
four	O
calcium	B-C0596235
ions	I-C0596235
,	O
respectively	O
.	O
	
both	O
gelsolin	B-C0061187
proteins	I-C0061187
lack	B-C0332268
a	O
c-terminal	B-C1514562
latch-helix	B-C1704821
indicating	O
a	O
more	O
rapid	B-C0456962
activation	B-C1879547
in	O
the	O
submicromolar	O
ca	B-C0201925
range	I-C0201925
.	O
	
we	O
suggest	O
that	O
a	O
gelsolin	B-C0061187
with	O
three	O
segments	B-C0441635
was	O
present	B-C0150312
in	O
the	O
last	O
common	O
ancestor	B-C0870134
of	O
the	O
ecdysozoan	B-C3578917
clade	O
panarthropoda	B-C1039396
onychophora	B-C1001576
,	O
tardigrada	B-C1010027
,	O
arthropoda	B-C0003903
,	O
primarily	B-C0205225
because	O
the	O
gelsolin	B-C0061187
of	O
all	O
non-ecdysozoa	O
studied	B-C2603343
so	O
far	O
except	O
chordata	B-C0920312
reveals	B-C0443289
this	O
number	O
of	O
segments	B-C0441635
.	O
	
mapping	B-C0030944
of	O
our	O
molecular	B-C0026382
data	I-C0026382
onto	O
a	O
well-established	B-C0443211
phylogeny	B-C0031797
revealed	B-C0443289
that	O
the	O
number	O
of	O
gelsolin	B-C0061187
segments	B-C0441635
does	O
not	O
correlate	B-C1707520
with	O
the	O
phylogenetic	B-C0031797
lineage	B-C1881379
but	O
rather	O
with	O
particular	O
functional	B-C0205245
demands	O
to	O
alter	B-C0392747
the	O
kinetics	B-C0022702
of	O
actin	B-C1155982
polymerization	I-C1155982
.	O
	
mir-424-5p	B-C1537908
participates	B-C0679823
in	O
esophageal	B-C0279626
squamous	I-C0279626
cell	I-C0279626
carcinoma	I-C0279626
invasion	B-C0027626
and	O
metastasis	B-C0027627
via	O
smad7	B-C1334470
pathway	B-C0037080
mediated	O
emt	B-C1523298
escc	B-C0279626
is	O
a	O
life-threatening	B-C2826244
disease	B-C0012634
due	O
to	O
invasion	B-C0027626
and	O
metastasis	B-C0027627
in	O
the	O
early	B-C2363430
stage	I-C2363430
.	O
	
great	O
efforts	O
had	O
been	O
made	O
to	O
detect	B-C0442726
the	O
molecular	B-C1521991
mechanisms	B-C0441712
which	O
led	O
to	O
the	O
invasion	B-C0027626
and	O
metastasis	B-C0027627
in	O
escc	B-C0279626
.	O
	
recent	O
evidence	B-C3887511
had	O
suggested	O
that	O
deregulation	B-C1880287
of	O
mir-424-5p	B-C1537908
took	O
an	O
important	O
role	B-C1705810
in	O
cancers	B-C0006826
.	O
	
however	O
,	O
its	O
role	B-C1705810
and	O
functional	B-C0205245
mechanism	B-C0441712
in	O
escc	B-C0279626
had	O
seldom	B-C0522498
been	O
elucidated	O
.	O
	
the	O
expression	B-C3244092
levels	I-C3244092
of	O
mir-424-5p	B-C1537908
were	O
detected	B-C0442726
in	O
escc	B-C0279626
tissues	B-C0040300
and	O
cell	B-C0085983
lines	I-C0085983
by	O
real-time	B-C1709846
pcr	I-C1709846
methods	I-C1709846
.	O
	
then	O
,	O
the	O
invasion	B-C0027626
,	O
metastasis	B-C0027627
and	O
proliferation	B-C0596290
ability	O
of	O
escc	B-C0279626
cell	B-C0085983
lines	I-C0085983
transfected	B-C0314641
with	O
mir-424-5p	B-C1537908
mimics	O
were	O
analyzed	B-C0936012
separately	O
by	O
transwell	B-C1510438
invasion	I-C1510438
assay	I-C1510438
,	O
wound	B-C1510438
healing	I-C1510438
assay	I-C1510438
and	O
cell	B-C3899698
proliferation	I-C3899698
assay	I-C3899698
.	O
	
finally	O
,	O
the	O
target	B-C0017337
gene	I-C0017337
of	O
mir-424-5p	B-C1537908
was	O
studied	O
and	O
verified	B-C1711411
by	O
luciferase	B-C1510438
activity	I-C1510438
assay	I-C1510438
.	O
	
and	O
the	O
role	B-C1705810
of	O
mir-424-5p	B-C1537908
in	O
emt	B-C1523298
was	O
also	O
investigated	B-C1292732
by	O
real-time	B-C1709846
pcr	I-C1709846
and	O
western	B-C0949466
blot	I-C0949466
assay	I-C0949466
.	O
	
we	O
showed	O
that	O
the	O
expression	B-C3244092
levels	I-C3244092
of	O
mir-424-5p	B-C1537908
were	O
decreased	B-C0205216
both	O
in	O
escc	B-C0279626
tissues	B-C0040300
and	O
cell	B-C0085983
lines	I-C0085983
.	O
	
furthermore	O
,	O
the	O
expression	B-C3244092
levels	I-C3244092
of	O
mir-424-5p	B-C1537908
were	O
negatively	O
linked	O
to	O
lymph	B-C0024204
node	I-C0024204
metastasis	B-C0027627
in	O
escc	B-C0279626
tissues	B-C0040300
.	O
	
restoration	O
of	O
mir-424-5p	B-C1537908
in	O
ec-1	B-C0597032
cells	I-C0597032
by	O
using	O
mir-424-5p	B-C1537908
mimics	O
could	O
decrease	B-C0547047
the	O
invasion	B-C0027626
,	O
metastasis	B-C0027627
and	O
proliferation	B-C0596290
of	O
ec-1	B-C0597032
cells	I-C0597032
,	O
indicating	O
its	O
role	B-C1705810
in	O
inhibition	B-C3463820
on	O
the	O
invasion	B-C0027626
and	O
metastasis	B-C0027627
ability	O
of	O
escc	B-C0279626
cells	B-C0597032
and	O
tissues	B-C0040300
.	O
	
in	O
addition	O
,	O
we	O
demonstrated	O
that	O
smad7	B-C1334470
was	O
a	O
specific	O
target	B-C0017337
gene	I-C0017337
for	O
mir-424-5p	B-C1537908
by	O
luciferase	B-C1510438
activity	I-C1510438
assay	I-C1510438
and	O
mir-424-5p	B-C1537908
could	O
not	O
only	O
negatively	B-C0205160
regulate	B-C0017263
smad7	B-C1334470
expression	B-C0017262
but	O
also	O
participate	O
in	O
emt	B-C1523298
via	O
smad7	B-C1334470
,	O
because	O
overexpression	B-C0017262
of	O
smad7	B-C1334470
could	O
partly	O
enhance	B-C2349975
the	O
mir-424-5p	B-C1537908
anti-emt	B-C0243095
function	B-C0542341
.	O
	
our	O
results	B-C1274040
described	O
that	O
mir-424-5p	B-C1537908
-	O
smad7	B-C1334470
pathway	B-C0037080
contributed	O
to	O
escc	B-C0279626
invasion	B-C0027626
and	O
metastasis	B-C0027627
and	O
up-regulation	B-C0041904
of	O
mir-424-5p	B-C1537908
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	B-C1292733
tumor	B-C1269955
invasion	I-C1269955
,	O
metastasis	B-C0027627
.	O
	
double-network	B-C0063083
hydrogel	I-C0063083
with	O
tunable	B-C0205556
mechanical	B-C1882330
performance	I-C1882330
and	O
biocompatibility	B-C0596177
for	O
the	O
fabrication	B-C3494260
of	O
stem	B-C0038250
cells	I-C0038250
-	O
encapsulated	B-C0225326
fibers	I-C0225326
and	O
3d	B-C1254362
assemble	I-C1254362
fabrication	B-C3494260
of	O
cell	B-C0038250
-	O
encapsulated	B-C0225326
fibers	I-C0225326
could	O
greatly	O
contribute	B-C1880177
to	O
tissue	B-C0596171
engineering	I-C0596171
and	O
regenerative	B-C1257974
medicine	I-C1257974
.	O
	
however	O
,	O
existing	B-C2347662
methods	B-C0449851
suffered	O
from	O
not	O
only	O
unavoidability	B-C0205556
of	O
cell	B-C0599732
damaging	I-C0599732
conditions	B-C0348080
and/or	O
sophisticated	B-C0681588
equipment	I-C0681588
,	O
but	O
also	O
unavailability	B-C0686905
of	O
proper	O
materials	B-C0520510
to	O
satisfy	O
both	O
mechanical	B-C0443254
and	O
biological	B-C0205460
expectations	B-C0679138
.	O
	
in	O
this	O
work	B-C0043227
,	O
a	O
simple	B-C0205352
method	B-C0449851
is	O
proposed	B-C1553874
to	O
prepare	B-C1521827
cell	B-C0038250
-	O
encapsulated	B-C0225326
fibers	I-C0225326
with	O
tunable	B-C0205556
mechanical	B-C0039526
strength	I-C0039526
and	O
stretching	B-C0871161
behavior	I-C0871161
as	O
well	O
as	O
diameter	B-C1301886
and	O
microstructure	B-C1254350
.	O
	
the	O
hydrogel	B-C0063083
fibers	B-C0225326
are	O
made	O
from	O
optimal	B-C2698651
combination	B-C0205195
of	O
alginate	B-C0102137
and	O
poly	B-C0005479
glycol	I-C0005479
,	O
characteristics	O
of	O
double-network	B-C0063083
hydrogel	I-C0063083
,	O
with	O
enough	O
stiffness	B-C0427008
and	O
flexibility	B-C0242808
to	O
create	B-C1706214
a	O
variety	B-C2346866
of	O
three	B-C0026377
dimensional	I-C0026377
structures	I-C0026377
like	O
parallel	B-C1254362
helical	I-C1254362
and	O
different	B-C1705242
knots	B-C1254362
without	I-C1254362
crack	I-C1254362
.	O
	
furthermore	O
,	O
such	O
hydrogel	B-C0063083
fibers	B-C0225326
exhibit	O
better	B-C0332272
compatibility	B-C0596177
as	O
indicated	B-C1444656
by	O
the	O
viability	B-C0443348
,	O
proliferation	B-C1514485
and	O
expression	B-C0205245
of	O
pluripotency	B-C1514185
markers	B-C0005516
of	O
embryonic	B-C0596508
stem	I-C0596508
cells	I-C0596508
encapsulated	B-C0205223
after	O
4-day	B-C3840892
culture	B-C0430400
.	O
	
the	O
double-network	B-C0063083
hydrogel	I-C0063083
possesses	B-C0850310
specific	B-C0205369
quick	B-C0456962
responses	B-C0871261
to	O
either	O
of	O
alginate	B-C0051154
lyase	I-C0051154
,	O
edta	B-C0013618
or	O
lower	O
environmental	B-C2983601
temperature	I-C2983601
which	O
facilitate	O
the	O
optional	O
degradation	B-C0243125
of	O
fibers	B-C0225326
or	O
fibrous	B-C1254362
assemblies	I-C1254362
to	O
release	O
the	O
cells	B-C0038250
encapsulated	B-C0205223
for	O
subsequent	B-C0332282
assay	B-C1510438
or	O
synchronous	B-C0439580
vitellogenin	B-C0042896
expression	B-C1171362
and	O
sexual	B-C0036887
maturation	I-C0036887
during	O
migration	B-C1533574
are	O
negatively	B-C0205160
correlated	B-C1707520
with	O
juvenile	B-C0022439
hormone	I-C0022439
levels	B-C0441889
in	O
mythimna	B-C1477488
separata	I-C1477488
annual	O
migration	B-C1533574
of	O
pests	B-C0869004
between	O
different	B-C1705242
seasonal	B-C0036497
habitats	B-C0871648
can	O
lead	B-C1522538
to	O
serious	O
crop	B-C0242775
damage	B-C1883709
.	O
	
reproductive	B-C0035150
immaturity	B-C0205252
is	O
generally	O
associated	O
with	O
the	O
migratory	B-C1533574
process	I-C1533574
oogenesis	B-C0029047
-	O
flight	B-C0039082
syndrome	I-C0039082
,	O
but	O
the	O
mechanism	B-C0441712
of	O
reproductive	B-C0597375
development	I-C0597375
during	O
migration	B-C1533574
varies	O
unpredictably	O
.	O
	
here	O
,	O
the	O
vitellogenin	O
gene	O
msvg	O
and	O
three	O
key	O
regulatory	O
enzyme	O
genes	O
msjhamt	O
,	O
msjheh	O
and	O
msjhe	O
related	O
to	O
juvenile	O
hormone	O
jh	O
synthesis	O
and	O
degradation	O
were	O
identified	O
and	O
characterized	O
in	O
mythimna	O
separata	O
.	O
	
the	O
relative	O
expression	O
of	O
msvg	O
varied	O
significantly	O
in	O
response	O
to	O
seasonal	O
changes	O
and	O
was	O
significantly	O
correlated	O
with	O
stages	O
of	O
ovarian	O
development	O
.	O
	
the	O
relatively	O
low	O
levels	O
of	O
jh	O
titer	O
did	O
not	O
differ	O
significantly	O
in	O
male	O
moths	O
but	O
slightly	O
increased	O
in	O
female	O
adults	O
during	O
the	O
migratory	O
season	O
,	O
which	O
was	O
consistent	O
with	O
changes	O
in	O
mrna	O
levels	O
for	O
msjhamt	O
,	O
msjheh	O
and	O
msjhe	O
.	O
	
jh	O
titer	O
was	O
negatively	O
associated	O
with	O
relative	O
seasonal	O
levels	O
of	O
vitellogenin	O
mrna	O
transcripts	O
and	O
with	O
ovarian	O
development	O
in	O
migrating	O
m	O
.	O
	
separata	O
.	O
	
the	O
synchrony	O
of	O
msvg	O
expression	O
with	O
sexual	O
maturation	O
highlighted	O
the	O
potential	O
of	O
msvg	O
transcript	O
levels	O
to	O
serve	O
as	O
an	O
index	O
to	O
monitor	O
the	O
adult	O
reproductive	O
status	O
.	O
	
in	O
addition	O
,	O
the	O
level	O
of	O
jh	O
and	O
sexual	O
maturity	O
were	O
correlated	O
with	O
the	O
extent	O
of	O
jh	O
in	O
regulating	O
the	O
msvg	O
expression	O
and	O
reproduction	O
during	O
seasonal	O
northern	O
and	O
southern	O
migration	I-C1533574
functional	B-C1274040
result	I-C1274040
after	O
cochlear	B-C0302559
implantation	I-C0302559
in	O
children	B-C0008059
and	O
adults	B-C0001675
with	O
single-sided	B-C0521785
deafness	I-C0521785
patients	B-C0030705
with	O
single-sided	B-C0521785
deafness	I-C0521785
ssd	B-C0521785
suffer	O
from	O
reduced	B-C0392756
binaural	B-C0596169
hearing	I-C0596169
i.e	O
,	O
sound	B-C0037710
localization	I-C0037710
and	O
speech	B-C0037817
in	O
noise	B-C0234747
discrimination	I-C0234747
.	O
	
cochlear	B-C0302559
implantation	I-C0302559
has	O
recently	O
been	O
introduced	O
for	O
patients	B-C0030705
with	O
ssd	B-C0521785
,	O
as	O
an	O
alternative	B-C1523987
to	O
hearing	B-C0018768
devices	I-C0018768
that	O
employ	O
contralateral	B-C0441988
routing	O
of	O
the	O
signal	B-C1710082
.	O
	
application	B-C0185125
to	O
children	B-C0008059
has	O
also	O
been	O
started	O
.	O
	
we	O
retrospectively	B-C0035363
analyze	O
a	O
case	O
series	O
of	O
4	O
children	B-C0008059
and	O
17	O
adults	B-C0001675
with	O
ssd	B-C0521785
,	O
treated	B-C0332293
with	I-C0332293
cochlear	B-C0302559
implantation	I-C0302559
.	O
	
the	O
outcome	B-C1274040
of	O
adult	B-C0001675
patients	B-C0030705
was	O
compared	O
with	O
a	O
control	B-C0009932
group	I-C0009932
of	O
27	O
patients	B-C0030705
with	O
bilateral	B-C0018775
profound	I-C0018775
hearing	I-C0018775
loss	I-C0018775
using	O
a	O
cochlear	B-C0009199
implant	I-C0009199
.	O
	
during	O
12	O
months	O
,	O
the	O
mean	B-C3533236
speech	B-C0597498
recognition	I-C0597498
score	B-C0449820
increased	O
from	O
30	O
to	O
41%	O
for	O
monosyllabic	B-C0282574
words	O
in	O
adults	O
,	O
and	O
from	O
58	O
to	O
89%	O
for	O
multisyllabic	O
numbers	O
.	O
	
the	O
cochlear	O
implant	O
ci	O
improved	O
hearing	O
in	O
noise	O
in	O
all	O
ssd	O
patients	O
,	O
as	O
was	O
demonstrated	O
by	O
a	O
significant	O
improvement	O
of	O
the	O
speech	O
reception	O
threshold	O
in	O
different	O
speech	O
and	O
noise	O
configurations	O
.	O
	
sound	O
localization	O
-correlated	O
angle	O
detection	O
error	O
improved	O
with	O
ci	O
use	O
at	O
every	O
time	O
point	O
.	O
	
the	O
maximum	O
word	O
recognition	O
score	O
for	O
monosyllabic	B-C0042926
words	I-C0042926
in	O
quiet	O
correlated	O
with	O
the	O
logarithm	O
of	O
the	O
duration	O
of	O
deafness	O
improvement	O
of	O
the	O
speech	O
reception	O
threshold	O
and	O
rms	O
angle	O
detection	O
error	O
by	O
the	O
ci	O
did	O
not	O
.	O
	
all	O
ssd	O
patients	O
benefitted	O
from	O
the	O
ci	O
in	O
different	O
hearing	O
situations	O
.	O
	
patients	O
with	O
ssd	O
for	O
a	O
long	O
period	O
can	O
improve	O
after	O
cochlear	O
implantation	I-C0302559
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
a	O
novel	O
optical	B-C0920367
coherence	I-C0920367
tomography	I-C0920367
based	O
parameter	B-C0549193
in	O
patients	B-C0030705
with	O
exudative	B-C0271084
age-related	I-C0271084
macular	I-C0271084
degeneration	I-C0271084
to	O
evaluate	O
choroidal	B-C0008520
structural	B-C0678594
changes	O
in	O
exudative	B-C0271084
age-related	I-C0271084
macular	I-C0271084
degeneration	I-C0271084
amd	B-C0242383
using	O
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
computed	B-C1880157
from	O
image	O
binarization	O
on	O
spectral	B-C0920367
domain	I-C0920367
optical	I-C0920367
coherence	I-C0920367
tomography	I-C0920367
with	O
enhanced	O
depth	B-C0011923
imaging	I-C0011923
.	O
	
this	O
prospective	O
case	B-C0150093
series	I-C0150093
included	O
42	O
consecutive	B-C1707491
patients	B-C0030705
with	O
unilateral	B-C0205092
exudative	B-C0271084
amd	I-C0271084
.	O
	
choroidal	B-C0008520
images	B-C0011923
were	O
segmented	O
into	O
luminal	B-C0524462
area	B-C0205146
and	O
stromal	O
area	O
.	O
	
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
was	O
defined	O
as	O
the	O
ratio	B-C0456603
of	O
luminal	B-C0524462
area	B-C0205146
to	O
total	O
choroid	O
area	B-C0205146
.	O
	
mean	B-C0444504
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
and	O
mean	B-C0444504
choroidal	B-C0392762
thickness	I-C0392762
between	O
study	B-C2603343
and	O
fellow	O
eyes	B-C0015392
of	O
the	O
same	O
patient	B-C0030705
with	O
dry	O
amd	B-C0242383
were	O
compared	O
using	O
student's	B-C0871453
t-test	I-C0871453
.	O
	
there	O
was	O
a	O
significantly	B-C4055638
lower	I-C4055638
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
in	O
eyes	B-C0015392
with	O
exudative	B-C0271084
amd	I-C0271084
60.14	O
4.55	O
vs	O
.	O
	
62.75	O
4.82	O
,	O
p	O
<	O
0.01	O
.	O
	
luminal	B-C0524462
area	I-C0524462
p	O
<	O
0.01	O
was	O
decreased	B-C0205216
in	O
eyes	B-C0015392
with	O
exudative	B-C0271084
amd	I-C0271084
but	O
there	O
was	O
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
in	O
total	O
choroid	O
area	B-C0205146
p	O
=	O
0.05	O
and	O
choroidal	O
thickness	O
p	O
=	O
0.93	O
between	O
study	B-C2603343
and	O
fellow	O
eyes	B-C0015392
.	O
	
eyes	B-C0015392
with	O
exudative	B-C0271084
amd	I-C0271084
demonstrated	O
reduced	B-C0392756
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
but	O
insignificant	O
differences	B-C1705242
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	B-C0015392
.	O
	
choroidal	B-C0392762
vascularity	I-C0392762
index	I-C0392762
may	O
be	O
a	O
potential	B-C3245505
noninvasive	B-C0243095
tool	I-C0243095
for	O
studying	B-C2603343
structural	B-C0678594
changes	O
in	O
choroid	B-C0008520
and	O
monitoring	O
choroidal	B-C0008521
disease	I-C0008521
in	O
exudative	B-C0271084
amd	I-C0271084
.	O
	
comparison	B-C1707455
of	O
esophageal	B-C2316724
,	O
rectal	B-C0489749
,	O
and	O
gastrointestinal	B-C0809794
temperatures	B-C0039476
during	O
passive	B-C0035253
rest	I-C0035253
after	O
exercise	B-C0015259
in	O
the	O
heat	B-C0018837
the	O
influence	B-C4054723
of	O
hydration	B-C1321013
it	O
is	O
unknown	O
how	O
valid	O
esophageal	B-C2316724
,	O
rectal	B-C0489749
,	O
and	O
gastrointestinal	B-C0809794
temperatures	B-C0039476
tes	B-C2316724
,	O
tre	B-C0489749
,	O
and	O
tgi	B-C0039476
compare	O
after	O
exercise-induced	B-C0239313
hyperthermia	B-C0015967
in	O
various	O
hydration	B-C1321013
states	I-C1321013
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C0008972
was	O
to	O
examine	O
the	O
differences	O
between	O
tes	B-C2316724
,	O
tre	B-C0489749
,	O
and	O
tgi	B-C0039476
during	O
passive	B-C0035253
rest	I-C0035253
following	O
exercise-induced	B-C0239313
hyperthermia	B-C0015967
under	O
two	O
different	O
hydration	B-C1321013
states	I-C1321013
euhydrated	B-C0231162
eu	B-C0231162
and	O
hypohydrated	B-C0011175
hy	B-C0011175
.	O
	
randomized-crossover	B-C0242817
design	I-C0242817
.	O
	
controlled	B-C2239193
laboratory	B-C0022877
setting	I-C0022877
.	O
	
nine	O
recreationally	B-C0034872
active	B-C0205177
male	B-C0086582
participants	B-C0679646
mean	O
sd	B-C0871420
age	B-C0001779
,	O
24	O
height	B-C0489786
,	O
177.3	O
body	B-C0005910
mass	I-C0005910
,	O
76.7	O
body	B-C0344335
fat	I-C0344335
,	O
14.7	O
.	O
	
participants	B-C0679646
completed	O
two	O
trials	B-C0008976
eu	B-C0231162
and	O
hy	B-C0011175
consisting	O
of	O
a	O
bout	B-C0741605
of	O
treadmill	B-C2712999
exercise	I-C2712999
a	O
10	O
minute	O
walk	O
ranging	B-C1514721
4.8	O
at	O
a	O
5%	O
grade	B-C0441800
followed	O
by	O
a	O
20	O
minute	B-C0439232
jog	B-C0022400
ranging	B-C1514721
8.0	O
at	O
a	O
1%	O
grade	O
in	O
a	O
hot	B-C0241922
environment	I-C0241922
ambient	B-C0428692
temperature	I-C0428692
,	O
39.3	O
relative	B-C0428696
humidity	I-C0428696
,	O
37.6	O
wet	B-C0242485
bulb	I-C0242485
globe	I-C0242485
temperature	I-C0242485
,	O
31.3	O
followed	O
by	O
passive	B-C0035253
rest	I-C0035253
.	O
	
root	B-C2347976
mean	I-C2347976
squared	I-C2347976
difference	I-C2347976
rmsd	B-C2347976
was	O
used	O
to	O
compare	O
the	O
variance	B-C1711260
of	O
temperature	B-C0005903
readings	I-C0005903
at	O
corresponding	O
time	B-C0439547
points	I-C0439547
for	O
tre	B-C0489749
vs	O
tgi	B-C0039476
,	O
tre	B-C0489749
vs	O
tes	B-C2316724
,	O
and	O
tgi	B-C0039476
vs	O
tes	B-C2316724
in	O
eu	B-C0231162
and	O
hy	B-C0011175
.	O
	
rmsd	B-C2347976
values	O
were	O
compared	O
using	O
three-way	B-C0002780
repeated	I-C0002780
measures	I-C0002780
anova	I-C0002780
.	O
	
post	O
hoc	O
analysis	B-C0936012
of	O
significant	O
main	O
effects	B-C1280500
was	O
done	O
using	O
tukey's	B-C0237913
hsd	I-C0237913
with	O
significance	O
set	O
at	O
p<0	O
.	O
	
rmsd	B-C2347976
values	I-C2347976
c	O
for	O
all	O
device	B-C0025080
comparisons	B-C1707455
were	O
significantly	B-C0237881
different	O
in	O
eu	B-C0231162
tre	B-C0489749
-	O
tgi	B-C0039476
,	O
0.11	O
tre	B-C0489749
-	O
tes	B-C2316724
,	O
1.58	O
tgi	B-C0039476
-	O
tes	B-C2316724
,	O
2.04	O
than	O
hy	B-C0011175
tre	B-C0489749
-	O
tgi	B-C0039476
,	O
0.22	O
tre	B-C0489749
-	O
tes	B-C2316724
,	O
1.27	O
tgi	B-C0039476
-	O
tes	B-C2316724
,	O
1.16	O
p<0	O
.	O
	
across	O
the	O
45-	O
minute	B-C0439232
bout	B-C0741605
of	O
passive	B-C0035253
rest	I-C0035253
,	O
there	O
were	O
no	O
differences	O
in	O
tre	B-C0489749
,	O
tgi	B-C0039476
and	O
tes	B-C2316724
between	O
eu	B-C0231162
and	O
hy	B-C0011175
trials	B-C0008976
p=0	O
.	O
	
during	O
passive	B-C0035253
rest	I-C0035253
after	O
exercise	B-C0015259
in	O
the	O
heat	B-C0018837
,	O
tre	B-C0489749
and	O
tgi	B-C0039476
were	O
in	O
good	O
agreement	O
when	O
tracking	O
body	B-C0005903
temperature	I-C0005903
,	O
with	O
a	O
better	O
agreement	O
appearing	O
in	O
those	O
maintaining	O
a	O
state	O
of	O
euhydration	B-C0231162
versus	O
those	O
who	O
became	O
hypohydrated	B-C0011175
during	O
exercise	B-C0015259
however	O
,	O
this	O
small	O
difference	O
does	O
not	O
appear	O
to	O
be	O
of	O
clinical	B-C2826293
significance	I-C2826293
.	O
	
annexin	B-C0103403
a1	I-C0103403
restores	O
aβ1-42	B-C0169424
-induced	O
blood-brain	B-C1831732
barrier	I-C1831732
disruption	I-C1831732
through	O
the	O
inhibition	B-C0021469
of	O
rhoa-rock	B-C0037080
signaling	I-C0037080
pathway	I-C0037080
the	O
blood-brain	B-C0005854
barrier	I-C0005854
bbb	B-C0005854
is	O
composed	O
of	O
brain	B-C4242462
capillary	I-C4242462
endothelial	B-C0225336
cells	I-C0225336
and	O
has	O
an	O
important	O
role	O
in	O
maintaining	O
homeostasis	B-C0019868
of	O
the	O
brain	B-C0006104
separating	O
the	O
blood	B-C0005767
from	O
the	O
parenchyma	B-C0933845
of	O
the	O
central	B-C1269563
nervous	I-C1269563
system	I-C1269563
cns	B-C1269563
.	O
	
it	O
is	O
widely	O
known	O
that	O
disruption	B-C1831732
of	I-C1831732
the	I-C1831732
bbb	I-C1831732
occurs	O
in	O
various	O
neurodegenerative	B-C0524851
diseases	I-C0524851
,	O
including	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
.	O
	
annexin	B-C0103403
a1	I-C0103403
anxa1	B-C0103403
,	O
an	O
anti-inflammatory	B-C0169911
messenger	I-C0169911
,	O
is	O
expressed	B-C1171362
in	O
brain	B-C0225336
endothelial	I-C0225336
cells	I-C0225336
and	O
regulates	O
the	O
bbb	B-C0005854
integrity	O
.	O
	
however	O
,	O
its	O
role	O
and	O
mechanism	B-C0678659
for	O
protecting	O
bbb	B-C0005854
in	O
ad	B-C0002395
have	O
not	O
been	O
identified	O
.	O
	
we	O
found	O
that	O
β-amyloid	B-C0169424
1-42	I-C0169424
aβ42	B-C0169424
bbb	B-C1831732
disruption	I-C1831732
was	O
rescued	O
by	O
human	B-C0034861
recombinant	I-C0034861
anxa1	I-C0034861
hranxa1	B-C0034861
in	O
the	O
murine	B-C0591833
brain	B-C0225336
endothelial	I-C0225336
cell	I-C0225336
line	I-C0225336
bend.3	I-C0225336
.	O
	
also	O
,	O
anxa1	B-C0103403
was	O
decreased	O
in	O
the	O
bend.3	B-C0225336
cells	I-C0225336
,	O
the	O
capillaries	B-C0006901
of	O
5xfad	B-C1514798
mice	I-C1514798
,	O
and	O
the	O
human	B-C0229671
serum	I-C0229671
of	O
patients	B-C0030705
with	O
ad	B-C0002395
.	O
	
to	O
find	O
out	O
the	O
mechanism	B-C0678659
by	O
which	O
anxa1	B-C0103403
recovers	O
the	O
bbb	B-C0005854
integrity	O
in	O
ad	B-C0002395
,	O
the	O
rhoa-rock	B-C0037080
signaling	I-C0037080
pathway	I-C0037080
was	O
examined	O
in	O
both	O
aβ42	B-C0169424
-treated	O
bend.3	B-C0225336
cells	I-C0225336
and	O
the	O
capillaries	B-C0006901
of	O
5xfad	B-C1514798
mice	I-C1514798
as	O
rhoa	B-C0643681
was	O
activated	B-C0599177
in	O
both	O
cases	O
.	O
	
rhoa	B-C1999216
inhibitors	I-C1999216
alleviated	O
aβ42	B-C0169424
-induced	O
bbb	B-C1831732
disruption	I-C1831732
and	O
constitutively	O
overexpressed	B-C1171362
rhoa-gtp	B-C0084340
active	O
form	O
of	O
rhoa	B-C0643681
attenuated	O
the	O
protective	O
effect	O
of	O
anxa1	B-C0103403
.	O
	
when	O
pericytes	B-C0598800
were	O
cocultured	B-C0282547
with	O
bend.3	B-C0225336
cells	I-C0225336
,	O
aβ42	B-C0169424
-induced	O
rhoa	B-C0599177
activation	I-C0599177
of	O
bend.3	B-C0225336
cells	I-C0225336
was	O
inhibited	B-C0311403
by	O
the	O
secretion	B-C0036536
of	O
anxa1	B-C0103403
from	O
pericytes	B-C0598800
.	O
	
taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
anxa1	B-C0103403
restores	O
aβ42	B-C0169424
-induced	O
bbb	B-C1831732
disruption	I-C1831732
through	O
inhibition	B-C0021469
of	O
rhoa-rock	B-C0037080
signaling	I-C0037080
pathway	I-C0037080
and	O
we	O
propose	O
anxa1	B-C0103403
as	O
a	O
therapeutic	B-C1611640
reagent	I-C1611640
,	O
protecting	O
against	O
the	O
breakdown	B-C1831732
of	I-C1831732
the	I-C1831732
bbb	I-C1831732
in	O
association	B-C0439849
of	O
kidney	B-C0022658
disease	I-C0022658
with	O
obstructive	B-C0520679
sleep	I-C0520679
apnea	I-C0520679
in	O
a	O
population	B-C0681876
study	I-C0681876
of	O
men	B-C0025266
to	O
determine	B-C1148554
the	O
relationship	B-C0439849
between	O
obstructive	B-C0520679
sleep	I-C0520679
apnea	I-C0520679
osa	B-C0520679
and	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
ckd	B-C1561643
.	O
	
previous	O
population	B-C0681876
studies	I-C0681876
of	O
the	O
association	B-C0439849
are	O
sparse	B-C0521114
,	O
conflicting	B-C0855281
and	O
confined	B-C0443288
largely	O
to	O
studies	B-C2603343
of	O
administrative	B-C3845829
data	B-C1511726
.	O
	
cross-sectional	B-C0010362
analysis	I-C0010362
in	O
unselected	O
participants	B-C0679646
of	O
the	O
men	B-C0009247
androgens	I-C0009247
inflammation	I-C0009247
lifestyle	I-C0009247
environment	I-C0009247
and	I-C0009247
stress	I-C0009247
mailes	I-C0009247
study	I-C0009247
,	O
aged	B-C0001779
>40	O
y	O
.	O
	
renal	B-C0022646
data	B-C1511726
were	O
available	O
on	O
812	O
men	B-C0025266
without	O
a	O
prior	B-C0332152
osa	B-C0520679
diagnosis	B-C0011900
who	O
underwent	O
full	O
in-home	B-C0442519
polysomnography	B-C0162701
embletta	B-C0182339
x100	I-C0182339
in	O
2010-2011	O
.	O
	
ckd	B-C1561643
was	O
defined	O
as	O
an	O
estimated	B-C3811844
glomerular	I-C3811844
filtration	I-C3811844
rate	I-C3811844
egfr	B-C3811844
<60	O
ml/min/1	O
or	O
egfr	B-C3811844
60	O
and	O
albuminuria	B-C0001925
albumin	B-C1655929
creatinine	I-C1655929
ratio	I-C1655929
3.0	O
mg/mmol	O
.	O
	
ckd	B-C1561643
10.5	O
,	O
n=85	O
stage	B-C1306673
1-3	O
,	O
9.7	O
stage	B-C1306673
4-5	O
,	O
0.7	O
of	O
predominantly	B-C0332251
mild	B-C1513302
severity	I-C1513302
showed	O
significant	B-C0750502
association	B-C0439849
s	O
with	O
osa	B-C0520679
ahi	O
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
severe	B-C0205082
osa	B-C0520679
ahi	O
30/h	O
or	B-C0028873
=2	O
,	O
95%	O
ci	O
,	O
and	O
respiratory	B-C0521346
related	O
arousal	B-C0233972
index	B-C0918012
7.6	O
or	B-C0028873
=2	O
,	O
95%ci	O
1.1	O
,	O
but	O
not	O
measures	B-C0079809
of	O
hypoxemia	B-C0700292
after	O
adjustment	B-C0456081
for	O
age	B-C0001779
,	O
hypertension	B-C0020538
,	O
diabetes	B-C0011847
,	O
smoking	B-C0037369
,	O
obesity	B-C0028754
,	O
and	O
nsaid	B-C3536840
use	B-C0457083
.	O
	
there	O
was	O
no	O
association	B-C0439849
of	O
ckd	B-C1561643
with	O
daytime	B-C0541854
sleepiness	I-C0541854
.	O
	
in	O
men	B-C0025266
with	O
ckd	B-C1561643
,	O
those	O
with	O
osa	B-C0520679
were	O
not	B-C1273937
significantly	I-C1273937
more	B-C0205172
likely	B-C0033204
to	O
report	B-C0700287
symptoms	B-C1457887
sleepiness	B-C0013144
,	O
snoring	B-C0037384
,	O
apneas	B-C0003578
or	O
be	O
identified	B-C0205396
with	O
the	O
stop	B-C1134635
osa	I-C1134635
screening	I-C1134635
questionnaire	I-C1134635
,	O
compared	O
to	O
men	B-C0025266
without	O
osa	B-C0520679
.	O
	
predominantly	B-C0332251
mild	B-C2945599
ckd	B-C1561643
is	O
associated	B-C0332281
with	I-C0332281
severe	B-C0205082
osa	B-C0520679
and	O
arousals	B-C0003808
.	O
	
further	O
population	B-C0681876
studies	I-C0681876
examining	B-C0332128
the	O
longitudinal	B-C0205127
relationship	B-C0439849
between	O
ckd	B-C1561643
and	O
osa	B-C0520679
are	O
warranted	B-C0205245
.	O
	
better	O
methods	B-C0025663
are	O
needed	B-C0027552
to	O
identify	B-C0020792
osa	B-C0520679
in	O
ckd	B-C1561643
which	O
may	O
have	O
few	B-C0205388
symptoms	B-C1457887
.	O
	
evidence	O
that	O
vitronectin	B-C0055023
is	O
a	O
potent	O
migration-enhancing	B-C0574031
factor	I-C0574031
for	O
cancer	B-C0597032
cells	I-C0597032
chaperoned	B-C0243041
by	O
fibrinogen	B-C0016006
a	O
novel	O
view	O
of	O
the	O
metastasis	B-C4255448
of	O
cancer	B-C0597032
cells	I-C0597032
to	O
low-	O
fibrinogen	B-C0016006
lymphatics	B-C0024235
and	O
body	B-C0333343
cavities	I-C0333343
diluted	B-C1948037
1%	O
plasma	B-C0032105
induces	O
migration	B-C1622501
of	O
malignant	B-C0334227
cell	I-C0334227
lines	I-C0334227
much	O
more	O
strongly	O
than	O
potent	O
pro-metastatic	B-C1521761
factors	I-C1521761
.	O
	
to	O
characterize	O
the	O
factor	B-C1521761
present	O
in	O
diluted	B-C1948037
plasma	B-C0032105
responsible	O
for	O
this	O
phenomenon	B-C1882365
we	O
performed	O
i	O
heat	B-C0018837
inactivation	B-C0544461
,	O
ii	O
dialysis	B-C0011945
,	O
iii	O
proteinase	B-C0059256
k	I-C0059256
treatment	B-C1522326
,	O
and	O
iv	O
molecular	B-C0016107
size	I-C0016107
filtration	I-C0016107
studies	I-C0016107
.	O
	
we	O
found	O
that	O
this	O
remarkable	O
pro-migratory	B-C0441655
activity	I-C0441655
of	O
diluted	B-C1948037
normal	O
plasma	B-C0032105
is	O
associated	O
with	O
a	O
50-100-kd	O
protein	B-C0033684
that	O
interacts	O
with	O
gαi	B-C0682972
protein-coupled	I-C0682972
receptors	I-C0682972
and	O
activates	O
p42/44	B-C0752312
mapk	I-C0752312
and	O
akt	B-C1623484
signaling	I-C1623484
in	O
target	O
cells	B-C0007634
.	O
	
since	O
this	O
pro-migratory	B-C0441655
activity	I-C0441655
of	O
1%	O
plasma	B-C0032105
decreases	O
at	O
higher	O
plasma	B-C0683150
concentrations	I-C0683150
>	O
20%	O
,	O
but	O
is	O
retained	O
in	O
serum	B-C0229671
,	O
we	O
hypothesized	O
that	O
fibrinogen	B-C0016006
may	O
be	O
involved	O
as	O
a	O
chaperone	B-C0243041
of	O
the	O
protein	B-C0033684
.	O
	
to	O
identify	O
the	O
pro-migratory	B-C0033684
protein	I-C0033684
present	O
in	O
diluted	B-C1948037
plasma	B-C0032105
and	O
fibrinogen	B-C0016006
-depleted	O
serum	B-C0229671
,	O
we	O
performed	O
gel	B-C0008559
filtration	I-C0008559
and	O
hydrophobic	B-C0008550
interaction	I-C0008550
chromatography	I-C0008550
followed	O
by	O
mass	B-C0037813
spectrometry	I-C0037813
analysis	I-C0037813
.	O
	
we	O
identified	O
several	O
putative	O
protein	B-C0033684
candidates	O
that	O
were	O
further	O
tested	O
in	B-C1533691
in	O
vitro	I-C1533691
experiments	B-C0681814
.	O
	
we	O
found	O
that	O
this	O
pro-migratory	B-C0574031
factor	I-C0574031
chaperoned	B-C0243041
by	O
fibrinogen	B-C0016006
is	O
vitronectin	B-C0055023
,	O
which	O
activates	O
upar	O
,	O
and	O
that	O
this	O
effect	O
can	O
be	O
inhibited	O
by	O
fibrinogen	B-C0016006
.	O
	
these	O
results	O
provide	O
a	O
novel	O
mechanism	B-C0678659
for	O
the	O
metastasis	B-C4255448
of	O
cancer	B-C0597032
cells	I-C0597032
to	O
lymphatics	B-C0024235
and	O
body	B-C0333343
cavities	I-C0333343
,	O
in	O
which	O
the	O
concentration	B-C1264643
of	O
fibrinogen	B-C0016006
is	O
low	O
,	O
and	O
thus	O
suggests	O
that	O
free	O
vitronectin	B-C0055023
stimulates	O
migration	B-C1622501
of	O
tumor	B-C0597032
cells	I-C0597032
.	O
	
development	B-C1527148
and	O
initial	B-C0205265
validation	B-C1519941
of	O
the	O
respirator	B-C3824912
comfort	B-C1331418
,	O
wearing	B-C0596545
experience	I-C0596545
,	O
and	O
function	B-C0542341
instrument	B-C0348000
r-comfi	B-C0348000
filtering	B-C3824912
face-piece	I-C3824912
respirators	I-C3824912
ffrs	B-C3824912
are	O
worn	O
to	O
protect	B-C1545588
health	B-C0018724
care	I-C0018724
personnel	I-C0018724
from	O
airborne	B-C1510837
particles	I-C1510837
however	O
,	O
clinical	B-C0008972
studies	I-C0008972
have	O
demonstrated	O
that	O
ffr	B-C3824912
adherence	B-C1510802
is	O
relatively	O
low	B-C0205251
in	O
some	O
settings	O
,	O
in	O
part	B-C0449719
,	O
due	O
to	O
discomfort	B-C2364135
and	O
intolerance	B-C0231199
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C0681814
was	O
to	O
develop	O
and	O
initially	B-C0205265
evaluate	B-C1516048
the	O
psychometric	B-C0871161
properties	I-C0871161
of	O
an	O
instrument	B-C0348000
designed	B-C0014677
to	O
measure	B-C0079809
the	O
comfort	B-C1331418
and	O
tolerability	B-C4053931
of	O
ffrs	B-C3824912
.	O
	
instrument	B-C0348000
items	O
were	O
developed	O
through	O
literature	B-C0282441
reviews	I-C0282441
,	O
focus	B-C0016400
groups	I-C0016400
,	O
and	O
several	B-C0443302
iterations	B-C1854293
of	O
ranking	B-C0699794
and	O
refining	O
by	O
experts	B-C0009817
.	O
	
psychometric	B-C0033920
evaluation	I-C0033920
of	O
the	O
instrument	B-C0348000
was	O
conducted	O
using	O
rasch	B-C3161035
partial	I-C3161035
credit	I-C3161035
model	I-C3161035
pcm	B-C3161035
analysis	B-C0936012
.	O
	
pivot	B-C0282574
anchoring	I-C0282574
was	O
used	O
to	O
specify	O
the	O
threshold	B-C0449864
defining	O
item	O
difficulty	B-C0332218
in	O
our	O
analyses	B-C0936012
,	O
this	O
was	O
the	O
point	B-C1552961
that	O
participants	B-C0679646
moved	O
from	O
possessing	B-C3154893
none	O
of	O
the	O
trait	B-C0599883
to	O
some	O
of	O
the	O
trait	B-C0599883
.	O
	
the	O
final	B-C3853528
instrument	B-C0348000
was	O
completed	B-C0205197
by	O
165	O
health	B-C0018724
care	I-C0018724
personnel	I-C0018724
from	O
3	O
veterans	B-C0042610
health	B-C2936317
administration	I-C2936317
facilities	I-C2936317
,	O
and	O
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
rasch	B-C3161035
pcm	I-C3161035
.	O
	
seven	O
items	O
were	O
removed	B-C0849355
because	O
they	O
1	O
violated	B-C0205556
the	I-C0205556
assumption	I-C0205556
of	I-C0205556
independence	I-C0205556
2	O
were	O
mis-fitting	B-C0205556
and/or	O
3	O
were	O
deemed	O
not	B-C2347946
relevant	I-C2347946
.	O
	
category	B-C0683312
function	B-C0542341
analysis	B-C0936012
demonstrated	O
that	O
all	O
categories	B-C0683312
progressed	B-C1272688
monotonically	B-C0205556
.	O
	
principal	B-C0429865
components	I-C0429865
analysis	I-C0429865
demonstrated	O
the	O
existence	B-C1547035
of	O
three	O
subscales	B-C0392762
discomfort	B-C2364135
,	O
general	O
wearing	B-C0596545
experience	I-C0596545
,	O
and	O
function	B-C0542341
.	O
	
final	B-C3853528
reliability	B-C2347947
analyses	B-C0936012
showed	O
that	O
the	O
scale	B-C0392762
had	O
moderate	B-C0205081
to	O
high	B-C2347947
person	I-C2347947
reliability	I-C2347947
and	O
high	O
item	O
reliability	B-C2347947
.	O
	
the	O
final	O
instrument	B-C0348000
contained	B-C0332256
21	O
items	O
.	O
	
until	O
now	O
,	O
to	O
our	O
knowledge	B-C0162340
no	O
instrument	B-C0348000
with	O
evidence	B-C3887511
supporting	O
its	O
reliability	B-C0035036
and	I-C0035036
validity	I-C0035036
to	O
assess	B-C1516048
discomfort	B-C2364135
and	O
tolerance	B-C1704410
of	O
ffrs	B-C3824912
among	O
health	B-C0018724
care	I-C0018724
personnel	I-C0018724
has	O
been	O
published	B-C0034037
.	O
	
a	O
21-item	O
psychometrically	B-C0079809
sound	I-C0079809
measure	I-C0079809
of	O
comfort	B-C1331418
and	O
tolerability	B-C4053931
of	O
ffrs	B-C3824912
,	O
respirator	B-C3824912
comfort	B-C1331418
,	O
wearing	B-C0596545
experience	I-C0596545
,	O
and	O
function	B-C0542341
instrument	B-C0348000
r-comfi	B-C0348000
,	O
was	O
developed	O
.	O
	
the	O
significance	B-C0750502
of	O
developing	O
such	O
an	O
instrument	B-C0348000
is	O
that	O
it	O
will	O
help	O
identify	O
respirators	B-C3824912
that	O
are	O
likely	O
to	O
have	O
better	O
adherence	B-C1510802
in	O
practice	B-C0032893
settings	O
.	O
	
the	O
r-comfi	B-C0348000
may	O
be	O
used	O
within	B-C0332285
and	O
beyond	O
the	O
va	B-C0018696
healthcare	I-C0018696
system	I-C0018696
as	O
a	O
psychometrically	B-C0348000
sound	I-C0348000
instrument	I-C0348000
to	O
evaluate	B-C1516048
the	O
comfort	B-C1331418
and	O
tolerability	B-C4053931
of	O
respirators	B-C3824912
,	O
including	O
developmental	B-C0458003
kidney	B-C4304779
transplant	I-C4304779
recipients	I-C4304779
after	O
nonrenal	B-C0029216
solid	I-C0029216
organ	I-C0029216
transplantation	I-C0029216
show	O
low	O
alloreactivity	B-C0301873
but	O
an	O
increased	O
risk	B-C0035647
of	O
infection	B-C3714514
the	O
number	O
of	O
kidney	B-C4304779
transplant	I-C4304779
recipients	I-C4304779
ktrs	B-C4304779
after	O
nonrenal	B-C0029216
solid	I-C0029216
organ	I-C0029216
transplantation	I-C0029216
sot	B-C0029216
has	O
increased	O
to	O
almost	O
5%	O
.	O
	
knowledge	O
on	O
patient	B-C0030705
and	O
allograft	B-C0040739
outcomes	B-C0085415
,	O
infections	B-C3714514
,	O
and	O
alloreactivity	B-C0301873
,	O
however	O
,	O
remains	O
scarce	O
.	O
	
we	O
studied	B-C2603343
40	O
ktrs	B-C4304779
after	O
nonrenal	B-C0029216
sot	I-C0029216
.	O
	
seven	O
hundred	O
and	O
twenty	O
primary	O
ktrs	B-C4304779
and	O
119	O
repeat	O
ktrs	B-C4304779
were	O
used	O
for	O
comparison	O
.	O
	
samples	B-C0504082
were	O
collected	O
pretransplantation	B-C1254367
,	O
at	O
+1	O
,	O
+2	O
,	O
and	O
+3	O
months	O
post-transplantation	B-C1254367
.	O
	
alloreactive	B-C0301873
and	O
cmv-specific	B-C0010825
t	B-C0039194
cells	I-C0039194
were	O
measured	O
by	O
interferon-γ	B-C0920508
elispot	I-C0920508
assay	I-C0920508
.	O
	
patient	B-C0030705
survival	B-C0038952
in	O
ktrs	B-C4304779
after	O
sot	B-C0029216
,	O
primary	O
and	O
repeat	O
ktrs	B-C4304779
was	O
comparable	O
.	O
	
while	O
death	B-C0011065
-censored	O
allograft	B-C0040739
survival	B-C0038952
was	O
comparable	O
between	O
ktrs	B-C4304779
after	O
sot	B-C0029216
and	O
primary	O
ktrs	B-C4304779
,	O
ktrs	B-C4304779
after	O
sot	B-C0029216
showed	O
superior	O
5-year	B-C0439234
death	B-C0011065
-censored	O
allograft	B-C0040739
survival	B-C0038952
of	O
92.5	O
compared	O
to	O
81.2	O
in	O
repeat	O
ktrs	B-C4304779
.	O
	
interestingly	O
,	O
ktrs	B-C4304779
after	O
sot	B-C0029216
show	O
less	O
preformed	O
panel-reactive	B-C1141951
antibodies	I-C1141951
,	O
frequencies	B-C0439603
of	O
alloreactive	B-C0301873
t	B-C0039194
cells	I-C0039194
,	O
and	O
acute	B-C3273245
rejections	I-C3273245
compared	O
to	O
repeat	O
ktrs	B-C4304779
.	O
	
ktrs	B-C4304779
after	O
sot	B-C0029216
,	O
however	O
,	O
show	O
higher	O
incidences	B-C0021149
of	O
ebv	B-C1701919
viremia	I-C1701919
and	O
ptld	B-C0432487
,	O
sepsis	B-C0243026
,	O
and	O
death	B-C0011065
from	O
sepsis	B-C0243026
.	O
	
impaired	O
cmv-specific	B-C0010825
cellular	B-C0020966
immunity	I-C0020966
was	O
associated	B-C0332281
with	I-C0332281
more	O
cmv	B-C0010825
replication	B-C0042774
compared	O
to	O
repeat	O
ktrs	B-C4304779
.	O
	
our	O
results	O
suggest	O
comparable	O
patient	B-C0030705
and	O
allograft	B-C0040739
outcomes	B-C0085415
in	O
ktrs	B-C4304779
after	O
sot	B-C0029216
and	O
primary	O
ktrs	B-C4304779
.	O
	
the	O
observed	O
low	O
alloreactivity	B-C0301873
may	O
contribute	O
to	O
excellent	O
allograft	B-C0040739
outcomes	B-C0085415
.	O
	
caution	O
should	O
be	O
taken	O
in	O
ktrs	B-C4304779
after	O
sot	B-C0029216
regarding	O
infectious	B-C0940933
complications	I-C0940933
due	O
to	O
improved	B-C0184511
protocol	B-C0442711
for	O
the	O
isolation	B-C0220862
of	O
naïve	O
follicular	B-C0242245
dendritic	I-C0242245
cells	I-C0242245
follicular	B-C0242245
dendritic	I-C0242245
cells	I-C0242245
fdcs	B-C0242245
in	O
lymphoid	B-C0502330
organs	I-C0502330
play	O
an	O
important	O
role	B-C1705810
in	O
the	O
humoral	B-C1155229
immune	I-C1155229
response	I-C1155229
.	O
	
however	O
,	O
because	O
the	O
isolation	B-C0204727
of	O
fdcs	B-C0242245
is	O
difficult	B-C0332218
due	O
to	O
their	O
very	O
small	B-C0700321
population	B-C0032683
size	I-C0032683
and	O
fragility	B-C0302113
under	O
mechanical	B-C0038442
and	O
chemical	B-C1254365
stresses	I-C1254365
,	O
the	O
genetic	B-C0314603
and	O
biochemical	B-C0205474
characteristics	B-C1521970
of	O
fdcs	B-C0242245
remain	O
unclear	B-C3845108
.	O
	
previously	O
,	O
we	O
identified	O
fdcs	B-C0242245
as	O
icam-1	B-C0063695
cells	B-C0007634
in	O
the	O
cd45	B-C0054961
-	B-C0205160
non-hematopoietic	B-C0805525
cell	I-C0805525
fraction	I-C0805525
from	O
naïve	O
mouse	B-C1519474
spleen	I-C1519474
after	O
cell	B-C0007616
separation	I-C0007616
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	B-C0205195
of	O
enzymes	B-C0014442
.	O
	
in	O
the	O
present	O
study	O
,	O
using	O
a	O
new	B-C0205314
combination	B-C0205195
of	O
enzymes	B-C0014442
,	O
we	O
found	O
that	O
fdcs	B-C0242245
are	O
highly	O
enriched	O
in	O
the	O
cd45	B-C0054961
-	B-C0205160
icam-1	B-C0063695
cd21	B-C0056184
/	O
35	B-C0009552
cell	B-C0805525
fraction	I-C0805525
.	O
	
cd45	B-C0054961
-	B-C0205160
icam-1	B-C0063695
cd21	B-C0056184
/	O
35	B-C0009552
cells	B-C0007634
in	O
the	O
mouse	B-C1519474
spleen	I-C1519474
retained	O
an	O
antigen	B-C0003320
administered	O
in	B-C1515655
vivo	I-C1515655
for	O
more	O
than	O
7	O
days	B-C0439228
.	O
	
moreover	O
,	O
cd45	B-C0054961
-	B-C0205160
icam-1	B-C0063695
cd21	B-C0056184
/	O
35	B-C0009552
cells	B-C0007634
isolated	B-C0205409
from	O
the	O
spleen	B-C1519474
of	I-C1519474
mice	I-C1519474
administered	O
with	O
a	O
cognate	B-C0003320
antigen	I-C0003320
enhanced	B-C2349975
the	O
survival	B-C0007620
and	O
proliferation	B-C1514485
of	O
antigen-specific	B-C0007634
b	I-C0007634
cells	I-C0007634
in	B-C1533691
vitro	I-C1533691
.	O
	
our	O
improved	B-C0184511
protocol	B-C0442711
for	O
the	O
isolation	B-C0220862
of	O
naïve	O
fdcs	B-C0242245
will	O
be	O
useful	O
for	O
the	O
analysis	B-C0936012
of	O
fdcs	B-C0242245
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
dental	B-C0226984
enamel	B-C2750331
defects	I-C2750331
in	O
german	B-C1556085
medieval	B-C0242321
and	O
early-modern-age	B-C0242818
populations	B-C1257890
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
frequency	B-C0439603
and	O
type	B-C0332307
of	O
developmental	B-C2750331
defects	I-C2750331
of	I-C2750331
enamel	I-C2750331
dde	B-C2750331
in	O
a	O
medieval	B-C0242321
and	O
an	O
early-modern-age	B-C0242818
population	B-C1257890
from	O
thuringia	B-C0017480
,	O
germany	I-C0017480
.	O
	
sixty-six	O
skeletons	B-C0816871
subdivided	B-C0332849
into	O
31	O
single	B-C0205171
burials	B-C0006407
12	O
c	O
and	O
35	O
individuals	B-C0237401
buried	B-C0006407
in	O
groups	B-C0441833
15	O
c	O
were	O
examined	B-C0332128
.	O
	
dde	B-C2750331
were	O
classified	B-C0008902
on	O
1	O
teeth	B-C0040426
according	O
to	O
the	O
dde	B-C2750331
index	B-C0918012
.	O
	
molar-incisor-hypomineralisation	B-C2350038
mih	B-C2350038
,	O
a	O
special	O
type	B-C0332307
of	O
dde	B-C2750331
,	O
was	O
recorded	B-C0034869
according	O
to	O
the	O
european	B-C0000877
academy	I-C0000877
of	I-C0000877
paediatric	I-C0000877
dentistry	I-C0000877
eapd	B-C0000877
criteria	B-C0243161
.	O
	
dde	B-C2750331
was	O
found	O
in	O
89.4	O
of	O
the	O
individuals	B-C0237401
single	B-C0205171
burials	B-C0006407
90.3	O
and	O
group	B-C0441833
burials	B-C0006407
88.6	O
.	O
	
hypoplastic	B-C0543481
pits	B-C1860853
were	O
the	O
most	O
frequent	B-C0332183
defect	B-C1457869
in	O
primary	B-C3266841
teeth	I-C3266841
and	O
linear	B-C0011351
enamel	I-C0011351
hypoplasia	I-C0011351
leh	B-C0011351
in	O
permanent	B-C1720362
teeth	I-C1720362
.	O
	
13	O
individuals	B-C0237401
24.1	O
showed	O
at	O
least	O
one	O
hypomineralised	B-C0085511
permanent	B-C0348070
tooth	I-C0348070
,	O
12.2	O
had	O
mih	B-C2350038
on	O
at	O
least	O
one	O
first	O
permanent	B-C0026367
molar	I-C0026367
and	O
10.0	O
in	O
permanent	B-C3161464
incisors	I-C3161464
.	O
	
second	B-C0227108
primary	I-C0227108
molars	I-C0227108
were	O
affected	B-C0392760
in	O
8.0	O
of	O
the	O
children	B-C0008059
and	O
juveniles	B-C3146221
.	O
	
no	O
individual	B-C0237401
suffered	O
from	O
affected	B-C0392760
molars	B-C0026367
and	O
incisors	B-C0021156
in	O
combination	B-C0205195
.	O
	
endogenous	B-C0205227
factors	B-C1521761
like	O
nutritional	B-C0162429
deficiencies	I-C0162429
and	O
health	B-C1398682
problems	I-C1398682
in	O
early	B-C1279919
childhood	B-C0231335
could	O
have	O
been	O
aetiological	B-C1314792
reasons	B-C0392360
of	O
dde	B-C2750331
and	O
mih	B-C2350038
.	O
	
the	O
frequency	B-C0439603
of	O
dde	B-C2750331
and	O
mih	B-C2350038
might	O
have	O
been	O
masked	B-C0150108
by	O
extended	B-C0231449
carious	B-C0011334
lesions	I-C0011334
,	O
dental	B-C2717979
wear	I-C2717979
and	O
ante-mortem	B-C0243095
tooth	B-C0080233
loss	I-C0080233
.	O
	
breast	B-C0006142
cancer	I-C0006142
detection	B-C0392762
rate	I-C0392762
,	O
incidence	B-C0021149
,	O
prevalence	B-C0220900
and	O
interval	B-C1272706
cancer	B-C0006826
-related	O
mammography	B-C0203028
screening	I-C0203028
times	B-C0040223
among	O
thai	B-C0337910
women	B-C0043210
a	O
recent	O
guideline	B-C0162791
by	O
the	O
american	B-C0002455
cancer	I-C0002455
society	I-C0002455
recommended	O
that	O
mammography	B-C0024671
mmg	B-C0024671
should	O
be	O
done	O
for	O
women	B-C0043210
starting	O
in	O
their	O
mid-40s	O
.	O
	
in	O
thailand	B-C0039725
,	O
information	O
on	O
opportunistic	B-C0422389
mammography	I-C0422389
screening	I-C0422389
is	O
limited	B-C0439801
and	O
data	B-C1511726
on	O
the	O
total	O
incidence	B-C0021149
of	O
breast	B-C0006142
cancer	I-C0006142
are	O
also	O
lacking	O
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C0008972
was	O
to	O
estimate	B-C0750572
the	O
breast	B-C0006142
cancer	I-C0006142
detection	B-C1516193
,	O
incident	B-C1551358
and	O
prevalence	B-C0220900
rates	I-C0220900
among	O
thai	B-C0337910
women	B-C0043210
.	O
	
we	O
retrospectively	O
reviewed	O
the	O
opportunistic	B-C0422389
mammography	I-C0422389
screening	I-C0422389
of	O
normal	O
women	B-C0043210
between	O
30	O
and	O
80	O
years	B-C0439234
who	O
underwent	O
the	O
procedure	B-C0220908
between	O
2001	O
and	O
2010	O
.	O
	
all	O
cases	O
were	O
followed	O
until	O
2012	O
.	O
	
the	O
detection	B-C0392762
rate	I-C0392762
was	O
calculated	O
for	O
the	O
whole	O
period	O
of	O
observation	B-C0302523
using	O
'	O
number	B-C0237753
of	O
women	B-C0043210
with	O
positive	B-C0586815
findings	I-C0586815
'	O
divided	O
by	O
'	O
total	B-C4288115
number	I-C4288115
of	O
women	B-C0043210
screened	B-C0199230
'	O
.	O
	
the	O
incidence	B-C1708485
rate	I-C1708485
was	O
calculated	B-C0444686
only	O
at	O
the	O
first	O
mmg	B-C0024671
while	O
the	O
subsequence	O
rate	O
was	O
calculated	O
based	O
on	O
all	O
new	O
cases	O
detected	B-C0442726
at	O
each	O
subsequent	O
mmg	B-C0024671
.	O
	
among	O
the	O
47	O
women	B-C0043210
,	O
there	O
were	O
152	O
mmgs	B-C0024671
or	O
approximately	O
3.2	O
occasions	O
per	O
person	B-C0027361
range	O
,	O
1-10	O
.	O
	
the	O
average	O
duration	B-C0449238
of	O
the	O
interval	B-C1272706
between	O
each	O
subsequence	O
visit	O
was	O
1.8	O
years	B-C0439234
.	O
	
overall	O
,	O
breast	B-C0006142
cancer	I-C0006142
was	O
detected	B-C0442726
in	O
543	O
women	B-C0043210
,	O
with	O
a	O
detection	B-C0392762
rate	I-C0392762
of	O
10.3	O
per	O
1	O
persons	B-C0027361
.	O
	
the	O
prevalence	B-C0220900
rate	I-C0220900
of	O
breast	B-C0006142
cancer	I-C0006142
at	O
the	O
first	O
visit	O
was	O
5.78	O
per	O
1	O
person	B-C0027361
s	O
.	O
	
the	O
incidence	B-C0021149
or	O
new	O
cases	O
detected	B-C0442726
at	O
any	O
follow-up	O
visit	O
was	O
10.4	O
per	O
1	O
person	B-C0027361
s	O
.	O
	
the	O
overall	O
interval	B-C1272706
cancer	O
was	O
0.91	O
per	O
1	O
women	B-C0043210
,	O
mainly	O
detected	B-C0442726
before	O
their	O
second	O
and	O
third	O
mmg	B-C0024671
,	O
with	O
a	O
rate	O
of	O
0.0	O
and	O
0.76	O
per	O
1	O
women	B-C0043210
.	O
	
opportunistic	B-C0422389
mammography	I-C0422389
screening	I-C0422389
in	O
thailand	B-C0039725
detected	B-C0442726
10	O
cases	O
of	O
breast	B-C0006142
cancer	I-C0006142
from	O
each	O
1	O
women	B-C0043210
.	O
	
this	O
paper	O
indicated	O
a	O
high	O
rate	O
of	O
cancer	B-C1516193
detection	I-C1516193
during	O
a	O
two	O
year	O
interval	B-C1272706
,	O
hence	O
,	O
a	O
screening	B-C0203028
mammogram	I-C0203028
assessment	O
of	O
groundwater	B-C0596631
vulnerability	B-C0332157
in	O
the	O
daule	B-C3178977
aquifer	I-C3178977
,	O
ecuador	B-C0013593
,	O
using	O
the	O
susceptibility	B-C0871511
index	I-C0871511
method	I-C0871511
the	O
guayas	B-C0017446
region	I-C0017446
in	O
ecuador	B-C0013593
is	O
economically	O
very	O
important	O
,	O
producing	O
68%	O
of	O
the	O
national	B-C0242775
crops	I-C0242775
.	O
	
the	O
main	O
agricultural	B-C0001829
activities	I-C0001829
threaten	O
the	O
groundwater	B-C0596631
therein	O
with	O
nitrate	B-C0699857
contamination	B-C2349974
given	O
the	O
large	O
fertiliser	B-C0015919
and	O
water	B-C0043047
needs	B-C0027552
.	O
	
the	O
present	O
work	O
tests	O
the	O
applicability	O
of	O
the	O
susceptibility	B-C0871511
index	I-C0871511
assessment	I-C0871511
method	I-C0871511
in	O
evaluating	O
the	O
impact	O
of	O
agricultural	B-C0001829
activities	I-C0001829
on	O
groundwater	B-C0596631
quality	B-C0332306
,	O
using	O
as	O
a	O
case	O
study	O
an	O
aquifer	B-C3178977
of	O
the	O
guayas	B-C0017446
river	B-C0205146
basin	I-C0205146
in	O
ecuador	B-C0013593
.	O
	
the	O
index	O
adapts	O
four	O
parameters	O
of	O
the	O
drastic	B-C0871511
method	I-C0871511
and	O
incorporated	O
a	O
new	O
land	B-C0814835
use	I-C0814835
parameter	O
.	O
	
results	O
show	O
that	O
the	O
areas	B-C0205146
highly	B-C0205250
vulnerable	B-C0332157
to	O
contamination	B-C2349974
are	O
located	O
in	O
irrigation	B-C2936278
perimeters	B-C1295726
of	O
dominant	O
paddy	B-C0562975
fields	I-C0562975
associated	O
with	O
the	O
high	O
recharge	O
rates	O
in	O
the	O
alluvial	B-C0055863
deposits	I-C0055863
.	O
	
respectively	O
,	O
moderately	B-C0205081
vulnerable	B-C0332157
and	O
low	B-C0205251
-	O
vulnerability	B-C0332157
areas	B-C0205146
correspond	O
to	O
aquatic	B-C0563034
environments	I-C0563034
and	O
forests	B-C0086312
,	O
semi-natural	B-C1710706
zones	I-C1710706
and	O
water	B-C2584335
bodies	I-C2584335
.	O
	
one	O
of	O
the	O
main	O
contributions	O
of	O
the	O
daule	B-C3178977
aquifer	I-C3178977
vulnerability	B-C0332157
is	O
likely	O
its	O
wide	B-C0332464
,	O
flat	B-C0870781
topography	I-C0870781
.	O
	
a	O
great	O
part	O
of	O
the	O
aquifer	B-C3178977
is	O
at	O
high	B-C4060526
risk	I-C4060526
of	I-C4060526
contamination	I-C4060526
by	O
nitrates	B-C0699857
if	O
a	O
code	O
of	O
good	B-C0205170
agricultural	B-C0001829
practices	I-C0001829
is	O
not	O
applied	O
.	O
	
therefore	O
the	O
implementation	O
of	O
a	O
monitoring	B-C0243095
network	I-C0243095
to	I-C0243095
control	I-C0243095
the	O
nitrates	B-C0699857
concentrations	B-C1446561
is	O
the	O
first	O
step	O
to	O
assure	O
groundwater	B-C0596631
quality	B-C0332306
for	O
drinking	B-C0599638
purposes	B-C1285529
.	O
	
heterogeneous	B-C0019409
depression	B-C0011570
trajectories	B-C1254367
in	O
multiple	B-C0026769
sclerosis	I-C0026769
patients	B-C0030705
trajectories	B-C1254367
of	O
depression	B-C0011570
over	O
time	O
may	O
be	O
heterogeneous	B-C0019409
in	O
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
patients	B-C0030705
.	O
	
describing	O
these	O
trajectories	B-C1254367
will	O
help	O
clinicians	B-C0871685
understand	O
better	O
the	O
progression	B-C0449258
of	O
depression	B-C0011570
in	O
ms	B-C0026769
patients	B-C0030705
to	O
aid	O
in	O
patient	O
care	O
decisions	O
.	O
	
latent	B-C0681947
class	I-C0681947
growth	I-C0681947
analysis	I-C0681947
lcga	B-C0681947
was	O
applied	O
to	O
3507	O
ms	B-C0026769
patients	B-C0030705
using	O
an	O
electronic	B-C2362543
health	I-C2362543
records	I-C2362543
ehr	I-C2362543
data	I-C2362543
base	I-C2362543
to	O
identify	O
subgroups	B-C1257890
of	O
ms	B-C0026769
patients	B-C0030705
based	O
on	O
self-reported	O
depression	B-C0740218
screening	I-C0740218
phq-9	B-C1718207
.	O
	
latent	B-C0205275
trajectory	B-C1254367
classes	O
were	O
used	O
for	O
group	B-C1257890
comparisons	O
based	O
on	O
baseline	B-C1442488
clinical	B-C0683325
characteristics	I-C0683325
.	O
	
three	O
subgroups	B-C1257890
were	O
found	O
characterized	O
by	O
high	B-C0205250
10.0	O
of	O
participants	B-C0679646
,	O
wavering	O
above	O
and	O
below	O
moderate	B-C0205081
26.2	O
and	O
low	B-C0205251
and	O
variable	B-C0439828
63.8	O
depression	B-C1319226
level	I-C1319226
trajectories	B-C1254367
.	O
	
the	O
subpopulation	B-C1257890
trajectories	B-C1254367
,	O
respectively	O
,	O
were	O
also	O
characterized	O
by	O
high	B-C0205250
,	O
moderate	B-C0205081
and	O
low	B-C0205251
ms	B-C0026769
disability	B-C0231170
at	O
baseline	B-C1442488
.	O
	
in	O
contrast	O
,	O
the	O
overall	O
average	O
trajectory	B-C1254367
was	O
slightly	O
declining	O
and	O
below	O
the	O
moderate	B-C0205081
depression	B-C0011570
threshold	B-C0449864
.	O
	
the	O
lcga	B-C0681947
approach	O
described	O
in	O
this	O
paper	O
and	O
applied	O
to	O
ms	B-C0026769
patients	B-C0030705
provides	O
a	O
template	B-C1705542
for	O
improved	O
use	O
of	O
an	O
ehr	B-C2362543
data	I-C2362543
base	I-C2362543
for	O
understanding	O
heterogeneous	B-C0019409
depression	B-C0740218
screening	I-C0740218
trajectories	B-C1254367
.	O
	
clinicians	B-C0871685
may	O
use	O
such	O
information	B-C1533716
to	O
more	O
closely	O
monitor	B-C0030695
patients	I-C0030695
that	O
are	O
expected	O
to	O
maintain	O
high	B-C0205250
or	O
unstable	B-C0443343
depression	B-C1319226
levels	I-C1319226
.	O
	
the	O
pla2	B-C0017337
gene	I-C0017337
mediates	O
the	O
humoral	B-C1155229
immune	I-C1155229
responses	I-C1155229
in	O
bactrocera	B-C1001509
dorsalis	I-C1001509
hendel	I-C1001509
the	O
phospholipase	B-C0017337
a2	I-C0017337
pla2	I-C0017337
gene	I-C0017337
encodes	B-C2700640
the	O
enzyme	B-C0014442
that	O
catalyzes	B-C0205245
the	O
hydrolysis	B-C0020291
of	O
phospholipids	B-C0031676
pls	B-C0031676
from	O
the	O
sn-2	B-C0733755
position	I-C0733755
.	O
	
however	O
,	O
little	O
is	O
known	O
about	O
its	O
role	B-C1704326
in	O
humoral	B-C1155229
immune	I-C1155229
responses	I-C1155229
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
investigated	B-C1292732
the	O
expression	B-C1956267
profile	I-C1956267
of	O
pla2	B-C0017337
in	O
different	B-C1705242
tissues	B-C0040300
and	O
developmental	B-C0870411
stages	I-C0870411
in	O
bactrocera	B-C1001509
dorsalis	I-C1001509
hendel	I-C1001509
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
transcriptional	B-C0040649
level	B-C0441889
of	O
pla2	B-C0017337
was	O
high	B-C0205250
in	O
the	O
egg	B-C1254358
and	O
mature	B-C1326793
stage	I-C1326793
and	O
in	O
the	O
testis	B-C0039597
tissue	B-C0040300
.	O
	
bacterial	B-C0004623
infection	I-C0004623
increased	O
the	O
expression	B-C0017262
of	O
pla2	B-C0017337
,	O
and	O
the	O
highest	O
degree	O
of	O
up-regulation	B-C0041904
appeared	O
in	O
the	O
fat	B-C0015665
body	I-C0015665
.	O
	
silencing	B-C0598496
pla2	B-C0017337
influenced	B-C4054723
the	O
expression	B-C0017262
of	O
immune-related	B-C0017337
genes	I-C0017337
,	O
including	O
myd88	B-C1417530
and	O
defensin	B-C0057256
in	O
the	O
toll	B-C1155478
pathway	I-C1155478
and	O
relish	B-C0033684
and	O
diptericin	B-C0033684
in	O
the	O
imd	B-C2753278
pathway	I-C2753278
.	O
	
moreover	O
,	O
the	O
expression	B-C0017262
of	O
myd88	B-C1417530
and	O
defensin	B-C0057256
was	O
down-regulated	B-C0013081
significantly	O
in	O
the	O
ds-pla2	B-C0017337
group	B-C0441833
compared	O
with	O
those	O
in	O
the	O
ds-egfp	B-C1258415
group	B-C0441833
when	O
b	B-C1001509
.	O
	
dorsalis	I-C1001509
was	O
infected	B-C0439663
with	O
l	B-C0023861
.	O
	
monocytogenes	I-C0023861
and	O
s	B-C0038172
.	O
	
aureus	I-C0038172
,	O
indicating	O
that	O
pla2	B-C0017337
was	O
involved	O
in	O
the	O
activation	B-C0017255
of	O
the	O
toll	B-C1155478
pathway	I-C1155478
.	O
	
meanwhile	O
,	O
infection	B-C3714514
with	O
l	B-C0023861
.	O
	
monocytogenes	I-C0023861
and	O
e	B-C0014834
.	O
	
coli	I-C0014834
,	O
which	O
activate	B-C1515877
the	O
imd	B-C2753278
pathway	I-C2753278
,	O
does	O
not	O
increase	B-C0442805
the	O
mrna	B-C0035696
levels	B-C0441889
of	O
relish	B-C0033684
and	O
diptericin	B-C0033684
in	O
the	O
ds-pla2	B-C0017337
group	B-C0441833
as	O
severely	O
as	O
it	O
increases	B-C0442805
those	O
in	O
the	O
ds-egfp	B-C1258415
group	B-C0441833
,	O
indicating	O
that	O
the	O
imd	B-C2753278
pathway	I-C2753278
was	O
also	O
repressed	B-C0205245
after	O
silencing	B-C0598496
pla2	B-C0017337
.	O
	
notably	O
,	O
the	O
development	B-C1527148
of	O
lipid	B-C0230704
droplets	I-C0230704
in	O
fat	B-C0015665
body	I-C0015665
cells	B-C0007634
was	O
influenced	B-C4054723
by	O
silencing	B-C0598496
pla2	B-C0017337
,	O
implying	O
that	O
pla2	B-C0017337
affects	O
the	O
function	B-C0542341
of	O
fat	B-C0015665
body	I-C0015665
tissue	B-C0040300
.	O
	
these	O
results	O
suggest	O
that	O
the	O
pla2	B-C0017337
gene	O
may	O
mediate	O
humoral	O
immune	O
responses	O
by	O
reducing	O
lipid	O
storage	O
in	O
fat	O
body	O
cells	O
in	O
b	O
.	O
	
dorsalis	I-C1001509
gambling	B-C0030662
disorders	I-C0030662
,	O
gambling	B-C0016995
type	O
preferences	O
,	O
and	O
psychiatric	B-C0205487
comorbidity	B-C0009488
among	O
the	O
thai	B-C0337910
general	I-C0337910
population	I-C0337910
results	O
of	O
the	O
2013	O
national	B-C3481515
mental	I-C3481515
health	I-C3481515
survey	I-C3481515
background	O
and	O
aims	O
to	O
estimate	O
the	O
prevalence	B-C0033105
of	O
problem	B-C0850474
and	O
pathological	B-C0030662
gambling	I-C0030662
,	O
gender	B-C0079399
and	O
age-group	B-C0027362
differences	O
in	O
gambling	B-C0016995
types	I-C0016995
,	O
and	O
comorbidities	B-C0009488
with	O
other	O
psychiatric	B-C0004936
disorders	I-C0004936
among	O
the	O
thai	B-C0337910
general	I-C0337910
population	I-C0337910
.	O
	
methods	O
analysis	O
was	O
conducted	O
on	O
4	O
participants	B-C0679646
of	O
thailand's	B-C0039725
2013	O
national	B-C3481515
mental	I-C3481515
health	I-C3481515
survey	I-C3481515
,	O
a	O
multistage	B-C0038951
stratified	I-C0038951
cluster	I-C0038951
survey	I-C0038951
,	O
using	O
the	O
composite	B-C0451085
international	I-C0451085
diagnostic	I-C0451085
interview	I-C0451085
.	O
	
diagnoses	B-C0011900
of	O
problem	B-C0850474
and	O
pathological	B-C0030662
gambling	I-C0030662
and	O
other	O
psychiatric	B-C0004936
disorders	I-C0004936
were	O
based	O
on	O
the	O
dsm-iv-tr	B-C0220952
criteria	I-C0220952
with	O
the	O
following	O
additional	O
criteria	B-C0243161
for	O
gamblers	B-C0858352
more	O
than	O
10	O
lifetime	B-C4071830
gambling	O
episodes	O
and	O
a	O
single	B-C1517945
year	I-C1517945
loss	I-C1517945
of	O
at	O
least	O
365	O
usd	B-C0562019
from	O
gambling	B-C0016995
.	O
	
results	O
the	O
estimated	O
lifetime	B-C4071830
prevalence	B-C0033105
rates	I-C0033105
of	O
pathological	B-C0030662
and	O
problem	B-C0850474
gambling	I-C0850474
were	O
0.90	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.51	O
and	O
1.14	O
95%	O
ci	B-C0009667
0.58	O
,	O
respectively	O
.	O
	
the	O
most	O
popular	O
type	O
of	O
gambling	B-C0016995
was	O
playing	B-C0018464
lotteries	I-C0018464
69.5	O
,	O
standard	B-C1710181
error	I-C1710181
se	B-C1710181
=	O
1.9	O
,	O
the	O
prevalence	B-C0033105
of	O
which	O
was	O
significantly	O
higher	O
among	O
females	B-C0086287
and	O
older	B-C0001792
age	I-C0001792
groups	I-C0001792
.	O
	
the	O
most	O
common	O
psychiatric	B-C0004936
disorders	I-C0004936
seen	O
among	O
pathological	B-C0030662
gamblers	I-C0030662
were	O
alcohol	B-C0085762
abuse	I-C0085762
57.4	O
,	O
nicotine	B-C0028043
dependence	I-C0028043
49.5	O
,	O
and	O
any	O
drug	B-C0013222
use	I-C0013222
disorder	I-C0013222
16.2	O
.	O
	
pathological	B-C0030662
gambling	I-C0030662
was	O
highly	O
prevalent	O
among	O
those	O
who	O
ever	O
experienced	O
major	B-C0024517
depressive	I-C0024517
episodes	I-C0024517
5.5	O
,	O
any	O
drug	B-C1510472
dependence	I-C1510472
5.1	O
,	O
and	O
intermittent	B-C0021776
explosive	I-C0021776
disorder	I-C0021776
4.8	O
.	O
	
the	O
association	O
between	O
pathological	B-C0030662
gambling	I-C0030662
was	O
strongest	O
with	O
a	O
history	O
of	O
major	B-C0024517
depressive	I-C0024517
episode	I-C0024517
adjusted	B-C0028873
odds	I-C0028873
ratio	I-C0028873
aor	B-C0028873
=	O
10.4	O
,	O
95%	O
ci	B-C0009667
2.80	O
.	O
	
conclusion	O
the	O
study	O
confirms	O
the	O
recognition	B-C0524637
of	O
gambling	B-C0030662
disorders	I-C0030662
as	O
a	O
public	B-C3244304
health	I-C3244304
concern	O
in	O
thailand	B-C0039725
and	O
suggests	O
a	O
need	O
for	O
culturally	B-C0220814
specific	O
preventive	B-C1456501
measures	O
for	O
pathological	B-C0030662
gamblers	I-C0030662
and	O
those	O
with	O
a	O
history	O
of	O
substance	B-C0038586
use	I-C0038586
disorders	I-C0038586
or	O
major	B-C1269683
depression	I-C1269683
.	O
	
synovial	B-C0039101
sarcoma	I-C0039101
of	O
the	O
hypopharynx	B-C0020629
in	O
a	O
pediatric	B-C1521725
patient	B-C0030705
case	B-C0085973
report	I-C0085973
synovial	B-C0039101
sarcoma	I-C0039101
ss	B-C0039101
is	O
uncommon	O
high	O
grade	O
soft	B-C0225317
tissue	I-C0225317
sarcoma	B-C1261473
,	O
accounting	O
for	O
less	O
than	O
10%	O
of	O
all	O
head	B-C1827431
and	I-C1827431
neck	I-C1827431
sarcomas	I-C1827431
.	O
	
also	O
,	O
about	O
10%	O
of	O
ss	B-C0039101
occur	O
within	O
the	O
head	B-C0018670
neck	B-C0027530
.	O
	
in	O
the	O
pediatric	B-C1521725
population	B-C1257890
,	O
ss	B-C0039101
is	O
an	O
extremely	O
rare	B-C0522498
head	B-C1827431
neck	I-C1827431
malignancy	I-C1827431
.	O
	
we	O
present	O
a	O
case	O
of	O
sixteen	O
years	O
old	O
boy	B-C0870221
diagnosed	B-C0011900
with	O
ss	B-C0039101
situated	O
of	O
the	O
hypopharynx	B-C0020629
treated	B-C0332293
by	I-C0332293
surgical	B-C0728940
excision	I-C0728940
and	O
post	B-C0241311
operative	I-C0241311
radio	B-C1522449
-	O
chemotherapy	B-C3665472
.	O
	
this	O
anatomical	B-C0923870
location	I-C0923870
brings	O
additional	O
functional	B-C0205245
challenges	B-C0805586
swallowing	B-C0011167
,	O
phonation	B-C0031577
,	O
respiration	B-C0035203
,	O
especially	O
in	O
the	O
pediatric	B-C1521725
population	B-C1257890
.	O
	
pre-operative	B-C0445204
and	O
even	O
post-operative	B-C0241311
histopathological	B-C0243140
diagnosis	B-C0011900
of	O
ss	B-C0039101
remains	O
difficult	O
.	O
	
optimal	B-C2698651
treatment	B-C0087111
of	O
head	B-C0018670
neck	B-C0027530
ss	B-C0039101
has	O
to	O
balance	O
functional	B-C0205245
and	O
oncologic	B-C0205478
aspects	B-C1879746
.	O
	
ss	B-C0039101
is	O
an	O
extremely	O
rare	B-C0522498
head	B-C1827431
neck	I-C1827431
malignancy	I-C1827431
in	O
pediatric	B-C1521725
population	B-C1257890
.	O
	
it	O
has	O
multifaceted	B-C0205291
challenges	B-C0805586
including	O
pre	O
and	O
post-operative	B-C0241311
histopathological	B-C0243140
diagnosis	B-C0011900
and	O
optimal	B-C2698651
modality	B-C0695347
of	O
treatment	B-C0087111
.	O
	
clinical	B-C0237512
judgment	I-C0237512
,	O
especially	O
in	O
the	O
pediatric	B-C1521725
population	B-C1257890
,	O
needs	O
to	O
balance	O
tumor	B-C0332648
free	I-C0332648
margins	I-C0332648
and	O
organ	B-C0029209
preservation	I-C0029209
in	O
head	B-C0018670
and	O
neck	B-C0027530
region	B-C0005898
.	O
	
ocular	B-C0028841
hypotensive	I-C0028841
effect	B-C1280500
of	O
the	O
novel	O
ep3	B-C1449580
/	O
fp	B-C0662784
agonist	B-C2987634
ono-9054	B-C4277062
versus	O
xalatan	B-C0593887
results	O
of	O
a	O
28-	O
day	B-C0439228
,	O
double-masked	B-C0013072
,	O
randomised	B-C0439605
study	B-C2603343
ono-9054	B-C4277062
is	O
being	O
developed	O
for	O
the	O
reduction	B-C0392756
of	O
intraocular	B-C0021888
pressure	I-C0021888
iop	B-C0021888
in	O
patients	B-C0030705
with	O
ocular	B-C0028841
hypertension	I-C0028841
oht	B-C0028841
and	O
open-angle	B-C0017612
glaucoma	I-C0017612
oag	B-C0017612
.	O
	
this	O
study	B-C2603343
compared	O
the	O
novel	O
dual	O
ep3	B-C1449580
/	O
fp	B-C0662784
agonist	B-C2987634
ono-9054	B-C4277062
with	O
the	O
fp	B-C0662784
agonist	B-C2987634
xalatan	B-C0593887
.	O
	
adults	B-C0001675
n=123	O
with	O
bilateral	O
mild/moderate	O
oag	B-C0017612
or	O
oht	B-C0028841
,	O
with	O
unmedicated	O
iop	B-C0021888
of	O
24	O
mm	O
hg	O
at	O
8	O
hours	O
,	O
21	O
mm	O
hg	O
at	O
10	O
hours	O
and	O
36	O
mm	O
hg	O
,	O
were	O
randomised	O
1	O
to	O
receive	O
ono-9054	B-C4277062
0.003	O
,	O
30	O
μg/ml	O
or	O
xalatan	B-C0593887
0.005	O
,	O
50	O
μg/ml	O
once	O
daily	B-C0332173
for	O
28	O
days	B-C0439228
.	O
	
day	B-C0439228
29	O
mean	O
diurnal	O
iop	B-C0021888
was	O
-7	O
mm	O
hg	O
for	O
ono-9054	B-C4277062
vs	O
-6	O
mm	O
hg	O
for	O
xalatan	B-C0593887
.	O
	
at	O
08	O
hours	O
,	O
the	O
iops	B-C0021888
were	O
comparable	O
,	O
and	O
at	O
all	O
later	O
time	O
points	O
the	O
decrease	B-C0547047
in	O
iop	B-C0021888
was	O
greater	O
for	O
ono-9054	B-C4277062
.	O
	
on	O
day	B-C0439228
29	O
,	O
the	O
odds	O
of	O
a	O
mean	O
iop	B-C0021888
reduction	B-C0392756
of	O
-25%	O
,	O
-30%	O
and	O
-35%	O
for	O
ono-9054	B-C4277062
were	O
2.39	O
,	O
2.37	O
and	O
4.85	O
times	O
more	O
,	O
respectively	O
,	O
than	O
the	O
odds	O
for	O
xalatan	B-C0593887
p<0	O
,	O
post	B-C0936012
hoc	I-C0936012
analyses	I-C0936012
.	O
	
the	O
percentage	O
of	O
subjects	O
achieving	O
target	O
iops	B-C0021888
on	O
day	B-C0439228
29	O
17	O
,	O
16	O
and	O
15	O
mm	O
hg	O
was	O
greater	O
for	O
ono-9054	B-C4277062
than	O
for	O
xalatan	B-C0593887
the	O
odds	O
of	O
achieving	O
an	O
iop	B-C0021888
15	O
mm	O
hg	O
for	O
ono-9054	B-C4277062
were	O
2.4	O
times	O
more	O
than	O
the	O
odds	O
for	O
xalatan	B-C0593887
p<0	O
,	O
post	B-C0936012
hoc	I-C0936012
analysis	I-C0936012
.	O
	
subjects	O
randomised	O
to	O
receive	O
ono-9054	B-C4277062
were	O
more	O
likely	O
to	O
achieve	O
a	O
greater	O
per	O
cent	O
reduction	O
in	O
iop	B-C0021888
and	O
were	O
more	O
likely	O
to	O
achieve	O
target	O
iops	B-C0021888
than	O
those	O
receiving	O
xalatan	B-C0593887
.	O
	
the	O
effects	O
of	O
ono-9054	B-C4277062
in	O
reducing	O
iop	B-C0021888
appear	O
to	O
persist	O
longer	O
than	O
those	O
of	O
xalatan	B-C0593887
.	O
	
whole-body	B-C0872279
strength	I-C0872279
training	I-C0872279
with	O
huber	B-C0014672
motion	I-C0014672
lab	I-C0014672
and	O
traditional	B-C0872279
strength	I-C0872279
training	I-C0872279
in	O
cardiac	B-C0700431
rehabilitation	I-C0700431
a	O
randomized	B-C0681867
controlled	I-C0681867
study	I-C0681867
isometric	B-C0022206
strengthening	I-C0022206
has	O
been	O
rarely	O
studied	O
in	O
patients	B-C0030705
with	O
coronary	B-C0010068
heart	I-C0010068
disease	I-C0010068
chd	B-C0010068
,	O
mainly	O
because	O
of	O
possible	O
potential	B-C0879626
side	I-C0879626
effects	I-C0879626
and	O
lack	B-C0332268
of	O
appropriate	B-C1548787
and	O
reliable	B-C3858758
devices	B-C0699733
.	O
	
we	O
aimed	O
to	O
compare	O
2	O
different	O
modes	B-C1513371
of	O
resistance	B-C0872279
training	I-C0872279
,	O
an	O
isometric	O
mode	B-C1513371
with	O
the	O
huber	B-C0014672
motion	I-C0014672
lab	I-C0014672
hml	B-C0014672
and	O
traditional	B-C0872279
strength	I-C0872279
training	I-C0872279
tst	B-C0872279
,	O
in	O
chd	B-C0010068
patients	B-C0030705
undergoing	O
a	O
cardiac	B-C0700431
rehabilitation	I-C0700431
program	O
.	O
	
we	O
randomly	O
assigned	O
50	O
patients	B-C0030705
to	O
hml	B-C0014672
or	O
tst	B-C0872279
.	O
	
patients	B-C0030705
underwent	O
complete	O
blinded	B-C0150108
evaluation	B-C0220825
before	O
and	O
after	O
the	O
rehabilitation	B-C0034991
program	I-C0034991
,	O
including	O
testing	B-C2959886
for	I-C2959886
cardiopulmonary	I-C2959886
exercise	I-C2959886
,	O
maximal	B-C0430022
isometric	I-C0430022
voluntary	I-C0430022
contraction	I-C0430022
,	O
endothelial	B-C0014257
function	B-C1254358
and	O
body	B-C0005885
composition	I-C0005885
.	O
	
after	O
4	O
weeks	B-C0439230
of	O
training	B-C0220931
16	O
sessions	O
,	O
the	O
groups	B-C0441833
did	O
not	O
differ	O
in	O
body	B-C0005885
composition	I-C0005885
,	O
anthropometric	B-C0003188
characteristics	B-C1521970
,	O
or	O
endothelial	B-C0014257
function	B-C1254358
.	O
	
with	O
hml	B-C0014672
,	O
peak	B-C0444505
power	B-C0445194
output	I-C0445194
p=0	O
,	O
maximal	B-C0205289
heart	B-C0018810
rate	I-C0018810
p<0	O
and	O
gain	B-C1517378
of	O
force	B-C0441722
measured	B-C0444706
in	O
the	O
chest	O
press	O
position	O
p<0	O
were	O
greater	B-C1704243
after	O
versus	O
before	O
training	B-C0015259
.	O
	
both	O
protocols	B-C2348563
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
chd	B-C0010068
patients	B-C0030705
.	O
	
a	O
training	B-C2348563
protocol	I-C2348563
involving	O
6s	O
phases	O
of	O
isometric	B-C0022205
contractions	I-C0022205
with	O
10s	O
of	O
passive	B-C3686820
recovery	B-C2004454
on	O
an	O
hml	B-C0014672
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	B-C0034991
programs	I-C0034991
for	O
patients	B-C0030705
with	O
chd	B-C0010068
and	O
improve	O
functional	B-C0205556
outcomes	I-C0205556
.	O
	
percutaneous	B-C1532338
coronary	I-C1532338
intervention	I-C1532338
and	O
heart	B-C0018821
surgery	I-C0018821
learning	B-C0023185
needs	B-C0686904
of	I-C0686904
patients	I-C0686904
in	O
jordan	B-C0022418
this	O
study	O
aimed	O
to	O
identify	O
and	O
prioritize	B-C0549179
the	O
perceived	B-C0030971
learning	B-C0023185
needs	B-C0686904
of	I-C0686904
patients	I-C0686904
who	O
underwent	O
percutaneous	B-C1532338
coronary	I-C1532338
intervention	I-C1532338
or	O
open-heart	B-C0189745
surgery	I-C0189745
.	O
	
identifying	O
learning	B-C0023185
needs	O
for	O
post-cardiac	B-C0184661
intervention	I-C0184661
patients	B-C0030705
is	O
essential	O
to	O
establish	O
successful	O
health	B-C0679897
education	I-C0679897
programmes	I-C0679897
based	O
on	O
patient	B-C0030705
central	B-C1279810
care	I-C1279810
.	O
	
a	O
descriptive	O
comparative	O
design	B-C1707689
was	O
employed	O
on	O
a	O
convenience	B-C3831015
sample	B-C1257890
of	O
260	O
patients	B-C0030705
who	O
underwent	O
a	O
percutaneous	B-C1532338
coronary	I-C1532338
intervention	I-C1532338
and	O
105	O
patients	B-C0030705
who	O
underwent	O
open-heart	B-C0189745
surgery	I-C0189745
patients	B-C0030705
.	O
	
participants	B-C0679646
had	O
completed	O
the	O
patient	B-C0030705
learning	B-C0282574
needs	I-C0282574
scale	I-C0282574
.	O
	
data	B-C1511726
were	O
collected	O
between	O
1	O
october	O
2014	O
and	O
31	O
june	O
2015	O
.	O
	
patients	B-C0030705
from	O
the	O
two	O
groups	B-C0441833
highly	O
requesting	O
health	B-C0846605
and	I-C0846605
recovery	I-C0846605
related	I-C0846605
information	I-C0846605
.	O
	
they	O
scored	O
all	O
learning	B-C0023185
need	I-C0023185
topics	B-C1555712
as	O
important	O
or	O
highly	O
important	O
for	O
them	O
.	O
	
the	O
top	O
priority	B-C0549179
learning	B-C0023185
need	O
for	O
both	O
patient	B-C0030705
groups	I-C0030705
was	O
'	O
information	B-C1533716
about	O
wound	B-C0886052
care	I-C0886052
'	O
,	O
and	O
the	O
lowest	O
priority	B-C0549179
learning	B-C0023185
need	O
topic	B-C1555712
was	O
'	O
physical	B-C0026606
activity	I-C0026606
'	O
.	O
	
the	O
learning	B-C0023185
needs	B-C0027552
of	O
both	O
groups	B-C0441833
were	O
very	O
close	O
,	O
which	O
indicated	O
that	O
educational	B-C0679717
secondary	I-C0679717
prevention	I-C0679717
programmes	I-C0679717
'	O
content	O
can	O
be	O
prepared	O
in	O
a	O
unified	O
structure	O
for	O
those	O
patients	B-C0030705
.	O
	
although	O
,	O
specific	O
headings	B-C0038545
can	O
be	O
used	O
to	O
address	O
the	O
unique	O
needs	B-C0027552
that	O
emerge	O
from	O
having	O
a	O
specific	O
cardiac	B-C0018787
interventional	B-C0184661
procedure	I-C0184661
.	O
	
the	O
fact	O
that	O
wound	B-C0886052
care	I-C0886052
and	O
medications	B-C2081612
are	O
areas	O
of	O
highest	O
learning	B-C0023185
needs	B-C0027552
for	O
patients	B-C0030705
requires	O
health	B-C0018735
policy	I-C0018735
decision	B-C0242170
makers	I-C0242170
to	O
address	O
these	O
topics	B-C1555712
at	O
the	O
time	B-C0040223
of	O
hospital	B-C0586003
discharge	I-C0586003
.	O
	
in	O
addition	O
,	O
a	O
policy	B-C0018735
focus	O
on	O
considering	O
patients	B-C0030705
'	O
actual	O
learning	B-C0023185
needs	B-C0027552
requires	O
establishment	B-C0442594
and	O
managerial	B-C0037438
support	I-C0037438
.	O
	
as	O
patients	B-C0030705
'	O
learning	B-C0023185
needs	B-C0027552
might	O
change	O
later	O
after	O
discharge	B-C0586003
,	O
the	O
health	B-C0018747
services	I-C0018747
should	O
be	O
proactive	O
and	O
focus	O
on	O
continuous	O
support	B-C0037438
for	O
patients	B-C0030705
after	O
hospital	B-C0586003
discharge	I-C0586003
.	O
	
secondary	B-C0679717
prevention	I-C0679717
programmes	I-C0679717
should	O
incorporate	O
health	B-C0018701
education	I-C0018701
topics	B-C1555712
based	O
on	O
patients	B-C0030705
'	O
own	O
views	O
.	O
	
this	O
can	O
be	O
done	O
by	O
giving	O
higher	O
priority	B-C0549179
to	O
understand	O
patients'	B-C0686904
needs	I-C0686904
,	O
put	O
much	O
more	O
effort	O
into	O
how	O
to	O
meet	O
patients	B-C0030705
'	O
information	B-C1533716
needs	B-C0027552
and	O
to	O
create	O
a	O
more	O
engaging	O
learning	B-C0023185
environment	B-C0014406
for	O
patients	B-C0030705
and	O
their	O
complications	B-C0009566
and	O
near-miss	O
events	B-C0441471
after	O
hepatectomy	B-C0019144
for	O
living-related	B-C1318453
liver	I-C1318453
donation	I-C1318453
an	O
italian	B-C0022277
single	B-C0475309
center	I-C0475309
report	B-C0684224
of	O
one	O
hundred	O
cases	B-C0868928
background	O
in	O
healthy	B-C3898900
individuals	B-C0237401
,	O
such	O
as	O
liver	B-C0348050
living	I-C0348050
donors	I-C0348050
,	O
potential	O
complications	B-C0009566
may	O
occur	O
during	O
surgery	B-C0543467
.	O
	
reporting	O
such	O
complications	B-C0009566
and	O
near-miss	O
events	O
is	O
mandatory	O
to	O
improve	O
living	B-C0348050
donor	I-C0348050
management	B-C1273870
and	O
safety	B-C0036043
.	O
	
material	O
and	O
methods	O
this	O
retrospective	B-C0035363
study	I-C0035363
was	O
performed	O
on	O
a	O
prospective	O
database	B-C0242356
with	O
the	O
aim	O
of	O
providing	O
a	O
brief	O
analysis	B-C0936012
of	O
the	O
perioperative	B-C1518988
,	O
medium-term	B-C1254367
,	O
and	O
long-term	B-C0443252
complications	B-C0009566
,	O
and	O
the	O
near-miss	O
events	B-C0441471
in	O
a	O
single	B-C0475309
center	I-C0475309
series	O
of	O
100	O
consecutive	O
liver	B-C0019144
resections	I-C0019144
for	O
adult	B-C0001675
-to-	O
adult	B-C0001675
living-donor	B-C0348050
liver	B-C0023911
transplantation	I-C0023911
.	O
	
results	O
only	O
23.3	O
of	O
potential	O
living	B-C0348050
donors	I-C0348050
underwent	O
surgery	B-C0543467
.	O
	
no	B-C1513916
living	B-C0348050
donor	I-C0348050
mortality	B-C0178686
was	O
reported	O
29	O
patients	B-C0030705
29%	O
experienced	O
at	O
least	O
one	O
complication	B-C0009566
.	O
	
five	O
patients	B-C0030705
developed	O
mild	B-C2945599
long-term	B-C0443252
dysfunction	B-C3887504
two	O
aborted	O
hepatectomies	B-C0019144
,	O
and	O
there	O
were	O
two	O
near-miss	O
events	B-C0441471
reported	O
.	O
	
conclusions	O
a	O
strategy	B-C0679199
for	O
an	O
accurate	O
assessment	B-C0220825
of	O
living	B-C0348050
donor	I-C0348050
complications	B-C0009566
and	O
strict	O
selection	B-C1707391
criterion	O
cannot	O
be	O
overemphasized	O
,	O
as	O
well	O
as	O
the	O
need	O
to	O
continuously	O
update	O
center	B-C0475309
patient	B-C1547647
outcome	I-C1547647
reports	B-C0684224
.	O
	
tooth	B-C2717979
wear	I-C2717979
as	O
a	O
means	O
to	O
quantify	B-C1709793
intra-specific	B-C0205369
variations	B-C0205419
in	O
diet	B-C0012155
and	O
chewing	B-C0024888
movements	B-C0026649
in	O
mammals	B-C0024660
,	O
tooth	B-C0040426
function	B-C0542341
,	O
and	O
its	O
efficiency	B-C0013682
,	O
depends	O
both	O
on	O
the	O
mechanical	B-C0376706
properties	B-C0871161
of	O
the	O
food	B-C0016452
and	O
on	O
chewing	B-C0024888
dynamics	B-C0729333
.	O
	
these	O
aspects	B-C1879746
have	O
rarely	O
been	O
studied	B-C2603343
in	O
combination	O
and/or	O
at	O
the	O
intra-specific	B-C0205369
level	O
.	O
	
here	O
we	O
applied	O
3d	B-C0450363
dental	B-C1550246
surface	B-C0205148
texture	B-C0449582
analysis	B-C0936012
to	O
a	O
sample	B-C2347026
of	O
field	B-C0042947
voles	I-C0042947
microtus	B-C1002449
agrestis	I-C1002449
trapped	O
from	O
finnish	B-C0016132
lapland	I-C0016132
at	O
different	O
seasons	B-C0036497
and	O
localities	B-C2828208
to	O
test	B-C0039593
for	O
inter-population	B-C1257890
variations	B-C0205419
.	O
	
we	O
also	O
explored	O
intra-individual	B-C1257890
variation	B-C0205419
in	O
chewing	B-C0024888
dynamics	B-C0729333
by	O
analysing	B-C0936012
two	O
facets	B-C0205148
on	O
the	O
second	B-C4082818
upper	I-C4082818
molars	I-C4082818
.	O
	
our	O
results	B-C0683954
confirm	O
that	O
the	O
two	O
localities	B-C2828208
have	O
similar	O
environments	B-C0014406
and	O
that	O
the	O
voles	B-C0042947
feed	B-C2987508
on	O
the	O
same	O
items	O
there	O
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
texture	B-C0449582
data	B-C1511726
suggest	O
that	O
diets	B-C0012155
are	O
seasonally	O
variable	B-C0439828
,	O
probably	O
due	O
to	O
varying	O
concentrations	B-C1446561
of	O
abrasives	B-C0450125
.	O
	
lastly	O
,	O
the	O
textures	B-C0449582
on	O
the	O
buccal	B-C1540415
facets	I-C1540415
are	O
more	O
isotropic	B-C1882365
and	O
their	O
direction	B-C0449738
deviates	B-C0012727
more	O
from	O
the	O
mesial	B-C1708982
chewing	B-C0024888
direction	B-C0449738
than	O
the	O
lingual	B-C0040408
facets	B-C0205148
.	O
	
we	O
interpret	B-C1285553
these	O
results	B-C0683954
as	O
reflecting	O
food	B-C0016452
,	O
rather	O
than	O
chewing	B-C0024888
,	O
movements	B-C0026649
,	O
where	O
food	B-C0311119
particles	I-C0311119
are	O
more	O
guided	O
on	O
the	O
lingual	B-C0040408
side	O
of	O
the	O
molars	B-C0026367
.	O
	
this	O
has	O
implications	O
for	O
the	O
application	O
of	O
dental	B-C2717979
microwear	I-C2717979
analysis	B-C0936012
to	O
fossils	B-C0016614
only	O
homologous	B-C0301883
facets	B-C0205148
can	O
be	O
compared	O
,	O
even	O
when	O
the	O
molar	B-C0026367
row	O
seems	O
to	O
constitute	O
a	O
functional	B-C0205245
unit	I-C0205245
.	O
	
human	B-C3891304
cathelicidin	I-C3891304
ll-37	I-C3891304
enhance	O
the	O
antibiofilm	B-C0243095
effect	I-C0243095
of	O
egcg	B-C0059438
on	O
streptococcus	B-C0038409
mutans	I-C0038409
streptococcus	B-C0038409
mutans	I-C0038409
forms	O
biofilms	B-C0081786
as	O
a	O
resistance	B-C4281815
mechanism	B-C0441712
against	O
antimicrobial	B-C1136254
agents	I-C1136254
in	O
the	O
human	B-C0086418
oral	B-C0226896
cavity	I-C0226896
.	O
	
we	O
recently	O
showed	O
that	O
human	B-C3891304
cathelicidin	I-C3891304
ll-37	I-C3891304
exhibits	O
inhibitory	B-C1280500
effects	I-C1280500
on	O
biofilm	B-C1325881
formation	I-C1325881
of	O
s	B-C0038409
.	O
	
mutans	I-C0038409
through	O
interaction	B-C1704675
with	O
lipoteichoic	B-C0065067
acid	I-C0065067
lta	B-C0065067
,	O
but	O
without	O
antibacterial	B-C0243095
or	O
biofilm	B-C0081786
dispersal	B-C0332624
abilities	I-C0332624
.	O
	
-	B-C0059438
gallate	I-C0059438
egcg	B-C0059438
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	B-C0039400
catechins	B-C0007404
that	O
has	O
the	O
greatest	O
anti-infective	B-C0243095
potential	I-C0243095
to	O
inhibit	B-C2249823
the	I-C2249823
growth	I-C2249823
of	O
various	O
microorganisms	B-C0445623
and	O
biofilm	B-C1325881
formation	I-C1325881
.	O
	
therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	B-C0220825
whether	O
ll-37	B-C3891304
interacts	O
with	O
egcg	B-C0059438
to	O
enhance	O
the	O
antibiofilm	B-C0243095
effect	I-C0243095
of	O
egcg	B-C0059438
on	O
s	B-C0038409
.	O
	
mutans	I-C0038409
biofilm	B-C1325881
formation	I-C1325881
.	O
	
clinical	O
s	B-C0038409
.	O
	
mutans	I-C0038409
strains	B-C1518614
n	O
=	O
10	O
isolated	O
from	O
children's	B-C0008059
saliva	B-C0036087
were	O
tested	B-C0039593
in	O
a	O
biofilm	B-C1325881
formation	I-C1325881
assay	B-C0005507
.	O
	
the	O
antibiofilm	B-C0243095
effect	I-C0243095
of	O
egcg	B-C0059438
with	O
and	O
without	O
ll-37	B-C3891304
was	O
analyzed	B-C0936012
by	O
the	O
minimum	O
biofilm	B-C0081786
eradication	B-C2700409
concentration	B-C1446561
assay	B-C0005507
and	O
confirmed	O
using	O
field	O
emission-scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
.	O
	
in	O
addition	O
,	O
the	O
interaction	B-C1704675
among	O
egcg	B-C0059438
,	O
ll-37	B-C3891304
,	O
and	O
lta	B-C0065067
of	O
s	B-C0038409
.	O
	
mutans	I-C0038409
was	O
determined	O
using	O
quartz	B-C2936414
crystal	I-C2936414
microbalance	I-C2936414
analysis	I-C2936414
.	O
	
egcg	B-C0059438
killed	O
100	O
%	O
of	O
planktonic	B-C0032071
s	B-C0038409
.	O
	
mutans	I-C0038409
within	O
5	O
h	O
,	O
inhibited	O
biofilm	B-C1325881
formation	I-C1325881
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	B-C0004611
cells	I-C0004611
in	O
preformed	O
biofilms	B-C0081786
within	O
3	O
h	O
at	O
a	O
concentration	B-C1446561
of	O
0.2	O
mg/ml	O
.	O
	
however	O
,	O
egcg	B-C0059438
did	O
not	O
appear	O
to	O
interact	O
with	O
lta	B-C0065067
.	O
	
ll-37	B-C3891304
effectively	O
enhanced	O
the	O
bactericidal	B-C0544570
activity	I-C0544570
of	O
egcg	B-C0059438
against	O
biofilm	B-C1325881
formation	I-C1325881
and	O
preformed	O
biofilms	B-C0081786
as	O
determined	O
by	O
quantitative	B-C0392762
crystal	B-C0017440
violet	I-C0017440
staining	B-C0487602
and	O
field	O
emission-scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
.	O
	
in	O
addition	O
,	O
quartz	B-C2936414
crystal	I-C2936414
microbalance	I-C2936414
analysis	I-C2936414
revealed	O
that	O
ll-37	B-C3891304
interacted	B-C1704675
with	O
egcg	B-C0059438
and	O
promoted	O
binding	B-C1167622
between	O
egcg	B-C0059438
and	O
lta	B-C0065067
of	O
s	B-C0038409
.	O
	
mutans	I-C0038409
.	O
	
we	O
show	O
that	O
ll-37	B-C3891304
enhances	O
the	O
antibiofilm	B-C0243095
effect	I-C0243095
of	O
egcg	B-C0059438
on	O
s	B-C0038409
.	O
	
mutans	I-C0038409
.	O
	
this	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	B-C0011331
treatment	I-C0011331
by	O
using	O
ll-37	B-C3891304
as	O
a	O
potential	O
antibiofilm	B-C1254351
compound	I-C1254351
.	O
	
discovery	B-C1880355
of	O
orally	B-C0226896
efficacious	B-C1704419
phosphoinositide-3-kinase	B-C1450115
delta	I-C1450115
inhibitors	B-C0014432
with	O
improved	B-C0184511
metabolic	B-C0311400
stability	B-C0205360
aberrant	B-C3537152
signaling	I-C3537152
of	O
phosphoinositide-3-kinase	B-C1450115
delta	I-C1450115
pi3k-delta	B-C1450115
has	O
been	O
implicated	O
in	O
numerous	O
pathologies	B-C0677042
including	O
hematological	B-C0376545
malignancies	I-C0376545
and	O
rheumatoid	B-C0003873
arthritis	I-C0003873
.	O
	
described	O
in	O
this	O
manuscript	O
is	O
the	O
discovery	B-C1880355
,	O
optimization	B-C2698650
and	O
in	B-C1515655
vivo	I-C1515655
evaluation	B-C0220825
of	O
a	O
novel	O
series	O
of	O
pyridine-containing	B-C0576798
pi3k-delta	B-C1450115
inhibitors	B-C0014432
.	O
	
this	O
work	O
led	O
to	O
the	O
discovery	B-C1880355
of	O
35	B-C1254351
,	O
a	O
highly	O
selective	O
inhibitor	B-C0014432
of	O
pi3k-delta	B-C1450115
which	O
displays	O
an	O
excellent	O
pharmacokinetic	B-C0031328
profile	I-C0031328
and	O
is	O
efficacious	B-C1704419
in	O
a	O
rodent	B-C1519106
model	I-C1519106
of	O
rheumatoid	B-C0003873
arthritis	I-C0003873
.	O
	
mobile	B-C1136360
phone	I-C1136360
use	B-C0457083
,	O
behavioural	B-C0233514
problems	I-C0233514
and	O
concentration	B-C0086045
capacity	B-C1516240
in	O
adolescents	B-C0205653
a	O
prospective	B-C0033522
study	I-C0033522
the	O
aim	O
of	O
this	O
study	B-C2603343
is	O
to	O
prospectively	O
investigate	B-C1292732
whether	O
exposure	B-C0332157
to	I-C0332157
radiofrequency	B-C0013835
electromagnetic	I-C0013835
fields	I-C0013835
rf-emf	B-C0013835
emitted	O
by	O
mobile	B-C1136360
phones	I-C1136360
and	O
other	O
wireless	B-C3825042
communication	I-C3825042
devices	I-C3825042
is	O
related	O
to	O
behavioural	B-C0233514
problems	I-C0233514
or	O
concentration	B-C0086045
capacity	B-C1516240
in	O
adolescents	B-C0205653
.	O
	
the	O
hermes	B-C0681814
health	B-C0018684
effects	B-C1280500
related	B-C0439849
to	O
mobile	B-C1136360
phone	I-C1136360
use	O
in	O
adolescents	B-C0205653
study	O
sample	B-C0681850
consisted	O
of	O
439	O
swiss	B-C0241315
adolescents	B-C0205653
aged	B-C0001779
12-17	O
years	B-C0439234
.	O
	
behavioural	B-C0233514
problems	I-C0233514
were	O
assessed	B-C1516048
using	O
the	O
strengths	B-C3472494
and	I-C3472494
difficulties	I-C3472494
questionnaire	I-C3472494
sdq	B-C3472494
,	O
concentration	B-C0086045
capacity	B-C1516240
of	O
the	O
adolescents	B-C0205653
was	O
measured	B-C0444706
by	O
means	O
of	O
a	O
standardized	B-C0237892
computerized	I-C0237892
cognitive	I-C0237892
test	I-C0237892
named	O
fakt	B-C0282574
.	O
	
cross-sectional	B-C0010362
and	O
longitudinal	B-C0023981
1year	B-C0439234
of	O
follow-up	B-C0589120
analyses	B-C0936012
were	O
performed	B-C0884358
to	O
investigate	B-C1292732
possible	O
associations	B-C0439849
between	O
behavioural	B-C0233514
problems	I-C0233514
and	O
concentration	B-C0086045
capacity	B-C1516240
and	O
different	B-C1705242
exposure	B-C0332157
measures	B-C0079809
self-reported	B-C2700446
and	O
operator	B-C0335223
-recorded	O
wireless	B-C3825042
communication	I-C3825042
device	I-C3825042
use	O
,	O
cumulative	B-C1511559
rf-emf	B-C0013835
brain	B-C0006104
and	O
whole	B-C0444584
body	I-C0444584
dose	O
and	O
measured	B-C0444706
personal	O
rf-emf	B-C0013835
exposure	B-C0332157
.	O
	
in	O
the	O
cross-sectional	B-C0010362
analyses	I-C0010362
behavioural	B-C0233514
problems	I-C0233514
were	O
associated	B-C0332281
with	I-C0332281
several	O
self-reported	B-C0684224
wireless	B-C0699733
device	I-C0699733
use	B-C0457083
measures	B-C0079809
but	O
not	O
operator	B-C0335223
-recorded	O
mobile	B-C1136360
phone	I-C1136360
use	B-C0457083
measures	B-C0079809
,	O
concentration	B-C0086045
capacity	B-C1516240
was	O
associated	B-C0332281
with	I-C0332281
several	O
self-reported	B-C2700446
and	O
operator	B-C0335223
-recorded	O
exposures	B-C0332157
.	O
	
the	O
longitudinal	B-C0023981
analyses	I-C0023981
point	O
towards	O
absence	B-C0332197
of	O
associations	B-C0439849
.	O
	
the	O
lack	B-C0332268
of	O
consistent	B-C0332290
exposure	B-C0332157
-response	O
patterns	B-C0449774
in	O
the	O
longitudinal	B-C0023981
analyses	I-C0023981
suggests	O
that	O
behavioural	B-C0233514
problems	I-C0233514
and	O
concentration	B-C0086045
capacity	B-C1516240
are	O
not	O
affected	B-C0392760
by	O
the	O
use	O
of	O
wireless	B-C3825042
communication	I-C3825042
devices	I-C3825042
or	O
rf-emf	B-C0013835
exposure	B-C0332157
.	O
	
information	B-C1533716
bias	B-C0242568
and	O
reverse	O
causality	O
are	O
likely	O
explanations	B-C0681841
for	O
the	O
observed	O
cross-sectional	B-C0010362
findings	I-C0010362
.	O
	
twisting	B-C0449851
method	I-C0449851
for	O
reducing	B-C0392756
friction	B-C0162691
during	O
insertion	B-C0021107
of	O
a	O
sheath	B-C1299426
introducer	B-C0179695
and	O
a	O
sheathless	B-C0221799
guiding	I-C0221799
catheter	I-C0221799
a	O
sheathless	B-C0449913
system	I-C0449913
that	O
inserts	B-C0441587
a	O
catheter	B-C0179724
directly	B-C1947931
into	O
the	O
artery	B-C0003842
can	O
reduce	B-C0392756
puncture	B-C1881711
site	B-C0230992
-related	O
complications	B-C0274317
through	O
a	O
2-fr	B-C0332519
reduction	I-C0332519
of	O
the	O
outer	B-C4086674
diameter	I-C4086674
.	O
	
however	O
,	O
the	O
gap	B-C3887622
between	O
the	O
dilator	B-C0180431
and	O
the	O
guiding	B-C0221799
catheter	I-C0221799
of	O
the	O
sheathless	B-C0449913
system	I-C0449913
is	O
larger	B-C0549177
than	O
the	O
gap	B-C3887622
between	O
the	O
dilator	B-C0180431
and	O
sheath	B-C1299426
of	O
the	O
introducer	B-C0179695
system	I-C0179695
,	O
resulting	O
in	O
stronger	O
insertion	B-C0021107
resistance	B-C1880315
.	O
	
a	O
twisting	B-C0449851
method	I-C0449851
with	O
rapid	B-C0456962
alternating	B-C0332270
rotation	B-C0035868
of	O
a	O
device	B-C0025080
to	O
the	O
left	O
and	O
right	O
during	O
insertion	B-C0021107
can	O
reduce	O
the	O
insertion	B-C0021107
resistance	O
.	O
	
this	O
method	O
can	O
be	O
effective	O
with	O
the	O
sheathless	O
system	O
which	O
has	O
a	O
larger	O
gap	O
.	O
	
to	O
examine	O
the	O
effect	O
of	O
size	O
reduction	O
on	O
the	O
sheathless	O
system	O
and	O
the	O
effect	O
of	O
insertion	O
resistance	O
reduction	O
using	O
the	O
twisting	O
method	O
,	O
we	O
developed	O
an	O
insertion	O
simulator	O
and	O
compared	O
insertion	O
resistance	O
to	O
a	O
5-fr	O
sheath	O
introducer	O
and	O
a	O
5-fr	O
sheathless	O
system	O
,	O
with	O
and	O
without	O
the	O
twisting	O
method	O
.	O
	
the	O
insertion	O
simulator	O
pushed	O
a	O
sheath	O
introducer	O
or	O
a	O
sheathless	O
system	O
toward	O
a	O
mock	O
artery	O
consisted	O
with	O
a	O
5-mm	O
urethane	O
and	O
a	O
1-mm	O
rubber	O
sheet	O
by	O
an	O
electrical	O
motor	O
with	O
or	O
without	O
twisting	O
motion	O
generated	O
by	O
a	O
crank	O
shaft	O
.	O
	
insertion	O
resistance	O
during	O
the	O
penetration	O
was	O
measured	O
by	O
a	O
tension	O
meter	O
.	O
	
the	O
insertion	O
resistance	O
was	O
less	O
with	O
the	O
5-fr	O
sheathless	O
system	O
than	O
with	O
the	O
5-fr	O
sheath	O
introducer	O
.	O
	
the	O
resistance	O
reduced	O
further	O
with	O
use	O
of	O
twisting	O
for	O
both	O
the	O
sheathed	O
and	O
sheathless	O
catheters	O
.	O
	
in	O
conclusion	O
,	O
the	O
experiment	O
suggests	O
the	O
benefits	O
of	O
twisting	O
insertion	O
of	O
a	O
sheathless	O
guiding	O
catheter	O
for	O
reduction	O
of	O
puncture	O
site	O
-related	O
complications	B-C0274317
unconventional	B-C2700116
protein	B-C1159339
secretion	I-C1159339
in	O
plants	B-C0032098
unconventional	B-C2700116
protein	B-C1159339
secretion	I-C1159339
ups	B-C1159339
describes	B-C1552738
secretion	B-C1159342
pathways	I-C1159342
that	O
bypass	O
one	O
or	O
several	B-C0443302
of	O
the	O
canonical	B-C0870245
secretion	B-C0036536
pit-stops	O
on	O
the	O
way	O
to	O
the	O
plasma	B-C0007603
membrane	I-C0007603
,	O
and/or	O
involve	B-C1314939
the	O
secretion	B-C0036536
of	O
leaderless	O
proteins	B-C0033684
.	O
	
so	O
far	O
,	O
alternatives	B-C1523987
to	O
conventional	B-C3538928
secretion	B-C0036536
were	O
primarily	B-C0205225
observed	B-C1441672
and	O
studied	B-C0008972
in	O
yeast	B-C0043393
and	O
animal	B-C0007634
cells	I-C0007634
.	O
	
the	O
sessile	B-C0205348
lifestyle	O
of	O
plants	B-C0032098
brings	O
with	O
it	O
unique	B-C1710548
restraints	O
on	O
how	O
they	O
adapt	B-C0001400
to	I-C0001400
adverse	I-C0001400
conditions	I-C0001400
and	O
environmental	B-C0557737
challenges	I-C0557737
.	O
	
recently	O
,	O
attention	B-C0004268
towards	O
unconventional	B-C2700116
secretion	B-C1159342
pathways	I-C1159342
in	O
plant	B-C3178867
cells	I-C3178867
has	O
substantially	O
increased	O
,	O
with	O
the	O
large	O
number	O
of	O
leaderless	O
proteins	B-C0033684
identified	B-C0205396
through	O
proteomic	B-C0872252
studies	I-C0872252
.	O
	
while	O
ups	B-C1159339
pathways	B-C1705987
in	O
plants	B-C0032098
are	O
certainly	O
not	O
yet	O
exhaustively	O
researched	O
,	O
an	O
emerging	O
notion	O
is	O
that	O
induction	B-C0205263
of	O
ups	B-C1159339
pathways	B-C1705987
is	O
correlated	B-C1707520
with	O
pathogenesis	B-C0699748
and	O
stress	B-C2350025
responses	I-C2350025
.	O
	
given	O
the	O
multitude	O
ups	B-C1159339
events	O
observed	O
,	O
comprehensively	B-C1880156
organizing	B-C1300196
the	O
routes	O
proteins	B-C0033684
take	O
to	O
the	O
apoplast	B-C1325756
in	O
defined	O
ups	B-C1159339
categories	O
is	O
challenging	O
.	O
	
with	O
the	O
establishment	B-C0443211
of	O
a	O
larger	O
collection	B-C1516698
of	O
studied	O
plant	B-C0032089
proteins	I-C0032089
taking	O
these	O
ups	B-C1159339
pathways	B-C1705987
,	O
a	O
clearer	O
picture	O
of	O
endomembrane	B-C1167315
trafficking	B-C0599896
as	O
a	O
whole	O
will	O
emerge	O
.	O
	
there	O
are	O
several	B-C0443302
novel	B-C0205314
enabling	B-C1171285
technologies	B-C0039421
,	O
such	O
as	O
vesicle	B-C1622418
proteomics	B-C0872252
and	O
chemical	B-C0220806
genomics	B-C0887950
,	O
with	O
great	O
potential	B-C3245505
for	O
dissecting	B-C0205239
secretion	B-C1159342
pathways	I-C1159342
,	O
providing	B-C1999230
information	B-C1533716
about	O
the	O
cargo	O
that	O
travels	O
along	O
them	O
and	O
the	O
conditions	O
that	O
induce	B-C0205263
neospora	B-C0242906
caninum	I-C0242906
in	O
axis	B-C0999597
deer	I-C0999597
axis	B-C0325211
axis	I-C0325211
and	O
fallow	B-C0325214
deer	I-C0325214
dama	B-C0325214
dama	I-C0325214
in	O
northern	B-C1709269
mexico	B-C0025885
serum	B-C1550100
samples	I-C1550100
from	O
18	O
axis	B-C0999597
deer	I-C0999597
axis	B-C0325211
axis	I-C0325211
and	O
19	O
fallow	B-C0325214
deer	I-C0325214
dama	B-C0325214
dama	I-C0325214
were	O
analyzed	O
with	O
an	O
enzyme-linked	B-C0014441
immunosorbent	I-C0014441
assay	I-C0014441
for	O
neospora	B-C0807090
caninum	I-C0807090
antibodies	I-C0807090
.	O
	
two	O
axis	B-C0325211
11%	O
and	O
two	O
fallow	B-C0325214
deer	I-C0325214
11%	O
were	O
positive	B-C1514241
for	O
n	B-C0807090
.	O
	
caninum	I-C0807090
antibodies	I-C0807090
.	O
	
the	O
abba	B-C2603343
study	I-C2603343
-	O
approach	O
bias	O
modification	O
in	O
bulimia	B-C2267227
nervosa	I-C2267227
and	O
binge	B-C0596170
eating	I-C0596170
disorder	I-C0596170
study	O
protocol	O
for	O
a	O
randomised	B-C0206035
controlled	I-C0206035
trial	I-C0206035
the	O
core	O
symptoms	B-C1457887
of	O
bulimia	B-C2267227
nervosa	I-C2267227
bn	B-C2267227
and	O
binge	B-C0596170
eating	I-C0596170
disorder	I-C0596170
bed	B-C0596170
are	O
recurrent	B-C1843777
episodes	I-C1843777
of	I-C1843777
binge	I-C1843777
eating	I-C1843777
.	O
	
despite	O
negative	B-C1306597
psychological	I-C1306597
and	O
physical	B-C1446390
consequences	I-C1446390
,	O
bn/bed	B-C0013473
patients	B-C0030705
show	O
uncontrollable	O
approach	O
tendencies	B-C0003618
towards	I-C0003618
food	I-C0003618
.	O
	
this	O
cognitive	B-C0237494
bias	I-C0237494
occurs	O
at	O
an	O
early	O
stage	O
of	O
information	B-C0700301
processing	I-C0700301
.	O
	
cognitive	B-C3162263
bias	I-C3162263
modification	I-C3162263
cbm	B-C3162263
directly	O
targets	O
such	O
biases	B-C0242568
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	B-C0087111
several	O
mental	B-C0004936
disorders	I-C0004936
.	O
	
in	O
alcohol	B-C0001973
addiction	I-C0001973
,	O
automatic	O
action	O
tendencies	O
towards	O
alcohol	B-C0679056
cues	I-C0679056
and	O
relapse	B-C0035020
rates	B-C1521828
were	O
successfully	O
reduced	O
by	O
a	O
specific	O
form	O
of	O
cbm	B-C3162263
,	O
termed	O
approach	O
bias	B-C1554963
modification	I-C1554963
.	O
	
based	O
on	O
these	O
findings	O
and	O
data	B-C1511726
from	O
a	O
proof-of-concept	B-C2603343
study	I-C2603343
in	O
people	B-C0027361
with	O
high	O
levels	O
of	O
food	B-C0872380
craving	I-C0872380
,	O
cbm	B-C1554963
is	O
considered	O
a	O
promising	O
new	O
treatment	B-C0679624
approach	I-C0679624
for	O
bn/bed	B-C0013473
.	O
	
given	O
the	O
similarities	O
between	O
bn/bed	B-C0013473
and	O
addictive	B-C0085281
disorders	I-C0085281
,	O
the	O
rationale	B-C2699007
for	O
using	O
approach	O
bias	B-C1554963
modification	I-C1554963
appears	O
to	O
be	O
particularly	O
strong	O
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
,	O
compared	O
to	O
a	O
sham	B-C3897046
training	I-C3897046
,	O
computerised	O
approach	O
bias	B-C1554963
modification	I-C1554963
10	O
sessions	O
can	O
reduce	O
binge-eating	B-C1843777
episodes	I-C1843777
in	O
bn/bed	B-C0013473
patients	B-C0030705
from	O
pre-treatment	B-C2709094
to	O
follow-up	O
.	O
	
additionally	O
,	O
we	O
will	O
investigate	O
whether	O
this	O
cbm	B-C3162263
programme	O
also	O
reduces	O
global	B-C2348867
eating	B-C0556019
disorder	I-C0556019
psychopathology	I-C0556019
,	O
trait	B-C0599883
and	O
cue-elicited	B-C0872380
food	I-C0872380
craving	I-C0872380
,	O
food	B-C0013470
intake	I-C0013470
as	O
well	O
as	O
approach	O
and	O
attentional	B-C4277667
bias	I-C4277667
towards	O
visual	B-C0010439
food	I-C0010439
cues	I-C0010439
.	O
	
treatment	B-C3468361
acceptance	I-C3468361
will	O
be	O
determined	O
by	O
attrition	B-C0814623
rates	I-C0814623
and	O
responses	B-C1706817
on	O
a	O
feedback	O
form	O
.	O
	
this	O
is	O
a	O
double-blind	B-C0013072
,	O
randomised	B-C0034656
,	O
placebo-controlled	B-C0599724
,	O
parallel-group	B-C0680731
superiority	I-C0680731
trial	I-C0680731
with	O
two	O
parallel	O
arms	O
.	O
	
a	O
total	O
of	O
54	O
bn/bed	B-C0013473
patients	B-C0030705
will	O
be	O
recruited	O
.	O
	
approach	O
bias	B-C0242568
towards	I-C0242568
food	I-C0242568
will	O
be	O
retrained	O
by	O
a	O
computer	O
task	O
adopting	O
an	O
implicit	B-C0681797
learning	I-C0681797
paradigm	I-C0681797
.	O
	
patients	B-C0030705
in	O
the	O
control	O
condition	O
sham	B-C3897046
will	O
conduct	O
a	O
similar	B-C3540678
task	I-C3540678
but	O
will	O
not	O
be	O
trained	O
to	O
avoid	O
food	B-C0010439
cues	I-C0010439
.	O
	
methods	O
against	O
bias	B-C0242568
include	O
public	B-C3897463
registration	I-C3897463
,	O
randomisation	B-C0034656
by	O
a	O
central	B-C1522486
study	I-C1522486
office	I-C1522486
,	O
standardisation	B-C0038136
of	I-C0038136
the	I-C0038136
treatments	I-C0038136
and	O
blinding	B-C0150108
of	I-C0150108
assessors	I-C0150108
.	O
	
furthermore	O
,	O
the	O
session	O
number	O
and	O
duration	O
will	O
be	O
equivalent	O
in	O
the	O
two	O
conditions	O
.	O
	
this	O
is	O
the	O
first	O
registered	O
randomised	B-C0206035
controlled	I-C0206035
trial	I-C0206035
of	O
approach	O
bias	B-C1554963
modification	I-C1554963
in	O
a	O
clinical	B-C0008976
bn/bed	I-C0008976
sample	I-C0008976
.	O
	
results	O
from	O
this	O
study	O
will	O
provide	O
an	O
indication	O
of	O
the	O
efficacy	O
of	O
approach	O
bias	B-C1554963
modification	I-C1554963
training	O
for	O
bn/bed	B-C0013473
and	O
the	O
potential	O
mechanisms	O
of	O
action	O
underlying	O
this	O
treatment	B-C0087111
.	O
	
protein	B-C0033684
design	B-C1707689
for	O
nanostructural	B-C0033629
engineering	I-C0033629
concluding	O
remarks	B-C0282411
and	O
future	O
directions	O
this	O
final	O
chapter	B-C0005990
aims	O
to	O
summarize	O
the	O
main	O
conclusions	B-C1830648
of	O
the	O
book	B-C0006002
and	O
to	O
point	O
to	O
possible	O
directions	O
for	O
further	O
research	B-C0035168
in	O
the	O
field	B-C0683945
of	O
protein	B-C0033684
design	B-C1707689
for	O
nanostructural	B-C0033629
engineering	I-C0033629
.	O
	
even	O
though	O
this	O
research	B-C0683945
field	I-C0683945
is	O
still	O
at	O
its	O
infancy	O
,	O
multidisciplinary	B-C0205556
research	B-C0035168
efforts	I-C0035168
in	O
the	O
design	B-C1707689
of	O
synthetic	B-C0597552
protein	I-C0597552
-based	O
nanostructures	B-C1450053
and	O
functional	B-C0205245
materials	B-C0520510
have	O
resulted	O
in	O
significant	O
progress	B-C1272688
.	O
	
the	O
chapters	B-C0005990
in	O
this	O
book	B-C0006002
cover	O
several	O
selected	O
examples	B-C1707959
of	O
the	O
most	O
recent	O
advances	B-C3854260
concerning	O
the	O
use	B-C1524063
of	I-C1524063
proteins	B-C0033684
and	O
peptides	B-C0030956
as	O
building	B-C1254372
blocks	I-C1254372
for	O
the	O
fabrication	B-C1254366
of	O
architectures	B-C1254372
and	O
functional	B-C0205245
nanostructures	B-C1450053
,	O
assemblies	B-C1706853
,	O
and	O
materials	B-C0520510
.	O
	
here	O
,	O
we	O
provide	O
a	O
general	O
overview	O
of	O
the	O
strategies	B-C0025664
that	O
can	O
be	O
employed	O
to	O
prepare	B-C1521827
functional	B-C0205245
protein	B-C0033684
-based	O
nanostructures	B-C1450053
,	O
and	O
nanostructured	B-C1450053
materials	I-C1450053
and	O
devices	B-C0699733
.	O
	
finally	O
,	O
we	O
highlight	O
some	O
of	O
the	O
main	O
aspects	B-C1879746
to	O
be	O
considered	O
by	O
the	O
research	B-C0035168
community	B-C0009462
to	O
set	O
the	O
path	O
for	O
the	O
near	O
future	O
synthesis	B-C1883254
,	O
characterization	B-C1880022
and	O
drug	B-C1254351
loading	B-C1708715
property	B-C0871161
of	O
monomethoxy-poly	B-C0032521
glycol	I-C0032521
mpeg-pcla	I-C0032521
copolymers	I-C0032521
amphiphilic	B-C0032521
block	I-C0032521
copolymers	I-C0032521
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	B-C0085104
delivery	I-C0085104
systems	I-C0085104
.	O
	
in	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy-poly	B-C0032521
ethylene	I-C0032521
glycol	I-C0032521
ε-caprolactone-co-d	I-C0032521
mpeg-pcla	I-C0032521
copolymers	I-C0032521
with	O
variable	O
composition	B-C0243176
of	O
poly	B-C0137734
ε-caprolactone	I-C0137734
pcl	B-C0137734
and	O
poly	B-C0071444
d	I-C0071444
pdlla	B-C0071444
were	O
prepared	O
via	O
ring-opening	B-C1880180
copolymerization	I-C1880180
of	O
ε-cl	B-C0908527
and	O
d	B-C0293984
in	O
the	O
presence	O
of	O
mpeg	B-C0066763
and	O
stannous	B-C0963887
octoate	I-C0963887
.	O
	
the	O
structure	B-C0678594
and	O
molecular	B-C0026385
weight	I-C0026385
were	O
characterized	B-C1880022
by	O
nuclear	B-C0028580
magnetic	I-C0028580
resonance	I-C0028580
nmr	B-C0028580
and	O
gel	B-C0008559
permeation	I-C0008559
chromatography	I-C0008559
gpc	B-C0008559
.	O
	
the	O
crystallinity	B-C0444626
,	O
hydrophilicity	B-C0475370
,	O
thermal	B-C0018837
stability	B-C0205360
and	O
hydrolytic	B-C0020291
degradation	B-C0243125
behavior	I-C0243125
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O
	
the	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	B-C0032521
mpeg-pcla	I-C0032521
copolymers	I-C0032521
have	O
adjustable	O
properties	B-C0871161
by	O
altering	O
the	O
composition	B-C0243176
of	O
pcla	B-C1744269
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	B-C0683325
applications	I-C0683325
.	O
	
besides	O
,	O
the	O
drug	B-C1254351
loading	B-C1708715
properties	B-C0871161
were	O
also	O
studied	O
.	O
	
docetaxel	B-C0246415
dtx	B-C0246415
could	O
be	O
entrapped	O
in	O
mpeg-pcla	B-C0032521
micelles	B-C0025938
with	O
high	B-C0205250
loading	B-C1708715
capacity	B-C1516240
and	O
encapsulation	B-C2348438
efficiency	B-C0013682
.	O
	
and	O
all	O
lyophilized	B-C0205556
dtx	B-C0246415
-loaded	O
mpeg-pcla	B-C0032521
micelles	B-C0025938
except	O
mpeg-pcl	B-C0032521
micelles	B-C0025938
were	O
readily	O
re-dissolved	B-C0205245
in	O
normal	B-C0445115
saline	I-C0445115
at	O
25	O
c	O
.	O
	
in	O
addition	O
,	O
dtx	B-C0246415
-loaded	O
mpeg-pcla	B-C0032521
micelles	B-C0025938
showed	O
a	O
slightly	O
enhanced	B-C2349975
antitumor	B-C2986475
activity	B-C0441655
compared	O
with	O
free	O
dtx	B-C0246415
.	O
	
furthermore	O
,	O
dtx	B-C0246415
micelles	B-C0025938
exhibited	O
a	O
slower	B-C0439834
and	O
sustained	B-C0443318
release	B-C1283071
behavior	B-C0871161
in	B-C1533691
vitro	I-C1533691
,	O
and	O
higher	B-C0205250
dtx	B-C0246415
concentration	B-C1264643
and	O
longer	O
retention	B-C0392762
time	I-C0392762
in	B-C1515655
vivo	I-C1515655
.	O
	
the	O
results	O
suggested	O
that	O
the	O
mpeg-pcla	B-C0032521
copolymer	I-C0032521
with	O
the	O
adjustable	O
ratio	B-C0456603
of	O
pcl	B-C0137734
to	O
pdlla	B-C0071444
may	O
be	O
a	O
promising	O
drug	B-C0013161
delivery	I-C0013161
carrier	I-C0013161
for	O
thyroid	B-C0007115
cancer	I-C0007115
burden	B-C1516167
in	O
central	B-C0007674
and	O
south	B-C0037713
america	I-C0037713
incidence	B-C0021149
of	O
thyroid	B-C0007115
cancer	I-C0007115
tc	B-C0007115
is	O
rapidly	B-C0456962
increasing	B-C0442808
worldwide	B-C0043236
,	O
but	O
little	O
is	O
known	O
about	O
the	O
tc	B-C0007115
burden	B-C1516167
in	O
central	B-C0007674
and	O
south	B-C0037713
america	I-C0037713
csa	B-C0002454
.	O
	
we	O
describe	O
the	O
geographic	B-C0442527
patterns	I-C0442527
and	O
trends	B-C0040833
of	O
tc	B-C0007115
by	O
sex	B-C0079399
in	O
csa	B-C0002454
.	O
	
we	O
obtained	O
regional	B-C0683928
-	O
and	O
national-level	B-C0681788
incidence	B-C1708485
data	B-C1511726
from	O
48	O
population-based	B-C1514227
cancer	I-C1514227
registries	I-C1514227
in	O
13	O
countries	B-C0454664
and	O
nationwide	O
cancer	B-C1516192
deaths	I-C1516192
from	O
the	O
who	B-C0043237
mortality	B-C0205848
database	B-C0242356
for	O
18	O
countries	B-C0454664
.	O
	
we	O
estimated	O
world	B-C2700280
population	O
age-standardized	B-C1706747
incidence	I-C1706747
rates	I-C1706747
asrs	B-C1706747
and	O
age-standardized	B-C1706748
mortality	I-C1706748
rates	I-C1706748
asmrs	B-C1706748
per	O
100	O
person	B-C0027361
-	O
years	B-C0439234
.	O
	
we	O
calculated	O
asrs	B-C1706747
by	O
histological	B-C0449574
subtype	I-C0449574
.	O
	
we	O
estimated	B-C0023732
the	I-C0023732
annual	I-C0023732
percentage	I-C0023732
change	I-C0023732
eapc	B-C0023732
to	O
describe	O
time	B-C0040833
trends	I-C0040833
.	O
	
between	O
csa	B-C0002454
countries	B-C0454664
,	O
tc	B-C0007115
incidence	B-C1708485
and	O
mortality	B-C0205848
rates	I-C0205848
varied	O
from	O
8-fold	O
to	O
12-fold	O
and	O
from	O
2-fold	O
to	O
5-fold	O
,	O
respectively	O
.	O
	
in	O
2003-2007	O
,	O
the	O
highest	B-C1522410
tc	B-C0007115
asrs	B-C1706747
in	O
females	B-C0086287
and	O
males	B-C0086582
were	O
in	O
ecuador	B-C0013593
16.0	O
and	O
3.5	O
,	O
respectively	O
,	O
brazil	B-C0006137
14.4	O
and	O
3.4	O
,	O
costa	B-C0010182
rica	I-C0010182
12.6	O
and	O
2.1	O
and	O
colombia	B-C3245499
10.7	O
and	O
2.5	O
.	O
	
the	O
highest	B-C1522410
asmrs	B-C1706748
were	O
in	O
ecuador	B-C0013593
,	O
colombia	B-C3245499
,	O
mexico	B-C0025885
,	O
peru	B-C0031238
and	O
panama	B-C0030266
0.68	O
in	O
females	B-C0086287
and	O
0.41	O
in	O
males	B-C0086582
.	O
	
papillary	B-C0238463
tc	I-C0238463
was	O
the	O
most	O
commonly	O
diagnosed	B-C0011900
histological	B-C0449574
subtype	I-C0449574
,	O
following	O
the	O
same	O
incidence	B-C1708485
pattern	I-C1708485
as	O
overall	O
tc	B-C0007115
.	O
	
in	O
argentinean	B-C0238689
,	O
brazilian	B-C0238815
,	O
chilean	B-C0239045
and	O
costa	B-C0239127
rican	I-C0239127
females	B-C0086287
tc	B-C0007115
incidence	B-C1708485
increased	B-C0205217
by	O
2.2	O
annually	B-C0332181
,	O
and	O
papillary	B-C0238463
tc	I-C0238463
increased	B-C0205217
by	O
9.1	O
annually	B-C0332181
,	O
while	O
mortality	B-C0205848
remained	O
stable	B-C0205360
between	O
1997	O
and	O
2008	O
.	O
	
in	O
males	B-C0086582
,	O
trends	B-C0040833
in	O
tc	B-C0007115
were	O
stable	B-C0205360
.	O
	
tc	B-C0007115
occurred	B-C1709305
more	O
frequently	B-C0332183
in	O
females	B-C0086287
than	O
in	O
males	B-C0086582
.	O
	
the	O
overall	B-C1561607
high	B-C0205250
incidence	B-C1708485
and	O
low	B-C0205251
mortality	B-C0205848
of	O
tc	B-C0007115
suggest	B-C1705535
identification	O
of	O
subclinical	B-C0277544
disease	I-C0277544
due	O
to	O
improved	B-C0332272
detection	B-C0449335
methods	I-C0449335
.	O
	
histopathological	B-C0243140
evaluation	B-C0220825
of	O
the	O
effectiveness	B-C1280519
of	O
glycyrrhizic	B-C0061751
acid	I-C0061751
as	O
a	O
radioprotector	B-C1318473
against	O
the	O
development	B-C1527148
of	O
radiation-induced	B-C0340126
lung	I-C0340126
fibrosis	I-C0340126
radiotherapy	B-C1522449
of	O
the	O
thorax	B-C0817096
often	O
causes	O
lung	B-C0032285
inflammation	I-C0032285
leading	O
to	O
fibrosis	B-C0034069
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
whether	O
the	O
use	O
of	O
glycyrrhizic	B-C0061751
acid	I-C0061751
gla	B-C0061751
could	O
improve	O
the	O
development	B-C1527148
of	O
lung	B-C0034069
fibrosis	I-C0034069
in	O
irradiated	B-C1522449
animals	B-C0003062
.	O
	
wistar	B-C0034716
rats	I-C0034716
were	O
divided	O
into	O
four	O
groups	B-C0441833
.	O
	
group	B-C0441833
a	I-C0441833
rats	B-C0034693
received	O
thoracic	B-C2169121
irradiation	I-C2169121
.	O
	
rats	B-C0034693
in	O
group	B-C0441833
b	I-C0441833
received	O
gla	B-C0061751
and	O
irradiation	B-C1522449
.	O
	
group	B-C0441833
c	I-C0441833
received	O
gla	B-C0061751
and	O
no	O
irradiation	B-C1522449
.	O
	
group	B-C0441833
d	I-C0441833
received	O
no	O
gla	B-C0061751
and	O
irradiation	B-C1522449
.	O
	
gla	B-C0061751
was	O
administered	B-C1521801
at	O
a	O
dose	B-C0178602
of	O
4	O
mg/kg	O
body	B-C0005910
weight	I-C0005910
using	O
an	O
intraperitoneal	B-C0021493
injection	I-C0021493
one	O
hour	O
before	O
thoracic	B-C2169121
irradiation	I-C2169121
.	O
	
radiation	B-C1522449
therapy	I-C1522449
was	O
delivered	O
on	O
a	O
cobalt-60	B-C0303395
unit	O
using	O
a	O
single	O
fraction	O
of	O
16	O
gy	O
.	O
	
the	O
animals	B-C0003062
were	O
sacrificed	O
at	O
32	O
weeks	O
following	O
thoracic	B-C2169121
irradiation	I-C2169121
.	O
	
the	O
lungs	B-C0024109
were	O
dissected	B-C0205239
and	O
blind	O
histopathological	B-C0243140
evaluation	B-C0220825
was	O
performed	O
.	O
	
histopathologically	B-C0243140
,	O
a	O
decrease	B-C0547047
statistically	O
not	O
significant	O
in	O
the	O
thickening	B-C0205400
of	O
alveolar	B-C0225695
or	O
bronchial	B-C1180039
wall	I-C1180039
,	O
formation	O
of	O
fibrous	B-C0334163
bands	I-C0334163
,	O
and	O
superimposed	O
collagen	B-C0009325
were	O
noted	O
in	O
the	O
animals	B-C0003062
in	O
group	B-C0441833
b	I-C0441833
as	O
compared	O
to	O
the	O
animals	B-C0003062
in	O
group	B-C0441833
a	I-C0441833
.	O
	
in	O
this	O
experimental	B-C0681814
study	I-C0681814
,	O
administration	B-C0001555
of	O
gla	B-C0061751
one	O
hour	O
before	O
thoracic	B-C2169121
irradiation	I-C2169121
may	O
be	O
a	O
protective	B-C0033613
agent	I-C0033613
against	O
radiation-induced	B-C0340126
fibrosis	I-C0340126
in	O
animals	B-C0003062
and	O
this	O
model	B-C0012644
avulsions	B-C0262386
of	O
triceps	B-C0559502
brachii	I-C0559502
associated	O
injuries	B-C3263722
and	O
surgical	B-C0543467
treatment	I-C0543467
a	O
case	O
series	O
this	O
study	B-C2603343
reports	O
the	O
clinical	B-C2708283
presentations	I-C2708283
,	O
intra	B-C0456904
-operative	I-C0456904
findings	B-C0243095
,	O
type	O
of	O
the	O
treatments	B-C0087111
,	O
outcome	B-C1274040
of	O
the	O
treatment	B-C0087111
and	O
specially	O
associated	O
injuries	B-C3263722
in	O
patients	B-C0030705
with	O
the	O
avulsion	B-C0262386
of	O
the	O
distal	B-C0205108
end	I-C0205108
of	O
the	O
triceps	B-C0448542
brachii	I-C0448542
tb	I-C0448542
tendon	I-C0448542
.	O
	
we	O
studied	O
6	O
patients	B-C0030705
with	O
rupture	B-C3203359
or	O
avulsion	B-C0262386
of	O
the	O
distal	B-C0205108
end	I-C0205108
of	O
the	O
tb	B-C0448542
tendon	I-C0448542
.	O
	
the	O
medical	B-C0025102
records	I-C0025102
,	O
imaging	B-C0242193
files	I-C0242193
,	O
clinical	B-C0205210
outcomes	B-C1274040
at	O
the	O
final	O
follow	B-C0589121
up	I-C0589121
visit	I-C0589121
were	O
reviewed	O
.	O
	
the	O
clinical	B-C0205210
outcomes	B-C1274040
were	O
assessed	O
by	O
mayo	B-C0282574
elbow	I-C0282574
score	I-C0282574
at	O
the	O
final	O
follow-up	B-C0589121
visit	I-C0589121
.	O
	
all	O
patients	B-C0030705
were	O
male	B-C0086582
,	O
4	O
of	O
them	O
having	O
injury	B-C3263722
in	O
the	O
left	B-C0230371
hand	I-C0230371
as	O
the	O
non-dominant	O
hand	B-C0018563
.	O
	
mean	O
age	B-C0001779
of	O
them	O
was	O
34.5	O
years	B-C0439234
.	O
	
all	O
cases	O
had	O
small	O
bony	B-C0443157
fleck	B-C0009938
in	O
the	O
posterior	O
of	O
elbow	B-C0013769
in	O
lateral	B-C0202571
radiograph	I-C0202571
.	O
	
three	O
patients	B-C0030705
had	O
associated	O
injuries	B-C3263722
-including	O
intra-articular	B-C0442108
fractures	B-C0016658
and	O
medial	B-C0840716
collateral	I-C0840716
ligament	I-C0840716
rupture	I-C0840716
.	O
	
in	O
one	O
case	O
v-y	B-C0087111
plasty	I-C0087111
of	O
the	O
distal	B-C0205108
tb	B-C0559502
was	O
done	O
.	O
	
in	O
4	O
patients	B-C0030705
the	O
results	O
of	O
surgery	B-C0543467
were	O
excellent	O
,	O
one	O
was	O
good	O
and	O
one	O
was	O
fair	O
.	O
	
although	O
tb	B-C0448542
tendon	I-C0448542
rupture	B-C3203359
is	O
rare	O
,	O
it	O
should	O
be	O
-considered	O
in	O
differential	O
diagnosis	B-C1704656
of	O
the	O
upper	B-C0749817
-extremity	I-C0749817
trauma	I-C0749817
and	O
its	O
associated	O
injuries	B-C3263722
prolyl-4-hydroxylase	B-C1451071
2	I-C1451071
and	O
3	B-C2002278
coregulate	O
murine	B-C0591833
erythropoietin	B-C0014822
in	O
brain	B-C0006104
pericytes	B-C0598800
a	O
classic	O
response	B-C1704632
to	O
systemic	B-C0205373
hypoxia	B-C0242184
is	O
the	O
increased	B-C0205217
production	B-C0014819
of	I-C0014819
red	I-C0014819
blood	I-C0014819
cells	I-C0014819
due	O
to	O
hypoxia-inducible	B-C0215848
factor	I-C0215848
hif	B-C0215848
induction	B-C0205263
of	O
erythropoietin	B-C0014822
epo	B-C0014822
.	O
	
epo	B-C0014822
is	O
a	O
glycoprotein	B-C0312438
hormone	I-C0312438
that	O
is	O
essential	O
for	O
normal	B-C0014819
erythropoiesis	I-C0014819
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	B-C0456918
renal	B-C1514842
interstitial	I-C1514842
fibroblast-like	I-C1514842
cells	I-C1514842
,	O
which	O
express	O
cellular	B-C0005516
markers	I-C0005516
characteristic	O
of	O
neuronal	B-C0027882
cells	I-C0027882
and	O
pericytes	B-C0598800
.	O
	
to	O
investigate	B-C1292732
whether	O
the	O
ability	O
to	O
synthesize	O
epo	B-C0014822
is	O
a	O
general	O
functional	B-C0205245
feature	B-C2348519
of	O
pericytes	B-C0598800
,	O
we	O
used	O
conditional	O
gene	B-C0242613
targeting	I-C0242613
to	O
examine	O
the	O
von	B-C0019562
hippel-lindau	I-C0019562
/	O
prolyl-4-hydroxylase	B-C3658213
domain	I-C3658213
phd	I-C3658213
axis	O
in	O
cell	B-C0007634
-	O
expressing	B-C1171362
neural	B-C1311695
glial	I-C1311695
antigen	I-C1311695
2	I-C1311695
,	O
a	O
known	O
molecular	B-C0005516
marker	I-C0005516
of	O
pericytes	B-C0598800
in	O
multiple	B-C0178784
organs	I-C0178784
.	O
	
we	O
found	O
that	O
pericytes	B-C0598800
in	O
the	O
brain	B-C0006104
synthesized	O
epo	B-C0014822
in	O
mice	B-C0026809
with	O
genetic	B-C0314603
hif	B-C0215848
activation	B-C1879547
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	B-C0205373
hypoxia	B-C0242184
with	O
the	O
induction	B-C0205263
of	O
epo	B-C0014822
.	O
	
using	O
high-resolution	B-C1719039
multiplex	O
in	B-C0162788
situ	I-C0162788
hybridization	I-C0162788
,	O
we	O
determined	O
that	O
brain	B-C0006104
pericytes	B-C0598800
represent	O
an	O
important	O
cellular	B-C0007634
source	I-C0007634
of	O
epo	B-C0014822
in	O
the	O
hypoxic	B-C0242184
brain	B-C0006104
up	O
to	O
70%	O
of	O
all	O
epo	B-C0014822
-	O
expressing	B-C1171362
cells	B-C0007634
.	O
	
we	O
furthermore	O
determined	O
that	O
epo	B-C0014822
transcription	B-C0040649
in	O
brain	B-C0006104
pericytes	B-C0598800
was	O
hif-2	B-C0215848
dependent	O
and	O
cocontrolled	O
by	O
phd2	B-C1451071
and	O
phd3	B-C2002278
,	O
oxygen	B-C0030054
-	O
and	O
2-oxoglutarate	B-C1291208
-dependent	O
prolyl-4-hydroxylases	B-C3658213
that	O
regulate	O
hif	B-C0215848
activity	B-C0243102
.	O
	
in	O
summary	O
,	O
our	O
studies	O
provide	O
experimental	B-C1517586
evidence	B-C3887511
that	O
pericytes	B-C0598800
in	O
the	O
brain	B-C0006104
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen	B-C0183211
sensors	I-C0183211
and	O
respond	O
to	O
hypoxia	B-C0242184
with	O
epo	B-C0014822
synthesis	O
.	O
	
our	O
findings	B-C2607943
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
epo	B-C0014822
may	O
represent	O
a	O
functional	B-C0205245
feature	B-C2348519
of	O
pericytes	B-C0598800
in	O
the	O
brain	B-C0006104
and	O
patient	B-C0030702
satisfaction	I-C0030702
with	O
pharmacist	B-C0031323
-led	O
collaborative	B-C0282116
follow-up	B-C3899107
care	I-C3899107
in	O
an	O
ambulatory	B-C1561561
rheumatology	B-C3812871
clinic	I-C3812871
patient	B-C0030702
satisfaction	I-C0030702
is	O
known	O
to	O
increase	O
with	O
pharmacist	B-C0031323
intervention	B-C0184661
in	O
general	B-C0029916
outpatient	I-C0029916
clinics	I-C0029916
and	O
with	O
nurse-led	B-C0086584
care	I-C0086584
in	O
rheumatology	B-C3812871
clinics	I-C3812871
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
and	O
compare	O
patient	B-C0030702
satisfaction	I-C0030702
with	O
two	O
different	O
types	O
of	O
care	B-C0017313
a	O
pharmacist	B-C0031323
physician	B-C0031831
collaborative	B-C0596657
model	I-C0596657
and	O
a	O
traditional	B-C0596657
physician	I-C0596657
model	I-C0596657
in	O
a	O
rheumatology	B-C3812871
clinic	I-C3812871
setting	O
.	O
	
a	O
cross-sectional	B-C0010362
survey	I-C0010362
of	O
inflammatory	B-C0003864
arthritis	I-C0003864
patients	B-C0030705
seen	O
during	O
a	O
follow-up	B-C0589121
visit	I-C0589121
in	O
edmonton	B-C0681784
,	O
alberta	B-C0681784
,	O
canada	B-C0006823
,	O
was	O
conducted	O
over	O
a	O
ten-week	B-C2347804
period	I-C2347804
.	O
	
patient	B-C0030702
satisfaction	I-C0030702
was	O
measured	O
using	O
a	O
modified	O
version	O
of	O
the	O
validated	O
leeds	B-C4039173
satisfaction	I-C4039173
questionnaire	I-C4039173
,	O
which	O
uses	O
a	O
five-point	O
likert	B-C0451267
scale	I-C0451267
to	O
measure	O
six	B-C0454192
dimensions	I-C0454192
of	O
satisfaction	B-C0030702
,	O
and	O
compared	O
between	O
the	O
collaborative	B-C0086388
care	I-C0086388
and	O
traditional	B-C0596657
physician	I-C0596657
models	I-C0596657
.	O
	
a	O
total	O
of	O
62	O
patients	B-C0030705
completed	O
the	O
questionnaire	B-C1879301
21	O
collaborative	B-C0086388
care	I-C0086388
and	O
41	O
traditional	B-C0596657
physician	I-C0596657
model	I-C0596657
.	O
	
the	O
average	O
age	O
of	O
respondents	B-C0282122
was	O
52	O
years	O
and	O
the	O
majority	O
were	O
female	B-C0086287
.	O
	
the	O
mean	B-C0451370
score	I-C0451370
for	I-C0451370
satisfaction	I-C0451370
across	O
the	O
six	B-C0454192
dimensions	I-C0454192
was	O
4.56	O
in	O
the	O
collaborative	B-C1273804
care	I-C1273804
group	I-C1273804
and	O
4.30	O
in	O
the	O
traditional	B-C0031831
physician	I-C0031831
group	I-C0031831
p	O
=	O
0.02	O
.	O
	
patient	B-C0030702
satisfaction	I-C0030702
in	O
the	O
collaborative	B-C1273804
care	I-C1273804
group	I-C1273804
was	O
consistently	O
higher	O
across	O
all	O
dimensions	O
.	O
	
no	B-C3842396
difference	I-C3842396
was	O
noted	O
between	O
participants	B-C0679646
seen	O
for	O
the	O
first	O
time	O
compared	O
with	O
those	O
seen	O
two	O
or	O
more	O
times	O
by	O
the	O
pharmacist	B-C0031323
.	O
	
a	O
collaborative	B-C0596657
care	I-C0596657
model	I-C0596657
can	O
exceed	O
the	O
already	O
high	B-C0679138
expectations	I-C0679138
for	O
care	B-C0030677
of	I-C0030677
patients	I-C0030677
with	O
inflammatory	B-C0003864
arthritis	I-C0003864
.	O
	
our	O
findings	O
support	O
the	O
role	O
of	O
pharmacists	B-C0031323
using	O
a	O
collaborative	B-C0086388
care	I-C0086388
approach	O
to	O
care	B-C0030677
for	I-C0030677
patients	I-C0030677
in	O
rheumatology	B-C3812871
clinics	I-C3812871
.	O
	
ontology	B-C1518584
-based	O
high	B-C0205250
-	O
level	B-C0441889
context	B-C0449255
inference	B-C0679201
for	O
human	B-C3826173
behavior	I-C3826173
identification	B-C0205396
recent	O
years	O
have	O
witnessed	O
a	O
huge	O
progress	B-C1280477
in	O
the	O
automatic	B-C0205554
identification	B-C0205396
of	O
individual	B-C0237401
primitives	B-C3645627
of	O
human	B-C3826173
behavior	I-C3826173
,	O
such	O
as	O
activities	B-C0026606
or	O
locations	B-C0450429
.	O
	
however	O
,	O
the	O
complex	B-C0439855
nature	B-C1262865
of	O
human	B-C3826173
behavior	I-C3826173
demands	O
more	O
abstract	O
contextual	B-C0449255
information	B-C1533716
for	O
its	O
analysis	O
.	O
	
this	O
work	O
presents	O
an	O
ontology	B-C1518584
-based	O
method	B-C0025663
that	O
combines	O
low	B-C0205251
-	O
level	B-C0441889
primitives	B-C3645627
of	O
behavior	B-C0004927
,	O
namely	O
activity	B-C0026606
,	O
locations	B-C0450429
and	O
emotions	B-C0013987
,	O
unprecedented	B-C0439673
to	O
date	B-C0011008
,	O
to	O
intelligently	O
derive	O
more	O
meaningful	O
high	B-C0205250
-	O
level	B-C0441889
context	B-C0449255
information	B-C1533716
.	O
	
the	O
paper	O
contributes	B-C1880177
with	O
a	O
new	O
open	O
ontology	B-C1518584
describing	O
both	O
low	B-C0205251
-	O
level	B-C0441889
and	O
high	B-C0205250
-	O
level	B-C0441889
context	B-C0449255
information	B-C1533716
,	O
as	O
well	O
as	O
their	O
relationships	B-C0439849
.	O
	
furthermore	O
,	O
a	O
framework	B-C1709697
building	O
on	O
the	O
developed	O
ontology	B-C1518584
and	O
reasoning	O
models	B-C3161035
is	O
presented	O
and	O
evaluated	O
.	O
	
the	O
proposed	O
method	O
proves	O
to	O
be	O
robust	O
while	O
identifying	O
high	B-C0205250
-	O
level	B-C0441889
contexts	B-C0449255
even	O
in	O
the	O
event	B-C0441471
of	O
erroneously	B-C0205556
-	O
detected	B-C0442726
low	B-C0205251
-l	O
evel	B-C0441889
context	B-C0449255
s	O
.	O
	
despite	O
reasonable	O
inference	B-C0679201
times	O
being	O
obtained	O
for	O
a	O
relevant	B-C2347946
set	B-C0036849
of	O
users	B-C1706077
and	O
instances	B-C1550608
,	O
additional	O
work	O
is	O
required	O
to	O
scale	O
to	O
long-term	O
scenarios	B-C0683579
with	O
a	O
large	O
number	O
of	O
characterization	B-C1880022
of	O
exposure	B-C0014412
in	O
epidemiological	B-C0002783
studies	I-C0002783
on	O
air	B-C0001873
pollution	I-C0001873
from	O
biodegradable	B-C0205556
wastes	B-C0043045
misclassification	B-C0008902
and	O
comparison	B-C1707455
of	O
exposure	B-C0014412
assessment	B-C0220825
strategies	B-C0035171
the	O
assignment	O
of	O
exposure	B-C0014412
is	O
one	O
of	O
the	O
main	O
challenges	O
faced	O
by	O
environmental	B-C0014406
epidemiologists	B-C1516908
.	O
	
however	O
,	O
misclassification	B-C0008902
of	O
exposures	B-C0014412
has	O
not	O
been	O
explored	O
in	O
population	B-C1257890
epidemiological	B-C0002783
studies	I-C0002783
on	O
air	B-C0001873
pollution	I-C0001873
from	O
biodegradable	B-C0205556
wastes	B-C0043045
.	O
	
the	O
objective	B-C2985627
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
use	O
of	O
different	O
approaches	O
for	O
assessing	O
exposure	B-C0014412
to	O
air	B-C0001873
pollution	I-C0001873
from	O
biodegradable	B-C0205556
wastes	B-C0043045
by	O
analyzing	B-C0936012
1	O
the	O
misclassification	B-C0008902
of	O
exposure	B-C0014412
that	O
is	O
committed	O
by	O
using	O
these	O
surrogates	B-C1551364
,	O
2	O
the	O
existence	O
of	O
differentia	B-C0443199
l	O
misclassification	B-C0008902
3	O
the	O
effects	B-C1280500
that	O
misclassification	B-C0008902
may	O
have	O
on	O
health	B-C0018684
effect	B-C1280500
estimates	B-C0750572
and	O
the	O
interpretation	B-C1285553
of	O
epidemiological	B-C0002783
results	B-C0683954
,	O
and	O
4	O
the	O
ability	O
of	O
the	O
exposure	B-C0014412
measures	O
to	O
predict	O
health	B-C1550208
outcomes	I-C1550208
using	O
10-fold	O
cross	B-C0681935
validation	I-C0681935
.	O
	
four	O
different	O
exposure	B-C0014412
assessment	B-C0220825
approaches	O
were	O
studied	B-C2603343
ammonia	B-C0002607
concentrations	B-C1446561
at	O
the	O
residence	B-C0237096
metric	B-C0025867
i	I-C0025867
,	O
distance	B-C0012751
to	O
the	O
closest	O
source	B-C0449416
metric	B-C0025867
ii	I-C0025867
,	O
number	O
of	O
sources	B-C0449416
within	O
certain	O
distances	B-C0012751
from	O
the	O
residence	B-C0237096
metric	B-C0025867
iiia	I-C0025867
,	O
b	B-C0025867
and	O
location	B-C0450429
in	O
a	O
specific	O
region	B-C0017446
metric	B-C0025867
iv	I-C0025867
.	O
	
exposure-response	B-C3161035
models	I-C3161035
based	O
on	O
metric	B-C0025867
i	I-C0025867
provided	O
the	O
highest	O
predictive	O
ability	O
72.3	O
and	O
goodness-of-fit	B-C0870608
,	O
followed	O
by	O
iv	B-C0025867
,	O
iii	B-C0025867
and	O
ii	B-C0025867
.	O
	
when	O
compared	O
to	O
metric	B-C0025867
i	I-C0025867
,	O
metric	B-C0025867
iv	I-C0025867
yielded	O
the	O
best	O
results	B-C0683954
for	O
exposure	B-C0014412
misclassification	B-C0008902
analysis	B-C0936012
and	O
interpretation	B-C1285553
of	O
health	B-C0018684
effect	B-C1280500
estimates	B-C0750572
,	O
followed	O
by	O
metric	B-C0025867
iiib	I-C0025867
,	O
iiia	B-C0025867
and	O
ii	B-C0025867
.	O
	
the	O
study	B-C2603343
showed	O
that	O
modelled	O
nh3	B-C0002607
concentrations	B-C1446561
provide	O
more	O
accurate	O
estimations	B-C0750572
of	O
true	O
exposure	B-C0014412
than	O
distances-based	O
surrogates	B-C1551364
,	O
and	O
that	O
distance-based	O
surrogates	B-C1551364
especially	O
those	O
based	O
on	O
distance	B-C0012751
to	O
the	O
closest	O
point	O
source	B-C0449416
are	O
imprecise	O
methods	O
to	O
identify	O
exposed	O
populations	B-C1257890
,	O
although	O
they	O
may	O
be	O
useful	O
for	O
initial	O
de	B-C0364051
ritis	I-C0364051
ratio	I-C0364051
ast/alt	I-C0364051
as	O
a	O
significant	B-C1514474
prognostic	I-C1514474
factor	I-C1514474
in	O
patients	B-C0030705
with	O
upper	B-C0751571
tract	I-C0751571
urothelial	I-C0751571
cancer	I-C0751571
treated	B-C1522326
with	O
surgery	B-C0038895
we	O
investigated	B-C1292732
the	O
clinical	B-C0220901
prognostic	I-C0220901
value	I-C0220901
of	O
preoperative	B-C0445204
de	B-C0364051
ritis	I-C0364051
ratio	I-C0364051
aspartate	I-C0364051
aminotransferase	I-C0364051
ast	I-C0364051
aminotransferase	I-C0364051
alt	I-C0364051
on	O
postsurgical	B-C0231287
survival	B-C0038952
outcomes	B-C1274040
in	O
patients	B-C0030705
with	O
upper	B-C0751571
tract	I-C0751571
urothelial	I-C0751571
cancer	I-C0751571
utuc	B-C0751571
.	O
	
we	O
retrospectively	B-C0035363
analyzed	I-C0035363
the	O
data	B-C1511726
of	O
623	O
patients	B-C0030705
who	O
underwent	O
radical	B-C0027732
nephrouretectomy	I-C0027732
for	O
utuc	B-C0751571
.	O
	
multivariate	B-C0681923
regression	I-C0681923
tests	B-C0392366
were	O
performed	O
to	O
identify	O
possible	B-C0439849
associations	I-C0439849
between	O
adverse	B-C0030660
pathologic	I-C0030660
events	I-C0030660
and	O
ast/alt	B-C0364051
.	O
	
the	O
risk	O
of	O
postoperative	B-C0032790
progression	B-C0449258
and	O
survival	B-C0038952
were	O
tested	B-C0039593
using	O
kaplan-meier	B-C1720943
analyses	I-C1720943
and	O
cox	B-C0010235
proportional	I-C0010235
hazards	I-C0010235
models	I-C0010235
.	O
	
according	O
to	O
the	O
receiver	B-C0034772
operator	I-C0034772
characteristic	I-C0034772
curve	I-C0034772
of	O
ast/alt	B-C0364051
for	O
cancer-specific	B-C1516192
mortality	I-C1516192
,	O
patients	B-C0030705
with	O
ast/alt	B-C0364051
value	O
1.5	O
were	O
regarded	O
as	O
the	O
high	O
ast/alt	B-C0364051
group	O
,	O
and	O
the	O
remaining	O
patients	B-C0030705
formed	O
the	O
low	O
ast/alt	B-C0364051
group	O
.	O
	
in	O
kaplan-meier	B-C1720943
analyses	I-C1720943
,	O
the	O
high	O
ast/alt	B-C0364051
group	O
showed	O
worse	O
progression-free	B-C0242792
survival	I-C0242792
pfs	B-C0242792
,	O
cancer-specific	B-C0038954
survival	I-C0038954
css	B-C0038954
,	O
and	O
overall	B-C4086681
survival	I-C4086681
all	O
p	O
<	O
001	O
.	O
	
elevated	O
ast/alt	B-C0364051
was	O
associated	B-C0332281
with	I-C0332281
higher	O
t	B-C0475455
stage	I-C0475455
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
,	O
1.577	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
1.077	O
p	O
=	O
033	O
and	O
higher	B-C0441800
cellular	I-C0441800
grade	I-C0441800
hr	B-C2985465
,	O
1.538	O
95%	O
ci	B-C0009667
,	O
1.034	O
p	O
=	O
041	O
in	O
multivariate	B-C0681923
regression	I-C0681923
tests	B-C0392366
.	O
	
in	O
multivariate	B-C0026777
cox	I-C0026777
analyses	I-C0026777
,	O
high	O
ast/alt	B-C0364051
was	O
revealed	O
as	O
an	O
independent	B-C2698872
predictor	I-C2698872
of	O
pfs	B-C0242792
hr	B-C2985465
,	O
2.335	O
95%	O
ci	B-C0009667
,	O
1.633	O
p	O
<	O
001	O
,	O
css	B-C0038954
hr	B-C2985465
,	O
2.550	O
1.689	O
p	O
<	O
001	O
,	O
and	O
overall	B-C4086681
survival	I-C4086681
hr	B-C2985465
,	O
2.069	O
95%	O
ci	B-C0009667
,	O
1.409	O
p	O
<	O
001	O
.	O
	
elevated	O
preoperative	B-C0445204
ast/alt	B-C0364051
was	O
a	O
significant	B-C2698872
predictor	I-C2698872
of	O
worse	B-C1457868
postoperative	B-C0032790
survival	B-C0038952
in	O
patients	B-C0030705
surgically	B-C0543467
treated	I-C0543467
for	O
utuc	B-C0751571
.	O
	
further	O
large	O
prospective	B-C0033522
studies	I-C0033522
are	O
needed	O
for	O
better	O
understanding	O
of	O
the	O
prognostic	B-C0220901
value	I-C0220901
of	O
preoperative	B-C0445204
ast/alt	B-C0364051
.	O
	
molecular	B-C2717775
simulation	I-C2717775
study	B-C2603343
on	O
concentration	B-C1446561
effects	B-C1704420
of	I-C1704420
rofecoxib	B-C0762662
with	O
popc	B-C0044576
bilayer	B-C0023768
the	O
interactions	B-C0687133
between	O
rofecoxib	B-C0762662
and	O
popc	B-C0044576
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine	B-C0044576
bilayer	B-C0023768
were	O
studied	B-C2603343
using	B-C1524063
all-atom	B-C2717775
molecular	I-C2717775
dynamics	I-C2717775
simulation	I-C2717775
method	B-C0025663
.	O
	
four	O
popc	B-C0044576
bilayer	B-C0023768
systems	B-C0449913
with	O
different	B-C1705242
number	B-C0237753
of	O
rofecoxib	B-C0762662
molecules	B-C0567416
were	O
constructed	B-C0205431
to	O
simulate	B-C1883725
different	B-C1705242
drug	B-C1254351
concentration	B-C1446561
.	O
	
the	O
free	B-C0678591
energy	I-C0678591
of	O
rofecoxib	B-C0762662
passing	B-C2828360
across	O
pure	B-C0205556
popc	B-C0044576
bilayer	B-C0023768
has	O
two	O
minima	B-C1524031
at	O
z	O
1.2nm	O
or	O
1.6nm	O
.	O
	
as	O
for	O
the	O
high	B-C0205250
concentration	B-C1446561
model	B-C0026344
,	O
the	O
minimum	B-C1524031
of	O
the	O
free	B-C0678591
energy	I-C0678591
profile	O
slightly	O
shifts	O
to	O
the	O
bilayer	B-C0023768
center	B-C0205099
.	O
	
moreover	O
,	O
the	O
energy	B-C0678592
change	I-C0678592
from	O
bulk	B-C3663211
water	I-C3663211
to	O
popc	B-C0044576
bilayer	B-C0023768
increases	B-C0442805
while	O
the	O
central	B-C0205099
barrier	B-C0028778
to	O
cross	B-C2828360
the	O
hydrophobic	B-C1254355
core	I-C1254355
of	O
bilayer	B-C0023768
slightly	B-C0750482
decreases	B-C0547047
,	O
suggesting	B-C1705535
that	O
increasing	B-C0442808
drug	B-C1254351
concentration	B-C1446561
makes	O
it	O
favorable	B-C0278250
for	O
rofecoxib	B-C0762662
to	O
partition	B-C1534709
into	O
the	O
bilayer	B-C0023768
and	O
easier	O
to	O
pass	B-C2828360
across	O
bialyer	B-C0023768
center	B-C0205099
.	O
	
energy	B-C1442080
analysis	B-C0936012
show	O
that	O
the	O
stabilization	B-C0205360
between	O
the	O
selected	B-C1707391
rofecoxib	B-C0762662
and	O
other	O
pre-inserted	B-C1883719
rofecoxib	B-C0762662
molecule	B-C0567416
is	O
mainly	O
due	O
to	O
van	B-C2346563
der	I-C2346563
waals	I-C2346563
interaction	I-C2346563
energy	B-C1442080
.	O
	
the	O
predicted	B-C0681842
permeability	B-C0031164
of	O
rofecoxib	B-C0762662
in	O
high	B-C0205250
concentration	B-C1446561
model	B-C0026344
slightly	O
weakens	B-C1762617
as	O
compared	B-C1707455
with	O
low	B-C0205251
concentration	B-C1446561
model	B-C0026344
.	O
	
short-term	B-C2827666
variability	I-C2827666
of	O
vitamin	B-C0042866
d	I-C0042866
-related	O
biomarkers	B-C0005516
quantifying	B-C1709793
the	O
variability	B-C2827666
of	O
biomarkers	B-C0005516
is	O
important	B-C3898777
,	O
as	O
high	O
within-person	O
variability	B-C2827666
can	O
lead	O
to	O
misclassification	B-C0008902
of	O
individuals	B-C0237401
.	O
	
short-term	O
variability	B-C2827666
of	O
important	B-C3898777
markers	B-C0005516
of	O
vitamin	B-C1159433
d	I-C1159433
metabolism	I-C1159433
is	O
relatively	O
unknown	O
.	O
	
a	O
repeatability	B-C2603343
study	I-C2603343
was	O
conducted	O
in	O
160	O
atherosclerosis	B-C0004153
risk	B-C0035647
in	O
communities	B-C1997894
study	I-C1997894
participants	I-C1997894
60%	O
female	B-C0086287
,	O
28%	O
black	B-C0005680
,	O
mean	O
age	B-C0001779
76	O
years	O
.	O
	
fasting	B-C1976106
serum	B-C0229671
was	O
drawn	O
at	O
2	O
time	O
points	O
,	O
a	O
median	O
of	O
6	O
range	O
3-13	O
weeks	B-C0439230
apart	O
.	O
	
vitamin	B-C0042872
d	I-C0042872
binding	I-C0042872
protein	I-C0042872
vdbp	B-C0042872
and	O
25-hydroxyvitamin	B-C0535968
d	I-C0535968
25	B-C0535968
were	O
measured	B-C0444706
by	O
lc-ms	B-C0872318
,	O
fibroblast	B-C0016026
growth	I-C0016026
factor	I-C0016026
fgf23	B-C0016026
and	O
parathyroid	B-C0030520
hormone	I-C0030520
pth	B-C0030520
by	O
enzyme-linked	B-C0086231
immunoassay	I-C0086231
,	O
and	O
calcium	B-C0006675
and	O
phosphorus	B-C0031705
by	O
roche	B-C0022885
cobas	I-C0022885
6000	I-C0022885
.	O
	
free	B-C1996904
and	O
bioavailable	B-C0935763
25	B-C0535968
were	O
calculated	B-C1441506
.	O
	
we	O
calculated	B-C1441506
the	O
within-person	B-C0681921
cv	I-C0681921
cvw	B-C0681921
,	O
intraclass	B-C1707429
correlation	I-C1707429
coefficient	I-C1707429
icc	B-C1707429
,	O
spearman	B-C0242929
rank	I-C0242929
correlation	I-C0242929
coefficient	I-C0242929
r	B-C0242929
,	O
and	O
percent	B-C0439165
reclassified	B-C0205542
.	O
	
the	O
cvw	B-C0681921
was	O
lowest	B-C1708760
for	O
calcium	B-C0006675
2.0	O
,	O
albumin	B-C0001924
3.6	O
,	O
25	B-C0535968
6.9	O
,	O
vdbp	B-C0042872
7.0	O
and	O
phosphorus	B-C0031705
7.6	O
intermediate	B-C1550465
for	O
free	B-C1996904
25	B-C0535968
9.0	O
and	O
bioavailable	B-C0935763
25	B-C0535968
9.9	O
and	O
highest	B-C1522410
for	O
pth	B-C0030520
16.7	O
and	O
fgf23	B-C0016026
17.8	O
.	O
	
reclassification	B-C0008902
was	O
highest	B-C1522410
for	O
pth	B-C0030520
,	O
vdbp	B-C0042872
,	O
and	O
phosphorus	B-C0031705
all	O
7.5	O
.	O
	
the	O
icc	B-C1707429
and	O
r	B-C0242929
were	O
highest	B-C1522410
0.80	O
for	O
25	B-C0535968
,	O
free	B-C1996904
25	B-C0535968
,	O
bioavailable	B-C0935763
25	B-C0535968
and	O
pth	B-C0030520
,	O
but	O
somewhat	O
lower	B-C0205251
approximately	B-C0332232
0.60	O
for	O
the	O
other	O
biomarkers	B-C0005516
.	O
	
six-	O
week	B-C0439230
short-term	B-C2827666
variability	I-C2827666
,	O
as	O
assessed	B-C1516048
by	O
cvw	B-C0681921
,	O
was	O
quite	B-C0205251
low	I-C0205251
for	O
vdbp	B-C0042872
,	O
calcium	B-C0006675
and	O
phosphorus	B-C0031705
,	O
but	O
fairly	B-C0205250
high	I-C0205250
for	O
fgf23	B-C0016026
and	O
pth	B-C0030520
.	O
	
as	O
such	O
,	O
multiple	B-C0242485
measurements	I-C0242485
of	O
fgf23	B-C0016026
and	O
pth	B-C0030520
may	O
be	O
needed	O
to	O
minimize	B-C1524031
misclassification	B-C0008902
.	O
	
these	O
results	B-C1274040
provide	O
insight	B-C0233820
into	O
the	O
extent	O
of	O
potential	B-C3245505
misclassification	B-C0008902
of	O
vitamin	B-C0042866
d	I-C0042866
markers	B-C0005516
in	O
research	B-C0035168
and	O
clinical	B-C4086198
settings	I-C4086198
.	O
	
fabrication	B-C1522240
of	O
gelatin	B-C0029224
methacrylate	I-C0029224
/	O
nanohydroxyapatite	B-C0020326
microgel	B-C0017243
arrays	B-C1510941
for	O
periodontal	B-C1448477
tissue	I-C1448477
regeneration	I-C1448477
periodontitis	B-C0031099
is	O
a	O
chronic	B-C0151317
infectious	I-C0151317
disease	I-C0151317
and	O
is	O
the	O
major	B-C1333617
cause	I-C1333617
of	O
tooth	B-C0080233
loss	I-C0080233
and	O
other	O
oral	B-C0029162
health	I-C0029162
issues	B-C0033213
around	O
the	O
world	B-C2700280
.	O
	
periodontal	B-C1448477
tissue	I-C1448477
regeneration	I-C1448477
has	O
therefore	O
always	O
been	O
the	O
ultimate	B-C0018017
goal	I-C0018017
of	O
dentists	B-C0011441
and	O
researchers	B-C0035173
.	O
	
existing	O
fabrication	B-C1522240
methods	B-C0025663
mainly	O
focused	B-C1285542
on	O
a	O
top-down	B-C0596171
tissue	I-C0596171
engineering	I-C0596171
strategy	B-C0679199
in	O
which	O
several	O
drawbacks	B-C0205556
remain	B-C0243095
,	O
including	O
low	B-C0205556
throughput	I-C0205556
and	O
limited	O
diffusion	B-C0012222
properties	B-C0871161
resulting	B-C0332294
from	O
a	O
large	B-C0242618
sample	I-C0242618
size	I-C0242618
.	O
	
gelatin	B-C0029224
methacrylate	I-C0029224
gelma	B-C0029224
is	O
a	O
kind	O
of	O
photocrosslinkable	B-C0178576
and	O
biocompatible	B-C0005479
hydrogel	B-C0063083
,	O
with	O
the	O
capacities	B-C1516240
of	O
enabling	B-C1171285
cell	B-C3831155
encapsulation	I-C3831155
and	O
regeneration	B-C1623047
of	I-C1623047
functional	I-C1623047
tissues	I-C1623047
.	O
	
here	O
,	O
we	O
developed	O
a	O
novel	B-C0205314
method	B-C0449851
to	O
fabricate	B-C1522240
gelma	B-C0029224
/	O
nanohydroxylapatite	B-C0020326
nha	B-C0020326
microgel	B-C0017243
arrays	B-C1510941
using	O
a	O
photocrosslinkable	B-C0178576
strategy	B-C0679199
.	O
	
the	O
viability	B-C0007620
,	O
proliferation	B-C0596290
,	O
and	O
osteogenic	B-C1159974
differentiation	I-C1159974
and	O
in	B-C1515655
vivo	I-C1515655
osteogenesis	B-C0029433
of	O
human	B-C0086418
periodontal	B-C0031093
ligament	I-C0031093
stem	B-C0038250
cells	I-C0038250
hpdlscs	B-C0038250
encapsulated	B-C0205223
in	O
microgels	B-C0017243
were	O
evaluated	B-C0220825
.	O
	
the	O
results	B-C1274040
suggested	B-C1705535
that	O
such	O
microgels	B-C0017243
provide	B-C1999230
great	O
potential	B-C3245505
for	O
periodontal	B-C1448477
tissue	I-C1448477
repair	I-C1448477
and	I-C1448477
regeneration	I-C1448477
.	O
	
microgel	B-C0017243
arrays	B-C1510941
were	O
fabricated	B-C1522240
by	O
blending	B-C0678946
different	B-C1705242
weight	B-C2919747
ratios	I-C2919747
of	O
gelma	B-C0029224
and	O
nha	B-C0020326
.	O
	
hpdlscs	B-C0038250
were	O
encapsulated	B-C0205223
in	O
gelma	B-C0029224
/	O
nha	B-C0020326
microgels	B-C0017243
of	O
various	O
ratios	B-C0456603
for	O
a	O
systematic	B-C0220922
evaluation	B-C0220825
of	O
cell	B-C0007620
viability	I-C0007620
,	O
proliferation	B-C0596290
,	O
and	O
osteogenic	B-C1159974
differentiation	I-C1159974
.	O
	
in	B-C1515655
vivo	I-C1515655
osteogenesis	B-C0029433
in	O
nude	B-C0025932
mice	I-C0025932
was	O
also	O
studied	O
.	O
	
the	O
gelma	B-C0029224
/	O
nha	B-C0020326
microgels	B-C0017243
exhibited	O
appropriate	B-C1548787
microarchitecture	B-C0205556
,	O
mechanical	B-C0808080
strength	I-C0808080
,	O
and	O
surface	B-C0205148
roughness	B-C0205556
,	O
thus	O
enabling	O
cell	B-C0007577
adhesion	I-C0007577
and	O
proliferation	B-C0596290
.	O
	
additionally	O
,	O
the	O
gelma	B-C0029224
/	O
nha	B-C0020326
microgels	B-C0017243
10%/2%	O
w/v	O
enhanced	B-C2349975
the	O
osteogenic	B-C1159974
differentiation	I-C1159974
of	O
hpdlscs	B-C0038250
by	O
elevating	B-C3163633
the	O
expression	B-C3244092
levels	I-C3244092
of	O
osteogenic	B-C0005516
biomarker	I-C0005516
genes	B-C0017337
,	O
such	O
as	O
alp	B-C0017337
,	O
bsp	B-C1415840
,	O
ocn	B-C1412791
,	O
and	O
runx2	B-C1419771
.	O
	
in	B-C1515655
vivo	I-C1515655
ectopic	B-C0574895
transplantation	B-C0040732
results	B-C1274040
showed	O
that	O
gelma	B-C0029224
/	O
nha	B-C0020326
microgels	B-C0017243
10%/2%	O
w/v	O
increased	B-C0205217
mineralized	B-C0040300
tissue	I-C0040300
formation	B-C1522492
with	O
abundant	B-C2346714
vascularization	B-C0042382
,	O
compared	B-C1707455
with	O
the	O
1%	O
,	O
3%	O
,	O
and	O
the	O
pure	O
gelma	B-C0029224
group	I-C0029224
.	O
	
the	O
gelma	B-C0029224
/	O
nha	B-C0020326
microgels	B-C0017243
10%/2%	O
w/v	O
facilitated	O
hpdlscs	B-C0038250
viability	B-C0007620
,	O
proliferation	B-C0596290
,	O
and	O
osteogenic	B-C1159974
differentiation	I-C1159974
in	B-C1533691
vitro	I-C1533691
and	O
further	B-C1517331
promoted	B-C0033414
new	B-C0205314
bone	B-C0029433
formation	I-C0029433
in	B-C1515655
vivo	I-C1515655
,	O
suggesting	O
that	O
the	O
gelma	B-C0029224
/	O
nha	B-C0020326
microgels	B-C0017243
10%/2%	O
w/v	O
provide	B-C1999230
great	O
potential	B-C3245505
for	O
periodontal	B-C1448477
tissue	I-C1448477
regeneration	I-C1448477
.	O
	
esomeprazole	B-C0937846
-	O
or	O
rabeprazole	B-C0378482
-based	O
triple	B-C0205174
therapy	B-C0087111
eradicated	O
helicobacter	B-C0079488
pylori	I-C0079488
comparably	O
regardless	B-C3641650
of	O
clarithromycin	B-C0055856
susceptibility	B-C1264642
and	O
cyp2c19	B-C1332828
genotypes	B-C0017431
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
assess	B-C1516048
the	O
efficacy	B-C1280519
of	O
esomeprazole	B-C0937846
-based	O
triple	B-C0205174
therapy	B-C0087111
compared	B-C1707455
with	O
rabeprazole	B-C0378482
-based	O
triple	B-C0205174
therapy	B-C0087111
according	O
to	O
cyp2c19	B-C1332828
genotype	B-C0017431
and	O
clarithromycin	B-C0055856
susceptibility	B-C1264642
status	B-C0449438
for	O
first-line	O
eradication	B-C0559761
therapy	I-C0559761
of	I-C0559761
helicobacter	I-C0559761
pylori	I-C0559761
h	B-C0079488
.	O
	
pylori	I-C0079488
in	O
japan	B-C0022341
.	O
	
we	O
enrolled	O
219	O
h	B-C0079488
.	O
	
pylori	I-C0079488
-	O
infected	B-C0030705
patients	I-C0030705
,	O
and	O
randomly	B-C0439605
allocated	B-C1706778
patients	B-C0030705
to	O
the	O
eac	B-C0030705
group	I-C0030705
esomeprazole	B-C0937846
20	O
mg	O
,	O
clarithromycin	B-C0055856
200	O
mg	O
,	O
amoxicillin	B-C0002645
750	O
mg	O
for	O
one	O
week	B-C0439230
,	O
with	O
all	O
drugs	B-C0013227
given	B-C1947971
twice	B-C0585361
daily	I-C0585361
or	O
rac	B-C0030705
group	I-C0030705
rabeprazole	B-C0378482
10	O
mg	O
,	O
clarithromycin	B-C0055856
200	O
mg	O
,	O
amoxicillin	B-C0002645
750	O
mg	O
for	O
one	O
week	B-C0439230
,	O
with	O
all	O
drugs	B-C0013227
given	B-C1947971
twice	B-C0585361
daily	I-C0585361
.	O
	
the	O
h	B-C0079488
.	O
	
pylori	I-C0079488
eradication	B-C1521828
rate	I-C1521828
according	O
to	O
the	O
pp	B-C0936012
analyses	I-C0936012
was	O
75.0	O
95%	O
ci	B-C0009667
65.2	O
in	O
the	O
eac	B-C0030705
group	I-C0030705
and	O
71.4	O
95%	O
ci	B-C0009667
61.4	O
in	O
the	O
rac	B-C0030705
group	I-C0030705
.	O
	
there	O
were	O
no	O
statistically	O
significant	O
differences	B-C1705242
.	O
	
the	O
eradication	B-C1521828
rates	I-C1521828
of	O
the	O
clarithromycin	B-C0055856
-resistant	O
/-	O
sensitive	O
strains	O
were	O
,	O
respectively	O
,	O
45.0	O
95%	O
ci	O
30.7	O
95%	O
ci	O
88.7	O
in	O
the	O
eac	O
group	O
and	O
39.5	O
95%	O
ci	O
25.6	O
95%	O
ci	O
81.9	O
in	O
the	O
rac	O
group	O
.	O
	
the	O
eradication	O
rate	O
of	O
the	O
clarithromycin	B-C0860039
-	O
sensitive	O
strains	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
resistant	O
strains	O
in	O
both	O
groups	O
.	O
	
in	O
conclusion	O
,	O
eac	O
and	O
rac	O
therapies	O
show	O
a	O
comparable	O
efficacy	O
regardless	O
of	O
the	O
cyp2c19	O
genotype	O
and	O
clarithromycin	O
susceptibility	O
status	O
in	O
japan	B-C0022341
optimization	O
of	O
early	B-C1279919
response	B-C1822578
monitoring	I-C1822578
and	O
prediction	O
of	O
cancer	B-C0006826
antiangiogenesis	B-C0281318
therapy	I-C0281318
via	O
noninvasive	B-C2986496
pet	B-C0032743
molecular	I-C0032743
imaging	I-C0032743
strategies	O
of	O
multifactorial	B-C1837655
bioparameters	B-C0549193
objective	O
antiangiogenesis	B-C0281318
therapy	I-C0281318
aat	B-C0281318
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	B-C0038952
for	O
suitable	O
patients	B-C0030705
in	O
clinical	B-C3176918
settings	I-C3176918
.	O
	
therefore	O
,	O
the	O
early	B-C1279919
definition	O
of	O
therapeutic	B-C1527144
effects	I-C1527144
is	O
urgently	O
needed	O
to	O
guide	O
cancer	B-C0006826
aat	B-C0281318
.	O
	
we	O
aimed	O
to	O
optimize	O
the	O
early	B-C1279919
response	B-C1822578
monitoring	I-C1822578
and	O
prediction	O
of	O
aat	B-C0281318
efficacy	B-C2348767
,	O
as	O
indicated	O
by	O
the	O
multi-targeted	O
anti-angiogenic	B-C0596087
drug	I-C0596087
sunitinib	B-C1176020
in	O
u87mg	B-C0027651
tumors	I-C0027651
,	O
using	O
noninvasive	B-C2986496
positron	B-C1699633
emission	I-C1699633
computed	I-C1699633
tomography	I-C1699633
pet	I-C1699633
molecular	I-C1699633
imaging	I-C1699633
strategies	O
of	O
multifactorial	B-C1837655
bioparameters	B-C0549193
.	O
	
methods	O
u87mg	B-C0027651
tumor	I-C0027651
mice	B-C0025929
were	O
treated	O
via	O
intragastric	B-C0442113
injections	B-C0021485
of	O
sunitinib	B-C1176020
80	O
mg/kg	O
or	O
vehicle	B-C0042444
for	O
7	O
consecutive	O
days	O
.	O
	
longitudinal	B-C0205127
micropet/ct	B-C1699633
scans	I-C1699633
with	O
18	B-C0046056
,	O
18	B-C3661419
,	O
18	B-C2700345
and	O
18	B-C3852643
ii	I-C3852643
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	B-C0025519
,	O
hypoxia	B-C0242184
,	O
apoptosis	B-C0162638
and	O
angiogenesis	B-C1519670
on	O
days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
and	O
13	O
following	O
therapy	B-C0087111
initiation	O
.	O
	
tumor	B-C0475358
tissues	I-C0475358
from	O
a	O
dedicated	O
group	O
of	O
mice	B-C0025929
were	O
collected	O
for	O
immunohistochemical	B-C1441616
ihc	B-C1441616
analysis	O
of	O
key	O
biomarkers	B-C0041365
glut-1	B-C1527589
,	O
ca-ix	B-C2351139
,	O
tunel	B-C0872284
,	O
ανβ3	B-C1138427
and	O
cd31	B-C0081939
at	O
the	O
time	O
points	O
of	O
pet	B-C1699633
imaging	I-C1699633
.	O
	
the	O
tumor	B-C0475440
sizes	I-C0475440
and	O
mouse	B-C0025929
weights	B-C0005910
were	O
measured	O
throughout	O
the	O
study	O
.	O
	
the	O
tumor	B-C0027651
uptake	B-C0243144
id%/gmax	O
,	O
the	O
ratios	O
of	O
the	O
tumor	B-C0027651
/	O
muscle	B-C0026845
t	B-C0027651
/	O
m	B-C0026845
for	O
each	O
probe	O
,	O
and	O
the	O
tumor	B-C0598934
growth	I-C0598934
ratios	B-C0456603
tgr	B-C0456603
were	O
calculated	O
and	O
used	O
for	O
statistical	B-C0871424
analyses	I-C0871424
of	O
the	O
differences	O
and	O
correlations	O
.	O
	
results	O
sunitinib	B-C1176020
successfully	O
inhibited	O
u87mg	B-C0598934
tumor	I-C0598934
growth	I-C0598934
with	O
significant	O
differences	O
in	O
the	O
tumor	B-C0475440
size	I-C0475440
from	O
day	O
9	O
after	O
sunitinib	B-C1176020
treatment	B-C1533734
compared	O
with	O
the	O
control	B-C0009932
group	I-C0009932
p	O
<	O
0.01	O
.	O
	
the	O
uptakes	B-C0243144
of	O
18	B-C3661419
reduced	O
hypoxia	B-C0242184
,	O
18	B-C2700345
increased	O
apoptosis	B-C0162638
and	O
18	B-C3852643
ii	I-C3852643
decreased	O
angiogenesis	B-C1519670
in	O
the	O
tumor	B-C0027651
lesions	B-C0221198
significantly	O
changed	O
during	O
the	O
early	B-C1279919
stage	O
days	O
1	O
to	O
3	O
of	O
sunitinib	O
treatment	O
however	O
,	O
the	O
uptake	O
of	O
18	O
increased	O
glucose	O
metabolism	O
was	O
significantly	O
different	O
during	O
the	O
late	O
stage	O
.	O
	
the	O
pet	O
imaging	O
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex	O
vivo	O
ihc	O
of	O
the	O
relevant	O
biomarkers	O
.	O
	
notably	O
,	O
the	O
pet	O
imaging	O
of	O
18	O
ii	O
and	O
18	O
was	O
significantly	O
correlated	O
all	O
p	O
<	O
0.05	O
with	O
tgr	O
,	O
whereas	O
the	O
imaging	O
of	O
18	O
and	O
18	O
was	O
not	O
significantly	O
correlated	O
with	O
tgr	O
.	O
	
conclusion	O
based	O
on	O
the	O
tumor	O
uptake	O
of	O
the	O
pet	O
probes	O
and	O
their	O
correlations	O
with	O
mvd	O
and	O
tgr	O
,	O
18	O
ii	O
pet	O
may	O
not	O
only	O
monitor	O
the	O
early	B-C2363430
response	O
but	O
also	O
precisely	O
predict	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
multi-targeted	O
,	O
anti-angiogenic	O
drug	O
sunitinib	O
in	O
u87mg	O
tumors	O
.	O
	
in	O
conclusion	O
,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	O
response	O
monitoring	O
and	O
efficacy	O
prediction	O
of	O
cancer	O
aat	O
using	O
noninvasive	O
pet	O
molecular	O
imaging	O
strategies	O
of	O
multifactorial	O
bioparameters	O
,	O
such	O
as	O
angiogenesis	O
imaging	O
with	O
18	O
ii	O
,	O
which	O
represents	O
an	O
rgd	O
-based	O
identifying	O
research	B-C0376368
priorities	I-C0376368
with	O
nurses	B-C0028661
at	O
a	O
tertiary	O
children's	B-C0008059
hospital	B-C0019994
in	O
the	O
united	B-C0041700
kingdom	I-C0041700
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
undertake	O
a	O
research	B-C0376368
priority	I-C0376368
setting	O
exercise	O
with	O
the	O
aim	O
of	O
maximizing	O
efficiency	B-C0013682
and	O
impact	B-C4049986
in	O
research	B-C0079816
activity	I-C0079816
undertaken	O
by	O
nurses	B-C0028661
at	O
one	O
children's	B-C0008059
tertiary	O
healthcare	B-C1274109
institution	I-C1274109
by	O
ensuring	O
the	O
clinical	B-C0025106
staff	I-C0025106
directly	O
shaped	O
a	O
coherent	B-C4068804
,	O
transparent	B-C0205556
and	O
consensus	B-C0376298
driven	O
nurse-led	B-C0681798
research	I-C0681798
agenda	I-C0681798
.	O
	
in	O
round	O
1	O
,	O
the	O
research	B-C0681795
topics	I-C0681795
of	O
147	O
nurses	B-C0028661
were	O
elicited	O
using	O
a	O
modified	B-C0035177
nominal	I-C0035177
group	I-C0035177
technique	I-C0035177
as	O
the	O
consensus	B-C0025663
method	I-C0025663
.	O
	
the	O
number	O
of	O
participants	B-C0679646
in	O
the	O
24	O
separate	O
discussions	O
ranged	O
from	O
3	O
to	O
21	O
,	O
generating	O
lists	O
of	O
between	O
6	O
and	O
23	O
topics	O
.	O
	
in	O
round	O
2	O
,	O
nurses	B-C0028661
from	O
the	O
clinical	B-C1547541
areas	I-C1547541
ranked	B-C0699794
topics	O
of	O
importance	O
resulting	O
in	O
a	O
set	O
of	O
four	O
to	O
five	O
priorities	B-C0376368
.	O
	
in	O
round	O
3	O
,	O
the	O
divisional	B-C0018676
heads	I-C0018676
of	O
nursing	B-C0028677
consulted	O
with	O
staff	B-C0025106
in	O
all	O
of	O
their	O
clinical	B-C1547541
areas	I-C1547541
to	O
each	O
finalize	O
their	O
five	O
divisional	B-C0376368
priorities	I-C0376368
.	O
	
the	O
nursing	B-C0027363
research	I-C0027363
working	I-C0027363
group	I-C0027363
discussed	O
and	O
refined	O
the	O
divisions'	B-C0376368
priorities	I-C0376368
and	O
voted	B-C0042978
on	O
the	O
final	O
list	O
to	O
agree	O
the	O
top	O
five	O
research	B-C0376368
priorities	I-C0376368
for	O
the	O
organization	B-C1274109
.	O
	
a	O
total	O
of	O
269	O
research	B-C0681795
topics	I-C0681795
were	O
initially	O
generated	O
.	O
	
following	O
three	O
rounds	O
of	O
ranking	B-C0699794
and	O
prioritizing	O
,	O
five	O
priorities	B-C0376368
were	O
agreed	O
at	O
divisional	B-C2919030
level	I-C2919030
,	O
and	O
from	O
these	O
,	O
the	O
five	O
top	O
organizational	B-C0376368
priorities	I-C0376368
were	O
selected	O
.	O
	
these	O
were	O
i	O
understanding	O
and	O
improving	O
all	O
aspects	O
of	O
the	O
patient	B-C0030705
journey	O
through	O
the	O
hospital	B-C0019994
system	I-C0019994
ii	O
play	B-C0032214
iii	O
staff	B-C0018684
wellbeing	I-C0018684
,	O
patient	B-C0017313
care	I-C0017313
and	O
productivity	B-C0033269
iv	O
team	B-C0043227
work	I-C0043227
-	O
linking	O
to	O
a	O
more	O
efficient	O
service	B-C0557854
and	O
v	O
supporting	B-C0030551
parents	I-C0030551
/	O
parent	B-C0030551
pathway	O
.	O
	
divisional	O
priorities	B-C0376368
have	O
been	O
disseminated	O
widely	O
to	O
clinical	B-C0086390
teams	I-C0086390
to	O
inform	O
a	O
patient-specific	B-C0681798
nurse-led	I-C0681798
research	I-C0681798
agenda	I-C0681798
.	O
	
organizational	B-C0376368
priorities	I-C0376368
agreed	O
upon	O
have	O
been	O
disseminated	O
through	O
management	B-C3273539
structures	I-C3273539
and	O
processes	O
to	O
ensure	O
engagement	O
at	O
all	O
levels	O
.	O
	
a	O
subgroup	B-C0027363
of	O
the	O
nursing	B-C0027363
research	I-C0027363
working	I-C0027363
group	I-C0027363
has	O
been	O
delegated	O
to	O
take	O
this	O
work	O
forward	O
so	O
that	O
the	O
agreed	O
priorities	B-C0376368
continue	O
to	O
contribute	O
towards	O
shaping	O
nurse-led	B-C0079816
research	I-C0079816
activity	I-C0079816
,	O
thereby	O
going	O
some	O
way	O
to	O
inform	O
and	O
embed	O
an	O
evidence-based	O
culture	O
of	O
accurate	B-C0443131
lungs	B-C0024109
segmentation	B-C0700381
on	O
ct	B-C0040405
chest	B-C0817096
images	B-C1704254
by	O
adaptive	B-C0870071
appearance-guided	I-C0870071
shape	I-C0870071
modeling	I-C0870071
to	O
accurately	B-C0443131
segment	B-C0700381
pathological	B-C1521733
and	O
healthy	B-C3898900
lungs	B-C0024109
for	O
reliable	B-C0205423
computer-aided	B-C0011905
disease	I-C0011905
diagnostics	I-C0011905
,	O
a	O
stack	B-C3272897
of	O
chest	B-C0817096
ct	B-C0040405
scans	B-C0441633
is	O
modeled	B-C0870071
as	O
a	O
sample	O
of	O
a	O
spatially	B-C1254362
inhomogeneous	I-C1254362
joint	B-C0205556
3d	I-C0205556
markov-gibbs	I-C0205556
random	I-C0205556
field	I-C0205556
mgrf	B-C0205556
of	O
voxel-wise	B-C2700259
lung	B-C0024109
and	O
chest	B-C0817096
ct	B-C0040405
image	B-C1704254
signals	B-C1710082
intensities	B-C0871362
.	O
	
the	O
proposed	B-C1553874
learnable	O
mgrf	B-C0205556
integrates	B-C1705422
two	O
visual	B-C0234621
appearance	B-C0700364
sub-models	B-C0026336
with	O
an	O
adaptive	O
lung	B-C0024109
shape	O
submodel	B-C0026336
.	O
	
the	O
first-order	O
appearance	B-C0700364
submodel	B-C0026336
accounts	O
for	O
both	O
the	O
original	B-C0205313
ct	B-C0040405
image	B-C1704254
and	O
its	O
gaussian	B-C0205556
scale	I-C0205556
space	I-C0205556
gss	I-C0205556
filtered	I-C0205556
version	I-C0205556
to	O
specify	O
local	O
and	O
global	O
signal	B-C1710082
properties	O
,	O
respectively	O
.	O
	
each	O
empirical	B-C1880496
marginal	B-C1947914
probability	B-C3826440
distribution	I-C3826440
of	O
signals	B-C1710082
is	O
closely	O
approximated	O
with	O
a	O
linear	B-C0205556
combination	I-C0205556
of	I-C0205556
discrete	I-C0205556
gaussians	I-C0205556
lcdg	B-C0205556
,	O
containing	O
two	O
positive	B-C0205556
dominant	I-C0205556
and	I-C0205556
multiple	I-C0205556
sign-alternate	I-C0205556
subordinate	I-C0205556
dgs	I-C0205556
.	O
	
the	O
approximation	O
is	O
separated	O
into	O
two	O
lcdgs	B-C0205556
to	O
describe	O
individually	O
the	O
lungs	B-C0024109
and	O
their	O
background	O
,	O
i.e	O
,	O
all	O
other	O
chest	B-C0817096
tissues	B-C0040300
.	O
	
the	O
second-order	O
appearance	B-C0700364
submodel	B-C0026336
quantifies	B-C1709793
conditional	B-C1701901
pairwise	B-C0392762
intensity	B-C0871362
dependencies	B-C3669743
in	O
the	O
nearest	O
voxel	O
26-neighborhood	O
in	O
both	O
the	O
original	B-C0205313
and	O
gss-filtered	B-C0205556
images	B-C1704254
.	O
	
the	O
shape	O
submodel	B-C0026336
is	O
built	O
for	O
a	O
set	O
of	O
training	B-C1511726
data	I-C1511726
and	O
is	O
adapted	O
during	O
segmentation	B-C0700381
using	O
both	O
the	O
lung	B-C0024109
and	O
chest	B-C0817096
appearances	B-C0700364
.	O
	
the	O
accuracy	B-C0443131
of	O
the	O
proposed	B-C1553874
segmentation	B-C0700381
framework	O
is	O
quantitatively	B-C0392762
assessed	B-C1516048
using	O
two	O
public	O
databases	B-C0242356
isbi	B-C0242356
vessel12	I-C0242356
challenge	I-C0242356
and	O
miccai	B-C0242356
lola11	I-C0242356
challenge	I-C0242356
and	O
our	O
own	O
database	B-C0242356
with	O
,	O
respectively	O
,	O
20	O
,	O
55	O
,	O
and	O
30	O
ct	B-C0040405
images	B-C1704254
of	O
various	O
lung	B-C0024109
pathologies	B-C0205469
acquired	O
with	O
different	O
scanners	B-C0183115
and	O
protocols	B-C0040808
.	O
	
quantitative	B-C0392762
assessment	B-C1516048
of	O
our	O
framework	O
in	O
terms	O
of	O
dice	B-C0392762
similarity	I-C0392762
coefficients	I-C0392762
,	O
95-percentile	B-C0392762
bidirectional	I-C0392762
hausdorff	I-C0392762
distances	I-C0392762
,	O
and	O
percentage	B-C0392762
volume	I-C0392762
differences	I-C0392762
confirms	O
the	O
high	O
accuracy	B-C0443131
of	O
our	O
model	B-C0026336
on	O
both	O
our	O
database	B-C0242356
98.4	O
,	O
2.2	O
mm	O
,	O
0.42	O
and	O
the	O
vessel12	B-C0242356
database	I-C0242356
99.0	O
,	O
2.1	O
mm	O
,	O
0.39	O
,	O
respectively	O
.	O
	
similarly	O
,	O
the	O
accuracy	B-C0443131
of	O
our	O
approach	O
is	O
further	O
verified	O
via	O
a	O
blind	O
evaluation	O
by	O
the	O
organizers	O
of	O
the	O
lola11	O
competition	O
,	O
where	O
an	O
average	O
overlap	O
of	O
98.0	O
with	O
the	O
expert's	O
segmentation	O
is	O
yielded	O
on	O
all	O
55	O
subjects	O
with	O
our	O
framework	O
being	O
ranked	O
first	O
among	O
all	O
the	O
state-of-the-art	O
techniques	O
compared	B-C1707455
influence	B-C4054723
of	O
different	B-C1705242
levels	B-C1306673
of	O
lipoic	B-C1424272
acid	I-C1424272
synthase	I-C1424272
gene	B-C0017262
expression	I-C0017262
on	O
diabetic	B-C0011881
nephropathy	I-C0011881
oxidative	B-C0242606
stress	I-C0242606
is	O
implicated	O
in	O
the	O
pathogenesis	B-C0699748
of	O
diabetic	B-C0011881
nephropathy	I-C0011881
dn	B-C0011881
but	O
outcomes	B-C1274040
of	O
many	O
clinical	B-C0008976
trials	I-C0008976
are	O
controversial	O
.	O
	
to	O
define	O
the	O
role	B-C1705810
of	O
antioxidants	B-C0003402
in	O
kidney	B-C0022646
protection	O
during	B-C0347984
the	O
development	B-C1527148
of	O
diabetic	B-C0011881
nephropathy	I-C0011881
,	O
we	O
have	O
generated	B-C3146294
a	O
novel	B-C0205314
genetic	B-C2986594
antioxidant	I-C2986594
mouse	I-C2986594
model	I-C2986594
with	O
over-	B-C0017262
or	I-C0017262
under-expression	I-C0017262
of	O
lipoic	B-C1424272
acid	I-C1424272
synthase	I-C1424272
gene	I-C1424272
lias	B-C1424272
.	O
	
these	O
models	B-C2986594
have	O
been	O
mated	B-C1260875
with	O
ins2akita/+	B-C0025929
mice	I-C0025929
,	O
a	O
type	B-C0836995
i	I-C0836995
diabetic	I-C0836995
mouse	B-C2986594
model	I-C2986594
.	O
	
we	O
compare	B-C1707455
the	O
major	B-C0205164
pathologic	B-C4086730
changes	I-C4086730
and	O
oxidative	B-C0242606
stress	I-C0242606
status	B-C0449438
in	O
two	O
new	O
strains	O
of	O
the	O
mice	B-C0025929
with	O
controls	O
.	O
	
our	O
results	B-C1274040
show	O
that	O
ins2akita/+	B-C0025929
mice	I-C0025929
with	O
under-expressed	B-C0017262
lias	B-C1424272
gene	I-C1424272
,	O
exhibit	O
higher	B-C0205250
oxidative	B-C0242606
stress	I-C0242606
and	O
more	B-C0205172
severe	B-C0205082
dn	B-C0011881
features	B-C2348519
albuminuria	B-C0001925
,	O
glomerular	B-C0445347
basement	I-C0445347
membrane	I-C0445347
thickening	I-C0445347
and	O
mesangial	B-C3553722
matrix	I-C3553722
expansion	I-C3553722
.	O
	
in	O
contrast	O
,	O
ins2akita/+	B-C0025929
mice	I-C0025929
with	O
highly	B-C0205250
-	O
expressed	B-C0017262
lias	B-C1424272
gene	I-C1424272
display	B-C0870432
lower	B-C0205251
oxidative	B-C0242606
stress	I-C0242606
and	O
less	B-C0547044
dn	B-C0011881
pathologic	B-C4086730
changes	I-C4086730
.	O
	
our	O
study	B-C2603343
demonstrates	B-C3687625
that	O
strengthening	O
endogenous	B-C0205227
antioxidant	B-C0003402
capacity	B-C1516240
could	O
be	O
an	O
effective	B-C0679723
strategy	I-C0679723
for	I-C0679723
prevention	I-C0679723
and	O
treatment	B-C1522326
of	O
assessment	B-C1516048
of	O
genetic	B-C0314603
relationship	B-C0439849
among	O
rhododendron	B-C0330429
cultivars	B-C1883525
using	O
amplified	B-C1955927
fragment	I-C1955927
length	I-C1955927
polymorphism	I-C1955927
and	O
inter-simple	B-C0684192
sequence	I-C0684192
repeat	I-C0684192
markers	B-C0012872
genetic	B-C0314603
relationships	B-C0439849
of	O
17	O
rhododendron	B-C0330429
cultivars	B-C1883525
,	O
china	B-C0008115
,	O
were	O
assessed	B-C1516048
using	O
inter-simple	B-C0684192
sequence	I-C0684192
repeat	I-C0684192
issr	B-C0684192
and	O
amplified	B-C1955927
fragment	I-C1955927
length	I-C1955927
polymorphism	I-C1955927
aflp	B-C1955927
markers	B-C0012872
.	O
	
a	O
total	O
of	O
133	O
bands	O
were	O
obtained	O
using	O
nine	O
selected	O
issr	B-C0684192
primers	B-C0206416
,	O
129	O
96.99	O
of	O
which	O
were	O
polymorphic	B-C1882417
267	O
bands	O
were	O
amplified	O
by	O
four	O
aflp	B-C1955927
primer	B-C0206416
pairs	I-C0206416
,	O
251	O
94.01	O
of	O
which	O
exhibited	O
polymorphism	B-C1882417
.	O
	
based	O
on	O
these	O
polymorphic	B-C1882417
products	B-C1514468
,	O
a	O
cluster	B-C0009085
analysis	I-C0009085
revealed	O
similarities	B-C2348205
between	O
the	O
results	B-C1274040
of	O
the	O
issr	B-C0684192
and	O
aflp	B-C1955927
.	O
	
all	O
of	O
the	O
cultivars	B-C1883525
were	O
clustered	B-C0332227
into	O
two	O
major	O
branches	B-C1254370
one	O
branch	B-C1254370
contained	O
the	O
same	O
four	O
cultivars	B-C1883525
,	O
and	O
the	O
other	O
cultivars	B-C1883525
were	O
separated	O
into	O
different	O
groups	B-C0441833
in	O
the	O
other	O
branch	B-C1254370
.	O
	
the	O
cluster	B-C1704332
results	B-C1274040
showed	O
that	O
the	O
genetic	B-C0314603
relationships	B-C0439849
of	O
the	O
17	O
cultivars	B-C1883525
were	O
partly	O
related	B-C0439849
to	O
their	O
morphological	B-C0543482
characteristics	B-C1521970
,	O
particularly	O
the	O
flowering	B-C1820370
phase	B-C0205390
.	O
	
therefore	O
,	O
the	O
results	B-C1274040
of	O
this	O
study	B-C2603343
support	O
the	O
classification	B-C0008902
of	O
rhododendron	B-C0330429
cultivars	B-C1883525
according	O
to	O
flowering	B-C1820370
phase	B-C0205390
.	O
	
in	O
addition	O
,	O
the	O
cluster	B-C1704332
results	B-C1274040
can	O
be	O
used	O
to	O
select	B-C1707391
suitable	O
parents	O
for	O
spontaneous	B-C0443158
activity	I-C0443158
is	O
correlated	B-C1707520
with	O
coding	B-C2700640
density	B-C0178587
in	O
primary	B-C2954070
auditory	I-C2954070
cortex	I-C2954070
sensory	B-C0027883
neurons	I-C0027883
across	O
sensory	B-C0234402
modalities	I-C0234402
and	O
specific	O
processing	B-C1709694
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous	B-C1254359
firing	I-C1254359
rates	I-C1254359
sfrs	B-C1254359
in	O
the	O
absence	O
of	O
sensory	B-C0683107
stimuli	I-C0683107
.	O
	
however	O
,	O
the	O
functional	B-C0205245
significance	B-C0750502
of	O
this	O
spontaneous	B-C0443158
activity	I-C0443158
is	O
not	O
well-understood	O
.	O
	
previous	O
studies	B-C2603343
in	O
the	O
auditory	B-C0587901
system	I-C0587901
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous	B-C0443158
activity	I-C0443158
are	O
correlated	B-C1707520
with	O
a	O
variety	O
of	O
physiological	B-C0205463
and	O
anatomic	B-C0220784
properties	O
,	O
suggesting	O
that	O
neurons	B-C0027882
with	O
differing	O
sfrs	B-C1254359
make	O
unique	O
contributions	O
to	O
the	O
encoding	B-C2700640
of	O
auditory	B-C0178490
stimuli	I-C0178490
.	O
	
additionally	O
,	O
altered	O
sfrs	B-C1254359
are	O
a	O
correlate	O
of	O
tinnitus	B-C0040264
,	O
arising	O
in	O
several	O
auditory	B-C0004302
areas	I-C0004302
after	O
exposure	O
to	O
ototoxic	B-C1407041
substances	B-C0439861
and	O
noise	B-C0028263
trauma	B-C3714660
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
recorded	B-C1537057
single-unit	I-C1537057
activity	I-C1537057
from	O
primary	B-C2954070
auditory	I-C2954070
cortex	I-C2954070
of	O
awake	O
marmoset	B-C0006764
monkeys	B-C0026447
while	O
delivering	O
wide-band	B-C0234402
random-spectrum	I-C0234402
stimuli	I-C0234402
and	O
white	B-C3161035
gaussian	I-C3161035
noise	I-C3161035
wgn	B-C3161035
to	O
examine	O
any	O
divergences	B-C0443204
in	O
stimulus	B-C0234402
encoding	B-C2700640
properties	O
across	O
sfr	O
classes	O
.	O
	
we	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous	B-C0443158
activity	I-C0443158
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	B-C1879547
relative	O
to	O
suppression	B-C1260953
across	O
a	O
variety	O
of	O
wide-band	B-C0234402
stimuli	I-C0234402
and	O
higher	O
driven	O
rates	O
in	O
response	B-C0871261
to	O
wgn	B-C3161035
.	O
	
moreover	O
,	O
response	B-C0242465
latencies	I-C0242465
to	O
wgn	B-C3161035
were	O
negatively	O
correlated	B-C1707520
with	O
the	O
level	O
of	O
activation	B-C1879547
in	O
response	B-C0871261
to	O
both	O
stimulus	B-C0234402
types	O
.	O
	
these	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous	B-C0443158
spiking	I-C0443158
may	O
play	O
during	O
normal	O
stimulus	B-C0234402
processing	B-C1709694
in	O
primary	B-C2954070
auditory	I-C2954070
cortex	I-C2954070
and	O
how	O
it	O
may	O
malfunction	B-C0231174
in	O
cases	O
of	O
systematic	B-C0079435
mapping	I-C0079435
of	O
functional	B-C0205245
enhancer	B-C0014290
-	O
promoter	B-C2350877
connections	B-C0205245
with	O
crispr	B-C3658200
interference	O
gene	O
expression	O
in	O
mammals	O
is	O
regulated	O
by	O
noncoding	O
elements	O
that	O
can	O
affect	O
physiology	O
and	O
disease	O
,	O
yet	O
the	O
functions	O
and	O
target	O
genes	O
of	O
most	O
noncoding	O
elements	O
remain	O
unknown	O
.	O
	
we	O
present	O
a	O
high-throughput	O
approach	O
that	O
uses	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
crispr	B-C0200924
interference	I-C0200924
crispri	O
to	O
discover	O
regulatory	O
elements	O
and	O
identify	O
their	O
target	O
genes	O
.	O
	
we	O
assess	O
>1	O
megabase	O
of	O
sequence	O
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	O
factors	O
,	O
myc	O
and	O
gata1	O
,	O
and	O
identify	O
nine	O
distal	O
enhancers	O
that	O
control	O
gene	O
expression	O
and	O
cellular	O
proliferation	O
.	O
	
quantitative	O
features	O
of	O
chromatin	O
state	O
and	O
chromosome	O
conformation	O
distinguish	O
the	O
seven	O
enhancers	O
that	O
regulate	O
myc	O
from	O
other	O
elements	O
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	O
for	O
predicting	O
enhancer	O
-	O
promoter	O
connectivity	O
.	O
	
this	O
crispri	O
-based	O
approach	O
can	O
be	O
applied	O
to	O
dissect	O
transcriptional	O
networks	O
and	O
interpret	O
the	O
contributions	O
of	O
noncoding	O
genetic	O
variation	O
to	O
human	O
disease	B-C0012634
proliferation	B-C0596290
-enhancing	O
effects	B-C1704420
of	I-C1704420
gastrodin	B-C0061139
on	O
rsc96	B-C0036387
schwann	I-C0036387
cells	I-C0036387
by	O
regulating	B-C1327622
erk1	B-C0082529
/	O
2	B-C0170168
and	O
pi3k	B-C0044602
signaling	B-C0037080
pathways	I-C0037080
the	O
proliferation	B-C0596290
and	O
migration	B-C1622501
of	O
schwann	B-C0036387
cells	I-C0036387
scs	B-C0036387
are	O
essential	O
in	O
the	O
process	B-C1522240
of	O
peripheral	B-C0196777
nerve	I-C0196777
repair	I-C0196777
.	O
	
a	O
large	O
amount	O
of	O
studies	O
focused	O
on	O
the	O
promotion	B-C0033414
of	O
the	O
growth	B-C0007595
of	O
scs	B-C0036387
for	O
cell	B-C3658313
based	I-C3658313
therapy	I-C3658313
.	O
	
gastrodin	B-C0061139
gas	B-C0061139
,	O
the	O
main	O
constituent	O
of	O
a	O
chinese	B-C0025124
traditional	I-C0025124
herbal	B-C2240391
medicine	I-C2240391
named	O
gastrodia	B-C1040858
elata	I-C1040858
blume	I-C1040858
,	O
has	O
been	O
reported	B-C0700287
to	O
be	O
associated	B-C0332281
with	I-C0332281
neuroprotective	B-C0598958
properties	I-C0598958
.	O
	
besides	O
,	O
gas	B-C0061139
activated	B-C1879547
mapk	B-C0752312
and	O
pi3k	B-C0044602
signaling	B-C0037080
pathways	I-C0037080
which	O
are	O
often	O
involved	O
in	O
growth	B-C0007595
of	O
nerve	B-C0027882
cells	I-C0027882
were	O
also	O
reported	B-C0700287
.	O
	
based	O
on	O
the	O
hypothesis	B-C1512571
that	O
gas	B-C0061139
may	O
have	O
an	O
effect	O
on	O
scs	B-C0036387
growth	B-C0007595
,	O
we	O
studied	O
the	O
effect	B-C1704420
of	I-C1704420
gas	B-C0061139
on	O
rat	B-C0034693
rsc96	B-C0036387
schwann	I-C0036387
cells	I-C0036387
scs	B-C0036387
and	O
further	O
explored	O
the	O
underlying	O
mechanism	B-C0441712
.	O
	
various	O
concentration	B-C1446561
of	O
gas	B-C0061139
0μm	O
,	O
50μm	O
,	O
100μm	O
,	O
and	O
200μm	O
was	O
used	O
for	O
treatment	B-C0087111
of	O
rsc96	B-C0036387
scs	I-C0036387
,	O
with	O
the	O
cell	B-C0596290
proliferation	I-C0596290
and	O
gene	B-C0017262
expression	I-C0017262
of	O
several	O
neurotrophic	B-C0027754
factors	I-C0027754
to	O
be	O
detected	O
.	O
	
regulation	B-C1327622
of	I-C1327622
mapk	B-C0752312
and	O
pi3k	B-C0044602
signaling	B-C0037080
pathways	I-C0037080
were	O
assayed	O
by	O
detecting	O
phosphorylation	B-C1158886
of	O
erk1	B-C0082529
/	O
2	B-C0170168
and	O
akt	B-C0164786
.	O
	
the	O
results	O
showed	O
that	O
gas	B-C0061139
could	O
effectively	O
promote	B-C0033414
proliferation	B-C0596290
of	O
rsc96	B-C0036387
scs	I-C0036387
in	O
a	O
dose	B-C0178602
-	O
and	O
time	B-C0040223
-dependent	O
manner	O
.	O
	
the	O
best	O
performance	O
was	O
obtained	O
at	O
the	O
concentration	B-C1446561
of	O
200μm	O
.	O
	
exploration	B-C1280903
of	O
the	O
underlying	O
mechanism	B-C0441712
showed	O
that	O
gas	B-C0061139
probably	O
affects	O
scs	B-C0036387
metabolism	B-C1524026
through	O
inhibiting	B-C3463820
erk1	B-C0082529
/	O
2	B-C0170168
phosphorylation	B-C1158886
and	O
activating	B-C1879547
akt	B-C0164786
phosphorylation	B-C1158886
in	O
rsc96	B-C0036387
scs	I-C0036387
.	O
	
this	O
study	O
may	O
provide	O
reference	O
for	O
its	O
application	O
in	O
treatment	B-C0087111
of	O
peripheral	B-C0262593
nerve	I-C0262593
injuries	I-C0262593
.	O
	
an	O
influenza	B-C3658219
a	I-C3658219
virus	I-C3658219
h7n9	I-C3658219
anti-neuraminidase	B-C0243095
monoclonal	B-C0003250
antibody	I-C0003250
with	O
prophylactic	B-C0199176
and	I-C0199176
therapeutic	I-C0199176
activity	I-C0199176
in	B-C1515655
vivo	I-C1515655
zoonotic	B-C0043528
a	B-C3658219
avian	I-C3658219
influenza	I-C3658219
viruses	I-C3658219
emerged	O
in	O
china	B-C0008115
in	O
2013	O
and	O
continue	O
to	O
be	O
a	O
threat	B-C0749385
to	O
human	B-C0086418
public	B-C0699943
health	I-C0699943
,	O
having	O
infected	B-C0439663
over	O
800	O
individuals	B-C0237401
with	O
a	O
mortality	B-C0205848
rate	I-C0205848
approaching	O
40%	O
.	O
	
treatment	B-C0683525
options	I-C0683525
for	O
people	O
infected	B-C0439663
with	O
a	B-C3658219
include	O
the	O
use	O
of	O
neuraminidase	B-C1443650
na	I-C1443650
inhibitors	I-C1443650
.	O
	
however	O
,	O
like	O
other	O
influenza	B-C0029341
viruses	I-C0029341
,	O
a	B-C3658219
can	O
become	O
resistant	B-C0332325
to	O
these	O
drugs	B-C0013227
.	O
	
the	O
use	O
of	O
monoclonal	B-C0003250
antibodies	I-C0003250
is	O
a	O
rapidly	O
developing	O
strategy	B-C0679199
for	O
controlling	O
influenza	B-C0029341
virus	I-C0029341
infection	B-C3714514
.	O
	
here	O
we	O
generated	O
a	O
murine	B-C0026809
monoclonal	B-C0003250
antibody	I-C0003250
3c10-3	B-C3849272
directed	O
against	O
the	O
na	B-C1545516
of	O
a	B-C3658219
and	O
show	O
that	O
prophylactic	B-C0445202
systemic	B-C0678812
administration	I-C0678812
of	O
3c10-3	B-C3849272
fully	O
protected	O
mice	O
from	O
lethal	O
challenge	O
with	O
wild-type	B-C1883559
a/anhui/1/2013	B-C0029347
h7n9	B-C3658219
.	O
	
further	O
,	O
post-	O
infection	B-C3714514
treatment	B-C0087111
with	O
a	O
single	O
systemic	B-C0205373
dose	B-C0178602
of	O
3c10-3	B-C3849272
at	O
either	O
24	O
,	O
48	O
or	O
72	O
h	O
post	O
a	B-C3658219
challenge	O
resulted	O
in	O
both	O
dose	B-C0178602
-	O
and	O
time	B-C0040223
-	O
dependent	B-C3244310
protection	B-C1545588
of	O
up	O
to	O
100%	O
of	O
mice	B-C0026809
,	O
demonstrating	O
therapeutic	B-C0302350
potential	B-C3245505
for	O
3c10-3	B-C3849272
.	O
	
epitope	B-C0242831
mapping	I-C0242831
revealed	O
that	O
3c10-3	B-C3849272
binds	B-C1167622
near	O
the	O
enzyme	B-C0014442
active	B-C0205681
site	I-C0205681
of	O
na	B-C1545516
,	O
and	O
functional	B-C0205245
characterization	O
showed	O
that	O
3c10-3	B-C3849272
inhibits	O
the	O
enzyme	B-C0243102
activity	I-C0243102
of	O
na	B-C1545516
and	O
restricts	O
the	O
cell	O
-to-	O
cell	O
spread	B-C0332261
of	O
the	O
virus	B-C0042776
in	O
cultured	B-C0007635
cells	I-C0007635
.	O
	
affinity	B-C1510827
analysis	B-C0936012
also	O
revealed	O
that	O
3c10-3	B-C3849272
binds	B-C1167622
equally	O
well	O
to	O
recombinant	B-C0034861
na	B-C1545516
of	O
wild-type	B-C1883559
a/anhui/1/2013	B-C0029347
and	O
to	O
a	O
variant	B-C0205419
na	B-C1545516
carrying	O
a	O
r289k	O
mutation	B-C0026882
known	O
to	O
infer	O
nai	B-C1443650
resistance	B-C4281815
.	O
	
these	O
results	O
suggest	O
that	O
3c10-3	B-C3849272
has	O
the	O
potential	B-C3245505
to	O
be	O
used	O
as	O
a	O
therapeutic	B-C0302350
to	O
treat	O
a	B-C3658219
infections	B-C3714514
either	O
as	O
an	O
alternative	B-C1523987
to	O
,	O
or	O
in	O
combination	B-C0205195
with	O
,	O
current	O
na	B-C1545516
antiviral	B-C0003451
inhibitors	I-C0003451
.	O
	
mechanisms	B-C0441712
of	O
ear	B-C0013443
trauma	B-C3714660
and	O
reconstructive	B-C0524865
techniques	B-C0449851
in	O
105	O
consecutive	B-C1707491
patients	B-C0030705
acquired	B-C0439661
auricular	B-C1549094
deformities	B-C0302142
may	O
diminish	B-C0205216
facial	B-C0871976
esthetics	I-C0871976
and	O
cause	O
psychological	B-C0815107
distress	I-C0815107
.	O
	
the	O
aim	O
of	O
this	O
article	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
type	O
of	O
injuries	B-C3263723
and	O
applied	B-C0524865
reconstructive	I-C0524865
techniques	B-C0449851
in	O
a	O
large	O
academic	B-C0000872
hospital	I-C0000872
in	O
the	O
netherlands	B-C0027778
.	O
	
a	O
retrospective	B-C1514923
chart	B-C0553620
review	I-C0553620
was	O
conducted	O
for	O
the	O
last	O
105	O
patients	B-C0030705
who	O
underwent	O
auricular	B-C1549094
reconstruction	B-C0524865
for	O
an	O
acquired	B-C0221430
deformity	I-C0221430
.	O
	
data	B-C1511726
concerning	O
gender	B-C0079399
,	O
affected	B-C3166323
side	I-C3166323
,	O
cause	B-C0552510
of	I-C0552510
injury	I-C0552510
,	O
anatomical	B-C0005898
region	I-C0005898
,	O
the	O
previous	O
and	O
further	O
surgeries	B-C0543467
,	O
type	O
of	O
cartilage	B-C0007301
,	O
and	O
skin	B-C3874019
cover	I-C3874019
used	I-C3874019
were	O
collected	O
and	O
analyzed	B-C0936012
.	O
	
105	O
patients	B-C0030705
were	O
included	O
.	O
	
acquired	B-C0439661
auricular	B-C1549094
deformities	B-C0302142
were	O
mainly	O
caused	O
by	O
bite	B-C0005658
injuries	I-C0005658
22	O
%	O
,	O
traffic	B-C0000932
accidents	I-C0000932
17	O
%	O
,	O
burns	B-C0006434
9.5	O
%	O
,	O
and	O
post-otoplasty	B-C0868838
complications	B-C0009566
9.5	O
%	O
.	O
	
the	O
upper	B-C0502136
third	I-C0502136
of	I-C0502136
the	I-C0502136
auricle	I-C0502136
was	O
most	O
often	O
injured	B-C0332664
41	O
%	O
,	O
followed	O
by	O
the	O
entire	B-C0013453
auricle	I-C0013453
19	O
%	O
.	O
	
70	O
%	O
of	O
cases	B-C0868928
required	O
reconstruction	B-C0524865
with	O
costal	B-C0222787
cartilage	I-C0222787
.	O
	
the	O
most	O
common	O
form	O
of	O
cutaneous	B-C0221912
cover	I-C0221912
was	O
a	O
postauricular	B-C0395655
skin	I-C0395655
flap	I-C0395655
40	O
%	O
of	O
cases	B-C0868928
.	O
	
this	O
study	B-C2603343
gives	O
a	O
complete	O
overview	O
of	O
causes	O
and	O
treatment	B-C0039798
of	O
acquired	B-C0439661
auricular	B-C1549094
deformities	B-C0302142
.	O
	
the	O
results	B-C1274040
are	O
comparable	O
with	O
the	O
results	O
of	O
similar	O
studies	B-C2603343
found	O
in	O
literature	B-C0023866
.	O
	
bite	B-C0561546
wounds	I-C0561546
are	O
the	O
leading	O
cause	O
of	O
acquired	B-C0439661
auricular	B-C1549094
injuries	B-C3263723
.	O
	
the	O
upper	B-C0502136
third	I-C0502136
is	O
most	O
commonly	O
affected	O
.	O
	
in	O
the	O
largest	O
percentage	O
of	O
reconstructions	B-C0524865
,	O
costal	B-C0222787
cartilage	I-C0222787
and	O
a	O
postauricular	B-C0440884
flap	I-C0440884
were	O
used	O
to	O
correct	O
the	O
anatomic	B-C0220784
assessment	B-C0220825
of	O
the	O
left	B-C1254362
main	I-C1254362
bifurcation	I-C1254362
and	O
dynamic	B-C1254362
bifurcation	I-C1254362
angles	I-C1254362
using	O
computed	B-C1536105
tomography	I-C1536105
angiography	I-C1536105
an	O
understanding	O
of	O
the	O
left	B-C1261082
main	I-C1261082
coronary	I-C1261082
artery	I-C1261082
lmca	B-C1261082
anatomy	B-C0700276
is	O
important	O
for	O
accurate	O
diagnosis	B-C1704338
and	O
therapeutic	B-C0087111
.	O
	
we	O
aimed	O
to	O
investigate	B-C1292732
lmca	B-C1261082
anatomy	B-C0700276
via	O
128-multisliced	B-C1536105
coronary	I-C1536105
computed-tomography-angiography	I-C1536105
ccta	B-C1536105
in	O
patients	B-C0030705
with	O
normal	O
lmca	B-C1261082
.	O
	
a	O
total	O
of	O
201	O
ccta	B-C1536105
studies	B-C0008972
were	O
included	O
in	O
this	O
study	B-C2603343
.	O
	
anatomical	B-C0700276
features	I-C0700276
of	O
lmca	B-C1261082
including	O
cross-sectional	B-C0552389
areas	I-C0552389
of	O
the	O
lmca	B-C1261082
ostial	B-C0444567
,	O
lmca	B-C1261082
distal	B-C0205108
,	O
lad	B-C3898617
ostial	I-C3898617
and	O
lcx	B-C0815994
ostial	B-C0444567
,	O
and	O
degree	O
of	O
tapering	O
and	O
lmca	B-C1261082
bifurcation	B-C1254362
angles	I-C1254362
ba	B-C1254362
in	O
the	O
form	O
of	O
lmca	B-C1261082
-	O
lcx	B-C0815994
ba	B-C1254362
,	O
lmca	B-C1261082
-	O
lad	B-C3898617
ba	B-C1254362
,	O
lad	B-C3898617
-	O
lcx	B-C0815994
ba	B-C1254362
at	O
end-diastole	B-C1562146
and	O
end-systole	B-C1563001
.	O
	
the	O
mean	O
age	B-C0001779
was	O
55	O
11	O
with	O
55.7	O
males	B-C0086582
.	O
	
rca	B-C0226042
was	O
dominant	B-C1527180
in	O
173	O
86.1	O
patients	B-C0030705
.	O
	
mean	O
lmca	B-C1261082
length	B-C1444754
was	O
10.0	O
mm	O
.	O
	
the	O
mean	O
values	O
of	O
lmca	B-C1261082
ostial	B-C0444567
,	O
lmca	B-C1261082
distal	B-C0205108
,	O
lad	B-C3898617
ostial	I-C3898617
and	O
lcx	B-C0815994
ostial	B-C0444567
areas	B-C0205146
were	O
18.2	O
mm²	O
,	O
13.2	O
,	O
9.0	O
mm²	O
and	O
7.6	O
mm²	O
,	O
respectively	O
.	O
	
lmca	B-C1261082
ostial	B-C0444567
-	O
distal	B-C0205108
area	B-C0205146
,	O
lmca	B-C1261082
distal	B-C0205108
-	O
lad	B-C3898617
ostial	I-C3898617
area	B-C0205146
and	O
lmca	B-C1261082
distal	B-C0205108
-	O
lcx	B-C0815994
ostial	B-C0444567
area	B-C1442066
ratios	I-C1442066
were	O
1.44	O
-	O
<1	O
in	O
47	O
23.4	O
,	O
53	O
26.4	O
,	O
47	O
23.4	O
patients	B-C0030705
,	O
respectively	O
,	O
and	O
were	O
1.69	O
in	O
19	O
9.5	O
,	O
24	O
,	O
40	O
patients	B-C0030705
respectively	O
.	O
	
systolic	B-C0026597
motion	I-C0026597
modifies	O
lmca	B-C1261082
bas	B-C1254362
systolic	B-C0026597
motion	I-C0026597
begets	O
an	O
increment	O
of	O
lmca	B-C1261082
-	O
lad	B-C3898617
angle	O
in	O
72.6	O
of	O
patients	B-C0030705
and	O
decrement	O
of	O
lad	B-C3898617
-	O
lcx	B-C0815994
angle	O
in	O
75.6	O
of	O
the	O
patients	B-C0030705
.	O
	
patients	B-C0030705
with	O
t-shaped	O
lad	B-C3898617
-	O
lcx	B-C0815994
ba	B-C1254362
was	O
shown	O
to	O
have	O
significantly	O
longer	O
lmca	B-C1261082
,	O
larger	O
lad	B-C3898617
ostial	I-C3898617
area	B-C0205146
,	O
larger	O
lcx	B-C0815994
ostial	B-C0444567
area	B-C0205146
and	O
higher	O
diastolic-to-systolic	B-C1514721
range	I-C1514721
dsr	B-C1514721
of	O
lad	B-C3898617
-	O
lcx	B-C0815994
ba	B-C1254362
compared	O
to	O
patients	B-C0030705
with	O
y-shaped	O
lad	B-C3898617
-	O
lcx	B-C0815994
ba	B-C1254362
.	O
	
lmca	B-C1261082
with	O
t-shaped	B-C0205108
distal	I-C0205108
ba	B-C1254362
was	O
found	O
to	O
have	O
significantly	O
longer	O
lmca	B-C1261082
,	O
larger	O
lad	B-C3898617
ostial	I-C3898617
area	B-C0205146
,	O
larger	O
lcx	B-C0815994
ostial	B-C0444567
area	B-C0205146
and	O
higher	O
dsr	B-C1514721
of	O
distal	B-C0205108
ba	B-C1254362
compared	O
to	O
patients	B-C0030705
with	O
y-shaped	B-C0205108
distal	I-C0205108
ba	B-C1254362
.	O
	
these	O
findings	B-C0243095
may	O
provide	O
useful	O
information	O
for	O
lmca	B-C1261082
bifurcation	B-C2348535
stenting	I-C2348535
or	O
designing	O
dedicated	O
stents	B-C0038257
for	O
a	O
three	B-C0205449
perspective	B-C2603343
study	I-C2603343
of	O
the	O
sense	O
of	O
home	B-C0442519
of	O
nursing	B-C0682287
home	I-C0682287
residents	I-C0682287
the	O
views	O
of	O
residents	B-C0682287
,	O
care	B-C0018724
professionals	I-C0018724
and	O
relatives	B-C0080103
the	O
sense	O
of	O
home	B-C0442519
of	O
nursing	B-C0682287
home	I-C0682287
residents	I-C0682287
is	O
a	O
multifactorial	B-C1837655
phenomenon	B-C1882365
which	O
is	O
important	B-C3898777
for	O
the	O
quality	B-C0332306
of	O
living	B-C0376558
.	O
	
the	O
purpose	B-C1285529
of	O
this	O
study	B-C2603343
is	O
to	O
investigate	B-C1292732
the	O
factors	B-C1521761
influencing	B-C4054723
the	O
sense	O
of	O
home	B-C0442519
of	O
older	B-C3826770
adults	I-C3826770
residing	B-C2982691
in	O
the	O
nursing	B-C0028688
home	I-C0028688
from	O
the	O
perspective	O
of	O
residents	B-C0682287
,	O
relatives	B-C0080103
and	O
care	B-C0018724
professionals	I-C0018724
.	O
	
a	O
total	O
of	O
78	O
participants	B-C0679646
n	O
=	O
24	O
residents	B-C0682287
,	O
n	O
=	O
18	O
relatives	B-C0080103
and	O
n	O
=	O
26	O
care	B-C0018724
professionals	I-C0018724
from	O
4	O
nursing	B-C0028688
homes	I-C0028688
in	O
the	O
netherlands	B-C0027778
engaged	O
in	O
a	O
qualitative	B-C0949415
study	I-C0949415
,	O
in	O
which	O
photography	O
was	O
as	O
a	O
supportive	O
tool	O
for	O
subsequent	B-C0332282
interviews	B-C0021822
and	O
focus	B-C0016400
groups	I-C0016400
.	O
	
the	O
data	B-C1511726
were	O
analyzed	O
based	O
on	O
open	B-C2827655
ended	I-C2827655
coding	I-C2827655
,	O
axial	B-C0205556
coding	I-C0205556
and	O
selective	B-C0205556
coding	I-C0205556
.	O
	
the	O
sense	O
of	O
home	B-C0442519
of	O
nursing	B-C0682287
home	I-C0682287
residents	I-C0682287
is	O
influenced	B-C4054723
by	O
a	O
number	O
of	O
jointly	O
identified	O
factors	B-C1521761
,	O
including	O
the	O
building	B-C1999269
and	O
interior	B-C0021751
design	I-C0021751
eating	B-C0392339
and	O
drinking	B-C0013124
autonomy	B-C0085862
and	O
control	B-C2587213
involvement	B-C1314939
of	O
relatives	B-C0080103
engagement	O
with	O
others	O
and	O
activities	B-C0441655
quality	B-C0034379
of	I-C0034379
care	I-C0034379
are	O
shared	O
themes	O
.	O
	
residents	B-C0682287
and	O
relatives	B-C0080103
stressed	O
the	O
importance	B-C3898777
of	O
having	O
a	O
connection	O
with	O
nature	B-C0349590
and	O
the	O
outdoors	B-C1709359
,	O
as	O
well	O
as	O
coping	B-C0009967
strategies	I-C0009967
.	O
	
relatives	B-C0080103
and	O
care	B-C0018724
professionals	I-C0018724
emphasized	O
the	O
role	O
the	O
organization	B-C0029246
of	O
facilitation	B-C0262752
of	O
care	B-C1947933
played	O
,	O
as	O
well	O
as	O
making	O
residents	B-C0682287
feel	O
like	O
they	O
still	O
matter	O
.	O
	
the	O
sense	O
of	O
home	B-C0442519
of	O
nursing	B-C0682287
home	I-C0682287
residents	I-C0682287
is	O
influenced	B-C4054723
by	O
a	O
multitude	B-C0439064
of	O
factors	B-C1521761
related	O
to	O
the	O
psychology	B-C1524060
of	O
the	O
residents	B-C0682287
,	O
and	O
the	O
social	B-C0037414
and	I-C0037414
built	I-C0037414
environmental	I-C0037414
contexts	I-C0037414
.	O
	
a	O
holistic	B-C0683249
understanding	O
of	O
which	O
factors	B-C1521761
influence	B-C4054723
the	O
sense	O
of	O
home	B-C0442519
of	O
residents	B-C0682287
can	O
lead	O
to	O
strategies	O
to	O
optimize	B-C2698650
this	O
sense	O
of	O
home	B-C0442519
.	O
	
this	O
study	B-C0949415
also	O
indicated	O
that	O
the	O
nursing	B-C0028688
home	I-C0028688
has	O
a	O
dual	O
nature	B-C0349590
as	O
a	O
place	O
of	O
residence	B-C0237096
and	O
a	O
place	B-C0442504
where	O
people	B-C0027361
are	O
supported	O
through	O
numerous	B-C0439064
integrating	O
one	B-C4277525
health	I-C4277525
in	O
national	B-C0027458
health	I-C0027458
policies	I-C0027458
of	O
developing	B-C0011750
countries	I-C0011750
india's	B-C0021201
lost	O
opportunities	O
globally	B-C2348867
,	O
the	O
threat	B-C0749385
of	O
infectious	B-C0009450
diseases	I-C0009450
,	O
particularly	O
emerging	B-C0872315
infectious	I-C0872315
diseases	I-C0872315
,	O
originating	B-C0439659
at	O
the	O
human	B-C0086418
-	O
animal	B-C0003062
-	O
environment	B-C0014406
interface	B-C1704675
,	O
has	O
caught	O
health	B-C1456613
systems	I-C1456613
off	O
guard	O
.	O
	
with	O
forecasts	O
that	O
future	O
pathogen	B-C0450254
emergence	B-C0872315
will	O
be	O
centred	O
in	O
hotspots	O
in	O
asia	B-C0003980
,	O
africa	B-C0001737
,	O
and	O
latin	B-C0023122
america	I-C0023122
,	O
the	O
need	O
to	O
prepare	O
policy	B-C0242456
frameworks	I-C0242456
that	O
can	O
combat	O
this	O
threat	B-C0749385
is	O
urgent	B-C0439609
.	O
	
emergence	B-C0872315
of	I-C0872315
diseases	I-C0872315
such	O
as	O
avian	B-C0016627
influenza	I-C0016627
and	O
ebola	B-C0282687
virus	I-C0282687
disease	I-C0282687
,	O
which	O
threatened	B-C0749385
social	B-C0728831
disruption	B-C0332453
,	O
have	O
established	B-C0443211
the	O
need	O
for	O
intersectoral	B-C4277663
coordination/collaboration	I-C4277663
.	O
	
these	O
events	B-C0441471
led	O
to	O
the	O
initiation	B-C1704686
of	O
establishing	B-C0443211
institutionalised	B-C0562359
collaborative	B-C0282116
frameworks	I-C0282116
in	O
india	B-C0021201
to	O
adopt	O
a	O
one	B-C4277525
health	I-C4277525
approach	I-C4277525
to	O
disease	B-C0085557
prevention	I-C0085557
and	I-C0085557
control	I-C0085557
.	O
	
however	O
,	O
the	O
gains	B-C1517378
made	O
in	O
influenza	B-C0021400
control	B-C2239193
could	O
not	O
be	O
adapted	O
to	O
other	O
infectious	B-C0009450
diseases	I-C0009450
.	O
	
intersectoral	B-C4277663
coordination	I-C4277663
was	O
briefly	O
carried	O
out	O
,	O
more	O
as	O
a	O
reactive	B-C0205332
response	O
to	O
threats	B-C0749385
.	O
	
the	O
systemic	B-C0205373
failure	B-C0231175
to	O
sustain	B-C0443318
such	O
efforts	O
have	O
therefore	O
,	O
only	O
undermined	O
a	O
coordinated	B-C0700114
response	B-C0443286
.	O
	
the	O
recent	O
draft	B-C1547277
national	B-C0027458
health	I-C0027458
policy	I-C0027458
,	O
2015	O
,	O
has	O
also	O
failed	B-C0231175
to	O
establish	B-C0443211
the	O
need	O
for	O
intersectoral	B-C4277663
coordination	I-C4277663
in	O
disease	B-C0085557
control	I-C0085557
approaches	I-C0085557
.	O
	
neglecting	O
the	O
need	O
to	O
endorse	O
linkages	B-C0332280
between	O
human	B-C0086418
health	B-C0018684
,	O
animal	B-C0003062
health	B-C0018684
and	O
husbandry	B-C0003052
,	O
agriculture	B-C0001829
,	O
and	O
environmental	B-C0014406
sectors	B-C1708237
,	O
has	O
led	O
to	O
duplicative	B-C0205173
and	O
weak	B-C0243095
response	I-C0243095
systems	I-C0243095
.	O
	
the	O
absence	B-C0332197
of	O
health	B-C3494320
impact	I-C3494320
assessment	I-C3494320
with	O
respect	O
to	O
the	O
development	B-C1527148
agenda	B-C0681473
in	O
policies	B-C0242456
,	O
has	O
cast	O
negative	B-C0205160
effects	B-C1280500
on	O
the	O
health	B-C0018684
and	O
wellbeing	B-C3813622
of	I-C3813622
man	I-C3813622
,	O
animal	B-C0003062
,	O
and	O
the	O
environment	B-C0014406
.	O
	
lack	B-C1398138
of	I-C1398138
attention	I-C1398138
to	O
building	O
core	O
capacity	B-C1516240
in	O
these	O
critical	B-C1511545
sectors	B-C1708237
has	O
further	O
raised	B-C0442818
challenges	B-C0805586
in	O
designing	O
and	O
deploying	B-C2825812
mitigation	B-C1553901
strategies	B-C0679199
.	O
	
with	O
developing	B-C0011750
countries	I-C0011750
like	O
india	B-C0021201
being	O
home	O
to	O
a	O
major	O
portion	B-C0449719
of	O
the	O
world's	B-C2700280
poorest	B-C0542537
livestock	B-C0335415
farmers	I-C0335415
,	O
the	O
absence	B-C0332197
of	O
a	O
policy	B-C0242456
discourse	B-C0009452
that	O
endorses	O
the	O
one	B-C4277525
health	I-C4277525
approach	I-C4277525
in	O
development	B-C1527148
and	O
health	B-C0018735
policies	I-C0018735
is	O
a	O
major	O
hurdle	B-C0009566
in	O
eliminating	B-C1883720
poverty	B-C0032854
and	O
poverty	B-C0032854
-	O
related	B-C0439849
diseases	B-C0012634
.	O
	
the	O
adoption	B-C0332162
of	O
one	B-C4277525
health	I-C4277525
approaches	I-C4277525
in	O
health	B-C0018684
and	O
related	O
sectoral	B-C0439741
policies	B-C0242456
is	O
a	O
critical	B-C1511545
policy	B-C0242456
requirement	O
for	O
india	B-C0021201
and	O
other	O
developing	B-C0011750
countries	I-C0011750
.	O
	
the	O
goal	O
should	O
be	O
to	O
not	O
just	O
establish	B-C0443211
preparedness	B-C1318963
plans	B-C0032074
,	O
but	O
also	O
to	O
encourage	B-C1511253
a	O
policy	B-C0282166
environment	I-C0282166
where	O
assessment	B-C0220825
and	O
mitigation	B-C1553901
of	O
downstream	B-C0522506
impacts	B-C4049986
of	O
different	O
agenda	B-C0681473
are	O
assessment	B-C0220825
of	O
demographic	B-C0011292
and	O
pathoanatomic	B-C0035648
risk	I-C0035648
factors	I-C0035648
in	O
recurrent	B-C2945760
patellofemoral	B-C0447801
instability	B-C0022410
the	O
warps/staid	B-C0008902
classification	I-C0008902
employs	O
clinical	B-C0205210
assessment	B-C0220825
of	O
presenting	O
features	B-C2348519
and	O
anatomic	B-C0220784
characteristics	B-C1521970
to	O
identify	O
two	O
distinct	O
subsets	B-C1515021
of	O
patients	B-C0030705
within	O
the	O
patellofemoral	B-C0427262
instability	I-C0427262
population	B-C0030705
.	O
	
the	O
purpose	B-C0681832
of	I-C0681832
this	I-C0681832
study	I-C0681832
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	B-C1698647
and	O
the	O
prevalence	B-C0220900
of	O
risky	B-C1444641
pathoanatomies	B-C1384516
in	O
patients	B-C0030705
classified	O
as	O
either	O
warps	B-C0008902
or	O
staid	B-C0008902
presenting	O
with	O
recurrent	B-C2945760
patellofemoral	B-C0447801
instability	B-C0022410
.	O
	
a	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
warps/staid	B-C0008902
classification	I-C0008902
with	O
the	O
banff	B-C0282574
patella	I-C0282574
instability	I-C0282574
instrument	I-C0282574
bpii	B-C0282574
,	O
the	O
marx	B-C0282574
activity	I-C0282574
scale	I-C0282574
and	O
the	O
patellar	B-C0030647
instability	B-C0021504
severity	I-C0021504
score	I-C0021504
iss	B-C0021504
.	O
	
a	O
convenience	O
sample	O
of	O
50	O
patients	B-C0030705
with	O
recurrent	B-C2945760
patellofemoral	B-C0447801
instability	B-C0022410
,	O
including	O
25	O
warps	B-C0008902
and	O
25	O
staid	B-C0008902
subtype	I-C0008902
patients	B-C0030705
,	O
were	O
assessed	B-C1516048
.	O
	
clinical	B-C1516606
data	I-C1516606
were	O
collected	O
including	O
assessment	B-C0220825
of	O
demographic	B-C0011292
risk	B-C0035648
factors	I-C0035648
sex	B-C0079399
,	O
bmi	B-C1305855
,	O
bilaterality	B-C0238767
of	O
symptoms	B-C1457887
,	O
affected	B-C0449642
limb	B-C0015385
side	I-C0015385
and	O
age	B-C0001779
at	O
first	O
dislocation	B-C0856775
and	O
pathoanatomic	B-C0035648
risk	I-C0035648
factors	I-C0035648
tt-tg	B-C0012751
distance	I-C0012751
,	O
patella	B-C0030647
height	B-C1317145
,	O
patellar	O
tilt	O
,	O
grade	B-C0441800
of	O
trochlear	B-C4274287
dysplasia	I-C4274287
,	O
beighton	B-C4273179
score	I-C4273179
and	O
rotational	B-C1704258
abnormalities	I-C1704258
of	O
the	O
tibia	B-C0040184
or	O
femur	B-C0015811
.	O
	
patients	B-C0030705
completed	O
the	O
bpii	B-C0282574
and	O
the	O
marx	B-C0282574
activity	I-C0282574
scale	I-C0282574
.	O
	
the	O
iss	B-C0021504
was	O
calculated	B-C1443182
from	O
the	O
clinical	B-C1516606
assessment	I-C1516606
data	I-C1516606
.	O
	
patients	B-C0030705
were	O
stratified	O
into	O
the	O
warps	B-C0008902
or	O
staid	B-C0008902
subtypes	I-C0008902
for	O
comparative	B-C0683941
analysis	I-C0683941
.	O
	
an	O
independent	O
t	B-C0871472
test	I-C0871472
was	O
used	O
to	O
compare	O
demographics	B-C1698647
,	O
the	O
pathoanatomic	B-C0035648
risk	I-C0035648
factors	I-C0035648
and	O
subjective	O
measures	O
between	O
the	O
groups	B-C0681860
.	O
	
convergent	B-C1510594
validity	I-C1510594
was	O
tested	O
with	O
a	O
pearson	B-C0871052
r	I-C0871052
correlation	I-C0871052
coefficient	I-C0871052
between	O
the	O
warps/staid	B-C0457451
and	O
iss	B-C0021504
scores	I-C0021504
.	O
	
demographic	B-C0011292
risk	I-C0011292
factors	I-C0011292
statistically	O
associated	B-C0332281
with	I-C0332281
a	O
warps	B-C0008902
subtype	I-C0008902
included	O
female	B-C0086287
sex	I-C0086287
,	O
age	B-C0001779
at	O
first	O
dislocation	B-C0856775
and	O
bilaterality	B-C0238767
.	O
	
pathoanatomic	B-C0035648
risk	I-C0035648
factors	I-C0035648
statistically	O
associated	B-C0332281
with	I-C0332281
a	O
warps	B-C0008902
subtype	I-C0008902
included	O
trochlear	B-C4274287
dysplasia	I-C4274287
,	O
tt-tg	B-C0012751
distance	I-C0012751
,	O
generalized	O
ligamentous	B-C0158359
laxity	I-C0158359
,	O
patellar	O
tilt	O
and	O
rotational	B-C1704258
abnormalities	I-C1704258
.	O
	
the	O
independent	O
t	B-C0871472
test	I-C0871472
revealed	O
a	O
significant	O
difference	O
between	O
the	O
iss	B-C0021504
scores	O
warps	B-C0008902
subtype	I-C0008902
m	O
=	O
4.4	O
,	O
sd	O
=	O
1.1	O
and	O
staid	B-C0008902
subtype	I-C0008902
m	O
=	O
2.5	O
,	O
sd	O
=	O
1.5	O
t	O
=	O
5.2	O
,	O
p	O
<	O
0.001	O
.	O
	
the	O
relationship	B-C0439849
between	O
the	O
warps/staid	B-C0457451
and	O
the	O
iss	B-C0021504
scores	I-C0021504
,	O
measured	O
using	O
a	O
pearson	B-C0871052
r	I-C0871052
correlation	I-C0871052
coefficient	I-C0871052
,	O
demonstrated	O
a	O
strong	O
relationship	B-C0439849
r	O
=	O
-0	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0.001	O
.	O
	
this	O
study	B-C0008972
has	O
demonstrated	O
statistically	B-C0237881
significant	I-C0237881
evidence	B-C3887511
that	O
certain	O
demographics	B-C1698647
and	O
pathoanatomies	B-C1384516
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
warps	B-C0008902
and	O
staid	B-C0008902
patellofemoral	B-C0447801
instability	B-C0022410
subtypes	B-C0449560
.	O
	
there	O
was	O
no	O
difference	O
in	O
quality-of-life	B-C0034380
or	O
activity	B-C0683317
level	I-C0683317
between	O
the	O
subtypes	B-C0449560
.	O
	
the	O
warps/staid	B-C0457451
score	I-C0457451
demonstrated	O
convergent	B-C1510594
validity	I-C1510594
to	O
the	O
iss	B-C0021504
and	O
divergent	B-C2349101
validity	I-C2349101
to	O
the	O
bpii	B-C0282574
score	I-C0282574
and	O
the	O
marx	B-C0282574
activity	I-C0282574
scale	I-C0282574
.	O
	
this	O
study	B-C0008972
has	O
further	O
validated	O
both	O
the	O
warps/staid	B-C0008902
classification	I-C0008902
and	O
the	O
iss	B-C0021504
of	O
patients	B-C0030705
that	O
present	O
with	O
recurrent	B-C2945760
patellofemoral	B-C0447801
instability	B-C0022410
.	O
	
expression	B-C1171362
of	O
caspase	B-C0291573
3	I-C0291573
in	O
ovarian	B-C0018120
follicle	I-C0018120
cells	B-C0007634
of	O
the	O
lizard	B-C0023916
podarcis	B-C1025381
sicula	I-C1025381
in	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase	B-C0291573
3	I-C0291573
plays	O
a	O
role	O
,	O
during	O
previtellogenesis	B-C0042895
,	O
in	O
the	O
ovarian	B-C0205065
follicular	B-C0040300
epithelium	I-C0040300
of	O
the	O
lizard	B-C0023916
podarcis	B-C1025381
sicula	I-C1025381
.	O
	
we	O
investigated	O
the	O
presence	O
and	O
localization	B-C0475264
of	O
proform	O
and	O
active	O
caspase	B-C0291573
3	I-C0291573
by	O
enzyme	B-C2717977
assay	I-C2717977
,	O
western	B-C0005863
blotting	I-C0005863
and	O
immunocytochemistry	B-C0242349
.	O
	
in	O
parallel	O
,	O
a	O
fragment	B-C1708096
of	O
caspase	B-C1413132
3	I-C1413132
was	O
cloned	B-C0598888
for	O
the	O
first	O
time	O
in	O
this	O
species	B-C1705920
,	O
sequenced	B-C1561491
and	O
used	O
for	O
in	B-C0162788
situ	I-C0162788
hybridization	I-C0162788
to	O
localize	B-C0392752
messengers	B-C0815028
and	O
analysed	O
by	O
a	O
phylogenetic	B-C1519068
survey	I-C1519068
to	O
shed	O
light	O
on	O
its	O
homology	B-C2697616
with	O
reptilian	B-C0035161
caspases	B-C0010656
.	O
	
results	O
demonstrated	O
that	O
1	O
the	O
follicle	B-C1571705
cells	B-C0007634
expressed	B-C1171362
a	O
caspase	B-C0010656
of	O
the	O
3/7	O
group	O
and	O
the	O
mrna	B-C0035696
for	O
caspase	B-C0291573
3	I-C0291573
was	O
transcribed	B-C0040649
in	O
the	O
stem	B-C0205390
phase	I-C0205390
and	O
was	O
completely	O
translated	B-C0597295
during	O
cell	B-C0007589
differentiation	I-C0007589
2	O
the	O
proform	B-C0033684
protein	I-C0033684
was	O
stored	O
during	O
the	O
differentiated	B-C0205615
nurse	I-C0205615
stage	I-C0205615
and	O
activated	B-C0599177
at	O
the	O
end	O
of	O
previtellogenesis	B-C0042895
provoking	O
the	O
degeneration	B-C0333467
of	I-C0333467
cells	I-C0333467
3	O
the	O
predicted	O
protein	B-C0002518
sequence	I-C0002518
,	O
although	O
partial	O
,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	B-C0035161
caspases	B-C0291573
3	I-C0291573
.	O
	
the	O
epithelial	B-C0014597
cells	I-C0014597
of	O
the	O
ovarian	B-C0018120
follicle	I-C0018120
,	O
therefore	O
,	O
do	O
not	O
employ	O
caspase	B-C0291573
3	I-C0291573
during	O
the	O
nurse	B-C0205615
stage	I-C0205615
but	O
,	O
instead	O
,	O
prepare	O
for	O
apoptosis	B-C0162638
increased	B-C0205217
acute	B-C0205178
mortality	B-C0205848
with	O
chemoradiotherapy	B-C0436307
for	O
locally	B-C0278996
advanced	I-C0278996
head	I-C0278996
and	I-C0278996
neck	I-C0278996
cancer	I-C0278996
in	O
patients	B-C0030705
70	O
years	B-C1510829
concurrent	B-C3178775
chemoradiotherapy	I-C3178775
crt	B-C3178775
is	O
the	O
standard	B-C2936643
of	I-C2936643
care	I-C2936643
for	O
many	O
sites	B-C0205145
of	O
locally	B-C1168401
advanced	I-C1168401
head	I-C1168401
and	I-C1168401
neck	I-C1168401
squamous	I-C1168401
cell	I-C1168401
carcinomas	I-C1168401
lahnc	B-C1168401
.	O
	
however	O
,	O
on	O
meta-analysis	B-C0920317
,	O
the	O
addition	O
of	O
chemotherapy	B-C3665472
did	O
not	O
improve	O
survival	B-C0220921
for	O
patients	B-C0030705
>70	O
years	B-C1510829
.	O
	
we	O
hypothesized	O
that	O
elderly	B-C0001792
patients	B-C0030705
treated	B-C1522326
with	O
crt	B-C3178775
would	O
have	O
increased	B-C0205217
toxicity	B-C0600688
without	O
similar	O
improvements	B-C2986411
in	O
survival	B-C0220921
.	O
	
a	O
single-institution	B-C2607850
,	O
irb-approved	B-C2346499
retrospective	B-C0035363
study	I-C0035363
took	O
place	O
from	O
2005	O
to	O
2012	O
including	O
369	O
patients	B-C0030705
treated	B-C1522326
with	O
crt	B-C3178775
for	O
lahnc	B-C1168401
.	O
	
multivariate	B-C0026348
models	I-C0026348
for	O
death	B-C1306577
at	O
3	O
months	B-C0439231
and	O
death	B-C1306577
over	O
time	B-C0040223
were	O
developed	O
using	O
logistic	B-C0206031
regression	I-C0206031
and	O
cox	B-C0870071
modeling	I-C0870071
,	O
respectively	O
.	O
	
patients	B-C0030705
70	O
years	B-C1510829
were	O
treated	B-C1522326
less	O
often	O
with	O
concurrent	B-C0205420
cisplatin	B-C0008838
dosed	O
every	O
3	O
weeks	B-C0439230
25.5	O
vs	O
.	O
	
71.4	O
,	O
respectively	O
and	O
more	O
often	O
with	O
weekly	B-C0439230
carboplatin	B-C0079083
31.9	O
vs	O
.	O
	
3.4	O
than	O
patients	B-C0030705
<70	O
years	B-C1510829
n=322	O
p<0	O
.	O
	
patients	B-C0030705
70	O
years	B-C1510829
experienced	O
increased	B-C0205217
toxicity	B-C0600688
during	O
treatment	B-C0087111
with	O
more	O
frequently	O
hospitalizations	B-C0019993
36.2	O
vs	O
.	O
	
21.1	O
p=0	O
and	O
a	O
lower	O
rate	O
of	O
peg	B-C0087111
removal	I-C0087111
at	O
last	O
follow-up	B-C1522577
or	O
death	B-C1306577
77.1	O
vs	O
.	O
	
92.9	O
p=0	O
.	O
	
a	O
higher	O
proportion	B-C1709707
of	O
patients	B-C0030705
70	O
years	B-C1510829
died	O
within	O
3	O
months	B-C0439231
12.8	O
vs	O
.	O
	
2.8	O
p=0	O
following	O
crt	B-C3178775
.	O
	
patients	B-C0030705
70	O
had	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
death	B-C1306577
at	O
3	O
months	B-C0439231
following	O
crt	B-C3178775
odds	B-C0028873
ratio	I-C0028873
5.19	O
,	O
95%	O
ci	B-C0009667
1.64	O
p=0	O
and	O
worse	O
survival	B-C0220921
over	O
time	B-C0040223
hazard	B-C2985465
ratio	I-C2985465
2.30	O
,	O
95%	O
ci	B-C0009667
1.34	O
p=0	O
.	O
	
patients	B-C0030705
70	O
years	B-C1510829
were	O
more	O
often	O
treated	B-C1522326
with	O
less	O
toxic	B-C1407029
chemotherapy	B-C3665472
,	O
yet	O
experienced	O
higher	O
rates	B-C1521828
of	O
hospitalization	B-C0019993
during	O
treatment	B-C0087111
and	O
increased	B-C0205217
rates	B-C1521828
of	O
acute	B-C0205178
mortality	B-C0205848
following	O
crt	B-C3178775
.	O
	
the	O
efficacy	B-C1280519
of	O
chemoradiotherapy	B-C0436307
for	O
elderly	B-C0001792
patients	B-C0030705
should	O
be	O
evaluated	O
in	O
a	O
prospective	B-C0205556
setting	I-C0205556
.	O
	
food	B-C3178753
security	I-C3178753
and	O
the	O
nutritional	B-C0392209
status	I-C0392209
of	O
children	B-C0008059
in	O
foster	B-C0599759
care	I-C0599759
new	O
horizons	O
in	O
the	O
protection	O
of	O
a	O
fragile	O
population	O
the	O
nutritional	B-C0392209
status	I-C0392209
of	O
foster	B-C0337544
children	I-C0337544
,	O
the	O
quality	B-C0332306
of	O
daily	B-C0016452
menus	I-C0016452
in	O
group	B-C0018257
homes	I-C0018257
and	O
the	O
food	B-C3178753
security	I-C3178753
inside	O
these	O
organizations	B-C1561598
have	O
been	O
poorly	O
studied	O
and	O
this	O
study	B-C2603343
means	O
to	O
investigate	O
them	O
.	O
	
a	O
sample	O
of	O
125	O
children	B-C0008059
,	O
ranging	O
in	O
age	O
from	O
0-17	O
years	O
,	O
among	O
seven	O
group	B-C0018257
homes	I-C0018257
group	B-C0681860
a	I-C0681860
was	O
compared	O
with	O
121	O
children	B-C0008059
of	O
the	O
general	B-C0683971
population	I-C0683971
we	O
group	B-C0681860
b	I-C0681860
.	O
	
to	O
evaluate	O
nutritional	B-C0392209
status	I-C0392209
,	O
bmi	B-C2227318
percentiles	I-C2227318
were	O
used	O
.	O
	
mean	B-C0444504
percentiles	B-C1264641
of	O
both	O
groups	B-C0681860
were	O
compared	O
through	O
statistical	B-C0871424
analysis	I-C0871424
.	O
	
both	O
nutritional	B-C0392209
and	O
caloric	B-C2164132
daily	I-C2164132
distributions	I-C2164132
in	O
each	O
organization	B-C1561598
were	O
obtained	O
using	O
the	O
24-hour	O
recall	B-C0025663
method	I-C0025663
.	O
	
a	O
specific	O
questionnaire	B-C0034394
was	O
administered	O
to	O
evaluate	O
food	B-C3178753
security	I-C3178753
.	O
	
from	O
the	O
analysis	B-C0936012
of	O
mean	B-C0444504
bmi	B-C1305855
-for-	O
age	B-C0001779
or	O
height-for-length	O
percentiles	B-C1264641
,	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	B-C3842396
between	O
group	B-C0681860
a	I-C0681860
and	O
group	B-C0681860
b	I-C0681860
.	O
	
the	O
average	B-C1510992
daily	B-C0332173
nutrient	B-C0392209
and	O
calorie	B-C0392209
distribution	I-C0392209
in	O
group	B-C0018257
homes	I-C0018257
proves	O
to	O
be	O
nearly	B-C0243095
optimal	I-C0243095
with	O
the	O
exception	O
of	O
a	O
slight	O
excess	B-C1979886
in	O
proteins	B-C0453858
and	O
a	O
slight	O
deficiency	B-C0011155
in	O
pufas	B-C0032615
.	O
	
moreover	O
,	O
a	O
low	B-C0231353
intake	I-C0231353
of	O
iron	B-C0518043
and	O
calcium	B-C0489458
was	O
revealed	O
.	O
	
all	O
organizations	B-C1561598
obtained	O
a	O
""""	O
high	B-C3178753
food	I-C3178753
security	I-C3178753
""""	O
profile	O
.	O
	
nutritional	B-C0392209
conditions	I-C0392209
of	O
foster	B-C0337544
children	I-C0337544
are	O
no	O
worse	O
than	O
that	O
of	O
children	B-C0008059
of	O
the	O
general	B-C0683971
population	I-C0683971
.	O
	
foster	B-C0599759
care	I-C0599759
provides	O
the	O
necessary	B-C0337645
conditions	I-C0337645
to	O
support	O
their	O
incontinence	B-C0021167
-associated	O
dermatitis	B-C0011603
reducing	B-C0392756
adverse	B-C0879626
events	I-C0879626
incontinence	B-C0021167
-associated	O
dermatitis	B-C0011603
iad	B-C0011603
is	O
a	O
common	O
problem	B-C0033213
in	O
patients	B-C0030705
with	O
faecal	B-C0015732
and/or	O
urinary	B-C0042024
incontinence	I-C0042024
.	O
	
urine	B-C0042036
alters	O
the	O
normal	O
skin	B-C1123023
flora	B-C0314761
and	O
increases	O
permeability	B-C0031164
of	O
the	O
stratum	B-C0221921
corneum	I-C0221921
and	O
faecal	B-C0015733
enzymes	B-C0014442
on	O
the	O
skin	B-C1123023
contribute	O
to	O
skin	B-C0849640
damage	I-C0849640
.	O
	
faecal	B-C0015733
bacteria	B-C0004611
can	O
then	O
penetrate	B-C0205321
the	O
skin	B-C1123023
,	O
increasing	O
the	O
risk	B-C0035647
of	O
secondary	B-C0442886
infection	I-C0442886
.	O
	
however	O
,	O
iad	B-C0011603
can	O
be	O
prevented	B-C0199176
and	O
healed	B-C0205249
with	O
timely	O
and	O
appropriate	B-C1548787
skin	B-C0455082
cleansing	I-C0455082
and	O
skin	B-C1543231
protection	I-C1543231
.	O
	
this	O
includes	O
appropriate	B-C1548787
use	O
of	O
containment	B-C0181299
devices	I-C0181299
.	O
	
this	O
article	O
also	O
looks	O
at	O
hartmann	B-C0085099
incontinence	I-C0085099
pads	I-C0085099
that	O
have	O
been	O
developed	O
to	O
absorb	O
the	O
fluids	B-C0302908
that	O
cause	O
iad	B-C0011603
and	O
maintain	O
the	O
skin's	B-C1123023
acidic	B-C0020283
ph	I-C0020283
.	O
	
the	O
acidic	B-C0020283
ph	I-C0020283
of	O
the	O
skin	B-C1123023
contributes	O
to	O
its	O
barrier	B-C2246986
function	I-C2246986
and	O
defence	O
against	O
infection	B-C3714514
.	O
	
therefore	O
,	O
maintaining	O
an	O
acidic	B-C0020283
ph	I-C0020283
will	O
help	O
protect	O
the	O
skin	B-C1123023
from	O
feasibility	B-C0015730
of	O
a	O
transition	B-C2700061
intervention	B-C0184661
aimed	B-C1947946
at	O
adolescents	B-C0205653
with	O
chronic	B-C0008679
illness	I-C0008679
international	B-C1512888
guidelines	B-C0162791
recommend	O
planned	O
and	O
structured	O
transition	B-C2700061
programmes	B-C0043113
for	O
adolescents	B-C0205653
with	O
chronic	B-C0008679
illness	I-C0008679
because	O
inadequate	B-C0205412
transition	B-C2700061
may	O
lead	O
to	O
poor	B-C0421179
disease	I-C0421179
control	I-C0421179
and	O
risk	B-C0035647
of	O
lacking	B-C0332268
outpatient	B-C0589125
follow-up	I-C0589125
.	O
	
to	O
investigate	B-C1292732
the	O
feasibility	B-C0015730
of	O
a	O
transition	B-C2700061
intervention	B-C0184661
aimed	B-C1947946
at	O
adolescents	B-C0205653
with	O
chronic	B-C0008679
illness	I-C0008679
focusing	B-C0589098
on	O
declines	B-C1136454
,	O
drop-outs	B-C0030686
,	O
no-shows	B-C4042858
and	O
advantages	B-C1254370
and	O
disadvantages	B-C1254370
of	O
participating	B-C0679823
.	O
	
we	O
invited	O
236	O
adolescents	B-C0205653
12-20	O
years	O
with	O
juvenile	B-C3495559
idiopathic	I-C3495559
arthritis	I-C3495559
jia	B-C3495559
to	O
participate	B-C0679823
in	O
a	O
randomised	B-C0206035
controlled	I-C0206035
trial	I-C0206035
rct	B-C0206035
transition	B-C2700061
intervention	B-C0184661
.	O
	
reasons	B-C0392360
for	O
decline	B-C1136454
and	O
drop-outs	B-C0030686
were	O
calculated	B-C0444686
.	O
	
adolescents	B-C0205653
'	O
experiences	B-C0596545
of	O
advantages	B-C1254370
and	O
disadvantages	B-C1254370
of	O
participating	B-C0679823
and	O
reasons	B-C0392360
for	O
no-shows	B-C4042858
were	O
investigated	B-C1292732
through	O
focus	B-C0016400
groups	I-C0016400
and	O
telephone	B-C0021823
interviews	I-C0021823
,	O
which	O
were	O
analysed	B-C0936012
using	O
thematic	B-C0949415
analysis	B-C0936012
.	O
	
one	O
hundred	O
and	O
twenty	O
of	O
the	O
236	O
eligible	O
patients	B-C0030705
declined	B-C1136454
to	I-C1136454
participate	I-C1136454
in	O
the	O
intervention	B-C0184661
and	O
20%	O
dropped	B-C0030686
out	I-C0030686
during	O
the	O
intervention	B-C0184661
.	O
	
unspecified	B-C0205370
declines	B-C1136454
and	O
practical	B-C0033213
issues	I-C0033213
were	O
the	O
most	O
common	B-C0205214
reason	B-C0392360
to	O
decline	B-C1136454
,	O
and	O
'	O
do	B-C0004927
not	I-C0004927
wish	I-C0004927
to	I-C0004927
continue	I-C0004927
'	O
was	O
the	O
most	O
common	B-C0205214
reason	B-C0392360
to	O
drop-out	B-C0030686
.	O
	
reasons	B-C0392360
for	O
no-shows	B-C4042858
were	O
forgetting	B-C0598853
and	O
being	O
too	O
busy	O
.	O
	
advantages	B-C1254370
of	O
participating	B-C0679823
were	O
stated	O
as	O
'	O
participating	B-C0679823
without	B-C0332288
parents	B-C0030551
'	O
,	O
'	O
trust	B-C0237935
and	O
confidentiality	B-C0009669
'	O
,	O
'being	O
able	O
to	O
set	O
the	O
agenda	B-C0681473
'	O
and	O
'	O
responsiveness	B-C0205342
'	O
.	O
	
disadvantages	B-C1254370
were	O
'	O
unclear	B-C3845108
aim	B-C1947946
of	O
the	O
study	B-C2603343
'	O
,	O
'meeting	O
others	O
with	O
jia	B-C3495559
'	O
,	O
'too	O
few	O
conversations	B-C0871703
'	O
and	O
'	O
transport	B-C0040802
issues	B-C0033213
'	O
.	O
	
many	O
adolescents	B-C0205653
had	O
difficulties	B-C1299586
understanding	B-C0162340
the	O
aim	B-C1947946
of	O
the	O
intervention	B-C0184661
.	O
	
however	O
,	O
most	O
participants	B-C0205653
appreciated	O
the	O
conversations	B-C0871703
about	O
identity	O
as	O
well	O
as	O
the	O
trust	B-C0237935
and	O
confidentiality	B-C0009669
in	O
the	O
communication	B-C0009452
.	O
	
in	O
the	O
future	O
,	O
adolescents	B-C0205653
should	O
be	O
offered	O
more	O
individually	O
organised	O
programmes	B-C0043113
according	O
to	O
their	O
preferences	B-C0558295
and	O
needs	O
in	O
cooperation	B-C0392337
with	O
parents	B-C0030551
and	O
health	B-C0018724
care	I-C0018724
providers	I-C0018724
.	O
	
high-throughput	B-C0872186
analysis	I-C0872186
of	O
the	O
igg	B-C0208205
n-glycome	I-C0208205
by	O
uplc	B-C0008565
-	O
flr	B-C0180919
as	O
biological	B-C0205460
and	O
clinical	B-C0205210
relevance	B-C2347946
of	O
glycosylation	B-C0017982
is	O
becoming	O
more	O
apparent	B-C0750489
,	O
interest	O
in	O
large	B-C2603343
scale	I-C2603343
studies	I-C2603343
of	O
the	O
glycome	B-C2348869
is	O
growing	O
.	O
	
glycans	B-C0032594
attached	O
to	O
immunoglobulin	B-C0020852
g	I-C0020852
igg	B-C0020852
were	O
shown	O
to	O
be	O
essential	B-C0205224
for	O
its	O
function	B-C0031843
and	O
igg	B-C0020852
glycosylation	B-C0017982
was	O
shown	O
to	O
change	B-C0392747
with	O
various	O
processes	B-C1522240
,	O
making	O
igg	B-C0020852
one	O
of	O
the	O
most	O
studied	O
glycoproteins	B-C0017968
.	O
	
many	O
approaches	B-C0449445
including	O
liquid	B-C0008565
chromatography	I-C0008565
,	O
capillary	B-C0596607
gel	I-C0596607
electrophoresis	I-C0596607
,	O
and	O
mass	B-C0037813
spectrometry	I-C0037813
were	O
developed	O
to	O
study	B-C2603343
igg	B-C0020852
glycosylation	B-C0017982
.	O
	
generation	B-C3146294
of	O
high-quality	B-C0205556
glycomics	B-C1512223
data	B-C1511726
in	O
a	O
high-throughput	B-C0872047
fashion	O
requires	O
reproducible	B-C0035149
and	O
robust	B-C2986815
sample	B-C3824791
preparation	I-C3824791
and	O
accurate	B-C0443131
and	O
reliable	O
quantitative	B-C0681919
analysis	I-C0681919
.	O
	
this	O
chapter	B-C1552857
presents	O
a	O
protocol	B-C2348563
for	O
an	O
optimized	O
and	O
high-throughput	B-C0872047
igg	B-C0208205
n-glycan	I-C0208205
release	B-C1283071
,	O
fluorescent	B-C0022885
labeling	I-C0022885
and	O
cleanup	B-C0243114
,	O
and	O
analysis	B-C0936012
of	O
fluorescently	B-C1708632
labeled	I-C1708632
igg	B-C0208205
n-glycans	I-C0208205
by	O
hydrophilic	B-C0008565
interaction	I-C0008565
liquid	I-C0008565
chromatography	I-C0008565
hilic	B-C0008565
on	O
an	O
ultra	B-C0008565
performance	I-C0008565
liquid	I-C0008565
chromatography	I-C0008565
uplc	B-C0008565
system	O
with	O
fluorescence	B-C0016315
flr	B-C0180919
detection	B-C1511790
.	O
	
biomimetic	B-C1136386
whitlockite	B-C0078483
inorganic	B-C1881215
nanoparticles	B-C1450054
-mediated	O
in	B-C0444498
situ	I-C0444498
remodeling	B-C0085268
and	O
rapid	O
bone	B-C0005972
regeneration	I-C0005972
bone	B-C0085268
remodeling	I-C0085268
process	O
relies	O
on	O
complex	B-C0439855
signaling	B-C0037080
pathway	I-C0037080
between	O
osteoblasts	B-C0029418
and	O
osteoclasts	B-C0029431
and	O
control	O
mechanisms	B-C0441712
to	O
achieve	O
homeostasis	B-C0019868
of	O
their	O
growth	B-C0007595
and	O
differentiation	B-C0007589
.	O
	
despite	O
previous	O
achievements	O
in	O
understanding	O
complicated	O
signaling	B-C0037080
pathways	I-C0037080
between	O
cells	B-C0007634
and	O
bone	B-C0262950
extracellular	B-C0015350
matrices	I-C0015350
during	O
bone	B-C0085268
remodeling	I-C0085268
process	O
,	O
a	O
role	O
of	O
local	O
ionic	B-C0022023
concentration	B-C1446561
remains	O
to	O
be	O
elucidated	B-C2986669
.	O
	
here	O
,	O
we	O
demonstrate	O
that	O
synthetic	B-C1883254
whitlockite	B-C0078483
wh	B-C0078483
ca18mg2	I-C0078483
nanoparticles	B-C1450054
can	O
recapitulate	B-C0205341
early-stage	O
of	O
bone	B-C0005972
regeneration	I-C0005972
through	O
stimulating	B-C1948023
osteogenic	B-C0007589
differentiation	I-C0007589
,	O
prohibiting	B-C1292733
osteoclastic	B-C0029431
activity	B-C0441655
,	O
and	O
transforming	B-C0040682
into	O
mechanically	O
enhanced	O
hydroxyapatite	B-C0020326
hap	B-C0020326
neo	B-C0391978
bone	I-C0391978
tissues	I-C0391978
by	O
continuous	O
supply	O
of	O
po4	B-C1601799
and	O
mg	B-C2346927
under	O
physiological	B-C0205463
conditions	B-C0348080
.	O
	
in	O
addition	O
,	O
based	O
on	O
their	O
structural	B-C0242481
analysis	I-C0242481
,	O
the	O
dynamic	O
phase	B-C0205390
transformation	B-C0040682
from	O
wh	B-C0078483
into	O
hap	B-C0020326
contributed	O
as	O
a	O
key	O
factor	B-C1521761
for	O
rapid	O
bone	B-C0005972
regeneration	I-C0005972
with	O
denser	B-C0439794
hierarchical	B-C0699032
neo-bone	B-C0262950
structure	B-C0678594
.	O
	
our	O
findings	B-C0243095
suggest	O
a	O
groundbreaking	O
concept	O
of	O
'	O
living	B-C0376558
bone	B-C0262950
minerals	B-C0026162
'	O
that	O
actively	B-C0205177
communicate	B-C0007582
with	O
the	O
surrounding	O
system	O
to	O
induce	B-C0205263
self-healing	B-C1254358
,	O
while	O
previous	O
notions	O
about	O
bone	B-C0262950
minerals	B-C0026162
have	O
been	O
limited	O
to	O
passive	B-C3686820
products	O
of	O
cellular	B-C0007634
mineralization	B-C1254358
.	O
	
is	O
the	O
inactivation	B-C0544461
of	O
dentin	B-C0011429
proteases	B-C1947941
by	O
crosslinkers	B-C0010360
reversible	B-C0205343
inactivation	B-C0544461
of	O
dentin	B-C0011429
proteases	B-C1947941
by	O
crosslinkers	B-C0010360
has	O
been	O
suggested	B-C1705535
as	O
a	O
way	O
to	O
prevent	B-C2700409
the	O
degradation	B-C0314674
of	O
dentin	B-C0011429
collagen	B-C0009325
in	O
the	O
hybrid	B-C0598148
layer	B-C1254362
.	O
	
however	O
,	O
it	O
is	O
not	B-C0439673
known	I-C0439673
if	O
the	O
inhibition	B-C3463820
is	O
reversible	B-C0205343
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	B-C0441655
the	O
inactivation	B-C0544461
effect	B-C1280500
of	O
various	O
crosslinkers	B-C0010360
on	O
dentin	B-C0011429
protease	B-C1947941
activity	B-C0243102
over	O
a	O
period	B-C1948053
of	O
6	O
months	O
.	O
	
demineralized	B-C0296481
dentin	I-C0296481
beams	I-C0296481
1	O
,	O
n=10/group	O
were	O
treated	B-C1522326
with	I-C1522326
1	O
1%	O
glutaraldehyde	B-C0017814
ga1	B-C0017814
,	O
2	O
5%	O
glutaraldehyde	B-C0017814
ga5	B-C0017814
,	O
3	O
1%	O
grape	B-C0772454
seed	I-C0772454
extract	I-C0772454
gs1	B-C0772454
,	O
4	O
5%	O
grape	B-C0772454
seed	I-C0772454
extract	I-C0772454
gs5	B-C0772454
,	O
5	O
10%	O
sumac	B-C4047315
berry	I-C4047315
extract	I-C4047315
s	B-C4047315
,	O
6	O
20μm	B-C0010467
curcumin	I-C0010467
cr20	B-C0010467
,	O
and	O
7	O
200μm	O
curcumin	B-C0010467
cr200	B-C0010467
for	O
5min	O
.	O
	
untreated	B-C0243095
beams	B-C0296481
served	O
as	O
control	B-C0009932
.	O
	
the	O
beams	B-C0296481
were	O
incubated	B-C1439852
up	O
to	O
6	O
months	O
and	O
incubation	B-C0358514
media	I-C0358514
were	O
used	O
to	O
analyze	B-C0936012
solubilized	B-C1948047
telopeptide	B-C0030956
ictp	B-C1101784
and	O
ctx	B-C1173299
fragments	B-C0030935
as	O
indicators	B-C1522602
of	O
mmp	B-C0623362
-	O
and	O
cathepsin	B-C0284930
k	I-C0284930
-mediated	O
degradation	B-C0314674
after	O
1	O
,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-C1439852
.	O
	
the	O
relative	B-C0205345
mmp	B-C0623362
activity	B-C1148560
of	O
dentin	B-C0296481
beams	I-C0296481
was	O
tested	O
using	O
a	O
generic	B-C1705810
mmp	B-C0623362
assay	B-C2717977
.	O
	
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
repeated-measures	B-C0871881
anova	B-C0002780
,	O
α=0	O
.	O
	
all	O
treated	B-C1522326
groups	B-C0441833
showed	O
significant	B-C0750502
decrease	B-C0547047
in	O
ctx	B-C1173299
release	O
32.2	O
dentin	B-C0011429
and	O
ictp	B-C1101784
1.8	O
dentin	B-C0011429
fragments	B-C0030935
during	O
the	O
first	O
month	O
of	O
incubation	B-C1439852
compared	B-C1707455
to	O
control	B-C0009932
1159pg/mg	O
and	O
72.9ng	O
dentin	B-C0011429
,	O
respectively	O
.	O
	
ga5	B-C0017814
,	O
gs5	B-C0772454
and	O
cr200	B-C0010467
maintained	B-C1314677
their	O
inhibitory	B-C3463820
effect	B-C1280500
during	O
6-month	O
incubation	B-C1439852
.	O
	
the	O
results	B-C1254595
were	O
confirmed	O
by	O
dry	B-C1254366
mass	I-C1254366
loss	I-C1254366
and	O
relative	B-C0205345
mmp	B-C0623362
activity	B-C1148560
following	O
6	O
months	O
.	O
	
the	O
results	B-C0683954
of	O
this	O
study	B-C2603343
indicate	O
that	O
the	O
long-term	B-C0023983
effect	I-C0023983
is	O
both	O
crosslinker	B-C0010360
and	O
dose	B-C1512045
dependent	I-C1512045
.	O
	
inhibition	B-C0021469
of	O
step61	B-C3883719
ameliorates	B-C0205556
deficits	B-C2987487
in	O
mouse	B-C0025929
and	O
hipsc	B-C3658289
-based	O
schizophrenia	B-C0036341
models	B-C0012644
the	O
brain	B-C0006104
-	O
specific	B-C0205369
tyrosine	B-C0085536
phosphatase	I-C0085536
,	O
step	B-C3883719
striatal-enriched	B-C3883719
protein	I-C3883719
tyrosine	I-C3883719
phosphatase	I-C3883719
is	O
an	O
important	O
regulator	B-C1704735
of	O
synaptic	B-C0027793
function	I-C0027793
.	O
	
step	B-C3883719
normally	O
opposes	O
synaptic	B-C0039062
strengthening	B-C0205556
by	O
increasing	B-C0205217
n-methyl	B-C0080093
d-aspartate	I-C0080093
glutamate	I-C0080093
receptor	I-C0080093
nmdar	B-C0080093
internalization	B-C0599281
through	O
dephosphorylation	B-C3160734
of	O
glun2b	B-C1741283
and	O
inactivation	B-C0314679
of	O
the	O
kinases	B-C0031727
extracellular	B-C0082529
signal-regulated	I-C0082529
kinase	I-C0082529
1	I-C0082529
/	O
2	B-C0170168
and	O
fyn	B-C1530914
.	O
	
here	O
we	O
show	O
that	O
step61	B-C3883719
is	O
elevated	B-C3163633
in	O
the	O
cortex	B-C1176472
in	O
the	O
nrg1	B-C1367656
knockout	B-C1522225
mouse	B-C2986594
model	I-C2986594
of	O
schizophrenia	B-C0036341
sz	B-C0036341
.	O
	
genetic	B-C0314603
reduction	B-C0441610
or	O
pharmacological	B-C0205464
inhibition	B-C3463820
of	O
step	B-C3883719
prevents	B-C1292733
the	O
loss	O
of	O
nmdars	B-C0080093
from	O
synaptic	B-C0039063
membranes	I-C0039063
and	O
reverses	O
behavioral	B-C0004930
deficits	I-C0004930
in	O
nrg1	B-C1367656
mice	B-C0025929
.	O
	
step61	B-C3883719
protein	I-C3883719
is	O
also	O
increased	B-C0205217
in	O
cortical	B-C1176472
lysates	B-C1881488
from	O
the	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
-	O
specific	B-C0205369
erbb2	B-C0069515
/	O
4	B-C0214098
mouse	B-C2986594
model	I-C2986594
of	O
sz	B-C0036341
,	O
as	O
well	O
as	O
in	O
human	B-C3658289
induced	I-C3658289
pluripotent	I-C3658289
stem	I-C3658289
cell	I-C3658289
hipsc	B-C3658289
forebrain	B-C0085140
neurons	B-C0027882
and	O
ngn2	B-C1422204
-	O
induced	B-C0205263
excitatory	B-C0027882
neurons	I-C0027882
,	O
from	O
two	O
independent	B-C0332291
sz	B-C0036341
patient	B-C0030705
cohorts	B-C0599755
.	O
	
in	O
these	O
selected	B-C1707391
sz	B-C0036341
models	B-C0012644
,	O
increased	B-C0205217
step61	B-C3883719
protein	B-C0542493
levels	I-C0542493
likely	O
reflect	O
reduced	B-C0392756
ubiquitination	B-C1519751
and	O
degradation	B-C0597297
.	O
	
these	O
convergent	B-C0205556
findings	B-C0243095
from	O
mouse	B-C0025929
and	O
hipsc	B-C3658289
sz	B-C0036341
models	B-C0012644
provide	B-C1999230
evidence	B-C3887511
for	O
step61	B-C3883719
dysfunction	B-C3887504
in	O
sz	B-C0036341
incident	B-C1551358
fracture	B-C0016658
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
risk	B-C0035647
of	O
mortality	B-C0205848
even	O
after	O
adjusting	O
for	O
frailty	B-C0424594
status	B-C0449438
in	O
elderly	B-C0001792
japanese	B-C1556094
men	B-C0025266
the	O
fujiwara-kyo	B-C0009247
osteoporosis	I-C0009247
risk	I-C0009247
in	I-C0009247
men	I-C0009247
formen	I-C0009247
cohort	I-C0009247
study	I-C0009247
frail	B-C0871754
elderly	B-C0001792
individuals	B-C0237401
have	O
elevated	B-C3163633
risks	B-C0035647
of	O
both	O
fracture	B-C0016658
and	O
mortality	B-C0205848
.	O
	
we	O
found	O
that	O
incident	B-C1551358
fractures	B-C0016658
were	O
associated	B-C0332281
with	I-C0332281
an	O
increased	B-C0205217
risk	B-C0035647
of	O
death	B-C1306577
even	O
after	O
adjusting	O
for	O
pre-fracture	B-C0016658
frailty	B-C0424594
status	B-C0449438
as	O
represented	O
by	O
physical	B-C0679543
performance	I-C0679543
tests	I-C0679543
and	O
laboratory	B-C0022885
tests	I-C0022885
for	O
common	O
geriatric	B-C1704440
diseases	B-C0012634
in	O
community-dwelling	B-C4045975
elderly	B-C0001792
japanese	B-C1556094
men	B-C0025266
.	O
	
while	O
fractures	B-C0016658
reportedly	O
increase	B-C0442805
the	O
risk	B-C0035647
of	O
mortality	B-C0205848
,	O
frailty	B-C0424594
may	O
complicate	B-C0231242
this	O
association	B-C0439849
,	O
generating	O
a	O
false-positive	B-C1112254
result	I-C1112254
.	O
	
we	O
evaluated	B-C0220825
this	O
association	B-C0439849
after	O
adjusting	O
for	O
pre-fracture	B-C0016658
levels	B-C0441889
of	O
frailty	B-C0424594
.	O
	
we	O
examined	B-C0332128
1998	O
community-dwelling	B-C4045975
ambulatory	B-C0439841
men	B-C0025266
aged	B-C0001779
65	O
years	B-C1510829
at	O
baseline	B-C1442488
in	O
the	O
fujiwara-kyo	B-C0009247
osteoporosis	I-C0009247
risk	I-C0009247
in	I-C0009247
men	I-C0009247
study	I-C0009247
for	O
frailty	B-C0424594
status	B-C0449438
as	O
represented	O
by	O
activities	B-C0001288
of	I-C0001288
daily	I-C0001288
living	I-C0001288
adl	B-C0001288
,	O
physical	B-C0679543
performance	I-C0679543
tests	I-C0679543
grip	B-C0429271
strength	I-C0429271
,	O
one-foot	B-C0516711
standing	I-C0516711
balance	I-C0516711
with	I-C0516711
eyes	I-C0516711
open	I-C0516711
,	O
timed	B-C2315460
10-m	I-C2315460
walk	I-C2315460
,	O
and	O
laboratory	B-C0022885
sera	I-C0022885
tests	I-C0022885
.	O
	
participants	O
were	O
then	O
followed	O
for	O
5	O
years	O
for	O
incident	O
clinical	O
fractures	O
and	O
death	O
.	O
	
effects	O
of	O
incident	O
fracture	O
on	O
death	O
were	O
determined	O
by	O
cox	O
proportional	O
hazards	O
model	O
with	O
the	O
first	O
fracture	O
during	O
follow-up	O
as	O
a	O
time-dependent	O
predictor	O
and	O
with	O
frailty	O
status	O
indices	O
as	O
covariates	O
.	O
	
we	O
identified	O
111	O
fractures	O
in	O
99	O
men	O
and	O
138	O
deaths	O
during	O
the	O
follow-up	O
period	O
median	O
follow-up	O
,	O
4.5	O
years	O
.	O
	
participants	O
with	O
incident	O
fractures	O
did	O
not	O
have	O
significantly	O
worse	O
frailty	O
statuses	O
,	O
but	O
did	O
show	O
a	O
significantly	O
higher	O
cumulative	O
mortality	O
rate	O
than	O
those	O
without	O
fractures	O
p	O
=	O
0.0047	O
.	O
	
age-adjusted	O
hazard	O
ratio	O
hr	O
of	O
death	O
for	O
incident	O
fracture	O
was	O
3.57	O
95	O
%	O
confidence	O
interval	O
2.05	O
,	O
6.24	O
.	O
	
when	O
adjusted	O
for	O
physical	O
performance	O
,	O
this	O
decreased	O
to	O
2.77	O
1.51	O
,	O
5.06	O
,	O
but	O
remained	O
significant	O
.	O
	
the	O
hr	O
showed	O
no	O
significant	O
change	O
when	O
adjusted	O
for	O
laboratory	O
test	O
results	O
3.96	O
2.26	O
,	O
6.94	O
.	O
	
exclusion	O
of	O
deaths	O
within	O
the	O
first	O
24	O
months	O
of	O
follow-up	O
did	O
not	O
alter	O
these	O
results	O
.	O
	
incident	O
clinical	O
fracture	O
was	O
associated	O
with	O
an	O
elevated	O
risk	O
of	O
death	O
independently	O
of	O
pre-fracture	O
levels	O
of	O
frailty	O
in	O
community-dwelling	O
elderly	O
men	B-C0025266
total	B-C0429629
energy	I-C0429629
expenditure	I-C0429629
in	O
obese	B-C0028754
kuwaiti	B-C0036375
primary	I-C0036375
school	I-C0036375
children	B-C0008059
assessed	B-C1516048
by	O
the	O
doubly-labeled	B-C0449851
water	I-C0449851
technique	I-C0449851
the	O
aim	O
of	O
this	O
pilot	B-C0031928
study	I-C0031928
was	O
to	O
assess	B-C1516048
body	O
composition	O
and	O
total	B-C0429629
energy	I-C0429629
expenditure	I-C0429629
tee	B-C0429629
in	O
35	O
obese	B-C0028754
7-9	O
years	B-C0439234
old	O
kuwaiti	B-C1257890
children	B-C0008059
18	O
girls	B-C0870604
and	O
17	O
boys	B-C0870221
.	O
	
total	B-C0429632
body	I-C0429632
water	I-C0429632
tbw	B-C0429632
and	O
tee	B-C0429629
were	O
assessed	B-C1516048
by	O
doubly-labeled	B-C0449851
water	I-C0449851
technique	I-C0449851
.	O
	
tbw	B-C0429632
was	O
derived	O
from	O
the	O
intercept	B-C3146232
of	O
the	O
elimination	B-C0231360
rate	I-C0231360
of	O
deuterium	B-C0011744
and	O
tee	B-C0429629
from	O
the	O
difference	B-C1705241
in	O
elimination	B-C0231360
rates	I-C0231360
of	O
18	B-C0030061
and	O
deuterium	B-C0011744
.	O
	
tbw	B-C0429632
was	O
used	O
to	O
estimate	B-C0750572
fat-free	B-C0424679
mass	I-C0424679
ffm	B-C0424679
,	O
using	O
hydration	B-C0596317
factors	B-C1521761
for	O
different	O
ages	B-C0001779
and	O
gender	B-C0079399
.	O
	
fat	B-C3656665
mass	I-C3656665
fm	B-C3656665
was	O
calculated	B-C1441506
as	O
the	O
difference	B-C1705241
between	O
body	B-C0005910
weight	I-C0005910
and	O
ffm	B-C0424679
.	O
	
body	B-C0005910
weight	I-C0005910
was	O
not	O
statistically	B-C1705241
different	I-C1705241
but	O
tbw	B-C0429632
was	O
significantly	B-C0205250
higher	I-C0205250
p	O
=	O
0.018	O
in	O
boys	B-C0870221
44.9	O
3.3	O
than	O
girls	B-C0870604
42.4	O
3.0	O
,	O
while	O
girls	B-C0870604
had	O
significantly	B-C0205250
higher	I-C0205250
estimated	B-C0750572
fm	B-C3656665
45.2	O
3.9	O
weight	O
%	O
versus	O
41.6	O
4.3	O
p	O
=	O
0.014	O
.	O
	
tee	B-C0429629
was	O
significantly	B-C0205250
higher	I-C0205250
in	O
boys	B-C0870221
2395	O
349	O
kcal/day	O
compared	O
with	O
girls	B-C0870604
1978	O
169	O
kcal/day	O
p	O
=	O
0.001	O
.	O
	
estimated	B-C0750572
physical	B-C3694575
activity	I-C3694575
level	I-C3694575
pal	B-C3694575
was	O
significantly	B-C0205250
higher	I-C0205250
in	O
boys	B-C0870221
1.61	O
0.167	O
versus	O
1.51	O
0.870	O
p	O
=	O
0.034	O
.	O
	
our	O
results	B-C1274040
provide	O
the	O
first	O
dataset	B-C0150098
of	O
tee	B-C0429629
in	O
7-9	O
years	B-C0439234
old	O
obese	B-C0028754
kuwaiti	B-C1257890
children	B-C0008059
and	O
highlight	O
important	O
gender	B-C0036866
differences	I-C0036866
to	O
be	O
considered	O
during	O
the	O
development	O
of	O
school	B-C0679800
based	I-C0679800
interventions	I-C0679800
targeted	O
to	O
combat	O
childhood	B-C2362324
obesity	I-C2362324
.	O
	
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
in	O
clinical	B-C0205210
kidney	B-C0022671
transplantation	I-C0022671
how	O
tolerant	B-C0231198
can	O
it	O
be	O
progress	B-C1280477
in	O
the	O
improvement	B-C2986411
of	O
short-term	B-C0443303
and	O
long-term	B-C0443252
outcomes	B-C0085415
of	O
kidney	B-C0022671
transplantation	I-C0022671
seems	O
to	O
have	O
reached	O
a	O
plateau	B-C2964353
,	O
partially	O
due	O
to	O
consequences	B-C0686907
of	I-C0686907
very	O
efficient	B-C0442799
,	O
but	O
nonspecific	B-C0750540
immunosuppressive	B-C0021081
drugs	I-C0021081
.	O
	
in	O
recent	O
years	O
,	O
various	O
forms	O
of	O
cell	B-C0302189
therapy	I-C0302189
,	O
including	O
the	O
use	O
of	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
,	O
have	O
been	O
put	O
forward	O
as	O
an	O
alternative	B-C1523987
strategy	B-C0679716
for	O
more	O
defined	O
therapy	B-C0087111
.	O
	
it	O
is	O
thought	O
that	O
these	O
therapies	B-C0087111
will	O
not	O
only	O
allow	O
controlled	B-C2587213
tapering	B-C0441640
of	O
immunosuppressive	B-C0021081
medication	I-C0021081
,	O
but	O
might	O
bring	O
us	O
also	O
closer	O
to	O
the	O
ambition	B-C0870128
of	O
generating	B-C3146294
donor	B-C0013018
-specific	O
immune	B-C1327458
regulation	I-C1327458
and	O
tolerance	B-C0020963
.	O
	
different	O
forms	O
of	O
alloimmunity	B-C0598604
,	O
including	O
direct	B-C0439851
,	O
indirect	B-C0439852
and	O
semi-direct	B-C0205556
alloantigen	B-C0002131
presentation	O
have	O
to	O
be	O
controlled	O
before	O
donor	B-C0013018
-specific	O
immune	B-C1327458
regulation	I-C1327458
can	O
be	O
reached	O
.	O
	
several	O
mechanisms	B-C0441712
have	O
been	O
described	O
how	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
can	O
affect	O
alloimmunity	B-C0598604
.	O
	
especially	O
,	O
the	O
interaction	B-C0007582
with	O
professional	O
antigen	B-C0003315
presenting	I-C0003315
cells	I-C0003315
,	O
like	O
dendritic	B-C0011306
cells	I-C0011306
,	O
is	O
of	O
critical	B-C1511545
importance	B-C3898777
.	O
	
this	O
review	O
will	O
discuss	O
the	O
current	B-C0521116
status	B-C0449438
of	O
ongoing	O
clinical	B-C0008976
trials	I-C0008976
with	O
mesenchymal	B-C3178844
stromal	I-C3178844
cells	I-C3178844
in	O
kidney	B-C0022671
transplantation	I-C0022671
and	O
specifically	O
concentrate	O
on	O
the	O
possibilities	O
and	O
impossibilities	O
of	O
how	O
these	O
therapeutic	B-C0087111
strategies	I-C0087111
can	O
contribute	B-C1880177
to	O
control	B-C0243148
of	O
the	O
different	O
forms	O
of	O
alloreactivity	B-C0598604
operation	O
in	O
organ	B-C0029216
transplantation	I-C0029216
.	O
	
facilitating	B-C1521761
factors	I-C1521761
and	O
barriers	B-C4045969
to	O
malaria	B-C0024530
research	B-C0035168
utilization	B-C0042153
for	O
policy	B-C0242440
development	I-C0242440
in	O
malawi	B-C0024548
research	B-C0035168
on	O
various	O
determinants	B-C1521761
of	O
health	B-C0018684
is	O
key	O
in	O
providing	B-C1999230
evidence	B-C3887511
for	O
policy	B-C0242440
development	I-C0242440
,	O
thereby	O
leading	O
to	O
successful	B-C1272703
interventions	O
.	O
	
utilization	B-C0042153
of	O
research	B-C0035168
is	O
an	O
intricate	B-C0439855
process	B-C1522240
requiring	O
an	O
understanding	O
of	O
contextual	B-C0683580
factors	I-C0683580
.	O
	
the	O
study	O
was	O
conducted	O
to	O
assess	O
enhancing	B-C2349975
factors	B-C1521761
and	O
barriers	B-C4045969
of	O
research	B-C0035168
utilization	B-C0042153
for	O
malaria	B-C0024530
policy	B-C0242440
development	I-C0242440
in	O
malawi	B-C0024548
.	O
	
qualitative	B-C0205556
research	B-C0035168
approach	O
was	O
used	O
through	O
in-depth	O
interviews	B-C0021822
with	O
39	O
key	O
informants	B-C0870704
that	O
included	O
malaria	B-C0024530
researchers	B-C0035173
,	O
policy	B-C0242170
makers	I-C0242170
,	O
programme	B-C0683739
managers	B-C0335141
,	O
and	O
key	B-C1257890
stakeholders	I-C1257890
.	O
	
purposive	B-C0681880
sampling	I-C0681880
and	O
snowballing	B-C2348215
techniques	I-C2348215
were	O
used	O
in	O
identifying	B-C0205396
key	O
informants	B-C0870704
.	O
	
interview	B-C0021822
transcripts	B-C0034869
were	O
entered	B-C1521975
in	O
qsr	B-C0037585
nvivo	I-C0037585
11	I-C0037585
software	I-C0037585
for	O
coding	O
and	O
analysis	B-C0936012
.	O
	
respondents	B-C0282122
identified	B-C0205396
global	B-C2348867
efforts	B-C0441655
as	O
key	O
in	O
advancing	O
knowledge	B-C3494164
translation	I-C3494164
,	O
while	O
local	B-C0205276
political	B-C0032380
will	I-C0032380
has	O
been	O
conducive	B-C3898897
for	O
research	B-C0035168
utilization	B-C0042153
.	O
	
other	O
factors	B-C1521761
were	O
availability	B-C0470187
of	I-C0470187
research	B-C0035168
,	O
availability	B-C0470187
of	I-C0470187
diverse	O
local	B-C0205276
researchers	B-C0035173
and	O
stakeholders	B-C1257890
supporting	B-C1521721
knowledge	B-C3494164
translation	I-C3494164
.	O
	
while	O
barriers	B-C4045969
included	O
lack	B-C0332268
of	O
platforms	O
for	O
researcher	B-C0035173
-	O
public	B-C0678367
engagement	B-C2937292
,	O
politics	B-C0032379
,	O
researchers'	B-C0035173
lack	B-C0332268
of	O
communication	B-C0870313
skills	I-C0870313
,	O
lack	B-C0332268
of	O
research	B-C0035168
collaborations	B-C0282116
,	O
funder	B-C0681805
driven	I-C0681805
research	I-C0681805
,	O
unknown	B-C0439673
world	B-C0043237
health	I-C0043237
organization	I-C0043237
policy	B-C0242456
position	O
,	O
and	O
the	O
lack	B-C0332268
of	O
a	O
malaria	B-C0024530
research	B-C0035168
repository	B-C3847505
.	O
	
overall	O
,	O
the	O
study	O
identified	B-C0205396
facilitating	B-C1521761
factors	I-C1521761
to	O
malaria	B-C0024530
research	B-C0035168
utilization	B-C0042153
for	O
policy	B-C0242440
development	I-C0242440
in	O
malawi	B-C0024548
.	O
	
these	O
factors	B-C1521761
need	O
to	O
be	O
systematically	B-C0220922
coordinated	B-C0700114
to	O
address	O
the	O
identified	B-C0205396
barriers	B-C4045969
and	O
improve	B-C0184511
on	O
malaria	B-C0024530
research	B-C0035168
utilization	B-C0042153
in	O
policy	B-C0242440
development	I-C0242440
.	O
	
malaria	B-C0024530
research	B-C0035168
can	O
be	O
key	O
in	O
the	O
implementation	B-C1708476
of	O
evidence-based	B-C3887511
interventions	O
to	O
reduce	B-C0392756
the	O
malaria	B-C0024530
burden	B-C2828008
and	O
assist	O
in	O
the	O
paradigm	B-C0681797
shift	I-C0681797
from	O
malaria	B-C0024530
control	B-C2587213
to	O
elimination	B-C1948029
in	O
altered	B-C0392747
interregional	B-C0005898
correlations	B-C1707520
between	O
serotonin	B-C0170657
transporter	I-C0170657
availability	B-C0470187
and	O
cerebral	B-C1988487
glucose	I-C1988487
metabolism	O
in	O
schizophrenia	O
a	O
high-resolution	O
pet	O
study	O
using	O
11	O
and	O
18	O
the	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	O
correlations	O
of	O
serotonin	O
transporter	O
sert	O
availability	O
with	O
glucose	B-C0596620
metabolism	I-C0596620
using	O
7-tesla	O
magnetic	O
resonance	O
imaging	O
mri	O
and	O
high-resolution	O
positron	O
emission	O
tomography	O
pet	O
with	O
11	O
11	O
and	O
18	O
18	O
in	O
antipsychotic-free	O
patients	O
with	O
schizophrenia	B-C0036341
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	O
functional	O
connectivity	O
in	O
schizophrenia	O
.	O
	
nineteen	O
patients	O
with	O
schizophrenia	O
and	O
18	O
healthy	O
controls	O
underwent	O
high-resolution	B-C0032743
pet	I-C0032743
and	O
mri	O
.	O
	
the	O
binding	O
potential	O
bpnd	O
of	O
11	B-C1570551
and	O
standardized	O
uptake	O
value	O
ratio	O
suvr	O
of	O
18	B-C0046056
were	O
obtained	O
.	O
	
in	O
sert	O
availability	O
,	O
the	O
region	O
of	O
interest	O
roi	O
analyses	O
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	O
,	O
except	O
for	O
the	O
anterior	O
hippocampus	O
where	O
the	O
sert	O
availability	O
was	O
lower	O
in	O
patients	O
with	O
schizophrenia	O
than	O
in	O
controls	O
.	O
	
the	O
roi	O
-	O
and	O
voxel	O
-based	O
analyses	O
revealed	O
that	O
the	O
18	O
suvr	O
values	O
were	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
in	O
the	O
right	O
superior	O
frontal	O
gyrus	O
and	O
medial	O
part	O
of	O
the	O
left	O
superior	O
frontal	O
gyrus	O
.	O
	
regarding	O
the	O
interregional	B-C0005898
correlations	B-C1707520
of	O
11	O
bpnd	O
with	O
18	O
suvr	O
,	O
more	O
widespread	O
positive	O
correlations	O
across	O
the	O
brain	O
regions	O
were	O
observed	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
with	O
schizophrenia	O
.	O
	
notably	O
,	O
the	O
patients	O
and	O
control	O
subjects	O
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	O
between	O
the	O
sert	O
availability	O
in	O
the	O
parietal	O
and	O
temporal	O
cortices	O
and	O
the	O
glucose	O
metabolism	O
in	O
the	O
posterior	O
cingulate	O
cortex	O
.	O
	
these	O
results	O
suggest	O
abnormal	O
functional	O
connectivity	O
between	O
the	O
higher-order	O
cortical	O
regions	O
in	O
schizophrenia	O
and	O
a	O
possible	O
important	O
role	O
of	O
the	O
posterior	O
cingulate	O
gyrus	O
and	O
its	O
related	O
circuitry	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-C0036341
urticarial	B-C0042109
exanthema	B-C0015230
due	O
to	O
hepatitis	B-C0019163
b	I-C0019163
in	O
a	O
pregnant	B-C0033011
woman	I-C0033011
,	O
mimicking	O
a	O
polymorphic	B-C0031736
eruption	I-C0031736
of	O
pregnancy	B-C0032961
hepatitis	B-C3854623
b	I-C3854623
virus	I-C3854623
hbv	I-C3854623
infection	I-C3854623
in	I-C3854623
pregnant	I-C3854623
women	I-C3854623
is	O
very	O
rare	O
in	O
western	B-C0017446
countries	I-C0017446
,	O
thus	O
,	O
cutaneous	B-C0221912
manifestation	B-C1280464
of	I-C1280464
hbv	B-C0019163
infection	I-C0019163
may	O
be	O
confused	O
with	O
a	O
dermatosis	B-C0037274
specific	O
of	O
pregnancy	B-C0032961
.	O
	
we	O
report	O
a	O
39-year-old	O
woman	B-C0043210
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	B-C0032961
with	O
a	O
pruritic	B-C0033771
rash	I-C0033771
,	O
which	O
consisted	O
of	O
generalized	O
erythematous	B-C0332477
plaques	I-C0332477
,	O
some	O
of	O
them	O
with	O
a	O
purple	B-C0243095
centre	I-C0243095
.	O
	
serology	B-C0036743
testing	I-C0036743
showed	O
acute	B-C0019163
hbv	I-C0019163
infection	I-C0019163
,	O
and	O
a	O
biopsy	B-C0005558
revealed	O
a	O
superficial	B-C0205124
and	O
interstitial	B-C3810076
perivascular	I-C3810076
inflammatory	I-C3810076
infiltrate	I-C3810076
of	O
lymphocytes	B-C0024264
and	O
eosinophils	B-C0014467
.	O
	
a	O
diagnosis	B-C0011900
of	O
exanthema	B-C0015230
due	O
to	O
acute	B-C0019163
hepatitis	I-C0019163
b	I-C0019163
infection	I-C0019163
was	O
established	O
.	O
	
the	O
patient	B-C0030705
delivered	B-C0559563
a	O
clinically	B-C0686744
healthy	I-C0686744
boy	I-C0686744
,	O
who	O
was	O
given	O
the	O
first	B-C0178602
dose	I-C0178602
of	O
the	O
hbv	B-C0474232
vaccine	I-C0474232
and	O
intravenous	B-C0085297
specific	I-C0085297
immunoglobulin	I-C0085297
,	O
followed	O
by	O
the	O
second	B-C0178602
dose	I-C0178602
2	O
months	O
later	O
,	O
and	O
did	O
not	O
get	O
infected	B-C0439663
with	O
hbv	B-C0019169
.	O
	
to	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
describing	O
hbv	B-C0019163
exanthema	B-C0015230
in	O
a	O
pregnant	B-C0033011
woman	I-C0033011
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	B-C0021289
,	O
avoiding	O
vertical	B-C0242648
transmission	I-C0242648
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	B-C1623038
and	O
hepatocellular	B-C2239176
carcinoma	I-C2239176
.	O
	
determination	O
of	O
the	O
mutant	B-C1273380
prevention	I-C1273380
concentration	I-C1273380
and	O
the	O
mutant	B-C0001555
selection	I-C0001555
window	I-C0001555
of	O
topical	B-C1136255
antimicrobial	I-C1136255
agents	I-C1136255
against	O
propionibacterium	B-C0033477
acnes	I-C0033477
determination	O
of	O
the	O
mutant	B-C1273380
prevention	I-C1273380
concentration	I-C1273380
mpc	B-C1273380
and	O
the	O
mutant	B-C0001555
selection	I-C0001555
window	I-C0001555
msw	B-C0001555
of	O
antimicrobial	B-C1136254
agents	I-C1136254
used	O
to	O
treat	O
pathogenic	B-C0450254
bacteria	B-C0004611
is	O
important	O
in	O
order	O
to	O
apply	O
effective	O
antimicrobial	B-C1136254
therapies	B-C0087111
.	O
	
here	O
,	O
we	O
determined	O
the	O
mpcs	B-C1273380
of	O
the	O
major	O
topical	B-C1136255
antimicrobial	I-C1136255
agents	I-C1136255
against	O
propionibacterium	B-C0033477
acnes	I-C0033477
and	O
staphylococcus	B-C0038172
aureus	I-C0038172
which	O
cause	O
skin	B-C0162627
infections	I-C0162627
and	O
compared	O
their	O
msws	B-C0001555
.	O
	
among	O
the	O
mpcs	B-C1273380
of	O
nadifloxacin	B-C0286402
and	O
clindamycin	B-C0008947
,	O
the	O
clindamycin	B-C0008947
mpc	B-C1273380
was	O
determined	O
to	O
be	O
the	O
lowest	B-C1708760
against	O
p	B-C0033477
.	O
	
acnes	I-C0033477
.	O
	
in	O
contrast	O
,	O
the	O
nadifloxacin	B-C0286402
mpc	B-C1273380
was	O
the	O
lowest	B-C1708760
against	O
s	B-C0038172
.	O
	
aureus	I-C0038172
.	O
	
calculations	B-C1956058
based	O
on	O
the	O
minimum	B-C1304747
inhibitory	I-C1304747
concentrations	I-C1304747
and	O
mpcs	B-C1273380
showed	O
that	O
clindamycin	B-C0008947
has	O
the	O
lowest	B-C1708760
msw	B-C0001555
against	O
both	O
p	B-C0033477
.	O
	
acnes	I-C0033477
and	O
s	B-C0038172
.	O
	
aureus	I-C0038172
.	O
	
nadifloxacin	B-C0286402
msws	B-C0001555
were	O
4-fold	O
higher	B-C0205250
against	O
p	B-C0033477
.	O
	
acnes	I-C0033477
than	O
against	O
s	B-C0038172
.	O
	
aureus	I-C0038172
.	O
	
it	O
is	O
more	O
likely	O
for	O
p	B-C0033477
.	O
	
acnes	I-C0033477
to	O
acquire	O
resistance	B-C0013203
to	O
fluoroquinolones	B-C0949665
than	O
s	B-C0038172
.	O
	
aureus	I-C0038172
.	O
	
therefore	O
,	O
topical	B-C0683174
application	I-C0683174
of	O
clindamycin	B-C0008947
contributes	O
very	O
little	O
to	O
the	O
emergence	O
of	O
resistant	B-C0013203
p	B-C0033477
.	O
	
acnes	I-C0033477
and	O
s	B-C0038172
.	O
	
aureus	I-C0038172
total	O
colectomy	B-C0009274
for	O
colon	B-C0347646
perforation	I-C0347646
after	O
kayexalate	B-C0124498
administration	B-C1533734
a	O
case	O
report	O
and	O
literature	B-C0282441
review	I-C0282441
of	O
a	O
rare	B-C0522498
complication	B-C0009566
kayexalate	B-C0124498
is	O
an	O
ion	B-C0022014
exchange	I-C0022014
resin	I-C0022014
that	O
is	O
commonly	O
used	O
to	O
acutely	O
treat	B-C0087111
patients	B-C0030705
with	O
hyperkalemia	B-C0020461
.	O
	
bowel	B-C0009324
ulceration	I-C0009324
and	O
necrosis	B-C0027540
is	O
a	O
rare	B-C0522498
and	O
uncommonly	O
recognized	O
complication	B-C0009566
of	O
kayexalate	B-C0124498
administration	B-C1533734
.	O
	
more	O
often	O
,	O
concomitant	B-C0521115
administration	B-C1533734
with	O
sorbitol	B-C0037688
is	O
reported	O
to	O
damage	B-C1883709
the	O
bowel	B-C0021853
however	O
,	O
there	O
are	O
reports	O
of	O
kayexalate	B-C0124498
administration	B-C1533734
causing	O
bowel	B-C2243080
necrosis	I-C2243080
without	O
sorbitol	B-C0037688
.	O
	
we	O
present	O
a	O
case	O
of	O
a	O
critically	B-C0010340
ill	I-C0010340
patient	B-C0030705
who	O
underwent	O
total	O
colectomy	B-C0009274
for	O
colonic	B-C3671268
necrosis	I-C3671268
secondary	O
to	O
oral	B-C0442027
kayexalate	B-C0124498
administration	B-C1533734
that	O
was	O
not	O
recognized	O
until	O
late	O
in	O
the	O
pathologic	B-C0030660
process	I-C0030660
.	O
	
we	O
also	O
review	B-C0282441
the	I-C0282441
literature	I-C0282441
to	O
further	O
investigate	O
this	O
total	B-C0439810
arsenic	B-C0003818
,	O
cadmium	B-C0006632
,	O
and	O
lead	B-C0023175
determination	B-C1148554
in	O
brazilian	B-C0035567
rice	I-C0035567
samples	B-C0370003
using	O
icp-ms	B-C1553183
this	O
study	B-C2603343
is	O
aimed	O
at	O
investigating	B-C1292732
a	O
suitable	O
method	B-C0025663
for	O
rice	B-C0035567
sample	B-C0370003
preparation	B-C1521827
as	O
well	O
as	O
validating	B-C1519941
and	O
applying	B-C0205245
the	O
method	B-C0025663
for	O
monitoring	B-C0205245
the	O
concentration	B-C1446561
of	O
total	B-C0439810
arsenic	B-C0003818
,	O
cadmium	B-C0006632
,	O
and	O
lead	B-C0023175
in	O
rice	B-C0035567
by	O
using	O
inductively	B-C1553183
coupled	I-C1553183
plasma	I-C1553183
mass	I-C1553183
spectrometry	I-C1553183
icp-ms	B-C1553183
.	O
	
various	O
rice	B-C0035567
sample	B-C0370003
preparation	B-C1521827
procedures	B-C2700391
were	O
evaluated	O
.	O
	
the	O
analytical	B-C0178476
method	I-C0178476
was	O
validated	B-C1519941
by	O
measuring	B-C0242485
several	O
parameters	B-C0449381
including	O
limit	B-C2718050
of	I-C2718050
detection	I-C2718050
lod	B-C2718050
,	O
limit	B-C1709793
of	I-C1709793
quantification	I-C1709793
loq	B-C1709793
,	O
linearity	B-C0392762
,	O
relative	B-C0242568
bias	I-C0242568
,	O
and	O
repeatability	B-C0205556
.	O
	
regarding	O
the	O
sample	B-C0370003
preparation	B-C1521827
,	O
recoveries	B-C0683340
of	O
spiked	B-C0370003
samples	I-C0370003
were	O
within	O
the	O
acceptable	B-C1514721
range	I-C1514721
from	O
89.3	O
to	O
98.2	O
for	O
muffle	B-C1708110
furnace	I-C1708110
,	O
94.2	O
to	O
103.3	O
for	O
heating	B-C0181153
block	I-C0181153
,	O
81.0	O
to	O
115.0	O
for	O
hot	B-C0182315
plate	I-C0182315
,	O
and	O
92.8	O
to	O
108.2	O
for	O
microwave	B-C0336756
.	O
	
validation	B-C1519941
parameters	B-C0449381
showed	O
that	O
the	O
method	B-C0025663
fits	O
for	O
its	O
purpose	O
,	O
being	O
the	O
total	B-C0439810
arsenic	B-C0003818
,	O
cadmium	B-C0006632
,	O
and	O
lead	B-C0023175
within	O
the	O
brazilian	O
legislation	O
limits	O
.	O
	
the	O
method	B-C0025663
was	O
applied	O
for	O
analyzing	B-C0936012
37	O
rice	B-C0035567
samples	B-C0370003
including	O
polished	B-C0035567
,	O
brown	B-C0452710
,	O
and	O
parboiled	B-C0035567
,	O
consumed	O
by	O
the	O
brazilian	B-C0032659
population	I-C0032659
.	O
	
the	O
total	B-C0439810
arsenic	B-C0003818
,	O
cadmium	B-C0006632
,	O
and	O
lead	B-C0023175
contents	B-C0456205
were	O
lower	O
than	O
the	O
established	O
legislative	B-C2937257
values	B-C0042295
,	O
except	O
for	O
total	B-C0439810
arsenic	B-C0003818
in	O
one	O
brown	B-C0452710
rice	I-C0452710
sample	B-C0370003
.	O
	
this	O
study	B-C2603343
indicated	O
the	O
need	O
to	O
establish	O
monitoring	B-C0205245
programs	B-C3484370
for	O
emphasizing	O
the	O
study	B-C2603343
on	O
this	O
type	B-C0332307
of	O
cereal	B-C0007757
,	O
aiming	O
at	O
promoting	O
the	O
public	B-C3244304
health	I-C3244304
.	O
	
safety	B-C0150755
precautions	I-C0150755
and	O
operating	B-C3889288
procedures	I-C3889288
in	O
an	O
a	O
bsl-4	B-C1443939
laboratory	B-C0022877
1	O
.	O
	
biosafety	B-C1443939
level	I-C1443939
4	I-C1443939
suit	B-C0022877
laboratory	I-C0022877
suite	B-C0442711
entry	I-C0442711
and	I-C0442711
exit	I-C0442711
procedures	I-C0442711
biosafety	B-C1443939
level	I-C1443939
4	I-C1443939
bsl-4	B-C1443939
suit	B-C0022877
laboratories	I-C0022877
are	O
specifically	O
designed	B-C1707689
to	O
study	B-C2603343
high-consequence	B-C0450254
pathogens	I-C0450254
for	O
which	O
neither	O
infection	B-C3714514
prophylaxes	B-C0199176
nor	O
treatment	B-C0087111
options	O
exist	O
.	O
	
the	O
hallmarks	O
of	O
these	O
laboratories	B-C0022877
are	O
custom-designed	B-C1707689
airtight	B-C0557698
doors	I-C0557698
,	O
dedicated	O
supply	B-C1561604
and	O
exhaust	B-C3273359
airflow	I-C3273359
systems	I-C3273359
,	O
a	O
negative-pressure	B-C1961760
environment	I-C1961760
,	O
and	O
mandatory	O
use	O
of	O
positive-pressure	B-C0376610
"""space"""	I-C0376610
suits	I-C0376610
.	O
	
the	O
risk	O
for	O
laboratory	B-C0022877
specialists	B-C0035173
working	O
with	O
highly	O
pathogenic	B-C0450254
agents	I-C0450254
is	O
minimized	O
through	O
rigorous	O
training	B-C0220931
and	O
adherence	O
to	O
stringent	O
safety	B-C0677563
protocols	I-C0677563
and	O
standard	B-C3889288
operating	I-C3889288
procedures	I-C3889288
.	O
	
researchers	B-C0035173
perform	O
the	O
majority	B-C0205164
of	O
their	O
work	B-C0043227
in	O
bsl-2	B-C1443937
laboratories	B-C0022877
and	O
switch	O
to	O
bsl-4	B-C1443939
suit	B-C0022877
laboratories	I-C0022877
when	O
work	O
with	O
a	O
high-consequence	B-C0450254
pathogen	I-C0450254
is	O
required	O
.	O
	
collaborators	B-C2827395
and	O
scientists	B-C0402112
considering	O
bsl-4	B-C1443939
projects	B-C0700032
should	O
be	O
aware	O
of	O
the	O
challenges	B-C0033213
associated	B-C0332281
with	I-C0332281
bsl-4	B-C1443939
research	B-C0035168
both	O
in	O
terms	O
of	O
experimental	B-C1517586
technical	B-C0449851
limitations	B-C0449295
in	O
bsl-4	B-C1443939
laboratory	B-C0022877
space	B-C1883067
and	O
the	O
increased	B-C0205217
duration	B-C0449238
of	O
such	O
experiments	B-C0681814
.	O
	
tasks	O
such	O
as	O
entering	B-C0205245
and	O
exiting	B-C0205245
the	O
bsl-4	B-C1443939
suit	B-C0022877
laboratories	I-C0022877
are	O
considerably	O
more	O
complex	B-C0439855
and	O
time-consuming	B-C3827829
compared	B-C1707455
to	O
bsl-2	B-C1443937
and	O
bsl-3	B-C1443938
laboratories	B-C0022877
.	O
	
the	O
focus	O
of	O
this	O
particular	O
article	B-C1706852
is	O
to	O
address	B-C0376649
basic	O
biosafety	B-C0036043
concerns	B-C2699424
and	O
describe	O
the	O
entrance	B-C0442711
and	I-C0442711
exit	I-C0442711
procedures	I-C0442711
for	O
the	O
bsl-4	B-C1443939
laboratory	B-C0022877
at	O
the	O
nih	B-C0027468
/	O
niaid	B-C1513895
integrated	B-C0598009
research	I-C0598009
facility	I-C0598009
at	O
fort	O
detrick	O
.	O
	
such	O
procedures	B-C0442711
include	O
checking	O
external	O
systems	O
that	O
support	O
the	O
bsl-4	B-C1443939
laboratory	B-C0022877
,	O
and	O
inspecting	O
and	O
donning	O
positive-pressure	B-C0376610
suits	I-C0376610
,	O
entering	O
the	O
laboratory	B-C0022877
,	O
moving	O
through	O
air	B-C0001876
pressure	I-C0001876
-	O
resistant	B-C0332325
doors	B-C0557698
,	O
and	O
connecting	O
to	O
air-supply	B-C0181222
hoses	I-C0181222
.	O
	
we	O
will	O
also	O
discuss	O
moving	B-C0560560
within	O
and	O
exiting	B-C0205245
the	O
bsl-4	B-C1443939
suit	B-C0022877
laboratories	I-C0022877
,	O
including	O
using	O
the	O
chemical	B-C0220806
shower	B-C0541748
and	O
removing	B-C1883720
and	O
storing	B-C1698986
positive-pressure	B-C0376610
suits	I-C0376610
.	O
	
masters	B-C0682271
athletes	I-C0682271
exemplars	O
of	O
successful	B-C0001811
aging	I-C0001811
global	B-C1257890
population	I-C1257890
aging	B-C0001811
has	O
raised	B-C0243095
academic	I-C0243095
interest	I-C0243095
in	O
successful	B-C0001811
aging	I-C0001811
to	O
a	O
public	B-C0034033
policy	I-C0034033
priority	O
.	O
	
currently	O
there	O
is	O
no	O
consensus	B-C0376298
regarding	O
the	O
definition	O
of	O
successful	B-C0001811
aging	I-C0001811
.	O
	
however	O
,	O
a	O
synthesis	O
of	O
research	O
shows	O
successful	B-C0001811
aging	I-C0001811
can	O
be	O
defined	O
as	O
a	O
late-life	B-C0233441
process	I-C0233441
of	I-C0233441
change	I-C0233441
characterized	O
by	O
high	B-C0516981
physical	I-C0516981
,	O
psychological	B-C0233398
,	O
cognitive	B-C0392335
,	O
and	O
social	B-C0037395
functioning	I-C0037395
.	O
	
masters	B-C0682271
athletes	I-C0682271
systematically	B-C2673163
train	I-C2673163
for	O
,	O
and	O
compete	B-C0679932
in	I-C0679932
,	O
organized	B-C0871489
forms	I-C0871489
of	I-C0871489
team	I-C0871489
and	O
individual	B-C0681652
sport	I-C0681652
specifically	O
designed	O
for	O
older	B-C0001792
adults	I-C0001792
.	O
	
masters	B-C0682271
athletes	I-C0682271
are	O
often	O
proposed	O
as	O
exemplars	O
of	O
successful	B-C0001811
aging	I-C0001811
.	O
	
however	O
,	O
their	O
aging	B-C0518170
status	I-C0518170
has	O
never	O
been	O
examined	O
using	O
a	O
comprehensive	B-C1880156
multidimensional	B-C2347299
successful	B-C0001811
aging	I-C0001811
definition	O
.	O
	
here	O
,	O
we	O
examine	O
the	O
successful	B-C0023866
aging	I-C0023866
literature	I-C0023866
,	O
propose	O
a	O
successful	B-C0001811
aging	I-C0001811
definition	O
based	O
on	O
this	O
literature	B-C0023866
,	O
present	O
evidence	O
which	O
suggests	O
masters	B-C0682271
athletes	I-C0682271
could	O
be	O
considered	O
exemplars	O
of	O
successful	B-C0001811
aging	I-C0001811
according	O
to	O
the	O
proposed	O
definition	O
,	O
and	O
list	O
future	O
experimental	B-C0681814
research	I-C0681814
non-specific	O
transient	O
mutualism	B-C0599514
between	O
the	O
plant	B-C0321773
parasitic	I-C0321773
nematode	I-C0321773
,	O
bursaphelenchus	B-C0997987
xylophilus	I-C0997987
,	O
and	O
the	O
opportunistic	O
bacterium	B-C0004611
serratia	B-C0445754
quinivorans	I-C0445754
bxf1	I-C0445754
,	O
a	O
plant-growth	B-C0597252
promoting	O
pine	B-C0330186
endophyte	B-C1265415
with	O
antagonistic	B-C0243076
effects	B-C1280500
the	O
aim	O
of	O
this	O
study	B-C2603343
is	O
to	O
understand	O
the	O
biological	O
role	O
of	O
serratia	B-C0445754
quinivorans	I-C0445754
bxf1	I-C0445754
,	O
a	O
bacterium	B-C0004611
commonly	O
found	O
associated	O
with	O
bursaphelenchus	B-C0997987
xylophilus	I-C0997987
,	O
the	O
plant	B-C0321773
parasitic	I-C0321773
nematode	I-C0321773
responsible	O
for	O
pine	B-C0330186
wilt	B-C0032080
disease	I-C0032080
.	O
	
therefore	O
,	O
we	O
studied	O
strain	B-C0445754
bxf1	I-C0445754
effect	O
in	O
pine	B-C0330186
wilt	B-C0032080
disease	I-C0032080
.	O
	
we	O
found	O
that	O
strain	B-C0445754
bxf1	I-C0445754
promoted	O
in	B-C1533691
vitro	I-C1533691
nematode	B-C1704319
reproduction	B-C0035150
.	O
	
moreover	O
,	O
the	O
presence	O
of	O
bacteria	B-C0004611
led	O
to	O
the	O
absence	O
of	O
nematode	B-C1704319
chitinase	B-C0017337
gene	I-C0017337
bxcht-1	I-C0017337
expression	B-C0017262
,	O
suggesting	O
an	O
effect	O
for	O
bacterial	B-C0004611
chitinase	B-C0008145
in	O
nematode	B-C1704319
reproduction	B-C0035150
.	O
	
nevertheless	O
,	O
strain	B-C0445754
bxf1	I-C0445754
was	O
unable	O
to	O
colonize	B-C4289767
the	O
nematode	B-C1704319
interior	O
,	O
bind	O
to	O
its	O
cuticle	B-C0596796
with	O
high	O
affinity	O
or	O
protect	O
the	O
nematode	B-C1704319
from	O
xenobiotic	B-C0043335
stress	B-C0449430
.	O
	
interestingly	O
,	O
strain	B-C0445754
bxf1	I-C0445754
was	O
able	O
to	O
promote	O
tomato	B-C0032098
and	O
pine	B-C0330186
plant-growth	B-C0597252
,	O
as	O
well	O
as	O
to	O
colonize	B-C4289767
its	O
interior	O
,	O
thus	O
,	O
acting	O
like	O
a	O
plant-growth	B-C0597252
promoting	O
endophyte	B-C1265415
.	O
	
consequently	O
,	O
strain	B-C0445754
bxf1	I-C0445754
failed	O
to	O
induce	O
wilting	B-C1457887
symptoms	I-C1457887
when	O
inoculated	O
in	O
pine	B-C0330186
shoot	B-C2700376
artificial	B-C3496294
incisions	I-C3496294
.	O
	
this	O
bacterium	B-C0004611
also	O
presented	O
strong	O
antagonistic	B-C0243076
activities	B-C0441655
against	O
fungi	B-C0016832
and	O
bacteria	B-C0004611
isolated	O
from	O
pinus	B-C1028819
pinaster	I-C1028819
.	O
	
our	O
results	O
suggest	O
that	O
b	B-C0997987
.	O
	
xylophilus	I-C0997987
does	O
not	O
possess	O
a	O
strict	O
symbiotic	B-C0562641
community	I-C0562641
capable	O
of	O
inducing	O
pine	B-C0330186
wilt	B-C0032080
disease	I-C0032080
symptoms	B-C1457887
as	O
previously	O
hypothesized	O
.	O
	
we	O
show	O
that	O
bacteria	B-C0004611
like	O
bxf1	B-C0445754
,	O
which	O
possess	O
plant-growth	B-C0597252
promoting	O
and	O
antagonistic	B-C0243076
effects	B-C1280500
,	O
may	O
be	O
opportunistically	O
associated	O
with	O
b	B-C0997987
.	O
	
xylophilus	I-C0997987
,	O
possibly	O
acquired	O
from	O
the	O
bacterial	B-C0004611
endophytic	B-C1265415
community	I-C1265415
of	O
the	O
host	B-C1167395
pine	B-C0330186
.	O
	
habitual	B-C0815170
physical	I-C0815170
activity	I-C0815170
is	O
associated	B-C0332281
with	I-C0332281
improved	O
anthropometric	B-C0815129
and	O
androgenic	B-C0002844
profile	B-C1979963
in	O
pcos	B-C0032460
a	O
cross-sectional	B-C0010362
study	I-C0010362
to	O
examine	O
the	O
effect	B-C1280500
of	O
habitual	B-C0815170
physical	I-C0815170
activity	I-C0815170
pa	B-C0026606
on	O
the	O
metabolic	B-C3853758
and	O
hormonal	B-C3495938
profiles	I-C3495938
of	O
women	B-C0043210
with	O
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
.	O
	
anthropometric	B-C0815129
,	O
metabolic	B-C0696138
and	O
hormonal	B-C0430022
assessment	I-C0430022
and	O
determination	O
of	O
habitual	B-C0815170
pa	I-C0815170
levels	O
with	O
a	O
digital	B-C2709220
pedometer	I-C2709220
were	O
evaluated	O
in	O
84	O
women	B-C0043210
with	O
pcos	B-C0032460
and	O
67	O
age-	O
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
controls	B-C0009932
.	O
	
pa	B-C0026606
status	O
was	O
defined	O
according	O
to	O
number	B-C1651669
of	I-C1651669
steps	I-C1651669
7500	O
steps	O
,	O
active	O
,	O
or	O
<7500	O
steps	O
,	O
sedentary	B-C0205254
.	O
	
bmi	B-C1305855
was	O
lower	O
in	O
active	O
women	B-C0043210
from	O
both	O
groups	O
.	O
	
active	O
pcos	B-C0032460
women	B-C0043210
presented	O
lower	O
waist	B-C0455829
circumference	I-C0455829
wc	B-C0455829
and	O
lipid	B-C3658347
accumulation	I-C3658347
product	I-C3658347
lap	B-C3658347
values	O
versus	O
sedentary	B-C0205254
pcos	B-C0032460
women	B-C0043210
.	O
	
in	O
the	O
control	B-C0009932
group	I-C0009932
,	O
active	O
women	B-C0043210
also	O
had	O
lower	O
wc	B-C0455829
,	O
lower	O
values	O
for	O
fasting	O
and	O
120-min	O
insulin	B-C0021641
,	O
and	O
lower	O
lap	B-C3658347
than	O
sedentary	B-C0009932
controls	I-C0009932
.	O
	
in	O
the	O
pcos	B-C0032460
group	O
,	O
androgen	B-C0002844
levels	O
were	O
lower	O
in	O
active	O
versus	O
sedentary	B-C0043210
women	I-C0043210
p	O
=	O
0.001	O
.	O
	
in	O
the	O
control	B-C0009932
group	I-C0009932
,	O
free	B-C1261412
androgen	I-C1261412
index	I-C1261412
fai	B-C1261412
was	O
also	O
lower	O
in	O
active	O
versus	O
sedentary	B-C0043210
women	I-C0043210
p	O
=	O
0.018	O
.	O
	
homeostasis	B-C1829779
model	I-C1829779
assessment	I-C1829779
of	O
insulin	B-C0021655
resistance	I-C0021655
and	O
2000	O
daily	O
step	O
increments	O
were	O
independent	O
predictors	B-C2698872
of	O
fai	B-C1261412
.	O
	
each	O
2000	O
daily	O
step	O
increment	O
was	O
associated	B-C0332281
with	I-C0332281
a	O
decrease	O
of	O
1.07	O
in	O
fai	B-C1261412
.	O
	
habitual	B-C0815170
pa	I-C0815170
was	O
associated	B-C0332281
with	I-C0332281
a	O
better	O
anthropometric	B-C0815129
and	O
androgenic	B-C0002844
profile	B-C1979963
in	O
geolocalization	B-C0017446
of	O
influenza	B-C0021400
outbreak	B-C0012652
within	O
an	O
acute	B-C0679878
care	I-C0679878
population	B-C1257890
a	O
layered-surveillance	B-C0220920
approach	B-C0449445
we	O
seek	O
to	O
use	O
a	O
novel	O
layered-surveillance	B-C0220920
approach	B-C0449445
to	O
localize	B-C0392752
influenza	B-C0021400
clusters	B-C0012641
within	O
an	O
acute	B-C0679878
care	I-C0679878
population	B-C1257890
.	O
	
the	O
first	O
layer	O
of	O
this	O
system	B-C0449913
is	O
a	O
syndromic	B-C0039082
surveillance	B-C1444548
screen	I-C1444548
to	O
guide	O
rapid	B-C1658604
polymerase	I-C1658604
chain	I-C1658604
reaction	I-C1658604
testing	I-C1658604
.	O
	
the	O
second	B-C0205436
layer	O
is	O
geolocalization	B-C0017446
and	O
cluster	B-C0009085
analysis	I-C0009085
of	O
these	O
patients	B-C0030705
.	O
	
we	O
posit	O
that	O
any	O
identified	B-C0205396
clusters	B-C0012641
could	O
represent	O
at-risk	B-C0242444
populations	I-C0242444
who	O
could	O
serve	O
as	O
high-yield	B-C0392762
targets	B-C1521840
for	O
preventive	B-C3836383
medical	I-C3836383
interventions	I-C3836383
.	O
	
this	O
was	O
a	O
prospective	B-C0033522
observational	I-C0033522
surveillance	I-C0033522
study	I-C0033522
.	O
	
patients	B-C0030705
were	O
screened	B-C0220908
with	O
a	O
previously	O
derived	O
clinical	B-C0282451
decision	I-C0282451
guideline	I-C0282451
that	O
has	O
a	O
90%	O
sensitivity	B-C0036667
and	O
30%	O
specificity	B-C0037791
for	O
influenza	B-C0021400
.	O
	
patients	B-C0030705
received	O
points	B-C1552961
for	O
the	O
following	O
signs	B-C0037088
and	I-C0037088
symptoms	I-C0037088
within	O
the	O
past	B-C1444637
7	O
days	B-C0439228
cough	B-C0010200
2	O
points	O
,	O
headache	B-C0018681
1	O
point	O
,	O
subjective	B-C0743979
fever	I-C0743979
1	O
point	O
,	O
and	O
documented	B-C0015967
fever	I-C0015967
at	O
triage	B-C0040861
temperature	B-C0039476
>38	O
100.4	O
1	O
point	O
.	O
	
patients	B-C0030705
scoring	B-C0449820
3	O
points	O
or	O
higher	O
were	O
indicated	B-C1444656
for	O
influenza	B-C0021400
testing	B-C0039593
.	O
	
patients	B-C0030705
were	O
tested	B-C0039593
with	O
xpert	B-C1510438
flu	I-C1510438
cepheid	B-C0683757
,	O
sunnyvale	B-C0017446
,	O
ca	B-C0006754
,	O
a	O
rapid	B-C1658604
polymerase	I-C1658604
chain	I-C1658604
reaction	I-C1658604
test	I-C1658604
.	O
	
positive	B-C1446409
results	B-C1274040
were	O
mapped	B-C3858752
with	O
arcgis	B-C0815319
esri	B-C0683757
,	O
redlands	B-C0017446
,	O
ca	B-C0006754
and	O
analyzed	B-C0936012
with	O
kernel	B-C4279908
density	I-C4279908
estimation	I-C4279908
to	O
create	O
heat	B-C0024779
maps	I-C0024779
.	O
	
there	O
were	O
1	O
patients	B-C0030705
tested	B-C0039593
with	O
xpert	B-C1510438
flu	I-C1510438
with	O
retrievable	B-C0205556
addresses	B-C1442065
within	O
the	O
greater	O
phoenix	B-C0815251
metro	I-C0815251
area	I-C0815251
.	O
	
one	O
hundred	O
sixty-seven	O
12%	O
of	O
them	O
tested	B-C0039593
positive	B-C2748182
for	I-C2748182
influenza	I-C2748182
a	I-C2748182
and	O
23	O
2%	O
tested	B-C0039593
positive	B-C2748175
for	I-C2748175
influenza	I-C2748175
b	I-C2748175
.	O
	
the	O
influenza	B-C0029347
a	I-C0029347
virus	I-C0029347
exhibited	O
a	O
clear	B-C1704332
cluster	I-C1704332
pattern	B-C0449774
within	O
this	O
patient	B-C0030705
population	B-C1257890
.	O
	
the	O
densest	B-C1704332
cluster	I-C1704332
was	O
located	B-C0450429
in	O
an	O
approximately	O
1-	O
square-mile	B-C1552923
region	B-C0017446
southeast	B-C1711190
of	O
our	O
hospital	B-C0019994
.	O
	
our	O
layered-surveillance	B-C0220920
approach	B-C0449445
was	O
effective	B-C1704419
in	O
localizing	B-C0392752
a	O
cluster	B-C1704332
of	O
influenza	B-C2062441
a	I-C2062441
outbreak	B-C0012652
.	O
	
this	O
region	B-C0017446
may	O
house	B-C2003847
a	O
high-yield	B-C0392762
target	B-C1521840
population	B-C1257890
for	O
public	B-C0699943
health	I-C0699943
intervention	I-C0699943
.	O
	
further	O
collaborative	B-C0282116
efforts	O
will	O
be	O
made	O
between	O
our	O
hospital	B-C0019994
and	O
the	O
maricopa	B-C3829199
county	I-C3829199
department	B-C3897811
of	I-C3897811
public	I-C3897811
health	I-C3897811
to	O
perform	B-C0884358
a	O
series	O
of	O
community	B-C0009462
vaccination	B-C0042196
events	B-C0441471
before	O
the	O
next	O
influenza	B-C0021400
season	B-C0036497
.	O
	
we	O
hope	O
these	O
efforts	O
will	O
ultimately	O
serve	O
to	O
reduce	B-C0392756
the	O
burden	B-C2828008
of	O
this	O
disease	B-C0012634
on	O
our	O
patient	B-C0030705
population	B-C1257890
,	O
and	O
that	O
this	O
system	B-C0449913
will	O
serve	O
as	O
a	O
framework	O
for	O
future	B-C0016884
investigations	B-C0220825
locating	O
at-risk	B-C0242444
populations	I-C0242444
.	O
	
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
pre-deployment	B-C1254367
predictor	B-C2698872
of	O
post-deployment	B-C1254367
ptsd	B-C0038436
symptoms	B-C1457887
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
is	O
a	O
physiological	O
measure	O
associated	O
with	O
autonomic	B-C0004388
nervous	I-C0004388
system	I-C0004388
activity	B-C0441655
.	O
	
this	O
study	B-C2603343
hypothesized	O
that	O
lower	O
pre-deployment	B-C1254367
hrv	B-C2350828
would	O
be	O
associated	O
with	O
higher	O
post-deployment	B-C1254367
post-traumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
symptoms	B-C1457887
.	O
	
three-hundred-forty-three	O
army	B-C0524647
national	I-C0524647
guard	I-C0524647
soldiers	I-C0524647
enrolled	O
in	O
the	O
warriors	B-C2603343
achieving	I-C2603343
resilience	I-C2603343
war	I-C2603343
study	I-C2603343
were	O
analyzed	O
.	O
	
the	O
primary	O
outcome	B-C1274040
was	O
ptsd	B-C0038436
symptom	B-C1457887
severity	B-C0392364
using	O
the	O
ptsd	B-C0038436
checklist	B-C0451524
-	O
military	B-C3245458
version	B-C0333052
pcl	B-C0451524
measured	O
at	O
baseline	B-C1442488
,	O
3-	O
and	O
12-	O
month	B-C0439231
post-deployment	B-C1254367
.	O
	
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
predictor	B-C2698872
variables	B-C0439828
included	O
high	B-C3854080
frequency	I-C3854080
power	I-C3854080
hf	B-C3854080
and	O
standard	B-C0871420
deviation	I-C0871420
of	O
the	O
normal	O
cardiac	B-C0425583
inter-beat	I-C0425583
interval	B-C1272706
sdnn	B-C1272706
.	O
	
generalized	O
linear	B-C3161035
mixed	I-C3161035
models	I-C3161035
revealed	O
that	O
the	O
pre-deployment	B-C1254367
pcl	B-C0451524
*	O
ln	B-C0237688
interaction	I-C0237688
term	O
was	O
significant	O
p<0	O
.	O
	
pre-deployment	B-C1254367
sdnn	B-C1272706
was	O
not	O
a	O
significant	O
predictor	B-C2698872
of	O
post-deployment	B-C1254367
pcl	B-C0451524
.	O
	
covariates	B-C0439828
included	O
age	B-C0001779
,	O
pre-deployment	B-C1254367
pcl	B-C0451524
,	O
race	B-C0034510
/	O
ethnicity	B-C0015031
,	O
marital	B-C0024819
status	I-C0024819
,	O
tobacco	B-C0543414
use	I-C0543414
,	O
childhood	B-C0008060
abuse	I-C0008060
,	O
pre-deployment	B-C1254367
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
,	O
and	O
previous	O
combat	B-C1710706
zone	I-C1710706
deployment	B-C2825812
.	O
	
pre-deployment	B-C1254367
heart	B-C0018810
rate	I-C0018810
variability	B-C2827666
predicts	O
post-deployment	B-C1254367
ptsd	B-C0038436
symptoms	B-C1457887
in	O
the	O
context	O
of	O
higher	O
pre-deployment	B-C1254367
pcl	B-C0451524
scores	B-C0449820
.	O
	
a	O
neuronal	B-C0027882
pi	B-C0765553
-dependent	O
program	B-C3484370
of	O
oligodendrocyte	B-C0028944
precursor	B-C1709634
recruitment	B-C2949735
and	O
myelination	B-C0596991
the	O
molecular	B-C1148560
trigger	I-C1148560
of	O
cns	B-C3714787
myelination	B-C0596991
is	O
unknown	B-C0439673
.	O
	
by	O
targeting	B-C1521840
pten	B-C1530899
in	O
cerebellar	B-C0007634
granule	I-C0007634
cells	I-C0007634
and	O
activating	B-C1879547
the	O
akt1	B-C0285558
-	O
mtor	B-C0293060
pathway	B-C0086982
,	O
we	O
increased	B-C0205217
the	O
caliber	O
of	O
normally	B-C0205307
unmyelinated	B-C1179986
axons	I-C1179986
and	O
the	O
expression	B-C1171362
of	O
numerous	B-C0439064
genes	B-C0017337
encoding	B-C2700640
regulatory	B-C0815047
proteins	I-C0815047
.	O
	
this	O
led	O
to	O
the	O
expansion	B-C0007595
of	O
genetically	B-C1883559
wild-type	I-C1883559
oligodendrocyte	B-C0028944
progenitor	B-C0038250
cells	I-C0038250
,	O
oligodendrocyte	B-C0028944
differentiation	B-C0007589
and	O
de	B-C1515568
novo	I-C1515568
myelination	B-C0596991
of	O
parallel	B-C3546707
fibers	I-C3546707
.	O
	
thus	O
,	O
a	O
neuronal	B-C0027882
program	B-C3484370
dependent	O
on	O
the	O
phosphoinositide	B-C0031621
pi	B-C0765553
is	O
sufficient	O
to	O
trigger	B-C1148560
all	O
steps	B-C1261552
of	O
atypical	O
microglial	B-C0206116
response	B-C0871261
to	O
biodiesel	B-C0012151
exhaust	I-C0012151
in	O
healthy	B-C3898900
and	O
hypertensive	B-C0020538
rats	B-C0034721
accumulating	O
evidence	B-C3887511
suggests	B-C1705535
a	O
deleterious	B-C0001688
role	B-C1705810
for	O
urban	B-C0442529
air	B-C0001873
pollution	I-C0001873
in	O
central	B-C0007682
nervous	I-C0007682
system	I-C0007682
cns	I-C0007682
diseases	I-C0007682
and	O
neurodevelopmental	B-C1535926
disorders	I-C1535926
.	O
	
microglia	B-C0206116
,	O
the	O
resident	O
innate	B-C0020969
immune	B-C0312740
cells	I-C0312740
and	O
sentinels	B-C0950580
in	O
the	O
brain	B-C0006104
,	O
are	O
a	O
common	B-C0205214
source	B-C0449426
of	O
neuroinflammation	B-C0683396
and	O
are	O
implicated	O
in	O
air	B-C0001873
pollution	I-C0001873
-	O
induced	B-C0205263
cns	B-C0007682
effects	I-C0007682
.	O
	
while	O
renewable	B-C3178762
energy	I-C3178762
,	O
such	O
as	O
soy-based	B-C2717891
biofuel	I-C2717891
,	O
is	O
of	O
increasing	B-C0442808
public	B-C0027361
interest	B-C0543488
,	O
there	O
is	O
little	B-C0700321
information	B-C1533716
on	O
how	O
soy	B-C2717891
biofuel	I-C2717891
may	O
affect	B-C1280500
the	O
brain	B-C0006104
,	O
especially	O
in	O
people	B-C0027361
with	O
preexisting	B-C0521987
disease	I-C0521987
conditions	I-C0521987
.	O
	
to	O
address	O
this	O
,	O
male	B-C0086582
spontaneously	B-C0034705
hypertensive	I-C0034705
rats	I-C0034705
shr	B-C0034705
and	O
normotensive	B-C2712122
wistar	B-C0034709
kyoto	I-C0034709
wky	I-C0034709
rats	I-C0034709
were	O
exposed	B-C0332157
to	I-C0332157
100%	B-C0012151
soy-based	I-C0012151
biodiesel	I-C0012151
exhaust	I-C0012151
100sbde	B-C0012151
0	O
,	O
50	O
,	O
150	O
and	O
500μg/m	O
by	O
inhalation	B-C0004048
,	O
4h/	O
day	B-C0439228
for	O
4	O
weeks	B-C0439230
5	O
days	B-C0439228
/	O
week	B-C0439230
.	O
	
ionized	B-C1455000
calcium-binding	I-C1455000
adapter	I-C1455000
molecule-1	I-C1455000
iba-1	B-C1455000
staining	B-C0487602
of	O
microglia	B-C0206116
in	O
the	O
substantia	B-C0038590
nigra	I-C0038590
revealed	B-C0443289
significant	B-C0750502
changes	B-C0392747
in	O
morphology	B-C0332437
with	O
100sbde	B-C0012151
exposure	B-C0332157
in	O
rats	B-C0034721
from	O
both	B-C1706086
genotypes	B-C0017431
,	O
where	O
shr	B-C0034705
were	O
less	B-C0439092
sensitive	B-C0332324
.	O
	
aconitase	B-C4234382
activity	I-C4234382
was	O
inhibited	B-C0311403
in	O
the	O
frontal	B-C0016733
cortex	I-C0016733
and	O
cerebellum	B-C0007765
of	O
wky	B-C0034709
rats	I-C0034709
exposed	B-C0332157
to	I-C0332157
100sbde	B-C0012151
.	O
	
no	B-C1518422
consistent	B-C0332529
changes	B-C0392747
occurred	B-C2745955
in	O
pro-inflammatory	B-C0333348
cytokine	B-C0079189
expression	B-C1171362
,	O
nitrated	B-C0033684
protein	I-C0033684
,	O
or	O
arginase1	B-C0003763
expression	B-C1171362
in	O
brain	B-C1273723
regions	I-C1273723
from	O
either	O
rat	B-C0034721
strain	I-C0034721
exposed	B-C0332157
to	I-C0332157
100sbde	B-C0012151
.	O
	
however	O
,	O
while	O
iba-1	B-C1455000
mrna	B-C1515670
expression	I-C1515670
was	O
not	B-C1518422
modified	B-C0392747
,	O
cx3cr1	B-C1870161
mrna	B-C1515670
expression	I-C1515670
was	O
lower	B-C0205251
in	O
the	O
striatum	B-C0010097
of	O
100sbde	B-C0012151
exposed	B-C0034721
rats	I-C0034721
regardless	B-C3641650
of	O
genotype	B-C0017431
,	O
suggesting	B-C1705535
a	O
downregulation	B-C0013081
of	O
the	O
fractalkine	B-C0663627
receptor	I-C0663627
on	O
microglia	B-C0206116
in	O
this	O
brain	B-C1273723
region	I-C1273723
.	O
	
together	O
,	O
these	O
data	B-C1511726
indicate	B-C0392360
that	O
while	O
microglia	B-C0206116
are	O
detecting	B-C0442726
and	O
responding	B-C0871261
to	O
100sbde	B-C0012151
exposure	B-C0332157
with	O
changes	B-C0392747
in	O
morphology	B-C0332437
,	O
there	O
is	O
reduced	B-C0392756
expression	B-C1171362
of	O
cx3cr1	B-C1870161
regardless	B-C3641650
of	O
genetic	B-C4042916
background	I-C4042916
and	O
the	O
activation	B-C0678666
response	B-C0871261
is	O
atypical	B-C0205182
without	O
traditional	B-C0443324
inflammatory	B-C0005516
markers	I-C0005516
of	O
m1	B-C0024432
or	O
m2	B-C4086555
activation	B-C0678666
in	O
the	O
pre-activation	B-C0243095
negativity	I-C0243095
pran	B-C0243095
in	O
brain	B-C0006104
potentials	B-C3245505
to	O
unfolding	B-C0025361
words	I-C0025361
we	O
describe	O
an	O
event-related	B-C0282171
potential	I-C0282171
erp	B-C0282171
effect	B-C1280500
termed	O
the	O
""""	O
pre-activation	B-C0243095
negativity	I-C0243095
""""	O
pran	B-C0243095
,	O
which	O
is	O
proposed	O
to	O
index	B-C0918012
the	O
degree	B-C0392762
of	I-C0392762
pre-activation	I-C0392762
of	O
upcoming	O
word	B-C1705313
-	O
internal	B-C0205102
morphemes	B-C0870914
in	O
speech	B-C0037817
processing	B-C1709694
.	O
	
using	O
lexical	B-C1882365
competition	I-C1882365
measures	B-C0079809
based	O
on	O
word-initial	B-C0037829
speech	I-C0037829
fragments	I-C0037829
wifs	B-C0037829
,	O
as	O
well	O
as	O
statistical	B-C0871424
analyses	I-C0871424
of	O
erp	B-C0282171
data	B-C1511726
from	O
three	O
experiments	B-C0681814
,	O
it	O
is	O
shown	O
that	O
the	O
pran	B-C0243095
is	O
sensitive	O
to	O
lexical	B-C1882365
competition	I-C1882365
and	O
that	O
it	O
reflects	O
the	O
degree	B-C0449286
of	O
predictive	B-C0681890
certainty	B-C0205423
the	O
negativity	B-C0205160
is	O
larger	B-C0549177
when	O
there	O
are	O
fewer	B-C0205388
upcoming	O
lexical	B-C1705313
competitors	B-C1257890
.	O
	
angiotensin-converting	B-C4015787
enzyme	I-C4015787
insertion/deletion	I-C4015787
polymorphism	I-C4015787
association	B-C0332281
with	I-C0332281
obesity	B-C0028754
and	O
some	O
related	O
disorders	B-C0012634
in	O
egyptian	B-C0337801
females	B-C0086287
a	O
case-control	B-C1518527
observational	I-C1518527
study	I-C1518527
according	O
to	O
the	O
who	B-C0043237
report	B-C0684224
in	O
2015	O
,	O
obesity	B-C0028754
is	O
the	O
fifth	O
leading	O
cause	B-C0007465
of	I-C0007465
death	I-C0007465
worldwide	B-C1254367
,	O
and	O
the	O
prevalence	B-C0220900
of	O
egyptian	B-C0337801
female	B-C0043210
obesity	B-C0028754
is	O
37.5	O
%	O
.	O
	
since	O
obesity	B-C0028754
is	O
highly	O
influenced	B-C4054723
by	O
genetics	B-C0314603
,	O
and	O
adipose	B-C0001527
tissue	I-C0001527
renin-angiotensin	B-C0035096
system	I-C0035096
is	O
over-activated	B-C0205245
in	O
obesity	B-C0028754
,	O
the	O
effect	B-C1704420
of	I-C1704420
angiotensin-converting	B-C4015787
enzyme	I-C4015787
ace	I-C4015787
insertion/deletion	I-C4015787
i/d	I-C4015787
polymorphism	I-C4015787
on	O
obesity	B-C0028754
and	O
related	O
disorders	B-C0012634
was	O
studied	O
in	O
several	O
populations	B-C1257890
,	O
because	O
of	O
its	O
effect	B-C1280500
on	O
ace	B-C2258685
activity	I-C2258685
.	O
	
our	O
objective	B-C0018017
was	O
to	O
study	B-C2603343
the	O
association	B-C0439849
of	O
ace	B-C4015787
i/d	I-C4015787
polymorphism	I-C4015787
with	O
obesity	B-C0028754
and	O
certain	O
related	O
disorders	B-C0012634
,	O
namely	O
hypertension	B-C0020538
,	O
insulin	B-C0021655
resistance	I-C0021655
and	O
metabolic	B-C0524620
syndrome	I-C0524620
,	O
in	O
egyptian	B-C0337801
females	B-C0086287
.	O
	
eighty	B-C3816958
female	B-C0043210
volunteers	B-C0020155
were	O
recruited	O
,	O
blood	B-C3826646
pressure	I-C3826646
and	O
body	B-C0203910
measurements	I-C0203910
were	O
recorded	B-C0205245
and	O
a	O
fasting	B-C0015663
blood	B-C0178913
sample	I-C0178913
was	O
obtained	O
for	O
the	O
quantitation	B-C1709793
of	O
glucose	B-C0017725
,	O
lipid	B-C0430044
profile	I-C0430044
,	O
insulin	B-C0021641
,	O
leptin	B-C0299583
and	O
identification	B-C0205396
of	O
ace	B-C4015787
i/d	I-C4015787
polymorphs	I-C4015787
.	O
	
subjects	B-C0080105
were	O
grouped	O
based	O
on	O
hypertension	B-C0020538
and	O
obesity	B-C4060989
states	I-C4060989
.	O
	
comparisons	B-C1707455
of	O
continuous	B-C0549178
parameters	B-C0449381
were	O
made	O
with	O
independent	B-C0085862
sample	B-C1709321
t-test	I-C1709321
between	O
two	O
groups	B-C0441833
.	O
	
the	O
frequencies	B-C0017270
of	O
ace	B-C1452534
genotypes	B-C0017431
and	O
alleles	B-C0002085
,	O
and	O
the	O
association	B-C0439849
between	O
gene	B-C0678951
polymorphism	I-C0678951
and	O
metabolic	B-C0311400
parameters	B-C0449381
were	O
assessed	B-C1516048
using	O
chi-square	B-C0008041
or	O
fisher's	B-C1708064
exact	I-C1708064
test	I-C1708064
.	O
	
genotype	B-C0017431
frequencies	B-C0017270
were	O
in	O
hardy-weinberg	B-C1547026
equilibrium	I-C1547026
for	O
all	O
groups	B-C0441833
.	O
	
genotype	B-C0017431
distribution	B-C1704711
did	O
not	O
differ	O
significantly	O
between	O
controls	B-C0009932
and	O
cases	B-C1706256
of	O
all	O
the	O
studied	O
disorders	B-C0012634
.	O
	
although	O
dd	B-C0007294
carriers	I-C0007294
had	O
apparently	O
higher	B-C0205250
parameters	B-C0449381
of	O
blood	B-C0005823
pressure	I-C0005823
,	O
lipid	B-C0430044
profile	I-C0430044
and	O
insulin	B-C0021655
resistance	I-C0021655
,	O
only	O
diastolic	B-C0428883
blood	I-C0428883
pressure	I-C0428883
was	O
almost	O
significant	B-C0750502
p	O
=	O
0.057	O
.	O
	
i-carriers	B-C0007294
were	O
significantly	O
less	O
susceptible	B-C0231204
to	O
hypertension	B-C0020538
than	O
dd	B-C0007294
carriers	I-C0007294
having	O
normal	B-C0205307
waist/hip	B-C0205682
ratio	I-C0205682
p	O
=	O
0.007	O
,	O
or	B-C0028873
=	O
17.29	O
,	O
ci	B-C0009667
=	O
1.81	O
and	O
normal	B-C0205307
conicity	B-C1254595
index	I-C1254595
p	O
=	O
0.024	O
,	O
or	B-C0028873
=	O
7.00	O
,	O
ci	B-C0009667
=	O
1.36	O
.	O
	
in	O
dd	B-C0007294
genotype	I-C0007294
carriers	I-C0007294
,	O
a	O
significant	B-C0750502
association	B-C0439849
was	O
found	O
between	O
insulin	B-C0021655
resistance	I-C0021655
and	O
high	B-C0231254
body	I-C0231254
mass	I-C0231254
index	I-C0231254
p	O
=	O
0.004	O
,	O
or	B-C0028873
=	O
8.89	O
,	O
ci	B-C0009667
=	O
1.94	O
,	O
waist	B-C0455829
circumference	I-C0455829
p	O
=	O
0.003	O
,	O
or	B-C0028873
=	O
9.63	O
,	O
ci	B-C0009667
=	O
2.14	O
and	O
waist/height	B-C1821269
ratio	I-C1821269
p	O
=	O
0.034	O
,	O
or	B-C0028873
=	O
6.86	O
,	O
ci	B-C0009667
=	O
1.25	O
,	O
although	O
the	O
variations	B-C0042333
in	O
percentages	B-C0439165
between	O
dd	B-C0007294
and	O
i-carriers	B-C0007294
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect	B-C1704420
of	I-C1704420
ace	B-C4015787
i/d	I-C4015787
on	O
such	O
an	O
association	B-C0439849
.	O
	
in	O
this	O
sample	B-C0370003
of	O
egyptian	B-C0337801
females	B-C0086287
,	O
ace	B-C4015787
i/d	I-C4015787
polymorphism	I-C4015787
was	O
not	B-C1273937
significantly	I-C1273937
associated	B-C0332281
with	I-C0332281
obesity	B-C0028754
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	B-C0012634
studied	O
.	O
	
the	O
i	B-C0002085
allele	I-C0002085
seemed	O
protective	O
against	O
hypertension	B-C0020538
in	O
subjects	B-C0080105
with	O
normal	B-C0205307
,	O
not	O
high	O
,	O
waist/hip	B-C0205682
ratio	I-C0205682
and	O
conicity	B-C1254595
index	I-C1254595
compared	O
to	O
dd	B-C0007294
genotype	I-C0007294
carriers	I-C0007294
.	O
	
expressed	B-C0017262
microrna	B-C1101610
associated	B-C0332281
with	I-C0332281
high	B-C0205250
rate	B-C1521828
of	O
egg	B-C0029965
production	I-C0029965
in	O
chicken	B-C0008051
ovarian	B-C0018120
follicles	I-C0018120
microrna	B-C1101610
mirna	B-C1101610
is	O
a	O
highly	O
conserved	O
class	O
of	O
small	O
noncoding	B-C0887909
rna	I-C0887909
about	O
19-24	O
nucleotides	B-C0028630
in	O
length	B-C1444754
that	O
function	B-C0542341
in	O
a	O
specific	O
manner	O
to	O
post-transcriptionally	B-C1514248
regulate	I-C1514248
gene	B-C0017262
expression	I-C0017262
in	O
organisms	B-C0029235
.	O
	
tissue	B-C0040300
mirna	B-C1101610
expression	B-C0017262
studies	B-C2603343
have	O
discovered	O
a	O
myriad	O
of	O
functions	B-C0542341
for	O
mirnas	B-C1101610
in	O
various	O
aspects	O
,	O
but	O
a	O
role	O
for	O
mirnas	B-C1101610
in	O
chicken	B-C0008051
ovarian	B-C1518744
tissue	I-C1518744
at	O
300	O
days	B-C0439228
of	O
age	B-C0001779
has	O
not	O
hitherto	O
been	O
reported	O
.	O
	
in	O
this	O
study	O
,	O
we	O
performed	O
the	O
first	O
mirna	B-C1101610
analysis	B-C0936012
of	O
ovarian	B-C1518744
tissues	I-C1518744
in	O
chickens	B-C0008051
with	O
low	B-C0205251
and	O
high	B-C0205250
rates	B-C1521828
of	O
egg	B-C0029965
production	I-C0029965
using	O
high-throughput	B-C2936623
sequencing	I-C2936623
.	O
	
by	O
comparing	O
low	B-C0205251
rate	B-C1521828
of	O
egg	B-C0029965
production	I-C0029965
chickens	B-C0008051
with	O
high	B-C0205250
rate	B-C1521828
of	O
egg	B-C0029965
production	I-C0029965
chickens	B-C0008051
,	O
17	O
significantly	O
differentially	O
expressed	B-C0017262
mirnas	B-C1101610
were	O
found	O
p	O
<	O
0.05	O
,	O
including	O
11	O
known	O
and	O
six	O
novel	O
mirnas	B-C1101610
.	O
	
we	O
found	O
that	O
all	O
11	O
known	O
mirnas	B-C1101610
were	O
involved	O
mainly	O
in	O
pathways	B-C0037080
of	O
reproduction	B-C0035150
regulation	B-C0017263
,	O
such	O
as	O
steroid	B-C0597517
hormone	I-C0597517
biosynthesis	I-C0597517
and	O
dopaminergic	B-C0039062
synapse	I-C0039062
.	O
	
additionally	O
,	O
expression	B-C0017262
profiling	O
of	O
six	O
randomly	O
selected	O
differentially	O
regulated	B-C0017263
mirnas	B-C1101610
were	O
validated	O
by	O
quantitative	B-C3179034
real-time	I-C3179034
polymerase	I-C3179034
chain	I-C3179034
reaction	I-C3179034
rt-qpcr	B-C3179034
.	O
	
some	O
mirnas	B-C1101610
,	O
such	O
as	O
gga-mir-34b	B-C1537746
,	O
gga-mir-34c	B-C1537747
and	O
gga-mir-216b	B-C2239687
,	O
were	O
reported	O
to	O
regulate	B-C0017263
processes	O
such	O
as	O
proliferation	B-C0596290
,	O
cell	B-C0007586
cycle	I-C0007586
,	O
apoptosis	B-C0162638
and	O
metastasis	B-C4255448
and	O
were	O
expressed	B-C0017262
differentially	O
in	O
ovaries	B-C0029939
of	O
chickens	B-C0008051
with	O
high	B-C0205250
rates	B-C1521828
of	O
egg	B-C0029965
production	I-C0029965
,	O
suggesting	O
that	O
these	O
mirnas	B-C1101610
have	O
an	O
important	O
role	O
in	O
ovary	B-C0029939
development	B-C0242290
and	O
reproductive	B-C0035150
management	I-C0035150
of	O
chicken	B-C0008051
.	O
	
furthermore	O
,	O
we	O
uncovered	O
that	O
a	O
significantly	O
up-regulated	B-C0041904
mirna	B-C1101610
-	O
gga-mir-200a-3p	B-C1537838
-is	O
ubiquitous	O
in	O
reproduction	B-C0035150
-	O
regulation	B-C0017263
-related	O
pathways	B-C0037080
.	O
	
this	O
mirna	B-C1101610
may	O
play	O
a	O
special	O
central	O
role	O
in	O
the	O
reproductive	B-C0035150
management	I-C0035150
of	O
chicken	B-C0008051
,	O
air	B-C0001873
pollution	I-C0001873
,	O
neighbourhood	B-C1254362
and	O
maternal	B-C1858460
-	O
level	B-C0441889
factors	B-C1521761
modify	B-C3242344
the	O
effect	B-C1280500
of	O
smoking	B-C0037369
on	O
birth	B-C0005612
weight	I-C0005612
a	O
multilevel	B-C0814909
analysis	I-C0814909
in	O
british	B-C0006193
columbia	I-C0006193
,	O
canada	B-C0006823
maternal	B-C1858460
smoking	B-C0037369
during	O
pregnancy	B-C0032961
negatively	B-C0205160
impacts	B-C4049986
fetal	B-C0743925
growth	I-C0743925
,	O
but	O
the	O
effect	B-C1280500
is	O
not	O
homogenous	B-C0439713
across	O
the	O
population	B-C0032659
.	O
	
we	O
sought	O
to	O
determine	O
how	O
the	O
relationship	B-C0439849
between	O
cigarette	B-C0694535
use	I-C0694535
and	O
fetal	B-C0743925
growth	I-C0743925
is	O
modified	B-C3840684
by	O
the	O
social	B-C0037414
and	O
physical	B-C0557720
environment	I-C0557720
.	O
	
birth	B-C0005609
records	I-C0005609
with	O
covariates	O
were	O
obtained	O
from	O
the	O
bc	B-C0242356
perinatal	I-C0242356
database	I-C0242356
registry	I-C0242356
n	O
=	O
232	O
.	O
	
maternal	B-C1858460
smoking	B-C1519386
status	I-C1519386
was	O
self-reported	B-C0681906
as	O
the	O
number	B-C0449788
of	O
cigarettes	B-C0677453
smoked	B-C0037369
per	B-C0439505
day	I-C0439505
usually	O
at	O
the	O
first	B-C1504204
prenatal	I-C1504204
care	I-C1504204
visit	I-C1504204
.	O
	
census	B-C0007663
dissemination	B-C0205221
areas	B-C0017446
das	B-C0017446
were	O
used	O
as	O
neighbourhood	B-C1254362
-	O
level	B-C0441889
units	B-C0439148
and	O
linked	O
to	O
individual	B-C0237401
births	B-C0005615
using	O
residential	B-C1552677
postal	I-C1552677
codes	I-C1552677
to	O
assign	B-C1516050
exposure	B-C0332157
to	I-C0332157
particulate	B-C1510837
air	B-C0001873
pollution	I-C0001873
pm2.5	O
and	O
neighbourhood	B-C1254362
-	O
level	B-C0441889
attributes	B-C0449234
such	O
as	O
socioeconomic	B-C0086996
status	I-C0086996
ses	B-C0086996
,	O
proportion	B-C1709707
of	O
post-secondary	B-C0683860
education	I-C0683860
,	O
immigrant	B-C0282163
density	B-C0178587
and	O
living	B-C0023913
in	O
a	O
rural	B-C0178837
place	I-C0178837
.	O
	
random	B-C0439605
coefficient	B-C1707429
models	B-C3161035
were	O
used	O
with	O
cigarettes	B-C0677453
/day	B-C0439505
modeled	B-C3161035
with	O
a	O
random	B-C0439605
slope	B-C0807955
to	O
estimate	B-C0750572
its	O
between-	O
da	B-C0017446
variability	B-C2827666
and	O
test	B-C0039593
cross-level	B-C0441889
interactions	B-C1704675
with	O
the	O
neighbourhood	B-C1254362
-	O
level	B-C0441889
variables	B-C0439828
on	O
continuous	B-C0549178
birth	B-C0005612
weight	I-C0005612
.	O
	
a	O
significant	B-C0750502
negative	B-C0205160
and	O
non-linear	O
association	B-C0439849
was	O
found	O
between	O
maternal	B-C1858460
smoking	B-C0037369
and	O
birth	B-C0005612
weight	I-C0005612
.	O
	
there	O
was	O
significant	B-C0750502
between-	O
da	B-C0017446
intercept	B-C3146232
variability	B-C2827666
in	O
birth	B-C0005612
weight	I-C0005612
as	O
well	O
as	O
between-	O
da	B-C0017446
slope	B-C0807955
variability	B-C2827666
of	O
maternal	B-C1858460
smoking	B-C0037369
on	O
birth	B-C0005612
weight	I-C0005612
of	O
which	O
68	O
and	O
30	O
%	O
respectively	O
was	O
explained	O
with	O
the	O
inclusion	B-C1512693
of	O
da	B-C0017446
-	O
level	B-C0441889
variables	B-C0439828
and	O
their	O
cross-level	B-C0441889
interactions	B-C1704675
.	O
	
high	B-C0205250
da	B-C0017446
-	O
level	B-C0441889
ses	B-C0086996
had	O
a	O
strong	B-C0442821
positive	B-C1446409
association	B-C0439849
with	O
birth	B-C0005612
weight	I-C0005612
but	O
the	O
effect	B-C1280500
was	O
moderated	B-C1881878
with	O
increased	B-C0442805
cigarettes	B-C0677453
/day	B-C0439505
.	O
	
conversely	O
,	O
heavy	B-C0459847
smokers	I-C0459847
showed	O
the	O
largest	B-C0443228
increases	B-C0442805
in	O
birth	B-C0005612
weight	I-C0005612
with	O
rising	B-C0442805
neighbourhood	B-C1254362
education	B-C1553770
levels	I-C1553770
.	O
	
increased	B-C0442805
levels	B-C0441889
of	O
pm2.5	B-C1510837
and	O
immigrant	B-C0282163
density	B-C0178587
were	O
negatively	B-C0205160
associated	B-C0332281
with	I-C0332281
birth	B-C0005612
weight	I-C0005612
,	O
but	O
showed	O
positive	B-C1446409
interactions	B-C1704675
with	O
increased	B-C0442805
levels	B-C0441889
of	O
smoking	B-C0037369
.	O
	
older	O
maternal	B-C0024915
age	I-C0024915
and	O
suspected	B-C0750491
drug	B-C0242510
or	O
alcohol	B-C0001948
use	I-C0001948
both	O
had	O
negative	B-C0205160
interactions	B-C1704675
with	O
increased	B-C0442805
levels	B-C0441889
of	O
maternal	B-C1858460
smoking	B-C0037369
.	O
	
maternal	B-C1858460
smoking	B-C0037369
had	O
a	O
negative	B-C0205160
and	O
non-linear	O
dose-response	B-C0678790
association	I-C0678790
with	O
birth	B-C0005612
weight	I-C0005612
which	O
was	O
highly	B-C0205250
variable	B-C0439828
between	O
neighbourhood	B-C1254362
s	O
and	O
evidence	B-C3887511
of	O
effect	B-C1280500
modification	B-C3840684
with	O
neighbourhood	B-C1254362
-	O
level	B-C0441889
factors	B-C1521761
.	O
	
these	O
results	B-C1274040
suggest	B-C1705535
that	O
focusing	O
exclusively	O
on	O
individual	B-C0237401
behaviours	B-C0004927
may	O
have	O
limited	B-C0439801
success	B-C0597535
in	O
improving	B-C1272745
outcomes	B-C1274040
without	B-C0332288
addressing	O
the	O
contextual	B-C0237482
influences	B-C4054723
at	O
the	O
neighbourhood	B-C1254362
-	O
level	B-C0441889
.	O
	
further	O
studies	B-C2603343
are	O
needed	O
to	O
corroborate	B-C1456348
our	O
findings	B-C0243095
and	O
to	O
understand	B-C0162340
how	O
neighbourhood	B-C1254362
-	O
level	B-C0441889
attributes	B-C0449234
interact	B-C1704675
with	O
smoking	B-C0037369
to	O
affect	B-C0001721
birth	B-C1286282
outcomes	I-C1286282
.	O
	
individual	B-C0237401
leg	B-C0224456
muscle	I-C0224456
contributions	B-C1880177
to	O
the	O
cost	O
of	O
walking	B-C0080331
effects	B-C1280500
of	O
age	B-C0001779
and	O
walking	B-C2009910
speed	I-C2009910
this	O
study	B-C2603343
examined	B-C0332128
the	O
contributions	B-C1880177
of	O
individual	B-C0237401
muscles	B-C0026845
to	O
changes	O
in	O
energetic	O
cost	B-C0220812
of	I-C0220812
transport	I-C0220812
cot	B-C0220812
over	O
seven	O
walking	B-C2009910
speeds	I-C2009910
,	O
and	O
compared	O
results	O
between	O
healthy	B-C0238598
young	I-C0238598
and	O
elderly	B-C0001792
subjects	I-C0001792
.	O
	
twenty	O
six	O
participants	B-C0679646
13	O
young	B-C0238598
aged	I-C0238598
18-30	O
13	O
old	B-C1999167
aged	I-C1999167
70-80	O
were	O
recruited	O
.	O
	
cot	B-C0220812
o2/kg	O
body	O
mass/km	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	B-C0030055
oxygen	I-C0030055
consumption	I-C0030055
recorded	O
during	O
steady	B-C0080331
state	I-C0080331
walking	I-C0080331
.	O
	
electromyography	B-C0013839
signals	B-C1710082
from	O
10	O
leg	B-C0224456
muscles	I-C0224456
were	O
used	O
to	O
calculate	O
the	O
cumulative	B-C0001288
activity	I-C0001288
required	I-C0001288
to	I-C0001288
traverse	I-C0001288
a	I-C0001288
unit	I-C0001288
of	I-C0001288
distance	I-C0001288
cmapd	B-C0001288
for	O
each	O
muscle	B-C0026845
at	O
each	O
speed	B-C0678536
.	O
	
in	O
the	O
old	B-C1999167
group	I-C1999167
cmapd	B-C0001288
was	O
correlated	B-C1707520
with	O
cot	B-C0220812
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	B-C0678536
speed	I-C0678536
for	O
all	O
studied	O
muscles	B-C0026845
.	O
	
soleus	B-C0242694
cmapd	B-C0001288
was	O
independent	O
of	O
speed	B-C0678536
in	O
the	O
young	B-C0238598
group	I-C0238598
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	B-C0001811
.	O
	
greater	B-C0220812
energy	I-C0220812
cost	I-C0220812
of	O
walking	B-C0080331
in	O
older	B-C0001792
individuals	B-C0237401
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	B-C0220812
cost	I-C0220812
of	O
all	O
lower	B-C2362789
limb	I-C2362789
muscles	I-C2362789
.	O
	
glycated	B-C0017853
hemoglobin	I-C0017853
hba1c	B-C0017853
correlation	B-C1707520
with	O
severity	B-C0439793
of	O
coronary	B-C0010054
artery	I-C0010054
disease	I-C0010054
in	O
non-diabetic	B-C0241863
patients	B-C0030705
-	O
a	O
hospital	B-C0019994
based	I-C0019994
study	B-C2603343
from	O
north-eastern	B-C0017446
india	I-C0017446
glycated	B-C1261236
hemoglobin	I-C1261236
hba1c	I-C1261236
levels	I-C1261236
are	O
predictive	B-C0681890
of	O
cardiovascular	B-C0007222
disease	I-C0007222
and	O
mortality	B-C0178686
in	O
patients	B-C0030705
with	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
however	O
,	O
association	O
of	O
hba1c	B-C0017853
with	O
coronary	B-C0010054
artery	I-C0010054
disease	I-C0010054
cad	B-C0010054
in	O
non-diabetics	B-C0241863
is	O
inconsistent	B-C0442809
.	O
	
to	O
evaluate	B-C0220825
the	O
correlation	B-C1707520
between	O
hba1c	B-C1261236
level	I-C1261236
and	O
severity	B-C0439793
of	O
cad	B-C0010054
in	O
non-diabetic	B-C0030705
patients	I-C0030705
using	O
syntax	B-C0449820
score	I-C0449820
in	O
a	O
cohort	B-C0599755
of	O
proven	O
cad	B-C0010054
on	O
angiography	B-C0002971
at	O
gauhati	B-C1708333
medical	I-C1708333
college	I-C1708333
,	O
guwahati	B-C0017446
,	O
assam	I-C0017446
,	O
india	B-C0021201
,	O
which	O
is	O
a	O
major	O
tertiary	B-C0337954
care	I-C0337954
hospital	I-C0337954
of	O
north-eastern	B-C0017446
india	I-C0017446
.	O
	
we	O
prospectively	O
collected	O
data	B-C1511726
of	O
non-diabetic	B-C0030705
patients	I-C0030705
with	O
proven	O
cad	B-C0010054
on	O
angiography	B-C0002971
from	O
june	O
2014	O
to	O
june	O
2015	O
.	O
	
patients	B-C0030705
were	O
divided	O
into	O
four	O
groups	B-C0441833
interquartiles	B-C2828255
according	O
to	O
hba1c	B-C1261236
levels	I-C1261236
,	O
less	O
than	O
4.8	O
,	O
4.8	O
to	O
5.1	O
,	O
5.1	O
to	O
5.6	O
,	O
and	O
5.6	O
to	O
6.5	O
.	O
	
severity	B-C0439793
of	O
cad	B-C0010054
was	O
assessed	B-C1516048
using	O
syntax	B-C0449820
score	I-C0449820
and	O
the	O
number	B-C3275120
of	I-C3275120
coronary	I-C3275120
vessels	I-C3275120
diseased	I-C3275120
.	O
	
we	O
compared	O
different	O
quartiles	B-C2828255
of	O
hba1c	B-C0017853
with	O
regard	O
to	O
syntax	B-C0449820
score	I-C0449820
and	O
number	O
of	O
diseased	B-C3275120
vessels	I-C3275120
.	O
	
a	O
total	O
of	O
346	O
patients	B-C0030705
were	O
included	O
in	O
the	O
study	B-C2603343
.	O
	
mean	O
age	B-C0001779
was	O
58.1	O
years	O
.	O
	
of	O
the	O
total	O
91.9	O
318	O
were	O
males	B-C0086582
,	O
44.8	O
155	O
were	O
hypertensives	B-C0857121
,	O
29.2	O
101	O
were	O
smokers	B-C0337664
and	O
34.7	O
120	O
were	O
dyslipidemic	B-C0243095
.	O
	
we	O
found	O
that	O
cad	B-C0010054
severity	B-C0439793
by	O
syntax	B-C0449820
score	I-C0449820
as	O
well	O
as	O
number	O
of	O
vessels	B-C0005847
involved	O
was	O
significantly	O
different	O
among	O
quartiles	B-C2828255
p-values	B-C1709380
<0	O
and	O
<0	O
respectively	O
.	O
	
increase	B-C0442805
in	O
hba1c	B-C1261236
level	I-C1261236
was	O
strongly	O
correlated	B-C1707520
with	O
disease	B-C0521117
severity	I-C0521117
and	O
higher	O
syntax	B-C0449820
score	I-C0449820
.	O
	
a	O
significant	O
increase	B-C0442805
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased	B-C3275120
vessels	I-C3275120
p-value	B-C1709380
<0	O
as	O
hba1c	B-C1261236
level	I-C1261236
increases	B-C0442805
.	O
	
age	B-C0001779
,	O
gender	B-C0079399
,	O
hypertension	B-C0020538
and	O
dyslipidemia	B-C0242339
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	B-C2828255
however	O
smoking	B-C0037369
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	B-C2698872
of	O
severity	B-C0439793
of	O
cad	B-C0010054
by	O
syntax	B-C0449820
score	I-C0449820
p	O
<0	O
.	O
	
from	O
this	O
clinical	B-C0008972
study	I-C0008972
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	B-C1707520
exists	O
between	O
hba1c	B-C0017853
and	O
severity	B-C0439793
of	O
cad	B-C0010054
by	O
syntax	B-C0449820
score	I-C0449820
as	O
well	O
as	O
number	O
of	O
vessels	B-C0005847
involved	O
in	O
non-	B-C0243095
diabetes	I-C0243095
.	O
	
on	O
the	O
relation	B-C0439849
between	O
face	B-C0870537
and	O
object	B-C0599621
recognition	I-C0599621
in	O
developmental	B-C0751842
prosopagnosia	I-C0751842
no	O
dissociation	B-C0086168
but	O
a	O
systematic	B-C0220922
association	B-C0439849
there	O
is	O
an	O
ongoing	O
debate	B-C0870392
about	O
whether	O
face	B-C0870537
recognition	I-C0870537
and	O
object	B-C0599621
recognition	I-C0599621
constitute	O
separate	B-C0443299
domains	B-C1880389
.	O
	
clarification	B-C2986669
of	O
this	O
issue	B-C0033213
can	O
have	O
important	B-C3898777
theoretical	B-C0871935
implications	B-C0205556
as	O
face	B-C0870537
recognition	I-C0870537
is	O
often	O
used	O
as	O
a	O
prime	O
example	B-C1707959
of	O
domain	B-C1880389
-	O
specificity	B-C0037791
in	O
mind	B-C0695534
and	O
brain	B-C0006104
.	O
	
an	O
important	B-C3898777
source	B-C0449416
of	O
input	B-C1708517
to	O
this	O
debate	B-C0870392
comes	O
from	O
studies	O
of	O
individuals	B-C0027361
with	O
developmental	B-C0751842
prosopagnosia	I-C0751842
,	O
suggesting	B-C1705535
that	O
face	B-C0870537
recognition	I-C0870537
can	O
be	O
selectively	B-C0221099
impaired	I-C0221099
.	O
	
we	O
put	O
the	O
selectivity	B-C0205556
hypothesis	B-C1512571
to	O
test	B-C0039593
by	O
assessing	O
the	O
performance	B-C1882330
of	O
10	O
individuals	B-C0027361
with	O
developmental	B-C0751842
prosopagnosia	I-C0751842
on	O
demanding	O
tests	O
of	O
visual	B-C0589087
object	I-C0589087
processing	I-C0589087
involving	B-C1314939
both	O
regular	B-C0205272
and	O
degraded	B-C1457868
drawings	B-C0013113
.	O
	
none	O
of	O
the	O
individuals	B-C0027361
exhibited	O
a	O
clear	O
dissociation	B-C0086168
between	O
face	B-C0870537
and	O
object	B-C0599621
recognition	I-C0599621
,	O
and	O
as	O
a	O
group	B-C0681860
they	O
were	O
significantly	B-C0750502
more	O
affected	B-C0392760
by	O
degradation	B-C1457868
of	O
objects	B-C0347997
than	O
control	B-C0009932
participants	B-C0679646
.	O
	
importantly	O
,	O
we	O
also	O
find	O
positive	B-C1446409
correlations	B-C1707520
between	O
the	O
severity	B-C0439793
of	O
the	O
face	B-C0870537
recognition	I-C0870537
impairment	B-C0221099
and	O
the	O
degree	B-C0449286
of	O
impaired	B-C0221099
performance	B-C1882330
with	O
degraded	B-C1457868
objects	B-C0347997
.	O
	
this	O
suggests	O
that	O
the	O
face	B-C0870537
and	O
object	B-C0599621
deficits	B-C2987487
are	O
systematically	O
related	B-C0439849
rather	O
than	O
coincidental	B-C0205420
.	O
	
we	O
conclude	O
that	O
at	O
present	O
,	O
there	O
is	O
no	O
strong	O
evidence	B-C3887511
in	O
the	O
literature	B-C0023866
on	O
developmental	B-C0751842
prosopagnosia	I-C0751842
supporting	O
domain	B-C1880389
-	O
specific	B-C0205369
accounts	O
of	O
face	B-C0870537
recognition	I-C0870537
.	O
	
reduced	B-C0577943
chest	I-C0577943
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
and	O
their	O
relationship	B-C0439849
to	O
lung	B-C0035245
function	I-C0035245
,	O
respiratory	B-C0521346
muscle	B-C0517349
strength	I-C0517349
,	O
and	O
exercise	B-C0162521
tolerance	I-C0162521
in	O
subjects	B-C0681850
with	O
copd	B-C0024117
advanced	O
air-flow	B-C0231999
limitation	B-C0449295
in	O
patients	B-C0030705
with	O
copd	B-C0024117
leads	O
to	O
a	O
reduction	B-C0392756
in	O
vital	B-C0042834
capacity	I-C0042834
,	O
respiratory	B-C0521346
muscle	B-C0517349
strength	I-C0517349
,	O
and	O
exercise	B-C0162521
capacity	I-C0162521
.	O
	
however	O
,	O
its	O
impact	O
on	O
chest	B-C0817096
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
is	O
unknown	B-C0439673
.	O
	
this	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	B-C0033106
of	O
patients	B-C0030705
with	O
copd	B-C0024117
with	O
reduced	B-C0577943
chest	I-C0577943
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
and	O
to	O
investigate	B-C1292732
the	O
effect	B-C1280500
of	O
reduced	B-C0577943
chest	I-C0577943
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
on	O
pulmonary	B-C0035245
function	I-C0035245
,	O
respiratory	B-C0521346
muscle	B-C0517349
strength	I-C0517349
,	O
and	O
exercise	B-C0162521
capacity	I-C0162521
.	O
	
in	O
51	O
elderly	B-C0001792
male	B-C0086582
subjects	B-C0681850
with	O
copd	B-C0024117
,	O
chest	B-C0817096
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
,	O
fvc	B-C3714541
,	O
fev1	B-C0849974
,	O
fev1/fvc	B-C3815113
,	O
maximal	B-C4083126
inspiratory	I-C4083126
pressure	I-C4083126
pimax	B-C4083126
,	O
maximal	B-C4082175
expiratory	I-C4082175
pressure	I-C4082175
pemax	B-C4082175
,	O
and	O
the	O
6-min	B-C0430515
walk	I-C0430515
distance	I-C0430515
6mwd	B-C0430515
were	O
assessed	B-C1516048
.	O
	
chest	B-C0205076
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
were	O
measured	B-C0444706
using	O
the	O
breathing	B-C0004048
movement	B-C0022885
scale	I-C0022885
0-8	O
at	O
the	O
3	O
regions	B-C0005898
upper	B-C0446469
chest	I-C0446469
,	O
lower	B-C0446470
chest	I-C0446470
,	O
and	O
abdomen	B-C0000726
.	O
	
reduced	B-C0700572
mobility	I-C0700572
was	O
defined	O
as	O
a	O
value	B-C1522609
lower	B-C2003888
than	O
the	O
lower	B-C1518030
limit	I-C1518030
of	I-C1518030
the	I-C1518030
normal	I-C1518030
scale	I-C1518030
.	O
	
the	O
unpaired	B-C1710574
t	I-C1710574
test	I-C1710574
,	O
mann-whitney	B-C1708930
test	I-C1708930
,	O
and	O
multiple	B-C0681923
regression	I-C0681923
analysis	I-C0681923
were	O
performed	B-C0884358
.	O
	
the	O
percentages	B-C0439165
of	O
subjects	B-C0681850
with	O
reduced	B-C0700572
mobility	I-C0700572
were	O
78%	O
for	O
the	O
upper	B-C0446469
chest	I-C0446469
,	O
76%	O
for	O
the	O
lower	B-C0446470
chest	I-C0446470
,	O
and	O
53%	O
for	O
the	O
abdomen	B-C0000726
.	O
	
the	O
subjects	B-C0681850
with	O
reduced	B-C0700572
mobility	I-C0700572
had	O
significantly	B-C4055638
low	I-C4055638
fvc	B-C3714541
,	O
fev1	B-C0849974
,	O
and	O
6mwd	B-C0430515
in	O
each	O
region	B-C0005898
and	O
significantly	B-C4055638
low	I-C4055638
fev1/fvc	B-C3815113
,	O
pimax	B-C4083126
,	O
and	O
pemax	B-C4082175
in	O
the	O
abdominal	B-C1720043
region	I-C1720043
compared	B-C1707455
with	O
those	O
with	O
nonreduced	O
mobility	B-C0449580
.	O
	
fvc	B-C3714541
and	O
6mwd	B-C0430515
were	O
independently	O
associated	B-C0332281
with	I-C0332281
the	O
scale	B-C0042295
values	I-C0042295
in	O
each	O
region	B-C0005898
and	O
with	O
the	O
abdominal	B-C0000726
scale	B-C0042295
value	I-C0042295
,	O
respectively	O
.	O
	
the	O
majority	O
of	O
subjects	B-C0681850
with	O
copd	B-C0024117
had	O
reduced	B-C0577943
chest	I-C0577943
and	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
,	O
which	O
was	O
independently	O
associated	B-C0332281
with	I-C0332281
fvc	B-C3714541
.	O
	
even	O
though	O
abdominal	B-C0836916
wall	I-C0836916
mobility	B-C0449580
was	O
relatively	O
preserved	O
compared	B-C1707455
with	O
chest	B-C0205076
wall	I-C0205076
mobility	B-C0449580
,	O
it	O
was	O
also	O
independently	O
associated	B-C0332281
with	I-C0332281
6mwd	B-C0430515
.	O
	
fgf21	B-C3887831
is	O
a	O
biomarker	B-C0005516
for	O
mitochondrial	B-C2245743
translation	I-C2245743
and	O
mtdna	B-C0012929
maintenance	B-C0024501
disorders	B-C0012634
to	O
validate	O
new	O
mitochondrial	B-C0162670
myopathy	I-C0162670
serum	B-C0229671
biomarkers	B-C0005516
for	O
diagnostic	B-C0011933
use	I-C0011933
.	O
	
we	O
analyzed	B-C0936012
serum	B-C0229671
fgf21	B-C3887831
s-fgf21	B-C3887831
and	O
gdf15	B-C1431343
from	O
patients	B-C0030705
with	O
1	O
mitochondrial	B-C0751651
diseases	I-C0751651
and	O
2	O
nonmitochondrial	B-C0012634
disorders	I-C0012634
partially	B-C0728938
overlapping	B-C1948020
with	O
mitochondrial	B-C0751651
disorder	I-C0751651
phenotypes	B-C0031437
.	O
	
we	O
3	O
did	O
a	O
meta-analysis	B-C0920317
of	O
s-fgf21	B-C3887831
in	O
mitochondrial	B-C0751651
disease	I-C0751651
and	O
4	O
analyzed	B-C0936012
s-fgf21	B-C3887831
and	O
skeletal	B-C0242692
muscle	I-C0242692
fgf21	B-C3887831
expression	B-C0017262
in	O
6	O
mouse	B-C0025929
models	B-C0599779
with	O
different	B-C1705242
muscle	B-C0026845
-	O
manifesting	B-C0205319
mitochondrial	B-C4021734
dysfunctions	I-C4021734
.	O
	
we	O
report	O
that	O
s-fgf21	B-C3887831
consistently	O
increases	B-C0442805
in	O
primary	B-C0205225
mitochondrial	B-C0162670
myopathy	I-C0162670
,	O
especially	O
in	O
patients	B-C0030705
with	O
mitochondrial	B-C2245743
translation	I-C2245743
defects	B-C0000768
or	O
mitochondrial	B-C4313882
dna	I-C4313882
mtdna	I-C4313882
deletions	I-C4313882
675	O
and	O
347	O
pg/ml	O
,	O
respectively	O
controls	B-C0009932
66	O
pg/ml	O
,	O
p	O
<	O
0.0001	O
for	O
both	O
.	O
	
this	O
is	O
corroborated	O
in	O
mice	B-C0025929
mtdna	B-C4313882
deletions	I-C4313882
1	O
vs	O
379	O
pg/ml	O
,	O
p	O
<	O
0.0001	O
.	O
	
however	O
,	O
patients	B-C0030705
and	O
mice	B-C0025929
with	O
structural	B-C0000768
respiratory	I-C0000768
chain	I-C0000768
subunit	I-C0000768
or	I-C0000768
assembly	I-C0000768
factor	I-C0000768
defects	I-C0000768
showed	O
low	B-C0205251
induction	B-C0205263
human	B-C0086418
335	O
pg/ml	O
,	O
p	O
<	O
0.05	O
mice	B-C0025929
335	O
pg/ml	O
,	O
not	B-C1273937
significant	I-C1273937
.	O
	
overall	B-C1561607
specificities	B-C0037791
of	O
fgf21	B-C3887831
and	O
gdf15	B-C1431343
to	O
find	O
patients	B-C0030705
with	O
mitochondrial	B-C0162670
myopathy	I-C0162670
were	O
89.3	O
vs	O
86.4	O
,	O
and	O
sensitivities	B-C1511883
67.3	O
and	O
76.0	O
,	O
respectively	O
.	O
	
however	O
,	O
gdf15	B-C1431343
was	O
increased	B-C0205217
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	B-C0348080
conditions	I-C0348080
.	O
	
s-fgf21	B-C3887831
is	O
a	O
specific	B-C0205369
biomarker	B-C0005516
for	O
muscle	B-C0026845
-	O
manifesting	B-C0205319
defects	B-C0000768
of	O
mitochondrial	B-C2245743
translation	I-C2245743
,	O
including	O
mitochondrial	B-C0026237
transfer-rna	B-C0035711
mutations	B-C0026882
and	O
primary	B-C0205225
and	O
secondary	B-C0175668
mtdna	B-C4313882
deletions	I-C4313882
,	O
the	O
most	O
common	O
causes	B-C0015127
of	O
mitochondrial	B-C0751651
disease	I-C0751651
.	O
	
however	O
,	O
normal	B-C0205307
s-fgf21	B-C3887831
does	O
not	B-C1513916
exclude	B-C0332196
structural	B-C0000768
respiratory	I-C0000768
chain	I-C0000768
complex	I-C0000768
or	I-C0000768
assembly	I-C0000768
factor	I-C0000768
defects	I-C0000768
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-C0430022
.	O
	
this	O
study	B-C2603343
provides	O
class	B-C0441887
iii	I-C0441887
evidence	B-C3887511
that	O
elevated	B-C3163633
s-fgf21	B-C3887831
accurately	O
distinguishes	O
patients	B-C0030705
with	O
mitochondrial	B-C0162670
myopathies	I-C0162670
from	O
patients	B-C0030705
with	O
other	O
conditions	B-C0348080
,	O
and	O
fgf21	B-C3887831
and	O
gdf15	B-C1431343
mitochondrial	B-C0162670
myopathy	I-C0162670
from	O
other	O
the	O
effects	B-C1704420
of	I-C1704420
captopril	B-C0006938
on	O
lipopolysaccharide	B-C0023810
induced	B-C0205263
learning	B-C0023186
and	O
memory	B-C0233794
impairments	I-C0233794
and	O
the	O
brain	B-C0006104
cytokine	B-C0079189
levels	B-C0441889
and	O
oxidative	B-C0311404
damage	B-C0010957
in	O
rats	B-C0034721
renin-angiotensin	B-C0035096
system	I-C0035096
has	O
a	O
role	O
in	O
inflammation	B-C0021368
and	O
also	O
involves	O
in	O
learning	B-C0023185
and	O
memory	B-C0025260
.	O
	
in	O
the	O
present	O
study	O
,	O
the	O
effects	B-C1704420
of	I-C1704420
captopril	B-C0006938
on	O
lipopolysaccharide	B-C0023810
lps	B-C0023810
induced	B-C0205263
learning	B-C0023186
and	O
memory	B-C0233794
impairments	I-C0233794
,	O
hippocampal	B-C0019564
cytokine	B-C0079189
levels	B-C0441889
and	O
brain	B-C0459385
tissues	I-C0459385
oxidative	B-C0311404
damage	B-C0010957
was	O
investigated	B-C1292732
.	O
	
the	O
rats	B-C0034721
were	O
divided	O
and	O
treated	O
1	O
saline	B-C0036082
control	B-C0009932
,	O
2	O
lps	B-C0023810
1mg/kg	O
,	O
3-5	O
10	O
,	O
50	O
or	O
100mg/kg	O
captopril	B-C0006938
30min	O
before	O
lps	B-C0023810
.	O
	
the	O
treatment	B-C0087111
was	O
started	O
since	O
six	O
days	B-C0439228
before	O
the	O
behavioral	B-C0683444
experiments	I-C0683444
and	O
continued	O
during	O
the	O
behavioral	B-C0683444
tests	I-C0683444
lps	B-C0023810
injection	B-C1533685
two	O
h	O
before	O
each	O
behavioral	B-C0683444
experiment	I-C0683444
.	O
	
administration	B-C1533734
of	O
lps	B-C0023810
prolonged	B-C0439590
the	O
escape	O
latency	B-C0205275
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
morris	B-C0683444
water	I-C0683444
maze	I-C0683444
mwm	I-C0683444
test	I-C0683444
p<0	O
while	O
,	O
shortened	O
the	O
latency	B-C0205275
to	O
enter	O
the	O
dark	B-C3649443
compartment	I-C3649443
in	O
passive	B-C0871047
avoidance	I-C0871047
pa	B-C0871047
test	B-C0683444
p<0	O
.	O
	
pretreatment	B-C3539076
by	O
all	O
doses	B-C0178602
of	O
captopril	B-C0006938
improved	B-C1272745
performances	B-C1882330
of	O
the	O
rats	B-C0034721
in	O
mwm	B-C0683444
p<0	O
and	O
also	O
prolonged	B-C0439590
the	O
latency	B-C0205275
to	O
enter	O
the	O
dark	B-C3649443
in	O
pa	B-C0871047
test	B-C0683444
p<0	O
.	O
	
lps	B-C0023810
also	O
increased	B-C0205217
il-6	B-C0021760
,	O
tnf-α	B-C1456820
,	O
malondialdehyde	B-C0024643
mda	B-C0024643
and	O
nitric	B-C0028128
oxide	I-C0028128
no	B-C0028128
metabolites	B-C0870883
in	O
the	O
hippocampal	B-C0019564
tissues	B-C0459385
p<0	O
which	O
were	O
prevented	B-C0199176
by	O
captopril	B-C0006938
p<0	O
.	O
	
the	O
thiol	B-C0574031
,	O
superoxide	B-C0038838
dismutase	I-C0038838
sod	B-C0038838
and	O
catalase	B-C0007367
cat	B-C0007367
in	O
the	O
hippocampus	B-C0019564
of	O
lps	B-C0023810
group	B-C0441833
were	O
lower	O
than	O
the	O
control	B-C0009932
p<0	O
while	O
,	O
they	O
were	O
enhanced	B-C2349975
when	O
the	O
aniamls	B-C0003062
were	O
pretreated	B-C3539076
by	O
captopril	B-C0006938
p<0	O
.	O
	
the	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	B-C0006938
improved	B-C1272745
the	O
lps	B-C0023810
-	O
induced	B-C0205263
learning	B-C0023186
and	O
memory	B-C0233794
impairments	I-C0233794
in	O
rats	B-C0034721
which	O
were	O
accompanied	O
with	O
attenuating	B-C0599946
hippocampal	B-C0019564
cytokine	B-C0079189
levels	B-C0441889
and	O
improving	B-C1272745
the	O
brain	B-C0459385
tissues	I-C0459385
oxidative	B-C0311404
damage	B-C0010957
criteria	B-C0243161
.	O
	
targeted	B-C2985566
therapy	I-C2985566
in	O
gastric	B-C0024623
cancer	I-C0024623
gastric	B-C0024623
cancer	I-C0024623
is	O
the	O
fourth	O
most	O
common	O
cancer	B-C0006826
worldwide	O
.	O
	
surgery	B-C0543467
in	O
combination	O
with	O
multimodal	B-C0009429
therapy	I-C0009429
provides	O
the	O
only	O
curative	B-C1273390
therapy	I-C1273390
until	O
now	O
.	O
	
the	O
importance	O
of	O
targeted	B-C2985566
therapy	I-C2985566
became	O
clear	O
over	O
the	O
last	O
few	O
years	B-C0439234
.	O
	
due	O
to	O
the	O
implication	B-C1314939
of	O
her2	B-C0242957
and	O
angiogenesis	B-C0302600
-directed	O
targeted	B-C2985566
therapies	I-C2985566
major	O
advances	O
in	O
the	O
treatment	B-C0087111
of	O
gastric	B-C0024623
cancer	I-C0024623
could	O
be	O
reached	O
.	O
	
nevertheless	O
,	O
benefits	O
in	O
survival	O
remain	O
unsatisfactory	O
and	O
the	O
development	O
of	O
resistance	B-C4281815
to	O
monoclonal	B-C0003250
antibodies	I-C0003250
is	O
arising	O
.	O
	
a	O
comprehensive	B-C1880156
and	O
comparative	B-C1579762
literature	B-C0023866
research	B-C0035168
was	O
performed	O
to	O
evaluate	B-C0220825
the	O
status	O
of	O
her2	B-C0242957
and	O
angiogenesis	B-C0302600
-directed	O
targeted	B-C2985566
therapy	I-C2985566
in	O
gastric	B-C0024623
cancer	I-C0024623
.	O
	
up	O
to	O
now	O
,	O
trastuzumab	B-C0728747
and	O
ramucirumab	B-C2742502
are	O
the	O
only	O
agents	B-C0003392
showing	O
remarkable	O
benefits	O
in	O
the	O
therapy	B-C0087111
for	O
the	O
patients	B-C0030705
suffering	O
from	O
gastric	B-C0024623
cancer	I-C0024623
.	O
	
the	O
limitations	O
of	O
targeted	B-C2985566
therapies	I-C2985566
in	O
gastric	B-C0024623
cancer	I-C0024623
are	O
mainly	O
associated	O
with	O
the	O
development	O
of	O
secondary	O
resistance	B-C4281815
.	O
	
addition	O
of	O
targeted	B-C2985566
therapy	I-C2985566
in	O
second-line	B-C1710038
treatment	I-C1710038
is	O
beneficial	O
when	O
compared	O
with	O
chemotherapy	B-C3665472
alone	O
.	O
	
nevertheless	O
,	O
results	B-C0808233
in	O
first-line	B-C1708063
treatment	I-C1708063
remain	O
modest	O
.	O
	
therefore	O
,	O
new	O
therapeutic	B-C1611640
agents	I-C1611640
and	O
combinations	B-C0013162
in	O
the	O
first-line	B-C1708063
treatment	I-C1708063
of	O
gastric	B-C0024623
cancer	I-C0024623
are	O
urgently	O
needed	O
and	O
remain	O
to	O
be	O
validated	O
in	O
clinical	B-C0008976
trials	I-C0008976
.	O
	
serum	B-C1277266
c-reactive	I-C1277266
protein	I-C1277266
in	O
children	B-C0008059
with	O
liver	B-C0023895
disease	I-C0023895
and	O
ascites	B-C0003962
the	O
diagnosis	B-C1704656
of	O
peritonitis	B-C0031154
as	O
a	O
complication	B-C0009566
of	O
cirrhosis	B-C0023890
is	O
an	O
important	O
clinical	O
problem	O
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
serum	B-C1277266
c-reactive	I-C1277266
protein	I-C1277266
levels	I-C1277266
as	O
a	O
diagnostic	B-C1511876
factor	I-C1511876
for	O
spontaneous	B-C0275551
bacterial	I-C0275551
peritonitis	I-C0275551
sbp	B-C0275551
in	O
child	B-C0030705
patients	I-C0030705
with	O
liver	B-C0023895
disease	I-C0023895
.	O
	
in	O
this	O
study	B-C2603343
,	O
150	O
children	B-C0008059
diagnosed	B-C1704656
with	O
liver	B-C0023895
disease	I-C0023895
and	O
ascites	B-C0003962
upon	O
admission	B-C0184666
to	O
nemazee	B-C0020027
teaching	I-C0020027
hospital	I-C0020027
shiraz	B-C0017446
,	O
iran	B-C0022065
were	O
examined	B-C0332128
.	O
	
patients	B-C0030705
were	O
divided	O
into	O
spontaneous	B-C0275551
bacterial	I-C0275551
peritonitis	I-C0275551
and	O
sterile	B-C0682554
ascetic	I-C0682554
fluid	I-C0682554
groups	I-C0682554
according	O
to	O
the	O
pmn	B-C0948762
count	I-C0948762
250/mm	O
in	O
the	O
ascetic	B-C0682554
fluids	I-C0682554
.	O
	
routine	B-C0022885
laboratory	I-C0022885
tests	I-C0022885
were	O
conducted	O
and	O
quantitative	O
c-reactive	B-C1277266
protein	I-C1277266
crp	I-C1277266
levels	I-C1277266
were	O
measured	O
for	O
all	O
of	O
the	O
patients	B-C0030705
.	O
	
accuracy	B-C0443131
,	O
sensitivity	B-C0036668
,	O
and	I-C0036668
specificity	I-C0036668
of	O
crp	B-C1277266
was	O
evaluated	O
for	O
diagnosis	B-C1704656
of	O
sbp	B-C0275551
.	O
	
of	O
150	O
cirrhotic	B-C1623038
patients	B-C0030705
,	O
109	O
patients	B-C0030705
presented	O
without	O
sbp	B-C0275551
52.29	O
male	B-C0025266
,	O
mean	B-C0001779
age	I-C0001779
5.02	O
4.49	O
years	B-C0439234
and	O
41	O
patients	B-C0030705
presented	O
with	O
sbp	B-C0275551
51.21	O
male	B-C0025266
,	O
mean	B-C0001779
age	I-C0001779
4.71	O
years	B-C0439234
.	O
	
cell	B-C0007584
counts	I-C0007584
,	O
protein	B-C0428479
levels	I-C0428479
,	O
albumin	B-C0428519
levels	I-C0428519
,	O
and	O
lactate	B-C0428346
dehydrogenize	I-C0428346
ldh	I-C0428346
levels	I-C0428346
of	O
the	O
ascetic	B-C0682554
fluid	I-C0682554
and	O
serum	B-C1550100
samples	I-C1550100
in	O
the	O
sbp	B-C0275551
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
sbp	B-C0275551
p	O
<	O
0.05	O
.	O
	
the	O
mean	O
sd	O
of	O
crp	B-C1277266
in	O
the	O
sbp	B-C0275551
group	O
36.89	O
23.43	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
sbp	B-C0275551
21.59	O
15.43	O
,	O
p	O
=	O
0.001	O
.	O
	
the	O
percentages	O
for	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
of	O
crp	B-C1277266
,	O
the	O
diagnosis	B-C1704656
of	O
sbp	B-C0275551
based	O
on	O
the	O
pmn	B-C0948762
count	I-C0948762
250/mm	O
,	O
and	O
cultured	B-C0003962
ascites	I-C0003962
were	O
69.23	O
,	O
90.25	O
,	O
88.43	O
,	O
and	O
84.32	O
,	O
respectively	O
.	O
	
the	O
areas	O
under	O
the	O
curve	O
of	O
crp	B-C1277266
for	O
sbp	B-C0275551
based	O
on	O
the	O
pmn	B-C0948762
count	I-C0948762
250/mm	O
and	O
cultured	B-C0003962
ascites	I-C0003962
was	O
0.94	O
ci	O
95%	O
0.90	O
to	O
0.96	O
and	O
0.85	O
ci	O
95%	O
0.84	O
to	O
0.92	O
,	O
respectively	O
p	O
<	O
0.001	O
.	O
	
our	O
study	B-C2603343
showed	O
that	O
crp	B-C1277266
is	O
a	O
marker	O
with	O
high	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
for	O
the	O
diagnosis	B-C1704656
of	O
sbp	B-C0275551
in	O
cirrhotic	B-C1623038
children	B-C0008059
.	O
	
structure	O
of	O
the	O
bacterial	B-C0521009
plant	B-C0032098
-	O
ferredoxin	B-C0015858
receptor	B-C0597357
fusa	B-C0059038
iron	B-C0302583
is	O
a	O
limiting	O
nutrient	B-C0678695
in	O
bacterial	B-C0004623
infection	I-C0004623
putting	O
it	O
at	O
the	O
centre	O
of	O
an	O
evolutionary	O
arms	O
race	O
between	O
host	B-C1167395
and	O
pathogen	B-C0450254
.	O
	
gram-negative	B-C0018150
bacteria	I-C0018150
utilize	O
tonb	B-C1437205
-dependent	O
outer	B-C1167331
membrane	I-C1167331
receptors	B-C0597357
to	O
obtain	O
iron	B-C0302583
during	O
infection	B-C3714514
.	O
	
these	O
receptors	B-C0597357
acquire	O
iron	B-C0302583
either	O
in	O
concert	O
with	O
soluble	O
iron-scavenging	B-C0142281
siderophores	I-C0142281
or	O
through	O
direct	B-C1704675
interaction	I-C1704675
and	O
extraction	B-C0185115
from	O
host	B-C1167395
proteins	B-C0033684
.	O
	
characterization	B-C1880022
of	O
these	O
receptors	B-C0597357
provides	O
invaluable	O
insight	O
into	O
pathogenesis	B-C0699748
.	O
	
however	O
,	O
only	O
a	O
subset	O
of	O
virulence	B-C0042765
-related	O
tonb	B-C1437205
-dependent	O
receptors	B-C0597357
have	O
been	O
currently	O
described	O
.	O
	
here	O
we	O
report	O
the	O
discovery	B-C1880355
of	O
fusa	B-C0059038
,	O
a	O
new	O
class	O
of	O
tonb	B-C1437205
-dependent	O
receptor	B-C0597357
,	O
which	O
is	O
utilized	O
by	O
phytopathogenic	B-C0030745
pectobacterium	I-C0030745
spp	I-C0030745
.	O
	
to	O
obtain	O
iron	B-C0302583
from	O
plant	B-C0032098
ferredoxin	B-C0015858
.	O
	
through	O
the	O
crystal	B-C0444626
structure	I-C0444626
of	O
fusa	B-C0059038
we	O
show	O
that	O
binding	B-C1167622
of	O
ferredoxin	B-C0015858
occurs	O
through	O
specialized	O
extracellular	B-C0243092
loops	I-C0243092
that	O
form	O
extensive	B-C0205231
interactions	B-C1704675
with	O
ferredoxin	B-C0015858
.	O
	
the	O
function	B-C0542341
of	O
fusa	B-C0059038
and	O
the	O
presence	O
of	O
homologues	B-C0162774
in	O
clinically	B-C3898777
important	I-C3898777
pathogens	B-C0450254
suggests	O
that	O
small	O
iron-containing	B-C0033684
proteins	I-C0033684
represent	O
an	O
iron	B-C0302583
source	B-C0449416
for	O
bacterial	B-C0521009
pathogens	B-C0450254
.	O
	
antigen	B-C0003320
masking	B-C0005520
during	O
fixation	B-C0085254
and	O
embedding	B-C1707903
,	O
dissected	B-C0205239
antigen	B-C0003320
masking	B-C0005520
in	O
routinely	O
processed	B-C1522240
tissue	B-C0040300
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	B-C0439064
factors	B-C1521761
.	O
	
we	O
sought	O
to	O
dissect	B-C0205239
the	O
effect	O
on	O
antigenicity	B-C3714634
of	O
each	O
step	B-C1261552
of	O
processing	B-C1709694
by	O
using	O
frozen	B-C0016741
sections	I-C0016741
as	O
proxies	B-C0600420
of	O
the	O
whole	B-C0040300
tissue	I-C0040300
.	O
	
an	O
equivalent	O
extent	O
of	O
antigen	B-C0003320
masking	B-C0005520
occurs	O
across	O
variable	O
fixation	B-C0085254
times	B-C0040223
at	O
room	B-C2348236
temperature	I-C2348236
.	O
	
most	O
antigens	B-C0003320
benefit	O
from	O
longer	O
fixation	B-C0085254
times	B-C0040223
>24	O
hr	O
for	O
optimal	O
detection	B-C0442726
after	O
antigen	B-C0003320
retrieval	B-C1514918
ar	B-C1514918
for	O
example	O
,	O
ki-67	B-C0208804
,	O
bcl-2	B-C1317122
,	O
er	B-C1545287
.	O
	
the	O
transfer	B-C0205245
to	O
a	O
graded	B-C0001975
alcohol	I-C0001975
series	B-C0205549
results	O
in	O
an	O
enhanced	O
staining	B-C1704680
effect	I-C1704680
,	O
reproduced	O
by	O
treating	B-C1522326
the	O
sections	B-C0016741
with	O
detergents	B-C0011740
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	B-C0032521
immunohistochemical	B-C1441616
detection	B-C0442726
system	B-C0449913
to	O
tissue	B-C0040300
structures	B-C0678594
.	O
	
a	O
second	O
round	O
of	O
masking	B-C0005520
occurs	O
upon	O
entering	O
the	O
clearing	B-C4055226
agent	I-C4055226
,	O
mostly	O
at	O
the	O
paraffin	B-C0030415
embedding	B-C1707903
step	B-C1261552
.	O
	
this	O
may	O
depend	O
on	O
the	O
non-freezable	B-C0205556
water	B-C0043047
removal	B-C1883720
.	O
	
ar	B-C1514918
fully	O
reverses	O
the	O
masking	B-C0005520
due	O
both	O
to	O
the	O
fixation	B-C0085254
time	B-C0040223
and	O
the	O
paraffin	B-C0030415
embedding	B-C1707903
.	O
	
ar	B-C1514918
itself	O
destroys	B-C1948029
some	O
epitopes	B-C0003316
which	O
do	O
not	O
survive	O
routine	B-C0205547
processing	B-C1709694
.	O
	
processed	B-C1522240
frozen	B-C0016741
sections	I-C0016741
are	O
a	O
tool	O
to	O
investigate	B-C1292732
fixation	B-C0085254
and	O
processing	B-C1709694
requirements	B-C1514873
for	O
antigens	B-C0003320
in	O
routine	B-C0205547
specimens	B-C0370003
.	O
	
synthesis	B-C1883254
of	O
1	B-C0212353
as	O
thermochemiluminescent	B-C1522485
labels	I-C1522485
for	O
ultrasensitive	B-C0005507
bioassays	I-C0005507
rational	B-C0681842
prediction	I-C0681842
of	O
olefin	B-C0002068
photooxygenation	B-C1254366
outcome	B-C1274040
by	O
using	O
a	O
chemometric	B-C0022885
approach	I-C0022885
great	O
interest	O
in	O
new	O
thermochemiluminescent	B-C0567416
tcl	I-C0567416
molecules	I-C0567416
,	O
for	O
example	O
,	O
in	O
bioanalytical	B-C0005507
assays	I-C0005507
,	O
has	O
prompted	O
the	O
design	B-C1707689
and	O
synthesis	B-C1883254
of	O
a	O
small	O
library	B-C0023621
of	O
more	O
than	O
30	O
olefins	B-C0002068
to	O
be	O
subjected	O
to	O
photooxygenation	B-C1254366
,	O
with	O
the	O
aim	O
of	O
obtaining	O
new	O
1	B-C0212353
tcl	B-C1522485
labels	I-C1522485
with	O
optimized	B-C0871161
properties	I-C0871161
.	O
	
fluorine	B-C0016330
atoms	O
on	O
the	O
acridan	B-C0283001
system	O
remarkably	O
stabilize	O
1	B-C0212353
when	O
they	O
are	O
located	O
in	O
the	O
3-	B-C1254362
and/or	I-C1254362
6-position	I-C1254362
4	O
h	O
and	O
4	O
i	O
.	O
	
on	O
the	O
other	O
hand	O
,	O
2	B-C0029224
acridan	I-C0029224
dioxetane	I-C0029224
4	O
j	O
showed	O
a	O
significantly	O
enhanced	O
fluorescence	B-C0392762
quantum	I-C0392762
yield	I-C0392762
with	O
respect	O
to	O
the	O
unsubstituted	B-C0029224
dioxetane	I-C0029224
4	O
a	O
.	O
	
some	O
of	O
the	O
synthesized	B-C1883254
olefins	B-C0002068
did	O
not	O
undergo	O
singlet	B-C1254366
oxygen	I-C1254366
addition	I-C1254366
and	O
a	O
rationale	B-C2699007
was	O
sought	O
to	O
ease	O
the	O
photooxygenation	B-C1254366
step	O
,	O
leading	O
to	O
the	O
tcl	B-C0029224
dioxetanes	I-C0029224
.	O
	
a	O
chemometric	B-C0022885
approach	I-C0022885
has	O
been	O
adopted	O
to	O
exploit	O
principal	B-C0936012
component	I-C0936012
analysis	I-C0936012
and	O
linear	B-C0936012
discriminant	I-C0936012
analysis	I-C0936012
of	O
the	O
structural	B-C0678594
and	O
electronic	B-C0282354
molecular	I-C0282354
descriptors	I-C0282354
obtained	O
by	O
dft	B-C2698650
optimizations	I-C2698650
of	O
olefins	B-C0002068
3	O
.	O
	
this	O
approach	B-C0449445
allows	O
the	O
steric	B-C0549193
and	I-C0549193
electronic	I-C0549193
parameters	I-C0549193
that	O
govern	O
dioxetane	B-C0029224
formation	B-C1522492
to	O
be	O
prostate	B-C2367589
external	I-C2367589
beam	I-C2367589
radiotherapy	I-C2367589
combined	B-C0205195
with	O
high-dose-rate	B-C0454270
brachytherapy	I-C0454270
dose	B-C0178602
-	O
volume	B-C0449468
parameters	B-C0449381
from	O
deformably-registered	B-C0002045
plans	I-C0002045
correlate	B-C1707520
with	O
late	B-C0205087
gastrointestinal	B-C0161819
complications	I-C0161819
derivation	B-C1441547
of	O
dose	B-C0178602
-	O
volume	B-C0449468
correlated	B-C1707520
with	O
toxicity	B-C0040539
for	O
multi-modal	B-C0087111
treatments	I-C0087111
can	O
be	O
difficult	B-C0332218
due	O
to	O
the	O
perceived	O
need	O
for	O
voxel-by-voxel	B-C0022885
dose	I-C0022885
accumulation	I-C0022885
.	O
	
with	O
data	B-C1511726
available	O
for	O
a	O
single	B-C0205171
-	O
institution	B-C0018704
cohort	B-C0599755
with	O
long	B-C0205166
follow-up	B-C1522577
,	O
an	O
investigation	B-C1292732
was	O
undertaken	O
into	O
rectal	B-C0205052
dose	B-C0178602
-	O
volume	B-C0449468
effects	B-C1280500
for	O
gastrointestinal	B-C1142499
toxicities	I-C1142499
after	O
deformably-registering	O
each	O
phase	B-C0205390
of	O
a	O
combined	B-C0205195
external	B-C2367589
beam	I-C2367589
radiotherapy	I-C2367589
ebrt	B-C2367589
high-dose-rate	B-C0454270
hdr	I-C0454270
brachytherapy	I-C0454270
prostate	B-C0194790
treatment	I-C0194790
.	O
	
one	O
hundred	O
and	O
eighteen	O
patients	B-C0030705
received	O
ebrt	B-C2367589
in	O
23	O
fractions	B-C1264633
of	O
2	O
gy	B-C0556636
and	O
hdr	B-C0454270
tg43	B-C0002045
algorithm	I-C0002045
in	O
3	O
fractions	B-C1264633
of	O
6.5	O
gy	B-C0556636
.	O
	
results	B-C0683954
for	O
the	O
late	B-C0450973
effects	I-C0450973
of	I-C0450973
normal	I-C0450973
tissues	I-C0450973
-	I-C0450973
subjective	I-C0450973
,	O
objective	I-C0450973
,	O
management	I-C0450973
and	I-C0450973
analytic	I-C0450973
toxicity	I-C0450973
assessments	I-C0450973
were	O
available	O
with	O
a	O
median	B-C0876920
follow-up	B-C1522577
of	O
72	O
months	B-C0439231
.	O
	
the	O
hdr	B-C0454270
ct	B-C0040405
was	O
deformably-registered	O
to	O
the	O
ebrt	B-C2367589
ct	B-C0040405
.	O
	
doses	B-C0178602
were	O
corrected	B-C0205202
for	O
dose	B-C0524811
fractionation	I-C0524811
.	O
	
rectum	B-C0034896
dose-volume	B-C3827011
histogram	I-C3827011
dvh	B-C3827011
parameters	B-C0449381
were	O
calculated	B-C1441506
in	O
two	O
ways	O
.	O
	
1	O
distribution-adding	B-C0025663
parameters	B-C0449381
were	O
calculated	B-C1441506
after	O
the	O
ebrt	B-C2367589
dose	B-C0178602
distribution	B-C1704711
was	O
3d-summed	O
with	O
the	O
registered	O
hdr	B-C0454270
dose	B-C0178602
distribution	B-C1704711
.	O
	
2	O
parameter-adding	B-C0025663
the	O
ebrt	B-C2367589
dvh	B-C3827011
parameters	B-C0449381
were	O
added	B-C1524062
to	O
hdr	B-C0454270
dvh	B-C3827011
parameters	B-C0449381
.	O
	
logistic	B-C0206031
regressions	I-C0206031
and	O
mann-whitney	B-C0242927
u-tests	I-C0242927
were	O
used	O
to	O
correlate	B-C1707520
parameters	B-C0449381
with	O
late	B-C0205087
peak	B-C0444505
toxicity	B-C0040539
dichotomised	B-C0332849
at	O
grade	B-C0441800
1	O
or	O
2	O
.	O
	
the	O
48-80	O
,	O
40-63	O
and	O
49-55	O
gy	B-C0556636
dose	B-C0178602
regions	B-C0205147
from	O
distribution-adding	B-C0025663
were	O
significantly	B-C0750502
correlated	B-C1707520
with	O
rectal	B-C0267596
bleeding	I-C0267596
,	O
urgency	B-C0085606
/	O
tenesmus	B-C0232726
and	O
stool	B-C0426642
frequency	I-C0426642
respectively	O
.	O
	
additionally	B-C1524062
,	O
urgency	B-C0085606
/	O
tenesmus	B-C0232726
and	O
anorectal	B-C0581362
pain	I-C0581362
were	O
associated	B-C0332281
with	I-C0332281
the	O
25-26	O
gy	B-C0556636
and	O
44-48	O
gy	B-C0556636
dose	B-C0178602
regions	B-C0205147
from	O
distribution-adding	B-C0025663
respectively	O
.	O
	
parameter-adding	B-C0025663
also	O
indicated	O
the	O
low	B-C0205251
-	O
mid	B-C0444598
dose	B-C0178602
region	B-C0205147
was	O
significantly	B-C0750502
correlated	B-C1707520
with	O
stool	B-C0426642
frequency	I-C0426642
and	O
proctitis	B-C0033246
.	O
	
this	O
study	B-C0681814
confirms	B-C0750484
significant	B-C0750502
dose-histogram	B-C3827011
effects	B-C1280500
for	O
gastrointestinal	B-C1142499
toxicities	I-C1142499
after	O
including	B-C0332257
deformable	B-C0002045
registration	I-C0002045
to	O
combine	B-C0205195
phases	B-C0205390
of	O
ebrt	B-C2367589
/	O
hdr	B-C0454270
prostate	B-C0376358
cancer	I-C0376358
treatment	B-C0087111
.	O
	
the	O
findings	B-C0243095
from	O
distribution-adding	B-C0025663
were	O
in	O
most	O
cases	B-C0868928
consistent	B-C0332290
with	I-C0332290
those	O
from	O
parameter-adding	B-C0025663
.	O
	
the	O
mid	B-C0444598
-	O
high	B-C0205250
dose	B-C0178602
range	B-C1514721
and	O
near	B-C1706276
maximum	B-C0806909
doses	B-C0178602
were	O
important	B-C3898777
for	O
rectal	B-C0267596
bleeding	I-C0267596
.	O
	
the	O
distribution-adding	B-C0025663
mid	B-C0444598
-	O
high	B-C0205250
dose	B-C0178602
range	B-C1514721
was	O
also	O
important	B-C3898777
for	O
stool	B-C0426642
frequency	I-C0426642
and	O
urgency	B-C0085606
/	O
tenesmus	B-C0232726
.	O
	
we	O
encourage	O
additional	B-C1524062
studies	B-C2603343
in	O
a	O
variety	B-C2346866
of	O
institutions	B-C1272753
using	O
a	O
variety	B-C2346866
of	O
dose	B-C0022885
accumulation	I-C0022885
methods	I-C0022885
with	O
appropriate	O
inter-fraction	B-C1254363
motion	I-C1254363
management	I-C1254363
.	O
	
prescription	B-C1521941
of	O
opioids	B-C0242402
for	O
breathlessness	B-C0013404
in	O
end-stage	B-C0205088
copd	B-C0024117
a	O
national	O
population-based	B-C1709599
study	I-C1709599
low-dose	B-C0445550
opioids	B-C0242402
can	O
relieve	B-C1301676
breathlessness	B-C0013404
but	O
may	O
be	O
underused	O
in	O
late-stage	B-C1279941
copd	B-C0024117
due	O
to	O
fear	B-C0015726
of	O
complications	B-C0009566
,	O
contributing	O
to	O
poor	O
symptom	B-C1274136
control	I-C1274136
.	O
	
we	O
aimed	O
to	O
study	B-C2603343
the	O
period	B-C1948053
prevalence	O
and	O
indications	B-C3146298
of	O
opioids	B-C0242402
actually	O
prescribed	B-C0278329
in	O
people	B-C0027361
with	O
end-stage	B-C0205088
copd	B-C0024117
.	O
	
the	O
study	B-C2603343
was	O
a	O
longitudinal	B-C0023981
,	O
population-based	B-C1709599
study	I-C1709599
of	O
patients	B-C0030705
starting	O
long-term	B-C0418996
oxygen	I-C0418996
therapy	I-C0418996
ltot	B-C0418996
for	O
copd	B-C0024117
between	O
october	O
1	O
,	O
2005	O
and	O
june	O
30	O
,	O
2009	O
in	O
sweden	B-C0038995
.	O
	
a	O
random	O
sample	O
n=2	O
of	O
their	O
dispensed	B-C1880359
opioid	B-C0242402
prescriptions	B-C1521941
was	O
obtained	O
from	O
the	O
national	B-C0282574
prescribed	I-C0282574
drugs	I-C0282574
register	I-C0282574
from	O
91	O
days	B-C0439228
before	O
starting	O
ltot	B-C0418996
until	O
the	O
first	O
of	O
ltot	B-C0418996
withdrawal	B-C2349954
,	O
death	B-C0011065
,	O
or	O
study	B-C2983670
end	I-C2983670
december	O
31	O
,	O
2009	O
.	O
	
we	O
analyzed	O
medication	O
type	O
,	O
dispensed	B-C0805077
quantity	I-C0805077
,	O
date	B-C0243095
of	I-C0243095
dispensing	I-C0243095
,	O
and	O
indications	B-C3146298
categorized	O
as	O
pain	B-C0030193
,	O
breathlessness	B-C0013404
,	O
other	O
,	O
or	O
unknown	O
.	O
	
in	O
total	O
,	O
2	O
copd	B-C0024117
patients	B-C0030705
59%	O
women	B-C0043210
were	O
included	O
.	O
	
during	O
a	O
median	O
follow-up	B-C1522577
of	O
1.1	O
interquartile	B-C1711350
range	I-C1711350
0.6	O
years	B-C0439234
,	O
1	O
patients	B-C0030705
46%	O
were	O
dispensed	B-C1880359
1	O
opioid	B-C0242402
prescription	B-C0033080
n=13	O
prescriptions	B-C0033080
.	O
	
the	O
most	O
frequently	O
prescribed	B-C0278329
opioids	B-C0242402
were	O
tramadol	B-C0040610
23%	O
,	O
oxycodone	B-C0030049
23%	O
,	O
morphine	B-C0026549
16%	O
,	O
and	O
codeine	B-C0009214
16%	O
.	O
	
average	O
dispensed	B-C0805077
quantity	I-C0805077
was	O
9.3	O
interquartile	B-C1711350
range	I-C1711350
3.7	O
defined	O
daily	B-C2348070
doses	I-C2348070
per	O
prescription	B-C0033080
.	O
	
in	O
the	O
random	O
sample	B-C0370003
,	O
the	O
most	O
commonly	O
stated	O
indication	B-C3146298
was	O
pain	B-C0030193
97%	O
,	O
with	O
only	O
2%	O
for	O
breathlessness	B-C0013404
and	O
1%	O
for	O
other	O
reasons	O
.	O
	
despite	O
evidence	O
that	O
supported	O
the	O
use	O
of	O
opioids	B-C0242402
for	O
the	O
relief	B-C1301676
of	O
breathlessness	B-C0013404
predating	O
this	O
study	B-C2603343
,	O
opioids	B-C0242402
are	O
rarely	O
prescribed	B-C0278329
to	O
relieve	B-C1301676
breathlessness	B-C0013404
in	O
oxygen-dependent	B-C1655730
copd	B-C0024117
,	O
potentially	O
contributing	O
to	O
less-than-optimal	O
symptom	B-C1274136
control	I-C1274136
.	O
	
this	O
study	B-C2603343
creates	O
a	O
baseline	B-C1442488
against	O
which	O
to	O
compare	O
future	O
changes	O
in	O
morphine	B-C0026549
in	B-C1515655
vivo	I-C1515655
3-dimensional	B-C0450363
strain	B-C1283195
mapping	I-C1283195
confirms	B-C0521093
large	B-C0549177
optic	B-C0029127
nerve	I-C0029127
head	I-C0029127
deformations	B-C0302142
following	B-C0332282
horizontal	B-C0015413
eye	I-C0015413
movements	I-C0015413
to	O
measure	B-C0079809
lamina	B-C0229114
cribrosa	I-C0229114
lc	B-C0229114
strains	B-C0302142
deformations	B-C0302142
following	B-C0332282
abduction	B-C0231456
and	O
adduction	B-C0231457
in	O
healthy	B-C1708335
subjects	I-C1708335
and	O
to	O
compare	B-C1707455
them	O
with	O
those	O
resulting	B-C1274040
from	O
a	O
relatively	B-C0205345
high	B-C0205250
acute	B-C0205178
intraocular	B-C0021888
pressure	I-C0021888
iop	B-C0021888
elevation	B-C0702240
.	O
	
a	O
total	B-C0439810
of	O
16	O
eyes	B-C0015392
from	O
8	O
healthy	B-C1708335
subjects	I-C1708335
were	O
included	B-C2700399
.	O
	
among	O
the	O
16	O
eyes	B-C0015392
,	O
11	O
had	O
peripapillary	B-C1719838
atrophy	I-C1719838
ppa	B-C1719838
.	O
	
for	O
each	B-C1457900
subject	B-C0681850
,	O
both	O
optic	B-C0029127
nerve	I-C0029127
heads	I-C0029127
onhs	B-C0029127
were	O
imaged	B-C1704922
using	O
optical	B-C0920367
coherence	I-C0920367
tomography	I-C0920367
oct	B-C0920367
at	O
baseline	B-C1442488
twice	B-C1948050
,	O
in	O
different	B-C1705242
gaze	B-C0590323
positions	B-C0733755
adduction	B-C0231457
and	O
abduction	B-C0231456
of	O
20	O
and	O
following	B-C0332282
an	O
acute	B-C0205178
iop	B-C0021888
elevation	B-C0702240
of	O
approximately	B-C0332232
20	O
mm	O
hg	B-C0025424
from	O
baseline	B-C1442488
via	O
ophthalmodynamometry	B-C0029085
.	O
	
strains	B-C0302142
of	O
lc	B-C0229114
for	O
all	O
loading	B-C0683579
scenarios	I-C0683579
were	O
mapped	B-C3858752
using	O
a	O
three-dimensional	B-C0450363
tracking	B-C0546881
algorithm	B-C0002045
.	O
	
in	O
all	O
16	O
eyes	B-C0015392
,	O
lc	B-C0229114
strains	B-C0302142
induced	B-C0205263
by	O
adduction	B-C0231457
and	O
abduction	B-C0231456
were	O
5.83	O
3.78	O
and	O
3.93	O
2.57	O
,	O
respectively	O
,	O
and	O
both	O
significantly	B-C4055637
higher	I-C4055637
than	O
the	O
control	B-C0009932
strains	B-C0302142
measured	B-C0444706
from	O
the	O
repeated	B-C0205341
baseline	B-C1442488
acquisitions	B-C1706701
p	O
<	O
0.01	O
.	O
	
strains	B-C0302142
of	O
lc	B-C0229114
in	O
adduction	B-C0231457
were	O
on	O
average	B-C1510992
higher	B-C0205250
than	O
those	O
in	O
abduction	B-C0231456
,	O
but	O
the	O
difference	B-C1705242
was	O
not	O
statistically	B-C0237881
significant	I-C0237881
p	O
=	O
0.07	O
.	O
	
strains	B-C0302142
of	O
lc	B-C0229114
induced	B-C0205263
by	O
iop	B-C0021888
elevations	B-C0702240
on	O
average	B-C1510992
21.13	O
7.61	O
mm	O
hg	B-C0025424
were	O
6.41	O
3.21	O
and	O
significantly	B-C4055637
higher	I-C4055637
than	O
the	O
control	B-C0009932
strains	B-C0302142
p	O
<	O
0.0005	O
.	O
	
gaze	B-C0590323
-	O
induced	B-C0205263
lc	B-C0229114
strains	B-C0302142
in	O
the	O
ppa	B-C1719838
group	B-C0030705
were	O
on	O
average	B-C1510992
larger	B-C0549177
than	O
those	O
in	O
the	O
non-ppa	B-C0030705
group	I-C0030705
however	O
,	O
the	O
relationship	B-C0439849
was	O
not	O
statistically	B-C0237881
significant	I-C0237881
.	O
	
our	O
results	B-C0683954
confirm	B-C1456348
that	O
horizontal	B-C0015413
eye	I-C0015413
movements	I-C0015413
generate	B-C0205556
significant	B-C0750502
onh	B-C0029127
strains	B-C0302142
,	O
which	O
is	O
consistent	B-C0332290
with	I-C0332290
our	O
previous	B-C0205156
estimations	B-C0680844
using	O
finite	B-C0600552
element	I-C0600552
analysis	I-C0600552
.	O
	
further	B-C2603343
studies	I-C2603343
are	O
needed	O
to	O
explore	O
a	O
possible	B-C0332149
link	O
between	O
onh	B-C0029127
strains	B-C0302142
induced	B-C0205263
by	O
eye	B-C0015413
movements	I-C0015413
and	O
axonal	B-C1832338
loss	I-C1832338
in	O
optic	B-C0029132
neuropathies	I-C0029132
.	O
	
simultaneously	B-C0521115
targeting	B-C1521840
myofibroblast	B-C4235370
contractility	I-C4235370
and	O
extracellular	B-C0015350
matrix	I-C0015350
cross-linking	B-C0332220
as	O
a	O
therapeutic	B-C0302350
concept	I-C0302350
in	O
airway	B-C0458827
fibrosis	B-C0016059
fibrosis	B-C0016059
after	O
solid	B-C0029216
organ	I-C0029216
transplantation	I-C0029216
is	O
considered	O
an	O
irreversible	B-C0205355
process	B-C1522240
and	O
remains	O
the	O
major	B-C0205164
cause	O
of	O
graft	B-C1167870
dysfunction	I-C1167870
and	O
death	B-C0011065
with	O
limited	B-C0439801
therapies	B-C0087111
.	O
	
this	O
remodeling	B-C0678692
is	O
characterized	B-C1880022
by	O
aberrant	B-C0443127
accumulation	B-C4055506
of	O
contractile	B-C0225360
myofibroblasts	I-C0225360
that	O
deposit	B-C0333562
excessive	B-C0442802
extracellular	B-C0015350
matrix	I-C0015350
ecm	B-C0015350
and	O
increase	B-C0442805
tissue	B-C2017125
stiffness	I-C2017125
.	O
	
studies	B-C2603343
demonstrate	O
,	O
however	O
,	O
that	O
a	O
stiff	B-C0427008
ecm	B-C0015350
itself	O
promotes	B-C0033414
fibroblast	B-C0016030
-to-	O
myofibroblast	B-C0225360
differentiation	B-C0007589
,	O
stimulating	B-C1879547
further	O
ecm	B-C0015350
production	B-C1883254
.	O
	
this	O
creates	O
a	O
positive	B-C0678664
feedback	I-C0678664
loop	I-C0678664
that	O
perpetuates	B-C0205556
fibrosis	B-C0016059
.	O
	
we	O
hypothesized	B-C1512571
that	O
simultaneously	B-C0521115
targeting	B-C1521840
myofibroblast	B-C4235370
contractility	I-C4235370
with	O
relaxin	B-C0035031
and	O
ecm	B-C0015350
stiffness	B-C0427008
with	O
lysyl	B-C0024375
oxidase	I-C0024375
inhibitors	B-C0014432
could	O
break	O
the	O
feedback	B-C0678663
loop	I-C0678663
,	O
reversing	B-C1555029
established	B-C0443211
fibrosis	B-C0016059
.	O
	
to	O
test	B-C0039593
this	O
,	O
we	O
used	O
the	O
orthotopic	B-C0040732
tracheal	I-C0040732
transplantation	I-C0040732
ott	B-C0040732
mouse	B-C2986594
model	I-C2986594
,	O
which	O
develops	O
robust	B-C2986815
fibrotic	B-C0334129
airway	B-C0458827
remodeling	B-C0678692
.	O
	
mice	B-C0025929
with	O
established	B-C0443211
fibrosis	B-C0016059
were	O
treated	B-C1522326
with	O
saline	B-C0036082
,	O
mono-	B-C0520016
,	O
or	O
combination	B-C0013218
therapies	I-C0013218
.	O
	
although	O
monotherapies	B-C0520016
had	O
no	B-C1301751
effect	I-C1301751
,	O
combining	B-C0013162
these	I-C0013162
agents	I-C0013162
decreased	B-C0205216
collagen	B-C0009325
deposition	B-C0333562
and	O
promoted	B-C0033414
re-epithelialization	B-C0334221
of	O
remodeled	B-C2717792
airways	I-C2717792
.	O
	
relaxin	B-C0035031
inhibited	B-C0311403
myofibroblast	B-C0225360
differentiation	B-C0007589
and	O
contraction	B-C1140999
in	O
a	O
matrix	B-C0015350
-	O
stiffness	B-C0427008
-	O
dependent	B-C3244310
manner	O
through	O
prostaglandin	B-C3813211
e2	I-C3813211
pge2	B-C3813211
.	O
	
furthermore	O
,	O
the	O
effect	B-C1280500
of	O
combination	B-C0013218
therapy	I-C0013218
was	O
lost	O
in	O
pge2	B-C0034835
receptor	I-C0034835
knockout	B-C0206745
and	O
pge2	B-C3813211
-	O
inhibited	B-C0311403
ott	B-C0040732
mice	B-C0025929
.	O
	
this	O
study	B-C2603343
revealed	B-C0443289
the	O
important	O
synergistic	B-C2986495
roles	B-C1705810
of	O
cellular	B-C1140999
contractility	I-C1140999
and	O
tissue	B-C2017125
stiffness	I-C2017125
in	O
the	O
maintenance	B-C0024501
of	O
fibrotic	B-C0334129
tissue	B-C0040300
and	O
suggests	O
a	O
new	O
therapeutic	B-C0302350
principle	B-C0678989
for	O
systemic	B-C1721358
matrix	I-C1721358
metalloproteinase-8	I-C1721358
response	B-C3714634
in	O
chronic	B-C0149517
tonsillitis	I-C0149517
the	O
development	B-C1527148
of	O
several	O
life-long	O
diseases	B-C0012634
,	O
such	O
as	O
coronary	B-C0010068
heart	I-C0010068
disease	I-C0010068
,	O
is	O
affected	O
by	O
low-grade	B-C1282907
systemic	B-C0205373
inflammation	B-C0021368
.	O
	
data	B-C1511726
on	O
the	O
potential	B-C3245505
long-term	B-C0443252
health	B-C0018684
effects	B-C1280500
of	O
chronic	B-C0149517
tonsillitis	I-C0149517
are	O
limited	O
.	O
	
many	O
inflammatory	B-C0021368
conditions	B-C0348080
present	O
with	O
enhanced	O
systemic	B-C1721358
matrix	I-C1721358
metalloproteinase	I-C1721358
mmp	B-C1721358
response	B-C3714634
.	O
	
in	O
head	B-C0278996
and	I-C0278996
neck	I-C0278996
cancer	I-C0278996
,	O
high	B-C0205250
plasma	B-C0032105
level	B-C0441889
of	O
tissue	B-C0145947
inhibitor	I-C0145947
of	I-C0145947
metalloproteinase	I-C0145947
timp	B-C0145947
predicts	B-C0681842
poor	B-C0278252
prognosis	I-C0278252
.	O
	
we	O
analyzed	O
s-mmp-8	B-C1721358
with	O
immunofluorometric	B-C0016350
assay	I-C0016350
and	O
s-timp-1	B-C0145947
with	O
an	O
immunosorbent	B-C1532280
assay	I-C1532280
in	O
175	O
consecutive	B-C1707491
patients	B-C0030705
undergoing	O
tonsillectomy	B-C0040423
for	O
benign	B-C0153936
tonsillar	I-C0153936
disease	I-C0153936
,	O
and	O
in	O
33	O
control	B-C0009932
patients	B-C0030705
with	O
tonsillar	B-C0280317
squamous	I-C0280317
cell	I-C0280317
carcinoma	I-C0280317
.	O
	
tonsillar	B-C0040421
human	B-C0021344
papillomavirus	I-C0021344
hpv	B-C0021344
status	O
was	O
determined	O
by	O
pcr	B-C0032520
.	O
	
in	O
patients	B-C0030705
with	O
benign	B-C0153936
tonsillar	I-C0153936
disease	I-C0153936
,	O
chronic	B-C0149517
tonsillitis	I-C0149517
without	O
hypertrophy	B-C0020564
was	O
associated	B-C0332281
with	I-C0332281
enhanced	O
systemic	B-C1721358
mmp-8	I-C1721358
response	B-C3714634
.	O
	
compared	O
to	O
patients	B-C0030705
with	O
benign	B-C0153936
tonsillar	I-C0153936
disease	I-C0153936
,	O
patients	B-C0030705
with	O
tonsillar	B-C0280317
squamous	I-C0280317
cell	I-C0280317
carcinoma	I-C0280317
had	O
significantly	B-C4055637
higher	I-C4055637
concentrations	B-C1446561
of	O
s-mmp-8	B-C1721358
and	O
s-timp-1	B-C0145947
.	O
	
neither	O
s-mmp-8	B-C1721358
nor	O
s-timp-1	B-C0145947
correlated	O
with	O
tonsillar	B-C0040421
hpv	B-C0021344
positivity	B-C1514241
.	O
	
addressing	B-C0376649
holistic	B-C0019844
health	I-C0019844
and	O
work	B-C0043227
empowerment	B-C0679959
through	B-C0332273
a	O
body-mind-spirit	B-C0679897
intervention	I-C0679897
program	I-C0679897
among	O
helping	B-C0018896
professionals	B-C0679924
in	O
continuous	B-C0549178
education	B-C0013621
a	O
pilot	B-C0031928
study	I-C0031928
to	O
examine	O
the	O
effectiveness	B-C1280519
of	O
a	O
body-mind-spirit	B-C0679897
bms	I-C0679897
intervention	I-C0679897
program	I-C0679897
in	O
improving	B-C1272745
the	O
holistic	B-C0019844
well-being	I-C0019844
and	O
work	B-C0043227
empowerment	B-C0679959
among	O
helping	B-C0018896
professionals	B-C0679924
in	O
continuous	B-C0549178
education	B-C0013621
.	O
	
forty-four	O
helping	B-C0018896
professionals	B-C0679924
,	O
who	O
were	O
in	O
their	O
first-year	O
part-time	O
postgraduate	B-C0597274
study	I-C0597274
,	O
participated	O
in	O
the	O
present	O
study	O
.	O
	
all	O
participants	B-C0679646
attended	B-C1456498
a	O
3-day	O
bms	B-C0679897
intervention	I-C0679897
program	I-C0679897
which	O
emphasized	O
a	O
holistic	B-C0683249
approach	I-C0683249
to	O
health	B-C0018684
and	O
well-being	B-C0018684
.	O
	
ratings	O
on	O
their	O
levels	B-C0441889
of	O
physical	B-C0231303
distress	I-C0231303
,	O
daily	B-C0037395
functioning	I-C0037395
,	O
affect	B-C0001721
,	O
spirituality	B-C0237104
,	O
and	O
psychologica	B-C0205486
l	O
empowerment	B-C0679959
at	O
work	B-C0043227
were	O
compared	O
before	O
and	O
immediately	O
after	O
the	O
intervention	B-C1273869
.	O
	
participants	B-C0679646
reported	O
significantly	O
lower	O
levels	B-C0441889
of	O
negative	B-C0243095
affect	I-C0243095
and	O
physical	B-C0231303
distress	I-C0231303
,	O
and	O
were	O
less	O
spiritually	B-C0243095
disoriented	I-C0243095
after	O
the	O
intervention	B-C1273869
.	O
	
enhanced	B-C2349975
levels	B-C0441889
of	O
daily	B-C0037395
functioning	I-C0037395
,	O
positive	B-C0018592
affect	I-C0018592
,	O
spiritual	B-C0683811
resilience	I-C0683811
,	O
and	O
tranquility	B-C0522165
were	O
also	O
reported	O
.	O
	
results	O
also	O
suggested	O
that	O
participants	B-C0679646
were	O
empowered	B-C0562342
at	O
work	B-C0043227
,	O
and	O
specifically	O
felt	O
more	O
able	O
to	O
make	O
an	O
impact	O
on	O
work	B-C0043227
outcomes	O
.	O
	
the	O
3-day	O
bms	B-C0679897
intervention	I-C0679897
program	I-C0679897
produced	O
a	O
positive	B-C0243095
and	O
measurable	B-C1513040
effec	B-C1280500
t	O
on	O
participants	B-C0679646
'	O
holistic	B-C0019844
well-being	I-C0019844
and	O
empowerment	B-C0679959
at	O
work	B-C0043227
.	O
	
educators	B-C0259853
in	O
related	O
fields	B-C2346620
could	O
incorporate	O
holistic	B-C0019844
practices	B-C0032893
into	O
the	O
curriculum	B-C0010478
to	O
better	O
prepare	O
the	O
future	O
practitioners	B-C1709627
,	O
leading	O
to	O
better	O
outcomes	O
both	O
to	O
the	O
professionals	B-C0679924
themselves	O
and	O
their	O
clients	B-C0008942
or	O
successful	B-C0399059
restoration	I-C0399059
of	O
severely	O
mutilated	B-C0332811
primary	B-C0021156
incisors	I-C0021156
using	O
a	O
novel	O
method	O
to	O
retain	O
zirconia	B-C3503915
crowns	B-C3853546
-	O
two	B-C0439234
year	I-C0439234
results	B-C1274040
this	O
manuscript	B-C0600659
describes	O
a	O
simple	O
reliable	B-C0449851
technique	I-C0449851
for	O
restoring	B-C0399059
severely	O
mutilated	B-C0332811
primary	B-C0021156
anterior	I-C0021156
teeth	I-C0021156
.	O
	
a	O
rigid	O
glass	B-C0017597
ionomer	I-C0017597
post	I-C0017597
is	O
created	O
over	O
which	O
zirconia	B-C3503915
crowns	B-C3853546
can	O
be	O
fitted	O
to	O
achieve	O
a	O
long-term	B-C0443252
stable	O
esthetic	B-C0010163
restoration	B-C0399059
for	O
primary	B-C0021156
anterior	I-C0021156
teeth	I-C0021156
.	O
	
children	B-C0008059
aged	O
2-5	O
years	B-C0439234
with	O
two	O
up	O
to	O
six	O
extensively	O
decayed	B-C0011334
upper	B-C0021156
primary	I-C0021156
incisors	I-C0021156
were	O
included	O
.	O
	
fuji	B-C0671561
ix	I-C0671561
was	O
condensed	O
into	O
an	O
intracanal	B-C0282543
space	I-C0282543
created	O
to	O
a	O
depth	B-C0205125
of	O
3mm	O
,	O
to	O
provide	O
a	O
core	B-C0444669
which	O
also	O
extended	O
3mm	O
supragingivally	B-C0086959
.	O
	
crown	B-C0399013
preparations	I-C0399013
were	O
completed	O
upon	O
these	O
cores	B-C0444669
.	O
	
zirconia	B-C3503915
crowns	B-C3853546
nusmile	B-C0947322
,	O
houston	B-C3812709
texas	I-C3812709
usa	B-C0041703
were	O
fitted	B-C3714578
and	O
cemented	B-C0011343
over	O
the	O
prepared	O
cores	B-C0444669
.	O
	
all	O
patients	B-C0030705
were	O
recalled	B-C1707680
at	O
regular	B-C1272706
intervals	I-C1272706
.	O
	
twenty-three	O
healthy	O
children	B-C0008059
with	O
86	O
restorations	B-C0399059
participated	O
in	O
the	O
study	B-C2603343
.	O
	
the	O
overall	B-C4086681
survival	I-C4086681
of	O
the	O
restorations	B-C0399059
was	O
95.3	O
after	O
12	O
months	B-C0439231
and	O
80.2	O
after	O
24	O
months	B-C0439231
.	O
	
according	O
to	O
kaplan-meier	B-C0038953
survival	I-C0038953
analysis	I-C0038953
,	O
the	O
median	B-C2986586
survival	I-C2986586
time	I-C2986586
was	O
not	O
reached	O
while	O
the	O
estimated	O
mean	B-C0086595
survival	I-C0086595
time	I-C0086595
was	O
22.9	O
months	B-C0439231
.	O
	
this	O
newly	O
described	O
clinical	B-C0376583
technique	I-C0376583
is	O
simple	O
and	O
reliable	B-C3858758
to	O
use	O
for	O
restoration	B-C0399059
of	O
extensively	O
decayed	B-C0011334
primary	B-C0021156
incisors	I-C0021156
.	O
	
use	O
of	O
zirconia	B-C3503915
crowns	B-C3853546
retained	O
using	O
this	O
technique	B-C0449851
offers	O
superior	B-C0004898
esthetic	I-C0004898
,	O
durable	O
restorations	B-C0399059
with	O
remarkable	O
gingival	B-C0541981
response	I-C0541981
up	O
to	O
24	O
reimbursement	B-C3242446
based	O
on	O
value	O
in	O
knee	B-C0187769
surgery	I-C0187769
what	O
you	O
need	O
to	O
know	O
about	O
the	O
medicare	B-C4277549
access	I-C4277549
and	I-C4277549
children's	I-C4277549
health	I-C4277549
insurance	I-C4277549
program	I-C4277549
reauthorization	I-C4277549
act	I-C4277549
of	I-C4277549
2015	I-C4277549
health	B-C0085552
care	I-C0085552
cost	I-C0085552
is	O
consuming	O
a	O
large	O
portion	O
of	O
the	O
nation's	B-C1555720
gross	B-C2936646
domestic	I-C2936646
product	I-C2936646
while	O
placing	O
added	O
economic	B-C1512163
burdens	I-C1512163
on	O
physicians	B-C0031831
and	O
their	O
patients	B-C0030705
.	O
	
with	O
total	B-C0185317
joint	I-C0185317
replacement	I-C0185317
being	O
one	O
of	O
the	O
early-targeted	O
procedures	B-C0184661
in	O
the	O
evolving	O
health	B-C0565997
care	I-C0565997
environment	I-C0565997
,	O
knee	B-C0334891
surgeons	I-C0334891
will	O
benefit	O
from	O
developing	O
a	O
critical	O
knowledge	O
on	O
health	B-C0206597
care	I-C0206597
reforms	I-C0206597
and	O
their	O
financial	O
implications	O
.	O
	
the	O
medicare	B-C4277549
access	I-C4277549
and	I-C4277549
children's	I-C4277549
health	I-C4277549
insurance	I-C4277549
program	I-C4277549
reauthorization	I-C4277549
act	I-C4277549
represents	O
a	O
cohesive	O
movement	O
toward	O
value-based	B-C0206597
payment	I-C0206597
reform	I-C0206597
and	O
contains	O
several	O
unchartered	O
rulings	O
that	O
require	O
detailed	O
attention	O
by	O
knee	B-C0334891
surgeons	I-C0334891
.	O
	
in	O
this	O
article	O
,	O
we	O
provide	O
a	O
contextual	B-C1254370
framework	I-C1254370
of	O
health	B-C0018719
care	I-C0018719
legislation	I-C0018719
that	O
has	O
led	O
to	O
the	O
formation	O
of	O
the	O
current	O
health	B-C0018735
policy	I-C0018735
,	O
and	O
present	O
a	O
comprehensive	B-C1880156
summary	B-C1706244
and	O
update	O
on	O
the	O
merit-based	B-C0282574
incentive	I-C0282574
payment	I-C0282574
systems	I-C0282574
and	O
alternative	B-C0282574
payment	I-C0282574
models	I-C0282574
reimbursement	I-C0282574
models	I-C0282574
.	O
	
empty	B-C1880497
capsids	B-C0006933
and	O
macrophage	B-C0024432
inhibition	B-C3463820
/	O
depletion	B-C0333668
increase	B-C0442805
raav	B-C1520007
transgene	B-C0282641
expression	B-C0017262
in	O
joints	B-C0022417
of	O
both	O
healthy	B-C3898900
and	O
arthritic	B-C0003864
mice	B-C0025929
gene	B-C0017296
therapy	I-C0017296
has	O
potential	B-C3245505
to	O
treat	B-C0087111
rheumatic	B-C0035435
diseases	I-C0035435
however	O
,	O
the	O
presence	B-C0150312
of	O
macrophages	B-C0024432
in	O
the	O
joint	B-C0022417
might	O
hamper	O
adeno-associated	B-C0001417
viral	I-C0001417
vector	B-C1520007
-mediated	O
gene	B-C1524066
delivery	I-C1524066
.	O
	
here	O
we	O
demonstrate	O
that	O
in	O
arthritic	B-C0003864
,	O
but	O
also	O
in	O
healthy	B-C3898900
,	O
mice	B-C0025929
administration	B-C2348003
of	I-C2348003
agents	I-C2348003
that	O
influence	B-C4054723
macrophage	B-C0024432
activity	B-C0441655
/	O
number	B-C0237753
and/or	O
addition	B-C1883712
of	O
empty	B-C1880497
decoy	B-C0006933
capsids	I-C0006933
substantially	O
improve	B-C0184511
the	O
efficacy	B-C1280519
of	O
recombinant	B-C1514798
adeno-associated	B-C0001417
viral	I-C0001417
vector	B-C1520007
5	O
transgene	B-C0282641
expression	B-C0017262
in	O
the	O
joint	B-C0022417
.	O
	
pretreatment	B-C3539076
with	O
triamcinolone	B-C0040864
or	O
clodronate	B-C0162357
liposomes	B-C0023828
improved	B-C0184511
luciferase	B-C0024075
expression	B-C0017262
over	O
a	O
period	B-C1948053
of	O
4	O
weeks	B-C0439230
.	O
	
similar	B-C2348205
results	B-C0683954
were	O
seen	O
when	O
empty	B-C1880497
decoy	B-C0006933
capsids	I-C0006933
were	O
added	B-C1524062
to	O
full	B-C0443225
genome	B-C0017428
containing	O
capsids	B-C0006933
in	O
a	O
5	O
ratio	B-C0456603
.	O
	
in	O
a	O
study	B-C0008972
to	O
assess	B-C1516048
the	O
duration	B-C0449238
of	O
expression	B-C0017262
as	O
well	O
as	O
to	O
investigate	B-C1292732
the	O
combination	B-C0205195
of	O
these	O
two	O
approaches	B-C1292724
,	O
we	O
observed	B-C1441672
a	O
synergistic	B-C2986495
enhancement	B-C2349975
of	O
gene	B-C0017262
expression	I-C0017262
,	O
sustained	B-C0443318
for	O
at	O
least	O
12	O
weeks	B-C0439230
.	O
	
the	O
enhancement	B-C2349975
of	O
gene	B-C0017262
expression	I-C0017262
was	O
independent	O
of	O
the	O
route	B-C0013153
of	I-C0013153
administration	I-C0013153
of	O
triamcinolone	B-C0040864
intra-articular	B-C0442108
or	O
intramuscular	B-C0442117
.	O
	
in	O
healthy	B-C3898900
mice	B-C0025929
it	O
was	O
demonstrated	O
that	O
the	O
combination	B-C0205195
improved	B-C0184511
expression	B-C0017262
of	O
the	O
transgene	B-C0282641
significantly	O
,	O
in	O
a	O
serotype	B-C0449943
independent	O
manner	O
.	O
	
these	O
data	B-C1511726
have	O
implications	O
for	O
future	O
applications	O
of	O
gene	B-C0017296
therapy	I-C0017296
to	O
the	O
joint	B-C0022417
and	O
for	O
other	O
tissues	B-C0040300
with	O
an	O
abundance	B-C2346714
of	O
an	O
inhibitory	B-C3463820
septum	B-C0814033
to	O
lateral	B-C0020654
hypothalamus	I-C0020654
circuit	B-C0814033
that	O
suppresses	B-C1260953
feeding	B-C0015745
feeding	B-C0015745
behavior	I-C0015745
is	O
orchestrated	B-C1300196
by	O
neural	B-C0814033
circuits	I-C0814033
primarily	O
residing	O
in	O
the	O
hypothalamus	B-C0020663
and	O
hindbrain	B-C0035507
.	O
	
however	O
,	O
the	O
relative	B-C0205345
influence	B-C4054723
of	O
cognitive	B-C1516691
and	O
emotional	B-C0013987
brain	B-C0682723
circuits	I-C0682723
to	O
the	O
feeding	B-C0015745
circuitry	B-C0260041
in	O
the	O
hypothalamus	B-C0020663
and	O
hindbrain	B-C0035507
remains	O
unclear	B-C3845108
.	O
	
here	O
,	O
using	B-C1524063
the	O
cell-type	B-C0449475
selectivity	O
of	O
genetic	B-C0017395
methods	I-C0017395
,	O
circuit	B-C0006117
mapping	I-C0006117
,	O
and	O
behavior	B-C0004927
assays	B-C0005507
,	O
we	O
sought	O
to	O
decipher	O
neural	B-C0814033
circuits	I-C0814033
emanating	O
from	O
the	O
septal	B-C0175232
nucleus	I-C0175232
to	O
the	O
lateral	B-C0020654
hypothalamus	I-C0020654
lh	B-C0020654
that	O
contribute	O
to	O
neural	B-C0598959
regulation	I-C0598959
of	O
food	B-C0013470
intake	I-C0013470
in	O
mice	B-C0025929
.	O
	
we	O
found	O
that	O
chemogenetic	B-C0205245
and	O
optogenetic	B-C0205245
activation	B-C1879547
of	O
septal	B-C0442004
vesicular	B-C1453453
gaba	I-C1453453
transporter	I-C1453453
vgat	B-C1453453
containing	B-C0332256
neurons	B-C0027882
or	O
their	O
projections	O
in	O
the	O
lh	B-C0020654
reduced	B-C0392756
food	B-C0013470
intake	I-C0013470
in	O
mice	B-C0025929
.	O
	
consistently	O
,	O
chemogenetic	B-C0205245
inhibition	B-C3463820
of	O
septal	B-C0442004
vgat	B-C1453453
neurons	B-C0027882
increased	B-C0205217
food	B-C0013470
intake	I-C0013470
.	O
	
furthermore	O
,	O
we	O
investigated	B-C1292732
a	O
previously	O
unknown	B-C0439673
neural	B-C0814033
circuit	I-C0814033
originating	B-C0439659
from	O
septal	B-C0442004
vgat	B-C1453453
neurons	B-C0027882
to	O
a	O
subset	B-C1515021
of	O
vgat	B-C1453453
neurons	B-C0027882
in	O
the	O
lh	B-C0020654
,	O
an	O
area	B-C0205146
involved	B-C1314939
in	O
homeostatic	B-C0019868
and	O
hedonic	B-C3714634
control	B-C0243148
of	O
energy	B-C0516979
states	I-C0516979
.	O
	
collectively	O
,	O
our	O
data	B-C1511726
reveal	B-C0443289
an	O
inhibitory	B-C3463820
septohypothalamic	B-C0005898
feeding	B-C0814033
circuit	I-C0814033
that	O
might	O
serve	O
as	O
a	O
therapeutic	B-C0302350
target	B-C1521840
for	O
the	O
treatment	B-C1522326
of	O
eating	B-C0013473
disorders	I-C0013473
such	O
as	O
anorexia	B-C0003125
nervosa	I-C0003125
.	O
	
our	O
results	O
demonstrate	O
that	O
top-down	O
projections	O
from	O
the	O
septum	B-C0814033
to	O
the	O
hypothalamus	B-C0020663
control	B-C0243148
food	B-C0013470
intake	I-C0013470
negatively	B-C0205160
.	O
	
given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain	B-C1273723
regions	I-C1273723
in	O
the	O
control	B-C0243148
of	O
feeding	B-C0015745
and	O
emotion	B-C0013987
-	O
related	B-C1552599
behaviors	B-C0004927
,	O
these	O
findings	B-C0243095
reveal	B-C0443289
previously	O
unknown	B-C0439673
neural	B-C0260041
circuitry	I-C0260041
that	O
is	O
likely	O
implicated	O
in	O
emotional	B-C0243152
aspects	I-C0243152
of	O
food	B-C0013470
intake	I-C0013470
and	O
provide	B-C1999230
new	O
insights	B-C0233820
into	O
the	O
development	B-C1527148
of	O
therapeutic	B-C0302350
targets	B-C1521840
for	O
the	O
treatment	B-C1522326
of	O
eating	B-C0013473
disorders	I-C0013473
.	O
	
human	B-C0086418
umbilical	B-C0162371
cord	I-C0162371
blood	I-C0162371
-	O
derived	B-C1550535
neural	B-C0007600
stem	I-C0007600
cell	I-C0007600
line	I-C0007600
as	O
a	O
screening	B-C0220908
model	B-C0026339
for	O
toxicity	B-C0600688
the	O
aim	B-C1947946
was	O
to	O
investigate	B-C1292732
whether	O
a	O
human	B-C0086418
neural	B-C1113654
stem	I-C1113654
cell	I-C1113654
nsc	B-C1113654
line	B-C0007600
derived	B-C1550535
from	O
human	B-C0086418
umbilical	B-C0162371
cord	I-C0162371
blood	I-C0162371
hucb	B-C0162371
can	O
be	O
used	O
for	O
toxicity	B-C0600688
study	B-C2603343
.	O
	
toxicity	B-C0600688
of	O
both	O
neurotoxic	B-C0260049
environmental	B-C0014406
xenobiotics	B-C0043335
,	O
methyl	B-C0066402
mercury	I-C0066402
chloride	I-C0066402
ch3hgcl	B-C0066402
,	O
lead	B-C0064711
acetate	I-C0064711
ch3coopb	B-C0064711
,	O
and	O
chlorpyrifos	B-C0013328
cp	B-C0013328
,	O
and	O
non-neurotoxic	B-C0243095
insecticide	B-C0021576
,	O
dichlorvos	B-C0012087
,	O
as	O
well	O
as	O
non-neurotoxic	B-C0243095
drugs	B-C1254351
,	O
theophylline	B-C0039771
and	O
acetaminophen	B-C0000970
were	O
assessed	B-C1516048
.	O
	
additionally	O
,	O
differentiation	B-C2945687
of	O
neuronal	B-C0521390
and	O
glial	B-C0027836
cell	I-C0027836
lines	I-C0027836
derived	B-C1550535
from	O
hucb	B-C0162371
was	O
elucidated	O
.	O
	
it	O
was	O
observed	B-C1441672
that	O
ch3hgcl	B-C0066402
was	O
more	O
toxic	B-C1407029
to	O
human	B-C0086418
nscs	B-C0007600
in	O
comparison	B-C1707455
to	O
ch3coopb	B-C0064711
and	O
cp	B-C0013328
.	O
	
the	O
minimum	B-C1304747
inhibitory	I-C1304747
concentration	I-C1304747
mic	I-C1304747
value	I-C1304747
against	O
nscs	B-C0007600
was	O
3	O
,	O
10	O
,	O
and	O
300	O
mg/l	O
,	O
in	O
each	O
staining	B-C0487602
process	I-C0487602
,	O
acridine	B-C0001185
orange	I-C0001185
/	O
ethidium	B-C0019873
bromide	I-C0019873
ao	B-C0001185
/	O
eb	B-C0019873
staining	B-C0487602
,	O
3-	B-C0094912
tetrazolium	I-C0094912
bromide	I-C0094912
mtt	B-C0094912
assay	B-C1510438
,	O
and	O
hoechst	B-C1441607
staining	I-C1441607
,	O
for	O
ch3hgcl	B-C0066402
,	O
cp	B-C0013328
,	O
and	O
ch3coopb	B-C0064711
,	O
respectively	O
.	O
	
ch3hgcl	B-C0066402
had	O
the	O
lc25	B-C0392762
value	B-C0042295
as	O
10.0	O
,	O
14.4	O
,	O
and	O
12.7	O
mg/l	O
,	O
by	O
staining	B-C0487602
method	I-C0487602
mentioned	O
in	O
succession	O
.	O
	
cp	B-C0013328
had	O
the	O
lc25	B-C0392762
value	B-C0042295
as	O
21.9	O
,	O
23.7	O
,	O
and	O
18.4	O
mg/l	O
similarly	O
,	O
ch3coopb	B-C0064711
had	O
lc25	B-C0392762
values	B-C0042295
,	O
successively	O
as	O
616.9	O
,	O
719.2	O
,	O
and	O
890.3	O
mg/l	O
.	O
	
lc50	B-C1443965
values	B-C0042295
ranged	B-C1514721
from	O
18.2	O
to	O
21.7	O
mg/l	O
for	O
ch3hgcl	B-C0066402
,	O
56.4	O
to	O
60.2	O
mg/l	O
for	O
cp	B-C0013328
,	O
and	O
1000	O
to	O
1460.1	O
for	O
ch3coopb	B-C0064711
.	O
	
theophylline	B-C0039771
,	O
acetaminophen	B-C0000970
,	O
and	O
dichlorvos	B-C0012087
had	O
no	O
impact	B-C4049986
on	O
the	O
viability	B-C0443348
of	O
nscs	B-C0007600
.	O
	
this	O
work	O
justified	O
that	O
hucb	B-C0162371
-	O
nsc	B-C0007600
model	B-C0026339
can	O
be	O
used	O
for	O
toxicity	B-C0600688
study	B-C2603343
.	O
	
mir	B-C1537859
221	I-C1537859
/	O
222	B-C1537860
as	O
new	O
players	O
in	O
tamoxifen	B-C0039286
resistance	B-C0013203
breast	B-C0007104
cancer	I-C0007104
is	O
the	O
most	O
frequent	O
cancer	B-C0006826
in	O
women	B-C0043210
.	O
	
despite	O
advances	O
in	O
early	B-C0596473
detection	I-C0596473
and	O
treatment	B-C0087111
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	B-C0205848
rate	I-C0205848
after	O
lung	B-C0242379
cancer	I-C0242379
.	O
	
around	O
85%	O
of	O
breast	B-C0678222
carcinomas	I-C0678222
are	O
er+	B-C1971473
thus	O
,	O
antiestrogens	B-C0014930
like	O
tamoxifen	B-C0039286
are	O
beneficial	O
.	O
	
although	O
,	O
tamoxifen	B-C0039286
is	O
useful	O
for	O
many	O
patients	B-C0030705
,	O
plenty	O
of	O
patients	B-C0030705
respond	B-C1320680
poorly	I-C1320680
to	O
initial	O
therapy	B-C0087111
or	O
recurrence	B-C0034897
occurs	O
in	O
about	O
30%	O
of	O
cases	O
,	O
because	O
tamoxifen	B-C0039286
resistance	B-C0013203
happens	O
.	O
	
drug	B-C0013203
resistance	I-C0013203
remains	O
a	O
major	O
clinical	B-C0205210
obstacle	O
to	O
successful	B-C0521982
treatment	I-C0521982
of	O
breast	B-C0007104
cancer	I-C0007104
and	O
more	O
than	O
90%	O
of	O
unsuccessful	B-C0438286
treatments	I-C0438286
are	O
because	O
of	O
acquired	B-C0439661
resistance	B-C0013203
and	O
multidrug	B-C0242640
resistance	I-C0242640
mdr	B-C0242640
is	O
a	O
major	O
contributor	O
.	O
	
micrornas	B-C1101610
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	B-C0887909
rnas	I-C0887909
.	O
	
besides	O
to	O
their	O
various	O
roles	O
in	O
gene	B-C0017262
expression	I-C0017262
,	O
mirnas	B-C1101610
are	O
considered	O
as	O
important	O
cancer	B-C0006826
therapeutic	B-C1513403
targets	I-C1513403
and	O
biomarkers	B-C0005516
.	O
	
since	O
2005	O
,	O
when	O
mirna	B-C1101610
deregulation	B-C1880287
was	O
first	O
reported	O
in	O
breast	B-C0007104
cancer	I-C0007104
,	O
more	O
than	O
1000	O
reports	B-C0684224
have	O
been	O
published	O
about	O
mirnas	B-C1101610
.	O
	
increasing	O
number	O
of	O
studies	B-C2603343
showed	O
the	O
importance	O
of	O
mirnas	B-C1101610
in	O
antiestrogen	B-C0854638
therapy	I-C0854638
,	O
especially	O
on	O
tamoxifen	B-C0039286
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	B-C0567416
are	O
involved	O
in	O
drug	B-C0013203
resistance	I-C0013203
.	O
	
due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
rna	B-C0035668
molecules	I-C0035668
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
mirnas	B-C1101610
as	O
a	O
new	O
player	O
in	O
breast	B-C0007104
cancer	I-C0007104
pathogenesis	B-C0699748
.	O
	
we	O
have	O
also	O
focused	O
on	O
cancer	B-C0006826
drug	B-C0013203
resistance	I-C0013203
mechanisms	B-C0441712
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	B-C1101610
,	O
mir	B-C1537859
221	I-C1537859
/	O
222	B-C1537860
,	O
involved	O
in	O
cell	B-C1516331
cycle	I-C1516331
deregulation	I-C1516331
in	O
breast	B-C0007104
cancer	I-C0007104
.	O
	
the	O
relationship	O
between	O
these	O
oncomirs	B-C1101610
with	O
resistance	B-C0013203
to	O
tamoxifen	B-C0039286
is	O
also	O
ultra-low	B-C0441655
activities	I-C0441655
of	O
a	O
common	O
radioisotope	B-C0034595
for	O
permission	B-C0521104
-free	O
tracking	B-C0546881
of	O
a	O
drosophilid	B-C0013138
fly	I-C0013138
in	O
its	O
natural	B-C0557745
habitat	I-C0557745
knowledge	O
of	O
a	O
species	B-C1705920
'	O
ecology	B-C0013546
,	O
including	O
its	O
movement	B-C0026649
in	O
time	B-C0040223
and	O
space	B-C1883067
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	B-C0005532
and	O
conservation	B-C2347858
.	O
	
while	O
numerous	O
tools	B-C0336791
for	O
tracking	B-C0546881
larger	O
animals	B-C0003062
are	O
available	O
,	O
millimetre-sized	B-C0021585
insects	I-C0021585
are	O
averse	O
to	O
standard	O
tracking	B-C0546881
and	O
labelling	B-C0022261
procedures	I-C0022261
.	O
	
here	O
,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra-low	B-C0441655
,	O
permission	B-C0521104
-	O
exempt	B-C0441655
activities	I-C0441655
of	O
the	O
metastable	B-C0022203
isomer	I-C0022203
of	O
the	O
radionuclide	B-C0034595
technetium-99	B-C0303612
for	O
labelling	B-C0022261
and	O
field	B-C0243095
detection	I-C0243095
of	O
the	O
mountain	B-C0442533
fly	B-C1704307
drosophila	B-C3766101
nigrosparsa	I-C3766101
.	O
	
we	O
demonstrate	O
that	O
an	O
activity	B-C0441655
of	O
less	O
than	O
10	O
mbq	O
is	O
sufficient	O
to	O
label	B-C0022261
dozens	O
of	O
flies	B-C0012578
and	O
detect	B-C0243095
single	I-C0243095
individuals	I-C0243095
using	O
standard	O
radiation	B-C0034533
protection	I-C0034533
monitors	B-C0034532
.	O
	
the	O
methodology	B-C3266812
presented	O
here	O
is	O
applicable	O
to	O
many	O
small-sized	B-C0748864
,	O
low-mobility	B-C0243095
animals	B-C0003062
as	O
well	O
as	O
independent	O
from	O
light	B-C0023693
and	O
weather	B-C0043085
conditions	B-C0348080
and	O
visual	B-C0243095
contact	I-C0243095
with	O
the	O
target	B-C1521840
organism	B-C0029235
.	O
	
injury	B-C0681625
surveillance	I-C0681625
of	O
female	B-C0086287
adult	B-C0001675
zumba	B-C1254363
dancers	B-C0335079
we	O
sought	O
to	O
describe	O
the	O
patterns	B-C0449774
of	O
injury	B-C0043251
and	O
to	O
establish	O
the	O
injury	B-C0043251
incidence	B-C1708485
rates	I-C1708485
associated	B-C0332281
with	O
zumba	B-C1254363
zumba	B-C1254363
dancers	B-C0335079
were	O
invited	O
to	O
complete	O
an	O
anonymous	O
web-based	B-C0282111
survey	B-C0038951
containing	O
13	O
demographic	B-C0011292
background	B-C1706907
and	O
14	O
1	O
yr	B-C0439234
retrospective	B-C1514923
injury	B-C0043251
history	B-C0019665
questions	B-C1522634
.	O
	
inclusion	B-C1512693
criteria	B-C0243161
stated	O
that	O
the	O
respondents	B-C0282122
had	O
to	O
be	O
aged	B-C0001779
18	O
-	O
64	O
yr	B-C0439234
and	O
currently	O
involved	O
in	O
group	B-C1257890
-based	O
classes	B-C0456387
of	O
zumba	B-C1254363
either	O
as	O
a	O
registered	B-C0556993
instructor	I-C0556993
or	O
class	B-C0456387
participant	B-C0679646
.	O
	
binomial	B-C0681925
logistic	I-C0681925
regression	I-C0681925
analysis	I-C0681925
was	O
used	O
to	O
predict	O
the	O
odds	B-C0028873
of	O
injury	B-C0043251
during	O
zumba	B-C1254363
and	O
mann-whitney	B-C1708930
tests	I-C1708930
were	O
employed	O
to	O
ascertain	O
differences	O
between	O
groups	B-C1257890
.	O
	
the	O
survey	B-C0038951
response	B-C1521828
rate	I-C1521828
was	O
74%	O
.	O
	
the	O
final	O
sample	O
of	O
respondents	B-C0282122
n	O
=	O
138	O
female	B-C0086287
=	O
100%	O
included	O
19	O
registered	B-C0556993
instructors	I-C0556993
and	O
119	O
class	B-C0456387
participants	B-C0679646
,	O
of	O
which	O
58%	O
and	O
16%	O
,	O
respectively	O
,	O
sustained	B-C0443318
1	O
injury	B-C0043251
during	O
zumba	B-C1254363
in	O
the	O
past	O
year	B-C0439234
.	O
	
the	O
odds	B-C0028873
of	O
injury	B-C0043251
was	O
7	O
95%	O
ci	B-C0009667
2	O
-	O
19	O
times	O
greater	B-C1704243
p	O
<	O
0.01	O
for	O
registered	B-C0556993
instructors	I-C0556993
than	O
for	O
class	B-C0456387
participants	B-C0679646
.	O
	
zumba	B-C1254363
dancers	B-C0335079
had	O
a	O
17	O
95%	O
ci	B-C0009667
7	O
-	O
28	O
%	O
greater	B-C1704243
p	O
<	O
0.01	O
odds	B-C0028873
of	O
injury	B-C0043251
for	O
every	O
1	O
h	B-C0439227
of	O
non-	O
zumba	B-C1254363
-	O
related	O
moderate	B-C0015259
to	I-C0015259
vigorous	I-C0015259
physical	I-C0015259
activity	I-C0015259
mvpa	B-C0015259
engagement	O
per	O
week	B-C0439230
.	O
	
the	O
injury	B-C0043251
incidence	B-C1708485
rate	I-C1708485
for	O
registered	B-C0556993
instructors	I-C0556993
and	O
class	B-C0456387
participants	B-C0679646
was	O
5.7	O
95%	O
ci	B-C0009667
3.1	O
-	O
8.2	O
and	O
3.9	O
95%	O
ci	B-C0009667
2.5	O
-	O
5.3	O
injuries	B-C0043251
per	O
1000	O
h	B-C0439227
of	O
exposure	B-C0205556
,	O
respectively	O
.	O
	
zumba	B-C1254363
presents	O
a	O
low	B-C3538919
risk	I-C3538919
of	O
injury	B-C0043251
for	O
registered	B-C0556993
instructors	I-C0556993
,	O
the	O
increased	B-C1444641
risk	I-C1444641
of	O
injury	B-C0043251
is	O
likely	O
due	O
to	O
the	O
high	O
total	O
volume	O
of	O
mvpa	B-C0015259
participated	B-C0679823
in	O
clinical	B-C0205210
features	B-C2348519
of	O
smokers	B-C0337664
with	O
radiological	B-C0807679
emphysema	B-C0034067
but	O
without	O
airway	B-C0458827
limitation	B-C0449295
the	O
clinical	B-C0683325
characteristics	I-C0683325
of	O
patients	B-C0030705
with	O
emphysema	B-C0034067
but	O
without	O
airway	B-C0458827
limitations	B-C0449295
remain	O
unknown	B-C0439673
.	O
	
the	O
goal	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
compare	B-C1707455
the	O
clinical	B-C0205210
features	B-C2348519
of	O
current	B-C3241966
and	O
former	B-C0337671
smokers	I-C0337671
without	O
airflow	B-C0231999
limitation	B-C0449295
who	O
have	O
radiologic	B-C0807679
emphysema	B-C0034067
on	O
chest	B-C0202823
ct	I-C0202823
scans	I-C0202823
vs	O
a	O
control	B-C0009932
group	I-C0009932
of	O
current	B-C3241966
and	O
ex-smokers	B-C0337671
without	O
emphysema	B-C0034067
.	O
	
subjects	B-C0681850
enrolled	O
had	O
anthropometric	B-C2459906
characteristics	I-C2459906
recorded	O
,	O
provided	B-C1999230
a	O
medical	B-C0262926
history	I-C0262926
,	O
and	O
underwent	O
low-dose	B-C0445550
chest	B-C0202823
ct	I-C0202823
scanning	I-C0202823
.	O
	
the	O
following	O
parameters	B-C0449381
were	O
also	O
evaluated	O
pulmonary	B-C0024119
function	I-C0024119
tests	I-C0024119
including	O
diffusion	B-C1516251
capacity	I-C1516251
for	I-C1516251
carbon	I-C1516251
monoxide	I-C1516251
dlco	B-C1516251
,	O
the	O
modified	O
medical	B-C4288768
research	I-C4288768
council	I-C4288768
dyspnea	I-C4288768
score	I-C4288768
,	O
copd	B-C4284282
assessment	I-C4284282
test	I-C4284282
cat	B-C4284282
,	O
and	O
6-min	B-C0430515
walk	I-C0430515
test	I-C0430515
6mwt	B-C0430515
.	O
	
a	O
comparison	B-C1707455
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
ct	B-C0040405
-	O
confirmed	B-C0750484
emphysema	B-C0034067
.	O
	
of	O
the	O
203	O
subjects	B-C0681850
,	O
154	O
had	O
emphysema	B-C0034067
,	O
and	O
49	O
did	O
not	O
.	O
	
adjusted	O
group	B-C2348561
comparisons	B-C1707455
revealed	B-C0443289
that	O
a	O
higher	O
proportion	B-C1709707
of	O
patients	B-C0030705
with	O
emphysema	B-C0034067
according	O
to	O
low-dose	B-C0445550
chest	B-C0202823
ct	I-C0202823
scanning	I-C0202823
had	O
an	O
abnormal	B-C4073173
dlco	I-C4073173
value	B-C1522609
<	O
80%	O
46%	O
vs	O
19%	O
p	O
=	O
02	O
,	O
a	O
decrease	B-C0547047
in	O
percentage	B-C0439165
of	O
oxygen	B-C0369768
saturation	I-C0369768
>	O
4%	O
during	O
the	O
6mwt	B-C0430515
8.5	O
vs	O
0	O
p	O
=	O
04	O
,	O
and	O
an	O
altered	B-C0392747
quality	B-C0034380
of	I-C0034380
life	I-C0034380
cat	B-C4284282
score	B-C0449820
10	O
32%	O
vs	O
14%	O
p	O
=	O
01	O
.	O
	
a	O
detailed	O
analysis	B-C0936012
of	O
the	O
cat	B-C4284282
questionnaire	I-C4284282
items	O
revealed	B-C0443289
that	O
more	O
patients	B-C0030705
with	O
emphysema	B-C0034067
had	O
a	O
score	B-C0449820
1	O
in	O
the	O
""""	O
chest	B-C0232292
tightness	I-C0232292
""""	O
p	O
=	O
05	O
and	O
""""	O
limitation	B-C0449295
when	O
doing	O
activities	B-C0441655
at	O
home	B-C0442519
""""	O
p	O
<	O
01	O
items	O
compared	B-C1707455
with	O
those	O
with	O
no	B-C0243095
emphysema	I-C0243095
.	O
	
they	O
also	O
experienced	O
significantly	O
more	O
exacerbations	B-C4086268
in	O
the	O
previous	O
year	B-C0439234
0.19	O
vs	O
0.04	O
p	O
=	O
02	O
.	O
	
a	O
significant	B-C0750502
proportion	B-C1709707
of	O
smokers	B-C0337664
with	O
emphysema	B-C0034067
according	O
to	O
low-dose	B-C0445550
chest	B-C0202823
ct	I-C0202823
scanning	I-C0202823
but	O
without	O
airway	B-C0458827
limitation	B-C0449295
had	O
alterations	B-C1515926
in	O
their	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
,	O
number	O
of	O
exacerbations	B-C4086268
,	O
dlco	B-C1516251
values	B-C1522609
,	O
and	O
oxygen	B-C0369768
saturation	I-C0369768
during	O
the	O
6mwt	B-C0430515
test	I-C0430515
.	O
	
anti-tumor	B-C1516031
activity	I-C1516031
of	O
sl4	B-C4278992
against	O
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
induction	B-C0205263
of	O
g2/m	B-C1517345
arrest	I-C1517345
through	O
modulation	B-C0678672
of	O
the	O
mapk	B-C0752312
-dependent	O
p21	B-C0288472
signaling	B-C0037083
pathway	I-C0037083
sl4	B-C4278992
,	O
a	O
chalcone	B-C0007935
-based	O
compound	B-C1706082
,	O
has	O
been	O
shown	O
to	O
retard	B-C0521111
tumor	B-C1269955
invasion	I-C1269955
and	O
angiogenesis	B-C1519670
by	O
suppressing	B-C1260953
hif1	B-C0215848
activity	B-C0441655
and	O
to	O
induce	B-C0205263
apoptosis	B-C0162638
by	O
promoting	B-C0033414
ros	B-C0162772
release	B-C1283071
.	O
	
here	O
,	O
we	O
report	B-C0684224
that	O
sl4	B-C4278992
is	O
able	O
to	O
inhibit	B-C3463820
the	O
proliferation	B-C0596290
of	O
different	B-C1705242
types	B-C0332307
of	O
breast	B-C1512505
cancer	I-C1512505
cell	I-C1512505
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
by	O
inducing	B-C0205263
g2/m	B-C1517345
cell	I-C1517345
cycle	I-C1517345
arrest	I-C1517345
.	O
	
our	O
results	B-C0683954
showed	O
that	O
sl4	B-C4278992
exhibited	B-C0870432
strong	B-C0442821
anti-proliferative	B-C0003392
activity	B-C0441655
in	O
several	O
human	B-C0086418
breast	B-C0678222
cancer	I-C0678222
cell	B-C0085983
lines	I-C0085983
,	O
with	O
ic50	B-C0600495
values	I-C0600495
lower	B-C2003888
than	O
1.3	O
μm	O
.	O
	
further	O
studies	B-C2603343
indicated	B-C1444656
that	O
sl4	B-C4278992
induced	B-C0205263
g2/m	B-C1517345
arrest	I-C1517345
in	O
these	O
cell	B-C0085983
lines	I-C0085983
.	O
	
mechanistically	B-C0598002
,	O
sl4	B-C4278992
reduces	B-C0392756
the	O
expression	B-C0017262
of	O
cyclin	B-C0297674
a2	I-C0297674
and	O
cdc25c	B-C0213045
and	O
decreases	B-C0547047
the	O
activity	B-C1537044
of	O
the	O
cdc2	B-C0080054
/	O
cyclin	B-C0385333
b1	I-C0385333
complex	B-C1704241
.	O
	
notably	O
,	O
sl4	B-C4278992
treatment	B-C1533734
resulted	B-C0332294
in	I-C0332294
an	O
obvious	O
increase	B-C0442805
in	O
p21	B-C0249197
mrna	B-C0035696
and	O
protein	B-C0033684
levels	B-C0441889
through	O
activation	B-C2259058
of	O
mapk	B-C1518102
signaling	I-C1518102
pathways	I-C1518102
,	O
but	O
not	O
the	O
tgf-β	B-C1155363
pathway	I-C1155363
.	O
	
sp600125	B-C0968383
and	O
pd98059	B-C0298346
,	O
specific	O
inhibitors	B-C0243077
of	O
jnk	B-C0291988
kinase	I-C0291988
and	O
erk	B-C0600388
kinase	I-C0600388
,	O
significantly	B-C0750502
blocked	B-C0332206
the	O
sl4	B-C4278992
-	O
induced	B-C0205263
g2/m	B-C1517345
phase	I-C1517345
arrest	I-C1517345
and	O
upregulation	B-C0041904
of	O
p21	B-C0288472
.	O
	
furthermore	O
,	O
sl4	B-C4278992
suppressed	B-C1260953
the	O
growth	B-C0007595
of	O
established	B-C0443211
breast	B-C1458155
tumors	I-C1458155
in	O
nude	B-C0025932
mice	I-C0025932
through	O
upregulation	B-C0041904
of	O
p21	B-C0288472
and	O
downregulation	B-C0013081
of	O
cdc25c	B-C0213045
,	O
and	O
displayed	B-C0870432
a	O
good	O
safety	B-C0036043
profile	B-C2003903
.	O
	
taken	O
together	O
,	O
these	O
findings	B-C0243095
demonstrate	B-C0443211
the	O
potential	B-C3245505
value	B-C1264628
of	O
sl4	B-C4278992
as	O
a	O
novel	O
multi-target	B-C0003392
anti-tumor	I-C0003392
drug	I-C0003392
candidate	I-C0003392
.	O
	
identification	B-C0205396
of	O
in-chain-functionalized	B-C1706082
compounds	I-C1706082
and	O
methyl-branched	B-C0002065
alkanes	I-C0002065
in	O
cuticular	B-C2699479
waxes	B-C0043076
of	O
triticum	B-C1123020
aestivum	I-C1123020
cv	I-C1123020
.	O
	
bethlehem	I-C1123020
in	O
this	O
work	O
,	O
cuticular	B-C2699479
waxes	B-C0043076
from	O
flag	B-C0242724
leaf	I-C0242724
blades	B-C2700402
and	O
peduncles	B-C2698753
of	O
triticum	B-C1123020
aestivum	I-C1123020
cv	I-C1123020
.	O
	
bethlehem	I-C1123020
were	O
investigated	B-C1292732
in	O
search	O
for	O
novel	B-C0205314
wax	B-C0043076
compounds	I-C0043076
.	O
	
seven	O
wax	B-C0043076
compound	I-C0043076
classes	B-C1705943
were	O
detected	B-C0442726
that	O
had	O
previously	O
not	O
been	O
reported	O
,	O
and	O
their	O
structures	B-C0220807
were	O
elucidated	O
using	O
gas	B-C0024868
chromatography-mass	I-C0024868
spectrometry	I-C0024868
of	O
various	O
derivatives	B-C0243072
.	O
	
six	O
of	O
the	O
classes	O
were	O
identified	O
as	O
series	B-C0205549
of	I-C0205549
homologs	I-C0205549
differing	B-C1705242
by	O
two	B-C1254350
methylene	I-C1254350
units	I-C1254350
,	O
while	O
the	O
seventh	O
was	O
a	O
homologous	B-C0205549
series	I-C0205549
with	O
homologs	B-C1254350
with	I-C1254350
single	I-C1254350
methylene	I-C1254350
unit	I-C1254350
differences	O
.	O
	
in	O
the	O
waxes	B-C0043076
of	O
flag	B-C0242724
leaf	I-C0242724
blades	B-C2700402
,	O
secondary	B-C0682927
alcohols	I-C0682927
predominantly	B-C1542147
c27	B-C0682927
and	O
c33	B-C0682927
,	O
primary	B-C0017951
/	O
secondary	B-C0017951
diols	I-C0017951
predominantly	B-C1542147
c28	B-C0017951
and	O
esters	B-C0014898
of	I-C0014898
primary	I-C0014898
/	O
secondary	B-C0014898
diols	I-C0014898
predominantly	B-C1542147
c50	B-C0014898
,	O
combining	O
c28	B-C0017945
diol	I-C0017945
with	O
c22	B-C0369760
acid	I-C0369760
were	O
found	O
,	O
all	O
sharing	O
similar	O
secondary	B-C1254350
hydroxyl	I-C1254350
group	I-C1254350
positions	I-C1254350
at	O
and	O
around	O
c-12	O
or	O
ω-12	O
.	O
	
7-	B-C0014898
and	O
8-hydroxy-2-alkanol	B-C0014898
esters	I-C0014898
predominantly	B-C1542147
c35	B-C0014898
,	O
7-	B-C0014898
and	O
8-oxo-2-alkanol	B-C0014898
esters	I-C0014898
predominantly	B-C1542147
c35	B-C0014898
,	O
and	O
4-alkylbutan-4-olides	B-C0022947
predominantly	B-C1542147
c28	B-C0022947
were	O
found	O
both	O
in	O
flag	B-C0242724
leaf	I-C0242724
and	O
peduncle	B-C2698753
wax	B-C0043076
mixtures	O
.	O
	
finally	O
,	O
a	O
series	B-C0205549
of	O
even	B-C1254350
-	O
and	O
odd-numbered	B-C1254350
alkane	I-C1254350
homologs	I-C1254350
was	O
identified	O
in	O
both	O
leaf	B-C0242724
and	O
peduncle	B-C2698753
waxes	B-C0043076
,	O
with	O
an	O
internal	B-C1254350
methyl	I-C1254350
branch	I-C1254350
preferentially	O
on	O
c-11	B-C0029224
and	O
c-13	B-C0029224
of	I-C0029224
homologs	I-C0029224
with	I-C0029224
even	I-C0029224
total	I-C0029224
carbon	I-C0029224
number	I-C0029224
and	O
on	O
c-12	B-C0029224
of	I-C0029224
odd-numbered	I-C0029224
homologs	I-C0029224
.	O
	
biosynthetic	B-C1721101
pathways	I-C1721101
are	O
suggested	O
for	O
all	O
compounds	B-C0205198
,	O
based	O
on	O
common	O
structural	B-C0220807
features	B-C2348519
and	O
matching	O
chain	B-C0596310
length	I-C0596310
profiles	B-C2003903
with	O
other	O
wheat	B-C1510495
wax	B-C0043076
compound	I-C0043076
pupillary	B-C4067879
response	I-C4067879
abnormalities	B-C1704258
in	O
depressive	B-C0011581
disorders	I-C0011581
depressive	B-C0011581
disorders	I-C0011581
lack	B-C0332268
objective	B-C1571702
physiological	B-C0205463
measurements	B-C0242485
to	O
characterize	B-C1880022
the	O
affected	B-C4285581
population	I-C4285581
and	O
facilitate	O
study	B-C0008972
of	O
relevant	B-C2347946
mechanisms	B-C0441712
.	O
	
the	O
melanopsin	B-C0670514
-	O
mediated	B-C0870868
light	B-C0037080
signaling	I-C0037080
pathway	I-C0037080
may	O
contribute	O
to	O
seasonal	B-C0036496
variation	I-C0036496
and	O
can	O
be	O
measured	B-C0444706
non-invasively	O
by	O
pupillometry	B-C0260180
.	O
	
we	O
prospectively	B-C0033522
studied	I-C0033522
changes	O
in	O
melanopsin	B-C0670514
-	O
mediated	B-C0870868
pupillary	B-C3537108
constriction	I-C3537108
in	O
19	O
participants	B-C0030705
with	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
mdd	B-C1269683
and	O
10	O
control	B-C0009932
across	O
the	O
summer	B-C1254367
and	I-C1254367
winter	I-C1254367
solstices	I-C1254367
.	O
	
the	O
melanopsin	B-C0670514
-	O
mediated	B-C0870868
response	I-C0870868
,	O
as	O
measured	B-C0444706
by	O
the	O
pupil's	B-C0728710
sustained	I-C0728710
constriction	I-C0728710
six	O
s	O
after	O
a	O
high	B-C0683109
intensity	I-C0683109
blue	B-C0303896
light	I-C0303896
stimulus	B-C0234402
,	O
was	O
marginally	O
attenuated	B-C0599946
in	O
those	O
with	O
mdd	B-C1269683
relative	O
to	O
controls	B-C0009932
p	B-C1709380
=0	O
.	O
	
the	O
participants	B-C0030705
with	O
mdd	B-C1269683
unexpectedly	O
showed	O
a	O
significantly	B-C0750502
reduced	B-C0392756
transient	B-C0205374
pupillary	B-C4067879
response	I-C4067879
to	O
low	B-C0683108
intensity	I-C0683108
red	B-C0563227
p	B-C1709380
=0	O
and	O
blue	B-C0303896
light	I-C0303896
p	B-C1709380
=0	O
,	O
but	O
not	O
high	B-C0683109
intensity	I-C0683109
red	B-C0563227
and	O
blue	B-C0303896
light	I-C0303896
.	O
	
sustained	O
pupillary	B-C3537108
constriction	I-C3537108
in	O
response	B-C4067879
to	O
high	B-C0683109
intensity	I-C0683109
blue	B-C0303896
light	I-C0303896
was	O
more	O
pronounced	O
with	O
increasing	B-C0442808
daylight	B-C0023693
hours	B-C0439227
p	B-C1709380
=0	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	B-C1571702
measured	B-C0444706
versus	O
estimated	B-C0750572
light	B-C1689916
exposure	I-C1689916
.	O
	
melanopsin	B-C0670514
-	O
mediated	B-C0870868
impairments	B-C0221099
in	O
pupil	B-C4067879
response	I-C4067879
may	O
serve	O
as	O
a	O
biological	B-C0005516
marker	I-C0005516
for	O
vulnerability	B-C1821973
to	O
depression	B-C0011570
in	O
low	B-C0683108
light	I-C0683108
conditions	B-C0348080
.	O
	
assessment	B-C0220825
of	O
these	O
and	O
other	O
responses	B-C0871261
to	O
light	B-C0023693
stimuli	B-C0234402
,	O
such	O
as	O
response	B-C0871261
to	O
low	B-C0683108
intensity	I-C0683108
light	I-C0683108
,	O
may	O
be	O
useful	O
for	O
the	O
study	B-C0008972
of	O
the	O
neurobiology	B-C0027817
of	O
mdd	B-C1269683
and	O
related	O
mood	B-C0525045
disorders	I-C0525045
.	O
	
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
in	O
cardiovascular	B-C0741949
pathology	I-C0741949
,	O
diagnosis	B-C1704656
,	O
and	O
therapy	B-C0087111
vast	O
parts	O
of	O
mammalian	B-C0024660
genomes	B-C0017428
encode	B-C2700640
for	O
transcripts	B-C1519595
that	O
are	O
not	O
further	O
translated	B-C1519614
into	I-C1519614
proteins	I-C1519614
.	O
	
the	O
purpose	B-C1285529
of	O
the	O
majority	B-C0205164
of	O
such	O
noncoding	B-C0887909
ribonucleic	I-C0887909
acids	I-C0887909
rnas	B-C0887909
remained	O
paradoxical	B-C0205310
for	O
a	O
long	O
time	O
.	O
	
however	O
,	O
a	O
growing	B-C0442808
body	O
of	O
evidence	B-C3887511
demonstrates	B-C3687625
that	O
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
are	O
dynamically	B-C0729333
expressed	B-C0017262
in	O
different	B-C1705242
cell	B-C0007634
types	I-C0007634
,	O
diseases	B-C0012634
,	O
or	O
developmental	B-C0870411
stages	I-C0870411
to	O
execute	B-C1705848
a	O
wide	B-C2346866
variety	I-C2346866
of	O
regulatory	B-C1704735
roles	I-C1704735
at	O
virtually	B-C0205556
every	O
step	B-C1261552
of	O
gene	B-C0017262
expression	I-C0017262
and	O
translation	B-C1519614
.	O
	
indeed	O
,	O
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
influence	B-C4054723
gene	B-C0017262
expression	I-C0017262
via	O
epigenetic	B-C1516924
modulations	I-C1516924
,	O
through	O
regulating	B-C0017263
alternative	B-C0002345
splicing	I-C0002345
,	O
or	O
by	O
acting	O
as	O
molecular	B-C0205556
sponges	I-C0205556
.	O
	
the	O
abundance	B-C2346714
of	O
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
in	O
the	O
cardiovascular	B-C0007226
system	I-C0007226
indicates	O
that	O
they	O
may	O
be	O
part	O
of	O
a	O
complex	B-C0439855
regulatory	B-C1720950
network	I-C1720950
governing	B-C2239193
physiology	B-C1254359
and	O
pathology	B-C0030660
of	O
the	O
heart	B-C0018787
.	O
	
in	O
this	O
review	O
,	O
we	O
discuss	O
the	O
multifaceted	B-C0205291
functions	B-C0542341
of	O
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
and	O
highlight	O
the	O
current	B-C0023866
literature	I-C0023866
with	O
an	O
emphasis	O
on	O
cardiac	B-C2263229
development	I-C2263229
and	O
disease	B-C0012634
.	O
	
furthermore	B-C1517331
,	O
as	O
the	O
enormous	B-C0205231
spectrum	O
of	O
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
potentially	B-C3245505
opens	O
up	O
new	O
avenues	B-C1254362
for	O
diagnosis	B-C1704656
and	O
prevention	B-C0199176
of	O
heart	B-C0018801
failure	I-C0018801
,	O
we	O
ultimately	O
evaluate	O
the	O
futuristic	B-C1552610
prospects	I-C1552610
of	O
long	B-C2982391
noncoding	I-C2982391
rnas	I-C2982391
as	O
biomarkers	B-C0005516
,	O
and	O
therapeutic	B-C0302350
targets	B-C0028622
for	O
the	O
treatment	B-C0087111
of	O
cardiovascular	B-C0007222
disorders	I-C0007222
,	O
flexible	B-C0443220
coordination	B-C0700114
of	O
stationary	B-C0439835
and	O
mobile	B-C0231435
conversations	B-C0871703
with	O
gaze	B-C0553544
resource	B-C0086914
allocation	I-C0086914
among	O
multiple	B-C0026606
joint	I-C0026606
activities	I-C0026606
gaze	B-C0553544
is	O
instrumental	O
in	O
coordinating	B-C0700114
face-to-face	B-C1553514
social	B-C0037420
interactions	I-C0037420
.	O
	
but	O
little	O
is	O
known	O
about	O
gaze	B-C0553544
use	O
when	O
social	B-C0037420
interactions	I-C0037420
co-occur	B-C1709305
with	O
other	O
joint	B-C0026606
activities	I-C0026606
.	O
	
we	O
investigated	B-C1292732
the	O
case	O
of	O
walking	B-C0080331
while	O
talking	B-C0234856
.	O
	
we	O
assessed	B-C1516048
how	O
gaze	B-C0553544
gets	O
allocated	B-C1706778
among	O
various	O
targets	B-C0039309
in	O
mobile	B-C0231435
conversations	B-C0871703
,	O
whether	O
allocation	B-C1706778
of	O
gaze	B-C0553544
to	O
other	O
targets	B-C0039309
affects	B-C0001721
conversational	B-C0871703
coordination	B-C0700114
,	O
and	O
whether	O
reduced	B-C0392756
availability	B-C0470187
of	I-C0470187
gaze	B-C0553544
for	O
conversational	B-C0871703
coordination	B-C0700114
affects	B-C0001721
conversational	B-C0871703
performance	B-C0597198
and	O
content	B-C0456205
.	O
	
in	O
an	O
experimental	B-C0681814
study	I-C0681814
,	O
pairs	O
were	O
videotaped	B-C0042654
in	O
four	O
conditions	B-C0449910
of	O
mobility	B-C0425245
standing	B-C0231472
still	I-C0231472
,	O
talking	B-C0234856
while	O
walking	B-C0522230
along	I-C0522230
a	I-C0522230
straight-line	I-C0522230
itinerary	I-C0522230
,	O
talking	B-C0234856
while	O
walking	B-C0080331
along	O
a	O
complex	B-C0439855
itinerary	I-C0439855
,	O
or	O
walking	B-C0080331
along	O
a	O
complex	B-C0439855
itinerary	I-C0439855
with	O
no	B-C0243095
conversational	I-C0243095
task	B-C3540678
.	O
	
gaze	B-C0553544
to	O
partners	B-C0026767
was	O
substantially	B-C0392756
reduced	I-C0392756
in	O
mobile	B-C0231435
conversations	B-C0871703
,	O
but	O
gaze	B-C0553544
was	O
still	O
used	O
to	O
coordinate	B-C0700114
conversation	B-C0871703
via	O
displays	B-C0870432
of	O
mutual	B-C1709100
orientation	B-C1704322
,	O
and	O
conversational	B-C0871703
performance	B-C0597198
and	O
content	B-C0456205
was	O
not	O
different	B-C1705242
between	O
stationary	B-C0439835
and	O
mobile	B-C0231435
conditions	B-C0449910
.	O
	
results	B-C0456984
expand	O
the	O
phenomena	B-C1882365
of	O
multitasking	O
to	O
joint	B-C0026606
activities	I-C0026606
.	O
	
sepsis	B-C0243026
clinical	B-C1516637
criteria	I-C1516637
in	O
emergency	B-C0562508
department	I-C0562508
patients	B-C0030705
admitted	B-C0184666
to	O
an	O
intensive	B-C0021708
care	I-C0021708
unit	I-C0021708
an	O
external	B-C0681836
validation	I-C0681836
study	I-C0681836
of	O
quick	B-C3494459
sequential	I-C3494459
organ	I-C3494459
failure	I-C3494459
assessment	I-C3494459
quick	B-C3494459
sequential	I-C3494459
organ	I-C3494459
failure	I-C3494459
assessment	I-C3494459
qsofa	B-C3494459
is	O
a	O
prognostic	B-C0449821
score	I-C0449821
for	O
patients	B-C0030705
with	O
sepsis	B-C0243026
.	O
	
our	O
aim	B-C1947946
was	O
to	O
compare	O
the	O
area	B-C0035787
under	I-C0035787
the	I-C0035787
receiver	I-C0035787
operating	I-C0035787
curve	I-C0035787
auroc	B-C0035787
,	O
sensitivity	B-C0036667
,	O
specificity	B-C0037791
,	O
and	O
likelihood	B-C0150102
ratios	I-C0150102
of	O
qsofa	B-C3494459
vs	O
.	O
	
systemic	B-C0242966
inflammation	I-C0242966
response	I-C0242966
syndrome	I-C0242966
sirs	B-C0242966
in	O
predicting	O
in-hospital	B-C0085556
mortality	I-C0085556
among	O
emergency	B-C0562508
department	I-C0562508
ed	B-C0562508
patients	B-C0030705
with	O
suspected	B-C3714514
infection	I-C3714514
admitted	B-C0184666
to	O
intensive	B-C0021708
care	I-C0021708
units	I-C0021708
icus	B-C0021708
.	O
	
we	O
conducted	O
a	O
retrospective	B-C2985505
cohort	I-C2985505
chart	I-C2985505
review	I-C2985505
study	I-C2985505
of	O
ed	B-C0562508
patients	B-C0030705
admitted	B-C0184666
to	O
an	O
icu	B-C0021708
with	O
suspected	B-C3714514
infection	I-C3714514
from	O
august	B-C3831448
1	O
,	O
2012	O
to	O
february	B-C3830166
28	O
,	O
2015	O
.	O
	
we	O
included	O
all	O
patients	B-C0030705
with	O
body	B-C1292527
fluid	I-C1292527
cultures	I-C1292527
sampled	I-C1292527
either	O
during	O
their	O
ed	B-C0562508
stay	O
without	O
antibiotic	B-C0199779
administration	I-C0199779
or	O
within	O
24	O
h	O
of	O
antibiotics	B-C0199779
administered	I-C0199779
in	O
the	O
ed	B-C0562508
.	O
	
trained	B-C1522486
chart	I-C1522486
abstractors	I-C1522486
blinded	O
to	O
the	O
study	B-C2603343
hypothesis	O
double-entered	B-C1511726
data	I-C1511726
from	O
each	O
patient's	B-C0030705
electronic	B-C2362543
medical	I-C2362543
record	I-C2362543
including	O
demographic	B-C0683970
characteristics	I-C0683970
,	O
vital	B-C0518766
signs	I-C0518766
,	O
laboratory	B-C0681827
study	I-C0681827
results	I-C0681827
,	O
physical	B-C0031809
examination	I-C0031809
findings	B-C0243095
,	O
and	O
in-hospital	B-C0085556
mortality	I-C0085556
.	O
	
we	O
then	O
calculated	O
the	O
auroc	B-C0035787
,	O
sensitivity	B-C0036667
,	O
specificity	B-C0037791
,	O
and	O
likelihood	B-C0150102
ratios	I-C0150102
for	O
qsofa	B-C3494459
and	O
sirs	B-C0242966
for	O
predicting	O
in-hospital	B-C0085556
mortality	I-C0085556
.	O
	
of	O
214	O
patients	B-C0030705
admitted	B-C0184666
to	O
an	O
icu	B-C0021708
with	O
presumed	B-C0243026
sepsis	I-C0243026
,	O
39	O
18.2	O
died	B-C3260027
during	I-C3260027
hospitalization	I-C3260027
.	O
	
the	O
auroc	B-C0035787
value	O
was	O
0.65	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.56	O
for	O
sirs	B-C0242966
vs	O
.	O
	
0.66	O
95%	O
ci	B-C0009667
0.57	O
for	O
qsofa	B-C3494459
2+	O
qsofa	B-C3494459
criteria	O
predicted	O
in-hospital	B-C0085556
mortality	I-C0085556
with	O
89.7	O
sensitivity	B-C0036667
,	O
27.4	O
specificity	B-C0037791
,	O
1.2	O
positive	B-C0150102
likelihood	I-C0150102
ratio	I-C0150102
,	O
and	O
0.4	O
negative	B-C0150102
likelihood	I-C0150102
ratio	I-C0150102
.	O
	
among	O
ed	B-C0562508
patients	B-C0030705
admitted	B-C0184666
to	O
an	O
icu	B-C0021708
,	O
the	O
sirs	B-C0242966
and	O
qsofa	B-C3494459
criteria	O
had	O
comparable	O
prognostic	B-C0449821
value	I-C0449821
for	O
predicting	O
in-hospital	B-C0085556
mortality	I-C0085556
.	O
	
these	O
prognostic	B-C0449821
values	I-C0449821
are	O
similar	O
to	O
those	O
reported	O
by	O
the	O
sepsis-3	B-C0282451
guidelines	I-C0282451
for	O
icu	B-C0021708
encounters	B-C3889614
.	O
	
repetitive	B-C0872259
transcranial	I-C0872259
magnetic	I-C0872259
stimulation	I-C0872259
improves	O
cognitive	B-C0392335
function	I-C0392335
of	O
alzheimer's	B-C0002395
disease	I-C0002395
patients	B-C0030705
repetitive	B-C0872259
transcranial	I-C0872259
magnetic	I-C0872259
stimulation	I-C0872259
rtms	B-C0872259
acts	O
as	O
a	O
kind	O
of	O
widely-applied	O
and	O
non-invasive	O
method	O
in	O
the	O
intervention	B-C0184661
of	O
some	O
neurological	B-C0027765
disorders	I-C0027765
.	O
	
this	O
prospective	B-C0033522
,	O
randomized	B-C0034656
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C1706408
trial	I-C1706408
investigates	B-C1292732
the	O
effect	O
of	O
rtms	B-C0872259
on	O
30	O
cases	B-C0868928
of	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
participants	B-C0679646
,	O
who	O
were	O
classified	O
into	O
mild	B-C2945599
and	O
moderate	B-C0205081
groups	B-C1257890
.	O
	
neuropsychological	B-C0027902
tests	I-C0027902
were	O
carried	O
out	O
using	O
the	O
ad	B-C0450989
assessment	I-C0450989
scale	I-C0450989
-	O
cognitive	B-C0282574
subscale	I-C0282574
adas	B-C0450989
-	O
cog	B-C0282574
,	O
mini-mental	B-C0451306
state	I-C0451306
examination	I-C0451306
mmse	B-C0451306
,	O
montreal	B-C3496286
cognitive	I-C3496286
assessment	I-C3496286
moca	B-C3496286
,	O
and	O
world	B-C0589055
health	I-C0589055
organization	I-C0589055
university	I-C0589055
of	I-C0589055
california-los	I-C0589055
angeles	I-C0589055
,	O
auditory	I-C0589055
verbal	I-C0589055
learning	I-C0589055
test	I-C0589055
who-ucla	B-C0589055
avlt	I-C0589055
before	O
,	O
immediately	O
after	O
,	O
and	O
6	O
weeks	B-C0439230
after	O
the	O
intervention	B-C0184661
.	O
	
in	O
this	O
work	O
,	O
data	B-C1511726
from	O
30	O
ad	B-C0002395
patients	B-C0030705
revealed	O
that	O
there	O
was	O
no	O
obvious	O
interaction	B-C0548930
effect	I-C0548930
of	O
time-by-group	O
.	O
	
the	O
adas	B-C0450989
-	O
cog	B-C0282574
,	O
mmse	B-C0451306
and	O
who-ucla	B-C0589055
avlt	I-C0589055
score	B-C0449820
in	O
the	O
rtms	B-C0872259
group	B-C1257890
was	O
significantly	O
improved	O
compared	B-C1707455
with	O
baselines	B-C1442488
at	O
6	O
weeks	B-C0439230
after	O
treatment	B-C0087111
all	O
p<0	O
.	O
	
meanwhile	O
,	O
moca	B-C3496286
scores	B-C0449820
were	O
also	O
obviously	O
ameliorated	B-C0184511
in	O
the	O
mild	B-C2945599
ad	B-C0002395
patients	B-C0030705
with	O
rtms	B-C0872259
.	O
	
besides	O
,	O
subgroup	B-C0936012
analysis	I-C0936012
showed	O
that	O
the	O
effect	O
of	O
rtms	B-C0872259
on	O
the	O
memory	B-C0025260
and	O
language	B-C0023008
of	O
mild	B-C2945599
ad	B-C0002395
patients	B-C0030705
was	O
superior	O
to	O
those	O
of	O
moderate	B-C0205081
ad	B-C0002395
patients	B-C0030705
.	O
	
in	O
conclusion	O
,	O
our	O
findings	B-C0243095
suggested	O
that	O
repetitive	B-C0872259
transcranial	I-C0872259
magnetic	I-C0872259
stimulation	I-C0872259
improves	O
cognitive	B-C0392335
function	I-C0392335
,	O
memory	B-C0025260
and	O
language	B-C0023008
level	B-C0441889
of	O
ad	B-C0002395
patients	B-C0030705
,	O
especially	O
in	O
the	O
mild	B-C2945599
stage	B-C0205390
of	O
ad	B-C0002395
.	O
	
thus	O
,	O
rtms	B-C0872259
can	O
be	O
recommended	O
as	O
a	O
promising	O
adjuvant	B-C0677850
therapy	I-C0677850
combined	O
with	O
cholinesterase	B-C0008425
inhibitors	I-C0008425
at	O
the	O
mild	B-C2945599
stage	B-C0205390
of	O
ad	B-C0002395
patients	B-C0030705
.	O
	
a	O
novel	B-C0205314
insulin/glucose	B-C1719133
model	B-C3161035
after	O
a	O
mixed-meal	B-C0202098
test	I-C0202098
in	O
patients	B-C0030705
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
on	O
insulin	B-C1140609
pump	I-C1140609
therapy	B-C0087111
current	B-C0521116
closed-loop	B-C0181334
insulin	I-C0181334
delivery	I-C0181334
methods	I-C0181334
stem	O
from	O
sophisticated	O
models	O
of	O
the	O
glucose-insulin	B-C1719133
g/i	I-C1719133
system	I-C1719133
,	O
mostly	B-C0750554
based	O
on	O
complex	B-C0439855
studies	B-C0008972
employing	B-C0557351
glucose	B-C0726401
tracer	I-C0726401
technology	I-C0726401
.	O
	
we	O
tested	B-C0039593
the	O
performance	B-C1882330
of	O
a	O
new	O
minimal	B-C3161035
model	I-C3161035
glukinsloop	B-C3161035
2.0	I-C3161035
of	O
the	O
g/i	B-C1719133
system	I-C1719133
to	O
characterize	B-C1880022
the	O
glucose	B-C1719133
and	I-C1719133
insulin	I-C1719133
dynamics	B-C3826426
during	O
multiple	B-C0439064
mixed	B-C0202098
meal	I-C0202098
tests	I-C0202098
mmt	B-C0202098
of	O
different	B-C1705242
sizes	B-C0456389
in	O
patients	B-C0030705
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
t1d	B-C0011854
on	O
insulin	B-C1140609
pump	I-C1140609
therapy	B-C0087111
continuous	B-C0393124
subcutaneous	I-C0393124
insulin	I-C0393124
infusion	I-C0393124
,	O
csii	B-C0393124
.	O
	
the	O
glukinsloop	B-C3161035
2.0	I-C3161035
identified	B-C0205396
the	O
g/i	B-C1719133
system	I-C1719133
,	O
provided	B-C1999230
a	O
close	O
fit	O
of	O
the	O
g/i	B-C1719133
time-courses	B-C0449247
and	O
showed	O
acceptable	B-C1879533
reproducibility	B-C1514863
of	O
the	O
g/i	B-C1719133
system	I-C1719133
parameters	B-C0449381
in	O
repeated	B-C0205341
studies	B-C0008972
of	O
identical	B-C0205280
and	O
double-sized	B-C0392762
mmts	B-C0202098
.	O
	
this	O
model	B-C3161035
can	O
provide	B-C1999230
a	O
fairly	O
good	O
and	O
reproducible	O
description	B-C0678257
of	O
the	O
g/i	B-C1719133
system	I-C1719133
in	O
t1d	B-C0011854
patients	B-C0030705
on	O
csii	B-C0393124
,	O
and	O
it	O
may	O
be	O
applied	B-C4048755
to	O
create	O
a	O
bank	O
of	O
"""virtual"""	B-C1553497
patients	I-C1553497
.	O
	
our	O
results	B-C0456984
might	O
be	O
relevant	B-C2347946
at	O
improving	B-C1272745
the	O
architecture	O
of	O
upcoming	O
closed-loop	B-C0443183
csii	B-C0393124
impact	B-C4049986
of	O
strategically	O
located	O
white	B-C2938912
matter	I-C2938912
hyperintensities	I-C2938912
on	O
cognition	B-C0009240
in	O
memory	B-C0442592
clinic	I-C0442592
patients	B-C0030705
with	O
small	B-C2733158
vessel	I-C2733158
disease	I-C2733158
studies	O
on	O
the	O
impact	B-C4049986
of	O
small	B-C2733158
vessel	I-C2733158
disease	I-C2733158
svd	B-C2733158
on	O
cognition	B-C0009240
generally	O
focus	B-C0205234
on	O
white	B-C2938912
matter	I-C2938912
hyperintensity	I-C2938912
wmh	B-C2938912
volume	B-C0449468
.	O
	
the	O
extent	B-C0439792
to	O
which	O
wmh	B-C2938912
location	B-C1515974
relates	B-C0439849
to	O
cognitive	B-C0392335
performance	I-C0392335
has	O
received	B-C1514756
less	B-C0439092
attention	B-C0004268
,	O
but	O
is	O
likely	O
to	O
be	O
functionally	B-C0205245
important	B-C3898777
.	O
	
we	O
examined	O
the	O
relation	B-C0439849
between	O
wmh	B-C2938912
location	B-C1515974
and	O
cognition	B-C0009240
in	O
a	O
memory	B-C0442592
clinic	I-C0442592
cohort	B-C0599755
of	O
patients	B-C0030705
with	O
sporadic	B-C0205422
svd	B-C2733158
.	O
	
a	O
total	O
of	O
167	O
patients	B-C0030705
with	O
svd	B-C2733158
were	O
recruited	O
from	O
memory	B-C0442592
clinics	I-C0442592
.	O
	
assumption-free	B-C0936012
region	I-C0936012
of	I-C0936012
interest-based	I-C0936012
analyses	I-C0936012
based	B-C1527178
on	O
major	O
white	B-C0682708
matter	I-C0682708
tracts	B-C1185740
and	O
voxel	B-C2700259
-	O
wise	B-C1527178
analyses	B-C0936012
were	O
used	B-C1524063
to	O
determine	O
the	O
association	B-C0439849
between	O
wmh	B-C2938912
location	B-C1515974
and	O
executive	B-C0935584
functioning	I-C0935584
,	O
visuomotor	B-C0025361
speed	I-C0025361
and	O
memory	B-C0025260
.	O
	
region	B-C0936012
of	I-C0936012
interest-based	I-C0936012
analyses	I-C0936012
showed	O
that	O
wmhs	B-C2938912
located	B-C1515974
particularly	O
within	B-C0332285
the	O
anterior	B-C2338170
thalamic	I-C2338170
radiation	I-C2338170
and	O
forceps	B-C0152325
minor	I-C0152325
were	O
inversely	B-C0439850
associated	B-C0332281
with	I-C0332281
both	O
executive	B-C0935584
functioning	I-C0935584
and	O
visuomotor	B-C0025361
speed	I-C0025361
,	O
independent	B-C0332291
of	I-C0332291
total	B-C0439810
wmh	B-C2938912
volume	B-C0449468
.	O
	
memory	B-C0025260
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
wmh	B-C2938912
volume	B-C0449468
in	O
the	O
forceps	B-C0152325
minor	I-C0152325
,	O
independent	B-C0332291
of	I-C0332291
total	B-C0439810
wmh	B-C2938912
volume	B-C0449468
.	O
	
an	O
independent	B-C0936012
assumption-free	I-C0936012
voxel-wise	I-C0936012
analysis	I-C0936012
identified	B-C0205396
strategic	O
voxels	B-C2700259
in	O
these	O
same	B-C0445247
tracts	B-C1185740
.	O
	
region	B-C0936012
of	I-C0936012
interest-based	I-C0936012
analyses	I-C0936012
showed	O
that	O
wmh	B-C2938912
volume	B-C0449468
within	B-C0332285
the	O
anterior	B-C2338170
thalamic	I-C2338170
radiation	I-C2338170
explained	O
6.8	O
of	O
variance	B-C1711260
in	O
executive	B-C0935584
functioning	I-C0935584
,	O
compared	B-C1707455
to	O
3.9	O
for	O
total	B-C0439810
wmh	B-C2938912
volume	B-C0449468
wmh	B-C2938912
volume	B-C0449468
within	B-C0332285
the	O
forceps	B-C0152325
minor	I-C0152325
explained	O
4.6	O
of	O
variance	B-C1711260
in	O
visuomotor	B-C0025361
speed	I-C0025361
and	O
4.2	O
of	O
variance	B-C1711260
in	O
memory	B-C0025260
,	O
compared	B-C1707455
to	O
1.8	O
and	O
1.3	O
respectively	O
for	O
total	B-C0439810
wmh	B-C2938912
volume	B-C0449468
.	O
	
our	O
findings	B-C0243095
identify	B-C0205396
the	O
anterior	B-C2338170
thalamic	I-C2338170
radiation	I-C2338170
and	O
forceps	B-C0152325
minor	I-C0152325
as	O
strategic	O
white	B-C0682708
matter	I-C0682708
tracts	B-C1185740
in	O
which	O
wmhs	B-C2938912
are	O
most	O
strongly	O
associated	B-C0332281
with	I-C0332281
cognitive	B-C0338656
impairment	I-C0338656
in	O
memory	B-C0442592
clinic	I-C0442592
patients	B-C0030705
with	O
svd	B-C2733158
.	O
	
wmh	B-C2938912
volumes	B-C0449468
in	O
individual	O
tracts	B-C1185740
explained	O
more	O
variance	B-C1711260
in	O
cognition	B-C0009240
than	O
total	B-C0439810
wmh	B-C2938912
burden	O
,	O
emphasizing	O
the	O
importance	B-C3898777
of	O
lesion	B-C2184261
location	I-C2184261
when	O
addressing	O
the	O
functional	B-C0205245
consequences	B-C0686907
of	I-C0686907
wmhs	B-C2938912
.	O
	
natural	B-C0205296
competence	B-C0086035
for	O
transformation	B-C0040683
while	O
most	O
molecular	B-C0260017
biologists	I-C0260017
are	O
familiar	O
with	O
the	O
artificial	B-C2004457
transformation	B-C0040683
of	I-C0040683
bacteria	I-C0040683
in	O
the	O
context	B-C0449255
of	O
laboratory	B-C0022877
cloning	B-C0009015
experiments	B-C0681814
,	O
natural	B-C0205296
competence	B-C0086035
for	O
transformation	B-C0040683
refers	O
to	O
a	O
specific	B-C0205369
physiological	B-C0205463
state	B-C1442792
in	O
which	O
prokaryotes	B-C0686817
are	O
able	O
to	O
take	O
up	O
genetic	B-C0440471
material	I-C0440471
from	O
their	O
surroundings	B-C1282914
.	O
	
occasionally	O
,	O
such	O
absorbed	B-C0205245
dna	B-C0012854
is	O
recombined	B-C0205195
into	O
the	O
organism's	B-C0029235
own	O
genome	B-C0017428
,	O
resulting	O
in	O
natural	B-C0205296
transformation	B-C0040683
figure	O
1	O
.	O
	
as	O
a	O
consequence	B-C0686907
,	O
natural	B-C0205296
competence	B-C0086035
for	O
transformation	B-C0040683
is	O
considered	O
a	O
primary	B-C0205225
mode	B-C1513371
of	O
horizontal	B-C0887912
gene	I-C0887912
transfer	I-C0887912
hgt	B-C0887912
in	O
prokaryotes	B-C0686817
,	O
together	O
with	O
conjugation	B-C0009757
direct	B-C1947931
cell	B-C0007634
to	O
cell	B-C0007634
transfer	B-C3244299
of	O
dna	B-C0012854
via	O
a	O
specialized	B-C1704211
conjugal	B-C0242435
pilus	I-C0242435
and	O
phage	B-C0004651
transduction	B-C0040667
dna	B-C0012854
transfer	B-C3244299
mediated	O
by	O
viruses	B-C0042776
.	O
	
hgt	B-C0887912
plays	O
a	O
major	O
role	O
in	O
bacterial	B-C0521009
evolution	B-C0015219
,	O
and	O
past	B-C1444637
research	B-C0035168
has	O
demonstrated	O
that	O
hgt	B-C0887912
,	O
including	O
natural	B-C0205296
competence	B-C0086035
for	O
transformation	B-C0040683
,	O
contributes	B-C1880177
to	O
the	O
emergence	O
of	O
pathogens	B-C0450254
and	O
the	O
spread	B-C0332261
of	O
virulence	B-C1136170
factors	I-C1136170
.	O
	
indeed	O
,	O
frederick	O
griffith	O
discovered	O
natural	B-C0205296
competence	B-C0086035
for	O
transformation	B-C0040683
in	O
1928	O
while	O
he	O
was	O
investigating	B-C1292732
the	O
exchange	B-C1749881
of	O
pathogenic	B-C3816499
traits	B-C0599883
in	O
pneumococci	B-C0038410
.	O
	
due	O
to	O
the	O
increase	B-C0442805
in	O
the	O
abundance	B-C2346714
and	O
spread	B-C0332261
of	O
multidrug-resistant	B-C4076168
microbes	I-C4076168
,	O
research	B-C0035168
on	O
hgt	B-C0887912
three-dimensional	B-C1275506
constructive	I-C1275506
interference	I-C1275506
in	I-C1275506
steady-state	I-C1275506
3d-ciss	I-C1275506
sequences	I-C1275506
and	O
phase-contrast	B-C0024485
mri	I-C0024485
of	O
arrested	B-C0270718
hydrocephalus	I-C0270718
to	O
evaluate	O
role	O
of	O
three-dimensional	B-C1275506
constructive	I-C1275506
interference	I-C1275506
in	I-C1275506
steady-state	I-C1275506
3d-ciss	I-C1275506
sequences	I-C1275506
and	O
phase-contrast	B-C0024485
magnetic	I-C0024485
resonance	I-C0024485
imaging	I-C0024485
pc-mri	B-C0024485
in	O
patients	B-C0030705
with	O
arrested	B-C0270718
hydrocephalus	I-C0270718
.	O
	
prospective	B-C0033522
study	I-C0033522
was	O
conducted	O
on	O
20	O
patients	B-C0030705
with	O
arrested	B-C0270718
hydrocephalus	I-C0270718
.	O
	
all	O
patients	B-C0030705
underwent	O
pc-mri	B-C0024485
and	O
3d-ciss	B-C1275506
for	O
assessment	B-C0220825
of	O
the	O
aqueduct	B-C0228168
.	O
	
axial	B-C0205131
through-plane	B-C1254362
,	O
sagittal	B-C0205129
in-plane	B-C1254362
pc-mri	B-C0024485
and	O
sagittal	B-C0205129
3d-ciss	B-C1275506
were	O
applied	O
to	O
assess	B-C0184514
the	O
cerebral	B-C0007769
aqueduct	I-C0007769
and	O
the	O
spontaneous	B-C0205359
third	B-C0844213
ventriculostomy	I-C0844213
if	O
present	O
.	O
	
aqueductal	B-C0228168
patency	B-C0175566
was	O
graded	B-C0441800
using	O
3d-ciss	B-C1275506
and	O
pc-mri	B-C0024485
.	O
	
quantitative	B-C0200767
analysis	I-C0200767
of	O
flow	O
through	O
the	O
aqueduct	B-C0228168
was	O
done	O
using	O
pc-mri	B-C0024485
.	O
	
the	O
causes	O
of	O
obstruction	B-C0028778
were	O
aqueductal	B-C0228168
obstruction	B-C0028778
in	O
75%	O
n=15	O
,	O
3rd	O
ventricular	B-C0042512
obstruction	I-C0042512
in	O
5%	O
n=1	O
and	O
4th	O
ventricular	B-C0042512
obstruction	I-C0042512
in	O
20	O
%	O
n=4	O
.	O
	
the	O
cause	O
of	O
arrest	B-C0237477
of	O
hydrocephalus	B-C0020255
was	O
spontaneous	B-C0205359
third	B-C0844213
ventriculostomy	I-C0844213
in	O
65%	O
n=13	O
,	O
endoscopic	B-C0844212
third	I-C0844212
ventriculostomy	I-C0844212
in	O
10%	O
n=2	O
,	O
ventriculo-peritoneal	B-C3874496
shunt	I-C3874496
in	O
5%	O
n=1	O
and	O
no	O
cause	O
could	O
be	O
detected	B-C0442726
in	O
20%	O
of	O
patients	B-C0030705
n=4	O
.	O
	
there	O
is	O
a	O
positive	B-C1446409
correlation	B-C1707520
r=	O
0.80	O
and	O
moderate	B-C0205081
agreement	B-C0680240
κ=	O
0.509	O
of	O
grading	B-C0441800
with	O
pc-mri	B-C0024485
and	O
3d-ciss	B-C1275506
sequences	I-C1275506
.	O
	
the	O
mean	B-C0392762
peak	I-C0392762
systolic	I-C0392762
velocity	I-C0392762
of	O
csf	B-C0007806
was	O
1.86	O
2.48	O
cm/sec	O
,	O
the	O
stroke	B-C0038455
volume	I-C0038455
was	O
6.43	O
13.81μl	O
,	O
and	O
the	O
mean	B-C0392762
flow	I-C0392762
was	O
0.21	O
0.32	O
ml/min	O
.	O
	
we	O
concluded	O
that	O
3d-ciss	B-C1275506
and	O
pc-mri	B-C0024485
are	O
non-invasive	B-C0205303
sequences	O
for	O
diagnosis	B-C0011900
of	O
the	O
level	O
and	O
cause	B-C0015127
of	O
arrested	B-C0270718
hydrocephalus	I-C0270718
.	O
	
historical	B-C0681698
environment	B-C0014406
is	O
reflected	O
in	O
modern	B-C0017404
population	I-C0017404
genetics	I-C0017404
and	O
biogeography	B-C2936603
of	O
an	O
island	B-C0022130
endemic	B-C0243130
lizard	B-C0023916
xantusia	B-C0999100
riversiana	I-C0999100
reticulata	I-C0999100
the	O
restricted	B-C1704711
distribution	I-C1704711
and	O
isolation	B-C0205409
of	O
island	B-C0022130
endemics	B-C0243130
often	O
produces	O
unique	O
genetic	B-C0042333
and	O
phenotypic	B-C0031437
diversity	B-C1880371
of	O
conservation	B-C2347858
interest	O
to	O
management	B-C3273539
agencies	B-C0237463
.	O
	
however	O
,	O
these	O
isolated	B-C0205409
species	B-C1705920
,	O
especially	O
those	O
with	O
sensitive	B-C0332324
life	B-C0598779
history	I-C0598779
traits	B-C0599883
,	O
are	O
at	O
high	B-C0332167
risk	I-C0332167
for	O
the	O
adverse	B-C0879626
effects	I-C0879626
of	O
genetic	B-C0917892
drift	I-C0917892
and	O
habitat	B-C0871648
degradation	B-C0243125
by	O
non-native	B-C0003070
wildlife	I-C0003070
.	O
	
here	O
,	O
we	O
study	B-C2603343
the	O
population	B-C1257890
genetic	B-C0042333
diversity	I-C0042333
,	O
structure	B-C0678594
,	O
and	O
stability	B-C0205360
of	O
a	O
classic	O
""""	O
island	B-C0023916
giant	I-C0023916
""""	O
xantusia	B-C0999100
riversiana	I-C0999100
,	O
the	O
island	B-C0023916
night	I-C0023916
lizard	I-C0023916
on	O
san	B-C0022130
clemente	I-C0022130
island	I-C0022130
,	O
california	B-C0006754
following	O
the	O
removal	B-C1883720
of	O
feral	B-C1510458
goats	I-C1510458
.	O
	
using	O
dna	B-C0012854
microsatellites	B-C1519302
,	O
we	O
found	O
that	O
this	O
population	B-C1257890
is	O
reasonably	O
genetically	B-C0314603
robust	B-C2986815
despite	O
historical	B-C0681698
grazing	B-C3178952
,	O
with	O
similar	O
effective	O
population	B-C0032683
sizes	I-C0032683
and	O
genetic	B-C0042333
diversity	I-C0042333
metrics	O
across	O
all	O
sampling	B-C0870078
locations	B-C0017446
irrespective	O
of	O
habitat	B-C0871648
type	O
and	O
degree	B-C0205556
of	I-C0205556
degradation	I-C0205556
.	O
	
however	O
,	O
we	O
also	O
found	O
strong	O
site-specific	B-C0449604
patterns	B-C0449774
of	O
genetic	B-C0042333
variation	I-C0042333
and	O
low	O
genetic	B-C0042333
diversity	I-C0042333
compared	O
to	O
mainland	B-C0035161
congeners	I-C0035161
,	O
warranting	O
continued	O
special	O
management	B-C3273539
as	O
an	O
island	B-C0022130
endemic	B-C0243130
.	O
	
we	O
identify	O
both	O
high	B-C0205250
and	O
low	B-C0205251
elevation	B-C0702240
areas	I-C0702240
that	O
remain	O
valuable	O
repositories	B-C3847505
of	O
genetic	B-C0042333
diversity	I-C0042333
and	O
provide	O
a	O
case	B-C0085973
study	I-C0085973
for	O
other	O
low-dispersal	B-C1254365
coastal	B-C0557760
organisms	B-C0029235
in	O
the	O
face	O
of	O
future	B-C0016884
climate	B-C2718051
change	I-C2718051
.	O
	
cross-species	O
rhesus	B-C0024400
cytomegalovirus	B-C0010823
infection	I-C0010823
of	O
cynomolgus	B-C0024399
macaques	I-C0024399
cytomegaloviruses	B-C0010825
cmv	B-C0010825
are	O
highly	O
species-specific	O
due	O
to	O
millennia	O
of	O
co-evolution	B-C0015219
and	O
adaptation	B-C0392673
to	O
their	O
host	B-C1167395
,	O
with	O
no	O
successful	O
experimental	O
cross-	O
species	B-C1705920
infection	B-C3714514
in	O
primates	B-C0033147
reported	O
to	O
date	O
.	O
	
accordingly	O
,	O
full	O
genome	B-C0017428
phylogenetic	B-C1519068
analysis	I-C1519068
of	O
multiple	O
new	O
cmv	B-C0010825
field	O
isolates	B-C1764827
derived	O
from	O
two	O
closely	O
related	O
nonhuman	B-C0237798
primate	I-C0237798
species	B-C1705920
,	O
indian-origin	B-C0425361
rhesus	B-C0024400
macaques	I-C0024400
rm	B-C0024400
and	O
mauritian	B-C0024944
-origin	O
cynomolgus	B-C0024399
macaques	I-C0024399
mcm	B-C0024399
,	O
revealed	O
distinct	O
and	O
tight	O
lineage	B-C1881379
clustering	O
according	O
to	O
the	O
species	B-C0449420
of	I-C0449420
origin	I-C0449420
,	O
with	O
mcm	B-C0024399
cmv	B-C0010825
isolates	B-C1764827
mirroring	O
the	O
limited	O
genetic	B-C0042333
diversity	I-C0042333
of	O
their	O
primate	B-C0033147
host	B-C1167395
that	O
underwent	O
a	O
population	O
bottleneck	O
400	O
years	O
ago	O
.	O
	
despite	O
the	O
ability	B-C0085732
of	O
rhesus	B-C0024400
cmv	B-C0010825
rhcmv	B-C0010825
laboratory	B-C0007635
strain	I-C0007635
68-1	O
to	O
replicate	B-C1883725
efficiently	O
in	O
mcm	B-C0024399
fibroblasts	B-C0016030
and	O
potently	O
inhibit	B-C2250749
antigen	I-C2250749
presentation	I-C2250749
to	O
mcm	B-C0024399
t	B-C0039194
cells	I-C0039194
in	B-C1533691
vitro	I-C1533691
,	O
rhcmv	B-C0010825
68-1	O
failed	O
to	O
productively	O
infect	B-C3714514
mcm	B-C0024399
in	B-C1515655
vivo	I-C1515655
,	O
even	O
in	O
the	O
absence	O
of	O
host	B-C1167395
cd8+	B-C0242629
t	I-C0242629
and	O
nk	B-C0022688
cells	I-C0022688
.	O
	
in	O
contrast	O
,	O
rhcmv	B-C0010825
clone	B-C1522642
68-1	O
,	O
genetically	B-C0314603
repaired	B-C1705181
to	O
express	B-C0017262
the	O
homologues	B-C1334043
of	O
the	O
hcmv	B-C0010825
anti-apoptosis	B-C1512772
gene	B-C0210337
ul36	I-C0210337
and	O
epithelial	B-C4277517
cell	I-C4277517
tropism	I-C4277517
genes	B-C2605215
ul128	I-C2605215
and	O
ul130	B-C1608605
absent	O
in	O
68-1	O
,	O
efficiently	O
infected	B-C3714514
mcm	B-C1257890
as	O
evidenced	O
by	O
the	O
induction	B-C0017391
of	O
transgene	B-C0282641
-specific	O
t	B-C0039194
cells	I-C0039194
and	O
virus	B-C0162633
shedding	I-C0162633
.	O
	
recombinant	B-C0034861
variants	I-C0034861
of	O
rhcmv	B-C0010825
68-1	O
and	O
68-1	O
revealed	O
that	O
expression	B-C0017262
of	O
either	O
ul36	B-C0210337
or	O
ul128	B-C2605215
together	O
with	O
ul130	B-C1608605
enabled	O
productive	O
mcm	B-C1257890
infection	B-C3714514
,	O
indicating	O
that	O
multiple	O
layers	O
of	O
cross-	O
species	B-C1705920
restriction	B-C0443288
operate	O
even	O
between	O
closely	O
related	O
hosts	B-C1167395
.	O
	
cumulatively	O
,	O
these	O
results	O
implicate	O
cell	B-C4277517
tropism	I-C4277517
and	O
evasion	O
of	O
apoptosis	B-C0162638
as	O
critical	O
determinants	B-C1521761
of	O
cmv	B-C0010825
transmission	B-C1160716
across	O
primate	B-C0033147
species	B-C1705920
barriers	O
,	O
and	O
extend	O
the	O
macaque	B-C0024398
model	B-C3161035
of	O
human	B-C0086418
cmv	B-C0010825
infection	B-C3714514
and	O
immunology	B-C0152036
to	O
mcm	B-C1257890
,	O
a	O
nonhuman	B-C0237798
primate	I-C0237798
species	B-C1705920
with	O
uniquely	O
simplified	O
host	B-C1167395
immunogenetics	B-C0021005
.	O
	
mildly	B-C2945599
raised	B-C0442818
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
2.5	O
m/s	O
in	O
pregnant	B-C0033011
women	I-C0033011
with	O
sickle	B-C0002895
cell	I-C0002895
disease	I-C0002895
is	O
not	O
associated	B-C0332281
with	I-C0332281
poor	B-C0542537
obstetric	B-C0205484
outcome	B-C1274040
-	O
an	O
observational	B-C0010362
cross-sectional	I-C0010362
study	I-C0010362
pulmonary	B-C0020542
hypertension	I-C0020542
is	O
associated	B-C0332281
with	I-C0332281
36%	O
mortality	B-C0024923
in	O
pregnancy	B-C0032961
,	O
and	O
6-10%	O
of	O
patients	B-C0030705
with	O
sickle	B-C0002895
cell	I-C0002895
disease	I-C0002895
have	O
pulmonary	B-C0020542
hypertension	I-C0020542
.	O
	
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
2.5	O
m/s	O
on	O
echocardiography	B-C0013516
is	O
a	O
well	O
validated	O
means	O
of	O
screening	B-C1710032
for	O
pulmonary	B-C0020542
hypertension	I-C0020542
in	O
the	O
non-pregnant	B-C0232973
population	B-C1257890
.	O
	
this	O
is	O
a	O
pilot	B-C0031928
study	I-C0031928
to	O
determine	O
if	O
this	O
is	O
a	O
useful	O
non-invasive	B-C0205303
screening	B-C0871311
test	I-C0871311
for	O
pulmonary	B-C0020542
hypertension	I-C0020542
in	O
pregnancy	B-C0032961
,	O
and	O
whether	O
raised	O
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
2.5	O
m/s	O
was	O
associated	B-C0332281
with	I-C0332281
poor	B-C0542537
outcomes	B-C1274040
.	O
	
this	O
is	O
a	O
cross-sectional	B-C0010362
study	I-C0010362
over	O
a	O
five-year	O
period	O
in	O
a	O
tertiary	B-C0587437
referral	I-C0587437
centre	I-C0587437
with	O
a	O
specialised	O
multidisciplinary	B-C0242933
clinic	I-C0242933
for	O
pregnant	B-C0033011
women	I-C0033011
with	O
sickle	B-C0002895
cell	I-C0002895
disease	I-C0002895
.	O
	
women	B-C0043210
with	O
sickle	B-C0002895
cell	I-C0002895
disease	I-C0002895
,	O
no	O
prior	O
pulmonary	B-C0020542
hypertension	I-C0020542
and	O
singleton	B-C1313913
pregnancies	B-C0032961
who	O
had	O
echocardiography	B-C0013516
with	O
a	O
measurable	O
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
in	O
pregnancy	B-C0032961
were	O
included	O
.	O
	
there	O
were	O
34	O
pregnancies	B-C0032961
,	O
of	O
which	O
eight	O
had	O
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
2.5	O
m/s	O
.	O
	
there	O
were	O
no	B-C1273937
significant	I-C1273937
differences	O
in	O
their	O
characteristics	B-C1521970
,	O
sickle	B-C0221283
cell	I-C0221283
-related	O
complications	B-C0009566
or	O
medical	B-C0205476
co-morbidities	B-C0026538
.	O
	
the	O
women	B-C0043210
with	O
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
2.5	O
m/s	O
had	O
similar	O
obstetric	B-C0205484
and	O
perinatal	B-C0178795
outcomes	B-C1274040
as	O
those	O
with	O
a	O
tricuspid	B-C2059632
regurgitant	I-C2059632
velocity	I-C2059632
a	O
randomized	B-C0206034
trial	I-C0206034
of	O
tlr-2	B-C0754728
agonist	B-C2987634
cadi-05	B-C2703083
targeting	B-C1521840
desmocollin-3	B-C1453561
for	O
advanced	B-C0205179
non-small-cell	B-C0007131
lung	I-C0007131
cancer	I-C0007131
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
to	O
evaluate	B-C0220825
synergy	B-C0013215
between	O
taxane	B-C0215136
plus	O
platinum	B-C0032207
chemotherapy	B-C3665472
and	O
cadi-05	B-C2703083
,	O
a	O
toll	B-C0754728
like	I-C0754728
receptor-2	I-C0754728
agonist	B-C2987634
targeting	B-C1521840
desmocollin-3	B-C1453561
as	O
a	O
first-line	B-C1708063
therapy	I-C1708063
in	O
advanced	B-C0205179
non-small-cell	B-C0007131
lung	I-C0007131
cancer	I-C0007131
nsclc	B-C0007131
.	O
	
patients	B-C0030705
with	O
advanced	B-C0205179
nsclc	B-C0007131
stage	O
iiib	O
or	O
iv	O
were	O
randomized	B-C3815594
to	O
cisplatin-paclitaxel	B-C0280455
chemotherapy	B-C3665472
group	B-C0441833
,	O
n	O
=	O
112	O
or	O
cisplatin-paclitaxel	B-C0280455
plus	O
cadi-05	B-C2703083
chemoimmunotherapy	B-C2986423
group	B-C0441833
,	O
n	O
=	O
109	O
.	O
	
cadi-05	B-C2703083
was	O
administered	B-C1621583
a	O
week	B-C0439230
before	O
chemotherapy	B-C3665472
and	O
on	O
days	B-C0439228
8	O
and	O
15	O
of	O
each	O
cycle	B-C1302181
and	O
every	O
month	B-C0439231
subsequently	O
for	O
12	O
months	B-C0439231
or	O
disease	B-C0242656
progression	I-C0242656
.	O
	
overall	B-C4086681
survival	I-C4086681
was	O
compared	O
using	O
a	O
log-rank	B-C0392366
test	I-C0392366
.	O
	
computed	B-C0040405
tomography	I-C0040405
was	O
carried	O
out	O
at	O
baseline	B-C1442488
,	O
end	O
of	O
two	O
cycles	B-C1302181
and	O
four	O
cycles	B-C1302181
.	O
	
response	B-C0237629
rate	I-C0237629
was	O
evaluated	B-C0220825
using	O
response	B-C1709926
evaluation	I-C1709926
criteria	I-C1709926
in	I-C1709926
solid	I-C1709926
tumors	I-C1709926
criteria	B-C0243161
by	O
an	O
independent	B-C0260194
radiologist	I-C0260194
.	O
	
as	O
per	O
intention-to-treat	B-C2718028
analysis	I-C2718028
,	O
no	O
survival	B-C0038952
benefit	B-C0814225
was	O
observed	O
between	O
two	O
groups	B-C0441833
208	O
versus	O
196	O
days	B-C0439228
hazard	B-C2985465
ratio	I-C2985465
,	O
0.86	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	O
0.63	O
p	O
=	O
0.3804	O
.	O
	
in	O
a	O
subgroup	B-C0936012
analysis	I-C0936012
,	O
improvement	B-C2986411
in	O
median	B-C2986586
survival	I-C2986586
by	O
127	O
days	B-C0439228
was	O
observed	O
in	O
squamous	B-C0027671
nscc	I-C0027671
with	O
chemoimmunotherapy	B-C2986423
hazard	B-C2985465
ratio	I-C2985465
,	O
0.55	O
95%	O
ci	O
0.32	O
p	O
=	O
0.046	O
.	O
	
in	O
patients	B-C0030705
receiving	O
planned	O
four	O
cycles	B-C1302181
of	O
chemotherapy	B-C3665472
,	O
there	O
was	O
improved	B-C2986411
median	B-C0444504
overall	B-C4086681
survival	I-C4086681
by	O
66	O
days	B-C0439228
299	O
versus	O
233	O
days	B-C0439228
hazard	B-C2985465
ratio	I-C2985465
,	O
0.64	O
95%	O
ci	O
0.41	O
to	O
0.98	O
p	O
=	O
0.04	O
in	O
the	O
chemoimmunotherapy	B-C2986423
group	B-C0441833
compared	O
with	O
the	O
chemotherapy	B-C3665472
group	B-C0441833
.	O
	
this	O
was	O
associated	B-C0332281
with	I-C0332281
the	O
improved	B-C2986411
survival	B-C0038952
by	O
17.48	O
at	O
the	O
end	O
of	O
1	O
year	B-C0439234
,	O
in	O
the	O
chemoimmunotherapy	B-C2986423
group	B-C0441833
.	O
	
systemic	B-C0877248
adverse	I-C0877248
events	I-C0877248
were	O
identical	B-C0205280
in	O
both	O
the	O
group	B-C0441833
s	O
.	O
	
there	O
was	O
no	O
survival	B-C0038952
benefit	B-C0814225
with	O
the	O
addition	B-C1883712
of	O
cadi-05	B-C2703083
to	O
the	O
combination	B-C0205195
of	O
cisplatin-paclitaxel	B-C0280455
in	O
patients	B-C0030705
with	O
advanced	B-C0205179
nsclc	B-C0007131
however	O
,	O
the	O
squamous	B-C0221910
cell	I-C0221910
subset	I-C0221910
did	O
demonstrate	O
a	O
survival	B-C0038952
sex	B-C0376558
life	I-C0376558
and	O
impact	B-C4049986
of	O
operative	B-C0038895
intervention	B-C0184661
on	O
sex	B-C0030193
life-related	I-C0030193
pain	I-C0030193
in	O
degenerative	B-C0011164
spinal	B-C0037949
conditions	O
an	O
analysis	B-C0936012
of	O
the	O
sport	B-C2603343
study	I-C2603343
this	O
study	B-C2603343
is	O
a	O
therapeutic	B-C2985505
retrospective	I-C2985505
cohort	I-C2985505
study	I-C2985505
objectives	O
this	O
study	B-C2603343
aims	O
to	O
determine	O
whether	O
sexual	B-C0278092
function	I-C0278092
is	O
relevant	O
for	O
patients	B-C0030705
with	O
spinal	B-C0037944
stenosis	I-C0037944
sps	B-C0037944
and	O
degenerative	B-C0264184
spondylolisthesis	I-C0264184
ds	B-C0264184
and	O
to	O
determine	O
the	O
impact	B-C4049986
of	O
operative	B-C0038895
inter	O
vqavention	O
on	O
sexual	B-C0278092
function	I-C0278092
for	O
these	O
patients	B-C0030705
.	O
	
the	O
benefits	O
of	O
nonoperative	B-C0039798
versus	O
operative	B-C0038895
treatment	B-C0039798
for	O
patients	B-C0030705
with	O
sps	B-C0037944
and	O
ds	B-C0264184
with	O
regards	O
to	O
sexual	B-C0278092
function	I-C0278092
are	O
unknown	O
.	O
	
demographic	B-C0011298
,	O
treatment	B-C0039798
,	O
and	O
follow-up	B-C1522577
data	B-C1511726
,	O
including	O
the	O
oswestry	O
disability	O
index	O
odi	O
,	O
were	O
obtained	O
on	O
patients	B-C0030705
enrolled	O
in	O
the	O
sport	B-C2603343
study	I-C2603343
.	O
	
based	O
on	O
the	O
response	O
to	O
question	O
9	O
in	O
the	O
odi	O
,	O
patients	B-C0030705
were	O
classified	O
into	O
a	O
sexual	B-C0441833
life	I-C0441833
relevant	I-C0441833
slr	B-C0441833
or	O
sexual	B-C0441833
life	I-C0441833
not	I-C0441833
relevant	I-C0441833
nr	I-C0441833
group	I-C0441833
.	O
	
univariate	B-C0683962
and	O
multivariate	B-C0026777
analysis	I-C0026777
of	O
patient	B-C0030705
characteristics	B-C1521970
comparing	O
the	O
nr	B-C0441833
and	O
slr	B-C0441833
group	I-C0441833
were	O
performed	O
.	O
	
operative	B-C0038895
treatment	B-C0039798
groups	B-C0441833
were	O
compared	O
to	O
the	O
nonoperative	B-C0039798
group	B-C0441833
with	O
regards	O
to	O
response	O
to	O
odi	O
question	O
9	O
to	O
determine	O
the	O
impact	B-C4049986
of	O
surgery	B-C0543467
on	O
sexual	B-C0278092
function	I-C0278092
.	O
	
a	O
total	O
of	O
1235	O
patients	B-C0030705
were	O
included	O
to	O
determine	O
relevance	O
of	O
sex	B-C0441833
life	I-C0441833
.	O
	
three	O
hundred	O
sixty-six	O
patients	B-C0030705
29%	O
were	O
included	O
in	O
the	O
nr	B-C0441833
group	I-C0441833
.	O
	
eight	O
hundred	O
sixty-nine	O
patients	B-C0030705
71%	O
were	O
included	O
in	O
the	O
slr	B-C0441833
group	I-C0441833
.	O
	
patients	B-C0030705
that	O
were	O
older	B-C0001792
,	O
female	B-C0086287
,	O
unmarried	B-C0037179
,	O
had	O
three	O
or	O
more	O
stenotic	B-C0441889
levels	I-C0441889
,	O
and	O
had	O
central	B-C0476189
stenosis	I-C0476189
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
nr	B-C0441833
group	I-C0441833
.	O
	
eight	O
hundred	O
twenty-five	O
patients	B-C0030705
were	O
included	O
in	O
the	O
analysis	B-C0936012
comparing	O
operative	B-C0038895
versus	O
nonoperative	B-C0039798
treatment	B-C0039798
.	O
	
at	O
all	O
follow-up	B-C1522577
time	O
points	O
,	O
the	O
operative	B-C0038895
groups	B-C0441833
had	O
a	O
lower	O
percentage	B-C0439165
of	O
patients	B-C0030705
reporting	O
pain	B-C0030193
with	O
their	O
sex	B-C0441833
life	I-C0441833
compared	O
to	O
the	O
nonoperative	B-C0039798
group	B-C0441833
p	O
<	O
0.05	O
at	O
all	O
time	O
points	O
except	O
between	O
more	O
than	O
one	O
level	O
fusion	O
and	O
nonoperative	B-C0039798
at	O
4	O
years	B-C0439234
'	O
follow-up	B-C1522577
.	O
	
sex	B-C0376558
life	I-C0376558
is	O
a	O
relevant	O
consideration	O
for	O
the	O
majority	O
of	O
patients	B-C0030705
with	O
ds	B-C0264184
and	O
sps	B-C0037944
operative	B-C0038895
treatment	B-C0039798
leads	O
to	O
improved	B-C0184511
sex	B-C0030193
life-related	I-C0030193
pain	I-C0030193
.	O
	
functional	B-C0936012
analyses	I-C0936012
of	O
ocrhs1	B-C0033684
and	O
ocuer1	B-C0033684
involved	O
in	O
udp-l-rhamnose	B-C0609108
biosynthesis	B-C0005572
in	O
ornithogalum	B-C0331605
caudatum	I-C0331605
udp-l-rhamnose	B-C0609108
udp-rha	B-C0609108
is	O
an	O
important	O
sugar	B-C1254351
donor	I-C1254351
for	O
the	O
synthesis	B-C0005572
of	O
rhamnose	B-C0035417
-containing	O
compounds	B-C1706082
in	O
plants	B-C0331605
.	O
	
however	O
,	O
only	O
a	O
few	O
enzymes	B-C0014442
and	O
their	O
encoding	B-C2700640
genes	B-C0017337
involved	O
in	O
udp-rha	B-C0609108
biosynthesis	B-C0005572
are	O
available	O
in	O
plants	B-C0331605
.	O
	
here	O
,	O
two	O
genes	B-C0017337
encoding	B-C2700640
rhamnose	B-C0014442
synthase	I-C0014442
rhs	B-C0014442
and	O
bi-functional	B-C0443560
udp-4-keto-6-deoxy-d-glucose	B-C0014442
udp-4k6dg	B-C0014442
3	B-C0014442
,	O
5-epimerase/udp-4-keto-l-rhamnose	I-C0014442
udp-4kr	B-C0014442
4-keto-reductase	B-C0014442
uer	B-C0014442
were	O
isolated	O
from	O
ornithogalum	B-C0331605
caudatum	I-C0331605
based	O
on	O
the	O
rna	B-C0035668
-	O
seq	B-C0026382
data	I-C0026382
.	O
	
the	O
ocrhs1	B-C0017337
gene	I-C0017337
has	O
an	O
orf	B-C0079941
open	B-C0079941
reading	I-C0079941
frame	I-C0079941
of	O
2019	O
bp	O
encoding	B-C2700640
a	O
tri-functional	B-C1750262
rhs	I-C1750262
enzyme	I-C1750262
.	O
	
in	B-C1533691
vitro	I-C1533691
enzymatic	B-C2717977
assays	I-C2717977
revealed	B-C0443289
ocrhs1	B-C0033684
can	O
really	O
convert	O
udp-d-glucose	B-C0077887
udp-glc	B-C0077887
into	O
udp-rha	B-C0609108
via	O
three	O
consecutive	B-C1707491
reactions	B-C0443286
.	O
	
biochemical	B-C0205474
evidences	B-C0332120
indicated	O
that	O
the	O
recombinant	B-C0034861
ocrhs1	I-C0034861
was	O
active	O
in	O
the	O
ph	O
range	O
of	O
5-11	O
and	O
over	O
the	O
temperature	B-C0457171
range	I-C0457171
of	O
0-60	O
c	O
.	O
	
the	O
km	B-C1706312
value	B-C1522609
of	O
ocrhs1	B-C0033684
for	O
udp-glc	B-C0077887
was	O
determined	O
to	O
be	O
1.52	O
10	O
m	O
.	O
	
ocrhs1	B-C0033684
is	O
a	O
multi-domain	B-C2326433
protein	I-C2326433
with	O
two	O
sets	O
of	O
cofactor-binding	B-C1323251
motifs	I-C1323251
.	O
	
the	O
cofactors	B-C1323251
dependent	O
properties	O
of	O
ocrhs1	B-C0033684
were	O
thus	O
characterized	O
in	O
this	O
research	B-C0035168
.	O
	
moreover	O
,	O
the	O
n-terminal	B-C0033684
portion	I-C0033684
of	I-C0033684
ocrhs1	I-C0033684
ocrhs1-n	B-C0033684
was	O
observed	O
to	O
metabolize	B-C0205245
udp-glc	B-C0077887
to	O
form	O
intermediate	O
udp-4k6dg	B-C1254348
.	O
	
ocuer1	B-C0017337
contains	O
an	O
orf	B-C0079941
of	O
906	O
bp	O
encoding	B-C2700640
a	O
polypeptide	B-C1305923
of	O
301	O
aa	B-C0002520
.	O
	
ocuer1	B-C0033684
shared	O
high	O
similarity	O
with	O
the	O
carboxy-terminal	B-C0033684
domain	I-C0033684
of	I-C0033684
ocrhs1	I-C0033684
ocrhs1-c	B-C0033684
,	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
udp-4k6dg	B-C1254348
into	O
udp-rha	B-C0609108
.	O
	
it	O
was	O
thus	O
reasonably	O
inferred	O
that	O
udp-glc	B-C0077887
could	O
be	O
bio-transformed	B-C0220798
into	O
udp-rha	B-C0609108
under	O
the	O
collaborating	O
action	O
of	O
ocrhs1-n	B-C0033684
and	O
ocuer1	B-C0033684
.	O
	
the	O
subsequently	O
biochemical	B-C0005507
assay	I-C0005507
verified	O
this	O
notion	O
.	O
	
importantly	O
,	O
expression	B-C3463810
profiles	I-C3463810
of	O
ocrhs1	B-C0033684
and	O
ocuer1	B-C0033684
revealed	B-C0443289
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	B-C0005572
of	O
rhamnose	B-C0035417
-containing	O
polysaccharides	B-C0032594
in	O
o	B-C0331605
.	O
	
caudatum	I-C0331605
.	O
	
differing	O
rates	O
of	O
antibody	B-C0003241
acquisition	B-C1706701
to	O
merozoite	B-C0444659
antigens	B-C0003320
in	O
malaria	B-C0024530
implications	O
for	O
immunity	B-C0020964
and	O
surveillance	B-C0733511
antibodies	B-C0003241
play	O
a	O
key	O
role	O
in	O
acquired	B-C0678209
human	I-C0678209
immunity	I-C0678209
to	O
plasmodium	B-C0024535
falciparum	I-C0024535
pf	I-C0024535
malaria	I-C0024535
and	O
target	O
merozoites	B-C0444659
to	O
reduce	O
or	O
prevent	O
blood	B-C0005767
-stage	O
replication	B-C0007590
and	O
the	O
development	O
of	O
disease	B-C0024530
.	O
	
merozoites	B-C0444659
present	O
a	O
complex	O
array	O
of	O
antigens	B-C0003320
to	O
the	O
immune	B-C0020962
system	I-C0020962
,	O
and	O
currently	O
,	O
there	O
is	O
only	O
a	O
partial	O
understanding	O
of	O
the	O
targets	O
of	O
protective	O
antibodies	B-C0003241
and	O
how	O
responses	B-C1314973
to	O
different	O
antigens	B-C0003320
are	O
acquired	B-C0439661
and	O
boosted	B-C1511253
.	O
	
we	O
hypothesized	O
that	O
there	O
would	O
be	O
differences	O
in	O
the	O
rate	O
of	O
acquisition	B-C1706701
of	O
antibodies	B-C0003241
to	O
different	O
antigens	B-C0003320
and	O
how	O
well	O
they	O
are	O
boosted	O
by	O
infection	B-C3714514
,	O
which	O
impacts	O
the	O
acquisition	B-C1706701
of	O
immunity	B-C0020964
.	O
	
we	O
examined	O
responses	B-C1314973
to	O
a	O
range	O
of	O
merozoite	B-C0444659
antigens	B-C0003320
in	O
2	O
different	O
cohorts	O
of	O
children	B-C0008059
and	O
adults	B-C0001675
with	O
different	O
age	B-C0001779
structures	O
and	O
levels	O
of	O
malaria	B-C0024530
exposure	O
.	O
	
overall	O
,	O
antibodies	B-C0003241
were	O
associated	O
with	O
age	B-C0001779
,	O
exposure	O
,	O
and	O
active	O
infection	B-C3714514
,	O
and	O
the	O
repertoire	O
of	O
responses	B-C1314973
increased	O
with	O
age	B-C0001779
and	O
active	O
infection	B-C3714514
.	O
	
however	O
,	O
rates	O
of	O
antibody	B-C0003241
acquisition	B-C1706701
varied	O
between	O
antigens	B-C0003320
and	O
different	O
regions	O
within	O
an	O
antigen	B-C0003320
following	O
exposure	O
to	O
malaria	B-C0024530
,	O
supporting	O
our	O
hypothesis	B-C1512571
.	O
	
antigen	B-C0003320
-specific	O
responses	B-C1314973
could	O
be	O
broadly	O
classified	O
into	O
early	O
response	B-C1314973
types	O
in	O
which	O
antibodies	B-C0003241
were	O
acquired	B-C0439661
early	O
in	O
childhood	B-C0231335
exposure	O
and	O
late	B-C0205087
response	I-C0205087
types	O
that	O
appear	O
to	O
require	O
substantially	O
more	O
exposure	O
for	O
the	O
development	O
of	O
substantial	O
levels	O
.	O
	
we	O
identified	O
antigen	O
-specific	O
responses	O
that	O
were	O
effectively	O
boosted	O
after	O
recent	O
infection	O
,	O
whereas	O
other	O
responses	O
were	O
not	O
.	O
	
these	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
acquisition	O
of	O
human	O
immunity	O
to	O
malaria	O
and	O
are	O
relevant	O
to	O
the	O
development	O
of	O
malaria	O
vaccines	O
targeting	O
merozoite	O
antigens	O
and	O
the	O
selection	O
of	O
antigens	O
for	O
use	O
in	O
malaria	O
surveillance	B-C0733511
variety	B-C2346866
of	O
dna	B-C0598312
replication	I-C0598312
activity	I-C0598312
among	O
cyanobacteria	B-C1047211
correlates	B-C0871083
with	O
distinct	O
respiration	B-C0035203
activity	I-C0035203
in	O
the	O
dark	B-C0010986
cyanobacteria	B-C1047211
exhibit	O
light	B-C0023693
-dependent	O
cell	B-C0007595
growth	I-C0007595
since	O
most	O
of	O
their	O
cellular	B-C0007634
energy	B-C1442080
is	O
obtained	O
by	O
photosynthesis	B-C0031764
.	O
	
in	O
synechococcus	B-C1003877
elongatus	I-C1003877
pcc	I-C1003877
7942	I-C1003877
,	O
one	O
of	O
the	O
model	O
cyanobacteria	B-C1047211
,	O
dna	B-C0598312
replication	I-C0598312
depends	O
on	O
photosynthetic	B-C0013846
electron	I-C0013846
transport	I-C0013846
.	O
	
however	O
,	O
the	O
critical	B-C1710082
signal	I-C1710082
for	O
the	O
regulatory	B-C1327622
mechanism	B-C0441712
of	O
dna	B-C0598312
replication	I-C0598312
has	O
not	O
been	O
identified	O
.	O
	
in	O
addition	O
,	O
conservation	B-C2347858
of	O
this	O
regulatory	B-C0441712
mechanism	I-C0441712
has	O
not	O
been	O
investigated	B-C1292732
among	O
cyanobacteria	B-C1047211
.	O
	
to	O
understand	O
this	O
regulatory	B-C1327622
signal	B-C1710082
and	O
its	O
dependence	O
on	O
light	B-C0023693
,	O
we	O
examined	O
the	O
regulation	B-C1327622
of	O
dna	B-C0598312
replication	I-C0598312
under	O
both	O
light	B-C0023693
and	O
dark	B-C0010986
conditions	O
among	O
three	O
model	B-C0026336
cyanobacteria	B-C1047211
,	O
s	B-C1003877
.	O
	
elongatus	I-C1003877
pcc	I-C1003877
7942	I-C1003877
,	O
synechocystis	B-C0995541
sp	I-C0995541
.	O
	
pcc	I-C0995541
6803	I-C0995541
and	O
anabaena	B-C1047885
sp	I-C1047885
.	O
	
pcc	I-C1047885
7120	I-C1047885
.	O
	
interestingly	O
,	O
dna	B-C0598312
replication	I-C0598312
activity	I-C0598312
in	O
synechocystis	B-C0995541
and	O
anabaena	B-C1047885
was	O
retained	B-C0333118
when	O
cells	B-C0007634
were	O
transferred	B-C4049693
to	I-C4049693
the	O
dark	B-C0010986
,	O
although	O
it	O
was	O
drastically	O
decreased	B-C0205216
in	O
s	B-C1003877
.	O
	
elongatus	I-C1003877
.	O
	
glycogen	B-C0599784
metabolism	I-C0599784
and	O
respiration	B-C0035203
were	O
higher	O
in	O
synechocystis	B-C0995541
and	O
anabaena	B-C1047885
than	O
in	O
s	B-C1003877
.	O
	
elongatus	I-C1003877
in	O
the	O
dark	B-C0010986
.	O
	
moreover	O
,	O
dna	B-C0598312
replication	I-C0598312
activity	I-C0598312
in	O
synechocystis	B-C0995541
and	O
anabaena	B-C1047885
was	O
reduced	B-C0205216
to	O
the	O
same	O
level	O
as	O
that	O
in	O
s	B-C1003877
.	O
	
elongatus	I-C1003877
by	O
inhibition	B-C3463820
of	O
respiratory	B-C0521346
electron	B-C0013846
transport	I-C0013846
after	O
transfer	O
to	O
the	O
dark	B-C0010986
.	O
	
these	O
results	O
demonstrate	O
that	O
there	O
is	O
disparity	B-C1290905
in	O
dna	B-C0598312
replication	I-C0598312
occurring	O
in	O
the	O
dark	B-C0010986
among	O
cyanobacteria	B-C1047211
,	O
which	O
is	O
caused	O
by	O
the	O
difference	B-C1705242
in	O
activity	B-C0205177
of	O
respiratory	B-C0521346
electron	B-C0013846
transport	I-C0013846
.	O
	
radiosensitization	B-C0279024
of	O
non-small-cell	B-C0007131
lung	I-C0007131
cancer	I-C0007131
cells	B-C0334227
and	O
xenografts	B-C0520484
by	O
the	O
interactive	B-C1704675
effects	I-C1704675
of	O
pemetrexed	B-C0210657
and	O
methoxyamine	B-C0066156
the	O
anti-folate	B-C1254351
pemetrexed	B-C0210657
is	O
a	O
radiosensitizer	B-C0034541
.	O
	
in	O
pre-clinical	B-C1514292
models	I-C1514292
,	O
pemetrexed	B-C0210657
is	O
more	O
effective	B-C1704419
along	O
with	O
the	O
base-excision-repair	B-C1158530
inhibitor	B-C1999216
methoxyamine	B-C0066156
.	O
	
we	O
tested	B-C0039593
whether	O
methoxyamine	B-C0066156
enhances	B-C2349975
pemetrexed	B-C0210657
-mediated	O
radiosensitization	B-C0279024
of	O
lung	B-C0152013
adenocarcinoma	I-C0152013
cells	O
and	O
xenografts	B-C0520484
.	O
	
a549	B-C4277577
and	O
h1299	B-C0334227
cells	I-C0334227
were	O
evaluated	O
for	O
cell	B-C0007586
cycle	I-C0007586
distribution	B-C1704711
by	O
flow	B-C0016263
cytometry	I-C0016263
,	O
radiosensitization	B-C0279024
by	O
clonogenic	B-C0041372
assay	I-C0041372
,	O
and	O
dna	B-C0012899
repair	I-C0012899
by	O
neutral	B-C0751980
comet	I-C0751980
assay	I-C0751980
and	O
repair	B-C1159338
protein	I-C1159338
activation	B-C0599177
.	O
	
h460	B-C0334227
cells	I-C0334227
were	O
included	O
in	O
some	O
studies	O
.	O
	
xenografts	B-C0520484
in	O
nude	B-C0025932
mice	I-C0025932
received	B-C0332154
drug	I-C0332154
s	O
and/or	O
radiation	B-C0851346
,	O
and	O
tumor	B-C0598934
growth	I-C0598934
was	O
monitored	O
by	O
caliper	B-C0175720
and	O
in	B-C0681829
vivo	I-C0681829
toxicity	B-C0600688
by	O
animal	B-C0005910
weight	I-C0005910
.	O
	
exposure	B-C0332157
to	I-C0332157
pemetrexed	B-C0210657
/	O
methoxyamine	B-C0066156
for	O
24	O
h1299	B-C0334227
,	O
h460	B-C0334227
or	O
48	O
a549	B-C4277577
before	O
irradiation	B-C1282930
resulted	O
in	O
accumulation	B-C4055506
of	O
cells	B-C0334227
near	O
the	O
radiosensitive	B-C1254362
g1/s	I-C1254362
border	I-C1254362
dose	B-C0178602
-	O
enhancement	B-C2349975
factors	B-C1521761
of	O
1.62	O
,	O
1.97	O
,	O
and	O
1.67	O
,	O
respectively	O
reduction	O
of	O
mean	O
inactivation	B-C0544461
dose	B-C0178602
by	O
32%	O
,	O
30%	O
,	O
and	O
46%	O
,	O
respectively	O
and	O
significant	O
reductions	O
of	O
sf2	O
and	O
sf4	O
p<0	O
.	O
	
radiosensitization	B-C0279024
was	O
associated	O
with	O
rapid	O
dna	B-C3155842
double-strand-break	I-C3155842
rejoining	I-C3155842
and	O
increased	O
levels	O
of	O
dna-pkcs	B-C0212694
.	O
	
both	O
tumor-growth	B-C0598934
rate	B-C0449249
and	O
tumor-growth	B-C0598934
delay	B-C0205421
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	B-C0066156
to	O
pemetrexed	B-C0210657
pre-irradiation	B-C1282930
p<0	O
no	O
mice	B-C0025932
lost	O
weight	O
during	O
treatment	B-C1522326
.	O
	
addition	O
of	O
methoxyamine	B-C0066156
to	O
pemetrexed	B-C0210657
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	B-C0030705
with	O
locally	O
advanced	O
non-squamous	B-C2585890
non-small-cell	I-C2585890
lung	I-C2585890
cancer	I-C2585890
.	O
	
using	O
language	B-C0023008
for	O
social	B-C0037420
interaction	I-C0037420
communication	B-C0009452
mechanisms	O
promote	O
recovery	O
from	O
chronic	B-C0205191
non-fluent	B-C0349390
aphasia	I-C0349390
clinical	B-C0008972
research	I-C0008972
highlights	O
the	O
importance	O
of	O
massed	B-C0870850
practice	I-C0870850
in	O
the	O
rehabilitation	B-C0034991
of	O
chronic	B-C0205191
post-stroke	B-C1254367
aphasia	B-C0003537
.	O
	
however	O
,	O
while	O
necessary	O
,	O
massed	B-C0870850
practice	I-C0870850
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	B-C1280477
in	O
speech-language	B-C0037831
therapy	I-C0037831
.	O
	
motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	B-C0027910
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	B-C0023008
as	O
a	O
tool	O
for	O
communication	B-C0009452
and	O
social	B-C0037420
interaction	I-C0037420
leads	O
to	O
synergistic	B-C1280500
effects	I-C1280500
in	O
left	B-C3495412
perisylvian	I-C3495412
eloquent	I-C3495412
areas	I-C3495412
.	O
	
here	O
,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	B-C0009452
language	B-C0233732
function	I-C0233732
on	O
the	O
outcome	B-C1274040
of	O
intensive	B-C0087111
aphasia	I-C0087111
therapy	I-C0087111
.	O
	
eighteen	O
individuals	B-C0237401
with	O
left-hemisphere	B-C2026233
lesions	I-C2026233
and	O
chronic	B-C0205191
non-fluent	B-C0349390
aphasia	I-C0349390
each	O
received	O
two	O
types	O
of	O
training	B-C0220931
in	O
counterbalanced	B-C1705176
order	I-C1705176
i	O
intensive	B-C0023017
language-action	I-C0023017
therapy	I-C0023017
ilat	B-C0023017
,	O
an	O
extended	O
form	O
of	O
constraint-induced	B-C0087111
aphasia	I-C0087111
therapy	I-C0087111
embedding	O
verbal	B-C2202690
utterances	I-C2202690
in	O
the	O
context	O
of	O
communication	B-C0009452
and	O
social	B-C0037420
interaction	I-C0037420
,	O
and	O
ii	O
naming	B-C0037585
therapy	I-C0037585
focusing	O
on	O
speech	B-C0037827
production	I-C0037827
per	I-C0037827
se	I-C0037827
.	O
	
both	O
types	O
of	O
training	B-C0220931
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
3.5	O
h	O
per	O
session	O
and	O
duration	B-C0449238
six	O
consecutive	O
working	O
days	B-C0439228
,	O
with	O
therapy	B-C0087111
materials	B-C0520510
and	O
number	B-C0243095
of	I-C0243095
utterances	I-C0243095
matched	O
between	O
treatment	B-C0087111
groups	I-C0087111
.	O
	
a	O
standardized	O
aphasia	B-C0003537
test	B-C0204458
battery	I-C0204458
revealed	O
significantly	O
improved	O
language	B-C0023008
performance	B-C0597198
with	O
ilat	B-C0023017
,	O
independent	O
of	O
when	O
this	O
method	B-C0025663
was	O
administered	O
.	O
	
in	O
contrast	O
,	O
naming	B-C0037585
therapy	I-C0037585
tended	O
to	O
benefit	O
language	B-C0023008
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	B-C0087111
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	B-C0220931
.	O
	
the	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed	B-C0870850
practice	I-C0870850
alone	O
promotes	O
recovery	O
from	O
chronic	B-C0205191
post-stroke	B-C1254367
aphasia	B-C0003537
.	O
	
instead	O
,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	B-C0023008
for	O
communication	B-C0009452
and	O
social	B-C0037420
interaction	I-C0037420
increases	O
the	O
efficacy	O
of	O
intensive	B-C0087111
aphasia	I-C0087111
therapy	I-C0087111
.	O
	
mir-27b	B-C1537730
inhibits	B-C3463820
gastric	B-C0699791
cancer	I-C0699791
metastasis	B-C0027627
by	O
targeting	B-C1521840
nr2f2	B-C1506576
increasing	B-C0442808
attention	B-C0004268
is	O
focused	O
on	O
the	O
down-regulation	B-C0013081
of	O
mirnas	B-C1101610
in	O
cancer	B-C0007097
process	I-C0007097
.	O
	
nuclear	B-C1506576
receptor	I-C1506576
subfamily	I-C1506576
2	I-C1506576
nr2f2	B-C1506576
,	O
also	O
known	O
as	O
coup-tfii	B-C1506576
is	O
involved	B-C1314939
in	O
the	O
development	B-C1527148
of	O
many	O
types	B-C0332307
of	O
cancers	B-C0007097
,	O
but	O
its	O
role	B-C1705810
in	O
gastric	B-C0699791
cancer	I-C0699791
remains	O
elusive	O
.	O
	
in	O
this	O
experiment	B-C0681814
,	O
oncomine	B-C0242356
and	O
kaplan-meier	B-C0242356
database	I-C0242356
revealed	B-C0443289
that	O
nr2f2	B-C1506576
was	O
up-regulated	B-C0041904
in	O
gastric	B-C0699791
cancer	I-C0699791
and	O
that	O
the	O
high	B-C0205250
nr2f2	B-C1506576
expression	B-C1171362
contributed	B-C1880177
to	O
poor	B-C0542537
survival	B-C0038954
.	O
	
microrna-27b	B-C1537730
was	O
targeted	B-C1521840
and	O
down-regulated	B-C0013081
by	O
nr2f2	B-C1506576
in	O
human	B-C0086418
gastric	B-C0699791
cancer	I-C0699791
tissues	B-C0040300
and	O
cells	B-C1518174
.	O
	
the	O
ectopic	B-C1512167
expression	I-C1512167
of	O
mir-27b	B-C1537730
inhibited	B-C0311403
gastric	B-C0699791
cancer	I-C0699791
cell	B-C0596290
proliferation	I-C0596290
and	O
tumor	B-C0598934
growth	I-C0598934
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
assays	B-C0005507
suggested	B-C1705535
that	O
the	O
overexpression	B-C0017262
of	O
mir-27b	B-C1537730
could	O
promote	B-C0033414
mgc-803	B-C0007634
cells	I-C0007634
'	O
migration	B-C1622501
and	O
invasion	B-C2699153
and	O
retard	B-C0521111
their	O
metastasis	B-C0027627
to	O
the	O
liver	B-C0023884
.	O
	
in	O
addition	O
,	O
down-regulation	B-C0013081
of	O
mir-27b	B-C1537730
enhanced	O
ges-1	B-C0007634
cells	I-C0007634
'	O
proliferation	B-C0596290
and	O
metastasis	B-C0027627
in	B-C1533691
vitro	I-C1533691
.	O
	
these	O
findings	B-C0243095
reveal	B-C0443289
that	O
mir-27b	B-C1537730
is	O
a	O
tumor	B-C0079427
suppressor	I-C0079427
in	O
gastric	B-C0699791
cancer	I-C0699791
and	O
a	O
biomarker	B-C0005516
for	O
improving	B-C1272745
patients	B-C0030705
'	O
promoting	B-C0033414
healthy	B-C3898900
growth	B-C0018270
or	O
feeding	B-C2987508
obesity	B-C0028754
the	O
need	B-C0027552
for	O
evidence	B-C3887511
-based	O
oversight	O
of	O
infant	B-C0021270
nutritional	B-C0242295
supplement	I-C0242295
claims	O
the	O
developmental	B-C0282574
origins	I-C0282574
of	I-C0282574
health	I-C0282574
and	I-C0282574
disease	I-C0282574
dohad	B-C0282574
model	O
recognizes	O
growth	B-C0018270
in	O
infancy	B-C0231330
and	O
childhood	B-C0231335
as	O
a	O
fundamental	O
determinant	O
of	O
lifespan	B-C0870809
health	B-C0018684
.	O
	
evidence	B-C0332120
of	I-C0332120
long-term	B-C0443252
health	B-C0018684
risks	B-C0035647
among	O
small	B-C0700321
neonates	B-C0021289
who	O
subsequently	O
grow	B-C0870861
rapidly	B-C0456962
poses	O
a	O
challenge	O
for	O
interventions	B-C1273869
aiming	O
to	O
support	O
healthy	B-C3898900
growth	B-C0018270
,	O
not	O
merely	O
drive	O
weight	B-C0043094
gain	I-C0043094
.	O
	
defining	O
healthy	B-C3898900
growth	B-C0018270
beyond	O
"""getting"	O
"bigger"""	O
is	O
essential	B-C0205224
as	O
infant	B-C0021270
and	O
young	B-C0332239
child	B-C0008059
feeding	B-C2987508
industries	B-C0021267
expand	O
.	O
	
liquid	B-C0302908
-based	O
nutritional	B-C0242295
supplements	I-C0242295
,	O
originally	O
formulated	B-C0016497
for	O
undernourished	B-C0162429
children	B-C0008059
,	O
are	O
increasingly	B-C0442808
marketed	B-C0683746
for	O
and	O
consumed	B-C2983605
by	O
children	B-C0008059
generally	O
.	O
	
clarifying	B-C2986669
the	O
nature	O
of	O
the	O
evidentiary	O
base	O
on	O
which	O
structure/function	O
claims	O
promoting	B-C0033414
""""	O
healthy	B-C3898900
growth	B-C0018270
""""	O
are	O
constructed	O
is	O
important	B-C3898777
to	O
curb	O
invalid	O
generalizations	O
.	O
	
evidence	B-C3887511
points	O
to	O
changing	O
social	B-C0728831
beliefs	B-C0004951
and	O
cultural	B-C0220814
practices	B-C0237607
surrounding	O
supplementary	B-C0038847
feeding	I-C0038847
,	O
raising	O
specific	B-C0205369
concerns	B-C2699424
about	O
the	O
long-term	B-C0443252
health	B-C0018684
consequences	B-C0686907
of	I-C0686907
an	O
associated	B-C0332281
altered	B-C0392747
feeding	B-C2987508
culture	B-C0220814
,	O
including	O
reduced	B-C0392756
dietary	B-C0012155
variety	B-C2346866
and	O
weight	B-C0043094
gain	I-C0043094
.	O
	
reassessing	B-C1516048
the	O
evidence	B-C0332120
for	I-C0332120
and	O
relevance	B-C2347946
of	O
dietary	B-C0242295
supplements'	I-C0242295
""""	O
promoting	B-C0033414
healthy	B-C3898900
growth	B-C0018270
""""	O
claims	O
for	O
otherwise	O
healthy	B-C3898900
children	B-C0008059
is	O
both	O
needed	B-C0027552
in	O
a	O
time	O
of	O
global	B-C2348867
obesity	B-C0028754
and	O
an	O
opportunity	B-C0683937
to	O
refine	O
intervention	B-C0184661
approaches	I-C0184661
among	O
small	B-C0700321
children	B-C0008059
for	O
whom	O
rapid	B-C0456962
subsequent	O
growth	B-C0018270
in	O
early	O
life	O
augments	O
risk	B-C0035647
for	O
chronic	B-C0008679
disease	I-C0008679
.	O
	
scientific	B-C0036397
and	O
health	B-C0086388
care	I-C0086388
partnerships	B-C1711206
are	O
needed	B-C0027552
to	O
consider	O
current	O
governmental	B-C0680773
oversight	O
shortfalls	O
in	O
protecting	O
vulnerable	O
populations	B-C1257890
from	O
overconsumption	B-C0441655
.	O
	
this	O
is	O
important	B-C3898777
on-site	B-C0205145
fertility	B-C1171194
preservation	I-C1171194
services	I-C1171194
for	O
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
in	O
a	O
comprehensive	B-C1708333
cancer	I-C1708333
center	I-C1708333
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
ayas	B-C0027362
receiving	O
cancer	B-C0920425
treatments	I-C0920425
that	O
may	O
impair	B-C0021359
fertility	I-C0021359
should	O
receive	O
counseling	B-C0010210
about	O
risk	B-C1171162
of	I-C1171162
infertility	I-C1171162
and	O
options	O
for	O
fertility	B-C1171194
preservation	I-C1171194
fp	B-C1171194
before	O
treatment	B-C0087111
and/or	O
during	O
survivorship	B-C0038955
.	O
	
our	O
objective	B-C0018017
was	O
to	O
define	O
the	O
aya	B-C0027362
patient	B-C0030705
population	B-C1257890
referred	O
to	O
an	O
on-site	B-C0009818
fertility	I-C0009818
consultation	I-C0009818
service	I-C0009818
within	O
a	O
comprehensive	B-C1708333
cancer	I-C1708333
center	I-C1708333
and	O
determine	O
factors	B-C1521761
associated	O
with	O
patients	B-C0030705
proceeding	O
with	O
fp	B-C3839343
treatment	I-C3839343
.	O
	
we	O
conducted	O
a	O
retrospective	B-C0035363
chart	I-C0035363
review	I-C0035363
of	O
aya	B-C0027362
women	B-C0043210
who	O
completed	O
a	O
consultation	B-C0009818
at	O
the	O
md	B-C0018747
anderson	I-C0018747
fertility	I-C0018747
preservation	I-C0018747
and	I-C0018747
family	I-C0018747
building	I-C0018747
service	I-C0018747
during	O
the	O
first	O
year	O
of	O
service	B-C0557854
.	O
	
records	B-C0025102
of	O
154	O
referred	O
aya	B-C0027362
patients	B-C0030705
were	O
reviewed	B-C1709940
for	O
age	B-C0001779
,	O
ethnicity	B-C0015031
,	O
cancer	B-C0872066
type	I-C0872066
gravidity	B-C0600457
and	O
parity	B-C0030563
,	O
survivorship	B-C0038955
status	B-C0449438
,	O
and	O
decision	O
to	O
pursue	O
fp	B-C3839343
treatment	I-C3839343
.	O
	
patients	B-C0030705
mean	O
age	O
29.7	O
were	O
caucasian	B-C0043157
55%	O
,	O
hispanic	B-C0086409
23%	O
,	O
and	O
african	B-C0085756
american	I-C0085756
10%	O
.	O
	
the	O
majority	O
of	O
women	B-C0043210
67%	O
were	O
seen	O
for	O
fp	B-C1171194
before	O
cancer	B-C0920425
treatment	I-C0920425
and	O
the	O
remaining	O
sought	O
options	B-C1518601
for	O
family	B-C0009861
building	I-C0009861
while	O
in	O
survivorship	B-C0038955
.	O
	
the	O
most	O
common	O
cancer	B-C0872066
types	I-C0872066
were	O
hematologic	B-C0376545
29%	O
,	O
breast	B-C0678222
25%	O
,	O
and	O
gynecologic	B-C0699889
23%	O
.	O
	
patients	B-C0030705
referred	O
to	O
an	O
on-site	B-C0009818
fertility	I-C0009818
consultation	I-C0009818
service	I-C0009818
were	O
medically	O
and	O
ethnically	B-C0243103
diverse	B-C1880371
.	O
	
interest	O
in	O
fertility	B-C1689849
counseling	I-C1689849
and	O
treatment	B-C0087111
was	O
apparent	O
in	O
both	O
survivorship	B-C0038955
pre-	B-C0920425
and	I-C0920425
postcancer	I-C0920425
treatment	I-C0920425
.	O
	
although	O
the	O
referral	B-C0034927
group	B-C0441833
was	O
ethnically	B-C0243103
diverse	B-C1880371
,	O
caucasian	B-C0043157
women	B-C0043210
were	O
most	O
likely	O
to	O
pursue	O
fp	B-C3839343
treatment	I-C3839343
compared	O
to	O
women	B-C0043210
of	O
other	O
results	B-C1274040
of	O
a	O
multicenter	B-C1096776
,	O
randomized	B-C0034656
,	O
controlled	B-C0936233
trial	I-C0936233
of	O
a	O
hydrogen	B-C0020281
peroxide	I-C0020281
-based	O
kit	B-C0812225
versus	O
a	O
benzoyl	B-C0005088
peroxide	I-C0005088
-based	O
kit	B-C0812225
in	O
mild-to-moderate	B-C1299392
acne	B-C0702166
objective	O
evaluate	B-C0220825
the	O
efficacy	B-C1280519
and	O
tolerability	B-C3274448
of	O
a	O
novel	O
hydrogen	B-C0020281
peroxide	I-C0020281
-based	O
regimen	B-C0040808
versus	O
a	O
benzoyl	B-C0005088
peroxide	I-C0005088
-based	O
regimen	B-C0040808
in	O
mild-to-moderate	B-C1299392
acne	B-C0702166
.	O
	
methods	B-C0025663
in	O
this	O
eight-	O
week	B-C0439230
multicenter	B-C1096776
study	I-C1096776
,	O
patients	B-C0030705
were	O
randomized	B-C0034656
to	O
either	O
a	O
hydrogen	B-C0020281
peroxide	I-C0020281
-based	O
or	O
a	O
benzoyl	B-C0005088
peroxide	I-C0005088
-based	O
regimen	B-C0040808
the	O
primary	B-C3274433
outcome	I-C3274433
measure	I-C3274433
of	O
clinical	B-C4055223
response	I-C4055223
was	O
assessed	B-C1516048
using	O
the	O
global	B-C1273712
acne	I-C1273712
grading	I-C1273712
system	I-C1273712
gags	B-C1273712
at	O
baseline	B-C1442488
four	O
weeks	B-C0439230
,	O
and	O
eight	O
weeks	B-C0439230
.	O
	
at	O
week	B-C0439230
8	O
,	O
a	O
patient	B-C0030705
self-satisfaction	B-C0034394
questionnaire	I-C0034394
was	O
administered	B-C1521801
.	O
	
investigators	B-C0035173
were	O
also	O
queried	B-C1522634
at	O
that	O
time	O
regarding	O
assessment	B-C0220825
of	O
tolerability	B-C3274448
and	O
cosmetic	B-C0010164
acceptability	B-C0814633
.	O
	
tolerability	B-C3274448
was	O
also	O
measured	B-C0444706
at	O
each	O
visit	B-C1512346
.	O
	
results	O
both	O
treatment	B-C0040808
regimens	I-C0040808
were	O
associated	B-C0332281
with	I-C0332281
improvement	B-C2986411
of	O
gags	B-C0449820
score	I-C0449820
at	O
week	B-C0439230
8	O
compared	B-C1707455
to	O
baseline	B-C1442488
p<0	O
.	O
	
gags	B-C0449820
score	I-C0449820
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
regimens	B-C0040808
over	O
the	O
same	O
period	B-C1948053
p=0	O
.	O
	
no	B-C1963761
significant	I-C1963761
adverse	I-C1963761
events	I-C1963761
were	O
reported	B-C0700287
or	O
observed	B-C1441672
in	O
either	O
treatment	B-C1522541
arm	I-C1522541
.	O
	
both	O
patients	B-C0030705
and	O
investigators	B-C0035173
found	O
both	O
regimens	B-C0040808
to	O
be	O
similarly	O
effective	B-C1704419
and	O
cosmetically	B-C0010164
acceptable	B-C0814633
.	O
	
conclusion	O
a	O
novel	O
hydrogen	B-C0020281
peroxide	I-C0020281
-based	O
regimen	B-C0040808
was	O
shown	O
to	O
be	O
comparable	B-C1707455
in	O
efficacy	B-C1280519
,	O
safety	B-C0036043
,	O
and	O
cosmetic	B-C0010164
acceptability	B-C0814633
to	O
a	O
benzoyl	B-C0005088
peroxide	I-C0005088
-based	O
regimen	B-C0040808
in	O
the	O
treatment	B-C0087111
of	O
mild-to-moderate	B-C1299392
acne	B-C0702166
.	O
	
multisensory	B-C0679019
integration	I-C0679019
in	O
the	O
virtual	B-C0020903
hand	I-C0020903
illusion	I-C0020903
with	O
active	B-C0231481
movement	I-C0231481
improving	O
the	O
sense	B-C0025361
of	I-C0025361
immersion	O
is	O
one	O
of	O
the	O
core	O
issues	O
in	O
virtual	O
reality	O
.	O
	
perceptual	O
illusions	O
of	O
ownership	O
can	O
be	O
perceived	O
over	O
a	O
virtual	O
body	O
in	O
a	O
multisensory	O
virtual	O
reality	O
environment	O
.	O
	
rubber	O
hand	O
and	O
virtual	O
hand	O
illusions	O
showed	O
that	O
body	O
ownership	O
can	O
be	O
manipulated	O
by	O
applying	O
suitable	O
visual	O
and	O
tactile	O
stimulation	O
.	O
	
in	O
this	O
study	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
multisensory	O
integration	O
in	O
the	O
virtual	O
hand	O
illusion	O
with	O
active	O
movement	O
.	O
	
a	O
virtual	O
xylophone	O
playing	O
system	O
which	O
can	O
interactively	O
provide	O
synchronous	O
visual	O
,	O
tactile	O
,	O
and	O
auditory	O
stimulation	O
was	O
constructed	O
.	O
	
we	O
conducted	O
two	O
experiments	O
regarding	O
different	O
movement	O
conditions	O
and	O
different	O
sensory	O
stimulations	O
.	O
	
our	O
results	O
demonstrate	O
that	O
multisensory	O
integration	O
with	O
free	O
active	O
movement	O
can	O
improve	O
the	O
sense	B-C0243095
of	I-C0243095
immersion	I-C0243095
in	O
virtual	B-C0871582
reality	I-C0871582
.	O
	
obstructive	B-C0549186
acute	B-C0001339
pancreatitis	I-C0001339
secondary	O
to	O
peg	B-C2985542
tube	I-C2985542
migration	B-C0549474
percutaneous	B-C0176751
gastrostomy	I-C0176751
is	O
a	O
well-established	O
method	B-C0449851
of	O
providing	O
enteral	B-C0014327
nutrition	I-C0014327
to	O
patients	B-C0030705
incapable	B-C1550518
of	O
oral	B-C0518037
intake	I-C0518037
,	O
or	O
for	O
whom	O
oral	B-C0518037
intake	I-C0518037
is	O
insufficient	B-C0231180
to	O
meet	O
metabolic	B-C0311400
needs	B-C0027552
.	O
	
in	O
comparison	O
to	O
total	B-C0030548
parenteral	I-C0030548
nutrition	I-C0030548
,	O
enteral	B-C0086225
feeding	I-C0086225
is	O
advantageous	O
in	O
that	O
it	O
helps	O
maintain	O
gut	B-C0699819
mucosal	B-C0026724
integrity	B-C1947912
,	O
which	O
decreases	O
the	O
risk	B-C0035647
of	O
bacterial	B-C0282583
translocation	I-C0282583
through	O
the	O
gastrointestinal	B-C0017189
tract	I-C0017189
.	O
	
complications	B-C0009566
include	O
bleeding	B-C0019080
,	O
aspiration	B-C0700198
,	O
internal	B-C0332675
organ	I-C0332675
injury	I-C0332675
,	O
perforation	B-C0151664
,	O
periostomal	B-C0341600
leaks	I-C0341600
,	O
tube	B-C1608950
dislodgement	I-C1608950
,	O
and	O
occlusion	B-C0028778
.	O
	
acute	B-C0001339
pancreatitis	I-C0001339
secondary	O
to	O
percutaneous	B-C2985542
gastrostomy	I-C2985542
tube	I-C2985542
migration	B-C0549474
is	O
rare	O
.	O
	
we	O
present	O
a	O
patient	B-C0030705
with	O
acute	B-C0205178
obstructive	B-C0549186
pancreatitis	B-C0030305
secondary	O
to	O
percutaneous	B-C2985542
gastrostomy	I-C2985542
tube	I-C2985542
migration	B-C0549474
.	O
	
a	O
tractable	B-C0205556
method	B-C0025663
for	O
measuring	B-C0444706
nanomaterial	B-C1450053
risk	B-C0035647
using	O
bayesian	B-C3161035
networks	I-C3161035
while	O
control	O
banding	B-C0185014
has	O
been	O
identified	O
as	O
a	O
suitable	O
framework	O
for	O
the	O
evaluation	B-C1550157
and	O
the	O
determination	O
of	O
potential	B-C3245505
human	B-C0086418
health	B-C0679809
risks	I-C0679809
associated	O
with	O
exposure	B-C0332157
to	I-C0332157
nanomaterials	B-C1450053
nms	B-C1450053
,	O
the	O
approach	O
currently	O
lacks	O
any	O
implementation	B-C1708476
that	O
enjoys	O
widespread	O
support	O
.	O
	
large	O
inconsistencies	O
in	O
characterisation	O
data	B-C1511726
,	O
toxicological	B-C4042799
measurements	B-C0242485
and	O
exposure	O
scenarios	O
make	O
it	O
difficult	O
to	O
map	O
and	O
compare	O
the	O
risk	B-C0035647
associated	O
with	O
nms	B-C1450053
based	O
on	O
physicochemical	B-C2350461
data	B-C1511726
,	O
concentration	B-C1446561
and	O
exposure	B-C0683172
route	I-C0683172
.	O
	
here	O
we	O
demonstrate	O
the	O
use	O
of	O
bayesian	B-C3161035
networks	I-C3161035
as	O
a	O
reliable	O
tool	B-C0449851
for	O
nm	B-C1450053
risk	B-C0035647
estimation	O
.	O
	
this	O
tool	B-C0449851
is	O
tractable	B-C0205556
,	O
accessible	B-C0205556
and	O
scalable	B-C0392762
.	O
	
most	O
importantly	O
,	O
it	O
captures	O
a	O
broad	O
span	O
of	O
data	B-C1511726
types	O
,	O
from	O
complete	O
,	O
high	O
quality	B-C0332306
data	B-C0150098
sets	I-C0150098
through	O
to	O
data	B-C0150098
sets	I-C0150098
with	O
missing	O
data	B-C1511726
and/or	O
values	B-C1522609
with	O
a	O
relatively	O
high	O
spread	O
of	O
probability	B-C3826440
distribution	I-C3826440
.	O
	
the	O
tool	B-C0449851
is	O
able	O
to	O
learn	O
iteratively	O
in	O
order	O
to	O
further	O
refine	O
forecasts	O
as	O
the	O
quality	B-C0332306
of	O
data	B-C1511726
available	O
improves	O
.	O
	
we	O
demonstrate	O
how	O
this	O
risk	B-C0035647
measurement	B-C0242485
approach	O
works	O
on	O
nms	B-C1450053
with	O
varying	O
degrees	O
of	O
risk	B-C0035647
potential	B-C3245505
,	O
namely	O
,	O
carbon	B-C1138408
nanotubes	I-C1138408
,	O
silver	B-C0037125
and	O
titanium	B-C0076733
dioxide	I-C0076733
.	O
	
the	O
results	O
afford	O
even	O
non-experts	B-C0027361
an	O
accurate	O
picture	O
of	O
the	O
occupational	O
risk	B-C0035647
probabilities	O
associated	O
with	O
these	O
nms	B-C1450053
and	O
,	O
in	O
doing	O
so	O
,	O
demonstrated	O
how	O
nm	B-C1450053
risk	B-C0035647
can	O
be	O
evaluated	B-C1550157
into	O
a	O
tractable	B-C0205556
,	O
quantitative	B-C0392762
risk	B-C0035647
gender	B-C0079399
and	O
direction	B-C0449738
of	O
effect	B-C1280500
of	O
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
in	O
a	O
longitudinal	B-C0023981
sample	I-C0023981
of	O
college	B-C0682177
students	I-C0682177
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
are	O
consistently	O
found	O
to	O
be	O
associated	B-C0332281
but	O
how	O
they	O
relate	B-C0439849
to	O
each	O
other	O
is	O
unclear	B-C3845108
.	O
	
the	O
present	O
study	B-C2603343
aimed	O
to	O
address	O
limitations	B-C0449295
in	O
the	O
literature	B-C0023866
of	O
comorbidity	B-C0009488
of	O
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
by	O
investigating	B-C1292732
the	O
direction	B-C0449738
of	O
effect	B-C1280500
between	O
the	O
phenotypes	B-C0031437
and	O
possible	O
gender	B-C0036866
differences	I-C0036866
in	O
college	B-C0682177
students	I-C0682177
.	O
	
we	O
utilized	O
data	B-C1511726
from	O
a	O
large	O
longitudinal	B-C0023981
study	I-C0023981
of	O
college	B-C0682177
students	I-C0682177
from	O
the	O
united	B-C0041703
states	I-C0041703
n	O
=	O
2607	O
.	O
	
three	O
waves	O
of	O
questionnaire-based	B-C0034394
data	B-C1511726
were	O
collected	O
over	O
the	O
first	O
two	O
years	B-C0439234
of	O
college	B-C0557806
in	O
2011-2013	O
.	O
	
cross-lagged	B-C2348012
models	I-C2348012
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	B-C0449738
of	O
effect	B-C1280500
of	O
internalizing	B-C0871786
symptoms	I-C0871786
and	O
alcohol	B-C0549393
problems	I-C0549393
.	O
	
possible	O
effects	B-C1280500
of	O
gender	B-C0079399
were	O
investigated	B-C1292732
using	O
multigroup	B-C0392762
modeling	I-C0392762
.	O
	
there	O
were	O
significant	B-C0750502
correlations	B-C1707520
between	O
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
.	O
	
a	O
direction	B-C0449738
of	O
effect	B-C1280500
was	O
found	O
between	O
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
but	O
differed	O
between	O
genders	B-C0079399
.	O
	
a	O
unidirectional	O
relationship	B-C0439849
varying	O
with	O
age	B-C0001779
was	O
identified	O
for	O
males	B-C0086582
where	O
alcohol	B-C0549393
problems	I-C0549393
initially	O
predicted	B-C0681842
internalizing	B-C0871786
symptoms	I-C0871786
followed	O
by	O
internalizing	B-C0871786
symptoms	I-C0871786
predicting	O
alcohol	B-C0549393
problems	I-C0549393
.	O
	
for	O
females	B-C0086287
,	O
a	O
unidirectional	O
relationship	B-C0439849
existed	O
wherein	O
alcohol	B-C0549393
problems	I-C0549393
predicted	O
internalizing	B-C0871786
symptoms	I-C0871786
.	O
	
conclusions/importance	O
we	O
conclude	O
that	O
the	O
relationship	B-C0439849
between	O
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
is	O
complex	B-C0439855
and	O
differ	O
between	O
genders	B-C0079399
.	O
	
in	O
males	B-C0086582
,	O
both	O
phenotypes	B-C0031437
are	O
predictive	B-C0681890
of	O
each	O
other	O
,	O
while	O
in	O
females	B-C0086287
the	O
relationship	B-C0439849
is	O
driven	O
by	O
alcohol	B-C0549393
problems	I-C0549393
.	O
	
importantly	O
,	O
our	O
study	B-C2603343
examines	O
a	O
population-based	B-C1709598
sample	I-C1709598
,	O
revealing	O
that	O
the	O
observed	O
relationships	B-C0439849
between	O
alcohol	B-C0549393
problems	I-C0549393
and	O
internalizing	B-C0871786
symptoms	I-C0871786
are	O
not	O
limited	O
to	O
individuals	B-C0027361
with	O
clinically	B-C0332140
diagnosed	I-C0332140
mental	B-C0025353
health	I-C0025353
or	O
substance	B-C0740858
use	I-C0740858
problems	I-C0740858
.	O
	
real-time	B-C1550177
monitoring	B-C1283169
of	O
vesicle	B-C1622418
ph	B-C0020283
in	O
an	O
endocytic	B-C0014139
pathway	B-C1704259
using	O
an	O
egf	B-C0242275
-	O
conjugated	B-C2347609
two-photon	I-C2347609
probe	I-C2347609
herein	O
,	O
we	O
developed	O
a	O
ratiometric	B-C2347609
two-photon	I-C2347609
probe	I-C2347609
bhs3	B-C2347609
-	O
egf	B-C0242275
,	O
derived	O
from	O
a	O
ph	B-C0020283
sensitive	B-C0332324
dye	O
and	O
epidermal	B-C0242275
growth	I-C0242275
factor	I-C0242275
egf	B-C0242275
,	O
for	O
real-time	B-C1550177
monitoring	B-C1283169
and	O
quantitative	B-C0392762
analysis	B-C0936012
of	O
acidic	B-C0524461
luminal	I-C0524461
ph	B-C0020283
values	B-C0042295
during	O
endocytic	B-C0014139
pathway	B-C1704259
activity	I-C1704259
.	O
	
two-photon	B-C1537066
microscopy	I-C1537066
imaging	I-C1537066
with	O
bhs3	B-C2347609
-	O
egf	B-C0242275
allows	O
the	O
quantitative	B-C0392762
analysis	B-C0936012
of	O
ph	B-C0020283
distributions	B-C1704711
of	O
single	O
vesicles	B-C1622418
and	O
their	O
dynamics	B-C3826426
in	O
receptor-mediated	B-C0597361
endocytosis	I-C0597361
in	O
body	B-C0005884
burden	I-C0005884
of	O
heavy	B-C0347988
metals	I-C0347988
among	O
hiv	B-C0744979
high	B-C0870646
risk	I-C0870646
population	I-C0870646
in	O
usa	B-C0041703
hiv	B-C0744979
high	B-C0870646
risk	I-C0870646
population	I-C0870646
may	O
face	O
not	O
only	O
the	O
threat	B-C0749385
of	O
hiv	B-C0019693
infection	I-C0019693
but	O
also	O
a	O
higher	B-C0205250
chance	B-C0237506
of	O
exposure	B-C0522741
to	I-C0522741
environmental	I-C0522741
contaminants	I-C0522741
.	O
	
however	O
,	O
no	O
previous	O
studies	B-C2603343
have	O
examined	B-C0332129
the	O
body	B-C0005884
burden	I-C0005884
of	O
environmental	B-C0014417
pollutants	I-C0014417
including	O
heavy	B-C0347988
metals	I-C0347988
among	O
hiv	B-C0744979
high	B-C0870646
risk	I-C0870646
populations	I-C0870646
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	O
whether	O
adults	B-C0001675
aged	I-C0001675
20-59	O
years	O
old	O
at	O
high	B-C0332167
risk	I-C0332167
of	I-C0332167
hiv	B-C0019693
infection	I-C0019693
have	O
higher	B-C0205250
blood	B-C0495719
levels	I-C0495719
of	I-C0495719
heavy	I-C0495719
metals	I-C0495719
compared	B-C1707455
to	O
those	O
with	O
low	B-C3538919
risk	I-C3538919
of	O
hiv	B-C0019693
infection	I-C0019693
in	O
united	B-C0041703
states	I-C0041703
.	O
	
we	O
used	O
the	O
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
nhanes	B-C0376344
1999-2010	O
to	O
compare	B-C1707455
exposures	B-C0332157
to	I-C0332157
heavy	B-C0347988
metals	I-C0347988
including	O
cadmium	B-C0006632
,	O
lead	B-C0023175
,	O
and	O
total	O
mercury	B-C0025424
by	O
hiv	B-C0744979
risk	B-C1319831
status	I-C1319831
.	O
	
the	O
results	B-C1274040
showed	O
that	O
people	B-C0027361
at	O
high	B-C0332167
risk	I-C0332167
of	I-C0332167
hiv	B-C0744979
had	O
higher	B-C0205250
blood	B-C0427728
concentrations	I-C0427728
of	O
all	O
heavy	B-C0347988
metals	I-C0347988
compared	B-C1707455
to	O
their	O
counterparts	O
with	O
lower	B-C0205251
hiv	B-C0744979
risks	I-C0744979
.	O
	
in	O
multivariate	B-C0023733
linear	I-C0023733
regression	I-C0023733
models	B-C0026336
,	O
hiv	B-C0744979
risk	I-C0744979
status	O
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
blood	B-C0855870
cadmium	I-C0855870
,	O
lead	B-C0853362
,	O
and	O
total	B-C0202414
mercury	I-C0202414
after	O
adjusting	B-C0456081
for	O
age	B-C0001779
,	O
sex	B-C0079399
,	O
race	B-C0034510
,	O
education	B-C0683842
,	O
and	O
poverty	B-C0032854
income	B-C0021162
ratio	B-C0456603
.	O
	
our	O
study	B-C2603343
suggests	O
that	O
people	B-C0027361
at	O
high	B-C0332167
risk	I-C0332167
of	I-C0332167
hiv	B-C0744979
have	O
significantly	O
higher	B-C0205250
body	B-C0005884
burden	I-C0005884
of	O
heavy	B-C0347988
metals	I-C0347988
including	O
cadmium	B-C0006632
,	O
lead	B-C0023175
,	O
and	O
mercury	B-C0025424
compared	B-C1707455
to	O
those	O
with	O
low	B-C3538919
risk	I-C3538919
of	O
hiv	B-C0744979
.	O
	
further	O
longitudinal	B-C0023981
study	I-C0023981
collecting	O
more	B-C0205172
pollutants	B-C0599786
are	O
warranted	B-C1552821
to	O
determine	O
the	O
potential	B-C3245505
health	B-C0018684
effects	B-C1280500
of	O
these	O
elevated	B-C3163633
pollutants	B-C0599786
on	O
both	O
hiv-infected	B-C0019693
and	O
hiv	B-C0744979
high-risk	B-C0870646
populations	I-C0870646
.	O
	
fluorescence-	B-C0079366
and	O
magnetic-activated	B-C0599662
cell	I-C0599662
sorting	I-C0599662
strategies	B-C0449851
to	O
separate	B-C0443299
spermatozoa	B-C0037868
involving	O
plural	B-C0439064
contributors	B-C1257890
from	O
biological	B-C2347026
mixtures	I-C2347026
for	O
human	B-C0242954
identification	I-C0242954
no	O
effective	O
method	B-C0449851
has	O
been	O
developed	O
to	O
distinguish	B-C0443299
sperm	B-C0037868
cells	I-C0037868
originating	O
from	O
different	O
men	B-C0025266
in	O
multi-suspect	B-C0750491
sexual	B-C0237236
assault	I-C0237236
cases	B-C0868928
.	O
	
here	O
we	O
combined	O
macs	B-C0599662
and	O
facs	B-C0079366
to	O
isolate	B-C0220862
single	B-C0205171
donor	B-C0013018
sperm	B-C0037868
cells	I-C0037868
from	O
forensic	B-C0370003
mixture	I-C0370003
samples	I-C0370003
including	O
female	B-C0043210
vaginal	B-C0042232
epithelial	B-C0014597
cells	I-C0014597
and	O
sperm	B-C0037868
cells	I-C0037868
from	O
multiple	B-C0439064
contributors	B-C1257890
.	O
	
sperms	B-C0037868
from	O
vaginal	B-C0444207
swab	I-C0444207
were	O
isolated	B-C0205409
by	O
macs	B-C0599662
using	O
fitc	B-C0085216
-conjugated	O
a	B-C1309095
kinase	I-C1309095
anchor	I-C1309095
protein	I-C1309095
3	I-C1309095
akap3	B-C1309095
antibody	B-C0003241
target	B-C0237401
individual	I-C0237401
sperm	B-C0037868
cells	I-C0037868
involving	O
two	O
or	O
three	O
donors	B-C0013018
were	O
separated	B-C0443299
by	O
facs	B-C0079366
using	O
fitc	B-C0085216
-labeled	O
blood	B-C0302043
group	I-C0302043
a/b	I-C0302043
antigen	I-C0302043
antibody	B-C0003241
.	O
	
this	O
procedure	B-C2700391
was	O
further	O
tested	B-C0039593
in	O
two	O
mock	B-C0562577
multi-suspect	B-C0750491
sexual	B-C0237236
assault	I-C0237236
samples	B-C0370003
and	O
one	O
practical	B-C0179660
casework	I-C0179660
sample	B-C0370003
.	O
	
our	O
results	O
showed	O
that	O
complete	B-C0205197
single	B-C0205171
donor	B-C0013018
str	B-C1519302
profiles	I-C1519302
could	O
be	O
successfully	O
obtained	O
from	O
sperm	B-C0037868
/	O
epithelial	B-C0014597
cell	I-C0014597
and	O
sperm	B-C0037868
mixtures	B-C0439962
from	O
two	O
contributors	B-C1257890
.	O
	
for	O
unbalanced	O
sperm	B-C0037868
/	O
epithelial	B-C0014597
cells	I-C0014597
and	O
sperm	B-C0037868
cells	I-C0037868
mixtures	B-C0439962
,	O
sensitivity	B-C0036667
results	O
revealed	O
that	O
target	B-C2939170
cells	I-C2939170
could	O
be	O
detected	B-C0442726
at	O
as	O
low	O
as	O
1	O
and	O
1	O
mixed	O
ratios	O
,	O
respectively	O
.	O
	
although	O
highly	O
relies	O
on	O
cell	B-C0007584
number	I-C0007584
and	O
blood	B-C1383165
types	I-C1383165
or	O
secretor	O
status	O
of	O
the	O
individuals	B-C0237401
,	O
this	O
procedure	B-C2700391
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic	B-C0200898
dna	I-C0200898
analysis	I-C0200898
of	O
multi-suspect	B-C0750491
sexual	B-C0237236
assault	I-C0237236
cases	B-C0868928
by	O
the	O
combined	O
use	B-C1524063
of	I-C1524063
facs	B-C0079366
and	O
macs	B-C0599662
based	O
on	O
sperm	B-C0037868
-specific	O
akap3	B-C1309095
antigen	B-C0003320
and	O
human	B-C0086418
blood	B-C0701817
type	I-C0701817
antigen	I-C0701817
.	O
	
the	O
role	O
of	O
the	O
iron	B-C0918182
stain	I-C0918182
in	O
assessing	B-C1516048
intracranial	B-C0151699
hemorrhage	I-C0151699
the	O
timing	B-C0449243
of	O
the	O
breakdown	O
of	O
red	B-C0014792
blood	I-C0014792
cells	I-C0014792
and	O
organization	B-C1300196
of	O
hemorrhage	B-C0019080
has	O
significance	B-C0237881
in	O
the	O
catabolism	B-C0699900
of	O
heme	B-C0018966
and	O
the	O
processing	B-C1709694
of	O
iron	B-C0302583
,	O
but	O
also	O
has	O
a	O
practical	O
application	B-C4048755
in	O
terms	O
of	O
assigning	B-C1516050
,	O
or	O
attempting	B-C1516084
to	O
assign	B-C1516050
,	O
a	O
time	B-C0449247
course	I-C0449247
with	O
respect	O
to	O
traumatic	B-C3714660
events	B-C0441471
e.g	O
.	O
	
contusions	B-C0009938
and	O
hemorrhages	B-C0019080
.	O
	
attempts	B-C1516084
to	O
date	B-C0009938
contusions	I-C0009938
,	O
however	O
,	O
have	O
generally	O
been	O
unsuccessful	B-C1272705
by	O
macroscopic	B-C1551402
observation	I-C1551402
,	O
whereas	O
the	O
microscopic	B-C0369671
observations	I-C0369671
provide	O
broad	O
data	B-C1511726
but	O
are	O
also	O
anatomically	B-C0220784
imprecise	B-C0205408
as	O
a	O
function	B-C0542341
of	O
time	B-C0040223
.	O
	
intracranial	B-C0581296
lesions	I-C0581296
are	O
of	O
particular	O
significance	B-C0237881
with	O
respect	O
to	O
the	O
timing	B-C0449243
of	O
organizing	B-C1300196
hemorrhage	B-C0019080
given	O
the	O
acute	B-C0205178
,	O
and	O
often	O
life-threatening	B-C2826244
nature	B-C0349590
of	O
the	O
hemorrhages	B-C0019080
,	O
and	O
the	O
medicolegal	B-C0420141
investigation	I-C0420141
into	O
potential	B-C3245505
crimes	B-C0010325
.	O
	
of	O
concern	O
is	O
that	O
the	O
prussian	B-C0033779
blue	I-C0033779
reaction	I-C0033779
for	O
iron	B-C0302583
,	O
a	O
relatively	O
straightforward	O
histochemical	B-C0019635
reaction	B-C0443286
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	B-C0439234
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic	B-C0086143
test	I-C0086143
for	O
chronicity	B-C0547045
.	O
	
therefore	O
,	O
this	O
study	B-C2603343
examined	B-C0332128
the	O
utility	O
of	O
the	O
prussian	B-C0060234
blue	I-C0060234
iron	I-C0060234
stain	I-C0060234
in	O
living	B-C0030705
patients	I-C0030705
with	O
intracranial	B-C0151699
hemorrhages	I-C0151699
and	O
well-defined	O
symptom	B-C4086878
onset	I-C4086878
,	O
to	O
test	O
whether	O
the	O
presence	B-C0150312
of	O
prussian	B-C0060234
blue	I-C0060234
reactivity	B-C0678596
could	O
be	O
correlated	B-C1707520
with	O
chronicity	B-C0547045
.	O
	
it	O
was	O
found	B-C0243095
that	O
out	O
of	O
12	O
cases	B-C0868928
with	O
intracranial	B-C0151699
hemorrhage	I-C0151699
,	O
eight	O
cases	B-C0868928
showed	O
at	O
least	O
focal	B-C0302583
iron	I-C0302583
reactivity	B-C0678596
.	O
	
the	O
duration	B-C0449238
from	O
symptom	B-C4086878
onset	I-C4086878
to	O
surgery	B-C0543467
in	O
those	O
eight	O
cases	B-C0868928
ranged	B-C1514721
from	O
<	O
24	O
hours	B-C0439227
to	O
more	O
than	O
3	O
days	B-C0439228
.	O
	
of	O
those	O
cases	B-C0868928
with	O
no	B-C0243095
iron	I-C0243095
reactivity	I-C0243095
,	O
the	O
duration	B-C0449238
from	O
symptom	B-C4086878
onset	I-C4086878
to	O
surgery	B-C0543467
ranged	O
from	O
<	O
24	O
hours	B-C0439227
to	O
six	O
days	B-C0439228
.	O
	
in	O
conclusion	O
,	O
the	O
prussian	B-C0033779
blue	I-C0033779
reaction	I-C0033779
was	O
unreliable	B-C0749770
as	O
an	O
indicator	B-C0021212
of	O
timing	B-C0449243
in	O
intracranial	B-C0151699
hemorrhage	I-C0151699
.	O
	
the	O
use	O
of	O
the	O
prussian	B-C0033779
blue	I-C0033779
reaction	I-C0033779
as	O
an	O
independent	B-C0021212
indicator	I-C0021212
of	O
chronicity	B-C0547045
is	O
therefore	O
not	O
valid	B-C2349099
and	O
can	O
be	O
misleading	O
.	O
	
caution	O
is	O
indicated	B-C1444656
when	O
employing	O
iron	B-C1522279
staining	I-C1522279
for	O
timing	B-C0449243
purposes	O
,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight	O
,	O
as	O
opposed	O
to	O
identify	O
,	O
pre-existing	B-C2347662
lesions	B-C0221198
.	O
	
with	O
respect	O
to	O
brain	B-C0221505
lesions	I-C0221505
,	O
the	O
prussian	B-C0033779
blue	I-C0033779
reaction	I-C0033779
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	B-C0205210
timing	B-C0449243
of	O
the	O
neurologic	B-C4314692
decline	I-C4314692
,	O
or	O
clinical	B-C1516606
data	I-C1516606
that	O
is	O
otherwise	O
more	O
accurate	B-C0443131
and	O
less	O
susceptible	B-C0231204
to	O
false	B-C0205557
positive	I-C0205557
results	I-C0205557
.	O
	
successful	B-C1272703
fetal	B-C0412564
tele-echo	I-C0412564
at	O
a	O
small	B-C0019994
regional	I-C0019994
hospital	I-C0019994
prenatal	B-C0033053
diagnosis	I-C0033053
of	O
complex	B-C0439855
congenital	B-C0152021
heart	I-C0152021
disease	I-C0152021
chd	B-C0152021
has	O
been	O
shown	O
to	O
improve	B-C0184511
newborn	B-C2239178
outcomes	B-C1274040
.	O
	
the	O
rate	O
of	O
prenatal	B-C0033053
diagnosis	I-C0033053
and	O
access	B-C0444454
to	O
fetal	B-C0412564
echocardiography	I-C0412564
vary	O
widely	O
across	O
the	O
united	B-C0041703
states	I-C0041703
.	O
	
a	O
clinical	B-C0412564
fetal	I-C0412564
tele-echo	I-C0412564
service	O
was	O
established	O
at	O
king's	B-C0565990
daughters	I-C0565990
medical	I-C0565990
center	I-C0565990
kdmc	B-C0565990
in	O
ashland	B-C3811365
,	O
ky	B-C0022557
,	O
a	O
region	O
in	O
eastern	B-C0022557
kentucky	I-C0022557
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital	B-C0334892
heart	I-C0334892
surgeon	I-C0334892
.	O
	
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
if	O
fetal	B-C0412564
tele-echo	I-C0412564
utilizing	O
local	B-C1954848
sonographers	I-C1954848
at	O
a	O
small	B-C0019994
regional	I-C0019994
hospital	I-C0019994
can	O
accurately	B-C0443131
and	O
efficiently	B-C0442799
identify	O
fetuses	B-C0015965
with	O
complex	B-C0439855
chd	B-C0152021
.	O
	
medical	B-C0025102
records	I-C0025102
were	O
reviewed	B-C1709940
for	O
all	O
mother-infant	B-C0596977
pairs	I-C0596977
who	O
had	O
fetal	B-C0412564
tele-echoes	I-C0412564
performed	B-C0884358
at	O
kdmc	B-C0565990
and	O
interpreted	B-C1285553
by	O
university	B-C0020028
of	I-C0020028
louisville	I-C0020028
pediatric	I-C0020028
cardiology	I-C0020028
between	O
march	O
2011	O
and	O
december	O
2013	O
.	O
	
findings	B-C0243095
on	O
fetal	B-C0412564
tele-echo	I-C0412564
were	O
compared	O
to	O
newborn	B-C0021289
echo	O
and	O
clinical	O
course	O
,	O
and	O
divided	O
into	O
four	O
groups	O
1	O
correct	O
-	O
no	O
difference	O
between	O
fetal	O
tele-echo	O
and	O
newborn	B-C0021289
echo	B-C0013516
,	O
2	O
likely	O
correct-normal	O
fetal	O
tele-echo	O
and	O
benign	O
newborn	O
course	O
,	O
3	O
major	O
difference	O
-one	O
that	O
affected	O
newborn	O
clinical	B-C0449259
course	I-C0449259
,	O
and	O
4	O
minor	O
difference	O
-did	O
not	O
affect	O
clinical	O
course	O
.	O
	
seventy-five	O
mother-infant	O
pairs	O
were	O
analyzed	O
.	O
	
fetal	O
tele-echoes	O
were	O
correct	B-C2349182
in	O
21%	O
,	O
likely	O
correct	O
in	O
56%	O
,	O
showed	O
major	O
differences	O
in	O
0%	O
,	O
and	O
showed	O
minor	O
differences	O
in	O
23%	O
.	O
	
for	O
identifying	O
complex	O
chd	O
,	O
fetal	O
tele-echo	O
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100%	O
.	O
	
the	O
average	O
number	O
of	O
fetal	O
echocardiograms	O
per	O
mother-infant	O
pair	O
was	O
1.1	O
.	O
	
fetal	O
tele-echocardiography	O
performed	O
by	O
local	O
sonographers	O
at	O
a	O
small	O
regional	O
hospital	O
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	O
with	O
complex	O
chd	B-C0152021
identification	B-C0205396
of	O
mineral	B-C0026162
-	O
binding	B-C1145667
peptides	B-C0030956
that	O
discriminate	B-C0205235
between	O
chalcopyrite	B-C0605435
and	O
enargite	B-C0026162
innovative	O
approaches	O
to	O
the	O
separation	B-C0443299
of	O
minerals	B-C0026162
and	O
subsequent	B-C0332282
extraction	B-C0684295
of	O
metals	B-C0025552
are	O
imperative	B-C3898777
owing	O
to	O
the	O
increasing	B-C0442808
mineralogical	B-C0026162
complexity	B-C0439855
of	O
ore	B-C0026162
deposits	I-C0026162
that	O
are	O
difficult	B-C0332218
or	O
even	O
impossible	B-C0243095
to	O
separate	B-C0443299
into	O
slurries	B-C1883043
or	O
solutions	B-C0037633
containing	B-C0332256
only	O
the	O
minerals	B-C0026162
or	O
metals	B-C0025552
of	O
interest	O
.	O
	
low	B-C0205251
recovery	B-C0237820
of	O
metal	B-C0026162
is	O
typical	B-C3538928
for	O
these	O
complex	B-C0439855
deposits	B-C0026162
leading	O
to	O
significant	B-C0750502
losses	B-C1517945
to	O
tailings	B-C0021265
.	O
	
in	B-C0332287
addition	I-C0332287
,	O
the	O
minerals	B-C0026162
often	O
contain	O
impurities	B-C2827365
,	O
some	O
toxic	B-C1407029
,	O
which	O
are	O
difficult	B-C0332218
and	O
costly	B-C0220812
to	O
control	B-C2587213
or	O
manage	O
during	O
the	O
processing	B-C1709694
of	O
a	O
concentrate	B-C4283884
or	O
other	O
mineral	B-C0026162
product	B-C1514468
.	O
	
one	O
example	B-C1707959
of	O
this	O
complex	B-C0439855
situation	O
is	O
the	O
significant	B-C0750502
economic	B-C0013557
and	O
environmental	B-C0014406
costs	B-C0010186
associated	B-C0332281
with	I-C0332281
diluting	B-C1948037
and	O
processing	B-C1709694
copper	B-C0009968
concentrates	B-C4283884
containing	B-C0332256
arsenic	B-C0003818
in	O
the	O
form	O
of	O
the	O
mineral	B-C0026162
enargite	I-C0026162
,	O
cu3	B-C0026162
ass4	I-C0026162
in	O
the	O
production	B-C0033268
of	O
pure	B-C1882508
copper	B-C0009968
.	O
	
to	O
overcome	O
these	O
separation	B-C0443299
problems	B-C0033213
,	O
we	O
have	O
utilized	O
phage	B-C1519025
display	I-C1519025
to	O
identify	B-C0205396
peptides	B-C0030956
that	O
demonstrate	O
selective	B-C0205556
recognition	B-C0205396
of	O
enargite	B-C0026162
and	O
the	O
arsenic	B-C0003818
-	O
free	B-C0332296
copper	B-C0389357
sulfide	I-C0389357
,	O
chalcopyrite	B-C0605435
.	O
	
screening	O
of	O
two	O
random	B-C0439605
peptide	B-C0751719
phage	I-C0751719
display	I-C0751719
libraries	I-C0751719
resulted	O
in	O
the	O
identification	B-C0205396
of	O
an	O
enargite	B-C0026162
-	O
selective	B-C0205556
peptide	B-C0030956
with	O
the	O
sequence	B-C0002518
mhkptvhikgpt	I-C0002518
and	O
a	O
chalcopyrite	B-C0605435
-	O
selective	B-C0205556
peptide	B-C0030956
with	O
the	O
sequence	B-C0002518
rkkkckgnccytpq	I-C0002518
.	O
	
mineral	B-C0026162
-	O
binding	B-C1145667
selectivity	B-C0205556
was	O
demonstrated	O
by	O
binding	B-C1145667
studies	B-C2603343
,	O
zeta	B-C0597697
potential	I-C0597697
determination	B-C1148554
and	O
immunochemistry	B-C0020986
.	O
	
peptides	B-C0030956
that	O
have	O
the	O
ability	B-C1299581
to	O
discriminate	B-C0205235
between	O
enargite	B-C0026162
and	O
chalcopyrite	B-C0605435
provide	O
a	O
greener	O
option	B-C1518601
for	O
the	O
separation	B-C0443299
of	O
arsenic	B-C0003818
containing	B-C0332256
contaminants	B-C2827365
from	O
copper	B-C0009968
concentrates	B-C4283884
.	O
	
this	O
represents	O
the	O
first	O
step	O
towards	O
a	O
major	B-C0205164
advance	B-C3854260
in	O
the	O
replacement	B-C0559956
or	O
reduction	B-C0392756
of	O
toxic	B-C1407029
collectors	B-C1516698
as	O
well	O
as	O
reducing	B-C0392756
the	O
level	B-C0441889
of	O
arsenic	B-C0003818
-	O
bearing	B-C0206243
minerals	B-C0026162
in	O
the	O
early	B-C1279919
stages	B-C1306673
of	O
mineral	B-C0026162
processing	B-C1709694
.	O
	
high-density	B-C0023821
lipoprotein	I-C0023821
-associated	O
sphingosine-1-phosphate	B-C0074992
activity	O
in	O
heterozygous	B-C0342882
familial	I-C0342882
hypercholesterolaemia	I-C0342882
patients	B-C0030705
with	O
heterozygous	B-C0342882
familial	I-C0342882
hypercholesterolaemia	I-C0342882
fh	B-C0342882
suffer	B-C0751408
from	O
high	B-C0858226
plasma	I-C0858226
cholesterol	I-C0858226
and	O
an	O
environment	B-C0014406
of	O
increased	O
oxidative	B-C0242606
stress	I-C0242606
.	O
	
we	O
examined	O
its	O
potential	O
effects	O
on	O
high-density	B-C0023821
lipoprotein	I-C0023821
hdl	B-C0023821
sphingosine-1-phosphate	B-C0074992
s1p	B-C0074992
content	O
hdl	B-C0023821
-	O
s1p	B-C0074992
and	O
hdl	B-C0023821
-mediated	O
protection	B-C3823580
against	I-C3823580
oxidative	I-C3823580
stress	I-C3823580
,	O
both	O
with	O
and	O
without	O
statin	B-C1314135
treatment	I-C1314135
.	O
	
in	O
a	O
case-control	B-C0007328
study	I-C0007328
,	O
hdl	B-C0023821
was	O
isolated	B-C0205409
from	O
12	O
fh	B-C0342882
patients	B-C0030705
with	O
and	O
without	O
statin	B-C1314135
treatment	I-C1314135
and	O
from	O
12	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
the	O
hdl	B-C0023821
-	O
s1p	B-C0074992
content	O
and	O
the	O
capacity	O
of	O
hdl	B-C0023821
to	O
protect	B-C1545588
cardiomyocytes	B-C0225828
against	O
oxidative	B-C0242606
stress	I-C0242606
in	B-C0681828
vitro	I-C0681828
were	O
measured	O
.	O
	
hdl	B-C0023821
-associated	O
s1p	B-C0074992
was	O
significantly	O
correlated	O
with	O
cell	B-C0524828
protection	I-C0524828
,	O
but	O
not	O
with	O
hdl-cholesterol	B-C0023822
or	O
apolipoprotein	B-C0085201
ai	I-C0085201
.	O
	
the	O
latter	O
did	O
not	O
correlate	O
with	O
hdl	B-C0023821
-mediated	O
cell	B-C0524828
protection	I-C0524828
.	O
	
neither	O
the	O
hdl	B-C0023821
-	O
s1p	B-C0074992
content	O
nor	O
hdl	B-C0023821
protective	O
capacity	O
differed	O
between	O
nontreated	O
fh	B-C0342882
patients	B-C0030705
and	O
controls	O
.	O
	
the	O
relative	O
amounts	O
of	O
apolipoprotein	B-C0085201
ai	I-C0085201
and	O
apolipoprotein	B-C1438565
m	I-C1438565
were	O
similar	O
between	O
controls	O
and	O
fh	B-C0342882
patients	B-C0030705
.	O
	
statin	B-C1314135
treatment	I-C1314135
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
measures	O
.	O
	
the	O
fh	B-C0342882
environment	B-C0014406
is	O
not	O
detrimental	O
to	O
hdl	B-C0023821
-	O
s1p	B-C0074992
content	O
or	O
hdl	B-C0023821
-	O
s1p	B-C0074992
-mediated	O
cell	B-C0524828
protection	I-C0524828
.	O
	
statin	B-C1314135
treatment	I-C1314135
does	O
not	O
modulate	O
hdl	B-C0023821
moberg	B-C1293918
picking-up	I-C1293918
test	I-C1293918
in	O
patients	B-C0030705
with	O
hand	B-C0263746
osteoarthritis	I-C0263746
clinical	B-C0947289
measurement	I-C0947289
.	O
	
the	O
moberg	B-C1293918
pick-up	I-C1293918
test	I-C1293918
mput	B-C1293918
was	O
previously	O
used	O
to	O
evaluate	O
functional	B-C3853978
performance	I-C3853978
in	O
patients	B-C0030705
with	O
hand	B-C0018563
inflammatory	B-C1290884
disease	I-C1290884
.	O
	
this	O
is	O
the	O
first	O
study	O
using	O
the	O
mput	B-C1293918
in	O
hand	B-C0263746
osteoarthritis	I-C0263746
oa	B-C0263746
.	O
	
compare	O
the	O
functional	B-C3853978
performance	I-C3853978
mput	B-C1293918
in	O
hand	B-C0263746
oa	I-C0263746
patients	B-C0030705
and	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
fifty	O
hand	B-C0263746
oa	I-C0263746
patients	B-C0030705
and	O
50	O
controls	B-C0009932
were	O
assessed	O
using	O
the	O
mput	B-C1293918
,	O
auscan	B-C3891717
and	O
cochin	B-C0034394
questionnaires	I-C0034394
,	O
grip	B-C0518032
and	O
pinch	B-C1720876
strength	I-C1720876
,	O
pain	B-C0030193
using	O
a	O
visual	B-C0042815
analog	I-C0042815
scale	I-C0042815
and	O
a	O
likert	B-C0451267
scale	I-C0451267
regarding	O
difficulty	O
to	O
perform	O
mput	B-C1293918
.	O
	
in	O
the	O
mput	B-C1293918
evaluation	B-C1261322
,	O
the	O
oa	B-C0263746
group	O
presented	O
a	O
statistically	B-C0237881
significant	I-C0237881
difference	O
from	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
the	O
oa	B-C0263746
group	O
spent	O
more	B-C0205172
time	B-C0040223
executing	O
test	B-C0392366
.	O
	
the	O
grip	B-C0518032
and	O
pinch	B-C1720876
strength	I-C1720876
measurements	I-C1720876
showed	O
higher	O
values	O
for	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
the	O
oa	B-C0263746
group	O
reported	O
a	O
greater	O
difficulty	B-C0332218
than	O
the	O
control	B-C0009932
group	I-C0009932
in	O
performing	O
the	O
test	B-C0392366
.	O
	
the	O
mput	B-C1293918
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	B-C0392366
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	B-C3853978
performance	I-C3853978
of	O
the	O
hand	B-C0263746
oa	I-C0263746
.	O
	
soymilk	B-C3825658
residue	B-C1709915
okara	B-C0960549
as	O
a	O
natural	B-C0205296
immobilization	B-C0205556
carrier	I-C0205556
for	O
lactobacillus	B-C0317608
plantarum	I-C0317608
cells	B-C0007634
enhances	B-C2349975
soymilk	B-C3825658
fermentation	B-C0015852
,	O
glucosidic	B-C0022179
isoflavone	I-C0022179
bioconversion	B-C0439836
,	O
and	O
cell	B-C0007620
survival	I-C0007620
under	O
simulated	B-C1704242
gastric	I-C1704242
and	O
intestinal	B-C0021853
conditions	B-C0348080
cell	B-C0282542
immobilization	I-C0282542
is	O
an	O
alternative	B-C1523987
to	O
microencapsulation	B-C0025974
for	O
the	O
maintenance	O
of	O
cells	B-C0007634
in	O
a	O
liquid	B-C0302908
medium	B-C1705217
.	O
	
however	O
,	O
artificial	B-C2004457
immobilization	B-C0205556
carriers	I-C0205556
are	O
expensive	O
and	O
pose	O
a	O
high	O
safety	B-C0036043
risk	B-C0035647
.	O
	
okara	B-C0960549
,	O
a	O
food-grade	B-C0016452
byproduct	B-C0439861
from	O
soymilk	B-C3825658
production	B-C0033268
,	O
is	O
rich	O
in	O
prebiotics	B-C2717875
.	O
	
lactobacilli	B-C0317608
could	O
provide	O
health	B-C0018684
enhancing	B-C2349975
effects	B-C1280500
to	O
the	O
host	B-C1167395
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
evaluate	O
the	O
potential	O
of	O
okara	B-C0960549
as	O
a	O
natural	O
immobilizer	O
for	O
l	B-C0007634
.	O
	
plantarum	I-C0007634
70810	I-C0007634
cells	I-C0007634
.	O
	
the	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
okara-immobilized	B-C0960549
l	B-C0007634
.	O
	
plantarum	I-C0007634
70810	I-C0007634
cells	I-C0007634
il	B-C0007634
on	O
soymilk	B-C3825658
fermentation	B-C0015852
,	O
glucosidic	B-C0022179
isoflavone	I-C0022179
bioconversion	B-C0439836
,	O
and	O
cell	B-C0007634
resistance	B-C4281815
to	O
simulated	B-C1704242
gastric	I-C1704242
and	O
intestinal	B-C0021853
stresses	B-C0449430
.	O
	
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
sem	B-C0026020
was	O
used	O
to	O
show	O
cells	B-C0007634
adherence	B-C1510802
to	O
the	O
surface	B-C0205148
of	O
okara	B-C0960549
.	O
	
lactic	B-C0064582
acid	I-C0064582
,	O
acetic	B-C0000983
acid	I-C0000983
and	O
isoflavone	B-C0022179
analyses	B-C0936012
in	O
unfermented	O
and	O
fermented	B-C1827145
soymilk	B-C3825658
were	O
performed	B-C0884358
by	O
hplc	B-C0201764
with	I-C0201764
uv	I-C0201764
detection	I-C0201764
.	O
	
viability	B-C0443348
and	O
growth	O
kinetics	O
of	O
immobilized	B-C0282542
and	O
free	B-C0007634
l	I-C0007634
.	O
	
plantarum	I-C0007634
70810	I-C0007634
cells	I-C0007634
fl	B-C0007634
were	O
followed	O
during	O
soymilk	B-C3825658
fermentation	B-C0015852
.	O
	
moreover	O
,	O
changes	B-C0392747
in	O
ph	B-C1304686
,	O
titrable	B-C0368606
acidity	I-C0368606
and	O
viscosity	B-C0042784
were	O
measured	B-C0444706
by	O
conventional	B-C0025663
methods	I-C0025663
.	O
	
for	O
in	B-C1533691
vitro	I-C1533691
testing	B-C0039593
of	O
simulated	O
gastrointestinal	B-C0521362
resistance	B-C4281815
,	O
fermented	B-C1827145
soymilk	B-C3825658
was	O
inoculated	B-C2987620
with	O
fl	B-C0007634
or	O
il	B-C0007634
and	O
an	O
aliquot	B-C1510844
incubated	B-C1439852
into	O
acidic	B-C1705217
mrs	I-C1705217
broth	I-C1705217
which	O
was	O
conveniently	O
prepared	O
to	O
simulate	O
gastric	B-C1704242
,	O
pancreatic	B-C0030296
juices	I-C0030296
and	O
bile	B-C0005404
salts	I-C0005404
.	O
	
survival	O
to	O
simulated	B-C1704242
gastric	I-C1704242
and	O
intestinal	B-C0021853
stresses	B-C0449430
was	O
evaluated	O
by	O
plate	B-C0201253
count	I-C0201253
of	I-C0201253
colony	I-C0201253
forming	I-C0201253
units	I-C0201253
on	O
mrs	B-C1720273
agar	I-C1720273
.	O
	
sem	B-C0026020
revealed	O
that	O
the	O
lactobacilli	B-C0317608
cells	B-C0007634
attached	B-C3714578
and	O
bound	O
to	O
the	O
surface	B-C0205148
of	O
okara	B-C0960549
.	O
	
compared	B-C1707455
with	O
fl	B-C0007634
,	O
il	B-C0007634
exhibited	O
a	O
significantly	O
higher	B-C0205250
specific	B-C0205369
growth	B-C0449249
rate	I-C0449249
,	O
shorter	B-C1806781
lag	B-C0205390
phase	I-C0205390
of	O
growth	B-C0018270
,	O
higher	O
productions	O
of	O
lactic	B-C0064582
and	O
acetic	B-C0000983
acids	I-C0000983
,	O
a	O
faster	B-C0456962
decrease	B-C0547047
in	O
ph	B-C1304686
and	O
increase	B-C0442805
in	O
titrable	B-C0368606
acidity	I-C0368606
,	O
and	O
a	O
higher	B-C0205250
soymilk	B-C3825658
viscosity	B-C0042784
.	O
	
similarly	O
,	O
il	B-C0007634
in	O
soymilk	B-C3825658
showed	O
higher	O
productions	O
of	O
daizein	B-C0022179
and	O
genistein	B-C0061202
compared	B-C1707455
with	O
the	O
control	B-C1550141
.	O
	
compared	B-C1707455
with	O
fl	B-C0007634
,	O
il	B-C0007634
showed	O
reinforced	O
resistance	O
to	O
simulatedgastric	B-C1704242
and	O
intestinal	B-C0021853
stresses	B-C0449430
in	B-C1533691
vitro	I-C1533691
that	O
included	O
low	B-C0728725
ph	I-C0728725
,	O
low	B-C0728725
ph	I-C0728725
plus	I-C0728725
pepsin	B-C0014442
,	O
pancreatin	B-C0030304
,	O
and	O
bile	B-C0005404
salt	I-C0005404
.	O
	
our	O
results	B-C1274040
indicate	O
that	O
okara	B-C0960549
is	O
a	O
new	O
potential	O
immobilization	B-C0205556
carrier	I-C0205556
to	O
enhance	B-C2349975
the	O
growth	B-C0018270
and	O
glucosidic	B-C0022179
isoflavone	I-C0022179
bioconversion	B-C0439836
activities	B-C0441655
of	O
l	B-C0317608
.	O
	
plantarum	I-C0317608
in	O
soymilk	B-C3825658
and	O
improve	B-C0184511
cell	B-C0007620
survivability	I-C0007620
following	O
simulated	B-C1704242
gastric	I-C1704242
and	O
intestinal	B-C0021853
conditions	B-C0348080
.	O
	
comparison	O
of	O
a	O
new	O
visual	B-C0543467
stylet	I-C0543467
discopo	I-C0543467
laryngeal	B-C0396618
mask	I-C0396618
airway	I-C0396618
placement	I-C0396618
vs	O
conventional	B-C0442775
blind	I-C0442775
technique	I-C0442775
a	O
prospective	O
randomized	B-C0034656
study	O
to	O
compare	O
the	O
ease	O
of	O
laryngeal	B-C0396618
mask	I-C0396618
airway	I-C0396618
lma	I-C0396618
insertion	I-C0396618
and	O
fiberoptic	B-C0449911
view	I-C0449911
of	O
lma	B-C0162645
after	O
placement	B-C1524072
using	O
the	O
discopo	B-C0543467
visual	I-C0543467
stylet-guided	I-C0543467
insertion	I-C0543467
and	O
conventional	B-C0442775
blind	I-C0442775
technique	I-C0442775
.	O
	
prospective	O
,	O
randomized	B-C0034656
controlled	B-C0681867
study	I-C0681867
.	O
	
operating	B-C0029064
room	I-C0029064
in	O
a	O
university	B-C0020028
hospital	I-C0020028
.	O
	
one	O
hundred	O
adult	B-C0001675
patients	B-C0030705
scheduled	O
for	O
elective	B-C0206058
surgery	I-C0206058
under	O
lma	B-C0162645
general	B-C0002915
anesthesia	I-C0002915
were	O
enrolled	O
.	O
	
patients	B-C0030705
were	O
randomly	B-C0034656
allocated	O
to	O
2	O
groups	B-C0681860
glma	B-C0681860
group	I-C0681860
using	O
a	O
visual	B-C0543467
stylet-guided	I-C0543467
technique	I-C0543467
n=50	O
and	O
blma	B-C0681860
group	I-C0681860
using	O
standard	O
blind	B-C0442775
technique	I-C0442775
n=50	O
.	O
	
correct	O
placement	B-C1524072
of	O
the	O
lma	B-C0162645
was	O
confirmed	O
using	O
clinical	B-C3173977
test	I-C3173977
along	O
with	O
fiberoptic	B-C1708050
assessment	B-C0220825
.	O
	
unblinded	B-C1511726
data	I-C1511726
were	O
collected	O
about	O
the	O
insertion	B-C0021107
time	O
,	O
the	O
first	O
attempt	O
success	B-C1521828
rate	I-C1521828
,	O
the	O
lma	B-C0162645
position	B-C1550045
adjustment	O
rate	O
,	O
fiberoptic	B-C0449911
view	I-C0449911
of	O
lma	B-C0162645
anatomical	B-C0277809
position	I-C0277809
,	O
hemodynamic	B-C4042806
responses	I-C4042806
,	O
and	O
the	O
adverse	B-C0001688
insertion	B-C0021107
responses	B-C0871261
bucking	B-C0852885
,	O
breathholding	B-C0235744
,	O
and	O
laryngospasm	B-C0920061
.	O
	
blinded	B-C1511726
data	I-C1511726
were	O
recorded	O
about	O
postoperative	B-C0032790
airway	B-C1301933
morbidity	I-C1301933
visible	O
blood	B-C0005835
staining	I-C0005835
on	O
lma	B-C0162645
at	O
removal	O
,	O
sore	B-C0242429
throat	I-C0242429
,	O
and	O
hoarseness	B-C0019825
.	O
	
insertion	B-C0021107
was	O
more	O
frequently	O
successful	O
at	O
the	O
first	O
attempt	O
in	O
glma	B-C0681860
than	O
that	O
in	O
blma	B-C0681860
group	I-C0681860
100%	O
vs	O
92%	O
p=	O
.	O
	
the	O
time	O
taken	O
for	O
establishing	O
effective	O
airway	O
was	O
shorter	O
in	O
glma	B-C0681860
than	O
that	O
in	O
blma	B-C0681860
54.8	O
vs	O
62.9	O
seconds	O
p=	O
.	O
	
the	O
patients	B-C0030705
in	O
blma	B-C0681860
group	I-C0681860
required	O
more	O
readjustment	O
and	O
reinsertion	B-C0021107
than	O
those	O
in	O
glma	B-C0681860
group	I-C0681860
38%	O
vs	O
0%	O
p=	O
.	O
	
the	O
fiberoptic	B-C0449911
view	I-C0449911
was	O
significantly	O
better	O
in	O
glma	B-C0681860
group	I-C0681860
p<	O
.	O
	
no	O
difference	O
between	O
the	O
2	O
groups	B-C0681860
existed	O
regarding	O
hemodynamic	B-C0149784
stress	I-C0149784
responses	I-C0149784
,	O
incidences	B-C0021149
of	O
adverse	B-C0001688
insertion	B-C0021107
responses	O
,	O
and	O
postoperative	B-C0032790
airway	B-C1301933
morbidity	I-C1301933
.	O
	
by	O
direct	O
visualizing	O
the	O
whole	O
process	O
of	O
lma	B-C0162645
insertion	B-C0021107
,	O
the	O
discopo	B-C0543467
visual	I-C0543467
stylet	I-C0543467
increases	O
the	O
success	B-C1521828
rate	I-C1521828
and	O
accuracy	B-C0443131
rate	I-C0443131
of	O
lma	B-C0162645
placement	B-C1524072
without	O
increasing	O
hemodynamic	B-C0149784
stress	I-C0149784
response	I-C0149784
or	O
incidences	B-C0021149
of	O
adverse	B-C0877248
events	I-C0877248
.	O
	
targeting	B-C1521840
brain	B-C0006104
and	O
peripheral	B-C0027880
plasticity	I-C0027880
of	O
the	O
lipidome	B-C0023779
in	O
acute	B-C0205178
kainic	B-C0022471
acid	I-C0022471
-	O
induced	B-C0205263
epileptic	B-C0014544
seizures	I-C0014544
in	O
mice	B-C0025929
via	O
quantitative	B-C3525763
mass	I-C3525763
spectrometry	I-C3525763
epilepsy	B-C0014544
is	O
a	O
highly	O
common	O
chronic	B-C1290882
neurological	I-C1290882
disorder	I-C1290882
,	O
manifested	B-C0205319
in	O
many	O
different	O
types	B-C0332307
,	O
affecting	O
1%	O
of	O
the	O
worldwide	O
human	B-C0086418
population	B-C1257890
.	O
	
the	O
molecular	B-C1148560
mechanisms	I-C1148560
of	O
epileptogenesis	B-C0014544
have	O
not	O
yet	O
been	O
clarified	O
,	O
and	O
pharmacoresistance	B-C2712961
exhibited	O
by	O
30-40%	O
of	O
epilepsy	B-C0014544
patients	B-C0030705
remains	O
a	O
major	O
obstacle	O
in	O
medical	B-C0205476
care	B-C0086388
.	O
	
growing	O
evidence	B-C3887511
indicates	O
a	O
role	O
of	O
lipid	B-C0023779
signalling	B-C0037080
pathways	I-C0037080
in	O
epileptogenesis	B-C0014544
,	O
thus	O
lipid	B-C0023779
signals	B-C0037080
emerge	O
as	O
potential	B-C3245505
biomarkers	B-C0005516
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic	B-C0014544
disorder	I-C0014544
,	O
as	O
well	O
as	O
potential	B-C3245505
therapeutic	B-C1611640
agents	I-C1611640
and	O
targets	B-C1521840
.	O
	
for	O
this	O
purpose	O
,	O
we	O
applied	O
a	O
lipidomic	B-C0023779
strategy	B-C0035171
to	O
unravel	O
lipid	B-C0023779
alterations	O
in	O
brain	B-C1273723
regions	I-C1273723
,	O
periphery	B-C0040300
tissues	I-C0040300
and	O
plasma	B-C0032105
that	O
are	O
specific	B-C0205369
for	O
acute	B-C0205178
epileptic	B-C0014544
seizures	I-C0014544
in	O
mice	B-C0025929
at	O
1h	O
after	O
seizure	B-C0014544
induction	B-C0205263
by	O
systemic	B-C3494163
kainic	B-C0022471
acid	I-C0022471
injection	B-C3494163
as	O
compared	B-C1707455
to	O
vehicle	B-C0009932
controls	I-C0009932
.	O
	
specifically	O
,	O
levels	B-C0441889
of	O
i	O
selected	O
phospholipids	B-C0031676
and	O
sphingomyelins	B-C0037906
,	O
ii	O
the	O
endocannabinoids	B-C1172779
anandamide	B-C0211726
aea	B-C0211726
and	O
2-arachidonoyl	B-C0299477
glycerol	I-C0299477
2-ag	B-C0299477
,	O
and	O
the	O
endocannabinoid	B-C1172779
-related	O
compounds	B-C1706082
oleoylethanolamide	B-C1454896
oea	B-C1454896
and	O
palmitoylethanolamide	B-C0069964
pea	B-C0069964
,	O
iii	O
arachidonic	B-C0003695
acid	I-C0003695
aa	B-C0003695
,	O
iv	O
selected	O
eicosanoids	B-C0013725
,	O
and	O
v	O
fatty	B-C0574031
acyl	I-C0574031
content	O
of	O
lipidome	B-C0023779
were	O
determined	O
in	O
pulverized	B-C3494163
tissues	B-C0459385
from	O
six	O
brain	B-C1273723
regions	I-C1273723
of	O
kainic	B-C0022471
acid	I-C0022471
induced	B-C0205263
epileptic	B-C0014544
seizure	I-C0014544
models	B-C0026336
and	O
vehicle	B-C0009932
controls	I-C0009932
hypothalamus	B-C0020663
,	O
hippocampus	B-C0019564
,	O
thalamus	B-C0039729
,	O
striatum	B-C0010097
,	O
cerebellum	B-C0007765
and	O
cerebral	B-C0007776
cortex	I-C0007776
,	O
and	O
from	O
peripheral	B-C0205100
organs	B-C0178784
,	O
such	O
as	O
heart	B-C0018787
and	O
lungs	B-C0024109
,	O
and	O
in	O
plasma	B-C0032105
.	O
	
alterations	O
in	O
lipid	B-C0023779
levels	O
after	O
acute	B-C0205178
epileptic	B-C0014544
seizures	I-C0014544
as	O
compared	B-C1707455
to	O
non-seizure	B-C0009932
controls	I-C0009932
were	O
found	O
to	O
be	O
brain	B-C1273723
region	I-C1273723
-	O
and	O
periphery	B-C0040300
tissue	I-C0040300
-	O
specific	B-C0205369
,	O
including	O
specific	B-C0205369
plasma	B-C0032105
lipid	B-C0023779
correlates	O
,	O
highlighting	O
their	O
value	O
as	O
marker	B-C0005516
candidates	I-C0005516
in	O
translational	O
research	B-C0681814
studies	I-C0681814
,	O
and/or	O
drug	B-C0920472
discovery	I-C0920472
and	O
response	B-C0085421
monitoring	I-C0085421
.	O
	
panitumumab	B-C0879427
-associated	O
encephalopathy	B-C0085584
after	O
accidental	O
intra-arterial	B-C1561451
application	B-C0185125
through	O
dislocated	B-C0025080
central	I-C0025080
venous	I-C0025080
access	I-C0025080
device	I-C0025080
acute	B-C0205178
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
cns	B-C3714787
toxicity	B-C3160947
and	O
immune	B-C0439662
-related	O
side	B-C0879626
effects	I-C0879626
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	B-C0003250
antibodies	I-C0003250
for	O
cancer	B-C0920425
therapy	I-C0920425
.	O
	
here	O
,	O
we	O
report	O
a	O
patient	B-C0030705
who	O
developed	O
of	O
acute-onset	B-C4014441
encephalopathy	I-C4014441
and	O
coma	B-C0009421
,	O
which	O
began	O
shortly	O
after	O
administration	B-C1621583
of	O
panitumumab	B-C0879427
for	O
the	O
treatment	B-C0087111
of	O
metastatic	B-C0948380
colorectal	I-C0948380
cancer	I-C0948380
.	O
	
echocardiography	B-C0013516
revealed	O
that	O
the	O
drug	B-C0013227
had	O
been	O
infused	O
into	O
the	O
left	B-C0225897
cardiac	I-C0225897
ventricle	I-C0225897
via	O
a	O
dislocated	B-C0025080
central	I-C0025080
venous	I-C0025080
line	I-C0025080
.	O
	
diffusion-weighted	B-C0598801
magnetic	I-C0598801
resonance	I-C0598801
imaging	I-C0598801
disclosed	O
multiple	O
cortical	B-C3149362
hyperintensities	I-C3149362
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	B-C0016733
lobes	I-C0016733
.	O
	
while	O
the	O
neurological	B-C0027765
condition	I-C0027765
improved	O
within	O
a	O
few	O
days	B-C0439228
,	O
the	O
patient	B-C0030705
died	B-C0011065
4	O
weeks	B-C0439230
later	O
.	O
	
it	O
seems	O
likely	O
that	O
the	O
administration	B-C1621583
of	O
the	O
antibody	B-C0003241
via	O
the	O
intra-arterial	B-C1561451
route	I-C1561451
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	B-C0012634
.	O
	
toxic	B-C0149504
encephalopathy	I-C0149504
may	O
be	O
a	O
hitherto	B-C0205156
unrecognized	O
complication	B-C0009566
of	O
panitumumab	B-C0879427
treatment	B-C0087111
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	B-C0030705
developing	O
cns	B-C3714787
symptoms	B-C1457887
undergoing	O
this	O
abundance	B-C2346714
and	O
characterization	B-C1880022
of	O
perfect	O
microsatellites	B-C1519302
on	O
the	O
cattle	B-C0007452
y	B-C0043381
chromosome	I-C0043381
microsatellites	B-C1519302
or	O
simple	B-C1519302
sequence	I-C1519302
repeats	I-C1519302
ssrs	B-C1519302
are	O
found	O
in	O
most	O
organisms	B-C0029235
and	O
play	O
an	O
important	O
role	O
in	O
genomic	B-C1517495
organization	I-C1517495
and	O
function	B-C0314627
.	O
	
to	O
characterize	B-C1880022
the	O
abundance	B-C2346714
of	O
ssrs	B-C1519302
1-6	O
base-pairs	B-C0600436
bp	B-C0600436
on	O
the	O
cattle	B-C0007452
y	B-C0043381
chromsome	I-C0043381
,	O
the	O
relative	O
frequency	B-C0439603
and	O
density	B-C0178587
of	O
perfect	O
or	O
uninterrupted	O
ssrs	B-C1519302
based	O
on	O
the	O
published	O
y	B-C0043381
chromosome	I-C0043381
sequence	B-C0162326
were	O
examined	B-C0332128
.	O
	
a	O
total	O
of	O
17	O
perfect	O
ssrs	B-C1519302
were	O
found	O
,	O
with	O
total	O
length	B-C1444754
of	O
324.78	O
kb	O
,	O
indicating	O
that	O
approximately	O
0.75	O
of	O
the	O
cattle	B-C0007452
y	B-C0043381
chromosome	I-C0043381
sequence	B-C0162326
43.30	O
mb	O
comprises	O
perfect	O
ssrs	B-C1519302
,	O
with	O
an	O
average	O
length	B-C0162326
of	O
18.80	O
bp	B-C0600436
.	O
	
the	O
relative	O
frequency	B-C0439603
and	O
density	B-C0178587
were	O
398.92	O
loci/mb	O
and	O
7500.62	O
bp	B-C0600436
/mb	O
,	O
respectively	O
.	O
	
the	O
proportions	O
of	O
the	O
six	O
classes	O
of	O
perfect	O
ssrs	B-C1519302
were	O
highly	O
variable	O
on	O
the	O
cattle	B-C0007452
y	B-C0043381
chromosome	I-C0043381
.	O
	
mononucleotide	B-C0028630
repeats	I-C0028630
had	O
a	O
total	O
number	O
of	O
8073	O
46.74	O
and	O
an	O
average	O
length	B-C0162326
of	O
15.45	O
bp	B-C0600436
,	O
and	O
were	O
the	O
most	O
abundant	O
ssrs	B-C1519302
class	O
,	O
while	O
the	O
percentages	O
of	O
di-	B-C0282524
,	O
tetra-	B-C0028630
,	O
tri-	B-C0028630
,	O
penta-	B-C0028630
,	O
and	O
hexa-nucleotide	B-C0028630
repeats	I-C0028630
were	O
22.86	O
,	O
11.98	O
,	O
11.58	O
,	O
6.65	O
,	O
and	O
0.19	O
,	O
respectively	O
.	O
	
different	O
classes	O
of	O
ssrs	B-C1519302
varied	O
in	O
their	O
repeat	O
number	O
,	O
with	O
the	O
highest	O
being	O
42	O
for	O
dinucleotides	B-C0028630
.	O
	
results	O
reveal	O
that	O
repeat	O
categories	O
a	B-C0001407
,	O
ac	B-C0004793
,	O
at	B-C0004793
,	O
aac	B-C0004793
,	O
agc	B-C0004793
,	O
gttt	B-C0004793
,	O
cttt	B-C0004793
,	O
attt	B-C0004793
,	O
and	O
aactg	B-C0004793
predominate	O
on	O
the	O
y	B-C0043381
chromosome	I-C0043381
.	O
	
this	O
study	B-C2603343
provides	O
insight	O
into	O
the	O
organization	O
of	O
cattle	B-C0007452
y	B-C0043381
chromosome	I-C0043381
repetitive	O
dna	B-C0012854
,	O
as	O
well	O
as	O
information	O
useful	O
for	O
developing	O
more	O
polymorphic	B-C1882417
cattle	B-C0007452
y-chromosome	B-C0043381
-specific	O
antenatal	B-C2828394
stressful	B-C0038444
life	I-C0038444
events	I-C0038444
and	O
postpartum	B-C0086839
depressive	B-C0086132
symptoms	I-C0086132
in	O
the	O
united	B-C0041703
states	I-C0041703
the	O
role	O
of	O
women's	B-C0043210
socioeconomic	B-C0086996
status	I-C0086996
indices	B-C0918012
at	O
the	O
state	B-C1711201
level	I-C1711201
approximately	O
10%-20%	O
of	O
women	B-C0043210
suffer	B-C0683278
from	O
postpartum	B-C0221074
depression	I-C0221074
ppd	B-C0221074
,	O
important	O
predictors	B-C2698872
of	O
which	O
are	O
antenatal	B-C2828394
stressful	B-C0038444
life	I-C0038444
event	I-C0038444
sle	B-C0038444
experiences	B-C0237609
.	O
	
the	O
association	B-C0439849
between	O
women's	B-C0043210
state-level	B-C1711201
socioeconomic	B-C0086996
status	I-C0086996
ses	B-C0086996
and	O
ppd	B-C0221074
has	O
not	O
been	O
explored	O
.	O
	
this	O
study	B-C0681814
aimed	O
to	O
examine	O
whether	O
the	O
association	B-C0439849
between	O
antenatal	B-C2828394
sle	B-C0038444
and	O
ppd	B-C0221074
symptoms	B-C1457887
was	O
moderated	B-C1881878
by	O
women's	B-C0043210
state-level	B-C1711201
ses	B-C0086996
.	O
	
data	B-C1511726
from	O
the	O
2009-2011	O
pregnancy	B-C0038951
risk	I-C0038951
assessment	I-C0038951
monitoring	I-C0038951
system	I-C0038951
prams	B-C0038951
were	O
used	O
.	O
	
state-level	B-C1711201
women's	B-C0043210
employment	B-C0014003
/	O
earnings	B-C0680989
and	O
social	B-C0728831
/	O
economic	B-C0013557
autonomy	B-C0085862
indices	B-C0918012
were	O
computed	O
from	O
indicators	B-C0021212
published	O
by	O
the	O
institute	B-C1561598
of	I-C1561598
women's	I-C1561598
policy	I-C1561598
research	I-C1561598
iwpr	B-C1561598
.	O
	
multilevel	B-C0681925
multivariable	I-C0681925
logistic	I-C0681925
regression	I-C0681925
analyses	I-C0681925
were	O
performed	O
.	O
	
among	O
91	O
women	B-C0043210
with	O
valid	B-C2349099
responses	B-C0871261
,	O
11.3	O
had	O
ppd	B-C0221074
symptoms	B-C1457887
,	O
prevalence	B-C0220900
ranging	O
from	O
7.1	O
in	O
illinois	B-C0020898
to	O
17.1	O
in	O
arkansas	B-C0003790
.	O
	
women	B-C0043210
who	O
experienced	O
all	O
four	O
stressor	B-C0597530
categories	B-C0683312
,	O
including	O
partner	B-C3887537
related	B-C0445223
,	O
traumatic	B-C0332663
,	O
emotional	B-C0849912
,	O
and	O
financial	B-C0376243
,	O
had	O
the	O
highest	O
odds	B-C0028873
adjusted	B-C0028873
odds	I-C0028873
ratio	I-C0028873
aor	B-C0028873
5.43	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
5.36	O
of	O
ppd	B-C0221074
symptoms	B-C1457887
.	O
	
the	O
odds	B-C0028873
of	O
experiencing	O
ppd	B-C0221074
symptoms	B-C1457887
decreased	B-C0205216
with	O
an	O
increase	B-C0442805
in	O
the	O
state-level	B-C1711201
social	B-C0728831
/	O
economic	B-C0013557
autonomy	B-C0085862
index	B-C0918012
aor	B-C0028873
0.75	O
95%	O
ci	B-C0009667
0.64	O
.	O
	
there	O
was	O
significant	O
cross-level	B-C0205556
interaction	I-C0205556
between	O
number	O
of	O
stressor	B-C0597530
categories	B-C0683312
experienced	O
and	O
state-level	B-C1711201
index	B-C0918012
.	O
	
screening	B-C1305399
for	O
antenatal	B-C2828394
sles	B-C0038444
can	O
help	O
identify	O
women	B-C0043210
at	B-C1444641
risk	I-C1444641
for	O
ppd	B-C0221074
symptoms	B-C1457887
.	O
	
that	O
the	O
odds	B-C0028873
of	O
having	O
ppd	B-C0221074
symptoms	B-C1457887
decreased	B-C0205216
with	O
increasing	B-C0442805
state-level	B-C1711201
social	B-C0728831
/	O
economic	B-C0013557
autonomy	B-C0085862
and	O
women	B-C0043210
residing	O
in	O
states	B-C1301808
with	O
lower	O
indices	B-C0918012
were	O
more	B-C0231204
vulnerable	I-C0231204
to	O
the	O
impacts	O
of	O
antenatal	B-C2828394
stressors	B-C0597530
,	O
could	O
have	O
policy	B-C0814846
implications	I-C0814846
related	O
to	O
improving	O
the	O
ses	B-C0086996
of	O
women	B-C0043210
in	O
these	O
multi-component	B-C0026339
model	I-C0026339
of	O
intramural	B-C0333200
hematoma	I-C0333200
a	O
novel	O
multi-component	B-C0026339
model	I-C0026339
is	O
introduced	O
for	O
studying	B-C2603343
interaction	B-C1704675
between	O
blood	B-C0232338
flow	I-C0232338
and	O
deforming	B-C1562006
aortic	B-C0507851
wall	I-C0507851
with	O
intramural	B-C0333200
hematoma	I-C0333200
imh	B-C0333200
.	O
	
the	O
aortic	B-C0507851
wall	I-C0507851
is	O
simulated	B-C0679083
by	O
a	O
composite	B-C0026339
structure	I-C0026339
submodel	I-C0026339
representing	O
material	B-C0205556
properties	I-C0205556
of	O
the	O
three	O
main	O
wall	B-C0934502
layers	I-C0934502
.	O
	
the	O
imh	B-C0333200
is	O
described	O
by	O
a	O
poroelasticity	B-C0026339
submodel	I-C0026339
which	O
takes	O
into	O
account	O
both	O
the	O
pressure	B-C0001876
inside	O
hematoma	B-C0018944
and	O
its	O
deformation	B-C1562006
.	O
	
the	O
submodel	B-C0026339
of	O
the	O
hematoma	B-C0018944
is	O
fully	O
coupled	O
with	O
the	O
aortic	B-C0026339
submodel	I-C0026339
as	O
well	O
as	O
with	O
the	O
submodel	B-C0026339
of	O
the	O
pulsatile	B-C0034106
blood	I-C0034106
flow	I-C0034106
.	O
	
model	B-C0679083
simulations	I-C0679083
are	O
used	O
to	O
investigate	B-C1292732
the	O
relation	O
between	O
the	O
peak	O
wall	O
stress	O
,	O
hematoma	B-C0018944
thickness	O
and	O
permeability	B-C0031164
in	O
patients	B-C0030705
of	O
different	O
age	B-C0001779
.	O
	
the	O
results	O
indicate	O
that	O
an	O
increase	O
in	O
hematoma	B-C0018944
thickness	O
leads	O
to	O
larger	O
wall	B-C0038435
stress	I-C0038435
,	O
which	O
is	O
in	O
agreement	O
with	O
clinical	B-C1516606
data	I-C1516606
.	O
	
further	O
simulations	B-C0679083
demonstrate	O
that	O
a	O
hematoma	B-C0018944
with	O
smaller	O
permeability	B-C0031164
results	O
in	O
larger	O
wall	B-C0038435
stress	I-C0038435
,	O
suggesting	O
that	O
blood	B-C0005778
coagulation	I-C0005778
in	O
hematoma	B-C0018944
might	O
increase	O
its	O
mechanical	B-C0243095
stability	I-C0243095
.	O
	
this	O
is	O
in	O
agreement	O
with	O
previous	O
experimental	B-C1517586
observations	B-C0302523
of	O
coagulation	B-C0005778
having	O
a	O
beneficial	B-C1280500
effect	I-C1280500
on	O
the	O
condition	O
of	O
a	O
patient	B-C0030705
with	O
the	O
the	O
impact	B-C4049986
of	I-C4049986
diabetes	B-C0011847
on	O
the	O
risk	B-C0035647
of	O
prostate	B-C0376358
cancer	I-C0376358
development	B-C1527148
according	O
to	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
a	O
10-year	O
nationwide	O
cohort	B-C0009247
study	I-C0009247
purpose	O
we	O
examined	O
the	O
association	O
between	O
obesity	B-C0028754
and	O
prostate	B-C0376358
cancer	I-C0376358
both	O
with	O
and	O
without	B-C0332288
diabetic	B-C0011847
patients	B-C0030705
included	O
in	O
the	O
analysis	O
using	O
nationally	O
representative	O
data	B-C1511726
of	O
the	O
korean	B-C1556095
population	I-C1556095
from	O
the	O
national	B-C0027452
health	I-C0027452
insurance	I-C0027452
system	I-C0027452
nhis	B-C0027452
.	O
	
materials	O
and	O
methods	O
of	O
the	O
424	O
participants	B-C0679646
who	O
underwent	O
health	B-C0260135
examinations	I-C0260135
in	O
2002-2008	O
,	O
139	O
men	B-C0025266
40	I-C0025266
years	I-C0025266
old	I-C0025266
and	O
without	B-C0332288
prostate	B-C0376358
cancer	I-C0376358
were	O
followed	O
from	O
the	O
beginning	O
of	O
2002	O
to	O
the	O
end	O
of	O
2012	O
.	O
	
multivariate	B-C0026777
adjusted	I-C0026777
cox	B-C0010235
regression	I-C0010235
analysis	I-C0010235
was	O
conducted	O
to	O
examine	O
the	O
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
and	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
for	O
the	O
association	O
between	O
prostate	B-C0376358
cancer	I-C0376358
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
both	O
with	O
and	O
without	B-C0332288
diabetes	B-C0011847
.	O
	
results	O
the	O
hr	B-C2985465
for	O
prostate	B-C0376358
cancer	I-C0376358
according	O
to	O
the	O
existence	O
of	O
diabetes	B-C0011847
was	O
stratified	B-C0205363
by	O
bmi	B-C1305855
in	O
both	O
age	B-C0001779
-	O
and	O
multivariable-adjusted	B-C0026777
models	I-C0026777
.	O
	
in	O
the	O
population	B-C1257890
without	B-C0332288
diabetes	B-C0011847
,	O
the	O
hr	B-C2985465
for	O
prostate	B-C0376358
cancer	I-C0376358
significantly	B-C0205217
increased	I-C0205217
as	O
bmi	B-C1305855
increased	O
beyond	O
the	O
reference	O
range	O
in	O
a	O
model	B-C0026777
adjusted	I-C0026777
for	I-C0026777
age	I-C0026777
and	I-C0026777
multiple	I-C0026777
variables	I-C0026777
however	O
,	O
the	O
increase	O
in	O
the	O
hr	B-C2985465
was	O
small	O
.	O
	
in	O
the	O
population	B-C1257890
with	O
diabetes	B-C0011847
,	O
the	O
hr	B-C2985465
for	O
prostate	B-C0376358
cancer	I-C0376358
significantly	B-C0205217
increased	I-C0205217
as	O
bmi	B-C1305855
increased	O
from	O
<	O
18.5	O
kg/m	O
to	O
within	O
the	O
reference	O
range	O
18.5	O
to	O
22.9	O
in	O
the	O
multivariable-adjusted	B-C0026777
model	I-C0026777
.	O
	
in	O
addition	O
,	O
a	O
marked	B-C0547047
decrease	I-C0547047
in	O
hr	B-C2985465
in	O
the	O
population	B-C1257890
with	O
bmi	B-C1305855
of	O
<	O
18.5	O
kg/m	O
was	O
seen	O
compared	O
to	O
the	O
reference	O
or	O
higher	O
bmi	B-C1305855
population	B-C1257890
.	O
	
conclusion	O
this	O
population	B-C1257890
-based	O
study	O
shows	O
the	O
evidence	O
of	O
association	O
between	O
obesity	B-C0028754
and	O
development	B-C1527148
of	O
prostate	B-C0376358
cancer	I-C0376358
,	O
and	O
the	O
risk	B-C0332167
increases	I-C0332167
vary	O
according	O
to	O
the	O
change	O
of	O
bmi	B-C1305855
category	O
and	O
the	O
existence	O
of	O
bioinformatic	B-C1140694
analysis	B-C0936012
of	O
codon	B-C0009221
usage	B-C0457083
and	O
phylogenetic	B-C1519069
relationships	I-C1519069
in	O
different	O
genotypes	B-C0017431
of	O
the	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
the	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
hcv	B-C0220847
has	O
six	O
major	O
genotypes	B-C0017431
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
phylogenetically	B-C1519068
investigate	I-C1519068
the	O
differences	O
between	O
the	O
genotypes	B-C0017431
of	O
hcv	B-C0220847
,	O
and	O
to	O
determine	O
the	O
types	O
of	O
amino	B-C0002520
acid	I-C0002520
codon	B-C0009221
usage	B-C0457083
in	O
the	O
structure	B-C2717802
of	I-C2717802
the	I-C2717802
virus	I-C2717802
in	O
order	O
to	O
discover	O
new	O
methods	O
for	O
treatment	B-C0418956
regimes	I-C0418956
.	O
	
the	O
codon	B-C0009221
usage	B-C0457083
of	O
the	O
six	O
genotypes	B-C0017431
of	O
the	O
hcv	B-C0220847
nucleotide	B-C0004793
sequence	I-C0004793
was	O
investigated	B-C1292732
through	O
the	O
online	O
application	O
available	O
on	O
the	O
website	B-C2349146
gene	I-C2349146
infinity	I-C2349146
.	O
	
also	O
,	O
phylogenetic	B-C1519068
analysis	I-C1519068
and	O
the	O
evolutionary	B-C0205556
relationship	I-C0205556
of	O
hcv	B-C0220847
genotypes	B-C0017431
were	O
analyzed	B-C0936012
with	O
mega	B-C0037585
7	I-C0037585
software	I-C0037585
.	O
	
the	O
six	O
genotypes	B-C0017431
of	O
hcv	B-C0220847
were	O
divided	O
into	O
two	O
groups	B-C0441833
based	O
on	O
their	O
codon	B-C0009221
usage	B-C0457083
properties	B-C0871161
.	O
	
in	O
the	O
first	O
group	B-C0441833
,	O
genotypes	B-C0017431
1	I-C0017431
and	I-C0017431
5	I-C0017431
74.02	O
,	O
and	O
in	O
the	O
second	O
group	B-C0441833
,	O
genotypes	B-C0017431
2	I-C0017431
and	I-C0017431
6	I-C0017431
72.43	O
were	O
shown	O
to	O
have	O
the	O
most	O
similarity	B-C2348205
in	O
terms	O
of	O
codon	B-C0009221
usage	B-C0457083
.	O
	
unlike	O
the	O
results	O
with	O
respect	O
to	O
determining	O
the	O
similarity	B-C2348205
of	O
codon	B-C0009221
usage	B-C0457083
,	O
the	O
phylogenetic	B-C1519068
analysis	I-C1519068
showed	O
the	O
closest	O
resemblance	B-C0205556
and	O
correlation	B-C1707520
between	O
genotypes	B-C0017431
1	I-C0017431
and	I-C0017431
4	I-C0017431
.	O
	
the	O
results	O
also	O
showed	O
that	O
hcv	B-C0220847
has	O
a	O
gc	B-C0028630
guanine	B-C0018321
-	O
cytosine	O
abundant	O
genome	O
structure	O
and	O
prefers	O
codons	O
with	O
gc	O
for	O
translation	O
.	O
	
genotypes	O
1	O
and	O
4	O
demonstrated	O
remarkable	O
similarity	O
in	O
terms	O
of	O
genome	O
sequences	O
and	O
proteins	O
,	O
but	O
surprisingly	O
,	O
in	O
terms	O
of	O
the	O
preferred	O
codons	O
for	O
gene	O
expression	O
,	O
they	O
showed	O
the	O
greatest	O
difference	O
.	O
	
more	O
studies	O
are	O
therefore	O
needed	O
to	O
confirm	O
the	O
results	O
and	O
select	O
the	O
best	O
approach	O
for	O
treatment	O
of	O
these	O
genotypes	O
based	O
on	O
their	O
codon	O
usage	O
properties	B-C0871161
chronic	B-C0205191
adiponectin	B-C2675518
deficiency	I-C2675518
leads	O
to	O
alzheimer's	B-C0002395
disease	I-C0002395
-like	O
cognitive	B-C0338656
impairments	I-C0338656
and	O
pathologies	B-C0030664
through	O
ampk	B-C2350345
inactivation	O
and	O
cerebral	B-C0006104
insulin	B-C0021655
resistance	I-C0021655
in	O
aged	B-C0001779
mice	B-C0026809
insulin	B-C0021655
resistance	I-C0021655
is	O
the	O
major	O
pathogenesis	B-C0699748
underlying	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
t2dm	B-C0011860
and	O
these	O
patients	B-C0030705
have	O
doubled	O
risk	B-C0035647
of	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
.	O
	
increasing	O
evidence	O
suggests	O
that	O
insulin	B-C0021655
resistance	I-C0021655
plays	O
an	O
important	O
role	O
in	O
ad	O
pathogenesis	B-C0699748
,	O
possibly	O
due	O
to	O
abnormal	O
gsk3β	B-C0244989
activation	B-C0014429
,	O
causing	O
intra-	B-C0175996
and	O
extracellular	B-C0521119
amyloid-beta	B-C3484390
aβ	B-C3484390
accumulation	O
.	O
	
adiponectin	B-C0389071
apn	B-C0389071
is	O
an	O
adipokine	B-C1955907
with	O
insulin-sensitizing	O
and	O
anti-inflammatory	B-C1515999
effects	I-C1515999
.	O
	
reduced	O
circulatory	O
apn	B-C0389071
level	O
is	O
associated	O
with	O
insulin	B-C0021655
resistance	I-C0021655
and	O
t2dm	B-C0011860
.	O
	
the	O
role	O
of	O
apn	B-C0389071
in	O
ad	B-C0002395
has	O
not	O
been	O
elucidated	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	B-C2675518
deficiency	I-C2675518
would	O
lead	O
to	O
cerebral	O
insulin	O
resistance	O
,	O
cognitive	O
decline	O
and	O
alzheimer's-like	O
pathology	O
in	O
mice	O
.	O
	
to	O
study	O
the	O
role	O
of	O
adiponectin	B-C2675518
in	O
cognitive	O
functions	O
,	O
we	O
employed	O
adiponectin-knockout	O
apn-ko	O
mice	O
and	O
demonstrated	O
chronic	O
apn	O
deficiency	I-C2675518
in	O
their	O
cns	O
.	O
	
behavioral	O
tests	O
were	O
performed	O
to	O
study	O
the	O
cognitions	O
of	O
male	O
apn-ko	O
mice	O
.	O
	
brains	O
and	O
tissue	O
lysates	O
were	O
collected	O
to	O
study	O
the	O
pathophysiological	O
and	O
molecular	O
changes	O
in	O
the	O
brain	O
of	O
apn-ko	O
mice	O
.	O
	
sh-sy5y	O
neuroblastoma	O
cell	O
line	O
was	O
used	O
to	O
study	O
the	O
molecular	O
mechanism	O
upon	O
apn	O
and	O
insulin	O
treatment	O
.	O
	
aged	O
apn	O
-deficient	O
mice	O
displayed	O
spatial	O
memory	O
and	O
learning	O
impairments	O
,	O
fear-conditioned	O
memory	O
deficit	O
as	O
well	O
as	O
anxiety	O
.	O
	
these	O
mice	O
also	O
developed	O
ad	O
pathologies	O
including	O
increased	O
cerebral	B-C0006104
aβ42	O
level	O
,	O
aβ	O
deposition	O
,	O
hyperphosphorylated	O
tau	O
proteins	O
,	O
microgliosis	O
and	O
astrogliosis	O
with	O
increased	O
cerebral	O
il-1β	O
and	O
tnfα	O
levels	O
that	O
associated	O
with	O
increased	O
neuronal	O
apoptosis	O
and	O
reduced	O
synaptic	O
proteins	O
levels	O
,	O
suggesting	O
apn	O
deficiency	O
may	O
lead	O
to	O
neuronal	O
and	O
synaptic	O
loss	O
in	O
the	O
brain	O
.	O
	
ad	O
pathologies	O
-associated	O
apn	O
-	O
ko	O
mice	O
displayed	O
attenuated	O
ampk	O
phosphorylation	O
and	O
impaired	O
insulin	B-C0021655
signaling	O
including	O
decreased	O
akt	O
induction	O
and	O
increased	O
gsk3β	O
activation	O
in	O
the	O
hippocampus	O
and	O
frontal	O
cortex	O
.	O
	
aged	O
apn	O
-ko	O
mice	O
developed	O
hippocampal	O
insulin	O
resistance	I-C0021655
with	O
reduced	O
pakt	O
induction	O
upon	O
intracerebral	O
insulin	O
injection	O
.	O
	
consistently	O
,	O
apn	O
treatment	O
in	O
sh-sy5y	O
cells	O
with	O
insulin	O
resistance	O
and	O
overexpressing	O
aβ	O
induce	O
higher	O
pakt	O
levels	O
through	O
adipor1	O
upon	O
insulin	O
treatment	O
whereas	O
the	O
induction	O
was	O
blocked	O
by	O
compound	O
c	O
,	O
indicating	O
apn	O
can	O
enhance	O
neuronal	O
insulin	O
sensitivity	O
through	O
ampk	O
activation	O
.	O
	
our	O
results	O
indicated	O
that	O
chronic	O
apn	O
deficiency	O
inactivated	O
ampk	O
causing	O
insulin	O
desensitization	O
and	O
elicited	O
ad-like	O
pathogenesis	O
in	O
aged	O
mice	O
which	O
also	O
developed	O
significant	O
cognitive	B-C0338656
impairments	O
and	O
psychiatric	O
symptoms	I-C0233401
can	O
inorganic	B-C0031603
phosphate	I-C0031603
explain	O
sag	B-C1511741
during	O
unfused	B-C0205257
tetanic	B-C0026820
contractions	I-C0026820
of	O
skeletal	B-C0242692
muscle	I-C0242692
we	O
test	O
the	O
hypothesis	B-C1512571
that	O
cytosolic	B-C1383501
inorganic	B-C0031603
phosphate	I-C0031603
pi	B-C0031603
can	O
account	O
for	O
the	O
contraction	B-C0026820
-	O
induced	B-C0205263
reductions	B-C0301630
in	O
twitch	B-C0231530
duration	B-C0449238
which	O
impair	B-C0221099
summation	O
and	O
cause	O
force	B-C0441722
to	O
decline	B-C1511741
sag	B-C1511741
during	O
unfused	B-C0205257
tetanic	B-C0026820
contractions	I-C0026820
of	O
fast-twitch	B-C0242873
muscle	I-C0242873
.	O
	
a	O
five-state	B-C0026336
model	I-C0026336
of	O
crossbridge	B-C2265877
cycling	I-C2265877
was	O
used	O
to	O
simulate	B-C0205173
twitch	B-C0231530
and	O
unfused	B-C0205257
tetanic	B-C0026820
contractions	I-C0026820
.	O
	
as	O
pi	B-C0031603
concentration	B-C1446561
pi	B-C0031603
was	O
increased	B-C0205217
from	O
0	O
to	O
30	O
mmol	O
,	O
twitch	B-C0231530
duration	B-C0449238
decreased	B-C0205216
,	O
with	O
progressive	B-C0205329
reductions	B-C0441610
in	O
sensitivity	B-C0332324
to	O
pi	B-C0031603
as	O
pi	B-C0031603
was	O
increased	B-C0205217
.	O
	
when	O
unfused	B-C0205257
tetani	O
were	O
simulated	B-C0679083
with	O
rising	O
pi	B-C0031603
,	O
sag	B-C1511741
was	O
most	O
pronounced	B-C4288581
when	O
initial	B-C0205265
pi	B-C0031603
was	O
low	B-C0205251
,	O
and	O
when	O
the	O
magnitude	B-C1704240
of	O
pi	B-C0031603
increase	B-C0205217
was	O
large	B-C0549177
.	O
	
fast-twitch	B-C0231530
extensor	B-C0224464
digitorum	I-C0224464
longus	I-C0224464
edl	I-C0224464
muscles	I-C0224464
sag-prone	B-C0205245
,	O
typically	O
low	O
basal	O
pi	B-C0031603
and	O
slow-twitch	B-C0231530
soleus	B-C0242694
muscles	I-C0242694
sag	B-C1511741
-	O
resistant	B-C1514892
,	O
typically	O
high	O
basal	O
pi	B-C0031603
were	O
isolated	B-C0205409
from	O
14	O
female	B-C0086287
c57bl/6	B-C1521751
mice	I-C1521751
.	O
	
muscles	B-C0026845
were	O
sequentially	O
incubated	B-C1439852
in	O
solutions	B-C0037633
containing	O
either	O
glucose	B-C0017725
or	O
pyruvate	B-C0244104
to	O
create	O
typical	B-C3538928
and	O
low	B-C0205251
pi	B-C0031603
environments	B-C0014406
,	O
respectively	O
.	O
	
twitch	B-C0231530
duration	B-C0449238
was	O
greater	O
p	O
<	O
0.05	O
in	O
pyruvate	B-C0244104
than	O
glucose	B-C0017725
in	O
both	O
muscles	B-C0026845
.	O
	
stimuli	B-C0234402
applied	B-C4048755
at	O
intervals	B-C1272706
approximately	O
three	O
times	O
the	O
time	O
to	O
peak	B-C0444505
twitch	B-C0231530
tension	B-C1442730
resulted	O
in	O
sag	B-C1511741
of	O
35.0	O
3.7	O
in	O
glucose	B-C0017725
and	O
50.5	O
1.4	O
in	O
pyruvate	B-C0244104
in	O
the	O
edl	B-C0224464
pyruvate	B-C0244104
>	O
glucose	B-C0017725
p	O
<	O
0.05	O
,	O
and	O
3.9	O
0.3	O
in	O
glucose	B-C0017725
and	O
37.8	O
2.7	O
in	O
pyruvate	B-C0244104
in	O
the	O
soleus	B-C0242694
pyruvate	B-C0244104
>	O
glucose	B-C0017725
p	O
<	O
0.05	O
.	O
	
the	O
influence	O
of	O
pi	B-C0031603
on	O
crossbridge	B-C2265877
cycling	I-C2265877
provides	O
a	O
tenable	B-C0441712
mechanism	I-C0441712
for	O
sag	B-C1511741
.	O
	
moreover	O
,	O
the	O
low	B-C1389277
basal	I-C1389277
pi	B-C0031603
in	O
fast-twitch	B-C0231530
relative	O
to	O
slow-twitch	B-C0231530
muscle	I-C0231530
has	O
promise	O
as	O
an	O
explanation	B-C0681841
for	O
the	O
fiber-type	B-C0242697
dependency	O
of	O
pancreatic	B-C0235974
cancer	I-C0235974
a	O
survival	B-C0038953
analysis	I-C0038953
study	B-C2603343
in	O
oklahoma	B-C0028914
pancreatic	B-C0235974
cancer	I-C0235974
is	O
among	O
the	O
most	O
deadly	B-C0006826
cancers	I-C0006826
.	O
	
risk	B-C0035648
factors	I-C0035648
associated	B-C0332281
with	I-C0332281
the	O
disease	B-C0012634
include	O
age	B-C0001779
,	O
race	B-C0034510
,	O
sex	B-C0079399
,	O
smoking	B-C1519386
status	I-C1519386
,	O
and	O
diabetes	B-C1317301
status	I-C1317301
.	O
	
we	O
conducted	O
a	O
prospective	B-C0033522
analysis	I-C0033522
of	O
risk	B-C0035648
factors	I-C0035648
and	O
length	B-C0023980
of	I-C0023980
survival	I-C0023980
among	O
pancreatic	B-C1516213
cancer	I-C1516213
patients	I-C1516213
living	O
in	O
oklahoma	B-C0028914
between	O
1997	O
and	O
2012	O
n=6	O
.	O
	
kaplan-meier	B-C1720944
survival	I-C1720944
curves	I-C1720944
were	O
created	B-C1706214
followed	O
by	O
the	O
log-rank	B-C0039593
test	I-C0039593
to	O
compare	O
difference	B-C1705242
in	O
the	O
survival	B-C2919552
time	I-C2919552
.	O
	
cox	B-C0033489
proportional	I-C0033489
hazard	I-C0033489
regression	I-C0033489
models	I-C0033489
were	O
used	O
to	O
examine	O
the	O
strength	B-C0205556
of	I-C0205556
association	I-C0205556
through	O
the	O
estimated	B-C0750572
hazard	B-C2985465
ratios	I-C2985465
.	O
	
the	O
median	B-C2986586
survival	I-C2986586
time	I-C2986586
of	O
the	O
cohort	B-C0599755
was	O
three	O
months	B-C0439231
.	O
	
significant	B-C0750502
risk	B-C0035648
factors	I-C0035648
for	O
reduced	B-C0392756
survival	B-C2919552
times	I-C2919552
included	O
age	B-C0001779
,	O
stage	B-C1514952
at	I-C1514952
diagnosis	I-C1514952
,	O
and	O
year	B-C3173168
of	I-C3173168
diagnosis	I-C3173168
.	O
	
results	B-C0456984
are	O
in	O
agreement	O
with	O
previous	O
research	B-C0243095
findings	I-C0243095
.	O
	
there	O
have	O
been	O
small	O
but	O
noteworthy	B-C2986411
improvements	I-C2986411
in	O
survival	B-C2919552
times	I-C2919552
for	O
pancreatic	B-C1516213
cancer	I-C1516213
patients	I-C1516213
in	O
oklahoma	B-C0028914
.	O
	
length	B-C0023980
of	I-C0023980
survival	I-C0023980
during	O
the	O
study	B-C2347804
period	I-C2347804
was	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
known	O
risk	B-C0035648
factors	I-C0035648
such	O
as	O
age	B-C0001779
and	O
stage	B-C1514952
of	I-C1514952
diagnosis	I-C1514952
.	O
	
biochemical	B-C0205474
and	O
proteomic	B-C0872252
analyses	B-C0936012
of	O
the	O
physiological	B-C0542478
response	I-C0542478
induced	O
by	O
individual	O
housing	B-C0020057
in	O
gilts	B-C0039005
provide	O
new	O
potential	B-C3245505
stress	B-C0449430
markers	B-C0005516
the	O
objective	B-C1571702
assessment	B-C0220825
of	O
animal	B-C0003062
stress	B-C0449430
and	O
welfare	O
requires	O
proper	O
laboratory	B-C0022877
biomarkers	B-C0005516
.	O
	
in	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	B-C0229671
composition	B-C0486616
in	O
gilts	B-C0039005
after	O
switching	O
their	O
housing	B-C0020057
,	O
from	O
pen	O
to	O
individual	O
stalls	B-C0020057
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	B-C0003062
discomfort	B-C2364135
.	O
	
blood	B-C0005767
and	O
saliva	B-C0438730
samples	I-C0438730
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	B-C0020057
system	O
.	O
	
biochemical	B-C0205474
analyses	B-C0936012
showed	O
adaptive	B-C0231193
changes	O
in	O
lipid	B-C0023779
and	O
protein	B-C0597299
metabolism	I-C0597299
after	O
the	O
housing	B-C0020057
switch	O
,	O
whereas	O
cortisol	B-C0020268
and	O
muscular	B-C0026845
markers	B-C0005516
showed	O
a	O
large	O
variability	B-C2827666
between	O
animals	B-C0003062
.	O
	
2d-dige	B-C2936240
and	O
itraq	B-C0282574
proteomic	B-C0872252
approaches	B-C0039152
revealed	O
variations	O
in	O
serum	B-C0036825
protein	I-C0036825
composition	B-C0486616
after	O
changing	O
housing	B-C0020057
and	O
diet	O
of	O
gilts	B-C0039005
.	O
	
both	O
techniques	B-C0449851
showed	O
alterations	B-C1515926
in	O
two	O
main	O
homeostatic	B-C1561987
mechanisms	I-C1561987
the	O
innate	B-C0020969
immune	I-C0020969
and	O
redox	B-C0030012
systems	O
.	O
	
the	O
acute	B-C0001347
phase	I-C0001347
proteins	I-C0001347
haptoglobin	B-C0018595
,	O
apolipoprotein	B-C0085201
a-i	I-C0085201
and	O
α1-antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	B-C0003402
enzyme	O
peroxiredoxin	B-C1137156
2	I-C1137156
were	O
found	O
differentially	O
expressed	O
by	O
2d-dige	B-C2936240
.	O
	
other	O
proteins	B-C0033684
related	O
to	O
the	O
innate	B-C0020969
immune	I-C0020969
system	I-C0020969
,	O
including	O
lactotransferrin	B-C0022942
,	O
protegrin	B-C0300261
3	I-C0300261
and	O
galectin	B-C0252527
1	I-C0252527
were	O
also	O
identified	O
by	O
itraq	B-C0282574
,	O
as	O
well	O
as	O
oxidative	B-C0242606
stress	I-C0242606
enzymes	B-C0014442
such	O
as	O
peroxiredoxin	B-C1137156
2	I-C1137156
and	O
glutathione	B-C1436542
peroxidase	I-C1436542
3	I-C1436542
.	O
	
proteomics	B-C0872252
also	O
revealed	O
the	O
decrease	B-C0392756
of	O
apolipoproteins	B-C0003591
,	O
and	O
the	O
presence	O
of	O
intracellular	B-C0178719
proteins	B-C0033684
in	O
serum	B-C0229671
,	O
which	O
may	O
indicate	O
physical	B-C1328749
injury	I-C1328749
to	O
tissues	B-C0040300
.	O
	
housing	B-C0020057
of	O
gilts	B-C0039005
in	O
individual	O
stalls	B-C0020057
and	O
diet	O
change	O
increase	O
lipid	B-C0023779
and	O
protein	B-C0597297
catabolism	I-C0597297
,	O
oxidative	B-C0242606
stress	I-C0242606
,	O
activate	O
the	O
innate	B-C0020969
immune	I-C0020969
system	I-C0020969
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	B-C0010957
damage	I-C0010957
.	O
	
we	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-C4076401
assessment	I-C4076401
in	O
gilts	B-C0039005
may	O
be	O
based	O
on	O
a	O
score	B-C0449820
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	B-C0023779
metabolites	B-C0870883
,	O
innate	B-C0020969
immunity	I-C0020969
and	O
oxidative	B-C0242606
stress	I-C0242606
markers	B-C0005516
and	O
intracellular	B-C0178719
proteins	B-C0033684
.	O
	
cultivation	B-C1511556
of	O
four	O
microalgae	B-C2936330
species	B-C1705920
in	O
the	O
effluent	B-C1550144
of	O
anaerobic	B-C3856828
digester	I-C3856828
for	O
biodiesel	B-C2717894
production	B-C0033268
this	O
study	B-C2603343
investigated	B-C1292732
if	O
an	O
effluent	B-C1550144
from	O
anaerobic	B-C3856828
digestion	I-C3856828
ad	I-C3856828
system	I-C3856828
can	O
be	O
used	B-C1524063
as	O
a	O
nutrients	B-C0678695
source	B-C0449416
for	O
the	O
microalgae	B-C2936330
cultivation	B-C1511556
,	O
and	O
in	O
so	O
doing	O
,	O
if	O
the	O
effluent	B-C1550144
can	O
be	O
properly	O
treated	B-C1522326
.	O
	
nitrogen	B-C0028158
and	O
phosphorus	B-C0031705
in	O
the	O
ad	B-C3856828
effluent	O
well	O
supported	O
microalgal	O
growth	O
,	O
and	O
their	O
removal	O
efficiency	O
reached	O
>97	O
and	O
99.2	O
,	O
respectively	O
.	O
	
among	O
four	O
different	O
algal	O
species	O
tested	O
,	O
micractinium	O
inermum	O
particularly	O
stood	O
out	O
,	O
showing	O
the	O
highest	O
biomass	O
and	O
fame	O
productivity	O
0.16gl	O
with	O
3.23gl	O
of	O
dry	O
cell	O
weight	O
,	O
and	O
0.04gl	O
with	O
27.54	O
w/w	O
of	O
fame	O
contents	O
,	O
respectively	O
.	O
	
as	O
the	O
concentrations	O
of	O
the	O
nutrients	O
decreased	O
over	O
time	O
,	O
the	O
fame	O
contents	O
were	O
increased	O
and	O
its	O
quality	O
as	O
well	O
,	O
satisfying	O
several	O
biodiesel	O
quality	O
standards	O
.	O
	
this	O
study	O
supports	O
that	O
the	O
ad	B-C3856828
effluent	B-C1550144
can	O
indeed	O
serve	O
as	O
a	O
cheap	O
and	O
nutrient	O
-	O
rich	O
medium	O
for	O
microalgae	O
cultivation	O
,	O
and	O
equally	O
importantly	O
,	O
microalgae	O
can	O
be	O
a	O
workable	O
treatment	O
option	O
for	O
antiviral	B-C0243095
activities	I-C0243095
of	O
selected	O
antimalarials	B-C0003374
against	B-C0521124
dengue	B-C0318759
virus	I-C0318759
type	I-C0318759
2	I-C0318759
and	O
zika	B-C0318793
virus	I-C0318793
in	O
a	O
previous	B-C0205156
study	B-C2603343
,	O
twelve	O
antimalarial	B-C0003374
compounds	I-C0003374
,	O
amodiaquine	B-C0002641
aq	B-C0002641
and	O
derivatives	B-C0243072
,	O
were	O
shown	O
to	O
have	O
potent	B-C1704419
anti-dengue	B-C0243095
viral	I-C0243095
denv	I-C0243095
activity	I-C0243095
by	O
using	O
the	O
stable	B-C0205360
denv2	B-C0318759
renilla	B-C1450145
luciferase	I-C1450145
reporter	B-C0206414
replicon	B-C0035142
expressing	B-C0017262
bhk-21	B-C0007634
cells	I-C0007634
,	O
infectivity	B-C0030657
plaque	B-C0032102
,	O
and	O
the	O
qrt-pcr	B-C1514628
assays	I-C1514628
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
performed	B-C0884358
molecular	B-C0600115
modeling	I-C0600115
on	O
these	O
compounds	B-C1254351
to	O
determine	O
their	O
stereo-electronic	B-C0205556
properties	I-C0205556
required	O
for	O
optimal	B-C2698651
antiviral	B-C0243095
activity	I-C0243095
.	O
	
based	O
on	O
the	O
similarity	B-C2348205
of	O
calculated	O
stereo-electronic	B-C0205556
profiles	I-C0205556
,	O
specifically	O
the	O
electrostatic	B-C0596484
potential	I-C0596484
profiles	I-C0596484
of	O
the	O
compounds	B-C1254351
,	O
and	O
in	B-C0178605
silico	I-C0178605
screening	I-C0178605
of	O
related	O
compounds	B-C1254351
from	O
literature	B-C0023866
,	O
we	O
identified	B-C0205396
three	O
additional	B-C1524062
compounds	B-C1254351
,	O
quinacrine	B-C0034403
qc	B-C0034403
,	O
mefloquine	B-C0025153
mq	B-C0025153
,	O
and	O
gsk369796	B-C3884469
.	O
	
analysis	O
of	O
their	O
antiviral	B-C0243095
activities	I-C0243095
indicated	O
that	O
all	O
three	B-C1254351
compounds	I-C1254351
have	O
high	B-C0205250
anti-denv	B-C0243095
activity	I-C0243095
in	O
the	O
denv2	B-C0318759
replicon	B-C0035142
expressing	B-C0017262
cells	B-C0007634
with	O
ec50	B-C0392762
values	I-C0392762
of	O
5.30	O
1.31	O
μm	O
qc	B-C0034403
,	O
3.22	O
0.37	O
μm	O
mq	B-C0025153
,	O
and	O
5.06	O
0.86	O
μm	O
gsk369796	B-C3884469
.	O
	
the	O
infectivity	B-C0032102
assays	I-C0032102
revealed	B-C0443289
the	O
ec50	B-C0392762
values	I-C0392762
of	O
7.09	O
1.67	O
μm	O
qc	B-C0034403
,	O
4.36	O
0.31	O
μm	O
mq	B-C0025153
and	O
3.03	O
0.35	O
μm	O
gsk369796	B-C3884469
.	O
	
the	O
mode	B-C1524059
of	I-C1524059
action	I-C1524059
of	O
these	O
compounds	B-C1254351
is	O
through	B-C0332273
inhibition	B-C3463820
of	O
autophagy	B-C0004391
,	O
thereby	O
affecting	B-C0392760
denv2	B-C0318759
replication	B-C0042774
.	O
	
moreover	O
,	O
these	O
compounds	B-C1254351
also	O
showed	O
antiviral	B-C0243095
activity	I-C0243095
against	B-C0521124
the	O
rapidly	O
emerging	O
zika	B-C0318793
virus	I-C0318793
zikv	B-C0318793
with	O
ec50	B-C0392762
values	I-C0392762
of	O
2.27	O
0.14	O
μm	O
qc	B-C0034403
,	O
3.95	O
0.21	O
μm	O
mq	B-C0025153
,	O
and	O
2.57	O
0.09	O
μm	O
1	O
in	O
100	O
babies	B-C0021270
the	O
fetal	B-C2985290
alcohol	I-C2985290
spectrum	I-C2985290
disorder	I-C2985290
pathway	B-C1705987
alcohol	B-C0001967
consumed	B-C0001948
during	O
pregnancy	B-C0032961
is	O
the	O
nation's	B-C0683734
leading	O
preventable	B-C2700409
cause	B-C0015127
of	O
developmental	B-C0008073
disabilities	I-C0008073
and	O
birth	B-C0220810
defects	I-C0220810
.	O
	
one	O
in	O
100	O
babies	B-C0021270
is	O
estimated	O
to	O
be	O
born	B-C0005615
with	O
alcohol-related	B-C3146244
damage	I-C3146244
,	O
according	O
to	O
the	O
world	B-C0043237
health	I-C0043237
organization	I-C0043237
.	O
	
fetal	B-C2985290
alcohol	I-C2985290
spectrum	I-C2985290
disorders	I-C2985290
fasds	B-C2985290
are	O
more	O
common	O
than	O
autism	B-C0004352
but	O
are	O
under-	O
genotyping	B-C1285573
of	O
german	B-C1556085
and	O
austrian	B-C0337795
taylorella	B-C0318205
equigenitalis	I-C0318205
isolates	B-C1764827
using	O
repetitive	B-C0032520
extragenic	I-C0032520
palindromic	I-C0032520
rep	I-C0032520
pcr	I-C0032520
and	O
pulsed-field	B-C0085117
gel	I-C0085117
electrophoresis	I-C0085117
pfge	B-C0085117
a	O
total	B-C0439810
of	O
124	O
taylorella	B-C0318205
t	I-C0318205
equigenitalis	I-C0318205
and	O
five	O
t	B-C1036797
.	O
	
asinigenitalis	I-C1036797
field	B-C1521738
isolates	B-C1764827
collected	B-C1516698
between	O
2002	O
and	O
2014	O
were	O
available	B-C0470187
for	O
genotyping	B-C1285573
using	O
rep-	B-C0032520
repetitive	I-C0032520
extragenic	I-C0032520
palindromic	I-C0032520
pcr	I-C0032520
and	O
pfge	B-C0085117
pulsed-field	B-C0085117
gel	I-C0085117
electrophoresis	I-C0085117
.	O
	
the	O
study	B-C2603343
comprised	O
79	O
t	B-C0318205
.	O
	
equigenitalis	I-C0318205
field	B-C1521738
isolates	B-C1764827
originating	O
from	O
ten	O
defined	O
breeds	B-C0006159
of	O
german	B-C0019944
horses	I-C0019944
and	O
revealed	B-C0443289
a	O
spectrum	B-C2827424
of	O
five	O
rep	B-C0004793
rep-e1-e4	B-C0017431
,	O
rep-e3a	B-C0017431
and	O
15	O
pfge	B-C0085117
te-a1-a9	B-C0017431
,	O
te-b1-b3	B-C0017431
,	O
te-c	B-C0017431
,	O
te-e1	B-C0017431
,	O
and	O
te-e2	B-C0017431
genotypes	B-C0017431
.	O
	
t	B-C0318205
.	O
	
equigenitalis	I-C0318205
field	B-C1521738
isolates	B-C1764827
n=40	O
obtained	B-C1301820
from	O
austrian	B-C0324170
lipizzaner	I-C0324170
horses	I-C0324170
were	O
differentiated	B-C0205556
into	O
three	O
rep	B-C0004793
rep-e1	B-C0017431
,	O
rep-e3a	B-C0017431
,	O
and	O
rep-e4	B-C0017431
and	O
three	O
pfge	B-C0085117
genotypes	B-C0017431
te-a2	B-C0017431
,	O
te-a5	B-C0017431
,	O
and	O
te-d	B-C0017431
those	O
isolated	B-C0205409
from	O
four	O
austrian	B-C0019944
trotters	I-C0019944
belonged	O
to	O
the	O
rep	B-C0004793
/	O
pfge	B-C0085117
genotype	B-C0017431
rep-e2/te-a1	B-C0017431
.	O
	
interestingly	O
,	O
a	O
t	B-C0318205
.	O
	
equigenitalis	I-C0318205
isolate	B-C1764827
recovered	B-C0521108
from	I-C0521108
a	O
holsteiner	B-C0019944
stallion	I-C0019944
living	B-C0376558
in	O
south	B-C0037712
africa	I-C0037712
revealed	B-C0443289
the	O
rep	B-C0004793
/	O
pfge	B-C0085117
genotype	B-C0017431
rep-e1/te-a5	B-C0017431
which	O
was	O
otherwise	O
exclusively	B-C1548966
present	B-C0150312
in	O
the	O
majority	B-C0680220
of	O
austrian	B-C0324170
lipizzaner	I-C0324170
horses	I-C0324170
in	O
our	O
study	B-C2603343
.	O
	
the	O
type	O
strain	B-C1518614
included	O
in	O
this	O
study	B-C2603343
revealed	B-C0443289
the	O
genotype	B-C0017431
rep	B-C0004793
/	O
pfge	B-C0085117
rep-e1/te-f	B-C0017431
.	O
	
six	O
strains	B-C1518614
of	O
t	B-C1036797
.	O
	
asinigenitalis	I-C1036797
including	O
the	O
type	O
strain	B-C1518614
were	O
separated	B-C0443299
into	O
three	O
rep	B-C0004793
rep-a1-a3	B-C0017431
and	O
six	O
pfge	B-C0085117
genotypes	B-C0017431
ta-a1	B-C0017431
,	O
ta-a2	B-C0017431
,	O
ta-a3	B-C0017431
,	O
ta-b	B-C0017431
,	O
ta-c	B-C0017431
,	O
ta-d	B-C0017431
.	O
	
overall	B-C1561607
,	O
the	O
generated	B-C3146294
rep	B-C0004793
and	O
pfge	B-C0085117
genotypes	B-C0017431
showed	O
a	O
good	B-C0205170
correlation	B-C1707520
,	O
whereas	O
rep-pcr	B-C0032520
proved	O
to	O
be	O
a	O
suitable	B-C0871511
method	I-C0871511
for	O
molecular	B-C1294203
epidemiological	I-C1294203
screening	I-C1294203
of	O
t	B-C0318205
.	O
	
equigenitalis	I-C0318205
and	O
t	B-C1036797
.	O
	
asinigenitalis	I-C1036797
isolates	B-C1764827
that	O
should	O
be	O
differentiated	B-C0205556
in	O
detail	B-C1522508
by	O
genotyping	B-C1285573
using	O
the	O
urokinase	B-C0042071
/	O
urokinase	B-C0071216
receptor	I-C0071216
system	O
in	O
mast	B-C0024880
cells	I-C0024880
effects	B-C1280500
of	O
its	O
functional	B-C0205245
interaction	B-C1704675
with	O
fmlf	B-C0597357
receptors	I-C0597357
mast	B-C0024880
cell	I-C0024880
and	O
basophils	B-C0004827
express	B-C0597360
the	O
high	B-C0597357
affinity	I-C0597357
receptor	I-C0597357
for	O
ige	B-C0020846
fcɛri	B-C0020846
and	O
are	O
primary	B-C0312740
effector	I-C0312740
cells	I-C0312740
of	O
allergic	B-C0020517
disorders	I-C0020517
.	O
	
the	O
urokinase	B-C0042071
upa	B-C0042071
plasminogen	B-C1622667
activation	I-C1622667
system	I-C1622667
is	O
involved	O
in	O
physiological	B-C0031845
and	O
pathological	B-C0030660
events	I-C0030660
based	O
on	O
cell	B-C1622501
migration	I-C1622501
and	O
tissue	B-C1254358
remodelling	I-C1254358
,	O
such	O
as	O
inflammation	B-C0021368
,	O
wound	B-C0043240
healing	I-C0043240
,	O
angiogenesis	B-C0302600
and	O
metastasis	B-C4255448
.	O
	
upa	B-C0042071
is	O
a	O
serine	B-C2717971
protease	I-C2717971
that	O
binds	O
upar	B-C0071216
,	O
a	O
high	B-C0119748
affinity	I-C0119748
glycosyl-phosphatidyl-inositol	I-C0119748
gpi	I-C0119748
receptor	B-C0597357
.	O
	
upar	B-C0071216
focuses	O
upa	B-C0042071
activity	B-C0243102
at	O
the	O
cell	B-C0699040
surface	I-C0699040
and	O
activates	B-C3822614
intracellular	I-C3822614
signaling	I-C3822614
through	O
lateral	O
interactions	B-C1704675
with	O
integrins	B-C0021701
,	O
receptor	B-C0206364
tyrosine	I-C0206364
kinases	I-C0206364
and	O
the	O
g-protein-coupled	B-C0872043
family	I-C0872043
of	O
fmlf	B-C0597357
chemotaxis	I-C0597357
receptors	I-C0597357
fprs	B-C0597357
.	O
	
we	O
investigated	B-C1292732
the	O
expression	B-C1171362
of	O
the	O
upa	B-C0042071
-	O
upar	B-C0071216
system	O
and	O
its	O
functional	B-C0205245
interaction	B-C1704675
with	O
fprs	B-C0597357
in	O
human	B-C0086418
mast	B-C0024880
cells	I-C0024880
mcs	B-C0024880
.	O
	
differently	O
from	O
basophils	B-C0004827
,	O
mcs	B-C0024880
produced	O
upa	B-C0042071
that	O
was	O
able	O
to	O
induce	O
their	O
chemotaxis	B-C0008018
.	O
	
indeed	O
,	O
mcs	B-C0024880
also	O
expressed	O
upar	B-C0071216
,	O
both	O
in	O
the	O
intact	O
and	O
in	O
a	O
cleaved	O
form	O
dii-diii-upar	B-C0071216
that	O
can	O
expose	O
,	O
at	O
the	O
n-terminus	O
,	O
the	O
srsry	B-C0002518
sequence	I-C0002518
,	O
able	O
to	O
interact	O
with	O
fprs	B-C0597357
and	O
to	O
mediate	O
cell	B-C2610454
chemotaxis	I-C2610454
.	O
	
mcs	B-C0024880
also	O
expressed	O
mrnas	B-C0035696
for	O
fprs	B-C0597357
that	O
were	O
functionally	O
active	O
indeed	O
,	O
upa	B-C0042071
and	O
a	O
soluble	B-C0030956
peptide	I-C0030956
upar84-95	B-C0071216
,	O
containing	O
the	O
srsry	B-C0002518
chemotactic	I-C0002518
sequence	I-C0002518
of	O
upar	B-C0071216
and	O
able	O
to	O
interact	O
with	O
fprs	B-C0597357
,	O
were	O
able	O
to	O
induce	O
mcs	B-C0024880
chemotaxis	B-C0008018
.	O
	
thus	O
,	O
upa	B-C0042071
is	O
a	O
potent	O
chemoattractant	B-C0008013
for	O
mcs	B-C0024880
acting	O
through	O
the	O
exposure	B-C0332157
of	O
the	O
chemotactic	B-C0008018
epitope	B-C0003316
of	O
upar	B-C0071216
,	O
that	O
is	O
an	O
endogenous	B-C0205227
ligand	B-C0023688
for	O
fprs	B-C0597357
.	O
	
the	O
same	O
mechanism	B-C0441712
could	O
be	O
involved	O
in	O
vegf-a	B-C0078058
secretion	B-C0036536
by	O
human	B-C0086418
mcs	B-C0024880
,	O
also	O
induced	B-C0205263
by	O
upa	B-C0042071
and	O
upar84-95	B-C0071216
stimulation	B-C1148560
.	O
	
psychogenic	B-C1142430
non-epileptic	I-C1142430
seizure	I-C1142430
in	O
patients	B-C0030705
with	O
intellectual	B-C3714756
disability	I-C3714756
with	O
special	O
focus	O
on	O
choice	B-C1707391
of	O
therapeutic	B-C0808232
intervention	I-C0808232
there	O
have	O
been	O
a	O
number	O
of	O
studies	B-C2603343
exploring	O
treatments	B-C0087111
for	O
psychogenic	B-C1142430
non-epileptic	I-C1142430
seizure	I-C1142430
pnes	B-C1142430
but	O
largely	O
neglecting	B-C0243095
the	O
sizable	O
subgroup	B-C1515021
of	O
patients	B-C0030705
with	O
intellectual	B-C3714756
disability	I-C3714756
id	B-C3714756
.	O
	
in	O
the	O
present	B-C0521116
study	B-C2603343
,	O
we	O
attempted	B-C1516084
to	O
demonstrate	B-C0205319
effects	B-C1704420
and	O
preferred	B-C0558295
modes	O
of	O
therapeutic	B-C0808232
intervention	I-C0808232
in	O
pnes	B-C1142430
patients	B-C0030705
with	O
id	B-C3714756
being	O
treated	B-C1522326
at	O
a	O
japanese	B-C1708333
municipal	I-C1708333
center	I-C1708333
with	O
a	O
short	B-C1806781
referral	B-C0034927
chain	I-C0034927
.	O
	
we	O
examined	B-C0332128
46	O
pnes	B-C1142430
patients	B-C0030705
with	O
id	B-C3714756
id	B-C3714756
group	B-C0441833
and	O
106	O
pnes	B-C1142430
patients	B-C0030705
without	O
id	B-C3714756
non-id	B-C0243095
group	B-C0441833
retrospectively	B-C1514923
in	O
case	B-C3842891
charts	I-C3842891
.	O
	
in	B-C0332287
addition	I-C0332287
to	I-C0332287
examining	B-C0332128
basic	O
demographic	B-C0011298
and	O
clinical	B-C1516606
data	I-C1516606
,	O
effects	B-C1704420
of	I-C1704420
different	B-C1705242
therapeutic	B-C0808232
intervention	I-C0808232
were	O
examined	B-C0332128
as	O
a	O
function	B-C0542341
of	O
decrease	B-C0547047
or	O
disappearance	B-C2746065
of	O
pnes	B-C1142430
attacks	O
in	O
the	O
id	B-C3714756
group	B-C0441833
.	O
	
age	B-C0001779
at	O
the	O
first	O
visit	B-C1512346
as	O
well	O
as	O
pnes	B-C1142430
onset	B-C0332162
was	O
younger	B-C0332239
in	O
the	O
id	B-C3714756
than	O
in	O
the	O
non-id	B-C0243095
group	B-C0441833
t=2	O
,	O
p=0	O
t=3	O
,	O
p=0	O
,	O
respectively	O
.	O
	
pnes	B-C1142430
-free	O
ratio	B-C0456603
at	O
the	O
last	O
visit	B-C1512346
tended	O
to	O
be	O
higher	B-C0205250
in	O
the	O
non-id	B-C0243095
group	B-C0441833
chi	O
square	O
=3	O
p=0	O
.	O
	
psychosis	O
was	O
more	O
often	O
encountered	O
in	O
the	O
id	O
group	B-C0441833
chi	B-C1552646
square	I-C1552646
=13	O
p=0	O
.	O
	
although	O
cognitive	O
therapy	O
and	O
pharmaco-therapeutic	O
approaches	O
were	O
quite	O
similarly	O
distributed	O
in	O
both	O
groups	O
,	O
environmental	O
adjustment	O
was	O
often	O
introduced	O
in	O
the	O
id	O
group	O
44%	O
as	O
compared	O
to	O
the	O
non-id	O
group	O
15%	O
chi	O
square	O
=14	O
p=0	O
.	O
	
brief	O
weekly	O
visit	O
service	O
is	O
also	O
more	O
often	O
utilized	O
by	O
the	O
patients	O
with	O
id	O
54%	O
than	O
by	O
those	O
without	O
id	O
35%	O
chi	O
square	O
=5	O
,	O
p=0	O
.	O
	
optimal	O
treatment	O
approaches	O
in	O
this	O
sizable	O
patient	O
subgroup	O
should	O
be	O
the	O
subject	O
of	O
future	O
prospective	O
studies	I-C0033522
effect	B-C1704420
of	I-C1704420
an	O
immunomodulatory	B-C1963758
regimen	I-C1963758
for	O
cancer	B-C0281206
prevention	I-C0281206
a	O
case	B-C0085973
report	I-C0085973
in	O
the	O
present	B-C0150312
case	B-C0085973
study	I-C0085973
,	O
an	O
immunomodulatory	B-C1963758
regimen	I-C1963758
for	O
cancer	B-C0281206
prevention	I-C0281206
is	O
reported	B-C0700287
.	O
	
a	O
patient	B-C0030705
with	O
an	O
abnormally	B-C1299351
high	I-C1299351
level	B-C0441889
of	O
the	O
tumor	B-C0041365
markers	I-C0041365
,	O
carbohydrate	B-C0248054
antigen-724	I-C0248054
ca724	B-C0248054
,	O
ca19-9	B-C0006613
and	O
carcinoembryonic	B-C0007082
antigen	I-C0007082
cea	B-C0007082
,	O
although	O
without	B-C0332288
any	O
detectable	B-C3830527
tumor	B-C0027651
,	O
was	O
treated	B-C0332293
with	I-C0332293
an	O
immunomodulatory	B-C1963758
therapy	I-C1963758
featuring	O
an	O
infusion	B-C0574032
of	O
cytokine-induced	B-C2348032
autologous	I-C2348032
killer	I-C2348032
cells	I-C2348032
ciks	B-C2348032
at	O
the	O
request	B-C1272683
of	O
the	O
patient	B-C0030705
.	O
	
following	O
the	O
therapy	B-C0087111
,	O
the	O
three	O
tumor	B-C0041365
markers	I-C0041365
rapidly	B-C0456962
decreased	B-C0205216
to	O
below	O
the	O
normal	B-C0086715
reference	I-C0086715
level	I-C0086715
,	O
although	O
there	O
still	O
were	O
slight	B-C2937276
fluctuations	B-C0231241
within	O
a	O
narrow	B-C0333164
range	B-C1514721
frequently	B-C0332183
.	O
	
the	O
patient	B-C0030705
was	O
monitored	B-C0150369
for	O
21	O
months	B-C0439231
to	O
the	O
present	B-C0150312
day	B-C0439228
and	O
no	B-C3809765
abnormality	I-C3809765
was	O
observed	B-C1441672
.	O
	
the	O
results	B-C0808233
indicated	O
that	O
this	O
therapy	B-C0087111
may	O
be	O
applied	O
as	O
a	O
novel	B-C0205314
strategy	O
that	O
is	O
effective	B-C1704419
and	O
reliable	B-C0205556
for	O
cancer	B-C0281206
prevention	I-C0281206
.	O
	
as	O
there	O
is	O
no	O
promising	O
regimen	B-C0087111
for	O
the	O
prevention	B-C0281206
of	I-C0281206
malignancies	I-C0281206
to	O
date	O
,	O
such	O
a	O
treatment	B-C0087111
may	O
become	O
a	O
major	B-C0205164
cancer	B-C0006826
prophylactic	B-C0199176
regimen	I-C0199176
,	O
particularly	O
for	O
patients	B-C0030705
who	O
are	O
at	O
a	O
high	B-C0332167
risk	I-C0332167
of	I-C0332167
cancer	B-C0006826
.	O
	
the	O
relationships	B-C0439849
between	O
rugby	B-C0035945
players'	B-C0679646
tackle	B-C0018578
training	B-C0220931
attitudes	B-C0004271
and	O
behaviour	B-C0004927
and	O
their	O
match	B-C0004271
tackle	I-C0004271
attitudes	I-C0004271
and	O
behaviour	B-C0004927
the	O
tackle	B-C0018578
event	O
in	O
rugby	B-C0035945
is	O
a	O
technical	B-C0205556
and	O
physical	B-C0205485
contest	B-C0040595
between	O
opposing	O
players	B-C0679646
.	O
	
a	O
player's	B-C0679646
ability	O
to	O
tolerate	B-C0680282
and	O
contest	B-C0040595
during	O
a	O
tackle	B-C0018578
is	O
a	O
prerequisite	B-C0679209
for	O
safe	B-C0814103
participation	B-C0679823
and	O
success	B-C0597535
in	O
rugby	B-C0035945
.	O
	
little	O
is	O
known	O
about	O
the	O
relationship	B-C0439849
between	O
tackle	B-C0220931
training	I-C0220931
and	O
tackling	B-C0018578
in	O
matches	B-C0150593
in	O
rugby	B-C0035945
union	I-C0035945
.	O
	
therefore	O
,	O
we	O
investigated	B-C1292732
the	O
relationships	B-C0439849
between	O
players'	B-C0679646
training	B-C0004271
attitudes	I-C0004271
and	O
behaviour	B-C0004927
and	O
their	O
match	B-C0004271
attitudes	I-C0004271
and	O
behaviour	B-C0004927
for	O
tackling	B-C0018578
in	O
rugby	B-C0035945
union	I-C0035945
.	O
	
a	O
questionnaire	B-C0034394
was	O
designed	O
to	O
assess	B-C0184514
attitude	B-C0004271
importance	O
and	O
behaviours	B-C0004927
frequency	B-C1561548
and	O
quantity	B-C1265611
among	O
junior	B-C1708595
under	O
19	O
players	B-C0679646
on	O
a	O
5-point	B-C0451267
likert	I-C0451267
scale	I-C0451267
.	O
	
questionnaires	B-C0034394
were	O
handed	O
out	O
to	O
220	O
players	B-C0679646
10	O
schools	B-C0036375
at	O
a	O
tournament	B-C0040595
and	O
75%	O
9	O
schools	B-C0036375
,	O
n=164	O
were	O
returned	O
for	O
analysis	B-C0936012
.	O
	
associations	B-C0004083
between	O
training	B-C0004271
attitudes	I-C0004271
and	O
behaviours	B-C0004927
were	O
tested	B-C0039593
using	O
the	O
χ	B-C0392366
test	I-C0392366
,	O
cramer's	I-C0392366
v	I-C0392366
and	I-C0392366
τ-b	I-C0392366
.	O
	
the	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	B-C0449851
to	O
prevent	B-C2700409
injuries	B-C0004161
in	O
training	B-C0220931
,	O
the	O
more	O
important	O
players	B-C0679646
rated	O
'own	O
safety'	O
τ-b=0	O
,	O
moderate	B-C0205081
,	O
z=3	O
,	O
p<0	O
,	O
'going	O
for	O
the	O
ball	B-C1706910
only'	O
τ-b=0	O
,	O
moderate	B-C0205081
,	O
z=4	O
,	O
p<0	O
and	O
'staying	O
on	O
feet'	O
τ-b=0	O
,	O
moderate	B-C0205081
,	O
z=3	O
,	O
p<0	O
in	O
match	B-C0150593
play	I-C0150593
.	O
	
the	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	B-C0449851
to	O
improve	B-C0184511
performance	B-C1882330
in	O
training	B-C0220931
,	O
the	O
more	O
important	O
players	B-C0679646
rated	O
actions	O
'going	O
for	O
ball	B-C1706910
only'	O
τ-b=0	O
,	O
moderate	B-C0205081
,	O
z=3	O
,	O
p<0	O
and	O
'	O
preventing	B-C2700409
the	O
ball	B-C1706910
carrier	O
from	O
retaining	B-C0333118
position	B-C0733755
'	O
τ-b=0	O
,	O
moderate	B-C0205081
,	O
z=3	O
,	O
p<0	O
in	O
match	B-C0150593
play	I-C0150593
.	O
	
this	O
is	O
the	O
first	O
study	B-C2603343
to	O
report	O
on	O
the	O
relationships	B-C0439849
between	O
players	B-C0679646
'	O
training	B-C0004271
attitudes	I-C0004271
and	O
behaviour	B-C0004927
and	O
their	O
match	B-C0004271
attitudes	I-C0004271
and	O
behaviour	B-C0004927
s	O
for	O
tackling	B-C0018578
in	O
rugby	B-C0035945
union	I-C0035945
.	O
	
the	O
importance	O
of	O
tackle	B-C0018578
training	B-C0220931
to	O
prevent	B-C2700409
injury	B-C0004161
,	O
and	O
the	O
amount	O
of	O
time	O
spent	O
on	O
technique	B-C0449851
to	O
prevent	B-C2700409
injuries	B-C0004161
,	O
was	O
associated	B-C0332281
with	I-C0332281
behaviours	B-C0004927
that	O
reduce	B-C0392756
the	O
risk	B-C0582456
of	I-C0582456
injury	I-C0582456
in	O
role	B-C1705810
of	O
oxidative	B-C0242606
stress	I-C0242606
and	O
inflammatory	B-C0333348
factors	B-C1521761
in	O
diabetic	B-C0011881
kidney	I-C0011881
disease	I-C0011881
diabetic	B-C0011881
nephropathy	I-C0011881
dn	B-C0011881
is	O
a	O
serious	B-C0205404
complication	B-C0009566
of	O
diabetes	B-C0011849
mellitus	I-C0011849
,	O
and	O
its	O
prevalence	B-C0033106
has	O
been	O
increasing	B-C0442808
in	O
developed	B-C0282613
countries	I-C0282613
.	O
	
diabetic	B-C0011881
nephropathy	I-C0011881
has	O
become	O
the	O
most	O
common	B-C0205214
single	B-C0205171
cause	O
of	O
end-stage	B-C0022661
renal	I-C0022661
disease	I-C0022661
worldwide	B-C2700280
.	O
	
oxidative	B-C0242606
stress	I-C0242606
and	O
inflammation	B-C0021368
factors	B-C1521761
are	O
hypothesized	B-C1512571
to	O
play	B-C1705810
a	I-C1705810
role	I-C1705810
in	O
the	O
development	B-C1527148
of	O
late	B-C0205087
diabetes	B-C0342257
complications	I-C0342257
.	O
	
chronic	B-C0342300
hyperglycemia	I-C0342300
increases	B-C0442805
oxidative	B-C0242606
stress	I-C0242606
,	O
significantly	B-C0392747
modifies	I-C0392747
the	O
structure	B-C0678594
and	O
function	B-C0031843
of	O
proteins	B-C0033684
and	O
lipids	B-C0023779
,	O
and	O
induces	B-C0205263
glycoxidation	B-C0260088
and	O
peroxidation	B-C0178796
.	O
	
therefore	O
,	O
hyperglycemia	B-C0020456
causes	O
auto-oxidation	B-C0311405
of	O
glucose	B-C0017725
,	O
glycation	B-C0598528
of	O
proteins	B-C0033684
,	O
and	O
activation	B-C1879547
of	O
polyol	B-C0441712
mechanism	I-C0441712
.	O
	
overproduction	B-C0033268
of	O
intracellular	B-C0178719
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
contributes	B-C1880177
to	O
several	B-C0443302
microvascular	B-C0443258
and	O
macrovascular	B-C0205245
complications	B-C0009566
of	O
dn	B-C0011881
.	O
	
on	O
the	O
other	O
hand	O
,	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
modulates	B-C0443264
signaling	B-C2611812
cascade	I-C2611812
of	O
immune	B-C0021054
factors	I-C0021054
.	O
	
an	O
increase	B-C0442805
in	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
can	O
increase	B-C0442805
the	O
production	B-C0033268
of	O
inflammatory	B-C0333348
cytokines	B-C0079189
,	O
and	O
likewise	O
,	O
an	O
increase	B-C0442805
in	O
inflammatory	B-C0333348
cytokines	B-C0079189
can	O
stimulate	B-C1948023
the	O
production	B-C0033268
of	O
free	B-C0016693
radicals	I-C0016693
.	O
	
some	O
studies	B-C0681814
have	O
shown	O
that	O
kidney	B-C0027697
inflammation	I-C0027697
is	O
serious	B-C0205404
in	O
promoting	B-C0033414
the	O
development	B-C1527148
and	O
progression	B-C0449258
of	O
dn	B-C0011881
.	O
	
inflammatory	B-C0333348
factors	B-C1521761
which	O
are	O
activated	B-C1879547
by	O
the	O
metabolic	B-C0311400
,	O
biochemical	B-C0205474
,	O
and	O
hemodynamic	B-C0019010
derangements	O
are	O
known	O
to	O
exist	B-C2987476
in	O
the	O
diabetic	B-C0011881
kidney	I-C0011881
.	O
	
this	O
review	B-C0282443
discusses	O
facts	O
for	O
oxidative	B-C0242606
stress	I-C0242606
and	O
inflammatory	B-C0333348
factors	B-C1521761
in	O
dn	B-C0011881
and	O
encompasses	O
the	O
role	B-C1705810
of	O
immune	B-C0007634
and	O
inflammatory	B-C0440752
cells	I-C0440752
,	O
inflammatory	B-C0333348
cytokines	B-C0079189
,	O
and	O
stress	B-C0242606
oxidative	I-C0242606
factors	B-C1521761
.	O
	
cobalt-60	B-C0025080
machines	I-C0025080
and	O
medical	B-C0023730
linear	I-C0023730
accelerators	I-C0023730
competing	B-C0039421
technologies	I-C0039421
for	O
external	B-C1517033
beam	I-C1517033
radiotherapy	I-C1517033
medical	B-C0023730
linear	I-C0023730
accelerators	I-C0023730
linacs	B-C0023730
and	O
cobalt-60	B-C0025080
machines	I-C0025080
are	O
both	O
mature	O
technologies	B-C0039421
for	O
external	B-C1517033
beam	I-C1517033
radiotherapy	I-C1517033
.	O
	
a	O
comparison	B-C1707455
is	O
made	O
between	O
these	O
two	O
technologies	B-C0039421
in	O
terms	O
of	O
infrastructure	B-C1514880
and	O
maintenance	B-C0024501
,	O
dosimetry	B-C0034603
,	O
shielding	B-C0243095
requirements	B-C1514873
,	O
staffing	B-C0087023
,	O
costs	B-C0010186
,	O
security	B-C1519222
,	O
patient	B-C0030705
throughput	B-C2986816
and	O
clinical	B-C0042153
use	I-C0042153
.	O
	
infrastructure	B-C1514880
and	O
maintenance	B-C0024501
are	O
more	O
demanding	B-C0699784
for	O
linacs	B-C0023730
due	O
to	O
the	O
complex	B-C3273359
electric	I-C3273359
componentry	I-C3273359
.	O
	
in	O
dosimetry	B-C0034603
,	O
a	O
higher	B-C0205250
beam	B-C1442080
energy	I-C1442080
,	O
modulated	B-C0443264
dose	B-C1512044
rate	I-C1512044
and	O
smaller	B-C0547044
focal	B-C2348694
spot	I-C2348694
size	I-C2348694
mean	O
that	O
it	O
is	O
easier	B-C0332219
to	O
create	B-C1706214
an	O
optimised	B-C2698650
treatment	B-C0087111
with	O
a	O
linac	B-C0023730
for	O
conformal	O
dose	B-C0178602
coverage	B-C1999244
of	O
the	O
tumour	B-C0027651
while	O
sparing	O
healthy	B-C0178784
organs	I-C0178784
at	O
risk	B-C0035647
.	O
	
in	O
shielding	B-C0243095
,	O
the	O
requirements	B-C1514873
for	O
a	O
concrete	B-C3273359
bunker	I-C3273359
are	O
similar	O
for	O
cobalt-60	B-C0025080
machines	I-C0025080
and	O
linacs	B-C0023730
but	O
extra	O
shielding	B-C0243095
and	O
protection	B-C1545588
from	O
neutrons	B-C0027946
are	O
required	O
for	O
linacs	B-C0023730
.	O
	
staffing	B-C3845726
levels	I-C3845726
can	O
be	O
higher	B-C0205250
for	O
linacs	B-C0023730
and	O
more	O
staff	B-C0681113
training	I-C0681113
is	O
required	O
for	O
linacs	B-C0023730
.	O
	
life	B-C0220812
cycle	I-C0220812
costs	I-C0220812
are	O
higher	B-C0205250
for	O
linacs	B-C0023730
,	O
especially	O
multi-energy	B-C0023730
linacs	I-C0023730
.	O
	
security	B-C1519222
is	O
more	O
complex	B-C0439855
for	O
cobalt-60	B-C0025080
machines	I-C0025080
because	O
of	O
the	O
high	B-C0205250
activity	B-C0441655
radioactive	B-C0182598
source	I-C0182598
.	O
	
patient	B-C0030705
throughput	B-C2986816
can	O
be	O
affected	B-C0392760
by	O
source	B-C0449416
decay	B-C2700592
for	O
cobalt-60	B-C0025080
machines	I-C0025080
but	O
poor	B-C0542537
maintenance	B-C0024501
and	O
breakdowns	B-C0014678
can	O
severely	O
affect	B-C0392760
patient	B-C0030705
throughput	B-C2986816
for	O
linacs	B-C0023730
.	O
	
in	O
clinical	B-C0042153
use	I-C0042153
,	O
more	O
complex	B-C0439855
treatment	B-C0087111
techniques	B-C0449851
are	O
easier	B-C0332219
to	O
achieve	O
with	O
linacs	B-C0023730
,	O
and	O
the	O
availability	B-C0470187
of	I-C0470187
electron	B-C0013840
beams	I-C0013840
on	O
high	B-C0205250
-	O
energy	B-C1442080
linacs	B-C0023730
can	O
be	O
useful	O
for	O
certain	O
treatments	B-C0087111
.	O
	
in	O
summary	O
,	O
there	O
is	O
no	O
simple	O
answer	O
to	O
the	O
question	O
of	O
the	O
choice	O
of	O
either	O
cobalt-60	B-C0025080
machines	I-C0025080
or	O
linacs	B-C0023730
for	O
radiotherapy	B-C1522449
in	O
low-	B-C1331016
and	O
middle-income	B-C0870890
countries	B-C0454664
.	O
	
in	O
fact	O
a	O
radiotherapy	B-C0587444
department	I-C0587444
with	O
a	O
combination	B-C0205195
of	O
technologies	B-C0039421
,	O
including	O
orthovoltage	B-C1704729
x-ray	I-C1704729
units	I-C1704729
,	O
may	O
be	O
an	O
option	B-C1518601
.	O
	
local	B-C0205276
needs	B-C0027552
,	O
conditions	B-C0348080
and	O
resources	B-C0035201
will	O
have	O
to	O
be	O
factored	O
into	O
any	O
decision	B-C0679006
on	O
technology	B-C0039421
taking	O
into	O
account	O
the	O
characteristics	B-C1521970
of	O
both	O
forms	O
of	O
teletherapy	B-C0419095
,	O
with	O
the	O
primary	O
goal	B-C0018017
being	O
the	O
sustainability	B-C0205245
of	O
the	O
radiotherapy	B-C0587559
service	I-C0587559
over	O
the	O
useful	O
lifetime	B-C4071830
of	O
the	O
design	B-C1707689
,	O
synthesis	B-C1883254
,	O
molecular	B-C3494274
docking	I-C3494274
,	O
anti-proteus	B-C0279516
mirabilis	I-C0279516
and	O
urease	B-C0041945
inhibition	B-C1524081
of	O
new	O
fluoroquinolone	B-C1254351
carboxylic	I-C1254351
acid	I-C1254351
derivatives	I-C1254351
new	O
hydroxamic	B-C0020314
acid	I-C0020314
,	O
hydrazide	B-C0682951
and	O
amide	B-C0002482
derivatives	I-C0002482
of	O
ciprofloxacin	B-C0008809
in	O
addition	O
to	O
their	O
analogues	B-C0243071
of	O
levofloxacin	B-C0282386
were	O
prepared	O
and	O
identified	O
by	O
different	O
spectroscopic	B-C0449851
techniques	I-C0449851
.	O
	
some	O
of	O
the	O
prepared	O
compounds	B-C1254351
revealed	O
good	O
activity	B-C2248397
against	O
the	O
urease	B-C0041945
splitting	O
bacteria	B-C0004611
,	O
proteus	B-C0033701
mirabilis	I-C0033701
.	O
	
the	O
urease	B-C0041945
inhibitory	B-C2248397
activity	I-C2248397
was	O
investigated	O
using	O
indophenol	B-C1318795
method	I-C1318795
.	O
	
most	O
of	O
the	O
tested	B-C0392366
compounds	B-C1254351
showed	O
better	O
activity	B-C2248397
than	O
the	O
reference	O
acetohydroxamic	B-C0050451
acid	I-C0050451
aha	B-C0050451
.	O
	
the	O
ciprofloxacin	B-C1254351
hydrazide	I-C1254351
derivative	I-C1254351
3a	I-C1254351
and	O
levofloxacin	B-C1254351
hydroxamic	I-C1254351
acid	I-C1254351
7	I-C1254351
experienced	O
the	O
highest	O
activity	B-C2248397
ic50	B-C0600495
=1	O
and	O
2.20μm	O
,	O
respectively	O
.	O
	
molecular	B-C3494274
docking	I-C3494274
study	I-C3494274
revealed	O
high	O
spontaneous	O
binding	B-C1167622
ability	I-C1167622
of	O
the	O
tested	B-C0392366
compounds	B-C1254351
to	O
the	O
active	B-C0205681
site	I-C0205681
of	O
interobserver	B-C0870736
and	O
intraobserver	B-C0870992
reliability	B-C2347947
of	O
clinical	B-C3845884
assessments	I-C3845884
in	O
knee	B-C0409959
osteoarthritis	I-C0409959
clinical	B-C1456356
examination	I-C1456356
of	O
the	O
knee	B-C0022742
is	O
subject	O
to	O
measurement	B-C0681899
error	I-C0681899
.	O
	
the	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	B-C0870736
and	O
intraobserver	B-C0870992
reliability	B-C2347947
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	B-C0030705
with	O
knee	B-C0409959
osteoarthritis	I-C0409959
oa	B-C0409959
.	O
	
we	O
studied	O
subjects	B-C0681850
with	O
symptomatic	B-C0231220
knee	B-C0409959
oa	I-C0409959
who	O
were	O
participants	B-C0679646
in	O
an	O
open-label	B-C1709323
clinical	I-C1709323
trial	I-C1709323
of	O
intraarticular	B-C0585373
steroid	I-C0585373
therapy	I-C0585373
.	O
	
following	O
standardization	B-C0038136
of	O
the	O
clinical	B-C0022885
test	I-C0022885
procedures	I-C0022885
,	O
2	O
clinicians	B-C0871685
assessed	B-C0220825
25	O
subjects	B-C0681850
independently	O
at	O
the	O
same	O
visit	B-C1512346
,	O
and	O
the	O
same	O
clinician	B-C0871685
assessed	B-C0220825
88	O
subjects	B-C0681850
over	O
an	O
interval	B-C1272706
period	I-C1272706
of	O
2-10	O
weeks	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	B-C0149783
intervention	B-C0184661
.	O
	
clinical	B-C1456356
examination	I-C1456356
included	B-C0332257
assessment	B-C0220825
of	O
bony	B-C0221610
enlargement	I-C0221610
,	O
crepitus	B-C0277964
,	O
quadriceps	B-C0555751
wasting	I-C0555751
,	O
knee	B-C0343166
effusion	I-C0343166
,	O
joint-line	B-C0446569
and	O
anserine	B-C0224834
tenderness	B-C0240094
,	O
and	O
knee	B-C0576094
range	I-C0576094
of	I-C0576094
movement	I-C0576094
rom	B-C0576094
.	O
	
intraclass	B-C0392762
correlation	I-C0392762
coefficients	I-C0392762
icc	B-C0392762
,	O
estimated	B-C0392762
kappa	I-C0392762
κ	B-C0392762
,	O
weighted	B-C0392762
kappa	I-C0392762
κω	B-C0392762
,	O
and	O
bland-altman	B-C0392762
plots	I-C0392762
were	O
used	O
to	O
determine	O
interobserver	B-C0870736
and	O
intraobserver	B-C0870992
levels	B-C0441889
of	O
agreement	B-C0680240
.	O
	
using	O
landis	B-C0871425
and	I-C0871425
koch	I-C0871425
criteria	I-C0871425
,	O
interobserver	B-C0237855
κ	I-C0237855
scores	I-C0237855
were	O
moderate	B-C0205081
for	O
patellofemoral	B-C0447801
joint	I-C0447801
κ	B-C0392762
=	O
0.53	O
and	O
anserine	B-C0224834
tenderness	B-C0240094
κ	B-C0392762
=	O
0.48	O
good	B-C0205170
for	O
bony	B-C0221610
enlargement	I-C0221610
κ	B-C0392762
=	O
0.66	O
,	O
quadriceps	B-C0555751
wasting	I-C0555751
κ	B-C0392762
=	O
0.78	O
,	O
crepitus	B-C0277964
κ	B-C0392762
=	O
0.78	O
,	O
medial	B-C0205098
tibiofemoral	B-C0447795
joint	I-C0447795
tenderness	B-C0240094
κ	B-C0392762
=	O
0.76	O
,	O
and	O
effusion	B-C0343166
assessed	O
by	O
ballottement	B-C0231756
κ	B-C0392762
=	O
0.73	O
and	O
bulge	B-C3696902
sign	I-C3696902
κω	B-C0392762
=	O
0.78	O
and	O
excellent	B-C1548784
for	O
lateral	B-C0205093
tibiofemoral	B-C0447795
joint	I-C0447795
tenderness	B-C0240094
κ	B-C0392762
=	O
1.00	O
,	O
flexion	B-C0231452
icc	B-C0392762
=	O
0.97	O
,	O
and	O
extension	B-C0231448
icc	B-C0392762
=	O
0.87	O
rom	B-C0576094
.	O
	
intraobserver	B-C0237855
κ	I-C0237855
scores	I-C0237855
were	O
moderate	B-C0205081
for	O
lateral	B-C0205093
tibiofemoral	B-C0447795
joint	I-C0447795
tenderness	B-C0234233
κ	B-C0392762
=	O
0.60	O
good	O
for	O
crepitus	O
κ	B-C0392762
=	O
0.78	O
,	O
effusion	B-C0343166
assessed	O
by	O
ballottement	B-C0231756
test	I-C0231756
κ	B-C0392762
=	O
0.77	O
,	O
patellofemoral	B-C0447801
joint	I-C0447801
κ	B-C0392762
=	O
0.66	O
,	O
medial	B-C0205098
tibiofemoral	B-C0447795
joint	I-C0447795
κ	B-C0392762
=	O
0.64	O
,	O
and	O
anserine	B-C0224834
tenderness	B-C0234233
κ	B-C0392762
=	O
0.73	O
and	O
excellent	B-C1548784
for	O
effusion	B-C0343166
assessed	O
by	O
bulge	B-C3696902
sign	I-C3696902
κω	B-C0392762
=	O
0.83	O
,	O
bony	B-C0221610
enlargement	I-C0221610
κ	B-C0392762
=	O
0.98	O
,	O
quadriceps	B-C0555751
wasting	I-C0555751
κ	B-C0392762
=	O
0.83	O
,	O
flexion	B-C0231452
icc	B-C0392762
=	O
0.99	O
,	O
and	O
extension	B-C0231448
icc	B-C0392762
=	O
0.96	O
rom	B-C0576094
.	O
	
among	O
individuals	B-C0237401
with	O
symptomatic	B-C0231220
knee	B-C0409959
oa	I-C0409959
,	O
the	O
reliability	B-C2347947
of	O
clinical	B-C1456356
examination	I-C1456356
of	O
the	O
knee	B-C0022742
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	B-C3540840
signs	I-C3540840
of	O
knee	B-C0409959
oa	I-C0409959
.	O
	
assessing	O
the	O
benefits	B-C0814225
of	O
targeted	B-C1521840
drug	B-C0085104
delivery	I-C0085104
by	O
nanocarriers	B-C1450053
a	O
partico/pharmacokinetic	B-C0031328
framework	I-C0031328
an	O
in	B-C1515655
vivo	I-C1515655
kinetic	B-C0031328
framework	I-C0031328
is	O
introduced	O
to	O
analyze	B-C0936012
and	O
predict	O
the	O
quantitative	B-C0392762
advantage	O
of	O
using	O
nanocarriers	B-C1450053
to	O
deliver	B-C0085104
drugs	I-C0085104
,	O
especially	O
anticancer	B-C0003392
agents	I-C0003392
,	O
compared	B-C1707455
to	O
administering	B-C1533734
the	O
same	O
drugs	B-C0013227
in	O
their	O
free	O
form	O
.	O
	
this	O
framework	B-C0178566
recognizes	O
three	O
levels	B-C0441889
of	O
kinetics	B-C0031327
.	O
	
first	O
is	O
the	O
particokinetics	B-C0022702
associated	B-C0332281
with	I-C0332281
deposition	B-C0333562
of	O
nanocarriers	B-C1450053
into	O
tissues	B-C0040300
associated	B-C0332281
with	I-C0332281
drug	B-C0728866
effect	I-C0728866
and	O
toxicity	B-C0600688
,	O
their	O
residence	B-C0237096
inside	O
those	O
tissues	B-C0040300
,	O
and	O
elimination	B-C0683141
of	O
the	O
nanocarriers	B-C1450053
from	O
the	O
body	B-C0242821
.	O
	
second	O
is	O
the	O
release	B-C0231360
pattern	I-C0231360
in	O
time	O
of	O
free	B-C0678752
drug	I-C0678752
from	O
the	O
nanocarriers	B-C1450053
.	O
	
third	O
is	O
the	O
pharmacokinetics	B-C0031327
of	O
free	B-C0678752
drug	I-C0678752
,	O
as	O
it	O
relates	O
to	O
deposition	B-C0333562
and	O
elimination	B-C0683141
processes	I-C0683141
in	O
the	O
target	B-C1521840
and	O
toxicity	B-C0600688
associated	B-C0439849
tissues	B-C0040300
,	O
and	O
total	B-C0087101
body	I-C0087101
clearance	I-C0087101
.	O
	
a	O
figure	O
of	O
merit	O
,	O
the	O
drug	B-C1637833
targeting	I-C1637833
index	I-C1637833
dti	B-C1637833
,	O
is	O
used	O
to	O
quantitate	B-C0392762
the	O
benefit	O
of	O
nanocarrier	B-C1450053
based	O
drug	B-C0085104
delivery	I-C0085104
by	O
considering	O
the	O
effects	B-C1280500
of	O
preferential	O
deposition	B-C0333562
of	O
nanoparticles	B-C1450054
into	O
target	B-C1521840
tissues	B-C0040300
and	O
relative	O
avoidance	O
of	O
tissues	B-C0040300
associated	B-C0332281
with	I-C0332281
drug	B-C0013221
toxicity	I-C0013221
,	O
compared	B-C1707455
to	O
drug	B-C0013227
that	O
is	O
administered	B-C1533734
in	O
its	O
free	O
form	O
.	O
	
general	O
methods	B-C0025663
are	O
derived	O
for	O
calculating	B-C1441506
dti	B-C1637833
when	O
appropriate	O
particokinetic	B-C0022702
,	O
pharmacokinetic	B-C0031328
,	O
and	O
drug	B-C1521828
release	I-C1521828
rate	I-C1521828
information	O
is	O
available	O
,	O
and	O
it	O
is	O
shown	O
that	O
relatively	O
simple	O
algebraic	O
forms	O
result	B-C1274040
when	O
some	O
common	O
assumptions	O
are	O
made	O
.	O
	
this	O
approach	O
may	O
find	O
use	O
in	O
developing	B-C0872152
and	O
selecting	O
nanocarrier	B-C1450053
formulations	B-C1705957
,	O
either	O
for	O
populations	B-C1257890
or	O
for	O
recombinant	B-C1514798
mhc	B-C0024518
tetramers	I-C0024518
for	O
isolation	B-C0204727
of	O
virus	B-C0042776
-	O
specific	B-C0205369
cd8	B-C0242629
cells	I-C0242629
from	O
healthy	B-C3898902
donors	I-C3898902
potential	B-C3245505
approach	O
for	O
cell	B-C0302189
therapy	I-C0302189
of	O
posttransplant	B-C0010823
cytomegalovirus	I-C0010823
infection	I-C0010823
patients	B-C0030705
undergoing	O
allogeneic	B-C1515895
hematopoietic	B-C0472699
stem	I-C0472699
cell	I-C0472699
transplantation	I-C0472699
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus	B-C1142560
reactivation	I-C1142560
,	O
which	O
in	O
the	O
absence	O
of	O
t-cell	B-C1817907
immunity	I-C1817907
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute	B-C0333361
inflammatory	I-C0333361
reaction	I-C0333361
and	O
damage	B-C0332675
of	I-C0332675
internal	I-C0332675
organs	I-C0332675
.	O
	
transfusion	B-C0086573
of	O
the	O
virus-specific	B-C0205369
donor	B-C0039194
t-lymphocytes	I-C0039194
represents	O
an	O
alternative	O
to	O
a	O
highly	B-C1407029
toxic	I-C1407029
and	O
often	O
ineffective	B-C3242229
antiviral	B-C0280274
therapy	I-C0280274
.	O
	
potentially	B-C3245505
promising	O
cell	B-C0302189
therapy	I-C0302189
approach	O
comprises	O
transfusion	B-C0086573
of	O
cytotoxic	B-C0039195
t-lymphocytes	I-C0039195
,	O
specific	B-C0205369
to	O
the	O
viral	B-C0003342
antigens	I-C0003342
,	O
immediately	O
after	O
their	O
isolation	B-C0204727
from	O
the	O
donor's	B-C0005775
blood	I-C0005775
circulation	I-C0005775
without	O
any	O
in	B-C1533691
vitro	I-C1533691
expansion	I-C1533691
.	O
	
specific	B-C0205369
t-cells	B-C0039194
could	O
be	O
separated	O
from	O
potentially	B-C3245505
alloreactive	B-C0024264
lymphocytes	I-C0024264
using	O
recombinant	B-C1514798
major	B-C0024518
histocompatibility	I-C0024518
complex	I-C0024518
mhc	B-C0024518
multimers	B-C1979934
,	O
carrying	O
synthetic	B-C0597551
viral	I-C0597551
peptides	I-C0597551
.	O
	
rapid	O
transfusion	B-C0086573
of	O
virus	B-C0042776
-	O
specific	B-C0205369
t-cells	B-C0039194
to	O
patients	B-C0030705
has	O
several	O
crucial	O
advantages	O
in	B-C1533691
comparison	O
with	O
methods	O
based	O
on	O
the	O
in	O
vitro	I-C1533691
expansion	I-C1533691
of	O
the	O
cells	B-C0007634
.	O
	
about	O
30%	O
of	O
hematopoietic	B-C0229601
stem	B-C3898902
cell	I-C3898902
donors	I-C3898902
and	O
46%	O
of	O
transplant	B-C0376387
recipients	I-C0376387
at	O
the	O
national	B-C1708333
research	I-C1708333
center	I-C1708333
for	I-C1708333
hematology	I-C1708333
were	O
carriers	O
of	O
the	O
hla-a*02	B-C0555908
allele	I-C0555908
.	O
	
moreover	O
,	O
94%	O
of	O
russian	B-C0337816
donors	B-C3898902
have	O
an	O
immune	B-C0301872
response	I-C0301872
against	O
the	O
cytomegalovirus	B-C0010825
cmv	B-C0010825
.	O
	
using	O
recombinant	B-C1514798
hla-a*02	B-C0555908
multimers	B-C1979934
carrying	O
an	O
immunodominant	B-C0205556
cytomegalovirus	B-C0030956
peptide	I-C0030956
nlv	B-C0030956
,	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy	B-C3898902
donors	I-C3898902
have	O
pronounced	O
t-cell	B-C1817907
immunity	I-C1817907
against	O
this	O
antigen	B-C0003320
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	B-C0040732
the	O
patients	B-C0030705
do	O
not	O
have	O
specific	B-C0205369
t-lymphocytes	B-C0039194
.	O
	
the	O
donor	B-C0007634
cells	I-C0007634
have	O
the	O
immune	B-C0031437
phenotype	I-C0031437
of	O
memory	B-C0682639
cells	I-C0682639
and	O
can	O
be	O
activated	B-C2259058
and	O
proliferate	B-C0596290
after	O
stimulation	O
with	O
the	O
specific	B-C0205369
antigen	B-C0003320
.	O
	
donor	B-C1395724
lymphocytes	I-C1395724
can	O
be	O
substantially	O
enriched	B-C0681540
to	O
significant	O
purity	B-C1882508
by	O
magnetic	B-C0599662
separation	I-C0599662
with	O
recombinant	B-C1514798
mhc	B-C0024518
multimers	B-C1979934
and	O
are	O
not	O
activated	B-C0678666
upon	O
cocultivation	B-C0282547
with	O
the	O
antigen	B-C0003320
-presenting	O
cells	B-C0007634
from	O
hla	B-C0019721
-	O
incompatible	B-C0013018
donors	I-C0013018
without	O
addition	O
of	O
the	O
specific	B-C0205369
antigen	B-C0003320
.	O
	
this	O
study	B-C2603343
demonstrated	O
that	O
strong	O
immune	B-C0301872
response	I-C0301872
to	O
cmv	B-C0010825
of	O
healthy	B-C3898902
donors	I-C3898902
and	O
prevalence	O
of	O
hla-a*02	B-C0555908
allele	I-C0555908
in	O
the	O
russian	B-C1257890
population	I-C1257890
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus-specific	B-C0205369
cells	B-C0007634
using	O
hla-a*02-nlv	B-C0555908
multimers	B-C1979934
.	O
	
after	O
the	O
transfusion	B-C1879316
,	O
these	O
cells	B-C0007634
should	O
protect	O
patients	B-C0030705
from	O
cmv	B-C0010825
without	O
development	O
of	O
allogeneic	B-C1515895
immune	B-C0301872
response	I-C0301872
.	O
	
outcomes	B-C0085415
of	O
chest	B-C0087111
wall	I-C0087111
resections	I-C0087111
in	O
pediatric	B-C1521725
sarcoma	B-C1261473
patients	B-C0030705
chest	B-C1290309
wall	I-C1290309
tumors	I-C1290309
in	O
pediatric	B-C1521725
patients	B-C0030705
are	O
rare	O
.	O
	
this	O
study	B-C2603343
evaluates	O
outcomes	B-C0085415
in	O
pediatric	B-C1521725
patients	B-C0030705
who	O
have	O
undergone	O
chest	B-C0087111
wall	I-C0087111
resections	I-C0087111
secondary	O
to	O
sarcomas	B-C1261473
.	O
	
a	O
retrospective	B-C0035363
review	I-C0035363
was	O
performed	O
for	O
patients	B-C0030705
<19years	O
old	O
who	O
underwent	O
chest	B-C0087111
wall	I-C0087111
resections	I-C0087111
for	O
sarcoma	B-C1261473
1999-2014	O
at	O
the	O
university	B-C1519805
of	I-C1519805
texas	I-C1519805
md	I-C1519805
anderson	I-C1519805
cancer	I-C1519805
center	I-C1519805
.	O
	
of	O
44	O
patients	B-C0030705
,	O
ewing's	B-C0553580
sarcoma	I-C0553580
n=18	O
and	O
osteosarcoma	B-C0029463
n=16	O
were	O
most	O
common	O
.	O
	
other	O
sarcomas	B-C1261473
included	O
synovial	B-C0039101
sarcoma	I-C0039101
,	O
chondrosarcoma	B-C0008479
,	O
and	O
rhabdomyosarcoma	B-C0035412
.	O
	
gore-tex	B-C0018088
or	O
a	O
marlex	B-C0005479
mesh	I-C0005479
and	O
methyl	B-C0005479
methacrylate	I-C0005479
sandwich	I-C0005479
was	O
used	O
in	O
22	O
patients	B-C0030705
,	O
and	O
9	O
children	B-C0008059
did	O
not	B-C3840851
require	I-C3840851
reconstruction	I-C3840851
.	O
	
twenty-four	O
54.5	O
patients	B-C0030705
had	O
normal	B-C0205307
activity	B-C0441655
,	O
3	O
6.8	O
had	O
occasional	B-C0231218
discomfort	I-C0231218
,	O
2	O
4.5	O
had	O
pain	B-C0684336
impairing	I-C0684336
function	I-C0684336
,	O
7	O
15.9	O
required	O
medication	B-C0013227
or	O
physical	B-C0949766
therapy	I-C0949766
for	O
impairment	B-C0684336
,	O
and	O
8	O
18.2	O
needed	O
additional	O
surgery	B-C0038894
.	O
	
five	O
children	B-C0008059
11.4	O
developed	O
scoliosis	B-C0036439
,	O
and	O
all	O
of	O
these	O
patients	B-C0030705
had	O
posterior	B-C0205095
rib	B-C1290243
tumors	I-C1290243
.	O
	
median	B-C4086681
overall	I-C4086681
survival	I-C4086681
for	O
the	O
entire	B-C0599755
cohort	I-C0599755
was	O
41.9	O
months	B-C0439231
.	O
	
histology	B-C0019638
p=0	O
,	O
location	B-C0450429
of	O
tumor	B-C0027651
on	O
the	O
ribs	B-C0035561
p=0	O
,	O
and	O
surgical	B-C0229985
margins	I-C0229985
p=0	O
were	O
significantly	B-C0332281
associated	I-C0332281
with	I-C0332281
overall	B-C4086681
survival	I-C4086681
.	O
	
tumors	B-C0027651
on	O
the	O
middle	O
and	O
posterior	B-C0205095
p=0	O
portions	O
of	O
the	O
ribs	B-C0035561
had	O
a	O
lower	O
chance	O
of	O
death	B-C0011065
.	O
	
scoliosis	B-C0036439
is	O
more	O
common	O
in	O
posterior	B-C0205095
rib	B-C0185827
resections	I-C0185827
.	O
	
histology	B-C0019638
,	O
location	B-C0450429
of	O
the	O
tumor	B-C0027651
,	O
and	O
surgical	B-C0229985
margins	I-C0229985
impact	O
survival	B-C0038952
,	O
but	O
,	O
type	O
of	O
reconstruction	O
does	O
not	O
.	O
	
iii	O
.	O
	
treatment	B-C3161471
study	I-C3161471
.	O
	
tetrabromobisphenol	B-C0076220
a	I-C0076220
activates	B-C1879547
the	O
hepatic	B-C0023884
interferon	B-C1512834
pathway	I-C1512834
in	O
rats	B-C0034721
tetrabromobisphenol	B-C0076220
a	I-C0076220
tbbpa	B-C0076220
is	O
a	O
widely	O
used	O
flame	B-C0016198
retardant	I-C0016198
in	O
printed	B-C1707396
circuit	I-C1707396
boards	I-C1707396
,	O
paper	B-C0030351
,	O
and	O
textiles	B-C0039717
.	O
	
in	O
a	O
two-year	B-C0439234
study	B-C2603343
,	O
tbbpa	B-C0076220
showed	O
evidence	O
of	O
uterine	B-C0042138
tumors	I-C0042138
in	O
female	B-C0086287
wistar-han	B-C2700261
rats	I-C2700261
and	O
liver	B-C0023903
and	O
colon	B-C0009375
tumors	I-C0009375
in	O
b6c3f1	B-C2698297
mice	I-C2698297
.	O
	
in	O
order	O
to	O
gain	O
further	O
insight	O
into	O
early	O
gene	B-C0017337
and	O
pathway	B-C1704259
changes	O
leading	O
to	O
cancer	B-C0027651
,	O
we	O
exposed	O
female	B-C0086287
wistar	B-C2700261
han	I-C2700261
rats	I-C2700261
to	O
tbbpa	B-C0076220
at	O
0	O
,	O
25	O
,	O
250	O
,	O
or	O
1000mg/kg	O
oral	B-C2698653
gavage	I-C2698653
in	O
corn	B-C0010029
oil	I-C0010029
,	O
5	O
week	B-C0439230
for	O
13	O
weeks	B-C0439230
.	O
	
because	O
at	O
the	O
end	O
of	O
the	O
tbbpa	B-C0076220
exposure	B-C0332157
period	O
,	O
there	O
were	O
no	O
treatment-related	O
effects	O
on	O
body	B-C0005910
weights	I-C0005910
,	O
liver	B-C0577053
or	O
uterus	B-C0567079
lesions	I-C0567079
,	O
and	O
liver	B-C0736253
and	O
uterine	B-C0736936
organ	I-C0736936
weights	B-C0043100
were	O
within	O
10%	O
of	O
controls	B-C0009932
,	O
only	O
the	O
high	O
dose	B-C0178602
animals	B-C0003062
were	O
analyzed	B-C0936012
.	O
	
analysis	B-C0936012
of	O
the	O
hepatic	B-C0023884
and	O
uterine	B-C0042149
transcriptomes	B-C3178810
showed	O
tbbpa	B-C0076220
-induced	O
changes	O
primarily	O
in	O
the	O
liver	B-C0023884
1000mg/kg	O
,	O
with	O
159	O
transcripts	B-C1519595
corresponding	O
to	O
132	O
genes	B-C0017337
differentially	O
expressed	B-C0017262
compared	O
to	O
controls	B-C0009932
fdr=0	O
.	O
	
pathway	B-C0868995
analysis	I-C0868995
showed	O
activation	B-C1879547
of	O
interferon	B-C0021747
ifn	B-C0021747
and	O
metabolic	B-C1706062
networks	I-C1706062
.	O
	
tbbpa	B-C0076220
induced	O
few	O
molecular	O
changes	O
in	O
the	O
uterus	B-C0042149
.	O
	
activation	B-C1879547
of	O
the	O
interferon	B-C1512834
pathway	I-C1512834
in	O
the	O
liver	B-C0023884
occurred	O
after	O
13-weeks	B-C0439230
of	O
tbbpa	B-C0076220
exposure	B-C0332157
,	O
and	O
with	O
longer	O
term	O
tbbpa	B-C0076220
exposure	B-C0332157
this	O
may	O
lead	O
to	O
immunomodulatory	B-C1963758
changes	B-C0392747
that	O
contribute	O
to	O
carcinogenic	B-C0596263
processes	I-C0596263
.	O
	
famous	B-C0870537
faces	I-C0870537
and	O
voices	B-C0920674
differential	B-C1705242
profiles	B-C0449774
in	O
early	B-C1279919
right	B-C0228232
and	O
left	B-C0228233
semantic	B-C0338462
dementia	I-C0338462
and	O
in	O
alzheimer's	B-C0002395
disease	I-C0002395
famous	B-C0870537
face	I-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
is	O
reported	O
to	O
be	O
impaired	B-C0221099
both	O
in	O
semantic	B-C0338462
dementia	I-C0338462
sd	B-C0338462
and	O
in	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
,	O
although	O
more	O
severely	B-C0205082
in	O
the	O
former	O
.	O
	
in	O
ad	B-C0002395
a	O
coexistence	O
of	O
perceptual	B-C0030971
impairment	B-C0221099
in	O
face	B-C0870537
and	O
voice	B-C0920674
processing	B-C0025361
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	B-C1882330
in	O
complex	B-C0439855
semantic	B-C0036612
tasks	B-C0441655
.	O
	
on	O
the	O
other	O
hand	O
,	O
in	O
sd	B-C0338462
both	O
face	B-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
disorders	B-C0012634
could	O
be	O
related	O
to	O
the	O
prevalence	B-C0220900
of	O
atrophy	B-C0333641
in	O
the	O
right	B-C0228232
temporal	I-C0228232
lobe	I-C0228232
rtl	B-C0228232
.	O
	
the	O
aim	O
of	O
the	O
present	O
study	B-C2603343
was	O
twofold	O
1	O
to	O
investigate	B-C1292732
famous	B-C0870537
faces	I-C0870537
and	O
voices	B-C0920674
recognition	I-C0920674
in	O
sd	B-C0338462
and	O
ad	B-C0002395
to	O
verify	O
if	O
the	O
two	O
diseases	B-C0012634
show	O
a	O
differential	B-C1705242
pattern	B-C0449774
of	O
impairment	B-C0221099
,	O
resulting	O
from	O
disruption	B-C0332453
of	O
different	O
cognitive	B-C0009240
mechanisms	B-C0441712
2	O
to	O
check	O
if	O
face	B-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
disorders	B-C0012634
prevail	O
in	O
patients	B-C0030705
with	O
atrophy	B-C0333641
mainly	O
affecting	O
the	O
rtl	B-C0228232
.	O
	
to	O
avoid	O
the	O
potential	B-C3245505
influence	B-C4054723
of	O
primary	B-C0205225
perceptual	B-C0030971
problems	B-C0033213
in	O
face	B-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
,	O
a	O
pool	O
of	O
patients	B-C0030705
suffering	O
from	O
early	B-C1279919
sd	B-C0338462
and	O
ad	B-C0002395
were	O
administered	B-C1521801
a	O
detailed	O
set	O
of	O
tests	B-C2081632
exploring	O
face	B-C0870537
and	O
voice	B-C0920674
perception	B-C0030971
.	O
	
thirteen	O
sd	B-C0338462
8	O
with	O
prevalence	B-C0220900
of	O
right	B-C0228232
and	O
5	O
with	O
prevalence	B-C0220900
of	O
left	B-C0228233
temporal	I-C0228233
atrophy	B-C0333641
and	O
25	O
ce	O
patients	B-C0030705
,	O
who	O
did	O
not	O
show	O
visual	B-C0234621
and	O
auditory	B-C0439825
perceptual	B-C0030971
impairment	B-C0221099
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	B-C1521801
an	O
experimental	B-C1517586
battery	B-C1555716
exploring	O
famous	B-C0870537
face	I-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
and	O
naming	B-C0392366
.	O
	
twelve	O
sd	B-C0338462
patients	B-C0030705
underwent	O
cerebral	B-C0006104
pet	B-C0032743
imaging	I-C0032743
and	O
were	O
classified	O
in	O
right	B-C0228232
and	O
left	B-C0228233
sd	B-C0338462
according	O
to	O
the	O
onset	O
modality	B-C0695347
and	O
to	O
the	O
prevalent	O
decrease	B-C0547047
in	O
fdg	B-C0046056
uptake	I-C0046056
in	O
right	B-C0228232
or	O
left	B-C0228233
temporal	I-C0228233
lobe	I-C0228233
respectively	O
.	O
	
correlation	B-C1707520
of	O
pet	B-C0032743
imaging	I-C0032743
and	O
famous	B-C0870537
face	I-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
was	O
performed	O
.	O
	
results	B-C1274040
showed	O
a	O
differential	B-C1705242
performance	B-C1882330
profile	B-C0449774
in	O
the	O
two	O
diseases	B-C0012634
,	O
because	O
ad	B-C0002395
patients	B-C0030705
were	O
significantly	O
impaired	B-C0221099
in	O
the	O
naming	B-C0392366
tests	I-C0392366
,	O
but	O
showed	O
preserved	O
recognition	B-C0524637
,	O
whereas	O
sd	B-C0338462
patients	B-C0030705
were	O
profoundly	O
impaired	B-C0221099
both	O
in	O
naming	B-C0392366
and	O
in	O
recognition	B-C0870537
of	I-C0870537
famous	I-C0870537
faces	I-C0870537
and	O
voices	B-C0920674
.	O
	
furthermore	O
,	O
face	B-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
disorders	B-C0012634
prevailed	O
in	O
sd	B-C0338462
patients	B-C0030705
with	O
rtl	B-C0228232
atrophy	B-C0333641
,	O
who	O
also	O
showed	O
a	O
conceptual	B-C1254372
impairment	B-C0221099
on	O
the	O
pyramids	B-C0451399
and	I-C0451399
palm	I-C0451399
trees	I-C0451399
test	I-C0451399
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	B-C0439824
modality	B-C0695347
.	O
	
finally	O
,	O
in	O
12	O
sd	B-C0338462
patients	B-C0030705
in	O
whom	O
pet	B-C0032743
was	O
available	O
,	O
a	O
strong	O
correlation	B-C1707520
between	O
fdg	B-C0046056
uptake	I-C0046056
and	O
face-to-name	B-C1708943
and	O
voice-to-name	B-C1708943
matching	I-C1708943
data	B-C1511726
was	O
found	O
in	O
the	O
right	B-C0228232
but	O
not	O
in	O
the	O
left	B-C0228233
temporal	I-C0228233
lobe	I-C0228233
.	O
	
the	O
data	B-C1511726
support	O
the	O
hypothesis	B-C1512571
of	O
a	O
different	O
cognitive	B-C0009240
basis	O
for	O
impairment	B-C0221099
of	O
face	B-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
in	O
the	O
two	O
dementias	B-C0338462
and	O
suggest	O
that	O
the	O
pattern	B-C0449774
of	O
impairment	B-C0221099
in	O
sd	B-C0338462
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	B-C0036612
representations	B-C1882932
,	O
while	O
a	O
defect	O
of	O
semantic	B-C0036612
control	B-C2587213
,	O
with	O
impaired	B-C0221099
naming	B-C0392366
and	O
preserved	B-C0524637
recognition	I-C0524637
might	O
be	O
hypothesized	O
in	O
ad	B-C0002395
.	O
	
furthermore	O
,	O
the	O
correlation	B-C1707520
between	O
face	B-C0870537
and	O
voice	B-C0920674
recognition	I-C0920674
disorders	B-C0012634
and	O
rtl	B-C0228232
damage	B-C0178314
are	O
consistent	O
with	O
the	O
hypothesis	B-C1512571
assuming	O
that	O
in	O
the	O
rtl	B-C0228232
person	B-C0027361
-specific	O
knowledge	B-C0376554
may	O
be	O
mainly	O
based	O
upon	O
non-verbal	B-C0681317
representations	I-C0681317
.	O
	
dry	B-C0151908
skin	I-C0151908
conditions	O
are	O
related	B-C0439849
to	O
the	O
recovery	B-C1521828
rate	I-C1521828
of	O
skin	B-C0037294
temperature	I-C0037294
after	O
cold	B-C0009264
stress	B-C0449430
rather	O
than	O
to	O
blood	B-C0232338
flow	I-C0232338
cutaneous	B-C0221912
blood	B-C0232338
flow	I-C0232338
plays	O
an	O
important	B-C3898777
role	O
in	O
the	O
thermoregulation	B-C0232416
,	O
oxygen	B-C0429622
supply	I-C0429622
,	O
and	O
nutritional	B-C0242739
support	I-C0242739
necessary	O
to	O
maintain	B-C0024501
the	O
skin	B-C1123023
.	O
	
however	O
,	O
there	O
is	O
little	O
evidence	B-C3887511
for	O
a	O
link	O
between	O
blood	B-C0232338
flow	I-C0232338
and	O
skin	B-C0037289
physiology	I-C0037289
.	O
	
therefore	O
,	O
we	O
conducted	O
surveys	B-C0038951
of	O
healthy	B-C1708335
volunteers	I-C1708335
to	O
determine	O
the	O
relationship	B-C0439849
s	O
between	O
dry	B-C0151908
skin	I-C0151908
properties	O
and	O
cutaneous	B-C0221912
vascular	B-C0232337
function	I-C0232337
.	O
	
water	O
content	O
of	O
the	O
stratum	B-C0221921
corneum	I-C0221921
,	O
transepidermal	B-C0232421
water	I-C0232421
loss	I-C0232421
,	O
and	O
visual	B-C1512080
dryness	I-C1512080
score	I-C1512080
were	O
investigated	B-C1292732
as	O
dry	B-C0151908
skin	I-C0151908
parameters	B-C0449381
.	O
	
cutaneous	B-C0221912
blood	B-C0232338
flow	I-C0232338
in	O
the	O
resting	B-C0679218
state	I-C0679218
,	O
the	O
recovery	B-C1521828
rate	I-C1521828
rr	B-C1521828
of	O
skin	B-C0037294
temperature	I-C0037294
on	O
the	O
hand	B-C0018563
after	O
a	O
cold-stress	B-C0022885
test	I-C0022885
,	O
and	O
the	O
responsiveness	B-C0205342
of	O
facial	B-C0222084
skin	I-C0222084
blood	B-C0232338
flow	I-C0232338
to	O
local	B-C0419138
cooling	I-C0419138
were	O
examined	B-C0332128
as	O
indices	B-C0918012
of	O
cutaneous	B-C0221912
vascular	B-C0232337
functions	I-C0232337
.	O
	
the	O
relationships	B-C0439849
between	O
dry	B-C0151908
skin	I-C0151908
parameters	B-C0449381
and	O
cutaneous	B-C0221912
vascular	B-C0232337
functions	I-C0232337
were	O
assessed	B-C1516048
.	O
	
the	O
rr	B-C1521828
correlated	B-C1707520
negatively	O
with	O
the	O
visual	B-C1512080
dryness	I-C1512080
score	I-C1512080
of	O
skin	B-C1123023
on	O
the	O
leg	B-C1140621
but	O
correlated	B-C1707520
positively	O
with	O
water	O
content	O
of	O
the	O
stratum	B-C0221921
corneum	I-C0221921
on	O
the	O
arm	O
.	O
	
no	O
significant	O
correlation	B-C1707520
between	O
the	O
resting	B-C0679218
state	I-C0679218
of	O
blood	B-C0232338
flow	I-C0232338
and	O
dry	B-C0151908
skin	I-C0151908
parameters	B-C0449381
was	O
observed	B-C1441672
.	O
	
in	O
both	O
the	O
face	B-C0015450
and	O
the	O
body	B-C0242821
,	O
deterioration	B-C0868945
in	O
skin	B-C0151908
dryness	I-C0151908
from	O
summer	B-C0241301
to	O
winter	B-C0241737
was	O
significant	B-C0750502
in	O
subjects	O
with	O
low	O
rr	B-C1521828
.	O
	
the	O
rr	B-C1521828
correlated	B-C1707520
well	O
with	O
the	O
responsiveness	B-C0205342
of	O
facial	B-C0222084
skin	I-C0222084
blood	B-C0232338
flow	I-C0232338
to	O
local	B-C0419138
cooling	I-C0419138
,	O
indicating	B-C1444656
that	O
the	O
rr	B-C1521828
affects	O
systemic	O
dry	B-C0151908
skin	I-C0151908
conditions	O
.	O
	
these	O
results	O
suggest	O
that	O
the	O
rr	B-C1521828
but	O
not	O
blood	B-C0232338
flow	I-C0232338
at	O
the	O
resting	B-C0679218
state	I-C0679218
is	O
associated	O
with	O
dry	B-C0151908
skin	I-C0151908
conditions	O
and	O
is	O
involved	O
in	O
skin	O
homeostasis	B-C0019868
during	O
seasonal	B-C0036496
environmental	B-C4060636
changes	I-C4060636
.	O
	
molar	B-C0080233
loss	I-C0080233
and	O
powder	B-C0301569
diet	I-C0301569
leads	O
to	O
memory	B-C0233794
deficit	I-C0233794
and	O
modifies	O
the	O
mrna	B-C1515670
expression	I-C1515670
of	O
brain-derived	B-C0107103
neurotrophic	I-C0107103
factor	I-C0107103
in	O
the	O
hippocampus	B-C0019564
of	O
adult	B-C0001675
mice	B-C0025929
it	O
is	O
known	O
that	O
tooth	B-C0080233
loss	I-C0080233
is	O
known	O
to	O
be	O
a	O
risk	B-C0035648
factor	I-C0035648
for	O
alzheimer's	B-C0002395
disease	I-C0002395
and	O
soft	B-C0301569
diet	I-C0301569
feeding	B-C2987508
induces	O
memory	B-C0233794
impairment	I-C0233794
.	O
	
recent	O
studies	O
have	O
shown	O
that	O
brain-derived	B-C0107103
neurotrophic	I-C0107103
factor	I-C0107103
bdnf	B-C0107103
is	O
associated	B-C0332281
with	I-C0332281
tooth	B-C0080233
loss	I-C0080233
or	O
soft	B-C0301569
diet	I-C0301569
in	O
young	O
animal	B-C0599779
model	I-C0599779
,	O
and	O
that	O
bdnf	B-C1332408
expression	B-C0017262
is	O
decreased	O
in	O
patients	B-C0030705
with	O
alzheimer's	B-C0002395
disease	I-C0002395
.	O
	
however	O
,	O
single	O
or	O
combined	O
effect	B-C1704420
of	I-C1704420
tooth	B-C0080233
loss	I-C0080233
and/or	O
soft	B-C0301569
diet	I-C0301569
on	O
brain	B-C0678908
function	I-C0678908
has	O
not	O
fully	O
understood	O
.	O
	
here	O
we	O
examined	O
the	O
effect	B-C1704420
of	I-C1704420
molar	B-C0080233
loss	I-C0080233
and	O
powder	B-C0301569
diet	I-C0301569
on	O
memory	B-C0025260
ability	I-C0025260
and	O
the	O
expression	B-C0017262
of	O
bdnf	B-C1332408
mrna	I-C1332408
in	O
the	O
hippocampus	B-C0019564
of	O
adult	B-C0001675
c57bl/6j	B-C0025929
mice	I-C0025929
.	O
	
twenty	O
eight-weeks-old	O
c57bl/6j	B-C0025929
mice	I-C0025929
were	O
divided	O
into	O
intact	O
molar	O
group	O
and	O
extracted	O
molar	O
group	O
.	O
	
they	O
were	O
randomly	B-C0034656
divided	O
into	O
the	O
i/s	O
group	O
intact	O
upper	B-C0927248
molar	I-C0927248
teeth	I-C0927248
/	O
solid	B-C0012155
diet	I-C0012155
feeding	B-C2987508
,	O
the	O
e/s	O
group	O
extracted	B-C0040440
upper	B-C0927248
molar	I-C0927248
teeth	I-C0927248
/	O
solid	B-C0012155
diet	I-C0012155
feeding	B-C2987508
,	O
the	O
i/p	O
group	O
intact	O
upper	B-C0927248
molar	I-C0927248
teeth	I-C0927248
/	O
powder	B-C0301569
diet	I-C0301569
feeding	B-C2987508
,	O
and	O
the	O
e/p	O
group	O
extracted	O
upper	B-C0927248
molar	I-C0927248
teeth	I-C0927248
/	O
powder	B-C0301569
diet	I-C0301569
feeding	B-C2987508
.	O
	
the	O
observation	O
periods	O
were	O
4	O
and	O
16-week	O
.	O
	
to	O
analyze	B-C0936012
the	O
memory	B-C0025260
ability	I-C0025260
,	O
the	O
step-through	O
passive	B-C0871047
avoidance	I-C0871047
test	O
was	O
conducted	O
.	O
	
bdnf-related	B-C1332408
mrna	I-C1332408
in	O
the	O
hippocampus	B-C0019564
was	O
analyzed	B-C0936012
by	O
real-time	B-C1709846
polymerase	I-C1709846
chain	I-C1709846
reaction	I-C1709846
rt-pcr	B-C1709846
.	O
	
at	O
4	O
weeks	O
later	O
,	O
we	O
performed	O
memory	B-C0022885
test	I-C0022885
and	O
isolated	O
brains	B-C0006104
to	O
analyze	B-C0936012
.	O
	
there	O
were	O
no	B-C3842396
differences	I-C3842396
in	O
memory	B-C0025260
function	I-C0025260
and	O
bdnf	B-C1332408
mrna	I-C1332408
level	O
between	O
these	O
four	O
groups	O
.	O
	
however	O
,	O
at	O
16	O
weeks	O
later	O
,	O
e/s	O
and	O
e/p	O
group	O
showed	O
memory	B-C0233794
impairment	I-C0233794
,	O
and	O
decreased	O
level	O
of	O
bdnf	B-C1332408
mrna	I-C1332408
.	O
	
whereas	O
,	O
the	O
powder	B-C0301569
diet	I-C0301569
had	O
no	B-C1301751
effect	I-C1301751
on	O
memory	B-C0025260
function	I-C0025260
and	O
bdnf	B-C1332408
mrna	I-C1332408
level	O
even	O
at	O
16	O
weeks	O
later	O
.	O
	
these	O
results	O
suggest	O
that	O
the	O
effect	B-C1704420
of	I-C1704420
molar	B-C0080233
loss	I-C0080233
and	O
powder	B-C0301569
diet	I-C0301569
on	O
memory	B-C0025260
function	I-C0025260
and	O
bdnf	B-C1332408
mrna	I-C1332408
levels	O
were	O
different	O
,	O
molar	B-C0080233
loss	I-C0080233
may	O
have	O
a	O
greater	O
long-term	B-C0023983
effect	I-C0023983
on	O
memory	B-C0025260
ability	I-C0025260
than	O
powder	B-C0301569
diet	I-C0301569
description	O
of	O
the	O
first	O
species	B-C1705920
of	O
fiorianteon	B-C0684063
olmi	I-C0684063
hymenoptera	B-C0020415
,	O
dryinidae	B-C1191214
from	O
the	O
afrotropical	B-C0017446
region	I-C0017446
fiorianteon	B-C0684063
sulcatumsp	I-C0684063
.	O
	
n	O
.	O
	
is	O
described	O
from	O
fianarantsoa	B-C0017446
province	I-C0017446
madagascar	B-C0024443
.	O
	
it	O
is	O
the	O
first	O
species	B-C1705920
of	O
fiorianteon	B-C0684063
found	O
in	O
the	O
afrotropical	B-C0017446
region	I-C0017446
.	O
	
the	O
genus	B-C1708235
fiorianteon	B-C0684063
can	O
be	O
distinguished	O
from	O
the	O
closely	O
related	O
genus	B-C1708235
conganteon	B-C0684063
by	O
the	O
distal	B-C0205108
part	O
of	O
the	O
stigmal	B-C0042449
vein	I-C0042449
,	O
which	O
is	O
as	O
long	B-C0205166
as	O
,	O
or	O
shorter	B-C0424641
than	O
the	O
proximal	B-C0205107
part	O
of	O
the	O
stigmal	B-C0042449
vein	I-C0042449
longer	O
than	O
the	O
proximal	B-C0205107
part	O
of	O
the	O
vein	B-C0042449
in	O
the	B-C0871893
daniel	I-C0871893
k	I-C0871893
.	O
	
inouye	I-C0871893
college	I-C0871893
of	I-C0871893
pharmacy	I-C0871893
scripts	I-C0871893
poha	B-C0016767
berry	I-C0016767
physalis	B-C0331245
peruviana	I-C0331245
with	O
potential	B-C3245505
anti-inflammatory	B-C1515999
and	O
cancer	B-C0281206
prevention	I-C0281206
activities	B-C0441655
the	B-C0036381
daniel	I-C0036381
k	I-C0036381
.	O
	
inouye	I-C0036381
college	I-C0036381
of	I-C0036381
pharmacy	I-C0036381
,	O
during	O
a	O
historic	B-C0441471
event	I-C0441471
in	O
spring	B-C0241232
2016	O
,	O
graduated	B-C0588053
the	O
first	O
two	O
students	B-C0038492
in	O
the	O
pacific	B-C0017446
region	I-C0017446
to	O
earn	O
a	O
phd	B-C1512022
in	O
pharmaceutical	B-C0031336
sciences	I-C0031336
at	O
the	O
university	B-C0041740
of	I-C0041740
hawai'i	I-C0041740
at	O
hilo	B-C0017446
.	O
	
the	O
college	B-C0036381
offers	O
phd	B-C1512022
programs	B-C3484370
in	O
these	O
five	O
disciplines	B-C1518533
cancer	B-C1516164
biology	I-C1516164
,	O
medicinal	B-C0008003
chemistry	I-C0008003
,	O
pharmaceutics	B-C4277728
,	O
pharmacognosy	B-C0031326
,	O
and	O
pharmacology	B-C0031330
.	O
	
one	O
of	O
the	O
pharmacognosy	B-C0031326
dissertations	B-C0376645
focused	O
on	O
plant-derived	B-C0032098
natural	B-C1566558
products	I-C1566558
with	O
potential	B-C3245505
anti-inflammatory	B-C1515999
and	O
cancer	B-C0006826
chemopreventive	B-C3273128
activities	B-C0441655
.	O
	
physalis	B-C0331245
peruviana	I-C0331245
pp	B-C0331245
l	O
.	O
	
originated	O
in	O
tropical	O
south	B-C0037713
america	I-C0037713
.	O
	
it	O
has	O
become	O
naturalized	B-C0205296
and	O
is	O
found	O
readily	O
on	O
the	O
island	B-C0017446
of	I-C0017446
hawai'i	I-C0017446
.	O
	
the	O
edible	B-C0032099
fruits	B-C0016767
are	O
commonly	O
known	O
as	O
cape	B-C0331245
gooseberry	I-C0331245
or	O
poha	B-C0331245
in	O
hawai'i	B-C0017446
.	O
	
in	O
part	O
of	O
our	O
study	O
,	O
three	O
new	O
withanolides	B-C1955897
,	O
physaperuvin	B-C1254351
g	I-C1254351
1	O
,	O
physaperuvins	B-C1254351
i-j	I-C1254351
2-3	O
,	O
along	O
with	O
four	O
known	O
withanolides	B-C1955897
,	O
namely	O
,	O
4β-hydroxywithanolide	B-C1254351
e	I-C1254351
4	O
,	O
withaperuvin	B-C1254351
c	I-C1254351
5	O
,	O
and	O
physalactone	B-C1254351
6	O
,	O
coagulin	B-C1254351
7	O
were	O
isolated	B-C0205409
from	O
the	O
aerial	B-C1136056
parts	I-C1136056
of	O
p	B-C0331245
.	O
	
peruviana	I-C0331245
.	O
	
in	O
addition	O
,	O
two	O
known	O
compounds	B-C1706082
,	O
phyperunolide	B-C1254351
f	I-C1254351
8	O
,	O
and	O
withanolide	B-C1254351
s	I-C1254351
9	O
,	O
were	O
isolated	B-C0205409
and	O
identified	O
from	O
the	O
poha	B-C0016767
berry	I-C0016767
fruits	I-C0016767
.	O
	
the	O
structures	B-C0678594
and	O
absolute	B-C2350023
stereochemistry	I-C2350023
of	O
new	O
compounds	O
from	O
poha	B-C0331245
were	O
elucidated	O
by	O
several	O
spectroscopy	B-C2984732
methods	I-C2984732
nuclear	B-C0877853
magnetic	I-C0877853
resonance	I-C0877853
nmr	I-C0877853
spectroscopy	I-C0877853
,	O
x-ray	B-C0043301
diffraction	I-C0043301
,	O
and	O
mass	B-C0037813
spectrometry	I-C0037813
analyses	B-C0936012
.	O
	
all	O
isolated	B-C0205409
poha	B-C0331245
compounds	B-C1706082
aerial	B-C1136056
parts	I-C1136056
and	O
fruits	B-C0016767
were	O
evaluated	O
for	O
their	O
anti-inflammatory	B-C1515999
activity	I-C1515999
with	O
lipopolysaccharide	B-C0023810
lps	B-C0023810
murine	B-C0026809
macrophage	B-C4042840
raw	I-C4042840
264.7	I-C4042840
cells	I-C4042840
,	O
and	O
tumor	B-C0041368
necrosis	I-C0041368
factor	I-C0041368
alpha	I-C0041368
tnf-α	B-C0041368
nuclear	B-C0079904
factor-kappa	I-C0079904
b	I-C0079904
nf-κb	B-C0079904
with	O
transfected	O
human	B-C2936239
embryonic	I-C2936239
kidney	I-C2936239
cells	I-C2936239
293	I-C2936239
.	O
	
most	O
of	O
the	O
isolated	B-C0205409
natural	B-C1566558
compounds	I-C1566558
showed	O
activity	B-C0205177
with	O
these	O
assays	B-C0005507
.	O
	
additional	O
studies	O
were	O
performed	O
with	O
models	B-C3161035
of	O
colon	B-C0007102
cancer	I-C0007102
.	O
	
specifically	O
,	O
4β-hydroxywithanolide	B-C1254351
e	I-C1254351
4hwe	B-C1254351
inhibited	B-C0311403
the	O
growth	B-C0018270
of	O
colon	B-C0007102
cancer	I-C0007102
monolayer	B-C0007585
and	O
spheroid	B-C0282501
cultures	B-C0007585
.	O
	
the	O
compound	B-C1706082
induced	B-C0205263
cell	B-C1155873
cycle	I-C1155873
arrest	I-C1155873
at	O
low	B-C1446561
concentrations	I-C1446561
and	O
apoptosis	B-C0162638
at	O
higher	B-C1446561
concentrations	I-C1446561
.	O
	
these	O
data	B-C1511726
suggest	O
the	O
ingestion	B-C0232478
of	O
poha	B-C0016767
berries	I-C0016767
may	O
have	O
some	O
effect	O
on	O
the	O
prevalence	O
of	O
colon	B-C0007102
cancer	I-C0007102
.	O
	
additionally	O
,	O
poha	B-C0016452
isolates	B-C1706082
compounds	I-C1706082
were	O
evaluated	O
for	O
their	O
growth	B-C1512280
inhibitory	I-C1512280
effects	I-C1512280
with	O
u251mg	B-C0017636
glioblastoma	I-C0017636
and	O
mda-mb-231	B-C3898556
breast	I-C3898556
cancer	I-C3898556
cells	I-C3898556
that	O
harbor	O
aberrantly-active	O
signal	B-C0253050
transducer	I-C0253050
and	I-C0253050
activation	I-C0253050
of	I-C0253050
transcription	I-C0253050
3	I-C0253050
stat3	I-C0253050
,	O
compared	O
to	O
normal	O
nih-3t3	B-C1257739
mouse	I-C1257739
fibroblasts	I-C1257739
.	O
	
this	O
work	O
has	O
led	O
to	O
the	O
filing	O
of	O
three	O
provisional	B-C0030650
patents	I-C0030650
with	O
the	O
university	B-C0041740
of	I-C0041740
hawai'i	I-C0041740
office	I-C0041740
of	I-C0041740
technology	I-C0041740
transfer	I-C0041740
and	I-C0041740
economic	I-C0041740
development	I-C0041740
.	O
	
air	B-C0001869
pollutant	I-C0001869
exposure	B-C0332157
within	O
a	O
few	O
days	O
of	O
delivery	B-C0011209
and	O
placental	B-C0000832
abruption	I-C0000832
in	O
japan	B-C0022341
placental	B-C0000832
abruption	I-C0000832
is	O
an	O
emergency	B-C0178292
obstetric	I-C0178292
complication	I-C0178292
.	O
	
although	O
the	O
etiology	B-C1314792
of	O
abruption	B-C0000832
is	O
not	O
fully	O
understood	O
,	O
acute	B-C0205178
stimuli	B-C0234402
,	O
such	O
as	O
ischemia	B-C0022116
and/or	O
inflammation	B-C0021368
,	O
are	O
associated	B-C0332281
with	I-C0332281
rupture	B-C0155760
of	I-C0155760
the	I-C0155760
decidual	I-C0155760
artery	I-C0155760
,	O
resulting	O
in	O
placental	B-C0233170
separation	I-C0233170
.	O
	
ischemia	B-C0022116
and	O
inflammation	B-C0021368
are	O
acute	B-C0205178
biologic	B-C0205460
effects	B-C1280500
of	O
air	B-C0001873
pollution	I-C0001873
.	O
	
using	O
a	O
case-crossover	B-C4288565
design	I-C4288565
,	O
we	O
tested	O
the	O
hypothesis	B-C1512571
that	O
a	O
short-term	B-C0443303
increase	B-C0442805
in	O
exposure	B-C0332157
to	O
air	B-C0001869
pollutants	I-C0001869
is	O
a	O
potential	B-C3245505
trigger	B-C0032930
of	O
placental	B-C0000832
abruption	I-C0000832
.	O
	
we	O
received	O
data	B-C1511726
for	O
western	B-C0017446
japan	I-C0017446
kyushu-okinawa	B-C0017446
districts	I-C0017446
from	O
the	O
japan	B-C0242356
perinatal	I-C0242356
registry	I-C0242356
network	I-C0242356
database	I-C0242356
.	O
	
from	O
2005	O
to	O
2010	O
,	O
821	O
singleton	B-C1313913
pregnant	B-C0033011
women	I-C0033011
with	O
placental	B-C0000832
abruption	I-C0000832
were	O
identified	O
.	O
	
we	O
assigned	O
daily	B-C0332173
concentrations	B-C1265611
of	O
air	B-C0001869
pollutants	I-C0001869
,	O
including	O
nitrogen	B-C0028160
dioxide	I-C0028160
no2	B-C0028160
,	O
suspended	B-C1510837
particulate	I-C1510837
matter	I-C1510837
,	O
ozone	B-C0030106
,	O
and	O
sulfur	B-C0038777
dioxide	I-C0038777
so2	B-C0038777
,	O
from	O
the	O
nearest	O
monitoring	B-C1883167
station	I-C1883167
to	O
the	O
respective	O
delivery	B-C0011209
hospital	B-C0019994
of	O
each	O
woman	B-C0043210
.	O
	
because	O
information	B-C1533716
on	O
the	O
onset	B-C0449244
day	I-C0449244
of	O
abruption	B-C0000832
was	O
not	O
obtained	O
,	O
we	O
assumed	O
the	O
case	B-C0868928
day	B-C0439228
to	O
be	O
1	O
day	B-C0439228
before	O
the	O
day	O
of	O
delivery	B-C0011209
.	O
	
exposure	B-C0332157
to	O
no2	B-C0028160
at	O
2	O
days'	O
lag	O
was	O
associated	B-C0332281
with	I-C0332281
placental	B-C0000832
abruption	I-C0000832
temperature	B-C0039476
adjusted	O
odds	B-C0028873
ratio	I-C0028873
per	O
10	O
ppb	O
increase	B-C0442805
=	O
1.4	O
95%	O
confidence	B-C0009667
interval	I-C0009667
=	O
1.1	O
,	O
1.8	O
.	O
	
the	O
association	B-C0439849
patterns	O
were	O
similar	O
,	O
when	O
we	O
restricted	O
to	O
participants	B-C0679646
who	O
delivered	B-C0011209
by	O
emergency	B-C0558380
cesarean	I-C0558380
1.4	O
,	O
1.1	O
,	O
1.9	O
,	O
or	O
who	O
delivered	B-C0011209
after	O
35	B-C0233042
weeks	I-C0233042
of	I-C0233042
gestation	I-C0233042
1.4	O
,	O
1.0	O
,	O
2.0	O
.	O
	
there	O
was	O
no	B-C1513916
association	I-C1513916
with	O
suspended	B-C1510837
particulate	I-C1510837
matter	I-C1510837
,	O
ozone	B-C0030106
,	O
or	O
so2	B-C0038777
.	O
	
we	O
observed	O
an	O
association	B-C0439849
between	O
no2	B-C0028160
exposure	B-C0332157
at	O
2	O
days	B-C0439228
before	O
the	O
day	B-C0439228
of	O
delivery	B-C0011209
and	O
placental	B-C0000832
abruption	I-C0000832
in	O
pregnant	B-C0033011
japanese	I-C0033011
women	I-C0033011
.	O
	
the	O
2016	O
infusion	B-C4316303
therapy	I-C4316303
standards	B-C0034925
of	O
practice	B-C0237607
approximately	O
every	O
5	O
years	O
,	O
the	O
infusion	B-C1708333
nurses	I-C1708333
society	I-C1708333
publishes	B-C0034037
evidence-based	B-C1510541
practice	I-C1510541
standards	B-C0034925
.	O
	
this	O
article	B-C1706852
provides	O
an	O
overview	O
of	O
the	O
process	B-C1522240
used	B-C1524063
in	O
standards	B-C0034925
development	B-C1527148
,	O
describes	O
the	O
format	B-C1301627
of	O
the	O
standards	B-C0034925
,	O
and	O
provides	B-C1999230
a	O
short	O
summary	B-C1706244
of	O
selected	B-C1707391
standards	B-C0034925
as	O
applied	B-C4048755
to	O
home	B-C0019855
care	I-C0019855
.	O
	
the	O
standards	B-C0034925
are	O
an	O
important	B-C3898777
document	B-C1301746
that	O
should	O
be	O
available	B-C0470187
to	O
every	B-C1948061
home	B-C0019855
care	I-C0019855
organization	B-C1708333
that	O
provides	B-C1999230
home	B-C0242945
infusion	I-C0242945
therapy	I-C0242945
.	O
	
datasets	B-C0150098
for	O
the	O
validation	B-C1519941
of	O
the	O
""""	O
in	B-C1515655
vivo	I-C1515655
""""	O
sirna	B-C1099354
-	O
silencing	B-C0598496
of	O
cd40	B-C1539081
and	O
for	O
the	O
detection	B-C1511790
of	O
new	O
markers	B-C0017393
of	O
atherosclerosis	B-C0003850
progression	B-C0242656
in	O
apoe	B-C1412481
-	O
deficient	B-C0011155
mice	B-C0025929
data	B-C1511726
presented	O
in	O
this	O
data	B-C1511726
in	B-C1515655
brief	O
article	O
correspond	O
to	O
the	O
article	O
""""	O
in	O
vivo	I-C1515655
""""	O
silencing	B-C0598496
of	O
cd40	B-C1539081
reduces	O
progression	B-C0242656
of	O
experimental	B-C0681814
atherogenesis	B-C1563937
through	O
a	O
nfκb	B-C0079904
/	O
mir-125b	B-C2352284
axis	O
and	O
reveals	O
new	O
potential	B-C3245505
mediators	B-C1363844
in	O
the	O
pathogenesis	B-C0699748
of	O
atherosclerosis	B-C0003850
""""	O
m	B-C1547383
.	O
	
hueso	I-C1547383
,	O
l	B-C1547383
.	O
	
de	I-C1547383
ramon	I-C1547383
,	O
e	B-C1547383
.	O
	
navarro	I-C1547383
,	O
e	B-C1547383
.	O
	
ripoll	I-C1547383
,	O
j.m	B-C1547383
.	O
	
cruzado	I-C1547383
,	O
j.m	B-C1547383
.	O
	
grinyo	I-C1547383
,	O
j	B-C1547383
.	O
	
torras	I-C1547383
,	O
2016	O
1	O
.	O
	
here	O
,	O
we	O
describe	O
the	O
validation	B-C1519941
of	O
the	O
silencing	B-C0598496
of	O
cd40	B-C1539081
expression	B-C0017262
with	O
a	O
specific	O
sirna	B-C1099354
in	O
apoe	B-C1412481
mouse	B-C0025929
aortas	B-C0003483
,	O
and	O
its	O
systemic	O
effects	O
on	O
splenic	B-C0037993
lymphocytic	B-C0079720
subpopulations	I-C0079720
as	O
well	O
as	O
on	O
the	O
infiltration	B-C0332448
of	O
aortic	B-C0226009
intima	I-C0226009
by	O
f4/80	B-C0007634
,	O
galectin-3	B-C0024432
macrophages	I-C0024432
or	O
by	O
nf-κb	B-C0007634
cells	I-C0007634
.	O
	
we	O
also	O
show	O
the	O
output	O
of	O
a	O
gene	B-C1138831
ontology	I-C1138831
and	O
tlda	B-C0936012
analysis	I-C0936012
which	O
allowed	O
the	O
detection	B-C1511790
of	O
potential	B-C3245505
mediators	B-C1363844
of	O
atherosclerosis	B-C0003850
progression	B-C0242656
.	O
	
we	O
provide	O
the	O
scientific	O
community	O
with	O
a	O
set	O
of	O
genes	B-C0017337
whose	O
expression	B-C0017262
is	O
increased	B-C0205217
during	O
atherosclerosis	B-C0003850
progression	B-C0242656
but	O
downregulated	B-C0013081
upon	O
cd40	B-C1539081
silencing	B-C0598496
.	O
	
investigation	B-C1552578
on	O
evaluation	B-C0220825
criteria	B-C0243161
of	O
backwashing	B-C1522240
effects	B-C1280500
for	O
a	O
pilot-scale	B-C0031928
baf	B-C0180861
treating	B-C1522326
petrochemical	B-C0220806
wastewater	B-C3494254
parameters	B-C0549193
for	O
evaluation	B-C0220825
criteria	B-C0243161
of	O
air	B-C0001861
-	O
water	B-C0043047
backwashing	B-C1522240
effect	B-C1280500
s	O
of	O
a	O
pilot-scale	B-C0031928
biological	B-C0180861
aerated	I-C0180861
filter	I-C0180861
baf	B-C0180861
treating	B-C1522326
petrochemical	B-C0220806
wastewater	B-C3494254
were	O
investigated	B-C1292732
.	O
	
the	O
parameters	B-C0549193
included	O
the	O
suspended	B-C1705537
solids	B-C0302909
ss	B-C0302909
and	O
specific	B-C0429627
oxygen	I-C0429627
uptake	I-C0429627
rate	I-C0429627
sour	B-C0429627
of	O
the	O
backwashing	B-C1522240
effluent	B-C1546612
,	O
recovery	B-C0237820
of	O
the	O
baf	B-C0180861
after	O
backwashing	B-C1522240
,	O
and	O
the	O
removal	B-C1883720
of	O
the	O
biomass	B-C0005535
/	O
bioactivity	B-C0205556
attached	B-C3714578
on	O
the	O
filter	B-C0180861
media	B-C1705217
after	O
backwashing	B-C1522240
.	O
	
results	B-C1274040
showed	O
that	O
the	O
weight	B-C0043100
of	O
the	O
total	B-C0439810
sludge	B-C0282346
produced	O
in	O
the	O
backwashing	B-C1522240
effluent	B-C1546612
increased	B-C0205217
with	O
the	O
increase	B-C0442805
in	O
water	B-C0043047
-	O
backwashing	B-C1522240
intensity	B-C0522510
,	O
while	O
the	O
total	B-C0439810
sour	B-C0429627
of	O
backwashing	B-C1522240
effluent	B-C1546612
rose	O
notably	B-C4288581
with	O
the	O
increase	B-C0442805
of	O
air	B-C0001861
-	O
backwashing	B-C1522240
intensity	B-C0522510
.	O
	
the	O
optimal	B-C2698651
backwashing	B-C1522240
intensity	B-C0522510
of	O
14	O
l/	O
for	O
air	B-C0001861
and	O
4	O
l/	O
for	O
water	B-C0043047
were	O
obtained	B-C1301820
.	O
	
when	O
the	O
baf	B-C0180861
was	O
backwashed	B-C1522240
on	O
this	O
condition	O
,	O
the	O
baf	B-C0180861
recovered	B-C0521108
with	O
high	B-C0205250
average	B-C1510992
removal	B-C1883720
of	O
chemical	B-C2936287
oxygen	I-C2936287
demand	I-C2936287
cod	B-C2936287
and	O
ammonia	B-C0368666
nitrogen	I-C0368666
formula	O
see	O
text	O
of	O
14.3	O
and	O
50.3	O
,	O
respectively	O
.	O
	
high	B-C0205250
amount	B-C1265611
of	O
biomass	B-C0005535
removal	B-C1883720
at	O
15.8	O
and	O
low	B-C0205251
level	B-C0441889
of	O
bioactivity	B-C0205556
removal	B-C1883720
at	O
8.8	O
attached	B-C3714578
on	O
the	O
filter	B-C0180861
media	B-C1705217
were	O
also	O
found	O
.	O
	
concentrations	B-C1446561
of	O
the	O
benzene	B-C0005036
,	O
toluene	B-C0040383
,	O
ethylbenzene	B-C0059792
and	O
o-	B-C0043368
,	O
m-	I-C0043368
,	O
p-	I-C0043368
xylenes	I-C0043368
btex	B-C0029224
and	O
phenol	B-C0070570
in	O
the	O
backwashed	B-C1522240
sludge	B-C0282346
were	O
analyzed	B-C0936012
,	O
showing	O
that	O
the	O
backwashing	B-C1522240
was	O
essential	B-C0205224
to	O
remove	B-C1883720
some	O
aromatic	B-C1510940
compounds	I-C1510940
adsorbed	B-C0001674
in	O
the	O
implementation	B-C1708476
of	O
infrared	B-C0260249
and	O
raman	B-C0037815
modalities	B-C0695347
for	O
glycosaminoglycan	B-C0017973
characterization	B-C0243175
in	O
complex	B-C0439855
systems	B-C0449913
glycosaminoglycans	B-C0017973
gags	B-C0017973
are	O
natural	B-C0205296
,	O
linear	B-C0205132
and	O
negatively	B-C0003075
charged	I-C0003075
heteropolysaccharides	B-C0032594
which	O
are	O
incident	B-C1551358
in	O
every	O
mammalian	B-C0024660
tissue	B-C0040300
.	O
	
they	O
consist	O
of	O
repeating	O
disaccharide	B-C0012611
units	B-C0439148
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	B-C1954876
or	O
non-sulfated	B-C0026492
monosaccharides	I-C0026492
.	O
	
depending	O
on	O
tissue	B-C0040300
types	B-C0332307
,	O
gags	B-C0017973
exhibit	O
structural	B-C0678594
heterogeneity	B-C0019409
such	O
as	O
the	O
position	B-C0733755
and	O
degree	B-C0449286
of	O
sulfation	B-C0597538
or	O
within	O
their	O
disaccharide	B-C0012611
units	B-C0439148
composition	B-C0205556
being	O
heparin	B-C0019134
,	O
heparan	B-C0019143
sulfate	I-C0019143
,	O
chondroitine	B-C0008466
sulfate	I-C0008466
,	O
dermatan	B-C0011602
sulfate	I-C0011602
,	O
keratan	B-C0022563
sulfate	I-C0022563
,	O
and	O
hyaluronic	B-C0020196
acid	I-C0020196
.	O
	
they	O
are	O
covalently	B-C1511539
linked	I-C1511539
to	O
a	O
core	B-C0444669
protein	B-C0033684
proteoglycans	B-C0033692
or	O
as	O
free	B-C1996904
chains	B-C1524075
hyaluronan	B-C0813622
.	O
	
gags	B-C0017973
affect	O
cell	B-C0007634
properties	B-C0871161
and	O
functions	B-C0007613
either	O
by	O
direct	B-C0439851
interaction	B-C1704675
with	O
cell	B-C0034800
receptors	I-C0034800
or	O
by	O
sequestration	B-C0443301
of	O
growth	B-C0018284
factors	I-C0018284
.	O
	
these	O
evidences	B-C0332120
of	I-C0332120
divert	B-C0743226
biological	B-C0205460
roles	B-C1705810
of	O
gags	B-C0017973
make	O
their	O
characterization	B-C0243175
at	O
cell	B-C0007634
and	O
tissue	B-C0040300
levels	B-C0441889
of	O
importance	O
.	O
	
thus	O
,	O
non-invasive	B-C0205303
techniques	B-C0449851
are	O
interesting	O
to	O
investigate	B-C1292732
,	O
to	O
qualitatively	B-C0205556
and	O
quantitatively	B-C0392762
characterize	O
gags	B-C0017973
in	B-C1533691
vitro	I-C1533691
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	B-C0348026
biomarkers	B-C0005516
and/or	O
as	O
therapeutic	B-C0302350
targets	B-C0085104
in	O
several	O
human	B-C0086418
diseases	B-C0012634
including	O
cancer	B-C0006826
.	O
	
infrared	B-C0260249
and	O
raman	B-C0037815
microspectroscopies	I-C0037815
and	O
imaging	B-C0079595
are	O
sensitive	B-C0332324
enough	O
to	O
differentiate	O
and	O
classify	B-C0008902
gag	B-C0017973
types	B-C0332307
and	O
subtypes	B-C0449560
in	O
spite	O
of	O
their	O
close	O
molecular	B-C0678594
structures	I-C0678594
.	O
	
spectroscopic	B-C0037812
markers	B-C0206015
characteristic	O
of	O
reference	O
gag	B-C0017973
molecules	B-C0567416
were	O
identified	B-C0205396
.	O
	
beyond	O
these	O
investigations	B-C1261322
of	O
the	O
standard	O
gag	B-C0017973
spectral	O
signature	O
,	O
infrared	B-C0260249
and	O
raman	B-C0037815
spectral	O
signatures	O
of	O
gag	B-C0017973
were	O
searched	O
in	O
complex	B-C0439855
biological	B-C0205460
systems	B-C0449913
like	O
cells	B-C0007634
.	O
	
the	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	B-C1708476
of	O
these	O
complementary	O
vibrational	B-C0022885
spectroscopy	I-C0022885
techniques	I-C0022885
,	O
and	O
to	O
discuss	O
their	O
potentials	O
,	O
advantages	O
and	O
disadvantages	O
for	O
gag	B-C0017973
analysis	B-C0002778
.	O
	
in	O
addition	O
,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
gag	B-C0017973
infrared	B-C0260249
and	O
raman	B-C0037815
spectral	O
signatures	O
from	O
conditioned	B-C0162518
media	I-C0162518
and	O
live	B-C0007634
cells	I-C0007634
,	O
targeting	B-C1521840
hif2	B-C1436532
in	O
clear	B-C0279702
cell	I-C0279702
renal	I-C0279702
cell	I-C0279702
carcinoma	I-C0279702
inactivation	O
of	O
the	O
von	B-C1566585
hippel-lindau	I-C1566585
tumor-suppressor	I-C1566585
protein	I-C1566585
pvhl	B-C1566585
is	O
the	O
signature	B-C0243095
"""truncal"""	I-C0243095
event	I-C0243095
in	O
clear	B-C0279702
cell	I-C0279702
renal	I-C0279702
cell	I-C0279702
carcinoma	I-C0279702
,	O
which	O
is	O
the	O
most	O
common	O
form	O
of	O
kidney	B-C1378703
cancer	I-C1378703
.	O
	
pvhl	B-C1566585
is	O
part	O
of	O
a	O
ubiquitin	B-C0077678
ligase	I-C0077678
the	O
targets	B-C1521840
the	O
α	B-C0599220
subunit	I-C0599220
of	O
the	O
hypoxia-inducible	B-C1528322
factor	I-C1528322
hif	I-C1528322
transcription	I-C1528322
factor	I-C1528322
for	O
destruction	B-C1948029
when	O
oxygen	O
is	O
available	O
.	O
	
preclinical	B-C1709630
studies	B-C0008972
strongly	O
suggest	O
that	O
deregulation	B-C1514542
of	O
hif	B-C1528322
,	O
and	O
particularly	O
hif2	B-C1436532
,	O
drives	O
pvhl	B-C1566585
-defective	O
renal	B-C1378703
carcinogenesis	I-C1378703
.	O
	
although	O
hif2α	B-C0538487
was	O
classically	O
considered	O
undruggable	B-C0205556
,	O
structural	O
and	O
chemical	O
work	O
by	O
rick	B-C0805191
bruick	I-C0805191
and	O
kevin	B-C0805191
gardner	I-C0805191
at	O
university	B-C0041740
of	I-C0041740
texas	I-C0041740
southwestern	I-C0041740
laid	O
the	O
foundation	O
for	O
the	O
development	O
of	O
small	B-C1328819
molecule	I-C1328819
direct	O
hif2α	B-C0243076
antagonists	I-C0243076
pt2385	B-C3896783
and	O
the	O
related	O
tool	O
compound	O
pt2399	B-C0243076
by	O
peloton	B-C0815266
therapeutics	I-C0815266
that	O
block	B-C0332206
the	O
dimerization	B-C1323327
of	O
hif2α	B-C0538487
with	O
its	O
partner	O
protein	B-C1506870
arnt1	I-C1506870
.	O
	
these	O
compounds	O
inhibit	B-C1512773
clear	I-C1512773
cell	I-C1512773
renal	I-C1512773
cell	I-C1512773
carcinoma	I-C1512773
growth	I-C1512773
in	O
preclinical	B-C1514292
models	I-C1514292
,	O
and	O
pt2385	B-C3896783
has	O
now	O
entered	O
the	O
clinic	B-C0442592
.	O
	
nonetheless	O
,	O
the	O
availability	O
of	O
such	B-C1254351
compounds	I-C1254351
,	O
together	O
with	O
clustered	B-C3658200
regularly	I-C3658200
interspaced	I-C3658200
short	I-C3658200
palindromic	I-C3658200
repeat	I-C3658200
crispr	B-C3658200
gene	B-C4277689
editing	I-C4277689
approaches	I-C4277689
,	O
has	O
revealed	O
a	O
previously	O
unappreciated	B-C0019409
heterogeneity	I-C0019409
among	O
clear	B-C0279702
cell	I-C0279702
renal	I-C0279702
carcinomas	I-C0279702
and	O
patient	B-C0030705
-derived	O
xenografts	B-C0520484
with	O
respect	O
to	O
hif2	B-C1436532
dependence	O
,	O
suggesting	O
that	O
predictive	B-C0041366
biomarkers	I-C0041366
will	O
be	O
needed	O
to	O
optimize	B-C2698650
the	O
use	O
of	O
such	B-C1254351
agents	I-C1254351
in	O
the	O
prevalence	B-C0683921
of	O
high-risk	B-C0332167
human	B-C0343641
papillomavirus	I-C0343641
infection	I-C0343641
among	O
women	B-C0086287
in	O
shaanxi	B-C0008115
province	B-C1514578
of	O
china	B-C0008115
a	O
hospital	B-C0019994
-based	O
investigation	B-C0220825
this	O
study	O
aimed	O
to	O
investigate	B-C1292732
the	O
characteristics	B-C1521970
of	O
female	B-C0086287
high-risk	B-C0343641
human	I-C0343641
papillomavirus	I-C0343641
hr-hpv	I-C0343641
infection	I-C0343641
in	O
shaanxi	B-C0008115
province	B-C1514578
of	O
china	B-C0008115
.	O
	
a	O
total	O
of	O
14	O
111	O
women	B-C0086287
were	O
enrolled	O
for	O
hpv	B-C0021344
genotyping	B-C2368152
test	I-C2368152
,	O
and	O
a	O
cytology	B-C0010818
,	O
and/or	O
cervix	B-C0195314
biopsy	I-C0195314
were	O
performed	O
in	O
partial	O
women	B-C0086287
.	O
	
of	O
these	O
women	B-C0086287
,	O
the	O
hpv	B-C0343641
infection	I-C0343641
rate	B-C1521828
was	O
30.21	O
,	O
and	O
26.73	O
were	O
caused	O
by	O
hr-hpv	B-C0021344
.	O
	
the	O
most	O
common	O
hr-hpv	B-C0021344
genotypes	B-C0017431
were	O
hpv-16	B-C0999806
,	O
hpv-58	B-C3641018
,	O
hpv-52	B-C3641016
,	O
hpv-18	B-C0999807
,	O
and	O
hpv-31	B-C2936597
.	O
	
the	O
prevalence	B-C0683921
of	O
hr-hpv	B-C0021344
among	O
women	B-C0086287
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
p	O
<	O
0.05	O
.	O
	
the	O
main	O
carcinogenic	B-C0007090
genotypes	B-C0017431
were	O
hpv-16	B-C0999806
,	O
hpv-18	B-C0999807
,	O
hpv-58	B-C3641018
,	O
hpv-52	B-C3641016
,	O
and	O
hpv-31	B-C2936597
.	O
	
hpv-16	B-C0999806
and	O
hpv-18	B-C0999807
combined	O
caused	O
80.79	O
of	O
cervical	B-C0007847
cancer	I-C0007847
cases	O
.	O
	
the	O
infection	B-C3714514
with	O
multiple	O
hr-hpvs	B-C0021344
was	O
not	B-C0205160
a	O
risk	B-C0035648
factor	I-C0035648
for	O
cervical	B-C0235656
lesions	I-C0235656
.	O
	
in	O
conclusion	O
,	O
hpv	B-C0343641
infection	I-C0343641
was	O
common	O
among	O
women	B-C0086287
in	O
shaanxi	B-C0008115
province	B-C1514578
.	O
	
women	B-C0086287
older	O
than	O
50	O
years	O
were	O
a	O
high-risk	B-C0684030
group	I-C0684030
for	O
hr-hpv	B-C0343641
infection	I-C0343641
and	O
cervical	B-C0007847
cancer	I-C0007847
.	O
	
hpv-16	B-C0999806
and	O
hpv-18	B-C0999807
were	O
the	O
main	O
carcinogenic	B-C0007090
genotypes	B-C0017431
in	O
this	O
novel	B-C0205314
and	O
lost	B-C0745777
forests	B-C0086312
in	O
the	O
upper	B-C0026081
midwestern	I-C0026081
united	I-C0026081
states	I-C0026081
,	O
from	O
new	B-C0205314
estimates	B-C0750572
of	O
settlement-era	B-C1254367
composition	O
,	O
stem	B-C0242767
density	B-C0178587
,	O
and	O
biomass	B-C0005535
euroamerican	B-C0683983
land-use	B-C0814835
and	O
its	O
legacies	B-C0242538
have	O
transformed	B-C0443172
forest	B-C0086312
structure	I-C0086312
and	O
composition	O
across	O
the	O
united	B-C0041703
states	I-C0041703
us	B-C0041703
.	O
	
more	B-C0205172
accurate	B-C0443131
reconstructions	B-C1706853
of	O
historical	B-C0175169
states	I-C0175169
are	O
critical	B-C1511545
to	O
understanding	O
the	O
processes	B-C1522240
governing	B-C0243148
past	B-C1444637
,	O
current	B-C0521116
,	O
and	O
future	B-C0016884
forest	B-C0086312
dynamics	B-C3826426
.	O
	
here	O
we	O
present	O
new	O
gridded	O
8x8km	O
reconstructions	B-C1706853
of	O
pre-settlement	B-C1254367
1800s	O
forest	B-C0086312
composition	O
and	O
structure	O
from	O
the	O
upper	B-C0026081
midwestern	I-C0026081
us	I-C0026081
minnesota	B-C0026183
,	O
wisconsin	B-C0043193
,	O
and	O
most	O
of	O
michigan	B-C1548669
,	O
using	O
19th	O
century	B-C0038951
public	I-C0038951
land	I-C0038951
survey	I-C0038951
system	I-C0038951
plss	B-C0038951
,	O
with	O
estimates	B-C0750572
of	O
relative	B-C0205345
composition	O
,	O
above-ground	B-C1282910
biomass	B-C0005535
,	O
stem	B-C0242767
density	B-C0178587
,	O
and	O
basal	B-C0205112
area	I-C0205112
for	O
28	O
tree	B-C0040811
types	B-C0332307
.	O
	
this	O
mapping	B-C1283195
is	O
more	O
robust	B-C2986815
than	O
past	B-C1444637
efforts	B-C1516084
,	O
using	O
spatially	O
varying	O
correction	B-C3166265
factors	I-C3166265
to	O
accommodate	O
sampling	B-C0815259
design	I-C0815259
,	O
azimuthal	B-C0205556
censoring	I-C0205556
,	O
and	O
biases	B-C0242568
in	O
tree	B-C0040811
selection	B-C1707391
.	O
	
we	O
compare	O
pre-settlement	B-C1254367
to	O
modern	B-C1254367
forests	B-C0086312
using	O
us	B-C0041703
forest	B-C0086312
service	B-C0557854
forest	B-C0242356
inventory	I-C0242356
and	I-C0242356
analysis	I-C0242356
fia	I-C0242356
data	I-C0242356
to	O
show	O
the	O
prevalence	B-C0220900
of	O
lost	B-C0745777
forests	B-C0086312
pre-settlement	B-C1254367
forests	B-C0086312
with	O
no	B-C1518422
current	B-C0521116
analog	B-C0205556
,	O
and	O
novel	B-C0205314
forests	B-C0086312
modern	B-C1254367
forests	B-C0086312
with	O
no	B-C1518422
past	B-C1444637
analogs	B-C0205556
.	O
	
differences	O
between	O
pre-settlement	B-C1254367
and	O
modern	B-C1254367
forests	B-C0086312
are	O
spatially	O
structured	O
owing	O
to	O
differences	O
in	O
land-use	B-C0814835
impacts	B-C4049986
and	O
accompanying	O
ecological	B-C0237534
responses	I-C0237534
.	O
	
modern	B-C1254367
forests	B-C0086312
are	O
more	O
homogeneous	B-C1881065
,	O
and	O
ecotonal	B-C0812409
gradients	B-C0812409
are	O
more	O
diffuse	B-C0205219
today	O
than	O
in	B-C1444637
the	I-C1444637
past	I-C1444637
.	O
	
novel	B-C0205314
forest	B-C0086312
assemblages	B-C1516698
represent	O
28%	O
of	O
all	O
fia	B-C0242356
cells	O
,	O
and	O
28%	O
of	O
pre-settlement	B-C1254367
forests	B-C0086312
no	B-C0243095
longer	I-C0243095
exist	B-C2987476
in	O
a	O
modern	B-C1254367
context	B-C0449255
.	O
	
lost	B-C0745777
forests	B-C0086312
include	O
tamarack	B-C0884985
forests	B-C0086312
in	O
northeastern	B-C1709272
minnesota	B-C0026183
,	O
hemlock	B-C0242872
and	O
cedar	B-C0949849
dominated	O
forests	B-C0086312
in	O
north-central	B-C0043193
wisconsin	I-C0043193
and	O
along	O
the	O
upper	B-C0025939
peninsula	I-C0025939
of	I-C0025939
michigan	I-C0025939
,	O
and	O
elm	B-C0330531
,	O
oak	B-C0330302
,	O
basswood	B-C1024812
and	O
ironwood	B-C0330803
forests	B-C0086312
along	O
the	O
forest	B-C0086312
-	O
prairie	B-C0442534
boundary	I-C0442534
in	O
south	B-C0026183
central	I-C0026183
minnesota	I-C0026183
and	O
eastern	B-C1707877
wisconsin	B-C0043193
.	O
	
novel	B-C0205314
fia	B-C0242356
forest	B-C0086312
assemblages	B-C1516698
are	O
distributed	O
evenly	O
across	O
the	O
region	B-C0017446
,	O
but	O
novelty	B-C2700116
shows	O
a	O
strong	B-C0442821
relationship	B-C0439849
to	O
spatial	B-C0012751
distance	I-C0012751
from	O
remnant	B-C1527428
forests	B-C0086312
in	O
the	O
upper	B-C0026081
midwest	I-C0026081
,	O
with	O
novelty	B-C2700116
predicted	B-C0681842
at	O
between	O
20	O
to	O
60km	O
from	O
remnants	B-C1527428
,	O
depending	O
on	O
historical	B-C0019659
forest	B-C0086312
type	I-C0086312
.	O
	
the	O
spatial	B-C1883067
relationships	B-C0439849
between	O
remnant	B-C1527428
and	O
novel	B-C0205314
forests	B-C0086312
,	O
shifts	B-C0333051
in	O
ecotone	B-C1254362
structure	I-C1254362
and	O
the	O
loss	B-C1517945
of	O
historic	B-C0019659
forest	B-C0086312
types	I-C0086312
point	O
to	O
significant	B-C0750502
challenges	O
for	O
land	B-C0557668
managers	B-C0335141
if	O
landscape	B-C0870781
restoration	O
is	O
a	O
priority	B-C0549179
.	O
	
the	O
spatial	O
signals	O
of	O
novelty	B-C2700116
and	O
ecological	B-C0162358
change	B-C0392747
also	O
point	O
to	O
potential	B-C3245505
challenges	O
in	O
using	O
modern	B-C1254367
spatial	B-C0037775
distributions	I-C0037775
of	O
species	B-C0032098
and	O
communities	B-C1253910
and	O
their	O
relationship	B-C0439849
to	O
underlying	O
geophysical	B-C2717748
and	O
climatic	B-C2350607
attributes	I-C2350607
in	O
understanding	O
potential	B-C3245505
responses	O
to	O
changing	B-C0392747
climate	B-C0008946
.	O
	
the	O
signal	B-C1710082
of	O
human	B-C0086418
settlement	B-C0036852
on	O
modern	B-C1254367
forests	B-C0086312
is	O
broad	B-C0332464
,	O
spatially	O
varying	O
and	O
acts	O
to	O
homogenize	B-C0205375
modern	B-C1254367
forests	B-C0086312
relative	B-C0205345
to	O
their	O
historic	B-C0019659
counterparts	O
,	O
with	O
significant	B-C0750502
implications	O
for	O
future	B-C0016884
management	B-C1273870
.	O
	
prevalence	B-C0220900
of	O
self-reported	B-C0681906
prescription	B-C0304227
drug	I-C0304227
use	B-C0457083
in	O
a	O
national	B-C0681788
sample	B-C0370003
of	O
u.s	B-C0041703
.	O
	
drivers	B-C0684312
drug	B-C1254351
-involved	O
driving	B-C0004379
has	O
become	O
an	O
increasing	B-C0442808
concern	B-C2699424
.	O
	
although	O
the	O
focus	O
has	O
been	O
on	O
illegal	B-C0086190
drugs	I-C0086190
,	O
there	O
is	O
evidence	B-C3887511
that	O
prescribed	B-C3166216
medications	I-C3166216
can	O
impair	B-C0877256
driving	I-C0877256
ability	I-C0877256
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-C1148554
the	O
self-reported	B-C0681906
prevalence	B-C0220900
of	O
prescription	B-C0304227
drug	I-C0304227
use	B-C0457083
,	O
including	O
medical	B-C0205476
and	O
nonmedical	B-C0243095
use	B-C0457083
,	O
among	O
a	O
nationally	B-C0681788
representative	B-C1882932
sample	B-C0370003
of	O
drivers	B-C0684312
and	O
to	O
report	O
related	O
driver	B-C0684312
characteristics	B-C1521970
.	O
	
as	O
part	O
of	O
the	O
2013-2014	O
national	B-C0242481
roadside	I-C0242481
survey	I-C0242481
,	O
drivers	B-C0684312
from	O
60	O
sites	O
were	O
randomly	B-C0439605
recruited	O
and	O
asked	O
to	O
complete	B-C0205197
a	O
survey	B-C0681817
on	O
prescription	B-C0304227
drug	I-C0304227
use	B-C0457083
.	O
	
almost	O
20%	O
of	O
drivers	B-C0684312
reported	O
using	O
a	O
prescription	B-C0304227
drug	I-C0304227
within	O
the	O
past	B-C1444637
2	O
days	B-C0439228
,	O
with	O
the	O
most	O
common	B-C1254351
drug	I-C1254351
class	I-C1254351
being	O
sedatives	B-C0036557
8.0	O
,	O
followed	O
by	O
antidepressants	B-C0003289
7.7	O
,	O
narcotics	B-C0027415
7.5	O
,	O
and	O
stimulants	B-C0304402
3.9	O
.	O
	
drivers	B-C0684312
who	O
reported	O
prescription	B-C0304227
drug	I-C0304227
use	B-C0457083
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	B-C0086287
,	O
older	B-C1518563
,	O
non-hispanic	B-C3843227
white	I-C3843227
,	O
and	O
report	O
disability	B-C0231170
.	O
	
three	O
of	O
four	O
drivers	B-C0684312
who	O
reported	O
medication	B-C0013227
use	B-C0457083
78.2	O
said	O
the	O
drug	B-C1254351
was	O
prescribed	B-C0278329
for	O
their	O
use	B-C0457083
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	B-C1521941
were	O
significantly	B-C4055637
higher	I-C4055637
for	O
males	B-C0086582
,	O
black/african	B-C0085756
american	I-C0085756
,	O
and	O
hispanic	B-C0086409
drivers	B-C0684312
,	O
and	O
lower	O
for	O
older	B-C1518563
drivers	B-C0684312
.	O
	
among	O
those	O
with	O
a	O
prescription	B-C1521941
,	O
taking	O
more	O
than	O
prescribed	B-C0278329
was	O
most	O
common	O
for	O
narcotics	B-C0027415
6.8	O
,	O
followed	O
by	O
sedatives	B-C0036557
4.8	O
,	O
stimulants	B-C0304402
3.8	O
,	O
and	O
antidepressants	B-C0003289
1.5	O
.	O
	
these	O
findings	B-C2607943
help	O
to	O
identify	O
drivers	B-C0684312
using	O
potentially	B-C0221099
impairing	I-C0221099
prescription	B-C0304227
drugs	I-C0304227
,	O
both	O
medically	B-C0205476
and	O
nonmedically	B-C0243095
,	O
and	O
may	O
inform	O
the	O
targeting	B-C1521840
of	O
interventions	B-C1273869
to	O
reduce	O
impaired	B-C0877256
driving	I-C0877256
related	O
to	O
repetitive	B-C2945760
and	O
prolonged	B-C0439590
omega-3	B-C0015689
fatty	I-C0015689
acid	I-C0015689
treatment	B-C0087111
after	B-C0687676
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
enhances	B-C2349975
long-term	B-C0443252
tissue	B-C0040300
restoration	B-C0087111
and	O
cognitive	B-C0009244
recovery	I-C0009244
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
tbi	B-C0876926
is	O
one	O
of	O
the	O
most	O
disabling	B-C4061999
clinical	I-C4061999
conditions	I-C4061999
that	O
could	O
lead	B-C1522538
to	O
neurocognitive	B-C4041080
disorders	I-C4041080
in	O
survivors	B-C0206194
.	O
	
our	O
group	B-C1705429
and	O
others	B-C1257890
previously	O
reported	B-C0684224
that	O
prophylactic	B-C0199176
enrichment	I-C0199176
of	O
dietary	B-C2699635
omega-3	B-C0015689
polyunsaturated	I-C0015689
fatty	I-C0015689
acids	I-C0015689
n-3	B-C0015689
pufas	I-C0015689
markedly	O
ameliorate	B-C0332303
cognitive	B-C0009241
deficits	I-C0009241
after	B-C0687676
tbi	B-C0876926
.	O
	
however	O
,	O
it	O
remains	O
unclear	B-C3845108
whether	O
a	O
clinically	B-C0443178
relevant	B-C2347946
therapeutic	B-C1276413
regimen	I-C1276413
with	O
n-3	B-C0015689
pufas	I-C0015689
administered	B-C1521801
after	B-C0687676
tbi	B-C0876926
would	O
still	O
offer	O
significant	O
improvement	B-C2986411
of	O
long-term	B-C0443252
cognitive	B-C0009244
recovery	I-C0009244
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
we	O
employed	O
the	O
decline	B-C1511741
of	O
spatial	O
cognitive	B-C0009241
function	I-C0009241
as	O
a	O
main	B-C1542147
outcome	B-C1274040
after	B-C0687676
tbi	B-C0876926
to	O
investigate	B-C1292732
the	O
therapeutic	B-C2348767
efficacy	I-C2348767
of	O
post	B-C0687676
-	O
tbi	B-C0876926
n-3	B-C0015689
pufa	I-C0015689
treatment	B-C0087111
and	O
the	O
underlying	O
mechanisms	B-C0441712
.	O
	
mice	B-C0025929
were	O
subjected	O
to	O
sham	B-C0141287
operation	I-C0141287
or	O
controlled	B-C2587213
cortical	B-C0007776
impact	B-C4049986
,	O
followed	O
by	O
random	B-C0814868
assignment	I-C0814868
to	O
receive	B-C1514756
the	O
following	O
four	B-C0205450
treatments	B-C0087111
1	O
vehicle	B-C0042444
control	B-C2587213
2	O
daily	B-C0332173
intraperitoneal	B-C0021493
injections	I-C0021493
of	O
n-3	B-C0015689
pufas	I-C0015689
for	O
2	O
weeks	B-C0439230
,	O
beginning	B-C0439659
2	O
h	B-C0439227
after	B-C0687676
tbi	B-C0876926
3	O
fish	B-C0556145
oil	I-C0556145
dietary	I-C0556145
supplementation	B-C0242297
throughout	O
the	O
study	B-C2603343
,	O
beginning	B-C0439659
1	O
day	B-C0439228
after	B-C0687676
tbi	B-C0876926
or	O
4	O
combination	B-C0205195
of	O
treatments	B-C0087111
2	O
and	O
3	O
.	O
	
spatial	O
cognitive	O
deficits	O
and	O
chronic	B-C0205191
brain	B-C0459385
tissue	I-C0459385
loss	B-C1517945
,	O
as	O
well	O
as	O
endogenous	B-C0205227
brain	B-C0161849
repair	I-C0161849
processes	I-C0161849
such	O
as	O
neurogenesis	B-C0814002
,	O
angiogenesis	B-C0302600
,	O
and	O
oligodendrogenesis	B-C3714634
,	O
were	O
evaluated	O
up	O
to	O
35	O
days	B-C0439228
after	B-C0687676
tbi	B-C0876926
.	O
	
the	O
results	B-C1274040
revealed	B-C0443289
prominent	O
spatial	O
cognitive	B-C0009241
deficits	I-C0009241
and	O
massive	B-C0522501
tissue	B-C0459385
loss	B-C1517945
caused	O
by	O
tbi	B-C0876926
.	O
	
among	O
all	O
mice	B-C0025929
receiving	B-C1514756
post-tbi	B-C0876926
n-3	B-C0015689
pufa	I-C0015689
treatments	B-C0087111
,	O
the	O
combined	B-C0205195
treatment	B-C0087111
of	O
fish	B-C0556145
oil	I-C0556145
dietary	I-C0556145
supplement	B-C0242295
and	O
n-3	B-C0015689
pufa	I-C0015689
injections	B-C1272883
demonstrated	B-C3687625
a	O
reproducible	B-C0683156
beneficial	I-C0683156
effect	I-C0683156
in	O
attenuating	O
cognitive	B-C0009241
deficits	I-C0009241
although	O
without	O
reducing	B-C0392756
gross	B-C0439806
tissue	B-C0459385
loss	B-C1517945
.	O
	
mechanistically	O
,	O
the	O
combined	O
treatment	B-C0087111
promoted	B-C0033414
post-tbi	B-C0876926
restorative	B-C0541662
processes	I-C0541662
in	O
the	O
brain	B-C0006104
,	O
including	B-C0332257
generation	O
of	O
immature	B-C0027882
neurons	I-C0027882
,	O
microvessels	B-C2350570
,	O
and	O
oligodendrocytes	B-C0028944
,	O
each	O
of	O
which	O
was	O
significantly	O
correlated	B-C1707520
with	O
the	O
improved	B-C0184511
cognitive	B-C1274040
recovery	I-C1274040
.	O
	
these	O
results	B-C1274040
indicated	B-C1444656
that	O
repetitive	B-C2945760
and	O
prolonged	B-C0439590
n-3	B-C0015689
pufa	I-C0015689
treatments	B-C0087111
after	B-C0687676
tbi	B-C0876926
are	O
capable	O
of	O
enhancing	B-C2349975
brain	B-C0006104
remodeling	B-C0678692
and	O
could	O
be	O
developed	O
as	O
a	O
potential	B-C3245505
therapy	B-C0087111
to	O
treat	O
tbi	B-C0876926
victims	B-C0680681
in	O
the	O
influence	B-C4054723
of	O
yeast	B-C0043393
and	O
lactic	B-C1210581
acid	I-C1210581
bacterium	I-C1210581
on	O
the	O
constituent	B-C0729650
profile	B-C1979963
of	O
soy	B-C0453374
sauce	I-C0453374
during	B-C0347984
fermentation	B-C0015852
soy	B-C0453374
sauce	I-C0453374
is	O
a	O
japanese	B-C0022341
traditional	B-C0443324
seasoning	B-C0349383
composed	B-C0392762
of	O
various	B-C0443302
constituents	B-C0729650
that	O
are	O
produced	B-C0033268
by	O
various	O
microbes	B-C0445623
during	B-C0347984
a	O
long-term	B-C0443252
fermentation	B-C0015852
process	I-C0015852
.	O
	
due	B-C0678226
to	I-C0678226
the	O
complexity	B-C0205245
of	O
the	O
process	B-C1522240
,	O
the	O
investigation	B-C0242481
of	O
the	O
constituent	B-C0729650
profile	B-C1979963
during	B-C0347984
fermentation	B-C0015852
is	O
difficult	B-C0243095
.	O
	
metabolomics	B-C1328813
,	O
the	O
comprehensive	B-C1880156
study	B-C2603343
of	O
low	B-C0205251
molecular	B-C0026385
weight	I-C0026385
compounds	B-C0205198
in	O
biological	B-C0205460
samples	B-C0370003
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	B-C0162340
of	O
the	O
constituent	B-C0729650
contribution	B-C1880177
to	O
food	B-C0596585
flavor	I-C0596585
characteristics	B-C1521970
.	O
	
therefore	O
,	O
metabolomics	B-C1328813
is	O
suitable	B-C3900053
for	O
the	O
analysis	B-C0936012
of	O
soy	B-C0453374
sauce	I-C0453374
fermentation	B-C0015852
.	O
	
unfortunately	O
,	O
only	O
few	O
and	O
unrefined	O
studies	B-C2603343
of	O
soy	B-C0453374
sauce	I-C0453374
fermentation	B-C0015852
using	B-C1524063
metabolomics	B-C1328813
approach	B-C0449445
have	O
been	O
reported	B-C0684224
.	O
	
therefore	O
,	O
we	O
investigated	B-C1292732
changes	B-C0392747
in	O
low	B-C0205251
molecular	B-C0026385
weight	I-C0026385
hydrophilic	B-C0392762
and	O
volatile	B-C0443769
compounds	I-C0443769
of	O
soy	B-C0453374
sauce	I-C0453374
using	O
gas	B-C0024868
chromatography/mass	I-C0024868
spectrometry	I-C0024868
gc/ms	B-C0024868
based	B-C1527178
non-targeted	B-C0205245
metabolic	B-C1328813
profiling	I-C1328813
.	O
	
the	O
data	B-C1511726
were	O
analyzed	B-C0936012
by	O
statistical	B-C0871424
analysis	I-C0871424
to	O
evaluate	O
influences	B-C4054723
of	O
yeast	B-C0043393
and	O
lactic	B-C1210581
acid	I-C1210581
bacterium	I-C1210581
on	O
the	O
constituent	B-C0729650
profile	B-C1979963
.	O
	
consequently	O
,	O
our	O
results	B-C1274040
suggested	B-C1705535
a	O
novel	B-C0205314
finding	B-C0243095
that	O
lactic	B-C1210581
acid	I-C1210581
bacterium	I-C1210581
affected	B-C0392760
the	O
production	B-C0033268
of	O
several	B-C0443302
constituents	B-C0729650
such	O
as	O
cyclotene	B-C0056829
,	O
furfural	B-C0016849
,	O
furfuryl	B-C0060863
alcohol	I-C0060863
and	O
methional	B-C0066117
in	O
the	O
soy	B-C0453374
sauce	I-C0453374
fermentation	B-C0015852
process	I-C0015852
.	O
	
low	B-C0205251
intensity	B-C0522510
sprint	B-C0454374
training	I-C0454374
with	O
blood	B-C0220931
flow	I-C0220931
restriction	I-C0220931
improves	O
100	O
m	O
dash	O
we	O
investigated	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
practical	B-C0220931
blood	I-C0220931
flow	I-C0220931
restriction	I-C0220931
pbfr	B-C0220931
of	O
leg	B-C0224456
muscles	I-C0224456
during	O
sprint	B-C0454374
training	I-C0454374
on	O
the	O
100	O
m	O
dash	O
time	B-C0040223
in	O
well-trained	B-C0038492
sport	I-C0038492
students	I-C0038492
.	O
	
participants	B-C0679646
performed	O
6x100	O
m	O
sprints	B-C0035953
at	O
60-70%	O
of	O
their	O
maximal	O
100	O
m	O
sprinting	B-C0678536
speed	I-C0678536
twice	B-C0556985
a	I-C0556985
week	I-C0556985
for	O
6	O
weeks	B-C0439230
,	O
either	O
with	O
ig	B-C2986530
n=12	O
or	O
without	O
pbfr	B-C0220931
cg	B-C0009932
n=12	O
.	O
	
the	O
100	O
m	O
dash	O
time	B-C0040223
significantly	O
decreased	B-C0205216
more	O
in	O
the	O
ig	B-C2986530
-0	O
s	O
than	O
in	O
the	O
cg	B-C0009932
-0	O
s	O
.	O
	
the	O
muscle	B-C0026845
thickness	B-C1280412
of	O
the	O
rectus	B-C0584894
femoris	I-C0584894
increased	B-C0205217
only	O
in	O
the	O
ig	B-C2986530
,	O
while	O
no	O
group	B-C0441833
by	O
time	B-C0040223
interactions	B-C1704675
were	O
found	O
for	O
the	O
muscle	B-C0026845
thickness	B-C1280412
of	O
the	O
biceps	B-C0224449
femoris	I-C0224449
and	O
the	O
biceps	B-C0559499
brachii	I-C0559499
.	O
	
the	O
maximal	B-C0392762
isometric	I-C0392762
force	I-C0392762
,	O
measured	O
using	O
a	O
leg	B-C4054656
press	I-C4054656
,	O
did	O
not	B-C0442739
change	I-C0442739
in	O
either	O
group	B-C0441833
.	O
	
however	O
,	O
the	O
rate	B-C0392762
of	I-C0392762
force	I-C0392762
development	I-C0392762
improved	O
in	O
the	O
ig	B-C2986530
.	O
	
growth	B-C0037663
hormone	I-C0037663
,	O
testosterone	B-C0039601
,	O
insulin-like	B-C0021665
growth	I-C0021665
factor	I-C0021665
1	I-C0021665
,	O
and	O
cortisol	B-C0020268
concentrations	B-C0392762
did	O
not	B-C0243095
significantly	I-C0243095
differ	I-C0243095
between	O
both	O
groups	B-C0441833
at	O
any	O
measurement	B-C0242485
time	B-C2348792
point	I-C2348792
pre	O
,	O
1	O
min	O
,	O
20	O
min	O
,	O
120	O
min	O
,	O
and	O
24	O
h	O
after	O
the	O
six	O
all-out	O
sprints	B-C0035953
of	O
the	O
first	O
training	B-C0220931
session	B-C1883016
.	O
	
the	O
muscle	B-C0410158
damage	I-C0410158
marker	B-C0005516
h-fabp	B-C1312696
increased	B-C0205217
significantly	O
more	O
in	O
the	O
cg	B-C0009932
than	O
in	O
the	O
ig	B-C2986530
.	O
	
the	O
pbfr	B-C0220931
improved	O
the	O
100	O
m	O
dash	O
time	B-C0040223
significantly	O
more	O
than	O
low	B-C0205251
-	O
intensity	B-C0522510
sprint	B-C0454374
interval	I-C0454374
training	I-C0454374
alone	O
.	O
	
other	O
noted	O
benefits	B-C0814225
of	O
training	B-C0220931
with	O
pbfr	B-C0220931
were	O
a	O
decreased	B-C0205216
level	B-C0441889
of	O
muscle	B-C0410158
damage	I-C0410158
,	O
a	O
greater	O
increase	B-C0442805
of	O
the	O
rectus	B-C0584894
femoris	I-C0584894
muscle	I-C0584894
thickness	B-C1280412
,	O
and	O
a	O
higher	B-C0205250
rate	B-C0392762
of	I-C0392762
force	I-C0392762
development	I-C0392762
.	O
	
however	O
,	O
the	O
tested	B-C0039593
hormones	B-C0019932
were	O
unable	O
to	O
explain	O
the	O
additional	O
beneficial	B-C1280500
effects	I-C1280500
.	O
	
sedation	B-C0344106
of	O
patients	B-C0030705
with	O
disorders	B-C0009792
of	I-C0009792
consciousness	I-C0009792
during	O
neuroimaging	B-C0679575
effects	O
on	O
resting	B-C4288291
state	I-C4288291
functional	I-C4288291
brain	I-C4288291
connectivity	I-C4288291
to	O
reduce	O
head	B-C0376591
movement	I-C0376591
during	O
resting	B-C4288291
state	I-C4288291
functional	I-C4288291
magnetic	I-C4288291
resonance	I-C4288291
imaging	I-C4288291
,	O
post-coma	B-C0151294
patients	B-C0030705
with	O
disorders	B-C0009792
of	I-C0009792
consciousness	I-C0009792
doc	B-C0009792
are	O
frequently	O
sedated	B-C0344106
with	O
propofol	B-C0033487
.	O
	
however	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	B-C0344106
on	O
the	O
brain	B-C0449774
connectivity	I-C0449774
patterns	I-C0449774
in	O
the	O
damaged	B-C0270611
brain	I-C0270611
essential	O
for	O
differential	B-C0011906
diagnosis	I-C0011906
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
aimed	O
to	O
assess	B-C0184514
these	O
effects	O
.	O
	
using	O
resting	B-C4288291
state	I-C4288291
functional	I-C4288291
magnetic	I-C4288291
resonance	I-C4288291
imaging	I-C4288291
3t	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-C0441633
patients	B-C0030705
for	O
diagnostic	B-C0348026
and	O
research	B-C0035168
purposes	B-C1285529
,	O
we	O
employed	O
a	O
seed-based	O
approach	O
to	O
examine	O
resting	B-C1707489
state	I-C1707489
connectivity	I-C1707489
in	O
higher-order	O
default	O
mode	O
,	O
bilateral	B-C0238767
external	B-C0680371
control	I-C0680371
,	O
and	O
salience	O
and	O
lower-order	O
auditory	B-C0439825
,	O
sensorimotor	B-C0237434
,	O
and	O
visual	B-C0234621
resting	B-C1882071
state	I-C1882071
networks	I-C1882071
and	O
connectivity	B-C1707489
with	O
the	O
thalamus	B-C0039729
,	O
in	O
20	O
healthy	B-C3898900
unsedated	B-C0243095
controls	B-C0009932
,	O
8	O
unsedated	B-C0243095
patients	B-C0030705
with	O
doc	B-C0009792
,	O
and	O
8	O
patients	B-C0030705
with	O
doc	B-C0009792
sedated	B-C0344106
with	O
propofol	B-C0033487
.	O
	
the	O
doc	B-C0009792
groups	O
were	O
matched	O
for	O
age	B-C0206132
at	I-C0206132
onset	I-C0206132
,	O
etiology	B-C1314792
,	O
time	B-C0243095
spent	I-C0243095
in	O
doc	B-C0009792
,	O
diagnosis	B-C0011900
,	O
standardized	B-C0449820
behavioral	I-C0449820
assessment	I-C0449820
scores	I-C0449820
,	O
movement	B-C0026649
intensities	B-C0522510
,	O
and	O
pattern	O
of	O
structural	B-C0270611
brain	I-C0270611
injury	I-C0270611
as	O
assessed	O
with	O
t1-based	B-C0200760
voxel-based	I-C0200760
morphometry	I-C0200760
.	O
	
doc	B-C0009792
were	O
associated	B-C0332281
with	I-C0332281
severely	O
impaired	O
resting	B-C1707489
state	I-C1707489
network	I-C1707489
connectivity	I-C1707489
in	O
all	O
but	O
the	O
visual	B-C0234621
network	B-C1882071
.	O
	
thalamic	B-C0039729
connectivity	B-C1707489
to	O
higher-order	O
network	O
regions	O
was	O
also	O
reduced	B-C0392756
.	O
	
propofol	B-C0033487
administration	B-C1533734
to	O
patients	B-C0030705
was	O
associated	B-C0332281
with	I-C0332281
minor	O
further	O
decreases	B-C0547047
in	O
thalamic	B-C0039729
and	O
insular	B-C0021640
connectivity	B-C1707489
.	O
	
our	O
findings	B-C2607943
indicate	O
that	O
connectivity	B-C1707489
decreases	B-C0547047
associated	B-C0332281
with	I-C0332281
propofol	B-C0033487
sedation	B-C0344106
,	O
involving	O
the	O
thalamus	B-C0039729
and	O
insula	B-C0021640
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
doc	B-C0009792
-associated	O
structural	B-C0270611
brain	I-C0270611
injury	I-C0270611
.	O
	
nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	B-C0039729
in	O
brain	B-C0003808
arousal	I-C0003808
,	O
its	O
disruption	B-C0332453
could	O
well	O
reflect	O
the	O
diminished	B-C0205216
movement	B-C0026649
obtained	O
in	O
these	O
patients	B-C0030705
.	O
	
however	O
,	O
more	O
research	B-C0035168
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	B-C0681799
question	I-C0681799
.	O
	
potassium	B-C1971021
depletion	I-C1971021
stimulates	B-C1948023
na-cl	B-C0074782
cotransporter	I-C0074782
via	O
phosphorylation	B-C0031715
and	O
inactivation	B-C0544461
of	O
the	O
ubiquitin	B-C0077678
ligase	I-C0077678
kelch-like	B-C4042100
3	I-C4042100
kelch-like	B-C4042100
3	I-C4042100
klhl3	B-C4042100
is	O
a	O
component	B-C1179435
of	O
an	O
e3	B-C0077678
ubiquitin	I-C0077678
ligase	I-C0077678
complex	I-C0077678
that	O
regulates	B-C1327622
blood	B-C0005823
pressure	I-C0005823
by	O
targeting	B-C1521840
with-no-lysine	B-C0031727
wnk	I-C0031727
kinases	I-C0031727
for	O
degradation	B-C0243125
.	O
	
mutations	B-C0026882
in	O
klhl3	B-C4042100
cause	O
constitutively	O
increased	B-C3278017
renal	I-C3278017
salt	I-C3278017
reabsorption	I-C3278017
and	O
impaired	B-C0221099
k	B-C0032821
secretion	B-C0036536
,	O
resulting	O
in	O
hypertension	B-C0020538
and	O
hyperkalemia	B-C0020461
.	O
	
although	O
clinical	B-C0008972
studies	I-C0008972
have	O
shown	O
that	O
dietary	B-C0162800
k	I-C0162800
intake	B-C1512806
affects	B-C0392760
blood	B-C0005823
pressure	I-C0005823
,	O
the	O
mechanisms	B-C0441712
have	O
been	O
obscure	B-C3845108
.	O
	
in	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
klhl3	B-C4042100
ubiquitin	B-C0077678
ligase	I-C0077678
complex	B-C1180347
is	O
involved	O
in	O
the	O
low-	O
k	B-C0032821
-mediated	O
activation	B-C0599177
of	O
na-cl	B-C0074782
cotransporter	I-C0074782
ncc	B-C0074782
in	O
the	O
kidney	B-C0022646
.	O
	
in	O
the	O
distal	B-C0022676
convoluted	I-C0022676
tubules	I-C0022676
of	O
mice	B-C0025929
eating	B-C0013470
a	O
low-k	B-C0948941
diet	I-C0948941
,	O
we	O
found	O
increased	O
klhl3	B-C4042100
phosphorylation	B-C0031715
at	O
s433	B-C1254362
klhl3	B-C4042100
,	O
a	O
modification	B-C3840684
that	O
impairs	B-C0221099
wnk	B-C0031727
binding	B-C1145667
,	O
and	O
also	O
reduced	O
total	O
klhl3	B-C4042100
levels	B-C0441889
.	O
	
these	O
changes	O
are	O
accompanied	O
by	O
the	O
accumulation	B-C4055506
of	O
the	O
target	B-C1521840
substrate	B-C3891814
wnk4	B-C1452813
,	O
and	O
activation	B-C0599177
of	O
the	O
downstream	B-C0522506
kinases	B-C1436950
spak	I-C1436950
ste20	B-C4307920
/	O
sps1	B-C1436950
-related	O
proline-alanine-rich	B-C1312482
protein	I-C1312482
kinase	I-C1312482
and	O
osr1	B-C1438448
oxidative	B-C1438448
stress-responsive	I-C1438448
1	I-C1438448
,	O
resulting	O
in	O
ncc	B-C0074782
phosphorylation	B-C0031715
and	O
its	O
accumulation	B-C4055506
at	O
the	O
plasma	B-C0007603
membrane	I-C0007603
.	O
	
increased	O
phosphorylation	B-C0031715
of	O
s433	B-C1254362
was	O
explained	O
by	O
increased	O
levels	B-C0441889
of	O
active	B-C0205177
,	O
phosphorylated	O
protein	B-C0033634
kinase	I-C0033634
c	I-C0033634
but	O
not	O
protein	B-C0010531
kinase	I-C0010531
a	I-C0010531
,	O
which	O
directly	O
phosphorylates	B-C0031715
s433	B-C1254362
.	O
	
moreover	O
,	O
in	O
hek	B-C2936239
cells	I-C2936239
expressing	B-C1171362
klhl3	B-C4042100
and	O
wnk4	B-C1452813
,	O
we	O
showed	O
that	O
the	O
activation	B-C0599177
of	O
protein	B-C0033634
kinase	I-C0033634
c	I-C0033634
by	O
phorbol	B-C0039654
12-myristate	I-C0039654
13-acetate	I-C0039654
induces	B-C0205263
klhl3	B-C4042100
and	O
increases	O
wnk4	B-C1452813
levels	B-C0441889
by	O
abrogating	O
its	O
ubiquitination	B-C1519751
.	O
	
these	O
data	B-C1511726
demonstrate	O
the	O
role	B-C1705810
of	O
klhl3	B-C4042100
in	O
low-	O
k	B-C0032821
-mediated	O
induction	B-C0205263
of	O
ncc	B-C0074782
this	O
physiologic	B-C0001400
adaptation	I-C0001400
reduces	O
distal	B-C0205108
electrogenic	B-C0232633
na	B-C2610987
reabsorption	I-C2610987
,	O
preventing	B-C1292733
further	O
renal	B-C0022646
k	B-C0032821
loss	B-C1517945
but	O
promoting	B-C0033414
increased	O
blood	B-C0005823
pressure	I-C0005823
.	O
	
the	O
relationship	B-C0439849
between	O
thoracic	B-C0817096
configuration	B-C0277809
and	O
changes	B-C0392747
in	O
volumes	B-C0449468
of	O
hemithoraces	B-C0934569
in	O
upright	B-C1280451
sitting	I-C1280451
purpose	O
some	O
patients	B-C0030705
with	O
respiratory	B-C0035204
disease	I-C0035204
exhibit	O
asymmetrical	B-C1821161
movement	I-C1821161
of	I-C1821161
the	I-C1821161
thorax	I-C1821161
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
relationship	B-C0439849
of	O
thoracic	B-C0817096
configuration	B-C0277809
with	O
changes	B-C0392747
in	O
thoracic	B-C0231961
volume	I-C0231961
in	O
13	O
sedentary	B-C0205254
healthy	B-C3898900
men	B-C0025266
.	O
	
subjects	O
and	O
methods	O
in	O
upright	B-C1280451
sitting	I-C1280451
,	O
84	O
reflective	B-C0008963
markers	I-C0008963
were	O
placed	O
on	O
the	O
anterior	B-C0205094
and	O
posterior	B-C0205095
aspects	B-C1879746
of	O
the	O
trunk	B-C0460005
to	O
record	O
thoracic	B-C0231961
volume	I-C0231961
during	O
quiet	B-C0439654
and	O
volitional	B-C0042950
deep	B-C1328799
breathing	I-C1328799
.	O
	
using	O
a	O
three-dimensional	B-C0025080
motion	I-C0025080
analyzer	I-C0025080
,	O
the	O
difference	B-C1705241
in	O
volume	B-C0449468
within	O
the	O
upper	B-C1282910
and	O
lower	B-C0441994
hemithoraces	B-C0934569
was	O
measured	B-C0444706
.	O
	
for	O
calculation	B-C1441506
of	O
the	O
thoracic	B-C0231961
volume	I-C0231961
six	O
imaginary	B-C2348964
hexahedra	I-C2348964
were	O
visualized	O
for	O
the	O
upper	B-C1282910
and	O
lower	B-C0441994
thorax	B-C0817096
using	O
four	O
reflective	B-C0008963
markers	I-C0008963
for	O
each	O
on	O
the	O
anterior	B-C0205094
and	O
posterior	B-C0205095
aspects	B-C1879746
of	O
the	O
thorax	B-C0817096
.	O
	
each	O
hexahedron	B-C2348964
was	O
then	O
divided	O
into	O
three	O
imaginary	B-C1254362
triangular	I-C1254362
pyramids	I-C1254362
to	O
calculate	B-C1441506
positional	B-C0240795
vectors	B-C0442335
.	O
	
finally	O
,	O
the	O
volume	B-C0449468
for	O
both	O
the	O
hexahedra	B-C2348964
and	O
triangular	B-C1254362
pyramids	I-C1254362
was	O
calculated	B-C1441506
.	O
	
four	O
thoracic	B-C0231961
volumes	I-C0231961
were	O
obtained	O
.	O
	
results	O
the	O
findings	B-C2607943
showed	O
that	O
the	O
left	B-C0205091
upper	B-C1282910
and	O
right	B-C0205090
lower	B-C0441994
hemithorax	B-C0934569
yielded	O
significantly	O
larger	B-C0549177
thoracic	B-C0231961
volumes	I-C0231961
.	O
	
conclusion	O
in	O
conclusion	B-C1707478
the	O
left	B-C0205091
upper	B-C1282910
and	O
right	B-C0205090
lower	B-C0441994
hemithoraces	B-C0934569
were	O
found	O
to	O
expand	B-C0205229
more	O
than	O
their	O
corresponding	O
sides	B-C0441987
.	O
	
understanding	O
the	O
characteristics	B-C1521970
of	O
thoracic	B-C0817096
excursion	B-C0232086
during	O
quiet	B-C0439654
and	O
volitional	B-C0042950
deep	B-C1328799
breathing	I-C1328799
could	O
be	O
of	O
value	B-C0332320
in	O
assessment	B-C0220825
and	O
instruction	B-C1442085
of	O
breathing	B-C4040465
techniques	I-C4040465
to	O
development	B-C1527148
of	O
the	O
four-item	B-C0260168
letter	I-C0260168
and	I-C0260168
shape	I-C0260168
drawing	I-C0260168
test	I-C0260168
lsd-4	B-C0260168
a	O
brief	O
bedside	B-C0282662
test	I-C0282662
of	O
visuospatial	B-C2370887
function	I-C2370887
conventional	B-C0439858
bedside	B-C0282662
tests	I-C0282662
of	O
visuospatial	B-C2370887
function	I-C2370887
such	O
as	O
the	O
clock	B-C0260168
drawing	I-C0260168
cdt	B-C0260168
and	O
intersecting	B-C0260168
pentagons	I-C0260168
ipt	B-C0260168
lack	B-C0332268
consistency	B-C0332529
in	O
delivery	O
and	O
interpretation	B-C0456377
.	O
	
we	O
compared	B-C1707455
performance	B-C1882330
on	O
a	O
novel	O
test	O
of	O
visuospatial	B-C0814069
ability	I-C0814069
-	O
the	O
lsd	B-C0260168
-	O
with	O
the	O
ipt	B-C0260168
,	O
cdt	B-C0260168
and	O
mmse	B-C0451306
in	O
180	O
acute	B-C0205178
elderly	B-C0001792
medical	B-C0205476
inpatients	B-C0021562
mean	B-C0444504
age	B-C0001779
79.7	O
range	B-C1514721
62-96	O
91	O
females	B-C0086287
50.6	O
.	O
	
124	O
69%	O
scored	B-C0449820
23	O
on	O
the	O
mmse	B-C0451306
60	O
with	O
mild	B-C2945599
score	B-C0449820
18-23	O
and	O
64	O
with	O
severe	B-C0205082
score	B-C0449820
17	O
impairment	B-C0221099
.	O
	
78	O
43%	O
scored	B-C0449820
6	O
on	O
the	O
cdt	B-C0260168
,	O
while	O
for	O
the	O
ipt	B-C0260168
,	O
87	O
47%	O
scored	B-C0449820
4	O
.	O
	
the	O
cdt	B-C0260168
and	O
ipt	B-C0260168
agreed	B-C3641827
on	O
the	O
classification	B-C0008902
of	O
138	O
patients	B-C0030705
77%	O
with	O
modest-	O
strong	B-C0442821
agreement	O
with	O
the	O
mmse	B-C0451306
categories	B-C0683312
.	O
	
correlation	B-C1707520
between	O
the	O
lsd	B-C0260168
and	O
visuospatial	B-C0260168
tests	I-C0260168
was	O
high	B-C0205250
.	O
	
a	O
four-item	B-C0333052
version	I-C0333052
of	O
the	O
lsd	B-C0260168
incorporating	O
items	B-C1551338
1	O
had	O
high	B-C0205250
correlation	B-C1707520
with	O
the	O
lsd-15	B-C0260168
and	O
strong	B-C0442821
association	B-C0332281
with	I-C0332281
mmse	B-C0451306
categories	B-C0683312
.	O
	
the	O
lsd-4	B-C0260168
provides	O
a	O
brief	O
and	O
easily	B-C0332219
interpreted	B-C1285553
bedside	B-C0282662
test	I-C0282662
of	O
visuospatial	B-C2370887
function	I-C2370887
that	O
has	O
high	B-C0205250
coverage	B-C1999244
of	O
elderly	B-C0001792
patients	B-C0030705
with	O
neurocognitive	B-C0338656
impairment	I-C0338656
,	O
good	O
agreement	O
with	O
conventional	B-C0439858
tests	O
of	O
visuospatial	B-C0814069
ability	I-C0814069
and	O
favourable	O
ability	O
to	O
identify	B-C0205396
significant	B-C0750502
cognitive	B-C0338656
impairment	I-C0338656
.	O
	
salvage	B-C0085405
therapy	I-C0085405
with	O
ceftolozane-tazobactam	B-C3656593
for	O
multidrug-resistant	B-C4039743
pseudomonas	I-C4039743
aeruginosa	I-C4039743
infections	B-C0854135
infections	B-C0854135
caused	O
by	O
multidrug-resistant	B-C4039743
pseudomonas	I-C4039743
aeruginosa	I-C4039743
mdrpa	B-C4039743
present	O
a	O
major	O
problem	O
for	O
therapeutic	B-C0086388
management	I-C0086388
.	O
	
we	O
report	O
here	O
our	O
experience	O
with	O
12	O
patients	B-C0030705
with	O
a	O
severe	O
mdrpa	B-C4039743
infection	B-C0854135
6	O
of	O
which	O
were	O
pneumonia	B-C0032285
who	O
received	O
salvage	B-C0085405
therapy	I-C0085405
with	O
ceftolozane-tazobactam	B-C3656593
after	O
inappropriate	O
empirical	B-C1299597
treatment	I-C1299597
and/or	O
suboptimal	B-C2984009
targeted	O
treatment	B-C0087111
.	O
	
although	O
10	O
of	O
the	O
12	O
patients	B-C0030705
83.3	O
experienced	O
septic	B-C0036983
shock	I-C0036983
,	O
only	O
3	O
patients	B-C0030705
25%	O
died	B-C0011065
during	O
the	O
follow-up	B-C1522577
period	O
.	O
	
microbiological	B-C0025951
cure	B-C1880198
in	O
7	O
patients	B-C0030705
ankaflavin	B-C1568221
and	O
monascin	B-C1871155
induce	B-C0205263
apoptosis	B-C0162638
in	O
activated	B-C1879547
hepatic	B-C2340138
stellate	I-C2340138
cells	I-C2340138
through	O
suppression	B-C0678671
of	O
the	O
akt	B-C0164786
/	O
nf-κb	B-C0079904
/	O
p38	B-C1451465
signaling	B-C0037080
pathway	I-C0037080
the	O
increased	B-C0205217
proliferation	B-C0596290
of	O
activated	B-C1879547
hepatic	B-C2340138
stellate	I-C2340138
cells	I-C2340138
hscs	B-C2340138
is	O
associated	B-C0332281
with	I-C0332281
hepatic	B-C0239946
fibrosis	I-C0239946
and	O
excessive	B-C0442802
extracellular	B-C0015350
matrix	I-C0015350
ecm	B-C0015350
protein	B-C0033684
production	O
.	O
	
we	O
examined	O
the	O
inhibitory	B-C3463820
effects	B-C1704420
of	I-C1704420
the	O
monascus	B-C0997449
purpureus	I-C0997449
-fermented	O
metabolites	B-C0870883
,	O
ankaflavin	B-C1568221
and	O
monascin	B-C1871155
15	O
and	O
30	O
μm	O
,	O
on	O
the	O
akt	B-C0164786
/	O
nuclear	B-C0079904
factor	I-C0079904
nf	I-C0079904
and	O
p38	B-C1120843
mitogen-activated	I-C1120843
protein	I-C1120843
kinase	I-C1120843
mapk	B-C1120843
signaling	B-C0037080
pathways	I-C0037080
in	O
hsc-t6	B-C0682523
activated	B-C0682523
hepatic	I-C0682523
stellate	I-C0682523
cell	I-C0682523
line	I-C0682523
.	O
	
ankaflavin	B-C1568221
and	O
monascin	B-C1871155
30	O
μm	O
induced	B-C0205263
apoptosis	B-C0162638
and	O
significantly	B-C0750502
inhibited	B-C0311403
cell	B-C0007595
growth	I-C0007595
cell	B-C0007620
viabilities	I-C0007620
80.2	O
5.43	O
and	O
62.8	O
8.20	O
,	O
respectively	O
,	O
versus	O
control	B-C0007634
cells	I-C0007634
p	O
<	O
0.05	O
.	O
	
apoptosis	B-C0162638
and	O
g1	B-C3178834
phase	I-C3178834
arrest	I-C3178834
g1	B-C0079395
phase	I-C0079395
percentages	B-C0439165
76.1	O
2.85	O
and	O
79.9	O
1.80	O
,	O
respectively	O
,	O
versus	O
control	B-C0007634
cells	I-C0007634
65.9	O
4.94	O
p	O
<	O
0.05	O
correlated	B-C1707520
with	O
increased	B-C0205217
p53	B-C0080055
and	O
p21	B-C0288472
levels	B-C0428479
and	O
caspase	B-C1150132
3	I-C1150132
activity	I-C1150132
and	O
decreased	B-C0205216
cyclin	B-C0174680
d1	I-C0174680
and	O
bcl-2-family	B-C3269083
protein	I-C3269083
levels	B-C0428479
p	O
<	O
0.05	O
,	O
all	O
cases	O
.	O
	
the	O
apoptotic	B-C1516044
effects	B-C1704420
of	I-C1704420
ankaflavin	B-C1568221
and	O
monascin	B-C1871155
were	O
hsc-t6	B-C0682523
-	O
specific	B-C0205369
,	O
suggesting	O
their	O
potential	B-C3245505
in	O
treating	B-C1522326
liver	B-C0239946
fibrosis	I-C0239946
.	O
	
low-volume	B-C3494217
vs	O
high-volume	B-C3494218
centers	I-C3494218
and	O
management	B-C0376636
of	I-C0376636
fournier's	I-C0376636
gangrene	I-C0376636
in	O
washington	O
state	O
fournier's	B-C0238419
gangrene	O
fg	O
is	O
a	O
life-threatening	O
infection	O
affecting	O
the	O
perineum	O
and	O
genitals	O
.	O
	
complex	O
patient	O
management	O
often	O
necessitates	O
transfer	O
to	O
tertiary	O
centers	O
.	O
	
we	O
aimed	O
to	O
characterize	O
hospital	O
transfer	O
patterns	O
and	O
assess	O
morbidity	O
among	O
patients	O
with	O
fg	O
in	O
washington	O
state	O
.	O
	
the	O
washington	O
state	O
comprehensive	O
hospital	O
abstract	O
reporting	O
system	O
includes	O
claims	O
from	O
all	O
hospital	O
discharges	O
in	O
washington	O
.	O
	
we	O
identified	O
patients	O
with	O
fg	O
between	O
2007	O
and	O
2013	O
,	O
based	O
on	O
diagnosis	O
and	O
treatment	O
codes	O
.	O
	
analyses	O
were	O
stratified	O
by	O
center	O
volume	O
low-volume	O
centers	O
lvcs	O
or	O
high-volume	O
centers	O
hvcs	O
,	O
and	O
transfer	O
status	O
.	O
	
variables	O
of	O
interest	O
included	O
number	O
of	O
debridements	O
,	O
septic	O
shock	O
,	O
acute	O
renal	O
failure	O
,	O
acute	O
respiratory	O
failure	O
,	O
length	O
of	O
hospitalization	O
,	O
and	O
death	O
.	O
	
we	O
identified	O
165	O
fg	O
patients	O
.	O
	
only	O
1	O
hvc	O
treated	O
more	O
than	O
2	O
fg	O
patients	O
per	O
year	O
.	O
	
overall	O
mortality	O
was	O
6.7	O
.	O
	
most	O
patients	O
57%	O
were	O
treated	O
entirely	O
at	O
lvcs	O
87%	O
of	O
patients	O
treated	O
at	O
the	O
hvc	O
were	O
transferred	O
from	O
an	O
lvc	O
.	O
	
high-volume	O
center	O
-treated	O
patients	O
had	O
similar	O
baseline	O
comorbidities	O
p	O
=	O
0.77	O
and	O
similar	O
mortality	O
p	O
=	O
0.87	O
,	O
despite	O
higher	O
rates	O
of	O
septic	O
shock	O
p	O
<	O
0.01	O
and	O
respiratory	O
failure	O
p	O
=	O
0.01	O
compared	O
with	O
lvc	O
patients	O
.	O
	
among	O
hvc	O
-	O
transferred	O
patients	O
,	O
immediate	O
compared	O
with	O
delayed	O
transfer	O
was	O
associated	O
with	O
fewer	O
debridements	O
p	O
<	O
0.01	O
,	O
lower	O
rates	O
of	O
septic	O
shock	O
p	O
=	O
0.05	O
,	O
and	O
acute	O
renal	O
failure	O
p	O
=	O
0.04	O
.	O
	
patients	O
treated	O
at	O
the	O
hvc	O
were	O
more	O
acutely	O
ill	O
,	O
yet	O
mortality	O
was	O
similar	O
compared	O
with	O
patients	O
treated	O
solely	O
at	O
lvcs	O
,	O
suggesting	O
a	O
benefit	O
to	O
transfer	O
of	O
high	O
acuity	O
patients	O
.	O
	
immediate	O
vs	O
delayed	O
transfer	O
may	O
benefit	O
fg	O
health	O
outcomes	O
however	O
,	O
this	O
may	O
also	O
reflect	O
greater	O
disease	O
acuity	O
of	O
patients	O
with	O
delayed	O
transfer	O
status	I-C0586512
functional	O
characterization	O
of	O
pneumocystis	B-C0032276
carinii	I-C0032276
inositol	B-C0596902
transporter	I-C0596902
1	I-C0596902
fungi	B-C0016832
in	O
the	O
genus	B-C0597258
pneumocystis	I-C0597258
live	O
in	O
the	O
lungs	B-C0024109
of	O
mammals	B-C0024660
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	B-C1302234
pneumonia	B-C0339961
pcp	B-C1535939
pneumocystis	B-C1535939
pneumonia	I-C1535939
in	O
hosts	B-C1167395
with	O
compromised	O
immune	B-C0020962
systems	I-C0020962
.	O
	
the	O
absence	O
of	O
a	O
continuous	O
in	B-C1533691
vitro	I-C1533691
culture	B-C0430400
system	I-C0430400
for	O
any	O
species	B-C1705920
of	O
pneumocystis	B-C0597258
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	B-C0016832
,	O
especially	O
for	O
the	O
discovery	B-C1880355
of	O
new	O
therapies	B-C0087111
.	O
	
we	O
recently	O
reported	O
that	O
pneumocystis	B-C0032276
carinii	I-C0032276
,	O
pneumocystis	B-C1499624
murina	I-C1499624
,	O
and	O
most	O
significantly	O
,	O
pneumocystis	B-C0320385
jirovecii	I-C0320385
lack	O
both	O
enzymes	B-C0014442
necessary	O
for	O
myo-inositol	B-C1156341
biosynthesis	I-C1156341
but	O
contain	O
genes	B-C1334043
with	I-C1334043
homologies	I-C1334043
to	O
fungal	B-C0016832
myo-inositol	B-C0021547
transporters	B-C0596902
.	O
	
since	O
myo-inositol	B-C0021547
is	O
essential	O
for	O
eukaryotic	B-C0015161
viability	B-C0007620
,	O
the	O
primary	O
transporter	B-C0596902
,	O
itr1	B-C0596902
,	O
was	O
functionally	B-C0205245
and	O
structurally	B-C0678594
characterized	O
in	O
p	B-C0032276
.	O
	
carinii	I-C0032276
the	O
predicted	O
structure	B-C1510464
of	O
p	B-C0032276
.	O
	
carinii	I-C0032276
itr1	B-C0596902
pcitr1	B-C0596902
contained	O
12	O
transmembrane	B-C1167322
alpha-helices	B-C0162805
with	O
intracellular	B-C0178719
c	B-C1707271
and	O
n	B-C1706793
termini	I-C1706793
,	O
consistent	O
with	O
other	O
inositol	B-C0021547
transporters	B-C0596902
.	O
	
the	O
apparent	O
km	O
was	O
0.94	O
0.08	O
mean	O
standard	O
deviation	O
,	O
suggesting	O
that	O
myo-inositol	B-C1159756
transport	I-C1159756
in	O
p	B-C0032276
.	O
	
carinii	I-C0032276
is	O
likely	O
through	O
a	O
low-affinity	O
,	O
highly	O
selective	O
transport	B-C0005528
system	I-C0005528
,	O
as	O
no	O
other	O
sugars	B-C0242209
or	O
inositol	B-C0021547
stereoisomers	B-C0376211
were	O
significant	O
competitive	B-C0005458
inhibitors	B-C0243077
.	O
	
glucose	B-C0178666
transport	I-C0178666
was	O
shown	O
to	O
use	O
a	O
different	O
transport	B-C0005528
system	O
.	O
	
the	O
myo-inositol	B-C1159756
transport	I-C1159756
was	O
distinct	O
from	O
mammalian	B-C0024660
transporters	B-C0596902
,	O
as	O
it	O
was	O
not	O
sodium	B-C1523889
dependent	I-C1523889
and	O
was	O
cytochalasin	B-C0010737
b	I-C0010737
resistant	B-C0332325
.	O
	
inositol	B-C1159756
transport	I-C1159756
in	O
these	O
fungi	B-C0016832
offers	O
an	O
attractive	B-C2346874
new	O
drug	B-C1254351
target	B-C1521840
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	B-C0016832
on	O
its	O
transport	B-C0005528
,	O
clear	O
differences	O
between	O
the	O
mammalian	B-C0024660
and	O
fungal	B-C0016832
transporters	B-C0596902
,	O
and	O
the	O
ability	O
of	O
the	O
host	B-C1167395
to	O
both	O
synthesize	O
and	O
transport	B-C0005528
this	O
critical	B-C1511545
nutrient	B-C0678695
,	O
predicting	O
low	B-C0205251
toxicity	B-C0600688
of	O
potential	B-C3245505
inhibitors	B-C0243077
to	O
the	O
fungal	B-C0016832
transporter	B-C0596902
.	O
	
myo-inositol	B-C0021547
is	O
a	O
sugarlike	B-C0242209
nutrient	B-C0678695
that	O
is	O
essential	B-C0205224
for	O
life	B-C0376558
in	O
most	O
organisms	B-C0029235
.	O
	
humans	B-C0086418
and	O
microbes	B-C0445623
alike	O
can	O
obtain	O
it	O
by	O
making	O
it	O
,	O
which	O
involves	O
only	O
2	O
enzymes	B-C0014442
,	O
by	O
taking	O
it	O
from	O
the	O
environment	B-C0014406
by	O
a	O
transport	B-C1519628
process	I-C1519628
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	B-C0007634
constituents	B-C0729650
.	O
	
inspection	O
of	O
the	O
genomes	B-C0085239
of	O
the	O
pathogenic	B-C3826297
fungi	I-C3826297
of	O
the	O
genus	B-C0597258
pneumocystis	I-C0597258
showed	O
that	O
these	O
pneumonia	B-C0339961
-	O
causing	B-C0678227
parasites	B-C0030498
could	O
not	O
make	O
myo-inositol	B-C0021547
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	B-C0014442
.	O
	
instead	O
,	O
we	O
found	O
evidence	O
of	O
inositol	B-C0021547
transporters	B-C0596902
,	O
which	O
would	O
import	O
the	O
sugar	B-C0242209
from	O
the	O
lungs	B-C0024109
where	O
the	O
fungi	B-C0016832
reside	O
.	O
	
in	O
the	O
present	O
report	O
,	O
we	O
characterized	O
the	O
transport	B-C0005528
of	O
myo-inositol	B-C0021547
in	O
the	O
fungus	B-C0016832
and	O
found	O
that	O
the	O
transporter	B-C0596902
was	O
highly	O
selective	O
for	O
myo-inositol	B-C0021547
and	O
did	O
not	O
transport	B-C0005528
any	O
other	O
molecules	B-C0567416
.	O
	
the	O
transport	B-C0005528
was	O
distinct	O
from	O
that	O
in	O
mammalian	B-C1512977
cells	I-C1512977
,	O
and	O
since	O
mammals	B-C0024660
can	O
both	O
make	O
and	O
transport	B-C0005528
myo-inositol	B-C0021547
,	O
while	O
pneumocystis	B-C0597258
fungi	I-C0597258
must	O
transport	B-C0005528
it	O
,	O
this	O
process	O
offers	O
a	O
potential	B-C3245505
new	O
drug	B-C1254351
target	B-C1521840
.	O
	
worldwide	B-C0332464
occurrence	B-C2745955
of	O
mycotoxins	B-C0026955
in	O
cereals	B-C0007757
and	O
cereal	B-C0007757
-	O
derived	B-C1441547
food	B-C0681562
products	I-C0681562
public	B-C0678367
health	B-C0018684
perspectives	B-C1254370
of	O
their	O
co-occurrence	O
cereal	B-C0007757
grains	I-C0007757
and	O
their	O
processed	B-C1522240
food	B-C0681562
products	I-C0681562
are	O
frequently	O
contaminated	B-C0205279
with	O
mycotoxins	B-C0026955
.	O
	
among	O
many	O
,	O
five	B-C0205451
major	B-C0205164
mycotoxins	B-C0026955
of	O
aflatoxins	B-C0001734
,	O
ochratoxins	B-C0028816
,	O
fumonisins	B-C0304082
,	O
deoxynivalenol	B-C0057445
,	O
and	O
zearalenone	B-C0043454
are	O
of	O
significant	O
public	B-C0678367
health	B-C0018684
concern	B-C2699424
as	O
they	O
can	O
cause	B-C0015127
adverse	B-C0879626
effects	I-C0879626
in	O
humans	B-C0086418
.	O
	
being	O
airborne	B-C3242389
or	O
soilborne	B-C0205245
,	O
the	O
cosmopolitan	O
nature	B-C0449783
of	O
mycotoxigenic	B-C0016832
fungi	I-C0016832
contribute	O
to	O
the	O
worldwide	B-C0332464
occurrence	B-C2745955
of	O
mycotoxins	B-C0026955
.	O
	
on	O
the	O
basis	B-C1527178
of	O
the	O
global	B-C2348867
occurrence	B-C2745955
data	B-C1511726
reported	B-C0700287
during	O
the	O
past	O
10	O
years	O
,	O
the	O
incidences	B-C0021149
and	O
maximum	B-C0806909
levels	B-C0441889
in	O
raw	B-C1709843
cereal	B-C0007757
grains	I-C0007757
were	O
55%	O
and	O
1642	O
μg/kg	O
for	O
aflatoxins	B-C0001734
,	O
29%	O
and	O
1164	O
μg/kg	O
for	O
ochratoxin	B-C0069299
a	I-C0069299
,	O
61%	O
and	O
71	O
μg/kg	O
for	O
fumonisins	B-C0304082
,	O
58%	O
and	O
41	O
μg/kg	O
,	O
for	O
deoxynivalenol	B-C0057445
,	O
and	O
46%	O
and	O
3049	O
μg/kg	O
for	O
zearalenone	B-C0043454
.	O
	
the	O
concentrations	B-C1446561
of	O
mycotoxins	B-C0026955
tend	O
to	O
be	O
lower	B-C0205251
in	O
processed	B-C1522240
food	B-C0681562
products	I-C0681562
the	O
incidences	B-C0021149
varied	O
depending	O
on	O
the	O
individual	O
mycotoxins	B-C0026955
,	O
possibly	O
due	B-C0678226
to	I-C0678226
the	O
varying	B-C0392747
stability	B-C0205360
during	B-C0347984
processing	B-C0016487
and	O
distribution	B-C1704711
of	O
mycotoxins	B-C0026955
.	O
	
it	O
should	O
be	O
noted	O
that	O
more	O
than	O
one	O
mycotoxin	B-C0026955
,	O
produced	B-C0678227
by	O
a	O
single	B-C0205171
or	O
several	B-C0443302
fungal	B-C0016832
species	B-C1705920
,	O
may	O
occur	O
in	O
various	B-C0439064
combinations	B-C0205195
in	O
a	O
given	O
sample	B-C0444315
or	O
food	B-C0016452
.	O
	
most	O
studies	B-C2603343
reported	B-C0700287
additive	B-C0442796
or	O
synergistic	B-C2986495
effects	B-C1280500
,	O
suggesting	B-C1705535
that	O
these	O
mixtures	B-C0439962
may	O
pose	O
a	O
significant	B-C0750502
threat	B-C0749385
to	O
public	B-C0678367
health	B-C0018684
,	O
particularly	O
to	O
infants	B-C0021270
and	O
young	B-C0728836
children	I-C0728836
.	O
	
therefore	O
,	O
information	B-C1533716
on	O
the	O
co-occurrence	O
of	O
mycotoxins	B-C0026955
and	O
their	O
interactive	B-C1704675
toxicity	B-C0600688
is	O
summarized	B-C0242482
locating	O
the	O
seventh	B-C0223178
cervical	I-C0223178
spinous	I-C0223178
process	I-C0223178
development	O
and	O
validation	O
of	O
a	O
multivariate	B-C0026348
model	I-C0026348
using	O
palpation	B-C0030247
and	O
personal	B-C2983694
information	I-C2983694
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	B-C0026348
prediction	I-C0026348
model	I-C0026348
,	O
guided	O
by	O
palpation	B-C0030247
and	O
personal	B-C2983694
information	I-C2983694
,	O
for	O
locating	O
the	O
seventh	B-C0223178
cervical	I-C0223178
spinous	I-C0223178
process	I-C0223178
c7sp	B-C0223178
.	O
	
a	O
single-blinded	B-C0010362
,	O
cross-sectional	I-C0010362
study	I-C0010362
at	O
a	O
primary	B-C1552443
to	I-C1552443
tertiary	I-C1552443
health	I-C1552443
care	I-C1552443
center	I-C1552443
was	O
conducted	O
for	O
model	B-C0920595
development	I-C0920595
and	O
temporal	B-C1519941
validation	I-C1519941
.	O
	
one-hundred	O
sixty	O
participants	B-C0679646
were	O
prospectively	O
included	O
for	O
model	B-C0920595
development	I-C0920595
n	O
=	O
80	O
and	O
time-split	B-C0681916
validation	I-C0681916
stages	I-C0681916
n	O
=	O
80	O
.	O
	
the	O
c7sp	B-C0223178
was	O
located	O
using	O
the	O
thorax-rib	B-C0030247
static	I-C0030247
method	I-C0030247
trsm	B-C0030247
.	O
	
participants	B-C0679646
underwent	O
chest	B-C0039985
radiography	I-C0039985
for	O
assessment	O
of	O
the	O
inner	B-C0205102
body	B-C0460148
structure	I-C0460148
located	O
with	O
trsm	B-C0030247
and	O
using	O
radio-opaque	B-C0181741
markers	I-C0181741
placed	O
over	O
the	O
skin	B-C1123023
.	O
	
age	B-C0001779
,	O
sex	B-C0079399
,	O
height	B-C0489786
,	O
body	B-C0518010
mass	I-C0518010
,	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
,	O
and	O
vertex-marker	B-C0012751
distanc	I-C0012751
e	O
dv-m	B-C0012751
were	O
used	O
to	O
predict	O
the	O
distance	B-C0012751
from	O
the	O
c7sp	B-C0223178
to	O
the	O
vertex	B-C0230003
dv-c7	B-C0012751
.	O
	
multivariate	B-C0034980
linear	I-C0034980
regression	I-C0034980
modeling	I-C0034980
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	B-C0870616
of	I-C0870616
residues	I-C0870616
,	O
receiver	B-C0035787
operating	I-C0035787
characteristic	I-C0035787
curves	I-C0035787
,	O
and	O
confusion	B-C1706074
tables	I-C1706074
were	O
analyzed	O
.	O
	
the	O
multivariate	B-C0026348
linear	I-C0026348
prediction	I-C0026348
model	I-C0026348
for	O
dv-c7	B-C0012751
in	O
centimeters	O
was	O
dv-c7	B-C0012751
=	O
0.986dv	O
+	O
0.018	O
+	O
0.014	O
-	O
1.008	O
.	O
	
receiver	B-C0035787
operating	I-C0035787
characteristic	I-C0035787
curves	I-C0035787
had	O
better	O
discrimination	O
of	O
dv-c7	B-C0012751
area	O
under	O
the	O
curve	O
=	O
0.661	O
95%	O
confidence	B-C0009667
interval	I-C0009667
=	O
0.541	O
p	O
=	O
015	O
than	O
dv-m	B-C0012751
area	O
under	O
the	O
curve	O
=	O
0.480	O
95%	O
confidence	B-C0009667
interval	I-C0009667
=	O
0.345	O
p	O
=	O
761	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
sensitivity	B-C0036667
=	O
41%	O
,	O
specificity	B-C0037791
=	O
63%	O
and	O
24.75	O
cm	O
sensitivity	B-C0036667
=	O
69%	O
,	O
specificity	B-C0037791
=	O
52%	O
.	O
	
the	O
c7sp	B-C0223178
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
dv-c7	B-C0012751
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
trsm	B-C0030247
in	O
the	O
development	O
sample	O
n	O
=	O
53	O
66%	O
vs	O
n	O
=	O
32	O
40%	O
,	O
p	O
<	O
001	O
.	O
	
better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
c7sp	B-C0223178
by	O
use	O
of	O
a	O
multivariate	B-C0026348
model	I-C0026348
that	O
incorporates	O
palpation	B-C0030247
and	O
personal	B-C2983694
information	I-C2983694
.	O
	
comparison	B-C1707455
of	O
leishmania	B-C1095819
typing	B-C0430416
results	B-C0456984
obtained	B-C1301820
from	O
16	O
european	B-C0015176
clinical	B-C1551301
laboratories	I-C1551301
in	O
2014	O
leishmaniasis	B-C0023281
is	O
endemic	B-C0544083
in	O
southern	B-C0037724
europe	I-C0037724
,	O
and	O
in	O
other	O
european	B-C0015176
countries	B-C0454664
cases	B-C0021149
are	O
diagnosed	B-C0011900
in	O
travellers	B-C0335278
who	O
have	O
visited	O
affected	B-C1879646
areas	I-C1879646
both	O
within	B-C0332285
the	O
continent	B-C0454690
and	O
beyond	O
.	O
	
prompt	B-C0205556
and	O
accurate	B-C0443131
diagnosis	B-C0011900
poses	O
a	O
challenge	O
in	O
clinical	B-C2986419
practice	I-C2986419
in	O
europe	B-C0015176
.	O
	
different	B-C1705242
methods	B-C0025663
exist	B-C2987476
for	O
identification	B-C0205396
of	O
the	O
infecting	B-C0439663
leishmania	B-C1095819
species	B-C1705920
.	O
	
sixteen	O
clinical	B-C1551301
laboratories	I-C1551301
in	O
10	O
european	B-C0015176
countries	B-C0454664
,	O
plus	O
israel	B-C0022271
and	O
turkey	B-C0041400
,	O
conducted	O
a	O
study	B-C2603343
to	O
assess	O
their	O
genotyping	B-C1285573
performance	B-C1882330
.	O
	
dna	B-C0012854
from	O
21	O
promastigote	B-C0684063
cultures	I-C0684063
of	O
13	O
species	B-C1705920
was	O
analysed	B-C0936012
blindly	B-C0205556
by	O
the	O
routinely	B-C0205547
used	O
typing	B-C0430416
method	B-C0025663
.	O
	
five	O
different	B-C1705242
molecular	B-C1513403
targets	I-C1513403
were	O
used	O
,	O
which	O
were	O
analysed	B-C0936012
with	O
pcr-based	B-C0032520
methods	B-C0025663
.	O
	
different	B-C1705242
levels	B-C0441889
of	O
identification	B-C0205396
were	O
achieved	B-C0432600
,	O
and	O
either	O
the	O
leishmania	B-C1095819
subgenus	B-C1883697
,	O
species	B-C1705920
complex	O
,	O
or	O
actual	O
species	B-C1705920
were	O
reported	B-C0684224
.	O
	
the	O
overall	B-C1561607
error	B-C0743559
rate	B-C1521828
of	O
strains	B-C1518614
placed	O
in	O
the	O
wrong	B-C3827420
complex	O
or	O
species	B-C1705920
was	O
8.5	O
.	O
	
various	O
reasons	B-C0392360
for	O
incorrect	B-C3827420
typing	B-C0430416
were	O
identified	B-C0205396
.	O
	
the	O
study	B-C2603343
shows	O
there	O
is	O
considerable	B-C0205556
room	O
for	O
improvement	B-C2986411
and	O
standardisation	B-C0038136
of	O
leishmania	B-C1095819
typing	B-C0430416
.	O
	
the	O
use	O
of	O
well	O
validated	B-C1519941
standard	B-C1710183
operating	I-C1710183
procedures	I-C1710183
is	O
recommended	B-C0034866
,	O
covering	O
testing	B-C0039593
,	O
interpretation	B-C0459471
,	O
and	O
reporting	B-C0700287
guidelines	B-C0162791
.	O
	
application	O
of	O
the	O
internal	B-C0205102
transcribed	B-C0205556
spacer	B-C0887858
1	I-C0887858
of	O
the	O
rdna	B-C0012931
array	B-C0600597
should	O
be	O
restricted	B-C0443288
to	O
old	B-C0205556
world	I-C0205556
samples	B-C2347026
,	O
while	O
the	O
heat-shock	B-C1415755
protein	I-C1415755
70	I-C1415755
gene	I-C1415755
and	O
the	O
mini-exon	B-C0026163
can	O
be	O
applied	B-C4048755
globally	B-C2348867
.	O
	
scoparone	B-C0074191
inhibits	O
lps	B-C0023810
-	O
simulated	B-C0205245
inflammatory	B-C1155266
response	I-C1155266
by	O
suppressing	B-C1260953
irf3	B-C1510506
and	O
erk	B-C0600388
in	O
bv-2	B-C0206116
microglial	I-C0206116
cells	I-C0206116
microglia	B-C0206116
activation	B-C1326120
and	O
the	O
release	O
of	O
various	O
inflammatory	B-C0333348
cytokines	B-C0079189
are	O
largely	O
related	O
to	O
neurological	B-C2359473
diseases	I-C2359473
,	O
including	O
parkinson's	B-C0030567
,	O
alzheimer's	B-C0002395
,	O
and	O
other	B-C0205394
brain	B-C0006111
diseases	I-C0006111
.	O
	
the	O
suppression	O
of	O
microglial	B-C0206116
cells	I-C0206116
using	O
natural	B-C0205296
bioactive	B-C0574031
compounds	I-C0574031
has	O
become	O
increasingly	B-C0442805
important	B-C3898777
for	O
brain	B-C0872120
therapy	I-C0872120
owing	O
to	O
the	O
expected	O
beneficial	B-C0683156
effect	I-C0683156
of	O
lower	B-C0205251
toxicity	B-C0040539
.	O
	
scoparone	B-C0074191
6	B-C0074191
,	O
a	O
major	O
bioactive	B-C0574031
compound	I-C0574031
found	B-C0150312
in	O
various	O
plant	B-C2698828
parts	I-C2698828
,	O
including	O
the	O
inner	O
shell	B-C1948022
of	O
chestnut	B-C0349771
castanea	B-C1047769
crenata	I-C1047769
,	O
was	O
evaluated	O
on	O
lipopolysaccharide	B-C0023810
lps	B-C0023810
activated	B-C1515877
bv-2	B-C0206116
microglia	I-C0206116
cells	I-C0206116
.	O
	
the	O
results	B-C1274040
indicated	B-C1444656
that	O
scoparone	B-C0074191
suppresses	B-C1260953
the	O
lps	B-C0023810
-	O
stimulated	B-C0205245
increase	B-C0442805
of	O
neuroinflammatory	B-C1155266
responses	I-C1155266
and	O
inhibited	B-C0311403
the	O
pro-inflammatory	B-C0333348
cytokine	B-C0079189
production	O
in	O
the	O
bv-2	B-C0206116
microglial	I-C0206116
cells	I-C0206116
.	O
	
a	O
mechanistic	B-C0441712
study	I-C0441712
showed	O
that	O
scoparone	B-C0074191
specifically	O
inhibited	B-C0311403
the	O
lps	B-C0023810
-	O
stimulated	B-C0205245
activation	B-C1326120
via	O
a	O
major	O
regulation	B-C1327622
of	O
irf-3	B-C1510506
and	O
a	O
regulation	B-C1327622
of	O
erk	B-C0600388
,	O
whereby	O
the	O
phosphorylation	B-C0031715
in	O
the	O
bv-2	B-C0206116
microglial	I-C0206116
cells	I-C0206116
is	O
blocked	B-C0332206
.	O
	
these	O
data	B-C1511726
suggest	B-C1705535
that	O
scoparone	B-C0074191
has	O
anti-neuroinflammatory	B-C1515999
effects	I-C1515999
in	O
lps	B-C0023810
-	O
activated	B-C1515877
bv-2	B-C0206116
microglial	I-C0206116
cells	I-C0206116
,	O
and	O
could	O
possibly	O
be	O
used	B-C1524063
in	O
the	O
development	B-C1527148
of	O
novel	B-C0205314
drugs	B-C0013227
for	O
the	O
prevention	B-C1456501
and	O
treatment	B-C1522326
of	O
neuroinflammatory	B-C2359473
diseases	I-C2359473
.	O
	
efficient	O
genome	B-C4279981
editing	I-C4279981
of	O
differentiated	B-C0205615
renal	B-C0022646
epithelial	B-C0014597
cells	I-C0014597
recent	O
advances	O
in	O
genome	B-C4279981
editing	I-C4279981
technologies	I-C4279981
have	O
enabled	O
the	O
rapid	O
and	O
precise	O
manipulation	B-C0178659
of	I-C0178659
genomes	I-C0178659
,	O
including	O
the	O
targeted	B-C4279981
introduction	I-C4279981
,	O
alteration	B-C4279981
,	O
and	O
removal	B-C4279981
of	I-C4279981
genomic	I-C4279981
sequences	I-C4279981
.	O
	
however	O
,	O
respective	O
methods	B-C0025663
have	O
been	O
described	O
mainly	O
in	O
non-differentiated	B-C0449475
or	O
haploid	B-C1257912
cell	B-C0449475
types	I-C0449475
.	O
	
genome	B-C4279981
editing	I-C4279981
of	O
well-differentiated	B-C0205615
renal	B-C0022646
epithelial	B-C0014597
cells	I-C0014597
has	O
been	O
hampered	O
by	O
a	O
range	O
of	O
technological	B-C0033213
issues	I-C0033213
,	O
including	O
optimal	B-C2698651
design	B-C1707689
,	O
efficient	B-C0442799
expression	B-C4279981
of	I-C4279981
multiple	I-C4279981
genome	I-C4279981
editing	I-C4279981
constructs	I-C4279981
,	O
attainable	B-C0205556
mutation	B-C3178846
rates	I-C3178846
,	O
and	O
best	O
screening	B-C0282574
strategies	I-C0282574
.	O
	
here	O
,	O
we	O
present	O
an	O
easily	O
implementable	O
workflow	B-C1710679
for	O
the	O
rapid	B-C0456962
generation	B-C4279981
of	I-C4279981
targeted	I-C4279981
heterozygous	I-C4279981
and	I-C4279981
homozygous	I-C4279981
genomic	I-C4279981
sequence	I-C4279981
alterations	I-C4279981
in	O
renal	B-C0022646
cells	B-C0007634
using	O
transcription	B-C4277678
activator-like	I-C4277678
effector	I-C4277678
nucleases	I-C4277678
talens	B-C4277678
and	O
the	O
clustered	B-C3658200
regularly	I-C3658200
interspaced	I-C3658200
short	I-C3658200
palindromic	I-C3658200
repeat	I-C3658200
crispr	I-C3658200
system	I-C3658200
.	O
	
we	O
demonstrate	O
the	O
versatility	O
of	O
established	O
protocols	B-C0442711
by	O
generating	B-C3146294
novel	B-C0205314
cellular	B-C0026336
models	I-C0026336
for	O
studying	B-C2603343
autosomal	B-C0085413
dominant	I-C0085413
polycystic	I-C0085413
kidney	I-C0085413
disease	I-C0085413
adpkd	B-C0085413
.	O
	
furthermore	O
,	O
we	O
show	O
that	O
cell	B-C4277689
culture-validated	I-C4277689
genetic	I-C4277689
modifications	I-C4277689
can	O
be	O
readily	O
applied	O
to	O
mouse	B-C4042879
embryonic	I-C4042879
stem	I-C4042879
cells	I-C4042879
mescs	B-C4042879
for	O
the	O
generation	B-C3146294
of	O
corresponding	O
mouse	B-C0025929
models	B-C0599779
.	O
	
the	O
described	O
procedure	B-C2700391
for	O
efficient	O
genome	B-C4279981
editing	I-C4279981
can	O
be	O
applied	O
to	O
any	O
cell	B-C0449475
type	I-C0449475
to	O
study	B-C2603343
physiological	B-C0031845
and	O
pathophysiological	B-C0030660
functions	I-C0030660
in	O
the	O
context	O
of	O
precisely	O
engineered	B-C1516876
genotypes	I-C1516876
.	O
	
right	B-C0225883
ventricular	I-C0225883
response	B-C0871261
during	B-C0347984
exercise	B-C0015259
in	O
patients	B-C0030705
with	O
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
right	B-C0225883
ventricular	I-C0225883
rv	B-C0225883
pump	B-C0080311
function	I-C0080311
is	O
of	O
essential	B-C0205224
clinical	B-C0205210
and	O
prognostic	B-C0220901
importance	B-C3898777
in	O
a	O
variety	B-C2346866
of	O
heart	B-C0018799
and	O
lung	B-C0024115
diseases	I-C0024115
.	O
	
while	O
the	O
evaluation	B-C0220825
of	O
rv	B-C0225883
performance	B-C1882330
at	O
rest	B-C0035253
has	O
been	O
implemented	O
in	O
the	O
clinical	B-C3176918
setting	I-C3176918
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	B-C0220825
during	B-C0347984
exercise	B-C0015259
may	O
provide	O
additional	B-C1524062
benefit	B-C0814225
.	O
	
with	O
this	O
aim	B-C1947946
,	O
we	O
evaluated	B-C0220825
the	O
exercise	B-C0015259
-	O
induced	B-C0205263
pulmonary	B-C1168444
arterial	I-C1168444
systolic	I-C1168444
pressure	I-C1168444
pasp	B-C1168444
increase	B-C0442805
during	B-C0347984
exercise	B-C0015259
in	O
patients	B-C0030705
with	O
severe	B-C0392364
chronic	B-C0024117
obstructive	I-C0024117
pulmonary	I-C0024117
disease	I-C0024117
copd	B-C0024117
as	O
an	O
expression	O
of	O
rv	B-C0225883
contractile	B-C0392762
reserve	I-C0392762
.	O
	
cardiopulmonary	B-C2959886
exercise	I-C2959886
testing	I-C2959886
cpet	B-C2959886
with	O
synchronic	B-C0013516
echocardiography	I-C0013516
was	O
performed	B-C0884358
in	O
81	O
patients	B-C0030705
.	O
	
patients	B-C0030705
were	O
classified	B-C0008902
into	O
two	O
groups	B-C0441833
according	O
to	O
an	O
exercise	B-C0015259
-	O
induced	B-C0205263
pasp	B-C1168444
increase	B-C0442805
above	O
30mmhg	O
high	B-C0205250
psap	B-C1168444
or	O
below	O
30mmhg	O
low	B-C0205251
psap	B-C1168444
during	B-C0347984
maximal	B-C0205289
exercise	B-C0015259
.	O
	
patients	B-C0030705
were	O
then	O
followed	B-C0332282
for	O
three	O
years	B-C0439234
.	O
	
sixteen	O
patients	B-C0030705
20%	O
had	O
low	B-C0205251
psap	B-C1168444
and	O
65	O
80%	O
showed	O
high	B-C0205250
psap	B-C1168444
.	O
	
these	O
were	O
not	B-C1273937
significant	I-C1273937
clinical	B-C0205210
and	O
functional	B-C0205245
differences	B-C1705241
.	O
	
low	B-C0205251
psap	B-C1168444
was	O
associated	B-C0332281
with	I-C0332281
a	O
significantly	B-C4055638
lower	I-C4055638
peak	B-C0444505
vo2	B-C0429627
mean	B-C0444504
sd	B-C0871420
,	O
35	O
2	O
%	O
predicted	B-C0681842
compared	B-C1707455
to	O
high	B-C0205250
psap	B-C1168444
response	B-C0871261
peak	B-C0444505
vo2	B-C0429627
45	O
3	O
%	O
predicted	B-C0681842
,	O
p=0	O
.	O
	
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
mortality	B-C0178686
were	O
age	B-C0001779
and	O
exercise	B-C0015259
-	O
induced	B-C0205263
pasp	B-C1168444
.	O
	
seventeen	O
patients	B-C0030705
died	O
during	B-C0347984
the	O
three	O
years	B-C0439234
of	O
follow-up	B-C1522577
7	O
39%	O
in	O
the	O
low	B-C0205251
psap	B-C1168444
group	B-C0441833
and	O
only	O
10	O
1%	O
in	O
the	O
high	B-C0205250
psap	B-C1168444
group	B-C0441833
,	O
p=0	O
.	O
	
cardiopulmonary	B-C2959886
exercise	I-C2959886
testing	I-C2959886
with	O
a	O
synchronic	B-C0013516
echocardiography	I-C0013516
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	B-C0220825
of	O
rv	B-C0225883
contractile	B-C0392762
reserve	I-C0392762
in	O
severe	B-C0392364
copd	B-C0024117
patients	B-C0030705
.	O
	
exercise	B-C0015259
-	O
induced	B-C0205263
psap	B-C1168444
emerges	O
as	O
a	O
possible	O
prognostic	B-C1514474
factor	I-C1514474
in	O
these	O
adverse	B-C1274040
outcomes	I-C1274040
in	O
older	B-C0001792
adults	I-C0001792
attending	B-C1999232
emergency	B-C0562508
departments	I-C0562508
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0920317
of	O
the	O
identification	B-C0282574
of	I-C0282574
seniors	I-C0282574
at	I-C0282574
risk	I-C0282574
isar	I-C0282574
screening	I-C0282574
tool	I-C0282574
older	B-C0001792
adults	I-C0001792
are	O
frequent	B-C0332183
users	O
of	O
emergency	B-C0013961
services	I-C0013961
and	O
demonstrate	O
high	B-C0205250
rates	B-C1521828
of	O
adverse	B-C1274040
outcomes	I-C1274040
following	O
emergency	B-C1527398
care	I-C1527398
.	O
	
to	O
perform	O
a	O
systematic	B-C1955832
review	I-C1955832
and	O
meta-analysis	B-C0920317
of	O
the	O
identification	B-C0282574
of	I-C0282574
seniors	I-C0282574
at	I-C0282574
risk	I-C0282574
isar	I-C0282574
screening	I-C0282574
tool	I-C0282574
,	O
to	O
determine	O
its	O
predictive	B-C1514307
value	I-C1514307
in	O
identifying	O
adults	B-C0001675
65	O
years	B-C0439234
at	O
risk	B-C0035647
of	O
functional	B-C4304688
decline	I-C4304688
,	O
unplanned	O
emergency	B-C0583237
department	I-C0583237
ed	I-C0583237
readmission	I-C0583237
,	O
emergency	B-C0013956
hospitalisation	B-C0019993
or	O
death	B-C1306577
within	O
180	O
days	B-C0439228
after	O
index	O
ed	B-C0586082
visit	I-C0586082
/	O
hospitalisation	B-C0019993
.	O
	
a	O
systematic	B-C0220922
literature	B-C0023866
search	B-C1706202
was	O
conducted	O
in	O
pubmed	B-C1138432
,	O
embase	B-C0282574
,	O
cinahl	B-C0282574
,	O
ebsco	B-C0282574
and	O
the	O
cochrane	B-C0282574
library	I-C0282574
to	O
identify	O
validation	B-C1519941
and	O
impact	B-C4049986
analysis	B-C0936012
studies	O
of	O
the	O
isar	B-C0282574
tool	I-C0282574
.	O
	
a	O
pre-specified	B-C2826245
isar	B-C0282574
score	B-C0449820
of	O
2	O
maximum	O
score	B-C0449820
6	O
points	O
was	O
used	O
to	O
identify	O
patients	B-C0030705
at	O
high	B-C0332167
risk	I-C0332167
of	I-C0332167
adverse	B-C1274040
outcomes	I-C1274040
.	O
	
a	O
bivariate	B-C3161035
random	I-C3161035
effects	I-C3161035
model	I-C3161035
generated	O
pooled	B-C2349200
estimates	B-C0750572
of	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
.	O
	
statistical	B-C0019409
heterogeneity	I-C0019409
was	O
explored	O
and	O
methodological	B-C0815254
quality	I-C0815254
was	O
assessed	O
using	O
validated	B-C0243161
criteria	I-C0243161
.	O
	
thirty-two	O
validation	B-C0681836
studies	I-C0681836
n	O
=	O
12	O
are	O
included	B-C0332257
.	O
	
at	O
2	O
,	O
the	O
pooled	B-C2349200
sensitivity	B-C0036667
of	O
the	O
isar	B-C0282574
for	O
predicting	O
ed	B-C0562508
return	B-C0332156
,	O
emergency	B-C0013956
hospitalisation	B-C0019993
and	O
mortality	B-C0205848
at	O
6	O
months	B-C0439231
is	O
0.80	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.70	O
,	O
0.82	O
95%	O
ci	B-C0009667
0.74	O
and	O
0.87	O
95%	O
ci	B-C0009667
0.75	O
,	O
respectively	O
,	O
with	O
a	O
pooled	B-C2349200
specificity	B-C0037791
of	O
0.31	O
95%	O
ci	B-C0009667
0.24	O
,	O
0.32	O
95%	O
ci	B-C0009667
0.24	O
and	O
0.35	O
95%	O
ci	B-C0009667
0.26	O
.	O
	
similar	O
values	B-C0042295
are	O
demonstrated	O
at	O
30	O
and	O
90	O
days	B-C0439228
.	O
	
three	O
heterogeneous	B-C0019409
impact	B-C4049986
analysis	B-C0936012
studies	O
examined	B-C0332128
the	O
clinical	B-C0205210
implementation	B-C1708476
of	O
the	O
isar	B-C0282574
and	O
reported	O
mixed	B-C2607943
findings	I-C2607943
across	O
patient	B-C0030705
and	O
process	B-C1522240
outcomes	B-C1274040
.	O
	
the	O
isar	B-C0282574
has	O
modest	O
predictive	B-C0681890
accuracy	B-C0443131
and	O
may	O
serve	O
as	O
a	O
decision-making	B-C0011109
adjunct	B-C1719882
when	O
determining	O
which	O
older	B-C0001792
adults	I-C0001792
can	O
be	O
safely	O
ecohydrological	B-C0870071
modeling	I-C0870071
and	O
environmental	B-C0014406
flow	B-C0806140
regime	B-C0243148
in	O
the	O
formoso	B-C0337050
river	I-C0337050
,	O
minas	B-C0006137
gerais	I-C0006137
state	I-C0006137
,	O
brazil	B-C0006137
this	O
paper	B-C1706852
aimed	O
at	O
determining	B-C0521095
the	O
environmental	B-C0014406
flow	B-C0806140
regime	O
in	O
a	O
1	B-C0439198
km	I-C0439198
stretch	B-C0012751
of	O
the	O
formoso	B-C0337050
river	I-C0337050
,	O
mg	B-C0006137
,	O
using	O
river2d	B-C0870071
model	I-C0870071
.	O
	
to	O
carry	O
out	O
the	O
ecohydrological	B-C0870071
modeling	I-C0870071
,	O
the	O
following	B-C0332282
information	B-C1533716
was	O
used	O
bathymetry	B-C0392762
,	O
physical	B-C0205485
and	O
hydraulic	B-C0205245
features	B-C2348519
,	O
and	O
the	O
habitat	B-C0871648
suitability	B-C3900053
index	I-C3900053
for	O
species	B-C1705920
of	O
the	O
hypostomus	B-C3128443
auroguttatus	I-C3128443
.	O
	
in	O
the	O
river2d	B-C0870071
,	O
the	O
weighted	B-C0439751
usable	B-C3827682
areas	B-C0205146
were	O
determined	B-C0521095
from	O
the	O
average	B-C1510992
long-term	B-C0443252
streamflows	B-C0442540
with	O
percentage	B-C0439165
from	O
10%	O
to	O
100%	O
.	O
	
those	O
streamflows	B-C0442540
were	O
simulated	O
for	O
the	O
later	B-C0205087
construction	B-C1881534
of	O
optimization	B-C2698650
matrices	B-C1704640
that	O
maximize	B-C0806909
the	O
habitat	B-C0871648
area	B-C0205146
throughout	B-C0332273
the	O
year	B-C0439234
.	O
	
for	O
h	B-C3128443
.	O
	
auroguttatus	I-C3128443
juvenile	B-C3146221
,	O
higher	B-C0205250
values	B-C0042295
of	O
weighted	B-C0439751
usable	B-C3827682
area	B-C0205146
were	O
associated	B-C0332281
with	I-C0332281
the	O
percentage	B-C0439165
of	O
60%	O
and	O
70%	O
of	O
the	O
average	B-C1510992
long-term	B-C0443252
streamflows	B-C0442540
in	O
october	B-C3828732
and	O
september	B-C3828193
,	O
respectively	O
.	O
	
for	O
h	B-C3128443
.	O
	
auroguttatus	I-C3128443
adult	B-C0001675
,	O
the	O
highest	B-C1522410
value	B-C0042295
of	O
weighted	B-C0439751
usable	B-C3827682
area	O
was	O
associated	O
with	O
the	O
percentage	O
of	O
100%	O
of	O
the	O
average	O
long-term	O
streamflow	O
in	O
september	O
.	O
	
the	O
environmental	O
flows	O
found	O
for	O
this	O
stretch	O
of	O
the	O
formoso	O
river	O
varied	O
over	O
the	O
year	O
.	O
	
the	O
lowest	O
environmental	O
flow	O
was	O
observed	O
in	O
december	O
2.85	O
m3	O
s-1	O
,	O
while	O
the	O
highest	O
was	O
observed	O
in	O
may	O
4.13	O
m3	O
s-1	O
.	O
	
this	O
paper	O
shows	O
the	O
importance	O
of	O
ecohydrological	O
studies	O
in	O
forming	O
a	O
basis	O
for	O
water	O
resources	O
management	O
actions	B-C3266814
risk	B-C0035648
factors	I-C0035648
for	O
hepatitis	B-C4288963
c	I-C4288963
virus	I-C4288963
infection	I-C4288963
in	O
the	O
colombian	B-C1553372
caribbean	B-C0206155
coast	I-C0206155
a	O
case-control	B-C0007328
study	I-C0007328
an	O
estimated	O
6.8	O
million	B-C1881839
people	B-C0027361
are	O
infected	B-C0439663
with	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
in	O
latin	B-C0023122
america	I-C0023122
,	O
of	O
which	O
less	B-C0439092
than	I-C0439092
1%	O
receives	O
antiviral	B-C2363964
treatment	I-C2363964
.	O
	
studies	B-C2603343
so	O
far	O
in	O
colombia	B-C3245499
have	O
attempted	B-C1516084
to	O
determine	O
the	O
prevalence	B-C0033106
of	O
the	O
disease	B-C0012634
in	O
some	O
risk	B-C0035647
groups	B-C1257890
,	O
thus	O
preventing	B-C1292733
the	O
identification	B-C0205396
of	O
other	O
factors	B-C1521761
potentially	B-C3245505
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	B-C3714514
.	O
	
to	O
identify	B-C0205396
traditional	O
and	O
non-traditional	O
risk	B-C0035648
factors	I-C0035648
for	O
chronic	B-C0524910
hepatitis	I-C0524910
c	I-C0524910
in	O
the	O
colombian	B-C1553372
caribbean	B-C0206155
coast	I-C0206155
.	O
	
this	O
was	O
a	O
case-control	B-C0007328
study	I-C0007328
1	O
matched	O
by	O
health	B-C0018724
care	I-C0018724
provider	I-C0018724
and	O
age	B-C0001779
10	O
years	B-C0439234
conducted	O
at	O
the	O
primary	B-C0033137
care	I-C0033137
level	I-C0033137
of	O
gastroenterology	B-C0017163
and	O
hepatology	B-C0086403
outpatient	B-C0086751
services	I-C0086751
.	O
	
all	O
patients	B-C0030705
with	O
a	O
positive	B-C1446409
elisa	B-C0014441
underwent	O
a	O
confirmatory	B-C0814857
viral	B-C1656394
load	I-C1656394
test	I-C1656394
.	O
	
a	O
multivariate	B-C0681925
logistic	I-C0681925
regression	I-C0681925
analysis	I-C0681925
identified	B-C0205396
the	O
independent	B-C2698872
predictors	I-C2698872
of	O
infection	B-C3714514
.	O
	
blood	B-C0005841
transfusion	I-C0005841
or	B-C0028873
=159	O
95%	O
ci	B-C0009667
35.4	O
p<0	O
and	O
history	B-C0551576
of	I-C0551576
hospitalization	I-C0551576
before	O
1994	O
or	B-C0028873
=4	O
95%	O
ci	B-C0009667
1.3	O
p=0	O
were	O
identified	B-C0205396
as	O
the	O
only	O
two	O
independent	B-C2698872
predictors	I-C2698872
of	O
infection	B-C3714514
.	O
	
it	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility	B-C0035149
of	I-C0035149
these	I-C0035149
results	I-C0035149
and	O
to	O
conduct	O
cost-effectiveness	B-C0010181
studies	B-C2603343
before	O
recommending	B-C0034866
their	O
use	B-C0457083
in	O
the	O
design	B-C1707689
of	O
new	B-C2348164
screening	I-C2348164
strategies	I-C2348164
.	O
	
quo	O
vadis	O
g	B-C1149462
protein-coupled	I-C1149462
receptor	I-C1149462
ligands	I-C1149462
a	O
tool	O
for	O
analysis	B-C0936012
of	O
the	O
emergence	B-C0750573
of	O
new	O
groups	B-C0441833
of	O
compounds	B-C1706082
over	B-C0040223
time	I-C0040223
exponential	B-C1552645
growth	B-C2911660
in	O
the	O
number	B-C0237753
of	O
compounds	B-C1706082
with	O
experimentally	B-C1517586
verified	B-C1711411
activity	B-C0441655
towards	O
particular	O
target	B-C1521840
has	O
led	O
to	O
the	O
emergence	B-C0750573
of	O
various	O
databases	B-C0242356
gathering	O
data	B-C1511726
on	O
biological	B-C0205460
activity	B-C0441655
.	O
	
in	O
this	O
study	B-C2603343
,	O
the	O
ligands	B-C0023688
of	O
family	B-C0682972
a	I-C0682972
of	I-C0682972
the	I-C0682972
g	I-C0682972
protein-coupled	I-C0682972
receptors	I-C0682972
that	O
are	O
collected	B-C1516695
in	O
the	O
chembl	B-C0242356
database	I-C0242356
were	O
examined	B-C0332128
,	O
and	O
special	O
attention	O
was	O
given	O
to	O
serotonin	B-C0034838
receptors	I-C0034838
.	O
	
sets	B-C1705195
of	O
compounds	B-C1706082
were	O
examined	B-C0332128
in	O
terms	O
of	O
their	O
appearance	B-C0700364
over	B-C0040223
time	I-C0040223
,	O
they	O
were	O
mapped	B-C1283195
to	O
the	O
chemical	B-C1254350
space	I-C1254350
of	O
drugs	B-C1254351
deposited	O
in	O
drugbank	B-C4255544
,	O
and	O
the	O
emergence	B-C0750573
of	O
structurally	B-C1254350
new	I-C1254350
clusters	I-C1254350
of	I-C1254350
compounds	I-C1254350
was	O
indicated	B-C1444656
.	O
	
in	O
addition	O
,	O
a	O
tool	O
for	O
detailed	O
analysis	B-C0936012
of	O
the	O
obtained	B-C1301820
visualizations	B-C1704922
was	O
prepared	B-C4082130
and	O
made	O
available	B-C0470187
online	B-C0683828
at	O
http	B-C0282574
,	O
which	O
enables	O
the	O
investigation	B-C1517586
of	O
chemical	B-C0220807
structures	I-C0220807
while	O
referring	B-C0205543
to	O
particular	O
data	B-C3176122
points	I-C3176122
depicted	O
in	O
the	O
figures	B-C0683878
and	O
changes	B-C0392747
in	O
compounds	B-C1706082
datasets	B-C0150098
over	B-C0040223
time	I-C0040223
.	O
	
diabetes	B-C0011847
and	O
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
in	O
black	B-C0043210
women	I-C0043210
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
is	O
higher	O
in	O
black	B-C0043210
women	I-C0043210
than	O
in	O
white	B-C0043210
women	I-C0043210
.	O
	
the	O
prevalence	B-C0220900
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
mellitus	I-C0011860
is	O
also	O
higher	O
,	O
yet	O
data	B-C1511726
on	O
whether	O
diabetes	B-C0011847
affects	B-C1280500
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
in	O
this	O
population	B-C1257890
are	O
lacking	B-C0332268
.	O
	
we	O
investigated	B-C1292732
the	O
relation	O
of	O
diabetes	B-C0011847
at	O
the	O
time	O
of	O
breast	B-C0678222
cancer	I-C0678222
diagnosis	B-C0011900
to	O
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
in	O
the	O
black	B-C0043210
women's	I-C0043210
health	B-C0086388
study	B-C2603343
,	O
a	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
.	O
	
1	O
black	B-C0043210
women	I-C0043210
with	O
invasive	B-C0205281
breast	B-C0678222
cancer	I-C0678222
diagnosed	B-C0011900
in	O
1995-2013	O
were	O
followed	B-C0332283
by	I-C0332283
mailed	O
questionnaires	B-C0034394
and	O
searches	O
of	O
the	O
national	B-C3889680
death	I-C3889680
index	I-C3889680
.	O
	
multivariable	B-C0034980
cox	I-C0034980
regression	I-C0034980
analysis	I-C0034980
was	O
used	O
to	O
compute	O
hazard	B-C2985465
ratios	I-C2985465
hrs	B-C2985465
for	O
diabetes	B-C0011847
in	O
relation	O
to	O
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
and	O
all-cause	O
mortality	B-C0026565
,	O
with	O
adjustment	O
for	O
age	B-C0001779
,	O
stage	B-C1300072
,	O
treatment	B-C3527083
modality	I-C3527083
,	O
estrogen	B-C0034804
receptor	I-C0034804
er	B-C0034804
status	B-C0449438
,	O
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
.	O
	
there	O
were	O
368	O
deaths	B-C1306577
during	O
follow-up	B-C1522577
,	O
of	O
which	O
273	O
were	O
due	O
to	O
breast	B-C0678222
cancer	I-C0678222
.	O
	
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
was	O
significantly	B-C4055637
increased	I-C4055637
in	O
women	B-C0043210
who	O
had	O
been	O
diagnosed	B-C0011900
with	O
diabetes	B-C0011847
at	O
least	O
5	O
years	O
before	O
breast	B-C0678222
cancer	I-C0678222
occurrence	B-C2745955
,	O
hr	B-C2985465
1.86	O
95%	O
ci	O
1.20	O
,	O
with	O
elevations	B-C0702240
observed	B-C1441672
for	O
both	O
er+	B-C1719706
and	O
er-	B-C1719707
breast	B-C0678222
cancer	I-C0678222
.	O
	
all-cause	O
mortality	B-C0026565
was	O
also	O
higher	O
in	O
diabetics	B-C0241863
,	O
with	O
hrs	B-C2985465
of	O
1.54	O
95%	O
ci	O
1.12	O
overall	B-C1561607
and	O
2.26	O
95%	O
ci	O
1.62	O
for	O
5-year	O
duration	O
of	O
diabetes	B-C0011847
relative	B-C0205345
to	O
non-diabetics	B-C0241863
.	O
	
our	O
results	B-C0456984
present	B-C0150312
the	O
first	O
solid	O
evidence	B-C3887511
of	O
a	O
positive	B-C1446409
association	O
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
with	O
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
in	O
black	B-C0043210
women	I-C0043210
.	O
	
given	O
the	O
higher	O
prevalence	B-C0220900
and	O
earlier	B-C1833334
onset	I-C1833334
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
in	O
black	B-C0043210
women	I-C0043210
,	O
it	O
is	O
likely	O
that	O
diabetes	B-C0011847
contributes	B-C1880177
to	O
racial	B-C0034510
disparities	B-C1171307
in	O
breast	B-C0678222
cancer	I-C0678222
mortality	B-C0026565
.	O
	
neuro-behcet	B-C0858762
disease	I-C0858762
presenting	B-C0449450
as	O
a	O
solitary	O
cerebellar	B-C0149854
hemorrhagic	I-C0149854
lesion	B-C0221198
a	O
case	B-C0085973
report	I-C0085973
and	O
review	B-C0282441
of	I-C0282441
the	I-C0282441
literature	I-C0282441
behcet's	B-C0004943
disease	I-C0004943
is	O
a	O
heterogeneous	B-C1858576
,	O
multisystem	B-C0559758
,	O
inflammatory	B-C1290884
disorder	I-C1290884
of	O
unknown	B-C0743626
etiology	I-C0743626
.	O
	
the	O
classic	O
triad	O
of	O
oral	B-C0149745
and	O
genital	B-C0151281
ulcerations	I-C0151281
in	O
conjunction	B-C2699427
with	O
uveitis	B-C0042164
was	O
originally	O
described	B-C1552738
by	O
the	O
turkish	B-C0549217
dermatologist	B-C0259831
hulusi	O
behcet	O
in	O
1937	O
,	O
but	O
associated	B-C0521989
symptoms	I-C0521989
of	O
the	O
cardiovascular	B-C0007226
,	O
central	B-C3714787
nervous	I-C3714787
,	O
pulmonary	B-C0884309
,	O
and	O
gastrointestinal	B-C0012240
systems	I-C0012240
were	O
later	O
identified	B-C0205396
.	O
	
in	O
fact	O
,	O
behcet's	B-C0004943
disease	I-C0004943
with	O
neurological	B-C0027765
involvement	I-C0027765
neuro-behcet's	B-C0858762
disease	I-C0858762
is	O
not	O
uncommon	O
.	O
	
patients	B-C0030705
with	O
neuro-behcet's	B-C0858762
disease	I-C0858762
typically	O
exhibit	O
a	O
diverse	O
array	O
of	O
symptoms	B-C1457887
,	O
most	B-C0205393
commonly	B-C0205214
in	O
the	O
brainstem	B-C0006121
and	O
diencephalic	B-C0012144
regions	B-C0205147
.	O
	
herein	O
,	O
we	O
report	B-C0684224
an	O
unusual	B-C2700116
case	B-C0868928
of	O
neuro-behcet's	B-C0858762
disease	I-C0858762
in	O
a	O
patient	B-C0030705
who	O
presented	B-C0449450
with	O
a	O
solitary	O
cerebellar	B-C0149854
hemorrhage	I-C0149854
.	O
	
a	O
39-year-old	B-C0001675
asian	B-C0078988
woman	B-C0043210
was	O
admitted	B-C0809949
to	O
our	O
hospital	B-C0019994
with	O
complaints	B-C0277786
of	O
a	O
sudden	B-C1276802
speech	B-C0233715
difficulty	I-C0233715
that	O
had	O
manifested	B-C0205319
the	O
same	B-C0445247
morning	B-C0332170
,	O
and	O
dizziness	B-C0012833
and	O
mild	B-C2945599
vomiting	B-C0042963
experienced	O
over	B-C0347984
the	O
previous	B-C0205156
3	O
days	B-C0439228
.	O
	
magnetic	B-C3890166
resonance	I-C3890166
images	I-C3890166
revealed	B-C0443289
target-like	O
hemorrhagic	B-C0149854
lesions	B-C0221198
in	O
the	O
right	B-C2335345
hemisphere	I-C2335345
of	I-C2335345
the	I-C2335345
cerebellum	I-C2335345
.	O
	
risk	B-C0035648
factors	I-C0035648
that	O
may	O
result	B-C1274040
in	O
cerebellar	B-C0149854
hemorrhage	I-C0149854
,	O
such	O
as	O
high	B-C0020538
blood	I-C0020538
pressure	I-C0020538
or	O
bleeding	B-C1458140
diathesis	I-C1458140
,	O
were	O
ruled	B-C1410834
out	I-C1410834
,	O
and	O
subsequent	B-C0332282
brain	B-C0006104
angiograms	B-C0002978
were	O
normal	B-C0205307
.	O
	
these	O
findings	B-C0243095
suggest	B-C1705535
that	O
the	O
patient's	B-C0030705
cerebellar	B-C0149854
hemorrhage	I-C0149854
could	O
have	O
been	O
due	B-C0678226
to	I-C0678226
intracranial	B-C0524466
vasculitis	B-C0042384
in	O
a	O
rare	B-C0522498
,	O
if	O
not	O
unique	O
,	O
complication	B-C0009566
of	O
neuro-behcet's	B-C0858762
disease	I-C0858762
.	O
	
intrinsic	B-C0205102
rifamycin	B-C0035609
resistance	B-C0949285
of	O
mycobacterium	B-C0445910
abscessus	I-C0445910
is	O
mediated	O
by	O
adp-ribosyltransferase	B-C0085748
mab_0591	B-C0017337
rifampicin	B-C0035608
,	O
a	O
potent	O
first-line	O
tb	B-C0013227
drug	I-C0013227
of	O
the	O
rifamycin	B-C0035609
group	I-C0035609
,	O
shows	O
only	O
little	O
activity	B-C0599112
against	O
the	O
emerging	O
pathogen	B-C0450254
mycobacterium	B-C0445910
abscessus	I-C0445910
.	O
	
reportedly	O
,	O
bacterial	B-C0151521
resistance	I-C0151521
to	O
rifampicin	B-C0035608
is	O
associated	O
with	O
polymorphisms	B-C0032529
in	O
the	O
target	O
gene	B-C0017337
rpob	I-C0017337
or	O
the	O
presence	O
of	O
enzymes	B-C0014442
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	B-C0035608
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
mab_0591	B-C0017337
arrmab	B-C0017337
rifampicin	B-C0035608
adp-ribosyltransferase	B-C0085748
arr_mab	B-C0085748
in	O
innate	O
high-level	O
rifampicin	B-C0035608
resistance	B-C0949285
in	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
.	O
	
recombinant	B-C1514798
escherichia	B-C0014834
coli	I-C0014834
and	O
mycobacterium	B-C0026926
tuberculosis	I-C0026926
strains	B-C1518614
expressing	B-C0017262
mab_0591	B-C0017337
were	O
generated	O
,	O
as	O
was	O
an	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
deletion	B-C1511760
mutant	I-C1511760
deficient	B-C0011155
for	O
mab_0591	B-C0017337
.	O
	
mic	B-C1510438
assays	I-C1510438
were	O
used	O
to	O
study	O
susceptibility	B-C1264642
to	O
rifampicin	B-C0035608
and	O
c25	B-C0006948
carbamate	I-C0006948
-modified	O
rifamycin	B-C0035609
derivatives	I-C0035609
.	O
	
heterologous	B-C0439860
expression	B-C0017262
of	O
mab_0591	B-C0017337
conferred	O
rifampicin	B-C0035608
resistance	B-C0949285
to	O
e	B-C0014834
.	O
	
coli	I-C0014834
and	O
m	B-C0026926
.	O
	
tuberculosis	I-C0026926
rifamycin	B-C0035609
mic	B-C1304747
values	I-C1304747
were	O
consistently	O
lower	O
for	O
the	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
δarrmab	B-C0678941
mutant	I-C0678941
as	O
compared	B-C1707455
with	O
the	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
atcc	I-C0445910
19977	I-C0445910
parental	B-C1518614
type	I-C1518614
strain	I-C1518614
.	O
	
the	O
rifamycin	B-C0035609
wt	B-C1883559
phenotype	B-C0031437
was	O
restored	O
after	O
complementation	B-C0178654
of	O
the	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
δarrmab	B-C0678941
mutant	I-C0678941
with	O
arrmab	B-C0085748
further	O
mic	B-C1304747
data	I-C1304747
demonstrated	O
that	O
a	O
c25	B-C0006948
modification	B-C3840684
increases	O
rifamycin	B-C0035609
activity	B-C0599112
in	O
wt	B-C1883559
m	B-C0445910
.	O
	
abscessus	I-C0445910
however	O
,	O
mic	B-C0681814
studies	I-C0681814
in	O
the	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
δarrmab	B-C0678941
mutant	I-C0678941
suggest	O
that	O
c25	B-C0006948
modified	O
rifamycins	B-C0035609
are	O
still	O
subject	O
to	O
modification	B-C3840684
by	O
arr_mab	B-C0085748
conclusions	O
our	O
findings	O
identify	O
arr_mab	B-C0085748
as	O
the	O
major	O
innate	O
rifamycin	B-C0035609
resistance	B-C0949285
determinant	O
of	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
.	O
	
our	O
data	O
also	O
indicate	O
that	O
arr_mab	B-C0085748
-mediated	O
rifamycin	B-C0035609
resistance	B-C0949285
in	O
m	B-C0445910
.	O
	
abscessus	I-C0445910
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
c25	B-C0006948
carbamate	I-C0006948
modification	B-C3840684
.	O
	
the	O
silorane-based	B-C3489777
resin	I-C3489777
composites	I-C3489777
a	O
review	B-C0282443
this	O
article	B-C1706852
aims	O
to	O
review	B-C0282443
the	O
research	B-C0035168
done	O
on	O
the	O
silorane-based	B-C3489777
resin	I-C3489777
composites	I-C3489777
sbrc	B-C3489777
regarding	O
polymerization	B-C0314672
shrinkage	B-C0332513
and	O
contraction	B-C0038442
stresses	I-C0038442
and	O
their	O
ability	O
to	O
improve	O
the	O
shortcomings	O
of	O
the	O
methacrylate-based	B-C0009570
resin	I-C0009570
composites	I-C0009570
mrbc	B-C0009570
.	O
	
special	O
attention	O
is	O
given	O
to	O
their	O
physical	B-C0597237
and	O
mechanical	B-C2350455
properties	I-C2350455
,	O
bond	B-C0678599
strength	I-C0678599
,	O
marginal	B-C0242981
adaptation	I-C0242981
,	O
and	O
cusp	B-C2350455
deflection	I-C2350455
.	O
	
the	O
clinical	B-C2826293
significance	I-C2826293
of	O
this	O
material	B-C0520510
is	O
critically	O
appraised	O
with	O
a	O
focus	O
on	O
the	O
ability	O
of	O
sbrc	B-C3489777
to	O
strengthen	O
the	O
tooth	B-C0040426
structure	I-C0040426
as	O
a	O
direct	B-C3503982
restorative	I-C3503982
material	I-C3503982
.	O
	
a	O
search	O
of	O
english	B-C0376245
peer-reviewed	B-C0282441
dental	I-C0282441
literature	I-C0282441
2003-2015	O
from	O
pubmed	B-C1138432
and	O
medline	B-C0025141
databases	B-C0242356
was	O
conducted	O
with	O
the	O
terms	O
""""	O
low	B-C0205251
shrinkage	B-C0332513
""""	O
and	O
""""	O
silorane	B-C3489777
composites	I-C3489777
""""	O
the	O
list	O
was	O
screened	O
,	O
and	O
70	O
articles	B-C1706852
that	O
were	O
relevant	O
to	O
the	O
objectives	B-C0018017
endoscopic	B-C0014245
endonasal	B-C0225425
surgery	B-C0543467
for	O
remission	B-C0544452
of	O
cushing's	B-C0010481
disease	I-C0010481
caused	O
by	O
ectopic	B-C0574895
intracavernous	B-C1512919
macroadenoma	B-C0344453
case	B-C0085973
report	I-C0085973
and	O
literature	B-C0282441
review	I-C0282441
complete	O
surgical	B-C0015252
resection	I-C0015252
of	O
an	O
acth-secreting	B-C1306214
pituitary	I-C1306214
adenoma	I-C1306214
is	O
the	O
gold	B-C0150110
standard	I-C0150110
of	O
treatment	B-C0087111
of	O
cushing's	B-C0010481
disease	I-C0010481
.	O
	
ectopic	B-C0574895
location	B-C0450429
of	O
these	O
adenomas	B-C0001430
is	O
an	O
extremely	O
rare	B-C0522498
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	B-C0011900
and	O
surgical	B-C0543467
success	B-C0597535
.	O
	
we	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	B-C0574895
intracavernous	B-C1512919
acth-secreting	B-C1306214
macroadenoma	I-C1306214
totally	O
resected	O
with	O
endoscopic	B-C0014245
endonasal	B-C0225425
surgery	B-C0543467
ees	B-C0396138
.	O
	
a	O
36	O
year	O
old	O
female	B-C0086287
presented	O
with	O
cushing	B-C0010481
syndrome	I-C0010481
.	O
	
increased	B-C0205217
acth	B-C0001655
,	O
serum	B-C0729349
cortisol	I-C0729349
and	O
free	B-C1985941
urine	I-C1985941
cortisol	I-C1985941
levels	B-C0441889
were	O
identified	O
,	O
however	O
the	O
pituitary	B-C0412679
mri	I-C0412679
failed	O
to	O
reveal	O
a	O
pituitary	B-C0032019
tumor	I-C0032019
instead	O
,	O
a	O
parasellar	B-C0221198
lesion	I-C0221198
in	O
the	O
left	O
cavernous	B-C0007473
sinus	I-C0007473
cs	B-C0007473
was	O
noticed	O
.	O
	
inferior	B-C0206084
petrosal	I-C0206084
sinus	I-C0206084
sampling	I-C0206084
demonstrated	O
a	O
significant	O
central	B-C0205099
-to-	O
peripheral	B-C0205100
and	O
lateralized	O
left-sided	O
acth	B-C0001655
gradient	O
.	O
	
the	O
patient	B-C0030705
underwent	O
ees	B-C0396138
.	O
	
no	B-C0243095
tumor	I-C0243095
was	O
found	O
in	O
the	O
sella	B-C0036609
,	O
however	O
,	O
the	O
left	O
cs	B-C0007473
was	O
widely	O
explored	O
and	O
a	O
tumor	B-C0027651
was	O
found	O
lateral	B-C0205093
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid	B-C0007272
artery	I-C0007272
.	O
	
there	O
were	O
no	B-C1513916
complications	B-C0009566
following	O
ees	B-C0396138
.	O
	
pathology	B-C0030664
confirmed	O
the	O
diagnosis	B-C0011900
of	O
an	O
acth-secreting	B-C1306214
adenoma	I-C1306214
.	O
	
during	O
the	O
immediately	O
postoperative	B-C0032790
course	O
serum	B-C0729349
cortisol	I-C0729349
levels	B-C0441889
dropped	O
below	O
5	O
mcg/dl	O
.	O
	
postoperative	B-C0032790
mri	B-C0024485
demonstrated	O
complete	O
tumor	B-C0015252
resection	I-C0015252
.	O
	
at	O
20	O
months	O
follow-up	B-C1522577
,	O
the	O
patient	B-C0030705
remains	O
in	O
clinical	B-C0205210
and	O
biochemical	B-C0205474
remission	B-C0544452
of	O
cushing's	B-C0010481
disease	I-C0010481
.	O
	
only	O
12	O
cases	O
of	O
ectopic	B-C0574895
intracavernous	B-C1512919
acth-secreting	B-C1306214
adenomas	I-C1306214
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	B-C0346306
.	O
	
the	O
presence	O
of	O
an	O
ectopic	B-C0574895
acth-secreting	B-C1306214
macroadenoma	I-C1306214
in	O
the	O
cs	B-C0007473
represents	O
a	O
surgical	B-C0543467
challenge	O
.	O
	
ees	B-C0396138
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	B-C0015252
of	O
ectopic	B-C0574895
intracavernous	B-C1512919
adenomas	B-C0001430
allowing	O
for	O
a	O
wide	O
exploration	B-C1280903
of	O
the	O
cs	B-C0007473
with	O
no	B-C1513916
surgical	B-C0543467
complications	B-C0009566
.	O
	
preliminary	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
of	O
habit	B-C0004933
reversal	I-C0004933
training	I-C0004933
for	O
treatment	B-C0087111
of	O
hair	B-C0040953
pulling	I-C0040953
in	O
youth	B-C0087178
this	O
study	B-C2603343
evaluated	B-C0220825
the	O
treatment	B-C0087111
efficacy	B-C1280519
of	O
habit	B-C0004933
reversal	I-C0004933
training	I-C0004933
hrt	B-C0004933
relative	O
to	O
treatment	B-C2347177
as	I-C2347177
usual	I-C2347177
tau	B-C2347177
for	O
children	B-C0008059
and	O
adolescents	B-C0205653
aged	B-C0001779
7-17	O
years	B-C0439234
with	O
a	O
primary	O
diagnosis	B-C1704656
of	O
trichotillomania	B-C0040953
ttm	B-C0040953
.	O
	
an	O
initial	O
assessment	B-C0220825
consisting	O
of	O
semistructured	O
interviews	B-C0021822
and	O
rating	B-C0681889
scales	I-C0681889
was	O
conducted	O
.	O
	
participants	B-C0679646
n	O
=	O
40	O
,	O
85%	O
female	B-C0086287
meeting	O
diagnostic	B-C0679228
criteria	I-C0679228
for	O
ttm	B-C0040953
were	O
randomized	B-C0034656
to	O
either	O
8	O
weekly	B-C0332174
sessions	O
of	O
hrt	B-C0004933
by	O
trained	O
therapists	B-C0871525
or	O
8	O
weeks	B-C0439230
of	O
tau	B-C2347177
.	O
	
one	O
week	B-C0439230
after	O
the	O
final	O
hrt	B-C0004933
session	O
or	O
final	O
tau	B-C2347177
week	B-C0439230
,	O
patients	B-C0030705
completed	O
a	O
posttreatment	B-C0237623
assessment	I-C0237623
,	O
followed	O
by	O
1-	O
and	O
3-	O
month	B-C0439231
follow-up	B-C1522577
assessments	B-C0220825
.	O
	
all	O
assessments	B-C0220825
were	O
conducted	O
by	O
a	O
trained	O
rater	B-C2697672
who	O
was	O
blinded	B-C0150108
to	O
treatment	B-C0087111
condition	B-C0348080
.	O
	
the	O
group	O
by	O
time	O
analysis	B-C0002780
of	I-C0002780
variance	I-C0002780
yielded	O
a	O
significant	B-C0750502
interaction	O
on	O
the	O
national	B-C0027466
institute	I-C0027466
of	I-C0027466
mental	I-C0027466
health	I-C0027466
-	O
trichotillomania	B-C0457451
severity	I-C0457451
scale	I-C0457451
total	I-C0457451
score	I-C0457451
f1	O
=	O
16.47	O
,	O
p	O
<	O
0.001	O
,	O
η	O
=	O
0.30	O
.	O
	
the	O
mean	B-C3533236
score	I-C3533236
decreased	O
from	O
12.67	O
4.60	O
at	O
baseline	B-C1442488
to	O
5.62	O
4.38	O
at	O
posttreatment	B-C0237623
in	O
the	O
hrt	B-C0004933
group	B-C1257890
t20	O
=	O
5.99	O
,	O
p	O
<	O
0.001	O
,	O
d	O
=	O
1.31	O
,	O
whereas	O
the	O
tau	B-C2347177
group	B-C1257890
changed	O
from	O
10.42	O
4.35	O
to	O
9.32	O
4.11	O
t18	O
=	O
1.34	O
,	O
p	O
=	O
0.20	O
,	O
d	O
=	O
0.31	O
.	O
	
the	B-C0457451
massachusetts	I-C0457451
general	I-C0457451
hospital-hair	I-C0457451
pulling	I-C0457451
scale	I-C0457451
total	I-C0457451
score	I-C0457451
decreased	O
from	O
15.14	O
3.86	O
at	O
baseline	B-C1442488
to	O
7.14	O
5.54	O
at	O
posttreatment	B-C0237623
in	O
the	O
hrt	B-C0004933
group	B-C1257890
t20	O
=	O
6.16	O
,	O
p	O
<	O
0.001	O
,	O
d	O
=	O
1.34	O
the	O
tau	B-C2347177
group	B-C1257890
changed	O
from	O
14.16	O
4.51	O
to	O
12.26	O
4.34	O
t18	O
=	O
1.50	O
,	O
p	O
=	O
0.15	O
,	O
d	O
=	O
0.34	O
.	O
	
on	O
the	O
clinical	B-C3639708
global	I-C3639708
impressions-improvement	I-C3639708
,	O
16/21	O
participants	B-C0679646
76%	O
were	O
rated	O
as	O
treatment	B-C0087111
responders	B-C0282122
in	O
the	O
hrt	B-C0004933
group	B-C1257890
versus	O
4/19	O
21%	O
in	O
the	O
tau	B-C2347177
group	B-C1257890
χ	O
=	O
12.13	O
,	O
p	O
<	O
0.001	O
,	O
v	O
=	O
0.55	O
.	O
	
at	O
1-	O
month	B-C0439231
follow-up	B-C1522577
,	O
10-12	O
treatment	B-C0087111
responders	B-C0282122
who	O
completed	O
the	O
assessment	B-C0220825
maintained	O
improvement	B-C2986411
.	O
	
at	O
3-	O
month	B-C0439231
follow-up	B-C1522577
,	O
six	O
of	O
eight	O
maintained	O
improvement	B-C2986411
.	O
	
hrt	B-C0004933
can	O
be	O
an	O
effective	O
treatment	B-C0087111
for	O
ttm	B-C0040953
in	O
fully	B-C0443225
endoscope	B-C0014243
-	O
controlled	B-C2587213
clipping	B-C0189711
bilateral	B-C0740385
middle	I-C0740385
cerebral	I-C0740385
artery	I-C0740385
aneurysm	I-C0740385
via	O
unilateral	B-C0087111
supraorbital	I-C0087111
keyhole	I-C0087111
approach	I-C0087111
clipping	B-C0189711
bilateral	B-C0740385
middle	I-C0740385
cerebral	I-C0740385
artery	I-C0740385
bmca	I-C0740385
aneurysms	I-C0740385
via	O
unilateral	B-C0087111
approach	I-C0087111
in	O
a	O
single-stage	B-C0543467
operation	I-C0543467
is	O
considered	O
as	O
a	O
challenge	O
procedure	O
.	O
	
to	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
study	O
in	O
surgical	B-C1515089
management	I-C1515089
of	O
patients	B-C0030705
with	O
bmca	B-C0740385
aneurysms	I-C0740385
by	O
fully	O
endoscope	B-C0014243
-	O
controlled	B-C2587213
techniques	B-C0449851
.	O
	
the	O
author	O
reported	O
a	O
patient	B-C0030705
with	O
bmca	B-C0740385
aneurysms	I-C0740385
who	O
underwent	O
aneurysms	B-C0189711
clipping	I-C0189711
via	O
a	O
unilateral	B-C0087111
supraorbital	I-C0087111
keyhole	I-C0087111
approach	I-C0087111
by	O
endoscope	B-C0014243
-	O
controlled	B-C2587213
microneurosurgery	B-C0524850
,	O
and	O
the	O
patient	B-C0030705
had	O
an	O
uneventful	O
postoperative	B-C0032790
course	I-C0032790
without	B-C0332288
neurologic	B-C0205494
impairment	B-C0684336
and	O
complication	B-C0009566
.	O
	
furthermore	O
,	O
the	O
author	O
discussed	O
the	O
advantages	O
and	O
adaptation	B-C1706477
of	O
endoscope	B-C0014243
-	O
controlled	B-C2587213
clipping	B-C0189711
bmca	B-C0740385
aneurysms	I-C0740385
via	O
unilateral	B-C0087111
supraorbital	I-C0087111
keyhole	I-C0087111
approach	I-C0087111
.	O
	
novel	B-C0205314
observations	B-C0302523
in	O
11	O
heteroresistant	B-C1514892
vancomycin-intermediate	B-C0042313
methicillin-resistant	B-C1265292
staphylococcus	I-C1265292
aureus	I-C1265292
strains	I-C1265292
from	O
south	B-C0021201
india	I-C0021201
we	O
report	O
here	O
the	O
draft	O
genome	B-C2348746
sequences	I-C2348746
of	O
11	O
heteroresistant	B-C1514892
vancomycin-intermediate	B-C1318880
staphylococcus	I-C1318880
aureus	I-C1318880
hvisa	I-C1318880
strains	I-C1318880
from	O
bloodstream	B-C2316160
infection	I-C2316160
.	O
	
all	O
strains	B-C1518614
harbor	O
mutations	B-C0026882
in	O
vrasr	B-C0017337
,	O
grasr	B-C0017337
,	O
walkr	B-C0017337
,	O
and/or	O
tcarab	B-C0017337
and	O
are	O
often	O
implicated	O
as	O
the	O
frequently	O
mutated	B-C0026882
candidate	O
genes	B-C0017337
in	O
hvisa	B-C1318880
phenotypes	B-C0031437
.	O
	
endpoints	B-C2349179
for	O
screening	B-C0199230
thyroid	B-C0549473
cancer	I-C0549473
in	O
the	O
republic	B-C0022773
of	I-C0022773
korea	I-C0022773
thyroid	B-C0040132
specialists	B-C1611835
'	O
perspectives	B-C0030971
cancer	B-C0199230
screening	I-C0199230
is	O
aimed	O
primarily	O
at	O
reducing	B-C0392756
deaths	B-C1306577
from	O
the	O
specific	O
cancer	B-C0006826
.	O
	
thyroid-specific	B-C0549473
cancer	I-C0549473
mortality	B-C0681679
may	O
be	O
the	O
most	O
ambitious	O
endpoint	B-C2349179
for	O
obtaining	O
estimates	B-C0750572
of	O
screening	B-C1710032
effect	B-C1280500
.	O
	
numerous	B-C0439064
observations	B-C1964257
have	O
accumulated	B-C4055506
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	B-C0549473
cancer	I-C0549473
mortality	B-C0681679
endpoint	B-C2349179
has	O
been	O
difficult	B-C0332218
to	O
study	O
and	O
is	O
confounded	O
by	O
population	B-C0086833
heterogeneity	I-C0086833
,	O
provision	B-C1283218
of	O
randomization	B-C0034656
,	O
and	O
requirement	B-C1514873
of	O
large	O
cohorts	B-C0599755
with	O
sufficiently	O
long	B-C1517942
follow-up	I-C1517942
due	O
to	O
the	O
excellent	B-C1961136
prognosis	B-C1516221
of	I-C1516221
the	I-C1516221
cancer	I-C1516221
.	O
	
accordingly	O
,	O
it	O
may	O
be	O
important	B-C3898777
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	B-C0549473
cancer	I-C0549473
screening	B-C0199230
efficacy	B-C1280519
.	O
	
recommendations	B-C0034866
against	O
thyroid	B-C0549473
cancer	I-C0549473
screening	B-C0199230
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	B-C1280519
not	O
only	O
in	O
significant	B-C0392756
reduction	I-C0392756
in	O
cancer	B-C0549473
mortality	B-C0681679
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	B-C2349179
s	O
.	O
	
it	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	B-C2349179
that	O
can	O
reliably	O
predict	O
reductions	B-C0282251
in	I-C0282251
mortality	I-C0282251
.	O
	
the	O
term	O
"""derivative"""	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	B-C2349179
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	B-C2349179
.	O
	
derivative	O
endpoints	B-C2349179
may	O
include	O
thyroid	B-C0549473
cancer	I-C0549473
incidence	B-C0021149
,	O
the	O
proportion	B-C1709707
of	O
early-stage	B-C2363430
tumors	B-C0027651
detected	B-C0442726
,	O
more	O
treatable	B-C1300072
stage	I-C1300072
,	O
the	O
identification	B-C0205396
of	O
small	B-C0475277
tumors	I-C0475277
to	O
maintain	O
in	O
observation	O
,	O
decrease	B-C0509797
in	I-C0509797
the	I-C0509797
number	I-C0509797
of	I-C0509797
people	I-C0509797
who	O
develop	O
metastatic	B-C0027627
disease	I-C0027627
,	O
the	O
increased	B-C0205217
chance	O
of	O
lesser	O
extent	O
surgery	B-C0543467
,	O
and	O
the	O
application	O
of	O
minimally	B-C2711297
invasive	I-C2711297
approaches	I-C2711297
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	B-C4274169
thyroid	B-C2242640
replacement	I-C2242640
therapy	I-C2242640
,	O
a	O
consistent	B-C0332290
follow-up	B-C1522577
,	O
low-dose	B-C0445550
or	O
no	O
rai	B-C0203778
administration	I-C0203778
and	O
risk	B-C2983699
factor	I-C2983699
assessments	I-C2983699
where	O
case	B-C1444481
findings	I-C1444481
should	O
be	O
continuous	B-C0549178
.	O
	
the	O
korean	B-C1556095
guidelines	O
for	O
thyroid	O
cancer	O
national-level	O
screening	O
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	O
thyroid	O
experts	O
.	O
	
it	O
was	O
concluded	O
that	O
the	O
evidence	O
is	O
insufficient	O
to	O
balance	O
the	O
benefits	O
and	O
harms	O
of	O
thyroid	O
cancer	O
screening	O
.	O
	
however	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	O
and	O
demand	O
a	O
complete	O
analysis	O
for	O
derivative	O
endpoints	O
,	O
and	O
offer	O
screening	O
participants	O
with	O
complete	O
information	O
necessary	O
to	O
make	O
decisions	O
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	O
cancer	O
is	O
screen-	O
identified	B-C0205396
zebrafish	B-C0043457
adult	B-C1171322
pigment	I-C1171322
stem	I-C1171322
cells	I-C1171322
are	O
multipotent	B-C1136335
and	O
form	B-C0440745
pigment	I-C0440745
cells	I-C0440745
by	O
a	O
progressive	B-C0205329
fate	B-C1160037
restriction	I-C1160037
process	I-C1160037
clonal	B-C0796368
analysis	I-C0796368
identifies	B-C0205396
shared	O
origin	O
of	O
all	O
pigment	B-C0440745
cell	I-C0440745
types	I-C0440745
skin	B-C1269684
pigment	I-C1269684
pattern	B-C1160421
formation	I-C1160421
is	O
a	O
paradigmatic	B-C0679667
example	O
of	O
pattern	B-C1160421
formation	I-C1160421
.	O
	
in	O
zebrafish	B-C0043457
,	O
the	O
adult	B-C0596090
body	B-C0229962
stripes	I-C0229962
are	O
generated	B-C1706214
by	O
coordinated	B-C0700114
rearrangement	B-C0007613
of	O
three	B-C0205449
distinct	O
pigment	B-C0440745
cell-types	I-C0440745
,	O
black	B-C0439541
melanocytes	B-C0025201
,	O
shiny	B-C0205556
iridophores	B-C0007634
and	O
yellow	B-C0221205
xanthophores	B-C0007634
.	O
	
a	O
stem	B-C0038250
cell	I-C0038250
origin	I-C0038250
of	O
melanocytes	B-C0025201
and	O
iridophores	B-C0007634
has	O
been	O
proposed	O
although	O
the	O
potency	B-C3245505
of	O
those	O
stem	B-C0038250
cells	I-C0038250
has	O
remained	B-C1527428
unclear	B-C3845108
.	O
	
xanthophores	B-C0007634
,	O
however	O
,	O
seemed	O
to	O
originate	O
predominantly	B-C1542147
from	O
proliferation	B-C0596290
of	O
embryonic	B-C0013935
xanthophores	B-C0007634
.	O
	
now	O
,	O
data	B-C1511726
from	O
singh	O
et	O
al	O
.	O
	
shows	O
that	O
all	O
three	B-C0205449
cell-types	B-C0007634
derive	B-C1441547
from	O
shared	O
stem	B-C0038250
cells	I-C0038250
,	O
and	O
that	O
these	O
cells	B-C0007634
generate	B-C1706214
peripheral	B-C0205100
neural	B-C1113654
cell-types	I-C1113654
too	O
.	O
	
furthermore	O
,	O
clonal	B-C1522642
compositions	B-C0205556
are	O
best	O
explained	O
by	O
a	O
progressive	B-C0205329
fate	B-C1160037
restriction	I-C1160037
model	I-C1160037
generating	B-C1706214
the	O
individual	B-C1705242
cell-types	B-C0007634
.	O
	
the	O
numbers	B-C0237753
of	O
adult	B-C1171322
pigment	I-C1171322
stem	I-C1171322
cells	I-C1171322
associated	B-C0332281
with	I-C0332281
the	O
dorsal	B-C0017070
root	I-C0017070
ganglia	I-C0017070
remain	B-C0243095
low	B-C0205251
,	O
but	O
progenitor	B-C0038250
numbers	B-C0237753
increase	B-C0442805
significantly	O
during	B-C0347984
larval	B-C1160209
development	I-C1160209
up	O
to	O
metamorphosis	B-C0277806
,	O
likely	O
via	O
production	O
of	O
partially	B-C0728938
restricted	B-C0443288
progenitors	B-C0038250
on	O
the	O
spinal	B-C0037941
nerves	I-C0037941
.	O
	
covalent	B-C1254351
modulators	I-C1254351
of	O
the	O
vacuolar	B-C0379099
atpase	I-C0379099
the	O
vacuolar	B-C0379099
h	I-C0379099
atpase	I-C0379099
v-atpase	B-C0379099
is	O
a	O
complex	B-C1704241
multisubunit	O
machine	B-C0449913
that	O
regulates	B-C1327622
important	O
cellular	B-C0007613
processes	I-C0007613
through	O
controlling	B-C2587213
acidity	B-C0920750
of	O
intracellular	B-C0178719
compartments	B-C2349967
in	O
eukaryotes	B-C0684063
.	O
	
existing	O
small-molecule	B-C1328819
modulators	B-C1254351
of	O
v-atpase	B-C0379099
either	O
are	O
restricted	B-C0443288
to	O
targeting	B-C0599894
one	O
membranous	B-C0205287
subunit	B-C1711351
of	O
v-atpase	B-C0379099
or	O
have	O
poorly	O
understood	B-C0162340
mechanisms	B-C0441712
of	O
action	O
.	O
	
small	B-C1328819
molecules	I-C1328819
with	O
novel	B-C0205314
and	O
defined	B-C0442825
mechanisms	B-C0441712
of	O
inhibition	B-C1148560
are	O
thus	O
needed	B-C0027552
to	O
functionally	B-C0205245
characterize	B-C1880022
v-atpase	B-C0379099
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	B-C0302350
relevance	B-C2347946
of	O
v-atpase	B-C0379099
in	O
human	B-C0086418
diseases	B-C0012634
.	O
	
we	O
have	O
discovered	O
electrophilic	B-C0205556
quinazolines	B-C0034407
that	O
covalently	B-C3158388
modify	I-C3158388
a	O
soluble	B-C1948047
catalytic	B-C0600499
subunit	I-C0600499
of	O
v-atpase	B-C0379099
with	O
high	B-C0205250
potency	B-C3854080
and	O
exquisite	O
proteomic	B-C0205556
selectivity	I-C0205556
as	O
revealed	B-C0443289
by	O
fluorescence	B-C0430876
imaging	I-C0430876
and	O
chemical	B-C1327760
proteomic	I-C1327760
activity-based	I-C1327760
profiling	I-C1327760
.	O
	
the	O
site	B-C0205145
of	O
covalent	O
modification	B-C0392747
was	O
mapped	B-C1283195
to	O
a	O
cysteine	B-C0010654
residue	B-C1709915
located	B-C0332285
in	I-C0332285
a	O
region	B-C1514562
of	O
v-atpase	B-C0379099
subunit	B-C0599220
a	I-C0599220
that	O
is	O
thought	B-C0039869
to	O
regulate	B-C1327622
the	O
dissociation	B-C0301643
of	O
v-atpase	B-C0379099
.	O
	
we	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
v-atpase	B-C0014432
inhibitor	I-C0014432
,	O
3-bromopyruvate	B-C0054130
,	O
also	O
targets	B-C1521840
the	O
same	B-C0445247
cysteine	B-C0010654
residue	B-C1709915
and	O
that	O
our	O
electrophilic	B-C0205556
quinazolines	B-C0034407
modulate	B-C0443264
the	O
function	B-C0542341
of	O
v-atpase	B-C0379099
in	O
cells	B-C0007634
.	O
	
with	O
their	O
well-defined	B-C0442825
mechanism	B-C0441712
of	O
action	B-C3266814
and	O
high	B-C0205250
proteomic	B-C0037791
specificity	I-C0037791
,	O
the	O
described	O
quinazolines	B-C0034407
offer	O
a	O
powerful	B-C3854080
set	B-C1705195
of	O
chemical	B-C2347609
probes	I-C2347609
to	O
investigate	B-C1292732
the	O
physiological	B-C0205463
and	O
pathological	B-C1521733
roles	B-C1705810
of	O
association	B-C0439849
of	O
radiomics	O
and	O
metabolic	B-C0311400
tumor	B-C0475276
volumes	I-C0475276
in	O
radiation	B-C3871222
treatment	I-C3871222
of	O
glioblastoma	B-C1621958
multiforme	I-C1621958
to	O
build	O
a	O
framework	O
for	O
investigation	B-C0220825
of	O
the	O
associations	B-C0439849
between	O
imaging	B-C0011923
,	O
clinical	B-C0454198
target	I-C0454198
volumes	I-C0454198
ctvs	B-C0454198
,	O
and	O
metabolic	B-C0311400
tumor	B-C0475276
volumes	I-C0475276
mtvs	B-C0475276
features	B-C1521970
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	B-C1533716
in	O
the	O
ctvs	B-C0454198
and	O
dependencies	O
between	O
these	O
volumes	B-C0475276
.	O
	
high-throughput	B-C0872047
extraction	I-C0872047
of	O
imaging	B-C0011923
and	O
metabolomic	B-C1328813
quantitative	B-C0392762
features	B-C1521970
from	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
and	O
magnetic	B-C1522706
resonance	I-C1522706
spectroscopic	I-C1522706
imaging	I-C1522706
of	O
glioblastoma	B-C1621958
multiforme	I-C1621958
gbm	B-C1621958
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	B-C0030705
.	O
	
in	O
radiation	B-C3871222
therapy	I-C3871222
of	O
gbm	B-C1621958
the	O
relevant	B-C2347946
metabolic	B-C0311400
tumor	B-C0475276
volumes	I-C0475276
mtvs	B-C0475276
are	O
related	O
to	O
aberrant	B-C0443127
levels	B-C0441889
of	O
n-acetyl	B-C0067684
aspartate	I-C0067684
naa	B-C0067684
and	O
choline	B-C0008405
cho	B-C0008405
.	O
	
the	O
corresponding	O
clinical	B-C0454198
target	I-C0454198
volumes	I-C0454198
ctvs	B-C0454198
for	O
radiation	B-C3871222
therapy	I-C3871222
are	O
based	O
on	O
contrast-enhanced	B-C1707501
t1-weighted	I-C1707501
ce-t1w	B-C1707501
and	O
t2-weighted	B-C3897397
t2w	I-C3897397
inversion	I-C3897397
recovery	I-C3897397
mri	I-C3897397
.	O
	
necrotic	B-C1334928
portions	I-C1334928
,	O
enhancing	B-C3830314
lesion	I-C3830314
,	O
and	O
edema	B-C0013604
were	O
manually	O
contoured	O
on	O
ce-t1w	B-C1704254
/	O
t2w	B-C1704254
images	I-C1704254
for	O
17	O
gbm	B-C1621958
patients	B-C0030705
.	O
	
clinical	B-C0454198
target	I-C0454198
volumes	I-C0454198
and	O
mtvs	B-C0475276
for	O
naa	B-C0067684
mtvnaa	B-C0475276
and	O
cho	B-C0008405
mtvcho	B-C0475276
were	O
constructed	O
.	O
	
imaging	B-C0011923
and	O
metabolic	B-C1864620
features	I-C1864620
related	O
to	O
size	B-C0456389
,	O
shape	B-C0332479
,	O
and	O
signal	B-C0871362
intensities	I-C0871362
of	O
the	O
volumes	B-C0449468
were	O
extracted	O
.	O
	
tumors	B-C0027651
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	B-C0036612
imaging	B-C2346469
traits	I-C2346469
by	O
a	O
neuroradiologist	B-C2985415
.	O
	
all	O
features	B-C1521970
were	O
investigated	B-C1292732
for	O
redundancy	B-C1313915
.	O
	
two-way	B-C1707520
correlations	I-C1707520
between	O
imaging	B-C1704254
and	O
ctvs	B-C0454198
/	O
mtvs	B-C0475276
features	O
were	O
visualized	O
as	O
heatmaps	B-C2697572
.	O
	
associations	B-C0439849
between	O
mtvnaa	B-C0475276
and	O
mtvcho	B-C0475276
and	O
imaging	B-C2346469
features	I-C2346469
were	O
studied	O
using	O
spearman	B-C1710141
correlation	I-C1710141
.	O
	
forty-eight	O
imaging	B-C2346469
features	I-C2346469
were	O
extracted	O
per	O
patient	B-C0030705
.	O
	
half	B-C2825407
of	O
the	O
imaging	B-C2346469
traits	I-C2346469
were	O
replaced	B-C0559956
with	O
automatically	O
extracted	O
continuous	B-C0439828
variables	I-C0439828
.	O
	
twenty	O
features	B-C2346469
were	O
extracted	O
from	O
ctvs	B-C0454198
and	O
mtvs	B-C0475276
.	O
	
a	O
series	O
of	O
semantic	B-C0036612
imaging	B-C2346469
traits	I-C2346469
were	O
replaced	B-C0559956
with	O
automatically	O
extracted	O
continuous	B-C0439828
variables	I-C0439828
.	O
	
there	O
were	O
multiple	O
22	O
significant	O
correlations	B-C1707520
of	O
imaging	B-C2346469
measures	I-C2346469
with	O
ctvs	B-C0454198
/	O
mtvnaa	B-C0475276
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
ctvs	B-C0454198
/	O
mtvcho	B-C0475276
.	O
	
a	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
mri	B-C0024485
and	O
magnetic	B-C1522706
resonance	I-C1522706
spectroscopic	I-C1522706
imaging	I-C1522706
radiomic	O
features	B-C1521970
and	O
ctvs	B-C0454198
/	O
mtvs	B-C0475276
has	O
been	O
established	O
.	O
	
the	O
mtv	B-C0475276
for	O
naa	B-C0067684
was	O
found	O
to	O
be	O
closely	O
associated	B-C0332281
with	I-C0332281
mri	B-C0024485
volumes	B-C0449468
,	O
whereas	O
very	O
few	O
imaging	B-C2346469
features	I-C2346469
were	O
related	O
to	O
mtvcho	B-C0475276
,	O
indicating	O
that	O
cho	B-C0008405
provides	O
additional	B-C1546922
information	I-C1546922
to	O
measurement	B-C0242485
of	O
fidgeting	B-C0424235
in	O
patients	B-C0030705
with	O
anorexia	B-C0003125
nervosa	I-C0003125
using	O
a	O
novel	O
shoe	B-C0036988
-based	O
monitor	B-C0596972
to	O
objectively	O
assess	O
seated	B-C4042775
non-exercise	B-C0026606
physical	I-C0026606
activity	I-C0026606
in	O
patients	B-C0030705
with	O
anorexia	B-C0003125
nervosa	I-C0003125
an	B-C0003125
relative	O
to	O
healthy	B-C2986479
controls	I-C2986479
hcs	B-C2986479
and	O
examine	O
the	O
associations	B-C0439849
between	O
this	O
physical	B-C0026606
activity	I-C0026606
,	O
eating	B-C0013473
disorder	I-C0013473
pathology	B-C0677042
,	O
and	O
levels	B-C0441889
of	O
anxiety	B-C0003467
and	O
depression	B-C0011570
.	O
	
eleven	O
inpatients	B-C0021562
with	O
an	B-C0003125
and	O
10	O
hcs	B-C2986479
wore	O
a	O
shoe	B-C0036988
-based	O
accelerometer	B-C0178951
smartshoe	B-C0178951
at	O
three	O
time	B-C1552717
points	I-C1552717
a	O
while	B-C2362314
eating	I-C2362314
lunch	I-C2362314
,	O
b	O
filling	B-C2362314
out	I-C2362314
questionnaires	I-C2362314
,	O
and	O
c	O
watching	B-C2362314
television	I-C2362314
for	I-C2362314
1h	I-C2362314
.	O
	
across	O
all	O
three	O
tasks	B-C3540678
,	O
patients	B-C0030705
with	O
an	B-C0003125
were	O
significantly	O
more	B-C0205177
active	I-C0205177
than	O
hcs	B-C2986479
,	O
thereby	O
engaging	O
in	O
a	O
greater	B-C0449286
degree	I-C0449286
of	O
restless	B-C3887611
or	O
fidgeting	B-C0424235
behavior	B-C0004927
.	O
	
degree	B-C0449286
of	O
physical	B-C0026606
activity	I-C0026606
was	O
positively	B-C1514241
correlated	I-C1514241
with	O
eating	B-C0013473
disorder	I-C0013473
psychopathology	B-C0033927
in	O
the	O
sample	O
with	O
an	B-C0003125
,	O
and	O
a	O
trend	O
towards	O
a	O
positive	B-C1514241
association	I-C1514241
between	O
physical	B-C0026606
activity	I-C0026606
and	O
levels	B-C0441889
of	O
depression	B-C0011570
and	O
anxiety	B-C0003467
was	O
also	O
found	O
in	O
this	O
sample	O
.	O
	
among	O
individuals	B-C0237401
with	O
an	B-C0003125
,	O
physical	B-C0026606
activity	I-C0026606
was	O
not	B-C1513916
significantly	O
correlated	B-C1707520
with	O
bmi	B-C1305855
,	O
duration	B-C3176590
of	I-C3176590
illness	I-C3176590
,	O
or	O
number	B-C3640790
of	I-C3640790
days	I-C3640790
since	O
hospital	B-C0184666
admission	I-C0184666
.	O
	
use	O
of	O
a	O
minimally	B-C2711297
invasive	I-C2711297
,	O
shoe	B-C0036988
-based	O
monitor	B-C0596972
revealed	O
patients	B-C0030705
with	O
an	B-C0003125
engaged	O
in	O
a	O
greater	B-C0449286
degree	I-C0449286
of	O
fidgeting	B-C0424235
relative	O
to	O
hcs	B-C2986479
during	O
quiet	O
,	O
seated	B-C4042775
tasks	B-C3540678
and	O
this	O
heightened	O
activity	B-C0026606
was	O
related	O
to	O
measures	B-C0079809
of	O
pathology	B-C0677042
.	O
	
non-exercise	B-C0026606
physical	I-C0026606
activity	I-C0026606
,	O
including	O
fidgeting	B-C0424235
,	O
may	O
warrant	O
further	O
clinical	B-C0205210
attention	O
in	O
this	O
patient	B-C0030705
population	I-C0030705
.	O
	
hospital	B-C0018704
clowning	I-C0018704
a	O
paediatrician's	B-C0237433
view	B-C0030971
this	O
study	B-C0681814
investigates	B-C1292732
the	O
current	B-C0521116
position	O
of	O
hospital	B-C0335094
clowns	I-C0335094
from	O
the	O
perspective	B-C0030971
of	O
paediatricians	B-C0237433
and	O
paediatric	B-C0259967
residents	I-C0259967
.	O
	
a	O
total	B-C0439810
of	O
14	O
attending	B-C0237433
paediatricians	I-C0237433
and	O
paediatric	B-C0259967
residents	I-C0259967
participated	B-C0679823
in	O
two	O
focus	B-C1883017
group	I-C1883017
sessions	I-C1883017
.	O
	
data	B-C1511726
were	O
analysed	B-C0936012
using	O
atlas.ti	B-C0037585
5.0	I-C0037585
.	O
	
in	O
general	B-C0205246
,	O
physicians	B-C0031831
reported	B-C0684224
positive	B-C1446409
experiences	B-C0596545
regarding	O
the	O
interaction	B-C0037420
between	O
hospital	B-C0335094
clowns	I-C0335094
and	O
paediatric	B-C0030705
patients	I-C0030705
on	O
the	O
ward	B-C1305702
.	O
	
physicians	B-C0031831
were	O
more	O
interested	B-C0543488
in	O
research	B-C0035168
on	O
children's	B-C3825851
perception	I-C3825851
of	O
hospital	B-C0335094
clowns	I-C0335094
than	O
in	O
research	B-C0035168
on	O
the	O
clinical	B-C3850123
efficacy	I-C3850123
of	O
hospital	B-C0018704
clowning	I-C0018704
.	O
	
no	B-C0205556
direct	I-C0205556
collaboration	B-C0282116
between	O
physicians	B-C0031831
and	O
hospital	B-C0335094
clowns	I-C0335094
was	O
reported	B-C0684224
.	O
	
however	O
,	O
physicians	B-C0031831
proposed	B-C1553874
conditions	B-C0348080
which	O
may	O
streamline	B-C0442799
their	O
encounters	B-C1947978
with	O
hospital	B-C0335094
clowns	I-C0335094
such	O
as	O
clear	B-C0009452
communication	I-C0009452
prior	B-C0332152
to	O
hospital	B-C0335094
clown	I-C0335094
visits	B-C1512346
,	O
and	O
the	O
condition	B-C0348080
that	O
visits	B-C0545082
do	O
not	O
impede	B-C0332454
medical	B-C0184661
interventions	I-C0184661
.	O
	
overall	B-C1561607
,	O
paediatricians	B-C0237433
and	O
paediatric	B-C0259967
residents	I-C0259967
view	B-C0030971
the	O
positive	B-C1446409
impact	B-C4049986
on	O
paediatric	B-C0030705
patients	I-C0030705
as	O
the	O
most	O
important	B-C3898777
aspect	B-C1879746
of	O
hospital	B-C0335094
clown	I-C0335094
visits	B-C1512346
,	O
rather	O
than	O
the	O
clinical	B-C3850123
efficacy	I-C3850123
of	O
hospital	B-C0018704
clowning	I-C0018704
.	O
	
in	O
light	O
of	O
the	O
growing	O
number	O
of	O
hospital	B-C0335094
clowns	I-C0335094
worldwide	B-C2700280
,	O
this	O
article	B-C1706852
provides	O
recommendations	B-C0034866
for	O
arranging	O
their	O
encounters	B-C1947978
with	O
paediatricians	B-C0237433
and	O
paediatric	B-C0259967
residents	I-C0259967
to	O
maintain	B-C0024501
optimal	B-C2698651
health	B-C0086388
care	I-C0086388
.	O
	
what	O
is	O
known	O
previous	B-C0205156
studies	B-C0681814
show	O
a	O
clinically	B-C0750502
significant	I-C0750502
pain	B-C0030193
-	O
and	O
anxiety	B-C0003467
-	O
reducing	B-C1280500
effect	I-C1280500
of	O
hospital	B-C0018704
clowning	I-C0018704
in	O
paediatric	B-C0030705
patients	I-C0030705
admitted	B-C0184666
to	I-C0184666
hospitals	I-C0184666
or	O
undergoing	B-C0205556
invasive	B-C0205281
medical	B-C0199171
procedures	I-C0199171
.	O
	
in	O
general	O
,	O
paediatricians	B-C0237433
have	O
positive	B-C1446409
ideas	B-C1254370
about	O
hospital	B-C0335094
clowns	I-C0335094
,	O
aside	O
from	O
personal	B-C0033023
prejudices	I-C0033023
.	O
	
what	O
is	O
new	O
this	O
novel	B-C0205314
study	B-C0681814
gives	O
deeper	O
insight	B-C0233820
into	O
day-to-day	B-C1254367
interaction	B-C0037420
between	O
paediatricians	B-C0237433
and	O
hospital	B-C0335094
clowns	I-C0335094
on	O
the	O
ward	B-C1305702
.	O
	
this	O
study	B-C0681814
provides	O
recommendations	B-C0034866
for	O
clinical	B-C0282451
practice	I-C0282451
to	O
arrange	O
encounters	B-C1947978
between	O
physicians	B-C0031831
and	O
hospital	B-C0335094
clowns	I-C0335094
during	O
hospital	B-C0335094
clown	I-C0335094
visits	B-C1512346
.	O
	
multiparametric	B-C1513748
estimation	I-C1513748
of	O
brain	B-C4042806
hemodynamics	I-C4042806
with	O
mr	B-C3891302
fingerprinting	I-C3891302
asl	I-C3891302
assessment	B-C0220825
of	O
brain	B-C4042806
hemodynamics	I-C4042806
without	O
exogenous	B-C0205228
contrast	B-C0009924
agents	I-C0009924
is	O
of	O
increasing	B-C0442808
importance	B-C3898777
in	O
clinical	B-C0869019
applications	I-C0869019
.	O
	
this	O
study	O
aims	O
to	O
develop	O
an	O
mr	B-C4287652
perfusion	I-C4287652
technique	I-C4287652
that	O
can	O
provide	O
noncontrast	B-C2825493
and	O
multiparametric	B-C1513748
estimation	I-C1513748
of	O
hemodynamic	B-C0019010
markers	B-C2745888
.	O
	
we	O
devised	O
an	O
arterial	B-C3891302
spin	I-C3891302
labeling	I-C3891302
asl	B-C3891302
method	O
based	O
on	O
the	O
principle	O
of	O
mr	B-C0024485
fingerprinting	I-C0024485
mrf	B-C0024485
,	O
referred	B-C0205543
to	O
as	O
mrf-asl	B-C3891302
.	O
	
by	O
taking	O
advantage	O
of	O
the	O
rich	O
information	B-C1533716
contained	O
in	O
mrf	B-C0024485
sequence	I-C0024485
,	O
up	O
to	O
seven	O
hemodynamic	B-C0019010
parameters	B-C0449381
can	O
be	O
estimated	B-C0750572
concomitantly	B-C0521115
.	O
	
feasibility	B-C0015730
demonstration	I-C0015730
,	O
flip	B-C2348681
angle	I-C2348681
optimization	B-C2698650
,	O
comparison	B-C1707455
with	O
look-locker	B-C3891302
asl	I-C3891302
,	O
reproducibility	B-C1514863
test	I-C1514863
,	O
sensitivity	B-C0332324
to	O
hypercapnia	B-C0020440
challenge	I-C0020440
,	O
and	O
initial	O
clinical	B-C0869019
application	I-C0869019
in	O
an	O
intracranial	B-C0394264
steno-occlusive	I-C0394264
process	I-C0394264
,	O
moyamoya	B-C0026654
disease	I-C0026654
,	O
were	O
performed	B-C0884358
to	O
evaluate	O
this	O
technique	B-C0449851
.	O
	
magnetic	B-C3891302
resonance	I-C3891302
fingerprinting	I-C3891302
asl	I-C3891302
provided	B-C1999230
estimation	O
of	O
up	O
to	O
seven	O
parameters	B-C0449381
,	O
including	O
b1+	B-C0392762
,	O
tissue	B-C0459385
t1	B-C2697938
,	O
cerebral	B-C0428714
blood	I-C0428714
flow	I-C0428714
cbf	B-C0428714
,	O
tissue	B-C0040300
bolus	B-C0243095
arrival	I-C0243095
time	I-C0243095
bat	B-C0243095
,	O
pass-through	O
arterial	B-C0003842
bat	B-C0243095
,	O
pass-through	O
blood	B-C0005850
volume	I-C0005850
,	O
and	O
pass-through	O
blood	B-C0919393
travel	I-C0919393
time	I-C0919393
.	O
	
coefficients	B-C1707429
of	O
variation	B-C0205419
of	O
the	O
estimated	B-C0750572
parameters	B-C0449381
ranged	O
from	O
0.2	O
to	O
9.6	O
.	O
	
hypercapnia	B-C0020440
resulted	O
in	O
an	O
increase	B-C0442805
in	O
cbf	B-C0428714
by	O
57.7	O
,	O
and	O
a	O
decrease	B-C0547047
in	O
bat	B-C0243095
by	O
13.7	O
and	O
24.8	O
in	O
tissue	B-C0040300
and	O
vessels	B-C0005847
,	O
respectively	O
.	O
	
patients	B-C0030705
with	O
moyamoya	B-C0026654
disease	I-C0026654
showed	O
diminished	B-C0205216
cbf	B-C0428714
and	O
lengthened	B-C0392744
bat	B-C0243095
that	O
could	B-C0442737
not	I-C0442737
be	I-C0442737
detected	I-C0442737
with	O
regular	B-C0205272
asl	B-C3891302
.	O
	
magnetic	B-C3891302
resonance	I-C3891302
fingerprinting	I-C3891302
asl	I-C3891302
is	O
a	O
promising	O
technique	B-C0449851
for	O
noncontrast	B-C2825493
,	O
multiparametric	B-C1513748
perfusion	B-C4038600
assessment	I-C4038600
.	O
	
magn	O
reson	O
med	O
,	O
2016	O
.	O
	
2016	O
international	B-C0018720
society	I-C0018720
for	I-C0018720
magnetic	I-C0018720
resonance	I-C0018720
in	I-C0018720
medicine	I-C0018720
.	O
	
acute	B-C0205178
sensitivity	B-C0332324
of	O
the	O
vernal	B-C2661017
pool	I-C2661017
fairy	I-C2661017
shrimp	I-C2661017
,	O
branchinecta	B-C2661017
lynchi	I-C2661017
anostraca	B-C0998204
branchinectidae	B-C1007142
,	O
and	O
surrogate	B-C4053457
species	B-C1705920
to	O
10	O
chemicals	B-C0220806
vernal	B-C2661017
pool	I-C2661017
fairy	I-C2661017
shrimp	I-C2661017
,	O
branchinecta	B-C2661017
lynchi	I-C2661017
,	O
branchiopoda	B-C0596222
anostraca	B-C0998204
and	O
other	O
fairy	B-C0998204
shrimp	I-C0998204
species	B-C1705920
have	O
been	O
listed	O
as	O
threatened	B-C2717883
or	O
endangered	B-C2717882
under	O
the	O
us	O
endangered	O
species	O
act	O
.	O
	
because	O
few	O
data	B-C1511726
exist	O
about	O
the	O
sensitivity	B-C0332324
of	O
branchinecta	B-C1007143
spp	B-C1705920
.	O
	
to	O
toxic	B-C0600688
effects	I-C0600688
of	O
contaminants	B-C2827365
,	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
they	O
are	O
adequately	B-C1031756
protected	I-C1031756
by	O
water	B-C0597680
quality	I-C0597680
criteria	B-C0243161
.	O
	
a	O
series	O
of	O
acute	B-C0022885
24-h	I-C0022885
lethality/immobilization	I-C0022885
tests	I-C0022885
was	O
conducted	O
with	O
3	O
species	B-C1705920
of	O
fairy	B-C0998204
shrimp	I-C0998204
b	B-C2661017
.	O
	
lynchi	I-C2661017
,	O
branchinecta	B-C1187775
lindahli	I-C1187775
,	O
and	O
thamnocephalus	B-C1041123
platyurus	I-C1041123
and	O
10	O
chemicals	B-C0220806
with	O
varying	O
modes	O
of	O
toxic	B-C1256754
action	I-C1256754
ammonia	B-C0002607
,	O
potassium	B-C0032821
,	O
chloride	B-C0008203
,	O
sulfate	B-C0038720
,	O
chromium	B-C0008574
,	O
copper	B-C0009968
,	O
nickel	B-C0028013
,	O
zinc	B-C0043481
,	O
alachlor	B-C0051051
,	O
and	O
metolachlor	B-C0066468
.	O
	
the	O
same	O
chemicals	B-C0220806
were	O
tested	O
in	O
48-	O
h	B-C0439227
tests	B-C0022885
with	O
other	O
branchiopods	B-C0596222
the	O
cladocerans	B-C0446344
daphnia	B-C1081963
magna	I-C1081963
and	O
ceriodaphnia	B-C1089376
dubia	I-C1089376
and	O
an	O
amphipod	B-C0598804
hyalella	B-C1676520
azteca	I-C1676520
,	O
and	O
in	O
96-	O
h	B-C0439227
tests	B-C0022885
with	O
snails	B-C0037378
physa	B-C0323946
gyrina	I-C0323946
and	O
lymnaea	B-C0323913
stagnalis	I-C0323913
.	O
	
median	O
effect	B-C1446561
concentrations	I-C1446561
ec50s	B-C1446561
for	O
b	B-C2661017
.	O
	
lynchi	I-C2661017
were	O
strongly	O
correlated	B-C1707520
r	O
=	O
0.975	O
with	O
ec50s	B-C1446561
for	O
the	O
commercially	O
available	O
fairy	B-C0998204
shrimp	I-C0998204
species	B-C1705920
t	B-C1041123
.	O
	
platyurus	I-C1041123
for	O
most	O
chemicals	B-C0220806
tested	O
.	O
	
comparison	B-C1707455
of	O
ec50s	B-C1446561
for	O
fairy	B-C0998204
shrimp	I-C0998204
and	O
ec50s	B-C1446561
for	O
invertebrate	B-C0021948
taxa	I-C0021948
tested	O
concurrently	O
and	O
with	O
other	O
published	O
toxicity	B-C0600688
data	B-C1511726
indicated	O
that	O
fairy	B-C0998204
shrimp	I-C0998204
were	O
relatively	O
sensitive	B-C0332324
to	O
potassium	B-C0032821
and	O
several	O
trace	B-C0723796
metals	I-C0723796
compared	B-C1707455
with	O
other	O
invertebrate	B-C0021948
taxa	I-C0021948
,	O
although	O
cladocerans	B-C0446344
,	O
amphipods	B-C0598804
,	O
and	O
mussels	B-C0026871
had	O
similar	O
broad	O
toxicant	B-C0599787
sensitivity	B-C0332324
.	O
	
interspecies	B-C3161035
correlation	I-C3161035
estimation	I-C3161035
models	I-C3161035
for	O
predicting	O
toxicity	B-C0600688
to	O
fairy	B-C0998204
shrimp	I-C0998204
from	O
surrogate	B-C4053457
species	B-C1705920
indicated	O
that	O
models	B-C3161035
with	O
cladocerans	B-C0446344
and	O
freshwater	B-C0026871
mussels	I-C0026871
as	O
surrogates	B-C4053457
produced	O
the	O
best	O
predictions	O
of	O
the	O
sensitivity	B-C0332324
of	O
fairy	B-C0998204
shrimp	I-C0998204
to	O
contaminants	B-C2827365
.	O
	
the	O
results	O
of	O
these	O
studies	B-C2603343
indicate	O
that	O
fairy	B-C0998204
shrimp	I-C0998204
are	O
relatively	O
sensitive	B-C0332324
to	O
a	O
range	O
of	O
toxicants	B-C0599787
,	O
but	O
endangered	O
species	O
act	O
-listed	O
fairy	B-C0998204
shrimp	I-C0998204
of	O
the	O
genus	B-C1007143
branchinecta	I-C1007143
were	O
not	O
consistently	O
more	O
sensitive	B-C0332324
than	O
other	O
fairy	B-C0998204
shrimp	I-C0998204
taxa	I-C0998204
.	O
	
bi-layered	B-C0005479
constructs	I-C0005479
of	O
poly	B-C1173093
-	O
β-tricalcium	B-C0106141
phosphate	I-C0106141
for	O
bone-soft	B-C0541689
tissue	I-C0541689
interface	B-C0205245
applications	I-C0205245
this	O
study	B-C2603343
aims	O
to	O
establish	O
a	O
facile	O
protocol	B-C2348563
for	O
the	O
preparation	B-C1521827
of	O
a	O
bi-layered	B-C0205556
poly	B-C1173093
pgs	B-C1173093
β-tricalcium	B-C0106141
phosphate	I-C0106141
β-tcp	B-C0106141
construct	B-C0005479
and	O
to	O
investigate	B-C1292732
its	O
potential	O
for	O
bone-soft	B-C0541689
tissue	I-C0541689
engineering	B-C0596171
applications	B-C0205245
.	O
	
the	O
layered	B-C0678594
structure	I-C0678594
was	O
prepared	O
by	O
distributing	B-C1704711
the	O
ceramic	B-C0007742
particles	B-C0597177
within	O
a	O
prepolymer	B-C0597177
synthesized	B-C1883254
in	O
a	O
microwave	B-C0336756
reactor	I-C0336756
followed	O
by	O
a	O
cross-linking	B-C0178576
of	O
the	O
final	O
construct	B-C0005479
in	O
vacuum	B-C0042221
<10mbar	O
.	O
	
the	O
vacuum	B-C0042221
stage	B-C1306673
led	O
to	O
the	O
separation	B-C0678621
of	O
cross-linked	B-C0178576
elastomer	B-C0013766
top	B-C1704458
and	O
ceramic	B-C0007742
bottom	B-C1511276
phases	B-C0205390
.	O
	
results	O
showed	O
that	O
addition	O
of	O
β-tcp	B-C0106141
particles	B-C0597177
to	O
the	O
elastomer	B-C0013766
matrix	I-C0013766
after	O
the	O
polymerization	B-C0314672
led	O
to	O
an	O
increase	B-C0442805
in	O
compression	B-C0376507
strength	I-C0376507
up	O
to	O
14	O
.	O
	
tensile	B-C0039526
strength	I-C0039526
σ	O
,	O
young's	B-C2350289
modulus	I-C2350289
e	O
,	O
and	O
elongation	B-C0392762
at	I-C0392762
break	I-C0392762
%	O
values	O
were	O
calculated	O
as	O
0.29	O
and	O
0.21	O
0.38	O
and	O
1.95	O
and	O
240	O
and	O
24	O
for	O
pgs	B-C1173093
and	O
pgs	B-C1173093
/	O
β-tcp	B-C0106141
bi-layered	B-C0005479
constructs	I-C0005479
,	O
respectively	O
.	O
	
morphology	B-C0678594
was	O
characterized	O
by	O
using	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
sem	B-C0026020
and	O
micro-computed	B-C2350281
tomography	I-C2350281
μ-ct	B-C2350281
.	O
	
tomography	B-C2350281
data	B-C1511726
revealed	O
an	O
open	B-C0080037
porosity	I-C0080037
of	O
35%	O
for	O
the	O
construct	B-C0005479
,	O
mostly	O
contributed	O
from	O
the	O
ceramic	B-C0205390
phase	I-C0205390
since	O
the	O
elastomer	B-C0013766
side	B-C0441987
has	O
no	O
pore	B-C1254362
.	O
	
homogeneous	B-C1881065
β-tcp	B-C0106141
distribution	B-C1704711
within	O
the	O
elastomeric	B-C0678594
structure	I-C0678594
was	O
observed	O
.	O
	
cell	B-C0681854
culture	I-C0681854
studies	I-C0681854
confirmed	O
biocompatibility	B-C0596177
with	O
poor	O
elastomer	B-C0013766
-	O
side	B-C0441987
and	O
good	O
bone	B-C0391978
-	O
side	B-C0441987
cell	B-C0887869
attachment	I-C0887869
.	O
	
in	O
a	O
further	O
study	O
to	O
investigate	B-C1292732
the	O
osteogenic	B-C0391978
properties	B-C0871161
,	O
the	O
construct	B-C0005479
were	O
loaded	O
with	O
bmp-2	B-C0527443
and/or	O
tgf-β1	B-C1704256
.	O
	
the	O
pgs	B-C1173093
/	O
β-tcp	B-C0106141
bi-layered	B-C0005479
constructs	I-C0005479
with	O
improved	O
mechanical	B-C0205556
and	O
biological	B-C0205460
properties	B-C0871161
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone-soft	B-C0541689
tissue	I-C0541689
interface	B-C0205245
applications	I-C0205245
where	O
soft	B-C0225317
tissue	I-C0225317
penetration	B-C0205321
is	O
a	O
effects	B-C1704420
of	I-C1704420
high-intensity	B-C4277545
training	I-C4277545
on	O
cardiovascular	B-C0850624
risk	I-C0850624
factors	I-C0850624
in	O
premenopausal	B-C0279752
and	O
postmenopausal	B-C0232970
women	B-C0043210
menopause	B-C0025320
is	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
risk	O
of	O
cardiovascular	B-C0007222
disease	I-C0007222
and	O
the	O
causal	O
factors	B-C1521761
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	B-C1517945
of	O
estrogen	B-C0014939
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal	B-C0019932
milieu	I-C0019932
.	O
	
however	O
,	O
which	O
factors	B-C1521761
contribute	B-C1880177
to	O
the	O
deterioration	B-C0868945
of	O
cardiometabolic	B-C0596675
health	I-C0596675
in	O
postmenopausal	B-C0232970
women	B-C0043210
is	O
debated	O
as	O
the	O
menopausal	B-C0025320
transition	B-C2700061
is	O
also	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
age	B-C0001779
and	O
fat	B-C3656665
mass	I-C3656665
.	O
	
furthermore	O
,	O
indications	B-C3146298
of	O
reduced	B-C0392756
cardiometabolic	B-C0596675
adaptations	B-C0392673
to	O
exercise	B-C0015259
in	O
postmenopausal	B-C0232970
women	B-C0043210
add	O
to	O
the	O
adverse	B-C0877248
health	B-C0018759
profile	I-C0018759
.	O
	
we	O
sought	O
to	O
evaluate	B-C0220825
risk	B-C0035648
factors	I-C0035648
for	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
and	O
cardiovascular	B-C0007222
disease	I-C0007222
in	O
late	B-C0205087
premenopausal	B-C0279752
and	O
early	B-C1279919
postmenopausal	B-C0232970
women	B-C0043210
,	O
matched	O
by	O
age	B-C0001779
and	O
body	B-C0005885
composition	I-C0005885
,	O
and	O
investigate	B-C1292732
the	O
effect	O
of	O
high-intensity	B-C4277545
training	I-C4277545
.	O
	
a	O
3-month	O
high-intensity	B-C4277545
aerobic	I-C4277545
training	I-C4277545
intervention	B-C0184661
,	O
involving	O
healthy	B-C3898900
,	O
nonobese	B-C0243095
,	O
late	B-C0205087
premenopausal	B-C0279752
n	O
=	O
40	O
and	O
early	B-C1279919
postmenopausal	B-C0232970
n	O
=	O
39	O
women	B-C0043210
was	O
conducted	O
and	O
anthropometrics	B-C2598145
,	O
body	B-C0005885
composition	I-C0005885
,	O
blood	B-C0005823
pressure	I-C0005823
,	O
lipid	B-C0850354
profile	I-C0850354
,	O
glucose	B-C0178665
tolerance	I-C0178665
,	O
and	O
maximal	B-C0030055
oxygen	I-C0030055
consumption	I-C0030055
were	O
determined	O
at	O
baseline	B-C1442488
and	O
after	O
the	O
intervention	B-C0184661
.	O
	
at	O
baseline	B-C1442488
,	O
the	O
groups	B-C1257890
matched	O
in	O
anthropometrics	B-C2598145
and	O
body	B-C0005885
composition	I-C0005885
,	O
and	O
only	O
differed	O
by	O
4.2	O
years	O
in	O
age	B-C0001779
mean	O
95%	O
confidence	B-C0237530
limits	I-C0237530
49.2	O
48.5	O
vs	O
53.4	O
52.4	O
years	O
.	O
	
time	O
since	O
last	O
menstrual	B-C0025344
period	I-C0025344
for	O
the	O
postmenopausal	B-C0232970
women	B-C0043210
was	O
mean	O
95%	O
confidecnce	B-C0237530
limits	I-C0237530
3.1	O
2.6	O
years	O
.	O
	
hormonal	B-C1287355
levels	I-C1287355
estrogen	B-C0014939
,	O
follicle	B-C0016774
stimulation	I-C0016774
hormone	I-C0016774
,	O
luteinizing	B-C0023607
hormone	I-C0023607
confirmed	O
menopausal	B-C1513126
status	I-C1513126
.	O
	
at	O
baseline	B-C1442488
the	O
postmenopausal	B-C0232970
women	B-C0043210
had	O
higher	O
total	B-C0543421
cholesterol	I-C0543421
p	O
<	O
001	O
,	O
low-density	B-C0023824
lipoprotein-cholesterol	I-C0023824
p	O
<	O
05	O
,	O
and	O
high-density	B-C0023822
lipoprotein-cholesterol	I-C0023822
p	O
<	O
001	O
than	O
the	O
premenopausal	B-C0279752
women	B-C0043210
.	O
	
the	O
training	O
intervention	B-C0184661
reduced	B-C0392756
body	B-C0005910
weight	I-C0005910
p	O
<	O
01	O
,	O
waist	B-C0455829
circumference	I-C0455829
p	O
<	O
01	O
,	O
and	O
improved	B-C0184511
body	B-C0005885
composition	I-C0005885
by	O
increasing	B-C0442808
lean	B-C0424678
body	I-C0424678
mass	I-C0424678
p	O
<	O
001	O
and	O
decreasing	B-C0442797
fat	B-C3656665
mass	I-C3656665
p	O
<	O
001	O
similarly	O
in	O
both	O
groups	B-C1257890
.	O
	
moreover	O
,	O
training	O
resulted	O
in	O
lower	B-C0277890
diastolic	I-C0277890
blood	I-C0277890
pressure	I-C0277890
p	O
<	O
05	O
,	O
resting	B-C1821417
heart	I-C1821417
rate	I-C1821417
p	O
<	O
001	O
,	O
total	B-C0543421
cholesterol	I-C0543421
p	O
<	O
01	O
,	O
low-density	B-C0023824
lipoprotein-cholesterol	I-C0023824
p	O
<	O
01	O
,	O
total	B-C0543421
cholesterol	I-C0543421
/	O
high-density	B-C0023822
lipoprotein-cholesterol	I-C0023822
index	O
p	O
<	O
01	O
,	O
and	O
improved	B-C0184511
plasma	B-C1276042
insulin	I-C1276042
concentration	I-C1276042
during	O
the	O
oral	B-C0029161
glucose	I-C0029161
tolerance	I-C0029161
test	I-C0029161
p	O
<	O
05	O
in	O
both	O
groups	B-C1257890
.	O
	
cardiovascular	B-C0850624
risk	I-C0850624
factors	I-C0850624
are	O
similar	O
in	O
late	B-C0205087
premenopausal	B-C0279752
and	O
early	B-C1279919
postmenopausal	B-C0232970
women	B-C0043210
,	O
matched	O
by	O
age	B-C0001779
and	O
body	B-C0005885
composition	I-C0005885
,	O
with	O
the	O
exception	O
that	O
postmenopausal	B-C0232970
women	B-C0043210
have	O
higher	O
high-	B-C0392885
and	O
low-density	B-C0202117
lipoprotein-cholesterol	I-C0202117
levels	I-C0202117
.	O
	
a	O
3-month	O
intervention	B-C0184661
of	O
high-intensity	B-C4277545
aerobic	I-C4277545
training	I-C4277545
reduces	O
risk	B-C0035648
factors	I-C0035648
for	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
and	O
cardiovascular	B-C0007222
disease	I-C0007222
to	O
a	O
similar	O
extent	O
in	O
late	B-C0205087
premenopausal	B-C0279752
and	O
early	B-C1279919
postmenopausal	B-C0232970
women	B-C0043210
.	O
	
correlation	B-C1707520
between	O
preoperative	B-C0445204
physical	B-C0311392
signs	I-C0311392
and	O
functional	B-C0205245
outcomes	B-C1274040
after	O
laminoplasty	B-C1535956
for	O
ossification	B-C0206366
of	I-C0206366
the	I-C0206366
posterior	I-C0206366
longitudinal	I-C0206366
ligament	I-C0206366
ossification	B-C0206366
of	I-C0206366
the	I-C0206366
posterior	I-C0206366
longitudinal	I-C0206366
ligament	I-C0206366
opll	B-C0206366
can	O
cause	O
myelopathy	B-C0005956
that	O
is	O
often	B-C0332183
managed	B-C0184516
surgically	B-C0543467
.	O
	
knowledge	B-C0162340
of	O
predictors	B-C2698872
of	O
surgical	B-C0543467
outcomes	B-C0085415
can	O
provide	B-C1999230
decision	B-C3242450
support	I-C3242450
to	O
surgeons	B-C0582175
.	O
	
the	O
aims	B-C1947946
of	O
this	O
study	B-C0681814
were	O
to	O
investigate	B-C1292732
the	O
relationships	B-C0439849
between	O
preoperative	B-C0445204
physical	B-C0311392
signs	I-C0311392
and	O
postoperative	B-C0032790
functional	B-C0205245
outcomes	B-C1274040
in	O
patients	B-C0030705
with	O
opll	B-C0206366
and	O
to	O
clarify	B-C2986669
whether	O
physical	B-C0311392
signs	I-C0311392
could	O
predict	B-C0681842
functional	B-C0205245
outcomes	B-C1274040
.	O
	
fifty-five	O
patients	B-C0030705
with	O
opll	B-C0206366
who	O
had	O
undergone	O
cervical	B-C2026796
laminoplasty	I-C2026796
were	O
included	B-C0332257
in	O
this	O
study	B-C0681814
.	O
	
six	O
physical	B-C0311392
signs	I-C0311392
including	O
hyperreflexia	B-C0151889
,	O
babinski	B-C0034935
sign	I-C0034935
,	O
sensory	B-C0152027
disturbance	I-C0152027
,	O
grip	B-C0429271
strength	I-C0429271
,	O
10-s	B-C0683443
grip	I-C0683443
and	I-C0683443
release	I-C0683443
test	I-C0683443
,	O
and	O
bladder	B-C0232841
dysfunction	I-C0232841
,	O
and	O
four	O
other	O
factors	B-C1521761
including	O
age	B-C0001779
,	O
duration	B-C0436359
of	I-C0436359
symptoms	I-C0436359
,	O
history	O
of	O
minor	B-C0555305
trauma	I-C0555305
and	O
preoperative	B-C0445204
japanese	B-C0449820
orthopaedic	I-C0449820
association	I-C0449820
joa	I-C0449820
score	I-C0449820
were	O
investigated	B-C1292732
as	O
potential	B-C3245505
predictive	B-C0681890
prognostic	B-C1514474
factors	I-C1514474
using	O
both	O
univariate	B-C0683962
and	O
multivariate	B-C0026777
analyses	I-C0026777
.	O
	
the	O
mean	B-C0444504
recovery	B-C1521828
rate	I-C1521828
of	O
joa	B-C0449820
score	I-C0449820
was	O
62.5	O
32.5	O
.	O
	
the	O
neurological	B-C0205494
recovery	B-C1521828
rate	I-C1521828
was	O
negatively	B-C0205160
associated	B-C0332281
with	I-C0332281
age	B-C0001779
p	O
=	O
0.002	O
,	O
the	O
duration	B-C0436359
of	I-C0436359
symptoms	I-C0436359
p	O
=	O
0.002	O
and	O
babinski	B-C0034935
sign	I-C0034935
p	O
=	O
0.007	O
,	O
whereas	O
it	O
was	O
positively	B-C1446409
correlated	B-C1707520
with	O
grip	B-C0429271
strength	I-C0429271
p	O
=	O
0.011	O
.	O
	
multiple	B-C0034980
logistic	I-C0034980
regression	I-C0034980
analyses	I-C0034980
revealed	B-C0443289
that	O
age	B-C0001779
odds	B-C0028873
ratio	I-C0028873
0.89	O
,	O
95%	O
ci	B-C0009667
0.81	O
and	O
babinski	B-C0034935
sign	I-C0034935
odds	B-C0028873
ratio	I-C0028873
0.18	O
,	O
95%	O
ci	B-C0009667
0.04	O
were	O
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
functional	B-C0205245
outcomes	B-C1274040
.	O
	
satisfactory	B-C0205410
functional	B-C0205245
outcomes	B-C1274040
could	O
be	O
expected	B-C1517001
for	O
patients	B-C0030705
who	O
are	O
young	B-C0332239
and	O
do	O
not	O
exhibit	O
the	O
babinski	B-C0034935
sign	I-C0034935
,	O
showing	O
that	O
the	O
babinski	B-C0034935
sign	I-C0034935
could	O
be	O
useful	B-C3827682
as	O
an	O
indicator	B-C1522602
of	O
the	O
window	B-C0205556
of	I-C0205556
opportunity	I-C0205556
for	O
achieving	B-C0205556
satisfactory	B-C0205410
functional	B-C0205245
outcomes	B-C1274040
.	O
	
bacteria	B-C0004611
and	O
hoverflies	B-C1005241
diptera	B-C0012578
syrphidae	B-C1005241
in	O
tree	B-C0927234
hollows	I-C0927234
from	O
the	O
iberian	B-C0086312
mediterranean	I-C0086312
forest	I-C0086312
saproxylic	B-C0021585
insect	I-C0021585
communities	I-C0021585
inhabiting	B-C0337646
tree	B-C0927234
hollows	I-C0927234
in	O
mediterranean	B-C0086312
forests	I-C0086312
depend	O
on	O
a	O
combination	O
of	O
physical	B-C1521970
characteristics	I-C1521970
and	O
interactions	B-C1704675
occurring	O
between	O
community	B-C1705920
member	I-C1705920
species	I-C1705920
.	O
	
despite	O
the	O
need	O
to	O
preserve	O
these	O
organisms	B-C0029235
,	O
little	O
is	O
known	O
about	O
their	O
interrelationships	B-C0439849
,	O
in	O
particular	O
those	O
relationships	B-C0439849
between	O
saproxylic	B-C0021585
insects	I-C0021585
and	O
microbiota	B-C3887843
occurring	O
in	O
these	O
microhabitats	B-C0871648
.	O
	
in	O
tree	B-C0927234
hollows	I-C0927234
of	O
quercus	B-C3457247
rotundifolia	I-C3457247
lamark	I-C3457247
that	O
hold	B-C0205245
water	I-C0205245
and	O
contain	O
dead	B-C0242724
leaves	I-C0242724
,	O
abundant	B-C0599840
microbial	I-C0599840
populations	I-C0599840
can	O
be	O
found	O
.	O
	
developing	O
on	O
them	O
are	O
the	O
larvae	B-C0023047
of	O
mallota	B-C3900907
dusmeti	I-C3900907
andréu	O
,	O
1926	O
diptera	B-C0012578
syrphidae	B-C1005241
,	O
a	O
vulnerable	B-C1705920
species	I-C1705920
iucn	B-C0683312
category	I-C0683312
marcos-garcía	B-C0027361
and	O
quinto	B-C0027361
2011	O
.	O
	
this	O
study	O
provides	O
the	O
first	O
data	O
on	O
the	O
microbiota	B-C3887843
living	B-C0337646
inside	I-C0337646
the	O
gut	B-C0699819
of	O
the	O
larvae	B-C0023047
of	O
m	B-C3900907
.	O
	
dusmeti	I-C3900907
,	O
as	O
well	O
as	O
the	O
microbiota	B-C3887843
in	O
the	O
hollow	B-C0332484
where	O
these	O
larvae	B-C0023047
develop	B-C0243107
.	O
	
bacteria	B-C0004611
were	O
identified	O
by	O
amplification	B-C1441475
and	I-C1441475
partial	I-C1441475
sequencing	I-C1441475
of	O
the	O
v1-v3	B-C0598666
regions	I-C0598666
and	O
the	O
complete	O
nucleotide	B-C0004793
sequence	I-C0004793
of	O
16s	B-C3537372
rrna	I-C3537372
genes	I-C3537372
.	O
	
we	O
found	O
eight	O
species	B-C0004611
of	I-C0004611
bacteria	I-C0004611
living	B-C0337646
in	I-C0337646
tree	B-C0927234
hollows	I-C0927234
and	O
three	O
species	B-C1705920
in	B-C0699819
the	I-C0699819
gut	I-C0699819
of	O
m	B-C3900907
.	O
	
dusmeti	I-C3900907
larvae	B-C0023047
bacillus	B-C0004590
cereus	I-C0004590
,	O
bacillus	B-C3715367
toyonensis	I-C3715367
,	O
and	O
lysinibacillus	B-C0314884
sphaericus	I-C0314884
the	O
filter-feeding	B-C0243095
mechanism	I-C0243095
characteristic	I-C0243095
of	O
m	B-C3900907
.	O
	
dusmeti	I-C3900907
larvae	B-C0023047
is	O
selective	O
in	O
enabling	O
ingestion	B-C0232478
of	O
bacteria	B-C0004611
impact	B-C0038039
sports	I-C0038039
and	O
bone	B-C0016658
fractures	I-C0016658
among	O
adolescents	B-C0205653
the	O
objective	O
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
different	B-C1705242
sports	B-C0038039
on	O
stress	B-C0016664
fractures	I-C0016664
among	O
adolescents	B-C0205653
during	O
a	O
9-	O
month	B-C0439231
follow-up	B-C1522577
period	B-C1948053
.	O
	
the	O
sample	B-C1257890
was	O
composed	O
of	O
184	O
adolescents	B-C0205653
divided	O
into	O
three	O
groups	B-C1257890
impact	B-C0038039
sports	I-C0038039
n	O
=	O
102	O
swimming	B-C0039003
n	O
=	O
35	O
non-sports	B-C0038039
n	O
=	O
47	O
.	O
	
the	O
occurrence	B-C2745955
of	O
stress	B-C0016664
fracture	I-C0016664
was	O
reported	O
by	O
participants	B-C0679646
and	O
coaches	B-C0876909
.	O
	
as	O
potential	O
confounders	B-C0009673
we	O
considered	O
age	B-C0001779
,	O
sex	B-C1522384
,	O
resistance	B-C0872279
training	I-C0872279
,	O
body	B-C0005885
composition	I-C0005885
variables	B-C0439828
and	O
age	B-C0001779
at	O
peak	B-C0444505
of	O
height	B-C0439830
velocity	I-C0439830
.	O
	
there	O
were	O
13	O
adolescents	B-C0205653
who	O
reported	O
fractures	B-C0016658
during	O
the	O
9-	O
month	B-C0439231
period	B-C1948053
.	O
	
bone	B-C0005938
mineral	I-C0005938
density	I-C0005938
values	B-C0042295
were	O
higher	O
in	O
adolescents	B-C0205653
engaged	O
in	O
impact	B-C0038039
sports	I-C0038039
p-value	B-C1709380
=	O
0.002	O
.	O
	
independently	O
of	O
confounders	B-C0009673
,	O
the	O
risk	B-C0035647
of	O
stress	B-C0016664
fracture	I-C0016664
was	O
lower	O
in	O
adolescents	B-C0205653
engaged	O
in	O
impact	B-C0038039
sports	I-C0038039
than	O
in	O
non-active	B-C0205653
adolescents	I-C0205653
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
=	O
0.23	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
=	O
0.05	O
to	O
0.98	O
,	O
while	O
swimming	B-C0039003
practice	B-C0032893
was	O
not	O
associated	O
to	O
lower	O
risk	B-C0035647
of	O
fracture	B-C0016658
hr	B-C2985465
=	O
0.49	O
95%	O
ci	B-C0009667
=	O
0.09	O
to	O
2.55	O
.	O
	
in	O
conclusion	O
,	O
the	O
findings	B-C0243095
from	O
this	O
study	B-C2603343
indicate	O
the	O
importance	O
of	O
sports	B-C0038039
participation	B-C0679823
among	O
adolescents	B-C0205653
in	O
the	O
reduction	B-C0392756
of	O
stress	B-C0016664
fracture	I-C0016664
risk	B-C0035647
,	O
especially	O
with	O
impact	B-C0038039
sports	I-C0038039
.	O
	
more	O
importantly	O
,	O
these	O
results	B-C1274040
could	O
be	O
relevant	B-C2347946
for	O
recognising	O
adolescents	B-C0205653
in	O
danger	O
of	O
not	O
reaching	O
their	O
potential	O
for	O
peak	B-C0444505
bone	B-C0005938
mass	I-C0005938
and	O
later	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
the	O
business	B-C0680840
of	O
health	B-C0018725
physics	I-C0018725
-	O
jobs	B-C0028811
in	O
a	O
changing	B-C0024825
market	I-C0024825
the	O
health	B-C0018725
physics	I-C0018725
profession	B-C0028811
was	O
born	O
abruptly	O
when	O
once	O
rare	O
and	O
precious	O
radioactive	B-C0182598
materials	I-C0182598
became	O
commonplace	B-C0205214
.	O
	
the	O
technological	B-C0681519
advancements	I-C0681519
that	O
triggered	O
an	O
industrial	B-C0439855
complex	I-C0439855
and	O
ended	O
world	B-C0681710
war	I-C0681710
ii	I-C0681710
demanded	O
radiation	B-C3825766
safety	I-C3825766
on	O
an	O
unprecedented	B-C0349674
scale	I-C0349674
.	O
	
until	O
then	O
,	O
protective	B-C3494257
measures	I-C3494257
against	I-C3494257
radiation	I-C3494257
were	O
largely	O
absent	O
in	O
laboratories	B-C0022877
.	O
	
over	O
the	O
subsequent	O
decades	O
,	O
health	B-C0334722
physicists	I-C0334722
began	O
protecting	B-C0034533
people	I-C0034533
and	O
the	O
environment	B-C0242228
in	O
a	O
wide	O
range	O
of	O
settings	O
including	O
medical	B-C0199168
,	O
research	B-C0035168
,	O
and	O
industrial	B-C0021267
.	O
	
the	O
use	B-C4060843
of	I-C4060843
radioactive	I-C4060843
materials	I-C4060843
and	O
radiation-generating	B-C2094479
devices	I-C2094479
is	O
prevalent	B-C0205391
today	I-C0205391
.	O
	
radiation	B-C4019308
doses	I-C4019308
occur	O
continuously	O
including	O
during	O
airline	B-C0001881
flights	I-C0001881
,	O
in	O
our	O
homes	O
,	O
during	O
medical	B-C0199171
procedures	I-C0199171
,	O
and	O
in	O
energy	O
production	O
.	O
	
radiation	B-C0851346
is	O
integral	B-C0205245
to	I-C0205245
numerous	I-C0205245
applications	I-C0205245
including	O
those	O
in	O
medicine	B-C0025118
,	O
dentistry	B-C0011438
,	O
manufacturing	B-C0682029
,	O
construction	O
,	O
scientific	B-C0683933
research	I-C0683933
,	O
nuclear	B-C0242446
electric	I-C0242446
power	I-C0242446
generation	I-C0242446
,	O
and	O
oil	B-C3179122
and	I-C3179122
gas	I-C3179122
exploration	I-C3179122
.	O
	
activities	O
that	O
were	O
once	O
groundbreaking	O
have	O
now	O
become	O
routine	B-C0205547
and	O
scripted	B-C0871893
.	O
	
at	O
higher	B-C4019308
doses	I-C4019308
,	O
health	B-C4060919
effects	I-C4060919
are	O
understood	B-C0205245
and	I-C0205245
avoided	I-C0205245
.	O
	
instruments	B-C3873809
for	I-C3873809
the	I-C3873809
detection	I-C3873809
and	I-C3873809
measurement	I-C3873809
of	I-C3873809
radiation	I-C3873809
are	O
at	O
times	O
smarter	O
than	O
their	O
users	O
.	O
	
ironically	O
,	O
the	O
same	O
health	B-C0018725
physics	I-C0018725
community	O
that	O
has	O
been	O
successful	O
in	O
demonstrating	O
that	O
exposures	B-C0015333
to	I-C0015333
radiation	I-C0015333
and	O
to	O
radioactive	B-C0182598
materials	I-C0182598
can	O
be	O
effectively	B-C0024679
managed	I-C0024679
is	O
shrinking	O
at	O
an	O
increasingly	O
rapid	B-C1521828
rate	I-C1521828
.	O
	
this	O
paper	O
highlights	O
the	O
creation	B-C1706214
of	O
past	O
and	O
current	O
jobs	B-C0028811
,	O
predicts	O
the	O
future	O
opportunities	B-C1516834
in	I-C1516834
the	I-C1516834
profession	I-C1516834
,	O
and	O
makes	O
recommendations	B-C0034866
necessary	O
to	O
protect	O
the	O
disappearing	B-C1273796
specialties	I-C1273796
.	O
	
permanence	B-C0547050
can	O
be	O
defended	B-C0680227
in	O
donation	B-C0282366
after	O
the	O
circulatory-respiratory	B-C0079221
determination	I-C0079221
of	I-C0079221
death	I-C0079221
dcdd	B-C0079221
,	O
the	O
dead	B-C0011065
donor	B-C0029206
rule	B-C0870077
requires	B-C0027552
that	O
the	O
donor	B-C0029206
be	O
dead	B-C0011065
before	B-C0332152
organ	B-C0029210
procurement	I-C0029210
can	O
proceed	O
.	O
	
under	O
the	O
relevant	B-C2347946
limb	I-C2347946
of	O
the	O
uniform	B-C1947938
determination	I-C1947938
of	I-C1947938
death	I-C1947938
act	I-C1947938
1981	I-C1947938
usa	I-C1947938
,	O
a	O
person	B-C0027361
is	O
dead	B-C0011065
when	O
the	O
cessation	B-C1880019
of	O
circulatory-respiratory	B-C0542341
function	I-C0542341
is	O
'	O
irreversible	B-C0243095
'	O
.	O
	
critics	B-C0335034
of	O
current	B-C0521116
practice	B-C0237607
in	O
dcdd	B-C0079221
have	O
argued	B-C0680226
that	O
the	O
donor	B-C0029206
is	O
not	O
dead	B-C0011065
at	O
the	O
time	B-C0040223
organs	B-C0178784
are	O
procured	B-C0029210
,	O
and	O
so	O
the	O
procurement	B-C0029210
of	I-C0029210
organs	I-C0029210
from	O
these	O
donors	B-C0029206
violates	O
the	O
dead	B-C0011065
donor	B-C0029206
rule	B-C0870077
.	O
	
we	O
offer	B-C1444648
a	O
new	B-C0205314
argument	B-C0680226
here	O
in	O
defence	B-C0680227
of	O
current	B-C0521116
dcdd	B-C0079221
practice	B-C0237607
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
the	O
interpretation	B-C0459471
of	O
the	O
requirement	B-C1514873
of	O
'	O
irreversibility	B-C0243095
'	O
as	O
untypeable	B-C0205370
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
subtypes	B-C0449560
in	O
pakistan	B-C0030211
a	O
neglected	O
section	O
diagnostically	B-C0348026
untypeable	B-C0205370
subtypes	B-C0449560
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
hcv	B-C0220847
subtypes	B-C0449560
in	O
pakistan	B-C0030211
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
chronically	B-C0151317
infected	I-C0151317
hcv	B-C0220847
patients	B-C0030705
with	O
known	O
viremia	B-C0042749
were	O
subjected	O
to	O
hcv	B-C0220847
genotyping	B-C2368152
.	O
	
among	O
the	O
total	O
retrieved	O
samples	B-C2347026
,	O
92.7	O
64/69	O
were	O
found	O
typeable	B-C0205309
while	O
7.24	O
5/69	O
were	O
diagnostically	B-C0348026
untypeable	B-C0205370
.	O
	
in	O
conclusion	B-C1707478
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	B-C0205370
hcv	B-C0220847
subtypes	B-C0449560
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	B-C0332307
-	O
specific	B-C0205369
genotyping	B-C2368152
assay	B-C0005507
and	O
consideration	O
of	O
primers	B-C0206416
for	O
proportionally	O
rare	B-C0522498
subtypes	B-C0449560
to	O
minimize	B-C0392756
the	O
number	O
of	O
untypeable	B-C0205370
hcv	B-C0220847
subtypes	B-C0449560
.	O
	
itpr3	B-C1416519
gene	I-C1416519
haplotype	B-C0018591
is	O
associated	O
with	O
cervical	B-C0279671
squamous	I-C0279671
cell	I-C0279671
carcinoma	I-C0279671
risk	B-C0035647
in	O
taiwanese	B-C1556096
women	B-C0043210
host	B-C0021005
immunogenetic	I-C0021005
background	O
plays	O
an	O
important	O
role	O
in	O
human	B-C0343641
papillomavirus	I-C0343641
hpv	I-C0343641
infection	I-C0343641
and	O
cervical	B-C1516170
cancer	I-C1516170
development	I-C1516170
.	O
	
inositol	B-C1416519
1	I-C1416519
receptor	I-C1416519
type	I-C1416519
3	I-C1416519
itpr3	B-C1416519
is	O
essential	O
for	O
both	O
immune	B-C1155000
activation	I-C1155000
and	O
cancer	B-C0006826
pathogenesis	B-C0699748
.	O
	
we	O
aim	O
to	O
investigate	O
if	O
itpr3	B-C1416519
genetic	B-C0032529
polymorphisms	I-C0032529
are	O
associated	O
with	O
the	O
risk	B-C0596244
of	I-C0596244
cervical	I-C0596244
cancer	I-C0596244
in	O
taiwanese	B-C1556096
women	B-C0043210
.	O
	
itpr3	B-C1416519
rs3748079	B-C0752046
a/g	I-C0752046
and	O
rs2229634	B-C0752046
c/t	I-C0752046
polymorphisms	I-C0752046
were	O
genotyped	B-C0017431
in	O
a	O
hospital-based	B-C2603343
study	I-C2603343
of	O
462	O
women	B-C0043210
with	O
cervical	B-C0279671
squamous	I-C0279671
cell	I-C0279671
carcinoma	I-C0279671
cscc	B-C0279671
and	O
921	O
age-matched	O
healthy	B-C2986479
control	I-C2986479
women	B-C0043210
.	O
	
the	O
presence	O
and	O
genotypes	B-C0017431
of	O
hpv	B-C0021344
in	O
cscc	B-C0279671
was	O
determined	O
.	O
	
no	O
significant	O
association	O
of	O
individual	O
itpr3	B-C1416519
variants	B-C0678941
were	O
found	O
among	O
controls	O
,	O
cscc	B-C0279671
,	O
and	O
hpv-16	B-C4288937
positive	I-C4288937
cscc	B-C0279671
.	O
	
however	O
,	O
we	O
found	O
a	O
significant	O
association	O
of	O
haplotype	B-C0018591
at	I-C0018591
between	O
cscc	B-C0279671
and	O
controls	O
or	B-C0028873
=	O
2.28	O
,	O
95%	O
ci	B-C0009667
1.31	O
,	O
p	O
=	O
2.83	O
10-3	O
and	O
the	O
or	B-C0028873
increased	O
further	O
in	O
cscc	B-C0279671
patients	B-C0030705
infected	I-C0030705
with	O
hpv-16	B-C0999806
or	B-C0028873
=	O
2.89	O
,	O
95%	O
ci	B-C0009667
1.55	O
,	O
p	O
=	O
4.54	O
10-4	O
.	O
	
the	O
linkage	B-C1517888
disequilibrium	I-C1517888
analysis	I-C1517888
demonstrated	O
that	O
itpr3	B-C1416519
association	B-C2717881
with	O
cscc	B-C0279671
was	O
independent	O
of	O
hla-drb1	B-C1415576
alleles	B-C0002085
.	O
	
in	O
conclusion	O
,	O
these	O
findings	O
suggest	O
that	O
at	B-C0018591
haplotype	I-C0018591
in	O
the	O
itpr3	B-C1416519
gene	I-C1416519
may	O
serve	O
as	O
a	O
potential	B-C0017393
marker	I-C0017393
for	O
genetic	B-C0314657
susceptibility	I-C0314657
to	O
defining	O
categories	B-C0683312
of	O
actionability	B-C0441655
for	O
secondary	B-C0175668
findings	B-C0243095
in	O
next-generation	B-C0162801
sequencing	I-C0162801
next-generation	B-C0162801
sequencing	I-C0162801
is	O
increasingly	O
used	O
in	O
clinical	B-C0205897
practice	I-C0205897
for	O
the	O
diagnosis	B-C0011900
of	O
mendelian	B-C1285355
diseases	I-C1285355
.	O
	
because	O
of	O
the	O
high	O
likelihood	O
of	O
secondary	B-C0175668
findings	B-C0243095
associated	O
with	O
this	O
technique	B-C0449851
,	O
the	O
process	O
of	O
informing	B-C0588446
patients	I-C0588446
is	O
beset	O
with	O
new	O
challenges	O
.	O
	
one	O
of	O
them	O
is	O
regarding	O
the	O
type	O
of	O
secondary	B-C0175668
findings	B-C0243095
that	O
ought	O
to	O
be	O
disclosed	O
to	O
patients	B-C0030705
.	O
	
the	O
aim	O
of	O
this	O
research	B-C0035168
is	O
to	O
propose	O
a	O
practical	O
implementation	B-C1708476
of	O
the	O
notion	O
of	O
actionability	B-C0441655
,	O
a	O
common	O
criteria	O
justifying	O
the	O
disclosure	B-C0012625
of	O
secondary	B-C0175668
findings	B-C0243095
but	O
whose	O
interpretation	B-C0459471
varies	O
greatly	O
among	O
professionals	B-C0679924
.	O
	
we	O
distinguish	O
three	O
types	O
of	O
actionability	B-C0441655
corresponding	O
to	O
1	O
well-established	O
medical	B-C0205476
actions	B-C3266814
,	O
2	O
patient	B-C0030705
-initiated	O
health-related	B-C0237121
actions	I-C0237121
and	O
3	O
life-plan	B-C0679006
decisions	I-C0679006
.	O
	
we	O
argue	O
that	O
actionability	B-C0441655
depends	O
on	O
the	O
characteristics	O
of	O
the	O
mutation	B-C0026882
or	O
gene	B-C0017337
and	O
on	O
the	O
values	O
of	O
patients	B-C0030705
.	O
	
in	O
discussing	O
the	O
return	O
of	O
secondary	B-C0175668
findings	B-C0243095
,	O
it	O
is	O
important	O
that	O
the	O
physician	B-C0031831
tries	O
to	O
get	O
an	O
impression	B-C1998467
of	O
the	O
specific	O
situation	O
and	O
values	O
of	O
patients	B-C0030705
.	O
	
regarding	O
variants	B-C0678941
of	O
uncertain	O
clinical	B-C2826293
significance	I-C2826293
in	O
actionable	O
genes	B-C0017337
,	O
we	O
found	O
that	O
different	O
understandings	O
of	O
autonomy	B-C0085862
lead	O
to	O
different	O
conclusions	B-C1707478
and	O
that	O
,	O
for	O
some	O
of	O
them	O
,	O
it	O
may	O
be	O
legitimate	O
to	O
refrain	O
from	O
returning	O
uncertain	O
allergen	B-C0002092
valency	B-C0392762
,	O
dose	B-C0178602
,	O
and	O
fcεri	B-C0162825
occupancy	B-C2827063
set	O
thresholds	B-C0449864
for	O
secretory	B-C1327439
responses	I-C1327439
to	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
and	O
motivate	O
design	B-C1707689
of	O
hypoallergens	B-C0002092
ag	B-C0037125
-mediated	O
crosslinking	B-C0178576
of	O
ige	B-C0020846
-	O
fcεri	B-C0162825
complexes	B-C0003313
activates	O
mast	B-C0024880
cells	I-C0024880
and	O
basophils	B-C0004827
,	O
initiating	O
the	O
allergic	B-C1527304
response	I-C1527304
.	O
	
of	O
34	O
donors	O
recruited	O
having	O
self-reported	B-C0681906
shrimp	B-C1628514
allergy	I-C1628514
,	O
only	O
35%	O
had	O
significant	O
levels	O
of	O
shrimp-specific	B-C1270759
ige	I-C1270759
in	O
serum	B-C0229671
and	O
measurable	O
basophil	B-C0004827
secretory	B-C1327616
responses	B-C0003261
to	O
rpen	B-C2924509
a	I-C2924509
1	I-C2924509
shrimp	B-C0037017
tropomyosin	B-C0041197
.	O
	
we	O
report	O
that	O
degranulation	O
is	O
linked	O
to	O
the	O
number	O
of	O
fcεri	B-C0162825
occupied	O
with	O
allergen-specific	B-C0443736
ige	I-C0443736
,	O
as	O
well	O
as	O
the	O
dose	B-C0178602
and	O
valency	B-C0392762
of	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
.	O
	
using	O
clustered	B-C4277689
regularly	I-C4277689
interspaced	I-C4277689
palindromic	I-C4277689
repeat-based	I-C4277689
gene	I-C4277689
editing	I-C4277689
,	O
human	O
rbl	O
cells	O
were	O
created	O
that	O
exclusively	O
express	O
the	O
human	O
fcεriα	B-C0162825
subunit	O
.	O
	
pen	B-C0531911
a	I-C0531911
1	I-C0531911
-	O
specific	B-C0443736
ige	I-C0443736
was	O
affinity	O
purified	O
from	O
shrimp	B-C0037017
-	O
positive	B-C1514241
plasma	B-C0032105
.	O
	
cells	O
primed	O
with	O
a	O
range	O
of	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
-	O
specific	B-C0443736
ige	I-C0443736
and	O
challenged	O
with	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
showed	O
a	O
bell-shaped	O
dose	B-C0178602
response	B-C3155125
for	I-C3155125
secretion	I-C3155125
,	O
with	O
optimal	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
doses	B-C0178602
of	O
0.1	O
ng/ml	O
.	O
	
mathematical	B-C0876936
modeling	I-C0876936
provided	O
estimates	O
of	O
receptor	B-C0034780
aggregation	I-C0034780
kinetics	B-C0022702
based	O
on	O
fcεri	B-C0162825
occupancy	O
with	O
ige	B-C0020846
and	O
allergen	B-C0002092
dose	B-C0178602
.	O
	
maximal	O
degranulation	O
was	O
elicited	O
when	O
2700	O
i	O
ge	B-C1270759
-	O
fcεri	B-C0162825
complexes	B-C0003313
were	O
occupied	O
with	O
specific	B-C1270759
ige	I-C1270759
and	O
challenged	O
with	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
ige	B-C1270759
epitope	B-C0003316
valency	B-C0392762
of	O
8	O
,	O
although	O
measurable	O
responses	O
were	O
achieved	O
when	O
only	O
a	O
few	O
hundred	O
fcεri	B-C0162825
were	O
occupied	O
.	O
	
prolonged	O
periods	O
of	O
pepsin	B-C0030909
-mediated	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
proteolysis	B-C0597304
,	O
which	O
simulates	O
gastric	B-C1704242
digestion	B-C0012238
,	O
were	O
required	O
to	O
diminish	O
secretory	B-C1327439
responses	I-C1327439
.	O
	
recombinant	B-C0599286
fragments	I-C0599286
60-79	O
aa	O
,	O
which	O
together	O
span	O
the	O
entire	O
length	O
of	O
tropomyosin	B-C0041197
,	O
were	O
weak	O
secretagogues	O
.	O
	
these	O
fragments	O
have	O
reduced	O
dimerization	B-C1323329
capacity	B-C1516240
,	O
compete	O
with	O
intact	O
pen	B-C0531911
a	I-C0531911
1	I-C0531911
for	O
binding	O
to	O
ige	B-C1270759
-	O
fcεri	B-C0162825
complexes	B-C0003313
,	O
and	O
represent	O
a	O
starting	O
point	O
for	O
the	O
design	O
of	O
promising	O
hypoallergens	B-C0002092
for	O
selected	B-C1707391
flavonoid	B-C0596577
compounds	I-C0596577
as	O
promising	O
inhibitors	B-C0243077
of	O
protein	B-C0108555
kinase	I-C0108555
ck2α	B-C1173607
and	O
ck2α'	B-C1449828
,	O
the	O
catalytic	B-C0600499
subunits	I-C0600499
of	O
ck2	B-C0108555
ck2	B-C0108555
is	O
a	O
ubiquitous	O
protein	B-C0108555
kinase	I-C0108555
involved	O
in	O
many	O
cell	B-C0007613
functions	I-C0007613
.	O
	
during	O
the	O
last	O
years	B-C0439234
it	O
became	O
an	O
interesting	O
target	B-C1521840
in	O
cancer	B-C1516225
research	I-C1516225
.	O
	
a	O
series	O
of	O
flavonoid	B-C0596577
compounds	I-C0596577
was	O
tested	B-C0039593
as	O
inhibitors	B-C0243077
of	O
protein	B-C0108555
kinase	I-C0108555
ck2	B-C0108555
.	O
	
several	O
substances	B-C0439861
were	O
found	O
to	O
be	O
highly	B-C0205250
active	B-C3858674
against	I-C3858674
both	O
catalytic	B-C0600499
subunits	I-C0600499
with	O
ic50	B-C0600495
values	B-C0042295
below	O
1	O
μm	O
in	O
case	O
of	O
ck2α'	B-C1449828
.	O
	
the	O
most	O
promising	O
inhibitor	B-C0243077
we	O
identified	B-C0205396
is	O
chrysoeriol	B-C0602970
with	O
ic50	B-C0600495
values	B-C0042295
of	O
250	O
and	O
34	O
nm	O
for	O
ck2α	B-C1173607
and	O
ck2α'	B-C1449828
,	O
fibrinogen	B-C0016006
a	O
marker	B-C0005516
in	O
predicting	O
diabetic	B-C1456868
foot	I-C1456868
ulcer	I-C1456868
severity	B-C0392364
aims	O
.	O
	
to	O
examine	B-C0220825
whether	O
fibrinogen	B-C1318051
levels	I-C1318051
are	O
a	O
valuable	O
biomarker	B-C0005516
for	O
assessing	B-C0220825
disease	B-C0521117
severity	I-C0521117
and	O
monitoring	B-C1283169
disease	B-C0242656
progression	I-C0242656
in	O
patients	B-C0030705
with	O
diabetic	B-C1456868
foot	I-C1456868
ulcer	I-C1456868
dfu	B-C1456868
.	O
	
methods	O
.	O
	
a	O
retrospective	B-C0035363
study	I-C0035363
was	O
designed	O
to	O
examine	O
the	O
utility	B-C0457083
of	O
fibrinogen	B-C0016006
in	O
estimating	O
disease	B-C0521117
severity	I-C0521117
in	O
patients	B-C0030705
with	O
dfu	B-C1456868
admitted	B-C0809949
to	O
our	O
hospital	B-C0019994
between	O
january	B-C3829466
2015	O
and	O
january	B-C3829466
2016	O
.	O
	
in	O
total	O
,	O
152	O
patients	B-C0030705
with	O
dfu	B-C1456868
were	O
enrolled	O
in	O
the	O
study	B-C0681860
group	I-C0681860
,	O
and	O
52	O
age	O
and	O
gender	B-C0079399
matched	O
people	B-C0030705
with	O
diabetes	B-C0011849
but	O
no	O
dfu	B-C1456868
were	O
included	O
as	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
dfu	B-C1456868
severity	B-C0392364
was	O
assessed	O
using	O
wagner	O
criteria	O
.	O
	
results	O
.	O
	
patients	B-C0030705
with	O
dfu	B-C1456868
were	O
divided	O
into	O
2	O
subgroups	B-C1515021
based	O
on	O
the	O
wagner	O
criteria	O
.	O
	
mean	O
fibrinogen	B-C1318051
values	I-C1318051
were	O
significantly	B-C4055637
higher	I-C4055637
in	O
patients	B-C0030705
with	O
dfu	B-C1456868
grade	B-C0441800
3	O
compared	O
to	O
those	O
with	O
dfu	B-C1456868
grades	B-C0441800
1-2	O
5.23	O
1.37	O
g/l	O
versus	O
3.61	O
1.04	O
g/l	O
.	O
	
using	O
roc	B-C0034772
statistic	I-C0034772
,	O
a	O
cut-off	B-C1522609
value	I-C1522609
of	O
5.13	O
g/l	O
indicated	O
the	O
possible	O
amputation	B-C0002688
with	O
a	O
sensitivity	B-C0036667
of	O
81.8	O
and	O
a	O
specificity	B-C0037791
of	O
78.9	O
positive	B-C1514243
predictive	I-C1514243
value	I-C1514243
ppv	B-C1514243
78.6	O
,	O
negative	B-C1513918
predictive	I-C1513918
value	I-C1513918
89.0	O
.	O
	
fibrinogen	B-C1318051
values	I-C1318051
were	O
found	O
to	O
be	O
correlated	O
with	O
crp	B-C0428528
levels	I-C0428528
,	O
neutrophil	B-C0200633
,	O
and	O
wbc	B-C0023508
count	I-C0023508
.	O
	
conclusions	O
.	O
	
fibrinogen	B-C1318051
levels	I-C1318051
might	O
be	O
a	O
valuable	O
tool	O
for	O
assessing	B-C0220825
the	O
disease	B-C0521117
severity	I-C0521117
and	O
monitoring	B-C1283169
the	O
disease	B-C0242656
progression	I-C0242656
in	O
patients	B-C0030705
with	O
nitrogen	B-C1158469
utilization	I-C1158469
efficiency	B-C0013682
and	O
prediction	B-C0681842
of	O
nitrogen	B-C0028158
excretion	B-C0221102
in	O
sheep	B-C0036945
offered	B-C1444648
fresh	B-C0331558
perennial	I-C0331558
ryegrass	I-C0331558
nitrogen	B-C0028158
excretion	B-C0221102
from	O
sheep	B-C0036945
production	B-C0557759
systems	I-C0557759
is	O
an	O
important	O
source	O
of	O
nitrate	B-C0699857
,	O
ammonia	B-C0002607
,	O
and	O
nitrous	B-C0028215
oxide	I-C0028215
responsible	O
for	O
groundwater	B-C0596631
pollution	B-C0392355
and	O
global	B-C0206217
warming	I-C0206217
.	O
	
the	O
present	O
study	B-C2603343
aimed	O
to	O
identify	B-C0205396
key	B-C1706198
parameters	I-C1706198
influencing	O
n	B-C1158469
utilization	I-C1158469
efficiency	B-C0013682
and	O
develop	O
prediction	B-C0681842
equations	B-C0552449
for	O
manure	B-C0024765
n	B-C0028158
,	O
feces	B-C0015733
n	B-C0028158
,	O
and	O
urine	B-C0042036
n	B-C0028158
outputs	B-C1709366
in	O
sheep	B-C0036945
.	O
	
data	B-C1511726
used	O
were	O
collected	O
from	O
82	O
sheep	B-C0036945
offered	B-C1444648
fresh	B-C0331558
perennial	I-C0331558
ryegrass	I-C0331558
as	O
the	O
sole	B-C0012155
diet	I-C0012155
in	O
6	O
metabolism	B-C0025519
experiments	B-C0681814
data	B-C1511726
from	O
non-grass-only	B-C0012155
diets	I-C0012155
were	O
not	B-C0445107
used	I-C0445107
.	O
	
sheep	B-C0036945
were	O
from	O
breeds	B-C1704650
of	O
highlander	B-C0027361
,	O
texel	B-C1297013
,	O
scottish	B-C0324108
blackface	I-C0324108
,	O
and	O
swaledale	B-C1296242
at	O
the	O
age	B-C0001779
of	O
5	O
to	O
18	O
mo	B-C0439231
and	O
weighing	O
from	O
24.5	O
to	O
62.7	O
kg	O
.	O
	
herbage	B-C0242775
was	O
harvested	B-C1522240
daily	B-C0332173
from	O
6	O
swards	B-C2700402
of	O
contrasting	O
harvest	B-C1522240
dates	B-C0011008
may	O
to	O
december	O
,	O
offering	B-C1444648
wide	O
variation	B-C0205419
in	O
feed	O
value	O
to	O
cover	O
the	O
range	B-C1514721
that	O
would	O
be	O
offered	B-C1444648
in	O
most	O
practical	O
farm	B-C0557759
situations	I-C0557759
.	O
	
before	O
the	O
commencement	O
of	O
each	O
study	B-C2603343
,	O
the	O
experimental	B-C1517586
sward	B-C2700402
was	O
harvested	B-C1522240
at	O
a	O
residual	B-C0489786
height	I-C0489786
of	O
4	O
cm	O
and	O
allowed	O
to	O
grow	B-C0018270
for	O
2	O
to	O
4	O
wk	B-C0439230
to	O
target	B-C1521840
an	O
average	O
pregrazing	O
sward	B-C2700402
height	B-C0489786
in	O
a	O
range	B-C1514721
of	O
8	O
to	O
15	O
cm	O
depending	B-C3244310
on	O
the	O
time	B-C0556970
of	I-C0556970
year	I-C0556970
.	O
	
sheep	B-C0036945
were	O
housed	B-C0557759
in	O
individual	O
pens	O
for	O
14	O
d	B-C0439228
and	O
then	O
transferred	B-C4049693
to	I-C4049693
individual	O
metabolism	B-C0025519
crates	O
for	O
4	O
d	B-C0439228
with	O
feed	B-C3853577
intake	B-C1512806
and	O
feces	B-C0015733
and	O
urine	B-C0042036
outputs	B-C1709366
measured	O
.	O
	
data	B-C1511726
were	O
analyzed	B-C0936012
using	O
the	O
linear	B-C0023732
mixed	I-C0023732
model	I-C0023732
procedure	I-C0023732
to	O
develop	O
prediction	B-C0681842
equations	B-C0552449
for	O
feces	B-C0015733
n	O
,	O
urine	B-C0042036
n	O
,	O
and	O
manure	B-C0024765
n	B-C0028158
outputs	B-C1709366
using	O
n	B-C0556048
intake	I-C0556048
,	O
herbage	B-C0242775
chemical	B-C0243176
composition	I-C0243176
,	O
and	O
digestibility	B-C1522240
with	O
effects	B-C1704420
of	I-C1704420
sex	B-C0079399
,	O
breed	B-C1704650
,	O
and	O
experimental	O
periods	B-C1948053
removed	B-C0849355
.	O
	
nitrogen	B-C0028158
intake	B-C1512806
was	O
the	O
best	B-C1522427
single	B-C2698872
predictor	I-C2698872
for	O
n	B-C0028158
output	B-C1709366
in	O
feces	B-C0015733
,	O
urine	B-C0042036
,	O
and	O
manure	B-C0024765
,	O
and	O
the	O
value	O
for	O
prediction	B-C0681842
of	O
manure	B-C0024765
n	B-C0028158
output	B-C1709366
was	O
greater	B-C1704243
than	O
those	O
for	O
feces	B-C0015733
n	B-C0028158
and	O
urine	B-C0042036
n	B-C0028158
0.86	O
vs	O
.	O
	
0.70	O
and	O
0.77	O
,	O
respectively	O
<	O
0.001	O
.	O
	
animal	B-C0003062
bw	B-C0005910
and	O
herbage	B-C0242775
dm	B-C0439861
,	O
ether	B-C0457929
extract	I-C0457929
,	O
ndf	B-C0012173
,	O
adf	B-C0012173
,	O
water	B-C0201929
soluble	I-C0201929
carbohydrate	I-C0201929
,	O
and	O
de	O
concentrations	O
and	O
n	B-C0028158
digestibility	B-C1522240
were	O
also	O
used	O
to	O
predict	B-C0681842
n	B-C0028158
outputs	B-C1709366
because	O
n	B-C0028158
intake	B-C1512806
may	O
not	B-C0686905
be	I-C0686905
available	I-C0686905
in	O
commercial	B-C0009433
practice	I-C0009433
.	O
	
the	O
prediction	B-C0681842
equations	B-C0552449
for	O
n	B-C1158469
utilizatio	I-C1158469
n	O
efficiency	B-C0013682
indicated	O
that	O
increasing	B-C0442808
feeding	B-C2987508
level	B-C0441889
and	O
me	B-C1442080
concentration	B-C1446561
and	O
reducing	B-C0392756
n	B-C0456228
concentration	I-C0456228
could	O
improve	B-C0184511
n	B-C1158469
utilization	I-C1158469
efficiency	B-C0013682
and	O
shift	O
n	B-C0028158
excretion	B-C0221102
into	O
feces	B-C0015733
rather	B-C3897775
than	I-C3897775
urine	B-C0042036
<	O
0.001	O
.	O
	
the	O
equations	B-C0552449
developed	O
in	O
the	O
current	O
study	B-C2603343
provide	O
an	O
approach	B-C0449445
for	O
sheep	B-C0036945
producers	B-C1709696
to	O
quantify	B-C1709793
n	B-C0028158
excretion	B-C0221102
against	O
production	B-C0033268
and	O
,	O
consequently	O
,	O
to	O
develop	O
their	O
own	O
mitigation	B-C0035171
strategies	I-C0035171
to	O
reduce	B-C0392756
the	O
environmental	B-C0282165
impact	I-C0282165
of	O
sheep	B-C0036945
production	B-C0557759
systems	I-C0557759
.	O
	
improving	B-C1272745
protein	B-C1180347
complex	I-C1180347
prediction	B-C0681842
by	O
reconstructing	B-C0282574
a	O
high-confidence	B-C1704725
protein-protein	B-C3178902
interaction	I-C3178902
network	I-C3178902
of	O
escherichia	B-C0014834
coli	I-C0014834
from	O
different	O
physical	B-C1704675
interaction	I-C1704675
data	B-C0011001
sources	I-C0011001
although	O
different	O
protein-protein	B-C0872079
physical	I-C0872079
interaction	I-C0872079
ppi	B-C0872079
datasets	B-C0150098
exist	O
for	O
escherichia	B-C0014834
coli	I-C0014834
,	O
no	O
common	O
methodology	B-C3266812
exists	O
to	O
integrate	B-C1705422
these	O
datasets	B-C0150098
and	O
extract	O
reliable	O
modules	B-C1709061
reflecting	O
the	O
existing	O
biological	B-C3714634
process	I-C3714634
and	O
protein	B-C1180347
complexes	I-C1180347
.	O
	
naïve	B-C0489829
bayesian	I-C0489829
formula	I-C0489829
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	B-C1705422
different	O
ppi	B-C0872079
datasets	B-C0150098
into	O
a	O
single	O
weighted	B-C0043100
ppi	B-C3178902
network	I-C3178902
,	O
but	O
detecting	O
proper	O
weights	B-C0043100
in	O
such	O
network	B-C1882071
is	O
still	O
a	O
major	O
problem	O
.	O
	
in	O
this	O
paper	O
,	O
we	O
proposed	O
a	O
new	O
methodology	B-C3266812
to	O
integrate	B-C1705422
various	O
physical	B-C0872079
ppi	I-C0872079
datasets	B-C0150098
into	O
a	O
single	O
weighted	B-C0043100
ppi	B-C3178902
network	I-C3178902
in	O
a	O
way	O
that	O
the	O
detected	B-C0442726
modules	B-C1709061
in	O
ppi	B-C3178902
network	I-C3178902
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	B-C0205245
modules	B-C1709061
.	O
	
we	O
used	O
the	O
co-expression	B-C0185117
modules	B-C1709061
as	O
functional	B-C0205245
modules	B-C1709061
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	B-C0205245
modules	B-C1709061
detected	B-C0442726
from	O
gene	B-C1138831
ontology	I-C1138831
terms	B-C1254370
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	B-C0150098
.	O
	
after	O
running	O
this	O
integrating	B-C1705422
methodology	B-C3266812
over	O
six	O
different	O
physical	B-C0872079
ppi	I-C0872079
datasets	B-C0150098
,	O
orthologous	B-C1709346
high-confidence	B-C1704725
interactions	B-C1704675
from	O
a	O
related	O
organism	B-C0029235
and	O
two	O
ap-ms	B-C0037813
ppi	B-C0872079
datasets	B-C0150098
gained	B-C0043094
high	I-C0043094
weights	I-C0043094
in	O
the	O
integrated	B-C1705422
networks	B-C1882071
,	O
while	O
the	O
weights	B-C0043100
for	O
one	O
ap-ms	B-C0037813
ppi	B-C0872079
dataset	B-C0150098
and	O
two	O
other	O
datasets	B-C0150098
derived	O
from	O
public	B-C0242356
databases	I-C0242356
have	O
converged	O
to	O
zero	O
.	O
	
the	O
majority	O
of	O
detected	B-C0442726
modules	B-C1709061
shaped	O
around	O
one	O
or	O
few	O
hub	B-C3179452
protein	I-C3179452
.	O
	
still	O
,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	B-C0033684
modules	B-C1709061
were	O
detected	B-C0442726
which	O
are	O
functionally	B-C0205245
relevant	B-C2347946
and	O
are	O
likely	O
to	O
construct	B-C2827421
protein	B-C1180347
complexes	I-C1180347
.	O
	
we	O
provided	O
a	O
new	O
high	B-C1704725
confidence	I-C1704725
protein	B-C1180347
complex	I-C1180347
prediction	B-C0681842
method	O
supported	O
by	O
functional	B-C0205245
studies	O
and	O
literature	B-C0023866
aav9	B-C1564874
-	O
npc1	B-C1417776
significantly	B-C0750502
ameliorates	B-C0243095
purkinje	B-C0034143
cell	I-C0034143
death	B-C0007587
and	O
behavioral	B-C0233514
abnormalities	I-C0233514
in	O
mouse	B-C0025929
npc	B-C0220756
disease	I-C0220756
niemann-pick	B-C0220756
type	I-C0220756
c	I-C0220756
npc	I-C0220756
disease	I-C0220756
is	O
a	O
fatal	B-C1302234
inherited	B-C0439660
neurodegenerative	B-C0524851
disorder	I-C0524851
caused	O
by	O
loss-of-function	B-C0243095
mutations	B-C0026882
in	O
the	O
npc1	B-C1417776
or	O
npc2	B-C1422736
gene	I-C1422736
.	O
	
there	O
is	O
no	O
effective	O
way	O
to	O
treat	B-C1292734
npc	B-C0220756
disease	I-C0220756
.	O
	
in	O
this	O
study	O
,	O
we	O
used	O
adeno-associated	B-C1564874
virus	I-C1564874
aav	B-C1564874
serotype	B-C0449943
9	I-C0449943
aav9	B-C1564874
to	O
deliver	O
a	O
functional	B-C0205245
npc1	B-C1417776
gene	I-C1417776
systemically	B-C0205373
into	O
npc1	B-C1417776
mice	B-C0206745
at	O
postnatal	B-C0419611
day	I-C0419611
4	I-C0419611
.	O
	
one	O
single	B-C0205171
aav9-npc1	B-C0021485
injection	I-C0021485
resulted	O
in	O
robust	B-C2986815
npc1	B-C1417776
expression	B-C0017262
in	O
various	O
tissues	B-C0040300
,	O
including	O
brain	B-C0006104
,	O
heart	B-C0018787
,	O
and	O
lung	B-C0024109
.	O
	
strikingly	O
,	O
aav9-mediated	B-C0086597
npc1	B-C1524066
delivery	I-C1524066
significantly	B-C0750502
promoted	B-C0033414
purkinje	B-C0034143
cell	I-C0034143
survival	B-C0038952
,	O
restored	O
locomotor	B-C0023946
activity	I-C0023946
and	O
coordination	B-C0237543
,	O
and	O
increased	B-C0205217
the	O
lifespan	B-C1254367
of	O
npc1	B-C1417776
mice	B-C0206745
.	O
	
our	O
work	O
suggests	O
that	O
aav-based	B-C0860404
gene	I-C0860404
therapy	I-C0860404
is	O
a	O
promising	O
means	O
to	O
treat	B-C1292734
npc	B-C0220756
disease	I-C0220756
.	O
	
executive	B-C0935584
functions	I-C0935584
deficits	B-C2987487
impair	B-C0221099
extinction	B-C0015347
of	O
generalization	B-C0017324
of	O
fear	B-C0015726
of	O
movement-related	B-C0240386
pain	I-C0240386
generalization	B-C0017324
of	O
fear	B-C0015726
of	O
movement-related	B-C0240386
pain	I-C0240386
across	O
novel	O
but	O
similar	O
movements	B-C0026649
can	O
lead	O
to	O
fear	B-C1327613
responses	I-C1327613
to	O
movements	B-C0026649
that	O
are	O
actually	O
not	O
associated	B-C0332281
with	I-C0332281
pain	B-C0030193
.	O
	
the	O
peak-shift	B-C1280500
effect	I-C1280500
describes	O
a	O
phenomenon	B-C1882365
whereby	O
particular	O
novel	O
movements	B-C0026649
elicit	B-C0449265
even	O
greater	O
fear	B-C1327613
responses	I-C1327613
than	O
the	O
original	O
pain-provoking	B-C1960719
movement	B-C0026649
cs+	B-C0234404
,	O
because	O
they	O
represent	O
a	O
more	O
extreme	O
version	O
of	O
the	O
cs+	B-C0234404
.	O
	
there	O
is	O
great	O
variance	B-C1711260
in	O
the	O
propensity	O
to	O
generalize	B-C0017324
as	O
well	O
as	O
the	O
speed	O
of	O
extinction	B-C0237613
learning	I-C0237613
when	O
these	O
novel	O
movements	B-C0026649
are	O
not	O
followed	O
by	O
pain	B-C0030193
.	O
	
it	O
can	O
be	O
argued	O
that	O
this	O
variance	B-C1711260
may	O
be	O
associated	B-C0332281
with	I-C0332281
executive	B-C0935584
function	I-C0935584
capacity	I-C0935584
,	O
as	O
individuals	B-C0237401
may	O
be	O
unable	O
to	O
intentionally	O
inhibit	B-C3894332
fear	I-C3894332
responses	I-C3894332
.	O
	
this	O
study	O
examined	B-C0332128
whether	O
executive	B-C0935584
function	I-C0935584
capacity	I-C0935584
contributes	O
to	O
generalization	B-C0017324
and	O
extinction	B-C0015347
of	O
generalization	B-C0017324
as	O
well	O
as	O
peak-shift	B-C0333051
of	O
conditioned	B-C1510535
fear	I-C1510535
of	O
movement-related	B-C0240386
pain	I-C0240386
and	O
expectancy	B-C0679138
.	O
	
healthy	B-C1708335
participants	I-C1708335
performed	O
a	O
proprioceptive	B-C2370956
fear	B-C0009647
conditioning	I-C0009647
task	I-C0009647
.	O
	
executive	B-C0935584
function	I-C0935584
tests	I-C0935584
assessing	O
updating	B-C1519814
,	O
switching	O
,	O
and	O
inhibition	B-C0021467
were	O
used	O
to	O
predict	O
changes	O
in	O
extinction	B-C0015347
of	O
fear	B-C0015726
of	O
movement-related	B-C0240386
pain	I-C0240386
and	O
pain	B-C0030193
expectancy	B-C0679138
generalization	B-C0017324
.	O
	
low	B-C0021467
inhibitory	I-C0021467
capacity	I-C0021467
was	O
associated	B-C0332281
with	I-C0332281
slower	O
extinction	B-C0015347
of	O
generalized	B-C0015726
fear	I-C0015726
of	O
movement-related	B-C0240386
pain	I-C0240386
and	O
pain	B-C0030193
expectancy	B-C0679138
.	O
	
evidence	O
was	O
found	O
in	O
favor	O
of	O
an	O
area-shift	B-C0333051
,	O
rather	O
than	O
a	O
peak-shift	B-C1280500
effect	I-C1280500
,	O
which	O
implies	O
that	O
the	O
peak	B-C0444505
conditioned	B-C1327613
fear	I-C1327613
response	I-C1327613
extended	O
to	O
,	O
but	O
did	O
not	O
shift	O
to	O
a	O
novel	O
stimulus	B-C0234402
.	O
	
participants	B-C0679646
with	O
low	O
inhibitory	B-C0021467
capacity	I-C0021467
may	O
have	O
difficulties	O
withholding	O
fear	B-C1327613
responses	I-C1327613
,	O
leading	O
to	O
a	O
slower	O
decrease	O
of	O
generalized	B-C0015726
fear	I-C0015726
over	O
time	B-C0040223
.	O
	
the	O
findings	B-C0243095
may	O
be	O
relevant	O
to	O
inform	O
treatments	B-C1522326
.	O
	
low	B-C0021467
inhibitory	I-C0021467
capacity	I-C0021467
is	O
not	O
associated	B-C0332281
with	I-C0332281
slower	O
generalization	B-C0017324
,	O
but	O
extinction	B-C0015347
of	O
fear	B-C0015726
generalization	B-C0017324
.	O
	
fear	B-C0015726
elicited	B-C0449265
by	I-C0449265
a	O
novel	O
safe	O
movement	B-C0026649
,	O
situated	O
outside	O
the	O
cs+/-	B-C0234404
continuum	O
on	O
the	O
cs+	B-C0234404
side	O
,	O
can	O
be	O
as	O
strong	O
as	O
to	O
the	O
original	O
stimulus	B-C0234402
predicting	O
the	O
robust	B-C2986815
dlpp	B-C0392762
with	O
nongreedy	B-C0205556
ℓ₁	I-C0205556
minimization	I-C0205556
and	O
maximization	B-C0205556
recently	O
,	O
discriminant	B-C0392762
locality	I-C0392762
preserving	I-C0392762
projection	I-C0392762
based	I-C0392762
on	I-C0392762
l1-norm	I-C0392762
dlpp-l1	B-C0392762
was	O
developed	O
for	O
robust	B-C2986815
subspace	B-C0023185
learning	I-C0023185
and	O
image	B-C1704922
classification	B-C0008902
.	O
	
it	O
obtains	O
projection	B-C0348018
vectors	B-C0442335
by	O
greedy	B-C0035171
strategy	I-C0035171
,	O
i.e	O
,	O
all	O
projection	B-C0348018
vectors	B-C0442335
are	O
optimized	O
individually	O
through	O
maximizing	B-C0205556
the	O
objective	B-C1571702
function	B-C0542341
.	O
	
thus	O
,	O
the	O
obtained	O
solution	B-C1706817
does	O
not	O
necessarily	O
best	O
optimize	O
the	O
corresponding	O
trace	B-C0002045
ratio	I-C0002045
optimization	I-C0002045
algorithm	I-C0002045
,	O
which	O
is	O
the	O
essential	O
objective	B-C1571702
function	B-C0542341
for	O
general	O
dimensionality	B-C0282574
reduction	I-C0282574
.	O
	
it	O
results	O
in	O
insufficient	O
recognition	B-C0237818
accuracy	B-C0443131
.	O
	
to	O
tackle	O
this	O
problem	O
,	O
we	O
propose	O
a	O
nongreedy	B-C0002045
algorithm	I-C0002045
to	O
solve	O
the	O
trace	B-C0489829
ratio	I-C0489829
formula	I-C0489829
of	O
dlpp-l1	B-C0392762
,	O
and	O
analyze	O
its	O
convergence	B-C2700387
.	O
	
experimental	O
results	O
on	O
three	O
databases	B-C0242356
illustrate	O
the	O
effectiveness	O
of	O
our	O
proposed	O
a	O
double-blind	B-C0013072
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
of	O
maternal	B-C0157460
postpartum	I-C0157460
deworming	B-C0199859
to	O
improve	O
infant	B-C0021270
weight	B-C0043094
gain	I-C0043094
in	O
the	O
peruvian	B-C1553375
amazon	O
nutritional	B-C0086153
interventions	I-C0086153
targeting	O
the	O
critical	B-C1511545
growth	B-C1397007
and	I-C1397007
development	I-C1397007
period	I-C1397007
before	O
two	O
years	O
of	O
age	B-C0001779
can	O
have	O
the	O
greatest	O
impact	O
on	O
health	B-C0018684
trajectories	B-C0750729
over	O
the	O
life	B-C1510618
course	I-C1510618
.	O
	
compelling	O
evidence	B-C3887511
has	O
demonstrated	O
that	O
interventions	B-C0808232
investing	O
in	O
maternal	B-C0024921
health	I-C0024921
in	O
the	O
first	O
1000	O
days	B-C0439228
of	O
life	B-C0376558
are	O
beneficial	O
for	O
both	O
mothers	B-C0026591
and	O
their	O
children	B-C0680063
.	O
	
one	O
such	O
potential	O
intervention	B-C0808232
is	O
deworming	B-C0199859
integrated	O
into	O
maternal	B-C0545491
postpartum	I-C0545491
care	I-C0545491
in	O
areas	B-C0205146
where	O
soil	B-C0037592
-	O
transmitted	B-C0332289
helminth	B-C0018893
sth	B-C0018893
infections	B-C0018889
are	O
endemic	B-C0277550
.	O
	
from	O
february	B-C3830166
to	O
august	B-C3831448
2014	O
,	O
1010	O
mother	B-C0026591
-	O
infant	B-C0021270
pairs	O
were	O
recruited	O
into	O
a	O
trial	B-C0008976
aimed	O
at	O
assessing	B-C0220825
the	O
effectiveness	B-C1280519
of	O
maternal	B-C0157460
postpartum	I-C0157460
deworming	B-C0199859
on	O
infant	B-C0021270
and	O
maternal	B-C0024921
health	I-C0024921
outcomes	B-C0085415
.	O
	
following	B-C0332282
delivery	B-C0005615
,	O
mothers	B-C0026591
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
single-	O
dose	B-C0178602
400	O
mg	O
albendazole	B-C0001911
or	O
placebo	B-C1696465
.	O
	
participants	B-C0679646
were	O
followed-up	B-C1522577
at	O
1	B-C4082115
and	O
6	B-C4082120
months	I-C4082120
postpartum	B-C0086839
.	O
	
there	O
was	O
no	B-C1273937
statistically	I-C1273937
significant	I-C1273937
difference	B-C1705241
in	O
mean	O
weight	B-C0043094
gain	I-C0043094
between	O
infants	B-C0021270
in	O
the	O
experimental	B-C0237950
and	O
control	B-C0009932
groups	I-C0009932
mean	B-C0392762
difference	I-C0392762
-0	O
95%	O
ci	B-C0009667
-0	O
,	O
0.08	O
at	O
6	B-C4082120
months	I-C4082120
of	O
age	B-C0001779
.	O
	
further	O
,	O
deworming	B-C0199859
had	O
no	B-C1301751
effect	I-C1301751
on	O
measured	O
infant	B-C0848889
morbidity	I-C0848889
indicators	B-C0018761
.	O
	
however	O
,	O
ad	B-C0026348
hoc	I-C0026348
analyses	I-C0026348
restricted	O
to	O
mothers	B-C0026591
who	O
tested	O
positive	B-C1514241
for	O
sths	B-C0018893
at	O
baseline	B-C1442488
suggest	O
that	O
infants	B-C0021270
of	O
mothers	B-C0026591
in	O
the	O
experimental	O
group	O
had	O
greater	O
mean	O
length	B-C0005890
gain	B-C1517378
in	O
cm	O
mean	B-C0392762
difference	I-C0392762
0.8	O
95%	O
ci	B-C0009667
0.1	O
,	O
1.4	O
and	O
length-for-age	B-C0449820
z-score	I-C0449820
mean	B-C0392762
difference	I-C0392762
0.5	O
95%	O
ci	B-C0009667
0.2	O
,	O
0.8	O
at	O
6	B-C4082120
months	I-C4082120
of	O
age	B-C0001779
.	O
	
in	O
a	O
study	B-C2348561
population	I-C2348561
composed	O
of	O
both	O
sth-infected	B-C0018889
and	O
uninfected	B-C3898900
mothers	B-C0026591
,	O
maternal	B-C0157460
postpartum	I-C0157460
deworming	B-C0199859
was	O
insufficient	B-C0231180
to	O
impact	O
infant	B-C0021270
growth	B-C0018270
and	O
morbidity	B-C0848889
indicators	B-C0018761
up	O
to	O
6	B-C4082120
months	I-C4082120
postpartum	B-C0086839
.	O
	
among	O
sth-infected	B-C0018889
mothers	B-C0026591
,	O
however	O
,	O
important	O
improvements	O
in	O
infant	B-C0021270
length	O
gain	O
and	O
length-for-age	B-C0517420
were	O
observed	O
.	O
	
the	O
benefits	O
of	O
maternal	B-C0157460
postpartum	I-C0157460
deworming	B-C0199859
should	O
be	O
further	O
investigated	O
in	O
study	B-C2348561
populations	I-C2348561
having	O
higher	O
overall	O
prevalences	B-C0033105
and	O
intensities	B-C4049786
of	O
sth	B-C0018889
infections	I-C0018889
and	O
,	O
in	O
particular	O
,	O
where	O
whipworm	B-C0040954
and	O
hookworm	B-C0019911
infections	I-C0019911
are	O
of	O
public	B-C0034024
health	I-C0034024
concern	I-C0034024
.	O
	
technical	O
note	O
a	O
preliminary	B-C0439611
comparative	B-C1579762
study	I-C1579762
between	O
classical	B-C0443177
and	O
interventional	B-C0034602
radiological	I-C0034602
approaches	I-C0034602
for	O
multi-phase	B-C0205390
post-mortem	B-C3697228
ct	I-C3697228
angiography	B-C0002978
multi-phase	B-C0205390
post-mortem	B-C1536105
computed	I-C1536105
tomography	I-C1536105
angiography	I-C1536105
mpmcta	B-C1536105
is	O
a	O
new	B-C0205314
diagnostic	B-C0430022
tool	I-C0430022
,	O
used	O
in	O
forensic	B-C1450224
pathology	I-C1450224
.	O
	
on	O
the	O
one	O
hand	O
,	O
this	O
technique	B-C0449851
allows	O
a	O
better	O
and	O
direct	B-C3846514
visualization	I-C3846514
of	O
vascular	B-C1402315
and	O
solid	B-C0440790
organ	I-C0440790
lesions	B-C0221198
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
invasiveness	B-C1301757
of	O
the	O
procedure	B-C2700391
-which	O
requires	O
surgical	B-C0243095
denudation	I-C0243095
inguinal	B-C0018246
and/or	O
cervical	B-C0205064
and	O
the	O
insertion	B-C0021107
of	O
surgical	B-C0520453
cannulas	I-C0520453
-leads	O
to	O
many	O
relatives	B-C0080103
refusing	B-C1705116
scientific	B-C0004398
autopsies	I-C0004398
.	O
	
our	O
hypothesis	B-C1512571
states	O
that	O
a	O
minimally-invasive	B-C2711297
procedure	I-C2711297
combining	O
interventional	B-C0344093
radiological	I-C0344093
techniques	I-C0344093
with	O
mpmcta	B-C1536105
replacement	B-C0559956
of	O
surgical	B-C0520453
cannulas	I-C0520453
by	O
radiological	B-C0085590
catheters	I-C0085590
will	O
improve	B-C0184511
the	O
approval	B-C0205540
rate	B-C1521828
of	O
scientific	B-C0004398
autopsies	I-C0004398
by	O
families	B-C0015576
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
feasibility	B-C0015730
of	O
the	O
minimally-invasive	B-C2711297
mpmcta	B-C1536105
approach	O
and	O
to	O
compare	B-C1707455
its	O
performance	B-C1882330
to	O
the	O
current	B-C0521116
reference-standard	B-C0034925
the	O
conventional	O
approach	O
.	O
	
we	O
included	O
consecutively	B-C1707491
16	O
corpses	B-C0006629
divided	O
in	O
two	O
groups	B-C0441833
according	O
to	O
the	O
contrast	B-C1979874
enhancement	B-C2349975
approach	O
radiological	B-C0085590
catheters	I-C0085590
n=8	O
,	O
and	O
surgical	B-C0520453
cannulas	I-C0520453
n=8	O
.	O
	
corpses	B-C0006629
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	B-C1511726
.	O
	
the	O
quality	B-C0332306
of	O
the	O
imaging	B-C0011923
procedure	I-C0011923
was	O
compared	B-C1707455
according	O
to	O
four	O
items	O
global	B-C0005847
vascular	I-C0005847
opacification	B-C0449584
,	O
cerebral	B-C0449584
venous	I-C0449584
opacification	I-C0449584
,	O
and	O
lower	B-C0023216
limbs	I-C0023216
opacification	B-C0449584
arterial	B-C0221464
and	O
venous	B-C0348013
.	O
	
a	O
minimally-invasive	B-C2711297
approach	I-C2711297
for	O
scientific	B-C0004398
autopsies	I-C0004398
is	O
feasible	O
through	O
a	O
radiological	B-C0085590
catheter	I-C0085590
.	O
	
vascular	B-C0005847
opacification	B-C0449584
was	O
optimal	B-C2698651
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	B-C1704419
than	O
the	O
control	B-C0009932
reference	I-C0009932
group	I-C0009932
using	O
surgical	B-C0520453
cannula	I-C0520453
incision	B-C0184898
associated	B-C0332281
with	I-C0332281
their	O
non-occlusive	B-C0205556
aspects	I-C0205556
.	O
	
correlations	B-C1707520
between	O
physical	B-C0026606
activity	I-C0026606
and	O
neurocognitive	B-C0392335
domain	I-C0392335
functions	I-C0392335
in	O
patients	B-C0030705
with	O
schizophrenia	B-C0036341
a	O
cross-sectional	B-C0010362
study	I-C0010362
neurocognitive	B-C4041080
dysfunction	I-C4041080
is	O
a	O
critical	O
target	O
symptom	B-C1457887
of	O
schizophrenia	B-C0036341
treatment	B-C0087111
.	O
	
a	O
positive	O
correlation	B-C1707520
between	O
physical	B-C0026606
activity	I-C0026606
level	O
and	O
neurocognitive	B-C0392335
function	I-C0392335
has	O
been	O
reported	O
in	O
healthy	B-C0237401
individuals	I-C0237401
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	B-C1707520
exists	O
in	O
patients	B-C0030705
with	O
schizophrenia	B-C0036341
and	O
whether	O
the	O
relationship	B-C0439849
is	O
different	O
according	O
to	O
inpatients	B-C0021562
or	O
outpatients	B-C0029921
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
examine	B-C0582103
the	O
differences	O
in	O
the	O
correlations	B-C1707520
between	O
physical	B-C0026606
activity	I-C0026606
and	O
multiple	O
neurocognitive	B-C0392335
domains	I-C0392335
in	O
inpatients	B-C0021562
and	O
outpatients	B-C0029921
with	O
schizophrenia	B-C0036341
and	O
obtain	O
suggestions	B-C1705535
for	O
further	O
study	B-C2603343
to	O
facilitate	O
this	O
field	O
.	O
	
twenty-nine	O
patients	B-C0030705
with	O
schizophrenia	B-C0036341
were	O
examined	B-C0582103
16	O
inpatients	B-C0021562
and	O
13	O
outpatients	B-C0029921
,	O
56.0	O
11.4	O
years	B-C0439234
of	O
age	B-C0001779
.	O
	
current	O
symptoms	B-C1457887
were	O
assessed	B-C1516048
using	O
the	O
positive	B-C1446409
and	O
negative	B-C0205160
symptom	B-C0429688
scale	I-C0429688
and	O
neurocognitive	B-C0392335
functions	I-C0392335
using	O
cognitrax	B-C0871696
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	B-C0872227
index	I-C0872227
nci	B-C0872227
and	O
11	O
domain	O
scores	B-C0449820
.	O
	
after	O
testing	O
,	O
participants	B-C0679646
wore	O
an	O
hja-750c	B-C0178951
accelerometer	I-C0178951
for	O
one	B-C4082116
week	I-C4082116
to	O
measure	B-C0079809
physical	B-C0026606
activity	I-C0026606
levels	O
and	O
durations	B-C0449238
.	O
	
partial	B-C0010101
correlation	I-C0010101
analyses	I-C0010101
were	O
performed	O
between	O
exercise	B-C0015259
and	O
cognitive	B-C0009240
parameters	B-C0449381
.	O
	
in	O
the	O
outpatient	B-C0029921
group	O
,	O
higher	B-C0205250
physical	B-C0026606
activity	I-C0026606
was	O
associated	O
with	O
faster	O
motor	B-C1513492
and	O
psychomotor	B-C0033923
speeds	B-C0678536
in	O
outpatients	B-C0029921
.	O
	
however	O
,	O
higher	B-C0205250
physical	B-C0026606
activity	I-C0026606
was	O
associated	B-C0332281
with	I-C0332281
lower	B-C0205251
overall	O
nci	B-C0872227
,	O
attention	B-C0004268
score	B-C0449820
,	O
and	O
memory	B-C0025260
scores	B-C0449820
in	O
inpatients	B-C0021562
.	O
	
although	O
higher	B-C0205250
physical	B-C0026606
activity	I-C0026606
was	O
associated	B-C0332281
with	I-C0332281
better	O
neurocognitive	B-C0392335
functions	I-C0392335
of	O
outpatients	B-C0029921
,	O
in	O
inpatients	B-C0021562
with	O
non-remitted	O
schizophrenia	B-C0036341
,	O
higher	B-C0205250
physical	B-C0026606
activity	I-C0026606
was	O
associated	B-C0332281
with	I-C0332281
worsening	O
of	O
several	O
cognitive	B-C0392335
domains	I-C0392335
.	O
	
in	O
a	O
future	O
study	B-C2603343
examining	B-C0582103
the	O
relationship	B-C0439849
between	O
physical	B-C0026606
activity	I-C0026606
and	O
neurocognitive	B-C0392335
function	I-C0392335
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	B-C0021562
and	O
outpatients	B-C0029921
are	O
needed	O
because	O
the	O
relationship	B-C0439849
is	O
different	O
between	O
inpatients	B-C0021562
and	O
a	O
completely	B-C0205197
calcified	B-C0175895
prostate	B-C0033572
prostatic	B-C1868729
calcification	I-C1868729
and	O
prostatic	B-C0149525
calculus	I-C0149525
formation	B-C1522492
is	O
commonly	O
seen	O
in	O
adult	B-C0001675
population	B-C1257890
with	O
chronic	B-C0085696
prostatitis	I-C0085696
,	O
however	O
,	O
gross	O
prostatic	B-C1868729
calcification	I-C1868729
which	O
involves	O
more	O
than	O
3	O
cm	O
of	O
the	O
gland	B-C0033572
is	O
quite	O
rare	B-C0522498
.	O
	
we	O
are	O
presenting	B-C0449450
here	O
one	O
such	O
case	B-C0868928
in	O
which	O
almost	O
whole	O
glandular	B-C0033572
prostate	I-C0033572
was	O
converted	B-C0392747
into	O
stone	B-C0006736
a	O
rare	B-C0522498
cause	B-C0015127
of	O
gastric	B-C0149700
obstruction	I-C0149700
lighters	B-C0336770
swallowing	B-C0011167
the	O
majority	B-C0205164
of	O
swallowed	B-C0520753
foreign	I-C0520753
bodies	I-C0520753
are	O
thrown	B-C0849355
spontaneously	B-C0205359
without	B-C0332288
causing	B-C0678227
complications	B-C0009566
in	O
the	O
digestive	B-C0012240
system	I-C0012240
.	O
	
multiple	B-C0439064
number	B-C0237753
of	O
foreign	B-C0016542
bodies	I-C0016542
may	O
be	O
swallowed	B-C0011167
by	O
psychiatric	B-C0748064
patients	I-C0748064
which	O
delay	B-C2718036
diagnosis	I-C2718036
and	O
increase	B-C0442805
the	O
complication	B-C0009566
rate	B-C1521828
.	O
	
long	B-C0205166
and	O
hard	B-C0018599
objects	B-C0016542
cannot	O
pass	O
through	O
the	O
pylorus	B-C0034196
,	O
and	O
may	O
cause	B-C0015127
obstruction	B-C0028778
,	O
ulceration	B-C3887532
,	O
bleeding	B-C0019080
and	O
perforation	B-C0549099
.	O
	
endoscopy	B-C0014245
is	O
used	B-C1524063
as	O
an	O
effective	B-C1704419
method	B-C0449851
in	O
such	O
cases	B-C0868928
.	O
	
an	O
exploratory	B-C0085704
laparatomy	I-C0085704
was	O
performed	B-C0884358
after	O
unsuccessful	B-C1272705
endoscopic	B-C0442418
foreign	B-C0016542
object	I-C0016542
removal	B-C0015252
in	O
a	O
28-year-old	O
schizophrenic	B-C0036341
patient	B-C0030705
with	O
gastric	B-C0162651
outlet	I-C0162651
obstruction	I-C0162651
due	B-C0678226
to	I-C0678226
multiple	B-C0439064
cigarette	B-C0336770
lighter	I-C0336770
swallowing	B-C0011167
.	O
	
ten	O
lighters	B-C0336770
were	O
removed	B-C0849355
from	O
the	O
stomach	B-C0038351
through	B-C0332273
gastrotomy	B-C0192401
and	O
one	O
more	O
lighter	B-C0336770
was	O
removed	B-C0849355
from	O
the	O
descending	B-C0227389
colon	I-C0227389
by	O
milking	B-C0185115
through	B-C0332273
the	O
anus	B-C0003461
.	O
	
the	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	B-C0033213
in	O
psychiatric	B-C0748064
patients	I-C0748064
who	O
underwent	O
surgery	B-C0543467
due	B-C0678226
to	I-C0678226
intake	B-C1512806
of	O
foreign	B-C0016542
bodies	I-C0016542
.	O
	
ceftaroline	B-C2001525
fosamil	I-C2001525
for	O
community-acquired	B-C0694549
pneumonia	I-C0694549
and	O
skin	B-C1123023
and	O
skin	B-C3714514
structure	I-C3714514
infections	I-C3714514
a	O
systematic	B-C1955832
review	I-C1955832
background	O
ceftaroline	B-C2001525
is	O
a	O
parentally	O
administered	B-C1621583
cephalosporin	B-C3536856
that	O
has	O
an	O
in	B-C1533691
vitro	I-C1533691
expanded	B-C0205229
spectrum	O
of	O
activity	B-C1321418
compared	B-C1707455
with	O
other	O
cephalosporins	B-C3536856
yet	O
data	B-C1511726
is	O
conflicting	O
regarding	O
its	O
place	O
in	O
therapy	B-C0087111
.	O
	
aim	O
of	O
the	O
review	B-C1955832
to	O
compare	B-C1707455
the	O
efficacy	B-C1280519
and	O
safety	B-C0036043
of	O
ceftaroline	B-C2001525
against	O
standard	O
antibiotic	B-C0003232
regimens	B-C0040808
for	O
community-acquired	B-C0694549
pneumonia	I-C0694549
cap	B-C0694549
and	O
complicated	B-C3714514
skin	I-C3714514
and	I-C3714514
skin	I-C3714514
structure	I-C3714514
infections	I-C3714514
csssis	B-C3714514
.	O
	
method	O
the	O
databases	B-C0242356
of	O
medline	B-C0025141
,	O
ebsco	B-C0242356
,	O
and	O
embase	B-C0242356
were	O
searched	O
up	O
to	O
june	O
2016	O
.	O
	
manual	B-C3259354
review	I-C3259354
of	I-C3259354
references	I-C3259354
was	I-C3259354
completed	I-C3259354
and	O
experts	B-C1522486
in	O
the	O
field	O
were	O
contacted	O
for	O
unpublished	B-C0887929
data	I-C0887929
.	O
	
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
of	O
ceftaroline	B-C2001525
in	O
cap	B-C0694549
or	O
csssi	B-C3714514
populations	B-C1257890
were	O
included	O
.	O
	
outcomes	B-C1274040
included	O
clinical	B-C3640840
cure	I-C3640840
,	O
mortality	B-C0205848
,	O
adverse	B-C0877248
events	I-C0877248
,	O
serious	B-C1519255
adverse	I-C1519255
events	I-C1519255
,	O
and	O
discontinuation	B-C4288399
due	O
to	O
adverse	B-C0877248
events	I-C0877248
.	O
	
meta-analysis	B-C0282458
was	O
used	O
to	O
pool	O
results	O
for	O
these	O
outcomes	B-C1274040
.	O
	
we	O
performed	O
subgroup	B-C1515021
analyses	B-C0936012
for	O
gram	B-C0085426
positive	I-C0085426
infections	I-C0085426
in	O
cap	B-C0694549
and	O
infections	B-C3714514
caused	O
by	O
methicillin-resistant	B-C1265292
staphylococcus	I-C1265292
aureus	I-C1265292
in	O
csssis	B-C3714514
.	O
	
risk	B-C0035647
of	O
bias	B-C0242568
was	O
assessed	O
for	O
all	O
studies	B-C2603343
.	O
	
results	O
six	O
trials	B-C0681815
three	O
for	O
each	O
indication	O
were	O
included	O
,	O
each	O
of	O
which	O
had	O
an	O
unclear	O
or	O
high	O
risk	B-C0035647
of	O
bias	B-C0242568
in	O
at	O
least	O
one	O
domain	O
.	O
	
for	O
cap	B-C0694549
,	O
ceftaroline	B-C2001525
was	O
significantly	O
more	O
efficacious	B-C1280519
in	O
achieving	O
clinical	B-C3640840
cure	I-C3640840
than	O
ceftriaxone	B-C0007561
risk	B-C0242492
ratio	I-C0242492
rr	B-C0242492
1.11	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
1.04	O
i	O
=	O
47%	O
.	O
	
for	O
csssis	B-C3714514
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
clinical	B-C3640840
cure	I-C3640840
between	O
ceftaroline	B-C2001525
and	O
vancomycin	B-C0042313
plus	O
aztreonam	B-C0004521
rr	B-C0242492
1.01	O
,	O
95%	O
ci	B-C0009667
0.97	O
i	O
=	O
0%	O
.	O
	
no	O
differences	O
were	O
found	O
for	O
overall	O
mortality	B-C0205848
,	O
serious	B-C1519255
adverse	I-C1519255
events	I-C1519255
,	O
discontinuation	B-C4288399
due	O
to	O
adverse	B-C0877248
events	I-C0877248
,	O
and	O
overall	O
adverse	B-C0877248
events	I-C0877248
.	O
	
conclusion	O
ceftaroline	B-C2001525
is	O
a	O
viable	O
therapeutic	B-C0949216
alternative	I-C0949216
for	O
patients	B-C0030705
with	O
cap	B-C0694549
and	O
csssis	B-C3714514
,	O
yet	O
identified	O
risks	B-C0035647
of	O
bias	B-C0242568
and	O
poor	B-C2924039
external	I-C2924039
validity	I-C2924039
preclude	O
it	O
from	O
being	O
recommended	O
as	O
a	O
first-line	B-C0003232
agent	I-C0003232
.	O
	
direct	O
effects	B-C1704420
of	I-C1704420
glucose	B-C0017725
,	O
insulin	B-C0021641
,	O
glp-1	B-C0061355
,	O
and	O
gip	B-C0017132
on	O
bulbospinal	B-C0005898
neurons	B-C0027882
in	O
the	O
rostral	B-C2328883
ventrolateral	I-C2328883
medulla	I-C2328883
in	O
neonatal	B-C0021289
wistar	B-C0034716
rats	I-C0034716
although	O
patients	B-C0030705
with	O
diabetes	B-C0011849
mellitus	I-C0011849
dm	B-C0011849
often	O
exhibit	O
hypertension	B-C0020538
,	O
the	O
mechanisms	B-C0441712
responsible	O
for	O
this	O
correlation	B-C1707520
are	O
not	O
well	O
known	O
.	O
	
we	O
hypothesized	O
that	O
the	O
bulbospinal	B-C0005898
neurons	B-C0027882
in	O
the	O
rostral	B-C2328883
ventrolateral	I-C2328883
medulla	I-C2328883
rvlm	B-C2328883
are	O
affected	B-C0392760
by	O
the	O
levels	B-C0441889
of	O
glucose	B-C0017725
,	O
insulin	B-C0021641
,	O
or	O
incretins	B-C1562292
glucagon	B-C0061355
like	I-C0061355
peptide-1	I-C0061355
glp-1	B-C0061355
or	O
glucose-dependent	B-C0017132
insulinotropic	I-C0017132
peptide	I-C0017132
gip	B-C0017132
in	O
patients	B-C0030705
with	O
dm	B-C0011849
.	O
	
to	O
investigate	B-C1292732
whether	O
rvlm	B-C2328883
neurons	B-C0027882
are	O
activated	B-C1879547
by	O
glucose	B-C0017725
,	O
insulin	B-C0021641
,	O
glp-1	B-C0061355
,	O
or	O
gip	B-C0017132
,	O
we	O
examined	O
changes	B-C0392747
in	O
the	O
membrane	B-C0025251
potentials	I-C0025251
of	O
bulbospinal	B-C0005898
rvlm	B-C2328883
neurons	B-C0027882
using	O
whole-cell	B-C0007634
patch-clamp	B-C0242625
technique	I-C0242625
during	O
superfusion	B-C1254366
with	O
various	O
levels	B-C0441889
of	O
glucose	B-C0017725
or	O
these	O
hormones	B-C0019932
in	O
neonatal	B-C0021289
wistar	B-C0034716
rats	I-C0034716
.	O
	
a	O
brainstem	B-C0006121
-	O
spinal	B-C0037925
cord	I-C0037925
preparation	B-C1521827
was	O
used	O
for	O
the	O
experiments	B-C0681814
.	O
	
a	O
low	B-C0205251
level	B-C0441889
of	O
glucose	B-C0017725
stimulated	O
bulbospinal	B-C0005898
rvlm	B-C2328883
neurons	B-C0027882
.	O
	
during	O
insulin	B-C0021641
superfusion	B-C1254366
,	O
almost	O
all	O
the	O
rvlm	B-C2328883
neurons	B-C0027882
were	O
depolarized	B-C0234081
,	O
while	O
during	O
glp-1	B-C0061355
or	O
gip	B-C0017132
superfusion	B-C1254366
,	O
almost	O
all	O
the	O
rvlm	B-C2328883
neurons	B-C0027882
were	O
hyperpolarized	B-C0522208
.	O
	
next	O
,	O
histological	B-C0019637
examinations	I-C0019637
were	O
performed	O
to	O
examine	O
transporters	B-C0017742
for	I-C0017742
glucose	I-C0017742
and	O
receptors	B-C0597357
for	O
insulin	B-C0021641
,	O
glp-1	B-C0061355
,	O
and	O
gip	B-C0017132
on	O
rvlm	B-C2328883
neurons	B-C0027882
.	O
	
low	B-C0205251
-	O
level	B-C0441889
glucose	B-C0017725
-	O
depolarized	B-C0234081
rvlm	B-C2328883
neurons	B-C0027882
exhibited	O
the	O
presence	B-C3854307
of	O
glucose	B-C0119484
transporter	I-C0119484
3	I-C0119484
glut3	B-C0119484
.	O
	
meanwhile	O
,	O
insulin	B-C0021641
-	O
depolarized	B-C0234081
,	O
glp-1	B-C0061355
-	O
hyperpolarized	B-C0522208
,	O
and	O
gip	B-C0017132
-	O
hyperpolarized	B-C0522208
rvlm	B-C2328883
neurons	B-C0027882
showed	O
each	O
of	O
the	O
respective	O
specific	B-C0205369
receptor	B-C0597357
.	O
	
these	O
results	O
indicate	O
that	O
a	O
low	B-C0205251
level	B-C0441889
of	O
glucose	B-C0017725
stimulates	B-C1948023
bulbospinal	B-C0005898
rvlm	B-C2328883
neurons	B-C0027882
via	O
specific	B-C0205369
transporters	B-C0017742
on	O
these	O
neurons	B-C0027882
,	O
inducing	B-C0205263
hypertension	B-C0020538
.	O
	
furthermore	O
,	O
an	O
increase	B-C0442805
in	O
insulin	B-C0021641
or	O
a	O
reduction	B-C0392756
in	O
incretins	B-C1562292
may	O
also	O
activate	B-C1879547
the	O
sympathetic	B-C0039044
nervous	I-C0039044
system	I-C0039044
and	O
induce	B-C0205263
hypertension	B-C0020538
by	O
activating	B-C1879547
rvlm	B-C2328883
neurons	B-C0027882
via	O
their	O
own	O
mechanisms	B-C0441712
of	O
compensation	B-C0001549
in	O
the	O
gait	B-C0016928
of	O
patients	B-C0030705
with	O
drop	B-C0085684
foot	I-C0085684
drop	B-C0085684
foot	I-C0085684
is	O
a	O
complex	O
syndrome	B-C0039082
,	O
with	O
multiple	B-C0439064
interactions	B-C1704675
between	O
joints	B-C0022417
and	O
muscles	B-C0026845
.	O
	
abnormalities	B-C1704258
in	O
movement	B-C0427096
patterns	I-C0427096
can	O
be	O
measured	O
using	O
motion	B-C0752188
capture	I-C0752188
techniques	I-C0752188
,	O
but	O
identifying	O
compensation	B-C0001549
mechanisms	B-C0441712
remains	O
challenging	O
.	O
	
in	O
order	O
to	O
identify	O
compensatory	O
mechanisms	B-C0441712
in	O
patients	O
with	O
drop	O
foot	O
,	O
this	O
study	O
evaluated	O
a	O
sample	O
of	O
15	O
such	O
patients	O
using	O
a	O
computerized	O
gait	O
analysis	O
system	O
,	O
as	O
compared	O
to	O
a	O
group	O
of	O
15	O
healthy	O
subjects	O
.	O
	
four	O
classes	O
of	O
parameters	O
were	O
distinguished	O
,	O
falling	O
in	O
differing	O
intervals	O
of	O
percentage	O
differences	O
between	O
the	O
groups	O
in	O
the	O
study	O
.	O
	
the	O
first	O
class	O
comprised	O
two	O
kinematic	O
parameters	O
for	O
which	O
the	O
values	O
of	O
percentage	O
differences	O
in	O
the	O
control	O
group	O
were	O
more	O
than	O
100%	O
greater	O
than	O
for	O
the	O
patient	O
group	O
.	O
	
the	O
second	O
class	O
comprised	O
two	O
kinetic	O
parameters	O
falling	O
in	O
the	O
interval	O
of	O
100-49%	O
.	O
	
in	O
the	O
third	O
class	O
,	O
in	O
the	O
49-20%	O
interval	O
the	O
main	O
differences	O
were	O
observed	O
for	O
spatiotemporal	O
parameters	O
,	O
whereas	O
in	O
the	O
20-4%	O
interval	O
the	O
differences	O
were	O
distributed	O
similarly	O
for	O
kinematic	O
,	O
kinetic	O
and	O
spatiotemporal	O
parameters	O
.	O
	
these	O
differences	O
in	O
gait	O
pattern	O
between	O
the	O
groups	O
may	O
be	O
related	O
to	O
both	O
primary	O
motor	O
deficits	O
and	O
secondary	O
compensatory	B-C0231186
mechanisms	B-C0441712
.	O
	
generally	O
,	O
we	O
conclude	O
that	O
drop	O
foot	O
affects	O
the	O
patients	B-C0030705
'	O
overall	O
kinematic	O
and	O
kinetic	O
gait	O
parameters	O
,	O
with	O
compensation	O
seen	O
as	O
a	O
chain	O
originating	O
from	O
a	O
change	O
of	O
movement	O
within	O
the	O
ankle	O
joint	I-C0003087
inhibitory	B-C3463820
effects	B-C1704420
of	I-C1704420
lactobacillus	B-C0317597
rhamnosus	I-C0317597
and	O
lactobacillus	B-C0022940
casei	I-C0022940
on	O
candida	B-C0006837
biofilm	B-C0081786
of	O
denture	B-C0457711
surface	I-C0457711
candida	B-C0006837
albicans	I-C0006837
biofilm	B-C0081786
is	O
associated	B-C0332281
with	I-C0332281
denture-related	B-C0038364
stomatitis	I-C0038364
and	O
oral	B-C0006849
candidiasis	I-C0006849
of	O
elderly	B-C0001792
.	O
	
probiotics	B-C0525033
are	O
beneficial	O
bacteria	B-C0004611
and	O
have	O
antibacterial	B-C0243095
activity	I-C0243095
against	O
pathogenic	B-C0004611
bacteria	I-C0004611
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	B-C1292732
the	O
antifungal	B-C0243095
activity	I-C0243095
of	O
various	O
probiotics	B-C0525033
against	O
c	B-C0006837
.	O
	
albicans	I-C0006837
and	O
the	O
inhibitory	B-C3463820
effects	B-C1704420
of	I-C1704420
probiotics	B-C0525033
on	O
candida	B-C0006837
biofilm	B-C0081786
on	O
the	O
denture	B-C0457711
surface	I-C0457711
.	O
	
the	O
spent	B-C0010454
culture	I-C0010454
media	I-C0010454
of	O
various	O
probiotics	B-C0525033
were	O
investigated	O
the	O
antifungal	B-C1280519
efficacy	I-C1280519
against	O
c	B-C0006837
.	O
	
albicans	I-C0006837
.	O
	
candida	B-C0006837
biofilm	B-C0081786
was	O
formed	O
on	O
a	O
denture	B-C3503992
base	I-C3503992
resin	I-C3503992
and	O
was	O
then	O
treated	B-C1522326
with	O
lactobacillus	B-C0317597
rhamnosus	I-C0317597
and	O
lactobacillus	B-C0022940
casei	I-C0022940
.	O
	
also	O
,	O
the	O
biofilm	B-C0081786
s	O
of	O
l	B-C0317597
.	O
	
rhamnosus	I-C0317597
and	O
l	B-C0022940
.	O
	
casei	I-C0022940
were	O
formed	O
and	O
were	O
sequentially	O
treated	B-C1522326
with	O
c	B-C0006837
.	O
	
albicans	I-C0006837
.	O
	
colony-forming	B-C0553561
units	I-C0553561
of	O
c	B-C0006837
.	O
	
albicans	I-C0006837
on	O
the	O
denture	B-C0457711
surface	I-C0457711
were	O
counted	O
after	O
spreading	B-C0332261
on	O
agar	B-C0001771
plate	B-C0180454
.	O
	
the	O
denture	B-C3503992
base	I-C3503992
resin	I-C3503992
was	O
treated	B-C1522326
with	O
the	O
spent	B-C0010454
culture	I-C0010454
media	I-C0010454
for	O
30	O
days	B-C0439228
,	O
after	O
which	O
the	O
denture	B-C0457711
surface	I-C0457711
roughness	B-C0243095
was	O
analyzed	O
with	O
an	O
atomic	B-C0242849
force	I-C0242849
microscope	I-C0242849
.	O
	
l	B-C0317597
.	O
	
rhamnosus	I-C0317597
and	O
l	B-C0022940
.	O
	
casei	I-C0022940
exhibited	O
stronger	O
antifungal	B-C0243095
activity	I-C0243095
than	O
other	O
probiotics	B-C0525033
.	O
	
the	O
spent	B-C0010454
culture	I-C0010454
medium	I-C0010454
of	O
l	B-C0317597
.	O
	
rhamnosus	I-C0317597
and	O
l	B-C0022940
.	O
	
casei	I-C0022940
exhibited	O
the	O
antifungal	B-C0243095
activity	I-C0243095
against	O
blastoconidia	B-C0521050
and	O
biofilm	B-C0081786
of	O
c	B-C0006837
.	O
	
albicans	I-C0006837
.	O
	
l	B-C0317597
.	O
	
rhamnosus	I-C0317597
and	O
l	B-C0022940
.	O
	
casei	I-C0022940
showed	O
the	O
antifungal	B-C0243095
activity	I-C0243095
against	O
candida	B-C0006837
biofilm	B-C0081786
,	O
and	O
the	O
biofilm	B-C0081786
of	O
l	B-C0317597
.	O
	
rhamnosus	I-C0317597
and	O
l	B-C0022940
.	O
	
casei	I-C0022940
inhibited	B-C3463820
formation	B-C1522492
of	O
candida	B-C0006837
biofilm	B-C0081786
on	O
denture	B-C0457711
surface	I-C0457711
.	O
	
neither	O
of	O
the	O
probiotics	B-C0525033
affected	O
the	O
surface	B-C0243095
roughness	I-C0243095
of	O
the	O
denture	B-C3503992
base	I-C3503992
resin	I-C3503992
.	O
	
l	B-C0317597
.	O
	
rhamnosus	I-C0317597
and	O
l	B-C0022940
.	O
	
casei	I-C0022940
may	O
be	O
the	O
ideal	O
probiotics	B-C0525033
for	O
the	O
prevention	B-C2700409
and	O
treatment	B-C0039798
of	O
denture-related	B-C0038364
stomatitis	I-C0038364
.	O
	
persistent	B-C0001869
organic	I-C0001869
pollutants	I-C0001869
pops	B-C0001869
in	O
the	O
atmosphere	B-C0004178
of	O
three	O
chilean	B-C0239045
cities	B-C0008848
using	O
passive	B-C3686820
air	B-C0178984
samplers	I-C0178984
in	O
this	O
study	B-C2603343
passive	B-C3686820
air	B-C0178984
samplers	I-C0178984
containing	O
polyurethane	B-C0071696
foam	I-C0071696
puf	B-C0071696
disks	B-C0180459
were	O
deployed	B-C2825812
in	O
three	O
cities	B-C0008848
across	O
chile	B-C0008107
santiago	B-C0017446
stg	B-C0017446
n=5	O
,	O
sampling	B-C0449705
sites	I-C0449705
,	O
concepciόn	B-C0017446
con	B-C0017446
n=6	O
and	O
temuco	B-C0017446
tem	B-C0017446
n=6	O
from	O
2008	O
to	O
2009	O
.	O
	
polychlorinated	B-C0032447
biphenyls	I-C0032447
pcbs	B-C0032447
7	O
indicator	B-C1522602
congeners	B-C0678518
,	O
chlorinated	B-C0360424
pesticides	I-C0360424
hexachlorocyclohexanes	B-C0005038
hchs	B-C0005038
,	O
dichlorodiphenyl	B-C0011041
trichloroethanes	I-C0011041
ddts	B-C0011041
and	O
flame	B-C0016198
retardants	I-C0016198
such	O
as	O
polybrominated	B-C2350562
diphenyl	I-C2350562
ethers	I-C2350562
pbdes	B-C2350562
were	O
determined	B-C0521095
by	I-C0521095
gas	B-C0024868
chromatography	I-C0024868
coupled	I-C0024868
mass	I-C0024868
spectrometry	I-C0024868
gc/ms	B-C0024868
.	O
	
a	O
sampling	B-C0870078
rate	B-C1521828
r	B-C1521828
typical	O
of	O
urban	B-C0178876
sites	I-C0178876
4m	O
was	O
used	O
to	O
estimate	B-C0750572
the	O
atmospheric	B-C0004178
concentrations	B-C1446561
of	O
individual	B-C1457900
compounds	B-C0205198
.	O
	
pcb	B-C0032447
concentrations	B-C1446561
in	O
the	O
air	B-C0001861
pg/m	O
ranged	B-C1514721
from	O
1-10	O
tem	B-C0017446
,	O
1-40	O
stg	B-C0017446
and	O
4-30	O
con	B-C0017446
.	O
	
higher	B-C1979900
molecular	I-C1979900
weight	I-C1979900
pcbs	B-C0032447
pcb	B-C0032447
-153	O
,	O
-180	O
were	O
detected	B-C0442726
at	O
industrial	B-C0442611
sites	I-C0442611
in	O
concepción	B-C0017446
.	O
	
the	O
hchs	B-C0005038
showed	O
a	O
prevalence	B-C0683919
of	O
γ-hch	B-C0005038
across	O
all	O
sites	B-C0205145
,	O
indicative	B-C1522602
of	O
inputs	B-C1708517
from	O
the	O
use	O
of	O
lindane	B-C0005038
but	O
a	O
limited	B-C0439801
use	O
of	O
technical	B-C1553014
hchs	B-C0005038
in	O
chile	B-C0008107
.	O
	
ddts	B-C0011041
were	O
detected	B-C0442726
with	O
a	O
prevalence	B-C0683919
of	O
p	B-C0011038
accounting	B-C0680857
for	O
50%	O
of	O
the	O
total	O
ddts	B-C0011041
.	O
	
pbde	B-C2350562
concentrations	B-C1446561
in	O
air	B-C0001861
pg/m	O
ranged	B-C1514721
from	O
1	O
to	O
55	O
stg	B-C0017446
,	O
0.5	O
to	O
20	O
con	B-C0017446
and	O
from	O
0.4	O
to	O
10	O
tem	B-C0017446
,	O
and	O
were	O
generally	O
similar	B-C2348205
to	O
those	O
reported	B-C0684224
for	O
many	O
other	O
urban	B-C0178876
areas	I-C0178876
globally	B-C2348867
.	O
	
the	O
pattern	B-C0449774
of	O
pbdes	B-C2350562
was	O
different	O
among	O
the	O
three	O
cities	B-C0008848
however	O
,	O
pbde	B-C2350562
-209	O
was	O
dominant	B-C1527180
at	O
most	O
of	O
the	O
sites	B-C0205145
.	O
	
these	O
results	B-C0683954
represent	O
one	O
of	O
the	O
few	O
assessments	B-C0220825
of	O
air	B-C0001861
concentrations	B-C1446561
of	O
pops	B-C0001869
across	O
different	O
urban	B-C0178876
areas	I-C0178876
within	O
the	O
same	O
country	B-C0454664
.	O
	
these	O
data	B-C1511726
will	O
support	B-C1521721
chilean	B-C0239045
commitments	B-C0870312
as	O
a	O
signatory	B-C4288222
to	O
the	O
stockholm	B-C0242359
convention	I-C0242359
on	O
pops	B-C0001869
and	O
for	O
reporting	B-C0011000
as	O
a	O
member	B-C2698041
country	B-C0454664
of	O
the	O
group	B-C0017446
of	I-C0017446
latin	I-C0017446
america	I-C0017446
and	I-C0017446
caribbean	I-C0017446
countries	I-C0017446
grulac	I-C0017446
region	I-C0017446
.	O
	
intraoperative	B-C0456904
ketamine	B-C0022614
reduces	B-C0392756
immediate	B-C0205253
postoperative	B-C0032790
opioid	B-C0002772
consumption	B-C1512806
after	O
spinal	B-C0919636
fusion	I-C0919636
surgery	I-C0919636
in	O
chronic	B-C0150055
pain	I-C0150055
patients	B-C0030705
with	O
opioid	B-C0002772
dependency	B-C0851827
a	O
randomized	B-C0034656
,	O
blinded	B-C2347038
trial	I-C2347038
perioperative	B-C1518988
handling	B-C1832073
of	O
surgical	B-C0871463
patients	I-C0871463
with	O
opioid	B-C0002772
dependency	B-C0851827
represents	O
an	O
important	B-C3898777
clinical	B-C0205210
problem	B-C0033213
.	O
	
animal	B-C0683949
studies	I-C0683949
suggest	O
that	O
ketamine	B-C0022614
attenuates	B-C0599946
central	B-C2938905
sensitization	I-C2938905
and	O
hyperalgesia	B-C0020429
and	O
thereby	O
reduces	B-C0392756
postoperative	B-C0032790
opioid	B-C0002772
tolerance	O
.	O
	
we	O
hypothesized	O
that	O
intraoperative	O
ketamine	O
would	O
reduce	O
immediate	O
postoperative	O
opioid	B-C0240601
consumption	O
compared	O
with	O
placebo	O
in	O
chronic	O
pain	O
patients	O
with	O
opioid	O
dependency	O
undergoing	O
lumbar	O
spinal	O
fusion	O
surgery	O
.	O
	
primary	O
outcome	O
was	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
.	O
	
secondary	O
outcomes	O
were	O
acute	O
pain	O
at	O
rest	O
and	O
during	O
mobilization	O
2	O
to	O
24	O
hours	O
postoperatively	O
visual	O
analogue	O
scale	O
,	O
adverse	O
events	O
,	O
and	O
persistent	O
pain	O
6	O
months	O
postoperatively	O
.	O
	
one	O
hundred	O
fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
intraoperative	O
s-ketamine	O
bolus	O
0.5	O
mg/kg	O
and	O
infusion	O
0.25	O
mg	O
or	O
placebo	O
.	O
	
postoperatively	O
,	O
patients	O
received	O
their	O
usual	O
opioids	O
,	O
paracetamol	O
and	O
iv	O
patient-controlled	O
analgesia	O
with	O
morphine	O
.	O
	
in	O
the	O
final	O
analyses	O
,	O
147	O
patients	O
were	O
included	O
.	O
	
patient-controlled	O
analgesia	O
iv	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
79	O
47	O
vs	O
121	O
53	O
mg	O
iv	O
,	O
mean	O
difference	O
42	O
mg	O
95%	O
confidence	O
interval	O
-59	O
to	O
-25	O
,	O
p	O
<	O
0.001	O
.	O
	
sedation	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	O
group	O
6	O
and	O
24	O
hours	O
postoperatively	O
.	O
	
there	O
were	O
no	O
significant	O
differences	O
regarding	O
acute	O
pain	O
,	O
nausea	O
,	O
vomiting	O
,	O
hallucinations	O
,	O
or	O
nightmares	O
.	O
	
back	O
pain	O
at	O
6	O
months	O
postoperatively	O
compared	O
with	O
preoperative	O
pain	O
was	O
significantly	O
more	O
improved	O
in	O
the	O
ketamine	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
p	O
=	O
0.005	O
.	O
	
in	O
conclusion	O
,	O
intraoperative	O
ketamine	O
significantly	O
reduced	O
morphine	O
consumption	O
0	O
to	O
24	O
hours	O
after	O
lumbar	O
fusion	O
surgery	O
in	O
opioid	O
-	O
dependent	O
patients	O
.	O
	
the	O
trend	O
regarding	O
less	O
persistent	O
pain	O
6	O
months	O
postoperatively	O
needs	O
further	O
investigation	B-C1292732
effects	B-C1704420
of	I-C1704420
argan	B-C2975054
oil	I-C2975054
on	O
the	O
mitochondrial	B-C0007613
function	I-C0007613
,	O
antioxidant	B-C0460002
system	I-C0460002
and	O
the	O
activity	B-C0243102
of	O
nadph	B-C0027303
-	O
generating	B-C3146294
enzymes	B-C0014442
in	O
acrylamide	B-C0050587
treated	B-C0332293
rat	B-C0034715
brain	B-C0006104
argan	B-C2975054
oil	I-C2975054
ao	B-C2975054
is	O
rich	O
in	O
minor	O
compounds	B-C1706082
such	O
as	O
polyphenols	B-C0071649
and	O
tocopherols	B-C0087096
which	O
are	O
powerful	O
antioxidants	B-C0003402
.	O
	
acrylamide	B-C0050587
acr	B-C0050587
has	O
been	O
classified	B-C0008902
as	O
a	O
neurotoxic	B-C0260049
agent	I-C0260049
in	O
animals	B-C0003062
and	O
humans	B-C0086418
.	O
	
mitochondrial	B-C0026237
oxidative	B-C0242606
stress	I-C0242606
and	O
dysfunction	B-C4021734
is	O
one	O
of	O
the	O
most	O
probable	B-C0033204
molecular	B-C0678659
mechanisms	I-C0678659
of	O
neurodegenerative	B-C0524851
diseases	I-C0524851
.	O
	
female	B-C0086287
sprague	B-C0034715
dawley	I-C0034715
rats	I-C0034715
were	O
exposed	B-C0332157
to	I-C0332157
acr	B-C0050587
50mg/kg	O
i.p	O
.	O
	
three	O
times	O
a	O
week	O
,	O
ao	B-C2975054
6ml/kg	O
,	O
per	O
day	O
or	O
together	O
for	O
30days	O
.	O
	
the	O
activities	B-C0441655
of	O
cytosolic	B-C1820051
enzymes	B-C0014442
such	O
as	O
xanthine	B-C0043317
oxidase	I-C0043317
xo	B-C0043317
,	O
glucose	B-C0017757
6-phosphate	I-C0017757
dehydrogenase	I-C0017757
g6pdh	B-C0017757
,	O
glutathione-s-transferase	B-C0017837
gst	B-C0017837
,	O
mitochondrial	B-C0026237
oxidative	B-C0242606
stress	I-C0242606
,	O
oxidative	B-C0030013
phosphorylation	I-C0030013
oxphos	B-C0030013
and	O
tricarboxylic	B-C0008858
acid	I-C0008858
cycle	I-C0008858
tca	B-C0008858
enzymes	B-C0014442
,	O
mitochondrial	B-C0026237
metabolic	B-C0025519
function	I-C0025519
,	O
adenosine	B-C0001480
triphosphate	I-C0001480
atp	B-C0001480
level	B-C0441889
and	O
acetylcholinesterase	B-C1149827
ache	I-C1149827
activity	I-C1149827
were	O
assessed	B-C1516048
in	O
rat	B-C0034715
brain	B-C0006104
.	O
	
cytosolic	B-C1820051
and	O
mitochondrial	B-C0026237
antioxidant	B-C0014442
enzymes	I-C0014442
were	O
significantly	B-C0750502
diminished	B-C0205216
in	O
the	O
brains	B-C0006104
of	O
rats	B-C0034715
treated	B-C0332293
with	I-C0332293
acr	B-C0050587
compared	B-C1707455
to	O
those	O
in	O
control	B-C0009932
.	O
	
besides	O
,	O
acr	B-C0050587
treatment	B-C0087111
resulted	B-C1274040
in	O
a	O
significant	B-C0750502
reduction	B-C0392756
in	O
brain	B-C0006104
atp	B-C0001480
level	B-C0441889
,	O
mitochondrial	B-C0026237
metabolic	B-C0025519
function	I-C0025519
,	O
oxphos	B-C0030013
and	O
tca	B-C0008858
enzymes	B-C0014442
.	O
	
administration	B-C1533734
of	O
ao	B-C2975054
restored	O
both	O
the	O
cytosolic	B-C1820051
and	O
mitochondrial	B-C0026237
oxidative	B-C0242606
stress	I-C0242606
by	O
normalizing	B-C1882115
nicotinamide	B-C0027303
adenine	I-C0027303
dinucleotide	I-C0027303
phosphate	I-C0027303
nadph	B-C0027303
generating	B-C3146294
enzymes	B-C0014442
.	O
	
in	O
addition	O
,	O
improved	B-C0184511
mitochondrial	B-C0007613
function	I-C0007613
primarily	O
enhancing	B-C2349975
nicotinamide	B-C0027270
adenine	I-C0027270
dinucleotide	I-C0027270
nadh	B-C0027270
generated	B-C3146294
enzymes	B-C0243102
activities	I-C0243102
and	O
atp	B-C0001480
level	B-C0441889
in	O
the	O
mitochondria	B-C0026237
.	O
	
the	O
reason	B-C0392360
for	O
ao's	B-C2975054
obvious	O
beneficial	B-C0683156
effects	I-C0683156
in	O
this	O
study	B-C2603343
may	O
be	O
due	O
to	O
synergistic	B-C0683168
effects	I-C0683168
of	O
its	O
different	B-C1705242
bioactive	B-C3714412
compounds	I-C3714412
which	O
is	O
especially	O
effective	B-C1704419
on	O
mitochondria	B-C0026237
.	O
	
modulation	B-C0443264
of	O
the	O
brain	B-C0006104
mitochondrial	B-C0007613
functions	I-C0007613
and	O
antioxidant	B-C0460002
systems	I-C0460002
by	O
ao	B-C2975054
may	O
lead	O
to	O
the	O
development	B-C1527148
of	O
new	O
mitochondria	B-C0026237
-	O
targeted	B-C0599894
antioxidants	B-C0003402
in	O
the	O
encaged	B-C0337189
chironomus	B-C1677085
riparius	I-C1677085
larvae	B-C0023047
in	O
assessment	B-C1516048
of	O
trace	B-C0723796
metal	I-C0723796
bioavailability	B-C0470187
and	O
transfer	B-C1705822
in	O
a	O
landfill	B-C1720817
leachate	I-C1720817
collection	B-C1516698
pond	B-C0337048
household	B-C0001288
wastes	B-C0018627
may	O
constitute	B-C0729650
a	O
vector	B-C0205556
of	O
environmental	B-C0014419
contamination	I-C0014419
when	O
buried	B-C1254362
,	O
in	O
particular	O
through	O
degradation	B-C0243125
and	O
production	O
of	O
leachates	B-C1720817
containing	B-C0332256
significant	B-C0750502
trace	B-C0723796
metal	I-C0723796
tm	B-C0723796
concentrations	B-C1446561
that	O
may	O
constitute	B-C0729650
a	O
serious	O
risk	B-C0035647
to	O
biota	B-C1253910
.	O
	
the	O
objectives	B-C0018017
of	O
this	O
study	B-C2603343
were	O
to	O
assess	B-C1516048
the	O
bioavailability	B-C0470187
and	O
transfer	B-C1705822
potential	B-C3245505
of	O
various	O
tms	B-C0723796
present	B-C0150312
in	O
water	B-C0043047
and	O
sediments	B-C0282590
in	O
a	O
reservoir	B-C0442537
receiving	B-C1514756
landfill	B-C1720817
leachates	I-C1720817
.	O
	
an	O
active	B-C0205177
biomonitoring	B-C0005517
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	B-C0443289
naive	O
laboratory	B-C1517710
organisms	I-C1517710
in	O
cages	B-C0337189
deployed	B-C2825812
in	B-C3539073
the	I-C3539073
field	I-C3539073
.	O
	
aquatic	B-C0596121
insects	I-C0596121
such	O
as	O
chironomus	B-C1677085
riparius	I-C1677085
larvae	B-C0023047
are	O
good	O
candidates	O
since	O
they	O
represent	B-C1882932
key	O
organisms	B-C0029235
in	O
the	O
trophic	B-C0596583
functioning	B-C0542341
of	O
aquatic	B-C0563034
ecosystems	I-C0563034
.	O
	
the	O
results	B-C0683954
show	O
that	O
water	B-C0043047
,	O
suspended	B-C1553403
particles	B-C0597177
,	O
and	O
sediments	B-C0282590
were	O
significant	B-C0750502
ly	O
contaminated	B-C0205279
by	O
various	O
tms	B-C0723796
as	B-C0003818
,	O
cd	B-C0006632
,	O
cu	B-C0009968
,	O
ni	B-C0028013
,	O
pb	B-C0023175
,	O
and	O
zn	B-C0043481
.	O
	
their	O
contribution	B-C1880177
to	O
the	O
transfer	B-C1705822
of	O
tms	B-C0723796
depends	O
,	O
however	O
,	O
on	O
the	O
specific	B-C0205369
element	B-C0013879
considered	B-C0750591
,	O
e.g	O
,	O
cd	B-C0006632
in	O
sediments	B-C0282590
or	O
pb	B-C0023175
in	O
both	O
suspended	B-C1553403
particles	B-C0597177
and	O
sediments	B-C0282590
.	O
	
the	O
internal	O
fate	O
of	O
tms	B-C0723796
was	O
investigated	B-C1292732
according	O
to	O
their	O
fractionation	B-C0016640
between	O
an	O
insoluble	B-C0205556
and	O
a	O
cytosolic	B-C1820051
fraction	B-C1264633
.	O
	
this	O
approach	O
revealed	B-C0443289
different	O
detoxification	B-C0150543
strategies	B-C0679199
capable	O
of	O
preventing	B-C1292733
the	O
induction	B-C0205263
of	O
deleterious	B-C0879626
effects	I-C0879626
at	O
the	O
individual	B-C0237401
scale	B-C1522412
.	O
	
however	O
,	O
the	O
accumulation	B-C4055506
of	O
several	O
tms	B-C0723796
in	O
c	B-C1677085
.	O
	
riparius	I-C1677085
larvae	B-C0023047
tissues	B-C0040300
may	O
also	O
represent	B-C1882932
a	O
significant	B-C0750502
load	O
potentially	B-C3245505
transferable	B-C1705822
to	O
higher	B-C0205250
trophic	B-C0596583
levels	B-C0441889
.	O
	
effects	O
of	O
binge-like	B-C0556346
ethanol	B-C0814017
exposure	I-C0814017
during	O
adolescence	B-C0001578
on	O
the	O
febrile	B-C0015967
response	B-C0871261
in	O
rats	B-C0034721
ethanol	B-C0814017
etoh	I-C0814017
exposure	I-C0814017
during	O
different	O
phases	B-C0205390
of	O
life	B-C0376558
may	O
increase	O
the	O
risk	B-C0582147
of	I-C0582147
infections	I-C0582147
and	O
cause	O
alterations	B-C1515926
in	O
the	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
.	O
	
the	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
binge-like	B-C0556346
etoh	B-C0814017
exposure	I-C0814017
in	O
adolescent	B-C0001578
rats	B-C0034721
on	O
the	O
febrile	B-C0015967
response	B-C0871261
that	O
was	O
induced	O
by	O
lipopolysaccharide	B-C0023810
lps	B-C0023810
and	O
interleukin-1β	B-C0021753
il-1β	B-C0021753
.	O
	
male	O
rats	B-C0034721
were	O
exposed	B-C0814017
to	I-C0814017
etoh	I-C0814017
from	O
postnatal	B-C0443281
days	I-C0443281
25	O
to	O
38	O
in	O
a	O
binge-like	B-C0556346
pattern	O
.	O
	
fever	B-C0015967
was	O
induced	O
by	O
lps	B-C0023810
5	O
and	O
50	O
μg/kg	O
,	O
intraperitoneally	B-C0442120
and	O
evaluated	O
on	O
postnatal	B-C0443281
days	I-C0443281
51	O
and	O
63	O
,	O
or	O
by	O
il-β	B-C0021753
3	O
ng	O
and	O
evaluated	O
on	O
postnatal	B-C0443281
day	I-C0443281
51	O
.	O
	
hematological	B-C0018943
parameters	O
,	O
the	O
status	O
of	O
peritoneal	B-C0206190
macrophages	I-C0206190
,	O
and	O
plasma	B-C0032105
and	O
cerebrospinal	B-C0007807
il-1β	B-C0021753
levels	B-C0441889
were	O
also	O
evaluated	O
on	O
postnatal	B-C0443281
day	I-C0443281
51	O
.	O
	
etoh	B-C0814017
exposure	I-C0814017
during	O
adolescence	B-C0001578
did	O
not	O
alter	O
normal	B-C0231262
body	I-C0231262
temperature	I-C0231262
.	O
	
however	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
febrile	B-C0015967
response	B-C0871261
that	O
was	O
induced	O
by	O
lps	B-C0023810
at	O
both	O
doses	O
was	O
observed	O
on	O
postnatal	B-C0443281
day	O
51	O
.	O
	
however	O
,	O
no	O
changes	O
in	O
the	O
febrile	B-C0015967
response	B-C0871261
were	O
observed	O
on	O
postnatal	B-C0443281
day	I-C0443281
63	O
in	O
etoh-exposed	B-C0814017
animals	B-C0034721
.	O
	
the	O
febrile	B-C0015967
response	B-C0871261
that	O
was	O
induced	O
by	O
intracerebroventricular	B-C0595818
il-1β	B-C0021753
also	O
significantly	O
decreased	O
in	O
animals	B-C0034721
that	O
received	O
binge-like	B-C0556346
etoh	B-C0814017
exposure	I-C0814017
during	O
adolescence	B-C0001578
.	O
	
acute	B-C1527415
oral	I-C1527415
treatment	I-C1527415
with	O
etoh	B-C0001962
24	O
h	O
prior	O
to	O
lps	B-C0023810
administration	B-C1533734
did	O
not	O
alter	O
the	O
febrile	B-C0015967
response	B-C0871261
that	O
was	O
induced	O
by	O
lps	B-C0023810
.	O
	
binge-like	B-C0556346
etoh	B-C0814017
exposure	I-C0814017
during	O
adolescence	B-C0001578
did	O
not	O
alter	O
hematological	B-C0018943
parameters	O
or	O
the	O
number	O
or	O
viability	B-C0007620
of	O
peritoneal	B-C0206190
macrophages	I-C0206190
.	O
	
binge-like	B-C0556346
etoh	B-C0814017
exposure	I-C0814017
did	O
not	O
alter	O
plasma	B-C0032105
il-1β	B-C0021753
levels	B-C0441889
but	O
reduced	O
the	O
cerebrospinal	B-C0007806
fluid	I-C0007806
levels	B-C0441889
of	O
this	O
cytokine	B-C0079189
.	O
	
these	O
results	O
suggest	O
that	O
binge-like	B-C0556346
etoh	B-C0814017
exposure	I-C0814017
during	O
adolescence	B-C0001578
causes	O
changes	O
in	O
the	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
that	O
can	O
impair	O
the	O
febrile	B-C0015967
response	B-C0871261
that	O
can	O
be	O
observed	O
after	O
the	O
cessation	B-C1880019
of	O
etoh	B-C0814017
exposure	I-C0814017
.	O
	
these	O
changes	O
were	O
reversible	O
and	O
appeared	O
to	O
involve	O
the	O
lps	B-C0023810
/	O
il-1β	B-C0021753
genital	B-C2945680
and	O
extragenital	B-C0018081
gonorrhea	I-C0018081
and	O
chlamydia	B-C0008149
in	O
children	B-C0008059
and	O
adolescents	B-C0205653
evaluated	B-C0220825
for	O
sexual	B-C0282350
abuse	I-C0282350
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
describe	O
the	O
use	O
of	O
a	O
nucleic	B-C0200932
acid	I-C0200932
amplification	I-C0200932
test	I-C0200932
in	O
detecting	B-C1511790
genital	B-C1993250
and	O
extragenital	B-C1993250
neisseria	I-C1993250
gonorrhoeae	I-C1993250
ng	B-C1993250
and	O
chlamydia	B-C0008151
trachomatis	I-C0008151
ct	B-C0008151
in	O
children	B-C0008059
and	O
adolescents	B-C0205653
assessed	B-C0184514
for	O
sexual	B-C0282350
abuse	I-C0282350
/	O
assault	B-C0237236
.	O
	
the	O
charts	O
of	O
children	B-C0008059
aged	B-C0001779
0	O
to	O
17	O
years	B-C0439234
,	O
consecutively	O
evaluated	B-C0220825
for	O
sexual	B-C0376695
victimization	I-C0376695
,	O
in	O
emergency	B-C0562508
department	I-C0562508
and	O
outpatient	B-C0013966
settings	I-C0013966
were	O
reviewed	O
.	O
	
data	B-C1511726
extracted	O
included	O
age	B-C0001779
,	O
sex	B-C0079399
,	O
type	O
of	O
sexual	B-C2229923
contact	I-C2229923
,	O
anogenital	B-C4071900
findings	B-C0243095
,	O
previous	B-C0205156
sexual	B-C2229923
contact	I-C2229923
,	O
toxicology	B-C2348811
results	I-C2348811
,	O
and	O
sites	B-C0205145
tested	B-C0022885
for	O
ng	B-C1993250
and	O
ct	B-C0008151
.	O
	
of	O
the	O
1319	O
patients	B-C0030705
who	O
were	O
tested	B-C0022885
,	O
579	O
were	O
tested	B-C0022885
at	O
more	O
than	O
1	O
site	B-C0205145
,	O
and	O
120	O
had	O
at	O
least	O
1	O
infected	B-C0439663
site	B-C0205145
.	O
	
chlamydia	B-C0008151
trachomatis	I-C0008151
was	O
identified	O
in	O
104	O
patients	B-C0030705
,	O
and	O
ng	B-C1993250
was	O
found	O
in	O
33	O
.	O
	
in	O
bivariate	B-C0681927
analysis	I-C0681927
,	O
a	O
positive	O
test	O
was	O
associated	B-C0332281
with	I-C0332281
female	B-C0086287
sex	I-C0086287
,	O
age	B-C0001779
older	O
than	O
11	O
years	B-C0439234
,	O
previous	B-C0205156
sexual	B-C2229923
contact	I-C2229923
,	O
acute	O
or	O
healed	B-C0205249
genital	B-C0560637
injury	I-C0560637
,	O
drug/alcohol	B-C4061089
intoxication	I-C4061089
,	O
and	O
examination	B-C0582103
within	O
72	O
hours	B-C0439227
of	O
sexual	B-C2229923
contact	I-C2229923
.	O
	
fifty-one	O
patients	B-C0030705
had	O
positive	B-C1514241
anal	B-C0003461
tests	B-C0022885
,	O
and	O
24	O
had	O
positive	B-C1514241
oral	B-C0442027
tests	B-C0022885
.	O
	
more	O
than	O
75%	O
of	O
patients	B-C0030705
with	O
positive	B-C1514241
extragenital	B-C0022885
tests	I-C0022885
had	O
additional	O
positive	B-C1514241
tests	B-C0022885
or	O
anogenital	B-C4071900
injury	B-C0178314
.	O
	
most	O
with	O
a	O
positive	B-C1514241
anal	B-C0003461
59%	O
or	O
oral	B-C0442027
77%	O
test	B-C0022885
did	O
not	O
report	O
that	O
the	O
assailant's	O
genitals	B-C0017420
came	O
into	O
contact	O
with	O
that	O
site	B-C0205145
.	O
	
positive	B-C1514241
tests	B-C0022885
for	O
ng	B-C1993250
and	O
ct	B-C0008151
in	O
patients	B-C0030705
evaluated	B-C0220825
for	O
sexual	B-C0376695
victimization	I-C0376695
may	O
represent	O
infection	B-C3714514
from	O
sexual	B-C2229923
contact	I-C2229923
,	O
contiguous	B-C0332261
spread	I-C0332261
of	O
infection	B-C3714514
,	O
or	O
the	O
presence	O
of	O
infected	B-C0036537
assailant	I-C0036537
secretions	I-C0036537
.	O
	
relying	O
on	O
patient	B-C0030705
reports	O
of	O
symptoms	B-C1457887
,	O
or	O
types	O
of	O
sexual	B-C2229923
contact	I-C2229923
,	O
to	O
determine	O
need	O
for	O
testing	O
may	O
miss	O
ng	B-C0948747
and	O
ct	B-C0518948
infections	I-C0518948
in	O
patients	B-C0030705
evaluated	B-C0220825
for	O
sexual	B-C0376695
victimization	I-C0376695
.	O
	
the	O
longitudinal	B-C0205127
effects	B-C1704420
of	I-C1704420
parenting	B-C0679001
on	O
adaptive	B-C0085880
behavior	I-C0085880
in	O
children	B-C0008059
with	O
fragile	B-C0016667
x	I-C0016667
syndrome	I-C0016667
several	O
studies	B-C2603343
have	O
reported	O
declines	B-C0392756
in	O
adaptive	B-C0085880
behavior	I-C0085880
amongst	O
children	B-C0008059
with	O
fragile	B-C0016667
x	I-C0016667
syndrome	I-C0016667
fxs	B-C0016667
starting	O
in	O
middle	B-C1254367
childhood	B-C0231335
.	O
	
we	O
examined	B-C0332128
the	O
effects	B-C1704420
of	I-C1704420
maternal	B-C0026591
responsivity	B-C2371924
on	O
adaptive	B-C0085880
behavior	I-C0085880
in	O
55	O
children	B-C0008059
with	O
fxs	B-C0016667
visited	O
5-6	O
times	O
in	O
their	O
homes	B-C0442513
from	O
early	O
through	O
middle	B-C1254367
childhood	B-C0231335
.	O
	
our	O
analyses	B-C0936012
indicated	O
that	O
sustained	B-C0443318
maternal	B-C0026591
responsivity	B-C2371924
had	O
a	O
significant	B-C0750502
positive	B-C4049986
impact	I-C4049986
on	O
the	O
trajectories	B-C1254362
of	O
communication	B-C0009452
and	O
to	O
a	O
lesser	O
extent	O
other	O
adaptive	B-C0085880
behavior	I-C0085880
domains	B-C1516778
through	O
middle	B-C1254367
childhood	B-C0231335
with	O
many	O
effects	B-C1280500
remaining	O
significant	B-C0750502
after	O
controlling	B-C2239193
for	O
autism	B-C4314700
symptoms	I-C4314700
and	O
developmental	B-C0008071
level	I-C0008071
.	O
	
for	O
children	B-C0008059
who	O
showed	O
declines	B-C0392756
in	O
adaptive	B-C0085880
behavior	I-C0085880
during	O
middle	B-C1254367
childhood	B-C0231335
,	O
sustained	B-C0443318
high	B-C0441889
levels	I-C0441889
of	O
maternal	B-C0026591
responsivity	B-C2371924
minimized	B-C1524031
the	O
amount	O
of	O
decline	B-C0392756
observed	B-C1441672
in	O
the	O
communication	B-C0009452
,	O
socialization	B-C0037447
,	O
and	O
daily	B-C0683251
living	I-C0683251
domains	I-C0683251
.	O
	
development	B-C1527148
and	O
validation	B-C1519941
of	O
a	O
new	O
reliable	O
method	B-C0022885
for	O
the	O
diagnosis	B-C0011900
of	O
avian	B-C0005595
botulism	B-C0006057
liver	B-C0023884
is	O
a	O
reliable	O
matrix	B-C1706515
for	O
laboratory	B-C0022885
confirmation	B-C0521091
of	I-C0521091
avian	B-C0005595
botulism	B-C0006057
using	O
real-time	B-C1709846
pcr	I-C1709846
.	O
	
here	O
,	O
we	O
developed	B-C1527148
,	O
optimized	B-C2698650
,	O
and	O
validated	B-C1519941
the	O
analytical	B-C0936012
steps	B-C1261552
preceding	B-C0332152
pcr	B-C0032520
to	O
maximize	O
the	O
detection	B-C0442726
of	O
clostridium	B-C4303900
botulinum	I-C4303900
group	I-C4303900
iii	I-C4303900
in	O
avian	B-C0005595
liver	B-C0023884
.	O
	
these	O
pre	B-C0332152
-	O
pcr	B-C0032520
steps	B-C1261552
included	O
enrichment	B-C0010454
incubation	B-C1439852
of	O
the	O
whole	O
liver	B-C0023884
maximum	O
25	O
g	O
at	O
37	B-C1545716
for	O
at	O
least	O
24	O
h	B-C0439227
in	O
an	O
anaerobic	B-C0179876
chamber	I-C0179876
and	O
dna	B-C3839098
extraction	I-C3839098
using	O
an	O
enzymatic	B-C0523169
digestion	I-C0523169
step	O
followed	O
by	O
a	O
dna	B-C0872148
purification	I-C0872148
step	O
.	O
	
conditions	O
of	O
sample	B-C2347026
storage	B-C1698986
before	O
analysis	B-C0936012
appear	O
to	O
have	O
a	O
strong	O
effect	B-C1280500
on	O
the	O
detection	B-C0442726
of	O
group	B-C4304189
iii	I-C4304189
c	I-C4304189
.	O
	
botulinum	I-C4304189
strains	I-C4304189
and	O
our	O
results	B-C1274040
recommend	O
storage	B-C1698986
at	O
temperatures	B-C0039476
below	O
-18	O
.	O
	
short-term	B-C0443303
storage	B-C1698986
at	O
5	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	B-C0439227
,	O
but	O
a	O
decrease	B-C0547047
in	O
sensitivity	B-C0332324
was	O
observed	O
at	O
48	O
h	B-C0439227
of	O
storage	B-C1698986
at	O
this	O
temperature	B-C0039476
.	O
	
analysis	B-C0936012
of	O
whole	O
livers	B-C0023884
maximum	O
25	O
g	O
is	O
required	O
and	O
pooling	B-C2349200
samples	B-C2347026
before	O
enrichment	B-C0040284
culturing	I-C0040284
must	O
be	O
avoided	O
.	O
	
pooling	B-C2349200
is	O
however	O
possible	O
before	O
or	O
after	O
dna	B-C3839098
extraction	I-C3839098
under	O
certain	O
conditions	O
.	O
	
whole	O
livers	B-C0023884
should	O
be	O
10-fold	O
diluted	O
in	O
enrichment	B-C0010454
medium	I-C0010454
and	O
homogenized	O
using	O
a	O
pulsifier	B-C0492537
blender	I-C0492537
microgen	O
,	O
surrey	B-C0454877
,	O
uk	B-C0041700
instead	O
of	O
a	O
conventional	O
paddle	B-C0492537
blender	I-C0492537
.	O
	
spiked	B-C0023884
liver	I-C0023884
samples	B-C2347026
showed	O
a	O
limit	O
of	O
detection	B-C0442726
of	O
5	O
spores	B-C0038028
/g	O
liver	B-C0023884
for	O
types	B-C4304189
c	I-C4304189
and	O
d	B-C4304187
and	O
250	O
spores	B-C0038028
/g	O
for	O
type	B-C4303900
e	I-C4303900
.	O
	
using	O
the	O
method	B-C0022885
developed	B-C1527148
here	O
,	O
the	O
analysis	B-C0936012
of	O
268	O
samples	B-C2347026
from	O
73	O
suspected	O
outbreaks	B-C0021149
showed	O
100%	O
specificity	B-C0037791
and	O
95.35	O
sensitivity	B-C0332324
compared	B-C1707455
with	O
other	O
pcr	B-C0032520
-based	O
methods	B-C0022885
considered	O
as	O
reference	O
.	O
	
the	O
mosaic	B-C4304189
type	I-C4304189
c	I-C4304189
/	O
d	B-C4304187
was	O
the	O
most	O
common	O
neurotoxin	B-C0027934
type	O
found	O
in	O
examined	O
samples	B-C2347026
,	O
which	O
included	O
both	O
wild	B-C0325328
and	O
domestic	B-C0324556
birds	I-C0324556
.	O
	
quality	B-C2936612
improvement	I-C2936612
of	O
liver	B-C0023884
ultrasound	B-C0041618
images	B-C1704922
using	O
fuzzy	B-C0162586
techniques	B-C0025663
liver	B-C0023884
ultrasound	B-C0041618
images	B-C1704922
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	B-C0011900
diffuse	B-C0023895
liver	I-C0023895
diseases	I-C0023895
like	O
fatty	B-C0015695
liver	I-C0015695
.	O
	
however	O
,	O
the	O
low	B-C0205251
quality	B-C0332306
of	O
such	O
images	B-C1704922
makes	O
it	O
difficult	O
to	O
analyze	B-C0936012
them	O
and	O
diagnose	B-C0011900
diseases	B-C0012634
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
,	O
therefore	O
,	O
is	O
to	O
improve	O
the	O
contrast	B-C1979874
and	O
quality	B-C0332306
of	O
liver	B-C0023884
ultrasound	B-C0041618
images	B-C1704922
.	O
	
in	O
this	O
study	B-C2603343
,	O
a	O
number	O
of	O
image	B-C1704922
contrast	B-C1979874
enhancement	B-C0002045
algorithms	I-C0002045
which	O
are	O
based	O
on	O
fuzzy	B-C0162586
logic	I-C0162586
were	O
applied	O
to	O
liver	B-C0023884
ultrasound	B-C0041618
images	B-C1704922
-	O
in	O
which	O
the	O
view	O
of	O
kidney	B-C0022646
is	O
observable	O
-	O
using	O
matlab2013b	B-C0037585
to	O
improve	O
the	O
image	B-C1704922
contrast	B-C1979874
and	O
quality	B-C0332306
which	O
has	O
a	O
fuzzy	B-C0162586
definition	B-C1704788
just	O
like	O
image	B-C1704922
contrast	B-C1979874
improvement	B-C2986411
algorithms	B-C0002045
using	O
a	O
fuzzy	B-C0162586
intensification	B-C0181273
operator	I-C0181273
,	O
contrast	B-C1979874
improvement	B-C2986411
algorithms	B-C0002045
applying	O
fuzzy	B-C0162586
image	B-C1704922
histogram	B-C0025663
hyperbolization	I-C0025663
,	O
and	O
contrast	B-C1979874
improvement	B-C2986411
algorithms	B-C0002045
by	O
fuzzy	B-C0162586
if-then	B-C0870077
rules	I-C0870077
.	O
	
with	O
the	O
measurement	B-C0242485
of	O
mean	B-C0743559
squared	I-C0743559
error	I-C0743559
and	O
peak	B-C0444505
signal	B-C2986823
to	I-C2986823
noise	I-C2986823
ratio	I-C2986823
obtained	O
from	O
different	O
images	B-C1704922
,	O
fuzzy	B-C0162586
methods	B-C0025663
provided	O
better	O
results	B-C1274040
,	O
and	O
their	O
implementation	B-C1708476
-	O
compared	B-C1707455
with	O
histogram	B-C0025663
equalization	I-C0025663
method	I-C0025663
-	O
led	O
both	O
to	O
the	O
improvement	B-C2986411
of	O
contrast	B-C1979874
and	O
visual	B-C0422976
quality	I-C0422976
of	O
images	B-C1704922
and	O
to	O
the	O
improvement	B-C2986411
of	O
liver	B-C0023884
segmentation	B-C0002045
algorithms	I-C0002045
results	O
in	O
images	B-C1704922
.	O
	
comparison	B-C1707455
of	O
the	O
four	O
algorithms	B-C0002045
revealed	O
the	O
power	O
of	O
fuzzy	B-C0162586
logic	I-C0162586
in	O
improving	O
image	B-C1704922
contrast	B-C1979874
compared	B-C1707455
with	O
traditional	O
image	B-C0178706
processing	I-C0178706
algorithms	B-C0002045
.	O
	
moreover	O
,	O
contrast	B-C1979874
improvement	B-C2986411
algorithm	O
based	O
on	O
a	O
fuzzy	B-C0162586
intensification	B-C0181273
operator	I-C0181273
was	O
selected	O
as	O
the	O
strongest	O
algorithm	B-C0002045
considering	O
the	O
measured	O
indicators	O
.	O
	
this	O
method	B-C0025663
can	O
also	O
be	O
used	O
in	O
future	O
studies	B-C2603343
on	O
other	O
ultrasound	B-C0041618
images	B-C1704922
for	O
quality	B-C2936612
improvement	I-C2936612
and	O
other	O
image	B-C0178706
processing	I-C0178706
and	O
analysis	B-C0936012
applications	B-C4048755
.	O
	
development	B-C1527148
of	O
the	O
pediatric	B-C2698752
quality	I-C2698752
of	I-C2698752
life	I-C2698752
inventory	I-C2698752
neurofibromatosis	B-C0027831
type	I-C0027831
1	I-C0027831
module	B-C3542953
items	B-C0871509
for	O
children	B-C0008059
,	O
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
qualitative	B-C0681940
methods	I-C0681940
health-related	B-C4279947
quality	I-C4279947
of	I-C4279947
life	I-C4279947
hrqol	B-C4279947
is	O
arguably	O
one	O
of	O
the	O
most	O
important	B-C3898777
measures	B-C0079809
in	O
evaluating	B-C0220825
effectiveness	B-C1280519
of	O
clinical	B-C1516635
treatments	I-C1516635
.	O
	
at	O
present	O
,	O
there	O
is	O
no	O
disease	B-C0012634
-	O
specific	B-C0205369
outcome	B-C0086749
measure	I-C0086749
to	O
assess	B-C0184514
the	O
hrqol	B-C4279947
of	O
children	B-C0008059
,	O
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
with	O
neurofibromatosis	B-C0027831
type	I-C0027831
1	I-C0027831
nf1	B-C0027831
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
develop	O
the	O
items	B-C0871509
and	O
support	O
the	O
content	B-C1510592
validity	I-C1510592
for	O
the	O
pediatric	B-C2698752
quality	I-C2698752
of	I-C2698752
life	I-C2698752
inventory	I-C2698752
pedsql	B-C2698752
nf1	B-C0027831
module	B-C3542953
for	O
children	B-C0008059
,	O
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
.	O
	
the	O
iterative	B-C1854293
process	B-C1522240
included	O
multiphase	B-C0681940
qualitative	I-C0681940
methods	I-C0681940
including	O
a	O
literature	B-C0282441
review	I-C0282441
,	O
survey	B-C0038951
of	O
expert	B-C0600219
opinions	I-C0600219
,	O
semi-structured	B-C0021822
interviews	I-C0021822
,	O
cognitive	B-C1516691
interviews	B-C0021822
and	O
pilot	B-C0031928
testing	I-C0031928
.	O
	
fifteen	O
domains	B-C1880389
were	O
derived	O
from	O
the	O
qualitative	B-C0681940
methods	I-C0681940
,	O
with	O
content	B-C0456205
saturation	O
achieved	O
,	O
resulting	O
in	O
115	O
items	B-C0871509
.	O
	
the	O
domains	B-C1880389
include	O
skin	B-C1123023
,	O
pain	B-C0030193
,	O
pain	B-C0030193
impact	B-C4049986
,	O
pain	B-C0002766
management	I-C0002766
,	O
cognitive	B-C0392335
functioning	I-C0392335
,	O
speech	B-C0037817
,	O
fine	B-C0678857
motor	I-C0678857
,	O
balance	B-C0205415
,	O
vision	B-C0042789
,	O
perceived	B-C0030971
physical	B-C0750731
appearance	I-C0750731
,	O
communication	B-C0009452
,	O
worry	B-C0233481
,	O
treatment	B-C0087111
,	O
medicines	B-C0013227
and	O
gastrointestinal	B-C0426576
symptoms	I-C0426576
.	O
	
this	O
study	O
is	O
limited	B-C0439801
because	O
all	O
participants	B-C0679646
are	O
recruited	O
from	O
a	O
single	B-C0205171
-	O
site	B-C0205145
.	O
	
qualitative	B-C0681940
methods	I-C0681940
support	O
the	O
content	B-C1510592
validity	I-C1510592
for	O
the	O
pedsql	B-C2698752
nf1	B-C0027831
module	B-C3542953
for	O
children	B-C0008059
,	O
adolescents	B-C0205653
and	O
young	B-C0238598
adults	I-C0238598
.	O
	
the	O
pedsql	B-C2698752
nf1	B-C0027831
module	B-C3542953
is	O
now	O
undergoing	O
national	B-C0039593
multisite	I-C0039593
field	I-C0039593
testing	I-C0039593
for	O
the	O
psychometric	B-C0033920
validation	B-C1519941
of	O
the	O
instrument	B-C0038951
development	B-C1527148
.	O
	
mimiviruses	B-C1671055
and	O
the	O
human	B-C0086418
interferon	B-C3652465
system	B-C0020962
viral	B-C1154492
evasion	I-C1154492
of	O
classical	B-C0443177
antiviral	B-C1155328
activities	I-C1155328
,	O
but	O
inhibition	B-C3463820
by	O
a	O
novel	O
interferon-β	B-C0015980
regulated	B-C1327622
immunomodulatory	B-C1963758
pathway	B-C1705987
in	O
this	O
review	B-C0282443
we	O
discuss	O
the	O
role	B-C1705810
of	O
mimiviruses	B-C1671055
as	O
potential	B-C3245505
human	B-C0086418
pathogens	B-C0450254
focusing	O
on	O
clinical	B-C0205210
and	O
evolutionary	B-C0015219
evidence	B-C3887511
.	O
	
we	O
also	O
propose	B-C1553874
a	O
novel	O
antiviral	B-C1155328
immunomodulatory	B-C0005525
pathway	B-C1705987
controlled	B-C2587213
by	O
interferon-β	B-C0015980
ifn-β	B-C0015980
and	O
mediated	O
by	O
immune-responsive	B-C3253749
gene	I-C3253749
1	I-C3253749
irg1	B-C3253749
and	O
itaconic	B-C0064110
acid	I-C0064110
,	O
its	O
product	B-C1514468
.	O
	
acanthamoeba	B-C1644952
polyphaga	I-C1644952
mimivirus	I-C1644952
apmv	B-C1644952
was	O
isolated	B-C0205409
from	O
amoebae	B-C0002642
in	O
a	O
hospital	B-C0019994
while	O
investigating	B-C1292732
a	O
pneumonia	B-C0032285
outbreak	B-C0012652
.	O
	
mimivirus	B-C1671055
ubiquity	B-C0205556
and	O
role	B-C1705810
as	O
protist	B-C0597305
pathogens	B-C0450254
are	O
well	O
understood	O
,	O
and	O
its	O
putative	B-C0205124
status	B-C1442792
as	O
a	O
human	B-C0086418
pathogen	B-C0450254
has	O
been	O
gaining	B-C1517378
strength	B-C0808080
as	O
more	O
evidence	B-C3887511
is	O
being	O
found	O
.	O
	
the	O
study	B-C2603343
of	O
apmv	B-C1644952
and	O
human	B-C0086418
cells	B-C0007634
interaction	B-C1752856
revealed	O
that	O
the	O
virus	B-C1671055
is	O
able	O
to	O
evade	B-C1654934
the	O
ifn	B-C0021747
system	B-C0020962
by	O
inhibiting	B-C3463820
the	O
regulation	B-C0017263
of	O
interferon	B-C3652465
-stimulated	O
genes	B-C0017337
,	O
suggesting	O
that	O
the	O
virus	B-C1671055
and	O
humans	B-C0086418
have	O
had	O
host-pathogen	B-C1752856
interactions	I-C1752856
.	O
	
it	O
also	O
has	O
shown	O
that	O
the	O
virus	B-C1671055
is	O
capable	B-C2698977
of	O
growing	O
on	O
ifn-α2	B-C2937361
,	O
but	O
not	O
on	O
ifn-β	B-C0015980
-	O
treated	B-C1522326
cells	B-C0007634
,	O
hinting	O
at	O
an	O
exclusive	B-C1548966
ifn-β	B-C0015980
antiviral	B-C1155328
pathway	B-C1705987
.	O
	
our	O
hypothesis	B-C1512571
based	B-C1705938
on	O
preliminary	B-C1548161
data	I-C1548161
and	O
published	B-C1706852
articles	I-C1706852
is	O
that	O
ifn-β	B-C0015980
preferentially	B-C0558295
upregulates	B-C0041904
irg1	B-C3253749
in	I-C3253749
human	I-C3253749
macrophagic	B-C0024432
cells	I-C0024432
,	O
which	O
in	O
turn	O
produces	O
itaconic	B-C0064110
acid	I-C0064110
.	O
	
this	O
metabolite	B-C0870883
links	O
metabolism	B-C0025519
to	O
antiviral	B-C1155328
activity	I-C1155328
by	O
inactivating	B-C0544461
the	O
virus	B-C1671055
,	O
in	O
a	O
novel	O
immunomodulatory	B-C1963758
pathway	B-C1705987
relevant	B-C2347946
for	O
apmv	B-C1644952
infections	B-C3714514
and	O
probably	O
to	O
other	O
infectious	B-C0009450
diseases	I-C0009450
heteroprotein	B-C0033684
complex	B-C1704241
formation	O
of	O
bovine	B-C1440867
lactoferrin	I-C1440867
and	O
pea	B-C3535674
protein	I-C3535674
isolate	B-C1875400
a	O
multiscale	O
structural	O
analysis	O
associative	B-C0205556
electrostatic	B-C0683119
interactions	I-C0683119
between	O
two	O
oppositely	B-C0205556
charged	B-C1706211
globular	B-C0178663
proteins	I-C0178663
,	O
lactoferrin	B-C0022942
lf	B-C0022942
and	O
pea	B-C3535674
protein	I-C3535674
isolate	B-C1875400
ppi	B-C3535674
,	O
the	O
latter	O
being	O
a	O
mixture	B-C0439962
of	O
vicilin	B-C0078228
,	O
legumin	B-C0064738
,	O
and	O
convicilin	B-C0056265
,	O
was	O
studied	B-C2603343
with	O
a	O
specific	B-C0205369
ppi	B-C3535674
/	O
lf	B-C0022942
molar	B-C2825550
ratio	I-C2825550
at	O
room	B-C1822393
temperature	I-C1822393
.	O
	
structural	B-C0678594
aspects	B-C1879746
of	O
the	O
electrostatic	B-C0376534
complexes	B-C1704241
probed	O
at	O
different	B-C1705242
length	B-C1444754
scales	B-C0449286
were	O
investigated	B-C1292732
as	O
a	O
function	B-C0542341
of	O
ph	B-C0020283
by	O
means	O
of	O
different	B-C1705242
complementary	B-C0449851
techniques	I-C0449851
,	O
namely	O
,	O
with	O
dynamic	B-C1882368
light	I-C1882368
scattering	I-C1882368
,	O
small-angle	B-C1537058
x-ray	I-C1537058
scattering	I-C1537058
saxs	B-C1660735
,	O
turbidity	B-C2700094
measurements	I-C2700094
,	O
and	O
atomic	B-C0242849
force	I-C0242849
microscopy	I-C0242849
afm	B-C0242849
.	O
	
irrespective	O
of	O
the	O
applied	O
techniques	B-C0449851
,	O
the	O
results	B-C0456984
consistently	B-C0332290
displayed	B-C0870432
that	O
complexation	B-C1704241
between	O
lf	B-C0022942
and	O
ppi	B-C3535674
did	O
occur	B-C1709305
.	O
	
in	O
an	O
optimum	B-C2698651
narrow	B-C0333164
range	B-C1514721
of	O
ph	B-C0020283
5.0	O
,	O
a	O
viscous	B-C0311419
liquid	B-C1304698
phase	B-C0205390
of	O
complex	B-C1704241
coacervate	B-C0302908
was	O
obtained	B-C1301820
upon	O
mild	O
centrifugation	B-C0007703
of	O
the	O
turbid	B-C0311420
lf	B-C0022942
-	O
ppi	B-C3535674
mixture	B-C0439962
with	O
a	O
maximum	B-C0806909
rh	O
,	O
turbidity	B-C0301633
and	O
the	O
ζ-potential	B-C0597697
being	O
close	O
to	O
zero	O
observed	B-C1441672
at	O
ph	B-C0020283
5.4	O
.	O
	
in	O
particular	O
,	O
the	O
saxs	B-C1660735
data	B-C1511726
demonstrated	O
that	O
the	O
coacervates	B-C0302908
were	O
densely	B-C0439794
assembled	B-C1706853
with	O
a	O
roughly	B-C0205556
spherical	B-C0332501
size	B-C0456389
distribution	B-C0037775
exhibiting	O
a	O
maximum	B-C0806909
extension	B-C0231448
of	O
80	O
nm	O
at	O
ph	B-C0020283
5.4	O
.	O
	
equally	O
,	O
afm	B-C0242849
image	B-C0200765
analysis	I-C0200765
showed	O
size	B-C0456389
distributions	B-C0037775
containing	B-C0332256
most	O
frequent	B-C0332183
cluster	B-C1704332
sizes	B-C0456389
around	O
40-80	O
nm	O
with	O
spherical	B-C0332501
to	O
elliptical	B-C1947977
shapes	I-C1947977
axis	O
aspect	O
ratio	O
2	O
as	O
well	O
as	O
less	O
frequent	B-C0332183
elongated	O
to	O
chainlike	B-C0205556
structures	B-C0678594
.	O
	
the	O
most	O
frequently	B-C0332183
observed	B-C1441672
compact	O
complexes	B-C1704241
,	O
we	O
identify	O
as	O
mainly	O
leading	O
to	O
lf	B-C0022942
-	O
ppi	B-C3535674
coacervation	B-C1882365
,	O
whereas	O
for	O
the	O
less	O
frequent	B-C0332183
chain-like	B-C0205418
aggregates	I-C0205418
,	O
we	O
hypothesize	O
that	O
additionally	O
ppi	B-C3535674
-	O
ppi	B-C3535674
facilitated	O
complexes	B-C1704241
visual	B-C0234621
outcome	B-C1274040
,	O
endocrine	B-C0678896
function	I-C0678896
and	O
tumor	B-C0027651
control	B-C2587213
after	O
fractionated	B-C4289264
stereotactic	I-C4289264
radiation	I-C4289264
therapy	I-C4289264
of	O
craniopharyngiomas	B-C0278875
in	I-C0278875
adults	I-C0278875
findings	O
in	O
a	O
prospective	B-C1709709
cohort	I-C1709709
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
examine	B-C0582103
visual	B-C0234621
outcome	B-C1274040
,	O
endocrine	B-C0678896
function	I-C0678896
and	O
tumor	B-C0027651
control	B-C2587213
in	O
a	O
prospective	B-C1709709
cohort	I-C1709709
of	O
craniopharyngioma	B-C0010276
patients	B-C0030705
,	O
treated	B-C0332293
with	I-C0332293
fractionated	B-C4289264
stereotactic	I-C4289264
radiation	I-C4289264
therapy	I-C4289264
fsrt	B-C4289264
.	O
	
sixteen	O
adult	B-C0001675
patients	B-C0030705
with	O
craniopharyngiomas	B-C0010276
were	O
eligible	B-C1548635
for	O
analysis	B-C0936012
.	O
	
they	O
were	O
treated	B-C0332293
with	I-C0332293
linear	B-C0221878
accelerator-based	I-C0221878
fsrt	B-C4289264
during	O
1999-2015	O
.	O
	
in	O
all	O
cases	B-C1706256
,	O
diagnosis	B-C1704656
was	O
confirmed	O
by	O
histological	B-C0205462
analysis	B-C0936012
.	O
	
the	O
prescription	B-C0033080
dose	B-C0178602
to	O
the	O
tumor	B-C0027651
was	O
54	O
gy	B-C0556636
median	B-C0876920
,	O
range	B-C1514721
48-54	O
in	O
1.8	O
or	O
2.0	O
gy	B-C0556636
per	O
fraction	B-C1264633
,	O
and	O
the	O
maximum	O
radiation	B-C4019308
dose	I-C4019308
to	O
the	O
optic	B-C0029130
nerves	I-C0029130
and	O
chiasm	B-C0029126
was	O
54.2	O
gy	B-C0556636
median	B-C0876920
,	O
range	B-C1514721
48.6	O
for	O
the	O
cohort	B-C0599755
.	O
	
serial	O
ophthalmological	B-C0200149
and	O
endocrine	B-C2960670
evaluations	I-C2960670
and	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
mri	B-C0024485
scans	B-C0441633
were	O
performed	O
at	O
regular	O
intervals	O
.	O
	
median	B-C0876920
follow-up	B-C1522577
was	O
3.3	O
years	B-C0439234
range	B-C1514721
1.1	O
,	O
3.7	O
years	B-C0439234
range	B-C1514721
0.8	O
,	O
and	O
3.6	O
years	B-C0439234
range	B-C1514721
0.7	O
for	O
visual	B-C0234621
outcome	B-C1274040
,	O
endocrine	B-C0678896
function	I-C0678896
,	O
and	O
tumor	B-C0027651
control	B-C2587213
,	O
respectively	O
.	O
	
visual	B-C0042812
acuity	I-C0042812
impairment	B-C0221099
was	O
present	O
in	O
10	O
patients	B-C0030705
62.5	O
and	O
visual	B-C3887875
field	I-C3887875
defects	I-C3887875
were	O
present	O
in	O
12	O
patients	B-C0030705
75%	O
before	O
fsrt	B-C4289264
.	O
	
one	O
patient	B-C0030705
developed	O
radiation-induced	B-C4302401
optic	I-C4302401
neuropathy	I-C4302401
at	O
seven	O
years	B-C0439234
after	O
fsrt	B-C4289264
.	O
	
thirteen	O
of	O
16	O
patients	B-C0030705
81.3	O
had	O
pituitary	B-C0020635
deficiency	I-C0020635
before	O
fsrt	B-C4289264
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary	B-C0020635
deficiency	I-C0020635
after	O
fsrt	B-C4289264
.	O
	
mean	B-C0444504
tumor	B-C0475276
volume	I-C0475276
pre-	O
fsrt	B-C4289264
was	O
2.72	O
cm	O
range	B-C1514721
0.20	O
and	O
post-	O
fsrt	B-C4289264
1.2	O
cm	O
range	B-C1514721
0.00	O
.	O
	
tumor	B-C0027651
control	B-C2587213
rate	B-C1521828
was	O
81.3	O
at	O
two	O
,	O
five	O
,	O
and	O
10	O
years	B-C0439234
after	O
fsrt	B-C4289264
.	O
	
fsrt	B-C4289264
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	B-C0599755
of	O
craniopharyngiomas	B-C0010276
,	O
with	O
only	O
one	O
case	B-C1706256
of	O
radiation-induced	B-C4302401
optic	I-C4302401
neuropathy	I-C4302401
and	O
no	O
case	B-C1706256
of	O
new	O
endocrinopathy	B-C0014130
.	O
	
tumor	B-C0027651
control	B-C2587213
rate	B-C1521828
scutellaria	B-C1999758
barbata	I-C1999758
d	I-C1999758
.	O
	
don	I-C1999758
extract	I-C1999758
inhibits	B-C3463820
the	O
tumor	B-C0598934
growth	I-C0598934
through	O
down-regulating	B-C0013081
of	O
treg	B-C0039198
cells	I-C0039198
and	O
manipulating	B-C2584326
th1	B-C1155080
/	O
th17	B-C3156592
immune	I-C3156592
response	I-C3156592
in	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
previous	O
studies	O
showed	O
scutellaria	B-C1999758
barbata	I-C1999758
d	I-C1999758
.	O
	
don	I-C1999758
extract	I-C1999758
sbe	B-C1999758
is	O
a	O
potent	O
inhibitor	B-C0018282
in	O
hepatoma	B-C0023903
and	O
could	O
improve	O
immune	B-C1817756
function	I-C1817756
of	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
.	O
	
however	O
,	O
the	O
immunomodulatory	B-C1148560
function	I-C1148560
of	O
sbe	B-C1999758
on	O
the	O
tumor	B-C0598934
growth	I-C0598934
of	O
hepatoma	B-C0023903
remains	O
unclear	B-C3845108
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
investigate	B-C1292732
the	O
anti-tumor	B-C2986475
effects	B-C1280500
of	O
sbe	B-C1999758
on	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
and	O
explore	O
the	O
underlying	O
immunomodulatory	B-C1148560
function	I-C1148560
.	O
	
the	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
were	O
treated	B-C1522326
by	O
sbe	B-C1999758
for	O
30	O
days	B-C0439228
.	O
	
the	O
effect	B-C1704420
of	I-C1704420
sbe	B-C1999758
on	O
the	O
proliferation	B-C0596290
of	O
hepg2	B-C2717940
cells	I-C2717940
in	B-C1533691
vitro	I-C1533691
,	O
the	O
growth	B-C0598934
of	I-C0598934
transplanted	I-C0598934
tumor	I-C0598934
,	O
the	O
cytotoxicity	B-C1159807
of	I-C1159807
natural	I-C1159807
killer	I-C1159807
nk	I-C1159807
cells	I-C1159807
in	O
spleen	B-C0037993
,	O
the	O
amount	B-C1265611
of	O
cd4	B-C3830403
treg	I-C3830403
cells	I-C3830403
and	O
th17	B-C2936411
cells	I-C2936411
in	O
tumor	B-C0475358
tissue	I-C0475358
,	O
and	O
the	O
levels	B-C0441889
of	O
il-10	B-C3179724
,	O
tgf-β	B-C0076930
,	O
il-17a	B-C1705947
,	O
il-2	B-C0021756
,	O
and	O
ifn-γ	B-C0211279
in	O
serum	B-C0229671
of	O
the	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
was	O
observered	O
.	O
	
il-17a	B-C1705947
was	O
injected	B-C0449894
to	O
the	O
sbe	B-C1999758
treated	B-C1522326
mice	B-C0025929
from	O
day	B-C0439228
9	O
post	B-C0687676
h22	B-C0677626
inoculation	B-C2987620
to	O
examine	O
its	O
effect	B-C1280500
on	O
tumor	B-C0598934
growth	I-C0598934
.	O
	
sbe	B-C1999758
treatment	B-C1522326
inhibited	B-C0311403
the	O
proliferation	B-C0596290
of	O
hepg2	B-C2717940
cells	I-C2717940
in	B-C1533691
vitro	I-C1533691
with	O
a	O
dose-dependent	B-C0205245
manner	I-C0205245
and	O
significantly	O
suppressed	B-C1260953
the	O
tumor	B-C0598934
growth	I-C0598934
of	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
.	O
	
meanwhile	O
,	O
it	O
increased	B-C0205217
nk	B-C1159807
cells'	I-C1159807
cytotoxicity	I-C1159807
in	O
spleen	B-C0037993
,	O
down-regulated	B-C0013081
the	O
amount	B-C1265611
of	O
cd4	B-C3830403
treg	I-C3830403
cells	I-C3830403
and	O
th17	B-C2936411
cells	I-C2936411
in	O
tumor	B-C0475358
tissue	I-C0475358
,	O
and	O
decreased	B-C0205216
il-10	B-C3179724
,	O
tgf-β	B-C0076930
,	O
and	O
il-17a	B-C1705947
levels	B-C0441889
p	O
<	O
0.01	O
whereas	O
increased	B-C0205217
il-2	B-C0021756
and	O
ifn-γ	B-C0211279
levels	B-C0441889
p	O
<	O
0.01	O
in	O
the	O
serum	B-C0229671
of	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
.	O
	
moreover	O
,	O
administration	B-C0001555
of	O
recombinant	B-C0025929
mouse	I-C0025929
il-17a	B-C1705947
reversed	B-C1555029
the	O
anti-tumor	B-C2986475
effects	B-C1280500
of	O
sbe	B-C1999758
.	O
	
sbe	B-C1999758
could	O
inhibit	B-C3463820
the	O
proliferation	B-C0596290
of	O
hepg2	B-C2717940
cells	I-C2717940
in	B-C1533691
vitro	I-C1533691
.	O
	
meanwhile	O
,	O
sbe	B-C1999758
also	O
could	O
inhibit	B-C3463820
the	O
growth	B-C0007595
of	O
h22	B-C0677626
implanted	B-C0027651
tumor	I-C0027651
in	O
hepatoma	B-C0677626
h22	I-C0677626
-bearing	O
mice	B-C0025929
,	O
and	O
this	O
function	B-C0542341
might	O
be	O
associated	B-C0332281
with	I-C0332281
immunomodulatory	B-C1148560
activity	I-C1148560
through	O
down-regulating	B-C0013081
of	O
treg	B-C0039198
cells	I-C0039198
and	O
manipulating	B-C2584326
th1	B-C1155080
/	O
th17	B-C3156592
immune	I-C3156592
response	I-C3156592
.	O
	
clinical	B-C0683325
characteristics	I-C0683325
of	O
genital	B-C0847922
chlamydia	I-C0847922
infection	I-C0847922
in	O
pelvic	B-C0242172
inflammatory	I-C0242172
disease	I-C0242172
chlamydia	B-C0008149
infection	I-C0008149
in	O
acute	B-C0149959
pelvic	I-C0149959
inflammatory	I-C0149959
disease	I-C0149959
pid	B-C0242172
is	O
associated	O
with	O
serious	O
complications	B-C0009566
including	O
ectopic	B-C0032987
pregnancy	I-C0032987
,	O
tubal	B-C0156415
infertility	I-C0156415
,	O
fitz-hugh-curtis	B-C0549148
syndrome	I-C0549148
and	O
tubo-ovarian	B-C0041343
abscess	I-C0041343
toa	B-C0041343
.	O
	
this	O
study	B-C2603343
compared	O
clinical	B-C1516606
and	O
laboratory	B-C1517709
data	I-C1517709
between	O
pid	B-C0242172
with	O
and	O
without	O
chlamydia	B-C0008149
infection	I-C0008149
.	O
	
the	O
medical	B-C0025102
records	I-C0025102
of	O
497	O
women	B-C0043210
who	O
were	O
admitted	O
with	O
pid	B-C0242172
between	O
2002	O
and	O
2011	O
were	O
reviewed	O
.	O
	
the	O
patients	B-C0030705
were	O
divided	O
into	O
two	O
groups	B-C1257890
pid	B-C0242172
with	O
and	O
without	O
chlamydia	B-C0008149
infection	I-C0008149
,	O
which	O
were	O
compared	O
in	O
terms	O
of	O
the	O
patients'	B-C0815172
characteristics	I-C0815172
,	O
clinical	B-C2708283
presentation	I-C2708283
,	O
and	O
laboratory	B-C0587081
findings	I-C0587081
,	O
including	O
inflammatory	B-C0333348
markers	B-C0005516
.	O
	
the	O
chlamydia	B-C1257890
and	O
non-chlamydia	B-C1257890
groups	I-C1257890
comprised	O
175	O
and	O
322	O
women	B-C0043210
,	O
respectively	O
.	O
	
the	O
patients	B-C0030705
in	O
the	O
chlamydia	B-C1257890
group	I-C1257890
were	O
younger	B-C0332239
and	O
had	O
a	O
higher	O
rate	O
of	O
toa	B-C0041343
,	O
a	O
longer	O
mean	B-C0444504
hospital	B-C3489408
stay	I-C3489408
,	O
and	O
had	O
undergone	O
more	O
surgeries	B-C0543467
than	O
the	O
patients	B-C0030705
in	O
the	O
non-	B-C1257890
chlamydia	I-C1257890
group	I-C1257890
.	O
	
the	O
erythrocyte	B-C1619634
sedimentation	I-C1619634
rate	I-C1619634
esr	B-C1619634
,	O
c-reactive	B-C0006560
protein	I-C0006560
crp	B-C0006560
,	O
and	O
ca-125	B-C0006610
level	B-C0441889
were	O
higher	O
in	O
the	O
chlamydia	B-C1257890
group	I-C1257890
than	O
in	O
the	O
non-chlamydia	B-C1257890
group	I-C1257890
,	O
but	O
there	O
was	O
no	O
significant	B-C0750502
difference	O
in	O
the	O
white	B-C2186576
blood	I-C2186576
cell	I-C2186576
count	I-C2186576
between	O
the	O
two	O
groups	B-C1257890
.	O
	
the	O
ca-125	B-C0006610
level	B-C0441889
was	O
the	O
strongest	O
predictor	B-C2698872
of	O
chlamydia	B-C0008149
infection	I-C0008149
,	O
followed	O
by	O
the	O
esr	B-C1619634
and	O
crp	B-C0006560
level	B-C0441889
.	O
	
the	O
area	B-C0205146
under	O
the	O
receiving	B-C0035787
operating	I-C0035787
curve	I-C0035787
for	O
ca-125	B-C0006610
,	O
esr	B-C1619634
,	O
and	O
crp	B-C0006560
was	O
0.804	O
,	O
0.755	O
,	O
and	O
0.663	O
,	O
respectively	O
.	O
	
chlamydia	B-C0008149
infection	I-C0008149
in	O
acute	B-C0149959
pid	I-C0149959
is	O
associated	O
with	O
increased	O
level	B-C0441889
of	O
inflammatory	B-C0333348
markers	B-C0005516
,	O
such	O
as	O
ca-125	B-C0006610
,	O
esr	B-C1619634
and	O
crp	B-C0006560
,	O
incidence	O
of	O
toa	B-C0041343
,	O
operation	B-C0543467
risk	B-C0035647
,	O
and	O
longer	O
incidence	B-C0021149
and	O
effect	B-C1704420
of	I-C1704420
variant	B-C0205419
histology	B-C0019638
on	O
oncological	B-C0085415
outcomes	I-C0085415
in	O
patients	B-C0030705
with	O
bladder	B-C0005684
cancer	I-C0005684
treated	B-C1522326
with	O
radical	B-C0194401
cystectomy	I-C0194401
we	O
sought	O
to	O
describe	O
incidence	B-C0021149
of	O
histological	B-C0205462
variants	B-C0205419
after	O
radical	B-C0194401
cystectomy	I-C0194401
rc	B-C0194401
due	O
to	O
bladder	B-C0005684
cancer	I-C0005684
bca	B-C0005684
.	O
	
moreover	O
,	O
we	O
investigated	O
survival	B-C0220921
outcomes	B-C0085415
accounting	O
for	O
this	O
parameter	O
.	O
	
we	O
retrospectively	B-C1514923
evaluated	B-C0220825
data	B-C1511726
from	O
1	O
patients	B-C0030705
with	O
bca	B-C0005684
treated	B-C1522326
with	O
rc	B-C0194401
between	O
1990	O
and	O
2013	O
at	O
a	O
single	B-C0587437
tertiary	I-C0587437
care	I-C0587437
referral	I-C0587437
center	I-C0587437
.	O
	
all	O
specimen	B-C0370003
were	O
evaluated	B-C0220825
by	O
dedicated	O
uropathologists	B-C1522486
.	O
	
univariable	B-C0034980
and	I-C0034980
multivariable	I-C0034980
cox	I-C0034980
regression	I-C0034980
analyses	I-C0034980
tested	O
the	O
effect	B-C1704420
of	I-C1704420
different	O
histopathological	B-C0243140
variant	B-C0205419
on	O
recurrence	B-C0034897
,	O
cancer-specific	B-C1516192
mortality	I-C1516192
csm	B-C1516192
,	O
and	O
overall	B-C0205848
mortality	I-C0205848
om	B-C0205848
after	O
accounting	O
for	O
all	O
available	O
confounders	B-C0009673
.	O
	
of	O
1	O
patients	B-C0030705
,	O
729	O
68.3	O
harbored	O
pure	B-C0751571
urothelial	I-C0751571
bca	I-C0751571
while	O
338	O
31.7	O
were	O
found	O
to	O
have	O
a	O
variant	B-C0205419
.	O
	
considering	O
uncommon	O
variants	B-C0205419
,	O
21	O
2.0	O
were	O
sarcomatoid	B-C0205697
,	O
10	O
0.9	O
lymphoepitelial	B-C0334254
,	O
19	O
1.8	O
small	B-C0262584
cell	I-C0262584
,	O
109	O
10.2	O
squamous	B-C0007137
,	O
89	O
8.3	O
micropapillary	B-C3472608
,	O
23	O
2.2	O
glandular	B-C0205854
,	O
34	O
3.2	O
mixed	O
variants	B-C0205419
,	O
and	O
33	O
3.1	O
were	O
found	O
with	O
other	O
types	O
of	O
variants	B-C0205419
.	O
	
with	O
a	O
median	B-C0876920
follow-up	B-C1522577
of	O
6.2	O
years	B-C0439234
,	O
343	O
recurrence	B-C0034897
,	O
365	O
csm	B-C1516192
,	O
and	O
451	O
om	B-C0205848
were	O
recorded	O
,	O
respectively	O
.	O
	
at	O
multivariable	B-C0034980
cox	I-C0034980
regression	I-C0034980
analyses	I-C0034980
,	O
the	O
presence	O
of	O
small	B-C0262584
cell	I-C0262584
variant	I-C0262584
was	O
associated	B-C0332281
with	I-C0332281
higher	O
recurrence	B-C0034897
hazard	B-C2985465
ratio	I-C2985465
hr	B-C2985465
=	O
3.47	O
,	O
p<0	O
,	O
csm	B-C1516192
hr	B-C2985465
=	O
3.30	O
,	O
p<0	O
,	O
and	O
om	B-C0205848
hr	B-C2985465
=	O
2.97	O
,	O
p<0	O
as	O
compared	O
with	O
pure	O
urothelial	B-C0751571
cancer	I-C0751571
.	O
	
conversely	O
,	O
no	B-C3842396
survival	I-C3842396
differences	I-C3842396
were	O
recorded	O
considering	O
other	O
histological	B-C0205462
variants	B-C0205419
all	O
p>	O
0.1	O
.	O
	
our	O
study	B-C1706256
confirms	O
that	O
histological	B-C0205462
variant	B-C0205419
is	O
not	O
an	O
infrequent	O
event	O
at	O
rc	B-C0194401
specimen	B-C0370003
.	O
	
however	O
,	O
in	O
our	O
single-center	B-C1708333
series	I-C1708333
,	O
only	O
patients	B-C0030705
found	O
with	O
small	B-C0262584
cell	I-C0262584
variant	I-C0262584
were	O
associated	B-C0332281
with	I-C0332281
a	O
negative	B-C0205160
effect	B-C1280500
on	O
survival	B-C0220921
after	O
psychometric	B-C0033920
properties	B-C0871161
of	O
the	O
japanese	B-C0376247
version	B-C0333052
of	O
short	B-C2964478
forms	I-C2964478
of	O
the	O
pain	B-C4273905
catastrophizing	I-C4273905
scale	I-C4273905
in	O
participants	B-C0679646
with	O
musculoskeletal	B-C0026858
pain	I-C0026858
a	O
cross-sectional	B-C0010362
study	I-C0010362
the	O
pain	B-C4273905
catastrophizing	I-C4273905
scale	I-C4273905
pcs	B-C4273905
is	O
a	O
commonly	O
used	O
as	O
measure	B-C0079809
of	O
pain	B-C3178745
catastrophizing	I-C3178745
.	O
	
the	O
scale	B-C4273905
comprises	O
13	O
items	B-C0871509
related	O
to	O
magnification	B-C0430022
,	O
rumination	B-C0232604
,	O
and	O
helplessness	B-C0150063
.	O
	
to	O
facilitate	O
quick	O
screening	B-C1710032
and	O
to	O
reduce	B-C0392756
participant's	B-C0679646
burden	B-C2828008
,	O
the	O
four-	O
item	B-C0871509
and	O
six-	O
item	B-C0871509
short	B-C2964478
forms	I-C2964478
of	O
the	O
english	B-C0376245
version	B-C0333052
of	O
the	O
pcs	B-C4273905
were	O
developed	O
.	O
	
the	O
purpose	O
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
evaluate	B-C0220825
the	O
psychometric	B-C0033920
properties	B-C0871161
of	O
a	O
japanese	B-C0376247
version	B-C0333052
of	O
the	O
short	B-C2964478
forms	I-C2964478
of	O
pcs	B-C4273905
using	O
a	O
contemporary	O
approach	B-C1292724
called	O
rasch	B-C0242481
analysis	I-C0242481
.	O
	
a	O
total	O
of	O
216	O
patients	B-C0030705
with	O
musculoskeletal	B-C0026857
disorders	I-C0026857
were	O
recruited	O
in	O
this	O
study	B-C2603343
.	O
	
participants	B-C0679646
completed	O
study	B-C2603343
measures	B-C0079809
,	O
which	O
included	O
the	O
pain	B-C1320357
intensity	I-C1320357
,	O
the	O
pain	B-C4273905
catastrophizing	I-C4273905
scale	I-C4273905
pcs	B-C4273905
,	O
and	O
the	O
tampa	B-C0349674
scale	I-C0349674
of	I-C0349674
kinesiophobia	I-C0349674
tsk	B-C0349674
.	O
	
furthermore	O
,	O
the	O
four-	O
item	B-C0871509
items	B-C0871509
3	O
,	O
6	O
,	O
8	O
,	O
and	O
11	O
and	O
six-	O
item	B-C0871509
items	B-C0871509
4	O
,	O
5	O
,	O
6	O
,	O
10	O
,	O
11	O
,	O
and	O
13	O
short	B-C2964478
forms	I-C2964478
of	O
the	O
japanese	B-C0376247
version	B-C0333052
of	O
pcs	B-C4273905
were	O
measured	O
.	O
	
we	O
used	O
rasch	B-C0242481
analysis	I-C0242481
to	O
analyze	B-C1524024
the	O
psychometric	B-C0033920
properties	B-C0871161
of	O
the	O
original	O
,	O
four-	O
item	B-C0871509
,	O
and	O
six-	O
item	B-C0871509
short	B-C2964478
forms	I-C2964478
of	O
pcs	B-C4273905
.	O
	
rasch	B-C0242481
analysis	I-C0242481
showed	O
that	O
both	O
short	B-C2964478
forms	I-C2964478
of	O
pcs	B-C4273905
had	O
acceptable	O
internal	O
consistency	B-C0332529
,	O
unidimensionality	B-C1707753
,	O
and	O
no	O
notable	O
dif	O
and	O
were	O
functional	B-C0205245
on	O
the	O
category	B-C0349674
rating	I-C0349674
scale	I-C0349674
.	O
	
however	O
,	O
four-	O
item	B-C0871509
short	B-C2964478
form	I-C2964478
of	O
pcs	B-C4273905
had	O
two	O
misfit	O
items	B-C0871509
.	O
	
six-	O
item	B-C0871509
short	B-C2964478
form	I-C2964478
of	O
pcs	B-C4273905
has	O
acceptable	O
psychometric	B-C0033920
properties	B-C0871161
and	O
is	O
suitable	O
for	O
use	O
in	O
participants	B-C0679646
with	O
musculoskeletal	B-C0026858
pain	I-C0026858
.	O
	
thus	O
,	O
six-	O
item	B-C0871509
can	O
be	O
used	O
as	O
brief	O
instruments	B-C0348000
to	O
evaluate	B-C0220825
pain	B-C3178745
catastrophizing	I-C3178745
.	O
	
a	O
novel	O
quantitative	B-C1709846
pcr	I-C1709846
detects	O
babesia	B-C0004572
infection	B-C3714514
in	O
patients	B-C0030705
not	O
identified	O
by	O
currently	O
available	O
non-nucleic	B-C1441475
acid	I-C1441475
amplification	I-C1441475
tests	I-C1441475
ticks	B-C0040203
transmit	B-C1444006
babesia	B-C0004574
microti	I-C0004574
,	O
the	O
causative	B-C0449411
agents	I-C0449411
of	O
babesiosis	B-C0004576
in	O
north	B-C0028405
america	I-C0028405
and	O
europe	B-C0015176
.	O
	
babesiosis	B-C0004576
is	O
now	O
endemic	B-C0277550
in	O
northeastern	B-C0017446
usa	B-C0041703
and	O
affects	O
people	B-C0027361
of	O
all	O
ages	B-C0001779
.	O
	
babesia	B-C0004572
species	I-C0004572
infect	O
erythrocytes	B-C0014792
and	O
can	O
be	O
transmitted	B-C0242781
through	O
blood	B-C0005841
transfusion	I-C0005841
.	O
	
whole	B-C0370231
blood	I-C0370231
and	O
blood	B-C0456388
products	I-C0456388
,	O
which	O
are	O
not	O
tested	O
for	O
babesia	B-C0004572
,	O
can	O
cause	O
transfusion	B-C0005841
-	O
transmitted	B-C0242781
babesiosis	B-C0004576
ttb	B-C0004576
resulting	O
in	O
severe	B-C0205082
consequences	B-C0686907
in	O
the	O
immuno-compromised	B-C0085393
patients	B-C0030705
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
epidemiological	B-C0002783
evaluation	I-C0002783
of	O
babesiosis	B-C0004576
in	O
a	O
tick-infested	B-C0040196
state	I-C0040196
.	O
	
we	O
examined	B-C0332128
blood	B-C0178913
samples	I-C0178913
from	O
192	O
patients	B-C0030705
who	O
visited	O
clinics	B-C0442592
during	O
the	O
active	O
tick-borne	B-C0040196
diseases	I-C0040196
season	B-C0036497
,	O
using	O
a	O
newly	O
developed	O
qpcr	B-C1709846
assay	I-C1709846
that	O
uses	O
the	O
specific	O
molecular	B-C0028630
beacon	I-C0028630
probe	I-C0028630
.	O
	
due	O
to	O
the	O
absence	B-C0332197
of	O
clear	O
symptomology	B-C1457887
,	O
clinical	B-C1882331
laboratories	I-C1882331
did	O
not	O
test	O
131	O
samples	B-C0178913
by	O
ifa	B-C0282647
,	O
fish	B-C0162789
or	O
microscopic	B-C0026018
examination	I-C0026018
of	O
giemsa-stained	B-C0017542
blood	B-C2238079
smears	I-C2238079
.	O
	
babesia	B-C0004572
infection	B-C3714514
was	O
detected	O
in	O
all	O
age	B-C0027362
groups	I-C0027362
by	O
fish	B-C0162789
and	O
microscopy	B-C0026018
notably	O
patients	B-C0030705
>40	O
years	B-C0439234
of	O
age	B-C0001779
represented	O
64%	O
of	O
tested	O
samples	B-C0178913
and	O
13%	O
were	O
younger	B-C0332239
patients	B-C0030705
.	O
	
we	O
tested	O
all	O
samples	B-C0178913
using	O
qpcr	B-C1709846
and	O
found	O
that	O
38%	O
were	O
positive	B-C1446409
for	O
babesia	B-C0004572
.	O
	
of	O
28	O
samples	B-C0178913
that	O
were	O
positive	B-C1446409
by	O
fish	B-C0162789
,	O
27	O
96%	O
were	O
also	O
positive	B-C1446409
by	O
qpcr	B-C1709846
indicating	O
high	O
congruency	O
between	O
nucleic	B-C0200932
acid	I-C0200932
based	I-C0200932
tests	I-C0200932
.	O
	
interestingly	O
,	O
of	O
78	O
asymptomatic	B-C0231221
samples	B-C0178913
not	O
tested	O
by	O
fish	B-C0162789
,	O
22	O
were	O
positive	B-C1446409
by	O
our	O
qpcr	B-C1709846
.	O
	
direct	O
detection	B-C1511790
of	O
babesia	B-C0004572
relies	O
upon	O
microscopic	B-C0026018
examination	I-C0026018
of	O
patient	B-C0030705
blood	B-C2238079
smears	I-C2238079
,	O
which	O
is	O
labor	O
intensive	O
,	O
difficult	O
to	O
scale	O
up	O
,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence	O
,	O
often	O
not	O
performed	O
.	O
	
in	O
fact	O
,	O
a	O
clinical	B-C1882331
laboratory	I-C1882331
examined	B-C0332128
only	O
23	O
of	O
86	O
blood	B-C0178913
samples	I-C0178913
obtained	O
from	O
two	O
different	O
counties	B-C0454664
by	O
microscopy	B-C0026018
.	O
	
by	O
considering	O
individuals	B-C0237401
positive	B-C1446409
for	O
babesia	B-C0004572
infection	B-C3714514
when	O
results	O
from	O
currently	O
available	O
microscopy	B-C0026018
,	O
fish	B-C0162789
or	O
serological	B-C0036743
tests	I-C0036743
were	O
positive	B-C1446409
,	O
we	O
found	O
that	O
our	O
qpcr	B-C1709846
is	O
highly	O
sensitive	B-C0332324
96.2	O
and	O
showed	O
a	O
specificity	B-C0037791
of	O
70.5	O
for	O
babesia	B-C0004572
.	O
	
robust	O
qpcr	B-C1709846
using	O
specific	O
probes	B-C0026381
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	B-C1704656
of	O
babesiosis	B-C0004576
in	O
patients	B-C0030705
in	O
conjunction	O
with	O
conventional	O
diagnostics	B-C1511890
,	O
or	O
as	O
a	O
stand-alone	O
test	O
,	O
especially	O
for	O
donated	O
blood	B-C1511226
screening	I-C1511226
.	O
	
the	O
use	O
of	O
a	O
nucleic	B-C0200932
acid	I-C0200932
amplification	I-C0200932
test	I-C0200932
based	O
screening	B-C1511226
of	I-C1511226
blood	I-C1511226
and	O
blood	B-C0456388
products	I-C0456388
could	O
prevent	O
historical	B-C0019659
relationships	I-C0019659
of	O
three	O
enigmatic	B-C0205556
phasianid	B-C0325635
genera	I-C0325635
aves	B-C0005595
galliformes	B-C0325589
inferred	O
using	O
phylogenomic	B-C2346460
and	I-C2346460
mitogenomic	I-C2346460
data	I-C2346460
the	O
phylogeny	B-C0031797
of	O
the	O
phasianidae	B-C0325635
pheasants	B-C0999292
,	O
partridges	B-C1828284
,	O
and	O
allies	B-C3973343
has	O
been	O
studied	O
extensively	O
.	O
	
however	O
,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic	B-C0205556
genera	I-C0205556
because	O
of	O
scarce	B-C0231180
dna	B-C0012854
source	B-C0449416
material	I-C0449416
and	O
limited	O
overlapping	O
phylogenetic	B-C0872179
data	I-C0872179
blood	B-C1035898
pheasants	I-C1035898
ithaginis	B-C1035898
,	O
snow	B-C3684199
partridges	I-C3684199
lerwa	B-C3684199
,	O
and	O
long-billed	B-C2291854
partridges	I-C2291854
rhizothera	B-C2291854
.	O
	
thus	O
,	O
phylogenetic	B-C0314647
positions	I-C0314647
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well-resolved	O
phylogeny	B-C0031797
.	O
	
previous	O
studies	O
using	O
different	O
data	B-C1511726
types	O
place	O
lerwa	B-C3684199
and	O
ithaginis	B-C1035898
in	O
similar	O
positions	O
,	O
but	O
the	O
absence	O
of	O
overlapping	B-C1948020
data	I-C1948020
means	O
the	O
relationship	B-C0439849
between	O
them	O
could	O
not	O
be	O
inferred	O
.	O
	
rhizothera	B-C2291854
was	O
originally	O
described	O
in	O
the	O
genus	O
perdix	B-C0999297
true	B-C0999297
partridges	I-C0999297
,	O
although	O
a	O
partial	O
cytochrome	B-C0010744
b	I-C0010744
cyb	B-C0010744
sequence	O
suggests	O
it	O
is	O
sister	B-C1546515
to	O
pucrasia	B-C0999301
koklass	B-C0999301
pheasant	I-C0999301
.	O
	
to	O
identify	O
robust	O
relationships	B-C0439849
among	O
ithaginis	B-C1035898
,	O
lerwa	B-C3684199
,	O
rhizothera	B-C2291854
,	O
and	O
their	O
phasianid	B-C0325635
relatives	I-C0325635
,	O
we	O
used	O
3692	O
ultra-conserved	B-C0678933
element	I-C0678933
uce	I-C0678933
loci	I-C0678933
and	O
complete	O
mitogenomes	B-C0017428
from	O
19	O
species	B-C1705920
including	O
previously	O
hypothesized	B-C1512571
relatives	B-C0439849
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid	B-C0325635
clades	I-C0325635
.	O
	
we	O
used	O
dna	B-C0012854
extracted	I-C0012854
from	O
historical	O
specimen	B-C1848515
toepads	I-C1848515
for	O
species	O
that	O
lacked	B-C2711421
fresh	I-C2711421
tissue	I-C2711421
in	O
museum	B-C0200345
collections	I-C0200345
.	O
	
maximum	O
likelihood	O
and	O
multispecies	B-C0026757
coalescent	I-C0026757
uce	I-C0026757
analyses	I-C0026757
strongly	O
supported	O
lerwa	B-C3684199
sister	B-C1546515
to	O
a	O
large	B-C0325635
clade	I-C0325635
which	O
included	O
ithaginis	B-C1035898
at	O
its	O
base	O
,	O
and	O
also	O
including	O
turkey	B-C3669390
,	O
grouse	B-C0325618
,	O
typical	O
pheasants	B-C0999292
,	O
tragopans	B-C0325686
,	O
pucrasia	B-C0999301
,	O
and	O
perdix	B-C0999297
.	O
	
rhizothera	B-C2291854
was	O
also	O
in	O
this	O
clade	B-C0325635
,	O
sister	B-C1546515
to	O
a	O
diverse	O
group	O
comprising	O
perdix	B-C0999297
,	O
typical	O
pheasants	B-C0999292
,	O
pucrasia	B-C0999301
,	O
turkey	B-C3669390
and	O
grouse	B-C0325618
.	O
	
mitogenomic	B-C0017298
genealogies	I-C0017298
differed	O
from	O
uces	B-C0205245
topologies	I-C0205245
,	O
supporting	O
a	O
sister	B-C1546515
relationship	I-C1546515
between	O
ithaginis	B-C1035898
and	O
lerwa	B-C3684199
rather	O
than	O
a	O
grade	O
.	O
	
the	O
position	O
of	O
rhizothera	B-C2291854
using	O
mitogenomes	B-C0017428
depended	O
on	O
analytical	B-C0936012
choices	I-C0936012
.	O
	
unpartitioned	O
and	O
codon-based	B-C0162802
analyses	I-C0162802
placed	O
rhizothera	B-C2291854
sister	B-C1546515
to	O
a	O
tragopan	B-C0325635
clade	I-C0325635
,	O
whereas	O
a	O
partitioned	O
dna	B-C0026343
model	I-C0026343
of	O
the	O
mitogenome	B-C0017428
was	O
congruent	B-C0439853
with	O
uce	B-C0243095
results	I-C0243095
.	O
	
in	O
all	O
mitogenome	B-C3854164
analyses	I-C3854164
,	O
pucrasia	B-C0999301
was	O
sister	B-C1546515
to	O
a	O
clade	B-C0325635
including	O
perdix	B-C0999297
and	O
the	O
typical	O
pheasants	B-C0999292
with	O
high	O
support	O
,	O
in	O
contrast	O
to	O
uces	O
and	O
published	B-C0993637
nuclear	I-C0993637
intron	I-C0993637
data	I-C0993637
.	O
	
due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	B-C0178476
provided	O
by	O
all	O
uce	B-C0178476
analyses	I-C0178476
,	O
we	O
have	O
identified	O
phylogenetic	B-C0031797
relationships	B-C0439849
of	O
these	O
three	O
enigmatic	B-C0205556
,	O
poorly-studied	O
,	O
phasianid	B-C0325635
taxa	I-C0325635
.	O
	
a	O
novel	B-C0205314
combination	O
treatment	B-C1522326
to	O
stimulate	B-C1292856
bone	B-C1321023
healing	I-C1321023
and	O
regeneration	B-C0005972
under	O
hypoxic	B-C0242184
conditions	I-C0242184
photobiomodulation	B-C4019433
and	O
melatonin	B-C0025219
melatonin	B-C0025219
has	O
anabolic	B-C3179309
effects	I-C3179309
on	O
the	O
bone	B-C0391978
,	O
even	O
under	O
hypoxia	B-C0242184
,	O
and	O
laser	B-C0871799
irradiation	I-C0871799
has	O
been	O
shown	O
to	O
improve	O
osteoblastic	B-C1159974
differentiation	I-C1159974
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
whether	O
laser	B-C0871799
irradiation	I-C0871799
and	O
melatonin	B-C0025219
would	O
have	O
synergistic	B-C2986495
effects	B-C1280500
on	O
osteoblastic	B-C1159974
differentiation	I-C1159974
and	O
mineralization	B-C2350989
under	O
hypoxic	B-C0242184
conditions	I-C0242184
.	O
	
mc3t3-e1	B-C0007634
cells	I-C0007634
were	O
exposed	O
to	O
1%	O
oxygen	B-C0860755
tension	I-C0860755
for	O
the	O
hypoxia	B-C0242184
condition	I-C0242184
.	O
	
the	O
cells	B-C0007634
were	O
divided	O
into	O
four	O
groups	B-C0441833
g1	B-C0441833
-	O
osteoblast	B-C1159974
differentiation	I-C1159974
medium	B-C0010454
only	O
as	O
the	O
hypoxic	B-C0242184
condition	I-C0242184
,	O
g2	B-C0441833
-	O
treatment	B-C1522326
with	O
50	O
μm	O
melatonin	B-C0025219
only	O
,	O
g3	B-C0441833
-	O
laser	B-C0871799
irradiation	I-C0871799
808	O
nm	O
,	O
80	O
mw	O
,	O
gaalas	B-C0392255
diode	I-C0392255
only	O
,	O
and	O
g4	B-C0441833
-	O
treatment	B-C1522326
with	O
50	O
μm	O
melatonin	B-C0025219
and	O
laser	B-C0871799
irradiation	I-C0871799
808	O
nm	O
,	O
80	O
mw	O
,	O
gaalas	B-C0392255
diode	I-C0392255
.	O
	
immunoblotting	B-C0020985
showed	O
that	O
osterix	B-C1312518
expression	B-C1171362
was	O
markedly	O
increased	B-C0205217
in	O
the	O
melatonin	B-C0025219
-	O
treated	B-C1522326
and	O
laser-irradiated	B-C0871799
cells	B-C0007634
at	O
48	O
and	O
72	O
h	O
.	O
	
in	O
addition	O
,	O
alkaline	B-C0002059
phosphatase	I-C0002059
activity	B-C0441655
significantly	O
increased	B-C0205217
and	O
continued	B-C0549178
to	O
rise	O
throughout	O
the	O
experiment	B-C0681814
.	O
	
alizarin	B-C1318906
red	I-C1318906
staining	I-C1318906
showed	O
markedly	O
increased	B-C0205217
mineralized	B-C2350989
nodules	B-C0035441
as	O
compared	O
with	O
only	O
melatonin	B-C0025219
-	O
treated	B-C1522326
or	O
laser-irradiated	B-C0871799
cells	B-C0007634
at	O
day	O
7	O
,	O
which	O
significantly	O
increased	B-C0205217
by	O
day	O
14	O
.	O
	
moreover	O
,	O
when	O
melatonin	B-C0025219
-	O
treated	B-C1522326
cells	B-C0007634
were	O
laser-irradiated	B-C0871799
,	O
the	O
differentiation	B-C0007589
and	O
mineralization	B-C2350989
of	O
cells	B-C0007634
were	O
found	O
to	O
involve	O
p38	B-C1120843
mapk	I-C1120843
and	O
prkd1	B-C2987025
signaling	B-C0037083
mechanisms	I-C0037083
.	O
	
however	O
,	O
the	O
enhanced	B-C2349975
effects	B-C1704420
of	I-C1704420
laser	B-C0871799
irradiation	I-C0871799
with	O
melatonin	B-C0025219
were	O
markedly	O
inhibited	B-C0311403
when	O
the	O
cells	B-C0007634
were	O
treated	B-C1522326
with	O
luzindole	B-C0065275
,	O
a	O
selective	O
melatonin	B-C2917356
receptor	I-C2917356
antagonist	I-C2917356
.	O
	
therefore	O
,	O
we	O
concluded	O
that	O
laser	B-C0871799
irradiation	I-C0871799
could	O
promote	O
the	O
effect	B-C1704420
of	I-C1704420
melatonin	B-C0025219
on	O
the	O
differentiation	B-C0007589
and	O
mineralization	B-C2350989
of	O
mc3t3-e1	B-C0007634
cells	I-C0007634
under	O
hypoxic	B-C0242184
conditions	I-C0242184
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin	B-C0065911
1/2	I-C0065911
receptors	I-C0065911
and	O
pkrd	B-C2987025
/	O
p38	B-C1120843
signaling	B-C0037080
pathways	I-C0037080
.	O
	
aquaporin-2	B-C0213238
excretion	B-C1373187
in	O
hospitalized	B-C0870668
patients	I-C0870668
with	O
cirrhosis	B-C1623038
relation	O
to	O
development	B-C1527148
of	O
renal	B-C1565489
insufficiency	I-C1565489
and	O
mortality	B-C0205848
urinary	B-C1524119
aquaporin-2	B-C0213238
aqp2	B-C0213238
is	O
a	O
parameter	O
of	O
water	B-C1159571
transport	I-C1159571
in	O
the	O
principal	B-C0007634
cells	I-C0007634
in	O
the	O
distal	B-C0005898
part	I-C0005898
of	O
the	O
nephron	B-C0027713
and	O
involved	O
in	O
water	B-C2584327
retention	I-C2584327
in	O
cirrhosis	B-C1623038
and	O
may	O
be	O
a	O
marker	B-C0005516
of	O
renal	B-C0232804
function	I-C0232804
.	O
	
the	O
aim	B-C1947946
of	O
the	O
study	B-C2603343
was	O
to	O
evaluate	O
aqp2	B-C0213238
as	O
a	O
predictor	B-C0683956
of	O
renal	B-C1565489
insufficiency	I-C1565489
and	O
death	B-C0011065
in	O
patients	B-C0030705
with	O
cirrhosis	B-C1623038
.	O
	
urine	B-C1610733
samples	I-C1610733
from	O
199	O
patients	B-C0030705
90	O
patients	B-C0030705
without	O
organ	B-C0349410
failure	I-C0349410
group	B-C0681860
1	I-C0681860
,	O
58	O
patients	B-C0030705
with	O
organ	B-C0349410
failure	I-C0349410
excluding	O
renal	B-C0035078
failure	I-C0035078
group	B-C0681860
2	I-C0681860
,	O
and	O
51	O
patients	B-C0030705
with	O
organ	B-C0349410
failure	I-C0349410
including	O
renal	B-C0035078
failure	I-C0035078
group	B-C0681860
3	I-C0681860
from	O
the	O
canonic	B-C2603343
study	I-C2603343
were	O
analyzed	O
for	O
urine	B-C0042036
aqp2	B-C0213238
and	O
urine	B-C0086741
osmolality	I-C0086741
.	O
	
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
aqp2	B-C0213238
between	O
the	O
three	O
groups	B-C0681860
.	O
	
urine	B-C0086741
osmolality	I-C0086741
was	O
significantly	B-C4055638
lower	I-C4055638
in	O
patients	B-C0030705
in	O
group	B-C0681860
3	I-C0681860
versus	O
group	B-C0681860
1	I-C0681860
and	O
group	B-C0681860
2	I-C0681860
p	O
=	O
0.0004	O
.	O
	
no	B-C1513916
relation	I-C1513916
was	O
found	O
between	O
aqp2	B-C0213238
and	O
glomerular	B-C0017654
filtration	I-C0017654
rate	I-C0017654
or	O
creatinine	B-C0010294
however	O
,	O
aqp2	B-C0213238
was	O
a	O
significant	O
predictor	B-C0683956
of	O
the	O
development	B-C1527148
of	O
renal	B-C1565489
insufficiency	I-C1565489
p	O
=	O
0.0485	O
.	O
	
in	O
a	O
univariate	B-C0683962
analysis	I-C0683962
,	O
aqp2	B-C0213238
was	O
a	O
significant	O
predictor	B-C0683956
of	O
14	O
and	O
28-day	O
survival	B-C0220921
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate	B-C0026777
analysis	I-C0026777
.	O
	
aquaporin-2	B-C0213238
was	O
not	O
associated	O
with	O
disease	B-C0521117
severity	I-C0521117
or	O
markers	B-C0008963
of	O
renal	B-C0232804
function	I-C0232804
but	O
was	O
a	O
predictor	B-C0683956
for	O
the	O
development	B-C1527148
of	O
renal	B-C1565489
insufficiency	I-C1565489
and	O
death	B-C0011065
.	O
	
therefore	O
,	O
its	O
future	O
use	O
as	O
marker	B-C0005516
of	O
renal	B-C1565489
insufficiency	I-C1565489
could	O
be	O
promising	O
,	O
but	O
further	O
research	B-C0035168
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	B-C0205210
decompression	B-C0408670
surgery	I-C0408670
alone	O
versus	O
decompression	B-C0408670
plus	O
fusion	B-C0919636
in	O
symptomatic	B-C0231220
lumbar	B-C0158288
spinal	I-C0158288
stenosis	I-C0158288
a	O
swiss	B-C0241315
prospective	B-C1709709
multi-center	I-C1709709
cohort	I-C1709709
study	I-C1709709
with	O
3	O
years	B-C0439234
of	O
follow-up	B-C0016441
retrospective	B-C0035363
analysis	I-C0035363
of	O
a	O
prospective	B-C1709709
,	O
multicenter	I-C1709709
cohort	I-C1709709
study	I-C1709709
.	O
	
to	O
estimate	O
the	O
added	O
effect	B-C1280500
of	O
surgical	B-C0919636
fusion	I-C0919636
as	O
compared	O
to	O
decompression	B-C0408670
surgery	I-C0408670
alone	O
in	O
symptomatic	B-C0231220
lumbar	B-C0158288
spinal	I-C0158288
stenosis	I-C0158288
patients	B-C0030705
with	O
spondylolisthesis	B-C0038016
.	O
	
the	O
optimal	B-C1515089
surgical	I-C1515089
management	I-C1515089
of	O
lumbar	B-C0158288
spinal	I-C0158288
stenosis	I-C0158288
patients	B-C0030705
with	O
spondylolisthesis	B-C0038016
remains	O
controversial	O
.	O
	
patients	B-C0030705
of	O
the	O
lsos	B-C0543472
with	O
confirmed	O
dlss	B-C0410636
and	O
spondylolisthesis	B-C0038016
were	O
enrolled	O
in	O
this	O
study	B-C1706256
.	O
	
the	O
outcomes	B-C0086750
of	O
this	O
study	B-C1706256
were	O
spinal	B-C0037944
stenosis	I-C0037944
measure	O
ssm	O
symptoms	O
score	O
range	O
1-5	O
,	O
best-worst	O
and	O
function	O
1-4	O
over	O
time	O
,	O
measured	O
at	O
baseline	O
,	O
6	O
,	O
12	O
,	O
24	O
and	O
36	O
months	O
follow-up	O
.	O
	
in	O
order	O
to	O
quantify	O
the	O
effect	O
of	O
fusion	O
surgery	O
as	O
compared	O
to	O
decompression	O
alone	O
and	O
number	O
of	O
decompressed	O
levels	O
,	O
we	O
used	O
mixed	O
effects	O
models	O
and	O
accounted	O
for	O
the	O
repeated	O
observations	O
in	O
main	O
outcomes	O
ssm	O
symptoms	O
and	O
ssm	O
function	O
over	O
time	O
.	O
	
in	O
addition	O
to	O
individual	O
patients	O
'	O
random	O
effects	O
,	O
we	O
also	O
fitted	O
random	O
slopes	O
for	O
follow-up	O
time	O
points	O
and	O
compared	O
these	O
two	O
approaches	O
with	O
akaike's	O
information	O
criterion	O
aic	O
and	O
the	O
chi-squared	O
test	O
.	O
	
confounders	O
were	O
adjusted	O
with	O
fixed	O
effects	O
for	O
age	O
,	O
gender	O
,	O
bmi	O
,	O
diabetes	O
,	O
cirs	O
musculoskeletal	O
disorders	O
and	O
duration	O
of	O
symptoms	O
.	O
	
one	O
hundred	O
and	O
thirty-one	O
patients	O
undergoing	O
decompression	O
surgery	O
alone	O
n	O
=	O
85	O
or	O
decompression	O
plus	O
fusion	O
surgery	O
n	O
=	O
46	O
were	O
included	O
in	O
this	O
study	O
.	O
	
in	O
the	O
multiple	O
mixed	O
effects	O
model	O
the	O
adjusted	O
effect	O
of	O
fusion	O
versus	O
decompression	O
alone	O
surgery	O
on	O
ssm	O
symptoms	O
was	O
0.06	O
95%	O
confidence	O
interval	O
,	O
ci	O
-0	O
to	O
0.27	O
and	O
-0	O
95%	O
ci	O
-0	O
to	O
0.10	O
on	O
ssm	O
function	O
,	O
respectively	O
.	O
	
among	O
the	O
patients	O
with	O
degenerative	O
lumbar	O
spinal	O
stenosis	O
and	O
spondylolisthesis	O
our	O
study	O
confirms	O
that	O
in	O
the	O
two	O
groups	O
,	O
decompression	O
alone	O
and	O
decompression	O
plus	O
fusion	O
,	O
patients	O
distinctively	O
benefited	O
from	O
surgical	O
treatment	O
.	O
	
when	O
adjusted	O
for	O
confounders	O
,	O
fusion	O
surgery	O
was	O
not	O
associated	O
with	O
a	O
more	O
favorable	O
outcome	O
in	O
both	O
ssm	O
scores	O
as	O
compared	O
to	O
decompression	O
alone	O
surgery	O
.	O
	
muscle	B-C0026845
synergies	B-C1704675
after	O
stroke	B-C0038454
are	O
correlated	O
with	O
perilesional	B-C1254362
high	B-C0392762
gamma	I-C0392762
movements	B-C0517907
can	O
be	O
factored	O
into	O
modules	B-C1709061
termed	O
""""	O
muscle	B-C0026845
synergies	B-C1704675
""""	O
.	O
	
after	O
stroke	B-C0038454
,	O
abnormal	B-C0205161
synergies	B-C1704675
are	O
linked	O
to	O
impaired	B-C0221099
movements	B-C0517907
however	O
,	O
their	O
neural	B-C0027882
basis	B-C1527178
is	O
not	O
understood	O
.	O
	
in	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-C0430797
signals	I-C0430797
from	O
the	O
perilesional	B-C1254362
cortex	B-C3499125
were	O
associated	O
with	O
synergies	B-C1704675
.	O
	
the	O
measured	O
synergies	B-C1704675
contained	B-C0332256
a	O
mix	O
of	O
both	O
normal	B-C0205307
and	O
abnormal	B-C0205161
patterns	B-C0449774
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O
	
interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	B-C0205307
and	O
abnormal	B-C0205161
synergies	B-C1704675
were	O
correlated	O
with	O
perilesional	B-C1254362
high	B-C0392762
gamma	I-C0392762
.	O
	
given	O
the	O
link	O
between	O
high	B-C0392762
gamma	I-C0392762
and	O
cortical	B-C0243095
spiking	I-C0243095
,	O
our	O
results	O
suggest	O
that	O
perilesional	B-C0243095
spiking	I-C0243095
may	O
organize	O
synergies	B-C1704675
after	O
assessing	B-C0184514
nitrous	B-C0028215
oxide	I-C0028215
effect	B-C1280500
using	O
electroencephalographically	B-C0013819
-based	O
depth	B-C0474710
of	I-C0474710
anesthesia	I-C0474710
measures	B-C0079809
cortical	B-C0007776
state	B-C0918012
and	O
cortical	B-C0007776
input	B-C0918012
existing	O
electroencephalography	B-C0013819
eeg	B-C0013819
based	O
depth	B-C0474710
of	I-C0474710
anesthesia	I-C0474710
monitors	B-C0184514
cannot	O
reliably	O
track	O
sedative	B-C0036557
or	O
anesthetic	B-C0002932
states	B-C0348080
during	O
n-methyl-d-aspartate	B-C3536824
nmda	I-C3536824
receptor	I-C3536824
antagonist	I-C3536824
based	O
anesthesia	B-C0002903
with	O
ketamine	B-C0022614
or	O
nitrous	B-C0028215
oxide	I-C0028215
n2o	B-C0028215
.	O
	
here	O
,	O
a	O
physiologically	B-C0205463
-motivated	O
depth	B-C0474710
of	I-C0474710
anesthesia	I-C0474710
monitoring	B-C1283169
algorithm	B-C0002045
based	O
on	O
autoregressive-moving-average	B-C3161035
arma	I-C3161035
modeling	I-C3161035
and	O
derivative	O
measures	O
of	O
interest	O
,	O
cortical	B-C0007776
state	B-C0918012
cs	B-C0918012
and	O
cortical	B-C0007776
input	B-C0918012
ci	B-C0918012
,	O
is	O
retrospectively	B-C0035363
applied	O
in	O
an	O
exploratory	B-C1292732
manner	O
to	O
the	O
nmda	B-C3536824
receptor	I-C3536824
antagonist	I-C3536824
n2o	B-C0028215
,	O
an	O
adjuvant	B-C0002904
anesthetic	I-C0002904
gas	I-C0002904
used	O
in	O
clinical	B-C0205245
practice	I-C0205245
.	O
	
composite	B-C0918012
cortical	I-C0918012
state	I-C0918012
ccs	B-C0918012
and	O
composite	B-C0918012
cortical	I-C0918012
state	I-C0918012
distance	I-C0918012
ccsd	B-C0918012
,	O
two	O
new	O
modifications	B-C3840684
of	O
cs	B-C0918012
,	O
along	O
with	O
cs	B-C0918012
and	O
ci	B-C0918012
were	O
evaluated	B-C0220825
on	O
electroencephalographic	B-C0013819
eeg	B-C0013819
data	B-C1511726
of	O
healthy	B-C2986479
control	I-C2986479
individuals	I-C2986479
undergoing	O
n2o	B-C0028215
inhalation	B-C0004048
up	O
to	O
equilibrated	B-C1547026
peak	B-C0457929
gas	I-C0457929
concentrations	I-C0457929
of	O
20	O
,	O
40	O
or	O
60%	O
n2o	B-C0028215
/	O
o2	B-C0030054
.	O
	
in	O
particular	O
,	O
ccsd	B-C0918012
has	O
been	O
devised	O
to	O
vary	O
consistently	O
for	O
increasing	B-C0205217
levels	B-C0441889
of	O
anesthetic	B-C0474704
concentration	I-C0474704
independent	B-C0332291
of	I-C0332291
the	O
anesthetic's	B-C0002932
microscopic	B-C0205288
mode	B-C1524059
of	I-C1524059
action	I-C1524059
for	O
both	O
n2o	B-C0028215
and	O
propofol	B-C0033487
.	O
	
the	O
strongest	O
effects	B-C1280500
were	O
observed	O
for	O
the	O
60%	O
peak	B-C0457929
gas	I-C0457929
concentration	I-C0457929
group	B-C1257890
.	O
	
for	O
the	O
50-60%	O
peak	B-C0441889
gas	I-C0441889
levels	I-C0441889
,	O
individuals	B-C0237401
showed	O
statistically	B-C0237881
significant	I-C0237881
reductions	B-C0441610
in	O
responsiveness	B-C3261286
compared	B-C1707455
to	O
rest	B-C0035253
,	O
and	O
across	O
the	O
group	B-C1257890
cs	B-C0918012
and	O
ccs	B-C0918012
increased	B-C0205217
by	O
39	O
and	O
42%	O
,	O
respectively	O
,	O
while	O
ccsd	B-C0918012
was	O
found	O
to	O
decrease	B-C0547047
by	O
398%	O
.	O
	
on	O
the	O
other	O
hand	O
a	O
clear	O
conclusion	B-C1707478
regarding	O
the	O
changes	O
in	O
ci	B-C0918012
could	O
not	O
be	O
reached	O
.	O
	
these	O
results	B-C1274040
indicate	O
that	O
,	O
contrary	B-C1521805
to	O
previous	O
depth	B-C0474710
of	I-C0474710
anesthesia	I-C0474710
monitoring	B-C1283169
measures	B-C0079809
,	O
the	O
cs	B-C0918012
,	O
ccs	B-C0918012
,	O
and	O
especially	O
ccsd	B-C0918012
measures	B-C0079809
derived	B-C1441547
from	O
frontal	B-C0205123
eeg	B-C0013819
are	O
potentially	B-C3245505
useful	O
for	O
differentiating	O
gas	B-C0457929
concentration	I-C0457929
and	O
responsiveness	B-C3261286
levels	I-C3261286
in	O
people	B-C0027361
under	O
n2o	B-C0028215
.	O
	
on	O
the	O
other	O
hand	O
,	O
determining	O
the	O
utility	B-C0457083
of	O
ci	B-C0918012
in	O
this	O
regard	O
will	O
require	O
larger	B-C0549177
sample	B-C0242618
sizes	I-C0242618
and	O
potentially	B-C3245505
higher	B-C0205250
gas	B-C0457929
concentrations	I-C0457929
.	O
	
future	O
work	O
will	O
assess	B-C0184514
the	O
sensitivity	B-C0036667
of	O
cs	B-C0918012
-based	O
and	O
ci	B-C0918012
measures	B-C0079809
to	O
other	O
anesthetics	B-C0002932
and	O
their	O
utility	B-C0457083
in	O
a	O
clinical	B-C0442592
environment	B-C0014406
.	O
	
dt	B-C3163713
mri	I-C3163713
microstructural	B-C0205556
cortical	B-C0007776
lesion	B-C0221505
damage	B-C1883709
does	O
not	O
explain	O
cognitive	B-C0338656
impairment	I-C0338656
in	O
ms	B-C0026769
we	O
combined	O
double	B-C0430022
inversion	I-C0430022
recovery	I-C0430022
dir	B-C0430022
and	O
diffusion	B-C3163713
tensor	I-C3163713
dt	I-C3163713
magnetic	I-C3163713
resonance	I-C3163713
imaging	I-C3163713
mri	I-C3163713
to	O
quantify	B-C1709793
the	O
severity	B-C0439793
of	O
cortical	B-C0007776
lesion	B-C0221505
cl	B-C0221505
microstructural	B-C0205556
tissue	B-C0040300
abnormalities	B-C0221430
in	O
a	O
large	B-C0549177
cohort	B-C0599755
of	O
relapse	B-C0035020
-	O
onset	B-C0332162
multiple	B-C0026769
sclerosis	I-C0026769
ms	B-C0026769
patients	B-C0030705
and	O
its	O
contribution	B-C1880177
to	O
cognitive	B-C0338656
dysfunction	I-C0338656
.	O
	
dir	B-C0430022
,	O
dt	B-C1537007
,	O
dual-echo	B-C0011923
,	O
and	O
three-dimensional	B-C0450363
3d	B-C0450363
t1-weighted	B-C0011923
scans	I-C0011923
were	O
acquired	O
from	O
149	O
ms	B-C0026769
patients	B-C0030705
and	O
40	O
controls	B-C0009932
.	O
	
cognitively	B-C0338656
impaired	I-C0338656
ci	B-C0338656
patients	B-C0030705
had	O
2	O
abnormal	B-C0205161
neuropsychological	B-C0027902
tests	I-C0027902
.	O
	
diffusivity	B-C3899378
values	I-C3899378
in	O
cls	B-C0221505
,	O
cortex	B-C0007776
,	O
white	B-C2752009
matter	I-C2752009
wm	I-C2752009
lesions	I-C2752009
,	O
and	O
normal-appearing	B-C0682708
na	I-C0682708
wm	I-C0682708
were	O
assessed	B-C1516048
.	O
	
predictors	B-C2698872
of	O
cognitive	B-C0338656
impairment	I-C0338656
were	O
identified	B-C0205396
using	O
a	O
random	B-C0936012
forest	I-C0936012
analysis	I-C0936012
.	O
	
compared	O
to	O
controls	B-C0009932
,	O
ms	B-C0026769
patients	B-C0030705
had	O
lower	B-C0205251
normalized	B-C1113695
brain	I-C1113695
volume	I-C1113695
nbv	B-C1113695
,	O
gray	B-C0392762
matter	I-C0392762
volume	I-C0392762
gmv	B-C0392762
,	O
wm	B-C3278845
volume	I-C3278845
,	O
lower	B-C0205251
fractional	B-C0392762
anisotropy	I-C0392762
fa	B-C0392762
,	O
and	O
higher	B-C0205250
mean	B-C3899378
diffusivity	I-C3899378
in	O
cortex	B-C0007776
and	O
normal-appearing	B-C0682708
white	I-C0682708
matter	I-C0682708
nawm	B-C0682708
.	O
	
a	O
total	O
of	O
44	O
29.5	O
patients	B-C0030705
were	O
ci	B-C0338656
.	O
	
compared	O
to	O
cognitively	B-C0030705
preserved	I-C0030705
cp	B-C0030705
,	O
ci	B-C0338656
patients	B-C0030705
had	O
higher	B-C0205250
t2	B-C0392762
wm	I-C0392762
lesion	I-C0392762
volume	I-C0392762
lv	B-C0392762
,	O
lower	B-C0205251
nbv	B-C1113695
and	O
gmv	B-C0392762
,	O
and	O
more	O
severe	B-C0205082
diffusivity	B-C3899378
abnormalities	B-C0221430
in	O
wm	B-C2752009
lesions	I-C2752009
,	O
cortex	B-C0007776
,	O
and	O
nawm	B-C0682708
.	O
	
cl	B-C0221505
measures	B-C0079809
did	O
not	B-C0243095
differ	I-C0243095
between	O
ci	B-C0030705
and	O
cp	B-C0030705
patients	I-C0030705
.	O
	
cortex	B-C0007776
fa	B-C0392762
,	O
age	B-C0001779
,	O
disease	B-C0872146
duration	I-C0872146
,	O
t2	B-C0392762
wm	I-C0392762
lv	I-C0392762
,	O
and	O
gmv	B-C0392762
best	O
predicted	O
ms	B-C0026769
-related	O
cognitive	B-C0338656
impairment	I-C0338656
c-statistic	O
=	O
0.88	O
.	O
	
""""	O
diffuse	B-C0205219
""""	O
gm	B-C0018220
and	O
nawm	B-C0682708
damage	B-C1883709
and	O
wm	B-C2752009
lesions	I-C2752009
,	O
rather	O
than	O
intrinsic	B-C0205102
cl	B-C0221505
damage	B-C1883709
,	O
contribute	O
to	O
cognitive	B-C0338656
impairment	I-C0338656
in	O
correlation	B-C1707520
between	O
the	O
histopathology	B-C0243140
of	O
chronic	B-C0263338
urticaria	I-C0263338
and	O
its	O
clinical	B-C0683325
picture	I-C0683325
chronic	B-C0263338
urticaria	I-C0263338
is	O
characterized	O
by	O
transient	B-C0205374
,	O
pruritic	B-C0748813
lesions	I-C0748813
of	O
varying	O
sizes	B-C0456389
,	O
with	O
central	B-C0205099
pallor	B-C0030232
and	O
well-defined	O
edges	O
,	O
with	O
disease	B-C0012634
duration	O
longer	O
than	O
six	O
weeks	B-C0439230
.	O
	
its	O
cellular	B-C1692321
infiltrate	I-C1692321
consists	O
of	O
neutrophils	B-C0027950
,	O
lymphocytes	B-C0024264
and	O
eosinophils	B-C0014467
.	O
	
there	O
is	O
a	O
subgroup	O
of	O
patients	B-C0030705
with	O
eosinophilic	B-C0014467
or	O
neutrophilic	B-C1304205
urticaria	I-C1304205
,	O
resistant	O
to	O
the	O
treatment	B-C0087111
with	O
antihistamines	B-C0003360
,	O
but	O
that	O
respond	O
to	O
a	O
combination	O
of	O
antihistamine	B-C0003360
with	O
other	O
drugs	B-C0013227
.	O
	
to	O
evaluate	O
the	O
present	O
infiltration	B-C0332448
in	O
chronic	B-C0263338
urticaria	I-C0263338
biopsies	B-C0005558
and	O
correlate	O
it	O
with	O
the	O
clinical	B-C0544450
disease	I-C0544450
activity	I-C0544450
and	O
response	B-C0521982
to	I-C0521982
treatment	I-C0521982
.	O
	
forty-one	O
patients	B-C0030705
with	O
chronic	B-C0263338
urticaria	I-C0263338
were	O
classified	O
according	O
to	O
the	O
score	B-C0457451
of	I-C0457451
severity	I-C0457451
of	O
the	O
disease	B-C0012634
,	O
response	B-C0521982
to	I-C0521982
treatment	I-C0521982
and	O
type	O
of	O
perivascular	B-C1692321
infiltrate	I-C1692321
.	O
	
inflammatory	B-C0541629
infiltrates	I-C0541629
were	O
divided	O
in	O
eosinophilic	B-C0014467
46.30	O
,	O
neutrophilic	B-C0027950
and	O
mixed	O
.	O
	
an	O
association	B-C0439849
was	O
found	O
between	O
the	O
eosinophilic	B-C0541629
infiltrate	I-C0541629
and	O
clinical	B-C0457451
scores	I-C0457451
of	O
greater	O
severity	B-C0439793
p	O
=	O
0.002	O
.	O
	
this	O
association	B-C0439849
shows	O
that	O
the	O
eosinophilic	B-C0541629
inflammatory	I-C0541629
infiltrates	I-C0541629
denote	O
high	O
clinical	B-C0037088
activity	I-C0037088
,	O
which	O
means	O
more	O
severe	B-C0205082
and	O
exuberant	O
clinical	B-C0683325
pictures	I-C0683325
of	O
the	O
barriers	B-C0679881
to	O
access	B-C0018748
and	I-C0018748
uptake	I-C0018748
of	O
antiretroviral	B-C1963724
therapy	I-C1963724
among	O
hiv-positive	B-C0019699
men	B-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
in	O
hanoi	B-C0681784
,	O
vietnam	B-C0042658
from	O
hiv	B-C1321876
testing	I-C1321876
to	O
treatment	B-C0087111
little	O
is	O
known	O
about	O
the	O
experiences	B-C0596545
of	O
vietnamese	B-C1561452
men	B-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
in	O
accessing	B-C0444454
hiv	B-C1321876
testing	I-C1321876
and	O
treatment	B-C0087111
.	O
	
we	O
aimed	O
to	O
explore	O
barriers	B-C0679881
to	O
access	B-C0018748
and	I-C0018748
uptake	I-C0018748
of	O
antiretroviral	B-C1963724
therapy	I-C1963724
art	B-C1963724
among	O
hiv-positive	B-C0019699
men	B-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
in	O
hanoi	B-C0681784
.	O
	
during	O
2015	O
,	O
we	O
conducted	O
qualitative	B-C0205556
interviews	B-C0021822
with	O
35	O
participants	B-C0679646
recruited	O
using	O
snowball	B-C2348215
sampling	I-C2348215
based	O
on	O
previous	O
research	B-C0035168
and	O
social	B-C0150775
networks	I-C0150775
.	O
	
key	O
individual	O
impediments	O
to	O
art	B-C1963724
uptake	O
included	O
inadequate	B-C0205412
preparation	B-C1521827
for	O
a	O
positive	B-C1446409
diagnosis	B-C0011900
and	O
the	O
dual	O
stigmatisation	B-C0038330
of	O
homosexuality	B-C0019900
and	O
hiv	B-C0019682
and	O
its	O
consequences	B-C1511482
,	O
leading	O
to	O
fear	B-C0015726
of	O
disclosure	B-C0012625
of	O
hiv	B-C0458074
status	I-C0458074
.	O
	
health	B-C0018696
system	I-C0018696
barriers	B-C0679881
included	O
lack	O
of	O
clarity	O
and	O
consistency	B-C0332529
about	O
how	O
to	O
register	O
for	O
and	O
access	B-C0018748
art	B-C1963724
,	O
failure	O
to	O
protect	O
patient	B-C0030705
confidentiality	B-C0009669
and	O
a	O
reticence	O
by	O
providers	B-C1138603
to	O
discuss	O
sexual	B-C0017249
identity	I-C0017249
and	O
same-sex	B-C0019900
issues	I-C0019900
.	O
	
results	O
suggest	O
fundamental	O
problems	O
in	O
the	O
way	O
hiv	B-C1321876
testing	I-C1321876
is	O
currently	O
delivered	O
in	O
hanoi	B-C0681784
,	O
including	O
a	O
lack	O
of	O
client-centred	O
counselling	B-C0010210
,	O
peer	B-C0679740
support	I-C0679740
and	O
clear	B-C0034927
referral	I-C0034927
pathways	O
.	O
	
overcoming	O
these	O
barriers	B-C0679881
will	O
require	O
educating	O
men	B-C2827413
who	I-C2827413
have	I-C2827413
sex	I-C2827413
with	I-C2827413
men	I-C2827413
about	O
the	O
benefits	B-C0814225
of	O
routine	B-C2188403
testing	I-C2188403
,	O
improving	B-C1272745
access	B-C0018748
to	O
quality	O
diagnostic	B-C0011929
services	I-C0011929
and	O
building	O
a	O
safe	O
,	O
confidential	B-C3846676
treatment	B-C0087111
environment	B-C0014406
for	O
hiv-positive	B-C0019699
men	B-C0025266
to	O
access	B-C0018748
,	O
receive	B-C1947933
and	I-C1947933
remain	I-C1947933
in	I-C1947933
care	I-C1947933
.	O
	
cdc45	B-C0755538
-	O
induced	B-C0205263
loading	B-C1708715
of	O
human	B-C0122446
rpa	I-C0122446
onto	O
single-stranded	B-C0012935
dna	I-C0012935
cell	B-C0755538
division	I-C0755538
cycle	I-C0755538
protein	I-C0755538
45	I-C0755538
cdc45	B-C0755538
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	B-C0684063
replicative	B-C1883725
dna	B-C0920283
helicase	I-C0920283
.	O
	
we	O
found	O
that	O
human	B-C0755538
cdc45	I-C0755538
forms	O
a	O
complex	B-C1704241
with	O
the	O
single-stranded	B-C0165675
dna	I-C0165675
ssdna	I-C0165675
binding	I-C0165675
protein	I-C0165675
rpa	I-C0165675
.	O
	
moreover	O
,	O
it	O
actively	O
loads	B-C1708715
rpa	B-C0165675
onto	O
nascent	O
ssdna	B-C0012935
.	O
	
pull-down	B-C0022885
assays	I-C0022885
and	O
surface	B-C0597731
plasmon	I-C0597731
resonance	I-C0597731
studies	I-C0597731
revealed	O
that	O
cdc45	B-C0755538
-	O
bound	B-C1167622
rpa	B-C0165675
complexed	B-C1704241
with	O
ssdna	B-C0012935
in	O
the	O
8-10	O
nucleotide	B-C1148916
binding	I-C1148916
mode	O
,	O
but	O
dissociated	B-C1148560
when	O
rpa	B-C0165675
covered	O
a	O
30-mer	B-C0004793
.	O
	
real-time	B-C0022885
analysis	I-C0022885
of	O
rpa	B-C0165675
-	O
ssdna	B-C0012935
binding	B-C1167622
demonstrated	O
that	O
cdc45	B-C0755538
catalytically	O
loaded	B-C1708715
rpa	B-C0165675
onto	O
ssdna	B-C0012935
.	O
	
this	O
placement	B-C1524072
reaction	B-C0443286
required	O
physical	B-C0392367
contacts	I-C0392367
of	O
cdc45	B-C0755538
with	O
the	O
rpa70a	B-C1514562
subdomain	I-C1514562
.	O
	
our	O
results	O
imply	O
that	O
cdc45	B-C0755538
controlled	O
stabilization	B-C1293130
of	O
the	O
8-	O
nt	B-C0028630
rpa	B-C0165675
binding	B-C1167622
mode	O
,	O
the	O
subsequent	O
rpa	B-C0165675
transition	O
into	O
30-mer	B-C0004793
mode	B-C1513371
and	O
facilitated	O
an	O
ordered	O
binding	B-C1167622
to	O
ssdna	B-C0012935
.	O
	
we	O
propose	O
that	O
a	O
cdc45	B-C0755538
-mediated	O
loading	B-C1708715
guarantees	O
a	O
seamless	O
deposition	B-C0333562
of	O
rpa	B-C0165675
on	O
newly	O
emerging	O
ssdna	B-C0012935
at	O
the	O
nascent	O
replication	B-C1167117
fork	I-C1167117
.	O
	
the	O
antineoplastic	B-C0003392
drug	I-C0003392
,	O
trastuzumab	B-C0728747
,	O
dysregulates	B-C0243095
metabolism	B-C0025519
in	O
ipsc	B-C2717959
-derived	O
cardiomyocytes	B-C0225828
the	O
targeted	B-C2985566
erbb2	I-C2985566
therapy	I-C2985566
,	O
trastuzumab	B-C0728747
,	O
has	O
had	O
a	O
tremendous	O
impact	B-C4049986
on	O
management	B-C0376636
of	O
patients	B-C0030705
with	O
her2+	B-C1960398
breast	I-C1960398
cancer	I-C1960398
,	O
leading	O
to	O
development	B-C1527148
and	O
increased	B-C0205217
use	O
of	O
further	O
her2	B-C0069515
targeted	B-C2985566
therapies	I-C2985566
.	O
	
the	O
major	O
clinical	B-C0205210
side	B-C0879626
effect	I-C0879626
is	O
cardiotoxicity	B-C0876994
but	O
the	O
mechanism	B-C0441712
is	O
largely	O
unknown	O
.	O
	
on	O
the	O
basis	O
that	O
gene	B-C0017262
expression	I-C0017262
is	O
known	O
to	O
be	O
altered	B-C0392747
in	O
multiple	B-C0439064
models	B-C0026343
of	O
heart	B-C0018801
failure	I-C0018801
,	O
we	O
examined	O
differential	B-C1519516
gene	I-C1519516
expression	I-C1519516
of	O
ipsc	B-C2717959
-derived	O
cardiomyocytes	B-C0225828
treated	B-C1522326
at	O
day	B-C0439228
11	O
with	O
the	O
erbb2	B-C1702024
targeted	O
monoclonal	B-C0003250
antibody	I-C0003250
,	O
trastuzumab	B-C0728747
for	O
48	O
h	O
and	O
the	O
small	B-C1268567
molecule	I-C1268567
tyrosine	I-C1268567
kinase	I-C1268567
inhibitor	I-C1268567
of	O
egfr	B-C0034802
and	O
erbb2	B-C1702024
.	O
	
transcriptome	B-C4086963
sequencing	I-C4086963
was	O
performed	B-C0884358
on	O
four	O
replicates	B-C1883725
from	O
each	O
group	B-C0441833
48	O
h	O
untreated	O
,	O
48	O
h	O
trastuzumab	B-C0728747
and	O
48	O
h	O
lapatinib	B-C1506770
and	O
differential	B-C1519516
gene	I-C1519516
expression	I-C1519516
analyses	B-C0936012
were	O
performed	B-C0884358
on	O
each	O
treatment	B-C1522326
group	B-C0441833
relative	O
to	O
untreated	O
cardiomyocytes	B-C0225828
.	O
	
517	O
and	O
1358	O
genes	B-C0017337
were	O
differentially	B-C0017262
expressed	I-C0017262
,	O
p	O
<	O
0.05	O
,	O
respectively	O
in	O
cardiomyocytes	B-C0225828
treated	B-C1522326
with	O
trastuzumab	B-C0728747
and	O
lapatinib	B-C1506770
.	O
	
gene	B-C1138831
ontology	I-C1138831
analyses	B-C0936012
revealed	O
in	O
cardiomyocytes	B-C0225828
treated	B-C1522326
with	O
trastuzumab	B-C0728747
,	O
significant	B-C0750502
down-regulation	B-C0013081
of	O
genes	B-C0017337
involved	O
in	O
small	B-C2752534
molecule	I-C2752534
metabolism	I-C2752534
p	O
=	O
3.22	O
10	O
and	O
cholesterol	B-C0008377
p	O
=	O
0.01	O
and	O
sterol	B-C0038323
p	O
=	O
0.03	O
processing	O
.	O
	
we	O
next	O
measured	B-C0444706
glucose	B-C1159527
uptake	I-C1159527
and	O
lactate	B-C0376261
production	B-C0205245
in	O
ipsc	B-C2717959
-derived	O
cardiomyocytes	B-C0225828
13	O
days	B-C0439228
post-plating	O
,	O
treated	B-C1522326
with	O
trastuzumab	B-C0728747
up	O
to	O
96	O
h	O
.	O
	
we	O
observed	B-C1441672
significantly	B-C0237881
decreased	B-C0205216
glucose	B-C1159527
uptake	I-C1159527
from	O
the	O
media	B-C0010454
of	O
ipsc	B-C2717959
-derived	O
cardiomyocytes	B-C0225828
treated	B-C1522326
with	O
trastuzumab	B-C0728747
as	O
early	O
as	O
24	O
h	O
p	O
=	O
0.001	O
and	O
consistently	B-C0332529
up	O
to	O
96	O
h	O
p	O
=	O
0.03	O
.	O
	
our	O
study	B-C2603343
suggests	O
dysregulation	B-C0243095
of	O
cardiac	B-C0018787
gene	B-C0017262
expression	I-C0017262
and	O
metabolism	B-C0025519
as	O
key	O
elements	O
of	O
erbb2	B-C0242957
signaling	B-C0037080
that	O
could	O
potentially	B-C3245505
be	O
early	O
biomarkers	B-C0005516
of	O
simvastatin	B-C0074554
promotes	O
hematoma	B-C0018944
absorption	B-C0000854
and	O
reduces	O
hydrocephalus	B-C0020255
following	O
intraventricular	B-C0240059
hemorrhage	I-C0240059
in	O
part	O
by	O
upregulating	B-C0041904
cd36	B-C1366645
we	O
previously	O
found	O
that	O
hematoma	B-C0018944
worsens	B-C1457868
hydrocephalus	B-C0020255
after	O
intraventricular	B-C0240059
hemorrhage	I-C0240059
ivh	B-C0240059
via	O
increasing	B-C0442808
iron	B-C0333596
deposition	I-C0333596
and	O
aggravating	O
ependymal	B-C0014472
cilia	B-C0008778
injury	B-C3263723
therefore	O
,	O
promoting	O
hematoma	B-C0018944
absorption	B-C0000854
may	O
be	O
a	O
promising	O
strategy	O
for	O
ivh	B-C0240059
.	O
	
recently	O
,	O
some	O
investigations	O
imply	O
that	O
simvastatin	B-C0074554
has	O
the	O
ability	O
of	O
accelerating	O
hematoma	B-C0018944
absorption	B-C0000854
.	O
	
thus	O
,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
the	O
efficacy	B-C1280519
of	O
simvastatin	B-C0074554
for	O
ivh	B-C0240059
in	O
rats	B-C0086893
.	O
	
intracerebral	B-C0475526
hemorrhage	I-C0475526
with	O
ventricular	O
extension	O
was	O
induced	O
in	O
adult	B-C0086582
male	I-C0086582
sprague-dawley	B-C0034715
rats	I-C0034715
after	O
autologous	B-C0849679
blood	I-C0849679
injection	I-C0849679
.	O
	
simvastatin	B-C0074554
or	O
vehicle	B-C0042444
was	O
administered	B-C0001563
orally	I-C0001563
at	O
1	O
day	O
after	O
ivh	B-C0240059
and	O
then	O
daily	O
for	O
1	O
week	O
.	O
	
mri	B-C3515983
studies	I-C3515983
were	O
performed	O
to	O
measure	B-C0242485
the	O
volumes	B-C2700258
of	O
intracranial	B-C0524466
hematoma	B-C0018944
and	O
lateral	B-C0152279
ventricle	I-C0152279
at	O
days	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
28	O
after	O
ivh	B-C0240059
.	O
	
motor	B-C0234130
and	O
neurocognitive	B-C3714634
functions	I-C3714634
were	O
assessed	B-C1516048
at	O
days	O
1	O
to	O
7	O
and	O
23	O
to	O
28	O
,	O
respectively	O
.	O
	
iron	B-C0333596
deposition	I-C0333596
,	O
iron	B-C0302583
-related	O
protein	B-C1171362
expression	I-C1171362
,	O
ependymal	B-C3686783
damage	I-C3686783
,	O
and	O
histology	B-C4048239
were	O
detected	B-C0442726
at	O
day	O
28	O
.	O
	
expression	B-C0017262
of	O
cd36	B-C1366645
scavenger	B-C0074129
receptor	I-C0074129
facilitating	O
phagocytosis	B-C0031308
was	O
examined	B-C0332128
at	O
day	O
3	O
after	O
ivh	B-C0240059
using	O
western	B-C0005863
blotting	I-C0005863
and	O
immunofluorescence	B-C0079603
.	O
	
simvastatin	B-C0074554
significantly	O
increased	B-C0205217
hematoma	B-C0018944
absorption	B-C0000854
ratio	B-C0456603
,	O
reduced	B-C0392756
ventricular	B-C1511726
volume	I-C1511726
,	O
and	O
attenuated	B-C1709219
neurological	I-C1709219
dysfunction	I-C1709219
post-	O
ivh	B-C0240059
.	O
	
in	O
addition	O
,	O
less	B-C4021076
iron	I-C4021076
accumulation	I-C4021076
and	O
more	O
cilia	B-C0008778
survival	B-C1709301
was	O
observed	O
in	O
the	O
simvastatin	B-C0074554
group	O
when	O
compared	O
with	O
the	O
control	B-C0009932
.	O
	
what's	O
more	O
,	O
higher	B-C0205250
expression	B-C0017262
of	O
cd36	B-C1366645
was	O
detected	B-C0442726
around	O
the	O
hematoma	B-C0018944
after	O
simvastatin	B-C0074554
administration	B-C1533734
.	O
	
simvastatin	B-C0074554
significantly	O
enhanced	O
brain	B-C0006104
hematoma	B-C0018944
absorption	B-C0000854
,	O
alleviated	B-C0020255
hydrocephalus	I-C0020255
,	O
and	O
improved	B-C0184511
neurological	B-C0205494
recovery	B-C2004454
after	O
experimental	B-C1517586
ivh	B-C0240059
,	O
which	O
may	O
in	O
part	O
by	O
upregulating	B-C0041904
cd36	B-C1366645
expression	B-C0017262
.	O
	
our	O
data	B-C1511726
suggest	O
that	O
early	O
simvastatin	B-C0074554
use	O
may	O
be	O
a	O
novel	B-C0205314
therapy	B-C0087111
for	O
ivh	B-C0240059
patients	B-C0030705
.	O
	
ampk	B-C2350345
-	O
autophagy	B-C0004391
inhibition	B-C3463820
sensitizes	O
icaritin	B-C1567768
-	O
induced	B-C0205263
anti-colorectal	B-C0243095
cancer	I-C0243095
cell	B-C0007613
activity	I-C0007613
the	O
current	B-C0521116
research	B-C0035168
studied	O
the	O
potential	B-C1280500
effect	I-C1280500
of	O
autophagy	B-C0004391
on	O
icaritin	B-C1567768
-	O
induced	B-C0205263
anti-colorectal	B-C0243095
cancer	I-C0243095
crc	B-C1527249
cell	B-C0007613
activity	I-C0007613
.	O
	
treatment	B-C1522326
of	O
icaritin	B-C1567768
in	O
both	O
primary	B-C0205225
and	O
established	B-C0443211
ht-29	B-C0282639
crc	B-C1527249
cells	B-C0007634
induced	B-C0205263
feedback	B-C1879547
activation	I-C1879547
of	O
autophagy	B-C0004391
,	O
evidenced	O
by	O
p62	B-C1420393
degradation	B-C0314674
,	O
beclin-1	B-C1412785
and	O
autophagy-related	B-C1825497
gene-5	I-C1825497
atg-5	B-C1825497
upregulation	B-C0041904
,	O
as	O
well	O
as	O
light	B-C1311384
chain	I-C1311384
3b	I-C1311384
lc3b	B-C1311384
gfp	B-C0120285
puncta	O
formation	B-C1522492
.	O
	
pharmacological	B-C0205464
inhibiting	B-C3463820
of	O
autophagy	B-C0004391
dramatically	O
potentiated	O
icaritin	B-C1567768
-	O
induced	B-C0205263
crc	B-C1527249
cell	B-C0007587
death	I-C0007587
and	O
apoptosis	B-C0162638
.	O
	
meanwhile	O
,	O
shrna	B-C2930586
-mediated	O
knockdown	B-C2350567
of	O
beclin-1	B-C1412785
or	O
atg-5	B-C1825497
also	O
sensitized	O
icaritin	B-C1567768
-	O
induced	B-C0205263
crc	B-C1527249
cell	B-C0007587
death	I-C0007587
and	O
apoptosis	B-C0162638
.	O
	
icaritin	B-C1567768
activated	B-C1879547
amp-activated	B-C2350345
protein	I-C2350345
kinase	I-C2350345
ampk	B-C2350345
signaling	B-C0037083
in	O
crc	B-C1527249
cells	B-C0007634
,	O
functioning	B-C0542341
as	O
the	O
upstream	O
signaling	B-C0037083
for	O
autophagy	B-C0004391
activation	B-C1879547
.	O
	
shrna	B-C2930586
/	O
sirna	B-C1099354
-mediated	O
knockdown	B-C2350567
of	O
ampkα1	B-C1418897
inhibited	B-C0311403
icaritin	B-C1567768
-	O
induced	B-C0205263
autophagy	B-C0004391
activation	B-C1879547
,	O
but	O
exacerbated	B-C1444749
crc	B-C1527249
cell	B-C0007587
death	I-C0007587
.	O
	
on	O
the	O
other	O
hand	O
,	O
the	O
ampk	B-C2350345
activator	O
compound	B-C1254351
13	I-C1254351
c13	B-C1254351
or	O
the	O
autophagy	B-C0004391
activator	O
mhy1485	B-C3661263
attenuated	B-C0599946
icaritin	B-C1567768
-	O
induced	B-C0205263
cytotoxicity	B-C0596402
.	O
	
in	O
nude	B-C0025932
mice	I-C0025932
,	O
icaritin	B-C1567768
oral	B-C0001563
administration	I-C0001563
induced	B-C0205263
ht-29	B-C0282639
tumor	B-C0598934
growth	I-C0598934
inhibition	B-C3463820
was	O
potentiated	O
when	O
combined	O
with	O
ampkα1	B-C1418897
shrna	B-C2930586
knockdown	B-C2350567
in	O
tumors	B-C0027651
.	O
	
we	O
conclude	O
that	O
feedback	B-C1879547
activation	I-C1879547
of	O
ampk	B-C2350345
-	O
autophagy	B-C0004391
pathway	B-C0037080
could	O
be	O
a	O
primary	O
resistance	B-C4281815
factor	B-C1521761
of	O
classification	B-C0008902
of	O
edible	B-C1517288
oils	I-C1517288
based	O
on	O
atr-ftir	B-C0206055
spectral	B-C1533716
information	I-C1533716
during	O
a	O
long	B-C1254366
heating	I-C1254366
treatment	I-C1254366
identification	B-C0205396
of	O
oil	B-C1517288
type	B-C0332307
and	O
its	O
qc	B-C0034378
are	O
important	O
concerns	O
in	O
food	B-C0016452
control	O
laboratories	O
.	O
	
classifying	O
edible	O
oils	O
that	O
have	O
not	O
been	O
used	O
i.e	O
,	O
unheated	O
with	O
the	O
aid	O
of	O
vibrational	O
spectroscopy	O
has	O
previously	O
been	O
reported	O
.	O
	
however	O
,	O
the	O
classification	O
of	O
used	O
i.e	O
,	O
heat-treated	O
oils	O
needs	O
special	O
attention	O
.	O
	
the	O
effect	O
of	O
long	O
heating	O
times	O
on	O
the	O
classification	O
of	O
four	O
kinds	O
of	O
edible	O
oils	O
canola	O
,	O
corn	O
,	O
frying	O
,	O
and	O
sunflower	O
based	O
on	O
attenuated	O
total	O
reflectance	O
atr	O
spectra	O
was	O
surveyed	O
.	O
	
the	O
sampling	O
was	O
done	O
on	O
the	O
oils	O
during	O
a	O
36	O
h	O
heating	O
process	O
at	O
170	O
.	O
	
the	O
atr-ftir	O
spectra	O
of	O
the	O
samples	O
were	O
collected	O
in	O
the	O
range	O
of	O
4000-550	O
cm-1	O
.	O
	
interval	O
extended	O
canonical	O
variates	O
analysis	O
ecva	O
,	O
as	O
a	O
variable	O
selection	O
and	O
classification	O
tool	O
,	O
was	O
used	O
to	O
determine	O
the	O
best	O
intervals	O
during	O
the	O
heating	O
procedure	O
for	O
classification	O
.	O
	
principal	O
component	O
analysis	O
discriminate	O
analysis	O
,	O
partial	O
least-squares	O
discriminate	O
analysis	O
,	O
and	O
ecva	O
were	O
performed	O
on	O
the	O
selected	O
intervals	O
and	O
on	O
the	O
total	O
heating	O
time	O
.	O
	
the	O
effect	O
of	O
autoscaling	O
and	O
mean-centering	O
,	O
as	O
data	O
preprocessing	O
methods	O
,	O
was	O
also	O
investigated	O
.	O
	
the	O
ecva	O
method	O
resulted	O
in	O
the	O
best	O
performances	O
for	O
classification	O
,	O
with	O
a	O
94%	O
cross-validated	O
nonerror	O
rate	O
one	O
misclassification	O
for	O
the	O
heating	O
process	O
times	O
of	O
24-27	O
and	O
33-36	O
intravitreal	B-C1517572
chemotherapy	B-C3665472
in	O
the	O
management	B-C0376636
of	O
vitreous	B-C0155365
disease	I-C0155365
in	O
retinoblastoma	B-C0035335
to	O
evaluate	O
the	O
therapeutic	B-C0085415
outcome	I-C0085415
of	O
intravitreal	B-C1517572
melphalan	B-C0025241
injection	B-C1272883
in	O
the	O
management	B-C0376636
of	O
vitreous	B-C0155365
disease	I-C0155365
in	O
patients	B-C0030705
with	O
retinoblastoma	B-C0035335
.	O
	
we	O
particularly	O
aimed	O
to	O
assess	O
whether	O
higher	B-C0205250
melphalan	B-C0025241
dose	B-C0178602
with	O
lower	B-C0205251
number	B-C0237753
of	O
injections	B-C1272883
was	O
more	O
effective	B-C1704419
and	O
associated	B-C0332281
with	I-C0332281
fewer	B-C0205388
side	B-C0879626
effects	I-C0879626
.	O
	
this	O
retrospective	B-C0035363
,	O
interventional	B-C3274035
,	O
noncomparative	B-C2603343
,	O
and	O
nonrandomized	B-C2603343
study	I-C2603343
included	O
39	O
eyes	B-C0015392
of	O
37	O
patients	B-C0030705
.	O
	
vitreous	B-C1719830
seeds	I-C1719830
were	O
classified	B-C0008902
as	O
dust	B-C0027651
,	O
sphere	B-C0027651
,	O
and	O
cloud	B-C0027651
types	I-C0027651
.	O
	
intravitreal	B-C1517572
injections	B-C1272883
were	O
performed	B-C0884358
through	B-C0332273
pars	B-C0229167
plana	I-C0229167
free	O
of	O
any	O
visible	B-C0205379
tumor	B-C0027651
using	B-C1524063
30-g	B-C0027551
needle	I-C0027551
.	O
	
response	B-C1817727
of	I-C1817727
the	I-C1817727
seeds	I-C1817727
disappearance	B-C0243095
,	O
conversion	B-C0439836
into	O
inactive	B-C1720491
debris	I-C1720491
,	O
or	O
progression	B-C0178874
and	O
enucleation	B-C0014392
rate	B-C1521828
were	O
determined	O
as	O
outcome	B-C0085415
measures	B-C0079809
.	O
	
all	O
patients	B-C0030705
previously	O
received	B-C1514756
systemic	B-C1883256
or	O
intra-arterial	B-C0842399
chemotherapy	I-C0842399
.	O
	
vitreous	B-C1719830
seeding	I-C1719830
was	O
primary	B-C0205225
in	O
54%	O
of	O
eyes	B-C0015392
and	O
secondary	B-C0175668
in	O
46%	O
of	O
eyes	B-C0015392
.	O
	
vitreous	B-C1719830
seeds	I-C1719830
were	O
classified	B-C0008902
as	O
dust	B-C0027651
in	O
9	O
23.1	O
eyes	B-C0015392
,	O
sphere	B-C0027651
in	O
24	O
61.5	O
eyes	B-C0015392
,	O
and	O
cloud	B-C0027651
in	O
6	O
15.4	O
eyes	B-C0015392
.	O
	
melphalan	B-C0025241
dose	B-C0178602
varied	O
between	O
20	O
and	O
40	O
µg	O
and	O
20	O
51.3	O
eyes	B-C0015392
received	B-C1514756
>30	O
µg	O
.	O
	
the	O
total	B-C4288115
number	I-C4288115
of	O
injections	B-C1272883
was	O
70	O
range	O
1-5	O
,	O
mean	B-C0444504
1.8	O
per	O
eye	B-C0015392
.	O
	
various	B-C0439064
types	B-C0332307
of	O
regression	B-C0684320
were	O
obtained	B-C1301820
in	O
27	O
69.2	O
eyes	B-C0015392
.	O
	
sphere-type	B-C0027651
seeds	I-C0027651
were	O
the	O
most	B-C0205393
responsive	B-C0205342
to	O
melphalan	B-C0025241
.	O
	
nonresponse	B-C3844724
and	O
disease	B-C0242656
progression	I-C0242656
were	O
noted	B-C4288581
in	O
12	O
30.8	O
eyes	B-C0015392
.	O
	
after	O
a	O
mean	B-C0444504
follow-up	B-C1522577
of	O
11.8	O
months	B-C0439231
,	O
17	O
44%	O
eyes	B-C0015392
were	O
enucleated	B-C1396718
.	O
	
vitreous	B-C0042909
hemorrhage	I-C0042909
18%	O
and	O
retinal	B-C0035322
pigment	I-C0035322
epithelial	I-C0035322
alterations	B-C1515926
8%	O
were	O
the	O
most	B-C0205393
common	B-C0205214
side	B-C0879626
effects	I-C0879626
.	O
	
intravitreal	B-C1517572
melphalan	B-C0025241
at	O
30-40	O
µg	O
in	O
1	O
or	O
2	O
injections	B-C1272883
proved	O
effective	B-C1704419
in	O
69.2	O
of	O
eyes	B-C0015392
with	O
vitreous	B-C0155365
disease	I-C0155365
.	O
	
fine	B-C0678594
structure	I-C0678594
of	O
the	O
anterior	B-C0015392
median	I-C0015392
eyes	I-C0015392
of	O
the	O
funnel	B-C0332495
-	O
web	B-C0037913
spider	I-C0037913
agelena	B-C1905695
labyrinthica	I-C1905695
araneae	B-C0037913
agelenidae	B-C0998353
only	O
few	O
electron	B-C0026019
microscopic	I-C0026019
studies	I-C0026019
exist	O
on	O
the	O
structure	B-C0678594
of	O
the	O
main	O
eyes	B-C0015392
anterior	B-C0015392
median	I-C0015392
eyes	I-C0015392
,	O
ame	B-C0015392
of	O
web	B-C0037913
spiders	I-C0037913
.	O
	
the	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	B-C0700276
of	O
the	O
ame	B-C0015392
in	O
the	O
funnel-web	O
spider	B-C0037913
agelena	B-C1905695
labyrinthica	I-C1905695
.	O
	
the	O
retina	B-C0035298
consists	O
of	O
two	O
separate	O
regions	B-C0205147
with	O
differently	O
arranged	O
photoreceptor	B-C0031760
cells	I-C0031760
.	O
	
its	O
central	B-C0205099
part	I-C0205099
has	O
sensory	B-C0034837
cells	I-C0034837
with	O
rhabdomeres	B-C1167266
on	O
2	O
,	O
3	O
,	O
or	O
4	O
sides	O
,	O
whereas	O
those	O
of	O
the	O
ventral	B-C1704448
retina	B-C0035298
have	O
only	O
two	O
rhabdomeres	B-C1167266
on	O
opposite	O
sides	O
.	O
	
in	O
addition	O
,	O
the	O
rhabdomeres	B-C1167266
of	O
the	O
ventral	B-C1704448
retina	B-C0035298
are	O
arranged	O
in	O
a	O
specific	O
way	O
whereas	O
in	O
the	O
most	O
ventral	B-C1704448
part	O
they	O
form	O
long	B-C0454236
tangential	I-C0454236
rows	I-C0454236
,	O
those	O
towards	O
the	O
center	B-C0205099
are	O
detached	O
and	O
are	O
arranged	O
radially	O
.	O
	
all	O
sensory	B-C0034837
cells	I-C0034837
are	O
wrapped	O
by	O
unpigmented	B-C0243095
pigment	B-C1179009
cell	I-C1179009
processes	B-C0007613
.	O
	
in	O
agelenid	B-C0998353
spiders	B-C0037913
the	O
axons	B-C0004461
of	O
the	O
sensory	B-C0034837
cells	I-C0034837
exit	O
from	O
the	O
middle	O
of	O
the	O
cell	B-C2752549
body	I-C2752549
their	O
fine	B-C0678594
structure	I-C0678594
and	O
course	O
through	O
the	O
eye	B-C0180233
cup	I-C0180233
is	O
described	O
in	O
detail	O
.	O
	
in	O
the	O
central	B-C0205099
part	I-C0205099
of	O
the	O
retina	B-C0035298
efferent	O
nerve	B-C0027749
fibres	I-C0027749
were	O
found	O
forming	O
synapses	B-C0039062
along	O
the	O
distal	B-C0205147
region	I-C0205147
of	O
the	O
receptor	B-C0034837
cells	I-C0034837
.	O
	
a	O
muscle	B-C0026845
is	O
attached	O
laterally	O
to	O
each	O
eye	B-C0180233
cup	I-C0180233
that	O
allows	O
mainly	O
rotational	B-C0445237
movements	B-C0015413
of	O
the	O
eyes	B-C0015392
.	O
	
the	O
optical	B-C0029141
performance	I-C0029141
image	B-C2699488
resolution	I-C2699488
of	O
these	O
main	O
eyes	B-C0015392
with	O
relatively	O
few	O
visual	B-C0007634
cells	I-C0007634
knocking	B-C2350567
down	I-C2350567
tcf8	B-C1420645
inhibits	O
high	B-C0860803
glucose	I-C0860803
-	O
and	O
angiotensin	B-C0003009
ii	I-C0003009
-	O
induced	B-C0205263
epithelial	B-C1523298
to	I-C1523298
mesenchymal	I-C1523298
transition	I-C1523298
in	O
podocytes	B-C1328818
epithelial	B-C1523298
to	I-C1523298
mesenchymal	I-C1523298
transition	I-C1523298
emt	B-C1523298
is	O
a	O
physiological	B-C2350828
phenomenon	I-C2350828
in	O
mammalian	B-C0024660
embryogenesis	B-C0013936
by	O
which	O
epithelial	B-C0014597
cells	I-C0014597
become	O
mesenchymal	B-C1257975
stem	I-C1257975
cells	I-C1257975
.	O
	
studies	O
have	O
indicated	O
that	O
an	O
inappropriate	O
emt	B-C1523298
plays	O
a	O
key	O
role	O
in	O
a	O
variety	O
of	O
pathogenic	B-C3816499
processes	B-C1522240
such	O
as	O
embryonic	B-C0013936
development	I-C0013936
and	O
tumor	B-C0027627
metastasis	I-C0027627
.	O
	
moreover	O
,	O
recent	O
studies	O
have	O
indicated	O
emt	B-C1523298
also	O
plays	O
an	O
important	O
role	O
in	O
renal	B-C0151650
fibrosis	I-C0151650
.	O
	
in	O
the	O
current	O
study	O
,	O
glucose	B-C0017725
and	O
angiotensin	B-C0003009
ii	I-C0003009
promoted	O
emt	B-C1523298
in	O
podocytes	B-C1328818
as	O
well	O
as	O
changes	O
in	O
the	O
cellular	B-C1521816
morphology	I-C1521816
of	O
podocytes	B-C1328818
.	O
	
a	O
high	B-C0205250
concentration	B-C1446561
of	O
glucose	B-C0017725
and	O
angiotensin	B-C0003009
ii	I-C0003009
also	O
promoted	O
podocyte	B-C1328818
movement	B-C1621968
and	O
migration	B-C1622501
.	O
	
moreover	O
,	O
a	O
high	B-C0205250
concentration	B-C1446561
of	O
glucose	B-C0017725
and	O
angiotensin	B-C0003009
ii	I-C0003009
promoted	O
tcf8	B-C1420645
expression	B-C0017262
.	O
	
inhibiting	B-C3463820
tcf8	B-C1420645
expression	B-C0017262
with	O
sirna	B-C1099354
reversed	O
emt	B-C1523298
in	O
podocytes	B-C1328818
in	O
the	O
presence	O
of	O
a	O
high	B-C0205250
concentration	B-C1446561
of	O
glucose	B-C0017725
and	O
angiotensin	B-C0003018
.	O
	
inhibiting	B-C3463820
tcf8	B-C1420645
expression	B-C0017262
also	O
reversed	O
changes	O
in	O
cellular	B-C1521816
morphology	I-C1521816
and	O
podocyte	B-C1328818
movement	B-C1621968
and	O
migration	B-C1622501
.	O
	
therefore	O
,	O
glucose	B-C0017725
and	O
angiotensin	B-C0003009
ii	I-C0003009
may	O
promote	O
emt	B-C1523298
in	O
podocytes	B-C1328818
via	O
temporal	O
upregulation	B-C0041904
of	O
host	B-C0034800
surface	I-C0034800
receptors	I-C0034800
provides	O
a	O
window	O
of	O
opportunity	O
for	O
bacterial	B-C0004614
adhesion	I-C0004614
and	O
disease	B-C0004623
host	B-C0034800
surface	I-C0034800
receptors	I-C0034800
provide	O
bacteria	B-C0004611
with	O
a	O
foothold	O
from	O
which	O
to	O
attach	B-C3714578
,	O
colonize	O
and	O
,	O
in	O
some	O
cases	O
,	O
invade	O
tissue	B-C0040300
and	O
elicit	O
human	B-C0086418
disease	B-C0012634
.	O
	
in	O
this	O
review	O
,	O
we	O
discuss	O
several	O
key	O
host	B-C0034800
receptors	I-C0034800
and	O
cognate	B-C0699040
adhesins	I-C0699040
that	O
function	O
in	O
bacterial	B-C0004611
pathogenesis	B-C0699748
.	O
	
in	O
particular	O
,	O
we	O
examine	O
the	O
elevated	B-C3163633
expression	B-C0597360
of	O
host	B-C0034800
surface	I-C0034800
receptors	I-C0034800
such	O
as	O
ceacam-1	B-C3540477
,	O
ceacam-6	B-C0376900
,	O
icam-1	B-C0063695
and	O
pafr	B-C0071234
in	O
response	B-C0542478
to	I-C0542478
specific	I-C0542478
stimuli	I-C0542478
.	O
	
we	O
explore	O
how	O
upregulated	B-C0949479
receptors	I-C0949479
,	O
in	O
turn	O
,	O
expose	O
the	O
host	B-C1167395
to	O
a	O
range	O
of	O
bacterial	B-C0004623
infections	I-C0004623
in	O
the	O
respiratory	B-C0035237
tract	I-C0035237
.	O
	
it	O
is	O
apparent	O
that	O
exploitation	O
of	O
receptor	B-C0597357
induction	B-C0205263
for	O
bacterial	B-C0004614
adherence	I-C0004614
is	O
not	O
unique	O
to	O
one	O
body	B-C0460002
system	I-C0460002
,	O
but	O
is	O
also	O
observed	O
in	O
the	O
central	B-C3714787
nervous	I-C3714787
,	O
gastrointestinal	B-C0012240
and	O
urogenital	B-C0042066
systems	I-C0042066
.	O
	
prokaryotic	B-C0686817
pathogens	B-C0699748
which	O
utilize	O
this	O
mechanism	O
for	O
their	O
infectivity	B-C3714514
include	O
streptococcus	B-C0038410
pneumoniae	I-C0038410
,	O
haemophilus	B-C0018483
influenzae	I-C0018483
,	O
neisseria	B-C0027575
meningitidis	I-C0027575
and	O
escherichia	B-C0014834
coli	I-C0014834
.	O
	
a	O
number	O
of	O
approaches	O
have	O
been	O
used	O
,	O
in	B-C1515654
both	O
in	O
vitro	I-C1515654
and	O
in	B-C1515657
vivo	I-C1515657
experimental	I-C1515657
models	I-C1515657
,	O
to	O
inhibit	O
bacterial	B-C0004614
attachment	I-C0004614
to	O
temporally	O
expressed	B-C0597360
host	B-C0034800
receptors	I-C0034800
.	O
	
some	O
of	O
these	O
novel	O
strategies	O
may	O
advance	O
future	O
targeted	B-C1521840
interventions	B-C1273869
for	O
the	O
prevention	B-C0199176
and	O
treatment	B-C0087111
of	O
bacterial	B-C0004623
disease	I-C0004623
.	O
	
optogenetic	B-C3494301
demonstration	B-C0441655
of	O
functional	B-C0205245
innervation	B-C0021516
of	O
mouse	B-C0025929
colon	B-C0009368
by	O
neurons	B-C0027882
derived	O
from	O
transplanted	B-C0700106
neural	B-C0027882
cells	I-C0027882
cell	B-C0302189
therapy	I-C0302189
offers	O
the	O
potential	O
to	O
treat	B-C1522326
gastrointestinal	B-C0854121
motility	I-C0854121
disorders	I-C0854121
caused	O
by	O
diseased	B-C0027882
or	O
absent	B-C0332197
enteric	B-C1304890
neurons	B-C0027882
.	O
	
we	O
examined	O
whether	O
neurons	B-C0027882
generated	O
from	O
transplanted	B-C0700106
enteric	B-C1304890
neural	B-C0027882
cells	I-C0027882
provide	O
a	O
functional	B-C0205245
innervation	B-C0021516
of	O
bowel	B-C0021853
smooth	B-C1267092
muscle	I-C1267092
in	O
mice	B-C0025929
.	O
	
enteric	B-C1304890
neural	B-C0027882
cells	I-C0027882
expressing	O
the	O
light-sensitive	B-C0022009
ion	I-C0022009
channel	I-C0022009
,	O
channelrhodopsin	B-C0033684
,	O
were	O
isolated	B-C0205409
from	O
the	O
fetal	B-C0521457
or	O
postnatal	B-C0443281
mouse	B-C0025929
bowel	B-C0021853
and	O
transplanted	B-C0700106
into	O
the	O
distal	B-C1517729
colon	I-C1517729
of	O
3-	O
to	O
4-	O
week	B-C0439230
-old	O
wild-type	B-C1883559
recipient	B-C0025929
mice	I-C0025929
.	O
	
intracellular	B-C0178719
electrophysiological	B-C0022885
recordings	I-C0022885
of	O
responses	B-C0205245
to	O
light	B-C0240188
stimulation	I-C0240188
of	O
the	O
transplanted	B-C0700106
cells	B-C0027882
were	O
made	O
from	O
colonic	B-C0009368
smooth	B-C1135918
muscle	I-C1135918
cells	I-C1135918
in	O
recipient	B-C0025929
mice	I-C0025929
.	O
	
electrical	B-C1254366
stimulation	I-C1254366
of	O
endogenous	B-C0205227
enteric	B-C1304890
neurons	B-C0027882
was	O
used	O
as	O
a	O
control	B-C0009932
.	O
	
the	O
axons	B-C0004461
of	O
graft	B-C0332835
-derived	O
neurons	B-C0027882
formed	O
a	O
plexus	B-C1184808
in	O
the	O
circular	B-C0734812
muscle	I-C0734812
layer	I-C0734812
.	O
	
selective	B-C1254366
stimulation	I-C1254366
of	O
graft	B-C0332835
-derived	O
cells	B-C0027882
by	O
light	B-C0023693
resulted	O
in	O
excitatory	B-C0234121
and	O
inhibitory	B-C0234122
junction	I-C0234122
potentials	I-C0234122
,	O
the	O
electrical	B-C0442828
events	B-C0441471
underlying	O
contraction	B-C0026820
and	O
relaxation	B-C0026836
,	O
respectively	O
,	O
in	O
colonic	B-C0009368
muscle	B-C1135918
cells	I-C1135918
.	O
	
graft	B-C0332835
-derived	O
excitatory	B-C0026609
and	O
inhibitory	B-C0026609
motor	I-C0026609
neurons	I-C0026609
released	O
the	O
same	O
neurotransmitters	B-C0027908
as	O
endogenous	B-C0205227
motor	B-C0026609
neurons	I-C0026609
-	O
acetylcholine	B-C0001041
and	O
a	O
combination	O
of	O
adenosine	B-C0001480
triphosphate	I-C0001480
and	O
nitric	B-C0028128
oxide	I-C0028128
,	O
respectively	O
.	O
	
graft	B-C0332835
-derived	O
neurons	B-C0027882
also	O
included	O
interneurons	B-C0021792
that	O
provided	O
synaptic	O
inputs	O
to	O
motor	O
neurons	B-C0027882
,	O
but	O
the	O
pharmacologic	B-C0871161
properties	I-C0871161
of	O
interneurons	B-C0021792
varied	O
with	O
the	O
age	B-C0001779
of	O
the	O
donors	B-C0013018
from	O
which	O
enteric	B-C1304890
neural	B-C0027882
cells	I-C0027882
were	O
obtained	O
.	O
	
enteric	B-C1304890
neural	B-C0027882
cells	I-C0027882
transplanted	B-C0700106
into	O
the	O
bowel	B-C0021853
give	O
rise	O
to	O
multiple	B-C0439064
functional	B-C0205245
types	B-C0332307
of	O
neurons	B-C0027882
that	O
integrate	O
and	O
provide	O
a	O
functional	B-C0205245
innervation	B-C0021516
of	O
the	O
smooth	B-C1267092
muscle	I-C1267092
of	O
the	O
bowel	B-C1283694
wall	I-C1283694
.	O
	
circuits	B-C0814033
composed	O
of	O
both	O
motor	B-C0026609
neurons	I-C0026609
and	O
interneurons	B-C0021792
were	O
established	O
,	O
but	O
the	O
age	B-C0001779
at	O
which	O
cells	B-C0027882
are	O
isolated	O
influences	O
the	O
neurotransmitter	B-C0027908
phenotype	B-C0031437
of	O
interneurons	B-C0021792
assessment	B-C0220825
of	O
vascular	B-C0183521
stent	I-C0183521
heating	B-C0018837
with	O
repetitive	B-C0872259
transcranial	I-C0872259
magnetic	I-C0872259
stimulation	I-C0872259
a	O
high	O
proportion	O
of	O
patients	B-C0030705
with	O
stroke	B-C0038454
do	O
not	O
qualify	O
for	O
repetitive	B-C0872259
transcranial	I-C0872259
magnetic	I-C0872259
stimulation	I-C0872259
rtms	B-C0872259
clinical	B-C0008972
studies	I-C0008972
due	O
to	O
the	O
presence	O
of	O
metallic	B-C0441290
stents	I-C0441290
.	O
	
the	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	B-C0025552
could	O
become	O
heated	B-C0018837
due	O
to	O
eddy	B-C0013790
currents	I-C0013790
.	O
	
however	O
,	O
to	O
date	O
,	O
no	O
clinical	B-C3899555
safety	I-C3899555
data	I-C3899555
are	O
available	O
regarding	O
the	O
risk	B-C0035647
of	O
metallic	B-C0441290
stents	I-C0441290
heating	B-C0018837
with	O
rtms	B-C0872259
.	O
	
we	O
tested	B-C0039593
the	O
safety	B-C1705187
of	O
common	O
rtms	B-C0872259
protocols	B-C0442711
1	O
hz	O
and	O
10	O
hz	O
with	O
stents	B-C0183521
used	O
commonly	O
in	O
stroke	B-C0038454
,	O
nitinol	B-C0068790
and	O
elgiloy	B-C0002154
.	O
	
in	O
our	O
method	O
,	O
stents	B-C0183521
were	O
tested	B-C0392366
in	O
gelled	B-C1382104
saline	B-C0036082
at	O
2	O
different	O
locations	B-C0450429
at	B-C0205099
the	I-C0205099
center	I-C0205099
and	O
at	O
the	O
lobe	B-C0796494
of	O
the	O
coil	B-C1705946
.	O
	
in	O
addition	O
,	O
at	O
each	O
location	B-C0450429
,	O
stent	B-C0441290
heating	B-C0018837
was	O
evaluated	B-C0220825
in	O
3	O
different	O
orientations	B-C1704322
parallel	B-C1254362
to	O
the	O
long	B-C0522487
axis	I-C0522487
of	O
coil	B-C1705946
,	O
parallel	B-C1254362
to	O
the	O
short	B-C0522488
axis	I-C0522488
of	O
the	O
coil	B-C1705946
,	O
and	O
perpendicular	B-C1295725
to	O
the	O
plane	O
of	O
the	O
coil	B-C1705946
.	O
	
we	O
found	O
that	O
stents	B-C0183521
did	O
not	O
heat	B-C0018837
to	O
more	O
than	O
1	O
with	O
either	O
1	O
hz	O
rtms	B-C0872259
or	O
10	O
hz	O
rtms	B-C0872259
in	O
any	O
configuration	O
or	O
orientation	B-C1704322
.	O
	
heating	B-C0018837
in	O
general	O
was	O
greater	B-C1704243
at	O
the	O
lobe	B-C0796494
when	O
the	O
stent	B-C0183521
was	O
oriented	B-C1704322
perpendicularly	B-C1295725
.	O
	
our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex	B-C2348480
vivo	I-C2348480
quantification	B-C1709793
of	O
stent	B-C0441290
heating	B-C0018837
.	O
	
we	O
have	O
found	O
that	O
heating	B-C0018837
of	O
stents	B-C0183521
was	O
well	O
below	O
the	O
food	B-C1708333
and	I-C1708333
drug	I-C1708333
administration	I-C1708333
standards	B-C0038137
of	O
2	O
.	O
	
thus	O
,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in	B-C1515655
vivo	I-C1515655
testing	B-C0039593
of	O
rtms	B-C0872259
10	O
hz	O
in	O
the	O
presence	O
of	O
implanted	B-C0021102
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
-	O
compatible	B-C1524057
stents	B-C0183521
in	O
animal	B-C0683949
studies	I-C0683949
.	O
	
when	O
planning	O
human	B-C0086418
safety	B-C1705187
studies	I-C1705187
though	O
,	O
geometry	B-C0449829
,	O
orientation	B-C1704322
,	O
and	O
location	B-C0450429
relative	O
to	O
the	O
coil	B-C1705946
clinical	B-C3889687
observation	I-C3889687
of	O
treatment	B-C1522326
of	O
chronic	B-C0749095
subdural	I-C0749095
hematoma	I-C0749095
with	O
novel	B-C0025080
double	I-C0025080
needle	I-C0025080
minimally	I-C0025080
invasive	I-C0025080
aspiration	I-C0025080
technology	I-C0025080
the	O
aim	B-C1947946
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
explore	O
the	O
clinical	B-C3850123
effects	I-C3850123
,	O
including	O
the	O
prevention	O
of	O
complications	B-C0009566
,	O
of	O
the	O
treatment	B-C1522326
of	O
chronic	B-C0749095
subdural	I-C0749095
hematoma	I-C0749095
with	O
double	B-C0025080
needle	I-C0025080
aspiration	I-C0025080
.	O
	
the	O
clinical	B-C1516606
data	I-C1516606
of	O
31	O
patients	B-C0030705
with	O
chronic	B-C0749095
subdural	I-C0749095
hematoma	I-C0749095
treated	B-C1522326
by	O
double	B-C0025080
yl-1	I-C0025080
needle	I-C0025080
double	O
skull	B-C0185154
drilling	I-C0185154
and	O
31	O
controls	O
treated	B-C1522326
by	O
traditional	O
drilling	B-C0185154
and	O
drainage	B-C0013103
were	O
analyzed	O
retrospectively	O
.	O
	
in	O
the	O
yl-1	B-C0025080
needle	I-C0025080
group	B-C0441833
,	O
only	O
1	O
patient	B-C0030705
was	O
with	O
hematoma	B-C0018944
recurrence	B-C2825055
,	O
1	O
patient	B-C0030705
was	O
with	O
intracranial	B-C0238376
pneumocephalus	I-C0238376
,	O
and	O
the	O
remaining	O
patients	B-C0030705
who	O
were	O
followed	O
up	O
for	O
3	O
months	B-C0439231
achieved	O
a	O
clinical	B-C3640840
cure	I-C3640840
.	O
	
in	O
the	O
traditional	B-C0185154
drilling	I-C0185154
and	O
drainage	B-C0013103
group	B-C0441833
,	O
13	O
patients	B-C0030705
were	O
with	O
hematoma	B-C0018944
recurrence	B-C2825055
within	O
3	O
months	B-C0439231
after	O
the	O
operation	B-C0543467
and	O
7	O
patients	B-C0030705
were	O
with	O
postoperative	B-C0032790
intracranial	B-C0238376
pneumocephalus	I-C0238376
.	O
	
the	O
method	B-C0025663
of	O
double	B-C0025080
yl-1	I-C0025080
needle	I-C0025080
is	O
better	O
than	O
the	O
traditional	B-C0185154
drilling	I-C0185154
and	O
drainage	B-C0013103
method	I-C0013103
for	O
the	O
treatment	B-C1522326
of	O
chronic	B-C0749095
subdural	I-C0749095
hematoma	I-C0749095
because	O
it	O
reduces	O
the	O
postoperative	B-C0032790
recurrence	B-C2825055
rate	O
and	O
the	O
impact	B-C4049986
of	O
adjunctive	B-C0677850
guanfacine	B-C0079466
extended	B-C1707968
release	I-C1707968
on	O
stimulant	B-C0304402
adherence	B-C1510802
in	O
children	B-C0008059
/	O
adolescents	B-C0205653
with	O
attention-deficit	B-C0041671
/	O
hyperactivity	B-C1263846
disorder	I-C1263846
to	O
assess	O
stimulant	B-C0304402
adherence	B-C1510802
among	O
children	B-C0008059
/	O
adolescents	B-C0205653
with	O
attention-deficit	B-C0041671
/	O
hyperactivity	B-C1263846
disorder	I-C1263846
adhd	B-C1263846
augmenting	B-C0449986
stimulants	I-C0449986
with	O
guanfacine	O
extended-release	O
gxr	O
.	O
	
inclusion	O
criteria	O
6-17	O
years	O
,	O
1	O
adhd	O
diagnosis	O
,	O
1	O
long-acting	O
and/or	O
short-acting	O
stimulant	O
with	O
gxr	O
augmentation	O
.	O
	
modified	O
medication	O
possession	O
ratio	O
mmpr	O
days	O
medication	O
available	O
/	O
days	O
in	O
period	O
,	O
excluding	O
medication	O
holidays	O
was	O
assessed	O
mmpr	O
<	O
0.80	O
nonadherent	O
.	O
	
regression	O
models	O
assessed	O
change	O
in	O
mmpr	O
adjusting	O
for	O
demographic	O
and	O
clinical	O
characteristics	O
.	O
	
among	O
patients	O
nonadherent	O
to	O
stimulants	B-C0304402
pre	O
-	O
augmentation	O
n	O
=	O
165	O
,	O
unadjusted	O
mean	O
sd	O
pre	O
-	O
and	O
post	O
-	O
stimulant	O
mmprs	O
were	O
0.68	O
0.11	O
and	O
0.87	O
0.16	O
.	O
	
adjusted	O
mean	O
change	O
in	O
mmpr	O
was	O
0.20	O
for	O
long-acting	O
versus	O
0.18	O
for	O
short-acting	O
stimulants	O
p	O
=	O
0.34	O
.	O
	
among	O
patients	O
nonadherent	O
to	O
stimulants	O
,	O
gxr	O
augmentation	O
was	O
associated	O
with	O
increased	O
stimulant	O
adherence	B-C1510802
bxb1	B-C1071338
phage	I-C1071338
recombinase	B-C0073020
assists	O
genome	B-C0017387
engineering	I-C0017387
in	O
drosophila	B-C0013139
melanogaster	I-C0013139
rapid	B-C0456962
and	O
reliable	B-C0205556
genome	B-C4277689
modifications	I-C4277689
provide	O
the	O
basis	O
for	O
detailed	O
in	B-C1515655
vivo	I-C1515655
functional	B-C0558024
analysis	I-C0558024
of	O
any	O
genomic	B-C1708234
entity	I-C1708234
gene	B-C0017337
,	O
regulatory	B-C2329837
dna	I-C2329837
,	O
non-coding	B-C0887909
rna	I-C0887909
,	O
etc	O
.	O
	
with	O
the	O
advent	O
of	O
crispr	B-C3658200
/	O
cas9	B-C4279981
genome	I-C4279981
editing	I-C4279981
technology	I-C4279981
,	O
manipulation	B-C0178659
of	O
a	O
particular	O
genomic	B-C0678933
locus	I-C0678933
has	O
become	O
a	O
routine	O
undertaking	O
in	O
variety	O
of	O
model	B-C0029235
organisms	I-C0029235
,	O
including	O
the	O
fruit	B-C0013139
fly	I-C0013139
drosophila	I-C0013139
melanogaster	I-C0013139
.	O
	
to	O
further	O
diversify	O
the	O
available	O
tools	O
for	O
genome	B-C0017387
engineering	I-C0017387
,	O
we	O
successfully	O
harnessed	O
the	O
phage	B-C1071338
recombinase	B-C0073020
bxb1	I-C0073020
to	O
perform	O
recombinase-mediated	O
cassette	O
exchange	O
rmce	O
in	O
d	B-C0013139
.	O
	
melanogaster	I-C0013139
.	O
	
we	O
demonstrate	O
that	O
bxb1	B-C1071338
possesses	O
highly	O
efficient	O
recombinase	B-C1148744
activity	I-C1148744
and	O
could	O
be	O
used	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
currently	O
available	O
recombinases	B-C0073020
for	O
creating	O
platforms	O
for	O
cassette	O
exchange	O
of	O
targeted	B-C0678933
loci	I-C0678933
.	O
	
tailor-made	B-C0013161
drug	I-C0013161
carrier	I-C0013161
comparison	B-C1707455
of	O
formation-dependent	O
physicochemical	B-C0871161
properties	I-C0871161
within	O
self-assembled	B-C0872376
aggregates	B-C0205418
for	O
an	O
optimal	B-C2698651
drug	B-C0013161
carrier	I-C0013161
self-assembled	B-C0872376
surfactant	B-C0038888
aggregates	B-C0205418
,	O
such	O
as	O
micelles	B-C0025938
and	O
vesicles	B-C1254350
,	O
have	O
been	O
investigated	O
for	O
their	O
application	B-C1524063
as	O
drug	B-C0013161
carriers	I-C0013161
in	O
the	O
treatment	B-C0087111
of	O
various	O
diseases	B-C0012634
.	O
	
however	O
,	O
the	O
characteristics	B-C1521970
that	O
decide	O
which	O
aggregate	B-C0205418
is	O
the	O
best	B-C1522427
drug	B-C0013161
carrier	I-C0013161
for	O
each	O
disease	B-C0012634
have	O
not	O
yet	O
been	O
clarified	O
.	O
	
in	O
order	O
to	O
design	B-C1707689
an	O
optimal	B-C2698651
drug	B-C0013161
carrier	I-C0013161
for	O
each	O
disease	B-C0012634
,	O
various	O
kinds	O
of	O
self-assembled	B-C0872376
aggregates	B-C0205418
,	O
such	O
as	O
spherical	B-C0025938
micelles	I-C0025938
,	O
lens-like	B-C1254350
vesicles	I-C1254350
,	O
and	O
tube-like	B-C1254350
vesicles	I-C1254350
,	O
were	O
evaluated	O
by	O
""""	O
multiple	B-C0449851
techniques	I-C0449851
""""	O
including	O
dynamic	B-C1882368
light	I-C1882368
scattering	I-C1882368
,	O
differential	B-C0006780
scanning	I-C0006780
calorimetry	I-C0006780
,	O
nuclear	B-C0877853
magnetic	I-C0877853
resonance	I-C0877853
spectroscopy	I-C0877853
,	O
and	O
fluorescence	B-C0037802
measurement	I-C0037802
using	O
the	O
laurdan	B-C0083196
probe	B-C0182400
.	O
	
these	O
studies	B-C2603343
led	O
to	O
the	O
compilation	O
of	O
a	O
database	B-C0242356
on	O
the	O
formation-dependent	O
properties	O
of	O
self-assembled	B-C0872376
aggregates	B-C0205418
.	O
	
as	O
the	O
relationship	B-C0439849
between	O
physicochemical	B-C0871161
properties	I-C0871161
of	O
self-assembled	B-C0872376
aggregates	B-C0205418
and	O
their	O
functions	B-C0542341
as	O
drug	B-C0013161
carriers	I-C0013161
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	B-C0242356
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	B-C2698651
drug	B-C0013161
carrier	I-C0013161
,	O
i.e	O
,	O
a	O
tailor-made	B-C0013161
drug	I-C0013161
carrier	I-C0013161
.	O
	
uridine	B-C0041984
stimulate	O
laxative	B-C0282090
effect	B-C1280500
in	O
the	O
loperamide	B-C0023992
-	O
induced	B-C0205263
constipation	B-C0009806
of	O
sd	B-C2699239
rats	I-C2699239
through	O
regulation	B-C1327386
of	O
the	O
machrs	B-C0034826
signaling	B-C0037080
pathway	I-C0037080
and	O
mucin	B-C0026682
secretion	B-C0036536
uridine	B-C0041984
urd	B-C0041984
,	O
which	O
has	O
been	O
reported	B-C0700287
as	O
a	O
major	B-C0205164
component	O
of	O
rna	B-C0035668
,	O
plays	O
an	O
important	B-C3898777
role	B-C1705810
in	O
various	O
biological	B-C3714634
process	I-C3714634
including	O
neuroprotection	B-C0598958
,	O
biochemical	B-C0678672
modulation	I-C0678672
and	O
glycolysis	B-C0017952
,	O
although	O
its	O
role	B-C1705810
in	O
constipation	B-C0009806
has	O
yet	O
to	O
be	O
established	B-C0443211
.	O
	
therefore	O
,	O
in	O
this	O
study	B-C2603343
,	O
we	O
investigated	B-C1292732
the	O
laxative	B-C0282090
effects	B-C1280500
of	O
urd	B-C0041984
on	O
chronic	B-C0205191
constipation	B-C0009806
.	O
	
the	O
constipation	B-C0009806
phenotypes	B-C0031437
and	O
their	O
related	O
mechanisms	B-C0441712
were	O
investigated	B-C1292732
in	O
the	O
transverse	B-C0227386
colons	I-C0227386
of	O
sd	B-C2699239
rats	I-C2699239
with	O
loperamide	B-C0023992
lop	B-C0023992
induced	B-C0205263
constipation	B-C0009806
after	O
treatment	B-C0087111
with	O
100	O
mg/kg	O
of	O
urd	B-C0041984
.	O
	
the	O
number	B-C0237753
,	O
weight	B-C0043100
and	O
water	B-C0043047
contents	B-C0456205
of	O
stools	B-C0015733
were	O
significantly	B-C0750502
higher	B-C0205250
in	O
the	O
lop	B-C0023992
+	O
urd	B-C0041984
treated	B-C0332154
group	B-C0441833
than	O
the	O
lop	B-C0023992
+	O
vehicle	B-C0042444
treated	B-C0332154
group	B-C0441833
,	O
while	O
food	B-C0013470
intake	I-C0013470
and	O
water	B-C0013123
consumption	I-C0013123
of	O
the	O
same	O
group	B-C0441833
were	O
maintained	O
at	O
a	O
constant	B-C1948059
level	B-C0441889
.	O
	
the	O
thickness	B-C1280412
of	O
the	O
mucosa	B-C0026724
layer	I-C0026724
,	O
muscle	B-C0026845
and	O
flat	B-C1180160
luminal	I-C1180160
surface	I-C1180160
,	O
as	O
well	O
as	O
the	O
number	B-C0237753
of	O
goblet	B-C0506994
cells	I-C0506994
,	O
paneth	B-C0227276
cells	I-C0227276
and	O
lipid	B-C0230704
droplets	I-C0230704
were	O
enhanced	B-C2349975
in	O
the	O
lop	B-C0023992
+	O
urd	B-C0041984
treated	B-C0332154
group	B-C0441833
.	O
	
furthermore	O
,	O
the	O
expression	B-C1171362
of	O
the	O
muscarinic	B-C0384752
acetylcholine	I-C0384752
receptors	I-C0384752
m2	I-C0384752
and	O
m3	B-C0289799
machr	B-C0384752
m2	I-C0384752
and	O
m3	B-C0289799
at	O
the	O
transcriptional	B-C1158770
and	O
translational	B-C3537096
level	B-C0441889
was	O
recovered	B-C0521108
in	O
the	O
lop	B-C0023992
+	O
urd	B-C0041984
treated	B-C0332154
group	B-C0441833
,	O
while	O
some	O
markers	B-C0005516
such	O
as	O
gα	B-C0887847
and	O
inositol	B-C0815032
triphosphate	I-C0815032
ip3	B-C0815032
in	O
their	O
downstream	B-C0522506
signaling	B-C0037080
pathway	I-C0037080
were	O
completely	O
recovered	B-C0521108
by	O
urd	B-C0041984
treatment	B-C0087111
.	O
	
moreover	O
,	O
the	O
ability	O
for	O
mucin	B-C0026682
secretion	B-C0036536
and	O
the	O
expression	B-C1171362
of	O
membrane	B-C0599635
water	I-C0599635
channel	I-C0599635
aquaporine	B-C1743716
8	I-C1743716
,	O
aqp8	B-C1743716
were	O
increased	B-C0205217
significantly	B-C0750502
in	O
the	O
lop	B-C0023992
+	O
urd	B-C0041984
treated	B-C0332154
group	B-C0441833
compared	B-C1707455
with	O
lop	B-C0023992
+	O
vehicle	B-C0042444
treated	B-C0332154
group	B-C0441833
.	O
	
finally	O
,	O
the	O
activity	B-C0441655
of	O
urd	B-C0041984
was	O
confirmed	O
in	O
primary	B-C1267092
smooth	I-C1267092
muscle	I-C1267092
of	O
rat	B-C0086893
intestine	B-C0814997
cells	I-C0814997
prismc	B-C1135918
based	O
on	O
gα	B-C0887847
expression	B-C1171362
and	O
ip3	B-C0815032
concentration	B-C1446561
.	O
	
the	O
results	B-C0683954
of	O
the	O
present	O
study	B-C2603343
provide	O
the	O
first	O
strong	B-C0442821
evidence	B-C3887511
that	O
urd	B-C0041984
can	O
be	O
considered	O
an	O
important	B-C3898777
candidate	O
for	O
improving	B-C1272745
chronic	B-C0205191
constipation	B-C0009806
induced	B-C0205263
by	O
lop	B-C0023992
treatment	B-C0087111
in	O
animal	B-C0599779
models	I-C0599779
.	O
	
characterization	B-C1880022
of	O
phytochrome	B-C0574031
interacting	I-C0574031
factors	I-C0574031
from	O
the	O
moss	B-C0282635
physcomitrella	B-C0996529
patens	I-C0996529
illustrates	O
conservation	B-C2347858
of	O
phytochrome	B-C0574031
signaling	I-C0574031
modules	I-C0574031
in	O
land	B-C1562025
plants	I-C1562025
across	O
the	O
plant	B-C0032098
kingdom	I-C0032098
,	O
phytochrome	B-C0031857
phy	B-C0031857
photoreceptors	B-C0031760
play	O
an	O
important	O
role	O
during	O
adaptive	B-C0231193
and	O
developmental	O
responses	B-C2945741
to	I-C2945741
light	I-C2945741
.	O
	
in	O
arabidopsis	B-C0162740
thaliana	I-C0162740
,	O
light-activated	O
phys	B-C0031857
accumulate	O
in	O
the	O
nucleus	B-C0007610
,	O
where	O
they	O
regulate	O
downstream	B-C1519315
signaling	I-C1519315
components	I-C1519315
,	O
such	O
as	O
phytochrome	B-C0574031
interacting	I-C0574031
factors	I-C0574031
pifs	B-C0574031
.	O
	
pifs	B-C0574031
are	O
transcription	B-C0040648
factors	I-C0040648
that	O
act	O
as	O
repressors	B-C1336789
of	O
photomorphogenesis	B-C1154971
their	O
inhibition	B-C2265391
by	O
phys	B-C0031857
leads	O
to	O
substantial	O
changes	O
in	O
gene	B-C0017262
expression	I-C0017262
.	O
	
the	O
nuclear	B-C0007613
function	I-C0007613
of	O
phys	B-C0031857
,	O
however	O
,	O
has	O
so	O
far	O
been	O
investigated	O
in	O
only	O
a	O
few	O
non-seed	B-C0032098
plants	I-C0032098
.	O
	
here	O
,	O
we	O
identified	O
putative	O
target	O
genes	B-C0017337
of	O
phy	B-C0031857
signaling	B-C3537152
in	O
the	O
moss	B-C0282635
physcomitrella	B-C0996529
patens	I-C0996529
and	O
found	O
light-regulated	B-C0017337
genes	I-C0017337
that	O
are	O
putative	O
orthologs	B-C1335144
of	O
pif-controlled	B-C0017337
genes	I-C0017337
in	O
arabidopsis	B-C0162741
.	O
	
phylogenetic	B-C1519068
analyses	I-C1519068
revealed	O
that	O
an	O
ancestral	O
pif-like	B-C0017337
gene	I-C0017337
was	O
already	O
present	O
in	O
streptophyte	B-C0002028
algae	I-C0002028
,	O
i.e	O
,	O
before	O
the	O
water-to-land	B-C2700061
transition	I-C2700061
of	O
plants	B-C0032098
.	O
	
the	O
pif	B-C0574031
homologs	I-C0574031
in	O
the	O
genome	B-C0017428
of	O
p	B-C0996529
.	O
	
patens	I-C0996529
resemble	O
arabidopsis	B-C0162741
pifs	B-C0574031
in	O
their	O
protein	B-C1510464
domain	I-C1510464
structure	I-C1510464
,	O
molecular	B-C1521991
properties	I-C1521991
,	O
and	O
physiological	B-C1254359
effects	I-C1254359
,	O
albeit	O
with	O
notable	O
differences	O
in	O
the	O
motif-dependent	O
phy	B-C0031857
interaction	B-C0596788
.	O
	
our	O
results	O
suggest	O
that	O
p	B-C0996529
.	O
	
patens	I-C0996529
pifs	B-C0574031
are	O
involved	O
in	O
phy	B-C0031857
signaling	B-C3537152
.	O
	
the	O
phy-pif	B-C0037080
signaling	I-C0037080
node	I-C0037080
that	O
relays	O
light	B-C1710082
signals	I-C1710082
to	O
target	O
genes	B-C0017337
has	O
been	O
largely	O
conserved	O
during	O
land	B-C1562025
plant	I-C1562025
evolution	B-C0015219
,	O
with	O
evidence	O
of	O
lineage-specific	B-C1254372
diversification	I-C1254372
.	O
	
conditional	B-C4042857
reprogramming	I-C4042857
and	O
long-term	B-C0443252
expansion	B-C0007595
of	O
normal	B-C1268443
and	O
tumor	B-C0431085
cells	I-C0431085
from	O
human	B-C0086418
biospecimens	B-C2347026
historically	O
,	O
it	O
has	O
been	O
difficult	O
to	O
propagate	B-C3146294
cells	B-C0007634
in	B-C1533691
vitro	I-C1533691
that	O
are	O
derived	O
directly	O
from	O
human	B-C0086418
tumors	B-C0027651
or	O
healthy	B-C0040300
tissue	I-C0040300
.	O
	
however	O
,	O
in	B-C1533691
vitro	I-C1533691
preclinical	B-C1514292
models	I-C1514292
are	O
essential	O
tools	O
for	O
both	O
the	O
study	B-C1516164
of	I-C1516164
basic	I-C1516164
cancer	I-C1516164
biology	I-C1516164
and	O
the	O
promotion	O
of	O
translational	B-C3494163
research	I-C3494163
,	O
including	O
drug	B-C0920472
discovery	I-C0920472
and	O
drug	B-C0085104
target	I-C0085104
identification	I-C0085104
.	O
	
this	O
protocol	B-C4042857
describes	O
conditional	B-C3850096
reprogramming	I-C3850096
cr	B-C3850096
,	O
which	O
involves	O
coculture	B-C0282547
of	O
irradiated	O
mouse	B-C0025929
fibroblast	B-C3179110
feeder	I-C3179110
cells	I-C3179110
with	O
normal	B-C1268443
and	O
tumor	B-C0027651
human	B-C0086418
epithelial	B-C0014597
cells	I-C0014597
in	O
the	O
presence	O
of	O
a	O
rho	B-C0389995
kinase	I-C0389995
inhibitor	B-C0014432
y-27632	B-C0667301
.	O
	
cr	B-C4042857
cells	B-C0007634
can	O
be	O
used	O
for	O
various	O
applications	O
,	O
including	O
regenerative	B-C1257974
medicine	I-C1257974
,	O
drug	B-C0013207
sensitivity	I-C0013207
testing	I-C0013207
,	O
gene	B-C0752248
expression	I-C0752248
profiling	I-C0752248
and	O
xenograft	B-C0520484
studies	I-C0520484
.	O
	
the	O
method	B-C4042857
requires	O
a	O
pathologist	B-C0334866
to	O
differentiate	O
healthy	B-C0040300
tissue	I-C0040300
from	O
tumor	B-C0475358
tissue	I-C0475358
,	O
and	O
basic	B-C0040284
tissue	I-C0040284
culture	I-C0040284
skills	O
.	O
	
the	O
protocol	B-C4042857
can	O
be	O
used	O
with	O
cells	B-C0007634
derived	O
from	O
both	O
fresh	B-C1519521
and	O
cryopreserved	B-C1511549
tissue	I-C1511549
samples	I-C1511549
.	O
	
as	O
approximately	O
1	O
million	O
cells	B-C0007634
can	O
be	O
generated	B-C3146294
in	O
7	O
d	O
,	O
the	O
technique	B-C4042857
is	O
directly	O
applicable	O
to	O
diagnostic	B-C0358514
and	O
predictive	B-C0681890
medicine	B-C0013227
.	O
	
moreover	O
,	O
the	O
epithelial	B-C0014597
cells	I-C0014597
can	O
be	O
propagated	B-C3146294
indefinitely	O
in	B-C1533691
vitro	I-C1533691
,	O
yet	O
retain	O
the	O
capacity	B-C1516240
to	O
become	O
fully	O
differentiated	B-C0007589
when	O
placed	O
into	O
conditions	B-C0014406
that	O
mimic	O
their	O
natural	B-C0557745
environment	I-C0557745
.	O
	
types	O
of	O
internal	B-C0018704
facilitation	I-C0018704
activities	B-C0441655
in	O
hospitals	B-C0019994
implementing	B-C0557981
evidence-based	I-C0557981
interventions	I-C0557981
implementation	B-C1708476
models	B-C3161035
,	O
frameworks	B-C1709697
,	O
and	O
theories	B-C0871935
recognize	O
the	O
importance	O
of	O
activities	B-C0441655
that	O
facilitate	O
implementation	B-C1708476
success	B-C0597535
.	O
	
however	O
,	O
little	O
is	O
known	O
about	O
internal	B-C0018704
facilitation	I-C0018704
activities	B-C0441655
that	O
hospital	B-C0031228
personnel	I-C0031228
engage	B-C1314939
in	O
during	O
implementation	B-C1708476
efforts	I-C1708476
.	O
	
the	O
aim	O
of	O
the	O
study	B-C2603343
was	O
to	O
examine	O
internal	B-C0018704
facilitation	I-C0018704
activities	B-C0441655
at	O
10	O
critical	B-C1552526
access	I-C1552526
hospitals	I-C1552526
in	O
rural	B-C0022037
iowa	I-C0022037
during	O
their	O
implementation	B-C1708476
of	O
teamstepps	B-C0080268
,	O
a	O
patient	B-C1113679
safety	I-C1113679
intervention	B-C0184661
,	O
and	O
to	O
identify	O
characteristics	B-C1521970
that	O
distinguish	O
different	O
types	O
of	O
facilitation	B-C0018704
activities	B-C0441655
.	O
	
we	O
followed	O
10	O
critical	B-C1552526
access	I-C1552526
hospitals	I-C1552526
for	O
2	O
years	B-C0439234
after	O
the	O
onset	B-C0332162
of	I-C0332162
implementation	B-C1708476
,	O
conducting	O
quarterly	B-C0332179
interviews	B-C0021822
with	O
key	B-C0870704
informants	I-C0870704
.	O
	
on	O
the	O
basis	O
of	O
the	O
transcripts	B-C0034869
from	O
the	O
first	O
two	O
quarters	B-C2825406
,	O
a	O
coding	B-C1705542
template	I-C1705542
was	O
developed	O
using	O
inductive	B-C0936012
analyses	I-C0936012
.	O
	
the	O
template	B-C1705542
was	O
then	O
applied	O
deductively	B-C0205556
to	O
code	O
all	O
interview	B-C0021822
transcripts	B-C0034869
.	O
	
using	O
comparative	B-C0683941
analysis	I-C0683941
,	O
we	O
examined	O
the	O
characteristics	B-C1521970
that	O
distinguish	O
between	O
the	O
facilitation	B-C0018704
types	O
.	O
	
we	O
identified	O
four	O
types	O
of	O
facilitation	B-C0018704
activities	B-C0441655
-	O
leadership	B-C0023181
,	O
buy-in	O
,	O
customization	B-C1880202
,	O
and	O
accountability	B-C0078889
.	O
	
individuals	B-C0237401
and	O
teams	B-C0871489
engaged	B-C1314939
in	O
different	O
types	O
of	O
facilitation	B-C0018704
activities	B-C0441655
,	O
both	O
in	O
a	O
planned	O
and	O
an	O
ad	B-C0243095
hoc	I-C0243095
manner	I-C0243095
.	O
	
these	O
activities	B-C0441655
targeted	O
at	O
both	O
people	B-C0027361
and	O
practices	B-C0237607
and	O
exhibited	O
varying	O
temporal	B-C4021204
patterns	I-C4021204
start	B-C1301880
and	O
peak	B-C1254367
time	I-C1254367
.	O
	
there	O
are	O
four	O
types	O
of	O
facilitation	B-C0018704
activities	B-C0441655
that	O
hospitals	B-C0019994
engage	B-C1314939
in	O
while	O
implementing	B-C1708476
evidence-based	B-C4042762
practices	I-C4042762
,	O
offering	O
a	O
parsimonious	B-C0205556
way	O
to	O
characterize	O
facilitation	B-C0018704
activities	B-C0441655
.	O
	
new	O
theoretical	B-C0871935
and	O
empirical	B-C0376367
research	B-C0683937
opportunities	I-C0683937
are	O
discussed	O
.	O
	
understanding	O
the	O
types	O
of	O
facilitation	B-C0018704
activities	B-C0441655
and	O
their	O
distinguishing	O
characteristics	B-C1521970
can	O
assist	O
managers	B-C0335141
in	O
planning	B-C1301732
and	O
executing	B-C1705848
implementations	B-C1708476
of	O
evidence-based	B-C4042762
interventions	I-C4042762
.	O
	
directing	B-C0314627
traffic	I-C0314627
on	I-C0314627
dna	I-C0314627
-how	O
transcription	B-C0040648
factors	I-C0040648
relieve	B-C1301676
or	O
induce	B-C0205263
transcriptional	B-C0598496
interference	I-C0598496
transcriptional	B-C0598496
interference	I-C0598496
ti	B-C0598496
is	O
increasingly	O
recognized	O
as	O
a	O
widespread	B-C0205391
mechanism	O
of	O
gene	B-C0017263
control	I-C0017263
,	O
particularly	O
given	O
the	O
pervasive	B-C0220900
nature	I-C0220900
of	O
transcription	B-C0040649
,	O
both	O
sense	B-C1883001
and	O
antisense	B-C0079249
,	O
across	O
all	O
kingdoms	B-C1708611
of	O
life	O
.	O
	
here	O
,	O
we	O
discuss	O
how	O
transcription	B-C0040648
factor	I-C0040648
binding	B-C0598135
kinetics	I-C0598135
strongly	O
influence	B-C4054723
the	O
ability	B-C0085732
of	O
a	O
transcription	B-C0040648
factor	I-C0040648
to	O
relieve	B-C1301676
or	O
induce	B-C0205263
ti	B-C0598496
.	O
	
acoustic	B-C0038186
startle	I-C0038186
response	I-C0038186
in	O
rats	B-C0034693
predicts	O
inter-individual	B-C0237401
variation	B-C1705242
in	O
fear	B-C0015726
extinction	B-C0015347
although	O
a	O
large	O
portion	O
of	O
the	O
population	B-C1257890
is	O
exposed	O
to	O
a	O
traumatic	B-C0332663
event	B-C0441471
at	O
some	O
point	O
,	O
only	O
a	O
small	O
percentage	B-C0439165
of	O
the	O
population	B-C1257890
develops	O
post-traumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
,	O
suggesting	O
the	O
presence	O
of	O
predisposing	B-C0032946
factors	I-C0032946
.	O
	
abnormal	B-C0205161
acoustic	B-C0038186
startle	I-C0038186
response	I-C0038186
asr	B-C0038186
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
ptsd	B-C0038436
,	O
implicating	O
it	O
as	O
a	O
potential	B-C3245505
predictor	B-C2698872
of	O
the	O
development	B-C0243107
of	O
ptsd	B-C0038436
-like	O
behavior	B-C0004927
.	O
	
since	O
poor	O
extinction	B-C0015347
and	O
retention	O
of	O
extinction	B-C0237613
learning	I-C0237613
are	O
characteristic	O
of	O
ptsd	B-C0038436
patients	B-C0030705
,	O
it	O
is	O
of	O
interest	O
to	O
determine	O
if	O
abnormal	B-C0205161
asr	B-C0038186
is	O
predictive	O
of	O
development	B-C0243107
of	O
such	O
deficits	B-C2987487
.	O
	
to	O
determine	O
whether	O
baseline	B-C1442488
asr	B-C0038186
has	O
utility	O
in	O
predicting	O
the	O
development	B-C0243107
of	O
ptsd	B-C0038436
-like	O
behavior	B-C0004927
,	O
the	O
relationship	O
between	O
baseline	B-C1442488
asr	B-C0038186
and	O
freezing	B-C0004927
behavior	I-C0004927
following	O
pavlovian	B-C0681797
fear	I-C0681797
conditioning	I-C0681797
was	O
examined	O
in	O
a	O
group	O
of	O
adult	B-C0001675
,	O
male	B-C0086582
sprague-dawley	B-C0034715
rats	I-C0034715
.	O
	
baseline	B-C1442488
acoustic	B-C0038186
startle	I-C0038186
response	I-C0038186
asr	B-C0038186
was	O
assessed	O
preceding	O
exposure	O
to	O
a	O
pavlovian	B-C0681797
fear	I-C0681797
conditioning	I-C0681797
paradigm	I-C0681797
where	O
freezing	B-C0004927
behavior	I-C0004927
was	O
measured	O
during	O
fear	B-C0681797
conditioning	I-C0681797
,	O
extinction	B-C0015347
training	B-C0220931
,	O
and	O
extinction	B-C0015347
testing	B-C0039593
.	O
	
although	O
there	O
was	O
no	O
relationship	O
between	O
baseline	B-C1442488
asr	B-C0038186
and	O
fear	B-C0015726
memory	B-C0025260
following	O
conditioning	B-C0681797
,	O
rats	B-C0034715
with	O
low	O
baseline	B-C1442488
asr	B-C0038186
had	O
significantly	O
lower	O
magnitude	O
of	O
retention	B-C0035280
of	O
the	O
extinction	B-C0015347
memory	B-C0025260
than	O
rats	B-C0034715
with	O
high	O
baseline	B-C1442488
asr	B-C0038186
.	O
	
the	O
results	O
suggest	O
that	O
baseline	B-C1442488
asr	B-C0038186
has	O
value	O
as	O
a	O
predictive	B-C0681890
index	B-C0918012
of	O
the	O
development	B-C0243107
of	O
a	O
ptsd	B-C0038436
-like	O
high	O
tacrolimus	B-C0085149
blood	B-C0699870
concentrations	I-C0699870
early	O
after	O
lung	B-C0024128
transplantation	I-C0024128
and	O
the	O
risk	B-C0035647
of	O
kidney	B-C0160420
injury	I-C0160420
lung	B-C0024109
transplant	B-C0376387
recipients	I-C0376387
often	O
develop	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
aki	B-C2609414
evolving	O
into	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
ckd	B-C1561643
.	O
	
the	O
immunosuppressant	B-C0021081
tacrolimus	B-C0085149
might	O
be	O
associated	B-C0332281
with	I-C0332281
the	O
emergence	O
of	O
aki	B-C2609414
.	O
	
we	O
analyzed	O
the	O
development	B-C1527148
and	O
recovery	B-C2004454
of	O
kidney	B-C0160420
injury	I-C0160420
after	O
lung	B-C0024128
transplantation	I-C0024128
and	O
related	O
aki	B-C2609414
to	O
whole-blood	B-C0370231
tacrolimus	B-C0085149
trough	B-C3640757
concentrations	I-C3640757
and	O
other	O
factors	O
causing	O
kidney	B-C0160420
injury	I-C0160420
.	O
	
we	O
retrospectively	B-C0035363
studied	I-C0035363
kidney	B-C0160420
injury	I-C0160420
in	O
186	O
lung-transplantation	B-C0024128
patients	B-C0030705
at	O
the	O
umc	B-C1708333
utrecht	I-C1708333
between	O
2001	O
and	O
2011	O
.	O
	
kidney	B-C0232804
function	I-C0232804
and	O
whole-blood	B-C0370231
tacrolimus	B-C0085149
trough	B-C3640757
concentrations	I-C3640757
were	O
determined	O
from	O
day	B-C0439228
1	O
to	O
14	O
and	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	B-C0439231
postoperative	B-C0032790
.	O
	
systemic	B-C0242966
inflammatory	I-C0242966
response	I-C0242966
syndrome	I-C0242966
sirs	B-C0242966
,	O
septic	B-C0036983
shock	I-C0036983
,	O
and	O
nephrotoxic	B-C1514118
medications	B-C4284232
were	O
evaluated	O
as	O
covariates	B-C0814913
for	O
aki	B-C2609414
.	O
	
we	O
analyzed	O
liver	B-C0160390
injury	I-C0160390
and	O
drug-drug	B-C0687133
interactions	I-C0687133
.	O
	
aki	B-C2609414
was	O
present	B-C0150312
in	O
85	O
46%	O
patients	B-C0030705
.	O
	
tacrolimus	B-C0085149
concentrations	B-C0699870
were	O
supra-therapeutic	B-C4049341
in	O
135	O
of	O
186	O
patients	B-C0030705
73%	O
.	O
	
aki	B-C2609414
in	O
the	O
first	O
week	B-C0439230
after	O
transplantation	B-C0024128
was	O
related	O
to	O
supra-therapeutic	B-C4049341
tacrolimus	B-C0085149
concentrations	B-C0699870
or	B-C0028873
1.55	O
95%	O
ci	B-C0009667
1.06	O
,	O
3	O
other	O
nephrotoxic	B-C3687832
drugs	I-C3687832
or	B-C0028873
1.96	O
95%	O
ci	B-C0009667
1.02	O
,	O
infection	B-C3714514
or	B-C0028873
2.48	O
95%	O
ci	B-C0009667
1.31	O
,	O
and	O
cystic	B-C0010674
fibrosis	I-C0010674
or	B-C0028873
2.17	O
95%	O
ci	B-C0009667
1.16	O
.	O
	
recovery	B-C1521828
rate	I-C1521828
of	O
aki	B-C2609414
was	O
lower	O
than	O
expected	O
19%	O
,	O
and	O
the	O
cumulative	O
incidence	B-C0220856
of	O
severe	O
ckd	B-C1561643
at	O
1	O
year	B-C0439234
was	O
15%	O
.	O
	
after	O
lung	B-C0024128
transplantation	I-C0024128
,	O
aki	B-C2609414
is	O
common	O
and	O
often	O
evolves	O
into	O
severe	B-C0205082
ckd	B-C1561643
,	O
which	O
is	O
a	O
known	O
cause	O
of	O
morbidity	B-C0026538
and	O
mortality	B-C0205848
.	O
	
supra-therapeutic	B-C4049341
whole-blood	B-C0370231
tacrolimus	B-C0085149
trough	B-C3640757
concentrations	I-C3640757
are	O
related	O
to	O
the	O
early	O
onset	O
of	O
aki	B-C2609414
.	O
	
conscientious	B-C0580939
targeting	B-C1521840
tacrolimus	B-C0085149
blood	B-C0699870
concentrations	I-C0699870
might	O
be	O
vital	B-C0442732
in	O
the	O
early	B-C0814494
phase	I-C0814494
after	O
lung	B-C0024128
transplantation	I-C0024128
.	O
	
what	O
is	O
known	O
about	O
this	O
subject	O
lung	B-C0024109
transplant	B-C0376387
recipients	I-C0376387
often	O
develop	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
evolving	O
into	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
increasing	O
both	O
morbidity	B-C0026538
and	O
mortality	B-C0026566
.	O
	
to	O
date	O
,	O
the	O
pathophysiology	B-C0031847
of	O
kidney	B-C0160420
injury	I-C0160420
after	O
lung	B-C0024128
transplantation	I-C0024128
has	O
not	O
been	O
fully	O
elucidated	O
.	O
	
the	O
immunosuppressant	B-C0021081
tacrolimus	B-C0085149
is	O
difficult	O
to	O
dose	B-C0678766
,	O
especially	O
in	O
the	O
unstable	B-C0443343
clinical	B-C3176918
setting	I-C3176918
,	O
and	O
is	O
nephrotoxic	B-C1514118
.	O
	
for	O
the	O
first	O
time	O
,	O
supra-therapeutic	B-C4049341
whole-blood	B-C0370231
tacrolimus	B-C0085149
trough	B-C3640757
concentrations	I-C3640757
are	O
related	O
to	O
the	O
emergence	O
of	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
in	O
the	O
first	O
days	B-C0439228
after	O
lung	B-C0024128
transplantation	I-C0024128
.	O
	
supra-therapeutic	B-C4049341
whole-blood	B-C0370231
tacrolimus	B-C0085149
trough	B-C3640757
concentrations	I-C3640757
often	O
occur	O
early	O
after	O
lung	B-C0024128
transplantation	I-C0024128
.	O
	
aki	B-C2609414
after	O
lung	B-C0024128
transplantation	I-C0024128
shows	O
low	B-C0205251
recovery	B-C2004454
rates	B-C1521828
.	O
	
zebrafish	B-C0043457
akt2	B-C0812230
is	O
essential	B-C0205224
for	O
survival	B-C0038952
,	O
growth	B-C0018270
,	O
bone	B-C0005939
development	I-C0005939
,	O
and	O
glucose	B-C1326961
homeostasis	I-C1326961
as	O
one	O
of	O
three	O
akt	B-C0166559
isoforms	B-C0597298
,	O
akt2	B-C1312419
plays	O
a	O
key	O
role	B-C1705810
in	O
the	O
regulation	B-C1327622
of	O
widely	O
divergent	O
cellular	B-C1325880
processes	I-C1325880
in	O
mammals	B-C0024660
.	O
	
however	O
,	O
its	O
role	B-C1705810
and	O
underlying	O
mechanisms	B-C0441712
in	O
zebrafish	B-C0043457
remain	O
largely	O
unknown	B-C0439673
.	O
	
to	O
elucidate	O
the	O
function	B-C0542341
of	O
akt2	B-C0812230
in	O
zebrafish	B-C0043457
,	O
we	O
generated	B-C2346631
zebrafish	B-C0043457
lacking	B-C0332268
akt2	B-C0812230
gene	I-C0812230
via	O
crispr/cas9	B-C3658355
technology	B-C0039421
.	O
	
akt2	B-C0812230
-	O
null	B-C0456148
zebrafish	B-C0043457
exhibit	O
partial	O
lethality	B-C3151529
and	O
severe	B-C0205082
growth	B-C0018270
deficiency	B-C0011155
,	O
which	O
is	O
different	O
from	O
those	O
observed	O
in	O
akt2	B-C0812230
-	O
null	B-C0456148
mice	B-C0025929
.	O
	
furthermore	O
,	O
akt2	B-C0812230
-	O
null	B-C0456148
zebrafish	B-C0043457
display	B-C0870432
deficiency	B-C0011155
in	O
fin	B-C2246747
ray	I-C2246747
development	I-C2246747
,	O
but	O
their	O
cartilage	B-C0007301
is	O
not	B-C2986417
affected	I-C2986417
.	O
	
similar	O
to	O
observations	B-C0302523
in	O
akt2	B-C0812230
-	O
null	B-C0456148
mice	B-C0025929
,	O
akt2	B-C0812230
-	O
null	B-C0456148
zebrafish	B-C0043457
display	B-C0870432
impaired	B-C0221099
glucose	B-C1326961
homeostasis	I-C1326961
.	O
	
however	O
,	O
in	O
contrast	O
to	O
that	O
in	O
akt2	B-C0812230
-	O
null	B-C0456148
mice	B-C0025929
,	O
insulin	B-C0202098
level	I-C0202098
is	O
lower	B-C0205251
in	O
akt2	B-C0812230
-	O
null	B-C0456148
zebrafish	B-C0043457
,	O
implicating	O
the	O
symptoms	B-C1457887
of	O
type	B-C0011854
i	I-C0011854
diabetes	I-C0011854
exhibited	O
in	O
akt2	B-C0812230
-	O
null	B-C0456148
zebrafish	B-C0043457
.	O
	
in	O
addition	O
,	O
transcriptome	B-C0752248
analysis	I-C0752248
reveals	B-C0443289
that	O
the	O
genes	B-C0017337
involved	O
in	O
metabolism	B-C0025519
and	O
osteogenesis	B-C0029433
are	O
disturbed	O
in	O
akt2	B-C0812230
-	O
null	B-C0456148
zebrafish	B-C0043457
.	O
	
taken	O
together	O
,	O
these	O
data	B-C1511726
not	O
only	O
support	O
an	O
important	O
role	B-C1705810
of	O
akt2	B-C0812230
in	O
zebrafish	B-C0043457
survival	B-C0038952
,	O
growth	B-C0018270
,	O
bone	B-C0005939
development	I-C0005939
and	O
glucose	B-C1326961
homeostasis	I-C1326961
,	O
but	O
also	O
suggest	O
that	O
akt2	B-C0812230
has	O
divergent	O
functions	B-C0542341
between	O
mice	B-C0025929
and	O
zebrafish	B-C0043457
,	O
even	O
though	O
they	O
are	O
evolutionarily	B-C0015219
conserved	B-C0969701
.	O
	
physiological	B-C0205463
properties	B-C0871161
and	O
behavioral	B-C0004927
correlates	B-C1707520
of	O
hippocampal	B-C0019564
granule	B-C0007634
cells	I-C0007634
and	O
mossy	B-C0007634
cells	I-C0007634
the	O
hippocampal	B-C0019564
dentate	B-C0152314
gyrus	I-C0152314
is	O
often	O
viewed	O
as	O
a	O
segregator	B-C0205245
of	O
upstream	B-C1254358
information	I-C1254358
.	O
	
physiological	B-C0031843
support	I-C0031843
for	O
such	O
function	B-C0542341
has	O
been	O
hampered	O
by	O
a	O
lack	B-C0332268
of	O
well-defined	B-C0442825
characteristics	B-C1521970
that	O
can	O
identify	O
granule	B-C0007634
cells	I-C0007634
and	O
mossy	B-C0007634
cells	I-C0007634
.	O
	
we	O
developed	O
an	O
electrophysiology	B-C0678837
-based	O
classification	B-C0008902
of	O
dentate	B-C0152314
granule	B-C0007634
cells	I-C0007634
and	O
mossy	B-C0007634
cells	I-C0007634
in	O
mice	B-C0025929
that	O
we	O
validated	O
by	O
optogenetic	B-C3494301
tagging	I-C3494301
of	O
mossy	B-C0007634
cells	I-C0007634
.	O
	
granule	B-C0007634
cells	I-C0007634
exhibited	O
sparse	O
firing	B-C0007613
,	O
had	O
a	O
single	B-C0205171
place	B-C1254362
field	I-C1254362
,	O
and	O
showed	O
only	O
modest	O
changes	B-C0392747
when	O
the	O
mouse	B-C0025929
was	O
tested	B-C0039593
in	O
different	O
mazes	B-C0870866
in	O
the	O
same	O
room	B-C1547703
.	O
	
in	O
contrast	O
,	O
mossy	B-C0007634
cells	I-C0007634
were	O
more	O
active	B-C0205177
,	O
had	O
multiple	B-C0439064
place	B-C1254362
fields	I-C1254362
and	O
showed	O
stronger	O
remapping	O
of	O
place	B-C1254362
fields	I-C1254362
under	O
the	O
same	O
conditions	B-C0348080
.	O
	
although	O
the	O
granule	B-C0007634
cell	I-C0007634
-	O
mossy	B-C0007634
cell	I-C0007634
synapse	B-C0039062
was	O
strong	O
and	O
facilitating	O
,	O
mossy	B-C0007634
cells	I-C0007634
rarely	O
"""inherited"""	O
place	B-C1254362
fields	I-C1254362
from	O
single	B-C0205171
granule	B-C0007634
cells	I-C0007634
.	O
	
our	O
findings	B-C2607943
suggest	O
that	O
the	O
granule	B-C0007634
cells	I-C0007634
and	O
mossy	B-C0007634
cells	I-C0007634
could	O
be	O
modulated	B-C0443264
separately	O
and	O
their	O
joint	O
action	B-C3266814
may	O
be	O
critical	O
for	O
pattern	B-C0205245
separation	I-C0205245
.	O
	
a	O
primer	O
on	O
intraosseous	B-C0595613
access	I-C0595613
history	B-C2004062
,	O
clinical	B-C0427350
considerations	I-C0427350
,	O
and	O
current	B-C0025080
devices	I-C0025080
intraosseous	B-C0595613
io	I-C0595613
access	I-C0595613
is	O
a	O
method	B-C0025663
recommended	O
by	O
the	O
american	B-C0002458
heart	I-C0002458
association	I-C0002458
and	O
the	O
european	B-C1708333
resuscitation	I-C1708333
council	I-C1708333
to	O
administer	B-C1621583
resuscitative	B-C1254351
drugs	I-C1254351
and	O
fluids	B-C1704353
when	O
intravenous	B-C0013125
iv	I-C0013125
access	I-C0013125
cannot	O
be	O
rapidly	O
or	O
easily	O
obtained	O
.	O
	
many	O
clinicians	B-C0871685
have	O
limited	B-C0376554
knowledge	I-C0376554
or	O
experience	B-C0596545
with	O
the	O
io	B-C0595613
route	I-C0595613
.	O
	
the	O
purpose	O
of	O
this	O
review	B-C0282443
was	O
to	O
provide	O
the	O
reader	O
with	O
a	O
succinct	B-C0282443
review	I-C0282443
of	O
the	O
history	B-C2004062
,	O
clinical	B-C0427350
considerations	I-C0427350
,	O
and	O
devices	B-C0025080
associated	B-C0332281
with	I-C0332281
io	B-C0595613
access	I-C0595613
.	O
	
narrative	O
review	O
.	O
	
university-based	O
academic	O
research	O
cell	O
.	O
	
not	O
applicable	O
.	O
	
not	O
applicable	O
.	O
	
io	B-C0595613
access	I-C0595613
is	O
a	O
lifesaving	O
bridge	O
to	O
definitive	O
vascular	O
access	O
that	O
may	O
be	O
considered	O
when	O
an	O
iv	O
cannot	O
be	O
rapidly	O
attained	O
and	O
the	O
patient's	O
outcome	O
may	O
be	O
negatively	O
affected	O
without	O
prompt	O
circulatory	O
access	O
.	O
	
the	O
io	B-C0595613
route	O
has	O
few	O
contraindications	O
for	O
use	O
and	O
a	O
low	O
rate	O
of	O
serious	O
complications	O
.	O
	
multiple	O
manual	O
and	O
powered	O
devices	O
that	O
may	O
be	O
placed	O
in	O
several	O
anatomic	O
sites	O
are	O
commercially	O
available	O
.	O
	
all	O
clinicians	O
who	O
provide	O
acute	O
care	O
or	O
respond	O
to	O
cardiovascular	O
emergencies	O
should	O
obtain	O
training	O
and	O
maintain	O
proficiency	O
in	O
placing	O
and	O
using	O
io	O
devices	O
as	O
the	O
io	O
route	O
is	O
recommended	O
by	O
the	O
major	O
resuscitation	O
organizations	O
as	O
the	O
preferred	O
route	O
of	O
infusion	O
when	O
rapid	O
,	O
reliable	O
iv	O
access	I-C0595613
is	O
c-5a-substituted	B-C0084937
validamine	I-C0084937
type	I-C0084937
glycosidase	B-C1960098
inhibitors	I-C1960098
a	O
series	O
of	O
n-alkyl	B-C1254351
derivatives	I-C1254351
of	O
the	O
d-galactosidase	B-C0005220
inhibitor	B-C0014432
1	B-C1254351
featuring	O
lipophilic	B-C0598631
substituents	B-C1254350
at	I-C1254350
position	I-C1254350
c-5a	I-C1254350
was	O
prepared	O
and	O
screened	B-C0373483
for	O
their	O
glycosidase	B-C0017976
inhibitory	B-C1524081
properties	I-C1524081
.	O
	
products	B-C1514468
turned	O
out	O
selective	O
for	O
β-galactosidases	B-C0005220
as	O
well	O
as	O
exposure	B-C1760428
to	I-C1760428
suicidal	I-C1760428
behaviors	I-C1760428
a	O
common	O
suicide	B-C0038661
risk	B-C0035648
factor	I-C0035648
or	O
a	O
personal	B-C1519021
negative	B-C1822593
life	I-C1822593
event	I-C1822593
numerous	B-C0439064
suicide	B-C0038661
risk	B-C0035648
factors	I-C0035648
have	O
been	O
proposed	O
but	O
not	O
adequately	O
validated	B-C0042283
for	I-C0042283
epidemiology	I-C0042283
,	O
treatment	B-C0087111
and	O
prevention	B-C2700409
efforts	I-C2700409
.	O
	
exposures	B-C1760428
to	I-C1760428
suicidal	I-C1760428
behaviors	I-C1760428
esb	B-C1760428
,	O
from	O
family	B-C0015576
and	O
friend	B-C0079382
suicide	B-C0038663
attempts	I-C0038663
and	O
completions	B-C0038661
,	O
were	O
tested	O
for	O
validity	B-C0042283
as	O
a	O
suicidal	B-C0038661
risk	B-C0035648
factor	I-C0035648
and	O
also	O
for	O
measurement	B-C0242485
and	O
construct	O
adequacy	B-C0814633
.	O
	
an	O
anonymous	B-C2346787
online	B-C0029038
survey	B-C0038951
yielded	O
713	O
participants	B-C0679646
aged	B-C0001779
18-71	O
,	O
who	O
reported	O
esb	B-C1760428
,	O
completed	O
the	O
suicidal	B-C0282574
affect-behavior-cognition	I-C0282574
scale	I-C0282574
sabcs	B-C0282574
,	O
and	O
comprised	O
a	O
broad	O
spectrum	O
on	O
those	O
variables	B-C0439828
.	O
	
tests	B-C0392366
of	O
dimensionality	B-C1707753
and	O
internal	B-C0870731
consistency	I-C0870731
showed	O
the	O
four	O
esb	B-C1760428
variables	B-C0439828
attempts	B-C0038663
/	O
completions	B-C0038661
through	O
family	B-C0015576
/	O
friends	B-C0079382
were	O
independent	B-C0332291
and	O
did	O
not	O
form	O
a	O
common	O
factor	O
or	O
an	O
identifiable	O
esb	B-C1760428
latent	B-C0205275
trait	B-C0599883
.	O
	
esb	B-C1760428
variables	B-C0439828
were	O
,	O
however	O
,	O
associated	O
with	O
demographic	B-C0578829
and	O
psychiatric	B-C0748059
histories	I-C0748059
.	O
	
a	O
battery	O
of	O
tests	B-C0392366
revealed	O
no	O
meaningful	O
associations	B-C0439849
between	O
esb	B-C1760428
and	O
total	O
suicidality	B-C3166387
or	O
suicide	B-C0038661
risk	B-C0035648
factors	I-C0035648
social	B-C0037438
support	I-C0037438
,	O
depression	B-C0011570
,	O
anxiety	B-C0003467
,	O
stress	B-C0038435
,	O
satisfaction	B-C0392352
with	I-C0392352
life	I-C0392352
and	O
emotional	B-C0237105
stability	I-C0237105
.	O
	
in	O
addition	O
,	O
in	O
contrast	O
to	O
previous	O
reports	B-C0684224
,	O
young	B-C0238598
adults	I-C0238598
n	O
=	O
200	O
aged	B-C0001779
18-20	O
showed	O
no	O
increased	B-C0205217
suicidality	B-C3166387
due	O
to	O
esb	B-C1760428
.	O
	
results	B-C1274040
showed	O
no	O
validity	B-C0042283
for	O
esb	B-C1760428
as	O
a	O
common	O
risk	B-C0035648
factor	I-C0035648
for	O
suicidality	B-C3166387
or	O
other	O
psychopathology	B-C0544667
,	O
or	O
as	O
a	O
latent	B-C0205275
trait	B-C0599883
.	O
	
esb	B-C1760428
showed	O
evidence	B-C3887511
as	O
a	O
personal	B-C1519021
negative	B-C1822593
life	I-C1822593
event	I-C1822593
with	O
individual	B-C0237401
effects	B-C1280500
and	O
direct	B-C0205511
anterior	I-C0205511
approach	I-C0205511
for	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
with	O
a	O
novel	O
mobile	B-C0183817
traction	I-C0183817
table	I-C0183817
-a	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
the	O
purpose	O
of	O
this	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
was	O
to	O
clarify	O
the	O
safety	O
and	O
efficacy	O
of	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
via	O
the	O
direct	B-C0205511
anterior	I-C0205511
approach	I-C0205511
in	O
the	O
supine	B-C0038846
position	I-C0038846
with	O
a	O
novel	O
mobile	B-C0183817
traction	I-C0183817
table	I-C0183817
.	O
	
the	O
first	O
experience	O
of	O
consecutive	B-C0035110
surgeries	I-C0035110
by	O
a	O
single	B-C0582175
surgeon	I-C0582175
using	O
the	O
direct	B-C0205511
anterior	I-C0205511
approach	I-C0205511
with	O
a	O
traction	B-C0183817
table	I-C0183817
is	O
described	O
with	O
a	O
two-year	O
follow-up	B-C1522577
period	O
.	O
	
of	O
121	O
patients	B-C0030705
,	O
100	O
patients	B-C0030705
without	O
previous	B-C3266738
hip	I-C3266738
surgeries	I-C3266738
,	O
severe	B-C0302142
deformity	I-C0302142
,	O
or	O
cemented	B-C0441496
implants	I-C0441496
were	O
divided	O
into	O
two	O
groups	B-C0441833
comprising	O
the	O
first	O
50	O
patients	B-C0030705
and	O
the	O
second	O
50	O
patients	B-C0030705
.	O
	
the	O
implant	B-C0038954
survival	I-C0038954
rate	I-C0038954
was	O
99%	O
at	O
the	O
two-year	O
follow-up	B-C1522577
.	O
	
revision	B-C0035110
surgery	I-C0035110
was	O
required	O
for	O
periprosthetic	B-C2609162
femoral	B-C0015802
fracture	I-C0015802
in	O
one	O
patient	B-C0030705
.	O
	
the	O
complication	B-C0009566
rate	B-C1521828
possibly	O
related	O
to	O
the	O
traction	B-C0183817
table	I-C0183817
was	O
5%	O
5	O
patients	B-C0030705
three	O
anterior	B-C1265658
dislocations	I-C1265658
,	O
one	O
periprosthetic	B-C2609162
femoral	B-C0015802
fracture	I-C0015802
,	O
and	O
one	O
intraoperative	B-C0034117
perforation	I-C0034117
caused	O
by	O
femoral	B-C0015802
rasping	I-C0015802
.	O
	
the	O
complication	B-C0009566
rate	B-C1521828
tended	O
to	O
decrease	B-C0547047
in	O
the	O
second	O
group	B-C0441833
compared	O
to	O
the	O
first	O
group	O
4%	O
versus	O
6%	O
.	O
	
mean	B-C3494201
surgical	I-C3494201
time	I-C3494201
72.0	O
minutes	O
versus	O
82.5	O
min	O
,	O
p	O
=	O
0.027	O
,	O
rate	B-C1521828
of	O
allogeneic	B-C0005841
blood	I-C0005841
transfusion	I-C0005841
2%	O
versus	O
24%	O
,	O
p	O
=	O
0.001	O
,	O
and	O
cup	B-C1821889
alignment	I-C1821889
in	O
the	O
safe	B-C1254362
zone	I-C1254362
100%	O
versus	O
88%	O
,	O
p	O
=	O
0.027	O
were	O
significantly	O
improved	O
in	O
the	O
second	O
group	B-C0441833
compared	O
to	O
the	O
first	O
group	B-C0441833
.	O
	
the	O
direct	B-C0205511
anterior	I-C0205511
approach	I-C0205511
with	O
a	O
novel	O
mobile	B-C0183817
traction	I-C0183817
table	I-C0183817
showed	O
a	O
positive	B-C0243095
learning	I-C0243095
curve	I-C0243095
for	O
surgical	B-C3494201
time	I-C3494201
,	O
rate	B-C1521828
of	O
allogeneic	B-C0005841
blood	I-C0005841
transfusion	I-C0005841
,	O
and	O
cup	B-C1821889
alignment	I-C1821889
in	O
the	O
safe	B-C1254362
zone	I-C1254362
.	O
	
the	O
binding	B-C0597358
orientations	B-C1704322
of	O
structurally	B-C0678594
-related	O
ligands	B-C0023688
can	O
differ	B-C1705242
a	O
cautionary	O
note	O
crystal	B-C0444626
structures	I-C0444626
can	O
identify	O
ligand-receptor	B-C0597358
interactions	I-C0597358
and	O
assist	O
the	O
development	O
of	O
novel	O
therapeutics	B-C0087111
,	O
but	O
experimental	B-C1517586
challenges	O
sometimes	O
necessitate	O
the	O
use	O
of	O
homologous	B-C1512488
proteins	I-C1512488
.	O
	
tropisetron	B-C0063322
is	O
an	O
orthosteric	B-C0023688
ligand	I-C0023688
at	O
both	O
5-ht3	B-C0295352
and	O
α7	B-C0051334
nach	I-C0051334
receptors	I-C0051334
and	O
its	O
binding	B-C0597358
orientation	B-C1704322
has	O
been	O
determined	O
in	O
the	O
structural	B-C1449549
homologue	I-C1449549
achbp	B-C1254349
pdbid	O
2wnc	O
.	O
	
co-crystallisation	B-C0010423
with	O
a	O
structurally	B-C0678594
-related	O
ligand	B-C0023688
,	O
granisetron	B-C0061863
,	O
reveals	O
an	O
almost	O
identical	B-C0205280
orientation	B-C1704322
pdbid	O
2yme	O
.	O
	
however	O
,	O
there	O
is	O
a	O
>1000-fold	O
difference	B-C1705242
in	O
the	O
affinity	B-C1510827
of	O
tropisetron	B-C0063322
at	O
5-ht3	B-C0295352
versus	O
α7	B-C0051334
nach	I-C0051334
receptors	I-C0051334
,	O
and	O
α7	B-C0051334
nach	I-C0051334
receptors	I-C0051334
do	O
not	B-C1518422
bind	B-C0597358
granisetron	B-C0061863
.	O
	
these	O
striking	O
pharmacological	B-C0205464
differences	B-C1705242
prompt	O
questions	O
about	O
which	O
receptor	B-C0597357
the	O
crystal	B-C0444626
structures	I-C0444626
most	O
closely	O
represent	O
and	O
whether	O
the	O
ligand	B-C0023688
orientations	B-C1704322
are	O
correct	O
.	O
	
here	O
we	O
probe	O
the	O
binding	B-C0597358
orientation	B-C1704322
of	O
tropisetron	B-C0063322
and	O
granisetron	B-C0061863
at	O
5-ht3	B-C0295352
receptors	I-C0295352
by	O
in	B-C3489666
silico	I-C3489666
modelling	B-C0013193
and	O
docking	B-C1522290
,	O
radioligand	B-C1517880
binding	I-C1517880
on	O
cysteine	B-C0010654
-	O
substituted	B-C0525038
5-ht3	B-C0295352
receptor	I-C0295352
mutants	B-C0596988
transiently	O
expressed	B-C0017262
in	O
hek	B-C2936239
293	I-C2936239
cells	I-C2936239
,	O
and	O
synthetic	B-C0598331
modification	I-C0598331
of	O
the	O
ligands	B-C0023688
.	O
	
for	O
15	O
of	O
the	O
23	O
cysteine	B-C0010654
substitutions	B-C0525038
,	O
the	O
effects	B-C1280500
on	O
tropisetron	B-C0063322
and	O
granisetron	B-C0061863
were	O
different	O
.	O
	
structure-activity	B-C0038477
relationships	I-C0038477
on	O
synthesised	O
derivatives	O
of	O
both	O
ligands	B-C0023688
were	O
also	O
consistent	O
with	O
different	O
orientations	B-C1704322
,	O
revealing	B-C0443289
that	O
contrary	O
to	O
the	O
crystallographic	B-C0010424
evidence	B-C3887511
from	O
achbp	B-C1254349
,	O
the	O
two	O
ligands	B-C0023688
adopt	O
different	B-C1705242
orientations	B-C1704322
in	O
the	O
5-ht3	B-C0295352
receptor	I-C0295352
binding	B-C0005456
site	I-C0005456
.	O
	
our	O
results	O
show	O
that	O
even	O
quite	O
structurally	B-C0678594
similar	O
molecules	B-C0567416
can	O
adopt	O
different	O
orientations	B-C1704322
in	O
the	O
same	O
binding	B-C0005456
site	I-C0005456
,	O
and	O
that	O
caution	O
may	O
be	O
needed	O
when	O
using	O
homologous	B-C1512488
proteins	I-C1512488
to	O
predict	O
ligand	B-C1517880
binding	I-C1517880
.	O
	
pancreatic	B-C0030274
neuroendocrine	B-C0746852
cancer	I-C0746852
with	O
liver	B-C0494165
metastases	I-C0494165
and	O
multiple	B-C0346989
peritoneal	I-C0346989
metastases	I-C0346989
report	O
of	O
one	O
case	O
pancreatic	B-C0030274
neuroendocrine	B-C0746852
tumor	I-C0746852
pnet	B-C0746852
is	O
a	O
rare	O
pancreatic	B-C0030297
tumor	I-C0030297
,	O
with	O
its	O
incidence	O
showing	O
a	O
rising	O
trend	O
in	O
recent	O
years	O
.	O
	
most	O
of	O
its	O
distant	B-C4297205
metastases	I-C4297205
are	O
found	B-C0150312
in	O
the	O
liver	B-C0023884
.	O
	
this	O
article	O
describes	O
a	O
59-year-old	O
male	B-C0150904
patient	I-C0150904
with	O
pnet	B-C0746852
with	O
liver	B-C0494165
metastasis	I-C0494165
and	O
multiple	B-C0854198
abdominal	I-C0854198
metastases	I-C0854198
,	O
focusing	O
on	O
the	O
management	B-C0376636
of	O
this	O
tumor	B-C0027651
in	O
its	O
advanced	B-C1254367
stage	I-C1254367
.	O
	
lignans	B-C0064971
from	O
the	O
fruits	B-C0016767
of	O
schisandra	B-C0696946
chinensis	I-C0696946
turcz	I-C0696946
baill	I-C0696946
inhibit	B-C3463820
proprotein	B-C1426592
convertase	I-C1426592
subtilisin/kexin	I-C1426592
type	I-C1426592
9	I-C1426592
expression	B-C0017262
bioactivity-guided	B-C0016640
fractionation	I-C0016640
of	O
the	O
fruits	B-C0016767
of	O
schisandra	B-C0696946
chinensis	I-C0696946
,	O
using	O
the	O
proprotein	B-C1426592
convertase	I-C1426592
subtilisin-kexin	I-C1426592
type	I-C1426592
9	I-C1426592
pcsk9	B-C1426592
mrna	B-C1515670
expression	I-C1515670
screening	B-C1510438
assay	I-C1510438
,	O
led	O
to	O
isolation	B-C0205409
of	O
two	B-C0205448
previously	B-C0439673
unknown	I-C0439673
lignans	B-C0064971
,	O
14-tigloylschinlignan	B-C0064971
d	I-C0064971
and	O
rel-	B-C0064971
,	O
8r	I-C0064971
,	O
7'r	I-C0064971
,	O
8'r	I-C0064971
e	I-C0064971
,	O
along	O
with	O
28	O
known	O
compounds	O
.	O
	
all	O
structures	B-C0220807
were	O
established	B-C0443211
by	O
nmr	B-C0877853
spectroscopic	I-C0877853
data	B-C1511726
as	O
well	O
as	O
cd	B-C0008813
and	O
ms	B-C0037813
analysis	B-C0936012
.	O
	
all	O
isolates	O
were	O
tested	B-C0039593
for	O
their	O
inhibitory	B-C3463820
activities	B-C0441655
on	O
the	O
mrna	B-C1515670
expression	I-C1515670
of	O
pcsk9	B-C1426592
.	O
	
of	O
the	O
tested	B-C0039593
compounds	O
,	O
four	B-C0205450
of	O
the	O
compounds	O
rel-	B-C0064971
,	O
8r	I-C0064971
,	O
7'r	I-C0064971
,	O
8'r	I-C0064971
e	I-C0064971
,	O
-	B-C0074176
c	I-C0074176
,	O
schinlignan	B-C0064971
d	I-C0064971
,	O
and	O
+	B-C0074177
b	I-C0074177
potently	O
inhibited	B-C0311403
pcsk9	B-C1426592
mrna	B-C1515670
expression	I-C1515670
with	O
ic50	B-C0600495
values	O
of	O
3.15	O
,	O
3.85	O
,	O
0.36	O
,	O
and	O
1.10	O
μm	O
,	O
respectively	O
.	O
	
furthermore	O
,	O
schinlignan	O
d	O
and	O
+	B-C0074177
b	I-C0074177
were	O
found	O
to	O
suppress	B-C1260953
pcsk9	B-C4255394
protein	B-C1171362
expressions	I-C1171362
and	O
schinlignan	B-C0064971
d	I-C0064971
deemed	O
to	O
increase	O
low	B-C0034821
density	I-C0034821
lipoprotein	I-C0034821
receptor	I-C0034821
expression	B-C0597360
.	O
	
a	O
comparison	O
of	O
outcomes	B-C0085415
in	O
morbidly	B-C0028756
obese	I-C0028756
,	O
obese	B-C0028754
and	O
non-obese	B-C0005910
patients	B-C0030705
undergoing	O
primary	B-C0086511
total	I-C0086511
knee	I-C0086511
and	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
obesity	B-C0028754
is	O
a	O
growing	O
public	B-C0678367
health	B-C1398682
issue	I-C1398682
with	O
the	O
prevalence	B-C0220900
of	O
morbid	B-C1319441
obesity	I-C1319441
,	O
body	I-C1319441
mass	I-C1319441
index	I-C1319441
bmi	I-C1319441
40	I-C1319441
kg/m	I-C1319441
increasing	B-C0442808
.	O
	
there	O
is	O
some	O
evidence	B-C3887511
these	O
patients	B-C0030705
have	O
more	O
peri-	B-C0280955
and	I-C0280955
post-operative	I-C0280955
complications	I-C0280955
and	O
poorer	B-C0085415
outcomes	I-C0085415
when	O
undergoing	O
arthroplasty	B-C0003893
procedures	I-C0003893
.	O
	
this	O
audit	O
aimed	O
to	O
determine	O
and	O
compare	O
the	O
outcomes	B-C0085415
of	O
non-obese	B-C0005910
,	O
obese	B-C0028754
and	O
morbidly	B-C0028756
obese	I-C0028756
patients	B-C0030705
undergoing	O
arthroplasty	B-C0003893
at	O
our	O
institution	B-C2607850
.	O
	
this	O
was	O
a	O
retrospective	B-C0184821
audit	I-C0184821
of	O
patients	B-C0030705
from	O
our	O
institution	B-C2607850
who	O
had	O
undergone	O
total	B-C0086511
knee	I-C0086511
tka	B-C0086511
or	O
total	B-C0040508
hip	I-C0040508
arthroplasty	I-C0040508
tha	B-C0040508
in	O
2009	O
.	O
	
data	B-C1511726
collected	B-C1516695
were	O
age	B-C0001779
,	O
gender	B-C0079399
,	O
bmi	B-C1305855
,	O
length	B-C0023303
of	I-C0023303
stay	I-C0023303
los	B-C0023303
,	O
oxford	B-C1997265
knee	I-C1997265
or	O
hip	B-C1998079
score	I-C1998079
oks	B-C1997265
/	O
ohs	B-C1998079
,	O
satisfaction	B-C3476649
and	O
complications	B-C0274311
up	O
to	O
two	O
years	B-C0439234
post	B-C0543467
operation	I-C0543467
.	O
	
patients	B-C0030705
were	O
divided	O
into	O
three	O
groups	B-C0441833
bmi	B-C0850114
<	I-C0850114
30	I-C0850114
,	O
bmi	B-C1305855
30-40	I-C1305855
and	O
bmi	B-C1561729
>	I-C1561729
40	I-C1561729
.	O
	
outcomes	B-C0085415
for	O
each	O
bmi	B-C1305855
group	B-C0441833
were	O
compared	O
.	O
	
1014	O
tka	B-C0086511
and	O
906	O
tha	B-C0040508
operations	B-C0543467
were	O
included	O
.	O
	
when	O
compared	O
to	O
obese	B-C0028754
and	O
non-obese	B-C0005910
patients	B-C0030705
,	O
morbidly	B-C0028756
obese	I-C0028756
patients	B-C0030705
undergoing	O
tka	B-C0086511
had	O
a	O
mean	O
los	B-C0023303
one	O
day	B-C0439228
longer	O
,	O
a	O
mean	B-C1997265
oks	I-C1997265
four	O
points	O
lower	O
and	O
higher	O
rates	O
of	O
postoperative	B-C0032787
problems	I-C0032787
,	O
37%	O
vs	O
.	O
	
21%	O
.	O
	
for	O
tha	B-C0040508
patients	B-C0030705
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
los	B-C0023303
,	O
ohs	B-C1998079
score	I-C1998079
was	O
two	O
points	O
lower	O
for	O
each	O
increasing	B-C0442808
bmi	B-C1305855
category	B-C0683312
and	O
postoperative	B-C0032787
problems	I-C0032787
increase	B-C0442805
from	O
25%	O
for	O
non-obese	B-C0005910
to	O
31%	O
for	O
obese	B-C0028754
and	O
38%	O
for	O
morbidly	B-C0028756
obese	I-C0028756
patients	B-C0030705
.	O
	
these	O
results	O
will	O
be	O
useful	O
in	O
informing	O
obese	B-C0028754
patients	B-C0030705
of	O
their	O
potential	O
outcomes	B-C0085415
following	O
tka	B-C0086511
or	O
tha	B-C0040508
.	O
	
these	O
patients	B-C0030705
can	O
then	O
make	O
a	O
more	O
informed	O
choice	O
before	O
proceeding	O
with	O
vitamin	B-C0574031
d	I-C0574031
receptor	I-C0574031
activator	I-C0574031
use	O
and	O
cause-specific	B-C1707318
death	I-C1707318
among	O
dialysis	B-C0011946
patients	B-C0030705
a	O
nationwide	B-C0009247
cohort	I-C0009247
study	I-C0009247
using	O
coarsened	B-C0026348
exact	I-C0026348
matching	I-C0026348
vitamin	B-C0574031
d	I-C0574031
receptor	I-C0574031
activators	I-C0574031
vdra	B-C0574031
may	O
exert	O
pleiotropic	B-C2936488
effects	I-C2936488
on	O
cardiovascular	B-C0007222
disease	I-C0007222
,	O
malignancy	B-C4282132
,	O
and	O
infections	B-C3714514
among	O
dialysis	B-C0011946
patients	B-C0030705
,	O
but	O
recent	O
studies	O
have	O
mainly	O
focused	O
on	O
cardiovascular	B-C0679250
outcomes	I-C0679250
.	O
	
among	O
8	O
patients	B-C0030705
who	O
started	O
dialysis	B-C0011946
in	O
2007	O
and	O
who	B-C0038954
survived	I-C0038954
until	O
january	O
1	O
,	O
2010	O
,	O
listed	O
in	O
the	O
renal	B-C0920631
data	I-C0920631
registry	I-C0920631
of	O
the	O
japanese	B-C1708333
society	I-C1708333
for	O
dialysis	B-C0011946
therapy	I-C0011946
,	O
5	O
vdra	B-C0574031
users	O
were	O
matched	O
to	O
3	O
non-users	O
based	O
on	O
clinically	B-C0205563
relevant	I-C0205563
variables	I-C0205563
at	O
the	O
end	O
of	O
2009	O
using	O
the	O
coarsened	B-C0026348
exact	I-C0026348
matching	I-C0026348
procedure	I-C0026348
.	O
	
until	O
december	O
31	O
,	O
2011	O
,	O
a	O
total	O
of	O
1	O
deaths	B-C0205848
occurred	O
,	O
of	O
which	O
468	O
42%	O
were	O
cardiovascular	B-C0376297
deaths	I-C0376297
,	O
229	O
20%	O
were	O
infection-related	B-C1306577
deaths	I-C1306577
,	O
and	O
141	O
12%	O
were	O
malignancy-related	B-C1516192
deaths	I-C1516192
.	O
	
multivariable	B-C0038953
survival	I-C0038953
analyses	I-C0038953
accounting	O
for	O
intra-region	B-C1707520
correlation	I-C1707520
revealed	O
that	O
vdra	B-C0574031
use	O
was	O
significantly	O
associated	O
with	O
lower	B-C1521828
rates	I-C1521828
of	O
infection	B-C3714514
-	O
and	O
malignancy	B-C4282132
-related	O
deaths	B-C0205848
subhazard	B-C2985465
ratio	I-C2985465
0.62	O
95%	O
ci	B-C0009667
,	O
0.52	O
and	O
0.70	O
95%	O
ci	B-C0009667
,	O
0.50	O
,	O
respectively	O
but	O
not	O
with	O
cardiovascular	B-C0376297
death	I-C0376297
subhazard	B-C2985465
ratio	I-C2985465
0.86	O
95%	O
ci	B-C0009667
,	O
0.72	O
.	O
	
future	O
randomized	B-C0206034
clinical	I-C0206034
trials	I-C0206034
with	O
a	O
sufficient	O
sample	B-C0242618
size	I-C0242618
and	O
an	O
adequate	O
follow-up	B-C1522577
period	O
are	O
warranted	O
to	O
test	O
the	O
clinical	B-C3850123
effectiveness	I-C3850123
of	O
vdra	B-C0574031
on	O
infection	B-C3714514
and	O
malignancy	B-C4282132
,	O
rather	O
than	O
cardiovascular	B-C0007222
disease	I-C0007222
,	O
among	O
dialysis	B-C0011946
patients	B-C0030705
.	O
	
burden	B-C2828008
of	O
cervical	B-C4048328
cancer	I-C4048328
and	O
role	O
of	O
screening	B-C1710032
in	O
india	B-C0021201
cervical	B-C4048328
cancer	I-C4048328
is	O
a	O
major	O
cause	O
of	O
cancer	B-C1516192
mortality	I-C1516192
in	O
women	B-C0043210
and	O
more	O
than	O
a	O
quarter	B-C2825406
of	O
its	O
global	B-C2348867
burden	B-C2828008
is	O
contributed	B-C1880177
by	O
developing	B-C0011750
countries	I-C0011750
.	O
	
in	O
india	B-C0021201
,	O
in	O
spite	O
of	O
alarmingly	O
high	O
figures	O
,	O
there	O
is	O
no	O
nationwide	O
government-sponsored	B-C0018109
screening	I-C0018109
program	I-C0018109
.	O
	
this	O
study	B-C2603343
was	O
conducted	B-C0205245
to	O
assess	B-C1516048
the	O
burden	B-C2828008
of	O
cervical	B-C4048328
cancer	I-C4048328
in	O
india	B-C0021201
and	O
review	B-C0699752
the	O
performance	B-C1882330
characteristics	B-C1521970
of	O
available	O
cervical	B-C4048328
cancer	I-C4048328
screening	B-C1710032
tools	O
,	O
so	O
as	O
to	O
provide	B-C1999230
evidence	B-C3887511
-based	O
recommendations	B-C0034866
for	O
application	O
of	O
most	O
practically	O
suited	O
screening	B-C2717746
test	I-C2717746
to	O
be	O
used	O
in	O
resource	B-C0035201
-poor	O
field	O
settings	O
.	O
	
medline	B-C0025141
and	O
web	B-C3841595
of	I-C3841595
science	I-C3841595
electronic	I-C3841595
database	I-C3841595
were	O
searched	B-C1706202
from	O
january	B-C3829466
1990	O
to	O
december	B-C3830550
2015	O
,	O
using	O
the	O
keywords	B-C1708608
such	O
as	O
""""	O
cervical	B-C4048328
cancer	I-C4048328
""""	O
,	O
""""	O
screening	B-C2717746
""""	O
,	O
""""	O
early	B-C0596473
detection	I-C0596473
""""	O
,	O
""""	O
cervical	B-C0856201
cytology	I-C0856201
""""	O
and	O
""""	O
visual	B-C3669138
inspection	I-C3669138
""""	O
,	O
and	O
their	O
corresponding	O
mesh	B-C1135584
terms	I-C1135584
in	O
combination	B-C0205195
with	O
boolean	B-C1881439
operators	I-C1881439
"""or"	O
,	O
and	O
two	O
authors	B-C3812881
independently	O
selected	B-C1707391
studies	B-C2603343
that	O
are	O
published	B-C1704324
in	O
english	B-C0376245
and	O
conducted	B-C0205245
in	O
india	B-C0021201
.	O
	
a	O
total	B-C0439810
of	O
11	O
studies	B-C2603343
were	O
found	B-C0150312
to	O
be	O
relevant	B-C2347946
and	O
eligible	B-C1548635
to	O
be	O
included	B-C0332257
in	O
the	O
present	B-C0150312
study	B-C2603343
.	O
	
in	O
india	B-C0021201
,	O
cervical	B-C4048328
cancer	I-C4048328
contributes	B-C1880177
to	O
approximately	B-C0332232
6-29%	O
of	O
all	O
cancers	B-C0006826
in	O
women	B-C0043210
.	O
	
the	O
age-adjusted	B-C1706747
incidence	I-C1706747
rate	I-C1706747
of	O
cervical	B-C4048328
cancer	I-C4048328
varies	O
widely	O
among	O
registries	B-C0034975
highest	B-C1522410
is	O
23.07	O
in	O
mizoram	B-C0681784
state	I-C0681784
and	O
the	O
lowest	B-C1708760
is	O
4.91	O
in	O
dibrugarh	B-C0681784
district	I-C0681784
.	O
	
the	O
pooled	O
estimates	B-C0750572
of	O
sensitivity	B-C0036667
and	O
specificity	B-C0037791
of	O
visual	B-C0430022
inspection	I-C0430022
with	I-C0430022
acetic	I-C0430022
acid	I-C0430022
via	B-C0430022
,	O
magnified	B-C0430022
via	I-C0430022
,	O
visual	B-C1519194
inspection	I-C1519194
with	I-C1519194
lugol's	I-C1519194
iodine	I-C1519194
vili	B-C1519194
,	O
cytology	B-C1305671
pap	B-C0079104
smear	I-C0079104
,	O
and	O
human	B-C2985459
papillomavirus	I-C2985459
dna	I-C2985459
were	O
found	O
to	O
be	O
67.65	O
and	O
84.32	O
,	O
65.36	O
and	O
85.76	O
,	O
78.27	O
and	O
87.10	O
,	O
62.11	O
and	O
93.51	O
,	O
and	O
77.81	O
and	O
91.54	O
,	O
respectively	O
.	O
	
in	O
developing	B-C0011750
countries	I-C0011750
because	O
of	O
lack	B-C0332268
of	O
necessary	O
infrastructure	B-C1998546
and	O
quality	B-C0034378
control	I-C0034378
,	O
high-quality	B-C0332306
cytology	B-C0199230
screening	I-C0199230
may	O
not	O
be	O
feasible	O
for	O
wide-scale	O
implementation	B-C1708476
.	O
	
hence	O
,	O
cervical	B-C4048328
cancer	I-C4048328
screening	B-C1710032
program	B-C3484370
based	O
on	O
visual	B-C2717746
screening	I-C2717746
test	I-C2717746
such	O
as	O
via	B-C0430022
/	O
vili	B-C1519194
should	O
be	O
adopted	O
as	O
an	O
integral	O
part	O
of	O
primary	O
health-care	B-C0086388
setup	I-C0086388
in	O
resource	B-C0035201
-	O
poor	B-C2700379
countries	B-C0454664
like	O
structural	B-C1880022
and	I-C1880022
tribometric	I-C1880022
characterization	I-C1880022
of	O
biomimetically	O
inspired	O
synthetic	O
""""	O
insect	B-C0021585
adhesives	B-C0001516
""""	O
background	O
based	O
on	O
previous	O
chemical	B-C3495389
analyses	I-C3495389
of	O
insect	B-C0021585
tarsal	B-C1550316
adhesives	B-C0001516
,	O
we	O
prepared	O
12	O
heterogeneous	B-C0019409
synthetic	B-C1883254
emulsions	B-C0014020
mimicking	O
the	O
polar/non-polar	B-C0243095
principle	I-C0243095
,	O
analysed	O
their	O
microscopical	B-C0678594
structure	I-C0678594
and	O
tested	O
their	O
adhesive	B-C0871161
,	O
frictional	B-C0871161
,	O
and	O
rheological	B-C0871161
properties	I-C0871161
.	O
	
results	O
the	O
prepared	B-C4082130
emulsions	B-C0014020
varied	O
in	O
their	O
consistency	B-C0332529
from	O
solid	B-C0205208
rubber-like	B-C0035918
,	O
over	O
soft	B-C0205358
elastic	B-C0450146
,	O
to	O
fluid	B-C1704353
watery	B-C0443350
or	O
oily	B-C0205556
.	O
	
with	O
droplet	B-C0456389
sizes	I-C0456389
>100	O
nm	O
,	O
all	O
the	O
emulsions	B-C0014020
belonged	O
to	O
the	O
common	O
type	O
of	O
macroemulsions	B-C0014020
.	O
	
the	O
emulsions	B-C0014020
of	O
the	O
first	B-C0079411
generation	I-C0079411
generally	O
showed	O
broader	O
droplet-size	B-C0456389
ranges	O
compared	O
with	O
the	O
second	B-C0079411
generation	I-C0079411
,	O
especially	O
when	O
less	O
defined	O
components	B-C1254370
such	O
as	O
petrolatum	B-C0031262
or	O
waxes	B-C0043076
were	O
present	O
in	O
the	O
lipophilic	B-C0598631
fraction	B-C1264633
of	O
the	O
first	B-C0079411
generation	I-C0079411
of	O
emulsions	B-C0014020
.	O
	
some	O
of	O
the	O
prepared	B-C4082130
emulsions	B-C0014020
showed	O
a	O
yield	B-C0243095
point	I-C0243095
and	O
were	O
bingham	B-C1254355
fluids	I-C1254355
.	O
	
tribometric	B-C0022885
adhesion	I-C0022885
was	O
tested	O
via	O
probe	B-C0022885
tack	I-C0022885
tests	I-C0022885
.	O
	
compared	O
with	O
the	O
""""	O
second	B-C0079411
generation	I-C0079411
""""	O
containing	O
less	O
viscous	B-C0311419
components	B-C0439861
,	O
the	O
""""	O
first	B-C0079411
generation	I-C0079411
""""	O
emulsions	B-C0014020
were	O
much	O
more	B-C0243095
adhesive	I-C0243095
31-93	O
mn	O
,	O
a	O
finding	O
attributable	O
to	O
their	O
highly	O
viscous	B-C0311419
components	B-C0439861
,	O
i.e	O
,	O
wax	B-C0043076
,	O
petrolatum	B-C0031262
,	O
gelatin	B-C0017237
and	O
poly	B-C0029224
alcohol	I-C0029224
.	O
	
in	O
the	O
second	B-C0079411
generation	I-C0079411
emulsions	B-C0014020
,	O
we	O
attained	O
much	O
lower	O
adhesivenesses	B-C0001515
,	O
ranging	O
between	O
1-18	O
mn	O
.	O
	
the	O
adhesive	B-C0001516
performance	B-C1882330
was	O
drastically	O
reduced	B-C0392756
in	O
the	O
emulsions	B-C0014020
that	O
contained	O
albumin	B-C0001924
as	O
the	O
protein	B-C0033684
component	I-C0033684
or	O
that	O
lacked	O
protein	B-C0033684
.	O
	
tribometric	B-C0022885
shear	I-C0022885
tests	I-C0022885
were	O
performed	O
at	O
moderate	O
normal	B-C0205556
loads	I-C0205556
.	O
	
our	O
measured	O
friction	B-C0162691
forces	I-C0162691
4-93	O
mn	O
in	O
the	O
first	O
and	O
0.1	O
mn	O
in	O
the	O
second	B-C0079411
generation	I-C0079411
emulsions	B-C0014020
were	O
comparatively	O
low	O
.	O
	
differences	B-C1705241
in	O
shear	B-C3825679
performance	B-C1882330
were	O
related	O
to	O
the	O
chemical	B-C0243176
composition	I-C0243176
and	O
emulsion	B-C0014020
structure	B-C0678594
.	O
	
conclusion	O
by	O
varying	O
their	O
chemical	B-C0243176
composition	I-C0243176
,	O
synthetic	O
heterogeneous	B-C0019409
adhesive	B-C0001516
emulsions	B-C0014020
can	O
be	O
adjusted	O
to	O
have	O
diverse	O
consistencies	B-C0332529
and	O
are	O
able	O
to	O
mimic	O
certain	O
rheological	B-C0871161
and	O
tribological	B-C0871161
properties	I-C0871161
of	O
natural	B-C0205296
tarsal	B-C1550316
insect	B-C0021585
adhesives	B-C0001516
.	O
	
opioids	B-C0242402
for	O
chronic	B-C0150055
pain	I-C0150055
the	O
cdc's	B-C0007670
12	O
recommendations	B-C0034866
the	O
centers	B-C0007670
for	I-C0007670
disease	I-C0007670
control	I-C0007670
and	I-C0007670
prevention	I-C0007670
has	O
issued	O
12	O
recommendations	B-C0034866
to	O
help	O
clinicians	B-C0871685
prescribe	B-C0033080
an	O
optimal	B-C2698651
and	O
safe	O
course	O
of	O
treatment	B-C0087111
for	O
three-dimensional	B-C0450363
hycosy	B-C0412553
with	O
perfluoropropane-albumin	B-C0389602
microspheres	I-C0389602
as	O
contrast	B-C0009924
agents	I-C0009924
and	O
normal	O
saline	B-C0036082
injections	B-C1533685
into	O
the	O
pelvic	B-C0559769
cavity	I-C0559769
for	O
morphological	B-C0332437
assessment	B-C0220825
of	O
the	O
fallopian	B-C0015560
tube	I-C0015560
in	O
infertile	B-C0021359
women	B-C0043210
to	O
apply	O
the	O
three-dimensional	B-C0450363
3d	B-C0450363
hysterosalpingo-contrast	B-C0412553
sonography	I-C0412553
hycosy	B-C0412553
with	O
perfluoropropane-albumin	B-C0389602
microspheres	I-C0389602
as	O
contrast	B-C0009924
agents	I-C0009924
and	O
normal	O
saline	B-C0036082
injections	B-C1533685
into	O
the	O
pelvic	B-C0559769
cavity	I-C0559769
for	O
assessment	B-C0015559
of	I-C0015559
the	I-C0015559
tubal	I-C0015559
patency	I-C0015559
and	O
adhesions	B-C4303544
of	I-C4303544
fimbrial	I-C4303544
parts	I-C4303544
.	O
	
fifty-five	O
infertile	B-C0021359
female	B-C0086287
patients	B-C0030705
were	O
recruited	O
to	O
undergo	O
3d	B-C0450363
hycosy	B-C0412553
with	O
normal	O
saline	B-C0036082
injected	B-C1533685
into	O
the	O
pelvic	B-C0559769
cavity	I-C0559769
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast	B-C0009924
agents	I-C0009924
from	O
the	O
fimbriae	B-C0227912
,	O
and	O
the	O
fimbrial	B-C4303544
adhesion	I-C4303544
was	O
confirmed	O
by	O
the	O
finger-like	B-C0348018
projections	I-C0348018
of	O
the	O
fimbriae	B-C0227912
and	O
their	O
floating	B-C0443223
and	O
moving	B-C1561509
status	I-C1561509
.	O
	
of	O
the	O
55	O
patients	B-C0030705
,	O
bilateral	B-C0243095
tubal	I-C0243095
patency	I-C0243095
was	O
observed	O
in	O
44	O
80.0	O
,	O
unilateral	B-C0243095
tubal	I-C0243095
patency	I-C0243095
and	O
the	O
other	O
partial	B-C1997620
occlusion	I-C1997620
in	O
7	O
12.7	O
,	O
unilateral	B-C0205092
partial	B-C1997620
occlusion	I-C1997620
and	O
the	O
other	O
complete	B-C0028778
occlusion	I-C0028778
in	O
3	O
5.4	O
,	O
and	O
bilateral	B-C0238767
complete	B-C0028778
occlusion	I-C0028778
in	O
1	O
1.8	O
.	O
	
the	O
fimbrial	B-C0227912
parts	I-C0227912
were	O
observed	O
in	O
105	O
fallopian	B-C0015560
tubes	I-C0015560
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger-like	B-C1254362
fimbriae	B-C0227912
floated	B-C0443223
and	O
moved	B-C1561509
in	O
the	O
pelvic	B-C0559769
cavity	I-C0559769
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	B-C4303544
to	O
the	O
pelvic	B-C0559769
cavity	I-C0559769
n	O
=	O
3	O
or	O
the	O
ovary	B-C0029939
and	O
intestine	B-C0021853
n	O
=	O
1	O
.	O
	
more	O
than	O
three	O
visible	O
,	O
quite	O
long	O
,	O
and	O
distributed	O
evenly	O
finger-like	B-C0348018
projection	I-C0348018
s	O
were	O
present	O
for	O
the	O
patent	B-C0175566
fimbrial	B-C0227912
parts	I-C0227912
however	O
,	O
fewer	B-C0205388
,	O
flat	B-C0205324
,	O
and	O
not	O
evenly	O
distributed	O
finger-like	B-C0348018
projection	I-C0348018
s	O
were	O
present	O
for	O
the	O
adhesive	B-C4303544
tubes	I-C4303544
.	O
	
no	O
serious	O
complications	B-C0009566
occurred	O
during	O
or	O
after	O
this	O
procedure	B-C0430022
.	O
	
combination	B-C0205195
of	O
3d	B-C0450363
hycosy	B-C0412553
with	O
normal	O
saline	B-C0036082
injected	B-C1533685
into	O
the	O
pelvic	B-C0559769
cavity	I-C0559769
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-C0430022
to	O
assess	O
tubal	O
patency	O
and	O
adhesions	B-C4303544
of	I-C4303544
the	I-C4303544
fimbrial	I-C4303544
parts	I-C4303544
.	O
	
challenging	B-C0805586
some	O
assumptions	O
about	O
empathy	B-C0013989
in	O
new	B-C0027978
zealand	I-C0027978
little	O
nursing	B-C0013636
or	O
medical	B-C0013631
curricula	I-C0013631
time	B-C0040223
,	O
if	O
any	O
,	O
is	O
specifically	O
devoted	O
to	O
the	O
enhancement	B-C2349975
of	O
empathy	B-C0013989
.	O
	
if	O
being	O
empathic	B-C0564547
is	O
important	B-C3898777
in	O
the	O
context	O
of	O
patient	B-C0017313
care	I-C0017313
,	O
it	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	O
in	O
students	B-C0038492
or	O
is	O
learned	O
by	O
students	B-C0038492
during	O
their	O
practicum	B-C0032929
in	O
the	O
company	O
of	O
experienced	B-C0237607
clinicians	B-C0871685
.	O
	
this	O
study	B-C2603343
aimed	O
to	O
compare	B-C1707455
self-reported	B-C2700446
empathy	B-C0013989
ratings	O
between	O
different	O
groups	B-C1257890
of	O
medical	B-C0038495
students	I-C0038495
and	O
one	O
cohort	B-C0599755
of	O
nursing	B-C0038496
students	I-C0038496
who	O
were	O
either	O
exposed	O
or	O
not	O
exposed	O
to	O
explicit	O
empathy	B-C0013989
training	B-C0220931
or	O
learning	B-C0023185
in	O
clinical	B-C3176918
settings	I-C3176918
in	O
the	O
presence	O
of	O
patients	B-C0030705
.	O
	
the	O
jefferson	B-C0034375
scale	I-C0034375
of	I-C0034375
physician	I-C0034375
empathy	I-C0034375
jspe	B-C0034375
was	O
completed	O
before	O
and	O
after	O
groups	O
of	O
medical	B-C0038495
and	O
nursing	B-C0038496
students	I-C0038496
had	O
been	O
exposed	O
to	O
various	O
extended	B-C0439590
periods	B-C1948053
of	O
practicum	B-C0032929
.	O
	
some	O
medical	B-C0038495
student	I-C0038495
cohorts	B-C0599755
undertook	O
brief	B-C1879313
empathy	B-C0013989
training	B-C0220931
,	O
whereas	O
others	O
had	O
no	O
exposure	O
.	O
	
the	O
nursing	O
student	O
cohort	O
had	O
no	O
formal	O
,	O
explicit	O
empathy	O
training	B-C0220931
.	O
	
irrespective	O
of	O
profession	O
,	O
length	O
of	O
practicum	O
or	O
exposure	O
to	O
specific	O
empathy	O
training	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
self-reported	O
jspe	O
scores	O
across	O
the	O
seven	O
different	O
cohorts	O
of	O
students	O
.	O
	
empathy	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	O
in	O
students	O
or	O
is	O
learned	O
by	O
students	O
during	O
their	O
practicum	O
discussion	O
if	O
empathy	O
is	O
caught	O
rather	O
than	O
taught	O
,	O
then	O
brief	O
efforts	O
to	O
enhance	O
empathy	O
may	O
be	O
futile	O
.	O
	
to	O
optimise	O
the	O
inherent	O
empathic	O
qualities	O
of	O
aspirant	O
health	O
professionals	O
,	O
explicit	O
consideration	O
should	O
be	O
given	O
to	O
how	O
empathy	O
is	O
influenced	O
by	O
the	O
practicum	O
experience	B-C0237607
surface	B-C0205148
mediated	O
cooperative	O
interactions	B-C0687133
of	I-C0687133
drugs	I-C0687133
enhance	B-C2349975
mechanical	B-C0563538
forces	I-C0563538
for	O
antibiotic	B-C0003232
action	B-C3266814
the	O
alarming	B-C0442805
increase	I-C0442805
of	O
pathogenic	B-C0450254
bacteria	I-C0450254
that	O
are	O
resistant	B-C0860044
to	I-C0860044
multiple	I-C0860044
antibiotics	I-C0860044
is	O
now	O
recognized	O
as	O
a	O
major	B-C4060919
health	I-C4060919
issue	I-C4060919
fuelling	O
demand	B-C0441516
for	O
new	O
drugs	B-C1254351
.	O
	
bacterial	B-C0151521
resistance	I-C0151521
is	O
often	O
caused	O
by	O
molecular	B-C0262496
changes	I-C0262496
at	O
the	O
bacterial	B-C0201029
surface	I-C0201029
,	O
which	O
alter	O
the	O
nature	O
of	O
specific	O
drug-target	B-C0687133
interactions	I-C0687133
.	O
	
here	O
,	O
we	O
identify	O
a	O
novel	O
mechanism	B-C0441712
by	O
which	O
drug-target	B-C0687133
interactions	I-C0687133
in	O
resistant	B-C1444090
bacteria	I-C1444090
can	O
be	O
enhanced	B-C2349975
.	O
	
we	O
examined	O
the	O
surface	B-C0205148
forces	O
generated	O
by	O
four	O
antibiotics	O
vancomycin	O
,	O
ristomycin	O
,	O
chloroeremomycin	O
and	O
oritavancin	O
against	O
drug-susceptible	O
and	O
drug-resistant	O
targets	O
on	O
a	O
cantilever	O
and	O
demonstrated	O
significant	O
differences	O
in	O
mechanical	O
response	O
when	O
drug-resistant	O
targets	O
are	O
challenged	O
with	O
different	O
antibiotics	O
although	O
no	O
significant	O
differences	O
were	O
observed	O
when	O
using	O
susceptible	O
targets	O
.	O
	
remarkably	O
,	O
the	O
binding	O
affinity	O
for	O
oritavancin	O
against	O
drug-resistant	O
targets	O
70	O
nm	O
was	O
found	O
to	O
be	O
11	O
times	O
stronger	O
than	O
for	O
vancomycin	O
800	O
μm	O
,	O
a	O
powerful	O
antibiotic	O
used	O
as	O
the	O
last	O
resort	O
treatment	O
for	O
streptococcal	O
and	O
staphylococcal	O
bacteria	O
including	O
methicillin-resistant	O
staphylococcus	O
aureus	O
mrsa	O
.	O
	
using	O
an	O
exactly	O
solvable	O
model	O
,	O
which	O
takes	O
into	O
account	O
the	O
solvent	O
and	O
membrane	O
effects	O
,	O
we	O
demonstrate	O
that	O
drug-target	O
interactions	O
are	O
strengthened	O
by	O
pronounced	O
polyvalent	O
interactions	O
catalyzed	O
by	O
the	O
surface	B-C0205148
itself	O
.	O
	
these	O
findings	O
further	O
enhance	O
our	O
understanding	O
of	O
antibiotic	O
mode	O
of	O
action	O
and	O
will	O
enable	O
development	O
of	O
more	O
effective	O
therapies	B-C0087111
intra-articular	B-C0442108
corticosteroids	B-C3536709
versus	O
intra-articular	B-C0442108
corticosteroids	B-C3536709
plus	B-C0332287
methotrexate	B-C0025677
in	O
oligoarticular	B-C3898105
juvenile	I-C3898105
idiopathic	I-C3898105
arthritis	I-C3898105
a	O
multicentre	B-C0206012
,	O
prospective	B-C0033522
,	O
randomised	B-C0206034
,	O
open-label	B-C0008976
trial	I-C0008976
little	O
evidence-based	O
information	O
is	O
available	O
to	O
guide	B-C2825826
the	O
treatment	B-C0087111
of	O
oligoarticular	B-C3898105
juvenile	I-C3898105
idiopathic	I-C3898105
arthritis	I-C3898105
.	O
	
we	O
aimed	O
to	O
investigate	B-C1292732
whether	O
oral	B-C1246896
methotrexate	I-C1246896
increases	B-C0442805
the	O
efficacy	B-C1280519
of	O
intra-articular	B-C4054701
corticosteroid	I-C4054701
therapy	I-C4054701
.	O
	
we	O
did	O
this	O
prospective	B-C0033522
,	O
open-label	B-C0008976
,	O
randomised	B-C0206034
trial	I-C0206034
at	O
ten	O
hospitals	B-C0019994
in	O
italy	B-C0022277
.	O
	
using	O
a	O
concealed	B-C0443189
computer-generated	B-C0745732
list	I-C0745732
,	O
children	B-C0008059
younger	B-C2237067
than	I-C2237067
18	O
years	B-C1510829
with	O
oligoarticular	B-C0439754
-	O
onset	B-C0277793
disease	I-C0277793
were	O
randomly	B-C0439605
assigned	B-C1516050
1	O
to	O
intra-articular	B-C0442108
corticosteroids	B-C3536709
alone	B-C0205171
or	O
in	B-C0205195
combination	I-C0205195
with	I-C0205195
oral	B-C1246896
methotrexate	I-C1246896
15	O
mg/m	O
maximum	B-C0806909
20	O
mg	O
.	O
	
corticosteroids	B-C3536709
used	O
were	O
triamcinolone	B-C0077004
hexacetonide	I-C0077004
shoulder	B-C0037009
,	O
elbow	B-C0013770
,	O
wrist	B-C1322271
,	O
knee	B-C0022745
,	O
and	O
tibiotalar	B-C0003087
joints	I-C0003087
or	O
methylprednisolone	B-C0600901
acetate	I-C0600901
ie	O
,	O
subtalar	B-C0038593
and	O
tarsal	B-C1527245
joints	I-C1527245
.	O
	
we	O
did	O
not	O
mask	O
patients	B-C0030705
or	O
investigators	B-C0008961
to	O
treatment	B-C0087111
assignments	B-C1516050
.	O
	
our	O
primary	B-C1274040
outcome	I-C1274040
was	O
the	O
proportion	B-C1709707
of	O
patients	B-C0030705
in	O
the	O
intention-to-treat	B-C2718028
population	B-C1257890
who	O
had	O
remission	B-C0544452
of	O
arthritis	B-C0003864
in	O
all	O
injected	B-C0021485
joints	B-C0022417
at	O
12	O
months	B-C0439231
.	O
	
this	O
trial	B-C0008976
is	O
registered	B-C1514821
with	O
european	B-C1254363
union	I-C1254363
clinical	I-C1254363
trials	I-C1254363
register	I-C1254363
,	O
eudract	B-C0282574
number	I-C0282574
2008-006741-70	O
.	O
	
between	O
july	B-C3829447
7	O
,	O
2009	O
,	O
and	O
march	B-C3829202
31	O
,	O
2013	O
,	O
we	O
screened	B-C2348582
226	O
participants	B-C0679646
and	O
randomly	B-C0439605
assigned	B-C1516050
102	O
to	O
intra-articular	B-C0442108
corticosteroids	B-C3536709
alone	B-C0205171
and	O
105	O
to	O
intra-articular	B-C0442108
corticosteroids	B-C3536709
plus	B-C0332287
methotrexate	B-C0025677
.	O
	
33	O
32%	O
patients	B-C0030705
assigned	B-C1516050
to	O
intra-articular	B-C0442108
corticosteroids	B-C3536709
alone	B-C0205171
and	O
39	O
37%	O
assigned	B-C1516050
to	O
intra-articular	B-C0442108
corticosteroids	B-C3536709
and	O
methotrexate	B-C0025677
therapy	B-C0087111
had	O
remission	B-C0544452
of	O
arthritis	B-C0003864
in	O
all	O
injected	B-C0021485
joints	B-C0022417
p=0	O
.	O
	
adverse	B-C0877248
events	I-C0877248
were	O
recorded	O
for	O
20	O
17%	O
patients	B-C0030705
who	O
received	O
methotrexate	B-C0025677
,	O
which	O
led	O
to	O
permanent	B-C0205355
treatment	B-C0087111
discontinuation	B-C1444662
in	O
two	O
patients	B-C0030705
one	O
due	O
to	O
increased	B-C1848701
liver	I-C1848701
transaminases	I-C1848701
and	O
one	O
due	O
to	O
gastrointestinal	B-C1096250
discomfort	I-C1096250
.	O
	
no	B-C1513916
patient	B-C0030705
had	O
a	O
serious	B-C0205404
adverse	B-C0877248
event	I-C0877248
.	O
	
concomitant	B-C2826730
administration	I-C2826730
of	O
methotrexate	B-C0025677
did	O
not	O
augment	B-C0442805
the	O
effectiveness	B-C1280519
of	O
intra-articular	B-C4054701
corticosteroid	I-C4054701
therapy	I-C4054701
.	O
	
future	B-C2603343
studies	I-C2603343
are	O
needed	O
to	O
define	O
the	O
optimal	B-C2698651
therapeutic	B-C0087111
strategies	I-C0087111
for	O
oligoarticular	B-C3898105
juvenile	I-C3898105
idiopathic	I-C3898105
arthritis	I-C3898105
.	O
	
italian	B-C1561598
agency	I-C1561598
of	I-C1561598
drug	I-C1561598
evaluation	I-C1561598
.	O
	
methylation	B-C1880239
analysis	I-C1880239
of	O
brca1	B-C0376571
and	O
apc	B-C0162832
in	O
breast	B-C0006142
cancer	I-C0006142
and	O
it's	O
relationship	B-C0439849
to	O
clinicopathological	B-C1521733
features	B-C2348519
promoter	B-C0376452
methylation	I-C0376452
of	O
tumor	B-C0079427
suppressor	I-C0079427
genes	I-C0079427
is	O
an	O
important	O
epigenetic	B-C1516924
alteration	I-C1516924
that	O
occurs	O
in	O
the	O
primary	B-C0205225
stages	B-C1306673
of	O
human	B-C0086418
tumors	B-C0027651
,	O
including	O
breast	B-C0006142
cancer	I-C0006142
.	O
	
identification	O
of	O
methylated	B-C0017337
genes	I-C0017337
and	O
their	O
relationship	B-C0439849
to	O
clinical	B-C0205210
features	B-C2348519
can	O
contribute	O
to	O
the	O
prognosis	B-C0033325
and	O
early	B-C0596473
detection	I-C0596473
of	O
tumors	B-C0027651
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
explored	O
the	O
methylation	B-C0376452
status	B-C0449438
of	O
apc	B-C0162832
and	O
brca1	B-C0376571
genes	I-C0376571
and	O
their	O
relationship	B-C0439849
to	O
clinical	B-C0205210
factors	B-C1521761
in	O
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
.	O
	
brca1	B-C0376571
and	O
apc	B-C0162832
promoter	B-C0376452
methylation	I-C0376452
was	O
examined	O
by	O
methylation	B-C0025723
-	O
specific	B-C3494189
multiplex	I-C3494189
ligation-dependent	I-C3494189
probe	I-C3494189
amplification	I-C3494189
ms-mlpa	B-C3494189
assay	B-C1510438
in	O
formalin-fixed	B-C2711483
paraffin	I-C2711483
embedded	I-C2711483
ffpe	I-C2711483
breast	I-C2711483
tissue	I-C2711483
from	O
75	O
patients	B-C0030705
.	O
	
apc	B-C0162832
promoter	B-C0376452
methylation	I-C0376452
was	O
detected	B-C0442726
in	O
30.67	O
breast	B-C0006142
cancer	I-C0006142
tissues	B-C0040300
and	O
brca1	B-C0376571
was	O
methylated	B-C0376452
in	O
9.33	O
of	O
breast	B-C1458155
tumors	I-C1458155
.	O
	
methylation	B-C0376452
of	O
apc	B-C0162832
was	O
associated	B-C0332281
with	I-C0332281
low	O
histological	B-C0456201
grade	I-C0456201
p	O
=	O
0.006	O
and	O
methylation	B-C0376452
of	O
brca1	B-C0376571
was	O
related	O
with	O
lymph	B-C0024204
node	I-C0024204
metastasis	B-C4255448
p	O
=	O
0.017	O
.	O
	
these	O
findings	B-C0243095
suggest	O
that	O
the	O
methylation	B-C0376452
status	B-C0449438
of	O
apc	B-C0162832
and	O
brca1	B-C0376571
can	O
be	O
a	O
predictive	B-C0005516
marker	I-C0005516
for	O
early	B-C0596473
detection	I-C0596473
and	O
better	O
management	B-C0376636
of	O
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
.	O
	
recombinant	B-C0034861
fibrinogen	B-C0016006
reveals	O
the	O
differential	B-C1705242
roles	O
of	O
α-	B-C0033684
and	O
γ-chain	B-C0033684
cross-linking	B-C0314675
and	O
molecular	B-C1521991
heterogeneity	B-C0019409
in	O
fibrin	B-C3156338
clot	I-C3156338
strain-stiffening	B-C0013764
essentials	O
fibrinogen	B-C0016006
circulates	B-C0175630
in	O
human	B-C0086418
plasma	B-C0032105
as	O
a	O
complex	B-C1704241
mixture	B-C0439962
of	O
heterogeneous	B-C0019409
molecular	B-C1521991
variants	B-C0205419
.	O
	
we	O
measured	B-C0444706
strain-stiffening	B-C0013764
of	O
recombinantly	B-C0034865
produced	O
fibrinogen	B-C0016006
upon	O
clotting	B-C0005778
.	O
	
factor	B-C0015528
xiii	I-C0015528
and	O
molecular	B-C1521991
heterogeneity	B-C0019409
alter	O
clot	B-C3156338
elasticity	B-C0013764
at	O
the	O
protofibril	B-C0015982
and	O
fiber	B-C1304649
level	O
.	O
	
this	O
highlights	O
the	O
hitherto	O
unknown	O
role	O
of	O
molecular	B-C1521991
composition	B-C0205198
in	O
fibrin	B-C3156338
clot	I-C3156338
mechanics	B-C0376706
.	O
	
background	O
fibrin	B-C0015982
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	B-C0019116
and	O
wound	B-C0043240
healing	I-C0043240
by	O
forming	O
strain-stiffening	B-C0013764
fibrous	B-C0243092
networks	I-C0243092
that	O
reinforce	O
blood	B-C0302148
clots	I-C0302148
.	O
	
the	O
molecular	B-C1521991
origin	O
of	O
fibrin's	B-C0015982
strain-stiffening	B-C0013764
behavior	O
remains	O
poorly	O
understood	O
,	O
primarily	O
because	O
plasma	B-C0032105
fibrinogen	B-C0016006
is	O
a	O
complex	B-C1704241
mixture	B-C0439962
of	O
heterogeneous	B-C0019409
molecular	B-C1521991
variants	B-C0205419
and	O
is	O
often	O
contaminated	O
by	O
plasma	B-C0033684
factors	I-C0033684
that	O
affect	O
clot	B-C3156338
properties	B-C0871161
.	O
	
objectives	O
and	O
methods	O
to	O
facilitate	O
mechanistic	B-C0205245
dissection	I-C0205245
of	O
fibrin	B-C0015982
nonlinear	B-C0013764
elasticity	I-C0013764
,	O
we	O
produced	O
a	O
homogeneous	B-C1881065
recombinant	B-C0034861
fibrinogen	B-C0016006
corresponding	O
to	O
the	O
main	O
variant	B-C0205419
in	O
human	B-C0086418
plasma	B-C0032105
,	O
termed	O
rfib610	B-C0016006
.	O
	
we	O
characterized	O
the	O
structure	B-C0678594
of	O
rfib610	B-C0016006
clots	B-C3156338
using	O
turbidimetry	B-C0041394
,	O
microscopy	B-C0026018
and	O
x-ray	B-C0043301
scattering	I-C0043301
.	O
	
we	O
used	O
rheology	B-C0599706
to	O
measure	B-C0079809
the	O
strain-stiffening	B-C0013764
behavior	O
of	O
the	O
clots	B-C3156338
and	O
determined	O
the	O
fiber	B-C1304649
properties	B-C0871161
by	O
modeling	B-C0870071
the	O
clots	B-C3156338
as	O
semi-flexible	B-C1882071
polymer	I-C1882071
networks	I-C1882071
.	O
	
results	O
we	O
show	O
that	O
addition	O
of	O
fxiii	B-C0015528
to	O
rfib610	B-C0016006
clots	B-C3156338
causes	O
a	O
dose-dependent	B-C0018599
stiffness	I-C0018599
increase	O
at	O
small	O
deformations	B-C0333067
and	O
renders	O
the	O
strain-stiffening	B-C0013764
response	O
reversible	O
.	O
	
we	O
find	O
that	O
γ-chain	B-C0033684
cross-linking	B-C0314675
contributes	O
to	O
clot	B-C3156338
elasticity	B-C0013764
by	O
changing	O
the	O
force-extension	B-C0205245
behavior	I-C0205245
of	O
the	O
protofibrils	B-C0015982
,	O
whereas	O
α-chain	B-C0033684
cross-linking	B-C0314675
stiffens	O
the	O
fibers	B-C1304649
,	O
as	O
a	O
consequence	O
of	O
tighter	B-C1948027
coupling	I-C1948027
between	O
the	O
constituent	O
protofibrils	B-C0015982
.	O
	
interestingly	O
,	O
rfib610	B-C0016006
protofibrils	B-C0015982
have	O
a	O
25%	O
larger	O
bending	B-C0018599
rigidity	I-C0018599
than	O
plasma	B-C0032105
-purified	O
fibrin	B-C0015982
protofibrils	B-C0015982
and	O
a	O
delayed	O
strain-stiffening	B-C0013764
,	O
indicating	O
that	O
molecular	B-C1521991
heterogeneity	B-C0019409
influences	B-C4054723
clot	B-C3156338
mechanics	B-C0376706
at	O
the	O
protofibril	B-C0015982
scale	I-C0015982
.	O
	
conclusions	O
fibrinogen	B-C0016006
molecular	B-C1521991
heterogeneity	B-C0019409
and	O
fxiii	B-C0015528
affect	O
the	O
mechanical	B-C0542341
function	I-C0542341
of	O
fibrin	B-C3156338
clots	I-C3156338
by	O
altering	O
the	O
nonlinear	B-C0871161
viscoelastic	I-C0871161
properties	I-C0871161
at	O
the	O
protofibril	B-C0230898
and	O
fiber	B-C1304649
scale	I-C1304649
.	O
	
this	O
work	O
provides	O
a	O
starting	O
point	O
to	O
investigate	B-C1292732
the	O
role	O
of	O
molecular	B-C1521991
heterogeneity	B-C0019409
of	O
plasma	B-C0032105
fibrinogen	B-C0016006
in	O
fibrin	B-C3156338
clot	I-C3156338
mechanics	B-C0376706
and	O
effects	O
of	O
display	B-C0870432
curvature	B-C0205134
,	O
display	B-C0870432
zone	B-C1710706
,	O
and	O
task	B-C0679599
duration	B-C0449238
on	O
legibility	B-C0870803
and	O
visual	B-C0004095
fatigue	I-C0004095
during	O
visual	B-C0679599
search	I-C0679599
task	I-C0679599
this	O
study	O
examined	O
the	O
effects	O
of	O
display	B-C0870432
curvature	B-C0205134
400	O
,	O
600	O
,	O
1200	O
mm	O
,	O
and	O
flat	B-C0205324
,	O
display	B-C0870432
zone	B-C1710706
5	O
zones	B-C1710706
,	O
and	O
task	B-C0679599
duration	B-C0449238
15	O
and	O
30	O
min	O
on	O
legibility	B-C0870803
and	O
visual	B-C0004095
fatigue	I-C0004095
.	O
	
each	O
participant	B-C0679646
completed	O
two	O
15-min	O
visual	B-C0679599
search	I-C0679599
task	I-C0679599
sets	O
at	O
each	O
curvature	B-C0205134
setting	B-C0442307
.	O
	
the	O
600-mm	O
and	O
1200-mm	O
settings	B-C0442307
yielded	O
better	O
results	O
than	O
the	O
flat	B-C0205324
setting	B-C0442307
in	O
terms	O
of	O
legibility	B-C0870803
and	O
perceived	O
visual	B-C0004095
fatigue	I-C0004095
.	O
	
relative	O
to	O
the	O
corresponding	O
centre	B-C0205099
zone	B-C1710706
,	O
the	O
outermost	O
zones	B-C1710706
of	O
the	O
1200-mm	O
and	O
flat	B-C0205324
settings	B-C0442307
showed	O
a	O
decrease	O
of	O
8%-37%	O
in	O
legibility	B-C0870803
,	O
whereas	O
those	O
of	O
the	O
flat	B-C0205324
setting	B-C0442307
showed	O
an	O
increase	B-C0442805
of	O
26%-45%	O
in	O
perceived	B-C0030971
visual	B-C0004095
fatigue	I-C0004095
.	O
	
across	O
curvature	B-C0205134
s	O
,	O
legibility	B-C0870803
decreased	B-C0205216
by	O
2%-8%	O
,	O
whereas	O
perceived	B-C0030971
visual	B-C0004095
fatigue	I-C0004095
increased	B-C0442805
by	O
22%	O
during	O
the	O
second	O
task	B-C0679599
set	I-C0679599
.	O
	
the	O
two	O
task	B-C0679599
sets	I-C0679599
induced	O
an	O
increase	B-C0442805
of	O
102%	O
in	O
the	O
eye	B-C0449820
complaint	I-C0449820
score	I-C0449820
and	O
a	O
decrease	O
of	O
0.3	O
hz	O
in	O
the	O
critical	B-C0234697
fusion	I-C0234697
frequency	I-C0234697
,	O
both	O
of	O
which	O
indicated	O
an	O
increase	B-C0442805
in	O
visual	B-C0004095
fatigue	I-C0004095
.	O
	
in	O
summary	O
,	O
a	O
curvature	B-C0205134
of	O
around	O
600	O
mm	O
,	O
central	B-C0205099
display	B-C0870432
zones	B-C1710706
,	O
and	O
frequent	O
breaks	B-C0449647
are	O
recommended	O
to	O
improve	B-C0184511
legibility	B-C0870803
and	O
reduce	O
visual	B-C0004095
fatigue	I-C0004095
.	O
	
predicting	O
changes	O
in	O
adaptive	B-C0231193
functioning	B-C0542341
and	O
behavioral	B-C0004927
adjustment	B-C0456081
following	O
treatment	B-C0087111
for	O
a	O
pediatric	B-C0220603
brain	I-C0220603
tumor	I-C0220603
a	O
report	B-C4255046
from	O
the	O
brain	B-C0006104
radiation	B-C1880171
investigative	I-C1880171
study	I-C1880171
consortium	I-C1880171
children	B-C0008059
are	O
at	O
risk	B-C0035647
for	O
behavioral	B-C0004927
and	O
adaptive	B-C0231193
difficulties	B-C0332218
following	O
pediatric	B-C0220603
brain	I-C0220603
tumor	I-C0220603
.	O
	
this	O
study	B-C2603343
explored	O
whether	O
familial	B-C0241888
/	O
demographic	B-C0011298
,	O
developmental	B-C0458003
,	O
diagnostic	B-C0348026
,	O
or	O
treatment	B-C0087111
-related	O
variables	B-C0439828
best	O
predict	O
posttreatment	B-C2709088
behavioral	B-C0004927
and	O
adaptive	B-C0231193
functioning	B-C0542341
.	O
	
participants	B-C0679646
included	O
40	O
children	B-C0008059
mean	B-C0444504
age	B-C0001779
=	O
12.76	O
years	O
,	O
sd	B-C0871420
=	O
4.01	O
posttreatment	B-C2709088
mean	B-C0444504
time	B-C0040223
since	O
diagnosis	B-C0011900
=	O
1.99	O
years	O
,	O
sd	B-C0871420
=	O
0.21	O
for	O
pediatric	B-C0220603
brain	I-C0220603
tumor	I-C0220603
.	O
	
parents	B-C0030551
rated	O
children	B-C0008059
's	O
behavioral	B-C0004927
adjustment	B-C0456081
and	O
adaptive	B-C0231193
functioning	B-C0542341
and	O
provided	O
demographic	B-C0011298
and	O
developmental	B-C0458003
histories	B-C0262926
.	O
	
diagnostic	B-C0011900
and	O
treatment	B-C0087111
-related	O
information	B-C1533716
was	O
abstracted	O
from	O
medical	B-C0025102
records	I-C0025102
.	O
	
ratings	B-C0871208
of	O
adaptive	B-C0231193
and	O
behavioral	B-C0004927
functioning	B-C0542341
approximately	O
2	O
years	O
postdiagnosis	B-C0011900
were	O
within	O
the	O
average	B-C1510992
range	B-C1514721
,	O
although	O
the	O
percentage	B-C0439165
of	O
children	B-C0008059
exceeding	O
clinical	B-C0205210
cutoffs	B-C1442160
for	O
impairment	B-C0221099
in	O
adaptive	B-C0231193
skills	B-C0678856
exceeded	O
expectation	B-C0679138
,	O
particularly	O
practical	O
skills	B-C0678856
.	O
	
premorbid	B-C4062485
behavior	I-C4062485
problems	B-C1546466
and	O
tumor	B-C0475440
size	I-C0475440
predicted	O
posttreatment	B-C2709088
adaptive	B-C0231193
functioning	B-C0542341
.	O
	
after	O
accounting	O
for	O
adaptive	B-C0231193
functioning	B-C0542341
near	O
diagnosis	B-C0011900
,	O
premorbid	B-C4062485
behavior	I-C4062485
problems	B-C1546466
predicted	O
declines	O
in	O
adaptive	B-C0231193
functioning	B-C0542341
2	O
years	O
postdiagnosis	B-C0011900
.	O
	
after	O
accounting	O
for	O
adjustment	B-C0456081
near	O
diagnosis	B-C0011900
,	O
no	O
variables	B-C0439828
predicted	O
declines	O
in	O
behavioral	B-C0004927
adjustment	B-C0456081
.	O
	
children	B-C0008059
may	O
be	O
vulnerable	B-C0231204
to	O
reduced	O
adaptive	B-C0231193
functioning	B-C0542341
following	O
pediatric	B-C0220603
brain	I-C0220603
tumor	I-C0220603
treatment	B-C0087111
,	O
especially	O
in	O
practical	O
skills	O
.	O
	
assessing	O
prediagnosis	B-C0011900
functioning	B-C0542341
and	O
diagnostic	B-C0011900
and	O
treatment	B-C0087111
-related	O
variables	B-C0439828
may	O
improve	B-C0184511
our	O
ability	B-C0085732
to	O
predict	O
those	O
at	O
greatest	O
risk	B-C0035647
,	O
although	O
those	O
factors	B-C1521761
may	O
be	O
less	O
helpful	B-C3898897
in	O
identifying	B-C0205396
children	B-C0008059
likely	O
to	O
develop	O
behavioral	B-C0004927
difficulties	B-C0332218
.	O
	
screening	B-C1710032
of	O
these	O
factors	B-C1521761
in	O
tertiary	B-C3494403
care	I-C3494403
and	O
long-term	B-C0443252
follow-up	B-C1522577
settings	O
may	O
improve	B-C0184511
identification	B-C0205396
of	O
those	O
at	O
greatest	O
need	B-C0027552
for	O
support	B-C0679879
services	I-C0679879
.	O
	
spine	B-C0080179
fracture	I-C0080179
prevalence	B-C0033105
in	O
a	O
nationally	B-C0681788
representative	I-C0681788
sample	O
of	O
us	B-C0041703
women	B-C0043210
and	O
men	B-C0025266
aged	B-C0001779
40	O
years	O
results	O
from	O
the	O
national	B-C0376344
health	I-C0376344
and	I-C0376344
nutrition	I-C0376344
examination	I-C0376344
survey	I-C0376344
nhanes	B-C0376344
2013-2014	O
spine	B-C0080179
fracture	I-C0080179
prevalence	B-C0033105
is	O
similar	O
in	O
men	B-C0025266
and	O
women	B-C0043210
,	O
increasing	O
from	O
<5	O
%	O
in	O
those	O
<60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
80	O
years	O
.	O
	
prevalence	B-C0033105
was	O
higher	B-C0205250
with	O
age	B-C0001779
,	O
lower	O
bone	O
mineral	O
density	O
bmd	O
,	O
and	O
in	O
those	O
meeting	O
criteria	O
for	O
spine	O
imaging	O
.	O
	
most	O
subjects	O
with	O
spine	O
fractures	O
were	O
unaware	O
of	O
them	O
.	O
	
spine	O
fractures	O
have	O
substantial	O
medical	O
significance	O
but	O
are	O
seldom	O
recognized	O
.	O
	
this	O
study	O
collected	O
contemporary	O
nationally	O
representative	O
spine	O
fracture	O
prevalence	O
data	O
.	O
	
cross-sectional	O
analysis	O
of	O
3330	O
us	O
adults	O
aged	O
40	O
years	O
participating	O
in	O
nhanes	O
2013-2014	O
with	O
evaluable	O
vertebral	O
fracture	O
assessment	O
vfa	O
.	O
	
vfa	O
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O
	
bmd	O
and	O
an	O
osteoporosis	O
questionnaire	O
were	O
collected	O
.	O
	
overall	O
spine	O
fracture	O
prevalence	O
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	O
and	O
women	O
.	O
	
prevalence	O
increased	O
with	O
age	B-C0001779
from	O
<5	O
%	O
in	O
those	O
<60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
80	O
years	O
.	O
	
fractures	O
were	O
more	O
common	O
in	O
non-hispanic	O
whites	O
and	O
in	O
people	O
with	O
lower	B-C0205251
body	O
mass	O
index	O
and	O
bmd	O
.	O
	
among	O
subjects	O
with	O
spine	O
fracture	O
,	O
26	O
%	O
met	O
bmd	O
criteria	O
for	O
osteoporosis	O
.	O
	
prevalence	O
was	O
higher	O
in	O
subjects	O
who	O
met	O
national	O
osteoporosis	O
foundation	O
nof	O
criteria	O
for	O
spine	O
imaging	O
14	O
vs	O
4.7	O
%	O
,	O
p	O
<	O
0.001	O
.	O
	
only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	O
fracture	O
diagnosed	O
by	O
vfa	O
had	O
a	O
self-reported	O
fracture	O
,	O
and	O
among	O
those	O
who	O
self-reported	O
a	O
spine	O
fracture	O
,	O
only	O
21	O
%	O
were	O
diagnosed	O
with	O
fracture	O
by	O
vfa	O
.	O
	
spine	O
fracture	O
prevalence	O
is	O
similar	O
in	O
women	O
and	O
men	O
and	O
increases	O
with	O
age	O
and	O
lower	O
bmd	O
,	O
although	O
most	O
subjects	O
with	O
spine	O
fracture	O
do	O
not	O
meet	O
bmd	O
criteria	O
for	O
osteoporosis	O
.	O
	
since	O
most	O
>90	O
%	O
individuals	O
were	O
unaware	O
of	O
their	O
spine	O
fractures	O
,	O
lateral	O
spine	O
imaging	O
is	O
needed	O
to	O
identify	O
these	O
women	O
and	O
men	O
.	O
	
spine	O
fracture	O
prevalence	O
was	O
threefold	O
higher	O
in	O
individuals	O
meeting	O
nof	O
criteria	O
for	O
spine	O
imaging	O
1	O
in	O
7	O
undergoing	O
vfa	O
.	O
	
identifying	O
spine	O
fractures	O
as	O
part	O
of	O
comprehensive	O
risk	O
assessment	O
may	O
improve	O
clinical	O
decision	O
making	I-C4042877
renieramycin	B-C1435644
m	I-C1435644
attenuates	O
cancer	B-C1956422
stem	I-C1956422
cell	I-C1956422
-like	O
phenotypes	B-C0031437
in	O
h460	B-C0597032
lung	B-C0024109
cancer	B-C0597032
cells	I-C0597032
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
cscs	B-C1956422
are	O
a	O
subpopulation	O
of	O
cancer	B-C0597032
cells	I-C0597032
that	O
possess	O
self-renewal	B-C1155711
and	O
differentiation	B-C0007589
capacities	O
.	O
	
cscs	B-C1956422
contribute	O
to	O
drug-resistance	B-C0013203
,	O
cancer	B-C0920420
recurrence	I-C0920420
and	O
metastasis	B-C4255448
,	O
thus	O
development	B-C1527148
of	O
csc	B-C1956422
-targeted	O
therapeutic	B-C0087111
strategies	I-C0087111
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer	B-C1516225
research	I-C1516225
.	O
	
in	O
this	O
study	B-C2603343
,	O
the	O
potential	O
efficacy	B-C1280519
of	O
renieramycin	B-C1435644
m	I-C1435644
rm	B-C1435644
isolated	O
from	O
the	O
sponge	B-C0032699
xestospongia	B-C1204055
species	I-C1204055
,	O
was	O
examined	B-C0332128
against	O
lung	B-C0024109
cscs	B-C1956422
.	O
	
colony	B-C0005507
and	I-C0005507
spheroid	I-C0005507
formation	I-C0005507
assays	I-C0005507
,	O
as	O
well	O
as	O
western	B-C0005863
blotting	I-C0005863
analysis	I-C0005863
of	O
lung	B-C0024109
csc	B-C1956422
protein	B-C0033684
markers	B-C0041365
were	O
employed	O
to	O
determine	O
the	O
csc	B-C1956422
-like	O
phenotypes	B-C0031437
of	O
h460	B-C0597032
lung	B-C0024109
cancer	B-C0597032
cells	I-C0597032
after	O
treatment	B-C0087111
with	O
rm	B-C1435644
at	O
non-toxic	B-C0678563
concentrations	I-C0678563
.	O
	
rm	B-C1435644
treatment	B-C0087111
reduced	O
significantly	O
colony	B-C0005507
and	I-C0005507
spheroid	I-C0005507
formation	I-C0005507
of	O
h460	B-C0597032
cells	I-C0597032
.	O
	
moreover	O
,	O
the	O
csc	B-C1956422
markers	B-C0041365
cd133	B-C0673026
,	O
cd44	B-C1097299
and	O
aldh1a1	B-C1721673
of	O
csc	B-C1956422
-enriched	O
h460	B-C0597032
cells	I-C0597032
were	O
reduced	O
significantly	O
following	O
rm	B-C1435644
treatment	B-C0087111
.	O
	
rm	B-C1435644
could	O
be	O
a	O
potent	O
anti-metastatic	B-C1516021
agent	I-C1516021
by	O
suppressing	O
lung	B-C0024109
csc	B-C1956422
-like	O
phenotypes	B-C0031437
in	O
h460	B-C0597032
cells	I-C0597032
.	O
	
physicochemical	O
characterization	O
of	O
chitosan	B-C0162969
-	O
hyaluronan	B-C0813622
-coated	O
solid	O
lipid	B-C1709148
nanoparticles	I-C1709148
for	O
the	O
targeted	O
delivery	B-C0565867
of	O
paclitaxel	B-C0144576
a	O
proof-of-concept	B-C2603343
study	I-C2603343
in	O
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
to	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	B-C1709148
lipid	I-C1709148
nanoparticles	I-C1709148
sln	B-C1709148
for	O
the	O
delivery	O
of	O
paclitaxel	B-C0144576
pax	B-C0144576
.	O
	
sln	B-C3898158
loaded	I-C3898158
with	I-C3898158
pax	I-C3898158
were	O
prepared	O
via	O
modified	O
high-pressure	B-C3828864
hot	I-C3828864
homogenization	I-C3828864
.	O
	
formulation	B-C0524527
parameters	I-C0524527
were	O
optimized	O
to	O
obtain	O
a	O
high-quality	B-C0085104
delivery	I-C0085104
system	I-C0085104
.	O
	
sln	B-C1709148
cores	O
were	O
coated	B-C1522408
,	O
layer-by-layer	I-C1522408
,	O
with	O
a	O
chitosan	B-C0162969
and	O
hyaluronan	B-C0813622
ha	B-C0813622
shell	O
.	O
	
selectivity	O
toward	O
ha	B-C0813622
receptors	B-C0597357
was	O
tested	O
in	O
a	O
breast	B-C1512505
cancer	I-C1512505
cell	I-C1512505
line	I-C1512505
,	O
mcf-7	B-C0596890
.	O
	
stable	B-C0205556
and	I-C0205556
reproducible	I-C0205556
nano-sized	B-C0205556
and	O
negatively	B-C1450054
charged	I-C1450054
nanoparticles	I-C1450054
resulted	O
.	O
	
findings	O
reveal	O
that	O
chitosan	B-C0162969
-	O
ha	B-C0813622
-coated	O
sln	B-C1709148
facilitated	O
the	O
targeting	B-C1521840
,	O
cellular	B-C3888108
uptake	I-C3888108
and	O
the	O
time-/dose-controlled	B-C1616334
delivery	I-C1616334
and	I-C1616334
release	I-C1616334
of	O
pax	B-C0144576
,	O
enhancing	O
intrinsic	B-C0870057
chemotherapeutic	I-C0870057
activities	I-C0870057
.	O
	
sln	B-C1709148
are	O
suitable	O
carrier	B-C1706209
candidates	I-C1706209
for	O
nano-oncology	B-C0278627
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	B-C0304497
potential	I-C0304497
overcoming	B-C0243095
multidrug-resistant	B-C0282588
cancer	I-C0282588
cells	I-C0282588
.	O
	
epigenetic	B-C4277689
editing	I-C4277689
of	O
ascl1	B-C1332009
gene	I-C1332009
in	O
neural	B-C1113654
stem	I-C1113654
cells	I-C1113654
by	O
optogenetics	B-C3494301
enzymes	B-C0014442
involved	O
in	O
epigenetic	B-C1516924
processes	I-C1516924
such	O
as	O
methyltransferases	B-C0025831
or	O
demethylases	B-C0014442
are	O
becoming	O
highly	B-C0205250
utilized	B-C0457083
for	O
their	O
persistent	B-C0012854
dna	I-C0012854
or	O
histone	B-C1156199
modifying	I-C1156199
efficacy	B-C1280519
.	O
	
herein	O
,	O
we	O
have	O
developed	O
an	O
optogenetic	B-C3494301
toolbox	B-C0282574
fused	O
to	O
the	O
catalytic	B-C0600499
domain	I-C0600499
cd	B-C0600499
of	O
dna-methyltransferase3a	B-C2348048
dnmt3a	B-C2348048
-	O
cd	B-C0600499
or	O
ten-eleven	B-C2987138
dioxygenase-1	I-C2987138
tet1	B-C2987138
-	O
cd	B-C0600499
for	O
loci	B-C1708726
-	O
specific	B-C0205369
alteration	B-C0026882
of	O
the	O
methylation	B-C0376452
state	B-C1442792
at	O
the	O
promoter	B-C0086860
of	O
ascl1	B-C1332009
mash1	B-C1332009
,	O
a	O
candidate	B-C0017337
proneuron	I-C0017337
gene	I-C0017337
.	O
	
optogenetical	B-C0033684
protein	I-C0033684
pairs	I-C0033684
,	O
cry2	B-C3813555
linked	O
to	O
dnmt3a	B-C2348048
-	O
cd	B-C0600499
or	O
tet1	B-C2987138
-	O
cd	B-C0600499
and	O
cib1	B-C1447592
fused	B-C0699952
to	O
a	O
transcription	B-C0033684
activator-like	I-C0033684
element	I-C0033684
tale	B-C0033684
locating	O
an	O
ascl1	B-C1332009
promoter	B-C0033413
region	I-C0033413
,	O
were	O
designed	O
for	O
site	B-C0449604
specific	I-C0449604
epigenetic	B-C4277689
editing	I-C4277689
.	O
	
a	O
differentially	B-C0443199
methylated	B-C1254362
region	I-C1254362
at	O
the	O
ascl1	B-C1332009
promoter	B-C0086860
,	O
isolated	B-C0205409
from	O
murine	B-C0035804
dorsal	B-C0017070
root	I-C0017070
ganglion	I-C0017070
hypermethylated	B-C0376452
and	O
striated	B-C0205364
cells	B-C0007634
hypomethylated	B-C0376452
,	O
was	O
targeted	B-C1521840
with	O
these	O
optogenetic-epigenetic	B-C0033684
constructs	I-C0033684
.	O
	
optimized	O
blue-light	B-C0303896
illumination	B-C0684292
triggered	B-C1444748
the	O
co-localization	B-C1254366
of	O
tale	B-C0033684
constructs	I-C0033684
with	O
dnmt3a	B-C2348048
-	O
cd	B-C0600499
or	O
tet1	B-C2987138
-	O
cd	B-C0600499
fusion	B-C0162768
proteins	I-C0162768
at	O
the	O
targeted	B-C1254362
site	I-C1254362
of	O
the	O
ascl1	B-C1332009
promoter	B-C0086860
.	O
	
we	O
found	O
that	O
this	O
spatiotemporal	B-C0205556
association	O
of	O
the	O
fusion	B-C0162768
proteins	I-C0162768
selectively	O
alters	B-C0392747
the	O
methylation	B-C0376452
state	B-C1442792
and	O
also	O
regulates	B-C0017263
gene	B-C0017255
activity	I-C0017255
.	O
	
this	O
proof	O
of	O
concept	B-C0178566
developed	O
herein	O
holds	O
immense	B-C1704243
promise	B-C1555307
for	O
the	O
ability	O
to	O
regulate	B-C1148560
gene	B-C0017255
activity	I-C0017255
via	O
epigenetic	B-C4277689
modulation	I-C4277689
with	O
spatiotemporal	B-C0205556
precision	B-C1706245
.	O
	
vaginal	B-C0404521
infections	I-C0404521
of	O
albanian	B-C0001909
women	B-C0043210
infected	B-C3714514
with	O
hpv	B-C0021344
and	O
their	O
impact	O
in	O
intraepithelial	B-C0206708
cervical	I-C0206708
lesions	I-C0206708
evidenced	O
by	O
pap	B-C3516630
test	I-C3516630
cervical	B-C0856201
cytology	I-C0856201
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-C1710031
of	O
the	O
population	O
in	O
identifying	O
precancerous	B-C0940937
lesions	I-C0940937
of	O
the	O
uterine	B-C0007874
cervix	I-C0007874
.	O
	
to	O
estimate	O
the	O
frequency	O
of	O
human	B-C4288937
papillomavirus	I-C4288937
hpv	I-C4288937
positivity	I-C4288937
in	O
a	O
group	O
of	O
albanian	B-C0001909
women	B-C0043210
,	O
the	O
prevalence	B-C0220900
of	O
vaginal	B-C0404521
coinfections	I-C0404521
,	O
and	O
the	O
relationship	O
of	O
coinfections	B-C0275524
with	O
hpv	B-C0021344
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	B-C0025568
or	O
cervical	B-C0206708
intraepithelial	I-C0206708
lesions	I-C0206708
cin	B-C0206708
.	O
	
in	O
this	O
retrospective	B-C0035363
study	I-C0035363
,	O
2075	O
vaginal	B-C0079104
smears	I-C0079104
were	O
examined	O
.	O
	
the	O
papanicolaou	B-C3888892
stain	I-C3888892
was	O
used	O
for	O
all	O
slides	O
.	O
	
the	O
new	B-C2121268
bethesda	I-C2121268
system	I-C2121268
2001	O
was	O
used	O
for	O
the	O
interpretations	B-C3526121
of	I-C3526121
the	I-C3526121
smears	I-C3526121
.	O
	
data	O
analysis	O
was	O
completed	O
using	O
the	O
statistical	B-C0010998
package	I-C0010998
for	I-C0010998
the	I-C0010998
social	I-C0010998
sciences	I-C0010998
version	I-C0010998
19.0	O
.	O
	
prevalence	B-C0220900
of	O
hpv	B-C4288937
positivity	I-C4288937
was	O
43.9	O
with	O
an	O
average	O
age	O
of	O
35.48	O
9.27	O
years	O
.	O
	
candida	B-C0006840
coinfection	I-C0006840
resulted	O
in	O
57.8	O
of	O
hpv	B-C4288937
positive	I-C4288937
women	B-C0043210
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O
	
gardnerella	B-C1622505
coinfection	I-C1622505
resulted	O
in	O
36	O
23%	O
,	O
mixed	B-C1400606
flora	I-C1400606
in	O
34	O
8%	O
,	O
and	O
trichomonas	B-C0040923
vaginalis	I-C0040923
in	O
50%	O
of	O
hpv	B-C4288937
positive	I-C4288937
woman	B-C0043210
.	O
	
among	O
the	O
women	B-C0043210
with	O
positive	B-C4288937
hpv	I-C4288937
,	O
19%	O
had	O
cin	B-C0206708
,	O
8%	O
had	O
metaplasia	B-C0025568
,	O
and	O
1%	O
had	O
metaplasia	B-C0025568
and	O
cin	B-C0206708
9%	O
of	O
the	O
women	B-C0043210
with	O
hpv	B-C0021344
had	O
cin1	B-C0349458
and	O
one	O
of	O
the	O
coinfections	B-C0275524
.	O
	
there	O
is	O
a	O
strong	O
relationship	O
between	O
cin1	B-C0349458
and	O
hpv	B-C4288937
positivity	I-C4288937
as	O
well	O
as	O
between	O
cin1	B-C0349458
and	O
coinfections	B-C0275524
.	O
	
hpv	B-C0343641
infection	I-C0343641
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	B-C0025568
,	O
and	O
bacterial	B-C0004623
coinfections	I-C0004623
in	O
hpv	B-C4288937
positive	I-C4288937
women	B-C0043210
have	O
a	O
statistically	B-C0237881
significant	I-C0237881
impact	O
in	O
the	O
development	O
of	O
a	O
case	O
of	O
acute	B-C0205178
hepatitis	B-C2063407
e	I-C2063407
infection	I-C2063407
in	O
a	O
patient	B-C0030705
with	O
non-hodgkin	B-C0024305
lymphoma	I-C0024305
treated	B-C0332293
successfully	O
with	O
ribavirin	B-C0035525
we	O
present	O
the	O
case	O
of	O
a	O
man	B-C0025266
who	O
,	O
following	O
immunosuppressive	B-C0021079
treatment	I-C0021079
for	O
non-hodgkin	B-C0024305
lymphoma	I-C0024305
,	O
became	O
infected	B-C0439663
with	O
viral	B-C0085293
hepatitis	I-C0085293
e	I-C0085293
.	O
	
acute	B-C0205178
hepatitis	B-C2063407
e	I-C2063407
virus	I-C2063407
infection	I-C2063407
should	O
be	O
considered	O
in	O
patients	B-C0030705
with	O
deranged	B-C0205556
liver	B-C0232741
function	I-C0232741
on	O
a	O
background	O
of	O
haematological	B-C0376545
malignancies	I-C0376545
or	O
immunosuppression	B-C4048329
,	O
even	O
without	O
travel	O
to	O
endemic	B-C0017446
regions	I-C0017446
.	O
	
whilst	O
clearance	O
is	O
usually	O
spontaneous	O
in	O
immune	B-C0439662
-	O
competent	B-C0086035
individuals	B-C0237401
,	O
these	O
at-risk	B-C0684030
groups	I-C0684030
may	O
develop	O
a	O
more	O
complicated	O
and	O
protracted	B-C1864936
disease	I-C1864936
course	I-C1864936
.	O
	
thus	O
awareness	O
is	O
important	O
as	O
additional	O
treatment	B-C0087111
with	O
ribavirin	B-C0035525
or	O
pegylated	B-C0907160
interferon	I-C0907160
may	O
be	O
required	O
,	O
as	O
in	O
this	O
case	O
,	O
in	O
order	O
to	O
help	O
achieve	O
commissioning	B-C0027363
through	O
competition	B-C0679932
and	O
cooperation	B-C0392337
in	O
the	O
english	B-C1556083
nhs	B-C0027462
under	O
the	O
health	B-C1254363
and	I-C1254363
social	I-C1254363
care	I-C1254363
act	I-C1254363
2012	I-C1254363
evidence	O
from	O
a	O
qualitative	B-C0949415
study	I-C0949415
of	O
four	O
clinical	B-C0027363
commissioning	I-C0027363
groups	I-C0027363
the	O
health	B-C1254363
and	I-C1254363
social	I-C1254363
care	I-C1254363
act	I-C1254363
2012	I-C1254363
'	O
hsca	B-C1254363
2012	I-C1254363
'	O
introduced	O
a	O
new	O
,	O
statutory	O
,	O
form	O
of	O
regulation	B-C0851285
of	O
competition	B-C0679932
into	O
the	O
national	B-C0027462
health	I-C0027462
service	I-C0027462
nhs	B-C0027462
,	O
while	O
at	O
the	O
same	O
time	O
recognising	O
that	O
cooperation	B-C0392337
was	O
necessary	O
.	O
	
nhs	B-C0027462
england's	B-C0282574
policy	I-C0282574
document	I-C0282574
,	O
the	O
five	B-C0282574
year	I-C0282574
forward	I-C0282574
view	I-C0282574
'	O
5yfv	B-C0282574
'	O
of	O
2014	O
placed	O
less	O
emphasis	O
on	O
competition	B-C0679932
without	O
altering	O
the	O
legislation	B-C0600657
.	O
	
we	O
explored	O
how	O
commissioners	B-C0949415
and	O
providers	B-C1138603
understand	O
the	O
complex	B-C0439855
regulatory	B-C0220905
framework	I-C0220905
,	O
and	O
how	O
they	O
behave	O
in	O
relation	O
to	O
competition	B-C0679932
and	O
cooperation	B-C0392337
.	O
	
we	O
carried	O
out	O
detailed	O
case	B-C0085973
studies	I-C0085973
in	O
four	O
clinical	B-C0027363
commissioning	I-C0027363
groups	I-C0027363
,	O
using	O
interviews	B-C0021822
and	O
documentary	B-C0936012
analysis	I-C0936012
to	O
explore	O
the	O
commissioners	B-C0949415
'	O
and	O
providers	B-C1138603
'	O
understanding	O
and	O
experience	O
of	O
competition	B-C0679932
and	O
cooperation	B-C0392337
.	O
	
we	O
conducted	O
42	O
interviews	B-C0021822
with	O
senior	B-C0335141
managers	I-C0335141
in	O
commissioning	B-C0027363
organisations	B-C0033282
and	O
senior	B-C0335141
managers	I-C0335141
in	O
nhs	B-C0027462
and	O
independent	B-C1273814
provider	I-C1273814
organisations	I-C1273814
acute	B-C0009482
and	I-C0009482
community	I-C0009482
services	I-C0009482
.	O
	
neither	O
commissioners	B-C0949415
nor	O
providers	B-C1138603
fully	O
understand	O
the	O
regulatory	B-C0220905
regime	I-C0220905
in	O
respect	O
of	O
competition	B-C0679932
in	O
the	O
nhs	B-C0027462
,	O
and	O
have	O
not	O
found	O
that	O
the	O
regulatory	B-C0220905
authorities	I-C0220905
have	O
provided	O
adequate	O
guidance	B-C0237645
.	O
	
despite	O
the	O
hsca	B-C1254363
2012	I-C1254363
promoting	B-C0033414
competition	B-C0679932
,	O
commissioners	B-C0949415
chose	O
mainly	O
to	O
use	O
collaborative	B-C0681804
strategies	I-C0681804
to	O
effect	O
major	O
service	B-C0557854
reconfigurations	O
,	O
which	O
is	O
endorsed	O
as	O
a	O
suitable	O
approach	O
by	O
providers	B-C1138603
.	O
	
nevertheless	O
,	O
commissioners	B-C0949415
are	O
using	O
competitive	B-C0679932
tendering	O
in	O
respect	O
of	O
more	O
peripheral	B-C0557854
services	I-C0557854
in	O
order	O
to	O
improve	O
quality	B-C0034379
of	I-C0034379
care	I-C0034379
and	O
value	B-C1548312
for	I-C1548312
money	I-C1548312
.	O
	
commissioners	B-C0949415
regard	O
the	O
use	O
of	O
competition	B-C0679932
and	O
cooperation	B-C0392337
as	O
appropriate	O
in	O
the	O
nhs	B-C0027462
currently	O
,	O
although	O
collaborative	B-C0681804
strategies	I-C0681804
appear	O
more	O
helpful	O
in	O
respect	O
of	O
large-scale	B-C0814860
changes	I-C0814860
.	O
	
however	O
,	O
the	O
current	O
regulatory	B-C0220905
framework	I-C0220905
contained	O
in	O
the	O
hsca	B-C1254363
2012	I-C1254363
,	O
particularly	O
since	O
the	O
publication	B-C0034036
of	O
the	O
5yfv	B-C0282574
,	O
is	O
not	O
clear	O
.	O
	
better	O
guidance	B-C0237645
should	O
be	O
issued	O
by	O
the	O
regulatory	B-C0220905
authorities	I-C0220905
.	O
	
prevalence	B-C0033105
and	O
correlates	B-C1707520
of	O
antibiotic	B-C0003232
sharing	B-C0237876
in	O
the	O
philippines	B-C0031529
antibiotic	B-C0003232
misconceptions	B-C2717766
and	O
community	B-C0009462
-	O
level	B-C0441889
access	O
to	O
non-medical	B-C0598464
sources	B-C0449416
of	O
antibiotics	B-C0003232
to	O
identify	O
sociodemographic	B-C0011292
,	O
knowledge	B-C0376554
and	O
attitudinal	B-C0004271
correlates	B-C1707520
to	O
antibiotic	B-C0003232
sharing	B-C0237876
among	O
a	O
community-based	B-C1709598
sample	I-C1709598
of	O
adults	B-C0001675
age	O
18	O
and	O
older	O
in	O
a	O
low-income	B-C1331016
setting	I-C1331016
of	O
the	O
philippines	B-C0031529
and	O
to	O
explore	O
community	B-C0009462
-	O
level	B-C0441889
data	B-C1511726
on	O
informal	B-C0243095
antibiotic	B-C0003232
distribution	B-C0024826
in	O
roadside	B-C1254362
stands	I-C1254362
i.e	O
,	O
sari-sari	B-C1254362
stands	I-C1254362
.	O
	
participants	B-C0679646
n	O
=	O
307	O
completed	B-C0205197
self-administered	B-C1519231
surveys	B-C0038951
.	O
	
correlates	B-C1707520
to	O
antibiotic	B-C0003232
sharing	B-C0237876
were	O
assessed	B-C1516048
using	O
logistic	B-C0206031
regression	I-C0206031
with	O
firth's	B-C0282574
bias-adjusted	I-C0282574
estimate	I-C0282574
s	O
.	O
	
study	O
staff	B-C0851286
also	O
visited	O
106	O
roadside	B-C1254362
stands	I-C1254362
and	O
collected	B-C4019276
data	I-C4019276
on	O
availability	B-C0470187
and	O
characteristics	O
of	O
antibiotics	B-C0003232
in	O
the	O
stands	B-C1254362
.	O
	
78%	O
had	O
shared	B-C0237876
antibiotics	B-C0003232
in	O
their	O
lifetime	B-C4071830
,	O
most	O
often	B-C0332183
with	O
family	B-C0086282
members	I-C0086282
.	O
	
in	O
multivariable	B-C0026777
analysis	I-C0026777
,	O
agreement	B-C0680240
with	O
the	O
belief	B-C0004951
that	O
it	O
is	O
safe	O
to	O
prematurely	B-C1254367
stop	B-C1947925
an	O
antibiotic	B-C0003232
course	B-C0750729
or	B-C0028873
2.8	O
,	O
ci	O
1.3	O
and	O
concerns	B-C2699424
about	O
antibiotic	B-C0850107
side	I-C0850107
effects	I-C0850107
or	B-C0028873
2.1	O
,	O
ci	O
1.1	O
were	O
significantly	O
associated	B-C0332281
with	I-C0332281
increased	B-C0205217
odds	O
of	O
reported	O
antibiotic	B-C0003232
sharing	B-C0237876
.	O
	
antibiotic	B-C0003232
sharing	B-C0237876
was	O
not	O
associated	B-C0332281
with	I-C0332281
sociodemographic	B-C0683970
characteristics	I-C0683970
or	O
antibiotic	B-C0003232
knowledge	B-C0376554
.	O
	
antibiotics	B-C0003232
were	O
widely	O
available	B-C0470187
in	O
60%	O
of	O
sampled	O
sari-sari	B-C1254362
stands	I-C1254362
,	O
in	O
which	O
59%	O
of	O
antibiotics	B-C0003232
were	O
missing	B-C2609381
expiration	I-C2609381
dates	I-C2609381
.	O
	
amoxicillin	B-C0002645
and	O
cephalexin	B-C0007716
were	O
the	O
most	O
commonly	B-C0205214
available	B-C0470187
antibiotics	B-C0003232
for	O
sale	O
at	O
the	O
stands	B-C1254362
60%	O
and	O
21%	O
,	O
respectively	O
.	O
	
antibiotic	B-C0003232
sharing	B-C0237876
was	O
common	B-C0205214
and	O
was	O
associated	B-C0332281
with	I-C0332281
misconceptions	B-C2717766
about	O
proper	O
antibiotic	B-C0003232
use	O
.	O
	
antibiotics	B-C0003232
were	O
widely	O
available	B-C0470187
in	O
sari-sari	B-C1254362
stands	I-C1254362
,	O
and	O
usually	O
without	B-C0332288
expiration	B-C3669020
information	I-C3669020
.	O
	
this	O
study	O
suggests	O
that	O
multipronged	O
and	O
locally	O
tailored	O
approaches	O
to	O
curbing	B-C2587213
informal	B-C0243095
antibiotic	B-C0003232
access	O
are	O
needed	O
in	O
the	O
philippines	B-C0031529
and	O
similar	O
southeast-asian	B-C0454709
countries	I-C0454709
.	O
	
automated	B-C0205554
characterization	B-C1880022
and	O
counting	B-C0750480
of	O
ki-67	B-C0033684
protein	I-C0033684
for	O
breast	B-C0006142
cancer	I-C0006142
prognosis	B-C0033325
a	O
quantitative	B-C0392762
immunohistochemistry	B-C0021044
approach	B-C0449445
ki-67	B-C0033684
protein	I-C0033684
expression	B-C1171362
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative	B-C1514489
status	I-C1514489
of	O
tumour	B-C0431085
cell	I-C0431085
s	O
and	O
deciding	O
the	O
future	B-C0016884
course	B-C0750729
of	O
therapy	B-C0087111
in	O
breast	B-C0006142
cancer	I-C0006142
.	O
	
immunohistochemical	B-C0021044
ihc	I-C0021044
determination	I-C0021044
of	O
ki-67	B-C4049944
score	I-C4049944
or	O
labelling	B-C0022885
index	I-C0022885
,	O
by	O
estimating	O
the	O
fraction	B-C1264633
of	I-C1264633
ki67	B-C0033684
positively	B-C1446409
stained	B-C2986582
tumour	B-C0431085
cells	I-C0431085
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-C0430022
to	O
assess	B-C0184514
tumour	B-C0027651
proliferation	B-C1514485
dowsett	O
et	O
al	O
.	O
	
2011	O
.	O
	
accurate	B-C0443131
manual	B-C1441639
counting	I-C1441639
of	O
these	O
cells	B-C0007634
specifically	B-C0205369
nuclei	B-C0007610
due	O
to	O
complex	B-C0439855
and	O
dense	B-C0439794
distribution	B-C1704711
of	O
cells	B-C0007634
,	O
therefore	O
,	O
becomes	O
critical	B-C1511545
and	O
presents	B-C0449450
a	O
major	B-C0205164
challenge	O
to	O
pathologists	B-C0334866
.	O
	
in	O
this	O
paper	O
,	O
we	O
suggest	O
a	O
hybrid	B-C0002045
clustering	I-C0002045
algorithm	I-C0002045
to	O
quantify	B-C1709793
the	O
proliferative	B-C1514489
index	I-C1514489
of	O
breast	B-C1512505
cancer	I-C1512505
cells	I-C1512505
based	O
on	O
automated	B-C1441489
counting	I-C1441489
of	O
ki-67	B-C0033684
nuclei	B-C0007610
.	O
	
the	O
proposed	O
methodology	B-C0430022
initially	B-C0205265
pre-processes	B-C1522240
the	O
ihc	B-C0021044
images	B-C1704254
of	O
ki-67	B-C0033684
stained	B-C2986582
slides	B-C0444330
of	O
breast	B-C0006142
cancer	I-C0006142
.	O
	
the	O
rgb	O
images	O
are	O
converted	O
to	O
grey	B-C1269776
,	O
l*a*b*	O
,	O
hsi	O
,	O
ycbcr	O
,	O
yiq	O
and	O
xyz	O
colour	B-C0876936
space	I-C0876936
.	O
	
all	O
the	O
stained	B-C2986582
cells	B-C0007634
are	O
then	O
characterized	B-C1880022
by	O
two	B-C0200768
stage	I-C0200768
segmentation	I-C0200768
process	I-C0200768
.	O
	
fuzzy	B-C0002045
c-means	I-C0002045
quantifies	B-C1709793
all	O
the	O
stained	B-C2986582
cells	B-C0007634
as	O
one	O
cluster	B-C1704332
.	O
	
the	O
blue	B-C1260957
channel	B-C1706095
of	O
the	O
first	B-C0441766
stage	I-C0441766
output	B-C1709366
is	O
given	O
as	O
input	O
to	O
k-means	B-C0009085
algorithm	I-C0009085
,	O
which	O
provides	O
separate	B-C0443299
cluster	B-C1704332
for	O
ki-67	B-C0033684
positive	B-C3842923
and	I-C3842923
negative	I-C3842923
cells	B-C0007634
.	O
	
the	O
count	B-C0750480
of	O
positive	B-C3842923
and	I-C3842923
negative	I-C3842923
nuclei	B-C0007610
is	O
used	O
to	O
calculate	B-C1443182
the	O
f-measure	B-C0079809
for	O
each	O
colour	B-C0876936
space	I-C0876936
.	O
	
a	O
comparative	B-C1579762
study	I-C1579762
of	O
our	O
work	O
with	O
the	O
expert	B-C0600219
opinion	I-C0600219
is	O
studied	O
to	O
evaluate	O
the	O
error	B-C0743559
rate	B-C1521828
.	O
	
the	O
positive	B-C3842923
and	I-C3842923
negative	I-C3842923
nuclei	B-C0007610
detection	B-C0442726
results	B-C1274040
for	O
all	O
colour	B-C0876936
space	I-C0876936
s	O
are	O
compared	B-C1707455
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
f-measure	B-C0079809
is	O
calculated	B-C1443182
.	O
	
the	O
f-measure	B-C0079809
for	O
l*a*b*	O
colour	B-C0876936
space	I-C0876936
0.8847	O
provides	O
the	O
best	O
statistical	B-C2828391
result	B-C1274040
as	O
compared	B-C1707455
to	O
grey	B-C1269776
,	O
hsi	O
,	O
ycbcr	O
,	O
yiq	O
and	O
xyz	O
colour	B-C0876936
space	I-C0876936
.	O
	
further	O
,	O
a	O
study	B-C2603343
is	O
carried	O
out	O
to	O
count	B-C0750480
nuclei	B-C0007610
manually	B-C1441639
and	O
automatically	B-C1441489
from	O
the	O
proposed	O
algorithm	B-C0002045
with	O
an	O
average	B-C1510992
error	B-C0743559
rate	B-C1521828
of	O
6.84	O
which	O
is	O
significant	B-C0750502
.	O
	
the	O
study	B-C2603343
provides	O
an	O
automated	B-C0205554
count	B-C0750480
of	O
positive	B-C3842923
and	I-C3842923
negative	I-C3842923
nuclei	B-C0007610
using	O
l*a*b*	O
colour	B-C0876936
space	I-C0876936
and	O
hybrid	B-C2697664
segmentation	I-C2697664
technique	I-C2697664
.	O
	
computerized	B-C1441489
evaluation	I-C1441489
of	O
proliferation	B-C1514489
index	I-C1514489
can	O
aid	O
pathologist	B-C0334866
in	O
assessing	O
breast	B-C0006142
cancer	I-C0006142
severity	B-C0439793
.	O
	
the	O
proposed	O
methodology	B-C0430022
,	O
further	O
,	O
has	O
the	O
potential	B-C3245505
advantage	O
of	O
saving	O
time	O
and	O
assisting	B-C0557034
in	O
decision	O
making	O
over	O
the	O
present	O
manual	B-C1441639
procedure	I-C1441639
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	B-C1521733
decision	B-C0023678
support	I-C0023678
system	I-C0023678
.	O
	
multitarget	B-C1521840
sensing	B-C0337438
of	I-C0337438
glucose	I-C0337438
and	O
cholesterol	B-C0201950
based	O
on	O
janus	B-C0063083
hydrogel	I-C0063083
microparticles	I-C0063083
a	O
visualized	B-C0234621
sensing	B-C0337438
method	I-C0337438
for	I-C0337438
glucose	I-C0337438
and	O
cholesterol	B-C0201950
was	O
developed	O
based	O
on	O
the	O
hemispheres	O
of	O
the	O
same	O
janus	B-C0063083
hydrogel	I-C0063083
microparticles	I-C0063083
.	O
	
single-phase	O
and	O
janus	B-C0063083
hydrogel	I-C0063083
microparticles	I-C0063083
were	O
both	O
generated	O
using	O
a	O
centrifugal	B-C1301962
microfluidic	B-C1449582
chip	I-C1449582
.	O
	
for	O
glucose	B-C0337438
sensing	I-C0337438
,	O
concanavalin	B-C0009630
a	I-C0009630
and	O
fluorescein	B-C0060538
labeled	I-C0060538
dextran	I-C0060538
used	O
for	O
competitive	B-C0005507
binding	I-C0005507
assay	I-C0005507
were	O
encapsulated	B-C0205223
in	O
alginate	B-C0002040
microparticles	B-C0597177
,	O
and	O
the	O
fluorescence	B-C0016315
of	O
the	O
microparticles	B-C0597177
was	O
positively	B-C1446409
correlated	B-C1707520
with	O
glucose	B-C0017725
concentration	B-C1446561
.	O
	
for	O
cholesterol	B-C0201950
sensing	I-C0201950
,	O
the	O
microparticles	B-C0597177
embedded	O
with	O
γ-fe2o3	B-C3652446
nanoparticles	I-C3652446
were	O
used	O
as	O
catalyst	B-C0175921
for	O
the	O
oxidation	B-C0030011
of	O
3	B-C0046880
by	O
h2o2	B-C0020281
,	O
an	O
enzymatic	B-C0014442
hydrolysis	B-C0020291
product	B-C1514468
of	O
cholesterol	B-C0008377
.	O
	
and	O
the	O
color	B-C0009393
transition	B-C2700061
was	O
more	O
sensitive	B-C0332324
in	O
the	O
microparticles	B-C0597177
than	O
in	O
solutions	B-C0037633
,	O
indicating	O
the	O
microparticles	B-C0597177
are	O
more	O
applicable	B-C1706839
for	O
visualized	B-C0234621
determination	B-C1148554
.	O
	
furthermore	O
,	O
janus	B-C0597177
microparticles	I-C0597177
were	O
employed	B-C0557351
for	O
multitarget	B-C1521840
sensing	B-C0205396
in	O
the	O
two	O
hemespheres	O
,	O
and	O
glucose	B-C0017725
and	O
cholesterol	B-C0008377
were	O
detected	B-C0442726
within	O
the	O
same	O
microparticles	B-C0597177
without	O
obvious	O
interference	B-C0521102
.	O
	
besides	O
,	O
the	O
particles	B-C0597177
could	O
be	O
manipulated	O
by	O
an	O
external	B-C0205101
magnetic	B-C0563533
field	I-C0563533
.	O
	
the	O
glucose	B-C0428548
and	O
cholesterol	B-C0428466
levels	I-C0428466
were	O
measured	B-C0444706
in	O
human	B-C0086418
serum	B-C0229671
utilizing	O
the	O
microparticles	B-C0597177
,	O
which	O
confirmed	B-C0750484
the	O
potential	B-C3245505
application	O
of	O
the	O
microparticles	B-C0597177
in	O
real	O
sample	B-C0370003
detection	B-C1511790
.	O
	
pi3k	B-C0044602
/	O
akt	B-C0164786
pathway	B-C0037080
a	O
potential	O
therapeutic	B-C0302350
target	B-C1521840
for	O
chronic	B-C0150055
pain	I-C0150055
chronic	B-C0150055
pain	I-C0150055
is	O
among	O
the	O
most	O
disabling	B-C0596452
and	O
costly	O
disorders	B-C0012634
,	O
with	O
prevalence	B-C0683921
ranging	B-C1514721
from	O
10%	O
to	O
55%	O
.	O
	
however	O
,	O
current	O
therapeutic	B-C0302350
strategies	O
for	O
chronic	B-C0150055
pain	I-C0150055
are	O
unsatisfactory	B-C0439856
due	O
to	O
our	O
poor	B-C0542537
understanding	B-C0162340
of	O
its	O
mechanisms	B-C0441712
.	O
	
thus	O
,	O
novel	O
therapeutic	B-C0302350
targets	B-C1521840
need	O
to	O
be	O
found	O
in	O
order	O
to	O
improve	B-C0184511
these	O
patients'	B-C0030705
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
pi3k	B-C0044602
and	O
its	O
downstream	B-C0522506
akt	B-C0164786
are	O
widely	O
expressed	B-C1171362
in	O
the	O
spinal	B-C0037925
cord	I-C0037925
,	O
particularly	O
in	O
the	O
laminae	B-C2340386
i-iv	I-C2340386
of	O
the	O
dorsal	B-C0228575
horn	I-C0228575
,	O
where	O
nociceptive	B-C0501409
c	I-C0501409
and	O
aδ	B-C0027750
fibers	I-C0027750
of	O
primary	B-C0205225
afferents	B-C0206309
principally	O
terminate	B-C2746065
.	O
	
recent	O
studies	B-C0008972
have	O
demonstrated	O
their	O
critical	B-C1511545
roles	B-C1705810
in	O
the	O
development	B-C1527148
and	O
maintenance	B-C0024501
of	O
chronic	B-C0150055
pain	I-C0150055
.	O
	
in	O
this	O
review	B-C0282443
,	O
we	O
summarized	O
the	O
roles	B-C1705810
and	O
mechanisms	B-C0441712
of	O
pi3k	B-C0044602
/	O
akt	B-C0164786
pathway	B-C0037080
in	O
the	O
progression	B-C0242656
of	O
chronic	B-C0150055
pain	I-C0150055
through	O
sciatic	B-C0161467
nerve	I-C0161467
injury	I-C0161467
,	O
diabetic	B-C0011882
neuropathy	I-C0011882
,	O
spinal	B-C0037929
cord	I-C0037929
injury	I-C0037929
,	O
bone	B-C0279530
cancer	I-C0279530
,	O
opioid	B-C0240601
tolerance	I-C0240601
,	O
or	O
opioid	B-C0242402
-	O
induced	B-C0205263
hyperalgesia	B-C0020429
.	O
	
no	O
free	B-C0004916
bed	I-C0004916
with	O
ventilator	B-C0087153
experience	O
of	O
a	O
public	B-C0334894
health	I-C0334894
specialist	I-C0334894
while	O
the	O
author	B-C3812881
was	O
dealing	O
with	O
a	O
poor	B-C0032854
elderly	B-C0015671
father	I-C0015671
struggling	O
to	O
shift	O
his	O
gravely	B-C0332664
injured	I-C0332664
young	B-C0332239
son	B-C0037683
to	O
a	O
government	B-C0337960
hospital	I-C0337960
due	O
to	O
the	O
high	O
cost	O
of	O
intensive	B-C0085559
care	I-C0085559
,	O
her	O
friends	B-C0079382
across	O
the	O
globe	B-C1254362
were	O
discussing	O
euthanasia	B-C0015187
in	O
the	O
social	B-C3179065
media	I-C3179065
.	O
	
while	O
marginalised	B-C3494319
groups	B-C1257890
of	I-C1257890
people	I-C1257890
are	O
struggling	O
to	O
access	B-C0015472
care	B-C1947933
in	O
india	B-C0021201
,	O
friends	B-C0079382
who	O
have	O
moved	O
to	O
developed	B-C0282613
parts	I-C0282613
of	I-C0282613
the	I-C0282613
world	I-C0282613
were	O
discussing	O
one's	O
choice	B-C1707391
to	O
live	B-C1548795
or	O
die	B-C0011065
the	O
poor	B-C0032854
father	B-C0015671
,	O
after	O
battling	B-C1407863
to	O
save	B-C1254370
his	O
son	B-C0037683
and	O
reaching	O
out	O
to	O
many	O
people	B-C0027361
for	O
help	B-C1269765
,	O
could	O
not	O
save	B-C1254370
him	O
.	O
	
early	B-C0814494
treatment	I-C0814494
might	O
have	O
helped	B-C1269765
the	O
young	B-C0332239
boy	B-C0870221
.	O
	
the	O
incident	B-C1551358
left	O
the	O
author	B-C3812881
thinking	O
about	O
how	O
the	O
poor	B-C0032854
are	O
denied	B-C2700401
care	B-C1947933
simply	O
because	O
they	O
cannot	O
afford	O
it	O
.	O
	
others	O
debate	B-C0870392
when	O
to	O
pull	B-C1254370
the	I-C1254370
plug	I-C1254370
on	O
the	O
patient	B-C0030705
.	O
	
how	O
many	O
families	B-C0015576
can	O
afford	O
such	O
care	B-C1947933
in	O
india	B-C0021201
when	O
nearly	O
71%	O
of	O
the	O
people	B-C0027361
are	O
paying	B-C3815933
out	I-C3815933
of	I-C3815933
pocket	I-C3815933
for	O
healthcare	B-C0086388
and	O
16%	O
are	O
pushed	O
below	B-C0860094
the	I-C0860094
poverty	I-C0860094
line	I-C0860094
every	B-C0332181
year	I-C0332181
,	O
can	O
we	O
even	O
think	B-C0039869
of	O
universal	B-C0376640
health	I-C0376640
coverage	I-C0376640
it	O
just	O
sounds	O
like	O
a	O
fancy	O
term	O
to	O
be	O
used	O
at	O
conferences	O
and	O
meetings	O
because	O
the	O
ground	O
reality	O
is	O
completely	O
different	I-C1705242
quantitative	B-C0392762
determination	B-C1148554
of	O
five	O
metabolites	B-C0870883
of	O
aspirin	B-C0004057
by	O
uhplc-ms	B-C4053724
/	O
ms	B-C0037813
coupled	B-C1948027
with	O
enzymatic	B-C1511131
reaction	I-C1511131
and	O
its	O
application	O
to	O
evaluate	O
the	O
effects	B-C1280500
of	O
aspirin	B-C0004057
dosage	B-C0178602
on	O
the	O
metabolic	B-C3853758
profile	I-C3853758
acetylsalicylic	B-C0004057
acid	I-C0004057
aspirin	B-C0004057
,	O
asa	B-C0004057
is	O
a	O
famous	O
drug	B-C0013227
for	O
cardiovascular	B-C0007222
diseases	I-C0007222
in	O
recent	O
years	B-C0439234
.	O
	
effects	O
of	O
asa	B-C0004057
dosage	B-C0178602
on	O
the	O
metabolic	B-C3853758
profile	I-C3853758
have	O
not	O
been	O
fully	O
understood	O
.	O
	
the	O
purpose	O
of	O
our	O
study	B-C2603343
is	O
to	O
establish	O
a	O
rapid	B-C0456962
and	O
reliable	B-C3858758
method	B-C0022885
to	O
quantify	B-C1709793
asa	B-C0004057
metabolites	B-C0870883
in	O
biological	B-C1706515
matrices	I-C1706515
,	O
especially	O
for	O
glucuronide	B-C0812407
metabolites	B-C0870883
whose	O
standards	O
are	O
not	O
commercially	O
available	O
.	O
	
then	O
we	O
applied	O
this	O
method	B-C0022885
to	O
evaluate	O
the	O
effects	O
of	O
asa	B-C0004057
dosage	B-C0178602
on	O
the	O
metabolic	B-C3853758
and	O
excretion	B-C0221102
profile	B-C0237801
of	O
asa	B-C0004057
metabolites	B-C0870883
in	O
rat	B-C0034721
urine	B-C0042036
.	O
	
salicylic	B-C0036079
acid	I-C0036079
sa	B-C0036079
,	O
gentisic	B-C0045555
acid	I-C0045555
ga	B-C0045555
and	O
salicyluric	B-C0073984
acid	I-C0073984
sua	B-C0073984
were	O
determined	O
directly	O
by	O
uhplc-ms	B-C4053724
/	O
ms	B-C0037813
,	O
while	O
salicyl	B-C0044622
phenolic	I-C0044622
glucuronide	I-C0044622
sapg	B-C0044622
and	O
salicyluric	B-C0752086
acid	I-C0752086
phenolic	I-C0752086
glucuronide	I-C0752086
suapg	B-C0752086
were	O
quantified	B-C1709793
indirectly	O
by	O
measuring	O
the	O
released	O
sa	B-C0036079
and	O
sua	B-C0073984
from	O
sapg	B-C0044622
and	O
suapg	B-C0752086
after	O
β-glucuronidase	B-C0017776
digestion	B-C0012238
.	O
	
sua	B-C0073984
and	O
suapg	B-C0752086
were	O
the	O
major	O
metabolites	B-C0870883
of	O
asa	B-C0004057
in	O
rat	B-C0034721
urine	B-C0042036
24	O
h	B-C0439227
after	O
asa	B-C0004057
administration	B-C0001555
,	O
which	O
accounted	O
for	O
50%	O
sua	B-C0073984
and	O
26%	O
suapg	B-C0752086
.	O
	
when	O
asa	B-C0004057
dosage	B-C0178602
was	O
increased	B-C0205217
,	O
the	O
contributions	O
dropped	O
to	O
32%	O
and	O
18%	O
,	O
respectively	O
.	O
	
the	O
excretion	B-C0221102
of	O
other	O
three	O
metabolites	B-C0870883
ga	B-C0045555
,	O
sa	B-C0036079
and	O
sapg	B-C0044622
however	O
showed	O
remarkable	O
increases	O
by	O
16%	O
,	O
6%	O
and	O
4%	O
,	O
respectively	O
.	O
	
in	O
addition	O
,	O
sua	B-C0073984
and	O
suapg	B-C0752086
were	O
mainly	O
excreted	B-C0221102
in	O
the	O
time	B-C1948053
period	I-C1948053
of	O
12-24	O
h	B-C0439227
,	O
while	O
ga	B-C0045555
was	O
excreted	B-C0221102
in	O
the	O
earlier	O
time	B-C1948053
periods	I-C1948053
0-4	O
h	B-C0439227
and	O
4-8	O
h	B-C0439227
.	O
	
sa	B-C0036079
was	O
mainly	O
excreted	B-C0221102
in	O
the	O
time	B-C1948053
period	I-C1948053
of	O
0-4	O
h	B-C0439227
and	O
12-24	O
h	B-C0439227
.	O
	
and	O
the	O
excretion	B-C0221102
of	O
sapg	B-C0044622
was	O
equally	O
distributed	O
in	O
the	O
four	O
time	B-C1948053
periods	I-C1948053
.	O
	
we	O
went	O
further	O
to	O
show	O
that	O
the	O
excretion	B-C0221102
of	O
five	O
metabolites	B-C0870883
in	O
rat	B-C0034721
urine	B-C0042036
was	O
delayed	O
when	O
asa	B-C0004057
dosage	B-C0178602
was	O
increased	B-C0205217
.	O
	
in	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
rapid	B-C0456962
and	O
sensitive	B-C0205342
method	B-C0022885
to	O
determine	O
the	O
five	O
asa	B-C0004057
metabolites	B-C0870883
sa	B-C0036079
,	O
ga	B-C0045555
,	O
sua	B-C0073984
,	O
sapg	B-C0044622
and	O
suapg	B-C0752086
in	O
rat	B-C0034721
urine	B-C0042036
.	O
	
we	O
showed	O
that	O
asa	B-C0004057
dosage	B-C0178602
could	O
significantly	O
influence	B-C4054723
the	O
metabolic	B-C3853758
and	O
excretion	B-C0221102
profile	B-C0237801
of	O
asa	B-C0004057
metabolites	B-C0870883
in	O
rat	B-C0034721
urine	B-C0042036
.	O
	
mismatch	B-C1155661
repair	I-C1155661
incompatibilities	B-C0679426
in	O
diverse	B-C1880371
yeast	B-C0036025
populations	B-C0017404
an	O
elevated	B-C3163633
mutation	B-C3178846
rate	I-C3178846
can	O
provide	O
cells	B-C0007634
with	O
a	O
source	B-C0449416
of	O
mutations	B-C0026882
to	O
adapt	O
to	O
changing	B-C0392747
environments	B-C0014406
.	O
	
we	O
identified	B-C0205396
a	O
negative	B-C0205160
epistatic	B-C0014589
interaction	I-C0014589
involving	B-C1314939
naturally	O
occurring	O
variants	B-C0205419
in	O
the	O
mlh1	B-C0879389
and	O
pms1	B-C0879390
mismatch	B-C1155661
repair	I-C1155661
mmr	B-C1155661
genes	B-C0017337
of	O
saccharomyces	B-C0036025
cerevisiae	I-C0036025
we	O
hypothesized	O
that	O
this	O
mmr	B-C1155661
incompatibility	B-C0679426
,	O
created	O
through	O
mating	B-C1260875
between	O
divergent	O
s	B-C0036025
.	O
	
cerevisiae	I-C0036025
,	O
yields	O
mutator	O
progeny	B-C0680063
that	O
can	O
rapidly	B-C0456962
but	O
transiently	O
adapt	O
to	O
an	O
environmental	B-C0871732
stress	I-C0871732
.	O
	
here	O
we	O
analyzed	B-C0936012
the	O
mlh1	B-C0879389
and	O
pms1	B-C0879390
genes	I-C0879390
across	O
1010	O
s	B-C0036025
.	O
	
cerevisiae	I-C0036025
natural	B-C0205296
isolates	B-C1764827
spanning	O
a	O
wide	O
range	B-C1514721
of	O
ecological	B-C0162358
sources	B-C0449416
tree	B-C0040811
exudates	B-C0015388
,	O
drosophila	B-C0013138
,	O
fruits	B-C0016767
,	O
and	O
various	O
fermentation	B-C0015852
and	O
clinical	B-C0205210
isolates	B-C1764827
and	O
geographical	B-C0565935
sources	B-C0449416
europe	B-C0015176
,	O
america	B-C0002454
,	O
africa	B-C0001737
,	O
and	O
asia	B-C0003980
.	O
	
we	O
identified	B-C0205396
one	O
homozygous	B-C0019904
clinical	B-C0205210
isolate	B-C1764827
and	O
18	O
heterozygous	B-C0019425
isolates	B-C1764827
containing	B-C0332256
the	O
incompatible	O
mmr	B-C1155661
genotype	B-C0017431
.	O
	
the	O
mlh1	B-C0879389
-	O
pms1	B-C0879390
gene	I-C0879390
combination	B-C0205195
isolated	B-C0205409
from	O
the	O
homozygous	B-C0019904
clinical	B-C0205210
isolate	B-C1764827
conferred	O
a	O
mutator	O
phenotype	B-C0031437
when	O
expressed	B-C0017262
in	O
the	O
s288c	O
laboratory	B-C0022877
background	B-C1706907
.	O
	
using	O
a	O
novel	O
reporter	B-C1522485
to	O
measure	B-C0079809
mutation	B-C3178846
rates	I-C3178846
,	O
we	O
showed	O
that	O
the	O
overall	B-C1561607
mutation	B-C3178846
rate	I-C3178846
in	O
the	O
homozygous	B-C0019904
incompatible	O
background	B-C1706907
was	O
similar	O
to	O
that	O
seen	O
in	O
compatible	B-C1524057
strains	B-C1518614
,	O
indicating	O
the	O
presence	O
of	O
suppressor	B-C0038859
mutations	I-C0038859
in	O
the	O
clinical	B-C0205210
isolate	B-C1764827
that	O
lowered	O
its	O
mutation	B-C3178846
rate	I-C3178846
.	O
	
this	O
observation	B-C0302523
and	O
the	O
identification	B-C0205396
of	O
18	O
heterozygous	B-C0019425
isolates	B-C1764827
,	O
which	O
can	O
lead	O
to	O
mmr	O
incompatible	O
genotypes	O
in	O
the	O
offspring	O
,	O
are	O
consistent	O
with	O
an	O
elevated	O
mutation	O
rate	O
rapidly	O
but	O
transiently	O
facilitating	O
adaptation	O
.	O
	
to	O
avoid	O
long-term	O
fitness	O
costs	O
,	O
the	O
incompatibility	O
is	O
apparently	O
buffered	O
by	O
mating	O
or	O
by	O
acquiring	O
suppressors	O
.	O
	
these	O
observations	O
highlight	O
effective	O
strategies	O
in	O
eukaryotes	O
to	O
avoid	O
long-term	O
fitness	O
costs	O
associated	O
with	O
elevated	O
mutation	O
rates	I-C3178846
mapping	B-C1283195
circulating	B-C0175630
serum	B-C0229671
mirnas	B-C1101610
to	O
their	O
immune	B-C0439662
-	O
related	B-C0332281
target	B-C1521840
mrnas	B-C0035696
evidence	B-C3887511
suggests	B-C1705535
that	O
circulating	B-C0175630
serum	B-C0229671
micrornas	B-C1101610
mirnas	B-C1101610
might	O
preferentially	O
target	B-C1521840
immune	B-C0439662
-	O
related	B-C0332281
mrnas	B-C0035696
.	O
	
if	O
this	O
were	O
the	O
case	O
,	O
we	O
hypothesized	O
that	O
immune	B-C0439662
-	O
related	B-C0332281
mrnas	B-C0035696
would	O
have	O
more	O
predicted	B-C0681842
serum	B-C0229671
mirna	B-C1523647
binding	I-C1523647
sites	B-C0205145
than	O
other	O
mrnas	B-C0035696
and	O
,	O
reciprocally	B-C1882911
,	O
that	O
serum	B-C0229671
mirnas	B-C1101610
would	O
have	O
more	O
immune	B-C0439662
-	O
related	B-C0332281
mrna	B-C0035696
targets	B-C1521840
than	O
non	B-C1518422
-	O
serum	B-C0229671
mirnas	B-C1101610
.	O
	
we	O
developed	B-C1527148
a	O
consensus	O
target	B-C1521840
predictor	O
using	O
the	O
random	B-C0205245
forest	I-C0205245
framework	I-C0205245
and	O
calculated	B-C0444686
the	O
number	O
of	O
predicted	B-C0681842
mirna	B-C1101610
-	O
mrna	B-C0035696
interactions	B-C2753463
in	O
various	O
subsets	B-C1515021
of	O
mirnas	B-C1101610
serum	B-C0229671
,	O
non	B-C1518422
-	O
serum	B-C0229671
and	O
mrnas	B-C0035696
immune	B-C0439662
related	B-C0332281
,	O
nonimmune	B-C0332281
related	I-C0332281
.	O
	
immune	B-C0439662
-	O
related	B-C0332281
mrnas	B-C0035696
were	O
predicted	B-C0681842
to	O
be	O
targeted	B-C1521840
by	O
serum	B-C0229671
mirna	B-C1101610
more	O
than	O
other	O
mrnas	B-C0035696
.	O
	
moreover	O
,	O
serum	B-C0229671
mirnas	B-C1101610
were	O
predicted	B-C0681842
to	O
target	B-C1521840
many	O
more	O
immune	B-C0439662
-	O
related	B-C0332281
mrna	B-C0035696
targets	B-C1521840
than	O
non	B-C1518422
-	O
serum	B-C0229671
mirnas	B-C1101610
however	O
,	O
these	O
two	O
biases	B-C0242568
in	O
immune	B-C0439662
-	O
related	B-C0332281
mrnas	B-C0035696
and	O
serum	B-C0229671
mirnas	B-C1101610
appear	O
to	O
be	O
completely	B-C0205197
independent	B-C0085862
.	O
	
immune	B-C0439662
-	O
related	B-C0332281
mrnas	B-C0035696
have	O
more	O
mirna	B-C1523647
binding	I-C1523647
sites	B-C0205145
in	O
general	O
,	O
not	O
just	O
for	O
serum	B-C0229671
mirnas	B-C1101610
likewise	O
,	O
serum	B-C0229671
mirnas	B-C1101610
target	B-C1521840
many	O
more	O
mrnas	B-C0035696
than	O
non	B-C1518422
-	O
serum	B-C0229671
mirnas	B-C1101610
overall	O
,	O
regardless	B-C3641650
of	O
whether	O
they	O
are	O
immune	B-C0439662
related	B-C0332281
or	O
not	O
.	O
	
nevertheless	O
,	O
these	O
two	O
independent	B-C0085862
phenomena	B-C1882365
result	B-C1274040
in	O
a	O
significantly	O
larger	O
number	O
of	O
predicted	B-C0681842
serum	B-C0229671
mirna	B-C1101610
-	O
immune	B-C0439662
mrna	B-C0035696
interactions	B-C2753463
oxidative	B-C0242606
stress	I-C0242606
and	O
immunosenescence	B-C0596761
in	O
spleen	B-C0037993
of	O
obese	B-C0025933
mice	I-C0025933
can	O
be	O
reversed	O
by	O
2-hydroxyoleic	B-C1436659
acid	I-C1436659
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
obesity	B-C0028754
on	O
oxidative	B-C0242606
stress	I-C0242606
and	O
leukocyte	B-C0023516
function	B-C0007613
in	O
spleen	B-C0037993
of	O
mice	B-C0025929
,	O
and	O
to	O
assess	O
whether	O
supplementation	B-C0242297
with	O
2-hydroxyoleic	B-C1436659
acid	I-C1436659
2-ohoa	B-C1436659
or	O
n-3	B-C0015689
polyunsaturated	I-C0015689
fatty	I-C0015689
acids	I-C0015689
pufa	B-C0015689
could	O
reverse	O
those	O
effects	O
.	O
	
female	B-C0086287
icr/cd1	B-C2697641
mice	I-C2697641
8	O
weeks	B-C0439230
old	O
,	O
n	O
=	O
24	O
received	O
an	O
obesogenic	B-C0012155
diet	I-C0012155
22%	O
fat	B-C0012171
for	O
4	O
weeks	B-C0439230
and	O
60%	O
fat	B-C0012171
for	O
14	O
weeks	B-C0439230
.	O
	
after	O
6	O
weeks	B-C0439230
,	O
mice	B-C0025929
were	O
split	O
in	O
three	O
groups	B-C0681860
n	O
=	O
8/	O
group	B-C0681860
no	B-C0681860
supplementation	I-C0681860
,	O
2-ohoa	B-C0681860
supplementation	I-C0681860
1500	O
mg	O
kg	O
and	O
n-3	B-C0681860
pufa	I-C0681860
supplementation	I-C0681860
epa	B-C0000545
+	O
dha	B-C0556150
,	O
3000	O
mg	O
kg	O
diet	O
.	O
	
eight	O
mice	B-C0025929
were	O
fed	O
standard	O
diet	B-C0012155
for	O
the	O
whole	O
duration	B-C0449238
of	O
the	O
study	B-C2603343
control	B-C0009932
group	I-C0009932
.	O
	
at	O
the	O
end	O
of	O
the	O
experiment	B-C0681814
,	O
the	O
following	O
variables	B-C0439828
were	O
assessed	B-C1516048
in	O
spleens	B-C0037993
levels	B-C0441889
of	O
reduced	B-C0017817
gsh	B-C0017817
and	O
oxidized	B-C0061516
gssg	I-C0061516
glutathione	I-C0061516
,	O
gsh	B-C0017817
/	O
gssg	B-C0061516
,	O
xanthine	B-C1151293
oxidase	I-C1151293
xo	I-C1151293
activity	I-C1151293
,	O
lipid	B-C0023775
peroxidation	I-C0023775
,	O
lymphocyte	B-C0312862
chemotaxis	I-C0312862
,	O
natural	B-C1317556
killer	I-C1317556
nk	I-C1317556
activity	I-C1317556
and	O
mitogen	B-C0026249
cona	B-C0009630
and	O
lps	B-C0023810
lymphocyte	B-C0596873
proliferation	I-C0596873
.	O
	
obese	B-C0424612
animals	B-C0003062
presented	O
higher	B-C0205250
gssg	B-C0061516
levels	B-C0441889
p	O
=	O
0.003	O
,	O
gssg	B-C0061516
/	O
gsh	B-C0017817
ratio	B-C0456603
p	O
=	O
0.013	O
,	O
lipid	B-C0023775
peroxidation	I-C0023775
p	O
=	O
0.004	O
,	O
xo	B-C1151293
activity	I-C1151293
p	O
=	O
0.015	O
and	O
lymphocyte	B-C0312862
chemotaxis	I-C0312862
p	O
<	O
0.001	O
,	O
and	O
lower	O
nk	B-C1317556
activity	I-C1317556
p	O
=	O
0.003	O
and	O
proliferation	B-C1514485
in	O
response	O
to	O
cona	B-C0009630
p	O
<	O
0.001	O
than	O
controls	B-C0009932
.	O
	
2-ohoa	B-C1436659
reversed	O
totally	O
or	O
partially	O
most	O
of	O
the	O
changes	B-C0443172
body	B-C0005910
weight	I-C0005910
,	O
fat	O
content	O
,	O
gssg	B-C0061516
levels	B-C0441889
,	O
gsh	B-C0017817
/	O
gssg	B-C0061516
,	O
lipid	B-C0023775
peroxidation	I-C0023775
,	O
chemotaxis	B-C0008018
and	O
proliferation	B-C0596290
,	O
all	O
p	O
<	O
0.05	O
,	O
while	O
n-3	B-C0015689
pufa	I-C0015689
reversed	O
the	O
increase	B-C0442805
in	O
xo	B-C1151293
activity	I-C1151293
p	O
=	O
0.032	O
.	O
	
in	O
conclusion	O
,	O
2-ohoa	B-C1436659
,	O
and	O
to	O
a	O
lesser	O
extent	O
n-3	B-C0015689
pufa	I-C0015689
,	O
could	O
ameliorate	O
the	O
oxidative	B-C0242606
stress	I-C0242606
and	O
alteration	B-C1515926
of	O
leukocyte	B-C0023516
function	B-C0007613
in	O
spleen	B-C0037993
of	O
obese	B-C0025933
mice	I-C0025933
.	O
	
our	O
findings	B-C0243095
support	O
a	O
link	O
between	O
obesity	B-C0028754
and	O
immunosenescence	B-C0596761
and	O
suggest	O
a	O
potential	O
therapeutic	B-C0302350
tool	I-C0302350
for	O
obesity	B-C0028754
-related	O
immune	B-C0021053
dysfunction	I-C0021053
.	O
	
assembly	B-C2611271
of	I-C2611271
the	I-C2611271
outermost	I-C2611271
spore	I-C2611271
layer	I-C2611271
pieces	O
of	O
the	O
puzzle	O
are	O
coming	O
together	O
certain	O
endospore-forming	B-C0014248
soil	I-C0014248
dwelling	I-C0014248
bacteria	I-C0014248
are	O
important	O
human	B-C0086418
,	O
animal	B-C0003062
or	O
insect	B-C0021585
pathogens	B-C0450254
.	O
	
these	O
organisms	B-C0450254
produce	O
spores	B-C0038027
containing	O
an	O
outer	B-C0243092
layer	I-C0243092
,	O
the	O
exosporium	B-C1623474
.	O
	
the	O
exosporium	B-C1623474
is	O
the	O
site	B-C2945843
of	I-C2945843
interactions	B-C1704675
between	O
the	O
spore	B-C0038027
and	O
the	O
soil	B-C0037592
environment	B-C0014406
and	O
between	O
the	O
spore	B-C0038027
and	O
the	O
infected	B-C0439663
host	B-C1167395
during	O
the	O
initial	B-C0205265
stages	B-C1306673
of	O
infection	B-C3714514
.	O
	
the	O
composition	B-C0486616
and	O
assembly	B-C2611271
process	I-C2611271
of	I-C2611271
the	I-C2611271
exosporium	I-C2611271
are	O
poorly	O
understood	O
.	O
	
this	O
is	O
partly	O
due	O
to	O
the	O
extreme	O
stability	B-C0205360
of	O
the	O
exosporium	B-C1623474
that	O
has	O
proven	O
to	O
be	O
refractive	O
to	O
existing	O
methods	B-C0025664
to	O
deconstruct	O
the	O
intact	B-C0205266
structure	B-C0678594
into	O
its	O
component	B-C1705248
parts	B-C0449719
.	O
	
although	O
more	O
than	O
20	O
proteins	B-C0004627
have	O
been	O
identified	B-C0205396
as	O
exosporium	B-C1623474
-	O
associated	B-C0332281
,	O
their	O
abundance	B-C2346714
,	O
relationship	B-C0439849
to	O
other	O
proteins	B-C0033684
and	O
the	O
processes	B-C1522240
by	O
which	O
they	O
are	O
assembled	B-C2611271
to	I-C2611271
create	I-C2611271
the	I-C2611271
exosporium	I-C2611271
are	O
largely	O
unknown	O
.	O
	
in	O
this	O
issue	O
of	O
molecular	B-C0025952
microbiology	I-C0025952
,	O
terry	O
,	O
jiang	O
,	O
and	O
colleagues	O
in	O
per	O
bullough's	O
laboratory	B-C0022877
show	O
that	O
the	O
exsy	B-C0033684
protein	I-C0033684
is	O
a	O
major	O
structural	B-C0582263
protein	I-C0582263
of	O
the	O
exosporium	B-C1623474
basal	I-C1623474
layer	I-C1623474
of	O
b	B-C0004590
.	O
	
cereus	I-C0004590
family	I-C0004590
spores	B-C0038027
and	O
that	O
it	O
can	O
self-assemble	B-C1706853
into	O
complex	B-C0439855
structures	B-C0678594
that	O
possess	O
many	O
of	O
the	O
structural	B-C0678594
features	B-C2348519
characteristic	B-C1521970
of	O
the	O
exosporium	B-C1623474
basal	I-C1623474
layer	I-C1623474
.	O
	
the	O
authors	B-C3812881
refined	O
a	O
model	B-C3161035
for	O
exosporium	B-C2611271
assembly	I-C2611271
.	O
	
their	O
findings	B-C0243095
may	O
have	O
implications	O
for	O
exosporium	B-C1623474
formation	B-C1522492
in	O
other	O
spore	B-C0014248
forming	I-C0014248
bacteria	I-C0014248
,	O
including	O
clostridium	B-C1264830
species	I-C1264830
.	O
	
skeletal	B-C0242692
muscle	I-C0242692
metabolic	O
adaptations	B-C0392673
to	O
endurance	B-C0031808
exercise	B-C4279936
training	I-C4279936
are	O
attainable	B-C0599946
in	O
mice	B-C0025929
with	O
simvastatin	B-C0074554
treatment	B-C0087111
we	O
tested	O
the	O
hypothesis	B-C1512571
that	O
a	O
6-week	O
regimen	B-C0040808
of	O
simvastatin	B-C0074554
would	O
attenuate	B-C0599946
skeletal	B-C0242692
muscle	I-C0242692
adaptation	B-C0392673
to	O
low-intensity	B-C0015259
exercise	I-C0015259
.	O
	
male	B-C0086582
c57bl/6j	B-C0025929
wildtype	I-C0025929
mice	I-C0025929
were	O
subjected	O
to	O
6-weeks	O
of	O
voluntary	B-C0035953
wheel	I-C0035953
running	I-C0035953
or	O
normal	O
cage	B-C0179512
activities	B-C0441655
with	O
or	O
without	O
simvastatin	B-C0074554
treatment	B-C0087111
20	O
mg/kg/d	O
,	O
n	O
=	O
7-8	O
per	O
group	O
.	O
	
adaptations	B-C0392673
in	B-C0681829
in	O
vivo	I-C0681829
fatigue	B-C0015672
resistance	B-C4281815
were	O
determined	O
by	O
a	O
treadmill	B-C0087110
running	I-C0087110
test	I-C0087110
,	O
and	O
by	O
ankle	B-C0581542
plantarflexor	I-C0581542
contractile	B-C0026820
assessment	O
.	O
	
the	O
tibialis	B-C0242690
anterior	I-C0242690
,	O
gastrocnemius	B-C0242691
,	O
and	O
plantaris	B-C0242693
muscles	I-C0242693
were	O
evaluated	B-C0220825
for	O
exercised	B-C0015259
-induced	O
mitochondrial	B-C0026237
adaptations	B-C0392673
i.e	O
,	O
biogenesis	B-C0005495
,	O
function	B-C0542341
,	O
autophagy	B-C0004391
.	O
	
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
weekly	O
wheel	B-C0441655
running	I-C0441655
distance	I-C0441655
between	O
control	O
and	O
simvastatin	B-C0074554
-	O
treated	B-C1522326
mice	B-C0025929
p	O
=	O
0.51	O
.	O
	
trained	B-C0220931
mice	B-C0025929
had	O
greater	O
treadmill	B-C2712999
running	I-C2712999
distance	B-C0012751
296%	O
,	O
p<0	O
,	O
and	O
ankle	B-C0581542
plantarflexor	I-C0581542
contractile	B-C0026820
fatigue	B-C0015672
resistance	B-C4281815
9%	O
,	O
p<0	O
compared	O
to	O
sedentary	O
mice	B-C0025929
,	O
independent	O
of	O
simvastatin	B-C0074554
treatment	B-C0087111
.	O
	
at	O
the	O
cellular	B-C0007634
level	I-C0007634
,	O
trained	B-C0220931
mice	B-C0025929
had	O
greater	O
mitochondrial	B-C3494456
biogenesis	I-C3494456
e.g	O
,	O
2-fold	O
greater	O
pgc1α	B-C1570275
expression	B-C1171362
,	O
p<0	O
and	O
mitochondrial	B-C0026237
content	O
e.g	O
,	O
25%	O
greater	O
citrate	B-C0008855
synthase	I-C0008855
activity	B-C0243102
,	O
p<0	O
,	O
independent	O
of	O
simvastatin	B-C0074554
treatment	B-C0087111
.	O
	
mitochondrial	B-C0026237
autophagy	B-C0004391
-related	O
protein	B-C0033684
contents	O
were	O
greater	O
in	O
trained	B-C0220931
mice	B-C0025929
e.g	O
,	O
40%	O
greater	O
bnip3	B-C1699488
,	O
p<0	O
,	O
independent	O
of	O
simvastatin	B-C0074554
treatment	B-C0087111
.	O
	
however	O
,	O
drp1	B-C1957127
,	O
a	O
marker	B-C0005516
of	O
mitochondrial	B-C0230871
fission	I-C0230871
,	O
was	O
less	O
in	O
simvastatin	B-C0074554
treated	B-C1522326
mice	B-C0025929
,	O
independent	O
of	O
exercise	B-C4279936
training	I-C4279936
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	B-C1704675
between	O
training	B-C0220931
and	O
statin	O
treatment	B-C0087111
p<0	O
for	O
lc3-ii	B-C3711208
protein	I-C3711208
content	B-C1446561
,	O
a	O
marker	B-C0005516
of	O
autophagy	B-C0004391
flux	O
.	O
	
these	O
data	O
indicate	O
that	O
whole	B-C0444584
body	I-C0444584
and	O
skeletal	B-C0242692
muscle	I-C0242692
adaptations	B-C0392673
to	O
endurance	B-C0031808
exercise	B-C4279936
training	I-C4279936
are	O
attainable	B-C0599946
with	O
simvastatin	B-C0074554
treatment	B-C0087111
,	O
but	O
simvastatin	B-C0074554
may	O
have	O
side	B-C0879626
effects	I-C0879626
on	O
muscle	B-C0026845
mitochondrial	B-C0026237
maintenance	O
via	O
autophagy	B-C0004391
,	O
which	O
could	O
have	O
long-term	B-C0443252
implications	O
on	O
muscle	B-C0026845
health	B-C0018684
.	O
	
evaluation	B-C0220825
and	O
treatment	B-C0039798
of	O
anemia	B-C0002871
in	O
premature	B-C0021294
infants	I-C0021294
anemia	B-C0002871
in	O
preterm	B-C4048294
infants	I-C4048294
is	O
the	O
pathophysiological	B-C0031847
process	B-C1522240
with	O
greater	O
and	O
more	O
rapid	O
decline	B-C0282251
in	O
hemoglobin	B-C0019046
compared	B-C1707455
to	O
the	O
physiological	B-C0205463
anemia	B-C0002871
in	O
infants	B-C0021270
.	O
	
there	O
is	O
a	O
need	O
for	O
transfusions	B-C0005841
and	O
administration	B-C1533734
of	O
human	B-C0376541
recombinant	I-C0376541
erythropoietin	I-C0376541
.	O
	
to	O
determine	B-C0205258
the	O
frequency	B-C0439603
of	O
anemia	B-C0002871
in	O
premature	B-C0021294
infants	I-C0021294
at	O
the	O
pediatric	B-C3839701
clinic	I-C3839701
,	O
university	I-C3839701
clinical	I-C3839701
center	I-C3839701
sarajevo	I-C3839701
,	O
as	O
well	O
as	O
parameter	B-C0549193
values	I-C0549193
in	O
the	O
blood	B-C0005771
count	I-C0005771
of	O
premature	B-C0021294
infants	I-C0021294
and	O
to	O
explore	O
a	O
relationship	B-C0439849
between	O
blood	B-C0005841
transfusions	I-C0005841
with	O
the	O
advent	O
of	O
intraventricular	B-C0240059
hemorrhage	I-C0240059
determine	B-C0205258
treatment	B-C0039798
outcome	O
in	O
preterm	B-C4048294
infants	I-C4048294
.	O
	
research	B-C0035168
is	O
retrospective	B-C0035363
study	I-C0035363
and	O
it	O
included	O
the	O
period	B-C0439531
of	O
six	O
months	B-C0439231
in	O
year	B-C0439234
2014	O
.	O
	
research	B-C0035168
included	O
100	O
patients	B-C0030705
,	O
gestational	B-C0017504
age	I-C0017504
<	O
37	O
weeks	B-C0439230
premature	B-C0021294
infants	I-C0021294
.	O
	
data	B-C1511726
were	O
collected	B-C1516695
by	O
examining	B-C0332128
the	O
medical	B-C0025102
records	I-C0025102
of	O
patients	B-C0030705
at	O
the	O
pediatric	B-C3839701
clinic	I-C3839701
,	O
uccs	I-C3839701
.	O
	
the	O
first	B-C0205435
group	B-C0441833
of	O
patients	B-C0030705
were	O
premature	B-C0021294
infants	I-C0021294
of	O
gestational	B-C0017504
age	I-C0017504
32	O
weeks	B-C0439230
62/100	O
and	O
the	O
second	B-C0205436
group	B-C0441833
were	O
premature	B-C0021294
infants	I-C0021294
of	O
gestational	B-C0017504
age	I-C0017504
33-37	O
weeks	B-C0439230
38/100	O
.	O
	
among	O
the	O
patients	B-C0030705
,	O
5%	O
were	O
boys	B-C0870221
and	O
46%	O
girls	B-C0870604
.	O
	
there	O
was	O
significant	B-C1705241
difference	I-C1705241
in	O
birth	B-C0005612
weight	I-C0005612
and	O
apgar	B-C0003533
score	I-C0003533
among	O
the	O
groups	B-C0441833
.	O
	
in	O
the	O
first	B-C0205435
group	B-C0441833
,	O
there	O
were	O
27.42	O
of	O
deaths	B-C1306577
,	O
while	O
in	O
the	O
second	B-C0205436
group	B-C0441833
,	O
there	O
were	O
only	O
10.53	O
of	O
deaths	B-C1306577
.	O
	
there	O
was	O
a	O
significant	B-C1705241
difference	I-C1705241
in	O
the	O
length	O
of	O
treatment	B-C0039798
.	O
	
there	O
was	O
a	O
statistically	B-C0237881
significant	I-C0237881
difference	B-C1705241
in	O
the	O
need	O
for	O
transfusion	B-C0005841
among	O
the	O
groups	B-C0441833
.	O
	
18	O
patients	B-C0030705
in	O
the	O
first	B-C0205435
group	B-C0441833
required	O
a	O
transfusion	B-C0005841
,	O
while	O
in	O
the	O
second	B-C0205436
group	B-C0441833
only	O
3	O
patients	B-C0030705
.	O
	
preterm	B-C4048294
infants	I-C4048294
of	O
gestational	B-C0017504
age	I-C0017504
32	O
weeks	B-C0439230
are	O
likely	O
candidates	B-C0030705
for	O
blood	B-C0005841
transfusion	I-C0005841
during	O
treatment	B-C0039798
.	O
	
preterm	B-C4048294
infants	I-C4048294
of	O
gestational	B-C0017504
age	I-C0017504
32	O
weeks	B-C0439230
have	O
the	O
risk	B-C0035647
of	O
intracranial	B-C0151699
bleeding	I-C0151699
associated	B-C0332281
with	I-C0332281
the	O
application	B-C0185125
of	O
blood	B-C0005841
transfusion	I-C0005841
in	O
the	O
first	O
week	B-C0439230
of	O
medial	B-C4254914
patellofemoral	I-C4254914
ligament	I-C4254914
reconstruction	B-C0547071
femoral	B-C0015811
tunnel	B-C1254362
accuracy	B-C0443131
relationship	O
to	O
disease	B-C0012634
-	O
specific	B-C0205369
quality	B-C0034380
of	I-C0034380
life	I-C0034380
medial	B-C4254914
patellofemoral	I-C4254914
ligament	I-C4254914
mpfl	B-C4254914
reconstruction	B-C0547071
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral	B-C0559397
patellar	I-C0559397
translation	I-C0559397
in	O
patients	B-C0030705
with	O
symptomatic	B-C0856775
patellofemoral	I-C0856775
instability	I-C0856775
.	O
	
correct	O
femoral	B-C0015811
tunnel	B-C1254362
position	B-C0733755
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
mpfl	B-C4254914
reconstruction	B-C0547071
,	O
but	O
the	O
accuracy	B-C0443131
of	O
this	O
statement	O
in	O
terms	O
of	O
patient	B-C0030698
outcomes	I-C0030698
has	O
not	O
been	O
tested	O
.	O
	
to	O
assess	O
the	O
accuracy	B-C0443131
of	O
femoral	B-C0015811
tunnel	B-C1254362
placement	B-C1533810
in	O
an	O
mpfl	B-C4254914
reconstruction	B-C0547071
cohort	B-C0599755
and	O
to	O
determine	O
the	O
correlation	B-C1707520
between	O
tunnel	B-C1254362
accuracy	B-C0443131
and	O
a	O
validated	B-C1519941
disease	B-C0012634
-	O
specific	B-C0205369
,	O
patient	B-C0030705
-reported	O
quality-of-life	B-C0034380
outcome	B-C0086749
measure	I-C0086749
.	O
	
case	O
series	O
level	O
of	O
evidence	O
,	O
4	O
.	O
	
between	O
june	B-C3829443
2008	O
and	O
february	B-C3830166
2014	O
,	O
a	O
total	O
of	O
206	O
subjects	B-C0080105
underwent	O
an	O
mpfl	B-C4254914
reconstruction	B-C0547071
.	O
	
lateral	B-C0205093
radiographs	B-C1306645
were	O
measured	O
to	O
determine	O
the	O
accuracy	B-C0443131
of	O
the	O
femoral	B-C0015811
tunnel	B-C1254362
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	B-C0015811
tunnel	B-C1254362
to	O
the	O
schöttle	B-C1254362
point	I-C1254362
.	O
	
banff	B-C0086749
patella	I-C0086749
instability	I-C0086749
instrument	I-C0086749
bpii	I-C0086749
scores	I-C0086749
were	O
collected	O
a	O
mean	B-C0444504
24	O
months	B-C0439231
postoperatively	B-C0032790
.	O
	
a	O
total	O
of	O
155	O
79.5	O
subjects	O
had	O
adequate	O
postoperative	B-C0032790
lateral	B-C0205093
radiographs	B-C1306645
and	O
complete	O
bpii	B-C0086749
scores	I-C0086749
.	O
	
the	O
mean	B-C0444504
duration	B-C0449238
of	O
follow-up	B-C1522577
sd	B-C0871420
was	O
24.4	O
8.2	O
months	B-C0439231
range	O
,	O
12-74	O
months	B-C0439231
.	O
	
measurement	B-C0242485
from	O
the	O
center	B-C0205099
of	O
the	O
femoral	B-C0015811
tunnel	B-C1254362
to	O
the	O
schöttle	B-C1254362
point	I-C1254362
resulted	O
in	O
143	O
92.3	O
tunnel	B-C1254362
s	O
being	O
categorized	O
as	O
""""	O
good	B-C0205170
""""	O
or	O
""""	O
ideal	B-C1512612
""""	O
there	O
were	O
8	O
failures	B-C1262018
in	O
the	O
cohort	B-C0599755
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	B-C0333042
tunnels	B-C1254362
.	O
	
the	O
mean	B-C0444504
distance	O
from	O
the	O
center	B-C0205099
of	O
the	O
mpfl	B-C4254914
tunnel	B-C1254362
to	O
the	O
center	B-C0205099
of	O
the	O
schöttle	B-C1254362
point	I-C1254362
was	O
5.9	O
4.2	O
mm	O
range	O
,	O
0.5	O
mm	O
.	O
	
the	O
mean	B-C0444504
postoperative	B-C0032790
bpii	B-C0086749
score	I-C0086749
was	O
65.2	O
22.5	O
range	O
,	O
9.2	O
.	O
	
pearson	B-C1709490
r	I-C1709490
correlation	I-C1709490
demonstrated	O
no	B-C1273937
statistically	I-C1273937
significant	I-C1273937
relationship	B-C0439849
between	O
accuracy	B-C0443131
of	O
femoral	B-C0015811
tunnel	B-C1254362
position	B-C0733755
and	O
bpii	B-C0086749
score	I-C0086749
r	O
=	O
-0	O
95%	O
ci	O
,	O
-0	O
to	O
0.08	O
.	O
	
there	O
was	O
no	B-C0332125
evidence	I-C0332125
of	I-C0332125
a	O
correlation	B-C1707520
between	O
the	O
accuracy	B-C0443131
of	O
mpfl	B-C4254914
reconstruction	B-C0547071
femoral	B-C0015811
tunnel	B-C1254362
in	O
relation	O
to	O
the	O
schöttle	B-C1254362
point	I-C1254362
and	O
disease	B-C0012634
-	O
specific	B-C0205369
quality-of-life	B-C3476431
scores	I-C3476431
.	O
	
graft	B-C1262018
failure	I-C1262018
was	O
not	O
related	O
to	O
femoral	B-C0015811
tunnel	B-C1254362
placement	B-C1533810
.	O
	
the	O
patellofemoral	B-C0856775
instability	I-C0856775
population	O
is	O
complex	O
,	O
and	O
patients	B-C0030705
present	O
with	O
multiple	O
risk	B-C0035648
factors	I-C0035648
that	O
,	O
in	O
addition	O
to	O
the	O
accuracy	B-C0443131
of	O
femoral	O
tunnel	B-C1254362
position	B-C0733755
,	O
contribute	O
to	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
and	O
warrant	O
further	O
evidence	O
for	O
instructions	B-C0039401
-based	O
updating	O
of	O
task-set	B-C0039333
representations	I-C0039333
the	O
informed	B-C1522154
fadeout	B-C0237614
effect	I-C0237614
the	O
cognitive	B-C0392335
system	I-C0392335
can	O
be	O
updated	O
rapidly	O
and	O
efficiently	O
to	O
maximize	O
performance	B-C0039333
in	O
cognitive	B-C0392335
tasks	I-C0392335
.	O
	
this	O
paper	O
used	O
a	O
task	B-C3540678
-	O
switching	B-C0392747
task	B-C3540678
to	O
explore	O
updating	O
at	O
the	O
level	B-C0441889
of	O
the	O
plausible	O
task	B-C3540678
-sets	O
held	O
for	O
future	O
performance	B-C0039333
.	O
	
previous	O
research	B-C0035168
suggested	O
a	O
""""	O
fadeout	B-C0237614
effect	I-C0237614
""""	O
,	O
performance	B-C0039333
improvement	B-C0039333
when	O
moving	O
from	O
task	B-C3540678
-	O
switching	B-C0392747
context	O
to	O
single-task	B-C2371306
context	O
,	O
yet	O
this	O
effect	O
could	O
reflect	O
passive	B-C3686820
learning	B-C0023185
rather	O
than	O
intentional	B-C1283828
control	B-C0243148
.	O
	
in	O
a	O
novel	O
""""	O
informed	B-C1522154
fadeout	B-C0033897
paradigm	B-C0681797
""""	O
,	O
one	O
of	O
two	O
tasks	B-C3540678
was	O
canceled	O
for	O
a	O
certain	O
number	O
of	O
trials	B-C0681815
and	O
participants	B-C0679646
were	O
informed	B-C1522154
or	O
uninformed	B-C0562357
regarding	O
task	B-C3540678
cancelation	B-C0205544
.	O
	
the	O
""""	O
informed	B-C1522154
fadeout	B-C0237614
effect	I-C0237614
""""	O
indicates	O
better	O
performance	B-C0039333
in	O
the	O
informed	B-C1522154
than	O
uninformed	B-C0562357
fadeout	B-C0237614
after	O
one	O
informed	B-C1522154
trial	B-C0681815
had	O
been	O
executed	B-C1705848
.	O
	
however	O
,	O
the	O
results	O
regarding	O
the	O
first	O
trial	B-C0681815
were	O
inconclusive	O
.	O
	
possible	O
underlying	O
mechanisms	B-C0441712
metacarpophalangeal	B-C0187606
joint	I-C0187606
arthrodesis	I-C0187606
of	O
the	O
thumb	B-C0040067
-	O
minimum	O
of	O
eight	O
months	B-C0439231
follow-up	B-C1522577
disorders	B-C0012634
of	O
the	O
thumb	B-C0224627
metacarpophalangeal	I-C0224627
mcp	I-C0224627
joint	I-C0224627
can	O
lead	O
to	O
significant	O
loss	B-C1517945
of	O
function	B-C1254359
and	O
pain	B-C0030193
.	O
	
thumb	B-C0224627
mcp	I-C0224627
arthrodesis	B-C0003881
following	O
traumatic	B-C3263723
injuries	I-C3263723
is	O
inadequately	O
described	B-C1552738
and	O
recent	O
studies	B-C2603343
have	O
questioned	O
the	O
outcome	B-C1274040
of	O
this	O
treatment	B-C0087111
.	O
	
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
report	B-C0700287
outcome	B-C1274040
and	O
disability	B-C0231170
following	O
thumb	B-C0224627
mcp	I-C0224627
joint	I-C0224627
arthrodesis	B-C0003881
in	O
the	O
treatment	B-C0087111
of	O
chronic	B-C0409364
instability	I-C0409364
after	O
traumatic	B-C3263723
injuries	I-C3263723
.	O
	
a	O
retrospective	B-C1514923
review	B-C0451610
of	O
26	O
patients	B-C0030705
operated	B-C0543467
on	O
with	O
mcp	B-C0224627
joint	I-C0224627
arthrodesis	B-C0003881
,	O
median	O
follow-up	B-C1522577
42	O
months	B-C0439231
8-104	O
months	B-C0439231
.	O
	
subjective	O
outcome	B-C1274040
was	O
assessed	B-C1516048
using	O
the	O
disabilities	B-C4295796
of	I-C4295796
the	I-C4295796
arm	I-C4295796
,	O
shoulder	I-C4295796
,	O
and	I-C4295796
hand-questionnaire	I-C4295796
dash	B-C4295796
.	O
	
in	O
addition	O
,	O
patient	B-C0030702
satisfaction	I-C0030702
,	O
pain	B-C0030193
,	O
stiffness	B-C0427008
,	O
and	O
impairment	B-C0221099
of	O
activities	B-C0001288
of	I-C0001288
daily	I-C0001288
living	I-C0001288
were	O
assessed	B-C1516048
on	O
a	O
visual	B-C3536884
analogue	I-C3536884
scale	I-C3536884
vas	B-C3536884
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	B-C2700391
again	O
.	O
	
two	O
patients	B-C0030705
7.7	O
needed	O
re-operation	B-C0035110
due	O
to	O
nonunion	B-C3897107
.	O
	
four	O
patients	B-C0030705
15.4	O
needed	O
hardware	B-C1096445
removal	I-C1096445
.	O
	
median	B-C0876920
dash	B-C4295796
-	O
score	B-C0449820
was	O
18	O
25-75%	O
range	B-C1514721
6-47	O
,	O
with	O
lower	O
dash	B-C4295796
score	B-C0449820
s	I-C0449820
being	O
better	O
.	O
	
score	B-C0449820
s	I-C0449820
were	O
significantly	O
worse	O
in	O
gender	B-C0079399
and	O
age	B-C0001779
matched	O
individuals	B-C0237401
p<0	O
.	O
	
median	B-C0876920
vas	B-C3536884
for	O
pain	B-C0030193
was	O
3.7	O
range	B-C1514721
0-8	O
.	O
	
more	O
than	O
50%	O
of	O
patients	B-C0030705
reported	O
mild	B-C0278138
,	O
moderate	B-C0278139
or	O
severe	B-C0278140
pain	I-C0278140
,	O
but	O
all	O
patients	B-C0030705
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	B-C2700391
again	O
.	O
	
our	O
data	B-C1511726
suggest	O
,	O
that	O
patients	B-C0030705
with	O
post-traumatic	B-C1254367
thumb	B-C0262649
injuries	I-C0262649
managed	O
with	O
thumb	B-C0224627
mcp	I-C0224627
joint	I-C0224627
arthrodesis	B-C0003881
perform	O
worse	O
than	O
gender	B-C0079399
and	O
age	B-C0001779
matched	O
individuals	B-C0237401
.	O
	
many	O
lived	O
with	O
pain	B-C0030193
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	B-C2700391
again	O
.	O
	
we	O
suggest	O
that	O
the	O
disability	B-C0451125
scale	I-C0451125
by	O
the	O
national	B-C1948070
board	I-C1948070
of	I-C1948070
industrial	I-C1948070
injuries	I-C1948070
should	O
be	O
reconsidered	O
for	O
patients	B-C0030705
operated	B-C0543467
on	O
with	O
thumb	B-C0224627
mcp	I-C0224627
arthrodesis	B-C0003881
.	O
	
pyoderma	B-C0085652
gangrenosum	I-C0085652
a	O
clinician's	B-C0871685
nightmare	B-C0028084
pyoderma	B-C0085652
gangrenosum	I-C0085652
pg	B-C0085652
is	O
a	O
rare	B-C0678236
disease	I-C0678236
and	O
that	O
affecting	O
specifically	O
the	O
sole	B-C0230463
of	I-C0230463
the	I-C0230463
foot	I-C0230463
,	O
is	O
even	O
rarer	O
.	O
	
here	O
,	O
we	O
report	B-C0684224
the	O
case	O
of	O
a	O
54-year-	O
old	B-C0580836
female	B-C0086287
admitted	B-C0184666
with	O
a	O
painful	B-C0030193
ulcer	B-C0041582
on	O
the	O
sole	B-C0230463
of	I-C0230463
the	I-C0230463
right	I-C0230463
foot	I-C0230463
which	O
was	O
initially	O
treated	B-C0332293
with	I-C0332293
empirical	O
antibiotics	B-C0003232
and	O
debridement	B-C0011079
.	O
	
the	O
disease	B-C0012634
was	O
found	O
to	O
spread	O
rapidly	B-C0456962
after	O
each	O
debridement	B-C0011079
.	O
	
the	O
culture	B-C2061903
reports	I-C2061903
were	O
negative	B-C0205160
rheumatology	B-C0035452
workup	B-C0750430
and	O
doppler	B-C0554756
study	I-C0554756
were	O
within	O
normal	B-C0442816
limits	I-C0442816
.	O
	
a	O
clinical	B-C0205210
suspicion	B-C0750491
of	O
pg	B-C0085652
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue	B-C3864006
biopsy	I-C3864006
.	O
	
she	O
was	O
started	B-C0419839
on	I-C0419839
oral	I-C0419839
steroids	I-C0419839
following	O
which	O
she	O
dramatically	O
improved	B-C0184511
.	O
	
thus	O
,	O
when	O
a	O
patient	B-C0030705
presents	O
with	O
a	O
rapidly	B-C0456962
expanding	O
painful	B-C0030193
ulcer	B-C0041582
in	O
a	O
vascular	B-C0015385
limb	I-C0015385
that	O
is	O
refractory	B-C0205269
to	O
antibiotic	B-C0338237
treatment	I-C0338237
and	O
exacerbating	B-C1444749
on	O
debridement	B-C0011079
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
visualization	B-C0178707
for	O
understanding	O
uncertainty	B-C0087130
in	O
activation	B-C1879547
volumes	B-C0449468
for	O
deep	B-C0394162
brain	I-C0394162
stimulation	I-C0394162
we	O
have	O
created	O
the	O
neurostimulation	B-C0282574
uncertainty	I-C0282574
viewer	I-C0282574
nuview	I-C0282574
or	I-C0282574
νview	I-C0282574
tool	I-C0282574
for	O
exploring	O
data	B-C1511726
arising	O
from	O
deep	B-C0394162
brain	I-C0394162
stimulation	I-C0394162
dbs	B-C0394162
.	O
	
simulated	B-C0679083
volume	B-C0392762
of	I-C0392762
tissue	I-C0392762
activated	I-C0392762
vta	B-C0392762
,	O
using	O
clinical	B-C0430022
electrode	I-C0430022
placements	I-C0430022
,	O
are	O
recorded	B-C0441655
along	O
with	O
patient	B-C0030705
outcomes	B-C0085415
in	O
the	O
unified	B-C3639721
parkinson's	I-C3639721
disease	I-C3639721
rating	I-C3639721
scale	I-C3639721
updrs	B-C3639721
.	O
	
the	O
data	B-C1511726
is	O
volumetric	B-C0205556
and	O
sparse	B-C0205556
,	O
with	O
multi-value	B-C0205556
patient	B-C0030705
results	B-C1274040
for	O
each	O
activated	B-C1879547
voxel	B-C2700259
in	O
the	O
simulation	B-C0679083
.	O
	
νview	B-C1254372
provides	O
a	O
collection	B-C1516698
of	O
visual	B-C0025663
methods	I-C0025663
to	O
explore	O
the	O
activated	B-C1879547
tissue	B-C0040300
to	O
enhance	O
understanding	O
of	O
electrode	B-C0013812
usage	B-C0457083
for	O
improved	O
therapy	B-C0087111
with	O
post-synthetic	O
conversion	B-C0439836
of	O
5-pivaloyloxymethyluridine	B-C0073347
present	B-C0150312
in	O
a	O
support-bound	O
rna	B-C0035668
oligomer	B-C0599219
into	O
biologically	B-C0205460
relevant	B-C2347946
derivatives	B-C0243072
of	O
5-methyluridine	B-C0073347
a	O
post-synthetic	O
reaction	B-C0443286
of	O
5-pivaloyloxymethyluridine	B-C0073347
present	B-C0150312
in	O
a	O
support-bound	O
rna	B-C0035668
oligomer	B-C0599219
with	O
various	O
nucleophilic	B-C0034760
reagents	I-C0034760
furnished	O
efficiently	O
the	O
corresponding	O
products	B-C1514468
bearing	O
one	O
aof	O
the	O
trna	B-C1817367
wobble	I-C1817367
5-methyluridines	B-C0073347
mnm	B-C0073347
,	O
cmnm	B-C0073347
,	O
τm	B-C0073347
,	O
nm	B-C0073347
,	O
inm	B-C0073347
or	O
cnm	B-C0073347
.	O
	
the	O
syntheses	B-C1883254
of	O
oligoribonucleotides	B-C0028956
modified	B-C0392747
with	O
inm	B-C0073347
and	O
cnm	B-C0073347
non-pharmacological	B-C0205245
treatments	B-C0087111
for	O
pain	B-C0451615
relief	I-C0451615
tens	B-C0040654
and	O
acupuncture	B-C0394664
acupuncture	B-C0394664
and	O
transcutaneous	B-C0040654
electrical	I-C0040654
nerve	I-C0040654
stimulation	I-C0040654
tens	B-C0040654
are	O
non-pharmacological	B-C0205245
methods	B-C0449851
that	O
have	O
been	O
used	O
for	O
millennia	B-C1948053
to	O
relieve	B-C0451615
pain	I-C0451615
.	O
	
as	O
with	O
all	O
complementary	B-C0936077
treatments	I-C0936077
,	O
efficacy	B-C1280519
evaluations	B-C0220825
face	O
two	O
hurdles	O
the	O
non-feasibility	O
of	O
double-blinding	B-C0013072
and	O
the	O
difficulty	O
in	O
identifying	O
the	O
optimal	B-C0029145
control	I-C0029145
population	I-C0029145
or	O
treatment	B-C0087111
.	O
	
nevertheless	O
,	O
recent	O
studies	O
of	O
good	B-C0205170
methodological	B-C0815254
quality	I-C0815254
have	O
demonstrated	O
benefits	B-C0814225
in	O
many	O
types	O
of	O
pain	B-C0030193
compared	O
to	O
conventional	B-C0439858
treatment	B-C0087111
.	O
	
the	O
mechanisms	B-C0441712
of	I-C0441712
action	I-C0441712
of	O
acupuncture	B-C0394664
and	O
tens	B-C0040654
,	O
which	O
are	O
increasingly	B-C0442808
well	O
understood	O
,	O
involve	O
endogenous	B-C0205227
pain	B-C1304888
control	I-C1304888
systems	I-C1304888
,	O
cerebral	B-C0027880
plasticity	I-C0027880
,	O
and	O
nonspecific	O
effects	B-C1280500
e.g	O
,	O
expectations	B-C0679138
and	O
placebo	B-C0032041
effect	I-C0032041
.	O
	
no	O
serious	O
adverse	B-C0879626
effects	I-C0879626
have	O
been	O
reported	O
.	O
	
these	O
data	B-C1511726
support	O
the	O
more	O
widespread	O
use	O
of	O
non-pharmacological	B-C0205245
pain	B-C0002766
management	I-C0002766
,	O
most	O
notably	O
in	O
patients	B-C0030705
with	O
chronic	B-C0150055
pain	I-C0150055
inadequately	O
relieved	B-C0332303
by	I-C0332303
medications	B-C0013227
synaptic	B-C0039062
and	O
neuronal	B-C0027882
autoantibody	B-C0004358
-	O
associated	B-C0332281
psychiatric	B-C0004936
syndromes	I-C0004936
controversies	B-C0680243
and	O
hypotheses	B-C1512571
autoimmune	B-C0393639
encephalitis	I-C0393639
ae	B-C0393639
mediated	O
by	O
antibodies	B-C0003241
against	O
synaptic	B-C0039062
and	O
neuronal	B-C0027882
surface	B-C0205148
targets	B-C1521840
frequently	B-C0332183
presents	B-C0150312
with	O
a	O
psychiatric	B-C0004936
syndrome	I-C0004936
.	O
	
in	O
these	O
patients	B-C0030705
,	O
removal	B-C0015252
of	I-C0015252
autoantibodies	B-C0004358
treats	B-C1522326
the	O
disease	B-C0012634
and	O
outcomes	B-C0085415
are	O
closely	O
linked	O
to	O
early	O
intervention	B-C0184661
.	O
	
the	O
discovery	B-C1880355
of	O
these	O
autoantibodies	B-C0004358
in	O
isolated	B-C0205409
psychiatric	B-C0004936
syndromes	I-C0004936
has	O
raised	B-C0442818
the	O
possibility	O
that	O
these	O
patients	B-C0030705
may	O
derive	O
similar	O
benefits	B-C0814225
from	O
immunotherapy	B-C0021083
,	O
a	O
potentially	B-C3245505
transformational	O
approach	B-C0449445
to	O
the	O
treatment	B-C0039798
of	O
mental	B-C0004936
illness	I-C0004936
.	O
	
although	O
open-label	B-C3640652
case	I-C3640652
series	I-C3640652
suggest	O
impressive	O
therapeutic	B-C0085415
outcomes	I-C0085415
,	O
the	O
pathological	B-C1521733
relevance	B-C2347946
of	O
these	O
autoantibodies	B-C0004358
outside	O
of	O
canonical	B-C0870245
presentations	I-C0870245
is	O
debated	O
.	O
	
the	O
advent	O
of	O
diagnostic	B-C0679228
criteria	I-C0679228
for	O
ae	B-C0393639
attempts	B-C1516084
to	O
facilitate	O
its	O
prompt	O
identification	B-C0205396
but	O
risks	B-C0035647
prematurely	O
neglecting	O
the	O
potential	B-C3245505
scientific	B-C0036397
and	O
clinical	B-C2826293
significance	I-C2826293
of	O
isolated	B-C0205409
syndromes	B-C0039082
that	O
do	O
not	O
satisfy	O
these	O
criteria	O
.	O
	
here	O
,	O
we	O
propose	O
using	O
a	O
syndrome	B-C0039082
-	O
level	B-C0441889
taxonomy	B-C0087066
that	O
has	O
occasional	B-C0521114
,	O
but	O
not	O
necessary	O
,	O
overlap	B-C1948020
with	O
ae	B-C0393639
synaptic	B-C0039062
and	O
neuronal	B-C0027882
autoantibody	B-C0004358
-	O
associated	B-C0332281
psychiatric	B-C0004936
syndromes	I-C0004936
or	O
""""	O
snaps	B-C0004936
""""	O
.	O
	
this	O
will	O
prevent	B-C1292733
confusion	O
with	O
ae	B-C0393639
and	O
act	B-C0597916
heuristically	I-C0597916
to	O
promote	B-C0033414
active	B-C0205177
investigation	B-C0220825
into	O
this	O
rare	B-C0522498
example	B-C1707959
of	O
psychopathology	B-C0033927
defined	B-C1704788
on	O
a	O
molecular	B-C0596958
level	I-C0596958
.	O
	
we	O
suggest	O
that	O
this	O
concept	B-C0178566
would	O
have	O
application	O
in	O
other	O
autoantibody	B-C0004358
-	O
associated	B-C0332281
syndromes	B-C0039082
including	B-C0332257
seizure	B-C0036572
,	O
cognitive	B-C1516691
,	O
and	O
movement	B-C0026650
disorders	I-C0026650
,	O
in	O
which	O
similar	B-C2348205
issues	B-C0033213
arise	O
.	O
	
we	O
review	B-C0699752
putative	O
direct	B-C1947931
and	O
indirect	B-C0439852
mechanisms	B-C0441712
and	O
outline	O
experimentally	B-C1517586
testable	O
hypotheses	B-C1512571
that	O
would	O
help	O
to	O
determine	O
prospectively	B-C0033522
in	O
whom	O
autoantibody	B-C0004358
detection	B-C1511790
is	O
relevant	B-C2347946
,	O
and	O
as	O
important	B-C3898777
,	O
in	O
whom	O
it	O
is	O
not	O
.	O
	
we	O
summarize	O
a	O
pragmatic	B-C0871858
approach	O
to	O
autoantibody	B-C0004358
testing	B-C0039593
and	O
management	B-C0376636
in	O
severe	B-C0205082
mental	B-C0004936
illness	I-C0004936
in	O
order	O
to	O
promptly	O
diagnose	B-C0011900
ae	B-C0393639
and	O
advocate	O
a	O
research	B-C0035168
-	O
orientated	B-C0424013
experimental	B-C1517586
medicine	B-C0013227
paradigm	B-C0681797
for	O
snaps	B-C0004936
,	O
where	O
there	O
is	O
greater	B-C1704243
equipoise	B-C0702057
.	O
	
we	O
conclude	O
that	O
snaps	B-C0004936
remains	O
a	O
nascent	O
area	O
of	O
clinical	B-C0205210
neuroscience	B-C0027910
with	O
great	O
potential	B-C3245505
and	O
in	O
ongoing	B-C0549178
need	B-C0027552
of	O
psychiatry	B-C0033873
-led	O
basic	O
and	O
clinical	B-C0008972
research	I-C0008972
.	O
	
nf-κb	B-C0079904
links	O
tlr2	B-C0754728
and	O
par1	B-C4048327
to	O
soluble	B-C1948047
immunomodulator	B-C1527392
factor	I-C1527392
secretion	B-C0036536
in	O
human	B-C0086418
platelets	B-C0005821
the	O
primary	B-C0205225
toll-like	B-C0670896
receptor	I-C0670896
tlr	B-C0670896
immune	B-C1511003
cell	I-C1511003
response	I-C1511003
pathway	I-C1511003
common	O
for	O
all	O
tlrs	B-C0670896
is	O
myd88	B-C0286648
-dependent	O
activation	B-C0599177
of	O
nf-κb	B-C0079904
,	O
a	O
seminal	B-C0036628
transcription	B-C0040648
factor	I-C0040648
for	O
many	O
chemokines	B-C0282554
and	O
cytokines	B-C0079189
.	O
	
remarkably	O
,	O
anucleate	B-C0005821
platelets	I-C0005821
express	O
the	O
nf-κb	B-C0079904
machinery	O
,	O
whose	O
role	O
in	O
platelets	B-C0005821
remains	O
poorly	O
understood	O
.	O
	
here	O
,	O
we	O
investigated	B-C1292732
the	O
contribution	B-C1880177
of	O
nf-κb	B-C0079904
in	O
the	O
release	B-C0391871
of	O
cytokines	B-C0079189
and	O
serotonin	B-C0036751
by	O
human	B-C0086418
platelets	B-C0005821
,	O
following	B-C0332282
selective	O
stimulation	O
of	O
tlr2	B-C0754728
and	O
protease	B-C4048327
activated	I-C4048327
receptor	I-C4048327
1	I-C4048327
par1	B-C4048327
,	O
a	O
classical	O
and	O
non-classical	O
pattern-recognition	B-C1564907
receptor	I-C1564907
,	O
respectively	O
,	O
able	O
to	O
participate	O
to	O
the	O
innate	B-C0020969
immune	I-C0020969
system	I-C0020969
.	O
	
we	O
discovered	O
that	O
platelet	B-C0005821
par1	B-C4048327
activation	B-C0599177
drives	O
the	O
process	O
of	O
nf-κb	B-C0079904
phosphorylation	B-C0031715
,	O
in	O
contrast	O
to	O
tlr2	B-C0754728
activation	B-C1514758
,	O
which	O
induces	B-C0205263
a	O
slower	O
phosphorylation	B-C0031715
process	I-C0031715
.	O
	
conversely	O
,	O
platelet	B-C0005821
par1	B-C4048327
and	O
tlr2	B-C0754728
activation	B-C1879547
induces	B-C0205263
similar	O
erk1/2	B-C2611094
,	O
p38	B-C1120843
,	O
and	O
akt	B-C0164786
phosphorylation	B-C0031715
.	O
	
moreover	O
,	O
we	O
found	O
that	O
engagement	O
of	O
platelet	B-C0005821
tlr2	B-C0754728
with	O
its	O
ligand	B-C0023688
,	O
pam3csk4	B-C1698795
,	O
significantly	B-C4055637
increases	I-C4055637
the	O
release	B-C0391871
of	O
scd62p	B-C0134835
,	O
rantes	B-C0072978
,	O
and	O
scd40l	B-C0167627
this	O
effect	B-C1280500
was	O
attenuated	B-C0332161
by	I-C0332161
incubating	B-C1439852
platelets	B-C0005821
with	O
a	O
blocking	B-C0332206
anti-tlr2	B-C3712029
antibody	I-C3712029
.	O
	
this	O
effect	B-C2348382
appeared	I-C2348382
selective	O
since	O
no	O
modulation	B-C0443264
of	O
serotonin	B-C1325900
secretion	I-C1325900
was	O
observed	B-C1441672
following	B-C0332282
platelet	B-C0005821
tlr2	B-C0754728
activation	B-C1514758
.	O
	
platelet	B-C0005821
release	B-C0391871
of	O
scd62p	B-C0134835
,	O
rantes	B-C0072978
,	O
and	O
scd40l	B-C0167627
following	B-C0332282
tlr2	B-C0754728
or	O
par1	B-C4048327
triggering	O
was	O
abolished	O
in	O
the	O
presence	B-C0150312
of	O
the	O
nf-κb	B-C0079904
inhibitor	B-C0243077
bay11-7082	B-C0969281
,	O
while	O
serotonin	B-C1979804
release	I-C1979804
following	B-C0332282
par1	B-C4048327
activation	B-C1514758
was	O
significantly	B-C4055638
decreased	I-C4055638
.	O
	
these	O
new	B-C0205314
findings	B-C2607943
support	O
the	O
concept	O
that	O
nf-κb	B-C0079904
is	O
an	O
important	O
player	O
in	O
platelet	B-C0005821
immunoregulations	B-C0678889
and	O
optical	B-C1883721
tweezers	I-C1883721
studies	B-C2603343
of	O
transcription	B-C0040649
by	O
eukaryotic	B-C0015161
rna	B-C0035681
polymerases	I-C0035681
transcription	B-C0040649
is	O
the	O
first	B-C1261552
step	I-C1261552
in	O
the	O
expression	B-C0017262
of	O
genetic	B-C0314603
information	B-C1533716
and	O
it	O
is	O
carried	B-C0206243
out	O
by	O
large	O
macromolecular	B-C1449655
enzymes	B-C0014442
called	O
rna	B-C0035681
polymerases	I-C0035681
.	O
	
transcription	B-C0040649
has	O
been	O
studied	B-C2603343
for	O
many	O
years	O
and	O
with	O
a	O
myriad	B-C1881938
of	O
experimental	B-C1517586
techniques	B-C0449851
,	O
ranging	B-C1514721
from	O
bulk	O
studies	B-C2603343
to	O
high-resolution	B-C0917793
transcript	I-C0917793
sequencing	I-C0917793
.	O
	
in	O
this	O
review	B-C0282443
,	O
we	O
emphasise	O
the	O
advantages	O
of	O
using	O
single-molecule	B-C0872367
techniques	B-C0449851
,	O
particularly	O
optical	B-C1883721
tweezers	I-C1883721
,	O
to	O
study	B-C2603343
transcription	B-C0040649
dynamics	B-C3826426
.	O
	
we	O
give	O
an	O
overview	B-C0814812
of	O
the	O
latest	O
results	B-C1274040
in	O
the	O
single-molecule	B-C0872367
transcription	B-C0040649
field	B-C1521738
,	O
focusing	O
on	O
transcription	B-C0040649
by	O
eukaryotic	B-C0015161
rna	B-C0035681
polymerases	I-C0035681
.	O
	
finally	O
,	O
we	O
evaluate	O
recent	O
quantitative	B-C0392762
models	B-C0026336
that	O
describe	B-C1552738
the	O
biophysics	B-C0005553
of	O
rna	B-C0035681
polymerase	I-C0035681
translocation	B-C0599893
and	O
backtracking	O
decreased	B-C1561548
frequencies	I-C1561548
of	O
peripheral	B-C0229664
blood	I-C0229664
cd4+cd25+cd127-foxp3+	B-C0039198
in	O
patients	B-C0030705
with	O
graves'	B-C0018213
disease	I-C0018213
and	O
graves'	B-C0339143
orbitopathy	I-C0339143
enhancing	B-C1280500
effect	I-C1280500
of	O
insulin	B-C0021665
growth	I-C0021665
factor-1	I-C0021665
on	O
treg	B-C0039198
cells	I-C0039198
graves'	B-C0339143
orbitopathy	I-C0339143
go	B-C0339143
is	O
characterized	B-C1880022
by	O
orbital	B-C0039194
t	I-C0039194
cell	I-C0039194
infiltration	B-C0332448
.	O
	
we	O
evaluated	B-C0220825
the	O
regulatory	B-C0039198
t	I-C0039198
treg	I-C0039198
cell	I-C0039198
fractions	B-C1264633
induced	B-C0205263
with	O
igf-1	B-C0021665
in	O
graves'	B-C0018213
disease	I-C0018213
gd	B-C0018213
with	O
and	O
without	O
go	B-C0339143
.	O
	
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
pbmcs	B-C1321301
were	O
obtained	O
from	O
13	O
patients	B-C0030705
with	O
gd	B-C0018213
without	O
eye	B-C0015411
manifestations	I-C0015411
10	O
patients	B-C0030705
with	O
active	B-C0205177
go	B-C0339143
and	O
12	O
patients	B-C0030705
with	O
nodular	B-C0018023
goiter	I-C0018023
ng	B-C0018023
.	O
	
all	O
the	O
patients	B-C0030705
from	O
gd	B-C0018213
,	O
go	B-C0339143
,	O
and	O
ng	B-C0018023
were	O
subclinical	B-C0745142
hyperthyroid	I-C0745142
.	O
	
we	O
analyzed	B-C0936012
the	O
expression	B-C0600223
of	I-C0600223
treg	I-C0600223
cell	I-C0600223
markers	I-C0600223
cd4	B-C0003323
,	O
cd25	B-C0007507
,	O
cd127	B-C0083032
,	O
foxp3	B-C4282118
on	O
t	B-C0039194
cells	I-C0039194
and	O
their	O
ability	O
to	O
respond	B-C1553423
to	I-C1553423
igf-1	B-C0021665
stimulation	B-C1948023
.	O
	
in	O
patients	B-C0030705
with	O
gd	B-C0018213
without	O
go	B-C0339143
,	O
we	O
found	O
lowered	B-C0439165
percentages	I-C0439165
of	O
cd4	B-C0039198
foxp3	I-C0039198
cells	I-C0039198
,	O
as	O
compared	O
to	O
nodular	B-C0018023
goiter	I-C0018023
1.77	O
vs	O
.	O
	
5.42	O
p=0	O
.	O
	
similarly	O
,	O
significantly	B-C1561548
reduced	I-C1561548
frequencies	I-C1561548
of	O
cd4	B-C0039198
and	O
cd4	B-C0039198
cells	I-C0039198
were	O
observed	B-C1441672
in	O
gd	B-C0018213
patients	B-C0030705
as	O
compared	O
to	O
nodular	B-C0018023
goiter	I-C0018023
patients	B-C0030705
with	O
hyperthyreosis	B-C0020550
,	O
0.7	O
vs	O
.	O
	
1.48	O
p=0	O
and	O
14.5	O
vs	O
.	O
	
37.2	O
p=0	O
,	O
respectively	O
.	O
	
in	O
go	B-C0339143
with	O
active	B-C0205177
go	B-C0339143
,	O
only	O
the	O
percentage	B-C0439165
of	O
cd4	B-C0039198
cells	I-C0039198
was	O
found	O
to	O
be	O
decreased	B-C0205216
versus	O
nodular	B-C0018023
goiter	I-C0018023
9.35	O
vs	O
.	O
	
37.2	O
p=0	O
.	O
	
stimulation	B-C1948023
of	O
pbmc	B-C1321301
derived	O
from	O
go	B-C0339143
patients	B-C0030705
with	O
igf-1	B-C0021665
resulted	O
in	O
significant	B-C1561548
increase	I-C1561548
of	I-C1561548
frequency	I-C1561548
of	O
both	O
cd4	B-C0039198
foxp3	I-C0039198
and	O
cd4	B-C0039198
foxp3	I-C0039198
cells	I-C0039198
.	O
	
decreased	B-C1561548
frequencies	I-C1561548
of	O
peripheral	B-C0229664
blood	I-C0229664
cd4	B-C0039198
in	O
patients	B-C0030705
with	O
gd	B-C0018213
and	O
go	B-C0339143
could	O
be	O
an	O
useful	B-C0005516
marker	I-C0005516
of	O
autoimmune	B-C0443146
process	I-C0443146
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future	B-C0039798
therapies	I-C0039798
.	O
	
this	O
is	O
the	O
first	O
study	B-C2603343
demonstrating	O
treg	B-C0039198
-	O
enhancing	B-C1280500
effects	I-C1280500
of	O
igf-1	B-C0021665
.	O
	
thus	O
igf-1	B-C0021665
can	O
be	O
accounted	O
for	O
modulating	B-C0443264
treg	B-C0039198
cell	I-C0039198
-related	O
action	B-C3266814
in	O
γ-butenolide	B-C0574031
and	O
furanone	B-C0574031
derivatives	I-C0574031
from	O
the	O
soil	B-C0037592
-derived	O
fungus	B-C0016832
aspergillus	B-C0446101
sclerotiorum	I-C0446101
psu-rspg178	B-C0446101
chromatographic	B-C0008550
separation	I-C0008550
of	O
the	O
broth	B-C2919900
extract	B-C2828366
of	O
the	O
soil	B-C0037592
-derived	O
fungus	B-C0016832
aspergillus	B-C0446101
sclerotiorum	I-C0446101
psu-rspg178	B-C0446101
resulted	O
in	O
isolation	B-C0205409
of	O
four	O
γ-butenolide-furanone	B-C0574031
dimers	I-C0574031
,	O
aspersclerotiorones	B-C0574031
a-d	I-C0574031
,	O
a	O
furanone	B-C0574031
derivative	I-C0574031
,	O
aspersclerotiorone	B-C0574031
e	I-C0574031
,	O
and	O
two	O
γ-butenolide	B-C0574031
derivatives	I-C0574031
,	O
aspersclerotiorones	B-C0574031
f	I-C0574031
and	O
g	B-C0574031
,	O
together	O
with	O
six	O
known	O
compounds	O
,	O
penicillic	B-C0030821
acid	I-C0030821
,	O
dihydropenicillic	B-C0574031
acid	I-C0574031
,	O
5	B-C0574031
acid	I-C0574031
,	O
6-methoxy-5	B-C0574031
acid	I-C0574031
,	O
coculnol	B-C0574031
and	O
4r	B-C0574031
.	O
	
their	O
structures	B-C0220807
were	O
determined	O
by	O
spectroscopic	B-C0037812
evidence	I-C0037812
.	O
	
for	O
aspersclerotiorones	B-C0574031
a	I-C0574031
and	O
b	B-C0574031
,	O
the	O
structures	B-C0220807
were	O
confirmed	O
by	O
single-crystal	B-C0206755
x-ray	I-C0206755
diffraction	I-C0206755
crystallography	I-C0206755
.	O
	
penicillic	O
acid	O
displayed	O
weak	O
antibacterial	B-C1271650
activity	I-C1271650
against	O
staphylococcus	B-C0038172
aureus	I-C0038172
and	O
escherichia	B-C0014834
coli	I-C0014834
with	O
equal	O
mic	B-C1304747
values	I-C1304747
of	O
128	O
μg/ml	O
,	O
and	O
it	O
was	O
noncytotoxic	B-C0205556
towards	O
african	B-C0026438
green	I-C0026438
monkey	I-C0026438
kidney	B-C0022646
fibroblast	B-C0016030
cells	I-C0016030
.	O
	
e3	B-C0077678
ligase	I-C0077678
rnf126	B-C3657865
directly	O
ubiquitinates	B-C1519751
frataxin	B-C0387678
,	O
promoting	B-C0033414
its	O
degradation	B-C0243125
identification	B-C0205396
of	O
a	O
potential	O
therapeutic	B-C0302350
target	B-C1521840
for	O
friedreich	B-C0016719
ataxia	I-C0016719
friedreich	B-C0016719
ataxia	I-C0016719
frda	B-C0016719
is	O
a	O
severe	O
genetic	B-C0314603
neurodegenerative	B-C0524851
disease	I-C0524851
caused	O
by	O
reduced	O
expression	B-C1171362
of	O
the	O
mitochondrial	B-C0949610
protein	I-C0949610
frataxin	B-C0387678
.	O
	
to	O
date	O
,	O
there	O
is	O
no	O
therapy	B-C0039798
to	O
treat	B-C0087111
this	O
condition	B-C0348080
.	O
	
the	O
amount	O
of	O
residual	B-C1609982
frataxin	B-C0387678
critically	O
affects	O
the	O
severity	B-C0439793
of	O
the	O
disease	B-C0012634
thus	O
,	O
attempts	O
to	O
restore	O
physiological	B-C0205463
frataxin	B-C0387678
levels	B-C0441889
are	O
considered	O
therapeutically	B-C0302350
relevant	B-C2347946
.	O
	
frataxin	B-C0387678
levels	B-C0441889
are	O
controlled	B-C0332298
by	I-C0332298
the	O
ubiquitin-proteasome	B-C1523807
system	I-C1523807
therefore	O
,	O
inhibition	B-C3463820
of	O
the	O
frataxin	B-C0387678
e3	B-C0077678
ligase	I-C0077678
may	O
represent	O
a	O
strategy	B-C0035171
to	O
achieve	O
an	O
increase	O
in	O
frataxin	B-C0387678
levels	B-C0441889
.	O
	
here	O
,	O
we	O
report	O
the	O
identification	B-C0205396
of	O
the	O
ring	B-C0077678
e3	I-C0077678
ligase	I-C0077678
rnf126	B-C3657865
as	O
the	O
enzyme	B-C0014442
that	O
specifically	O
mediates	O
frataxin	B-C0387678
ubiquitination	B-C1519751
and	O
targets	O
it	O
for	O
degradation	B-C0243125
.	O
	
rnf126	B-C3657865
interacts	B-C1704675
with	O
frataxin	B-C0387678
and	O
promotes	B-C0033414
its	O
ubiquitination	B-C1519751
in	O
a	O
catalytic	B-C1264638
activity	I-C1264638
-	O
dependent	B-C0851827
manner	O
,	O
both	O
in	B-C1515655
vivo	I-C1515655
and	O
in	B-C1533691
vitro	I-C1533691
.	O
	
most	O
importantly	O
,	O
rnf126	B-C3657865
depletion	B-C0333668
results	O
in	O
frataxin	B-C0387678
accumulation	B-C4055506
in	O
cells	B-C0007634
derived	O
from	O
frda	B-C0016719
patients	B-C0030705
,	O
highlighting	O
the	O
relevance	B-C2347946
of	O
rnf126	B-C3657865
as	O
a	O
new	O
therapeutic	B-C0302350
target	B-C1521840
for	O
friedreich	B-C0016719
ataxia	I-C0016719
.	O
	
enhancing	O
doctors'	B-C0031831
competencies	B-C0008956
in	O
communication	B-C0009452
with	O
and	O
activation	B-C1879547
of	O
older	B-C1999167
patients	B-C0030705
the	O
promoting	B-C0033414
active	B-C0205177
aging	B-C0001811
practa	B-C3898714
computer-based	B-C3898714
intervention	I-C3898714
study	I-C3898714
demographic	B-C0011298
changes	B-C0392747
over	O
the	O
past	O
decades	B-C2981279
call	O
for	O
the	O
promotion	B-C0677273
of	I-C0677273
health	I-C0677273
and	I-C0677273
disease	I-C0677273
prevention	I-C0677273
for	O
older	B-C1999167
patients	B-C0030705
,	O
as	O
well	O
as	O
strategies	O
to	O
enhance	O
their	O
independence	B-C0085862
,	O
productivity	B-C0033269
,	O
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
our	O
objective	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
computer-based	B-C0281163
educational	I-C0281163
intervention	I-C0281163
designed	O
for	O
general	B-C0017319
practitioners	I-C0017319
gps	B-C0017319
to	O
promote	O
active	B-C0205177
aging	B-C0001811
.	O
	
the	O
promoting	B-C0033414
active	O
aging	B-C0001811
practa	B-C3898714
study	O
consisted	O
of	O
a	O
baseline	B-C0034394
questionnaire	I-C0034394
,	O
implementation	B-C1708476
of	O
an	O
intervention	B-C0184661
,	O
and	O
a	O
follow-up	B-C4054939
questionnaire	I-C4054939
that	O
was	O
administered	B-C1621583
1	O
month	O
after	O
the	O
intervention	B-C3898714
.	O
	
a	O
total	O
of	O
151	O
primary	B-C1552443
care	I-C1552443
facilities	I-C1552443
response	B-C0237629
rate	I-C0237629
151/767	O
,	O
19.7	O
and	O
503	O
gps	B-C0017319
response	B-C0237629
rate	I-C0237629
503/996	O
,	O
50.5	O
agreed	O
to	O
participate	B-C0679823
in	O
the	O
baseline	B-C0282121
assessment	I-C0282121
.	O
	
at	O
the	O
follow-up	B-C0016441
,	O
393	O
gps	B-C0017319
filled	O
in	O
the	O
questionnaires	B-C0034394
response	B-C0237629
rate	I-C0237629
,	O
393/503	O
,	O
78.1	O
,	O
but	O
not	O
all	O
of	O
them	O
took	O
part	O
in	O
the	O
intervention	B-C0184661
.	O
	
the	O
final	O
study	B-C0681860
group	I-C0681860
of	O
225	O
gps	B-C0017319
participated	O
in	O
3	O
study	O
conditions	O
e-learning	B-C0009597
knowledge	B-C0162340
plus	O
skills	B-C0678856
modelling	B-C3161035
,	O
n=42	O
,	O
a	O
pdf	B-C1706852
article	I-C1706852
knowledge	B-C0162340
only	O
,	O
n=89	O
,	O
and	O
control	B-C0009932
no	B-C0332288
intervention	B-C3898714
,	O
n=94	O
.	O
	
we	O
measured	O
the	O
outcome	O
as	O
scores	B-C0449820
on	O
the	O
patients	B-C0030705
expectations	B-C0282574
scale	I-C0282574
,	O
communication	B-C0282574
scale	I-C0282574
,	O
attitude	B-C0282574
toward	I-C0282574
treatment	I-C0282574
and	I-C0282574
health	I-C0282574
scale	I-C0282574
,	O
and	O
self-efficacy	B-C0282574
scale	I-C0282574
.	O
	
gps	B-C0017319
participating	O
in	O
e-learning	B-C0009597
demonstrated	O
a	O
significant	B-C0750502
rise	O
in	O
their	O
perception	B-C0030971
of	O
older	B-C1999167
patients	B-C0030705
'	O
expectations	B-C0679138
for	O
disease	B-C0681841
explanation	I-C0681841
wald	O
χ	O
,	O
p<	O
and	O
in	O
perception	B-C0030971
of	O
motivational	B-C0026605
aspect	O
of	O
older	B-C1999167
patients	B-C0030705
'	O
attitude	O
toward	O
treatment	B-C0039798
and	O
health	B-C0018684
wald	O
χ	O
,	O
p=	O
in	O
comparison	O
with	O
both	O
the	O
control	B-C0009932
and	O
pdf	B-C0681860
article	I-C0681860
groups	I-C0681860
.	O
	
we	O
observed	O
additional	O
between-	O
group	B-C0681860
differences	O
at	O
the	O
level	B-C0441889
of	O
statistical	B-C0038215
trend	O
.	O
	
gps	B-C0017319
participating	O
in	O
the	O
pdf	B-C1706852
article	I-C1706852
intervention	B-C0184661
demonstrated	O
a	O
decline	O
in	O
self-assessed	O
communication	B-C0009452
,	O
both	O
at	O
the	O
level	B-C0441889
of	O
global	B-C0449820
scoring	I-C0449820
wald	O
χ	O
,	O
p<	O
and	O
at	O
the	O
level	B-C0441889
of	O
20	O
of	O
26	O
specific	B-C0679160
behaviors	I-C0679160
all	O
p<	O
.	O
	
factors	O
moderating	O
the	O
effects	B-C1704420
of	I-C1704420
the	O
intervention	B-C0184661
were	O
the	O
number	O
of	O
patients	B-C0030705
per	O
gp	B-C0017319
and	O
the	O
facility's	O
organizational	B-C0687114
structure	I-C0687114
.	O
	
both	O
methods	O
were	O
suitable	O
,	O
but	O
in	O
different	O
areas	B-C0205146
and	O
under	O
different	O
conditions	B-C0348080
.	O
	
the	O
key	O
benefit	O
of	O
the	O
pdf	B-C1706852
article	I-C1706852
intervention	B-C0184661
was	O
raising	O
doctors	B-C0031831
'	O
reflection	O
on	O
limitations	B-C0449295
in	O
their	O
communication	B-C0870313
skills	I-C0870313
,	O
whereas	O
e-learning	B-C0009597
was	O
more	O
effective	B-C1704419
in	O
changing	O
their	O
perception	O
of	O
older	B-C1999167
patients	B-C0030705
'	O
proactive	O
attitude	O
,	O
especially	O
among	O
gps	B-C0017319
working	O
in	O
privately	B-C0033173
owned	I-C0033173
facilities	I-C0033173
and	O
having	O
a	O
greater	O
number	O
of	O
assigned	B-C1516050
patients	B-C0030705
.	O
	
although	O
we	O
did	O
not	O
achieve	O
all	O
expected	O
effects	B-C1704420
of	I-C1704420
the	O
practa	B-C3898714
intervention	I-C3898714
,	O
both	O
its	O
forms	O
seem	O
promising	O
in	O
terms	O
of	O
enhancing	O
the	O
competencies	B-C0008956
of	O
doctors	B-C0031831
in	O
communication	B-C0009452
with	O
and	O
activation	O
of	O
older	B-C1999167
patients	B-C0030705
.	O
	
the	O
consummatory	B-C0009829
and	O
motivational	B-C0026605
behaviors	B-C0004927
for	O
natural	B-C0205296
rewards	B-C0035397
following	O
long-term	O
withdrawal	B-C1707825
from	O
morphine	B-C0026549
no	O
anhedonia	B-C0178417
but	O
persistent	O
maladaptive	B-C0562443
behaviors	I-C0562443
for	O
high-value	O
rewards	B-C0035397
the	O
negative	O
affective	O
state	O
,	O
e.g	O
,	O
anhedonia	B-C0178417
,	O
emerges	O
after	O
abstinence	B-C3843422
from	O
abused	B-C0086190
drugs	I-C0086190
may	O
be	O
linked	O
to	O
the	O
motivational	B-C0026605
processes	B-C1522240
of	O
drug	B-C0556446
craving	I-C0556446
and	O
relapse	B-C0035020
.	O
	
although	O
anhedonia	B-C0178417
diminishes	O
over	O
time	O
with	O
drug	B-C0237443
abstinence	I-C0237443
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	B-C0178417
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	B-C1707825
.	O
	
the	O
behavioral	B-C0004927
responses	B-C0871261
to	O
natural	B-C0205296
rewards	B-C0035397
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	B-C0439230
withdrawal	B-C1707825
from	O
morphine	B-C0026549
.	O
	
male	B-C0086582
rats	B-C0034693
were	O
pretreated	O
with	O
either	O
a	O
binge-like	O
morphine	B-C0026549
paradigm	B-C0681797
or	O
daily	B-C0332173
saline	B-C0199797
injection	I-C0199797
for	O
5	O
days	B-C0439228
.	O
	
the	O
consummatory	B-C0009829
and	O
motivational	B-C0026605
behaviors	B-C0004927
for	O
three	O
natural	B-C0205296
rewards	B-C0035397
sucrose	B-C0038636
solutions	I-C0038636
4	O
,	O
15	O
,	O
and	O
60%	O
,	O
social	B-C0728831
stimulus	B-C0234402
male	B-C0086582
rat	B-C0034693
,	O
and	O
sexual	B-C0036865
stimulus	B-C0234402
estrous	B-C0014948
female	B-C0086287
rat	B-C0034693
were	O
examined	O
under	O
varied	O
testing	B-C0449910
conditions	I-C0449910
.	O
	
the	O
morphine	B-C0026549
-	O
withdrawn	B-C1707825
rats	B-C0034693
significantly	O
increased	O
their	O
intake	O
of	O
15%	O
sucrose	B-C0038636
solution	I-C0038636
during	O
the	O
1-h	O
consumption	B-C0683443
test	I-C0683443
and	O
their	O
operant	B-C0009651
responding	I-C0009651
for	O
15%	O
sucrose	B-C0038636
solution	I-C0038636
under	O
a	O
progressive	B-C0871209
ratio	I-C0871209
pr	I-C0871209
schedule	I-C0871209
of	I-C0871209
reinforcement	I-C0871209
.	O
	
when	O
obtaining	O
a	O
reinforcer	B-C0178826
was	O
associated	O
with	O
a	O
0.5	O
ma	O
foot	B-C0016504
shock	B-C0013870
under	O
a	O
pr-punishment	B-C0035008
schedule	I-C0035008
,	O
the	O
morphine	B-C0026549
-	O
withdrawn	B-C1707825
rats	B-C0034693
showed	O
a	O
higher	O
performance	O
for	O
60%	O
sucrose	B-C0038636
solution	I-C0038636
.	O
	
meanwhile	O
,	O
the	O
morphine	B-C0026549
-	O
withdrawn	B-C1707825
rats	B-C0034693
displayed	O
a	O
higher	O
motivation	B-C0026605
to	O
sexual	B-C0036865
stimulus	B-C0234402
during	O
the	O
free-approach	B-C0683443
test	I-C0683443
and	O
more	O
approaching	O
behaviors	B-C0004927
towards	O
sexual	B-C0036865
stimulus	B-C0234402
in	O
a	O
conflict-based	B-C0683444
approach	I-C0683444
test	I-C0683444
concurrent	O
presence	O
of	O
reward	B-C0035397
and	O
aversive	B-C1510994
stimulus	I-C1510994
.	O
	
no	B-C1513916
anhedonia	B-C0178417
-like	O
behavior	B-C0004927
but	O
sensitized	B-C0332324
behaviors	B-C0004927
for	O
natural	B-C0205296
rewards	B-C0035397
were	O
found	O
after	O
long-term	O
morphine	B-C0026549
withdrawal	B-C1707825
.	O
	
notably	O
,	O
the	O
morphine	B-C0026549
-	O
withdrawn	B-C1707825
rats	B-C0034693
displayed	O
persistent	O
motivated	B-C0026605
behaviors	B-C0004927
for	O
high-value	O
rewards	B-C0035397
60%	O
sucrose	B-C0038636
and	O
sexual	B-C0036865
stimulus	B-C0234402
in	O
the	O
conflict	B-C0683443
tests	I-C0683443
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	B-C0026549
-	O
treated	B-C1522326
rats	B-C0034693
.	O
	
extracellular	B-C0521119
self-assembly	B-C0872376
of	O
functional	B-C0205245
and	O
tunable	B-C0033684
protein	I-C0033684
conjugates	I-C0033684
from	O
bacillus	B-C0004595
subtilis	I-C0004595
the	O
ability	O
to	O
stably	B-C0205360
and	O
specifically	O
conjugate	B-C1160466
recombinant	B-C0034861
proteins	I-C0034861
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	B-C0017387
multifunctional	B-C0205245
enzymes	B-C0014442
,	O
protein	B-C0872285
therapeutics	I-C0872285
,	O
and	O
novel	B-C0205314
biological	B-C0005479
materials	I-C0005479
.	O
	
while	O
many	O
of	O
these	O
applications	B-C0869019
have	O
been	O
illustrated	O
through	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
intracellular	B-C0178719
protein	B-C1160466
conjugation	I-C1160466
methods	O
,	O
extracellular	B-C0521119
self-assembly	B-C0872376
of	O
protein	B-C0033684
conjugates	I-C0033684
offers	O
unique	O
advantages	O
simplifying	O
purification	B-C0597301
,	O
reducing	B-C0392756
toxicity	B-C0600688
and	O
burden	B-C2828008
,	O
and	O
enabling	O
tunability	B-C0205556
.	O
	
exploiting	O
the	O
recently	O
described	O
spytag-spycatcher	B-C0022885
system	I-C0022885
,	O
we	O
describe	O
here	O
how	O
enzymes	B-C0014442
and	O
structural	B-C0582263
proteins	I-C0582263
can	O
be	O
genetically	B-C0314627
encoded	I-C0314627
to	O
covalently	B-C1511539
conjugate	B-C1160466
in	O
culture	B-C0010454
media	I-C0010454
following	O
programmable	B-C1327616
secretion	I-C1327616
from	O
bacillus	B-C0004595
subtilis	I-C0004595
.	O
	
using	O
this	O
approach	O
,	O
we	O
demonstrate	O
how	O
self-conjugation	B-C1160466
of	O
a	O
secreted	B-C1327616
industrial	O
enzyme	B-C0014442
,	O
xyna	B-C0149034
,	O
dramatically	O
increases	B-C0205217
its	O
resilience	B-C1821534
to	O
boiling	B-C0018851
,	O
and	O
we	O
show	O
that	O
cellular	B-C0007634
consortia	I-C0007634
can	O
be	O
engineered	B-C0017387
to	O
self-assemble	B-C0872376
functional	B-C0205245
protein-protein	B-C0033684
conjugates	I-C0033684
with	O
tunable	O
composition	O
.	O
	
this	O
novel	B-C0205314
genetically	B-C0314627
encoded	I-C0314627
modular	B-C0449913
system	I-C0449913
provides	O
a	O
flexible	B-C0443220
strategy	I-C0443220
for	O
protein	B-C1160466
conjugation	I-C1160466
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	B-C0521119
self-assembly	B-C0872376
.	O
	
vascular	B-C4082861
smooth	I-C4082861
muscle	I-C4082861
cell	I-C4082861
peroxisome	B-C0166417
proliferator-activated	I-C0166417
receptor	I-C0166417
γ	I-C0166417
protects	O
against	O
endothelin-1	B-C0079281
-	O
induced	B-C0205263
oxidative	B-C0242606
stress	I-C0242606
and	O
inflammation	B-C0021368
peroxisome	B-C0166417
proliferator-activated	I-C0166417
receptor	I-C0166417
γ	I-C0166417
pparγ	B-C0166417
agonists	B-C0243192
reduce	B-C0392756
blood	B-C0005823
pressure	I-C0005823
and	O
vascular	B-C0178324
injury	I-C0178324
in	O
hypertensive	B-C0857121
rodents	B-C0035804
.	O
	
pparγ	B-C0166417
inactivation	B-C0314679
in	O
vascular	B-C4082861
smooth	I-C4082861
muscle	I-C4082861
cells	I-C4082861
vsmc	B-C4082861
enhances	B-C2349975
vascular	B-C0178324
injury	I-C0178324
.	O
	
transgenic	B-C0025936
mice	I-C0025936
overexpressing	B-C1171362
endothelin	B-C0079281
et	I-C0079281
selectively	O
in	O
the	O
endothelium	B-C0014257
eet-1	B-C0079281
exhibit	O
endothelial	B-C0856169
dysfunction	I-C0856169
,	O
increased	B-C0205217
oxidative	B-C0242606
stress	I-C0242606
and	O
inflammation	B-C0021368
.	O
	
we	O
hypothesized	B-C1512571
that	O
inactivation	B-C0314679
of	O
the	O
pparγ	B-C1335238
gene	I-C1335238
in	O
vsmc	B-C4082861
smpparγ	B-C1335238
would	O
exaggerate	B-C0442801
et-1	B-C0079281
-	O
induced	B-C0205263
vascular	B-C0178324
injury	I-C0178324
.	O
	
eet-1	B-C0079281
,	O
smpparγ	B-C0166417
and	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
mice	B-C0025929
were	O
treated	B-C0332154
with	O
tamoxifen	B-C0039286
for	O
5	O
days	O
and	O
studied	B-C2603343
4	O
weeks	O
later	O
.	O
	
sbp	B-C0871470
was	O
higher	B-C0205250
in	O
eet-1	B-C0079281
and	O
unaffected	B-C2986417
by	O
smpparγ	B-C0166417
inactivation	B-C0314679
.	O
	
mesenteric	B-C0025465
artery	I-C0025465
vasodilatory	B-C0042401
responses	B-C0871261
to	O
acetylcholine	B-C0001041
were	O
impaired	B-C0221099
only	O
in	O
smpparγ	B-C0166417
.	O
	
n-nitro-l-arginine	B-C0083536
methyl	I-C0083536
ester	I-C0083536
abrogated	B-C3242341
relaxation	B-C0035028
responses	B-C0871261
,	O
and	O
the	O
ednra	B-C1414262
/	O
ednrb	B-C1414263
mrna	B-C0035696
ratio	B-C0456603
was	O
decreased	B-C0205216
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
,	O
which	O
could	O
indicate	B-C3146298
that	O
nitric	B-C0028128
oxide	I-C0028128
production	B-C1883254
was	O
enhanced	B-C2349975
by	O
et-1	B-C0079281
stimulation	B-C0599177
of	O
endothelin	B-C0218584
type	I-C0218584
b	I-C0218584
receptors	I-C0218584
.	O
	
mesenteric	B-C0025465
artery	I-C0025465
media	B-C1705217
/	O
lumen	B-C1301906
was	O
greater	B-C1704243
only	O
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
.	O
	
mesenteric	B-C0025465
artery	I-C0025465
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
increased	B-C0205217
in	O
smpparγ	B-C0166417
and	O
were	O
further	O
enhanced	B-C2349975
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
.	O
	
perivascular	B-C0442165
fat	B-C0206131
monocyte	I-C0206131
/	O
macrophage	B-C0024432
infiltration	B-C0332448
was	O
higher	B-C0205250
in	O
eet-1	B-C0079281
and	O
smpparγ	B-C0166417
and	O
increased	B-C0205217
further	O
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
.	O
	
spleen	B-C0037993
cd11b	B-C1983879
cells	I-C1983879
were	O
increased	B-C0205217
in	O
smpparγ	B-C0166417
and	O
further	O
enhance	B-C2349975
d	O
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
,	O
whereas	O
ly-6c	B-C0440752
monocytes	I-C0440752
increased	B-C0205217
in	O
eet-1	B-C0079281
and	O
smpparγ	B-C0166417
but	O
not	O
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
.	O
	
spleen	B-C0037993
t	B-C0039198
regulatory	I-C0039198
lymphocytes	I-C0039198
increased	B-C0205217
in	O
smpparγ	B-C0166417
and	O
decreased	B-C0205216
in	O
eet-1	B-C0079281
,	O
and	O
decreased	B-C0205216
further	O
in	O
eet-1	B-C0079281
/	O
smpparγ	B-C0166417
.	O
	
vsmc	B-C4082861
pparγ	B-C0166417
inactivation	B-C0314679
exaggerates	B-C0442801
et-1	B-C0079281
-	O
induced	B-C0205263
vascular	B-C0178324
injury	I-C0178324
,	O
supporting	O
a	O
protective	O
role	B-C1705810
for	O
pparγ	B-C0166417
in	O
hypertension	B-C0020538
through	O
modulation	B-C0443264
of	O
pro-oxidant	B-C0162772
and	O
proinflammatory	B-C0333348
pathways	B-C1704259
.	O
	
paradoxically	O
,	O
et-1	B-C0079281
overexpression	B-C1171362
preserved	O
endothelial	B-C0014257
function	B-C0542341
in	O
smpparγ	B-C0166417
mice	B-C0025929
,	O
presumably	O
by	O
enhancing	B-C2349975
nitric	B-C0028128
oxide	I-C0028128
through	O
stimulation	B-C0599177
of	O
endothelin	B-C0218584
type	I-C0218584
b	I-C0218584
receptors	I-C0218584
.	O
	
prospective	O
evaluation	B-C0220825
of	O
opioid	B-C0240602
consumption	I-C0240602
after	O
distal	B-C0435585
radius	I-C0435585
fracture	I-C0435585
repair	B-C0543467
surgery	I-C0543467
pain	B-C0002766
management	I-C0002766
and	O
opioid	B-C0240602
consumption	I-C0240602
after	O
distal	B-C0435585
radius	I-C0435585
fracture	I-C0435585
drf	B-C0435585
open	B-C0747060
reduction	I-C0747060
and	I-C0747060
internal	I-C0747060
fixation	I-C0747060
orif	I-C0747060
are	O
highly	O
variable	O
and	O
poorly	O
understood	O
.	O
	
to	O
optimize	B-C1273380
postoperative	B-C0032790
opioid	B-C0002772
dosage	B-C0178602
and	O
better	O
understand	O
opioid	B-C0240602
consumption	I-C0240602
patterns	O
after	O
drf	B-C0435585
-	O
orif	B-C0747060
,	O
we	O
conducted	O
a	O
prospective	B-C0033522
study	I-C0033522
with	O
the	O
hypothesis	B-C1512571
that	O
opioid	B-C0240602
consumption	I-C0240602
would	O
increase	B-C0442805
with	O
worsening	B-C0332271
fracture	B-C0016658
classification	B-C0008902
and	O
various	O
patient	B-C1548106
demographics	I-C1548106
.	O
	
all	O
patients	B-C0030705
who	O
underwent	O
drf	B-C0435585
-	O
orif	B-C0747060
were	O
consecutively	O
enrolled	O
over	O
a	O
6-month	B-C0439231
period	I-C0439231
.	O
	
information	O
collected	O
included	O
patient	B-C1548106
demographics	I-C1548106
,	O
fracture	B-C0457357
type	I-C0457357
,	O
anesthesia	B-C1305863
type	I-C1305863
,	O
amount	B-C0178602
and	O
type	B-C0332307
of	O
opioid	B-C0002772
prescribed	B-C0278329
,	O
number	B-C0237753
of	O
pills	B-C0002772
taken	B-C1883727
,	O
reason	B-C1550000
for	O
stopping	B-C0850893
,	O
and	O
adverse	B-C0877248
events	I-C0877248
.	O
	
statistical	B-C0871424
analysis	I-C0871424
was	O
performed	O
.	O
	
ninety-eight	O
patients	B-C0030705
79	O
female	B-C0043210
,	O
19	O
male	B-C0025266
were	O
eligible	O
for	O
the	O
study	O
.	O
	
mean	O
age	O
was	O
58	O
years	O
.	O
	
of	O
the	O
98	O
patients	B-C0030705
,	O
45	O
received	O
general	B-C0002915
anesthesia	I-C0002915
,	O
and	O
53	O
received	O
regional	B-C1304876
anesthesia	I-C1304876
with	O
a	O
single-shot	O
peripheral	B-C0198807
nerve	I-C0198807
block	I-C0198807
.	O
	
mean	O
opioid	B-C0240602
consumption	I-C0240602
morphine	B-C0026549
equivalence	B-C0205163
over	O
a	O
mean	O
of	O
4.8	O
postoperative	B-C0032790
days	I-C0032790
range	O
,	O
0-16	O
days	O
was	O
58.5	O
mg	O
range	O
,	O
0-280	O
mg	O
.	O
	
there	O
were	O
no	B-C1273937
significant	I-C1273937
differences	O
in	O
opioid	B-C0240602
consumption	I-C0240602
between	O
the	O
general	B-C0002915
and	O
regional	B-C1304876
anesthesia	I-C1304876
groups	O
.	O
	
mean	O
opioid	B-C0240602
consumption	I-C0240602
for	O
the	O
3	O
fracture-type	B-C0457357
groups	O
ao/ota	B-C0559822
arbeitsgemeinschaft	I-C0559822
für	I-C0559822
osteosynthesefragen/orthopaedic	I-C0559822
trauma	I-C0559822
association	I-C0559822
classification	I-C0559822
was	O
57.7	O
mg	O
class	B-C0008902
a	I-C0008902
,	O
60.3	O
mg	O
class	B-C0008902
b	I-C0008902
,	O
and	O
62.0	O
mg	O
class	B-C0008902
c	I-C0008902
.	O
	
demographic	B-C0011289
analysis	I-C0011289
revealed	O
an	O
inverse	B-C0439850
relationship	B-C0439849
between	O
age	B-C0001779
and	O
opioid	B-C0240602
use	I-C0240602
.	O
	
similarly	O
,	O
there	O
was	O
a	O
trend	O
toward	O
more	O
opioid	B-C0240602
consumption	I-C0240602
among	O
self-pay	B-C3530213
and	O
medicaid	B-C0025071
patients	B-C0030705
.	O
	
opioid	B-C0240602
consumption	I-C0240602
after	O
drf	B-C0435585
-	O
orif	B-C0747060
was	O
equivalent	B-C0205163
for	O
general	B-C0002915
and	O
regional	B-C1304876
anesthesia	I-C1304876
.	O
	
a	O
significant	O
relationship	B-C0439849
was	O
found	O
between	O
increasing	B-C3550265
age	I-C3550265
and	O
decreasing	B-C0442797
opioid	B-C0240602
consumption	I-C0240602
.	O
	
worsening	B-C0332271
fracture	B-C0559822
classification	I-C0559822
and	O
self-payment	B-C3530213
/	O
medicaid	B-C0025071
payment	I-C0025071
trended	O
toward	O
increasing	B-C0442808
opioid	B-C0240602
consumption	I-C0240602
.	O
	
mean	O
overall	O
opioid	B-C0240602
consumption	I-C0240602
morphine	B-C0026549
equivalence	B-C0205163
was	O
58.5	O
mg	O
,	O
or	O
14.6	O
pills	B-C0994475
of	O
oxycodone/acetaminophen	B-C0717368
5/325	O
mg	O
.	O
	
surgeons	B-C0582175
should	O
take	O
these	O
findings	O
into	O
account	O
when	O
optimizing	B-C1273380
opioid	B-C0002772
prescribing	O
after	O
drf	B-C0435585
repair	B-C0543467
.	O
	
entrapment	B-C0917811
of	O
the	O
posterior	B-C0228931
femoral	I-C0228931
cutaneous	I-C0228931
nerve	I-C0228931
and	O
its	O
inferior	B-C0229962
cluneal	I-C0229962
branches	I-C0229962
anatomical	B-C0277809
basis	I-C0277809
of	O
surgery	B-C1274039
for	O
inferior	B-C0027796
cluneal	I-C0027796
neuralgia	I-C0027796
the	O
apparent	O
failure	O
of	O
pudendal	B-C0228959
nerve	I-C0228959
surgery	B-C1274039
in	O
some	O
patients	B-C0030705
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	B-C0917811
of	O
other	O
adjacent	B-C0027740
nerve	I-C0027740
structures	I-C0027740
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	B-C0027796
cluneal	I-C0027796
neuralgia	I-C0027796
.	O
	
via	O
its	O
numerous	O
collateral	B-C0229962
branches	I-C0229962
,	O
the	O
posterior	B-C0228931
femoral	I-C0228931
cutaneous	I-C0228931
nerve	I-C0228931
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	B-C0230422
surface	I-C0230422
of	I-C0230422
the	I-C0230422
thigh	I-C0230422
,	O
the	O
infragluteal	B-C0229962
fold	I-C0229962
,	O
the	O
skin	B-C1123023
over	O
the	O
ischial	B-C0223656
tuberosity	I-C0223656
,	O
but	O
also	O
the	O
lateral	B-C0005898
anal	I-C0005898
region	I-C0005898
,	O
scrotum	B-C0036471
or	O
labium	B-C0227760
majus	I-C0227760
via	O
its	O
perineal	B-C0739940
branch	I-C0739940
.	O
	
we	O
described	O
the	O
pathophysiological	B-C0031847
features	B-C1521970
of	O
cluneal	B-C0027796
neuralgia	I-C0027796
,	O
the	O
surgical	B-C0011918
technique	I-C0011918
and	O
our	O
preliminary	B-C1548161
results	I-C1548161
.	O
	
we	O
performed	O
a	O
transmuscular	B-C1997294
approach	I-C1997294
leading	O
to	O
the	O
fat	B-C0015665
of	O
the	O
deep	O
gluteal	B-C0282082
region	I-C0282082
.	O
	
exploration	B-C1280903
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	B-C0224429
,	O
looking	O
for	O
potential	O
entrapments	B-C0917811
affecting	O
the	O
posterior	B-C0228931
femoral	I-C0228931
cutaneous	I-C0228931
nerve	I-C0228931
and	O
the	O
sciatic	B-C0036394
nerve	I-C0036394
.	O
	
nerve	B-C0196571
decompression	I-C0196571
on	O
the	O
lateral	B-C0230424
surface	I-C0230424
of	O
the	O
ischial	B-C0223656
tuberosity	I-C0223656
was	O
then	O
performed	O
.	O
	
a	O
constant	O
anatomical	B-C0277809
finding	I-C0277809
must	O
be	O
highlighted	O
the	O
presence	O
of	O
a	O
lateral	B-C0225331
fibrous	I-C0225331
expansion	B-C0196940
from	O
the	O
ischium	B-C0223653
passing	O
behind	O
the	O
nerves	B-C0027740
and	O
vessels	B-C0005847
,	O
especially	O
the	O
posterior	B-C0228931
femoral	I-C0228931
cutaneous	I-C0228931
nerve	I-C0228931
and	O
its	O
perineal	B-C0739941
branches	I-C0739941
.	O
	
in	O
our	O
patients	B-C0030705
,	O
release	O
of	O
this	O
expansion	B-C0196940
allowed	O
decompression	B-C0196571
of	O
the	O
nerve	B-C0917811
trapped	I-C0917811
by	O
this	O
expansion	B-C0196940
.	O
	
cluneal	B-C0027796
neuralgia	I-C0027796
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	B-C0240717
pain	I-C0240717
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	B-C1997249
neuralgia	I-C1997249
.	O
	
surgery	B-C1274039
should	O
be	O
performed	O
via	O
a	O
transgluteal	B-C0444462
approach	I-C0444462
.	O
	
a	O
lateral	B-C0223653
ischial	I-C0223653
obstacle	O
must	O
be	O
investigated	B-C1292732
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	B-C0225331
expansion	B-C0196940
,	O
which	O
,	O
like	O
a	O
retinaculum	B-C0224996
,	O
can	O
cause	O
nerve	B-C0917811
entrapment	I-C0917811
.	O
	
methods	B-C0025663
to	O
study	B-C2603343
autophagy	B-C0004391
in	O
zebrafish	B-C0043457
autophagy	B-C0004391
cellular	B-C0004391
self-eating	I-C0004391
is	O
a	O
highly	O
regulated	O
degradation	B-C0314674
process	I-C0314674
of	O
the	O
eukaryotic	B-C0015161
cell	I-C0015161
during	O
which	O
parts	O
of	O
the	O
cytoplasm	B-C0010834
are	O
delivered	B-C1705822
into	O
,	O
and	O
broken	B-C0443161
down	I-C0443161
within	O
,	O
the	O
lysosomal	B-C0521450
compartment	I-C0521450
.	O
	
the	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	B-C0221102
of	O
superfluous	O
and	O
damaged	O
cellular	B-C0243092
constituents	I-C0243092
,	O
thereby	O
mediating	O
macromolecular	B-C1148560
and	O
organellar	B-C1254358
turnover	I-C1254358
.	O
	
in	O
addition	O
to	O
maintaining	O
cellular	B-C2244223
homeostasis	I-C2244223
,	O
autophagy	B-C0004391
is	O
involved	O
in	O
various	O
other	O
cellular	B-C1325880
and	O
developmental	B-C0678723
processes	I-C0678723
by	O
degrading	B-C0314674
specific	O
regulatory	B-C0815047
proteins	I-C0815047
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	B-C0178719
pathogens	B-C0450254
.	O
	
the	O
physiological	B-C0205463
roles	I-C0205463
and	O
pathological	B-C1521733
involvement	O
of	O
autophagy	B-C0004391
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	B-C0684063
model	B-C0026339
systems	I-C0026339
ranging	O
from	O
yeast	B-C0043393
to	O
mice	B-C0026809
.	O
	
such	O
a	O
tractable	O
animal	B-C0599779
model	I-C0599779
applied	O
only	O
recently	O
for	O
autophagy	B-C0004391
researchis	O
the	O
zebrafish	B-C0043457
danio	B-C0043457
rerio	I-C0043457
,	O
which	O
also	O
facilitates	O
the	O
analysis	B-C0936012
of	O
more	O
specific	O
biological	B-C3714634
processes	I-C3714634
such	O
as	O
tissue	B-C1623047
regeneration	I-C1623047
.	O
	
in	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	B-C0025664
and	I-C0025664
tools	I-C0025664
that	O
are	O
used	O
to	O
monitor	O
autophagic	B-C0243092
structures	I-C0243092
and	O
to	O
assay	B-C0005507
autophagic	B-C0007613
responses	I-C0007613
in	O
this	O
vertebrate	B-C0042567
organism	I-C0042567
.	O
	
we	O
place	O
emphasis	O
on	O
genetic	B-C0017395
functional	I-C0017395
approaches	I-C0017395
applied	O
for	O
exploring	O
novel	O
cellular	B-C1325880
and	O
developmental	B-C0678723
roles	I-C0678723
of	O
the	O
autophagic	B-C0004391
process	I-C0004391
.	O
	
healthcare	B-C0086388
usage	B-C0457083
and	O
economic	B-C0681024
impact	I-C0681024
of	O
non-treated	B-C0332155
obesity	B-C0028754
in	O
italy	B-C0022277
findings	B-C2607943
from	O
a	O
retrospective	B-C1514923
administrative	B-C3845829
and	O
clinical	B-C1516642
database	I-C1516642
analysis	B-C0936012
investigate	B-C1292732
the	O
prevalence	B-C0683921
of	O
obesity	B-C0028754
in	O
italy	B-C0022277
and	O
examine	O
its	O
resource	B-C0035201
consumption	B-C0243095
and	O
economic	B-C0681024
impact	I-C0681024
on	O
the	O
italian	B-C0022277
national	B-C0282574
healthcare	I-C0282574
system	I-C0282574
nhs	B-C0282574
.	O
	
retrospective	B-C1514923
,	O
observational	B-C1518527
and	O
real-life	B-C2603343
study	I-C2603343
.	O
	
data	B-C1511726
from	O
three	O
health	B-C1708333
units	I-C1708333
from	O
northern	B-C1709269
bergamo	B-C0017446
,	O
lombardy	B-C0017446
,	O
central	B-C0205099
grosseto	B-C0017446
,	O
tuscany	B-C0017446
and	O
southern	B-C1710133
naples	B-C0017446
,	O
campania	B-C0017446
italy	B-C0022277
.	O
	
all	O
patients	B-C0030705
aged	B-C0001779
18	B-C0439234
years	I-C0439234
with	O
at	O
least	O
one	O
recorded	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
measurement	B-C0242485
between	O
1	O
january	O
2009	O
and	O
31	O
december	O
2012	O
were	O
included	O
.	O
	
information	B-C1533716
retrieved	O
from	O
the	O
databases	B-C0242356
included	O
primary	B-C1511726
care	I-C1511726
data	I-C1511726
,	O
medical	B-C1521941
prescriptions	I-C1521941
,	O
specialist	B-C2090905
consultations	I-C2090905
and	O
hospital	B-C0743221
discharge	I-C0743221
records	I-C0743221
from	O
2009-2013	O
.	O
	
costs	B-C0010186
associated	B-C0332281
with	I-C0332281
these	O
data	B-C1511726
were	O
also	O
calculated	B-C1441506
.	O
	
data	B-C1511726
are	O
presented	O
for	O
two	O
time	B-C1948053
periods	I-C1948053
1	B-C0439234
year	I-C0439234
after	O
bmi	B-C1305855
measurement	B-C0242485
and	O
study	O
end	O
.	O
	
primary	B-C0205225
-to	O
estimate	B-C0750572
health	B-C0018741
resources	I-C0018741
consumption	B-C0243095
and	O
the	O
associated	O
economic	B-C0681024
impact	I-C0681024
on	O
the	O
italian	B-C0022277
nhs	B-C0282574
.	O
	
secondary	B-C0205436
-the	O
prevalence	B-C0683921
and	O
characteristics	B-C1521970
of	O
subjects	B-C0080105
by	O
bmi	B-C1305855
category	B-C0683312
.	O
	
20	O
159	O
adult	B-C0001675
subjects	B-C0080105
with	O
at	O
least	O
one	O
documented	B-C2724372
bmi	I-C2724372
measurement	B-C0242485
.	O
	
subjects	B-C0080105
with	O
bmi	B-C1305855
30	O
kg/m	O
were	O
defined	O
as	O
obese	B-C0028754
.	O
	
the	O
prevalence	B-C0683921
of	O
obesity	B-C0028754
was	O
22.2	O
n=4471	O
and	O
increased	B-C0205217
with	O
age	B-C0001779
.	O
	
at	O
the	O
1-year	B-C0439234
observation	B-C0302523
period	B-C1948053
,	O
obese	B-C0028754
subjects	B-C0080105
who	O
did	O
not	O
receive	O
treatment	B-C0087111
for	O
their	O
obesity	B-C0028754
experienced	O
longer	B-C0449238
durations	I-C0449238
of	O
hospitalisation	B-C0019993
median	O
length	O
5	B-C0439228
days	I-C0439228
vs	O
3	B-C0439228
days	I-C0439228
,	O
used	O
more	O
prescription	B-C0304227
drugs	I-C0304227
75.0	O
vs	O
57.7	O
,	O
required	O
more	O
specialised	B-C1704211
outpatient	B-C0029921
healthcare	B-C0086388
mean	B-C0392762
number	I-C0392762
5.3	O
vs	O
4.4	O
and	O
were	O
associated	B-C0332281
with	I-C0332281
greater	B-C0010186
costs	I-C0010186
,	O
primarily	O
owing	O
to	O
prescription	B-C0304227
drugs	I-C0304227
and	O
hospital	B-C0184666
admissions	I-C0184666
mean	B-C0010186
annual	I-C0010186
cost	I-C0010186
per	O
year	B-C0439234
per	O
patient	B-C0030705
460.6	O
vs	O
288.0	O
for	O
drug	B-C0033081
prescriptions	I-C0033081
,	O
422.7	O
vs	O
279.2	O
for	O
hospitalisations	B-C0019993
and	O
283.2	O
vs	O
251.7	O
for	O
outpatient	B-C0002423
care	I-C0002423
,	O
compared	O
with	O
normal	B-C2712185
weight	I-C2712185
subjects	B-C0080105
.	O
	
similar	O
findings	B-C2607943
were	O
observed	O
for	O
the	O
period	B-C1948053
up	O
to	O
data	B-C1511726
cut-off	O
mean	O
follow-up	B-C1522577
of	O
2.7	O
years	O
.	O
	
untreated	B-C0332155
obesity	B-C0028754
has	O
a	O
significant	O
economic	B-C0681024
impact	I-C0681024
on	O
the	O
italian	B-C0022277
healthcare	B-C0282574
system	I-C0282574
,	O
highlighting	O
the	O
need	O
to	O
raise	O
awareness	B-C0004448
and	O
proactively	O
treat	B-C0087111
obese	O
effects	B-C1704420
of	I-C1704420
heat	B-C0018837
treatment	B-C1522326
on	O
conformation	B-C0033625
and	O
cell	B-C0007595
growth	I-C0007595
activity	O
of	O
alpha-	B-C0002287
lactalbumin	I-C0002287
and	O
beta-lactoglobulin	B-C0005248
from	O
market	B-C1318228
milk	B-C2825079
heat	B-C0018837
processes	B-C1522240
,	O
low	B-C0205251
temperature	B-C0039476
for	O
long	B-C0205166
time	B-C0040223
ltlt	B-C3825956
pasteurization	B-C3825956
and	O
ultra-heat	B-C3179136
treatment	I-C3179136
uht	I-C3179136
sterilization	I-C3179136
,	O
are	O
essential	O
for	O
commercial	O
market	B-C1318228
milk	B-C2825079
to	O
improve	O
the	O
shelf	B-C4279909
life	I-C4279909
of	O
raw	B-C1442323
milk	I-C1442323
and	O
ensure	O
microbial	O
safety	O
.	O
	
we	O
evaluated	O
the	O
effects	O
of	O
heat	O
experience	O
on	O
the	O
molecular	O
properties	O
of	O
α-lactalbumin	O
α-la	O
and	O
β-lactoglobulin	O
β-lg	O
isolated	O
from	O
four	O
types	O
of	O
market	O
milk	B-C2825079
such	O
as	O
ltlt-a	O
66	O
for	O
30	O
min	O
,	O
ltlt-b	O
65	O
for	O
30	O
min	O
,	O
uht-i	O
130	O
for	O
2	O
s	O
,	O
indirect	O
heating	O
and	O
uht-d	O
135	O
for	O
2	O
s	O
,	O
direct	O
heating	O
samples	O
.	O
	
we	O
examined	O
molecular	O
conformations	O
using	O
circular	O
dichroism	O
spectrum	O
measurement	O
and	O
cell	O
growth	O
activity	O
using	O
the	O
wst-1	O
method	O
for	O
the	O
proteins	O
.	O
	
α-la	O
isolated	O
from	O
each	O
of	O
these	O
four	O
types	O
of	O
market	O
milk	O
displayed	O
no	O
significant	O
structural	O
difference	O
as	O
compared	O
to	O
raw	O
milk	O
α-la	O
,	O
while	O
α-la	O
of	O
uht-i	O
only	O
inhibited	O
cell	O
growth	O
of	O
an	O
intestinal	O
epithelial	O
cell	O
line	O
more	O
potently	O
than	O
raw	O
milk	O
α-la	O
.	O
	
in	O
the	O
case	O
of	O
β-lg	O
,	O
only	O
the	O
uht-i	O
sample	O
demonstrated	O
a	O
drastic	O
change	O
in	O
structure	O
,	O
while	O
it	O
did	O
not	O
exhibit	O
any	O
cytotoxicity	O
.	O
	
we	O
found	O
that	O
cell	O
viability	O
effects	O
of	O
α-la	O
and	O
β-lg	O
are	O
attributable	O
to	O
the	O
type	O
of	O
uht	O
indirect	O
and	O
direct	O
.	O
	
these	O
findings	O
indicate	O
that	O
the	O
effect	O
of	O
heat	O
treatment	O
on	O
whey	O
proteins	O
should	O
carefully	O
be	O
investigated	O
comparison	B-C1707455
of	O
270	B-C0977876
versus	O
320	B-C0977877
mg	I-C0977877
i/ml	I-C0977877
of	I-C0977877
iodixanol	I-C0977877
in	O
1	O
image	B-C4076410
assessment	I-C4076410
of	O
both	O
renal	B-C0035065
arteries	I-C0035065
and	O
veins	B-C0042449
with	O
dual-energy	B-C0729619
spectral	I-C0729619
ct	I-C0729619
imaging	I-C0729619
in	O
late	B-C0205390
arterial	I-C0205390
phase	I-C0205390
and	O
their	O
influence	B-C4054723
on	O
renal	B-C0232804
function	I-C0232804
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
compare	B-C1707455
the	O
image	B-C0806487
quality	I-C0806487
of	O
renal	B-C0035065
arteries	I-C0035065
and	O
veins	B-C0042449
with	O
dual-energy	B-C0729619
spectral	I-C0729619
computed	I-C0729619
tomography	I-C0729619
ct	I-C0729619
imaging	I-C0729619
in	O
late	B-C0205390
arterial	I-C0205390
phase	I-C0205390
using	O
270	B-C0977876
and	O
320	B-C0977877
mg	I-C0977877
i/ml	I-C0977877
of	I-C0977877
iodixanol	I-C0977877
and	O
their	O
influence	B-C4054723
on	O
renal	B-C0232804
function	I-C0232804
.	O
	
a	O
total	O
of	O
1062	O
patients	B-C0030705
underwent	O
renal	B-C1637292
ct	I-C1637292
angiography	I-C1637292
with	O
270	B-C0977876
or	O
320	B-C0977877
mg	I-C0977877
i/ml	I-C0977877
of	I-C0977877
iodixanol	I-C0977877
with	O
dual-energy	B-C0729619
spectral	I-C0729619
ct	I-C0729619
imaging	I-C0729619
in	O
late	B-C0205390
arterial	I-C0205390
phase	I-C0205390
.	O
	
image	B-C0806487
quality	I-C0806487
and	O
their	O
influence	B-C4054723
on	O
renal	B-C0232804
function	I-C0232804
were	O
compared	B-C1707455
.	O
	
there	O
were	O
no	O
significant	O
differences	O
of	O
ct	B-C1522609
value	I-C1522609
,	O
signal-to-noise	B-C2986823
ratio	I-C2986823
,	O
contrast-to-noise	B-C0456603
ratio	I-C0456603
,	O
and	O
subjective	O
score	B-C0449820
of	O
renal	B-C0580863
vessels	I-C0580863
between	O
2	O
groups	O
all	O
p	O
>	O
0.05	O
.	O
	
the	O
incidence	B-C0021149
of	O
contrast-induced	B-C4055183
nephropathy	I-C4055183
in	O
patients	B-C0030705
with	O
abnormal	B-C0151746
renal	I-C0151746
function	I-C0151746
using	O
320	B-C0977877
mg	I-C0977877
i/ml	I-C0977877
of	I-C0977877
iodixanol	I-C0977877
was	O
significantly	O
higher	O
than	O
using	O
270	B-C0977876
mg	I-C0977876
i/ml	I-C0977876
of	I-C0977876
iodixanol	I-C0977876
p	O
=	O
0.043	O
.	O
	
the	O
renal	B-C0035065
arteries	I-C0035065
and	O
veins	B-C0042449
can	O
be	O
fully	O
assessed	O
in	O
late	B-C0205390
arterial	I-C0205390
phase	I-C0205390
with	O
270	B-C0977876
mg	I-C0977876
i/ml	I-C0977876
of	I-C0977876
iodixanol	I-C0977876
using	O
dual-energy	B-C0177779
spectral	I-C0177779
ct	I-C0177779
scan	I-C0177779
with	O
better	O
preserved	O
renal	B-C0232804
function	I-C0232804
.	O
	
effect	O
of	O
magnesium	B-C1096534
supplementation	I-C1096534
on	O
depression	B-C0011570
status	B-C0449437
in	O
depressed	B-C0011570
patients	B-C0030705
with	O
magnesium	B-C0024473
deficiency	I-C0024473
a	O
randomized	B-C0034656
,	O
double-blind	B-C0013072
,	O
placebo-controlled	B-C1706408
trial	I-C1706408
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	B-C0728866
of	O
magnesium	B-C1096534
supplementation	I-C1096534
on	O
the	O
depression	B-C0011570
status	B-C0449437
of	O
depressed	B-C0011570
patients	B-C0030705
suffering	B-C0231303
from	O
magnesium	B-C0024473
deficiency	I-C0024473
.	O
	
sixty	B-C0243095
depressed	I-C0243095
people	I-C0243095
suffering	B-C0231303
from	O
hypomagnesemia	B-C0151723
participated	O
in	O
this	B-C0008976
trial	I-C0008976
.	O
	
the	O
individuals	B-C0237401
were	O
randomly	B-C0034656
categorized	I-C0034656
into	O
two	O
groups	B-C0441833
of	O
30	O
members	O
one	O
receiving	O
two	O
250-mg	O
tablets	B-C0024477
of	I-C0024477
magnesium	I-C0024477
oxide	I-C0024477
mg	B-C0024477
daily	O
and	O
the	O
other	O
receiving	O
placebo	B-C1696465
pg	B-C1696465
for	O
8	O
wk	O
.	O
	
the	O
beck	B-C4273959
depression	I-C4273959
inventory-ii	I-C4273959
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum	B-C0202125
magnesium	I-C0202125
was	I-C0202125
measured	I-C0202125
.	O
	
at	O
the	O
end	O
of	O
intervention	O
,	O
88.5	O
of	O
the	O
mg	B-C0024477
and	O
48.1	O
of	O
the	O
pg	B-C1696465
p	O
=	O
0.002	O
had	O
a	O
normal	B-C1442943
level	I-C1442943
of	I-C1442943
magnesium	I-C1442943
.	O
	
the	O
mean	O
changes	B-C1826990
of	I-C1826990
serum	I-C1826990
magnesium	I-C1826990
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	B-C0441833
.	O
	
after	O
the	O
intervention	O
,	O
the	O
mean	B-C2960571
beck	I-C2960571
score	I-C2960571
significantly	B-C4055638
declined	I-C4055638
.	O
	
however	O
,	O
in	O
the	O
mg	B-C0024477
,	O
this	O
reduction	O
was	O
more	B-C1299395
significant	I-C1299395
than	O
in	O
the	O
pg	B-C1696465
p	O
=	O
0.02	O
,	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	B-C0441833
experienced	O
15.65	O
8.9	O
reduction	O
,	O
but	O
in	O
the	O
pg	B-C1696465
,	O
it	O
declined	O
by	O
10.40	O
7.9	O
.	O
	
daily	B-C0678263
consumption	I-C0678263
of	O
500	O
mg	O
magnesium	B-C0024477
oxide	I-C0024477
tablets	I-C0024477
for	O
8	O
wk	O
by	O
depressed	B-C0011570
patients	B-C0030705
suffering	B-C0231303
from	O
magnesium	B-C0024473
deficiency	I-C0024473
leads	O
to	O
improvements	O
in	O
depression	B-C0011570
status	B-C0449437
and	O
magnesium	B-C1442943
levels	I-C1442943
.	O
	
therefore	O
,	O
assessment	B-C0202125
of	I-C0202125
the	I-C0202125
magnesium	I-C0202125
serum	I-C0202125
and	O
resolving	O
this	O
deficiency	B-C0024473
positively	O
influence	O
the	O
treatment	B-C0087111
of	O
depressed	B-C0011570
patients	B-C0030705
.	O
	
the	O
influence	B-C4054723
of	O
cognitive	B-C0870301
load	I-C0870301
on	O
metabolic	B-C0025519
cost	B-C0015316
of	O
transport	B-C1554194
during	O
overground	B-C0080331
walking	I-C0080331
in	O
healthy	B-C3898900
,	O
young	B-C0238598
adults	I-C0238598
our	O
aim	O
was	O
to	O
examine	O
whether	O
cognitive	B-C0025361
processing	I-C0025361
during	O
walking	B-C0080331
increases	B-C0442805
the	O
metabolic	B-C0025519
cost	B-C0015316
of	O
transport	B-C1554194
in	O
healthy	B-C3898900
young	B-C0238598
adults	I-C0238598
.	O
	
twenty	O
healthy	B-C3898900
,	O
young	B-C0238598
adults	I-C0238598
completed	O
five	O
conditions	B-C0348080
1	O
walking	B-C0080331
at	O
a	O
self	B-C0036588
-	O
selected	B-C1707391
speed	B-C0678536
spontaneous	B-C0205359
single-task	B-C0441655
,	O
2	O
seated	B-C4042775
resting	B-C0035253
baseline	B-C1442488
,	O
3	O
performing	O
cognitive	B-C0009240
task	B-C0441655
while	O
seated	B-C4042775
cognitive	B-C0009240
single-task	B-C0441655
,	O
4	O
walking	B-C0080331
while	O
simultaneously	B-C0521115
performing	B-C0884358
the	O
cognitive	B-C0009240
task	B-C0441655
dual-task	B-C0441655
,	O
and	O
5	O
single-task	B-C0441655
walking	B-C0080331
at	O
a	O
speed	B-C0678536
that	O
matched	B-C1708943
the	O
participant's	B-C0679646
dual-task	B-C0441655
gait	B-C2009910
speed	I-C2009910
matched	B-C1708943
single-task	B-C0441655
.	O
	
rate	B-C1521828
of	I-C1521828
oxygen	I-C1521828
consumption	I-C1521828
v	B-C1521828
was	O
recorded	O
during	O
all	O
conditions	B-C0348080
.	O
	
gait	B-C2009910
speed	I-C2009910
and	O
cost	B-C0015316
of	O
walking	B-C0080331
cw	B-C0015316
oxygen	B-C0030055
consumed	I-C0030055
per	I-C0030055
distance	I-C0030055
traveled	I-C0030055
were	O
recorded	O
during	O
all	O
walking	B-C0080331
conditions	B-C0348080
.	O
	
reaction	B-C0034746
time	I-C0034746
and	O
accuracy	B-C0443131
of	O
responses	B-C0871261
in	O
the	O
cognitive	B-C0009240
task	B-C0441655
were	O
recorded	O
during	O
all	O
cognitive	B-C0009240
task	B-C0441655
conditions	B-C0348080
.	O
	
data	B-C1511726
from	O
the	O
fifth	O
minute	B-C0439232
of	O
each	O
5-	O
min	B-C0439232
condition	B-C0348080
were	O
analyzed	B-C0936012
.	O
	
there	O
was	O
no	O
difference	O
in	O
v	B-C1521828
between	O
the	O
dual-task	B-C0441655
and	O
matched	B-C1708943
single-task	B-C0441655
walking	B-C0080331
conditions	B-C0348080
.	O
	
v	B-C1521828
in	O
the	O
seated	B-C4042775
cognitive	B-C0009240
condition	B-C0348080
was	O
significantly	O
smaller	O
than	O
both	O
walking	B-C0080331
conditions	B-C0348080
,	O
but	O
was	O
not	O
significantly	O
different	O
than	O
zero	O
.	O
	
cw	B-C0015316
was	O
significantly	O
greater	O
during	O
the	O
matched	B-C1708943
single-task	B-C0441655
walking	B-C0080331
condition	B-C0348080
than	O
during	O
the	O
dual-task	B-C0441655
walking	B-C0080331
condition	B-C0348080
.	O
	
however	O
,	O
the	O
difference	O
in	O
cw	B-C0015316
was	O
so	O
small	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
clinically	B-C0205210
significant	B-C0750502
0.008	O
mlo2/kg/m	O
,	O
95%	O
ci	O
0.002	O
.	O
	
cognitive	B-C0025361
processing	I-C0025361
while	O
walking	B-C0080331
may	O
not	O
increase	B-C0442805
energy	B-C1442080
demands	O
of	O
walking	B-C0080331
in	O
healthy	B-C3898900
young	B-C0238598
adults	I-C0238598
.	O
	
maintaining	O
non-preferred	O
gait	B-C2009910
speed	I-C2009910
matched	B-C1708943
speed	B-C0678536
overground	O
continuously	O
for	O
5	O
min	B-C0439232
may	O
require	O
attentional	B-C0004268
resources	B-C0035201
,	O
and	O
thereby	O
increase	B-C0442805
metabolic	B-C0025519
costs	B-C0015316
relative	O
to	O
walking	B-C0080331
at	O
habitual	B-C0205353
speed	B-C0678536
.	O
	
problem-based	B-C0243013
learning	I-C0243013
using	O
patient	B-C0030705
-simulated	O
videos	O
showing	O
daily	O
life	O
for	O
a	O
comprehensive	O
clinical	O
approach	O
we	O
examined	O
whether	O
problem-based	O
learning	O
tutorials	O
using	O
patient	B-C3463807
-simulated	I-C3463807
videos	I-C3463807
showing	O
daily	B-C0332173
life	B-C0376558
are	O
more	O
practical	O
for	O
clinical	O
learning	O
,	O
compared	O
with	O
traditional	O
paper-based	O
problem-based	O
learning	O
,	O
for	O
the	O
consideration	O
rate	O
of	O
psychosocial	O
issues	O
and	O
the	O
recall	O
rate	O
for	O
experienced	O
learning	O
.	O
	
twenty-two	O
groups	O
with	O
120	O
fifth-	O
year	O
students	O
were	O
each	O
assigned	O
paper-based	O
problem-based	O
learning	O
and	O
video	O
-based	O
problem-based	O
learning	O
using	O
patient	O
-simulated	O
videos	O
.	O
	
we	O
compared	O
target	O
achievement	O
rates	O
in	O
questionnaires	O
using	O
the	O
wilcoxon	O
signed-rank	O
test	O
and	O
discussion	O
contents	O
diversity	O
using	O
the	O
mann-whitney	O
u	O
test	O
.	O
	
a	O
follow-up	O
survey	O
used	O
a	O
chi-square	O
test	O
to	O
measure	O
students	O
'	O
recall	O
of	O
cases	O
in	O
three	O
categories	O
video	O
,	O
paper	O
,	O
and	O
non-experienced	O
.	O
	
video	O
-based	O
problem-based	O
learning	O
displayed	O
significantly	O
higher	O
achievement	O
rates	O
for	O
imagining	O
authentic	O
patients	O
p=0	O
,	O
incorporating	O
a	O
comprehensive	B-C1880156
approach	O
including	O
psychosocial	O
aspects	O
p<0	O
,	O
and	O
satisfaction	O
with	O
sessions	O
p=0	O
.	O
	
no	O
significant	O
differences	O
existed	O
in	O
the	O
discussion	O
contents	O
diversity	O
regarding	O
the	O
international	O
classification	O
of	O
primary	O
care	O
second	O
edition	O
codes	O
and	O
chapter	O
types	O
or	O
in	O
the	O
rate	O
of	O
psychological	O
codes	O
.	O
	
in	O
a	O
follow-up	O
survey	O
comparing	O
video	O
and	O
paper	O
groups	O
to	O
non-experienced	O
groups	O
,	O
the	O
rates	O
were	O
higher	O
for	O
video	O
χ	O
,	O
p<0	O
and	O
paper	O
χ	O
,	O
p=0	O
.	O
	
although	O
the	O
video	O
rate	O
tended	O
to	O
be	O
higher	O
than	O
the	O
paper	O
rate	O
,	O
no	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
.	O
	
patient	O
-simulated	O
videos	O
showing	O
daily	O
life	O
facilitate	O
imagining	O
true	O
patients	O
and	O
support	O
a	O
comprehensive	O
approach	O
that	O
fosters	O
better	O
memory	O
.	O
	
the	O
clinical	B-C0205210
patient	O
-simulated	O
video	O
method	O
is	O
more	O
practical	O
and	O
clinical	O
problem-based	O
tutorials	O
can	O
be	O
implemented	O
if	O
we	O
create	O
patient	O
-simulated	O
videos	O
for	O
each	O
symptom	O
as	O
teaching	O
materials	I-C0039402
forensic	B-C0681831
characteristics	I-C0681831
and	O
phylogenetic	B-C1519068
analyses	I-C1519068
of	O
the	O
chinese	B-C0152035
yi	B-C1257890
population	I-C1257890
via	O
19	O
x-chromosomal	B-C0043292
str	B-C0598994
loci	B-C0678933
the	O
demographic	B-C0683970
characteristics	I-C0683970
and	O
genetic	B-C0032529
polymorphism	I-C0032529
data	B-C1511726
of	O
56	O
chinese	B-C0152035
nationalities	B-C0027473
or	O
31	O
administrative	B-C2919030
divisions	I-C2919030
in	O
chinese	B-C0008115
mainland	I-C0008115
have	O
repeatedly	O
been	O
the	O
genetic	B-C0243064
research	I-C0243064
hotspots	B-C0205146
.	O
	
while	O
most	O
genetic	B-C2827447
studies	I-C2827447
focused	O
on	O
some	O
particular	O
chinese	B-C0152035
populations	B-C1257890
based	O
on	O
autosomal	B-C0596142
or	O
y-chromosomal	B-C0043381
genetic	B-C0017393
markers	I-C0017393
,	O
the	O
forensic	B-C0681831
characteristics	I-C0681831
and	O
phylogenetic	B-C1519068
analyses	I-C1519068
of	O
the	O
seventh	O
largest	O
chinese	B-C0152035
population	B-C1257890
yi	B-C0015031
ethnicity	I-C0015031
on	O
the	O
x-chromosomal	B-C0043292
genetic	B-C0017393
markers	I-C0017393
are	O
scarce	O
.	O
	
here	O
,	O
allele	B-C0017270
frequencies	I-C0017270
and	O
forensic	B-C0449381
statistical	I-C0449381
parameters	I-C0449381
for	O
19	O
x-chromosomal	B-C0043292
short	B-C0598994
tandem	I-C0598994
repeat	I-C0598994
loci	B-C0678933
dxs7424-dxs101	B-C0678933
,	O
dxs6789-dxs6809	B-C0678933
,	O
dxs7423-dxs10134	B-C0678933
,	O
dxs10103-hprtb-dxs10101	B-C0678933
,	O
dxs10159-dxs10162-dxs10164	B-C0678933
,	O
dxs10148-dxs10135-dxs8378	B-C0678933
,	O
and	O
dxs7132-dxs10079-dxs10074-dxs10075	B-C0678933
of	O
331	O
chinese	B-C0152035
yi	B-C0237401
individuals	I-C0237401
were	O
obtained	O
.	O
	
all	O
19	O
x-chromosomal	B-C0043292
short	B-C0598994
tandem	I-C0598994
repeat	I-C0598994
str	B-C0598994
loci	B-C0678933
in	O
females	B-C0043210
were	O
consistent	O
with	O
the	O
hardy-weinberg	O
equilibrium	O
test	O
.	O
	
a	O
total	O
of	O
214	O
alleles	B-C0002085
were	O
identified	B-C0205396
with	O
the	O
corresponding	O
allele	B-C0017270
frequencies	I-C0017270
spanned	O
from	O
0.0019	O
to	O
0.6106	O
.	O
	
the	O
combined	O
pe	B-C0392762
,	O
pdf	B-C0392762
,	O
and	O
pdm	B-C0392762
were	O
0.9999999214	O
,	O
0.9999999999999999999993	O
,	O
and	O
0.9999999999998	O
,	O
respectively	O
.	O
	
the	O
high	O
combined	O
meckrüger	B-C0392762
,	O
meckishida	B-C0392762
,	O
mecdesmarais	B-C0392762
,	O
and	O
mecdesmarais	B-C0392762
duo	I-C0392762
were	O
achieved	O
as	O
0.9999999617638	O
,	O
0.9999999999971	O
,	O
0.9999999999971	O
,	O
and	O
0.9999999931538	O
,	O
respectively	O
.	O
	
the	O
findings	B-C0243095
suggested	O
that	O
the	O
panel	B-C0441833
of	O
19	O
x-str	B-C0598994
loci	B-C0678933
is	O
highly	O
polymorphic	B-C1882417
and	O
informative	B-C2986490
in	O
the	O
yi	B-C0015031
ethnic	I-C0015031
population	I-C0015031
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
powerful	O
tool	B-C0336791
in	O
forensic	B-C0870773
complex	I-C0870773
kinship	I-C0870773
identification	I-C0870773
.	O
	
population	B-C0242481
differentiation	I-C0242481
analyses	I-C0242481
among	O
12	O
populations	B-C1257890
indicated	O
that	O
significant	O
differences	B-C1705242
in	O
genetic	B-C1136352
structure	I-C1136352
were	O
observed	O
in	O
between	O
the	O
yi	B-C0015031
ethnicity	I-C0015031
and	O
the	O
chinese	B-C0152035
uyghur	B-C1257890
as	O
well	O
as	O
kazakh	B-C1257890
,	O
and	O
genetic	B-C1881065
homogeneity	I-C1881065
existed	O
in	O
similar	O
ethno-origin	B-C0015031
or	O
geographic	B-C0032659
origin	I-C0032659
populations	I-C0032659
.	O
	
loss	B-C1517945
of	O
snf5	B-C0812273
induces	B-C0205263
formation	B-C1522492
of	O
an	O
aberrant	B-C0443127
swi/snf	B-C1167093
complex	I-C1167093
the	O
swi/snf	B-C1167093
chromatin	B-C1167087
remodeling	I-C1167087
complex	I-C1167087
is	O
highly	O
conserved	O
from	O
yeast	B-C0043393
to	O
human	B-C0086418
,	O
and	O
aberrant	B-C0443127
swi/snf	B-C1167093
complexes	I-C1167093
contribute	O
to	O
human	B-C0086418
disease	B-C0012634
.	O
	
the	O
snf5/smarcb1/ini1	B-C0812273
subunit	B-C1711351
of	O
swi/snf	B-C1167093
is	O
a	O
tumor	B-C0079427
suppressor	I-C0079427
frequently	O
lost	B-C0745777
in	O
pediatric	B-C1521725
rhabdoid	B-C0206743
cancers	I-C0206743
.	O
	
we	O
examined	O
the	O
effects	B-C1704420
of	I-C1704420
snf5	B-C0812273
loss	B-C1517945
on	O
the	O
composition	B-C0243095
,	O
nucleosome	B-C1623159
binding	I-C1623159
,	O
recruitment	O
,	O
and	O
remodeling	O
activities	O
of	O
yeast	B-C0043393
swi/snf	B-C1167093
.	O
	
the	O
snf5	B-C0812273
subunit	B-C1711351
is	O
shown	O
by	O
crosslinking-mass	B-C0037813
spectrometry	I-C0037813
cx-ms	B-C0037813
and	O
subunit	B-C1711351
deletion	B-C1294202
analysis	I-C1294202
to	O
interact	O
with	O
the	O
atpase	B-C1510701
domain	I-C1510701
of	O
snf2	B-C0246454
and	O
to	O
form	O
a	O
submodule	B-C1959595
consisting	O
of	O
snf5	B-C0812273
,	O
swp82	B-C0017337
,	O
and	O
taf14	B-C0017337
.	O
	
snf5	B-C0812273
promotes	O
binding	B-C1623159
of	O
the	O
snf2	B-C0246454
atpase	B-C1510701
domain	I-C1510701
to	O
nucleosomal	B-C1623161
dna	I-C1623161
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
swi/snf	B-C1167093
.	O
	
snf5	B-C0812273
is	O
also	O
required	O
for	O
swi/snf	B-C1167093
recruitment	O
by	O
acidic	B-C0040648
transcription	I-C0040648
factors	I-C0040648
.	O
	
rna-seq	B-C0162803
analysis	I-C0162803
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
snf5	B-C0812273
are	O
required	O
in	B-C1515655
vivo	I-C1515655
for	O
swi/snf	B-C1167093
regulation	B-C0017263
of	I-C0017263
gene	I-C0017263
expression	I-C0017263
.	O
	
thus	O
,	O
loss	B-C1517945
of	O
snf5	B-C0812273
alters	O
the	O
structure	B-C0678594
and	O
function	B-C0542341
of	O
identifying	O
the	O
presence	B-C0150312
of	O
parkinson's	B-C0030567
disease	I-C0030567
using	O
low-frequency	B-C0205213
fluctuations	B-C0231239
in	O
bold	B-C1705491
signals	I-C1705491
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
is	O
a	O
chronic	B-C0205191
,	O
progressive	B-C0205329
,	O
and	O
degenerative	B-C1880269
neurological	B-C0027765
disorder	I-C0027765
that	O
is	O
characterized	B-C1880022
by	O
the	O
degeneration	B-C1880269
of	O
dopamine	B-C1512035
neurons	I-C1512035
in	O
the	O
substantia	B-C0038590
nigra	I-C0038590
and	O
the	O
formation	B-C1522492
of	O
intracellular	B-C0178719
lewy	B-C0085200
inclusion	I-C0085200
bodies	I-C0085200
.	O
	
resting-state	B-C4288291
functional	I-C4288291
magnetic	I-C4288291
resonance	I-C4288291
imaging	I-C4288291
rs-fmri	B-C4288291
has	O
demonstrated	O
evidence	B-C3887511
of	O
changes	O
in	O
metabolic	B-C0311400
patterns	B-C0449774
in	O
individuals	B-C0237401
with	O
pd	B-C0030567
.	O
	
the	O
purpose	B-C1285529
of	O
this	O
study	B-C2603343
was	O
to	O
determine	O
whether	O
the	O
presence	B-C0150312
of	O
pd	B-C0030567
could	O
be	O
""""	O
predicted	B-C0681842
""""	O
based	O
on	O
resting	O
fluctuations	B-C0231239
in	O
the	O
blood	B-C1655730
oxygenation	I-C1655730
level	I-C1655730
dependent	I-C1655730
signal	I-C1655730
.	O
	
we	O
utilized	O
rs-fmri	B-C4288291
to	O
measure	O
the	O
amplitude	B-C2346753
of	O
low-frequency	B-C0205213
fluctuation	B-C0231239
alff	B-C0231239
and	O
the	O
fractional	O
alff	B-C0231239
falff	B-C0231239
in	O
51	O
patients	B-C0030705
with	O
pd	B-C0030567
and	O
50	O
age	B-C0001779
-	O
and	O
sex	B-C1522384
-matched	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
compared	O
with	O
the	O
healthy	B-C2986479
controls	I-C2986479
,	O
the	O
individuals	B-C0237401
with	O
pd	B-C0030567
exhibited	O
altered	O
alffs	B-C0231239
in	O
the	O
bilateral	B-C0238767
lingual	B-C0152308
gyrus	I-C0152308
and	O
left	B-C2334169
putamen	I-C2334169
and	O
an	O
altered	O
falff	B-C0231239
in	O
the	O
right	B-C2953249
cerebellum	I-C2953249
posterior	I-C2953249
lobe	I-C2953249
.	O
	
support	B-C2699740
vector	I-C2699740
machines	I-C2699740
svms	B-C2699740
,	O
which	O
comprise	O
a	O
supervised	O
pattern	B-C1518918
recognition	I-C1518918
method	B-C0025663
that	O
enables	O
predictions	B-C0681842
at	O
the	O
individual	B-C0237401
level	B-C0441889
,	O
were	O
trained	O
to	O
separate	O
individuals	B-C0237401
with	O
pd	B-C0030567
from	O
healthy	B-C2986479
controls	I-C2986479
based	O
on	O
the	O
alff	B-C0231239
and	O
falff	B-C0231239
.	O
	
using	O
the	O
leave-one-out	O
cross-validation	B-C0681935
method	I-C0681935
to	O
analyze	B-C0936012
our	O
sample	B-C0370003
,	O
we	O
reliably	O
distinguished	O
the	O
participants	B-C0679646
with	O
pd	B-C0030567
from	O
the	O
controls	B-C0009932
with	O
92%	O
sensitivity	B-C2349185
and	O
87%	O
specificity	B-C0037791
.	O
	
overall	O
,	O
these	O
findings	B-C2607943
suggest	O
that	O
the	O
svm	B-C2699740
-	O
neuroimaging	B-C0679575
approach	O
may	O
be	O
of	O
particular	O
clinical	B-C0205210
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
pd	B-C0030567
at	O
the	O
individual	B-C0237401
level	B-C0441889
.	O
	
rs-fmri	B-C4288291
should	O
be	O
considered	O
for	O
development	B-C1527148
as	O
a	O
biomarker	B-C0005516
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	B-C0220825
of	O
methylation	B-C0376452
dynamics	B-C3826426
during	O
folliculogenesis	B-C1160267
and	O
early	B-C1279919
embryo	B-C0013936
development	I-C0013936
in	O
sheep	B-C0036945
genome	B-C0017428
-wide	O
dna	B-C0376452
methylation	I-C0376452
reprogramming	O
occurs	O
during	O
mammalian	B-C0024660
gametogenesis	B-C0017001
and	O
early	B-C1279919
embryogenesis	B-C0013936
.	O
	
post	B-C0687676
-	O
fertilization	B-C0015914
demethylation	B-C2755352
of	O
paternal	B-C0337493
and	O
maternal	B-C1858460
genomes	B-C0017428
is	O
considered	O
to	O
occur	O
by	O
an	O
active	O
and	O
passive	O
mechanism	O
respectively	O
,	O
in	O
most	O
mammals	B-C0024660
but	O
sheep	B-C0036945
in	O
this	O
species	O
no	O
loss	O
of	O
methylation	B-C0025723
was	O
observed	O
in	O
either	O
pronucleus	B-C1167158
.	O
	
post	B-C0687676
-	O
fertilization	B-C0015914
reprogramming	O
relies	O
on	O
methylating	B-C0014442
and	O
demethylating	B-C0014442
enzymes	I-C0014442
and	O
co-factors	O
that	O
are	O
stored	O
during	O
oocyte	B-C1155900
growth	I-C1155900
,	O
concurrently	O
with	O
the	O
re-methylation	B-C0376452
of	O
the	O
oocyte	B-C0029045
itself	O
.	O
	
the	O
crucial	O
remodelling	O
of	O
the	O
oocyte	B-C0029045
epigenetic	O
baggage	O
often	O
overlaps	O
with	O
potential	O
interfering	O
events	O
such	O
as	O
exposure	O
to	O
assisted	O
reproduction	B-C0035157
technologies	I-C0035157
or	O
environmental	B-C4060636
changes	I-C4060636
.	O
	
here	O
,	O
we	O
report	O
a	O
temporal	O
analysis	O
of	O
methylation	B-C0025723
dynamics	B-C3826426
during	O
folliculogenesis	B-C1160267
and	O
early	B-C1279919
embryo	B-C0013936
development	I-C0013936
in	O
sheep	B-C0036945
.	O
	
we	O
characterized	O
global	O
dna	B-C0376452
methylation	I-C0376452
and	O
hydroxymethylation	B-C3830412
by	O
immunofluorescence	B-C0016318
and	O
relatively	O
quantified	O
the	O
expression	B-C1171362
of	O
the	O
enzymes	B-C0014442
and	O
co-factors	O
mainly	O
responsible	O
for	O
their	O
remodelling	O
dna	B-C0012873
methyltransferases	I-C0012873
dnmts	B-C0012873
,	O
ten-eleven	B-C0033684
translocation	I-C0033684
tet	I-C0033684
proteins	I-C0033684
and	O
methyl-cpg-binding	B-C4277657
domain	I-C4277657
mbd	B-C4277657
proteins	B-C0033684
.	O
	
our	O
results	O
illustrate	O
for	O
the	O
first	O
time	O
the	O
patterns	O
of	O
hydroxymethylation	B-C3830412
during	O
oocyte	B-C1155900
growth	I-C1155900
.	O
	
we	O
observed	O
different	O
patterns	O
of	O
methylation	B-C0376452
and	O
hydroxymethylation	B-C3830412
between	O
the	O
two	O
parental	B-C1167158
pronuclei	I-C1167158
,	O
suggesting	O
that	O
male	B-C1622926
pronucleus	I-C1622926
undergoes	O
active	O
demethylation	B-C2755352
also	O
in	O
sheep	B-C0036945
.	O
	
finally	O
,	O
we	O
describe	O
gene	B-C0017337
-specific	O
accumulation	O
dynamics	B-C3826426
for	O
methylating	B-C0014442
and	O
demethylating	B-C0014442
enzymes	I-C0014442
during	O
oocyte	B-C1155900
growth	I-C1155900
and	O
observe	O
patterns	O
of	O
expression	B-C1171362
associated	O
with	O
developmental	B-C0458003
competence	B-C0086035
in	O
a	O
differential	O
model	O
of	O
oocyte	B-C0029045
potential	O
.	O
	
our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
methylation	B-C0025723
dynamics	B-C3826426
during	O
folliculogenesis	B-C1160267
and	O
early	B-C1279919
embryo	B-C0013936
development	I-C0013936
and	O
improves	O
the	O
overall	O
picture	O
of	O
early	B-C1279919
rearrangements	O
that	O
will	O
originate	O
the	O
embryo	B-C0013935
epigenome	B-C0017428
.	O
	
network	B-C1882071
analysis	B-C0936012
reveals	B-C0443289
why	O
xylella	B-C0995982
fastidiosa	I-C0995982
will	O
persist	O
in	O
europe	B-C0015176
the	O
insect	B-C0021573
vector	I-C0021573
borne	O
bacterium	B-C0004611
xylella	B-C0995982
fastidiosa	I-C0995982
was	O
first	O
detected	O
in	O
olive	B-C0996956
trees	I-C0996956
in	O
southern	B-C0022277
italy	I-C0022277
in	O
2013	O
,	O
and	O
identified	O
as	O
the	O
main	O
culprit	O
behind	O
the	O
'	O
olive	B-C0012634
quick	I-C0012634
decline	I-C0012634
syndrome	I-C0012634
'	O
.	O
	
since	O
then	O
,	O
the	O
disease	B-C0012634
has	O
spread	O
rapidly	O
through	O
italy's	B-C0022277
main	O
olive	B-C0069449
oil	I-C0069449
producing	O
region	B-C0017446
.	O
	
the	O
epidemiology	B-C0002783
of	O
the	O
outbreak	B-C0012652
is	O
largely	O
unstudied	O
,	O
with	O
the	O
list	O
of	O
x	B-C0995982
.	O
	
fastidiosa	I-C0995982
hosts	B-C1167395
and	O
vectors	B-C0021573
in	O
europe	B-C0015176
likely	O
incomplete	O
,	O
and	O
the	O
role	O
humans	B-C0086418
play	O
in	O
dispersal	B-C0332261
unknown	B-C0439673
.	O
	
these	O
knowledge	B-C0376554
gaps	B-C3887622
have	O
led	O
to	O
management	B-C1273870
strategies	I-C1273870
based	O
on	O
general	O
assumptions	O
that	O
require	O
,	O
among	O
others	O
,	O
local	O
vector	B-C0031249
control	I-C0031249
and	O
,	O
in	O
certain	O
areas	B-C0681784
,	O
the	O
destruction	B-C1948029
of	O
infected	B-C0032098
plants	I-C0032098
and	O
healthy	B-C3898900
ones	O
around	O
them	O
in	O
an	O
attempt	O
to	O
eradicate	B-C1883720
or	O
halt	B-C2746065
the	O
spreading	B-C0332261
pest	B-C0032064
.	O
	
here	O
we	O
show	O
that	O
,	O
regardless	O
of	O
epidemiological	B-C0014508
uncertainties	B-C0087130
,	O
the	O
mere	O
distribution	O
of	O
olive	B-C0996956
orchards	O
in	O
southern	O
italy	O
makes	O
the	O
chances	O
of	O
eradicating	O
x	O
.	O
	
fastidiosa	O
from	O
the	O
region	O
extremely	O
slim	O
.	O
	
our	O
results	O
imply	O
that	O
southern	O
italy	O
is	O
becoming	O
a	O
reservoir	O
for	O
x	O
.	O
	
fastidiosa	O
.	O
	
as	O
a	O
consequence	O
,	O
management	O
strategies	O
should	O
keep	O
the	O
prevalence	O
of	O
x	O
.	O
	
fastidiosa	O
in	O
the	O
region	O
as	O
low	O
as	O
possible	O
,	O
primarily	O
through	O
vector	O
control	O
,	O
lest	O
the	O
pathogen	O
,	O
that	O
has	O
also	O
been	O
detected	O
in	O
southern	O
france	O
and	O
the	O
island	O
of	O
mallorca	O
spain	O
,	O
continues	O
spreading	O
through	O
italy	O
and	O
europe	B-C0015176
novel	O
biomarkers	B-C0005516
for	O
patients	B-C0030705
with	O
idiopathic	B-C0332240
acute	B-C0701807
anterior	I-C0701807
uveitis	I-C0701807
neutrophil	B-C0027950
to	O
lymphocyte	B-C0024264
ratio	B-C0456603
and	O
platelet	B-C0005821
to	O
lymphocyte	B-C0024264
ratio	B-C0456603
to	O
assess	B-C1516048
the	O
levels	B-C0441889
of	O
the	O
neutrophil	B-C0027950
to	O
lymphocyte	B-C0024264
ratio	B-C0456603
n	B-C0027950
/	O
l	B-C0024264
and	O
the	O
platelet	B-C0005821
to	O
lymphocyte	B-C0024264
ratio	B-C0456603
p	B-C0005821
/	O
l	B-C0024264
in	O
patients	B-C0030705
with	O
idiopathic	B-C0332240
acute	B-C0701807
anterior	I-C0701807
uveitis	I-C0701807
aau	B-C0701807
and	O
to	O
compare	B-C1707455
with	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
thirty-six	O
male	B-C0025266
patients	B-C0030705
with	O
idiopathic	B-C0332240
aau	B-C0701807
and	O
36	O
male	B-C0025266
healthy	B-C3898900
subjects	B-C2349001
were	O
enrolled	O
in	O
this	O
retrospective	B-C0035363
study	I-C0035363
.	O
	
complete	B-C0205197
ophthalmological	B-C0200149
examination	I-C0200149
and	O
complete	O
blood	B-C1879889
count	I-C1879889
measurements	I-C1879889
results	B-C0683954
of	O
all	O
subjects	B-C2349001
were	O
evaluated	B-C0220825
.	O
	
there	O
was	O
a	O
significant	B-C0750502
difference	O
in	O
n	B-C0027950
/	O
l	B-C0024264
and	O
p	B-C0005821
/	O
l	B-C0024264
between	O
idiopathic	B-C0332240
aau	B-C0701807
and	O
control	B-C0009932
groups	I-C0009932
p=0	O
,	O
p=0	O
.	O
	
also	O
,	O
correlation	B-C0010101
analysis	I-C0010101
revealed	O
a	O
significant	B-C0750502
correlation	B-C1707520
between	O
c-reactive	B-C0006560
protein	I-C0006560
crp	B-C0006560
and	O
n	B-C0027950
/	O
l	B-C0024264
p=0	O
r=0	O
.	O
	
our	O
study	B-C0008972
for	O
the	O
first	O
time	O
provides	O
evidence	B-C0332120
of	I-C0332120
n	B-C0027950
/	O
l	B-C0024264
and	O
p	B-C0005821
/	O
l	B-C0024264
may	O
be	O
useful	B-C3827682
biomarkers	B-C0005516
in	O
patients	B-C0030705
with	O
idiopathic	B-C0332240
aau	B-C0701807
.	O
	
n	B-C0027950
/	O
l	B-C0024264
is	O
correlated	B-C1707520
with	O
crp	B-C0006560
,	O
so	O
it	O
can	O
be	O
a	O
useful	B-C3827682
biomarker	B-C0005516
to	O
predict	O
the	O
prognosis	B-C0033325
in	O
idiopathic	B-C0332240
aau	B-C0701807
.	O
	
comparison	B-C1707455
between	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
and	O
b-mode	B-C1302166
ultrasound	I-C1302166
in	O
detecting	B-C0442726
and	O
estimating	B-C0750572
the	O
extent	B-C0439792
of	O
human	B-C0086418
carotid	B-C0577631
atherosclerosis	I-C0577631
in	O
mri	B-C3515983
studies	I-C3515983
of	O
carotid	B-C0751633
plaques	I-C0751633
,	O
ultrasound	B-C1302166
is	O
used	O
to	O
find	B-C0243095
plaques	B-C0332461
,	O
which	O
are	O
later	O
imaged	B-C1704254
using	O
mri	B-C0024485
.	O
	
the	O
performance	B-C1882330
in	O
plaque	B-C0332461
detection	B-C0442726
has	O
not	O
been	O
compared	B-C1707455
between	O
the	O
modalities	B-C1275506
.	O
	
the	O
aim	O
of	O
the	O
current	O
study	B-C2603343
was	O
to	O
compare	B-C1707455
the	O
performance	B-C1882330
of	O
mri	B-C0024485
and	O
ultrasound	B-C1302166
in	O
detecting	B-C0442726
carotid	B-C0751633
artery	I-C0751633
plaques	I-C0751633
and	O
measuring	B-C0444706
extent	B-C0439792
of	O
atherosclerosis	B-C0004153
.	O
	
subjects	B-C0681850
with	O
at	O
least	O
one	O
plaque	B-C0332461
height	B-C0392762
2	O
mm	O
on	O
ultrasound	B-C1302166
were	O
imaged	B-C1704254
using	O
mri	B-C0024485
.	O
	
the	O
number	B-C0237753
of	O
plaques	B-C0332461
and	O
their	O
height	B-C0392762
was	O
measured	B-C0444706
in	O
both	O
modalities	B-C1275506
plaque	B-C0332461
area	B-C0205146
and	O
volume	B-C0449468
were	O
analysed	B-C0936012
on	O
ultrasound	B-C1302166
and	O
mri	B-C0024485
,	O
respectively	O
.	O
	
thirty-eight	B-C0392762
subjects	B-C0681850
were	O
included	B-C0332257
.	O
	
mri	B-C0024485
detected	B-C0442726
plaques	B-C0332461
in	O
95%	O
of	O
carotid	B-C0007272
arteries	I-C0007272
with	O
a	O
plaque	B-C0332461
height	B-C0392762
of	O
2	O
mm	O
on	O
ultrasound	B-C1302166
and	O
in	O
all	O
carotid	B-C0007272
arteries	I-C0007272
with	O
a	O
plaque	B-C0332461
exceeding	O
2	O
mm	O
.	O
	
mri	B-C0024485
detected	B-C0442726
53%	O
of	O
the	O
plaques	B-C0332461
with	O
a	O
height	B-C0392762
below	O
2	O
mm	O
.	O
	
the	O
plaque	B-C0332461
height	B-C0392762
measured	B-C0444706
with	O
both	O
techniques	B-C0449851
correlated	B-C1707520
significantly	O
,	O
0	O
,	O
p<0	O
.	O
	
ultrasound	B-C1302166
-derived	O
plaque	B-C0332461
height	B-C0392762
and	O
plaque	B-C0332461
area	B-C0205146
correlated	B-C1707520
similarly	B-C2348205
to	O
mri	B-C0024485
-derived	O
plaque	B-C0332461
volume	B-C0449468
,	O
r	O
=	O
0	O
p<0	O
and	O
r	O
=	O
0	O
p	O
=	O
0	O
,	O
respectively	O
.	O
	
we	O
conclude	O
that	O
mri	B-C0024485
has	O
a	O
similar	B-C2348205
sensitivity	B-C1511883
to	O
ultrasound	B-C1302166
in	O
finding	B-C0243095
carotid	B-C0751633
artery	I-C0751633
plaques	I-C0751633
that	O
are	O
2	O
mm	O
or	O
higher	B-C0205250
.	O
	
in	O
smaller	B-C0547044
plaques	B-C0332461
,	O
mri	B-C0024485
detects	B-C0442726
fewer	B-C0205388
plaques	B-C0332461
.	O
	
multiple	B-C0751633
carotid	I-C0751633
plaques	I-C0751633
seen	O
on	O
ultrasound	B-C1302166
most	O
often	O
are	O
a	O
misinterpretation	O
of	O
the	O
anatomy	B-C1384516
and	O
correspond	O
to	O
a	O
single	B-C0332461
plaque	I-C0332461
.	O
	
plaque	B-C0332461
height	B-C0392762
on	O
ultrasound	B-C1302166
is	O
comparable	O
to	O
plaque	B-C0332461
height	B-C0392762
on	O
mri	B-C0024485
and	O
correlates	B-C1707520
fairly	O
well	O
with	O
plaque	B-C0332461
volume	B-C0449468
on	O
mri	B-C0024485
making	O
it	O
an	O
interesting	O
proxy	O
for	O
plaque	B-C0332461
burden	B-C2828008
.	O
	
lightweight	O
open-cell	B-C0243092
scaffolds	I-C0243092
from	O
sea	B-C0036488
urchin	I-C0036488
spines	B-C0005479
with	O
superior	O
material	B-C0520510
properties	B-C0871161
for	O
bone	B-C0185364
defect	I-C0185364
repair	I-C0185364
sea	B-C0036488
urchin	I-C0036488
spines	B-C0005479
heterocentrotus	B-C1003462
mammillatus	I-C1003462
,	O
with	O
a	O
hierarchical	O
open-cell	B-C0243092
structure	I-C0243092
similar	O
to	O
that	O
of	O
human	B-C0086418
trabecular	B-C0222660
bone	I-C0222660
and	O
superior	O
mechanical	B-C0871161
property	I-C0871161
compressive	B-C0376507
strength	I-C0376507
43.4	O
mpa	O
suitable	B-C3900053
for	O
machining	B-C0441655
to	O
shape	B-C0348078
,	O
were	O
explored	O
for	O
potential	B-C3245505
applications	B-C0205245
of	O
bone	B-C0185364
defect	I-C0185364
repair	I-C0185364
.	O
	
finite	B-C0600552
element	I-C0600552
analyses	I-C0600552
reveal	O
that	O
the	O
compressive	O
stress	B-C0038435
concentrates	B-C2003864
along	O
the	O
dense	B-C0439794
growth	B-C0971859
rings	I-C0971859
and	O
dissipates	B-C0439742
through	O
strut	O
structures	B-C0700276
of	I-C0700276
the	I-C0700276
stereoms	I-C0700276
,	O
indicating	O
that	O
the	O
exquisite	O
mesostructures	B-C0678594
play	O
an	O
important	B-C3898777
role	O
in	O
high	O
strength	B-C0205556
-to-	O
weight	B-C0043100
ratios	B-C0456603
.	O
	
the	O
fracture	B-C0016658
strength	B-C0205556
of	O
magnesium	B-C0024467
-	O
substituted	B-C0106141
tricalcium	I-C0106141
phosphate	I-C0106141
β-tcmp	B-C0005479
scaffolds	I-C0005479
produced	O
by	O
hydrothermal	B-C1254366
conversion	B-C0439836
of	O
urchin	B-C0036488
spines	B-C0005479
is	O
about	O
9.3	O
mpa	O
,	O
comparable	B-C1707455
to	O
that	O
of	O
human	B-C0086418
trabecular	B-C0222660
bone	I-C0222660
.	O
	
new	O
bone	B-C0262950
forms	B-C1522492
along	O
outer	O
surfaces	B-C0205148
of	O
β-tcmp	B-C0005479
scaffolds	I-C0005479
after	O
implantation	B-C0021107
in	O
rabbit	B-C3887509
femoral	B-C0015802
defects	I-C0015802
for	O
one	O
month	B-C0439231
and	O
grows	B-C0971859
into	O
the	O
majority	O
of	O
the	O
inner	O
open-cell	B-C1179886
spaces	I-C1179886
postoperation	B-C1882428
in	O
three	O
month	B-C0439231
s	O
,	O
showing	O
tight	B-C0920352
interface	I-C0920352
between	O
the	O
scaffold	B-C0005479
and	O
regenerative	B-C0005972
bone	I-C0005972
tissue	I-C0005972
.	O
	
fusion	B-C1293131
of	O
beagle	B-C0324306
lumbar	B-C0507372
facet	I-C0507372
joints	I-C0507372
using	O
a	O
ti-6al-4v	B-C0076732
cage	I-C0076732
and	O
β-tcmp	B-C0005479
scaffold	I-C0005479
can	O
be	O
completed	B-C0205197
within	O
seven	O
months	B-C0439231
with	O
obvious	O
biodegradation	B-C0005482
of	O
the	O
β-tcmp	B-C0005479
scaffold	I-C0005479
,	O
which	O
is	O
nearly	O
completely	B-C0205197
degraded	B-C0005482
and	O
replaced	B-C1299987
by	I-C1299987
newly	O
formed	B-C0205431
bone	B-C0262950
ten	O
months	B-C0439231
after	O
implantation	B-C0021107
.	O
	
thus	O
,	O
sea	B-C0036488
urchin	I-C0036488
spines	B-C0005479
suitable	O
for	O
machining	B-C0441655
to	O
shape	B-C0348078
have	O
advantages	O
for	O
production	O
of	O
biodegradable	B-C0005482
artificial	B-C0440261
grafts	I-C0440261
for	O
bone	B-C0185364
defect	I-C0185364
repair	I-C0185364
.	O
	
melatonin	B-C0025219
and	O
nitric	B-C0028128
oxide	I-C0028128
regulate	B-C3269637
sunflower	B-C0947381
seedling	B-C3156975
growth	I-C3156975
under	O
salt	B-C1154956
stress	I-C1154956
accompanying	O
differential	O
expression	B-C1171362
of	O
cu/zn	B-C0010461
sod	I-C0010461
and	O
mn	B-C0024708
sod	I-C0024708
salinity	B-C1154956
results	I-C1154956
in	O
significant	B-C0392756
reduction	I-C0392756
in	O
sunflower	B-C0947381
helianthus	B-C0947381
annuus	I-C0947381
l	I-C0947381
seedling	B-C3156975
growth	I-C3156975
and	O
excessive	O
generation	O
of	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
.	O
	
present	O
work	O
highlights	O
the	O
possible	O
role	O
of	O
melatonin	B-C0025219
as	O
an	O
antioxidant	B-C0003402
through	O
its	O
interaction	O
with	O
nitric	B-C0028128
oxide	I-C0028128
no	B-C0028128
,	O
and	O
as	O
an	O
early	O
and	O
long	O
distance	O
nacl-stress	B-C1154956
sensing	O
signaling	B-C1519315
molecule	I-C1519315
in	O
seedling	B-C0242437
cotyledons	B-C0242769
.	O
	
exogenous	B-C0205228
melatonin	B-C0025219
15µm	O
nacl	B-C0037494
120mm	O
inhibit	B-C3463820
seedling	B-C3156975
growth	I-C3156975
,	O
which	O
is	O
also	O
correlated	O
with	O
no	B-C0028128
availability	O
,	O
accumulation	O
of	O
potential	B-C0038836
superoxide	I-C0038836
anion	I-C0038836
o2	B-C0038836
and	O
peroxynitrite	B-C0136157
anion	I-C0136157
onoo	B-C0136157
,	O
extent	O
of	O
tyrosine-nitration	B-C4050156
of	O
proteins	B-C0033684
,	O
spatial	B-C0475264
localization	I-C0475264
and	O
activity	B-C1151619
of	I-C1151619
superoxide	I-C1151619
dismutase	I-C1151619
sod	B-C0038838
isoforms	B-C0597298
.	O
	
no	B-C0028128
acts	O
as	O
a	O
positive	O
modulator	O
of	O
melatonin	B-C0025219
accumulation	O
in	O
seedling	B-C0242437
cotyledons	B-C0242769
as	O
a	O
long-distance	B-C1514991
signaling	I-C1514991
response	I-C1514991
.	O
	
modulation	B-C2246284
of	I-C2246284
superoxide	I-C2246284
anion	I-C2246284
and	O
peroxynitrite	B-C0136157
anion	I-C0136157
content	O
by	O
melatonin	B-C0025219
highlights	O
its	O
crucial	O
role	O
in	O
combating	O
deleterious	O
effects	O
of	O
ros	B-C0162772
and	O
reactive	B-C0969698
nitrogen	I-C0969698
species	I-C0969698
rns	O
.	O
	
present	O
findings	O
provide	O
evidence	O
for	O
an	O
interaction	O
between	O
melatonin	B-C0025219
and	O
no	B-C0028128
in	O
their	O
effect	O
on	O
seedling	B-C3156975
growth	I-C3156975
under	O
salt	B-C1154956
stress	I-C1154956
accompanying	I-C1154956
differential	O
modulation	O
of	O
two	O
sod	B-C0038838
isoforms	B-C0597298
,	O
i.e	O
.	O
	
cu/zn	B-C0010461
sod	I-C0010461
and	O
mn	B-C0024708
sod	I-C0024708
.	O
	
the	O
physiological	B-C0205463
role	O
and	O
regulation	B-C1327622
of	O
aquaporins	B-C0599635
in	O
teleost	B-C0599050
germ	B-C0017471
cells	I-C0017471
the	O
unicellular	O
germ	B-C0017471
cells	I-C0017471
and	O
gametes	B-C2718310
of	O
oviparous	B-C1568405
teleosts	B-C0599050
lack	O
the	O
osmoregulatory	B-C1510659
organs	B-C0178784
present	O
in	O
juveniles	B-C3146221
and	O
adults	B-C0001675
,	O
yet	O
during	O
development	B-C0243107
and	O
particularly	O
at	O
spawning	B-C2826216
,	O
they	O
face	O
tremendous	O
osmotic	B-C0311417
challenges	B-C0033213
when	O
released	O
into	O
the	O
external	B-C0205101
aquatic	B-C0563034
environment	I-C0563034
.	O
	
increasing	O
evidence	O
suggests	O
that	O
transmembrane	B-C0599635
water	I-C0599635
channels	I-C0599635
aquaporins	B-C0599635
evolved	O
to	O
play	O
vital	O
adaptive	O
roles	O
that	O
mitigate	B-C1553901
the	O
osmotic	B-C3661513
and	O
oxidative	B-C0242606
stress	I-C0242606
problems	B-C0033213
of	O
the	O
developing	B-C0243107
oocytes	B-C0029045
,	O
embryos	B-C0013935
and	O
spermatozoa	B-C0037868
.	O
	
in	O
this	O
chapter	O
,	O
we	O
provide	O
a	O
short	O
overview	O
of	O
the	O
diversity	B-C1880371
of	O
the	O
aquaporin	B-C0599635
superfamily	O
in	O
teleosts	B-C0599050
,	O
and	O
summarize	O
the	O
findings	O
that	O
uncovered	O
a	O
highly	O
specific	O
molecular	B-C1817179
regulation	I-C1817179
of	O
aquaporins	B-C0599635
during	O
oogenesis	B-C0029047
and	O
spermatogenesis	B-C0037864
.	O
	
we	O
further	O
review	O
the	O
multiple	O
functions	O
that	O
these	O
channels	B-C0599635
play	O
during	O
the	O
establishment	O
of	O
egg	B-C0029974
buoyancy	B-C1622066
and	O
the	O
activation	B-C1879547
and	O
detoxification	B-C0150543
of	O
spermatozoa	B-C0037868
in	O
the	O
marine	B-C0036493
environment	B-C0014406
.	O
	
caribbean	B-C0206155
massive	B-C0324034
corals	I-C0324034
not	B-C0521109
recovering	I-C0521109
from	I-C0521109
repeated	O
thermal	B-C0871732
stress	I-C0871732
events	B-C0441471
during	O
2005-2013	O
massive	B-C0324034
coral	I-C0324034
bleaching	B-C1254365
events	B-C0441471
associated	O
with	O
high	O
sea	B-C0036493
surface	B-C0205148
temperatures	B-C0039476
are	O
forecast	O
to	O
become	O
more	O
frequent	B-C0332183
and	O
severe	B-C0205082
in	O
the	O
future	O
due	O
to	O
climate	B-C2718051
change	I-C2718051
.	O
	
monitoring	B-C0302523
colony	B-C0596092
recovery	B-C0237820
from	O
bleaching	B-C1254365
disturbances	O
over	O
multiyear	B-C0332168
time	I-C0332168
frames	I-C0332168
is	O
important	O
for	O
improving	O
predictions	O
of	O
future	O
coral	B-C0324034
community	B-C0009462
changes	B-C0392747
.	O
	
however	O
,	O
there	O
are	O
currently	O
few	O
multiyear	B-C2603343
studies	I-C2603343
describing	O
long-term	B-C0443252
outcomes	B-C1274040
for	O
coral	B-C1063194
colonies	B-C0596092
following	O
acute	B-C1254365
bleaching	I-C1254365
events	B-C0441471
.	O
	
we	O
recorded	O
colony	B-C0596092
pigmentation	B-C0031911
and	O
size	B-C0456389
for	O
bleached	B-C0441833
and	O
unbleached	B-C0441833
groups	I-C0441833
of	O
co-located	O
conspecifics	O
of	O
three	O
major	O
reef-building	B-C0997908
scleractinian	I-C0997908
corals	B-C0324034
orbicella	B-C1013977
franksi	I-C1013977
,	O
siderastrea	B-C1063194
siderea	I-C1063194
,	O
and	O
stephanocoenia	B-C1062911
michelini	I-C1062911
n	O
=	O
198	O
total	O
in	O
bocas	B-C0681784
del	I-C0681784
toro	I-C0681784
,	O
panama	B-C0030266
,	O
during	O
the	O
major	O
2005	O
bleaching	B-C1254365
event	B-C0441471
and	O
then	O
monitored	B-C0302523
pigmentation	B-C0031911
status	B-C0449438
and	O
changes	O
live	B-C0040300
tissue	I-C0040300
colony	B-C0596092
size	B-C0456389
for	O
8	O
years	B-C0439234
2005-2013	O
.	O
	
corals	B-C0324034
that	O
were	O
bleached	B-C1254365
in	O
2005	O
demonstrated	O
markedly	O
different	O
response	O
trajectories	O
compared	O
to	O
unbleached	O
colony	B-C0596092
groups	B-C0441833
,	O
with	O
extensive	O
live	B-C0040300
tissue	I-C0040300
loss	B-C1517945
for	O
bleached	B-C1254365
corals	B-C0324034
of	O
all	O
species	B-C1705920
following	O
bleaching	B-C1254365
,	O
with	O
mean	O
live	B-C0040300
tissue	I-C0040300
losses	B-C1517945
per	O
colony	B-C0596092
9	O
months	B-C0439231
postbleaching	B-C1254367
of	O
26.2	O
5.4	O
se	O
for	O
o	B-C1013977
.	O
	
franksi	I-C1013977
,	O
35.7	O
4.7	O
se	O
for	O
s	B-C1062911
.	O
	
michelini	I-C1062911
,	O
and	O
11.2	O
3.9	O
se	O
for	O
s	B-C1063194
.	O
	
siderea	I-C1063194
.	O
	
two	O
species	B-C1705920
,	O
o	B-C1013977
.	O
	
franksi	I-C1013977
and	O
s	B-C1062911
.	O
	
michelini	I-C1062911
,	O
later	O
recovered	O
to	O
net	O
positive	B-C1446409
growth	B-C0018270
,	O
which	O
continued	O
until	O
a	O
second	O
thermal	B-C0871732
stress	I-C0871732
event	B-C0441471
in	O
2010	O
.	O
	
following	O
this	O
event	B-C0441471
,	O
all	O
species	B-C1705920
again	O
lost	B-C0745777
tissue	B-C0040300
,	O
with	O
previously	O
unbleached	O
colony	B-C0596092
species	B-C1705920
groups	B-C0441833
experiencing	O
greater	O
declines	O
than	O
conspecific	O
sample	O
groups	B-C0441833
,	O
which	O
were	O
previously	O
bleached	B-C1254365
,	O
indicating	O
a	O
possible	O
positive	O
acclimative	B-C0237446
response	I-C0237446
.	O
	
however	O
,	O
despite	O
this	O
beneficial	O
effect	O
for	O
previously	O
bleached	B-C1254365
corals	B-C0324034
,	O
all	O
groups	B-C0441833
experienced	O
substantial	O
net	O
tissue	B-C0040300
loss	B-C1517945
between	O
2005	O
and	O
2013	O
,	O
indicating	O
that	O
many	O
important	O
caribbean	B-C0206155
reef-building	B-C0324034
corals	I-C0324034
will	O
likely	O
suffer	O
continued	O
tissue	B-C0040300
loss	B-C1517945
and	O
may	O
be	O
unable	O
to	O
maintain	O
current	O
benthic	B-C1254362
coverage	I-C1254362
when	O
faced	O
with	O
future	O
thermal	B-C0871732
stress	I-C0871732
forecast	O
for	O
the	O
region	B-C0017446
,	O
even	O
with	O
potential	O
benefits	O
from	O
bleaching	B-C1254365
-related	O
preparation	B-C1521827
and	O
characterization	B-C1880022
of	O
gastrointestinal	B-C0521362
wafer	B-C0991560
formulations	B-C1707824
many	O
active	B-C1254351
pharmaceutical	I-C1254351
ingredients	I-C1254351
api	B-C1254351
have	O
a	O
very	O
poor	O
or	O
highly	O
variable	B-C0439828
bioavailability	B-C0005508
after	O
oral	B-C0001563
administration	I-C0001563
.	O
	
one	O
possibility	O
to	O
overcome	B-C2983310
this	O
problem	O
might	O
be	O
found	O
in	O
the	O
application	O
of	O
mucoadhesive	B-C0013058
dosage	I-C0013058
forms	I-C0013058
like	O
gastrointestinal	B-C0521362
wafers	B-C0991560
.	O
	
however	O
,	O
a	O
currently	B-C0521116
unsolved	B-C1710576
challenge	O
is	O
the	O
control	B-C0243148
of	O
the	O
adhesion	B-C0175633
of	O
the	O
wafer	B-C0991560
to	O
the	O
intestinal	B-C0026727
mucus	I-C0026727
.	O
	
one	O
suggested	O
solution	O
might	O
be	O
the	O
combination	B-C0205195
of	O
gastrointestinal	B-C0521362
wafers	B-C0991560
and	O
expanding	B-C0205245
systems	I-C0205245
.	O
	
such	O
a	O
combination	B-C0205195
requires	O
thin	B-C0991560
and	I-C0991560
elastic	I-C0991560
wafers	I-C0991560
which	O
are	O
further	O
characterized	B-C1880022
by	O
an	O
unidirectional	B-C3850077
drug	I-C3850077
release	I-C3850077
.	O
	
in	O
this	O
study	B-C2603343
gastrointestinal	B-C0521362
,	O
twolayered	B-C0991560
wafers	I-C0991560
containing	O
a	O
water-insoluble	B-C0205556
backing	I-C0205556
layer	I-C0205556
and	O
a	O
drug-loaded	B-C0392762
,	O
mucoadhesive	B-C0205556
layer	I-C0205556
were	O
fabricated	O
by	O
casting	B-C0449851
solvent	I-C0449851
technique	I-C0449851
.	O
	
the	O
backing	B-C0205556
layer	I-C0205556
consists	O
of	O
ethocel	B-C1254351
standard	I-C1254351
10	I-C1254351
premium	I-C1254351
and	O
the	O
mucoadhesive	B-C0205556
layer	I-C0205556
was	O
prepared	O
using	O
a	O
mixture	B-C0439962
of	O
methocel	B-C3886467
e15	I-C3886467
premium	I-C3886467
lv	I-C3886467
,	O
polyvinyl	B-C0032623
alcohol	I-C0032623
and	O
macrogol	B-C4076208
400	I-C4076208
.	O
	
the	O
wafers	B-C0991560
were	O
characterized	B-C1880022
regarding	O
their	O
appearance	B-C0700364
,	O
mechanical	B-C0205556
properties	I-C0205556
and	O
dissolution	B-C3850077
profiles	I-C3850077
as	O
well	O
as	O
the	O
influence	B-C4054723
of	O
backing	B-C0205556
layer	I-C0205556
thickness	B-C1280412
on	O
drug	B-C0441655
transfer	I-C0441655
and	O
their	O
ability	O
of	O
unidirectional	B-C3850077
drug	I-C3850077
release	I-C3850077
.	O
	
the	O
wafers	B-C0991560
with	O
backing	B-C0205556
layer	I-C0205556
thickness	B-C1280412
of	O
500μg	B-C0059756
ethocel	I-C0059756
/cm	O
presented	O
adequate	B-C0205411
mechanical	B-C0205556
properties	I-C0205556
,	O
a	O
drug	B-C0441655
transfer	I-C0441655
about	O
73%	O
and	O
unidirectional	B-C3850077
drug	I-C3850077
release	I-C3850077
.	O
	
discovery	B-C1880355
of	O
<i>neopanorpa	B-C4005338
chillcotti</i>	I-C4005338
byers	I-C4005338
mecoptera	B-C1001487
panorpidae	B-C1015340
from	O
tibet	B-C0040182
,	O
china	B-C0008115
,	O
with	O
discussion	O
of	O
its	O
generic	B-C1254370
status	I-C1254370
neopanorpa	B-C4005338
chillcotti	I-C4005338
byers	I-C4005338
,	O
1971	O
was	O
originally	O
described	O
from	O
kathmandu	B-C0681784
in	O
nepal	B-C0027689
and	O
is	O
now	O
found	O
to	O
be	O
distributed	O
in	O
gyirong	B-C0681784
,	O
tibet	B-C0040182
in	O
china	B-C0008115
.	O
	
the	O
species	O
is	O
redescribed	O
and	O
illustrated	O
based	O
on	O
new	B-C0439861
material	I-C0439861
from	O
china	B-C0008115
and	O
nepal	B-C0027689
.	O
	
the	O
generic	B-C1254370
status	I-C1254370
of	O
this	O
species	B-C1705920
is	O
briefly	O
passive	B-C4288441
case	I-C4288441
detection	I-C4288441
of	O
malaria	B-C0024530
in	O
ratanakiri	B-C0681784
province	I-C0681784
cambodia	B-C0681784
to	O
detect	B-C0442726
villages	B-C0562518
at	B-C3843761
higher	I-C3843761
risk	I-C3843761
for	O
malaria	B-C0024530
cambodia	B-C0681784
reduced	B-C0392756
malaria	B-C0024530
incidence	B-C0021149
by	O
more	O
than	O
75%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	B-C1521840
of	O
the	O
millennium	B-C0018017
development	I-C0018017
goal	I-C0018017
6	I-C0018017
.	O
	
the	O
cambodian	B-C0681784
government	B-C0018104
aims	B-C1947946
to	O
eliminate	B-C0849355
all	O
forms	O
of	O
malaria	B-C0024530
by	O
2025	O
.	O
	
the	O
country's	B-C0454664
malaria	B-C0024530
incidence	B-C0021149
is	O
highly	B-C0205250
variable	B-C0439828
at	O
provincial	B-C0681784
level	B-C0441889
,	O
but	O
less	O
is	O
known	O
at	O
village	B-C0562518
level	B-C0441889
.	O
	
this	O
study	B-C2603343
used	O
passive	B-C4288441
case	I-C4288441
detection	I-C4288441
pcd	B-C4288441
data	O
at	O
village	B-C0562518
level	B-C0441889
in	O
ratanakiri	B-C0681784
province	I-C0681784
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	B-C0021149
trends	B-C1521798
and	O
identify	B-C0205396
high-risk	B-C0332167
areas	I-C0332167
of	I-C0332167
malaria	B-C0024530
to	O
be	O
primarily	B-C0205225
targeted	B-C1521840
towards	O
malaria	B-C0024530
elimination	B-C0849355
.	O
	
in	O
2010	O
,	O
the	O
cambodian	B-C0681784
malaria	B-C0024530
programme	B-C0376691
created	O
a	O
malaria	B-C0021428
information	I-C0021428
system	I-C0021428
mis	B-C0021428
to	O
capture	O
malaria	B-C0024530
information	B-C1533716
at	O
village	B-C0562518
level	B-C0441889
through	O
pcd	B-C4288441
by	O
village	B-C0562518
malaria	B-C0018724
workers	I-C0018724
and	O
health	B-C0018704
facilities	I-C0018704
.	O
	
the	O
mis	B-C0021428
data	B-C1511726
of	O
ratanakiri	B-C0681784
province	I-C0681784
2010-2014	O
were	O
used	O
to	O
calculate	B-C1441506
annual	B-C0332181
incidence	B-C1708485
rates	I-C1708485
by	O
plasmodium	B-C0032148
species	I-C0032148
at	O
province	B-C0681784
and	O
commune	B-C0598781
levels	B-C0441889
.	O
	
for	O
estimating	B-C0750572
the	O
trend	B-C1521798
at	O
provincial	B-C0681784
level	B-C0441889
only	O
villages	B-C0562518
reporting	B-C0700287
each	O
year	B-C0439234
were	O
selected	O
.	O
	
the	O
communal	B-C0009462
incidences	B-C0021149
and	O
the	O
number	O
of	O
cases	B-C0868928
per	B-C3887962
village	B-C0562518
were	O
visualized	O
on	O
a	O
map	B-C0024779
per	O
plasmodium	B-C0032148
species	I-C0032148
and	O
per	B-C0439508
year	I-C0439508
.	O
	
analysis	B-C0814928
of	I-C0814928
spatial	I-C0814928
clustering	I-C0814928
of	O
village	B-C0562518
malaria	B-C0024530
cases	B-C0868928
by	O
plasmodium	B-C0032148
species	I-C0032148
was	O
performed	B-C0884358
by	O
year	B-C0439234
.	O
	
overall	O
,	O
malaria	B-C0024530
annual	B-C0332181
incidence	B-C1708485
rates	I-C1708485
per	O
1000	O
inhabitants	B-C0030705
decreased	B-C0392756
from	O
86	O
2010	O
to	O
30	O
2014	O
.	O
	
falciparum	B-C0032150
incidence	B-C0021149
decreased	B-C0392756
by	O
79%	O
in	O
2014	O
compared	B-C1707455
to	O
2010	O
ci	B-C0009667
95%	O
76-82%	O
more	O
rapidly	B-C0456962
than	O
vivax	B-C0032154
incidence	B-C0021149
by	O
19%	O
in	O
2014	O
compared	B-C1707455
to	O
2010	O
ci	B-C0009667
95%	O
5-32%	O
.	O
	
there	O
were	O
ten	O
to	O
16	O
significant	B-C0750502
spatial	B-C0012641
clusters	I-C0012641
each	O
year	B-C0439234
.	O
	
big	B-C0012641
clusters	I-C0012641
tended	O
to	O
extend	B-C0439792
along	O
the	O
cambodian-vietnamese	B-C0681784
border	I-C0681784
and	O
along	O
the	O
sesan	B-C0337050
river	I-C0337050
.	O
	
three	O
clusters	B-C0012641
appeared	O
throughout	O
all	O
years	B-C0439234
2010-2014	O
one	O
with	O
21	O
villages	B-C0562518
appeared	O
each	O
year	B-C0439234
,	O
the	O
second	O
shrunk	B-C0547047
progressively	B-C0205329
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	B-C1534709
into	O
two	O
smaller	O
clusters	B-C0012641
in	O
2013	O
and	O
2014	O
.	O
	
the	O
decline	B-C0868945
of	O
malaria	B-C0024530
burden	B-C2828008
can	O
be	O
attributed	O
to	O
intensive	B-C0521110
malaria	B-C0441655
control	I-C0441655
activities	I-C0441655
implemented	B-C1708476
in	O
the	O
areas	B-C0205146
distribution	B-C0520511
of	O
a	O
long-lasting	B-C0549178
insecticidal	B-C2717999
net	I-C2717999
per	O
person	B-C0027361
and	O
early	B-C0596473
diagnosis	I-C0596473
and	O
prompt	B-C0871157
treatment	B-C1522326
.	O
	
dihydro-artemisinin	B-C0058108
piperaquine	B-C0071105
was	O
the	O
only	O
first-line	B-C1708063
treatment	I-C1708063
for	O
all	O
malaria	B-C0024530
cases	B-C0868928
.	O
	
no	O
radical	B-C0439807
treatment	B-C1522326
with	O
primaquine	B-C0071105
was	O
provided	O
for	O
plasmodium	B-C0032154
vivax	I-C0032154
cases	B-C0868928
,	O
which	O
could	O
explain	O
the	O
slow	B-C0439834
decrease	B-C0547047
of	O
p	B-C0032154
.	O
	
vivax	I-C0032154
due	O
to	O
relapses	B-C0035020
.	O
	
to	O
achieve	B-C0205197
malaria	B-C0024530
elimination	B-C0849355
by	O
2025	O
,	O
priority	B-C0549179
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	B-C0205360
malaria	B-C0012641
clusters	I-C0012641
interaction	B-C0851537
of	I-C0851537
lifestyle	I-C0851537
,	O
behaviour	B-C0004927
or	O
systemic	B-C0442893
diseases	I-C0442893
with	O
dental	B-C0011334
caries	I-C0011334
and	O
periodontal	B-C0031090
diseases	I-C0031090
consensus	B-C0086050
report	I-C0086050
of	I-C0086050
group	I-C0086050
2	I-C0086050
of	I-C0086050
the	I-C0086050
joint	I-C0086050
efp/orca	I-C0086050
workshop	I-C0086050
on	O
the	O
boundaries	O
between	O
caries	B-C0011334
and	O
periodontal	B-C0031090
diseases	I-C0031090
periodontal	B-C0031090
diseases	I-C0031090
and	O
dental	B-C0011334
caries	I-C0011334
are	O
the	O
most	O
common	B-C0012634
diseases	I-C0012634
of	O
humans	O
and	O
the	O
main	O
cause	O
of	O
tooth	B-C0080233
loss	I-C0080233
.	O
	
both	O
diseases	B-C0012634
can	O
lead	O
to	O
nutritional	B-C0012160
compromise	I-C0012160
and	O
negative	O
impacts	O
upon	O
self-esteem	B-C0036597
and	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
.	O
	
as	O
complex	B-C0008679
chronic	I-C0008679
diseases	I-C0008679
,	O
they	O
share	O
common	B-C0035648
risk	I-C0035648
factors	I-C0035648
,	O
such	O
as	O
a	O
requirement	O
for	O
a	O
pathogenic	B-C0599030
plaque	I-C0599030
biofilm	I-C0599030
,	O
yet	O
they	O
exhibit	O
distinct	B-C0277785
pathophysiologies	I-C0277785
.	O
	
multiple	B-C0332157
exposures	I-C0332157
contribute	O
to	O
their	O
causal	O
pathways	O
,	O
and	O
susceptibility	B-C0012655
involves	I-C0012655
risk	B-C0035648
factors	I-C0035648
that	O
are	O
inherited	B-C0439660
e.g	O
.	O
	
genetic	B-C0042333
variants	I-C0042333
,	O
and	O
those	O
that	O
are	O
acquired	O
e.g	O
.	O
	
socio-economic	B-C0086996
factors	I-C0086996
,	O
biofilm	B-C0081786
load	O
or	O
composition	O
,	O
smoking	B-C0037369
,	O
carbohydrate	B-C0489461
intake	I-C0489461
.	O
	
identification	O
of	O
these	O
factors	O
is	O
crucial	O
in	O
the	O
prevention	B-C0679698
of	I-C0679698
both	I-C0679698
diseases	I-C0679698
as	O
well	O
as	O
in	O
their	B-C0376636
management	I-C0376636
.	O
	
to	O
systematically	O
appraise	O
the	O
scientific	B-C0023866
literature	I-C0023866
to	O
identify	O
potential	B-C0035648
risk	I-C0035648
factors	I-C0035648
for	O
caries	B-C0011334
and	O
periodontal	B-C0031090
diseases	I-C0031090
.	O
	
one	O
systematic	B-C1955832
review	I-C1955832
genetic	B-C0814299
risk	I-C0814299
factors	I-C0814299
,	O
one	O
narrative	B-C0815257
review	I-C0815257
role	B-C1511900
of	I-C1511900
diet	I-C1511900
and	I-C1511900
nutrition	I-C1511900
and	O
reference	B-C0586393
documentation	I-C0586393
for	O
modifiable	B-C0035648
acquired	I-C0035648
risk	I-C0035648
factors	I-C0035648
common	O
to	O
both	O
disease	O
groups	O
,	O
formed	O
the	O
basis	O
of	O
the	O
report	O
.	O
	
there	O
is	O
moderately	O
strong	O
evidence	O
for	O
a	O
genetic	B-C0243095
contribution	I-C0243095
to	O
periodontal	B-C0031090
diseases	I-C0031090
and	O
caries	B-C0011336
susceptibility	I-C0011336
,	O
with	O
an	O
attributable	B-C0814766
risk	I-C0814766
estimated	O
to	O
be	O
up	O
to	O
50%	O
.	O
	
the	O
genetics	B-C0017399
literature	I-C0017399
for	O
periodontal	B-C0031090
disease	I-C0031090
is	O
more	O
substantial	O
than	O
for	O
caries	B-C0011334
and	O
genes	B-C0017337
associated	B-C0332281
with	I-C0332281
chronic	B-C0266929
periodontitis	I-C0266929
are	O
the	O
vitamin	B-C0919430
d	I-C0919430
receptor	I-C0919430
vdr	B-C0919430
,	O
fc	B-C1414553
gamma	I-C1414553
receptor	I-C1414553
iia	I-C1414553
fc-γriia	B-C1414553
and	O
interleukin	B-C1334098
10	I-C1334098
il10	I-C1334098
genes	I-C1334098
.	O
	
for	O
caries	O
,	O
genes	O
involved	O
in	O
enamel	O
formation	O
amelx	O
,	O
ambn	O
,	O
enam	O
,	O
tuft	O
,	O
mmp20	O
,	O
and	O
klk4	O
,	O
salivary	O
characteristics	O
aqp5	O
,	O
immune	O
regulation	O
and	O
dietary	O
preferences	O
had	O
the	O
largest	O
impact	O
.	O
	
no	O
common	O
genetic	O
variants	O
were	O
found	O
.	O
	
fermentable	O
carbohydrates	O
sugars	O
and	O
starches	O
were	O
the	O
most	O
relevant	O
common	O
dietary	O
risk	O
factor	O
for	O
both	O
diseases	O
,	O
but	O
associated	O
mechanisms	O
differed	O
.	O
	
in	O
caries	O
,	O
the	O
fermentation	O
process	O
leads	O
to	O
acid	O
production	O
and	O
the	O
generation	O
of	O
biofilm	O
components	O
such	O
as	O
glucans	O
.	O
	
in	O
periodontitis	O
,	O
glycaemia	O
drives	O
oxidative	O
stress	O
and	O
advanced	O
glycation	O
end-products	O
may	O
also	O
trigger	O
a	O
hyper	O
inflammatory	O
state	O
.	O
	
micronutrient	O
deficiencies	O
,	O
such	O
as	O
for	O
vitamin	O
c	O
,	O
vitamin	O
d	O
or	O
vitamin	O
b12	O
,	O
may	O
be	O
related	O
to	O
the	O
onset	O
and	O
progression	O
of	O
both	O
diseases	O
.	O
	
functional	O
foods	O
or	O
probiotics	O
could	O
be	O
helpful	O
in	O
caries	O
prevention	O
and	O
periodontal	O
disease	O
management	O
,	O
although	O
evidence	O
is	O
limited	O
and	O
biological	O
mechanisms	O
not	O
fully	O
elucidated	O
.	O
	
hyposalivation	O
,	O
rheumatoid	O
arthritis	O
,	O
smoking/tobacco	O
use	O
,	O
undiagnosed	O
or	O
sub-optimally	O
controlled	O
diabetes	O
and	O
obesity	O
are	O
common	O
acquired	O
risk	O
factors	O
for	O
both	O
caries	O
and	O
periodontal	O
diseases	I-C0850664
intestinal	B-C0021853
micropatches	B-C0991556
for	O
oral	B-C0442027
insulin	B-C3165280
delivery	I-C3165280
diabetes	B-C0011849
mellitus	I-C0011849
has	O
become	O
a	O
major	O
public	B-C1554189
health	I-C1554189
issue	I-C1554189
that	O
has	O
almost	O
reached	O
epidemic	B-C0220823
proportions	I-C0220823
worldwide	O
.	O
	
injectable	B-C0544377
insulin	I-C0544377
has	O
been	O
typically	O
utilized	O
for	O
the	O
management	B-C0376636
of	O
this	O
chronic	B-C0008679
disease	I-C0008679
.	O
	
however	O
,	O
lack	B-C0376405
of	I-C0376405
patient	I-C0376405
compliance	I-C0376405
with	O
injectable	B-C0086466
formulations	B-C1705957
has	O
spurred	O
the	O
development	O
of	O
oral	B-C0442027
insulin	B-C0021641
formulations	B-C1705957
,	O
which	O
although	O
appealing	O
,	O
face	O
several	O
delivery	B-C1533734
challenges	B-C0805586
.	O
	
we	O
have	O
developed	O
novel	O
mucoadhesive	B-C0001516
intestinal	B-C0021853
patches	B-C0991556
,	O
several	O
hundred	O
micrometers	B-C0439201
in	O
dimension	B-C0439534
micropatches	B-C0991556
that	O
address	O
the	O
challenges	B-C0805586
of	O
oral	B-C0442027
insulin	B-C3165280
delivery	I-C3165280
.	O
	
the	O
micropatches	B-C0991556
adhere	B-C3714578
to	O
the	O
intestinal	B-C0021839
mucosa	I-C0021839
,	O
release	O
their	O
drug	B-C1254351
load	O
rapidly	B-C0456962
within	O
30	O
min	O
and	O
are	O
effective	B-C1704419
in	O
lowering	B-C0595883
blood	I-C0595883
glucose	I-C0595883
levels	I-C0595883
in	B-C1515655
vivo	I-C1515655
.	O
	
when	O
insulin	B-C0021641
-loaded	O
micropatches	B-C0991556
were	O
administered	B-C1533734
with	O
a	O
permeation	B-C1254351
enhancer	I-C1254351
and	O
protease	B-C0033607
inhibitor	I-C0033607
,	O
a	O
peak	B-C0444505
efficacy	B-C1280519
of	O
34%	O
drop	B-C0595883
in	I-C0595883
blood	I-C0595883
glucose	I-C0595883
levels	I-C0595883
was	O
observed	O
within	O
3	O
h	O
.	O
	
efficacy	B-C1280519
further	O
improved	O
to	O
41%	O
when	O
micropatches	B-C0991556
were	O
administered	B-C1533734
in	O
multiple	B-C1960418
doses	I-C1960418
.	O
	
here	O
,	O
we	O
describe	O
the	O
design	O
of	O
micropatches	B-C0991556
as	O
an	O
oral	B-C0442027
insulin	B-C0021641
formulation	B-C1705957
and	O
report	O
their	O
in	B-C1515655
vivo	I-C1515655
efficacy	B-C1280519
.	O
	
hybrid	B-C0026339
automata	I-C0026339
models	I-C0026339
of	O
cardiac	B-C0018827
ventricular	I-C0018827
electrophysiology	B-C0430467
for	O
real-time	B-C1550177
computational	B-C0205245
applications	I-C0205245
virtual	O
heart	B-C0026339
models	I-C0026339
have	O
been	O
proposed	O
for	O
closed	B-C0443183
loop	I-C0443183
validation	B-C1519941
of	O
safety	B-C0036043
-	O
critical	B-C1511545
embedded	O
medical	B-C0025080
devices	I-C0025080
,	O
such	O
as	O
pacemakers	B-C0810633
.	O
	
these	O
models	B-C0026339
must	O
react	O
in	O
real-time	B-C1550177
to	O
off-the-shelf	O
medical	B-C0025080
devices	I-C0025080
.	O
	
real-time	B-C1550177
performance	B-C1882330
can	O
be	O
obtained	B-C1301820
by	O
implementing	O
models	B-C0026339
in	O
computer	B-C0009602
hardware	I-C0009602
,	O
and	O
methods	B-C0025664
of	O
compiling	O
classes	O
of	O
hybrid	B-C0026339
automata	I-C0026339
ha	B-C0026339
onto	O
fpga	B-C0025080
have	O
been	O
developed	O
.	O
	
models	B-C0026339
of	O
ventricular	B-C2339371
cardiac	I-C2339371
cell	I-C2339371
electrophysiology	B-C0430467
have	O
been	O
described	B-C1552738
using	O
ha	B-C0026339
which	O
capture	B-C1254366
the	O
complex	O
nonlinear	O
behavior	B-C1521970
of	O
biological	B-C0449913
systems	I-C0449913
.	O
	
however	O
,	O
many	O
models	B-C0026339
that	O
have	O
been	O
used	O
for	O
closed-loop	B-C0443183
validation	B-C1519941
of	O
pacemakers	B-C0810633
are	O
highly	O
abstract	B-C1552863
and	O
do	O
not	O
capture	B-C1254366
important	B-C3898777
characteristics	B-C1521970
of	O
the	O
dynamic	B-C0729333
rate	B-C0237629
response	I-C0237629
.	O
	
we	O
developed	O
a	O
new	O
ha	B-C0026339
model	I-C0026339
of	O
cardiac	B-C0225828
cells	I-C0225828
which	O
captures	B-C1254366
dynamic	B-C0729333
behavior	B-C1521970
and	O
we	O
implemented	O
the	O
model	B-C0026339
in	O
hardware	B-C0009602
.	O
	
this	O
potentially	B-C3245505
enables	O
modeling	B-C0870071
the	O
heart	B-C0018787
with	O
over	O
1	O
million	B-C1881839
dynamic	B-C0729333
cells	B-C0007634
,	O
making	O
the	O
approach	O
ideal	B-C1512612
for	O
closed	B-C0443183
loop	I-C0443183
testing	B-C0039593
of	O
medical	B-C0025080
devices	I-C0025080
.	O
	
comparison	B-C1707455
of	O
pulse	B-C3494431
wave	I-C3494431
velocity	I-C3494431
derived	O
from	O
accelerometer	B-C0178951
and	O
reflective	B-C0203341
photo-plethysmography	I-C0203341
signals	I-C0203341
placed	O
at	O
the	O
carotid	B-C0007272
and	O
femoral	B-C0015801
artery	I-C0015801
carotid	B-C0007272
-	O
femoral	B-C0015801
pulse	B-C3494431
wave	I-C3494431
velocity	I-C3494431
is	O
an	O
established	B-C0079809
measure	I-C0079809
to	O
assess	B-C0184514
cardiovascular	B-C1113685
risk	I-C1113685
and	O
an	O
interesting	O
surrogate	B-C0549193
parameter	I-C0549193
towards	O
non-invasive	B-C4301970
continuous	I-C4301970
blood	I-C4301970
pressure	I-C4301970
inference	I-C4301970
.	O
	
due	O
to	O
progress	B-C1280477
in	O
sensing	O
technologies	O
for	O
wearable	B-C0183210
wrist	I-C0183210
worn	I-C0183210
sensors	I-C0183210
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo-plethysmography	B-C0162599
and	O
high	B-C0178951
fidelity	I-C0178951
accelerometer	I-C0178951
s	I-C0178951
available	O
offering	O
access	O
to	O
pulse	B-C0034107
information	I-C0034107
from	O
larger	B-C0003842
arteries	I-C0003842
complemented	O
by	O
blood	B-C0005850
volume	I-C0005850
changes	O
in	O
the	O
superficial	B-C0040300
tissue	I-C0040300
.	O
	
in	O
this	O
work	O
we	O
compare	O
pulse	B-C3494431
wave	I-C3494431
velocities	I-C3494431
derived	O
from	O
accelerometer	B-C0178951
and	O
reflective	B-C0203341
photo-plethysmography	I-C0203341
signals	I-C0203341
placed	O
at	O
the	O
carotid	B-C0007272
and	O
femoral	B-C0015801
artery	I-C0015801
.	O
	
we	O
discuss	O
the	O
different	O
underlying	O
physiological	B-C0031845
processes	I-C0031845
for	O
the	O
two	O
sensing	B-C1254370
principles	I-C1254370
and	O
present	O
experimental	B-C2825142
results	I-C2825142
obtained	O
in	O
a	O
study	B-C2603343
with	O
healthy	B-C1708335
subjects	I-C1708335
.	O
	
constructive	B-C0243095
and	I-C0243095
unproductive	I-C0243095
processing	I-C0243095
of	O
traumatic	B-C3203533
experiences	I-C3203533
in	O
trauma-focused	B-C0579049
cognitive-behavioral	I-C0579049
therapy	I-C0579049
for	O
youth	B-C0087178
although	O
there	O
is	O
substantial	O
evidence	B-C3887511
to	O
support	O
the	O
efficacy	B-C1280519
of	O
cognitive-behavioral	B-C0579049
treatments	I-C0579049
cbt	B-C0579049
for	O
posttraumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
,	O
there	O
is	O
some	O
debate	O
about	O
how	O
these	O
treatments	B-C0087111
have	O
their	O
effects	O
.	O
	
modern	O
learning	B-C0870794
theory	I-C0870794
and	O
cognitive	B-C0282574
and	I-C0282574
emotional	I-C0282574
processing	I-C0282574
theories	I-C0282574
highlight	O
the	O
importance	O
of	O
reducing	O
avoidance	B-C0870186
,	O
facilitating	O
the	O
constructive	B-C0517168
processing	I-C0517168
of	I-C0517168
feared	I-C0517168
experiences	I-C0517168
,	O
and	O
strengthening	O
new	O
inhibitory	B-C0679066
learning	I-C0679066
.	O
	
we	O
examined	O
variables	O
thought	O
to	O
be	O
associated	O
with	O
unproductive	B-C0243095
and	I-C0243095
constructive	I-C0243095
processing	I-C0243095
of	O
traumatic	B-C3203533
experiences	I-C3203533
in	O
a	O
sample	O
of	O
81	O
youth	O
with	O
elevated	O
ptsd	B-C0038436
symptoms	B-C1457887
,	O
who	O
received	O
trauma-focused	B-C0579049
cognitive	I-C0579049
behavioral	I-C0579049
therapy	I-C0579049
tf-cbt	B-C0579049
for	O
abuse	B-C0237206
or	O
traumatic	B-C3203533
interpersonal	B-C0679461
loss	I-C0679461
.	O
	
sessions	B-C1883017
during	O
the	O
trauma	B-C3494322
narrative	I-C3494322
phase	I-C3494322
of	O
tf-cbt	B-C0579049
were	O
coded	O
for	O
indicators	O
of	O
unproductive	B-C0243095
processing	I-C0243095
overgeneralization	B-C0563151
,	O
rumination	B-C0154575
,	O
avoidance	B-C0870186
and	O
constructive	B-C0243095
processing	I-C0243095
decentering	B-C0243095
,	O
accommodation	B-C1832072
of	I-C1832072
corrective	I-C1832072
information	I-C1832072
,	O
as	O
well	O
as	O
levels	B-C3165349
of	I-C3165349
negative	I-C3165349
emotion	I-C3165349
.	O
	
in	O
previous	B-C0205156
analyses	O
of	O
this	O
trial	O
ready	O
et	O
al	O
,	O
2015	O
,	O
more	O
overgeneralization	B-C0563151
during	O
the	O
narrative	B-C3494322
phase	I-C3494322
predicted	O
less	O
improvement	O
in	O
internalizing	B-C0237088
symptoms	I-C0237088
at	O
posttreatment	B-C0679865
and	O
a	O
worsening	B-C0332271
of	O
externalizing	B-C0237088
symptoms	I-C0237088
over	O
the	O
12-month	O
follow-up	B-C1522577
.	O
	
in	O
contrast	O
,	O
more	O
accommodation	B-C1832072
predicted	I-C1832072
improvement	I-C1832072
in	O
internalizing	B-C0237088
symptoms	I-C0237088
and	O
also	O
moderated	B-C1881878
the	O
negative	B-C0205160
effects	B-C1704420
of	I-C1704420
overgeneralization	B-C0563151
on	O
internalizing	B-C0237088
and	I-C0237088
externalizing	I-C0237088
symptoms	I-C0237088
.	O
	
the	O
current	O
study	O
examined	O
correlates	O
of	O
overgeneralization	B-C0563151
and	O
accommodation	B-C1832072
.	O
	
overgeneralization	B-C0563151
was	O
associated	B-C0332281
with	I-C0332281
more	O
rumination	B-C0154575
,	O
less	O
decentering	O
,	O
and	O
more	O
negative	B-C3165349
emotion	I-C3165349
,	O
suggesting	B-C0038659
immersion	B-C3714592
in	O
trauma	B-C3203533
-related	O
material	O
.	O
	
accommodation	B-C1832072
was	O
associated	B-C0332281
with	I-C0332281
less	O
avoidance	B-C0870186
and	O
more	O
decentering	B-C0243095
,	O
suggesting	O
a	O
healthy	B-C3898900
distance	O
from	O
trauma	B-C3203533
-related	O
material	O
that	O
might	O
allow	O
for	O
processing	O
and	O
cognitive	B-C1392786
change	I-C1392786
.	O
	
decentering	O
also	O
predicted	B-C0681842
improvement	B-C2986411
in	O
externalizing	B-C0237088
symptoms	I-C0237088
at	O
posttreatment	B-C0679865
.	O
	
rumination	B-C0154575
and	O
avoidance	B-C0870186
showed	O
important	O
associations	O
with	O
overgeneralization	B-C0563151
and	O
accommodation	B-C1832072
,	O
respectively	O
,	O
but	O
did	O
not	O
predict	O
treatment	B-C0085415
outcomes	I-C0085415
.	O
	
this	O
study	O
identifies	O
correlates	O
of	O
overgeneralization	B-C0563151
and	O
accommodation	B-C1832072
that	O
might	O
shed	O
light	O
on	O
how	O
these	O
variables	O
relate	O
to	O
unproductive	B-C0243095
and	I-C0243095
constructive	I-C0243095
processing	I-C0243095
of	O
traumatic	B-C3203533
experiences	I-C3203533
.	O
	
giant	B-C0017526
antrochoanal	B-C0008298
polyp	I-C0008298
-a	O
rare	B-C0522498
presentation	B-C0449450
antrochoanal	B-C0008298
polyp	I-C0008298
acp	B-C0008298
,	O
also	O
called	O
as	O
killian	B-C0008298
polyp	I-C0008298
,	O
is	O
an	O
infrequent	O
,	O
benign	B-C0221198
lesion	I-C0221198
of	O
maxillary	B-C0024947
origin	O
in	O
non-atopic	O
patients	B-C0030705
.	O
	
the	O
antrochoanal	B-C0008298
polyp	I-C0008298
is	O
shaped	O
according	O
to	O
the	O
anatomical	B-C0220784
constraints	O
of	O
the	O
lateral	B-C0456482
nasal	I-C0456482
wall	I-C0456482
,	O
particularly	O
the	O
middle	B-C0225401
meatus	I-C0225401
and	O
antrum	B-C1549092
,	O
resembling	O
typically	O
a	O
dumbbell	B-C0686912
.	O
	
here	O
presenting	O
a	O
common	O
problem	B-C0033213
with	O
unusual	B-C2700116
presentation	B-C0449450
.	O
	
effects	B-C1280500
of	O
obesity	B-C0028754
on	O
il-33	B-C2976122
/	O
st2	B-C3849696
system	B-C0449913
in	O
heart	B-C0018787
,	O
adipose	B-C0001527
tissue	I-C0001527
and	O
liver	B-C0023884
study	B-C0008972
in	O
the	O
experimental	B-C0086272
model	I-C0086272
of	O
zucker	B-C0034719
rats	I-C0034719
suppression	B-C3849696
of	I-C3849696
tumorigenicity	I-C3849696
2	I-C3849696
st2	B-C3849696
mediates	O
the	O
effect	B-C1280500
of	O
interleukin-33	B-C2976122
il-33	B-C2976122
.	O
	
few	O
data	O
are	O
reported	O
on	O
the	O
relationship	B-C0439849
between	O
il-33	B-C2976122
/	O
st2	B-C3849696
and	O
obesity	B-C0028754
.	O
	
we	O
aimed	O
to	O
investigate	O
effects	B-C1280500
of	O
obesity	B-C0028754
on	O
il-33	B-C2976122
/	O
st2	B-C3849696
system	B-C0449913
in	O
heart	B-C0018787
,	O
adipose	B-C0001527
tissue	I-C0001527
and	O
liver	B-C0023884
in	O
a	O
rodent	B-C1519106
model	I-C1519106
of	O
obesity	B-C0028754
.	O
	
the	O
relationship	B-C0439849
of	O
cardiac	B-C1272575
expression	B-C1171362
of	O
il-33	B-C2976122
/	O
st2	B-C3849696
system	B-C0449913
with	O
natriuretic	B-C1144709
peptides	I-C1144709
nps	B-C1144709
system	B-C0449913
and	O
inflammatory	B-C3155540
mediators	I-C3155540
was	O
also	O
studied	O
.	O
	
mrna	B-C1515670
expression	I-C1515670
of	O
il-33	B-C1825595
/	O
st2	B-C1420442
system	B-C0449913
was	O
evaluated	O
in	O
cardiac	B-C0189784
,	O
adipose	B-C0001527
and	O
hepatic	B-C0193388
biopsies	I-C0193388
from	O
obese	B-C0034719
zucker	I-C0034719
rats	I-C0034719
o	B-C0034719
and	O
controls	B-C0009932
co	B-C0009932
.	O
	
expression	B-C1171362
levels	O
of	O
sst2	B-C3852857
was	O
significantly	O
lower	O
in	O
o	B-C0034719
rats	I-C0034719
compared	O
with	O
co	B-C0009932
p<0	O
in	O
all	O
tissues	B-C0040300
.	O
	
besides	O
,	O
the	O
mrna	B-C0035696
levels	O
of	O
il-33	B-C1825595
decreased	O
significant	O
in	O
fat	O
of	O
o	B-C0034719
respect	O
to	O
co	B-C0009932
,	O
while	O
,	O
expression	B-C0017262
levels	O
of	O
st2l	B-C1416400
was	O
significantly	O
higher	O
in	O
liver	B-C0023884
of	O
co	B-C0009932
than	O
in	O
o	B-C0034719
.	O
	
a	O
strong	O
relationship	B-C0439849
of	O
il-33	B-C2976122
/	O
st2	B-C3849696
with	O
nps	B-C1144709
and	O
classical	O
inflammatory	B-C3155540
mediators	I-C3155540
was	O
observed	O
in	O
cardiac	B-C1272575
tissue	I-C1272575
.	O
	
expression	B-C1171362
of	O
sst2	B-C3852857
in	O
cardiac	B-C1272575
,	O
adipose	B-C0001527
and	O
liver	B-C0023884
tissue	I-C0023884
decreased	O
in	O
o	B-C0034719
compared	O
with	O
controls	B-C0009932
,	O
suggesting	O
an	O
involvement	O
for	O
il-33	B-C2976122
/	O
st2	B-C3849696
system	B-C0449913
in	O
molecular	B-C1148560
mechanisms	I-C1148560
of	O
obesity	B-C0028754
.	O
	
the	O
strong	O
relationships	B-C0439849
with	O
np	B-C1144709
systems	B-C0449913
and	O
inflammatory	B-C3155540
mediators	I-C3155540
could	O
suggest	O
an	O
involvement	O
for	O
il-33	B-C2976122
/	O
st2	B-C3849696
in	O
molecular	B-C1704259
pathways	I-C1704259
leading	O
to	O
cardiac	B-C3277906
dysfunction	I-C3277906
and	O
inflammation	B-C0021368
associated	O
with	O
cxcl14	B-C1335988
-	O
cxcr4	B-C2352110
and	O
cxcl12	B-C1528383
-	O
cxcr4	B-C2352110
axes	O
may	O
play	O
important	O
roles	O
in	O
the	O
unique	O
invasion	B-C1269955
process	B-C1522240
of	O
endometrioid	B-C0206687
carcinoma	I-C0206687
with	O
melf-pattern	B-C0449774
myoinvasion	B-C1269955
the	O
term	O
""""	O
melf-pattern	B-C0449774
myometrial	B-C0521387
invasion	B-C1269955
""""	O
melf	B-C0449774
pattern	I-C0449774
denotes	O
an	O
unusual	B-C2700116
morphology	B-C0332437
of	O
myometrial	B-C0521387
invasion	B-C1269955
in	O
endometrioid	B-C0206687
carcinomas	I-C0206687
,	O
and	O
is	O
associated	B-C0332281
with	I-C0332281
frequent	O
lymphovascular	B-C1708790
invasion	I-C1708790
and	O
lymph	B-C0024232
node	I-C0024232
metastasis	I-C0024232
.	O
	
in	O
this	O
study	O
,	O
tumor	B-C0334227
cells	I-C0334227
were	O
directly	O
collected	B-C1516695
from	O
a	O
melf	B-C0449774
pattern	I-C0449774
site	O
,	O
using	O
laser	B-C1113652
microdissection	I-C1113652
.	O
	
comprehensive	B-C1880156
microarray	B-C1449575
analysis	I-C1449575
of	O
the	O
genes	B-C0017337
was	O
conducted	O
,	O
and	O
based	O
on	O
the	O
results	O
,	O
expression	B-C1171362
of	O
a	O
metastasis	B-C2352110
progression	I-C2352110
gene	I-C2352110
,	O
cxcr4	I-C2352110
,	O
and	O
its	O
ligands	B-C1749457
cxcl14	B-C1335988
and	O
cxcl12	B-C1528383
,	O
was	O
further	O
investigated	B-C1292732
.	O
	
in	B-C0681828
vitro	I-C0681828
studies	I-C0681828
of	O
endometrioid	B-C0206687
carcinoma	I-C0206687
cell	B-C0085983
lines	I-C0085983
revealed	O
elevated	B-C3163633
invasion	B-C1269955
activity	B-C0441655
in	O
a	O
manner	O
dependent	O
on	O
the	O
cxcl14	B-C1335988
-	O
cxcr4	B-C2352110
or	O
cxcl12	B-C1528383
-	O
cxcr4	B-C2352110
axis	O
.	O
	
immunohistochemical	B-C1441616
analysis	I-C1441616
of	O
93	O
melf	B-C0441833
group	I-C0441833
,	O
46	O
non-melf	B-C0441833
group	I-C0441833
,	O
47	O
cases	O
illustrated	O
cxcr4	B-C2352110
was	O
expressed	B-C1171362
in	O
all	O
endometrioid	B-C0206687
carcinomas	I-C0206687
,	O
while	O
based	O
on	O
cxcl14	B-C1335988
and	O
cxcl12	B-C1528383
expression	B-C1171362
score	B-C0449820
,	O
high	B-C1709707
proportions	I-C1709707
of	O
cells	B-C0007634
were	O
positive	B-C1446409
at	O
the	O
sites	B-C0205145
of	O
the	O
melf	B-C0449774
pattern	I-C0449774
p<0	O
.	O
	
there	O
was	O
no	B-C0243095
significant	I-C0243095
difference	I-C0243095
in	O
progression-free	B-C0242792
survival	I-C0242792
or	O
overall	B-C4086681
survival	I-C4086681
between	O
melf	B-C0441833
group	I-C0441833
and	O
non-melf	B-C0441833
group	I-C0441833
by	O
kaplan-meier	B-C1720943
analysis	I-C1720943
.	O
	
these	O
findings	O
suggest	O
a	O
possibility	O
that	O
cells	B-C0007634
at	O
the	O
sites	B-C0205145
of	O
melf	B-C0449774
pattern	I-C0449774
had	O
acquired	O
increased	B-C0205217
invasiveness	B-C0027626
through	O
the	O
function	B-C0031843
of	O
the	O
cxcl14	B-C1335988
-	O
cxcr4	B-C2352110
and	O
cxcl12	B-C1528383
-	O
cxcr4	B-C2352110
crude	B-C1709843
4-methylcyclohexanemethanol	B-C4277102
mchm	B-C4277102
did	O
not	O
cause	B-C0015127
skin	B-C0152030
irritation	I-C0152030
in	O
humans	B-C0086418
in	O
48-h	B-C0439586
patch	B-C0030646
test	I-C0030646
crude	B-C1709843
4-methylcyclohexanemethanol	B-C4277102
mchm	B-C4277102
is	O
an	O
industrial	B-C0021267
chemical	B-C0220806
used	O
to	O
wash	B-C0441648
and	O
clean	B-C1947930
coal	B-C0009131
.	O
	
on	O
january	O
9th	O
,	O
2014	O
approximately	O
10	B-C0560013
gallons	I-C0560013
of	O
a	O
mixture	B-C0439962
containing	O
crude	B-C1709843
mchm	B-C4277102
were	O
released	O
into	O
the	O
elk	B-C0337050
river	I-C0337050
near	O
charleston	B-C0017446
,	O
west	B-C0043127
virginia	I-C0043127
,	O
contaminating	B-C0205279
the	O
local	B-C0205276
water	B-C0043062
supply	I-C0043062
.	O
	
following	O
the	O
spill	B-C0392355
,	O
residents	B-C2347958
reported	B-C0700287
numerous	B-C0439064
health	B-C0871764
complaints	I-C0871764
,	O
and	O
sought	O
medical	B-C0496675
attention	I-C0496675
for	O
ailments	B-C0221423
including	O
rashes	B-C0015230
and	O
itching	B-C0033774
.	O
	
the	O
relationship	B-C0439849
between	O
the	O
complaints	B-C0871764
and	O
the	O
spill	B-C0392355
were	O
unknown	O
,	O
as	O
such	O
symptoms	B-C1457887
are	O
reported	B-C0700287
frequently	B-C0332183
in	O
the	O
background	O
.	O
	
in	O
this	O
study	B-C2603343
,	O
the	O
primary	B-C0205225
irritation	B-C0152030
potential	B-C3245505
of	O
crude	B-C1709843
mchm	B-C4277102
was	O
evaluated	B-C1292732
in	O
206	O
individuals	B-C0237401
who	O
underwent	O
48	B-C0439586
hour	I-C0439586
semi-occluded	B-C1947917
patch	B-C0030646
testing	I-C0030646
.	O
	
mchm	B-C4277102
concentrations	B-C1446561
assessed	O
in	O
this	O
study	B-C2603343
were	O
1	O
,	O
5	O
,	O
15	O
,	O
and	O
100	O
ppm	O
.	O
	
no	O
appreciable	O
skin	B-C0221743
reactions	I-C0221743
were	O
observed	O
in	O
individuals	B-C0237401
at	O
any	O
concentration	B-C1446561
.	O
	
three	O
of	O
the	O
five	O
concentrations	B-C1446561
evaluated	B-C1292732
were	O
above	O
the	O
highest	O
measured	B-C1446561
concentration	I-C1446561
of	O
mchm	B-C4277102
in	O
the	O
tap	B-C2919405
water	I-C2919405
of	O
residents	B-C2347958
in	O
west	B-C0043127
virginia	I-C0043127
3.7	O
ppm	O
.	O
	
the	O
results	B-C1274040
of	O
this	O
study	B-C2603343
suggest	O
that	O
crude	B-C1709843
mchm	B-C4277102
would	O
not	O
be	O
a	O
dermal	B-C0221928
irritant	B-C0022108
for	O
the	O
vast	O
majority	O
,	O
if	O
not	O
all	O
,	O
potentially	O
exposed	O
persons	B-C0027361
at	O
the	O
concentrations	B-C1446561
in	O
the	O
water	B-C2919405
reported	B-C0700287
after	O
the	O
new	B-C0205314
metabolites	B-C0870883
from	O
the	O
sponge	B-C0032699
-derived	O
fungus	B-C0016832
aspergillus	B-C1085656
sydowii	I-C1085656
j05b-7f-4	I-C1085656
two	O
new	B-C0205314
metabolites	B-C0870883
,	O
diorcinolic	B-C0870883
acid	I-C0870883
1	O
and	O
β-d-glucopyranosyl	B-C3253665
aspergillusene	I-C3253665
a	I-C3253665
8	O
,	O
together	O
with	O
six	O
diphenylethers	B-C0870883
2-7	O
,	O
a	O
diketopiperazine	B-C0058171
9	O
,	O
a	O
chromone	B-C0008594
10	O
and	O
a	O
xanthone	B-C0078604
11	O
were	O
isolated	B-C0205409
from	O
the	O
fungus	B-C0016832
aspergillus	B-C1085656
sydowii	I-C1085656
derived	O
from	O
the	O
marine	B-C0032699
sponge	I-C0032699
stelletta	B-C2800556
sp	I-C2800556
.	O
	
the	O
planar	O
structures	O
and	O
their	O
relative	O
configurations	B-C0026377
were	O
elucidated	O
by	O
analysing	O
1d	B-C0028580
,	O
2d	I-C0028580
nmr	I-C0028580
and	O
hresims	B-C0201742
data	B-C1511726
.	O
	
compound	B-C1706082
8	O
is	O
the	O
first	O
glycoside	B-C0017977
of	O
phenolic	B-C0359916
bisabolane	B-C0036847
sesquiterpenes	I-C0036847
.	O
	
compounds	B-C1254351
1	I-C1254351
and	I-C1254351
8	I-C1254351
exhibited	O
mild	B-C2945599
cytotoxicity	B-C0596402
against	O
kb	B-C0022539
human	B-C0022539
nasopharyngeal	I-C0022539
carcinoma	I-C0022539
cells	I-C0022539
,	O
hepg2	B-C2717940
human	B-C2717940
liver	I-C2717940
cancer	I-C2717940
cells	I-C2717940
and	O
hct	B-C1258005
116	I-C1258005
human	B-C1258005
colon	I-C1258005
cancer	I-C1258005
cells	I-C1258005
.	O
	
all	O
compounds	B-C1254351
were	O
evaluated	B-C0220825
for	O
antibacterial	B-C0441655
activity	I-C0441655
and	O
their	O
abilities	O
to	O
suppress	B-C1260953
lps	B-C0023810
-induced	O
nitric	B-C0028128
oxide	I-C0028128
no	B-C0028128
production	O
.	O
	
compounds	B-C1254351
2	I-C1254351
and	I-C1254351
4-7	I-C1254351
showed	O
mild	B-C2945599
antibacterial	B-C0243095
activity	I-C0243095
against	O
human	B-C0086418
pathogen	B-C0450254
staphylococcus	B-C0038172
aureus	I-C0038172
and	O
fish	B-C0016163
pathogens	B-C0450254
streptococcus	B-C0318186
iniae	I-C0318186
and	O
vibrio	B-C1265314
ichthyoenteri	I-C1265314
,	O
and	O
compounds	B-C1706082
4	I-C1706082
and	I-C1706082
7	I-C1706082
weakly	O
suppressed	B-C1260953
no	B-C0028128
the	O
neural	B-C3714606
legacy	B-C0242538
of	O
a	O
single	O
concussion	B-C0006107
it	O
has	O
been	O
hypothesized	B-C1512571
that	O
concussions	B-C0006107
impart	B-C0332261
lasting	B-C0443252
brain	B-C0270611
damage	I-C0270611
,	O
even	O
after	O
a	O
patient	B-C0030705
has	O
ostensibly	O
recovered	B-C0521108
.	O
	
this	O
hypothesis	B-C1512571
is	O
based	O
largely	B-C0549177
upon	O
neuropathological	B-C1521733
studies	B-C2603343
in	O
deceased	B-C0011065
athletes	B-C0238703
,	O
however	O
,	O
leaving	O
open	O
the	O
question	O
of	O
whether	O
it	O
can	O
be	O
detected	B-C1511790
in	B-C0681829
vivo	I-C0681829
.	O
	
we	O
measured	B-C0444706
neural	B-C3714606
responses	B-C0871261
to	O
speech	B-C0037817
in	O
collegiate	B-C0682177
student	I-C0682177
-	O
athletes	B-C0238703
with	O
a	O
history	B-C0683519
of	O
a	O
single	O
concussion	B-C0006107
from	O
which	O
they	O
had	O
recovered	B-C0521108
.	O
	
these	O
student	B-C0038492
-	O
athletes	B-C0238703
had	O
weaker	B-C1762617
responses	B-C0871261
to	O
speech	B-C0037817
than	O
age	B-C0001779
-	O
and	O
position	B-C0733755
-	O
matched	B-C1708943
peers	B-C0679739
.	O
	
this	O
group	B-C0681860
difference	B-C1705242
suggests	B-C1705535
that	O
concussions	B-C0006107
engender	B-C0015127
small	B-C0700321
,	O
but	O
detectable	B-C3830527
,	O
changes	B-C0392747
in	O
brain	B-C0678908
function	I-C0678908
prior	B-C0332152
to	O
the	O
emergence	B-C0175673
of	O
frank	B-C1947931
behavioral	B-C2706099
indications	I-C2706099
.	O
	
enhanced	O
performance	B-C1882330
of	O
colorimetric	B-C0009407
biosensing	B-C0005567
on	O
paper	B-C0030351
microfluidic	B-C1449576
platforms	I-C1449576
through	O
chemical	B-C0205245
modification	I-C0205245
and	O
incorporation	B-C0243126
of	O
nanoparticles	B-C1450054
this	O
chapter	O
describes	O
two	O
different	O
methodologies	B-C0015194
used	O
to	O
improve	O
the	O
analytical	B-C1882330
performance	I-C1882330
of	O
colorimetric	B-C0009407
paper	B-C0030351
-based	O
biosensors	B-C0600364
.	O
	
microfluidic	B-C1449582
paper-based	I-C1449582
analytical	I-C1449582
devices	I-C1449582
μpads	B-C1449582
have	O
been	O
produced	O
by	O
a	O
stamping	B-C1254366
process	I-C1254366
and	O
co2	B-C0007012
laser	B-C0348007
ablation	I-C0348007
and	O
modified	B-C0205349
,	O
respectively	O
,	O
through	O
an	O
oxidation	B-C1254366
step	B-C1261552
and	O
incorporation	O
of	O
silica	B-C0037098
nanoparticles	B-C1450054
on	O
the	O
paper	B-C0030351
structure	I-C0030351
.	O
	
both	O
methods	B-C0025663
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	B-C0033213
associated	B-C0332281
with	I-C0332281
colorimetric	B-C0009407
detection	I-C0009407
,	O
the	O
heterogeneity	B-C0019409
of	O
the	O
color	B-C0009393
distribution	B-C1704711
in	O
the	O
detection	B-C1710706
zones	I-C1710706
.	O
	
the	O
modification	B-C0205245
steps	B-C1261552
are	O
necessary	O
to	O
improve	O
the	O
interaction	B-C1704675
between	O
the	O
paper	B-C0030351
surface	B-C0205148
and	O
the	O
selected	O
enzymes	B-C0014442
.	O
	
the	O
enhanced	O
performance	B-C1882330
has	O
ensured	O
reliability	B-C2347947
for	O
quantitative	B-C0392762
analysis	B-C0936012
of	O
clinically	B-C0205210
relevant	O
cxcr4	B-C2352110
cd184	B-C2352110
expression	B-C1171362
on	O
stem	B-C0411265
cell	I-C0411265
harvest	I-C0411265
and	O
cd34	B-C0054953
cells	B-C0007634
post-transplant	B-C1254367
cxcr4	B-C2352110
is	O
a	O
receptor	B-C0597357
for	O
stromal-derived	B-C0218504
factor-1	I-C0218504
sdf-1	B-C0218504
,	O
a	O
molecule	B-C0567416
that	O
has	O
a	O
chemotactic	B-C0008018
activity	B-C0441655
for	O
lymphocytes	B-C0024264
and	O
is	O
important	O
in	O
homing	B-C0007613
of	O
hematopoietic	B-C0018956
stem	I-C0018956
cells	I-C0018956
to	O
their	O
adult	B-C0005953
marrow	I-C0005953
.	O
	
we	O
evaluated	B-C0220825
the	O
cxcr4	B-C2352110
cd184	B-C2352110
expression	B-C1171362
in	O
the	O
harvest	B-C0038250
cells	I-C0038250
and	O
in	O
the	O
post-transplant	B-C1254367
bone	B-C0005953
marrow	I-C0005953
bm	B-C0005953
and	O
its	O
relation	B-C0439849
to	O
engraftment	B-C0301944
,	O
as	O
determined	O
by	O
the	O
consensus	B-C0935549
criteria	I-C0935549
and	O
chimerism	B-C0333678
.	O
	
this	O
is	O
a	O
prospective	B-C0033522
study	I-C0033522
which	O
included	O
30	O
patients	B-C0030705
undergoing	O
hematopoietic	B-C0472699
stem	I-C0472699
cell	I-C0472699
transplantation	I-C0472699
15	O
patients	B-C0030705
received	B-C1514756
autograft	B-C0040736
and	O
15	O
patients	B-C0030705
received	B-C1514756
allograft	B-C0040739
on	O
dates	O
between	O
january	O
2012	O
and	O
may	O
2014	O
.	O
	
we	O
assessed	B-C1516048
cd184	B-C2352110
cxcr4	B-C2352110
using	O
flow	B-C0016263
cytometry	I-C0016263
in	O
the	O
harvest	B-C0038250
cells	I-C0038250
together	O
with	O
post-transplant	B-C1254367
bm	B-C0005953
assessment	B-C0220825
on	O
day	O
28	O
and	O
day	O
90	O
for	O
complete	B-C0205197
morphologic	B-C0543482
,	O
molecular	B-C2236970
studies	I-C2236970
,	O
and	O
detection	B-C1511790
of	O
cd184	B-C2352110
expression	B-C1171362
on	O
cd34	B-C0054953
cells	B-C0007634
with	O
chimerism	B-C0333678
studies	O
on	O
total	B-C0439810
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
.	O
	
diagnoses	B-C0011900
of	O
the	O
enrolled	O
patients	B-C0030705
were	O
as	O
follows	O
seven	O
24.1	O
with	O
acute	B-C0023467
myeloid	I-C0023467
leukemia	I-C0023467
,	O
eight	O
27.6	O
with	O
multiple	B-C0026764
myeloma	I-C0026764
,	O
four	O
13.8	O
with	O
acute	B-C0023449
lymphoblastic	I-C0023449
leukemia	I-C0023449
,	O
three	O
10.3	O
with	O
non-hodgkin	B-C0024305
lymphoma	I-C0024305
,	O
two	O
6.9	O
with	O
myelodysplastic	B-C3463824
syndromes	I-C3463824
,	O
two	O
6.9	O
with	O
aplastic	B-C0002874
anemia	I-C0002874
,	O
two	O
6.9	O
with	O
chronic	B-C0023473
myeloid	I-C0023473
leukemia	I-C0023473
,	O
one	O
3.4	O
with	O
hodgkin	B-C0019829
lymphoma	I-C0019829
,	O
and	O
one	O
3.4	O
with	O
plasmacytomas	B-C0032131
.	O
	
one	O
patient	B-C0030705
died	B-C1546956
and	O
was	O
excluded	B-C2828389
from	O
the	O
study	B-C0008972
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	B-C0301944
.	O
	
there	O
was	O
no	B-C1513916
statistical	B-C0237881
significance	I-C0237881
between	O
the	O
level	B-C0428479
of	O
cd184	B-C2352110
in	O
stem	B-C0411265
cell	I-C0411265
harvest	I-C0411265
and	O
the	O
prediction	B-C0681842
of	O
successful	B-C1272703
engraftment	B-C0301944
p>0	O
as	O
well	O
as	O
in	O
day	O
28	O
bm	B-C0438737
sample	I-C0438737
p>0	O
,	O
whereas	O
there	O
was	O
a	O
statistical	B-C0237881
significance	I-C0237881
between	O
the	O
level	B-C0428479
of	O
cd184	B-C2352110
in	O
day	O
90	O
bm	B-C0438737
sample	I-C0438737
and	O
the	O
occurrence	B-C2745955
of	O
successful	B-C1272703
engraftment	B-C0301944
p=0	O
.	O
	
sdf-1	B-C0218504
/	O
cxcr4	B-C2352110
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	B-C0301944
however	O
,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	B-C1516048
their	O
expression	B-C1171362
post-transplant	B-C1254367
.	O
	
evaluating	O
the	O
ligand	O
chemokine	B-C0282554
,	O
sdf-1	B-C0218504
or	O
its	O
receptor	B-C0597357
cxcr4	B-C2352110
may	O
serve	O
as	O
potential	B-C3245505
surrogate	B-C0086589
markers	I-C0086589
for	O
assessment	B-C0220825
of	O
genetic	B-C0042333
diversity	I-C0042333
of	O
taenia	B-C0221085
saginata	I-C0221085
cestoda	B-C1706526
cyclophyllidea	B-C0322145
from	O
lao	B-C0023034
people's	I-C0023034
democratic	I-C0023034
republic	I-C0023034
and	O
northeastern	B-C0017446
thailand	B-C0039725
based	O
on	O
mitochondrial	B-C0012929
dna	I-C0012929
taenia	B-C0221085
saginata	I-C0221085
is	O
a	O
tapeworm	B-C1706526
found	O
in	O
cattle	B-C0007452
worldwide	O
.	O
	
analysis	B-C0936012
of	O
genetic	B-C0042333
diversity	I-C0042333
in	O
different	O
geographical	B-C0032659
populations	I-C0032659
of	O
t	B-C0221085
.	O
	
saginata	I-C0221085
not	O
only	O
helps	O
to	O
understand	O
the	O
origin	B-C0439659
,	O
transmission	B-C1521797
and	O
spread	B-C0332261
of	O
this	O
organism	B-C0029235
,	O
but	O
also	O
to	O
evaluate	O
the	O
selection	O
pressures	O
acting	O
on	O
t	B-C0221085
.	O
	
saginata	I-C0221085
and	O
how	O
it	O
is	O
responding	O
to	O
them	O
.	O
	
however	O
,	O
there	O
are	O
few	O
reports	O
of	O
the	O
genetic	B-C0042333
variability	I-C0042333
of	O
t	B-C0221085
.	O
	
saginata	I-C0221085
populations	I-C0221085
in	O
different	O
regions	B-C0017446
of	O
the	O
world	B-C2700280
,	O
including	O
lao	B-C0023034
pdr	I-C0023034
and	O
thailand	B-C0039725
.	O
	
we	O
report	O
the	O
genetic	B-C0012929
diversity	I-C0012929
of	O
t	B-C0221085
.	O
	
saginata	I-C0221085
populations	I-C0221085
in	O
lao	B-C0023034
pdr	I-C0023034
and	O
northeastern	B-C0017446
thailand	B-C0039725
together	O
with	O
sequences	B-C0162326
of	O
t	B-C0221085
.	O
	
saginata	I-C0221085
from	O
other	O
countries	B-C0454664
deposited	O
in	O
genbank	B-C0598211
.	O
	
mitochondrial	B-C1537985
cox1	I-C1537985
sequence	B-C0162802
analysis	I-C0162802
revealed	O
that	O
15	O
and	O
8	O
haplotypes	B-C0018591
were	O
identified	O
in	O
30	O
and	O
21	O
t	B-C0221085
.	O
	
saginata	I-C0221085
isolates	O
from	O
lao	B-C0023034
pdr	I-C0023034
and	O
northeastern	B-C0017446
thailand	B-C0039725
,	O
respectively	O
.	O
	
fifty-three	O
haplotypes	B-C0018591
were	O
identified	O
from	O
98	O
sequences	B-C0162326
.	O
	
phylogenetic	B-C1519068
tree	I-C1519068
and	O
haplotype	B-C0242481
network	I-C0242481
analyses	I-C0242481
revealed	O
that	O
global	B-C2348867
isolates	O
of	O
t	B-C0221085
.	O
	
saginata	I-C0221085
were	O
genetically	O
divided	O
into	O
five	O
groups	B-C0441833
a	B-C0441833
,	O
b	B-C0441833
,	O
c1	B-C0441833
,	O
c2	B-C0441833
and	O
d	B-C0441833
.	O
	
taenia	B-C0221085
saginata	I-C0221085
isolates	O
from	O
lao	B-C0023034
pdr	I-C0023034
and	O
northeastern	B-C0017446
thailand	B-C0039725
belonged	O
to	O
either	O
group	B-C0441833
a	I-C0441833
or	O
b	B-C0441833
.	O
	
taenia	B-C0221085
saginata	I-C0221085
from	O
western	B-C0017446
thailand	B-C0039725
clustered	O
in	O
groups	B-C0441833
c1	I-C0441833
,	O
c2	B-C0441833
and	O
d	B-C0441833
,	O
and	O
populations	B-C0684063
from	O
the	O
northeast	B-C0017446
and	O
western	B-C0017446
thailand	B-C0039725
were	O
found	O
to	O
be	O
genetically	O
distinct	O
.	O
	
taenia	B-C0221085
saginata	I-C0221085
isolates	O
in	O
lao	B-C0023034
pdr	I-C0023034
and	O
thailand	B-C0039725
were	O
also	O
found	O
to	O
be	O
genetically	B-C0042333
diverse	I-C0042333
but	O
the	O
degree	O
of	O
genetic	B-C0917892
differentiation	I-C0917892
was	O
low	O
.	O
	
taenia	B-C0221085
saginata	I-C0221085
populations	I-C0221085
from	O
lao	B-C0023034
pdr	I-C0023034
and	O
northeastern	B-C0017446
thailand	B-C0039725
are	O
genetically	O
distinct	O
from	O
the	O
population	B-C0684063
in	O
western	B-C0017446
thailand	B-C0039725
and	O
it	O
is	O
proposed	O
that	O
t	B-C0221085
.	O
	
saginata	I-C0221085
has	O
been	O
dispersed	O
by	O
different	O
transmission	B-C1521797
routes	I-C1521797
in	O
southeast	B-C0003983
asia	I-C0003983
.	O
	
development	O
of	O
a	O
novel	B-C0205314
near-infrared	B-C1289901
fluorescent	B-C0016315
theranostic	B-C4046052
combretastain	B-C0056154
a-4	I-C0056154
analogue	B-C0002776
,	O
yk-5-252	B-C1254351
,	O
to	O
target	O
triple	B-C3539878
negative	I-C3539878
breast	I-C3539878
cancer	I-C3539878
the	O
treatment	B-C0087111
of	O
triple	B-C3539878
negative	I-C3539878
breast	I-C3539878
cancer	I-C3539878
tnbc	B-C3539878
is	O
a	O
significant	O
challenge	O
to	O
cancer	B-C1516225
research	I-C1516225
.	O
	
the	O
lack	O
of	O
hormone	B-C0019929
receptors	I-C0019929
limits	O
the	O
treatment	B-C0087111
options	O
available	O
to	O
patients	B-C0030705
with	O
this	O
diagnosis	B-C0011900
,	O
forcing	O
them	O
to	O
endure	O
prolonged	O
radiation	B-C1522449
and	O
chemotherapy	B-C3665472
.	O
	
anti-angiogenesis	B-C0281318
is	O
a	O
chemotherapeutic	O
strategy	O
that	O
targets	O
the	O
vasculature	B-C3714653
of	O
tumors	B-C0027651
.	O
	
combretastatin	B-C0056154
a-4	I-C0056154
ca-4	B-C0056154
is	O
a	O
well-known	O
vasculature	B-C3714653
-	O
disrupting	O
agent	O
,	O
which	O
has	O
been	O
shown	O
to	O
effectively	O
kill	O
a	O
variety	O
of	O
cancers	B-C0006826
through	O
inhibition	B-C3463820
of	O
tubulin	B-C0041348
polymerization	B-C0314672
.	O
	
due	O
to	O
its	O
toxicity	B-C0600688
,	O
small	O
molecule	O
analogues	B-C0002776
of	O
ca-4	B-C0056154
have	O
been	O
sought	O
out	O
.	O
	
we	O
have	O
designed	O
a	O
novel	B-C0205314
dual	O
action	O
ca-4	B-C0056154
prodrug	B-C0033262
,	O
yk-5-252	B-C1254351
,	O
which	O
releases	O
the	O
drug	B-C1254351
through	O
a	O
disulfide	B-C0813982
bond	I-C0813982
cleavage	B-C0596311
mechanism	B-C0441712
and	O
contains	O
a	O
near-infrared	B-C1289901
nir	B-C1289901
fluorophore	B-C0598447
,	O
which	O
allows	O
fluorescence	B-C0016315
monitoring	O
of	O
cleavage	B-C0596311
.	O
	
this	O
disulfide	B-C0813982
linkage	I-C0813982
causes	O
ca-4	B-C0056154
to	O
become	O
effective	O
only	O
when	O
released	O
by	O
glutathione	B-C0017817
gsh	B-C0017817
reducing	O
the	O
toxicity	B-C0600688
of	O
the	O
drug	B-C1254351
while	O
simultaneously	O
releasing	O
the	O
nir	B-C1289901
fluorophore	B-C0598447
.	O
	
therefore	O
the	O
prodrug	B-C0033262
,	O
yk-5-252	B-C1254351
,	O
represents	O
a	O
novel	B-C0205314
ca-4	B-C0056154
analogue	B-C0002776
which	O
has	O
reduced	O
toxicity	B-C0600688
and	O
can	O
be	O
used	O
for	O
theranostics	B-C4046052
imaging	B-C0079595
.	O
	
epidemiological	B-C0014508
patterns	B-C0449774
of	O
bovine	B-C0007452
besnoitiosis	B-C0005146
in	O
an	O
endemic	B-C0302891
beef	B-C0175923
cattle	I-C0175923
herd	B-C1690528
reared	B-C3687023
under	O
extensive	O
conditions	O
bovine	B-C0007452
besnoitiosis	B-C0005146
is	O
a	O
parasitic	B-C0030499
disease	I-C0030499
caused	O
by	O
the	O
protozoan	B-C0033739
besnoitia	B-C0320701
besnoiti	I-C0320701
.	O
	
described	O
many	O
decades	O
ago	O
,	O
recent	O
epidemiological	B-C0002783
studies	I-C0002783
reveal	O
its	O
important	O
spread	O
within	O
europe	B-C0015176
in	O
the	O
last	O
years	B-C0439234
.	O
	
to	O
date	O
,	O
many	O
epidemiological	B-C0014508
aspects	B-C1879746
related	O
to	O
life	O
cycle	O
,	O
routes	O
of	O
transmission	B-C0242781
,	O
incidence	B-C1708485
rates	I-C1708485
and	O
associated	O
risk	B-C0035648
factors	I-C0035648
are	O
lacking	B-C0332268
hence	O
,	O
the	O
establishment	O
of	O
appropriate	B-C0009449
disease	I-C0009449
control	I-C0009449
programmes	B-C0009457
poses	O
an	O
important	O
challenge	O
.	O
	
thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	B-C2603343
was	O
to	O
determine	O
the	O
epidemiological	B-C0014508
pattern	B-C0449774
of	O
the	O
disease	B-C0012634
in	O
an	O
endemic	B-C0302891
herd	B-C1690528
reared	B-C3687023
under	O
extensive	O
conditions	O
spanish	B-C0037747
pyrenees	B-C0442533
by	O
identifying	O
main	O
factors	O
associated	B-C0332281
with	I-C0332281
infection	B-C3714514
and	O
clinical	B-C0012634
disease	I-C0012634
dynamics	B-C3826426
.	O
	
the	O
study	B-C0681876
population	I-C0681876
consisted	O
of	O
276	O
brown	B-C0324052
swiss	I-C0324052
and	O
pirenaica	B-C0007452
adult	B-C0596888
animals	I-C0596888
and	O
145	O
calves	B-C3668829
born	B-C0005615
and	O
weaned	B-C0420986
at	O
the	O
farm	B-C0557759
during	O
the	O
study	B-C2603343
.	O
	
three	O
sampling	B-C0870078
time	B-C0332168
frames	I-C0332168
were	O
used	O
january	O
2010	O
,	O
september	O
2010	O
and	O
february	O
2011	O
,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	B-C0010339
designated	O
as	O
mountain	B-C0442533
and	O
valley	B-C0563004
periods	B-C0010339
.	O
	
the	O
data	B-C1511726
related	O
to	O
animals	B-C0003062
breed	B-C1704650
,	O
sex	B-C0079399
and	O
age	B-C0001779
and	O
herd	B-C1690528
management	B-C1273870
animal	B-C1642385
grouping	I-C1642385
and	O
time	B-C0040223
in	O
housing	B-C0020057
were	O
recorded	O
.	O
	
the	O
data	B-C0010995
collection	I-C0010995
methodology	B-C3266812
was	O
mainly	O
based	O
on	O
clinical	B-C1456356
examinations	I-C1456356
and	O
defining	O
the	O
serological	B-C0205473
status	B-C0449438
against	O
bovine	B-C0007452
besnoitiosis	B-C0005146
by	O
the	O
immunofluorescent	B-C0016318
antibody	I-C0016318
testing	I-C0016318
of	O
blood	B-C0178913
samples	I-C0178913
.	O
	
the	O
total	O
prevalence	B-C0033105
among	O
adult	B-C0596888
animals	I-C0596888
was	O
38.34	O
ci	B-C0009667
95%	O
34.53	O
,	O
with	O
18.54	O
of	O
seropositive	B-C0521143
animals	B-C0003062
showing	O
clinical	O
signs	O
.	O
	
in	O
regard	O
to	O
the	O
cumulative	B-C0021149
incidence	I-C0021149
,	O
34.57	O
of	O
new	B-C0205314
infections	B-C3714514
were	O
detected	B-C0442726
during	O
the	O
mountain	B-C0442533
period	B-C0010339
,	O
in	O
contrast	O
to	O
the	O
24.59	O
observed	O
in	O
the	O
valley	B-C0563004
period	B-C0010339
.	O
	
the	O
incidence	B-C1708485
density	I-C1708485
was	O
0.058	O
and	O
0.061	O
new	B-C0205314
infections	B-C3714514
per	O
animal	B-C0003062
-	O
month	B-C0439231
for	O
the	O
mountain	B-C0442533
and	O
valley	B-C0563004
periods	B-C0010339
,	O
respectively	O
.	O
	
according	O
to	O
the	O
seroepidemiological	B-C0036744
study	I-C0036744
,	O
the	O
seroconversion	B-C4042908
probability	B-C0033204
of	O
b	B-C0320701
.	O
	
besnoiti	I-C0320701
infection	B-C3714514
was	O
directly	O
associated	B-C0332281
with	I-C0332281
the	O
number	B-C0237753
of	O
seropositive	B-C0521143
cows	B-C0007452
with	O
whom	O
an	O
animal	B-C0003062
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	B-C0020057
period	B-C0010339
duration	B-C0449238
,	O
supporting	O
horizontal	B-C4288956
transmission	I-C4288956
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	B-C0012634
spread	B-C0332261
.	O
	
in	O
addition	O
,	O
the	O
risk	B-C0035647
of	O
developing	O
the	O
clinical	B-C0449259
course	I-C0449259
increased	B-C0205217
with	O
age	B-C0001779
,	O
and	O
the	O
presence	B-C0150312
of	O
clinical	B-C3540840
signs	I-C3540840
was	O
related	O
to	O
higher	B-C0205250
antibody	B-C0003261
responses	I-C0003261
.	O
	
among	O
calves	B-C3668829
from	O
3.1	O
to	O
7.1	O
months	B-C0439231
old	B-C0580836
sampled	O
once	O
at	O
weaning	B-C0043084
,	O
the	O
total	O
seroprevalence	B-C0600367
was	O
15.17	O
ci	B-C0009667
95%	O
9.36	O
,	O
and	O
the	O
chronic	B-C0205191
stage	B-C1306673
was	O
observed	O
in	O
three	O
animals	B-C0003062
,	O
supporting	O
the	O
ability	O
of	O
b	B-C0320701
.	O
	
besnoiti	I-C0320701
to	O
infect	B-C3714514
and	O
even	O
cause	B-C0015127
disease	B-C0012634
in	O
animals	B-C0003062
less	O
than	O
6	O
months	B-C0439231
old	B-C0580836
.	O
	
finally	O
,	O
the	O
risk	B-C0035647
of	O
calf	B-C3668829
seroconversion	B-C4042908
was	O
positively	O
related	O
to	O
the	O
serological	B-C0205473
status	B-C0449438
of	O
the	O
cows	B-C0007452
,	O
suggesting	O
postnatal	B-C0443281
transmission	B-C0242781
between	O
dams	B-C0007452
and	O
offspring	B-C3668829
by	O
contact	O
during	O
the	O
suckling	B-C0003068
period	B-C0010339
.	O
	
a	O
fast	B-C0237913
small-sample	I-C0237913
kernel	I-C0237913
independence	I-C0237913
test	I-C0237913
for	O
microbiome	B-C1956108
community	B-C0009462
-	O
level	B-C0242481
association	I-C0242481
analysis	I-C0242481
to	O
fully	O
understand	O
the	O
role	B-C1705810
of	O
microbiome	B-C1956108
in	O
human	B-C0086418
health	B-C0018684
and	O
diseases	B-C0012634
,	O
researchers	B-C0035173
are	O
increasingly	O
interested	O
in	O
assessing	B-C1516048
the	O
relationship	B-C0439849
between	O
microbiome	B-C1956108
composition	I-C1956108
and	O
host	B-C1167395
genomic	B-C0017428
data	B-C1511726
.	O
	
the	O
dimensionality	B-C1707753
of	O
the	O
data	B-C1511726
as	O
well	O
as	O
complex	B-C0439855
relationships	B-C0439849
between	O
microbiota	B-C3887843
and	O
host	B-C1167395
genomics	B-C0017428
pose	O
considerable	O
challenges	B-C0805586
for	O
analysis	B-C0936012
.	O
	
in	O
this	O
article	O
,	O
we	O
apply	O
a	O
kernel	B-C0237913
rv	I-C0237913
coefficient	I-C0237913
krv	I-C0237913
test	I-C0237913
to	O
evaluate	O
the	O
overall	B-C1561607
association	B-C0439849
between	O
host	B-C1167395
gene	B-C0017262
expression	I-C0017262
and	O
microbiome	B-C1956108
composition	I-C1956108
.	O
	
the	O
krv	B-C0237913
statistic	I-C0237913
can	O
capture	O
nonlinear	B-C1707520
correlations	I-C1707520
and	O
complex	B-C0439855
relationships	B-C0439849
among	O
the	O
individual	O
data	B-C1609081
types	I-C1609081
and	O
between	O
gene	B-C0017262
expression	I-C0017262
and	O
microbiome	B-C1956108
composition	I-C1956108
through	O
measuring	O
general	O
dependency	B-C1254370
.	O
	
testing	B-C0039593
proceeds	O
via	O
a	O
similar	O
route	O
as	O
existing	O
tests	B-C0392366
of	O
the	O
generalized	O
rv	B-C1707429
coefficients	I-C1707429
and	O
allows	O
for	O
rapid	O
p-value	B-C1709380
calculation	B-C1441506
.	O
	
strategies	B-C0205245
to	O
allow	O
adjustment	O
for	O
confounding	B-C0009673
effects	I-C0009673
,	O
which	O
is	O
crucial	O
for	O
avoiding	O
misleading	O
results	B-C1274040
,	O
and	O
to	O
alleviate	O
the	O
problem	B-C0033213
of	O
selecting	O
the	O
most	O
favorable	O
kernel	B-C1881303
are	O
considered	O
.	O
	
simulation	B-C0679083
studies	I-C0679083
show	O
that	O
krv	B-C1707429
is	O
useful	O
in	O
testing	B-C0039593
statistical	B-C0085862
independence	I-C0085862
with	O
finite	O
samples	O
given	O
the	O
kernels	B-C1881303
are	O
appropriately	O
chosen	O
,	O
and	O
can	O
powerfully	O
identify	O
existing	O
associations	B-C0439849
between	O
microbiome	B-C1956108
composition	I-C1956108
and	O
host	B-C1167395
genomic	B-C0017428
data	B-C1511726
while	O
protecting	O
type	B-C0441729
i	I-C0441729
error	B-C0743559
.	O
	
we	O
apply	O
the	O
krv	B-C1707429
to	O
a	O
microbiome	B-C1956108
study	B-C2603343
examining	O
the	O
relationship	B-C0439849
between	O
host	B-C1167395
transcriptome	B-C3178810
and	O
microbiome	B-C1956108
composition	I-C1956108
within	O
the	O
context	B-C0449255
of	O
inflammatory	B-C0021390
bowel	I-C0021390
disease	I-C0021390
and	O
are	O
able	O
to	O
derive	O
new	O
biological	O
insights	O
and	O
provide	O
formal	O
inference	O
on	O
prior	O
qualitative	B-C0449576
observations	I-C0449576
.	O
	
an	O
analysis	B-C0936012
of	O
systematic	B-C0220922
elemental	B-C0013879
changes	B-C0443172
in	O
decomposing	B-C0262950
bone	I-C0262950
the	O
aim	B-C1947946
of	O
this	O
pilot	B-C0031928
study	I-C0031928
was	O
to	O
investigate	B-C1292732
compositional	B-C0486616
changes	B-C0443172
in	O
bone	B-C0262950
during	O
decomposition	B-C2700592
.	O
	
elemental	B-C0013879
concentrations	B-C1446561
of	O
barium	B-C0004749
,	O
calcium	B-C0006675
,	O
iron	B-C0302583
,	O
potassium	B-C0032821
,	O
magnesium	B-C0024467
,	O
zinc	B-C0043481
and	O
phosphorus	B-C0031705
in	O
porcine	B-C0039005
bone	B-C0262950
as	O
an	O
experimental	B-C1517586
analog	B-C0243071
for	O
human	B-C0086418
bone	B-C0262950
were	O
analyzed	B-C0936012
by	O
inductively	B-C0260252
coupled	I-C0260252
plasma	I-C0260252
optical	I-C0260252
emission	I-C0260252
spectroscopy	I-C0260252
icp-oes	B-C0260252
.	O
	
the	O
samples	B-C0444227
were	O
taken	O
from	O
porcine	B-C0039005
bone	B-C0262950
subjected	B-C1550501
to	O
shallow	B-C0006407
burial	I-C0006407
and	O
surface	B-C0825429
depositions	B-C0333562
at	O
28-	O
day	B-C0439228
intervals	B-C1272706
for	O
a	O
period	B-C1948053
of	O
140	O
days	B-C0439228
.	O
	
results	B-C0683954
indicated	B-C1444656
that	O
icp-oes	B-C0260252
elemental	B-C0013879
profiling	B-C2003903
has	O
potential	B-C3245505
to	O
be	O
developed	B-C0205556
as	O
a	O
forensic	B-C0022885
test	I-C0022885
for	O
determining	B-C0205556
whether	O
a	O
bone	B-C0444227
sample	I-C0444227
originates	O
from	O
the	O
early	B-C1279919
stages	B-C1306673
of	O
soft	B-C0225317
tissue	I-C0225317
putrefaction	B-C0333532
.	O
	
significant	B-C0443172
changes	I-C0443172
in	O
iron	B-C0302583
,	O
sodium	B-C0037473
and	O
potassium	B-C0032821
concentrations	B-C1446561
were	O
found	B-C0150312
over	B-C0347984
140	O
days	B-C0439228
.	O
	
these	O
elements	B-C0013879
are	O
known	B-C0205309
to	O
be	O
primarily	B-C0205225
associated	B-C0332281
with	I-C0332281
proteins	B-C0033684
and/or	O
tissue	B-C0162367
fluids	I-C0162367
within	O
the	O
bone	B-C0262950
.	O
	
changes	B-C0443172
in	O
their	O
respective	O
concentrations	B-C1446561
may	O
therefore	O
be	O
linked	O
to	O
dehydration	B-C1963090
over	O
time	B-C0040223
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	B-C0040223
since	B-C1711239
deposition	B-C0333562
.	O
	
chasing	O
ghosts	O
allopolyploid	O
origin	O
of	O
oxyria	B-C1066614
sinensis	I-C1066614
polygonaceae	B-C0524882
from	O
its	O
only	O
diploid	B-C0012568
congener	B-C0678518
and	O
an	O
unknown	O
ancestor	B-C0870134
reconstructing	O
the	O
origin	B-C0005495
of	O
a	O
polyploid	B-C0032578
species	B-C1705920
is	O
particularly	O
challenging	O
when	O
an	O
ancestor	B-C0870134
has	O
become	O
extinct	B-C1720991
.	O
	
under	O
such	O
circumstances	O
,	O
the	O
extinct	B-C1720991
donor	O
of	O
a	O
genome	B-C0017428
found	O
in	O
the	O
polyploid	B-C0032578
may	O
be	O
treated	O
as	O
a	O
'ghost'	O
species	B-C1705920
in	O
that	O
its	O
prior	O
existence	B-C1547035
is	O
recognized	O
through	O
the	O
presence	B-C3854307
of	O
its	O
genome	B-C0017428
in	O
the	O
polyploid	B-C0032578
.	O
	
in	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
polyploid	B-C0032578
origin	B-C0005495
of	O
oxyria	B-C1066614
sinensis	I-C1066614
2n	O
=	O
40	O
for	O
which	O
only	O
one	O
congeneric	B-C0678518
species	B-C1705920
is	O
known	O
,	O
that	O
is	O
diploid	B-C0012568
o	B-C1481306
.	O
	
digyna	I-C1481306
2n	O
=	O
14	O
.	O
	
genomic	B-C0162788
in	I-C0162788
situ	I-C0162788
hybridization	I-C0162788
gish	B-C0162788
,	O
transcriptome	B-C0752248
,	O
phylogenetic	B-C1519068
and	O
demographic	B-C0011289
analyses	I-C0011289
,	O
and	O
ecological	B-C0282574
niche	I-C0282574
modelling	I-C0282574
were	O
conducted	O
for	O
this	O
purpose	O
.	O
	
gish	B-C0162788
revealed	O
that	O
o	B-C1066614
.	O
	
sinensis	I-C1066614
comprised	O
14	O
chromosomes	B-C1135923
from	O
o	B-C1481306
.	O
	
digyna	I-C1481306
and	O
26	O
chromosomes	B-C1135923
from	O
an	O
unknown	O
ancestor	B-C0870134
.	O
	
transcriptome	B-C0752248
analysis	I-C0752248
indicated	O
that	O
following	O
divergence	B-C0443204
from	O
o	B-C1481306
.	O
	
digyna	I-C1481306
,	O
involving	O
genome	B-C0017261
duplication	I-C0017261
around	O
12	O
million	O
years	O
ago	O
ma	O
,	O
a	O
second	O
genome	B-C0017261
duplication	I-C0017261
occurred	O
approximately	O
6	O
ma	O
to	O
give	O
rise	O
to	O
o	B-C1066614
.	O
	
sinensis	I-C1066614
.	O
	
oxyria	B-C1066614
sinensis	I-C1066614
was	O
shown	O
to	O
contain	O
homologous	B-C0162774
gene	I-C0162774
sequences	I-C0162774
divergent	B-C0443204
from	O
those	O
present	O
in	O
o	B-C1481306
.	O
	
digyna	I-C1481306
in	O
addition	O
to	O
a	O
set	O
that	O
clustered	B-C0017258
with	O
those	O
in	O
o	B-C1481306
.	O
	
digyna	I-C1481306
.	O
	
coalescent	B-C0876936
simulations	I-C0876936
indicated	O
that	O
o	B-C1066614
.	O
	
sinensis	I-C1066614
expanded	O
its	O
distribution	B-C3494413
approximately	O
6-7	O
ma	O
,	O
possibly	O
following	O
the	O
second	O
polyploidization	B-C0032578
event	I-C0032578
,	O
whereas	O
o	B-C1481306
.	O
	
digyna	I-C1481306
expanded	O
its	O
range	O
much	O
later	O
.	O
	
it	O
was	O
also	O
indicated	O
that	O
the	O
distributions	B-C3494413
of	O
both	O
species	B-C1705920
contracted	B-C0205245
and	I-C0205245
re-expanded	I-C0205245
during	O
the	O
pleistocene	B-C3826560
climatic	I-C3826560
oscillations	I-C3826560
.	O
	
ecological	B-C0282574
niche	I-C0282574
modelling	I-C0282574
similarly	O
suggested	O
that	O
both	O
species	B-C1705920
experienced	O
changes	O
in	O
their	O
distributional	B-C3494413
ranges	O
in	O
response	O
to	O
quaternary	B-C3826560
climatic	I-C3826560
changes	I-C3826560
.	O
	
the	O
extinction	B-C1720991
of	O
the	O
unknown	O
'ghost'	O
tetraploid	B-C0333694
species	B-C1705920
implicated	O
in	O
the	O
origin	B-C0005495
of	O
o	B-C1066614
.	O
	
sinensis	I-C1066614
could	O
have	O
resulted	O
from	O
superior	O
adaptation	B-C0000934
of	O
o	B-C1066614
.	O
	
sinensis	I-C1066614
to	O
repeated	B-C3826560
climatic	I-C3826560
changes	I-C3826560
primitive	B-C0206663
neuroectodermal	I-C0206663
tumors	I-C0206663
of	O
the	O
female	B-C0017421
genital	I-C0017421
tract	I-C0017421
a	O
morphologic	B-C0332437
,	O
immunohistochemical	B-C1441616
,	O
and	O
molecular	B-C1521991
study	B-C2603343
of	O
19	O
cases	B-C1706256
primary	B-C0206663
primitive	I-C0206663
neuroectodermal	I-C0206663
tumor	I-C0206663
pnet	B-C0206663
of	O
the	O
female	B-C0017421
genital	I-C0017421
tract	I-C0017421
is	O
rare	O
,	O
and	O
its	O
proper	O
classification	B-C0008902
remains	O
unclear	O
.	O
	
the	O
clinical	B-C0205210
,	O
histologic	B-C0205462
,	O
and	O
immunophenotypic	B-C0079611
features	B-C2348519
as	O
well	O
as	O
ewsr1	B-C0808901
rearrangement	B-C0017287
status	O
of	O
19	O
gynecologic	B-C0205480
pnets	B-C0206663
,	O
including	O
10	O
ovarian	B-C0205065
,	O
8	O
uterine	B-C0042149
,	O
and	O
1	O
vulvar	B-C0042993
tumors	B-C0027651
,	O
are	O
herein	O
reported	B-C0684224
.	O
	
patient	B-C0030705
age	B-C0001779
ranged	B-C1514721
from	O
12	O
to	O
68	O
years	B-C0439234
,	O
with	O
a	O
median	O
age	B-C0001779
of	O
20	O
and	O
51	O
years	B-C0439234
among	O
those	O
with	O
ovarian	B-C0205065
and	O
uterine	B-C0042149
pnets	B-C0206663
,	O
respectively	O
.	O
	
morphologic	B-C0332437
features	B-C2348519
of	O
central	B-C3714787
nervous	I-C3714787
system	I-C3714787
cns	B-C3714787
tumors	B-C0027651
were	O
seen	O
in	O
15	O
pnets	B-C0206663
,	O
including	O
9	O
medulloblastomas	B-C0025149
,	O
3	O
ependymomas	B-C0014474
,	O
2	O
medulloepitheliomas	B-C0334596
,	O
and	O
1	O
glioblastoma	B-C0017636
,	O
consistent	O
with	O
central	B-C0206663
pnet	I-C0206663
.	O
	
the	O
remaining	O
4	O
pnets	B-C0206663
were	O
composed	O
entirely	O
of	O
undifferentiated	B-C0205618
small	B-C0007634
round	I-C0007634
blue	I-C0007634
cells	I-C0007634
and	O
were	O
classified	O
as	O
ewing	B-C0684337
sarcoma/peripheral	I-C0684337
pnet	I-C0684337
.	O
	
eight	O
pnets	B-C0206663
were	O
associated	O
with	O
another	O
tumor	B-C0027651
type	O
,	O
including	O
5	O
ovarian	B-C0205065
mature	B-C1368910
cystic	I-C1368910
teratomas	I-C1368910
,	O
2	O
endometrial	B-C1282907
low-grade	I-C1282907
endometrioid	B-C0206687
carcinomas	I-C0206687
,	O
and	O
a	O
uterine	B-C0280630
carcinosarcoma	I-C0280630
.	O
	
by	O
immunohistochemistry	B-C0021044
,	O
17	O
pnets	B-C0206663
expressed	O
at	O
least	O
1	O
marker	B-C0041366
of	O
neuronal	B-C1518294
differentiation	I-C1518294
,	O
including	O
synaptophysin	B-C0085255
,	O
nse	B-C1880904
,	O
cd56	B-C0108754
,	O
s100	B-C0027758
,	O
and	O
chromogranin	B-C0008586
in	O
10	O
,	O
8	O
,	O
14	O
,	O
8	O
,	O
and	O
1	O
tumors	B-C0027651
,	O
respectively	O
.	O
	
gfap	B-C0017626
was	O
positive	O
in	O
4	O
pnets	B-C0206663
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type	O
.	O
	
membranous	B-C0025255
cd99	B-C0058889
and	O
nuclear	B-C0521447
fli-1	B-C1437505
staining	B-C0487602
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	B-C0027651
,	O
respectively	O
,	O
and	O
concurrent	O
expression	B-C1171362
of	O
both	O
markers	B-C0041366
was	O
seen	O
in	O
both	O
central	B-C0206663
and	O
ewing	B-C0684337
sarcoma/peripheral	I-C0684337
pnet	I-C0684337
s	O
.	O
	
all	O
tumors	B-C0027651
expressed	B-C1171362
vimentin	B-C0042666
,	O
whereas	O
keratin	B-C0022564
cocktail	O
cam5.2	B-C0910360
,	O
ae1/ae3	B-C1545476
staining	B-C0487602
was	O
only	O
focally	O
present	O
in	O
4	O
pnets	B-C0206663
.	O
	
fluorescence	B-C0162789
in	I-C0162789
situ	I-C0162789
hybridization	I-C0162789
was	O
successful	O
in	O
all	O
cases	B-C1706256
and	O
confirmed	O
ewsr1	B-C0808901
rearrangement	B-C0017287
in	O
2	O
of	O
4	O
tumors	B-C0027651
demonstrating	O
morphologic	B-C0332437
features	B-C2348519
of	O
ewing	B-C0684337
sarcoma/peripheral	I-C0684337
pnet	I-C0684337
and	O
concurrent	O
cd99	B-C0058889
and	O
fli-1	B-C1437505
expression	B-C1171362
.	O
	
in	O
conclusion	O
,	O
central	B-C0206663
and	O
ewing	B-C0684337
sarcoma/peripheral	I-C0684337
pnets	I-C0684337
may	O
be	O
encountered	O
in	O
the	O
female	B-C0017421
genital	I-C0017421
tract	I-C0017421
with	O
central	B-C0206663
pnets	I-C0206663
being	O
more	O
common	O
.	O
	
central	B-C0206663
pnets	I-C0206663
show	O
a	O
spectrum	B-C2827424
of	O
morphologic	B-C0332437
features	B-C2348519
that	O
overlaps	O
with	O
cns	B-C3714787
tumors	B-C0027651
but	O
lack	O
ewsr1	B-C0808901
rearrangement	B-C0017287
s	O
.	O
	
gfap	B-C0017626
expression	B-C1171362
supports	O
a	O
morphologic	B-C0332437
impression	O
of	O
central	B-C0206663
pnet	I-C0206663
and	O
is	O
absent	O
in	O
ewing	O
sarcoma/peripheral	B-C0684337
pnet	I-C0684337
.	O
	
ewing	B-C0684337
sarcoma/peripheral	I-C0684337
pnets	I-C0684337
lack	O
morphologic	B-C0332437
features	B-C2348519
of	O
cns	B-C3714787
tumors	B-C0027651
.	O
	
surgical	B-C0728940
excision	I-C0728940
of	O
heterotopic	B-C0029396
ossification	I-C0029396
leads	O
to	O
re-emergence	B-C1254367
of	O
mesenchymal	B-C1257975
stem	I-C1257975
cell	I-C1257975
populations	I-C1257975
responsible	O
for	O
recurrence	B-C0034897
trauma-induced	O
heterotopic	B-C0029396
ossification	I-C0029396
ho	B-C0029396
occurs	O
after	O
severe	B-C0205082
musculoskeletal	B-C0272448
injuries	I-C0272448
and	O
burns	B-C0562038
,	O
and	O
presents	O
a	O
significant	B-C0750502
barrier	O
to	O
patient	B-C0030705
rehabilitation	B-C0034991
.	O
	
interestingly	O
,	O
the	O
incidence	B-C0021149
of	O
ho	B-C0029396
significantly	O
increases	B-C0205217
with	O
repeated	B-C0035110
operations	I-C0035110
and	O
after	O
resection	B-C0728940
of	O
previous	O
ho	B-C0029396
.	O
	
treatment	B-C0087111
of	O
established	O
heterotopic	B-C0029396
ossification	I-C0029396
is	O
challenging	O
because	O
surgical	B-C0728940
excision	I-C0728940
is	O
often	O
incomplete	B-C0205257
,	O
with	O
evidence	B-C0332120
of	I-C0332120
persistent	B-C0205322
heterotopic	B-C4061353
bone	I-C4061353
.	O
	
as	O
a	O
result	O
,	O
patients	B-C0030705
may	O
continue	B-C0549178
to	O
report	O
the	O
signs	B-C3540840
or	I-C3540840
symptoms	I-C3540840
of	O
ho	B-C0029396
,	O
including	O
chronic	B-C0150055
pain	I-C0150055
,	O
nonhealing	B-C3845448
wounds	B-C0043250
,	O
and	O
joint	B-C0231589
restriction	I-C0231589
.	O
	
in	O
this	O
study	B-C0008972
,	O
we	O
designed	O
a	O
model	B-C2986594
of	O
recurrent	B-C2945760
ho	B-C0029396
that	O
occurs	O
after	O
surgical	B-C0728940
excision	I-C0728940
of	O
mature	B-C0205286
ho	B-C0029396
in	O
a	O
mouse	B-C2986594
model	I-C2986594
of	O
hind-limb	B-C0001074
achilles'	I-C0001074
tendon	I-C0001074
transection	B-C0152060
with	O
dorsal	B-C0205095
burn	B-C0006434
injury	I-C0006434
.	O
	
we	O
first	O
demonstrated	O
that	O
key	B-C3898777
signaling	B-C0037080
mediators	B-C0033684
of	O
ho	B-C0029396
,	O
including	O
bone	B-C1155364
morphogenetic	I-C1155364
protein	I-C1155364
signaling	I-C1155364
,	O
are	O
diminished	O
in	O
mature	B-C0682560
bone	I-C0682560
.	O
	
however	O
,	O
upon	O
surgical	B-C0728940
excision	I-C0728940
,	O
we	O
have	O
noted	O
upregulation	B-C0041904
of	O
downstream	B-C0522506
mediators	B-C0033684
of	O
osteogenic	B-C0599660
differentiation	B-C2945687
,	O
including	O
psmad	B-C1566789
1	I-C1566789
/	O
5	B-C0529859
.	O
	
additionally	O
,	O
surgical	B-C0728940
excision	I-C0728940
resulted	O
in	O
re-emergence	B-C1254367
of	O
a	O
mesenchymal	B-C1257975
cell	I-C1257975
population	I-C1257975
marked	O
by	O
expression	B-C0597360
of	O
platelet-derived	B-C0290067
growth	I-C0290067
factor	I-C0290067
receptor-α	I-C0290067
pdgfrα	B-C0290067
and	O
present	B-C0150312
in	O
the	O
initial	B-C0205265
developing	O
ho	B-C0029396
lesion	B-C0221198
but	O
absent	B-C0332197
in	O
mature	B-C0205286
ho	B-C0029396
.	O
	
in	O
the	O
recurrent	B-C2945760
lesion	B-C0221198
,	O
these	O
pdgfrα	B-C0290067
+	O
mesenchymal	B-C1257975
cells	I-C1257975
are	O
also	O
highly	O
proliferative	B-C0334094
,	O
similar	O
to	O
the	O
initial	B-C0205265
developing	O
ho	B-C0029396
lesion	B-C0221198
.	O
	
these	O
findings	O
indicate	O
that	O
surgical	B-C0728940
excision	I-C0728940
of	O
ho	B-C0029396
results	B-C0683954
in	O
recurrence	B-C0034897
through	O
similar	O
mesenchymal	B-C1257975
cell	I-C1257975
populations	I-C1257975
and	O
signaling	B-C0037080
mechanisms	B-C0441712
that	O
are	O
present	B-C0150312
in	O
the	O
initial	B-C0205265
developing	O
ho	B-C0029396
lesion	B-C0221198
.	O
	
these	O
results	B-C0683954
are	O
consistent	B-C0332290
with	I-C0332290
findings	B-C0243095
in	O
patients	B-C0030705
that	O
new	O
foci	B-C0205234
of	O
ectopic	B-C1384482
bone	I-C1384482
can	O
develop	O
in	O
excision	B-C0728940
sites	B-C1515974
and	O
are	O
likely	O
related	O
to	O
de	B-C1515568
novo	I-C1515568
formation	B-C1522492
rather	O
than	O
extension	B-C0231448
of	O
unresected	B-C2986425
bone	B-C1384482
.	O
	
extended	B-C0868939
release	I-C0868939
of	O
flurbiprofen	B-C0016377
from	O
tromethamine	B-C0041175
-	O
buffered	B-C0006353
hpmc	B-C0063242
hydrophilic	B-C0475370
matrix	B-C0039225
tablets	I-C0039225
the	O
ph	B-C0020283
-	O
dependent	B-C3244310
solubility	B-C0037628
of	O
a	O
drug	B-C1254351
can	O
lead	O
to	O
ph	B-C0020283
-	O
dependent	B-C3244310
drug	B-C3850077
release	I-C3850077
from	O
hydrophilic	B-C0475370
matrix	B-C0039225
tablets	I-C0039225
.	O
	
adding	O
buffer	B-C1659042
salts	I-C1659042
to	O
the	O
formulation	B-C0013058
to	O
attempt	B-C1516084
to	O
mitigate	B-C1553901
this	O
can	O
impair	B-C0221099
matrix	B-C0596317
hydration	I-C0596317
and	O
negatively	B-C0205160
impact	B-C4049986
drug	B-C3850077
release	I-C3850077
.	O
	
an	O
evaluation	B-C0220825
of	O
the	O
buffering	B-C0006353
of	O
hydrophilic	B-C0475370
matrix	B-C0039225
tablets	I-C0039225
containing	O
a	O
ph	B-C0020283
-	O
dependent	B-C3244310
solubility	B-C0037628
weak	B-C1254351
acid	I-C1254351
drug	I-C1254351
flurbiprofen	B-C0016377
,	O
identified	B-C0205396
as	O
possessing	B-C3154893
a	O
deleterious	B-C1280500
effect	I-C1280500
on	O
hydroxypropyl	B-C0063242
methylcellulose	I-C0063242
hpmc	B-C0063242
solubility	B-C0037628
,	O
swelling	B-C1522240
and	O
gelation	B-C1522240
,	O
with	O
respect	O
to	O
drug	B-C3850077
dissolution	I-C3850077
and	O
the	O
characteristics	B-C1521970
of	O
the	O
hydrophilic	B-C0475370
matrix	B-C0017243
gel	I-C0017243
layer	I-C0017243
in	O
the	O
presence	B-C0332443
of	O
tromethamine	B-C0041175
as	O
a	O
buffer	B-C0006353
was	O
undertaken	O
.	O
	
the	O
inclusion	B-C1512693
of	O
tromethamine	B-C0041175
as	O
an	O
alkalizing	B-C0304463
agent	I-C0304463
afforded	O
ph	B-C0020283
-	O
independent	B-C0332291
flurbiprofen	B-C0016377
release	B-C0868939
from	O
matrices	B-C0439861
based	O
on	O
both	O
hpmc	B-C0063242
2910	I-C0063242
e	I-C0063242
series	I-C0063242
and	O
2208	B-C0063242
k	I-C0063242
series	I-C0063242
,	O
while	O
concomitantly	B-C0521115
decreasing	B-C0442797
the	O
apparent	O
critical	B-C1280500
effect	I-C1280500
on	O
dissolution	B-C3850077
mediated	B-C0086597
by	O
this	O
drug	B-C1254351
with	O
respect	O
to	O
the	O
early	O
pseudo-gel	B-C1522492
layer	I-C1522492
formation	I-C1522492
and	O
functionality	B-C0205245
.	O
	
drug	B-C1707824
release	I-C1707824
profiles	I-C1707824
were	O
unaffected	B-C2986417
by	O
matrix	B-C0439861
ph-changes	B-C0243095
resulting	O
from	O
loss	B-C1517945
of	O
tromethamine	B-C0041175
over	B-C1254367
time	I-C1254367
,	O
suggesting	O
that	O
hpmc	B-C0063242
inhibited	B-C0311403
precipitation	B-C0032931
of	O
drug	B-C1254351
from	O
supersaturated	B-C0037633
solution	I-C0037633
in	O
the	O
hydrated	B-C0596317
matrix	I-C0596317
.	O
	
we	O
propose	O
that	O
facilitation	B-C0234112
of	O
diffusion-based	B-C0012222
release	B-C0868939
of	O
potentially	O
deleterious	B-C1254351
drugs	I-C1254351
in	O
hydrophilic	B-C0475370
matrices	B-C0439861
may	O
be	O
achieved	O
through	O
judicious	O
selection	O
of	O
a	O
buffering	B-C0006353
species	I-C0006353
.	O
	
the	O
influence	B-C4054723
of	O
slope	B-C1254362
on	O
spartium	B-C1014924
junceum	I-C1014924
root	B-C0242726
system	I-C0242726
morphological	B-C0332437
,	O
anatomical	B-C0220784
and	O
biomechanical	B-C0205556
adaptation	B-C0392673
root	B-C0242726
systems	I-C0242726
have	O
a	O
pivotal	O
role	B-C1705810
in	O
plant	B-C0032098
anchorage	B-C2825961
and	O
their	O
mechanical	B-C1704675
interactions	I-C1704675
with	O
the	O
soil	B-C0037592
may	O
contribute	O
to	O
soil	B-C0037592
reinforcement	B-C0205245
and	O
stabilization	B-C0205360
of	O
slide-prone	B-C1254362
slopes	I-C1254362
.	O
	
in	O
order	O
to	O
understand	O
the	O
responses	B-C0871261
of	O
root	B-C0242726
system	I-C0242726
to	O
mechanical	B-C0038442
stress	I-C0038442
induced	B-C0205263
by	O
slope	B-C1254362
,	O
samples	B-C0370003
of	O
spartium	B-C1014924
junceum	I-C1014924
l	I-C1014924
,	O
growing	B-C0205245
in	O
slope	B-C1254362
and	O
in	O
plane	B-C1254362
natural	B-C0205296
conditions	I-C0205296
,	O
were	O
compared	O
in	O
their	O
morphology	B-C0332437
,	O
biomechanical	B-C0871161
properties	I-C0871161
and	O
anatomical	B-C0502371
features	I-C0502371
.	O
	
soils	B-C0037592
sampled	B-C0870078
in	O
slope	B-C1254362
and	O
plane	B-C1254362
revealed	O
similar	O
characteristics	B-C1521970
,	O
with	O
the	O
exception	B-C1705847
of	O
organic	B-C0439861
matter	I-C0439861
content	B-C0456205
and	O
penetrometer	B-C4281815
resistance	I-C4281815
,	O
both	O
higher	O
in	O
slope	B-C1254362
.	O
	
slope	B-C1254362
significantly	O
influenced	B-C4054723
root	B-C0242726
morphology	B-C0332437
and	O
in	O
particular	O
the	O
distribution	B-C1704711
of	O
lateral	B-C0205093
roots	B-C0242726
along	O
the	O
soil	B-C0037592
depth	B-C0205125
.	O
	
indeed	O
,	O
first-order	B-C1373201
lateral	B-C0205093
roots	B-C0242726
of	O
plants	B-C0032098
growing	B-C0205245
on	O
slope	B-C1254362
condition	B-C0348080
showed	O
an	O
asymmetric	B-C0332514
distribution	B-C1704711
between	O
up-	B-C1254362
and	O
down-slope	B-C1254362
.	O
	
contrarily	O
,	O
this	O
asymmetric	B-C0332514
distribution	B-C1704711
was	O
not	O
observed	O
in	O
plants	B-C0032098
growing	B-C0205245
in	O
plane	B-C1254362
.	O
	
the	O
tensile	B-C0039526
strength	I-C0039526
was	O
higher	O
in	O
lateral	B-C0205093
roots	B-C0242726
growing	B-C0205245
up-slope	B-C1254362
and	O
in	O
plane	B-C1254362
conditions	B-C0348080
than	O
in	O
those	O
growing	B-C0205245
down-slope	B-C1254362
.	O
	
anatomical	B-C0242481
investigations	I-C0242481
revealed	O
that	O
,	O
while	O
roots	B-C0242726
grown	O
up-slope	B-C1254362
had	O
higher	O
area	B-C0205146
covered	O
by	O
xylem	B-C1720877
fibers	I-C1720877
,	O
the	O
ratio	B-C0456603
of	O
xylem	B-C1720877
and	O
phloem	B-C1720878
fibers	I-C1720878
to	O
root	B-C0242726
diameter	B-C1301886
did	O
not	O
differ	O
among	O
the	O
three	O
conditions	B-C0348080
,	O
as	O
also	O
,	O
no	B-C3842396
differences	I-C3842396
were	O
found	O
for	O
xylem	B-C1720877
fiber	I-C1720877
cell	B-C0007623
wall	I-C0007623
thickness	B-C1280412
.	O
	
roots	B-C0242726
growing	B-C0205245
up-slope	B-C1254362
were	O
the	O
main	O
contributors	O
to	O
anchorage	B-C2825961
properties	B-C0871161
,	O
which	O
included	O
higher	O
strength	B-C0039526
and	O
higher	O
number	O
of	O
fibers	B-C1260603
in	O
the	O
xylematic	B-C1720877
tissues	B-C1514137
.	O
	
results	O
suggested	O
that	O
a	O
combination	O
of	O
root	B-C0242726
-	O
specific	B-C0205369
morphological	B-C0332437
,	O
anatomical	B-C0220784
and	O
biomechanical	B-C0205556
traits	B-C0599883
,	O
determines	O
anchorage	B-C2825961
functions	B-C0542341
in	O
slope	B-C1254362
conditions	B-C0348080
.	O
	
altered	O
expression	B-C0017262
of	O
the	O
olr59	B-C1418155
,	O
ethe1	B-C1428025
,	O
and	O
slc10a2	B-C1420087
genes	I-C1420087
in	O
the	O
liver	B-C1882726
of	O
f344	B-C0034703
rats	I-C0034703
by	O
neonatal	B-C0021289
thyroid	B-C0347610
hormone	I-C0347610
disruption	I-C0347610
many	O
concerns	O
have	O
been	O
expressed	O
regarding	O
the	O
possible	O
adverse	O
effects	O
of	O
thyroid	B-C0347610
hormone-disrupting	I-C0347610
chemicals	B-C0018624
in	O
the	O
environment	B-C0014406
.	O
	
the	O
disruption	B-C0347610
of	I-C0347610
thyroid	I-C0347610
hormones	I-C0347610
in	O
the	O
neonatal	B-C0935562
period	I-C0935562
may	O
lead	O
to	O
permanent	B-C1280500
effects	I-C1280500
on	O
thyroid	B-C0040135
hormone	I-C0040135
homeostasis	B-C0019868
as	O
well	O
as	O
related	O
developmental	B-C0008073
disorders	I-C0008073
,	O
as	O
thyroid	B-C0040135
hormones	I-C0040135
are	O
essential	O
for	O
regulating	B-C1160191
the	I-C1160191
growth	I-C1160191
and	O
differentiation	B-C1519519
of	I-C1519519
many	I-C1519519
tissues	I-C1519519
.	O
	
to	O
understand	O
the	O
long-term	O
alteration	O
in	O
gene	B-C0017262
expressions	I-C0017262
by	O
neonatal	B-C0021289
administration	B-C0199780
of	I-C0199780
thyroid	I-C0199780
hormone	I-C0199780
-like	O
chemicals	O
in	O
general	O
,	O
we	O
identified	O
genes	B-C0017262
whose	I-C0017262
expression	I-C0017262
was	O
altered	B-C0392747
in	O
the	O
liver	B-C1882726
,	O
an	O
important	O
component	O
of	O
the	O
thyroid	B-C0040135
hormone	I-C0040135
axis	O
,	O
by	O
neonatal	B-C0021289
exposure	B-C0332157
to	I-C0332157
triiodothyronine	B-C0041014
t3	B-C0041014
.	O
	
t3	B-C0041014
was	O
administered	B-C0199780
to	O
male	B-C0034703
f344	I-C0034703
rats	I-C0034703
on	O
postnatal	B-C0443281
days	I-C0443281
1	O
,	O
3	O
,	O
and	O
5	O
week	O
0	O
.	O
	
at	O
8	O
weeks	O
of	O
age	O
,	O
cdna	B-C1609488
microarray	I-C1609488
analysis	I-C1609488
was	O
used	O
to	O
identify	O
hepatic	B-C0205054
genes	B-C0017337
whose	O
expression	B-C0017262
was	O
altered	O
by	O
neonatal	B-C0021289
exposure	B-C0332157
to	I-C0332157
t3	B-C0041014
.	O
	
among	O
the	O
up-regulated	B-C0041904
genes	I-C0041904
that	O
were	O
identified	O
,	O
the	O
expression	B-C0017262
of	O
olr59	B-C1418155
,	O
ethe1	B-C1428025
,	O
and	O
slc10a2	B-C1420087
increased	O
specifically	O
in	O
rats	B-C0034721
neonatally	B-C0021289
exposed	B-C0332157
to	I-C0332157
t3	B-C0041014
.	O
	
interestingly	O
,	O
altered	O
hepatic	B-C0205054
expression	B-C0017262
of	I-C0017262
these	I-C0017262
genes	I-C0017262
indeed	O
increased	O
when	O
a	O
hydroxylated	B-C4086502
polybrominated	I-C4086502
diphenyl	I-C4086502
ether	I-C4086502
pbde	B-C4086502
,	O
oh-bde42	B-C4086502
,	O
which	O
is	O
capable	O
of	O
binding	B-C1323384
to	I-C1323384
the	I-C1323384
tr	I-C1323384
,	O
was	O
given	O
neonatally	B-C0021289
.	O
	
our	O
data	O
demonstrated	O
that	O
neonatal	B-C0021289
exposure	O
to	O
thyroid	B-C0040135
hormones	I-C0040135
could	O
affect	O
the	O
long-term	O
expression	B-C0017262
of	I-C0017262
the	I-C0017262
genes	I-C0017262
,	O
which	O
could	O
be	O
useful	O
markers	O
for	O
neonatal	B-C0856669
effects	I-C0856669
by	O
thyroid	B-C0040135
hormone	I-C0040135
-	O
disrupting	B-C0018624
chemicals	I-C0018624
.	O
	
the	O
psychometric	B-C0033920
costs	I-C0033920
of	O
applicants	B-C0696628
'	O
faking	B-C0871743
examining	O
measurement	B-C0242485
invariance	O
and	O
retest	B-C0237828
correlations	I-C0237828
across	O
response	B-C0009647
conditions	I-C0009647
this	O
study	O
examines	B-C0205360
the	I-C0205360
stability	I-C0205360
of	O
the	O
response	B-C0009647
process	I-C0009647
and	O
the	O
rank-order	B-C0871206
of	O
respondents	B-C0282122
responding	B-C0009647
to	O
3	O
personality	B-C0582654
scales	I-C0582654
in	O
4	O
different	O
response	B-C0009647
conditions	I-C0009647
.	O
	
applicants	B-C0696628
to	O
the	O
university	B-C0041740
college	I-C0041740
of	I-C0041740
teacher	I-C0041740
education	I-C0041740
styria	B-C0017446
n	O
=	O
243	O
completed	O
personality	B-C0582654
scales	I-C0582654
as	O
part	O
of	O
their	O
college	B-C0009352
admission	I-C0009352
process	I-C0009352
.	O
	
half	O
a	O
year	O
later	O
,	O
they	O
retook	O
the	O
same	O
personality	B-C0582654
scales	I-C0582654
in	O
1	O
of	O
3	O
randomly	B-C0814868
assigned	I-C0814868
experimental	O
response	B-C0009647
conditions	I-C0009647
honest	B-C0870663
,	O
faking-good	B-C0871743
,	O
or	O
reproduce	O
.	O
	
longitudinal	B-C0023981
means	I-C0023981
and	O
covariance	B-C0814908
structure	I-C0814908
analyses	I-C0814908
showed	O
that	O
applicants	B-C0696628
'	O
response	B-C0009647
processes	I-C0009647
could	O
be	O
partially	O
reproduced	O
after	O
half	O
a	O
year	O
,	O
and	O
respondents	B-C0282122
seemed	O
to	O
rely	O
on	O
an	O
honest	B-C0870663
response	B-C0009647
behavior	I-C0009647
as	O
a	O
frame	B-C1711364
of	I-C1711364
reference	I-C1711364
.	O
	
additionally	O
,	O
applicants	B-C0696628
'	O
faking	B-C0871743
behavior	I-C0871743
and	O
instructed	O
faking	B-C0871743
faking-good	B-C0871743
caused	O
differences	O
in	O
the	O
latent	B-C0205275
retest	B-C0237828
correlations	I-C0237828
and	O
consistently	O
affected	O
measurement	B-C0242485
properties	O
.	O
	
the	O
varying	O
latent	B-C0205275
retest	B-C0237828
correlations	I-C0237828
indicated	B-C1444656
that	O
faking	B-C0871743
can	O
distort	B-C0700135
respondents	B-C0282122
'	O
rank-order	B-C0871206
and	O
thus	O
the	O
fairness	B-C2911689
of	O
subsequent	O
selection	B-C0011109
decisions	I-C0011109
,	O
depending	O
on	O
the	O
kind	O
of	O
faking	B-C0871743
behavior	I-C0871743
.	O
	
instructed	O
faking	B-C0871743
faking-good	B-C0871743
even	O
affected	O
weak	O
measurement	B-C0242485
invariance	O
,	O
whereas	O
applicants	B-C0696628
'	O
faking	B-C0871743
behavior	I-C0871743
did	O
not	O
.	O
	
consequently	O
,	O
correlations	B-C1707520
with	O
personality	B-C0582654
scales	I-C0582654
-which	O
can	O
be	O
utilized	O
for	O
predictive	B-C0681898
validity	I-C0681898
-may	O
be	O
readily	O
interpreted	B-C1285553
for	O
applicants	B-C0696628
.	O
	
faking	B-C0871743
behavior	I-C0871743
also	O
introduced	O
a	O
uniform	B-C0242568
bias	I-C0242568
,	O
implying	O
that	O
the	O
classically	O
observed	O
mean	B-C0392762
raw	I-C0392762
score	I-C0392762
differences	O
may	O
not	O
be	O
readily	O
intraspinal	B-C1334264
meningioma	I-C1334264
with	O
malignant	B-C1608408
transformation	I-C1608408
and	O
distant	B-C1269798
metastasis	I-C1269798
meningioma	B-C0025286
is	O
typically	O
considered	O
to	O
be	O
a	O
benign	B-C0086692
tumor	I-C0086692
.	O
	
malignant	B-C1608408
transformation	I-C1608408
and	O
metastasis	B-C0027627
of	O
meningiomas	B-C0025286
are	O
rare	B-C0522498
.	O
	
moreover	O
,	O
most	O
meningiomas	B-C0025286
are	O
intracranial	B-C0524466
,	O
and	O
there	O
are	O
few	O
reports	B-C0684224
on	O
intraspinal	B-C1334264
meningiomas	I-C1334264
.	O
	
this	O
report	B-C0684224
aimed	O
to	O
describe	O
the	O
clinical	B-C0683325
features	I-C0683325
and	O
pathological	B-C1521733
findings	B-C0243095
of	O
a	O
case	B-C1706256
of	O
malignant	B-C1608408
transformation	I-C1608408
and	O
distant	B-C1269798
metastasis	I-C1269798
of	O
intraspinal	B-C1334264
meningioma	I-C1334264
,	O
with	O
a	O
review	B-C0699752
of	I-C0699752
the	O
literature	B-C0023866
.	O
	
a	O
44-year-old	O
man	B-C0025266
with	O
a	O
bilateral	B-C0238767
lower	B-C1836296
limb	I-C1836296
paresis	I-C1836296
was	O
diagnosed	B-C0011900
with	O
an	O
intradural	B-C1334255
extramedullary	I-C1334255
tumor	I-C1334255
of	I-C1334255
the	I-C1334255
thoracic	I-C1334255
spine	I-C1334255
.	O
	
primary	B-C0205225
tumor	B-C0472422
resection	I-C0472422
was	O
performed	B-C0884358
,	O
and	O
the	O
histological	B-C0449575
findings	I-C0449575
revealed	O
atypical	B-C0431122
meningioma	I-C0431122
.	O
	
the	O
meningioma	B-C0025286
recurred	B-C0034897
2	O
years	B-C0439234
after	O
the	O
primary	B-C0205225
surgery	B-C0543467
,	O
and	O
a	O
second	B-C0205436
resection	B-C0728940
was	O
performed	B-C0884358
,	O
but	O
only	O
partial	B-C0728938
resection	B-C0728940
was	O
possible	O
because	O
of	O
decreased	B-C0205216
motor	B-C0282617
evoked	I-C0282617
potential	I-C0282617
.	O
	
at	O
age	B-C0001779
48	O
,	O
the	O
patient's	B-C0030705
lower	B-C1836296
limb	I-C1836296
weakness	I-C1836296
returned	B-C0034897
,	O
and	O
a	O
third	B-C0205437
resection	B-C0728940
was	O
performed	B-C0884358
,	O
and	O
the	O
histological	B-C0449575
finding	I-C0449575
remained	O
atypical	B-C0431122
meningioma	I-C0431122
.	O
	
at	O
age	B-C0001779
54	O
,	O
the	O
tumor	B-C0027651
increased	B-C0205217
and	O
stereotactic	B-C0085203
irradiation	I-C0085203
was	O
performed	B-C0884358
.	O
	
at	O
age	B-C0001779
60	O
,	O
the	O
patient	B-C0030705
was	O
diagnosed	B-C0011900
with	O
metastatic	B-C0027627
tumors	I-C0027627
of	O
the	O
rib	B-C0035561
,	O
lumbar	B-C0024091
vertebra	I-C0024091
,	O
cervical	B-C0728985
spine	I-C0728985
,	O
and	O
sacrum	B-C0036037
.	O
	
biopsy	B-C0005558
of	O
the	O
rib	B-C0035561
metastatic	B-C2939420
tumor	I-C2939420
was	O
performed	B-C0884358
,	O
and	O
the	O
histological	B-C0449575
findings	I-C0449575
revealed	O
anaplastic	B-C0259785
meningioma	I-C0259785
.	O
	
this	O
case	B-C1706256
is	O
the	O
first	O
report	B-C0684224
of	O
an	O
intraspinal	B-C1334264
meningioma	I-C1334264
that	O
transformed	B-C1608408
from	O
atypical	B-C0431122
to	O
anaplastic	B-C0259785
meningioma	I-C0259785
with	O
distant	B-C1269798
hematogenous	I-C1269798
metastasis	I-C1269798
.	O
	
epidemiology	B-C0014507
and	O
risk	B-C0035648
factors	I-C0035648
associated	B-C0332281
with	I-C0332281
surgical	B-C0038941
site	I-C0038941
infection	I-C0038941
after	O
different	O
types	B-C0332307
of	O
hepatobiliary	B-C1319408
and	I-C1319408
pancreatic	I-C1319408
surgery	I-C1319408
surgical	B-C0038941
site	I-C0038941
infection	I-C0038941
ssi	B-C0038941
is	O
one	O
of	O
the	O
most	O
common	O
healthcare-associated	B-C0010356
infections	I-C0010356
hais	B-C0010356
however	O
,	O
ssi	B-C0038941
after	O
hepatobiliary	B-C1319408
and	I-C1319408
pancreatic	I-C1319408
surgery	I-C1319408
hbps	B-C1319408
has	O
not	O
been	O
well	O
investigated	B-C1292732
in	O
a	O
large	B-C0549177
cohort	B-C0599755
of	O
patients	B-C0030705
.	O
	
this	O
study	O
analyzed	O
the	O
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
ssi	B-C0038941
following	O
hbps	B-C1319408
in	O
japan	B-C0022341
,	O
using	O
a	O
japanese	B-C0242356
national	I-C0242356
database	I-C0242356
.	O
	
data	B-C1511726
on	O
hbps	B-C1319408
performed	B-C0884358
between	O
2012	O
and	O
2014	O
were	O
extracted	B-C1707635
from	O
a	O
national	B-C0282574
monitoring	I-C0282574
system	I-C0282574
for	O
hai	B-C0010356
the	O
japan	B-C0419786
nosocomial	I-C0419786
infections	I-C0419786
surveillance	I-C0419786
.	O
	
using	O
multivariate	B-C0206031
logistic	I-C0206031
regression	I-C0206031
,	O
i	O
assessed	B-C1516048
the	O
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
ssi	B-C0038941
.	O
	
the	O
cumulative	B-C1511559
incidence	B-C0021149
of	O
ssi	B-C0038941
following	O
hbps	B-C1319408
was	O
15.6	O
2873/18	O
.	O
	
the	O
incidence	B-C0021149
of	O
ssi	B-C0038941
after	O
pancreatoduodenectomy	B-C0085162
was	O
28.0	O
,	O
which	O
was	O
significantly	B-C4055637
higher	I-C4055637
than	O
that	O
after	O
liver	B-C0019144
resection	I-C0019144
and	O
other	O
types	B-C0332307
of	O
hbps	B-C1319408
8.8	O
and	O
15.5	O
,	O
respectively	O
.	O
	
among	O
the	O
four	O
traditional	B-C0443324
risk	B-C0035648
factors	I-C0035648
,	O
the	O
american	B-C2346733
society	I-C2346733
of	I-C2346733
anesthesiologists	I-C2346733
score	B-C0449820
was	O
ineffective	B-C3242229
for	O
predicting	B-C0681842
ssi	B-C0038941
in	O
the	O
final	O
model	B-C3161035
of	O
all	O
three	O
types	B-C0332307
of	O
surgery	B-C0543467
.	O
	
additional	O
risk	B-C0035648
factors	I-C0035648
were	O
identified	B-C0205396
,	O
including	O
age	B-C0001779
and	O
male	B-C0086582
gender	I-C0086582
.	O
	
the	O
incidence	B-C0021149
of	O
and	O
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
ssi	B-C0038941
after	O
the	O
three	O
types	B-C0332307
of	O
hbps	B-C1319408
analyzed	O
differed	O
significantly	O
.	O
	
to	O
accurately	B-C0443131
compare	B-C1707455
hospital	B-C0019994
performance	B-C0871017
in	O
relation	B-C0439849
to	O
ssi	B-C0038941
following	O
hbps	B-C1319408
,	O
the	O
operative	B-C0543467
procedure	I-C0543467
category	B-C0683312
in	O
the	O
surveillance	B-C1254363
system	I-C1254363
must	O
be	O
divided	B-C0332849
into	O
three	O
signature	B-C1514562
of	O
an	O
aggregation	B-C0332621
-	O
prone	B-C0033422
conformation	O
of	O
tau	B-C0085401
the	O
self-assembly	B-C0872376
of	O
the	O
microtubule	B-C0026046
associated	B-C0332281
tau	B-C0085401
protein	I-C0085401
into	O
fibrillar	B-C0230674
cell	I-C0230674
inclusions	I-C0230674
is	O
linked	B-C0449379
to	O
a	O
number	B-C0237753
of	O
devastating	O
neurodegenerative	B-C0524851
disorders	I-C0524851
collectively	O
known	O
as	O
tauopathies	B-C0949664
.	O
	
the	O
mechanism	B-C0441712
by	O
which	O
tau	B-C0085401
self-assembles	B-C0872376
into	O
pathological	B-C1521733
entities	B-C1551338
is	O
a	O
matter	O
of	O
much	O
debate	B-C0870392
,	O
largely	B-C0549177
due	B-C0678226
to	I-C0678226
the	O
lack	O
of	O
direct	B-C1947931
experimental	B-C1517586
insights	B-C0233820
into	O
the	O
earliest	B-C2363430
stages	I-C2363430
of	O
aggregation	B-C0332621
.	O
	
we	O
present	O
pulsed	B-C0022885
double	I-C0022885
electron-electron	I-C0022885
resonance	I-C0022885
measurements	B-C0242485
of	O
two	O
key	O
fibril	B-C0225328
-	O
forming	B-C1522492
regions	B-C0205147
of	O
tau	B-C0085401
,	O
phf6	B-C1608562
and	O
phf6*	B-C0033684
,	O
in	O
transient	B-C0205374
as	O
aggregation	B-C0332621
happens	O
.	O
	
by	O
monitoring	O
the	O
end-to-end	B-C0012751
distance	I-C0012751
distribution	B-C1704711
of	O
these	O
segments	O
as	O
a	O
function	B-C0542341
of	O
aggregation	B-C0332621
time	B-C0040223
,	O
we	O
show	O
that	O
the	O
phf6	B-C0033684
regions	B-C0205147
dramatically	O
extend	B-C0231448
to	O
distances	B-C0012751
commensurate	B-C0205163
with	O
extended	B-C0231449
β-strand	B-C0600383
structures	I-C0600383
within	O
the	O
earliest	B-C2363430
stages	I-C2363430
of	O
aggregation	B-C0332621
,	O
well	O
before	O
fibril	B-C0225328
formation	B-C1522492
.	O
	
combined	B-C0205195
with	O
simulations	B-C0679083
,	O
our	O
experiments	B-C0681814
show	O
that	O
the	O
extended	B-C0231449
β-strand	B-C0600383
conformational	I-C0600383
state	B-C1442792
of	O
phf6	B-C0033684
is	O
readily	O
populated	O
under	O
aggregating	B-C0332621
conditions	B-C0348080
,	O
constituting	O
a	O
defining	O
signature	B-C1514562
of	O
aggregation	B-C0332621
-	O
prone	B-C0033422
tau	B-C0085401
,	O
and	O
as	O
such	O
,	O
a	O
possible	O
target	B-C1521840
for	O
therapeutic	B-C0808232
interventions	I-C0808232
.	O
	
design	B-C1707689
,	O
synthesis	B-C0007987
,	O
and	O
cytotoxic	B-C0596402
evaluation	B-C0220825
of	O
certain	O
7-chloro-4-	B-C0034424
derivatives	B-C0243072
as	O
vegfr-ii	B-C0378796
inhibitors	B-C0243077
signaling	B-C0037080
pathway	I-C0037080
inhibition	B-C3463820
of	O
vegfr-ii	B-C0378796
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	B-C0006826
management	B-C0376636
.	O
	
in	O
the	O
current	B-C2603343
study	I-C2603343
,	O
the	O
synthesis	B-C0007987
of	O
novel	B-C0205314
1-4-	B-C0034424
derivatives	B-C0243072
4a-t	B-C0034424
was	O
achieved	O
through	O
the	O
amination	B-C0002505
of	O
2-chloro-1-	B-C0034424
3	I-C0034424
with	O
different	O
secondary	B-C0002508
amines	I-C0002508
.	O
	
the	O
structures	B-C0026383
of	O
the	O
target	B-C1521840
compounds	B-C1706082
were	O
confirmed	B-C0521093
by	I-C0521093
ir	B-C0037807
,	O
1	B-C3850001
h-nmr	I-C3850001
,	O
13	B-C3850003
c-nmr	I-C3850003
,	O
hrms	B-C0037813
,	O
and	O
microanalysis	B-C0013844
.	O
	
compounds	B-C1706082
4a-t	B-C0034424
were	O
subjected	O
to	O
in	B-C1533691
vitro	I-C1533691
anticancer	B-C0920425
screening	B-C1710032
against	O
human	B-C0678222
breast	I-C0678222
cancer	I-C0678222
mcf-7	B-C0596890
and	O
prostate	B-C0600139
cancer	I-C0600139
pc3	B-C0007634
cell	B-C0007600
lines	I-C0007600
.	O
	
the	O
highest	O
cytotoxicty	B-C0596402
against	O
both	O
cell	B-C0007600
lines	I-C0007600
was	O
displayed	O
by	O
2-	B-C0034424
4q	I-C0034424
,	O
with	O
ic50	B-C0600495
values	I-C0600495
of	O
6.502	O
and	O
11.751	O
μm	O
against	O
mcf-7	B-C0596890
and	O
pc3	B-C0007634
cells	I-C0007634
,	O
respectively	O
,	O
compared	B-C1707455
with	O
the	O
standard	B-C0920479
drug	I-C0920479
doxorubicin	B-C0013089
mcf-7	B-C0596890
6.774	O
μm	O
,	O
pc3	B-C0007634
7.7316	O
μm	O
.	O
	
due	O
to	O
its	O
notable	O
activity	B-C0441655
toward	O
mcf-7	B-C0596890
cells	I-C0596890
,	O
4q	B-C0034424
was	O
further	O
evaluated	O
as	O
vegfr-ii	B-C0378796
inhibitor	B-C0243077
,	O
showing	O
an	O
ic50	B-C0600495
of	O
1.38	O
μm	O
compared	O
to	O
sorafenib	B-C1516119
0.33	O
μm	O
.	O
	
the	O
docking	B-C1522290
study	O
proved	O
that	O
4q	B-C0034424
has	O
a	O
binding	B-C1167622
mode	I-C1167622
akin	O
to	O
that	O
of	O
vegfr-ii	B-C0378796
inhibitors	B-C0243077
.	O
	
the	O
erbb3	B-C0072460
receptor	I-C0072460
tyrosine	I-C0072460
kinase	I-C0072460
negatively	O
regulates	B-C1327622
paneth	B-C0227276
cells	I-C0227276
by	O
pi3k	B-C0044602
-	O
dependent	B-C3244310
suppression	B-C0038855
of	O
atoh1	B-C1412626
paneth	B-C0227276
cells	I-C0227276
pcs	B-C0227276
,	O
a	O
secretory	B-C1519221
population	I-C1519221
located	O
at	O
the	O
base	O
of	O
the	O
intestinal	B-C3686613
crypt	I-C3686613
,	O
support	O
the	O
intestinal	B-C0021853
stem	B-C0038250
cells	I-C0038250
isc	B-C0038250
with	O
growth	B-C0018284
factors	I-C0018284
and	O
participate	O
in	O
innate	B-C0020969
immunity	I-C0020969
by	O
releasing	O
antimicrobial	B-C4084937
peptides	I-C4084937
,	O
including	O
lysozyme	B-C3541379
and	O
defensins	B-C0057256
.	O
	
pc	B-C0227276
dysfunction	B-C3887504
is	O
associated	O
with	O
disorders	B-C0012634
such	O
as	O
crohn's	B-C0010346
disease	I-C0010346
and	O
necrotizing	B-C0520459
enterocolitis	I-C0520459
,	O
but	O
the	O
specific	O
pathways	B-C1148560
regulating	B-C1327622
pc	B-C0227276
development	B-C0815089
and	O
function	B-C0007613
are	O
not	O
fully	O
understood	O
.	O
	
here	O
we	O
tested	O
the	O
role	O
of	O
the	O
neuregulin	B-C0072460
receptor	I-C0072460
erbb3	I-C0072460
in	O
control	O
of	O
pc	B-C0227276
differentiation	B-C0007589
and	O
the	O
isc	B-C2350292
niche	I-C2350292
.	O
	
intestinal	B-C0021853
epithelial	B-C0221908
erbb3	B-C0812265
knockout	B-C0599772
caused	O
precocious	B-C1279930
appearance	B-C0700364
of	O
pcs	B-C0227276
as	O
early	O
as	O
postnatal	B-C0443281
day	B-C3842672
7	I-C3842672
,	O
and	O
substantially	O
increased	B-C0205217
the	O
number	O
of	O
mature	B-C0205286
pcs	B-C0227276
in	O
adult	B-C0025929
mouse	I-C0025929
ileum	B-C0020885
.	O
	
erbb3	B-C0072460
loss	O
had	O
no	O
effect	O
on	O
other	O
secretory	B-C0282637
lineages	I-C0282637
,	O
but	O
increased	B-C0205217
expression	B-C1171362
of	O
the	O
isc	B-C0038250
marker	O
lgr5	B-C0762578
.	O
	
erbb3	B-C0072460
-null	O
intestines	B-C0021853
had	O
elevated	O
levels	O
of	O
the	O
atoh1	B-C1412626
transcription	B-C0040648
factor	I-C0040648
,	O
which	O
is	O
required	O
for	O
secretory	O
fate	O
determination	O
,	O
while	O
atoh1	B-C1567779
cells	B-C0007634
had	O
reduced	O
erbb3	B-C0812265
,	O
suggesting	O
reciprocal	B-C1882911
negative	B-C0205160
regulation	B-C1327622
.	O
	
erbb3	B-C0072460
-null	O
intestinal	B-C0814997
progenitor	I-C0814997
cells	I-C0814997
showed	O
reduced	B-C0392756
activation	B-C1879547
of	O
the	O
pi3k-akt	B-C2984369
and	O
erk	B-C1148560
mapk	I-C1148560
pathways	I-C1148560
.	O
	
inhibiting	O
these	O
pathways	B-C1148560
in	O
ht29	B-C0007634
cells	I-C0007634
increased	B-C0205217
levels	O
of	O
atoh1	B-C1412626
and	O
the	O
pc	B-C0227276
marker	O
lyz	B-C1416945
.	O
	
conversely	O
,	O
erbb3	B-C0072460
activation	O
suppressed	B-C0038855
lyz	B-C1416945
and	O
atoh1	B-C1412626
in	O
a	O
pi3k	B-C0044602
-	O
dependent	B-C3244310
manner	O
.	O
	
expansion	O
of	O
the	O
pc	B-C0227276
compartment	O
in	O
erbb3	B-C0072460
-null	O
intestines	B-C0021853
was	O
accompanied	O
with	O
elevated	O
er	B-C3178870
stress	I-C3178870
and	O
inflammation	B-C0021368
markers	B-C0005516
,	O
raising	O
the	O
possibility	O
that	O
negative	B-C0205160
regulation	B-C1327622
of	O
pcs	B-C0227276
by	O
erbb3	B-C0072460
is	O
necessary	O
to	O
maintain	O
homeostasis	B-C0019868
.	O
	
taken	O
together	O
,	O
our	O
data	B-C1511726
suggest	O
that	O
erbb3	B-C0072460
restricts	O
pc	B-C0227276
numbers	O
through	O
pi3k	B-C0044602
-mediated	O
suppression	B-C0038855
of	O
atoh1	B-C1412626
levels	O
leading	O
to	O
inhibition	O
of	O
pc	B-C0227276
differentiation	B-C0007589
,	O
with	O
important	O
implications	O
for	O
regulation	B-C0007613
of	O
the	O
isc	B-C2350292
niche	I-C2350292
.	O
	
cdf	B-C3826440
-	O
quantile	B-C1709792
distributions	B-C0038205
for	O
modelling	B-C3161035
random	B-C1705098
variables	I-C1705098
on	O
the	O
unit	B-C1552654
interval	I-C1552654
this	O
paper	O
introduces	O
a	O
two-parameter	B-C0549193
family	O
of	O
distributions	B-C0038205
for	O
modelling	B-C3161035
random	B-C1705098
variables	I-C1705098
on	O
the	O
0	O
interval	B-C1552654
by	O
applying	O
the	O
cumulative	B-C3826440
distribution	I-C3826440
function	I-C3826440
of	O
one	O
'	O
parent'	B-C3826440
distribution	I-C3826440
to	O
the	O
quantile	B-C1709792
function	B-C1705273
of	O
another	O
.	O
	
family	O
members	O
have	O
explicit	O
probability	B-C2986804
density	I-C2986804
functions	B-C1705273
,	O
cumulative	B-C3826440
distribution	I-C3826440
functions	I-C3826440
and	O
quantile	B-C1709792
s	O
in	O
a	O
location	B-C0450429
parameter	B-C0549193
and	O
a	O
dispersion	B-C0332624
parameter	B-C0549193
.	O
	
they	O
capture	O
a	O
wide	O
variety	B-C2346866
of	O
shapes	B-C0332479
that	O
the	O
beta	B-C1552649
and	O
kumaraswamy	B-C3826440
distributions	I-C3826440
cannot	B-C0243095
.	O
	
they	O
are	O
amenable	B-C3900053
to	O
likelihood	B-C0023707
inference	I-C0023707
,	O
and	O
enable	O
a	O
wide	O
variety	B-C2346866
of	O
quantile	B-C1709792
regression	B-C0034980
models	I-C0034980
,	O
with	O
predictors	B-C2698872
for	O
both	O
the	O
location	B-C0450429
and	O
dispersion	B-C0332624
parameters	B-C0549193
.	O
	
we	O
demonstrate	O
their	O
applicability	O
to	O
psychological	B-C0033909
research	B-C0242481
problems	I-C0242481
and	O
their	O
utility	B-C0457083
in	O
modelling	B-C3161035
real	B-C3272377
data	I-C3272377
.	O
	
first	B-C0205435
and	O
second	B-C0205436
generation	B-C0079411
dess	B-C1322815
reduce	B-C0392756
diabetes	B-C0011847
adverse	B-C0879626
effect	I-C0879626
on	O
mortality	B-C0205848
and	O
re-intervention	B-C0184661
in	O
multivessel	B-C0005847
coronary	B-C0010054
disease	I-C0010054
9-	O
year	B-C0439234
analysis	B-C0936012
diabetes	B-C0011847
portends	B-C0205245
an	O
increased	B-C0205217
risk	B-C0035647
of	O
adverse	B-C0879626
early	B-C1279919
and	O
late	B-C0205087
outcomes	B-C1274040
in	O
patients	B-C0030705
undergoing	O
pci	B-C1532338
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
aimed	O
to	O
investigate	B-C1292732
if	O
the	O
adverse	B-C0879626
effect	I-C0879626
of	O
diabetes	B-C0011849
mellitus	I-C0011849
dm	B-C0011849
on	O
early	B-C1279919
and	O
late	B-C0205087
pci	B-C1532338
outcomes	B-C1274040
is	O
reduced	B-C0392756
with	O
drug-eluting	B-C1322815
des	B-C1322815
compared	O
to	O
bare-metal	B-C2825200
bms	I-C2825200
stents	I-C2825200
.	O
	
we	O
reviewed	B-C1552617
the	O
mount	B-C0019994
sinai	I-C0019994
beth	I-C0019994
israel	I-C0019994
hospital	I-C0019994
first	B-C0205435
pci	B-C1532338
experience	O
for	O
multivessel	B-C0005847
coronary	B-C0010054
artery	I-C0010054
disease	I-C0010054
cad	B-C0010054
,	O
1998-2009	O
.	O
	
patients	B-C0030705
were	O
excluded	B-C2828389
if	O
they	O
had	O
single-vessel	B-C0581374
cad	I-C0581374
,	O
emergency	B-C1561583
,	O
no	B-C1513916
stent	B-C0038257
,	O
prior	B-C0332152
bypass	B-C0185098
graft	I-C0185098
or	O
myocardial	B-C0027051
infarction	I-C0027051
<24h	O
.	O
	
diabetes	B-C0011847
-	O
effect	B-C1280500
was	O
derived	O
from	O
9-	O
year	B-C0439234
all-cause	O
mortality	B-C0205848
and	O
re-intervention	B-C0184661
risk-adjusted	B-C2985465
hazard	I-C2985465
ratios	I-C2985465
ahr	B-C2985465
95%	O
confidence	B-C0009667
intervals	I-C0009667
for	O
des	B-C1322815
n=2679	O
48%	O
three-vessel	B-C3272265
39%	O
dm	B-C0011849
and	O
bms	B-C2825200
n=2651	O
40%	O
three-vessel	B-C3272265
33%	O
dm	B-C0011849
and	O
then	O
stratified	O
based	O
on	O
stent	B-C0038257
des	B-C1322815
/	O
bms	B-C2825200
and	O
vessel	B-C0042373
disease	I-C0042373
two	B-C0581375
/	O
three	B-C3272265
.	O
	
diabetes	B-C0011847
-	O
effect	B-C1280500
on	O
mortality	B-C0205848
was	O
lower	B-C0205556
for	O
des	B-C1322815
ahrdm/nodm	B-C2985465
=1	O
1.14	O
versus	O
bms	B-C2825200
ahrdm/nodm	B-C2985465
=1	O
1.50	O
,	O
but	O
this	O
was	O
predominantly	B-C1542147
driven	O
by	O
two-vessel	B-C0581375
patients	B-C0030705
.	O
	
this	O
diabetes	B-C0011847
effect	B-C1280500
was	O
similar	O
for	O
first	B-C0205435
des1	B-C1322815
ahrdm/nodm	B-C2985465
=1	O
1.14	O
and	O
second	B-C0205436
des2	B-C1322815
ahrdm/nodm	B-C2985465
=1	O
0.77	O
generation	B-C0079411
des	B-C1322815
.	O
	
re-intervention	B-C0184661
comparisons	B-C1707455
were	O
similarly	O
increased	B-C0205217
by	O
diabetes	B-C0011847
in	O
all	O
sub-cohorts	B-C0599755
.	O
	
our	O
analysis	B-C0936012
of	O
a	O
large	O
real-world	O
pci	B-C1532338
series	O
indicates	O
that	O
diabetes	B-C0011847
is	O
associated	B-C0332281
with	I-C0332281
worse	B-C1457868
9-	O
year	B-C0439234
mortality	B-C0205848
irrespective	B-C1254372
of	O
stent	B-C0038257
type	B-C0332307
,	O
albeit	O
this	O
is	O
mitigated	O
to	O
varying	O
degrees	O
with	O
des	B-C1322815
,	O
particularly	O
in	O
des2	B-C1322815
and	O
in	O
case	O
of	O
2-vessel	B-C0581375
disease	I-C0581375
.	O
	
a	O
complementary	B-C1254372
stent	B-C0038257
-	O
effect	B-C1280500
analysis	B-C0936012
confirmed	B-C0750484
des	B-C1322815
-to-	O
bms	B-C2825200
and	O
des2	B-C1322815
-to-	O
des1	B-C1322815
superiority	B-C0205556
in	O
both	O
diabetics	B-C0241863
and	O
lycopene	B-C0065331
and	O
risk	B-C0035647
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
a	O
meta-analysis	B-C0920317
of	O
observational	B-C0552617
studies	I-C0552617
the	O
aim	O
of	O
current	O
meta-analysis	B-C0920317
was	O
to	O
investigate	B-C1292732
the	O
relation	O
between	O
lycopene	B-C0065331
and	O
risk	B-C0035647
of	O
cardiovascular	B-C0007222
diseases	I-C0007222
cvd	B-C0007222
.	O
	
studies	B-C2603343
concerning	O
about	O
the	O
association	O
between	O
lycopene	B-C0065331
and	O
risk	B-C0035647
of	O
cvd	B-C0007222
were	O
searched	O
on	O
pubmed	B-C1138432
,	O
embase	B-C0282574
,	O
and	O
web	B-C0282574
of	I-C0282574
science	I-C0282574
from	O
inception	O
to	O
october	O
2016	O
.	O
	
a	O
total	O
of	O
14	O
eligible	B-C2603343
studies	I-C2603343
were	O
identified	B-C0205396
.	O
	
a	O
significantly	O
inverse	B-C1708567
association	I-C1708567
with	O
a	O
pooled	O
risk	B-C0242492
ratio	I-C0242492
rr	B-C0242492
of	O
0.83	O
95%	O
ci	B-C0009667
0.76	O
was	O
shown	O
between	O
lycopene	B-C0065331
exposure	B-C0332157
and	O
risk	B-C0035647
of	O
cvd	B-C0007222
.	O
	
findings	B-C0243095
were	O
similar	O
restricting	O
to	O
dietary	B-C0012155
studies	B-C2603343
rr	B-C0242492
=	O
0.87	O
,	O
95%	O
ci	B-C0009667
=	O
0.79	O
and	O
biomarker	B-C0005516
studies	B-C2603343
rr	B-C0242492
=	O
0.74	O
,	O
95%	O
ci	B-C0009667
=	O
0	O
.	O
	
62-0	O
.	O
	
dietary	B-C0012155
lycopene	B-C0065331
intake	B-C1512806
was	O
statistically	B-C0237881
significant	I-C0237881
for	O
coronary	B-C0010068
heart	I-C0010068
disease	I-C0010068
chd	B-C0010068
rr	B-C0242492
0.87	O
95%	O
ci	B-C0009667
0.76	O
and	O
stroke	B-C0038454
rr	B-C0242492
0.83	O
95%	O
ci	B-C0009667
0.69	O
pooled	O
risk	B-C1519101
estimate	I-C1519101
was	O
generally	O
similar	O
for	O
lycopene	B-C0065331
biomarker	B-C0005516
concentrations	O
,	O
but	O
the	O
association	O
was	O
only	O
statistically	B-C0237881
significant	I-C0237881
for	O
stroke	B-C0038454
rr	B-C0242492
0.65	O
95%	O
ci	B-C0009667
0.42	O
.	O
	
subgroup	B-C1515021
analyses	B-C0936012
showed	O
that	O
retrospective	B-C0035363
and	O
low	O
quality	O
studies	B-C2603343
were	O
statistically	B-C0237881
significant	I-C0237881
sources	O
of	O
heterogeneity	B-C0019409
.	O
	
higher	O
lycopene	B-C0065331
exposure	B-C0332157
is	O
inversely	B-C1708567
associated	I-C1708567
with	O
a	O
lower	O
risk	B-C0035647
of	O
cvd	B-C0007222
.	O
	
further	O
well-designed	O
randomized	B-C0206034
clinical	I-C0206034
trials	I-C0206034
are	O
required	O
to	O
assess	O
the	O
role	O
of	O
lycopene	B-C0065331
on	O
bacteria	B-C0004611
from	O
wheat	B-C1123020
and	O
cucurbit	B-C0446254
plant	B-C0242726
roots	I-C0242726
metabolize	B-C0025519
pahs	B-C0032458
and	O
aromatic	B-C0020245
root	B-C0242726
exudates	B-C1720935
implications	B-C0392360
for	O
rhizodegradation	B-C1720751
the	O
chemical	B-C1537001
interaction	I-C1537001
between	O
plants	B-C0032098
and	O
bacteria	B-C0004611
in	O
the	O
root	B-C0242726
zone	B-C1710706
can	O
lead	O
to	O
soil	B-C0037592
decontamination	B-C0205245
.	O
	
bacteria	B-C0004611
which	O
degrade	B-C0243125
pahs	B-C0032458
have	O
been	O
isolated	B-C0205409
from	O
the	O
rhizospheres	B-C2936389
of	O
plant	B-C0032098
species	B-C1705920
with	O
varied	O
biological	B-C0205460
traits	B-C0599883
,	O
however	O
,	O
it	O
is	O
not	O
known	O
what	O
phytochemicals	B-C0577749
promote	O
contaminant	B-C2827365
degradation	B-C0243125
.	O
	
one	O
monocot	B-C0032098
and	O
two	O
dicotyledon	B-C0032098
plants	I-C0032098
were	O
grown	B-C0597252
in	O
pah	B-C0032458
-	O
contaminated	B-C0205279
soil	B-C0037592
from	O
a	O
manufactured	B-C3273359
gas	I-C3273359
plant	I-C3273359
mgp	B-C3273359
site	B-C0205145
.	O
	
a	O
phytotoxicity	B-C0005507
assay	I-C0005507
confirmed	O
greater	O
soil	B-C0037592
decontamination	B-C0205245
in	O
rhizospheres	B-C2936389
when	O
compared	B-C1707455
to	O
bulk	O
soil	B-C0037592
controls	B-C2587213
.	O
	
bacteria	B-C0004611
were	O
isolated	B-C0205409
from	O
plant	B-C0242726
roots	I-C0242726
rhizobacteria	B-C0004611
and	O
selected	B-C1707391
for	O
growth	B-C0018270
on	O
anthracene	B-C0003162
and	O
chrysene	B-C0055655
on	O
pah	B-C0032458
-	O
amended	B-C1691222
plates	B-C1139067
.	O
	
rhizosphere	B-C2936389
isolates	B-C1764827
metabolized	B-C0025519
3-	O
and	O
4-ring	O
pahs	B-C0032458
and	O
pah	B-C0032458
catabolic	B-C0311402
intermediates	O
in	O
liquid	B-C1439852
incubations	I-C1439852
.	O
	
aromatic	B-C0020245
root	B-C0242726
exudate	B-C1720935
compounds	I-C1720935
,	O
namely	O
flavonoids	B-C0596577
and	O
simple	B-C0031428
phenols	I-C0031428
,	O
were	O
also	O
substrates	B-C3891814
for	O
isolated	B-C0205409
rhizobacteria	B-C0004611
.	O
	
in	O
particular	O
,	O
the	O
phenolic	B-C0031428
compounds	I-C0031428
-	O
morin	B-C0066801
,	O
caffeic	B-C0054433
acid	I-C0054433
,	O
and	O
protocatechuic	B-C0072489
acid	I-C0072489
-	O
appear	O
to	O
be	O
linked	O
to	O
bacterial	B-C0004611
degradation	B-C0243125
of	O
3-	O
and	O
4-	O
ring	O
pahs	B-C0032458
in	O
the	O
joint	B-C2825511
model	I-C2825511
imputation	I-C2825511
to	O
estimate	B-C0750572
the	O
treatment	B-C1518681
effect	I-C1518681
on	O
long-term	B-C0443252
survival	B-C0038952
using	O
auxiliary	B-C0441471
events	I-C0441471
clinical	B-C0008976
trial	I-C0008976
duration	B-C0449238
may	O
be	O
a	O
concern	O
in	O
clinical	B-C0008972
research	I-C0008972
,	O
especially	O
in	O
cancer	B-C1516640
trials	I-C1516640
where	O
the	O
endpoint	B-C2347784
is	O
overall	B-C4086681
survival	I-C4086681
.	O
	
a	O
surrogate	B-C0162488
endpoint	I-C0162488
can	O
be	O
used	O
as	O
an	O
auxiliary	B-C0439828
variable	I-C0439828
to	O
analyze	B-C0936012
the	O
treatment	B-C1518681
effect	I-C1518681
earlier	O
.	O
	
at	O
an	O
early	O
time	O
point	O
,	O
the	O
high	O
number	O
of	O
censored	B-C3889994
observations	B-C0302523
can	O
be	O
compensated	B-C0205432
by	O
the	O
imputation	B-C2825511
of	O
the	O
unobserved	B-C0243095
deaths	B-C1306577
times	O
.	O
	
we	O
propose	O
to	O
use	O
predictions	B-C0681842
of	O
the	O
risk	B-C0035647
of	O
death	B-C0011065
from	O
a	O
joint	B-C2825511
model	I-C2825511
for	O
a	O
recurrent	B-C2945760
event	B-C0441471
and	O
a	O
terminal	B-C0205088
event	B-C0441471
,	O
which	O
account	O
for	O
disease	B-C0277556
relapse	I-C0277556
information	B-C1533716
.	O
	
two	O
imputation	B-C2825511
methods	I-C2825511
were	O
compared	B-C1707455
sampling	B-C0036150
from	O
the	O
estimated	B-C0392762
parametric	I-C0392762
distribution	I-C0392762
of	O
the	O
survival	B-C2919552
time	I-C2919552
and	O
sampling	B-C0036150
using	O
its	O
nonparametric	B-C0242932
estimation	I-C0242932
.	O
	
the	O
treatment	B-C1518681
effect	I-C1518681
and	O
its	O
standard	B-C1710181
error	I-C1710181
were	O
estimated	B-C0750572
via	O
multiple	B-C2825511
imputations	I-C2825511
.	O
	
the	O
performances	B-C1882330
of	O
the	O
two	O
methods	B-C0025663
were	O
compared	B-C1707455
in	O
terms	O
of	O
bias	B-C0242568
in	O
the	O
estimates	B-C0750572
,	O
standard	B-C1710181
errors	I-C1710181
,	O
and	O
coverage	B-C2700387
probability	B-C0033204
.	O
	
both	O
methods	B-C0025663
were	O
then	O
retrospectively	B-C1514923
applied	B-C4048755
to	O
two	O
randomized	B-C0206034
clinical	I-C0206034
trials	I-C0206034
studying	O
the	O
effect	B-C1280500
of	O
adjuvant	B-C1522673
chemotherapy	B-C3665472
in	O
breast	B-C0006142
cancer	I-C0006142
patients	B-C0030705
.	O
	
the	O
corneal	B-C1182610
epithelial	I-C1182610
barrier	B-C1704511
and	O
its	O
developmental	B-C0458003
role	O
in	O
isolating	B-C0205409
corneal	B-C1182610
epithelial	I-C1182610
and	O
conjunctival	B-C1182611
cells	I-C1182611
from	O
one	O
another	O
during	O
development	B-C1527148
,	O
the	O
corneal	B-C0459875
epithelium	I-C0459875
ce	B-C0459875
and	O
the	O
conjunctiva	B-C0009758
are	O
derived	O
from	O
the	O
surface	B-C1515087
ectoderm	I-C1515087
.	O
	
here	O
we	O
have	O
examined	B-C0332128
how	O
,	O
during	O
development	B-C1527148
,	O
the	O
cells	B-C0007634
of	O
these	O
two	O
issues	O
become	O
isolated	B-C0205409
from	O
each	O
other	O
.	O
	
epithelia	B-C0014609
from	O
the	O
anterior	B-C0003151
eyes	I-C0003151
of	O
chicken	B-C0008046
embryos	I-C0008046
were	O
labeled	B-C1522485
with	O
the	O
fluorescent	B-C0016320
,	O
lipophilic	B-C0013343
dye	I-C0013343
,	O
1	B-C2350183
perchlorate	I-C2350183
dii	B-C2350183
.	O
	
dii	B-C2350183
was	O
placed	O
on	O
the	O
epithelial	B-C2327105
surface	I-C2327105
of	O
the	O
developing	O
anterior	B-C0003151
eye	I-C0003151
and	O
its	O
diffusion	B-C0012222
was	O
monitored	O
by	O
fluorescence	B-C0026022
microscopy	I-C0026022
.	O
	
concomitant	O
morphologic	B-C0332437
changes	B-C0392747
in	O
the	O
surface	B-C2327105
cells	I-C2327105
of	I-C2327105
these	I-C2327105
epithelial	I-C2327105
were	O
examined	B-C0332128
by	O
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
.	O
	
immunofluorescence	B-C0079604
was	O
used	O
to	O
analyze	O
the	O
expression	B-C1171362
of	O
cytokeratin	B-C1313613
k3	I-C1313613
,	O
zo-1	B-C3503764
,	O
n-cadherin	B-C0027215
and	O
connexin-43	B-C0110613
and	O
the	O
function	B-C0031843
of	O
gap	B-C0206117
junctions	I-C0206117
was	O
analyzed	B-C0936012
using	O
a	O
cut-loading	B-C0392762
with	O
the	O
fluorescent	B-C0016320
dye	I-C0016320
rhodamine-dextran	B-C0073196
.	O
	
prior	O
to	O
embryonic	B-C0013936
day	B-C0439228
8	O
e	B-C0013936
8	O
,	O
dii	B-C2350183
placed	O
on	O
the	O
surface	B-C0205148
of	O
the	O
ce	B-C0459875
spreads	B-C0332261
throughout	O
all	O
the	O
epithelial	B-C0014597
cells	I-C0014597
of	O
the	O
anterior	B-C0003151
eye	I-C0003151
.	O
	
when	O
older	B-C0015392
eyes	I-C0015392
were	O
similarly	O
labeled	B-C1522485
,	O
dye	B-C0013343
diffusion	B-C0012222
was	O
restricted	B-C0443288
to	O
the	O
ce	B-C0459875
.	O
	
similarly	O
,	O
diffusion	B-C0012222
of	O
dii	B-C2350183
placed	O
on	O
the	O
conjunctival	B-C0009758
surface	B-C0205148
after	O
e	B-C0013936
8	O
was	O
restricted	B-C0443288
to	O
the	O
conjunctiva	B-C0009758
.	O
	
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
showed	O
that	O
developmentally	B-C1527148
1	O
physical	B-C4060664
separations	I-C4060664
progressively	B-C0205329
form	O
between	O
the	O
cells	B-C1182610
of	O
the	O
ce	B-C0459875
and	O
those	O
of	O
the	O
conjunctiva	B-C0009758
,	O
and	O
2	O
by	O
e	B-C0013936
8	O
these	O
separations	B-C0205245
form	O
a	O
ring	B-C0229119
that	O
completely	O
encompasses	O
the	O
cornea	B-C0010031
.	O
	
the	O
functional	B-C0205245
restriction	B-C0443288
of	O
gap	B-C0206117
junctions	I-C0206117
between	O
these	O
tissues	B-C0014609
did	O
not	O
occur	B-C1709305
until	O
e	B-C0013936
14	O
.	O
	
during	O
ocular	B-C1517080
development	I-C1517080
,	O
a	O
barrier	B-C1704511
to	O
the	O
diffusion	B-C0012222
of	O
dii	B-C2350183
forms	O
between	O
the	O
contiguous	B-C0205283
ce	B-C0459875
and	O
conjunctiva	B-C0009758
prior	O
to	O
the	O
differential	B-C1705242
expression	B-C1171362
of	O
gap	B-C0206117
junctions	I-C0206117
within	O
these	O
longitudinal	B-C0023981
study	I-C0023981
of	O
bovine	B-C0007452
rotavirus	B-C1002306
group	I-C1002306
a	I-C1002306
in	O
newborn	B-C0003065
calves	B-C3668829
from	O
vaccinated	B-C1519885
and	O
unvaccinated	B-C0243095
dairy	B-C0175925
herds	I-C0175925
reports	O
of	O
rotavirus	B-C0035870
excretion	B-C0504085
in	O
calves	B-C3668829
usually	O
result	O
from	O
cross-sectional	B-C0010362
studies	I-C0010362
,	O
and	O
in	O
face	O
of	O
the	O
conflicting	O
results	O
regarding	O
protection	B-C0150259
of	O
calves	B-C3668829
born	B-C0005615
to	O
vaccinated	B-C1519885
dams	B-C0007452
against	O
diarrhea	B-C0011991
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
rotavirus	B-C0035870
excretion	B-C0504085
in	O
dairy	B-C3668829
calves	I-C3668829
born	O
to	O
vaccinated	B-C1519885
or	O
unvaccinated	B-C0243095
dams	B-C0007452
,	O
to	O
identify	O
the	O
genotypes	B-C0017431
of	O
bovine	B-C0007452
rotavirus	B-C1002306
group	I-C1002306
a	I-C1002306
rva	B-C1002306
strains	B-C1518614
isolated	O
from	O
these	O
animals	B-C3668829
as	O
well	O
as	O
to	O
investigate	O
characteristics	O
of	O
the	O
disease	B-C0012634
in	O
naturally	B-C0205296
occurring	B-C1709305
circumstances	O
throughout	O
the	O
first	B-C3278912
month	I-C3278912
of	I-C3278912
life	I-C3278912
.	O
	
five	O
hundred	O
fifty-two	O
fecal	B-C0475362
samples	I-C0475362
were	O
taken	O
from	O
56	O
calves	B-C3668829
,	O
28	O
from	O
each	O
farm	B-C0557759
and	O
,	O
in	O
the	O
vaccinated	B-C1519885
herd	B-C0175925
,	O
11/281	O
samples	B-C0475362
3.91	O
taken	O
from	O
six	O
different	O
calves	B-C3668829
tested	B-C1514241
positive	I-C1514241
for	O
rva	B-C1002306
while	O
in	O
the	O
unvaccinated	B-C0243095
herd	O
,	O
3/271	O
samples	B-C0475362
1.11	O
taken	O
from	O
3	O
different	O
calves	B-C3668829
tested	B-C1514241
positive	I-C1514241
.	O
	
the	O
genotyping	B-C2368152
of	O
the	O
vp7	B-C0017337
genes	I-C0017337
showed	O
91.2	O
nucleotide	B-C0004793
sequence	I-C0004793
identity	O
to	O
g6	B-C0017431
genotype	I-C0017431
ncdv	B-C1518614
strain	I-C1518614
,	O
and	O
for	O
the	O
vp4	B-C0017337
gene	I-C0017337
,	O
strains	B-C1518614
from	O
the	O
vaccinated	B-C1519885
herd	O
were	O
96.6	O
related	O
to	O
b223	B-C1518614
strain	I-C1518614
,	O
while	O
strains	B-C1518614
from	O
the	O
unvaccinated	B-C0243095
herd	B-C0175925
were	O
88%	O
related	O
to	O
p	B-C0017431
genotype	I-C0017431
uk	B-C1518614
strain	I-C1518614
.	O
	
genotypes	B-C0017431
found	O
in	O
this	O
study	O
were	O
g6p	B-C0017431
in	O
the	O
vaccinated	B-C1519885
herd	B-C0175925
and	O
g6p	B-C0017431
in	O
the	O
unvaccinated	B-C0243095
herd	B-C0175925
.	O
	
all	O
calves	B-C3668829
infected	B-C0439663
with	O
rotavirus	B-C0035870
presented	O
an	O
episode	O
of	O
diarrhea	B-C0011991
in	O
the	O
first	O
month	O
of	O
life	O
,	O
and	O
the	O
discrepancy	O
between	O
the	O
genotypes	B-C0017431
found	O
in	O
the	O
commercial	B-C0042210
vaccine	I-C0042210
g6p	B-C0017431
and	O
g10p	B-C0017431
and	O
the	O
rotavirus	B-C0035870
strains	B-C1518614
circulating	O
in	O
both	O
vaccinated	B-C1519885
and	O
unvaccinated	B-C0243095
herds	B-C0175925
show	O
the	O
importance	O
of	O
keeping	O
constant	B-C1948059
surveillance	B-C0038842
in	O
order	O
to	O
avoid	O
potential	B-C3245505
causes	B-C0015127
of	O
vaccination	B-C0042196
failure	B-C0162643
.	O
	
gene	B-C0017337
-based	O
genome-wide	B-C2350277
association	I-C2350277
study	I-C2350277
identified	B-C0205396
19p13.3	B-C1520850
for	O
lean	B-C0424678
body	I-C0424678
mass	I-C0424678
lean	B-C0424678
body	I-C0424678
mass	I-C0424678
lbm	B-C0424678
is	O
a	O
complex	O
trait	B-C0599883
for	O
human	B-C0086418
health	B-C0018684
.	O
	
to	O
identify	O
genomic	B-C0678933
loci	I-C0678933
underlying	O
lbm	B-C0424678
,	O
we	O
performed	O
a	O
gene	B-C0017337
-based	O
genome-wide	B-C2350277
association	I-C2350277
study	I-C2350277
of	O
lean	B-C0392762
mass	I-C0392762
index	I-C0392762
lmi	B-C0392762
in	O
1000	O
unrelated	B-C0445356
caucasian	B-C0043157
subjects	B-C0080105
,	O
and	O
replicated	B-C0205173
in	O
2283	O
unrelated	B-C0445356
caucasians	B-C0043157
subjects	B-C0080105
.	O
	
gene	B-C0017337
-based	O
association	B-C2350277
analyses	I-C2350277
highlighted	O
the	O
significant	O
associations	B-C0439849
of	O
three	O
genes	B-C0017337
uqcr	B-C1540163
,	O
tcf3	B-C1336596
and	O
mbd3	B-C1417051
in	O
one	O
single	B-C0205171
locus	B-C0678933
19p13.3	B-C1520850
discovery	B-C0205556
p	O
=	O
6.10	O
10	O
,	O
1.65	O
10	O
and	O
1.10	O
10	O
replication	B-C1883725
p	O
=	O
2.21	O
10	O
,	O
1.84	O
10	O
and	O
6.95	O
10	O
combined	O
p	O
=	O
2.26	O
10	O
,	O
4.86	O
10	O
and	O
1.15	O
10	O
,	O
respectively	O
.	O
	
these	O
results	O
,	O
together	O
with	O
the	O
known	O
functional	B-C0205245
relevance	B-C2347946
of	O
the	O
three	O
genes	B-C0017337
to	O
lmi	B-C0392762
,	O
suggested	O
that	O
the	O
19p13.3	B-C1520850
region	B-C0205147
containing	O
uqcr	B-C1540163
,	O
tcf3	B-C1336596
and	O
mbd3	B-C1417051
genes	I-C1417051
was	O
a	O
novel	O
locus	B-C0678933
underlying	O
lean	B-C0424678
mass	I-C0424678
variation	B-C0042333
.	O
	
basal	B-C0205112
ryanodine	B-C1753335
receptor	I-C1753335
activity	I-C1753335
suppresses	B-C1260953
autophagic	B-C0333781
flux	B-C2348693
the	O
inositol	B-C0063592
1	I-C0063592
receptors	I-C0063592
ip3rs	B-C0063592
and	O
intracellular	B-C3158759
ca	I-C3158759
signaling	I-C3158759
are	O
critically	B-C1511545
involved	B-C1314939
in	O
regulating	B-C1327622
different	B-C1705242
steps	B-C1261552
of	O
autophagy	B-C0004391
,	O
a	O
lysosomal	B-C0024369
degradation	B-C1511758
pathway	I-C1511758
.	O
	
the	O
ryanodine	B-C0917729
receptors	I-C0917729
ryr	B-C0917729
,	O
intracellular	B-C1153434
ca	I-C1153434
channels	I-C1153434
mainly	O
expressed	B-C1171362
in	O
excitable	B-C1562285
cell	B-C0449475
types	I-C0449475
including	B-C0332257
muscle	B-C0026845
and	O
neurons	B-C0027882
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	B-C0205231
studied	B-C2603343
in	O
relation	O
to	O
autophagy	B-C0004391
.	O
	
yet	O
,	O
aberrant	B-C0443127
expression	B-C1171362
and	O
excessive	B-C0442802
activity	B-C1537044
of	O
ryrs	B-C0917729
in	O
these	O
tissues	B-C0040300
has	O
been	O
implicated	B-C2945640
in	O
the	O
onset	B-C0332162
of	I-C0332162
several	B-C0443302
diseases	B-C0012634
including	B-C0332257
alzheimer's	B-C0002395
disease	I-C0002395
,	O
where	O
impaired	B-C0221099
autophagy	B-C0004391
regulation	B-C1327622
contributes	B-C1880177
to	O
the	O
pathology	B-C0205469
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
determined	B-C1148554
whether	O
pharmacological	B-C0007992
ryr	B-C0917729
inhibition	B-C3463820
could	O
modulate	B-C0443264
autophagic	B-C0333781
flux	B-C2348693
in	O
ectopic	B-C0574895
ryr	B-C0917729
-	O
expressing	B-C1171362
models	B-C3161035
,	O
like	O
hek293	B-C2936239
cells	I-C2936239
and	O
in	O
cell	B-C0449475
types	I-C0449475
that	O
endogenously	B-C0205227
express	B-C1171362
ryr	B-C0917729
s	O
,	O
like	O
c2c12	B-C0596995
myoblasts	I-C0596995
and	O
primary	B-C0205225
hippocampal	B-C0019564
neurons	B-C0027882
.	O
	
importantly	B-C3898777
,	O
ryr3	B-C0524964
overexpression	B-C1171362
in	O
hek293	B-C2936239
cells	I-C2936239
impaired	B-C0221099
the	O
autophagic	B-C0333781
flux	B-C2348693
.	O
	
conversely	O
,	O
in	O
all	O
cell	B-C0007634
models	B-C3161035
tested	B-C0039593
,	O
pharmacological	B-C0007992
inhibition	B-C3463820
of	O
endogenous	B-C0205227
or	O
ectopically	B-C0574895
expressed	B-C1171362
ryrs	B-C0917729
,	O
using	O
dantrolene	B-C0010976
or	O
ryanodine	B-C0035983
,	O
augmented	B-C0205217
autophagic	B-C0333781
flux	B-C2348693
by	O
increasing	B-C0442808
lysosomal	B-C0024369
turn-over	B-C0597297
number	B-C0237753
of	O
autophagosomes	B-C3887595
and	O
autolysosomes	B-C0230822
measured	B-C0444706
as	O
mcherry	B-C3489546
-	O
lc3	B-C3540600
punctae	I-C3540600
/	O
cell	B-C0007634
increased	B-C0205217
from	O
70.37	O
in	O
control	B-C0009932
hek	B-C0007634
ryr3	I-C0007634
cells	I-C0007634
to	O
111.18	O
and	O
98.14	O
after	O
dantrolene	B-C0010976
and	O
ryanodine	B-C0035983
treatments	B-C1533734
,	O
respectively	O
.	O
	
moreover	O
,	O
in	O
differentiated	B-C1159966
c2c12	B-C0596995
cells	I-C0596995
,	O
transmission	B-C0678118
electron	I-C0678118
microscopy	I-C0678118
demonstrated	B-C0443289
that	O
dantrolene	B-C0010976
treatment	B-C1533734
decreased	B-C0205216
the	O
number	B-C0237753
of	O
early	O
autophagic	B-C0333781
vacuoles	B-C0042219
from	O
5.9	O
to	O
1.8	O
per	O
cellular	B-C0007634
cross	B-C0552389
section	I-C0552389
.	O
	
the	O
modulation	B-C0678672
of	O
the	O
autophagic	B-C0333781
flux	B-C2348693
could	O
be	O
linked	O
to	O
the	O
functional	B-C0205245
inhibition	B-C3463820
of	O
ryr	B-C0054493
channels	I-C0054493
as	O
both	O
ryr	B-C0917729
inhibitors	B-C0243077
efficiently	B-C0442799
diminished	O
the	O
number	B-C0237753
of	O
cells	B-C0007634
showing	O
spontaneous	B-C0205359
ryr3	B-C0524964
activity	B-C1537044
in	O
the	O
hek293	B-C2936239
cell	I-C2936239
model	B-C3161035
from	O
41.14	O
in	O
control	B-C0009932
cells	B-C0007634
to	O
18.70	O
and	O
9.74	O
after	O
dantrolene	B-C0010976
and	O
ryanodine	B-C0035983
treatments	B-C1533734
,	O
respectively	O
.	O
	
in	O
conclusion	B-C1707478
,	O
basal	B-C0205112
ryr	B-C0917729
-mediated	O
ca	B-C1820193
events	I-C1820193
suppress	B-C1260953
autophagic	B-C0333781
flux	B-C2348693
at	O
the	O
level	B-C0441889
of	O
the	O
fluoride	B-C0016327
concentration	B-C1446561
in	O
saliva	B-C0036087
and	O
biofilm	B-C0081786
fluid	I-C0081786
following	O
the	O
application	B-C0185125
of	O
three	O
fluoride	B-C0016326
varnishes	I-C0016326
most	O
of	O
the	O
commercially	O
available	O
fluoride	B-C0016326
varnishes	I-C0016326
fv	B-C0016326
have	O
not	O
been	O
evaluated	B-C0220825
for	O
their	O
cariostatic	B-C3179394
properties	I-C3179394
.	O
	
consequently	B-C3845876
,	O
the	O
aim	B-C1947946
of	O
this	O
in	B-C1515655
vivo	I-C1515655
study	B-C2603343
was	O
to	O
investigate	B-C0220825
intra	B-C0442107
-	O
oral	B-C0442027
fluoride	B-C0016327
retention	B-C0333117
and	O
clearance	B-C0231360
patterns	I-C0231360
from	O
three	O
different	O
fv	B-C0016326
.	O
	
eighteen	O
subjects	B-C0080105
7-11	O
years	B-C1510829
participated	O
in	O
a	O
laboratory	B-C0022877
analyst	B-C0870132
-	O
blinded	B-C0150108
,	O
randomized	B-C0034656
,	O
crossover	B-C0150097
study	I-C0150097
comparing	B-C1707455
the	O
ability	B-C0085732
of	O
5%	O
sodium	B-C0016326
fluoride	I-C0016326
varnishes	I-C0016326
cavityshield-cs	B-C0016326
,	O
enamel	B-C0016326
pro-ep	I-C0016326
,	O
vanish-v	B-C0016326
to	O
enhance	B-C2349975
fluoride	B-C0016327
concentrations	B-C1446561
in	O
biofilm	B-C0081786
fluid	I-C0081786
,	O
centrifuged	B-C3897072
and	O
whole	B-C0444667
saliva	B-C0036087
over	O
a	O
period	B-C1948053
of	O
48h	O
after	O
a	O
single	O
fv	B-C0016326
application	O
.	O
	
similar	O
fluoride	B-C0016327
concentration	B-C1446561
time	B-C0439545
patterns	I-C0439545
were	O
noted	B-C1317574
for	O
all	O
investigated	B-C0449433
fv	B-C0016326
and	O
studied	B-C2603343
variables	B-C0439828
,	O
with	O
the	O
highest	B-C1522410
fluoride	B-C0016327
concentrations	B-C1446561
observed	B-C1441672
for	O
the	O
first	O
biological	B-C2347026
sample	I-C2347026
collected	B-C1516698
after	O
fv	B-C0016326
application	O
30min	O
.	O
	
mean	B-C2348148
area	B-C0376690
under	I-C0376690
fluoride	I-C0376690
clearance	I-C0376690
curve	I-C0376690
values	B-C0042295
were	O
μg	O
f/g	O
or	O
ml	O
biofilm	B-C0081786
fluid	I-C0081786
-	O
cs	B-C0016326
472	O
,	O
ep	B-C0016326
423	O
,	O
v	B-C0016326
1264	O
centrifuged	B-C3897072
saliva	B-C0036087
-	O
cs	B-C0016326
42	O
,	O
ep	B-C0016326
19	O
,	O
v	B-C0016326
41	O
whole	B-C0444667
saliva	B-C0036087
-	O
cs	B-C0016326
68	O
,	O
ep	B-C0016326
64	O
,	O
v	B-C0016326
60	O
.	O
	
v	B-C0016326
delivered	O
more	O
fluoride	B-C0016327
to	O
biofilm	B-C0081786
fluid	I-C0081786
than	O
cs	B-C0016326
p=0	O
and	O
ep	B-C0016326
p=0	O
,	O
which	O
did	O
not	O
differ	O
p=0	O
.	O
	
for	O
centrifuged	B-C3897072
saliva	B-C0036087
,	O
cs	B-C0016326
and	O
v	B-C0016326
were	O
not	O
significantly	B-C0750502
different	O
p=0	O
,	O
but	O
resulted	B-C1274040
in	O
higher	B-C1522410
fluoride	B-C0016327
retention	B-C0333117
than	O
ep	B-C0016326
p<0	O
.	O
	
no	O
significant	B-C0750502
differences	O
among	O
fv	B-C0016326
were	O
observed	B-C1441672
for	O
whole	B-C0444667
saliva	B-C0036087
p=0	O
.	O
	
the	O
present	B-C0150312
study	B-C2603343
has	O
shown	O
that	O
fv	B-C0016326
vary	O
in	O
their	O
ability	B-C0085732
to	O
deliver	O
fluoride	B-C0016327
intra	B-C0442107
-	O
orally	B-C0442027
potentially	B-C3245505
related	B-C0439849
to	O
formulation	O
differences	B-C1705242
.	O
	
to	O
what	O
extent	B-C0439792
the	O
present	B-C0150312
findings	B-C0243095
relate	B-C0439849
to	O
clinical	B-C3850123
efficacy	I-C3850123
remains	O
,	O
however	O
,	O
to	O
be	O
determined	B-C1148554
.	O
	
clinical	B-C0008972
research	I-C0008972
that	O
investigates	B-C0220825
fluoride	B-C0016327
release	B-C0205556
patterns	B-C0449774
into	O
saliva	B-C0036087
and	O
biofilm	B-C0081786
fluid	I-C0081786
from	O
different	O
fv	B-C0016326
products	I-C0016326
is	O
insufficient	B-C0231180
.	O
	
more	O
research	B-C0242481
is	O
needed	O
to	O
investigate	B-C0220825
different	O
fv	B-C0016326
formulations	I-C0016326
for	O
their	O
efficacy	B-C1280519
in	O
order	O
to	O
help	O
clinicians	B-C0871685
make	O
better	B-C0332272
evidence	B-C3887511
based	O
treatment	B-C1522326
the	O
prognostic	B-C1514474
value	I-C1514474
of	O
extranodal	B-C3899187
extension	I-C3899187
in	O
human	B-C0021344
papillomavirus	I-C0021344
-associated	O
oropharyngeal	B-C0280313
squamous	I-C0280313
cell	I-C0280313
carcinoma	I-C0280313
extranodal	B-C3899187
or	I-C3899187
extracapsular	I-C3899187
extension	I-C3899187
ene	B-C3899187
is	O
an	O
adverse	B-C1514474
prognostic	I-C1514474
factor	I-C1514474
in	O
patients	B-C0030705
with	O
head	B-C0278996
and	I-C0278996
neck	I-C0278996
cancers	I-C0278996
who	O
undergo	O
primary	B-C2081627
surgery	I-C2081627
.	O
	
however	O
,	O
the	O
significance	O
of	O
ene	B-C3899187
in	O
human	B-C2828150
papillomavirus	I-C2828150
hpv	I-C2828150
oropharyngeal	I-C2828150
squamous	I-C2828150
cell	I-C2828150
carcinoma	I-C2828150
opscc	I-C2828150
is	O
not	O
well	O
established	O
,	O
and	O
single-institution	B-C2607850
studies	B-C2603343
have	O
not	B-C0443211
established	I-C0443211
that	O
ene	B-C3899187
predicts	B-C0681842
inferior	B-C0542339
outcome	B-C1274040
.	O
	
the	O
authors	O
investigated	O
the	O
prognostic	B-C1514474
value	I-C1514474
of	O
ene	B-C3899187
in	O
hpv	B-C0021344
-	O
positive	B-C1446409
patients	B-C0030705
who	O
underwent	O
primary	B-C2081627
surgery	I-C2081627
and	O
whether	O
adjuvant	B-C3178761
chemoradiation	I-C3178761
improved	O
overall	B-C4086681
survival	I-C4086681
os	B-C4086681
compared	B-C1707455
with	O
radiation	B-C0851346
alone	I-C0851346
in	O
ene	B-C3899187
-	O
positive	B-C1446409
patients	B-C0030705
.	O
	
patients	B-C0030705
who	O
underwent	O
primary	B-C2081627
surgery	I-C2081627
for	O
pathologic	B-C1521733
t1	I-C1521733
pt1	B-C1521733
through	O
pt4	B-C0027651
tumors	I-C0027651
,	O
pathologic	B-C1521733
n1	I-C1521733
pn1	B-C1521733
through	O
pn3	B-C0024204
lymph	I-C0024204
node	I-C0024204
status	B-C0449438
,	O
hpv-positive	B-C2828150
opscc	I-C2828150
were	O
identified	B-C0205396
in	O
the	O
national	B-C3826808
cancer	I-C3826808
data	I-C3826808
base	I-C3826808
from	O
2010	O
through	O
2012	O
.	O
	
features	B-C1521970
associated	B-C0332281
with	I-C0332281
ene	B-C3899187
were	O
analyzed	B-C0936012
.	O
	
univariable	B-C0034980
and	I-C0034980
multivariable	I-C0034980
cox	I-C0034980
regression	I-C0034980
analyses	I-C0034980
identified	B-C0205396
predictors	B-C2698872
of	O
os	B-C4086681
.	O
	
the	O
effect	B-C1280500
of	O
adjuvant	B-C3162256
treatment	I-C3162256
on	O
os	B-C4086681
in	O
ene	B-C3899187
-	O
positive	B-C1446409
cohort	B-C0009247
was	O
also	O
evaluated	B-C0220825
.	O
	
in	O
total	O
,	O
1043	O
patients	B-C0030705
met	O
inclusion	B-C1512693
criteria	I-C1512693
,	O
among	O
whom	O
43.5	O
were	O
ene	B-C3899187
-	O
positive	B-C1446409
.	O
	
of	O
the	O
ene	B-C3899187
-	O
positive	B-C1446409
patients	B-C0030705
who	O
had	O
treatment	B-C0087111
details	O
available	O
,	O
72%	O
received	B-C1514756
concurrent	B-C3178775
chemoradiotherapy	I-C3178775
,	O
16%	O
received	B-C1514756
radiotherapy	B-C0038886
,	O
and	O
12%	O
received	B-C1514756
no	B-C0332288
adjuvant	B-C3162256
treatment	I-C3162256
.	O
	
after	O
a	O
median	B-C0876920
follow-up	B-C1522577
of	O
28.4	O
months	B-C0439231
,	O
ene	B-C3899187
was	O
associated	B-C0332281
with	I-C0332281
worse	B-C1457868
3-	O
year	B-C0439234
os	B-C4086681
89.3	O
vs	O
93.6	O
p	O
=	O
01	O
.	O
	
on	O
multivariable	B-C0034980
analysis	I-C0034980
that	O
included	B-C0332257
involved	O
lymph	B-C0024204
nodes	I-C0024204
,	O
only	O
ene	B-C3899187
,	O
lymphovascular	B-C1708790
invasion	I-C1708790
,	O
pt3/pt4	B-C0027651
tumors	I-C0027651
,	O
and	O
charlson-deyo	B-C0449820
score	I-C0449820
were	O
associated	B-C0332281
with	I-C0332281
worse	B-C1457868
os	B-C4086681
.	O
	
among	O
ene	B-C3899187
-	O
positive	B-C1446409
patients	B-C0030705
,	O
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
3-	O
year	B-C0439234
os	B-C4086681
between	O
those	O
who	O
received	B-C1514756
adjuvant	B-C3178761
concurrent	I-C3178761
chemoradiotherapy	I-C3178761
versus	O
radiotherapy	B-C0038886
alone	I-C0038886
89.6	O
vs	O
89.3	O
,	O
respectively	O
p	O
=	O
55	O
.	O
	
propensity	B-C2718044
score	I-C2718044
-	O
matched	B-C0086766
comparison	I-C0086766
revealed	B-C0443289
similar	O
results	B-C1274040
.	O
	
ene	B-C3899187
is	O
associated	B-C0332281
with	I-C0332281
inferior	B-C0542339
os	B-C4086681
in	O
patients	B-C0030705
with	O
hpv-positive	B-C2828150
opscc	I-C2828150
.	O
	
however	O
,	O
os	B-C4086681
was	O
not	B-C4049139
better	I-C4049139
with	O
adjuvant	B-C3178761
chemoradiotherapy	I-C3178761
compared	B-C1707455
with	O
radiotherapy	B-C0038886
alone	I-C0038886
in	O
ene	B-C3899187
-	O
positive	B-C1446409
patients	B-C0030705
.	O
	
the	O
current	B-C0035176
findings	I-C0035176
support	I-C0035176
the	O
need	O
for	O
prospective	B-C0033522
studies	I-C0033522
of	O
adjuvant	B-C3178761
chemoradiation	I-C3178761
in	O
hpv	B-C0021344
-	O
positive	B-C1446409
patients	B-C0030705
with	O
ene	B-C3899187
.	O
	
psychological	B-C0815107
distress	I-C0815107
is	O
more	O
prevalent	O
in	O
fertile	B-C0015895
age	B-C0001779
and	O
premenopausal	B-C0206158
women	B-C0043210
with	O
pcos	B-C0032460
symptoms	B-C1457887
-15-yr	O
follow-up	B-C1522577
polycystic	B-C0032460
ovary	I-C0032460
syndrome	I-C0032460
pcos	B-C0032460
is	O
associated	O
with	O
increased	O
psychological	B-C0815107
distress	I-C0815107
obesity	B-C0028754
and	O
hyperandrogenism	B-C0206081
being	O
suggested	O
as	O
key	O
promoters	B-C0033414
.	O
	
to	O
investigate	B-C1292732
the	O
prevalence	B-C0683921
of	O
anxiety	B-C0003469
/	O
depression	B-C0011581
and	O
their	O
coexistence	O
in	O
women	B-C0043210
with	O
pcos	B-C0032460
/	O
pcos	B-C0032460
symptoms	B-C1457887
at	O
age	B-C0001779
s	O
31	O
and	O
46	O
.	O
	
the	O
roles	O
of	O
obesity	B-C0028754
,	O
hyperandrogenism	B-C0206081
and	O
awareness	B-C0004448
of	O
pcos	B-C0032460
on	O
psychological	B-C0815107
distress	I-C0815107
were	O
also	O
assessed	B-C1516048
.	O
	
population	B-C1709599
based	I-C1709599
follow-up	I-C1709599
.	O
	
northern	B-C0016132
finland	I-C0016132
birth	B-C1706962
cohort	I-C1706962
1966	O
with	O
15-	O
year	B-C0439234
follow-up	B-C1522577
.	O
	
at	O
age	B-C0001779
31	O
a	O
questionnaire-based	B-C1134635
screening	I-C1134635
for	O
oligoamenorrhea	B-C0028949
oa	B-C0028949
and	O
hirsutism	B-C0271610
h	B-C0271610
2188	O
asymptomatic	B-C0231221
controls	B-C0009932
,	O
331	O
oa	B-C0028949
,	O
323	O
h	B-C0271610
,	O
125	O
oa	B-C0028949
+	O
h	B-C0271610
pcos	B-C0032460
.	O
	
46	O
year	B-C0439234
old	O
follow-up	B-C1522577
1576	O
controls	B-C0009932
,	O
239	O
oa	B-C0028949
,	O
231	O
h	B-C0271610
and	O
85	O
pcos	B-C0032460
.	O
	
questionnaire-based	B-C1134635
screening	I-C1134635
for	O
anxiety	B-C0003469
and	O
depression	B-C0086132
symptoms	I-C0086132
hopkins	B-C0451218
symptom	I-C0451218
checklist-25	I-C0451218
and	O
previously	O
diagnosed	B-C0011900
/	O
treated	B-C0332154
depression	B-C0011581
at	O
age	B-C0001779
31	O
and	O
46	O
.	O
	
bmi	B-C1305855
,	O
serum	B-C4064092
testosterone	I-C4064092
/	O
free	B-C0428629
androgen	I-C0428629
index	I-C0428629
fai	B-C0428629
and	O
awareness	B-C0004448
of	O
polycystic	B-C0032460
ovaries	I-C0032460
/	O
pcos	B-C0032460
on	O
psychological	B-C0815107
distress	I-C0815107
were	O
also	O
assessed	B-C1516048
.	O
	
population-based	B-C1709597
prevalence	I-C1709597
of	O
anxiety	B-C0003469
and/or	O
depression	B-C0011581
in	O
women	B-C0043210
with	O
pcos	B-C0032460
/	O
pcos	B-C0032460
symptoms	B-C1457887
at	O
age	B-C0001779
s	O
31	O
and	O
46	O
.	O
	
anxiety	B-C0003469
and/or	O
depression	B-C0086132
symptoms	I-C0086132
,	O
their	O
coexistence	O
and	O
rate	O
of	O
depression	B-C0011581
were	O
increased	O
at	O
age	B-C0001779
31	O
and	O
46	O
in	O
women	B-C0043210
with	O
pcos	B-C0032460
or	O
isolated	O
h	B-C0271610
compared	O
with	O
controls	B-C0009932
.	O
	
high	O
bmi	B-C1305855
or	O
hyperandrogenism	B-C0206081
did	O
not	O
associate	O
with	O
increased	O
anxiety	B-C0003469
or	O
depression	B-C0086132
symptoms	I-C0086132
.	O
	
the	O
awareness	B-C0004448
of	O
pcos	B-C0032460
was	O
associated	O
with	O
increased	O
anxiety	B-C0003469
.	O
	
women	B-C0043210
with	O
pcos	B-C0032460
or	O
isolated	O
h	B-C0271610
present	O
more	O
often	O
with	O
anxiety	B-C0003469
and/or	O
depression	B-C0086132
symptoms	I-C0086132
and	O
their	O
coexistence	O
compared	O
with	O
controls	B-C0009932
.	O
	
high	O
bmi	B-C1305855
or	O
hyperandrogenism	B-C0206081
did	O
not	O
provoke	O
psychological	B-C0815107
distress	I-C0815107
in	O
pcos	B-C0032460
.	O
	
the	O
awareness	B-C0004448
of	O
pcos	B-C0032460
increased	O
anxiety	B-C0003469
but	O
did	O
not	O
associate	O
with	O
severe	O
anxiety	B-C0003469
or	O
the	O
use	B-C1524063
of	I-C1524063
oxford	B-C1561598
nanopore	I-C1561598
native	B-C0302891
barcoding	B-C2936547
for	O
complete	B-C0205197
genome	B-C2348746
assembly	I-C2348746
the	O
oxford	B-C1561598
nanopore	I-C1561598
technologies	I-C1561598
minion	B-C0025080
is	O
a	O
mobile	B-C0231435
dna	O
sequencer	O
that	O
can	O
produce	O
long	B-C0162326
read	I-C0162326
sequences	I-C0162326
with	O
a	O
short	O
turn-around	B-C1254367
time	I-C1254367
.	O
	
here	O
we	O
report	B-C0684224
the	O
first	O
demonstration	O
of	O
single	B-C2348746
contig	I-C2348746
genome	I-C2348746
assembly	I-C2348746
using	B-C1524063
oxford	B-C1561598
nanopore	I-C1561598
native	B-C0302891
barcoding	B-C2936547
when	O
applied	B-C4048755
to	O
a	O
multiplexed	B-C0017430
library	I-C0017430
of	O
12	O
samples	B-C2347026
and	O
combined	B-C0205195
with	O
existing	B-C2987476
illumina	O
short-read	B-C0950138
data	I-C0950138
.	O
	
this	O
paves	O
the	O
way	O
for	O
the	O
closure	B-C1521802
of	O
multiple	B-C0439064
bacterial	B-C0085238
genomes	I-C0085238
from	O
a	O
single	B-C0205171
minion	B-C0025080
sequencing	B-C1328887
run	B-C1704688
,	O
given	O
the	O
availability	B-C0470187
of	I-C0470187
existing	B-C2987476
short-read	B-C0950138
data	I-C0950138
.	O
	
the	O
strain	B-C1518614
we	O
used	B-C1524063
,	O
mho_001	B-C1518614
,	O
represents	O
the	O
important	O
community-acquired	O
methicillin	B-C0079830
resistant	I-C0079830
staphylococcus	B-C0038172
aureus	I-C0038172
lineage	O
usa300	B-C1518614
.	O
	
using	B-C1524063
a	O
hybrid	O
assembly	B-C2348746
of	O
existing	B-C2987476
short	B-C0205556
read	I-C0205556
and	O
barcoded	B-C0162326
long	I-C0162326
read	I-C0162326
sequences	I-C0162326
from	O
multiplexed	B-C1547368
data	I-C1547368
,	O
we	O
completed	O
a	O
genome	B-C0017428
of	O
the	O
s	B-C0038172
.	O
	
aureus	I-C0038172
usa300	B-C1518614
strain	I-C1518614
mho_001	I-C1518614
.	O
	
the	O
long-read	B-C0950138
data	I-C0950138
represented	O
only	O
5-10%	O
of	O
an	O
average	B-C1510992
minion	B-C0025080
run	B-C1704688
7x	O
genomic	B-C0017428
coverage	B-C1999244
,	O
but	O
,	O
using	B-C1524063
standard	B-C0034925
tools	B-C0037589
,	O
this	O
was	O
sufficient	B-C0205410
to	O
complete	B-C0205197
the	O
circular	B-C0035639
chromosome	I-C0035639
of	O
s	B-C0038172
.	O
	
aureus	I-C0038172
strain	B-C1518614
mho_001	I-C1518614
2.86	O
mb	O
and	O
two	O
complete	B-C0205197
plasmids	B-C0032136
27	O
kb	O
and	O
3	O
kb	O
.	O
	
minor	B-C0205165
differences	B-C1705242
were	O
noted	B-C4288581
when	O
compared	B-C1707455
to	O
usa300	B-C1518614
reference	O
genome	B-C0017428
,	O
usa300_fpr3757	B-C0085238
,	O
including	B-C0332257
the	O
translocation	B-C0282583
,	O
loss	B-C1517945
and	O
gain	B-C1517378
of	O
mobile	B-C1257903
genetic	I-C1257903
elements	I-C1257903
.	O
	
here	O
we	O
demonstrate	O
that	O
minion	B-C0025080
reads	B-C1704688
,	O
multiplexed	B-C0205245
using	B-C1524063
native	B-C0302891
barcoding	B-C2936547
,	O
can	O
be	O
used	B-C1524063
in	O
combination	B-C0205195
with	O
short-read	B-C0950138
data	I-C0950138
,	O
to	O
fully	O
complete	B-C0205197
a	O
bacterial	B-C0085238
genome	I-C0085238
.	O
	
the	O
ability	O
to	O
complete	B-C0205197
multiple	B-C0439064
genomes	B-C0017428
,	O
for	O
which	O
short-read	B-C0950138
data	I-C0950138
is	O
already	O
available	B-C0243095
,	O
from	O
a	O
single	B-C0205171
minion	B-C0025080
run	B-C1704688
is	O
set	O
to	O
impact	B-C4049986
on	O
our	O
understanding	B-C0162340
of	O
accessory	B-C1883702
genome	B-C0017428
content	I-C0017428
,	O
plasmid	B-C0032136
diversity	B-C1880371
and	O
genome	B-C0017428
rearrangements	B-C0017287
.	O
	
doxorubicin	B-C0013089
has	O
dose-dependent	B-C1512045
toxicity	B-C0600688
on	O
mouse	B-C0025929
ovarian	B-C0018120
follicle	I-C0018120
development	B-C0243107
,	O
hormone	B-C0312431
secretion	I-C0312431
,	O
and	O
oocyte	B-C1160520
maturation	I-C1160520
doxorubicin	B-C0013089
dox	B-C0013089
,	O
one	O
of	O
the	O
most	O
commonly	B-C0205214
used	O
anticancer	B-C0003392
medications	I-C0003392
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	B-C0015895
by	O
damaging	B-C1883709
ovarian	B-C0018120
follicles	I-C0018120
however	O
,	O
the	O
dose-dependent	B-C1512045
toxicity	B-C0600688
of	O
dox	B-C0013089
on	O
the	O
dynamic	B-C0729333
follicle	B-C0018120
development	B-C0243107
and	O
oocyte	B-C1160520
maturation	I-C1160520
has	O
not	O
been	O
well-defined	O
.	O
	
our	O
objective	B-C0018017
is	O
to	O
determine	O
the	O
effects	B-C1704420
of	I-C1704420
human	B-C0086418
-	O
relevant	B-C2347946
exposure	B-C0332157
levels	B-C0441889
of	O
dox	B-C0013089
on	O
follicular	B-C0018120
functions	B-C0542341
across	O
developmental	B-C0243107
time	B-C0040223
.	O
	
in	B-C1533691
vitro	I-C1533691
cultured	B-C0430400
multilayered	B-C0737234
secondary	I-C0737234
mouse	I-C0737234
follicles	I-C0737234
were	O
treated	B-C1522326
with	O
dox	B-C0013089
at	O
0	O
,	O
2	O
,	O
20	O
,	O
100	O
,	O
and	O
200	O
nm	O
for	O
24	O
h	O
,	O
and	O
follicle	B-C0018120
development	B-C0243107
,	O
hormone	B-C0312431
secretion	I-C0312431
,	O
and	O
oocyte	B-C1160520
maturation	I-C1160520
were	O
analyzed	O
.	O
	
dox	B-C0013089
caused	O
dose-dependent	B-C1512045
toxicity	B-C0600688
on	O
follicle	B-C1155902
growth	I-C1155902
,	O
survival	B-C0220921
,	O
and	O
secretion	B-C0312431
of	O
17β-estradiol	B-C0014912
e2	B-C0014912
.	O
	
at	O
200	O
nm	O
,	O
dox	B-C0013089
induced	B-C0205263
dna	B-C0012860
damage	I-C0012860
and	O
apoptosis	B-C0162638
in	O
follicle	B-C0018120
somatic	B-C1257909
cells	I-C1257909
first	O
and	O
then	O
in	O
oocytes	B-C0029045
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	B-C0243144
of	O
dox	B-C0013089
first	O
to	O
the	O
somatic	B-C1257909
cells	I-C1257909
followed	O
by	O
germ	B-C0017471
cells	I-C0017471
.	O
	
follicles	B-C0018120
treated	B-C1522326
with	O
dox	B-C0013089
at	O
0	O
,	O
2	O
,	O
and	O
20	O
nm	O
showed	O
similar	O
oocyte	B-C0029045
metaphase	B-C1155832
ii	I-C1155832
mii	B-C1155832
percentages	B-C0439165
after	O
in	B-C1533691
vitro	I-C1533691
oocyte	B-C1160520
maturation	I-C1160520
however	O
,	O
20	O
nm	O
dox	B-C0013089
significantly	O
increased	B-C0205217
the	O
number	O
of	O
mii	B-C1155832
oocytes	B-C0029045
with	O
abnormal	B-C0205161
spindle	B-C1166795
morphology	B-C0332437
and	O
chromosome	B-C0008633
misalignment	B-C1275957
.	O
	
in	O
an	O
effort	O
to	O
harmonize	O
the	O
in	B-C0681828
vitro	I-C0681828
study	I-C0681828
to	O
in	B-C1515655
vivo	I-C1515655
treatment	B-C1522326
,	O
dose-dependent	B-C1512045
toxicity	B-C0600688
on	O
oocyte	B-C1160520
meiotic	I-C1160520
maturation	I-C1160520
was	O
found	O
in	O
16-day-old	O
cd-1	B-C0025929
mice	I-C0025929
treated	B-C1522326
with	O
dox	B-C0013089
at	O
0	O
,	O
0.4	O
,	O
2	O
,	O
and	O
10	O
mg/kg	O
,	O
consistent	B-C0332290
with	I-C0332290
the	O
in	B-C1533691
vitro	I-C1533691
oocyte	B-C1160520
maturation	I-C1160520
outcomes	B-C1274040
.	O
	
our	O
study	B-C2603343
demonstrates	O
that	O
dox	B-C0013089
has	O
dose-dependent	B-C1512045
toxicity	B-C0600688
on	O
ovarian	B-C0018120
follicle	I-C0018120
development	B-C0243107
,	O
hormone	B-C0312431
secretion	I-C0312431
,	O
and	O
oocyte	B-C1160520
maturation	I-C1160520
,	O
which	O
are	O
three	O
key	O
factors	B-C1521761
to	O
support	O
the	O
female	B-C0278049
reproductive	I-C0278049
and	O
endocrine	B-C0678896
functions	I-C0678896
.	O
	
involvement	O
of	O
apoptotic	B-C3269135
pathways	I-C3269135
in	O
docosahexaenoic	B-C0556150
acid	I-C0556150
-induced	O
benefit	O
in	O
prostate	B-C0376358
cancer	I-C0376358
pathway-focused	O
gene	B-C1880945
expression	I-C1880945
analysis	I-C1880945
using	O
rt	B-C3179034
profile	I-C3179034
pcr	I-C3179034
array	I-C3179034
system	I-C3179034
present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	B-C3269135
pathways	I-C3269135
that	O
involved	O
in	O
docosahexaenoic	B-C0556150
acid	I-C0556150
dha	B-C0556150
apoptosis	B-C0162638
of	O
prostate	B-C0376358
cancer	I-C0376358
cells	B-C0334227
.	O
	
human	B-C0086418
prostate	B-C0376358
cancer	I-C0376358
du145	B-C0334227
cells	I-C0334227
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	B-C0016157
oil	I-C0016157
,	O
omega-3	B-C0015689
pufa	I-C0015689
dha	B-C0556150
,	O
and	O
eicosapentaenoic	B-C0000545
acid	I-C0000545
,	O
epa	B-C0000545
,	O
or	O
omega-6	B-C0133860
pufa	I-C0133860
arachidonic	B-C0003695
acid	I-C0003695
,	O
aa	B-C0003695
.	O
	
cell	B-C0007620
viability	I-C0007620
and	O
apoptosis	B-C0162638
were	O
evaluated	O
by	O
mtt	B-C2986858
assay	I-C2986858
and	O
hoechst	B-C1441607
staining	I-C1441607
.	O
	
pathway-focused	O
gene	B-C0752248
expression	I-C0752248
profiling	I-C0752248
of	O
du145	B-C0334227
cells	I-C0334227
was	O
analyzed	O
with	O
the	O
rt	O
profile	O
pcr	O
array	O
system	O
.	O
	
the	O
results	O
were	O
verified	O
by	O
real	B-C3179034
time	I-C3179034
quantitative	I-C3179034
polymerase	I-C3179034
chain	I-C3179034
reaction	I-C3179034
rt-qpcr	B-C3179034
.	O
	
aa	B-C0003695
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	B-C0007620
of	O
du145	B-C0334227
cells	I-C0334227
.	O
	
however	O
,	O
exposure	O
with	O
fish	B-C0016157
oil	I-C0016157
,	O
epa	B-C0000545
,	O
or	O
dha	B-C0556150
for	O
24	O
h	O
significantly	O
affected	O
cell	B-C0007620
viability	I-C0007620
.	O
	
the	O
growth	B-C1512773
inhibition	I-C1512773
of	O
dha	B-C0556150
was	O
more	O
pronounced	O
than	O
that	O
of	O
epa	B-C0000545
and	O
showed	O
a	O
time-dependent	O
increase	O
.	O
	
dha	B-C0556150
exposure	O
caused	O
typical	O
apoptotic	B-C1516044
characteristics	O
.	O
	
ten	O
genes	B-C0017337
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	B-C0017337
were	O
less	O
expressed	O
following	O
dha	B-C0556150
exposure	O
.	O
	
rt-qpcr	B-C3179034
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
dha	B-C0556150
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	B-C0017337
.	O
	
kegg	O
pathway	O
analysis	O
showed	O
that	O
dha	B-C0556150
may	O
induce	O
the	O
apoptosis	B-C0162638
of	O
cancer	B-C0334227
cells	I-C0334227
preferentially	O
through	O
mediating	O
p53	B-C2984306
,	O
mapk	B-C2611831
,	O
tnf	B-C1519684
,	O
pi3k/akt	B-C2984369
,	O
and	O
nf-κb	B-C1513838
signaling	I-C1513838
pathways	I-C1513838
.	O
	
our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
dha	B-C0556150
on	O
human	B-C0086418
prostate	B-C0376358
carcinoma	I-C0376358
cell	B-C0334227
line	I-C0334227
du145	I-C0334227
.	O
	
the	O
pro-apoptotic	O
effect	O
of	O
dha	B-C0556150
on	O
du145	B-C0334227
cells	I-C0334227
may	O
involve	O
mediation	O
various	O
pathways	B-C0037080
,	O
especially	O
p53	B-C2984306
,	O
mapk	B-C2611831
,	O
tnf	B-C1519684
,	O
pi3k/akt	B-C2984369
,	O
and	O
nf-κb	B-C1513838
signaling	I-C1513838
pathways	I-C1513838
.	O
	
molecular	B-C1258062
mechanisms	I-C1258062
of	O
dha	B-C0556150
on	O
apoptosis	B-C0162638
of	O
cancer	B-C0334227
cells	I-C0334227
medication	B-C2317067
reconciliation	I-C2317067
during	O
hospitalization	B-C0019993
and	O
in	O
hospital-home	B-C1254363
interface	I-C1254363
an	O
observational	B-C0035363
retrospective	I-C0035363
study	I-C0035363
medication	B-C0025115
errors	I-C0025115
are	O
one	O
of	O
the	O
leading	O
causes	O
of	O
patient	B-C3658342
harms	I-C3658342
.	O
	
medication	B-C2317067
reconciliation	I-C2317067
is	O
a	O
fundamental	O
process	O
that	O
to	O
be	O
effective	O
,	O
it	O
should	O
be	O
embraced	O
during	O
each	O
single	O
care	B-C4019071
transition	I-C4019071
.	O
	
our	O
objectives	O
were	O
to	O
investigate	B-C1292732
current	O
medication	B-C2317067
reconciliation	I-C2317067
practices	O
in	O
the	O
2	O
fondazione	B-C0019994
toscana	I-C0019994
gabriele	I-C0019994
monasterio	I-C0019994
hospitals	I-C0019994
and	O
comprehensively	O
assess	B-C0332306
the	I-C0332306
quality	I-C0332306
of	O
medication	B-C2317067
reconciliation	I-C2317067
practices	O
between	O
inpatient	B-C0021562
and	O
outpatient	B-C0029921
care	B-C1947933
by	O
analyzing	B-C0936012
the	O
medication	B-C1254363
patterns	I-C1254363
6	O
months	B-C0439231
before	O
admission	B-C0184666
,	O
during	O
hospitalization	B-C0019993
,	O
and	O
9	O
months	B-C0439231
after	O
discharge	B-C0030685
for	O
a	O
selected	O
group	O
of	O
patients	B-C0030705
with	O
cardiovascular	B-C0007222
diseases	I-C0007222
.	O
	
a	O
retrospective	B-C0035363
observational	I-C0035363
study	I-C0035363
was	O
conducted	O
in	O
the	O
cardiothoracic	B-C0587505
department	I-C0587505
of	O
the	O
fondazione	B-C0019994
toscana	I-C0019994
gabriele	I-C0019994
monasterio	I-C0019994
hospitals	I-C0019994
.	O
	
medication	B-C1553893
history	I-C1553893
was	O
reviewed	B-C1709940
for	O
all	O
the	O
patients	B-C0030705
admitted	B-C0184666
from	O
and	O
discharged	B-C0030685
to	O
the	O
community	B-C0009462
,	O
from	O
january	O
to	O
march	O
2013	O
.	O
	
patients	B-C0030705
were	O
excluded	O
if	O
they	O
had	O
less	O
than	O
4	O
drugs	B-C3687832
or	O
less	O
than	O
2	O
drugs	B-C3687832
for	O
cardiovascular	B-C0007226
system	I-C0007226
in	O
their	O
prescription	B-C3533331
list	I-C3533331
at	O
admission	B-C0184666
or	O
if	O
they	O
died	B-C4264514
during	O
follow-up	B-C1522577
.	O
	
we	O
selected	O
714	O
patients	B-C0030705
,	O
and	O
we	O
obtained	O
the	O
clinical	B-C0025102
charts	I-C0025102
and	O
all	O
drug	B-C0033081
prescriptions	I-C0033081
collected	O
during	O
patients	B-C0030705
'	O
hospitalization	B-C0019993
by	O
the	O
electronic	B-C1737029
clinical	I-C1737029
recording	I-C1737029
system	I-C1737029
.	O
	
we	O
also	O
analyzed	B-C0936012
the	O
list	B-C3533331
of	I-C3533331
prescriptions	I-C3533331
of	O
this	O
sample	O
of	O
patients	B-C0030705
,	O
from	O
6	O
months	B-C0439231
before	O
admission	B-C0184666
to	O
9	O
months	B-C0439231
after	O
discharge	B-C0030685
,	O
extracted	O
from	O
the	O
regional	B-C0282574
prescription	I-C0282574
registry	I-C0282574
.	O
	
in	O
the	O
resulting	O
sample	O
,	O
prescriptions	B-C0033081
were	O
analyzed	B-C0936012
to	O
assess	O
unintentional	B-C1283932
discrepancies	B-C1290905
.	O
	
the	O
study	B-C2603343
included	O
298	O
patients	B-C0030705
mean	O
age	B-C0001779
,	O
71.2	O
years	B-C0439234
,	O
according	O
to	O
the	O
inclusion	B-C0243161
and	I-C0243161
exclusion	I-C0243161
criteria	I-C0243161
.	O
	
among	O
14	O
prescriptions	B-C0033081
analyzed	B-C0936012
,	O
we	O
found	O
4363	O
discrepancies	B-C1290905
14.6	O
discrepancies	B-C1290905
per	O
patient	B-C0030705
.	O
	
among	O
these	O
discrepancies	B-C1290905
,	O
1310	O
were	O
classified	O
as	O
unintentional	B-C1283932
4.4	O
discrepancies	B-C1290905
per	O
patient	B-C0030705
.	O
	
among	O
unintentional	B-C1283932
discrepancies	B-C1290905
,	O
only	O
63	O
4.8	O
took	O
place	O
during	O
hospitalization	B-C0019993
.	O
	
although	O
at	O
the	O
hospital-home	B-C1254363
interface	I-C1254363
,	O
33.1	O
of	O
unintentional	B-C1283932
discrepancies	B-C1290905
were	O
detected	O
through	O
the	O
comparison	B-C1707455
between	O
the	O
patients	B-C0030705
'	O
declared	O
therapy	B-C0039798
and	O
the	O
previous	O
medication	B-C1254363
consumption	I-C1254363
and	O
62.1	O
were	O
identified	O
in	O
the	O
comparison	B-C1707455
between	O
the	O
prescription	B-C0033081
at	O
the	O
discharge	B-C0030685
and	O
the	O
following	O
medication	B-C1254363
pattern	I-C1254363
at	O
home	B-C0442519
.	O
	
medication	B-C0025115
errors	I-C0025115
have	O
important	O
implications	O
for	O
patient	B-C1113679
safety	I-C1113679
,	O
and	O
their	O
identification	O
is	O
a	O
main	O
target	O
for	O
improving	O
clinical	B-C1254363
practice	I-C1254363
.	O
	
the	O
comparison	B-C1707455
between	O
the	O
medication	B-C1254363
patterns	I-C1254363
acquired	O
through	O
the	O
regional	B-C0282574
prescription	I-C0282574
registry	I-C0282574
before	O
and	O
after	O
hospitalization	B-C0019993
outlined	O
critical	O
touchpoint	O
in	O
the	O
current	O
medication	B-C2317067
reconciliation	I-C2317067
process	O
,	O
calling	O
for	O
the	O
definition	O
of	O
shared	O
medication	B-C2317067
reconciliation	I-C2317067
standards	O
between	O
hospitals	B-C0019994
and	O
primary	B-C0018747
care	I-C0018747
services	I-C0018747
to	O
minimize	O
medication	B-C0025115
discrepancies	I-C0025115
and	O
enhance	O
patient	B-C1113679
safety	I-C1113679
.	O
	
autologous	B-C0181074
vs	O
irradiated	B-C0181074
homologous	I-C0181074
costal	I-C0181074
cartilage	I-C0181074
as	O
graft	B-C0181074
material	I-C0181074
in	O
rhinoplasty	B-C0035467
studies	O
comparing	O
surgical	O
results	O
of	O
rhinoplasty	B-C0035467
using	O
autologous	B-C0181074
costal	I-C0181074
cartilage	I-C0181074
acc	B-C0181074
and	O
irradiated	B-C0181074
homologous	I-C0181074
costal	I-C0181074
cartilage	I-C0181074
ihcc	B-C0181074
are	O
rare	O
.	O
	
to	O
compare	O
the	O
clinical	B-C0456984
results	I-C0456984
of	O
major	O
augmentation	B-C0176371
rhinoplasty	I-C0176371
using	O
acc	B-C0181074
vs	O
ihcc	B-C0181074
and	O
analyze	O
the	O
histologic	B-C4048239
properties	I-C4048239
of	O
both	O
types	O
of	O
cartilage	B-C0007301
.	O
	
a	O
retrospective	B-C0008972
clinical	I-C0008972
study	I-C0008972
was	O
conducted	O
among	O
patients	B-C0030705
who	O
had	O
undergone	O
rhinoseptoplasty	B-C0189054
using	O
acc	B-C0181074
or	O
ihcc	B-C0181074
from	O
january	O
1	O
,	O
2009	O
,	O
to	O
december	O
31	O
,	O
2014	O
.	O
	
patients	B-C0030705
were	O
followed	B-C1522577
up	I-C1522577
for	O
more	O
than	O
1	O
year	O
after	O
surgery	B-C0543467
and	O
the	O
histologic	B-C4048239
characteristics	I-C4048239
of	O
acc	B-C0181074
and	O
ihcc	B-C0181074
were	O
compared	B-C1707455
.	O
	
the	O
details	O
of	O
the	O
surgical	B-C0543467
procedures	I-C0543467
and	O
complications	B-C0221082
,	O
including	O
warping	B-C0221082
,	O
infection	B-C3714514
,	O
resorption	B-C2985494
,	O
and/or	O
donor-site	B-C1444716
morbidity	B-C0026538
,	O
were	O
evaluated	B-C0220825
by	O
reviewing	O
medical	B-C0025102
records	I-C0025102
and	O
facial	B-C0441468
photographs	I-C0441468
.	O
	
patients	B-C0030705
'	O
subjective	B-C0439655
satisfaction	B-C0242428
with	O
aesthetic	B-C0870111
and	O
functional	B-C0205245
results	B-C1274040
was	O
evaluated	B-C0220825
using	O
a	O
questionnaire	B-C0034394
.	O
	
the	O
details	O
of	O
the	O
surgical	B-C0543467
procedures	I-C0543467
and	O
complications	B-C0221082
,	O
including	O
warping	B-C0221082
,	O
infection	B-C3714514
,	O
resorption	B-C2985494
,	O
and/or	O
donor-site	B-C1444716
morbidity	B-C0026538
patients	B-C0030705
'	O
subjective	B-C0439655
satisfaction	B-C0242428
with	O
aesthetic	B-C0870111
and	O
functional	B-C0205245
results	B-C1274040
'	O
objective	B-C1571702
evaluation	B-C1261322
of	O
surgical	B-C0543467
outcomes	B-C1274040
,	O
including	O
symmetry	B-C2825575
,	O
dorsal	B-C0205095
height	B-C0489786
,	O
dorsal	B-C0205095
length	B-C1444754
,	O
dorsal	B-C0205095
width	B-C0487742
,	O
tip	B-C0243095
projection	I-C0243095
,	O
tip	B-C0243095
rotation	I-C0243095
,	O
tip	B-C0243095
width	I-C0243095
,	O
and	O
overall	B-C1561607
result	B-C1274040
and	O
histologic	B-C0205462
structures	B-C0678594
.	O
	
objective	B-C1571702
evaluation	B-C0220825
of	O
surgical	B-C0543467
outcomes	B-C1274040
was	O
graded	O
using	O
the	O
objective	B-C1571702
rhinoplasty	B-C0035467
outcome	B-C4274403
score	I-C4274403
,	O
which	O
assessed	O
symmetry	B-C2825575
,	O
dorsal	B-C0205095
height	B-C0489786
,	O
dorsal	B-C0205095
length	B-C1444754
,	O
dorsal	B-C0205095
width	B-C0487742
,	O
tip	B-C0243095
projection	I-C0243095
,	O
tip	B-C0243095
rotation	I-C0243095
,	O
tip	B-C0243095
width	I-C0243095
,	O
and	O
overall	B-C1561607
result	B-C1274040
.	O
	
histologic	B-C4048239
structures	I-C4048239
were	O
evaluated	B-C0220825
using	O
hematoxylin	B-C0523207
and	I-C0523207
eosin	I-C0523207
,	O
masson	B-C1294297
trichrome	I-C1294297
,	O
alcian	B-C1293946
blue	I-C1293946
,	O
and	O
verhoeff	B-C1294321
elastic	I-C1294321
stains	I-C1294321
.	O
	
a	O
total	O
of	O
63	O
patients	B-C0030705
27	O
males	B-C0086582
and	O
36	O
females	B-C0086287
mean	O
sd	O
age	O
,	O
30.6	O
9.5	O
years	O
had	O
rhinoseptoplasty	B-C0189054
using	O
acc	B-C0181074
and	O
20	O
9	O
males	B-C0086582
and	O
11	O
females	B-C0086287
mean	O
sd	O
age	O
,	O
35.4	O
15.4	O
years	O
had	O
rhinoseptoplasty	B-C0189054
using	O
ihcc	B-C0181074
.	O
	
among	O
observed	B-C1441672
complications	B-C0221082
,	O
only	O
notable	B-C4288581
resorption	B-C2985494
occurred	B-C1709305
more	O
frequently	B-C0332183
in	O
patients	B-C0030705
using	O
ihcc	B-C0181074
6	O
30%	O
than	O
with	O
acc	B-C0181074
2	O
3%	O
p	O
=	O
002	O
.	O
	
in	O
subjective	B-C0439655
evaluations	B-C0220825
of	O
aesthetic	B-C0870111
satisfaction	B-C0242428
,	O
patients	B-C0030705
who	O
received	B-C1514756
acc	B-C0181074
showed	O
significantly	B-C0750502
greater	B-C1704243
satisfaction	B-C0242428
37	O
of	O
51	O
patients	B-C0030705
73%	O
were	O
very	B-C3840671
satisfied	I-C3840671
than	O
did	O
those	O
who	O
received	B-C1514756
ihcc	B-C0181074
6	O
of	O
20	O
30%	O
p	O
=	O
001	O
.	O
	
however	O
,	O
there	O
was	O
no	O
between-group	O
difference	O
in	O
subjective	B-C0439655
functional	B-C0205245
outcomes	B-C1274040
4	O
of	O
51	O
patients	B-C0030705
receiving	B-C1514756
acc	B-C0181074
8%	O
and	O
5	O
of	O
20	O
receiving	B-C1514756
ihcc	B-C0181074
25%	O
were	O
satisfied	B-C0242428
p	O
=	O
50	O
and	O
45	O
of	O
51	O
receiving	B-C1514756
acc	B-C0181074
88%	O
and	O
15	O
of	O
20	O
receiving	B-C1514756
ihcc	B-C0181074
75%	O
were	O
very	B-C3840671
satisfied	I-C3840671
p	O
=	O
15	O
.	O
	
regarding	O
objective	B-C1571702
aesthetic	B-C0870111
outcomes	B-C1274040
,	O
all	O
scores	B-C0449820
for	O
both	O
acc	B-C0181074
and	O
ihcc	B-C0181074
were	O
more	O
than	O
3.1	O
between	O
good	B-C0205170
and	O
excellent	B-C1961136
.	O
	
histologic	B-C0344441
analyses	I-C0344441
showed	O
larger	B-C0549177
,	O
more	O
evenly	O
distributed	O
,	O
uniform	B-C0205375
chondrocytes	B-C0225369
and	O
more	O
collagens	B-C0009325
and	O
proteoglycan	B-C0033692
contents	B-C1550605
in	O
acc	B-C0181074
than	O
in	O
ihcc	B-C0181074
.	O
	
compared	B-C1707455
with	O
patients	B-C0030705
receiving	B-C1514756
ihcc	B-C0181074
,	O
those	O
receiving	B-C1514756
acc	B-C0181074
for	O
rhinoseptoplasty	B-C0189054
showed	O
superior	B-C0205250
aesthetic	B-C0870111
satisfaction	B-C0242428
acc	B-C0181074
also	O
had	O
less	B-C0547044
frequent	B-C0332183
notable	B-C4288581
resorption	B-C2985494
.	O
	
autologous	B-C0181074
costal	I-C0181074
cartilage	I-C0181074
also	O
had	O
better	B-C0332272
histologic	B-C4048239
properties	I-C4048239
than	O
ihcc	B-C0181074
did	O
,	O
suggesting	O
it	O
as	O
an	O
ideal	B-C1512612
graft	B-C0181074
material	I-C0181074
with	O
less	B-C0547044
chance	B-C0237506
of	O
long-term	B-C0443252
resorption	B-C2985494
.	O
	
testing	O
the	O
ret	B-C0694890
and	O
sema3d	B-C1419945
genetic	B-C0596610
interaction	I-C0596610
in	O
mouse	B-C0025929
enteric	B-C1522995
nervous	I-C1522995
system	I-C1522995
development	I-C1522995
for	O
most	O
multigenic	B-C0567439
disorders	I-C0567439
,	O
clinical	B-C1280464
manifestation	I-C1280464
penetrance	B-C0524899
and	O
presentation	B-C0449450
expressivity	B-C0449450
are	O
likely	O
to	O
be	O
an	O
outcome	B-C1274040
of	O
genetic	B-C0596610
interaction	I-C0596610
between	O
multiple	O
susceptibility	B-C0919542
genes	I-C0919542
.	O
	
here	O
,	O
using	O
gene	B-C0814039
knockouts	I-C0814039
in	O
mice	B-C0025929
we	O
evaluated	O
genetic	B-C0596610
interaction	I-C0596610
between	O
loss	O
of	O
ret	B-C0694890
and	O
loss	O
of	O
sema3d	B-C1419945
,	O
two	O
hirschsprung	B-C0019569
disease	I-C0019569
susceptibility	B-C0919542
genes	I-C0919542
.	O
	
we	O
intercrossed	O
ret	B-C0694890
and	O
sema3d	B-C1419945
double	O
null	O
heterozygotes	O
to	O
generate	B-C0205245
mice	I-C0205245
with	O
the	O
nine	O
possible	O
genotypes	B-C0017431
and	O
assessed	B-C1516048
survival	I-C1516048
by	O
counting	B-C1285573
various	I-C1285573
genotypes	I-C1285573
,	O
myenteric	B-C0027028
plexus	I-C0027028
presence	O
by	O
acetylcholinesterase	B-C0201829
staining	I-C0201829
and	O
embryonic	B-C0815083
day	I-C0815083
12.5	I-C0815083
e12.5	B-C0815083
intestine	B-C3178810
transcriptome	I-C3178810
by	O
rna-sequencing	B-C0162327
.	O
	
survival	B-C0038954
rates	I-C0038954
of	O
ret	B-C0694890
wildtype	B-C0694890
,	O
null	O
heterozygote	O
and	O
null	O
homozygote	O
mice	B-C0025929
at	O
e12.5	B-C0815083
,	O
birth	B-C0005615
and	O
weaning	B-C0043084
were	O
not	O
influenced	O
by	O
the	O
genotypes	B-C0017431
at	O
sema3d	B-C1419945
locus	B-C1708726
and	O
vice-versa	O
.	O
	
loss	O
of	O
myenteric	B-C0027028
plexus	I-C0027028
was	O
observed	O
only	O
in	O
all	O
ret	B-C0694890
null	O
homozygotes	O
,	O
irrespective	O
of	O
the	O
genotypes	B-C0017431
at	O
sema3d	B-C1419945
locus	B-C1708726
,	O
and	O
sema3d	B-C1419945
null	O
heterozygote	B-C0019425
and	O
homozygote	B-C0019904
mice	I-C0019904
had	O
normal	O
intestinal	B-C1619351
innervation	I-C1619351
.	O
	
as	O
compared	O
to	O
wildtype	B-C1883559
mice	I-C1883559
intestinal	I-C1883559
gene	B-C0017262
expression	I-C0017262
,	O
loss	O
of	O
ret	B-C0694890
in	O
null	O
homozygotes	O
led	O
to	O
differential	O
expression	B-C0017262
of	I-C0017262
300	I-C0017262
genes	I-C0017262
,	O
whereas	O
loss	O
of	O
sema3d	B-C1419945
in	O
null	O
homozygotes	O
had	O
no	B-C0332125
major	O
consequence	O
and	O
there	O
was	O
no	O
evidence	I-C0332125
supporting	O
major	O
interaction	B-C0596610
between	I-C0596610
the	I-C0596610
two	I-C0596610
genes	I-C0596610
influencing	O
intestine	B-C3178810
transcriptome	I-C3178810
.	O
	
overall	O
,	O
given	O
the	O
null	B-C2985437
alleles	I-C2985437
and	O
phenotypic	B-C1285572
assays	I-C1285572
used	O
,	O
we	O
did	O
not	B-C0332125
find	I-C0332125
evidence	I-C0332125
for	O
genetic	B-C0596610
interaction	I-C0596610
between	O
ret	B-C0694890
and	O
sema3d	B-C1419945
affecting	O
survival	O
,	O
presence	O
of	O
myenteric	B-C0027028
plexus	I-C0027028
or	O
intestine	B-C3178810
transcriptome	I-C3178810
.	O
	
pembrolizumab	B-C3658706
for	O
the	O
treatment	B-C0087111
of	O
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
in	O
the	O
last	O
years	O
,	O
a	O
spectacular	O
development	B-C1527148
of	O
immunotherapeutic	B-C0876248
agents	I-C0876248
aimed	O
at	O
the	O
pd-1	B-C2986635
/	O
pd-l1	B-C4300350
axis	O
has	O
taken	O
place	O
.	O
	
this	O
development	B-C1527148
of	O
these	O
checkpoint	B-C0243077
inhibitors	I-C0243077
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	B-C0087111
of	O
lung	B-C0242379
cancer	I-C0242379
in	O
first	B-C1708063
and	O
second	B-C1710038
line	I-C1710038
.	O
	
the	O
limited	B-C0439801
toxicity	B-C0013221
profile	O
and	O
the	O
ability	O
to	O
treat	B-C0087111
for	O
prolonged	B-C0439590
periods	B-C1948053
,	O
even	O
in	O
smokers	B-C0337664
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	B-C0259990
.	O
	
areas	O
covered	O
this	O
review	B-C0282443
highlights	O
the	O
results	B-C1274040
of	O
recent	O
clinical	B-C0008976
trials	I-C0008976
on	O
pembrolizumab	B-C3658706
for	O
the	O
treatment	B-C0087111
of	O
non-small	B-C0007131
cell	I-C0007131
lung	I-C0007131
cancer	I-C0007131
.	O
	
the	O
authors	B-C3812881
discuss	O
both	O
first	B-C1708063
and	O
second	B-C1710038
line	I-C1710038
treatment	I-C1710038
with	O
pembrolizumab	B-C3658706
as	O
monotherapy	B-C0087111
and	O
in	O
combination	B-C0013218
therapies	I-C0013218
.	O
	
additionally	O
,	O
implications	O
of	O
the	O
pd-l1	B-C4300350
immunohistochemistry	B-C0020980
assay	I-C0020980
with	O
the	O
22c3	B-C0003241
antibody	I-C0003241
and	O
its	O
use	B-C0457083
in	O
clinical	B-C0008967
practice	I-C0008967
and	O
trials	B-C0008976
is	O
discussed	O
.	O
	
expert	O
commentary	O
a	O
higher	B-C0205250
overall	B-C3272903
response	I-C3272903
,	O
overall	B-C4086681
survival	I-C4086681
and	O
a	O
moderate	B-C0205081
toxicity	B-C0013221
profile	O
is	O
observed	O
with	O
the	O
use	B-C0457083
of	O
pembrolizumab	B-C3658706
,	O
compared	O
to	O
chemotherapy	B-C3665472
,	O
in	O
both	O
first	B-C1708063
and	O
second	B-C1710038
line	I-C1710038
.	O
	
these	O
promising	O
results	B-C1274040
have	O
already	O
translated	O
into	O
the	O
registration	B-C1514821
of	O
pembrolizumab	B-C3658706
in	O
first	B-C1708063
and	O
second	B-C1710038
line	I-C1710038
in	O
patients	B-C0030705
with	O
a	O
high	B-C0205250
expression	B-C1171362
of	O
pd-l1	B-C4300350
.	O
	
however	O
,	O
as	O
pd-l1	B-C4300350
staining	B-C0487602
does	O
not	O
sufficiently	O
discriminate	O
responders	B-C0919876
from	O
non-responders	B-C0919875
for	O
all	O
checkpoint	B-C0243077
inhibitors	I-C0243077
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	B-C0681890
biomarker	B-C0005516
.	O
	
synchronisms	B-C0439580
between	O
bud	B-C2700462
and	O
cambium	B-C2339480
phenology	B-C0205556
in	O
black	B-C0996604
spruce	I-C0996604
early	B-C1279919
-	O
flushing	B-C1882955
provenances	B-C1709753
exhibit	O
early	B-C1279919
xylem	B-C1720877
formation	B-C1522492
bud	B-C2700462
and	O
cambial	B-C2339480
phenology	B-C0205556
represent	B-C1882932
the	O
adaptation	B-C0392673
of	O
species	B-C1705920
to	O
the	O
local	B-C0205276
environment	B-C0014406
that	O
allows	O
the	O
growing	B-C0036497
season	I-C0036497
to	O
be	O
maximized	B-C0442805
while	O
minimizing	B-C0392756
the	O
risk	B-C0035647
of	O
frost	B-C0020746
for	O
the	O
developing	B-C1527148
tissues	B-C1514137
.	O
	
the	O
temporal	B-C2362314
relationship	B-C0439849
between	O
the	O
apical	B-C0205111
and	O
radial	B-C0442038
meristems	B-C0242728
can	O
help	O
in	O
the	O
understanding	O
of	O
tree	B-C0040811
growth	B-C0018270
as	O
a	O
whole	O
process	O
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
cambial	O
phenology	O
in	O
black	O
spruce	O
picea	O
mariana	O
mill	O
b.s	O
provenances	O
classified	O
as	O
early	O
and	O
late	O
bud	O
flushing	O
.	O
	
the	O
different	O
phases	O
of	O
cambial	O
phenology	O
were	O
assessed	O
on	O
wood	O
microcores	O
sampled	O
weekly	O
from	O
april	O
to	O
october	O
in	O
2014	O
and	O
2015	O
from	O
61	O
trees	O
growing	O
in	O
a	O
provenance	O
trial	O
in	O
quebec	O
,	O
canada	O
.	O
	
trees	O
showing	O
an	O
early	O
bud	O
flush	O
also	O
exhibited	O
early	O
reactivation	O
of	O
xylem	O
differentiation	O
,	O
although	O
an	O
average	O
difference	O
of	O
12	O
days	O
for	O
buds	O
corresponded	O
to	O
small	O
although	O
significant	O
differences	O
of	O
4	O
days	O
for	O
xylem	O
.	O
	
provenances	O
with	O
early	O
bud	O
flush	O
had	O
an	O
early	O
bud	O
set	O
and	O
completed	O
xylem	O
formation	O
earlier	O
than	O
late	O
bud	O
flush	O
provenances	O
.	O
	
no	O
significant	O
difference	O
in	O
the	O
period	O
of	O
xylem	O
formation	O
and	O
total	O
growth	B-C0018270
was	O
observed	O
between	O
the	O
flushing	O
classes	O
.	O
	
our	O
results	O
demonstrate	O
that	O
the	O
ecotype	O
differentiation	O
of	O
black	O
spruce	O
provenances	O
represented	O
by	O
the	O
phenological	O
adaptation	O
of	O
buds	O
to	O
the	O
local	O
climate	O
corresponds	O
to	O
specific	O
growth	O
dynamics	O
of	O
the	O
xylem	B-C1720877
an	O
approach	O
for	O
liposome	B-C0023828
immobilization	B-C0020944
using	O
sterically	B-C0205556
stabilized	I-C0205556
micelles	B-C0025938
ssms	B-C0025938
as	O
a	O
precursor	B-C1709634
for	O
bio-layer	B-C0021730
interferometry	I-C0021730
-	O
based	B-C1527178
interaction	B-C1704675
studies	B-C2603343
non-fluidic	B-C0205556
bio-layer	B-C0021730
interferometry	I-C0021730
bli	B-C0021730
has	O
rapidly	B-C0456962
become	O
a	O
standard	B-C1442989
tool	O
for	O
monitoring	B-C0005517
almost	O
all	O
biomolecular	B-C0205556
interactions	B-C1704675
in	O
a	O
label-free	B-C0205556
,	O
real-time	B-C1550177
and	O
high-throughput	B-C0205556
manner	O
.	O
	
high	B-C0205250
-	O
efficiency	B-C0013682
screening	B-C0022885
methods	I-C0022885
which	O
measure	B-C0079809
the	O
kinetics	B-C0022702
of	O
liposomes	B-C0023828
with	O
a	O
variety	B-C2346866
of	O
compounds	B-C1706082
require	O
the	O
immobilization	B-C0020944
of	O
liposomes	B-C0023828
.	O
	
in	O
this	O
work	O
,	O
a	O
method	B-C0449851
is	O
described	B-C1552738
for	O
immobilizing	B-C0020944
liposomes	B-C0023828
for	O
interaction	B-C1704675
studies	B-C2603343
,	O
based	B-C1527178
on	O
the	O
biophysical	B-C2350452
principles	I-C2350452
of	O
this	O
biosensor	B-C0600364
platform	B-C1710360
.	O
	
the	O
immobilization	B-C0020944
approach	O
includes	B-C0332257
the	O
loading	B-C1708715
of	O
dspe-peg	B-C0664515
-	O
biotin	B-C0005575
containing	O
sterically	B-C0205556
stabilized	I-C0205556
micelles	B-C0025938
ssms	B-C0025938
which	O
are	O
restructured	B-C0205556
in	O
a	O
buffer	B-C0205556
change	I-C0205556
step	O
,	O
resulting	B-C0332294
in	I-C0332294
an	O
accessible	O
substrate	B-C3891814
for	O
liposome	B-C0023828
immobilization	B-C0020944
.	O
	
liposomes	B-C0023828
in	O
a	O
concentration	B-C1446561
of	O
5mm	O
of	O
varying	O
composition	B-C0486616
and	O
fluidity	B-C0596579
were	O
immobilized	B-C0020944
on	O
the	O
sensor	B-C0600364
surface	B-C0205148
by	O
inserting	O
the	O
hydrophobic	B-C0598629
residues	B-C1709915
of	O
the	O
former	B-C0205156
loaded	O
ssms	B-C0025938
.	O
	
this	O
proof	O
of	O
principle	O
was	O
carried	O
out	O
using	O
cytochrome	B-C0010749
c	I-C0010749
as	O
a	O
membrane-interacting	B-C0205556
model	O
protein	B-C0033684
.	O
	
the	O
binding	B-C0033618
of	O
cytochrome	B-C0010749
c	I-C0010749
to	O
the	O
immobilized	B-C0020944
liposomes	B-C0023828
was	O
demonstrated	O
,	O
and	O
the	O
derived	O
kinetic	B-C0022702
and	O
affinity	B-C1510827
constants	B-C1547014
were	O
similar	B-C2348205
to	O
values	B-C0042295
given	O
in	O
the	O
literature	B-C0023866
.	O
	
in	O
order	O
to	O
obtain	O
a	O
detailed	B-C1522508
understanding	B-C0162340
of	O
this	O
surface	B-C0205148
,	O
and	O
to	O
show	O
the	O
integrity	B-C1947912
of	O
the	O
liposomes	B-C0023828
,	O
confocal	B-C0026022
fluorescence	I-C0026022
microscopy	I-C0026022
was	O
used	O
.	O
	
images	O
of	O
immobilized	B-C0020944
liposomes	B-C0023828
containing	B-C0332256
calcein	B-C0060549
in	O
the	O
aqueous	B-C0599956
core	B-C0444669
indicated	B-C1444656
intact	B-C0205266
vesicles	B-C1622418
.	O
	
a	O
combination	B-C0205195
of	O
this	O
simple	O
liposome	B-C0023828
immobilization	B-C0020944
approach	O
,	O
the	O
possibility	O
of	O
automation	B-C0004376
on	O
bli	B-C0021730
systems	B-C0449913
with	O
high	B-C0205556
throughput	I-C0205556
within	O
an	O
acceptable	B-C1879533
timescale	O
and	O
excellent	B-C1961136
reproducibility	B-C1514863
makes	O
this	O
assay	B-C0005507
suitable	B-C3900053
for	O
basic	O
research	B-C0035168
as	O
well	O
as	O
for	O
industrial	B-C0868973
and	O
regulatory	B-C2347934
applications	I-C2347934
.	O
	
exercise	B-C0015259
increases	B-C0205217
lactoferrin	B-C0022942
,	O
but	O
decreases	B-C0547047
lysozyme	B-C0026794
in	O
salivary	B-C0442040
granulocytes	B-C0018183
intracellular	B-C0022942
lactoferrin	I-C0022942
lac	B-C0022942
and	O
lysozyme	B-C0026794
lys	B-C0026794
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	B-C0021368
and	O
promoting	B-C0033414
host	B-C0524828
protection	I-C0524828
.	O
	
while	O
exercise	B-C0015259
has	O
demonstrated	O
an	O
increase	B-C0205217
in	O
lac	B-C0022942
and	O
lys	B-C0026794
concentration	B-C1446561
in	O
exocrine	B-C0504082
solutions	I-C0504082
,	O
little	O
is	O
known	O
regarding	O
intracellular	B-C1446561
concentration	I-C1446561
changes	I-C1446561
in	O
response	O
to	O
exercise	B-C0015259
.	O
	
to	O
quantify	B-C1709793
intracellular	O
lac	B-C0022942
and	O
lys	B-C0026794
concentration	B-C1446561
before	O
and	O
after	O
exercise	B-C0015259
in	O
salivary	B-C0442040
cd45	B-C0018183
cells	I-C0018183
.	O
	
11	O
males	B-C0086582
20.3	O
0.8	O
years	B-C0439234
,	O
57.2	O
7.6	O
ml/kg/min	O
v	B-C0392762
,	O
11.1	O
3.9	O
body	B-C0344335
fat	I-C0344335
ran	B-C0035953
for	O
45	O
min	B-C0439232
at	O
75%	O
of	O
vo2pk	B-C0392762
.	O
	
12	O
ml	O
of	O
stimulated	B-C0036087
saliva	I-C0036087
were	O
collected	B-C1516698
pre	B-C1439922
and	O
immediately	O
post	B-C1979962
exercise	I-C1979962
.	O
	
saliva	B-C0036087
was	O
filtered	O
through	O
a	O
30-µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	B-C0023516
cd45	B-C0023516
and	O
granulocytes	B-C0018183
cd45	B-C0018183
using	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
median	B-C0392762
fluorescent	I-C0392762
intensity	I-C0392762
mfi	B-C0392762
of	O
lac	B-C0022942
increased	B-C0205217
from	O
pre	B-C1439922
64	O
46	O
mfi	B-C0392762
to	O
post	B-C1979962
117	O
88	O
mfi	B-C0392762
exercise	B-C0015259
p	O
<0	O
.	O
	
lys	B-C0026794
mfi	B-C0392762
decreased	B-C0205216
with	O
exercise	B-C0015259
pre	B-C1439922
16	O
8249	O
post	B-C1439922
11	O
6875	O
p	O
<0	O
.	O
	
acute	B-C0035953
running	I-C0035953
resulted	O
in	O
an	O
increased	B-C0205217
lac	B-C0022942
concentration	B-C1446561
which	O
could	O
lead	O
to	O
a	O
decrease	B-C0205216
in	O
inflammation	B-C0021368
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti-inflammatory	B-C1515999
effects	I-C1515999
of	O
exercise	B-C0015259
.	O
	
conversely	O
,	O
the	O
exercise	B-C0015259
-associated	O
decrease	B-C0547047
of	O
intracellular	B-C0026794
lys	I-C0026794
content	O
could	O
be	O
the	O
cause	B-C0015127
of	O
increased	B-C0205217
lys	B-C0026794
in	O
exocrine	B-C0504082
solutions	I-C0504082
.	O
	
chronic	B-C0598391
enzyme	I-C0598391
replacement	I-C0598391
to	O
the	O
brain	B-C0006104
of	O
a	O
late	B-C0022340
infantile	I-C0022340
neuronal	I-C0022340
ceroid	I-C0022340
lipofuscinosis	I-C0022340
mouse	B-C0025929
has	O
differential	O
effects	B-C1280500
on	O
phenotypes	B-C0031437
of	O
disease	B-C0012634
late	B-C0022340
infantile	I-C0022340
neuronal	I-C0022340
ceroid	I-C0022340
lipofuscinosis	I-C0022340
lincl	B-C0022340
is	O
a	O
fatal	B-C1302234
inherited	O
neurodegenerative	B-C0524851
disease	I-C0524851
caused	O
by	O
loss	O
of	O
lysosomal	B-C1430948
protease	I-C1430948
tripeptidyl	I-C1430948
peptidase	I-C1430948
1	I-C1430948
tpp1	B-C1430948
.	O
	
we	O
have	O
investigated	O
the	O
effects	B-C1280500
of	O
chronic	B-C0677897
intrathecal	I-C0677897
it	I-C0677897
administration	I-C0677897
using	O
enzyme	B-C0598391
replacement	I-C0598391
therapy	I-C0598391
ert	B-C0598391
to	O
the	O
brain	B-C0006104
of	O
an	O
lincl	B-C0022340
mouse	B-C2986594
model	I-C2986594
,	O
in	O
which	O
locomotor	B-C0234130
function	I-C0234130
declines	O
dramatically	O
prior	O
to	O
early	B-C1836407
death	I-C1836407
.	O
	
median	O
lifespan	B-C0870809
was	O
significantly	O
extended	O
from	O
126	O
days	B-C0439228
to	O
>259	O
days	B-C0439228
when	O
chronic	B-C1831734
it	I-C1831734
treatment	I-C1831734
was	O
initiated	O
before	O
the	O
onset	B-C0449244
of	O
disease	B-C0012634
.	O
	
while	O
treated	O
animals	B-C0003062
lived	O
longer	O
and	O
showed	O
little	O
sign	O
of	O
locomotor	B-C0521654
dysfunction	I-C0521654
as	O
measured	O
by	O
stride	O
length	O
,	O
some	O
or	O
all	O
depending	O
on	O
regimen	O
still	O
died	B-C0011065
prematurely	O
.	O
	
one	O
explanation	O
is	O
that	O
cerebrospinal	B-C0007806
fluid	I-C0007806
csf	B-C0007806
delivery	B-C1705822
may	O
not	O
deliver	B-C1705822
tpp1	B-C1530775
to	O
all	O
brain	B-C1273723
regions	I-C1273723
.	O
	
morphological	B-C0543482
studies	B-C2603343
support	O
this	O
,	O
showing	O
delivery	B-C1705822
of	O
tpp1	B-C1530775
to	O
ventral	B-C1273723
,	O
but	O
not	O
deeper	O
and	O
dorsal	B-C1273723
regions	I-C1273723
.	O
	
when	O
it	B-C1831734
treatment	I-C1831734
is	O
initiated	O
in	O
severely	B-C0205082
affected	B-C0392760
lincl	B-C0022340
mice	B-C0025929
,	O
lifespan	B-C0870809
was	O
extended	O
modestly	O
in	O
most	O
but	O
dramatically	O
extended	O
in	O
approximately	O
one-third	O
of	O
the	O
cohort	B-C0599755
.	O
	
treatment	B-C1522326
improved	O
locomotor	B-C0234130
function	I-C0234130
in	O
these	O
severely	O
compromised	O
animals	B-C0003062
after	O
it	O
had	O
declined	O
to	O
the	O
point	O
at	O
which	O
animals	B-C0003062
normally	O
die	B-C0011065
.	O
	
this	O
indicates	O
that	O
some	O
pathology	B-C0677042
in	O
lincl	B-C0022340
is	O
reversible	B-C0205343
and	O
does	O
not	O
simply	O
reflect	O
neuronal	B-C2754100
death	I-C2754100
.	O
	
5-bromo-2-aryl	B-C0005050
benzimidazole	I-C0005050
derivatives	I-C0005050
as	O
non-cytotoxic	B-C2827065
potential	B-C3245505
dual	O
inhibitors	B-C0014432
of	O
α-glucosidase	B-C0002272
and	O
urease	B-C0041945
enzymes	I-C0041945
on	O
the	O
basis	O
of	O
previous	O
report	B-C0684224
on	O
promising	O
α-glucosidase	B-C0002272
inhibitory	B-C1152555
activity	I-C1152555
of	O
5-bromo-2-aryl	B-C0005050
benzimidazole	I-C0005050
derivatives	I-C0005050
,	O
these	O
derivatives	O
were	O
further	O
screened	B-C0373483
for	O
urease	B-C0041945
inhibitory	B-C1152555
and	O
cytotoxicity	B-C0201622
activity	I-C0201622
in	O
order	O
to	O
get	O
more	B-C3245505
potent	I-C3245505
and	O
non-cytotoxic	B-C2827065
potential	B-C3245505
dual	O
inhibitor	B-C0014432
for	O
the	O
patients	B-C0030705
suffering	O
from	O
diabetes	B-C0011847
as	O
well	O
as	O
peptic	B-C0030920
ulcer	I-C0030920
.	O
	
in	O
this	O
study	B-C2603343
,	O
all	O
compounds	B-C1254351
showed	O
varying	O
degree	B-C0678792
of	I-C0678792
potency	I-C0678792
in	O
the	O
range	O
of	O
ic50	B-C0600495
=8	O
as	O
compared	O
to	O
standard	B-C0034925
thiourea	B-C0039958
ic50	B-C0600495
=21	O
.	O
	
it	O
is	O
worth	O
mentioning	O
that	O
derivatives	B-C1254351
7	I-C1254351
ic50	B-C0600495
=12	O
,	O
8	B-C1254351
ic50	B-C0600495
=10	O
,	O
11	B-C1254351
ic50	B-C0600495
=13	O
,	O
14	B-C1254351
ic50	B-C0600495
=15	O
and	O
22	B-C1254351
ic50	B-C0600495
=8	O
were	O
found	O
to	O
be	O
more	O
potent	B-C0014432
inhibitors	I-C0014432
than	O
standard	B-C0034925
.	O
	
all	O
compounds	B-C1254351
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-C0201622
towards	O
3t3	B-C0085087
mouse	B-C1513528
fibroblast	I-C1513528
cell	I-C1513528
line	I-C1513528
and	O
found	O
to	O
be	O
completely	O
non-toxic	B-C0243095
.	O
	
previously	O
benzimidazole	B-C0005050
1-25	I-C0005050
were	O
also	O
showed	O
α-glucosidase	B-C0002272
inhibitory	B-C1152555
potential	I-C1152555
.	O
	
in	B-C3489666
silico	I-C3489666
studies	B-C2603343
were	O
performed	O
on	O
the	O
lead	B-C1254351
molecules	I-C1254351
i.e	O
.	O
	
2	B-C1254351
,	O
7	B-C1254351
,	O
8	B-C1254351
,	O
11	B-C1254351
,	O
14	B-C1254351
,	O
and	O
22	B-C1254351
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding	B-C0687133
interaction	I-C0687133
of	O
compounds	B-C1254351
with	O
the	O
active	B-C0205681
site	I-C0205681
of	O
urease	B-C0041945
enzyme	I-C0041945
.	O
	
intra-articular	B-C0442108
implantation	B-C0021107
of	O
collagen	B-C0009325
scaffold	B-C0337143
carriers	B-C0025080
is	O
safe	B-C0557723
in	O
both	O
native	B-C0302891
and	O
arthrofibrotic	B-C1142253
rabbit	B-C3887509
knee	B-C0022745
joints	I-C0022745
sustained	B-C0443318
intra-articular	B-C0442108
delivery	B-C3850077
of	I-C3850077
pharmacological	I-C3850077
agents	I-C3850077
is	O
an	O
attractive	B-C2346874
modality	B-C0695347
but	O
requires	O
use	B-C0457083
of	O
a	O
safe	B-C0557723
carrier	B-C0025080
that	O
would	O
not	O
induce	B-C0205263
cartilage	B-C0549421
damage	I-C0549421
or	O
fibrosis	B-C0016059
.	O
	
collagen	B-C0009325
scaffolds	B-C0337143
are	O
widely	O
available	B-C0470187
and	O
could	O
be	O
used	O
intra-articularly	B-C0442108
,	O
but	O
no	O
investigation	B-C0220825
has	O
looked	O
at	O
the	O
safety	B-C0036043
of	O
collagen	B-C0009325
scaffolds	B-C0337143
within	O
synovial	B-C0224507
joints	I-C0224507
.	O
	
the	O
aim	B-C1947946
of	O
this	O
study	B-C2603343
was	O
to	O
determine	B-C0205258
the	O
safety	B-C0036043
of	O
collagen	B-C0009325
scaffold	B-C0337143
implantation	B-C0021107
in	O
a	O
validated	B-C1519941
in	B-C1515655
vivo	I-C1515655
animal	B-C0003062
model	O
of	O
knee	B-C1142253
arthrofibrosis	I-C1142253
.	O
	
a	O
total	O
of	O
96	O
rabbits	B-C3887509
were	O
randomly	B-C0439605
and	O
equally	B-C0205163
assigned	B-C1516050
to	O
four	O
different	B-C1705242
groups	B-C0441833
arthrotomy	B-C0185160
alone	O
arthrotomy	B-C0185160
and	O
collagen	B-C0009325
scaffold	B-C0337143
placement	B-C0441587
contracture	B-C0009918
surgery	B-C0543467
and	O
contracture	B-C0009918
surgery	B-C0543467
and	O
collagen	B-C0009325
scaffold	B-C0337143
placement	B-C0441587
.	O
	
animals	B-C0003062
were	O
killed	B-C0162388
in	O
equal	B-C0205163
numbers	O
at	O
72	O
hours	B-C0439227
,	O
two	O
weeks	B-C0439230
,	O
eight	O
weeks	B-C0439230
,	O
and	O
24	O
weeks	B-C0439230
.	O
	
joint	B-C0009918
contracture	I-C0009918
was	O
measured	B-C0444706
,	O
and	O
cartilage	B-C0007301
and	O
synovial	B-C1550315
samples	B-C0370003
underwent	O
histological	B-C0002778
analysis	I-C0002778
.	O
	
animals	B-C0003062
that	O
underwent	O
arthrotomy	B-C0185160
had	O
equivalent	B-C0205163
joint	B-C0009918
contractures	I-C0009918
regardless	O
of	O
scaffold	B-C0337143
implantation	B-C0021107
-13	O
versus	O
-10	O
,	O
equivalence	O
limit	O
15	O
.	O
	
animals	B-C0003062
that	O
underwent	O
surgery	B-C0543467
to	O
induce	B-C0205263
contracture	B-C0009918
did	O
not	O
demonstrate	O
equivalent	B-C0205163
joint	B-C0009918
contracture	I-C0009918
s	O
with	O
41.8	O
or	O
without	O
53.9	O
collagen	O
scaffold	O
implantation	O
.	O
	
chondral	O
damage	O
occurred	O
in	O
similar	O
rates	O
with	O
11	O
of	O
48	O
and	O
without	O
nine	O
of	O
48	O
scaffold	O
implantation	O
.	O
	
no	O
significant	O
difference	O
in	O
synovitis	O
was	O
noted	O
between	O
groups	O
.	O
	
absorption	O
of	O
the	O
collagen	O
scaffold	O
occurred	O
within	O
eight	O
weeks	O
in	O
all	O
animals	O
conclusion	O
our	O
data	O
suggest	O
that	O
intra-articular	O
implantation	O
of	O
a	O
collagen	O
sponge	O
does	O
not	O
induce	O
synovitis	O
or	O
cartilage	O
damage	O
.	O
	
implantation	O
in	O
a	O
native	O
joint	B-C0009918
does	O
not	O
seem	O
to	O
induce	O
contracture	I-C0009918
.	O
	
implantation	O
of	O
the	O
collagen	O
sponge	O
in	O
a	O
rabbit	O
knee	O
model	O
of	O
contracture	O
may	O
decrease	O
the	O
severity	O
of	O
the	O
contracture	O
cite	O
this	O
article	O
j	O
.	O
	
a	O
.	O
	
walker	O
,	O
t	O
.	O
	
j	O
.	O
	
ewald	O
,	O
e	O
.	O
	
lewallen	O
,	O
a	O
.	O
	
van	O
wijnen	O
,	O
a	O
.	O
	
d	O
.	O
	
hanssen	O
,	O
b	O
.	O
	
f	O
.	O
	
morrey	O
,	O
m	O
.	O
	
e	O
.	O
	
morrey	O
,	O
m	O
.	O
	
p	O
.	O
	
abdel	O
,	O
j	O
.	O
	
sanchez-sotelo	O
.	O
	
intra-articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints	O
.	O
	
bone	O
joint	O
res	O
2016	O
.	O
	
doi	O
host	B-C1167395
immune	B-C0301872
recognition	I-C0301872
of	O
the	O
epidemic	B-C0014499
cystic	B-C0010674
fibrosis	I-C0010674
pathogen	B-C0450254
burkholderia	B-C1482113
dolosa	I-C1482113
burkholderia	B-C1482113
dolosa	I-C1482113
caused	O
an	O
outbreak	O
in	O
the	O
cystic	B-C0010674
fibrosis	I-C0010674
cf	B-C0010674
clinic	O
at	O
boston	B-C0020017
children's	I-C0020017
hospital	I-C0020017
from	O
1998	O
to	O
2005	O
and	O
led	O
to	O
the	O
infection	B-C3714514
of	O
over	O
40	O
patients	B-C0030705
,	O
many	O
of	O
whom	O
died	B-C0011065
due	O
to	O
complications	B-C0009566
from	O
infection	B-C3714514
by	O
this	O
organism	B-C1482113
.	O
	
to	O
assess	O
whether	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
significantly	O
contributes	O
to	O
disease	B-C0012634
or	O
is	O
recognized	O
by	O
the	O
host	B-C1167395
immune	B-C0301872
response	I-C0301872
,	O
mice	B-C0026809
were	O
infected	B-C0439663
with	O
a	O
sequenced	O
outbreak	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
strain	I-C1482113
,	O
au0158	B-C1482113
,	O
and	O
responses	B-C0871261
compared	O
to	O
the	O
well-studied	O
cf	B-C0010674
pathogen	B-C0450254
,	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
in	O
parallel	O
,	O
mice	B-C0026809
were	O
also	O
infected	B-C0439663
with	O
a	O
polar	O
flagellin	B-C0016192
mutant	B-C0596988
of	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
to	O
examine	O
the	O
role	O
of	O
flagella	B-C0016192
in	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
lung	B-C0024109
colonization	B-C4289767
.	O
	
the	O
results	O
showed	O
a	O
higher	B-C0205250
persistence	B-C0546816
in	O
the	O
host	B-C1167395
by	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
strains	I-C1482113
and	O
yet	O
neutrophil	B-C0027950
recruitment	O
and	O
cytokine	B-C0079189
production	B-C0005572
were	O
lower	O
compared	O
to	O
p	B-C0033809
.	O
	
aeruginosa	I-C0033809
the	O
ability	O
of	O
host	B-C1167395
immune	B-C0007634
cells	I-C0007634
to	O
recognize	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
was	O
then	O
assessed	O
and	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
induced	O
a	O
robust	O
cytokine	B-C0079189
response	O
in	O
cultured	B-C0007635
cells	I-C0007635
and	O
this	O
effect	O
was	O
dependent	O
on	O
the	O
flagella	B-C0016192
only	O
when	O
bacteria	B-C0004611
were	O
dead	B-C0011065
.	O
	
together	O
,	O
these	O
results	O
suggest	O
that	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
can	O
be	O
recognized	O
by	O
host	B-C1819995
cells	I-C1819995
in	B-C1533691
vitro	I-C1533691
but	O
may	O
avoid	O
or	O
suppress	B-C1260953
the	O
host	B-C1167395
immune	B-C0301872
response	I-C0301872
in	B-C1515655
vivo	I-C1515655
through	O
unknown	O
mechanisms	O
.	O
	
b	B-C1482113
.	O
	
dolosa	I-C1482113
was	O
then	O
compared	O
to	O
other	O
burkholderia	B-C1264855
species	I-C1264855
and	O
found	O
to	O
induce	O
similar	O
levels	O
of	O
cytokine	B-C0079189
production	B-C0005572
despite	O
being	O
internalized	O
by	O
macrophages	B-C0024432
more	O
than	O
b	B-C1187839
.	O
	
cenocepacia	I-C1187839
strains	I-C1187839
.	O
	
these	O
data	B-C1511726
suggest	O
that	O
b	B-C1482113
.	O
	
dolosa	I-C1482113
au0158	I-C1482113
may	O
act	O
differently	O
with	O
host	B-C1819995
cells	I-C1819995
and	O
is	O
it	O
recognized	O
differently	O
by	O
immune	B-C0020962
systems	I-C0020962
compared	O
other	O
burkholderia	B-C0282676
strains	I-C0282676
or	O
visualization	B-C0243095
and	O
targeting	B-C1521840
of	O
lgr5	B-C1537570
human	B-C0086418
colon	B-C0009368
cancer	B-C1956422
stem	I-C1956422
cells	I-C1956422
the	O
cancer	B-C1956422
stem	I-C1956422
cell	I-C1956422
csc	B-C1956422
theory	B-C0871935
highlights	O
a	O
self-renewing	B-C4042950
subpopulation	B-C0449560
of	O
cancer	B-C0334227
cells	I-C0334227
that	O
fuels	O
tumour	B-C0598934
growth	I-C0598934
.	O
	
the	O
existence	B-C1547035
of	O
human	B-C0086418
cscs	B-C1956422
is	O
mainly	O
supported	O
by	O
xenotransplantation	B-C0520484
of	O
prospectively	O
isolated	B-C3829491
cells	I-C3829491
,	O
but	O
their	O
clonal	B-C1522642
dynamics	B-C3826426
and	O
plasticity	B-C0678558
remain	O
unclear	O
.	O
	
here	O
,	O
we	O
show	O
that	O
human	B-C0086418
lgr5	B-C1537570
colorectal	B-C0334227
cancer	I-C0334227
cells	I-C0334227
serve	O
as	O
cscs	B-C1956422
in	O
growing	O
cancer	B-C0006826
tissues	B-C0040300
.	O
	
lineage	B-C1881379
-	O
tracing	B-C0022885
experiments	I-C0022885
with	O
a	O
tamoxifen	B-C0039286
-inducible	O
cre	B-C1744318
knock-in	B-C2350597
allele	B-C0002085
of	O
lgr5	B-C3640115
reveal	O
the	O
self-renewal	B-C4042950
and	O
differentiation	B-C0007589
capacity	B-C1516240
of	O
lgr5	B-C1537570
tumour	B-C0334227
cells	I-C0334227
.	O
	
selective	O
ablation	B-C0547070
of	O
lgr5	B-C1537570
cscs	B-C1956422
in	O
lgr5	B-C1537570
-i	O
caspase9	B-C1332668
knock-in	B-C2350597
organoids	B-C0029250
leads	O
to	O
tumour	B-C1718423
regression	I-C1718423
,	O
followed	O
by	O
tumour	B-C0598934
regrowth	I-C0598934
driven	O
by	O
re-emerging	O
lgr5	B-C1537570
cscs	B-C1956422
.	O
	
krt20	B-C1426926
knock-in	B-C2350597
reporter	B-C0206414
marks	O
differentiated	B-C0007589
cancer	B-C0334227
cells	I-C0334227
that	O
constantly	O
diminish	O
in	O
tumour	B-C0475358
tissues	I-C0475358
,	O
while	O
reverting	O
to	O
lgr5	B-C1537570
cscs	B-C1956422
and	O
contributing	O
to	O
tumour	B-C0598934
regrowth	I-C0598934
after	O
lgr5	B-C1537570
csc	B-C1956422
ablation	B-C0547070
.	O
	
we	O
also	O
show	O
that	O
combined	O
chemotherapy	B-C3665472
potentiates	O
targeting	B-C1521840
of	O
lgr5	B-C1537570
cscs	B-C1956422
.	O
	
these	O
data	B-C1511726
provide	O
insights	O
into	O
the	O
plasticity	B-C0678558
of	O
cscs	B-C1956422
and	O
their	O
potential	B-C3245505
as	O
a	O
therapeutic	B-C0302350
target	B-C1521840
in	O
human	B-C0086418
colorectal	B-C1527249
cancer	I-C1527249
.	O
	
the	O
use	O
of	O
a	O
software	B-C0037585
-	O
assisted	B-C1269765
method	B-C0025663
to	O
estimate	B-C0750572
fetal	B-C0751992
weight	I-C0751992
at	O
and	O
near	O
term	B-C0232991
using	O
magnetic	B-C0024485
resonance	I-C0024485
imaging	I-C0024485
the	O
aim	O
of	O
this	O
study	B-C2603343
was	O
to	O
apply	O
a	O
semi-automated	B-C0205554
calculation	B-C1441506
method	B-C0025663
of	O
fetal	B-C0015965
body	B-C0178521
volume	I-C0178521
and	O
,	O
thus	O
,	O
of	O
magnetic	B-C0751992
resonance-estimated	I-C0751992
fetal	I-C0751992
weight	I-C0751992
mr-efw	B-C0751992
prior	O
to	O
planned	B-C1301732
delivery	B-C0005615
and	O
to	O
evaluate	B-C0220825
whether	O
the	O
technique	B-C0449851
of	O
measurement	B-C0242485
could	O
be	O
simplified	B-C0205352
while	O
remaining	B-C1527428
accurate	B-C0443131
.	O
	
mr-efw	B-C0751992
was	O
calculated	B-C0444686
using	O
a	O
semi-automated	B-C0205554
method	B-C0025663
at	O
38.6	O
weeks	B-C0439230
of	O
gestation	B-C0032961
in	O
36	O
patients	B-C0030705
and	O
compared	O
to	O
the	O
picture	B-C0182281
archiving	I-C0182281
and	I-C0182281
communication	I-C0182281
system	I-C0182281
pacs	B-C0182281
.	O
	
per	O
patient	B-C0030705
,	O
8	O
sequences	B-C1519249
were	O
acquired	B-C0439661
with	O
a	O
slice	B-C3829566
thickness	I-C3829566
of	O
4-8	O
mm	O
and	O
an	O
intersection	B-C3887622
gap	I-C3887622
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O
	
the	O
median	B-C2939193
absolute	B-C0205344
relative	B-C0743559
errors	I-C0743559
for	O
mr-efw	B-C0751992
and	O
the	O
time	B-C0040223
of	O
planimetric	B-C0242485
measurements	I-C0242485
were	O
calculated	B-C0444686
for	O
all	O
8	O
sequences	B-C1519249
and	O
for	O
each	O
method	B-C0025663
assisted	B-C3204107
vs	O
.	O
	
pacs	B-C0182281
,	O
and	O
the	O
difference	O
between	O
the	O
methods	B-C0025663
was	O
calculated	B-C0444686
.	O
	
the	O
median	B-C2939193
delivery	O
weight	O
was	O
3	O
g	O
.	O
	
the	O
overall	O
median	B-C2939193
relative	B-C0743559
error	I-C0743559
for	O
all	O
288	O
mr-efw	B-C0751992
calculations	B-C1441506
was	O
2.4	O
using	O
the	O
semi-automated	B-C0205554
method	B-C0025663
and	O
2.2	O
for	O
the	O
pacs	B-C0182281
method	B-C0025663
.	O
	
measurements	B-C0242485
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	B-C1519249
using	O
the	O
assisted	B-C3204107
method	B-C0025663
p	O
=	O
0.313	O
or	O
the	O
pacs	B-C0182281
p	O
=	O
0.118	O
,	O
while	O
the	O
time	B-C0040223
of	O
planimetric	B-C0242485
measurement	I-C0242485
decreased	B-C0205216
significantly	O
with	O
a	O
larger	O
gap	B-C3887622
p	O
<	O
0.001	O
and	O
in	O
the	O
assisted	B-C3204107
method	B-C0025663
compared	O
to	O
the	O
pacs	B-C0182281
method	B-C0025663
p	O
<	O
0.01	O
.	O
	
our	O
simplified	B-C0205352
mr-efw	B-C0751992
measurement	B-C0242485
showed	O
a	O
dramatic	B-C0547047
decrease	I-C0547047
in	O
time	B-C0040223
of	O
planimetric	B-C0242485
measurement	I-C0242485
without	O
a	O
decrease	B-C0547047
in	O
the	O
accuracy	B-C0598285
of	O
weight	B-C0751992
estimates	B-C0681916
.	O
	
abiraterone	B-C0754011
-	O
induced	B-C0458082
rhabdomyolysis	B-C0035410
resulting	O
in	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
a	O
case	B-C0007320
report	I-C0007320
and	O
review	B-C0282441
of	I-C0282441
the	I-C0282441
literature	I-C0282441
abiraterone	B-C0754011
,	O
a	O
cyp17	B-C3160096
inhibitor	I-C3160096
,	O
blocks	O
androgen	B-C1157302
biosynthesis	I-C1157302
in	O
multiple	O
tissue	B-C0040300
types	O
.	O
	
in	O
combination	O
with	O
prednisone	B-C0032952
,	O
it	O
is	O
approved	O
as	O
a	O
first-line	B-C1708063
treatment	I-C1708063
for	O
metastatic	B-C2939420
castration-resistant	B-C1328504
prostate	I-C1328504
cancer	I-C1328504
.	O
	
we	O
present	O
a	O
case	B-C1706256
of	O
rhabdomyolysis	B-C0035410
associated	O
with	O
abiraterone	B-C0754011
therapy	B-C0087111
resulting	O
in	O
acute	B-C2609414
on	O
chronic	B-C0205191
kidney	B-C0160420
injury	I-C0160420
in	O
a	O
patient	B-C0030705
with	O
metastatic	B-C2939420
castration-resistant	B-C1328504
prostate	I-C1328504
cancer	I-C1328504
.	O
	
strict	O
monitoring	B-C1516647
should	O
be	O
employed	O
in	O
patients	B-C0030705
started	O
on	O
abiraterone	B-C0754011
who	O
have	O
additional	O
risk	B-C0035648
factors	I-C0035648
for	O
developing	O
association	B-C0439849
between	O
xrcc1	B-C1366475
and	O
ercc1	B-C1333355
single-nucleotide	B-C0752046
polymorphisms	I-C0752046
and	O
the	O
efficacy	B-C1280519
of	O
concurrent	B-C3178775
radiochemotherapy	I-C3178775
in	O
patients	B-C0030705
with	O
esophageal	B-C0279626
squamous	I-C0279626
cell	I-C0279626
carcinoma	I-C0279626
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	B-C1292732
the	O
association	B-C0439849
between	O
single-nucleotide	B-C0752046
polymorphisms	I-C0752046
snps	B-C0752046
in	O
x-ray	B-C1366475
repair	I-C1366475
cross-complementing	I-C1366475
1-399	I-C1366475
xrcc1-399	B-C1366475
or	O
excision	B-C1333355
repair	I-C1333355
cross-complementation	I-C1333355
group	I-C1333355
1-118	I-C1333355
ercc1-118	B-C1333355
and	O
the	O
short-term	B-C0443303
efficacy	B-C1280519
of	O
radiochemotherapy	B-C0436307
,	O
tumor	B-C0027627
metastasis	I-C0027627
and	O
relapse	B-C0035020
,	O
as	O
well	O
as	O
the	O
survival	B-C2919552
time	I-C2919552
in	O
patients	B-C0030705
with	O
esophageal	B-C0279626
squamous	I-C0279626
cell	I-C0279626
carcinoma	I-C0279626
escc	B-C0279626
.	O
	
taqman	B-C3179034
probe-based	I-C3179034
quantitative	I-C3179034
polymerase	I-C3179034
chain	I-C3179034
reaction	I-C3179034
qpcr	B-C3179034
was	O
conducted	O
to	O
examine	B-C0332128
the	O
levels	B-C0441889
of	O
xrcc1-399	B-C1366475
and	O
ercc1-118	B-C1333355
snps	B-C0752046
in	O
the	O
peripheral	B-C0229664
blood	I-C0229664
of	O
50	O
patients	B-C0030705
with	O
pathologically	B-C1521733
confirmed	B-C0750484
escc	B-C0279626
.	O
	
in	O
addition	O
,	O
the	O
associations	B-C0439849
between	O
different	B-C1705242
genotypes	B-C0017431
and	O
short-term	B-C0443303
therapeutic	B-C2348767
efficacy	I-C2348767
the	O
complete	B-C0677874
remission	I-C0677874
cr	B-C0677874
rate	B-C1521828
,	O
tumor	B-C0027627
metastasis	I-C0027627
and	O
relapse	B-C0035020
,	O
as	O
well	O
as	O
the	O
survival	B-C2919552
time	I-C2919552
following	O
concurrent	B-C3178775
radiochemotherapy	I-C3178775
,	O
were	O
determined	B-C0521095
.	O
	
a	O
total	O
of	O
50	O
escc	B-C0279626
patients	B-C0030705
who	O
received	O
concurrent	B-C3178775
radiochemotherapy	I-C3178775
were	O
enrolled	O
.	O
	
it	O
was	O
found	O
that	O
the	O
short-term	B-C0443303
therapeutic	B-C2348767
efficacy	I-C2348767
cr	B-C0677874
rate	B-C1521828
was	O
higher	O
in	O
the	O
group	B-C0441833
of	O
patients	B-C0030705
carrying	O
the	O
homozygous	B-C0026882
mutation	I-C0026882
of	O
xrcc1-399	B-C1366475
a	B-C0001443
/	O
a	B-C0001443
genotype	B-C0017431
than	O
in	O
the	O
group	B-C0441833
of	O
patients	B-C0030705
without	O
the	O
xrcc1-399	B-C1366475
mutation	B-C0026882
g	B-C0018330
/	O
g	B-C0018330
genotype	B-C0017431
.	O
	
in	O
addition	O
,	O
the	O
cr	B-C0677874
rate	B-C1521828
was	O
significantly	B-C4055637
increased	I-C4055637
in	O
patients	B-C0030705
carrying	O
one	O
or	O
two	O
ercc1-118	B-C1333355
c	O
alleles	B-C0002085
c	B-C0010715
/	O
c	B-C0010715
or	O
c	B-C0010715
/	O
t	B-C0040077
genotype	B-C0017431
compared	B-C1707455
with	O
patients	B-C0030705
lacking	O
the	O
c	B-C0010715
allele	B-C0002085
t	B-C0040077
/	O
t	B-C0040077
genotype	B-C0017431
.	O
	
the	O
differences	O
were	O
statistically	B-C0237881
significant	I-C0237881
a	B-C0001443
/	O
a	B-C0001443
vs	O
.	O
	
g	B-C0018330
/	O
g	B-C0018330
,	O
p=0	O
t	B-C0040077
t	B-C0040077
vs	O
.	O
	
c	B-C0010715
/	O
t	B-C0040077
+	O
c	B-C0010715
/	O
c	B-C0010715
,	O
p=0	O
.	O
	
during	O
the	O
follow-up	B-C0589120
period	I-C0589120
,	O
the	O
group	B-C0441833
of	O
patients	B-C0030705
carrying	O
the	O
homozygous	B-C0026882
mutation	I-C0026882
of	O
xrcc1-399	B-C1366475
a	B-C0001443
/	O
a	B-C0001443
genotype	B-C0017431
exhibited	O
a	O
markedly	B-C0392756
reduced	I-C0392756
risk	B-C0035647
of	O
metastasis	B-C4255448
and	O
relapse	B-C0035020
compared	B-C1707455
with	O
the	O
group	B-C0441833
of	O
patients	B-C0030705
carrying	O
non-mutated	O
xrcc1-399	B-C1366475
g	B-C0018330
/	O
g	B-C0018330
genotype	B-C0017431
p=0	O
.	O
	
by	O
contrast	O
,	O
ercc1-118	B-C1333355
snp	B-C0752046
was	O
not	O
associated	B-C0332281
with	I-C0332281
the	O
risk	B-C0035647
of	O
metastasis	B-C4255448
and	O
recurrence	B-C0034897
p>0	O
.	O
	
the	O
combined	O
results	O
of	O
univariate	B-C0683962
and	O
multivariate	B-C0034980
cox	I-C0034980
regression	I-C0034980
analysis	I-C0034980
showed	O
that	O
the	O
snp	B-C0752046
in	O
ercc1-118	B-C1333355
was	O
closely	O
associated	B-C0332281
with	I-C0332281
survival	B-C2919552
time	I-C2919552
.	O
	
the	O
mean	B-C0086595
survival	I-C0086595
time	I-C0086595
was	O
significantly	B-C0750502
prolonged	B-C0439590
in	O
patients	B-C0030705
carrying	O
1	O
or	O
2	O
c	B-C0010715
alleles	B-C0002085
c	B-C0010715
/	O
c	B-C0010715
or	O
c	B-C0010715
/	O
t	B-C0040077
genotype	B-C0017431
compared	B-C1707455
with	O
patients	B-C0030705
lacking	O
the	O
c	B-C0010715
allele	B-C0002085
t	B-C0040077
/	O
t	B-C0040077
genotype	B-C0017431
t	B-C0040077
/	O
t	B-C0040077
vs	O
.	O
	
c	B-C0010715
/	O
c	B-C0010715
,	O
hr	B-C2985465
=12	O
,	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
,	O
p<0	O
t	B-C0040077
t	B-C0040077
vs	O
.	O
	
c	B-C0010715
/	O
t	B-C0040077
+	O
c	B-C0010715
/	O
c	B-C0010715
,	O
hr	B-C2985465
=11	O
,	O
95%	O
ci	B-C0009667
=3	O
,	O
p<0	O
.	O
	
however	O
,	O
xrcc1-399	B-C1366475
snp	B-C0752046
had	O
no	B-C1301751
effect	I-C1301751
on	O
survival	B-C2919552
time	I-C2919552
p>0	O
.	O
	
xrccl-399	B-C1366475
snp	B-C0752046
was	O
associated	B-C0332281
with	I-C0332281
the	O
short-term	B-C0443303
therapeutic	B-C2348767
efficacy	I-C2348767
the	O
cr	B-C0677874
rate	B-C1521828
and	O
tumor	B-C0027627
metastasis	I-C0027627
/	O
relapse	B-C0035020
in	O
escc	B-C0279626
patients	B-C0030705
who	O
received	O
the	O
docetaxel	B-C1880380
plus	I-C1880380
cisplatin	I-C1880380
tp	I-C1880380
regimen	I-C1880380
-based	O
concurrent	B-C3178775
radiochemotherapy	I-C3178775
.	O
	
by	O
contrast	O
,	O
ercc1-118	B-C1333355
snp	B-C0752046
was	O
significantly	B-C0750502
associated	B-C0332281
with	I-C0332281
the	O
short-term	B-C0443303
therapeutic	B-C2348767
efficacy	I-C2348767
the	O
cr	B-C0677874
rate	B-C1521828
and	O
survival	B-C2919552
time	I-C2919552
in	O
escc	B-C0279626
patients	B-C0030705
who	O
received	O
tp	B-C1880380
regimen	I-C1880380
-based	O
concurrent	B-C3178775
radiochemotherapy	I-C3178775
.	O
	
ventricular	B-C0199648
pacing	I-C0199648
site	B-C1254362
separation	I-C1254362
by	O
cardiac	B-C1522601
computed	B-C0040405
tomography	I-C0040405
validation	B-C1519941
for	O
the	O
prediction	B-C0681842
of	O
clinical	B-C4055223
response	I-C4055223
to	O
cardiac	B-C1167956
resynchronization	I-C1167956
therapy	I-C1167956
cardiac	B-C1167956
resynchronization	I-C1167956
therapy	I-C1167956
crt	B-C1167956
fails	O
to	O
provide	B-C1999230
benefit	B-C0814225
in	O
up	O
to	O
one-third	O
of	O
patients	B-C0030705
.	O
	
maximizing	O
the	O
geographic	B-C1254362
separation	I-C1254362
of	O
right	B-C1254362
and	O
left	B-C1254362
ventricular	B-C0199648
pacing	I-C0199648
lead	B-C0442031
sites	I-C0442031
has	O
been	O
suggested	B-C1705535
as	O
one	O
way	O
to	O
improve	B-C0184511
response	B-C0871261
.	O
	
cardiac	B-C0202850
ct	I-C0202850
provides	B-C1999230
an	O
opportunity	B-C0683937
to	O
explore	O
3-dimensional	B-C0450363
inter-lead	B-C1254362
distance	I-C1254362
ild	B-C1254362
measures	B-C0079809
for	O
the	O
prediction	B-C0681842
of	O
crt	B-C1167956
response	B-C0871261
.	O
	
the	O
objective	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
investigate	B-C1292732
associations	B-C0439849
between	O
standardized	B-C1442989
measures	B-C0079809
of	O
ild	B-C1254362
by	O
cardiac	B-C0202850
ct	I-C0202850
and	O
echocardiographic	B-C0013516
response	B-C0871261
to	O
crt	B-C1167956
.	O
	
forty-two	O
consecutive	B-C1707491
patients	B-C0030705
undergoing	O
crt	B-C1167956
had	O
serial	O
clinical	B-C4084924
and	O
echocardiographic	B-C0013516
evaluations	B-C0220825
performed	B-C0884358
in	B-C0332287
addition	I-C0332287
to	I-C0332287
a	O
post-procedural	B-C3272301
cardiac	B-C1522601
-gated	O
ct	B-C0040405
with	O
blinded	B-C0150108
measurement	B-C0242485
of	O
direct	B-C1947931
and	O
circumferential	B-C0205113
via	O
the	O
myocardium	B-C0027061
ild	B-C1254362
measures	B-C0079809
.	O
	
clinical	B-C4055223
response	I-C4055223
to	O
crt	B-C1167956
,	O
the	O
primary	B-C0456984
clinical	I-C0456984
outcome	I-C0456984
,	O
was	O
defined	O
as	O
a	O
15%	O
reduction	B-C0392756
in	O
lvesv	B-C0080308
using	O
echocardiography	B-C0013516
at	O
6-months	O
.	O
	
the	O
mean	B-C0001779
age	I-C0001779
and	O
ejection	B-C2700378
fraction	I-C2700378
was	O
63.6	O
8.9	O
years	O
and	O
25.2	O
7.8	O
,	O
respectively	O
.	O
	
the	O
primary	B-C3274433
outcome	I-C3274433
occurred	B-C1709305
in	O
35	O
of	O
42	O
patients	B-C0030705
83%	O
.	O
	
both	O
direct	B-C1947931
and	O
circumferential	B-C0205113
ct	B-C0040405
-based	O
ild	B-C1254362
measures	B-C0079809
were	O
associated	B-C0332281
with	I-C0332281
the	O
primary	B-C3274433
outcome	I-C3274433
by	O
univariate	B-C0683962
analysis	I-C0683962
.	O
	
receiver	B-C0034772
operator	I-C0034772
characteristic	I-C0034772
analysis	B-C0936012
identified	O
circumferential	B-C0205113
ild	B-C1254362
to	O
have	O
the	O
strongest	O
predictive	B-C0681890
accuracy	B-C0443131
auc	O
0.78	O
.	O
	
inter-	B-C0021713
and	O
intra-observer	B-C0021861
reproducibility	B-C1514863
of	O
ct	B-C0040405
-derived	O
ild	B-C1254362
measures	B-C0079809
was	O
excellent	B-C1961136
.	O
	
circumferential	B-C0205113
ild	B-C1254362
measures	B-C0079809
on	O
cardiac	B-C0202850
ct	I-C0202850
are	O
predictive	B-C0681890
of	O
clinical	B-C4055223
response	I-C4055223
to	O
crt	B-C1167956
.	O
	
incorporation	B-C0243126
of	O
these	O
measures	B-C0079809
into	O
the	O
selection	B-C1707391
of	O
optimal	B-C2698651
pacing	B-C0199640
targets	B-C1521840
,	O
particularly	O
from	O
pre-procedural	B-C3272300
ct	B-C0040405
coronary	B-C3495141
vein	I-C3495141
imaging	B-C0011923
may	O
be	O
of	O
therapeutic	B-C0302350
benefit	B-C0814225
and	O
warrants	O
further	O
iodine	B-C2348268
storage	I-C2348268
and	O
metabolism	B-C0025519
of	O
mild	B-C1299392
to	I-C1299392
moderate	I-C1299392
iodine-deficient	B-C0342927
pregnant	B-C0032961
rats	B-C0034693
severe	B-C0342927
iodine	I-C0342927
deficiency	I-C0342927
during	B-C0585037
pregnancy	I-C0585037
results	I-C0585037
in	O
neurodevelopmental	B-C1535926
disorders	I-C1535926
in	O
children	B-C0008059
,	O
while	O
the	O
consequences	B-C0686907
of	I-C0686907
mild	B-C0342927
to	I-C0342927
moderate	I-C0342927
iodine	I-C0342927
deficiency	I-C0342927
mmid	B-C0342927
are	O
uncertain	B-C0087130
.	O
	
the	O
concentration	B-C0523726
of	I-C0523726
iodine	I-C0523726
in	O
the	O
thyroid	B-C0040132
is	O
the	O
most	O
accurate	O
indicator	O
of	O
iodine	B-C2348268
nutrition	I-C2348268
.	O
	
this	O
study	O
aimed	O
to	O
evaluate	O
whether	O
the	O
iodine	B-C2348268
stores	I-C2348268
in	O
the	O
thyroid	B-C0040132
cover	I-C0040132
the	O
needs	O
of	O
the	O
mother	B-C0545509
and	I-C0545509
the	I-C0545509
fetus	I-C0545509
in	O
iodine	B-C0021968
-	O
sufficient	B-C0205410
and	O
mmid	B-C0342927
conditions	O
by	O
inductively	B-C1553183
coupled	I-C1553183
plasma-mass	I-C1553183
spectrometry	I-C1553183
.	O
	
one	O
hundred	O
four-week-old	O
female	B-C0034716
wistar	I-C0034716
rats	I-C0034716
were	O
randomly	O
divided	O
into	O
mmid	B-C0342927
low	B-C3714384
iodine	I-C3714384
intake	I-C3714384
l	O
and	O
normal	B-C3840145
normal	B-C3840145
iodine	I-C3840145
intake	I-C3840145
n	O
groups	B-C0441833
.	O
	
the	O
rats	B-C0034693
were	O
fed	B-C2987508
for	I-C2987508
the	I-C2987508
next	I-C2987508
three	I-C2987508
months	I-C2987508
,	O
and	O
after	B-C0086839
pregnancy	I-C0086839
they	O
were	O
further	O
divided	B-C1515021
into	I-C1515021
two	I-C1515021
subgroups	I-C1515021
,	O
respectively	O
low	B-C2745994
iodine	I-C2745994
pregnancy	B-C0032961
lp	B-C2745994
and	O
low	B-C2745994
iodine	I-C2745994
pregnancy	B-C0032961
with	O
iodine	B-C3661599
supplement	I-C3661599
lp+	B-C3661599
,	O
and	O
normal	B-C3840145
iodine	I-C3840145
intake	I-C3840145
pregnancy	B-C0032961
np	B-C0032961
and	O
normal	B-C3840145
iodine	I-C3840145
intake	I-C3840145
pregnancy	B-C0032961
with	O
iodine	B-C3661599
supplement	I-C3661599
np+	B-C3661599
.	O
	
the	O
iodine	B-C4263590
intake	I-C4263590
of	O
pregnant	B-C0032961
rats	B-C0034693
in	O
the	O
np+	B-C3661599
and	O
lp+	B-C3661599
groups	I-C3661599
was	O
twice	O
as	O
much	O
as	O
in	O
the	O
np	B-C3840145
and	O
lp	B-C2745994
groups	I-C2745994
.	O
	
the	O
rats	B-C0034693
were	O
sacrificed	O
on	O
gestational	B-C0439671
day	I-C0439671
15	O
and	O
postnatal	B-C0443281
day	I-C0443281
7	O
.	O
	
the	O
iodine	B-C0523726
concentration	I-C0523726
in	O
the	O
thyroid	B-C0040132
of	O
the	O
maternal	B-C1858460
and	O
newborn	B-C2239178
rats	B-C0034693
,	O
maternal	B-C4064645
serum	I-C4064645
,	O
placenta	B-C0032043
,	O
and	O
amniotic	B-C0002638
fluid	I-C0002638
were	O
determined	O
by	O
inductively	B-C1553183
coupled	I-C1553183
plasma-mass	I-C1553183
spectrometry	I-C1553183
.	O
	
the	O
concentration	B-C0523726
of	I-C0523726
iodine	I-C0523726
in	O
the	O
thyroid	B-C0040132
of	O
the	O
n	B-C3840145
group	I-C3840145
was	O
significantly	B-C4055637
higher	I-C4055637
than	O
that	O
in	O
the	O
l	B-C2745994
group	I-C2745994
before	B-C3840692
pregnancy	I-C3840692
.	O
	
the	O
concentration	B-C0523726
of	I-C0523726
iodine	I-C0523726
in	O
the	O
maternal	B-C2228489
thyroids	I-C2228489
of	O
the	O
lp	B-C2745994
group	I-C2745994
decreased	O
during	B-C0585037
pregnancy	I-C0585037
,	O
whereas	O
that	O
of	O
the	O
np	B-C3840145
group	I-C3840145
did	O
not	O
change	O
significantly	O
.	O
	
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
iodine	B-C0523726
concentration	I-C0523726
in	O
the	O
thyroid	B-C0040132
of	O
mothers	B-C0026591
and	O
offspring	B-C0680063
between	O
the	O
np	B-C3840145
and	O
np+	B-C3661599
groups	I-C3661599
,	O
but	O
it	O
was	O
significant	O
between	O
lp	B-C0032961
and	O
lp+	B-C3661599
groups	I-C3661599
.	O
	
the	O
concentration	B-C0523726
of	I-C0523726
iodine	I-C0523726
in	O
amniotic	B-C0002638
fluid	I-C0002638
was	O
significantly	O
different	O
between	O
the	O
four	O
groups	B-C0441833
.	O
	
there	O
is	O
sufficient	O
iodine	B-C2348268
storage	I-C2348268
in	O
the	O
thyroid	B-C0040132
of	O
maternal	B-C1858460
rats	B-C0034693
with	O
normal	B-C4263590
iodine	I-C4263590
intake	I-C4263590
during	B-C0585037
pregnancy	I-C0585037
,	O
and	O
there	O
is	O
no	O
need	O
for	O
iodine	B-C3661575
supplementation	I-C3661575
.	O
	
however	O
,	O
iodine	B-C2348268
stores	I-C2348268
are	O
insufficient	O
in	O
rats	B-C0034693
with	O
mmid	B-C0342927
.	O
	
iodine	B-C3661575
supplementation	I-C3661575
can	O
increase	O
the	O
iodine	B-C0523726
concentration	I-C0523726
in	O
the	O
thyroid	B-C0040132
of	O
maternal	B-C1858460
rats	B-C0034693
with	O
mmid	B-C0342927
and	O
their	O
offspring	B-C0680063
,	O
as	O
well	O
as	O
in	O
the	O
amniotic	B-C0002638
fluid	I-C0002638
during	B-C0585037
pregnancy	I-C0585037
.	O
	
omega	B-C0015689
3	I-C0015689
fatty	I-C0015689
acids	I-C0015689
reduce	B-C0392756
bone	B-C0005974
resorption	I-C0005974
while	O
promoting	B-C1371285
bone	I-C1371285
generation	I-C1371285
in	O
rat	B-C0034721
apical	B-C0031030
periodontitis	I-C0031030
this	O
study	O
evaluated	B-C0220825
the	O
effects	B-C1704420
of	I-C1704420
the	O
dietary	B-C0242295
supplement	I-C0242295
omega	B-C0015689
3	I-C0015689
polyunsaturated	I-C0015689
fatty	I-C0015689
acids	I-C0015689
ω-3	B-C0015689
pufas	I-C0015689
on	O
pulp	B-C0011406
exposure	I-C0011406
-induced	O
apical	B-C0031030
periodontitis	I-C0031030
ap	B-C0031030
in	O
rats	B-C0034721
.	O
	
twenty-eight	O
male	B-C0086582
rats	B-C0034721
were	O
divided	O
into	O
groups	B-C1257890
control	O
untreated	B-C0332155
rats	B-C0034721
c	O
,	O
control	O
rats	B-C0034721
treated	B-C1522326
with	I-C1522326
ω-3	B-C0015689
pufas	I-C0015689
alone	O
c-o	O
,	O
rats	B-C0034721
with	O
pulp	B-C0011406
exposure	I-C0011406
-induced	O
ap	B-C0031030
,	O
and	O
rats	B-C0034721
with	O
pulp	B-C0011406
exposure	I-C0011406
-induced	O
ap	B-C0031030
treated	B-C1522326
with	I-C1522326
ω-3	B-C0015689
pufas	I-C0015689
ap	B-C0031030
-o	O
.	O
	
the	O
ω-3	B-C0015689
pufas	I-C0015689
were	O
administered	B-C0001563
orally	I-C0001563
,	O
once	O
a	O
day	O
,	O
for	O
15	O
days	O
before	O
pulp	B-C0011406
exposure	I-C0011406
and	O
,	O
subsequently	O
,	O
30	O
days	O
after	O
pulp	B-C0011406
exposure	I-C0011406
.	O
	
rats	B-C0034721
were	O
killed	B-C0162388
30	O
days	O
after	O
pulp	B-C0011406
exposure	I-C0011406
,	O
and	O
jaws	B-C0022359
were	O
subjected	O
to	O
histologic	B-C0681853
and	O
immunohistochemical	B-C1441616
analyses	B-C0936012
.	O
	
immunohistochemical	B-C1441616
analyses	B-C0936012
were	O
performed	O
to	O
detect	O
tartrate-resistant	B-C0297331
acid	I-C0297331
phosphatase	I-C0297331
-	O
positive	B-C1446409
osteoclasts	B-C0029431
and	O
osteocalcin	B-C0029419
-	O
positive	B-C1446409
osteoblasts	B-C0029418
on	O
the	O
bone	B-C0825429
surface	I-C0825429
of	O
periapical	B-C0729269
area	I-C0729269
.	O
	
results	O
were	O
statistically	O
evaluated	B-C0220825
by	O
using	O
analysis	B-C0002780
of	I-C0002780
variance	I-C0002780
and	O
tukey	B-C0392762
honestly	I-C0392762
significant	I-C0392762
difference	I-C0392762
,	O
and	O
p	O
<	O
05	O
was	O
considered	O
statistically	B-C0237881
significant	I-C0237881
.	O
	
the	O
bone	B-C0005974
resorption	I-C0005974
lesion	B-C0221198
was	O
significantly	B-C4055637
larger	I-C4055637
in	O
the	O
ap	B-C0031030
group	O
compared	O
with	O
ap	B-C0031030
-o	O
,	O
c	O
,	O
and	O
c-o	O
groups	B-C1257890
p	O
<	O
05	O
.	O
	
the	O
level	B-C0441889
of	O
inflammatory	B-C0302158
cell	I-C0302158
infiltration	I-C0302158
was	O
significantly	O
elevated	O
,	O
and	O
the	O
number	O
of	O
tartrate-resistant	B-C0297331
acid	I-C0297331
phosphatase	I-C0297331
-	O
positive	B-C1446409
osteoclasts	B-C0029431
was	O
significantly	B-C4055637
higher	I-C4055637
in	O
the	O
periapical	B-C0729269
lesions	B-C0221198
of	O
the	O
ap	B-C0031030
group	O
compared	O
with	O
ap	B-C0031030
-o	O
,	O
c	O
,	O
and	O
c-o	O
groups	B-C1257890
p	O
<	O
05	O
.	O
	
the	O
number	O
of	O
osteocalcin	B-C0029419
-	O
positive	B-C1446409
osteoblasts	B-C0029418
was	O
significantly	O
increased	B-C0205217
in	O
the	O
ap	B-C0031030
-o	O
group	O
compared	O
with	O
the	O
ap	B-C0031030
group	O
p	O
>	O
05	O
.	O
	
supplementation	B-C0242297
with	O
ω-3	B-C0015689
pufas	I-C0015689
not	O
only	O
suppresses	B-C1260953
bone	B-C0005974
resorption	I-C0005974
but	O
also	O
promotes	B-C1371285
new	I-C1371285
bone	I-C1371285
formation	I-C1371285
in	O
the	O
periapical	B-C0729269
area	I-C0729269
of	O
rats	B-C0034721
with	O
ap	B-C0031030
in	O
conjunction	B-C2699427
with	O
downregulation	B-C0013081
of	O
inflammatory	B-C0302158
cell	I-C0302158
infiltration	I-C0302158
into	O
the	O
magr	B-C0033684
alone	O
is	O
insufficient	B-C0231180
to	O
confer	O
cellular	B-C2754478
calcium	I-C2754478
responses	I-C2754478
to	O
magnetic	B-C0563532
stimulation	B-C1292856
magnetic	B-C0563532
manipulation	B-C0947647
of	O
cell	B-C0007613
activity	I-C0007613
offers	O
advantages	B-C0814225
over	O
optical	B-C0947647
manipulation	I-C0947647
but	O
an	O
ideal	O
tool	O
remains	O
elusive	O
.	O
	
the	O
magr	B-C0033684
protein	I-C0033684
was	O
found	O
through	O
its	O
interaction	B-C0872079
with	O
cryptochrome	B-C2717939
cry	B-C2717939
and	O
the	O
protein	B-C0033684
in	O
solution	B-C0037633
appeared	O
to	O
respond	B-C0871261
to	O
magnetic	B-C0563532
stimulation	B-C1292856
ms	B-C1292856
.	O
	
after	O
we	O
initiated	O
an	O
investigation	B-C0220825
on	O
the	O
specific	O
role	B-C1705810
of	O
magr	B-C0033684
in	O
cellular	B-C2754478
response	I-C2754478
to	O
ms	B-C1292856
,	O
a	O
subsequent	O
study	B-C2603343
claimed	O
that	O
magr	B-C0033684
expression	B-C1171362
alone	O
could	O
achieve	O
cellular	B-C1326120
activation	I-C1326120
by	O
ms	B-C1292856
.	O
	
here	O
we	O
report	O
that	O
despite	O
systematically	B-C0220922
testing	B-C0039593
different	O
ways	O
of	O
measuring	B-C0444706
intracellular	B-C0178719
calcium	B-C0006675
and	O
different	O
ms	B-C1292856
protocols	B-C0442711
,	O
it	O
was	O
not	O
possible	O
to	O
detect	B-C0442726
any	O
cellular	B-C0007634
or	O
neuronal	B-C0027882
responses	B-C0871261
to	O
ms	B-C1292856
in	O
magr	B-C0033684
-	O
expressing	B-C1171362
hek	B-C2936239
cells	I-C2936239
or	O
primary	B-C0205225
neurons	B-C0027882
from	O
the	O
dorsal	B-C0205095
root	B-C0017070
ganglion	I-C0017070
and	O
the	O
hippocampus	B-C0019564
.	O
	
by	O
contrast	O
,	O
in	O
neurons	B-C0027882
co-expressing	B-C1171362
magr	B-C0033684
and	O
channelrhodopin	B-C3253054
,	O
optical	B-C1292856
but	O
not	O
ms	B-C1292856
increased	B-C0205217
calcium	B-C3158761
influx	I-C3158761
in	O
hippocampal	B-C0019564
neurons	B-C0027882
.	O
	
our	O
results	O
indicate	O
that	O
magr	B-C0033684
alone	O
is	O
not	B-C0231180
sufficient	I-C0231180
to	O
confer	O
cellular	B-C0007634
magnetic	B-C2754103
responses	I-C2754103
.	O
	
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
and	O
fluid	B-C0546817
overload	I-C0546817
in	O
infants	B-C0021270
and	O
children	B-C0008059
after	O
cardiac	B-C0018821
surgery	I-C0018821
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
is	O
a	O
common	O
and	O
serious	B-C0205404
complication	B-C0009566
after	O
congenital	B-C2037615
heart	I-C2037615
surgery	I-C2037615
,	O
particularly	O
among	O
infants	B-C0021270
.	O
	
this	O
comorbidity	B-C0009488
has	O
been	O
independently	O
associated	B-C0332281
with	I-C0332281
adverse	B-C0879626
outcomes	I-C0879626
including	O
an	O
increase	B-C0442805
in	O
mortality	B-C0178686
.	O
	
postoperative	B-C0032790
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
has	O
a	O
complex	O
pathophysiology	B-C0031847
with	O
many	O
risk	B-C0035648
factors	I-C0035648
,	O
and	O
therefore	O
no	B-C0746919
single	I-C0746919
medication	I-C0746919
or	O
therapy	B-C0746919
has	O
been	O
demonstrated	O
to	O
be	O
effective	B-C1704419
for	O
treatment	B-C0087111
or	O
prevention	B-C2700409
.	O
	
however	O
,	O
it	O
has	O
been	O
established	O
that	O
the	O
associated	O
fluid	B-C0546817
overload	I-C0546817
is	O
one	O
of	O
the	O
major	O
determinants	B-C1521761
of	O
morbidity	B-C0026538
,	O
particularly	O
in	O
infants	B-C0021270
after	O
cardiac	B-C0018821
surgery	I-C0018821
.	O
	
therefore	O
,	O
in	O
the	O
absence	B-C0332197
of	O
an	O
intervention	B-C0184661
to	O
prevent	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
,	O
much	O
of	O
the	O
effort	O
to	O
improve	B-C1272747
outcomes	B-C0085415
has	O
focused	O
on	O
treating	B-C0039798
and	O
preventing	B-C2700409
fluid	B-C0546817
overload	I-C0546817
.	O
	
early	B-C1279919
renal	B-C0206074
replacement	I-C0206074
therapy	I-C0206074
,	O
often	O
in	O
the	O
form	O
of	O
peritoneal	B-C0031139
dialysis	I-C0031139
,	O
has	O
been	O
shown	O
to	O
be	O
safe	B-C0036043
and	O
beneficial	B-C0814225
in	O
infants	B-C0021270
with	O
oliguria	B-C0028961
after	O
heart	B-C0018821
surgery	I-C0018821
.	O
	
as	O
understanding	O
of	O
the	O
pathophysiology	B-C0031847
of	O
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
and	O
the	O
ability	O
to	O
confidently	O
diagnose	B-C0011900
it	O
earlier	O
continues	O
to	O
evolve	O
,	O
it	O
is	O
likely	O
that	O
novel	O
preventative	B-C2700409
and	O
therapeutic	B-C0808232
interventions	I-C0808232
systems	B-C0449913
toxicology	B-C0040541
real	O
world	B-C2700280
applications	B-C0205245
and	O
opportunities	B-C1254370
systems	B-C0449913
toxicology	B-C0040541
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	B-C0001688
biological	I-C0001688
effects	I-C0001688
of	O
xenobiotics	B-C0043335
are	O
characterized	B-C1880022
from	O
empirical	B-C1880496
end	B-C2349179
points	I-C2349179
to	O
describing	O
modes	B-C1513371
of	O
action	B-C3266814
as	O
adverse	B-C0001688
outcome	B-C1274040
pathways	B-C1705987
and	O
perturbed	B-C1882071
networks	I-C1882071
.	O
	
toward	O
this	O
aim	O
,	O
systems	B-C0449913
toxicology	B-C0040541
entails	O
the	O
integration	B-C1705422
of	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
toxicity	B-C0600688
data	B-C1511726
with	O
computational	B-C0009609
modeling	I-C0009609
.	O
	
this	O
evolving	O
approach	B-C1292724
depends	O
critically	O
on	O
data	B-C1511726
reliability	B-C2347947
and	O
relevance	B-C2347946
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	B-C0332306
of	O
experimental	B-C0086272
models	I-C0086272
and	O
bioanalysis	B-C0242481
techniques	I-C0242481
used	O
to	O
generate	O
toxicological	B-C0205472
data	B-C1511726
.	O
	
systems	B-C0449913
toxicology	B-C0040541
involves	O
the	O
use	O
of	O
large-scale	O
data	B-C0150098
streams	I-C0150098
"""big"	O
data	B-C1511726
""""	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	B-C0242481
measurements	I-C0242481
that	O
require	O
computational	B-C1880157
means	O
for	O
obtaining	O
informative	B-C2986490
results	B-C1274040
.	O
	
thus	O
,	O
integrative	B-C0936012
analysis	I-C0936012
of	O
multiple	B-C0439064
molecular	B-C0242485
measurements	I-C0242485
,	O
particularly	O
acquired	O
by	O
omics	B-C0022885
strategies	I-C0022885
,	O
is	O
a	O
key	O
approach	B-C1292724
in	O
systems	B-C0449913
toxicology	B-C0040541
.	O
	
in	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	B-C1533691
vitro	I-C1533691
test	O
systems	O
and	O
bioanalytical	B-C0022885
strategies	I-C0022885
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	B-C0205245
observed	O
network	B-C1882071
perturbations	B-C0332453
to	O
phenotypes	B-C0031437
,	O
which	O
will	O
require	O
understanding	O
pathways	B-C1705987
and	O
networks	B-C1882071
that	O
give	O
rise	O
to	O
adverse	B-C0001688
responses	I-C0001688
.	O
	
this	O
summary	B-C1552616
perspective	O
from	O
a	O
2016	O
systems	B-C0449913
toxicology	B-C0040541
meeting	B-C0556656
,	O
an	O
international	B-C0086047
conference	I-C0086047
held	O
in	O
the	O
alps	B-C0017446
of	O
switzerland	B-C0039021
,	O
describes	O
the	O
limitations	B-C0449295
and	O
opportunities	B-C1254370
of	O
selected	O
emerging	O
applications	B-C0205245
in	O
this	O
rapidly	O
advancing	O
field	O
.	O
	
systems	B-C0449913
toxicology	B-C0040541
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	B-C0001688
biological	I-C0001688
effects	I-C0001688
of	O
xenobiotics	B-C0043335
are	O
characterized	B-C1880022
,	O
from	O
empirical	B-C1880496
end	B-C2349179
points	I-C2349179
to	O
pathways	B-C1705987
of	O
toxicity	B-C0600688
.	O
	
this	O
requires	O
the	O
integration	B-C1705422
of	O
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
data	B-C1511726
with	O
computational	B-C0009609
modeling	I-C0009609
.	O
	
test	O
systems	O
and	O
bioanalytical	B-C0022885
technologies	I-C0022885
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	B-C1511726
reliability	B-C2347947
and	O
relevance	B-C2347946
is	O
an	O
ongoing	O
concern	O
.	O
	
the	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	B-C1705987
approach	B-C1292724
is	O
determining	O
how	O
to	O
link	B-C0205245
observed	O
network	B-C1882071
perturbations	B-C0332453
to	O
phenotypic	B-C0031437
toxicity	B-C0600688
.	O
	
validating	B-C1519941
signs	B-C0037088
and	I-C0037088
symptoms	I-C0037088
from	O
an	O
actual	O
mass	B-C1955957
casualty	I-C1955957
incident	I-C1955957
to	O
characterize	B-C1880022
an	O
irritant	B-C1254354
gas	I-C1254354
syndrome	I-C1254354
agent	I-C1254354
igsa	B-C1254354
exposure	O
a	O
first	O
step	O
in	O
the	O
development	B-C1527148
of	O
a	O
novel	B-C0205314
igsa	B-C1254354
triage	B-C0040861
algorithm	B-C0002045
chemical	B-C0678803
exposures	I-C0678803
can	O
pose	O
a	O
significant	B-C0750502
threat	B-C0749385
to	O
life	B-C0376558
.	O
	
rapid	O
assessment	B-C0220825
by	O
first	B-C3824749
responders	I-C3824749
/	O
emergency	B-C0557519
nurses	I-C0557519
is	O
required	B-C1514873
to	O
reduce	B-C0392756
death	B-C0011065
and	O
disability	B-C0231170
.	O
	
currently	O
,	O
no	B-C1518422
informatics	B-C0037589
tools	I-C0037589
for	O
irritant	B-C1254354
gas	I-C1254354
syndrome	I-C1254354
agent	I-C1254354
s	O
igsa	B-C1254354
exposures	B-C0332157
exist	B-C2987476
to	O
process	B-C1522240
victims	B-C0680681
efficiently	B-C0442799
,	O
continuously	B-C0549178
monitor	B-C1283169
for	O
latent	B-C0205275
signs/symptoms	B-C0037088
,	O
or	O
make	O
triage	B-C0040861
recommendations	B-C0034866
.	O
	
this	O
study	B-C2603343
describes	O
the	O
first	O
step	O
in	O
developing	O
ed	B-C0562508
informatics	B-C0037589
tools	I-C0037589
for	O
chemical	B-C2350599
incidents	I-C2350599
validation	B-C1519941
of	O
signs/symptoms	B-C0037088
that	O
characterize	B-C1880022
an	O
igsa	B-C1254354
syndrome	B-C0039082
.	O
	
data	B-C3259344
abstracted	I-C3259344
from	O
146	O
patients	B-C0030705
treated	B-C0087111
for	O
chlorine	B-C0239049
exposure	I-C0239049
in	O
one	O
emergency	B-C0562508
department	I-C0562508
during	B-C0347984
a	O
2005	O
train	B-C0337199
derailment	I-C0337199
and	O
152	O
patients	B-C0030705
not	B-C1518422
exposed	B-C0239049
to	I-C0239049
chlorine	I-C0239049
a	O
comparison	B-C0009932
group	I-C0009932
were	O
mapped	B-C3858752
to	O
93	O
possible	O
signs/symptoms	B-C0037088
within	O
2	O
tools	B-C0037589
wiser	B-C0037589
and	O
chemm-ist	B-C0037589
designed	B-C1707689
to	O
assist	B-C1269765
emergency	B-C3178988
responders	I-C3178988
/	O
emergency	B-C0557519
nurses	I-C0557519
with	O
managing	O
hazardous	B-C0018626
material	I-C0018626
exposures	B-C0332157
.	O
	
inferential	B-C0032685
statistics	I-C0032685
χ	O
fisher's	B-C0237913
exact	I-C0237913
test	I-C0237913
and	O
diagnostics	B-C0086143
tests	I-C0086143
were	O
used	B-C1524063
to	O
examine	O
mapped	B-C3858752
signs/symptoms	B-C0037088
of	O
persons	B-C0027361
who	O
were	O
and	O
were	O
not	O
exposed	B-C0239049
to	I-C0239049
chlorine	I-C0239049
.	O
	
three	O
clusters	B-C1704332
of	O
signs/symptoms	B-C0037088
are	O
statistically	B-C2828391
associated	B-C0332281
with	I-C0332281
an	O
igsa	B-C1254354
syndrome	B-C0039082
p	O
<	O
01	O
respiratory	B-C0521346
shortness	B-C0013404
of	I-C0013404
breath	I-C0013404
,	O
wheezing	B-C0043144
,	O
coughing	B-C0010200
,	O
and	O
choking	B-C0008301
chest	B-C0235710
discomfort	I-C0235710
tightness	B-C0232292
,	O
pain	B-C0008031
,	O
and	O
burning	B-C0740396
,	O
and	O
eye	B-C0015392
,	O
nose	B-C0028429
and/or	O
throat	B-C3665375
pain	B-C0030193
,	O
irritation	B-C0441723
,	O
and	O
burning	B-C0085624
.	O
	
the	O
syndrome	B-C0039082
requires	O
the	O
presence	B-C0150312
of	O
signs/symptoms	B-C0037088
from	O
at	O
least	O
2	O
of	O
these	O
clusters	B-C1704332
.	O
	
the	O
latency	B-C0023103
period	I-C0023103
must	O
also	O
be	O
considered	B-C0750591
for	O
exposed	B-C1998203
/	O
potentially	B-C3245505
exposed	B-C1998203
persons	I-C1998203
.	O
	
this	O
study	B-C2603343
uses	B-C1524063
actual	O
patient	B-C2707520
data	I-C2707520
from	O
a	O
chemical	B-C2350599
incident	I-C2350599
to	O
characterize	B-C1880022
and	O
validate	B-C1519941
signs/symptoms	B-C0037088
of	O
an	O
igsa	B-C1254354
syndrome	B-C0039082
.	O
	
validating	B-C1519941
signs/symptoms	B-C0037088
is	O
the	O
first	O
step	O
in	O
developing	O
new	B-C0205314
ed	B-C0562508
informatics	B-C0037589
tools	I-C0037589
with	O
the	O
potential	B-C3245505
to	O
revolutionize	O
the	O
process	B-C1522240
by	O
which	O
emergency	B-C0557519
nurses	I-C0557519
manage	O
triage	B-C0040861
victims	B-C0680681
of	O
chemical	B-C2350599
incidents	I-C2350599
.	O
	
fyn	B-C1442788
regulates	O
multipolar	B-C1254362
-	O
bipolar	B-C0443156
transition	B-C2700061
and	O
neurite	B-C1753129
morphogenesis	I-C1753129
of	O
migrating	B-C1326504
neurons	I-C1326504
in	O
the	O
developing	B-C1818475
neocortex	I-C1818475
fyn	B-C1442788
is	O
a	O
non-receptor	B-C0243095
protein	B-C0033681
tyrosine	I-C0033681
kinase	I-C0033681
that	O
belongs	O
to	O
src	B-C0282625
family	I-C0282625
kinases	I-C0282625
.	O
	
fyn	B-C1442788
plays	O
a	O
critical	O
role	O
in	O
neuronal	B-C1326504
migration	I-C1326504
,	O
but	O
the	O
mechanism	B-C0441712
remains	O
unclear	B-C3845108
.	O
	
here	O
,	O
we	O
reported	O
that	O
suppression	B-C0038855
of	O
fyn	B-C1442788
expression	B-C1171362
in	O
mouse	B-C1522579
cerebral	I-C1522579
cortex	I-C1522579
led	O
to	O
migration	B-C2750249
defects	I-C2750249
of	O
both	O
early-born	B-C1279919
and	O
late-born	B-C0205087
neurons	B-C0027882
.	O
	
morphological	B-C0543482
analysis	B-C0936012
showed	O
that	O
loss	O
of	O
fyn	B-C1442788
function	O
impaired	O
multipolar	B-C1254362
-	O
bipolar	B-C0443156
transition	B-C2700061
of	O
newly	O
generated	B-C3146294
neurons	B-C0027882
and	O
neurite	B-C1753129
formation	I-C1753129
in	O
the	O
early	O
phase	B-C0205390
of	O
migration	B-C1326504
.	O
	
moreover	O
,	O
fyn	B-C1442788
inhibition	B-C1519619
increased	O
the	O
length	O
of	O
leading	B-C0007613
process	I-C0007613
and	O
decreased	O
the	O
branching	B-C0205384
number	O
of	O
the	O
migrating	B-C1326504
cortical	I-C1326504
neurons	I-C1326504
.	O
	
together	O
,	O
these	O
results	O
indicate	O
that	O
fyn	B-C1442788
controls	B-C2587213
neuronal	B-C1326504
migration	I-C1326504
by	O
regulating	B-C1327622
the	O
cytoskeletal	B-C0010853
dynamics	B-C3826426
and	O
multipolar	B-C1254362
-	O
bipolar	B-C0443156
transition	B-C2700061
of	O
newly	B-C0750546
generated	B-C3146294
neurons	B-C0027882
during	O
cortical	B-C1818475
development	I-C1818475
.	O
	
closing	B-C0443183
the	I-C0443183
loop	I-C0443183
in	O
adults	B-C0001675
,	O
children	B-C0008059
and	O
adolescents	B-C0205653
with	O
suboptimally	B-C2732401
controlled	I-C2732401
type	I-C2732401
1	I-C2732401
diabetes	I-C2732401
under	O
free	B-C0870587
living	B-C0337645
conditions	I-C0337645
a	O
psychosocial	B-C0542298
substudy	B-C2603343
the	O
objective	O
was	O
to	O
explore	O
psychosocial	B-C1458132
experiences	I-C1458132
of	O
closed	B-C0181334
loop	I-C0181334
technology	I-C0181334
for	O
adults	B-C0001675
,	O
children	B-C0008059
,	O
and	O
adolescents	B-C0205653
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
and	O
their	O
parents	B-C0030551
taking	O
part	O
in	O
two	O
multicenter	B-C1096776
,	O
free	B-C0870587
-	O
living	B-C0337645
,	O
randomized	B-C0034656
crossover	B-C0150097
home	I-C0150097
studies	I-C0150097
.	O
	
participants	B-C0679646
using	O
insulin	B-C1140609
pump	I-C1140609
therapy	B-C0087111
were	O
randomized	B-C0034656
to	O
either	O
12	O
weeks	B-C0439230
of	O
automated	B-C0205554
closed-loop	B-C0443183
glucose	B-C0726398
control	I-C0726398
,	O
then	O
12	O
weeks	B-C0439230
of	O
sensor	B-C0183210
augmented	B-C0205217
insulin	B-C1140609
pump	I-C1140609
therapy	B-C0087111
open	B-C0559530
loop	I-C0559530
,	O
or	O
vice	O
versa	O
.	O
	
closed	B-C0443183
loop	I-C0443183
was	O
used	O
for	O
24	O
hours	B-C0439227
by	O
adults	B-C0001675
and	O
overnight	B-C0439583
only	O
by	O
children	B-C0008059
and	O
adolescents	B-C0205653
.	O
	
participants	B-C0679646
completed	O
the	O
diabetes	B-C0034394
technology	I-C0034394
questionnaire	I-C0034394
dtq	B-C0034394
periodically	B-C0332182
and	O
shared	O
their	O
views	B-C0449911
in	O
semistructured	B-C0681913
interviews	I-C0681913
.	O
	
this	O
analysis	B-C0936012
characterizes	B-C3875152
the	O
impact	B-C4049986
of	O
the	O
technology	B-C0039421
,	O
positive	B-C1446409
and	O
negative	B-C3853545
aspects	O
of	O
living	B-C0337645
with	O
the	O
device	B-C0025080
,	O
alongside	O
participants	B-C0679646
'	O
expectations	B-C0679138
,	O
hopes	B-C0392347
,	O
and	O
anxieties	B-C0003467
.	O
	
participants	B-C0679646
were	O
32	O
adults	B-C0001675
,	O
age	O
38.6	O
9.6	O
years	B-C0439234
,	O
55%	O
male	B-C0086582
,	O
and	O
26	O
children	B-C0008059
,	O
mean	O
age	B-C0001779
12	O
years	B-C0439234
range	O
6-18	O
years	B-C0439234
,	O
54%	O
male	B-C0086582
.	O
	
dtq	B-C0034394
results	B-C1274040
indicated	O
moderately	B-C4049986
favorable	I-C4049986
impact	I-C4049986
of	O
,	O
and	O
satisfaction	O
with	O
,	O
both	O
open	B-C0559530
and	O
closed	B-C0443183
loop	I-C0443183
interventions	B-C0184661
,	O
but	O
little	O
evidence	B-C3887511
of	O
a	O
comparative	B-C0681074
advantage	I-C0681074
of	O
either	O
.	O
	
key	O
positive	B-C1446409
themes	I-C1446409
included	O
perceived	O
improved	B-C1873605
blood	I-C1873605
glucose	I-C1873605
control	I-C1873605
,	O
improved	B-C2939150
general	I-C2939150
well-being	I-C2939150
,	O
particularly	O
on	O
waking	B-C0442696
,	O
improved	B-C0037313
sleep	I-C0037313
,	O
reduced	B-C0392756
burden	B-C2828008
of	O
diabetes	B-C0011847
,	O
and	O
visibility	B-C0205556
of	O
data	B-C1511726
.	O
	
key	O
negative	B-C3853545
themes	I-C3853545
included	O
having	O
to	O
carry	O
around	O
the	O
equipment	B-C0014672
and	O
dislike	B-C0870431
of	O
the	O
pump	B-C1140609
and	O
second	O
cannula	B-C0520453
ie	O
,	O
sensor	B-C0183210
inserted	O
.	O
	
overall	O
,	O
participants	B-C0679646
reported	O
a	O
positive	B-C1446409
experience	B-C0683573
of	O
the	O
closed	B-C0181334
loop	I-C0181334
technology	I-C0181334
.	O
	
results	B-C1274040
are	O
consistent	B-C0332290
with	I-C0332290
previous	O
research	O
with	O
size	B-C0456389
of	O
equipment	B-C0014672
continuing	O
to	O
be	O
a	O
problem	B-C0033213
.	O
	
progress	O
is	O
being	O
made	O
in	O
the	O
usability	B-C0457083
of	O
the	O
closed-loop	B-C0181334
system	I-C0181334
.	O
	
serum	B-C0229671
levels	B-C0441889
of	O
genomic	B-C3272453
dna	I-C3272453
of	O
α1	B-C1332772
collagen	I-C1332772
are	O
elevated	B-C3163633
in	O
scleroderma	B-C0011644
patients	B-C0030705
recent	O
studies	O
have	O
indicated	O
that	O
various	O
nucleic	B-C0028606
acids	I-C0028606
are	O
present	O
in	O
human	B-C0086418
sera	B-C0229671
,	O
and	O
attracted	O
attention	O
for	O
their	O
potential	O
as	O
novel	O
disease	B-C1511983
markers	I-C1511983
in	O
many	O
human	B-C0086418
diseases	B-C0012634
.	O
	
in	O
this	O
study	O
,	O
we	O
tried	O
to	O
evaluate	O
the	O
possibility	O
that	O
dna	B-C0012854
and	O
rna	B-C0035668
of	O
collagens	B-C1333079
exist	O
in	O
human	B-C0086418
sera	B-C0229671
,	O
and	O
determined	O
whether	O
their	O
serum	B-C0229671
levels	B-C0441889
can	O
be	O
useful	O
biomarkers	B-C0005516
in	O
scleroderma	B-C0011644
patients	B-C0030705
.	O
	
the	O
rna	B-C0035668
or	O
dna	B-C0012854
of	O
collagens	B-C1333079
were	O
purified	B-C1998793
from	O
sera	B-C0229671
,	O
and	O
detected	B-C0442726
by	O
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
or	O
quantitated	B-C1709793
by	O
real-time	B-C1709846
polymerase	I-C1709846
chain	I-C1709846
reaction	I-C1709846
.	O
	
among	O
approximately	O
18	O
360	B-C1332772
bases	I-C1332772
of	I-C1332772
full-length	I-C1332772
α1	I-C1332772
collagen	I-C1332772
dna	B-C0012854
,	O
various	O
regions	B-C0017337
were	O
detected	B-C0442726
by	O
polymerase	B-C0032520
chain	I-C0032520
reaction	I-C0032520
in	O
human	B-C0086418
sera	B-C0229671
.	O
	
however	O
,	O
α2	B-C1332773
collagen	I-C1332773
dna	B-C0012854
,	O
α1	B-C1332772
collagen	I-C1332772
rna	B-C0035668
or	O
α2	B-C1332773
collagen	I-C1332773
rna	B-C0035668
were	O
not	B-C0243095
detectable	I-C0243095
.	O
	
α1	B-C1332772
collagen	I-C1332772
dna	B-C0012854
in	O
sera	B-C0229671
was	O
quantitative	B-C0392762
using	O
our	O
method	O
.	O
	
the	O
levels	B-C0441889
of	O
serum	B-C0229671
α1	B-C1332772
collagen	I-C1332772
dna	B-C0012854
were	O
significantly	O
increased	B-C0205217
in	O
scleroderma	B-C0011644
patients	B-C0030705
compared	O
with	O
healthy	B-C2986479
control	I-C2986479
subjects	B-C0080105
or	O
systemic	B-C0024141
lupus	I-C0024141
erythematosus	I-C0024141
patients	B-C0030705
.	O
	
according	O
to	O
the	O
receiver-operator	B-C0035787
curve	I-C0035787
analysis	I-C0035787
,	O
serum	B-C0229671
α1	B-C1332772
collagen	I-C1332772
dna	B-C0012854
levels	B-C0441889
were	O
shown	O
to	O
be	O
effective	O
as	O
a	O
diagnostic	B-C1511876
marker	I-C1511876
of	O
scleroderma	B-C0011644
.	O
	
furthermore	O
,	O
when	O
we	O
determined	O
the	O
association	B-C0439849
of	O
serum	B-C0229671
α1	B-C1332772
collagen	I-C1332772
dna	B-C0012854
levels	B-C0441889
with	O
clinical	B-C0205210
/	O
laboratory	B-C0022877
features	B-C1521970
in	O
scleroderma	B-C0011644
patients	B-C0030705
,	O
those	O
with	O
elevated	B-C3163633
α1	B-C1332772
collagen	I-C1332772
dna	B-C0012854
levels	B-C0441889
showed	O
significantly	O
higher	O
prevalence	B-C0220900
of	O
pitting	B-C0012634
scars	I-C0012634
/	O
ulcers	B-C0041582
.	O
	
in	O
summary	O
,	O
elevation	B-C3163633
of	O
serum	B-C0229671
α1	B-C1332772
collagen	I-C1332772
dna	B-C0012854
levels	B-C0441889
in	O
scleroderma	B-C0011644
patients	B-C0030705
may	O
be	O
useful	O
as	O
the	O
diagnostic	B-C1511876
marker	I-C1511876
,	O
reflecting	O
the	O
presence	O
of	O
vasculopathy	B-C0042373
.	O
	
jou	O
metabolite	B-C0870883
mapping	B-C1283195
by	O
consecutive	O
nanostructure	B-C1450053
and	O
silver-assisted	B-C0037813
mass	I-C0037813
spectrometry	I-C0037813
imaging	I-C0037813
on	O
tissue	B-C2316368
sections	I-C2316368
nanostructure-based	B-C0037813
mass	I-C0037813
spectrometry	I-C0037813
imaging	I-C0037813
msi	B-C0037813
is	O
a	O
promising	O
technology	O
for	O
molecular	B-C1537028
imaging	I-C1537028
of	O
small	B-C1328819
molecules	I-C1328819
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix-assisted	B-C1537028
molecular	I-C1537028
imaging	I-C1537028
approaches	O
.	O
	
here	O
,	O
we	O
have	O
enhanced	O
these	O
surfaces	B-C0205148
with	O
silver	B-C0037125
ag	B-C0037125
to	O
provide	O
a	O
second	O
tier	O
of	O
msi	B-C0282574
data	I-C0282574
from	O
a	O
single	O
sample	O
.	O
	
msi	B-C0282574
data	I-C0282574
was	O
acquired	O
through	O
the	O
application	B-C4048755
of	O
laser	B-C0282597
desorption/ionization	I-C0282597
mass	I-C0282597
spectrometry	I-C0282597
to	O
biological	B-C0444062
samples	I-C0444062
imprinted	O
onto	O
desorption/ionization	B-C1254366
on	I-C1254366
silicon	I-C1254366
dios	B-C1254366
substrates	B-C3891814
.	O
	
following	O
initial	O
analysis	B-C0936012
,	O
ultra-thin	B-C1522408
ag	I-C1522408
layers	I-C1522408
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
msi	B-C0037813
analysis	I-C0037813
ag-dios	B-C0282597
msi	I-C0282597
.	O
	
this	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small	B-C1328819
molecules	I-C1328819
including	O
environmental	B-C0014406
contaminants	B-C2827365
and	O
sebum	B-C0036511
components	O
.	O
	
subsequently	O
,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	B-C0023779
and	O
metabolites	B-C0870883
in	O
fore-stomach	B-C1517295
sections	I-C1517295
from	O
a	O
6-bromoisatin	B-C3493005
chemopreventative	B-C3273128
murine	B-C2986594
mouse	I-C2986594
model	I-C2986594
.	O
	
dios	B-C0037813
msi	I-C0037813
allowed	O
mapping	B-C1283195
of	O
common	O
ions	B-C0022023
in	O
fingermarks	O
as	O
well	O
as	O
6-bromoisatin	B-C3493005
metabolites	B-C0870883
and	O
lipids	B-C0023779
in	O
murine	B-C1517295
fore-stomach	I-C1517295
.	O
	
furthermore	O
,	O
dios	B-C0037813
msi	I-C0037813
was	O
complemented	O
by	O
the	O
ag-dios	B-C0282597
msi	I-C0282597
of	O
ag-adductable	B-C0023779
lipids	I-C0023779
such	O
as	O
wax	B-C0014898
esters	I-C0014898
in	O
fingermarks	O
and	O
cholesterol	B-C0008377
in	O
murine	B-C1517295
fore-stomach	I-C1517295
.	O
	
gastrointestinal	B-C0017119
acid	I-C0017119
condensation	B-C0596312
products	B-C0566267
of	O
6-bromoisatin	B-C3493005
,	O
such	O
as	O
the	O
6	B-C0574031
mapped	O
herein	O
,	O
are	O
very	O
challenging	O
to	O
isolate	B-C0220862
and	O
characterize	B-C1880022
.	O
	
by	O
re-analyzing	O
the	O
same	O
tissue	B-C0040300
imprints	O
,	O
this	O
metabolite	B-C0870883
was	O
readily	O
detected	O
by	O
dios	B-C1254366
,	O
placed	O
in	O
a	O
tissue-specific	B-C1955394
spatial	I-C1955394
context	I-C1955394
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid	B-C0007613
distributions	I-C0007613
acquired	O
using	O
ag-dios	B-C0282597
msi	I-C0282597
.	O
	
the	O
ability	O
to	O
place	O
metabolite	B-C0870883
and	O
lipid	B-C0023779
classes	O
in	O
a	O
tissue-specific	B-C1955394
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
msi	B-C0037813
analyses	I-C0037813
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use	O
,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small	B-C1328819
molecules	I-C1328819
,	O
in	O
particular	O
for	O
metabolites	B-C0870883
that	O
are	O
typically	O
undetectable	B-C3827727
towards	O
culturally	B-C3850087
competent	I-C3850087
paediatric	I-C3850087
oncology	I-C3850087
care	I-C3850087
.	O
	
a	O
qualitative	B-C0949415
study	I-C0949415
from	O
the	O
perspective	B-C1711364
of	O
care	B-C0018724
providers	I-C0018724
in	O
order	O
to	O
gain	O
more	O
insight	O
on	O
the	O
influence	B-C4054723
of	O
ethnic	B-C0680174
diversity	B-C1880371
in	O
paediatric	B-C0030755
cancer	B-C0920687
care	I-C0920687
,	O
the	O
perspectives	B-C1711364
of	O
care	B-C0018724
providers	I-C0018724
were	O
explored	O
.	O
	
semi-structured	B-C0683518
interviews	I-C0683518
were	O
conducted	O
among	O
12	O
paediatric	B-C0279158
oncologists	I-C0279158
and	O
13	O
nurses	B-C0028661
of	O
two	O
different	O
paediatric	B-C0587485
oncology	I-C0587485
wards	I-C0587485
and	O
were	O
analysed	B-C0936012
using	O
a	O
framework	B-C0025663
method	I-C0025663
.	O
	
we	O
found	O
that	O
care	B-C0018724
providers	I-C0018724
described	O
the	O
contact	O
with	O
turkish	B-C0549217
and	O
moroccan	B-C1257890
parents	B-C0030551
as	O
more	O
difficult	O
.	O
	
they	O
offered	O
two	O
reasons	O
for	O
this	O
1	O
language	B-C0237167
barriers	I-C0237167
between	O
care	B-C0018724
provider	I-C0018724
and	O
parents	B-C0030551
hindered	B-C0205245
the	O
exchange	B-C0870706
of	I-C0870706
information	I-C0870706
2	O
cultural	B-C0810880
barriers	I-C0810880
between	O
care	B-C0018724
provider	I-C0018724
and	O
parents	B-C0030551
about	O
sharing	O
the	O
diagnosis	B-C0011900
and	O
palliative	B-C1285530
perspective	B-C1711364
hindered	B-C0205245
communication	B-C0009452
.	O
	
care	B-C0018724
providers	I-C0018724
reported	O
different	O
solutions	B-C2699488
to	O
deal	O
with	O
these	O
barriers	B-C0009454
,	O
such	O
as	O
using	O
an	O
interpreter	B-C0150646
and	O
improving	O
their	O
cultural	B-C0376554
knowledge	I-C0376554
about	O
their	O
patients	B-C0030705
.	O
	
they	O
,	O
however	O
,	O
were	O
not	O
using	O
interpreters	B-C0150646
sufficiently	O
and	O
were	O
unaware	O
of	O
the	O
importance	O
of	O
eliciting	B-C0474408
parents	B-C0030551
'	O
perspectives	B-C1711364
.	O
	
communication	B-C0009452
techniques	B-C0449851
to	O
overcome	O
dilemmas	B-C1510640
between	O
parents	B-C0030551
and	O
care	B-C0018724
providers	I-C0018724
were	O
not	O
used	O
and	O
care	B-C0018724
providers	I-C0018724
were	O
unaware	O
of	O
stereotypes	B-C3825635
and	O
prejudice	B-C0033023
.	O
	
care	B-C0018724
providers	I-C0018724
should	O
be	O
offered	O
insight	O
in	O
cultural	B-C0810880
barriers	I-C0810880
they	O
are	O
unaware	O
of	O
.	O
	
training	B-C0220931
in	O
cultural	B-C0679748
competence	I-C0679748
might	O
be	O
a	O
possibility	O
to	O
overcome	O
manifest	B-C0205319
barriers	B-C0009454
.	O
	
obesogenic	B-C0028754
eating	B-C0015745
behaviors	I-C0015745
mediate	O
the	O
relationships	B-C0439849
between	O
psychological	B-C0848067
problems	I-C0848067
and	O
bmi	B-C1305855
in	O
children	B-C0008059
to	O
examine	O
the	O
association	B-C0439849
between	O
psychological	B-C0848067
problems	I-C0848067
and	O
weight	B-C0005910
status	B-C0449438
in	O
children	B-C0008059
aged	B-C0001779
3.5	O
to	O
4	O
years	B-C0439234
and	O
test	O
whether	O
obesogenic	B-C0028754
eating	B-C0015745
behaviors	I-C0015745
mediate	O
this	O
relationship	B-C0439849
.	O
	
this	O
study	O
is	O
a	O
cross-sectional	B-C0010362
secondary	I-C0010362
analysis	I-C0010362
of	O
data	B-C1511726
from	O
first-time	B-C0026591
mothers	I-C0026591
n	O
=	O
194	O
in	O
the	O
control	O
arm	O
of	O
the	O
nourish	B-C0206035
randomized	I-C0206035
controlled	I-C0206035
trial	I-C0206035
.	O
	
at	O
child	B-C0008059
age	O
3.5	O
to	O
4	O
years	O
,	O
maternal	O
-reported	O
child	B-C0008059
eating	O
behaviors	O
and	O
psychological	O
problems	O
were	O
collected	O
via	O
valid	O
tools	O
,	O
and	O
child	O
weight	O
and	O
height	O
data	O
were	O
collected	O
by	O
trained	O
study	O
staff	O
.	O
	
pearson's	O
correlations	O
and	O
linear	O
regressions	O
examined	O
associations	O
between	O
eating	O
behaviors	O
,	O
psychological	O
problems	O
,	O
and	O
bmi	O
z	O
score	O
.	O
	
multiple	O
mediation	O
models	O
were	O
tested	O
by	O
assessing	O
indirect	O
effects	O
of	O
psychological	O
problems	O
on	O
bmi	O
z	O
score	O
via	O
obesogenic	O
eating	O
behaviors	O
.	O
	
peer	O
problems	O
were	O
associated	O
with	O
both	O
higher	O
food	O
responsiveness	O
and	O
emotional	O
overeating	O
and	O
directly	O
with	O
higher	O
bmi	O
z	O
score	O
.	O
	
this	O
relationship	O
was	O
partially	O
mediated	O
by	O
emotional	O
overeating	O
.	O
	
both	O
emotional	O
overeating	O
and	O
food	O
responsiveness	O
fully	O
mediated	O
the	O
association	O
between	O
emotional	O
problems	O
and	O
bmi	O
z	O
score	O
,	O
and	O
food	O
responsiveness	O
fully	O
mediated	O
the	O
association	O
between	O
conduct	O
problems	O
and	O
bmi	O
z	O
score	O
.	O
	
the	O
findings	O
suggest	O
that	O
children	O
with	O
psychological	O
problems	O
may	O
also	O
display	O
obesogenic	O
eating	O
behaviors	O
,	O
which	O
may	O
result	O
in	O
higher	O
bmi	O
.	O
	
this	O
needs	O
to	O
be	O
considered	O
in	O
the	O
clinical	O
management	O
of	O
both	O
pediatric	O
overweight	O
/	O
obesity	O
and	O
psychological	O
problems	I-C0848067
homocysteine	B-C0019878
as	O
a	O
peripheral	B-C0205100
biomarker	B-C0005516
in	O
bipolar	B-C0005586
disorder	I-C0005586
a	O
meta-analysis	B-C0920317
bipolar	B-C0005586
disorder	I-C0005586
bd	B-C0005586
is	O
a	O
psychiatric	B-C0004936
disorder	I-C0004936
with	O
an	O
uncertain	B-C0087130
aetiology	B-C1314792
.	O
	
recently	O
,	O
special	O
attention	O
has	O
been	O
given	O
to	O
homocysteine	B-C0019878
hcy	B-C0019878
,	O
as	O
it	O
has	O
been	O
suggested	O
that	O
alterations	B-C1515926
in	O
1-carbon	B-C1158831
metabolism	I-C1158831
might	O
be	O
implicated	O
in	O
diverse	O
psychiatric	B-C0004936
disorders	I-C0004936
.	O
	
however	O
,	O
there	O
is	O
uncertainty	B-C0087130
regarding	O
possible	O
alterations	B-C1515926
in	O
peripheral	B-C0205100
hcy	B-C0019878
levels	O
in	O
bd	B-C0005586
.	O
	
this	O
study	O
comprises	O
a	O
meta-analysis	B-C0920317
comparing	O
serum	B-C1278080
and	O
plasma	B-C1278165
hcy	I-C1278165
levels	I-C1278165
in	O
persons	B-C0027361
with	O
bd	B-C0005586
and	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
we	O
conducted	O
a	O
systematic	B-C0220922
search	B-C1706202
for	O
all	O
eligible	B-C1548635
english	O
and	O
non-english	O
peer-reviewed	B-C2985503
articles	I-C2985503
.	O
	
nine	O
cross-sectional	B-C0010362
studies	I-C0010362
were	O
included	B-C0332257
in	O
the	O
meta-analyses	B-C0920317
,	O
providing	B-C1999230
data	B-C1511726
on	O
1547	O
participants	B-C0679646
.	O
	
random-effects	B-C1280500
meta-analysis	B-C0920317
showed	O
that	O
serum	B-C1278080
and	O
plasma	B-C1278165
levels	I-C1278165
of	I-C1278165
hcy	I-C1278165
were	O
increased	B-C0205217
in	O
subjects	B-C0681850
with	O
bd	B-C0005586
in	O
either	O
mania	B-C0338831
or	O
euthymia	B-C0948853
when	O
compared	B-C1707455
to	O
healthy	B-C2986479
controls	I-C2986479
,	O
with	O
a	O
large	O
effect	B-C0814843
size	I-C0814843
in	O
the	O
mania	B-C0338831
group	B-C1257890
g=0	O
,	O
95%	O
ci	B-C0009667
0.8	O
,	O
p<0	O
,	O
n=495	O
and	O
a	O
small	O
effect	B-C1280500
in	O
the	O
euthymia	B-C0948853
group	B-C1257890
g=0	O
,	O
95%	O
ci	B-C0009667
0.11	O
,	O
p=0	O
,	O
n=1052	O
.	O
	
our	O
meta-analysis	B-C0920317
provides	O
evidence	O
that	O
hcy	B-C0920051
levels	I-C0920051
are	I-C0920051
elevated	I-C0920051
in	O
persons	B-C0027361
with	O
bd	B-C0005586
during	O
mania	B-C0338831
and	O
euthymia	B-C0948853
.	O
	
peripheral	B-C0205100
hcy	B-C0019878
could	O
be	O
considered	B-C0750591
as	O
a	O
potential	B-C3245505
biomarker	B-C0005516
in	O
bd	B-C0005586
,	O
both	O
of	O
trait	B-C0599883
since	O
it	O
is	O
increased	B-C0205217
in	O
euthymia	B-C0948853
,	O
and	O
also	O
of	O
state	B-C1442792
since	O
its	O
increase	B-C0442805
is	O
more	O
accentuated	B-C1997416
in	O
mania	B-C0338831
.	O
	
longitudinal	B-C0023981
studies	I-C0023981
are	O
needed	O
to	O
clarify	O
the	O
relationship	B-C0439849
between	O
bipolar	B-C0005586
disorder	I-C0005586
and	O
hcy	B-C0019878
,	O
as	O
well	O
as	O
the	O
usefulness	B-C3827682
of	O
peripheral	B-C0205100
hcy	B-C0019878
as	O
both	O
a	O
trait	B-C0599883
and	O
state	B-C1442792
biomarker	B-C0005516
in	O
structural	B-C0581602
modification	I-C0581602
of	O
lipopolysaccharide	B-C0023810
conferred	O
by	O
mcr-1	B-C0017337
in	O
gram-negative	B-C0018150
eskape	I-C0018150
pathogens	B-C0450254
mcr-1	B-C0017337
was	O
initially	O
reported	O
as	O
the	O
first	O
plasmid	B-C0032136
-mediated	O
colistin	B-C0009316
resistance	B-C2945710
gene	I-C2945710
in	O
clinical	B-C1764827
isolates	I-C1764827
of	O
escherichia	B-C0014834
coli	I-C0014834
and	O
klebsiella	B-C0001699
pneumoniae	I-C0001699
in	O
china	B-C0008115
and	O
has	O
subsequently	O
been	O
identified	O
worldwide	O
in	O
various	O
species	B-C1705920
of	O
the	O
family	B-C0014346
enterobacteriaceae	I-C0014346
mcr-1	B-C0017337
encodes	O
a	O
phosphoethanolamine	B-C2248757
transferase	I-C2248757
,	O
and	O
its	O
expression	B-C0017262
has	O
been	O
shown	O
to	O
generate	O
phosphoethanolamine	B-C0070939
-modified	O
bis-phosphorylated	B-C0023767
hexa-acylated	I-C0023767
lipid	I-C0023767
a	I-C0023767
in	O
e	B-C0014834
.	O
	
coli	I-C0014834
here	O
,	O
we	O
investigated	O
the	O
effects	B-C1704420
of	I-C1704420
mcr-1	B-C0017337
on	O
colistin	B-C0009316
susceptibility	B-C0427965
and	O
on	O
lipopolysaccharide	B-C0023810
structures	B-C0678594
in	O
laboratory	B-C0022877
and	O
clinical	B-C0205210
strains	B-C0456178
of	O
the	O
gram-negative	B-C0018150
eskape	I-C0018150
enterococcus	B-C0085495
faecium	I-C0085495
,	O
staphylococcus	B-C0038172
aureus	I-C0038172
,	O
k	B-C0001699
.	O
	
pneumoniae	I-C0001699
,	O
acinetobacter	O
baumannii	O
,	O
pseudomonas	O
aeruginosa	O
,	O
and	O
enterobacter	O
species	O
pathogens	O
,	O
which	O
are	O
often	O
treated	O
clinically	O
by	O
colistin	O
.	O
	
the	O
effects	O
of	O
mcr-1	O
on	O
colistin	O
resistance	O
were	O
determined	O
using	O
mic	O
assays	O
of	O
laboratory	O
and	O
clinical	O
strains	O
of	O
e	O
.	O
	
coli	O
,	O
k	B-C0001699
.	O
	
pneumoniae	I-C0001699
,	O
a	O
.	O
	
baumannii	O
,	O
and	O
p	O
.	O
	
aeruginosa	O
lipid	O
a	O
structural	O
changes	O
resulting	O
from	O
mcr-1	O
were	O
analyzed	O
by	O
mass	O
spectrometry	O
.	O
	
the	O
introduction	O
of	O
mcr-1	O
led	O
to	O
colistin	O
resistance	O
in	O
e	O
.	O
	
coli	O
,	O
k	O
.	O
	
pneumoniae	O
,	O
and	O
a	O
.	O
	
baumannii	O
but	O
only	O
moderately	O
reduced	O
susceptibility	O
in	O
p	O
.	O
	
aeruginosa	O
phosphoethanolamine	O
modification	O
of	O
lipid	O
a	O
was	O
observed	O
consistently	O
for	O
all	O
four	O
species	O
.	O
	
these	O
findings	O
highlight	O
the	O
risk	O
of	O
colistin	O
resistance	O
as	O
a	O
consequence	O
of	O
mcr-1	O
expression	O
among	O
eskape	O
pathogens	O
,	O
especially	O
in	O
k	O
.	O
	
pneumoniae	O
and	O
a	O
.	O
	
baumannii	O
furthermore	O
,	O
the	O
observation	O
that	O
lipid	O
a	O
structures	O
were	O
modified	O
despite	O
only	O
modest	O
increases	O
in	O
colistin	O
mics	O
in	O
some	O
instances	O
suggests	O
more	O
sophisticated	O
surveillance	O
methods	O
may	O
need	O
to	O
be	O
developed	O
to	O
track	O
the	O
dissemination	O
of	O
mcr-1	O
or	O
plasmid	O
-mediated	O
phosphoethanolamine	O
transferases	O
in	O
effects	B-C1280500
of	O
transplanted	B-C0935850
human	B-C0086418
cord	B-C0162371
blood	I-C0162371
-	O
mononuclear	B-C0806987
cells	I-C0806987
on	O
pulmonary	B-C0020542
hypertension	I-C0020542
in	O
immunodeficient	B-C0599920
mice	I-C0599920
and	O
their	O
distribution	B-C1704711
to	O
investigate	B-C0220825
the	O
effects	B-C1280500
of	O
human	B-C0086418
umbilical	B-C0162371
cord	I-C0162371
blood	I-C0162371
-derived	O
mononuclear	B-C0806987
cell	I-C0806987
hucb	B-C0162371
-	O
mnc	B-C0806987
transplantation	B-C0935850
on	O
pulmonary	B-C0020542
hypertension	I-C0020542
ph	B-C0020542
induced	B-C0205263
by	O
monocrotaline	B-C0085241
mct	B-C0085241
in	O
immunodeficient	B-C0599920
mice	I-C0599920
and	O
their	O
distribution	B-C1704711
.	O
	
mct	B-C0085241
was	O
administered	B-C1521801
to	O
balb/c	B-C0025919
slc-nu/nu	I-C0025919
mice	I-C0025919
,	O
and	O
ph	B-C0020542
was	O
induced	B-C0205263
in	O
mice	B-C0025919
4	O
weeks	O
later	O
.	O
	
fresh	B-C0443224
hucb	B-C0162371
-	O
mncs	B-C0806987
harvested	B-C0411265
from	O
a	O
human	B-C0086418
donor	B-C0013018
after	O
her	O
delivery	B-C1705822
were	O
injected	B-C0021494
intravenously	I-C0021494
into	O
those	O
ph	B-C0020542
mice	B-C0025919
.	O
	
the	O
medial	B-C0205098
thickness	B-C1280412
of	O
pulmonary	B-C4243802
arterioles	I-C4243802
,	O
ratio	B-C0456603
of	O
right	B-C0225883
ventricular	I-C0225883
to	O
septum	B-C0018819
plus	B-C0332287
left	B-C0225897
ventricular	I-C0225897
weight	B-C0043100
rv	B-C0225883
/	O
s	B-C0018819
+	O
lv	B-C0225897
,	O
and	O
ratio	B-C0456603
of	O
acceleration	B-C3655682
time	I-C3655682
to	O
ejection	B-C0812388
time	I-C0812388
of	O
pulmonary	B-C4071554
blood	I-C4071554
flow	I-C4071554
waveform	B-C0450448
at	B-C3655682
/	O
et	B-C0812388
were	O
determined	B-C0521095
4	O
weeks	O
after	O
hucb	B-C0162371
-	O
mnc	B-C0806987
transplantation	B-C0935850
.	O
	
to	O
reveal	B-C0443289
the	O
incorporation	B-C0243126
into	O
the	O
lung	B-C0024109
,	O
cmtmr	B-C0761898
-	O
labeled	B-C1522485
hucb	B-C0162371
-	O
mncs	B-C0806987
were	O
observed	B-C1441672
in	O
the	O
lung	B-C0024109
by	O
fluorescent	B-C0026022
microscopy	I-C0026022
.	O
	
dir-labeled	B-C0034551
hucb	B-C0162371
-	O
mncs	B-C0806987
were	O
detected	B-C0442726
in	O
the	O
lung	B-C0024109
and	O
other	O
organs	B-C0178784
by	O
bioluminescence	B-C2955764
images	I-C2955764
.	O
	
medial	B-C0205098
thickness	B-C1280412
,	O
rv	B-C0225883
/	O
s	B-C0018819
+	O
lv	B-C0225897
and	O
at	B-C3655682
/	O
et	B-C0812388
were	O
significantly	B-C0750502
improved	B-C0184511
4	O
weeks	O
after	O
hucb	B-C0162371
-	O
mnc	B-C0806987
transplantation	B-C0935850
compared	B-C1707455
with	O
those	O
in	O
mice	B-C0025919
without	O
hucb	B-C0162371
-	O
mnc	B-C0806987
transplantation	B-C0935850
.	O
	
cmtmr	B-C0761898
-	O
positive	B-C1446409
hucb	B-C0162371
-	O
mncs	B-C0806987
were	O
observed	B-C1441672
in	O
the	O
lung	B-C0024109
3	O
hours	O
after	O
transplantation	B-C0935850
.	O
	
bioluminescence	B-C0162404
signals	B-C1710082
were	O
detected	B-C0442726
more	O
strongly	B-C0442821
in	O
the	O
lung	B-C0024109
than	O
in	O
other	O
organs	B-C0178784
for	O
24	O
hours	O
after	O
transplantation	B-C0935850
.	O
	
the	O
results	B-C0683954
indicate	B-C1444656
that	O
hucb	B-C0162371
-	O
mncs	B-C0806987
are	O
incorporated	B-C0243126
into	O
the	O
lung	B-C0024109
early	B-C1279919
after	O
hucb	B-C0162371
-	O
mnc	B-C0806987
transplantation	B-C0935850
and	O
improve	B-C0184511
mct	B-C0085241
-	O
induced	B-C0205263
ph	B-C0020542
.	O
	
interprofessional	B-C0243095
barriers	I-C0243095
a	O
study	O
of	O
quality	B-C2936612
improvement	I-C2936612
work	I-C2936612
among	O
nurses	B-C0028661
and	O
physicians	B-C0031831
this	O
article	O
studies	O
interprofessional	B-C0243095
barriers	I-C0243095
between	O
nurses	B-C0028661
and	O
physicians	B-C0031831
in	O
the	O
context	B-C0449255
of	O
quality	B-C2936612
improvement	I-C2936612
work	I-C2936612
.	O
	
a	O
total	O
of	O
17	O
nurses	B-C0028661
and	O
10	O
physicians	B-C0031831
were	O
interviewed	B-C0018260
at	O
2	O
hospitals	B-C0019994
in	O
sweden	B-C0038995
.	O
	
the	O
study	B-C0439845
uncovered	I-C0439845
a	O
number	B-C4296486
of	I-C4296486
barriers	I-C4296486
relating	O
to	O
both	O
the	O
relative	O
status	O
of	O
each	B-C0441833
group	I-C0441833
and	O
their	O
defined	O
areas	B-C0678341
of	I-C0678341
responsibility	I-C0678341
.	O
	
recovery	B-C0237820
from	O
alcohol	B-C0001973
dependence	I-C0001973
do	O
smoking	B-C0037369
indicators	B-C1522602
predict	O
abstinence	B-C3843422
there	O
is	O
inconsistent	B-C0442809
evidence	B-C3887511
about	O
the	O
potential	B-C3245505
influence	B-C4054723
of	O
smoking	B-C0037369
on	O
recovery	B-C0237820
from	O
alcohol	B-C0001973
dependence	I-C0001973
.	O
	
our	O
study	B-C0947630
aimed	O
at	O
assessing	B-C0184514
the	O
impact	B-C4049986
of	O
smoking-behavior	B-C1519383
on	O
relapse	B-C0035020
during	O
a	O
12	O
months	B-C0439231
follow-up	B-C1522577
period	B-C1948053
following	O
a	O
detoxification	B-C0150543
in	O
patients	B-C0030705
with	O
alcohol	B-C0001956
use	I-C0001956
disorder	I-C0001956
aud	B-C0001956
.	O
	
three	O
hundred	O
patients	B-C0030705
with	O
aud	B-C0001956
74.9	O
smoking	B-C0037369
were	O
recruited	O
from	O
two	O
inpatient	B-C0021562
detoxification	B-C1708333
units	I-C1708333
in	O
psychiatric	B-C0020021
hospitals	I-C0020021
in	O
germany	B-C0017480
and	O
their	O
alcohol	B-C0001948
consumption	I-C0001948
was	O
prospectively	O
followed	O
for	O
1	O
year	B-C0439234
.	O
	
data	B-C1511726
on	O
different	O
indicators	B-C1522602
of	O
smoking	B-C1519383
behavior	I-C1519383
was	O
gathered	O
.	O
	
cox	B-C0033489
regression	I-C0033489
model	I-C0033489
was	O
used	O
to	O
evaluate	B-C0220825
potential	B-C3245505
risk	B-C0035648
factors	I-C0035648
on	O
time	O
to	O
relapse	B-C0035020
of	O
alcohol	B-C0001948
consumption	I-C0001948
.	O
	
two	O
hundred	O
seventy-nine	O
participants	B-C0679646
n	O
=	O
279	O
were	O
included	O
in	O
the	O
final	B-C3853528
analysis	B-C0936012
.	O
	
smoking	B-C0037369
increased	B-C0205217
the	O
risk	B-C0035647
for	O
alcohol	B-C0035020
relapse	I-C0035020
hazard	B-C2985465
ratio	I-C2985465
=	O
3.962	O
,	O
95%	O
ci	B-C0009667
1.582	O
.	O
	
however	O
,	O
this	O
increased	B-C0205217
risk	B-C0035647
is	O
slightly	O
reduced	B-C0392756
with	O
higher	O
numbers	O
of	O
daily	B-C0332173
consumed	B-C0459840
cigarettes	I-C0459840
hazard	B-C2985465
ratio	I-C2985465
per	B-C3887962
cigarette	B-C0459840
=	O
986	O
,	O
95%	O
ci	B-C0009667
976-	O
.	O
	
smoking	B-C1276355
reduced	I-C1276355
the	O
probability	B-C0033204
of	O
maintaining	B-C0024501
alcohol	B-C3843422
abstinence	I-C3843422
significantly	B-C0750502
,	O
whereas	O
higher	B-C0205250
number	O
of	O
cigarettes	B-C0459840
smoked	I-C0459840
daily	B-C0332173
diminished	B-C0205216
the	O
increased	B-C0205217
risk	B-C0035647
of	O
alcohol	B-C0035020
relapse	I-C0035020
in	O
alcohol-dependent	B-C0001973
patients	B-C0030705
.	O
	
coordinated	B-C0700114
psychiatric	B-C0205487
and	O
substance	B-C0740858
abuse	I-C0740858
interventions	B-C0184661
for	O
different	O
subgroups	B-C1515021
of	O
patients	B-C0030705
with	O
aud	B-C0001956
in	O
the	O
post-acute	B-C0814495
treatment	I-C0814495
phase	I-C0814495
are	O
necessary	O
.	O
	
individualized	B-C1881197
treatment	B-C1522326
planning	O
is	O
especially	O
important	O
in	O
smoking	B-C0037369
patients	B-C0030705
with	O
aud	B-C0001956
who	O
are	O
vulnerable	O
for	O
a	O
relapse	B-C0035020
to	I-C0035020
alcohol	I-C0035020
drinking	I-C0035020
and	O
for	O
somatic	B-C2986476
complications	B-C0009566
.	O
	
our	O
findings	B-C0243095
might	O
support	O
individualized	B-C1881197
treatment	B-C0599880
plans	I-C0599880
similar	O
patterns	B-C0449774
of	O
neural	B-C1254358
activity	I-C1254358
predict	O
memory	B-C0025260
function	I-C0025260
during	O
encoding	B-C0679058
and	O
retrieval	B-C0679061
neural	B-C0242406
networks	I-C0242406
that	O
span	B-C2700613
the	O
medial	B-C0039485
temporal	I-C0039485
lobe	I-C0039485
mtl	B-C0039485
,	O
prefrontal	B-C0162783
cortex	I-C0162783
,	O
and	O
posterior	B-C4252868
cortical	I-C4252868
regions	I-C4252868
are	O
essential	O
to	O
episodic	B-C0561843
memory	I-C0561843
function	I-C0561843
in	O
humans	B-C0086418
.	O
	
encoding	B-C0679058
and	O
retrieval	B-C0679061
are	O
supported	O
by	O
the	O
engagement	O
of	O
both	O
distinct	O
neural	B-C0027792
pathways	I-C0027792
across	O
the	O
cortex	B-C0007776
and	O
common	O
structures	B-C0678594
within	O
the	O
medial	B-C0039485
temporal	I-C0039485
lobes	I-C0039485
.	O
	
however	O
,	O
the	O
degree	O
to	O
which	O
memory	B-C1285654
performance	I-C1285654
can	O
be	O
determined	O
by	O
neural	B-C0597043
processing	I-C0597043
that	O
is	O
common	O
to	O
encoding	B-C0679058
and	O
retrieval	B-C0679061
remains	O
to	O
be	O
determined	O
.	O
	
to	O
identify	O
neural	B-C1704864
signatures	I-C1704864
of	O
successful	O
memory	B-C0025260
function	I-C0025260
,	O
we	O
administered	O
a	O
delayed	O
free-recall	B-C3540678
task	I-C3540678
to	O
187	O
neurosurgical	B-C0524850
patients	B-C0030705
implanted	B-C0021107
with	O
subdural	B-C0038541
or	O
intraparenchymal	B-C0933845
depth	B-C0491577
electrodes	I-C0491577
.	O
	
we	O
developed	O
multivariate	B-C0282574
classifiers	I-C0282574
to	O
identify	O
patterns	B-C0449774
of	O
spectral	O
power	O
across	O
the	O
brain	B-C0006104
that	O
independently	O
predicted	O
successful	O
episodic	B-C0679058
encoding	I-C0679058
and	O
retrieval	B-C0679061
.	O
	
during	O
encoding	B-C0679058
and	O
retrieval	B-C0679061
,	O
patterns	B-C0449774
of	O
increased	O
high	B-C0205212
frequency	I-C0205212
activity	B-C1254358
in	O
prefrontal	B-C0162783
,	O
mtl	B-C0039485
,	O
and	O
inferior	B-C0030560
parietal	I-C0030560
cortices	I-C0030560
,	O
accompanied	O
by	O
widespread	O
decreases	O
in	O
low	B-C0205213
frequency	I-C0205213
power	O
across	O
the	O
brain	B-C0006104
predicted	O
successful	O
memory	B-C0025260
function	I-C0025260
.	O
	
using	O
a	O
cross-decoding	B-C0026777
approach	I-C0026777
,	O
we	O
demonstrate	O
the	O
ability	O
to	O
predict	O
memory	B-C0025260
function	I-C0025260
across	O
distinct	O
phases	O
of	O
the	O
free-recall	B-C3540678
task	I-C3540678
.	O
	
furthermore	O
,	O
we	O
demonstrate	O
that	O
classifiers	B-C0282574
that	O
combine	O
information	O
from	O
both	O
encoding	B-C0679058
and	O
retrieval	B-C0679061
states	I-C0679061
can	O
outperform	O
task-independent	B-C3161035
models	I-C3161035
.	O
	
these	O
findings	O
suggest	O
that	O
the	O
engagement	O
of	O
a	O
core	O
memory	B-C0025260
network	I-C0025260
during	O
either	O
encoding	B-C0679058
or	O
retrieval	B-C0679061
shapes	B-C0332479
the	O
ability	B-C4303539
to	I-C4303539
remember	I-C4303539
the	I-C4303539
past	I-C4303539
,	O
despite	O
distinct	O
neural	B-C1254358
interactions	I-C1254358
that	O
facilitate	O
encoding	B-C0679058
and	O
trump's	B-C0086418
got	O
the	O
right	B-C1254370
idea	I-C1254370
i	O
am	O
a	O
us	B-C0041703
nursing	B-C0038496
student	I-C0038496
and	O
feel	B-C0013987
that	O
obamacare	B-C2936611
is	O
a	O
bad	B-C1254370
idea	I-C1254370
.	O
	
i'm	O
disappointed	B-C0870427
that	O
president	B-C1527114
trump	B-C0086418
was	O
not	B-C0243095
able	I-C0243095
to	I-C0243095
get	I-C0243095
rid	I-C0243095
of	I-C0243095
it	O
last	B-C0439231
month	I-C0439231
.	O
	
bilirubin	B-C0005437
and	O
atherosclerotic	B-C0004153
diseases	B-C0012634
bilirubin	B-C0005437
is	O
the	O
final	O
product	B-C1514468
of	O
heme	B-C1157876
catabolism	I-C1157876
in	O
the	O
systemic	B-C0678860
circulation	I-C0678860
.	O
	
for	O
decades	B-C2981279
,	O
increased	B-C0205217
serum	B-C0229671
/	O
plasma	B-C0032105
bilirubin	B-C0005437
levels	B-C0441889
were	O
considered	O
an	O
ominous	O
sign	B-C0311392
of	O
an	O
underlying	O
liver	B-C0023895
disease	I-C0023895
.	O
	
however	O
,	O
data	B-C1511726
from	O
recent	O
years	B-C0439234
convincingly	O
suggest	O
that	O
mildly	O
elevated	B-C3163633
bilirubin	B-C0005437
concentrations	B-C1446561
are	O
associated	B-C0439849
with	O
protection	B-C1545588
against	O
various	O
oxidative	B-C0242606
stress	I-C0242606
-mediated	O
diseases	B-C0012634
,	O
atherosclerotic	O
conditions	O
being	O
the	O
most	O
clinically	O
relevant	O
.	O
	
although	O
scarce	O
data	O
on	O
beneficial	O
effects	O
of	O
bilirubin	O
had	O
been	O
published	O
also	O
in	O
the	O
past	O
,	O
it	O
took	O
until	O
1994	O
when	O
the	O
first	O
clinical	O
study	O
demonstrated	O
an	O
increased	O
risk	O
of	O
coronary	O
heart	O
disease	O
in	O
subjects	O
with	O
low	O
serum	O
bilirubin	O
levels	O
,	O
and	O
bilirubin	O
was	O
found	O
to	O
be	O
a	O
risk	O
factor	O
for	O
atherosclerotic	O
diseases	B-C0012634
independent	O
of	O
standard	O
risk	O
factors	O
.	O
	
consistent	O
with	O
these	O
results	O
,	O
we	O
proved	O
in	O
our	O
own	O
studies	O
,	O
that	O
subjects	O
with	O
mild	O
elevation	O
of	O
serum	O
levels	O
of	O
unconjugated	O
bilirubin	O
benign	O
hyperbilirubinemia	O
,	O
gilbert	O
syndrome	O
have	O
much	O
lower	O
prevalence	O
/	O
incidence	O
of	O
coronary	O
heart	O
as	O
well	O
as	O
peripheral	O
vascular	O
disease	O
.	O
	
we	O
have	O
also	O
demonstrated	O
that	O
this	O
association	O
is	O
even	O
more	O
general	O
,	O
with	O
serum	O
bilirubin	O
being	O
a	O
biomarker	O
of	O
numerous	O
other	O
diseases	O
,	O
often	O
associated	O
with	O
increased	O
risk	O
of	O
atherosclerosis	O
.	O
	
in	O
addition	O
,	O
very	O
recent	O
data	O
have	O
demonstrated	O
biological	O
pathways	O
modulated	O
by	O
bilirubin	O
,	O
which	O
are	O
responsible	O
for	O
observed	O
strong	O
clinical	O
associations	B-C0439849
an	O
automated	B-C0205554
,	O
pharmacist	B-C0031323
-driven	O
initiative	B-C0424093
improves	B-C0184511
quality	B-C0034379
of	I-C0034379
care	I-C0034379
for	O
staphylococcus	B-C1142423
aureus	I-C1142423
bacteremia	I-C1142423
infectious	B-C0009450
diseases	I-C0009450
id	B-C0009450
consultation	B-C0009818
and	O
antimicrobial	B-C0086388
stewardship	I-C0086388
intervention	I-C0086388
have	O
been	O
shown	O
to	O
improve	B-C0184511
the	O
management	B-C0376636
of	O
staphylococcus	B-C1142423
aureus	I-C1142423
bacteremia	I-C1142423
sab	B-C1142423
.	O
	
as	O
the	O
workload	B-C0085122
of	O
antimicrobial	B-C0086388
stewardship	I-C0086388
programs	I-C0086388
asps	B-C0086388
continues	O
to	O
increase	O
,	O
asps	B-C0086388
must	O
find	O
a	O
way	O
to	O
maximize	O
the	O
efficiency	B-C0033335
of	I-C0033335
the	I-C0033335
program	I-C0033335
while	O
optimizing	O
patient	B-C0030705
outcomes	B-C1274040
.	O
	
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	B-C0220825
the	O
impact	B-C4049986
of	O
incorporating	O
health	B-C0008960
informatics	I-C0008960
into	O
the	O
management	B-C0376636
of	O
sab	B-C1142423
via	O
a	O
pharmacist	B-C0031323
-driven	O
initiative	B-C0424093
.	O
	
retrospective	B-C1514923
,	O
single-center	O
quasi-experimental	B-C1510570
study	B-C2603343
of	O
hospitalized	B-C0030705
patients	I-C0030705
with	O
sab	B-C1142423
.	O
	
during	O
the	O
intervention	B-C0184661
period	B-C1948053
,	O
pharmacists	B-C0031323
were	O
alerted	O
to	O
patients	B-C0030705
with	O
sab	B-C1142423
via	O
a	O
patient	B-C0030705
scoring	B-C0025080
tool	I-C0025080
integrated	O
into	O
the	O
electronic	B-C2362543
medical	I-C2362543
record	I-C2362543
.	O
	
pharmacists	B-C0031323
utilized	O
the	O
scoring	B-C0025080
tool	I-C0025080
and	O
the	O
institution's	B-C2607850
evidence-based	B-C1510541
practice	I-C1510541
guideline	B-C0162791
to	O
make	O
standardized	B-C0034866
recommendations	I-C0034866
to	O
promote	O
adherence	B-C1510802
to	O
sab	B-C1142423
quality-of-care	B-C0034379
measures	B-C0079809
and	O
encourage	O
id	B-C0009450
consultation	B-C0009818
.	O
	
the	O
primary	B-C0205225
outcome	B-C1274040
was	O
overall	O
compliance	B-C3714738
along	O
with	O
adherence	B-C1510802
to	O
individual	B-C0237401
quality-of-care	B-C0034379
components	B-C1705248
.	O
	
secondary	B-C0175668
clinical	O
outcomes	B-C1274040
were	O
also	O
analyzed	B-C0936012
.	O
	
84	O
patients	B-C0030705
were	O
identified	O
for	O
study	B-C2603343
inclusion	B-C1512693
,	O
45	O
in	O
the	O
pre-	O
intervention	B-C0184661
and	O
39	O
in	O
the	O
intervention	B-C0184661
group	B-C0441833
.	O
	
as	O
a	O
whole	O
,	O
all	O
four	O
quality-of-care	B-C0034379
components	B-C1705248
for	O
the	O
management	B-C0376636
of	O
sab	B-C1142423
were	O
significantly	B-C0750502
more	O
frequently	O
adhered	O
to	O
in	O
the	O
intervention	B-C0184661
group	B-C0441833
68.9	O
vs	O
.	O
	
92.3	O
p=0	O
.	O
	
the	O
incidence	B-C0021149
of	O
id	B-C0009450
consult	B-C0009818
improved	B-C0184511
significantly	B-C0750502
by	O
almost	O
20%	O
in	O
the	O
intervention	B-C0184661
group	B-C0441833
75.6	O
vs	O
.	O
	
94.9	O
,	O
p=0	O
.	O
	
no	O
statistically	B-C0237881
significant	I-C0237881
differences	B-C1705242
in	O
duration	O
of	O
bacteremia	B-C0004610
,	O
length-of-stay	B-C0023303
,	O
infection	B-C3714514
-related	O
length-of-stay	B-C0023303
,	O
or	O
readmission	B-C0030700
were	O
observed	O
between	O
the	O
groups	B-C0441833
.	O
	
the	O
incidence	B-C0021149
of	O
all-cause	O
mortality	B-C0026565
was	O
6-fold	O
higher	O
in	O
the	O
pre-	O
intervention	B-C0184661
group	B-C0441833
compared	O
to	O
the	O
intervention	B-C0184661
group	B-C0441833
15.6	O
vs	O
.	O
	
2.6	O
,	O
p=0	O
.	O
	
an	O
automated	B-C0205554
,	O
pharmacist	B-C0031323
-driven	O
intervention	B-C0184661
for	O
the	O
management	B-C0376636
of	O
patients	B-C0030705
with	O
sab	B-C1142423
demonstrated	O
a	O
significant	B-C0750502
improvement	B-C2986411
in	O
patients	B-C0030705
receiving	O
an	O
id	B-C0009450
consult	B-C0009818
,	O
targeted	B-C1521840
antimicrobial	B-C0443071
therapy	I-C0443071
,	O
and	O
adherence	B-C1510802
to	O
all	O
sab	B-C1142423
quality-of-care	B-C0034379
measures	B-C0079809
.	O
	
as	O
antimicrobial	B-C0086388
stewardship	I-C0086388
becomes	O
a	O
mandatory	B-C1514873
aspect	O
of	O
healthcare	B-C0086388
in	O
all	O
hospitals	B-C0019994
in	O
the	O
u.s	B-C0041703
,	O
asps	B-C0086388
will	O
be	O
forced	B-C0443221
to	O
find	B-C0243095
ways	O
to	O
provide	O
more	O
efficient	B-C0442799
,	O
impactful	B-C4049986
,	O
disease	B-C0012634
state-based	O
patient	B-C0017313
care	I-C0017313
.	O
	
our	O
study	B-C2603343
provides	O
the	O
framework	O
for	O
and	O
data	B-C1511726
to	O
support	O
this	O
intervention	B-C0184661
in	O
one	O
of	O
the	O
most	O
clinically	B-C0443178
important	I-C0443178
infectious	B-C0009450
diseases	I-C0009450
.	O
	
involvement	O
of	O
intracellular	B-C0175996
zn	B-C0043481
signaling	B-C4236609
in	O
ltp	B-C0206249
at	O
perforant	B-C0524810
pathway	I-C0524810
-	O
ca1	B-C2717851
pyramidal	I-C2717851
cell	I-C2717851
synapse	I-C2717851
physiological	B-C0205463
significance	O
of	O
synaptic	B-C4236609
zn	I-C4236609
signaling	I-C4236609
was	O
examined	O
at	O
perforant	B-C0524810
pathway	I-C0524810
-	O
ca1	B-C2717851
pyramidal	I-C2717851
cell	I-C2717851
synapses	I-C2717851
.	O
	
in	B-C1515655
vivo	I-C1515655
long-term	B-C0206249
potentiation	I-C0206249
ltp	B-C0206249
at	O
perforant	B-C0524810
pathway	I-C0524810
-	O
ca1	B-C2717851
pyramidal	I-C2717851
cell	I-C2717851
synapses	I-C2717851
was	O
induced	O
using	O
a	O
recording	O
electrode	B-C0013812
attached	O
to	O
a	O
microdialysis	B-C0206056
probe	B-C0182400
and	O
the	O
recording	O
region	O
was	O
locally	O
perfused	B-C0031001
with	O
artificial	B-C0220806
cerebrospinal	I-C0220806
fluid	I-C0220806
acsf	B-C0220806
via	O
the	O
microdialysis	B-C0206056
probe	B-C0182400
.	O
	
perforant	B-C0524810
pathway	I-C0524810
ltp	B-C0206249
was	O
not	O
attenuated	O
under	O
perfusion	B-C0031001
with	O
caedta	B-C0021212
10	O
mm	O
,	O
an	O
extracellular	B-C0521119
zn	B-C0043481
chelator	O
,	O
but	O
attenuated	O
under	O
perfusion	B-C0031001
with	O
znaf-2da	B-C0021212
50	O
μm	O
,	O
an	O
intracellular	B-C0175996
zn	B-C0043481
chelator	O
,	O
suggesting	O
that	O
intracellular	B-C0175996
zn	B-C0043481
signaling	B-C4236609
is	O
required	O
for	O
perforant	B-C0524810
pathway	I-C0524810
ltp	B-C0206249
.	O
	
even	O
in	O
rat	B-C1882598
brain	I-C1882598
slices	I-C1882598
bathed	O
in	O
caedta	B-C0021212
in	O
acsf	B-C0220806
,	O
intracellular	B-C0175996
zn	B-C0043481
level	O
,	O
which	O
was	O
measured	O
with	O
intracellular	B-C0175996
znaf-2	B-C0021212
,	O
was	O
increased	O
in	O
the	O
stratum	B-C3498968
lacunosum-moleculare	I-C3498968
where	O
perforant	B-C0524810
pathway	I-C0524810
-	O
ca1	B-C2717851
pyramidal	I-C2717851
cell	I-C2717851
synapses	I-C2717851
were	O
contained	O
after	O
tetanic	B-C1292856
stimulation	I-C1292856
.	O
	
these	O
results	O
suggest	O
that	O
intracellular	B-C0175996
zn	B-C0043481
signaling	B-C4236609
,	O
which	O
originates	O
in	O
internal	O
stores/	O
proteins	B-C0033684
,	O
is	O
involved	O
in	O
ltp	B-C0206249
at	O
perforant	B-C0524810
pathway	I-C0524810
-	O
ca1	B-C2717851
pyramidal	I-C2717851
cell	I-C2717851
synapses	I-C2717851
.	O
	
because	O
the	O
influx	B-C0007613
of	O
extracellular	B-C0521119
zn	B-C0043481
,	O
which	O
originates	O
in	O
presynaptic	B-C0007613
zn	I-C0007613
release	I-C0007613
,	O
is	O
involved	O
in	O
ltp	B-C0206249
at	O
schaffer	B-C3544403
collateral	I-C3544403
-	O
ca1	B-C2717851
pyramidal	I-C2717851
cell	I-C2717851
synapses	I-C2717851
,	O
synapse	B-C0039062
-dependent	O
zn	B-C0043481
dynamics	O
may	O
be	O
involved	O
in	O
plasticity	B-C4042875
of	O
postsynaptic	B-C0682686
ca1	B-C0206441
pyramidal	I-C0206441
cells	I-C0206441
.	O
	
20s	B-C0014442
immunoproteasomes	I-C0014442
remove	O
formaldehyde	B-C0016564
-	O
damaged	B-C1883709
cytoplasmic	B-C1333198
proteins	I-C1333198
suppressing	B-C1260953
caspase-independent	B-C3820502
cell	I-C3820502
death	I-C3820502
immunoproteasomes	B-C0014442
are	O
known	O
for	O
their	O
involvement	B-C1314939
in	O
antigen	B-C0206431
presentation	I-C0206431
.	O
	
however	O
,	O
their	O
broad	B-C0332464
tissue	B-C0040300
presence	B-C0150312
and	O
other	O
evidence	B-C0332120
are	O
indicative	B-C0392360
of	I-C0392360
nonimmune	B-C0031843
functions	I-C0031843
.	O
	
we	O
examined	O
a	O
role	O
for	O
immunoproteasomes	B-C0014442
in	O
cellular	B-C1817908
responses	I-C1817908
to	O
the	O
endogenous	B-C0205227
and	O
environmental	B-C0007091
carcinogen	I-C0007091
formaldehyde	B-C0016564
fa	B-C0016564
that	O
binds	O
to	O
cytosolic	B-C1383501
and	O
nuclear	B-C0028589
proteins	I-C0028589
producing	O
proteotoxic	B-C0449430
stress	I-C0449430
and	O
genotoxic	B-C0598309
dna	B-C0012854
-	O
histone	B-C0019652
crosslinks	B-C0178576
.	O
	
we	O
found	O
that	O
immunoproteasomes	B-C0014442
were	O
important	B-C3898777
for	O
suppression	B-C1260953
of	O
a	O
caspase-independent	B-C3820502
cell	I-C3820502
death	I-C3820502
and	O
the	O
long-term	B-C0443252
survival	B-C0220921
of	O
fa-treated	B-C0007634
cells	I-C0007634
.	O
	
all	O
major	O
genotoxic	B-C0598309
responses	B-C0871261
to	O
fa	B-C0016564
,	O
including	O
replication	B-C1511692
inhibition	I-C1511692
and	O
activation	B-C1879547
of	O
the	O
transcription	B-C0080055
factor	I-C0080055
p53	I-C0080055
and	O
the	O
apical	B-C0205111
atm	B-C3711796
and	O
atr	B-C3711837
kinases	I-C3711837
,	O
were	O
unaffected	B-C2986417
by	O
immunoproteasome	B-C0014442
inactivity	B-C3244312
.	O
	
immunoproteasome	O
inhibition	B-C3463820
enhanced	B-C2349975
activation	B-C1879547
of	O
the	O
cytosolic	B-C1383501
protein	B-C0033684
damage	B-C1883709
sensor	B-C0121235
hsf1	I-C0121235
,	O
elevated	B-C0441889
levels	I-C0441889
of	O
k48-polyubiquitinated	B-C3820607
cytoplasmic	B-C1333198
proteins	I-C1333198
and	O
increased	B-C0205217
depletion	B-C0333668
of	O
unconjugated	B-C0522530
ubiquitin	B-C0041538
.	O
	
we	O
further	O
found	O
that	O
fa	B-C0016564
induced	B-C0205263
the	O
disassembly	B-C1707798
of	O
26s	B-C0014442
immunoproteasomes	I-C0014442
,	O
but	O
not	O
standard	O
26s	B-C0286330
proteasomes	I-C0286330
,	O
releasing	O
the	O
20s	B-C0014442
catalytic	I-C0014442
immunoproteasome	I-C0014442
.	O
	
fa-treated	B-C0007634
cells	I-C0007634
also	O
had	O
higher	B-C1265611
amounts	I-C1265611
of	O
small	O
activators	B-C0753808
pa28αβ	I-C0753808
and	O
pa28γ	B-C0893173
bound	O
to	O
20s	B-C0014442
particles	I-C0014442
.	O
	
our	O
findings	O
highlight	O
the	O
significance	B-C0750502
of	O
nonnuclear	B-C1883709
damage	I-C1883709
in	O
fa	B-C0016564
injury	O
and	O
reveal	O
a	O
major	O
role	O
for	O
immunoproteasomes	B-C0014442
in	O
elimination	O
of	O
fa-damaged	B-C1883709
cytoplasmic	B-C1333198
proteins	I-C1333198
through	O
ubiquitin	B-C0041538
-	O
independent	B-C0085862
proteolysis	B-C0597304
.	O
	
musculoskeletal	B-C0026858
pain	I-C0026858
profile	B-C1518848
of	O
obese	B-C0028754
individuals	B-C0027361
attending	B-C1999232
a	O
multidisciplinary	B-C0596660
weight	I-C0596660
management	I-C0596660
service	I-C0596660
obesity	B-C0028754
is	O
associated	B-C0332281
with	I-C0332281
numerous	B-C0439064
chronic	B-C0008679
diseases	I-C0008679
,	O
including	B-C0332257
musculoskeletal	B-C0026858
msk	I-C0026858
pain	I-C0026858
,	O
which	O
impacts	B-C4049986
on	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
qol	B-C0034380
.	O
	
there	O
is	O
,	O
however	O
,	O
limited	O
research	O
providing	O
a	O
comprehensive	B-C1880156
msk	B-C0026858
pain	I-C0026858
profile	B-C1518848
of	O
an	O
obese	B-C0028754
cohort	B-C0599755
.	O
	
this	O
retrospective	B-C2985505
study	I-C2985505
utilized	O
a	O
patient	B-C0030705
database	B-C0242356
at	O
a	O
national	B-C0596660
weight	I-C0596660
management	I-C0596660
service	I-C0596660
wms	B-C0596660
.	O
	
following	O
ethical	B-C1136353
approval	B-C2346845
,	O
anonymized	B-C3858751
patient	B-C2707520
data	I-C2707520
were	O
statistically	B-C0871424
analyzed	I-C0871424
to	O
develop	O
a	O
pain	B-C0030193
profile	B-C1518848
,	O
investigate	B-C1292732
relationships	B-C0439849
between	O
pain	B-C0030193
,	O
sleep	B-C0037313
,	O
and	O
function	B-C0516981
,	O
and	O
explore	O
variables	B-C0439828
associated	B-C0332281
with	I-C0332281
having	O
low	B-C0024031
back	I-C0024031
pain	I-C0024031
lbp	B-C0024031
and	O
knee	B-C0231749
pain	I-C0231749
.	O
	
overall	O
,	O
915	O
individuals	B-C0027361
attended	O
the	O
wms	B-C0596660
from	O
january	O
2011	O
to	O
september	O
2015	O
male	B-C0025266
,	O
35%	O
n=318	O
ci	B-C0009667
=32-38	O
female	B-C0043210
,	O
65%	O
n=597	O
ci	B-C0009667
=62-68	O
mean	B-C0444504
age	B-C0001779
44.6	O
.	O
	
mean	B-C0444504
bmi	B-C1305855
was	O
50.7	O
kg/m2	O
class	O
iii	O
obese	B-C0028754
bmi	B-C1305855
40	O
kg/m2	O
,	O
92%	O
n=835	O
ci	B-C0009667
=91-94	O
.	O
	
approximately	B-C0332232
91%	O
reported	O
msk	B-C0026858
pain	I-C0026858
lbp	B-C0024031
,	O
69%	O
n=539	O
ci	B-C0009667
=65-	O
72	O
mean	B-C0444504
nrs	O
7.4	O
knee	B-C0231749
pain	I-C0231749
,	O
58%	O
n=447	O
ci	B-C0009667
=55-61	O
mean	B-C0444504
nrs	O
6.8	O
.	O
	
class	O
iii	O
obese	B-C0028754
and	O
multi-site	B-C1254362
pain	B-C0030193
patients	B-C0030705
had	O
lower	B-C2003888
qol	B-C0034380
and	O
physical	B-C0026606
activity	I-C0026606
levels	B-C0441889
,	O
reduced	B-C0392756
sleep	B-C0037313
,	O
and	O
poorer	B-C2700379
physical	B-C0516981
function	I-C0516981
than	O
less	B-C0547044
obese	B-C0028754
patients	B-C0030705
and	O
those	O
without	B-C0332288
pain	B-C0030193
p<0	O
.	O
	
relationships	B-C0439849
were	O
found	O
between	O
demographic	B-C0011298
,	O
pain	B-C0030193
,	O
self-report	B-C0681906
,	O
psychological	B-C0205486
,	O
and	O
functional	B-C0205245
measures	B-C0079809
p<0	O
.	O
	
patients	B-C0030705
who	O
slept	B-C0243095
fewer	I-C0243095
hours	I-C0243095
and	O
had	O
poorer	B-C2700379
functional	B-C0243095
outcomes	I-C0243095
were	O
more	O
likely	O
to	O
have	O
lbp	B-C0024031
patients	B-C0030705
who	O
were	O
divorced	B-C0086170
,	O
had	O
lower	B-C2003888
qol	B-C0034380
,	O
and	O
more	O
frequent	B-C0332183
nocturia	B-C0028734
were	O
more	O
likely	O
to	O
have	O
knee	B-C0231749
pain	I-C0231749
p<0	O
.	O
	
multi-site	B-C1254362
msk	B-C0026858
pain	I-C0026858
is	O
prevalent	B-C0220900
and	O
severe	B-C0205082
in	O
obese	B-C0028754
patients	B-C0030705
and	O
is	O
negatively	B-C1513916
associated	B-C0332281
with	I-C0332281
most	O
self-report	O
and	O
functional	B-C0243095
outcomes	I-C0243095
.	O
	
this	O
high	O
prevalence	B-C0220900
suggests	O
pain	B-C0002766
management	I-C0002766
strategies	O
must	O
be	O
considered	O
when	O
treating	B-C0087111
obesity	B-C0028754
.	O
	
primary	B-C0205225
management	B-C0376636
and	O
outcome	B-C1274040
-	O
open	B-C0339881
laryngotracheal	I-C0339881
trauma	I-C0339881
acute	B-C0205178
external	B-C0443212
injury	I-C0443212
to	O
the	O
larynx	B-C0023078
is	O
both	O
life	B-C2826244
threatening	I-C2826244
and	O
a	O
potential	O
long	B-C0443252
term	I-C0443252
management	B-C0680830
challenge	O
.	O
	
as	O
otorhinolaryngologist	B-C0334893
we	O
must	O
be	O
prepared	O
and	O
well	O
versed	O
to	O
manage	O
these	O
patients	B-C0030705
.	O
	
in	O
our	O
study	O
seven	O
patients	B-C0030705
of	O
open	B-C0339881
laryngeal	I-C0339881
traumas	I-C0339881
were	O
managed	O
by	O
primary	B-C0441503
closure	I-C0441503
.	O
	
in	O
five	O
patients	B-C0030705
nature	B-C0449499
of	I-C0449499
injury	I-C0449499
was	O
known	O
in	O
other	O
two	O
patients	B-C0030705
exact	O
nature	B-C0449499
of	I-C0449499
injury	I-C0449499
was	O
not	O
known	O
.	O
	
after	O
primary	B-C0441503
closure	I-C0441503
five	O
patients	B-C0030705
with	O
known	O
injury	B-C3263723
survived	B-C0038952
and	O
two	O
patients	B-C0030705
with	O
unknown	O
injury	B-C3263723
died	B-C0011065
.	O
	
as	O
per	O
our	O
experience	B-C0557355
,	O
we	O
recommend	O
primary	B-C0441503
closure	I-C0441503
,	O
if	O
the	O
exact	O
nature	B-C0449499
of	I-C0449499
injury	I-C0449499
is	O
known	O
as	O
the	O
outcome	B-C1274040
is	O
definitely	O
comparative	O
kinematic	B-C0558820
gait	I-C0558820
analysis	I-C0558820
in	O
young	B-C0332239
and	O
old	B-C0580836
beagle	B-C1296765
dogs	I-C1296765
age-related	B-C0851454
involution	B-C0333953
in	O
dogs	B-C1296765
involves	O
loss	B-C1837108
of	I-C1837108
muscle	I-C1837108
mass	I-C1837108
and	O
changes	O
in	O
connective	B-C0009780
tissue	I-C0009780
and	O
articular	B-C0007303
cartilage	I-C0007303
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-C0332128
whether	O
an	O
age-related	B-C0851454
influence	O
on	O
joint	B-C1820723
mobility	I-C1820723
can	O
be	O
detected	B-C0442726
in	O
the	O
absence	B-C0332197
of	O
diseases	B-C0012634
.	O
	
five	O
young	B-C0332239
ø	O
2.0	O
years	B-C0439234
and	O
five	O
old	B-C0580836
ø	O
10.4	O
years	B-C0439234
healthy	B-C3898900
and	O
sound	B-C1296765
beagle	I-C1296765
dogs	I-C1296765
were	O
measured	B-C0444706
during	O
locomotion	B-C0023946
on	O
a	O
treadmill	B-C0184069
by	O
computer-assisted	B-C2362103
gait	B-C0558820
analysis	I-C0558820
.	O
	
angles	B-C0205143
of	O
the	O
shoulder	B-C0037009
,	O
elbow	B-C0013770
,	O
carpal	B-C1262468
,	O
hip	B-C0019558
,	O
stifle	B-C1456798
and	O
tarsal	B-C1527245
joints	I-C1527245
were	O
analyzed	B-C0936012
,	O
including	O
joint	B-C0392762
angle	I-C0392762
progression	I-C0392762
curves	I-C0392762
,	O
minimum	B-C1524031
and	O
maximum	B-C0806909
joint	B-C0022417
angles	B-C0205143
and	O
range	B-C2607871
of	I-C2607871
motion	I-C2607871
rom	B-C2607871
.	O
	
the	O
old	B-C0580836
group	B-C0681850
showed	O
a	O
smaller	O
maximum	O
joint	B-C0022417
angle	B-C0205143
p	O
=	O
0.037	O
and	O
rom	B-C2607871
p	O
=	O
0.037	O
of	O
the	O
carpal	B-C1262468
joint	I-C1262468
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	B-C0037009
,	O
elbow	B-C0013770
and	O
carpal	B-C1262468
joint	I-C1262468
.	O
	
the	O
descriptive	B-C0678257
analysis	I-C0678257
of	O
the	O
progression	B-C0392762
curves	I-C0392762
revealed	O
less	B-C0231455
flexion	I-C0231455
and	O
extension	B-C0231448
of	O
the	O
joints	B-C0022417
of	O
the	O
forelimb	B-C0016555
.	O
	
this	O
indicates	O
restricted	B-C0443288
joint	B-C1820723
mobility	I-C1820723
of	O
the	O
forelimb	B-C0016555
but	O
primarily	O
of	O
the	O
carpal	B-C1262468
joint	I-C1262468
.	O
	
findings	B-C2607943
in	O
the	O
joints	B-C0022417
of	O
the	O
hindlimb	B-C1522391
were	O
not	O
consistent	B-C0332290
contrasting	O
alterations	B-C1515926
may	O
be	O
due	O
to	O
a	O
compensatory	B-C0231186
mechanism	B-C0441712
.	O
	
as	O
most	O
alterations	B-C1515926
were	O
found	B-C0150312
in	O
the	O
distal	B-C0224640
joints	I-C0224640
,	O
these	O
should	O
receive	O
particular	B-C0589098
attention	I-C0589098
when	O
examining	O
elderly	B-C1296765
dogs	I-C1296765
.	O
	
propensity	B-C2718044
score	I-C2718044
matched	O
comparison	B-C1707455
of	O
partial	B-C0728938
to	O
whole	B-C0444667
gland	B-C0033572
cryotherapy	B-C3544233
for	O
intermediate-risk	B-C3640764
prostate	B-C0376358
cancer	I-C0376358
an	O
analysis	B-C0936012
of	O
the	O
cold	B-C0282574
registry	I-C0282574
data	I-C0282574
to	O
compare	O
the	O
oncological	B-C0027651
and	O
functional	B-C0205245
outcomes	B-C0085415
of	O
partial	B-C0728938
versus	O
whole	B-C0444667
-	O
gland	B-C0033572
cryotherapy	B-C3544233
for	O
men	B-C0025266
with	O
intermediate-risk	B-C3640764
prostate	B-C0376358
cancer	I-C0376358
.	O
	
men	B-C0025266
with	O
intermediate-risk	B-C3640764
prostate	B-C0376358
cancer	I-C0376358
treated	B-C0332293
with	I-C0332293
primary	B-C0205225
prostate	B-C3544233
cryotherapy	I-C3544233
from	O
1993-2013	O
were	O
selected	O
from	O
the	O
cryo	B-C0282574
on-line	I-C0282574
data	I-C0282574
registry	I-C0282574
for	O
a	O
1	O
matched	B-C0150103
comparison	B-C1707455
between	O
those	O
undergoing	O
whole	B-C0444667
-	O
gland	B-C0033572
and	O
partial	B-C0728938
prostate	B-C3544233
cryotherapy	I-C3544233
targeted-ablation	B-C0547070
,	O
unilateral/bilateral	B-C0547070
nerve-sparing	I-C0547070
ablations	I-C0547070
.	O
	
a	O
propensity	B-C2718044
score	I-C2718044
was	O
developed	O
based	O
on	O
age	B-C0001779
,	O
pre-biopsy	B-C0229671
serum	I-C0229671
psa	B-C0138741
,	O
biopsy	B-C2123503
gleason	I-C2123503
score	I-C2123503
,	O
clinical	B-C0205563
stage	I-C0205563
,	O
prostate	B-C1441416
volume	I-C1441416
,	O
neoadjuvant	B-C1515985
androgen	I-C1515985
deprivation	I-C1515985
status	B-C0449438
,	O
year	B-C0439234
of	O
surgery	B-C0543467
and	O
pre-treatment	B-C2709094
potency	O
.	O
	
outcomes	B-C0085415
were	O
biochemical	B-C3897727
progression-free	B-C0242792
survival	I-C0242792
bpfs	B-C0242792
using	O
astro	B-C0935549
and	O
phoenix	B-C0935549
criteria	I-C0935549
,	O
12-month	O
continence	B-C0542565
strictly	O
pad-free	O
and	O
sexual	B-C0278092
function	I-C0278092
potency	O
sufficient	B-C0205410
for	O
sexual	B-C0009253
intercourse	I-C0009253
.	O
	
after	O
propensity	B-C2718044
score	I-C2718044
-	O
matching	B-C0150103
,	O
bpfs	B-C0242792
was	O
compared	B-C1707455
using	O
kaplan-meier	B-C1720943
analysis	I-C1720943
and	O
functional	B-C0205245
outcomes	B-C0085415
using	O
chi-square	B-C0008041
tests	I-C0008041
.	O
	
in	O
all	O
,	O
897	O
men	B-C0025266
were	O
identified	B-C0205396
731	O
whole	B-C0444667
-	O
gland	B-C0033572
and	O
166	O
partial	B-C0728938
.	O
	
post-matching	B-C1254367
,	O
166	O
pairs	O
of	O
men	B-C0025266
were	O
analysed	B-C0936012
mean	O
follow-up	B-C1522577
31	O
months	O
.	O
	
the	O
2/5	O
year	O
bpfs	B-C0242792
rate	B-C1521828
was	O
87.2	O
for	O
whole	B-C0444667
-	O
gland	B-C0033572
vs	O
.	O
	
80.7	O
for	O
partial	B-C0728938
ablation	B-C0547070
using	O
phoenix	B-C0935549
p=0	O
and	O
72.3	O
for	O
whole	B-C0444667
gland	B-C0033572
vs	O
.	O
	
82.1	O
for	O
partial	B-C0728938
ablation	B-C0547070
using	O
astro	B-C0935549
criteria	O
p=0	O
.	O
	
of	O
164	O
pairs	O
,	O
the	O
12-month	O
continence	B-C0542565
rate	B-C1521828
was	O
similar	B-C2348205
94.1	O
vs	O
.	O
	
95.1	O
p=0	O
.	O
	
of	O
139	O
pairs	O
,	O
the	O
12-month	O
rate	O
of	O
successful	B-C1272703
intercourse	B-C0009253
was	O
29.5	O
for	O
whole	B-C0444667
-	O
gland	B-C0033572
and	O
46.8	O
for	O
partial	B-C0728938
ablation	B-C0547070
or	O
2.1	O
,	O
p=0	O
.	O
	
the	O
incidence	B-C0021149
of	O
post-treatment	B-C2709088
urinary	B-C0080274
retention	I-C0080274
was	O
6.0	O
and	O
6.6	O
p=0	O
following	O
whole	B-C0444667
-	O
gland	B-C0033572
and	O
partial	B-C0728938
ablation	B-C0547070
respectively	O
and	O
that	O
of	O
rectourethral	B-C0268875
fistula	I-C0268875
was	O
1.2	O
and	O
0%	O
p=0	O
conclusion	O
partial	B-C0728938
ablation	B-C0547070
results	B-C0808233
in	O
better	B-C0332272
post-treatment	B-C2709088
sexual	B-C0278092
function	I-C0278092
compared	B-C1707455
to	O
whole	B-C0444667
-	O
gland	B-C0033572
ablation	B-C0547070
in	O
men	B-C0025266
with	O
intermediate-risk	B-C3640764
prostate	B-C0376358
cancer	I-C0376358
.	O
	
we	O
did	O
not	O
observe	O
a	O
difference	O
in	O
early	B-C1279919
bpfs	B-C0242792
between	O
the	O
two	O
abnormal	B-C0205161
metabolic	B-C0311400
brain	B-C0006104
network	B-C0598941
associated	O
with	O
parkinson's	B-C0030567
disease	I-C0030567
replication	B-C1883725
on	O
a	O
new	O
european	B-C0239307
sample	B-C2347026
the	O
purpose	O
of	O
this	O
study	B-C2603343
was	O
to	O
identify	B-C0205396
the	O
specific	O
metabolic	B-C0311400
brain	B-C0006104
pattern	B-C0449774
characteristic	B-C1521970
for	O
parkinson's	B-C0030567
disease	I-C0030567
pd	B-C0030567
parkinson's	B-C0449782
disease-related	I-C0449782
pattern	I-C0449782
pdrp	B-C0449782
,	O
using	O
network	B-C0598941
analysis	O
of	O
18f	B-C0872169
positron	I-C0872169
emission	I-C0872169
tomography	I-C0872169
fdg-pet	B-C0872169
brain	B-C0006104
images	B-C1704254
in	O
a	O
cohort	B-C0599755
of	O
slovenian	B-C0037334
pd	B-C0030567
patients	B-C0030705
.	O
	
twenty	O
pd	B-C0030567
patients	B-C0030705
age	B-C0001779
70.1	O
7.8	O
years	B-C0439234
,	O
movement	B-C3639714
disorder	I-C3639714
society	I-C3639714
unified	I-C3639714
parkinson's	I-C3639714
disease	I-C3639714
motor	I-C3639714
rating	I-C3639714
scale	I-C3639714
mds-updrs-iii	B-C3639714
38.3	O
12.2	O
disease	B-C0872146
duration	I-C0872146
4.3	O
4.1	O
years	B-C0439234
and	O
20	O
age	B-C0001779
-	O
matched	B-C1708943
normal	B-C0009932
controls	I-C0009932
ncs	B-C0009932
underwent	O
fdg-pet	B-C0872169
brain	B-C0203860
imaging	I-C0203860
.	O
	
an	O
automatic	B-C0026336
voxel-based	I-C0026336
scaled	I-C0026336
subprofile	I-C0026336
model	I-C0026336
/	O
principal	B-C0429865
component	I-C0429865
analysis	I-C0429865
ssm	B-C0026336
/	O
pca	B-C0429865
was	O
applied	O
to	O
these	O
scans	B-C0441633
for	O
pdrp	B-C0449782
-	O
slovenia	B-C0037334
identification	B-C0205396
.	O
	
the	O
pattern	B-C0449782
was	O
characterized	B-C1880022
by	O
relative	O
hypermetabolism	B-C0342952
in	O
pallidum	B-C0017651
,	O
putamen	B-C0034169
,	O
thalamus	B-C0039729
,	O
brain	B-C0006121
stem	I-C0006121
,	O
and	O
cerebellum	B-C0007765
associated	O
with	O
hypometabolism	B-C0347938
in	O
sensorimotor	B-C3499125
cortex	I-C3499125
,	O
posterior	B-C3853037
parietal	I-C3853037
,	O
occipital	B-C1184145
,	O
and	O
frontal	B-C0016733
cortices	I-C0016733
.	O
	
the	O
expression	B-C1254370
of	O
pdrp	B-C0449782
-	O
slovenia	B-C0037334
discriminated	O
pd	B-C0030567
patients	B-C0030705
from	O
ncs	B-C0009932
p	O
<	O
0.0001	O
and	O
correlated	B-C1707520
positively	O
with	O
patients	B-C0030705
'	O
clinical	B-C0205210
score	B-C0449820
mds-updrs-iii	B-C3639714
,	O
p	O
=	O
0.03	O
.	O
	
additionally	O
,	O
its	O
topography	B-C0392918
agrees	O
well	O
with	O
the	O
original	O
pdrp	B-C0449782
p	O
<	O
0.001	O
identified	B-C0205396
in	O
american	B-C0596070
cohort	B-C0599755
of	O
pd	B-C0030567
patients	B-C0030705
.	O
	
we	O
validated	O
the	O
pdrp	B-C0449782
-	O
slovenia	B-C0037334
expression	B-C1254370
on	O
additional	O
fdg-pet	B-C0872169
scans	B-C0441633
of	O
20	O
pd	B-C0030567
patients	B-C0030705
,	O
20	O
ncs	B-C0009932
,	O
and	O
25	O
patients	B-C0030705
with	O
atypical	B-C4302185
parkinsonism	I-C4302185
ap	B-C4302185
.	O
	
we	O
confirmed	O
that	O
the	O
expression	B-C1254370
of	O
pdrp	B-C0449782
-	O
slovenia	B-C0037334
manifests	O
good	O
diagnostic	B-C0598285
accuracy	I-C0598285
with	O
specificity	B-C1511884
and	O
sensitivity	B-C1511883
of	O
85-90%	O
at	O
optimal	O
pattern	B-C0449782
expression	B-C1254370
cutoff	O
for	O
discrimination	O
of	O
pd	B-C0030567
patients	B-C0030705
and	O
ncs	B-C0009932
and	O
is	O
not	O
expressed	O
in	O
ap	B-C4302185
.	O
	
pdrp	B-C0449782
-	O
slovenia	B-C0037334
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-C1517324
imaging	I-C1517324
biomarker	B-C0005516
independent	O
of	O
patient	B-C0030705
population	B-C1257890
.	O
	
it	O
accurately	O
differentiates	O
pd	B-C0030567
patients	B-C0030705
from	O
ncs	B-C0009932
and	O
ap	B-C4302185
and	O
correlates	O
well	O
with	O
the	O
clinical	B-C0205210
measure	B-C0079809
of	O
pd	B-C0030567
progression	B-C0242656
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
gestational	B-C0439671
use	B-C1524063
of	I-C1524063
antidepressants	B-C0003289
and	O
antipsychotics	B-C0040615
on	O
neonatal	B-C0021289
outcomes	B-C1274040
for	O
women	B-C0043210
with	O
severe	B-C0205082
mental	B-C0004936
illness	I-C0004936
psychotropic	B-C0033978
medication	I-C0033978
use	B-C1524063
occurs	B-C2745955
in	O
8%	O
of	O
pregnancies	B-C0032961
,	O
with	O
rates	B-C2359857
increasing	B-C0442808
,	O
and	O
often	B-C0332183
multiple	B-C0439064
medications	B-C0013227
prescribed	B-C0278329
.	O
	
this	O
study	B-C2603343
aims	O
to	O
determine	O
if	O
the	O
use	B-C1524063
of	I-C1524063
psychotropic	B-C0033978
medication	I-C0033978
,	O
in	O
a	O
cohort	B-C0599755
of	O
women	B-C0043210
with	O
severe	B-C0205082
mental	B-C0004936
illness	I-C0004936
,	O
increases	B-C0442805
rates	B-C0032975
of	O
special	B-C0204795
care	I-C0204795
nursery	I-C0204795
admission	B-C0184666
and	O
reports	B-C0025102
differences	B-C1705242
between	O
antidepressant	B-C0003289
and	O
antipsychotic	B-C0040615
medication	I-C0040615
use	B-C1524063
either	O
alone	B-C0205171
or	O
in	O
combination	B-C0013162
.	O
	
a	O
retrospective	B-C2985505
database	I-C2985505
analysis	I-C2985505
from	I-C2985505
a	I-C2985505
cohort	I-C2985505
with	O
severe	B-C0205082
mental	B-C0004936
illness	I-C0004936
in	O
pregnancy	B-C0032961
identified	B-C0205396
268	O
pregnant	B-C0033011
women	I-C0033011
who	O
were	O
grouped	B-C0008902
according	O
to	O
medication	B-C0013227
type	B-C0332307
.	O
	
demographic	B-C0681668
,	O
obstetric	B-C0205484
and	O
neonatal	B-C0021289
variables	B-C0439828
were	O
analysed	B-C0936012
using	B-C1524063
t-tests	B-C0871472
,	O
χ	O
,	O
analysis	B-C0936012
of	O
variance	B-C1711260
and	O
logistic	B-C0681925
regression	I-C0681925
analysis	I-C0681925
for	O
special	B-C0204795
care	I-C0204795
nursery	I-C0204795
admission	B-C0184666
.	O
	
the	O
medication	B-C0030705
groups	I-C0030705
consisted	O
of	O
women	B-C0043210
taking	B-C0030705
no	I-C0030705
psychotropic	I-C0030705
medications	I-C0030705
n	O
=	O
67	O
those	B-C0030705
taking	I-C0030705
antipsychotics	I-C0030705
n	O
=	O
87	O
those	B-C0030705
taking	I-C0030705
antidepressants	I-C0030705
n	O
=	O
55	O
those	B-C0030705
taking	I-C0030705
and	I-C0030705
a	I-C0030705
combination	I-C0030705
of	I-C0030705
antidepressants/antipsychotics	I-C0030705
n	O
=	O
59	O
.	O
	
rates	B-C2359857
of	O
special	B-C0204795
care	I-C0204795
nursery	I-C0204795
admission	B-C0184666
in	O
women	B-C0043210
who	O
took	O
psychotropic	B-C0033978
medication	I-C0033978
41.3	O
were	O
elevated	O
compared	B-C1707455
to	O
those	B-C0030705
who	I-C0030705
did	I-C0030705
not	I-C0030705
26.9	O
p	O
=	O
0.035	O
,	O
and	O
were	O
significantly	B-C0750502
raised	B-C0442818
when	O
compared	B-C1707455
to	O
the	O
general	B-C0683971
population	I-C0683971
p	O
<	O
0.000	O
.	O
	
no	B-C3842396
significant	I-C3842396
difference	I-C3842396
occurred	O
between	O
the	O
medication	B-C0030705
groups	I-C0030705
.	O
	
a	O
significant	B-C0750502
adjusted	O
odds	B-C0028873
ratio	I-C0028873
of	O
2.79	O
95%	O
ci	O
1.286	O
was	O
found	B-C0150312
for	O
special	B-C0204795
care	I-C0204795
nursery	I-C0204795
and	O
psychiatric	B-C0237457
admission	I-C0237457
during	B-C0347984
pregnancy	B-C0032961
but	O
not	O
for	O
psychotropic	B-C0033978
medication	I-C0033978
.	O
	
rates	B-C0032975
of	O
special	B-C0204795
care	I-C0204795
nursery	I-C0204795
admission	B-C0184666
are	O
elevated	O
in	O
neonates	B-C0021289
of	O
women	B-C0043210
with	O
severe	B-C0205082
mental	B-C0004936
illness	I-C0004936
taking	O
psychotropic	B-C0033978
medication	I-C0033978
,	O
but	O
were	O
not	O
different	O
for	O
monotherapy	B-C3846440
or	O
polytherapy	B-C0013218
when	O
prescribing	B-C0278329
antidepressants	B-C0003289
or	O
antipsychotic	B-C0040615
medication	I-C0040615
.	O
	
additional	O
vulnerability	B-C1821973
occurs	B-C2745955
in	O
the	O
neonates	B-C0021289
of	O
women	B-C0043210
with	O
a	O
mental	B-C0004936
illness	I-C0004936
and	O
paediatric	B-C0237433
presence	O
at	O
delivery	B-C0005615
is	O
does	O
intrawound	B-C0042313
vancomycin	I-C0042313
application	B-C4048755
during	O
spine	B-C2608059
surgery	I-C2608059
create	O
vancomycin-resistant	B-C0752078
organism	B-C0029235
surgical	B-C0038941
site	I-C0038941
infection	I-C0038941
ssi	B-C0038941
following	O
spine	B-C2608059
surgery	I-C2608059
is	O
a	O
morbid	B-C0205556
and	O
expensive	B-C1171258
complication	I-C1171258
.	O
	
the	O
use	O
of	O
intrawound	B-C0042313
vancomycin	I-C0042313
is	O
emerging	O
as	O
a	O
solution	O
to	O
reduce	O
ssi	B-C0038941
.	O
	
the	O
development	O
of	O
vancomycin-resistant	B-C0752078
pathogens	B-C0450254
is	O
an	O
understandable	O
concern	O
.	O
	
to	O
determine	O
the	O
occurrence	B-C2745955
of	O
vancomycin-resistant	B-C0752078
ssi	B-C0038941
in	O
patients	B-C0030705
with	O
and	O
without	O
use	O
of	O
intrawound	B-C0042313
vancomycin	I-C0042313
.	O
	
patients	B-C0030705
undergoing	O
elective	O
spine	O
surgery	O
were	O
dichotomized	O
based	O
on	O
whether	O
intrawound	O
vancomycin	O
was	O
applied	O
.	O
	
outcome	O
was	O
occurrence	O
of	O
ssi	O
requiring	O
return	O
to	O
the	O
operating	O
room	O
within	O
postoperative	O
90	O
days	O
.	O
	
the	O
intrawound	O
culture	O
and	O
vancomycin	O
minimal	O
inhibitory	O
concentrations	O
mic	O
were	O
reviewed	O
.	O
	
analyses	O
were	O
conducted	O
to	O
compare	O
the	O
pathogen	O
profile	O
and	O
mic	O
for	O
vancomycin	O
in	O
patients	O
who	O
received	O
vancomycin	O
and	O
those	O
who	O
did	O
not	O
.	O
	
of	O
the	O
total	O
2802	O
patients	O
,	O
43%	O
n	O
=	O
1215	O
had	O
intrawound	O
vancomycin	O
application	O
during	O
the	O
index	O
surgery	O
.	O
	
the	O
use	O
of	O
vancomycin	O
was	O
associated	O
with	O
significantly	O
lower	O
deep	O
ssi	O
rates	O
1.6	O
n	O
=	O
20	O
vs	O
2.5	O
n	O
=	O
40	O
,	O
p	O
=	O
02	O
.	O
	
the	O
occurrence	O
of	O
staphylococcus	O
aureus	O
ssi	O
was	O
significantly	O
lower	O
in	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	O
vancomycin	O
32%	O
vs	O
65%	O
,	O
p	O
=	O
003	O
.	O
	
none	O
of	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	O
vancomycin	O
powder	O
,	O
and	O
subsequently	O
developed	O
an	O
s	O
aureus	O
ssi	O
,	O
demonstrated	O
pathogens	O
with	O
resistance	O
to	O
vancomycin	O
.	O
	
all	O
patients	O
had	O
mic	O
<	O
2	O
μg/ml	O
,	O
the	O
vancomycin	O
susceptibility	O
threshold	O
.	O
	
the	O
occurrence	O
of	O
gram-negative	O
ssi	O
28%	O
vs	O
7%	O
and	O
culture	O
negative	O
fluid	O
collection	O
16%	O
vs	O
5%	O
was	O
higher	O
in	O
the	O
vancomycin	O
cohort	O
.	O
	
the	O
use	O
of	O
intrawound	O
vancomycin	O
during	O
the	O
index	O
spine	O
surgery	O
was	O
protective	O
against	O
ssi	O
following	O
spine	O
surgery	O
.	O
	
the	O
application	O
of	O
intrawound	O
vancomycin	O
during	O
index	O
surgery	O
does	O
not	O
appear	O
to	O
create	O
vancomycin-resistant	O
organisms	O
in	O
the	O
event	O
of	O
an	O
ssi	B-C0038941
adequacy	B-C0808073
criteria	B-C0243161
for	O
thyroid	B-C0193787
fna	I-C0193787
evaluated	B-C0220825
by	O
thinprep	B-C0430022
slides	I-C0430022
only	O
adequacy	B-C0808073
criteria	B-C0243161
for	O
thyroid	B-C0193787
fine-needle	I-C0193787
aspiration	I-C0193787
fna	B-C0193787
recommended	B-C0034866
by	O
the	O
bethesda	B-C0022885
system	I-C0022885
for	I-C0022885
reporting	I-C0022885
thyroid	I-C0022885
cytopathology	I-C0022885
tbs	B-C0022885
were	O
developed	O
with	O
smears	B-C0444186
,	O
but	O
they	O
are	O
commonly	O
applied	B-C4048755
to	O
thinpreps	B-C0430022
tps	B-C0430022
.	O
	
this	O
study	O
evaluated	B-C0220825
adequacy	B-C0808073
in	O
tps	B-C0430022
at	O
different	O
diagnostic	B-C0348026
thresholds	B-C0449864
.	O
	
all	O
fna	B-C0193787
procedures	I-C0193787
performed	B-C0884358
between	O
2010	O
and	O
2015	O
with	O
matched	B-C1708943
surgical	B-C0370003
specimens	I-C0370003
were	O
analyzed	B-C0936012
.	O
	
cell	B-C0007584
counts	I-C0007584
and	O
cytological	B-C0205471
features	B-C2348519
were	O
evaluated	B-C0220825
in	O
all	O
initially	O
nondiagnostic	B-C0686919
nd	B-C0686919
cases	B-C0681850
.	O
	
nd	B-C0686919
cases	B-C0681850
were	O
reclassified	B-C0205542
into	O
tbs	B-C0022885
categories	B-C0683312
by	O
2	O
pathologists	B-C0334866
,	O
and	O
the	O
results	B-C1274040
were	O
compared	B-C1707455
with	O
surgical	B-C1274040
outcomes	I-C1274040
.	O
	
one	O
hundred	B-C0392762
forty-six	I-C0392762
of	O
the	O
151	O
cases	B-C0681850
initially	O
classified	B-C0008902
as	O
nd	B-C0686919
were	O
available	B-C0470187
for	O
review	B-C0699752
,	O
and	O
they	O
had	O
a	O
mean	B-C0444504
cell	B-C0007584
count	I-C0007584
of	O
60.5	O
standard	B-C0871420
deviation	I-C0871420
,	O
71.4	O
.	O
	
interobserver	B-C0680240
agreement	I-C0680240
on	O
the	O
reclassification	B-C0008902
of	O
nd	B-C0686919
cases	B-C0681850
was	O
moderate	B-C0205081
k	O
=	O
0.57	O
,	O
and	O
consensus	B-C0376298
yielded	B-C0392762
48	O
nd	B-C0686919
cases	B-C0681850
33%	O
,	O
72	O
benign	B-C0205183
cases	B-C0681850
49%	O
,	O
24	O
cases	B-C0681850
of	O
atypia	B-C0741302
of	O
undetermined	B-C1272585
significance	I-C1272585
16%	O
,	O
and	O
2	O
cases	B-C0681850
suspicious	B-C4050405
for	I-C4050405
malignancy	I-C4050405
1%	O
.	O
	
lowering	B-C2003888
the	O
diagnostic	B-C0348026
threshold	B-C0449864
to	O
any	O
follicular	B-C1571705
cells	B-C0007634
yielded	B-C0392762
a	O
sensitivity	B-C0036667
of	O
92%	O
,	O
a	O
specificity	B-C0037791
of	O
60%	O
,	O
a	O
positive	B-C1514243
predictive	I-C1514243
value	I-C1514243
of	O
59%	O
,	O
a	O
negative	B-C1513918
predictive	I-C1513918
value	I-C1513918
of	O
92%	O
,	O
and	O
a	O
false-negative	B-C0205558
rate	B-C1521828
of	O
7.7	O
,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	B-C0348026
cases	B-C0681850
were	O
93%	O
,	O
58%	O
,	O
59%	O
,	O
93%	O
,	O
and	O
7.7	O
,	O
respectively	O
.	O
	
including	O
cases	B-C0681850
with	O
>60	O
cells	B-C0007634
but	O
lacking	B-C0332268
6	O
groups	B-C0681860
containing	B-C2700400
at	O
least	O
10	O
cells	B-C0007634
did	O
not	O
affect	O
test	B-C0871060
performance	I-C0871060
.	O
	
nuclear	B-C0333902
enlargement	I-C0333902
,	O
pallor	B-C0030232
,	O
grooves	B-C1184482
,	O
and	O
the	O
presence	B-C0150312
of	O
histiocytoid	B-C1516945
cells	I-C1516945
in	O
initially	O
nd	B-C0686919
fna	B-C0193787
correlated	B-C1707520
with	O
malignancy	B-C4282132
.	O
	
in	O
thyroid	B-C0193787
fna	I-C0193787
examined	B-C0332128
with	O
tp	B-C0430022
only	O
,	O
lowering	B-C2003888
the	O
adequacy	B-C0808073
threshold	B-C0449864
and	O
eliminating	O
the	O
requirement	B-C1514873
of	O
6	O
groups	B-C0681860
of	O
at	O
least	O
10	O
cells	B-C0007634
did	O
not	O
significantly	B-C0750502
affect	O
test	B-C0871060
performance	I-C0871060
if	O
cytological	B-C0205471
features	B-C2348519
associated	B-C0332281
with	I-C0332281
malignancy	B-C4282132
were	O
absent	B-C0332197
.	O
	
silk	B-C0074529
i	I-C0074529
and	O
silk	B-C0074529
ii	I-C0074529
studied	B-C2603343
by	O
fast	B-C0006780
scanning	I-C0006780
calorimetry	I-C0006780
using	O
fast	B-C0006780
scanning	I-C0006780
calorimetry	I-C0006780
fsc	B-C0006780
,	O
we	O
investigated	B-C1292732
the	O
glass	B-C2700061
transition	I-C2700061
and	O
crystal	B-C0444626
melting	B-C0599882
of	O
samples	B-C0370003
of	O
b	B-C0323309
.	O
	
mori	I-C0323309
silk	B-C1449666
fibroin	I-C1449666
containing	O
silk	B-C0074529
i	I-C0074529
and/or	O
silk	B-C0074529
ii	I-C0074529
crystal	B-C0444626
s	O
.	O
	
due	O
to	O
the	O
very	O
short	B-C1806781
residence	B-C0237096
times	B-C0040223
at	O
high	B-C0205250
temperatures	B-C0039476
during	O
such	O
measurements	B-C0242485
,	O
thermal	B-C0018837
decomposition	B-C2700592
of	O
silk	B-C0074529
protein	I-C0074529
can	O
be	O
significantly	B-C0750502
suppressed	B-C0443189
.	O
	
fsc	B-C0006780
was	O
performed	B-C0884358
at	O
2000k/s	O
using	O
the	O
mettler	B-C0006780
flash	I-C0006780
dsc1	I-C0006780
on	O
fibroin	B-C0016042
films	B-C1561572
with	O
masses	B-C1306372
around	O
130-270ng	O
.	O
	
films	B-C1561572
were	O
prepared	O
with	O
different	B-C1705242
crystalline	B-C0444626
fractions	B-C1264633
ranging	O
from	O
0.26	O
to	O
0.50	O
and	O
with	O
different	B-C1705242
crystal	B-C0444626
structures	I-C0444626
silk	B-C0074529
i	I-C0074529
,	O
silk	B-C0074529
ii	I-C0074529
,	O
or	O
mixed	O
by	O
varying	O
the	O
processing	B-C1709694
conditions	B-C0348080
.	O
	
these	O
included	O
water	B-C0043047
annealing	B-C0150247
at	O
different	B-C1705242
temperatures	B-C0039476
,	O
exposure	B-C0332157
to	I-C0332157
50%	O
meoh	B-C0001963
in	O
water	B-C0043047
,	O
or	O
autoclaving	B-C0179177
.	O
	
the	O
resulting	B-C1274040
crystal	B-C0444626
structure	I-C0444626
was	O
examined	O
using	O
wide	B-C0205143
angle	I-C0205143
x-ray	B-C1306645
scattering	I-C1306645
.	O
	
degree	B-C0449286
of	O
crystallinity	B-C0444626
was	O
evaluated	B-C0332128
from	O
fourier	B-C0206055
transform	I-C0206055
infrared	I-C0206055
ftir	I-C0206055
spectroscopy	I-C0206055
and	O
from	O
analysis	B-C0936012
of	O
the	O
heat	B-C2349063
capacity	I-C2349063
increment	B-C1705117
at	O
the	O
glass	B-C1257885
transition	I-C1257885
temperature	I-C1257885
.	O
	
silk	B-C1449666
fibroin	I-C1449666
films	B-C1561572
prepared	O
by	O
water	B-C0043047
annealing	B-C0150247
at	O
25	O
were	O
the	O
least	O
crystalline	B-C0444626
and	O
had	O
silk	B-C0074529
i	I-C0074529
structure	B-C1510464
.	O
	
ftir	B-C0206055
and	O
fsc	B-C0006780
studies	B-C2603343
showed	O
that	O
films	B-C1561572
prepared	O
by	O
autoclaving	B-C0179177
or	O
50%	O
meoh	B-C0001963
exposure	B-C0332157
were	O
the	O
most	O
crystalline	B-C0444626
and	O
had	O
silk	B-C0074529
ii	I-C0074529
structure	B-C1510464
.	O
	
intermediate	B-C0205103
crystalline	B-C0444626
fraction	B-C1264633
and	O
mixed	O
silk	B-C0074529
i	I-C0074529
/	O
silk	B-C0074529
ii	I-C0074529
structure	B-C1510464
s	O
were	O
found	O
in	O
films	B-C1561572
prepared	O
by	O
water	B-C0043047
annealing	B-C0150247
at	O
37	O
.	O
	
fsc	B-C0006780
results	B-C0683954
indicate	O
that	O
silk	B-C0074529
i	I-C0074529
i	O
crystals	O
exhibit	O
endotherms	O
of	O
narrower	O
width	O
and	O
have	O
higher	O
mean	O
melting	O
temperature	O
tm	O
,	O
compared	O
to	O
silk	B-C0074529
i	I-C0074529
crystals	O
which	O
melt	O
at	O
tm	O
.	O
	
films	O
containing	O
mixed	O
silk	O
i	I-C0074529
/	O
silk	O
ii	O
structure	O
showed	O
two	O
clearly	O
separated	O
endothermic	O
peaks	O
.	O
	
evidence	O
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	O
s	O
melt	O
separately	O
and	O
do	O
not	O
thermal	O
ly	O
interconvert	O
on	O
the	O
extremely	O
short	O
time	O
scale	O
0.065s	O
between	O
onset	O
and	O
end	O
of	O
melting	O
of	O
the	O
fsc	O
experiment	O
.	O
	
silkworm	O
silk	O
is	O
a	O
naturally	O
occurring	O
biomaterial	O
.	O
	
the	O
fibroin	O
component	O
of	O
silk	O
forms	O
two	O
types	O
of	O
crystals	B-C0444626
.	O
	
silk	O
properties	O
depend	O
upon	O
the	O
amount	O
and	O
type	O
of	O
crystals	O
,	O
and	O
their	O
stability	O
.	O
	
one	O
measure	O
of	O
stability	O
is	O
crystal	O
melting	O
temperature	O
.	O
	
crystal	O
s	O
which	O
are	O
more	O
stable	O
have	O
a	O
higher	O
melting	O
temperature	O
.	O
	
until	O
now	O
,	O
it	O
has	O
been	O
challenging	O
to	O
study	O
thermal	O
behavior	O
of	O
silk	O
crystal	O
s	O
because	O
they	O
degrade	O
at	O
high	O
temperature	O
.	O
	
to	O
avoid	O
degradation	O
,	O
and	O
study	O
the	O
melting	O
properties	O
of	O
silk	O
biomaterial	O
,	O
we	O
heated	O
silk	O
at	O
a	O
very	O
fast	O
rate	O
of	O
2000k/s	O
using	O
a	O
special	O
calorimeter	O
.	O
	
we	O
have	O
shown	O
that	O
the	O
two	O
crystal	O
types	O
have	O
very	O
different	O
melting	O
temperature	O
s	O
,	O
indicating	O
that	O
one	O
crystal	O
type	O
is	O
much	O
more	O
stable	O
than	O
the	O
leonurine	B-C0064761
attenuates	B-C0599946
hyperalgesia	B-C0020429
in	O
mice	B-C0026809
with	O
induced	B-C0205263
adenomyosis	B-C0341858
background	O
adenomyosis	B-C0341858
,	O
defined	O
as	O
the	O
invasion	B-C2699153
of	O
endometrial	B-C0227848
glands	I-C0227848
and	O
stroma	B-C0927195
into	O
the	O
myometrium	B-C0027088
,	O
is	O
a	O
common	B-C0205214
gynecological	B-C0017411
disorder	I-C0017411
.	O
	
in	O
the	O
present	O
study	O
we	O
report	B-C0684224
on	O
the	O
effect	B-C1280500
of	O
leonurine	B-C0064761
on	O
icr	B-C0025925
mice	I-C0025925
with	O
adenomyosis	B-C0341858
induced	B-C0205263
by	O
neonatal	B-C2939425
tamoxifen	B-C0039286
.	O
	
material	O
and	O
methods	O
after	O
being	O
treated	B-C1522326
with	O
tamoxifen	B-C0039286
for	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
,	O
we	O
assessed	B-C1516048
body	B-C0005910
weight	I-C0005910
and	O
pain	B-C0030193
modulation	O
in	O
mice	B-C0026809
in	O
hotplate	B-C0182315
tests	B-C0022885
.	O
	
the	O
mice	B-C0026809
were	O
divided	B-C0332849
into	O
5	O
groups	B-C0441833
a	O
low-dose	B-C0445550
leonurine	B-C0064761
treatment	B-C0087111
group	B-C0441833
,	O
a	O
high-dose	B-C0444956
leonurine	B-C0064761
treatment	B-C0087111
group	B-C0441833
,	O
a	O
valproic	B-C0042291
acid	I-C0042291
vpa	B-C0042291
treatment	B-C0087111
group	B-C0441833
,	O
a	O
vehicle	B-C0042444
only	B-C0205171
treatment	B-C0087111
group	B-C0441833
,	O
and	O
a	O
blank	B-C0750479
control	B-C0009932
group	I-C0009932
.	O
	
we	O
evaluated	B-C0220825
body	B-C0005910
weight	I-C0005910
,	O
pain	O
modulation	O
in	O
hotplate	B-C0182315
tests	B-C0022885
,	O
and	O
the	O
depth	B-C0205125
of	O
myometrial	B-C0521387
infiltration	B-C0332448
.	O
	
immunoreactivity	B-C0597879
staining	B-C0487602
of	O
progesterone	B-C0034833
receptor	I-C0034833
pr	B-C0034833
,	O
nuclear	B-C1567061
factor-κb	I-C1567061
phosphorylated-p65	I-C1567061
p-p65	B-C1567061
,	O
cyclooxygenase-2	B-C1447194
cox-2	B-C1447194
,	O
and	O
oxytocin	B-C3849099
receptor	I-C3849099
otr	B-C3849099
was	O
evaluated	B-C0220825
by	O
immunohistochemistry	B-C0021044
.	O
	
results	O
the	O
measurement	B-C0242485
of	O
the	O
body	B-C0005910
weight	I-C0005910
,	O
myometrial	B-C0521387
infiltration	B-C0332448
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	B-C2939425
tamoxifen	B-C0039286
treatment	B-C0087111
led	O
to	O
adenomyosis	B-C0341858
.	O
	
leonurine	B-C0064761
treatment	B-C0087111
appeared	O
to	O
decrease	B-C0547047
hyperalgesia	B-C0020429
and	O
myometrial	B-C0521387
infiltration	B-C0332448
.	O
	
immunoreactivity	B-C0597879
staining	B-C0487602
showed	O
decreased	B-C0205216
p-p65	B-C1567061
,	O
cox-2	B-C1447194
,	O
and	O
otr	B-C3849099
protein	B-C1171362
expressions	I-C1171362
.	O
	
conclusions	O
our	O
results	O
indicate	O
that	O
leonurine	B-C0064761
attenuates	B-C0599946
hyperalgesia	B-C0020429
in	O
mice	B-C0026809
with	O
induced	B-C0205263
adenomyosis	B-C0341858
via	O
down-regulating	B-C0013081
expressions	B-C1171362
of	O
p-p65	B-C1567061
,	O
cox-2	B-C1447194
,	O
and	O
otr	B-C3849099
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	B-C1522326
adenomyosis	B-C0341858
.	O
	
a	O
randomized	B-C0034656
,	O
head-to-head	B-C0205556
study	B-C2603343
of	O
virtual	B-C3494470
reality	I-C3494470
exposure	I-C3494470
therapy	I-C3494470
for	O
posttraumatic	B-C0038436
stress	I-C0038436
disorder	I-C0038436
virtual	B-C3494470
reality	I-C3494470
exposure	I-C3494470
therapy	I-C3494470
vret	B-C3494470
is	O
one	O
of	O
the	O
few	O
interventions	B-C1273869
supported	B-C1521721
by	O
randomized	B-C0282440
controlled	I-C0282440
trials	I-C0282440
for	O
the	O
treatment	B-C0087111
of	O
combat-related	B-C0038436
posttraumatic	I-C0038436
stress	I-C0038436
disorder	I-C0038436
ptsd	B-C0038436
in	O
active	B-C2135638
duty	I-C2135638
service	I-C2135638
members	B-C0680022
.	O
	
a	O
comparative	B-C1579762
effectiveness	I-C1579762
study	I-C1579762
was	O
conducted	O
to	O
determine	O
if	O
virtual	B-C0871582
reality	I-C0871582
technology	B-C0039421
itself	O
improved	B-C0184511
outcomes	B-C0085415
,	O
or	O
if	O
similar	B-C2348205
results	B-C1274040
could	O
be	O
achieved	B-C0001072
with	O
a	O
control	B-C0870527
exposure	I-C0870527
therapy	I-C0870527
cet	B-C0870527
condition	B-C0348080
.	O
	
service	B-C0557854
members	B-C0680022
with	O
combat-related	B-C0038436
ptsd	I-C0038436
were	O
randomly	B-C0439605
selected	B-C1707391
to	O
receive	B-C1514756
nine	O
weeks	B-C0439230
of	O
vret	B-C3494470
or	O
cet	B-C0870527
.	O
	
assessors	B-C0401803
,	O
but	O
not	O
therapists	B-C0871525
,	O
were	O
blinded	B-C0150108
.	O
	
ptsd	B-C0038436
symptom	B-C1457887
improvement	B-C2986411
was	O
assessed	B-C1516048
one	O
week	B-C0439230
and	O
3	O
months	B-C0439231
after	O
the	O
conclusion	B-C1707478
of	O
treatment	B-C0087111
using	O
the	O
clinician-administered	B-C0349674
ptsd	I-C0349674
scale	I-C0349674
caps	B-C0349674
.	O
	
a	O
small	B-C0700321
crossover	O
component	O
was	O
included	B-C0332257
.	O
	
results	B-C1274040
demonstrated	O
that	O
ptsd	B-C0038436
symptoms	B-C1457887
improved	B-C0184511
with	O
both	O
treatments	B-C0087111
,	O
but	O
there	O
were	O
no	O
statistically	B-C0237881
significant	I-C0237881
differences	B-C3842396
between	O
groups	B-C0441833
.	O
	
dropout	B-C0030686
rates	B-C1521828
were	O
higher	B-C0205250
in	O
vret	B-C3494470
.	O
	
of	O
those	O
who	O
received	B-C1514756
vret	B-C3494470
,	O
13/42	O
31%	O
showed	O
>30%	O
improvement	B-C2986411
on	O
the	O
caps	B-C0349674
,	O
versus	O
16/43	O
37%	O
who	O
received	B-C1514756
cet	B-C0870527
.	O
	
three	O
months	B-C0439231
after	O
treatment	B-C0087111
,	O
>30%	O
improvement	B-C2986411
was	O
seen	O
in	O
10/33	O
30%	O
of	O
vret	B-C3494470
participants	B-C0679646
and	O
12/33	O
36%	O
in	O
cet	B-C0870527
.	O
	
participants	B-C0679646
who	O
crossed	B-C0243095
over	I-C0243095
n	O
=	O
11	O
showed	O
no	O
statistically	B-C0237881
significant	I-C0237881
improvements	B-C2986411
in	O
a	O
second	B-C0205436
round	O
of	O
treatment	B-C0087111
,	O
regardless	B-C3641650
of	O
condition	B-C0348080
.	O
	
this	O
study	B-C2603343
supported	B-C1521721
the	O
utility	B-C3669222
of	O
exposure	B-C0870527
therapy	I-C0870527
for	O
ptsd	B-C0038436
,	O
but	O
did	O
not	O
support	B-C1521721
additional	B-C1524062
benefit	B-C0814225
by	O
the	O
inclusion	B-C1512693
of	O
virtual	B-C0871582
reality	I-C0871582
.	O
	
accounting	B-C0680857
for	O
linkage	B-C0023746
disequilibrium	I-C0023746
in	O
genome	B-C2349866
scans	I-C2349866
for	O
selection	B-C0036576
without	B-C0332288
individual	B-C0443299
genotypes	B-C0017431
the	O
local	B-C0036449
score	I-C0036449
approach	I-C0036449
detecting	B-C0282579
genomic	I-C0282579
footprints	I-C0282579
of	O
selection	B-C0036576
is	O
an	O
important	O
step	O
in	O
the	O
understanding	O
of	O
evolution	B-C0015219
.	O
	
accounting	O
for	O
linkage	B-C0023746
disequilibrium	I-C0023746
in	O
genome	B-C2349866
scans	I-C2349866
increases	O
detection	B-C1511790
power	B-C3854080
,	O
but	O
haplotype	B-C0018591
-based	O
methods	O
require	O
individual	B-C0443299
genotypes	B-C0017431
and	O
are	O
not	O
applicable	O
on	O
pool-sequenced	B-C1509144
samples	I-C1509144
.	O
	
we	O
propose	O
to	O
take	O
advantage	O
of	O
the	O
local	B-C0036449
score	I-C0036449
approach	I-C0036449
to	O
account	O
for	O
linkage	B-C0023746
disequilibrium	I-C0023746
in	O
genome	B-C2349866
scans	I-C2349866
for	O
selection	B-C0036576
,	O
cumulating	B-C1516698
possibly	O
small	O
signals	B-C0037080
from	O
single	O
markers	B-C0017393
over	O
a	O
genomic	B-C1517520
segment	I-C1517520
,	O
to	O
clearly	O
pinpoint	O
a	O
selection	B-C0036576
signal	B-C0037080
.	O
	
using	O
computer	B-C0009609
simulations	I-C0009609
,	O
we	O
demonstrate	O
that	O
this	O
approach	O
detects	B-C0442726
selection	B-C0036576
with	O
higher	O
power	O
than	O
several	O
state-of-the-art	B-C0700033
single-marker	B-C0017393
,	O
windowing	O
or	O
haplotype	B-C0018591
-based	O
approaches	O
.	O
	
we	O
illustrate	O
this	O
on	O
two	O
benchmark	B-C0525063
data	B-C0150098
sets	I-C0150098
including	O
individual	B-C0443299
genotypes	B-C0017431
,	O
for	O
which	O
we	O
obtain	O
similar	O
results	O
with	O
the	O
local	B-C0036449
score	I-C0036449
and	O
one	O
haplotype	B-C0018591
-based	O
approach	O
.	O
	
finally	O
,	O
we	O
apply	O
the	O
local	B-C0036449
score	I-C0036449
approach	I-C0036449
to	O
pool-seq	B-C0282574
data	I-C0282574
obtained	O
from	O
a	O
divergent	B-C1705242
selection	B-C0036576
experiment	B-C0681814
on	O
behaviour	B-C0004927
in	O
quail	B-C0034374
and	O
obtain	O
precise	O
and	O
biologically	B-C0205460
coherent	B-C4068804
selection	B-C0036576
signals	B-C0037080
while	O
competing	O
methods	O
fail	O
to	O
highlight	O
any	O
clear	O
selection	B-C0036576
signature	O
,	O
our	O
method	O
detects	B-C0442726
several	O
regions	O
involving	O
genes	B-C0017337
known	O
to	O
act	O
on	O
social	B-C0728831
responsiveness	B-C0205342
or	O
autistic	B-C4314654
traits	I-C4314654
.	O
	
although	O
we	O
focus	O
here	O
on	O
the	O
detection	B-C0442726
of	O
positive	B-C1446409
selection	B-C0036576
from	O
multiple	B-C0282574
population	I-C0282574
data	I-C0282574
,	O
the	O
local	B-C0036449
score	I-C0036449
approach	I-C0036449
is	O
general	O
and	O
can	O
be	O
applied	O
to	O
other	O
genome	B-C2349866
scans	I-C2349866
for	O
selection	B-C0036576
or	O
other	O
genomewide	B-C2350277
analyses	I-C2350277
such	O
as	O
is	O
uv	B-C0041625
-	O
induced	B-C0205263
electron-driven	B-C1254365
proton	I-C1254365
transfer	I-C1254365
active	B-C0205177
in	O
a	O
chemically	B-C0205556
modified	I-C0205556
a	B-C0001407
t	B-C0040087
dna	B-C0012854
base	B-C0600436
pair	I-C0600436
transient	B-C0037806
electronic	I-C0037806
and	I-C0037806
vibrational	I-C0037806
absorption	I-C0037806
spectroscopies	I-C0037806
have	O
been	O
used	O
to	O
investigate	B-C1292732
whether	O
uv	B-C0041625
-	O
induced	B-C0205263
electron-driven	B-C1254365
proton	I-C1254365
transfer	I-C1254365
edpt	B-C1254365
mechanisms	B-C0441712
are	O
active	B-C0205177
in	O
a	O
chemically	B-C0205556
modified	I-C0205556
adenine	B-C0001407
-	O
thymine	B-C0040087
a	B-C0001407
t	B-C0040087
dna	B-C0012854
base	B-C0600436
pair	I-C0600436
.	O
	
to	O
enhance	O
the	O
fraction	B-C1264633
of	I-C1264633
biologically	B-C2347946
relevant	I-C2347946
watson-crick	B-C0020276
wc	I-C0020276
hydrogen-bonding	I-C0020276
motifs	B-C3178796
and	O
eliminate	O
undesired	O
hoogsteen	B-C1254350
structures	I-C1254350
,	O
a	O
chemically	B-C0205556
modified	I-C0205556
derivative	B-C1527240
of	I-C1527240
a	I-C1527240
was	O
synthesized	O
,	O
8-	O
8tba	O
.	O
	
equimolar	O
solutions	O
of	O
8tba	O
and	O
silyl-protected	O
t	O
nucleosides	O
in	O
chloroform	O
yield	O
a	O
mixture	O
of	O
wc	O
pairs	O
,	O
reverse	O
wc	O
pairs	O
,	O
and	O
residual	O
monomers	O
.	O
	
unlike	O
previous	O
transient	O
absorption	O
studies	O
of	O
wc	O
guanine	O
-	O
cytosin	O
e	O
g	O
c	O
pairs	O
,	O
no	O
clear	O
spectroscopic	O
or	O
kinetic	O
evidence	O
was	O
identified	O
for	O
the	O
participation	O
of	O
edpt	O
in	O
the	O
excited-state	O
relaxation	O
dynamics	O
of	O
8tba	O
t	O
pairs	O
,	O
although	O
ultrafast	O
sub-100	O
fs	O
edpt	O
cannot	O
be	O
discounted	O
.	O
	
monomer-like	O
dynamics	O
are	O
proposed	O
to	O
dominate	O
in	O
8tba	O
t	I-C0040087
monitoring	B-C1283169
proteolytic	B-C1514570
processing	I-C1514570
events	B-C0441471
by	O
quantitative	B-C3525763
mass	I-C3525763
spectrometry	I-C3525763
protease	B-C1150095
activity	I-C1150095
plays	O
a	O
key	O
role	B-C3871154
in	O
a	O
wide	O
variety	O
of	O
biological	B-C3714634
processes	I-C3714634
including	B-C0332257
gene	B-C0017262
expression	I-C0017262
,	O
protein	B-C0597297
turnover	I-C0597297
and	O
development	B-C0678723
.	O
	
misregulation	B-C0243095
of	O
these	O
proteins	B-C0033684
has	O
been	O
associated	B-C0332281
with	I-C0332281
many	O
cancer	B-C0872066
types	I-C0872066
such	O
as	O
prostate	B-C0376358
,	O
breast	B-C0006142
,	O
and	O
skin	B-C0007114
cancer	I-C0007114
.	O
	
thus	O
,	O
the	O
identification	B-C0205396
of	O
protease	B-C0030940
substrates	B-C3891814
will	O
provide	B-C1999230
key	O
information	B-C1533716
to	O
understand	B-C0162340
proteolysis	B-C0597304
-related	O
pathologies	B-C0030664
.	O
	
areas	O
covered	B-C0439844
proteomics	B-C0872252
-based	O
methods	B-C0025663
to	O
investigate	B-C1292732
proteolysis	B-C0597304
activity	I-C0597304
,	O
focusing	O
on	O
substrate	B-C3891814
identification	B-C0205396
,	O
protease	B-C0030940
specificity	B-C0678612
and	O
their	O
applications	B-C0441485
in	O
systems	B-C1450477
biology	I-C1450477
are	O
reviewed	B-C1709940
.	O
	
their	O
quantification	B-C1709793
strategies	O
,	O
challenges	B-C0805586
and	O
pitfalls	B-C0205556
are	O
underlined	O
and	O
the	O
biological	B-C0205460
implications	O
of	O
protease	B-C0030940
malfunction	B-C0231174
are	O
highlighted	O
.	O
	
expert	B-C0600219
commentary	I-C0600219
dysregulated	B-C0243095
protease	B-C1150095
activity	I-C1150095
is	O
a	O
hallmark	B-C0205556
for	O
some	O
disease	B-C0012634
pathologies	B-C0030664
such	O
as	O
cancer	B-C0006826
.	O
	
current	B-C0521116
biochemical	B-C0205474
approaches	B-C1292724
are	O
low	B-C0205251
throughput	B-C0392762
and	O
some	O
are	O
limited	B-C0439801
by	O
the	O
amount	B-C1265611
of	O
sample	B-C2347026
required	B-C1514873
to	O
obtain	B-C1301820
reliable	O
results	B-C0456984
.	O
	
mass	B-C0037813
spectrometry	I-C0037813
based	O
proteomics	B-C0872252
provides	B-C1999230
a	O
suitable	B-C3900053
platform	B-C1710360
to	O
investigate	B-C1292732
protease	B-C1150095
activity	I-C1150095
,	O
providing	B-C1999230
information	B-C1533716
about	O
substrate	B-C0038592
specificity	I-C0038592
and	O
mapping	B-C0030944
cleavage	B-C0002518
sites	I-C0002518
.	O
	
diabetic	B-C0011881
nephropathy	I-C0011881
as	O
the	O
cause	B-C1314792
of	O
end-stage	B-C0022661
kidney	I-C0022661
disease	I-C0022661
reported	O
on	O
the	O
medical	B-C3261387
evidence	I-C3261387
form	I-C3261387
cms2728	B-C3261387
at	O
a	O
single	O
center	B-C0475309
background	O
end-stage	B-C0022661
renal	I-C0022661
disease	I-C0022661
esrd	B-C0022661
incidence	B-C0021149
due	O
to	O
type	B-C0441730
2	I-C0441730
diabetic	B-C0011881
nephropathy	I-C0011881
dn	B-C0011881
is	O
35-50%	O
,	O
according	O
to	O
the	O
united	B-C1622900
states	I-C1622900
renal	I-C1622900
data	I-C1622900
system	I-C1622900
.	O
	
methods	O
a	O
single-	O
center	B-C0475309
,	O
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
to	O
determine	O
incidence	B-C0021149
and	O
diagnostic	B-C0598285
accuracy	I-C0598285
for	O
type	B-C0441730
2	I-C0441730
dn	B-C0011881
as	O
the	O
primary	B-C0205225
cause	B-C1314792
of	O
esrd	B-C0022661
code	O
250.40	O
on	O
the	O
center	B-C0041718
for	I-C0041718
medicare	I-C0041718
medicaid	I-C0041718
cms	B-C0041718
medical	B-C3261387
evidence	I-C3261387
report	I-C3261387
form	I-C3261387
cms2728	B-C3261387
submitted	B-C1515023
at	O
renal	B-C0206074
replacement	I-C0206074
therapy	I-C0206074
initiation	O
.	O
	
all	O
patients	B-C0030705
18	O
years	B-C0439234
of	O
age	B-C0001779
with	O
a	O
cms2728	B-C3261387
submitted	B-C1515023
between	O
1	O
march	O
2006	O
and	O
31	O
march	O
2015	O
at	O
a	O
single	O
academic	B-C1552471
military	I-C1552471
medical	I-C1552471
center	I-C1552471
esrd	B-C0022661
network	O
5	O
were	O
included	O
.	O
	
medical	B-C0025102
records	I-C0025102
of	O
those	O
with	O
a	O
code	O
250.40	O
diagnosis	B-C0011900
were	O
reviewed	B-C1709940
to	O
determine	O
whether	O
they	O
met	O
the	O
kidney	B-C1708333
disease	I-C1708333
outcomes	I-C1708333
quality	I-C1708333
initiative	I-C1708333
kdoqi	B-C1708333
2007	O
criteria	B-C0679228
for	O
dn	B-C0011881
.	O
	
results	O
esrd	B-C0022661
incidence	B-C0021149
secondary	O
to	O
type	B-C0441730
2	I-C0441730
dn	B-C0011881
was	O
18.7	O
56/299	O
individual	B-C0027361
cms2728	B-C3261387
submissions	B-C1515022
over	O
9.09	O
years	O
.	O
	
in	O
all	O
,	O
12/56	O
21.4	O
did	O
not	O
meet	O
kdoqi	B-C0679228
criteria	I-C0679228
for	O
type	B-C0441730
2	I-C0441730
dn	B-C0011881
.	O
	
although	O
all	O
had	O
diabetes	B-C0011847
,	O
those	O
not	B-C3828770
meeting	I-C3828770
criteria	I-C3828770
had	O
shorter	O
disease	B-C0872031
duration	I-C0872031
p	O
=	O
0.007	O
,	O
were	O
more	O
likely	O
to	O
have	O
active	B-C0205177
urine	B-C1261248
sediment	I-C1261248
p	O
=	O
0.006	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
macroalbuminuria	B-C1654921
p	O
=	O
0.037	O
or	O
retinopathy	B-C0035309
p	O
=	O
0.002	O
prior	O
to	O
esrd	B-C0022661
.	O
	
on	O
exact	O
logistic	B-C0206031
regression	I-C0206031
,	O
retinopathy	B-C0035309
was	O
significantly	O
associated	B-C0332281
with	I-C0332281
kdoqi	B-C1708333
-predicted	O
dn	B-C0011881
odds	B-C0028873
ratio	I-C0028873
=	O
19.16	O
confidence	B-C0009667
interval	I-C0009667
2.76	O
,	O
p	O
=	O
0.0009	O
.	O
	
conclusions	B-C1707478
in	O
this	O
single-	O
center	B-C0475309
cohort	B-C2985505
,	O
21.4	O
identified	B-C0205396
as	O
having	O
type	B-C0441730
2	I-C0441730
dn	B-C0011881
as	O
the	O
primary	B-C0205225
cause	B-C1314792
of	O
esrd	B-C0022661
were	O
incorrectly	O
assigned	B-C1516050
per	O
kdoqi	B-C1708333
2007	O
clinical	B-C0205210
criteria	B-C0679228
.	O
	
if	O
replicated	B-C0205173
in	O
larger	B-C0549177
populations	B-C1257890
,	O
this	O
could	O
have	O
substantial	O
implications	O
regarding	O
the	O
epidemiology	B-C0014507
of	O
esrd	B-C0022661
in	O
the	O
socioeconomic	B-C0748878
predictors	B-C2698872
of	O
adherence	B-C0516638
behavior	I-C0516638
among	O
hiv-positive	B-C0019699
patients	B-C0030705
receiving	B-C1514756
antiretroviral	B-C1963724
therapy	I-C1963724
in	O
selangor	B-C0017446
,	O
malaysia	B-C0024552
medication	B-C2364172
adherence	I-C2364172
remains	O
a	O
critical	B-C1511545
link	O
between	O
the	O
prescribed	B-C0278329
art	B-C1963724
regimen	B-C0040808
and	O
treatment	B-C0085415
outcome	I-C0085415
.	O
	
several	B-C0443302
factors	B-C1521761
may	O
influence	B-C4054723
adherence	B-C0516638
behavior	I-C0516638
.	O
	
this	O
cross-sectional	B-C0010362
study	I-C0010362
aimed	B-C1947946
to	O
highlight	O
socioeconomic	B-C0748878
predictors	B-C2698872
of	O
adherence	B-C0516638
behavior	I-C0516638
among	O
a	O
cohort	B-C0599755
of	O
242	O
adult	B-C0001675
malaysian	B-C0240293
patients	B-C0030705
receiving	B-C1514756
antiretroviral	B-C1963724
therapy	I-C1963724
in	O
hospital	B-C0019994
sungai	I-C0019994
buloh	I-C0019994
,	O
malaysia	B-C0024552
,	O
where	O
they	O
were	O
enrolled	O
in	O
a	O
parent	O
study	O
single-blinded	B-C0242570
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
between	O
january	B-C3829466
and	O
december	B-C3830550
2014	O
.	O
	
statistical	B-C0871424
analysis	I-C0871424
of	O
secondary	B-C0683944
data	I-C0683944
on	O
adherence	B-C0516638
behavior	I-C0516638
and	O
sociodemographic	B-C0683970
characteristics	I-C0683970
of	O
the	O
patients	B-C0030705
revealed	B-C0443289
mean	B-C0243095
age	I-C0243095
of	O
33.4	O
years	B-C0439234
and	O
ranged	B-C1514721
from	O
18	O
to	O
64	O
years	B-C0439234
88.8	O
were	O
males	B-C0086582
.	O
	
a	O
total	O
of	O
224	O
93%	O
patients	B-C0030705
who	O
completed	O
6	O
months'	O
adherence	B-C1254363
assessment	I-C1254363
were	O
included	B-C0332257
in	O
the	O
model	O
.	O
	
of	O
these	O
,	O
135	O
60.3	O
achieved	B-C0432600
optimal	B-C2698651
adherence	B-C1510802
.	O
	
multivariate	B-C0034980
binary	I-C0034980
logistic	I-C0034980
regression	I-C0034980
analysis	I-C0034980
revealed	B-C0443289
that	O
patient's	B-C0030705
income	B-C0021162
and	O
ethnicity	B-C0243103
were	O
significant	B-C0750502
predictors	B-C2698872
of	O
adherence	B-C0516638
behavior	I-C0516638
.	O
	
this	O
may	O
be	O
valuable	O
for	O
targeted	B-C1521840
programmatic	B-C0184661
interventions	I-C0184661
to	O
further	O
enhance	B-C2349975
successful	B-C0521982
treatment	I-C0521982
outcomes	B-C1274040
among	O
the	O
target	B-C0039309
population	I-C0039309
.	O
	
a	O
tobramycin	B-C0040341
vector	I-C0040341
enhances	B-C2349975
synergy	B-C1318081
and	O
efficacy	B-C0598333
of	O
efflux	B-C1254351
pump	I-C1254351
inhibitors	I-C1254351
against	B-C0521124
multidrug-resistant	B-C0242640
gram-negative	B-C0018150
bacteria	I-C0018150
drug	B-C1512072
efflux	I-C1512072
mechanisms	B-C0441712
interact	B-C0687133
synergistically	B-C2986495
with	O
the	O
outer	B-C1167331
membrane	I-C1167331
permeability	B-C0007605
barrier	B-C0028778
of	O
gram-negative	B-C0018150
bacteria	I-C0018150
,	O
leading	B-C1522538
to	O
intrinsic	B-C0205102
resistance	B-C4281815
that	O
presents	O
a	O
major	B-C0205164
challenge	B-C0805586
for	O
antibiotic	B-C0003232
drug	B-C1512068
development	I-C1512068
.	O
	
efflux	B-C1254351
pump	I-C1254351
inhibitors	I-C1254351
epis	B-C1254351
which	O
block	B-C0332206
the	O
efflux	B-C1512072
of	O
antibiotics	B-C0003232
synergize	B-C0205195
antibiotics	B-C0003232
,	O
but	O
the	O
clinical	B-C1512068
development	I-C1512068
of	O
epi	B-C1254351
/	O
antibiotic	B-C0003232
combination	B-C0013218
therapy	I-C0013218
to	O
treat	B-C0087111
multidrug-resistant	B-C0242640
mdr	B-C0242640
gram-negative	B-C0085423
infections	I-C0085423
has	O
been	O
challenging	B-C0805586
.	O
	
this	O
is	O
in	O
part	O
caused	B-C0015127
by	O
the	O
inefficiency	B-C0231184
of	O
current	B-C0521116
epis	B-C1254351
to	O
penetrate	B-C0205321
the	O
outer	B-C1167331
membrane	I-C1167331
and	O
resist	B-C4281815
efflux	B-C1512072
.	O
	
we	O
demonstrate	O
that	O
conjugation	B-C1160466
of	O
a	O
tobramycin	B-C0040341
tob	B-C0040341
vector	O
to	O
epis	B-C1254351
like	O
nmp	B-C0044097
,	O
paroxetine	B-C0070122
,	O
or	O
dbp	B-C0428883
enhances	B-C2349975
synergy	B-C1318081
and	O
efficacy	B-C0598333
of	O
epis	B-C1254351
in	O
combination	B-C0205195
with	O
tetracycline	B-C1744619
antibiotics	I-C1744619
against	O
mdr	B-C0242640
gram-negative	B-C0018150
bacteria	I-C0018150
including	O
pseudomonas	B-C0033809
aeruginosa	I-C0033809
.	O
	
besides	O
potentiating	B-C2242637
tetracycline	B-C1744619
antibiotics	I-C1744619
,	O
tob	B-C0040341
-	O
epi	B-C1254351
conjugates	B-C0596313
can	O
also	O
suppress	B-C1260953
resistance	B-C4281815
development	B-C1527148
to	O
the	O
tetracycline	B-C1744619
antibiotic	I-C1744619
minocycline	B-C0026187
,	O
thereby	O
providing	B-C1999230
a	O
strategy	B-C0679199
to	O
develop	B-C1527148
more	O
effective	B-C1704419
adjuvants	B-C0001552
to	O
rescue	O
tetracycline	B-C1744619
antibiotics	I-C1744619
from	O
resistance	B-C4281815
in	O
mdr	B-C0242640
gram-negative	B-C0018150
bacteria	I-C0018150
.	O
	
detection	B-C1511790
of	O
ama-m2	B-C0312621
in	O
human	B-C0086418
saliva	B-C0036087
potentials	B-C3245505
in	O
diagnosis	B-C0011900
and	O
monitoring	B-C1283169
of	O
primary	B-C0008312
biliary	I-C0008312
cholangitis	I-C0008312
serum	B-C0229671
anti-mitochondrial	B-C0312621
antibody	I-C0312621
type	I-C0312621
2	I-C0312621
ama-m2	B-C0312621
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	B-C0005516
for	O
the	O
diagnosis	B-C0011900
of	O
primary	B-C0008312
biliary	I-C0008312
cholangitis	I-C0008312
pbc	B-C0008312
.	O
	
however	O
,	O
serological	B-C0036743
tests	I-C0036743
have	O
many	O
limitations	B-C0449295
,	O
including	O
inconvenience	B-C4062984
,	O
invasiveness	B-C1301757
,	O
and	O
infection	B-C0582147
risks	I-C0582147
.	O
	
thus	O
,	O
a	O
less	B-C0547044
invasive	B-C0205281
approach	B-C0449445
to	O
detect	B-C0442726
ama-m2	B-C1446191
titer	I-C1446191
is	O
desirable	O
.	O
	
we	O
examined	O
salivary	B-C0036087
ama-m2	B-C0312621
of	O
potential	B-C3245505
pbc	B-C0008312
patients	B-C0030705
and	O
found	O
that	O
ama-m2	B-C0312621
could	O
be	O
detected	B-C0442726
only	O
in	O
saliva	B-C0036087
of	O
serum	B-C0229671
ama-m2-positive	B-C4021051
pbc	B-C0008312
patients	B-C0030705
,	O
but	O
not	O
in	O
saliva	B-C0036087
of	O
serum	B-C0229671
ama-m2-negative	B-C0853205
pbc	B-C0008312
patients	B-C0030705
,	O
oral	B-C0206139
lichen	I-C0206139
planus	I-C0206139
patients	B-C0030705
olp	B-C0206139
patients	B-C0030705
,	O
or	O
healthy	B-C2986479
controls	I-C2986479
.	O
	
furthermore	O
,	O
the	O
concentration	B-C1446561
of	O
salivary	B-C0036087
ama-m2	B-C0312621
was	O
positively	B-C1707520
correlated	I-C1707520
with	O
the	O
amount	B-C1265611
of	O
serum	B-C0229671
ama-m2	B-C0312621
in	O
patients	B-C0030705
.	O
	
the	O
salivary	B-C0036087
inflammatory	B-C0079189
cytokines	I-C0079189
were	O
increased	B-C0205217
in	O
the	O
pbc	B-C0008312
,	O
consistent	B-C0332290
with	I-C0332290
the	O
results	B-C1274040
of	O
serum	B-C0229671
test	B-C0022885
.	O
	
these	O
findings	O
indicated	O
that	O
saliva	B-C0036087
might	O
be	O
a	O
less	B-C0547044
invasive	B-C0205281
and	O
cost-effective	B-C1511536
medium	B-C1705217
to	O
accurately	O
test	B-C0039593
for	O
ama-m2	B-C2825862
levels	I-C2825862
and	O
this	O
is	O
a	O
promising	O
development	B-C1527148
for	O
the	O
diagnosis	B-C0011900
and	O
monitoring	B-C1283169
of	O
mental	B-C0025353
health	I-C0025353
and	O
associated	B-C0332281
factors	B-C1521761
among	O
young	B-C0332239
offenders	B-C0699726
in	O
chile	B-C0008107
a	O
cross-sectional	B-C0010362
study	I-C0010362
few	O
studies	O
in	O
latin	B-C0023122
america	I-C0023122
have	O
explored	O
mental	B-C0004936
disorder	I-C0004936
among	O
young	B-C0332239
offenders	B-C0699726
,	O
or	O
variables	B-C0439828
associated	B-C0332281
with	I-C0332281
it	O
.	O
	
our	O
aim	O
was	O
to	O
test	O
for	O
associations	B-C0439849
between	O
childhood	B-C0231335
adversity	B-C3900081
or	O
substance	B-C4061432
misuse	I-C4061432
and	O
psychiatric	B-C0004936
disorders	I-C0004936
among	O
young	B-C0332239
offenders	B-C0699726
.	O
	
sentenced	B-C0860081
adolescent	B-C0205653
offenders	B-C0699726
were	O
recruited	B-C2949735
from	O
young	B-C0332239
offenders'	B-C0699726
institutions	B-C0442681
or	O
community	B-C3162245
centres	I-C3162245
provided	O
by	O
the	O
chilean	B-C0680773
national	I-C0680773
service	I-C0680773
for	I-C0680773
minors	I-C0680773
.	O
	
psychiatric	B-C0004936
disorders	I-C0004936
were	O
assessed	B-C1516048
using	O
the	O
mini	B-C0021819
international	I-C0021819
neuropsychiatric	I-C0021819
interview	I-C0021819
,	O
conducted	O
by	O
trained	B-C0033908
psychologists	I-C0033908
.	O
	
a	O
trained	B-C0037467
sociologist	I-C0037467
used	O
an	O
ad	B-C0021822
hoc	I-C0021822
interview	I-C0021822
to	O
collect	O
information	B-C1533716
about	O
childhood	B-C4298416
experiences	I-C4298416
,	O
including	O
parenting	B-C3836557
,	O
trauma	B-C3714660
,	O
education	B-C0013622
and	O
substance	B-C4061432
misuse	I-C4061432
.	O
	
multivariable	B-C0206031
logistic	I-C0206031
regressions	I-C0206031
were	O
used	O
to	O
analyse	B-C0010998
data	I-C0010998
.	O
	
the	O
most	O
prevalent	O
psychiatric	B-C0004936
disorders	I-C0004936
among	O
the	O
935	O
participants	B-C0679646
were	O
marijuana	B-C0006870
dependence	I-C0006870
disorder	I-C0006870
,	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
,	O
and	O
anxiety	B-C0003469
disorders	I-C0003469
.	O
	
substance	B-C0038586
use	I-C0038586
disorders	I-C0038586
were	O
less	O
frequent	O
among	O
young	B-C0332239
offenders	B-C0699726
who	O
were	O
serving	O
their	O
sentence	B-C0392751
in	O
young	B-C0332239
offenders'	B-C0699726
institutions	B-C0442681
than	O
among	O
those	O
serving	O
in	O
community	B-C3162245
centres	I-C3162245
and	O
more	O
frequent	B-C0332183
among	O
those	O
who	O
started	B-C1272689
to	O
use	B-C0024809
marijuana	I-C0024809
at	O
an	O
earlier	B-C0001779
age	I-C0001779
.	O
	
among	O
other	O
variables	B-C1705098
,	O
childhood	B-C0008060
maltreatment	I-C0008060
was	O
related	O
to	O
major	B-C1269683
depressive	I-C1269683
disorder	I-C1269683
,	O
and	O
maternal	B-C3494405
death	I-C3494405
to	O
anxiety	B-C0003469
disorders	I-C0003469
.	O
	
higher	O
educational	B-C0013658
status	I-C0013658
was	O
related	O
to	O
a	O
lower	B-C0205213
frequency	I-C0205213
of	O
depressive	B-C0011581
and	O
anxiety	B-C0003469
disorders	I-C0003469
.	O
	
our	O
findings	B-C0243095
suggest	B-C1705535
that	O
greater	O
efforts	O
must	O
be	O
made	O
to	O
identify	B-C0205396
vulnerable	B-C0231204
young	B-C0332239
people	B-C0027361
much	O
earlier	B-C1279919
.	O
	
few	B-C0205388
of	O
these	O
young	B-C0332239
offenders	B-C0699726
with	O
mental	B-C0025353
health	I-C0025353
problems	B-C0033213
had	O
been	O
well	O
adjusted	B-C0456081
in	O
health	B-C0018684
,	O
education	B-C0013622
or	O
socially	B-C0037397
before	O
this	O
period	B-C1948053
of	O
detention	B-C0237567
.	O
	
effects	B-C1704420
of	I-C1704420
regular	B-C0205272
water	B-C2712391
-	O
and	O
land-based	B-C0015259
exercise	I-C0015259
on	O
physical	B-C0516981
function	I-C0516981
after	O
5	O
years	B-C0439234
a	O
long-term	B-C0023981
study	I-C0023981
on	O
the	O
well-being	O
of	O
older	B-C1556094
japanese	I-C1556094
adults	B-C0001792
to	O
investigate	B-C1292732
the	O
effects	B-C1280500
of	O
5	O
years	B-C0439234
of	O
physical	B-C0015259
exercise	I-C0015259
on	O
functional	B-C0205245
parameters	B-C0549193
among	O
older	B-C1556094
japanese	I-C1556094
adults	B-C0001792
who	O
carried	O
out	O
water	B-C2712391
-	O
or	O
land-based	B-C0015259
exercise	I-C0015259
.	O
	
we	O
retrospectively	B-C1514923
investigated	B-C1292732
data	B-C1511726
from	O
5707	O
medical	B-C0582103
examinations	I-C0582103
and	O
enrolled	B-C1516879
77	O
older	B-C0001792
adults	I-C0001792
into	O
the	O
study	B-C2603343
.	O
	
eligible	O
participants	B-C0679646
had	O
to	O
be	O
aged	B-C0001779
60	O
years	B-C0439234
,	O
and	O
engaged	O
in	O
water-based	B-C2712391
exercise	I-C2712391
n	O
=	O
38	O
or	O
a	O
combination	B-C0205195
of	O
water	B-C2712391
-	O
and	O
land-based	B-C0015259
exercise	I-C0015259
n	O
=	O
39	O
for	O
at	O
least	O
80%	O
of	O
their	O
total	B-C0429931
exercise	I-C0429931
time	I-C0429931
for	O
over	O
5	O
years	B-C0439234
at	O
our	O
fitness	B-C0600623
center	I-C0600623
.	O
	
in	O
statistical	B-C0871424
analysis	I-C0871424
,	O
a	O
two-way	B-C1710497
repeated-measures	I-C1710497
analysis	I-C1710497
of	I-C1710497
variance	I-C1710497
was	O
carried	O
out	O
to	O
examine	B-C0332128
the	O
effects	B-C1280500
over	O
time	B-C0040223
and	O
by	O
exercise	B-C2708664
type	I-C2708664
,	O
and	O
the	O
changes	B-C0392747
in	O
each	O
parameter	B-C0549193
over	O
5	O
years	B-C0439234
were	O
also	O
compared	B-C1707455
between	O
the	O
two	O
groups	B-C0441833
.	O
	
we	O
found	B-C0243095
significant	B-C0750502
main	B-C1542147
effects	B-C1280500
and	O
an	O
interaction	B-C1704675
between	O
time	B-C0040223
and	O
exercise	B-C2708664
type	I-C2708664
for	O
gait	B-C2009910
speed	I-C2009910
,	O
with	O
an	O
early	B-C0547047
decline	I-C0547047
in	O
the	O
combined	B-C0205195
exercise	B-C0441833
group	I-C0441833
,	O
as	O
well	O
as	O
significant	B-C0750502
main	B-C1542147
effects	B-C1704420
of	I-C1704420
time	B-C0040223
,	O
showing	O
a	O
functional	B-C4304688
decline	I-C4304688
in	O
grip	B-C0429271
strength	I-C0429271
,	O
one-leg	B-C0231472
standing	I-C0231472
time	B-C0040223
and	O
step/height	B-C0427127
ratio	B-C0456603
in	O
both	O
exercise	B-C2708664
types	I-C2708664
at	O
the	O
5-	O
year	B-C0439234
follow	B-C1522577
up	I-C1522577
.	O
	
the	O
5-	O
year	B-C0439234
changes	B-C0392747
in	O
each	O
parameter	B-C0549193
did	O
not	O
differ	O
between	O
the	O
two	O
groups	B-C0441833
despite	O
the	O
frequency	B-C0556455
of	I-C0556455
exercise	I-C0556455
,	O
even	O
though	O
we	O
found	B-C0243095
a	O
negative	B-C0205160
correlation	B-C1707520
between	O
changes	B-C0392747
in	O
one-leg	B-C0231472
standing	I-C0231472
time	B-C0040223
and	O
total	B-C0439810
amount	B-C1265611
of	O
water-based	B-C2712391
exercise	I-C2712391
.	O
	
contrary	O
to	O
expectations	B-C0679138
,	O
these	O
results	B-C1274040
suggest	B-C1705535
that	O
regular	B-C0205272
engagement	O
in	O
water-based	B-C2712391
exercise	I-C2712391
,	O
even	O
combined	B-C0205195
with	O
land-based	B-C0015259
exercise	I-C0015259
,	O
might	O
have	O
poor	O
long-term	B-C0443252
benefits	B-C0814225
for	O
maintaining	B-C1314677
physical	B-C2607857
performance	I-C2607857
in	O
older	B-C0001792
adults	I-C0001792
.	O
	
combined	B-C0205195
exposures	B-C0028798
of	O
whole-body	B-C4060689
vibration	I-C4060689
and	O
awkward	B-C2112849
posture	I-C2112849
a	O
cross	B-C0010362
sectional	I-C0010362
investigation	I-C0010362
among	O
occupational	B-C0028811
drivers	B-C0684312
by	O
means	O
of	O
simultaneous	B-C0521115
field	B-C0242485
measurements	I-C0242485
multifactorial	B-C1837655
workloads	B-C0085122
such	O
as	O
whole-body	B-C4060689
vibration	I-C4060689
wbv	B-C4060689
,	O
awkward	B-C2112849
posture	I-C2112849
and	O
heavy	O
lifting	B-C0206244
are	O
potential	B-C3245505
predictors	B-C0035648
for	O
low	B-C0024031
back	I-C0024031
pain	I-C0024031
lbp	B-C0024031
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
investigate	B-C1292732
the	O
association	B-C0439849
between	O
lbp	B-C0024031
and	O
these	O
exposures	B-C0028798
among	O
102	O
professional	B-C0028811
drivers	B-C0684312
.	O
	
the	O
combined	B-C0205195
exposures	B-C0028798
of	O
wbv	B-C4060689
and	O
posture	O
are	O
measured	B-C0444706
at	O
different	B-C1705242
workplaces	B-C0162579
.	O
	
health	B-C0018684
and	O
personal	O
data	B-C1511726
as	O
well	O
as	O
information	B-C1533716
about	O
lifting	B-C0206244
tasks	B-C3540678
are	O
collected	B-C1516698
by	O
a	O
questionnaire	B-C0034394
.	O
	
the	O
daily	B-C0332173
vibration	B-C0677519
exposure	I-C0677519
value	B-C1522609
odds	B-C0028873
ratio	I-C0028873
1.69	O
and	O
an	O
index	B-C1881192
for	O
awkward	B-C2112849
posture	I-C2112849
odds	B-C0028873
ratio	I-C0028873
1.63	O
show	O
significant	B-C0750502
association	B-C0439849
with	O
the	O
occurence	B-C2745955
of	O
lbp	B-C0024031
.	O
	
awkward	B-C2112849
posture	I-C2112849
and	O
heavy	O
lifting	B-C0206244
appear	B-C0700364
to	O
be	O
more	O
strongly	O
associated	B-C0332281
with	I-C0332281
sick	B-C0242807
leave	I-C0242807
than	O
wbv	B-C4060689
exposure	B-C0028798
.	O
	
furthermore	O
,	O
a	O
combination	B-C0205195
of	O
the	O
measurement	B-C0242485
results	B-C1274040
of	O
wbv	B-C4060689
and	O
awkward	B-C2112849
posture	I-C2112849
into	O
one	O
quantity	B-C1265611
also	O
shows	O
significant	B-C0750502
correlation	B-C1707520
to	O
lbp	B-C0024031
.	O
	
the	O
combined	B-C0205195
exposure	B-C0028798
of	O
wbv	B-C4060689
and	O
awkward	B-C2112849
posture	I-C2112849
can	O
be	O
described	B-C1552738
in	O
terms	O
of	O
the	O
daily	B-C0332173
vibration	B-C0677519
exposure	I-C0677519
and	O
the	O
index	B-C1881192
for	O
awkward	B-C2112849
posture	I-C2112849
.	O
	
this	O
facilitates	O
work	B-C0162579
place	I-C0162579
assessments	B-C1516048
and	O
future	B-C0016884
research	B-C0035168
in	O
this	O
area	B-C0205146
.	O
	
practitioner	O
summary	O
for	O
the	O
first	O
time	O
,	O
quantitative	B-C0392762
measures	B-C0079809
combining	O
whole-body	B-C4060689
vibration	I-C4060689
and	O
awkward	B-C2112849
posture	I-C2112849
exposures	B-C0028798
have	O
shown	O
to	O
correlate	B-C1707520
with	O
the	O
occurrence	B-C2745955
of	O
low	B-C0024031
back	I-C0024031
pain	I-C0024031
significantly	O
.	O
	
this	O
validates	O
the	O
proposed	O
quantities	B-C1265611
and	O
measurement	B-C0242485
methods	B-C0025664
,	O
which	O
facilitate	O
workplace	B-C0162579
assessments	B-C1516048
and	O
assist	B-C1269765
in	O
the	O
design	B-C1707689
of	O
further	B-C0016884
studies	B-C2603343
which	O
are	O
necessary	O
to	O
establish	B-C0443211
a	O
causal	B-C0274281
exposure	I-C0274281
-	O
response	B-C0871261
relationship	B-C0439849
.	O
	
association	B-C0439849
of	O
ckip-1	B-C1826600
p21a	I-C1826600
polymorphism	B-C0752046
with	O
risk	B-C0035647
of	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
in	O
a	O
chinese	B-C0152035
population	I-C0152035
pathological	B-C1521733
cardiac	B-C1383860
hypertrophy	I-C1383860
is	O
an	O
independent	O
risk	B-C0035648
factor	I-C0035648
for	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
.	O
	
casein	B-C1309499
kinase-2	I-C1309499
interacting	I-C1309499
protein-1	I-C1309499
ckip-1	B-C1309499
can	O
inhibit	O
pathological	B-C1521733
cardiac	B-C1383860
hypertrophy	I-C1383860
.	O
	
therefore	O
,	O
we	O
investigated	B-C1292732
whether	O
ckip-1	B-C1826600
nonsynonymous	B-C0752046
polymorphism	I-C0752046
rs2306235	I-C0752046
pro21ala	B-C0026882
contributes	O
to	O
risk	B-C0035647
and	O
prognosis	B-C0033325
of	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
in	O
a	O
chinese	B-C0152035
population	I-C0152035
.	O
	
a	O
total	O
of	O
923	O
adult	B-C0001675
patients	B-C0030705
with	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
and	O
1020	O
age	B-C0001779
-	O
and	O
gender	B-C0079399
-matched	O
healthy	B-C2986479
controls	I-C2986479
were	O
recruited	O
.	O
	
ckip-1	B-C1826600
rs2306235	I-C1826600
polymorphism	B-C0752046
was	O
genotyped	B-C1285573
using	O
pcr	B-C0032520
-	O
restriction	B-C3714764
fragment	I-C3714764
length	I-C3714764
polymorphism	I-C3714764
.	O
	
additional	O
follow-up	B-C1522577
data	B-C1511726
for	O
140	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
patients	B-C0030705
was	O
evaluated	B-C0220825
.	O
	
the	O
rs2306235	B-C1826600
g	B-C0002085
allele	I-C0002085
was	O
associated	O
with	O
an	O
increased	B-C0205217
risk	B-C0035647
of	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
or	B-C0028873
=	O
1.38	O
,	O
95%	O
ci	B-C0009667
=	O
1.09	O
,	O
p	B-C1709380
=	O
0.007	O
,	O
especially	O
in	O
patients	B-C0030705
with	O
hypertension	B-C0020538
or	B-C0028873
=	O
1.45	O
,	O
95%	O
ci	B-C0009667
=	O
1.09	O
,	O
p	O
=	O
0.006	O
and	O
coronary	B-C0010068
heart	I-C0010068
disease	I-C0010068
or	B-C0028873
=	O
1.41	O
,	O
95%	O
ci	B-C0009667
=	O
1.09	O
,	O
p	B-C1709380
=	O
0.010	O
after	O
adjustment	O
for	O
multiple	B-C1979763
cardiovascular	I-C1979763
risk	B-C0035648
factors	I-C0035648
.	O
	
however	O
,	O
rs2306235	B-C1826600
polymorphism	B-C0752046
was	O
not	O
associated	O
with	O
cardiovascular	B-C0205848
mortality	I-C0205848
in	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
p	O
=	O
0.875	O
.	O
	
ckip-1	B-C1826600
rs2306235	I-C1826600
polymorphism	B-C0752046
may	O
be	O
a	O
risk	B-C0035648
factor	I-C0035648
for	O
chronic	B-C0264716
heart	I-C0264716
failure	I-C0264716
in	O
a	O
chinese	B-C0814942
han	I-C0814942
population	I-C0814942
.	O
	
linking	O
phenological	B-C0023675
events	I-C0023675
in	O
migratory	B-C0600537
passerines	I-C0600537
with	O
a	O
changing	B-C2718051
climate	I-C2718051
50	O
years	B-C0439234
in	O
the	O
laurel	B-C0030853
highlands	I-C0030853
of	I-C0030853
pennsylvania	I-C0030853
advanced	B-C0449243
timing	I-C0449243
of	O
both	O
seasonal	B-C0036497
migration	O
and	O
reproduction	B-C0232896
in	O
birds	B-C0005595
has	O
been	O
strongly	O
associated	B-C0332281
with	I-C0332281
a	O
warming	B-C0178683
climate	I-C0178683
for	O
many	O
bird	B-C0005595
species	B-C1705920
.	O
	
phenological	B-C0023675
responses	I-C0023675
to	O
climate	B-C0008946
linking	O
these	O
stages	B-C1306673
may	O
ultimately	O
impact	B-C4049986
fitness	B-C2349186
.	O
	
we	O
analyzed	B-C0936012
five	O
decades	B-C2981279
of	O
banding	B-C1511726
data	I-C1511726
from	O
17	O
migratory	B-C0600537
bird	I-C0600537
species	B-C1705920
to	O
investigate	O
1	O
how	O
spring	B-C0241232
arrival	B-C1706079
related	O
to	O
timing	B-C0449243
of	O
breeding	B-C0178477
,	O
2	O
if	O
the	O
interval	B-C1272706
between	O
arrival	B-C1706079
and	O
breeding	B-C0178477
has	O
changed	O
with	O
increasing	B-C0442808
spring	B-C0241232
temperatures	B-C0039476
,	O
and	O
3	O
whether	O
arrival	B-C1706079
timing	B-C0449243
or	O
breeding	B-C0178477
timing	B-C0449243
best	O
predicted	O
local	B-C2015882
productivity	I-C2015882
.	O
	
four	O
of	O
17	O
species	B-C1705920
,	O
all	O
mid-	B-C0600537
to	I-C0600537
long-distance	I-C0600537
migrants	I-C0600537
,	O
hatched	B-C0598016
young	O
earlier	O
in	O
years	B-C0439234
when	O
migrants	B-C0026093
arrived	B-C1706079
earlier	B-C1279919
to	O
the	O
breeding	B-C1254362
grounds	I-C1254362
1	O
day	B-C0439228
advancement	I-C0439228
.	O
	
the	O
interval	B-C1272706
between	O
arrival	B-C1706079
on	O
breeding	B-C1254362
grounds	I-C1254362
and	O
appearance	B-C0700364
of	O
juveniles	B-C3146221
shortened	B-C1282927
with	O
warmer	O
spring	B-C0241232
temperatures	B-C0039476
for	O
12	O
species	B-C1705920
1-6	O
days	B-C0439228
for	O
every	O
1	O
increase	B-C0442805
and	O
over	O
time	O
for	O
seven	O
species	B-C1705920
1-8	O
days	O
per	O
decade	B-C2981279
,	O
suggesting	O
that	O
some	O
migratory	B-C0600537
passerines	I-C0600537
adapt	O
to	O
climate	B-C2718051
change	I-C2718051
by	O
laying	B-C1622979
more	B-C4036056
quickly	I-C4036056
after	O
arrival	B-C0574839
or	O
reducing	B-C0392756
the	O
time	B-C0040223
from	O
laying	B-C1622979
to	O
fledging	O
.	O
	
we	O
found	O
more	O
support	O
for	O
the	O
former	B-C0750523
,	O
that	O
the	O
rate	B-C1521828
of	O
reproductive	B-C0035150
advancement	I-C0035150
was	O
higher	B-C0205250
than	O
that	O
for	O
arrival	B-C0574839
in	O
warm	B-C0178683
years	I-C0178683
.	O
	
timing	B-C0449243
of	O
spring	B-C0241232
arrival	B-C1706079
and	O
breeding	B-C0178477
were	O
both	O
poor	B-C0542537
predictors	B-C2698872
of	O
avian	B-C0005595
productivity	B-C0033269
for	O
most	O
migrants	B-C0600537
analyzed	B-C0936012
.	O
	
nevertheless	O
,	O
we	O
found	O
evidence	B-C3887511
that	O
fitness	B-C2717777
benefits	O
may	O
occur	O
from	O
shifts	B-C2347509
to	O
earlier	O
spring	B-C0241232
arrival	B-C1706079
for	O
the	O
multi-brooded	B-C0326953
song	I-C0326953
sparrow	I-C0326953
.	O
	
our	O
results	B-C1274040
uniquely	O
demonstrate	O
that	O
co-occurring	O
avian	B-C0005595
species	B-C1705920
are	O
phenologically	B-C0023675
plastic	I-C0023675
in	O
their	O
response	B-C0871261
to	O
climate	B-C2718051
change	I-C2718051
on	O
their	O
breeding	B-C1254362
grounds	I-C1254362
.	O
	
if	O
migrants	B-C0026093
continue	O
to	O
show	O
a	O
weaker	B-C1762617
response	B-C0871261
to	O
temperatures	B-C0039476
during	O
migration	O
than	O
breeding	B-C0178477
,	O
and	O
the	O
window	B-C1272706
between	O
arrival	B-C1706079
and	O
optimal	B-C0178477
breeding	I-C0178477
shortens	B-C1282927
further	O
,	O
biological	O
constraints	O
to	O
plasticity	B-C0678558
may	O
limit	O
the	O
ability	B-C0085732
of	O
species	B-C1705920
to	O
adapt	O
successfully	O
to	O
future	B-C0687712
warming	I-C0687712
.	O
	
mucosal	B-C0026724
igm	B-C1292066
antibody	I-C1292066
with	O
d-mannose	B-C0024742
affinity	B-C1510827
in	O
fugu	B-C0949586
takifugu	I-C0949586
rubripes	I-C0949586
is	O
utilized	O
by	O
a	O
monogenean	B-C0322374
parasite	B-C0030498
heterobothrium	B-C1499594
okamotoi	I-C1499594
for	O
host	B-C1658611
recognition	I-C1658611
how	O
parasites	B-C0030498
recognize	B-C0524637
their	O
definitive	B-C0443196
hosts	B-C1167395
is	O
a	O
mystery	O
however	O
,	O
parasitism	B-C0677482
is	O
reportedly	O
initiated	O
by	O
recognition	B-C0524637
of	O
certain	O
molecules	B-C0567416
on	O
host	B-C2752522
surfaces	I-C2752522
.	O
	
fish	B-C0016163
ectoparasites	B-C0562634
make	O
initial	B-C1320656
contact	I-C1320656
with	O
their	O
hosts	B-C1167395
at	O
body	B-C0489451
surfaces	I-C0489451
,	O
such	O
as	O
skin	B-C1123023
and	O
gills	B-C0017558
,	O
which	O
are	O
covered	B-C0439844
with	O
mucosa	B-C0026724
that	O
are	O
similar	O
to	O
those	O
of	O
mammalian	B-C0699819
guts	I-C0699819
.	O
	
fish	B-C0016163
are	O
among	O
the	O
most	O
primitive	B-C0042567
vertebrates	I-C0042567
with	O
immune	B-C0020962
systems	I-C0020962
that	O
are	O
equivalent	O
to	O
those	O
in	O
mammals	B-C0024660
,	O
and	O
they	O
produce	O
and	O
secrete	B-C0036536
igm	B-C0020861
into	O
mucus	B-C0026727
.	O
	
in	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
monogenean	B-C0322374
parasite	B-C0030498
heterobothrium	B-C1499594
okamotoi	I-C1499594
utilizes	O
igm	B-C0020861
to	O
recognize	B-C0678894
its	O
host	B-C1167395
,	O
fugu	B-C0949586
takifugu	I-C0949586
rubripes	I-C0949586
oncomiracidia	I-C0949586
are	O
infective	B-C0686891
larvae	I-C0686891
of	O
h	B-C1499594
.	O
	
okamotoi	I-C1499594
that	O
shed	O
their	O
cilia	B-C0008778
and	O
metamorphose	B-C0025558
into	O
juveniles	B-C3146221
when	O
exposed	O
to	O
purified	B-C1998793
d-mannose	B-C0024742
-	O
binding	B-C1145667
fractions	B-C1264633
from	O
fugu	B-C0949586
mucus	O
.	O
	
using	O
liquid	O
chromatography-tandem	O
mass	O
spectrometry	O
analysis	O
,	O
proteins	O
contained	O
in	O
the	O
fraction	O
were	O
identified	O
as	O
d-mannose	O
-specific	O
igm	O
with	O
two	O
d-mannose	O
-binding	O
lectins	O
.	O
	
however	O
,	O
although	O
deciliation	O
was	O
significantly	O
induced	O
by	O
igm	O
and	O
was	O
inhibited	O
by	O
d-mannose	O
or	O
a	O
specific	O
ab	O
against	O
fugu	B-C0949586
igm	O
,	O
other	O
lectins	O
had	O
no	O
effect	O
,	O
and	O
igm	O
without	O
d-mannose	O
affinity	O
induced	O
deciliation	O
to	O
a	O
limited	O
degree	O
.	O
	
subsequent	O
immunofluorescent	O
staining	O
experiments	O
showed	O
that	O
fugu	O
d-mannose	O
-specific	O
igm	O
binds	O
ciliated	O
epidermal	O
cells	O
of	O
oncomiracidium	O
.	O
	
these	O
observations	O
suggest	O
that	O
deciliation	O
is	O
triggered	O
by	O
binding	O
of	O
fugu	O
igm	O
to	O
cell	O
surface	O
ags	O
via	O
ag	O
binding	O
sites	O
.	O
	
moreover	O
,	O
concentrations	O
of	O
d-mannose	O
-	O
binding	O
igm	O
in	O
gill	O
mucus	B-C0026727
were	O
sufficient	O
to	O
induce	O
deciliation	O
in	O
vitro	O
,	O
indicating	O
that	O
h	O
.	O
	
okamotoi	O
parasites	O
initially	O
use	O
host	O
abs	O
to	O
colonize	O
host	O
gills	B-C0017558
balb/c	B-C0025919
mice	I-C0025919
immunized	B-C0020971
with	O
a	O
combination	O
of	O
virus-like	B-C0333785
particles	I-C0333785
incorporating	O
kaposi	B-C0376526
sarcoma-associated	I-C0376526
herpesvirus	I-C0376526
kshv	B-C0376526
envelope	O
glycoproteins	B-C0767120
gpk8.1	I-C0767120
,	O
gb	B-C0761135
,	O
and	O
gh	B-C1142879
/	O
gl	B-C2606403
induced	O
comparable	O
serum	B-C0229671
neutralizing	B-C0475463
antibody	I-C0475463
activity	B-C1621287
to	O
uv	B-C0041625
-	O
inactivated	B-C0544461
kshv	B-C0376526
infection	O
with	O
kaposi	B-C0376526
sarcoma-associated	I-C0376526
herpesvirus	I-C0376526
kshv	B-C0376526
is	O
estimated	O
to	O
account	O
for	O
over	O
44	O
new	O
cases	O
of	O
kaposi	B-C0036220
sarcoma	I-C0036220
annually	O
,	O
with	O
84%	O
occurring	O
in	O
africa	B-C0001737
,	O
where	O
the	O
virus	B-C0376526
is	O
endemic	O
.	O
	
to	O
date	O
,	O
there	O
is	O
no	O
prophylactic	B-C0042210
vaccine	I-C0042210
against	O
kshv	B-C0376526
.	O
	
kshv	B-C0376526
gpk8.1	B-C0767120
,	O
gb	B-C0761135
,	O
and	O
gh	B-C1142879
/	O
gl	B-C2606403
glycoproteins	I-C2606403
,	O
implicated	O
in	O
the	O
virus	B-C0376526
entry	O
into	O
host	B-C1819995
cells	I-C1819995
,	O
are	O
attractive	O
vaccine	B-C0042210
targets	B-C1521840
for	O
eliciting	O
potent	O
neutralizing	B-C0475463
antibodies	I-C0475463
nabs	B-C0475463
against	O
virus	B-C0042769
infection	I-C0042769
.	O
	
we	O
incorporated	O
gpk8.1	B-C0767120
,	O
gb	B-C0761135
,	O
or	O
gh	O
/	O
gl	O
on	O
the	O
surface	O
of	O
virus-like	O
particles	O
vlps	O
and	O
characterized	O
these	O
vlps	O
for	O
their	O
composition	O
,	O
size	O
,	O
and	O
functionality	O
.	O
	
to	O
determine	O
which	O
viral	O
glycoprotein	O
elicit	O
the	O
most	O
effective	O
serum	O
-	O
nabs	O
,	O
we	O
immunized	O
balb/c	O
mice	O
with	O
gpk8.1	O
,	O
gb	B-C0761135
,	O
or	O
gh	B-C1142879
/	O
gl	B-C2606403
vlps	O
individually	O
or	O
in	O
combination	O
.	O
	
neutralizing	O
antibody	O
assay	O
revealed	O
that	O
sera	O
from	O
mice	O
immunized	O
with	O
the	O
vlps	O
inhibited	O
kshv	O
infection	O
of	O
hek-293	O
cells	O
in	O
a	O
dose-dependent	O
manner	O
.	O
	
as	O
a	O
single	O
immunogen	O
,	O
gpk8.1	O
vlps	O
stimulated	O
comparable	O
nab	O
activity	O
to	O
that	O
of	O
uv	O
-	O
inactivated	O
kshv	O
uv-kshv	O
.	O
	
in	O
contrast	O
,	O
uv-kshv	O
stimulated	O
higher	O
titers	O
of	O
nab	O
compared	O
to	O
gb	O
p	O
=	O
0.0316	O
or	O
gh	O
/	O
gl	O
p	O
=	O
0.0486	O
.	O
	
mice	O
immunized	O
with	O
the	O
combination	O
of	O
gb	O
and	O
gh	O
/	O
gl	O
vlps	O
had	O
a	O
better	O
nab	O
response	O
than	O
those	O
immunized	O
with	O
either	O
gb	O
p	O
=	O
0.0268	O
,	O
or	O
gh	O
/gl	O
p	O
=	O
0.0397	O
as	O
single	O
vlp	O
immunogens	O
.	O
	
immunization	O
with	O
any	O
vlp	O
combination	O
stimulated	O
comparable	O
nab	O
activity	O
to	O
uv-kshv	O
serum	O
.	O
	
our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
kshv	O
gpk8.1	O
,	O
gb	O
,	O
and	O
gh	O
/	O
gl	O
glycoproteins	O
can	O
be	O
incorporated	O
onto	O
the	O
surface	O
of	O
vlps	O
and	O
used	O
as	O
prophylactic	O
vaccine	O
candidates	O
,	O
with	O
potential	O
to	O
prevent	O
kshv	O
infection	B-C0042769
a	O
missense	B-C0599155
variant	B-C0205419
,	O
rs373863828-a	B-C3469921
p.arg457gln	I-C3469921
,	O
of	I-C3469921
crebrf	I-C3469921
and	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
in	O
oceanic	B-C0682094
populations	I-C0682094
it	O
has	O
been	O
suggested	O
that	O
a	O
'thrifty'	O
genotype	B-C0017431
hypothesis	B-C1512571
can	O
account	O
for	O
high	B-C1512456
prevalence	I-C1512456
of	O
obesity	B-C0028754
in	O
the	O
island	B-C0022130
populations	B-C1257890
of	O
oceania	B-C0282279
.	O
	
a	O
recent	O
genome-wide	B-C2350277
association	I-C2350277
study	I-C2350277
revealed	O
that	O
a	O
missense	B-C0599155
variant	B-C0205419
,	O
rs373863828-a	B-C3469921
p.arg457gln	I-C3469921
,	O
of	I-C3469921
the	I-C3469921
crebrf	I-C3469921
gene	I-C3469921
encoding	O
creb3	B-C1447550
regulatory	I-C1447550
factor	I-C1447550
was	O
associated	B-C0332281
with	I-C0332281
an	O
excessive	B-C0442802
increase	B-C0442805
in	O
body	B-C1305855
mass	I-C1305855
index	I-C1305855
bmi	B-C1305855
in	O
samoans	B-C1556103
.	O
	
in	O
the	O
present	O
study	O
,	O
the	O
association	O
of	O
rs373863828-a	B-C3469921
with	O
an	O
increase	B-C0442805
in	O
bmi	B-C1305855
was	O
examined	B-C0332128
in	O
four	O
austronesian	B-C0682410
an	B-C0682410
speaking	B-C0234856
populations	B-C1257890
in	O
oceania	B-C0282279
.	O
	
we	O
found	O
that	O
rs373863828-a	B-C3469921
was	O
frequently	O
observed	O
frequency	O
of	O
0.15	O
in	O
tongans	B-C0337933
polynesians	B-C0240790
,	O
and	O
was	O
strongly	O
associated	B-C0332281
with	I-C0332281
higher	O
bmi	B-C1305855
p=6	O
10	O
.	O
	
a	O
single	O
copy	O
of	O
the	O
rs373863828-a	B-C3469921
allele	B-C0002085
increased	B-C0205217
bmi	B-C1305855
by	O
3.09	O
kg	O
m	O
after	O
adjustment	O
of	O
age	B-C0001779
and	O
sex	B-C1522384
.	O
	
no	B-C1273937
significant	I-C1273937
association	B-C0439849
was	O
detected	B-C1511790
in	O
the	O
other	O
three	O
an	B-C0682410
-	O
speaking	B-C0234856
populations	B-C1257890
melanesians	B-C0337924
and	O
micronesians	B-C1556099
living	B-C0376558
in	O
solomon	B-C0037623
islands	I-C0037623
.	O
	
this	O
was	O
probably	O
due	O
to	O
the	O
low	B-C0205251
allele	B-C0017270
frequency	I-C0017270
0.02	O
of	O
rs373863828-a	B-C3469921
as	O
well	O
as	O
small	O
sample	B-C0242618
size	I-C0242618
.	O
	
the	O
rs373863828-a	B-C3469921
allele	B-C0002085
was	O
not	O
found	O
in	O
both	O
an	B-C0682410
-	O
speaking	B-C0234856
and	O
non-	O
an	B-C0682410
-	O
speaking	B-C0234856
melanesians	B-C0337924
living	O
in	O
papua	B-C0030375
new	I-C0030375
guinea	I-C0030375
.	O
	
our	O
results	O
suggest	O
that	O
rs373863828-a	B-C3469921
of	I-C3469921
crebrf	I-C3469921
,	O
a	O
promising	O
thrifty	O
variant	B-C0205419
,	O
arose	O
in	O
recent	O
ancestors	B-C0870134
of	O
an	B-C0682410
-	O
speaking	B-C0234856
polynesians	B-C0240790
vaccination	B-C0042196
of	O
piglets	B-C0039005
at	O
2	O
and	O
3	O
weeks	O
of	O
age	O
with	O
ingelvac	B-C1516086
prrsflex	I-C1516086
eu	I-C1516086
provides	O
protection	B-C1545588
against	O
heterologous	B-C0439860
field	O
challenge	O
in	O
the	O
face	O
of	O
homologous	B-C0301883
maternally	B-C0729663
derived	I-C0729663
antibodies	I-C0729663
due	O
to	O
difficulties	O
in	O
eradicating	B-C3178994
porcine	B-C0376538
reproductive	I-C0376538
and	I-C0376538
respiratory	I-C0376538
syndrome	I-C0376538
prrs	B-C0376538
linked	O
to	O
biosecurity	O
challenges	O
,	O
transmission	B-C1160716
of	I-C1160716
the	I-C1160716
virus	I-C1160716
and	O
the	O
lack	O
of	O
efficient	B-C0442799
diva	B-C0887908
vaccines	I-C0887908
,	O
successful	B-C1272703
control	B-C0243148
of	O
prrs	B-C0376538
requires	O
a	O
combination	O
of	O
strict	O
management	B-C0376636
measures	I-C0376636
and	O
vaccination	B-C0042196
of	O
both	O
sows	B-C0684075
and	O
piglets	B-C0039005
.	O
	
the	O
present	O
study	B-C2603343
aimed	O
to	O
assess	B-C0184514
the	O
efficacy	B-C1280519
of	O
a	O
recently	O
developed	O
mlv	B-C1516086
vaccine	I-C1516086
ingelvac	B-C1516086
prrsflex	I-C1516086
eu	I-C1516086
in	O
piglets	B-C0039005
at	O
2	O
and	O
3-weeks	O
of	O
age	O
in	O
the	O
presence	B-C0150312
of	O
homologous	B-C0301883
maternally	B-C0729663
derived	I-C0729663
antibodies	I-C0729663
as	O
the	O
dams	O
were	O
vaccinated	B-C0042196
with	O
the	O
same	O
vaccine	B-C0042210
strain	I-C0042210
reprocyc	B-C1516086
prrs	I-C1516086
eu	I-C1516086
.	O
	
the	O
study	B-C2603343
was	O
carried	O
out	O
on	O
a	O
hungarian	B-C1296656
farrow	I-C1296656
to	O
finish	O
farm	B-C0557759
naturally	B-C0439663
infected	I-C0439663
with	O
prrsv	B-C0376536
.	O
	
the	O
study	B-C2603343
was	O
designed	O
as	O
a	O
blind	B-C2347038
,	O
placebo	B-C1706408
controlled	I-C1706408
side	O
by	O
side	O
trial	O
.	O
	
orf5	B-C0758157
sequence	B-C1710052
similarity	I-C1710052
of	O
the	O
vaccine	B-C0042210
strain	I-C0042210
and	O
the	O
resident	B-C1257890
field	I-C1257890
strain	I-C1257890
was	O
87.8	O
%	O
.	O
	
prrs	B-C0376538
specific	O
real-time	B-C3179034
quantitative	I-C3179034
pcr	I-C3179034
was	O
performed	O
from	O
serum	B-C1550100
samples	I-C1550100
to	O
measure	B-C0079809
both	O
the	O
viral	B-C1261478
load	I-C1261478
and	O
the	O
frequency	O
of	O
virus	B-C1167762
positive	I-C1167762
animals	B-C0003062
.	O
	
at	O
the	O
time	O
of	O
the	O
natural	B-C3714514
infection	I-C3714514
observed	B-C1441672
in	O
the	O
control	B-C0009932
group	I-C0009932
at	O
10-12	O
weeks	O
of	O
age	O
,	O
the	O
number	O
of	O
viraemic	B-C0243095
animals	B-C0003062
did	O
not	O
increase	O
significantly	O
in	O
the	O
vaccinated	B-C0042196
group	O
.	O
	
to	O
understand	O
the	O
infection	B-C3714514
dynamics	B-C3826426
,	O
positive	B-C1446409
pcr	B-C0032520
samples	B-C0370003
with	O
low	O
ct	O
values	O
were	O
sequenced	O
orf5	B-C0758157
and	O
the	O
data	B-C0010992
analysis	I-C0010992
indicated	B-C1444656
the	O
circulation	B-C0237318
of	O
wild	O
type	O
virus	B-C0042776
in	O
both	O
groups	O
,	O
however	O
wild	O
type	O
virus	O
was	O
only	O
found	O
in	O
non-vaccinated	O
animals	O
.	O
	
our	O
data	B-C1511726
indicate	O
that	O
piglets	B-C0039005
vaccinated	B-C0042196
at	O
as	O
early	O
as	O
2	O
weeks	O
of	O
age	O
with	O
ingelvac	B-C1516086
prrsflex	I-C1516086
eu	I-C1516086
were	O
protected	O
both	O
in	O
terms	O
of	O
proportion	B-C1709707
of	O
viraemic	B-C0243095
animals	B-C0003062
and	O
viraemia	B-C0042749
levels	O
.	O
	
it	O
has	O
to	O
be	O
highlighted	O
that	O
these	O
results	O
were	O
achieved	O
in	O
piglets	B-C0039005
with	O
high	O
levels	O
of	O
homologous	B-C0301883
maternally	B-C0729663
derived	I-C0729663
antibodies	I-C0729663
mda	B-C0729663
at	O
the	O
time	O
of	O
lung	B-C0034079
nodule	I-C0034079
in	O
french	B-C0016703
guiana	I-C0016703
in	O
a	O
immunocompetent	B-C1512656
patient	B-C0030705
we	O
report	O
the	O
case	B-C1706256
of	O
an	O
immunocompetent	B-C1512656
french	B-C1556084
soldier	B-C0524647
stationed	O
in	O
french	B-C0016703
guiana	I-C0016703
,	O
who	O
developed	O
symptomatic	B-C0231220
pulmonary	B-C1306038
histoplasmosis	I-C1306038
.	O
	
comparison	B-C1707455
of	O
occlusive	B-C1947917
and	O
open	B-C0175566
application	B-C4048755
in	O
a	O
psoriasis	B-C0008976
plaque	I-C0008976
test	I-C0008976
design	I-C0008976
,	O
exemplarily	O
using	O
investigations	B-C1292732
of	O
mapracorat	B-C3252363
0.1	O
ointment	B-C0028912
versus	O
vehicle	B-C0042444
and	O
reference	B-C1706462
drugs	B-C0013227
psoriasis	B-C0008976
plaque	I-C0008976
tests	I-C0008976
ppts	B-C0008976
are	O
important	O
tools	O
in	O
the	O
early	O
phases	O
of	O
antipsoriatic	B-C1874314
drug	B-C0872152
development	I-C0872152
.	O
	
two	O
distinct	O
ppt	B-C0008976
design	I-C0008976
variants	O
open	B-C0013153
vs	O
.	O
	
occluded	B-C0013153
drug	I-C0013153
application	I-C0013153
are	O
commonly	O
used	O
,	O
but	O
no	O
previous	O
work	O
has	O
aimed	O
to	O
directly	O
compare	O
and	O
contrast	O
their	O
performance	O
.	O
	
we	O
compared	O
the	O
antipsoriatic	B-C1874314
efficacy	O
of	O
mapracorat	B-C3252363
0.1	O
ointment	B-C0028912
and	O
reference	B-C1706462
drugs	B-C0013227
reported	O
in	O
2	O
separate	O
studies	B-C2603343
,	O
representing	O
open	B-C0008976
and	O
occluded	B-C0008976
ppt	I-C0008976
designs	I-C0008976
.	O
	
the	O
drug	B-C0728866
effect	I-C0728866
size	O
was	O
measured	O
by	O
sonography	B-C0041618
mean	O
change	O
in	O
echo-poor	O
band	O
thickness	B-C1280412
,	O
chromametry	B-C0022885
,	O
and	O
standardized	O
clinical	B-C3845884
assessment	I-C3845884
.	O
	
antipsoriatic	B-C1874314
effects	B-C0728866
were	O
detectable	O
for	O
the	O
study	B-C2603343
drugs	B-C0013227
in	O
both	O
occluded	B-C0008976
and	O
open	B-C0008976
ppts	I-C0008976
.	O
	
differences	O
between	O
the	O
potency	B-C0678792
of	O
antipsoriatic	B-C1874314
drugs	I-C1874314
and	O
vehicle	B-C0042444
were	O
observable	O
.	O
	
the	O
total	O
antipsoriatic	B-C1874314
effect	B-C0728866
size	O
appeared	O
to	O
be	O
higher	O
in	O
the	O
occluded	B-C0008976
ppt	I-C0008976
than	O
the	O
open	B-C0008976
ppt	I-C0008976
,	O
despite	O
the	O
shorter	O
treatment	B-C0444921
duration	I-C0444921
2	O
vs	O
.	O
	
4	O
weeks	B-C0439230
.	O
	
effect	B-C0728866
dynamics	B-C3826426
over	O
time	B-C0040223
revealed	O
greater	O
differences	O
between	O
some	O
study	B-C2603343
drugs	B-C0013227
in	O
the	O
open	B-C0008976
ppt	I-C0008976
compared	O
to	O
the	O
occluded	B-C0008976
ppt	I-C0008976
.	O
	
taking	O
the	O
higher	O
technical	B-C1710348
challenges	I-C1710348
for	O
the	O
open	B-C0008976
ppt	I-C0008976
into	O
account	O
,	O
we	O
recommend	O
the	O
occluded	B-C0008976
ppt	I-C0008976
as	O
a	O
standard	O
screening	B-C0013206
setting	O
in	O
early	B-C1279919
drug	B-C0872152
development	I-C0872152
.	O
	
in	O
special	O
cases	O
,	O
considering	O
certain	O
drug	B-C0013227
aspects	B-C1879746
or	O
study	B-C2603343
objectives	O
that	O
would	O
require	O
procedural	O
adaptations	O
,	O
an	O
open	B-C0008976
ppt	I-C0008976
could	O
be	O
the	O
better-suited	O
design	O
.	O
	
finally	O
,	O
both	O
ppt	B-C0008976
models	O
show	O
clear	O
advantages	O
classification	B-C0008902
as	O
phase	B-C0920321
i	I-C0920321
studies	I-C0920321
,	O
small	O
number	O
of	O
psoriatic	O
subjects	O
,	O
relatively	O
short	O
study	B-C2603343
duration	B-C0449238
,	O
excellent	O
discrimination	O
between	O
compounds	B-C1706082
and	O
concentrations	B-C1264643
,	O
parallel	O
measurement	B-C0242485
of	O
treatment	B-C0521982
response	I-C0521982
,	O
and	O
go/no	O
go	O
decisions	O
very	O
early	B-C1279919
in	O
clinical	B-C1512068
development	I-C1512068
.	O
	
insurance	B-C0376629
coverage	I-C0376629
and	O
utilization	B-C0042153
at	O
a	O
sexually	B-C0338053
transmitted	I-C0338053
disease	I-C0338053
clinic	I-C0338053
in	O
a	O
medicaid	B-C0025071
expansion	O
state	B-C1301808
in	O
rhode	B-C0035487
island	I-C0035487
,	O
the	O
patient	B-C2936611
protection	I-C2936611
and	I-C2936611
affordable	I-C2936611
care	I-C2936611
act	I-C2936611
has	O
led	O
to	O
over	O
95%	O
of	O
the	O
state's	B-C1301808
population	B-C0032659
being	O
insured	B-C1548605
.	O
	
we	O
evaluated	B-C0220825
insurance	B-C0376629
coverage	I-C0376629
and	O
barriers	B-C0243095
to	O
insurance	B-C0021682
use	O
among	O
patients	B-C0030705
presenting	O
for	O
services	B-C1704289
at	O
the	O
rhode	B-C0035487
island	I-C0035487
sexually	B-C0338053
transmitted	I-C0338053
disease	I-C0338053
std	I-C0338053
clinic	I-C0338053
.	O
	
we	O
analyzed	B-C0936012
factors	B-C1521761
associated	B-C0332281
with	I-C0332281
insurance	B-C0376629
coverage	I-C0376629
and	O
utilization	B-C0042153
among	O
patients	B-C0030705
presenting	O
for	O
std	B-C0036916
services	B-C1704289
between	O
july	B-C3829447
and	O
december	B-C3830550
2015	O
.	O
	
a	O
total	O
of	O
692	O
patients	B-C0030705
had	O
insurance	B-C1548070
information	I-C1548070
available	B-C1511733
of	O
those	O
,	O
40%	O
were	O
uninsured	B-C0087134
.	O
	
patients	B-C0030705
without	B-C0087134
insurance	I-C0087134
were	O
more	O
likely	O
than	O
those	O
with	O
insurance	B-C0021682
to	O
be	O
nonwhite	O
50%	O
among	O
uninsured	B-C0087134
,	O
compared	O
with	O
40%	O
among	O
insured	B-C1548605
p	O
=	O
0.014	O
and	O
hispanic	B-C0086409
or	O
latino/a	B-C0086528
25%	O
,	O
compared	O
with	O
16%	O
p	O
=	O
0.006	O
,	O
and	O
less	O
likely	O
to	O
be	O
men	B-C0025266
who	O
have	O
sex	B-C0009253
with	O
men	B-C0025266
27%	O
,	O
compared	O
with	O
39%	O
p	O
=	O
0.001	O
.	O
	
of	O
those	O
with	O
health	B-C0021682
insurance	I-C0021682
,	O
26%	O
obtained	O
coverage	B-C0376629
as	O
a	O
result	B-C1274040
of	O
the	O
affordable	B-C2936611
care	I-C2936611
act	I-C2936611
,	O
and	O
56%	O
of	O
those	O
were	O
previously	O
uninsured	B-C0087134
.	O
	
among	O
uninsured	B-C0087134
individuals	I-C0087134
,	O
barriers	B-C0243095
to	O
obtaining	O
health	B-C0021682
insurance	I-C0021682
included	O
cost	B-C0087112
and	O
unemployment	B-C0041674
.	O
	
among	O
those	O
with	B-C1548605
insurance	I-C1548605
,	O
43%	O
reported	O
willingness	B-C0600109
to	O
use	O
insurance	B-C0021682
for	O
std	B-C0036916
services	B-C1704289
.	O
	
barriers	B-C0243095
to	O
insurance	B-C0021682
use	O
included	O
concerns	O
about	O
anonymity	B-C0871649
and	O
out-of-pocket	B-C3815933
costs	I-C3815933
.	O
	
despite	O
expanded	O
insurance	B-C0021682
access	B-C0015472
,	O
many	O
individuals	B-C0237401
presenting	O
to	O
the	O
rhode	B-C0035487
island	I-C0035487
std	B-C0338053
clinic	I-C0338053
were	O
uninsured	B-C0087134
.	O
	
among	O
those	O
who	O
were	O
insured	B-C1548605
,	O
significant	O
barriers	B-C0243095
still	O
existed	O
to	O
using	O
insurance	B-C0021682
.	O
	
std	B-C0338053
clinics	I-C0338053
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
providing	O
safety-net	B-C3658319
std	B-C0036916
services	B-C1704289
in	O
states	B-C1301808
with	O
low	O
uninsured	B-C0087134
rates	B-C1521828
.	O
	
both	O
public	B-C0678367
and	O
private	B-C0679727
insurers	B-C0021675
are	O
needed	O
to	O
address	O
financial	B-C4062976
barriers	I-C4062976
and	O
optimize	B-C2698650
payment	B-C0680264
structures	B-C0678594
for	O
molecular	B-C1294399
subtyping	I-C1294399
of	O
treponema	B-C0040840
pallidum	I-C0040840
and	O
associated	B-C1521761
factors	I-C1521761
of	O
serofast	B-C3841011
status	B-C0449438
in	O
early	B-C0348148
syphilis	I-C0348148
patients	B-C0030705
identified	B-C0205396
novel	O
genotype	B-C0017431
and	O
cytokine	B-C0079189
marker	B-C0005516
serofast	B-C3841011
,	O
a	O
persistent	B-C0205322
nontreponemal	B-C0205473
serological	I-C0205473
response	B-C0521982
observed	B-C1441672
in	O
early	B-C0348148
syphilis	I-C0348148
patients	B-C0030705
after	O
conventional	B-C2945704
treatment	I-C2945704
,	O
remains	O
a	O
concern	B-C2699424
of	O
clinicians	B-C0871685
and	O
syphilis	B-C0348148
patients	B-C0030705
.	O
	
no	O
consensus	O
has	O
been	O
established	O
,	O
however	O
,	O
that	O
defines	O
an	O
effective	B-C1704419
treatment	B-C0040808
strategy	I-C0040808
and	O
clarifies	B-C2986669
the	O
pathogenesis	B-C0699748
.	O
	
in	O
this	O
study	B-C2603343
,	O
517	O
patients	B-C0030705
with	O
early	B-C0348148
syphilis	I-C0348148
were	O
enrolled	B-C1516879
and	O
treated	B-C1522326
.	O
	
twelve	O
months	B-C0439231
after	O
treatment	B-C0087111
,	O
79.3	O
410/517	O
of	O
patients	B-C0030705
achieved	O
serological	B-C0205473
cure	B-C1880198
,	O
20.1	O
104/517	O
were	O
serofast	B-C3841011
,	O
and	O
0.6	O
3/517	O
were	O
serological	B-C0205473
failures	B-C0231174
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
demonstrated	O
that	O
older	B-C1999167
age	I-C1999167
>40	O
years	B-C0439234
and	O
lower	O
baseline	B-C1442488
rpr	B-C3835799
titer	I-C3835799
1	O
were	O
associated	B-C0332281
with	I-C0332281
serofast	B-C3841011
status	B-C0449438
.	O
	
we	O
also	O
identified	O
21	O
t	B-C0040840
.	O
	
pallidum	I-C0040840
molecular	B-C0449560
subtypes	I-C0449560
among	O
early	B-C0348148
syphilis	I-C0348148
patients	B-C0030705
and	O
detected	O
a	O
new	O
subtype	B-C0449560
,	O
14i/a	I-C0449560
.	O
	
we	O
found	O
that	O
the	O
proportion	O
of	O
14i/a	B-C0449560
type	I-C0449560
in	O
serofast	B-C3841011
patients	B-C0030705
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	B-C0030705
with	O
serological	B-C0205473
cure	B-C1880198
,	O
predicting	O
an	O
increasing	B-C0442808
risk	B-C0035647
of	O
serofast	B-C3841011
status	B-C0449438
.	O
	
levels	O
of	O
chemerin	O
were	O
higher	O
in	O
the	O
serum	O
of	O
serofast	O
cases	O
than	O
serological	O
cure	O
cases	O
,	O
potentially	O
indicating	O
a	O
novel	O
cytokine	O
marker	O
for	O
serofast	O
in	O
early	O
syphilis	O
patients	O
after	O
therapy	O
.	O
	
we	O
hope	O
that	O
these	O
results	O
contribute	O
to	O
improve	O
guidelines	O
for	O
the	O
management	O
of	O
syphilis	O
patients	O
who	O
experience	O
serofast	B-C3841011
total	O
fluorescence	B-C0016315
fingerprinting	B-C0016126
of	O
pesticides	B-C0031253
a	O
reliable	O
approach	O
for	O
continuous	B-C0549178
monitoring	B-C0014416
of	I-C0014416
soils	I-C0014416
and	I-C0014416
waters	I-C0014416
the	O
present	O
work	O
relates	O
to	O
the	O
creation	B-C1706214
/	O
extension	B-C0231448
of	O
a	O
database	B-C0242356
of	O
total	B-C0037802
excitation-emission	I-C0037802
and	I-C0037802
total	I-C0037802
synchronous	I-C0037802
fluorescence	I-C0037802
matrices	I-C0037802
teems	B-C0037802
and	I-C0037802
tsfms	I-C0037802
along	O
with	O
optimal	B-C0037802
synchronous	I-C0037802
fluorescence	I-C0037802
spectra	I-C0037802
sfs	B-C0037802
to	O
fingerprint	B-C0016126
pesticides	B-C0031253
widely	O
used	O
in	O
morocco	B-C0026544
.	O
	
this	O
spectrometric	B-C0436196
multi-component	I-C0436196
fingerprinting	I-C0436196
may	O
permit	O
the	O
direct	O
detection	B-C0430417
of	I-C0430417
pesticides	I-C0430417
persisting	B-C0037594
in	I-C0037594
soil	I-C0037594
or	O
water	B-C0043053
.	O
	
the	O
objective	O
of	O
the	O
current	O
investigation	O
is	O
to	O
detect	B-C0430417
four	I-C0430417
pesticide	I-C0430417
remains	O
in	O
agricultural	B-C0562975
soils	I-C0562975
by	O
applying	O
the	O
spectrometric	B-C0037802
fingerprinting	I-C0037802
results	O
.	O
	
they	O
are	O
the	O
commercial	O
i	O
insecticide	B-C0021578
axlera	I-C0021578
5g	I-C0021578
carbamate	B-C0021578
,	O
ii	O
fungicide	B-C0392419
orsalis	I-C0392419
5%	I-C0392419
sc	I-C0392419
triazole	B-C0392419
,	O
iii	O
insecticide	B-C0597329
force	I-C0597329
0	I-C0597329
g	I-C0597329
pyrethrinoid	B-C0597329
and	O
iv	O
insecticide	B-C0021576
proclaim	I-C0021576
05	I-C0021576
sg	I-C0021576
non-assigned	O
.	O
	
the	O
agricultural	B-C0001827
plantations	I-C0001827
monitored	I-C0001827
are	O
located	O
in	O
the	O
great	B-C0017446
agricultural	I-C0017446
doukkala	I-C0017446
region	I-C0017446
at	O
the	O
western	B-C0017446
atlantic	I-C0017446
side	I-C0017446
of	O
morocco	B-C0026544
,	O
where	O
these	O
chemicals	B-C0220806
engagement	O
of	O
cellular	B-C0074202
prion	I-C0074202
protein	I-C0074202
with	O
the	O
co-chaperone	B-C0243041
hsp70	B-C0243043
/	O
90	O
organizing	O
protein	O
regulates	O
the	O
proliferation	O
of	O
glioblastoma	O
stem-like	O
cells	O
glioblastoma	O
gbm	O
,	O
a	O
highly	O
aggressive	O
brain	O
tumor	O
,	O
contains	O
a	O
subpopulation	O
of	O
glioblastoma	O
stem-like	O
cells	O
gscs	O
that	O
play	O
roles	O
in	O
tumor	O
maintenance	O
,	O
invasion	O
,	O
and	O
therapeutic	O
resistance	O
.	O
	
gscs	O
are	O
therefore	O
a	O
promising	O
target	O
for	O
gbm	O
treatment	O
.	O
	
our	O
group	O
identified	O
the	O
cellular	O
prion	O
protein	O
prp	O
and	O
its	O
partner	O
,	O
the	O
co-chaperone	O
hsp70	B-C0018850
/	I-C0018850
90	I-C0018850
organizing	I-C0018850
protein	I-C0018850
hop	O
,	O
as	O
potential	O
target	O
candidates	O
due	O
to	O
their	O
role	O
in	O
gbm	O
tumorigenesis	O
and	O
in	O
neural	O
stem	O
cell	O
maintenance	O
.	O
	
gscs	O
expressing	O
different	O
levels	O
of	O
prp	O
were	O
cultured	O
as	O
neurospheres	O
with	O
growth	O
factors	O
,	O
and	O
characterized	O
with	O
stem	O
cells	O
markers	O
and	O
adhesion	O
molecules	O
markers	O
through	O
immunofluorescence	O
and	O
flow	O
cytometry	O
.	O
	
we	O
than	O
evaluated	O
gsc	O
self-renewal	O
and	O
proliferation	O
by	O
clonal	O
density	O
assays	O
and	O
brdu	O
incorporation	O
,	O
respectively	O
,	O
in	O
front	O
of	O
recombinant	O
hop	O
treatment	O
,	O
combined	O
or	O
not	O
with	O
a	O
hop	O
peptide	O
which	O
mimics	O
the	O
prp	O
binding	O
site	O
.	O
	
stable	O
silencing	O
of	O
hop	O
was	O
also	O
performed	O
in	O
parental	O
and/or	O
prp	O
-depleted	O
cell	O
populations	O
,	O
and	O
proliferation	O
in	O
vitro	O
and	O
tumor	O
growth	O
in	O
vivo	O
were	O
evaluated	O
.	O
	
migration	O
assays	O
were	O
performed	O
on	O
laminin-1	O
pre-coated	O
glass	O
.	O
	
we	O
observed	O
that	O
,	O
when	O
gbm	O
cells	O
are	O
cultured	O
as	O
neurospheres	O
,	O
they	O
express	O
specific	O
stemness	O
markers	O
such	O
as	O
cd133	O
,	O
cd15	O
,	O
oct4	O
,	O
and	O
sox2	O
prp	O
is	O
upregulated	O
compared	O
to	O
monolayer	O
culture	O
and	O
co-localizes	O
with	O
cd133	O
.	O
	
prp	O
silencing	O
downregulates	O
the	O
expression	O
of	O
molecules	O
associated	O
with	O
cancer	O
stem	O
cells	O
,	O
upregulates	O
markers	O
of	O
cell	O
differentiation	O
and	O
affects	O
gsc	O
self-renewal	O
,	O
pointing	O
to	O
a	O
pivotal	O
role	O
for	O
prp	O
in	O
the	O
maintenance	O
of	O
gscs	O
.	O
	
exogenous	O
hop	O
treatment	O
increases	O
proliferation	O
and	O
self-renewal	O
of	O
gscs	O
in	O
a	O
prp	O
-dependent	O
manner	O
while	O
hop	O
knockdown	O
disturbs	O
the	O
proliferation	O
process	O
.	O
	
in	O
vivo	O
,	O
prp	O
and/or	O
hop	O
knockdown	O
potently	O
inhibits	O
the	O
growth	O
of	O
subcutaneously	O
implanted	O
glioblastoma	O
cells	O
.	O
	
in	O
addition	O
,	O
disruption	O
of	O
the	O
prp	O
-	O
hop	O
complex	O
by	O
a	O
hop	O
peptide	O
,	O
which	O
mimics	O
the	O
prp	O
binding	O
site	O
,	O
affects	O
gsc	O
self-renewal	O
and	O
proliferation	O
indicating	O
that	O
the	O
hop	O
-	O
prp	O
complex	O
is	O
required	O
for	O
gsc	O
stemness	O
.	O
	
furthermore	O
,	O
prp	O
-depleted	O
gscs	O
downregulate	O
cell	O
adhesion-related	O
proteins	O
and	O
impair	O
cell	O
migration	O
indicating	O
a	O
putative	O
role	O
for	O
prp	O
in	O
the	O
cell	O
surface	O
stability	O
of	O
cell	O
adhesion	O
molecules	O
and	O
gbm	O
cell	O
invasiveness	O
,	O
respectively	O
.	O
	
in	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
the	O
modulation	O
of	O
hop	O
-	O
prp	O
engagement	O
or	O
the	O
decrease	O
of	O
prp	O
and	O
hop	O
expression	O
may	O
represent	O
a	O
potential	O
therapeutic	O
intervention	O
in	O
gbm	O
,	O
regulating	O
glioblastoma	O
stem-like	O
cell	O
self-renewal	O
,	O
proliferation	O
,	O
and	O
migration	I-C1622501
cyclic	B-C0272282
thrombocytopenia	I-C0272282
synchronizing	B-C0439580
with	O
the	O
menstrual	B-C0025329
cycle	I-C0025329
showing	O
periodic	B-C0332182
phases	B-C0205390
of	O
thrombocytopenia	B-C0040034
and	O
rebound	B-C0034897
thrombocytosis	B-C0836924
a	O
37-	O
year	B-C1510829
-old	O
woman	B-C0043210
was	O
admitted	B-C0184666
to	O
our	O
hospital	B-C0019994
for	O
purpura	B-C0034150
involving	O
the	O
extremities	B-C0278454
and	O
thrombocytopenia	B-C0040034
.	O
	
prednisolone	B-C0032950
psl	B-C0032950
was	O
administered	B-C1521801
based	O
on	O
a	O
diagnosis	B-C0011900
of	O
idiopathic	B-C0398650
thrombocytopenic	I-C0398650
purpura	I-C0398650
itp	B-C0398650
,	O
but	O
was	O
not	B-C1301751
effective	I-C1301751
for	O
maintaining	B-C0024501
her	O
platelet	B-C0032181
count	I-C0032181
within	O
the	O
normal	B-C0086715
range	I-C0086715
,	O
which	O
showed	O
cyclic	B-C0681684
fluctuation	I-C0681684
corresponding	O
to	O
the	O
menstrual	B-C0025329
cycle	I-C0025329
.	O
	
therefore	O
,	O
we	O
discontinued	B-C1444662
psl	B-C0032950
,	O
and	O
cyclic	B-C0272282
thrombocytopenia	I-C0272282
ctp	B-C0272282
was	O
diagnosed	B-C0011900
.	O
	
ctp	B-C0272282
is	O
a	O
rare	B-C0678236
disease	I-C0678236
which	O
is	O
usually	O
treated	B-C1522326
as	O
itp	B-C0398650
but	O
with	O
no	B-C4282382
response	I-C4282382
.	O
	
although	O
the	O
exact	O
cause	B-C0085978
of	O
ctp	B-C0272282
is	O
uncertain	B-C0087130
,	O
in	O
our	O
case	B-C1706256
,	O
a	O
hormonal	B-C0920552
mechanism	I-C0920552
may	O
be	O
responsible	O
for	O
fluctuating	B-C0231241
platelet	B-C0032181
count	I-C0032181
.	O
	
comparative	B-C1261322
evaluation	I-C1261322
of	O
iodine-131	B-C0879568
metaiodobenzylguanidine	I-C0879568
and	O
18-fluorodeoxyglucose	B-C0046056
positron	B-C0032743
emission	I-C0032743
tomography	I-C0032743
in	O
assessing	O
neural	B-C2931189
crest	I-C2931189
tumors	I-C2931189
will	O
they	O
play	O
a	O
complementary	O
role	O
18-fluorodeoxyglucose	B-C0046056
positron	B-C0032743
emission	I-C0032743
tomography	I-C0032743
fdg-pet	B-C0032743
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	B-C0006826
.	O
	
however	O
,	O
its	O
precise	O
clinical	B-C2347795
role	I-C2347795
in	O
the	O
neural	B-C2931189
crest	I-C2931189
cell	I-C2931189
tumors	I-C2931189
continues	O
to	O
evolve	O
.	O
	
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine-131	B-C0879568
metaiodobenzylguanidine	I-C0879568
131	B-C0879568
and	O
fdg-pet	B-C0032743
of	O
head	O
to	O
head	O
in	O
patients	B-C0030705
with	O
neural	B-C2931189
crest	I-C2931189
tumors	I-C2931189
both	O
qualitatively	B-C0034375
and	O
semiquantitatively	B-C2986822
and	O
to	O
determine	O
their	O
clinical	B-C0422813
utility	I-C0422813
in	O
disease	B-C0243095
status	I-C0243095
evaluation	I-C0243095
and	O
further	B-C0376636
management	I-C0376636
.	O
	
a	O
total	O
of	O
32	O
patients	B-C0030705
who	O
had	O
undergone	O
131	B-C0879568
and	O
fdg-pet	B-C0032743
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	B-C0205469
grouped	O
into	O
three	O
categories	O
neuroblastoma	B-C0027819
,	O
pheochromocytoma	B-C0031511
,	O
and	O
medullary	B-C0238462
carcinoma	I-C0238462
thyroid	I-C0238462
.	O
	
in	O
18	O
patients	B-C0030705
of	O
neuroblastoma	B-C0027819
,	O
fdg	B-C0032743
pet	I-C0032743
and	O
131	B-C0879568
showed	O
patient-specific	B-C4304945
sensitivity	I-C4304945
of	O
84%	O
and	O
72%	O
,	O
respectively	O
.	O
	
the	O
mean	O
maximum	B-C2986846
standardized	I-C2986846
uptake	I-C2986846
value	I-C2986846
suvmax	B-C2986846
of	O
primary	B-C1402294
lesions	I-C1402294
in	O
patients	B-C0030705
with	O
unfavorable	B-C4048239
histology	I-C4048239
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable	B-C4048239
histology	I-C4048239
5.18	O
2.38	O
vs	O
.	O
	
3.21	O
1.69	O
.	O
	
the	O
mean	O
suvmax	B-C2986846
of	O
two	O
common	O
sites	O
posterior	B-C0223646
superior	I-C0223646
iliac	I-C0223646
spine	I-C0223646
psis	B-C0223646
and	O
greater	B-C0223865
trochanter	I-C0223865
was	O
higher	O
in	O
patients	B-C0030705
with	O
involved	O
marrow	B-C0376152
than	O
those	O
with	O
uninvolved	O
one	O
2.36	O
and	O
2.75	O
vs	O
.	O
	
1.26	O
and	O
1.34	O
,	O
respectively	O
.	O
	
the	O
ratio	O
of	O
suvmax	B-C2986846
of	O
the	O
involved/	O
contralateral	B-C0441988
normal	I-C0441988
sites	I-C0441988
was	O
2.16	O
1.9	O
.	O
	
in	O
equivocal	B-C0332241
bone	B-C0427694
marrow	I-C0427694
results	I-C0427694
,	O
the	O
uptake	O
pattern	O
with	O
suv	B-C2348529
estimation	O
can	O
depict	O
metastatic	B-C1522484
involvement	I-C1522484
and	O
help	O
in	O
redirecting	O
the	O
biopsy	B-C1301128
site	I-C1301128
.	O
	
among	O
seven	O
patients	B-C0030705
of	O
pheochromocytoma	B-C0031511
,	O
fdg-pet	B-C0032743
revealed	O
100%	O
patient-specific	B-C4304945
sensitivity	I-C4304945
.	O
	
fdg-pet	B-C0032743
detected	O
more	O
metastatic	B-C0205234
foci	I-C0205234
than	O
131	B-C0879568
18	O
vs	O
.	O
	
13	O
sites	O
.	O
	
in	O
seven	O
patients	B-C0030705
of	O
medullary	B-C0238462
carcinoma	I-C0238462
thyroid	I-C0238462
,	O
fdg-pet	B-C0032743
localized	O
residual	O
,	O
recurrent	B-C0277556
,	O
or	O
metastatic	B-C0027627
disease	I-C0027627
with	O
much	O
higher	O
sensitivity	O
32	O
metastatic	B-C0205234
foci	I-C0205234
with	O
72%	O
patient	B-C4304945
specific	I-C4304945
sensitivity	I-C4304945
than	O
131	B-C0879568
,	O
trending	O
along	O
the	O
higher	B-C0863135
serum	I-C0863135
calcitonin	I-C0863135
levels	I-C0863135
.	O
	
fdg-pet	B-C0032743
is	O
not	O
only	O
a	O
good	O
complementary	B-C0695347
modality	I-C0695347
in	O
the	O
management	O
of	O
neural	B-C2931189
crest	I-C2931189
cell	I-C2931189
tumors	I-C2931189
but	O
also	O
it	O
can	O
even	O
be	O
superior	O
,	O
especially	O
in	O
cases	O
of	O
131	B-C0879568
nonavid	B-C0027651
tumors	I-C0027651
.	O
	
progressive	B-C0441597
occlusion	I-C0441597
and	O
recanalization	B-C0034771
after	O
endovascular	B-C0087111
treatment	I-C0087111
for	O
287	O
unruptured	B-C0002940
small	I-C0002940
aneurysms	I-C0002940
<5mm	O
a	O
single-center	B-C1274109
6-year	B-C0439234
experience	B-C0596545
we	O
aimed	O
to	O
investigate	O
the	O
effect	B-C1280500
of	O
coiling	B-C0444764
for	O
small	O
unruptured	B-C0007766
intracranial	I-C0007766
aneurysms	I-C0007766
uias	B-C0007766
on	O
progressive	B-C0441597
occlusio	I-C0441597
n	O
and	O
recanalization	B-C0034771
,	O
and	O
the	O
dubious	O
factors	O
related	O
to	O
progressive	B-C0441597
occlusion	I-C0441597
and	O
recanalization	B-C0034771
among	O
uias	B-C0007766
without	O
complete	O
occlusion	B-C0441597
.	O
	
a	O
total	O
of	O
264	O
patients	B-C0030705
with	O
287	O
small	O
uias	B-C0007766
were	O
coiled	O
in	O
our	O
institute	B-C0021622
between	O
june	O
2009	O
and	O
december	O
2014	O
.	O
	
all	O
uias	B-C0007766
enrolled	O
were	O
divided	O
into	O
small	O
3-5mm	O
and	O
very	O
small	O
<3mm	O
group	B-C0441833
s	O
,	O
and	O
uias	B-C0007766
without	O
initial	O
complete	O
occlusion	B-C0441597
were	O
divided	O
into	O
progressive	B-C0205329
,	O
stable	B-C0205360
and	O
recanalization	B-C0034771
groups	B-C0441833
.	O
	
baseline	B-C1442488
characteristics	B-C1521970
,	O
procedure	B-C0087111
-related	O
complications	B-C0009566
,	O
angiographic	B-C0002978
follow-up	B-C1522577
results	I-C1522577
,	O
and	O
clinical	B-C0085415
outcomes	I-C0085415
were	O
statistically	B-C0871424
analyzed	I-C0871424
.	O
	
among	O
287	O
aneurysms	B-C0002940
,	O
211	O
aneurysms	B-C0002940
73.5	O
were	O
completely	O
coiled	O
,	O
three	O
1.2	O
intraoperative	B-C0456904
ruptures	B-C3203359
and	O
12	O
4.2	O
perioperative	B-C1518988
thromboembolic	B-C0040038
events	I-C0040038
occurred	O
.	O
	
angiographic	B-C0002978
follow-up	B-C1522577
was	O
available	O
for	O
174	O
patients	B-C0030705
65.9	O
,	O
the	O
incidence	B-C0021149
of	O
recanalization	B-C0034771
was	O
5.7	O
.	O
	
among	O
56	O
aneurysms	B-C0002940
without	O
complete	O
occlusion	B-C0441597
,	O
43	O
76.8	O
had	O
progressive	B-C0441597
occlusion	I-C0441597
and	O
6	O
had	O
recanalization	B-C0034771
.	O
	
anatomic	B-C0243095
results	I-C0243095
of	O
initial	O
and	O
follow-up	B-C1522577
between	O
small	O
and	O
very	O
small	O
groups	B-C0441833
were	O
similar	O
in	O
both	O
groups	B-C0441833
.	O
	
on	O
logistic	B-C0681925
regression	I-C0681925
analysis	I-C0681925
,	O
smaller	O
size	B-C0456389
<3mm	O
without	O
complete	O
occlusion	B-C0441597
related	O
to	O
recanalization	B-C0034771
or	O
,	O
8.0	O
,	O
95%	O
ci	O
,	O
1.3	O
,	O
p=0	O
.	O
	
our	O
study	B-C2603343
suggested	O
that	O
coil	B-C0013931
embolization	I-C0013931
of	O
small	O
uias	B-C0007766
can	O
achieve	O
a	O
high	O
rate	O
of	O
progressive	B-C0441597
occlusion	I-C0441597
and	O
low	O
rate	O
of	O
recanalization	B-C0034771
during	O
follow-up	B-C1522577
.	O
	
anatomic	B-C0243095
results	I-C0243095
of	O
initial	O
and	O
follow-up	B-C1522577
between	O
small	O
3-5mm	O
and	O
very	O
small	O
<3mm	O
groups	B-C0441833
were	O
similar	O
in	O
both	O
groups	B-C0441833
.	O
	
what's	O
more	O
,	O
smaller	O
size	O
<3mm	O
without	O
complete	O
occlusion	B-C0441597
may	O
relate	O
to	O
selection	B-C1707391
of	O
an	O
artificial	B-C2004457
diet	B-C0012155
for	O
laboratory	B-C0022877
rearing	B-C1441721
of	O
opogona	B-C3002762
sacchari	I-C3002762
lepidoptera	B-C0023338
tineidae	B-C1009208
bojer	O
,	O
1856	O
the	O
banana	B-C3002762
moth	I-C3002762
opogona	I-C3002762
sacchari	I-C3002762
bojer	B-C3002762
lepidoptera	B-C0023338
tineidae	B-C1009208
is	O
a	O
polyphagous	B-C0684063
pest	I-C0684063
that	O
can	O
cause	O
serious	B-C0205404
damage	B-C1883709
,	O
in	O
particular	O
to	O
banana	B-C0004722
crops	B-C0242775
in	O
southern	B-C1710133
brazil	B-C0006137
.	O
	
the	O
insect	B-C0021585
is	O
a	O
quarantine	O
pest	B-C0684063
in	O
several	O
countries	B-C0454664
,	O
including	O
argentina	B-C0003761
,	O
the	O
main	O
consumer	B-C1707496
market	B-C1318228
for	O
bananas	B-C0004722
from	O
southern	B-C1710133
brazil	B-C0006137
.	O
	
little	O
information	B-C1533716
is	O
available	O
about	O
the	O
biology	B-C0005532
and	O
ecology	B-C0013546
of	O
this	O
moth	B-C0026593
,	O
such	O
as	O
a	O
suitable	O
diet	B-C0012155
for	O
laboratory	B-C0022877
rearing	B-C1441721
.	O
	
in	O
order	O
to	O
provide	O
support	O
for	O
integrated	O
pest	B-C0031249
management	I-C0031249
of	O
the	O
pest	B-C0684063
,	O
this	O
study	B-C2603343
furnished	O
data	B-C1511726
for	O
selecting	O
two	O
diets	B-C0012155
suitable	O
for	O
continuous	O
laboratory	B-C0022877
rearing	B-C1441721
of	O
o	B-C3002762
.	O
	
sacchari	I-C3002762
,	O
one	O
based	O
on	O
dried	B-C1512080
beans	B-C0004896
,	O
wheat	B-C0016452
germ	I-C0016452
,	O
soy	B-C0016452
bran	I-C0016452
,	O
brewer's	B-C0036025
yeast	I-C0036025
,	O
and	O
casein	B-C0007332
and	O
another	O
diet	B-C0012155
with	O
wheat	B-C0016452
germ	I-C0016452
and	O
casein	B-C0007332
as	O
protein	B-C0033684
sources	B-C0449416
.	O
	
with	O
both	O
diets	B-C0012155
,	O
the	O
viability	B-C0443348
of	O
the	O
egg	B-C0029974
-	O
adult	B-C0001675
period	B-C1948053
exceeded	O
68%	O
,	O
with	O
fertility	B-C0015895
over	O
338	O
eggs	B-C0029974
per	O
female	B-C0043210
.	O
	
a	O
corrected	O
biotic	B-C1253910
potential	B-C3245505
analysis	B-C0936012
gave	O
similar	O
values	B-C0042295
for	O
the	O
two	O
the	O
impact	B-C4049986
on	O
productivity	B-C0033269
of	O
a	O
hypothetical	B-C0039371
tax	I-C0039371
on	O
sugar-sweetened	B-C0005329
beverages	I-C0005329
to	O
quantify	O
the	O
potential	B-C3245505
impact	B-C4049986
of	O
an	O
additional	B-C1524062
20%	O
tax	B-C0039371
on	O
sugar-sweetened	B-C0005329
beverages	I-C0005329
ssbs	B-C0005329
on	O
productivity	B-C0033269
in	O
australia	B-C0004340
.	O
	
we	O
used	O
a	O
multi-state	B-C0023682
lifetable	I-C0023682
markov	I-C0023682
model	I-C0023682
to	O
examine	B-C0332128
the	O
potential	B-C3245505
impact	B-C4049986
of	O
an	O
additional	B-C1524062
20%	O
tax	B-C0039371
on	O
ssbs	B-C0005329
on	O
total	B-C4071830
lifetime	I-C4071830
productivity	B-C0033269
in	O
the	O
paid	B-C0009433
and	I-C0009433
unpaid	I-C0009433
sectors	I-C0009433
of	O
the	O
economy	B-C0870462
.	O
	
the	O
study	B-C2348561
population	I-C2348561
consisted	O
of	O
australians	B-C0238711
aged	B-C0001779
20	O
years	B-C0439234
or	O
older	B-C0001792
in	O
2010	O
,	O
whose	O
health	B-C1550208
and	O
other	O
relevant	B-C2347946
outcomes	B-C1274040
were	O
modelled	B-C0870071
over	O
their	O
remaining	B-C1527428
lifetime	B-C4071830
.	O
	
the	O
ssbs	B-C0005329
tax	B-C0039371
was	O
estimated	B-C0750572
to	O
reduce	B-C0392756
the	O
number	B-C0237753
of	O
people	B-C0027361
with	O
obesity	B-C0028754
by	O
1.96	O
of	O
the	O
entire	O
population	B-C1257890
437	O
fewer	O
persons	B-C0027361
with	O
obesity	B-C0028754
,	O
and	O
reduce	B-C0392756
the	O
number	B-C0237753
of	O
employees	B-C0599987
with	O
obesity	B-C0028754
by	O
317	O
persons	B-C0027361
.	O
	
these	O
effects	B-C1280500
translated	O
into	O
productivity	B-C0033269
gains	B-C1517378
in	O
the	O
paid	B-C0009433
sector	I-C0009433
of	O
au	O
million	B-C1881839
for	O
the	O
working	B-C0043227
-	O
age	B-C0001779
population	B-C1257890
95%	O
confidence	B-C0009667
interval	I-C0009667
au	O
million	B-C1881839
to	O
au	O
million	B-C1881839
,	O
using	O
the	O
human	B-C0700103
capital	I-C0700103
approach	B-C0449445
.	O
	
in	O
the	O
unpaid	B-C0009433
sector	I-C0009433
,	O
the	O
potential	B-C3245505
productivity	B-C0033269
gains	B-C1517378
amounted	B-C1265611
to	O
au	O
million	B-C1881839
au	O
million	B-C1881839
to	O
au	O
million	B-C1881839
using	O
the	O
replacement	B-C0025663
cost	I-C0025663
method	I-C0025663
.	O
	
these	O
productivity	B-C0033269
benefits	B-C0814225
are	O
in	O
addition	O
to	O
the	O
health	B-C0086387
benefits	I-C0086387
of	O
35	O
life	B-C0080071
years	I-C0080071
gained	B-C1517378
and	O
a	O
reduction	B-C0392756
in	O
healthcare	B-C0085552
costs	I-C0085552
of	O
au	O
million	B-C1881839
.	O
	
an	O
additional	B-C1524062
20%	O
tax	B-C0039371
on	O
ssbs	B-C0005329
not	O
only	O
improves	B-C0184511
health	B-C1550208
outcomes	I-C1550208
and	O
reduces	B-C0392756
healthcare	B-C0085552
costs	I-C0085552
,	O
but	O
provides	O
productivity	B-C0033269
gains	B-C1517378
in	O
both	O
the	O
paid	B-C0009433
and	I-C0009433
unpaid	I-C0009433
sectors	I-C0009433
of	O
the	O
keeping	O
the	O
spirits	O
up	O
the	O
effect	B-C1280500
of	O
teachers'	B-C0221457
and	O
parents'	B-C0030551
emotional	B-C0600015
support	I-C0600015
on	O
children's	B-C0008059
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
working	B-C0025265
memory	I-C0025265
,	O
used	O
to	O
temporarily	B-C0025265
store	I-C0025265
and	O
mentally	O
manipulate	O
information	B-C1533716
,	O
is	O
important	O
for	O
children's	B-C0008059
learning	B-C0023185
.	O
	
it	O
is	O
therefore	O
valuable	O
to	O
understand	O
which	O
contextual	O
factors	B-C1521761
promote	B-C0033414
or	O
hinder	B-C3463820
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
.	O
	
recent	O
research	B-C0035168
shows	O
positive	B-C1446409
associations	B-C0439849
between	O
positive	B-C1446409
parent-child	B-C0030542
and	O
teacher-student	B-C0871486
interactions	I-C0871486
and	O
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
and	O
development	B-C1527148
.	O
	
however	O
,	O
no	O
study	B-C2603343
has	O
yet	O
experimentally	B-C1292732
investigated	I-C1292732
how	O
parents	B-C0030551
and	O
teachers	B-C0221457
affect	O
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
.	O
	
based	O
on	O
attachment	B-C0871935
theory	I-C0871935
,	O
the	O
current	O
study	B-C2603343
investigated	B-C1292732
the	O
role	O
of	O
parent	B-C0030551
and	O
teacher	B-C0221457
emotional	B-C0600015
support	I-C0600015
in	O
promoting	B-C0033414
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
by	O
buffering	O
the	O
negative	B-C0205160
effect	B-C1280500
of	O
social	B-C0871388
stress	I-C0871388
.	O
	
questionnaires	B-C0034394
and	O
an	O
experimental	B-C0242481
session	I-C0242481
were	O
completed	O
by	O
170	O
children	B-C0008059
from	O
grade	O
1	O
to	O
2	O
mage	O
=	O
7	O
years	B-C0439234
6	O
months	B-C0439231
,	O
sd	O
=	O
7	O
months	B-C0439231
.	O
	
questionnaires	B-C0034394
were	O
used	O
to	O
assess	O
children's	B-C0008059
perceptions	B-C0030971
of	O
the	O
teacher-student	B-C0871486
and	O
parent-child	B-C0030542
relationship	I-C0030542
.	O
	
during	O
an	O
experimental	B-C0242481
session	I-C0242481
,	O
working	B-C0025265
memory	I-C0025265
was	O
measured	O
with	O
the	O
corsi	B-C0681907
task	I-C0681907
backward	I-C0681907
milner	O
,	O
1971	O
in	O
a	O
pre-	B-C1707689
and	O
post-test	B-C1707689
design	I-C1707689
.	O
	
in-between	O
the	O
tests	B-C0392366
stress	B-C0038435
was	O
induced	B-C0205263
in	O
the	O
children	B-C0008059
using	O
the	O
cyberball	B-C0681797
paradigm	I-C0681797
williams	O
et	O
al	O
,	O
2000	O
.	O
	
emotional	B-C0600015
support	I-C0600015
was	O
manipulated	B-C0018578
between-subjects	O
through	O
an	O
audio	B-C3273156
message	B-C0470166
either	O
a	O
weather	B-C0043085
report	B-C0684224
,	O
a	O
supportive	B-C0600015
message	B-C0470166
of	O
a	O
stranger	B-C1257890
,	O
a	O
supportive	B-C0600015
message	B-C0470166
of	O
a	O
parent	B-C0030551
,	O
or	O
a	O
supportive	B-C0600015
message	B-C0470166
of	O
a	O
teacher	B-C0221457
.	O
	
results	B-C1274040
of	O
repeated	B-C0871881
measures	I-C0871881
anova	B-C0002780
showed	O
no	O
clear	O
effect	B-C1280500
of	O
the	O
stress	B-C0038435
induction	B-C0205263
.	O
	
nevertheless	O
,	O
an	O
effect	B-C1280500
of	O
parent	B-C0030551
and	O
teacher	B-C0221457
support	B-C0600015
was	O
found	O
and	O
depended	O
on	O
the	O
quality	B-C0332306
of	O
the	O
parent-child	B-C0030542
relationship	I-C0030542
.	O
	
when	O
children	B-C0008059
had	O
a	O
positive	B-C1446409
relationship	B-C0439849
with	O
their	O
parent	B-C0030551
,	O
support	B-C0600015
of	O
parents	B-C0030551
and	O
teachers	B-C0221457
had	O
little	O
effect	B-C1280500
on	O
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
.	O
	
when	O
children	B-C0008059
had	O
a	O
negative	B-C0205160
relationship	B-C0439849
with	O
their	O
parent	B-C0030551
,	O
a	O
supportive	B-C0600015
message	B-C0470166
of	O
that	O
parent	B-C0030551
decreased	O
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
,	O
while	O
a	O
supportive	B-C0600015
message	B-C0470166
from	O
the	O
teacher	B-C0221457
increased	O
performance	B-C1285654
.	O
	
in	O
sum	O
,	O
the	O
current	O
study	B-C2603343
suggests	O
that	O
parents	B-C0030551
and	O
teachers	B-C0221457
can	O
support	B-C0600015
working	B-C0025265
memory	I-C0025265
performance	B-C1285654
by	O
being	O
supportive	B-C0600015
for	O
the	O
child	B-C0008059
.	O
	
teacher	B-C0221457
support	B-C0600015
is	O
most	O
effective	B-C1704419
when	O
the	O
child	B-C0008059
has	O
a	O
negative	B-C0205160
relationship	B-C0439849
with	O
the	O
parent	B-C0030551
.	O
	
these	O
insights	O
can	O
give	O
direction	O
to	O
specific	O
measures	O
aimed	O
at	O
preventing	B-C1292733
and	O
resolving	B-C3714811
working	B-C0025265
memory	I-C0025265
problems	B-C0033213
and	O
related	O
management	B-C1273870
of	O
tachyarrhythmia	B-C0080203
during	O
pregnancy	B-C0032961
maternal	B-C1858460
tachyarrhythmia	B-C0080203
is	O
a	O
common	B-C0205214
complication	B-C0009566
during	O
pregnancy	B-C0032961
due	O
to	O
hormonal	B-C1134488
changes	I-C1134488
that	O
enhance	B-C2349975
pre-existing	B-C2347662
arrhythmias	B-C0080203
or	O
induce	B-C0205263
new	O
arrhythmias	B-C0080203
in	O
the	O
presence	B-C0150312
of	O
congenital	B-C0018798
heart	I-C0018798
defects	I-C0018798
in	O
pregnant	B-C0033011
females	I-C0033011
.	O
	
presence	B-C0150312
of	O
tachyarrhythmia	B-C0080203
during	O
pregnancy	B-C0032961
poses	O
risk	B-C0035647
to	O
the	O
mother	B-C0026591
and	O
fetus	B-C0015965
,	O
calling	B-C0679006
for	O
proper	B-C0087111
treatment	I-C0087111
with	O
medications	B-C0013227
.	O
	
use	O
of	O
antiarrhythmic	B-C0003195
drugs	I-C0003195
in	O
cases	O
of	O
maternal	B-C1858460
tachyarrhythmia	B-C0080203
must	O
give	O
due	O
consideration	B-C0750591
of	O
potential	B-C3245505
teratogenic	B-C0232910
side	I-C0232910
effects	I-C0232910
.	O
	
utilization	B-C0042153
of	O
antiarrhythmic	B-C0003195
drugs	I-C0003195
during	O
pregnancy	B-C0032961
has	O
been	O
well	O
studied	B-C2603343
some	O
result	B-C1274040
in	O
minimal	B-C0547040
fetal	B-C0015965
harm	B-C0005604
or	O
none	O
at	O
all	O
.	O
	
new	O
techniques	B-C0449851
,	O
such	O
as	O
cardiac	B-C0162563
ablation	I-C0162563
,	O
have	O
also	O
been	O
implemented	B-C1708476
with	O
minimal	B-C0547040
or	O
no	O
radiation	B-C0015333
exposure	I-C0015333
to	O
the	O
fetus	B-C0015965
or	O
mother	B-C0026591
.	O
	
pregnant	B-C0033011
women	I-C0033011
with	O
tachyarrhythmia	B-C0080203
have	O
been	O
successfully	B-C1272703
treated	B-C0332154
with	O
little	B-C0700321
to	O
no	O
impact	B-C4049986
on	O
the	O
developing	B-C3824789
fetus	I-C3824789
as	O
result	B-C1274040
of	O
increasing	B-C0442808
experience	B-C0596545
with	O
antiarrhythmic	B-C0003195
drugs	I-C0003195
and	O
progress	B-C1280477
of	O
new	O
procedural	B-C2700391
techniques	B-C0449851
.	O
	
hif-1α	B-C0965644
overexpression	B-C1514559
improves	B-C0184511
transplanted	B-C1257990
bone	I-C1257990
mesenchymal	I-C1257990
stem	I-C1257990
cells	I-C1257990
survival	B-C0007620
in	O
rat	B-C0012644
mcao	I-C0012644
stroke	I-C0012644
model	I-C0012644
bone	B-C1257975
mesenchymal	I-C1257975
stem	I-C1257975
cells	I-C1257975
bmscs	B-C1257975
death	B-C0007587
after	O
transplantation	B-C1257990
is	O
a	O
serious	O
obstacle	O
impacting	O
on	O
the	O
outcome	O
of	O
cell	B-C0302189
therapy	I-C0302189
for	O
cerebral	B-C0007785
infarction	I-C0007785
.	O
	
this	O
study	B-C0008972
was	O
aimed	B-C1947946
to	O
investigate	B-C1292732
whether	O
modification	B-C0392747
of	O
bmscs	B-C1257975
with	O
hypoxia-inducible	B-C0965644
factor	I-C0965644
1α	I-C0965644
hif-1α	B-C0965644
could	O
enhance	B-C2349975
the	O
survival	B-C0007620
of	O
the	O
implanted	B-C1257990
bmscs	I-C1257990
.	O
	
bmscs	B-C1257975
were	O
isolated	B-C3827940
from	O
wistar	B-C0034716
rats	I-C0034716
,	O
and	O
were	O
infected	B-C3714514
with	O
hif-1α-gfp	B-C1520007
lentiviral	I-C1520007
vector	I-C1520007
or	O
hif-1α	B-C1099354
sirna	I-C1099354
.	O
	
the	O
modified	B-C0392747
bmscs	B-C1257975
were	O
exposed	O
to	O
oxygen-glucose	B-C4236781
deprivation	I-C4236781
ogd	I-C4236781
condition	I-C4236781
,	O
cellular	B-C0007620
viability	I-C0007620
and	O
apoptosis	B-C0162638
were	O
then	O
assessed	B-C1516048
.	O
	
an	O
inhibitor	B-C1254351
of	O
ampk	B-C2350345
compound	B-C1254351
c	I-C1254351
was	O
used	O
to	O
detect	B-C1511790
whether	O
ampk	B-C2350345
and	O
mtor	B-C1447315
were	O
implicated	O
in	O
the	O
functions	O
of	O
hif-1α	B-C0965644
on	O
bmscs	B-C0007620
survival	I-C0007620
.	O
	
besides	O
,	O
ultrastructure	O
of	O
bmscs	B-C1257975
was	O
observed	O
and	O
the	O
expression	B-C1171362
of	I-C1171362
autophagy	I-C1171362
markers	I-C1171362
was	O
measured	O
.	O
	
the	O
modified	B-C0392747
bmscs	B-C1257975
were	O
transplanted	B-C1257990
into	O
middle	B-C0740391
cerebral	I-C0740391
artery	I-C0740391
occlusion	I-C0740391
mcao	B-C0740391
model	B-C0012644
of	I-C0012644
rats	I-C0012644
,	O
and	O
the	O
cerebral	B-C0007785
infarction	I-C0007785
volume	B-C0449468
and	O
neurological	B-C0027767
function	I-C0027767
was	O
assessed	B-C1516048
.	O
	
the	O
results	O
indicated	O
that	O
hif-1α	B-C1514559
overexpression	I-C1514559
protected	O
ogd	B-C4236781
induced	B-C0205263
injury	B-C3263723
by	O
promoting	O
cellular	B-C0007620
viability	I-C0007620
and	O
inhibiting	B-C0021469
apoptosis	B-C0162638
.	O
	
ampk	B-C2350345
was	O
activated	O
while	O
mtor	B-C1447315
was	O
inactivated	B-C0544461
by	O
hif-1α	B-C1514559
overexpression	I-C1514559
,	O
and	O
that	O
might	O
be	O
through	O
which	O
hif-1α	B-C0965644
functioned	O
bmscs	B-C0007620
survival	I-C0007620
.	O
	
hif-1α	B-C1514559
overexpression	I-C1514559
promoted	O
autophagy	B-C0004391
more	O
important	O
,	O
compound	B-C1254351
c	I-C1254351
abolished	O
the	O
induction	B-C0014431
of	I-C0014431
hif-1α	I-C0014431
on	O
autophagy	B-C0004391
.	O
	
transplantation	B-C1257990
of	I-C1257990
the	I-C1257990
overexpressed	I-C1257990
hif-1α	I-C1257990
of	I-C1257990
bmscs	I-C1257990
into	O
the	O
mcao	B-C0012644
rats	I-C0012644
reduced	O
brain	B-C0007785
infarct	I-C0007785
volume	B-C0449468
and	O
improved	B-C0184511
neurobehavioral	B-C2986478
outcome	I-C2986478
besides	O
,	O
it	O
inhibited	O
pro-inflammatory	B-C0079189
cytokines	I-C0079189
generation	O
while	O
promoted	O
neurotrophin	B-C0132298
secretion	B-C1159339
.	O
	
in	O
conclusion	O
,	O
hif-1α	B-C0965644
might	O
be	O
contributed	O
in	O
the	O
survival	B-C0007620
of	I-C0007620
bmscs	I-C0007620
by	O
regulating	O
the	O
activation	B-C0014429
of	I-C0014429
ampk	I-C0014429
and	I-C0014429
mtor	I-C0014429
,	O
as	O
well	O
as	O
by	O
promoting	O
associations	B-C0439849
between	O
major	B-C0557155
life	I-C0557155
events	I-C0557155
and	O
adherence	B-C1510802
,	O
glycemic	B-C3267174
control	I-C3267174
,	O
and	O
psychosocial	B-C0033963
characteristics	I-C0033963
in	O
teens	B-C1521910
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
this	O
cross-sectional	B-C0010362
study	I-C0010362
assessed	B-C1516048
the	O
type	O
of	O
major	B-C0557155
life	I-C0557155
events	I-C0557155
occurring	O
in	O
a	O
contemporary	O
sample	O
of	O
teens	B-C1521910
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
and	O
the	O
association	B-C0439849
between	O
event	B-C0441471
frequency	I-C0441471
and	O
demographic	B-C0011292
,	O
diabetes	B-C0948092
management	I-C0948092
,	O
and	O
psychosocial	B-C0033963
characteristics	I-C0033963
.	O
	
parents	B-C0030551
of	O
178	O
teens	B-C1521910
completed	O
the	O
life	B-C0557155
events	I-C0557155
checklist	B-C1707357
to	O
report	O
major	O
events	B-C0441471
teens	B-C1521910
had	O
experienced	B-C0023672
in	O
the	O
last	O
year	B-C0439234
42%	O
experienced	B-C0023672
0	O
to	O
1	O
event	B-C0441471
n	O
=	O
75	O
,	O
32%	O
experienced	B-C0023672
2	O
to	O
3	O
events	B-C0441471
n	O
=	O
57	O
,	O
and	O
26%	O
experienced	B-C0023672
4+	O
events	B-C0441471
n	O
=	O
46	O
.	O
	
teens	B-C1521910
and	O
parents	B-C0030551
completed	O
validated	O
measures	B-C0079809
of	O
treatment	B-C0516958
adherence	I-C0516958
,	O
diabetes	B-C0011847
-specific	O
self-efficacy	B-C0600564
,	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
,	O
and	O
diabetes	B-C0011847
-specific	O
family	B-C0233542
conflict	I-C0233542
.	O
	
parent-youth	B-C0021822
interview	I-C0021822
and	O
chart	B-C0541653
review	I-C0541653
provided	O
demographics	B-C0011287
and	O
diabetes	B-C0948092
management	I-C0948092
data	O
.	O
	
mean	O
number	O
of	O
events	B-C0441471
/	O
teen	B-C1521910
was	O
2.6	O
2.7	O
range	O
=	O
0-15	O
.	O
	
the	O
most	O
common	O
events	B-C0441471
were	O
""""	O
hospitalization	B-C0019993
of	O
a	O
family	B-C0086282
member	I-C0086282
""""	O
24%	O
,	O
""""	O
getting	B-C0243095
a	I-C0243095
bad	I-C0243095
report	I-C0243095
card	I-C0243095
""""	O
20%	O
,	O
"""serious"	O
arguments	B-C0680226
between	O
parents	B-C0030551
""""	O
19%	O
,	O
and	O
""""	O
serious	B-C0221423
illness	I-C0221423
/	O
injury	B-C3263722
in	O
a	O
family	B-C0086282
member	I-C0086282
""""	O
19%	O
.	O
	
compared	O
with	O
teens	B-C1521910
experiencing	O
0	O
to	O
1	O
event	B-C0441471
,	O
teens	B-C1521910
experiencing	O
4+	O
events	B-C0441471
were	O
less	O
likely	O
to	O
have	O
married	O
parents	B-C0030551
p	O
=	O
01	O
and	O
a	O
parent	B-C0030551
with	O
a	O
college	B-C0542560
degree	I-C0542560
p	O
=	O
006	O
.	O
	
teen	B-C1521910
s	O
with	O
4+	O
events	B-C0441471
had	O
significantly	O
poorer	O
adherence	B-C1510802
p	O
=	O
002	O
teen	B-C1521910
,	O
p	O
=	O
02	O
parent	B-C0030551
,	O
lower	O
self-efficacy	B-C0600564
p	O
=	O
03	O
teen	B-C1521910
,	O
p	O
<	O
0001	O
parent	B-C0030551
,	O
poorer	O
quality	B-C0034380
of	I-C0034380
life	I-C0034380
p	O
<	O
0001	O
teen	B-C1521910
,	O
p	O
<	O
0001	O
parent	B-C0030551
,	O
and	O
more	O
conflict	B-C0233542
p	O
=	O
006	O
teen	B-C1521910
,	O
p	O
=	O
02	O
parent	B-C0030551
than	O
teens	B-C1521910
with	O
fewer	O
events	B-C0441471
.	O
	
in	O
a	O
multivariate	B-C3161035
model	I-C3161035
r	O
2	O
=	O
0.21	O
,	O
p	O
<	O
0001	O
controlling	O
for	O
demographic	B-C0011292
and	O
diabetes	B-C0948092
management	I-C0948092
characteristics	O
,	O
fewer	O
events	B-C0441471
was	O
associated	O
with	O
lower	O
a1c	B-C0019018
p	O
=	O
0009	O
.	O
	
occurrence	O
of	O
more	O
major	B-C0557155
life	I-C0557155
events	I-C0557155
was	O
associated	B-C0332281
with	I-C0332281
poorer	O
diabetes	B-C3274787
care	I-C3274787
and	O
a1c	B-C0019018
and	O
more	O
negative	O
psychosocial	B-C0243156
qualities	I-C0243156
in	O
teens	B-C1521910
with	O
type	B-C0011854
1	I-C0011854
diabetes	I-C0011854
.	O
	
metabolomics	B-C1328813
,	O
nutrition	B-C0392209
,	O
and	O
potential	B-C3245505
biomarkers	B-C0005516
of	O
food	B-C0920525
quality	I-C0920525
,	O
intake	B-C1512806
,	O
and	O
health	B-C0018759
status	I-C0018759
diet	B-C0012155
,	O
dietary	B-C1517289
patterns	I-C1517289
,	O
and	O
other	O
environmental	B-C0686732
factors	I-C0686732
such	O
as	O
exposure	B-C0332157
to	I-C0332157
toxins	B-C0040549
are	O
playing	O
an	O
important	O
role	B-C1705810
in	O
the	O
prevention	B-C2700409
/	O
development	B-C1527148
of	O
many	O
diseases	B-C0012634
,	O
like	O
obesity	B-C0028754
,	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
,	O
and	O
consequently	O
on	O
the	O
health	B-C0018759
status	I-C0018759
of	O
individuals	B-C0237401
.	O
	
a	O
major	O
challenge	O
nowadays	O
is	O
to	O
identify	B-C0205396
novel	B-C0205314
biomarkers	B-C0005516
to	O
detect	B-C0442726
as	O
early	B-C1279919
as	O
possible	O
metabolic	B-C0311400
dysfunction	B-C3887504
and	O
to	O
predict	B-C0681842
evolution	B-C0205245
of	O
health	B-C0018759
status	I-C0018759
in	O
order	O
to	O
refine	O
nutritional	B-C0850410
advices	I-C0850410
to	O
specific	O
population	B-C1257890
groups	I-C1257890
.	O
	
omics	B-C0039421
technologies	I-C0039421
such	O
as	O
genomics	B-C0887950
,	O
transcriptomics	O
,	O
proteomics	B-C0872252
,	O
and	O
metabolomics	B-C1328813
coupled	B-C1948027
with	O
statistical	B-C0037589
and	O
bioinformatics	B-C0037589
tools	I-C0037589
have	O
already	O
shown	O
great	O
potential	B-C3245505
in	O
this	O
research	B-C0683945
field	I-C0683945
even	O
if	O
so	O
far	O
only	O
few	O
biomarkers	B-C0005516
have	O
been	O
validated	O
.	O
	
for	O
the	O
past	O
two	O
decades	B-C2981279
,	O
important	O
analytical	B-C0022885
techniques	I-C0022885
have	O
been	O
developed	B-C0205245
to	O
detect	B-C0442726
as	O
many	O
metabolites	B-C0870883
as	O
possible	O
in	O
human	B-C0086418
biofluids	B-C0005889
such	O
as	O
urine	B-C0042036
,	O
blood	B-C0005767
,	O
and	O
saliva	B-C0036087
.	O
	
in	O
the	O
field	O
of	O
food	B-C0920526
science	I-C0920526
and	O
nutrition	B-C0028707
,	O
many	O
studies	B-C2603343
have	O
been	O
carried	O
out	O
for	O
food	B-C0016452
authenticity	B-C0205556
,	O
quality	B-C0332306
,	O
and	O
safety	B-C0036043
,	O
as	O
well	O
as	O
for	O
food	B-C0016487
processing	I-C0016487
.	O
	
furthermore	O
,	O
metabolomic	B-C1328813
investigations	B-C1292732
have	O
been	O
carried	O
out	O
to	O
discover	B-C1880355
new	O
early	B-C1279919
biomarkers	B-C0005516
of	O
metabolic	B-C0311400
dysfunction	B-C3887504
and	O
predictive	B-C0681890
biomarkers	B-C0005516
of	O
developing	O
pathologies	B-C0030664
obesity	B-C0028754
,	O
metabolic	B-C0039082
syndrome	I-C0039082
,	O
type-2	B-C0011860
diabetes	I-C0011860
,	O
etc	O
.	O
	
great	O
emphasis	O
is	O
also	O
placed	O
in	O
the	O
development	B-C1527148
of	O
methodologies	B-C0086912
to	O
identify	B-C0205396
and	O
validate	O
biomarkers	B-C0005516
of	O
nutrients	B-C0678695
exposure	B-C0332157
.	O
	
draft	B-C0162326
genome	I-C0162326
sequence	I-C0162326
of	O
bacillus	B-C0004590
cereus	I-C0004590
la2007	I-C0004590
,	O
a	O
human-pathogenic	B-C3494793
isolate	I-C3494793
harboring	O
anthrax	B-C1254288
-like	O
plasmids	O
we	O
present	O
the	O
genome	O
sequence	O
of	O
bacillus	O
cereus	O
la2007	O
,	O
a	O
strain	O
isolated	O
in	O
2007	O
from	O
a	O
fatal	O
pneumonia	O
case	O
in	O
louisiana	O
.	O
	
sequence-based	O
genome	O
analysis	O
revealed	O
that	O
la2007	O
carries	O
a	O
plasmid	O
highly	O
similar	O
to	O
bacillus	O
anthracis	O
pxo1	O
,	O
including	O
the	O
genes	O
responsible	O
for	O
the	O
production	O
and	O
regulation	O
of	O
anthrax	O
toxin	I-C0051962
developing	O
elite	B-C1522427
neurospora	B-C0027923
crassa	I-C0027923
strains	B-C1518614
for	O
cellulosic	B-C0007648
ethanol	B-C0678710
production	I-C0678710
using	O
fungal	B-C0521033
breeding	B-C1260875
the	O
demand	O
for	O
renewable	B-C3178762
and	O
sustainable	B-C3178763
energy	I-C3178763
has	O
generated	B-C3146294
considerable	O
interest	B-C0543488
in	O
the	O
conversion	B-C0439836
of	O
cellulosic	B-C0007648
biomass	B-C0005535
into	O
liquid	B-C0302908
fuels	B-C0556991
such	O
as	O
ethanol	B-C0001962
using	O
a	O
filamentous	B-C0016832
fungus	I-C0016832
.	O
	
while	O
attempts	B-C1516084
have	O
been	O
made	O
to	O
study	B-C2603343
cellulose	B-C1157836
metabolism	I-C1157836
through	O
the	O
use	B-C1524063
of	I-C1524063
knock-out	B-C1522225
mutants	B-C0596988
,	O
there	O
have	O
been	O
no	O
systematic	B-C0220922
effort	O
to	O
characterize	B-C1880022
natural	B-C0205296
variation	B-C0042333
for	O
cellulose	B-C1157836
metabolism	I-C1157836
in	O
ecotypes	B-C3178911
adapted	B-C0001398
to	O
different	B-C1705242
habitats	B-C0871648
.	O
	
here	O
,	O
we	O
characterized	B-C1880022
natural	B-C0205296
variation	B-C0042333
in	O
saccharification	B-C1254366
of	O
cellulose	B-C0007648
and	O
fermentation	B-C0015852
in	O
73	O
ecotypes	B-C3178911
and	O
89	O
laboratory	B-C0022877
strains	B-C1518614
of	O
the	O
model	B-C3161035
fungus	B-C0016832
neurospora	B-C0027923
crassa	I-C0027923
.	O
	
we	O
observed	B-C1441672
significant	B-C0750502
variation	B-C0042333
in	O
both	O
traits	B-C0599883
among	O
natural	B-C0205296
and	O
laboratory	B-C2346631
generated	I-C2346631
populations	B-C0016832
,	O
with	O
some	O
elite	B-C1522427
strains	B-C1518614
performing	B-C0884358
better	B-C0332272
than	O
the	O
reference	B-C0034925
strain	B-C1518614
.	O
	
in	O
the	O
f1	B-C0314650
population	I-C0314650
n345	I-C0314650
,	O
15%	O
of	O
the	O
population	B-C0016832
outperformed	O
both	O
parents	B-C0016832
with	O
the	O
top	O
performing	B-C0884358
strain	B-C1518614
having	O
10%	O
improvement	B-C2986411
in	O
ethanol	B-C0678710
production	I-C0678710
.	O
	
these	O
results	B-C1254595
suggest	O
that	O
natural	B-C0205296
alleles	B-C0002085
can	O
be	O
exploited	O
through	O
fungal	B-C0521033
breeding	B-C1260875
for	O
developing	O
elite	B-C1522427
industrial	B-C0021267
strains	B-C1518614
for	O
bioethanol	B-C0678710
production	I-C0678710
.	O
	
the	O
role	O
of	O
the	O
hippocampus	B-C0019564
and	O
the	O
function	O
of	O
calcitonin	B-C0006669
gene-related	I-C0006669
peptide	I-C0006669
in	O
the	O
mechanism	O
of	O
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
accelerating	O
fracture-healing	B-C0162542
this	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	B-C0019564
plays	O
in	O
accelerated	O
fracture-healing	B-C0162542
after	O
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	B-C0006669
gene-related	I-C0006669
peptide	I-C0006669
cgrp	B-C0006669
during	O
this	O
process	O
.	O
	
experiments	O
were	O
carried	O
out	O
on	O
male	O
sprague-dawley	B-C0034715
rats	I-C0034715
that	O
were	O
split	O
into	O
four	O
groups	B-C0441833
at	O
random	O
tbi	B-C0876926
-	O
fracture	B-C0016658
group	B-C0441833
,	O
fracture	B-C0016658
-	O
only	B-C0205171
group	B-C0441833
,	O
tbi	B-C0876926
-	O
only	B-C0205171
group	B-C0441833
,	O
and	O
control	B-C0009932
group	I-C0009932
.	O
	
in	O
the	O
first	O
week	O
,	O
blood	B-C0178913
specimen	I-C0178913
would	O
be	O
drawn	O
from	O
rats	B-C0034715
among	O
the	O
groups	B-C0441833
except	O
those	O
of	O
the	O
control	B-C0009932
group	I-C0009932
at	O
three-time	O
points	O
24	O
,	O
72	O
and	O
168	O
hours	O
post	B-C0687676
-	O
damage	B-C0270611
.	O
	
these	O
rats	B-C0034715
would	O
be	O
assessed	O
from	O
the	O
neurological	B-C0205494
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	B-C0270611
injury	I-C0270611
.	O
	
blood	B-C1277698
samples	I-C1277698
were	O
also	O
taken	O
from	O
the	O
control	B-C0009932
group	I-C0009932
24	O
hours	O
before	O
the	O
injury	B-C0270611
,	O
and	O
whole	O
brain	B-C0459385
tissues	I-C0459385
in	O
the	O
injured	B-C0332664
groups	B-C0441833
were	O
harvested	B-C0185110
at	O
72	O
and	O
168	O
hours	O
post	B-C0687676
-	O
injury	B-C0270611
.	O
	
we	O
compared	O
the	O
serum	B-C0229671
cgrp	B-C0006669
concentration	B-C1446561
,	O
the	O
distribution	O
of	O
cgrp	B-C0006669
,	O
the	O
cgrp	B-C0006669
expression	B-C1171362
,	O
and	O
the	O
expression	B-C1171362
of	O
cgrp	B-C0006669
in	O
the	O
hippocampus	B-C0019564
,	O
the	O
expression	B-C1171362
of	O
cgrp	B-C0006669
in	O
the	O
hippocampus	B-C0019564
,	O
the	O
expression	B-C1171362
of	O
cgrp	B-C0006669
in	O
the	O
hippocampus	B-C0019564
,	O
and	O
the	O
expression	B-C1171362
of	O
cgrp	B-C0006669
in	O
the	O
brain	B-C0006104
by	O
immunohistochemistry	B-C0021044
,	O
western	B-C0949466
blotting	I-C0949466
,	O
rt	B-C0035380
-	O
of	O
cgrp	B-C0017337
rna	B-C1515670
expression	I-C1515670
levels	O
.	O
	
neurological	B-C0027853
examinations	I-C0027853
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	B-C0007776
cortex	I-C0007776
,	O
cerebellum	B-C0007765
,	O
and	O
brain	B-C0006121
stem	I-C0006121
showed	O
significant	O
differences	O
pre	B-C0332152
-	O
and	O
post	B-C0687676
-	O
injury	B-C0270611
p	O
<	O
0.001	O
.	O
	
elisa	B-C0014441
analysis	I-C0014441
indicated	O
a	O
great	O
density	O
of	O
cgrp	B-C0006669
in	O
tbi	B-C0876926
-	O
fracture	B-C0016658
group	B-C0441833
at	O
different	O
time	O
points	O
.	O
	
furthermore	O
,	O
in	O
the	O
tbi	B-C0876926
-	O
fracture	B-C0016658
group	B-C0441833
,	O
cgrp	B-C0006669
in	O
both	O
hippocampus	B-C0019564
and	O
the	O
whole	B-C1269537
brain	I-C1269537
showed	O
a	O
noticeable	O
augment	O
in	O
rt-pcr	B-C0599161
and	O
western	B-C0949466
blot	I-C0949466
analysis	I-C0949466
at	O
72	O
and	O
168	O
h	O
post	B-C0687676
-	O
injury	B-C0270611
,	O
and	O
only	B-C0205171
in	O
this	O
group	O
,	O
immunohistochemistry	B-C0021044
analysis	I-C0021044
indicated	O
that	O
cgrp	B-C0006669
was	O
present	O
in	O
the	O
hippocampus	B-C0019564
at	O
168	O
hours	O
post	B-C0687676
-	O
injury	B-C0270611
.	O
	
we	O
observed	O
that	O
the	O
hippocampus	B-C0019564
and	O
cgrp	B-C0006669
were	O
responsible	O
for	O
quick	O
bone-healing	B-C3687232
mechanisms	O
.	O
	
we	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	B-C0019564
in	O
accelerated	O
fracture	B-C0162542
healing	I-C0162542
.	O
	
cgrp	B-C0006669
expression	B-C1171362
,	O
as	O
determined	O
by	O
ihc	B-C0021044
,	O
cannot	O
be	O
observed	O
in	O
other	O
groups	B-C0441833
,	O
indicating	O
that	O
the	O
hippocampus	B-C0019564
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	B-C0006104
that	O
responds	O
to	O
""""	O
big	B-C0449430
stress	I-C0449430
bone	B-C0391978
extracellular	B-C0015350
matrix	I-C0015350
hydrogel	B-C0600484
enhances	O
osteogenic	B-C0007589
differentiation	I-C0007589
of	O
c2c12	B-C0596995
myoblasts	I-C0596995
and	O
mouse	B-C0025929
primary	O
calvarial	B-C0205950
cells	B-C0007634
hydrogel	B-C0600484
scaffolds	I-C0600484
derived	O
from	O
the	O
extracellular	B-C0015350
matrix	I-C0015350
ecm	B-C0015350
of	O
mammalian	B-C0040300
tissues	I-C0040300
have	O
been	O
successfully	O
used	O
to	O
promote	O
tissue	B-C0043240
repair	I-C0043240
in	B-C1533691
vitro	I-C1533691
and	O
in	B-C1515655
vivo	I-C1515655
.	O
	
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
osteogenic	B-C0029433
potential	I-C0029433
of	O
ecm	B-C0015350
hydrogels	B-C0600484
prepared	O
from	O
demineralized	B-C1832069
and	O
decellularized	B-C0005479
bovine	I-C0005479
bone	I-C0005479
in	O
the	O
presence	O
and	O
absence	O
of	O
osteogenic	B-C0010454
medium	I-C0010454
.	O
	
culture	B-C0430400
of	O
c2c12	B-C0596995
and	O
mouse	B-C0025929
primary	O
calvarial	B-C0205950
cells	B-C0007634
mpcs	B-C0007634
on	O
decellularized	B-C0005479
bone	I-C0005479
ecm	I-C0005479
becm	B-C0005479
and	O
demineralized	B-C1832069
bone	I-C1832069
matrix	I-C1832069
dbm	B-C1832069
gels	B-C0600484
resulted	O
in	O
increased	O
expression	B-C0600223
of	O
osteogenic	B-C0017393
gene	I-C0017393
markers	I-C0017393
,	O
including	O
a	O
3.6	O
and	O
13.4	O
increase	O
in	O
osteopontin	B-C0069676
and	O
15.7	O
and	O
27.1	O
increase	O
in	O
osteocalcin	B-C0029419
when	O
mpcs	B-C0007634
were	O
cultured	B-C0430400
upon	O
becm	B-C0005479
with	O
basal	B-C0010454
and	O
osteogenic	B-C0010454
media	I-C0010454
,	O
respectively	O
.	O
	
becm	B-C0005479
hydrogels	B-C0600484
stimulated	O
the	O
osteogenic	B-C0007589
differentiation	I-C0007589
of	O
c2c12	B-C0596995
and	O
mpcs	B-C0007634
even	O
in	O
the	O
absence	O
of	O
osteogenic	B-C0010454
medium	I-C0010454
.	O
	
these	O
results	O
suggest	O
that	O
becm	B-C0005479
hydrogel	B-C0600484
scaffolds	I-C0600484
may	O
have	O
great	O
utility	O
in	O
future	O
clinical	B-C0205210
applications	B-C4048755
for	O
bone	B-C0391978
tissue	B-C0596171
engineering	I-C0596171
.	O
	
prostate-specific	B-C0138741
antigen	I-C0138741
increase	B-C0442805
during	O
dutasteride	B-C0754659
to	O
indicate	O
the	O
need	O
for	O
prostate	B-C0194804
biopsy	I-C0194804
influence	O
of	O
prostatic	B-C0033581
inflammation	I-C0033581
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	B-C0936012
the	O
significance	O
of	O
an	O
increase	B-C0442805
in	O
total	B-C2123607
prostate-specific	I-C2123607
antigen	I-C2123607
psa	I-C2123607
serum	I-C2123607
levels	I-C2123607
despite	O
dutasteride	B-C0754659
treatment	B-C0087111
as	O
a	O
predictor	B-C2698872
of	O
prostate	B-C0376358
cancer	I-C0376358
pc	B-C0376358
at	O
biopsy	B-C0005558
.	O
	
we	O
focused	O
our	O
attention	O
on	O
the	O
rate	B-C1521828
of	O
the	O
first	O
psa	B-C0138741
increase	O
and	O
on	O
the	O
influence	O
of	O
prostatic	O
inflammation	O
.	O
	
from	O
2011	O
to	O
2016	O
,	O
365	O
men	O
with	O
a	O
previous	O
negative	O
prostate	O
biopsy	O
and	O
persistent	O
elevated	O
psa	B-C0138741
levels	O
received	O
dutasteride	O
treatment	O
.	O
	
the	O
population	O
was	O
followed	O
for	O
a	O
range	O
of	O
12-48	O
months	O
.	O
	
one	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
psa	O
increase	B-C0442805
>0	O
ng/ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow-up	O
were	O
included	O
in	O
group	O
a	O
and	O
underwent	O
a	O
new	O
prostate	O
biopsy	O
.	O
	
in	O
group	O
a	O
,	O
the	O
psa	O
increase	O
was	O
associated	O
with	O
pc	O
at	O
the	O
re-biopsy	O
in	O
66%	O
of	O
cases	O
.	O
	
the	O
percentage	O
of	O
psa	O
reduction	O
after	O
6	O
months	O
of	O
treatment	O
was	O
not	O
a	O
significant	O
indicator	O
of	O
the	O
risk	O
for	O
pc	O
.	O
	
the	O
distribution	O
of	O
inflammatory	O
infiltrates	O
significantly	O
p<00	O
varied	O
from	O
positive	O
to	O
negative	O
prostate	O
biopsies	O
.	O
	
the	O
relative	O
risk	O
for	O
pc	O
at	O
biopsy	O
significantly	O
increase	O
d	O
according	O
to	O
psa	O
level	O
during	O
dutasteride	O
.	O
	
treatment	O
with	O
dutasteride	O
can	O
help	O
to	O
analyze	O
psa	O
kinetic	O
.	O
	
a	O
persistent	O
prostatic	B-C0033581
inflammation	I-C0033581
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
psa	O
kinetic	O
during	O
dutasteride	O
treatment	B-C0087111
neurological	B-C4314692
decline	I-C4314692
in	O
an	O
elderly	B-C0001792
with	O
repaired	B-C0205340
myelomeningocele	B-C0025312
complicated	B-C0231242
with	O
lumbar	B-C0158288
canal	I-C0158288
stenosis	I-C0158288
a	O
case	B-C0085973
report	I-C0085973
tethered	B-C0080218
cord	I-C0080218
syndrome	I-C0080218
is	O
a	O
well-known	O
complication	B-C0009566
after	O
myelomeningocele	B-C0025312
mmc	B-C0025312
repair	B-C1705181
in	O
childhood	B-C0231335
.	O
	
however	O
,	O
late	O
complications	B-C0009566
in	O
adults	B-C0001675
with	O
a	O
repaired	B-C0205340
mmc	B-C0025312
are	O
not	O
well	O
understood	O
.	O
	
in	O
particular	O
,	O
the	O
influence	B-C4054723
of	O
a	O
degenerative	B-C0575157
spinal	I-C0575157
deformity	I-C0575157
on	O
a	O
sustained	B-C0443318
tethered	B-C1842369
cord	I-C1842369
is	O
still	O
unclear	O
.	O
	
a	O
63-year-old	B-C0001675
man	B-C0086582
with	O
a	O
repaired	B-C0205340
mmc	B-C0025312
presented	O
with	O
a	O
progressive	B-C0243095
gait	I-C0243095
disturbance	I-C0243095
and	O
numbness	B-C0028643
in	O
both	O
lower	B-C0023216
limbs	I-C0023216
.	O
	
magnetic	B-C1704922
resonance	I-C1704922
images	I-C1704922
demonstrated	O
that	O
the	O
tethered	B-C1842369
spinal	I-C1842369
cord	I-C1842369
was	O
compressed	B-C0332260
by	O
severe	B-C0205082
canal	B-C0158288
stenosis	I-C0158288
along	O
the	O
entire	B-C1269871
lumbar	I-C1269871
spine	I-C1269871
.	O
	
after	O
a	O
multi-level	B-C0578803
lumbar	I-C0578803
decompression	I-C0578803
surgery	B-C0543467
,	O
the	O
patient	B-C1115804
recovered	I-C1115804
to	O
baseline	B-C1442488
neurological	B-C0205494
status	O
.	O
	
in	O
adults	B-C0001675
with	O
a	O
repaired	B-C0205340
mmc	B-C0025312
,	O
lumbar	B-C0158288
canal	I-C0158288
stenosis	I-C0158288
should	O
be	O
investigated	B-C1292732
as	O
a	O
possible	O
cause	O
of	O
late	O
neurological	B-C4314692
decline	I-C4314692
.	O
	
clinical	O
manifestations	O
may	O
be	O
complicated	B-C0231242
by	O
the	O
coexistence	O
of	O
both	O
the	O
original	O
and	O
subsequent	O
neurological	B-C0027765
disorders	I-C0027765
.	O
	
because	O
these	O
additional	O
disorders	B-C0012634
result	O
from	O
compressive	B-C0037926
myelopathy	I-C0037926
,	O
early	O
surgical	B-C0376530
decompression	I-C0376530
is	O
indicated	O
to	O
avoid	O
irreversible	O
spinal	B-C0012634
cord	I-C0012634
dysfunction	I-C0012634
.	O
	
epidemiology	B-C0014507
of	O
polyomavirus	B-C0005670
bk	I-C0005670
bkv	B-C0005670
and	O
the	O
emergent	B-C0750573
african	B-C0001737
variant	B-C0205419
in	O
kidney	B-C0022646
and	O
bone	B-C0005953
marrow	I-C0005953
transplant	B-C0376387
recipients	I-C0376387
in	O
the	O
fundacion	B-C1708333
valle	I-C1708333
del	I-C1708333
lili	I-C1708333
in	I-C1708333
cali	I-C1708333
,	O
colombia	B-C3245499
to	O
describe	O
the	O
epidemiology	B-C0014507
of	O
bkv	B-C0005670
and	O
to	O
assess	B-C1516048
the	O
presence	B-C0150312
of	O
the	O
african	B-C0001737
variant	B-C0205419
in	O
bone	B-C0005953
marrow	I-C0005953
and	O
kidney	B-C4304779
transplant	I-C4304779
patients	I-C4304779
who	O
have	O
suspected	B-C0332147
bkv	B-C0005670
reactivation	B-C4086768
.	O
	
a	O
descriptive	B-C0002783
study	I-C0002783
was	O
conducted	B-C3844519
,	O
using	O
institutional	B-C0034869
records	I-C0034869
,	O
at	O
the	O
fundación	B-C1708333
valle	I-C1708333
del	I-C1708333
lili	I-C1708333
,	O
cali	I-C1708333
-	O
colombia	B-C3245499
.	O
	
the	O
overall	B-C0033106
prevalence	I-C0033106
of	O
bkv	B-C0005670
during	O
the	O
study	O
period	O
was	O
51%	O
.	O
	
the	O
african	B-C0001737
variant	B-C0205419
was	O
identified	B-C0205396
in	O
49.4	O
of	O
samples	B-C0370003
that	O
were	O
positive	B-C1446409
for	O
bkv	B-C0005670
.	O
	
50.6	O
of	O
the	O
samples	B-C0370003
were	O
found	O
to	O
have	O
the	O
wild	B-C1883559
strain	B-C0456178
of	O
bkv	B-C0005670
.	O
	
among	O
bkv	B-C0005670
positive	B-C1446409
patients	B-C0030705
,	O
57%	O
were	O
kidney	B-C4304779
transplant	I-C4304779
recipients	I-C4304779
and	O
43%	O
were	O
bone	B-C0005953
marrow	I-C0005953
transplant	B-C0376387
recipients	I-C0376387
.	O
	
this	O
is	O
the	O
first	O
epidemiological	B-C0002783
study	I-C0002783
describing	O
the	O
african	B-C0001737
variant	B-C0205419
of	O
bkv	B-C0005670
in	O
thaw	B-C1710378
-and-use	O
target	B-C0221284
cells	I-C0221284
pre-labeled	B-C1708632
with	O
calcein	B-C0016320
am	I-C0016320
for	O
antibody-dependent	B-C0201624
cell-mediated	I-C0201624
cytotoxicity	I-C0201624
assays	I-C0201624
in	B-C1533691
vitro	I-C1533691
antibody-dependent	B-C0201624
cell-mediated	I-C0201624
cytotoxicity	I-C0201624
adcc	I-C0201624
assays	I-C0201624
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic	B-C0003241
antibodies	I-C0003241
.	O
	
in	O
adcc	B-C0201624
assays	I-C0201624
,	O
target	B-C0221284
cells	I-C0221284
bound	O
by	O
the	O
antibodies	B-C0003241
are	O
lysed	B-C0024348
by	O
activated	B-C1879547
effector	B-C0312740
cells	I-C0312740
following	O
interactions	O
between	O
the	O
fc	B-C0021032
region	I-C0021032
of	O
the	O
bound	O
antibody	B-C0003241
and	O
fcγ	B-C0034805
receptors	I-C0034805
on	O
effector	B-C0312740
cells	I-C0312740
.	O
	
target	B-C0221284
cell	I-C0221284
lysis	B-C0024348
is	O
typically	O
measured	O
by	O
quantification	B-C1709793
of	O
released	O
endogenous	B-C0205227
enzymes	B-C0014442
,	O
e.g	O
,	O
lactate	B-C0022917
dehydrogenase	I-C0022917
,	O
or	O
measurement	O
of	O
released	O
exogenous	B-C0205228
labels	B-C1522485
,	O
e.g	O
,	O
51	B-C0303212
,	O
europium	B-C0015180
or	O
calcein	B-C0060549
.	O
	
adcc	B-C0201624
assays	I-C0201624
based	O
on	O
the	O
detection	O
of	O
exogenous	B-C0205228
labels	B-C1522485
released	O
from	O
lysed	B-C0024348
target	B-C0221284
cells	I-C0221284
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation	B-C1320226
times	I-C1320226
.	O
	
however	O
,	O
target	B-C0221284
cells	I-C0221284
are	O
usually	O
labeled	B-C1708632
immediately	O
prior	O
to	O
assay	B-C1510438
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-C1510438
variations	B-C0205419
due	O
to	O
differences	O
in	O
target	B-C0221284
cell	I-C0221284
conditions	O
and	O
labeling	B-C2347885
/	O
handling	B-C0037793
processes	I-C0037793
.	O
	
in	O
this	O
report	O
,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-C1710378
-and-use	O
pre-labeled	B-C1708632
target	B-C0221284
cells	I-C0221284
for	O
adcc	B-C0201624
assays	I-C0201624
.	O
	
thaw	B-C1710378
-and-use	O
target	B-C0221284
cells	I-C0221284
in	O
our	O
experiments	O
were	O
pre-labeled	B-C1708632
with	O
the	O
fluorescent	B-C0016320
dye	I-C0016320
calcein	I-C0016320
am	I-C0016320
,	O
cryopreserved	B-C0010405
in	O
single-use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-C1510438
after	O
thawing	B-C2025613
.	O
	
upon	O
thaw	B-C1710378
,	O
the	O
pre-labeled	B-C1708632
cells	B-C0007634
displayed	O
viability	B-C0007620
and	O
label	B-C1522485
retention	B-C0333118
comparable	O
to	O
freshly	O
labeled	B-C1708632
cells	B-C0007634
,	O
responded	O
to	O
adcc	B-C0003272
mediated	O
by	O
both	O
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
and	O
engineered	B-C0022688
natural	I-C0022688
killer	I-C0022688
cells	I-C0022688
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
adcc	B-C0201624
assays	I-C0201624
.	O
	
implementation	O
of	O
thaw	B-C1710378
-and-use	O
pre-labeled	B-C1708632
target	B-C0221284
cells	I-C0221284
in	O
adcc	B-C0201624
assays	I-C0201624
can	O
help	O
to	O
alleviate	O
both	O
cell	B-C0007585
culture	I-C0007585
and	O
dye	B-C0886517
labeling	I-C0886517
derived	O
variability	O
,	O
increase	O
the	O
flexibility	O
of	O
assay	B-C1510438
scheduling	O
and	O
improve	O
assay	B-C0332529
consistency	I-C0332529
and	O
pathways	B-C1704259
and	O
genes	B-C0017337
associated	B-C0332281
with	I-C0332281
immune	B-C0020962
dysfunction	B-C0277785
in	O
sheep	B-C0036945
paratuberculosis	B-C0030524
multibacillary	B-C0243095
and	O
paucibacillary	B-C0243095
paratuberculosis	B-C0030524
are	O
both	O
caused	O
by	O
mycobacterium	B-C0085442
avium	I-C0085442
subspecies	I-C0085442
paratuberculosis	I-C0085442
.	O
	
multibacillary	B-C0243095
lesions	B-C0221198
are	O
composed	O
largely	O
of	O
infected	B-C0439663
epithelioid	B-C0014603
macrophages	I-C0014603
and	O
paucibacillary	B-C0243095
lesions	B-C0221198
contain	O
t	B-C0039194
cells	I-C0039194
but	O
few	O
bacteria	B-C0004611
.	O
	
multibacillary	B-C0243095
disease	B-C0012634
is	O
similar	O
to	O
human	O
lepromatous	B-C0023348
leprosy	I-C0023348
,	O
with	O
variable/high	O
levels	O
of	O
antibody	B-C0003241
and	O
a	O
dysfunctional	B-C0031847
immune	B-C0301872
response	I-C0301872
.	O
	
animals	B-C0003062
with	O
paucibacillary	B-C0243095
disease	B-C0012634
have	O
high	O
cell-mediated	B-C0020966
immunity	I-C0020966
and	O
variable	B-C0441889
levels	I-C0441889
of	O
antibody	B-C0003241
.	O
	
this	O
study	O
aims	O
to	O
characterize	O
the	O
immunological	B-C1532237
dysfunction	I-C1532237
using	O
truseq	B-C0282574
analysis	B-C0936012
of	O
the	O
ileocaecal	B-C0700426
lymph	B-C0024204
node	I-C0024204
that	O
drains	O
disease	B-C0012634
lesions	B-C0221198
.	O
	
immune	B-C0020962
dysfunction	B-C0277785
is	O
highlighted	O
by	O
repression	B-C0920533
of	O
tcr	B-C0524889
/	O
cd3	B-C0017337
genes	I-C0017337
,	O
t	B-C0034790
cell	I-C0034790
co-receptors	I-C0034790
/	O
co-stimulators	B-C3203085
,	O
t	B-C1155065
cell	I-C1155065
activation	I-C1155065
and	O
signal-transduction	B-C0037083
genes	B-C0017337
.	O
	
inflammation	B-C0021368
was	O
an	O
acute	B-C0001349
phase	I-C0001349
response	I-C0001349
and	O
chronic	B-C0021376
inflammation	I-C0021376
,	O
with	O
little	O
evidence	O
of	O
acute	B-C0333361
inflammation	I-C0333361
.	O
	
the	O
high	O
levels	O
of	O
immunoglobulin	B-C0021027
and	O
plasma	B-C0032112
cell	I-C0032112
transcripts	B-C1519595
is	O
consistent	O
with	O
the	O
anti-map	B-C0003261
antibody	I-C0003261
responses	I-C0003261
in	O
paratuberculosis	B-C0030524
sheep	B-C0036945
.	O
	
also	O
notable	O
was	O
the	O
overwhelming	O
reduction	B-C0392756
in	O
mast	B-C0024880
cell	I-C0024880
transcripts	B-C1519595
,	O
potentially	O
affecting	B-C0392760
dc	B-C1817431
activation	I-C1817431
of	I-C1817431
the	I-C1817431
immune	I-C1817431
response	I-C1817431
.	O
	
this	O
study	O
also	O
shows	O
that	O
there	O
were	O
no	O
fundamental	O
differences	O
in	O
the	O
gene	B-C0017262
expression	I-C0017262
patterns	O
in	O
multibacillary	B-C0243095
and	O
paucibacillary	B-C0243095
disease	B-C0012634
,	O
no	O
shift	O
in	O
t	B-C0039194
cell	I-C0039194
genes	B-C0017337
from	O
th1	B-C0242632
to	O
th2	B-C0242633
pattern	O
but	O
rather	O
an	O
incremental	B-C1705117
decline	O
into	O
immune	B-C0020962
dysfunction	B-C0277785
leading	O
to	O
multibacillary	B-C0243095
pathology	B-C0012634
.	O
	
modified	B-C0392747
frailty	B-C4075886
index	I-C4075886
predicts	B-C0681842
postoperative	B-C0231287
outcomes	B-C0086749
in	O
older	B-C3826770
gastrointestinal	B-C0685938
cancer	I-C0685938
patients	B-C0030705
frailty	B-C0424594
disproportionately	B-C0205556
impacts	B-C4049986
older	B-C3826770
patients	B-C0030705
with	O
gastrointestinal	B-C0685938
cancer	I-C0685938
,	O
rendering	B-C0205245
them	O
at	O
increased	B-C3553618
risk	I-C3553618
for	I-C3553618
poor	I-C3553618
outcomes	I-C3553618
.	O
	
a	O
frailty	B-C4075886
index	I-C4075886
may	O
aid	O
in	O
preoperative	B-C0445204
risk	B-C0035647
stratification	B-C1514983
.	O
	
we	O
hypothesized	B-C1512571
that	O
high	O
modified	B-C4075885
frailty	I-C4075885
index	I-C4075885
mfi	I-C4075885
scores	I-C4075885
are	O
associated	B-C0332281
with	I-C0332281
adverse	B-C1705586
outcomes	I-C1705586
after	O
tumor	B-C0027651
resection	B-C0015252
in	O
older	B-C3826770
,	O
gastrointestinal	B-C0685938
cancer	I-C0685938
patients	B-C0030705
.	O
	
patients	B-C0030705
60-90	B-C3826770
years	I-C3826770
old	I-C3826770
who	O
underwent	B-C0205245
gastrointestinal	B-C0744337
tumor	I-C0744337
resection	I-C0744337
were	O
identified	B-C0205396
in	O
the	O
2005-2012	O
nsqip	B-C1532051
participant	B-C0679646
use	O
file	O
.	O
	
mfi	B-C4075885
was	O
defined	O
by	O
11	O
previously	B-C0205156
described	B-C1552738
,	O
preoperative	B-C0445204
variables	B-C0439828
.	O
	
frailty	B-C0424594
was	O
defined	O
by	O
an	O
mfi	B-C4075885
score	I-C4075885
>0	O
.	O
	
the	O
postoperative	B-C0032786
course	I-C0032786
was	O
evaluated	B-C0220825
using	O
univariate	B-C0683962
and	O
multivariate	B-C0026777
analysis	I-C0026777
.	O
	
41	O
455	O
patients	B-C0030705
mean	O
age	O
72.4	O
years	O
,	O
47.4	O
female	B-C0086287
were	O
identified	B-C0205396
.	O
	
the	O
most	O
prevalent	B-C0205391
form	I-C0205391
of	O
cancer	B-C0006826
was	O
colorectal	B-C1527249
69.3	O
,	O
n	O
=	O
28	O
708	O
and	O
2.8	O
of	O
patients	B-C0030705
were	O
frail	B-C0871754
n	O
=	O
1	O
.	O
	
frail	B-C0871754
patients	B-C0030705
were	O
significantly	B-C0750502
more	B-C0750501
likely	I-C0750501
to	O
have	O
increased	B-C3840528
length	I-C3840528
of	I-C3840528
stay	I-C3840528
11.7	O
vs	O
9.0	O
days	O
,	O
major	B-C0205164
complications	B-C0009566
29.1	O
vs	O
17.9	O
,	O
and	O
30-day	O
mortality	B-C0026565
5.6	O
vs	O
2.5	O
,	O
all	O
p	O
<	O
0.001	O
.	O
	
multivariate	B-C0026777
analysis	I-C0026777
identified	B-C0205396
mfi	B-C4075885
as	O
an	O
independent	B-C0085862
predictor	B-C2698872
of	O
major	B-C0205164
complications	B-C0009566
or	O
1.52	O
,	O
95%ci	O
1.39	O
,	O
p	O
<	O
0.001	O
and	O
30-day	O
mortality	B-C0026565
or	O
1.48	O
,	O
95%ci	O
1.24	O
,	O
p	O
<	O
0.001	O
.	O
	
mfi	B-C4075885
was	O
associated	B-C0332281
with	I-C0332281
the	O
incidence	B-C0021149
of	O
postoperative	B-C0231287
complications	B-C0009566
and	O
mortality	B-C0026565
in	O
older	B-C3826770
surgical	B-C0871463
patients	I-C0871463
with	O
gastrointestinal	B-C0685938
cancer	I-C0685938
.	O
	
spermatocytic	B-C0334517
tumor	I-C0334517
with	O
sarcoma	B-C1261473
a	O
rare	B-C0522498
testicular	B-C0039590
neoplasm	I-C0039590
spermatocytic	B-C0334517
tumor	I-C0334517
,	O
formerly	O
known	O
as	O
spermatocytic	B-C0334517
seminoma	I-C0334517
,	O
is	O
an	O
uncommon	B-C0522498
testicular	B-C0039590
neoplasm	I-C0039590
which	O
is	O
a	O
distinct	O
clinicopathologic	B-C0205469
entity	I-C0205469
from	O
classic	O
seminoma	B-C0036631
.	O
	
these	O
tumors	B-C0027651
are	O
not	O
associated	O
with	O
germ	B-C4021985
cell	I-C4021985
neoplasia	I-C4021985
in	O
situ	O
,	O
other	O
germ	B-C0205851
cell	I-C0205851
tumors	I-C0205851
,	O
or	O
isochromosome	B-C1515647
12p	I-C1515647
.	O
	
although	O
typically	O
,	O
these	O
tumors	B-C0027651
have	O
an	O
excellent	B-C1961136
prognosis	B-C0033325
occasional	B-C0868928
cases	I-C0868928
are	O
associated	B-C0332281
with	I-C0332281
sarcoma	B-C1261473
and	O
have	O
a	O
very	B-C0278252
poor	I-C0278252
prognosis	I-C0278252
.	O
	
we	O
present	O
a	O
case	B-C1706256
of	O
spermatocytic	B-C0334517
tumor	I-C0334517
with	O
sarcoma	B-C1261473
showing	O
a	O
chondrosarcomatous	B-C0008479
component	I-C0008479
,	O
discuss	O
the	O
pathologic	B-C1317598
findings	I-C1317598
and	O
differential	B-C0011906
diagnosis	I-C0011906
and	O
provide	O
follow-up	B-C1522577
information	B-C1533716
.	O
	
remote	B-C0205157
ischemic	B-C0376466
conditioning	I-C0376466
and	O
renal	B-C0022646
protection	B-C1545588
over	O
the	O
course	O
of	O
the	O
last	O
2	O
decades	O
,	O
the	O
concept	O
of	O
remote	B-C0205157
ischemic	B-C0376466
conditioning	I-C0376466
ric	B-C0376466
has	O
attracted	O
considerable	O
research	B-C0035168
interest	B-C0543488
,	O
because	O
ric	B-C0376466
,	O
in	O
most	O
of	O
its	O
embodiments	O
offers	O
an	O
inexpensive	O
way	O
of	O
protecting	B-C1545588
tissues	B-C0040300
against	O
ischemic	B-C0475224
damage	B-C0010957
inflicted	O
by	O
a	O
number	O
of	O
medical	B-C0205476
conditions	B-C0348080
or	O
procedures	B-C0199171
.	O
	
acute	B-C2609414
kidney	I-C2609414
injury	I-C2609414
aki	B-C2609414
is	O
a	O
common	O
side	B-C0001688
effect	I-C0001688
in	O
the	O
context	O
of	O
various	O
medical	B-C0199171
procedures	I-C0199171
,	O
and	O
ric	B-C0376466
has	O
been	O
suggested	O
as	O
a	O
means	O
of	O
reducing	O
its	O
incidence	O
.	O
	
outcomes	B-C1274040
regarding	O
kidney	B-C0232804
function	I-C0232804
have	O
been	O
reported	O
in	O
numerous	O
studies	B-C0079816
that	O
evaluated	O
the	O
effects	B-C1704420
of	I-C1704420
ric	B-C0376466
in	O
a	O
variety	O
of	O
settings	O
eg	O
,	O
cardiac	B-C0018821
surgery	I-C0018821
,	O
interventions	B-C0184661
requiring	O
intravenous	B-C0013125
administration	I-C0013125
of	O
contrast	B-C0009924
media	I-C0009924
.	O
	
although	O
several	O
individual	O
studies	B-C0079816
have	O
implied	O
a	O
beneficial	O
effect	B-C1704420
of	I-C1704420
ric	B-C0376466
in	O
preserving	O
kidney	B-C0232804
function	I-C0232804
,	O
3	O
recently	O
published	O
randomized	B-C0206035
controlled	I-C0206035
trials	I-C0206035
evaluating	O
more	O
than	O
1000	O
patients	B-C0030705
each	O
effect	B-C1704420
of	I-C1704420
remote	B-C0376442
ischemic	I-C0376442
preconditioning	I-C0376442
in	O
the	O
cardiac	B-C0018821
surgery	I-C0018821
,	O
remote	B-C0376442
ischaemic	I-C0376442
preconditioning	I-C0376442
for	O
heart	B-C0018821
surgery	I-C0018821
,	O
and	O
e	B-C0010055
ric	I-C0010055
ca	I-C0010055
were	O
negative	O
.	O
	
however	O
,	O
aki	O
or	O
any	O
other	O
index	O
of	O
renal	O
function	O
was	O
not	O
a	O
stand-alone	O
primary	O
end	O
point	O
in	O
any	O
of	O
these	O
trials	O
.	O
	
on	O
the	O
other	O
hand	O
,	O
a	O
range	O
of	O
meta-analyses	O
each	O
including	O
thousands	O
of	O
participants	O
have	O
reported	O
mixed	O
results	O
,	O
with	O
the	O
most	O
recent	O
among	O
them	O
showing	O
benefit	O
from	O
ric	B-C0376466
,	O
pinpointing	O
at	O
the	O
same	O
time	O
a	O
number	O
of	O
shortcomings	O
in	O
published	O
studies	O
,	O
adversely	O
affecting	O
the	O
quality	O
of	O
available	O
data	O
.	O
	
the	O
present	O
review	O
provides	O
a	O
critical	O
appraisal	O
of	O
the	O
current	O
state	O
of	O
this	O
field	O
of	O
research	O
.	O
	
it	O
is	O
the	O
opinion	O
of	O
the	O
authors	O
of	O
this	O
review	O
that	O
there	O
is	O
a	O
clear	O
need	O
for	O
a	O
common	O
clinical	O
trial	O
framework	O
for	O
ischemic	O
conditioning	O
studies	O
.	O
	
if	O
the	O
current	O
babel	O
of	O
definitions	O
,	O
procedures	O
,	O
outcomes	O
,	O
and	O
goals	O
persists	O
,	O
it	O
is	O
most	O
likely	O
that	O
soon	O
ischemic	O
conditioning	O
will	O
be	O
"""yesterday's"	O
"news"""	O
with	O
no	O
definitive	O
conclusions	O
having	O
been	O
reached	O
in	O
terms	O
of	O
its	O
real	O
clinical	O
utility	I-C0008971
temporal	B-C2362314
and	O
spatial	B-C1254362
variability	B-C2827666
of	O
fungal	B-C2717804
structures	I-C2717804
and	O
host	B-C0301872
responses	I-C0301872
in	O
an	O
incompatible	B-C1155325
rust-wheat	I-C1155325
interaction	I-C1155325
information	B-C1533716
about	O
temporal	B-C2362314
and	O
spatial	B-C1254362
variability	B-C2827666
of	O
fungal	B-C2717804
structures	I-C2717804
and	O
host	B-C0301872
responses	I-C0301872
is	O
scarce	B-C0231180
in	O
comparison	B-C1707455
to	O
the	O
vast	O
amount	B-C1265611
of	O
genetic	B-C0314603
,	O
biochemical	B-C0205474
,	O
and	O
physiological	B-C0205463
studies	B-C2603343
of	O
host-pathogen	B-C1752856
interactions	I-C1752856
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
used	B-C0457083
avirulent	B-C0205556
wild	B-C1883559
type	I-C1883559
and	O
virulent	B-C1520022
mutant	B-C0678941
isolates	B-C1764827
of	O
puccinia	B-C1001443
striiformis	I-C1001443
to	O
characterize	B-C1880022
the	O
interactions	B-C1704675
in	O
wheat	B-C0043137
carrying	B-C0206243
yellow	B-C1001443
rust	I-C1001443
yr2	B-C1001443
resistance	B-C4087433
.	O
	
both	O
conventional	B-C1442989
and	O
advanced	B-C0205179
microscopic	B-C0205288
techniques	B-C0449851
were	O
used	B-C0457083
for	O
a	O
detailed	B-C1522508
study	B-C2603343
of	O
morphology	B-C0332437
and	O
growth	B-C0018270
of	O
fungal	B-C0521033
colonies	B-C1947989
and	O
associated	B-C0332281
host	B-C0301872
cell	I-C0301872
responses	I-C0301872
.	O
	
the	O
growth	B-C0018270
of	O
the	O
wild	B-C1883559
type	I-C1883559
isolates	B-C1764827
was	O
highly	B-C0205250
restricted	B-C0443288
due	O
to	O
hypersensitive	B-C0020517
response	I-C0020517
hr	B-C0020517
,	O
plant	B-C0032098
cell	B-C0007587
death	I-C0007587
indicated	B-C1444656
by	O
autofluorescence	B-C0544711
and	O
change	B-C0392747
in	O
the	O
shape	B-C0332479
of	O
the	O
affected	B-C0392760
plant	B-C3178867
cells	I-C3178867
.	O
	
the	O
host	B-C0301872
response	I-C0301872
appeared	B-C0700364
post	B-C0687676
-	O
haustorial	B-C2717804
,	O
but	O
large	B-C0549177
variation	B-C0205419
in	O
the	O
time	B-C0040223
and	O
stage	B-C0205390
of	O
arrest	B-C0333951
was	O
observed	B-C1441672
for	O
individual	B-C0237401
fungal	B-C0521033
colonies	B-C1947989
,	O
probably	B-C0750492
due	O
to	O
a	O
delay	B-C0205421
between	B-C0205103
detection	B-C1511790
and	O
response	B-C0871261
.	O
	
some	O
colonies	B-C1947989
were	O
stopped	B-C2746065
right	B-C0205253
after	I-C0205253
the	O
formation	B-C1522492
of	O
the	O
primary	B-C0948192
infection	I-C0948192
hyphae	B-C0521057
whereas	O
others	O
formed	B-C0205431
highly	B-C0205250
branched	B-C2700384
mycelia	B-C0949695
.	O
	
hr	B-C0020517
was	O
first	O
observed	B-C1441672
in	O
host	B-C1819995
cells	I-C1819995
in	O
direct	B-C1947931
contact	B-C0392367
with	O
fungal	B-C2717804
structures	I-C2717804
,	O
after	O
which	O
the	O
defense	B-C1154988
responses	I-C1154988
spread	B-C0332261
to	O
adjacent	B-C0205117
host	B-C1819995
cells	I-C1819995
,	O
and	O
eventually	O
led	O
to	O
encasement	B-C1254362
of	O
the	O
fungal	B-C0521033
colony	B-C1947989
.	O
	
several	B-C0443302
cells	B-C0007634
with	O
hr	B-C0020517
contained	B-C2700400
haustoria	B-C2717804
,	O
which	O
were	O
small	B-C0700321
and	O
underdeveloped	B-C0205252
,	O
but	O
some	B-C0205392
cells	B-C0007634
contained	B-C2700400
normal	B-C0205307
sized	B-C0456389
haustoria	B-C2717804
without	O
signs	B-C0037088
of	O
hypersensitivity	B-C0020517
.	O
	
the	O
growth	B-C0018270
of	O
the	O
virulent	B-C1520022
mutants	B-C0678941
in	O
the	O
resistant	B-C0332325
plants	B-C0032098
was	O
similar	B-C2348205
to	O
the	O
growth	B-C0018270
in	O
plants	B-C0032098
without	O
yr2	B-C1001443
resistance	B-C4087433
,	O
which	O
is	O
a	O
strong	B-C0442821
indication	B-C3146298
that	O
the	O
incompatible	B-C1881865
phenotype	B-C0031437
was	O
associated	B-C0332281
with	O
yr2	B-C1001443
.	O
	
the	O
interaction	B-C1704675
between	B-C0205103
p	B-C1001443
.	O
	
striiformis	I-C1001443
and	O
wheat	B-C0043137
with	O
yr2	B-C1001443
resistance	B-C4087433
was	O
highly	B-C0205250
variable	B-C0439828
in	O
time	B-C0040223
and	O
space	B-C1254362
,	O
which	O
demonstrate	B-C0443289
that	O
histological	B-C0019638
studies	B-C2603343
are	O
important	B-C3898777
for	O
a	O
deeper	B-C0162340
understanding	I-C0162340
of	O
host-pathogen	B-C1752856
interactions	I-C1752856
and	O
plant	B-C0032098
defense	B-C0520990
mechanisms	B-C0441712
in	O
the	O
effects	B-C1704420
of	I-C1704420
messages	B-C0470166
about	O
the	O
causes	B-C0015127
of	O
obesity	B-C0028754
on	O
disciplinary	B-C1552598
action	I-C1552598
decisions	B-C0679006
for	O
overweight	B-C1561826
employees	B-C0599987
we	O
investigated	B-C1292732
the	O
impact	B-C4049986
of	O
messages	B-C0470166
about	O
the	O
causes	B-C0015127
of	O
obesity	B-C0028754
controllable	B-C2911690
or	O
uncontrollable	B-C0205318
on	O
the	O
disciplinary	B-C1552598
action	I-C1552598
consequences	B-C0686907
selected	O
for	O
obese	B-C0028754
employees	B-C0599987
in	O
response	B-C0871261
to	O
a	O
work-related	B-C1698590
mistake	B-C0743559
.	O
	
participants	B-C0679646
read	O
about	O
either	O
the	O
controllable	B-C2911690
or	O
uncontrollable	B-C0205318
causes	B-C0015127
of	O
obesity	B-C0028754
before	O
reviewing	B-C1704362
an	O
ostensible	B-C0750489
employee	B-C0599987
file	B-C0016094
that	O
included	O
a	O
description	O
of	O
an	O
employee	B-C0599987
mistake	B-C0743559
.	O
	
depending	O
on	O
condition	O
,	O
the	O
file	B-C0016094
contained	O
a	O
photo	B-C0441468
of	O
the	O
employee	B-C0599987
that	O
either	O
depicted	O
them	O
as	O
obese	B-C0028754
or	O
average	B-C1510992
weight	B-C0005910
.	O
	
participants	B-C0679646
were	O
more	O
willing	O
to	O
withhold	B-C1705116
a	O
raise	O
or	O
promotion	B-C0681129
from	O
an	O
obese	B-C0028754
employee	B-C0599987
than	O
from	O
an	O
average	B-C1510992
-	O
weight	B-C0005910
employee	B-C0599987
.	O
	
further	O
,	O
there	O
was	O
little	O
evidence	B-C3887511
that	O
the	O
messages	B-C0470166
about	O
the	O
causes	B-C0015127
of	O
obesity	B-C0028754
affected	B-C0392760
participants	B-C0679646
'	O
perceived	B-C0517445
control	I-C0517445
and	O
self-efficacy	B-C0600564
for	O
healthy	B-C3898900
behaviors	B-C0004927
.	O
	
experience	B-C0596545
is	O
instrumental	B-C1704339
in	O
tuning	B-C0006751
a	O
link	B-C2986575
between	O
language	B-C0023008
and	O
cognition	B-C0009240
evidence	B-C3887511
from	O
6-	B-C0001779
to	I-C0001779
7-	I-C0001779
month-old	I-C0001779
infants	B-C0021270
'	O
object	O
categorization	B-C0008902
at	B-C1744681
birth	I-C1744681
,	O
infants	B-C0021270
not	O
only	O
prefer	O
listening	B-C2584303
to	O
human	B-C0086418
vocalizations	B-C0009452
,	O
but	O
also	O
have	O
begun	B-C0439659
to	O
link	B-C2986575
these	O
vocalizations	B-C0009452
to	O
cognition	B-C0009240
for	O
infants	B-C0021270
as	O
young	B-C0332239
as	O
three	B-C1442461
months	I-C1442461
of	O
age	B-C0001779
,	O
listening	B-C2584303
to	O
human	B-C0086418
language	B-C0023008
supports	O
object	O
categorization	B-C0008902
,	O
a	O
core	B-C0444669
cognitive	B-C1516691
capacity	B-C1516240
.	O
	
this	O
precocious	B-C1279930
link	B-C0449379
is	O
initially	B-C0205265
broad	B-C0332464
at	O
3	O
and	O
4	O
months	O
,	O
vocalizations	B-C0009452
of	O
both	B-C1706086
humans	B-C0086418
and	O
nonhuman	B-C0237798
primates	I-C0237798
support	O
categorization	B-C0008902
.	O
	
but	O
by	O
6	B-C4082120
months	I-C4082120
,	O
infants	B-C0021270
have	O
narrowed	B-C0333164
the	O
link	B-C2986575
only	O
human	B-C0086418
vocalizations	B-C0009452
support	O
object	O
categorization	B-C0008902
.	O
	
here	O
we	O
ask	O
what	O
guides	O
infants	B-C0021270
as	O
they	O
tune	B-C0006751
their	O
initially	B-C0205265
broad	B-C0332464
link	B-C2986575
to	O
a	O
more	O
precise	B-C2828393
one	O
,	O
engaged	O
only	O
by	O
the	O
vocalizations	B-C0009452
of	O
our	O
species	B-C1705920
.	O
	
across	O
three	O
studies	B-C2603343
,	O
we	O
use	O
a	O
novel	B-C0205314
exposure	B-C0332157
paradigm	B-C0681797
to	O
examine	O
the	O
effects	B-C1280500
of	O
experience	B-C0596545
.	O
	
we	O
document	O
that	O
merely	O
exposing	B-C0332157
infants	B-C0021270
to	O
nonhuman	B-C0237798
primate	I-C0237798
vocalizations	B-C0009452
enables	B-C1171285
infants	B-C0021270
to	O
preserve	O
the	O
early	B-C1279919
-	O
established	B-C0443211
link	B-C2986575
between	O
this	O
signal	B-C1710082
and	O
categorization	B-C0008902
.	O
	
in	O
contrast	O
,	O
exposing	B-C0332157
infants	B-C0021270
to	O
backward	B-C1555029
speech	B-C0037817
-	O
a	O
signal	B-C1710082
that	O
fails	B-C0231175
to	O
support	B-C1521721
categorization	B-C0008902
at	O
any	O
age	B-C0001779
-	O
offers	O
no	O
such	O
advantage	O
.	O
	
our	O
findings	B-C0243095
reveal	B-C0443289
the	O
power	B-C3854080
of	O
early	B-C1279919
experience	B-C0596545
as	O
infants	B-C0021270
specify	O
which	O
signals	B-C1710082
,	O
from	O
an	O
initially	B-C0205265
broad	B-C0332464
set	O
,	O
they	O
will	O
continue	B-C0549178
to	O
link	B-C2986575
to	O
bone	B-C1390464
degeneration	I-C1390464
and	O
its	O
recovery	O
in	O
smp30/gnl	B-C1419366
-	O
knockout	B-C0206745
mice	I-C0206745
senescence	B-C1451963
marker	I-C1451963
protein-30	I-C1451963
smp30	B-C1451963
decreases	O
androgen	B-C0002844
-independently	O
with	O
aging	B-C0001811
and	O
is	O
a	O
lactone	B-C0022947
-	O
hydrolyzing	B-C0014442
enzyme	I-C0014442
gluconolactonase	B-C0051129
gnl	B-C0051129
that	O
is	O
involved	O
in	O
vitamin	B-C0003968
c	I-C0003968
biosynthesis	B-C0005572
.	O
	
in	O
the	O
present	O
study	B-C2603343
,	O
bone	B-C0262950
properties	O
of	O
smp30/gnl	B-C1419366
knockout	B-C0206745
ko	I-C0206745
mice	I-C0206745
with	O
deficiency	B-C0011155
in	O
vitamin	B-C0003968
c	I-C0003968
synthesis	B-C0005572
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
smp30/gnl	B-C1451963
and	O
exogenous	B-C0205228
vitamin	B-C0003968
c	I-C0003968
supplementation	B-C0302837
on	O
bone	B-C0029433
formation	I-C0029433
.	O
	
mineral	B-C0005963
content	I-C0005963
bmc	B-C0005963
and	O
mineral	B-C0005938
density	I-C0005938
bmd	B-C0005938
of	O
the	O
mandible	B-C0024687
and	O
femur	B-C0015811
of	O
smp30/gnl	B-C1419366
ko	B-C0206745
and	O
wild-type	B-C1520150
mice	I-C1520150
at	O
2	O
and	O
3	O
months	B-C0439231
of	O
age	B-C0001779
with	O
or	O
without	O
vitamin	B-C0003968
c	I-C0003968
supplementation	B-C0302837
were	O
measured	O
by	O
dual-energy	B-C1510486
x-ray	I-C1510486
absorptiometry	I-C1510486
.	O
	
body	B-C0005910
and	O
bone	B-C0262950
weight	B-C0043100
of	O
both	O
age	B-C0596090
groups	I-C0596090
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild-type	B-C1520150
mice	I-C1520150
.	O
	
the	O
bones	B-C0262950
of	O
smp30/gnl	B-C1419366
ko	B-C0206745
mice	I-C0206745
were	O
rough	O
and	O
porous	O
,	O
with	O
bmc	B-C0005963
and	O
bmd	B-C0005938
significantly	O
below	O
wild-type	B-C1520150
.	O
	
oral	B-C0226896
supplementation	B-C0302837
with	O
vitamin	B-C0003968
c	I-C0003968
eliminated	O
differences	O
in	O
body	B-C0005910
weight	I-C0005910
,	O
bone	B-C0262950
weight	O
,	O
bmc	B-C0005963
,	O
and	O
bmd	B-C0005938
between	O
smp30/gnl	B-C1419366
ko	B-C0206745
and	O
wild-type	B-C1520150
mice	I-C1520150
at	O
each	O
age	B-C0001779
.	O
	
these	O
results	O
indicate	O
that	O
bone	B-C1390464
degeneration	I-C1390464
in	O
smp30/gnl	B-C1419366
ko	B-C0206745
mice	I-C0206745
was	O
caused	O
by	O
lack	O
of	O
vitamin	B-C0003968
c	I-C0003968
,	O
and	O
that	O
this	O
mouse	B-C0025930
strain	I-C0025930
is	O
an	O
appropriate	O
model	B-C0599779
for	O
bone	B-C0596204
metabolism	I-C0596204
in	O
humans	B-C0086418
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	B-C0005572
vitamin	B-C0003968
c	I-C0003968
.	O
	
utility	O
of	O
post-mortem	B-C0004398
genetic	B-C1517514
testing	I-C1517514
in	O
cases	O
of	O
sudden	B-C2721586
arrhythmic	I-C2721586
death	I-C2721586
syndrome	I-C2721586
sudden	B-C2721586
arrhythmic	I-C2721586
death	I-C2721586
syndrome	I-C2721586
sads	B-C2721586
describes	O
a	O
sudden	B-C0011071
death	I-C0011071
with	O
negative	O
autopsy	B-C0004398
and	O
toxicological	B-C0205472
analysis	B-C0936012
.	O
	
cardiac	B-C0019247
genetic	I-C0019247
disease	I-C0019247
is	O
a	O
likely	O
etiology	B-C1314792
.	O
	
this	O
study	B-C2603343
investigated	B-C1292732
the	O
clinical	B-C0205210
utility	I-C0205210
and	O
combined	O
yield	O
of	O
post-mortem	B-C0004398
genetic	B-C1517514
testing	I-C1517514
molecular	B-C0004398
autopsy	I-C0004398
in	O
cases	O
of	O
sads	B-C2721586
and	O
comprehensive	B-C1880156
clinical	B-C4084924
evaluation	I-C4084924
of	O
surviving	B-C0038952
relatives	B-C0080103
.	O
	
we	O
evaluated	B-C0220825
302	O
expertly	O
validated	O
sads	B-C2721586
cases	O
with	O
suitable	O
dna	B-C0012854
median	O
age	B-C0001779
24	O
years	O
65%	O
males	B-C0086582
who	O
underwent	O
next-generation	B-C3274765
sequencing	B-C1294197
using	O
an	O
extended	O
panel	B-C0441833
of	O
77	O
primary	B-C0017337
electrical	I-C0017337
disorder	I-C0017337
and	O
cardiomyopathy	B-C0017337
genes	I-C0017337
.	O
	
pathogenic	B-C3816499
and	O
likely	O
pathogenic	B-C0205419
variants	I-C0205419
were	O
classified	O
using	O
american	B-C1708333
college	I-C1708333
of	I-C1708333
medical	I-C1708333
genetics	I-C1708333
acmg	B-C1708333
consensus	B-C0162791
guidelines	I-C0162791
.	O
	
the	O
yield	O
of	O
combined	O
molecular	B-C0004398
autopsy	I-C0004398
and	O
clinical	B-C4084924
evaluation	I-C4084924
in	O
82	O
surviving	B-C0015576
families	I-C0015576
was	O
evaluated	B-C0220825
.	O
	
a	O
gene-level	B-C2350277
rare	I-C2350277
variant	I-C2350277
association	I-C2350277
analysis	I-C2350277
was	O
conducted	O
in	O
sads	B-C2721586
cases	O
versus	O
controls	B-C0009932
.	O
	
a	O
clinically	B-C0205556
actionable	I-C0205556
pathogenic	B-C3816499
or	O
likely	O
pathogenic	B-C0205419
variant	I-C0205419
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
13%	O
.	O
	
the	O
main	O
etiologies	B-C1314792
established	O
were	O
catecholaminergic	B-C4053736
polymorphic	I-C4053736
ventricular	I-C4053736
tachycardia	I-C4053736
and	O
long	B-C0023976
qt	I-C0023976
syndrome	I-C0023976
17	O
6%	O
and	O
11	O
4%	O
,	O
respectively	O
.	O
	
gene-based	B-C2350277
rare	I-C2350277
variants	I-C2350277
association	I-C2350277
analysis	I-C2350277
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	B-C0205419
variants	I-C0205419
in	O
ryr2	B-C1419779
p	O
=	O
5	O
10	O
.	O
	
combining	O
molecular	B-C0004398
autopsy	I-C0004398
with	O
clinical	B-C4084924
evaluation	I-C4084924
in	O
surviving	B-C0015576
families	I-C0015576
increased	O
diagnostic	B-C0205556
yield	I-C0205556
from	O
26%	O
to	O
39%	O
.	O
	
molecular	B-C0004398
autopsy	I-C0004398
for	O
electrical	B-C0017337
disorder	I-C0017337
and	O
cardiomyopathy	B-C0017337
genes	I-C0017337
,	O
using	O
acmg	B-C1708333
guidelines	B-C0162791
for	O
variant	B-C0008902
classification	I-C0008902
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
sads	B-C2721586
.	O
	
our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	B-C4053736
polymorphic	I-C4053736
ventricular	I-C4053736
tachycardia	I-C4053736
and	O
long	B-C0023976
qt	I-C0023976
syndrome	I-C0023976
,	O
especially	O
the	O
ryr2	B-C1419779
gene	I-C1419779
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	B-C0017337
.	O
	
furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	B-C4084924
and	O
genetic	B-C0846617
evaluation	I-C0846617
.	O
	
binding	B-C1145667
of	O
dead-box	B-C0072382
helicase	I-C0072382
dhh1	B-C1100944
to	O
the	O
5'utr	B-C0600493
of	O
ash1	B-C1426004
mrna	B-C0035696
represses	B-C1519619
localized	O
translation	B-C1519614
of	O
ash1	B-C1426004
in	O
yeast	B-C0043393
cells	B-C0007634
local	B-C1519614
translation	I-C1519614
of	O
specific	B-C0205369
mrnas	B-C0035696
is	O
regulated	B-C1326447
by	O
dynamic	O
changes	O
in	O
their	O
subcellular	B-C0729605
localization	B-C0475264
,	O
and	O
these	O
changes	B-C0392747
are	O
due	O
to	O
complex	B-C0439855
mechanisms	B-C0441712
controlling	B-C2239193
cytoplasmic	B-C0521449
mrna	B-C1523053
transport	I-C1523053
.	O
	
the	O
budding	B-C0014181
yeast	I-C0014181
saccharomyces	B-C0036025
cerevisiae	I-C0036025
is	O
well	O
suited	O
to	O
studying	O
these	O
mechanisms	B-C0441712
because	O
many	O
of	O
its	O
transcripts	B-C1519595
are	O
transported	B-C1519628
from	O
the	O
mother	B-C0007634
cell	I-C0007634
to	O
the	O
budding	B-C1155616
daughter	B-C0007634
cell	I-C0007634
.	O
	
here	O
,	O
we	O
investigated	B-C1292732
the	O
translational	B-C1157519
control	I-C1157519
of	O
ash1	B-C1426004
mrna	B-C0035696
after	O
transport	B-C1519628
and	O
localization	B-C0475264
.	O
	
we	O
show	O
that	O
although	O
ash1	B-C1426004
transcripts	O
were	O
translated	O
after	O
they	O
reached	O
the	O
bud-tip	O
,	O
some	O
mrnas	O
were	O
bound	O
by	O
the	O
rna-binding	O
protein	O
puf6	O
and	O
were	O
non-polysomal	O
.	O
	
we	O
also	O
found	O
that	O
the	O
dead-box	O
helicase	O
dhh1	O
complexed	O
with	O
the	O
untranslated	O
ash1	B-C1426004
mrna	O
and	O
puf6	O
.	O
	
loss	O
of	O
dhh1	O
affected	O
local	O
translation	O
of	O
ash1	O
mrna	O
and	O
resulted	O
in	O
delocalization	O
of	O
ash1	O
transcript	O
in	O
the	O
bud	O
.	O
	
forcibly	O
shifting	O
the	O
non-polysomal	O
ash1	O
mrna	O
into	O
polysomes	O
was	O
associated	O
with	O
dhh1	O
dissociation	O
.	O
	
we	O
further	O
demonstrated	O
that	O
dhh1	O
is	O
not	O
recruited	O
to	O
ash1	O
mrna	O
co-transcriptionally	O
,	O
suggesting	O
that	O
it	O
could	O
bind	O
to	O
ash1	O
mrna	O
within	O
the	O
cytoplasm	O
.	O
	
of	O
note	O
,	O
dhh1	O
bound	O
to	O
the	O
5	O
utr	O
of	O
ash1	O
mrna	O
and	O
inhibited	O
its	O
translation	O
in	O
vitro	O
.	O
	
these	O
results	O
suggest	O
that	O
after	O
localization	O
to	O
the	O
bud	O
tip	O
,	O
a	O
portion	O
of	O
the	O
localized	O
ash1	O
mrna	O
becomes	O
translationally	O
inactive	O
,	O
because	O
of	O
binding	O
of	O
dhh1	O
and	O
puf6	O
to	O
the	O
5'	O
and	O
3'	O
utrs	O
of	O
ash1	O
mrna	B-C0035696
the	O
abundance	B-C2346714
of	O
endofungal	B-C0004611
bacterium	I-C0004611
rhizobium	B-C0085472
radiobacter	I-C0085472
syn	O
.	O
	
agrobacterium	B-C0085472
tumefaciens	I-C0085472
increases	B-C0442805
in	O
its	O
fungal	B-C0521033
host	B-C1167395
piriformospora	B-C1025512
indica	I-C1025512
during	O
the	O
tripartite	O
sebacinalean	B-C1665458
symbiosis	B-C0039029
with	O
higher	B-C1562025
plants	I-C1562025
rhizobium	B-C0085472
radiobacter	I-C0085472
syn	O
.	O
	
agrobacterium	B-C0085472
tumefaciens	I-C0085472
,	O
syn	O
.	O
	
""""	O
agrobacterium	B-C3560206
fabrum	I-C3560206
""""	O
is	O
an	O
endofungal	B-C0004611
bacterium	I-C0004611
of	O
the	O
fungal	B-C0521033
mutualist	B-C0599514
piriformospora	B-C1025512
syn	O
.	O
	
serendipita	B-C1916017
indica	B-C1025512
basidiomycota	B-C0004810
,	O
which	O
together	O
form	O
a	O
tripartite	O
sebacinalean	B-C1665458
symbiosis	B-C0039029
with	O
a	O
broad	O
range	O
of	O
plants	B-C0032098
.	O
	
r	B-C0085472
.	O
	
radiobacter	I-C0085472
strain	B-C1518614
f4	I-C1518614
rrf4	B-C1518614
,	O
isolated	O
from	O
p	B-C1025512
.	O
	
indica	I-C1025512
dsm	I-C1025512
11827	I-C1025512
,	O
induces	B-C0205263
growth	B-C0018270
promotion	B-C0033414
and	O
systemic	B-C1155264
resistance	I-C1155264
in	O
cereal	B-C0007757
crops	B-C0242775
,	O
including	O
barley	B-C0004755
and	O
wheat	B-C0087114
,	O
suggesting	O
that	O
r	B-C0085472
.	O
	
radiobacter	I-C0085472
contributes	O
to	O
a	O
successful	O
symbiosis	B-C0039029
.	O
	
here	O
,	O
we	O
studied	O
the	O
impact	B-C4049986
of	O
endobacteria	B-C0004611
on	O
the	O
morphology	B-C0332437
and	O
the	O
beneficial	O
activity	O
of	O
p	B-C1025512
.	O
	
indica	I-C1025512
during	O
interactions	B-C1704675
with	O
plants	B-C0032098
.	O
	
low	O
numbers	O
of	O
endobacteria	B-C0004611
were	O
detected	B-C0442726
in	O
the	O
axenically	B-C0598869
grown	I-C0598869
p	B-C1025512
.	O
	
indica	I-C1025512
long	B-C0443252
term	I-C0443252
lab-cultured	B-C0430400
,	O
lcpiri	B-C1025512
whereas	O
mycelia	B-C0949695
colonizing	B-C4289767
the	O
plant	B-C0242726
root	I-C0242726
contained	O
increased	B-C0205217
numbers	O
of	O
bacteria	B-C0004611
.	O
	
higher	O
numbers	O
of	O
endobacteria	B-C0004611
were	O
also	O
found	O
in	O
axenic	B-C0598869
cultures	I-C0598869
of	O
p	B-C1025512
.	O
	
indica	I-C1025512
that	O
was	O
freshly	O
re-isolated	B-C0205409
ripiri	B-C1025512
from	O
plant	B-C0242726
roots	I-C0242726
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic	B-C0598869
re-cultivation	I-C0598869
.	O
	
prolonged	B-C0439590
treatments	B-C0087111
of	O
p	B-C1025512
.	O
	
indica	I-C1025512
cultures	B-C0200954
with	O
various	O
antibiotics	B-C0003232
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	B-C0004611
,	O
though	O
the	O
number	O
of	O
detectable	B-C3830527
endobacteria	B-C0004611
decreased	B-C0205216
significantly	B-C0750502
,	O
resulting	O
in	O
partial-cured	B-C0243095
p	B-C1025512
.	O
	
indica	I-C1025512
pcpiri	B-C1025512
.	O
	
pcpiri	B-C1025512
showed	O
reduced	B-C0392756
growth	B-C0018270
in	O
axenic	B-C0598869
cultures	I-C0598869
and	O
poor	B-C0542537
sporulation	B-C2613267
.	O
	
consistent	B-C0332290
with	I-C0332290
this	O
,	O
pcpiri	B-C1025512
also	O
showed	O
reduced	B-C0392756
plant	B-C0597252
growth	I-C0597252
promotion	B-C0033414
and	O
reduced	B-C0392756
systemic	B-C1155264
resistanc	I-C1155264
e	O
against	O
powdery	B-C0319635
mildew	I-C0319635
infection	B-C3714514
as	O
compared	O
with	O
ripiri	B-C1025512
and	O
lcpiri	B-C1025512
.	O
	
these	O
results	B-C1274040
are	O
consistent	B-C0332290
with	I-C0332290
the	O
assumption	O
that	O
the	O
endobacterium	B-C0004611
r	B-C0085472
.	O
	
radiobacter	I-C0085472
improves	B-C0184511
p	B-C1025512
.	O
	
indica's	I-C1025512
fitness	B-C4305181
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
sebacinalean	B-C1665458
symbiosis	B-C0039029
.	O
	
stem	B-C0038250
cell	I-C0038250
registry	B-C0920695
programme	B-C3484370
for	O
patients	B-C0030705
with	O
ischemic	B-C0349782
cardiomyopathy	I-C0349782
undergoing	O
coronary	B-C0010055
artery	I-C0010055
bypass	I-C0010055
grafting	I-C0010055
what	O
benefits	B-C0814225
does	O
it	O
derive	O
standardization	B-C0038136
of	O
stem	B-C0872278
cell	I-C0872278
therapy	I-C0872278
requires	O
application	O
of	O
appropriate	O
methods	B-C2911685
to	O
evaluate	B-C0220825
safety	B-C0511730
and	I-C0511730
efficac	I-C0511730
y	O
,	O
including	O
long-term	B-C0443252
pharmacovigilance	B-C3178990
.	O
	
to	O
accomplish	O
this	O
objective	B-C0018017
,	O
a	O
long-term	B-C0443252
registry	B-C0037585
programme	I-C0037585
was	O
installed	O
.	O
	
we	O
analysed	O
150	O
patients	B-C0030705
with	O
ischemic	B-C0349782
cardiomyopathy	I-C0349782
,	O
who	O
received	B-C1514756
intramyocardial	B-C0027061
cd133+	B-C1511246
bone	I-C1511246
marrow	I-C1511246
mononuclear	I-C1511246
stem	I-C1511246
cell	I-C1511246
treatment	B-C0087111
combined	B-C0205195
with	O
coronary	B-C0010055
artery	I-C0010055
bypass	I-C0010055
grafting	I-C0010055
cabg	B-C0010055
or	O
cabg	B-C0010055
alone	B-C0205171
.	O
	
the	O
mortality	B-C0026565
rate	I-C0026565
,	O
major	B-C0205164
adverse	B-C0243095
cerebral	I-C0243095
and	O
cardiac	B-C1556247
events	I-C1556247
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	B-C0220825
for	O
the	O
time	B-C1948053
period	I-C1948053
up	O
to	O
14	O
years	O
follow-up	B-C1522577
.	O
	
as	O
a	O
result	O
,	O
we	O
have	O
stratified	B-C0205363
the	O
patient	B-C0030705
population	B-C1257890
96	O
patients	B-C0030705
into	O
responders	B-C0919876
and	O
non-responders	B-C0919875
.	O
	
furthermore	O
,	O
the	O
analysis	B-C0936012
of	O
relevant	B-C2347946
predictors	B-C2698872
of	O
good	B-C0184785
response	I-C0184785
to	O
cd133+	B-C1511246
bone	I-C1511246
marrow	I-C1511246
mononuclear	I-C1511246
stem	I-C1511246
cell	I-C1511246
treatment	B-C0087111
was	O
performed	B-C0884358
.	O
	
several	B-C0443302
positive	O
tendencies	O
related	O
to	O
stem	B-C1504389
cells	I-C1504389
transplantation	I-C1504389
were	O
demonstrated	O
.	O
	
first	O
,	O
no	B-C0243095
significant	I-C0243095
difference	B-C1705242
in	O
major	B-C0205164
adverse	B-C0243095
cardiovascular	I-C0243095
and	O
cerebral	B-C0243095
events	I-C0243095
was	O
observed	B-C1441672
between	O
stem	B-C0038250
cell	I-C0038250
and	O
control	B-C0009932
group	I-C0009932
up	O
to	O
14	O
years	O
follow-up	B-C1522577
.	O
	
second	O
,	O
an	O
improvement	B-C2986411
of	O
left	B-C0428772
ventricle	I-C0428772
ejection	I-C0428772
fraction	I-C0428772
lvef	B-C0428772
in	O
stem	B-C0038250
cell	I-C0038250
group	B-C0441833
retained	B-C0333118
for	O
5	O
years	O
in	O
contrast	B-C1979874
with	O
cabg	B-C0010055
-	O
only	B-C0205171
group	B-C0441833
,	O
where	O
no	O
significant	O
changes	O
in	O
lvef	B-C0428772
after	O
2	O
years	O
were	O
observed	O
.	O
	
in	O
addition	O
,	O
lvef	B-C0428772
under	O
30%	O
and	O
left	B-C0919652
ventricle	I-C0919652
end	I-C0919652
diastolic	I-C0919652
diameter	I-C0919652
above	O
60	O
mm	O
were	O
independent	O
predictors	B-C2698872
of	O
functional	B-C0205245
response	O
to	O
cd133+	B-C0007634
cell	I-C0007634
therapy	B-C0302189
.	O
	
participants	B-C0679646
with	O
overt	B-C0018801
heart	I-C0018801
failure	I-C0018801
benefit	B-C0814225
most	B-C0205393
from	O
cabg	B-C0010055
combined	B-C0205195
with	O
intramyocardial	B-C0027061
injection	B-C1533685
of	O
cd133+	B-C1511246
bone	I-C1511246
marrow	I-C1511246
mononuclear	I-C1511246
cell	I-C1511246
within	O
the	O
group	B-C0441833
.	O
	
an	O
improvement	B-C2986411
lvef	B-C0428772
in	O
stem	B-C0038250
cell	I-C0038250
group	B-C0441833
remained	O
for	O
5	O
years	O
in	O
contrast	B-C1979874
with	O
the	O
cabg	B-C0010055
-	O
only	B-C0205171
group	B-C0441833
.	O
	
the	O
patients	B-C0030705
,	O
in	O
whom	O
the	O
improvement	B-C2986411
of	O
both	O
lvef	B-C0428772
and	O
lved	B-C0919652
was	O
observed	B-C1441672
,	O
have	O
benefited	O
by	O
increased	B-C0205217
life	B-C0023671
expectancy	I-C0023671
.	O
	
effects	B-C1280500
of	O
environmental	B-C0014406
factors	B-C1521761
and	O
metallic	B-C0025552
electrodes	B-C0013812
on	O
ac	B-C0442830
electrical	B-C0013777
conduction	I-C0013777
through	O
dna	B-C0012854
molecule	I-C0012854
deoxyribonucleic	B-C0012854
acid	I-C0012854
dna	I-C0012854
is	O
one	O
of	O
the	O
best	O
candidate	O
materials	O
for	O
various	O
device	B-C0699733
applications	B-C4048755
such	O
as	O
in	O
electrodes	B-C0013812
for	O
rechargeable	B-C0337088
batteries	I-C0337088
,	O
biosensors	B-C0600364
,	O
molecular	B-C0025080
electronics	I-C0025080
,	O
medical	B-C0025080
-	O
and	O
biomedical	B-C0025080
-	O
applications	B-C4048755
etc	O
.	O
	
hence	O
,	O
it	O
is	O
worthwhile	O
to	O
examine	O
the	O
mechanism	O
of	O
charge	B-C0563548
transport	I-C0563548
in	O
the	O
dna	B-C0012854
molecule	I-C0012854
,	O
however	O
,	O
still	O
a	O
question	O
without	O
a	O
clear	O
answer	O
is	O
dna	B-C0012854
a	O
molecular	B-C1521991
conducting	B-C0457405
material	B-C0520510
wire	B-C1705105
,	O
semiconductor	B-C0036623
,	O
or	O
insulator	B-C3273359
the	O
answer	O
,	O
after	O
the	O
published	O
data	O
,	O
is	O
still	O
ambiguous	O
without	O
any	O
confirmed	O
and	O
clear	O
scientific	O
answer	O
.	O
	
dna	B-C0012854
is	O
found	O
to	O
be	O
always	O
surrounded	O
with	O
different	O
electric	B-C0563548
charges	I-C0563548
,	O
ions	B-C0022023
,	O
and	O
dipoles	B-C0813981
.	O
	
these	O
surrounding	O
charges	B-C0563548
and	O
electric	B-C3273359
barrier	I-C3273359
due	O
to	O
metallic	B-C0025552
electrodes	B-C0013812
as	O
environmental	B-C0014406
factors	B-C1521761
efs	B-C1521761
play	O
a	O
substantial	O
role	O
when	O
measuring	B-C0444706
the	O
electrical	O
conductivity	O
through	O
λ-double	O
helix	O
dna	O
molecule	O
suspended	O
between	O
metallic	O
electrodes	O
.	O
	
we	O
found	O
that	O
strong	O
frequency	O
dependence	O
of	O
ac	O
-	O
complex	O
conductivity	O
comes	O
from	O
the	O
electrical	O
conduction	O
of	O
efs	O
.	O
	
this	O
leads	O
to	O
superimposing	O
serious	O
incorrect	O
experimental	O
data	O
to	O
measured	O
ones	O
.	O
	
at	O
1	O
mhz	O
,	O
we	O
carried	O
out	O
a	O
first	O
control	O
experiment	O
on	O
electrical	O
conductivity	O
with	O
and	O
without	O
the	O
presence	O
of	O
dna	O
molecule	O
.	O
	
if	O
there	O
are	O
possible	O
electrical	O
conduction	O
due	O
to	O
stray	O
ions	O
and	O
contribution	O
of	O
substrate	O
,	O
we	O
will	O
detected	O
them	O
.	O
	
this	O
control	O
experiment	O
revealed	O
that	O
there	O
is	O
an	O
important	O
role	O
played	O
by	O
the	O
environmental	O
-	O
charges	O
around	O
dna	O
molecule	O
and	O
any	O
experiment	O
should	O
consider	O
this	O
role	O
.	O
	
we	O
have	O
succeeded	O
to	O
measure	O
both	O
electrical	O
conductivity	O
due	O
to	O
efs	O
σ	O
env	O
and	O
electrical	O
conductivity	O
due	O
to	O
dna	O
molecule	O
σ	O
dna	O
independently	O
by	O
carrying	O
the	O
measurements	O
at	O
different	O
dna	O
-	O
lengths	O
and	O
subtracting	O
the	O
data	O
.	O
	
we	O
carried	O
out	O
measurements	O
as	O
a	O
function	O
of	O
frequency	O
f	O
and	O
temperature	O
t	O
in	O
the	O
ranges	O
0.1	O
hz	O
<	O
f	O
<	O
1	O
mhz	O
and	O
288	O
k	O
<	O
t	O
<	O
343	O
k	O
.	O
	
the	O
measured	O
conductivity	O
σ	O
mes	O
portrays	O
a	O
metal	O
-like	O
behavior	O
at	O
high	O
frequencies	O
near	O
1	O
mhz	O
.	O
	
however	O
,	O
we	O
found	O
that	O
σ	O
dna	O
was	O
far	O
from	O
this	O
behavior	O
because	O
the	O
conduction	O
due	O
to	O
efs	O
superimposes	O
σ	O
dna	O
,	O
in	O
particular	O
at	O
low	O
frequencies	O
.	O
	
by	O
measuring	B-C0444706
the	O
electrical	B-C0013777
conductivity	I-C0013777
at	O
different	O
lengths	O
40	O
,	O
60	O
,	O
80	O
,	O
and	O
100	O
nm	O
,	O
we	O
have	O
succeeded	O
not	O
only	O
to	O
separate	O
the	O
electrical	O
conduction	O
of	O
the	O
dna	O
molecule	O
from	O
all	O
efs	O
effects	O
that	O
surround	O
the	O
molecule	O
,	O
but	O
also	O
to	O
present	O
accurate	O
values	O
of	O
σ	O
dna	O
and	O
the	O
dielectric	O
constant	O
of	O
the	O
molecule	O
ε'dna	O
as	O
a	O
function	O
of	O
temperature	O
and	O
frequency	O
.	O
	
furthermore	O
,	O
in	O
order	O
to	O
explain	O
these	O
data	O
,	O
we	O
present	O
a	O
model	O
describing	O
the	O
electrical	O
conduction	O
through	O
dna	O
molecule	O
dna	O
is	O
a	O
classical	O
semiconductor	O
with	O
charges	O
,	O
dipoles	O
and	O
ions	O
that	O
result	O
in	O
creation	O
of	O
localized	O
energy	O
-	O
states	O
less	O
in	O
the	O
extended	O
bands	O
and	O
in	O
the	O
energy	O
gap	O
of	O
the	O
dna	O
molecule	O
.	O
	
this	O
model	O
explains	O
clearly	O
the	O
mechanism	O
of	O
charge	O
transfer	O
mechanism	O
in	O
the	O
dna	O
,	O
and	O
it	O
sheds	O
light	O
on	O
why	O
the	O
charge	O
transfer	O
through	O
the	O
dna	O
can	O
lead	O
to	O
insulating	O
,	O
semiconducting	O
,	O
or	O
metallic	O
behavior	O
on	O
the	O
same	O
time	O
.	O
	
the	O
model	O
considers	O
charges	O
on	O
dna	O
,	O
in	O
the	O
extended	O
bands	O
,	O
either	O
could	O
be	O
free	O
to	O
move	O
under	O
electric	O
field	O
or	O
localized	O
in	O
potential	O
wells/hills	O
.	O
	
localization	O
of	O
charges	O
in	O
dna	O
is	O
an	O
intrinsic	O
structural	O
-	O
property	O
of	O
this	O
solitaire	O
molecule	O
.	O
	
at	O
all	O
temperatures	O
,	O
the	O
expected	O
increase	O
in	O
thermal	O
-	O
induced	O
charge	O
is	O
attributed	O
to	O
the	O
delocalization	O
of	O
holes	O
or/and	O
electrons	O
in	O
potential	O
hills	O
or/and	O
potential	O
wells	O
which	O
accurately	O
accounts	O
for	O
the	O
total	O
electric	O
and	O
dielectric	O
behavior	O
through	O
dna	O
molecule	O
.	O
	
we	O
succeeded	O
to	O
fit	O
the	O
experiment	O
al	O
data	O
to	O
the	O
proposed	O
model	O
with	O
reasonable	O
magnitudes	O
of	O
potential	O
hills/wells	O
that	O
are	O
in	O
the	O
energy	O
range	O
from	O
0.068	O
next-generation	B-C2936622
sequencing	I-C2936622
approaches	B-C1292724
to	O
define	O
the	O
role	B-C1705810
of	O
the	O
autophagy	B-C0007613
lysosomal	I-C0007613
pathway	I-C0007613
in	O
human	B-C0086418
disease	B-C0012634
the	O
example	B-C1707959
of	O
lysoplex	B-C0442711
next-generation	B-C2936622
sequencing	I-C2936622
ngs	I-C2936622
technologies	I-C2936622
have	O
deeply	O
changed	O
the	O
throughput	B-C2986816
of	O
genetic	B-C0679560
testing	I-C0679560
allowing	O
analyzing	O
millions	O
of	O
dna	B-C0684192
fragments	I-C0684192
in	O
parallel	B-C0205556
.	O
	
one	O
key	O
application	B-C0205245
is	O
the	O
understanding	O
of	O
genetically	B-C0314603
heterogeneous	B-C1858576
and	O
complex	B-C0012634
diseases	I-C0012634
where	O
50-100	O
different	O
genes	B-C0017337
may	O
converge	O
to	O
control	B-C0243148
the	O
same	O
pathways	B-C1704259
.	O
	
these	O
disorders	B-C0012634
cannot	O
be	O
studied	O
using	O
traditional	B-C0443324
approaches	B-C1292724
,	O
based	O
on	O
gene-by-gene	B-C1511897
sanger	I-C1511897
sequencing	I-C1511897
.	O
	
we	O
have	O
set	O
up	O
an	O
ngs	B-C2936622
protocol	B-C0442711
based	O
on	O
a	O
specific	O
selection	B-C1707391
of	O
dna	B-C0012854
regions	I-C0012854
belonging	O
to	O
about	O
900	O
genes	B-C0017337
of	O
the	O
autophagy-lysosomal	B-C0007613
alp	I-C0007613
pathway	I-C0007613
.	O
	
we	O
here	O
specify	O
all	O
the	O
technical	B-C1261552
steps	I-C1261552
and	O
challenges	B-C0805586
of	O
our	O
protocol	B-C0442711
,	O
named	O
lysoplex	B-C0442711
.	O
	
this	O
is	O
based	O
on	O
the	O
haloplex	O
technology	O
and	O
together	O
with	O
high-coverage	B-C0687728
sequencing	I-C0687728
empowers	O
a	O
high	O
and	O
uniform	O
coverage	O
of	O
alp	B-C0017337
genes	I-C0017337
.	O
	
lysoplex	B-C0442711
outplays	O
other	O
ngs	B-C2936622
applications	B-C0205245
in	O
sensitivity	B-C0036668
and	I-C0036668
specificity	I-C0036668
,	O
providing	O
an	O
accurate	O
picture	O
of	O
all	O
variations	B-C0042333
in	O
alp	B-C0017337
genes	I-C0017337
.	O
	
typical	O
skin	B-C0281980
injuries	I-C0281980
in	O
children	B-C0008059
with	O
autism	B-C1510586
spectrum	I-C1510586
disorder	I-C1510586
pediatric	B-C1521725
skin	B-C0281980
injuries	I-C0281980
have	O
primarily	O
been	O
described	O
in	O
typically	O
developing	B-C0008059
children	I-C0008059
.	O
	
our	O
objectives	B-C0018017
were	O
to	O
describe	O
the	O
prevalence	B-C0683921
and	O
pattern	B-C0449774
of	O
skin	B-C0281980
injuries	I-C0281980
of	O
children	B-C0008059
with	O
autism	B-C1510586
spectrum	I-C1510586
disorder	I-C1510586
asd	B-C1510586
,	O
to	O
describe	O
how	O
this	O
compared	O
with	O
previously	O
demonstrated	O
skin	B-C0281980
injury	I-C0281980
locations	B-C0552513
in	O
typically	O
developing	B-C0008059
children	I-C0008059
,	O
and	O
to	O
identify	O
differences	B-C1705242
in	O
skin	B-C0281980
injury	I-C0281980
frequency	B-C0439603
and	O
locations	B-C0552513
between	O
autistic	B-C0175842
children	I-C0175842
with	O
and	O
without	O
self-injurious	B-C0085271
behaviors	I-C0085271
sibs	B-C0085271
.	O
	
children	B-C0008059
with	O
asd	B-C1510586
were	O
recruited	O
between	O
september	B-C3828193
of	O
2011	O
and	O
september	B-C3828193
of	O
2014	O
.	O
	
demographic	B-C0011292
information	I-C0011292
was	O
obtained	O
from	O
the	O
caregiver	B-C0085537
.	O
	
all	O
skin	B-C0281980
injuries	I-C0281980
and	O
their	O
locations	B-C0552513
were	O
documented	B-C1301725
.	O
	
of	O
the	O
41	O
children	B-C0008059
enrolled	O
,	O
half	O
were	O
reported	O
to	O
have	O
sibs	B-C0085271
.	O
	
the	O
most	O
identified	O
skin	B-C0281980
injury	I-C0281980
locations	B-C0552513
were	O
the	O
legs	B-C1140621
,	O
knees	B-C0022742
,	O
and	O
back	B-C0004600
.	O
	
children	B-C0008059
with	O
autism	B-C0004352
1	O
obtain	O
skin	B-C0281980
injuries	I-C0281980
frequently	O
and	O
in	O
similar	O
locations	B-C0552513
as	O
typically	O
developing	B-C0008059
children	I-C0008059
and	O
2	O
rarely	O
obtain	O
skin	B-C0281980
injuries	I-C0281980
to	O
locations	B-C0552513
that	O
are	O
considered	O
uncommon	O
for	O
accidental	B-C0151736
injuries	I-C0151736
despite	O
reports	O
of	O
is	O
total	B-C0186781
elbow	I-C0186781
arthroplasty	I-C0186781
safe	B-C0036043
as	O
an	O
outpatient	B-C1299353
procedure	I-C1299353
ambulatory	B-C1321139
surgery	I-C1321139
centers	I-C1321139
are	O
the	O
preferred	B-C0815184
setting	I-C0815184
for	O
many	O
procedures	B-C2700391
formerly	O
performed	B-C0884358
in	O
a	O
hospital	B-C0019994
setting	B-C0815184
.	O
	
this	O
study	B-C2603343
sought	O
to	O
determine	O
whether	O
outpatient	B-C0029921
total	B-C0186781
elbow	I-C0186781
arthroplasty	I-C0186781
tea	B-C0186781
is	O
as	O
safe	B-C0036043
as	O
inpatient	B-C0021562
tea	B-C0186781
.	O
	
a	O
retrospective	B-C0035363
analysis	I-C0035363
was	O
performed	B-C0884358
of	O
inpatient	B-C0021562
ip	B-C0021562
versus	O
outpatient	B-C0029921
op	B-C0029921
tea	B-C0186781
by	O
a	O
single	B-C0205171
surgeon	B-C0582175
over	O
a	O
period	O
of	O
18	O
years	B-C0439234
.	O
	
demographic	B-C0011289
,	O
social	B-C0699806
,	O
and	O
comorbidity	B-C1516737
measures	I-C1516737
as	O
well	O
as	O
complication	B-C0009566
rates	B-C1521828
were	O
analyzed	B-C0936012
and	O
stratified	B-C0205363
by	O
ip	B-C0021562
or	O
op	B-C0029921
status	B-C0449438
.	O
	
bivariate	B-C0681927
comparison	I-C0681927
showed	O
increased	B-C0205217
prevalence	B-C0033105
of	O
coronary	B-C1956346
artery	I-C1956346
disease	I-C1956346
in	O
the	O
op	B-C0029921
group	B-C1257890
32%	O
vs	O
.	O
	
7%	O
and	O
increased	B-C0205217
age	B-C0001779
in	O
the	O
ip	B-C0021562
group	B-C1257890
68	O
years	B-C0439234
vs	O
.	O
	
58	O
years	B-C0439234
.	O
	
all	O
other	O
demographic	B-C0011289
,	O
social	B-C0699806
,	O
and	O
comorbidity	B-C1516737
factors	I-C1516737
were	O
comparable	B-C1707455
between	O
the	O
ip	B-C0021562
and	O
op	B-C0029921
groups	B-C1257890
,	O
although	O
more	B-C0205172
infections	B-C3714514
were	O
seen	B-C0205397
in	O
the	O
ip	B-C0021562
group	B-C1257890
.	O
	
the	O
surgeons'	B-C0582175
initial	B-C2936637
learning	I-C2936637
curve	I-C2936637
occurred	B-C1709305
mostly	O
within	O
the	O
ip	B-C0021562
group	B-C1257890
.	O
	
most	O
important	O
,	O
no	B-C3842396
difference	I-C3842396
in	O
complication	B-C0009566
rate	B-C1521828
was	O
observed	B-C1441672
between	O
the	O
ip	B-C0021562
and	O
op	B-C0029921
groups	B-C1257890
.	O
	
developmental	B-C0458003
hypoxia	B-C0242184
has	O
negligible	B-C0332269
effects	B-C1280500
on	O
long-term	B-C0443252
hypoxia	B-C0242184
tolerance	B-C1704410
and	O
aerobic	B-C0282636
metabolism	I-C0282636
of	O
atlantic	B-C0327949
salmon	I-C0327949
salmo	B-C0327949
salar	I-C0327949
exposure	B-C0332157
to	I-C0332157
developmental	B-C0458003
hypoxia	B-C0242184
can	O
have	O
long-term	B-C0443252
impacts	B-C4049986
on	O
the	O
physiological	B-C0031845
performance	B-C1882330
of	O
fish	B-C0016163
because	O
of	O
irreversible	B-C0205245
plasticity	B-C0678558
.	O
	
wild	B-C0445392
and	O
captive-reared	B-C0243095
atlantic	B-C0327949
salmon	I-C0327949
salmo	B-C0327949
salar	I-C0327949
can	O
be	O
exposed	B-C0332157
to	I-C0332157
hypoxic	B-C0242184
conditions	B-C0348080
during	O
development	B-C1527148
and	O
continue	B-C0549178
to	O
experience	O
fluctuating	B-C0231241
oxygen	B-C0030054
levels	B-C0441889
as	O
juveniles	B-C3146221
and	O
adults	B-C0001675
.	O
	
here	O
,	O
we	O
examine	B-C0332128
whether	O
developmental	B-C0458003
hypoxia	B-C0242184
impacts	B-C4049986
subsequent	B-C0332282
hypoxia	B-C0242184
tolerance	B-C1704410
and	O
aerobic	B-C1510824
performance	B-C1882330
of	O
atlantic	B-C0327949
salmon	I-C0327949
.	O
	
individuals	B-C0016163
at	O
8	O
were	O
exposed	B-C0332157
to	I-C0332157
50%	O
hypoxia	B-C0242184
or	O
100%	O
normoxia	B-C0311411
dissolved	B-C0369768
oxygen	I-C0369768
do	I-C0369768
saturation	I-C0369768
as	O
percent	O
of	O
air	B-C0522534
saturation	I-C0522534
from	O
fertilization	B-C3826354
for	O
100	O
d	O
800	O
degree	O
days	O
and	O
then	O
raised	B-C0442818
in	O
normoxic	B-C0311411
conditions	B-C0348080
for	O
a	O
further	O
15	O
mo	O
.	O
	
at	O
18	O
mo	O
after	O
fertilization	B-C3826354
,	O
aerobic	B-C1510824
scope	B-C1710028
was	O
calculated	B-C1441506
in	O
normoxia	B-C0311411
100%	O
do	B-C0030054
and	O
acute	B-C0205178
18	O
h	O
hypoxia	B-C0242184
50%	O
do	B-C0030054
from	O
the	O
difference	B-C1705242
between	O
the	O
minimum	B-C1524031
and	O
maximum	B-C0806909
oxygen	B-C0030055
consumption	I-C0030055
rates	B-C1521828
formula	O
see	O
text	O
and	O
formula	O
see	O
text	O
,	O
respectively	O
at	O
10	O
.	O
	
hypoxia	B-C0242184
tolerance	B-C1704410
was	O
determined	B-C0521095
as	O
the	O
do	B-C0030054
at	O
which	O
loss	B-C0278126
of	I-C0278126
equilibrium	I-C0278126
loe	B-C0278126
occurred	B-C1709305
in	O
a	O
constantly	O
decreasing	B-C0442797
do	B-C0030054
environment	O
.	O
	
there	O
was	O
no	B-C3842396
difference	I-C3842396
in	O
formula	O
see	O
text	O
,	O
formula	O
see	O
text	O
,	O
or	O
aerobic	B-C1510824
scope	B-C1710028
between	O
fish	B-C0016163
raised	B-C0442818
in	O
hypoxia	B-C0242184
or	O
normoxia	B-C0311411
.	O
	
there	O
was	O
some	O
evidence	B-C3887511
that	O
hypoxia	B-C0242184
tolerance	B-C1704410
was	O
lower	B-C2003888
higher	O
do	B-C0030054
at	O
loe	B-C0278126
in	O
hypoxia	B-C0242184
-	O
raised	B-C0442818
fish	B-C0016163
compared	O
with	O
those	O
raised	B-C0442818
in	O
normoxia	B-C0311411
,	O
but	O
the	O
magnitude	B-C1704240
of	O
the	O
effect	B-C1280500
was	O
small	B-C0700321
12.52	O
do	B-C0030054
vs	O
.	O
	
11.73	O
do	B-C0030054
at	O
loe	B-C0278126
.	O
	
acute	B-C0205178
hypoxia	B-C0242184
significantly	O
reduced	B-C0392756
aerobic	B-C1510824
scope	B-C1710028
by	O
reducing	B-C0392756
formula	O
see	O
text	O
,	O
while	O
formula	O
see	O
text	O
remained	O
unchanged	B-C0442739
.	O
	
interestingly	O
,	O
acute	B-C0205178
hypoxia	B-C0242184
uncovered	O
individual	B-C0016163
-level	O
relationships	B-C0439849
between	O
do	B-C0030054
at	O
loe	B-C0278126
and	O
formula	O
see	O
text	O
,	O
formula	O
see	O
text	O
,	O
and	O
aerobic	B-C1510824
scope	B-C1710028
.	O
	
we	O
discuss	O
our	O
findings	B-C2607943
in	O
the	O
context	O
of	O
developmental	B-C0458003
trajectories	O
and	O
the	O
role	O
of	O
aerobic	B-C1510824
performance	B-C1882330
in	O
hypoxia	B-C0242184
tolerance	B-C1704410
.	O
	
ldl	B-C0023823
particle	B-C0392762
number	I-C0392762
and	O
size	B-C0030608
and	O
cardiovascular	B-C3887460
risk	B-C0035647
anything	O
new	O
under	O
the	O
sun	O
we	O
provide	O
here	O
an	O
up-to-date	O
perspective	O
on	O
the	O
potential	B-C3245505
use	B-C0457083
of	O
ldl	B-C0023823
particle	B-C0392762
number	I-C0392762
and	O
size	B-C0030608
as	O
complementary	O
risk	B-C0035648
factors	I-C0035648
to	O
predict	O
and	O
manage	O
cardiovascular	B-C0007222
disease	I-C0007222
cvd	B-C0007222
risk	B-C0035647
in	O
the	O
clinical	B-C0205210
realm	O
.	O
	
studies	B-C0008972
show	O
that	O
a	O
significant	B-C0750502
proportion	B-C1709707
of	O
the	O
population	B-C1257890
has	O
discordant	B-C3639994
ldl	B-C0023823
particle	B-C0392762
number	I-C0392762
and	O
cholesterol	B-C0008377
indices	B-C0918012
non-hdl	B-C0729627
cholesterol	I-C0729627
hdl-c	B-C0023822
.	O
	
data	O
also	O
show	O
that	O
risk	O
prediction	O
may	O
be	O
improved	O
when	O
using	O
information	B-C1533716
on	O
ldl	B-C0023823
particle	B-C0392762
number	I-C0392762
in	O
patients	B-C0030705
with	O
discordant	B-C3639994
particle	B-C0392762
number	I-C0392762
and	O
cholesterol	B-C0008377
data	O
.	O
	
yet	O
,	O
most	O
of	O
the	O
current	O
cvd	B-C0007222
guidelines	B-C0282451
conclude	O
that	O
ldl	B-C0023823
particle	B-C0392762
number	I-C0392762
is	O
not	O
superior	O
to	O
cholesterol	B-C0008377
indices	B-C0918012
,	O
including	O
non-hdl-c	B-C0729627
concentrations	B-C1446561
,	O
in	O
predicting	O
cvd	B-C0007222
risk	B-C0035647
.	O
	
ldl	B-C0023823
particle	B-C0030608
size	I-C0030608
,	O
on	O
the	O
other	O
hand	O
,	O
has	O
not	O
been	O
independently	O
associated	B-C0332281
with	I-C0332281
cvd	B-C0007222
risk	B-C0035647
after	O
adjustment	B-C0456081
for	O
other	O
risk	B-C0035648
factors	I-C0035648
such	O
as	O
ldl	B-C0023824
cholesterol	I-C0023824
,	O
triglycerides	B-C0041004
,	O
and	O
hdl-c	B-C0023822
and	O
that	O
routine	O
use	O
of	O
information	B-C1533716
pertaining	O
to	O
particle	B-C0030608
size	I-C0030608
to	O
determine	O
and	O
manage	O
patients'	B-C0030705
risk	B-C0035647
is	O
not	O
yet	O
justified	O
.	O
	
additional	B-C1524062
studies	B-C0008972
are	O
required	O
to	O
settle	O
the	O
debate	B-C0870392
on	O
which	O
of	O
cholesterol	B-C0008377
indices	B-C0918012
and	O
ldl	B-C0023823
particle	B-C0392762
number	I-C0392762
is	O
the	O
best	O
predictor	O
of	O
cvd	B-C0007222
risk	B-C0035647
,	O
and	O
if	O
such	O
measures	B-C0079809
should	O
be	O
integrated	O
in	O
clinical	B-C0087111
practice	I-C0087111
.	O
	
the	O
emerging	B-C1880177
contribution	I-C1880177
of	O
social	B-C0043041
wasps	I-C0043041
to	O
grape	B-C0032080
rot	I-C0032080
disease	I-C0032080
ecology	B-C0013546
grape	B-C0032080
sour	I-C0032080
bunch	I-C0032080
rot	I-C0032080
is	O
a	O
polymicrobial	B-C0598196
disease	I-C0598196
of	O
vineyards	B-C4279988
that	O
causes	O
millions	B-C1881839
of	O
dollars	B-C0562019
in	O
lost	B-C0681042
revenue	I-C0681042
per	B-C0439508
year	I-C0439508
due	O
to	O
decreased	B-C0205216
quality	B-C0332306
of	O
grapes	B-C0018208
and	O
resultant	B-C0043188
wine	I-C0043188
.	O
	
the	O
disease	B-C0012634
is	O
associated	B-C0332281
with	I-C0332281
damaged	B-C1883709
berries	B-C0005135
infected	B-C0439663
with	O
a	O
community	B-C0009462
of	O
acetic	B-C0018150
acid	I-C0018150
bacteria	I-C0018150
,	O
yeasts	B-C0043393
,	O
and	O
filamentous	B-C0369241
fungi	I-C0369241
that	O
results	O
in	O
rotting	B-C2700592
berries	B-C0005135
with	O
high	B-C0205250
amounts	B-C1265611
of	O
undesirable	O
volatile	B-C1963547
acidity	B-C0001128
.	O
	
many	O
insect	B-C0021585
species	B-C1705920
cause	O
the	O
initial	B-C0205265
grape	B-C0018208
berry	B-C0005135
damage	B-C1883709
that	O
can	O
lead	O
to	O
this	O
disease	B-C0012634
,	O
but	O
most	O
studies	B-C0681814
have	O
focused	B-C1285542
on	O
the	O
role	B-C1705810
of	O
fruit	B-C0013138
flies	I-C0013138
in	O
facilitating	O
symptoms	B-C1457887
and	O
vectoring	B-C0021573
the	O
microorganisms	B-C0445623
of	O
this	O
disease	B-C0012634
complex	B-C0439855
.	O
	
like	O
fruit	B-C0013138
flies	I-C0013138
,	O
social	B-C0043041
wasps	I-C0043041
are	O
abundant	B-C2346714
in	O
vineyards	B-C4279988
where	O
they	O
feed	O
on	O
ripe	B-C0005135
berries	I-C0005135
and	O
cause	O
significant	B-C0750502
damage	B-C1883709
,	O
while	O
also	O
dispersing	B-C0332624
yeasts	B-C0043393
involved	B-C1314939
in	O
wine	B-C0043188
fermentation	B-C0015852
.	O
	
despite	O
this	O
,	O
their	O
possible	O
role	B-C1705810
in	O
disease	B-C0012634
facilitation	O
and	O
dispersal	B-C0012634
of	I-C0012634
grape	I-C0012634
rots	I-C0012634
has	O
not	O
been	O
explored	O
.	O
	
we	O
tested	B-C0039593
the	O
hypothesis	B-C1512571
that	O
the	O
paper	B-C0446349
wasp	I-C0446349
polistes	B-C1005260
dominulus	I-C1005260
could	O
facilitate	O
grape	B-C0012634
sour	I-C0012634
rot	I-C0012634
in	O
the	O
absence	B-C0332197
of	O
other	O
insect	B-C0021573
vectors	I-C0021573
.	O
	
using	O
marker	B-C1294197
gene	I-C1294197
sequencing	I-C1294197
we	O
characterized	B-C1880022
the	O
bacterial	B-C0004611
and	O
fungal	B-C0016832
community	B-C0009462
of	O
wild-caught	B-C0001675
adults	I-C0001675
.	O
	
we	O
used	O
a	O
sterilized	O
foraging	B-C0205146
arena	I-C0205146
to	O
determine	O
if	O
these	O
wasps	B-C0043041
transfer	O
viable	B-C0443348
microorganisms	B-C0445623
when	O
foraging	B-C2752984
.	O
	
we	O
then	O
tested	B-C0039593
if	O
wasps	B-C0043041
harboring	O
their	O
native	B-C0079891
microbial	B-C0599840
community	B-C0009462
,	O
or	O
those	O
inoculated	B-C2987620
with	O
sour	B-C0012634
rot	I-C0012634
,	O
had	O
an	O
effect	B-C1280500
on	O
grape	B-C0012634
sour	I-C0012634
rot	I-C0012634
incidence	B-C0021149
and	O
severity	B-C0439793
using	O
a	O
laboratory	B-C0017446
foraging	I-C0017446
arena	I-C0017446
.	O
	
we	O
found	O
that	O
all	O
wasps	B-C0043041
harbor	O
some	O
portion	O
of	O
the	O
sour	B-C0012634
rot	I-C0012634
microbial	B-C0599840
community	B-C0009462
and	O
that	O
they	O
have	O
the	O
ability	B-C0085732
to	O
transfer	O
viable	B-C0443348
microorganisms	B-C0445623
when	O
foraging	B-C2752984
.	O
	
foraging	B-C2752984
by	O
inoculated	B-C2987620
and	O
uninoculated	B-C0043041
wasps	I-C0043041
led	O
to	O
an	O
increase	B-C0442805
in	O
berry	B-C0032080
rot	I-C0032080
disease	I-C0032080
symptom	B-C1457887
severity	B-C0439793
and	O
incidence	B-C0021149
.	O
	
our	O
results	B-C0459422
indicate	O
that	O
paper	B-C0446349
wasps	I-C0446349
can	O
facilitate	O
sour	B-C0032080
rot	I-C0032080
diseases	I-C0032080
in	O
the	O
absence	B-C0332197
of	O
other	B-C0021573
vectors	I-C0021573
and	O
that	O
the	O
mechanism	B-C0441712
of	O
this	O
facilitation	O
may	O
include	O
both	O
increasing	B-C0442808
host	B-C1167395
susceptibility	B-C0012655
and	O
transmitting	B-C0332289
these	O
microbial	B-C0599840
communities	B-C0009462
to	O
the	O
grapes	B-C0018208
.	O
	
social	B-C0043041
wasps	I-C0043041
are	O
understudied	O
but	O
relevant	B-C2347946
players	I-C2347946
in	O
the	O
sour	B-C0012634
rot	I-C0012634
ecology	B-C0013546
of	O
low-intensity	B-C4042796
pulsed	I-C4042796
ultrasound	I-C4042796
reduces	O
periodontal	B-C2350270
atrophy	I-C2350270
in	O
occlusal	B-C0011382
hypofunctional	B-C0679221
teeth	B-C0040426
to	O
clarify	O
whether	O
low-intensity	B-C4042796
pulsed	I-C4042796
ultrasound	I-C4042796
lipus	B-C4042796
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	B-C0679221
periodontal	B-C0031093
ligament	I-C0031093
pdl	B-C0031093
and	O
interradicular	B-C0932533
alveolar	I-C0932533
bone	I-C0932533
irab	B-C0932533
.	O
	
twelve-	O
week	B-C0439230
-old	O
male	B-C0086582
sprague-dawley	B-C0034715
rats	I-C0034715
were	O
divided	O
into	O
three	O
groups	B-C1257890
n	O
=	O
5	O
each	O
a	O
normal	B-C0011382
occlusion	I-C0011382
c	O
group	B-C1257890
,	O
an	O
occlusal	B-C0011382
hypofunction	B-C0679221
h	O
group	B-C1257890
,	O
and	O
an	O
occlusal	B-C1257890
hypofunction	I-C1257890
group	I-C1257890
subjected	O
to	O
lipus	B-C4042796
hl	O
treatment	B-C0087111
.	O
	
hypofunctional	B-C0679221
occlusion	B-C0011382
of	O
the	O
maxillary	B-C4082817
first	I-C4082817
molar	I-C4082817
m1	B-C4082817
of	O
the	O
h	B-C1257890
and	O
hl	B-C1257890
groups	I-C1257890
was	O
induced	O
by	O
the	O
bite-raising	B-C0376583
technique	I-C0376583
.	O
	
only	O
the	O
hl	B-C1257890
group	I-C1257890
was	O
irradiated	O
with	O
lipus	B-C4042796
for	O
5	O
days	B-C0439228
.	O
	
the	O
irab	B-C0932533
and	O
pdl	B-C0031093
of	O
m1	B-C4082817
were	O
examined	O
by	O
microcomputed	B-C2350281
tomography	I-C2350281
micro-ct	B-C2350281
analysis	B-C0936012
.	O
	
to	O
quantify	O
mrna	B-C0035696
expression	B-C1171362
of	O
cytokines	B-C0079189
involved	O
in	O
pdl	B-C0031093
proliferation	B-C1514485
and	O
development	B-C1527148
,	O
real-time	B-C0599161
reverse	I-C0599161
transcription	I-C0599161
quantitative	I-C0599161
pcr	I-C0599161
qrt-pcr	B-C0599161
was	O
performed	O
for	O
twist	B-C1421244
family	I-C1421244
bhlh	I-C1421244
transcription	I-C1421244
factor	I-C1421244
1	I-C1421244
twist1	B-C1421244
,	O
periostin	B-C1424662
,	O
and	O
connective	B-C1413791
tissue	I-C1413791
growth	I-C1413791
factor	I-C1413791
ctgf	B-C1413791
in	O
the	O
pdl	B-C0031093
samples	B-C0370003
.	O
	
micro-ct	B-C2350281
analysis	B-C0936012
showed	O
that	O
the	O
pdl	B-C0031093
volume	B-C0449468
was	O
decreased	O
in	O
the	O
h	B-C1257890
group	I-C1257890
compared	O
with	O
that	O
of	O
the	O
c	B-C1257890
and	O
hl	B-C1257890
groups	I-C1257890
.	O
	
both	O
bone	B-C1317149
volume	I-C1317149
per	O
tissue	B-C0449468
volume	I-C0449468
bv	B-C1317149
/	O
tv	B-C0449468
of	O
irab	B-C0932533
was	O
decreased	O
in	O
the	O
h	B-C1257890
group	I-C1257890
compared	O
with	O
that	O
in	O
the	O
c	B-C1257890
group	I-C1257890
.	O
	
lipus	B-C4042796
exposure	O
restored	O
bv	B-C1317149
/	O
tv	B-C0449468
in	O
the	O
irab	B-C0932533
of	O
the	O
hl	B-C1257890
group	I-C1257890
.	O
	
qrt-pcr	B-C0599161
analysis	B-C0936012
showed	O
that	O
twist1	B-C1421244
,	O
periostin	B-C1424662
,	O
and	O
ctgf	B-C1413791
mrna	B-C0035696
levels	B-C0441889
were	O
decreased	O
in	O
the	O
h	B-C1257890
group	I-C1257890
and	O
increased	O
in	O
the	O
hl	B-C1257890
group	I-C1257890
.	O
	
lipus	B-C4042796
exposure	O
reduced	O
the	O
atrophic	B-C0333641
changes	B-C0392747
of	O
alveolar	B-C0932533
bone	I-C0932533
by	O
inducing	B-C0205263
the	O
upregulation	B-C0041904
of	O
periostin	B-C1424662
and	O
ctgf	B-C1413791
expression	B-C1171362
to	O
promote	O
pdl	B-C0031093
healing	B-C0043240
after	O
induction	B-C0857127
of	O
occlusal	B-C0011382
hypofunction	B-C0679221
.	O
	
radiologic	B-C0043299
assessment	I-C0043299
of	O
quality	O
of	O
root	B-C0035848
canal	I-C0035848
fillings	I-C0035848
and	O
periapical	B-C0729269
status	I-C0729269
in	O
an	O
austrian	B-C0337795
subpopulation	B-C1257890
-	O
an	O
observational	B-C1518527
study	I-C1518527
progress	B-C1280477
in	O
endodontic	B-C0700632
techniques	I-C0700632
and	O
methodological	O
advances	O
have	O
altered	O
root	B-C0035849
canal	I-C0035849
therapy	I-C0035849
over	O
the	O
last	O
decades	O
.	O
	
these	O
techniques	O
and	O
methods	O
need	O
periodical	B-C0031082
documentation	B-C0920316
.	O
	
this	O
observational	B-C1518527
study	I-C1518527
determined	O
the	O
current	O
prevalence	B-C0220900
of	O
endodontic	B-C0700632
treatments	I-C0700632
,	O
and	O
investigated	B-C1292732
the	O
relationship	O
of	O
various	O
factors	O
with	O
the	O
periapical	B-C0729269
status	I-C0729269
in	O
a	O
lower	O
austrian	B-C0337795
subpopulation	B-C1257890
.	O
	
one	O
thousand	O
orthopantomograms	B-C0034579
of	O
first-time	O
university	B-C0020028
adult	O
patients	B-C0030705
radiographed	B-C1306645
at	O
an	O
outpatient	B-C0029916
clinic	I-C0029916
were	O
evaluated	B-C0220825
.	O
	
for	O
each	O
tooth	B-C0040426
,	O
the	O
presence	B-C0150312
of	O
periradicular	B-C0031028
pathosis	I-C0031028
and/or	O
endodontic	B-C0700632
treatment	I-C0700632
was	O
recorded	O
,	O
as	O
was	O
the	O
quality	O
of	O
post-	O
endodontic	B-C0700632
treatment	I-C0700632
homogeneity	B-C1881065
and	O
length	O
of	O
root	B-C0035848
canal	I-C0035848
fillings	I-C0035848
preparation	B-C2938896
failures	I-C2938896
posts	B-C0183062
/	O
screws	B-C0301559
apicoectomies	B-C0003571
coronal	B-C0204297
restorations	I-C0204297
.	O
	
two	O
evaluators	B-C1707957
,	O
blinded	B-C0150108
to	O
each	O
other	O
,	O
scored	B-C0449820
all	O
teeth	B-C0040426
.	O
	
in	O
cases	O
of	O
disagreement	O
,	O
they	O
joined	O
for	O
a	O
consensus	O
score	B-C0449820
.	O
	
in	O
all	O
,	O
22	O
teeth	B-C0449772
were	I-C0449772
counted	I-C0449772
.	O
	
of	O
these	O
,	O
2	O
teeth	B-C0040426
12.9	O
had	O
periapical	B-C0031028
pathosis	I-C0031028
,	O
while	O
2	O
teeth	B-C0040426
had	O
undergone	O
root	B-C0035849
canal	I-C0035849
treatment	I-C0035849
.	O
	
of	O
the	O
endodontically	B-C0376699
treated	I-C0376699
teeth	I-C0376699
,	O
52%	O
showed	O
no	O
radiographic	B-C0444708
signs	O
of	O
apical	B-C4082298
periodontitis	I-C4082298
,	O
while	O
44.9	O
had	O
overt	O
apical	B-C1402310
lesions	I-C1402310
,	O
and	O
3	O
revealed	O
widened	B-C1290664
periodontal	I-C1290664
ligament	I-C1290664
space	I-C1290664
.	O
	
the	O
majority	O
of	O
the	O
root	B-C0035848
canal	I-C0035848
fillings	I-C0035848
was	O
inhomogeneous	O
70.4	O
75.4	O
were	O
rated	O
too	O
short	O
,	O
and	O
3.8	O
too	O
long	O
.	O
	
the	O
presence	B-C0150312
of	O
apical	B-C0524789
pathosis	B-C0012634
was	O
significantly	B-C1707520
correlated	I-C1707520
odds	B-C0028873
ratio	I-C0028873
or	B-C0028873
2.556	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
2.076	O
p<0	O
with	O
poor	O
root	B-C0035848
canal	I-C0035848
fillings	I-C0035848
length	O
and	O
homogeneity	B-C1881065
.	O
	
posts	B-C0183062
or	O
screws	B-C0301559
positively	O
affected	O
periapical	B-C0729269
status	I-C0729269
or	B-C0028873
1.853	O
ci	O
1.219	O
p	O
=	O
0.004	O
,	O
but	O
endodontically	B-C0376699
treated	I-C0376699
posterior	I-C0376699
teeth	I-C0376699
were	O
infrequently	O
restored	B-C0565067
posts	B-C0183062
,	O
7.5	O
screws	B-C0301559
,	O
2.7	O
.	O
	
best	O
results	O
were	O
found	O
for	O
teeth	B-C0040426
with	O
both	O
appropriate	O
endodontic	B-C0700632
treatment	I-C0700632
and	O
adequate	O
coronal	B-C0204297
restoration	I-C0204297
.	O
	
a	O
high	B-C1512456
prevalence	I-C1512456
of	O
periradicular	B-C1852169
radiolucencies	I-C1852169
was	O
observed	O
with	O
root	B-C0040426
canal	I-C0040426
filled	I-C0040426
teeth	I-C0040426
,	O
along	O
with	O
high	O
numbers	O
of	O
unmet	O
treatment	B-C0087111
needs	O
.	O
	
periapical	B-C0729269
health	B-C0018684
was	O
associated	B-C0332281
with	I-C0332281
adequate	O
root	B-C0035848
canal	I-C0035848
obturation	I-C0035848
and	O
high-grade	O
postendodontic	B-C2368673
restorations	I-C2368673
,	O
and	O
quality	O
regarding	O
these	O
latter	O
aspects	O
is	O
considered	O
mandatory	O
to	O
promote	O
periapical	B-C0729269
health	B-C0018684
.	O
	
chemical	B-C0243176
composition	I-C0243176
and	O
amino	B-C0002520
acid	I-C0002520
digestibility	B-C0392762
of	O
soybean	B-C0037733
meal	I-C0037733
produced	O
in	O
the	O
united	B-C0041703
states	I-C0041703
,	O
china	B-C0008115
,	O
argentina	B-C0003761
,	O
brazil	B-C0006137
,	O
or	O
india	B-C0021201
an	O
experiment	O
was	O
conducted	O
to	O
compare	O
nutritional	B-C1521739
composition	B-C0243176
of	O
soybean	B-C0037733
meal	I-C0037733
sbm	B-C0037733
produced	O
in	O
china	B-C0008115
,	O
argentina	B-C0003761
,	O
brazil	B-C0006137
,	O
the	O
u.s	B-C0041703
or	O
india	B-C0021201
and	O
the	O
apparent	B-C0392762
ileal	I-C0392762
digestibility	I-C0392762
aid	B-C0392762
and	O
the	O
standardized	B-C0392762
ileal	I-C0392762
digestibility	I-C0392762
sid	B-C0392762
of	O
cp	B-C0033684
and	O
aa	B-C0002520
in	O
these	O
sbm	B-C0037733
when	O
fed	O
to	O
growing	O
pigs	B-C0039005
.	O
	
five	O
sources	O
of	O
sbm	B-C0037733
from	O
china	B-C0008115
,	O
argentina	B-C0003761
,	O
brazil	B-C0006137
,	O
and	O
the	O
u.s	B-C0041703
and	O
4	O
sources	O
from	O
india	B-C0021201
were	O
collected	O
for	O
a	O
total	O
of	O
24	O
sources	O
of	O
sbm	B-C0037733
.	O
	
all	O
samples	O
were	O
analyzed	O
for	O
energy	B-C1442080
,	O
dm	B-C1720884
,	O
and	O
nutrients	B-C0678695
,	O
and	O
each	O
source	O
was	O
included	O
in	O
a	O
cornstarch	B-C1384515
based	I-C1384515
diet	I-C1384515
in	O
which	O
sbm	B-C0037733
was	O
the	O
only	O
aa	B-C0002520
contributing	O
ingredient	B-C1550600
.	O
	
an	O
n-free	B-C0012155
diet	I-C0012155
was	O
also	O
formulated	O
.	O
	
twenty-five	O
barrows	O
initial	O
bw	O
30.53	O
1.73	O
kg	O
were	O
equipped	O
with	O
a	O
t-cannula	O
in	O
the	O
distal	B-C0227327
ileum	I-C0227327
and	O
randomly	O
allotted	O
to	O
a	O
25	O
8	O
youden	B-C0035171
square	I-C0035171
design	I-C0035171
with	O
25	O
diets	B-C0012155
and	O
8	O
periods	B-C1948053
.	O
	
results	O
indicate	O
that	O
the	O
concentration	B-C0457929
of	O
cp	B-C0033684
was	O
greater	O
<	O
0.05	O
in	O
sbm	B-C0037733
from	O
brazil	B-C0006137
and	O
india	B-C0021201
49.3	O
and	O
49.5	O
,	O
respectively	O
than	O
in	O
sbm	B-C0037733
from	O
china	B-C0008115
,	O
argentina	B-C0003761
,	O
or	O
the	O
u.s	B-C0041703
.	O
	
45.1	O
,	O
46.7	O
,	O
and	O
47.3	O
,	O
respectively	O
,	O
as-fed	O
basis	O
.	O
	
the	O
concentration	B-C0457929
of	O
most	O
indispensable	O
aa	B-C0002520
followed	O
the	O
same	O
pattern	O
as	O
cp	B-C0033684
with	O
the	O
exception	O
that	O
sbm	B-C0037733
from	O
the	O
u.s	B-C0041703
.	O
	
contained	O
more	O
<	O
0.05	O
indispensable	O
aa	B-C0002520
than	O
sbm	B-C0037733
from	O
china	B-C0008115
or	O
argentina	B-C0003761
.	O
	
however	O
,	O
sbm	B-C0037733
from	O
india	B-C0021201
contained	O
more	O
<	O
0.05	O
trypsin	B-C0041242
inhibitors	I-C0041242
than	O
sbm	B-C0037733
from	O
the	O
other	O
countries	B-C0454664
.	O
	
a	O
greater	O
<	O
0.05	O
aid	B-C0392762
and	O
sid	B-C0392762
of	O
cp	B-C0033684
and	O
most	O
aa	B-C0002520
was	O
observed	O
in	O
sbm	B-C0037733
from	O
the	O
u.s	B-C0041703
.	O
	
compared	O
with	O
sbm	B-C0037733
from	O
brazil	B-C0006137
,	O
argentina	B-C0003761
,	O
and	O
india	B-C0021201
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
sbm	B-C0037733
from	O
the	O
u.s	B-C0041703
.	O
	
and	O
sbm	B-C0037733
from	O
china	B-C0008115
.	O
	
however	O
,	O
because	O
of	O
the	O
lower	O
concentration	B-C0457929
of	O
aa	B-C0002520
in	O
sbm	B-C0037733
from	O
china	B-C0008115
,	O
the	O
concentration	B-C0457929
of	O
standardized	B-C0392762
ileal	I-C0392762
digestible	I-C0392762
aa	B-C0002520
in	O
sbm	B-C0037733
from	O
china	B-C0008115
was	O
less	O
<	O
0.05	O
than	O
in	O
sbm	B-C0037733
from	O
the	O
u.s	B-C0041703
.	O
	
soybean	O
meal	O
from	O
the	O
u.s	B-C0041703
.	O
	
or	O
brazil	B-C0006137
had	O
less	O
<	O
0.05	O
variability	O
in	O
sid	B-C0392762
values	O
than	O
sbm	B-C0037733
from	O
argentina	B-C0003761
,	O
china	B-C0008115
,	O
or	O
india	B-C0021201
.	O
	
in	O
conclusion	O
,	O
the	O
sid	B-C0392762
of	O
cp	B-C0033684
and	O
aa	B-C0002520
is	O
dependent	O
on	O
the	O
country	B-C0454664
where	O
the	O
sbm	B-C0037733
is	O
produced	O
.	O
	
this	O
difference	O
and	O
the	O
variability	O
within	O
each	O
country	B-C0454664
should	O
be	O
evaluated	O
when	O
formulating	B-C0012164
diets	I-C0012164
for	O
developing	B-C1527148
understanding	B-C0162340
of	O
object	B-C0347997
fall	B-C0085639
going	O
beyond	O
inhibitory	B-C3463820
processes	B-C1522240
a	O
study	B-C2603343
is	O
reported	B-C0684224
where	O
118	O
participants	B-C0679646
aged	B-C0001779
between	O
10	O
years	O
and	O
early	B-C1279919
20s	O
drew	O
the	O
trajectories	B-C0750729
they	O
expected	B-C1517001
objects	B-C0347997
to	O
follow	B-C4281991
as	O
they	O
fell	B-C0085639
.	O
	
the	O
younger	B-C0332239
participants	B-C0679646
typically	B-C3538928
anticipated	B-C3840775
backward	B-C0439781
trajectories	B-C0750729
during	O
fall	B-C0085639
from	O
moving	B-C0560560
carriers	B-C3888060
while	O
forward	B-C0439780
but	O
non-parabolic	B-C0750729
trajectories	I-C0750729
were	O
relatively	B-C0205345
more	B-C0205172
frequent	B-C0332183
amongst	O
the	O
older	B-C0001792
participants	I-C0001792
.	O
	
both	O
patterns	B-C0449774
suggest	B-C1705535
strong	B-C0442821
sociocultural	B-C0680352
influences	B-C4054723
,	O
with	O
implications	B-C3146298
for	O
models	B-C3161035
that	O
regard	O
development	B-C1527148
in	O
this	O
area	B-C0178566
as	O
purely	B-C2963144
the	O
inhibition	B-C3463820
of	O
principles	B-C0678989
established	B-C0443211
in	O
infancy	B-C0231330
.	O
	
statement	B-C1710187
of	O
contribution	B-C1880177
what	O
is	O
already	O
known	B-C0205309
on	O
this	O
subject	B-C0681850
research	B-C0035168
with	O
infants	B-C0021270
demonstrates	B-C0443289
an	O
early	B-C1279919
-	O
established	B-C0443211
belief	B-C0004951
that	O
dropped	B-C1705648
objects	B-C0347997
fall	B-C0085639
straight	B-C0445291
down	B-C0205104
.	O
	
the	O
erroneous	B-C1547323
expectations	B-C0679138
that	O
pre-schoolers	B-C0008100
hold	B-C1948035
about	O
object	B-C0347997
fall	B-C0085639
are	O
consistent	B-C0332290
with	I-C0332290
failure	B-C0680095
to	O
inhibit	B-C3463820
the	O
presumption	B-C1254370
of	O
straight	B-C0445291
-	O
down	B-C0205104
fall	B-C0085639
,	O
in	O
contexts	B-C0449255
where	O
it	O
is	O
inappropriate	B-C1548788
.	O
	
what	O
does	O
this	O
study	B-C2603343
add	O
the	O
research	B-C0035168
replicates	B-C0205173
and	O
extends	B-C0231448
research	B-C0035168
with	O
older	B-C0001792
participants	I-C0001792
,	O
which	O
indicates	B-C3146298
errors	B-C0743559
that	O
cannot	O
be	O
explained	B-C3526595
via	O
failed	B-C0231175
inhibition	B-C3463820
of	O
straight	B-C0445291
-	O
down	B-C0205104
fall	B-C0085639
.	O
	
it	O
is	O
the	O
first	O
study	B-C2603343
to	O
trace	O
patterns	B-C0449774
of	O
errors	B-C0743559
across	O
late	B-C0205087
childhood	B-C0231335
,	O
adolescence	B-C0001578
and	O
early	B-C1279919
adulthood	B-C0700597
.	O
	
a	O
consequence	B-C0686907
of	I-C0686907
the	O
findings	B-C0243095
is	O
that	O
adequate	B-C0205411
modelling	B-C3714583
in	O
developmental	B-C1511810
psychology	I-C1511810
must	O
consider	B-C0750591
multilayered	B-C1254372
interactions	B-C1704675
between	O
prior	B-C0332152
representations	B-C1882932
and	O
sociocultural	B-C0680352
experiences	B-C0596545
.	O
	
attenuation	B-C0599946
of	O
high	B-C0017725
glucose	I-C0017725
-	O
induced	B-C0205263
rat	B-C0034693
cardiomyocyte	B-C0225828
apoptosis	B-C0162638
by	O
exendin-4	B-C0167117
via	O
intervention	B-C0184661
of	O
ho-1	B-C0538674
/	O
nrf-2	B-C0289507
and	O
the	O
pi3k/akt	B-C2984369
signaling	I-C2984369
pathway	I-C2984369
exendin-4	B-C0167117
,	O
a	O
glucagon-like	B-C2917359
peptide-1	I-C2917359
receptor	I-C2917359
agonist	I-C2917359
,	O
demonstrated	O
cytoprotective	B-C0524828
actions	I-C0524828
beyond	O
glycemic	B-C0522082
control	I-C0522082
in	O
recent	O
studies	O
.	O
	
the	O
aims	B-C1947946
of	O
the	O
present	O
study	B-C2603343
were	O
to	O
investigate	B-C1292732
the	O
effects	B-C1704420
of	I-C1704420
exendin-4	B-C0167117
on	O
high	B-C0017725
glucose	I-C0017725
hg	B-C0017725
induced	B-C0205263
cardiomyocyte	B-C0225828
apoptosis	B-C0162638
and	O
the	O
possible	O
mechanisms	B-C0441712
.	O
	
rat	B-C0034693
cardiomyocytes	B-C0225828
were	O
divided	O
into	O
3	O
groups	B-C0681860
normal	B-C0017725
glucose	I-C0017725
group	B-C0681860
ng	B-C0017725
group	B-C0681860
,	O
hg	B-C0017725
group	B-C0681860
and	O
hg	B-C0017725
+	O
exendin-4	B-C0167117
group	B-C0681860
hg	B-C0017725
+	O
ex	B-C0167117
group	B-C0681860
.	O
	
cardiomyocyte	B-C0225828
apoptosis	B-C0162638
was	O
evaluated	O
by	O
double-staining	B-C0022885
with	O
annexin	B-C0085216
v-fluorescein	I-C0085216
isothiocyanate	I-C0085216
fitc	B-C0085216
propidium	B-C0033470
iodide	I-C0033470
pi	B-C0033470
and	O
flow	B-C0016263
cytometry	I-C0016263
.	O
	
intracellular	B-C0178719
reactive	B-C1537052
oxygen	I-C1537052
species	I-C1537052
ros	I-C1537052
production	B-C0542341
was	O
detected	B-C0442726
by	O
2	B-C0670829
diacetate	I-C0670829
dchf-da	B-C0670829
incubation	B-C1439852
and	O
fluorescence	B-C0026022
microscopy	I-C0026022
.	O
	
ly294002	B-C0251991
ly	B-C0251991
,	O
a	O
phosphoinositide	B-C0044602
3-kinase	I-C0044602
pi3k	B-C0044602
pathway	B-C1704259
inhibitor	B-C1999216
,	O
was	O
added	O
to	O
the	O
medium	B-C0010454
of	O
the	O
hg	B-C0017725
+	O
ex	B-C0167117
+	O
ly	B-C0251991
group	B-C0681860
for	O
further	O
western	B-C0949466
blot	I-C0949466
analysis	I-C0949466
.	O
	
the	O
proteins	B-C0033684
analyzed	B-C0936012
involved	O
oxidative	B-C0242606
stress	I-C0242606
-	O
associated	B-C0033684
proteins	I-C0033684
,	O
heme	B-C0538674
oxygenase-1	I-C0538674
ho-1	B-C0538674
and	O
nuclear	B-C0289507
factor	I-C0289507
e2-related	I-C0289507
factor	I-C0289507
2	I-C0289507
nrf-2	B-C0289507
,	O
and	O
apoptosis	B-C0162638
-	O
associated	B-C0033684
proteins	I-C0033684
,	O
caspase-3	B-C0291573
,	O
bax/b-cell	B-C0219474
lymphoma	I-C0219474
2	I-C0219474
bcl-2	B-C0219474
and	O
p-akt	B-C0164786
/	O
akt	B-C0164786
.	O
	
hg	B-C0017725
treatment	B-C1522326
induced	B-C0205263
cardiomyocyte	B-C0225828
apoptosis	B-C0162638
p	O
=	O
0.00	O
and	O
clearly	O
upregulated	B-C0041904
ros	B-C0162772
production	B-C0542341
p	O
=	O
0.00	O
exendin-4	B-C0167117
co-incubation	B-C1439852
also	O
ameliorated	O
cardiomyocyte	B-C0225828
apoptosis	B-C0162638
p	O
=	O
0.004	O
and	O
decreased	B-C0205216
ros	B-C0162772
p	O
=	O
0.00	O
level	B-C0441889
significantly	B-C0750502
.	O
	
ho-1	B-C0538674
and	O
nrf-2	B-C0289507
protein	B-C1171362
expression	I-C1171362
levels	B-C0441889
decreased	B-C0205216
significantly	B-C0750502
in	O
the	O
hg	B-C0017725
group	B-C0681860
p	O
<	O
0.05	O
,	O
but	O
the	O
levels	B-C0441889
were	O
elevated	B-C3163633
by	O
exendin-4	B-C0167117
intervention	B-C0184661
p	O
<	O
0.05	O
.	O
	
furthermore	O
,	O
exendin-4	B-C0167117
attenuated	B-C0599946
hg	B-C0017725
-	O
induced	B-C0205263
higher	O
protein	B-C1171362
expression	I-C1171362
,	O
including	O
cleaved	O
caspase-3	B-C0291573
and	O
bax	B-C0219474
,	O
increased	B-C0205217
the	O
expression	B-C1171362
of	O
bcl-2	B-C4042483
protein	I-C4042483
p	O
<	O
0.05	O
.	O
	
however	O
,	O
these	O
impacts	B-C4049986
of	O
exendin-4	B-C0167117
were	O
counteracted	O
significantly	B-C0750502
by	O
co-incubation	B-C1439852
with	O
ly294002	B-C0251991
.	O
	
in	O
addition	O
,	O
exendin-4	B-C0167117
ameliorated	O
hg	B-C0017725
-	O
induced	B-C0205263
p-akt	B-C0164786
/	O
akt	B-C0164786
lower	B-C1171362
expression	I-C1171362
,	O
and	O
this	O
impact	B-C4049986
was	O
also	O
suppressed	B-C1260953
by	O
ly294002	B-C0251991
.	O
	
exendin-4	B-C0167117
ameliorates	O
hg	B-C0017725
-	O
induced	B-C0205263
cardiomyocyte	B-C0225828
apoptosis	B-C0162638
,	O
and	O
the	O
mechanisms	B-C0441712
may	O
involve	O
anti-oxidative	B-C1148560
stress	I-C1148560
via	O
the	O
ho-1	B-C0538674
/	O
nrf-2	B-C0289507
system	O
,	O
as	O
well	O
as	O
intervention	B-C0184661
of	O
the	O
pi3k/akt	B-C2984369
signaling	I-C2984369
pathway	I-C2984369
.	O
	
kmap-o	B-C0679897
framework	I-C0679897
for	O
care	B-C2735310
management	I-C2735310
research	B-C0035168
of	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
to	O
review	B-C1704362
impacts	B-C4049986
of	O
interventions	B-C1273869
involving	O
self-management	B-C3698325
education	I-C3698325
,	O
health	B-C4255176
coaching	I-C4255176
,	O
and	O
motivational	B-C0683474
interviewing	I-C0683474
for	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
.	O
	
a	O
thorough	O
review	B-C1552617
of	O
the	O
scientific	B-C0023866
literature	I-C0023866
on	O
diabetes	B-C0011847
care	B-C2735310
and	I-C2735310
management	I-C2735310
was	O
executed	O
by	O
a	O
research	B-C0035168
team	B-C0871489
.	O
	
this	O
article	B-C1706852
summarizes	O
important	O
findings	B-C2607943
in	O
regard	O
to	O
the	O
validity	B-C2349101
of	O
developing	B-C0205245
a	O
comprehensive	B-C1880156
behavioral	B-C1254370
system	I-C1254370
as	O
a	O
framework	B-C0679897
for	O
empirical	B-C1880496
investigation	B-C0220825
.	O
	
the	O
behavioral	B-C1254370
system	I-C1254370
framework	B-C0679897
consists	O
of	O
patients	B-C0030705
'	O
knowledge	B-C0518904
k	B-C0518904
,	O
motivation	B-C0026605
m	B-C0026605
,	O
attitude	B-C0004271
a	B-C0004271
,	O
and	O
practice	B-C0237607
p	B-C0237607
as	O
predictor	B-C2698872
variables	B-C0439828
for	O
diabetes	B-C0011847
care	B-C0518889
outcomes	I-C0518889
o	B-C0518889
.	O
	
care	B-C2735310
management	I-C2735310
strategies	O
or	O
health	B-C0679897
education	I-C0679897
programs	I-C0679897
serve	O
as	O
the	O
intervention	B-C1273869
variable	B-C0439828
that	O
directly	O
influences	B-C4054723
k	B-C0518904
,	O
m	B-C0026605
,	O
a	B-C0004271
,	O
and	O
p	B-C0237607
and	O
then	O
indirectly	O
affects	O
the	O
variability	B-C2827666
in	O
patient	B-C0030705
care	B-C0518889
outcomes	I-C0518889
of	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
.	O
	
this	O
review	B-C0282443
contributes	O
to	O
the	O
understanding	O
of	O
the	O
kmap-o	B-C0679897
framework	I-C0679897
and	O
how	O
it	O
can	O
guide	B-C0681467
the	O
care	B-C2735310
management	I-C2735310
of	O
patients	B-C0030705
with	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
.	O
	
it	O
will	O
allow	O
the	O
tailoring	O
of	O
interventions	B-C1273869
to	O
be	O
more	O
effective	O
through	O
knowledge	B-C0518904
enhancement	B-C2349975
,	O
increased	B-C0520939
motivation	I-C0520939
,	O
attitudinal	B-C0004271
changes	B-C0392747
,	O
and	O
improved	B-C0184511
preventive	B-C1516623
practice	I-C1516623
to	O
reduce	B-C0392756
the	O
progression	B-C0242656
of	O
type	B-C0011860
2	I-C0011860
diabetes	I-C0011860
and	O
comorbidities	B-C0009488
.	O
	
furthermore	O
,	O
the	O
use	B-C1524063
of	I-C1524063
health	B-C2936756
information	I-C2936756
technology	I-C2936756
for	O
enhancing	B-C2349975
changes	B-C0392747
in	O
kmap	B-C0679897
and	O
communications	B-C0009452
is	O
advocated	O
in	O
health	B-C0018738
promotion	I-C0018738
and	O
bayesian	B-C0242196
and	O
phylogenic	B-C1519068
approaches	I-C1519068
for	O
studying	O
relationships	B-C0439849
among	O
table	B-C0996956
olive	I-C0996956
cultivars	I-C0996956
to	O
enhance	O
table	B-C0996956
olive	I-C0996956
tree	I-C0996956
authentication	B-C0205556
,	O
relationship	B-C0439849
,	O
and	O
productivity	B-C0033269
,	O
we	O
consider	O
the	O
analysis	B-C0936012
of	O
18	O
worldwide	O
table	B-C0996956
olive	I-C0996956
cultivars	I-C0996956
olea	B-C0996956
europaea	I-C0996956
l	I-C0996956
based	O
on	O
morphological	B-C0332437
,	O
biological	B-C0205460
,	O
and	O
physicochemical	B-C0017393
markers	I-C0017393
analyzed	O
by	O
bioinformatic	B-C0037589
and	O
biostatistic	B-C0037589
tools	I-C0037589
.	O
	
accordingly	O
,	O
we	O
assess	O
the	O
relationships	B-C0439849
between	O
the	O
studied	O
varieties	B-C0205419
,	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
potential	O
productivity	B-C0033269
-	O
quantitative	B-C0392762
parameter	B-C0549193
links	O
on	O
the	O
other	O
hand	O
.	O
	
the	O
bioinformatic	B-C0037589
analysis	B-C0936012
based	O
on	O
the	O
graphical	B-C0870616
representation	I-C0870616
of	O
the	O
matrix	B-C1880593
of	I-C1880593
euclidean	I-C1880593
distances	I-C1880593
,	O
the	O
principal	B-C0429865
components	I-C0429865
analysis	I-C0429865
,	O
unweighted	B-C1881045
pair	I-C1881045
group	I-C1881045
method	I-C1881045
with	O
arithmetic	B-C0444504
mean	I-C0444504
,	O
and	O
principal	B-C0936012
coordinate	I-C0936012
analysis	I-C0936012
pcoa	B-C0936012
revealed	O
three	O
major	O
clusters	B-C1704332
which	O
were	O
not	O
correlated	O
with	O
the	O
geographic	B-C1517526
origin	B-C0584985
.	O
	
the	O
statistical	B-C0871424
analysis	I-C0871424
based	O
on	O
kendall's	O
and	O
spearman	B-C0242929
correlation	I-C0242929
coefficients	I-C0242929
suggests	O
two	O
highly	O
significant	O
associations	B-C0439849
with	O
both	O
fruit	B-C0016767
color	B-C0009393
and	O
pollinization	B-C1522786
and	O
the	O
productivity	B-C0033269
character	O
.	O
	
these	O
results	B-C1274040
are	O
confirmed	O
by	O
the	O
multiple	B-C0023733
linear	I-C0023733
regression	I-C0023733
prediction	I-C0023733
models	I-C0023733
.	O
	
in	O
fact	O
,	O
based	O
on	O
the	O
coefficient	B-C2827748
of	I-C2827748
determination	I-C2827748
r	B-C2827748
2	I-C2827748
value	O
,	O
the	O
best	O
model	B-C3161035
demonstrated	O
the	O
power	B-C3854080
of	O
the	O
pollinization	B-C1522786
on	O
the	O
tree	O
productivity	B-C0033269
r	B-C2827748
2	I-C2827748
=	O
0.846	O
.	O
	
moreover	O
,	O
the	O
derived	O
directed	B-C1706232
acyclic	I-C1706232
graph	I-C1706232
showed	O
that	O
only	O
two	O
direct	O
influences	B-C4054723
are	O
detected	B-C0442726
effect	B-C1280500
of	O
tolerance	B-C1704410
on	O
fruit	B-C0016767
and	O
stone	B-C0205556
symmetry	I-C0205556
on	O
side	O
and	O
effect	B-C1280500
of	O
tolerance	B-C1704410
on	O
stone	B-C0205556
form	I-C0205556
and	O
oil	B-C0028908
content	B-C0456205
on	O
the	O
other	O
side	O
.	O
	
this	O
work	O
provides	O
better	O
understanding	O
of	O
the	O
diversity	B-C1880371
available	O
in	O
worldwide	O
table	B-C0996956
olive	I-C0996956
cultivars	I-C0996956
and	O
supplies	O
an	O
important	O
contribution	O
for	O
olive	B-C0996956
breeding	B-C0006159
and	O
wiedemann-rautenstrauch	B-C0406586
syndrome	I-C0406586
with	O
bilateral	B-C0238767
tarsal	B-C1303000
kink	I-C1303000
three	O
sutures	B-C0038968
for	O
correction	B-C1947976
the	O
authors	O
describe	O
a	O
5-	O
month-old	B-C0580836
male	B-C0086582
infant	B-C0021270
with	O
wiedemann-rautenstrauch	B-C0406586
syndrome	I-C0406586
,	O
which	O
is	O
an	O
extremely	O
rare	B-C0522498
condition	B-C0012634
.	O
	
he	O
had	O
tarsal	B-C1303000
kink	I-C1303000
in	O
upper	B-C0585636
eyelids	I-C0585636
in	O
both	B-C0229118
eyes	I-C0229118
.	O
	
the	O
authors	O
treated	B-C1522326
bilateral	B-C0238767
tarsal	B-C1303000
kink	I-C1303000
with	O
an	O
everting	B-C0455231
suture	B-C0038968
via	O
a	O
transconjunctival	B-C0442347
approach	I-C0442347
under	O
local	B-C0002921
anesthesia	I-C0002921
.	O
	
the	O
indications	B-C0392360
for	O
laparoscopic	B-C0030279
pancreatectomy	I-C0030279
laparoscopic	B-C0030279
pancreatectomy	I-C0030279
is	O
not	O
yet	O
established	O
as	O
a	O
routine	B-C1298805
procedure	I-C1298805
everywhere	O
in	O
germany	B-C0017480
or	O
in	O
other	O
countries	B-C0454664
.	O
	
few	O
data	B-C1511726
are	O
available	O
on	O
its	O
short-	B-C0085415
and	I-C0085415
long-term	I-C0085415
outcomes	I-C0085415
.	O
	
from	O
2008	O
onward	O
,	O
a	O
working	B-C1883562
group	I-C1883562
initiated	O
by	O
10	O
centers	B-C0475309
and	O
currently	O
comprising	O
34	O
centers	B-C0475309
has	O
gathered	O
data	B-C1511726
on	O
all	O
cases	B-C0868928
of	O
laparoscopic	B-C0030279
pancreatectomy	I-C0030279
.	O
	
procedures	B-C0087111
in	O
which	O
laparoscopy	B-C1883297
was	O
converted	O
to	O
open	B-C4283938
surgery	I-C4283938
are	O
also	O
included	O
.	O
	
the	O
registry	B-C0034975
now	O
contains	O
550	O
data	B-C1511726
sets	O
representing	O
267	O
cases	B-C0868928
of	O
benign	B-C0086692
disease	I-C0086692
,	O
244	O
malignancies	B-C0006826
,	O
and	O
39	O
borderline	B-C0027651
tumors	I-C0027651
.	O
	
the	O
most	O
common	O
procedure	B-C0087111
was	O
laparoscopic	B-C0030279
left	I-C0030279
pancreatectomy	I-C0030279
,	O
followed	O
by	O
resection	B-C0015252
of	O
the	O
head	B-C0227579
of	I-C0227579
the	I-C0227579
pancreas	I-C0227579
and	O
tumor	B-C0027651
enucleation	B-C1283063
.	O
	
the	O
most	O
common	O
intraoperative	B-C0021890
complication	I-C0021890
was	O
hemorrhage	B-C0019080
,	O
with	O
a	O
frequency	O
of	O
3%	O
.	O
	
the	O
rate	B-C1521828
of	O
conversion	B-C0439836
to	O
open	B-C4283938
surgery	I-C4283938
was	O
35%	O
if	O
minilaparotomies	B-C0026168
are	O
excluded	O
,	O
the	O
conversion	B-C0439836
rate	B-C1521828
was	O
only	O
16%	O
.	O
	
39%	O
of	O
patients	B-C0030705
developed	O
a	O
pancreatic	B-C0030290
fistula	I-C0030290
after	O
surgery	B-C0543467
usually	O
grade	O
a	O
or	O
b	O
,	O
with	O
1.5	O
grade	O
c	O
and	O
3%	O
underwent	O
reoperation	B-C0035110
because	O
of	O
postoperative	B-C0032788
hemorrhage	I-C0032788
.	O
	
the	O
procedure-related	B-C0277599
mortality	I-C0277599
was	O
1.3	O
.	O
	
91%	O
of	O
the	O
patients	B-C0030705
reported	O
only	O
very	O
mild	O
postoperative	B-C0030201
pain	I-C0030201
.	O
	
6.7	O
newly	O
developed	O
diabetes	B-C0011849
mellitus	I-C0011849
after	O
the	O
procedure	B-C0087111
.	O
	
the	O
patient	B-C0030705
cohort	B-C0599755
in	O
the	O
registry	B-C0034975
consists	O
of	O
persons	B-C0027361
who	O
were	O
selected	O
to	O
undergo	O
laparoscopic	B-C0030279
pancreatectomy	I-C0030279
by	O
the	O
participating	O
hospital	B-C0019994
teams	B-C0871489
,	O
and	O
the	O
data	B-C1511726
are	O
thus	O
inherently	O
affected	O
by	O
selection	B-C0036577
bias	I-C0036577
.	O
	
the	O
operative	B-C0543467
procedures	I-C0543467
that	O
they	O
underwent	O
reflect	O
the	O
current	O
practice	O
of	O
laparoscopic	B-C0030279
pancreatectomy	I-C0030279
in	O
germany	B-C0017480
.	O
	
the	O
complication	B-C0009566
rates	B-C1521828
are	O
similar	O
to	O
those	O
of	O
open	B-C4283938
surgery	I-C4283938
.	O
	
selection	B-C0036577
bias	I-C0036577
can	O
be	O
avoided	O
only	O
by	O
a	O
randomized	B-C0206034
trial	I-C0206034
.	O
	
associations	O
of	O
neurod2	B-C1417684
polymorphisms	B-C0678951
and	O
change	B-C0392747
of	O
cognitive	B-C0338656
dysfunctions	I-C0338656
in	O
schizophrenia	B-C0036341
and	O
schizoaffective	B-C0036337
disorder	I-C0036337
after	O
eight	O
weeks	B-C0439230
of	O
antipsychotic	B-C0040615
treatment	B-C0087111
neurod2	B-C1417684
is	O
a	O
neurospecific	B-C0206678
helix-loop-helix	I-C0206678
transcription	B-C0040648
factor	I-C0040648
which	O
has	O
an	O
impact	B-C4049986
on	O
the	O
regulation	B-C0017263
of	O
glutamatergic	B-C0220839
and	O
gabaergic	B-C0016904
genes	B-C0017337
.	O
	
we	O
investigated	B-C1292732
an	O
association	O
of	O
neurod2	B-C1417684
with	O
neurocognitive	B-C0338656
dysfunctions	I-C0338656
in	O
schizophrenia	B-C0036341
and	O
schizoaffective	B-C0036337
disorder	I-C0036337
patients	B-C0030705
before	O
and	O
during	O
treatment	B-C0087111
with	O
different	O
second-generation	B-C0040615
antipsychotics	I-C0040615
.	O
	
patients	B-C0030705
were	O
genotyped	B-C0017431
for	O
four	O
different	O
polymorphisms	B-C0678951
of	O
the	O
neurod2	B-C1417684
gene	B-C0017337
rs9889354	B-C0678951
,	O
rs1877032	B-C0678951
,	O
rs12453682	B-C0678951
and	O
rs11078918	B-C0678951
.	O
	
cognitive	B-C0392335
function	I-C0392335
was	O
assessed	B-C1516048
at	O
baseline	B-C1442488
and	O
week	B-C0439230
8	O
.	O
	
results	B-C1274040
of	O
individual	O
neuropsychological	B-C0027902
tests	I-C0027902
were	O
assigned	O
to	O
six	O
cognitive	B-C4050130
domains	I-C4050130
reaction	B-C0034746
time	I-C0034746
and	O
quality	B-C0332306
executive	B-C0935584
function	I-C0935584
working	B-C1563351
,	O
verbal	B-C0561770
and	O
visual	B-C0542316
memory	I-C0542316
and	O
a	O
general	O
cognitive	B-C1516691
index	B-C0918012
.	O
	
167	O
patients	B-C0030705
were	O
included	O
in	O
the	O
study	B-C2603343
.	O
	
the	O
neurod2	B-C1417684
exonic	B-C0678951
polymorphism	I-C0678951
rs11078918	I-C0678951
showed	O
significant	O
associations	O
with	O
verbal	B-C0561770
memory	I-C0561770
and	O
executive	B-C0935584
functions	I-C0935584
,	O
whereas	O
the	O
neurod2	B-C1417684
polymorphism	B-C0678951
rs12453682	I-C0678951
was	O
significantly	O
associated	O
with	O
working	B-C1563351
and	O
verbal	B-C0561770
memory	I-C0561770
,	O
executive	B-C0935584
functions	I-C0935584
and	O
with	O
a	O
cognitive	B-C1516691
index	B-C0918012
.	O
	
significant	O
associations	O
were	O
found	O
at	O
baseline	B-C1442488
and	O
after	O
eight	O
weeks	B-C0439230
.	O
	
moreover	O
,	O
significant	O
associations	O
between	O
the	O
change	B-C0392747
in	O
neuropsychological	B-C0027902
test	I-C0027902
results	B-C1274040
during	O
antipsychotic	B-C0040615
treatment	B-C0087111
and	O
the	O
neurod2	B-C1417684
polymorphisms	B-C0678951
rs11078918	B-C0678951
and	O
rs12453682	B-C0678951
were	O
observed	O
.	O
	
our	O
findings	O
suggest	O
that	O
the	O
neurod2	B-C1417684
gene	I-C1417684
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	B-C0031847
of	O
neurocognitive	B-C0338656
dysfunctions	I-C0338656
as	O
well	O
as	O
in	O
the	O
change	B-C0392747
of	O
cognitive	B-C0525041
symptoms	I-C0525041
under	O
antipsychotic	B-C0040615
treatment	B-C0087111
in	O
schizophrenia	B-C0036341
and	O
schizoaffective	B-C0036337
disorder	I-C0036337
.	O
	
new	B-C0205314
diterpenoids	B-C0012780
from	O
clerodendranthus	B-C2311252
spicatus	I-C2311252
two	O
new	B-C0205314
diterpenoids	B-C0012780
,	O
neoorthosiphonones	B-C0012780
b	I-C0012780
and	O
c	B-C0012780
1	B-C0012780
and	O
2	B-C0012780
,	O
and	O
one	O
known	O
diterpenoid	B-C0012780
,	O
were	O
isolated	B-C0205409
from	O
the	O
aerial	B-C1136056
parts	I-C1136056
of	O
clerodendranthus	B-C2311252
spicatus	I-C2311252
.	O
	
their	O
structures	B-C0678594
including	O
absolute	B-C0205344
configurations	B-C0449830
were	O
determined	B-C0521095
by	I-C0521095
comprehensive	O
spectroscopic	B-C0022885
analyses	I-C0022885
and	O
x-ray	B-C0206755
crystallographic	I-C0206755
methods	I-C0206755
.	O
	
no	O
compound	B-C0205198
was	O
found	O
to	O
inhibit	B-C0521111
fibronectin	B-C0016055
production	B-C0033268
at	O
the	O
concentration	B-C1446561
stalk	B-C1947953
versus	O
base	B-C0700276
invasion	B-C1269955
in	O
pt1	B-C0332391
papillary	B-C0699885
cancers	I-C0699885
of	I-C0699885
the	I-C0699885
bladder	I-C0699885
improved	O
substaging	O
system	O
predicting	O
risk	B-C0035647
of	O
progression	B-C0242656
pathologic	B-C0332391
stage	I-C0332391
t1	I-C0332391
pt1	B-C0332391
bladder	B-C0699885
cancers	I-C0699885
are	O
a	O
clinically	B-C0205210
heterogeneous	B-C0019409
group	I-C0019409
.	O
	
however	O
,	O
current	O
staging	B-C0178759
guidelines	O
for	O
superficially	B-C0205124
invasive	B-C0677898
cancers	I-C0677898
do	O
not	O
acknowledge	O
the	O
variability	B-C2827666
in	O
type	O
and	O
extent	O
of	O
lamina	B-C1269980
propria	I-C1269980
invasion	I-C1269980
in	O
papillary	B-C1368911
urothelial	I-C1368911
carcinomas	I-C1368911
puc	B-C1368911
,	O
and	O
historically	O
proposed	O
substaging	O
systems	O
showed	O
either	O
high	O
inter-observer	B-C0021713
variation	I-C0021713
or	O
limited	B-C0439801
value	I-C0439801
in	O
predicting	O
patient	B-C0030698
outcomes	I-C0030698
.	O
	
herein	O
we	O
reappraise	B-C0184514
pt1	B-C0332391
puc	B-C1368911
substaging	O
,	O
aiming	B-C1947946
to	O
identify	B-C0205396
a	O
novel	B-C0205314
scheme	B-C1519193
which	O
is	O
reproducible	B-C1524057
and	O
prognostically	B-C0220901
meaningful	O
.	O
	
stage	B-C0332391
pt1	I-C0332391
puc	B-C1368911
diagnosed	B-C0011900
during	O
years	B-C0439234
1999-2015	O
were	O
retrospectively	B-C0035363
reviewed	I-C0035363
and	O
characterized	B-C1880022
as	O
focal	B-C0205234
invasion	B-C2699153
confined	O
to	O
papillary	B-C1947953
stalk	I-C1947953
,	O
focal	B-C0205234
invasion	B-C1269955
of	O
tumor	B-C0027651
base	B-C0700276
,	O
or	O
extensive	O
invasion	B-C1269955
of	O
tumor	B-C0027651
base	B-C0700276
.	O
	
cases	B-C0868928
with	O
concurrent	B-C0205420
flat	B-C1300924
carcinoma	I-C1300924
in-situ	I-C1300924
,	O
angiolymphatic	B-C1708790
invasion	I-C1708790
,	O
absent	B-C0332197
muscularis	B-C0225358
propria	I-C0225358
,	O
or	O
clinically	B-C0205210
advanced	B-C0679246
disease	I-C0679246
were	O
excluded	B-C0332196
.	O
	
we	O
calculated	O
cumulative	B-C1511559
incidence	B-C0021149
of	O
recurrence	B-C0679254
,	O
progression	B-C0242656
,	O
and	O
death	B-C0011065
by	O
tumor	B-C1519691
subtype	I-C1519691
and	O
evaluated	B-C0220825
differential	B-C0035648
risks	I-C0035648
using	O
log-rank	B-C0237913
tests	I-C0237913
and	O
kaplan-meier	B-C1720944
curves	I-C1720944
stratified	B-C0205363
by	O
type	B-C0332307
and	O
extent	B-C1269793
of	I-C1269793
invasion	I-C1269793
.	O
	
among	O
62	O
patients	B-C0030705
satisfying	O
inclusion	B-C1512693
criteria	B-C0243161
,	O
22	O
of	O
29	O
patients	B-C0030705
with	O
base	B-C0700276
extensive	B-C0205231
invasion	B-C1269955
progressed	B-C1280477
while	O
4	O
of	O
13	O
with	O
base	B-C0700276
focal	B-C0205234
and	O
0	O
of	O
20	O
with	O
stalk	B-C1947953
only	O
invasion	B-C1269955
progressed	B-C1280477
.	O
	
there	O
was	O
strong	O
evidence	O
that	O
base	B-C0700276
extensive	O
patients	B-C0030705
had	O
higher	O
risk	B-C0035647
of	O
progression	B-C0242656
and	O
death	B-C0011065
due	O
to	O
bladder	B-C0699885
cancer	I-C0699885
than	O
base	B-C0700276
focal	B-C0205234
or	O
stalk	B-C1947953
only	O
counterparts	O
p<0	O
.	O
	
however	O
,	O
tumor	B-C1519691
subtype	I-C1519691
was	O
not	O
significantly	O
associated	O
with	O
risk	B-C0035647
of	O
recurrence	B-C0679254
p=0	O
.	O
	
we	O
propose	O
an	O
innovative	O
substaging	O
approach	O
for	O
reporting	O
site	O
and	O
extent	O
of	O
lamina	B-C1269980
propria	I-C1269980
invasion	I-C1269980
in	O
patients	B-C0030705
with	O
pt1	B-C0332391
puc	B-C1368911
allowing	O
patient	B-C0030705
stratification	B-C0205363
for	O
risk	B-C0035647
of	O
progression	B-C0242656
.	O
	
basic	B-C0681833
science	I-C0681833
and	O
pathogenesis	B-C0699748
of	O
ageing	B-C0001811
with	O
hiv	B-C0019693
potential	O
mechanisms	B-C0441712
and	O
biomarkers	B-C0005516
the	O
increased	O
prevalence	B-C0220900
of	O
age	B-C0001779
-related	O
comorbidities	B-C0009488
and	O
mortality	B-C0178686
is	O
worrisome	B-C0233481
in	O
ageing	B-C0001811
hiv-infected	B-C0019693
patients	B-C0030705
.	O
	
here	O
,	O
we	O
aim	B-C1947946
to	O
analyse	B-C0936012
the	O
different	O
ageing	B-C0001811
mechanisms	B-C0441712
with	O
regard	O
to	O
hiv	B-C0019693
infection	I-C0019693
.	O
	
ageing	B-C0001811
results	O
from	O
the	O
time	B-C0040223
-	O
dependent	B-C3244310
accumulation	B-C4055506
of	O
random	O
cellular	B-C0599732
damage	I-C0599732
.	O
	
epigenetic	B-C1516924
modifications	I-C1516924
and	O
mitochondrial	B-C0012929
dna	I-C0012929
haplogroups	B-C0018591
modulate	B-C0443264
ageing	B-C0001811
.	O
	
in	O
antiretroviral	B-C1963724
treatment	I-C1963724
-controlled	O
patients	B-C0030705
,	O
epigenetic	B-C0085759
clock	I-C0085759
appears	O
to	O
be	O
advanced	O
,	O
and	O
some	O
haplogroups	B-C0018591
are	O
associated	O
with	O
hiv	B-C0019693
infection	I-C0019693
severity	B-C0439793
.	O
	
telomere	B-C1515263
shortening	I-C1515263
is	O
enhanced	O
in	O
hiv-infected	B-C0019693
patients	B-C0030705
because	O
of	O
hiv	B-C0019682
and	O
some	O
nucleoside	B-C1579410
analogue	I-C1579410
reverse	B-C0282519
transcriptase	I-C0282519
inhibitors	I-C0282519
.	O
	
mitochondria	B-C0026237
-related	O
oxidative	B-C0242606
stress	I-C0242606
and	O
mitochondrial	B-C0012929
dna	I-C0012929
mutations	B-C0026882
are	O
increased	O
during	O
ageing	B-C0001811
and	O
also	O
by	O
some	O
nucleoside	B-C1579410
analogue	I-C1579410
reverse	B-C0282519
transcriptase	I-C0282519
inhibitors	I-C0282519
.	O
	
overall	O
,	O
increased	O
inflammation	B-C0021368
or	O
'	O
inflammageing	B-C0021368
'	O
is	O
a	O
major	O
driver	O
of	O
ageing	B-C0001811
and	O
could	O
result	O
from	O
cell	B-C0007581
senescence	I-C0007581
with	O
secreted	O
proinflammatory	B-C0243042
mediators	I-C0243042
,	O
altered	O
gut	B-C2985398
microbiota	I-C2985398
,	O
and	O
coinfections	B-C0275524
.	O
	
in	O
hiv-infected	B-C0019693
patients	B-C0030705
,	O
the	O
level	B-C0441889
of	O
inflammation	B-C0021368
and	O
innate	B-C0020969
immunity	I-C0020969
activation	B-C1879547
is	O
enhanced	O
and	O
related	O
to	O
most	O
comorbidities	B-C0009488
and	O
to	O
mortality	B-C0178686
.	O
	
this	O
status	O
could	O
result	O
,	O
in	O
addition	O
to	O
age	B-C0001779
,	O
from	O
the	O
virus	B-C0042776
itself	O
or	O
viral	B-C0042736
protein	I-C0042736
released	O
from	O
reservoirs	B-C0012653
,	O
from	O
hiv	B-C0019682
-enhanced	O
gut	B-C0699819
permeability	B-C0031164
and	O
dysbiosis	B-C3658208
,	O
from	O
antiretroviral	B-C1963724
treatment	I-C1963724
,	O
from	O
frequent	O
cytomegalovirus	B-C0010825
and	O
hepatitis	B-C0220847
c	I-C0220847
virus	I-C0220847
coinfections	B-C0275524
,	O
and	O
also	O
from	O
personal	O
and	O
environmental	B-C1516998
factors	I-C1516998
,	O
as	O
central	O
fat	B-C0333574
accumulation	I-C0333574
or	O
smoking	B-C0037369
.	O
	
adaptive	B-C0678209
immune	I-C0678209
activation	B-C1879547
and	O
immunosenescence	B-C0596761
are	O
associated	O
with	O
comorbidities	B-C0009488
and	O
mortality	B-C0178686
in	O
the	O
general	B-C0683971
population	I-C0683971
but	O
are	O
less	O
predictive	B-C0681890
in	O
hiv-infected	B-C0019693
patients	B-C0030705
.	O
	
biomarkers	B-C0005516
to	O
evaluate	B-C0220825
ageing	B-C0001811
in	O
hiv-infected	B-C0019693
patients	B-C0030705
are	O
required	O
.	O
	
numerous	O
systemic	B-C0205373
or	O
cellular	B-C0440752
inflammatory	I-C0440752
,	O
immune	B-C0439662
activation	B-C1879547
,	O
oxidative	B-C0242606
stress	I-C0242606
,	O
or	O
senescence	O
markers	B-C0005516
can	O
be	O
tested	B-C0039593
in	O
serum	B-C0229671
or	O
peripheral	B-C1321301
blood	I-C1321301
mononuclear	I-C1321301
cells	I-C1321301
.	O
	
the	O
novel	O
european	B-C0015176
study	B-C2603343
to	O
establish	O
biomarkers	B-C0005516
of	O
human	B-C0002045
ageing	I-C0002045
mark-age	I-C0002045
algorithm	I-C0002045
,	O
evaluating	B-C0220825
the	O
biological	B-C0205460
age	B-C0001779
,	O
is	O
currently	O
assessed	O
in	O
hiv-infected	B-C0019693
patients	B-C0030705
and	O
reveals	O
an	O
advanced	O
biological	B-C0205460
age	B-C0001779
.	O
	
some	O
enhanced	O
inflammatory	B-C0333348
or	O
innate	B-C0020969
immune	I-C0020969
activation	B-C1879547
markers	B-C0005516
are	O
interesting	O
but	O
still	O
not	O
validated	O
for	O
the	O
patient's	B-C0030705
follow-up	B-C1522577
.	O
	
to	O
be	O
able	O
to	O
assess	O
patients	B-C0030705
'	O
biological	B-C0205460
age	B-C0001779
is	O
an	O
important	O
objective	O
to	O
improve	O
their	O
mesothelial	B-C0225335
cell	I-C0225335
adherence	B-C0334154
to	O
vascular	B-C0005846
prostheses	I-C0005846
and	O
their	O
subsequent	B-C0332282
growth	B-C0018270
in	B-C1533691
vitro	I-C1533691
cell	B-C0007634
seeding	B-C1705192
may	O
decrease	B-C0547047
the	O
thrombogenicity	B-C0040053
of	O
implanted	B-C0021102
vascular	B-C0879126
grafts	I-C0879126
,	O
but	O
its	O
application	O
is	O
hampered	O
by	O
the	O
limited	O
availability	B-C0470187
of	I-C0470187
autologous	B-C0439859
endothelial	B-C0225336
cells	I-C0225336
.	O
	
human	B-C0086418
peritoneal	B-C0442034
mesothelial	B-C0225335
cells	I-C0225335
have	O
blood	B-C0232338
flow	I-C0232338
supporting	B-C0332306
qualities	I-C0332306
and	O
are	O
readily	B-C0470187
available	I-C0470187
.	O
	
this	O
study	O
investigated	B-C1292732
the	O
adherence	B-C0334154
of	O
mesothelial	B-C0225335
cells	I-C0225335
to	O
vascular	B-C0005846
prostheses	I-C0005846
and	O
their	O
subsequent	B-C0332282
growth	B-C0018270
in	B-C1533691
vitro	I-C1533691
.	O
	
circular	B-C1282913
pieces	B-C2982836
of	O
various	O
vascular	B-C1801960
prosthetic	B-C0444752
materials	I-C0444752
were	O
seeded	B-C1705192
with	O
51chromium-labeled	B-C0303212
mesothelial	B-C0225335
and	O
endothelial	B-C0225336
cells	I-C0225336
and	O
left	O
for	O
either	O
5	O
,	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
120	O
minutes	B-C0439232
.	O
	
the	O
unattached	B-C3841381
cells	B-C0007634
were	O
removed	B-C0849355
and	O
the	O
degree	B-C0449286
of	O
cell	B-C0007634
attachment	B-C1947904
was	O
measured	B-C0444706
.	O
	
the	O
number	B-C0237753
of	O
mesothelial	B-C0225335
cells	I-C0225335
to	O
dacron	B-C0947693
increased	B-C0205217
during	O
the	O
first	O
60	O
min	B-C0439232
up	O
to	O
35.2	O
%	O
of	O
the	O
seeded	B-C1705192
inoculum	B-C0439861
where	O
after	O
a	O
plateau	B-C2964353
was	O
reached	B-C0243095
.	O
	
scanning	B-C0026020
electron	I-C0026020
microscopy	I-C0026020
showed	O
spreaded	B-C0332261
mesothelial	B-C0225335
cells	I-C0225335
adherent	B-C0334154
to	O
the	O
dacron	B-C0947693
fibers	I-C0947693
.	O
	
a	O
significant	B-C0750502
increase	B-C0442805
in	O
adherence	B-C0334154
was	O
observed	B-C1441672
after	O
preincubation	B-C0022885
of	O
dacron	B-C0947693
with	O
10	O
μg/ml	O
fibronectin	B-C0016055
,	O
but	O
no	B-C3844714
improvement	I-C3844714
was	O
found	B-C0150312
after	O
preincubation	B-C0022885
with	O
human	B-C0086418
serum	B-C0036773
albumin	I-C0036773
or	O
gelatin	B-C0017237
.	O
	
mesothelial	B-C0225335
cells	I-C0225335
adhered	B-C3714578
better	O
to	O
gelcoated	B-C1522408
than	O
to	O
gelsealed	B-C0205556
or	O
plain	B-C0947693
dacron	I-C0947693
.	O
	
the	O
adherence	B-C0334154
of	O
mesothelial	B-C0225335
cells	I-C0225335
to	O
eptfe	B-C0015312
teflon	B-C0699518
was	O
significantly	B-C0750502
poorer	B-C2700379
.	O
	
no	B-C1273937
significant	I-C1273937
differences	B-C1705242
in	O
adherence	B-C0334154
were	O
found	B-C0150312
between	O
mesothelial	B-C0225335
and	O
endothelial	B-C0225336
cells	I-C0225336
.	O
	
mesothelial	B-C0225335
cell	I-C0225335
growth	B-C0018270
on	O
dacron	B-C0947693
resulted	B-C1274040
in	O
a	O
modest	B-C0442805
increase	I-C0442805
in	O
the	O
number	B-C0237753
of	O
viable	B-C1441322
cells	I-C1441322
during	O
27	O
days	B-C0439228
,	O
which	O
implies	O
biocompatibility	B-C0596177
of	O
dacron	B-C0947693
and	O
mesothelial	B-C0225335
cells	I-C0225335
in	B-C1533691
vitro	I-C1533691
.	O
	
anterolateral	B-C0332194
entorhinal	B-C0175196
cortex	I-C0175196
volume	B-C0449468
predicted	O
by	O
altered	O
intra-item	B-C0449335
configural	I-C0449335
processing	I-C0449335
recent	O
functional	O
imaging	B-C1881134
studies	I-C1881134
have	O
proposed	O
that	O
the	O
human	B-C0086418
entorhinal	B-C0175196
cortex	I-C0175196
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	B-C0332194
alerc	B-C0175196
and	O
posteromedial	B-C1179848
pmerc	B-C0175196
subregions	B-C0005898
.	O
	
the	O
alerc	B-C0175196
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
alzheimer's	B-C0002395
disease	I-C0002395
pathology	B-C0677042
,	O
yet	O
its	O
cognitive	B-C0392335
function	I-C0392335
remains	O
poorly	O
understood	O
.	O
	
previous	O
human	B-C0086418
fmri	B-C0376335
studies	I-C0376335
have	O
focused	O
on	O
its	O
role	O
in	O
object	B-C0347997
memory	B-C0025260
,	O
but	O
rodent	B-C0035804
studies	B-C0683949
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal	B-C0175196
cortex	I-C0175196
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial	B-C0012727
properties	I-C0012727
of	O
objects	B-C0347997
.	O
	
in	O
order	O
to	O
investigate	O
the	O
cognitive	B-C0935657
effects	I-C0935657
of	O
human	B-C0086418
alerc	B-C0175196
volume	B-C0449468
differences	O
,	O
we	O
developed	O
an	O
eyetracking-based	O
task	O
to	O
evaluate	B-C0220825
intra-item	B-C0449335
configural	I-C0449335
processing	I-C0449335
i.e	O
,	O
processing	B-C1709694
the	O
arrangement	B-C0449830
of	O
an	O
object's	B-C0347997
features	O
,	O
and	O
used	O
manual	B-C0700381
segmentation	I-C0700381
based	O
on	O
a	O
recently-	O
developed	B-C2348563
protocol	I-C2348563
to	O
delineate	O
the	O
alerc	B-C0175196
/	O
pmerc	B-C0175196
as	O
well	O
as	O
other	O
medial	B-C0039485
temporal	I-C0039485
lobe	I-C0039485
mtl	B-C0039485
subregions	B-C0005898
.	O
	
in	O
a	O
group	O
of	O
older	O
adult	B-C0001675
men	B-C0025266
and	O
women	B-C0043210
at	O
varying	O
stages	B-C1306673
of	O
brain	B-C0235946
atrophy	I-C0235946
and	O
cognitive	B-C0234985
decline	I-C0234985
,	O
we	O
found	O
that	O
intra-item	B-C0449335
configural	I-C0449335
processing	I-C0449335
-	O
regardless	O
of	O
an	O
object's	B-C0347997
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alerc	B-C0175196
volume	B-C0449468
,	O
but	O
not	O
by	O
the	O
volume	B-C0449468
of	O
any	O
other	O
mtl	B-C0039485
subregion	I-C0039485
.	O
	
these	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	B-C0086418
alerc	B-C0175196
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	B-C0347997
processing	B-C1709694
,	O
namely	O
attending	O
to	O
the	O
arrangement	B-C0449830
of	O
an	O
object's	B-C0347997
component	O
features.significance	O
statement	O
alzheimer's	B-C0002395
disease	I-C0002395
pathology	B-C0677042
appears	O
earliest	O
in	O
brain	B-C1273723
regions	I-C1273723
that	O
overlap	O
with	O
the	O
anterolateral	B-C0332194
entorhinal	B-C0175196
cortex	I-C0175196
alerc	B-C0175196
.	O
	
however	O
,	O
the	O
cognitive	B-C0009240
role	I-C0009240
of	O
the	O
alerc	B-C0175196
is	O
poorly	O
understood	O
.	O
	
previous	O
human	B-C0178693
studies	I-C0178693
treat	B-C0087111
the	O
alerc	B-C0175196
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal	B-C2326929
cortex	I-C2326929
,	O
supporting	O
object	B-C0347997
memory	B-C0025260
.	O
	
animal	B-C0683949
studies	I-C0683949
suggest	O
that	O
the	O
alerc	B-C0175196
may	O
support	O
the	O
spatial	B-C0012727
properties	I-C0012727
of	O
objects	B-C0347997
.	O
	
in	O
a	O
group	O
of	O
older	O
adult	B-C0001675
humans	B-C0086418
at	O
the	O
earliest	B-C2363430
stages	I-C2363430
of	O
cognitive	B-C0234985
decline	I-C0234985
,	O
we	O
show	O
that	O
alerc	B-C0175196
volume	B-C0449468
selectively	O
predicted	O
configural	B-C0449335
processing	I-C0449335
attention	B-C0004268
to	O
the	O
spatial	B-C0449830
arrangement	I-C0449830
of	O
an	O
object's	B-C0347997
parts	O
.	O
	
this	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive	B-C0009240
role	I-C0009240
related	O
to	O
alerc	B-C0175196
volume	B-C0449468
in	O
humans	B-C0086418
.	O
	
this	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early	B-C0449335
detection	I-C0449335
method	I-C0449335
for	O
alzheimer's	B-C0002395
disease	I-C0002395
pathology	B-C0677042
.	O
	
alcohol	B-C3494740
brief	I-C3494740
intervention	I-C3494740
in	O
primary	B-C0033137
care	I-C0033137
blood	B-C0005823
pressure	I-C0005823
outcomes	B-C2015879
in	O
hypertensive	B-C0020538
patients	B-C0030705
in	O
clinical	B-C0008976
trials	I-C0008976
alcohol	B-C3494740
brief	I-C3494740
intervention	I-C3494740
bi	B-C3494740
in	O
adult	B-C0001675
primary	B-C0033137
care	I-C0033137
has	O
been	O
efficacious	B-C1704419
in	O
reducing	B-C0392756
alcohol	B-C0001948
consumption	I-C0001948
,	O
but	O
we	O
know	O
little	O
about	O
its	O
impact	B-C4049986
on	O
health	B-C0085415
outcomes	I-C0085415
.	O
	
hypertension	B-C0020538
is	O
a	O
prevalent	O
and	O
costly	O
chronic	B-C4315615
condition	I-C4315615
in	O
the	O
u.s	B-C0041703
.	O
	
and	O
worldwide	B-C2348867
,	O
and	O
alcohol	B-C0001948
use	I-C0001948
is	O
a	O
modifiable	O
hypertension	B-C0020538
risk	B-C0035648
factor	I-C0035648
.	O
	
to	O
evaluate	O
the	O
effect	B-C1280500
of	O
receiving	O
bi	B-C3494740
for	O
unhealthy	B-C4303858
drinking	I-C4303858
on	O
blood	B-C1753303
pressure	I-C1753303
bp	I-C1753303
control	I-C1753303
among	O
adult	B-C0001675
hypertensive	B-C0020538
patients	B-C0030705
by	O
analyzing	B-C0683944
secondary	I-C0683944
data	I-C0683944
from	O
a	O
clustered	B-C0009085
,	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
on	O
alcohol	B-C0420032
screening	I-C0420032
,	O
brief	B-C0814459
intervention	I-C0814459
and	O
referral	B-C0814457
to	I-C0814457
treatment	I-C0814457
sbirt	B-C1254363
implementation	B-C1708476
by	O
primary	B-C0033131
care	I-C0033131
physicians	I-C0033131
pcp	B-C0033131
intervention	I-C0033131
arm	I-C0033131
and	O
non-physician	B-C0027363
providers	I-C0027363
and	O
medical	B-C0334914
assistants	I-C0334914
npp	B-C0027363
ma	B-C0334914
intervention	I-C0334914
arm	I-C0334914
in	O
a	O
large	O
,	O
integrated	B-C0282599
health	I-C0282599
care	I-C0282599
delivery	I-C0282599
system	I-C0282599
.	O
	
observational	B-C1518527
,	O
prospective	B-C1709709
cohort	I-C1709709
study	I-C1709709
.	O
	
3811	O
adult	B-C0001675
hypertensive	B-C0020538
primary	B-C0030705
care	I-C0030705
patients	I-C0030705
screening	B-C1710032
positive	O
for	O
past-year	B-C4086728
heavy	B-C0687132
drinking	I-C0687132
at	O
baseline	B-C1442488
,	O
of	O
which	O
1422	O
37%	O
had	O
an	O
electronic	B-C2362543
health	I-C2362543
record	I-C2362543
bp	B-C0005823
measure	O
at	O
baseline	B-C1442488
and	O
18-month	B-C0439231
follow-up	B-C1522577
.	O
	
change	B-C1268766
in	I-C1268766
bp	I-C1268766
and	O
controlled	B-C1753303
bp	I-C1753303
systolic/diastolic	B-C2704328
bp	I-C2704328
<140/90	O
mmhg	B-C0439475
.	O
	
overall	O
no	O
significant	O
associations	B-C0439849
were	O
found	O
between	O
alcohol	B-C3494740
bi	I-C3494740
and	O
bp	B-C1268766
change	I-C1268766
at	O
18-month	B-C0439231
follow-up	B-C1522577
when	O
analyzing	O
the	O
combined	O
sample	O
of	O
subjects	B-C0080105
in	O
both	O
intervention	B-C0027363
arms	I-C0027363
.	O
	
however	O
,	O
moderation	O
analyses	O
found	O
that	O
receiving	O
bi	B-C3494740
for	O
positive	O
past-year	B-C4086728
unhealthy	B-C4303858
drinking	I-C4303858
was	O
positively	O
associated	B-C0332281
with	I-C0332281
better	O
bp	B-C1753303
control	I-C1753303
at	O
18months	B-C0439231
in	O
the	O
pcp	B-C0033131
intervention	I-C0033131
arm	I-C0033131
,	O
and	O
for	O
those	O
with	O
lower	O
heavy	B-C0687132
drinking	I-C0687132
frequency	B-C0439603
and	O
poor	O
bp	B-C1753303
control	I-C1753303
at	O
the	O
index	B-C1710032
screening	I-C1710032
.	O
	
our	O
findings	O
suggest	O
that	O
hypertensive	B-C0020538
patients	B-C0030705
may	O
benefit	B-C0814225
from	O
receiving	O
physician	B-C0031831
brief	B-C0814459
intervention	I-C0814459
for	O
unhealthy	B-C4303858
alcohol	I-C4303858
use	I-C4303858
in	O
primary	B-C0033137
care	I-C0033137
.	O
	
findings	O
also	O
highlight	O
potential	O
population-level	B-C0814225
benefits	I-C0814225
of	O
alcohol	B-C3494740
bi	I-C3494740
if	O
widely	O
applied	O
,	O
suggesting	O
a	O
need	O
for	O
the	O
development	O
of	O
innovative	O
strategies	O
to	O
facilitate	O
sbirt	B-C1254363
delivery	I-C1254363
in	O
primary	B-C0033137
care	I-C0033137
unusual	B-C2700116
asymptomatic	B-C0275522
presentation	I-C0275522
of	O
bladder	B-C0005695
cancer	I-C0005695
metastatic	B-C0347002
to	I-C0347002
the	I-C0347002
penis	I-C0347002
penile	B-C0347002
metastasis	I-C0347002
is	O
an	O
extremely	B-C0678236
rare	I-C0678236
event	I-C0678236
and	O
mainly	O
originate	O
from	O
primary	O
pelvic	B-C0030797
tumor	B-C0475445
sites	I-C0475445
such	O
us	O
urinary	B-C0005682
bladder	I-C0005682
,	O
gastro-intestinal	B-C0017189
tract	I-C0017189
and	O
prostate	B-C0033572
and	O
more	O
rarely	O
from	O
respiratory	B-C0035237
system	I-C0035237
,	O
bone	B-C0005967
tumors	I-C0005967
and	O
melanoma	B-C0025202
.	O
	
here	O
we	O
describe	O
the	O
unusual	B-C2700116
presentation	B-C0449450
of	O
two	O
bladder	B-C0751571
urothelial	I-C0751571
cancer	I-C0751571
metastatic	B-C0036525
to	I-C0036525
the	O
penis	B-C0030851
with	O
no	B-C0231221
relevant	I-C0231221
clinical	I-C0231221
symptoms	I-C0231221
.	O
	
namely	O
,	O
a	O
69	O
years-old	O
man	O
with	O
a	O
warthy	O
lesions	B-C0221198
of	O
the	O
foreskin	B-C0545925
and	I-C0545925
the	I-C0545925
glans	I-C0545925
misunderstood	O
for	O
a	O
condylomata	B-C0302180
that	O
at	O
histological	B-C0019637
and	O
immunohistochemical	B-C1441616
analysis	I-C1441616
showed	O
a	O
bladder	B-C2145472
urothelial	I-C2145472
carcinoma	I-C2145472
and	O
a	O
71	O
years-old	O
man	O
with	O
reddish	B-C1260956
skin	B-C2168434
lesion	I-C2168434
of	I-C2168434
the	I-C2168434
glans	I-C2168434
,	O
a	O
previous	O
history	B-C0567322
of	I-C0567322
bladder	I-C0567322
and	O
urethral	B-C2145472
carcinoma	I-C2145472
and	O
histological	B-C1335292
pagetoid	I-C1335292
spread	I-C1335292
of	O
urothelial	B-C2145472
cancer	I-C2145472
to	B-C0227948
the	I-C0227948
glans	I-C0227948
.	O
	
recurrent	B-C0278827
bladder	I-C0278827
urothelial	I-C0278827
carcinoma	I-C0278827
is	O
usually	O
a	O
visceral	B-C0042779
disease	B-C0012634
that	O
rarely	O
presents	O
as	O
a	O
superficial	O
asymptomatic	B-C0231221
skin	B-C0037284
lesion	I-C0037284
.	O
	
the	O
two	O
reported	O
cases	B-C0231221
were	I-C0231221
asymptomatic	I-C0231221
superficial	B-C0347002
penis	I-C0347002
metastases	I-C0347002
with	O
a	O
relatively	O
slow	O
growth	O
and	O
a	O
fairy	B-C0278250
good	I-C0278250
prognosis	I-C0278250
after	O
conservative	B-C0449446
surgical	I-C0449446
approach	I-C0449446
.	O
	
accurate	O
clinical	B-C0242803
examination	I-C0242803
of	I-C0242803
the	I-C0242803
penis	I-C0242803
is	I-C0242803
mandatory	I-C0242803
for	I-C0242803
males	I-C0242803
with	O
history	B-C0567322
of	I-C0567322
bladder	I-C0567322
cancer	I-C0567322
.	O
	
the	O
bachelorette	O
female	B-C0086287
siamese	B-C0599049
fighting	I-C0599049
fish	I-C0599049
avoid	B-C0443288
males	B-C0086582
exposed	B-C0332157
to	I-C0332157
an	O
estrogen	B-C0014939
mimic	B-C0205245
due	O
to	O
improper	B-C3827420
disposal	B-C1707797
and	O
a	O
lack	B-C0332268
of	O
removal	B-C1883720
during	O
the	O
wastewater	B-C3494254
treatment	B-C1522326
process	I-C1522326
,	O
endocrine	B-C0521425
disrupting	B-C0332454
chemicals	B-C0220806
enter	O
aquatic	B-C0563034
ecosystems	I-C0563034
where	O
they	O
exert	O
detrimental	O
effects	B-C1280500
on	O
fish	B-C0016163
behavior	B-C0004927
and	O
physiology	B-C0031843
.	O
	
perhaps	O
the	O
most	O
well-studied	O
and	O
prevalent	B-C0220900
edc	B-C0220806
is	O
17α-ethinylestradiol	B-C0015011
ee2	B-C0015011
,	O
an	O
active	O
ingredient	B-C1550600
in	O
oral	B-C0009905
contraceptives	I-C0009905
,	O
which	O
is	O
known	O
to	O
cause	O
dramatic	O
reductions	B-C0392756
in	O
male	B-C0086582
-typical	O
behaviors	B-C0004927
.	O
	
while	O
it	O
is	O
likely	O
that	O
alterations	B-C1515926
in	O
male	B-C0086582
courtship	B-C0237548
behavior	B-C0004927
decrease	B-C0547047
reproductive	B-C2717777
fitness	I-C2717777
,	O
this	O
is	O
rarely	O
explicitly	O
examined	O
.	O
	
to	O
this	O
end	O
,	O
whether	O
ee2	B-C0015011
exposure	B-C0332157
reduces	B-C0392756
male	B-C0086582
attractiveness	B-C0871078
to	O
female	B-C0086287
siamese	B-C0599049
fighting	I-C0599049
fish	I-C0599049
,	O
betta	B-C0599049
splendens	I-C0599049
,	O
was	O
investigated	B-C1292732
by	O
showing	O
females	B-C0086287
video	B-C3463807
images	B-C1704922
of	O
exposed	B-C2348484
and	O
unexposed	B-C2349018
males	B-C0086582
.	O
	
females	B-C0086287
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
exposure	B-C0332157
conditions	B-C0348080
exposed	B-C0332157
to	I-C0332157
ee2	B-C0015011
,	O
control	B-C0009932
and	O
each	O
subject	B-C0681850
then	O
viewed	O
four	B-C0205450
different	B-C1705242
video	B-C3463807
combinations	B-C0205195
of	O
male	B-C0086582
conspecifics	B-C1510537
courting	B-C0237548
exposed	B-C2348484
+	O
exposed	B-C2348484
courting	B-C0237548
unexposed	B-C2349018
+	O
unexposed	B-C2349018
courting	B-C0237548
unexposed	B-C2349018
+	O
exposed	B-C2348484
swimming	B-C0039003
unexposed	B-C2349018
+	O
exposed	B-C2348484
.	O
	
females	B-C0086287
,	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
were	O
exposed	B-C0332157
to	I-C0332157
ee2	B-C0015011
,	O
directed	O
markedly	O
less	O
behavior	B-C0004927
towards	O
exposed	B-C2348484
males	B-C0086582
,	O
especially	O
when	O
they	O
viewed	O
an	O
exposed	B-C2348484
male	B-C0086582
and	O
an	O
unexposed	B-C2349018
male	B-C0086582
simultaneously	B-C0521115
.	O
	
these	O
findings	O
demonstrate	O
that	O
ee2	B-C0015011
can	O
have	O
significant	B-C0750502
individual	B-C0205171
-	O
and	O
population-level	B-C1257890
consequences	B-C0686907
on	O
fitness	B-C0031812
by	O
disrupting	B-C0332454
sexual	B-C0024909
selection	I-C0024909
and	O
,	O
ultimately	O
,	O
the	O
success	B-C0597535
of	O
exposed	B-C2348484
males	B-C0086582
.	O
	
targeting	B-C1521840
accuracy	B-C0443131
of	O
single-isocenter	B-C1881275
intensity-modulated	B-C1512814
radiosurgery	B-C0085203
for	O
multiple	O
lesions	B-C0221198
to	O
investigate	B-C1292732
the	O
targeting	B-C1521840
accuracy	B-C0443131
of	O
intensity-modulated	B-C1512814
srs	B-C0085203
imrs	B-C0085203
plans	B-C0599880
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	B-C0006104
metastases	B-C4255448
with	O
a	O
single	B-C1881275
isocenter	I-C1881275
.	O
	
a	O
home-made	B-C0001222
acrylic	I-C0001222
phantom	B-C0282611
able	O
to	O
support	O
a	O
film	B-C1561572
ebt3	B-C1561572
in	O
its	O
coronal	B-C0205123
plane	I-C0205123
was	O
used	O
.	O
	
the	O
phantom	B-C0282611
was	O
ct	B-C0040405
scanned	I-C0040405
and	O
three	O
coplanar	O
small	O
targets	B-C1521840
a	O
central	B-C0205099
and	O
two	O
peripheral	B-C0205100
were	O
outlined	O
in	O
the	O
eclipse	B-C2363849
system	I-C2363849
.	O
	
peripheral	B-C0205100
targets	B-C1521840
were	O
6	O
cm	O
apart	O
from	O
the	O
central	B-C0205099
one	O
.	O
	
a	O
reference	O
imrs	B-C0085203
plan	B-C0599880
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	B-C1521840
,	O
but	O
only	O
a	O
single	B-C1881275
isocenter	I-C1881275
located	O
at	O
the	O
center	O
of	O
the	O
central	B-C0205099
target	B-C1521840
was	O
used	O
.	O
	
after	O
positioning	B-C1550045
the	O
phantom	B-C0282611
on	O
the	O
linac	B-C0023730
using	O
the	O
room	B-C1547703
lasers	B-C0023089
,	O
a	O
cbct	B-C0040405
scan	I-C0040405
was	O
acquired	O
and	O
the	O
reference	O
plan	B-C0599880
were	O
mapped	B-C1283195
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	B-C1881275
at	O
the	O
intersection	B-C1555443
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	B-C1561572
showing	O
the	O
linac	B-C0023730
isocenter	B-C1881275
.	O
	
the	O
mapped	B-C1283195
plan	B-C0599880
was	O
then	O
recalculated	B-C1441506
and	O
delivered	B-C1705822
.	O
	
the	O
film	B-C1561572
dose	B-C0087111
distribution	I-C0087111
was	O
derived	O
using	O
a	O
cloud	B-C3873720
computing	I-C3873720
application	I-C3873720
www.radiochromic	B-C3873720
that	O
uses	O
a	O
triple-channel	O
dosimetry	B-C0016103
algorithm	B-C0002045
.	O
	
comparison	O
of	O
dose	B-C0087111
distributions	I-C0087111
using	O
the	O
gamma	B-C1708185
index	I-C1708185
5%/1	O
mm	O
were	O
performed	O
over	O
a	O
5	O
5	O
cm	O
region	O
centered	O
over	O
each	O
target	B-C1521840
.	O
	
2d	B-C0333051
shifts	I-C0333051
required	O
to	O
get	O
the	O
best	O
gamma	B-C0017011
passing	O
rates	O
on	O
the	O
peripheral	B-C0205100
target	B-C1521840
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	B-C0205099
target	B-C1521840
.	O
	
the	O
experiment	B-C0681814
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	B-C0481503
.	O
	
average	O
2d	B-C0333051
shifts	I-C0333051
required	O
to	O
achieve	O
optimal	O
gamma	B-C0017011
passing	O
rates	O
99%	O
,	O
97%	O
,	O
99%	O
were	O
0.7	O
mm	O
sd	O
0.3	O
mm	O
,	O
0.8	O
mm	O
sd	O
0.4	O
mm	O
and	O
0.8	O
mm	O
sd	O
0.3	O
mm	O
,	O
for	O
the	O
central	B-C0205099
and	O
the	O
two	O
peripheral	B-C0205100
targets	B-C1521840
,	O
respectively	O
.	O
	
no	O
statistical	O
differences	O
p	O
>	O
0.05	O
were	O
found	O
for	O
targeting	B-C1521840
accuracy	B-C0443131
between	O
the	O
central	B-C0205099
and	O
the	O
two	O
peripheral	B-C0205100
targets	B-C1521840
.	O
	
the	O
study	B-C2603343
revealed	O
a	O
targeting	B-C1521840
accuracy	B-C0443131
within	O
1	O
mm	O
for	O
off-	O
isocenter	B-C1881275
targets	B-C1521840
within	O
6	O
cm	O
of	O
the	O
linac	B-C0023730
isocenter	B-C1881275
,	O
when	O
a	O
single-isocenter	B-C1881275
imrs	B-C0085203
plan	B-C0599880
physical	B-C0026606
activity	I-C0026606
limits	B-C0439801
the	O
effects	B-C1704420
of	I-C1704420
age	B-C0001779
and	O
alzheimer's	B-C0002395
disease	I-C0002395
on	O
postural	B-C0683212
control	I-C0683212
the	O
aim	B-C1947946
was	O
to	O
study	O
the	O
possible	O
influence	B-C4054723
of	O
physical	B-C0026606
activity	I-C0026606
on	O
the	O
postural	B-C0205278
performance	B-C1882330
of	O
subjects	B-C2349001
with	O
alzheimer's	B-C0002395
disease	I-C0002395
ad	B-C0002395
.	O
	
the	O
postural	B-C0205278
performance	B-C1882330
i.e	O
.	O
	
surface	B-C4263416
area	I-C4263416
of	O
the	O
center	B-C0012727
of	I-C0012727
foot	I-C0012727
pressure	I-C0012727
displacement	I-C0012727
of	O
3	O
groups	B-C0441833
was	O
compared	B-C1707455
alzheimer	B-C0441833
active	I-C0441833
group	I-C0441833
aa	B-C0441833
,	O
alzheimer	B-C0441833
non-active	I-C0441833
group	I-C0441833
ana	B-C0441833
and	O
healthy	B-C0441833
non-active	I-C0441833
group	I-C0441833
hna	B-C0441833
.	O
	
the	O
aa	B-C1257890
group's	I-C1257890
postural	B-C0205278
performance	B-C1882330
was	O
superior	B-C1282910
to	O
that	O
of	O
the	O
ana	B-C0441833
and	O
hna	B-C0441833
groups	I-C0441833
.	O
	
ad	B-C0002395
disturbed	O
postural	B-C0205278
performance	B-C1882330
but	O
participation	B-C0679823
in	O
regular	B-C0205272
physical	B-C0026606
activity	I-C0026606
made	O
it	O
possible	O
to	O
limit	B-C0439801
the	O
disturbing	B-C1280500
effects	I-C1280500
of	O
ad	B-C0002395
to	O
a	O
surprising	O
extent	O
,	O
since	O
the	O
postural	B-C0205278
performance	B-C1882330
of	O
active	B-C0080105
ad	I-C0080105
subjects	I-C0080105
was	O
also	O
superior	B-C1282910
to	O
that	O
of	O
healthy	B-C1708335
subjects	I-C1708335
.	O
	
lamp-2	B-C1563373
mediates	O
oxidative	B-C0242606
stress	I-C0242606
-dependent	O
cell	B-C0007587
death	I-C0007587
in	O
zn	B-C2346521
-	O
treated	B-C0087111
lung	B-C0024109
epithelium	B-C0014597
cells	I-C0014597
zinc	B-C0043481
is	O
an	O
essential	O
element	B-C0013879
for	O
the	O
biological	B-C0460002
system	I-C0460002
.	O
	
however	O
,	O
excessive	O
exogenous	B-C0205228
zn	B-C2346521
would	O
disrupt	O
cellular	B-C2263139
zn	I-C2263139
homeostasis	I-C2263139
and	O
cause	B-C0600688
toxicity	I-C0600688
.	O
	
in	O
particular	O
,	O
zinc	B-C0351669
salts	I-C0351669
or	O
zno	B-C0043491
nanoparticles	B-C1450054
exposure	O
could	O
induce	O
respiratory	B-C0560313
injury	I-C0560313
.	O
	
although	O
previous	O
studies	O
have	O
indicated	O
that	O
organelle	B-C0029219
damage	B-C0599732
including	O
mitochondria	B-C0026237
or	O
lysosomes	B-C0024369
and	O
reactive	B-C0162772
oxygen	I-C0162772
species	I-C0162772
ros	B-C0162772
production	O
are	O
involved	O
in	O
zn	B-C2346521
-induced	O
toxicity	B-C0600688
,	O
the	O
interplay	O
between	O
mitochondria	B-C0026237
/	O
lysosomes	B-C0024369
damage	B-C0599732
and	O
ros	B-C0162772
production	O
is	O
obscure	O
.	O
	
herein	O
,	O
we	O
demonstrated	O
that	O
zn	B-C2346521
could	O
induce	O
deglycosylation	B-C1157972
of	O
lysosome-associated	B-C3539735
membrane	I-C3539735
protein	I-C3539735
1	I-C3539735
and	O
2	B-C1563373
lamp-1	B-C3539735
and	O
lamp-2	B-C1563373
,	O
which	O
primarily	O
locate	O
in	O
late	O
endosomes	B-C0034850
/	O
lysosomes	B-C0024369
,	O
in	O
a549	B-C0014597
lung	I-C0014597
epithelium	I-C0014597
cells	I-C0014597
.	O
	
intriguingly	O
,	O
lamp-2	B-C1416790
knockdown	B-C2350567
further	O
aggravated	B-C1444749
zn	B-C2346521
-mediated	O
ros	B-C0162772
production	O
and	O
cell	B-C0007587
death	I-C0007587
,	O
indicating	O
lamp-2	B-C1563373
not	O
lamp-1	B-C3539735
was	O
involved	O
in	O
zn	B-C2346521
-induced	O
toxicity	B-C0600688
.	O
	
our	O
results	O
provide	O
a	O
new	O
insight	O
that	O
lamp-2	B-C1563373
contributes	O
to	O
the	O
ros	B-C0162772
clearance	O
and	O
cell	B-C0007587
death	I-C0007587
induced	O
by	O
zn	B-C2346521
treatment	B-C0087111
,	O
which	O
would	O
help	O
us	O
to	O
get	O
a	O
better	O
understanding	O
of	O
zn	B-C2346521
-induced	O
toxicity	B-C0600688
in	O
respiratory	B-C0035237
system	I-C0035237
.	O
	
fluorescence	B-C0430022
hyperspectral	I-C0430022
imaging	I-C0430022
fhsi	B-C0430022
using	O
a	O
spectrally	B-C0205556
resolved	B-C3714811
detector	B-C0025080
array	I-C0025080
the	O
ability	O
to	O
resolve	B-C2699488
multiple	B-C0439064
fluorescent	B-C1522240
emissions	I-C1522240
from	O
different	B-C1705242
biological	B-C0205460
targets	B-C1521840
in	O
video	B-C0869019
rate	I-C0869019
applications	I-C0869019
,	O
such	O
as	O
endoscopy	B-C0014245
and	O
intraoperative	B-C3898703
imaging	I-C3898703
,	O
has	O
traditionally	O
been	O
limited	B-C0439801
by	O
the	O
use	O
of	O
filter-based	B-C0205556
imaging	B-C0025080
systems	I-C0025080
.	O
	
hyperspectral	B-C0430022
imaging	I-C0430022
hsi	B-C0430022
facilitates	O
the	O
detection	B-C1511790
of	O
both	O
spatial	B-C0037775
and	O
spectral	B-C1883073
information	B-C1533716
in	O
a	O
single	B-C0441655
data	I-C0441655
acquisition	I-C0441655
,	O
however	O
,	O
instrumentation	B-C0021632
for	O
hsi	B-C0430022
is	O
typically	O
complex	B-C0439855
,	O
bulky	B-C0392762
and	O
expensive	B-C0205556
.	O
	
we	O
sought	O
to	O
overcome	B-C2983310
these	O
limitations	B-C0449295
using	O
a	O
novel	B-C0205314
robust	B-C2986815
and	O
low	B-C0392762
cost	I-C0392762
hsi	B-C0430022
camera	B-C0179533
based	O
on	O
a	O
spectrally	B-C0025080
resolved	I-C0025080
detector	I-C0025080
array	I-C0025080
srda	B-C0025080
.	O
	
we	O
integrated	B-C1705422
this	O
hsi	B-C0430022
camera	B-C0179533
into	O
a	O
wide-field	B-C0243095
reflectance-based	B-C1514813
imaging	B-C2697665
system	I-C2697665
operating	B-C0205245
in	O
the	O
near-infrared	B-C1532326
range	B-C1514721
to	O
assess	B-C0184514
the	O
suitability	O
for	O
in	B-C1708481
vivo	I-C1708481
imaging	I-C1708481
of	O
exogenous	B-C0205228
fluorescent	B-C0009924
contrast	I-C0009924
agents	I-C0009924
.	O
	
using	O
this	O
fluorescence	B-C0430022
hsi	I-C0430022
fhsi	B-C0430022
system	B-C0449913
,	O
we	O
were	O
able	O
to	O
accurately	B-C0443131
resolve	B-C2699488
the	O
presence	B-C3854307
and	O
concentration	B-C1446561
of	O
at	O
least	O
7	O
fluorescent	B-C0016320
dyes	I-C0016320
in	O
solution	B-C0037633
.	O
	
we	O
also	O
demonstrate	O
high	B-C0205250
spectral	B-C2827423
unmixing	I-C2827423
precision	B-C1706245
,	O
signal	B-C1710082
linearity	B-C0205556
with	O
dye	B-C0013343
concentration	B-C1446561
and	O
at	O
depth	B-C0205125
in	O
tissue	B-C0040300
mimicking	B-C4042849
phantoms	B-C0282611
,	O
and	O
delineate	B-C0243095
4	O
fluorescent	B-C0016320
dyes	I-C0016320
in	B-C1515655
vivo	I-C1515655
.	O
	
our	O
approach	O
,	O
including	B-C0332257
statistical	B-C0205556
background	B-C1706907
removal	O
,	O
could	O
be	O
directly	B-C1947931
generalised	B-C0205246
to	O
broader	B-C1138667
spectral	I-C1138667
ranges	B-C1514721
,	O
for	O
example	O
,	O
to	O
resolve	B-C2699488
tissue	B-C0040300
reflectance	B-C1514813
or	O
autofluorescence	B-C0544711
and	O
in	O
future	B-C0016884
be	O
tailored	O
to	O
video	B-C0869019
rate	I-C0869019
applications	I-C0869019
requiring	O
snapshot	O
hsi	B-C0430022
data	B-C0441655
acquisition	I-C0441655
.	O
	
biochemical	B-C0205474
studies	B-C2603343
of	O
amylase	B-C0002712
,	O
lipase	B-C0023764
and	O
protease	B-C0030940
in	O
callosobruchus	B-C1024702
maculatus	I-C1024702
coleoptera	B-C0009276
chrysomelidae	B-C1001499
populations	B-C1257890
fed	O
with	O
vigna	B-C0996865
unguiculata	I-C0996865
grain	B-C0007757
cultivated	B-C0242481
with	O
diazotrophic	B-C0004611
bacteria	I-C0004611
strains	I-C0004611
the	O
objective	O
of	O
this	O
study	B-C2603343
was	O
to	O
evaluate	O
the	O
enzymatic	B-C0243102
activity	I-C0243102
of	O
homogenates	B-C3829671
of	O
insects	B-C0021585
fed	O
on	O
grain	B-C0007757
of	O
cowpea	B-C0996865
,	O
vigna	B-C0996865
unguiculata	I-C0996865
l	I-C0996865
,	O
cultivars	B-C0032098
grown	O
with	O
different	O
nitrogen	B-C0028158
sources	O
.	O
	
for	O
the	O
experiment	O
we	O
used	O
aliquots	O
of	O
the	O
homogenate	B-C3829671
of	O
100	O
unsexed	O
adult	B-C0001675
insects	B-C0021585
,	O
emerged	O
from	O
10	O
g	O
of	O
grain	B-C0007757
obtained	O
from	O
four	O
cowpea	B-C0996865
cultivars	B-C0032098
'	O
brs	B-C0032098
acauã	I-C0032098
'	O
,	O
'	O
brs	B-C0032098
carijó	I-C0032098
'	O
,	O
'	O
brs	B-C0032098
pujante	I-C0032098
'	O
,	O
and	O
'	O
brs	B-C0032098
tapaihum	I-C0032098
'	O
grown	O
under	O
different	O
regimes	O
of	O
nitrogen	B-C0028158
sources	O
mineral	B-C0026162
fertilizer	B-C0015919
,	O
inoculation	B-C0022885
with	O
strains	B-C0004611
of	I-C0004611
diazotrophs	I-C0004611
br	B-C3917457
3267	I-C3917457
,	O
br	B-C3917456
3262	I-C3917456
,	O
br	B-C0004611
3299	I-C0004611
inpa	B-C0004611
03-11b	I-C0004611
,	O
03-84	B-C0004611
ufla	I-C0004611
,	O
as	O
well	O
as	O
the	O
control	B-C0009932
with	O
soil	B-C0037592
nitrogen	B-C0028158
.	O
	
the	O
parameters	O
evaluated	O
were	O
enzymatic	B-C0243102
activities	I-C0243102
of	O
insect	B-C0021585
protease	B-C0030940
,	O
amylase	B-C0002712
and	O
lipase	B-C0023764
and	O
the	O
starch	B-C0038179
content	O
of	O
the	O
grains	B-C0007757
.	O
	
there	O
were	O
differences	O
in	O
the	O
enzymatic	B-C0243102
activity	I-C0243102
of	O
amylase	B-C0002712
,	O
lipase	B-C0023764
and	O
protease	B-C0030940
of	O
insect	B-C0021585
homogenate	B-C3829671
according	O
to	O
the	O
food	B-C0016452
source	O
.	O
	
a	O
lower	O
activity	B-C0243102
of	I-C0243102
the	I-C0243102
enzyme	I-C0243102
amylase	B-C0002712
from	O
c	B-C1024702
.	O
	
maculatus	I-C1024702
homogenate	B-C3829671
was	O
observed	O
when	O
insects	B-C0021585
were	O
fed	O
grain	B-C0007757
of	O
the	O
cultivar	B-C0032098
brs	I-C0032098
carijó	I-C0032098
.	O
	
a	O
lower	O
activity	B-C1149836
of	I-C1149836
lipase	I-C1149836
enzyme	I-C1149836
from	O
c	B-C1024702
.	O
	
maculatus	I-C1024702
homogenate	B-C3829671
was	O
observed	O
when	O
the	O
insects	B-C0021585
fed	O
on	O
grain	B-C0007757
from	O
the	O
interaction	O
of	O
the	O
cultivar	B-C0032098
tapaihum	I-C0032098
inoculated	O
with	O
br	B-C3917456
3262	I-C3917456
diazotrophs	I-C3917456
.	O
	
the	O
lowest	O
proteolytic	B-C0597304
activity	I-C0597304
was	O
observed	O
in	O
homogenate	B-C3829671
of	O
insects	B-C0021585
fed	O
on	O
interaction	O
of	O
'	O
brs	B-C0032098
carijó	I-C0032098
'	O
inoculated	O
with	O
br	B-C3917456
3262	I-C3917456
diazotroph	I-C3917456
s	O
.	O
	
starch	B-C0038179
content	O
correlated	O
positively	O
with	O
the	O
amylase	B-C1150038
activity	I-C1150038
of	O
c	B-C1024702
.	O
	
maculatus	I-C1024702
homogenate	B-C3829671
.	O
	
the	O
cultivar	B-C0032098
brs	I-C0032098
carijó	I-C0032098
had	O
a	O
different	O
behavior	O
from	O
the	O
other	O
cultivars	B-C0032098
,	O
according	O
to	O
the	O
cluster	B-C0009085
analysis	I-C0009085
.	O
	
the	O
correlation	B-C0010100
of	I-C0010100
the	I-C0010100
results	I-C0010100
of	O
the	O
survey	B-C0038951
snot-20	I-C0038951
of	O
objective	B-C2985627
studies	I-C2985627
of	O
nasal	B-C0027429
obstruction	I-C0027429
and	O
the	O
geometry	O
of	O
the	O
nasal	B-C0027423
cavities	I-C0027423
in	O
this	O
paper	O
were	O
verified	O
the	O
correlation	B-C0010100
between	I-C0010100
the	I-C0010100
results	I-C0010100
of	O
the	O
survey	B-C0038951
snot-20	I-C0038951
and	O
the	O
results	B-C0243095
of	I-C0243095
the	I-C0243095
objective	I-C0243095
tests	I-C0243095
of	O
nasal	B-C0027429
obstruction	I-C0027429
which	O
are	O
rhinomanometry	B-C0430615
and	O
acoustic	B-C0430619
rhinometry	I-C0430619
before	O
and	O
after	O
surgical	B-C0543467
treatment	I-C0543467
,	O
such	O
as	O
septoplasty	B-C0844334
,	O
septoconchoplasty	B-C0430022
,	O
ethmoidectomy	B-C0189149
and	O
septoethmoidectomy	B-C0430022
.	O
	
the	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	B-C0030705
diagnosed	B-C0011900
routinely	O
in	O
the	O
rhinomanometry	B-C0430615
laboratory	B-C0022877
of	O
the	O
department	B-C4047590
of	I-C4047590
otolaryngology	I-C4047590
at	O
the	O
medical	B-C0000872
university	I-C0000872
of	O
warsaw	B-C0681784
,	O
reporting	O
rhinological	B-C0029896
problems	I-C0029896
.	O
	
data	B-C1511726
were	O
obtained	O
from	O
70	O
women	B-C0043210
31	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	B-C0025266
68	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age	O
.	O
	
the	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
rhinometrics	B-C0025080
sre	I-C0025080
2100	I-C0025080
which	O
combines	O
the	O
rhinomanometer	B-C0183043
rhinostream	B-C0183043
and	O
acoustic	B-C3881541
rhinometer	I-C3881541
rhinoscan	B-C3881541
interacoustics	B-C0025080
as	I-C0025080
denmark	B-C0011318
.	O
	
survey	B-C0038951
snot-20	I-C0038951
sino-nasal	B-C0038951
outcome	I-C0038951
test-20	I-C0038951
in	O
polish	B-C0681784
was	O
completed	O
by	O
patients	B-C0030705
before	B-C1254367
surgery	I-C1254367
and	O
during	B-C0032790
the	I-C0032790
postoperative	I-C0032790
control	I-C0032790
visits	I-C0032790
.	O
	
the	O
calculated	O
correlations	O
between	O
the	O
objective	B-C0449381
parameter	I-C0449381
,	O
which	O
was	O
the	O
resistance	B-C4281815
to	O
the	O
flow	B-C0429203
of	I-C0429203
air	I-C0429203
through	I-C0429203
the	I-C0429203
nasal	I-C0429203
cavity	I-C0429203
,	O
and	O
the	O
subjective	B-C0243095
feelings	I-C0243095
of	I-C0243095
respondents	I-C0243095
expressed	O
in	O
the	O
survey	B-C0038951
snot-20	I-C0038951
were	O
generally	B-C1762617
weak	I-C1762617
,	O
and	O
statistical	B-C0237881
significance	I-C0237881
was	O
achieved	O
with	O
respect	O
to	O
the	O
first	B-C0038949
question	I-C0038949
survey	I-C0038949
the	O
severity	B-C0027429
of	I-C0027429
the	I-C0027429
nose	I-C0027429
obstruction	I-C0027429
for	O
all	O
components	O
of	O
resistance	B-C4281815
flow	I-C4281815
.	O
	
the	O
feeling	O
of	O
nasal	B-C0027429
obstruction	I-C0027429
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	B-C0030705
with	O
rhinological	B-C0029896
problems	I-C0029896
.	O
	
emergency	B-C0562508
department	I-C0562508
use	B-C0457083
and	O
barriers	B-C0679881
to	O
wellness	B-C0018684
a	O
survey	B-C0038951
of	O
emergency	B-C0562508
department	I-C0562508
frequent	B-C0332183
users	B-C1706077
there	O
is	O
no	O
common	O
understanding	O
of	O
how	O
needs	B-C0027552
of	O
emergency	B-C0562508
department	I-C0562508
ed	B-C0562508
frequent	B-C0332183
users	B-C1706077
differ	O
from	O
other	O
patients	B-C0030705
.	O
	
this	O
study	B-C2603343
sought	O
to	O
examine	O
how	O
to	O
best	O
serve	O
this	O
population	B-C1257890
.	O
	
examinations	B-C0582103
of	O
why	O
ed	B-C0562508
frequent	B-C0332183
users	B-C1706077
present	B-C0150312
to	O
the	O
ed	B-C0562508
,	O
what	O
barriers	B-C0679881
to	O
care	B-C0017313
exist	B-C2987476
,	O
and	O
what	O
service	B-C0557854
offerings	O
may	O
help	O
these	O
patients	B-C0030705
achieve	O
an	O
optimal	B-C2698651
level	B-C0441889
of	O
health	B-C0018684
were	O
conducted	O
.	O
	
we	O
performed	O
a	O
prospective	B-C0033522
study	I-C0033522
of	O
frequent	B-C0332183
ed	B-C0562508
users	B-C1706077
in	O
an	O
adult	B-C0001675
only	O
,	O
level	B-C0040786
1	I-C0040786
trauma	I-C0040786
center	I-C0040786
with	O
approximately	B-C0332232
90	O
visits	B-C1512346
per	B-C0439508
year	I-C0439508
.	O
	
frequent	B-C0332183
ed	B-C0562508
users	B-C1706077
were	O
defined	O
as	O
those	O
who	O
make	O
four	O
or	O
more	O
ed	B-C0586082
visits	I-C0586082
in	O
a	O
12	O
month	B-C0439231
period	B-C1948053
.	O
	
participants	B-C0679646
were	O
administered	B-C1521801
a	O
piloted	B-C0681913
structured	I-C0681913
interview	I-C0681913
by	O
a	O
trained	B-C0035173
researcher	I-C0035173
querying	B-C1522634
demographics	B-C0011298
,	O
ed	B-C0562508
usage	B-C0457083
,	O
perceived	B-C0205556
barriers	I-C0205556
to	O
care	B-C0017313
,	O
and	O
potential	O
aids	B-C0205556
to	O
maintaining	B-C2371475
health	I-C2371475
.	O
	
of	O
1	O
screened	B-C1710032
patients	B-C0030705
,	O
297	O
were	O
identified	B-C0205396
as	O
frequent	B-C0332183
ed	B-C0562508
users	B-C1706077
.	O
	
one	O
hundred	O
frequent	B-C0332183
ed	B-C0562508
users	B-C1706077
were	O
enrolled	O
.	O
	
the	O
mean	B-C0001779
age	I-C0001779
was	O
48	O
years	B-C1510829
95%	O
ci	B-C0009667
45-51	O
.	O
	
the	O
majority	O
of	O
subjects	B-C0080105
were	O
female	B-C0043210
64%	O
,	O
64/100	O
,	O
95%	O
ci	B-C0009667
55-73%	O
,	O
white	B-C1257890
61%	O
,	O
60/98	O
,	O
95%	O
ci	B-C0009667
52-71%	O
and	O
insured	B-C1548605
by	O
medicaid	B-C0025071
55%	O
,	O
47/86	O
,	O
95%	O
ci	B-C0009667
44-65%	O
or	O
medicare	B-C0018717
23%	O
,	O
20/86	O
,	O
95%	O
ci	B-C0009667
14-32%	O
.	O
	
subjects	B-C0080105
had	O
a	O
median	B-C0439536
of	O
6	O
ed	B-C0586082
visits	I-C0586082
,	O
and	O
2	O
inpatient	B-C0420512
admissions	I-C0420512
in	O
the	O
past	B-C1444637
12	O
months	B-C0439231
at	O
this	O
hospital	B-C0019994
.	O
	
most	O
frequent	B-C0332183
ed	B-C0562508
users	B-C1706077
61%	O
,	O
59/96	O
,	O
95%	O
ci	B-C0009667
52-71%	O
stated	O
the	O
primary	B-C1549995
reason	I-C1549995
for	O
their	O
visit	B-C1512346
was	O
that	O
they	O
felt	O
that	O
their	O
health	B-C1398682
problem	I-C1398682
could	O
only	O
be	O
treated	B-C1522326
in	O
an	O
ed	B-C0562508
.	O
	
transportation	B-C1554194
presented	O
as	O
a	O
major	B-C0205164
barrier	B-C0205556
to	O
few	B-C0205388
patients	B-C0030705
7%	O
,	O
7/95	O
,	O
95%	O
ci	B-C0009667
3-14%	O
.	O
	
subjects	B-C0080105
stated	O
that	O
""""	O
after-hours	B-C1136313
options	I-C1136313
,	O
besides	O
the	O
ed	B-C0562508
for	O
minor	B-C0205165
health	B-C2362508
issues	I-C2362508
""""	O
63%	O
,	O
60/95	O
,	O
95%	O
ci	B-C0009667
53-73%	O
and	O
having	O
"""a"	O
nurse	B-C0028661
to	O
work	B-C0043227
with	O
you	O
one-on-one	B-C0557987
to	O
help	O
manage	B-C0184516
health	B-C0086388
care	I-C0086388
needs	B-C0027552
""""	O
53%	O
,	O
50/95	O
,	O
95%	O
ci	B-C0009667
43-63%	O
would	O
be	O
most	O
helpful	O
in	O
achieving	O
optimal	B-C2698651
health	B-C0018684
.	O
	
this	O
study	B-C2603343
characterized	B-C1880022
ed	B-C0562508
frequent	B-C0332183
users	B-C1706077
and	O
identified	B-C0205396
several	B-C0443302
opportunities	B-C0683937
to	O
better	O
serve	O
this	O
population	B-C1257890
.	O
	
by	O
understanding	O
barriers	B-C0205556
to	O
care	B-C0017313
from	O
the	O
patient	B-C0030705
perspective	O
,	O
health	B-C1456613
systems	I-C1456613
can	O
potentially	O
address	O
unmet	O
needs	B-C0027552
that	O
prevent	B-C2700409
wellness	B-C0018684
in	O
this	O
contralateral	B-C0441988
superior	B-C1384733
cerebellar	I-C1384733
artery	I-C1384733
syndrome	I-C1384733
a	O
consequence	B-C0686907
of	I-C0686907
brain	B-C0553686
herniation	I-C0553686
vascular	B-C0005847
compromise	B-C2945640
is	O
a	O
well-known	O
consequence	B-C0686907
of	I-C0686907
brain	B-C0553686
herniation	I-C0553686
syndromes	B-C0039082
.	O
	
transtentorial	B-C0522519
brain	B-C0553686
herniation	I-C0553686
most	O
often	O
involves	O
posterior	B-C0149576
cerebral	I-C0149576
arteries	I-C0149576
.	O
	
however	O
,	O
isolated	B-C0205409
involvement	B-C1314939
of	O
contralateral	B-C0441988
superior	B-C0149575
cerebellar	I-C0149575
artery	I-C0149575
sca	B-C0149575
during	O
unilateral	B-C0205092
impending	B-C0332190
brain	B-C0553686
herniation	I-C0553686
is	O
reported	B-C0700287
only	O
once	O
and	O
we	O
present	O
another	O
case	O
of	O
this	O
exceedingly	O
rare	B-C0522498
entity	B-C1551338
.	O
	
a	O
24-year-old	O
man	B-C0025266
was	O
referred	O
to	O
us	O
with	O
impending	B-C0332190
herniation	B-C0019270
due	O
to	O
a	O
multiloculated	B-C0205293
hydrocephalus	B-C0020255
,	O
and	O
during	O
the	O
course	B-C0242656
of	I-C0242656
illness	I-C0242656
,	O
he	O
developed	O
an	O
isolated	B-C0205409
sca	B-C0149575
ischemia	B-C0022116
in	O
the	O
opposite	O
side	O
of	O
the	O
most	O
dilated	B-C0700124
entrapped	O
horn	B-C0019939
.	O
	
in	O
the	O
current	O
article	B-C1706852
we	O
discuss	O
the	O
probable	O
pathophysiologic	B-C0031847
mechanisms	B-C0441712
of	O
this	O
phenomenon	B-C1882365
,	O
as	O
well	O
as	O
recommending	O
more	O
inclusive	B-C0332257
brain	B-C0006104
studies	O
in	O
cases	O
suspected	B-C0750491
of	O
kernohan-woltman	B-C0030660
notch	I-C0030660
phenomenon	I-C0030660
in	O
unilateral	B-C0205092
brain	B-C0553686
herniation	I-C0553686
.	O
	
the	O
rationale	B-C2699007
for	O
this	O
commentary	B-C0282411
is	O
that	O
contralateral	B-C0441988
sca	B-C0149575
transient	B-C0022118
ischemia	I-C0022118
or	O
infarct	B-C0021308
might	O
be	O
the	O
underdiagnosed	B-C0243095
underlying	O
pathomechanism	B-C0030660
of	O
ipsilateral	B-C0441989
hemiparesis	B-C0018989
occurring	O
in	O
many	O
cases	O
of	O
this	O
somehow	O
vague	B-C0205408
phenomenon	B-C1882365
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
clinical	B-C0870294
supervision	I-C0870294
on	O
supervisees	B-C1257890
and	O
patients	B-C0030705
in	O
cognitive-behavioral	B-C0009244
therapy	I-C0009244
a	O
study	B-C2348563
protocol	I-C2348563
for	O
a	O
systematic	B-C1955832
review	I-C1955832
clinical	B-C0870294
supervision	I-C0870294
by	O
a	O
senior	B-C0871525
therapist	I-C0871525
is	O
a	O
very	O
common	O
practice	B-C0032893
in	O
psychotherapist	B-C0557555
training	B-C0220931
and	O
psychiatric	B-C0597312
care	I-C0597312
settings	O
.	O
	
though	O
clinical	B-C0870294
supervision	I-C0870294
is	O
advocated	O
by	O
most	O
educational	B-C0681325
and	I-C0681325
governing	I-C0681325
institutions	I-C0681325
,	O
the	O
effects	O
of	O
clinical	B-C0870294
supervision	I-C0870294
on	O
the	O
supervisees	B-C1257890
'	O
competence	B-C0086035
,	O
e.g	O
,	O
attitudes	B-C0004271
,	O
behaviors	B-C0004927
,	O
and	O
skills	B-C0678856
,	O
as	O
well	O
as	O
on	O
treatment	B-C0085415
outcomes	I-C0085415
and	O
other	O
patient	B-C0030705
variables	O
are	O
debated	O
and	O
largely	O
unknown	O
.	O
	
evidence-based	B-C1510541
practice	I-C1510541
is	O
advocated	O
in	O
clinical	B-C3176918
settings	I-C3176918
but	O
has	O
not	O
yet	O
been	O
fully	O
implemented	O
in	O
educational	O
or	O
clinical	O
training	O
settings	O
.	O
	
the	O
aim	O
of	O
this	O
systematic	B-C1955832
review	I-C1955832
is	O
to	O
synthesize	O
and	O
present	O
the	O
empirical	B-C0023866
literature	I-C0023866
regarding	O
effects	O
of	O
clinical	B-C0870294
supervision	I-C0870294
in	O
cognitive-behavioral	B-C0009244
therapy	I-C0009244
.	O
	
this	O
study	O
will	O
include	O
a	O
systematic	B-C1955832
review	I-C1955832
of	O
the	O
literature	B-C0023866
to	O
identify	O
studies	O
that	O
have	O
empirically	O
investigated	O
the	O
effects	O
of	O
supervision	O
on	O
supervised	B-C0557555
psychotherapists	I-C0557555
and/or	O
the	O
supervisees'	O
patients	B-C0030705
.	O
	
a	O
comprehensive	O
search	O
strategy	O
will	O
be	O
conducted	O
to	O
identify	O
published	O
controlled	O
studies	O
indexed	B-C0918012
in	O
the	O
medline	B-C0025141
,	O
embase	B-C0282574
,	O
psycinfo	B-C1140129
,	O
and	O
cochrane	B-C0282574
library	I-C0282574
databases	I-C0282574
.	O
	
data	B-C1511726
on	O
supervision	O
outcomes	O
in	O
both	O
psychotherapists	B-C0557555
and	O
their	O
patients	B-C0030705
will	O
be	O
extracted	O
,	O
synthesized	O
,	O
and	O
reported	B-C0684224
.	O
	
risk	O
of	O
bias	O
and	O
quality	O
of	O
the	O
included	O
studies	O
will	O
be	O
assessed	O
systematically	O
.	O
	
this	O
systematic	B-C1955832
review	I-C1955832
will	O
rigorously	O
follow	O
established	O
guidelines	B-C0162791
for	O
systematic	B-C1955832
reviews	I-C1955832
in	O
order	O
to	O
summarize	O
and	O
present	O
the	O
evidence	O
base	O
for	O
clinical	B-C0870294
supervision	I-C0870294
in	O
cognitive-behavioral	B-C0009244
therapy	I-C0009244
and	O
may	O
aid	O
further	O
research	B-C0035168
higher	B-C0332167
risk	I-C0332167
of	I-C0332167
revision	B-C0439617
for	O
infection	B-C3714514
using	O
systemic	B-C0205373
clindamycin	B-C0008947
prophylaxis	B-C0282638
than	O
with	O
cloxacillin	B-C0009077
background	O
and	O
purpose	O
-	O
clindamycin	B-C0008947
has	O
not	O
been	O
compared	O
with	O
other	O
antibiotics	B-C0003232
for	O
prophylaxis	B-C0282638
in	O
arthroplasty	B-C0003893
.	O
	
since	O
2009	O
,	O
the	O
swedish	B-C0034975
knee	I-C0034975
arthroplasty	I-C0034975
register	I-C0034975
skar	O
has	O
been	O
collecting	O
information	O
on	O
the	O
prophylactic	O
antibiotic	O
regime	O
used	O
at	O
every	O
individual	O
operation	O
.	O
	
in	O
sweden	O
,	O
when	O
there	O
is	O
allergy	O
to	O
penicillin	O
,	O
clindamycin	O
has	O
been	O
the	O
recommended	O
alternative	O
.	O
	
we	O
examined	O
whether	O
there	O
were	O
differences	O
in	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	O
depending	O
on	O
which	O
antibiotic	O
was	O
used	O
as	O
systemic	O
prophylaxis	O
.	O
	
patients	O
and	O
methods	O
-	O
patients	O
who	O
had	O
a	O
total	O
knee	O
arthroplasty	O
tka	O
performed	O
due	O
to	O
osteoarthritis	O
oa	O
during	O
the	O
years	O
2009-2015	O
were	O
included	O
in	O
the	O
study	O
.	O
	
information	O
on	O
which	O
antibiotic	O
was	O
used	O
was	O
available	O
for	O
80	O
operations	O
55	O
patients	O
.	O
	
survival	O
statistics	O
were	O
used	O
to	O
calculate	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	O
until	O
the	O
end	O
of	O
2015	O
,	O
comparing	O
the	O
group	O
of	O
patients	O
who	O
received	O
cloxacillin	O
with	O
those	O
who	O
received	O
clindamycin	O
as	O
systemic	O
prophylaxis	O
.	O
	
results	O
-	O
cloxacillin	O
was	O
used	O
in	O
90%	O
of	O
the	O
cases	O
,	O
clindamycin	O
in	O
7%	O
,	O
and	O
cephalosporins	O
in	O
2%	O
.	O
	
the	O
risk	O
of	O
being	O
revised	O
due	O
to	O
infection	O
was	O
higher	O
when	O
clindamycin	O
was	O
used	O
than	O
when	O
cloxacillin	O
was	O
used	O
rr	O
=1	O
,	O
95%	O
ci	O
1.2	O
p	O
=	O
0.001	O
.	O
	
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
revision	O
rate	O
for	O
other	O
causes	O
p	O
=	O
0.2	O
.	O
	
interpretation	O
-	O
we	O
advise	O
that	O
patients	O
reporting	O
allergic	O
reaction	O
to	O
penicillin	O
should	O
have	O
their	O
allergic	O
history	O
explored	O
.	O
	
in	O
the	O
absence	O
of	O
a	O
clear	O
history	O
of	O
type-i	O
allergic	O
reaction	O
e.g	O
.	O
	
urticaria	O
,	O
anaphylaxis	O
,	O
or	O
bronchospasm	O
,	O
we	O
suggest	O
the	O
use	O
of	O
a	O
third-generation	O
cephalosporin	O
instead	O
of	O
clindamycin	O
as	O
perioperative	O
prophylaxis	O
when	O
undergoing	O
a	O
tkr	O
.	O
	
no	O
recommendation	O
can	O
be	O
given	O
regarding	O
patients	O
with	O
type-1	O
allergy	B-C0020517
pcvmzm	B-C1516769
using	O
the	O
probabilistic	B-C1516769
classification	I-C1516769
vector	I-C1516769
machines	I-C1516769
model	I-C1516769
combined	I-C1516769
with	I-C1516769
a	I-C1516769
zernike	I-C1516769
moments	I-C1516769
descriptor	O
to	O
predict	B-C0681842
protein-protein	B-C0872079
interactions	I-C0872079
from	O
protein	B-C0002518
sequences	I-C0002518
protein-protein	B-C0872079
interactions	I-C0872079
ppis	B-C0872079
are	O
essential	O
for	O
most	O
living	B-C0029235
organisms	I-C0029235
'	O
process	O
.	O
	
thus	O
,	O
detecting	O
ppis	B-C0872079
is	O
extremely	O
important	O
to	O
understand	O
the	O
molecular	B-C1521991
mechanisms	B-C0441712
of	O
biological	B-C0449913
systems	I-C0449913
.	O
	
although	O
many	O
ppis	B-C0872079
data	O
have	O
been	O
generated	O
by	O
high-throughput	B-C0872047
technologies	I-C0872047
for	O
a	O
variety	O
of	O
organisms	B-C0029235
,	O
the	O
whole	O
interatom	O
is	O
still	O
far	O
from	O
complete	O
.	O
	
in	O
addition	O
,	O
the	O
high-throughput	B-C0872047
technologies	I-C0872047
for	O
detecting	O
ppis	B-C0872079
has	O
some	O
unavoidable	B-C1457869
defects	I-C1457869
,	O
including	O
time	B-C0040223
consumption	I-C0040223
,	O
high	O
cost	B-C0010186
,	O
and	O
high	O
error	B-C0392762
rate	I-C0392762
.	O
	
in	O
recent	O
years	O
,	O
with	O
the	O
development	O
of	O
machine	B-C0376284
learning	I-C0376284
,	O
computational	B-C1516769
methods	I-C1516769
have	O
been	O
broadly	O
used	O
to	O
predict	O
ppis	B-C0872079
,	O
and	O
can	O
achieve	O
good	O
prediction	B-C0681842
rate	O
.	O
	
in	O
this	O
paper	O
,	O
we	O
present	O
here	O
pcvmzm	B-C1516769
,	O
a	O
computational	B-C1516769
method	I-C1516769
based	O
on	O
a	O
probabilistic	B-C2699740
classification	I-C2699740
vector	I-C2699740
machines	I-C2699740
pcvm	I-C2699740
model	I-C2699740
and	O
zernike	B-C0026346
moments	I-C0026346
zm	I-C0026346
descriptor	I-C0026346
for	O
predicting	B-C0681842
the	O
ppis	B-C0872079
from	O
protein	B-C0033684
amino	B-C0002518
acids	I-C0002518
sequences	I-C0002518
.	O
	
specifically	O
,	O
a	O
zernike	B-C0026346
moments	I-C0026346
zm	I-C0026346
descriptor	I-C0026346
is	O
used	O
to	O
extract	O
protein	B-C0033684
evolutionary	O
information	B-C1533716
from	O
position-specific	B-C2717845
scoring	I-C2717845
matrix	I-C2717845
pssm	B-C2717845
generated	O
by	O
position-specific	B-C2698333
iterated	I-C2698333
basic	I-C2698333
local	I-C2698333
alignment	I-C2698333
search	I-C2698333
tool	I-C2698333
psi-blast	I-C2698333
.	O
	
then	O
,	O
pcvm	B-C2699740
classifier	I-C2699740
is	O
used	O
to	O
infer	O
the	O
interactions	B-C0872079
among	O
protein	B-C0033684
.	O
	
when	O
performed	O
on	O
ppis	B-C0872079
datasets	O
of	O
yeast	B-C0043393
and	O
h	B-C0079488
.	O
	
pylori	I-C0079488
,	O
the	O
proposed	O
method	O
can	O
achieve	O
the	O
average	O
prediction	B-C0681842
accuracy	B-C0443131
of	O
94.48	O
and	O
91.25	O
,	O
respectively	O
.	O
	
in	O
order	O
to	O
further	O
evaluate	O
the	O
performance	O
of	O
the	O
proposed	O
method	O
,	O
the	O
state-of-the-art	B-C0038199
support	B-C2699740
vector	I-C2699740
machines	I-C2699740
svm	B-C2699740
classifier	I-C2699740
is	O
used	O
and	O
compares	O
with	O
the	O
pcvm	B-C2699740
model	I-C2699740
.	O
	
experimental	B-C2825142
results	I-C2825142
on	O
the	O
yeast	B-C0043393
dataset	O
show	O
that	O
the	O
performance	O
of	O
pcvm	B-C2699740
classifier	I-C2699740
is	O
better	O
than	O
that	O
of	O
svm	B-C2699740
classifier	I-C2699740
.	O
	
the	O
experimental	B-C2825142
results	I-C2825142
indicate	O
that	O
our	O
proposed	O
method	O
is	O
robust	O
,	O
powerful	O
and	O
feasible	O
,	O
which	O
can	O
be	O
used	O
as	O
a	O
helpful	O
tool	O
for	O
proteomics	B-C0035168
research	I-C0035168
.	O
	
conditional	B-C1701901
knockdown	B-C2350567
of	O
endogenous	B-C0205227
micrornas	B-C1101610
in	O
cho	B-C0085080
cells	I-C0085080
using	O
tet-on-sandi	B-C0017397
sponge	I-C0017397
vectors	I-C0017397
micrornas	B-C1101610
mirnas	B-C1101610
are	O
small	O
,	O
noncoding	B-C0887909
rnas	I-C0887909
of	O
about	O
22	O
nucleotides	B-C0028630
in	O
length	O
and	O
have	O
proven	O
to	O
be	O
useful	O
targets	B-C1521840
for	O
genetic	B-C4277689
modifications	I-C4277689
for	O
desirable	O
phenotype	B-C0031437
in	O
the	O
biotech	B-C0005574
industry	B-C0021267
.	O
	
the	O
use	O
of	O
constitutively	O
expressed	O
""""	O
mirna	B-C0017397
"sponge"""	I-C0017397
vectors	I-C0017397
in	O
which	O
multiple	O
,	O
tandem	B-C1101610
mirna	I-C1101610
binding	B-C0005456
sites	I-C0005456
containing	O
transcripts	B-C1519595
are	O
transcriptionally	B-C1158770
regulated	I-C1158770
by	O
a	O
constitutive	O
promoter	B-C0086860
for	O
down	B-C0013081
regulating	I-C0013081
the	O
levels	O
of	O
endogenous	B-C0205227
micrornas	B-C1101610
in	O
chinese	B-C0085080
hamster	I-C0085080
ovary	I-C0085080
cho	I-C0085080
cells	I-C0085080
has	O
shown	O
to	O
be	O
more	O
advantageous	O
than	O
using	O
synthetic	O
antisense	B-C0079925
oligonucleotides	I-C0079925
.	O
	
the	O
application	O
of	O
mirna	B-C0599566
sponges	I-C0599566
in	O
biotechnological	B-C0005574
processes	B-C1522240
,	O
however	O
,	O
could	O
be	O
more	O
effective	B-C1704419
,	O
if	O
expression	B-C0017262
of	O
mirna	B-C0599566
sponges	I-C0599566
could	O
be	O
tuned	O
.	O
	
in	O
this	O
chapter	O
,	O
we	O
present	O
a	O
method	O
for	O
the	O
generation	O
of	O
stable	O
cho	B-C0085080
cell	I-C0085080
lines	I-C0085080
expressing	B-C0017262
a	O
tet-on-sandi-mirna-sponge	B-C0599566
that	O
is	O
in	O
theory	O
expressed	O
only	O
in	O
the	O
presence	O
of	O
an	O
forest	B-C0086312
protected	B-C0017446
areas	I-C0017446
governance	B-C0243148
in	O
zimbabwe	B-C0043476
shift	B-C2347509
needed	O
away	O
from	O
a	O
long	B-C3714536
history	I-C3714536
of	O
local	B-C0205276
community	B-C0009462
exclusion	B-C2828389
in	O
this	O
literature	O
review	O
based	O
paper	O
we	O
explored	O
the	O
concept	B-C0178566
of	O
exclusion	B-C2828389
of	O
local	B-C0205276
communities	B-C0009462
from	O
accessing	B-C0015472
resources	B-C0027492
in	O
forest	B-C0086312
protected	B-C0017446
areas	I-C0017446
fpas	B-C0017446
in	O
zimbabwe	B-C0043476
.	O
	
we	O
discussed	O
the	O
colonial	B-C0870077
and	O
post	B-C0687676
-	O
colonial	B-C0870077
forms	I-C0870077
,	O
causes	O
and	O
mechanisms	B-C0441712
of	O
exclusion	B-C2828389
and	O
their	O
social	B-C0037403
,	O
economic	B-C0013551
and	O
ecological	B-C0870460
outcomes	I-C0870460
.	O
	
we	O
examined	B-C0332128
the	O
range	B-C1514721
of	O
powers	B-C0037430
embodied	O
in	O
and	O
exercised	O
through	O
various	O
mechanisms	O
,	O
processes	B-C1522240
and	O
social	B-C0037397
relations	I-C0037397
and	O
their	O
impact	B-C4049986
on	O
local	B-C0205276
communities	B-C0009462
'	O
access	B-C0015472
to	O
fpa	B-C0017446
resources	B-C0027492
and	O
associated	O
benefits	B-C0814225
along	O
the	O
historical	B-C0681698
trajectory	B-C0392747
of	O
forest	B-C0086312
governance	B-C0243148
in	O
zimbabwe	B-C0043476
.	O
	
results	O
showed	O
that	O
the	O
forms	B-C0348078
and	O
extent	B-C0439792
of	O
exclusion	B-C2828389
changed	B-C0443172
over	B-C0347984
time	B-C0040223
in	O
tandem	O
with	O
the	O
shifting	B-C0333051
political	B-C0032381
and	O
economic	B-C0282159
landscape	I-C0282159
.	O
	
during	O
the	O
colonial	B-C1254367
period	I-C1254367
,	O
it	O
was	O
total	O
exclusion	B-C2828389
whereby	O
people	B-C0027361
were	O
evicted	B-C2828389
from	O
forest	B-C0086312
land	B-C0557668
as	O
well	O
as	O
being	O
denied	B-C0332319
access	B-C0015472
to	O
basic	B-C1527178
resources	B-C0027492
for	O
their	O
livelihoods	O
.	O
	
local	B-C0205276
communities	B-C0009462
'	O
access	B-C0015472
to	O
low	B-C0205251
value	B-C1522609
fpa	B-C0017446
resources	B-C0027492
improved	B-C0184511
during	O
the	O
post-colonial	B-C1254367
period	I-C1254367
but	O
access	B-C0015472
to	O
high	B-C0205250
value	B-C1522609
resources	B-C0027492
like	O
commercial	B-C0043217
timber	I-C0043217
as	O
well	O
as	O
sharing	B-C0237876
income	B-C0021162
benefits	B-C0814225
derived	B-C1441547
from	O
fpa	B-C0017446
commercial	B-C0441655
activities	I-C0441655
remained	O
a	O
pipe	B-C1254372
dream	I-C1254372
.	O
	
regulation	B-C0851285
,	O
legitimation	B-C0023637
,	O
force	O
and	O
markets	O
constituted	O
the	O
mixture	O
of	O
the	O
power	O
elements	O
that	O
fpa	B-C0017446
governing	B-C0243148
authorities	B-C0599437
used	O
to	O
exclude	B-C2828389
local	B-C0205276
communities	B-C0009462
.	O
	
these	O
powers	O
remained	O
intact	B-C0205266
despite	O
attempts	O
at	O
collaborative	B-C0282116
governance	B-C0243148
in	O
the	O
1990s	O
.	O
	
however	O
,	O
from	O
the	O
year	O
2000	O
,	O
local	B-C0205276
communities	B-C0009462
expressed	B-C0455212
their	O
dissatisfaction	B-C0870433
with	O
the	O
centralised	B-C0034982
exclusionary	I-C0034982
governance	I-C0034982
system	I-C0034982
by	O
invading	O
the	O
fpas	B-C0017446
rendering	O
them	O
ungovernable	B-C0243095
.	O
	
there	O
is	O
therefore	O
a	O
need	O
for	O
policy	B-C0242456
reform	B-C0392747
within	O
the	O
fpa	B-C0017446
sector	B-C1708237
to	O
improve	B-C0184511
the	O
current	B-C0521116
dire	B-C0013956
situation	I-C0013956
.	O
	
renal	B-C0085808
arterial	I-C0085808
mycotic	I-C0085808
aneurysm	I-C0085808
after	O
kidney	B-C0022671
transplantation	I-C0022671
mycotic	B-C0085808
aneurysm	I-C0085808
is	O
a	O
rare	O
condition	O
mostly	O
attributable	B-C0449234
to	O
candida	B-C0006836
or	O
aspergillus	B-C0004034
species	I-C0004034
.	O
	
about	O
20	O
cases	O
of	O
candida	B-C0006836
-related	O
arteritis	B-C0003860
have	O
been	O
reported	O
in	O
kidney	B-C0022671
transplant	I-C0022671
patients	B-C0030705
.	O
	
herein	O
,	O
we	O
report	B-C0684224
the	O
case	O
of	O
a	O
40-year-	O
old	O
man	O
who	O
received	O
a	O
kidney	B-C0022646
from	O
a	O
deceased	O
donor	B-C0013018
in	O
whom	O
an	O
accidental	B-C0521129
digestive	B-C0850041
wound	I-C0850041
was	O
made	O
during	O
organ	B-C0162438
retrieval	I-C0162438
.	O
	
he	O
presented	O
with	O
sudden	O
anuria	B-C0003460
47	O
days	O
after	O
renal	B-C0022671
transplantation	I-C0022671
revealing	O
a	O
large	O
mycotic	B-C0085808
aneurysm	I-C0085808
of	O
the	O
kidney	B-C1720289
graft	I-C1720289
renal	B-C0035065
artery	I-C0035065
.	O
	
organs	B-C0178784
derived	O
from	O
donors	B-C0013018
in	O
whom	O
a	O
digestive	B-C0850041
breach	I-C0850041
is	O
noticed	O
should	O
be	O
used	B-C1710588
with	I-C1710588
caution	I-C1710588
.	O
	
risk	B-C0596244
of	I-C0596244
cancer	I-C0596244
in	O
patients	B-C0030705
with	O
heart	B-C0018801
failure	I-C0018801
who	O
use	O
digoxin	B-C0012265
a	O
10-year	O
follow-up	B-C0016441
study	I-C0016441
and	O
cell	B-C0007634
-based	O
verification	B-C1711411
heart	B-C0018801
failure	I-C0018801
hf	B-C0018801
is	O
the	O
leading	O
cause	B-C0007465
of	I-C0007465
death	I-C0007465
in	O
the	O
world	B-C2700280
and	O
digoxin	B-C0012265
remains	O
one	O
of	O
the	O
oldest	O
therapies	B-C0087111
for	O
hf	B-C0018801
.	O
	
however	O
,	O
its	O
safety	B-C0036043
and	O
efficacy	B-C1280519
have	O
been	O
controversial	O
since	O
its	O
initial	O
use	B-C0457083
and	O
there	O
is	O
uncertainty	B-C0087130
about	O
its	O
long-term	B-C0443252
efficacy	B-C1280519
and	O
safety	B-C0036043
.	O
	
recently	O
,	O
the	O
repositioning	B-C0556030
of	O
cardiac	B-C0007158
glycosides	I-C0007158
is	O
to	O
function	B-C0542341
in	O
anti-tumor	B-C0920425
activity	I-C0920425
via	O
multiple	B-C0439064
working	B-C1705987
pathways	I-C1705987
.	O
	
it	O
is	O
interesting	O
to	O
compare	B-C1707455
the	O
potential	B-C3245505
effects	B-C1280500
of	O
digoxin	B-C0012265
in	O
clinical	B-C0205210
patients	B-C0030705
and	O
cell	B-C0085983
lines	I-C0085983
.	O
	
first	O
,	O
we	O
analyze	O
patient	B-C1955348
information	I-C1955348
retrieved	O
from	O
the	O
national	B-C0242356
health	I-C0242356
insurance	I-C0242356
research	I-C0242356
database	I-C0242356
of	O
taiwan	B-C0039260
between	O
january	O
1	O
,	O
2000	O
and	O
december	O
31	O
,	O
2000	O
.	O
	
this	O
retrospective	B-C0035363
study	I-C0035363
included	O
a	O
study	O
cohort	B-C0599755
1	O
patients	B-C0030705
and	O
a	O
comparison	B-C1707455
cohort	B-C0599755
.	O
	
our	O
analytical	B-C1511726
data	I-C1511726
suggested	O
that	O
patients	B-C0030705
taking	O
digoxin	B-C0012265
are	O
at	O
an	O
increased	B-C0205217
risk	B-C0596244
of	I-C0596244
cancers	I-C0596244
,	O
including	O
breast	B-C0006142
,	O
liver	B-C0345904
,	O
and	O
lung	B-C0684249
cancers	I-C0684249
,	O
during	O
the	O
10-year	O
follow-up	B-C1522577
period	I-C1522577
.	O
	
in	O
contrast	O
to	O
the	O
anti-tumor	B-C0920425
function	I-C0920425
of	O
digoxin	B-C0012265
,	O
we	O
further	O
examined	O
the	O
potential	B-C3245505
pathway	B-C1291081
of	O
digoxin	B-C0012265
via	O
the	O
cell	B-C0007634
-based	O
strategy	B-C0679199
using	O
several	O
breast	B-C0678222
cancer	I-C0678222
cell	B-C0085983
lines	I-C0085983
,	O
including	O
mcf-7	B-C0596890
,	O
bt-474	B-C0085983
,	O
mad-mb-231	B-C0085983
,	O
and	O
zr-75-1	B-C0085983
.	O
	
digoxin	B-C0012265
consistently	O
exerted	O
its	O
cytotoxicity	B-C0596402
to	O
these	O
four	O
cell	B-C0085983
lines	I-C0085983
with	O
various	O
range	O
of	O
concentration	B-C1446561
.	O
	
however	O
,	O
the	O
proliferation	B-C1514485
of	O
zr-75-1	B-C0085983
cells	I-C0085983
was	O
the	O
only	O
cell	B-C0085983
lines	I-C0085983
induced	O
by	O
digoxin	B-C0012265
and	O
the	O
others	O
were	O
dramatically	O
suppressed	B-C1260953
by	O
digoxin	B-C0012265
.	O
	
the	O
responsiveness	B-C0205342
of	O
srsf3	B-C1419994
to	O
digoxin	B-C0012265
might	O
be	O
involved	O
with	O
cell-type	B-C0449475
differences	B-C1705242
.	O
	
in	O
summary	O
,	O
we	O
combined	O
a	O
cohort	B-C0009247
study	I-C0009247
for	O
digoxin	B-C0012265
treatment	B-C0087111
for	O
hf	B-C0018801
patients	B-C0030705
with	O
a	O
cell	B-C0007634
-based	O
strategy	B-C0679199
that	O
addresses	O
the	O
translation	O
issue	O
,	O
which	O
revealed	O
the	O
complexity	B-C0439855
of	O
personalized	B-C2718059
medicine	I-C2718059
.	O
	
comparison	O
and	O
outcome	O
analysis	B-C0679830
of	I-C0679830
patients	I-C0679830
with	O
takotsubo	B-C1739395
cardiomyopathy	I-C1739395
triggered	B-C1444748
by	I-C1444748
emotional	B-C0086209
stress	I-C0086209
or	O
physical	B-C0231302
stress	I-C0231302
background	O
previous	O
studies	O
revealed	O
that	O
takotsubo	B-C1739395
cardiomyopathy	I-C1739395
ttc	B-C1739395
is	O
triggered	B-C1444748
by	I-C1444748
physical	B-C0231302
and	O
emotional	B-C0086209
stresses	I-C0086209
.	O
	
this	O
study	O
was	O
performed	O
to	O
determine	O
the	O
short-	B-C0443303
and	O
long-term	B-C0443252
prognostic	O
impact	O
of	O
emotional-	B-C0086209
and	O
physical	B-C0231302
stress	I-C0231302
associated	B-C0332281
with	I-C0332281
ttc	B-C1739395
.	O
	
methods	O
and	O
results	O
our	O
institutional	B-C0242356
database	I-C0242356
constituted	O
a	O
collective	O
of	O
84	O
patients	B-C0030705
diagnosed	B-C0011900
with	O
ttc	B-C1739395
between	O
2003	O
and	O
2015	O
.	O
	
the	O
patients	B-C0030705
were	O
divided	O
into	O
two	O
groups	B-C0441833
as	O
per	O
the	O
presence	O
of	O
emotional	B-C0086209
stress	I-C0086209
n	O
=	O
24	O
,	O
21%	O
or	O
physical	B-C0231302
stress	I-C0231302
n	O
=	O
60	O
,	O
52.6	O
.	O
	
the	O
endpoint	B-C2349179
was	O
a	O
composite	B-C0205199
of	O
in-hospital	B-C0243095
events	I-C0243095
thromboembolic	B-C0040038
events	I-C0040038
and	O
life-threatening	B-C2826244
arrhythmias	B-C0003811
,	O
myocardial	B-C0027051
infarction	I-C0027051
,	O
all-	O
cause	B-C1408525
of	I-C1408525
mortality	I-C1408525
,	O
re-hospitalization	B-C1254363
due	O
to	O
heart	B-C0018801
failure	I-C0018801
,	O
stroke	B-C0038454
,	O
and	O
recurrence	B-C0034897
of	O
ttc	B-C1739395
.	O
	
a	O
kaplan-meier	B-C1720943
analysis	I-C1720943
indicated	O
a	O
significantly	O
lower	O
event-free	O
survival	B-C0038954
rate	I-C0038954
over	O
a	O
mean	O
follow-up	B-C1522577
of	O
5	O
years	O
in	O
the	O
emotional	B-C0086209
group	B-C0441833
than	O
the	O
physical	B-C0231302
stress	I-C0231302
group	B-C0441833
log-rank	O
,	O
p	O
<	O
0.01	O
.	O
	
multivariate	B-C0034980
cox	I-C0034980
regression	I-C0034980
analysis	I-C0034980
revealed	O
only	O
emotional	B-C0086209
stress	I-C0086209
hr	O
0.4	O
,	O
95%	O
ci	O
0.2	O
,	O
p	O
<	O
0.05	O
as	O
a	O
negative	B-C0243095
independent	I-C0243095
predictor	I-C0243095
of	O
the	O
primary	O
endpoint	B-C2349179
.	O
	
conclusion	O
rates	O
of	O
in-hospital	B-C0243095
events	I-C0243095
and	O
short-	B-C0443303
as	O
well	O
as	O
long-term	B-C0443252
events	O
were	O
significantly	O
lower	O
in	O
ttc	B-C1739395
patients	B-C0030705
suffering	B-C0683278
from	O
emotional	B-C0086209
stress	I-C0086209
as	O
compared	O
to	O
patients	B-C0030705
with	O
physical	B-C0231302
stress	I-C0231302
.	O
	
surviving	B-C0220921
moment	B-C0040223
to	O
moment	B-C0040223
the	O
experience	B-C0596545
of	O
living	B-C0376558
in	O
a	O
state	B-C0278060
of	O
ambivalence	B-C0233495
for	O
those	O
with	O
recurrent	B-C2945760
suicide	B-C0038663
attempts	I-C0038663
this	O
qualitative	B-C0949415
study	I-C0949415
aimed	O
to	O
capture	O
the	O
experience	B-C0596545
of	O
living	B-C0376558
in	O
the	O
ambivalent	B-C0233495
space	I-C0233495
between	O
life	B-C0376558
and	O
death	B-C1546949
for	O
adults	B-C0001675
with	O
recurrent	B-C2945760
suicide	B-C0038663
attempts	I-C0038663
rsa	B-C0038663
.	O
	
it	O
sought	O
to	O
expand	B-C0205229
upon	O
an	O
earlier	O
study	B-C2603343
that	O
explored	O
the	O
processes	B-C0025361
involved	B-C1314939
in	O
transitioning	B-C2700061
away	O
from	O
rsa	B-C0038663
among	O
adults	B-C0001675
,	O
which	O
revealed	B-C0443289
that	O
occupying	O
this	O
ambivalent	B-C0233495
space	I-C0233495
is	O
a	O
crucial	O
part	O
of	O
this	O
process	B-C1522240
.	O
	
interpretive	B-C0936012
phenomenological	I-C0936012
analysis	I-C0936012
ipa	B-C0936012
was	O
used	O
.	O
	
this	O
methodology	B-C3266812
was	O
designed	B-C1707689
to	O
explore	O
the	O
lived	B-C0596545
experiences	I-C0596545
and	O
meaning	B-C0025361
making	I-C0025361
and	O
enabled	O
interpretation	B-C0871180
of	O
the	O
multidimensional	B-C2347299
subjective	B-C0439655
experiences	B-C0596545
of	O
rsa	B-C0038663
participants	B-C0679646
.	O
	
in-depth	O
semi-structured	B-C0681913
interviews	I-C0681913
were	O
conducted	B-C0441655
with	O
eight	O
adult	B-C0043210
women	I-C0043210
with	O
a	O
history	B-C0019665
of	O
rsa	B-C0038663
who	O
had	O
participated	B-C0679823
in	O
a	O
therapeutic	B-C0808232
intervention	I-C0808232
at	O
the	O
research	B-C0035168
site	B-C0205145
skills	B-C0678856
for	O
safer	B-C0376558
living	I-C0376558
a	O
psychosocial	B-C0542298
/	O
psychoeducational	B-C0871175
intervention	I-C0871175
for	O
people	B-C0027361
with	O
recurrent	B-C2945760
suicide	B-C0038663
attempts	I-C0038663
sfsl	B-C0376558
/	O
pisa	B-C0038663
.	O
	
the	O
six	O
stages	B-C1306673
of	O
ipa	B-C0936012
were	O
followed	O
to	O
analyse	B-C0936012
the	O
interview	B-C0683518
data	B-C1511726
.	O
	
analysis	B-C0936012
revealed	B-C0443289
the	O
superordinate	B-C0869035
theme	I-C0869035
,	O
'	O
surviving	B-C0220921
moment	B-C0040223
to	O
moment	B-C0040223
'	O
,	O
which	O
refers	O
to	O
a	O
precarious	B-C0278060
state	I-C0278060
of	O
making	B-C0011109
decisions	I-C0011109
about	O
one's	O
life	B-C0376558
and	O
destiny	B-C0016884
on	O
a	O
moment	B-C0040223
-to-	O
moment	B-C0040223
basis	O
without	O
clear	O
commitment	B-C0870312
to	O
either	O
life	B-C0376558
or	O
death	B-C1546949
.	O
	
two	O
subordinate	B-C0869035
themes	I-C0869035
were	O
identified	B-C0205396
'	O
deciding	B-C0205556
not	O
to	O
die	B-C4061184
in	O
the	O
moment	B-C0040223
'	O
when	O
the	O
participants	B-C0679646
were	O
more	O
invested	B-C0205245
in	O
dying	B-C4061184
than	O
living	B-C0376558
and	O
'	O
deciding	B-C0205556
to	O
live	B-C0376558
in	O
the	O
moment	B-C0040223
'	O
when	O
they	O
were	O
more	O
invested	B-C0205245
in	O
living	B-C0376558
than	O
dying	B-C4061184
.	O
	
the	O
study	B-C2603343
illuminated	O
the	O
complex	B-C0439855
process	B-C1522240
of	O
making	B-C0011109
decisions	I-C0011109
about	O
ones'	O
destiny	B-C0016884
on	O
a	O
moment	B-C0040223
-to-	O
moment	B-C0040223
basis	O
.	O
	
it	O
revealed	B-C0443289
the	O
torment	O
experienced	B-C0596545
when	O
occupying	O
this	O
state	B-C0278060
,	O
while	O
paradoxically	B-C0205310
,	O
also	O
revealing	O
how	O
indecision	B-C0423908
about	O
life	B-C0376558
and	O
death	B-C1546949
provided	B-C1999230
a	O
lifeline	B-C0376558
opportunity	B-C0205556
for	O
those	O
with	O
rsa	B-C0038663
.	O
	
clinicians	B-C0871685
who	O
recognize	O
the	O
subtle	O
distinctions	O
associated	B-C0332281
with	I-C0332281
this	O
in-between	O
state	B-C0278060
can	O
tailor	O
their	O
interventions	B-C0184661
accordingly	O
.	O
	
surviving	B-C0220921
moment	B-C0040223
to	O
moment	B-C0040223
is	O
characterized	B-C1880022
by	O
a	O
state	B-C0278060
of	O
emotional	B-C0849912
flux	I-C0849912
and	O
uncertainty	B-C0087130
about	O
one's	O
destiny	B-C0016884
,	O
where	O
the	O
person	B-C0027361
has	O
not	O
fully	O
committed	O
to	O
either	O
life	B-C0376558
or	O
death	B-C1546949
.	O
	
within	O
this	O
state	B-C0278060
,	O
there	O
are	O
two	O
interlinked	B-C0025361
subprocesses	I-C0025361
,	O
whereby	O
the	O
person	B-C0027361
is	O
leaning	B-C0558295
more	O
towards	O
death	B-C1546949
or	O
life	B-C0376558
.	O
	
a	O
critical	O
feature	B-C2348519
in	O
working	B-C0043227
with	O
this	O
client	B-C0008942
group	I-C0008942
is	O
to	O
recognize	O
their	O
ambiguity	B-C2346729
and	O
the	O
fragility	B-C3553489
and	O
temporality	B-C0040226
of	O
their	O
decisions	B-C0679006
about	O
their	O
destiny	B-C0016884
.	O
	
the	O
practitioner	B-C1709627
has	O
an	O
opportunity	B-C0205556
to	O
be	O
a	O
catalyst	O
in	O
the	O
momentum	O
towards	O
life	B-C0376558
by	O
demonstrating	O
understanding	B-C0162340
of	O
this	O
survival	B-C0220921
struggle	B-C0243095
and	O
tailoring	B-C0184661
intervention	I-C0184661
to	O
fit	O
with	O
the	O
nuanced	B-C0025361
processes	I-C0025361
within	O
this	O
does	O
a	O
policy	B-C0242456
of	O
earlier	B-C3710446
induction	I-C3710446
affect	O
labour	B-C0022864
outcomes	B-C1274040
in	O
women	B-C0033011
induced	B-C0205263
for	O
postmaturity	B-C0221007
a	O
retrospective	B-C1514923
analysis	B-C0936012
in	O
a	O
tertiary	B-C0337954
hospital	I-C0337954
in	O
the	O
north	B-C1709269
of	O
england	B-C0014282
to	O
investigate	B-C1292732
whether	O
a	O
change	B-C0392747
in	O
the	O
management	B-C1273870
of	O
postmature	B-C0032993
pregnancy	I-C0032993
to	O
earlier	B-C3710446
induction	I-C3710446
affects	O
the	O
length	B-C0566679
of	I-C0566679
labour	I-C0566679
and	O
the	O
induction	B-C0259787
process	I-C0259787
.	O
	
secondly	O
,	O
to	O
assess	B-C1516048
the	O
feasibility	B-C0015730
of	O
the	O
research	B-C0242481
process	I-C0242481
to	O
inform	O
a	O
future	B-C0016884
larger	B-C2603343
study	I-C2603343
.	O
	
a	O
change	B-C0392747
in	O
management	B-C1273870
of	O
postmature	B-C0032993
pregnancy	I-C0032993
in	O
an	O
nhs	B-C0027462
hospital	B-C0019994
in	O
october	B-C3828732
2013	O
,	O
from	O
induction	B-C0259787
at	O
42	O
weeks	B-C0439230
gestation	B-C0032961
to	O
induction	B-C0259787
between	O
41-42	O
weeks	B-C0439230
,	O
provided	B-C1999230
an	O
opportunity	B-C0683937
to	O
conduct	O
a	O
retrospective	B-C1514923
analysis	B-C0936012
.	O
	
pre-existing	B-C2347662
data	B-C1511726
from	O
the	O
maternity	B-C0681108
database	B-C0242356
and	O
casenotes	B-C3842891
were	O
collected	B-C1516698
and	O
primary	B-C0086750
outcomes	I-C0086750
analysed	B-C0936012
using	O
the	O
mann-whitney	B-C1708930
test	I-C1708930
and	O
the	O
hodges-lehman	B-C0009667
confidence	I-C0009667
interval	I-C0009667
for	O
differences	B-C1705242
in	O
medians	B-C0876920
.	O
	
a	O
large	B-C0008848
city	I-C0008848
based	O
tertiary	B-C0587437
referral	I-C0587437
hospital	I-C0587437
in	O
the	O
north	B-C1709269
of	O
england	B-C0014282
.	O
	
125	O
women	B-C0033011
induced	B-C0205263
before	O
the	O
change	B-C0392747
in	O
policy	B-C0242456
were	O
compared	B-C1707455
with	O
309	O
women	B-C0033011
induced	B-C0205263
after	O
the	O
change	B-C0392747
.	O
	
primary	B-C0086750
outcomes	I-C0086750
were	O
length	B-C1444754
of	O
1st	B-C0022871
and	O
2nd	B-C0022872
stage	I-C0022872
of	I-C0022872
labour	I-C0022872
,	O
overall	O
length	B-C0566679
of	I-C0566679
labour	I-C0566679
,	O
length	B-C1444754
of	O
induction	B-C0259787
to	O
established	B-C0443211
labour	B-C0022864
and	O
length	B-C1444754
of	O
induction	B-C0259787
to	O
birth	B-C0005615
.	O
	
the	O
median	B-C0876920
overall	O
length	B-C0566679
of	I-C0566679
labour	I-C0566679
for	O
women	B-C0033011
induced	B-C0205263
at	O
42	O
weeks	B-C0439230
was	O
6.5	O
hours	B-C0439227
,	O
while	O
for	O
women	B-C0033011
induced	B-C0205263
at	O
41-42	O
weeks	B-C0439230
this	O
was	O
5.2	O
hours	B-C0439227
.	O
	
the	O
difference	B-C1705242
was	O
not	O
statistically	B-C0237881
significant	I-C0237881
p=0	O
,	O
95%	O
ci	B-C0009667
for	O
median	B-C0876920
difference	B-C1705242
-0	O
to	O
1.93	O
hours	B-C0439227
with	O
a	O
small	B-C0814843
effect	I-C0814843
size	I-C0814843
pearson's	B-C0871052
r=-0	O
.	O
	
the	O
median	B-C0876920
length	B-C1444754
of	O
induction	B-C0259787
to	O
birth	B-C0005615
was	O
13.6	O
hours	B-C0439227
for	O
women	B-C0033011
induced	B-C0205263
at	O
42	O
weeks	B-C0439230
and	O
16.5	O
hours	B-C0439227
for	O
women	B-C0033011
induced	B-C0205263
at	O
41-42	O
weeks	B-C0439230
.	O
	
this	O
difference	B-C1705242
was	O
also	O
not	O
statistically	B-C0237881
significant	I-C0237881
p=0	O
,	O
95%	O
ci	B-C0009667
for	O
median	B-C0876920
difference	B-C1705242
-7	O
to	O
1.20	O
hours	B-C0439227
with	O
a	O
small	B-C0814843
effect	I-C0814843
size	I-C0814843
pearson's	B-C0871052
r=-0	O
.	O
	
this	O
study	B-C2603343
demonstrated	O
no	O
statistically	B-C0237881
significant	I-C0237881
difference	B-C1705242
s	O
in	O
length	B-C0566679
of	I-C0566679
labour	I-C0566679
and	O
induction	B-C0259787
following	O
a	O
change	B-C0392747
in	O
the	O
management	B-C1273870
of	O
postmature	B-C0032993
pregnancy	I-C0032993
to	O
earlier	B-C3710446
induction	I-C3710446
.	O
	
a	O
large	B-C2603343
study	I-C2603343
is	O
needed	O
to	O
establish	B-C0443211
definitively	O
the	O
effects	B-C1704420
of	I-C1704420
earlier	B-C3710446
induction	I-C3710446
on	O
labour	B-C0022864
outcomes	B-C1274040
.	O
	
liquid	B-C0872318
chromatography-mass	I-C0872318
spectrometry	I-C0872318
-based	O
quantitative	B-C0022885
proteomics	I-C0022885
analysis	I-C0022885
reveals	O
chondroprotective	O
effects	O
of	O
astragaloside	O
iv	O
in	O
interleukin-1β	O
-	O
induced	O
sw1353	O
chondrocyte-like	O
cells	O
chondrocyte	O
apoptosis	O
played	O
a	O
key	O
role	O
on	O
the	O
progression	O
of	O
osteoarthritis	O
oa	O
.	O
	
safe	O
and	O
effective	O
drugs	O
are	O
urgently	O
needed	O
for	O
the	O
treatment	O
of	O
oa	O
.	O
	
previous	O
study	O
reported	O
that	O
astragaloside	O
iv	O
asg-iv	O
had	O
exerted	O
a	O
protective	O
effect	O
against	O
articular	O
cartilage	O
degeneration	O
by	O
promoting	O
rapid	O
proliferation	O
of	O
chondrocyte	O
.	O
	
therefore	O
,	O
the	O
aim	O
of	O
our	O
study	O
is	O
to	O
explore	O
the	O
effects	O
and	O
mechanisms	O
of	O
asg-iv	O
in	O
chondrocyte	O
apoptosis	O
.	O
	
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantitation	O
itraq	O
quantitative	O
proteomics	B-C0872252
was	O
used	O
to	O
quantitatively	O
detect	O
and	O
map	O
proteins	O
in	O
sw1353	O
chondrocyte-like	O
cells	O
pre-treated	O
with	O
asg-iv	O
or	O
interleukin-1β	O
il-1β	O
or	O
asg-iv	O
+	O
il-1β	O
.	O
	
the	O
itraq-labeled	O
peptides	O
were	O
fractionated	O
by	O
high-accuracy	O
liquid	O
chromatography-mass	O
spectrometry	O
lc-ms	O
.	O
	
cell	O
apoptosis	O
and	O
differentially	O
expressed	O
proteins	O
was	O
detected	O
by	O
flow	O
cytometry	O
fcm	O
,	O
quantitative	O
real-time	O
polymerase	O
chain	O
reaction	O
qrt-pcr	O
,	O
and	O
western	O
blotting	O
,	O
respectively	O
.	O
	
the	O
apoptosis	O
of	O
the	O
il-1β	O
-	O
induced	O
sw1353	O
cells	O
treated	O
with	O
asg-iv	O
was	O
greatly	O
inhibited	O
.	O
	
bioinformatics	O
analysis	O
revealed	O
that	O
gamma	O
actin	O
1	O
actg1	O
and	O
yes	O
associated	O
protein	O
1	O
yap1	O
,	O
participating	O
in	O
the	O
hippo	O
signaling	O
pathway	O
and	O
vitronectin	O
vtn	O
and	O
collagen	O
type	O
i	O
alpha	O
1	O
chain	O
col1a1	O
,	O
involving	O
in	O
the	O
extracellular	O
matrix	O
ecm	O
interaction	O
signaling	O
pathway	O
,	O
were	O
all	O
significantly	O
up-regulated	O
in	O
the	O
il-1β	O
-	O
induced	O
sw1353	O
cells	O
after	O
treatment	O
with	O
asg-iv	O
.	O
	
the	O
qrt-pcr	O
and	O
western	O
blotting	O
results	O
confirmed	O
the	O
up-regulation	O
of	O
these	O
four	O
genes	O
.	O
	
asg-iv	O
played	O
a	O
positive	O
role	O
in	O
human	O
osteoarthritic	O
chondrocyte	O
apoptosis	O
,	O
possibly	O
through	O
modulation	O
of	O
the	O
hippo	O
signaling	O
pathway	O
by	O
up-regulating	O
yap1	O
and	O
actg1	O
expression	O
,	O
and	O
also	O
by	O
up-regulating	O
vtn	O
and	O
col1a1	O
,	O
which	O
are	O
involved	O
in	O
the	O
ecm-receptor	O
interaction	O
pathway	O
.	O
	
taken	O
together	O
,	O
all	O
the	O
results	O
suggested	O
that	O
asg-iv	O
had	O
a	O
novel	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
oa	B-C0029408
open-label	B-C1709323
,	O
multicentre	I-C1709323
safety	I-C1709323
study	I-C1709323
of	O
vemurafenib	B-C3192263
in	O
3219	O
patients	B-C0030705
with	O
braf	B-C3811884
mutation	I-C3811884
-	O
positive	B-C1514241
metastatic	B-C0278883
melanoma	I-C0278883
2-year	O
follow-up	B-C1522577
data	B-C1511726
and	O
long-term	B-C0443252
responders'	B-C0936012
analysis	I-C0936012
the	O
orally	B-C0442027
available	O
braf	B-C3838813
kinase	I-C3838813
inhibitor	I-C3838813
vemurafenib	B-C3192263
is	O
an	O
effective	B-C1704419
and	O
tolerable	B-C4053931
treatment	B-C0683525
option	I-C0683525
for	O
patients	B-C0030705
with	O
metastatic	B-C0278883
melanoma	I-C0278883
harbouring	O
braf	B-C3811884
mutations	I-C3811884
.	O
	
we	O
assessed	B-C1516048
the	O
safety	B-C0678800
of	O
vemurafenib	B-C3192263
in	O
a	O
large	B-C0549177
population	B-C1257890
of	O
patients	B-C0030705
with	O
few	O
alternative	B-C1523987
treatment	B-C0683525
options	I-C0683525
we	O
report	O
updated	O
2-year	O
safety	B-C0678800
.	O
	
this	O
was	O
an	O
open-label	B-C1709323
,	O
multicentre	I-C1709323
study	I-C1709323
of	O
vemurafenib	B-C3192263
960	O
mg	O
bid	O
in	O
patients	B-C0030705
with	O
previously	O
treated	B-C1522326
or	O
untreated	B-C0332155
braf	B-C3811884
mutation	I-C3811884
-	O
positive	B-C1514241
metastatic	B-C0278883
melanoma	I-C0278883
cobas	B-C0025080
4800	I-C0025080
braf	B-C1504359
v600	I-C1504359
mutation	I-C1504359
test	I-C1504359
.	O
	
the	O
primary	B-C0205225
end-point	B-C2349179
was	O
safety	B-C0678800
efficacy	O
end-points	B-C2349179
were	O
secondary	B-C0175668
.	O
	
an	O
exploratory	B-C0936012
analysis	I-C0936012
was	O
performed	O
to	O
assess	B-C0184514
safety	B-C0678800
outcomes	B-C0085415
in	O
patients	B-C0030705
with	O
long	B-C0205166
duration	B-C0237585
of	I-C0237585
response	I-C0237585
dor	B-C0237585
12	O
or	O
24	O
months	B-C0439231
.	O
	
after	O
a	O
median	B-C0549183
follow-up	B-C1522577
of	O
32.2	O
months	B-C0439231
95%	O
ci	O
,	O
31.1	O
months	B-C0439231
,	O
3079/3219	O
patients	B-C0030705
96%	O
had	O
discontinued	B-C0558681
treatment	I-C0558681
.	O
	
adverse	B-C0877248
events	I-C0877248
aes	B-C0877248
were	O
largely	O
consistent	B-C0332290
with	I-C0332290
previous	O
reports	O
the	O
most	O
common	O
all-grade	O
treatment	B-C0039798
-related	O
aes	B-C0877248
were	O
arthralgia	B-C0003862
37%	O
,	O
alopecia	B-C0002170
25%	O
and	O
hyperkeratosis	B-C0870082
23%	O
the	O
most	O
common	O
grade	O
3/4	O
treatment	B-C0039798
-related	O
aes	B-C0877248
were	O
squamous	B-C0553723
cell	I-C0553723
carcinoma	I-C0553723
of	I-C0553723
the	I-C0553723
skin	I-C0553723
8%	O
and	O
keratoacanthoma	B-C0022572
8%	O
.	O
	
in	O
the	O
exploratory	B-C0936012
analysis	I-C0936012
,	O
patients	B-C0030705
with	O
dor	B-C0237585
12	O
months	B-C0439231
n	O
=	O
287	O
or	O
24	O
months	B-C0439231
n	O
=	O
133	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3/4	O
aes	B-C0877248
than	O
the	O
overall	B-C1561607
population	B-C1257890
.	O
	
no	O
new	O
specific	B-C0205369
safety	B-C0183301
signals	I-C0183301
were	O
observed	O
with	O
longer	O
vemurafenib	B-C3192263
exposure	O
.	O
	
after	O
2	O
years'	O
follow-up	O
,	O
safety	O
was	O
maintained	O
in	O
this	O
large	O
group	O
of	O
patients	O
with	O
braf	O
mutation	O
-	O
positive	O
metastatic	O
melanoma	O
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical	O
practice	O
than	O
typical	O
clinical	O
trial	O
populations	O
.	O
	
these	O
data	O
suggest	O
that	O
long-term	O
vemurafenib	B-C0743284
treatment	O
is	O
effective	O
and	O
tolerable	O
without	O
the	O
development	O
of	O
new	O
safety	O
signals	I-C0183301
collecting	B-C0010995
and	O
reporting	B-C0011000
safety	I-C0011000
data	I-C0011000
and	O
monitoring	B-C1516647
trial	I-C1516647
conduct	I-C1516647
in	O
pragmatic	B-C3658215
trials	I-C3658215
pragmatic	B-C3658215
trials	I-C3658215
offer	O
the	O
opportunity	B-C0683937
to	O
obtain	O
real-life	B-C0376558
data	B-C1511726
on	O
the	O
relative	O
effectiveness	B-C1280519
and	O
safety	B-C0036043
of	O
a	O
treatment	B-C0087111
before	O
or	O
after	O
market	B-C2981648
authorisation	I-C2981648
.	O
	
this	O
is	O
the	O
penultimate	B-C1547566
paper	I-C1547566
in	O
a	O
series	O
of	O
eight	O
,	O
describing	O
the	O
impact	O
of	O
design	B-C0013171
choices	B-C1707391
on	O
the	O
practical	O
implementation	B-C1708476
of	O
pragmatic	B-C3658215
trials	I-C3658215
.	O
	
this	O
paper	B-C1547566
focuses	O
on	O
the	O
practical	O
challenges	O
of	O
collecting	B-C0010995
and	O
reporting	B-C0011000
safety	I-C0011000
data	I-C0011000
and	O
of	O
monitoring	B-C1516647
trial	I-C1516647
conduct	I-C1516647
while	O
maintaining	O
routine	O
clinical	B-C0695275
care	I-C0695275
practice	I-C0695275
.	O
	
current	O
ich	B-C0282574
guidance	O
recommends	O
that	O
,	O
all	O
serious	B-C1519255
adverse	I-C1519255
events	I-C1519255
saes	B-C1519255
and	O
all	O
drug	B-C1254351
-related	O
events	O
must	O
be	O
reported	O
in	O
an	O
interventional	B-C0184661
trial	B-C0008976
.	O
	
in	O
line	O
with	O
current	O
guidance	O
,	O
we	O
propose	O
a	O
risk	B-C0035647
based	O
approach	B-C0449445
to	O
the	O
collection	B-C0010995
of	O
non	B-C1513916
-	O
drug	B-C1254351
related	O
non-serious	B-C1518404
aes	I-C1518404
,	O
and	O
even	O
serious	B-C2826307
events	I-C2826307
not	O
related	O
to	O
treatment	B-C0087111
based	O
on	O
the	O
risk	B-C0035647
profile	B-C2003903
of	O
the	O
medicine	B-C0013227
/class	O
in	O
the	O
patient	B-C0030705
population	B-C1257890
of	O
interest	O
.	O
	
different	O
options	O
available	O
to	O
support	O
the	O
collection	B-C0010995
and	O
reporting	B-C0011000
of	I-C0011000
safety	I-C0011000
data	I-C0011000
whilst	O
minimizing	O
study	B-C2603343
-related	O
follow-up	B-C0589121
visits	I-C0589121
are	O
discussed	O
.	O
	
a	O
risk	B-C0035647
-based	O
approach	B-C0449445
to	O
monitoring	B-C1516647
trial	I-C1516647
conduct	I-C1516647
is	O
also	O
discussed	O
,	O
highlighting	O
the	O
difference	O
in	O
the	O
balance	O
of	O
risks	B-C0035647
likely	O
to	O
occur	O
in	O
a	O
pragmatic	B-C3658215
trial	I-C3658215
compared	O
to	O
traditional	O
clinical	B-C0008976
trials	I-C0008976
,	O
and	O
the	O
careful	O
consideration	O
that	O
must	O
be	O
given	O
to	O
the	O
mitigation	B-C1553901
and	O
management	B-C0035649
of	I-C0035649
these	I-C0035649
risks	I-C0035649
in	O
order	O
to	O
maintain	O
routine	O
a	O
pilot	B-C0031928
study	I-C0031928
of	O
intraocular	B-C1096279
lens	I-C1096279
explantation	I-C1096279
in	O
69	O
eyes	B-C0015392
in	O
chinese	B-C0030705
patients	I-C0030705
to	O
study	O
the	O
effects	O
of	O
intraocular	B-C1096279
lens	I-C1096279
iol	I-C1096279
explantation	I-C1096279
and	O
demographic	B-C0683970
characteristics	I-C0683970
.	O
	
retrospective	B-C1514923
non-comparative	B-C0150093
case	I-C0150093
series	I-C0150093
.	O
	
clinical	B-C1516606
data	I-C1516606
recorded	O
from	O
patient	B-C1268547
charts	I-C1268547
included	O
the	O
following	O
demographic	B-C0683970
,	O
preoperative	B-C0205908
and	O
postoperative	B-C0032790
characteristics	B-C1521970
complications	B-C0009566
surgical	B-C0683469
methods	I-C0683469
,	O
and	O
changes	O
in	O
visual	B-C0200150
acuity	I-C0200150
.	O
	
a	O
total	O
of	O
69	O
eyes	B-C0015392
in	O
67	O
chinese	B-C0152035
patients	B-C0030705
who	O
received	O
iol	B-C1096279
explants	I-C1096279
were	O
studied	O
.	O
	
the	O
patients	B-C0030705
'	O
mean	O
age	B-C0001779
at	O
the	O
time	B-C1254367
of	I-C1254367
explantation	I-C1254367
was	O
46.1	O
years	O
old	O
sd	O
22.5	O
6-85	O
,	O
and	O
37	O
patients	B-C0150905
were	I-C0150905
female	I-C0150905
55.2	O
.	O
	
regarding	O
employment	B-C0014003
,	O
47.8	O
were	O
farmers	B-C0221460
,	O
23.9	O
were	O
retired	B-C4076599
,	O
16.4	O
were	O
students	B-C0038492
,	O
4.5	O
were	O
unemployed	B-C0041674
,	O
3%	O
were	O
workers	B-C1527116
,	O
and	O
4.5	O
were	O
other	O
including	O
staff	B-C1552089
members	I-C1552089
,	O
teachers	B-C0221457
and	O
officers	B-C1549461
.	O
	
the	O
main	O
reasons	O
for	O
explantation	B-C0561946
were	O
dislocation	B-C0012691
/	O
decentration	B-C2609312
in	O
41	O
cases	O
59.4	O
and	O
retinal	B-C0035305
detachment	I-C0035305
in	O
10	O
cases	O
14.5	O
.	O
	
the	O
third	O
most	O
prevalent	B-C0015127
cause	I-C0015127
was	O
incorrect	B-C1627355
lens	I-C1627355
power	I-C1627355
in	O
7	O
eyes	B-C0015392
10.1	O
.	O
	
the	O
remaining	O
reasons	O
were	O
endophthalmitis	B-C0014236
in	O
6	O
cases	O
8.7	O
,	O
posterior	B-C1444680
capsular	I-C1444680
opacity	I-C1444680
in	O
3	O
eyes	B-C0015392
4.3	O
,	O
and	O
impacting	B-C4049986
retinal	B-C0197770
surgery	I-C0197770
operation	I-C0197770
in	O
2	O
cases	O
2.9	O
.	O
	
the	O
main	O
comorbidities	B-C0009488
were	O
high	B-C0271183
myopia	I-C0271183
in	O
18	O
eyes	B-C0015392
26.1	O
,	O
trauma	B-C3714660
in	O
8	O
eyes	B-C0015392
11.6	O
,	O
retinal	B-C0035305
detachment	I-C0035305
in	O
6	O
eyes	B-C0015392
8.7	O
,	O
congenital	B-C0009691
cataracts	I-C0009691
in	O
8	O
eyes	B-C0015392
11.6	O
,	O
and	O
marfan's	B-C0024796
syndrome	I-C0024796
in	O
2	O
eyes	B-C0015392
2.9	O
.	O
	
the	O
mean	B-C1254367
time	I-C1254367
from	I-C1254367
implantation	I-C1254367
to	I-C1254367
explantation	I-C1254367
was	O
4.0y	O
sd	O
4.2	O
0.005	O
.	O
	
treatment	B-C0032786
after	I-C0032786
explantation	I-C0032786
included	O
posterior	B-C1298763
chamber	I-C1298763
iol	I-C1298763
implantation	I-C1298763
in	O
44	O
eyes	B-C0015392
63.8	O
and	O
aphakia	B-C0003534
in	O
25	O
eyes	B-C0015392
36.2	O
.	O
	
after	B-C0241311
surgery	I-C0241311
,	O
the	O
best	B-C1690532
corrected	I-C1690532
visual	I-C1690532
ability	I-C1690532
bcva	B-C1690532
was	O
improved	O
in	O
50	O
cases	O
72.5	O
,	O
including	O
28	O
patients	B-C0030705
40.6	O
in	O
whom	O
visual	B-C0042812
ability	I-C0042812
was	O
improved	O
by	O
more	O
than	O
two	O
lines	O
.	O
	
dislocation	B-C0012691
/	O
decentration	B-C2609312
is	O
the	O
main	B-C0015127
cause	I-C0015127
for	O
explantation	B-C0561946
,	O
and	O
high	B-C0271183
myopia	I-C0271183
is	O
a	O
main	B-C0035648
risk	I-C0035648
factor	I-C0035648
.	O
	
posterior	B-C1298763
chamber	I-C1298763
iol	I-C1298763
implantation	I-C1298763
remains	O
the	O
most	O
elected	O
treatment	B-C0032786
after	I-C0032786
explantation	I-C0032786
.	O
	
improvement	B-C2986411
of	O
older	B-C0001792
-	O
person	B-C0027361
-	O
specific	B-C0205369
qol	B-C0034380
after	O
hearing	B-C0018768
aid	I-C0018768
fitting	B-C0185023
and	O
its	O
relation	B-C0439849
to	O
social	B-C0037420
interaction	I-C0037420
this	O
study	B-C2603343
aimed	B-C1947946
to	O
investigate	B-C1292732
whether	O
hearing	B-C0018768
aids	I-C0018768
use	O
is	O
associated	B-C0332281
with	I-C0332281
improvement	B-C2986411
of	O
older	B-C0001792
-	O
person	B-C0027361
-	O
specific	B-C0205369
qol	B-C0034380
and	O
whether	O
social	B-C0037420
interactions	I-C0037420
modify	B-C0392747
the	O
association	B-C0439849
.	O
	
the	O
whoqol-old	B-C0034394
questionnaire	I-C0034394
was	O
answered	B-C1706817
by	O
105	O
older	B-C0001792
adults	I-C0001792
aged	B-C0001779
60	O
to	O
90	O
years	O
who	O
were	O
newly	B-C0750546
fitted	B-C0185023
hearing	B-C0018768
aids	I-C0018768
on	O
the	O
day	O
of	O
fitting	B-C0185023
and	O
at	O
2	O
-	O
6	O
months	O
afterward	B-C0205087
.	O
	
the	O
associations	B-C0439849
between	O
the	O
daily	O
hours	O
of	O
hearing	B-C0018768
aid	I-C0018768
usage	B-C0457083
and	O
social	B-C0683633
relations	I-C0683633
with	O
changes	B-C0392747
in	O
the	O
whoqol-old	B-C0034394
total	B-C2964552
score	I-C2964552
after	O
hearing	B-C0018768
aids	I-C0018768
fitting	B-C0185023
were	O
estimated	B-C0750572
adjusting	B-C0849719
for	O
possible	B-C0332149
confounders	B-C0009673
.	O
	
older	B-C0001792
persons	B-C0027361
with	O
hearing	B-C3887873
loss	I-C3887873
experienced	B-C1709305
significant	B-C0750502
increases	B-C0442805
in	O
whoqol-old	B-C0034394
total	B-C2964552
score	I-C2964552
after	O
hearing	B-C0018768
aid	I-C0018768
fitting	B-C0185023
.	O
	
regular	B-C0205272
use	B-C1524063
of	I-C1524063
hearing	B-C0018768
aid	I-C0018768
was	O
associated	B-C0332281
with	I-C0332281
a	O
greater	B-C1704243
increase	B-C0442805
in	O
the	O
total	B-C2964552
score	I-C2964552
.	O
	
the	O
combined	B-C0205195
categorical	B-C0683312
variable	B-C0439828
of	O
social	B-C0683633
relations	I-C0683633
and	O
hearing	B-C0018768
aid	I-C0018768
usage	B-C0457083
revealed	B-C0443289
no	O
separate	B-C0443299
effects	B-C1280500
of	O
these	O
two	O
variables	B-C0439828
,	O
but	O
a	O
combined	B-C0205195
effect	B-C1280500
only	O
those	O
with	O
frequent	B-C0332183
social	B-C0037420
interactions	I-C0037420
who	O
used	O
their	O
hearing	B-C0018768
aid	I-C0018768
regularly	B-C0205272
had	O
a	O
significantly	B-C0750502
greater	B-C1704243
increase	B-C0442805
in	O
whoqol-old	B-C0034394
total	B-C2964552
score	I-C2964552
.	O
	
this	O
study's	B-C2603343
findings	B-C2607943
indicate	B-C1521902
that	O
hearing	B-C0018768
aid	I-C0018768
fitting	B-C0185023
may	O
be	O
associated	B-C0332281
with	I-C0332281
a	O
subsequent	B-C0332282
improvement	B-C2986411
in	O
older	B-C0001792
-	O
person	B-C0027361
-	O
specific	B-C0205369
qol	B-C0034380
by	O
improvements	B-C2986411
in	O
hearing	B-C0018767
due	O
to	O
the	O
hearing	B-C0018768
aid	I-C0018768
,	O
and	O
possibly	B-C0332149
enhanced	B-C2349975
communication	B-C0009452
opportunities	B-C0237506
.	O
	
enhancing	O
comparative	B-C2718022
effectiveness	I-C2718022
research	I-C2718022
with	O
automated	B-C0205554
pediatric	B-C1521725
pneumonia	B-C0032285
detection	B-C1511790
in	O
a	O
multi-institutional	B-C0026738
clinical	B-C0205210
repository	B-C3847505
a	O
phis	B-C0679918
+	O
pilot	B-C0031928
study	I-C0031928
community-acquired	B-C0694549
pneumonia	I-C0694549
is	O
a	O
leading	O
cause	O
of	O
pediatric	B-C1521725
morbidity	B-C0026538
.	O
	
administrative	B-C1292785
data	B-C1511726
are	O
often	O
used	O
to	O
conduct	O
comparative	B-C2718022
effectiveness	I-C2718022
research	I-C2718022
cer	B-C2718022
with	O
sufficient	O
sample	B-C0242618
sizes	I-C0242618
to	O
enhance	O
detection	B-C0442726
of	O
important	B-C3898777
outcomes	B-C1274040
.	O
	
however	O
,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification	B-C0743559
errors	I-C0743559
because	O
of	O
the	O
variable	B-C0439828
accuracy	B-C0443131
of	O
discharge	B-C1555319
diagnosis	I-C1555319
codes	B-C0805701
.	O
	
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	B-C0205554
,	O
scalable	B-C1513040
,	O
and	O
accurate	B-C0443131
method	B-C0025663
to	O
determine	B-C0521095
the	O
presence	B-C0150312
or	O
absence	B-C0332197
of	O
pneumonia	B-C0032285
in	O
children	B-C0008059
using	O
chest	B-C1531652
imaging	I-C1531652
reports	B-C4274373
.	O
	
the	O
multi-institutional	B-C0026738
phis	B-C0679918
+	O
clinical	B-C0205210
repository	B-C3847505
was	O
developed	O
to	O
support	O
pediatric	B-C1521725
cer	B-C2718022
by	O
expanding	O
an	O
administrative	B-C1292785
database	B-C0242356
of	O
children's	B-C0020017
hospitals	I-C0020017
with	O
detailed	O
clinical	B-C0205210
data	B-C1511726
.	O
	
to	O
develop	O
a	O
scalable	B-C1513040
approach	O
to	O
find	B-C0243095
patients	B-C0030705
with	O
bacterial	B-C0004626
pneumonia	I-C0004626
more	O
accurately	O
,	O
we	O
developed	O
a	O
natural	B-C0027489
language	I-C0027489
processing	I-C0027489
nlp	B-C0027489
application	B-C0205556
to	O
extract	O
relevant	B-C2347946
information	B-C1533716
from	O
chest	B-C1531652
diagnostic	I-C1531652
imaging	I-C1531652
reports	B-C4274373
.	O
	
domain	B-C1880389
experts	B-C0009817
established	B-C0443211
a	O
reference	B-C0034925
standard	I-C0034925
by	O
manually	B-C3842330
annotating	B-C0205245
282	O
reports	B-C4274373
to	O
train	O
and	O
then	O
test	O
the	O
nlp	B-C0027489
application	B-C0205556
.	O
	
findings	O
of	O
pleural	B-C0032227
effusion	I-C0032227
,	O
pulmonary	B-C0235896
infiltrate	I-C0235896
,	O
and	O
pneumonia	B-C0032285
were	O
automatically	B-C3842331
extracted	O
from	O
the	O
reports	B-C4274373
and	O
then	O
used	O
to	O
automatically	B-C3842331
classify	B-C0008902
whether	O
a	O
report	B-C4274373
was	O
consistent	B-C0332290
with	I-C0332290
bacterial	B-C0004626
pneumonia	I-C0004626
.	O
	
compared	B-C1707455
with	O
the	O
annotated	O
diagnostic	B-C0011923
imaging	I-C0011923
reports	B-C4274373
reference	B-C0034925
standard	I-C0034925
,	O
the	O
most	O
accurate	B-C0443131
implementation	B-C1708476
of	O
machine	B-C0376284
learning	I-C0376284
algorithms	B-C0002045
in	O
our	O
nlp	B-C0027489
application	B-C0205556
allowed	O
extracting	O
relevant	B-C2347946
findings	B-C2607943
with	O
a	O
sensitivity	B-C0036667
of	O
939	O
and	O
a	O
positive	B-C1446409
predictive	B-C1514307
value	I-C1514307
of	O
925	O
.	O
	
it	O
allowed	O
classifying	B-C0008902
reports	B-C4274373
with	O
a	O
sensitivity	B-C0036667
of	O
71	O
,	O
a	O
positive	B-C1446409
predictive	B-C1514307
value	I-C1514307
of	O
86	O
,	O
and	O
a	O
specificity	B-C0037791
of	O
962	O
.	O
	
when	O
compared	B-C1707455
with	O
each	O
of	O
the	O
domain	B-C1880389
experts	B-C0009817
manually	B-C3842330
annotating	B-C0205245
these	O
reports	B-C0025102
,	O
the	O
nlp	B-C0027489
application	B-C0205556
allowed	O
for	O
significantly	B-C4055637
higher	I-C4055637
sensitivity	B-C0036667
71	O
vs	O
527	O
and	O
similar	O
positive	B-C1446409
predictive	B-C1514307
value	I-C1514307
and	O
specificity	B-C0037791
.	O
	
nlp	B-C0027489
-based	O
pneumonia	B-C0032285
information	B-C1533716
extraction	O
of	O
pediatric	B-C1521725
diagnostic	B-C0011923
imaging	I-C0011923
reports	B-C4274373
performed	B-C0884358
better	O
than	O
domain	B-C1880389
experts	B-C0009817
in	O
this	O
pilot	B-C0031928
study	I-C0031928
.	O
	
nlp	B-C0027489
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	B-C1533716
from	O
a	O
large	O
collection	B-C1516698
of	O
imaging	B-C4274373
reports	I-C4274373
to	O
facilitate	O
determination	B-C1254363
of	O
volatile	B-C2350439
organic	I-C2350439
compounds	I-C2350439
exhaled	B-C0231800
by	O
cell	B-C0682523
lines	I-C0682523
derived	B-C1441547
from	O
hematological	B-C0376545
malignancies	I-C0376545
background	O
the	O
gas	B-C0017110
human	B-C0086418
exhaled	B-C0231800
contains	O
many	O
volatile	B-C2350439
organic	I-C2350439
compounds	I-C2350439
vocs	B-C2350439
,	O
which	O
is	O
related	O
to	O
the	O
health	B-C0018759
status	I-C0018759
of	O
body	B-C0242821
.	O
	
analysis	B-C0936012
of	O
vocs	B-C2350439
has	O
been	O
proposed	O
as	O
a	O
noninvasive	B-C2986496
diagnostic	B-C0430022
tool	I-C0430022
for	O
certain	O
cancers	B-C0027651
.	O
	
detailed	O
research	O
on	O
the	O
vocs	B-C2350439
in	O
gas	B-C0017110
exhaled	B-C0231800
by	O
cell	B-C0007634
can	O
characterize	O
cell	B-C0449475
type	I-C0449475
specific	O
metabolites	B-C0870883
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	B-C0041366
markers	I-C0041366
in	O
clinical	B-C0205897
practice	I-C0205897
.	O
	
methods	O
solid	B-C1720881
phase	I-C1720881
microextraction	I-C1720881
-	O
gas	B-C0008555
chromatography	I-C0008555
-	O
mass	B-C0037813
spectrometry	I-C0037813
was	O
used	O
to	O
detect	O
vocs	B-C2350439
in	O
the	O
headspace	O
of	O
tissue	B-C0492793
culture	I-C0492793
flask	I-C0492793
in	O
non-hodgkin's	B-C0024305
lymphoma	I-C0024305
cell	B-C0085983
line	I-C0085983
jeko	I-C0085983
and	O
acute	B-C0085669
mononuclear	I-C0085669
leukemia	I-C0085669
cell	B-C0085983
line	I-C0085983
shi-1	I-C0085983
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	B-C0017110
biomarkers	B-C0041366
of	O
hematological	B-C0376545
malignancies	I-C0376545
.	O
	
while	O
macrophage	B-C0024432
cells	I-C0024432
and	O
lymphocytic	B-C0024264
cells	I-C0024264
were	O
acted	O
as	O
control	B-C0009932
.	O
	
the	O
blank	B-C0441833
group	I-C0441833
was	O
only	O
the	O
rpmi	B-C0010454
1640	I-C0010454
medium	I-C0010454
containing	O
10%	O
fetal	B-C3812213
calf	I-C3812213
serum	I-C3812213
that	O
without	O
cells	B-C0007634
.	O
	
results	O
comparing	O
to	O
control	B-C0009932
group	I-C0009932
,	O
the	O
concentration	B-C1446561
of	O
dimethyl	B-C0574031
sulphide	I-C0574031
,	O
2	B-C0574031
,	O
methylbenzene	B-C0040383
,	O
o-xylene	B-C0046596
,	O
dodecane	B-C0067942
and	O
1	B-C0574031
in	O
jeko	B-C0085983
cells	I-C0085983
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	B-C0001962
,	O
hexanal	B-C0068007
and	O
benzaldehyde	B-C0005023
was	O
lower	O
.	O
	
in	O
shi-1	B-C0085983
cells	I-C0085983
,	O
the	O
levels	O
of	O
2	B-C0574031
,	O
benzene	B-C0005036
,	O
4-methyldecane	B-C0574031
,	O
chloroform	B-C0008238
,	O
3	B-C0574031
dodecane	I-C0574031
and	O
hexadecane	B-C0068005
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	B-C0001978
and	O
cyclohexanol	B-C0010569
were	O
distinctly	O
reduced	O
.	O
	
conclusions	O
this	O
pilot	B-C0031928
study	I-C0031928
revealed	O
that	O
the	O
malignant	B-C0376545
hematological	I-C0376545
cells	B-C0007634
could	O
change	O
the	O
components	O
of	O
vocs	B-C2350439
in	O
the	O
cell	B-C3830103
culture	I-C3830103
flask	I-C3830103
in	O
a	O
cell	B-C0449475
type	I-C0449475
specific	O
pattern	O
.	O
	
the	O
traits	O
of	O
vocs	B-C2350439
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	B-C0376545
malignancies	I-C0376545
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	B-C0041366
in	O
diagnosis	B-C0011900
of	O
malignant	B-C0205282
hematological	B-C0018939
diseases	I-C0018939
.	O
	
intratympanic	B-C1517566
steroid	I-C1517566
delivery	I-C1517566
by	O
an	O
indwelling	O
catheter	O
in	O
refractory	O
severe	O
sudden	O
sensorineural	O
hearing	O
loss	O
many	O
studies	O
over	O
the	O
last	O
decade	O
showed	O
favorable	O
outcomes	O
with	O
intratympanic	O
it	O
steroid	B-C0038317
treatment	O
,	O
alone	O
as	O
salvage	O
treatment	O
or	O
in	O
combination	O
with	O
conventional	O
systemic	O
therapy	O
st	O
.	O
	
however	O
,	O
in	O
severe	O
to	O
profound	O
sensorineural	O
hearing	O
loss	O
resistant	O
to	O
st	O
,	O
the	O
optimal	O
infusion	O
mode	O
,	O
the	O
type	O
and	O
concentration	O
of	O
the	O
solution	O
,	O
the	O
preferable	O
drug	O
,	O
its	O
total	O
amount	O
,	O
and	O
the	O
duration	O
and	O
fractionation	O
of	O
the	O
treatment	O
are	O
still	O
debated	O
.	O
	
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	O
and	O
the	O
outcomes	O
of	O
a	O
direct	O
and	O
constant	O
it	O
delivery	O
of	O
dexamethasone	O
dex	O
by	O
means	O
of	O
a	O
new	O
indwelling	B-C0007439
catheter	I-C0007439
.	O
	
a	O
prospective	O
case-control	O
study	O
in	O
a	O
tertiary	O
referral	O
university	O
hospital	O
.	O
	
ninety-nine	O
subjects	O
treated	O
with	O
st	O
only	O
and	O
28	O
with	O
additional	O
it	O
dex	O
have	O
been	O
included	O
in	O
the	O
study	O
.	O
	
a	O
4	O
fr	O
catheter	O
inserted	O
in	O
a	O
sub-annular	O
fashion	O
with	O
a	O
minimal	O
postero-inferior	O
tympanotomy	O
through	O
and	O
endocanalar	O
approach	O
under	O
local	O
anesthesia	O
.	O
	
dex	O
4mg/ml	O
delivered	O
daily	O
,	O
up	O
to	O
7	O
days	O
.	O
	
daily	O
bone	O
and	O
air-conducted	O
pure	O
tone	O
and	O
speech	O
audiometry	O
were	O
performed	O
with	O
a	O
follow-up	O
at	O
1	O
,	O
3	O
,	O
6	O
months	O
after	O
treatment	O
.	O
	
twenty-one	O
out	O
of	O
28	O
patients	O
75%	O
refractory	B-C4275242
to	O
st	O
gained	O
on	O
average	O
24.0db	O
hl	O
after	O
it	O
-	O
dex	O
,	O
compared	O
to	O
35.4	O
average	O
6.7db	O
hl	O
of	O
those	O
receiving	O
only	O
medical	O
st	O
p<0	O
.	O
	
no	O
significant	O
side	O
effects	O
were	O
noted	O
.	O
	
in	O
severe	I-C4275242
to	O
profound	O
sudden	I-C4275242
deafness	O
refractory	O
to	O
conventional	O
st	O
,	O
the	O
daily	O
perfusion	O
of	O
4mg/ml	O
dex	O
through	O
an	O
intratympanic	O
catheter	O
is	O
an	O
easy	O
,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	O
to	O
receive	O
a	O
drug	O
in	O
the	O
middle	O
ear	O
in	O
a	O
repeatable	O
or	O
sustained	O
form	O
,	O
with	O
minimal	O
discomfort	O
and	O
a	O
partial	O
rescue	O
67.86	O
and	O
a	O
speech	O
recognition	O
gain	O
of	O
design	B-C1707689
,	O
synthesis	B-C1883254
and	O
anti-tumor	B-C1148560
activity	I-C1148560
study	B-C2603343
of	O
novel	O
histone	B-C1512474
deacetylase	I-C1512474
inhibitors	I-C1512474
containing	O
isatin	B-C0022115
-based	O
caps	B-C1254350
and	O
o-phenylenediamine	B-C0043796
-based	O
zinc	B-C1254350
binding	I-C1254350
groups	I-C1254350
as	O
a	O
hot	O
topic	O
of	O
epigenetic	B-C1655731
studies	I-C1655731
,	O
histone	B-C0019643
deacetylases	I-C0019643
hdacs	B-C0019643
are	O
related	O
to	O
lots	O
of	O
diseases	B-C0012634
,	O
especially	O
cancer	B-C0027651
.	O
	
further	O
researches	B-C0035168
indicated	O
that	O
different	B-C1705242
hdac	B-C0019643
isoforms	I-C0019643
played	O
various	O
roles	B-C1705810
in	O
a	O
wide	O
range	O
of	O
tumor	B-C4263544
types	I-C4263544
.	O
	
herein	O
a	O
novel	O
series	B-C0205549
of	O
hdac	B-C1512474
inhibitors	I-C1512474
with	O
isatin	B-C0022115
-based	O
caps	B-C1254350
and	O
o-phenylenediamine	B-C0043796
-based	O
zinc	B-C1254350
binding	I-C1254350
groups	I-C1254350
have	O
been	O
designed	B-C1707689
and	O
synthesized	B-C1883254
through	B-C0332273
scaffold	B-C0022885
hopping	I-C0022885
strategy	I-C0022885
.	O
	
among	O
these	O
compounds	B-C1706082
,	O
the	O
most	O
potent	O
compound	B-C1706082
9n	I-C1706082
exhibited	O
similar	O
if	O
not	O
better	B-C0332272
hdac	B-C0019643
inhibition	B-C1524081
and	O
antiproliferative	B-C1148560
activities	I-C1148560
against	O
multiple	B-C0439064
tumor	B-C0085983
cell	I-C0085983
lines	I-C0085983
compared	B-C1707455
with	O
the	O
positive	B-C1883676
control	I-C1883676
entinostat	B-C2743752
ms-275	B-C1510480
.	O
	
additionally	O
,	O
compared	B-C1707455
with	O
ms-275	B-C1510480
ic50	B-C0600495
values	B-C1522609
for	O
hdac1	B-C2718309
,	O
2	B-C0768528
and	O
3	B-C1098658
were	O
0.163	O
,	O
0.396	O
and	O
0.605µm	O
,	O
respectively	O
,	O
compound	B-C1706082
9n	I-C1706082
with	O
ic50	B-C0600495
values	B-C1522609
of	O
0.032	O
,	O
0.256	O
and	O
0.311µm	O
for	O
hdac1	B-C2718309
,	O
2	B-C0768528
and	O
3	B-C1098658
respectively	O
,	O
showed	O
a	O
moderate	O
hdac1	B-C2718309
selectivity	B-C0205556
.	O
	
efficacy	B-C1280519
of	O
42	O
pharmacologic	B-C1254351
cotreatment	B-C0087111
strategies	O
added	O
to	O
antipsychotic	B-C0040615
monotherapy	B-C0087111
in	O
schizophrenia	B-C0036341
systematic	O
overview	O
and	O
quality	B-C0332306
appraisal	O
of	O
the	O
meta-analytic	B-C0920317
evidence	B-C3887511
limited	O
treatment	B-C0087111
responses	B-C0871261
in	O
schizophrenia	B-C0036341
prompted	O
the	O
testing	O
of	O
combining	O
an	O
antipsychotic	B-C0040615
drug	I-C0040615
treatment	B-C0087111
with	O
a	O
second	O
psychotropic	B-C0033978
medication	B-C0013227
.	O
	
a	O
comprehensive	O
evaluation	B-C0220825
of	O
the	O
efficacy	B-C1280519
of	O
multiple	O
medication	B-C0013227
combinations	B-C0013162
is	O
missing	O
.	O
	
to	O
summarize	O
and	O
compare	O
the	O
meta-analytically	B-C0920317
determined	O
efficacy	B-C1280519
of	O
pharmacologic	B-C1254351
combination	B-C0013162
strategies	O
of	O
antipsychotic	B-C0040615
drugs	I-C0040615
in	O
adults	B-C0001675
with	O
schizophrenia	B-C0036341
.	O
	
systematic	O
search	O
of	O
pubmed	B-C1138432
and	O
psycinfo	B-C1140129
until	O
may	O
13	O
,	O
2016	O
.	O
	
meta-analyses	B-C0920317
of	O
randomized	B-C0206034
clinical	I-C0206034
trials	I-C0206034
comparing	O
the	O
efficacy	B-C1280519
of	O
antipsychotic	B-C0040615
drugs	I-C0040615
combined	O
with	O
other	O
antipsychotic	B-C0040615
or	O
nonantipsychotic	B-C0013227
medications	I-C0013227
vs	O
placebos	B-C1696465
or	O
antipsychotic	B-C0040615
monotherapy	B-C0087111
among	O
adults	B-C0001675
with	O
schizophrenia	B-C0036341
.	O
	
independent	O
reviewers	B-C1882950
extracted	O
the	O
data	B-C1511726
and	O
assessed	O
the	O
quality	B-C0332306
of	O
the	O
methods	B-C0025663
of	O
the	O
included	O
meta-analyses	B-C0920317
using	O
a	O
measurement	B-C1955832
tool	I-C1955832
to	I-C1955832
assess	I-C1955832
systematic	I-C1955832
reviews	I-C1955832
amstar	B-C1955832
,	O
adding	O
6	O
new	O
items	O
to	O
rate	O
their	O
quality	B-C0332306
.	O
	
effect	B-C0814843
sizes	I-C0814843
,	O
expressed	O
as	O
standardized	B-C1828170
mean	I-C1828170
difference	I-C1828170
/hedges	O
g	O
or	O
risk	B-C0028873
ratio	I-C0028873
,	O
were	O
compared	O
separately	O
for	O
combinations	B-C0013162
with	O
any	O
antipsychotic	B-C0040615
drug	I-C0040615
and	O
for	O
combinations	B-C0013162
with	O
clozapine	B-C0009079
.	O
	
the	O
primary	O
outcome	O
was	O
total	O
symptom	B-C1457887
reduction	B-C0392756
.	O
	
secondary	O
outcomes	O
included	O
positive	B-C1446409
and	O
negative	B-C0205160
symptoms	B-C1457887
,	O
treatment	B-C0582427
recommendations	I-C0582427
by	O
authors	O
,	O
study-defined	O
inefficacies	B-C0231184
,	O
cognitive	B-C1516691
and	O
depressive	B-C0086132
symptoms	I-C0086132
,	O
discontinuation	B-C0457454
of	O
treatment	B-C0087111
because	O
of	O
any	O
cause	O
,	O
and	O
inefficacies	B-C0231184
or	O
intolerabilities	O
.	O
	
of	O
3397	O
publications	O
,	O
29	O
meta-analyses	B-C0920317
testing	O
42	O
combination	B-C0013162
strategies	O
in	O
381	O
individual	B-C0237401
trials	O
and	O
among	O
19	O
833	O
participants	B-C0679646
were	O
included	O
.	O
	
for	O
total	O
symptom	B-C1457887
reductions	B-C0441610
,	O
32	O
strategies	O
that	O
augmented	O
any	O
antipsychotic	B-C0040615
drug	I-C0040615
and	O
5	O
strategies	O
that	O
augmented	O
clozapine	B-C0009079
were	O
examined	O
.	O
	
fourteen	O
combination	B-C0013162
treatments	B-C0087111
outperformed	O
controls	O
standard	B-C1828170
mean	I-C1828170
difference	I-C1828170
/hedges	O
g	O
,	O
-1	O
95%	O
ci	B-C0009667
,	O
-2	O
to	O
-0	O
to	O
-0	O
95%	O
ci	B-C0009667
,	O
-0	O
to	O
-0	O
p	O
=	O
05	O
.	O
	
no	O
combination	B-C0013162
strategies	O
with	O
clozapine	B-C0009079
outperformed	O
controls	O
.	O
	
the	O
quality	B-C0332306
of	O
the	O
methods	B-C0025663
of	O
the	O
meta-analyses	B-C0920317
was	O
generally	O
high	B-C0205250
mean	B-C3533236
score	I-C3533236
,	O
9	O
of	O
a	O
maximum	B-C0449820
score	I-C0449820
of	O
11	O
but	O
the	O
quality	B-C0332306
of	O
the	O
meta-analyzed	B-C0920317
studies	I-C0920317
was	O
low	B-C0205251
mean	B-C3533236
score	I-C3533236
,	O
2.8	O
of	O
a	O
maximum	B-C0449820
score	I-C0449820
of	O
8	O
.	O
	
treatment	B-C0582427
recommendations	I-C0582427
correlated	O
with	O
the	O
effect	B-C0814843
size	I-C0814843
correlation	B-C0392762
coefficient	I-C0392762
,	O
0.22	O
95%	O
ci	B-C0009667
,	O
0.35	O
p	O
<	O
001	O
,	O
yet	O
effect	B-C0814843
sizes	I-C0814843
were	O
inversely	O
correlated	O
with	O
study	O
quality	B-C0332306
correlation	B-C0392762
coefficient	I-C0392762
,	O
-0	O
95%	O
ci	B-C0009667
,	O
0.01	O
to	O
-0	O
p	O
=	O
02	O
.	O
	
meta-analyses	B-C0920317
of	O
21	O
interventions	O
fully	O
or	O
partially	O
recommended	O
their	O
use	O
,	O
with	O
recommendations	B-C0034866
being	O
positively	B-C1446409
correlated	O
with	O
the	O
effect	B-C0814843
sizes	I-C0814843
of	O
the	O
pooled	O
intervention	O
.	O
	
however	O
,	O
the	O
effect	B-C0814843
sizes	I-C0814843
were	O
inversely	O
correlated	O
with	O
meta-analyzed	B-C0920317
study	I-C0920317
quality	B-C0332306
,	O
reducing	B-C0392756
confidence	B-C1704726
in	O
these	O
recommendations	B-C0034866
.	O
	
higher	B-C0205250
-	O
quality	B-C0332306
trials	O
and	O
patient	B-C0030705
-based	O
meta-analyses	B-C0920317
are	O
needed	O
to	O
determine	O
whether	O
subpopulations	B-C1257890
might	O
benefit	O
from	O
combination	B-C0013162
treatment	B-C0087111
,	O
as	O
no	O
single	O
strategy	O
can	O
be	O
recommended	O
for	O
patients	B-C0030705
with	O
schizophrenia	B-C0036341
based	O
on	O
the	O
current	O
meta-analytic	B-C0920317
literature	B-C0023866
.	O
	
involvement	B-C1314939
of	O
vascular	B-C0005847
aldosterone	B-C0075233
synthase	I-C0075233
in	O
phosphate	B-C1601799
-	O
induced	B-C0205263
osteogenic	B-C0243095
transformation	I-C0243095
of	O
vascular	B-C0005847
smooth	B-C1135918
muscle	I-C1135918
cells	I-C1135918
vascular	B-C0342649
calcification	I-C0342649
resulting	O
from	O
hyperphosphatemia	B-C0085681
is	O
a	O
major	O
determinant	O
of	O
mortality	B-C0178686
in	O
chronic	B-C1561643
kidney	I-C1561643
disease	I-C1561643
ckd	B-C1561643
.	O
	
vascular	B-C0342649
calcification	I-C0342649
is	O
driven	O
by	O
aldosterone	B-C0002006
-sensitive	O
osteogenic	B-C0243095
transformation	I-C0243095
of	O
vascular	B-C0005847
smooth	B-C1135918
muscle	I-C1135918
cells	I-C1135918
vsmcs	B-C1135918
.	O
	
we	O
show	O
that	O
even	O
in	O
absence	B-C0332197
of	O
exogenous	B-C0205228
aldosterone	B-C0002006
,	O
silencing	B-C1148560
and	O
pharmacological	B-C1148560
inhibition	I-C1148560
spironolactone	B-C0037982
,	O
eplerenone	B-C0961485
of	O
the	O
mineralocorticoid	B-C0066563
receptor	I-C0066563
mr	B-C0066563
ameliorated	O
phosphate	B-C1601799
-	O
induced	B-C0205263
osteo-	B-C0243095
/	O
chondrogenic	B-C0243095
transformation	I-C0243095
of	O
primary	B-C0205225
human	B-C0086418
aortic	B-C0003483
smooth	B-C1135918
muscle	I-C1135918
cells	I-C1135918
haosmcs	B-C1135918
.	O
	
high	O
phosphate	B-C1601799
concentrations	B-C0392762
up-regulated	B-C0041904
aldosterone	B-C0075233
synthase	I-C0075233
cyp11b2	B-C1527416
expression	B-C1171362
in	O
haosmcs	B-C1135918
.	O
	
silencing	B-C1148560
and	O
deficiency	B-C0033626
of	O
cyp11b2	B-C1527416
in	O
vsmcs	B-C1135918
ameliorated	O
phosphate	B-C1601799
-	O
induced	B-C0205263
osteogenic	B-C1254358
reprogramming	I-C1254358
and	O
calcification	B-C1533591
.	O
	
phosphate	B-C1601799
treatment	B-C1522326
was	O
followed	O
by	O
nuclear	B-C0887840
export	I-C0887840
of	O
apex1	B-C0140145
,	O
a	O
cyp11b2	B-C1413857
transcriptional	B-C1336789
repressor	I-C1336789
.	O
	
apex1	B-C0140145
silencing	B-C1148560
up-regulated	B-C0041904
cyp11b2	B-C1413857
expression	B-C0017262
and	O
stimulated	O
osteo-	B-C0243095
/	O
chondrogenic	B-C0243095
transformation	I-C0243095
.	O
	
apex1	B-C0140145
overexpression	B-C1514559
blunted	O
the	O
phosphate	B-C1601799
-	O
induced	B-C0205263
osteo-	B-C0243095
/	O
chondrogenic	B-C0243095
transformation	I-C0243095
and	O
calcification	B-C1533591
of	O
haosmcs	B-C1135918
.	O
	
cyp11b2	B-C1413857
expression	B-C0017262
was	O
higher	O
in	O
aortic	B-C0003483
tissue	B-C0040300
of	O
hyperphosphatemic	B-C0085681
klotho-hypomorphic	B-C0025929
kl/kl	I-C0025929
mice	I-C0025929
than	O
in	O
wild-type	B-C1883559
mice	B-C0025929
.	O
	
in	O
adrenalectomized	B-C0025929
kl/kl	I-C0025929
mice	I-C0025929
,	O
spironolactone	B-C0037982
treatment	B-C1522326
still	O
significantly	O
ameliorated	O
aortic	B-C0003483
osteoinductive	B-C1254358
reprogramming	I-C1254358
.	O
	
our	O
findings	B-C2607943
suggest	O
that	O
vsmcs	B-C1135918
express	O
aldosterone	B-C0075233
synthase	I-C0075233
,	O
which	O
is	O
up-regulated	B-C0041904
by	O
phosphate	B-C1601799
-	O
induced	B-C0205263
disruption	B-C0332453
of	O
apex1	B-C0140145
-dependent	O
gene	B-C0038855
suppression	I-C0038855
.	O
	
vascular	B-C0005847
cyp11b2	B-C1527416
may	O
contribute	O
to	O
stimulation	O
of	O
vsmcs	B-C1135918
osteo-	B-C0243095
/	O
chondrogenic	B-C0243095
transformation	I-C0243095
during	O
fairness	B-C2911689
the	O
hidden	O
challenge	B-C0805586
for	O
competency-based	B-C0150562
postgraduate	I-C0150562
medical	I-C0150562
education	I-C0150562
programs	I-C0150562
competency-based	B-C0681326
medical	I-C0681326
education	I-C0681326
systems	I-C0681326
allow	O
institutions	B-C0681325
to	O
individualize	B-C0205245
teaching	B-C0039403
practices	I-C0039403
to	O
meet	B-C1550543
the	O
needs	B-C0027552
of	O
diverse	B-C0038492
learners	I-C0038492
.	O
	
yet	O
,	O
the	O
focus	O
on	O
continuous	O
improvement	B-C2986411
and	O
individualization	B-C0205245
of	O
curricula	B-C0010478
does	O
not	O
exempt	O
programs	B-C3484370
from	O
treating	O
learners	B-C0038492
in	O
a	O
fair	B-C0243095
manner	I-C0243095
.	O
	
when	O
learners	B-C0038492
fail	O
to	O
meet	O
key	O
competencies	B-C0086035
and	O
are	O
placed	O
on	O
probation	B-C0687758
or	O
dismissed	B-C2348301
from	O
training	B-C0040607
programs	I-C0040607
,	O
issues	B-C0033213
of	O
fairness	B-C2911689
may	O
form	O
the	O
basis	O
of	O
their	O
legal	B-C0282574
claims	I-C0282574
.	O
	
in	O
a	O
literature	O
search	O
,	O
we	O
found	O
no	O
in-depth	O
examination	B-C0033336
of	O
fairness	B-C2911689
.	O
	
in	O
this	O
paper	O
,	O
we	O
utilize	O
a	O
systems	O
lens	O
to	O
examine	B-C0332128
fairness	B-C2911689
within	O
postgraduate	B-C0013633
medical	I-C0013633
education	I-C0013633
contexts	B-C0449255
,	O
focusing	O
on	O
educational	B-C0243095
opportunities	I-C0243095
,	O
assessment	B-C0220825
practices	I-C0220825
,	O
decision-making	B-C0011111
processes	I-C0011111
,	O
fairness	B-C2911689
from	O
a	O
legal	B-C1301860
standpoint	I-C1301860
,	O
and	O
fairness	B-C2911689
in	O
the	O
context	B-C0449255
of	O
the	O
learning	B-C1510556
environment	I-C1510556
.	O
	
while	O
we	O
provide	O
examples	O
of	O
fairness	B-C2911689
issues	B-C0033213
within	O
us	B-C0041703
training	B-C0040607
programs	I-C0040607
,	O
concerns	O
regarding	O
fairness	B-C2911689
are	O
relevant	O
in	O
any	O
medical	B-C0681326
education	I-C0681326
system	I-C0681326
which	O
utilizes	O
a	O
competency-based	B-C1254370
education	I-C1254370
framework	I-C1254370
.	O
	
assessment	B-C0033336
oversight	O
committees	B-C1522486
and	O
annual	B-C0033336
programmatic	I-C0033336
evaluations	I-C0033336
,	O
while	O
recommended	O
,	O
will	O
not	O
guarantee	O
fairness	B-C2911689
within	O
postgraduate	B-C0150562
medical	I-C0150562
education	I-C0150562
programs	I-C0150562
,	O
but	O
they	O
can	O
provide	O
a	O
window	O
into	O
'hidden'	O
threats	O
to	O
fairness	B-C2911689
,	O
as	O
everything	O
from	O
training	B-C0220931
experiences	I-C0220931
to	O
assessment	B-C0220825
practices	I-C0220825
may	O
be	O
examined	B-C0332128
by	O
these	O
committees	B-C1522486
.	O
	
one	O
of	O
the	O
first	O
steps	O
programs	B-C3484370
can	O
take	O
is	O
to	O
recognize	O
that	O
threats	O
to	O
fairness	B-C2911689
may	O
exist	O
in	O
any	O
educational	B-C0150562
program	I-C0150562
,	O
including	O
their	O
own	O
,	O
and	O
begin	O
conversations	B-C0871703
about	O
how	O
to	O
address	O
these	O
us3	B-C0033684
and	O
us9	B-C2001544
proteins	B-C0033684
contribute	O
to	O
the	O
stromal	B-C1336515
invasion	I-C1336515
of	O
bovine	B-C0021335
herpesvirus	I-C0021335
1	I-C0021335
in	O
the	O
respiratory	B-C0751974
mucosa	I-C0751974
bovine	B-C3687301
herpesvirus	I-C3687301
1	I-C3687301
bhv-1	I-C3687301
infection	I-C3687301
may	O
lead	O
to	O
conjunctivitis	B-C0009763
,	O
upper	B-C0458578
respiratory	I-C0458578
tract	I-C0458578
problems	B-C0033213
,	O
pneumonia	B-C0032285
,	O
genital	B-C0178829
disorders	I-C0178829
and	O
abortion	B-C0156543
.	O
	
bhv-1	B-C0021335
is	O
able	O
to	O
spread	B-C0332261
quickly	O
in	O
a	O
plaque	B-C0332461
-wise	O
manner	B-C0205245
and	O
invade	B-C0205245
by	O
breaching	B-C3203359
the	O
basement	B-C0004799
membrane	I-C0004799
bm	B-C0004799
barrier	B-C0682585
in	O
the	O
respiratory	B-C0751974
mucosa	I-C0751974
.	O
	
bhv-1	B-C0021335
us3	B-C0033684
,	O
a	O
serine/threonine	B-C0072402
kinase	I-C0072402
,	O
induces	B-C0205263
a	O
dramatic	O
cytoskeletal	B-C1511632
reorganization	I-C1511632
and	O
bhv-1	B-C0021335
us9	B-C2001544
,	O
a	O
tail-anchored	B-C0025252
membrane	I-C0025252
protein	I-C0025252
,	O
is	O
required	O
for	O
axonal	B-C0004462
transport	I-C0004462
of	O
viruses	B-C0042776
in	O
neurons	B-C0027882
.	O
	
in	O
this	O
study	B-C2603343
,	O
we	O
investigated	B-C1292732
the	O
role	B-C1705810
of	O
us3	B-C0033684
and	O
us9	B-C2001544
during	O
bhv-1	B-C3687301
infection	I-C3687301
in	O
the	O
respiratory	B-C0751974
mucosa	I-C0751974
.	O
	
first	O
,	O
we	O
constructed	O
and	O
characterized	B-C1880022
bhv-1	B-C0021335
us3	B-C0017337
null	B-C0042776
,	O
us9	B-C0017337
null	B-C0042776
and	O
revertant	B-C0042776
viruses	I-C0042776
.	O
	
then	O
,	O
we	O
analysed	B-C0936012
the	O
viral	B-C0042774
replication	I-C0042774
and	O
plaque	B-C0332461
size	B-C0456389
latitude	O
in	O
madin-darby	B-C0598829
bovine	I-C0598829
kidney	I-C0598829
mdbk	B-C0598829
cells	B-C0598829
and	O
the	O
respiratory	B-C0751974
mucosa	I-C0751974
as	O
well	O
as	O
viral	B-C1656555
penetration	I-C1656555
depth	O
underneath	O
the	O
bm	B-C0004799
of	O
the	O
respiratory	B-C0751974
mucosa	I-C0751974
when	O
inoculated	B-C2987620
with	O
these	O
recombinant	B-C0085391
viruses	I-C0085391
.	O
	
knockout	B-C1522225
of	O
us3	B-C0017337
resulted	O
in	O
a	O
1	O
log10	O
reduction	B-C0392756
in	O
viral	B-C2713348
titre	I-C2713348
and	O
plaque	B-C0332461
size	B-C0456389
latitude	B-C1627936
in	O
mdbk	B-C0598829
cells	I-C0598829
and	O
the	O
trachea	B-C0225584
mucosa	I-C0225584
.	O
	
there	O
were	O
no	B-C1513916
defects	B-C1457869
in	O
the	O
cell-to-cell	B-C1160712
spread	I-C1160712
observed	B-C1441672
for	O
bhv-1	B-C0021335
us9	B-C0017337
null	B-C0042776
virus	I-C0042776
.	O
	
both	O
bhv-1	B-C0021335
us3	B-C0017337
null	B-C0042776
and	O
us9	B-C0017337
null	B-C0042776
viruses	I-C0042776
showed	O
a	O
significant	B-C0750502
reduction	B-C0392756
of	O
plaque	B-C0332461
penetration	B-C0205321
underneath	O
the	O
bm	B-C0004799
however	O
,	O
penetration	B-C0205321
was	O
not	O
completely	O
inhibited	B-C3463820
.	O
	
in	O
conclusion	B-C1707478
,	O
the	O
current	O
findings	B-C0035168
demonstrated	O
that	O
us3	B-C0017337
and	O
us9	B-C0017337
play	O
an	O
important	O
role	B-C1705810
in	O
the	O
invasion	B-C1336515
of	O
bhv-1	B-C0021335
through	O
the	O
bm	B-C0004799
of	O
the	O
respiratory	B-C0751974
mucosa	I-C0751974
,	O
which	O
shows	O
the	O
way	O
forward	O
for	O
research	B-C0035168
-based	O
attenuation	B-C0599946
of	O
viruses	B-C0042776
in	O
order	O
to	O
make	O
safer	O
and	O
better	B-C0332272
-	O
performing	B-C0884358
vaccines	B-C0042210
.	O
	
traumatic	B-C0876926
brain	I-C0876926
injury	I-C0876926
and	O
depression	B-C0011570
in	O
a	O
community	B-C0009462
-	O
based	B-C1527178
sample	O
a	O
cohort	B-C0009247
study	I-C0009247
across	O
the	O
adult	B-C0001675
life	B-C0870809
span	I-C0870809
to	O
determine	O
whether	O
self-reported	O
traumatic	B-C0876926
brain	I-C0876926
injuries	I-C0876926
tbis	B-C0876926
are	O
associated	B-C0332281
with	I-C0332281
""""	O
cases	B-C1706256
""""	O
of	O
clinically	B-C2826293
significant	I-C2826293
depression	B-C0011570
in	O
the	O
general	B-C0009462
community	I-C0009462
.	O
	
to	O
examine	O
interactions	B-C1704675
between	O
variables	B-C1705098
previously	O
linked	O
to	O
depression	B-C0011570
after	O
a	O
tbi	B-C0876926
.	O
	
population	B-C1257890
-based	O
community	B-C0009462
study	B-C2603343
canberra	B-C0454764
and	O
queanbeyan	B-C0681784
,	O
australia	B-C0004340
.	O
	
three	B-C0205449
age	B-C2348001
cohorts	I-C2348001
young	B-C0332239
,	O
middle-aged	B-C0205847
,	O
and	O
older	B-C0001792
adults	B-C0001675
aged	B-C0001779
20-24	O
,	O
40-44	O
,	O
and	O
60-64	B-C4035747
years	I-C4035747
at	O
baseline	B-C1442488
randomly	B-C0439605
selected	B-C1707391
from	O
the	O
electoral	O
roll	O
and	O
followed	B-C0332283
across	O
3	O
waves	O
4	O
years	B-C0439234
apart	I-C0439234
.	O
	
a	O
total	O
of	O
7397	O
,	O
6621	O
,	O
and	O
6042	O
people	B-C0027361
provided	O
their	O
tbi	B-C0876926
history	O
in	O
waves	O
1	O
to	O
3	O
.	O
	
lifetime	B-C4071830
tbilifetime	O
sustained	B-C0443318
at	O
any	O
time	B-C0040223
since	B-C1711239
birth	B-C0005615
,	O
recent	B-C0332185
tbirecent	O
in	O
the	O
preceding	B-C0332152
4	O
years	B-C0439234
,	O
and	O
multiple	B-C0439064
tbimultiple	O
more	O
than	O
1	O
tbis	B-C0876926
,	O
current	B-C0521116
depression	B-C0011570
,	O
and	O
known	O
risk	B-C0035648
factors	I-C0035648
for	O
depression	B-C0011570
age	B-C0001779
,	O
sex	B-C0079399
,	O
marital	B-C0024819
/	O
employment	B-C0242271
status	I-C0242271
,	O
prior	B-C2133631
history	I-C2133631
of	O
depression	B-C0011570
,	O
medical	B-C0243095
conditions	I-C0243095
,	O
recent	O
life	B-C0441471
events	I-C0441471
,	O
alcohol	B-C0001948
consumption	I-C0001948
,	O
social	B-C0037438
support	I-C0037438
,	O
physical	B-C0026606
activity	I-C0026606
.	O
	
generalized	O
estimating	O
equations	B-C0552449
demonstrated	O
a	O
significant	O
association	B-C0439849
between	O
sustaining	O
a	O
tbi	B-C0876926
and	O
experiencing	O
clinically	B-C2826293
significant	I-C2826293
depression	B-C0011570
cases	B-C1706256
,	O
even	O
after	O
controlling	B-C2239193
for	O
multiple	B-C0439064
demographic	B-C0011292
and	O
health	B-C0018684
/	O
lifestyle	B-C0023676
factors	B-C1521761
.	O
	
there	O
is	O
an	O
enduring	O
association	B-C0439849
between	O
depression	B-C0011570
and	O
tbi	B-C0876926
,	O
suggesting	O
that	O
,	O
following	O
a	O
tbi	B-C0876926
,	O
individuals	B-C0237401
should	O
be	O
monitored	B-C1521743
and	O
supported	O
to	O
optimize	O
their	O
long-term	B-C0443252
psychological	B-C0025353
health	I-C0025353
.	O
	
cs	B-C0162969
-	O
peg	B-C0032483
decorated	O
plga	B-C0071599
nano-prototype	I-C0071599
for	O
delivery	B-C3850077
of	O
bioactive	B-C0574031
compounds	I-C0574031
a	O
novel	B-C0205314
approach	B-C0449445
for	O
induction	B-C0205263
of	O
apoptosis	B-C0162638
in	O
hepg2	B-C2717940
cell	I-C2717940
line	I-C2717940
polymer	B-C0032521
-	O
based	B-C1527178
nanoparticles	B-C1450054
are	O
used	B-C1524063
as	O
vectors	B-C0442335
for	O
cancer	B-C0007097
drug	B-C0039798
delivery	I-C0039798
.	O
	
the	O
bioactive	B-C0574031
compounds	I-C0574031
quercetin	B-C0034392
,	O
ellagic	B-C0013900
acid	I-C0013900
and	O
gallic	B-C0016979
acid	I-C0016979
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	B-C0003402
but	O
also	O
chemopreventive	B-C1516463
candidates	I-C1516463
against	B-C0521124
various	B-C0439064
types	B-C0332307
of	O
cancers	B-C0007097
.	O
	
to	O
circumvent	O
the	O
low	B-C0205251
bioavailability	B-C0005508
and	O
the	O
short	B-C1806781
half-life	B-C0018517
time	B-C0040223
obstacles	B-C0332206
,	O
we	O
hypothesized	O
a	O
novel	B-C0205314
plga	B-C0071599
nano-platform	I-C0071599
functionalized	B-C0205245
with	O
cs	B-C0162969
and	O
peg	B-C0032483
to	O
encapsulate	B-C0205223
these	O
phytochemicals	B-C0577749
.	O
	
this	O
encapsulation	B-C2348438
will	O
protect	B-C1545588
the	O
compounds	B-C1254351
from	O
the	O
phagocytic	B-C3888108
uptake	I-C3888108
and	O
deliver	B-C3850077
plga-cs-peg	B-C1254351
nano-prototype	I-C1254351
with	O
high	O
biodegradability	B-C0205556
and	O
biosafety	B-C0205556
.	O
	
three	O
consequent	O
types	B-C0332307
of	O
plga-based	B-C1254351
nanocomposites	I-C1254351
were	O
prepared	B-C1521827
and	O
characterized	B-C1880022
.	O
	
furthermore	O
,	O
we	O
investigated	B-C1292732
the	O
newly	O
synthesized	B-C1883254
nano-formulations	B-C1707824
against	B-C0521124
human	B-C0086418
hepatocellular	B-C2239176
carcinoma	I-C2239176
hepg2	B-C2717940
and	O
colorectal	B-C1527249
cancer	I-C1527249
hct	B-C1258005
116	I-C1258005
cell	B-C0682523
lines	I-C0682523
using	B-C1524063
cell	B-C1512773
growth	I-C1512773
inhibition	I-C1512773
assays	B-C1510438
,	O
followed	B-C0332283
by	I-C0332283
apoptosis	B-C0162638
and	O
necrosis	B-C0027540
assays	B-C1510438
using	B-C1524063
flow	B-C0016263
cytometry	I-C0016263
to	O
detect	B-C0022885
the	O
underlying	O
mechanism	B-C0441712
of	O
hepg2	B-C2717940
cell	B-C0007587
death	I-C0007587
.	O
	
through	O
malvern	O
zeta	O
sizer	O
,	O
we	O
recorded	O
that	O
the	O
average	B-C1510992
diameters	B-C1301886
of	O
the	O
nano-prototypes	B-C1450054
ranged	O
from	O
150	O
to	O
300nm	O
.	O
	
the	O
cytotoxic	B-C1551412
activity	I-C1551412
of	O
quercetin	B-C0034392
,	O
ellagic	B-C0013900
acid	I-C0013900
,	O
and	O
gallic	B-C0016979
acid	I-C0016979
-	O
encapsulated	B-C0205223
plga	B-C0071599
,	O
plga-cs	B-C1254351
,	O
and	O
plga-cs-peg	B-C1254351
nano-prototypes	I-C1254351
it	O
has	O
been	O
found	B-C0150312
that	O
they	O
reduce	B-C0392756
the	O
ic50s	B-C0600495
of	O
the	O
hepg2	B-C2717940
cells	I-C2717940
values	B-C1522609
by	O
2.2	O
,	O
2.9	O
,	O
2.8	O
folds	B-C1880833
,	O
1	O
,	O
1.5	O
,	O
2.7	O
folds	B-C1880833
,	O
and	O
0.9	O
,	O
0.7	O
,	O
1.5	O
folds	B-C1880833
,	O
respectively	O
.	O
	
mechanistically	O
,	O
the	O
nano-platforms	O
of	O
quercetin	B-C0034392
seem	O
to	O
be	O
dependent	B-C0851827
on	O
both	O
apoptosis	B-C0162638
and	O
necrosis	B-C0027540
,	O
while	O
those	O
of	O
ellagic	B-C0013900
acid	I-C0013900
and	O
gallic	B-C0016979
acid	I-C0016979
are	O
mainly	O
dependent	B-C0851827
on	O
apoptosis	B-C0162638
.	O
	
cs	B-C0162969
-	O
peg	B-C0032483
-blended	O
plga	B-C0071599
nano-delivery	B-C0449914
system	I-C0449914
of	O
quercetin	B-C0034392
,	O
ellagic	B-C0013900
acid	I-C0013900
and	O
gallic	B-C0016979
acid	I-C0016979
can	O
potentiate	B-C2349975
apoptosis-mediated	B-C0162638
cell	B-C0007587
death	I-C0007587
in	O
hepg2	B-C2717940
cell	I-C2717940
line	I-C2717940
.	O
	
fingerprint	B-C0016126
-based	O
background	B-C0243095
checks	I-C0243095
for	O
personal	B-C1522486
care	I-C1522486
workers	I-C1522486
stakeholder	B-C0027361
views	B-C1254370
of	O
policy	B-C0242456
criteria	B-C0243161
decision	B-C1257890
makers	I-C1257890
face	O
difficult	O
choices	O
when	O
tasked	O
with	O
identifying	O
and	O
implementing	B-C1708476
appropriate	O
mechanisms	B-C0441712
for	O
protecting	B-C0516529
the	O
elderly	B-C0001792
and	O
other	O
vulnerable	B-C1562367
adults	I-C1562367
from	O
abuse	B-C1546935
.	O
	
a	O
pilot	B-C0031928
project	I-C0031928
involving	O
fingerprint	B-C0016126
-based	O
criminal	B-C2607966
history	O
background	B-C0243095
checks	I-C0243095
for	O
personal	B-C1522486
care	I-C1522486
workers	I-C1522486
in	O
michigan	B-C1548669
has	O
supplied	O
an	O
opportunity	B-C0683937
to	O
examine	O
one	O
such	O
mechanism	B-C0441712
.	O
	
in	O
conjunction	B-C2699427
with	O
the	O
pilot	B-C0031928
project	I-C0031928
,	O
we	O
have	O
conducted	O
a	O
stakeholder	B-C1522486
analysis	B-C0936012
with	O
the	O
aim	O
of	O
informing	O
decision	B-C1257890
makers	I-C1257890
about	O
stakeholder	B-C0027361
perceptions	B-C0030971
of	O
standard	B-C3244099
policy	B-C0242456
criteria	B-C0243161
like	O
effectiveness	B-C1280519
,	O
efficiency	B-C0013682
,	O
and	O
equity	B-C0237597
.	O
	
we	O
employed	O
focus	B-C0681860
groups	I-C0681860
and	O
a	O
web-based	B-C0038951
survey	I-C0038951
to	O
collect	B-C0010995
data	B-C1511726
from	O
stakeholders	B-C0027361
.	O
	
while	O
stakeholders	B-C0027361
generally	O
see	O
fingerprint	B-C0016126
-based	O
background	B-C0243095
checks	I-C0243095
for	O
personal	B-C1522486
care	I-C1522486
workers	I-C1522486
as	O
potentially	O
effective	B-C1704419
and	O
as	O
a	O
net	B-C0814225
benefit	I-C0814225
,	O
they	O
also	O
point	O
to	O
a	O
variety	O
of	O
contingencies	B-C0441471
.	O
	
they	O
also	O
recognize	O
difficulties	B-C0425101
and	O
constraints	B-C0443288
for	O
government	B-C0018104
involvement	B-C1314939
.	O
	
this	O
preliminary	B-C0936012
analysis	I-C0936012
provides	O
solid	O
foundational	B-C1533716
information	I-C1533716
for	O
decision	B-C1257890
makers	I-C1257890
and	O
for	O
more	O
extensive	O
benefit-cost	B-C0010174
analysis	I-C0010174
.	O
	
penetrating	B-C0205321
craniomaxillofacial	B-C0024961
injury	I-C0024961
caused	O
by	O
a	O
pneumatic	O
nail	O
gun	O
craniomaxillofacial	B-C0418073
injuries	O
can	O
be	O
complex	O
,	O
requiring	O
a	O
multidisciplinary	O
approach	O
.	O
	
the	O
primary	O
survey	O
is	O
always	O
the	O
first	O
step	O
in	O
trauma	O
management	O
prior	O
to	O
proceeding	O
with	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
a	O
26-	O
year	O
-old	O
man	O
presented	O
with	O
a	O
penetrating	O
nail	O
gun	O
injury	O
through	O
the	O
oral	O
and	O
nasal	O
cavities	O
.	O
	
he	O
did	O
not	O
present	O
in	O
extremis	O
but	O
required	O
elective	O
endotracheal	O
intubation	O
for	O
intraoperative	O
assessment	O
and	O
treatment	O
.	O
	
airway	O
management	O
was	O
enhanced	O
by	O
the	O
use	O
of	O
lingual	O
nerve	O
and	O
inferior	O
alveolar	O
nerve	O
blocks	O
via	O
the	O
vazirani-akinosi	O
technique	O
to	O
maintain	O
spontaneous	O
respiration	O
while	O
the	O
tongue	O
was	O
distracted	O
from	O
the	O
palate	O
.	O
	
the	O
nail	O
was	O
removed	O
and	O
rapid	O
sequence	O
induction	O
initiated	O
for	O
orotracheal	O
intubation	O
.	O
	
local	O
nerve	O
blocks	O
can	O
be	O
an	O
effective	O
tool	O
in	O
the	O
armamentarium	O
of	O
the	O
craniomaxillofacial	O
trauma	O
surgeon	O
in	O
managing	O
blunt	O
and	O
penetrating	O
injuries	O
.	O
	
we	O
demonstrate	O
its	O
utility	O
in	O
airway	O
management	O
when	O
a	O
penetrating	O
foreign	O
body	O
in	O
the	O
upper	O
airway	O
precludes	O
orotracheal	O
or	O
nasotracheal	O
design	O
of	O
a	O
candidate	O
vibrational	B-C1710082
signal	I-C1710082
for	O
mating	B-C1260875
disruption	B-C0332453
against	O
the	O
glassy-winged	B-C0600235
sharpshooter	I-C0600235
,	O
homalodisca	B-C1218186
vitripennis	I-C1218186
the	O
glassy-winged	B-C0600235
sharpshooter	I-C0600235
gwss	B-C0600235
,	O
homalodisca	B-C1218186
vitripennis	I-C1218186
,	O
is	O
an	O
important	O
pest	B-C0021585
of	O
grapevines	B-C0682492
due	O
to	O
its	O
ability	O
to	O
transmit	B-C0332289
xylella	B-C0995982
fastidiosa	I-C0995982
,	O
the	O
causal	B-C0314732
agent	I-C0314732
of	O
pierce's	B-C0032080
disease	I-C0032080
.	O
	
gwss	B-C0600235
mating	B-C1260875
communication	B-C0003046
is	O
based	O
on	O
vibrational	B-C1710082
signals	I-C1710082
therefore	O
,	O
vibrational	B-C0205556
mating	B-C1260875
disruption	B-C0332453
could	O
be	O
an	O
alternative	B-C1523987
to	O
insecticides	B-C0021576
for	O
suppression	B-C0678671
of	O
gwss	B-C0600235
population	B-C1257890
.	O
	
our	O
objectives	B-C0018017
were	O
to	O
identify	O
spectral	B-C1883073
features	B-C2348519
of	O
female	B-C0086287
signal	B-C1710082
that	O
elicit	O
male	B-C0086582
signaling	B-C3158821
,	O
design	O
disruptive	B-C0332454
signals	B-C1710082
able	O
to	O
alter	B-C0392747
male	B-C0086582
perception	B-C0030971
and	O
acceptance	B-C0000899
of	O
a	O
female	B-C0086287
,	O
and	O
determine	O
the	O
signal	B-C0871362
intensity	I-C0871362
required	O
for	O
future	O
field	O
applications	O
.	O
	
results	B-C0683954
showed	O
that	O
male	B-C0086582
responses	B-C0871261
to	O
playback	B-C0441655
of	O
modified	B-C0392747
female	B-C0086287
signals	B-C1710082
were	O
significantly	B-C0750502
reduced	B-C0392756
by	O
60-75%when	O
part	O
of	O
the	O
female	B-C0086287
signal	B-C1705248
spectral	I-C1705248
components	I-C1705248
above	O
or	O
below	O
400	O
hz	O
were	O
deleted	O
.	O
	
playback	B-C0441655
bioassays	B-C0005507
showed	O
that	O
transmission	B-C1521797
of	O
an	O
80	O
hz	O
pure	O
frequency	B-C0237917
tone	I-C0237917
to	O
plants	B-C0032098
completely	O
suppressed	B-C1260953
male	B-C0086582
signaling	B-C3158821
to	O
female	B-C0086287
signal	B-C0441655
playback	I-C0441655
,	O
even	O
if	O
the	O
disruptive	B-C0332454
signal	B-C3828024
amplitude	I-C3828024
was	O
10	O
db	O
lower	O
than	O
the	O
female	B-C0086287
signal	B-C0441655
playback	I-C0441655
.	O
	
although	O
the	O
mechanism	B-C0441712
underlying	O
cessation	B-C1880019
of	O
male	B-C0086582
signaling	B-C3158821
activity	O
in	O
the	O
presence	B-C0150312
of	O
disruption	B-C0332453
is	O
not	O
yet	O
understood	O
,	O
results	B-C0683954
suggest	O
that	O
an	O
80	O
hz	O
vibrational	B-C1710082
signal	I-C1710082
should	O
be	O
tested	O
in	O
laboratory	B-C0022877
and	O
field	B-C0868962
experiments	I-C0868962
to	O
assess	B-C1516048
its	O
efficacy	B-C1280519
in	O
disrupting	O
mating	B-C1260875
of	O
barriers	B-C0205556
and	O
facilitators	B-C0205556
to	O
smoking	B-C0085134
cessation	I-C0085134
in	O
a	O
cancer	B-C0006826
context	B-C0449255
a	O
qualitative	B-C0949415
study	I-C0949415
of	O
patient	B-C0030705
,	O
family	B-C0015576
and	O
professional	B-C0679924
views	B-C0205556
continued	B-C0549178
smoking	B-C0037369
after	O
cancer	B-C0006826
adversely	B-C0879626
affects	I-C0879626
quality	B-C0518214
of	I-C0518214
life	I-C0518214
and	O
survival	B-C0220921
,	O
but	O
one	O
fifth	O
of	O
cancer	B-C0006826
survivors	B-C0206194
still	O
smoke	B-C0037369
.	O
	
despite	O
its	O
demands	O
,	O
cancer	B-C0006826
presents	O
an	O
opportunity	O
for	O
positive	B-C1446409
behaviour	B-C0542299
change	I-C0542299
.	O
	
smoking	B-C0037369
often	O
occurs	O
in	O
social	B-C0687744
groups	I-C0687744
,	O
therefore	O
interventions	B-C0184661
which	O
target	B-C1521840
families	B-C0015576
and	O
individuals	B-C0027361
may	O
be	O
more	O
successful	B-C1272703
.	O
	
this	O
qualitative	B-C0949415
study	I-C0949415
explored	O
patients	B-C0030705
,	O
family	B-C0086282
members	I-C0086282
and	O
health	B-C1704312
professionals	I-C1704312
'	O
views	B-C0205556
and	O
experiences	B-C0596545
of	O
smoking	B-C0037369
and	O
smoking	B-C0085134
cessation	I-C0085134
after	O
cancer	B-C0006826
,	O
in	O
order	O
to	O
inform	O
future	O
interventions	B-C0184661
.	O
	
in-depth	B-C0683518
qualitative	I-C0683518
interviews	I-C0683518
n	O
=	O
67	O
with	O
29	O
patients	B-C0030705
,	O
14	O
family	B-C0086282
members	I-C0086282
and	O
24	O
health	B-C1704312
professionals	I-C1704312
.	O
	
data	B-C1511726
were	O
analysed	O
using	O
the	O
'framework'	B-C0449851
method	I-C0449851
.	O
	
few	O
patient	B-C0030705
s	O
and	O
family	B-C0086282
members	I-C0086282
had	O
used	O
national	B-C0027462
health	I-C0027462
service	I-C0027462
nhs	B-C0027462
smoking	B-C0085134
cessation	I-C0085134
services	B-C0018747
and	O
more	O
than	O
half	O
still	O
smoked	B-C0037369
.	O
	
most	O
recalled	O
little	O
'	O
smoking	B-C0037369
-related'	O
discussion	B-C0557050
with	O
clinicians	B-C0871685
but	O
were	O
receptive	O
to	O
talking	O
openly	O
.	O
	
clinicians	B-C0871685
revealed	O
several	O
barriers	B-C0205556
to	O
discussion	B-C0557050
.	O
	
participants	B-C0679646
'	O
continued	B-C0549178
smoking	B-C0037369
was	O
explained	O
by	O
the	O
stress	B-C0038435
of	O
diagnosis	B-C0920688
desire	O
to	O
maintain	O
personal	B-C1519021
control	B-C0243148
and	O
lack	B-C0332268
of	O
connection	O
between	O
smoking	B-C0037369
,	O
cancer	B-C0006826
and	O
health	B-C0018684
.	O
	
a	O
range	O
of	O
barriers	B-C0205556
to	O
smoking	B-C0085134
cessation	I-C0085134
exist	O
for	O
patients	B-C0030705
and	O
family	B-C0086282
members	I-C0086282
.	O
	
these	O
are	O
insufficiently	B-C0231180
assessed	B-C1516048
and	O
considered	O
by	O
clinicians	B-C0871685
.	O
	
interventions	B-C0184661
improving	B-C1272745
the	O
sexual	B-C2362326
health	I-C2362326
of	O
young	B-C0087178
people	I-C0087178
with	O
mobility	B-C0518456
impairments	I-C0518456
challenges	B-C0805586
and	O
recommendations	B-C0034866
this	O
mixed-method	B-C0681814
study	I-C0681814
a	O
describes	O
challenges	B-C0805586
to	O
providing	B-C1999230
sexual	B-C2362326
health	I-C2362326
services	B-C0018747
to	O
youth	B-C0087178
with	O
mobility	B-C0518456
impairments	I-C0518456
from	O
the	O
perspective	B-C0449911
of	O
health	B-C0018724
care	I-C0018724
providers	I-C0018724
and	O
experts	B-C0009817
and	O
b	O
describes	O
and	O
compares	B-C1707455
sexual	B-C2362326
health	I-C2362326
-related	O
experiences	B-C0596545
of	O
youth	B-C0087178
with	O
mobility	B-C0518456
impairments	I-C0518456
.	O
	
secondary	B-C0683944
data	I-C0683944
analysis	I-C0683944
of	I-C0683944
my	I-C0683944
path	I-C0683944
,	O
a	O
study	B-C0681814
focused	B-C1285542
on	O
the	O
transition	B-C2700061
to	O
adulthood	B-C0700597
for	O
youth	B-C0087178
with	O
mobility	B-C0518456
impairments	I-C0518456
.	O
	
using	O
an	O
exploratory	B-C0035171
sequential	I-C0035171
design	I-C0035171
,	O
qualitative	B-C0681942
data	I-C0681942
n	O
=	O
10	O
were	O
analyzed	B-C0936012
using	O
systematic	B-C0220922
content	B-C0681915
analysis	I-C0681915
followed	O
by	O
quantitative	B-C0681919
analysis	I-C0681919
of	I-C0681919
survey	I-C0681919
data	I-C0681919
n	O
=	O
337	O
.	O
	
challenges	B-C0805586
included	B-C0332257
not	B-C0205556
talking	I-C0205556
about	O
sex	B-C1522384
,	O
managing	O
sexual	B-C0233896
development	I-C0233896
,	O
adaptation	B-C0000934
and	O
instruction	B-C1442085
,	O
parent	B-C0680075
roles	I-C0680075
,	O
and	O
safety	B-C0036043
.	O
	
survey	B-C0038951
data	B-C1511726
showed	O
that	O
youth	B-C0087178
with	O
mobility	B-C0518456
impairments	I-C0518456
are	O
diverse	B-C1880371
in	O
their	O
experiences	B-C0596545
with	O
sexual	B-C0036864
behavior	I-C0036864
and	O
sources	B-C0449416
of	O
sexual	B-C2362326
health	I-C2362326
information	B-C1533716
.	O
	
although	O
connected	B-C2986575
with	O
primary	B-C0018724
care	I-C0018724
providers	I-C0018724
,	O
few	O
received	B-C1514756
information	B-C1533716
about	O
sexual	B-C2362326
health	I-C2362326
.	O
	
interventions	B-C1273869
to	O
improve	B-C0184511
youths	B-C0087178
'	O
well-being	B-C0018684
should	O
include	B-C2700399
comprehensive	B-C0009586
care	I-C0009586
and	O
education	B-C0018701
that	O
promotes	B-C0033414
and	O
supports	B-C1521721
healthy	B-C3898900
sexual	B-C0233896
development	I-C0233896
.	O
	
understanding	B-C0162340
the	O
interrelationship	B-C0439849
between	O
the	O
synthesis	B-C0220781
of	O
urea	B-C0041942
and	O
gluconeogenesis	B-C0017715
by	O
formulating	O
an	O
overall	B-C1561607
balanced	B-C0552449
equation	I-C0552449
it	O
is	O
well	O
known	O
that	O
a	O
strong	O
metabolic	B-C0311400
interrelationship	B-C0439849
exists	O
between	O
ureagenesis	B-C0597619
and	O
gluconeogenesis	B-C0017715
.	O
	
in	O
this	O
paper	O
,	O
we	O
present	O
a	O
detailed	O
,	O
overall	B-C1561607
equation	B-C0552449
,	O
describing	O
a	O
possible	O
metabolic	B-C0311400
link	B-C0449379
between	O
ureagenesis	B-C0597619
and	O
gluconeogenesis	B-C0017715
.	O
	
we	O
adopted	O
a	O
guided	B-C0449445
approach	I-C0449445
in	O
which	O
we	O
strongly	O
suggest	O
that	O
students	B-C0038492
,	O
when	O
faced	O
with	O
the	O
problem	B-C0033213
of	O
obtaining	B-C1706701
the	O
overall	B-C1561607
equation	B-C0552449
of	O
a	O
metabolic	B-C1291081
pathway	I-C1291081
,	O
carefully	O
account	O
for	O
all	O
atoms	B-C0567415
and	O
charges	B-C1706211
of	O
the	O
single	O
reactions	B-C0443286
,	O
as	O
well	O
as	O
the	O
cellular	B-C1660642
localizations	I-C1660642
of	O
the	O
substrates	B-C3891814
,	O
and	O
the	O
related	O
transport	B-C1519628
systems	B-C0449913
.	O
	
if	O
this	O
suggestion	O
is	O
always	O
taken	O
into	O
account	O
,	O
a	O
balanced	B-C0205415
,	O
overall	B-C1561607
equation	B-C0552449
of	O
a	O
metabolic	B-C1291081
pathway	I-C1291081
will	O
be	O
obtained	O
,	O
which	O
strongly	O
facilitates	O
the	O
discussion	O
of	O
its	O
physiological	B-C0205463
role	O
.	O
	
unfortunately	O
,	O
textbooks	B-C0039712
often	O
report	B-C0684224
unbalanced	O
overall	B-C1561607
equations	B-C0552449
of	O
metabolic	B-C1291081
pathways	I-C1291081
,	O
including	O
ureagenesis	B-C0597619
and	O
gluconeogenesis	B-C0017715
.	O
	
most	O
likely	O
the	O
reason	O
is	O
that	O
metabolism	B-C0025519
and	O
enzymology	B-C0014445
have	O
been	O
neglected	O
for	O
about	O
three	O
decades	O
,	O
owing	O
to	O
the	O
remarkable	O
advances	O
of	O
molecular	B-C0026376
biology	I-C0026376
and	O
molecular	B-C0086345
genetics	I-C0086345
.	O
	
in	O
this	O
paper	B-C1706852
,	O
we	O
strongly	O
suggest	O
that	O
students	B-C0038492
,	O
when	O
faced	O
with	O
the	O
problem	O
of	O
obtaining	O
the	O
overall	B-C1561607
reaction	B-C0443286
of	O
a	O
metabolic	B-C1291081
pathway	I-C1291081
,	O
carefully	O
control	O
if	O
the	O
single	O
reactions	B-C0443286
are	O
properly	O
balanced	B-C0205415
for	O
atoms	B-C0567415
and	O
charges	B-C1706211
.	O
	
following	O
this	O
suggestion	B-C1705535
,	O
we	O
were	O
able	O
to	O
obtain	O
an	O
overall	B-C1561607
equation	B-C0552449
describing	O
the	O
metabolic	B-C0311400
interrelationship	B-C0439849
between	O
ureagenesis	B-C0597619
and	O
gluconeogenesis	B-C0017715
,	O
in	O
which	O
urea	B-C0041942
and	O
glucose	B-C0017725
are	O
the	O
final	B-C3853528
products	B-C1514468
.	O
	
the	O
aim	O
is	O
to	O
better	O
rationalize	B-C1552821
this	O
topic	B-C1706203
and	O
to	O
convince	O
students	B-C0038492
and	O
teachers	B-C0221457
that	O
metabolism	B-C0025519
is	O
an	O
important	O
and	O
rewarding	O
chapter	B-C1552857
of	O
human	B-C3826168
physiology	I-C3826168
.	O
	
delineation	O
of	O
b-cell	B-C0004561
epitopes	B-C0003316
of	O
salmonella	B-C0036125
enterica	I-C0036125
serovar	I-C0036125
typhi	I-C0036125
hemolysin	B-C2603981
e	I-C2603981
potential	B-C3245505
antibody	B-C0003241
therapeutic	B-C0087111
target	B-C1521840
hemolysin	B-C2603981
e	I-C2603981
hlye	B-C2603981
is	O
an	O
immunogenic	B-C0872192
novel	B-C0205314
pore	B-C1325742
-forming	O
toxin	B-C0073997
involved	O
in	O
the	O
pathogenesis	B-C0699748
of	O
typhoid	B-C0041466
fever	I-C0041466
.	O
	
thus	O
,	O
mapping	B-C1283195
of	O
b-cell	B-C0004561
epitopes	B-C0003316
of	O
salmonella	B-C0036125
enterica	I-C0036125
serovar	I-C0036125
typhi	I-C0036125
s	B-C0036125
.	O
	
typhi	I-C0036125
is	O
critical	B-C1511545
to	O
identify	O
key	O
immunogenic	B-C1254362
regions	I-C1254362
of	O
hlye	B-C2603981
.	O
	
a	O
random	O
20-mer	O
peptide	B-C0376436
library	I-C0376436
was	O
used	O
for	O
biopanning	O
with	O
enriched	O
anti-hlye	B-C0312586
polyclonal	I-C0312586
antibodies	I-C0312586
from	O
typhoid	B-C0041466
patient	B-C0030705
sera	B-C0229671
.	O
	
bioinformatic	B-C1140694
tools	B-C0037589
were	O
used	O
to	O
refine	O
,	O
analyze	B-C0936012
and	O
map	B-C1283195
the	O
enriched	O
peptide	B-C0920679
sequences	I-C0920679
against	O
the	O
protein	B-C0033684
to	O
identify	O
the	O
epitopes	B-C0003316
.	O
	
the	O
analysis	B-C0936012
identified	O
both	O
linear	B-C0205132
and	O
conformational	B-C1254362
epitopes	B-C0003316
on	O
the	O
hlye	B-C2603981
protein	I-C2603981
.	O
	
the	O
predicted	B-C0681842
linear	B-C0205132
gaaagivag	B-C0002518
and	O
conformational	B-C1254362
epitope	B-C0003316
pysqesvlsadsqnqk	B-C0002518
were	O
further	O
validated	O
against	O
the	O
pooled	O
sera	B-C0229671
.	O
	
the	O
identified	O
epitopes	B-C0003316
were	O
then	O
used	O
to	O
isolate	B-C0204727
epitope	B-C0003316
specific	O
monoclonal	B-C0003250
antibodies	I-C0003250
by	O
antibody	B-C0003241
phage	B-C1519025
display	I-C1519025
.	O
	
monoclonal	B-C1432679
scfv	I-C1432679
antibodies	B-C0003241
were	O
enriched	O
for	O
both	O
linear	B-C0205132
and	O
conformational	B-C1254362
epitopes	B-C0003316
.	O
	
molecular	B-C3494274
docking	I-C3494274
was	O
performed	O
to	O
elucidate	O
the	O
antigen-antibody	B-C1268869
interaction	I-C1268869
of	O
the	O
monoclonal	B-C0003250
antibodies	I-C0003250
against	O
the	O
epitopes	B-C0003316
on	O
the	O
hlye	B-C2603981
monomer	B-C0312811
and	O
oligomer	B-C0599219
structure	I-C0599219
.	O
	
an	O
in-depth	O
view	O
of	O
the	O
mechanistic	O
and	O
positional	B-C0240795
characteristics	B-C1521970
of	O
the	O
antibodies	B-C0003241
and	O
epitope	B-C0003316
for	O
hlye	B-C2603981
was	O
successfully	O
accomplished	O
by	O
a	O
combination	B-C0205195
of	O
phage	B-C1519025
display	I-C1519025
and	O
bioinformatic	B-C1140694
analysis	B-C0936012
.	O
	
the	O
predicted	B-C0681842
function	B-C0542341
and	O
structure	B-C0678594
of	O
the	O
antibodies	B-C0003241
highlights	O
the	O
possibility	O
of	O
utilizing	O
the	O
antibodies	B-C0003241
as	O
neutralizing	B-C1254351
agents	I-C1254351
for	O
typhoid	B-C0041466
fever	I-C0041466
.	O
	
comparison	B-C1707455
of	O
electrospun	B-C1254366
and	O
solvent	B-C1254366
cast	I-C1254366
polylactic	B-C0071443
acid	I-C0071443
pla	B-C0071443
poly	B-C0032623
alcohol	I-C0032623
pva	B-C0032623
inserts	B-C0005479
as	O
potential	O
ocular	B-C0015392
drug	B-C0042444
delivery	I-C0042444
vehicles	I-C0042444
the	O
purpose	O
of	O
this	O
work	O
was	O
to	O
develop	O
,	O
characterize	O
and	O
compare	O
electrospun	B-C1881960
nanofiber	I-C1881960
inserts	B-C0005479
enis	B-C1881960
and	O
solvent	B-C1254366
cast	I-C1254366
polymeric	B-C0032521
inserts	B-C0005479
scis	B-C0032521
for	O
ocular	B-C0015392
drug	B-C0085104
delivery	I-C0085104
.	O
	
eni	B-C1881960
and	O
sci	B-C0032521
of	O
1%	O
,	O
5%	O
and	O
10%	O
w/w	O
dexamethasone	B-C0011777
were	O
fabricated	B-C1254366
using	O
a	O
blend	B-C0678946
of	O
poly-lactic	B-C0071443
acid	I-C0071443
pla	B-C0071443
and	O
poly-vinyl	B-C0032623
alcohol	I-C0032623
pva	B-C0032623
.	O
	
inserts	B-C0005479
were	O
characterized	O
for	O
morphology	B-C0332437
,	O
thickness	B-C1280412
,	O
ph	B-C0020283
,	O
drug	B-C0456205
content	I-C0456205
,	O
drug	B-C0205556
crystallinity	I-C0205556
,	O
in	B-C1533691
vitro	I-C1533691
drug	B-C3850077
release	I-C3850077
,	O
sterility	B-C0232920
,	O
dimethylformamide	B-C0012426
dmf	B-C0012426
and	O
chloroform	B-C0008238
content	B-C0456205
,	O
and	O
cytotoxicity	B-C0596402
.	O
	
the	O
thickness	B-C1280412
of	O
1%	O
,	O
5%	O
,	O
and	O
10%	O
dexamethasone	B-C0011777
-loaded	O
enis	B-C1881960
were	O
found	O
to	O
be	O
50μm	O
,	O
62.5μm	O
,	O
and	O
93.3μm	O
,	O
respectively	O
,	O
with	O
good	O
folding	B-C0518031
endurance	I-C0518031
.	O
	
scis	B-C0032521
were	O
brittle	B-C3810845
,	O
with	O
thickness	B-C1280412
values	O
>200μm	O
.	O
	
drug	B-C3850077
release	I-C3850077
rates	B-C1521828
from	O
1%	O
,	O
5%	O
and	O
10%	O
enis	B-C1881960
were	O
found	O
to	O
be	O
0.62μg	O
,	O
1.46μg	O
,	O
and	O
2.30μg	O
,	O
respectively	O
,	O
while	O
those	O
from	O
scis	B-C0032521
were	O
erratic	O
.	O
	
dmf	B-C0012426
content	B-C0456205
in	O
enis	B-C1881960
and	O
scis	B-C0032521
were	O
0.007	O
w/w	O
and	O
0.123	O
w/w	O
,	O
respectively	O
,	O
while	O
chloroform	B-C0008238
was	O
not	B-C0442737
detected	I-C0442737
.	O
	
no	B-C1513916
cytotoxicity	B-C0596402
was	O
observed	O
from	O
enis	B-C1881960
in	O
cultured	B-C0007635
bovine	B-C3667982
corneal	B-C0225336
endothelial	I-C0225336
cells	I-C0225336
for	O
up	O
to	O
24h	O
.	O
	
we	O
conclude	O
that	O
enis	B-C1881960
are	O
better	O
than	O
scis	B-C0032521
and	O
could	O
be	O
utilized	O
as	O
a	O
potential	O
delivery	B-C0085104
system	I-C0085104
for	O
treating	B-C1522326
anterior	B-C0348014
segment	I-C0348014
ocular	B-C0015397
diseases	I-C0015397
.	O
	
quantitative	B-C0392762
regulation	B-C1327622
of	O
histone	B-C4284633
variant	I-C4284633
h2a.z	I-C4284633
during	B-C0347984
cell	B-C0007586
cycle	I-C0007586
by	O
ubiquitin	B-C1523807
proteasome	I-C1523807
system	I-C1523807
and	O
sumo-targeted	B-C2247240
ubiquitin	I-C2247240
ligases	I-C2247240
quantitative	B-C0392762
control	B-C2587213
of	O
histones	B-C0019652
and	O
histone	B-C1529369
variants	I-C1529369
during	B-C0347984
cell	B-C0007586
cycle	I-C0007586
is	O
relevant	B-C2347946
to	O
their	O
epigenetic	B-C1160465
functions	I-C1160465
.	O
	
we	O
found	O
that	O
the	O
level	B-C0441889
of	O
yeast	B-C4284633
histone	I-C4284633
variant	I-C4284633
h2a.z	I-C4284633
in	O
the	O
g2/m-phase	B-C3824600
is	O
actively	B-C0205177
kept	O
low	O
by	O
the	O
ubiquitin	B-C1523807
proteasome	I-C1523807
system	I-C1523807
and	O
sumo-targeted	B-C2247240
ubiquitin	I-C2247240
ligases	I-C2247240
.	O
	
overexpression	B-C1514559
of	O
h2a.z	B-C4284633
induced	B-C1155864
defects	I-C1155864
in	I-C1155864
mitotic	I-C1155864
progression	I-C1155864
,	O
suggesting	B-C1705535
functional	B-C0205245
importance	B-C3898777
of	O
this	O
quantitative	B-C0392762
control	B-C2587213
.	O
	
tyrphostin	B-C1254351
ag-related	I-C1254351
compounds	I-C1254351
attenuate	O
h2o2	B-C0020281
-	O
induced	B-C0205263
trpm2	B-C1505166
-	O
dependent	B-C0851827
and	O
-	O
independent	B-C0332291
cellular	B-C0007634
responses	B-C0871261
trpm2	B-C1505166
is	O
a	O
ca	B-C0006685
channel	I-C0006685
that	O
is	O
activated	B-C1879547
by	O
h2o2	B-C0020281
.	O
	
trpm2	B-C1505166
-mediated	O
ca	B-C0600431
signaling	I-C0600431
has	O
been	O
implicated	O
in	O
the	O
aggravation	B-C0541889
of	O
inflammatory	B-C1290884
diseases	I-C1290884
.	O
	
therefore	O
,	O
the	O
development	B-C1527148
of	O
trpm2	B-C1505166
inhibitors	B-C0033671
to	O
prevent	O
the	O
aggravation	B-C0541889
of	O
these	O
diseases	B-C0012634
is	O
expected	O
.	O
	
we	O
recently	O
reported	O
that	O
some	O
tyrphostin	B-C1254351
ag-related	I-C1254351
compounds	I-C1254351
inhibited	B-C0311403
the	O
h2o2	B-C0020281
-	O
induced	B-C0205263
activation	B-C1879547
of	O
trpm2	B-C1505166
by	O
scavenging	B-C3537124
the	I-C3537124
intracellular	I-C3537124
hydroxyl	I-C3537124
radical	I-C3537124
.	O
	
in	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	B-C1704420
of	I-C1704420
ag-related	B-C1254351
compounds	I-C1254351
on	O
h2o2	B-C0020281
-	O
induced	B-C0205263
cellular	B-C0007634
responses	B-C0871261
in	O
human	B-C0086418
monocytic	B-C0026473
u937	B-C0600531
cells	I-C0600531
,	O
which	O
functionally	B-C0205245
express	B-C1171362
trpm2	B-C1505166
.	O
	
the	O
effects	B-C1704420
of	I-C1704420
ag-related	B-C1254351
compounds	I-C1254351
on	O
h2o2	B-C0020281
-	O
induced	B-C0205263
changes	B-C0392747
in	O
intracellular	B-C0178719
ca	B-C0596235
concentrations	B-C1446561
,	O
extracellular	B-C0600388
signal-regulated	I-C0600388
kinase	I-C0600388
erk	B-C0600388
activation	B-C1879547
,	O
and	O
cxcl8	B-C1698756
secretion	B-C1159339
were	O
assessed	O
using	O
u937	B-C0600531
cells	I-C0600531
.	O
	
ca	B-C3158761
influxes	I-C3158761
via	O
trpm2	B-C1505166
in	O
response	O
to	O
h2o2	B-C0020281
were	O
blocked	B-C0028778
by	O
ag-related	B-C1254351
compounds	I-C1254351
.	O
	
ag-related	B-C1254351
compounds	I-C1254351
also	O
inhibited	B-C0311403
the	O
h2o2	B-C0020281
-	O
induced	B-C0205263
activation	B-C1879547
of	O
erk	B-C0600388
,	O
and	O
subsequent	O
secretion	B-C1159339
of	O
cxcl8	B-C1698756
mediated	O
by	O
trpm2	B-C1505166
-	O
dependent	B-C0851827
and	O
-	O
independent	B-C0332291
mechanisms	B-C0441712
.	O
	
our	O
results	O
show	O
that	O
ag-related	B-C1254351
compounds	I-C1254351
inhibit	B-C0311403
h2o2	B-C0020281
-	O
induced	B-C0205263
cxcl8	B-C1698756
secretion	B-C1159339
following	O
erk	B-C0600388
activation	B-C1879547
,	O
which	O
is	O
mediated	O
by	O
trpm2	B-C1505166
-	O
dependent	B-C0851827
and	O
-	O
independent	B-C0332291
mechanisms	B-C0441712
in	O
u937	B-C0600531
cells	I-C0600531
.	O
	
we	O
previously	O
reported	O
that	O
ag-related	B-C1254351
compounds	I-C1254351
blocked	B-C0028778
h2o2	B-C0020281
-	O
induced	B-C0205263
trpm2	B-C1505166
activation	B-C1879547
by	O
scavenging	B-C3537124
the	I-C3537124
hydroxyl	I-C3537124
radical	I-C3537124
.	O
	
the	O
inhibitory	B-C3463820
effects	B-C1280500
of	O
ag-related	B-C1254351
compounds	I-C1254351
on	O
trpm2	B-C1505166
-	O
independent	B-C0332291
responses	B-C0871261
may	O
be	O
due	O
to	O
scavenging	B-C3537124
of	I-C3537124
the	I-C3537124
hydroxyl	I-C3537124
radical	I-C3537124
.	O
	
shared	B-C3179495
decision	I-C3179495
making	I-C3179495
in	O
the	O
uk	B-C0041700
moving	O
towards	O
wider	O
uptake	O
shared	B-C3179495
decision	I-C3179495
making	I-C3179495
sdm	B-C3179495
is	O
firmly	O
on	O
the	O
policy	B-C0242456
agenda	B-C0681473
in	O
the	O
uk	B-C0041700
and	O
a	O
recent	O
legal	B-C1301860
ruling	B-C0022424
has	O
confirmed	O
its	O
importance	O
.	O
	
policymakers	B-C0242170
,	O
ethicists	B-C0086267
,	O
professional	B-C1522486
regulators	I-C1522486
and	O
societies	B-C0037455
,	O
patient	B-C1561598
organisations	I-C1561598
and	O
now	O
the	O
courts	B-C0178572
are	O
committed	O
to	O
ensuring	O
that	O
sdm	B-C3179495
becomes	O
the	O
norm	B-C0205307
throughout	O
the	O
nhs	B-C0027462
,	O
but	O
an	O
unfavourable	O
economic	B-C0683773
climate	I-C0683773
makes	O
this	O
especially	O
challenging	O
.	O
	
considerable	O
progress	B-C1280477
has	O
been	O
made	O
over	O
the	O
last	O
few	O
years	B-C0439234
,	O
with	O
new	O
learning	B-C0023185
from	O
demonstration	B-C0237560
sites	B-C0205145
,	O
various	O
initiatives	B-C0424093
in	O
capacity	B-C2718026
building	I-C2718026
and	O
training	B-C0220931
,	O
wider	O
availability	O
of	O
patient	B-C0030705
decision	B-C0086104
aids	I-C0086104
,	O
and	O
important	O
leadership	B-C0023181
initiatives	B-C0424093
.	O
	
enthusiasm	B-C0424090
for	O
this	O
way	O
of	O
working	B-C0043227
is	O
growing	O
among	O
clinicians	B-C0871685
,	O
patients	B-C0030705
and	O
managers	B-C0335141
,	O
but	O
it	O
could	O
be	O
undermined	O
if	O
sdm	B-C3179495
comes	O
to	O
be	O
seen	O
primarily	O
as	O
a	O
means	B-C1704970
of	O
cost	B-C0010176
control	I-C0010176
.	O
	
lactate	B-C0022924
induces	O
osteoblast	B-C1159974
differentiation	I-C1159974
by	O
stabilization	B-C1152620
of	O
hif1α	B-C0965644
aerobic	B-C0598754
glycolysis	I-C0598754
is	O
involved	O
in	O
osteoblast	B-C1159974
differentiation	I-C1159974
induced	O
by	O
wnt	B-C1520113
signaling	I-C1520113
or	O
pth	B-C0030520
treatment	B-C1522326
.	O
	
however	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
lactate	B-C0022924
,	O
the	O
end	O
product	O
of	O
aerobic	B-C0598754
glycolysis	I-C0598754
,	O
plays	O
any	O
role	O
in	O
osteoblast	B-C1159974
differentiation	I-C1159974
.	O
	
herein	O
we	O
report	O
that	O
in	O
cultures	B-C0007585
of	O
osteoblast-lineage	B-C0029418
cells	I-C0029418
,	O
lactate	B-C0022924
promoted	O
alkaline	B-C0002059
phosphatase	I-C0002059
-positive	O
cell	B-C0007613
formation	I-C0007613
,	O
increased	O
the	O
activity	B-C0243102
of	O
alkaline	B-C0002059
phosphatase	I-C0002059
,	O
and	O
induced	O
the	O
expression	B-C1171362
of	O
osteocalcin	B-C0029419
.	O
	
this	O
osteoblast	B-C1159974
differentiation	I-C1159974
-inducing	O
effect	O
of	O
lactate	B-C0022924
can	O
be	O
inhibited	B-C0311403
by	O
blocking	B-C0332206
its	O
entry	O
into	O
cells	B-C0007634
with	O
mct1	B-C3812715
sirna	B-C1099354
or	O
inhibitors	B-C0033671
,	O
and	O
by	O
interfering	O
with	O
its	O
metabolism	B-C0025519
by	O
using	O
specific	O
sirnas	B-C1099354
for	O
ldhb	B-C0022918
and	O
pdh	B-C0034343
.	O
	
moreover	O
,	O
lactate	B-C0022924
stabilized	O
hif1α	B-C0965644
expression	B-C1171362
and	O
inhibited	B-C0311403
hif1α	B-C0965644
activity	B-C1537044
,	O
with	O
bay87-2243	B-C0033671
lowering	O
the	O
osteoblast	B-C1159974
differentiation	I-C1159974
-inducing	O
effect	O
of	O
lactate	B-C0022924
.	O
	
thus	O
,	O
these	O
findings	B-C0243095
reveal	O
an	O
unrecognized	O
role	O
for	O
aerobic	B-C0598754
glycolysis	I-C0598754
in	O
osteoblast	B-C1159974
differentiation	I-C1159974
via	O
its	O
end	O
product	O
,	O
committee	B-C2699414
opinion	O
no	O
.	O
	
701	O
summary	O
choosing	O
the	O
route	B-C0449444
of	O
hysterectomy	B-C0020699
for	O
benign	B-C0205183
disease	B-C0012634
hysterectomy	B-C0020699
is	O
one	O
of	O
the	O
most	O
frequently	O
performed	O
surgical	B-C0543467
procedures	I-C0543467
in	O
the	O
united	B-C0041703
states	I-C0041703
.	O
	
selection	B-C1707391
of	O
the	O
route	B-C0449444
of	O
hysterectomy	B-C0020699
for	O
benign	B-C0205183
causes	O
can	O
be	O
influenced	O
by	O
the	O
size	B-C0456389
and	O
shape	B-C0332479
of	O
the	O
vagina	B-C0042232
and	O
uterus	B-C0042149
accessibility	O
to	O
the	O
uterus	B-C0042149
extent	O
of	O
extrauterine	B-C0012634
disease	I-C0012634
the	O
need	O
for	O
concurrent	O
procedures	O
surgeon	B-C0582175
training	B-C0220931
and	O
experience	B-C0596545
average	O
case	B-C0392762
volume	I-C0392762
available	O
hospital	B-C0019994
technology	B-C0752189
,	O
devices	B-C0025080
,	O
and	O
support	O
whether	O
the	O
case	O
is	O
emergent	O
or	O
scheduled	O
and	O
preference	O
of	O
the	O
informed	O
patient	B-C0030705
.	O
	
vaginal	B-C0195117
and	O
laparoscopic	B-C0751429
procedures	I-C0751429
are	O
considered	O
""""	O
minimally	B-C2711297
invasive	I-C2711297
""""	O
surgical	B-C0449446
approaches	I-C0449446
because	O
they	O
do	O
not	O
require	O
a	O
large	O
abdominal	B-C0198488
incision	I-C0198488
and	O
,	O
thus	O
,	O
typically	O
are	O
associated	O
with	O
shortened	O
hospitalization	B-C0019993
and	O
postoperative	B-C4061108
recovery	I-C4061108
times	I-C4061108
compared	O
with	O
open	O
abdominal	B-C0404077
hysterectomy	I-C0404077
.	O
	
minimally	B-C2711297
invasive	I-C2711297
approaches	I-C2711297
to	O
hysterectomy	B-C0020699
should	O
be	O
performed	O
,	O
whenever	O
feasible	O
,	O
based	O
on	O
their	O
well-documented	O
advantages	O
over	O
abdominal	B-C0404077
hysterectomy	I-C0404077
.	O
	
the	O
vaginal	B-C0175672
approach	I-C0175672
is	O
preferred	O
among	O
the	O
minimally	B-C2711297
invasive	I-C2711297
approaches	I-C2711297
.	O
	
laparoscopic	B-C0404089
hysterectomy	I-C0404089
is	O
a	O
preferable	O
alternative	O
to	O
open	O
abdominal	B-C0404077
hysterectomy	I-C0404077
for	O
those	O
patients	B-C0030705
in	O
whom	O
a	O
vaginal	B-C0020700
hysterectomy	I-C0020700
is	O
not	O
indicated	O
or	O
feasible	O
.	O
	
although	O
minimally	B-C2711297
invasive	I-C2711297
approaches	I-C2711297
to	O
hysterectomy	B-C0020699
are	O
the	O
preferred	O
route	B-C0449444
,	O
open	B-C4283938
abdominal	B-C0404077
hysterectomy	I-C0404077
remains	O
an	O
important	O
surgical	O
option	O
for	O
some	O
patients	B-C0030705
.	O
	
the	O
obstetrician	B-C0334897
-	O
gynecologist	B-C0237419
should	O
discuss	O
the	O
options	O
with	O
patients	B-C0030705
and	O
make	O
clear	O
recommendations	O
on	O
which	O
route	B-C0449444
of	O
hysterectomy	B-C0020699
will	O
maximize	O
benefits	B-C0814225
and	O
minimize	O
risks	B-C0035647
given	O
the	O
specific	O
clinical	O
situation	O
.	O
	
the	O
relative	O
advantages	O
and	O
disadvantages	O
of	O
the	O
approaches	B-C1292724
to	O
hysterectomy	B-C0020699
should	O
be	O
discussed	O
in	O
the	O
context	O
of	O
the	O
patient	B-C0030705
's	O
values	O
and	O
preferences	B-C0376409
,	O
and	O
the	O
patient	B-C0030705
and	O
health	B-C0018724
care	I-C0018724
provider	I-C0018724
measuring	B-C0444706
nonlinear	B-C0205556
signal	B-C1710082
combination	B-C0205195
using	O
eeg	B-C0013819
relatively	B-C0205345
little	O
is	O
known	O
about	O
the	O
processes	B-C1522240
,	O
both	O
linear	B-C0205132
and	O
nonlinear	B-C0205556
,	O
by	O
which	O
signals	B-C1710082
are	O
combined	B-C0205195
beyond	O
v1	B-C0038446
.	O
	
by	O
presenting	O
two	O
stimulus	B-C0234402
components	B-C1705248
simultaneously	B-C0521115
,	O
flickering	B-C0243095
at	O
different	B-C1705242
temporal	B-C0871500
frequencies	I-C0871500
frequency	B-C0871396
tagging	B-C0183825
while	O
measuring	B-C0444706
steady-state	B-C0678587
visual	B-C0015217
evoked	I-C0015217
potentials	I-C0015217
,	O
we	O
can	O
assess	B-C0184514
responses	B-C0871261
to	O
the	O
individual	O
components	B-C1705248
,	O
including	O
direct	B-C1947931
measurements	B-C0242485
of	O
suppression	B-C0221103
on	O
each	O
other	O
,	O
and	O
various	O
nonlinear	B-C0205556
responses	B-C0871261
to	O
their	O
combination	B-C0205195
found	O
at	O
intermodulation	B-C0205556
frequencies	B-C0871396
.	O
	
the	O
result	B-C0456984
is	O
a	O
rather	O
rich	O
dataset	B-C0150098
of	O
frequencies	B-C0871396
at	O
which	O
responses	B-C0871261
can	O
be	O
found	O
.	O
	
we	O
presented	O
pairs	B-C1709450
of	O
sinusoidal	B-C1254362
gratings	I-C1254362
at	O
different	B-C1705242
temporal	B-C0871500
frequencies	I-C0871500
,	O
forming	O
plaid	B-C0243095
patterns	I-C0243095
that	O
were	O
""""	O
coherent	B-C4068804
""""	O
looking	B-C0456340
like	I-C0456340
a	I-C0456340
checkerboar	I-C0456340
d	O
and	O
""""	O
noncoherent	B-C0243095
""""	O
looking	O
like	O
a	O
pair	B-C1709450
of	O
transparently	B-C0522503
overlaid	B-C0456341
gratings	I-C0456341
,	O
and	O
found	O
clear	O
intermodulation	B-C0205556
responses	B-C0871261
to	O
compound	B-C0205198
stimuli	B-C0234402
,	O
indicating	O
nonlinear	B-C0205556
summation	B-C0234109
.	O
	
this	O
might	O
have	O
been	O
attributed	O
to	O
cross-orientation	B-C1704322
suppression	B-C0221103
except	O
that	O
the	O
pattern	B-C0449774
of	O
intermodulation	B-C0205556
responses	B-C0871261
differed	B-C0205556
for	O
coherent	B-C4068804
and	O
noncoherent	B-C0243095
patterns	B-C0449774
,	O
whereas	O
the	O
effects	B-C1704420
of	I-C1704420
suppression	B-C0221103
measured	O
at	O
the	O
component	B-C1705248
frequencies	B-C0871396
did	O
not	O
.	O
	
a	O
two-stage	B-C3161035
model	I-C3161035
of	O
nonlinear	B-C0205556
summation	B-C0234109
involving	O
conjunction	B-C2699427
detection	B-C1511790
with	O
a	O
logical	B-C1705253
and	B-C0282574
gate	I-C0282574
described	O
the	O
data	B-C1511726
well	O
,	O
capturing	O
the	O
difference	B-C1705241
between	O
coherent	B-C4068804
and	O
noncoherent	B-C0243095
plaids	B-C1254362
over	O
a	O
wide	O
array	B-C1510941
of	O
possible	B-C0332149
response	B-C0237629
frequencies	I-C0237629
.	O
	
multistimulus	B-C0205556
frequency	B-C0871396
-tagged	O
eeg	B-C0013819
in	O
combination	B-C0205195
with	O
computational	B-C3850009
modeling	I-C3850009
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	B-C2699427
of	O
these	O
signals	B-C1710082
.	O
	
in	O
the	O
current	O
study	B-C2603343
the	O
results	B-C0456984
suggest	O
a	O
second-order	B-C0597439
mechanism	I-C0597439
responding	O
selectively	B-C0205556
to	O
coherent	B-C4068804
plaid	B-C0243095
patterns	I-C0243095
.	O
	
sleep	B-C0235161
loss	I-C0235161
promotes	B-C0033414
astrocytic	B-C0521395
phagocytosis	B-C0031308
and	O
microglial	B-C1326169
activation	I-C1326169
in	O
mouse	B-C1522579
cerebral	I-C1522579
cortex	I-C1522579
we	O
previously	O
found	O
that	O
mertk	B-C1259418
and	O
its	O
ligand	B-C1567829
gas6	I-C1567829
,	O
astrocytic	B-C0521395
genes	B-C0017337
involved	O
in	O
phagocytosis	B-C0031308
,	O
are	O
upregulated	B-C0041904
after	B-C0687676
acute	B-C0205178
sleep	B-C0037316
deprivation	I-C0037316
.	O
	
these	O
results	O
suggested	O
that	O
astrocytes	B-C0004112
may	O
engage	O
in	O
phagocytic	B-C0031308
activity	I-C0031308
during	B-C0347984
extended	B-C0231449
wake	B-C0442696
,	O
but	O
direct	B-C1947931
evidence	B-C3887511
was	O
lacking	B-C0332268
.	O
	
studies	B-C2603343
in	O
humans	B-C0086418
and	O
rodents	B-C0035804
also	O
found	B-C0150312
that	O
sleep	B-C0235161
loss	I-C0235161
increases	B-C0442805
peripheral	B-C0205100
markers	B-C0005516
of	O
inflammation	B-C0021368
,	O
but	O
whether	O
these	O
changes	B-C0392747
are	O
associated	B-C0332281
with	I-C0332281
neuroinflammation	B-C0683396
and/or	O
activation	B-C1326120
of	O
microglia	B-C0206116
,	O
the	O
brain's	B-C0006104
resident	O
innate	B-C0312740
immune	I-C0312740
cells	I-C0312740
,	O
was	O
unknown	B-C0439673
.	O
	
here	O
we	O
used	B-C1524063
serial	B-C0026020
block-face	I-C0026020
scanning	I-C0026020
electron	I-C0026020
microscopy	I-C0026020
to	O
obtain	O
3d	O
volume	B-C0449468
measurements	B-C0242485
of	O
synapses	B-C0039062
and	O
surrounding	B-C1282914
astrocytic	B-C0521395
processes	B-C3714634
in	O
mouse	B-C0025929
frontal	B-C0016733
cortex	I-C0016733
after	B-C0687676
6-8	O
h	O
of	O
sleep	B-C0037313
,	O
spontaneous	B-C0205359
wake	B-C0442696
,	O
or	O
sleep	B-C0037316
deprivation	I-C0037316
sd	B-C0037316
and	O
after	B-C0687676
chronic	B-C0443288
5	I-C0443288
d	I-C0443288
sleep	I-C0443288
restriction	I-C0443288
csr	B-C0443288
.	O
	
astrocytic	B-C0521395
phagocytosis	B-C0031308
,	O
mainly	O
of	O
presynaptic	B-C1179895
components	I-C1179895
of	I-C1179895
large	I-C1179895
synapses	I-C1179895
,	O
increased	B-C0205217
after	B-C0687676
both	B-C1706086
acute	B-C0205178
and	O
chronic	B-C0205191
sleep	B-C0235161
loss	I-C0235161
relative	B-C0205345
to	O
sleep	B-C0037313
and	O
wake	B-C0442696
.	O
	
mertk	B-C1259417
expression	B-C1171362
and	O
lipid	B-C0023775
peroxidation	I-C0023775
in	O
synaptoneurosomes	B-C0039067
also	O
increased	B-C0205217
to	O
a	O
similar	B-C2348205
extent	B-C0439792
after	B-C0687676
short	B-C1806781
and	O
long	B-C0205166
sleep	B-C0235161
loss	I-C0235161
,	O
suggesting	O
that	O
astrocytic	B-C0521395
phagocytosis	B-C0031308
may	O
represent	B-C1882932
the	O
brain's	B-C0006104
response	B-C0871261
to	O
the	O
increase	B-C0442805
in	O
synaptic	B-C0027793
activity	I-C0027793
associated	B-C0332281
with	I-C0332281
prolonged	B-C0439590
wake	B-C0442696
,	O
clearing	B-C2963144
worn	O
components	O
of	O
heavily	O
used	B-C1524063
synapses	B-C0039062
.	O
	
using	B-C1524063
confocal	B-C0242842
microscopy	I-C0242842
,	O
we	O
then	O
found	B-C0150312
that	O
csr	B-C0443288
but	O
not	B-C1518422
sd	B-C0037316
mice	B-C0025929
show	O
morphological	B-C0543482
signs	B-C0037088
of	O
microglial	B-C1326169
activation	I-C1326169
and	O
enhanced	B-C2349975
microglial	B-C0521398
phagocytosis	B-C0031308
of	O
synaptic	B-C3893360
elements	I-C3893360
,	O
without	B-C0332288
obvious	O
signs	B-C0037088
of	O
neuroinflammation	B-C0683396
in	O
the	O
csf	B-C0007806
.	O
	
because	O
low	B-C0205251
-	O
level	B-C0441889
sustained	B-C0443318
microglia	B-C1326169
activation	I-C1326169
can	O
lead	O
to	O
abnormal	B-C0205161
responses	B-C0871261
to	O
a	O
secondary	B-C0175668
insult	B-C0598698
,	O
these	O
results	B-C1274040
suggest	B-C1705535
that	O
chronic	B-C0205191
sleep	B-C0235161
loss	I-C0235161
,	O
through	B-C0332273
microglia	B-C0206116
priming	B-C0007613
,	O
may	O
predispose	O
the	O
brain	B-C0006104
to	O
further	B-C1517331
damage	B-C1883709
significance	O
statement	O
we	O
find	B-C0243095
that	O
astrocytic	B-C0521395
phagocytosis	B-C0031308
of	O
synaptic	B-C3893360
elements	I-C3893360
,	O
mostly	O
of	O
presynaptic	B-C3893360
origin	I-C3893360
and	O
in	O
large	B-C0549177
synapses	B-C0039062
,	O
is	O
upregulated	B-C0041904
already	O
after	B-C0687676
a	O
few	B-C0205388
hours	B-C0439227
of	O
sleep	B-C0037316
deprivation	I-C0037316
and	O
shows	O
a	O
further	B-C1517331
significant	B-C0750502
increase	B-C0442805
after	B-C0687676
prolonged	B-C0439590
and	O
severe	B-C0205082
sleep	B-C0235161
loss	I-C0235161
,	O
suggesting	O
that	O
it	O
may	O
promote	B-C0033414
the	O
housekeeping	B-C0020053
of	O
heavily	O
used	B-C1524063
and	O
strong	B-C0442821
synapses	B-C0039062
in	O
response	B-C0871261
to	O
the	O
increased	B-C0205217
neuronal	B-C0027882
activity	B-C0007613
of	O
extended	B-C0231449
wake	B-C0442696
.	O
	
by	O
contrast	B-C1979874
,	O
chronic	B-C0443288
sleep	I-C0443288
restriction	I-C0443288
but	O
not	B-C1518422
acute	B-C0205178
sleep	B-C0235161
loss	I-C0235161
activates	B-C1326120
microglia	B-C0206116
,	O
promotes	B-C0033414
their	O
phagocytic	B-C0031308
activity	I-C0031308
,	O
and	O
does	O
so	O
in	O
the	O
absence	B-C0332197
of	O
overt	O
signs	B-C0037088
of	O
neuroinflammation	B-C0683396
,	O
suggesting	O
that	O
like	O
many	O
other	B-C0205394
stressors	B-C0597530
,	O
extended	B-C0231449
sleep	B-C1821308
disruption	I-C1821308
may	O
lead	O
to	O
a	O
state	B-C1442792
of	O
sustained	B-C0443318
microglia	B-C1326169
activation	I-C1326169
,	O
perhaps	O
increasing	B-C0442808
the	O
brain's	B-C0006104
susceptibility	B-C1264642
to	O
other	B-C0205394
forms	B-C1522492
of	O
reflections	B-C2603343
on	O
hip	B-C0744924
fracture	I-C0744924
recovery	I-C0744924
from	O
older	B-C0001792
adults	I-C0001792
enrolled	O
in	O
a	O
clinical	B-C0008976
trial	I-C0008976
this	O
study	B-C2603343
describes	O
patients'	B-C0030705
perspectives	B-C0678958
on	O
recovery	B-C0237820
during	O
participation	B-C0679823
in	O
a	O
randomized	B-C0206035
controlled	I-C0206035
trial	I-C0206035
that	O
tested	B-C0392366
a	O
postoperative	B-C0032790
hip	B-C0019557
fracture	I-C0019557
management	B-C0039798
program	I-C0039798
b4	B-C0442592
clinic	I-C0442592
,	O
compared	B-C1707455
with	O
usual	B-C0511425
care	I-C0511425
,	O
on	O
mobility	B-C0449580
.	O
	
semistructured	B-C0678594
qualitative	B-C0205556
interviews	B-C0021822
were	O
conducted	O
with	O
50	O
older	B-C0001792
adults	I-C0001792
with	O
hip	B-C0019557
fracture	I-C0019557
from	O
both	O
groups	B-C1257890
twice	O
over	O
12	O
months	O
.	O
	
a	O
total	B-C0439810
of	O
32	O
women	B-C0043210
64%	O
and	O
18	O
men	B-C0025266
36%	O
participated	B-C0679823
in	O
the	O
study	B-C2603343
with	O
a	O
mean	B-C0444504
age	B-C0001779
at	O
baseline	B-C1442488
of	O
82	O
range	B-C1514721
=	O
65-98	O
years	O
.	O
	
a	O
total	B-C0439810
of	O
40	O
participants	B-C0679646
reported	B-C0700287
recovery	B-C0237820
goals	B-C0018017
at	O
some	O
point	O
during	O
their	O
recovery	B-C0237820
from	O
hip	B-C0019557
fracture	I-C0019557
but	O
only	O
18	O
participants	B-C0679646
realized	B-C4304473
their	O
goals	B-C0018017
within	O
12	O
months	O
.	O
	
recovering	B-C2004454
mobility	B-C0449580
,	O
returning	B-C0332156
to	O
prefracture	B-C0441655
activities	I-C0441655
,	O
and	O
obtaining	B-C1301820
stable	B-C0205360
health	B-C0018684
were	O
the	O
most	B-C0205393
commonly	B-C0205214
reported	B-C0700287
goals	B-C0018017
.	O
	
participants	B-C0679646
described	O
good	B-C0205170
social	B-C1540833
support	I-C1540833
,	O
access	B-C0444454
to	O
physiotherapy	B-C0949766
,	O
and	O
positive	B-C1446409
perspective	B-C0678958
as	O
most	B-C0205393
important	B-C3898777
to	O
recovery	B-C0237820
.	O
	
these	O
factors	B-C1521761
were	O
influenced	B-C4054723
by	O
participants	B-C0679646
'	O
knowledge	B-C0376554
,	O
resources	B-C0035201
,	O
and	O
monthly	O
contact	B-C1705415
with	O
study	B-C2603343
staff	B-C0851286
perceived	B-C0030971
as	O
a	O
form	O
of	O
social	B-C1540833
support	I-C1540833
.	O
	
the	O
most	B-C0205393
frequently	B-C0332183
reported	B-C0700287
barriers	B-C0679881
to	O
participants	B-C0679646
'	O
recovery	B-C0237820
were	O
the	O
onset	B-C0332162
of	I-C0332162
complications	B-C0009566
,	O
pain	B-C0030193
,	O
and	O
limited	B-C1948144
access	I-C1948144
to	O
physiotherapy	B-C0949766
.	O
	
potential	B-C3245505
implications	B-C0392360
of	O
these	O
findings	B-C0243095
include	B-C2700399
design	B-C1707689
and	O
modification	B-C3840684
of	O
new	O
or	O
preexisting	B-C2347662
fracture	B-C0016658
programs	B-C3484370
,	O
prioritizing	B-C0549179
patient	B-C0030675
engagement	I-C0030675
and	O
enhanced	B-C2349975
knowledge	B-C0376554
for	O
future	B-C0016884
clinical	B-C0008972
research	I-C0008972
in	O
hip	B-C0744924
fracture	I-C0744924
recovery	I-C0744924
.	O
	
it	O
takes	O
biking	O
to	O
learn	B-C0023185
physical	B-C0026606
activity	I-C0026606
improves	B-C0184511
learning	B-C0023185
a	O
second	B-C0557074
language	I-C0557074
recent	O
studies	B-C2603343
have	O
shown	O
that	O
concurrent	B-C0205420
physical	B-C0026606
activity	I-C0026606
enhances	B-C2349975
learning	B-C0023185
a	O
completely	O
unfamiliar	O
l2	B-C0557074
vocabulary	B-C0042926
as	O
compared	O
to	O
learning	B-C0023185
it	O
in	O
a	O
static	B-C0441463
condition	B-C0348080
.	O
	
in	O
this	O
paper	O
we	O
report	O
a	O
study	B-C2603343
whose	O
aim	O
is	O
twofold	O
to	O
test	O
for	O
possible	B-C0332149
positive	B-C1446409
effects	B-C1704420
of	I-C1704420
physical	B-C0026606
activity	I-C0026606
when	O
l2	B-C0557074
learning	B-C0023185
has	O
already	O
reached	O
some	O
level	B-C0441889
of	O
proficiency	B-C0678997
,	O
and	O
to	O
test	O
whether	O
the	O
assumed	O
better	B-C0332272
performance	B-C1882330
when	O
engaged	O
in	O
physical	B-C0026606
activity	I-C0026606
is	O
limited	O
to	O
the	O
linguistic	B-C0023741
level	B-C0441889
probed	O
at	O
training	B-C2673163
i.e	O
.	O
	
l2	B-C0557074
vocabulary	B-C0042926
tested	B-C0039593
by	O
means	O
of	O
a	O
word-picture	B-C0242481
verification	I-C0242481
task	I-C0242481
,	O
or	O
whether	O
it	O
extends	O
also	O
to	O
the	O
sentence	B-C0876929
level	B-C0441889
which	O
was	O
tested	B-C0039593
by	O
means	O
of	O
a	O
sentence	B-C0242481
semantic	I-C0242481
judgment	I-C0242481
task	I-C0242481
.	O
	
the	O
results	O
show	O
that	O
chinese	B-C0152035
speakers	I-C0152035
with	O
basic	B-C4036283
knowledge	I-C4036283
of	O
english	B-C0376245
benefited	B-C0814225
from	O
physical	B-C0026606
activity	I-C0026606
while	O
learning	B-C0023185
a	O
set	O
of	O
new	O
words	B-C0042926
.	O
	
furthermore	O
,	O
their	O
better	B-C0332272
performance	B-C1882330
emerged	O
also	O
at	O
the	O
sentential	B-C0876929
level	B-C0441889
,	O
as	O
shown	O
by	O
their	O
performance	B-C1882330
in	O
a	O
semantic	B-C0242481
judgment	I-C0242481
task	I-C0242481
.	O
	
finally	O
,	O
an	O
interesting	O
temporal	O
asymmetry	O
between	O
the	O
lexical	B-C1705313
and	O
the	O
sentential	B-C0876929
level	B-C0441889
emerges	O
,	O
with	O
the	O
difference	O
between	O
the	O
experimental	B-C0441833
and	O
control	B-C0009932
group	I-C0009932
emerging	O
from	O
the	O
1st	O
testing	B-C1883016
session	I-C1883016
at	O
the	O
lexical	B-C1705313
level	B-C0441889
but	O
after	O
several	O
weeks	O
at	O
the	O
sentential	B-C0876929
level	B-C0441889
.	O
	
the	O
added	B-C1524062
value	B-C1522609
of	O
cardiac	B-C0428776
index	I-C0428776
and	O
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
monitoring	B-C1283169
to	O
mean	B-C0428886
arterial	I-C0428886
pressure	I-C0428886
-	O
guided	B-C0087111
volume	I-C0087111
therapy	I-C0087111
in	O
moderate-risk	B-C2066139
abdominal	I-C2066139
surgery	I-C2066139
coguide	B-C0087111
a	O
pragmatic	B-C3658312
multicentre	B-C0206012
randomised	B-C0206035
controlled	I-C0206035
trial	I-C0206035
there	O
is	O
disagreement	B-C0681800
regarding	O
the	O
benefits	B-C0814225
of	O
goal-directed	B-C1271494
therapy	I-C1271494
in	O
moderate-risk	B-C2066139
abdominal	I-C2066139
surgery	I-C2066139
.	O
	
therefore	O
,	O
we	O
tested	B-C0392366
the	O
hypothesis	B-C1512571
that	O
the	O
addition	B-C0332287
of	O
non-invasive	B-C0205303
cardiac	B-C0428776
index	I-C0428776
and	O
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
monitoring	B-C1283169
to	O
mean	B-C0428886
arterial	I-C0428886
pressure	I-C0428886
-based	O
goal-directed	B-C1271494
therapy	I-C1271494
would	O
reduce	B-C0392756
the	O
incidence	B-C0021149
of	O
postoperative	B-C0032787
complications	I-C0032787
in	O
patients	B-C0030705
having	O
moderate-risk	B-C2066139
abdominal	I-C2066139
surgery	I-C2066139
.	O
	
in	O
this	O
pragmatic	B-C3658312
multicentre	B-C0206012
randomised	B-C0206035
controlled	I-C0206035
trial	I-C0206035
,	O
we	O
randomly	B-C0034656
allocated	I-C0034656
244	O
patients	B-C0030705
by	O
envelope	B-C0013113
drawing	I-C0013113
in	O
a	O
1	O
fashion	O
,	O
stratified	B-C0205363
per	O
centre	O
.	O
	
all	O
patients	B-C0030705
had	O
mean	B-C0428886
arterial	I-C0428886
pressure	I-C0428886
,	O
cardiac	B-C0428776
index	I-C0428776
and	O
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
measured	B-C0444706
continuously	B-C0549178
.	O
	
in	O
one	O
group	B-C0441833
,	O
healthcare	B-C0018724
professionals	I-C0018724
were	O
blinded	B-C0150108
to	O
cardiac	B-C0428776
index	I-C0428776
and	O
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
values	B-C1522609
and	O
were	O
asked	O
to	O
guide	O
haemodynamic	B-C0087111
therapy	I-C0087111
only	O
based	O
on	O
mean	B-C0428886
arterial	I-C0428886
pressure	I-C0428886
control	B-C0009932
group	I-C0009932
.	O
	
in	O
the	O
second	O
group	B-C0441833
,	O
cardiac	B-C0428776
index	I-C0428776
and	O
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
values	B-C1522609
were	O
displayed	B-C0870432
and	O
kept	O
within	O
target	B-C1521840
ranges	B-C1514721
following	O
a	O
pre-defined	B-C0002045
algorithm	I-C0002045
ci-ppv	B-C0441833
group	I-C0441833
.	O
	
the	O
primary	B-C2986535
endpoint	I-C2986535
was	O
the	O
incidence	B-C0021149
of	O
postoperative	B-C0032787
complications	I-C0032787
within	B-C3845590
30	I-C3845590
days	I-C3845590
.	O
	
one	O
hundred	O
and	O
seventy-five	O
patients	B-C0030705
were	O
eligible	B-C1548635
for	O
final	B-C3853528
analysis	B-C0936012
.	O
	
overall	B-C1561607
complication	B-C0009566
rates	I-C0009566
were	O
similar	O
42/94	O
44.7	O
vs	O
.	O
	
38/81	O
46.9	O
in	O
the	O
control	B-C0009932
and	O
ci-ppv	B-C0441833
groups	I-C0441833
,	O
respectively	O
p	O
=	O
0.95	O
.	O
	
the	O
ci-ppv	B-C0441833
group	I-C0441833
had	O
lower	B-C0205251
mean	B-C0444504
sd	B-C0871420
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
values	B-C1522609
9.5	O
2.0	O
vs	O
.	O
	
11.9	O
4.6	O
p	O
=	O
0.003	O
and	O
higher	B-C0205250
mean	B-C0444504
sd	B-C0871420
cardiac	B-C0428776
indices	I-C0428776
2.76	O
0.62	O
l	O
min	O
m	O
vs	O
.	O
	
2.53	O
0.66	O
l	O
min	O
m	O
p	O
=	O
0.004	O
than	O
the	O
control	B-C0009932
group	I-C0009932
.	O
	
in	O
moderate-risk	B-C2066139
abdominal	I-C2066139
surgery	I-C2066139
,	O
we	O
observed	B-C1441672
no	O
additional	B-C0439062
value	I-C0439062
of	O
cardiac	B-C0428776
index	I-C0428776
and	O
pulse	B-C0949236
pressure	I-C0949236
variation	B-C0205419
-	O
guided	B-C0087111
haemodynamic	I-C0087111
therapy	I-C0087111
to	O
mean	B-C0428886
arterial	I-C0428886
pressure	I-C0428886
-	O
guided	B-C0087111
volume	I-C0087111
therapy	I-C0087111
with	O
regard	O
to	O
postoperative	B-C0032787
complications	I-C0032787
.	O
	
anterior	B-C0376511
single	I-C0376511
implants	I-C0376511
with	O
different	O
neck	B-C1254362
designs	B-C1707689
5	O
year	B-C0439234
results	O
of	O
a	O
randomized	B-C0206034
clinical	I-C0206034
trial	I-C0206034
the	O
design	B-C1707689
of	O
the	O
implant	B-C0376511
neck	I-C0376511
might	O
be	O
significant	O
for	O
preservation	B-C1514402
of	O
marginal	B-C0205284
bone	B-C0005931
.	O
	
to	O
compare	O
the	O
5-year	B-C0439234
radiographic	B-C0444708
and	O
clinical	B-C0205210
outcome	B-C1274040
of	O
single	B-C0376511
anterior	I-C0376511
implants	I-C0376511
provided	O
with	O
a	O
smooth	B-C0205357
neck	O
,	O
a	O
rough	O
neck	O
or	O
a	O
scalloped	O
rough	O
neck	O
.	O
	
93	O
patients	O
with	O
a	O
missing	O
anterior	O
tooth	O
in	O
the	O
maxilla	O
were	O
included	O
.	O
	
at	O
random	O
,	O
patients	O
received	O
an	O
implant	O
with	O
a	O
1.5	O
mm	O
smooth	B-C1254362
neck	I-C1254362
""""	O
smooth	O
group	O
""""	O
,	O
a	O
rough	B-C1254362
neck	I-C1254362
with	O
grooves	O
""""	O
rough	B-C1254362
group	O
""""	O
or	O
a	O
scalloped	O
rough	O
neck	I-C1254362
with	O
grooves	O
""""	O
scalloped	O
group	O
""""	O
.	O
	
implants	O
were	O
installed	O
in	O
healed	O
sites	O
.	O
	
follow-up	O
visits	O
were	O
conducted	O
after	O
final	O
crown	O
delivery	O
and	O
1	O
year	O
and	O
5	O
years	O
later	O
.	O
	
scalloped	O
implants	O
showed	O
significantly	O
more	O
initial	O
marginal	O
bone	O
resorption	O
.	O
	
the	O
total	O
amount	O
of	O
bone	O
loss	O
was	O
1.26	O
0.90	O
mm	O
in	O
the	O
smooth	O
group	O
,	O
1.20	O
1.1	O
mm	O
in	O
the	O
rough	O
group	O
and	O
2.28	O
0.97	O
mm	O
in	O
the	O
scalloped	O
group	O
p	O
<	O
05	O
.	O
	
survival	O
rates	O
were	O
96.2	O
for	O
the	O
smooth	O
and	O
scalloped	O
group	O
and	O
100%	O
for	O
the	O
rough	O
group	O
.	O
	
scalloped	O
implants	O
showed	O
deeper	O
pocket	O
depths	O
,	O
more	O
bleeding	O
and	O
more	O
technical	O
complications	O
.	O
	
there	O
were	O
no	O
differences	O
in	O
esthetic	O
outcome	O
nor	O
in	O
patient	O
satisfaction	O
.	O
	
for	O
anterior	O
single	O
tooth	O
replacements	O
,	O
scalloped	O
implants	O
show	O
less	O
favorable	O
radiographic	O
and	O
clinical	O
outcome	O
compared	O
to	O
regular	O
implants	O
with	O
a	O
smooth	O
neck	O
or	O
rough	O
neck	B-C1254362
recessive	B-C0026882
mutations	I-C0026882
in	O
msto1	B-C1957185
cause	O
mitochondrial	B-C3494415
dynamics	I-C3494415
impairment	B-C0221099
,	O
leading	O
to	O
myopathy	B-C0026848
and	O
ataxia	B-C0004134
we	O
report	O
here	O
the	O
first	O
families	B-C0015576
carrying	O
recessive	O
variants	B-C0205419
in	O
the	O
msto1	B-C1826310
gene	I-C1826310
compound	B-C4264438
heterozygous	I-C4264438
mutations	B-C0026882
were	O
identified	O
in	O
two	O
sisters	O
and	O
in	O
an	O
unrelated	O
singleton	O
case	O
,	O
who	O
presented	O
a	O
multisystem	O
complex	O
phenotype	O
mainly	O
characterized	O
by	O
myopathy	O
and	O
cerebellar	O
ataxia	O
.	O
	
human	O
msto1	O
is	O
a	O
poorly	O
studied	O
protein	O
,	O
suggested	O
to	O
have	O
mitochondrial	O
localization	O
and	O
to	O
regulate	O
morphology	O
and	O
distribution	O
of	O
mitochondria	O
.	O
	
as	O
for	O
other	O
mutations	B-C0026882
affecting	O
genes	O
involved	O
in	O
mitochondrial	O
dynamics	O
,	O
no	O
biochemical	O
defects	O
typical	O
of	O
mitochondrial	O
disorders	O
were	O
reported	O
.	O
	
studies	O
in	O
patients	O
'	O
fibroblasts	O
revealed	O
that	O
msto1	O
protein	O
levels	O
were	O
strongly	O
reduced	O
,	O
the	O
mitochondrial	O
network	O
was	O
fragmented	O
and	O
the	O
fusion	O
events	O
among	O
mitochondria	O
were	O
decreased	O
,	O
confirming	O
the	O
deleterious	O
effect	O
of	O
the	O
identified	B-C0205396
variants	O
and	O
the	O
role	O
of	O
msto1	O
in	O
modulating	O
mitochondrial	O
dynamics	O
.	O
	
we	O
also	O
found	O
that	O
msto1	O
is	O
mainly	O
a	O
cytosolic	O
protein	O
.	O
	
these	O
findings	O
indicate	O
recessive	O
mutations	O
in	O
msto1	O
as	O
a	O
new	O
cause	O
for	O
inherited	O
neuromuscular	O
disorders	O
with	O
multisystem	O
features	O
.	O
	
this	O
article	O
is	O
protected	O
by	O
copyright	O
.	O
	
all	O
rights	O
a	O
miniature	O
bird	B-C0005595
-borne	O
passive	B-C0178984
air	I-C0178984
sampler	I-C0178984
for	O
monitoring	B-C1283169
halogenated	B-C0016198
flame	I-C0016198
retardants	I-C0016198
birds	B-C0005595
have	O
been	O
used	O
intensively	O
as	O
biomonitors	B-C0025080
of	O
halogenated	B-C0016198
flame	I-C0016198
retardants	I-C0016198
hfrs	B-C0016198
,	O
and	O
several	O
studies	B-C2603343
have	O
reported	O
elevated	O
tissue	B-C0040300
concentrations	B-C1446561
and	O
inter-	O
individual	B-C0237401
variability	B-C2827666
for	O
these	O
contaminants	B-C2827365
.	O
	
while	O
diet	B-C0012155
is	O
known	O
to	O
be	O
an	O
important	O
exposure	B-C0332157
pathway	B-C1705987
for	O
hfrs	B-C0016198
in	O
birds	B-C0005595
,	O
it	O
has	O
been	O
suggested	B-C1705535
that	O
exposure	B-C0332157
through	O
air	B-C0001861
may	O
represent	B-C1882932
an	O
underestimated	O
source	B-C0449416
of	O
hfrs	B-C0016198
for	O
certain	O
species	B-C1705920
.	O
	
however	O
,	O
a	O
method	B-C0025663
was	O
not	B-C0686905
available	I-C0686905
for	O
measuring	B-C0444706
the	O
atmospheric	B-C0004178
exposure	B-C0332157
of	O
individual	B-C0237401
birds	B-C0005595
to	O
hfrs	B-C0016198
or	O
other	O
semi-volatile	B-C1963547
contaminants	B-C2827365
.	O
	
the	O
goal	B-C0018017
of	O
this	O
study	B-C2603343
was	O
to	O
develop	O
a	O
bird	B-C0005595
-borne	O
passive	B-C0178984
air	I-C0178984
sampler	I-C0178984
pas	B-C0178984
enabling	O
the	O
determination	B-C1148554
of	O
individual	B-C0237401
atmospheric	B-C0004178
exposure	B-C0332157
to	O
gas	B-C0017110
-	O
and	O
particle-phase	B-C0597177
hfrs	B-C0016198
using	O
the	O
ring-billed	B-C1061035
gull	I-C1061035
larus	B-C1061035
delawarensis	I-C1061035
nesting	B-C0870949
in	O
the	O
montreal	B-C0681784
area	I-C0681784
qc	B-C0034390
,	O
canada	B-C0006823
.	O
	
the	O
new	O
miniaturized	O
elliptical-shaped	B-C1947977
pas	B-C0178984
mean	B-C0043100
weight	I-C0043100
2.72g	O
was	O
tested	B-C0039593
using	O
two	B-C0022885
sorbent	I-C0022885
types	I-C0022885
during	O
three	O
exposure	B-C2826764
periods	I-C2826764
one	O
,	O
two	O
and	O
three	O
weeks	O
.	O
	
results	B-C1274040
showed	O
that	O
pas	B-C0178984
using	O
polyurethane	B-C0071696
foam	I-C0071696
puf	B-C0071696
combined	O
with	O
a	O
glass	B-C0060317
fiber	I-C0060317
filter	B-C0545227
collected	I-C0545227
all	O
major	O
polybrominated	B-C2350562
diphenyl	I-C2350562
ethers	I-C2350562
pbdes	B-C2350562
and	O
exhibited	O
better	B-C1882330
performance	I-C1882330
for	O
collecting	B-C1516698
highly	B-C0598629
hydrophobic	I-C0598629
decabde	B-C2350562
mixture	B-C0439962
congeners	B-C0678518
compared	B-C1707455
to	I-C1707455
the	O
pas	B-C0178984
using	O
polydimethylsiloxane	B-C0137758
pdms	B-C0137758
.	O
	
emerging	O
hfrs	B-C0016198
including	O
hexabromobenzene	B-C0062598
,	O
dechlorane	B-C3180256
604	I-C3180256
component	I-C3180256
b	I-C3180256
,	O
and	O
dechlorane	B-C2351195
plus	I-C2351195
dp	B-C2351195
isomers	B-C0022203
also	O
were	O
sampled	B-C0441621
by	O
the	O
puf	B-C0071696
-based	O
pas	B-C0178984
.	O
	
sampling	B-C0441621
rates	B-C1521828
for	O
most	O
hfrs	B-C0016198
were	O
comparable	B-C1707455
between	O
the	O
three	O
exposure	B-C2826764
periods	I-C2826764
.	O
	
this	O
novel	O
bird	B-C0005595
-borne	O
pas	B-C0178984
provides	O
valuable	B-C1533716
information	I-C1533716
on	O
the	O
non-dietary	B-C0332157
exposure	I-C0332157
of	O
free-ranging	B-C3845292
birds	B-C0005595
to	O
post	B-C0032790
endodontic	B-C0030193
pain	I-C0030193
following	O
single-visit	O
root	B-C0282543
canal	I-C0282543
preparation	I-C0282543
with	O
rotary	B-C0011377
vs	O
reciprocating	B-C0011377
instruments	I-C0011377
a	O
meta-analysis	B-C0920317
of	O
randomized	B-C0206034
clinical	I-C0206034
trials	I-C0206034
in	O
endodontic	B-C0035849
therapy	I-C0035849
,	O
continuous	O
rotary	B-C0587378
instrumentation	I-C0587378
reduced	O
debris	B-C0440266
compared	O
to	O
reciprocal	B-C0587378
instrumentation	I-C0587378
,	O
which	O
might	O
affect	O
the	O
incidence	B-C0021149
of	O
post-endodontic	B-C0030193
pain	I-C0030193
pp	B-C0030193
.	O
	
the	O
aim	O
of	O
our	O
study	B-C2603343
was	O
to	O
assess	O
whether	O
pp	B-C0030193
incidence	B-C0021149
and	O
levels	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
rotary	B-C0011377
or	O
reciprocal	B-C0011377
instruments	I-C0011377
.	O
	
in	O
this	O
meta-analysis	B-C0920317
the	O
pubmed	B-C1138432
and	O
em	B-C0242356
databases	I-C0242356
were	O
searched	O
for	O
prospective	O
clinical	B-C0206034
randomized	I-C0206034
trials	I-C0206034
published	O
before	O
april	O
20	O
,	O
2016	O
,	O
using	O
combinations	O
of	O
the	O
keywords	O
root	B-C0282543
canal	I-C0282543
preparation	I-C0282543
/	O
instrumentation	B-C0587378
/	O
treatment	B-C0087111
/	O
therapy	B-C0087111
post-operative	B-C0032790
/	O
endodontic	B-C0030193
pain	I-C0030193
reciprocal	B-C0011377
and	O
rotary	B-C0011377
instruments	I-C0011377
.	O
	
three	O
studies	B-C2603343
were	O
included	O
,	O
involving	O
a	O
total	O
of	O
1	O
patients	B-C0030705
,	O
659	O
treated	O
with	O
reciprocating	B-C0011377
instruments	I-C0011377
and	O
658	O
treated	O
with	O
rotary	B-C0011377
instruments	I-C0011377
.	O
	
pp	B-C0030193
was	O
reported	O
in	O
139	O
patients	B-C0030705
in	O
the	O
reciprocating	B-C1257890
group	I-C1257890
and	O
172	O
in	O
the	O
rotary	B-C1257890
group	I-C1257890
.	O
	
the	O
pp	B-C0030193
incidence	B-C0021149
odds	O
ratio	O
was	O
1.27	O
with	O
95%	O
confidence	B-C0009667
interval	I-C0009667
ci	B-C0009667
0.25	O
,	O
6.52	O
favoring	O
rotary	B-C0011377
instruments	I-C0011377
.	O
	
the	O
mild	B-C2945599
,	O
moderate	B-C0205081
and	O
severe	B-C0205082
pp	B-C0030193
levels	O
odds	O
ratios	O
were	O
0.31	O
0.11	O
,	O
0.84	O
,	O
2.24	O
0.66	O
,	O
7.59	O
and	O
11.71	O
0.63	O
,	O
218.15	O
,	O
respectively	O
.	O
	
no	O
evidence	O
of	O
publication	O
bias	O
was	O
found	O
.	O
	
rotary	B-C0011377
instrument	I-C0011377
choice	O
in	O
endodontic	B-C0035849
therapy	I-C0035849
is	O
associated	B-C0332281
with	I-C0332281
a	O
lower	O
incidence	B-C0021149
of	O
pp	B-C0030193
than	O
reciprocating	B-C0011377
instruments	I-C0011377
,	O
while	O
reciprocating	B-C0011377
instruments	I-C0011377
are	O
associated	B-C0332281
with	I-C0332281
less	O
mild	O
pp	B-C0030193
incidence	B-C0021149
.	O
	
high	O
throughput	O
resistance	B-C1514892
profiling	B-C2003903
of	O
plasmodium	B-C0032150
falciparum	I-C0032150
infections	O
based	O
on	O
custom	O
dual	O
indexing	O
and	O
illumina	O
next	O
generation	O
sequencing-technology	O
genetic	O
polymorphisms	O
in	O
p	O
.	O
	
falciparum	O
can	O
be	O
used	O
to	O
indicate	O
the	O
parasite's	O
susceptibility	O
to	O
antimalarial	O
drugs	O
as	O
well	O
as	O
its	O
geographical	O
origin	O
.	O
	
both	O
of	O
these	O
factors	O
are	O
key	O
to	O
monitoring	O
development	O
and	O
spread	O
of	O
antimalarial	O
drug	O
resistance	O
.	O
	
in	O
this	O
study	O
,	O
we	O
combine	O
multiplex	O
pcr	O
,	O
custom	O
designed	O
dual	O
indexing	O
and	O
miseq	O
sequencing	O
for	O
high	O
throughput	O
snp	O
-	O
profiling	O
of	O
457	O
malaria	O
infections	O
from	O
guinea-bissau	O
,	O
at	O
the	O
cost	O
of	O
10	O
usd	O
per	O
sample	O
.	O
	
by	O
amplifying	O
and	O
sequencing	O
15	O
genetic	O
fragments	O
,	O
we	O
cover	O
20	O
resistance	O
-conferring	O
snps	O
occurring	O
in	O
pfcrt	O
,	O
pfmdr1	O
,	O
pfdhfr	O
,	O
pfdhps	O
,	O
as	O
well	O
as	O
the	O
entire	O
length	O
of	O
pfk13	O
,	O
and	O
the	O
mitochondrial	O
barcode	O
for	O
parasite	O
origin	O
.	O
	
snps	O
of	O
interest	O
were	O
sequenced	O
with	O
an	O
average	O
depth	O
of	O
2	O
reads	O
,	O
and	O
bases	O
were	O
called	O
for	O
the	O
various	O
snp	O
-	O
positions	O
with	O
a	O
p-value	O
below	O
0.05	O
,	O
for	O
89.8	O
of	O
samples	O
.	O
	
the	O
snp	O
data	O
indicates	O
that	O
artemisinin	O
resistance	O
-conferring	O
snps	O
in	O
pfk13	O
are	O
absent	O
from	O
the	O
studied	O
area	O
of	O
guinea-bissau	O
,	O
while	O
the	O
pfmdr1	O
86	O
n	O
allele	O
is	O
found	O
at	O
a	O
high	O
prevalence	O
.	O
	
the	O
mitochondrial	O
barcodes	O
are	O
unanimous	O
and	O
accommodate	O
a	O
west	O
african	O
origin	O
of	O
the	O
parasites	O
.	O
	
with	O
this	O
method	O
,	O
very	O
reliable	O
high	O
throughput	O
surveillance	O
of	O
antimalarial	O
drug	O
resistance	O
becomes	O
more	O
affordable	O
than	O
ever	O
a	O
systematic	B-C1955832
review	I-C1955832
investigating	B-C1292732
psychosocial	B-C0243156
aspects	I-C0243156
of	O
egg	B-C4053456
sharing	I-C4053456
in	O
the	O
united	B-C0041700
kingdom	I-C0041700
and	O
their	O
potential	B-C3245505
effects	B-C1280500
on	O
egg	B-C4053456
donation	I-C4053456
numbers	B-C0237753
this	O
review	B-C0282443
aims	O
to	O
provide	O
an	O
up-to-date	O
knowledge	B-C0376554
of	O
the	O
psychosocial	B-C0243156
aspects	I-C0243156
of	O
egg	B-C4053456
donation	I-C4053456
from	O
the	O
perspectives	O
of	O
the	O
egg	B-C0029975
share	I-C0029975
donor	I-C0029975
and	O
their	O
recipient	B-C1709854
.	O
	
it	O
explores	O
the	O
motives	B-C0869035
,	O
experiences	B-C0596545
and	O
attitudes	B-C0004271
of	O
egg	B-C0029975
sharers	I-C0029975
and	O
their	O
views	O
towards	O
donor	B-C0029975
anonymity	B-C0871649
and	O
disclosure	B-C0012625
.	O
	
conclusions	B-C1707478
are	O
made	O
on	O
how	O
these	O
findings	B-C0243095
can	O
guide	B-C0282451
clinical	I-C0282451
practice	I-C0282451
and	O
improve	O
egg	B-C4053456
sharing	I-C4053456
numbers	B-C0237753
.	O
	
a	O
systematic	B-C0220922
search	B-C1706202
of	O
peer-reviewed	B-C2985503
journals	I-C2985503
of	O
four	O
computerized	B-C0871696
databases	I-C0871696
was	O
undertaken	O
.	O
	
eleven	O
studies	B-C2603343
were	O
included	O
in	O
the	O
review	B-C0282443
.	O
	
psychosocial	B-C0243156
aspects	I-C0243156
towards	O
donation	B-C4053456
were	O
positive	B-C1446409
from	O
the	O
egg	B-C0029975
share	I-C0029975
donor	I-C0029975
and	O
recipient	B-C1709854
.	O
	
concerns	B-C2699424
raised	B-C0442818
were	O
whether	O
participating	B-C0679823
in	O
the	O
egg	B-C4053456
sharing	I-C4053456
scheme	B-C1519193
would	O
impact	B-C4049986
on	O
their	O
success	B-C0679864
rates	B-C1521828
,	O
as	O
well	O
as	O
frustration	B-C0016770
expressed	B-C1551042
by	O
a	O
minority	B-C0026192
regarding	O
the	O
lack	B-C1998986
of	I-C1998986
knowledge	I-C1998986
of	O
egg	B-C4053456
sharing	I-C4053456
outside	O
of	O
fertility	B-C0015895
clinics	B-C0442592
.	O
	
the	O
2005	O
legislative	B-C2937257
changes	B-C0392747
in	O
the	O
uk	B-C0041700
have	O
not	O
caused	O
the	O
anticipated	O
dramatic	O
decrease	B-C0547047
in	O
egg	B-C4053456
donation	I-C4053456
however	O
,	O
oocyte	B-C0242813
donation	I-C0242813
still	O
falls	O
short	O
of	O
demand	B-C0441516
.	O
	
egg	B-C4053456
sharing	I-C4053456
provides	O
a	O
practical	B-C1518601
option	I-C1518601
for	O
more	O
patients	B-C0030705
to	O
access	B-C1554204
ivf	B-C0015915
,	O
whilst	O
also	O
providing	O
more	O
donor	B-C3267027
oocytes	I-C3267027
.	O
	
improved	O
information	B-C0681319
provision	I-C0681319
will	O
result	B-C1274040
in	O
greater	O
awareness	B-C0004448
of	O
egg	B-C4053456
sharing	I-C4053456
,	O
with	O
the	O
potential	B-C3245505
to	O
recruit	B-C2949735
more	O
donors	O
and	O
meet	B-C1550543
the	O
needs	O
of	O
recipients	B-C1709854
currently	B-C0521116
on	O
long	O
waiting	B-C0043010
lists	I-C0043010
.	O
	
medication	B-C0237125
regimen	I-C0237125
complexity	B-C0237522
and	O
prevalence	B-C0033105
of	O
potentially	B-C4042848
inappropriate	I-C4042848
medicines	I-C4042848
in	O
older	B-C0001792
patients	B-C0030705
after	O
hospitalisation	B-C0019993
background	O
there	O
is	O
a	O
relative	B-C0205345
paucity	O
of	O
information	B-C1533716
to	O
characterise	O
potential	B-C3245505
changes	B-C0392747
in	O
medication	B-C0237125
regimen	I-C0237125
complexity	B-C0237522
and	O
prevalence	B-C0033105
of	O
prescribing	B-C2239117
of	O
potentially	B-C4042848
inappropriate	I-C4042848
medications	I-C4042848
after	O
hospitalisation	B-C0019993
,	O
both	O
in	O
australia	B-C0004340
and	O
elsewhere	O
.	O
	
objective	B-C0018017
to	O
evaluate	B-C0220825
medication	B-C0237125
regimen	I-C0237125
complexity	B-C0237522
and	O
the	O
prevalence	B-C0033105
of	O
potentially	B-C4042848
inappropriate	I-C4042848
medications	I-C4042848
before	B-C0332152
and	O
after	O
admission	B-C0184666
to	I-C0184666
hospital	I-C0184666
.	O
	
setting	O
general	B-C1708333
medical	I-C1708333
units	I-C1708333
of	O
a	O
tertiary	B-C0337954
care	I-C0337954
hospital	I-C0337954
in	O
australia	B-C0004340
.	O
	
methods	O
retrospective	B-C2985505
cohort	I-C2985505
study	I-C2985505
of	O
patients	B-C0030705
aged	B-C0001779
65	O
years	O
and	O
above	O
.	O
	
medication	B-C2081612
complexity	B-C0237522
was	O
measured	B-C0444706
by	O
using	O
the	O
medication	B-C0282574
regimen	I-C0282574
complexity	I-C0282574
index	I-C0282574
mrci	B-C0282574
.	O
	
main	B-C3274433
outcome	I-C3274433
measure	I-C3274433
the	O
primary	B-C3274433
outcome	I-C3274433
was	O
the	O
change	B-C0392747
in	O
the	O
medication	B-C0282574
regimen	I-C0282574
complexity	I-C0282574
index	I-C0282574
for	O
all	O
prescribed	B-C3166216
medications	I-C3166216
after	O
hospitalization	B-C0019993
.	O
	
results	B-C0456984
a	O
convenience	B-C0150095
sample	I-C0150095
of	O
100	O
patients	B-C0030705
was	O
included	B-C0332257
in	O
the	O
study	B-C2603343
.	O
	
there	O
was	O
a	O
significant	B-C0750502
change	B-C0392747
in	O
the	O
mean	B-C0444504
medication	B-C2081612
complexity	B-C0237522
score	B-C0449820
as	O
measured	B-C0444706
using	O
the	O
mrci	B-C0282574
,	O
increasing	B-C0205217
from	O
29	O
at	O
the	O
time	B-C3854259
of	I-C3854259
admission	I-C3854259
to	O
32	O
at	O
the	O
time	B-C3864299
of	I-C3864299
discharge	I-C3864299
p	O
<	O
0.05	O
.	O
	
factors	B-C1521761
such	O
as	O
baseline	B-C1442488
medication	B-C0237125
regimen	I-C0237125
complexity	B-C0237522
pre-admission	B-C0559269
mrci	B-C0282574
and	O
length	B-C0023303
of	I-C0023303
stay	I-C0023303
in	I-C0023303
the	I-C0023303
hospitals	I-C0023303
appear	B-C0700364
to	O
influence	B-C4054723
the	O
change	B-C0392747
in	O
medication	B-C2081612
complexity	B-C0237522
.	O
	
however	O
,	O
the	O
proportion	B-C1709707
of	O
patients	B-C0030705
prescribed	B-C0278329
at	O
least	O
one	O
potentially	B-C4042848
inappropriate	I-C4042848
medicine	I-C4042848
pim	B-C4042848
decreased	B-C4055638
significantly	I-C4055638
,	O
from	O
52%	O
pre-hospitalization	B-C0019993
to	O
42%	O
at	B-C3871203
discharge	I-C3871203
p	O
=	O
0.04	O
.	O
	
conclusions	O
relative	B-C0205345
to	O
the	O
time	B-C3854259
of	I-C3854259
admission	I-C3854259
,	O
overall	B-C1561607
medication	B-C2081612
complexity	B-C0237522
increased	B-C0205217
and	O
the	O
proportion	B-C1709707
of	O
patients	B-C0030705
who	O
were	O
prescribed	B-C0278329
pims	B-C4042848
decreased	B-C0205216
after	O
